{"meta":{"query_hash":"295742b6fa46","filters":{"topic":"CAR-T cell therapy research"},"cohort_total":2024,"direct_labels_cover":5,"predictions_cover":2024,"exported":2024,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/295742b6fa46","api":"https://metacan.xera.ac/api/v1/cohort?topic=CAR-T+cell+therapy+research"},"results":[{"id":"W131397720","doi":"10.3833/pdr.v2011i5.1473","title":"Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Business","score_opus":0.2517164448078097,"score_gpt":0.43659777920550064,"score_spread":0.18488133439769094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W131397720","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009744058,0.07652071,0.0019792838,0.018431956,0.0024741308,0.00029793623,0.00085079035,0.0003910136,0.8893101],"genre_scores_gemma":[0.09663953,0.0444077,0.005419466,0.0071189553,0.0017632586,0.00022580422,0.0016795945,0.00018132928,0.8425643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988667,0.00014409405,0.000060694652,0.00014118689,0.00064649404,0.00014088693],"domain_scores_gemma":[0.99856085,0.00035189246,0.00018018353,0.00008863005,0.0004819341,0.00033643813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016540319,0.0004662272,0.0003862891,0.00079365954,0.00083060766,0.0013283722,0.0003869409,0.0021612286,0.09689659],"category_scores_gemma":[0.001942438,0.0002218568,0.00049562287,0.00057449285,0.00060517556,0.0014618252,0.00080803054,0.0013846846,0.02050132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007164581,0.00026575042,0.0010393066,0.0010850701,0.00002843492,0.0014259509,0.00031977423,0.000111742585,0.03154284,0.028737761,0.29620394,0.6385229],"study_design_scores_gemma":[0.000062439736,0.00020470915,0.0011621474,0.00016385011,0.000010840728,0.000837556,0.000044551674,0.00004723129,0.003163948,0.00042298588,0.9938725,0.0000072358134],"about_ca_topic_score_codex":0.004392122,"about_ca_topic_score_gemma":0.007614599,"teacher_disagreement_score":0.09689659,"about_ca_system_score_codex":0.0012556321,"about_ca_system_score_gemma":0.0037513396,"threshold_uncertainty_score":0.3241514},"labels":[],"label_agreement":null},{"id":"W1460819011","doi":"10.4049/jimmunol.194.supp.206.37","title":"Deep profiling of single T cell receptor repertoire and phenotype with targeted RNA-seq (TECH2P.927)","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"T-cell receptor; Biology; CD8; T cell; Gene; Deep sequencing; FOXP3; Amplicon; Molecular biology; Genetics; Computational biology; Polymerase chain reaction; Antigen; Genome; Immune system","score_opus":0.027794646758186606,"score_gpt":0.2699135668608347,"score_spread":0.24211892010264807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1460819011","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45653763,0.001859028,0.43430588,0.00034316618,0.0003299657,0.0006696318,0.08058906,0.015241085,0.010124508],"genre_scores_gemma":[0.50242245,0.0010178445,0.4111211,0.001345249,0.00013951559,0.0027567388,0.06408031,0.005777141,0.011339606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994492,0.000047226073,0.000024962812,0.00025305586,0.0001551524,0.00007037771],"domain_scores_gemma":[0.99971396,0.00010343668,0.000033799228,0.000049548875,0.00006453615,0.000034552577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088360434,0.0006443184,0.0008506974,0.00047706216,0.0005443261,0.0009419515,0.00059193256,0.0006244664,0.0040437733],"category_scores_gemma":[0.0005067895,0.00041367562,0.0007775764,0.0004921727,0.00039572816,0.0002665071,0.00063311757,0.0011732477,0.002114062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024730683,0.000049987306,0.0034824857,0.00040545576,0.00012831076,0.00011457408,0.0001657405,0.00263881,0.96694034,0.00082356564,0.0037525517,0.021250948],"study_design_scores_gemma":[0.00013730895,0.00052576925,0.060779803,0.00009612394,0.00035396253,0.0007225954,0.00025031884,0.12123119,0.75305295,0.0038472596,0.05883161,0.0001710587],"about_ca_topic_score_codex":0.0009009427,"about_ca_topic_score_gemma":0.003164303,"teacher_disagreement_score":0.0040437733,"about_ca_system_score_codex":0.00030229538,"about_ca_system_score_gemma":0.000439334,"threshold_uncertainty_score":0.013527811},"labels":[],"label_agreement":null},{"id":"W1484293858","doi":"","title":"Antibody Examination Practice at the Canadian Patent Office: Immune to Change?","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scrutiny; Interpretation (philosophy); Jurisprudence; Law; Political science; Law and economics; Medicine; Engineering ethics; Sociology; Engineering; Computer science","score_opus":0.03390859746517152,"score_gpt":0.32529781374666394,"score_spread":0.29138921628149245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1484293858","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014652673,0.010787376,0.0033975707,0.8038811,0.0026302347,0.00010624938,0.000115048766,0.0001344905,0.16429529],"genre_scores_gemma":[0.5047916,0.01356314,0.005799417,0.36263812,0.002541679,0.000104359984,0.00014218684,0.00018020942,0.110239245],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.9513812,0.005801854,0.001314317,0.005407309,0.02821334,0.007881948],"domain_scores_gemma":[0.94757664,0.01877235,0.0029559426,0.0031932297,0.019854158,0.0076476773],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.032689814,0.00038510456,0.00057184225,0.0025986913,0.02417671,0.016483195,0.004651316,0.016363107,0.011596193],"category_scores_gemma":[0.08795582,0.0005651095,0.0006614976,0.0029322195,0.02626207,0.0067164516,0.0045223245,0.013150255,0.0013686012],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004460711,0.00007770327,0.0073563107,0.00020225592,0.00003124794,0.0015556737,0.013122505,0.00023304635,0.001222517,0.6057416,0.24598236,0.12443013],"study_design_scores_gemma":[0.000028385411,0.00005559089,0.009623119,0.00040918813,0.000026518994,0.00078876986,0.007394979,0.00030493454,0.00052931876,0.030666059,0.9500261,0.0001469624],"about_ca_topic_score_codex":0.8497232,"about_ca_topic_score_gemma":0.90808433,"teacher_disagreement_score":0.9673102,"about_ca_system_score_codex":0.07277961,"about_ca_system_score_gemma":0.21367934,"threshold_uncertainty_score":0.52805555},"labels":[],"label_agreement":null},{"id":"W1503366801","doi":"10.4049/jimmunol.188.supp.124.3","title":"A specialized tube to make enrichment of specific cell subsets faster and easier (124.3)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Centrifugation; Differential centrifugation; Peripheral blood mononuclear cell; CD19; Pipette; Cell; Chromatography; Chemistry; Molecular biology; Biology; In vitro; Biochemistry","score_opus":0.031912582575127545,"score_gpt":0.302126773513856,"score_spread":0.27021419093872845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1503366801","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05058523,0.0028982619,0.86677814,0.0013743218,0.0038366253,0.0072142137,0.006073289,0.030607635,0.030632252],"genre_scores_gemma":[0.037809342,0.0016794777,0.87300223,0.0022878828,0.00094097696,0.008621548,0.015825476,0.002942531,0.05689049],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982345,0.00030682984,0.0002454503,0.0004590091,0.00048755045,0.00026655933],"domain_scores_gemma":[0.99873024,0.00037419732,0.00013830271,0.00024605275,0.00033455578,0.00017655376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016165507,0.0022059283,0.001621851,0.0020620113,0.0010007861,0.0010578915,0.001999415,0.0018070723,0.037557874],"category_scores_gemma":[0.0019423567,0.001400591,0.0016163582,0.001132801,0.0006218893,0.0010842315,0.0011115458,0.0023846214,0.040206797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031766543,0.00036781686,0.0009402588,0.0005810627,0.000041936455,0.00044823068,0.00012762756,0.00023973544,0.905483,0.001802308,0.024447829,0.06520247],"study_design_scores_gemma":[0.00021997705,0.0011241015,0.0089001935,0.00029043897,0.00030582587,0.0018407259,0.00006342581,0.0071383044,0.7293782,0.0009435564,0.24966785,0.00012744367],"about_ca_topic_score_codex":0.00033418872,"about_ca_topic_score_gemma":0.0006707937,"teacher_disagreement_score":0.037557874,"about_ca_system_score_codex":0.00036646132,"about_ca_system_score_gemma":0.00083179487,"threshold_uncertainty_score":0.12564361},"labels":[],"label_agreement":null},{"id":"W1504284254","doi":"10.4049/jimmunol.188.supp.46.4","title":"Inducible B effector cells (iBECs) for cancer immunotherapy (46.4)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"CD80; Medicine; CD86; Cancer research; Immunology; Cytotoxic T cell; Immunotherapy; Adoptive cell transfer; T cell; Biology; CD40; Immune system; In vitro","score_opus":0.038275709970793104,"score_gpt":0.35256542540662417,"score_spread":0.31428971543583106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1504284254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94828683,0.006283053,0.028538764,0.00032287222,0.0003233816,0.00049751485,0.0014021313,0.0009317583,0.013413673],"genre_scores_gemma":[0.9656804,0.002086879,0.012428544,0.0002134707,0.000063645944,0.0003052783,0.0018420806,0.000078679615,0.017301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986255,0.000024715448,0.000011262459,0.000026223737,0.00003384509,0.000041388143],"domain_scores_gemma":[0.9999465,0.0000058607898,0.000012606309,0.000010201348,0.0000068190698,0.0000180684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017465538,0.00048084027,0.00019061168,0.00027247344,0.00011913248,0.00039051636,0.00015673123,0.00032463728,0.0034781843],"category_scores_gemma":[0.00006650995,0.000100636724,0.00023838916,0.000111795845,0.00009687216,0.00015877801,0.00024786164,0.0008844361,0.0019338949],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010037207,0.00007986752,0.00017744006,0.000055784014,0.00000444691,0.000037717,0.000010089102,0.00006003856,0.9957826,0.00020817896,0.0001208614,0.0033625886],"study_design_scores_gemma":[0.0000689368,0.00079123577,0.0018662919,0.000022070073,0.000033045148,0.00044986513,0.000020876285,0.0006438958,0.97185713,0.00011493144,0.0241277,0.000004121053],"about_ca_topic_score_codex":0.00009133239,"about_ca_topic_score_gemma":0.000110649686,"teacher_disagreement_score":0.0034781843,"about_ca_system_score_codex":0.00011756172,"about_ca_system_score_gemma":0.0001290385,"threshold_uncertainty_score":0.011635721},"labels":[],"label_agreement":null},{"id":"W153967471","doi":"10.4049/jimmunol.186.supp.46.4","title":"Inflammatory cytokines determine the susceptibility of human CD8 T cells to Fas-mediated activation-induced cell death through modulation of FasL and c-FLIP expression (46.4)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"CD8; T cell; Programmed cell death; Cytotoxic T cell; Fas ligand; TCIRG1; Cell biology; Apoptosis; Biology; Molecular biology; Immunology; Chemistry; Immune system; Interleukin 21; In vitro; Biochemistry","score_opus":0.05902705006003339,"score_gpt":0.3086606830461397,"score_spread":0.2496336329861063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W153967471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99575305,0.0021514592,0.0010315763,0.000060030132,0.00002201085,0.000039068687,0.00023831986,0.000023735756,0.00068071764],"genre_scores_gemma":[0.99643326,0.000871806,0.0010934053,0.000060524333,0.00001586226,0.000069657435,0.00030422537,0.000007449126,0.0011437499],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997329,0.0000687158,0.0000317947,0.000037711514,0.000051430772,0.00007735325],"domain_scores_gemma":[0.9998534,0.000041007406,0.00004097871,0.000014153748,0.000022081325,0.000028451008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001880386,0.0003390294,0.00024246506,0.00017384274,0.000121625126,0.00034639722,0.000080166625,0.00032512666,0.002322072],"category_scores_gemma":[0.0002150511,0.00012906962,0.00022975542,0.00013533018,0.00017843422,0.00021911967,0.0001523783,0.00060748303,0.0005404722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028159097,0.00003081236,0.00016376631,0.00003255216,0.0000031762859,0.000030928324,0.000020288244,0.000031853906,0.9986292,0.000015812244,0.000018540091,0.00074142375],"study_design_scores_gemma":[0.0000577008,0.00096931687,0.0060195406,0.000009384732,0.00001833403,0.00031444003,0.000047204092,0.00040372528,0.99108607,0.000046602298,0.0010229946,0.0000047695225],"about_ca_topic_score_codex":0.00017256547,"about_ca_topic_score_gemma":0.000250536,"teacher_disagreement_score":0.002322072,"about_ca_system_score_codex":0.00018778864,"about_ca_system_score_gemma":0.00011177624,"threshold_uncertainty_score":0.0077680945},"labels":[],"label_agreement":null},{"id":"W1543052164","doi":"10.1038/mt.2015.119","title":"T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice","year":2015,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research","keywords":"NKG2D; Chimeric antigen receptor; Immunotherapy; Receptor; Adoptive cell transfer; Cancer research; Antigen; Biology; T cell; Cytotoxic T cell; Immunology; Cell biology; Molecular biology; In vitro; Immune system; Biochemistry","score_opus":0.017646758895214415,"score_gpt":0.27537780957187835,"score_spread":0.2577310506766639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1543052164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9808836,0.0017594566,0.011111432,0.00033189726,0.00012208664,0.00026476654,0.0008806979,0.0005848747,0.0040611555],"genre_scores_gemma":[0.9837948,0.0012836553,0.0071577705,0.00021929383,0.000024661591,0.00035678403,0.0009831807,0.00010541016,0.006074524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99947304,0.00009647993,0.00004998844,0.00011861339,0.00012132506,0.00014053003],"domain_scores_gemma":[0.99978,0.00004555742,0.000070301314,0.00003582499,0.000020500724,0.000047832822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003560187,0.0009170312,0.0004752281,0.00048589308,0.00021915665,0.0005049249,0.0004069432,0.0010535266,0.0012067322],"category_scores_gemma":[0.00019240427,0.00029678046,0.00039243494,0.00020497503,0.0004583328,0.00031922795,0.0002630913,0.001569283,0.0007541045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019712333,0.00008402225,0.00010654054,0.000037884907,0.000009363535,0.00005791067,0.000023096294,0.00020661775,0.99785477,0.00022199428,0.00011246143,0.001088239],"study_design_scores_gemma":[0.000088555105,0.00082353805,0.00065462856,0.000012291851,0.000020708849,0.00035203347,0.00001717148,0.0012941272,0.9942781,0.000073332056,0.002378211,0.0000072166813],"about_ca_topic_score_codex":0.00066440867,"about_ca_topic_score_gemma":0.00061190047,"teacher_disagreement_score":0.0012067322,"about_ca_system_score_codex":0.00041747154,"about_ca_system_score_gemma":0.00031841244,"threshold_uncertainty_score":0.0040369034},"labels":[],"label_agreement":null},{"id":"W1543857745","doi":"10.3389/fimmu.2015.00247","title":"Adoptive T Cell Therapy Targeting CD1 and MR1","year":2015,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; University of Toronto; Canadian Institutes of Health Research; Government of Ontario","keywords":"T cell; CD1; Adoptive cell transfer; Antigen; Immunotherapy; Immunology; Effector; Human leukocyte antigen; Biology; Cancer research; Cell biology; Medicine; Antigen-presenting cell; Immune system","score_opus":0.04836614119864218,"score_gpt":0.34278296991815316,"score_spread":0.29441682871951097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1543857745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007375489,0.99455005,0.0006450921,0.00032334818,0.00026101837,0.000013970128,0.000031026673,0.000023482873,0.0034145038],"genre_scores_gemma":[0.00318587,0.99317485,0.000515066,0.00026927784,0.00016242171,0.000018648052,0.000062220664,0.0000029521798,0.002608676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992347,0.000010666295,0.000007441035,0.00001589901,0.00003125365,0.000011352523],"domain_scores_gemma":[0.99994457,0.000018820712,0.000009294537,0.0000019041141,0.000016879067,0.000008424284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002449039,0.0004696686,0.00063952507,0.00096825825,0.00014672885,0.0004854477,0.00039084503,0.00063514826,0.0027713913],"category_scores_gemma":[0.00018052683,0.00012268452,0.0002600964,0.00072454265,0.00022525543,0.0005721434,0.0003686485,0.0009514926,0.0020341508],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084797975,0.00010211502,0.00017539726,0.008446175,0.0000381904,0.00022340992,0.000045180233,0.0002447331,0.012837224,0.004073083,0.020116484,0.95361316],"study_design_scores_gemma":[0.000018583314,0.00017190306,0.00057233596,0.00090542884,0.000058888698,0.0016404919,0.000039336708,0.000101457335,0.0038868512,0.0012376583,0.99135464,0.000012464615],"about_ca_topic_score_codex":0.00035550265,"about_ca_topic_score_gemma":0.00060542795,"teacher_disagreement_score":0.0027713913,"about_ca_system_score_codex":0.00029084773,"about_ca_system_score_gemma":0.0004106467,"threshold_uncertainty_score":0.0092712045},"labels":[],"label_agreement":null},{"id":"W1547750496","doi":"10.1038/leu.2015.155","title":"Antileukemia multifunctionality of CD4+ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer","year":2015,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"University of Warwick; Uehara Memorial Foundation; Fujita Health University; Takeda Science Foundation","keywords":"Cytotoxic T cell; CD8; Biology; Interleukin 21; Adoptive cell transfer; Leukemia; T-cell receptor; T cell; Natural killer T cell; Interleukin 3; Immunotherapy; Cancer research; Interleukin 12; Streptamer; ZAP70; Immunology; Molecular biology; Antigen; Immune system; Genetics","score_opus":0.02644519815614984,"score_gpt":0.25639002476318545,"score_spread":0.2299448266070356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1547750496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968836,0.00035895657,0.0016694178,0.00004271535,0.00001805521,0.000017030852,0.00006456521,0.000058708578,0.0008870164],"genre_scores_gemma":[0.9980565,0.00014973586,0.0008352922,0.000014908419,0.00000842328,0.00001351699,0.000075270305,0.00001329761,0.0008330579],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985933,0.00003284779,0.000011397311,0.000026857002,0.00001917166,0.000050361443],"domain_scores_gemma":[0.9999194,0.000018010676,0.00002371178,0.000011427731,0.000007574672,0.000019747647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017395336,0.00040493882,0.00021317456,0.0002696889,0.000119137134,0.00032557733,0.0001741447,0.00026996544,0.0010345205],"category_scores_gemma":[0.00008894206,0.00014668619,0.00015686176,0.000102979495,0.0002011771,0.00018032368,0.00016232788,0.0004535554,0.00027804845],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015948225,0.000024971501,0.000071864946,0.000010892805,0.0000020813166,0.000029384471,0.000010559733,0.00011679026,0.99857736,0.00015631603,0.000015932834,0.0008243736],"study_design_scores_gemma":[0.00005249515,0.00033147846,0.0007422988,0.0000018883308,0.000019646182,0.0001559903,0.000010521892,0.0011525865,0.99617165,0.000052649266,0.0013056725,0.0000032422802],"about_ca_topic_score_codex":0.00021497546,"about_ca_topic_score_gemma":0.00023160182,"teacher_disagreement_score":0.0010345205,"about_ca_system_score_codex":0.00016457714,"about_ca_system_score_gemma":0.00014447545,"threshold_uncertainty_score":0.0034608245},"labels":[],"label_agreement":null},{"id":"W1556179571","doi":"10.1080/2162402x.2015.1008354","title":"T cell receptor-therapy in HBV-related hepatocellularcarcinoma","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Wellcome Trust","keywords":"T-cell receptor; Chimeric antigen receptor; Adoptive cell transfer; Medicine; Antigen; Immunology; Hepatitis B virus; T cell; Receptor; Cell therapy; Hepatitis B; Cancer research; Virology; Cell; Virus; Immune system; Biology; Internal medicine","score_opus":0.05337410790290423,"score_gpt":0.30603250749086675,"score_spread":0.25265839958796255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556179571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97544765,0.014649249,0.003369552,0.00039404727,0.0000801167,0.00011144454,0.000049508097,0.00013740399,0.005760961],"genre_scores_gemma":[0.9938257,0.0040975646,0.00061070966,0.000063869906,0.000019295532,0.00003215362,0.000051223902,0.000007875595,0.0012917669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999422,0.000020784715,0.0000035083576,0.000005514276,0.00001042182,0.000017734266],"domain_scores_gemma":[0.9999709,0.000008468607,0.0000059203235,0.0000043460573,0.0000034152827,0.0000068213767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016313008,0.00017100759,0.00021044578,0.0002130108,0.000113484835,0.00015474788,0.00013758443,0.00027488178,0.001216833],"category_scores_gemma":[0.00011269524,0.000055898254,0.00013347193,0.00015583592,0.00020249885,0.00015698027,0.00013534258,0.0004358204,0.00027481577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002536457,0.0015830458,0.001965156,0.0008446382,0.000051829746,0.00235758,0.00015516742,0.0018820857,0.8747978,0.002388505,0.00107725,0.110360354],"study_design_scores_gemma":[0.001538947,0.012541973,0.0069096438,0.00006260786,0.0001632259,0.0067326226,0.000095615556,0.0053547993,0.9412655,0.00082930987,0.024484009,0.000021686317],"about_ca_topic_score_codex":0.00038984927,"about_ca_topic_score_gemma":0.0005083486,"teacher_disagreement_score":0.001216833,"about_ca_system_score_codex":0.00017731669,"about_ca_system_score_gemma":0.00020508314,"threshold_uncertainty_score":0.004070699},"labels":[],"label_agreement":null},{"id":"W1556899888","doi":"10.1111/j.1600-065x.2011.01065.x","title":"The TNF receptor super family in immune regulation","year":2011,"lang":"en","type":"article","venue":"Immunological Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Immunology; Tumor necrosis factor receptor; Biology; Receptor; Tumor necrosis factor alpha; Genetics","score_opus":0.14590713457191773,"score_gpt":0.3516593720056134,"score_spread":0.2057522374336957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556899888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012470332,0.9879981,0.0008244234,0.002482897,0.0018407253,0.0000068385566,0.000036875434,0.000025744577,0.0055372845],"genre_scores_gemma":[0.026762977,0.9533493,0.0008201964,0.0022663819,0.0053624897,0.00002477439,0.00012365381,0.000013463873,0.01127668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997454,0.000059484453,0.00002092313,0.000038367794,0.00009541082,0.00004025641],"domain_scores_gemma":[0.9998018,0.000052804753,0.000035830417,0.000008324449,0.000054103402,0.000047058147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005726445,0.0005343166,0.00071779516,0.00045882305,0.0002505324,0.0009801643,0.00047299036,0.00096633437,0.004236392],"category_scores_gemma":[0.00038546877,0.00009012281,0.00024068025,0.0004217805,0.0005394246,0.0007779763,0.0005933976,0.0016585491,0.0029093],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006480891,0.000086015825,0.0007347206,0.004757107,0.00010159577,0.0013054594,0.0003892072,0.00059066166,0.026209118,0.06415529,0.12784848,0.7731742],"study_design_scores_gemma":[0.000051400304,0.00019506314,0.001300333,0.0007943581,0.000040393494,0.0022323742,0.00009728637,0.00015684635,0.0023394255,0.011657165,0.98111904,0.000016336331],"about_ca_topic_score_codex":0.00031482973,"about_ca_topic_score_gemma":0.00031661798,"teacher_disagreement_score":0.004236392,"about_ca_system_score_codex":0.0007125241,"about_ca_system_score_gemma":0.0007166366,"threshold_uncertainty_score":0.014172196},"labels":[],"label_agreement":null},{"id":"W1558461865","doi":"10.4049/jimmunol.188.supp.124.9","title":"A simple and rapid method for the isolation of untouched human memory CD8 T cells (124.9)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"CD8; Cytotoxic T cell; Immunomagnetic separation; Antigen; Biology; Cell biology; Antibody; Immunology; Molecular biology; Chemistry; In vitro; Biochemistry","score_opus":0.04958857896967336,"score_gpt":0.37592114523412995,"score_spread":0.3263325662644566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558461865","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1696853,0.011510657,0.7841888,0.0006965429,0.0017959976,0.0051395106,0.007493536,0.0043563005,0.015133381],"genre_scores_gemma":[0.28078285,0.0049511264,0.6550092,0.00093049626,0.00036756523,0.0065350793,0.016320247,0.0005833313,0.034520105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994752,0.00008872059,0.000063214895,0.00011932446,0.00018481932,0.00006872934],"domain_scores_gemma":[0.99984586,0.000037362428,0.000015543505,0.000033535507,0.00004228448,0.000025374595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003368868,0.0009975595,0.000515645,0.0007208095,0.0003433779,0.00039452183,0.00077206496,0.00051900477,0.00566733],"category_scores_gemma":[0.0003028882,0.00042393265,0.00038090083,0.00039467512,0.00017434805,0.00027589264,0.00052689924,0.00097643177,0.006706236],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081570404,0.0000811077,0.00017915232,0.00013456565,0.000009807993,0.000066607514,0.000019484849,0.000053707834,0.9756447,0.00016886943,0.0013899732,0.02217052],"study_design_scores_gemma":[0.00015430473,0.00075511175,0.0046931473,0.0000689264,0.000099899,0.0013105117,0.000023010693,0.0020513698,0.9165781,0.00037097555,0.07385244,0.000042253854],"about_ca_topic_score_codex":0.00017693872,"about_ca_topic_score_gemma":0.0004363504,"teacher_disagreement_score":0.00566733,"about_ca_system_score_codex":0.00012405195,"about_ca_system_score_gemma":0.00022475683,"threshold_uncertainty_score":0.018959105},"labels":[],"label_agreement":null},{"id":"W1558649589","doi":"10.4049/jimmunol.1403145","title":"Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Avidity; T-cell receptor; CD8; T cell; Cytotoxic T cell; Peptide; Biology; Immune system; Antigen; Molecular biology; Chemistry; Cell biology; Immunology; Biochemistry; In vitro","score_opus":0.04405224908136289,"score_gpt":0.34109835500132574,"score_spread":0.29704610591996283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558649589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951342,0.0003181032,0.004047142,0.00000864455,0.0000029454686,0.000014697893,0.0000816529,0.000023157103,0.0003695575],"genre_scores_gemma":[0.9969708,0.00010728163,0.0024147856,0.00001133915,0.0000031345398,0.000022893917,0.00014340857,0.000009744531,0.0003166466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978226,0.00004168435,0.000018676954,0.000074632546,0.000046520927,0.000036242593],"domain_scores_gemma":[0.9998024,0.000079495585,0.000042493823,0.00002295452,0.000028248682,0.00002432139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002326316,0.00022212282,0.00024483338,0.00026103895,0.00008727516,0.00023146738,0.000079221405,0.00023980824,0.00089653855],"category_scores_gemma":[0.0003200382,0.00010076318,0.000092222166,0.00012315983,0.000117844334,0.00015775063,0.0001256732,0.00034456135,0.00025857775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078326,0.0000075217954,0.0013309942,0.000009344346,0.0000022471258,0.000006732412,0.000015376734,0.00005652893,0.9972753,0.000008931842,0.0000040227724,0.0012046804],"study_design_scores_gemma":[0.000008346804,0.0005127951,0.032623004,0.0000044884514,0.000022237542,0.0004316095,0.000044066965,0.004230397,0.9614214,0.000052646876,0.0006444817,0.0000045971324],"about_ca_topic_score_codex":0.0001038564,"about_ca_topic_score_gemma":0.0001503879,"teacher_disagreement_score":0.00089653855,"about_ca_system_score_codex":0.00009642498,"about_ca_system_score_gemma":0.00005045493,"threshold_uncertainty_score":0.0029992461},"labels":[],"label_agreement":null},{"id":"W1566703402","doi":"10.1212/wnl.84.14_supplement.p7.201","title":"Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201)","year":2015,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; University of British Columbia","funders":"","keywords":"Ocrelizumab; Medicine; Demographics; Multiple sclerosis; Relapsing remitting; Clinical trial; Internal medicine; Family medicine; Demography; Psychiatry","score_opus":0.11844849721392953,"score_gpt":0.3645933301292611,"score_spread":0.24614483291533157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1566703402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97208494,0.006032943,0.00066420244,0.0005682113,0.00014256257,0.0032923282,0.010011822,0.000038476315,0.0071644885],"genre_scores_gemma":[0.9674956,0.0018027346,0.0011661829,0.0016011451,0.00031092056,0.006305016,0.017508574,0.000020698968,0.0037890412],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9992841,0.00021077147,0.000104913386,0.00014472731,0.00015192438,0.000103636725],"domain_scores_gemma":[0.99856323,0.00028017737,0.00034850385,0.000082627295,0.00013562608,0.00058989966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020153278,0.00086646184,0.0012465785,0.00042951258,0.000665394,0.0005542445,0.0003882609,0.0006174016,0.0063360627],"category_scores_gemma":[0.0020197674,0.0003248252,0.0007995504,0.0004259859,0.00044160007,0.0005257572,0.00039598512,0.0014012641,0.00086660055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5803581,0.01306475,0.28511178,0.0015852016,0.002328062,0.0010712553,0.00045905475,0.0010640714,0.011314335,0.00044701088,0.018313747,0.08488266],"study_design_scores_gemma":[0.23032814,0.15868329,0.55603194,0.0004076554,0.003570905,0.0027210133,0.0003677497,0.0010334963,0.0029121109,0.0006546663,0.043159362,0.00012974345],"about_ca_topic_score_codex":0.0006122972,"about_ca_topic_score_gemma":0.0009962636,"teacher_disagreement_score":0.0063360627,"about_ca_system_score_codex":0.0004657575,"about_ca_system_score_gemma":0.0010202306,"threshold_uncertainty_score":0.021196246},"labels":[],"label_agreement":null},{"id":"W1574902133","doi":"10.1038/nri1257","title":"T-cell development made simple","year":2004,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Lymphopoiesis; Cell biology; Thymocyte; Extracellular matrix; Function (biology); Biology; Stem cell; Cellular differentiation; Receptor; Chemistry; T cell; Haematopoiesis; Immunology; Biochemistry; Gene; Immune system","score_opus":0.05349645198295755,"score_gpt":0.3988182439844727,"score_spread":0.34532179200151514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1574902133","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017761876,0.98696405,0.0012300501,0.0022660964,0.004702907,0.000011829427,0.000022246144,0.00003908992,0.00458608],"genre_scores_gemma":[0.0016987914,0.9869467,0.0009278103,0.0025376815,0.0018603259,0.000027426855,0.000044653014,0.000010029892,0.0059465887],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996692,0.00007045823,0.000031355794,0.00006774699,0.0001166925,0.00004464422],"domain_scores_gemma":[0.9996289,0.00016179404,0.000025652324,0.000025270161,0.00011549024,0.00004290944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013431554,0.0016644883,0.0024089243,0.0011211493,0.00059951097,0.0018850081,0.0015534577,0.002963808,0.0054449067],"category_scores_gemma":[0.00084728276,0.0005859796,0.00061809923,0.0011514155,0.0021070805,0.0035372307,0.0013562992,0.006083395,0.005310467],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024666483,0.00011273555,0.00016142095,0.00819052,0.00008546748,0.00043069827,0.00008850268,0.00076164276,0.009154592,0.05381255,0.15379208,0.77316314],"study_design_scores_gemma":[0.000027087544,0.000046072415,0.000103336904,0.00062198954,0.000021947046,0.00040883056,0.000022739605,0.00006308858,0.0008048693,0.0064463643,0.99142355,0.000010240926],"about_ca_topic_score_codex":0.00075609697,"about_ca_topic_score_gemma":0.0013085576,"teacher_disagreement_score":0.0054449067,"about_ca_system_score_codex":0.0014915556,"about_ca_system_score_gemma":0.0013134379,"threshold_uncertainty_score":0.01821506},"labels":[],"label_agreement":null},{"id":"W1585793952","doi":"10.1111/j.1365-2567.2011.03550.x","title":"Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade","year":2011,"lang":"en","type":"article","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Biotechnology and Biological Sciences Research Council; Directorate for Biological Sciences","keywords":"Blockade; CD8; Biology; Chemistry; Immunology; Medicine; Internal medicine; Receptor; Immune system","score_opus":0.02305902225775291,"score_gpt":0.24560267586284384,"score_spread":0.22254365360509093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585793952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968727,0.0011575796,0.0009392563,0.000037587917,0.000025229247,0.000016340462,0.00012252238,0.000048700025,0.0007800086],"genre_scores_gemma":[0.9967895,0.00035251194,0.0005847956,0.00004699357,0.0000115435705,0.000027951155,0.00018226632,0.000014906784,0.001989462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990463,0.000015704016,0.000012717838,0.000016653126,0.00001885742,0.000031468247],"domain_scores_gemma":[0.99983776,0.000025595167,0.000040010724,0.000015975613,0.00001180676,0.00006878727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018399971,0.00029008728,0.00022351759,0.0001547315,0.000070143346,0.000231474,0.0001993509,0.00024401752,0.0010038868],"category_scores_gemma":[0.00018217092,0.00011292998,0.00013831224,0.00005626255,0.00024018376,0.00017785144,0.00013226969,0.0005562882,0.00034962854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002512033,0.00005096418,0.00025559973,0.000025826479,0.0000037158413,0.00011103398,0.00002334294,0.000048548343,0.9965238,0.00009073243,0.000048107548,0.002567039],"study_design_scores_gemma":[0.00014965843,0.0029039257,0.016649907,0.000014453464,0.000035774887,0.0020711534,0.00007901313,0.0010189519,0.97147435,0.00015177445,0.005442431,0.000008684298],"about_ca_topic_score_codex":0.00016547675,"about_ca_topic_score_gemma":0.00025101512,"teacher_disagreement_score":0.0010038868,"about_ca_system_score_codex":0.0001404769,"about_ca_system_score_gemma":0.00013789767,"threshold_uncertainty_score":0.003358364},"labels":[],"label_agreement":null},{"id":"W1587247252","doi":"10.1038/nri1259","title":"Translational research in immunology: Japanese perspectives","year":2004,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; RIKEN; Canadian Institutes of Health Research","keywords":"Translational research; Immunology; Clinical immunology; Tumor immunology; Biology; Computational biology; Medicine; Immune system; Pathology; Immunotherapy","score_opus":0.1123179514854199,"score_gpt":0.477389463997891,"score_spread":0.3650715125124711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1587247252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023892044,0.9937018,0.00010426892,0.0017217357,0.0038390893,0.0000030137967,0.0000066537546,0.000008531346,0.0005910451],"genre_scores_gemma":[0.00035684972,0.99117005,0.00025501382,0.0032897966,0.004019511,0.000009405481,0.000018740424,0.0000040689847,0.0008765962],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99931335,0.00016158479,0.00010356981,0.00013467134,0.00018664483,0.00010022919],"domain_scores_gemma":[0.9984042,0.0006722624,0.00011558076,0.000054060398,0.0004946639,0.00025925145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037027558,0.0022891937,0.0036819181,0.004068669,0.0010834582,0.0038315533,0.001977697,0.0058134985,0.006085526],"category_scores_gemma":[0.002440339,0.00066070055,0.0009012256,0.005429116,0.0025822143,0.0068183695,0.0024968144,0.0064422027,0.003356682],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021174997,0.00019501426,0.00026001627,0.017326932,0.00014906118,0.0004157698,0.00019156926,0.00026547292,0.001451499,0.013296586,0.3051149,0.6611215],"study_design_scores_gemma":[0.000049445072,0.0000501251,0.0004924087,0.0029822495,0.00011718877,0.00049063354,0.000098518656,0.000049037837,0.00008506595,0.002885267,0.99267983,0.000020148746],"about_ca_topic_score_codex":0.0020847844,"about_ca_topic_score_gemma":0.0062781554,"teacher_disagreement_score":0.006085526,"about_ca_system_score_codex":0.002585199,"about_ca_system_score_gemma":0.005227691,"threshold_uncertainty_score":0.020358086},"labels":[],"label_agreement":null},{"id":"W1592754702","doi":"10.4049/jimmunol.1401717","title":"Specific Roles of Each TCR Hemichain in Generating Functional Chain-Centric TCR","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Avidity; T-cell receptor; Biology; Major histocompatibility complex; T cell; clone (Java method); Gene rearrangement; Gene; Repertoire; Antigen; Molecular biology; Cell biology; Immunology; Genetics; Immune system","score_opus":0.05067838008250416,"score_gpt":0.29385822090145947,"score_spread":0.2431798408189553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592754702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996436,0.00020242132,0.002179063,0.000008159914,0.0000028342802,0.000009472484,0.00004090706,0.00001772877,0.0011033921],"genre_scores_gemma":[0.99787307,0.00012563678,0.0011676183,0.0000110381325,0.0000031750824,0.000006861691,0.00009597072,0.00000863865,0.00070801127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998778,0.000017864832,0.000007731478,0.000028215809,0.000027050699,0.00004126297],"domain_scores_gemma":[0.9998697,0.000026350828,0.000020558087,0.00002415055,0.000018377747,0.00004088394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000141014,0.00022584596,0.00009859852,0.00010631496,0.000083789404,0.00031382134,0.00016686505,0.00014252587,0.00056362187],"category_scores_gemma":[0.000111258996,0.00008809392,0.00010316389,0.00008276412,0.000105250176,0.0001581787,0.0002406557,0.00028992913,0.0001768591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050350827,0.0000075914777,0.00062838197,0.000008534222,0.0000016025145,0.000022378144,0.000007759736,0.00008704416,0.99795973,0.0000604862,0.000006726549,0.0011594731],"study_design_scores_gemma":[0.00000969855,0.00025335405,0.013241848,0.0000052280643,0.000019484005,0.00054251665,0.000042592994,0.0016249645,0.9829852,0.000067972855,0.0012038713,0.0000032885875],"about_ca_topic_score_codex":0.00015847097,"about_ca_topic_score_gemma":0.00036559073,"teacher_disagreement_score":0.00056362187,"about_ca_system_score_codex":0.00016139892,"about_ca_system_score_gemma":0.000168889,"threshold_uncertainty_score":0.0018854737},"labels":[],"label_agreement":null},{"id":"W1595298938","doi":"10.1111/cei.12465","title":"Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice","year":2014,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Leona M. and Harry B. Helmsley Charitable Trust; Canadian Institutes of Health Research; University of Massachusetts Medical School; National Cancer Institute; National Institutes of Health; National Institute on Drug Abuse; Canadian Diabetes Association","keywords":"Cytotoxic T cell; Biology; Antigen; Immunology; T cell; CD8; Major histocompatibility complex; Antigen-presenting cell; T-cell receptor; Cell biology; Immune system; In vitro","score_opus":0.09438824903010129,"score_gpt":0.38201046209632167,"score_spread":0.2876222130662204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1595298938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8850566,0.004616731,0.095470764,0.0006346536,0.00039342162,0.0020666828,0.0032798774,0.0018781199,0.006603169],"genre_scores_gemma":[0.9487272,0.002327529,0.03499566,0.00021561494,0.000059158327,0.0013349825,0.0031118807,0.00019736112,0.009030677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993087,0.000114710354,0.000129205,0.00014111874,0.00017515443,0.00013110794],"domain_scores_gemma":[0.9997552,0.000041950334,0.000071284834,0.000056918165,0.000028016142,0.000046592795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006752477,0.0005641916,0.00043656552,0.00046776567,0.00022633765,0.0007503479,0.00069671555,0.0006711957,0.0016058711],"category_scores_gemma":[0.0003089245,0.0004825626,0.00045974876,0.0002890305,0.00039079695,0.00033968373,0.000382291,0.0016737634,0.00094544387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022526202,0.00015352937,0.00017142064,0.000071120245,0.000013920877,0.000118064025,0.00010746162,0.0003058236,0.99222505,0.0007450215,0.000266726,0.0055966107],"study_design_scores_gemma":[0.0002037473,0.00081054243,0.0013786093,0.000026518555,0.000049137718,0.0008262889,0.000034506065,0.0033296112,0.9768579,0.00015324018,0.01631255,0.000017345445],"about_ca_topic_score_codex":0.0005812055,"about_ca_topic_score_gemma":0.0004556398,"teacher_disagreement_score":0.0016058711,"about_ca_system_score_codex":0.00041160005,"about_ca_system_score_gemma":0.00032020453,"threshold_uncertainty_score":0.0053721666},"labels":[],"label_agreement":null},{"id":"W1600048668","doi":"10.4049/jimmunol.171.7.3407","title":"Death Decoy Receptor TR6/DcR3 Inhibits T Cell Chemotaxis In Vitro and In Vivo","year":2003,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Université de Montréal","funders":"Canadian Institutes of Health Research; Heart And Stroke Foundation Of Quebec; Roche Organ Transplant Research Foundation; Kidney Foundation of Canada; Heart and Stroke Foundation of Canada","keywords":"Chemotaxis; In vivo; In vitro; Decoy; Cell biology; Receptor; Chemistry; Biology; Biochemistry; Genetics","score_opus":0.01840289684404731,"score_gpt":0.2821109137389473,"score_spread":0.2637080168949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1600048668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264246,0.0023051435,0.0015687081,0.00026712005,0.00009405949,0.000039750186,0.00039116511,0.00023136502,0.0024602094],"genre_scores_gemma":[0.99296826,0.0011410419,0.001580457,0.00012798313,0.000030288205,0.000053447253,0.0008405191,0.000029931283,0.003228047],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997732,0.00004531999,0.000013748302,0.000026963755,0.000046435096,0.00009429297],"domain_scores_gemma":[0.99990535,0.000012682263,0.00001921391,0.0000140821,0.000011700465,0.000037018268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018581409,0.0005143363,0.00041251056,0.0001899232,0.00014076667,0.00022267608,0.00024718384,0.00028512077,0.0013828487],"category_scores_gemma":[0.0001242846,0.00010948081,0.0002857467,0.00013980048,0.00019324246,0.00012515408,0.00012025487,0.0009977977,0.0006661008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073890545,0.00026183497,0.00009930555,0.0000623478,0.0000068904174,0.00006021107,0.000017033857,0.00017096946,0.99535596,0.00009098288,0.0002962797,0.0028393732],"study_design_scores_gemma":[0.00014988409,0.0028018623,0.0020042157,0.000006574767,0.000022712526,0.0002669446,0.00002010189,0.002497373,0.9899766,0.00003469316,0.002213657,0.0000054169896],"about_ca_topic_score_codex":0.0010949898,"about_ca_topic_score_gemma":0.0013544661,"teacher_disagreement_score":0.0013828487,"about_ca_system_score_codex":0.00026159754,"about_ca_system_score_gemma":0.0004079078,"threshold_uncertainty_score":0.0046260953},"labels":[],"label_agreement":null},{"id":"W1755519748","doi":"10.1093/cid/civ615","title":"T-Cell Therapy: Options for Infectious Diseases: Table 1.","year":2015,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; UBS Optimus Foundation; European and Developing Countries Clinical Trials Partnership; European Commission","keywords":"Medicine; Table (database); Infectious disease (medical specialty); Intensive care medicine; Virology; Internal medicine; Disease; Data mining","score_opus":0.16972029812464032,"score_gpt":0.4852632705340213,"score_spread":0.315542972409381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1755519748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017784302,0.99163425,0.00025993958,0.0007597146,0.00069960294,0.000029259132,0.00012617804,0.000035371864,0.006277804],"genre_scores_gemma":[0.0013200891,0.9909237,0.000610334,0.0009274223,0.00049375213,0.00002943878,0.00021019424,0.0000073571123,0.005477793],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986863,0.000023526192,0.000017032447,0.000021855207,0.00005420442,0.000014718904],"domain_scores_gemma":[0.9998173,0.000084417356,0.000026576883,0.000006743236,0.000038558075,0.000026396328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029934137,0.00077738374,0.0009219939,0.0019003574,0.00027694335,0.0010092658,0.00069846364,0.001076595,0.016875202],"category_scores_gemma":[0.00041852568,0.0001850016,0.00041595846,0.0013852695,0.0003276905,0.0010479256,0.0005714657,0.0017519189,0.009492144],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006215417,0.00008375373,0.00010026962,0.009328749,0.00003573315,0.00018976202,0.00004022719,0.00017916584,0.0021370952,0.0032422517,0.08096962,0.9036312],"study_design_scores_gemma":[0.000013791209,0.00006465175,0.00021438947,0.002030676,0.00002559338,0.00088054687,0.000019948993,0.00003872243,0.00026497967,0.001131991,0.99530715,0.0000075434796],"about_ca_topic_score_codex":0.00059864967,"about_ca_topic_score_gemma":0.0017018927,"teacher_disagreement_score":0.016875202,"about_ca_system_score_codex":0.0003852072,"about_ca_system_score_gemma":0.0006797648,"threshold_uncertainty_score":0.05645317},"labels":[],"label_agreement":null},{"id":"W1774891022","doi":"10.1080/19420862.2016.1227665","title":"Antibody Engineering &amp; Therapeutics 2016: The Antibody Society's annual meeting, December 11–15, 2016, San Diego, CA","year":2016,"lang":"en","type":"article","venue":"mAbs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viventia Bio (Canada); Simon Fraser University","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Bispecific antibody; Daratumumab; Antibody; Medicine; Session (web analytics); Immunology; Computer science; Monoclonal antibody; World Wide Web","score_opus":0.02193367853374353,"score_gpt":0.32755611131672957,"score_spread":0.30562243278298606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1774891022","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050348607,0.19469336,0.018992301,0.041009523,0.10165358,0.0009459744,0.0053854757,0.0031996453,0.62908524],"genre_scores_gemma":[0.0039459392,0.050836325,0.0040277243,0.001644785,0.005319408,0.00023187391,0.0027450195,0.00035872823,0.9308902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988599,0.0001013632,0.000056940236,0.00019432107,0.00063786434,0.00014962134],"domain_scores_gemma":[0.99913687,0.000045678593,0.00008598102,0.000028620883,0.000341302,0.00036153616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023715296,0.002359029,0.0010674467,0.001237793,0.0010512588,0.0045827804,0.0011999935,0.0018044689,0.1193144],"category_scores_gemma":[0.0011512713,0.0006712126,0.0006904405,0.001100025,0.00064575044,0.0020824573,0.0017783477,0.002949853,0.115889415],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000115322495,0.000092102746,0.00020850924,0.00033735277,0.000010936412,0.000054598273,0.000028164024,0.00020585768,0.0047634477,0.0016942217,0.8510018,0.14148776],"study_design_scores_gemma":[0.000009516594,0.000037450307,0.0002780838,0.00007585717,0.0000030009899,0.000052664625,0.000015780457,0.00013645062,0.00084874005,0.00040138487,0.99813616,0.000004855652],"about_ca_topic_score_codex":0.0014338107,"about_ca_topic_score_gemma":0.0043669078,"teacher_disagreement_score":0.1193144,"about_ca_system_score_codex":0.0019491906,"about_ca_system_score_gemma":0.0033372098,"threshold_uncertainty_score":0.39914644},"labels":[],"label_agreement":null},{"id":"W1848034928","doi":"10.1182/blood-2014-11-612903","title":"Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Chimeric antigen receptor; Antigen; Receptor; Adoptive cell transfer; Genetically engineered; Molecular biology; Cell biology; Chemistry; Biology; Virology; Immunology; T cell; Immune system; Gene; Biochemistry","score_opus":0.0622499523900424,"score_gpt":0.3304704845190863,"score_spread":0.2682205321290439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1848034928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937552,0.0011900224,0.0035980064,0.00007665739,0.000018186623,0.000056948575,0.00011347794,0.00018324971,0.0010081152],"genre_scores_gemma":[0.9960049,0.00062495185,0.0019558552,0.000036501595,0.0000149395355,0.000048939743,0.0002608354,0.000023528306,0.0010295125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988496,0.00002008029,0.000009036053,0.000019728255,0.000026623917,0.000039516213],"domain_scores_gemma":[0.9999316,0.000015398307,0.00001857518,0.000009651834,0.0000056854497,0.000019089084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016760464,0.000417272,0.00027813224,0.00022198012,0.00010607831,0.00029823242,0.00018539556,0.00027185716,0.00063316256],"category_scores_gemma":[0.00010516519,0.000107167405,0.00022927661,0.00018372676,0.00022249715,0.00021815697,0.00018452803,0.0007283565,0.00025614194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025899324,0.00015777799,0.00024766749,0.0000462229,0.000013681731,0.000060013208,0.000027494765,0.00026592036,0.9920169,0.00019008966,0.00013419925,0.006580962],"study_design_scores_gemma":[0.00014823381,0.0035829332,0.001828,0.000005180444,0.0000468301,0.0005611833,0.00001817393,0.0019349472,0.98757356,0.00006427255,0.004230481,0.0000061963256],"about_ca_topic_score_codex":0.00059809105,"about_ca_topic_score_gemma":0.00062056276,"teacher_disagreement_score":0.00063316256,"about_ca_system_score_codex":0.00024552416,"about_ca_system_score_gemma":0.00024263434,"threshold_uncertainty_score":0.0021181107},"labels":[],"label_agreement":null},{"id":"W1848220679","doi":"10.1186/1471-2407-3-21","title":"Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment","year":2003,"lang":"en","type":"article","venue":"BMC Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Allergy and Infectious Diseases; U.S. Department of Defense","keywords":"CTL*; Adoptive cell transfer; Cytotoxic T cell; CD8; Immunotherapy; Immunology; Cancer research; Ex vivo; Medicine; T cell; Cell therapy; In vivo; Biology; Immune system; In vitro; Stem cell; Cell biology","score_opus":0.13128983042894174,"score_gpt":0.34173204699587895,"score_spread":0.2104422165669372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1848220679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8800891,0.06580379,0.038566343,0.00395846,0.0004274345,0.00032370057,0.00020546904,0.0004553257,0.010170437],"genre_scores_gemma":[0.9819666,0.009835921,0.0057345424,0.00050945475,0.00019182143,0.00021820582,0.00015889744,0.000033049597,0.0013513968],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99948525,0.00017532143,0.00004617402,0.00007018734,0.00013210389,0.00009083057],"domain_scores_gemma":[0.99919707,0.0004884937,0.0001418656,0.00007248032,0.000049067294,0.00005102245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015502844,0.0004917488,0.0004515346,0.00027154552,0.00014148795,0.0007614016,0.00050987676,0.00088436744,0.0016451401],"category_scores_gemma":[0.00094287744,0.00011873067,0.00029507017,0.00014326151,0.00057543354,0.00066998135,0.00035713453,0.0016866424,0.00044753123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091752684,0.00093490887,0.0022116117,0.001694764,0.000114503804,0.0007659755,0.00019876128,0.0036254781,0.86320156,0.0070648473,0.0018757957,0.11739423],"study_design_scores_gemma":[0.00041237663,0.0165689,0.0064070676,0.0005235044,0.0005177102,0.014983649,0.00020022086,0.010105677,0.87233865,0.007020656,0.070885055,0.000036566144],"about_ca_topic_score_codex":0.00012466502,"about_ca_topic_score_gemma":0.000117015035,"teacher_disagreement_score":0.0016451401,"about_ca_system_score_codex":0.00046481632,"about_ca_system_score_gemma":0.00030220026,"threshold_uncertainty_score":0.008198798},"labels":[],"label_agreement":null},{"id":"W1877911682","doi":"10.1038/nm.3910","title":"NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","year":2015,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":848,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Cytotoxic T cell; Antigen; Medicine; Multiple myeloma; Immunology; T-cell receptor; Chimeric antigen receptor; Cancer research; Bone marrow; T cell; Immune system; Biology; In vitro","score_opus":0.0176906565937794,"score_gpt":0.2984853652944252,"score_spread":0.2807947087006458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1877911682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934987,0.0009567653,0.0029169384,0.00014187115,0.0000610922,0.00003442731,0.00021949619,0.0001503323,0.0020205344],"genre_scores_gemma":[0.9960991,0.0003610855,0.0008772976,0.000046410012,0.000020226018,0.000026732128,0.0001923636,0.000028623946,0.0023482079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997602,0.000029415687,0.000016248156,0.00004202815,0.000056501794,0.000095626034],"domain_scores_gemma":[0.999892,0.00002834448,0.000024960109,0.00001801513,0.000010885904,0.000025895168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020363014,0.0003482764,0.0003135623,0.00026839634,0.00022131382,0.0004685252,0.00026497123,0.0004861706,0.0011651802],"category_scores_gemma":[0.0001442373,0.00021566216,0.00022010358,0.0001738068,0.00026101308,0.00039107315,0.00026042966,0.0017402844,0.0004297251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002512022,0.0001656622,0.00011647602,0.000021892587,0.0000085897345,0.000042874843,0.000033644345,0.0003432578,0.99625057,0.0002738402,0.00015255754,0.0023394255],"study_design_scores_gemma":[0.00008139917,0.000636154,0.0013807133,0.000004126142,0.00002620684,0.00014625801,0.000032098575,0.002046412,0.9930623,0.00010153426,0.0024782699,0.000004438164],"about_ca_topic_score_codex":0.00054957607,"about_ca_topic_score_gemma":0.00092092634,"teacher_disagreement_score":0.0011651802,"about_ca_system_score_codex":0.0003676954,"about_ca_system_score_gemma":0.00023351535,"threshold_uncertainty_score":0.0038979053},"labels":[],"label_agreement":null},{"id":"W192314534","doi":"10.4049/jimmunol.186.supp.46.9","title":"A rapid method for the isolation of untouched naive CD8 T cells from peripheral blood mononuclear cells (46.9)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"CD8; Cytotoxic T cell; Peripheral blood mononuclear cell; Flow cytometry; Molecular biology; T cell; Biology; Antigen; Antigen-presenting cell; Chemistry; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.0440716771957844,"score_gpt":0.3086865900586058,"score_spread":0.2646149128628214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W192314534","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0332866,0.008767449,0.91261446,0.0007161802,0.0021266465,0.010168698,0.0100646205,0.008465499,0.013789865],"genre_scores_gemma":[0.059967905,0.00671598,0.8578372,0.0011971168,0.00067802955,0.016941281,0.024162084,0.001089194,0.031411145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982488,0.00033437347,0.00019528792,0.00032093152,0.00068246934,0.00021817128],"domain_scores_gemma":[0.9993068,0.00018790932,0.000055558186,0.0001587617,0.00019763433,0.00009341783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011769998,0.0024503598,0.0013376003,0.0019316983,0.00071591954,0.0008174311,0.0018290152,0.0009870529,0.0138323],"category_scores_gemma":[0.001019925,0.001056874,0.0010052732,0.0009861614,0.000451285,0.0006363404,0.0012544332,0.002328407,0.027810633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017037515,0.0002478932,0.00035343057,0.000499768,0.00003214139,0.0001523153,0.000058682574,0.000117202806,0.95612746,0.00042874872,0.009080515,0.032731462],"study_design_scores_gemma":[0.0003441647,0.0014125076,0.0077784304,0.00028290093,0.00025314724,0.0030780793,0.00007337507,0.003994435,0.78149396,0.0008567194,0.20025899,0.00017333089],"about_ca_topic_score_codex":0.00038760356,"about_ca_topic_score_gemma":0.00089229416,"teacher_disagreement_score":0.0138323,"about_ca_system_score_codex":0.0002576974,"about_ca_system_score_gemma":0.00056684815,"threshold_uncertainty_score":0.04627365},"labels":[],"label_agreement":null},{"id":"W1963522404","doi":"10.1182/blood-2011-10-384388","title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1445,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"CD19; Medicine; Chimeric antigen receptor; Cytokine; Cytokine release syndrome; Adoptive cell transfer; Immunology; Cell therapy; T cell; Ex vivo; Antigen; Cancer research; In vivo; Cell; Immune system; Biology","score_opus":0.05428349638532947,"score_gpt":0.3184524654414508,"score_spread":0.2641689690561213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963522404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967495,0.0008973131,0.00045490015,0.00024060807,0.00006232497,0.0007498222,0.00008857776,0.000034206383,0.00072266767],"genre_scores_gemma":[0.995672,0.0007260587,0.0010478913,0.00035458003,0.00007879116,0.0010736742,0.00027608743,0.000011770516,0.00075914385],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99942774,0.00028026378,0.000037086716,0.000074157055,0.000058693277,0.0001220119],"domain_scores_gemma":[0.9993486,0.00015107637,0.00011040594,0.0000818807,0.000042547505,0.0002655142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016709332,0.0009955988,0.001492646,0.00038290393,0.00045930545,0.00084571267,0.0007270167,0.0013251556,0.0009461116],"category_scores_gemma":[0.0009567952,0.0003508429,0.0005381507,0.00033630597,0.0010336092,0.0005743157,0.0003275893,0.0026718776,0.00028702916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3528416,0.1326993,0.010694955,0.0014704325,0.0009877714,0.0025216232,0.0009788645,0.00794664,0.25670248,0.0022381179,0.0039246418,0.22699358],"study_design_scores_gemma":[0.18227096,0.78299403,0.0057836715,0.00004252941,0.00020822267,0.0010562064,0.000058032823,0.00222621,0.021527687,0.00032717877,0.0034756067,0.00002966603],"about_ca_topic_score_codex":0.0003833731,"about_ca_topic_score_gemma":0.00066891586,"teacher_disagreement_score":0.0016709332,"about_ca_system_score_codex":0.0006570096,"about_ca_system_score_gemma":0.0010375046,"threshold_uncertainty_score":0.008836806},"labels":[],"label_agreement":null},{"id":"W1963617813","doi":"10.5015/utmj.v87i3.1265","title":"An Interview with Dr. Tak W. Mak","year":2010,"lang":"en","type":"article","venue":"University of Toronto Medical Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Library science; Carcinogenesis; Biology; Political science; Genetics; Cancer","score_opus":0.019287347984752172,"score_gpt":0.29556488616097604,"score_spread":0.27627753817622386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963617813","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003224905,0.0032447043,0.00017340096,0.97138155,0.014203502,0.000053652246,0.00016209827,0.0000467345,0.0075093503],"genre_scores_gemma":[0.019583432,0.004126314,0.0003857463,0.92243487,0.004987762,0.00022845395,0.00013130385,0.00007365745,0.048048474],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979221,0.001002395,0.000075192234,0.0001768804,0.0003583863,0.00046504728],"domain_scores_gemma":[0.9915815,0.0021725919,0.00030293522,0.00009783798,0.0017022411,0.004142818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004292863,0.0007844798,0.00090619136,0.0008215451,0.013715171,0.0033582635,0.0011763402,0.009788816,0.020892706],"category_scores_gemma":[0.014704995,0.00060711725,0.00050653087,0.0011427102,0.0022697796,0.0053091096,0.002935358,0.024659334,0.0084009655],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023168219,0.000039400133,0.0004947262,0.000042496646,0.0000025216048,0.0004596484,0.0061695194,0.00001858649,0.0000755604,0.0006662756,0.9863652,0.0056430046],"study_design_scores_gemma":[0.000023098997,0.000078706835,0.00184009,0.00021313765,0.0000050890885,0.0015588413,0.05394147,0.00008193931,0.00008598836,0.00083373894,0.94127923,0.00005865999],"about_ca_topic_score_codex":0.02102608,"about_ca_topic_score_gemma":0.040776663,"teacher_disagreement_score":0.02102608,"about_ca_system_score_codex":0.0052210963,"about_ca_system_score_gemma":0.00672163,"threshold_uncertainty_score":0.06989306},"labels":[],"label_agreement":null},{"id":"W1965468259","doi":"10.1016/j.clim.2009.03.323","title":"F.60. CD4+CD25+Foxp3+ T Cells are Cytotoxic for Human Neurons","year":2009,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cytotoxic T cell; FOXP3; IL-2 receptor; Cell biology; Chemistry; Immunology; Cancer research; Biology; In vitro; Immune system; Biochemistry","score_opus":0.12531112768824668,"score_gpt":0.45328004616357775,"score_spread":0.32796891847533105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965468259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8985679,0.0045358804,0.009106089,0.0022376145,0.00090949156,0.00020746829,0.0017356427,0.00086824765,0.08183159],"genre_scores_gemma":[0.9574922,0.0015711165,0.0027051882,0.00073991116,0.000282576,0.00014442236,0.0015187472,0.00009429711,0.035451535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997576,0.00002735902,0.000015867776,0.00005330432,0.000033804376,0.00011210748],"domain_scores_gemma":[0.9998549,0.00004338954,0.000017316015,0.000023346463,0.000019539002,0.000041522642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026294033,0.00049465697,0.0002578859,0.00044120374,0.00035730636,0.00044800094,0.00018904208,0.0009916958,0.01282198],"category_scores_gemma":[0.00033653545,0.00022629947,0.00041890307,0.00013173763,0.00033096012,0.00040691448,0.00028434925,0.0010441302,0.0024853733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002101798,0.0005865685,0.00095460535,0.00015589941,0.000038547572,0.00092580455,0.00007630062,0.00026619548,0.95862836,0.0022024522,0.006296453,0.02776704],"study_design_scores_gemma":[0.0008481236,0.0035435709,0.015952192,0.00007923839,0.00012342392,0.0050740144,0.00013968993,0.0024596096,0.9254769,0.002982387,0.043295357,0.000025581283],"about_ca_topic_score_codex":0.00074605667,"about_ca_topic_score_gemma":0.00050988916,"teacher_disagreement_score":0.01282198,"about_ca_system_score_codex":0.00027020465,"about_ca_system_score_gemma":0.00024651992,"threshold_uncertainty_score":0.042893767},"labels":[],"label_agreement":null},{"id":"W1968020819","doi":"10.1016/j.pcl.2014.10.001","title":"Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies","year":2014,"lang":"en","type":"review","venue":"Pediatric Clinics of North America","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Hematopoietic cell; Transplantation; Malignancy; Immunology; Hematopoietic stem cell transplantation; Cancer; Leukemia; Oncology; Haematopoiesis; Immune system; Cancer research; Stem cell; Internal medicine","score_opus":0.044349233649137905,"score_gpt":0.346508210763165,"score_spread":0.3021589771140271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968020819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056275327,0.99922895,0.000057351008,0.00015170245,0.00009294891,0.0000026928074,0.0000069700186,0.000002701566,0.00040038888],"genre_scores_gemma":[0.00038873483,0.99900526,0.000105912986,0.00014184717,0.00011664536,0.0000027767267,0.00001200596,6.075734e-7,0.00022634948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998098,0.000036352427,0.000026096868,0.000030026085,0.00007728059,0.000020463907],"domain_scores_gemma":[0.9995023,0.0002940985,0.00006544439,0.000011252153,0.00009290813,0.0000340177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078359107,0.0007219507,0.0014921174,0.002580693,0.00030265065,0.000978944,0.00090186426,0.0010689384,0.0035222918],"category_scores_gemma":[0.00092978176,0.00027759446,0.00054803974,0.002561631,0.00066135573,0.0012673349,0.00079410884,0.0022097435,0.0012672233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007211681,0.00008121119,0.00017171649,0.011230613,0.00008254131,0.00014378788,0.000037398015,0.0003218662,0.0009779749,0.0037346692,0.020976175,0.96217],"study_design_scores_gemma":[0.00004162995,0.00012711836,0.0007482269,0.004458962,0.00017862002,0.0011409593,0.00006199503,0.00011103332,0.0004474222,0.0019619116,0.99070346,0.000018721546],"about_ca_topic_score_codex":0.0014559071,"about_ca_topic_score_gemma":0.0036499128,"teacher_disagreement_score":0.0035222918,"about_ca_system_score_codex":0.0006251956,"about_ca_system_score_gemma":0.0012144702,"threshold_uncertainty_score":0.011783302},"labels":[],"label_agreement":null},{"id":"W1968504589","doi":"10.1371/journal.pone.0041074","title":"Stimulation of Wnt/ß-Catenin Pathway in Human CD8+ T Lymphocytes from Blood and Lung Tumors Leads to a Shared Young/Memory Phenotype","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada","keywords":"Wnt signaling pathway; Cytotoxic T cell; Biology; CD8; Stem cell; T cell; Cell biology; Adoptive cell transfer; Cancer research; Immunology; Molecular biology; Signal transduction; Antigen; Immune system; Biochemistry; In vitro","score_opus":0.05546506743339357,"score_gpt":0.28910696466842933,"score_spread":0.23364189723503576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968504589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633247,0.0011394423,0.001133798,0.000048701866,0.000017586308,0.000028693164,0.00018916624,0.00004630972,0.0010638],"genre_scores_gemma":[0.9950335,0.00046000833,0.00091063074,0.000041612842,0.000010060181,0.00004840903,0.000722726,0.000009537068,0.0027634925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990785,0.000015285374,0.000010413286,0.000024709216,0.00001907211,0.000022687604],"domain_scores_gemma":[0.9999634,0.0000068496956,0.00000960531,0.0000051955312,0.000005035033,0.000009860937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008021847,0.00019415132,0.00012639417,0.00010549162,0.00008126901,0.00021593481,0.00007136421,0.00018406796,0.0016174759],"category_scores_gemma":[0.000077981385,0.00009956716,0.0001802073,0.00010489277,0.00006785833,0.000110796864,0.00011583857,0.00043502884,0.0004743243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013446329,0.000034946795,0.00029399162,0.000030304445,0.0000025544578,0.000049142596,0.000019286354,0.000030300835,0.9975442,0.00003590665,0.000044585453,0.0017802794],"study_design_scores_gemma":[0.000037364407,0.001150542,0.0042399103,0.0000074352965,0.000020894131,0.0004924615,0.000031300726,0.00044839576,0.9908212,0.00004133836,0.002706816,0.0000024907595],"about_ca_topic_score_codex":0.00018217387,"about_ca_topic_score_gemma":0.0003883653,"teacher_disagreement_score":0.0016174759,"about_ca_system_score_codex":0.00010516229,"about_ca_system_score_gemma":0.000115843315,"threshold_uncertainty_score":0.0054109693},"labels":[],"label_agreement":null},{"id":"W1968805055","doi":"10.1038/cgt.2008.96","title":"Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells","year":2008,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"National Institutes of Health; Prostate Cancer Foundation","keywords":"LNCaP; Fas ligand; Cancer research; Cytotoxic T cell; Prostate cancer; Transduction (biophysics); Biology; Cancer cell; Apoptosis; Immunology; Cancer; In vitro; Programmed cell death","score_opus":0.030397075779760866,"score_gpt":0.3157771978177423,"score_spread":0.2853801220379814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968805055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855058,0.0026237215,0.0059746588,0.00022908098,0.000113733644,0.00010824539,0.0004904153,0.0003276393,0.0046266736],"genre_scores_gemma":[0.9905248,0.00067692524,0.0021168536,0.0000652331,0.00002379078,0.00004574244,0.00034593156,0.00004444135,0.006156334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99954885,0.000060513798,0.000028561397,0.00006351094,0.00012828829,0.0001701748],"domain_scores_gemma":[0.9997744,0.000077519304,0.000036182082,0.000036430578,0.000025235375,0.000050139748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036183075,0.0004610933,0.0004265434,0.0006053454,0.00029807494,0.0007977244,0.0003755209,0.000585143,0.002215231],"category_scores_gemma":[0.00023443135,0.00026810914,0.00045453815,0.0003246342,0.00037142457,0.00040089551,0.00034448222,0.0016626455,0.00077929295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019228112,0.00015438056,0.00011619642,0.00003531655,0.000012666468,0.000059068443,0.00007633454,0.00020324395,0.99550015,0.00062698784,0.00013145262,0.0028919592],"study_design_scores_gemma":[0.000049104066,0.00028176737,0.0004847782,0.0000039831893,0.000019205274,0.00014746266,0.000026169959,0.0009920473,0.9960674,0.00005979684,0.001864613,0.0000036014233],"about_ca_topic_score_codex":0.0014461213,"about_ca_topic_score_gemma":0.0016100722,"teacher_disagreement_score":0.002215231,"about_ca_system_score_codex":0.0005686778,"about_ca_system_score_gemma":0.0005552473,"threshold_uncertainty_score":0.007410705},"labels":[],"label_agreement":null},{"id":"W1969405636","doi":"10.1007/s10549-009-0559-y","title":"Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model","year":2009,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Adoptive cell transfer; CD8; Stroma; Pathology; Cytotoxic T cell; Infiltration (HVAC); Ovalbumin; Lymph node; Immunotherapy; Stromal cell; Cancer research; T cell; Breast cancer; Biology; Medicine; Immunology; Cancer; Immune system; Immunohistochemistry; Internal medicine; In vitro","score_opus":0.04772655796454484,"score_gpt":0.34449636715946963,"score_spread":0.2967698091949248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969405636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99843305,0.00026915534,0.0004784543,0.000030974992,0.0000086209075,0.000013111736,0.00015113286,0.000024992953,0.00059042015],"genre_scores_gemma":[0.9978683,0.00015302139,0.00027155047,0.000014929024,0.000008994921,0.00002616789,0.0002515921,0.00000818402,0.001397107],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967456,0.000053783035,0.00002594114,0.000038451522,0.00010367079,0.0001035305],"domain_scores_gemma":[0.99907875,0.00019066957,0.00031008257,0.00007542865,0.00007882917,0.00026612205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026987022,0.00028721697,0.00030847627,0.00070025417,0.00017896653,0.00041807888,0.00017311476,0.00042311812,0.0012617987],"category_scores_gemma":[0.00033496125,0.0002649073,0.00021652425,0.00022320154,0.00028972686,0.00032802744,0.00029700607,0.0009708104,0.0002964462],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015786663,0.0003138659,0.002993426,0.000020345231,0.000014302145,0.00008500714,0.000042330776,0.00024012,0.99357283,0.00006623458,0.0000490145,0.0010239606],"study_design_scores_gemma":[0.00007418404,0.0038940343,0.07167591,0.0000083845325,0.00007729768,0.000676391,0.000145287,0.004051832,0.91846347,0.00015575356,0.000755574,0.00002183244],"about_ca_topic_score_codex":0.00068590563,"about_ca_topic_score_gemma":0.0008445067,"teacher_disagreement_score":0.0012617987,"about_ca_system_score_codex":0.00029072518,"about_ca_system_score_gemma":0.00015395033,"threshold_uncertainty_score":0.0042211413},"labels":[],"label_agreement":null},{"id":"W1972406166","doi":"10.4161/onci.27156","title":"An allogeneic NK cell line engineered to express chimeric antigen receptors","year":2013,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Labex Immuno-Oncology; Institut National Du Cancer; Ligue Contre le Cancer; Agence Nationale de la Recherche","keywords":"Cytotoxic T cell; Chimeric antigen receptor; Antigen; Interleukin 21; NK-92; Biology; Antibody; Antibody-dependent cell-mediated cytotoxicity; Adoptive cell transfer; Immunology; Natural killer T cell; Immunotherapy; Cancer research; T cell; Monoclonal antibody; Immune system; CD8; In vitro","score_opus":0.019229888736515183,"score_gpt":0.29912613956505857,"score_spread":0.2798962508285434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972406166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597417,0.0025695101,0.023395907,0.00037431513,0.00048160445,0.00023801679,0.0021838213,0.0005785959,0.010436626],"genre_scores_gemma":[0.98415965,0.0007757146,0.0076487274,0.00010404534,0.000029691631,0.00012942393,0.0016872636,0.00006480427,0.0054007494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967504,0.000037469938,0.000048324706,0.00008230083,0.00010496864,0.000051893665],"domain_scores_gemma":[0.99989223,0.000019941315,0.000018523539,0.000029269266,0.000017094964,0.000023012193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015695796,0.0004201911,0.0005487415,0.00023658495,0.00014144507,0.00047137047,0.00038686563,0.00047785704,0.0018997832],"category_scores_gemma":[0.00016158633,0.00015376724,0.0002608133,0.00021800913,0.00019398791,0.00028058336,0.000262678,0.0013763241,0.0014416291],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021101326,0.00014301052,0.00027435625,0.000047493177,0.0000105259805,0.00021280115,0.00003073434,0.00045311527,0.99491864,0.0005890488,0.00019620695,0.0029129873],"study_design_scores_gemma":[0.00016099209,0.0006953564,0.0010471699,0.000013715198,0.000056270826,0.0017705313,0.00002887117,0.0064544673,0.97301775,0.00015795817,0.016583344,0.000013518527],"about_ca_topic_score_codex":0.0003568398,"about_ca_topic_score_gemma":0.0002847424,"teacher_disagreement_score":0.0018997832,"about_ca_system_score_codex":0.00029824578,"about_ca_system_score_gemma":0.0002190075,"threshold_uncertainty_score":0.006355405},"labels":[],"label_agreement":null},{"id":"W1976188450","doi":"10.1016/s0041-1345(00)02125-4","title":"Generation of partial agonist ligands of the T-cell receptor by engineering of antibodies against CD3","year":2001,"lang":"en","type":"article","venue":"Transplantation Proceedings","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Agonist; Antibody; Receptor; Partial agonist; CD3; Chemistry; Immunology; Biology; Medicine; Cell biology; Biochemistry; Antigen; CD8","score_opus":0.027627751245534706,"score_gpt":0.27203847230993816,"score_spread":0.24441072106440345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976188450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512826,0.0009812225,0.04266333,0.00019985017,0.000074988704,0.00007434761,0.00036907147,0.00025752,0.004097065],"genre_scores_gemma":[0.98497427,0.0004552016,0.009864933,0.000069409594,0.000008919021,0.000045530556,0.00043233903,0.00007370772,0.0040758112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988186,0.000023754752,0.000009506492,0.00001819656,0.000025981237,0.000040686846],"domain_scores_gemma":[0.9999143,0.000023299426,0.000019652856,0.000011566305,0.000012077893,0.000019097384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016693825,0.00036426366,0.00022675694,0.00017636921,0.00019972379,0.00040623255,0.0002762327,0.00031649633,0.0017568434],"category_scores_gemma":[0.00017355986,0.00019555158,0.00022836555,0.00014992258,0.00013519295,0.00017413557,0.00030973964,0.0008610869,0.00062248885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006800294,0.000019454761,0.00006469897,0.000019006231,0.000005249603,0.00004009301,0.000016440492,0.0003320759,0.99706525,0.0005573941,0.0000742488,0.0017381704],"study_design_scores_gemma":[0.00001547002,0.00006884924,0.00021138771,0.000002286363,0.000013258305,0.00015365193,0.000010867124,0.0013161341,0.9948655,0.00007090156,0.003268708,0.0000031211769],"about_ca_topic_score_codex":0.00043058378,"about_ca_topic_score_gemma":0.00068495685,"teacher_disagreement_score":0.0017568434,"about_ca_system_score_codex":0.00033670265,"about_ca_system_score_gemma":0.0002127443,"threshold_uncertainty_score":0.0058772564},"labels":[],"label_agreement":null},{"id":"W1979479636","doi":"10.1007/s00262-015-1662-z","title":"The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Elsa U. Pardee Foundation","keywords":"Radiation therapy; Cytotoxic T cell; Glioma; Immunotherapy; Temozolomide; Medicine; Cell therapy; Cancer research; CD8; Immune system; Parenchyma; Immunology; Cell; Pathology; Biology; Internal medicine; In vitro","score_opus":0.025060749338043902,"score_gpt":0.30951494330881996,"score_spread":0.28445419397077604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979479636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699594,0.0057726456,0.00094222155,0.0005079826,0.00010234513,0.00003947631,0.00008778471,0.000035369732,0.005516256],"genre_scores_gemma":[0.99861836,0.0006042193,0.00010677745,0.0001028943,0.000054238968,0.000011903282,0.0000674823,0.0000038124394,0.00043027784],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99983895,0.00006989932,0.000008538509,0.000020004023,0.000028135606,0.00003437126],"domain_scores_gemma":[0.99973613,0.000088779554,0.00006805193,0.000046596037,0.000021074125,0.000039303784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030957608,0.00018451466,0.00033465328,0.00012561918,0.00022642444,0.00036138072,0.00018866626,0.0002484124,0.001682269],"category_scores_gemma":[0.00079059484,0.000056717803,0.00028720163,0.00014354497,0.00027928015,0.00025201414,0.00020151018,0.00064760534,0.00030298613],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0515623,0.002405794,0.091431156,0.0007538238,0.00068518193,0.0017745913,0.00037054555,0.0031372982,0.095211685,0.0024027582,0.0030164514,0.74724853],"study_design_scores_gemma":[0.007438124,0.21641555,0.4757232,0.0004354643,0.0025219258,0.02696895,0.0011560892,0.009509061,0.17288987,0.005563475,0.081301965,0.00007633644],"about_ca_topic_score_codex":0.00039998637,"about_ca_topic_score_gemma":0.0006973669,"teacher_disagreement_score":0.001682269,"about_ca_system_score_codex":0.00035766163,"about_ca_system_score_gemma":0.000501967,"threshold_uncertainty_score":0.005627811},"labels":[],"label_agreement":null},{"id":"W1979942820","doi":"10.1002/ijc.10325","title":"Adenosine acts through an A<sub>3</sub> receptor to prevent the induction of murine anti‐CD3‐activated killer T cells","year":2002,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Faculty of Medicine, Dalhousie University; Killam Trusts; Dalhousie University; Natural Sciences and Engineering Research Council of Canada; Dalhousie Medical Research Foundation","keywords":"Adenosine; Cytotoxic T cell; Biology; Adenosine A2B receptor; Adenosine receptor; Adenosine deaminase; Adenosine A3 receptor; T cell; Molecular biology; Receptor; Endocrinology; Biochemistry; Immunology; Immune system; Agonist; In vitro","score_opus":0.041876414396230126,"score_gpt":0.3541307143807335,"score_spread":0.3122542999845034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979942820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98407227,0.004932124,0.005759755,0.0001662004,0.00012307719,0.00008258584,0.00052788114,0.00025626767,0.0040798187],"genre_scores_gemma":[0.9924551,0.0013420822,0.0026827403,0.00010365527,0.000043809985,0.00006164714,0.00059237157,0.000028418423,0.002690192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987626,0.00002289288,0.000013282859,0.000018805793,0.000028308485,0.000040523126],"domain_scores_gemma":[0.9999306,0.000010243731,0.000028301978,0.000009748235,0.000008400042,0.00001278781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009747939,0.00036917112,0.0002114083,0.00009215729,0.00011954351,0.0002375338,0.000164639,0.0001846972,0.0012384533],"category_scores_gemma":[0.00007292176,0.0000973097,0.00021583293,0.0000696701,0.000117585485,0.00013490205,0.000112719965,0.0004191825,0.00080454187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011596978,0.000015655041,0.000046345616,0.000027377264,0.0000041642775,0.00003964468,0.0000045837814,0.0000465338,0.9985588,0.00005865517,0.000059989645,0.0010223173],"study_design_scores_gemma":[0.00004279519,0.000634585,0.0017229209,0.000006069955,0.000021998005,0.0003030025,0.000008645842,0.0007245239,0.99270356,0.0000384291,0.003789902,0.0000035515268],"about_ca_topic_score_codex":0.00037619311,"about_ca_topic_score_gemma":0.0006398887,"teacher_disagreement_score":0.0012384533,"about_ca_system_score_codex":0.00018819411,"about_ca_system_score_gemma":0.0001624361,"threshold_uncertainty_score":0.0041430593},"labels":[],"label_agreement":null},{"id":"W1981955743","doi":"10.1158/1538-7445.am2013-3972","title":"Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD28; Electroporation; Cancer research; Ex vivo; Transduction (biophysics); Genetic enhancement; CD19; Viral vector; T cell; Antigen; Medicine; Immunology; Biology; In vivo; Immune system; Gene; Recombinant DNA","score_opus":0.07944169261502196,"score_gpt":0.39057946450735204,"score_spread":0.31113777189233005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981955743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973283,0.00065142155,0.0006012427,0.000048708207,0.000038230013,0.00004530014,0.00035378456,0.00005530143,0.000877601],"genre_scores_gemma":[0.9944259,0.00052871124,0.0014654357,0.00004150672,0.000017705444,0.00008518762,0.0008193133,0.000050040548,0.0025662712],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997464,0.00006543297,0.000020955658,0.00003452521,0.00006115325,0.00007150283],"domain_scores_gemma":[0.9997228,0.00009451184,0.000049835788,0.000030481442,0.000025654364,0.00007674538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041352736,0.00052726455,0.00041240107,0.00030249718,0.000133121,0.00027985562,0.000292152,0.0004407161,0.0016879259],"category_scores_gemma":[0.00020931293,0.00017534303,0.0002997538,0.00023119169,0.00022369987,0.0002707222,0.00012719468,0.0007500881,0.00040726454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017781478,0.0007632956,0.00023778313,0.000041475505,0.000012294454,0.000032954642,0.000037079757,0.00045011984,0.9932025,0.00006074469,0.00021526807,0.003168377],"study_design_scores_gemma":[0.0000750958,0.0063359225,0.0012989264,0.0000035521612,0.000023396935,0.00004635612,0.000011395711,0.0008847364,0.99067324,0.000009515328,0.0006327248,0.000005090857],"about_ca_topic_score_codex":0.001579533,"about_ca_topic_score_gemma":0.0014798745,"teacher_disagreement_score":0.0016879259,"about_ca_system_score_codex":0.00034915088,"about_ca_system_score_gemma":0.000308326,"threshold_uncertainty_score":0.005646646},"labels":[],"label_agreement":null},{"id":"W1983098174","doi":"10.1038/sj.cgt.7700595","title":"Intramuscular gene transfer of soluble B7.1/IgG1 fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination","year":2003,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada","keywords":"DNA vaccination; Electroporation; Immune system; Adjuvant; Fusion protein; Antigen; CTL*; Molecular biology; Biology; Cytotoxic T cell; Carcinoembryonic antigen; Antibody; Adoptive cell transfer; Genetic enhancement; Immunoglobulin G; Fusion gene; Recombinant DNA; Immunology; T cell; Gene; Cancer; In vitro; CD8; Biochemistry; Immunization","score_opus":0.050493848064465066,"score_gpt":0.34780160852314007,"score_spread":0.297307760458675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983098174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871875,0.0017697058,0.0074912836,0.00021341881,0.00012029781,0.00012288886,0.00025552852,0.0002411974,0.002598263],"genre_scores_gemma":[0.9911731,0.0006469,0.0038331943,0.000081560276,0.00005297651,0.00007072145,0.00040939727,0.000047863574,0.003684342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996654,0.000045603054,0.000016903554,0.000054518845,0.00006296265,0.00015468536],"domain_scores_gemma":[0.99978846,0.0000738027,0.00003647121,0.000025271951,0.000023888333,0.00005211436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046249776,0.0006070296,0.0005969094,0.00083224475,0.00022350051,0.00042781775,0.00036726976,0.0007358368,0.0012564803],"category_scores_gemma":[0.00021351731,0.0002979539,0.00039426392,0.00029087378,0.00045327796,0.00031447544,0.00026780128,0.0013929603,0.0007059853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001648358,0.0000924199,0.00005182883,0.000027202643,0.0000041760386,0.0000242407,0.00001178675,0.000115283634,0.99805754,0.00013884829,0.000048165373,0.001263602],"study_design_scores_gemma":[0.00006488779,0.00050665316,0.0004296528,0.0000049382934,0.000022252298,0.000069592934,0.000009219684,0.0010583433,0.9970156,0.000052498097,0.00076328905,0.0000030102117],"about_ca_topic_score_codex":0.00093188183,"about_ca_topic_score_gemma":0.0010022441,"teacher_disagreement_score":0.0012564803,"about_ca_system_score_codex":0.0005757984,"about_ca_system_score_gemma":0.0005126658,"threshold_uncertainty_score":0.0042033195},"labels":[],"label_agreement":null},{"id":"W1984150894","doi":"10.1371/journal.pone.0016700","title":"Anti-Leukemia Activity of In Vitro-Expanded Human Gamma Delta T Cells in a Xenogeneic Ph+ Leukemia Model","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"University of Toronto","keywords":"Bone marrow; Clonogenic assay; Cytotoxic T cell; Leukemia; Spleen; In vitro; Immunology; Molecular biology; Biology; Chemistry; Cancer research","score_opus":0.11613691442097497,"score_gpt":0.30059894980939245,"score_spread":0.1844620353884175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984150894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956993,0.0005054933,0.0022024615,0.00004348228,0.000016593101,0.00003530125,0.0002553381,0.00006636487,0.0011755432],"genre_scores_gemma":[0.99511623,0.00062207656,0.0017629645,0.000030034731,0.000012356347,0.000043272452,0.00043551787,0.000018626522,0.0019588384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998697,0.000035642403,0.000012233115,0.000027788526,0.000024739067,0.000029817116],"domain_scores_gemma":[0.99994767,0.000011585856,0.00001395116,0.0000101315145,0.0000050327217,0.000011709152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017983122,0.0003922313,0.00028467286,0.00015975845,0.000069354246,0.00022384473,0.00019401807,0.00021021575,0.00086852786],"category_scores_gemma":[0.00006493689,0.000090991874,0.00016625455,0.000105608065,0.0001392518,0.00016285578,0.00015391877,0.0005266399,0.00022827281],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019582553,0.00012490893,0.00013903588,0.000031590713,0.000004066901,0.000043467364,0.00001923665,0.0003051629,0.9974654,0.00008267605,0.000050406004,0.0015382892],"study_design_scores_gemma":[0.000035369587,0.0010953941,0.0007639955,0.0000031600541,0.000012712594,0.00013460363,0.0000067861824,0.0007898927,0.9959394,0.00001880334,0.001198326,0.0000016019322],"about_ca_topic_score_codex":0.00055547623,"about_ca_topic_score_gemma":0.00046243911,"teacher_disagreement_score":0.00086852786,"about_ca_system_score_codex":0.00017542497,"about_ca_system_score_gemma":0.00014690314,"threshold_uncertainty_score":0.0029055476},"labels":[],"label_agreement":null},{"id":"W1984454936","doi":"10.4161/onci.1.2.18231","title":"Anti-leukemia activity of human gamma delta T cells","year":2012,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; University of Toronto; Western University","funders":"","keywords":"Leukemia; Chronic lymphocytic leukemia; Cancer research; Adoptive cell transfer; Medicine; Immunology; T cell; Immune system","score_opus":0.040782841344297514,"score_gpt":0.3459616183447385,"score_spread":0.305178777000441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984454936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9570371,0.021477751,0.005052497,0.0010931358,0.00065622776,0.00011735336,0.00040876842,0.0002481037,0.013909117],"genre_scores_gemma":[0.97312474,0.012567032,0.0031418267,0.0007840052,0.00027040727,0.00006846192,0.00081460306,0.00003691719,0.009191891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998956,0.000026691137,0.000008700868,0.000018735178,0.000027490489,0.00002278294],"domain_scores_gemma":[0.99992216,0.000030349987,0.000008230786,0.000014576074,0.000012811261,0.000011898007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022178868,0.00027154552,0.00017048432,0.0001858031,0.000078831865,0.00041649307,0.00013624158,0.00025646106,0.0015759725],"category_scores_gemma":[0.00016187083,0.000057497262,0.00015619623,0.00011912249,0.00012566638,0.00014647779,0.00013520842,0.0005542059,0.00048390485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064767175,0.00018975555,0.0006347459,0.00018110625,0.000022882396,0.00019159653,0.00006262841,0.00037278968,0.92658436,0.00091756164,0.0014597247,0.068735175],"study_design_scores_gemma":[0.00015846621,0.0011661211,0.00140706,0.000021282787,0.000050038103,0.00069078105,0.000030071873,0.00038372076,0.9517886,0.00013804344,0.04415948,0.0000062777967],"about_ca_topic_score_codex":0.00027133437,"about_ca_topic_score_gemma":0.00048032886,"teacher_disagreement_score":0.0015759725,"about_ca_system_score_codex":0.00018377652,"about_ca_system_score_gemma":0.0002160289,"threshold_uncertainty_score":0.00527215},"labels":[],"label_agreement":null},{"id":"W1988486780","doi":"10.1038/cgt.2011.18","title":"Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice","year":2011,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"","keywords":"Cytotoxic T cell; Immunology; CTL*; Immunotherapy; CD8; HER2/neu; Cancer research; Antibody; Immune system; Antigen; Adjuvant; Biology; Medicine; Cancer; Breast cancer; Internal medicine","score_opus":0.03215954182566027,"score_gpt":0.3251027456786804,"score_spread":0.29294320385302014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988486780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688727,0.0005999138,0.0011028611,0.00007897767,0.00008640464,0.00005585399,0.00018712785,0.000112506685,0.00088909385],"genre_scores_gemma":[0.99519277,0.00039975854,0.0013476047,0.000054754677,0.000044636643,0.000055579076,0.0002938224,0.000032178606,0.002578881],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971443,0.00006178663,0.000024884948,0.000041784526,0.000044875345,0.000112130976],"domain_scores_gemma":[0.9996203,0.00013124316,0.0000606117,0.000044647535,0.0000215537,0.00012157541],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004044462,0.0006846038,0.0005976181,0.00054094143,0.0001624547,0.00036984694,0.00041742122,0.0005318517,0.0014804525],"category_scores_gemma":[0.00033745123,0.0002631086,0.000401749,0.00020013403,0.00034765986,0.0003891159,0.00020412644,0.0013170475,0.00029162684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024446463,0.0008721582,0.0001334489,0.000043526907,0.000011070601,0.000075044394,0.000041475636,0.00031621728,0.9930768,0.0002844557,0.000071532515,0.0026296088],"study_design_scores_gemma":[0.00037328465,0.0035463425,0.00080399244,0.000008692389,0.000046567915,0.00010348535,0.000017475078,0.0019564081,0.9923109,0.00010021873,0.00072578544,0.0000068016598],"about_ca_topic_score_codex":0.00097164046,"about_ca_topic_score_gemma":0.0012551246,"teacher_disagreement_score":0.0014804525,"about_ca_system_score_codex":0.00032228068,"about_ca_system_score_gemma":0.0005951934,"threshold_uncertainty_score":0.0049526095},"labels":[],"label_agreement":null},{"id":"W1989273697","doi":"10.1172/jci32103","title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":835,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; School of Medicine, Stanford University; National Heart, Lung, and Blood Institute; School of Medicine, Oregon Health and Science University; National Cancer Institute; National Institutes of Health; National Center for Research Resources; Cancer Research Institute","keywords":"Adoptive cell transfer; Cytotoxic T cell; Biology; CD8; Effector; Immunology; T cell; Immunotherapy; Antigen; Cell biology; Immune system; In vitro; Genetics","score_opus":0.07917265780015434,"score_gpt":0.3354791466112934,"score_spread":0.25630648881113904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989273697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97847855,0.0036406976,0.009754099,0.00017827736,0.00005068616,0.00025279258,0.00028131533,0.0004153759,0.0069481744],"genre_scores_gemma":[0.98848236,0.0014239431,0.004903432,0.00018334297,0.000049148086,0.00027821196,0.000578579,0.00009474689,0.0040063336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975616,0.00004994841,0.000016055224,0.000071273345,0.000045634777,0.00006090161],"domain_scores_gemma":[0.99976045,0.00004220549,0.000040959625,0.0000869851,0.000028028555,0.000041310966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042948985,0.00042306908,0.00035920477,0.0005848957,0.0005870761,0.00059383974,0.00039482996,0.0004556172,0.0018402982],"category_scores_gemma":[0.00045952047,0.00027994957,0.00019296848,0.0001983725,0.0005313896,0.00030742638,0.00032729743,0.0011675952,0.0007054214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004774024,0.00029548464,0.0011758874,0.00006777641,0.000018623003,0.0003592419,0.00028157557,0.00014119971,0.9800284,0.0006529295,0.0003346977,0.016166912],"study_design_scores_gemma":[0.00061022333,0.00534559,0.014426242,0.00014521717,0.0001688309,0.0060637454,0.0003326036,0.002870362,0.9279571,0.0028458987,0.039204605,0.000029687471],"about_ca_topic_score_codex":0.0005058554,"about_ca_topic_score_gemma":0.00062195037,"teacher_disagreement_score":0.0018402982,"about_ca_system_score_codex":0.00031307276,"about_ca_system_score_gemma":0.00022581709,"threshold_uncertainty_score":0.006156385},"labels":[],"label_agreement":null},{"id":"W1995172908","doi":"10.1097/01.tp.0000332697.73980.0c","title":"ADOPTIVE TRANSFER OF CD4+CD25+ REGULATORY CELLS COMBINED WITH LOW-DOSE SIROLIMUS PRESERVES SUPPRESSIVE FUNCTION OF REGULATORY T CELLS AND DELAYED ACUTE REJECTION OF RENAL ALLOGRAFTS IN CYNOMOLGUS MONKEYS","year":2008,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Sirolimus; Adoptive cell transfer; IL-2 receptor; Function (biology); Regulatory T cell; Medicine; Immunology; FOXP3; Cell biology; Internal medicine; Biology; Immune system; T cell","score_opus":0.011629538001184764,"score_gpt":0.23509310440200626,"score_spread":0.2234635664008215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995172908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729,0.0007917941,0.00066764577,0.00008439322,0.000043062337,0.000025085625,0.000099386314,0.00010087521,0.0008977804],"genre_scores_gemma":[0.99612623,0.00055577257,0.00068263075,0.00005856163,0.000036456917,0.00003505807,0.00022174799,0.000020628964,0.0022629234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976426,0.00003696881,0.00001699739,0.00004402968,0.000040840856,0.00009678464],"domain_scores_gemma":[0.99992144,0.000009161833,0.000019176217,0.0000136469125,0.000005451198,0.000031026022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021962836,0.0004818694,0.0005316074,0.0005036629,0.00022377902,0.00032309286,0.00034938613,0.00031004718,0.00093994924],"category_scores_gemma":[0.00014393957,0.00017018612,0.0002604031,0.00015877893,0.0003055924,0.00027265714,0.000115860435,0.0007935593,0.0003199656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012597176,0.00032544343,0.00032924733,0.000031758227,0.000012884752,0.000089712805,0.0000243789,0.00013839368,0.9913878,0.00016951772,0.00017061182,0.006060497],"study_design_scores_gemma":[0.0004959221,0.0043256287,0.0076101846,0.000013124126,0.00016771619,0.00040816006,0.000051384548,0.0022900389,0.9813394,0.00019588105,0.0030826866,0.000019825098],"about_ca_topic_score_codex":0.0011295204,"about_ca_topic_score_gemma":0.0014985501,"teacher_disagreement_score":0.0011295204,"about_ca_system_score_codex":0.00026742468,"about_ca_system_score_gemma":0.00043087592,"threshold_uncertainty_score":0.0031443834},"labels":[],"label_agreement":null},{"id":"W1995574992","doi":"10.1016/s0008-8749(02)00508-7","title":"Synergistic effect of adoptive T-cell therapy and intratumoral interferon γ-inducible protein-10 transgene expression in treatment of established tumors","year":2002,"lang":"en","type":"article","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Adoptive cell transfer; Biology; Cancer research; Cytotoxic T cell; Immunotherapy; Cell therapy; CD8; T cell; IL-2 receptor; Perforin; Interleukin 21; Genetic enhancement; Immunology; Cell; Immune system; In vitro","score_opus":0.027188119436949737,"score_gpt":0.2616038370125026,"score_spread":0.23441571757555288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995574992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99337316,0.0020937654,0.0015111865,0.00012295095,0.00014068354,0.00010386976,0.00013168188,0.000108469896,0.0024143062],"genre_scores_gemma":[0.99592626,0.0010191369,0.0010647381,0.000035711648,0.000035438472,0.000062828025,0.00011338959,0.000016273,0.001726384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99972504,0.00007054405,0.0000176082,0.000035167144,0.000049823688,0.00010176912],"domain_scores_gemma":[0.99982566,0.000056260513,0.000020296575,0.000028311424,0.000009927049,0.00005959252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040747752,0.00063462125,0.00079021836,0.00061795226,0.00021415182,0.00046134964,0.00037530475,0.00048312597,0.0012971052],"category_scores_gemma":[0.00020887335,0.00024774965,0.0005003652,0.00037947643,0.0005035854,0.00029493828,0.00029985353,0.0011727868,0.0003156237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005793553,0.0027369154,0.00072478066,0.00017736894,0.00010506087,0.00038251744,0.0001157792,0.002195755,0.965114,0.00074208475,0.000420097,0.021492038],"study_design_scores_gemma":[0.0007164546,0.010757094,0.002489021,0.000015011882,0.0002486538,0.0004646351,0.000052029096,0.0022003944,0.98017967,0.00012979412,0.0027331715,0.000013995616],"about_ca_topic_score_codex":0.0009096846,"about_ca_topic_score_gemma":0.0017409681,"teacher_disagreement_score":0.0012971052,"about_ca_system_score_codex":0.00032506435,"about_ca_system_score_gemma":0.00074195757,"threshold_uncertainty_score":0.0043392777},"labels":[],"label_agreement":null},{"id":"W1998048839","doi":"10.4161/21624011.2014.958951","title":"Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8<sup>+</sup>T-cell therapy","year":2014,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Autoimmunity; Cytotoxic T cell; Adoptive cell transfer; Immune system; CD8; Immunology; T cell; Inflammation; Cancer research; Immunotherapy; Immunity; Immune checkpoint; Biology; Medicine; In vitro; Biochemistry","score_opus":0.03481339900123783,"score_gpt":0.3126402239680923,"score_spread":0.2778268249668545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998048839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9252034,0.028923318,0.028323762,0.0063795107,0.00057594816,0.00024594326,0.00017784827,0.00068993005,0.009480344],"genre_scores_gemma":[0.98447686,0.0050512995,0.0074371863,0.0009163813,0.00018562315,0.000097826975,0.000057670102,0.000048469443,0.0017286444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997738,0.00006080437,0.000022344671,0.000026684576,0.000056299676,0.000060227252],"domain_scores_gemma":[0.9996631,0.00012559979,0.000060658702,0.00007294187,0.000023998202,0.00005374335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011521253,0.0004242789,0.00048480148,0.0002089837,0.00020953816,0.00064710155,0.00037447613,0.0008731917,0.0008460205],"category_scores_gemma":[0.0006104309,0.00017450773,0.00025392894,0.00011719929,0.00074589887,0.00070545904,0.00031033906,0.0020771252,0.00040703223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003122837,0.0014404312,0.0042070565,0.00063844485,0.00009156692,0.0018729001,0.00012598655,0.0021387618,0.83690184,0.008236357,0.002826908,0.13839692],"study_design_scores_gemma":[0.0015534743,0.014306733,0.008216958,0.00024957178,0.000319548,0.0136540225,0.0001683662,0.005900157,0.8638439,0.011542289,0.08018191,0.000063040636],"about_ca_topic_score_codex":0.00011089739,"about_ca_topic_score_gemma":0.0002107954,"teacher_disagreement_score":0.0011521253,"about_ca_system_score_codex":0.00024929765,"about_ca_system_score_gemma":0.0002901481,"threshold_uncertainty_score":0.006093085},"labels":[],"label_agreement":null},{"id":"W1998487002","doi":"10.1016/j.tips.2010.05.003","title":"Fighting cancers from within: augmenting tumor immunity with cytokine therapy","year":2010,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Immune system; Adjuvant; Immunology; Cytokine; Immunity; Medicine; Immunotherapy; Vaccination; Enthusiasm; Psychology","score_opus":0.1874054981151227,"score_gpt":0.46626342224757616,"score_spread":0.27885792413245347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998487002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022643279,0.99709487,0.0004412969,0.00038961382,0.0003620714,0.00001158893,0.00002189178,0.000019166777,0.0014331959],"genre_scores_gemma":[0.0012277758,0.9963445,0.0005589078,0.00035366483,0.00030489094,0.000019643072,0.00004277698,0.0000031603026,0.0011447337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998404,0.000026146892,0.000017396369,0.000032076685,0.00006265043,0.000021295704],"domain_scores_gemma":[0.99981385,0.00008601106,0.00002714233,0.000008071639,0.000042728945,0.000022146565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058415387,0.0012390604,0.0021477686,0.0014868921,0.00026440618,0.0011298772,0.0009037047,0.0010090735,0.0032503973],"category_scores_gemma":[0.00044283987,0.00031122204,0.00052592234,0.0015275665,0.0006277418,0.0013918371,0.00055286527,0.002666068,0.0033086876],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017639268,0.00021890899,0.00012730365,0.007687602,0.00010104285,0.00014578714,0.000029767261,0.000531854,0.005331581,0.004203241,0.03135616,0.9500902],"study_design_scores_gemma":[0.000103445025,0.00020962577,0.0004735767,0.0011272542,0.00012915752,0.0008722637,0.000042575673,0.00019398422,0.0016714027,0.0024272543,0.99272776,0.00002164811],"about_ca_topic_score_codex":0.0006463659,"about_ca_topic_score_gemma":0.0017271816,"teacher_disagreement_score":0.0032503973,"about_ca_system_score_codex":0.00060963456,"about_ca_system_score_gemma":0.00080050225,"threshold_uncertainty_score":0.010873616},"labels":[],"label_agreement":null},{"id":"W1999935620","doi":"10.1016/j.leukres.2009.12.008","title":"A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Terry Fox Research Institute","keywords":"Dasatinib; Diphtheria toxin; Tyrosine kinase; Imatinib; Cancer research; Leukemia; Imatinib mesylate; Fusion protein; Progenitor cell; Biology; Immunology; Stem cell; Signal transduction; Microbiology; Cell biology; Toxin; Myeloid leukemia; Recombinant DNA; Biochemistry","score_opus":0.020862546613417465,"score_gpt":0.3207704883987825,"score_spread":0.29990794178536506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999935620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950493,0.0013060708,0.00089837087,0.00013367241,0.0000591653,0.00008347242,0.00038968597,0.000087514476,0.0019926385],"genre_scores_gemma":[0.99549097,0.0012584752,0.0008771237,0.000070677626,0.000035197532,0.000077744946,0.000923285,0.000023701734,0.0012428976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996438,0.00007971754,0.000035917943,0.00002602618,0.00007548246,0.00013912482],"domain_scores_gemma":[0.99978346,0.000090617104,0.00002809648,0.000026064841,0.000011947486,0.000059829905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043648086,0.000509843,0.0007345284,0.00056745816,0.000316284,0.0007490755,0.00043280516,0.0004060113,0.0014718896],"category_scores_gemma":[0.00027930332,0.00028849143,0.00047624568,0.00051422796,0.00032881994,0.00031625052,0.00046197846,0.001112254,0.0005116694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029946472,0.0007010774,0.0011336121,0.00011010563,0.00004818464,0.00038611417,0.0000793543,0.0008758325,0.98319936,0.00052176224,0.0005861627,0.009363772],"study_design_scores_gemma":[0.00096444384,0.0046119946,0.014064361,0.000015009925,0.00016102615,0.0014861479,0.00008704896,0.0031621899,0.9700473,0.00021003053,0.005174655,0.000015874899],"about_ca_topic_score_codex":0.0007134203,"about_ca_topic_score_gemma":0.0015221077,"teacher_disagreement_score":0.0014718896,"about_ca_system_score_codex":0.00049357157,"about_ca_system_score_gemma":0.0005509828,"threshold_uncertainty_score":0.0049239397},"labels":[],"label_agreement":null},{"id":"W2004715375","doi":"10.1371/journal.pone.0028232","title":"B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Protein kinase B; p38 mitogen-activated protein kinases; MAPK/ERK pathway; Cell biology; Chemistry; PI3K/AKT/mTOR pathway; Cancer research; Kinase; Signal transduction; Biology","score_opus":0.10702791174885241,"score_gpt":0.304363100164806,"score_spread":0.1973351884159536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004715375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926237,0.0023356038,0.0011148244,0.0001459293,0.00007724516,0.000054668042,0.00038826678,0.000072136354,0.0031875668],"genre_scores_gemma":[0.9905537,0.0018681639,0.0017659536,0.00008809375,0.000039622268,0.00013044817,0.0013460219,0.000021737711,0.004186163],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975485,0.000043805027,0.00001826072,0.000022319544,0.00005038928,0.00011038007],"domain_scores_gemma":[0.99992955,0.000012810549,0.000010339511,0.0000070334327,0.000010776951,0.000029452589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011969555,0.0005860743,0.0003289485,0.00032176953,0.00026593625,0.00027680927,0.00024572652,0.00028894318,0.002806944],"category_scores_gemma":[0.00008104759,0.00013130998,0.00041752547,0.00017486734,0.00024098589,0.00017323448,0.00019111797,0.0008017791,0.00079080433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043566464,0.00013753858,0.000099326324,0.0000602448,0.000011737821,0.000050027073,0.00001433692,0.00005257437,0.9975828,0.000071128314,0.00007805921,0.0014065868],"study_design_scores_gemma":[0.00005715197,0.0007543007,0.0016138915,0.0000050596504,0.000015220689,0.00010167504,0.000028168486,0.00039514253,0.99544877,0.000038910457,0.0015379357,0.0000036851432],"about_ca_topic_score_codex":0.0007759417,"about_ca_topic_score_gemma":0.0009779899,"teacher_disagreement_score":0.002806944,"about_ca_system_score_codex":0.00026176695,"about_ca_system_score_gemma":0.00038504897,"threshold_uncertainty_score":0.009390116},"labels":[],"label_agreement":null},{"id":"W2004772469","doi":"10.1073/pnas.1221609110","title":"T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Avidity; T-cell receptor; Autoimmunity; CD8; Immunotherapy; Biology; T cell; Immunology; Antigen; Receptor; Immune system; Cytotoxic T cell; Cell biology; Adoptive cell transfer; In vitro; Cancer research; Biochemistry","score_opus":0.04937329098992603,"score_gpt":0.3259618820631226,"score_spread":0.27658859107319655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004772469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926474,0.0018194724,0.0045827157,0.000031064275,0.0000047231383,0.000013681225,0.00002402857,0.00002601832,0.0008509745],"genre_scores_gemma":[0.9980106,0.00036708673,0.0013780223,0.000022791835,0.00000464444,0.0000081971375,0.000023121718,0.000005451423,0.00018007222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99957424,0.00014243332,0.000047194473,0.000064126725,0.00009513338,0.00007694231],"domain_scores_gemma":[0.99965894,0.00016536313,0.00005799568,0.000031783617,0.000030259094,0.000055580043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005156128,0.00028221912,0.00041576897,0.00046766896,0.00014342087,0.0006794332,0.00024157898,0.00061575376,0.0006951755],"category_scores_gemma":[0.00046121154,0.0003207386,0.0001630842,0.00027226258,0.00033346977,0.00037784013,0.0002848548,0.0007756482,0.0003055219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007518675,0.000024690487,0.0013513657,0.000023746445,0.000004185896,0.000021247743,0.0000100710195,0.00027508673,0.9968838,0.00009633531,0.0000062155545,0.0012279719],"study_design_scores_gemma":[0.000021028249,0.0007624786,0.028018536,0.000012705837,0.000053446965,0.0008093863,0.00005118466,0.0058393897,0.9631371,0.0006280196,0.0006513999,0.000015278009],"about_ca_topic_score_codex":0.00021431483,"about_ca_topic_score_gemma":0.00038042798,"teacher_disagreement_score":0.0006951755,"about_ca_system_score_codex":0.0004179436,"about_ca_system_score_gemma":0.00018968576,"threshold_uncertainty_score":0.003032446},"labels":[],"label_agreement":null},{"id":"W2005406905","doi":"10.1371/journal.pone.0032420","title":"Embryonic Stem Cell-Derived Factors Inhibit T Effector Activation and Induce T Regulatory Cells by Suppressing PKC-θ Activation","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"King Saud bin Abdulaziz University for Health Science; Canadian Blood Services; Canadian Institutes of Health Research; Government of Ontario; University of Ottawa","keywords":"Cell biology; Protein kinase C; T cell; Embryonic stem cell; IL-2 receptor; Signal transduction; Biology; Transcription factor; FOXP3; Chemistry; Immune system; Immunology; Biochemistry","score_opus":0.05209488130475428,"score_gpt":0.2657956606357296,"score_spread":0.21370077933097534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005406905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98203236,0.0072625945,0.0064485013,0.00012391576,0.000096281015,0.00006679897,0.0003945169,0.0001746256,0.003400376],"genre_scores_gemma":[0.98763776,0.004618551,0.0029631446,0.000078852776,0.00002836551,0.000050294297,0.0005009153,0.000032010244,0.0040901843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997944,0.000037682195,0.000038179867,0.000033349315,0.000058735306,0.000037668073],"domain_scores_gemma":[0.99987924,0.00002898851,0.00003755236,0.000019966537,0.000014350955,0.000019907311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016084644,0.00047298966,0.00029061377,0.00030961947,0.00008575588,0.0003162638,0.00012860353,0.00018595305,0.0015238806],"category_scores_gemma":[0.00015762297,0.00011573678,0.0003223772,0.00019197619,0.00020127764,0.00016864632,0.00014882046,0.0006569636,0.00044518663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008205914,0.00003398476,0.00021070962,0.00007568754,0.000010718774,0.000055890614,0.000010527527,0.00006559211,0.9957426,0.00014287488,0.00004737674,0.0035219628],"study_design_scores_gemma":[0.000014348586,0.00018943178,0.0021657436,0.000008324687,0.000028012106,0.00013935,0.0000148307245,0.00027482686,0.99406505,0.000042014595,0.0030559592,0.0000021905569],"about_ca_topic_score_codex":0.00019353288,"about_ca_topic_score_gemma":0.0003905201,"teacher_disagreement_score":0.0015238806,"about_ca_system_score_codex":0.00014809666,"about_ca_system_score_gemma":0.0002020071,"threshold_uncertainty_score":0.005097866},"labels":[],"label_agreement":null},{"id":"W2006202814","doi":"10.1002/eji.200636726","title":"JNK2 negatively regulates CD8<sup>+</sup> T cell effector function and anti‐tumor immune response","year":2007,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases","keywords":"Biology; Cytotoxic T cell; CD8; Immune system; Effector; Cell biology; Granzyme B; T cell; Immunology; In vitro; Biochemistry","score_opus":0.014185191460929473,"score_gpt":0.2609474413674198,"score_spread":0.24676224990649034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006202814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984798,0.005559308,0.0027519413,0.00031814835,0.00011949785,0.0000524922,0.00064496935,0.0001495997,0.0056060744],"genre_scores_gemma":[0.9911929,0.001490422,0.0012908359,0.00014399573,0.00004479473,0.000052955238,0.0008456274,0.000031228876,0.004907223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998105,0.00003080912,0.000014338724,0.000032142452,0.00004676427,0.00006554972],"domain_scores_gemma":[0.999915,0.0000074011623,0.000028454822,0.0000060085067,0.000011612468,0.000031483825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001524671,0.0007748027,0.00027452924,0.00016270118,0.0002049678,0.0003921795,0.00027003136,0.00030174767,0.003129153],"category_scores_gemma":[0.000095168296,0.00013054765,0.00020623814,0.00010986693,0.00025726852,0.00029431103,0.00022826651,0.0006325624,0.00093748874],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004697432,0.00005108946,0.00024179062,0.00014596469,0.000006100812,0.000090445385,0.000008594863,0.0000781447,0.9972458,0.00010989586,0.00015327563,0.0013992626],"study_design_scores_gemma":[0.000109768596,0.00040884217,0.010206766,0.000019698395,0.000033222233,0.00088050566,0.00005055665,0.0023259008,0.97899216,0.00013063506,0.006831276,0.000010558803],"about_ca_topic_score_codex":0.0001708376,"about_ca_topic_score_gemma":0.00024997193,"teacher_disagreement_score":0.003129153,"about_ca_system_score_codex":0.00029264178,"about_ca_system_score_gemma":0.00022129588,"threshold_uncertainty_score":0.010468066},"labels":[],"label_agreement":null},{"id":"W2007861438","doi":"10.1016/j.celrep.2013.06.016","title":"A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters","year":2013,"lang":"en","type":"article","venue":"Cell Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Corepressor; Enhancer; Repressor; Promoter; Germinal center; Biology; BCL6; Epigenetics; Cell biology; Psychological repression; Chromatin; Death-associated protein 6; Genetics; Transcription factor; B cell; Gene; Nuclear protein; Gene expression","score_opus":0.023551413400595068,"score_gpt":0.2725848694703221,"score_spread":0.24903345606972704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007861438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91539705,0.004336037,0.07149057,0.00034273064,0.00008866579,0.000084603795,0.0002566961,0.00071480474,0.007288849],"genre_scores_gemma":[0.98482186,0.00041022967,0.01096291,0.00009041248,0.00001668458,0.0000580067,0.00020320395,0.000045418048,0.0033913772],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997055,0.000039178714,0.000015212715,0.00009907722,0.00009170505,0.000049212354],"domain_scores_gemma":[0.9998266,0.00002585365,0.000029133535,0.000039169638,0.000021739666,0.000057602934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032471374,0.00032322996,0.000265638,0.0003184534,0.00033702864,0.0008895637,0.00048667646,0.00045870364,0.0022830116],"category_scores_gemma":[0.00020029802,0.0002985078,0.0003377697,0.00016900209,0.0004792716,0.0007220196,0.00082991057,0.0006893868,0.0010513678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001314614,0.00002375953,0.0004087147,0.000035419424,0.0000064967144,0.000056152865,0.000038046164,0.00006197267,0.99352175,0.0028989871,0.000051024308,0.0027661878],"study_design_scores_gemma":[0.000082845734,0.00028432402,0.0032149293,0.000008251862,0.0000138064115,0.0011598804,0.000058165424,0.001411026,0.9878491,0.0011915863,0.0047134915,0.000012587364],"about_ca_topic_score_codex":0.00013102367,"about_ca_topic_score_gemma":0.00022706004,"teacher_disagreement_score":0.0022830116,"about_ca_system_score_codex":0.00040207032,"about_ca_system_score_gemma":0.00014927995,"threshold_uncertainty_score":0.007637441},"labels":[],"label_agreement":null},{"id":"W2008355700","doi":"10.1089/hum.2010.126","title":"T-Cell Receptor Gene Therapy in Human Melanoma-Bearing Immune-Deficient Mice: Human but not Mouse T Cells Recapitulate Outcome of Clinical Studies","year":2011,"lang":"en","type":"article","venue":"Human Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Erasmus+; Institute of Genetics; Erasmus Medisch Centrum; European Commission","keywords":"Genetic enhancement; Immune system; Immunology; Melanoma; Biology; Receptor; Cancer research; Cell therapy; Gene; Cell; Medicine; Genetics","score_opus":0.25570744165459464,"score_gpt":0.42328980427734475,"score_spread":0.16758236262275011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008355700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877396,0.002703103,0.006171132,0.00013418224,0.00006878016,0.00035789268,0.0006429958,0.00021550956,0.0019667877],"genre_scores_gemma":[0.99118114,0.0016743591,0.0033286463,0.000120871,0.000023485069,0.0003335841,0.0010210286,0.00006182625,0.002255029],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996898,0.00007969301,0.000038426446,0.000067153625,0.00005988007,0.00006515833],"domain_scores_gemma":[0.9998677,0.000018314846,0.0000344207,0.000038757553,0.000015267655,0.000025512732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055555033,0.00062445033,0.00060431875,0.000425155,0.00013799198,0.0004382661,0.00023016654,0.00059848593,0.0011554032],"category_scores_gemma":[0.00022765007,0.00015971459,0.00035388957,0.00024808056,0.00030684334,0.0003291367,0.00014861058,0.0010643627,0.00052340614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053205516,0.00039069023,0.00028279747,0.000055540433,0.000012932449,0.00007653229,0.00003213358,0.00021282908,0.9954032,0.00013367609,0.00011371827,0.0027539015],"study_design_scores_gemma":[0.00022148566,0.0073312516,0.0036661816,0.000021535952,0.000097132324,0.0012951922,0.000029822733,0.0013331875,0.9795151,0.00011217306,0.006364896,0.000012068472],"about_ca_topic_score_codex":0.0003849361,"about_ca_topic_score_gemma":0.00035814854,"teacher_disagreement_score":0.0011554032,"about_ca_system_score_codex":0.0002673222,"about_ca_system_score_gemma":0.0003082966,"threshold_uncertainty_score":0.003865242},"labels":[],"label_agreement":null},{"id":"W2010214177","doi":"10.1371/journal.pone.0094817","title":"Development of Genetically Flexible Mouse Models of Sarcoma Using RCAS-TVA Mediated Gene Delivery","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Sarcoma; Mesenchymal stem cell; Biology; Progenitor cell; Cancer research; Oncogene; Population; Cell cycle; Cell; Immunology; Medicine; Pathology; Stem cell; Cell biology; Genetics","score_opus":0.1370266237838407,"score_gpt":0.29660518469194,"score_spread":0.15957856090809933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010214177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8879366,0.0034209765,0.08488334,0.0009911322,0.0006078596,0.0018807485,0.0073157577,0.0023354718,0.010628151],"genre_scores_gemma":[0.89111215,0.0045965123,0.063749015,0.00027839164,0.00006887037,0.003007407,0.0057997624,0.00046584228,0.0309222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991698,0.00011241114,0.00013103835,0.00019673964,0.00024374816,0.00014629863],"domain_scores_gemma":[0.9993007,0.000107173924,0.00025474824,0.000112364876,0.000057773443,0.0001672304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088205526,0.0011487982,0.0005871707,0.0019025059,0.00045590027,0.0009163351,0.0011476901,0.001406876,0.0042129466],"category_scores_gemma":[0.0003192069,0.000865891,0.0008520668,0.00055921124,0.0010240342,0.00082154165,0.0005411911,0.0030936366,0.0020055205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015487798,0.00017926762,0.00018696557,0.00006282158,0.000016209287,0.00009541119,0.00005769524,0.00033417853,0.99583554,0.0010780345,0.00018049557,0.0018184131],"study_design_scores_gemma":[0.00012286258,0.0010231083,0.0015420102,0.000042633594,0.00004183116,0.00060568156,0.00006572429,0.002872395,0.98260754,0.00027514523,0.01077867,0.00002238559],"about_ca_topic_score_codex":0.00087038404,"about_ca_topic_score_gemma":0.0015697426,"teacher_disagreement_score":0.0042129466,"about_ca_system_score_codex":0.00079669466,"about_ca_system_score_gemma":0.0005576427,"threshold_uncertainty_score":0.014093697},"labels":[],"label_agreement":null},{"id":"W2010618607","doi":"10.1016/j.stem.2008.09.001","title":"The Systematic Production of Cells for Cell Therapies","year":2008,"lang":"en","type":"review","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":302,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University Health Network; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; John Simon Guggenheim Memorial Foundation","keywords":"Expediting; Bioprocess; Biomanufacturing; Biology; Biotechnology; Biochemical engineering; Cell therapy; Stem cell; Risk analysis (engineering); Engineering; Cell biology; Systems engineering; Medicine","score_opus":0.06763248157530957,"score_gpt":0.33158083660507354,"score_spread":0.263948355029764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010618607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014788045,0.99694794,0.00090857653,0.00027706887,0.00029863897,0.000015862282,0.000024926047,0.000008719469,0.0013704497],"genre_scores_gemma":[0.0008935601,0.9969517,0.0009513091,0.00024606168,0.00013589583,0.000019964069,0.00004750865,0.0000032604125,0.00075075356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993869,0.00014054554,0.00007117721,0.00010466443,0.00024584663,0.000050873343],"domain_scores_gemma":[0.9992399,0.00046199086,0.00008681893,0.00004804167,0.00013431475,0.000028886769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001815344,0.0015059916,0.0026001525,0.0026505347,0.00039589073,0.0016538611,0.0016725018,0.0018866335,0.0029315685],"category_scores_gemma":[0.0014384106,0.0005338523,0.00094931206,0.0025595375,0.0012771762,0.0021476643,0.0014261445,0.0025241505,0.002330609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010911219,0.00010139384,0.00016258909,0.023517335,0.00010204378,0.00028898029,0.00006963628,0.0006509837,0.009236264,0.014291967,0.021658894,0.9298108],"study_design_scores_gemma":[0.000031032192,0.00009339577,0.00025088692,0.0024470475,0.00008803416,0.00069381326,0.000044959423,0.000074250354,0.0033624081,0.0025816488,0.9903161,0.000016527221],"about_ca_topic_score_codex":0.0009967957,"about_ca_topic_score_gemma":0.0014640634,"teacher_disagreement_score":0.0029315685,"about_ca_system_score_codex":0.0010623676,"about_ca_system_score_gemma":0.0016500759,"threshold_uncertainty_score":0.00980705},"labels":[],"label_agreement":null},{"id":"W2011291539","doi":"10.1016/j.tmrv.2007.05.007","title":"Cellular Therapies: A Canadian Blood Services Research and Development Symposium","year":2007,"lang":"en","type":"article","venue":"Transfusion Medicine Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine","score_opus":0.07950197469516655,"score_gpt":0.37290959930709583,"score_spread":0.29340762461192926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011291539","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038953065,0.36385038,0.0016697057,0.40628043,0.11309952,0.0004710627,0.00083109026,0.0001959308,0.10970654],"genre_scores_gemma":[0.0358026,0.35126048,0.004303249,0.07127958,0.023989042,0.0002624976,0.0012509763,0.00011555883,0.51173604],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99608386,0.00029710156,0.00009244876,0.0001057964,0.0027619875,0.0006587853],"domain_scores_gemma":[0.9930355,0.00032625554,0.00012699443,0.00006802178,0.0047046575,0.0017385557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009246606,0.001655419,0.0008922856,0.0034700988,0.0055444483,0.005885093,0.0017254616,0.0072084637,0.025230294],"category_scores_gemma":[0.0039142435,0.00056830037,0.0013344124,0.0024682647,0.0020951282,0.0015371785,0.0014859495,0.0041015144,0.0032276884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007859265,0.000065128144,0.00029451973,0.00015518516,0.000016891157,0.00008879788,0.000054891425,0.00017521906,0.00043184735,0.001976067,0.95148116,0.045181695],"study_design_scores_gemma":[0.000030702242,0.00003523176,0.001643788,0.00016925557,0.000029364226,0.000050349005,0.00011724437,0.00011682984,0.00021736887,0.0003883717,0.9971825,0.00001907382],"about_ca_topic_score_codex":0.7931022,"about_ca_topic_score_gemma":0.943201,"teacher_disagreement_score":0.95790607,"about_ca_system_score_codex":0.04209394,"about_ca_system_score_gemma":0.13122879,"threshold_uncertainty_score":0.41623247},"labels":[],"label_agreement":null},{"id":"W2013046654","doi":"10.1016/j.cellimm.2012.01.004","title":"The activation, by antigen, of naïve TCR transgenic CD4 T cells cultured at physiological, rather than artificially high, frequencies more accurately reflects the in vivo activation of normal numbers of naïve CD4+ T cells","year":2012,"lang":"en","type":"article","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Biology; T-cell receptor; Molecular biology; Cell biology; In vivo; T cell; Population; CD80; CD40; In vitro; Immunology; Cytotoxic T cell; Immune system; Biochemistry; Genetics","score_opus":0.04038695446152873,"score_gpt":0.3019408328044642,"score_spread":0.2615538783429355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013046654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97399956,0.0008777895,0.02172387,0.000120289376,0.00014329512,0.00004703561,0.00030135404,0.00019849795,0.0025882768],"genre_scores_gemma":[0.9835746,0.0005389387,0.012669747,0.00011439767,0.00007067429,0.0001437716,0.00077954313,0.0001093498,0.001998854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986743,0.00048431318,0.0001768934,0.00027145428,0.00025697565,0.00013604405],"domain_scores_gemma":[0.99920565,0.0004379276,0.00006790208,0.00018016291,0.000042164775,0.00006620021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089263776,0.0007746927,0.00059526745,0.00046286336,0.00028733007,0.0011447334,0.00032298354,0.00075414724,0.0015955103],"category_scores_gemma":[0.00095379795,0.0002858369,0.00018691154,0.00041455374,0.0007209641,0.00080545474,0.00033713452,0.002564364,0.00050899974],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026317677,0.0001298862,0.0009392501,0.000048098525,0.0000058658893,0.000031744225,0.000052717234,0.00020883823,0.996639,0.00024203074,0.00004976438,0.0013897186],"study_design_scores_gemma":[0.000018623994,0.0003583496,0.0019531595,0.000004774423,0.00001886298,0.00015226117,0.000027711849,0.0019795552,0.99457127,0.00014305238,0.00076863257,0.0000038099122],"about_ca_topic_score_codex":0.00023607977,"about_ca_topic_score_gemma":0.00032975763,"teacher_disagreement_score":0.0015955103,"about_ca_system_score_codex":0.00034106313,"about_ca_system_score_gemma":0.00024204908,"threshold_uncertainty_score":0.0053374767},"labels":[],"label_agreement":null},{"id":"W2014381944","doi":"10.1017/s0317167100002055","title":"Human Autologous In Vitro Models of Glioma Immunogene Therapy Using B7-2, GM-CSF, and IL12","year":2002,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"Fondation pour la Recherche Médicale; University of Alberta; Congress of Neurological Surgeons","keywords":"Interleukin 12; Peripheral blood mononuclear cell; Cytotoxic T cell; Glioma; Immunology; CD8; Cancer research; Biology; Granulocyte macrophage colony-stimulating factor; Immunotherapy; Molecular biology; Immune system; Cytokine; In vitro","score_opus":0.10671148152665887,"score_gpt":0.3251389034829766,"score_spread":0.2184274219563177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014381944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96766806,0.007610343,0.012224066,0.00038203158,0.00034002317,0.00056257116,0.002618518,0.0003275308,0.0082668],"genre_scores_gemma":[0.9830357,0.003429634,0.0062237126,0.000109869245,0.000060405986,0.00049587904,0.0023589095,0.000037851678,0.0042481553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994968,0.00012613776,0.000052268362,0.0000926839,0.0001231285,0.00010900012],"domain_scores_gemma":[0.99980503,0.000042672906,0.00003441434,0.000053405824,0.000023196408,0.000041256113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035079825,0.00087641424,0.00057539163,0.00044748816,0.00019396645,0.0006020083,0.0006130864,0.0006159628,0.0031531984],"category_scores_gemma":[0.00010399176,0.00019306364,0.000457672,0.00044308347,0.00031500717,0.00023776627,0.00032685368,0.0013933616,0.0017509761],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012293105,0.001244137,0.00038598638,0.00032339344,0.00003613808,0.00027774152,0.00011095669,0.001106504,0.99078006,0.00050898717,0.00069583306,0.0033009686],"study_design_scores_gemma":[0.00015528401,0.003957449,0.0010937246,0.000030188565,0.000071450435,0.0005797675,0.000047582635,0.0019330801,0.9854155,0.000097070886,0.006609734,0.000009134585],"about_ca_topic_score_codex":0.00089548336,"about_ca_topic_score_gemma":0.0010219481,"teacher_disagreement_score":0.0031531984,"about_ca_system_score_codex":0.00064113125,"about_ca_system_score_gemma":0.00037613843,"threshold_uncertainty_score":0.010548532},"labels":[],"label_agreement":null},{"id":"W2014711973","doi":"10.1038/sj.cgt.7700685","title":"Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins","year":2004,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Carcinoembryonic antigen; Fusion protein; Antibody; Molecular biology; Fc receptor; Chemistry; Antigen; Monoclonal antibody; Fragment crystallizable region; Chimeric antigen receptor; Immunoglobulin G; Receptor; T cell; Immune system; Biology; Recombinant DNA; Immunology; Biochemistry; Cancer","score_opus":0.043963003631289674,"score_gpt":0.3274272862154109,"score_spread":0.2834642825841212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014711973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85300714,0.021286305,0.10644513,0.00095917174,0.00032738506,0.00053099974,0.00048170768,0.00054531515,0.01641672],"genre_scores_gemma":[0.94367677,0.005337334,0.04162684,0.0002950178,0.00007816053,0.00016617493,0.0008857352,0.000037862774,0.007896189],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980646,0.000030473993,0.000007677724,0.00003699534,0.00007089059,0.000047591515],"domain_scores_gemma":[0.9999447,0.000015646432,0.000007993131,0.000007494907,0.000009153146,0.000015008761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019028953,0.0003466896,0.00025082685,0.0005352716,0.00024196437,0.0003317334,0.0002860498,0.00058792415,0.0012889839],"category_scores_gemma":[0.00017139332,0.00011511654,0.00026952077,0.0002832818,0.00030975585,0.0002847964,0.00031425545,0.0008224651,0.0003922586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008865097,0.000052617517,0.00015290763,0.000041881427,0.00000770644,0.000110158864,0.000023547545,0.0001054173,0.9916631,0.0015106979,0.00027873795,0.0059645614],"study_design_scores_gemma":[0.000028869263,0.00034897798,0.0010580407,0.0000055911687,0.00002766904,0.0009402469,0.0000158978,0.0021706002,0.98240685,0.00023825731,0.01275099,0.000008001681],"about_ca_topic_score_codex":0.0006155719,"about_ca_topic_score_gemma":0.0011935561,"teacher_disagreement_score":0.0012889839,"about_ca_system_score_codex":0.00046186705,"about_ca_system_score_gemma":0.00029718198,"threshold_uncertainty_score":0.004312098},"labels":[],"label_agreement":null},{"id":"W2015663429","doi":"10.1038/mt.2013.255","title":"Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor","year":2013,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; McMaster University","keywords":"Immune system; Immunogenicity; Immunosuppression; Immunotherapy; CD8; Immunology; Melanoma; Cancer immunotherapy; Cytotoxic T cell; Adoptive cell transfer; T cell; Vaccination; Acquired immune system; Cancer research; Biology; Medicine; In vitro","score_opus":0.021438038717656427,"score_gpt":0.291111750775051,"score_spread":0.2696737120573946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015663429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919431,0.0018229292,0.004083822,0.00014899691,0.000044449836,0.000064190666,0.000053426764,0.00018140368,0.0016576161],"genre_scores_gemma":[0.9969332,0.00041781028,0.0014926248,0.00005496888,0.000023811164,0.000037537648,0.000049504823,0.000014530508,0.00097610184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998776,0.000028074537,0.00000967819,0.000025214356,0.000023716262,0.00003578157],"domain_scores_gemma":[0.9999082,0.000027279553,0.000022188635,0.000015507443,0.000008963745,0.000017856073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002009279,0.00032753183,0.00029688745,0.00020756303,0.00008820538,0.00023591527,0.00011914964,0.0002546119,0.00091017224],"category_scores_gemma":[0.00016096367,0.00010434319,0.00019099445,0.00008468045,0.00023118153,0.00016274789,0.00015372575,0.0009627348,0.0002767573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015567907,0.00012714822,0.00023429288,0.000040246076,0.0000046923305,0.00007106907,0.000021110925,0.0002594739,0.99442863,0.00021630517,0.00006664864,0.0043746904],"study_design_scores_gemma":[0.000096215554,0.0018754827,0.0019283353,0.00000989374,0.00002062536,0.00034229897,0.00001761407,0.00229841,0.99020547,0.00022702952,0.002975359,0.000003212438],"about_ca_topic_score_codex":0.00015816663,"about_ca_topic_score_gemma":0.0002655233,"teacher_disagreement_score":0.00091017224,"about_ca_system_score_codex":0.00014994259,"about_ca_system_score_gemma":0.00021229243,"threshold_uncertainty_score":0.003044784},"labels":[],"label_agreement":null},{"id":"W2020138546","doi":"10.1038/cmi.2012.37","title":"A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling","year":2012,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Saskatchewan; Saskatchewan Cancer Agency","funders":"Canadian Institutes of Health Research; Saskatchewan Health Research Foundation","keywords":"CTL*; Melanoma; CD40; Term (time); Immunology; Medicine; Cancer research; Biology; Virology; Immune system; Cytotoxic T cell; Genetics; CD8","score_opus":0.018455802643470517,"score_gpt":0.25652043286581316,"score_spread":0.23806463022234264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020138546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97798336,0.0031296131,0.014148874,0.0005830819,0.00022819256,0.00016072724,0.00027272187,0.00033073133,0.0031626609],"genre_scores_gemma":[0.9893622,0.0010060305,0.0058180536,0.00017678711,0.000046914334,0.0000945043,0.00034676044,0.000017768894,0.00313099],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999169,0.000011090633,0.0000050989543,0.000016925233,0.000018285798,0.000031715026],"domain_scores_gemma":[0.99996257,0.0000060171765,0.000007078886,0.0000035912935,0.0000063723737,0.000014481169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116424046,0.0004514371,0.00027247734,0.00021350205,0.00016278282,0.0004127076,0.00027175507,0.0005138747,0.0012186215],"category_scores_gemma":[0.00009932051,0.00015497676,0.00023819241,0.000107741216,0.00019994538,0.00036211422,0.0002182943,0.0008425339,0.000438277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019221063,0.00015632008,0.000090453184,0.00006709818,0.000007810632,0.00009400962,0.000016740583,0.0003399432,0.99197996,0.00034655505,0.00021397459,0.0064949836],"study_design_scores_gemma":[0.00031123403,0.002024054,0.0006901415,0.000011200403,0.00006061941,0.00046115628,0.000022453902,0.0044511165,0.9830856,0.00030037347,0.008570201,0.000011827265],"about_ca_topic_score_codex":0.00038472406,"about_ca_topic_score_gemma":0.0004123977,"teacher_disagreement_score":0.0012186215,"about_ca_system_score_codex":0.00033621123,"about_ca_system_score_gemma":0.00037364743,"threshold_uncertainty_score":0.0040766597},"labels":[],"label_agreement":null},{"id":"W2022364340","doi":"10.4161/2162402x.2014.990803","title":"miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunosuppression; Tumor microenvironment; Adoptive cell transfer; Blockade; Medicine; CD8; Cytotoxic T cell; Immune system; T cell; Immunology; Cancer research; Tumor-infiltrating lymphocytes; Biology; Internal medicine; Receptor","score_opus":0.028752533743026068,"score_gpt":0.28106612261061253,"score_spread":0.2523135888675865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022364340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783539,0.004584752,0.009427643,0.00032767325,0.00017110471,0.0000933492,0.00029220394,0.00048877764,0.0062606432],"genre_scores_gemma":[0.99359894,0.0011976308,0.0028823968,0.00006440817,0.000028967977,0.000048771733,0.00011893657,0.00003228891,0.002027623],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997689,0.00004855154,0.000021012705,0.000032718923,0.00007027573,0.00005858618],"domain_scores_gemma":[0.99989724,0.0000210232,0.000025851507,0.00001273883,0.000012984049,0.00003017149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021683931,0.00044914073,0.0003616454,0.00028454425,0.0002289293,0.00060682365,0.00018214,0.00030846687,0.0017803498],"category_scores_gemma":[0.00016832341,0.00010324202,0.00028356822,0.00016392954,0.00028219598,0.00026454186,0.00019466718,0.0011164551,0.00058832724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018038356,0.00013294714,0.00013407193,0.000045823086,0.0000100351235,0.00006603882,0.000019836183,0.00019035157,0.992912,0.00018892103,0.00011572788,0.006003904],"study_design_scores_gemma":[0.0000147039655,0.00052776857,0.00071234896,0.0000043656682,0.000027312684,0.00016772216,0.0000120558125,0.00061292766,0.99411076,0.00006409089,0.0037417419,0.0000042219062],"about_ca_topic_score_codex":0.0003362829,"about_ca_topic_score_gemma":0.0006899232,"teacher_disagreement_score":0.0017803498,"about_ca_system_score_codex":0.0002444061,"about_ca_system_score_gemma":0.00032370642,"threshold_uncertainty_score":0.005955875},"labels":[],"label_agreement":null},{"id":"W2022374489","doi":"10.1002/pbc.24437","title":"Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation","year":2012,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; Children’s Oncology Group; National Institutes of Health; Children's Hospital of Philadelphia; American Cancer Society","keywords":"Medicine; Oncology; Hematopoietic stem cell transplantation; Stem cell; Transplantation; Internal medicine","score_opus":0.1817762848082525,"score_gpt":0.44492386670492745,"score_spread":0.263147581896675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022374489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001966617,0.826949,0.0008819934,0.074262865,0.073799014,0.00009164181,0.00021152067,0.00013755936,0.02346971],"genre_scores_gemma":[0.0016625678,0.9254534,0.001841898,0.028761255,0.013366035,0.000076693505,0.00027375098,0.000057505895,0.028506797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988858,0.00017371717,0.00013227305,0.00011790689,0.0005643246,0.00012595778],"domain_scores_gemma":[0.99704,0.00095527456,0.00025783648,0.00011973608,0.001134976,0.00049221836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002727765,0.0008518967,0.0010625017,0.0028681008,0.0007316184,0.0021429118,0.0011540805,0.0037852288,0.0166584],"category_scores_gemma":[0.003947212,0.0003713594,0.0007571346,0.0030955032,0.001417103,0.0026341432,0.0021999332,0.007968498,0.01158382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002908478,0.000025389496,0.00006820869,0.0015277301,0.000016839113,0.000098369754,0.000030841355,0.00006539415,0.00025880916,0.0067092837,0.6427009,0.34846917],"study_design_scores_gemma":[0.000006608596,0.000009201898,0.00008909234,0.0006513497,0.0000040804794,0.00017857144,0.000009638126,0.000007958446,0.00005215,0.0006498014,0.9983382,0.000003203422],"about_ca_topic_score_codex":0.002863769,"about_ca_topic_score_gemma":0.004957743,"teacher_disagreement_score":0.0166584,"about_ca_system_score_codex":0.0022301355,"about_ca_system_score_gemma":0.006571813,"threshold_uncertainty_score":0.0557279},"labels":[],"label_agreement":null},{"id":"W2023548208","doi":"10.1016/s0092-8674(00)00140-9","title":"Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is a Death Receptor for Granzyme B during Cytotoxic T Cell–Induced Apoptosis","year":2000,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":388,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta","funders":"","keywords":"Cytotoxic T cell; Granzyme B; Biology; Granzyme; Perforin; Cell biology; Granzyme A; Apoptosis; Molecular biology; Cancer research; Biochemistry; In vitro","score_opus":0.028643670292111612,"score_gpt":0.2806585660275285,"score_spread":0.25201489573541686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023548208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97477835,0.008681697,0.007669363,0.00066786027,0.00018264056,0.000042553398,0.00017279797,0.00023721438,0.007567423],"genre_scores_gemma":[0.9929899,0.0011327722,0.0010867802,0.00007894277,0.000033795728,0.000017188366,0.00020595426,0.000019513336,0.0044351304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997013,0.000056031426,0.000018943485,0.00003969701,0.000075299075,0.00010861023],"domain_scores_gemma":[0.99989545,0.000013854389,0.000030175122,0.000014803638,0.000021173424,0.000024451803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024359999,0.00043264034,0.00023997591,0.00037635848,0.00049696973,0.00094367,0.00030619695,0.0005814861,0.0019040365],"category_scores_gemma":[0.00026775175,0.00021520742,0.00029191613,0.00018498182,0.00033901175,0.0007924991,0.00039070533,0.0012813013,0.00089492084],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009364547,0.00003276661,0.0006607587,0.000075712334,0.000019996902,0.0005685518,0.000079400794,0.00022014778,0.9890265,0.0022800271,0.0003529559,0.005746679],"study_design_scores_gemma":[0.00009160691,0.00036391366,0.0077323355,0.000028641418,0.00005665136,0.003589487,0.00025071146,0.002471814,0.9677319,0.0012993431,0.016369626,0.000013991311],"about_ca_topic_score_codex":0.00034080716,"about_ca_topic_score_gemma":0.00033904877,"teacher_disagreement_score":0.0019040365,"about_ca_system_score_codex":0.0009665582,"about_ca_system_score_gemma":0.0002643661,"threshold_uncertainty_score":0.0070129633},"labels":[],"label_agreement":null},{"id":"W2024119342","doi":"10.1158/1535-7163.targ-11-c225","title":"Abstract C225: Differential regulation of simultaneous antitumor and alloreactive CD8+ T cell responses in the same host by rapamycin.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Epitope; Immunogenicity; Vaccinia; Biology; CD8; T cell; Cytotoxic T cell; Immune system; Cancer; Adjuvant; Virus; Antigen; Immunology; Cancer research; Virology; In vitro; Recombinant DNA; Genetics; Gene","score_opus":0.03717051993193556,"score_gpt":0.30991346684701493,"score_spread":0.2727429469150794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024119342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98992634,0.0012759934,0.0017097549,0.00012426618,0.00011737314,0.000054951804,0.00052825373,0.00023107504,0.0060318774],"genre_scores_gemma":[0.98958206,0.000539704,0.002041666,0.00009727803,0.00005434907,0.0000462092,0.00083089905,0.000060354894,0.006747426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999052,0.000012324961,0.000007689672,0.000022445603,0.000018784489,0.000033426124],"domain_scores_gemma":[0.99992144,0.000010519651,0.000012663856,0.000010217878,0.000007889817,0.000037322232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071477676,0.00032342476,0.00022027134,0.00026592382,0.0001414904,0.00018622399,0.00015718202,0.00025352617,0.0032158496],"category_scores_gemma":[0.000059750222,0.000073850395,0.00014682444,0.00011958923,0.00016630325,0.00010243954,0.00010533441,0.00042581253,0.0007952729],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045426787,0.000057510526,0.00011787269,0.000029695977,0.0000032536036,0.00006817421,0.0000056496388,0.0000604632,0.99602795,0.00007777895,0.00024089315,0.0028565673],"study_design_scores_gemma":[0.000043777007,0.0011980941,0.0048943507,0.0000055619926,0.000020079384,0.00039473473,0.00001622667,0.0005289661,0.98958707,0.000045539426,0.0032600577,0.0000056091985],"about_ca_topic_score_codex":0.00038972477,"about_ca_topic_score_gemma":0.0005536389,"teacher_disagreement_score":0.0032158496,"about_ca_system_score_codex":0.00022007881,"about_ca_system_score_gemma":0.00016860999,"threshold_uncertainty_score":0.010758102},"labels":[],"label_agreement":null},{"id":"W2028133066","doi":"10.1158/2159-8290.cd-13-0064","title":"Hit Parade for Adoptive Cell Transfer Therapy: The Best T Cells for Superior Clinical Responses","year":2013,"lang":"en","type":"letter","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adoptive cell transfer; Parade; Cell therapy; Cancer; Cancer therapy; Medicine; Cell; Computational biology; Computer science; Biology; T cell; Immunology; Internal medicine; Political science; Genetics; Immune system","score_opus":0.11753330179108,"score_gpt":0.3915685188405148,"score_spread":0.2740352170494348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028133066","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034324586,0.05157603,0.008095619,0.8525653,0.021408858,0.00045114412,0.0005313208,0.00042727077,0.030619869],"genre_scores_gemma":[0.3101875,0.048627514,0.015125073,0.5055023,0.0578938,0.0010169302,0.00072235725,0.0002852327,0.06063933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989587,0.00032027945,0.00011794969,0.00014448729,0.00031361447,0.00014490235],"domain_scores_gemma":[0.9987841,0.0007735442,0.000060224695,0.000071627124,0.00017465377,0.00013585313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016739762,0.0005113249,0.0011583627,0.00043580832,0.00062803354,0.0020378549,0.0005279208,0.0060642264,0.0048115696],"category_scores_gemma":[0.0039178557,0.00024419182,0.00051997474,0.00034654108,0.0013101664,0.0015095451,0.00039911718,0.008333138,0.004401088],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021237216,0.0007338546,0.002779626,0.0010657576,0.000085317784,0.012524286,0.00027091915,0.0015119679,0.033269532,0.026345061,0.64181817,0.27747187],"study_design_scores_gemma":[0.0024945745,0.002993021,0.0030663281,0.0004047827,0.00013024754,0.015824083,0.00039321848,0.0044934507,0.03574175,0.039235964,0.8950949,0.00012770653],"about_ca_topic_score_codex":0.0002114575,"about_ca_topic_score_gemma":0.00081580586,"teacher_disagreement_score":0.0060642264,"about_ca_system_score_codex":0.0014617493,"about_ca_system_score_gemma":0.000677414,"threshold_uncertainty_score":0.016096234},"labels":[],"label_agreement":null},{"id":"W2033172239","doi":"10.1038/leu.2011.99","title":"Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy","year":2011,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Institutes of Health; Government of Ontario; Ontario Institute for Cancer Research","keywords":"Ex vivo; Medicine; Granzyme; Immunotherapy; Perforin; CD8; Immunology; Myeloid leukemia; Leukemia; Granzyme B; Cancer research; CD34; Adoptive cell transfer; Peripheral blood mononuclear cell; Granzyme A; T cell; In vivo; Stem cell; Biology; Immune system; In vitro","score_opus":0.014339668091707055,"score_gpt":0.2535317871441942,"score_spread":0.23919211905248716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033172239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99397707,0.0013352582,0.001614027,0.00010254479,0.000048920752,0.000048050733,0.00012864047,0.000030990348,0.0027144768],"genre_scores_gemma":[0.99754566,0.0004407005,0.00071878976,0.000041618634,0.000033027896,0.000020695867,0.0002120423,0.000003839114,0.0009835192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999317,0.000021206486,0.0000054913266,0.000013225727,0.000012102466,0.000016191801],"domain_scores_gemma":[0.9999628,0.000015619791,0.0000033858926,0.0000074710224,0.0000035178412,0.000007161457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014874697,0.0001882738,0.00030606182,0.00015221217,0.00009369291,0.00025768462,0.00013274059,0.00014917635,0.00182281],"category_scores_gemma":[0.00013311338,0.000072343275,0.00012370867,0.00008386702,0.00012794364,0.0001262513,0.00013621587,0.00037965446,0.0002120335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002353402,0.00065565394,0.0027709445,0.00012037702,0.000027659795,0.000471052,0.00007593756,0.00079315103,0.94131833,0.0006041786,0.00033681522,0.050472613],"study_design_scores_gemma":[0.0011584519,0.008504328,0.022958426,0.000025976824,0.00021669135,0.0036899834,0.00011447508,0.0039759935,0.94172376,0.00057187455,0.017047225,0.000012748586],"about_ca_topic_score_codex":0.00019698977,"about_ca_topic_score_gemma":0.00027476257,"teacher_disagreement_score":0.00182281,"about_ca_system_score_codex":0.00007838278,"about_ca_system_score_gemma":0.00016986219,"threshold_uncertainty_score":0.006097853},"labels":[],"label_agreement":null},{"id":"W2033380259","doi":"10.1002/path.1777","title":"PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including <i>BCL‐6, CD10, CD20</i> and <i>CD22</i> : identification of PU.1 putative binding sites in the <i>BCL‐6</i> promotor","year":2005,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"BCL6; Germinal center; B cell; CD22; Molecular biology; Biology; Population; Follicular lymphoma; PAX5; Transcription factor; Cell; Gene; Diffuse large B-cell lymphoma; B-cell lymphoma; Lymphoma; Antibody; Genetics; Immunology; Medicine","score_opus":0.02743003368574839,"score_gpt":0.3033733703464049,"score_spread":0.2759433366606565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033380259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949007,0.0017767721,0.002053767,0.000054960394,0.000012221442,0.00000793102,0.0002668104,0.00008943049,0.0008373988],"genre_scores_gemma":[0.9944554,0.0006167248,0.0016336835,0.000027709968,0.000011187216,0.000028085336,0.00085373514,0.000011847683,0.0023616608],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998599,0.00001319492,0.000005889945,0.00004938207,0.000037095186,0.00003454968],"domain_scores_gemma":[0.9996965,0.00008976163,0.000093404546,0.000017961827,0.00003552117,0.000066898014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102952494,0.00017807118,0.00016034051,0.0004208395,0.00012904427,0.00032379714,0.00012243185,0.00021783792,0.0031390125],"category_scores_gemma":[0.00025541373,0.00016562987,0.00013704301,0.00030179834,0.0002463418,0.00019983543,0.00020714647,0.00044234097,0.0005835276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010781469,0.000024285122,0.0059004496,0.00003944922,0.000008653489,0.000033095144,0.000031006213,0.000024031922,0.9916967,0.000035395726,0.00003923319,0.0020599207],"study_design_scores_gemma":[0.000016579339,0.0006018677,0.33355215,0.00001367564,0.000031431526,0.0017134238,0.00010636617,0.0009849312,0.6592823,0.00013894771,0.003547318,0.000010956822],"about_ca_topic_score_codex":0.00033211443,"about_ca_topic_score_gemma":0.00031965278,"teacher_disagreement_score":0.0031390125,"about_ca_system_score_codex":0.00015145975,"about_ca_system_score_gemma":0.0001109032,"threshold_uncertainty_score":0.010501087},"labels":[],"label_agreement":null},{"id":"W2036481615","doi":"10.1371/journal.pone.0013940","title":"Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Breast Cancer Research Alliance; Government of Ontario; Ontario Institute for Cancer Research; Campbell Institute","keywords":"Tumor-infiltrating lymphocytes; Melanoma; Cancer research; Medicine; Biology; Pathology; Immunology; Immunotherapy; Immune system","score_opus":0.04171770144823088,"score_gpt":0.28033857371009296,"score_spread":0.23862087226186207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036481615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816714,0.0019828365,0.011805478,0.0000647721,0.000023426619,0.0005904118,0.0010438467,0.00009157846,0.00272626],"genre_scores_gemma":[0.97271186,0.0011039383,0.018616844,0.00009515263,0.00004452371,0.00046476384,0.004028204,0.00003096318,0.0029036803],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998586,0.000030203319,0.00001822024,0.000029730296,0.000036654255,0.000026482292],"domain_scores_gemma":[0.9998753,0.000033108947,0.000014349448,0.000022734643,0.00003204796,0.000022419774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003634596,0.00022259585,0.00013756384,0.00029366108,0.00012951963,0.00024073973,0.00014283144,0.00021129487,0.0016081447],"category_scores_gemma":[0.00026984912,0.00006898769,0.00017117038,0.00016808796,0.000121413424,0.00016827816,0.00028251688,0.00031143663,0.0010365472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002344406,0.000112336595,0.0046199327,0.00010389179,0.0000057212187,0.00017519215,0.000103981794,0.00029506962,0.98175734,0.00008510705,0.0001521505,0.012354911],"study_design_scores_gemma":[0.000119051925,0.003921042,0.04866492,0.000082154475,0.00006413807,0.0031958192,0.0002841828,0.002567269,0.919599,0.00026286373,0.021223629,0.00001588696],"about_ca_topic_score_codex":0.0002140271,"about_ca_topic_score_gemma":0.00024752202,"teacher_disagreement_score":0.0016081447,"about_ca_system_score_codex":0.00009907627,"about_ca_system_score_gemma":0.00018649976,"threshold_uncertainty_score":0.0053797364},"labels":[],"label_agreement":null},{"id":"W2037319473","doi":"10.1111/imr.12129","title":"Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy","year":2013,"lang":"en","type":"review","venue":"Immunological Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Adoptive cell transfer; Cell therapy; Immunotherapy; T cell; Immunology; Cancer; Antigen; Cancer immunotherapy; Cancer research; Chimeric antigen receptor; Adoptive immunotherapy; Cell; Biology; Medicine; Immune system; Internal medicine","score_opus":0.288011356370987,"score_gpt":0.47790319856529384,"score_spread":0.18989184219430683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037319473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024453975,0.99660397,0.00061572395,0.00014981425,0.00020386302,0.000016151002,0.000020608863,0.000017577131,0.0021276833],"genre_scores_gemma":[0.0014124587,0.9960349,0.00071209733,0.0001429107,0.00007795199,0.000023995692,0.000053456148,0.000003333803,0.0015388866],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998393,0.000026656693,0.000015295058,0.00002404101,0.00007653562,0.000018162722],"domain_scores_gemma":[0.9998907,0.000041758823,0.000018390054,0.0000054418056,0.000029678951,0.00001402943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005219834,0.0010269622,0.0010837168,0.0021370435,0.00025532048,0.00078956044,0.00085806055,0.0010775791,0.0034310385],"category_scores_gemma":[0.0003312041,0.0003145975,0.00045335552,0.002295223,0.00048080823,0.001144166,0.0006033878,0.0016015368,0.0038627046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055594926,0.00012424245,0.000117255404,0.0082622,0.000051568888,0.00019453432,0.00004476829,0.0006160865,0.009722989,0.0059566777,0.019566597,0.9552875],"study_design_scores_gemma":[0.000020532,0.00007205867,0.00037944305,0.0011578905,0.000041682608,0.00087663747,0.000024956851,0.00012240655,0.0021388286,0.0015745367,0.99357563,0.000015322099],"about_ca_topic_score_codex":0.0007313995,"about_ca_topic_score_gemma":0.0009756135,"teacher_disagreement_score":0.0034310385,"about_ca_system_score_codex":0.00067080715,"about_ca_system_score_gemma":0.00075689575,"threshold_uncertainty_score":0.011478007},"labels":[],"label_agreement":null},{"id":"W2037604674","doi":"10.1016/s1098-3015(10)70902-5","title":"PSS7 THE COST-EFFECTIVENESS OF RANIBIZUMAB COMPARED TO PDT-VAND BSC FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CANADA","year":2008,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Macular degeneration; Ranibizumab; Medicine; Ophthalmology; Oncology; Internal medicine; Optometry; Chemotherapy","score_opus":0.11774405482990875,"score_gpt":0.3684899964738832,"score_spread":0.25074594164397446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037604674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93363214,0.02705307,0.00041323973,0.009363337,0.00024592248,0.0005013323,0.0107751,0.000056818164,0.017959142],"genre_scores_gemma":[0.98900014,0.0057010334,0.00041870127,0.0006241171,0.00007167904,0.000050709183,0.0014424653,0.000012607632,0.0026786851],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984523,0.00044282855,0.0001157423,0.000100567486,0.0005363734,0.00035228365],"domain_scores_gemma":[0.9977456,0.0005256606,0.000317402,0.00003555915,0.00083807594,0.000537631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094537897,0.000367097,0.0008609175,0.0008913509,0.00082738785,0.0013858712,0.0007221396,0.0006644027,0.004995162],"category_scores_gemma":[0.0051499642,0.00028591047,0.0015649109,0.0020216107,0.0004949876,0.0003880241,0.00038837068,0.00079396664,0.00016768262],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16720565,0.0021419376,0.26950985,0.004326107,0.008129363,0.0014859822,0.0005647338,0.04105983,0.004758083,0.0071874917,0.039553486,0.4540775],"study_design_scores_gemma":[0.027902946,0.01188622,0.8649704,0.0013579106,0.013905799,0.001090613,0.001733425,0.044665392,0.0026499052,0.0014145806,0.028099494,0.00032338148],"about_ca_topic_score_codex":0.967604,"about_ca_topic_score_gemma":0.9768598,"teacher_disagreement_score":0.054055404,"about_ca_system_score_codex":0.054055404,"about_ca_system_score_gemma":0.047521457,"threshold_uncertainty_score":0.39220124},"labels":[],"label_agreement":null},{"id":"W2037616844","doi":"10.1016/j.blre.2014.08.002","title":"Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment","year":2014,"lang":"en","type":"review","venue":"Blood Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Università di Bologna","keywords":"Immunology; Context (archaeology); Medicine; Myeloid leukemia; Adjuvant; Graft-versus-host disease; Immune system; Blockade; Myeloid; Disease; Transplantation; Leukemia; Cell therapy; Cell; Biology; Internal medicine; Receptor","score_opus":0.08429626560051727,"score_gpt":0.35123953303396205,"score_spread":0.26694326743344476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037616844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001464328,0.9977608,0.00020680981,0.0006755405,0.0003624378,0.0000038608428,0.000014868481,0.000009186074,0.0008200747],"genre_scores_gemma":[0.0012836847,0.99681216,0.00024752237,0.0005773318,0.00023216325,0.0000065408285,0.000029538181,0.00000234753,0.0008087178],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986184,0.000029149625,0.000013454641,0.000022592596,0.00005336879,0.000019497926],"domain_scores_gemma":[0.9997913,0.00010403631,0.000022006987,0.000007354214,0.000054375687,0.000020952984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000547256,0.00052238116,0.0009794805,0.00081190537,0.0001898142,0.0009921981,0.0007983917,0.0010023338,0.0033106597],"category_scores_gemma":[0.00058757263,0.00016145417,0.00035628607,0.00073911034,0.00046258594,0.0010647456,0.00048600126,0.0023507937,0.0019120787],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114060735,0.00008080616,0.0001184979,0.006677055,0.00007468382,0.000101395584,0.000031189815,0.00032497343,0.0040301178,0.007849742,0.04195471,0.93864274],"study_design_scores_gemma":[0.000027375945,0.00009512754,0.00030050208,0.0012350914,0.000064880136,0.0004732984,0.000034120505,0.000086101376,0.0008268902,0.0026401286,0.9942035,0.000013055195],"about_ca_topic_score_codex":0.0005815116,"about_ca_topic_score_gemma":0.0015610408,"teacher_disagreement_score":0.0033106597,"about_ca_system_score_codex":0.0005303184,"about_ca_system_score_gemma":0.0007708068,"threshold_uncertainty_score":0.011075258},"labels":[],"label_agreement":null},{"id":"W2044365745","doi":"10.1038/nm1134","title":"Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells","year":2004,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institutes of Health","keywords":"BCL6; Corepressor; Cancer research; Biology; Psychological repression; Repressor; Lymphoma; Cell biology; B cell; Transcription factor; Gene; Germinal center; Genetics; Immunology; Gene expression; Antibody","score_opus":0.019227616320513556,"score_gpt":0.2900272092528044,"score_spread":0.27079959293229083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044365745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99060446,0.001168406,0.004319068,0.00029091444,0.00005320431,0.000020823963,0.0003886711,0.00016049678,0.0029939632],"genre_scores_gemma":[0.99602723,0.00027979273,0.0014529466,0.00005423005,0.000014906867,0.000016697892,0.00031238777,0.000031360123,0.0018103349],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966526,0.000048831327,0.000022594704,0.00005857413,0.000094842544,0.000109881075],"domain_scores_gemma":[0.99979895,0.00007395164,0.00003559708,0.000030276495,0.00001542694,0.00004578949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022845417,0.00031259944,0.00026595907,0.0003260131,0.000286175,0.0005709349,0.00034686978,0.00040421804,0.0023793958],"category_scores_gemma":[0.00016427394,0.00020146505,0.00024457744,0.00021081972,0.00034337922,0.0003297397,0.00025092732,0.0013404412,0.00072224386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017730978,0.00002973853,0.0000826447,0.000013038869,0.0000031378966,0.00003278753,0.000010289718,0.00007979404,0.99844307,0.00034872454,0.00004359254,0.0007358501],"study_design_scores_gemma":[0.000031327647,0.00014468376,0.00082922576,0.0000016229066,0.000009470876,0.00019786696,0.00001975465,0.00114705,0.9963953,0.00014151125,0.0010799858,0.0000021072892],"about_ca_topic_score_codex":0.0003109023,"about_ca_topic_score_gemma":0.0005080093,"teacher_disagreement_score":0.0023793958,"about_ca_system_score_codex":0.00036272043,"about_ca_system_score_gemma":0.000161568,"threshold_uncertainty_score":0.007959843},"labels":[],"label_agreement":null},{"id":"W2045257451","doi":"10.1016/j.jim.2014.03.012","title":"Adapting in vitro embryonic stem cell differentiation to the study of locus control regions","year":2014,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research; National Institutes of Health; New York State Stem Cell Science; National Institute of General Medical Sciences; Canada Research Chairs","keywords":"Biology; Transgene; Chromatin; Embryonic stem cell; Gene; Locus control region; Cellular differentiation; Reporter gene; Genetics; Gene expression; Regulation of gene expression; Locus (genetics); Computational biology; Cell biology; Enhancer","score_opus":0.06945535665012202,"score_gpt":0.3900136198179751,"score_spread":0.3205582631678531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045257451","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6768343,0.0022524905,0.31604972,0.00024245403,0.00016570858,0.00016423207,0.00028579973,0.000251413,0.0037538444],"genre_scores_gemma":[0.87670875,0.0034421047,0.113670066,0.00017967974,0.000045361492,0.00014183235,0.0007674221,0.00019542666,0.0048493943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997807,0.000071240436,0.000021040765,0.00004059773,0.00005884585,0.000027541017],"domain_scores_gemma":[0.9997594,0.00010054866,0.00003263338,0.000060713854,0.000025703917,0.00002091951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006092301,0.00038448317,0.00025730825,0.0002632584,0.00021099168,0.0007007582,0.00047865984,0.0004105563,0.0009784885],"category_scores_gemma":[0.00041602447,0.00026193573,0.0003433694,0.00018542455,0.00046136652,0.00029321626,0.00043253644,0.0011455357,0.00037969573],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011251735,0.000006947718,0.000117133786,0.0000151514805,0.0000017038427,0.000021017559,0.000018826511,0.00017008735,0.99805343,0.00026613558,0.0000064716387,0.0013119037],"study_design_scores_gemma":[0.000009147291,0.000078379286,0.0010185953,0.0000045907523,0.000014913907,0.00019490946,0.00003409656,0.0015438633,0.9939493,0.00031473764,0.0028326844,0.000004785446],"about_ca_topic_score_codex":0.0007804623,"about_ca_topic_score_gemma":0.0014019408,"teacher_disagreement_score":0.0009784885,"about_ca_system_score_codex":0.00028893736,"about_ca_system_score_gemma":0.0002847869,"threshold_uncertainty_score":0.0032734275},"labels":[],"label_agreement":null},{"id":"W2052914628","doi":"10.1182/blood-2006-04-013813","title":"Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Biology; Molecular biology; Progenitor cell; CD38; Diphtheria toxin; Leukemia; Haematopoiesis; Cancer research; Interleukin 15; CD34; Interleukin; Immunology; Stem cell; Cytokine; Cell biology; Microbiology; Toxin","score_opus":0.017335440033182554,"score_gpt":0.25592899077339853,"score_spread":0.238593550740216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052914628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871397,0.00020393723,0.00065034855,0.0000066748025,9.069013e-7,0.000007686843,0.0001311712,0.000016831837,0.00026847213],"genre_scores_gemma":[0.99803346,0.00017209524,0.0009701711,0.00001585123,0.000002513915,0.000020284826,0.00043284628,0.000008458706,0.0003442586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987173,0.000021425363,0.0000140108195,0.00003486277,0.000030861,0.000027051618],"domain_scores_gemma":[0.9998615,0.00004667754,0.00004207709,0.000010735701,0.000011284659,0.000027729026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014419852,0.0001717665,0.00013528192,0.00038958548,0.000070890506,0.00028499632,0.000069215625,0.0002230288,0.0008793858],"category_scores_gemma":[0.00027533897,0.00012329766,0.0000860699,0.00017312681,0.00014074787,0.00010910583,0.00013583477,0.0002371543,0.0003330733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016555157,0.000013945924,0.012345447,0.000009303802,0.0000042183,0.000028529019,0.000027994352,0.000055873094,0.98597485,0.000030004612,0.000018988409,0.0013251768],"study_design_scores_gemma":[0.000030795665,0.0004932041,0.41406566,0.000010786897,0.00004910154,0.0015191742,0.0001354171,0.0026490532,0.5796236,0.00013416712,0.0012820374,0.000007023099],"about_ca_topic_score_codex":0.00020544013,"about_ca_topic_score_gemma":0.0003226293,"teacher_disagreement_score":0.0008793858,"about_ca_system_score_codex":0.00013030489,"about_ca_system_score_gemma":0.00005918568,"threshold_uncertainty_score":0.0029417872},"labels":[],"label_agreement":null},{"id":"W2053967595","doi":"10.1084/jem.20091918","title":"Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","year":2010,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":887,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Howard Hughes Medical Institute; University College London; Swim Across America; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute","keywords":"Cytotoxic T cell; Adoptive cell transfer; Cancer research; Biology; CD8; Melanoma; Interleukin 21; Immunology; Antigen; In vitro; Biochemistry","score_opus":0.01306096873143876,"score_gpt":0.30389109359166705,"score_spread":0.2908301248602283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053967595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943129,0.0009933778,0.0027686255,0.00006107385,0.000029806146,0.00004500581,0.000092594346,0.00012053475,0.0015760536],"genre_scores_gemma":[0.99076325,0.00065336074,0.0027511015,0.00007118329,0.00003659421,0.000064302425,0.00025688316,0.00004940706,0.0053539667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984694,0.000018566949,0.000014401932,0.00003710496,0.000032860757,0.000050043924],"domain_scores_gemma":[0.99980706,0.000036175607,0.00004334189,0.000035643974,0.000013548268,0.00006411475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017296973,0.00053672533,0.00024059424,0.00025506355,0.00011015583,0.0003558341,0.00024194639,0.00034549375,0.0012620079],"category_scores_gemma":[0.0001350923,0.00014781646,0.00018953643,0.0000941881,0.00029054758,0.00029039194,0.00022549997,0.0011131432,0.0005706656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009673174,0.00009856728,0.00023215561,0.000020400577,0.0000032771645,0.000056559154,0.000013818499,0.000088620545,0.99716824,0.00008490672,0.000024733925,0.00211191],"study_design_scores_gemma":[0.00008262957,0.0014056762,0.0028043154,0.000011171153,0.000027618878,0.0005781196,0.00003015734,0.0010834829,0.99192965,0.0001766534,0.0018649867,0.000005473393],"about_ca_topic_score_codex":0.00015992398,"about_ca_topic_score_gemma":0.00024528714,"teacher_disagreement_score":0.0012620079,"about_ca_system_score_codex":0.0002606331,"about_ca_system_score_gemma":0.0002263025,"threshold_uncertainty_score":0.0042218566},"labels":[],"label_agreement":null},{"id":"W2054635400","doi":"10.1007/s10555-014-9542-0","title":"Immunotherapy of melanoma: Present options and future promises","year":2015,"lang":"en","type":"review","venue":"Cancer and Metastasis Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Ipilimumab; Medicine; Melanoma; Immunotherapy; Clinical trial; Oncology; Immune system; Immunology; Nivolumab; Adjuvant; Monoclonal antibody; CTLA-4; Internal medicine; T cell; Antibody; Cancer research","score_opus":0.1540316203694242,"score_gpt":0.444403877725553,"score_spread":0.2903722573561288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054635400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044980774,0.99902403,0.00006633909,0.00034956477,0.00020567233,0.0000019082465,0.000006581539,0.0000044223757,0.00029656722],"genre_scores_gemma":[0.00045566785,0.998517,0.000113487076,0.00032670924,0.00027332304,0.0000033115073,0.00001358942,8.500859e-7,0.00029608104],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998202,0.00003841563,0.00001951021,0.000029053912,0.00006346883,0.000029332457],"domain_scores_gemma":[0.99957293,0.00022709406,0.000048398448,0.000010106336,0.00008517538,0.00005626609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008707863,0.00084080844,0.0015024444,0.0014743403,0.00028191687,0.0013187797,0.000881028,0.0013576567,0.004097605],"category_scores_gemma":[0.00091128296,0.0002710179,0.0005223008,0.0013180589,0.0006399985,0.0018647363,0.000853088,0.002765103,0.0016304416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110312314,0.00007933413,0.00014644729,0.011508019,0.000070436865,0.000116398514,0.000041904746,0.00036900747,0.0016954404,0.0036045655,0.047270045,0.934988],"study_design_scores_gemma":[0.000044126264,0.00013693878,0.0005297887,0.0041164774,0.00013267853,0.00065355416,0.00006793193,0.000158983,0.00033163198,0.0031361086,0.9906715,0.00002031302],"about_ca_topic_score_codex":0.00081214175,"about_ca_topic_score_gemma":0.0025467605,"teacher_disagreement_score":0.004097605,"about_ca_system_score_codex":0.0005677747,"about_ca_system_score_gemma":0.0011043319,"threshold_uncertainty_score":0.013707876},"labels":[],"label_agreement":null},{"id":"W2056056608","doi":"10.1038/cgt.2009.80","title":"Human neural stem cells transduced with IFN-β and cytosine deaminase genes intensify bystander effect in experimental glioma","year":2009,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"National Science Council","keywords":"Cytosine deaminase; Bystander effect; Glioma; Cancer research; Suicide gene; Prodrug; Neural stem cell; Genetic enhancement; Biology; Stem cell; Pharmacology; Gene; Immunology; Cell biology; Biochemistry","score_opus":0.03365276231240223,"score_gpt":0.33831107962555396,"score_spread":0.30465831731315174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056056608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99681693,0.00094079046,0.0010179236,0.000052034942,0.000034392735,0.00003505843,0.00008628227,0.00006417301,0.00095253036],"genre_scores_gemma":[0.99754804,0.00051389856,0.00058599096,0.000021550024,0.000012513096,0.000028131228,0.00011535331,0.00001611549,0.0011583478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979836,0.000053362142,0.00001737803,0.000025795833,0.000041232313,0.000063857166],"domain_scores_gemma":[0.99988925,0.00003992154,0.000016106655,0.000023305576,0.000008583125,0.000022852082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003584223,0.0005080282,0.000536073,0.0006613019,0.00018760718,0.00031126296,0.00020915252,0.0003674095,0.0015969024],"category_scores_gemma":[0.00014085245,0.00020845076,0.00040062005,0.00033534982,0.00046544592,0.00034392189,0.000223069,0.0008054399,0.00027681745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076210743,0.00016537301,0.00017139685,0.000041949243,0.000011946131,0.00008297764,0.000055932833,0.00008631486,0.99644816,0.0002823313,0.000057209298,0.0018342101],"study_design_scores_gemma":[0.00006079419,0.00061175134,0.0007985544,0.0000022428787,0.00002984075,0.00012515031,0.000023516277,0.00042881028,0.9972222,0.00006515799,0.00062996714,0.0000020791658],"about_ca_topic_score_codex":0.0010971011,"about_ca_topic_score_gemma":0.00072046235,"teacher_disagreement_score":0.0015969024,"about_ca_system_score_codex":0.00026290523,"about_ca_system_score_gemma":0.00027691934,"threshold_uncertainty_score":0.005342126},"labels":[],"label_agreement":null},{"id":"W2056397238","doi":"10.1186/2051-1426-2-s3-p17","title":"Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Modular design; Antigen; Receptor; T cell; Cell biology; Cancer research; Biology; Immunology; Computer science; Chemistry; Immune system; Genetics","score_opus":0.034115129421557464,"score_gpt":0.360206308257852,"score_spread":0.3260911788362945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056397238","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.630815,0.01811819,0.30377185,0.0017731445,0.0010710495,0.0005675602,0.0007952676,0.0033095707,0.039778285],"genre_scores_gemma":[0.88808054,0.005760076,0.075085945,0.0005900849,0.0001706091,0.00025585876,0.00066730136,0.00022274253,0.029166833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980265,0.00003347616,0.000014064309,0.000047420846,0.000067218745,0.000035181216],"domain_scores_gemma":[0.99992096,0.000013473092,0.000019828143,0.000010462179,0.000013203832,0.000022062652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003166014,0.00041315006,0.00018406323,0.0006207556,0.00022991956,0.00045714856,0.0004087067,0.0005799919,0.003528785],"category_scores_gemma":[0.00013684701,0.00025961502,0.0003039629,0.0002447195,0.00026983858,0.00046704258,0.00032131918,0.0010245611,0.0015911456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045955814,0.000039385883,0.000029861672,0.000051366762,0.000005215301,0.000066379514,0.000016529268,0.00010122933,0.99223316,0.00076782814,0.00051440054,0.0061286837],"study_design_scores_gemma":[0.000025886553,0.00021601537,0.00029494616,0.0000059282916,0.000019484927,0.0005484756,0.000009476735,0.0016733592,0.9830589,0.00012914461,0.014005214,0.000013061728],"about_ca_topic_score_codex":0.00031991221,"about_ca_topic_score_gemma":0.00045706358,"teacher_disagreement_score":0.003528785,"about_ca_system_score_codex":0.00030559095,"about_ca_system_score_gemma":0.00021668366,"threshold_uncertainty_score":0.011804938},"labels":[],"label_agreement":null},{"id":"W2056809624","doi":"10.1182/blood-2014-10-609271","title":"Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; National Institutes of Health","keywords":"T-cell receptor; Thymocyte; Biology; Cancer research; Receptor; Transgene; Signal transduction; Immunology; Survivin; Antigen; T cell; Cell biology; Molecular biology; Cancer; Gene; Genetics; CD8; Immune system","score_opus":0.04458352362943507,"score_gpt":0.3033461817699167,"score_spread":0.2587626581404816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056809624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99462694,0.0007049934,0.0028553498,0.000046805962,0.00002180521,0.000041416646,0.00024381641,0.00013057611,0.0013283258],"genre_scores_gemma":[0.995972,0.00037508085,0.0013392165,0.000032056752,0.0000074059417,0.000021588345,0.0003018289,0.00003410084,0.0019167472],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999718,0.000038463575,0.000033151064,0.000068132715,0.00005838241,0.00008381434],"domain_scores_gemma":[0.99974376,0.000044676344,0.00007289336,0.000043820128,0.000018989384,0.00007584656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015332171,0.0003117405,0.00022199623,0.0002719808,0.00012404662,0.00050024263,0.00022209255,0.00025349934,0.0013927155],"category_scores_gemma":[0.00015822727,0.0001760693,0.00023380744,0.00013258753,0.00016235388,0.00021662976,0.00024589853,0.00075869967,0.0005255663],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026786578,0.000016222835,0.00014720386,0.000010064836,0.0000026791213,0.000031756077,0.0000059864537,0.000023820112,0.9992481,0.000052538133,0.000009098485,0.0004258439],"study_design_scores_gemma":[0.000016096776,0.0003142479,0.0025122373,0.0000050216627,0.000022864824,0.00042100635,0.000021311222,0.0005534106,0.9941619,0.000025989742,0.0019433886,0.0000024438875],"about_ca_topic_score_codex":0.00027698826,"about_ca_topic_score_gemma":0.0004946117,"teacher_disagreement_score":0.0013927155,"about_ca_system_score_codex":0.0002917709,"about_ca_system_score_gemma":0.00017835853,"threshold_uncertainty_score":0.0046591163},"labels":[],"label_agreement":null},{"id":"W2057283586","doi":"10.1093/emboj/cdf588","title":"Inducible gene deletion reveals different roles for B‐Raf and Raf‐1 in B‐cell antigen receptor signalling","year":2002,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Leibniz-Gemeinschaft; Deutsche Forschungsgemeinschaft","keywords":"Biology; Signalling; Gene; B cell; B-cell receptor; Antigen; Genetics; Receptor; Molecular biology; Cell biology; Cancer research; Antibody","score_opus":0.06014735966484382,"score_gpt":0.3056308840700656,"score_spread":0.24548352440522178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057283586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912977,0.0011271246,0.0041684667,0.00017988877,0.000037621143,0.000033176962,0.0008350839,0.00015281164,0.0021682563],"genre_scores_gemma":[0.9893327,0.0006829572,0.0032627028,0.000078081626,0.000017233684,0.000054201588,0.0017001356,0.00015158535,0.004720465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99959546,0.000048455055,0.00004027975,0.00007216009,0.0001012402,0.00014234263],"domain_scores_gemma":[0.99960667,0.00009347725,0.000120977194,0.00005553337,0.000022601462,0.000100697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027196083,0.00078611827,0.00033549196,0.0006967195,0.00031300262,0.0009824899,0.0009544397,0.0006925962,0.0034666639],"category_scores_gemma":[0.00021066862,0.00055582233,0.0005039234,0.00033915706,0.00069267466,0.0005340093,0.00048791405,0.0019724127,0.0021591277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019318775,0.000029797331,0.00006485238,0.000011672154,0.0000034531852,0.000031610714,0.0000074447594,0.00003813882,0.9989367,0.00032422633,0.00002085087,0.0003381738],"study_design_scores_gemma":[0.00004241488,0.000068634465,0.0011916594,0.0000039011884,0.000023348986,0.0002501563,0.000031060106,0.00056090235,0.99638176,0.00008878285,0.001351482,0.000005909344],"about_ca_topic_score_codex":0.00064798805,"about_ca_topic_score_gemma":0.00091039995,"teacher_disagreement_score":0.0034666639,"about_ca_system_score_codex":0.0007238821,"about_ca_system_score_gemma":0.00031678707,"threshold_uncertainty_score":0.0115971565},"labels":[],"label_agreement":null},{"id":"W2057893105","doi":"10.1182/blood-2010-03-272336","title":"CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Christie (Canada); McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Antigen; Biology; Immunology; Antigen presentation; Antigen-presenting cell; Cytotoxic T cell; Population; Haematopoiesis; CD8; T cell; Hematopoietic stem cell; Stem cell; Cell biology; Immune system; Medicine","score_opus":0.012551380640342715,"score_gpt":0.2585916342091094,"score_spread":0.2460402535687667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057893105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695146,0.00066350785,0.001633989,0.000022015096,0.000006125364,0.000012672614,0.000031920834,0.000044653905,0.0006336002],"genre_scores_gemma":[0.9980101,0.00016541188,0.0010040879,0.000014186359,0.000005168222,0.000013182043,0.00007342894,0.00000769383,0.0007067781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985266,0.000022392363,0.000015078623,0.000028233404,0.000026867172,0.00005478656],"domain_scores_gemma":[0.999881,0.000032323416,0.000029176605,0.00002449234,0.0000140757165,0.000018897716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022627036,0.00022961485,0.00014200211,0.00015193767,0.00008672678,0.0003041603,0.0001580849,0.00015658679,0.0006245322],"category_scores_gemma":[0.00018671934,0.000105558036,0.00012482512,0.000065753506,0.00016741935,0.00022114317,0.00018138367,0.00034718207,0.00021831741],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098394616,0.000024288296,0.0006590027,0.000014940612,0.0000027880053,0.00004416296,0.000022355824,0.000046067664,0.99573475,0.00010470068,0.00001631213,0.003232202],"study_design_scores_gemma":[0.000026583624,0.0004772372,0.007556388,0.000007251165,0.000024896339,0.00036737093,0.000047880105,0.001208773,0.9887827,0.000091007205,0.0014068512,0.0000030742126],"about_ca_topic_score_codex":0.00019383022,"about_ca_topic_score_gemma":0.00031382852,"teacher_disagreement_score":0.0006245322,"about_ca_system_score_codex":0.00018305737,"about_ca_system_score_gemma":0.00015036497,"threshold_uncertainty_score":0.002089262},"labels":[],"label_agreement":null},{"id":"W2060346254","doi":"10.1038/sj.cgt.7700213","title":"T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors","year":2000,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institutes of Health","keywords":"Epitope; Cytolysis; Biology; T cell; Immune system; Antibody; Chimeric antigen receptor; Antigen; Molecular biology; Virology; Cytotoxic T cell; Immunology; In vitro","score_opus":0.02669625071036997,"score_gpt":0.29264648787782516,"score_spread":0.2659502371674552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060346254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981934,0.0025476713,0.010948467,0.000091092814,0.000045318913,0.00006631549,0.00013030884,0.0002049045,0.0040320223],"genre_scores_gemma":[0.9954507,0.0005430356,0.0018108155,0.000032287353,0.00001175675,0.00004220175,0.00011854786,0.000033036486,0.0019576587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996942,0.00006619709,0.000014033711,0.000060581795,0.000049867784,0.0001151821],"domain_scores_gemma":[0.99990654,0.00003282576,0.00002102943,0.000019100407,0.000007971184,0.000012508017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033629363,0.00058973243,0.00044176556,0.00049015606,0.00021977961,0.0005047476,0.0005656249,0.00071430503,0.0014075903],"category_scores_gemma":[0.00020866632,0.00023063707,0.0003728221,0.00025132502,0.00036547202,0.00042552667,0.00041268519,0.00094344304,0.00044972292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003214145,0.000075365475,0.00011498638,0.00005753019,0.000020893638,0.00007992853,0.00004200994,0.0007278808,0.99400616,0.001375503,0.00011523502,0.0030631924],"study_design_scores_gemma":[0.00004611559,0.00023397307,0.00035798782,0.0000038490675,0.000027388221,0.00023768752,0.000012949129,0.0023253106,0.99489033,0.0001352999,0.001724923,0.0000041091284],"about_ca_topic_score_codex":0.0008498229,"about_ca_topic_score_gemma":0.00069650775,"teacher_disagreement_score":0.0014075903,"about_ca_system_score_codex":0.000529799,"about_ca_system_score_gemma":0.0002625976,"threshold_uncertainty_score":0.004708886},"labels":[],"label_agreement":null},{"id":"W2062752944","doi":"10.1016/j.molonc.2014.05.002","title":"From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting","year":2014,"lang":"en","type":"editorial","venue":"Molecular Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Biomarker; PTEN; Oncology; Immunohistochemistry; Medicine; Internal medicine; Computational biology; Bioinformatics; Biology; Genetics","score_opus":0.04979045729444718,"score_gpt":0.4495815692546231,"score_spread":0.3997911119601759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062752944","genre_codex":"methods","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021566283,0.2808271,0.4887635,0.17583005,0.00555216,0.001535037,0.0021260353,0.0028992486,0.020900615],"genre_scores_gemma":[0.19705915,0.102651045,0.6386969,0.04601586,0.0074869664,0.0020265034,0.0029399826,0.0005612829,0.0025623413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96522486,0.018644491,0.003865242,0.0042801797,0.007048554,0.0009366339],"domain_scores_gemma":[0.9349206,0.028762227,0.004894745,0.0077728136,0.01949597,0.0041536484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08544163,0.0021085558,0.0033960894,0.0052060527,0.00077280076,0.011460124,0.003992051,0.0040529617,0.0036924318],"category_scores_gemma":[0.07599553,0.0010011633,0.001362507,0.0038335253,0.0040606447,0.009393899,0.008566459,0.009711507,0.0030472786],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009862297,0.00042998904,0.027374724,0.00473794,0.000536611,0.0005560122,0.0012923651,0.006231119,0.00946326,0.07505961,0.03315364,0.8401786],"study_design_scores_gemma":[0.0004705457,0.0037135135,0.025446195,0.015914224,0.0010053847,0.0028955992,0.002859416,0.031175882,0.02381059,0.35027516,0.54179454,0.0006389414],"about_ca_topic_score_codex":0.0011675128,"about_ca_topic_score_gemma":0.0007092242,"teacher_disagreement_score":0.08544163,"about_ca_system_score_codex":0.0034935838,"about_ca_system_score_gemma":0.009612594,"threshold_uncertainty_score":0.45186388},"labels":[],"label_agreement":null},{"id":"W2063178906","doi":"10.1089/hum.2004.15.945","title":"Combined Immunotherapy and Antiangiogenic Therapy of Cancer with Microencapsulated Cells","year":2004,"lang":"en","type":"article","venue":"Human Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Angiostatin; Immunotherapy; Medicine; Cancer research; Angiogenesis; Cancer immunotherapy; Genetic enhancement; Melanoma; Pharmacology; Immunology; Immune system; Biology","score_opus":0.026762385993778042,"score_gpt":0.30824109233987224,"score_spread":0.2814787063460942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063178906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9712506,0.0060737925,0.020251933,0.00013190285,0.00020258529,0.00020395097,0.00012059059,0.00016718284,0.0015973578],"genre_scores_gemma":[0.9792839,0.002033802,0.016102204,0.00005986321,0.000063642794,0.00012892517,0.00011712993,0.000022678692,0.0021878402],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997899,0.000026328606,0.000015573274,0.00005583688,0.00006799545,0.000044333676],"domain_scores_gemma":[0.99993086,0.00001540999,0.000017862065,0.0000113481465,0.000007952372,0.000016497921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019761812,0.00053866574,0.00048915116,0.00033056436,0.000101022655,0.0003356431,0.00028431945,0.0004253989,0.00056497107],"category_scores_gemma":[0.00007684595,0.00015400803,0.00039940208,0.00018166425,0.00027883638,0.00024834633,0.00024183732,0.00068522943,0.00022339507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006747936,0.00007473753,0.00012089118,0.00006825963,0.000013087874,0.000053604475,0.000012389389,0.0002997883,0.9954572,0.00010089196,0.000027088334,0.0037046236],"study_design_scores_gemma":[0.0000280188,0.0007205156,0.00072276976,0.000004068049,0.00004240011,0.00017106661,0.0000066777448,0.0011060666,0.99495333,0.000020615189,0.002219252,0.000005239563],"about_ca_topic_score_codex":0.00028823136,"about_ca_topic_score_gemma":0.00069301703,"teacher_disagreement_score":0.00056497107,"about_ca_system_score_codex":0.00023123116,"about_ca_system_score_gemma":0.0002232358,"threshold_uncertainty_score":0.0018900037},"labels":[],"label_agreement":null},{"id":"W2063847092","doi":"10.5582/ddt.2011.v5.3.107","title":"Prospects of cancer biotherapy","year":2011,"lang":"en","type":"article","venue":"Drug Discoveries & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"Radiation therapy; Medicine; Immune system; Cancer research; Cancer; Targeted therapy; Cancer cell; Immunotherapy; Cancer treatment; Genetic enhancement; Chemotherapy; Immunology; Oncology; Internal medicine; Biology; Gene","score_opus":0.05589061693243864,"score_gpt":0.33978204868637296,"score_spread":0.28389143175393433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063847092","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046043936,0.87606335,0.012618271,0.043985948,0.003892903,0.000059547954,0.00037412162,0.00018378148,0.05821771],"genre_scores_gemma":[0.08007969,0.85536253,0.009154402,0.018651482,0.005293209,0.00018221558,0.00058435596,0.000060944883,0.03063118],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938416,0.00015874355,0.000021966829,0.00011674848,0.00019829343,0.000120128796],"domain_scores_gemma":[0.99918264,0.00029806703,0.00007455649,0.000048862756,0.00024242778,0.00015347068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017796744,0.0006746295,0.00074522075,0.0011933799,0.0006994921,0.0019547457,0.0009342204,0.0030412003,0.020311933],"category_scores_gemma":[0.0013611867,0.00019337758,0.0007046749,0.0010016809,0.0018414389,0.0032167824,0.0012195301,0.0037528793,0.005986164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038509435,0.00043084493,0.0012480937,0.0029342389,0.000058543268,0.0005977886,0.0002465302,0.0018473373,0.012126803,0.29626936,0.09461032,0.589245],"study_design_scores_gemma":[0.000042408108,0.00037746245,0.00093209185,0.0007806549,0.00003599157,0.00089704583,0.00019577098,0.0010991936,0.004061087,0.09943434,0.89210254,0.000041411073],"about_ca_topic_score_codex":0.0007124725,"about_ca_topic_score_gemma":0.000864042,"teacher_disagreement_score":0.020311933,"about_ca_system_score_codex":0.0016348984,"about_ca_system_score_gemma":0.0018564995,"threshold_uncertainty_score":0.06795013},"labels":[],"label_agreement":null},{"id":"W2064357373","doi":"10.12816/0003140","title":"Immunotherapy for B-Cell Neoplasms Using T-Cells Expressing Chimeric Antigen Receptors : From Antigen Choice to Clinical Implementation","year":2012,"lang":"en","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of Saskatchewan; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Chimeric antigen receptor; Antigen; CD19; Immunotherapy; Immunology; Medicine; Immune system; B cell; Cancer research; Antibody","score_opus":0.06092115815099508,"score_gpt":0.39461125777776707,"score_spread":0.333690099626772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064357373","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30524266,0.6019651,0.05879872,0.014742683,0.00040588042,0.00035900352,0.000070688955,0.0002680123,0.018147215],"genre_scores_gemma":[0.6777056,0.2778868,0.034567785,0.0029222872,0.00053539104,0.00020017514,0.00011163025,0.000051052713,0.0060192673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981254,0.00007136946,0.00001113874,0.000019747817,0.00005839083,0.000026823802],"domain_scores_gemma":[0.9998616,0.00007321968,0.000024939172,0.000006932925,0.000018631894,0.000014718014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011339649,0.00025549266,0.0003646118,0.00034399732,0.00018611146,0.0008191882,0.00025414574,0.0007384616,0.0015852132],"category_scores_gemma":[0.00039936384,0.00012658643,0.00018532592,0.00024419345,0.00064138277,0.0007095379,0.0003268677,0.0008022988,0.00035483512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063579803,0.0006106048,0.003431547,0.0022193987,0.000037434802,0.00080618134,0.00045989358,0.002113256,0.27088952,0.024833068,0.0028489886,0.6911143],"study_design_scores_gemma":[0.00087050855,0.012912979,0.008349824,0.0012546284,0.00020966885,0.011868753,0.0008499974,0.006522314,0.46045712,0.026216833,0.4703976,0.00008966788],"about_ca_topic_score_codex":0.0002490064,"about_ca_topic_score_gemma":0.00044779238,"teacher_disagreement_score":0.0015852132,"about_ca_system_score_codex":0.000451585,"about_ca_system_score_gemma":0.00066687295,"threshold_uncertainty_score":0.0059970617},"labels":[],"label_agreement":null},{"id":"W2068343048","doi":"10.1182/blood-2013-11-536433","title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":617,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Concordance; Lymphoma; Diffuse large B-cell lymphoma; Gene expression profiling; Germinal center; Pathology; Cancer research; Medicine; Computational biology; Biology; Molecular biology; B cell; Gene expression; Gene; Immunology; Internal medicine; Antibody; Genetics","score_opus":0.025362049045606384,"score_gpt":0.3065655540313091,"score_spread":0.2812035049857027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068343048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98419756,0.00063204713,0.012415973,0.000028075581,0.000008527747,0.00015856134,0.00045315927,0.000077690645,0.0020284783],"genre_scores_gemma":[0.99117833,0.00021896622,0.0071980674,0.00003618392,0.000004921175,0.000111354886,0.0007285285,0.000030092655,0.0004934628],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879223,0.00034236026,0.00015962598,0.0003000481,0.00026139777,0.00014432275],"domain_scores_gemma":[0.9989724,0.0003717181,0.00018230802,0.00022922181,0.00018844935,0.000055914268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020222506,0.00022643263,0.0002258845,0.0015623904,0.00029535362,0.0008473554,0.0002518047,0.0004407344,0.00083964947],"category_scores_gemma":[0.0019202717,0.00021891063,0.00015686205,0.0005637371,0.00052145956,0.00034168994,0.00039442745,0.00026458953,0.0003644356],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019035666,0.00012290712,0.49879402,0.00013237215,0.00013348328,0.0006088132,0.00064848014,0.0010197549,0.46700436,0.0005972022,0.00028223183,0.028752787],"study_design_scores_gemma":[0.00008189058,0.0007175337,0.72735053,0.000060454582,0.00020484354,0.0043152897,0.0010557881,0.010841826,0.24819526,0.0007130057,0.0064304555,0.00003307789],"about_ca_topic_score_codex":0.0015573855,"about_ca_topic_score_gemma":0.003719024,"teacher_disagreement_score":0.0020222506,"about_ca_system_score_codex":0.00034755532,"about_ca_system_score_gemma":0.00018980859,"threshold_uncertainty_score":0.010694802},"labels":[],"label_agreement":null},{"id":"W2068574639","doi":"10.1002/ijc.20043","title":"Synergistic effect of lymphotactin and interferon γ‐inducible protein‐10 transgene expression in T‐cell localization and adoptive T‐cell therapy of tumors","year":2004,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"University of Saskatchewan","keywords":"CD8; Adoptive cell transfer; Cytotoxic T cell; CXCR3; Biology; T cell; Granzyme B; Molecular biology; Transgene; Immunology; Cancer research; Chemokine; In vitro; Antigen; Immune system; Chemokine receptor; Biochemistry","score_opus":0.015375306465241453,"score_gpt":0.3273272014006939,"score_spread":0.31195189493545245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068574639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921307,0.0019665086,0.0034192484,0.00008819262,0.00009449584,0.00009227155,0.00009208001,0.00010169695,0.0020147245],"genre_scores_gemma":[0.99507624,0.0008976514,0.0023802086,0.000048814116,0.000017877486,0.000070249844,0.00009891569,0.000009554883,0.0014004124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998398,0.000031052434,0.0000136794015,0.000028344486,0.000036292582,0.00005082514],"domain_scores_gemma":[0.99993694,0.000012830475,0.000013775071,0.000005845205,0.000004148011,0.000026410115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014658691,0.00052208075,0.00032285086,0.00022300222,0.000058942078,0.00028406802,0.00017609062,0.00025457208,0.0007074185],"category_scores_gemma":[0.00009403258,0.00014452504,0.00023655112,0.00013808439,0.00019890434,0.00019855189,0.00024906124,0.00048802365,0.00018621671],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045715348,0.0001991729,0.00018729219,0.000088416586,0.000015019062,0.000093807845,0.000023397584,0.00036330035,0.9931044,0.000103403574,0.00007494257,0.005289595],"study_design_scores_gemma":[0.00015241341,0.0030198907,0.0021052707,0.000015342046,0.00010264641,0.00038553556,0.00003024172,0.0020834415,0.98872674,0.000049440827,0.0033211182,0.000007961194],"about_ca_topic_score_codex":0.00035851766,"about_ca_topic_score_gemma":0.0007342859,"teacher_disagreement_score":0.0007074185,"about_ca_system_score_codex":0.00018301026,"about_ca_system_score_gemma":0.00026057175,"threshold_uncertainty_score":0.0023665428},"labels":[],"label_agreement":null},{"id":"W2070037020","doi":"10.1186/2051-1426-2-s3-p5","title":"A clinical grade cell-based artificial APT, aAPC/mOKT3, for unbiased expansion of CD3+ T lymphocytes","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adoptive cell transfer; CD3; Medicine; Tumor-infiltrating lymphocytes; T cell; Cancer research; Cancer; Immunology; Internal medicine; Immunotherapy; CD8; Immune system","score_opus":0.07337979631303736,"score_gpt":0.4284327000562539,"score_spread":0.3550529037432165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070037020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8685954,0.005387342,0.10779922,0.0010174857,0.0002071427,0.00056117587,0.0019555222,0.0012856615,0.01319098],"genre_scores_gemma":[0.9421931,0.0014066609,0.045569494,0.00023110368,0.00003509327,0.00016208479,0.0013677654,0.00014044016,0.008894289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975234,0.000055494078,0.000022298276,0.00004799549,0.000096440555,0.000025475367],"domain_scores_gemma":[0.999861,0.000035624285,0.00002105685,0.000027029562,0.000026418285,0.000028801209],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035065014,0.00026724424,0.0001427556,0.00024576893,0.0001779152,0.000458072,0.00017169477,0.00029519427,0.0026173387],"category_scores_gemma":[0.00038425822,0.000100379184,0.00010232922,0.00017770057,0.00020766756,0.0001486405,0.0001809432,0.0006038221,0.00097378355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011007462,0.000030809584,0.00042752872,0.00003484707,0.0000051811307,0.000024091933,0.000015251516,0.00030922194,0.9919012,0.00028139167,0.00033489993,0.006525432],"study_design_scores_gemma":[0.000021598453,0.00013678818,0.000933679,0.000004448625,0.000014153567,0.00020387793,0.000004987881,0.0016671437,0.98890847,0.00009003949,0.008011357,0.0000034760208],"about_ca_topic_score_codex":0.00044066887,"about_ca_topic_score_gemma":0.0009272299,"teacher_disagreement_score":0.0026173387,"about_ca_system_score_codex":0.0002624299,"about_ca_system_score_gemma":0.00034111712,"threshold_uncertainty_score":0.008755863},"labels":[],"label_agreement":null},{"id":"W2070049862","doi":"10.1371/journal.pbio.0060156","title":"Micromanagement of Lymphomas","year":2008,"lang":"en","type":"article","venue":"PLoS Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Biology; breakpoint cluster region; B-cell receptor; Antigen; B cell; Cell biology; B-1 cell; Naive B cell; Immune system; Clonal deletion; Receptor; Antibody; Molecular biology; Antigen-presenting cell; T cell; Immunology; T-cell receptor; Genetics","score_opus":0.05988049581368391,"score_gpt":0.31350806457063857,"score_spread":0.25362756875695464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070049862","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770339,0.005678318,0.006261086,0.00040875465,0.00015513555,0.00006832859,0.00016242755,0.0002610263,0.009970968],"genre_scores_gemma":[0.9918767,0.0009191472,0.0015004888,0.00006563823,0.00003198537,0.000032713982,0.000104139064,0.000018221519,0.0054509086],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998938,0.000023671859,0.000003751273,0.000019804398,0.000021604097,0.00003744648],"domain_scores_gemma":[0.9999356,0.000017283752,0.000010393177,0.000009741591,0.0000070881933,0.000019996382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013603103,0.0001632043,0.00015390234,0.00027638784,0.00020008117,0.00037208234,0.00016766872,0.00021592411,0.0027044243],"category_scores_gemma":[0.00013303483,0.000122224,0.00011472402,0.00013139853,0.00015030475,0.00018914448,0.00022331989,0.00043551016,0.0005304271],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017044424,0.000069676265,0.000432197,0.00005644112,0.0000068595873,0.00018130739,0.00004530602,0.00013766566,0.9871748,0.0012369592,0.0003449076,0.010143477],"study_design_scores_gemma":[0.00006817121,0.0005958606,0.0029803717,0.000008777444,0.000023718407,0.00066348567,0.00009443069,0.0012832381,0.97632515,0.0003847655,0.017567884,0.000004198462],"about_ca_topic_score_codex":0.00074437156,"about_ca_topic_score_gemma":0.0012391584,"teacher_disagreement_score":0.0027044243,"about_ca_system_score_codex":0.0002436876,"about_ca_system_score_gemma":0.00021952449,"threshold_uncertainty_score":0.009047151},"labels":[],"label_agreement":null},{"id":"W2070396091","doi":"10.1016/j.jval.2014.03.416","title":"Evolving Treatment Patterns in Metastatic Melanoma in Canada","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vemurafenib; Trametinib; Dacarbazine; Internal medicine; Metastatic melanoma; Ipilimumab; Oncology; Salvage therapy; Melanoma; Lomustine; Temozolomide; Targeted therapy; Cancer; Chemotherapy; Vincristine; Immunotherapy","score_opus":0.06466749246790013,"score_gpt":0.34066119184665805,"score_spread":0.27599369937875795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070396091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402166,0.007091338,0.00050252705,0.022682248,0.00015311396,0.00014104873,0.007163917,0.000064646694,0.021984562],"genre_scores_gemma":[0.99064726,0.002615171,0.00032210053,0.0014244972,0.000028909728,0.000021666743,0.0010073523,0.000035314388,0.003897645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975955,0.00016775931,0.00015478519,0.00021272941,0.0007347544,0.0011344417],"domain_scores_gemma":[0.99293315,0.00040509924,0.0012575566,0.000083223764,0.0026897185,0.0026312878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007902846,0.00019568198,0.00036319808,0.0026914862,0.0029325695,0.0021001017,0.001560919,0.00078050356,0.0059763966],"category_scores_gemma":[0.0054188934,0.00028924938,0.00054908206,0.007278799,0.0010457922,0.00055656134,0.0009998941,0.001361107,0.0002668824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038294742,0.00016114456,0.9204265,0.00019992092,0.00008275779,0.0006236377,0.0033519925,0.0012498002,0.00092588476,0.0037674245,0.016841503,0.05198649],"study_design_scores_gemma":[0.0000376536,0.00007542842,0.96594864,0.00025974223,0.000054372027,0.00058185216,0.011410923,0.0015276392,0.00037627848,0.0005059046,0.019163629,0.000058003654],"about_ca_topic_score_codex":0.99398345,"about_ca_topic_score_gemma":0.99756515,"teacher_disagreement_score":0.08660805,"about_ca_system_score_codex":0.08660805,"about_ca_system_score_gemma":0.09649986,"threshold_uncertainty_score":0.62838835},"labels":[],"label_agreement":null},{"id":"W2071392212","doi":"10.1097/01.tp.0000330554.83483.f5","title":"ALLOREACTIVE REGULATORY T CELLS CAN CONTROL THE EARLY STAGE OF REJECTION BY THE DIRECT PATHWAY.","year":2008,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"Cell biology; Control (management); Immunology; Biology; Computer science","score_opus":0.017526829876886373,"score_gpt":0.25370052755431133,"score_spread":0.23617369767742497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071392212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74857366,0.080178864,0.032812927,0.0034980697,0.0026610186,0.0004574027,0.00049442664,0.001360163,0.12996338],"genre_scores_gemma":[0.955848,0.009876306,0.004549789,0.0005265824,0.00065756415,0.00009749977,0.00024144915,0.000075860655,0.028126953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99962044,0.000113856106,0.000015080772,0.00006293461,0.0000880474,0.00009954373],"domain_scores_gemma":[0.9997862,0.00005666045,0.000040820218,0.0000381044,0.000026449557,0.000051793624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004909905,0.000571341,0.00031859768,0.0003723458,0.00019282686,0.00080560404,0.00034001286,0.0007229401,0.0156147005],"category_scores_gemma":[0.00072773657,0.00014453717,0.0003197869,0.00012653707,0.00044998282,0.00054864684,0.00046806785,0.0018652403,0.003959063],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010393605,0.00074199354,0.0030435068,0.0005241996,0.00005840398,0.0009005644,0.00015471199,0.00050999894,0.7831598,0.013146877,0.005373827,0.19134668],"study_design_scores_gemma":[0.0010632391,0.012169617,0.022612337,0.0004947558,0.0003884346,0.012919747,0.00044605226,0.005038277,0.7163035,0.01661746,0.21188504,0.00006148003],"about_ca_topic_score_codex":0.00011188351,"about_ca_topic_score_gemma":0.00032618162,"teacher_disagreement_score":0.0156147005,"about_ca_system_score_codex":0.00017281709,"about_ca_system_score_gemma":0.00027638313,"threshold_uncertainty_score":0.05223632},"labels":[],"label_agreement":null},{"id":"W2071754795","doi":"10.4161/onci.26770","title":"TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity","year":2013,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Retargeting; T cell; T-cell receptor; Cancer research; Antigen; CD3; Bispecific antibody; Immunity; Co-stimulation; Cell; Chimeric antigen receptor; Medicine; Stimulation; Antibody; Immunology; Immune system; CD28; CD8; Biology; Computer science; Monoclonal antibody; Internal medicine","score_opus":0.023860766809999833,"score_gpt":0.2860688319584116,"score_spread":0.2622080651484118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071754795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835835,0.0015694887,0.012010706,0.00014143513,0.00008085968,0.00007803084,0.00007739267,0.00040093146,0.002057574],"genre_scores_gemma":[0.9932661,0.00039876855,0.0044653234,0.00006367482,0.000024084535,0.0000254512,0.000071668175,0.000026448204,0.0016584906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996886,0.00004130406,0.000017914113,0.00006572706,0.00006771698,0.000118783435],"domain_scores_gemma":[0.9999249,0.000013769677,0.000016035929,0.000011306133,0.000008666523,0.00002525049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015919097,0.00052654033,0.00040547963,0.00027179264,0.00012554001,0.00040408745,0.00025662422,0.00048499004,0.0017088848],"category_scores_gemma":[0.00011188148,0.00015013502,0.00028596335,0.00020619802,0.00018703152,0.00033102132,0.00032373265,0.0007725456,0.00047877073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010670596,0.00008101304,0.00006521281,0.000024516099,0.000004951663,0.00004157717,0.0000070384367,0.00023125217,0.9952069,0.000114343486,0.000070029746,0.0040465384],"study_design_scores_gemma":[0.00003931352,0.00044579507,0.00052378926,0.0000022082822,0.000024702253,0.00014201547,0.0000051412358,0.0017131473,0.99532545,0.000046618195,0.0017266964,0.0000052353876],"about_ca_topic_score_codex":0.00029264763,"about_ca_topic_score_gemma":0.000720791,"teacher_disagreement_score":0.0017088848,"about_ca_system_score_codex":0.000216988,"about_ca_system_score_gemma":0.0002732734,"threshold_uncertainty_score":0.0057168007},"labels":[],"label_agreement":null},{"id":"W2076379671","doi":"10.1371/journal.pone.0030229","title":"Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"National Cancer Institute; American Society of Hematology; National Institutes of Health; Cancer Research Institute","keywords":"T cell; CD8; Cytotoxic T cell; Biology; Cell biology; IL-2 receptor; FOXP3; Antigen-presenting cell; Interleukin 21; Immune system; Immunology; In vitro; Biochemistry","score_opus":0.10944666410691732,"score_gpt":0.323557040482938,"score_spread":0.21411037637602065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076379671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97039604,0.0027194992,0.022766273,0.0001344131,0.00010393467,0.00020325137,0.00040848294,0.00026964,0.002998487],"genre_scores_gemma":[0.9805233,0.001068297,0.015823634,0.00007054722,0.00006539783,0.000117269905,0.0005642631,0.0000344858,0.0017329385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981576,0.00003830198,0.000022204005,0.00004725371,0.00004543396,0.00003111385],"domain_scores_gemma":[0.9998807,0.000030633873,0.000024567049,0.00002109463,0.000010936884,0.000032065072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020772082,0.0005323112,0.00021613152,0.00021248806,0.000095344876,0.000341194,0.00021105002,0.0003759764,0.0013795786],"category_scores_gemma":[0.00010811934,0.000094529205,0.00023568685,0.000120825556,0.00016204041,0.00016918781,0.0002624254,0.00074224855,0.0005800909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013591509,0.0001250983,0.0002271236,0.00008256642,0.000006061847,0.00006620556,0.000017598393,0.00027912288,0.99609995,0.0000700368,0.000070695634,0.0028196527],"study_design_scores_gemma":[0.000054517535,0.0007132306,0.00082225463,0.000011390644,0.00003422364,0.00038210175,0.000007675746,0.0013450168,0.99278295,0.00003515676,0.0038079417,0.0000035692303],"about_ca_topic_score_codex":0.00009099925,"about_ca_topic_score_gemma":0.0001400656,"teacher_disagreement_score":0.0013795786,"about_ca_system_score_codex":0.0001271857,"about_ca_system_score_gemma":0.00015612967,"threshold_uncertainty_score":0.004615128},"labels":[],"label_agreement":null},{"id":"W2077416999","doi":"10.1002/cyto.b.20115","title":"Flow cytometric assessment of autologous γδ T cells in patients with acute myeloid leukemia: Potential effector cells for immunotherapy?","year":2006,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"University Health Network","keywords":"Medicine; Immunophenotyping; Immunology; Immunotherapy; Bone marrow; Myeloid; T cell; Flow cytometry; Myeloid leukemia; Minimal residual disease; Immune system; Population; Leukemia","score_opus":0.020395248722752318,"score_gpt":0.3542690597803617,"score_spread":0.3338738110576094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077416999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955187,0.0022324622,0.0012472847,0.0001361912,0.000016286442,0.00003636123,0.000089815374,0.00004630509,0.0006765692],"genre_scores_gemma":[0.9981365,0.0004132493,0.0010093547,0.00007829898,0.0000370897,0.000022929411,0.000120812976,0.000003307929,0.0001783213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997818,0.00008359313,0.000025978687,0.00004036325,0.000043885022,0.000024373734],"domain_scores_gemma":[0.9996213,0.00018111506,0.00008541149,0.000023715178,0.000044626755,0.000043852797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049868727,0.00027103754,0.00034904887,0.0005139462,0.00015043265,0.0003522898,0.0001895807,0.00040003314,0.0009947252],"category_scores_gemma":[0.0014721319,0.00010517191,0.000075828866,0.00034752104,0.0002612025,0.00026160976,0.00011292631,0.00029954064,0.00040094135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051405663,0.00027423922,0.7742027,0.00027337048,0.00006189906,0.0010900481,0.0005574423,0.00067799166,0.120186016,0.00022601092,0.001079945,0.096229814],"study_design_scores_gemma":[0.00029898295,0.0056785094,0.89769614,0.00010480096,0.00023595872,0.013191678,0.00064624276,0.0063950834,0.06929733,0.0007689675,0.005653615,0.000032679443],"about_ca_topic_score_codex":0.00023901367,"about_ca_topic_score_gemma":0.00021040105,"teacher_disagreement_score":0.0009947252,"about_ca_system_score_codex":0.00018909923,"about_ca_system_score_gemma":0.00010416863,"threshold_uncertainty_score":0.0033276677},"labels":[],"label_agreement":null},{"id":"W2077633929","doi":"10.1097/cji.0b013e318243f213","title":"Cytotoxic T-lymphocyte Immunotherapy for Ovarian Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute","keywords":"Ovarian cancer; Cytotoxic T cell; Immunotherapy; Medicine; Cancer immunotherapy; Immunology; Lymphocyte; Cancer; Cancer research; Immune system; Internal medicine; Biology","score_opus":0.03650980964972917,"score_gpt":0.3572020405419712,"score_spread":0.320692230892242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077633929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946997,0.003991368,0.00042747095,0.00007445459,0.000014704049,0.00004884467,0.000009366084,0.000016652815,0.0007173409],"genre_scores_gemma":[0.99824715,0.0008195486,0.00039000085,0.00005026643,0.000035412988,0.0000321252,0.000036887584,0.0000027398448,0.0003859124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999879,0.000063113665,0.0000038290136,0.000013644316,0.000016922717,0.000023485705],"domain_scores_gemma":[0.999943,0.00001835044,0.000008772955,0.000007575494,0.000006913714,0.000015373598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033442013,0.00019740494,0.0003125145,0.000114860835,0.00018113342,0.00018971488,0.000083017294,0.00024847707,0.00086378644],"category_scores_gemma":[0.00027965772,0.0000620363,0.00013323376,0.00008587273,0.00018122101,0.000119777076,0.000096582255,0.0002714275,0.00019093456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011166101,0.0043482357,0.04229322,0.0003619791,0.000074426476,0.0009684273,0.00034243555,0.0010018238,0.6297541,0.00041781552,0.0009780689,0.30829346],"study_design_scores_gemma":[0.008570681,0.38964203,0.22733149,0.00016579211,0.00062006334,0.013871748,0.0003683359,0.008468007,0.31444347,0.0016698166,0.034787457,0.00006105273],"about_ca_topic_score_codex":0.00018332864,"about_ca_topic_score_gemma":0.00027034612,"teacher_disagreement_score":0.00086378644,"about_ca_system_score_codex":0.00017944514,"about_ca_system_score_gemma":0.00025109484,"threshold_uncertainty_score":0.0028896928},"labels":[],"label_agreement":null},{"id":"W2078469038","doi":"10.1371/journal.pone.0056820","title":"Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Ministry of Education, Culture, Sports, Science and Technology","keywords":"Cancer research; In vivo; Lung cancer; CCR2; Biology; Receptor; Cell biology; Chemistry; Medicine; Chemokine receptor; Chemokine; Biochemistry; Genetics; Pathology","score_opus":0.05567032743398227,"score_gpt":0.2829390526640674,"score_spread":0.22726872523008512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078469038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978884,0.00040870867,0.0007687457,0.00003076628,0.000026317379,0.000025314896,0.000084866326,0.000042076994,0.00072485144],"genre_scores_gemma":[0.9979018,0.00019253574,0.00066682807,0.000029002784,0.000011980982,0.000027919383,0.00015003925,0.000014145184,0.0010057369],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999655,0.00007515684,0.000026666856,0.000059809157,0.00006270158,0.000120705074],"domain_scores_gemma":[0.9998573,0.000027960383,0.000039504535,0.000020109324,0.000013718363,0.000041393843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021260882,0.00055289426,0.00038932986,0.00017573786,0.00012273566,0.00035986575,0.00021026988,0.00033401928,0.0014868695],"category_scores_gemma":[0.000116838215,0.00012463922,0.00024678587,0.00013040334,0.00025365796,0.00022110267,0.0001901031,0.00073777826,0.00048025028],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013809784,0.000063526735,0.00007027947,0.000024641633,0.0000039846987,0.000048040787,0.000011624907,0.00007298847,0.9990977,0.000049226455,0.000025597597,0.00039437218],"study_design_scores_gemma":[0.000051842784,0.00096973055,0.0009763552,0.000003124353,0.000023123255,0.00025575163,0.000016247937,0.0008607357,0.9958502,0.000010416725,0.0009782626,0.000004131546],"about_ca_topic_score_codex":0.00034609865,"about_ca_topic_score_gemma":0.00042805888,"teacher_disagreement_score":0.0014868695,"about_ca_system_score_codex":0.00022631565,"about_ca_system_score_gemma":0.00017700941,"threshold_uncertainty_score":0.004974067},"labels":[],"label_agreement":null},{"id":"W2078523816","doi":"10.1016/j.ymthe.2005.09.018","title":"Recombinant Adenovirus Vaccines Can Successfully Elicit CD8+ T Cell Immunity under Conditions of Extreme Leukopenia","year":2005,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Antigen; Cytotoxic T cell; Immunology; Biology; Bone marrow; CD8; Immune system; Immunity; Immunization; Radioresistance; Virology; Leukopenia; Cell culture; In vitro","score_opus":0.040569501405109946,"score_gpt":0.31546352850991566,"score_spread":0.2748940271048057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078523816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967554,0.000678657,0.0021174776,0.000026265523,0.000011815585,0.000024221845,0.000043877582,0.00004289935,0.00029944364],"genre_scores_gemma":[0.9979557,0.0003577567,0.0012346208,0.000012520729,0.0000059586578,0.000022681712,0.00010790451,0.000007645853,0.0002953319],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997943,0.000060599126,0.000024988107,0.000024723711,0.00003495031,0.000060485265],"domain_scores_gemma":[0.9998765,0.00004134824,0.000032312237,0.00002079953,0.000008175206,0.000020794216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032566208,0.00031662913,0.00030423654,0.00014193443,0.00007075704,0.0003109207,0.00012553786,0.00022044277,0.00047650043],"category_scores_gemma":[0.00022266059,0.000119126904,0.00018048502,0.00006752421,0.00024444482,0.00025942572,0.0001935685,0.0005272869,0.00014382967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015486739,0.000038202736,0.00027174788,0.000033542412,0.000006040223,0.000035634446,0.000020333466,0.00015235796,0.99790823,0.000094112766,0.000013968857,0.0012708909],"study_design_scores_gemma":[0.00004552291,0.0020166275,0.0017924148,0.000008117547,0.000027360556,0.00030770001,0.000033845372,0.00086701644,0.9935044,0.00007473696,0.001317667,0.0000045122124],"about_ca_topic_score_codex":0.00012501083,"about_ca_topic_score_gemma":0.00017182628,"teacher_disagreement_score":0.00047650043,"about_ca_system_score_codex":0.00012511374,"about_ca_system_score_gemma":0.00009103874,"threshold_uncertainty_score":0.0017222762},"labels":[],"label_agreement":null},{"id":"W2079589100","doi":"10.1016/j.critrevonc.2009.08.005","title":"Treatment for metastatic malignant melanoma: Old drugs and new strategies","year":2009,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Directorate for Biological Sciences","keywords":"Medicine; Dacarbazine; Melanoma; Metastatic melanoma; Immunotherapy; Clinical trial; Oncology; Chemotherapy; First line; Refractory (planetary science); Cancer; Internal medicine; Cancer research","score_opus":0.2065223788696071,"score_gpt":0.5077436865363419,"score_spread":0.3012213076667348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079589100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000086492415,0.9983437,0.00014174943,0.0005013267,0.0003263857,0.000004556928,0.000009673642,0.0000067683973,0.0005794261],"genre_scores_gemma":[0.00066563074,0.9975569,0.00025781867,0.0005629819,0.00039659202,0.000007587531,0.000021726424,0.000002044179,0.00052864634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997719,0.00004713705,0.000025220348,0.00004099519,0.00009301059,0.000021754406],"domain_scores_gemma":[0.99964094,0.00019007169,0.000040951763,0.000012569857,0.00008415747,0.000031258118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083284057,0.0009940658,0.002157735,0.001696681,0.00033967983,0.0010524056,0.0011388942,0.0012838073,0.003211121],"category_scores_gemma":[0.00076683774,0.0003014202,0.0006609018,0.0014212169,0.0007271023,0.0017448098,0.00059366884,0.0029909485,0.0018844097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012123578,0.00010651914,0.00011693641,0.006730667,0.000098646284,0.00019925613,0.000035347195,0.00041696551,0.0014651684,0.0025199845,0.055310067,0.93287927],"study_design_scores_gemma":[0.0000911512,0.0001847812,0.000527711,0.0024679329,0.00016334852,0.001205615,0.000050583425,0.00019966543,0.00045242632,0.0020299682,0.9926052,0.000021680144],"about_ca_topic_score_codex":0.0010029285,"about_ca_topic_score_gemma":0.0027331468,"teacher_disagreement_score":0.003211121,"about_ca_system_score_codex":0.0006814756,"about_ca_system_score_gemma":0.0007929497,"threshold_uncertainty_score":0.010742247},"labels":[],"label_agreement":null},{"id":"W2079809618","doi":"10.1038/mt.2011.298","title":"Cell Fate Control Gene Therapy Based on Engineered Variants of Human Deoxycytidine Kinase","year":2012,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Suicide gene; Deoxycytidine kinase; Thymidine kinase; Biology; Genetic enhancement; Cell biology; Cancer research; Gene; Genetics; Deoxycytidine; Cancer","score_opus":0.024715979408354426,"score_gpt":0.2928219588182776,"score_spread":0.2681059794099232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079809618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8795496,0.0065688323,0.10585587,0.00024006102,0.00019450375,0.00028518037,0.0005744497,0.0005902111,0.006141352],"genre_scores_gemma":[0.95720655,0.0024672637,0.036319003,0.0000853841,0.000026954402,0.000106684936,0.00032232152,0.000062964165,0.0034029023],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998271,0.000022906253,0.000016188409,0.000047432724,0.000057677666,0.000028735758],"domain_scores_gemma":[0.99990416,0.000020095773,0.000035150915,0.000018687177,0.000009337384,0.000012536983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016905929,0.00037527058,0.00022118998,0.00021150024,0.0001179644,0.00038261604,0.00024345558,0.00035913524,0.00044294394],"category_scores_gemma":[0.00014318516,0.00015252439,0.00021060536,0.00016344429,0.00031736685,0.0002265674,0.00020935005,0.0005205751,0.00023246353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022999513,0.000008926367,0.00006797461,0.000023139086,0.0000024340575,0.000029046314,0.000010704482,0.00015580686,0.9967667,0.0005165299,0.000034383855,0.0023613619],"study_design_scores_gemma":[0.000008662559,0.000095551106,0.00020567828,0.000002977633,0.0000059748777,0.0002280541,0.0000031355555,0.00070000044,0.99441624,0.000060063194,0.004269837,0.0000038699673],"about_ca_topic_score_codex":0.00036994283,"about_ca_topic_score_gemma":0.00043458535,"teacher_disagreement_score":0.00044294394,"about_ca_system_score_codex":0.00042680858,"about_ca_system_score_gemma":0.00023102666,"threshold_uncertainty_score":0.0030967593},"labels":[],"label_agreement":null},{"id":"W2080601632","doi":"10.1371/journal.pone.0068916","title":"Quantifying Biomass Changes of Single CD8+ T Cells during Antigen Specific Cytotoxicity","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Center for AIDS Research, University of California Los Angeles; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles; Natural Sciences and Engineering Research Council of Canada; National Institutes of Health; National Cancer Institute; Center for AIDS Research, University of Washington; Howard Hughes Medical Institute","keywords":"Cytotoxic T cell; Mass cytometry; Single-cell analysis; Flow cytometry; CD8; Population; Cytotoxicity; Cell biology; T cell; Cell; Intracellular; Antigen-presenting cell; Chemistry; Biology; Antigen; Molecular biology; Immunology; Immune system; In vitro; Phenotype; Biochemistry; Medicine","score_opus":0.16671218482417297,"score_gpt":0.2961743190881353,"score_spread":0.12946213426396233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080601632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94553727,0.0011535215,0.050322548,0.00009497557,0.000047800368,0.000088075765,0.00048633173,0.00033943335,0.001930019],"genre_scores_gemma":[0.9497758,0.0011176816,0.045026828,0.00011891187,0.0000262462,0.0003347664,0.0005724781,0.0000834892,0.0029437202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99957293,0.00005756048,0.000022656373,0.00011039977,0.00017138003,0.00006507782],"domain_scores_gemma":[0.9996834,0.00011614435,0.000074559284,0.000029926096,0.00006582647,0.000030147325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042413294,0.00048369067,0.00036207383,0.00064624794,0.0002971358,0.00054306554,0.000369401,0.0005092014,0.0010509994],"category_scores_gemma":[0.00058397884,0.00024954282,0.00019163969,0.0005243104,0.00033689546,0.0005676437,0.00038126882,0.0008810062,0.00037227265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057760884,0.000013519008,0.0005055767,0.000027338148,0.0000030993797,0.00001985504,0.00006586436,0.00020486959,0.9960658,0.00006813481,0.000024528788,0.0029437146],"study_design_scores_gemma":[0.0000075824123,0.00016986764,0.0048489487,0.0000057084653,0.000011527536,0.00006580835,0.00007888798,0.005121994,0.9888545,0.00017429274,0.0006522015,0.0000086781865],"about_ca_topic_score_codex":0.00045958423,"about_ca_topic_score_gemma":0.00092439743,"teacher_disagreement_score":0.0010509994,"about_ca_system_score_codex":0.0005357384,"about_ca_system_score_gemma":0.00028943393,"threshold_uncertainty_score":0.003887117},"labels":[],"label_agreement":null},{"id":"W2081113588","doi":"10.1016/j.biomaterials.2014.07.029","title":"siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers","year":2014,"lang":"en","type":"article","venue":"Biomaterials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Alberta Innovates; Alberta Innovates - Health Solutions; Alberta Cancer Foundation","keywords":"Small interfering RNA; Jurkat cells; Gene silencing; RNA interference; Cancer research; Cell; Lipofectamine; Cell growth; Chemistry; Cell biology; Molecular biology; Biology; Transfection; Cell culture; T cell; Biochemistry; Immunology; RNA; Immune system","score_opus":0.029160782149316902,"score_gpt":0.2984648197056167,"score_spread":0.26930403755629984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081113588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710944,0.009397763,0.01321548,0.0002597326,0.00013024453,0.00011339564,0.00007018497,0.000254792,0.005463958],"genre_scores_gemma":[0.9914129,0.0015617571,0.0031064607,0.000053261087,0.00001610495,0.00004175426,0.000032820903,0.000028040777,0.003746919],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988484,0.000027048205,0.000007442905,0.000026471524,0.000023411667,0.000030906464],"domain_scores_gemma":[0.9999393,0.000020252706,0.000016472086,0.00000737331,0.000007787968,0.000008899424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002260752,0.00031510988,0.00019620846,0.00033540383,0.00018938088,0.00038769376,0.00016926431,0.00039657502,0.0012079512],"category_scores_gemma":[0.00013718683,0.00012946369,0.0002342783,0.00012345979,0.0002476193,0.00037948784,0.00020064131,0.00036258454,0.0003408213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010858063,0.000043645283,0.00008182695,0.00009864651,0.000008260863,0.00012679069,0.000040974403,0.00023602968,0.9920912,0.00040242597,0.00010752288,0.0066540893],"study_design_scores_gemma":[0.000024236735,0.00039394264,0.00042277138,0.000007739068,0.000029632582,0.00020549777,0.000022115622,0.0012137337,0.99446,0.000051849518,0.003164552,0.0000040052464],"about_ca_topic_score_codex":0.0006825966,"about_ca_topic_score_gemma":0.0009414752,"teacher_disagreement_score":0.0012079512,"about_ca_system_score_codex":0.00026521183,"about_ca_system_score_gemma":0.00020710281,"threshold_uncertainty_score":0.004041016},"labels":[],"label_agreement":null},{"id":"W2081783238","doi":"10.1126/scisignal.2004113","title":"BIM, PUMA, and the Achilles’ Heel of Oncogene Addiction","year":2013,"lang":"en","type":"review","venue":"Science Signaling","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Oncogene; Epigenetics; Phenotype; Biology; Cancer research; Addiction; Puma; Cancer; CRISPR; Medicine; Neuroscience; Genetics; Apoptosis; Gene; Cell cycle","score_opus":0.07743560108723829,"score_gpt":0.38838772421854184,"score_spread":0.31095212313130355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081783238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011383892,0.99800843,0.00010818028,0.000710505,0.00018593151,0.0000015781861,0.0000071272448,0.0000063481043,0.00085818744],"genre_scores_gemma":[0.0010593283,0.99730706,0.00012252117,0.00038989173,0.0002224693,0.0000043975424,0.000013204983,0.000001451369,0.0008796671],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983954,0.000036231784,0.000015206007,0.000023083203,0.000065387605,0.000020452653],"domain_scores_gemma":[0.99979705,0.00009977061,0.000020999214,0.000008789645,0.00004593049,0.000027505715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006248998,0.0006025152,0.0010455596,0.0015937279,0.0003315883,0.00096614746,0.0007129099,0.0012274875,0.0024704318],"category_scores_gemma":[0.00054760894,0.00027941226,0.00028238952,0.0012243002,0.0009504547,0.001786887,0.0006954472,0.0025951897,0.0015817537],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000932045,0.000063460495,0.00017930499,0.0051916013,0.00005917442,0.00029992647,0.0000724296,0.00037780078,0.0022520071,0.021987608,0.048826065,0.9205973],"study_design_scores_gemma":[0.000013122876,0.00004208108,0.00035586013,0.0011059978,0.000020167397,0.00095739384,0.0000551605,0.00006270224,0.00038499295,0.006910524,0.99008,0.000012097086],"about_ca_topic_score_codex":0.00088761083,"about_ca_topic_score_gemma":0.0022890498,"teacher_disagreement_score":0.0024704318,"about_ca_system_score_codex":0.00084066787,"about_ca_system_score_gemma":0.0009018201,"threshold_uncertainty_score":0.008264422},"labels":[],"label_agreement":null},{"id":"W2083962744","doi":"10.1002/eji.200636938","title":"Non‐myeloablative mixed chimerism approaches and tolerance, a split decision","year":2007,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"Chimera (genetics); Immune tolerance; Clonal deletion; Biology; Immunology; Bone marrow; Antigen; CD8; Haematopoiesis; Transplantation Chimera; Mixed lymphocyte reaction; Immune system; T cell; Stem cell; Hematopoietic cell; Cell biology; Genetics; Gene","score_opus":0.0361690223443372,"score_gpt":0.2871695163606968,"score_spread":0.2510004940163596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083962744","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76684564,0.021274475,0.19580944,0.001088953,0.000351664,0.0006141622,0.00021006928,0.00029671876,0.01350885],"genre_scores_gemma":[0.96160144,0.0033786409,0.028529141,0.0003640132,0.000069044894,0.00022524402,0.00017410606,0.000031798063,0.0056265513],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958116,0.00015016137,0.000038605696,0.00006233434,0.000121405545,0.00004634531],"domain_scores_gemma":[0.9997454,0.00007532711,0.00009121868,0.000038638493,0.000014808278,0.000034675773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073104026,0.00032610513,0.0002728436,0.0002698365,0.00023274208,0.00065976207,0.0005929173,0.00054266787,0.002833924],"category_scores_gemma":[0.00030794647,0.00018720156,0.00020639591,0.00017057017,0.0006785664,0.0004137444,0.00043448946,0.0013436434,0.00027513085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066323084,0.00022139522,0.0007961731,0.00047046662,0.000049176026,0.00046695684,0.00014317244,0.00075094047,0.93641365,0.027766794,0.00036505522,0.03189303],"study_design_scores_gemma":[0.00013621345,0.0018307293,0.002092766,0.0000722769,0.00009306081,0.004385666,0.000064173044,0.003713049,0.95771265,0.0072194305,0.022660516,0.00001953453],"about_ca_topic_score_codex":0.000085191765,"about_ca_topic_score_gemma":0.0001498607,"teacher_disagreement_score":0.002833924,"about_ca_system_score_codex":0.00034167204,"about_ca_system_score_gemma":0.0002842059,"threshold_uncertainty_score":0.009480476},"labels":[],"label_agreement":null},{"id":"W2086451783","doi":"10.1186/s12967-015-0495-z","title":"Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture","year":2015,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Genome Canada","keywords":"Priming (agriculture); Immunology; Antigen; CD8; Population; Biology; Minor histocompatibility antigen; T cell; Antigen-presenting cell; Major histocompatibility complex; Immune system; Medicine","score_opus":0.11521047356614113,"score_gpt":0.35692543894881884,"score_spread":0.24171496538267773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086451783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7875145,0.0102596795,0.19129416,0.0005147423,0.00035997882,0.0014943848,0.0011339606,0.00069778593,0.006730885],"genre_scores_gemma":[0.85871154,0.0044314275,0.1310866,0.0002812504,0.0001798,0.0023004,0.0013020671,0.0002224424,0.0014843747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995173,0.00011074625,0.00008977763,0.00009293221,0.00011851552,0.000070711576],"domain_scores_gemma":[0.99928206,0.0002800626,0.00016074501,0.000071763374,0.00013247275,0.00007292658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084770756,0.00072045653,0.00047926247,0.0003508553,0.0002616457,0.0006377499,0.0005030161,0.0005827625,0.0013813864],"category_scores_gemma":[0.0012103042,0.00019831804,0.00026852687,0.0003302667,0.00028537613,0.00049993995,0.0005425546,0.0010632778,0.00082050846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017903178,0.00017249909,0.00070887356,0.00019002517,0.0000069273324,0.00007241737,0.00009248466,0.0018748535,0.98959523,0.00028114207,0.00023583586,0.006590534],"study_design_scores_gemma":[0.000039366496,0.0009683446,0.0025917003,0.0000768649,0.000052901876,0.0002056154,0.00006801933,0.006441554,0.9818448,0.0003167786,0.0073603694,0.000033683576],"about_ca_topic_score_codex":0.00022180857,"about_ca_topic_score_gemma":0.00061300315,"teacher_disagreement_score":0.0013813864,"about_ca_system_score_codex":0.00032925187,"about_ca_system_score_gemma":0.00044664054,"threshold_uncertainty_score":0.0046212077},"labels":[],"label_agreement":null},{"id":"W2087289616","doi":"10.1586/erv.11.88","title":"Optimizing vaccine-induced CD8<sup>+</sup>T-cell immunity: focus on recombinant adenovirus vectors","year":2011,"lang":"en","type":"review","venue":"Expert Review of Vaccines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"CD8; Virology; Cytotoxic T cell; Biology; Immunology; Population; T cell; Memory T cell; Viral vector; Adenoviridae; Antigen; Transgene; Genetic enhancement; Recombinant DNA; Immune system; Medicine; In vitro; Genetics; Gene","score_opus":0.08485817954589985,"score_gpt":0.38656943356336637,"score_spread":0.3017112540174665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087289616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049296865,0.9971494,0.00077817304,0.00030387228,0.00012748722,0.000013422966,0.000018624038,0.000014963123,0.0011011414],"genre_scores_gemma":[0.0015737303,0.99620134,0.0010925113,0.00020461179,0.00007527857,0.000019399404,0.00004270672,0.000003949739,0.0007864968],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997589,0.000055714834,0.000026027488,0.00004411952,0.00008732242,0.000027894168],"domain_scores_gemma":[0.99970204,0.00013814776,0.000046784444,0.000010614985,0.00007955236,0.000022768756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010040762,0.0010278814,0.001391643,0.0016445403,0.00014933305,0.0009696226,0.00087734417,0.001285494,0.0022837264],"category_scores_gemma":[0.0006142553,0.0003424723,0.00057277473,0.001592869,0.0005117491,0.001559267,0.0004947235,0.001946269,0.0021822085],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015059042,0.0002138779,0.0002103908,0.020570535,0.00011302746,0.00027815002,0.000060499642,0.0014279366,0.02227291,0.0085686175,0.014818727,0.93131477],"study_design_scores_gemma":[0.00008881415,0.00040277428,0.0009227354,0.002988625,0.00016168976,0.0015594076,0.000068966714,0.00039628905,0.009231174,0.0030628291,0.98107713,0.00003943958],"about_ca_topic_score_codex":0.0007131742,"about_ca_topic_score_gemma":0.00091934303,"teacher_disagreement_score":0.0022837264,"about_ca_system_score_codex":0.00085624977,"about_ca_system_score_gemma":0.00095247617,"threshold_uncertainty_score":0.0076398253},"labels":[],"label_agreement":null},{"id":"W2087846338","doi":"10.1038/scibx.2011.183","title":"EMMPRIN's new clothes","year":2011,"lang":"en","type":"article","venue":"Science-Business eXchange","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Matrix metalloproteinase; Regulator; Master regulator; Neuroscience; Medicine; Computational biology; Psychology; Biology; Internal medicine; Gene; Genetics; Transcription factor","score_opus":0.1358298003475303,"score_gpt":0.3316468873210078,"score_spread":0.19581708697347747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087846338","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014921274,0.012140011,0.0024463476,0.119716644,0.05691236,0.0000776714,0.00027850844,0.000988075,0.8059483],"genre_scores_gemma":[0.0020288879,0.001254465,0.00042429846,0.010258818,0.0030368753,0.000017355173,0.00004830214,0.00011610753,0.98281485],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876165,0.0001983658,0.000037663453,0.00012844584,0.00072624447,0.00014769186],"domain_scores_gemma":[0.9981325,0.00043919665,0.00009702225,0.00025155797,0.00047580458,0.00060393865],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014704026,0.0007484558,0.0005554164,0.0009746811,0.002034753,0.005514329,0.000986527,0.0043916693,0.3733985],"category_scores_gemma":[0.005439564,0.0003282868,0.00069160905,0.0005470057,0.0011001843,0.0037718283,0.0025440776,0.005839776,0.17311166],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000325995,0.000036808127,0.00005468445,0.000041504405,0.000003881228,0.000088799374,0.000033422704,0.000035345307,0.00022677836,0.0078922855,0.92549235,0.06606157],"study_design_scores_gemma":[0.0000031240024,0.0000073785336,0.00009352633,0.000026381545,0.0000010802011,0.00008761085,0.000032406682,0.00003078332,0.00006517606,0.00081732374,0.9988324,0.0000027989092],"about_ca_topic_score_codex":0.0010096148,"about_ca_topic_score_gemma":0.0030381947,"teacher_disagreement_score":0.3733985,"about_ca_system_score_codex":0.0012322799,"about_ca_system_score_gemma":0.0012832241,"threshold_uncertainty_score":0.893771},"labels":[],"label_agreement":null},{"id":"W2089572944","doi":"10.1586/14737167.2015.1017563","title":"Cost–effectiveness of therapies for melanoma","year":2015,"lang":"en","type":"review","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University; BC Cancer Agency; Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Dabrafenib; Medicine; Vemurafenib; Ipilimumab; Trametinib; Melanoma; Intensive care medicine; Cost effectiveness; Oncology; Disease; Internal medicine; Metastatic melanoma; Immunotherapy; Cancer; Cancer research","score_opus":0.22221636620857801,"score_gpt":0.6187242438974649,"score_spread":0.39650787768888696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089572944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005010538,0.9969627,0.00018517002,0.0007782852,0.000097749486,0.000028945442,0.00012230496,0.0000027821047,0.0013209025],"genre_scores_gemma":[0.012951098,0.98523486,0.000702352,0.00040766608,0.00019629847,0.00006694795,0.0001285313,0.0000031680527,0.00030903268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976324,0.0010782595,0.00036853898,0.00014241728,0.000680745,0.00009768278],"domain_scores_gemma":[0.9964953,0.0025705583,0.0005957343,0.000037369064,0.00025635702,0.000044718516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029223813,0.00092063064,0.0025055395,0.0033218374,0.00018901468,0.0015358501,0.0009848375,0.001313705,0.008868388],"category_scores_gemma":[0.008093286,0.00031261283,0.0031197502,0.0031959477,0.0003602473,0.0011138889,0.0006660872,0.0013937153,0.0005405381],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004938665,0.00010108006,0.00090603344,0.08574153,0.0043257535,0.00014331273,0.000038985,0.001863736,0.0003189077,0.007396628,0.0110026505,0.88766754],"study_design_scores_gemma":[0.0011919645,0.001255607,0.020469116,0.24677445,0.02151628,0.0045940503,0.00045800803,0.0031350043,0.0019710143,0.024435459,0.67404515,0.00015380915],"about_ca_topic_score_codex":0.0029486022,"about_ca_topic_score_gemma":0.0041602994,"teacher_disagreement_score":0.008868388,"about_ca_system_score_codex":0.0027646245,"about_ca_system_score_gemma":0.0026497596,"threshold_uncertainty_score":0.029667735},"labels":[],"label_agreement":null},{"id":"W2090444045","doi":"10.1002/eji.200737443","title":"The T cell antigen receptor: “The Hunting of the Snark”","year":2007,"lang":"en","type":"review","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"T-cell receptor; Biology; Major histocompatibility complex; T cell; Gene; Genetics; Immune system","score_opus":0.06913682266927274,"score_gpt":0.3529011281434265,"score_spread":0.28376430547415377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090444045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007091139,0.99400854,0.00019709278,0.0029074124,0.0018641835,0.000002338281,0.0000055236505,0.000007730392,0.0009362736],"genre_scores_gemma":[0.0009674662,0.99097085,0.00034329534,0.0031633251,0.0027569735,0.0000060408624,0.000014152669,0.0000037473708,0.0017741567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99954706,0.00011293743,0.00003898702,0.000076201075,0.00018488939,0.000039885617],"domain_scores_gemma":[0.9992711,0.00035058527,0.000056999324,0.000024699651,0.00021801327,0.00007870679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013283418,0.00092478417,0.0013656288,0.0019783785,0.0005311698,0.0015928957,0.0011229118,0.0025982587,0.001980445],"category_scores_gemma":[0.0015381383,0.00031238582,0.00043330443,0.0020591286,0.0020458067,0.004456716,0.0007651876,0.004032786,0.0027472118],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011170155,0.00005603182,0.0001544573,0.0045734607,0.00004859533,0.00029844462,0.0001173844,0.00021736113,0.0015598029,0.0201914,0.22817247,0.7444989],"study_design_scores_gemma":[0.0000104973815,0.000037066267,0.00016326603,0.000904092,0.00001395991,0.0007825944,0.000052230356,0.000033178836,0.0001865186,0.0042146975,0.9935923,0.0000095731],"about_ca_topic_score_codex":0.0009803786,"about_ca_topic_score_gemma":0.0011492497,"teacher_disagreement_score":0.0025982587,"about_ca_system_score_codex":0.0012528128,"about_ca_system_score_gemma":0.0012325922,"threshold_uncertainty_score":0.009089828},"labels":[],"label_agreement":null},{"id":"W2090651585","doi":"10.1158/0008-5472.can-11-3589","title":"The Mixed Lineage Leukemia (MLL) Fusion–Associated Gene <i>AF4</i> Promotes CD133 Transcription","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Canadian Institute for Advanced Research","keywords":"Fusion gene; Gene; Leukemia; Biology; Genetics; Lineage (genetic); Transcription factor; Cancer research; Computational biology","score_opus":0.10541274828704732,"score_gpt":0.40275766184470135,"score_spread":0.297344913557654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090651585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795673,0.0007557963,0.014340675,0.0002705087,0.00003481042,0.00008043656,0.0010646173,0.00045043198,0.003435346],"genre_scores_gemma":[0.97992307,0.0005005431,0.013918311,0.00011326216,0.0000135828095,0.00008322416,0.0013011096,0.00011282609,0.004034137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975127,0.000036361464,0.000020165071,0.000046704186,0.00009179062,0.00005371975],"domain_scores_gemma":[0.99983895,0.000056635832,0.00003960411,0.00001767709,0.000018250748,0.000028959712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018862453,0.00035459606,0.00028872176,0.00032191927,0.00025808637,0.00045316864,0.00021071301,0.00020392005,0.0022904768],"category_scores_gemma":[0.00018998822,0.00019812713,0.00034265438,0.00020044434,0.0003350555,0.00020071039,0.00036146666,0.0007180817,0.0005897369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002672493,0.000009579519,0.000096951895,0.00001071433,0.000001932229,0.000010104479,0.0000055433484,0.000036460504,0.9992157,0.00008269958,0.000044673747,0.00045888207],"study_design_scores_gemma":[0.000008799997,0.00006021965,0.00084639207,0.0000017921809,0.0000057187794,0.00006260659,0.000008603019,0.00075605005,0.9960438,0.000029595685,0.0021744235,0.0000019819481],"about_ca_topic_score_codex":0.0012600241,"about_ca_topic_score_gemma":0.0027067775,"teacher_disagreement_score":0.0022904768,"about_ca_system_score_codex":0.00063884276,"about_ca_system_score_gemma":0.0003893737,"threshold_uncertainty_score":0.0076624155},"labels":[],"label_agreement":null},{"id":"W2093933397","doi":"10.1038/sj.onc.1208334","title":"Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors","year":2004,"lang":"en","type":"article","venue":"Oncogene","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; T-cell receptor; Transgene; Thymocyte; Clonal deletion; Negative selection; Cancer research; Genetics; Lymphoma; T cell; Immunology; Gene; Immune system","score_opus":0.023364628346616397,"score_gpt":0.2923473955752778,"score_spread":0.2689827672286614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093933397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938519,0.0012217785,0.0018887324,0.0001536773,0.00006457957,0.000034853816,0.00032237236,0.00024046408,0.0022217045],"genre_scores_gemma":[0.9965366,0.00023482983,0.0006192603,0.000026973166,0.000012798606,0.000024311541,0.00025540078,0.000033229364,0.002256585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99937516,0.00012674952,0.00004201621,0.00009795014,0.00009935932,0.00025879132],"domain_scores_gemma":[0.99962354,0.00009550833,0.00009450291,0.00007092144,0.000018798026,0.000096735035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002086476,0.000497483,0.0003355914,0.0006967713,0.0002747628,0.00076420757,0.00036363673,0.00056476,0.0023398153],"category_scores_gemma":[0.00024580196,0.0002786801,0.0004989331,0.0002428799,0.0005494907,0.00043479187,0.00058963575,0.0019897476,0.0012158232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001924541,0.00002249438,0.00020985481,0.000021274678,0.00000566668,0.00016883873,0.00001817418,0.000097155294,0.9980971,0.00029600313,0.000048981598,0.0008220694],"study_design_scores_gemma":[0.00002174584,0.00012974258,0.002400594,0.0000038274684,0.000019131065,0.00041030176,0.000060693194,0.0007424066,0.9943889,0.00009867661,0.0017199438,0.0000040663376],"about_ca_topic_score_codex":0.00030562852,"about_ca_topic_score_gemma":0.0005882263,"teacher_disagreement_score":0.0023398153,"about_ca_system_score_codex":0.00056478777,"about_ca_system_score_gemma":0.00026519893,"threshold_uncertainty_score":0.007827461},"labels":[],"label_agreement":null},{"id":"W2097018577","doi":"10.1186/1479-5876-9-63","title":"Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy","year":2011,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"CD8; Melanoma; Cancer research; Adoptive cell transfer; Immunotherapy; Adoptive immunotherapy; Cytotoxic T cell; Cancer immunotherapy; T cell; Medicine; Tumor-infiltrating lymphocytes; Immunology; Biology; In vitro; Immune system; Biochemistry","score_opus":0.056013678362032485,"score_gpt":0.3482293450844783,"score_spread":0.2922156667224458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097018577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97593,0.0042981533,0.017904328,0.00012441936,0.00005901614,0.00009710317,0.0002178434,0.00020823746,0.0011609016],"genre_scores_gemma":[0.9902484,0.0009292245,0.007704886,0.00005703071,0.000028480143,0.00007816523,0.0002958879,0.000029157032,0.00062882685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997445,0.000093979914,0.000015925387,0.000055632685,0.000054369306,0.000035577017],"domain_scores_gemma":[0.99971694,0.0000890548,0.00007437821,0.000051535757,0.000029739325,0.000038341685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033750737,0.0004410452,0.00027434688,0.00020676937,0.00013572925,0.00059883174,0.00029921296,0.0004003862,0.0014748317],"category_scores_gemma":[0.00025352713,0.000091112386,0.00028832976,0.00016470572,0.00025052953,0.00036864236,0.00034559602,0.0005307192,0.0005795139],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029628183,0.00012625106,0.00039376115,0.000071688584,0.00000811739,0.00006958893,0.00003018051,0.00027905154,0.99389005,0.000051645693,0.00004514819,0.0047381544],"study_design_scores_gemma":[0.000036104262,0.002856766,0.004179346,0.000024976229,0.00008745313,0.0008751058,0.00006404881,0.0017277016,0.9861838,0.000098930715,0.0038547695,0.000010959079],"about_ca_topic_score_codex":0.000076333825,"about_ca_topic_score_gemma":0.000097349344,"teacher_disagreement_score":0.0014748317,"about_ca_system_score_codex":0.00017362309,"about_ca_system_score_gemma":0.00015064984,"threshold_uncertainty_score":0.0049337745},"labels":[],"label_agreement":null},{"id":"W2097514222","doi":"10.1002/emmm.201100165","title":"PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8+ T cells","year":2011,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Versus Arthritis; University College London","keywords":"T-cell receptor; CD28; Cell biology; Cytotoxic T cell; CD8; T cell; Signal transduction; Biology; Ubiquitin ligase; Molecular biology; Chemistry; Immune system; Immunology; In vitro; Ubiquitin; Biochemistry","score_opus":0.03756454992700576,"score_gpt":0.3166916339564182,"score_spread":0.27912708402941244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097514222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264413,0.002244774,0.0022752963,0.00018588126,0.000036201684,0.000022102815,0.00012529768,0.00010059678,0.002365716],"genre_scores_gemma":[0.99618834,0.00061883644,0.0007890355,0.00006783954,0.000019855173,0.000020989532,0.00018530237,0.000017599401,0.0020921982],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976104,0.0000437099,0.000015461776,0.000049246926,0.000053735497,0.000076736535],"domain_scores_gemma":[0.9998944,0.000021135716,0.000023851278,0.0000114408795,0.000012114231,0.00003705346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014923768,0.00036301272,0.00031545223,0.00018134841,0.0001925109,0.00055436866,0.00017734189,0.00030931912,0.0022231985],"category_scores_gemma":[0.00014719606,0.00018653696,0.0002452862,0.00009869993,0.00019691071,0.00021953684,0.00028338254,0.0011181266,0.0011310898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016568661,0.000050925504,0.000205552,0.00003964388,0.0000036371516,0.00004913031,0.000009924514,0.00007449387,0.99627763,0.00007487992,0.0000757256,0.0029727584],"study_design_scores_gemma":[0.000038410417,0.00026523112,0.0038115361,0.0000066665934,0.000019782381,0.00042860606,0.000021194473,0.0015929622,0.99065334,0.00008326175,0.0030753475,0.0000036076933],"about_ca_topic_score_codex":0.000100889425,"about_ca_topic_score_gemma":0.00015888282,"teacher_disagreement_score":0.0022231985,"about_ca_system_score_codex":0.00028291848,"about_ca_system_score_gemma":0.00017599041,"threshold_uncertainty_score":0.0074373484},"labels":[],"label_agreement":null},{"id":"W2101928501","doi":"10.4049/jimmunol.0902181","title":"Bim-Mediated Apoptosis Is Not Necessary for Thymic Negative Selection to Ubiquitous Self-Antigens","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Fondation pour la Recherche Médicale","keywords":"Negative selection; Repertoire; Biology; Selection (genetic algorithm); Clonal deletion; Thymocyte; Nerve growth factor IB; Apoptosis; CD8; Self Tolerance; Mechanism (biology); Central tolerance; Cell biology; Immunology; T cell; Antigen; T-cell receptor; Immune tolerance; Genetics; Immune system; Transcription factor; Computer science; Gene","score_opus":0.022841009114509307,"score_gpt":0.3170039209102526,"score_spread":0.2941629117957433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101928501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949976,0.0008863356,0.0018676576,0.00009018074,0.00002736491,0.000010826639,0.00013558847,0.000069708614,0.0019146868],"genre_scores_gemma":[0.99636143,0.0002841061,0.00087538885,0.000042298205,0.000010257656,0.000020953594,0.00042971582,0.000023385746,0.0019526102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995296,0.00008798057,0.00004099776,0.00006100283,0.0001620859,0.000118395765],"domain_scores_gemma":[0.9992312,0.00016749202,0.0001722285,0.00012612913,0.0000792658,0.00022375492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004044468,0.00017873819,0.00033659145,0.0003251623,0.00021252695,0.0005019928,0.00041403045,0.00025218818,0.0025246402],"category_scores_gemma":[0.000622866,0.0001842376,0.00017045082,0.0001358555,0.00033484504,0.0004374482,0.00050711306,0.00063022244,0.0006150851],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026017125,0.000051439707,0.0010768347,0.0000448405,0.0000060568227,0.0001657409,0.000021181759,0.00008532871,0.9947524,0.0006037984,0.0000695869,0.0028625715],"study_design_scores_gemma":[0.00008936428,0.0006321753,0.018489666,0.000025688454,0.00003495406,0.0034828314,0.0001040188,0.0026325844,0.9663911,0.00067340996,0.0074287895,0.000015409334],"about_ca_topic_score_codex":0.00018932075,"about_ca_topic_score_gemma":0.00031135912,"teacher_disagreement_score":0.0025246402,"about_ca_system_score_codex":0.00030771433,"about_ca_system_score_gemma":0.00035951106,"threshold_uncertainty_score":0.008445799},"labels":[],"label_agreement":null},{"id":"W2108334708","doi":"10.3389/fimmu.2013.00221","title":"Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies","year":2013,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Chimeric antigen receptor; Adoptive cell transfer; Antigen; Immunology; Genome editing; Receptor; Biology; Perspective (graphical); Genome; T cell; Computational biology; Medicine; Genetics; Immune system; Computer science; Gene","score_opus":0.015015016267789023,"score_gpt":0.26508284523526454,"score_spread":0.25006782896747554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108334708","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30754003,0.2775285,0.36296692,0.015369919,0.0015121968,0.00040190967,0.00050033873,0.0015306614,0.03264954],"genre_scores_gemma":[0.8448086,0.07128269,0.07081084,0.002299115,0.0004825507,0.00017345372,0.00024366299,0.00014089537,0.00975808],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981755,0.000055488545,0.0000077363675,0.000036121997,0.00005746913,0.000025696148],"domain_scores_gemma":[0.99984777,0.00006676587,0.00002220315,0.000023603006,0.000015929614,0.000023718878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005108426,0.0003208634,0.00032375238,0.0002829897,0.00017752392,0.0009508106,0.0003224694,0.0008313143,0.0017835237],"category_scores_gemma":[0.0004198912,0.00013453721,0.000249823,0.00019860944,0.0006413079,0.0008409246,0.00037499506,0.0014090213,0.00060171407],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031661894,0.00013487678,0.00031630354,0.0006158052,0.000026445132,0.00028689305,0.00018083793,0.0018584263,0.8412426,0.024518562,0.0016181743,0.12888443],"study_design_scores_gemma":[0.00016619332,0.0018362823,0.0010081101,0.00013950946,0.0001330744,0.0021916013,0.00013260376,0.004767646,0.7702543,0.017046005,0.20228472,0.00003995127],"about_ca_topic_score_codex":0.0001803431,"about_ca_topic_score_gemma":0.00020077566,"teacher_disagreement_score":0.0017835237,"about_ca_system_score_codex":0.00032931278,"about_ca_system_score_gemma":0.00030566377,"threshold_uncertainty_score":0.0059664845},"labels":[],"label_agreement":null},{"id":"W2114219301","doi":"10.4049/jimmunol.1300521","title":"Complete TCR-α Gene Locus Control Region Activity in T Cells Derived In Vitro from Embryonic Stem Cells","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Research Resources; National Institute of General Medical Sciences; National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research","keywords":"Biology; T-cell receptor; Transgene; Embryonic stem cell; Gene; Locus control region; Locus (genetics); Reporter gene; Stem cell; T cell; Cellular differentiation; Genetics; Molecular biology; Gene expression; Cell biology; Promoter; Immune system","score_opus":0.028440671084610052,"score_gpt":0.264324315485082,"score_spread":0.23588364440047196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114219301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92114997,0.003175219,0.06693779,0.00013553913,0.00009114753,0.0002505411,0.0019018503,0.0005339082,0.0058239424],"genre_scores_gemma":[0.9696482,0.001986041,0.017575288,0.00007039977,0.000028578917,0.00018582838,0.00475097,0.00012834005,0.005626248],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99958616,0.00008780122,0.00006814836,0.00006933194,0.0001423644,0.000046193483],"domain_scores_gemma":[0.9997216,0.00007891751,0.000051559593,0.000077412515,0.000036544283,0.000033869244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036590506,0.00034646576,0.00029620779,0.0003210828,0.000122992,0.00050876185,0.00023453597,0.00019499563,0.0008771247],"category_scores_gemma":[0.00024931168,0.00021060997,0.00024518569,0.00024266349,0.00024582562,0.00020340834,0.00022365528,0.0007826124,0.00085342705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031674153,0.0000123668415,0.000081740574,0.000021685077,0.0000029121675,0.000026224085,0.000014192669,0.00009166068,0.9987664,0.000111289795,0.00001992044,0.0008199741],"study_design_scores_gemma":[0.000013788214,0.00011697303,0.00051620445,0.0000059202634,0.000013646669,0.00013651882,0.000007209286,0.0005399295,0.9964585,0.00004161695,0.0021479034,0.0000018848149],"about_ca_topic_score_codex":0.00032926066,"about_ca_topic_score_gemma":0.00048244346,"teacher_disagreement_score":0.0008771247,"about_ca_system_score_codex":0.00025696456,"about_ca_system_score_gemma":0.0002840637,"threshold_uncertainty_score":0.0029342175},"labels":[],"label_agreement":null},{"id":"W2114643167","doi":"10.4049/jimmunol.1200979","title":"Comparative and Functional Evaluation of In Vitro Generated to Ex Vivo CD8 T Cells","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Cytotoxic T cell; CD8; Biology; Cell biology; Ex vivo; In vitro; Haematopoiesis; Immune system; Immunology; Stem cell; Biochemistry","score_opus":0.10106963564029958,"score_gpt":0.3725239955399382,"score_spread":0.2714543598996386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114643167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894498,0.0008744855,0.0074181026,0.0000309367,0.000028355127,0.000037194703,0.00034087588,0.00004782672,0.0017724179],"genre_scores_gemma":[0.9908558,0.0006042812,0.0056326785,0.000052854903,0.000029563504,0.00008623032,0.000820736,0.000032706,0.001885183],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967086,0.00012085361,0.0000465679,0.00005597802,0.00005393945,0.0000517953],"domain_scores_gemma":[0.99962986,0.00015578335,0.00004213612,0.000050679446,0.00006897547,0.000052534604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041136786,0.0004250855,0.00019638626,0.00026236236,0.00011432356,0.00037119447,0.00018902657,0.0003549867,0.0014516646],"category_scores_gemma":[0.00032760366,0.00009014611,0.00015799435,0.00013911074,0.00019756536,0.00023566237,0.00018226595,0.00059917313,0.00034968453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008413199,0.00004317593,0.00014280604,0.00003605169,0.0000026614114,0.000027805527,0.000022016802,0.000058949918,0.9985103,0.000039094684,0.0000066275666,0.001026435],"study_design_scores_gemma":[0.000011819061,0.0007025637,0.0031156086,0.0000065660633,0.000024313247,0.00030692015,0.00003254614,0.00047263104,0.9941764,0.00003824762,0.0011087764,0.0000035190244],"about_ca_topic_score_codex":0.00006968054,"about_ca_topic_score_gemma":0.000091004804,"teacher_disagreement_score":0.0014516646,"about_ca_system_score_codex":0.0000965608,"about_ca_system_score_gemma":0.00006898303,"threshold_uncertainty_score":0.004856348},"labels":[],"label_agreement":null},{"id":"W2115339711","doi":"10.1126/scitranslmed.3002207","title":"Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8 <sup>+</sup> T Cells","year":2011,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"In vitro; Cytotoxic T cell; Cancer research; Chemistry; CD8; Biology; Cell biology; Molecular biology; Immunology; Biochemistry; Antigen","score_opus":0.08711942904721322,"score_gpt":0.3547967759323328,"score_spread":0.26767734688511957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115339711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799855,0.0023169965,0.011846729,0.00033336965,0.000082341125,0.00009501151,0.00020762222,0.00032346378,0.0048090615],"genre_scores_gemma":[0.9939833,0.0006102761,0.003133221,0.00022358395,0.00003424712,0.00005057054,0.00027389065,0.000024631967,0.001666254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987185,0.000040479066,0.000007985402,0.000033851666,0.00001855702,0.000027177344],"domain_scores_gemma":[0.9999113,0.000020725247,0.00001816093,0.000024677698,0.000010550309,0.000014566577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036555465,0.00028039003,0.00019686922,0.0001376108,0.00011352921,0.00036938937,0.00013293479,0.0002778611,0.0016577803],"category_scores_gemma":[0.00029412674,0.00010372575,0.00011614539,0.00005725848,0.00023093568,0.00019400401,0.000110485205,0.0006130738,0.00054177997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059549644,0.00065712025,0.002116831,0.000081446466,0.000020097737,0.00018008632,0.000090097405,0.00032143746,0.9639807,0.000688421,0.0009120828,0.03035622],"study_design_scores_gemma":[0.0003258222,0.01071185,0.0070596165,0.00006732326,0.000101551304,0.0034222845,0.000080514474,0.003956983,0.94235885,0.00090627174,0.0309917,0.000017185734],"about_ca_topic_score_codex":0.00013498182,"about_ca_topic_score_gemma":0.0001399624,"teacher_disagreement_score":0.0016577803,"about_ca_system_score_codex":0.00016423274,"about_ca_system_score_gemma":0.00013195198,"threshold_uncertainty_score":0.0055458546},"labels":[],"label_agreement":null},{"id":"W2119966117","doi":"10.1126/scitranslmed.3000885","title":"Of Mice and Men: How an Oncogene Transgresses the Limits and Predisposes to T Cell Acute Lymphoblastic Leukemia","year":2010,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Lymphoblastic Leukemia; Medicine; Leukemia; Cancer research; Oncogene; Immunology; Internal medicine; Cancer; Cell cycle","score_opus":0.02828802231561585,"score_gpt":0.3272745458485826,"score_spread":0.2989865235329668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119966117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9656745,0.0078404015,0.008319958,0.0039851167,0.0004435003,0.0001065649,0.0008618892,0.0007403006,0.012027724],"genre_scores_gemma":[0.97324276,0.0048678606,0.003639122,0.0014992007,0.00011499622,0.000099137666,0.00030254852,0.00018873655,0.016045766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994418,0.00019524925,0.000030994226,0.00014388419,0.00009027085,0.000097796685],"domain_scores_gemma":[0.9997261,0.00006864577,0.00007052328,0.000048286725,0.00000840973,0.00007797108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000572459,0.0008311091,0.0004258568,0.0009542315,0.00052031985,0.0006826863,0.00040660278,0.0010867438,0.0062489887],"category_scores_gemma":[0.00044688457,0.00038334404,0.000440287,0.00033549196,0.0012334767,0.0007768684,0.0007390798,0.0010347448,0.0009410044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027032176,0.00046238996,0.005036983,0.00016930264,0.000116622075,0.0024893177,0.00039387777,0.00029394234,0.94888896,0.012941528,0.0020353154,0.024468541],"study_design_scores_gemma":[0.00083885586,0.007256983,0.03856911,0.00021751053,0.0005611375,0.039571688,0.0012408877,0.002083081,0.75036144,0.012366417,0.1467452,0.0001876228],"about_ca_topic_score_codex":0.00049677433,"about_ca_topic_score_gemma":0.0007124759,"teacher_disagreement_score":0.0062489887,"about_ca_system_score_codex":0.00025912168,"about_ca_system_score_gemma":0.00028506914,"threshold_uncertainty_score":0.020904899},"labels":[],"label_agreement":null},{"id":"W2120261661","doi":"10.1158/0008-5472.can-11-1659","title":"B Effector Cells Activated by a Chimeric Protein Consisting of IL-2 and the Ectodomain of TGF-β Receptor II Induce Potent Antitumor Immunity","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Ectodomain; Antigen; Medicine; Cancer research; Immunology; CD8; Cytotoxic T cell; Tumor antigen; Molecular biology; Immune system; Biology; Receptor; Immunotherapy; In vitro; Internal medicine","score_opus":0.05778358443386004,"score_gpt":0.37915640540113293,"score_spread":0.3213728209672729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120261661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959746,0.0007318713,0.0017405812,0.000032253552,0.000025130883,0.000037858954,0.00014472172,0.00008809122,0.0012247628],"genre_scores_gemma":[0.9942526,0.00066068635,0.001963388,0.00005073091,0.000019644685,0.0000482884,0.00054404914,0.000021933169,0.0024386789],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998591,0.000018977453,0.000010712541,0.000023775561,0.00003547958,0.000051902527],"domain_scores_gemma":[0.99989617,0.00001528193,0.000029110399,0.000013451419,0.000009436443,0.000036605434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014682193,0.0005142961,0.0002793025,0.00026765448,0.00008598958,0.00030851713,0.0001264372,0.00027160117,0.0011650726],"category_scores_gemma":[0.00005851577,0.00013655698,0.00028412923,0.00011888497,0.00011515256,0.00014464706,0.0001810987,0.0009327062,0.0005296667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052571435,0.000030618008,0.00007814855,0.000012103139,0.000002329174,0.000020887315,0.0000060628654,0.000018027331,0.9994267,0.00002088821,0.000008604555,0.00032310563],"study_design_scores_gemma":[0.000053111136,0.00065269467,0.0031117005,0.000007697883,0.00002761325,0.00028612986,0.000028549679,0.0006436839,0.99298334,0.00003169766,0.0021711292,0.0000026769997],"about_ca_topic_score_codex":0.000114957926,"about_ca_topic_score_gemma":0.00016255557,"teacher_disagreement_score":0.0011650726,"about_ca_system_score_codex":0.000111334346,"about_ca_system_score_gemma":0.00011605361,"threshold_uncertainty_score":0.0038975477},"labels":[],"label_agreement":null},{"id":"W2120672212","doi":"10.1158/0008-5472.can-06-4309","title":"Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Medulloblastoma; Cancer research; Adoptive cell transfer; Medicine; Immunology; T cell; Biology; Immune system","score_opus":0.09518931613407072,"score_gpt":0.44727331356468614,"score_spread":0.3520839974306154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120672212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916038,0.0014402198,0.0025864504,0.0001519981,0.00021941711,0.00032137363,0.0008491825,0.00023504418,0.002592528],"genre_scores_gemma":[0.9902856,0.0013774986,0.0026103796,0.000091923845,0.00006974847,0.00030055418,0.0009706089,0.00005893368,0.0042347717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994879,0.00008713281,0.000058105434,0.00011820974,0.00010550232,0.00014321465],"domain_scores_gemma":[0.9995839,0.00012432027,0.00008821446,0.000074667565,0.000031232314,0.00009769108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003712421,0.00090647116,0.0005965889,0.00061534345,0.00026114972,0.00034433822,0.00048072133,0.0006674655,0.002132977],"category_scores_gemma":[0.00029469572,0.00024290191,0.00060832285,0.00027130797,0.00048327955,0.0003667381,0.00030166228,0.002049009,0.0005771701],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013697246,0.0014583132,0.00030000522,0.00011355237,0.000036846217,0.0002395096,0.00011239236,0.0005504766,0.99201256,0.00044471674,0.0002437744,0.0031180186],"study_design_scores_gemma":[0.00026501573,0.006033062,0.0008954813,0.000017962866,0.000035540063,0.00032480317,0.000051058545,0.0019240088,0.98812187,0.000098257464,0.002225841,0.0000070304427],"about_ca_topic_score_codex":0.0022078224,"about_ca_topic_score_gemma":0.0020414335,"teacher_disagreement_score":0.0022078224,"about_ca_system_score_codex":0.000586196,"about_ca_system_score_gemma":0.00059655274,"threshold_uncertainty_score":0.0071355104},"labels":[],"label_agreement":null},{"id":"W2122826668","doi":"10.1186/1479-0556-2-15","title":"Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC.","year":2004,"lang":"en","type":"article","venue":"Genetic Vaccines and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hector Stiftung; McMaster University","keywords":"Lymphoma; Cytokine; Cancer research; Peripheral blood mononuclear cell; Cytotoxic T cell; Immune system; Molecular biology; Medicine; Cell culture; Cytotoxicity; Immunology; Biology; In vitro","score_opus":0.013691741329263039,"score_gpt":0.28165763387356885,"score_spread":0.2679658925443058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122826668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850188,0.0066971267,0.004242112,0.00010880258,0.00015376054,0.00009458189,0.00078453217,0.00009818354,0.0028022262],"genre_scores_gemma":[0.9898873,0.0019790926,0.004607982,0.00006699432,0.000031587562,0.00010014887,0.001084682,0.00002259059,0.0022196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995158,0.00021270881,0.000045236477,0.00006682637,0.00009259077,0.00006682204],"domain_scores_gemma":[0.99971384,0.0001307815,0.00003651432,0.00004164002,0.000043023563,0.000034286524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039302613,0.0004481118,0.00030286712,0.000189376,0.00012251233,0.00046813034,0.00017635644,0.00026727276,0.0013916707],"category_scores_gemma":[0.0002847079,0.00012916049,0.0002892538,0.0002033087,0.0001486402,0.00017968295,0.00018092766,0.0005592537,0.0007523205],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065816747,0.00018117696,0.0003131347,0.00011866327,0.000011857565,0.00008401888,0.000047821504,0.0001372062,0.9961158,0.00004706798,0.000087389904,0.0021975518],"study_design_scores_gemma":[0.000058939353,0.0014001515,0.002533361,0.000013055029,0.000027982163,0.00023962151,0.000045431538,0.0011666293,0.99232376,0.000015668096,0.0021710366,0.0000042779075],"about_ca_topic_score_codex":0.0008598583,"about_ca_topic_score_gemma":0.0010779457,"teacher_disagreement_score":0.0013916707,"about_ca_system_score_codex":0.00024303234,"about_ca_system_score_gemma":0.00018046507,"threshold_uncertainty_score":0.004655659},"labels":[],"label_agreement":null},{"id":"W2123380826","doi":"10.25011/cim.v33i6.14584","title":"Discovery research to clinical trial: A ten year journey","year":2010,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"Michael Smith Health Research BC; Canadian Institutes of Health Research; Terry Fox Foundation; Cancer Research Society","keywords":"Medicine; Clinical trial; Internal medicine","score_opus":0.5668532213575824,"score_gpt":0.55408223613295,"score_spread":0.01277098522463238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123380826","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011861789,0.15487777,0.015616925,0.7767873,0.039899506,0.00086478994,0.00029297583,0.0010993653,0.009375312],"genre_scores_gemma":[0.024496168,0.26353145,0.13656689,0.45793074,0.08930503,0.004627578,0.0019931828,0.0011155979,0.020433292],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9188212,0.040539067,0.008923568,0.00487965,0.02091428,0.005922211],"domain_scores_gemma":[0.6991636,0.17220207,0.008803797,0.014598205,0.03628477,0.06894746],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.23126309,0.004306352,0.008641233,0.006661834,0.005541008,0.031710833,0.007827849,0.03074097,0.04000569],"category_scores_gemma":[0.19620226,0.0027604655,0.0046033342,0.00552597,0.017613364,0.029952861,0.01615385,0.03637734,0.016468484],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009832317,0.0014994539,0.00095917366,0.002906792,0.00037886613,0.00086607767,0.0016171454,0.0009956455,0.00093955337,0.056199633,0.6129449,0.3197095],"study_design_scores_gemma":[0.0017015008,0.0028407166,0.0010764555,0.0072472505,0.00019981762,0.0010994714,0.002834014,0.0018094108,0.00034883275,0.13251397,0.8480531,0.00027539377],"about_ca_topic_score_codex":0.0033601932,"about_ca_topic_score_gemma":0.0030183396,"teacher_disagreement_score":0.23126309,"about_ca_system_score_codex":0.008869,"about_ca_system_score_gemma":0.05640267,"threshold_uncertainty_score":0.94798946},"labels":[],"label_agreement":null},{"id":"W2124668663","doi":"10.1158/2326-6066.cir-14-0222","title":"Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Hospital for Sick Children","keywords":"T-cell receptor; Chemistry; Major histocompatibility complex; Antigen; T cell; Biology; Epitope; Molecular biology; Cell biology; Immunology; Immune system","score_opus":0.09014275203993506,"score_gpt":0.39063135939160626,"score_spread":0.3004886073516712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124668663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98883003,0.0010605055,0.009025238,0.000046821937,0.000012810418,0.000040033727,0.00007456331,0.0000665658,0.0008434024],"genre_scores_gemma":[0.99458754,0.0008865087,0.0037741493,0.00003205906,0.000009159628,0.000029864521,0.000096457836,0.000017226943,0.00056694634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980944,0.000034284152,0.00001700153,0.000035576002,0.00005254304,0.00005108182],"domain_scores_gemma":[0.9998863,0.00002177373,0.00004634018,0.000011873685,0.000012364897,0.000021343201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019974721,0.0003426312,0.00022241977,0.0002006614,0.000084147476,0.00035569692,0.00016537958,0.00018936158,0.0006779924],"category_scores_gemma":[0.00013625587,0.000136835,0.00015271765,0.00017466703,0.00014312564,0.00020986189,0.00019029407,0.0005348626,0.00018917136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002626826,0.000019754674,0.000084420506,0.000013276481,0.0000021640874,0.000009107264,0.0000047591466,0.0002464494,0.99867296,0.000060455928,0.000007826269,0.0008525669],"study_design_scores_gemma":[0.00001954895,0.0004726526,0.0011583647,0.0000057008874,0.00003015801,0.00017497824,0.000016186894,0.002610822,0.9937649,0.00006043408,0.001680517,0.000005678071],"about_ca_topic_score_codex":0.00011031687,"about_ca_topic_score_gemma":0.00022528463,"teacher_disagreement_score":0.0006779924,"about_ca_system_score_codex":0.00019559803,"about_ca_system_score_gemma":0.00018166321,"threshold_uncertainty_score":0.0022681355},"labels":[],"label_agreement":null},{"id":"W2130024935","doi":"10.4161/onci.23621","title":"Lessons learned from a highly-active CD22-specific chimeric antigen receptor","year":2013,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"CD22; Chimeric antigen receptor; Epitope; Antigen; Bispecific antibody; Receptor; Antibody; Immunology; Computational biology; Cancer research; Medicine; Immunotherapy; Biology; Monoclonal antibody; Internal medicine; Immune system","score_opus":0.07570445915132859,"score_gpt":0.34021376943611,"score_spread":0.2645093102847814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130024935","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07985567,0.5460273,0.05086187,0.27610922,0.008582378,0.00010455859,0.00045118874,0.00042905236,0.037578773],"genre_scores_gemma":[0.4028776,0.48327392,0.025350323,0.055174634,0.009562154,0.00013053048,0.00037365436,0.0001706297,0.023086503],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99949026,0.0001686251,0.000036632475,0.00007328077,0.00014820766,0.00008300965],"domain_scores_gemma":[0.9989856,0.0004378756,0.00004206084,0.00009798174,0.00020964979,0.00022694288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029563804,0.00055846927,0.00079002255,0.00031897056,0.0004258032,0.0017804914,0.000937621,0.0017217433,0.0027286187],"category_scores_gemma":[0.0023870491,0.00025109557,0.0004327387,0.00023795926,0.0028449409,0.0036458448,0.0010038485,0.0074072266,0.0013260134],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014755572,0.000864894,0.0022593373,0.003290638,0.00021141664,0.004901283,0.0012840076,0.005720936,0.0755814,0.19577055,0.11414434,0.5944957],"study_design_scores_gemma":[0.0003719386,0.0020999105,0.0016668463,0.000832104,0.00014493556,0.006300937,0.00097108,0.0034243276,0.038738426,0.12190708,0.823414,0.00012842845],"about_ca_topic_score_codex":0.00081433053,"about_ca_topic_score_gemma":0.0010609445,"teacher_disagreement_score":0.0029563804,"about_ca_system_score_codex":0.0009908275,"about_ca_system_score_gemma":0.0009858565,"threshold_uncertainty_score":0.015635014},"labels":[],"label_agreement":null},{"id":"W2132636334","doi":"10.4049/jimmunol.192.supp.65.9","title":"Translational control of memory CD8 T cell differentiation (LYM4P.752)","year":2014,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; CD8; Cytotoxic T cell; Cell biology; T cell; Transcriptome; Gene expression; Translation (biology); Memory T cell; Cellular differentiation; Antigen; Messenger RNA; Immunology; Gene; Immune system; Genetics; In vitro","score_opus":0.013980575158538388,"score_gpt":0.26965158199532585,"score_spread":0.25567100683678745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132636334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372065,0.0014639888,0.0020834121,0.00007398759,0.000034195586,0.000012935348,0.00042578342,0.00007741118,0.0021074936],"genre_scores_gemma":[0.9956792,0.000302691,0.0011589376,0.00004753878,0.000011601473,0.000017198661,0.0004888818,0.000022417855,0.002271534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993324,0.00000869514,0.0000036528374,0.00002191688,0.000012488838,0.000019947498],"domain_scores_gemma":[0.99995065,0.000007187418,0.000012290342,0.000004912793,0.000009478448,0.00001540013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009916152,0.00019993719,0.000115059476,0.00019812978,0.00016408796,0.00028476762,0.00009501451,0.00015028784,0.0018141615],"category_scores_gemma":[0.00008727708,0.00007456106,0.00012775991,0.00012506281,0.00017263195,0.00012837833,0.00017248651,0.0002854877,0.00051581656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066987275,0.000006260808,0.00019395135,0.000011044255,8.493891e-7,0.00001892388,0.0000061913443,0.000027173,0.9985819,0.000096473545,0.000048023587,0.0009422256],"study_design_scores_gemma":[0.000020074676,0.00023500145,0.021878,0.000008137353,0.000009178156,0.00010465556,0.000047498565,0.0014285811,0.9722959,0.00019163603,0.0037748602,0.000006580315],"about_ca_topic_score_codex":0.000578165,"about_ca_topic_score_gemma":0.0009435199,"teacher_disagreement_score":0.0018141615,"about_ca_system_score_codex":0.00040044633,"about_ca_system_score_gemma":0.00015309834,"threshold_uncertainty_score":0.006068945},"labels":[],"label_agreement":null},{"id":"W2135832041","doi":"10.7150/jca.6572","title":"Optimizing the Immune System to Achieve Control of the Metastatic Malignant Lesion","year":2013,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision BioLogic (Canada)","funders":"","keywords":"Immune system; Immunotherapy; Malignancy; Medicine; Lesion; Cancer immunotherapy; Immunology; Cancer research; Computer science; Pathology","score_opus":0.030698494210376372,"score_gpt":0.3332146775319073,"score_spread":0.30251618332153096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135832041","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06927928,0.5083367,0.064002,0.26263702,0.06136992,0.0004024675,0.0002482282,0.0005823352,0.033142038],"genre_scores_gemma":[0.38964015,0.3439398,0.0548273,0.106105335,0.031549834,0.00022513515,0.00028474492,0.00024271914,0.07318503],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995677,0.00013071351,0.00003572987,0.000051929528,0.00014119546,0.00007267432],"domain_scores_gemma":[0.9997497,0.000107623775,0.000041177103,0.000016133139,0.000053563228,0.000031810705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015182877,0.00044261196,0.0003870728,0.00044924734,0.000365685,0.0015490405,0.00037922343,0.0015282684,0.003402889],"category_scores_gemma":[0.0008723115,0.00014596817,0.00041093826,0.00017826451,0.0007317457,0.0014446493,0.00048363092,0.002290393,0.0007513136],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006777399,0.00054784433,0.0035325156,0.0019324642,0.00014567716,0.0015552194,0.00042853318,0.0015392657,0.21796288,0.048241917,0.11994916,0.6034867],"study_design_scores_gemma":[0.0001135898,0.0011109917,0.0023837062,0.00026144035,0.00015069243,0.0032736522,0.00037451976,0.002011489,0.092616804,0.012016833,0.8856303,0.00005600711],"about_ca_topic_score_codex":0.00028920305,"about_ca_topic_score_gemma":0.0012020499,"teacher_disagreement_score":0.003402889,"about_ca_system_score_codex":0.0007550026,"about_ca_system_score_gemma":0.00069728243,"threshold_uncertainty_score":0.011383772},"labels":[],"label_agreement":null},{"id":"W2136875369","doi":"10.1111/j.1600-6143.2012.04286.x","title":"Cord Blood T Cells Retain Early Differentiation Phenotype Suitable for Immunotherapy After TCR Gene Transfer to Confer EBV Specificity","year":2012,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute for Health and Care Research; Cancer Research UK; NHS Blood and Transplant","keywords":"Immunology; Antigen; T-cell receptor; Adoptive cell transfer; Immunotherapy; Immune system; Transplantation; Cytotoxic T cell; Biology; Medicine; T cell; Cancer research; In vitro; Internal medicine","score_opus":0.019279022799342356,"score_gpt":0.2850536739189206,"score_spread":0.26577465111957826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136875369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916847,0.001046308,0.003129262,0.000083402425,0.000040817824,0.000045405697,0.000346653,0.00016396081,0.0034595337],"genre_scores_gemma":[0.99497616,0.00024968432,0.0008402074,0.00003563943,0.000013886301,0.000019267309,0.00044937994,0.000039704963,0.003376079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998348,0.00002888644,0.000016612152,0.00002487015,0.000031043575,0.000063835745],"domain_scores_gemma":[0.99975806,0.000046301022,0.000038713413,0.0000644762,0.000039872586,0.00005246323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016596266,0.00021097496,0.00022486917,0.00021718795,0.00020501178,0.0005147701,0.00021495965,0.00036507455,0.003462698],"category_scores_gemma":[0.00022335908,0.000119043674,0.00020120837,0.00022674266,0.00017891415,0.00019069841,0.00019110522,0.0009044726,0.0016944751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019387408,0.00004778781,0.0006784608,0.000014281296,0.00000406701,0.00017549441,0.000043740998,0.00004801453,0.9946672,0.00020424604,0.00009197183,0.003831018],"study_design_scores_gemma":[0.000045876397,0.00045031394,0.010008675,0.000010356953,0.000033611523,0.0019257485,0.000065002656,0.00054230576,0.97960806,0.0001666625,0.007136259,0.000007116424],"about_ca_topic_score_codex":0.00056962145,"about_ca_topic_score_gemma":0.00069539476,"teacher_disagreement_score":0.003462698,"about_ca_system_score_codex":0.000204128,"about_ca_system_score_gemma":0.00019677632,"threshold_uncertainty_score":0.011583865},"labels":[],"label_agreement":null},{"id":"W2138051343","doi":"10.1002/stem.2115","title":"In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination","year":2015,"lang":"en","type":"review","venue":"Stem Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Biology; Induced pluripotent stem cell; Embryonic stem cell; Cell biology; Stem cell; Progenitor cell; Haematopoiesis; Cellular differentiation; In vitro; Immunology; Genetics","score_opus":0.1004801585316933,"score_gpt":0.33762347317055624,"score_spread":0.23714331463886296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138051343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011361467,0.991735,0.0022106827,0.00045897058,0.00023851772,0.000016501539,0.00006078308,0.000026443171,0.004116982],"genre_scores_gemma":[0.0047613634,0.99089384,0.0021004744,0.00034679665,0.00012777033,0.000020170773,0.00009630283,0.0000048867864,0.0016483362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987304,0.000021296926,0.000017430817,0.000019356632,0.000056822417,0.000012072109],"domain_scores_gemma":[0.99991095,0.000040276213,0.000013992621,0.0000040802015,0.000021997954,0.000008687851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040474976,0.00040524045,0.0006393498,0.0007627684,0.00015499006,0.0005826198,0.0004987486,0.00056685135,0.0018476371],"category_scores_gemma":[0.0002457956,0.00017116517,0.0003151991,0.00078798423,0.00030742402,0.00070985063,0.000351421,0.001043636,0.0013104947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058324906,0.00007771401,0.00029808874,0.016026836,0.00006437049,0.00042239565,0.00014541074,0.0006043647,0.044731073,0.01474052,0.013865726,0.9089651],"study_design_scores_gemma":[0.000014387231,0.00012348298,0.0005652441,0.0014160356,0.00008206785,0.0014139441,0.00007034814,0.00015775015,0.0187888,0.0040014475,0.9733474,0.000019184667],"about_ca_topic_score_codex":0.0003598267,"about_ca_topic_score_gemma":0.0005681761,"teacher_disagreement_score":0.0018476371,"about_ca_system_score_codex":0.0002711766,"about_ca_system_score_gemma":0.00041551853,"threshold_uncertainty_score":0.006180942},"labels":[],"label_agreement":null},{"id":"W2140080463","doi":"10.1021/bi900674m","title":"Steady-State and Stopped-Flow Kinetic Studies of Three <i>Escherichia coli</i> NfsB Mutants with Enhanced Activity for the Prodrug CB1954","year":2009,"lang":"en","type":"article","venue":"Biochemistry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Biotechnology and Biological Sciences Research Council","keywords":"Mutant; Enzyme kinetics; Prodrug; Escherichia coli; Enzyme; Chemistry; Biology; Biochemistry; Active site; Gene","score_opus":0.031236943259429304,"score_gpt":0.31376420359354235,"score_spread":0.282527260334113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140080463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955706,0.0003322191,0.002896409,0.000071351744,0.00002657391,0.000017143602,0.00054140337,0.00013182311,0.0004124416],"genre_scores_gemma":[0.99240375,0.00039914914,0.0041998033,0.00004540847,0.000010109212,0.000048162623,0.0017188874,0.000056699344,0.0011181141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996196,0.000072790404,0.00003715629,0.00008501389,0.00010784699,0.00007756512],"domain_scores_gemma":[0.9992687,0.0002856798,0.00012645051,0.000055296583,0.00018975972,0.00007403771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061185355,0.00059375033,0.0006868712,0.00029134421,0.00020860444,0.0005228155,0.0006556282,0.0006612398,0.0006849177],"category_scores_gemma":[0.00073752203,0.00019024254,0.00044344732,0.0004706288,0.0003300067,0.0003491018,0.00013169229,0.0011885699,0.00033917438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000313871,0.0001630792,0.0007413214,0.000047742702,0.000028852057,0.000060394403,0.00009669543,0.00044128744,0.99666756,0.00015899504,0.00011370548,0.0011664352],"study_design_scores_gemma":[0.00002615299,0.000378048,0.0049463003,0.000008896629,0.000031076994,0.000089015906,0.00006136064,0.008355399,0.9854499,0.000059543316,0.00055674696,0.000037445712],"about_ca_topic_score_codex":0.0016159011,"about_ca_topic_score_gemma":0.00082796515,"teacher_disagreement_score":0.0016159011,"about_ca_system_score_codex":0.00064672023,"about_ca_system_score_gemma":0.00019879208,"threshold_uncertainty_score":0.004692316},"labels":[],"label_agreement":null},{"id":"W2140619977","doi":"10.4049/jimmunol.1202970","title":"Loss of T Cell Progenitor Checkpoint Control Underlies Leukemia Initiation in <i>Rag1</i>-Deficient Nonobese Diabetic Mice","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; University of Toronto; University of Cambridge; California Institute of Technology","keywords":"Biology; Nod; Transcriptome; NOD mice; Progenitor cell; Genetics; Cell biology; Cancer research; Gene; Stem cell; Gene expression","score_opus":0.0148439948634221,"score_gpt":0.2643098244594854,"score_spread":0.2494658295960633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140619977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971493,0.00036450708,0.0012784894,0.000034184613,0.000006129735,0.000010096707,0.0005019011,0.00011604478,0.0005392851],"genre_scores_gemma":[0.99636936,0.0003621806,0.00080242666,0.000040904713,0.00000671934,0.000019798497,0.00064826076,0.00004418588,0.0017061327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985945,0.000009994412,0.000014009738,0.00004863528,0.000029524117,0.000038264443],"domain_scores_gemma":[0.99975985,0.000011743989,0.000120606106,0.000015021107,0.000007843406,0.00008496356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009140078,0.0003941478,0.00022087406,0.00039399488,0.00015366623,0.00036973623,0.00018529764,0.00024374615,0.0010405891],"category_scores_gemma":[0.000086236505,0.0002047502,0.0002577281,0.0001703129,0.0002537039,0.0001495264,0.00026440038,0.00080674374,0.00033589153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011901589,0.000015620259,0.0006801639,0.00000951719,0.0000027574736,0.000058677706,0.000010491047,0.000035056575,0.9985415,0.00005722029,0.000012810273,0.00045722022],"study_design_scores_gemma":[0.000063605476,0.00043230856,0.085672155,0.000018056387,0.00004522165,0.0018140089,0.00010086452,0.001422816,0.9076636,0.0002313436,0.0025216576,0.000014289799],"about_ca_topic_score_codex":0.0005257457,"about_ca_topic_score_gemma":0.00062272116,"teacher_disagreement_score":0.0010405891,"about_ca_system_score_codex":0.00027288005,"about_ca_system_score_gemma":0.00013416506,"threshold_uncertainty_score":0.00348109},"labels":[],"label_agreement":null},{"id":"W2141410122","doi":"10.1158/1078-0432.ccr-07-0674","title":"Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":466,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; Immunology; Adoptive cell transfer; Cancer research; T cell; Homing (biology); Medicine; Ex vivo; Systemic administration; CD28; Immunotherapy; Leukemia; In vivo; Biology; Immune system","score_opus":0.1267420617162681,"score_gpt":0.4841363589671988,"score_spread":0.35739429725093075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141410122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933211,0.0009434708,0.0041535837,0.00007915941,0.000019313013,0.000080266866,0.00014111584,0.00020193466,0.0010600749],"genre_scores_gemma":[0.99465466,0.00062596385,0.0025466685,0.00003272002,0.000020809637,0.00004856656,0.00027487395,0.000035363366,0.0017602791],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998746,0.000015081225,0.000008949701,0.000025850873,0.000039994,0.00003544489],"domain_scores_gemma":[0.9999207,0.0000125923825,0.000028597186,0.000012114966,0.0000073008787,0.000018731453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001151104,0.00043785915,0.00031862652,0.00017176321,0.00008756335,0.00023363074,0.00015450842,0.0001957822,0.0008215331],"category_scores_gemma":[0.00010757818,0.0000828088,0.00016769639,0.000098124576,0.00016677089,0.00013602298,0.000117466916,0.000588138,0.00031625837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012131326,0.00011408352,0.0003105089,0.000033994267,0.000006670906,0.000038437393,0.000012061975,0.00031584842,0.99465215,0.00008313387,0.00007679385,0.0042350544],"study_design_scores_gemma":[0.00010962312,0.0013032261,0.0019123127,0.0000066204266,0.000037358266,0.0003946045,0.000011744083,0.0015929192,0.9917,0.000033960892,0.0028952614,0.0000023164428],"about_ca_topic_score_codex":0.00037435035,"about_ca_topic_score_gemma":0.0006079035,"teacher_disagreement_score":0.0008215331,"about_ca_system_score_codex":0.00021176357,"about_ca_system_score_gemma":0.0002447907,"threshold_uncertainty_score":0.0027483106},"labels":[],"label_agreement":null},{"id":"W2144004068","doi":"10.1182/blood.v98.10.2887","title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":250,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"John and Lucille Van Geest Foundation; North West Cancer Research; Trent University; Nottingham Trent University","keywords":"Myeloid leukemia; K562 cells; Biology; Human leukocyte antigen; Cytotoxic T cell; Fusion protein; Leukemia; Cancer research; Immunology; Antigen; In vitro; Genetics; Recombinant DNA","score_opus":0.048150746881359716,"score_gpt":0.2904851457881751,"score_spread":0.24233439890681535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144004068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923711,0.0008232632,0.0041804686,0.0001246728,0.000022805794,0.000012147834,0.00026990878,0.000047280806,0.0021484483],"genre_scores_gemma":[0.99609286,0.00040842366,0.0018768711,0.000059714483,0.000011681858,0.000010865485,0.00036968075,0.000009333783,0.0011606475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999213,0.000009169646,0.0000043524033,0.000019847295,0.00003062881,0.000014669719],"domain_scores_gemma":[0.9999149,0.00002447568,0.000019253677,0.000011443438,0.000014778338,0.000015066825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008687403,0.00015332742,0.00008628282,0.00013382724,0.00016070371,0.00021397464,0.00009110301,0.00026189175,0.0021766764],"category_scores_gemma":[0.00014004463,0.000060946917,0.00007647692,0.00012725363,0.00023509591,0.00016831602,0.000214789,0.0003174667,0.00043682155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032853877,0.0000051218262,0.00034747965,0.00001046491,0.000002006352,0.0000558932,0.000010522433,0.0000069055395,0.99896085,0.0000806052,0.00002710286,0.0004601606],"study_design_scores_gemma":[0.000018780946,0.00013427854,0.008424232,0.0000032706466,0.000012039457,0.002317066,0.00006421469,0.0004926628,0.9855278,0.0001643244,0.0028384414,0.0000029385878],"about_ca_topic_score_codex":0.00018116571,"about_ca_topic_score_gemma":0.0002375741,"teacher_disagreement_score":0.0021766764,"about_ca_system_score_codex":0.00010978189,"about_ca_system_score_gemma":0.0000899336,"threshold_uncertainty_score":0.0072817206},"labels":[],"label_agreement":null},{"id":"W2145284843","doi":"10.1158/0008-5472.can-14-3283","title":"Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Research UK","keywords":"Biology; Cancer research","score_opus":0.15296459169601045,"score_gpt":0.4465292280537598,"score_spread":0.2935646363577493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145284843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932729,0.0005936818,0.0045644315,0.00007940826,0.000026120617,0.000049781254,0.00013570616,0.00012388716,0.0011540062],"genre_scores_gemma":[0.99578226,0.00035390223,0.002867096,0.000034422956,0.000011227373,0.00004558166,0.00009308693,0.000024595089,0.0007878636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998242,0.000033318458,0.00001859871,0.000041615953,0.000031318457,0.000050919487],"domain_scores_gemma":[0.9998847,0.00002493012,0.000043033335,0.000013213204,0.000009365455,0.00002465333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001835408,0.0003171784,0.00022218765,0.00022416702,0.00012342988,0.00035844365,0.00017578295,0.0002541719,0.0009159632],"category_scores_gemma":[0.00014877335,0.00011399948,0.00022032151,0.00013846385,0.00027640656,0.00019180037,0.0001857838,0.00061224174,0.00023429259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092639486,0.00003745866,0.0000928299,0.000020052337,0.0000025326433,0.000024083973,0.000012982161,0.00019516179,0.99734724,0.0003023699,0.000019376523,0.0018533394],"study_design_scores_gemma":[0.000028348559,0.00034098173,0.0006487939,0.0000031385412,0.000015473568,0.00011613933,0.0000121878775,0.00094177754,0.9964269,0.000104240644,0.0013588511,0.0000032760368],"about_ca_topic_score_codex":0.000110747744,"about_ca_topic_score_gemma":0.00020711368,"teacher_disagreement_score":0.0009159632,"about_ca_system_score_codex":0.00022469126,"about_ca_system_score_gemma":0.00021603944,"threshold_uncertainty_score":0.0030642152},"labels":[],"label_agreement":null},{"id":"W2149734942","doi":"10.1007/s11248-006-9030-6","title":"Ubiquitous expression of mRFP-1 in vivo by site-directed transgenesis","year":2006,"lang":"en","type":"article","venue":"Transgenic Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; McGill University","keywords":"Biology; Transgene; Green fluorescent protein; Transgenesis; Cell biology; Molecular biology; Genetically modified mouse; Genetics; Gene; Embryo; Reproductive technology","score_opus":0.05248255087783065,"score_gpt":0.3722276798583937,"score_spread":0.31974512898056306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149734942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7018205,0.005192013,0.26268673,0.0014892285,0.00075927115,0.001152944,0.0070719463,0.0049670218,0.014860287],"genre_scores_gemma":[0.864627,0.0029364626,0.09775377,0.00030023398,0.0001226038,0.0006439719,0.005861829,0.0013375852,0.026416503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988152,0.00013631886,0.00012575829,0.00037454188,0.00026392026,0.000284298],"domain_scores_gemma":[0.99930704,0.00016053133,0.00014364612,0.00017720192,0.0000757606,0.0001357811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013094704,0.0010463075,0.00095950224,0.0014112466,0.0006414213,0.0012734291,0.0014886226,0.0012496518,0.0041207187],"category_scores_gemma":[0.0005005706,0.0008877842,0.0008658696,0.000797944,0.0010291218,0.0011048302,0.00073833286,0.0032025182,0.0035125413],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064841115,0.000027998327,0.00003770865,0.00003627637,0.0000057662987,0.000032515385,0.00003548405,0.00005390261,0.9975562,0.0007097829,0.00015327026,0.0012863679],"study_design_scores_gemma":[0.000027780383,0.00006633585,0.0003128723,0.000008616646,0.000021283939,0.00022007458,0.000023272754,0.0009343332,0.99311453,0.000120294455,0.005142779,0.000007785204],"about_ca_topic_score_codex":0.001058326,"about_ca_topic_score_gemma":0.0015077622,"teacher_disagreement_score":0.0041207187,"about_ca_system_score_codex":0.0008756295,"about_ca_system_score_gemma":0.00080555456,"threshold_uncertainty_score":0.013785124},"labels":[],"label_agreement":null},{"id":"W2150305853","doi":"10.4049/jimmunol.1203240","title":"Control of In Vivo Collateral Damage Generated by T Cell Immunity","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Bystander effect; T cell; CD8; Immune system; Biology; In vivo; Immunology; Cell biology","score_opus":0.013009218876555964,"score_gpt":0.2702400980035213,"score_spread":0.2572308791269653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150305853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899979,0.0010606793,0.0073708207,0.000059055343,0.000029332032,0.000045073488,0.000037479123,0.00015727649,0.0012423081],"genre_scores_gemma":[0.9959627,0.0004550283,0.0021295468,0.000022138567,0.000016831409,0.000033987963,0.000049822327,0.000017635297,0.0013123418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997228,0.00006419371,0.000023036922,0.00005991106,0.000054430897,0.000075671145],"domain_scores_gemma":[0.9997845,0.000035670375,0.00006688898,0.000046643334,0.000014030589,0.000052252508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036632703,0.00047736123,0.00036628876,0.000210232,0.00016100219,0.00049678475,0.00017610304,0.000364556,0.0012656521],"category_scores_gemma":[0.0001653575,0.00011557895,0.00023937924,0.00008490742,0.00033190995,0.00026777934,0.00024944622,0.0010235519,0.0002620364],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116586976,0.00007712015,0.00013312872,0.00003118094,0.000003925844,0.000037341557,0.000019439782,0.00015982274,0.99740595,0.00027800523,0.000028434899,0.0017090578],"study_design_scores_gemma":[0.000028007164,0.001332981,0.00058467913,0.000007372859,0.00001613615,0.00026185974,0.000020394114,0.0012938797,0.9950932,0.00012069068,0.0012378631,0.0000029629302],"about_ca_topic_score_codex":0.00012004418,"about_ca_topic_score_gemma":0.00023177348,"teacher_disagreement_score":0.0012656521,"about_ca_system_score_codex":0.00018405938,"about_ca_system_score_gemma":0.00022584725,"threshold_uncertainty_score":0.004234016},"labels":[],"label_agreement":null},{"id":"W2154006657","doi":"10.1634/theoncologist.10-9-760","title":"Nimotuzumab: Evidence of Clinical Benefit Without Rash","year":2005,"lang":"en","type":"letter","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rash; Nimotuzumab; Dermatology; Pharmacology; Oncology; Intensive care medicine; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.23652912594375666,"score_gpt":0.4906644354273119,"score_spread":0.2541353094835552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154006657","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21989448,0.44624072,0.0036731197,0.06595781,0.008063592,0.0012459793,0.004308559,0.0006384502,0.24997729],"genre_scores_gemma":[0.7810729,0.117607236,0.0030125447,0.05249056,0.007437662,0.00040914433,0.0035137986,0.0001271965,0.03432909],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99929786,0.00037435925,0.0000493393,0.00006959091,0.00016572833,0.00004310552],"domain_scores_gemma":[0.9983265,0.00092172384,0.00023656728,0.000088186884,0.0001527437,0.00027430462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016893543,0.00038906327,0.0015100547,0.00024227002,0.00023000069,0.000655662,0.0004276861,0.0010101286,0.016181907],"category_scores_gemma":[0.003886994,0.00011073213,0.0004961317,0.0003822077,0.00042257656,0.0005227298,0.0002376414,0.0016467269,0.002944124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05861572,0.000914393,0.004417874,0.005449785,0.0011197097,0.0020920068,0.00007751133,0.00045578904,0.012555376,0.004354825,0.10435469,0.8055924],"study_design_scores_gemma":[0.080873065,0.051257264,0.04680753,0.0028135963,0.002578766,0.012321099,0.00013751443,0.001396072,0.012984119,0.008563293,0.7801874,0.00008025631],"about_ca_topic_score_codex":0.00018044491,"about_ca_topic_score_gemma":0.00068517524,"teacher_disagreement_score":0.016181907,"about_ca_system_score_codex":0.00066960853,"about_ca_system_score_gemma":0.00051790325,"threshold_uncertainty_score":0.054133892},"labels":[],"label_agreement":null},{"id":"W2155493718","doi":"10.4049/jimmunol.1102757","title":"Substrate Rigidity Regulates Human T Cell Activation and Proliferation","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Common Fund; National Institutes of Health; National Eye Institute; York University; University of Pennsylvania","keywords":"CD28; Ex vivo; T cell; Materials science; Cytotoxic T cell; CD8; Cell biology; Cell growth; T-cell receptor; Priming (agriculture); Cell adhesion; Biophysics; Chemistry; Cell; In vitro; Biology; Immunology; Immune system; Biochemistry","score_opus":0.03637093820036858,"score_gpt":0.31530961644803185,"score_spread":0.2789386782476633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155493718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944078,0.0022380126,0.0008918748,0.000049622533,0.00001059279,0.000011976435,0.00018388525,0.000029551471,0.0021767616],"genre_scores_gemma":[0.9974752,0.0008566152,0.00056793966,0.000034108823,0.000010695778,0.0000136054,0.00022754392,0.000012498111,0.00080175244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997979,0.000050408944,0.000016204556,0.000034207264,0.00005974268,0.000041624062],"domain_scores_gemma":[0.9997584,0.000100813195,0.00006773094,0.000019331523,0.000024900193,0.00002882331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016321661,0.00025742137,0.00013053072,0.00019645986,0.00013283214,0.00045888338,0.00010217496,0.00023123424,0.0022929704],"category_scores_gemma":[0.00037583933,0.00016225872,0.00011268514,0.00017777039,0.00014644943,0.0001756546,0.00020854955,0.0002369362,0.00056194613],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018614548,0.000014875946,0.0010257357,0.000019594869,0.0000036502493,0.000053780266,0.000018922523,0.00018522942,0.99594814,0.00003083632,0.00004008336,0.0024731043],"study_design_scores_gemma":[0.000016480115,0.000532314,0.05977203,0.00001252743,0.000020927842,0.00046125683,0.000093184295,0.0023233164,0.93321186,0.0000909084,0.0034496137,0.000015539918],"about_ca_topic_score_codex":0.00021302239,"about_ca_topic_score_gemma":0.00025829067,"teacher_disagreement_score":0.0022929704,"about_ca_system_score_codex":0.00017691088,"about_ca_system_score_gemma":0.00008552965,"threshold_uncertainty_score":0.0076707006},"labels":[],"label_agreement":null},{"id":"W2157049259","doi":"10.3747/co.21.1661","title":"Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cetuximab; Medicine; Vemurafenib; KRAS; Colorectal cancer; Trametinib; Cancer research; Dabrafenib; Targeted therapy; Oncology; Epidermal growth factor receptor; Kinase; Internal medicine; Refractory (planetary science); EGFR inhibitors; Cancer; Melanoma; MAPK/ERK pathway; Metastatic melanoma; Biology","score_opus":0.1687028635476653,"score_gpt":0.43949911364329836,"score_spread":0.270796250095633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157049259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957417,0.0011841448,0.0005177893,0.00019544594,0.00004229416,0.0001224206,0.000057032707,0.000038007303,0.0021010987],"genre_scores_gemma":[0.998198,0.0004267037,0.00047393393,0.0000727758,0.0000431903,0.00002804323,0.00015052354,0.0000075970133,0.00059921894],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998696,0.000034605477,0.000010890281,0.000021800231,0.000024462111,0.00003871012],"domain_scores_gemma":[0.999853,0.000036247337,0.000020477051,0.000017068702,0.000009574674,0.00006363911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023535069,0.0003944626,0.00094580237,0.00032307312,0.0002635952,0.00037424956,0.0003428936,0.0003697142,0.00087020284],"category_scores_gemma":[0.000348211,0.00017439196,0.0003348323,0.00021580554,0.0002683086,0.0002131835,0.00026753917,0.00086381356,0.0002638927],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02683231,0.009687028,0.012489184,0.00037514683,0.00040741597,0.012188273,0.00043646264,0.012088305,0.6485126,0.0006441057,0.0023452067,0.27399388],"study_design_scores_gemma":[0.017263705,0.46801975,0.12697197,0.0000943302,0.0012599481,0.035989374,0.0003156394,0.034294754,0.2810188,0.0008016346,0.033784702,0.00018544726],"about_ca_topic_score_codex":0.0012803936,"about_ca_topic_score_gemma":0.0033200083,"teacher_disagreement_score":0.0012803936,"about_ca_system_score_codex":0.00048380825,"about_ca_system_score_gemma":0.000299937,"threshold_uncertainty_score":0.0035102963},"labels":[],"label_agreement":null},{"id":"W2157193492","doi":"10.1586/14760584.2013.843456","title":"Mobilizing and evaluating anticancer T cells: pitfalls and solutions","year":2013,"lang":"en","type":"review","venue":"Expert Review of Vaccines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Clinical trial; Immunotherapy; Medicine; Cancer immunotherapy; Cancer; Immunology; Immune system; Pathology; Internal medicine","score_opus":0.16076705040350686,"score_gpt":0.48535803052621684,"score_spread":0.32459098012271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157193492","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011033677,0.99791604,0.00051346247,0.0007746403,0.00013989504,0.000008142122,0.000010122575,0.0000057621,0.00052163954],"genre_scores_gemma":[0.001105074,0.99658054,0.0011371892,0.00046751497,0.00024772345,0.000021664087,0.000021230584,0.0000036292058,0.00041545593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99928445,0.00026923665,0.00009189067,0.0000888275,0.00022514322,0.00004049234],"domain_scores_gemma":[0.9985273,0.00089724513,0.00011750924,0.000050924828,0.00036002503,0.000046906724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027510251,0.0007364229,0.001975679,0.0018046243,0.00025492595,0.001520378,0.0012063254,0.0018507262,0.00240043],"category_scores_gemma":[0.0021030777,0.00033878768,0.00066147675,0.0015274478,0.0010903308,0.0023341386,0.00079485687,0.0022370918,0.0020292772],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069952024,0.00006867326,0.00020004748,0.018301155,0.00007492142,0.00019004381,0.00010642583,0.000471675,0.0045643323,0.009368319,0.017806357,0.94877815],"study_design_scores_gemma":[0.000032624717,0.00016364729,0.0005518395,0.008034894,0.00017537495,0.0016115267,0.00020632774,0.00027259477,0.0034099382,0.009196352,0.97630537,0.000039445353],"about_ca_topic_score_codex":0.0010066167,"about_ca_topic_score_gemma":0.0019850112,"teacher_disagreement_score":0.0027510251,"about_ca_system_score_codex":0.00075688097,"about_ca_system_score_gemma":0.0018570599,"threshold_uncertainty_score":0.014548957},"labels":[],"label_agreement":null},{"id":"W2157706519","doi":"10.1007/s00280-011-1798-2","title":"Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Research Resources; National Cancer Institute; Frank A. Campini Foundation","keywords":"Sunitinib; Medicine; Pharmacokinetics; Neutropenia; Dosing; Tolerability; Refractory (planetary science); Internal medicine; Tyrosine-kinase inhibitor; Pharmacology; Gastroenterology; Urology; Adverse effect; Toxicity; Cancer","score_opus":0.03107978894315848,"score_gpt":0.350450297542223,"score_spread":0.3193705085990645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157706519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99929583,0.00022636565,0.00007124073,0.000034428645,0.0000053896565,0.00005296136,0.00015256238,0.0000067611754,0.00015433748],"genre_scores_gemma":[0.998601,0.00034580333,0.00023009199,0.00006655745,0.00002647975,0.00006714764,0.0003884634,0.000009909292,0.0002646656],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972457,0.000097167,0.000018838624,0.000052606516,0.000054810476,0.000052042447],"domain_scores_gemma":[0.9993773,0.00012168469,0.00019900591,0.000057130885,0.00004330715,0.0002015604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005331582,0.00056709134,0.0012757636,0.000249061,0.0003259553,0.00046547834,0.00034210682,0.00042785855,0.001063867],"category_scores_gemma":[0.0008261663,0.00026737293,0.0008906162,0.00040004664,0.0005484222,0.00067312346,0.00016131415,0.0015373182,0.0002466511],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42722812,0.036330894,0.22761829,0.0007186762,0.0031181348,0.0020496377,0.0017273017,0.0060012834,0.1291055,0.0004828036,0.0038017482,0.16181757],"study_design_scores_gemma":[0.05412961,0.48125103,0.42936692,0.000036674122,0.0017425176,0.0026649232,0.00067340565,0.0034227397,0.021604735,0.00012687074,0.00488672,0.00009387984],"about_ca_topic_score_codex":0.0018562585,"about_ca_topic_score_gemma":0.0020418689,"teacher_disagreement_score":0.0018562585,"about_ca_system_score_codex":0.0009608723,"about_ca_system_score_gemma":0.00077056116,"threshold_uncertainty_score":0.0069716573},"labels":[],"label_agreement":null},{"id":"W2159926306","doi":"10.1007/s00262-009-0788-2","title":"Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells","year":2009,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Leids Universitair Medisch Centrum; Universiteit Leiden; Wallace H. Coulter Foundation; Cancer Research Institute; Bill and Melinda Gates Foundation","keywords":"ELISPOT; Peripheral blood mononuclear cell; Immunology; Medicine; Antigen; Chemistry; In vitro","score_opus":0.0256241263572497,"score_gpt":0.3322961344563678,"score_spread":0.3066720080991181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159926306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8899807,0.008976047,0.084914416,0.00048054525,0.0007401585,0.0025373963,0.003231771,0.00079405063,0.008345075],"genre_scores_gemma":[0.82510716,0.004137099,0.15057342,0.0007836038,0.0002062792,0.0040947204,0.007893586,0.00029193083,0.0069121546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9882123,0.00501,0.0017420803,0.0012147533,0.0033950105,0.00042588712],"domain_scores_gemma":[0.99671376,0.0012840491,0.0004238556,0.00046316686,0.0009784393,0.00013676022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061369985,0.0011044561,0.0007507636,0.00092051923,0.00076578325,0.0017666515,0.0010069904,0.0009949409,0.0015677081],"category_scores_gemma":[0.005411366,0.00048187544,0.0008038542,0.0007545301,0.00060572114,0.0006217091,0.0010665399,0.00079454266,0.0011575641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002115872,0.00042932882,0.005132849,0.00065897027,0.0000827076,0.0001272726,0.0004002199,0.0010464373,0.9741362,0.00033513544,0.0006491707,0.014885998],"study_design_scores_gemma":[0.000043712298,0.0015781017,0.0051115965,0.00010402249,0.00009668436,0.00023528753,0.00011088522,0.0020508457,0.9857373,0.0001108663,0.004771992,0.000048626756],"about_ca_topic_score_codex":0.0014294751,"about_ca_topic_score_gemma":0.0024663317,"teacher_disagreement_score":0.0061369985,"about_ca_system_score_codex":0.0005138443,"about_ca_system_score_gemma":0.0011326467,"threshold_uncertainty_score":0.03245592},"labels":[],"label_agreement":null},{"id":"W2161751938","doi":"10.1158/0008-5472.can-05-0436","title":"Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Antigen; Chimeric antigen receptor; Cancer research; In vivo; Prostate cancer; Cancer; Glutamate carboxypeptidase II; Adoptive cell transfer; Immunology; T cell; Prostate; Biology; Medicine; Immune system; Internal medicine","score_opus":0.05288526224692186,"score_gpt":0.4252216114787874,"score_spread":0.37233634923186554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161751938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96006584,0.008856467,0.02413823,0.0003608718,0.00013140224,0.00029376353,0.0003109097,0.00074835867,0.005094195],"genre_scores_gemma":[0.9884171,0.0027870634,0.0052466425,0.00021192631,0.000056476096,0.00014641522,0.00033456914,0.00003728843,0.0027626185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985325,0.000030435862,0.0000060751327,0.00003074727,0.00003607,0.00004339501],"domain_scores_gemma":[0.99995613,0.000011924709,0.0000104829505,0.0000090800195,0.0000041489966,0.000008243022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014562576,0.00038861865,0.00025461212,0.00017569565,0.000080662234,0.00030777857,0.00018961144,0.0002858366,0.0008435979],"category_scores_gemma":[0.00013282214,0.00009010597,0.00026267173,0.00010251058,0.00014913468,0.000107411004,0.00013113116,0.00065026537,0.0004173647],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029788047,0.00021217616,0.0003172031,0.00010570639,0.000017445538,0.00011497926,0.000036727753,0.00039804648,0.9801002,0.0004791509,0.00037918144,0.017541226],"study_design_scores_gemma":[0.00023520958,0.0036296132,0.002038917,0.000025765019,0.00007469732,0.0009671872,0.000022314167,0.0024375147,0.9756967,0.00018198256,0.014680334,0.00000980397],"about_ca_topic_score_codex":0.0004142851,"about_ca_topic_score_gemma":0.0004758457,"teacher_disagreement_score":0.0008435979,"about_ca_system_score_codex":0.00017118981,"about_ca_system_score_gemma":0.00030705758,"threshold_uncertainty_score":0.002822101},"labels":[],"label_agreement":null},{"id":"W2163158239","doi":"10.1084/jem.20060998","title":"Synergy between the pre–T cell receptor and Notch: cementing the αβ lineage choice","year":2006,"lang":"en","type":"review","venue":"The Journal of Experimental Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Progenitor cell; Notch signaling pathway; T-cell receptor; Lineage (genetic); Cell biology; Biology; T cell; Progenitor; Haematopoiesis; Receptor; Signal transduction; Stem cell; Immunology; Genetics; Gene; Immune system","score_opus":0.09096115410738888,"score_gpt":0.4148267785781319,"score_spread":0.323865624470743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163158239","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007642687,0.9957769,0.00043715507,0.00021938878,0.00014907819,0.0000061195656,0.000014564764,0.000019019471,0.002613436],"genre_scores_gemma":[0.0026912622,0.99482334,0.0005121653,0.00016261637,0.00011105761,0.0000107287,0.000024962086,0.0000024056553,0.0016614837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999025,0.000017218821,0.000011219363,0.00001924716,0.0000407584,0.000009090415],"domain_scores_gemma":[0.99989605,0.000037038124,0.000018316709,0.000006000513,0.000025921217,0.000016694708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003407916,0.0006776687,0.0010347049,0.001186006,0.00018206915,0.00070077454,0.0007653966,0.00080019265,0.0028188145],"category_scores_gemma":[0.00024480934,0.0002782744,0.00020842689,0.0011558644,0.00042067788,0.0009794226,0.00035526315,0.00075357576,0.0036145637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110727706,0.0000576717,0.0001545525,0.0056334366,0.00004996218,0.00030837703,0.00003808687,0.0004688535,0.011291981,0.003890075,0.012264221,0.9657319],"study_design_scores_gemma":[0.000034292436,0.0001310308,0.0011621468,0.00086761947,0.00006431035,0.001994969,0.00007676254,0.0001175171,0.0037678059,0.0028333792,0.9889311,0.000019106777],"about_ca_topic_score_codex":0.000446895,"about_ca_topic_score_gemma":0.0008372287,"teacher_disagreement_score":0.0028188145,"about_ca_system_score_codex":0.0004136342,"about_ca_system_score_gemma":0.0004610957,"threshold_uncertainty_score":0.009429932},"labels":[],"label_agreement":null},{"id":"W2163766654","doi":"10.5966/sctm.2014-0294","title":"Concise Review: Process Development Considerations for Cell Therapy","year":2015,"lang":"en","type":"review","venue":"Stem Cells Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Commercialization; Process (computing); Risk analysis (engineering); Clinical trial; New product development; Computer science; Identification (biology); Cell therapy; Product (mathematics); Resource (disambiguation); Medicine; Business; Stem cell","score_opus":0.229728009574061,"score_gpt":0.43651379201537255,"score_spread":0.20678578244131154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163766654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062822124,0.9957539,0.0005637397,0.0007580173,0.001348357,0.000018668521,0.000018799945,0.000010012667,0.0014657527],"genre_scores_gemma":[0.00057086017,0.99639684,0.0006603024,0.00062605075,0.0006736709,0.000026291478,0.00003592673,0.0000042467395,0.001005874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894136,0.00023622994,0.00016457806,0.00013069766,0.0004668182,0.000060337323],"domain_scores_gemma":[0.99830794,0.00088981,0.00028770365,0.000054801123,0.00039731967,0.00006231458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017882277,0.0014897692,0.0016375608,0.0019335441,0.0005069002,0.0023821194,0.0014360893,0.0022518022,0.006433291],"category_scores_gemma":[0.0027303267,0.00046370286,0.00083622895,0.0025812944,0.00093425903,0.003268437,0.0010515202,0.003206832,0.004920089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010553579,0.000087089415,0.00006845728,0.061733466,0.00008394755,0.0004034941,0.00013463084,0.0008771005,0.0044730245,0.018481668,0.08674783,0.82680374],"study_design_scores_gemma":[0.000014471948,0.00008176881,0.00013427314,0.004826038,0.00005912762,0.0007315491,0.00005145383,0.00012434745,0.00079578575,0.0022167417,0.990944,0.000020301544],"about_ca_topic_score_codex":0.0009153582,"about_ca_topic_score_gemma":0.0013081521,"teacher_disagreement_score":0.006433291,"about_ca_system_score_codex":0.0011385201,"about_ca_system_score_gemma":0.0027641973,"threshold_uncertainty_score":0.02152145},"labels":[],"label_agreement":null},{"id":"W2166891849","doi":"10.1084/jem.20010032","title":"Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance","year":2002,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Immunotherapy; T cell; Cancer research; Antigen; Tumor antigen; Biology; Avidity; Immunology; Antigen presentation; Cross-presentation; Immune system","score_opus":0.052986425692390954,"score_gpt":0.38244690927748526,"score_spread":0.3294604835850943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166891849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99795306,0.00032634108,0.00095195364,0.000024310875,0.0000082613005,0.000011955391,0.00003361931,0.000029395802,0.0006611148],"genre_scores_gemma":[0.9983891,0.0002304085,0.0005667238,0.000016082216,0.000008409999,0.000010671258,0.00007681943,0.000009311374,0.00069245446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997503,0.00006240497,0.000015866872,0.00004538565,0.00006120361,0.000064726984],"domain_scores_gemma":[0.99976236,0.0000711183,0.00006701059,0.000038981358,0.000015773552,0.000044813813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020940875,0.00060757133,0.00029838088,0.00027151548,0.00008216357,0.00032274803,0.00017681542,0.00039782358,0.0009784317],"category_scores_gemma":[0.00016278948,0.00018309717,0.00022649094,0.00014418973,0.00029679632,0.0003035441,0.00032851315,0.0008267486,0.00024832596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106985455,0.000060876853,0.00008911655,0.0000137621255,0.0000017425108,0.000050820196,0.000009829383,0.00010005816,0.9990791,0.00007834721,0.000007721184,0.0004015262],"study_design_scores_gemma":[0.000044586355,0.0012850126,0.00122888,0.000003451429,0.000014954797,0.00039576812,0.000012829951,0.0020876618,0.9941246,0.00007747234,0.0007215541,0.0000033913834],"about_ca_topic_score_codex":0.00026363542,"about_ca_topic_score_gemma":0.0003349137,"teacher_disagreement_score":0.0009784317,"about_ca_system_score_codex":0.0002615943,"about_ca_system_score_gemma":0.00016505773,"threshold_uncertainty_score":0.003273189},"labels":[],"label_agreement":null},{"id":"W2170981225","doi":"10.1038/nbt1395","title":"Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","year":2008,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Immunotherapy; Major histocompatibility complex; Biology; Immunology; T cell; Cancer research; Antigen; Immune system","score_opus":0.017552820196238515,"score_gpt":0.3226385269139143,"score_spread":0.3050857067176758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170981225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653975,0.0033066925,0.020809224,0.00041523576,0.00029868036,0.00024775925,0.00013171251,0.00028969804,0.009103491],"genre_scores_gemma":[0.993374,0.0008266762,0.0031418414,0.000080305275,0.0000623955,0.00006150218,0.00007357816,0.000026068872,0.002353633],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997981,0.000048553975,0.000012125455,0.000055731474,0.000035765115,0.00004975577],"domain_scores_gemma":[0.99990654,0.00002781373,0.000020878439,0.000018706978,0.0000081214275,0.000017950053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022822189,0.00043423296,0.00036806625,0.0002759676,0.00020548853,0.00055854756,0.00029261666,0.00047630156,0.0016465255],"category_scores_gemma":[0.00020473673,0.00017971295,0.00018229168,0.00014114933,0.00020040882,0.00037014976,0.0003283306,0.001524062,0.00052622746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031247947,0.0003086429,0.00018649982,0.000118821656,0.00001631449,0.00014574156,0.00005573144,0.00060103927,0.9830064,0.002692066,0.000366389,0.012189776],"study_design_scores_gemma":[0.00021131137,0.0017085816,0.00064841873,0.000024614767,0.00007266753,0.0008009522,0.000050863233,0.004427982,0.97959787,0.00080732227,0.011644143,0.0000052204637],"about_ca_topic_score_codex":0.00015061566,"about_ca_topic_score_gemma":0.00019434781,"teacher_disagreement_score":0.0016465255,"about_ca_system_score_codex":0.00015277286,"about_ca_system_score_gemma":0.00027593787,"threshold_uncertainty_score":0.005508125},"labels":[],"label_agreement":null},{"id":"W2179030446","doi":"10.18632/oncotarget.6175","title":"Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy","year":2015,"lang":"en","type":"review","venue":"Oncotarget","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Natural Science Foundation of Guangxi Province; VGH and UBC Hospital Foundation","keywords":"Medicine; Microvesicles; Cancer research; Targeted therapy; Cancer; Cancer therapy; Cell; microRNA; Internal medicine; Biology","score_opus":0.106303381061443,"score_gpt":0.401792904577189,"score_spread":0.29548952351574603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179030446","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83958656,0.058310717,0.08495312,0.0023861309,0.0014593784,0.00042696146,0.00056051085,0.00083300896,0.011483646],"genre_scores_gemma":[0.9703954,0.011052376,0.012601186,0.0005012577,0.00014465382,0.00018432681,0.00021341663,0.000060231723,0.0048472723],"study_design_codex":"bench_or_experimental","study_design_gemma":"systematic_review","domain_scores_codex":[0.9998852,0.000022761313,0.000007223593,0.000024936931,0.000034801753,0.000024986304],"domain_scores_gemma":[0.9999503,0.000010876908,0.000010689371,0.0000059091117,0.00001067061,0.000011523286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023419633,0.00034006327,0.000319022,0.00029804683,0.0002198693,0.0006162076,0.00022573401,0.00058890507,0.0009350228],"category_scores_gemma":[0.00015323695,0.00010433305,0.0004605655,0.0001712703,0.00023235007,0.0006397338,0.00053446816,0.0005884452,0.0004389242],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035712155,0.00017673893,0.00036989283,0.00041333356,0.000040839805,0.0004617676,0.000074847965,0.00062839634,0.9383313,0.0022990122,0.0016810632,0.05516562],"study_design_scores_gemma":[0.000096373,0.0007610791,0.0007598107,0.00004006352,0.000121339435,0.0011129037,0.000051598774,0.0057303933,0.95757097,0.0006833899,0.03304834,0.000023675671],"about_ca_topic_score_codex":0.00012993068,"about_ca_topic_score_gemma":0.00015056424,"teacher_disagreement_score":0.0009350228,"about_ca_system_score_codex":0.00021827662,"about_ca_system_score_gemma":0.00024799377,"threshold_uncertainty_score":0.0031279325},"labels":[],"label_agreement":null},{"id":"W2179389093","doi":"10.1093/annonc/mdv382","title":"Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; European Research Council; National Institutes of Health; Genome British Columbia; Canadian Cancer Society; Ludwig Institute for Cancer Research; Canadian Institutes of Health Research; Genome Canada; Ovarian Cancer Research Fund; U.S. Department of Defense","keywords":"Immunotherapy; Medicine; Personalized medicine; Cancer immunotherapy; Precision medicine; Clinical trial; Cancer; Computational biology; Genomic sequencing; Bioinformatics; Internal medicine; Gene; Genome; Biology; Genetics; Pathology","score_opus":0.24542338659995216,"score_gpt":0.5002399680797417,"score_spread":0.25481658147978953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179389093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062486375,0.9969464,0.00018731681,0.0016571382,0.0004002879,0.000002632298,0.000011483828,0.000007783971,0.00072454405],"genre_scores_gemma":[0.001002975,0.99616903,0.00025714294,0.0013328865,0.00057878566,0.000004900122,0.000018418941,0.0000018822847,0.00063401106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997559,0.00006126743,0.000021941725,0.000037685884,0.000094248906,0.00002887912],"domain_scores_gemma":[0.9992501,0.00047105283,0.00007221315,0.000017097236,0.00013460437,0.000054969518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009134863,0.0006985315,0.0014437613,0.0014640376,0.00033214956,0.0014651979,0.00088239444,0.0019072881,0.0045433375],"category_scores_gemma":[0.0012652177,0.00024051739,0.00046991446,0.0013770038,0.0007964635,0.0024007885,0.0009713961,0.0033647043,0.0016693424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006633416,0.0000672146,0.00023386483,0.0092870025,0.000097562006,0.00018036464,0.000050912233,0.00040874482,0.0013023332,0.012764667,0.065581486,0.9099594],"study_design_scores_gemma":[0.000019941639,0.00005352746,0.00034911878,0.002663422,0.000079586855,0.00078993075,0.000061031482,0.00013866565,0.0002544308,0.0059743966,0.9895984,0.000017664415],"about_ca_topic_score_codex":0.00082361326,"about_ca_topic_score_gemma":0.0028102028,"teacher_disagreement_score":0.0045433375,"about_ca_system_score_codex":0.0008048287,"about_ca_system_score_gemma":0.0013496309,"threshold_uncertainty_score":0.015198946},"labels":[],"label_agreement":null},{"id":"W2184558141","doi":"10.1158/1078-0432.ccr-15-2023","title":"Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; University of Victoria; Simon Fraser University; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Canada's Michael Smith Genome Sciences Centre","keywords":"Follicular lymphoma; Lymphoma; CD8; Biology; Immunogenicity; Immunology; Immunotherapy; Cancer research; Antigen; Immune system","score_opus":0.26599864206247,"score_gpt":0.5073295551678475,"score_spread":0.24133091310537752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2184558141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931288,0.0012794958,0.004098791,0.00020046295,0.000007772874,0.00006280744,0.000048503898,0.000075296804,0.0010980662],"genre_scores_gemma":[0.9963607,0.00033537237,0.0027173313,0.00022706091,0.000029543675,0.000029074272,0.00007776303,0.0000066820076,0.00021637868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979705,0.00006468688,0.000016384567,0.000054501015,0.00003801618,0.00002940757],"domain_scores_gemma":[0.9998529,0.000060631755,0.000032040825,0.000018074948,0.000017107908,0.000019139403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039476543,0.00028716604,0.0003009074,0.00030123434,0.00015541256,0.00044202965,0.00015994212,0.00044656178,0.0011736233],"category_scores_gemma":[0.0005056047,0.000119786666,0.00013304435,0.00013748252,0.00019517979,0.00024328135,0.00021958543,0.00042766263,0.00042026705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013637224,0.00039611754,0.23174894,0.00029776167,0.00006050463,0.0020511667,0.00047643392,0.002150613,0.63803273,0.0004146868,0.0011222031,0.121885225],"study_design_scores_gemma":[0.0004791535,0.005358701,0.39068672,0.000266203,0.00043733066,0.051818177,0.0009201708,0.026043687,0.50111604,0.0028815363,0.019946946,0.000045313518],"about_ca_topic_score_codex":0.000150627,"about_ca_topic_score_gemma":0.00019578554,"teacher_disagreement_score":0.0011736233,"about_ca_system_score_codex":0.00021535353,"about_ca_system_score_gemma":0.00014517212,"threshold_uncertainty_score":0.003926158},"labels":[],"label_agreement":null},{"id":"W2185958617","doi":"10.7150/thno.12040","title":"A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab","year":2015,"lang":"en","type":"article","venue":"Theranostics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Institute of General Medical Sciences; McGill University; University of Utah","keywords":"Pretargeting; CD20; Rituximab; Lymphoma; Medicine; Cancer research; B-cell lymphoma; Radioimmunotherapy; Monoclonal antibody; Pharmacology; Antibody; Immunology","score_opus":0.05752494232739792,"score_gpt":0.36146813677482886,"score_spread":0.30394319444743095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185958617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767903,0.004929822,0.015390445,0.00013533713,0.000052623367,0.000107429594,0.00009475793,0.00019931134,0.0022999072],"genre_scores_gemma":[0.9889442,0.0013057273,0.0071573034,0.000101155645,0.000021171734,0.00007108628,0.00009158159,0.000019902644,0.0022877809],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992454,0.000010190739,0.0000050402714,0.00002085408,0.000018638824,0.000020809797],"domain_scores_gemma":[0.99995375,0.000008631848,0.000017715509,0.0000058680807,0.000006268022,0.000007695665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083840074,0.00043948254,0.00016688637,0.00013325778,0.00008039959,0.00019606689,0.00017419369,0.0003198857,0.001109081],"category_scores_gemma":[0.00009596514,0.000099504134,0.00021314916,0.00008343595,0.00011620011,0.00019747797,0.00015979486,0.00033662785,0.0002670252],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042790078,0.000031104835,0.00004443921,0.00003947394,0.000002812247,0.000026231217,0.0000061184946,0.00013813742,0.99680066,0.00008647551,0.000027473463,0.0027541856],"study_design_scores_gemma":[0.000018347104,0.00050244725,0.0006565728,0.0000028217698,0.000009825209,0.0001269834,0.0000036158367,0.00081876555,0.9958853,0.000027190046,0.0019439348,0.00000410728],"about_ca_topic_score_codex":0.0002110319,"about_ca_topic_score_gemma":0.00045465253,"teacher_disagreement_score":0.001109081,"about_ca_system_score_codex":0.00023694974,"about_ca_system_score_gemma":0.00012923009,"threshold_uncertainty_score":0.00371027},"labels":[],"label_agreement":null},{"id":"W2200809230","doi":"10.3892/ol.2015.4069","title":"Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma","year":2015,"lang":"en","type":"article","venue":"Oncology Letters","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; Canadian Institutes of Health Research; National Health and Medical Research Council; Hunter Cancer Research Alliance","keywords":"Ipilimumab; Medicine; Metastatic melanoma; Melanoma; Toxicity; Molecular medicine; Oncology; Oncogene; Cancer; Internal medicine; Cell cycle; Cancer research; Immunotherapy","score_opus":0.10931781929838652,"score_gpt":0.4357684455983323,"score_spread":0.32645062629994576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2200809230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945913,0.0036359872,0.00017591735,0.00016430767,0.0000056737117,0.000032604497,0.00032983057,0.000005173033,0.0010591281],"genre_scores_gemma":[0.99863666,0.00071615115,0.000118582415,0.000054446533,0.000012957098,0.000013362499,0.00036785795,0.0000014591241,0.000078399426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99909997,0.00040188723,0.000118894204,0.00008346573,0.00022850938,0.000067301866],"domain_scores_gemma":[0.9983929,0.00032907628,0.00091636844,0.000067468536,0.00016485597,0.00012934166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001769075,0.00011437458,0.00028806378,0.00040257233,0.00028957357,0.0007304275,0.00022469065,0.00018908823,0.00032934293],"category_scores_gemma":[0.002893491,0.00009441489,0.00025939554,0.000564207,0.00039994693,0.0003142336,0.00022836488,0.00027934034,0.000075743956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00205447,0.00014126516,0.96889883,0.00020025621,0.0002084308,0.00068331725,0.00025481303,0.0011992637,0.0024238806,0.00013046178,0.00052181754,0.023283131],"study_design_scores_gemma":[0.00006363159,0.001170051,0.99407226,0.000032005588,0.00007464458,0.0014597484,0.00019283881,0.0006148502,0.00072979275,0.000075404,0.0015034848,0.000011402827],"about_ca_topic_score_codex":0.0029581883,"about_ca_topic_score_gemma":0.0075612194,"teacher_disagreement_score":0.0029581883,"about_ca_system_score_codex":0.0019675489,"about_ca_system_score_gemma":0.0008513178,"threshold_uncertainty_score":0.01427561},"labels":[],"label_agreement":null},{"id":"W2202293179","doi":"10.1016/j.exphem.2015.06.026","title":"From stem cells to T cells, in vitro applications and in vivo implications","year":2015,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biology; Progenitor cell; Stem cell; Haematopoiesis; Cell biology; CD34; Stromal cell; Lineage markers; Bone marrow; Immunology; In vitro; Molecular biology; Cancer research; Genetics","score_opus":0.04236395684393758,"score_gpt":0.3629172667746409,"score_spread":0.32055330993070336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202293179","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3412782,0.5432001,0.04186798,0.02397017,0.001853136,0.00023169779,0.00051082595,0.00034016615,0.046747755],"genre_scores_gemma":[0.79958814,0.16417043,0.012332263,0.003995472,0.0017731101,0.00013454325,0.00038185628,0.00009331785,0.017530864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995585,0.00022308277,0.00003130622,0.000050269384,0.00007122481,0.00006558709],"domain_scores_gemma":[0.99949956,0.0002698787,0.00004577757,0.000046844252,0.00006540377,0.00007248678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001379988,0.0005870921,0.00037944206,0.0009738531,0.00042870286,0.0020859693,0.0006759633,0.0013118972,0.005954805],"category_scores_gemma":[0.0008679558,0.00034675954,0.00050021545,0.0004906901,0.00137777,0.0011040253,0.0004619679,0.0029615895,0.0008846338],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027327754,0.0013537796,0.002110199,0.0025141893,0.000089759655,0.0017939018,0.0011079373,0.0025359232,0.74125606,0.043657593,0.0052662613,0.19558156],"study_design_scores_gemma":[0.00022533014,0.005332221,0.00379797,0.00046877452,0.00021335494,0.004462605,0.0015095645,0.0016449306,0.81298923,0.034215108,0.13510545,0.00003559071],"about_ca_topic_score_codex":0.0005184225,"about_ca_topic_score_gemma":0.0008990437,"teacher_disagreement_score":0.005954805,"about_ca_system_score_codex":0.0005298763,"about_ca_system_score_gemma":0.0005909072,"threshold_uncertainty_score":0.019920826},"labels":[],"label_agreement":null},{"id":"W2208384071","doi":"10.1158/1078-0432.ccr-15-2361","title":"Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; University of Chicago; Connaught Fund; Universitätsspital Zürich; Universität Zürich; Berlin Institute of Health; University of Toronto","keywords":"T-cell receptor; Biology; Cancer research; Cancer; Antigen; Targeted therapy; Adoptive cell transfer; Cancer cell; Avidity; T cell; Molecular biology; Immunology; Immune system; Genetics","score_opus":0.22862007228663447,"score_gpt":0.49842278518530214,"score_spread":0.26980271289866764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208384071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993403,0.0011551881,0.0046170237,0.00006853176,0.000022096248,0.00005524924,0.000049330556,0.00010710824,0.0005225141],"genre_scores_gemma":[0.99609405,0.0006711353,0.0023087931,0.000028116785,0.000016861408,0.00003079863,0.00008185163,0.000013837381,0.0007545166],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998975,0.000010582469,0.000008472396,0.000027898433,0.00002598568,0.000029548424],"domain_scores_gemma":[0.9999137,0.000018627179,0.000034765555,0.000009848859,0.000006758398,0.000016174856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012676169,0.00043703063,0.0002838644,0.0002227179,0.00009808397,0.00020478282,0.00019752902,0.00037460364,0.0007195779],"category_scores_gemma":[0.000108814704,0.00008072917,0.00028002614,0.0001317953,0.00027924046,0.00017281709,0.00013315552,0.0004995396,0.0002447685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009190277,0.000072485214,0.00021167423,0.00005312902,0.000006586333,0.00007859557,0.000010407986,0.00020108379,0.9965932,0.000085912834,0.000028654315,0.0025663087],"study_design_scores_gemma":[0.00007252668,0.001405416,0.0009644482,0.000007724383,0.000042747222,0.00074480666,0.000008988308,0.0012110309,0.9943504,0.00004880736,0.0011401041,0.0000030593253],"about_ca_topic_score_codex":0.00015745757,"about_ca_topic_score_gemma":0.00015728996,"teacher_disagreement_score":0.0007195779,"about_ca_system_score_codex":0.00017244967,"about_ca_system_score_gemma":0.00017796458,"threshold_uncertainty_score":0.0024072528},"labels":[],"label_agreement":null},{"id":"W2211214375","doi":"10.1200/jco.2014.32.18_suppl.lba9000","title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Ipilimumab; Gastroenterology; Cancer; Immunotherapy","score_opus":0.06520723822404939,"score_gpt":0.4496459923851462,"score_spread":0.3844387541610968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211214375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974486,0.0014269174,0.000105493506,0.000041182317,0.0000072456965,0.00013383407,0.0005586093,0.000009998947,0.0002681266],"genre_scores_gemma":[0.99834335,0.00040799132,0.00016607544,0.00006369222,0.000022754864,0.00010334827,0.0007111638,0.0000032721146,0.00017839551],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994393,0.00021331312,0.000057532812,0.00012902202,0.00009880374,0.000062002335],"domain_scores_gemma":[0.9995408,0.000104856095,0.00019938765,0.000032617318,0.00002541063,0.00009702155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018499574,0.0005982025,0.0011327966,0.0004647665,0.00029600423,0.00065100327,0.00038546638,0.0005446995,0.0009835908],"category_scores_gemma":[0.00096900703,0.00051345484,0.0015880255,0.00067515566,0.0003826649,0.0003508324,0.00045465014,0.0006164124,0.00029425186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26115793,0.003527038,0.6184239,0.0011102997,0.008218682,0.0005779627,0.00037504095,0.003039217,0.022374645,0.00012264132,0.002078931,0.078993656],"study_design_scores_gemma":[0.0289565,0.09825937,0.8532086,0.00009496186,0.007994635,0.0012355156,0.00014065352,0.001988439,0.003558193,0.00015858562,0.0043520452,0.000052424766],"about_ca_topic_score_codex":0.0010928208,"about_ca_topic_score_gemma":0.0021490075,"teacher_disagreement_score":0.0018499574,"about_ca_system_score_codex":0.001074811,"about_ca_system_score_gemma":0.0007612435,"threshold_uncertainty_score":0.009783685},"labels":[],"label_agreement":null},{"id":"W2221239533","doi":"10.1186/s40425-015-0099-4","title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Terry Fox Foundation; Government of Ontario","keywords":"Chimeric antigen receptor; Antigen; Cytotoxic T cell; Degranulation; Ankyrin repeat; Tumor antigen; Antibody; Biology; Cancer research; Immunology; Cell biology; Receptor; Immunotherapy; Immune system; In vitro; Gene; Genetics","score_opus":0.04065385021059447,"score_gpt":0.38164280807278034,"score_spread":0.34098895786218586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2221239533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9311397,0.00177644,0.063999586,0.00013383535,0.000060207243,0.00016223463,0.00022485373,0.00037172745,0.002131428],"genre_scores_gemma":[0.95803905,0.0008000017,0.03706901,0.00008108515,0.000011846339,0.00014252891,0.0003923571,0.00007139775,0.0033927064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997662,0.00006126176,0.000020442767,0.00003847595,0.00007676759,0.000036800913],"domain_scores_gemma":[0.9998487,0.000036580317,0.00006276662,0.000016915477,0.000017493592,0.00001741494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024482055,0.00038634913,0.00018111597,0.00019237236,0.00010494081,0.0002725849,0.000320998,0.00037296113,0.0010857013],"category_scores_gemma":[0.00026920976,0.00015682362,0.00022286618,0.0001379395,0.00020059406,0.0002445371,0.0002480872,0.00050378963,0.0005573948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000778341,0.000025020507,0.00013012266,0.00006205747,0.000009634147,0.00011658804,0.000017035107,0.000928398,0.9951082,0.0005020392,0.000083162144,0.002939865],"study_design_scores_gemma":[0.000033919965,0.00033046718,0.0005056878,0.000008248386,0.000018945966,0.0005994943,0.0000113765,0.0023496323,0.9891767,0.0001441932,0.00681279,0.00000850655],"about_ca_topic_score_codex":0.00009922423,"about_ca_topic_score_gemma":0.00015330694,"teacher_disagreement_score":0.0010857013,"about_ca_system_score_codex":0.00032965798,"about_ca_system_score_gemma":0.00014387535,"threshold_uncertainty_score":0.003632009},"labels":[],"label_agreement":null},{"id":"W2230036583","doi":"10.4049/jimmunol.194.supp.143.6","title":"Retroviral transfer for a chimeric antigen receptor to generate regulatory T-like cells for the suppression of undesired immune responses. (VAC7P.1036)","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"FOXP3; Adoptive cell transfer; Immune system; Immunology; Chimeric antigen receptor; Biology; Antigen; Autoimmunity; Antigen-presenting cell; Cell biology; T cell","score_opus":0.05798689285139266,"score_gpt":0.3217708482802225,"score_spread":0.2637839554288298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230036583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9379632,0.0029868446,0.048979085,0.0004961467,0.00047559774,0.0007177788,0.0022465955,0.0010219123,0.005112896],"genre_scores_gemma":[0.9551659,0.00097396475,0.030302746,0.00025701377,0.000071016555,0.0004325631,0.002695194,0.00020991203,0.00989168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997086,0.00005041358,0.000030688567,0.000059604183,0.00008648571,0.00006411687],"domain_scores_gemma":[0.9998578,0.000027955759,0.000040441726,0.000023354836,0.000020152702,0.000030357962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003713642,0.0005260111,0.00027503906,0.0003574523,0.00016115978,0.0004013674,0.00044066258,0.00077759865,0.0024251312],"category_scores_gemma":[0.00014923597,0.00022000687,0.0004147164,0.00021856338,0.00028251443,0.00016934809,0.0002277632,0.0011057346,0.0015887552],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054733457,0.000052076775,0.00005360949,0.000043946573,0.0000066969214,0.00010477156,0.000015632066,0.00013452217,0.99739766,0.0003579212,0.00012593601,0.0016525048],"study_design_scores_gemma":[0.00014290592,0.000837569,0.00090954505,0.000017934975,0.00004040399,0.0013020595,0.000017799546,0.0037121843,0.9775712,0.00010506626,0.015331772,0.000011538055],"about_ca_topic_score_codex":0.00031774983,"about_ca_topic_score_gemma":0.0002502569,"teacher_disagreement_score":0.0024251312,"about_ca_system_score_codex":0.00030373604,"about_ca_system_score_gemma":0.0002148527,"threshold_uncertainty_score":0.008112907},"labels":[],"label_agreement":null},{"id":"W2232969484","doi":"10.1182/blood.v124.21.1624.1624","title":"Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Diffuse large B-cell lymphoma; Tissue microarray; Immunohistochemistry; Concordance; Lymphoma; Pathology; Gene expression profiling; Biology; Germinal center; Cancer research; Medicine; Gene expression; Gene; B cell; Bioinformatics; Immunology; Antibody; Genetics","score_opus":0.013016549360451162,"score_gpt":0.2711677360484875,"score_spread":0.2581511866880363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232969484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791497,0.00055943814,0.0008431136,0.000023626384,0.000004367046,0.000014431079,0.00016947184,0.000007954633,0.00046267593],"genre_scores_gemma":[0.9988111,0.00013483247,0.0006313811,0.000016643848,0.0000035772098,0.000013824722,0.00023386024,0.0000033211686,0.00015147569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99965525,0.00010037026,0.00003360732,0.00008077692,0.00007420628,0.00005580982],"domain_scores_gemma":[0.999616,0.00015380705,0.0000941099,0.00003719047,0.00006009326,0.000038777893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000560227,0.00011867611,0.00017258635,0.000730692,0.00016770886,0.00037817127,0.000119111806,0.00020819136,0.0007393414],"category_scores_gemma":[0.0006061375,0.000113504204,0.00008745244,0.00047055492,0.00039642965,0.0001609646,0.00018597681,0.00022740777,0.00020419322],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014479982,0.000080398946,0.6276729,0.000088213346,0.0000954875,0.00041566955,0.00020458936,0.00029805998,0.35852596,0.00011212144,0.00018909464,0.010869448],"study_design_scores_gemma":[0.00004727046,0.00056171766,0.92381066,0.000015203507,0.000096687356,0.0016531212,0.00050543627,0.0021766268,0.069444604,0.00015140243,0.0015263209,0.000010846386],"about_ca_topic_score_codex":0.00042019552,"about_ca_topic_score_gemma":0.0011652296,"teacher_disagreement_score":0.0007393414,"about_ca_system_score_codex":0.0001918869,"about_ca_system_score_gemma":0.00010399761,"threshold_uncertainty_score":0.002962768},"labels":[],"label_agreement":null},{"id":"W2264439609","doi":"10.4049/jimmunol.188.supp.111.45","title":"Cellular and molecular profiling of CD8 T cell differentiation with respect to positive and negative selection in vitro reveals a role for Notch signaling (111.45)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Cell biology; Biology; Notch signaling pathway; CD8; Stromal cell; Progenitor cell; Cellular differentiation; Cytotoxic T cell; Haematopoiesis; T cell; Negative selection; Stem cell; Immunology; Signal transduction; Cancer research; Antigen; Immune system; In vitro; Genetics","score_opus":0.01238562688592718,"score_gpt":0.27571373303465935,"score_spread":0.26332810614873214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264439609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987988,0.00079750264,0.0066659455,0.000038758255,0.000014231685,0.00003684925,0.0008379144,0.00007013156,0.0035505847],"genre_scores_gemma":[0.98784643,0.00062142016,0.0061302413,0.00003651063,0.000008621182,0.00006779436,0.0016840922,0.000038640996,0.003566281],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998785,0.000024043627,0.000013750536,0.00002151989,0.00003054218,0.00003167575],"domain_scores_gemma":[0.9999107,0.000032012562,0.000012808181,0.000011240552,0.000011209123,0.000022078402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104619576,0.00020429079,0.000110357374,0.00022945966,0.00012774784,0.00026433964,0.00010458516,0.0001368076,0.0010857095],"category_scores_gemma":[0.00007157705,0.00008690792,0.00012575173,0.00020329608,0.00009731862,0.00009664489,0.00012295248,0.00034706527,0.00042316449],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018346273,0.000004918398,0.0000911891,0.000004527248,6.3655875e-7,0.000007357376,0.000005549832,0.0000113553615,0.9995652,0.000023982742,0.0000044753237,0.00026255887],"study_design_scores_gemma":[0.0000030049603,0.0000995841,0.0038522908,0.0000027056522,0.000008080274,0.00008597417,0.00001792706,0.0005915809,0.9945352,0.000027250935,0.0007748043,0.0000016865738],"about_ca_topic_score_codex":0.00033078884,"about_ca_topic_score_gemma":0.00064061914,"teacher_disagreement_score":0.0010857095,"about_ca_system_score_codex":0.00011049216,"about_ca_system_score_gemma":0.00006844786,"threshold_uncertainty_score":0.003632009},"labels":[],"label_agreement":null},{"id":"W2281961904","doi":"10.1188/16.onf.131-132","title":"Innovation, Creation, Inspiration","year":2016,"lang":"en","type":"editorial","venue":"Oncology nursing forum","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine","score_opus":0.02492412686004447,"score_gpt":0.4035082028614964,"score_spread":0.37858407600145194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281961904","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006811708,0.06151617,0.00044816517,0.06454636,0.8618316,0.00002193341,0.000030525207,0.00009033518,0.011446772],"genre_scores_gemma":[0.003673736,0.07385192,0.00045104325,0.054501243,0.83138883,0.00007639867,0.000041555304,0.00012914186,0.035886172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99134105,0.0023132872,0.00080874434,0.0009413504,0.0041346364,0.00046097214],"domain_scores_gemma":[0.9780789,0.014357493,0.00095123984,0.0010821023,0.0037704555,0.001759788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065896693,0.0027285407,0.0020775334,0.0031427566,0.0042118505,0.018048463,0.0025591662,0.013889665,0.016984068],"category_scores_gemma":[0.031857118,0.0008881416,0.0015158837,0.0016919039,0.011270616,0.012823339,0.004238374,0.019800076,0.010688447],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020546444,0.000015825723,0.000035537043,0.00090012583,0.000013102368,0.00011340295,0.0002921304,0.000048187932,0.000081352315,0.012214253,0.960502,0.025763601],"study_design_scores_gemma":[0.000009143618,0.000011024144,0.00004834096,0.00058941514,0.000006655315,0.00010939225,0.00015744103,0.000029965473,0.000043763263,0.004639807,0.9943481,0.0000069771645],"about_ca_topic_score_codex":0.0013799059,"about_ca_topic_score_gemma":0.0027783357,"teacher_disagreement_score":0.018048463,"about_ca_system_score_codex":0.0042947116,"about_ca_system_score_gemma":0.0057472973,"threshold_uncertainty_score":0.056817412},"labels":[],"label_agreement":null},{"id":"W2289192290","doi":"10.1096/fasebj.22.2_supplement.516","title":"Interleukin‐12 immunotherapy in a murine model of leukemia","year":2008,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"CTL*; Cytotoxic T cell; CD8; Immunotherapy; Immunology; Cancer research; Systemic administration; T cell; Population; Medicine; Interleukin 2; Antigen; In vivo; Biology; Immune system; In vitro","score_opus":0.05248198627890809,"score_gpt":0.3080619103356193,"score_spread":0.2555799240567112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2289192290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97867364,0.0035054663,0.010358459,0.0009117999,0.00032942824,0.00064696826,0.0012062798,0.0007760529,0.0035919482],"genre_scores_gemma":[0.9725363,0.0036245855,0.013388081,0.00030638577,0.000105508916,0.0007693049,0.001178984,0.000115192546,0.007975682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992563,0.00023086037,0.00008097055,0.000113422495,0.0001421747,0.00017614712],"domain_scores_gemma":[0.9996141,0.000077067576,0.000112210866,0.0000746469,0.000026934074,0.00009498152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073106226,0.0015950995,0.00085833896,0.0013693647,0.0004013425,0.0006530611,0.00061330997,0.0011962862,0.001553724],"category_scores_gemma":[0.0002619257,0.00042941392,0.0005599497,0.00045569343,0.00079822016,0.0006516333,0.0004905641,0.0029181922,0.00064728665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016252587,0.0017314553,0.00023319694,0.00018477999,0.000020214193,0.00027996098,0.000106568,0.0011654645,0.9879373,0.0011725997,0.00030192753,0.005241188],"study_design_scores_gemma":[0.0008713772,0.013880406,0.001202855,0.00008149743,0.000088518966,0.0010780388,0.000060160903,0.0053962995,0.9656101,0.0005395888,0.011157793,0.000033390323],"about_ca_topic_score_codex":0.000859604,"about_ca_topic_score_gemma":0.0009562908,"teacher_disagreement_score":0.0015950995,"about_ca_system_score_codex":0.00088123034,"about_ca_system_score_gemma":0.00060457486,"threshold_uncertainty_score":0.0063937902},"labels":[],"label_agreement":null},{"id":"W2300532045","doi":"10.4049/jimmunol.190.supp.177.7","title":"Novel immunotherapy for AML using DNT cells (P4348)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Ontario Power Generation","funders":"","keywords":"Myeloid leukemia; Leukemia; Bone marrow; Cancer research; CD8; CD33; CD34; Immunology; Ex vivo; Immunotherapy; In vivo; Myeloid; Stem cell; Medicine; Biology; Immune system; Cell biology","score_opus":0.048363747561261855,"score_gpt":0.3332003433325073,"score_spread":0.2848365957712454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300532045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817654,0.00487924,0.007200195,0.00020000829,0.00009760611,0.00022273035,0.0003775994,0.00015528352,0.0051019676],"genre_scores_gemma":[0.9884828,0.0020882038,0.00538665,0.00009651517,0.000038137467,0.00012581746,0.00061328826,0.000009824316,0.0031587097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999423,0.000010663342,0.0000040919767,0.000013005653,0.000018033621,0.000012011756],"domain_scores_gemma":[0.9999808,0.0000027581266,0.0000048776565,0.0000029841635,0.000002059714,0.0000065153026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000803307,0.0002697794,0.00020474025,0.00019663585,0.00007788165,0.00022290592,0.00013878717,0.00025961056,0.0010180484],"category_scores_gemma":[0.00005394494,0.00007359646,0.00015963755,0.00012867062,0.00010645526,0.000118034506,0.00020426176,0.00034280666,0.00033546635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022548405,0.00027240545,0.0006149621,0.00011143231,0.0000116175715,0.00013810143,0.000022845648,0.0008521739,0.9689196,0.0006278882,0.00037671137,0.027826848],"study_design_scores_gemma":[0.00041602613,0.006514295,0.00827254,0.000044340668,0.00007504367,0.0024576979,0.000027818453,0.0055705737,0.92439204,0.0005821288,0.051634416,0.000013110139],"about_ca_topic_score_codex":0.0001625269,"about_ca_topic_score_gemma":0.00025764483,"teacher_disagreement_score":0.0010180484,"about_ca_system_score_codex":0.000116487776,"about_ca_system_score_gemma":0.00013380453,"threshold_uncertainty_score":0.0034056902},"labels":[],"label_agreement":null},{"id":"W2301752124","doi":"10.1093/annonc/mdu344.44","title":"A Phase Ii Study (Nct01883323) Evaluating the Infusion of Autologous Tumor-Infiltrating Lymphocytes (Til) and Low-Dose Interleukin-2 (Il-2) Therapy Following Non-Myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients with Metastatic Melanoma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Cyclophosphamide; Oncology; Chemotherapy; Internal medicine","score_opus":0.06449802489123993,"score_gpt":0.40676060335234526,"score_spread":0.3422625784611053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301752124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98792136,0.0012052486,0.00086630386,0.0006539744,0.00028996688,0.004798827,0.0016016263,0.00011761989,0.0025451551],"genre_scores_gemma":[0.97933596,0.0014744558,0.002753493,0.0016022933,0.00044409512,0.0074977586,0.003152503,0.000049050002,0.0036904397],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964404,0.00018551899,0.000016823155,0.000059908514,0.000021806833,0.00007195154],"domain_scores_gemma":[0.9993431,0.00014175272,0.00010485325,0.000062035,0.000031090036,0.00031720308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013167195,0.0013974999,0.0021282467,0.0003801463,0.0004380245,0.00092967233,0.0007958122,0.0017337996,0.005810774],"category_scores_gemma":[0.0008645403,0.00058215327,0.0012604005,0.00047765533,0.0010930232,0.0007624875,0.0003360555,0.003981183,0.001386839],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87107235,0.050800186,0.0034995228,0.00051765103,0.0006537635,0.00016357013,0.00020186354,0.0011031907,0.023256304,0.0002601424,0.0025005678,0.045970865],"study_design_scores_gemma":[0.7126205,0.27976567,0.0039284406,0.000020734717,0.0002308945,0.00010753363,0.00003572818,0.00042425375,0.0011834821,0.00012539899,0.0015444417,0.000012989815],"about_ca_topic_score_codex":0.0008697461,"about_ca_topic_score_gemma":0.0022856514,"teacher_disagreement_score":0.005810774,"about_ca_system_score_codex":0.0006983268,"about_ca_system_score_gemma":0.0019282583,"threshold_uncertainty_score":0.019438982},"labels":[],"label_agreement":null},{"id":"W2303852857","doi":"10.1172/jci82771","title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":476,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of British Columbia; Canadian Blood Services","keywords":"Chimeric antigen receptor; Immunology; Antigen; Immunotherapy; Human leukocyte antigen; Transplantation; Immune system; Cell therapy; Adoptive cell transfer; Major histocompatibility complex; Biology; Graft-versus-host disease; T cell; Medicine; Stem cell; Cell biology","score_opus":0.10537970307624715,"score_gpt":0.3739260898684617,"score_spread":0.26854638679221454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303852857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9308006,0.0071739526,0.0548041,0.00038078672,0.00029049936,0.00040879947,0.0002823237,0.0007336018,0.0051252767],"genre_scores_gemma":[0.9795344,0.0018945996,0.014840607,0.00022813698,0.000066808556,0.00014457921,0.00035418858,0.00004087841,0.0028959422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997614,0.000063803374,0.000015824615,0.00005079233,0.000059107377,0.000049085924],"domain_scores_gemma":[0.9999409,0.000013574152,0.000013430102,0.000011384976,0.00000936993,0.000011337086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003262628,0.00038324317,0.0003330088,0.00028371965,0.00012214652,0.0003561421,0.00022817533,0.00049189274,0.0013501768],"category_scores_gemma":[0.000153015,0.000092959766,0.0003394854,0.00015870671,0.00025897694,0.00021669154,0.00021101942,0.00092796615,0.00038972386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016618,0.00018350576,0.000336318,0.00007476154,0.00001384096,0.00011081023,0.000034522618,0.00043221706,0.9860745,0.0008106382,0.00019423002,0.011568443],"study_design_scores_gemma":[0.00018520876,0.0022168711,0.0012342817,0.000021194463,0.00007446376,0.0011832431,0.00004146446,0.0046593435,0.968056,0.00033149196,0.021981733,0.000014732194],"about_ca_topic_score_codex":0.00019628425,"about_ca_topic_score_gemma":0.00027529066,"teacher_disagreement_score":0.0013501768,"about_ca_system_score_codex":0.00013799027,"about_ca_system_score_gemma":0.00026189125,"threshold_uncertainty_score":0.004516721},"labels":[],"label_agreement":null},{"id":"W2304098313","doi":"10.3324/haematol.2015.132712","title":"Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Adoptive cell transfer; Immunology; Receptor; Biology; Cell therapy; T cell; Chimeric antigen receptor; Antigen; Graft-versus-host disease; Endogeny; Cancer research; Receptor expression; Immune system; Stem cell; Cell biology; Endocrinology","score_opus":0.03489163423556973,"score_gpt":0.29882062272251286,"score_spread":0.26392898848694313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304098313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992851,0.0018193295,0.0036435043,0.00005428081,0.00003848322,0.000046847992,0.00006813593,0.00006886117,0.0014094982],"genre_scores_gemma":[0.99672,0.00088338007,0.0011973963,0.000027198279,0.000012786783,0.000021273892,0.00009270695,0.000010706686,0.0010344229],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998323,0.000030493504,0.000012632211,0.000026272306,0.0000470297,0.000051196475],"domain_scores_gemma":[0.9999279,0.0000136392455,0.00002200097,0.000010765285,0.000007535504,0.000018156608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011522703,0.00045492302,0.00033428243,0.0002198869,0.0000731398,0.000259743,0.00017736555,0.00026799386,0.0008446134],"category_scores_gemma":[0.0000930371,0.000078866906,0.00019835055,0.00009483003,0.00013660738,0.0001249958,0.00014083514,0.0006199958,0.00025390353],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006975485,0.000095226824,0.000080397214,0.00002848841,0.0000049172204,0.000030666873,0.000009192992,0.00011944324,0.9976775,0.00008050249,0.000023296576,0.0017806303],"study_design_scores_gemma":[0.00003679041,0.0018198945,0.001373771,0.0000057535563,0.00005165825,0.00042770096,0.000009230009,0.0010440351,0.99275607,0.00004396287,0.0024276336,0.0000034863085],"about_ca_topic_score_codex":0.00020106703,"about_ca_topic_score_gemma":0.00024899808,"teacher_disagreement_score":0.0008446134,"about_ca_system_score_codex":0.00013115817,"about_ca_system_score_gemma":0.00014821716,"threshold_uncertainty_score":0.0028255582},"labels":[],"label_agreement":null},{"id":"W2313438481","doi":"10.2741/200","title":"Thymus-bound: the many features of T cell progenitors","year":2011,"lang":"en","type":"review","venue":"Frontiers in Bioscience-Scholar","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Lymphopoiesis; Progenitor cell; Haematopoiesis; Bone marrow; Progenitor; Lineage (genetic); Biology; Stem cell; Cell biology; Immunology; Transplantation; T cell; Cancer research; Medicine; Immune system; Genetics; Internal medicine; Gene","score_opus":0.046047318286260415,"score_gpt":0.3354656723612491,"score_spread":0.28941835407498867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313438481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000455103,0.99359256,0.0010306556,0.00038895351,0.00027495174,0.0000069546704,0.000025133979,0.000021854737,0.004203794],"genre_scores_gemma":[0.0033037302,0.99140936,0.00093236694,0.00031952484,0.0002604831,0.000014578434,0.000044432785,0.000004965728,0.0037105356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998505,0.000021005462,0.000014595032,0.000038772345,0.000060739374,0.000014301249],"domain_scores_gemma":[0.9998852,0.000046576235,0.000016235608,0.0000055530545,0.000029186858,0.000017250557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002746489,0.0005063615,0.0010131829,0.0011454829,0.00027604078,0.0010504159,0.00055162306,0.0009230746,0.0018502224],"category_scores_gemma":[0.00026657138,0.00018062825,0.00022279669,0.0010759132,0.0007297498,0.0010096082,0.00044433188,0.0014302124,0.0026675037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006526265,0.00003378679,0.00020818683,0.006714831,0.000019949153,0.00047263977,0.000120498145,0.00026578584,0.020340502,0.011022261,0.011949471,0.94878674],"study_design_scores_gemma":[0.0000068455283,0.000060593244,0.000661782,0.00068733015,0.000021386577,0.0029558486,0.00007611527,0.000046537072,0.0044562635,0.0024733883,0.9885415,0.00001230151],"about_ca_topic_score_codex":0.000631917,"about_ca_topic_score_gemma":0.00078543765,"teacher_disagreement_score":0.0018502224,"about_ca_system_score_codex":0.00051576196,"about_ca_system_score_gemma":0.00060788036,"threshold_uncertainty_score":0.0061895847},"labels":[],"label_agreement":null},{"id":"W2314878272","doi":"10.1042/bst20150254","title":"Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells","year":2016,"lang":"en","type":"review","venue":"Biochemical Society Transactions","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Wellcome Trust","keywords":"Extravasation; Homing (biology); CD8; Adoptive cell transfer; Cytotoxic T cell; Medicine; Cancer research; Angiogenesis; T cell; Immunology; Pericyte; Infiltration (HVAC); Blood vessel; Pathology; Antigen; Biology; Immune system; Endothelial stem cell; Internal medicine","score_opus":0.06953278686535672,"score_gpt":0.372831998871406,"score_spread":0.30329921200604926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314878272","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8330331,0.08784115,0.060171515,0.0045179357,0.00063315814,0.0012645874,0.00041395635,0.0012593396,0.010865296],"genre_scores_gemma":[0.9650818,0.017546304,0.012813,0.0007081792,0.00014520732,0.00049859093,0.00021856862,0.000041743322,0.0029465766],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996927,0.00009702445,0.000018767121,0.000050420946,0.00005108316,0.00009007057],"domain_scores_gemma":[0.9998535,0.000050299088,0.000030964147,0.000020846395,0.000020930318,0.000023388437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009066223,0.0005399035,0.00072580593,0.00031954917,0.00016217286,0.0009211847,0.0006865751,0.001132639,0.0013277764],"category_scores_gemma":[0.00032756402,0.00025031777,0.00048710086,0.00025401032,0.0005641177,0.0011333314,0.00037103723,0.0022139794,0.00041189248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019263232,0.0018414432,0.0016086755,0.0019644646,0.00009692792,0.0005094012,0.00026632627,0.0033845128,0.86173326,0.006273509,0.0016832516,0.11871184],"study_design_scores_gemma":[0.0009479499,0.016413584,0.0049046366,0.00029757275,0.00039944655,0.0021407695,0.00025888628,0.0080964025,0.9187412,0.0023557078,0.04538739,0.0000565803],"about_ca_topic_score_codex":0.0002605839,"about_ca_topic_score_gemma":0.000289959,"teacher_disagreement_score":0.0013277764,"about_ca_system_score_codex":0.00040681753,"about_ca_system_score_gemma":0.00031952662,"threshold_uncertainty_score":0.004794717},"labels":[],"label_agreement":null},{"id":"W2315367769","doi":"10.1042/bst20150251","title":"SHP-1: the next checkpoint target for cancer immunotherapy?","year":2016,"lang":"en","type":"review","venue":"Biochemical Society Transactions","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Wellcome Trust","keywords":"Protein tyrosine phosphatase; Immunotherapy; Cancer immunotherapy; Cytotoxic T cell; Cancer research; Immune system; Regulator; Antigen; Proto-oncogene tyrosine-protein kinase Src; Biology; Immune checkpoint; T cell; Fusion protein; Cell biology; Phosphorylation; Immunology; Biochemistry; In vitro; Recombinant DNA","score_opus":0.0845359419127644,"score_gpt":0.38984653570998384,"score_spread":0.3053105937972195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315367769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001940163,0.99790037,0.00017528397,0.00048646596,0.00021300314,0.0000047129083,0.000018634724,0.000010287853,0.0009971668],"genre_scores_gemma":[0.0011056793,0.9968246,0.00022129779,0.00033574106,0.0001569486,0.000007640939,0.00003936222,0.000002095219,0.0013066398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999925,0.000010970631,0.000007438322,0.000013070133,0.00003179808,0.000011717847],"domain_scores_gemma":[0.9999291,0.000021504913,0.000012028918,0.0000025041993,0.000021604981,0.000013314329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002892182,0.00061093055,0.0009958602,0.001254469,0.00020129204,0.0007278988,0.0006277927,0.00095718086,0.0030775808],"category_scores_gemma":[0.00024602283,0.00019675739,0.00030264602,0.0011180631,0.0003330428,0.0012245213,0.00045950623,0.0017823627,0.002658067],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000889718,0.00007782871,0.00014308556,0.007967592,0.00006122837,0.00018585539,0.000045361852,0.00034009924,0.004884681,0.003953774,0.033984654,0.9482668],"study_design_scores_gemma":[0.000019103203,0.00008603246,0.00045370954,0.0012405326,0.00004861687,0.0008775893,0.000048873804,0.00009084975,0.0008524856,0.002084813,0.9941849,0.000012672324],"about_ca_topic_score_codex":0.0005149011,"about_ca_topic_score_gemma":0.001337117,"teacher_disagreement_score":0.0030775808,"about_ca_system_score_codex":0.00046661694,"about_ca_system_score_gemma":0.00055091217,"threshold_uncertainty_score":0.01029551},"labels":[],"label_agreement":null},{"id":"W2323183075","doi":"10.1038/srep23821","title":"CD4+ and CD8+ TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Japan Society for the Promotion of Science; Canadian Institutes of Health Research; National Cancer Institute; Universiteit Leiden; National Institutes of Health; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation","keywords":"Avidity; T-cell receptor; Cytotoxic T cell; CD8; Biology; Cell biology; Immunology; T cell; Antigen; Immune system; Genetics; In vitro","score_opus":0.028772189044475507,"score_gpt":0.29616678453415485,"score_spread":0.26739459548967937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323183075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954665,0.00040500783,0.0027138854,0.000027265009,0.0000053524236,0.000010524778,0.00003936445,0.00005482136,0.0012773449],"genre_scores_gemma":[0.9976382,0.000146431,0.0013910707,0.00003714667,0.000007152349,0.000012697995,0.0001229353,0.000018574692,0.00062582747],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997317,0.00003898544,0.000020775824,0.000047275433,0.000059015278,0.00010231818],"domain_scores_gemma":[0.9997979,0.000046052817,0.0000339578,0.000042432395,0.000020360665,0.00005931072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023749372,0.00032475617,0.00024046305,0.00020809726,0.00013808202,0.00049795385,0.00021080184,0.00032431618,0.0015015568],"category_scores_gemma":[0.00023013669,0.00015011155,0.00019494488,0.00016361612,0.00023396265,0.00029312007,0.00042969995,0.0006643232,0.00056920596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085668384,0.000017747423,0.000932352,0.000013734092,0.0000048372435,0.00003209187,0.000023671591,0.0000664777,0.9957574,0.00009586995,0.000016240865,0.0029537717],"study_design_scores_gemma":[0.00007831114,0.0014023185,0.032531023,0.000014146499,0.000074664385,0.003201133,0.00023206386,0.0029227023,0.9541666,0.00072064553,0.0046404875,0.00001593891],"about_ca_topic_score_codex":0.00009870199,"about_ca_topic_score_gemma":0.00017282367,"teacher_disagreement_score":0.0015015568,"about_ca_system_score_codex":0.00013540595,"about_ca_system_score_gemma":0.000098197954,"threshold_uncertainty_score":0.005023241},"labels":[],"label_agreement":null},{"id":"W2327586678","doi":"10.1158/1538-7445.am2015-4701","title":"Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Computer Research Institute of Montréal","funders":"","keywords":"Medicine; CD28; Immunology; Antigen; Immunotherapy; Immune system; Multiple myeloma; Oncology; Cancer; Internal medicine; Leukapheresis; T cell; Stem cell; CD34; Biology","score_opus":0.11997577695296056,"score_gpt":0.43846624403139967,"score_spread":0.3184904670784391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327586678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973936,0.000255055,0.00033917438,0.000052456486,0.000033561235,0.0000564461,0.00036788636,0.00004131493,0.001460458],"genre_scores_gemma":[0.9963722,0.00009211473,0.00028765178,0.00006231725,0.000018152241,0.00007034737,0.00045330793,0.000007928508,0.0026360413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998857,0.00001832295,0.000008514628,0.00002105996,0.000020809623,0.000045633205],"domain_scores_gemma":[0.9999205,0.000010687289,0.000016619531,0.000006153768,0.0000062378904,0.000039907216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013274731,0.00028640483,0.00029860856,0.00012296949,0.00013861102,0.0002416536,0.00010721422,0.0002509491,0.002871938],"category_scores_gemma":[0.0000862148,0.00006518363,0.00012888404,0.00009391599,0.00020228002,0.0001731453,0.00009208078,0.00079178845,0.0005221803],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006550757,0.0013712733,0.0018126125,0.00006024398,0.00001056535,0.00014320112,0.00003905742,0.00026946305,0.98050755,0.00013578533,0.00058800715,0.008511561],"study_design_scores_gemma":[0.0013564541,0.0640314,0.037109803,0.00002594207,0.0000821068,0.0009821656,0.000117959666,0.0029221023,0.8849614,0.000170398,0.008225603,0.0000145837475],"about_ca_topic_score_codex":0.00027392898,"about_ca_topic_score_gemma":0.0003906616,"teacher_disagreement_score":0.002871938,"about_ca_system_score_codex":0.00014180604,"about_ca_system_score_gemma":0.00020226749,"threshold_uncertainty_score":0.0096075535},"labels":[],"label_agreement":null},{"id":"W2328382622","doi":"10.1038/sj.leu.2402079","title":"Suppressed apoptosis of pre-B cells in bone marrow of pre-leukemic p190bcr/abl transgenic mice","year":2001,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Medical Research Council Canada","keywords":"Apoptosis; Bone marrow; Biology; Genetically modified mouse; Leukemia; Carcinogenesis; B cell; Cancer research; Flow cytometry; Transgene; Molecular biology; Immunology; Antibody; Cancer; Biochemistry; Genetics","score_opus":0.017765350528368383,"score_gpt":0.28255142525930055,"score_spread":0.2647860747309322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328382622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872377,0.0023926115,0.004636414,0.00043366302,0.00010762614,0.00009019159,0.0016872071,0.0005198649,0.0028946362],"genre_scores_gemma":[0.9883012,0.00090142543,0.0016989139,0.00014180486,0.000039347946,0.00009906639,0.0011144703,0.00013580873,0.007567937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995053,0.00006275374,0.000046957146,0.00010156672,0.00013876687,0.00014460812],"domain_scores_gemma":[0.99960214,0.000056161,0.00010019861,0.000049588194,0.000044098848,0.00014780936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003001321,0.00069860445,0.0006960711,0.0012931549,0.00038908795,0.0006109102,0.00045072442,0.00082488765,0.003657844],"category_scores_gemma":[0.00020815007,0.00044034404,0.00039923386,0.00033413043,0.00048083437,0.00048166787,0.00032167445,0.0025782762,0.0013140768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031356624,0.000051226176,0.00012190916,0.000016136783,0.000006234023,0.00008299619,0.000021400017,0.00003008587,0.9983708,0.00018681695,0.000060013423,0.0007388979],"study_design_scores_gemma":[0.00011253654,0.00045612347,0.0029733386,0.000007656082,0.000032498578,0.0007132185,0.000045025325,0.00073057495,0.9921481,0.00016563885,0.0026076226,0.000007660443],"about_ca_topic_score_codex":0.0009795047,"about_ca_topic_score_gemma":0.00083227333,"teacher_disagreement_score":0.003657844,"about_ca_system_score_codex":0.00039570397,"about_ca_system_score_gemma":0.00029161962,"threshold_uncertainty_score":0.012236714},"labels":[],"label_agreement":null},{"id":"W2333997296","doi":"10.1038/nbt.3525","title":"Quality cell therapy manufacturing by design","year":2016,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Wildlife Fund Canada; University of Toronto","funders":"Health Canada; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Government of Canada; University of Pennsylvania","keywords":"Biopharmaceutical; Quality by Design; Quality (philosophy); Manufacturing process; New product development; Risk analysis (engineering); Good manufacturing practice; Computer science; Product (mathematics); Biochemical engineering; Process (computing); Population; Process development; Manufacturing engineering; Engineering; Medicine; Business; Biotechnology; Operations management; Biology","score_opus":0.028718145894029157,"score_gpt":0.33436713477928703,"score_spread":0.3056489888852579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333997296","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029331848,0.003179379,0.93024904,0.0010710525,0.0006052619,0.0011535035,0.0002860017,0.0010136256,0.033110294],"genre_scores_gemma":[0.25254592,0.0025393611,0.72100335,0.0008509875,0.00021857687,0.0012797565,0.0005655472,0.0004706603,0.020525783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964132,0.0005428908,0.00024344638,0.0004400197,0.0021419227,0.00021858864],"domain_scores_gemma":[0.9977525,0.00039679045,0.00035353022,0.00056244264,0.0008466971,0.000088021436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043824385,0.0011286556,0.0010140433,0.0011807402,0.00083718775,0.002973176,0.0013801536,0.0014623132,0.0077220807],"category_scores_gemma":[0.0025104792,0.00097492075,0.0012552615,0.0006973257,0.0013334983,0.0014281016,0.0015667024,0.0014709549,0.003482049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032602932,0.00038073747,0.0016894261,0.001384939,0.00012353288,0.00020672934,0.0003320653,0.019771295,0.7182428,0.08309242,0.0069592632,0.1674908],"study_design_scores_gemma":[0.00025653245,0.0016100575,0.0014708447,0.00018012307,0.00019146736,0.0006835309,0.00012017083,0.029642807,0.7956804,0.016542261,0.1535342,0.000087529],"about_ca_topic_score_codex":0.0006042505,"about_ca_topic_score_gemma":0.0009925847,"teacher_disagreement_score":0.0077220807,"about_ca_system_score_codex":0.0022200423,"about_ca_system_score_gemma":0.002053641,"threshold_uncertainty_score":0.025832951},"labels":[],"label_agreement":null},{"id":"W2338745842","doi":"10.1158/2326-6074.cricimteatiaacr15-a084","title":"Abstract A084: Identification of mutation-reactive T cells in patients with gastrointestinal cancers","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"clone (Java method); Cancer research; Cancer; CD8; Biology; Somatic cell; Mutation; Germline mutation; Cancer cell; Cell culture; Metastasis; Human leukocyte antigen; Exome sequencing; T cell; Molecular biology; Antigen; Immunology; Gene; Genetics; Immune system","score_opus":0.041750560219818406,"score_gpt":0.37331365738303157,"score_spread":0.3315630971632132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338745842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990709,0.00009309592,0.00008580546,0.00003681388,0.0000083015775,0.000008234516,0.00019765308,0.000008780615,0.00049036567],"genre_scores_gemma":[0.9994549,0.00002284649,0.00007528641,0.000033323304,0.000010683993,0.000008712939,0.00017262722,0.0000030353992,0.00021849634],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998017,0.000034948174,0.000020695918,0.00006861654,0.000036737485,0.000037325804],"domain_scores_gemma":[0.9996568,0.00009617381,0.00008029801,0.00001879098,0.00005649773,0.00009148823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013593365,0.00033532616,0.00028418694,0.00075829774,0.00043550288,0.00043413092,0.00022034423,0.00064428744,0.003433144],"category_scores_gemma":[0.0008309278,0.00017251265,0.00021028251,0.000505805,0.00016397533,0.0002533795,0.00017469219,0.00045873385,0.0005463012],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081266224,0.00013222996,0.9716538,0.000028344662,0.000039014558,0.002378388,0.00011941607,0.00008450217,0.020159507,0.00003922475,0.00045879508,0.004094198],"study_design_scores_gemma":[0.00003289965,0.0006229866,0.98710036,0.000010282279,0.00006214061,0.007994257,0.00026284845,0.00056975026,0.0024312588,0.00007606841,0.00082794356,0.000009211879],"about_ca_topic_score_codex":0.0006125757,"about_ca_topic_score_gemma":0.00029616625,"teacher_disagreement_score":0.003433144,"about_ca_system_score_codex":0.00017104934,"about_ca_system_score_gemma":0.00009662306,"threshold_uncertainty_score":0.011484981},"labels":[],"label_agreement":null},{"id":"W2339374946","doi":"10.1038/mtm.2016.22","title":"Biodistribution studies: understanding international expectations","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Session (web analytics); Agency (philosophy); Biodistribution; Scopus; Regulatory agency; Medicine; Political science; Presentation (obstetrics); Food and drug administration; Library science; Medical education; Pharmacology; MEDLINE; Business; Public administration; Biotechnology; Computer science; Law; Sociology; Social science","score_opus":0.41642445970119,"score_gpt":0.569495207973406,"score_spread":0.153070748272216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339374946","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003861374,0.053109247,0.027565287,0.83947295,0.0061839013,0.00025133355,0.00016712592,0.00024163272,0.069147125],"genre_scores_gemma":[0.23487735,0.121057406,0.059093002,0.53559506,0.014463168,0.00234081,0.00095380336,0.00092041824,0.030698933],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8556182,0.07873433,0.012059431,0.008702665,0.039288614,0.0055968766],"domain_scores_gemma":[0.7167912,0.15450431,0.023131792,0.017358972,0.06239575,0.025817994],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.2871494,0.0013799972,0.0016065004,0.0034401533,0.0055298205,0.028299477,0.0058663534,0.012920176,0.008350766],"category_scores_gemma":[0.22095169,0.0016479347,0.0013786533,0.0027056541,0.022444172,0.03139065,0.020685803,0.02889826,0.0035691354],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002590498,0.0002918806,0.004135293,0.0027567067,0.000080927966,0.00059054134,0.012543822,0.0010062053,0.0020313174,0.3898399,0.26700312,0.31946132],"study_design_scores_gemma":[0.0000354194,0.00027030145,0.0021616395,0.005134562,0.00003836872,0.0007104434,0.011307904,0.0006209104,0.0011774226,0.2561924,0.7222239,0.00012676051],"about_ca_topic_score_codex":0.0023192766,"about_ca_topic_score_gemma":0.0033970724,"teacher_disagreement_score":0.7128506,"about_ca_system_score_codex":0.016313562,"about_ca_system_score_gemma":0.03244606,"threshold_uncertainty_score":0.8790717},"labels":[],"label_agreement":null},{"id":"W2343859107","doi":"10.1016/j.jim.2016.04.010","title":"A global look into human T cell subsets before and after cryopreservation using multiparametric flow cytometry and two-dimensional visualization analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Cryopreservation; Flow cytometry; Immunophenotyping; Biology; Peripheral blood mononuclear cell; Cytotoxic T cell; Immunology; Cytometry; Andrology; Molecular biology; Cell biology; In vitro; Medicine; Genetics","score_opus":0.04975519665246256,"score_gpt":0.44132915878342843,"score_spread":0.39157396213096585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343859107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667604,0.003297053,0.025496794,0.00018297747,0.00008072163,0.00008692669,0.0008196345,0.00016482292,0.0031107177],"genre_scores_gemma":[0.9821577,0.0013369748,0.012112718,0.0001751493,0.000047687015,0.00021069573,0.0009947504,0.000082803024,0.0028814804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998646,0.000019423354,0.000014151344,0.000037380236,0.00002626068,0.000038182217],"domain_scores_gemma":[0.99989986,0.000024161645,0.000011967476,0.000018764566,0.000032591186,0.000012739968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024832526,0.00023716401,0.0002406073,0.00045959343,0.00035295103,0.0004958145,0.00019418575,0.00028538893,0.0016793917],"category_scores_gemma":[0.00018397972,0.00012952148,0.00022682398,0.00035717094,0.00018763724,0.00042767057,0.00023834709,0.000520063,0.00031112914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002571159,0.000022559672,0.0010630876,0.00003156747,0.0000073916476,0.00002657031,0.00010342435,0.000057300538,0.9940819,0.000086841064,0.000058016023,0.004204236],"study_design_scores_gemma":[0.000030098043,0.00040465186,0.055081133,0.000020560266,0.00013405393,0.00037524282,0.00040689012,0.0020519095,0.9358796,0.00046036387,0.0051273378,0.00002811617],"about_ca_topic_score_codex":0.00040193464,"about_ca_topic_score_gemma":0.00044824596,"teacher_disagreement_score":0.0016793917,"about_ca_system_score_codex":0.000112758134,"about_ca_system_score_gemma":0.00013508316,"threshold_uncertainty_score":0.0056180954},"labels":[],"label_agreement":null},{"id":"W2345568581","doi":"10.1186/s12916-016-0623-5","title":"Cancer immunotherapy: the beginning of the end of cancer?","year":2016,"lang":"en","type":"review","venue":"BMC Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Oncolytic virus; Medicine; Immunotherapy; Cancer immunotherapy; Cancer; Adoptive cell transfer; Immune system; Immune checkpoint; Monoclonal antibody; Immunology; Cytotoxic T cell; Cancer research; Antibody; T cell; Biology; Internal medicine","score_opus":0.1089515662707683,"score_gpt":0.4438961115139246,"score_spread":0.3349445452431563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345568581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011595861,0.9922678,0.0002721336,0.0045903064,0.0010262054,0.0000038939907,0.000010891585,0.000009179544,0.0017036353],"genre_scores_gemma":[0.0019515364,0.99071443,0.0004040522,0.0031761487,0.0017348296,0.000010242681,0.000028817682,0.0000063836455,0.0019735475],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994023,0.00017943147,0.00004579018,0.00007252667,0.00022794049,0.000072056624],"domain_scores_gemma":[0.99895155,0.000572254,0.000073338146,0.000046319517,0.0002129408,0.00014358952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015440057,0.0006029354,0.0014293614,0.0011362907,0.0007225568,0.00217765,0.00096077746,0.0026480602,0.0043425225],"category_scores_gemma":[0.0016515998,0.00025044594,0.00044037073,0.0014889437,0.0020189323,0.005180742,0.0012124175,0.004487047,0.0027765739],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013949707,0.00009464237,0.00027745246,0.008940312,0.00005969657,0.00024017143,0.00032696314,0.00024364665,0.0022002251,0.03918065,0.102519356,0.84577733],"study_design_scores_gemma":[0.000009676535,0.000060099337,0.00018320183,0.0013032164,0.000014936528,0.0004805421,0.00015511525,0.000031815645,0.00023611033,0.008781876,0.9887327,0.000010713073],"about_ca_topic_score_codex":0.0007679514,"about_ca_topic_score_gemma":0.0014761244,"teacher_disagreement_score":0.0043425225,"about_ca_system_score_codex":0.0011104024,"about_ca_system_score_gemma":0.0016756201,"threshold_uncertainty_score":0.014527202},"labels":[],"label_agreement":null},{"id":"W2396404964","doi":"10.1186/s13048-016-0236-9","title":"Adoptive immunotherapy against ovarian cancer","year":2016,"lang":"en","type":"review","venue":"Journal of Ovarian Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Università degli Studi di Torino; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; University Health Network","keywords":"Medicine; Immunotherapy; Debulking; Ovarian cancer; Tumor-infiltrating lymphocytes; Oncology; Adoptive cell transfer; Immunology; Cell therapy; Minimal residual disease; Disease; Cancer; Internal medicine; Immune system; T cell; Cell","score_opus":0.1929220044923839,"score_gpt":0.4955053859190608,"score_spread":0.3025833814266769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396404964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022436451,0.9988471,0.00008888301,0.00011009763,0.00011844994,0.000007721667,0.000008777886,0.000004994868,0.0005894644],"genre_scores_gemma":[0.0015810786,0.9974927,0.00013122475,0.00015784676,0.00012882956,0.000013382204,0.000024067278,9.547884e-7,0.00046997465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998683,0.000025609379,0.000015608679,0.000020932146,0.000053226704,0.000016273963],"domain_scores_gemma":[0.9998882,0.00004931353,0.00001985635,0.000004253929,0.000025680569,0.000012756889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005303796,0.0006909421,0.0009790182,0.0016138232,0.00020976525,0.00065003085,0.0007193852,0.00092365616,0.0020358406],"category_scores_gemma":[0.0003588955,0.00023203481,0.0004579197,0.0010731678,0.00037120722,0.00079205324,0.0006278522,0.0014463073,0.0012606046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093883005,0.00013962138,0.00019132819,0.017559031,0.000095102245,0.00024343553,0.000059007372,0.00032235007,0.004493975,0.002397086,0.01651184,0.9578932],"study_design_scores_gemma":[0.000072626935,0.00030784443,0.0012054591,0.0037018142,0.00015502497,0.0021740072,0.000051523002,0.00011013524,0.001957088,0.0016824632,0.9885633,0.00001876626],"about_ca_topic_score_codex":0.0004891262,"about_ca_topic_score_gemma":0.0009426097,"teacher_disagreement_score":0.0020358406,"about_ca_system_score_codex":0.00034400175,"about_ca_system_score_gemma":0.00054003834,"threshold_uncertainty_score":0.006810546},"labels":[],"label_agreement":null},{"id":"W2397071140","doi":"10.1158/2326-6074.cricimteatiaacr15-a176","title":"Abstract A176: Efficacy and safety of allogeneic double negative T cell as anti-AML therapy and its underlying mechanism","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Chemotherapy; Leukemia; CD8; Minimal residual disease; Stem cell; Immunotherapy; Oncology; Immunology; Transplantation; Cytotoxic T cell; Cancer research; Internal medicine; Immune system; In vitro; Biology","score_opus":0.16024945242818145,"score_gpt":0.42543022106325934,"score_spread":0.2651807686350779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397071140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926352,0.0034607942,0.0006300868,0.00010930967,0.00014722161,0.00013323853,0.00023899939,0.0000356687,0.0026094187],"genre_scores_gemma":[0.9949065,0.0011902576,0.0005390741,0.00012716965,0.000098787394,0.000070238326,0.0004909244,0.000007638704,0.002569361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999379,0.000012686378,0.0000071160603,0.0000127345,0.000019514628,0.000010007958],"domain_scores_gemma":[0.9999403,0.000008894274,0.000014825847,0.000008930873,0.0000072939233,0.000019857367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013018839,0.00028693888,0.00031367177,0.00015712791,0.00012811113,0.0002455307,0.00019678497,0.0003257975,0.0021518776],"category_scores_gemma":[0.00013597486,0.000053754833,0.00016858347,0.00013894873,0.00015634748,0.00017799325,0.00008333742,0.00051412475,0.00042822128],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014166955,0.0042958567,0.0032639026,0.00041781637,0.00007037363,0.0011634474,0.00011043046,0.0007197328,0.8740503,0.00084628677,0.001308806,0.09958607],"study_design_scores_gemma":[0.005375251,0.17250387,0.026622243,0.00009831404,0.00033946513,0.007371532,0.00013232906,0.0035898958,0.73353124,0.0006411568,0.04975631,0.000038400005],"about_ca_topic_score_codex":0.00022112165,"about_ca_topic_score_gemma":0.00017933447,"teacher_disagreement_score":0.0021518776,"about_ca_system_score_codex":0.00015561067,"about_ca_system_score_gemma":0.0002856037,"threshold_uncertainty_score":0.007198751},"labels":[],"label_agreement":null},{"id":"W2398298261","doi":"10.1182/blood-2015-08-664250","title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"CD19; Immunology; Leukemia; Medicine; Cancer research; Biology; Antigen","score_opus":0.031122916195809064,"score_gpt":0.2884574029197534,"score_spread":0.2573344867239443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398298261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99131197,0.0012479769,0.0047176057,0.00007184145,0.000055679877,0.00009462429,0.00054517994,0.00017891134,0.0017763192],"genre_scores_gemma":[0.9904254,0.0011275776,0.0036273398,0.00008508525,0.00004488144,0.00014040206,0.0008871292,0.00004158942,0.0036206197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997274,0.00003582536,0.000028854678,0.00006226444,0.000056126646,0.00008947995],"domain_scores_gemma":[0.99987113,0.000017530441,0.00003873781,0.00002014569,0.00000850212,0.00004391813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015827299,0.0008666076,0.00037566596,0.0003692899,0.00016660322,0.00035247422,0.00024249603,0.00040029478,0.001785003],"category_scores_gemma":[0.00008303187,0.00016663832,0.00024292043,0.00017905631,0.00023700036,0.00032568257,0.00026575147,0.0012894977,0.0005269736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001498764,0.0001386618,0.00014199842,0.00003181287,0.000004227871,0.000030794417,0.000010340505,0.00006189741,0.9982133,0.00015117497,0.000039848503,0.0010259467],"study_design_scores_gemma":[0.00006139143,0.0019219621,0.0017119653,0.000005445532,0.000032891257,0.00037107905,0.0000130167555,0.00058759144,0.99285614,0.00006879208,0.0023658199,0.000003861531],"about_ca_topic_score_codex":0.00019580478,"about_ca_topic_score_gemma":0.00031355277,"teacher_disagreement_score":0.001785003,"about_ca_system_score_codex":0.00018401463,"about_ca_system_score_gemma":0.00018589401,"threshold_uncertainty_score":0.0059714317},"labels":[],"label_agreement":null},{"id":"W2413352928","doi":"10.1016/j.exphem.2016.06.002","title":"Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Stichting Kinderen Kankervrij","keywords":"Progenitor cell; Biology; Haematopoiesis; CD8; Cell biology; T cell; Stem cell; CD34; Cancer research; Immunology; Molecular biology; Immune system","score_opus":0.02300132305908279,"score_gpt":0.3063083605959264,"score_spread":0.2833070375368436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413352928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982183,0.0013144431,0.009913321,0.00041750312,0.000092806564,0.00016527386,0.0007992171,0.0006295277,0.0044849953],"genre_scores_gemma":[0.99112755,0.000628534,0.0038299584,0.00013041798,0.000029284316,0.00027857255,0.00057370035,0.00006202109,0.0033400552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995158,0.000109919245,0.0000623349,0.00007694851,0.00010101996,0.00013405528],"domain_scores_gemma":[0.9996674,0.000068207664,0.00010665572,0.00006549565,0.00001480653,0.00007740883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004598989,0.0011346067,0.00042154055,0.00086760183,0.00027893955,0.0008142607,0.0004988984,0.0007523589,0.0017256464],"category_scores_gemma":[0.00024365715,0.0003572038,0.0005551089,0.00029057416,0.0008546452,0.00056715216,0.00067947665,0.0013120297,0.0006104044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034962656,0.00010415294,0.00038351992,0.000031229138,0.00000785112,0.00020337329,0.000025283905,0.00007354097,0.9972077,0.0007923515,0.000063019404,0.00075830164],"study_design_scores_gemma":[0.00004355129,0.00015545085,0.0013610447,0.000003173448,0.000018821369,0.00042355698,0.000026495447,0.00051608396,0.9960885,0.00010884619,0.001249351,0.000005027729],"about_ca_topic_score_codex":0.00045084624,"about_ca_topic_score_gemma":0.0004891684,"teacher_disagreement_score":0.0017256464,"about_ca_system_score_codex":0.00046406945,"about_ca_system_score_gemma":0.00035602276,"threshold_uncertainty_score":0.005772829},"labels":[],"label_agreement":null},{"id":"W2416659570","doi":"10.1038/mto.2015.14","title":"Chimeric antigen receptor–engineered T cells as oncolytic virus carriers","year":2015,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Oncolytic virus; Chimeric antigen receptor; Adoptive cell transfer; Virus; Immune system; Antigen; Cancer research; Antibody; Immunology; Receptor; Biology; Immunotherapy; Virology; T cell","score_opus":0.035945221340119994,"score_gpt":0.3239435815978033,"score_spread":0.2879983602576833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416659570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8541168,0.021359587,0.115643136,0.00043464356,0.00037256238,0.0005396217,0.00041433715,0.00063513103,0.0064842016],"genre_scores_gemma":[0.9651944,0.0044526737,0.026711678,0.0001259977,0.00003859122,0.00017961112,0.00028257605,0.000053461823,0.00296102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997265,0.00009171537,0.000016461547,0.00004128443,0.00006597347,0.00005808706],"domain_scores_gemma":[0.99992585,0.00001855514,0.000022165234,0.0000102229915,0.000011059678,0.000012064793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002859091,0.00039091078,0.00024815105,0.000286818,0.000079667465,0.00042010844,0.00038227713,0.0006038647,0.00069065107],"category_scores_gemma":[0.00020297378,0.0001879022,0.00031965767,0.00018695912,0.00024420186,0.0003717014,0.0002632245,0.0007021754,0.00050165656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013737923,0.00006272864,0.00008670401,0.0001042355,0.000015810527,0.00007694189,0.000028511784,0.0010302835,0.989753,0.0011086487,0.00023510496,0.007360678],"study_design_scores_gemma":[0.000111803056,0.0012255987,0.00032951517,0.000020687543,0.00005045249,0.0005400975,0.00001777106,0.0071875844,0.97462547,0.00036268626,0.015513373,0.000015007035],"about_ca_topic_score_codex":0.00035428753,"about_ca_topic_score_gemma":0.0002760718,"teacher_disagreement_score":0.00069065107,"about_ca_system_score_codex":0.00024597684,"about_ca_system_score_gemma":0.00021204562,"threshold_uncertainty_score":0.0023103952},"labels":[],"label_agreement":null},{"id":"W2485297274","doi":"10.1158/1538-7445.am2016-846","title":"Abstract 846: Improving T-cell receptor clonotyping of T-cell lymphomas using hybrid-Capture and next-generation sequencing","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network; Calgary Laboratory Services","funders":"","keywords":"T-cell receptor; Biology; Sanger sequencing; T cell; Molecular biology; DNA sequencing; Gene rearrangement; Computational biology; Genetics; Gene","score_opus":0.1702651020974911,"score_gpt":0.37797427230038,"score_spread":0.2077091702028889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485297274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6605834,0.0011270734,0.32889128,0.00020905305,0.00007778905,0.00032023177,0.0026896463,0.002753973,0.003347611],"genre_scores_gemma":[0.6198754,0.00054925575,0.370175,0.0003194009,0.000044082346,0.0003057423,0.005634155,0.00040282405,0.0026941013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998965,0.00027931025,0.00006512636,0.0002898078,0.00031186122,0.000088836554],"domain_scores_gemma":[0.9994492,0.00018072313,0.00004954478,0.00007481052,0.00019900617,0.000046778325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011766927,0.00056411396,0.0003454328,0.0007557901,0.00026184233,0.0008516869,0.00045801504,0.0004907828,0.0017679594],"category_scores_gemma":[0.0012101948,0.00024827413,0.00040584893,0.0003933211,0.000259221,0.0002916741,0.00064215774,0.0004944491,0.0012849492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000087157336,0.000030574975,0.0043255566,0.00008225256,0.000021101492,0.000040229854,0.00004221476,0.0011197618,0.97677726,0.00015488255,0.00035187238,0.0169671],"study_design_scores_gemma":[0.000018793471,0.00020850632,0.018239452,0.000016337364,0.00006194827,0.0004846572,0.000044727833,0.02663582,0.9478244,0.0003041884,0.0061333,0.00002789475],"about_ca_topic_score_codex":0.0010561032,"about_ca_topic_score_gemma":0.0020890355,"teacher_disagreement_score":0.0017679594,"about_ca_system_score_codex":0.00026240814,"about_ca_system_score_gemma":0.00038447639,"threshold_uncertainty_score":0.0062230825},"labels":[],"label_agreement":null},{"id":"W2485508368","doi":"10.1186/s12967-016-0791-2","title":"Melanoma and immunotherapy bridge 2015","year":2016,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Sunnybrook Health Science Centre; University Health Network; Royal Victoria Hospital; Princess Margaret Cancer Centre; Health Sciences Centre","funders":"Hungarian Scientific Research Fund; Harry J. Lloyd Charitable Trust; Melanoma Research Alliance; GlaxoSmithKline","keywords":"Melanoma; Ipilimumab; Immunotherapy; Immune checkpoint; Tumor microenvironment; Cancer research; Medicine; Cancer immunotherapy; Cancer; PI3K/AKT/mTOR pathway; Blockade; Immune system; Immunology; Internal medicine; Biology; Receptor; Signal transduction","score_opus":0.041907919345375626,"score_gpt":0.35480410493217523,"score_spread":0.3128961855867996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485508368","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061800564,0.121279724,0.0039647436,0.028838802,0.036406897,0.0003765491,0.0016914171,0.0013752036,0.7998866],"genre_scores_gemma":[0.019137515,0.052879523,0.0023473005,0.01082889,0.011981261,0.00021643359,0.0025456913,0.0002390279,0.89982444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99959403,0.00006394778,0.00003234454,0.00009993908,0.00014705653,0.00006277961],"domain_scores_gemma":[0.99949706,0.00006623859,0.000049526032,0.000052865238,0.00015119092,0.0001830508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067140034,0.0007160495,0.00043496146,0.0011864268,0.0005438674,0.00283373,0.0007284446,0.0019432221,0.2612155],"category_scores_gemma":[0.0011085141,0.0003011924,0.0006105062,0.0005238126,0.00042619833,0.0014669473,0.0014464092,0.0027598788,0.14724979],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012634599,0.0001095102,0.00058506255,0.00050677103,0.000029918358,0.0003819869,0.000039881306,0.0001609344,0.0028836157,0.0079821935,0.41337472,0.57381904],"study_design_scores_gemma":[0.000014968403,0.0000422292,0.0007345705,0.00017800125,0.000007029627,0.0007554675,0.000017561712,0.00007135722,0.0002482883,0.0014694737,0.9964573,0.0000038204403],"about_ca_topic_score_codex":0.00058953656,"about_ca_topic_score_gemma":0.0014595635,"teacher_disagreement_score":0.2612155,"about_ca_system_score_codex":0.0010647695,"about_ca_system_score_gemma":0.0010652356,"threshold_uncertainty_score":0.8738529},"labels":[],"label_agreement":null},{"id":"W2486023327","doi":"10.1002/stem.2465","title":"Efficient Regeneration of Human Vα24+ Invariant Natural Killer T Cells and Their Anti-Tumor Activity In Vivo","year":2016,"lang":"en","type":"article","venue":"Stem Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Sciences Centre Foundation","keywords":"Biology; Reprogramming; Induced pluripotent stem cell; Cytotoxic T cell; Cancer immunotherapy; Immunotherapy; Natural killer T cell; Cell biology; Cancer research; In vivo; Immunology; Immune system; In vitro; Cell; T cell; Embryonic stem cell; Biochemistry","score_opus":0.021652407618799805,"score_gpt":0.2746484096368931,"score_spread":0.25299600201809325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486023327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98819834,0.001270691,0.0075363102,0.00006546289,0.00005347498,0.00016964955,0.00040355584,0.00016584531,0.0021367208],"genre_scores_gemma":[0.99344146,0.00045522134,0.0031340793,0.000030880212,0.000011084048,0.00007964814,0.000508064,0.000031383803,0.0023081622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981195,0.00003457541,0.000030041101,0.000038324415,0.00004541503,0.00003968512],"domain_scores_gemma":[0.99989176,0.000016108832,0.000030184912,0.00003075728,0.000011624364,0.00001950059],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030263275,0.00032116516,0.00021294582,0.00032191802,0.000105289015,0.0003546572,0.00020138266,0.00026737215,0.0012935343],"category_scores_gemma":[0.00016346548,0.00012178378,0.0002514801,0.00015270834,0.00020994594,0.00016548543,0.00018935344,0.00050277554,0.00050227926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002494503,0.00010982582,0.0001958238,0.000037623886,0.000008728436,0.00009017439,0.000028197188,0.00027138094,0.99198383,0.00020925085,0.00008418839,0.0067316177],"study_design_scores_gemma":[0.00004876251,0.00042262246,0.00069228024,0.0000047228527,0.000016986312,0.0003440936,0.000011088468,0.0007130428,0.99501735,0.00007089872,0.002655512,0.000002705859],"about_ca_topic_score_codex":0.00018402463,"about_ca_topic_score_gemma":0.00012020901,"teacher_disagreement_score":0.0012935343,"about_ca_system_score_codex":0.000119025855,"about_ca_system_score_gemma":0.0001719179,"threshold_uncertainty_score":0.004327297},"labels":[],"label_agreement":null},{"id":"W2488182312","doi":"10.1038/icb.2016.45","title":"Purity of transferred CD8<sup>+</sup> T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP‐1","year":2016,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Cardiff University; Wellcome Trust; Wellcome","keywords":"Adoptive cell transfer; Cytotoxic T cell; CD8; Cancer research; Immunology; Immunotherapy; Biology; T cell; Cell biology; Immune system; Biochemistry; In vitro","score_opus":0.014596609812870911,"score_gpt":0.28392477736033767,"score_spread":0.26932816754746675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488182312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9239027,0.0031315384,0.058642507,0.0007504644,0.0001627394,0.00064487074,0.000636841,0.00079768786,0.011330481],"genre_scores_gemma":[0.98224604,0.0005403027,0.011664231,0.0001809325,0.000067311594,0.00048808378,0.0006196075,0.0001693765,0.004024169],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992446,0.00021150916,0.000088143155,0.00012295909,0.00023264745,0.000100236444],"domain_scores_gemma":[0.99941766,0.00018106968,0.00012919813,0.00011551507,0.000095447416,0.00006116604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000762538,0.0005417572,0.00046787207,0.00035429734,0.00029292735,0.00089777634,0.000321435,0.00047965028,0.002280466],"category_scores_gemma":[0.0007038822,0.00020087522,0.00021310465,0.00020771548,0.00035628304,0.00043529226,0.00044465114,0.0012405454,0.001316971],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027284943,0.00020597405,0.00087637705,0.000049515536,0.000013174289,0.000045301545,0.00004191123,0.00031256577,0.98818123,0.00057732844,0.00021779609,0.009206066],"study_design_scores_gemma":[0.00005430537,0.00057338725,0.002343629,0.000017263534,0.000046489902,0.00040557858,0.00002450439,0.0019127224,0.9902395,0.0002864003,0.00409053,0.000005640661],"about_ca_topic_score_codex":0.00014101749,"about_ca_topic_score_gemma":0.00024020001,"teacher_disagreement_score":0.002280466,"about_ca_system_score_codex":0.00023051816,"about_ca_system_score_gemma":0.00026441048,"threshold_uncertainty_score":0.0076289177},"labels":[],"label_agreement":null},{"id":"W2489660615","doi":"10.1182/blood.v126.23.3252.3252","title":"Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lymphoma; Context (archaeology); Cancer research; Biology; Immunophenotyping; Transplantation; Leukemia; Computational biology; Medicine; Immunology; Flow cytometry; Internal medicine","score_opus":0.14710807587399818,"score_gpt":0.3776092034881212,"score_spread":0.23050112761412303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489660615","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14807817,0.010434594,0.24628973,0.0035281181,0.0013365911,0.0049543926,0.44896445,0.08279416,0.053619847],"genre_scores_gemma":[0.16206777,0.006762449,0.17598863,0.0009885934,0.00031809908,0.006497256,0.6166119,0.007829425,0.0229359],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974859,0.000642038,0.00026677534,0.00025267707,0.0010929477,0.0002596664],"domain_scores_gemma":[0.9912212,0.0015492955,0.0008072904,0.003705088,0.0013196343,0.0013974638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067459354,0.0008765261,0.0012049554,0.004174506,0.00067624357,0.0024279878,0.0034054224,0.0014181304,0.022974862],"category_scores_gemma":[0.0048115584,0.000748023,0.00087207335,0.0031673184,0.0005034721,0.0026747112,0.003503978,0.0026672587,0.01307746],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067532784,0.002328937,0.0135949515,0.0020133331,0.0003303806,0.0027282278,0.00058263994,0.0101423925,0.2389694,0.016887214,0.46105793,0.24461137],"study_design_scores_gemma":[0.001640985,0.0021746217,0.010480748,0.00065485743,0.00029377305,0.0044983597,0.00020912524,0.015219817,0.15970738,0.0048688524,0.8000289,0.000222553],"about_ca_topic_score_codex":0.0007613603,"about_ca_topic_score_gemma":0.001564607,"teacher_disagreement_score":0.022974862,"about_ca_system_score_codex":0.000785578,"about_ca_system_score_gemma":0.0015291215,"threshold_uncertainty_score":0.07685852},"labels":[],"label_agreement":null},{"id":"W2503724939","doi":"10.1158/1538-7445.am2016-2300","title":"Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Antigen; Immunoglobulin light chain; Flow cytometry; CD28; Single-chain variable fragment; Biology; CD8; Monoclonal antibody; Antibody; T cell; Immunology; Immune system","score_opus":0.06752122905625818,"score_gpt":0.3716309087200256,"score_spread":0.3041096796637674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503724939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581886,0.00089176587,0.0066259797,0.00018422048,0.000060379927,0.00036272226,0.0008443448,0.0003651471,0.004846418],"genre_scores_gemma":[0.9905901,0.0005165356,0.0039186217,0.00010085585,0.000016361693,0.00016782935,0.0010528542,0.00003209846,0.0036047222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998878,0.00001533057,0.0000070345213,0.000021553507,0.000026206451,0.00004204795],"domain_scores_gemma":[0.99996233,0.0000052732225,0.000005697577,0.0000035948083,0.0000072617954,0.000015839423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001386089,0.00039941602,0.00028268984,0.00020392724,0.00011080901,0.0003374926,0.00020803459,0.0003512259,0.0025855815],"category_scores_gemma":[0.00009502049,0.000086387045,0.00020104594,0.0001365924,0.00014789091,0.00013816419,0.00017173652,0.000710754,0.00064007443],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002514437,0.00035464062,0.00045253691,0.000073428455,0.0000136678555,0.00019737489,0.00003852103,0.0003244395,0.99090403,0.0006101417,0.0006028827,0.006176849],"study_design_scores_gemma":[0.00011693029,0.0023731173,0.0021762727,0.000008239782,0.00004861673,0.00095590344,0.000019744804,0.0022167633,0.98360175,0.00010669463,0.008368527,0.0000075391004],"about_ca_topic_score_codex":0.00092627003,"about_ca_topic_score_gemma":0.0008553438,"teacher_disagreement_score":0.0025855815,"about_ca_system_score_codex":0.0003495144,"about_ca_system_score_gemma":0.00046556263,"threshold_uncertainty_score":0.008649647},"labels":[],"label_agreement":null},{"id":"W2506102763","doi":"10.1158/1538-7445.am2016-1481","title":"Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Antigen; Cancer research; Flow cytometry; Antibody; CD3; Monoclonal antibody; Population; Peripheral blood mononuclear cell; Immunophenotyping; Medicine; Cancer; Immunology; Biology; Internal medicine; In vitro; CD8","score_opus":0.11999431366524654,"score_gpt":0.43986873323908154,"score_spread":0.319874419573835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2506102763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903077,0.00079395686,0.004851924,0.00016152956,0.00007474819,0.0004047099,0.00083735446,0.000155938,0.0024122375],"genre_scores_gemma":[0.991884,0.00048237055,0.0036744585,0.00013784897,0.000014097705,0.0003121138,0.0013391377,0.000025963698,0.0021299785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998068,0.00004107481,0.000010639064,0.000031683205,0.0000534505,0.000056496025],"domain_scores_gemma":[0.9999151,0.0000145306985,0.000012812111,0.000008844181,0.000019647176,0.000029090414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036900607,0.00050913007,0.00041650122,0.00016487433,0.00011613177,0.00031934056,0.00037501293,0.00055539334,0.0020950404],"category_scores_gemma":[0.00017542765,0.00013565422,0.00025465098,0.00012849785,0.00017326933,0.00015218923,0.00017554242,0.001277014,0.0004708051],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085729174,0.0019399329,0.00046146178,0.00016307403,0.000034307748,0.00010089638,0.00006489403,0.0014079174,0.98423415,0.00029498944,0.0010307657,0.009410409],"study_design_scores_gemma":[0.00039679522,0.024767917,0.0021830443,0.000017117687,0.00006400272,0.00043398293,0.000037043486,0.0041553243,0.9618014,0.00010679889,0.0060250643,0.000011516957],"about_ca_topic_score_codex":0.0006146682,"about_ca_topic_score_gemma":0.0007243186,"teacher_disagreement_score":0.0020950404,"about_ca_system_score_codex":0.00023767471,"about_ca_system_score_gemma":0.0003012062,"threshold_uncertainty_score":0.007008612},"labels":[],"label_agreement":null},{"id":"W2507694805","doi":"10.1182/blood.v118.21.2470.2470","title":"Effects of LMO2 on Human T-Cell Development Are Modulated by Notch Signaling","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Toronto","funders":"","keywords":"Biology; Cancer research; Myeloid; Haematopoiesis; Leukemia; Myeloid leukemia; Progenitor cell; Severe combined immunodeficiency; Stem cell; Immunology; Hematopoietic stem cell; Genetic enhancement; Cell biology; Gene; Genetics","score_opus":0.03933927042758498,"score_gpt":0.2833253290993687,"score_spread":0.24398605867178372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507694805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968748,0.0010690611,0.00031532728,0.00006198785,0.000015105527,0.000017963852,0.00024225451,0.000024519139,0.0013789511],"genre_scores_gemma":[0.9977895,0.0004529257,0.00026794724,0.00005255744,0.000006443284,0.000027085644,0.0003418038,0.00000734715,0.0010545135],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990666,0.000027479733,0.000008378368,0.000010660767,0.000017713355,0.000029076633],"domain_scores_gemma":[0.9999399,0.000016623215,0.000010913339,0.000006193565,0.0000059672666,0.000020359557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010941559,0.00018089333,0.00015748326,0.00014673152,0.000095282165,0.00025139068,0.000110721565,0.00017547983,0.0014444188],"category_scores_gemma":[0.00010505214,0.000057155048,0.00013977248,0.00012567021,0.0001361116,0.00011224223,0.00015542486,0.0003068659,0.000281507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005952999,0.000082957566,0.00030816597,0.000036113128,0.0000057450834,0.000096323914,0.000022050686,0.00007410888,0.99720323,0.00007082594,0.00007724079,0.001427948],"study_design_scores_gemma":[0.00007198899,0.0009529105,0.0066145416,0.0000071378067,0.000018712944,0.0001718562,0.000072311836,0.00069557276,0.98851216,0.000039342194,0.0028392929,0.00000406885],"about_ca_topic_score_codex":0.00046365804,"about_ca_topic_score_gemma":0.00060947164,"teacher_disagreement_score":0.0014444188,"about_ca_system_score_codex":0.00015616512,"about_ca_system_score_gemma":0.00013543655,"threshold_uncertainty_score":0.004832089},"labels":[],"label_agreement":null},{"id":"W2507731619","doi":"10.1182/blood.v118.21.87.87","title":"Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Diffuse large B-cell lymphoma; CHOP; Rituximab; Oncology; Internal medicine; Proportional hazards model; International Prognostic Index; Medicine; Pathology; Biology; Immunohistochemistry; Lymphoma; Immunology","score_opus":0.020916844062654837,"score_gpt":0.255847837616466,"score_spread":0.23493099355381117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507731619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99919146,0.00009653824,0.0002853424,0.000009301091,0.0000020776313,0.000008718139,0.00023535307,0.0000042107617,0.00016712684],"genre_scores_gemma":[0.99863344,0.000046767247,0.00049249607,0.000016049558,0.0000048422016,0.000020862817,0.00056715537,0.0000034949355,0.00021488944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998202,0.000056722554,0.000014668123,0.000050409206,0.000035872446,0.000022159764],"domain_scores_gemma":[0.9996413,0.00016352381,0.00010453634,0.000024205161,0.00002384981,0.000042579373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004079704,0.00023801715,0.0002098865,0.00081071095,0.00009532115,0.00040128914,0.00014828559,0.00029688602,0.0011790685],"category_scores_gemma":[0.0006167496,0.00013457687,0.00021781509,0.00047886337,0.0002207648,0.00019850061,0.00018202681,0.00028697663,0.0003039168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035212997,0.00010538738,0.9672847,0.000027140311,0.00016888752,0.00016001587,0.00007932739,0.00051060104,0.020791534,0.000042887797,0.00016371856,0.007144597],"study_design_scores_gemma":[0.00011531593,0.0009996737,0.99116814,0.000004150204,0.00010399404,0.0005868666,0.00010466943,0.002236591,0.0041522705,0.000118605094,0.00040217332,0.000007534294],"about_ca_topic_score_codex":0.00020944749,"about_ca_topic_score_gemma":0.00031903657,"teacher_disagreement_score":0.0011790685,"about_ca_system_score_codex":0.00014572953,"about_ca_system_score_gemma":0.000073455674,"threshold_uncertainty_score":0.003944397},"labels":[],"label_agreement":null},{"id":"W2508398069","doi":"10.1007/978-1-4939-3801-8_11","title":"Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes","year":2016,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Chimeric antigen receptor; Adoptive cell transfer; Receptor; Antigen; Virology; Biology; Immunology; Cancer research; Molecular biology; Immunotherapy; Immune system; T cell; Genetics","score_opus":0.02493786642087454,"score_gpt":0.4078942568493336,"score_spread":0.3829563904284591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508398069","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97401243,0.00094160164,0.020828975,0.00016085539,0.00006719906,0.00018555386,0.0003626872,0.00011306436,0.0033275068],"genre_scores_gemma":[0.98876417,0.00035682102,0.006644414,0.00004231915,0.000011190319,0.000076462544,0.00034738999,0.000045067532,0.003712196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996057,0.00010110587,0.000032216787,0.00005559691,0.000089663205,0.00011584021],"domain_scores_gemma":[0.9998903,0.00003964783,0.00002206305,0.000022178996,0.000010284223,0.000015477173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046396107,0.00036119952,0.00024926485,0.0002394201,0.00019609026,0.0006892866,0.00035977212,0.0005276474,0.0016806584],"category_scores_gemma":[0.00026751545,0.000260057,0.00033902176,0.00019233531,0.00031986402,0.0002320377,0.00037457113,0.001005299,0.00047105513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020878193,0.000038686132,0.00011266411,0.000029593171,0.00000976004,0.00006505684,0.000048798895,0.00033459632,0.9951881,0.0018690969,0.00005305351,0.0020417897],"study_design_scores_gemma":[0.0000445218,0.00021110455,0.0002486898,0.0000049943355,0.000020757998,0.00017654533,0.000023723725,0.001061105,0.99321073,0.000118719465,0.004876105,0.0000030742985],"about_ca_topic_score_codex":0.0004968849,"about_ca_topic_score_gemma":0.0005299349,"teacher_disagreement_score":0.0016806584,"about_ca_system_score_codex":0.0004479382,"about_ca_system_score_gemma":0.00036336746,"threshold_uncertainty_score":0.005622387},"labels":[],"label_agreement":null},{"id":"W2508616096","doi":"10.1172/jci86437","title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; University of Toronto; Ministero dello Sviluppo Economico; Genome Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Ontario Ministry of Economic Development and Innovation; Novartis Pharma; Ontario Genomics Institute; Wellcome Trust; Pfizer; Princess Margaret Cancer Foundation; National Institutes of Health; Ontario Genomics","keywords":"Adoptive immunotherapy; Immunotherapy; Bromodomain; Persistence (discontinuity); Adoptive cell transfer; Function (biology); Cancer research; Immunology; Biology; T cell; Computational biology; Immune system; Cell biology; Epigenetics; Genetics","score_opus":0.12780423115335657,"score_gpt":0.3737692853268149,"score_spread":0.24596505417345835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508616096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992584,0.0011420583,0.0041220174,0.00011458886,0.000054498192,0.00010397755,0.0001700064,0.00019810436,0.001510815],"genre_scores_gemma":[0.9936619,0.0007581504,0.0026061162,0.00005771619,0.000020921048,0.00011289316,0.00030434795,0.000024508405,0.002453446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996463,0.000073718555,0.000029364604,0.00005503843,0.00009576206,0.00009985903],"domain_scores_gemma":[0.9998368,0.00003125825,0.00004198542,0.000024177707,0.000015496045,0.00005022874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047149535,0.00064737664,0.0005404763,0.0006320206,0.00020136115,0.00035484514,0.00044469885,0.00048095395,0.001136039],"category_scores_gemma":[0.00017332139,0.00022833723,0.00032092826,0.00024906863,0.0003265911,0.00037567256,0.00023438888,0.0015152812,0.0003174634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030726552,0.00040248677,0.00007114396,0.000032629872,0.0000069814855,0.000021754451,0.000022773305,0.00013184547,0.9971269,0.00009891376,0.000050106555,0.0017271403],"study_design_scores_gemma":[0.0000857696,0.0024901424,0.0007738524,0.00000465325,0.000025453453,0.00009439859,0.00001295288,0.0013272074,0.99416345,0.00005814835,0.00095988903,0.0000040242917],"about_ca_topic_score_codex":0.00038903306,"about_ca_topic_score_gemma":0.00070834573,"teacher_disagreement_score":0.001136039,"about_ca_system_score_codex":0.00032753497,"about_ca_system_score_gemma":0.00025834292,"threshold_uncertainty_score":0.0038003922},"labels":[],"label_agreement":null},{"id":"W2512229218","doi":"10.1093/intimm/dxq203","title":"Column-free methods for the fast and versatile isolation of highly purified, functional and expandable human regulatory T cell populations (LL3-3)","year":2010,"lang":"en","type":"article","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Population; Interleukin-7 receptor; Chemistry; IL-2 receptor; Immunology; Cell biology; Molecular biology; Biology; T cell; Medicine; Immune system","score_opus":0.04206263198002131,"score_gpt":0.3701477093093158,"score_spread":0.3280850773292945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512229218","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015273066,0.019075712,0.8891556,0.0028439912,0.0023053845,0.0016378155,0.007569987,0.018939236,0.043199267],"genre_scores_gemma":[0.077005416,0.03043561,0.6444178,0.0054202676,0.0015278043,0.00611412,0.034929976,0.005013547,0.19513544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99842876,0.0002309333,0.00008002243,0.00017167858,0.0009528948,0.00013575482],"domain_scores_gemma":[0.9995739,0.00012526168,0.000049885228,0.00008154471,0.00011160455,0.000057777997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001178764,0.0019691826,0.0008762647,0.0017379556,0.0007083609,0.0012885093,0.0013870609,0.0012588138,0.035678796],"category_scores_gemma":[0.0009453803,0.0009457591,0.0011775268,0.0010349783,0.0005050116,0.0009614446,0.0012737808,0.002991816,0.054126013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010696342,0.00020057615,0.00024365284,0.0008550915,0.00004525792,0.00019978694,0.00009700348,0.00022977425,0.8405368,0.0028691902,0.049990166,0.10462566],"study_design_scores_gemma":[0.0000984427,0.00030328502,0.00168603,0.00015868514,0.00006741509,0.001379427,0.00004727744,0.0019349555,0.59446144,0.0029443367,0.39682686,0.000091882415],"about_ca_topic_score_codex":0.0006619334,"about_ca_topic_score_gemma":0.0015839074,"teacher_disagreement_score":0.035678796,"about_ca_system_score_codex":0.0006282868,"about_ca_system_score_gemma":0.0008731842,"threshold_uncertainty_score":0.11935747},"labels":[],"label_agreement":null},{"id":"W2513504681","doi":"10.1158/2326-6066.cir-16-0179","title":"Zeroing in on Tumor-Reactive TILs","year":2016,"lang":"en","type":"letter","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Adoptive cell transfer; Cancer immunotherapy; Cancer; Immunotherapy; Cancer research; Adoptive immunotherapy; Tumor cells; Medicine; Immunology; T cell; Immune system; Internal medicine","score_opus":0.11938313846503769,"score_gpt":0.4404190876862732,"score_spread":0.3210359492212355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513504681","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49699757,0.024337068,0.05001809,0.18472901,0.027734268,0.00056552596,0.0006263657,0.0030082131,0.21198393],"genre_scores_gemma":[0.8798923,0.0039838483,0.00505855,0.0358831,0.006620576,0.0001077393,0.00017560196,0.00012306633,0.06815526],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962306,0.00009836391,0.000021716285,0.000058728827,0.000100115496,0.00009798987],"domain_scores_gemma":[0.9995752,0.00019954176,0.00004053743,0.00007506145,0.00006107524,0.000048569313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028595273,0.00040298182,0.0003952318,0.00019321518,0.00042384048,0.00075741427,0.00025528885,0.0017131813,0.0040241326],"category_scores_gemma":[0.0012367329,0.00010984137,0.0003602605,0.00009772966,0.00044265165,0.00055898906,0.00024504567,0.0028888886,0.002687611],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002871351,0.0007203134,0.008862596,0.0008844819,0.00008764232,0.056845304,0.00073603354,0.0013461635,0.19063672,0.03983763,0.18528764,0.51188403],"study_design_scores_gemma":[0.00035081757,0.0017735953,0.0040317075,0.0001761814,0.00011210814,0.048015896,0.00040370304,0.0046137674,0.20020033,0.028915415,0.7113643,0.000042115793],"about_ca_topic_score_codex":0.00020478926,"about_ca_topic_score_gemma":0.0003228924,"teacher_disagreement_score":0.0040241326,"about_ca_system_score_codex":0.00082190736,"about_ca_system_score_gemma":0.00020115275,"threshold_uncertainty_score":0.013462007},"labels":[],"label_agreement":null},{"id":"W2514206384","doi":"10.1158/2159-8290.cd-16-0789","title":"Activating TCR Signaling to Thwart T-ALL","year":2016,"lang":"en","type":"letter","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"T-cell receptor; CD3; T cell; Biology; Apoptosis; Cell biology; Negative selection; Cancer research; Programmed cell death; Leukemia; Immunology; Cancer; CD8; Immune system; Gene; Genetics","score_opus":0.05794416019105975,"score_gpt":0.35355197102179325,"score_spread":0.2956078108307335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514206384","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0113821635,0.037706506,0.0016294146,0.89125276,0.036090177,0.00009678239,0.00015636928,0.000483744,0.021202179],"genre_scores_gemma":[0.13503008,0.044508796,0.002281994,0.6819287,0.0940995,0.000193073,0.00019935914,0.00011208265,0.04164642],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993218,0.0001527546,0.00006485232,0.00007561224,0.0002701634,0.00011489437],"domain_scores_gemma":[0.99911803,0.00045671372,0.00006821714,0.00007146286,0.00015361492,0.00013185023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107318,0.00058247626,0.00062960404,0.00034940962,0.00070361834,0.0011163115,0.0005452392,0.0069687106,0.0031540946],"category_scores_gemma":[0.0035388833,0.00023887468,0.00060872827,0.00017597195,0.0010188381,0.0012198084,0.00068517495,0.011049398,0.0044333125],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034983526,0.00026510598,0.0012470651,0.00035608528,0.00005556332,0.004544486,0.0001367964,0.0004395792,0.009416061,0.01554961,0.7510037,0.21663615],"study_design_scores_gemma":[0.0004459534,0.000558928,0.001253462,0.00033604016,0.000038662147,0.006610634,0.00013067566,0.0009556005,0.004521319,0.021855237,0.9632646,0.000028898594],"about_ca_topic_score_codex":0.00038232855,"about_ca_topic_score_gemma":0.00094287744,"teacher_disagreement_score":0.0069687106,"about_ca_system_score_codex":0.001686575,"about_ca_system_score_gemma":0.00071289565,"threshold_uncertainty_score":0.012237012},"labels":[],"label_agreement":null},{"id":"W2514926023","doi":"10.1097/cji.0000000000000134","title":"Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns","year":2016,"lang":"en","type":"review","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Suicide gene; Cancer immunotherapy; Immune system; Cancer; Antigen; Cancer cell; Medicine; Cancer research; Haematopoiesis; Immunology; Genetic enhancement; Biology; Stem cell; Internal medicine; Gene","score_opus":0.04820959936286296,"score_gpt":0.38546702949439904,"score_spread":0.3372574301315361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514926023","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002468073,0.99733365,0.00063058274,0.00029027558,0.00012420387,0.000010655951,0.000007888703,0.000010091816,0.0013458931],"genre_scores_gemma":[0.0014630884,0.9962442,0.0009425819,0.00023499994,0.00010602555,0.000015471023,0.000016640273,0.000003623714,0.00097342924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997205,0.000052286643,0.000028119883,0.00003842579,0.00013962026,0.000020897021],"domain_scores_gemma":[0.9997284,0.00014726268,0.000035234643,0.000014606142,0.00005457732,0.000019896981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092238013,0.00077634695,0.0011329046,0.0022874845,0.00030309416,0.0011143363,0.00080616504,0.0013661478,0.002431186],"category_scores_gemma":[0.00062440423,0.00029082442,0.00052536774,0.0016653563,0.00083459826,0.0015221302,0.0007625003,0.002491412,0.0016782106],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042936594,0.0001390318,0.00015070244,0.0131980805,0.000069192174,0.00023816283,0.00011822263,0.0006185273,0.012160428,0.016056145,0.013656118,0.9435524],"study_design_scores_gemma":[0.000016008467,0.00010436742,0.0003410513,0.0016794164,0.000051487314,0.0012684548,0.00005455416,0.00012478417,0.0035369254,0.0031103238,0.98969567,0.000016956934],"about_ca_topic_score_codex":0.0005564542,"about_ca_topic_score_gemma":0.00090506783,"teacher_disagreement_score":0.002431186,"about_ca_system_score_codex":0.0006390699,"about_ca_system_score_gemma":0.0008408805,"threshold_uncertainty_score":0.008133113},"labels":[],"label_agreement":null},{"id":"W2517307419","doi":"10.1016/j.exphem.2016.06.221","title":"Stroma-free, serum-free differentiation and expansion of hematopoietic progenitors to the T cell lineage","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Progenitor cell; CD34; Biology; Haematopoiesis; Stromal cell; Molecular biology; Cell biology; T cell; CD8; CD38; CD3; Stem cell; Immunology; Antigen; Cancer research; Immune system","score_opus":0.016806643182092774,"score_gpt":0.3026090281807192,"score_spread":0.2858023849986264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517307419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98354936,0.0016804581,0.0066201864,0.00009070822,0.00004286355,0.000106797066,0.0008425311,0.00010978334,0.0069573186],"genre_scores_gemma":[0.9877666,0.00060973584,0.0048885746,0.000063938016,0.0000147886085,0.000055327357,0.0013734269,0.0000482433,0.005179313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998678,0.00003463057,0.000015561007,0.000019563066,0.000032636577,0.00002970914],"domain_scores_gemma":[0.9999167,0.000026774276,0.000012968499,0.000013307132,0.000009129013,0.000021085814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019659572,0.00019033291,0.00016433503,0.00019569354,0.00014039857,0.000247243,0.0002457743,0.00018883814,0.0024982176],"category_scores_gemma":[0.00013996908,0.00011272158,0.00014674159,0.00024556092,0.0001215828,0.0001288983,0.00028407344,0.0005259637,0.0004573757],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005310175,0.000090790825,0.00032893877,0.000047888774,0.0000054605043,0.000089615234,0.00003651653,0.00025626476,0.99502397,0.00036527478,0.00020894608,0.0030153228],"study_design_scores_gemma":[0.000060403494,0.00022505313,0.0018924435,0.000005791879,0.000011984641,0.00018696139,0.000011790017,0.00090988236,0.9922139,0.000054899177,0.0044243783,0.000002519997],"about_ca_topic_score_codex":0.0006592847,"about_ca_topic_score_gemma":0.0018311641,"teacher_disagreement_score":0.0024982176,"about_ca_system_score_codex":0.00013291792,"about_ca_system_score_gemma":0.00031467187,"threshold_uncertainty_score":0.008357346},"labels":[],"label_agreement":null},{"id":"W2524917460","doi":"10.1016/j.cell.2016.08.032","title":"Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells","year":2016,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Biology; Suppressor; Lymphoma; Cancer research; Cell biology; Immunology; Genetics; Gene","score_opus":0.018274862974997697,"score_gpt":0.26503782767556433,"score_spread":0.24676296470056663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524917460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956434,0.0006571912,0.0018992237,0.00009570716,0.00004424895,0.000027642818,0.00017558123,0.00017012577,0.0012868003],"genre_scores_gemma":[0.99756277,0.000107680615,0.00057001243,0.000018797742,0.00000983068,0.000019651641,0.00014411088,0.000029750674,0.0015374266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995053,0.000109744,0.00004256181,0.000075883305,0.000084268926,0.00018227832],"domain_scores_gemma":[0.9997892,0.000061280574,0.000048400794,0.00003828146,0.000011170371,0.000051692372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035617145,0.0004299843,0.00039582452,0.00054116343,0.00027205964,0.00064938253,0.0005660213,0.00072889245,0.0023499306],"category_scores_gemma":[0.000265458,0.00028083628,0.00035746256,0.00022738999,0.0007835735,0.00051048875,0.000352728,0.0016015025,0.0004747633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006010656,0.00018808332,0.00024577286,0.00003439084,0.0000117625195,0.00016408032,0.000049280367,0.00029986343,0.99508286,0.001076434,0.000093167335,0.0021532604],"study_design_scores_gemma":[0.000085145046,0.0006335051,0.0011185341,0.0000032501239,0.000022942328,0.00050678203,0.000045218556,0.0016515711,0.99358964,0.00015425704,0.0021831123,0.000005919398],"about_ca_topic_score_codex":0.0006349071,"about_ca_topic_score_gemma":0.0005333908,"teacher_disagreement_score":0.0023499306,"about_ca_system_score_codex":0.00036121072,"about_ca_system_score_gemma":0.0002743278,"threshold_uncertainty_score":0.007861316},"labels":[],"label_agreement":null},{"id":"W2531414011","doi":"10.1182/blood.v110.11.579.579","title":"Targeted ‘Off-the-Shelf’ Tumor Immunotherapy Using Allogeneic T-Cell Precursors.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adoptive cell transfer; Cytotoxic T cell; Immunology; Cancer research; T cell; Major histocompatibility complex; Biology; Antigen; Immunotherapy; Chimeric antigen receptor; Transplantation; Stem cell; Immune system; Medicine; Cell biology; In vitro; Internal medicine","score_opus":0.024396877895186513,"score_gpt":0.3006860082770211,"score_spread":0.27628913038183456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531414011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821222,0.0016952062,0.011925434,0.000077460085,0.00011330295,0.00012053632,0.00026403234,0.00019893632,0.0034828333],"genre_scores_gemma":[0.9911876,0.00062264164,0.005052455,0.000052375362,0.000019839481,0.00005509228,0.00036834314,0.00002274842,0.0026189268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990463,0.000014915883,0.000007648156,0.000026506152,0.000029494353,0.000016903248],"domain_scores_gemma":[0.9999521,0.000005816023,0.000014289219,0.000008863996,0.000006101281,0.00001279826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008477013,0.00029872387,0.00014872896,0.000110990906,0.000066646324,0.00024640805,0.00019522743,0.00026650075,0.0011887143],"category_scores_gemma":[0.00007239393,0.00006988163,0.00012068497,0.000080251535,0.0000936896,0.00014822041,0.00014169616,0.00053671846,0.0005003018],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009182099,0.00008571376,0.00019102186,0.00003964931,0.000003295664,0.000059838705,0.000009686994,0.00011477778,0.99456465,0.00014647341,0.000075394375,0.004617693],"study_design_scores_gemma":[0.000027739163,0.0009054066,0.0011793349,0.000008440916,0.00003015601,0.00060527894,0.000011690653,0.0011057226,0.99089885,0.00007212289,0.0051529,0.0000023911775],"about_ca_topic_score_codex":0.00007472392,"about_ca_topic_score_gemma":0.00010343073,"teacher_disagreement_score":0.0011887143,"about_ca_system_score_codex":0.00006156295,"about_ca_system_score_gemma":0.00011610696,"threshold_uncertainty_score":0.0039767027},"labels":[],"label_agreement":null},{"id":"W2531711809","doi":"10.1182/blood.v120.21.3625.3625","title":"SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Leukemia; Stem cell; Cancer; Immunology; Biology","score_opus":0.018398359243683517,"score_gpt":0.27549451968944527,"score_spread":0.2570961604457618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531711809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989291,0.0004786589,0.00009598977,0.00003896076,0.000004879041,0.000048388498,0.000060592836,0.000014515926,0.00032889526],"genre_scores_gemma":[0.9988574,0.0002699462,0.00032966703,0.000064284926,0.000023658442,0.000048611564,0.00020592434,0.0000017991057,0.0001987579],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99989724,0.000030086527,0.000008445313,0.000020360494,0.000020173286,0.000023729304],"domain_scores_gemma":[0.999795,0.000036651607,0.000050873787,0.000009934984,0.000007798832,0.000099805526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030213114,0.00028043386,0.00062057487,0.00025070013,0.00017363003,0.00021655293,0.00016330284,0.00018423215,0.001042529],"category_scores_gemma":[0.00027321247,0.00012487441,0.00018913925,0.00020021609,0.00022699141,0.00020151153,0.0001624403,0.00036204656,0.00019130559],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12227381,0.011664868,0.22494757,0.00046276432,0.00044582857,0.0016598934,0.000495689,0.0032821572,0.31475344,0.00042248136,0.00281746,0.31677407],"study_design_scores_gemma":[0.055250127,0.35191444,0.5049569,0.0000704226,0.0007840023,0.004526203,0.00020901613,0.0063992674,0.062466677,0.0003783061,0.012994071,0.000050558658],"about_ca_topic_score_codex":0.00031935307,"about_ca_topic_score_gemma":0.0008978383,"teacher_disagreement_score":0.001042529,"about_ca_system_score_codex":0.0002998824,"about_ca_system_score_gemma":0.00044557443,"threshold_uncertainty_score":0.003487587},"labels":[],"label_agreement":null},{"id":"W2534178318","doi":"10.1016/j.it.2016.09.008","title":"T Cell Genesis: In Vitro Veritas Est ?","year":2016,"lang":"en","type":"review","venue":"Trends in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Immunotherapy; Cancer immunotherapy; Immune system; Immunology; Chimeric antigen receptor; Haematopoiesis; Biology; Progenitor cell; Induced pluripotent stem cell; Antigen; Cell therapy; Stem cell; Cancer research; Antigen-presenting cell; T cell; Cell biology; Embryonic stem cell","score_opus":0.06661487666658868,"score_gpt":0.3849451041923543,"score_spread":0.3183302275257656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534178318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015518525,0.9966414,0.00030391393,0.00104813,0.00076880836,0.00000420858,0.000016387756,0.000006843915,0.0010551168],"genre_scores_gemma":[0.0019293373,0.99452025,0.00041766866,0.0009565917,0.0010888028,0.000015400863,0.000045215696,0.0000034058592,0.001023443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99953353,0.00013625619,0.000049083814,0.00007777902,0.00013205282,0.00007138589],"domain_scores_gemma":[0.9992918,0.0003755173,0.00007357199,0.0000397077,0.00015903011,0.00006031257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018148558,0.001066862,0.002139639,0.0008440921,0.00034057183,0.0025695907,0.0015248894,0.0023900375,0.0050760284],"category_scores_gemma":[0.0014243461,0.00036872775,0.000641616,0.0007796004,0.0013191389,0.0029160897,0.0010667894,0.0038760498,0.0034909372],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026959836,0.00015242785,0.0004228127,0.011881219,0.00011358653,0.00040422252,0.00012162475,0.00045668453,0.0059764464,0.018880174,0.055671554,0.90564966],"study_design_scores_gemma":[0.00004121793,0.00015550114,0.00031394695,0.0025455202,0.0001156466,0.0010205272,0.00012568773,0.00013256914,0.0019069114,0.0050519253,0.98857075,0.000019740324],"about_ca_topic_score_codex":0.0005587267,"about_ca_topic_score_gemma":0.0009606933,"teacher_disagreement_score":0.0050760284,"about_ca_system_score_codex":0.00079880795,"about_ca_system_score_gemma":0.001534912,"threshold_uncertainty_score":0.016981006},"labels":[],"label_agreement":null},{"id":"W2536114475","doi":"10.3791/54697","title":"Generating &lt;em&gt;De Novo&lt;/em&gt; Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain","year":2016,"lang":"en","type":"article","venue":"Journal of Visualized Experiments","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Princess Margaret Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Ontario Institute for Cancer Research","keywords":"T-cell receptor; Antigen; Biology; Transduction (biophysics); Cell biology; T cell; Chimeric antigen receptor; Cloning (programming); Computational biology; Molecular biology; Immunology; Immune system; Computer science; Biochemistry","score_opus":0.0315232736830054,"score_gpt":0.3764037305717227,"score_spread":0.3448804568887173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536114475","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7075103,0.0015052574,0.27593344,0.0002985939,0.00023897924,0.00072822545,0.0025182224,0.0016337965,0.009633206],"genre_scores_gemma":[0.876492,0.0014696678,0.09334004,0.0001781351,0.000039327275,0.00034704362,0.0041628024,0.00052858435,0.023442397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997923,0.000038607777,0.0000177499,0.000047254674,0.000061942425,0.000042097134],"domain_scores_gemma":[0.99985766,0.00002433452,0.000040812898,0.00003312921,0.00002052904,0.000023564984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037870216,0.00049725996,0.00028698758,0.000302402,0.00016595428,0.00048691378,0.0005712547,0.00042029185,0.0022353216],"category_scores_gemma":[0.00021033725,0.00031434474,0.00027722947,0.00030708013,0.0002738715,0.00027159188,0.00037308896,0.00097069674,0.0013849621],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000068076915,0.000039069837,0.00010952726,0.00003982002,0.000009879193,0.00006438186,0.000025911384,0.0003751953,0.9938147,0.0011158062,0.0002624575,0.004075129],"study_design_scores_gemma":[0.000013283764,0.00007379662,0.00032064776,0.0000036058307,0.000013656157,0.00010157763,0.000009672055,0.001163517,0.9872218,0.00007664024,0.0109978765,0.0000039627544],"about_ca_topic_score_codex":0.00057705515,"about_ca_topic_score_gemma":0.0009248195,"teacher_disagreement_score":0.0022353216,"about_ca_system_score_codex":0.00043953088,"about_ca_system_score_gemma":0.00032067776,"threshold_uncertainty_score":0.0074778795},"labels":[],"label_agreement":null},{"id":"W2536860185","doi":"10.1182/blood.v114.22.620.620","title":"Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"BCL6; Diffuse large B-cell lymphoma; Germinal center; Tissue microarray; Gene expression profiling; Cancer research; Biology; Lymphoma; Molecular biology; B cell; Immunohistochemistry; Computational biology; Gene expression; Gene; Antibody; Genetics; Immunology","score_opus":0.03007597998786294,"score_gpt":0.30898896765822115,"score_spread":0.2789129876703582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536860185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946773,0.0008774793,0.0037828994,0.000027043114,0.000007205348,0.00008322124,0.00019462875,0.000019773734,0.00033049798],"genre_scores_gemma":[0.9945679,0.0004357487,0.0039615873,0.00004965315,0.000008956266,0.00005790859,0.00062879146,0.000018519926,0.000270971],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990695,0.00035252364,0.00005648301,0.00023128568,0.00022941883,0.00006091953],"domain_scores_gemma":[0.9989397,0.00048114272,0.00014085963,0.00017240894,0.00019750692,0.00006828111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024406791,0.0003798152,0.00040579538,0.0010217436,0.00024508307,0.00043468413,0.0002961818,0.00046543218,0.000563045],"category_scores_gemma":[0.0020059186,0.00038984328,0.00029689254,0.0005137679,0.0005985344,0.00028373537,0.0002507556,0.00041302544,0.00045955775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052449354,0.0012987005,0.43030125,0.00023381144,0.0003405892,0.0013662907,0.0010181279,0.00056717626,0.50095,0.00014921083,0.00039965747,0.05813022],"study_design_scores_gemma":[0.00034198313,0.0051835915,0.9031956,0.000021218699,0.0005134725,0.00794734,0.0005154158,0.005588397,0.07320843,0.00014881096,0.0032915291,0.0000442153],"about_ca_topic_score_codex":0.0021213596,"about_ca_topic_score_gemma":0.0017439256,"teacher_disagreement_score":0.0024406791,"about_ca_system_score_codex":0.00028374913,"about_ca_system_score_gemma":0.00014980783,"threshold_uncertainty_score":0.012907684},"labels":[],"label_agreement":null},{"id":"W2538054564","doi":"10.1017/cjn.2016.367","title":"PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; McMaster University","funders":"","keywords":"CD3; Cancer research; Antigen; Cytotoxic T cell; Medicine; Antibody; Cytotoxicity; T cell; Immunotherapy; Immunology; In vitro; Biology; CD8; Immune system","score_opus":0.06129883404073664,"score_gpt":0.3289810666139488,"score_spread":0.26768223257321216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538054564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880483,0.0023969475,0.003824061,0.00032964192,0.00013079427,0.0005933215,0.0010716359,0.00015002032,0.0034552817],"genre_scores_gemma":[0.9894281,0.0019956643,0.002792564,0.00022750841,0.000027537617,0.000495194,0.0017224657,0.000028619548,0.0032823898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980897,0.00004228324,0.000009367246,0.00002510892,0.00005091536,0.000063317464],"domain_scores_gemma":[0.99990904,0.000012728621,0.0000127145595,0.000008946143,0.000020170368,0.000036399542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047483435,0.00061708945,0.0005462512,0.00026910892,0.00016842569,0.00049920235,0.00042617356,0.00053406786,0.0019489994],"category_scores_gemma":[0.00018687447,0.00022576113,0.00037456932,0.0001840013,0.00020860226,0.00022360602,0.00020425474,0.0020270285,0.0005079826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014030761,0.0042934166,0.00038616176,0.00035860232,0.000076205644,0.00015926409,0.00011705738,0.003034689,0.97667366,0.0004729826,0.0015011772,0.011523622],"study_design_scores_gemma":[0.0011918254,0.060495142,0.003713108,0.000058231326,0.00019332721,0.00075368833,0.00012084523,0.0058885724,0.91300255,0.00029459037,0.014263248,0.0000249826],"about_ca_topic_score_codex":0.00092939776,"about_ca_topic_score_gemma":0.0018850053,"teacher_disagreement_score":0.0019489994,"about_ca_system_score_codex":0.00033660638,"about_ca_system_score_gemma":0.00055289164,"threshold_uncertainty_score":0.0065200925},"labels":[],"label_agreement":null},{"id":"W2539531174","doi":"10.1016/j.jtho.2016.09.008","title":"ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Clinical trial; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Immunotherapy; Cancer","score_opus":0.027884889969543695,"score_gpt":0.41439323166111675,"score_spread":0.38650834169157305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539531174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878457,0.0041788286,0.00020789937,0.00075881905,0.00025157986,0.0001882475,0.0015334297,0.00021538988,0.0048201494],"genre_scores_gemma":[0.9919991,0.0013099675,0.0002745883,0.00054874184,0.00011760443,0.00009789356,0.0015487808,0.00004124601,0.004062166],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997948,0.000050394272,0.00001480771,0.000040815587,0.00003798402,0.000061245395],"domain_scores_gemma":[0.9997167,0.000059352136,0.000056735076,0.00003422168,0.000020613994,0.00011235763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005737328,0.0003807095,0.0009936151,0.00030207064,0.00024958138,0.0011988841,0.0006179555,0.0008316043,0.008694057],"category_scores_gemma":[0.00071808044,0.00024017112,0.00079612015,0.00023785359,0.00037421027,0.0005956733,0.00023649947,0.0022440613,0.0014543004],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24425928,0.016319087,0.013184037,0.0015164104,0.0015103753,0.0005696276,0.00019285624,0.002421005,0.08255983,0.0010708622,0.022584282,0.61381227],"study_design_scores_gemma":[0.31869873,0.38550565,0.11742133,0.000476979,0.0040862723,0.0034820852,0.0003121385,0.011887093,0.08702356,0.0009625887,0.06990495,0.00023862747],"about_ca_topic_score_codex":0.0012247995,"about_ca_topic_score_gemma":0.0029011723,"teacher_disagreement_score":0.008694057,"about_ca_system_score_codex":0.0009784824,"about_ca_system_score_gemma":0.0010505083,"threshold_uncertainty_score":0.029084504},"labels":[],"label_agreement":null},{"id":"W2543488039","doi":"10.1200/jco.2015.33.15_suppl.e14019","title":"ZW38, a bispecific CD3 x CD19 azymetric antibody to deplete human leukemic B cells by the “controlled” activation of T cells.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"CD19; Antibody; Blinatumomab; Antigen; T cell; Cancer research; Cytokine; Immune system; CD3; B cell; Cytotoxic T cell; Immunology; Molecular biology; Medicine; Biology; In vitro; CD8; Biochemistry","score_opus":0.2066256439881135,"score_gpt":0.5094023533349838,"score_spread":0.30277670934687034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2543488039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95686615,0.005090492,0.02353068,0.0003643258,0.000066283326,0.00043334978,0.00076256,0.0005302795,0.012355876],"genre_scores_gemma":[0.97128266,0.0021362428,0.018001484,0.00012335952,0.000017284683,0.00017649065,0.0008280321,0.00004218936,0.0073922575],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998982,0.000016266538,0.0000063271714,0.000021417063,0.000033837063,0.000023906865],"domain_scores_gemma":[0.99996126,0.00000418481,0.000016029495,0.000004033892,0.000005158177,0.000009413399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015131987,0.000572638,0.000104384795,0.0002611908,0.00008663676,0.00012194541,0.00035784685,0.00025148827,0.002263564],"category_scores_gemma":[0.00007434445,0.00012978395,0.00013838004,0.00012820106,0.00014559952,0.00020749457,0.00024922373,0.00034004723,0.00069024216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007322466,0.00003399581,0.00009732243,0.000045118166,0.0000048173893,0.000045872534,0.000008785881,0.0001463744,0.9933182,0.00026175112,0.00018967527,0.0057748696],"study_design_scores_gemma":[0.00006260579,0.00060339435,0.0006206059,0.0000069593502,0.000010826645,0.00049949595,0.000006100835,0.0009156762,0.98991746,0.00005206746,0.0073013925,0.0000034011841],"about_ca_topic_score_codex":0.00041077082,"about_ca_topic_score_gemma":0.0007108587,"teacher_disagreement_score":0.002263564,"about_ca_system_score_codex":0.00028899522,"about_ca_system_score_gemma":0.00020811435,"threshold_uncertainty_score":0.0075724125},"labels":[],"label_agreement":null},{"id":"W2545245164","doi":"10.1186/s13073-016-0369-x","title":"Approaches to modernize the combination drug development paradigm","year":2016,"lang":"en","type":"review","venue":"Genome Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Government of Ontario","keywords":"Precision medicine; Paradigm shift; Exploit; Drug development; Informatics; Medicine; Regulatory science; Transformative learning; Computer science; Drug discovery; Flexibility (engineering); Risk analysis (engineering); Computational biology; Data science; Bioinformatics; Drug; Biology; Psychology; Engineering; Pharmacology","score_opus":0.2797227624177357,"score_gpt":0.36757413963859303,"score_spread":0.08785137722085734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2545245164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024585184,0.9881499,0.002876862,0.0031360025,0.00041699514,0.000033889602,0.000027513635,0.000035347923,0.0050776773],"genre_scores_gemma":[0.0044613834,0.98572254,0.0048879725,0.0022697065,0.0005688611,0.00007758258,0.000060380306,0.000010890445,0.00194072],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992398,0.00022869573,0.00008663051,0.00012246327,0.00026310518,0.000059330046],"domain_scores_gemma":[0.9990528,0.0005754074,0.0001021076,0.00005293066,0.00016268752,0.000054078755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002317298,0.0010822074,0.0015202435,0.0025442785,0.00035539677,0.0019432063,0.0017383818,0.0019624047,0.0056185178],"category_scores_gemma":[0.0017610362,0.00046637192,0.0012077936,0.001493778,0.0015649721,0.0033146432,0.0014817457,0.0053987214,0.0027246366],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009854575,0.00016377283,0.00016644075,0.011287853,0.00021661351,0.0003932342,0.00014279263,0.0016808653,0.0019969528,0.06521087,0.025990102,0.89265203],"study_design_scores_gemma":[0.00004614568,0.00015446251,0.00022099899,0.0018032605,0.0000995004,0.0010147176,0.000052383646,0.0003196807,0.0006506185,0.016322773,0.97929037,0.000025111663],"about_ca_topic_score_codex":0.0010655654,"about_ca_topic_score_gemma":0.0018117238,"teacher_disagreement_score":0.0056185178,"about_ca_system_score_codex":0.0017565038,"about_ca_system_score_gemma":0.0020108798,"threshold_uncertainty_score":0.018795788},"labels":[],"label_agreement":null},{"id":"W2548887552","doi":"10.1158/2326-6066.imm2016-b079","title":"Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Antigen; Flow cytometry; Antibody; Population; Peripheral blood mononuclear cell; Immunophenotyping; Monoclonal antibody; Cancer research; Immunology; Medicine; Chimeric antigen receptor; Immunotherapy; Biology; In vitro; Immune system","score_opus":0.13215498967667308,"score_gpt":0.44975309362495114,"score_spread":0.31759810394827803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548887552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945328,0.0009255153,0.0013592307,0.00022636612,0.00014071338,0.00019338167,0.0007442776,0.00022557932,0.00165199],"genre_scores_gemma":[0.992374,0.0009408886,0.0014759897,0.00012318684,0.000040451603,0.0003219261,0.0012822861,0.000034027464,0.0034071172],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997261,0.00004606106,0.000021517902,0.0000467907,0.000059340862,0.00010010816],"domain_scores_gemma":[0.99987245,0.000015446505,0.0000202887,0.000017175267,0.000016881118,0.000057713954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003738646,0.00070537336,0.0008273973,0.0004991431,0.0002016232,0.00033661406,0.0004680248,0.0006964364,0.0019974273],"category_scores_gemma":[0.0001417079,0.00022559353,0.000487478,0.00029266352,0.00033556842,0.00031462868,0.00018846472,0.0020406127,0.00056596653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003986506,0.005568776,0.00019210845,0.00022475031,0.00006071364,0.00011832987,0.00009469504,0.00074647146,0.9763776,0.00035912753,0.001057104,0.011213787],"study_design_scores_gemma":[0.0007970295,0.054216165,0.0023576727,0.00002280221,0.00013006697,0.00021132799,0.000077714685,0.0033583294,0.93547404,0.00015957763,0.0031752966,0.00002006143],"about_ca_topic_score_codex":0.0016383849,"about_ca_topic_score_gemma":0.001313027,"teacher_disagreement_score":0.0019974273,"about_ca_system_score_codex":0.00031694566,"about_ca_system_score_gemma":0.00053169666,"threshold_uncertainty_score":0.006682098},"labels":[],"label_agreement":null},{"id":"W2551364694","doi":"10.1182/blood.v112.11.574.574","title":"Gamma Delta T Cells (GDTCs) to Eliminate Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia (CML) : A Pre-Clinical Model","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Minimal residual disease; Peripheral blood mononuclear cell; Medicine; Flow cytometry; clone (Java method); Molecular biology; Immunology; Concanavalin A; Immunophenotyping; Leukemia; Chemistry; Biology; In vitro","score_opus":0.049167904948384175,"score_gpt":0.3399301732050876,"score_spread":0.2907622682567034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551364694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845151,0.004082624,0.0054690526,0.0004239785,0.00011742738,0.00045119834,0.00042279603,0.00013204516,0.0043856986],"genre_scores_gemma":[0.99145484,0.0017464294,0.0030583355,0.00017633729,0.000053947344,0.00020823095,0.00053649873,0.0000153307,0.002750096],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99984944,0.00004611602,0.000010385109,0.000025249645,0.0000319113,0.000036857295],"domain_scores_gemma":[0.99992764,0.000020049438,0.000008021096,0.000012652394,0.000007925174,0.000023794022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039228887,0.00041870825,0.00028487897,0.00029132838,0.00014163388,0.00027351637,0.00033539283,0.0003953797,0.0015402267],"category_scores_gemma":[0.00016396142,0.00009694386,0.00019427242,0.00015018313,0.00030127482,0.00016167045,0.00024538283,0.0011437861,0.0005025053],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014257849,0.0014778647,0.00107163,0.00022673994,0.000013299647,0.00030655364,0.000080159574,0.0006822846,0.97740036,0.0008736011,0.0007724616,0.01566926],"study_design_scores_gemma":[0.0013609593,0.03748754,0.006858164,0.000099808625,0.000111417336,0.0037405435,0.00011346951,0.0051741432,0.9150584,0.0008066762,0.029173283,0.000015731246],"about_ca_topic_score_codex":0.00026642022,"about_ca_topic_score_gemma":0.0003188827,"teacher_disagreement_score":0.0015402267,"about_ca_system_score_codex":0.00019020989,"about_ca_system_score_gemma":0.00023082165,"threshold_uncertainty_score":0.0051525235},"labels":[],"label_agreement":null},{"id":"W2551609581","doi":"10.1097/mph.0000000000000703","title":"Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia; BC Children's Hospital; BC Cancer Agency","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Oncology; Lymphoma; Adverse effect; Internal medicine; Cancer; Refractory (planetary science); Progressive disease; Disease; Immunotherapy","score_opus":0.03797851027425286,"score_gpt":0.357507728957379,"score_spread":0.3195292186831261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551609581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92428535,0.06190146,0.0023620226,0.0026515494,0.00030539467,0.00010747161,0.00011360058,0.0001912743,0.008081804],"genre_scores_gemma":[0.9872177,0.009835442,0.0013046137,0.0006040354,0.00012495772,0.00002794791,0.000091704635,0.000019621642,0.00077386823],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998994,0.000035725476,0.00001337331,0.000010317009,0.000015756797,0.000025475709],"domain_scores_gemma":[0.99986947,0.00004120726,0.000024664949,0.0000071967584,0.000010987297,0.000046462024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019280316,0.0002272257,0.00045476478,0.00020262825,0.0003471781,0.00022995181,0.00019278201,0.00040555757,0.00045069476],"category_scores_gemma":[0.00039064072,0.00010342165,0.0002713817,0.00014702647,0.00022211394,0.00021801038,0.00020422398,0.000865167,0.00017857022],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004742398,0.0009650818,0.07599894,0.0019279936,0.0004417472,0.22372329,0.0016301472,0.005182391,0.07949007,0.002642649,0.013870656,0.5893846],"study_design_scores_gemma":[0.0028989455,0.016185658,0.12120488,0.0011889806,0.0010377984,0.5557365,0.0015015726,0.009267915,0.08131748,0.0025781197,0.2069894,0.00009273396],"about_ca_topic_score_codex":0.0009718006,"about_ca_topic_score_gemma":0.0038402283,"teacher_disagreement_score":0.0009718006,"about_ca_system_score_codex":0.00056231907,"about_ca_system_score_gemma":0.00046029693,"threshold_uncertainty_score":0.0040799975},"labels":[],"label_agreement":null},{"id":"W2552600182","doi":"10.1182/blood.v116.21.3298.3298","title":"Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Regimen; Stem cell; Oncology; Myeloid leukemia; Myelodysplastic syndromes; Phases of clinical research; Gastroenterology; Clinical trial; Pharmacology; Bone marrow; Biology","score_opus":0.031739725853460424,"score_gpt":0.33958333020650794,"score_spread":0.30784360435304753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552600182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708,0.0004590989,0.0003262957,0.00015127649,0.000018448907,0.00036592627,0.00028994007,0.000052718893,0.0012563197],"genre_scores_gemma":[0.9957164,0.00032334973,0.0008514822,0.00020954003,0.000054232834,0.00047254947,0.0010840119,0.000011677322,0.0012767661],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998555,0.000057568515,0.0000108624745,0.000021330783,0.000016276721,0.000038380073],"domain_scores_gemma":[0.9995764,0.00008889617,0.000079407146,0.00002765708,0.000016063517,0.00021163793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057995267,0.0007725164,0.0007798575,0.00018750058,0.00022110797,0.00032740945,0.0002869583,0.00049660675,0.0028562923],"category_scores_gemma":[0.00037240438,0.00016480344,0.00037511624,0.00016107714,0.00047608864,0.00031643902,0.00015338254,0.0013142363,0.0005111217],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48468488,0.049482413,0.039289903,0.0006321671,0.0008805209,0.000824014,0.00055959495,0.0060146353,0.19765896,0.00067322794,0.00779723,0.21150246],"study_design_scores_gemma":[0.23855306,0.6749063,0.04863754,0.00005176324,0.0003669946,0.0010335887,0.000080045495,0.0029132296,0.027406711,0.00033095473,0.005682619,0.000037185087],"about_ca_topic_score_codex":0.00035915428,"about_ca_topic_score_gemma":0.0010899288,"teacher_disagreement_score":0.0028562923,"about_ca_system_score_codex":0.00039423179,"about_ca_system_score_gemma":0.0005356388,"threshold_uncertainty_score":0.009555221},"labels":[],"label_agreement":null},{"id":"W2554791934","doi":"10.1182/blood.v106.11.3323.3323","title":"Functional and Molecular Analysis of Maturation of Thymocytes in Bcl10 or Malt1 Deficient Mice.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Biology; T-cell receptor; BCL10; Cell biology; CD8; T cell; Cytotoxic T cell; Negative selection; Transgene; Molecular biology; Immune system; Cancer research; Immunology; Lymphoma; In vitro; Genetics; Gene","score_opus":0.019880569465848454,"score_gpt":0.28697990934894885,"score_spread":0.2670993398831004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554791934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052787,0.0015627322,0.0040073297,0.0000903623,0.000036016452,0.000065205684,0.0018438296,0.00023853795,0.0016281557],"genre_scores_gemma":[0.98803586,0.0011541183,0.003300143,0.00005626995,0.000012731176,0.00008890883,0.0017802545,0.00015353676,0.005418124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997975,0.000020692774,0.00001855966,0.000055951376,0.00005746672,0.000049818893],"domain_scores_gemma":[0.9993911,0.00007222582,0.00020721155,0.000032742788,0.000050117225,0.00024656096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001595283,0.00063353166,0.00019000254,0.001043454,0.00019633665,0.00039978625,0.0003772421,0.0006497629,0.0033739307],"category_scores_gemma":[0.00019140869,0.00033527883,0.00030403677,0.0002760384,0.00030528344,0.00031137455,0.00025927788,0.0009114541,0.0011001576],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078957615,0.000015312413,0.00020267679,0.00001541139,0.0000019801726,0.000076105345,0.000009804141,0.000012927307,0.99919325,0.000030261386,0.000007220315,0.00035611482],"study_design_scores_gemma":[0.00004667757,0.00040423992,0.019196415,0.000020143452,0.000035390443,0.0020232024,0.00006844689,0.00074876135,0.9750392,0.00010888732,0.0022977656,0.000010873803],"about_ca_topic_score_codex":0.00052801165,"about_ca_topic_score_gemma":0.00064431195,"teacher_disagreement_score":0.0033739307,"about_ca_system_score_codex":0.00037789324,"about_ca_system_score_gemma":0.00013221976,"threshold_uncertainty_score":0.011286914},"labels":[],"label_agreement":null},{"id":"W2556774727","doi":"10.1101/085910","title":"Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapy","year":2016,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Tumor-infiltrating lymphocytes; Melanoma; Adoptive cell transfer; Ex vivo; CD8; Immunotherapy; Immunology; Cancer research; T cell; Phenotype; Medicine; Biology; Immune system; In vivo","score_opus":0.044921024017284754,"score_gpt":0.27885834531680154,"score_spread":0.23393732129951678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556774727","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4918163,0.0020752957,0.49704018,0.0005460794,0.00009567313,0.0003306717,0.0007883623,0.0007843913,0.0065229973],"genre_scores_gemma":[0.95238304,0.0008360924,0.04468164,0.000090527195,0.000017632117,0.00015836676,0.00020083111,0.00006847808,0.0015634025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998423,0.00004423156,0.000008228434,0.000030994997,0.000051656527,0.000022635457],"domain_scores_gemma":[0.999908,0.000026089823,0.000029030178,0.000014851392,0.00001060868,0.000011413203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044679278,0.00059814804,0.00034718655,0.00024795736,0.000086825414,0.00060423784,0.00031194327,0.0003127789,0.0016013347],"category_scores_gemma":[0.00029250592,0.00017001937,0.000310308,0.00015234342,0.00020581423,0.00031681513,0.0003313554,0.0007536483,0.00058386807],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015853526,0.00018815973,0.0013897972,0.00015095992,0.000029273038,0.00008141464,0.000030482428,0.08324037,0.8930504,0.0054290458,0.0004939616,0.015757568],"study_design_scores_gemma":[0.00006007517,0.0010972873,0.0010497984,0.00002683271,0.00006139503,0.00020420756,0.000031432817,0.33943698,0.6454673,0.0021256646,0.010416627,0.000022458085],"about_ca_topic_score_codex":0.00027978705,"about_ca_topic_score_gemma":0.0004373315,"teacher_disagreement_score":0.0016013347,"about_ca_system_score_codex":0.00035161924,"about_ca_system_score_gemma":0.00023611376,"threshold_uncertainty_score":0.005357027},"labels":[],"label_agreement":null},{"id":"W2557043878","doi":"10.1093/intimm/dxq141","title":"CTL-based immunotherapy (PP-109)","year":2010,"lang":"en","type":"article","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"CTL*; Immunotherapy; Virology; Immunology; Medicine; Computational biology; Biology; Immune system; CD8","score_opus":0.019425011160685346,"score_gpt":0.34029186535423345,"score_spread":0.3208668541935481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557043878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68879217,0.045297112,0.049034074,0.005457447,0.0038161397,0.0014971498,0.0015941699,0.002254396,0.20225725],"genre_scores_gemma":[0.89752835,0.0055576763,0.009057515,0.0019577334,0.00041396293,0.00043868026,0.0014270088,0.00008380671,0.083535254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998511,0.000035653127,0.0000071648583,0.00003641375,0.00003635414,0.00003332323],"domain_scores_gemma":[0.99996734,0.00000813009,0.000004708886,0.000004942938,0.0000040004634,0.0000108261665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015411233,0.0003808458,0.0002584466,0.000212274,0.00012507271,0.0004814195,0.00027153283,0.00072522927,0.0146207735],"category_scores_gemma":[0.00013962276,0.00009907334,0.0002871181,0.00014042655,0.00021076266,0.00022707021,0.00037817526,0.0015826299,0.005640951],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010415545,0.002290591,0.0011660159,0.00081424083,0.00012234613,0.0009977429,0.000115925955,0.00095091504,0.63919985,0.008314767,0.021567907,0.3234182],"study_design_scores_gemma":[0.0020075897,0.00936141,0.008152755,0.0004032934,0.00033066084,0.0100039365,0.00010947299,0.0076846164,0.5301008,0.003990534,0.42782933,0.000025570636],"about_ca_topic_score_codex":0.00013689582,"about_ca_topic_score_gemma":0.00024447884,"teacher_disagreement_score":0.0146207735,"about_ca_system_score_codex":0.00026156215,"about_ca_system_score_gemma":0.0002247022,"threshold_uncertainty_score":0.048911393},"labels":[],"label_agreement":null},{"id":"W2557455968","doi":"10.1182/blood.v118.21.3235.3235","title":"Development of a Novel Method for in Vitro Analysis of CD8 Thymocyte Selection and Maturation,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"CD8; Stromal cell; Biology; Thymocyte; Cell biology; T cell; T-cell receptor; Major histocompatibility complex; Immunology; Molecular biology; Cancer research; Immune system","score_opus":0.05900095867821804,"score_gpt":0.3447154979956255,"score_spread":0.2857145393174075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557455968","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.089643255,0.0032541493,0.89674133,0.00015344511,0.0003491454,0.00084933575,0.0018260636,0.0016498998,0.0055333227],"genre_scores_gemma":[0.17310312,0.0033380403,0.80345815,0.00017227833,0.000111579415,0.001986793,0.0055911606,0.00067840115,0.011560471],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99959224,0.00009204959,0.000051564184,0.0001072052,0.00011309009,0.00004385487],"domain_scores_gemma":[0.99965954,0.00009846079,0.000043622927,0.000076703436,0.00007185213,0.00004981325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050342554,0.0009028982,0.00040999815,0.0010114985,0.00035504103,0.0005189016,0.0006030578,0.00048232122,0.0032908455],"category_scores_gemma":[0.0003490675,0.00046446425,0.00036846107,0.00043016553,0.00022489746,0.0003159296,0.0004214417,0.001093305,0.003266549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012120948,0.000013885461,0.000037500904,0.000027656417,0.0000022540617,0.000015236823,0.0000060523735,0.000020554935,0.9977932,0.00006690865,0.000030843577,0.001973825],"study_design_scores_gemma":[0.000010691111,0.00011075107,0.0008615618,0.000014768035,0.000024109982,0.00025643036,0.000013036238,0.0016811974,0.98822194,0.00011256973,0.008685436,0.000007480943],"about_ca_topic_score_codex":0.00031579766,"about_ca_topic_score_gemma":0.0009252839,"teacher_disagreement_score":0.0032908455,"about_ca_system_score_codex":0.00021584917,"about_ca_system_score_gemma":0.00026484494,"threshold_uncertainty_score":0.011008918},"labels":[],"label_agreement":null},{"id":"W2559957079","doi":"10.1038/mtm.2016.74","title":"Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Cancer research; Haematopoiesis; Transduction (biophysics); Leukemia; Biology; Immunotherapy; Myeloid; Stem cell; Immunology; Medicine; Immune system; Cell biology","score_opus":0.11771135276962931,"score_gpt":0.464357905794052,"score_spread":0.3466465530244227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559957079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8868688,0.0010833397,0.09088847,0.000810104,0.0003181117,0.006571161,0.0052824887,0.0012641505,0.006913451],"genre_scores_gemma":[0.9555108,0.0009901958,0.03079149,0.00027700554,0.00007039583,0.0028024341,0.0042645936,0.00019891924,0.0050942055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990694,0.00033686732,0.000073080635,0.00011611864,0.00024719865,0.0001572548],"domain_scores_gemma":[0.99940276,0.00016245033,0.00007093804,0.00012913364,0.00015066916,0.00008409066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029038812,0.0008396111,0.00061611243,0.00037865524,0.00040883408,0.0009232892,0.00056367344,0.00055672077,0.0044859243],"category_scores_gemma":[0.0010178894,0.00023382127,0.00043818323,0.00026370306,0.0006457548,0.0003517909,0.00028667526,0.0019942815,0.0014164014],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070525386,0.0018158284,0.0009434739,0.00015888184,0.000025329524,0.00009788091,0.0002101495,0.0012717114,0.98308736,0.00069689256,0.0016384694,0.009348756],"study_design_scores_gemma":[0.00023898896,0.0067602205,0.0013064604,0.000021010228,0.0000424053,0.00026191093,0.000039512855,0.0017657278,0.9811195,0.0001313068,0.00830584,0.000007118492],"about_ca_topic_score_codex":0.00078399474,"about_ca_topic_score_gemma":0.0010463877,"teacher_disagreement_score":0.0044859243,"about_ca_system_score_codex":0.0005821355,"about_ca_system_score_gemma":0.0014526767,"threshold_uncertainty_score":0.015357375},"labels":[],"label_agreement":null},{"id":"W2559960264","doi":"10.1182/blood.v124.21.3717.3717","title":"Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; Child and Family Research Institute","funders":"","keywords":"Immune system; Antigen; Immunology; Biology; Chimeric antigen receptor; Leukemia; Epitope; Immunotherapy; Cancer research; T cell; Immune tolerance","score_opus":0.029530755368999295,"score_gpt":0.29937104822267463,"score_spread":0.26984029285367533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559960264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978529,0.0005134248,0.0009747054,0.00002704823,0.000006671484,0.000010151411,0.00010723176,0.000051413866,0.00045651555],"genre_scores_gemma":[0.99878365,0.00014543193,0.00030181394,0.000021732136,0.0000034853517,0.00000832589,0.00023893625,0.0000096848025,0.000486969],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983644,0.00003461143,0.000015877411,0.000022450226,0.000036677953,0.000053924927],"domain_scores_gemma":[0.9996239,0.00007007802,0.000120188095,0.00005716253,0.000031434043,0.00009717741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016756772,0.00024416158,0.00017912341,0.00016996394,0.00009568188,0.00031413534,0.00019975599,0.00024348809,0.0010380192],"category_scores_gemma":[0.00019595589,0.000101104866,0.00020537376,0.00010061301,0.00018855081,0.00014626216,0.00025447988,0.00054915407,0.0004744224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006821958,0.00002447378,0.00041783342,0.000011267073,0.000002913625,0.000042955115,0.0000065922445,0.000038828704,0.9985518,0.00006535809,0.000014680872,0.00075511297],"study_design_scores_gemma":[0.00004415528,0.0009307541,0.032368574,0.000013409315,0.000031886004,0.0010800654,0.00007593063,0.002208972,0.9604805,0.0001505916,0.0026079435,0.000007212965],"about_ca_topic_score_codex":0.00020548381,"about_ca_topic_score_gemma":0.00019822974,"teacher_disagreement_score":0.0010380192,"about_ca_system_score_codex":0.00015913208,"about_ca_system_score_gemma":0.000106740285,"threshold_uncertainty_score":0.003472507},"labels":[],"label_agreement":null},{"id":"W2562371662","doi":"10.1182/blood.v104.11.2538.2538","title":"Autologous Gamma-Delta T (GD-T) Cells in Acute Myeloid Leukemia (AML): Potential Immune Effector Cells for Minimal Disease?.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Immune system; Immunology; Myeloid; T cell; Medicine; Population; Cancer research; Flow cytometry","score_opus":0.00960392900285659,"score_gpt":0.2671208666193089,"score_spread":0.2575169376164523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562371662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663264,0.0013016606,0.0013000608,0.00010609572,0.000012754169,0.000025237632,0.000052746516,0.000024583014,0.0005442843],"genre_scores_gemma":[0.9985746,0.0002025113,0.0007431458,0.00004968076,0.000015035957,0.000010002456,0.000066060114,0.0000022303304,0.00033680056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999428,0.000017082937,0.000005253634,0.000012270419,0.000009997037,0.0000126134055],"domain_scores_gemma":[0.9999125,0.000033304463,0.000014653455,0.0000072544426,0.000007884016,0.000024369509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022020686,0.00015186901,0.00020124695,0.00016672733,0.00009393444,0.00024420835,0.000112559275,0.00023694344,0.0010274726],"category_scores_gemma":[0.00027826033,0.00006868823,0.00008945556,0.00008267294,0.00023043157,0.0001631461,0.00015279281,0.0002563557,0.00021586234],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010405496,0.00032332182,0.0691722,0.00026131197,0.00003517241,0.0016018838,0.00024100409,0.00055697,0.8541092,0.0007765157,0.0004770125,0.062039893],"study_design_scores_gemma":[0.0014588122,0.020262778,0.2882407,0.00008118309,0.00030118565,0.02242202,0.00040457785,0.0060793147,0.6427069,0.0027116674,0.015301137,0.000029764307],"about_ca_topic_score_codex":0.00017861705,"about_ca_topic_score_gemma":0.0001631035,"teacher_disagreement_score":0.0010274726,"about_ca_system_score_codex":0.00013055997,"about_ca_system_score_gemma":0.000092914306,"threshold_uncertainty_score":0.003437221},"labels":[],"label_agreement":null},{"id":"W2563072979","doi":"10.1016/s1525-0016(16)33457-8","title":"649. Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fibroblast growth factor receptor 4; Immunohistochemistry; Molecular biology; Cancer research; Biology; Fusion protein; Antibody; Receptor; Fibroblast growth factor receptor; Recombinant DNA; Immunology; Fibroblast growth factor; Gene","score_opus":0.026978972563908698,"score_gpt":0.29250451104614145,"score_spread":0.26552553848223276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563072979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97242546,0.0041905516,0.008773698,0.00041147738,0.00016359697,0.00045759292,0.00059547654,0.0003603975,0.012621678],"genre_scores_gemma":[0.9746731,0.0030991987,0.007995214,0.00023918725,0.00003956269,0.00033740493,0.0016665928,0.000030396837,0.011919386],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999267,0.000011041193,0.000005111751,0.000011419731,0.000021024942,0.000024761932],"domain_scores_gemma":[0.9999757,0.000003486142,0.0000041872704,0.0000019014839,0.0000074850964,0.000007212392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013882927,0.0003407164,0.00025067,0.00025680487,0.0001125245,0.00021269683,0.00019784209,0.00042037357,0.002375557],"category_scores_gemma":[0.000069181384,0.000110527886,0.00028502266,0.00008630191,0.00011674867,0.00011363893,0.00013163818,0.0003767517,0.0010989278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019652574,0.0002514197,0.00044938602,0.000106794585,0.000019944539,0.0001865213,0.00003155283,0.0003858902,0.97854555,0.00032754586,0.0007463307,0.018752545],"study_design_scores_gemma":[0.0005314629,0.0072044665,0.005954479,0.00003476441,0.00017782419,0.0018146578,0.000050156417,0.004492557,0.93543917,0.00019331739,0.0440917,0.000015369385],"about_ca_topic_score_codex":0.00072707736,"about_ca_topic_score_gemma":0.001175831,"teacher_disagreement_score":0.002375557,"about_ca_system_score_codex":0.00023623332,"about_ca_system_score_gemma":0.00023846143,"threshold_uncertainty_score":0.007946968},"labels":[],"label_agreement":null},{"id":"W2564086249","doi":"10.1158/1538-7445.am2015-ct226","title":"Abstract CT226: A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Leukapheresis; Ipilimumab; CD80; Immunotherapy; Immunology; Priming (agriculture); CD8; Cell therapy; Antigen-presenting cell; T cell; Antigen; Cytotoxic T cell; Internal medicine; Oncology; Immune system; CD40; In vitro; Cell; Stem cell; Biology","score_opus":0.17990204074965363,"score_gpt":0.4271268304117442,"score_spread":0.24722478966209058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564086249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961803,0.00040130728,0.00054192654,0.00013165186,0.00007714183,0.0011177363,0.00035663473,0.00004364133,0.001149575],"genre_scores_gemma":[0.9948789,0.00064401986,0.0008676394,0.00011237879,0.00013251045,0.0007791065,0.0006302554,0.000017409046,0.001937769],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996424,0.00013780281,0.000022245975,0.000058575915,0.000059989026,0.00007903553],"domain_scores_gemma":[0.9996617,0.00006179421,0.000038032642,0.000049447488,0.000024678222,0.00016442493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007580525,0.0011882059,0.0012542384,0.00044104582,0.0005820917,0.0006857707,0.00080922554,0.0007711308,0.0031413245],"category_scores_gemma":[0.000444981,0.00033385245,0.00083220715,0.00036205607,0.0006457705,0.0004516448,0.00028843014,0.0025550919,0.0009025356],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07303509,0.1561492,0.0022516511,0.0007350026,0.0004519057,0.0015477536,0.00067340815,0.0029261615,0.711872,0.00037299114,0.0015289477,0.048455965],"study_design_scores_gemma":[0.017676545,0.8937674,0.005501336,0.000021073332,0.0003323755,0.0007205781,0.000057409154,0.0009799888,0.07840149,0.000064297594,0.0024545852,0.000022988146],"about_ca_topic_score_codex":0.0019121979,"about_ca_topic_score_gemma":0.0021861817,"teacher_disagreement_score":0.0031413245,"about_ca_system_score_codex":0.00045042118,"about_ca_system_score_gemma":0.0010209812,"threshold_uncertainty_score":0.010508716},"labels":[],"label_agreement":null},{"id":"W2564655741","doi":"10.1016/s1525-0016(16)33216-6","title":"407. A Novel Rabbit Antibody-Derived, Anti-CD123 LV/CAR Construct for AML Immunotherapy","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Interleukin-3 receptor; Chimeric antigen receptor; Myelopoiesis; Cancer research; Immunotherapy; Haematopoiesis; Immunology; Immunotoxin; Antibody; Myeloid leukemia; Biology; Antigen; Cytotoxic T cell; Progenitor cell; Cancer immunotherapy; Monoclonal antibody; Stem cell; Immune system; Cell biology; In vitro","score_opus":0.026582898935742005,"score_gpt":0.327772995134769,"score_spread":0.301190096199027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564655741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8998342,0.0021532471,0.07833259,0.0006990563,0.00013648543,0.00048621654,0.0011287045,0.0011985858,0.016031016],"genre_scores_gemma":[0.94152504,0.0011194429,0.03681851,0.00024324439,0.00003547858,0.00029800794,0.0024273435,0.00023002237,0.017302828],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998429,0.000026766556,0.000012658635,0.000034838064,0.000048095924,0.000034695822],"domain_scores_gemma":[0.99994135,0.000008180711,0.000011374638,0.0000066009525,0.000010489707,0.000022071583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016480517,0.00038455447,0.00027558662,0.00026808714,0.0001898868,0.0003369769,0.00031811628,0.0005508187,0.003403442],"category_scores_gemma":[0.000107830834,0.00020372124,0.00033378816,0.00014119859,0.00020654908,0.00022447179,0.00024866193,0.00073582557,0.0018441649],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007157248,0.000057202473,0.00012806035,0.000035205147,0.000004447502,0.000055148077,0.000023839219,0.00015190017,0.99418616,0.0006303901,0.00023219977,0.0044237226],"study_design_scores_gemma":[0.000042456326,0.00031298038,0.0005576728,0.000006762464,0.000023613338,0.000408356,0.000008068248,0.0023641565,0.98040694,0.000085750486,0.015776351,0.0000069708367],"about_ca_topic_score_codex":0.0006129684,"about_ca_topic_score_gemma":0.0004904479,"teacher_disagreement_score":0.003403442,"about_ca_system_score_codex":0.00048143213,"about_ca_system_score_gemma":0.00034380078,"threshold_uncertainty_score":0.011385679},"labels":[],"label_agreement":null},{"id":"W2565750033","doi":"10.1007/978-3-319-48066-4_15","title":"Promising Immunotherapeutic Approaches in Clinical Trials","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Monoclonal antibody; Nivolumab; Ipilimumab; Clinical trial; Immunotherapy; Cancer; Pembrolizumab; Chimeric antigen receptor; Antibody; Immunology; Melanoma; Cancer immunotherapy; Antigen; Oncology; Cancer research; Internal medicine","score_opus":0.49952443829530163,"score_gpt":0.47340625695037064,"score_spread":0.02611818134493099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565750033","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017342115,0.5494148,0.031605776,0.02515556,0.013552751,0.00024169522,0.0005875342,0.00046976565,0.37723795],"genre_scores_gemma":[0.014289322,0.384137,0.025697112,0.020555995,0.005245283,0.00047064392,0.00073753094,0.00041358208,0.5484534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964774,0.00011442864,0.000018577666,0.000034120258,0.0001528394,0.000032245436],"domain_scores_gemma":[0.99960095,0.00025175945,0.00002018245,0.000024429499,0.000062545245,0.000040207895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017498895,0.0007614118,0.00055216963,0.00076756073,0.00040552468,0.0023993556,0.0007824133,0.0014357768,0.03549881],"category_scores_gemma":[0.0014151596,0.00031316828,0.00031523698,0.0006089018,0.00089331117,0.0027072448,0.0011323716,0.0035744826,0.0137296915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011794717,0.000111058725,0.000053447082,0.001053957,0.000013453616,0.00016405122,0.00013973206,0.0007712632,0.0038369833,0.112419605,0.28406012,0.5972584],"study_design_scores_gemma":[0.000021169182,0.000038374023,0.00004015696,0.00037612932,0.0000071710883,0.00024100771,0.000023692017,0.00017820757,0.000850047,0.029126395,0.9690911,0.000006568077],"about_ca_topic_score_codex":0.0003626573,"about_ca_topic_score_gemma":0.0013171379,"teacher_disagreement_score":0.03549881,"about_ca_system_score_codex":0.0011164215,"about_ca_system_score_gemma":0.0012463186,"threshold_uncertainty_score":0.11875528},"labels":[],"label_agreement":null},{"id":"W2567305346","doi":"10.7490/f1000research.1097361.1","title":"A clinical grade cell-based artificial APC, aAPC/mOKT3, for unbiased expansion of CD3+ lymphocytes","year":2014,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CD80; Biology; T cell; Molecular biology; Cancer research; Immunology; CD40; Cytotoxic T cell; In vitro; Immune system; Biochemistry","score_opus":0.09470279552810677,"score_gpt":0.39928785896147495,"score_spread":0.30458506343336816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567305346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8780095,0.0053536273,0.10325231,0.00060052366,0.00011995747,0.0009835236,0.0016610436,0.0011729063,0.008846645],"genre_scores_gemma":[0.9317616,0.0019155855,0.05820339,0.00019361915,0.000034266737,0.00035900855,0.0016255501,0.00010929232,0.005797615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997532,0.00004564265,0.00002477549,0.000051432457,0.00009795664,0.00002693425],"domain_scores_gemma":[0.9998703,0.000026291755,0.000025906858,0.000023468932,0.000024684547,0.000029344335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022486167,0.00030290554,0.0001619539,0.00031421141,0.00016642903,0.0003102243,0.00015572913,0.00033700533,0.0015864772],"category_scores_gemma":[0.00026056427,0.00010359033,0.00013704537,0.00022318876,0.00015806245,0.00013708431,0.00018632771,0.0006733715,0.0007320051],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060477007,0.000033102595,0.00028928506,0.00003237737,0.0000031861289,0.000041122737,0.0000101854175,0.000116542695,0.99422425,0.00015516212,0.00018189421,0.004852504],"study_design_scores_gemma":[0.000022850756,0.00021870207,0.0016889562,0.0000072323987,0.00001875092,0.0010106863,0.0000052727682,0.0012987219,0.9840582,0.000052775355,0.011613021,0.0000047937824],"about_ca_topic_score_codex":0.00030953268,"about_ca_topic_score_gemma":0.0007223643,"teacher_disagreement_score":0.0015864772,"about_ca_system_score_codex":0.00021511222,"about_ca_system_score_gemma":0.00035140995,"threshold_uncertainty_score":0.005307257},"labels":[],"label_agreement":null},{"id":"W2568716921","doi":"10.1182/blood.v120.21.3016.3016","title":"Discovering Optimal Targets for Adoptive T-Cell Immunotherapy of Leukemia.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Antigen; Immunology; Adoptive cell transfer; Immunotherapy; CD8; Transplantation; CTL*; Leukemia; Cancer research; Cancer immunotherapy; Minor histocompatibility antigen; Biology; T cell; Major histocompatibility complex; Immune system; Medicine; Internal medicine","score_opus":0.022728131410619568,"score_gpt":0.2976592045055155,"score_spread":0.2749310730948959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568716921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91821396,0.03729837,0.036641065,0.0009201919,0.0001373982,0.00046720039,0.0011335307,0.00031795126,0.0048702667],"genre_scores_gemma":[0.9456906,0.0118402485,0.037199747,0.00034333885,0.000065437125,0.00028645943,0.0014234915,0.00005199792,0.00309877],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988997,0.000023523868,0.000008037952,0.000018069086,0.000034523313,0.000025908554],"domain_scores_gemma":[0.9999398,0.0000120407885,0.000019503965,0.0000044442922,0.000011912512,0.000012275777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026150627,0.0003425982,0.00029762485,0.0003807723,0.00010239052,0.00044371648,0.0002116691,0.00037407814,0.0011507027],"category_scores_gemma":[0.00015506159,0.00014701161,0.00021405076,0.00026116715,0.000115395924,0.0004530773,0.00019510703,0.00052576297,0.00072040025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012510855,0.00007152945,0.0003781556,0.0001203443,0.000006832509,0.000029916207,0.000011739391,0.0005446819,0.9832011,0.00028394998,0.00018888665,0.01503786],"study_design_scores_gemma":[0.000111383,0.0019738195,0.0029458413,0.00004282378,0.000065895016,0.0002649435,0.00007023913,0.0048852554,0.9720987,0.00084542925,0.016684618,0.0000109624325],"about_ca_topic_score_codex":0.00012662675,"about_ca_topic_score_gemma":0.00029294632,"teacher_disagreement_score":0.0011507027,"about_ca_system_score_codex":0.00022887911,"about_ca_system_score_gemma":0.00017043279,"threshold_uncertainty_score":0.0038494468},"labels":[],"label_agreement":null},{"id":"W2570331680","doi":"10.1182/blood.v124.21.2490.2490","title":"Selective Depletion of Recipient-Alloreactive T-Cells While Retaining Viral-Specific and Memory T-Cells Enables Safe and Efficacious Haplo-Identical HSCT","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Immunology; Antigen; Cancer immunotherapy; Cancer research; Immunotherapy; Medicine; Biology; Immune system","score_opus":0.016833925913653618,"score_gpt":0.25102648556191937,"score_spread":0.23419255964826574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570331680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8540503,0.005530858,0.104235746,0.00033198376,0.00022552977,0.0005877029,0.0028803928,0.002476594,0.029680932],"genre_scores_gemma":[0.94453955,0.0023449496,0.035360634,0.00016996812,0.000043359956,0.00027046812,0.0018776252,0.000121493096,0.015271952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998425,0.000022555432,0.0000098580995,0.000035014185,0.00006616778,0.000023856843],"domain_scores_gemma":[0.9999491,0.000007552918,0.000017666498,0.000009342783,0.0000065122013,0.000009845808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016659907,0.00029975834,0.00016958077,0.00026345876,0.00012256864,0.00028596498,0.00024804886,0.0002779019,0.0042493944],"category_scores_gemma":[0.000097382945,0.00012534959,0.00014292599,0.00013741529,0.0001232256,0.0001914503,0.0001522107,0.0005032713,0.0024824373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004505236,0.000023028384,0.00007444664,0.000028692622,0.0000013194679,0.000023761195,0.0000045445236,0.000033999295,0.99645907,0.00016086425,0.00017539423,0.002969804],"study_design_scores_gemma":[0.00001303387,0.00043190827,0.0018920824,0.0000086745995,0.000009058674,0.00042111482,0.0000070170713,0.0004228352,0.98932856,0.00007176694,0.007390105,0.0000037016882],"about_ca_topic_score_codex":0.00006699896,"about_ca_topic_score_gemma":0.00012314503,"teacher_disagreement_score":0.0042493944,"about_ca_system_score_codex":0.000105175626,"about_ca_system_score_gemma":0.00011509262,"threshold_uncertainty_score":0.014215648},"labels":[],"label_agreement":null},{"id":"W2573216598","doi":"10.1007/s40265-017-0690-8","title":"Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies","year":2017,"lang":"en","type":"review","venue":"Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; CD19; Cell therapy; Immunology; Lymphoma; Chronic lymphocytic leukemia; B cell; Cancer research; Clinical trial; T cell; Leukemia; Antigen; Oncology; Stem cell; Internal medicine; Immune system; Biology; Antibody","score_opus":0.15225248355467466,"score_gpt":0.40610138065618046,"score_spread":0.2538488971015058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573216598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012129069,0.9982774,0.00019392346,0.0005125219,0.00022184382,0.0000031207842,0.000015381576,0.000007736282,0.00064673036],"genre_scores_gemma":[0.0008958114,0.997783,0.00020272087,0.0003913508,0.00021336516,0.0000051853594,0.000024112127,0.0000017377807,0.00048266814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998679,0.000021004447,0.000013714115,0.000026276,0.00005006999,0.00002098885],"domain_scores_gemma":[0.99969435,0.00017397372,0.000029453076,0.0000074199083,0.000064816515,0.00003003304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006753422,0.0006770713,0.0010441198,0.0011287217,0.00019654213,0.00094749214,0.0008118168,0.0011875893,0.0024298052],"category_scores_gemma":[0.00071958645,0.00020350651,0.00037501956,0.0010965922,0.0005781794,0.0014683659,0.00063016237,0.0025667555,0.0012571609],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011382066,0.00008628741,0.00012766459,0.0103993695,0.000070352566,0.0001812954,0.000044579698,0.0004709475,0.0028499665,0.006724565,0.038339827,0.9405914],"study_design_scores_gemma":[0.0000326363,0.00009869643,0.00027851446,0.0014656659,0.00007469326,0.0006952723,0.000034884717,0.000113769,0.0007742533,0.0020543705,0.99436486,0.000012378177],"about_ca_topic_score_codex":0.0008071955,"about_ca_topic_score_gemma":0.0018186545,"teacher_disagreement_score":0.0024298052,"about_ca_system_score_codex":0.0006392076,"about_ca_system_score_gemma":0.0009962778,"threshold_uncertainty_score":0.008128524},"labels":[],"label_agreement":null},{"id":"W2573460873","doi":"10.1136/jnnp-2016-315106.143","title":"OCRELIZUMAB IN PRIMARY PROGRESSIVE MS: THE ORATORIO STUDY","year":2016,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"","keywords":"Placebo; Medicine; Ocrelizumab; Clinical endpoint; Adverse effect; Internal medicine; Clinical trial; Surgery; Pathology; Rituximab","score_opus":0.019005072194279514,"score_gpt":0.3005907274350342,"score_spread":0.2815856552407547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573460873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85966855,0.11436619,0.00042304856,0.0028593945,0.00067724835,0.0011392824,0.004319527,0.00010158081,0.016445074],"genre_scores_gemma":[0.9589282,0.026047247,0.00074447895,0.004022735,0.00087106664,0.0011245684,0.0030475704,0.000030980667,0.005183199],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994821,0.00021021858,0.00003324419,0.00009003718,0.00007735589,0.00010713359],"domain_scores_gemma":[0.99933076,0.0001451612,0.00022254963,0.00006769242,0.000068955414,0.00016485118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021378307,0.00088779646,0.0014017532,0.00016501965,0.00022565117,0.0007447866,0.00052531937,0.0011118753,0.003738662],"category_scores_gemma":[0.0011574136,0.00019541757,0.001654191,0.0002885349,0.0003656489,0.00038652835,0.00030868014,0.0014180696,0.00062611303],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7479322,0.0036728713,0.016998671,0.011086374,0.007898167,0.0005592371,0.000354816,0.0011433767,0.01374253,0.0008014267,0.019895732,0.17591457],"study_design_scores_gemma":[0.7827073,0.093167916,0.07757739,0.001757669,0.010788407,0.0012637168,0.000120959194,0.0008945094,0.0017820416,0.000757963,0.029105313,0.00007675052],"about_ca_topic_score_codex":0.0012217759,"about_ca_topic_score_gemma":0.0021788576,"teacher_disagreement_score":0.003738662,"about_ca_system_score_codex":0.0005555575,"about_ca_system_score_gemma":0.0006366707,"threshold_uncertainty_score":0.012507081},"labels":[],"label_agreement":null},{"id":"W2575232561","doi":"10.1126/scitranslmed.aag2196","title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","year":2017,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"Ben and Catherine Ivy Foundation; National Cancer Institute; National Institute of Neurological Disorders and Stroke; Wellcome; Royal Society; Wellcome Trust","keywords":"Glioma; Cytotoxic T cell; Cancer research; Immunotherapy; Reporter gene; Medicine; Genetic enhancement; Gene; Pet imaging; Pathology; Immunology; Biology; Gene expression; Positron emission tomography; Immune system; Nuclear medicine; In vitro; Genetics","score_opus":0.04301497310250961,"score_gpt":0.3738410366915573,"score_spread":0.3308260635890477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575232561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97696346,0.0018534891,0.018516922,0.00022869796,0.000025711817,0.00004981234,0.00019119312,0.00022907647,0.0019415398],"genre_scores_gemma":[0.99097204,0.0007035066,0.0063581956,0.000034517452,0.000009822379,0.00003337837,0.0001511536,0.00003542904,0.0017019105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999068,0.000021704289,0.0000034727552,0.000019644369,0.000017147511,0.00003126902],"domain_scores_gemma":[0.99996793,0.000007738844,0.000009170371,0.000002947132,0.0000049362943,0.000007310379],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028318324,0.00036114253,0.00028788974,0.0002885613,0.000105905376,0.00026166238,0.00043728523,0.00050405,0.00062228745],"category_scores_gemma":[0.00016254922,0.00015988402,0.00017505954,0.000229501,0.00026331138,0.00030161766,0.0001810407,0.0003868151,0.00019448574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002854451,0.00005710159,0.00022167162,0.000067260495,0.000009029736,0.00022799504,0.00006343759,0.0010707299,0.99045664,0.0007769294,0.0002245241,0.006539326],"study_design_scores_gemma":[0.00005132964,0.0006411082,0.0012553697,0.0000072541225,0.000040948424,0.000710699,0.00004147697,0.009276642,0.9859847,0.00014740638,0.0018325533,0.000010530294],"about_ca_topic_score_codex":0.0038745978,"about_ca_topic_score_gemma":0.002152226,"teacher_disagreement_score":0.0038745978,"about_ca_system_score_codex":0.00050024147,"about_ca_system_score_gemma":0.00045303325,"threshold_uncertainty_score":0.007704079},"labels":[],"label_agreement":null},{"id":"W2578427280","doi":"10.1182/blood.v126.23.1355.1355","title":"Efficacy and Safety of Allogeneic Double Negative T Cell As a Cellular Therapy for AML and Its Underlying Mechanism","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chemotherapy; Myeloid leukemia; Leukemia; CD8; Minimal residual disease; Medicine; Immunology; Hematopoietic stem cell transplantation; Chemotherapy regimen; Transplantation; Haematopoiesis; Stem cell; Cancer research; Oncology; Internal medicine; Immune system; Biology","score_opus":0.08970118677423887,"score_gpt":0.3391773637705651,"score_spread":0.24947617699632624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578427280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516535,0.0027362464,0.0009962225,0.00004309786,0.000031425192,0.000055664113,0.00005940238,0.000017694008,0.00089494296],"genre_scores_gemma":[0.9985241,0.0006006167,0.0002690523,0.000029644667,0.000014882,0.000021290458,0.00008783358,0.0000014002154,0.0004512235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999187,0.00002334597,0.000007417689,0.00001790855,0.000021389376,0.000011285951],"domain_scores_gemma":[0.99994385,0.000013030825,0.000014407615,0.0000100642965,0.0000054560946,0.000013158705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001476887,0.00017901482,0.00024084235,0.000110683555,0.000092033115,0.00020884127,0.00011721595,0.00019288239,0.0005627504],"category_scores_gemma":[0.00012253429,0.000038982937,0.0001230658,0.00008996139,0.0002003899,0.000105915264,0.00008142182,0.00027782904,0.0001036856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005741915,0.0017438167,0.0058788545,0.00026724345,0.00004265082,0.00033799108,0.0000956079,0.0014978574,0.90841645,0.00090646214,0.00026828994,0.07480278],"study_design_scores_gemma":[0.00136133,0.08666449,0.034592632,0.000071723196,0.000251361,0.0037485878,0.00014279895,0.007910033,0.84424806,0.0007190465,0.020271696,0.000018320932],"about_ca_topic_score_codex":0.00015678893,"about_ca_topic_score_gemma":0.00017220025,"teacher_disagreement_score":0.0005627504,"about_ca_system_score_codex":0.00013466417,"about_ca_system_score_gemma":0.00016310193,"threshold_uncertainty_score":0.0018826127},"labels":[],"label_agreement":null},{"id":"W2579077000","doi":"10.1182/blood.v114.22.3580.3580","title":"PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Biology; Jurkat cells; Genetic enhancement; CD19; Gene delivery; T cell; Cell biology; Transgene; Viral vector; Transfection; Cell therapy; Ex vivo; Molecular biology; Flow cytometry; Immune system; In vivo; Gene; Stem cell; Immunology; Genetics; Recombinant DNA","score_opus":0.02661883014036972,"score_gpt":0.2510072339640696,"score_spread":0.22438840382369987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579077000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8744112,0.00887513,0.090756215,0.0012838872,0.00042133333,0.00053858216,0.00058627833,0.0006137796,0.022513587],"genre_scores_gemma":[0.956206,0.0021353995,0.017107593,0.00020695945,0.00004464625,0.0002076815,0.0005104302,0.00007651434,0.023504848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976844,0.00003732894,0.000013993041,0.000056426816,0.000065340435,0.00005857794],"domain_scores_gemma":[0.99992085,0.0000188439,0.00002309019,0.000009500301,0.000013733793,0.000013964925],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039875953,0.0003475709,0.00020806416,0.00021125434,0.00019484229,0.000543537,0.0002588908,0.00062606914,0.0024002816],"category_scores_gemma":[0.0001715444,0.00019305314,0.00023780095,0.0001485375,0.00031278367,0.00038155844,0.00025801724,0.000853686,0.000810397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009977324,0.00008185197,0.00009535712,0.000040199433,0.0000034378609,0.000039746406,0.000024314199,0.000115285446,0.9912464,0.0009415092,0.00026476575,0.007047437],"study_design_scores_gemma":[0.000024159426,0.0002604537,0.0003564155,0.000006089092,0.000012606956,0.00012897709,0.00000961441,0.001045956,0.9916047,0.00010124898,0.006445827,0.0000039079564],"about_ca_topic_score_codex":0.00041614703,"about_ca_topic_score_gemma":0.00042604315,"teacher_disagreement_score":0.0024002816,"about_ca_system_score_codex":0.00063784077,"about_ca_system_score_gemma":0.0004267002,"threshold_uncertainty_score":0.008029759},"labels":[],"label_agreement":null},{"id":"W2581462115","doi":"10.1172/jci.insight.89580","title":"Transient stimulation expands superior antitumor T cells for adoptive therapy","year":2017,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; National Institutes of Health; University of Toronto; National Cancer Institute; Princess Margaret Cancer Foundation","keywords":"CD28; Adoptive cell transfer; Cell therapy; CD8; Immunotherapy; Cytotoxic T cell; T cell; Immunology; Cancer research; Stimulation; Medicine; Chimeric antigen receptor; Antigen; Biology; Cell biology; Immune system; In vitro; Stem cell; Internal medicine","score_opus":0.07534149144604835,"score_gpt":0.3615606458141226,"score_spread":0.28621915436807427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581462115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817068,0.0020491853,0.013012857,0.00013359576,0.00005770396,0.00010587139,0.00028391293,0.00025187354,0.0023981202],"genre_scores_gemma":[0.99279845,0.00068310887,0.0050215544,0.00007453905,0.00002924157,0.00006713817,0.00028525112,0.00003642832,0.0010042483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997631,0.000050216993,0.000026155794,0.000037606773,0.00007000241,0.000053103387],"domain_scores_gemma":[0.9998599,0.00005158704,0.000024549956,0.000024093493,0.000014163145,0.000025577776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025190582,0.0003781756,0.00033222145,0.00025312885,0.00008590025,0.00050027674,0.00015565415,0.0003416644,0.00162703],"category_scores_gemma":[0.00018548466,0.00010717057,0.00021119474,0.00015609692,0.00015135825,0.0002681421,0.00029168636,0.0010261822,0.0005185231],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056627636,0.00008449492,0.00012346587,0.000021935706,0.0000037006798,0.000018626111,0.000013793837,0.00012881136,0.9968078,0.00010594571,0.000044062213,0.0025907143],"study_design_scores_gemma":[0.000033373253,0.00074138684,0.0016752059,0.000007800861,0.000041524538,0.0002060278,0.000014060631,0.001772743,0.9929969,0.00009946572,0.0024073585,0.0000042607467],"about_ca_topic_score_codex":0.000112932554,"about_ca_topic_score_gemma":0.00026308728,"teacher_disagreement_score":0.00162703,"about_ca_system_score_codex":0.00016935794,"about_ca_system_score_gemma":0.00016857783,"threshold_uncertainty_score":0.005442977},"labels":[],"label_agreement":null},{"id":"W2581473011","doi":"10.1182/blood.v114.22.3032.3032","title":"Superior Cytotoxicity of Clonal Versus Polyclonal Gamma Delta T Cells against Philadelphia Chromosome Positive and B-CLL Derived Leukemic Cells.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; Immunology; Flow cytometry; Molecular biology; Cancer research","score_opus":0.019217311547471562,"score_gpt":0.2717472288953481,"score_spread":0.2525299173478765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581473011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923684,0.00163591,0.0012015658,0.000051394007,0.000068101384,0.000048977687,0.0003393684,0.000092323244,0.004193973],"genre_scores_gemma":[0.9957147,0.0005148469,0.00071307144,0.000041957202,0.00004312466,0.00004888104,0.000613681,0.000015502552,0.002294181],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966156,0.00010265708,0.00004084519,0.000052205734,0.00007693318,0.00006571338],"domain_scores_gemma":[0.99959034,0.00020034412,0.000034803033,0.00006736085,0.00005598056,0.00005119517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044186495,0.00036446494,0.00039820682,0.0003091549,0.00011229341,0.00035083838,0.00023093063,0.00042279536,0.0030462197],"category_scores_gemma":[0.00038153987,0.00012559163,0.00019701607,0.00017737944,0.00013864564,0.00022841149,0.00024267692,0.0005912072,0.000696674],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017466022,0.00039641449,0.00086336234,0.00013188843,0.000013813138,0.000051597985,0.00004763013,0.0004133608,0.98004824,0.00019144137,0.00025496457,0.01584076],"study_design_scores_gemma":[0.00034417404,0.014715805,0.010897603,0.0000397831,0.000075825745,0.0007931203,0.00005318335,0.0032323084,0.96667475,0.00013513598,0.0030269471,0.000011336302],"about_ca_topic_score_codex":0.000301409,"about_ca_topic_score_gemma":0.00034692802,"teacher_disagreement_score":0.0030462197,"about_ca_system_score_codex":0.00014497251,"about_ca_system_score_gemma":0.00018500564,"threshold_uncertainty_score":0.010190606},"labels":[],"label_agreement":null},{"id":"W2583075130","doi":"10.1016/j.molmed.2016.12.004","title":"Cell-Based Therapeutics: Making a Faustian Pact with Biology","year":2017,"lang":"en","type":"article","venue":"Trends in Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Context (archaeology); Synthetic biology; Biology; Computational biology; Repurposing; Systems biology; Neuroscience; Computer science","score_opus":0.05970813121522932,"score_gpt":0.40620568239687505,"score_spread":0.3464975511816457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583075130","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047236187,0.28356147,0.066600464,0.5894831,0.020344645,0.00009308496,0.00019988505,0.00064689666,0.0343469],"genre_scores_gemma":[0.21078146,0.3243614,0.11067516,0.24956428,0.048032515,0.0005585576,0.00029748937,0.00080574624,0.054923393],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955499,0.0016284949,0.00021539484,0.00066802645,0.0016009787,0.00033723013],"domain_scores_gemma":[0.98588413,0.009142983,0.0006353101,0.0012318679,0.0018384717,0.0012671918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019578833,0.0020804636,0.0030818253,0.0026846728,0.0033828574,0.012731245,0.0029344242,0.009291775,0.012398747],"category_scores_gemma":[0.0122321,0.0008141083,0.0012488841,0.00088913064,0.032363873,0.035412993,0.008072424,0.026365725,0.004831117],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033795595,0.00034490795,0.0009987237,0.0013785942,0.00017393913,0.00037068175,0.0013244365,0.0015732362,0.005740139,0.62714016,0.12987381,0.23074347],"study_design_scores_gemma":[0.0001045948,0.0004329719,0.00043976295,0.00083450193,0.00007455546,0.00051744515,0.0009895115,0.0014454946,0.0036433232,0.48645726,0.5049489,0.00011168025],"about_ca_topic_score_codex":0.0014573816,"about_ca_topic_score_gemma":0.0022344869,"teacher_disagreement_score":0.019578833,"about_ca_system_score_codex":0.004514254,"about_ca_system_score_gemma":0.004741879,"threshold_uncertainty_score":0.103544},"labels":[],"label_agreement":null},{"id":"W2583613336","doi":"10.18632/oncotarget.15088","title":"Turn to TCRs when CARs fail","year":2017,"lang":"en","type":"letter","venue":"Oncotarget","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Computational biology; Neuroscience; Biology","score_opus":0.04420339295434641,"score_gpt":0.3412371811177224,"score_spread":0.297033788163376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583613336","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011617203,0.0028263154,0.0002974062,0.9654502,0.020902872,0.000019085099,0.000041284286,0.00009517883,0.009205921],"genre_scores_gemma":[0.023622993,0.0037974692,0.0007019589,0.8939869,0.055376586,0.00008315709,0.00007140505,0.0000624893,0.022297127],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985008,0.00036133546,0.00013430555,0.00015282867,0.00051196094,0.0003388641],"domain_scores_gemma":[0.99700963,0.0018240607,0.00019506057,0.00013362293,0.0003918447,0.00044575968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013887872,0.00069021055,0.0009742819,0.00051246496,0.0023316836,0.0034109273,0.00084380736,0.027472246,0.009315714],"category_scores_gemma":[0.014088205,0.00044485615,0.00095920253,0.00030670562,0.002182271,0.0025750287,0.0012987588,0.031305917,0.0081941355],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118357144,0.000064315114,0.00079744426,0.00006619067,0.00002409819,0.007189425,0.00011058684,0.00012856787,0.00079573307,0.008771833,0.947861,0.03407245],"study_design_scores_gemma":[0.00023689555,0.00016153608,0.00048499778,0.0002417783,0.000053900614,0.008931001,0.00033912883,0.00084976526,0.0014064639,0.032546453,0.9547042,0.000043916236],"about_ca_topic_score_codex":0.000981927,"about_ca_topic_score_gemma":0.0018245348,"teacher_disagreement_score":0.027472246,"about_ca_system_score_codex":0.0023911586,"about_ca_system_score_gemma":0.0015458475,"threshold_uncertainty_score":0.03116411},"labels":[],"label_agreement":null},{"id":"W2584913109","doi":"10.1172/jci89455","title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Peter MacCallum Cancer Centre","keywords":"Chimeric antigen receptor; Cancer research; Adenosine; T cell; CD8; Antigen; Adenosine A2A receptor; Immunology; Receptor; Chemistry; Medicine; Adenosine receptor; Biology; Pharmacology; Immune system; Internal medicine","score_opus":0.11478170529418573,"score_gpt":0.4295939475704932,"score_spread":0.31481224227630744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584913109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921644,0.0014699142,0.002654593,0.00014893054,0.00007224015,0.000082086546,0.00014997198,0.00017578523,0.0030821494],"genre_scores_gemma":[0.9960777,0.0005923281,0.0017640606,0.00006496799,0.00003502261,0.000046448335,0.0001227478,0.000020225312,0.0012765182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99958414,0.00010374757,0.000029044199,0.00004939812,0.00009955862,0.00013402764],"domain_scores_gemma":[0.9998485,0.000053541913,0.000027890736,0.000014397711,0.000016224642,0.00003950728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003970367,0.00039948203,0.00067598687,0.00037215985,0.00014589344,0.00055455783,0.00022753095,0.0004665189,0.0016431849],"category_scores_gemma":[0.00020800305,0.00013479442,0.00024762237,0.00020085856,0.00025290356,0.00037040265,0.0002507716,0.0010776925,0.00040793384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042167044,0.0005311714,0.0001624055,0.00007232574,0.000018187555,0.000054075073,0.000036924033,0.0005547605,0.9899156,0.00034997353,0.00029409013,0.0075889537],"study_design_scores_gemma":[0.00020873218,0.006333898,0.002387104,0.000010914641,0.000066693116,0.00022922405,0.000030663694,0.003298592,0.9827687,0.00009310337,0.004563765,0.0000086347445],"about_ca_topic_score_codex":0.00038401503,"about_ca_topic_score_gemma":0.0008864263,"teacher_disagreement_score":0.0016431849,"about_ca_system_score_codex":0.00030827985,"about_ca_system_score_gemma":0.00031648696,"threshold_uncertainty_score":0.0054969788},"labels":[],"label_agreement":null},{"id":"W2586528038","doi":"10.1016/s0923-7534(21)00568-8","title":"410P Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Melanoma; Adverse effect; Oncology; Metastatic melanoma; Retrospective cohort study; Confidence interval; Surgery; Immunotherapy; Cancer; Cancer research","score_opus":0.08230944959589033,"score_gpt":0.40613393726275415,"score_spread":0.32382448766686384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586528038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307936,0.00045404362,0.00011720362,0.00040247064,0.000012103962,0.000072123374,0.0010470047,0.000016659766,0.0047990214],"genre_scores_gemma":[0.9931994,0.0008152015,0.00017036768,0.00047624233,0.000008411758,0.00007232655,0.0010730112,0.000009126855,0.00417581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976593,0.000042114814,0.000016134123,0.000041496303,0.000062632396,0.0000716268],"domain_scores_gemma":[0.9996308,0.000047907666,0.000048176516,0.00002591758,0.0001288625,0.0001183907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004850035,0.00021346826,0.00023371942,0.00039606646,0.0005381805,0.0006018153,0.0004029113,0.00022565869,0.0021751772],"category_scores_gemma":[0.00052366935,0.00017385567,0.00022533425,0.0008240337,0.00027389007,0.00025240297,0.00033087019,0.0006196024,0.0006344017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021609848,0.0035870147,0.5437259,0.0002889702,0.0006148478,0.0024845982,0.0011626845,0.003704767,0.15227678,0.00089813164,0.012951617,0.25669476],"study_design_scores_gemma":[0.0013714967,0.0060475194,0.96830064,0.000058074344,0.00032666247,0.0007945589,0.0009988786,0.0018013349,0.010848092,0.00020500796,0.009192855,0.00005486567],"about_ca_topic_score_codex":0.4296563,"about_ca_topic_score_gemma":0.6617926,"teacher_disagreement_score":0.57034373,"about_ca_system_score_codex":0.005210458,"about_ca_system_score_gemma":0.0058361306,"threshold_uncertainty_score":0.85431087},"labels":[],"label_agreement":null},{"id":"W2587000238","doi":"10.1093/neuonc/now212.409","title":"IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; Cytotoxic T cell; Monoclonal antibody; Cancer research; Antibody; T cell; Glioma; Biology; Immunology; Immune system; In vitro","score_opus":0.05883081224816337,"score_gpt":0.37817687441619924,"score_spread":0.31934606216803585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587000238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97981536,0.0030486274,0.0034184188,0.0007215329,0.00042639882,0.0007225724,0.0036747977,0.0011008581,0.0070714313],"genre_scores_gemma":[0.97439945,0.0034090977,0.003391934,0.00032008364,0.00006717705,0.001552832,0.0052457284,0.00013133476,0.011482297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995988,0.00004680032,0.00003113384,0.000075700016,0.00008443031,0.00016315065],"domain_scores_gemma":[0.9998636,0.000010626902,0.000028035163,0.000018637158,0.000019529301,0.00005953752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005113298,0.0013489961,0.0014313149,0.0008304838,0.00033334264,0.000502851,0.000681003,0.00091216515,0.0032109057],"category_scores_gemma":[0.00015927765,0.0003708298,0.0009049101,0.0005032533,0.00045958709,0.00045384845,0.00026030478,0.002934861,0.00107862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004259419,0.0073128,0.00043734134,0.00048494156,0.00013074337,0.00029270342,0.00020353084,0.0012807763,0.9628524,0.00096391665,0.003285835,0.018495608],"study_design_scores_gemma":[0.0011488021,0.04323826,0.004413443,0.00006314771,0.00029580013,0.0005014932,0.00012558456,0.004156389,0.93545747,0.00031735512,0.010243108,0.000039148734],"about_ca_topic_score_codex":0.0034100278,"about_ca_topic_score_gemma":0.004132435,"teacher_disagreement_score":0.0034100278,"about_ca_system_score_codex":0.0006663021,"about_ca_system_score_gemma":0.0010313616,"threshold_uncertainty_score":0.010741532},"labels":[],"label_agreement":null},{"id":"W2587952432","doi":"10.1182/blood.v106.11.63.63","title":"Adoptive Transfer of In Vitro Generated T Cell Precursors Enhances Donor T Cell Reconstitution and Graft-Versus-Tumor Activity in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; Bone marrow; T cell; Transplantation; Immunology; CD8; Stromal cell; Lymphopoiesis; Adoptive cell transfer; Cancer research; Molecular biology; Cell biology; Antigen; Internal medicine; Immune system; Medicine","score_opus":0.021396971761077764,"score_gpt":0.2620470736761161,"score_spread":0.24065010191503836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587952432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99628264,0.000827938,0.0011507532,0.000049032307,0.00006409941,0.00006292529,0.00019120332,0.00012169408,0.0012497248],"genre_scores_gemma":[0.99601066,0.00058583124,0.0011726625,0.000045974375,0.000037552905,0.00005117345,0.00035059967,0.000025336443,0.0017201593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996828,0.00008726365,0.000030405434,0.000052057094,0.000067375244,0.00008016803],"domain_scores_gemma":[0.9996674,0.00006678693,0.000092937116,0.000038250382,0.000017200282,0.00011749754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029647222,0.0006741706,0.00039587962,0.0003974523,0.0001310959,0.00043020162,0.00033402693,0.00032377124,0.0014534703],"category_scores_gemma":[0.0001775991,0.0001651059,0.000291412,0.0001540772,0.00025668956,0.00025247183,0.00021566114,0.0014621301,0.0004403044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034885388,0.00053212966,0.000207658,0.00004408553,0.0000085124575,0.0000557448,0.000031063722,0.000101235215,0.996338,0.00008953953,0.0000726082,0.0021705765],"study_design_scores_gemma":[0.00009906394,0.003997188,0.0026525897,0.000018276014,0.000048842492,0.00024231501,0.000029289613,0.0011277312,0.9902712,0.0000376817,0.0014718918,0.000003914055],"about_ca_topic_score_codex":0.00023326524,"about_ca_topic_score_gemma":0.00038982788,"teacher_disagreement_score":0.0014534703,"about_ca_system_score_codex":0.00015102753,"about_ca_system_score_gemma":0.00015651603,"threshold_uncertainty_score":0.0048623085},"labels":[],"label_agreement":null},{"id":"W2592318296","doi":"10.1080/2162402x.2017.1299303","title":"Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma","year":2017,"lang":"en","type":"review","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Immune system; Medicine; Melanoma; Immune checkpoint; Adjuvant; Immunotherapy; Blockade; Immunology; Cancer research; Internal medicine; Receptor","score_opus":0.09316718438393705,"score_gpt":0.39413803994122476,"score_spread":0.3009708555572877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592318296","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008313057,0.99944395,0.000066223576,0.0001240442,0.000067145185,0.0000028121876,0.000011252378,0.0000029482717,0.00019836337],"genre_scores_gemma":[0.0012399878,0.9981116,0.00017956362,0.00012352965,0.00012223881,0.000007435631,0.000029678775,9.942797e-7,0.00018493489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996736,0.000077886354,0.000062088424,0.00005409156,0.00010994268,0.000022314814],"domain_scores_gemma":[0.99926656,0.0004230337,0.00011018505,0.000015818712,0.00015600797,0.000028387869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010934492,0.0009198998,0.0019195288,0.0029003033,0.00015784797,0.0009342943,0.0009005093,0.001100914,0.001561805],"category_scores_gemma":[0.0017683172,0.00027472904,0.0008171689,0.0017418441,0.00048577195,0.00093865243,0.0005940526,0.0017486197,0.00080896576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010203782,0.000060556333,0.0007196837,0.012243681,0.00022061661,0.000128847,0.00003495782,0.0003407101,0.00067131885,0.0015092139,0.013821117,0.9701474],"study_design_scores_gemma":[0.00009522747,0.00035582765,0.008570914,0.026130427,0.0014283112,0.0038601768,0.0001804193,0.0007137185,0.0015667531,0.005654247,0.95134896,0.00009499689],"about_ca_topic_score_codex":0.0010753117,"about_ca_topic_score_gemma":0.001462167,"teacher_disagreement_score":0.0029003033,"about_ca_system_score_codex":0.0005842583,"about_ca_system_score_gemma":0.0007787117,"threshold_uncertainty_score":0.005782783},"labels":[],"label_agreement":null},{"id":"W2594407313","doi":"10.1158/2326-6074.tumimm16-pr09","title":"Abstract PR09: A novel chimeric antigen receptor containing JAK-STAT signaling domains mediates superior antitumor effects","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Cancer research; CD19; Cytokine; CD28; STAT5; T cell; T-cell receptor; JAK-STAT signaling pathway; Cytokine receptor; Signal transduction; Immunology; Biology; Medicine; Tyrosine kinase; Cell biology; Antigen; Immune system","score_opus":0.08268631610408858,"score_gpt":0.4196002134770678,"score_spread":0.33691389737297917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594407313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904794,0.0012757285,0.0053045917,0.00019464124,0.00004865423,0.000054470464,0.00037553662,0.00022369508,0.002043308],"genre_scores_gemma":[0.9949915,0.00033050057,0.0022588423,0.000041812607,0.000009305838,0.000022798818,0.000559878,0.00001901765,0.0017665055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998839,0.000018707125,0.000010554527,0.00002223088,0.000033089847,0.00003138985],"domain_scores_gemma":[0.99994993,0.0000070731144,0.00001318085,0.0000059446284,0.0000063461307,0.00001754619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014440849,0.00036062422,0.00020605259,0.00014944117,0.00008928376,0.00029019822,0.00028358796,0.00033218533,0.001882942],"category_scores_gemma":[0.00007187959,0.00011889948,0.00024869086,0.000109090855,0.00020681215,0.0002261804,0.00017334652,0.0006595926,0.0007596449],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015249956,0.00006134335,0.00006616939,0.000023378116,0.000003825694,0.00002663268,0.0000042343663,0.00014238023,0.998054,0.0001528652,0.00008697595,0.0012256718],"study_design_scores_gemma":[0.00017105526,0.0012694314,0.0010686081,0.0000036959775,0.000027986413,0.00042469037,0.0000072544694,0.0023274287,0.99061066,0.000036123078,0.004048393,0.000004563231],"about_ca_topic_score_codex":0.0002710856,"about_ca_topic_score_gemma":0.00023989125,"teacher_disagreement_score":0.001882942,"about_ca_system_score_codex":0.00027284102,"about_ca_system_score_gemma":0.00020411282,"threshold_uncertainty_score":0.0062990785},"labels":[],"label_agreement":null},{"id":"W2594697025","doi":"10.1158/2326-6074.tumimm16-a74","title":"Abstract A74: CAR-T cells harboring camelid single domain antibody as targeting agent to CEACAM6 antigen in pancreatic cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Helix Biopharma (Canada)","funders":"","keywords":"Antigen; Antibody; Cancer research; Cytotoxic T cell; Biology; CD28; Chimeric antigen receptor; T cell; Pancreatic cancer; Molecular biology; Immunology; Cancer; Immune system; In vitro; CD8; Biochemistry","score_opus":0.0871099523506898,"score_gpt":0.44197770087871424,"score_spread":0.35486774852802444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594697025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904868,0.0013363671,0.0036096664,0.00014147827,0.00008450922,0.000095227646,0.00064166734,0.0002358013,0.0033684957],"genre_scores_gemma":[0.99364835,0.00042873496,0.0019214789,0.000097948556,0.000026595244,0.00006730192,0.0007269165,0.000023696544,0.0030589476],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998242,0.000023771287,0.000013895558,0.000053752778,0.000030614738,0.000053683772],"domain_scores_gemma":[0.9999472,0.00000952689,0.000008237063,0.000007679274,0.000010322354,0.000016959077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012602842,0.0002849648,0.00037978406,0.0002718043,0.00016912249,0.00034626204,0.00023856104,0.00059029507,0.0024866194],"category_scores_gemma":[0.000088933324,0.00013219014,0.00043606042,0.0002386384,0.00013371703,0.000203064,0.00018274764,0.0006461503,0.0009716603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019821063,0.000091426475,0.00017885368,0.000038731792,0.0000064237024,0.000119286735,0.000015148955,0.00014184564,0.997652,0.00010292696,0.00020916415,0.0012459966],"study_design_scores_gemma":[0.00006465149,0.0011312565,0.002051373,0.000004976856,0.00002933503,0.0007235454,0.00001596117,0.0017386234,0.9898262,0.000036223788,0.0043711048,0.000006617156],"about_ca_topic_score_codex":0.0006788604,"about_ca_topic_score_gemma":0.00024607373,"teacher_disagreement_score":0.0024866194,"about_ca_system_score_codex":0.00035733153,"about_ca_system_score_gemma":0.00015615171,"threshold_uncertainty_score":0.008318543},"labels":[],"label_agreement":null},{"id":"W2594993143","doi":"10.1182/blood.v120.21.1909.1909","title":"Irradiated NK-92 Targets AML Leukemic Stem Cells in Vivo and Gene-Modified CD16+NK-92 Mediates Antibody Dependent Cell Mediated Cytotoxicity (ADCC) Against CD123+ Cells","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cancer research; Leukemia; Stem cell; CD38; CD34; Cytotoxic T cell; Biology; Immunology; Antibody; Monoclonal antibody; In vitro; Cell biology","score_opus":0.020130242991296392,"score_gpt":0.27302105172603636,"score_spread":0.25289080873473996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594993143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683607,0.00051129266,0.0013108341,0.00003902738,0.000013223818,0.000042828546,0.00017076285,0.000072849434,0.0010030286],"genre_scores_gemma":[0.99617034,0.00033609106,0.0013490572,0.000020050118,0.0000068476643,0.00004060871,0.00043851975,0.000017388838,0.001621084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986124,0.00002534872,0.000012366992,0.000027482887,0.00003521692,0.00003829766],"domain_scores_gemma":[0.9999311,0.000013323502,0.00001875027,0.000012973498,0.0000051221928,0.000018746228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015072786,0.00042214376,0.0003461112,0.00015972524,0.0000749217,0.00025027693,0.00025643883,0.00023844006,0.0017203997],"category_scores_gemma":[0.00007159863,0.00013863784,0.00020717709,0.000137498,0.00024971896,0.00018180374,0.00015395269,0.0006471358,0.00051326986],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025194557,0.00009736516,0.00015144318,0.00003022005,0.0000056627186,0.000021955613,0.00001620116,0.00011133798,0.9981244,0.00007296752,0.000032274012,0.0010842573],"study_design_scores_gemma":[0.000064118954,0.0014919433,0.0015792492,0.0000047912563,0.000013569421,0.0001426081,0.000011990262,0.00072270026,0.99507165,0.00001824689,0.00087733427,0.0000018340621],"about_ca_topic_score_codex":0.0005966753,"about_ca_topic_score_gemma":0.00059940445,"teacher_disagreement_score":0.0017203997,"about_ca_system_score_codex":0.00019437025,"about_ca_system_score_gemma":0.00019240446,"threshold_uncertainty_score":0.0057553053},"labels":[],"label_agreement":null},{"id":"W2596837612","doi":"10.1182/blood.v128.22.221.221","title":"Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Clinical endpoint; Clinical trial; Internal medicine; Cytokine release syndrome; Adverse effect; Salvage therapy; Oncology; Chimeric antigen receptor; Chemotherapy; Immunotherapy; Cancer","score_opus":0.009385437605929787,"score_gpt":0.2620527594645376,"score_spread":0.2526673218586078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596837612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950193,0.00093825057,0.00048695394,0.00044752745,0.000058055553,0.0011613847,0.0009410281,0.000037855156,0.0009096143],"genre_scores_gemma":[0.99434066,0.00047044273,0.00093368266,0.00057095464,0.000094983116,0.0011356011,0.0017201861,0.00001899396,0.00071450573],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9971872,0.0022079318,0.00008504862,0.00022103189,0.000109808425,0.00018894071],"domain_scores_gemma":[0.99751735,0.0007174353,0.00057397346,0.00031656318,0.00013756144,0.0007370527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058652023,0.0011375481,0.0012933846,0.0003265964,0.00033573754,0.00087535015,0.00070758164,0.0010024231,0.0030529234],"category_scores_gemma":[0.0029230204,0.00037318212,0.0015277745,0.0004384479,0.0012835481,0.0007547853,0.00071992737,0.0022057698,0.0005908951],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90614605,0.016756123,0.023866042,0.0004263244,0.0021724035,0.0003275272,0.00028323583,0.0011592613,0.011949582,0.00051167933,0.0025445002,0.033857334],"study_design_scores_gemma":[0.51520216,0.44378185,0.031687554,0.000033509303,0.0015441844,0.00030189782,0.00015470965,0.0009515177,0.002777101,0.0004131252,0.0031198827,0.00003239073],"about_ca_topic_score_codex":0.0005374956,"about_ca_topic_score_gemma":0.0013254705,"teacher_disagreement_score":0.0058652023,"about_ca_system_score_codex":0.0007064046,"about_ca_system_score_gemma":0.0016674529,"threshold_uncertainty_score":0.031018496},"labels":[],"label_agreement":null},{"id":"W2597783812","doi":"10.1158/1078-0432.ccr-15-2440","title":"Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target","year":2017,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Blockade; Medicine; Cancer research; Fusion protein; Cytokine; Chimeric antigen receptor; T cell; Cancer; Antibody; Immunology; Immunotherapy; Antigen; Receptor; Biology; Immune system; Internal medicine; Gene","score_opus":0.6778716969775834,"score_gpt":0.676147262922812,"score_spread":0.0017244340547714065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597783812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023927848,0.9970847,0.0001672416,0.00026866858,0.00024363137,0.000011099634,0.000025594185,0.000007284505,0.0019525662],"genre_scores_gemma":[0.0011786523,0.99670607,0.00026339057,0.00030739987,0.000112945774,0.00001532275,0.00005142319,0.0000020928433,0.0013626629],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989533,0.000017945502,0.0000118648495,0.000018625806,0.00004326568,0.000012848626],"domain_scores_gemma":[0.999874,0.000045533383,0.000015451526,0.000003911402,0.00004648271,0.0000145815175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046140086,0.000687822,0.0010234875,0.0020010418,0.00021801182,0.0009270135,0.00065525935,0.0008637473,0.003302278],"category_scores_gemma":[0.0003001284,0.00024110333,0.00046103023,0.0013503953,0.00031471148,0.0009912244,0.00044093045,0.0016722821,0.0024065706],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013229388,0.00011667035,0.00014479719,0.014876757,0.00010926051,0.00022337744,0.00005515992,0.00047714176,0.0057956283,0.0058783605,0.028577838,0.94361264],"study_design_scores_gemma":[0.000035200428,0.00015674913,0.00045604314,0.0026735668,0.00009879767,0.0007162779,0.00004588944,0.00013021508,0.0013458522,0.0015676171,0.9927579,0.000015941745],"about_ca_topic_score_codex":0.0009158834,"about_ca_topic_score_gemma":0.0014310784,"teacher_disagreement_score":0.003302278,"about_ca_system_score_codex":0.00069012836,"about_ca_system_score_gemma":0.00084501144,"threshold_uncertainty_score":0.0110471845},"labels":[],"label_agreement":null},{"id":"W2597968140","doi":"10.1182/blood.v128.22.5193.5193","title":"In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxic T cell; Medicine; Chimeric antigen receptor; CD20; Immunology; Antigen; Antibody; Cancer research; Monoclonal antibody; In vitro; Biology; Immunotherapy; Immune system","score_opus":0.04747231502687925,"score_gpt":0.34110462667759395,"score_spread":0.2936323116507147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597968140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914517,0.0038968557,0.0017319607,0.000039809078,0.000045896897,0.000056691646,0.00055206986,0.000039532253,0.0021855442],"genre_scores_gemma":[0.99005836,0.002135612,0.002328566,0.000033279764,0.000026307887,0.000073893774,0.0025327608,0.0000101111,0.0028011415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99946886,0.0001969859,0.00009405396,0.00006603426,0.000109828165,0.00006423748],"domain_scores_gemma":[0.99974626,0.00010362851,0.000018258823,0.000055574135,0.00004756764,0.000028769135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049904105,0.00046706508,0.00034589777,0.00026299048,0.00016929288,0.00033362623,0.00021295395,0.00027390858,0.0021945795],"category_scores_gemma":[0.0002122564,0.000202205,0.0002926239,0.00037139092,0.00015363212,0.0001994009,0.00020402312,0.00046868244,0.00050488306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078388525,0.00036852728,0.0009895317,0.00018842098,0.000039930987,0.00008093867,0.000096474854,0.0003512297,0.9928437,0.00014434784,0.00013360934,0.0039794054],"study_design_scores_gemma":[0.00011654173,0.003812353,0.008339485,0.000020373685,0.000077005876,0.00037054124,0.00006410874,0.0023470072,0.98262835,0.000050065642,0.0021621606,0.000011961845],"about_ca_topic_score_codex":0.0014604797,"about_ca_topic_score_gemma":0.0010957255,"teacher_disagreement_score":0.0021945795,"about_ca_system_score_codex":0.00023259169,"about_ca_system_score_gemma":0.00017015496,"threshold_uncertainty_score":0.0073416233},"labels":[],"label_agreement":null},{"id":"W2602369513","doi":"10.1200/jco.2016.71.3024","title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Fludarabine; Lymphoma; Chemotherapy; Chimeric antigen receptor; Follicular lymphoma; Cyclophosphamide; Mantle cell lymphoma; Gastroenterology; Internal medicine; Immunology; T cell; Immune system","score_opus":0.1467258729733652,"score_gpt":0.46062969264205533,"score_spread":0.31390381966869013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602369513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969813,0.0013028574,0.00064533716,0.000066753295,0.000010809682,0.00004527376,0.00006466509,0.0000676531,0.00081526773],"genre_scores_gemma":[0.9992944,0.00016050038,0.00015390794,0.000051991137,0.000010893632,0.000012834048,0.0001404398,0.000003990675,0.000171058],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997973,0.00005159119,0.000019345276,0.00002917856,0.000035357036,0.000067218265],"domain_scores_gemma":[0.9995208,0.000097554584,0.00019967346,0.000032936146,0.000017432121,0.00013162353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002928173,0.00029574247,0.0004287445,0.00021993408,0.00026900787,0.00018090506,0.00015776837,0.00025969325,0.0013737947],"category_scores_gemma":[0.000530619,0.00017575947,0.0002850955,0.00017353687,0.00035262614,0.0001311708,0.00019409448,0.00061795174,0.00025141705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021374274,0.0019357357,0.2398129,0.00057127926,0.0003779139,0.011091143,0.00042542067,0.0020719105,0.6125956,0.0006984404,0.002184309,0.10686103],"study_design_scores_gemma":[0.004789542,0.04143709,0.75022686,0.000059008686,0.00058569893,0.050516695,0.00022840497,0.0037478977,0.13871735,0.00051071687,0.009141023,0.000039733364],"about_ca_topic_score_codex":0.00069317623,"about_ca_topic_score_gemma":0.00090830226,"teacher_disagreement_score":0.0013737947,"about_ca_system_score_codex":0.0003843886,"about_ca_system_score_gemma":0.00016566145,"threshold_uncertainty_score":0.004595816},"labels":[],"label_agreement":null},{"id":"W2603085196","doi":"10.1158/0008-5472.can-16-3247","title":"Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Directorate for Biological Sciences; Medical Research Council Canada; University of Oxford; National Institute for Health and Care Research; Cancer Research UK; Pancreatic Cancer UK","keywords":"Epitope; Cancer immunotherapy; Cancer; Immunotherapy; Cancer research; Monoclonal antibody; Antibody; Antigen; T cell; T-cell receptor; Cancer cell; Biology; Immune system; Context (archaeology); Immunology","score_opus":0.13443582584041167,"score_gpt":0.4802923012255702,"score_spread":0.3458564753851585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603085196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9575995,0.0044889012,0.029068697,0.0003722727,0.00020107809,0.0005823303,0.00027580952,0.00035595064,0.0070555503],"genre_scores_gemma":[0.9806451,0.0013830154,0.014705452,0.00012150367,0.000032699714,0.00013414006,0.00040459496,0.000023983564,0.0025494108],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998228,0.000033228545,0.000011648197,0.000032606735,0.000048584265,0.000051062678],"domain_scores_gemma":[0.9999112,0.0000142148465,0.000016405578,0.000011177127,0.000020244182,0.000026748989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002744421,0.0004917643,0.00031065967,0.00036766334,0.0001392797,0.00037878088,0.00037868842,0.00057998777,0.0013441247],"category_scores_gemma":[0.00017691121,0.00018852564,0.00033849163,0.00014720307,0.00013301428,0.0002115676,0.00018390027,0.00079182006,0.00066978217],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000817534,0.00017543805,0.00015066021,0.000028489727,0.000010457272,0.00007071667,0.000008841535,0.0004203979,0.9921624,0.00020542614,0.00014952227,0.0065359175],"study_design_scores_gemma":[0.0001948383,0.0017293189,0.00093532144,0.000009022188,0.000045791938,0.0008575784,0.000006731373,0.004994379,0.98317367,0.00006937004,0.007976707,0.000007333952],"about_ca_topic_score_codex":0.00051605975,"about_ca_topic_score_gemma":0.0003894078,"teacher_disagreement_score":0.0013441247,"about_ca_system_score_codex":0.00040136662,"about_ca_system_score_gemma":0.00038265507,"threshold_uncertainty_score":0.004496515},"labels":[],"label_agreement":null},{"id":"W2604684472","doi":"10.1182/blood.v128.22.1852.1852","title":"Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cytokine release syndrome; Medicine; CD8; Toxicity; CD19; Immunology; T cell; Internal medicine; Gastroenterology; Chimeric antigen receptor; Antigen; Immune system","score_opus":0.008121120329729692,"score_gpt":0.23716369371763285,"score_spread":0.22904257338790315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604684472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759597,0.0009829128,0.00075504876,0.00002110546,0.0000040157397,0.000042802534,0.00009034858,0.000017523274,0.00049021596],"genre_scores_gemma":[0.9990452,0.00014490786,0.00038185745,0.000017484934,0.000004245214,0.000029576386,0.00013674509,0.0000016470115,0.00023821853],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997838,0.00007385523,0.00002167281,0.000025467325,0.00006810199,0.000027175238],"domain_scores_gemma":[0.9995254,0.00010003367,0.00024308196,0.000024653687,0.000060655613,0.00004617755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004402452,0.00022167791,0.00023544295,0.00024922017,0.000081152924,0.00022761557,0.00013304917,0.00018221104,0.0007690994],"category_scores_gemma":[0.0005810197,0.00008317681,0.0001468614,0.00018350474,0.00014951386,0.00016636684,0.00012613302,0.00035472825,0.00012236674],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010686502,0.0006651735,0.52253884,0.00032055262,0.00017228845,0.00078672165,0.00022799471,0.001685556,0.38408348,0.00017008015,0.00059458194,0.07806827],"study_design_scores_gemma":[0.00026170327,0.023036567,0.5409997,0.00003907853,0.00031529367,0.0032506026,0.00014338407,0.0039441637,0.4255593,0.00014102331,0.0022958682,0.000013356142],"about_ca_topic_score_codex":0.00018224599,"about_ca_topic_score_gemma":0.00024089767,"teacher_disagreement_score":0.0007690994,"about_ca_system_score_codex":0.00019458201,"about_ca_system_score_gemma":0.00013916858,"threshold_uncertainty_score":0.0025729537},"labels":[],"label_agreement":null},{"id":"W2604892075","doi":"10.1182/blood.v128.22.1841.1841","title":"ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Blinatumomab; CD19; Antibody; T cell; Antibody-drug conjugate; Cancer research; B cell; Immunology; Medicine; Molecular biology; Chemistry; Biology; Immune system; Monoclonal antibody","score_opus":0.013718849653266661,"score_gpt":0.2543328361908271,"score_spread":0.24061398653756041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604892075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9535295,0.00907047,0.016338848,0.00073918776,0.00015729138,0.0003595419,0.00084903615,0.0005899094,0.018366165],"genre_scores_gemma":[0.9816026,0.00196075,0.007491176,0.00020365516,0.000021468475,0.00010017496,0.0005415297,0.000031474592,0.008047228],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999155,0.000012647245,0.0000055799574,0.000018155673,0.000027981967,0.000020104031],"domain_scores_gemma":[0.99996877,0.0000022866664,0.000011354639,0.0000023394894,0.0000060018197,0.000009262439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111430265,0.00046229613,0.00016259015,0.00020530031,0.00008680596,0.00019055099,0.00034892047,0.00034513604,0.0029776406],"category_scores_gemma":[0.00012275696,0.00013282214,0.00015764221,0.00014146637,0.00012797464,0.00037512215,0.00031582778,0.00040834374,0.00077836664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000365447,0.000110816996,0.00014427921,0.00016817545,0.00001591777,0.00020376148,0.000026239539,0.0009132356,0.9677605,0.0007845777,0.0012258629,0.028281165],"study_design_scores_gemma":[0.00020158467,0.0022917923,0.00071037526,0.000011934337,0.000030922914,0.001220433,0.000011573069,0.0034456465,0.96824026,0.00018169987,0.023638368,0.00001548506],"about_ca_topic_score_codex":0.00054195843,"about_ca_topic_score_gemma":0.0005084513,"teacher_disagreement_score":0.0029776406,"about_ca_system_score_codex":0.00035646596,"about_ca_system_score_gemma":0.00019117903,"threshold_uncertainty_score":0.009961188},"labels":[],"label_agreement":null},{"id":"W2605822943","doi":"10.1200/jco.2012.30.15_suppl.tps8604","title":"OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncolytic virus; Clinical endpoint; Internal medicine; Melanoma; Stage (stratigraphy); Randomized controlled trial; Clinical trial; Phases of clinical research; Oncology; Immune system; Gastroenterology; Urology; Surgery; Immunology; Cancer; Cancer research","score_opus":0.1822183919849854,"score_gpt":0.5002039924997621,"score_spread":0.3179856005147767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605822943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821592,0.0029722983,0.00094579597,0.0010210705,0.00046851984,0.006187126,0.0027382616,0.00019593048,0.0033117835],"genre_scores_gemma":[0.9755023,0.0018660731,0.002770137,0.0018682,0.00056281214,0.008593065,0.003366341,0.00006068652,0.0054103984],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99943393,0.00031632106,0.000019887328,0.00010115495,0.000045153683,0.00008353432],"domain_scores_gemma":[0.9989473,0.0002754738,0.00028947563,0.000086546366,0.00004580943,0.0003553609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002273519,0.0018767114,0.002216724,0.0005007846,0.00035807258,0.0010094354,0.00096677226,0.0016185774,0.0101319235],"category_scores_gemma":[0.0016538327,0.0007219906,0.001497287,0.0003691456,0.0013751981,0.0011727565,0.00052595773,0.003122574,0.001555522],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9833576,0.005026464,0.0006761537,0.00020307644,0.00033125957,0.00002747717,0.000029132929,0.00034897475,0.0025153924,0.000107285785,0.00083602,0.0065410594],"study_design_scores_gemma":[0.90640974,0.08983486,0.0016227085,0.000020463192,0.00028906798,0.000053694333,0.000016362188,0.0005001301,0.00042848027,0.00019143762,0.0006219567,0.000011203958],"about_ca_topic_score_codex":0.0007172508,"about_ca_topic_score_gemma":0.0014108085,"teacher_disagreement_score":0.0101319235,"about_ca_system_score_codex":0.0009796838,"about_ca_system_score_gemma":0.00097321265,"threshold_uncertainty_score":0.033894658},"labels":[],"label_agreement":null},{"id":"W2608951168","doi":"10.1182/blood.v120.21.2560.2560","title":"A Highly Selective Anti-ROR1 Monoclonal Antibody Inhibits Human Acute Myeloid Leukemia CD34+ Cell Survival and Self-Renewal.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"","keywords":"Biology; Myeloid leukemia; Leukemia; Cancer research; Stem cell; CD34; Acute leukemia; Stromal cell; Bone marrow; Population; Myeloid; Immunology; Molecular biology; Medicine; Cell biology","score_opus":0.01692193652536604,"score_gpt":0.29997526656942486,"score_spread":0.2830533300440588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608951168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876725,0.00407472,0.0036417623,0.00013857646,0.000043018943,0.00011074008,0.00036991065,0.00019935684,0.0037494572],"genre_scores_gemma":[0.9864146,0.0018171995,0.0054760342,0.00007959566,0.000027867309,0.000115965835,0.0015554512,0.000023895966,0.0044892854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980384,0.00004226303,0.000012470192,0.000030133018,0.000053082258,0.000058266996],"domain_scores_gemma":[0.99992526,0.000020304407,0.000010941649,0.0000096248405,0.000012295834,0.00002158023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020392549,0.00036065796,0.0002753471,0.00030044615,0.00014370398,0.00013771358,0.0002647177,0.000268637,0.0018899632],"category_scores_gemma":[0.000112081696,0.0001628376,0.0001923542,0.00019494191,0.00012388834,0.00009839545,0.00017001209,0.00046262366,0.0007353549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000841693,0.000060757135,0.000120398414,0.000023401344,0.000004256206,0.000016901198,0.0000049657024,0.000037881644,0.9976546,0.000049244405,0.00009653051,0.0018468468],"study_design_scores_gemma":[0.00007389719,0.0012483817,0.005195094,0.000007777164,0.000027113794,0.00040930437,0.0000082128345,0.0011786713,0.9876917,0.000027919921,0.0041289898,0.0000028111685],"about_ca_topic_score_codex":0.00040501935,"about_ca_topic_score_gemma":0.0010789365,"teacher_disagreement_score":0.0018899632,"about_ca_system_score_codex":0.00023142106,"about_ca_system_score_gemma":0.00019124139,"threshold_uncertainty_score":0.0063225627},"labels":[],"label_agreement":null},{"id":"W2609196580","doi":"10.1080/2162402x.2017.1321184","title":"Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma","year":2017,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; University of Victoria; Simon Fraser University; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Lymphoma; CD8; Human leukocyte antigen; Immunology; Cytotoxic T cell; Antigen; Immune system; T cell; Biology; Cancer research; Medicine; Genetics","score_opus":0.0506683785153188,"score_gpt":0.34524345492769154,"score_spread":0.29457507641237274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609196580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99940944,0.000035647237,0.0001595485,0.0000073796846,0.0000013076674,0.0000042426327,0.00003350246,0.0000039373144,0.00034502876],"genre_scores_gemma":[0.99958676,0.000024811705,0.000092266615,0.000012721461,0.0000014820147,0.0000045228276,0.00008216903,0.000003233207,0.00019210017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999013,0.000019446476,0.000009349529,0.000027473741,0.000014421215,0.00002811086],"domain_scores_gemma":[0.9999087,0.000032900483,0.0000091671345,0.00001568344,0.000008783989,0.000024714138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119427525,0.00010267582,0.00009635347,0.0003172903,0.0001831693,0.00021196256,0.000120883524,0.00020393134,0.0015056789],"category_scores_gemma":[0.00022777906,0.000101838115,0.000105073676,0.0001831927,0.00017527917,0.00008891908,0.00019989468,0.00019037066,0.00021314956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008230452,0.000090130554,0.05799864,0.000024418416,0.000027127084,0.001910747,0.00049080653,0.00024719653,0.9298116,0.00018312923,0.00013382467,0.008259251],"study_design_scores_gemma":[0.00014928359,0.0019496748,0.7030956,0.000023306317,0.00016256527,0.028823778,0.0013345545,0.0038462484,0.255319,0.0005177263,0.0047562663,0.000021889748],"about_ca_topic_score_codex":0.0005368868,"about_ca_topic_score_gemma":0.0006447911,"teacher_disagreement_score":0.0015056789,"about_ca_system_score_codex":0.00013164408,"about_ca_system_score_gemma":0.0000498553,"threshold_uncertainty_score":0.00503695},"labels":[],"label_agreement":null},{"id":"W2609629414","doi":"10.1111/trf.14094","title":"Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with high‐risk leukemia","year":2017,"lang":"en","type":"article","venue":"Transfusion","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Peripheral blood mononuclear cell; Medicine; Apheresis; Immunotherapy; Cell; Internal medicine; Cancer; Biology","score_opus":0.016491352304269874,"score_gpt":0.26347789029391083,"score_spread":0.24698653798964096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609629414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377763,0.0015082277,0.0040004645,0.000047390193,0.000006453101,0.00009297292,0.00009762844,0.000039328672,0.0004299123],"genre_scores_gemma":[0.99036205,0.0008872675,0.008172902,0.00004137066,0.000025910438,0.00007614586,0.0003323137,0.000017992983,0.0000842101],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981585,0.0008242778,0.00018688645,0.00023319782,0.00048476737,0.000112336034],"domain_scores_gemma":[0.99824786,0.0006646374,0.0006526051,0.00014495276,0.00017817697,0.000111785215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002978058,0.00032913388,0.00041624345,0.0006003524,0.00023312827,0.0009240637,0.00037453452,0.00020177168,0.0005588319],"category_scores_gemma":[0.004615681,0.0001386557,0.00021780969,0.00074765773,0.00035848364,0.00044202438,0.00056449603,0.00027064065,0.00022344236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041863257,0.00041127866,0.80573666,0.0003175843,0.00012621419,0.001090385,0.0008882606,0.0028473896,0.03161077,0.00028673376,0.0008955805,0.15160282],"study_design_scores_gemma":[0.00043329055,0.008613708,0.8793486,0.0001503598,0.00038989176,0.0109424,0.0010818011,0.008703135,0.08281876,0.00035168635,0.0071252976,0.000041146013],"about_ca_topic_score_codex":0.00033825324,"about_ca_topic_score_gemma":0.00043543894,"teacher_disagreement_score":0.002978058,"about_ca_system_score_codex":0.0004469214,"about_ca_system_score_gemma":0.0006217287,"threshold_uncertainty_score":0.015749633},"labels":[],"label_agreement":null},{"id":"W2610080631","doi":"10.1016/j.ymthe.2017.04.010","title":"Perspectives on Manufacturing of High-Quality Cell Therapies","year":2017,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality (philosophy); Business; Biotechnology; Biology","score_opus":0.04017176802711962,"score_gpt":0.35569623676941486,"score_spread":0.3155244687422952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610080631","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020471292,0.40723467,0.29984903,0.13635188,0.019838603,0.00079586986,0.0014541821,0.0010555104,0.11294899],"genre_scores_gemma":[0.25403067,0.3303856,0.3368724,0.027688526,0.007817703,0.0016076745,0.0024106288,0.00093303825,0.038253743],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949309,0.0013173772,0.0002789525,0.0004901486,0.0025808793,0.00040178042],"domain_scores_gemma":[0.9921933,0.0024947955,0.00064630783,0.0010655723,0.0030482612,0.00055181404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010995838,0.0010711128,0.0012035937,0.0017113187,0.0009974679,0.006119341,0.0025362028,0.005117382,0.018179676],"category_scores_gemma":[0.009844189,0.0008028387,0.001933857,0.0013587264,0.0032244253,0.006949898,0.0031179474,0.004971582,0.0064250855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006010568,0.0004990393,0.0009408681,0.005497802,0.0001781704,0.0013999548,0.0008029096,0.01034446,0.09146588,0.48884764,0.0890686,0.31035367],"study_design_scores_gemma":[0.00016410902,0.00076065026,0.0006312312,0.0011162243,0.000057809655,0.00082860974,0.0004168673,0.0025388412,0.048409753,0.12156558,0.8234139,0.000096345626],"about_ca_topic_score_codex":0.0015941899,"about_ca_topic_score_gemma":0.0015500897,"teacher_disagreement_score":0.018179676,"about_ca_system_score_codex":0.0041368804,"about_ca_system_score_gemma":0.0027125916,"threshold_uncertainty_score":0.060817122},"labels":[],"label_agreement":null},{"id":"W2611322156","doi":"10.15173/m.v1i26.948","title":"Chimeric Antigen Receptors: The Future of Cancer Immunotherapy","year":2014,"lang":"en","type":"article","venue":"The Meducator","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; Cancer; Receptor; Immunology; Medicine; Antigen; Immune system; Internal medicine","score_opus":0.015394156067549106,"score_gpt":0.33340639458003285,"score_spread":0.3180122385124837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611322156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00533022,0.947795,0.013248356,0.019523319,0.0013810871,0.000037163143,0.0000678941,0.00017771966,0.012439265],"genre_scores_gemma":[0.07627568,0.8847421,0.01644012,0.0076342844,0.003917215,0.000116497715,0.00021662965,0.000050465234,0.010607015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995461,0.00012539864,0.000016393458,0.000057619458,0.00017484154,0.00007961379],"domain_scores_gemma":[0.9995117,0.00021681741,0.00004421896,0.000016606988,0.00011828248,0.00009231988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024191237,0.00058507966,0.00062549365,0.0008666662,0.00026928165,0.0015947267,0.0008759141,0.002667042,0.0040936647],"category_scores_gemma":[0.0012061881,0.00025175288,0.00040274084,0.00058539206,0.001273634,0.0030852612,0.00064728106,0.0025408152,0.0012691589],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052719115,0.00030348563,0.0006748378,0.0010706234,0.00004533631,0.00033829594,0.00018183932,0.0026006538,0.027261682,0.11513729,0.04178874,0.81007004],"study_design_scores_gemma":[0.00016514042,0.001140841,0.00070744316,0.0007020198,0.000052188265,0.0015796275,0.00012489369,0.0049288096,0.010749588,0.046674777,0.9331139,0.000060661736],"about_ca_topic_score_codex":0.00050387945,"about_ca_topic_score_gemma":0.00054103014,"teacher_disagreement_score":0.0040936647,"about_ca_system_score_codex":0.0016445653,"about_ca_system_score_gemma":0.0010966564,"threshold_uncertainty_score":0.013694704},"labels":[],"label_agreement":null},{"id":"W2612204637","doi":"10.1080/21645515.2017.1314874","title":"A new therapeutic potential for cancers: One CAR with 2 different engines!","year":2017,"lang":"en","type":"letter","venue":"Human Vaccines & Immunotherapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Chimeric antigen receptor; Antigen; Immune system; NK-92; Immunotherapy; Cancer immunotherapy; MHC class I; Cytotoxic T cell; Biology; Immunology; Antigen-presenting cell; Cancer research; Major histocompatibility complex; T cell; In vitro","score_opus":0.054112037923925736,"score_gpt":0.32526531025099725,"score_spread":0.27115327232707154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612204637","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04528504,0.61288035,0.122379065,0.12825327,0.013383427,0.0006349671,0.00055876974,0.0018824582,0.074742645],"genre_scores_gemma":[0.36995134,0.28147975,0.11744936,0.090343736,0.008709822,0.0018942677,0.001025056,0.00055093016,0.12859568],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991893,0.00017780208,0.00002924063,0.0001812479,0.00022812065,0.00019436011],"domain_scores_gemma":[0.99969625,0.00008590422,0.000025356141,0.000034170953,0.00006287279,0.00009543589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013581772,0.001212231,0.0012669511,0.0012550785,0.0007264017,0.0030504758,0.0012724646,0.004083692,0.010057595],"category_scores_gemma":[0.00083638035,0.0005115433,0.0017448938,0.0004487994,0.0017758851,0.0062755286,0.0024014588,0.0050904932,0.0038042373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011834421,0.00089390203,0.0014332874,0.0025055155,0.00026384162,0.0013865374,0.0005834883,0.0016173159,0.12021904,0.20767951,0.08036244,0.5818716],"study_design_scores_gemma":[0.00030812251,0.002502553,0.00076031935,0.0006241335,0.00023476654,0.0048137167,0.00029941738,0.0020189667,0.037939414,0.046895,0.90338457,0.00021909252],"about_ca_topic_score_codex":0.0006119413,"about_ca_topic_score_gemma":0.0007117419,"teacher_disagreement_score":0.010057595,"about_ca_system_score_codex":0.001235309,"about_ca_system_score_gemma":0.0008386368,"threshold_uncertainty_score":0.033646047},"labels":[],"label_agreement":null},{"id":"W2612845307","doi":"","title":"CORD BLOOD-DERIVED MESENCHYMAL STROMAL CELLS DOWN-MODULATE CD4+ T-CELL ACTIVATION BY INDUCING IL-10 PRODUCING TH1 CELLS","year":2013,"lang":"en","type":"article","venue":"2013 CIS Annual Meeting: Regulation & Dysregulation of Immunity April 25 - 28, 2013","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Mesenchymal stem cell; Stromal cell; Cell biology; Cord blood; Cell; Chemistry; Immunology; Biology; Molecular biology; Cancer research; Biochemistry","score_opus":0.01685769129565926,"score_gpt":0.257580438712427,"score_spread":0.24072274741676772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612845307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910794,0.0023836016,0.0016076022,0.00035081862,0.00020654642,0.000051738745,0.00034406222,0.00012985527,0.0038465254],"genre_scores_gemma":[0.9925782,0.0013773362,0.0011092154,0.00020283263,0.000077573226,0.00003814181,0.00038096242,0.00002426023,0.004211442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997502,0.00005445846,0.000023050477,0.000028524628,0.000059442147,0.00008436517],"domain_scores_gemma":[0.999899,0.000021901942,0.000023574297,0.000009855931,0.0000120761415,0.000033511682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001590218,0.00041176035,0.00028584996,0.0002982876,0.00015058392,0.0004939997,0.00015555993,0.00024242947,0.003895596],"category_scores_gemma":[0.00014371464,0.00014544661,0.000314402,0.00018390098,0.00025663647,0.00012926731,0.00020226439,0.0011134391,0.00095809],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041827548,0.00015201214,0.00042554058,0.00007434328,0.000014284598,0.00013621653,0.00003090644,0.00010998966,0.99131525,0.00013452407,0.00035346494,0.0068351408],"study_design_scores_gemma":[0.00009818879,0.0009933263,0.00625871,0.000020309917,0.0000672983,0.00032644623,0.00010276123,0.00076498504,0.9851344,0.00010036086,0.006127096,0.000005998976],"about_ca_topic_score_codex":0.00087122625,"about_ca_topic_score_gemma":0.0020876355,"teacher_disagreement_score":0.003895596,"about_ca_system_score_codex":0.00023501746,"about_ca_system_score_gemma":0.0003696659,"threshold_uncertainty_score":0.013032138},"labels":[],"label_agreement":null},{"id":"W2621545768","doi":"10.1002/hon.2439_20","title":"Analysis of preclinical and clinical samples after treatment with a <scp>CD37</scp> targeting antibody drug conjugate (<scp>AGS67E</scp>) support a high level of <scp>CD37</scp> expression in <scp>NHL</scp>","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Antibody; Flow cytometry; Antibody-drug conjugate; Medicine; Cancer research; Monoclonal antibody; Molecular biology; Immunology; Biology","score_opus":0.12475944141595334,"score_gpt":0.42955576042117627,"score_spread":0.3047963190052229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621545768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773003,0.0039824024,0.008307993,0.00017507802,0.00013276623,0.0006948371,0.0038646888,0.00032845355,0.0052134455],"genre_scores_gemma":[0.9783493,0.0014213334,0.0054074293,0.00030832354,0.00005608422,0.00082204,0.009321555,0.00006139173,0.004252463],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997607,0.000036004592,0.000014730528,0.000051479605,0.000097238924,0.000039813487],"domain_scores_gemma":[0.9997218,0.000048628124,0.00004522518,0.000037208814,0.00009028554,0.00005678609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036658204,0.00034134224,0.00033770647,0.00034793458,0.00021754588,0.00032744132,0.00015710485,0.00041042562,0.0030369528],"category_scores_gemma":[0.00027205006,0.00012027781,0.00023062543,0.00025549656,0.00026193247,0.00013876324,0.00014758593,0.000700826,0.0009041146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023787152,0.00083371735,0.004368704,0.00018243825,0.000046841153,0.00019343686,0.00007921368,0.00044444104,0.97886866,0.00008957674,0.0010624062,0.011451894],"study_design_scores_gemma":[0.0003486204,0.011231438,0.04033767,0.00003345087,0.0001745704,0.0013822918,0.00014849009,0.0022171892,0.9313833,0.00017611365,0.012547942,0.000018908953],"about_ca_topic_score_codex":0.00047402058,"about_ca_topic_score_gemma":0.00084197975,"teacher_disagreement_score":0.0030369528,"about_ca_system_score_codex":0.00030043843,"about_ca_system_score_gemma":0.0003001155,"threshold_uncertainty_score":0.010159612},"labels":[],"label_agreement":null},{"id":"W2624207812","doi":"10.1002/hon.2438_72","title":"PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Leukapheresis; Mantle cell lymphoma; Autologous stem-cell transplantation; Internal medicine; Vaccination; Rash; Minimal residual disease; Adverse effect; Peripheral blood mononuclear cell; Oncology; Gastroenterology; Immunology; Lymphoma; CD34; Bone marrow; Stem cell","score_opus":0.043524360428083414,"score_gpt":0.38495610131224156,"score_spread":0.3414317408841582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624207812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194884,0.0022174797,0.0009697934,0.00044205875,0.0001256748,0.0020562643,0.00072009704,0.00011864397,0.0014011724],"genre_scores_gemma":[0.9890408,0.0011699474,0.0016805169,0.0008750894,0.00013986269,0.0028198666,0.0020493348,0.000026152713,0.0021984675],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99975044,0.000110565954,0.0000136399985,0.000040934927,0.000026566793,0.00005795526],"domain_scores_gemma":[0.9997633,0.000027207483,0.0000492183,0.000023745593,0.00001707163,0.00011945747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009227668,0.0008870296,0.0008907354,0.0002676726,0.00021985086,0.0005688396,0.00044548183,0.00073936506,0.0033030377],"category_scores_gemma":[0.00041327535,0.00028953713,0.0006438362,0.00020692043,0.00050058466,0.0004751903,0.00036181058,0.0017747927,0.0007436203],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5727655,0.07356512,0.007724418,0.001276446,0.001304078,0.00041428517,0.00042921942,0.004896369,0.12775555,0.0005513855,0.006767704,0.20254987],"study_design_scores_gemma":[0.42185625,0.5558279,0.00688864,0.00005854431,0.00028439783,0.00025204374,0.00004678745,0.001132879,0.009087886,0.00022278576,0.0043201535,0.000021759846],"about_ca_topic_score_codex":0.0003666808,"about_ca_topic_score_gemma":0.0006770177,"teacher_disagreement_score":0.0033030377,"about_ca_system_score_codex":0.0005671441,"about_ca_system_score_gemma":0.0010023271,"threshold_uncertainty_score":0.011049807},"labels":[],"label_agreement":null},{"id":"W2626261656","doi":"10.1080/14656566.2017.1340938","title":"Novel therapy for childhood acute lymphoblastic leukemia","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Clinical trial; Intensive care medicine; Disease; Minimal residual disease; Oncology; Risk stratification; Lymphoblastic Leukemia; Expert opinion; Internal medicine; Leukemia","score_opus":0.17184688914497115,"score_gpt":0.48562954739914893,"score_spread":0.3137826582541778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626261656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016752505,0.9971777,0.00018516209,0.0005785838,0.00034884218,0.000010907547,0.000037846065,0.000010089738,0.0014833586],"genre_scores_gemma":[0.0012657105,0.9970099,0.00023044858,0.0004569349,0.00021272826,0.000011551829,0.000060787395,0.0000021281205,0.0007498993],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981934,0.000042016367,0.000021591653,0.000034006298,0.00006669741,0.000016311173],"domain_scores_gemma":[0.9998313,0.00007863017,0.00002998455,0.0000048264524,0.00004309564,0.000012065137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003884979,0.00045083187,0.00080434565,0.0011891463,0.00017379982,0.0006250249,0.00056954654,0.00075631717,0.0055195903],"category_scores_gemma":[0.00056133856,0.00013254354,0.00051075715,0.0007787161,0.00025744445,0.0007122267,0.0004904124,0.0016192233,0.0023179462],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000762457,0.00005018029,0.00010249751,0.015189494,0.00009108991,0.00015857529,0.00004011909,0.00026317904,0.0017451394,0.0033421034,0.027913624,0.95102775],"study_design_scores_gemma":[0.00003473317,0.000096888674,0.0003896196,0.004453733,0.000110145826,0.0010225177,0.000029194645,0.00008529074,0.0005956301,0.0014626532,0.99170834,0.000011175639],"about_ca_topic_score_codex":0.0006343673,"about_ca_topic_score_gemma":0.0013878313,"teacher_disagreement_score":0.0055195903,"about_ca_system_score_codex":0.00045515076,"about_ca_system_score_gemma":0.0006513638,"threshold_uncertainty_score":0.018464923},"labels":[],"label_agreement":null},{"id":"W2666106632","doi":"10.1016/j.trsl.2017.06.009","title":"Antigen-specific regulatory T cells: are police CARs the answer?","year":2017,"lang":"en","type":"review","venue":"Translational research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Immunology; Immune system; Autoimmunity; Antigen; Chimeric antigen receptor; Cell therapy; Polyclonal antibodies; Major histocompatibility complex; Biology; T-cell receptor; T cell; Medicine; Stem cell; Cell biology","score_opus":0.4782631353955542,"score_gpt":0.5226650620180232,"score_spread":0.044401926622469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2666106632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045703055,0.99620676,0.00010342296,0.0020624702,0.0008540564,0.0000025921056,0.000013314447,0.0000055819773,0.00070611824],"genre_scores_gemma":[0.0006528097,0.9960699,0.00012816196,0.0016657858,0.0008001588,0.000005959895,0.000022883878,0.0000015483482,0.00065272284],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996755,0.0000815502,0.00003159068,0.00005604601,0.00010829869,0.000046997222],"domain_scores_gemma":[0.9990796,0.00049791735,0.000085399246,0.000024010556,0.0002288207,0.000084280764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015206576,0.00086733076,0.0014984317,0.0011416749,0.00037483883,0.0017235006,0.001311689,0.0025955688,0.005539726],"category_scores_gemma":[0.0018525788,0.00024970894,0.00044035434,0.0011916022,0.0011168103,0.0022790313,0.0008818477,0.0037948594,0.0027236263],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011288595,0.000049805178,0.0001466765,0.00811246,0.000058461123,0.00011150315,0.00005208772,0.00018218445,0.00077095785,0.009365839,0.09299851,0.8880386],"study_design_scores_gemma":[0.00002747632,0.000051836672,0.00018102338,0.0029823307,0.000059475944,0.00033680812,0.00007443681,0.000040516545,0.000175523,0.0041665365,0.99189246,0.000011556017],"about_ca_topic_score_codex":0.0010808005,"about_ca_topic_score_gemma":0.00227304,"teacher_disagreement_score":0.005539726,"about_ca_system_score_codex":0.0008364235,"about_ca_system_score_gemma":0.0018987636,"threshold_uncertainty_score":0.018532217},"labels":[],"label_agreement":null},{"id":"W2727251202","doi":"10.1002/eji.201646732","title":"Curtailed T‐cell activation curbs effector differentiation and generates CD8<sup>+</sup> T cells with a naturally‐occurring memory stem cell phenotype","year":2017,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Ministero della Salute; Fondazione Italiana per la Ricerca sul Cancro; European Research Council; Fondazione Cariplo; European Commission; Wellcome Trust","keywords":"Biology; Effector; Phenotype; Cytotoxic T cell; Cell biology; Cell; CD8; T cell; Genetics; Gene; Antigen; In vitro; Immune system","score_opus":0.015503367576592549,"score_gpt":0.24834962890308623,"score_spread":0.2328462613264937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727251202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595934,0.0004995917,0.0021389269,0.00004781472,0.00001610086,0.000025891037,0.00017358045,0.00008689504,0.0010518151],"genre_scores_gemma":[0.9963084,0.00020870205,0.0014723287,0.000055469827,0.000010992913,0.00002736899,0.00030080706,0.000024500601,0.0015914409],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988496,0.000022889782,0.000015724117,0.000020212206,0.000024839872,0.000031364445],"domain_scores_gemma":[0.9998896,0.000027439564,0.000027748136,0.000018700204,0.000008354743,0.000028078704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001092767,0.00029932428,0.0002152269,0.00014301855,0.000058958158,0.00027363686,0.00016021413,0.00023404184,0.0016849971],"category_scores_gemma":[0.00010683152,0.00008555102,0.00016308748,0.00007933261,0.00018654477,0.00011994634,0.00020921156,0.000512014,0.00043664957],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056950947,0.000018827628,0.000109348686,0.000014603704,0.0000016573173,0.000040331426,0.000008409691,0.000050259372,0.99886394,0.000043828393,0.000025426089,0.00076656236],"study_design_scores_gemma":[0.00001670906,0.00038627198,0.0014996864,0.000005262545,0.000010252534,0.0003165488,0.000014119462,0.00070127327,0.9950873,0.00003928725,0.0019204986,0.0000028001348],"about_ca_topic_score_codex":0.00016982641,"about_ca_topic_score_gemma":0.0002764838,"teacher_disagreement_score":0.0016849971,"about_ca_system_score_codex":0.000120725934,"about_ca_system_score_gemma":0.00014005987,"threshold_uncertainty_score":0.005636871},"labels":[],"label_agreement":null},{"id":"W2731890350","doi":"","title":"c-Myb Dependent Smooth Muscle Cell Differentiation from Mouse Embryonic Stem Cells","year":2011,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Embryonic stem cell; Stem cell; Cell biology; MYB; Biology; Cellular differentiation; Myocyte; Genetics; Transcription factor; Gene","score_opus":0.00646697671264232,"score_gpt":0.171243234624626,"score_spread":0.1647762579119837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731890350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94080025,0.004329319,0.031937756,0.0002603808,0.00018458764,0.0006508763,0.002730471,0.000279052,0.018827207],"genre_scores_gemma":[0.8835432,0.008389274,0.053777028,0.0002577,0.000060188533,0.0008286598,0.0075152745,0.00012879686,0.045499988],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998561,0.000013287254,0.000018327406,0.000034256496,0.00005171447,0.000026260608],"domain_scores_gemma":[0.99994063,0.000010972958,0.000010273986,0.000010362192,0.0000130229455,0.000014795781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025346503,0.00027527884,0.00017662282,0.00022251012,0.00016166168,0.00027043532,0.0002610188,0.0002477695,0.0014750769],"category_scores_gemma":[0.000081615544,0.00025072595,0.00028456977,0.00013658042,0.00013536657,0.00012174546,0.00024936444,0.00082903716,0.0010742735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002152257,0.000011105717,0.00004713994,0.000033342945,9.839032e-7,0.000026291254,0.000018857765,0.000029820605,0.9984487,0.00015374397,0.000036183486,0.0011723366],"study_design_scores_gemma":[0.000015520503,0.00017097249,0.0017613012,0.00002146981,0.000008699607,0.00011479853,0.000015106936,0.0007425758,0.98684514,0.00005487713,0.010245596,0.000003955621],"about_ca_topic_score_codex":0.00039139015,"about_ca_topic_score_gemma":0.0010879413,"teacher_disagreement_score":0.0014750769,"about_ca_system_score_codex":0.00017973865,"about_ca_system_score_gemma":0.00027072814,"threshold_uncertainty_score":0.004934609},"labels":[],"label_agreement":null},{"id":"W2734515449","doi":"10.1016/j.ymthe.2017.07.004","title":"Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy","year":2017,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":280,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Research and Development; Graduate Women – New South Wales; Northwest University; Department of Health and Social Care; NIH Clinical Center; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; Government of Canada; Geoffrey Beene Cancer Research Center; National Institute for Health and Care Research; National Cancer Research Institute","keywords":"Chimeric antigen receptor; CD19; Lymphoma; Medicine; Antigen; Receptor; Immunology; B cell; Cell; Cancer research; Biology; T cell; Antibody; Internal medicine; Immune system","score_opus":0.02657168721673962,"score_gpt":0.30328610520036575,"score_spread":0.2767144179836261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734515449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96491885,0.017333835,0.0053027174,0.0015604738,0.0004070473,0.0002721617,0.0009490766,0.00028699933,0.008968764],"genre_scores_gemma":[0.99348664,0.0011913285,0.00028663437,0.00063443393,0.00015061001,0.000054213506,0.0008566394,0.00003411724,0.0033053253],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99959975,0.00006359151,0.000040509596,0.000055118748,0.00006062051,0.00018042777],"domain_scores_gemma":[0.9987243,0.0004406428,0.00019781414,0.00018570642,0.00005289746,0.0003986341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00086435414,0.0004929573,0.001443908,0.00037247414,0.0006457554,0.00038623385,0.0004465918,0.0009310454,0.0015419429],"category_scores_gemma":[0.0010135632,0.00021506894,0.00095249066,0.00038953367,0.00045463632,0.0005637511,0.00039832207,0.0018938567,0.00060092256],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075038,0.010896506,0.0620462,0.0019140638,0.0022073193,0.100740604,0.0014134509,0.007119655,0.1790522,0.003795987,0.009437323,0.5463387],"study_design_scores_gemma":[0.016739702,0.12178243,0.54654187,0.00029882215,0.0028385546,0.1706581,0.00047420134,0.008057553,0.06334949,0.0042266715,0.06478031,0.000252334],"about_ca_topic_score_codex":0.00088914676,"about_ca_topic_score_gemma":0.0017295444,"teacher_disagreement_score":0.0015419429,"about_ca_system_score_codex":0.0005777514,"about_ca_system_score_gemma":0.00033744227,"threshold_uncertainty_score":0.005158305},"labels":[],"label_agreement":null},{"id":"W2735819532","doi":"10.4049/immunohorizons.1700022","title":"Transfection of FcγRIIIa (CD16) Alone Can Be Sufficient To Enable Human αβTCR T Lymphocytes To Mediate Antibody-Dependent Cellular Cytotoxicity","year":2017,"lang":"en","type":"article","venue":"ImmunoHorizons","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Institut National de la Santé et de la Recherche Médicale","keywords":"Antibody-dependent cell-mediated cytotoxicity; CD16; Transfection; Fc receptor; Jurkat cells; Cell biology; Molecular biology; Biology; Immunology; CD3; Chemistry; Antibody; Immune system; Monoclonal antibody; T cell; Cell culture; CD8","score_opus":0.0320016045442368,"score_gpt":0.34345838496717995,"score_spread":0.31145678042294317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735819532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98104,0.00087847264,0.014009411,0.000081334,0.00010508712,0.0001835722,0.00046988795,0.00015843443,0.0030737594],"genre_scores_gemma":[0.9852684,0.00072863215,0.008129568,0.000057162226,0.000023029359,0.00015568118,0.001169161,0.00005923435,0.004409118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99952865,0.000092923685,0.000071480026,0.00009537076,0.00011360899,0.000098016026],"domain_scores_gemma":[0.99980515,0.000051077655,0.00003183174,0.00006324216,0.000027696147,0.000021098747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041821046,0.0003948806,0.00040204637,0.00015123982,0.00011700802,0.00059381255,0.0001424309,0.00034489445,0.002551024],"category_scores_gemma":[0.0002550434,0.00014039227,0.00028473095,0.00018928359,0.0002075488,0.00017277178,0.0002708913,0.0006820058,0.001178503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082029386,0.000045146746,0.0001532312,0.00004196537,0.000005911424,0.000042028933,0.000036912203,0.00009629074,0.9981269,0.00012172302,0.00003478428,0.0012131121],"study_design_scores_gemma":[0.00002802204,0.0002678799,0.00060092815,0.000007607412,0.000020629059,0.00022038141,0.000017984115,0.000645196,0.99202687,0.000031521715,0.006129587,0.0000033444167],"about_ca_topic_score_codex":0.0004229927,"about_ca_topic_score_gemma":0.0003391155,"teacher_disagreement_score":0.002551024,"about_ca_system_score_codex":0.00024876127,"about_ca_system_score_gemma":0.000327138,"threshold_uncertainty_score":0.008534014},"labels":[],"label_agreement":null},{"id":"W2740810776","doi":"10.1158/1538-7445.am2017-3770","title":"Abstract 3770: CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumors expressing VEGFR2","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Antibody; Angiogenesis; Cancer research; Kinase insert domain receptor; Vascular endothelial growth factor; Biology; Antigen; Molecular biology; Immunology; Vascular endothelial growth factor A; VEGF receptors","score_opus":0.09703834215230762,"score_gpt":0.44731707181678015,"score_spread":0.35027872966447254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740810776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9659792,0.0028290348,0.019040562,0.0005048644,0.00030181563,0.00022197345,0.0017336368,0.0006230739,0.008765897],"genre_scores_gemma":[0.9790796,0.0005998601,0.008594025,0.00023839746,0.000046355162,0.000101854566,0.0022270859,0.00005553243,0.009057224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982315,0.000020045452,0.000016065214,0.000045746863,0.000040364073,0.000054576663],"domain_scores_gemma":[0.99995804,0.000007229564,0.0000071470813,0.0000046027676,0.000010318814,0.0000125898505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016840352,0.00037064884,0.00033100048,0.00028046113,0.00016226259,0.00029244347,0.00037624096,0.00069234136,0.0025458303],"category_scores_gemma":[0.00007779822,0.00014438055,0.00037296466,0.00019360485,0.00014355633,0.00020357211,0.00017207058,0.00061094074,0.0011949553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011824782,0.00006924118,0.00009397834,0.000034367113,0.0000082549295,0.00008187639,0.000009523782,0.00012315284,0.997897,0.0001571813,0.000363931,0.0010432701],"study_design_scores_gemma":[0.000038691174,0.00038192957,0.0005893233,0.0000025386862,0.000019099129,0.00028804972,0.0000047431536,0.0013903787,0.99260956,0.00002152755,0.004649561,0.0000046657756],"about_ca_topic_score_codex":0.0006022795,"about_ca_topic_score_gemma":0.0003112962,"teacher_disagreement_score":0.0025458303,"about_ca_system_score_codex":0.00046926405,"about_ca_system_score_gemma":0.00016218476,"threshold_uncertainty_score":0.008516669},"labels":[],"label_agreement":null},{"id":"W2741674151","doi":"10.1158/1538-7445.am2017-3758","title":"Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Antigen; Population; Flow cytometry; Antibody; Peripheral blood mononuclear cell; Immunophenotyping; Cancer research; Monoclonal antibody; Immunology; Chimeric antigen receptor; Medicine; CD3; Biology; Immunotherapy; CD8; In vitro; Immune system","score_opus":0.19397652111056424,"score_gpt":0.4941647106937867,"score_spread":0.30018818958322246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741674151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927568,0.0012966244,0.0018891195,0.00025526766,0.00017407526,0.00017696754,0.000753045,0.00024776996,0.0024503358],"genre_scores_gemma":[0.99103034,0.0009918938,0.0014731073,0.00011121198,0.000029625078,0.00023062013,0.0010261808,0.000032188276,0.0050748414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976724,0.000028840557,0.000017646194,0.00004264436,0.000056282985,0.000087410044],"domain_scores_gemma":[0.99992335,0.0000081943535,0.000010998068,0.0000088908,0.000011194544,0.00003734587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000288335,0.0007646359,0.000685316,0.0004644498,0.00016861498,0.0002844493,0.00035534188,0.000519214,0.0022917467],"category_scores_gemma":[0.00012583844,0.00018568446,0.00036158436,0.00026369674,0.0003374271,0.00030969208,0.0001807618,0.0014721699,0.00049411785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026782257,0.0027230193,0.00020124475,0.0002330616,0.00004692829,0.00010413015,0.00010493054,0.00073030574,0.9804166,0.00045865908,0.0009975967,0.011305345],"study_design_scores_gemma":[0.00048171694,0.032564044,0.0021671175,0.000023302986,0.00011615679,0.00018836101,0.00008950548,0.0030606815,0.9566689,0.000194958,0.004425001,0.000020165264],"about_ca_topic_score_codex":0.0028499488,"about_ca_topic_score_gemma":0.0023890669,"teacher_disagreement_score":0.0028499488,"about_ca_system_score_codex":0.0004379502,"about_ca_system_score_gemma":0.00060350425,"threshold_uncertainty_score":0.0076666474},"labels":[],"label_agreement":null},{"id":"W2745610517","doi":"10.1016/j.ccell.2017.07.012","title":"A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma","year":2017,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Oncolytic virus; Immunotherapy; Glioblastoma; Cancer immunotherapy; Cancer research; Cancer; Computational biology; Medicine; Biology; Tumor cells; Internal medicine","score_opus":0.041652691385909615,"score_gpt":0.3458401190213027,"score_spread":0.3041874276353931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745610517","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012902841,0.0109893,0.00031585275,0.9687783,0.015010978,0.00001857255,0.000036393194,0.00003559357,0.0035246727],"genre_scores_gemma":[0.03222679,0.016326591,0.0008653072,0.8481096,0.086899474,0.00009095884,0.00006817656,0.00003298621,0.015380208],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992398,0.0002584724,0.000068014895,0.00007102956,0.0002447837,0.00011785806],"domain_scores_gemma":[0.9986375,0.00085387024,0.00006984589,0.000042991756,0.00016711782,0.00022858336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012227567,0.00047723614,0.0008919146,0.0004073051,0.0015940433,0.0015160395,0.0008684972,0.017326128,0.003832254],"category_scores_gemma":[0.005108492,0.00022748281,0.00073311443,0.00024386913,0.0017938261,0.002300059,0.0010401336,0.018234368,0.0022752536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033453686,0.00015909372,0.0007535527,0.00021427129,0.00004298544,0.0069224904,0.000111450994,0.00035450514,0.001046093,0.018795112,0.896439,0.07482686],"study_design_scores_gemma":[0.00051304867,0.00039630925,0.0006271614,0.00039256792,0.000065927874,0.0068302937,0.00030017385,0.0013780639,0.0013004701,0.0587997,0.9293351,0.00006116288],"about_ca_topic_score_codex":0.0010401233,"about_ca_topic_score_gemma":0.002791601,"teacher_disagreement_score":0.017326128,"about_ca_system_score_codex":0.0022251923,"about_ca_system_score_gemma":0.0015561722,"threshold_uncertainty_score":0.01614499},"labels":[],"label_agreement":null},{"id":"W2745636200","doi":"10.1200/jco.2017.35.15_suppl.10523","title":"Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Adverse effect; Quality of life (healthcare); Internal medicine; Interim analysis; Transplantation; Clinical trial; Refractory (planetary science); Surgery; Oncology","score_opus":0.07681099857292675,"score_gpt":0.42978525930950356,"score_spread":0.3529742607365768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745636200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990594,0.0003279671,0.0000373214,0.000037081958,0.0000034639602,0.000022657801,0.00027034807,0.0000032797177,0.00023854017],"genre_scores_gemma":[0.99942243,0.0001061758,0.000044103155,0.00003294997,0.0000047032913,0.00002397783,0.00030512924,5.4700035e-7,0.000060008213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997148,0.00011736592,0.000025203326,0.000039688308,0.000047477133,0.000055533554],"domain_scores_gemma":[0.99937904,0.00009828289,0.00030547992,0.000017641463,0.000033751443,0.00016588854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008453409,0.0001800213,0.00037352616,0.00018851343,0.00015593968,0.00042097573,0.00017302483,0.000249094,0.0009061577],"category_scores_gemma":[0.0010546026,0.00009336612,0.00046121088,0.00035972532,0.00019670748,0.00033110433,0.00030781847,0.0005621928,0.00013050485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01831583,0.0014716389,0.94830585,0.00014998116,0.00041302977,0.00028349814,0.00026234495,0.0005969953,0.0017350126,0.000038644772,0.0008451753,0.027582021],"study_design_scores_gemma":[0.0006550552,0.014461766,0.9827031,0.000019118816,0.0001815812,0.00043129278,0.00013358769,0.00048610658,0.00045932486,0.000023784403,0.00043719437,0.000008090036],"about_ca_topic_score_codex":0.000769028,"about_ca_topic_score_gemma":0.0010524177,"teacher_disagreement_score":0.0009061577,"about_ca_system_score_codex":0.0004110068,"about_ca_system_score_gemma":0.0002148392,"threshold_uncertainty_score":0.0044706464},"labels":[],"label_agreement":null},{"id":"W2746101152","doi":"10.1016/s0140-6736(17)31816-0","title":"KEYNOTE-006: a success in melanoma, but a long way to go","year":2017,"lang":"en","type":"letter","venue":"The Lancet","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Ipilimumab; Medicine; Nivolumab; Melanoma; Dacarbazine; Internal medicine; Oncology; Discontinuation; Adverse effect; Trametinib; Cancer; Immunotherapy; Cancer research","score_opus":0.06118385273849644,"score_gpt":0.35217894887002316,"score_spread":0.29099509613152674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746101152","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010576061,0.0047546276,0.000055931698,0.96244,0.029637074,0.000006411057,0.00004484447,0.000018753506,0.0029366715],"genre_scores_gemma":[0.00208835,0.0031127993,0.0001240664,0.9157966,0.06659348,0.000023991393,0.000033749693,0.000032620857,0.012194264],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99607,0.0012832049,0.00026073758,0.00050157984,0.0012674711,0.00061699015],"domain_scores_gemma":[0.9923396,0.004062855,0.00045998348,0.00021428992,0.001208496,0.0017148221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00359939,0.0011146081,0.0017464303,0.0005571831,0.0034130383,0.006024361,0.0019248959,0.055202406,0.019223316],"category_scores_gemma":[0.018747455,0.0005294671,0.0014522321,0.0005320505,0.0042407634,0.0058199707,0.0024453367,0.052553505,0.01734698],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007799078,0.000019751358,0.00009902644,0.0000734095,0.000010970864,0.00043960803,0.000033075317,0.000027890379,0.000118274336,0.0027393822,0.98796296,0.008397592],"study_design_scores_gemma":[0.00019782454,0.00009845165,0.00026965913,0.00038104993,0.000021626296,0.0005144662,0.00023857871,0.00013721318,0.00017091072,0.01382597,0.9841037,0.00004058374],"about_ca_topic_score_codex":0.0033529052,"about_ca_topic_score_gemma":0.0057632183,"teacher_disagreement_score":0.055202406,"about_ca_system_score_codex":0.0050586085,"about_ca_system_score_gemma":0.0036651867,"threshold_uncertainty_score":0.064308345},"labels":[],"label_agreement":null},{"id":"W2747143180","doi":"10.13034/jsst.v10i1.116","title":"Revolutionizing Cancer Therapeutics: Molecular Pathways and Techniques in Cancer Immunotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Student Science and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; Cancer; Medicine; Cancer cell; Cancer treatment; Cancer research; Immunology; Internal medicine","score_opus":0.049124493848262805,"score_gpt":0.40551647146991365,"score_spread":0.35639197762165087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747143180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0028270225,0.9229092,0.01718219,0.029060174,0.004022428,0.0001261739,0.00013653259,0.00019178366,0.023544477],"genre_scores_gemma":[0.025989467,0.93869054,0.012290121,0.010687888,0.0026193855,0.0002232978,0.00014948731,0.00005652425,0.009293226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998735,0.00039963814,0.00006868925,0.00016477081,0.0004829518,0.00014894166],"domain_scores_gemma":[0.9990638,0.00046852976,0.00009087213,0.00007416039,0.00019035695,0.000112351845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002534694,0.0009368526,0.0011332866,0.0017320588,0.0007226755,0.003055736,0.0010570412,0.0022870393,0.0061610946],"category_scores_gemma":[0.0017623344,0.0004377083,0.0011047234,0.001334706,0.0033033534,0.0053297603,0.001726879,0.0071792193,0.0027480638],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033325204,0.0004397966,0.0006569745,0.010198907,0.00018035315,0.0005930435,0.0006934403,0.002202461,0.04108083,0.33524913,0.06330526,0.54506654],"study_design_scores_gemma":[0.000070565526,0.00049007597,0.00048541848,0.0016326283,0.00007089024,0.00079134095,0.00028402917,0.00078932365,0.009176259,0.08473917,0.90141845,0.000051906365],"about_ca_topic_score_codex":0.0008353402,"about_ca_topic_score_gemma":0.0011162333,"teacher_disagreement_score":0.0061610946,"about_ca_system_score_codex":0.0020190293,"about_ca_system_score_gemma":0.002247753,"threshold_uncertainty_score":0.020610929},"labels":[],"label_agreement":null},{"id":"W2748186599","doi":"10.3389/fmed.2017.00134","title":"More Haste, Less Speed: Could Public–Private Partnerships Advance Cellular Immunotherapies?","year":2017,"lang":"en","type":"review","venue":"Frontiers in Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Genome Canada; Université de Montréal; Hôpital Maisonneuve-Rosemont; Simon Fraser University","funders":"Alberta Innovates; Genome Alberta; Stem Cell Network; Génome Québec; Genome Canada","keywords":"Commercialization; Business; Private sector; Public relations; Cancer immunotherapy; Public sector; Marketing; Cancer; Immunotherapy; Political science; Economics; Medicine; Economic growth","score_opus":0.22687117474745241,"score_gpt":0.42279938533500394,"score_spread":0.19592821058755153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748186599","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010295591,0.058050003,0.030716853,0.81918263,0.007009118,0.00019792811,0.0001878426,0.00021137421,0.07414864],"genre_scores_gemma":[0.58500016,0.11349017,0.03634915,0.20514691,0.00853461,0.00052571634,0.0002734149,0.00033609604,0.050343793],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9798753,0.013286164,0.000553644,0.001096966,0.0028141981,0.0023736001],"domain_scores_gemma":[0.96166694,0.024322856,0.0027830133,0.002660272,0.0044061583,0.004160744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03854696,0.00058857375,0.0006856122,0.0013196259,0.0030652944,0.015946083,0.001582669,0.009459875,0.017853236],"category_scores_gemma":[0.038224913,0.0005343095,0.0015037261,0.0016882521,0.007842729,0.039855596,0.0087934155,0.009749911,0.0034653563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001382353,0.000111901,0.001075614,0.000893592,0.000055086613,0.00036208137,0.0015930381,0.0011458334,0.00043335464,0.7621881,0.06013293,0.17187011],"study_design_scores_gemma":[0.0000737646,0.00009779344,0.00052468636,0.0012545574,0.00003652445,0.0002653613,0.0025817088,0.00080693676,0.0005693423,0.43983182,0.5539154,0.0000421618],"about_ca_topic_score_codex":0.0019001423,"about_ca_topic_score_gemma":0.0028147923,"teacher_disagreement_score":0.03854696,"about_ca_system_score_codex":0.006461212,"about_ca_system_score_gemma":0.017793726,"threshold_uncertainty_score":0.20385826},"labels":[],"label_agreement":null},{"id":"W2748227909","doi":"10.1016/j.exphem.2017.06.301","title":"Generation of a new, human growth factor-dependent, de novo model of AML from c-MYC-transduced normal human CD34+ hematopoietic cells","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Haematopoiesis; CD34; Myeloid leukemia; Biology; Bone marrow; Leukemia; Cancer research; Myeloid; CD33; Progenitor cell; Stromal cell; Cord blood; Immunology; Stem cell; Molecular biology; Cell biology","score_opus":0.1093038196477219,"score_gpt":0.38482649031607685,"score_spread":0.27552267066835495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748227909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680085,0.00048185015,0.02472588,0.00034793688,0.00015101148,0.00054156344,0.0016435775,0.0002985488,0.003801002],"genre_scores_gemma":[0.9817615,0.00032269218,0.010951431,0.00007356833,0.00001948664,0.0001864042,0.0011846363,0.00005956524,0.0054406733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979407,0.00002579385,0.000024027157,0.000047179292,0.00007843694,0.00003051899],"domain_scores_gemma":[0.9997851,0.00004326161,0.000049264738,0.000038668444,0.000016880802,0.00006681442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003097668,0.00042268593,0.00038439102,0.0005006297,0.00028073214,0.00055460626,0.00057316164,0.00059715804,0.0018843745],"category_scores_gemma":[0.00019183621,0.00021829888,0.00026560508,0.00015889932,0.00032259454,0.00032274405,0.00036541303,0.0013964608,0.00047789374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018696187,0.00015687264,0.0001722173,0.000026836977,0.000007287617,0.000114859395,0.000051181894,0.0005389716,0.9950649,0.0020541844,0.00015896783,0.0014668879],"study_design_scores_gemma":[0.00010141231,0.00050637533,0.001053293,0.0000052427567,0.00002398713,0.00059742236,0.000024062372,0.004101099,0.98432726,0.00033070543,0.008921705,0.0000075126536],"about_ca_topic_score_codex":0.0008498098,"about_ca_topic_score_gemma":0.0009330551,"teacher_disagreement_score":0.0018843745,"about_ca_system_score_codex":0.00053919666,"about_ca_system_score_gemma":0.00031550397,"threshold_uncertainty_score":0.006303847},"labels":[],"label_agreement":null},{"id":"W2749189538","doi":"10.1016/j.jss.2006.12.420","title":"P236","year":2007,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD8; NOD mice; Biology; T-cell receptor; Downregulation and upregulation; Transgene; Molecular biology; Insulitis; Genetically modified mouse; Nod; Cancer research; Laser capture microdissection; Islet; T cell; Antigen; Immunology; Immune system; Gene expression; Endocrinology; Gene; Autoimmunity; Diabetes mellitus","score_opus":0.17742359097034613,"score_gpt":0.507812912080879,"score_spread":0.3303893211105329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749189538","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014295923,0.0034230582,0.001266853,0.007664596,0.011759926,0.00011777557,0.0010151402,0.00051763706,0.9728054],"genre_scores_gemma":[0.0030169992,0.0008645463,0.0003271034,0.0013168772,0.002181261,0.000028032198,0.00033121053,0.000098132514,0.9918358],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983776,0.000015254624,0.000009492447,0.000028945817,0.00008375558,0.000024637977],"domain_scores_gemma":[0.99945873,0.00009281755,0.000020645695,0.00005636906,0.00021856303,0.00015301103],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029161322,0.0006526535,0.00042778353,0.00095455896,0.0010443849,0.0026028387,0.0007046853,0.0017972626,0.6876986],"category_scores_gemma":[0.0012621839,0.0002655296,0.0004217976,0.0006302801,0.0005744655,0.0009561035,0.0007739257,0.001217535,0.44684982],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011394065,0.000046940677,0.00030454755,0.00010000277,0.0000072138287,0.00036302983,0.00003192442,0.000055735032,0.0011532427,0.005244185,0.83670443,0.15587483],"study_design_scores_gemma":[0.000016320844,0.00003299933,0.0007613096,0.000065277585,0.000003910381,0.0007037203,0.00003293287,0.00006360618,0.0003951517,0.0020716104,0.9958488,0.0000043995965],"about_ca_topic_score_codex":0.0020977366,"about_ca_topic_score_gemma":0.005693544,"teacher_disagreement_score":0.3123014,"about_ca_system_score_codex":0.00067283714,"about_ca_system_score_gemma":0.00078997883,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2750629076","doi":"10.1016/j.exphem.2017.09.002","title":"Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Lenalidomide; Transcription factor; Cancer research; Downregulation and upregulation; Diffuse large B-cell lymphoma; Cereblon; Biology; IRF4; Ubiquitin ligase; Molecular biology; Lymphoma; Genetics; Gene; Ubiquitin; Multiple myeloma; Immunology","score_opus":0.027510226992156314,"score_gpt":0.35983815069253416,"score_spread":0.33232792370037784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750629076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998042,0.000441908,0.00037061243,0.000041110532,0.00001398722,0.0000062701647,0.00016152333,0.000016572907,0.0009059312],"genre_scores_gemma":[0.99828976,0.00014616475,0.00026324665,0.000027649474,0.000004778223,0.0000075927574,0.00029222565,0.0000068832396,0.00096171163],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984443,0.00002605972,0.000010998511,0.000030661846,0.000028322784,0.000059497892],"domain_scores_gemma":[0.9999647,0.000006784005,0.000009704404,0.0000047507547,0.000003817809,0.000010334768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000816361,0.00012755602,0.00014047316,0.0001602071,0.00021270577,0.0003552528,0.00011509273,0.00011656568,0.0014611114],"category_scores_gemma":[0.00007395265,0.00010404731,0.00014827696,0.00014020044,0.00017052723,0.00010591385,0.00010213162,0.00032764053,0.0003874139],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043885247,0.000038593847,0.0007144079,0.000016328453,0.0000049805426,0.000019821351,0.000023994064,0.00004432248,0.99772125,0.00010474271,0.000035884404,0.00083671074],"study_design_scores_gemma":[0.00008299015,0.0002662044,0.020368548,0.0000056525937,0.000030581803,0.00014505396,0.00015953367,0.0012889832,0.97428584,0.00007686996,0.0032849812,0.0000047228605],"about_ca_topic_score_codex":0.0010045862,"about_ca_topic_score_gemma":0.0015214803,"teacher_disagreement_score":0.0014611114,"about_ca_system_score_codex":0.00034635596,"about_ca_system_score_gemma":0.00015463016,"threshold_uncertainty_score":0.0048879385},"labels":[],"label_agreement":null},{"id":"W2751257824","doi":"10.2217/rme-2017-0031","title":"Opportunities and Challenges for the Cellular Immunotherapy Sector: A Global Landscape of Clinical Trials","year":2017,"lang":"en","type":"article","venue":"Regenerative Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta; Genome Canada","funders":"Genome Alberta; Alberta Innovates - Health Solutions; University of Alberta; Stem Cell Network; Génome Québec; Canadian Institutes of Health Research; Genome Canada","keywords":"Clinical trial; Identification (biology); Business; Translational research; Immunotherapy; Medicine; Cancer; Biology","score_opus":0.5894884327791456,"score_gpt":0.5097814868901752,"score_spread":0.07970694588897043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751257824","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003454351,0.1545046,0.008389079,0.8193966,0.0034187918,0.00014228081,0.00029935382,0.00016570743,0.010229244],"genre_scores_gemma":[0.16210455,0.37428015,0.060328763,0.36386284,0.026709778,0.0014718286,0.0014467635,0.00053938676,0.009255892],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.96241385,0.02186899,0.0030415703,0.0031104418,0.006730893,0.0028342658],"domain_scores_gemma":[0.8536424,0.08186973,0.008312515,0.005986674,0.026111053,0.024077615],"candidate_categories":["bibliometrics"],"consensus_categories":[],"category_scores_codex":[0.13721783,0.001236021,0.00256245,0.003754759,0.0033137028,0.021235773,0.003980691,0.012150375,0.01928261],"category_scores_gemma":[0.07869703,0.00075455126,0.0022512248,0.003580124,0.010992006,0.024469813,0.009482255,0.014668975,0.0051143505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012547639,0.0008004056,0.005727608,0.0044970876,0.0002406827,0.0007360291,0.0011109036,0.0032026197,0.003589991,0.19790937,0.18008086,0.6008496],"study_design_scores_gemma":[0.00059347204,0.0014160103,0.0047032717,0.00598915,0.00022298627,0.0014906529,0.0039901626,0.0026676713,0.0013777862,0.24748239,0.72986174,0.00020471193],"about_ca_topic_score_codex":0.0017183439,"about_ca_topic_score_gemma":0.0021010872,"teacher_disagreement_score":0.99624527,"about_ca_system_score_codex":0.0063765636,"about_ca_system_score_gemma":0.03383339,"threshold_uncertainty_score":0.72568595},"labels":[],"label_agreement":null},{"id":"W2753212558","doi":"10.1016/j.clml.2017.07.213","title":"Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Interim; Diffuse large B-cell lymphoma; Oncology; Interim analysis; Internal medicine; Clinical trial; Chimeric antigen receptor; Refractory (planetary science); Phases of clinical research; Medicine; Follicular lymphoma; Lymphoma; Biology; Cancer; Immunotherapy","score_opus":0.039864800314428975,"score_gpt":0.37971674502119257,"score_spread":0.3398519447067636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753212558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9379078,0.018129239,0.003386597,0.008943494,0.0014287942,0.0031809069,0.011789616,0.00070966146,0.014523966],"genre_scores_gemma":[0.937161,0.0072457213,0.0061404356,0.013289467,0.00074591424,0.0031349014,0.02184775,0.0002805075,0.010154175],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999348,0.0003443851,0.000021559856,0.00008760126,0.00004833576,0.00015010947],"domain_scores_gemma":[0.9990426,0.00024648325,0.00013433625,0.00009692492,0.0000638473,0.00041577886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033325283,0.0018303607,0.0025182876,0.0002996789,0.00033476015,0.0018858955,0.0010135232,0.001365197,0.004316788],"category_scores_gemma":[0.001661057,0.00051216903,0.002516428,0.00036232936,0.0011328042,0.001503172,0.0006146881,0.004239401,0.0015647188],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75014424,0.0084715495,0.007861417,0.0015501755,0.005848302,0.0004517209,0.00033194828,0.0068738563,0.013704182,0.0015635316,0.046967868,0.15623124],"study_design_scores_gemma":[0.8203355,0.13283935,0.0173411,0.0001910233,0.0027828962,0.00060625875,0.00013938121,0.0025207552,0.0020517402,0.0025138638,0.018605983,0.00007220638],"about_ca_topic_score_codex":0.0008611205,"about_ca_topic_score_gemma":0.0037014366,"teacher_disagreement_score":0.004316788,"about_ca_system_score_codex":0.0011398357,"about_ca_system_score_gemma":0.001879884,"threshold_uncertainty_score":0.017624319},"labels":[],"label_agreement":null},{"id":"W2753890414","doi":"10.1158/1078-0432.ccr-16-3065","title":"Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Clinical trial; Medicine; Surrogate endpoint; Oncology; Clinical endpoint; Milestone; Clinical study design; Drug development; Cancer; Internal medicine; Phases of clinical research; Biomarker; Pharmacology; Drug","score_opus":0.511372098794355,"score_gpt":0.6422053277657701,"score_spread":0.13083322897141514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753890414","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2947968,0.13586277,0.42279488,0.024121555,0.005307313,0.03178465,0.018174311,0.0014268407,0.065730825],"genre_scores_gemma":[0.81790143,0.008193358,0.13420744,0.0049177003,0.0016897755,0.025243375,0.005316179,0.00029111555,0.0022395987],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7200614,0.24694319,0.018539658,0.0035590862,0.009936955,0.0009597266],"domain_scores_gemma":[0.75252956,0.17271422,0.043963846,0.018739542,0.00903304,0.0030198363],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.214657,0.0019493289,0.003077082,0.0030087293,0.0005908596,0.005545587,0.0013353105,0.0018421613,0.0026498316],"category_scores_gemma":[0.23683947,0.00035284975,0.0030732786,0.0038473306,0.002226979,0.004463472,0.0032363152,0.0041587492,0.00090826594],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03908412,0.0016987943,0.12346603,0.018901495,0.009671037,0.00020918385,0.0014148211,0.024137931,0.0057547567,0.05772683,0.019655576,0.6982795],"study_design_scores_gemma":[0.014473105,0.08165504,0.24007551,0.011247864,0.01387122,0.0022030557,0.0015921402,0.09352826,0.028614221,0.30120248,0.21067446,0.00086273765],"about_ca_topic_score_codex":0.00018022259,"about_ca_topic_score_gemma":0.00030347612,"teacher_disagreement_score":0.214657,"about_ca_system_score_codex":0.0015078742,"about_ca_system_score_gemma":0.0027935305,"threshold_uncertainty_score":0.9684677},"labels":[],"label_agreement":null},{"id":"W2754249088","doi":"10.4049/jimmunol.196.supp.55.16","title":"Defining the role of Tim-3 in T cells","year":2016,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"École Nationale d'Administration Publique","funders":"","keywords":"Cytotoxic T cell; T cell; Immune system; Effector; Cell biology; Biology; Stimulation; IL-2 receptor; Ectopic expression; Immunology; T-cell receptor; In vitro; Neuroscience; Cell culture; Genetics","score_opus":0.013075516426153205,"score_gpt":0.2875619280963081,"score_spread":0.27448641167015486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754249088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8998255,0.049509387,0.0350747,0.003881674,0.00052141777,0.00017006289,0.0012479763,0.00014725074,0.009622049],"genre_scores_gemma":[0.9753876,0.010268891,0.010548394,0.00063748745,0.00017256134,0.00007028145,0.0005321,0.00001745674,0.0023652227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986446,0.000027714594,0.00001535882,0.000019404337,0.000026257621,0.000046809004],"domain_scores_gemma":[0.99989927,0.000013151668,0.000025180681,0.000011730963,0.000023283217,0.000027466484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049365015,0.00030357277,0.0001461746,0.00037725398,0.00024418227,0.0007618916,0.00029835472,0.0004951698,0.0012457519],"category_scores_gemma":[0.00017323531,0.00008822775,0.00029533842,0.00025668147,0.0005026679,0.0008198754,0.0003519709,0.0010461251,0.0005443157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041367795,0.00007975083,0.0014203442,0.00035416344,0.000018105751,0.00016833427,0.00008505574,0.00027353043,0.9774484,0.0056779347,0.0004110966,0.013649564],"study_design_scores_gemma":[0.00007267642,0.0007198055,0.014310169,0.00014677108,0.000080533515,0.0011685606,0.00031349316,0.0040705428,0.9307886,0.005708566,0.042596336,0.000023906538],"about_ca_topic_score_codex":0.0003558226,"about_ca_topic_score_gemma":0.00035545471,"teacher_disagreement_score":0.0012457519,"about_ca_system_score_codex":0.00075441,"about_ca_system_score_gemma":0.00037929884,"threshold_uncertainty_score":0.0054736733},"labels":[],"label_agreement":null},{"id":"W2754671817","doi":"10.1016/j.jcyt.2017.06.009","title":"A roadmap for cost-of-goods planning to guide economic production of cell therapy products","year":2017,"lang":"en","type":"review","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Engineering and Physical Sciences Research Council; Natural Sciences and Engineering Research Council of Canada","keywords":"Procurement; Cog; Product (mathematics); Process (computing); Production (economics); Business; Transformative learning; Risk analysis (engineering); Computer science; Economics; Marketing","score_opus":0.24824589398353608,"score_gpt":0.47717196651248867,"score_spread":0.22892607252895258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754671817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011373647,0.8510694,0.037306916,0.03224758,0.0036787074,0.0004319235,0.0010706441,0.00043073876,0.07262683],"genre_scores_gemma":[0.01687009,0.9035688,0.060987603,0.004393185,0.0010005442,0.00043849784,0.0012006824,0.00010750095,0.011433082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984981,0.00037248232,0.00012956468,0.00012637397,0.0007117568,0.00016166267],"domain_scores_gemma":[0.9967906,0.0014666234,0.00028611015,0.00008471389,0.0011722653,0.00019964241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042714416,0.002186006,0.0017758091,0.004597288,0.0006534935,0.005650226,0.0032173435,0.0031413424,0.024237206],"category_scores_gemma":[0.0059741964,0.0006943386,0.0014987269,0.004593345,0.0012042113,0.0059701484,0.002351316,0.004591457,0.0056966576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000659372,0.00017273184,0.0001908262,0.007428155,0.00006989462,0.00022102181,0.000071134295,0.006523076,0.00095891644,0.13570583,0.0815115,0.767081],"study_design_scores_gemma":[0.000022252969,0.00008226673,0.0003565926,0.0079297,0.00006499299,0.00015924675,0.00019502352,0.001883087,0.0005067397,0.043872766,0.94488907,0.000038305334],"about_ca_topic_score_codex":0.008497002,"about_ca_topic_score_gemma":0.010166303,"teacher_disagreement_score":0.024237206,"about_ca_system_score_codex":0.0068749166,"about_ca_system_score_gemma":0.017120892,"threshold_uncertainty_score":0.08108157},"labels":[],"label_agreement":null},{"id":"W2755752847","doi":"10.1038/leu.2017.290","title":"Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia","year":2017,"lang":"en","type":"letter","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Lymphoblastic Leukemia; Immune system; Immunology; Antigen; Medicine; Acute lymphocytic leukemia; Leukemia; Asparaginase","score_opus":0.04461783480646685,"score_gpt":0.32009800181135867,"score_spread":0.2754801670048918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755752847","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14721294,0.039178602,0.016241703,0.7216323,0.02737957,0.00034698466,0.00021636736,0.0005200379,0.047271512],"genre_scores_gemma":[0.74581075,0.017146643,0.008192705,0.17613283,0.024701888,0.00042842986,0.00021246388,0.000103514336,0.027270773],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99970645,0.000103086604,0.000021764043,0.00002982746,0.000072538925,0.00006617871],"domain_scores_gemma":[0.9996463,0.00023036689,0.00002454394,0.00002758347,0.000034410255,0.000036692807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000540885,0.00025805365,0.00043724626,0.00015790323,0.00039177953,0.0007584181,0.0003698755,0.0029940899,0.0021163498],"category_scores_gemma":[0.0012773077,0.00010821382,0.00026409404,0.00008912188,0.00059812097,0.0005438448,0.00039799884,0.003668915,0.0009340054],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025970337,0.0010586326,0.0049452297,0.0009560758,0.00012247816,0.02447834,0.00027759065,0.0028119998,0.071211234,0.06475606,0.4015805,0.42520475],"study_design_scores_gemma":[0.0014971544,0.0020660702,0.0020283165,0.00013212264,0.00011072009,0.024451308,0.00019975817,0.008277627,0.063500725,0.02937016,0.8683247,0.00004135351],"about_ca_topic_score_codex":0.000117228585,"about_ca_topic_score_gemma":0.00025256161,"teacher_disagreement_score":0.0029940899,"about_ca_system_score_codex":0.0008557905,"about_ca_system_score_gemma":0.0002720716,"threshold_uncertainty_score":0.0070798993},"labels":[],"label_agreement":null},{"id":"W2756071038","doi":"10.1182/blood-2017-06-793141","title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Juno Therapeutics; National Institutes of Health","keywords":"Chimeric antigen receptor; Cytokine release syndrome; CD19; Immunology; Receptor; Antigen; Medicine; Cell therapy; Cytokine; Immunotherapy; Cancer research; Biology; Cell; Immune system; Internal medicine; Biochemistry","score_opus":0.021497684031937653,"score_gpt":0.2764908282456986,"score_spread":0.25499314421376096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756071038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412185,0.0017625546,0.0027718963,0.000072414914,0.000022742295,0.000040566854,0.00024944593,0.00006529689,0.00089315453],"genre_scores_gemma":[0.99819946,0.00025439932,0.0009800277,0.000033118864,0.000018681632,0.000016537912,0.0002710366,0.0000059128233,0.000220734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970144,0.000080644495,0.000034380402,0.0000459672,0.0000922318,0.000045371613],"domain_scores_gemma":[0.9982222,0.0005465198,0.0007314143,0.00007521549,0.00016059288,0.00026408423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061556336,0.0002860315,0.0004356835,0.0005996933,0.00012026611,0.0005685274,0.0001428937,0.00030758086,0.00060665625],"category_scores_gemma":[0.0018484242,0.00010761317,0.00023179535,0.00044667354,0.00014497874,0.0003440662,0.00018552464,0.00055903033,0.00017461009],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009454043,0.00031513802,0.846564,0.000093958595,0.0002186729,0.0013558863,0.00016800164,0.005309955,0.07205258,0.00036469422,0.00069341046,0.063409545],"study_design_scores_gemma":[0.000089096895,0.004299868,0.9217983,0.00003909524,0.00027779274,0.003169505,0.00011771012,0.029425437,0.038175948,0.00042854698,0.002135611,0.000043053187],"about_ca_topic_score_codex":0.00035554552,"about_ca_topic_score_gemma":0.0004309363,"teacher_disagreement_score":0.00061556336,"about_ca_system_score_codex":0.00021221775,"about_ca_system_score_gemma":0.00018424673,"threshold_uncertainty_score":0.0032554865},"labels":[],"label_agreement":null},{"id":"W2757868227","doi":"10.2741/4605","title":"Immune ligands for cytotoxic T Lymphocytes CTLS in cancer stem cells CSCS","year":2017,"lang":"en","type":"article","venue":"Frontiers in bioscience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Cytotoxic T cell; Immune system; Cancer stem cell; Cancer; Cancer research; Cancer cell; Stem cell; Immunology; Immunotherapy; Biology; Medicine; Cell biology; In vitro; Internal medicine; Genetics","score_opus":0.038385817761890324,"score_gpt":0.33806210878583753,"score_spread":0.2996762910239472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757868227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8032164,0.15483618,0.013112021,0.0028354528,0.00041230794,0.00012201989,0.00026811485,0.00033735912,0.024860207],"genre_scores_gemma":[0.9623706,0.023698192,0.0029562353,0.0004006536,0.00019633853,0.000055530392,0.00022914557,0.000019589217,0.01007378],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999149,0.000018264027,0.000006118383,0.000014626348,0.000028193777,0.00001788682],"domain_scores_gemma":[0.99991,0.000023119375,0.000026480877,0.0000054813086,0.000019310699,0.000015644442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000150839,0.00020595477,0.00024916718,0.000465966,0.00014989456,0.0004165731,0.00015526371,0.0002815282,0.0025186792],"category_scores_gemma":[0.00013605476,0.000059586855,0.0001885206,0.00024357352,0.00028157193,0.00031635637,0.00023261007,0.000452235,0.00044984152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035046283,0.00015711019,0.002133855,0.00076509506,0.000019030605,0.0006173454,0.00017849567,0.00051128486,0.8557917,0.0077312114,0.0013989172,0.13034552],"study_design_scores_gemma":[0.000050276176,0.0013179835,0.009267032,0.00018776221,0.00009751916,0.0027733862,0.0003197205,0.0017445331,0.8624425,0.0036439607,0.11813791,0.000017434037],"about_ca_topic_score_codex":0.00016080827,"about_ca_topic_score_gemma":0.0003101004,"teacher_disagreement_score":0.0025186792,"about_ca_system_score_codex":0.00039020844,"about_ca_system_score_gemma":0.00025820304,"threshold_uncertainty_score":0.008425832},"labels":[],"label_agreement":null},{"id":"W2760319029","doi":"10.1016/j.cjca.2017.07.056","title":"RNA-SEQ DATA ANALYSIS IDENTIFIES STEM CELL TRANSCRIPTOMIC SIGNATURES UNDERPINNING THE THERAPEUTIC EFFECTIVENESS OF PATIENT CELLS IN THE IMPACT-CABG TRIAL","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Transcriptome; Ejection fraction; Bioinformatics; Stem cell; Stem-cell therapy; Clinical trial; Gene expression; Heart failure; Oncology; Computational biology; Internal medicine; Gene; Biology; Genetics; Transplantation","score_opus":0.05987179097038111,"score_gpt":0.3432953018408447,"score_spread":0.28342351087046364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760319029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802223,0.0016688068,0.0035710516,0.0012655263,0.00022319784,0.00017949012,0.009256118,0.000086303065,0.0035272504],"genre_scores_gemma":[0.980489,0.0006751064,0.0040052994,0.0015542108,0.00022227115,0.0004514184,0.010956978,0.000074224496,0.0015714827],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998803,0.0004447957,0.00008385959,0.00025108582,0.00026934932,0.00014798489],"domain_scores_gemma":[0.9985896,0.00081806927,0.00019745821,0.000107227446,0.00017637777,0.00011120983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025349727,0.00035653004,0.00085015444,0.00040631735,0.00033648382,0.0013744072,0.00031449043,0.0005697417,0.0027854047],"category_scores_gemma":[0.003473875,0.00018846974,0.00073540077,0.00049214927,0.0005013066,0.00033307614,0.0003891369,0.0011144711,0.00058966555],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09853873,0.0026463394,0.3043479,0.0018937025,0.0052911746,0.0007400891,0.0012478671,0.013304745,0.34414166,0.0049894913,0.023497296,0.19936101],"study_design_scores_gemma":[0.0065382496,0.014269225,0.7304492,0.00048432147,0.0094256,0.0012532745,0.0022208719,0.037314773,0.14126775,0.014365451,0.042060506,0.00035080753],"about_ca_topic_score_codex":0.00044733737,"about_ca_topic_score_gemma":0.0011824893,"teacher_disagreement_score":0.0027854047,"about_ca_system_score_codex":0.0002797449,"about_ca_system_score_gemma":0.0007029042,"threshold_uncertainty_score":0.013406396},"labels":[],"label_agreement":null},{"id":"W2762831145","doi":"10.1016/j.omtm.2017.10.003","title":"Targeted Cell-to-Cell Delivery of Protein Payloads via the Granzyme-Perforin Pathway","year":2017,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"BC Cancer Foundation; Genome British Columbia","keywords":"Granzyme; Granzyme B; Perforin; Cell biology; Cytotoxic T cell; Biology; Granzyme A; Chemistry; Biochemistry","score_opus":0.08815676302751622,"score_gpt":0.431487083930083,"score_spread":0.34333032090256677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762831145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9542392,0.0017450675,0.042168763,0.0001782515,0.000036876092,0.000081521895,0.0002200722,0.00025636706,0.0010739358],"genre_scores_gemma":[0.975964,0.0016757279,0.019949555,0.0000688471,0.000009744585,0.000055456745,0.00022881047,0.00003420862,0.0020136014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991345,0.000016173355,0.000007067894,0.000019830188,0.000023264614,0.000020247413],"domain_scores_gemma":[0.9999378,0.000012354973,0.000022939528,0.000008272624,0.0000062981335,0.000012440597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012505159,0.00028441355,0.00024353407,0.000118667056,0.00012331142,0.00032579002,0.0001740529,0.00029778806,0.0005751994],"category_scores_gemma":[0.000114408176,0.00008987607,0.00020445445,0.00012526319,0.00021277007,0.00032553545,0.00033532106,0.0004497695,0.00032074287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021707849,0.000012390542,0.000065839726,0.000029018049,0.00000338548,0.0000505611,0.000010122417,0.0002190881,0.99731547,0.0002583905,0.000022661132,0.0019912561],"study_design_scores_gemma":[0.000009448913,0.00012486045,0.00026081715,0.0000026491832,0.00000860121,0.00014927631,0.0000075812154,0.0008408424,0.99593794,0.0000617486,0.0025924938,0.0000036668685],"about_ca_topic_score_codex":0.000112853,"about_ca_topic_score_gemma":0.00015116988,"teacher_disagreement_score":0.0005751994,"about_ca_system_score_codex":0.00024901994,"about_ca_system_score_gemma":0.00021175994,"threshold_uncertainty_score":0.0019241571},"labels":[],"label_agreement":null},{"id":"W2763124655","doi":"10.4049/jimmunol.196.supp.140.34","title":"The increase in thymopoiesis following T cell progenitor therapy is dependent upon the input population and continued interaction between developing T cells and the thymic microenvironment.","year":2016,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Thymocyte; Biology; Lymphopoiesis; Progenitor cell; Haematopoiesis; Population; T cell; Cell biology; Immunology; Recombination-activating gene; Stem cell; Andrology; Internal medicine; Immune system; Biochemistry; Medicine","score_opus":0.01583986409306786,"score_gpt":0.2770231082955858,"score_spread":0.26118324420251793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763124655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934155,0.0018880272,0.0026100671,0.000027954318,0.000020262762,0.000027811417,0.00019950814,0.00006305637,0.0017478815],"genre_scores_gemma":[0.99512863,0.0007504832,0.0016751997,0.00003055386,0.00001365919,0.00004040725,0.0003119021,0.000023424,0.0020257328],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988437,0.000019468078,0.0000113029055,0.000021512691,0.000039502513,0.000023855111],"domain_scores_gemma":[0.9998863,0.000027204835,0.000023534642,0.000013849652,0.000011941526,0.000037264155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012440981,0.00021405729,0.00019379215,0.00016447048,0.00008573011,0.0002562973,0.00010879655,0.00016131336,0.0013204287],"category_scores_gemma":[0.00008541823,0.00007061442,0.00013011417,0.0000795743,0.00012017428,0.0001190808,0.00014954308,0.0006812588,0.00026893168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010527622,0.00003198488,0.0004390297,0.000024660672,0.0000029687967,0.000030785654,0.000009419101,0.000027946573,0.9964798,0.000034809604,0.000018386334,0.0027949894],"study_design_scores_gemma":[0.00000975571,0.0011983834,0.011668671,0.000011765209,0.000021803055,0.0004483426,0.000027039125,0.00041179894,0.98411256,0.000053070857,0.0020346576,0.0000021724836],"about_ca_topic_score_codex":0.00008413561,"about_ca_topic_score_gemma":0.00017870749,"teacher_disagreement_score":0.0013204287,"about_ca_system_score_codex":0.000092452334,"about_ca_system_score_gemma":0.00012502512,"threshold_uncertainty_score":0.0044172406},"labels":[],"label_agreement":null},{"id":"W2763751953","doi":"10.1158/2159-8290.cd-17-0698","title":"Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1364,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Juno Therapeutics","keywords":"Neurotoxicity; Medicine; Cytokine release syndrome; Immunology; Bone marrow; Blood–brain barrier; Pericyte; Endothelium; Chimeric antigen receptor; Cancer research; Immunotherapy; Endothelial stem cell; Internal medicine; Central nervous system; Immune system; Toxicity; Biology","score_opus":0.017069140314072143,"score_gpt":0.30439871479742864,"score_spread":0.2873295744833565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763751953","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075185173,0.42324287,0.00060431194,0.4862315,0.07027319,0.00012365777,0.00068694015,0.00021056471,0.01110847],"genre_scores_gemma":[0.06331016,0.35523936,0.00055849814,0.40285763,0.1501054,0.00034576954,0.0006228997,0.00012418689,0.026836067],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985103,0.00047093126,0.0001132152,0.00028151285,0.00046751965,0.00015653048],"domain_scores_gemma":[0.9965102,0.001984771,0.00029197085,0.00009550216,0.00089235086,0.00022510432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030795129,0.00077226624,0.0010945988,0.001021493,0.00076922216,0.00190897,0.0015187713,0.009621013,0.0030028897],"category_scores_gemma":[0.0048096953,0.00040419566,0.00085642724,0.00084754714,0.0015168968,0.001169175,0.00090962136,0.014093644,0.0018719629],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010204465,0.00016863523,0.0023046406,0.0013695271,0.00019836081,0.0016505667,0.0002077975,0.00023873476,0.003600594,0.003389147,0.86549985,0.12035166],"study_design_scores_gemma":[0.000800859,0.0007806738,0.018696977,0.003718309,0.00044072815,0.002297348,0.0003195995,0.000806917,0.0034726474,0.005841668,0.96267617,0.00014817821],"about_ca_topic_score_codex":0.007923318,"about_ca_topic_score_gemma":0.010802173,"teacher_disagreement_score":0.009621013,"about_ca_system_score_codex":0.0036451938,"about_ca_system_score_gemma":0.002487114,"threshold_uncertainty_score":0.026447892},"labels":[],"label_agreement":null},{"id":"W2765591174","doi":"10.3389/fimmu.2017.01460","title":"Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells","year":2017,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; FOXP3; Immune system; Adoptive cell transfer; Immunology; Autoimmunity; Antigen; Cell therapy; Transplantation; T cell; Biology; Regulatory T cell; Immune tolerance; Stem cell; Cancer research; Medicine; Cell biology; IL-2 receptor","score_opus":0.05643181468725787,"score_gpt":0.313203595503149,"score_spread":0.25677178081589114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765591174","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052702916,0.996384,0.0008191466,0.00021569972,0.00026373347,0.000010284747,0.000016797982,0.000019101508,0.0017440564],"genre_scores_gemma":[0.0028097364,0.9948456,0.00066312624,0.00026553814,0.00013966719,0.000014677049,0.000035546742,0.00000386261,0.0012221554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998388,0.000025237723,0.000014199442,0.000027607704,0.00007181952,0.000022290233],"domain_scores_gemma":[0.9999095,0.000033970886,0.000015698972,0.0000039893744,0.000024767292,0.000012037897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004983577,0.00081196456,0.0008092441,0.0013138871,0.00014572189,0.0006590981,0.00068024214,0.0008207381,0.0013112469],"category_scores_gemma":[0.00031573416,0.00021396301,0.00031730483,0.0009873003,0.00046300195,0.0009264294,0.00054885476,0.0014068887,0.0013424814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000791434,0.00009130023,0.00013761965,0.00920541,0.000055247732,0.00019971875,0.000056045235,0.0008609266,0.019940676,0.0102217235,0.014140028,0.9450121],"study_design_scores_gemma":[0.000024097157,0.0001398697,0.00038120477,0.0009739782,0.000046634013,0.0008865822,0.000031539203,0.00019656717,0.005127067,0.0022497058,0.9899255,0.000017265073],"about_ca_topic_score_codex":0.00044130697,"about_ca_topic_score_gemma":0.0005809513,"teacher_disagreement_score":0.0013138871,"about_ca_system_score_codex":0.0005794278,"about_ca_system_score_gemma":0.0005668238,"threshold_uncertainty_score":0.004386544},"labels":[],"label_agreement":null},{"id":"W2766125827","doi":"10.1136/jclinpath-2017-204761","title":"T cell clonality assessment: past, present and future","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Pfizer Canada; Terry Fox Research Institute; Terry Fox Foundation; Canada Foundation for Innovation; Ontario Institute for Cancer Research; Pfizer; Princess Margaret Cancer Foundation; University of Calgary; Multiple Myeloma Research Foundation","keywords":"Computational biology; Biology; Bioinformatics; Cell; T cell; Function (biology); Immunology; Genetics; Immune system","score_opus":0.33858689799350855,"score_gpt":0.5972838326131215,"score_spread":0.2586969346196129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766125827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022673466,0.9971244,0.00063404284,0.00089681894,0.00019009544,0.0000069088305,0.000018850145,0.000013867528,0.00088832795],"genre_scores_gemma":[0.0023009179,0.99424464,0.0016804626,0.00063378364,0.0005023077,0.000020372836,0.00003910072,0.0000075747953,0.0005708668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925846,0.0001772232,0.00009268407,0.00015184587,0.00027131458,0.000048475224],"domain_scores_gemma":[0.9972439,0.0017013588,0.00024047616,0.00007504509,0.0005991844,0.00014009043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003239829,0.0008581517,0.0013214087,0.0033424303,0.00034350657,0.0019092398,0.0011926867,0.0018238827,0.0018910409],"category_scores_gemma":[0.002755546,0.00037592405,0.00053473795,0.0020710032,0.0015134448,0.0028382177,0.0008974689,0.0021416426,0.0013496137],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055376266,0.000042202755,0.0007766618,0.005264788,0.00003943029,0.00019330613,0.00010660453,0.00028403485,0.0019552386,0.0064983126,0.013463551,0.97132057],"study_design_scores_gemma":[0.000014039617,0.00018372833,0.0019938513,0.004191138,0.00012389438,0.003344353,0.00022162545,0.00044864326,0.0030557534,0.0082893055,0.9780622,0.0000713969],"about_ca_topic_score_codex":0.0012628844,"about_ca_topic_score_gemma":0.0017171835,"teacher_disagreement_score":0.0033424303,"about_ca_system_score_codex":0.0009834957,"about_ca_system_score_gemma":0.0014155592,"threshold_uncertainty_score":0.01713401},"labels":[],"label_agreement":null},{"id":"W2766414528","doi":"10.3389/fimmu.2017.01418","title":"Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data","year":2017,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Simon Fraser University","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health; Agence Nationale de la Recherche; Genentech; Illumina; National Institute of Allergy and Infectious Diseases; Amgen","keywords":"Computer science; Acquired immune system; Data sharing; Protocol (science); Reuse; USable; Data science; Computational biology; Immune system; Medicine; Immunology; Biology; World Wide Web","score_opus":0.0581464792657464,"score_gpt":0.33131980892766344,"score_spread":0.27317332966191704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766414528","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reproducibility","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"reproducibility","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.074052654,0.006622583,0.84864235,0.00983027,0.0031582299,0.0015165656,0.021675648,0.0117446985,0.022757024],"genre_scores_gemma":[0.34684572,0.0037303204,0.5823588,0.0046581454,0.002023268,0.0029117754,0.043827657,0.007896257,0.005748036],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.7372102,0.122264445,0.022234194,0.026449423,0.08853054,0.003311225],"domain_scores_gemma":[0.4222056,0.13240625,0.018376267,0.35606238,0.06748466,0.0034647982],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.20524389,0.0015972734,0.00280366,0.00937022,0.0029696682,0.01467402,0.0077063604,0.0024235744,0.004032587],"category_scores_gemma":[0.33150557,0.0016207471,0.0024731017,0.009490664,0.006702701,0.00876162,0.01325078,0.0044007585,0.0055878554],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018572445,0.00044134335,0.06974568,0.0045932755,0.0039677783,0.00087030034,0.009145501,0.011606882,0.091357455,0.080754235,0.06026995,0.66539043],"study_design_scores_gemma":[0.00036768185,0.00080602965,0.061599854,0.0034124402,0.0017804444,0.0020693145,0.0024778335,0.032776136,0.22990893,0.15637627,0.5077101,0.0007149416],"about_ca_topic_score_codex":0.0032151772,"about_ca_topic_score_gemma":0.0034548119,"teacher_disagreement_score":0.7947561,"about_ca_system_score_codex":0.0031282548,"about_ca_system_score_gemma":0.0097557865,"threshold_uncertainty_score":0.9800758},"labels":[],"label_agreement":null},{"id":"W2766745670","doi":"10.1182/blood-2017-07-793760","title":"Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Juno Therapeutics; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Washington State University","keywords":"Chimeric antigen receptor; Immunotherapy; Medicine; CD19; Antigen; Immunology; Virology; Cancer research; Immune system","score_opus":0.030049117923058317,"score_gpt":0.31668949529388235,"score_spread":0.28664037737082404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766745670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903266,0.0044367034,0.001954277,0.0001759053,0.0000807364,0.000111378205,0.00036766796,0.000025948135,0.0025207475],"genre_scores_gemma":[0.9978795,0.0005294741,0.00026337296,0.00007712168,0.000068913476,0.000030017025,0.00031990657,0.000007690146,0.00082415465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897635,0.00040639474,0.00010497944,0.00010860839,0.000200367,0.00020326336],"domain_scores_gemma":[0.9961808,0.0015756906,0.0013766794,0.00032445867,0.00016827814,0.00037413085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00147506,0.00029539948,0.00070252386,0.00016009362,0.00020207818,0.0005917357,0.00023760584,0.00028278446,0.0032524557],"category_scores_gemma":[0.0030718746,0.00015678506,0.0012661972,0.0002845003,0.00015448352,0.00035883105,0.00043313843,0.0014040224,0.00019027048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054014727,0.0019206542,0.76434755,0.00075736316,0.0045433748,0.0030923085,0.00014265162,0.00353261,0.0069552255,0.0010406496,0.0039897575,0.15566304],"study_design_scores_gemma":[0.0009270134,0.00953772,0.9654205,0.00014167151,0.0021586549,0.004207913,0.00010027741,0.007854798,0.0026237129,0.0008219693,0.0061744074,0.000031396874],"about_ca_topic_score_codex":0.00061845395,"about_ca_topic_score_gemma":0.00084680895,"teacher_disagreement_score":0.0032524557,"about_ca_system_score_codex":0.00032674219,"about_ca_system_score_gemma":0.0006106072,"threshold_uncertainty_score":0.01088053},"labels":[],"label_agreement":null},{"id":"W2767090199","doi":"10.1158/1078-0432.ccr-17-2228","title":"Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Institutes of Health; Canadian Cancer Society; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Immunotherapy; Leukemia; Medicine; Immunology; Myeloid; Cancer research; Biology; Immune system","score_opus":0.42368212276545314,"score_gpt":0.5829602507286331,"score_spread":0.15927812796317997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767090199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977236,0.012455497,0.006912162,0.0002797197,0.00008664396,0.00011227242,0.00011692612,0.00005894562,0.0027418183],"genre_scores_gemma":[0.99484575,0.0025367024,0.0012783307,0.00009313598,0.000029160923,0.000041839827,0.00010766934,0.0000034420948,0.0010638735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992,0.000022943235,0.000006127126,0.000019234873,0.000018050803,0.000013727732],"domain_scores_gemma":[0.99997544,0.000003904289,0.0000074333293,0.0000043108985,0.0000025279464,0.0000063987636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013787046,0.00028830173,0.00017440958,0.0001082548,0.000063552005,0.00026314624,0.00015010654,0.00019344561,0.00076473673],"category_scores_gemma":[0.00006230493,0.00005088842,0.000116158786,0.000071417104,0.00019248777,0.0001564019,0.00016299388,0.0003312218,0.00014962467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008453648,0.0003189789,0.0020843614,0.00026982903,0.00002231982,0.00037503088,0.0000429474,0.000785901,0.95762527,0.0016183613,0.0003138764,0.03569775],"study_design_scores_gemma":[0.0005898294,0.010790437,0.012390125,0.00008471575,0.00018942766,0.008612816,0.00011184261,0.006363585,0.9216873,0.001606166,0.03755636,0.000017395569],"about_ca_topic_score_codex":0.000049287468,"about_ca_topic_score_gemma":0.000080190104,"teacher_disagreement_score":0.00076473673,"about_ca_system_score_codex":0.00012370088,"about_ca_system_score_gemma":0.00011252033,"threshold_uncertainty_score":0.002558291},"labels":[],"label_agreement":null},{"id":"W2767484600","doi":"10.1093/neuonc/nox168.913","title":"RTHP-31. A 40-YEAR MULTI-INSTITUTIONAL REVIEW OF INTRACRANIAL GERM CELL TUMORS IN ADOLESCENTS AND YOUNG ADULT","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Germ cell tumors; Germinoma; Radiation therapy; Internal medicine; Cancer; Surgery; Pediatrics","score_opus":0.03156829688521367,"score_gpt":0.3459923063730421,"score_spread":0.31442400948782845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767484600","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.940698,0.02893248,0.0009932391,0.00035530186,0.00012083201,0.00050878257,0.019047797,0.00011036621,0.0092330985],"genre_scores_gemma":[0.9705573,0.010946366,0.0016507583,0.00027574392,0.000110942405,0.00033606682,0.014053523,0.00003533887,0.00203403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993253,0.00012664014,0.00021410703,0.000086106964,0.00017530374,0.00007258135],"domain_scores_gemma":[0.9963321,0.00055131456,0.0017728461,0.00017103809,0.0009046457,0.00026807023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092336227,0.00016005228,0.0002451646,0.002300222,0.00037010916,0.00043123955,0.00038236135,0.0002136281,0.0018350729],"category_scores_gemma":[0.002742239,0.0001613529,0.00028488683,0.0023536796,0.00019211975,0.00037965502,0.00040284893,0.00018236817,0.0005179067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019720805,0.0000385962,0.9210365,0.0011845286,0.00012300907,0.009285771,0.00077939854,0.00011027094,0.0022926682,0.0000982219,0.0069429087,0.057910804],"study_design_scores_gemma":[0.000015020729,0.00012895152,0.95457417,0.0004591747,0.00009510728,0.020207567,0.00065478554,0.0001094794,0.0010516132,0.000027255372,0.02266678,0.000010163484],"about_ca_topic_score_codex":0.007181807,"about_ca_topic_score_gemma":0.009601046,"teacher_disagreement_score":0.007181807,"about_ca_system_score_codex":0.0006216004,"about_ca_system_score_gemma":0.0015555301,"threshold_uncertainty_score":0.014279962},"labels":[],"label_agreement":null},{"id":"W2767574526","doi":"10.1182/blood-2017-05-787598","title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Transgene; Biology; Cancer research; CRISPR; Immunology; Molecular biology; Cell biology; T cell; Genetics; Gene; Immune system","score_opus":0.034131408438636324,"score_gpt":0.3280309917116137,"score_spread":0.2938995832729774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767574526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847996,0.0007289553,0.00940085,0.0001810598,0.00006153004,0.00005026574,0.0006087171,0.00055491517,0.0036140233],"genre_scores_gemma":[0.9955272,0.00022893726,0.0024340674,0.00003881586,0.000009655343,0.000012531794,0.00033122642,0.000040649662,0.0013770022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997489,0.000039867045,0.000027845648,0.00006426515,0.000063019754,0.000056031262],"domain_scores_gemma":[0.9998845,0.000034484856,0.000027570051,0.000018539018,0.000008693125,0.000026201365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017944019,0.00028034727,0.00024785052,0.0002075559,0.00009696023,0.0004891444,0.00019675682,0.00036020332,0.0018649003],"category_scores_gemma":[0.00022578952,0.000097991506,0.00015462324,0.00012818689,0.00017996295,0.00012273695,0.00015169274,0.0005508762,0.0003437695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010482073,0.000036723668,0.00023430426,0.000018683544,0.000009225495,0.00006809389,0.000013033654,0.00020603226,0.9958151,0.00018991192,0.00011982668,0.0031842396],"study_design_scores_gemma":[0.0000536795,0.00039694604,0.0016327605,0.0000047442727,0.000053968237,0.00063121354,0.000016323524,0.0019198343,0.9899677,0.00010369389,0.0052133156,0.0000058872556],"about_ca_topic_score_codex":0.0004483295,"about_ca_topic_score_gemma":0.00083077385,"teacher_disagreement_score":0.0018649003,"about_ca_system_score_codex":0.00021039702,"about_ca_system_score_gemma":0.00018098477,"threshold_uncertainty_score":0.0062387586},"labels":[],"label_agreement":null},{"id":"W2767639660","doi":"10.1093/neuonc/nox168.182","title":"CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Epithelial cell adhesion molecule; Antigen; Population; Monoclonal antibody; Cancer research; Flow cytometry; Antibody; Cancer stem cell; Cancer; Metastasis; Biology; Immunology; Medicine; Genetics","score_opus":0.08009285261940259,"score_gpt":0.40502036812942266,"score_spread":0.3249275155100201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767639660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97500855,0.002235413,0.015768481,0.00023155818,0.000061160106,0.00065935287,0.0013799036,0.00016660053,0.0044890093],"genre_scores_gemma":[0.97502327,0.0012857902,0.011818044,0.00026777346,0.000018234521,0.0003780519,0.0043601636,0.000028567625,0.0068200855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985814,0.000026986267,0.000009016184,0.000030611598,0.00004059232,0.000034536606],"domain_scores_gemma":[0.9999497,0.00001213361,0.0000053735153,0.000004271639,0.000013124466,0.000015449188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022453173,0.0003875801,0.00028460883,0.00021524639,0.000104938,0.00018931643,0.00023162435,0.00048288493,0.0016878663],"category_scores_gemma":[0.00017014408,0.000128442,0.0002716408,0.00013502521,0.00007659443,0.000095194075,0.00016284878,0.0005951401,0.00043095314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008111839,0.00009354067,0.000105117055,0.0000486531,0.0000073394203,0.000032536707,0.000012720093,0.0002418104,0.9968747,0.00004496013,0.00012443308,0.0023329235],"study_design_scores_gemma":[0.00005175892,0.0016935375,0.0023291495,0.000010161084,0.000029965851,0.0003041733,0.000013764317,0.0023550477,0.9893596,0.000037447066,0.0038097145,0.000005711921],"about_ca_topic_score_codex":0.00047362313,"about_ca_topic_score_gemma":0.0008495107,"teacher_disagreement_score":0.0016878663,"about_ca_system_score_codex":0.0001789655,"about_ca_system_score_gemma":0.00011363373,"threshold_uncertainty_score":0.0056464076},"labels":[],"label_agreement":null},{"id":"W2768137129","doi":"10.1111/imm.12870","title":"Immune correlates of clinical outcome in melanoma","year":2017,"lang":"en","type":"review","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Immunotherapy; Blockade; Melanoma; Immune system; Immunology; Immune checkpoint; Medicine; Antibody; Cancer research; Internal medicine","score_opus":0.2773866442031829,"score_gpt":0.5278624877814799,"score_spread":0.25047584357829705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768137129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21843772,0.76762265,0.00078247517,0.0016151307,0.00049258687,0.00004226466,0.0008932951,0.000038455702,0.010075414],"genre_scores_gemma":[0.7826457,0.211939,0.00044206867,0.0006906549,0.001136647,0.000061216626,0.0013200332,0.000014478343,0.0017502265],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997936,0.00006988061,0.000027412189,0.000042512416,0.00003815585,0.000028477509],"domain_scores_gemma":[0.9992663,0.0002717857,0.00028307206,0.000020402133,0.00009243728,0.0000660093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004524558,0.0001663118,0.00047153514,0.0006570494,0.00008964651,0.00048004228,0.00021071502,0.00029149844,0.0014288144],"category_scores_gemma":[0.0016845625,0.000046783352,0.00021672045,0.0008150468,0.00018197336,0.00020052829,0.00027543897,0.00053529,0.00033124798],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002126933,0.00017143686,0.5611641,0.002573868,0.0008809068,0.0013485132,0.0002481702,0.00072170893,0.0048873387,0.0015201644,0.007773349,0.41658345],"study_design_scores_gemma":[0.000029025901,0.00057667645,0.9661389,0.00060373655,0.00036487362,0.0029836579,0.00013553255,0.0002969926,0.0004733159,0.0012784638,0.027092176,0.000026610835],"about_ca_topic_score_codex":0.00027320048,"about_ca_topic_score_gemma":0.0002820467,"teacher_disagreement_score":0.0014288144,"about_ca_system_score_codex":0.00018447718,"about_ca_system_score_gemma":0.00013912439,"threshold_uncertainty_score":0.0047798753},"labels":[],"label_agreement":null},{"id":"W2768576952","doi":"10.1158/0008-5472.can-16-1911","title":"TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; American Association for Cancer Research","keywords":"Triple-negative breast cancer; Triple negative; Cancer; Breast cancer; Medicine; Cancer research; Internal medicine","score_opus":0.14082927648636506,"score_gpt":0.4641538463131926,"score_spread":0.32332456982682756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768576952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868776,0.0036190045,0.004190337,0.000376549,0.00007219964,0.00013238336,0.000115416835,0.00018566527,0.004430692],"genre_scores_gemma":[0.992151,0.0016061995,0.0032018728,0.000085090636,0.000014984695,0.000060747832,0.00012039399,0.000016018077,0.0027435904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999409,0.000013242634,0.0000032641124,0.000011149991,0.00001332935,0.000018190867],"domain_scores_gemma":[0.99997663,0.0000034919217,0.000005210068,0.0000028040004,0.0000036775482,0.000008083777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001376427,0.00022484771,0.00021821668,0.00018239078,0.000094804906,0.00022807156,0.00015945849,0.00024109117,0.0014998885],"category_scores_gemma":[0.00005408577,0.000092142,0.00016124571,0.00008336405,0.00018371941,0.00015783655,0.00014034635,0.0005871475,0.00033999115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052429055,0.00037294134,0.00053541723,0.00012488986,0.000015109288,0.00020535594,0.00004407224,0.00071581244,0.9708919,0.0006091158,0.0008327345,0.025128275],"study_design_scores_gemma":[0.0004001764,0.007481497,0.004792546,0.000026079453,0.0000961369,0.0025006803,0.00006650007,0.005566453,0.95961785,0.00022958708,0.019208876,0.000013690254],"about_ca_topic_score_codex":0.000397258,"about_ca_topic_score_gemma":0.00065799407,"teacher_disagreement_score":0.0014998885,"about_ca_system_score_codex":0.00022198755,"about_ca_system_score_gemma":0.00020521694,"threshold_uncertainty_score":0.005017638},"labels":[],"label_agreement":null},{"id":"W2769557540","doi":"10.4049/jimmunol.190.supp.132.49","title":"Utilizing dual-specific CD4+ T cells in combination with oncolytic virotherapy for treatment of cancer (P2118)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncolytic virus; Adoptive cell transfer; Chimeric antigen receptor; Cancer research; CD8; Cytotoxic T cell; T cell; Immunology; Cell therapy; Medicine; Immune system; Biology; Tumor cells; Stem cell; Cell biology; In vitro","score_opus":0.040831989705213706,"score_gpt":0.3340263686037616,"score_spread":0.29319437889854794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769557540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98394114,0.001972951,0.009496088,0.00031128636,0.00014020166,0.00026574463,0.00016083279,0.00027697577,0.003434863],"genre_scores_gemma":[0.98814595,0.0007424931,0.00792457,0.000089162706,0.00004398293,0.00015571562,0.00014331439,0.000021862621,0.002732966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998857,0.000019079984,0.000008352782,0.00002400936,0.000024745643,0.000038140406],"domain_scores_gemma":[0.999964,0.00000564913,0.0000066877346,0.00000582137,0.0000033537917,0.000014494951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012359089,0.00043714582,0.00030666174,0.0003028169,0.00014393422,0.00043651203,0.0002443467,0.00040772508,0.00075800484],"category_scores_gemma":[0.00008336373,0.00013643476,0.0002577522,0.00014103363,0.00022689426,0.00016135121,0.00022225015,0.0006294094,0.0002336715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046913448,0.00053765025,0.00038313767,0.000078407975,0.00002442294,0.00009058616,0.000019698091,0.0011774024,0.9754041,0.0004353268,0.00031617167,0.021063833],"study_design_scores_gemma":[0.0003080451,0.004794902,0.0018457149,0.000011120818,0.000089584275,0.0005453644,0.000015283313,0.005912814,0.9780449,0.0001995605,0.008221394,0.000011324108],"about_ca_topic_score_codex":0.0006829717,"about_ca_topic_score_gemma":0.0008846595,"teacher_disagreement_score":0.00075800484,"about_ca_system_score_codex":0.00025992238,"about_ca_system_score_gemma":0.0003733102,"threshold_uncertainty_score":0.0025357604},"labels":[],"label_agreement":null},{"id":"W2773872797","doi":"10.1038/nchembio.2529","title":"Human antibody-based chemically induced dimerizers for cell therapeutic applications","year":2017,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Damon Runyon Cancer Research Foundation; University of California, San Francisco; University of Toronto; Howard Hughes Medical Institute; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Small molecule; Antibody; Epitope; Computational biology; Cell; Chemistry; Cell biology; Phage display; Chemical biology; Cell signaling; Signal transduction; Biology; Biochemistry; Immunology","score_opus":0.03464166878283531,"score_gpt":0.4088710815662788,"score_spread":0.3742294127834435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773872797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8795861,0.012785774,0.084601104,0.0011468097,0.00042707066,0.00046000307,0.0005135683,0.00057416706,0.019905388],"genre_scores_gemma":[0.9735007,0.002400752,0.0143796485,0.0003652945,0.000052754298,0.00009628822,0.00036744363,0.00006982687,0.008767248],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983895,0.000060017996,0.000007793969,0.000029406896,0.00003441249,0.000029416882],"domain_scores_gemma":[0.999928,0.000018740056,0.000014851207,0.000010604007,0.000009992275,0.000017732817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039810166,0.0003186496,0.00014354565,0.00019338384,0.00020492423,0.00030329623,0.00034703582,0.00044808895,0.004010743],"category_scores_gemma":[0.0002199582,0.00016977574,0.00019044128,0.00016618292,0.0001886927,0.0003338302,0.00026248622,0.000861801,0.0008889862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011404495,0.00008836907,0.000078677316,0.000053647644,0.000008495732,0.000031001,0.000033459295,0.0003767204,0.9919897,0.0015739449,0.0005269856,0.005124929],"study_design_scores_gemma":[0.000027913251,0.00023267533,0.00014076273,0.000004461373,0.000009103112,0.00008710003,0.000010583769,0.0008394597,0.99222857,0.00015457271,0.006261061,0.0000037948496],"about_ca_topic_score_codex":0.00014648099,"about_ca_topic_score_gemma":0.000311179,"teacher_disagreement_score":0.004010743,"about_ca_system_score_codex":0.00032087654,"about_ca_system_score_gemma":0.00020110863,"threshold_uncertainty_score":0.013417244},"labels":[],"label_agreement":null},{"id":"W2777439917","doi":"10.1136/bmjopen-2017-019321","title":"Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"BMJ Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Health Canada; Ottawa Hospital; University of Winnipeg; Canada's Michael Smith Genome Sciences Centre; University of Ottawa","funders":"Ottawa Hospital Anesthesia Alternate Funds Association","keywords":"Medicine; Chimeric antigen receptor; Meta-analysis; Protocol (science); Immunology; Systematic review; Antigen; Oncology; Immunotherapy; MEDLINE; Bioinformatics; Intensive care medicine; Internal medicine; Alternative medicine; Pathology; Immune system","score_opus":0.31165593145801906,"score_gpt":0.5167738930980517,"score_spread":0.2051179616400326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777439917","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023166966,0.030632423,0.004689063,0.0014624723,0.00077692023,0.9388199,0.019806413,0.000315054,0.0011810921],"genre_scores_gemma":[0.0030419382,0.007170606,0.005533025,0.0006401778,0.000054696327,0.98120373,0.0017696177,0.000026615555,0.00055947696],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9664815,0.014455837,0.011058457,0.0028349943,0.0039065173,0.0012627322],"domain_scores_gemma":[0.9701056,0.01244264,0.008049785,0.002479831,0.0060613756,0.0008608229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.052522186,0.0054184953,0.02601128,0.013149,0.0023394679,0.006505835,0.0054017664,0.005791361,0.03597264],"category_scores_gemma":[0.08218732,0.003904434,0.030496001,0.012648373,0.00311994,0.006078579,0.0044217,0.004001985,0.0034244105],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025619024,0.0000566599,0.00052294286,0.96225995,0.01787611,0.00016061394,0.00031177068,0.0006429869,0.00045113993,0.0011052303,0.0060925884,0.007958106],"study_design_scores_gemma":[0.028803498,0.0016431733,0.0059662326,0.6561875,0.19730698,0.0004489083,0.0008495859,0.0018819887,0.0017257126,0.007734155,0.09695729,0.0004950416],"about_ca_topic_score_codex":0.006764133,"about_ca_topic_score_gemma":0.013626404,"teacher_disagreement_score":0.052522186,"about_ca_system_score_codex":0.01244739,"about_ca_system_score_gemma":0.030168695,"threshold_uncertainty_score":0.27776718},"labels":[],"label_agreement":null},{"id":"W2785134906","doi":"10.1182/blood.v130.suppl_1.5215.5215","title":"Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University; Juravinski Hospital","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Quality of life (healthcare); Refractory (planetary science); Lymphoma; Chemotherapy regimen; Internal medicine; Oncology; Chemotherapy; Biology; Nursing","score_opus":0.02112061102851404,"score_gpt":0.29239476268406583,"score_spread":0.2712741516555518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785134906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99878734,0.0005067603,0.00006878253,0.000058251793,0.0000053905273,0.00005537362,0.00025776395,0.0000070771102,0.0002532863],"genre_scores_gemma":[0.9991417,0.00017189409,0.00010242557,0.00006332441,0.000010954502,0.00006672871,0.00034679065,8.519021e-7,0.0000952883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976236,0.00010734662,0.00002234612,0.00003666097,0.00003733847,0.00003410348],"domain_scores_gemma":[0.99951255,0.000080631566,0.00024375295,0.000014584228,0.000029255163,0.00011918016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007642971,0.00019798816,0.00044208026,0.0001620914,0.00013619429,0.00041370557,0.00015539819,0.00027165402,0.0009909204],"category_scores_gemma":[0.0008817637,0.00009930648,0.00044819512,0.00029041796,0.00017548152,0.00030642474,0.00023194215,0.0005994579,0.00012973842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12541854,0.007878053,0.7262024,0.00061329536,0.0014567771,0.00037717677,0.00034436956,0.0023506056,0.007977339,0.00007885588,0.0023969945,0.1249057],"study_design_scores_gemma":[0.008426753,0.0948424,0.89063275,0.00006235913,0.00061273575,0.00056570367,0.00013801479,0.0017257289,0.0015245692,0.000067470995,0.0013813423,0.000020157446],"about_ca_topic_score_codex":0.000352631,"about_ca_topic_score_gemma":0.0005601197,"teacher_disagreement_score":0.0009909204,"about_ca_system_score_codex":0.00034168016,"about_ca_system_score_gemma":0.00020016666,"threshold_uncertainty_score":0.0040420294},"labels":[],"label_agreement":null},{"id":"W2785907460","doi":"10.1182/blood.v130.suppl_1.5211.5211","title":"Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Oncology; Biology; Internal medicine; Proportional hazards model; Diffuse large B-cell lymphoma; Medicine; Pharmacology; Lymphoma","score_opus":0.024839222204071004,"score_gpt":0.34428355097916125,"score_spread":0.3194443287750902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785907460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940394,0.0035704672,0.0005187568,0.00020605182,0.000014924651,0.00014058566,0.00028998748,0.00005857861,0.0011612871],"genre_scores_gemma":[0.99752516,0.00086911424,0.0005646186,0.00023019112,0.000020311649,0.000079445934,0.00033905206,0.000007548705,0.00036463005],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99974996,0.00011033648,0.000023800867,0.000039574195,0.000048507438,0.000027795348],"domain_scores_gemma":[0.99953985,0.00012102623,0.00018365159,0.000024904652,0.000050758947,0.0000798417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005669411,0.0002183378,0.00052434386,0.00016165874,0.00016576875,0.00037166753,0.0002198146,0.0002124285,0.0007769405],"category_scores_gemma":[0.00078899367,0.000108681765,0.00024957565,0.0001912961,0.00016359506,0.00023073649,0.00014158472,0.0007166495,0.00029621512],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08704106,0.0072231763,0.2896895,0.0011151135,0.0008701586,0.0016125058,0.00064125174,0.0039669885,0.16235209,0.000299482,0.0054593426,0.43972945],"study_design_scores_gemma":[0.018843735,0.25424376,0.6377328,0.00019554692,0.0010851701,0.007969477,0.00048339376,0.0075064343,0.045151316,0.0005162623,0.026200201,0.000071882896],"about_ca_topic_score_codex":0.0003342349,"about_ca_topic_score_gemma":0.0011395541,"teacher_disagreement_score":0.0007769405,"about_ca_system_score_codex":0.0005409917,"about_ca_system_score_gemma":0.00048166284,"threshold_uncertainty_score":0.0039251447},"labels":[],"label_agreement":null},{"id":"W2787301955","doi":"10.1056/nejmoa1709866","title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5641,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Lymphoblastic Leukemia; Medicine; Leukemia; Immunology","score_opus":0.008970916473494756,"score_gpt":0.2580174046244769,"score_spread":0.24904648815098215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787301955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416226,0.00483854,0.00010257769,0.0001284074,0.000010276701,0.000053731772,0.00024936566,0.000009907524,0.00044486552],"genre_scores_gemma":[0.99656516,0.0024807765,0.00023246548,0.00014937886,0.000020680807,0.00006278391,0.00038978527,0.0000029425762,0.00009601995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99952054,0.00020334327,0.00004581631,0.00006734966,0.00008908368,0.00007382015],"domain_scores_gemma":[0.9989594,0.00023381847,0.0005184502,0.000023509776,0.000056792316,0.00020796979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009311221,0.00026483356,0.0005624764,0.00033339605,0.00028876745,0.0004206438,0.00018541112,0.00036876113,0.00066012307],"category_scores_gemma":[0.0016103329,0.00016438017,0.000251108,0.00065043767,0.00038346613,0.00026711813,0.00031860676,0.0005081175,0.00013963474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036429837,0.00024009761,0.96823084,0.00023673143,0.00015106359,0.0006509574,0.00032715514,0.00019760514,0.0017356374,0.00005193985,0.0006015313,0.023933465],"study_design_scores_gemma":[0.0010339059,0.009685196,0.97622573,0.000120486395,0.00033044154,0.0047326167,0.0005431211,0.00022368839,0.0010917219,0.000075592994,0.005925158,0.000012372952],"about_ca_topic_score_codex":0.0026713605,"about_ca_topic_score_gemma":0.004454808,"teacher_disagreement_score":0.0026713605,"about_ca_system_score_codex":0.00055834715,"about_ca_system_score_gemma":0.0009771023,"threshold_uncertainty_score":0.0053116083},"labels":[],"label_agreement":null},{"id":"W2787578932","doi":"10.1038/nm.4478","title":"A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":600,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; T-cell receptor; CD28; Cell biology; Signal transduction; T cell; Biology; STAT5; Cytokine; Cancer research; Antigen; Immunology; Immune system","score_opus":0.013873236535743582,"score_gpt":0.3217982719610501,"score_spread":0.3079250354253065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787578932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402654,0.0012588226,0.0025212576,0.000150736,0.000040228457,0.000027985387,0.00016056723,0.000107263506,0.0017066095],"genre_scores_gemma":[0.99720675,0.0002920841,0.0012485158,0.000034748467,0.000010654637,0.000010721358,0.000256029,0.000012493817,0.00092800055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998596,0.000021520938,0.000010329494,0.000022132082,0.000037643487,0.000048741385],"domain_scores_gemma":[0.9998976,0.000025573103,0.000021036363,0.000014934239,0.000010144078,0.00003083061],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022143562,0.00034972487,0.000270716,0.00022405568,0.00013474494,0.00045677132,0.00027036289,0.0004336474,0.0014678136],"category_scores_gemma":[0.00012785058,0.0001275261,0.00022077384,0.00019501256,0.00027193106,0.0003345732,0.00019328928,0.0009054612,0.00048333692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023024526,0.000079034806,0.000109753244,0.000019620556,0.0000068737154,0.000052908705,0.000007908882,0.00021948272,0.99720615,0.00033260524,0.00008313649,0.0016521874],"study_design_scores_gemma":[0.00016558066,0.0010235793,0.0013909774,0.0000039206716,0.000051959756,0.0007371823,0.000018614735,0.0028840364,0.98914343,0.00010158248,0.004470358,0.000008731103],"about_ca_topic_score_codex":0.00022765684,"about_ca_topic_score_gemma":0.00025587075,"teacher_disagreement_score":0.0014678136,"about_ca_system_score_codex":0.00033761648,"about_ca_system_score_gemma":0.00025178815,"threshold_uncertainty_score":0.00491035},"labels":[],"label_agreement":null},{"id":"W2788965461","doi":"10.1097/cji.0000000000000216","title":"Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products","year":2018,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"David Geffen School of Medicine, University of California, Los Angeles; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; UCLA AIDS Institute; Center for AIDS Research, University of Washington; Jonsson Comprehensive Cancer Center; Parker Institute for Cancer Immunotherapy","keywords":"Flow cytometry; Ex vivo; T cell; Immunology; T-cell receptor; Transgene; Cell therapy; Cell; Genetically modified mouse; Medicine; Biology; Cancer research; In vivo; Immune system; Biochemistry","score_opus":0.03856796019210099,"score_gpt":0.28483959101902384,"score_spread":0.24627163082692285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788965461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976248,0.00029853752,0.001533801,0.000012445197,0.000006519297,0.000031833373,0.00018252785,0.000022184948,0.00028731188],"genre_scores_gemma":[0.9976222,0.00017099078,0.001285982,0.000033742985,0.0000051642423,0.00005730615,0.00041562848,0.000013416964,0.00039564574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984086,0.000025789155,0.00001541313,0.00003499637,0.000058072874,0.000024874902],"domain_scores_gemma":[0.9997625,0.0000580195,0.000064594584,0.000026659041,0.000052718748,0.0000355266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024107206,0.00013685915,0.00015295797,0.00016376238,0.00005857696,0.00031483904,0.00014212186,0.00014751487,0.00055283395],"category_scores_gemma":[0.00043551472,0.000078316814,0.0001101697,0.00015358905,0.00011385728,0.00016203408,0.00009351001,0.00031397186,0.00014441925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004109013,0.00007317016,0.003699512,0.00001946729,0.000010360063,0.000058259775,0.000057568395,0.00025022295,0.9897317,0.00003693158,0.000041807358,0.0056100087],"study_design_scores_gemma":[0.000028676464,0.002896121,0.058117703,0.000008403147,0.000077598095,0.00054619554,0.00005858915,0.0022853944,0.9346231,0.000043414784,0.0013063106,0.000008545626],"about_ca_topic_score_codex":0.00019699654,"about_ca_topic_score_gemma":0.00016324679,"teacher_disagreement_score":0.00055283395,"about_ca_system_score_codex":0.00011931903,"about_ca_system_score_gemma":0.00008469264,"threshold_uncertainty_score":0.0018494129},"labels":[],"label_agreement":null},{"id":"W2792513622","doi":"10.1016/j.ymthe.2018.03.011","title":"Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma","year":2018,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Centers for Disease Control and Prevention; Medical Research Council; Bloodwise","keywords":"T-cell receptor; Tumor microenvironment; CD11c; Cancer research; T cell; Biology; Melanoma; Immunotherapy; Immunology; Antigen-presenting cell; Cancer immunotherapy; Chimeric antigen receptor; Cell biology; Immune system; Phenotype; Gene","score_opus":0.029995863977328407,"score_gpt":0.3176004062087195,"score_spread":0.2876045422313911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792513622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588674,0.001955159,0.0011192372,0.000051173578,0.00001687854,0.000054187614,0.000034331617,0.00002876162,0.00085343287],"genre_scores_gemma":[0.9978713,0.00060799776,0.0006738656,0.000037913367,0.000011480109,0.000031847034,0.00003376274,0.000007736616,0.0007239364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999833,0.000051894538,0.00001202798,0.00002659751,0.000031969194,0.000044468634],"domain_scores_gemma":[0.9999064,0.000023338273,0.000025322053,0.000006335339,0.000009461483,0.000029256815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021012878,0.00020018822,0.00024370525,0.00017528234,0.00008612474,0.00022511565,0.000069769565,0.000244196,0.00067742146],"category_scores_gemma":[0.00014675908,0.00008300535,0.00011755891,0.00006903113,0.00013024824,0.00012699676,0.00012604236,0.00047755698,0.00021290926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023738384,0.00014382467,0.00034124317,0.000031871685,0.0000030564752,0.0000395266,0.000018502737,0.000078719655,0.9963102,0.00005184912,0.000024345685,0.0027193776],"study_design_scores_gemma":[0.00017531449,0.0044837473,0.011381113,0.000017240343,0.000059917194,0.0006637243,0.00008342186,0.0019705265,0.97681046,0.00015813216,0.004190497,0.0000057552415],"about_ca_topic_score_codex":0.00010161946,"about_ca_topic_score_gemma":0.00018748073,"teacher_disagreement_score":0.00067742146,"about_ca_system_score_codex":0.00011630498,"about_ca_system_score_gemma":0.00013743888,"threshold_uncertainty_score":0.0022661686},"labels":[],"label_agreement":null},{"id":"W2794671395","doi":"10.1111/ajt.14747","title":"Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs","year":2018,"lang":"en","type":"review","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Heart, Lung, and Blood Institute; Horizon 2020 Framework Programme; National Institutes of Health; Canadian Institutes of Health Research; European Commission; BC Children's Hospital","keywords":"Allorecognition; Chimeric antigen receptor; Immunology; Cytotoxic T cell; T cell; Effector; Antigen; Immune system; Transplantation; Cell therapy; Receptor; Biology; Medicine; Cell biology; Stem cell; Genetics","score_opus":0.07733087107896719,"score_gpt":0.39568142814846646,"score_spread":0.3183505570694993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794671395","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41731238,0.063728765,0.46526295,0.0034540764,0.002995498,0.00069648906,0.0005997856,0.003901668,0.042048454],"genre_scores_gemma":[0.833867,0.028609678,0.112250045,0.0022848824,0.0004265853,0.0005607727,0.0006633578,0.00032054784,0.021017184],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996542,0.000054498112,0.00002659052,0.00006192424,0.00012222963,0.000080555204],"domain_scores_gemma":[0.99987304,0.00003072964,0.000041987383,0.0000143972275,0.000021662654,0.000018212493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038953923,0.00068735407,0.0003259317,0.0004973443,0.00016804357,0.00065515225,0.0004605629,0.00094035367,0.0018127493],"category_scores_gemma":[0.0002638537,0.00024572486,0.0005202851,0.00020898248,0.00046027167,0.00057519664,0.00037220045,0.0016560212,0.0012183001],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006506646,0.00006655885,0.00007913797,0.00026532623,0.000017712124,0.00010705457,0.00004548856,0.0005105581,0.97651196,0.0037237173,0.0007913564,0.017815974],"study_design_scores_gemma":[0.00005422711,0.0007745302,0.00025014218,0.000045775076,0.000058387577,0.00056346337,0.00003783377,0.0026492781,0.94404274,0.0011121467,0.050384436,0.000027005028],"about_ca_topic_score_codex":0.00021937219,"about_ca_topic_score_gemma":0.00027983534,"teacher_disagreement_score":0.0018127493,"about_ca_system_score_codex":0.00036538375,"about_ca_system_score_gemma":0.0002466927,"threshold_uncertainty_score":0.006064296},"labels":[],"label_agreement":null},{"id":"W2799371896","doi":"10.1016/j.jcyt.2018.02.010","title":"T cells engineered with T-cell antigen coupler (TAC) receptors display robust efficacy against solid and liquid tumor xenografts in the absence of any toxicity","year":2018,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; T-cell receptor; Antigen; Receptor; Cell biology; T cell; Major histocompatibility complex; Chemistry; Immunology; Cancer research; Biology; Molecular biology; Immune system; Biochemistry","score_opus":0.019141914678027904,"score_gpt":0.2796416926210811,"score_spread":0.2604997779430532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799371896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888608,0.0009705166,0.0054014525,0.000084602776,0.000042583855,0.00006208181,0.0002869539,0.0003076576,0.0039834804],"genre_scores_gemma":[0.99526983,0.00028821363,0.0016846766,0.000028334684,0.0000080817945,0.000028900507,0.0003386659,0.000040900977,0.0023123925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984527,0.000021839363,0.000010584964,0.000029720939,0.00004910259,0.000043426837],"domain_scores_gemma":[0.9998734,0.000029792836,0.00003486592,0.000020812284,0.000014903729,0.000026188609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015147708,0.0004109839,0.0002605752,0.00026672162,0.00013004546,0.00044802146,0.00017703812,0.00040117747,0.0012516571],"category_scores_gemma":[0.0001229669,0.000094274175,0.00018598513,0.00015957121,0.0002784538,0.00022641948,0.00015893948,0.0006633954,0.00048841967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007304182,0.000041952582,0.00006797748,0.000015491962,0.000003943387,0.000020109499,0.000013213889,0.00011145558,0.9982273,0.00015032283,0.00009035034,0.001184795],"study_design_scores_gemma":[0.00001252722,0.00020074102,0.0003383671,0.0000014731764,0.000009288484,0.000058258956,0.0000057220104,0.00037134686,0.9981741,0.000015032435,0.0008115777,0.0000016859153],"about_ca_topic_score_codex":0.0007852576,"about_ca_topic_score_gemma":0.0007782306,"teacher_disagreement_score":0.0012516571,"about_ca_system_score_codex":0.00020835338,"about_ca_system_score_gemma":0.00014754709,"threshold_uncertainty_score":0.0041872263},"labels":[],"label_agreement":null},{"id":"W2799722841","doi":"10.1016/j.beha.2018.04.002","title":"Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety","year":2018,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"King's College London; Medical Research Council; British Lung Foundation; National Institute for Health and Care Research; Medical Research Council Canada; King's Health Partners; Cancer Research UK","keywords":"Chimeric antigen receptor; Medicine; Clinical trial; Immunotherapy; Cell therapy; Adoptive cell transfer; Population; Immunology; Oncology; T cell; Internal medicine; Cell; Immune system; Biology","score_opus":0.4215104802943227,"score_gpt":0.6003140329752126,"score_spread":0.17880355268088988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799722841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029783786,0.9970329,0.0005380561,0.0006247419,0.0002208024,0.000023336297,0.00002838236,0.000008938344,0.0012249539],"genre_scores_gemma":[0.0025700945,0.9945825,0.0011602766,0.0007802137,0.00018681971,0.000038199225,0.000062200445,0.0000043618497,0.0006154427],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995309,0.00011939087,0.000060833096,0.00007935599,0.00016738479,0.000042059964],"domain_scores_gemma":[0.99837554,0.0011118192,0.00016771926,0.000041929376,0.0002337295,0.00006928865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026470756,0.00066872116,0.0014763387,0.0011440156,0.00017672138,0.0016303182,0.0014813951,0.0014721313,0.003961568],"category_scores_gemma":[0.00255361,0.0002527729,0.00068109744,0.0008888041,0.00062823505,0.0014609395,0.0005803558,0.0028549454,0.0015935191],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016628129,0.000117154945,0.00018608205,0.020873697,0.00011528979,0.00014627229,0.00004951516,0.00066140865,0.0029596277,0.008559885,0.012722793,0.9534419],"study_design_scores_gemma":[0.00010657941,0.0004004403,0.0005581977,0.00803292,0.0002516582,0.0009904525,0.00006262238,0.0001726296,0.002029523,0.003735361,0.98363656,0.000023094146],"about_ca_topic_score_codex":0.00072759786,"about_ca_topic_score_gemma":0.0013303745,"teacher_disagreement_score":0.003961568,"about_ca_system_score_codex":0.00088464556,"about_ca_system_score_gemma":0.0022859864,"threshold_uncertainty_score":0.013999224},"labels":[],"label_agreement":null},{"id":"W2800862488","doi":"10.1016/j.ebiom.2018.04.020","title":"Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy","year":2018,"lang":"en","type":"review","venue":"EBioMedicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; Immunotherapy; Tumor microenvironment; Medicine; Viral therapy; Cancer research; Immunology; Coronavirus disease 2019 (COVID-19); Tumor cells; Pathology; Immune system","score_opus":0.08349230093765672,"score_gpt":0.39991262404596356,"score_spread":0.3164203231083068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800862488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025551426,0.99734074,0.00033597113,0.00033915043,0.00021908173,0.000005130318,0.000012096667,0.000010989484,0.0014813291],"genre_scores_gemma":[0.0018313227,0.9964896,0.0003215606,0.00023073835,0.00016478541,0.0000094430825,0.000020523108,0.0000021836806,0.0009298109],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998796,0.000020881122,0.000014271691,0.00002142684,0.000048037182,0.000015710753],"domain_scores_gemma":[0.9998809,0.000059847895,0.000016293365,0.000004593717,0.000026824357,0.000011436263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036904216,0.0005277875,0.00061787135,0.00151855,0.00023164158,0.00081640936,0.0005007061,0.0011316771,0.0022126283],"category_scores_gemma":[0.00036270815,0.00017654101,0.00037538813,0.0009585087,0.00042633183,0.001118394,0.000500286,0.0014673239,0.0012457347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057376707,0.00008182178,0.00016788964,0.013126772,0.000058220205,0.00026378687,0.00011030861,0.00047813766,0.00804924,0.010948366,0.024280386,0.9423777],"study_design_scores_gemma":[0.000006301718,0.00007534739,0.0003209649,0.0013908945,0.000037930356,0.0010586298,0.000052859024,0.00009897523,0.001875088,0.0020372986,0.9930333,0.000012425877],"about_ca_topic_score_codex":0.0004735382,"about_ca_topic_score_gemma":0.00082023104,"teacher_disagreement_score":0.0022126283,"about_ca_system_score_codex":0.00045843722,"about_ca_system_score_gemma":0.0005684385,"threshold_uncertainty_score":0.007401943},"labels":[],"label_agreement":null},{"id":"W2801354368","doi":"10.1111/bjh.15232","title":"A tale of two antibodies: obinutuzumab <i>versus</i> rituximab","year":2018,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Centers for Disease Control and Prevention","keywords":"Obinutuzumab; Rituximab; Medicine; CD20; Clinical trial; Immunology; Oncology; Context (archaeology); Dosing; Lymphoma; Internal medicine; Biology","score_opus":0.06548623625567729,"score_gpt":0.39946261266057015,"score_spread":0.33397637640489286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801354368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001346377,0.997943,0.00007165627,0.00094442244,0.0002642217,0.000004794467,0.000011848213,0.0000053228455,0.00062018185],"genre_scores_gemma":[0.0012603044,0.99640083,0.00019716338,0.0010520817,0.00027451303,0.000010068531,0.00002748744,0.0000030795497,0.0007744188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99967444,0.00007762924,0.00006016111,0.000052208048,0.000102495134,0.000033097178],"domain_scores_gemma":[0.9996111,0.00022534937,0.000048806196,0.000011311482,0.00007038475,0.00003302679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011284095,0.00058300665,0.0016279062,0.0021696452,0.00034619763,0.0013582238,0.000906983,0.0015960825,0.0038651072],"category_scores_gemma":[0.001088877,0.0002882748,0.0006871177,0.0016172357,0.0006115574,0.002325987,0.0007739615,0.0025423914,0.0013443636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022202401,0.000056480683,0.00012874002,0.027562633,0.0001781631,0.00018978138,0.000112954076,0.00022695126,0.0019928152,0.008026838,0.042687517,0.9186152],"study_design_scores_gemma":[0.00003995879,0.00013171903,0.00045121927,0.009089277,0.0001547808,0.0009443622,0.000092547765,0.000050101775,0.0004253474,0.003610689,0.98499507,0.000014924904],"about_ca_topic_score_codex":0.00088042207,"about_ca_topic_score_gemma":0.0019858235,"teacher_disagreement_score":0.0038651072,"about_ca_system_score_codex":0.00092695426,"about_ca_system_score_gemma":0.0013074926,"threshold_uncertainty_score":0.012930036},"labels":[],"label_agreement":null},{"id":"W2802158658","doi":"10.1038/s41591-018-0031-9","title":"CAR T cells for childhood diffuse midline gliomas","year":2018,"lang":"en","type":"letter","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Chimeric antigen receptor; Glioma; Mutant; Antigen; Cancer research; Medicine; Receptor; Pathology; Biology; Immunology; Immune system; Immunotherapy; Internal medicine; Genetics; Gene","score_opus":0.016336221712926296,"score_gpt":0.3207687209710808,"score_spread":0.30443249925815447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802158658","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0053377617,0.015056444,0.00061577745,0.9476093,0.019513054,0.00003099891,0.00008264484,0.00010832919,0.011645714],"genre_scores_gemma":[0.1490979,0.024223642,0.00207197,0.69705546,0.09246798,0.00017524685,0.00018091207,0.00010665622,0.034620117],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.9995346,0.00011607602,0.000056511242,0.00005285825,0.000121535195,0.00011848434],"domain_scores_gemma":[0.99865294,0.0007699579,0.00010103031,0.00005806022,0.00015772397,0.0002602575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006793399,0.00045591564,0.00072765053,0.00033210745,0.0013391044,0.0011647175,0.000616131,0.013733444,0.0039641787],"category_scores_gemma":[0.004752172,0.00025911772,0.00059732795,0.00019523878,0.0013169685,0.0011122461,0.0009540201,0.010441479,0.0019392762],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027047773,0.00009001675,0.002066984,0.00029078237,0.000045418285,0.045353115,0.00016284811,0.0006319692,0.0019753815,0.015516899,0.85875356,0.074842565],"study_design_scores_gemma":[0.00038869615,0.0003841413,0.0015459224,0.0004200325,0.00008575612,0.048859287,0.00027820776,0.0012713283,0.0027194123,0.022912558,0.92109305,0.000041680512],"about_ca_topic_score_codex":0.0014394288,"about_ca_topic_score_gemma":0.0032025962,"teacher_disagreement_score":0.013733444,"about_ca_system_score_codex":0.0024922842,"about_ca_system_score_gemma":0.0013514078,"threshold_uncertainty_score":0.018082857},"labels":[],"label_agreement":null},{"id":"W2802233748","doi":"10.1016/j.jcyt.2018.02.012","title":"BCMA-specific TAC receptor-engineered T cells for multiple myeloma","year":2018,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Receptor; Antigen; Cell biology; Cancer research; T cell; Biology; Immunology; Molecular biology; Immune system; Biochemistry","score_opus":0.04063145682494303,"score_gpt":0.30919427135994704,"score_spread":0.268562814535004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802233748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92190486,0.016695106,0.043052696,0.0009837153,0.0004742317,0.00030516292,0.0004267878,0.00088986737,0.015267534],"genre_scores_gemma":[0.98914284,0.0018517344,0.0053161797,0.00012283224,0.00002755526,0.00006680515,0.00012249756,0.000028743118,0.003320688],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998964,0.000017213988,0.0000054326383,0.000021950002,0.000032849257,0.000026078777],"domain_scores_gemma":[0.9999708,0.000006770344,0.000006121918,0.0000056228632,0.0000046881783,0.000006051028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013924742,0.00028476844,0.0001755046,0.00028166082,0.00020563944,0.00042510903,0.00028643076,0.0004548849,0.0016879797],"category_scores_gemma":[0.0001303474,0.000115204726,0.00016299778,0.00018380789,0.00018305772,0.00024131607,0.00021486457,0.00083116855,0.00045156237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016972396,0.00016899408,0.00010967132,0.00007858227,0.000012334457,0.000075844175,0.00003664627,0.0007155322,0.9793388,0.0012990559,0.0005640772,0.017430633],"study_design_scores_gemma":[0.000083073806,0.00055408746,0.0005571743,0.000012510528,0.000044932858,0.0004146713,0.000017027238,0.003175312,0.9787733,0.00030349952,0.01605768,0.0000067561105],"about_ca_topic_score_codex":0.0010097461,"about_ca_topic_score_gemma":0.001150996,"teacher_disagreement_score":0.0016879797,"about_ca_system_score_codex":0.00043872447,"about_ca_system_score_gemma":0.0002871266,"threshold_uncertainty_score":0.005646825},"labels":[],"label_agreement":null},{"id":"W2802513889","doi":"10.1038/s41568-018-0009-4","title":"Oncolytic viruses as engineering platforms for combination immunotherapy","year":2018,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of Ottawa; BC Cancer Agency; Ottawa Hospital; University of British Columbia; Ontario Institute for Cancer Research","funders":"","keywords":"Oncolytic virus; Cytotoxic T cell; Immunotherapy; Immune checkpoint; Immune system; Cancer immunotherapy; Antigen; Melanoma; Cancer; Cancer research; Immunology; Priming (agriculture); T cell; Medicine; Biology; Internal medicine; In vitro","score_opus":0.08964551249103939,"score_gpt":0.46388039306834317,"score_spread":0.3742348805773038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802513889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011974229,0.99799347,0.00028217438,0.00030039312,0.0003152419,0.0000055485934,0.00001586932,0.000011260537,0.00095623505],"genre_scores_gemma":[0.0008348871,0.9979265,0.0001938453,0.00017677089,0.00013233267,0.000007810922,0.000033701424,0.000002268411,0.00069186493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997924,0.000033466877,0.00002110319,0.000031998523,0.00008881894,0.000032255484],"domain_scores_gemma":[0.9996916,0.00014868988,0.00003979028,0.000013313452,0.00007714518,0.000029563449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083008816,0.0008793699,0.0010259569,0.0017374733,0.00022667545,0.0012680027,0.0009654983,0.0011555501,0.0032935322],"category_scores_gemma":[0.00073043234,0.00035419516,0.00045687583,0.0014837494,0.0005994661,0.0016293112,0.0010603499,0.002401627,0.0023946634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008103902,0.000065469736,0.000086786844,0.008524377,0.00006138687,0.00013021952,0.000043601558,0.00049414864,0.004483343,0.009109715,0.033894632,0.9430252],"study_design_scores_gemma":[0.0000134645625,0.00004693896,0.00013076719,0.00108377,0.000044764492,0.00039519582,0.000019582994,0.000075389056,0.0010858629,0.0017186983,0.995375,0.000010564616],"about_ca_topic_score_codex":0.0005317648,"about_ca_topic_score_gemma":0.00095777155,"teacher_disagreement_score":0.0032935322,"about_ca_system_score_codex":0.0007678088,"about_ca_system_score_gemma":0.0008492707,"threshold_uncertainty_score":0.011017978},"labels":[],"label_agreement":null},{"id":"W2802710454","doi":"10.1016/j.omtm.2018.04.007","title":"An Integrated Approach toward the Biomanufacturing of Engineered Cell Therapy Products in a Stirred-Suspension Bioreactor","year":2018,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Alberta Innovates - Health Solutions","keywords":"Biomanufacturing; Bioreactor; Microcarrier; Cell therapy; Cell culture; Process development; Bioprocess; Biochemical engineering; Stem cell; Biotechnology; Biology; Process engineering; Cell biology; Engineering","score_opus":0.15738111655114348,"score_gpt":0.44549887193408755,"score_spread":0.28811775538294404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802710454","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23671995,0.0040969425,0.7519004,0.0004508829,0.00034843493,0.000811248,0.00040264765,0.002604154,0.0026654243],"genre_scores_gemma":[0.32452542,0.0025987648,0.6683828,0.00020125689,0.00008964187,0.00063790724,0.0006852102,0.000105954445,0.0027730512],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985241,0.00014904037,0.00014398244,0.00035661884,0.000726469,0.00009974047],"domain_scores_gemma":[0.9997023,0.000060486793,0.00008768589,0.000045488545,0.00006257396,0.000041492865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010090033,0.0010984961,0.00080947817,0.00083581236,0.00044862446,0.0010873077,0.0011166715,0.0010765817,0.00048691564],"category_scores_gemma":[0.00039054782,0.0006111568,0.001008886,0.00044491948,0.0005078834,0.00067150017,0.0010098966,0.0015032078,0.000666392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034151766,0.00008434992,0.00007987575,0.000058262227,0.0000104818855,0.00003049747,0.000027084143,0.00043981554,0.9934663,0.00033870942,0.00007429826,0.0053560724],"study_design_scores_gemma":[0.000017831222,0.0002826717,0.0003084591,0.0000049202717,0.000027810951,0.00012226205,0.000007852537,0.0046044705,0.9916459,0.0000650156,0.0028876814,0.000025234312],"about_ca_topic_score_codex":0.0011069708,"about_ca_topic_score_gemma":0.0019235418,"teacher_disagreement_score":0.0011166715,"about_ca_system_score_codex":0.0009260085,"about_ca_system_score_gemma":0.0013696332,"threshold_uncertainty_score":0.0067186356},"labels":[],"label_agreement":null},{"id":"W2802900288","doi":"10.1016/j.jcyt.2018.02.304","title":"A new immunotherapy approach against acute lymphoblastic leukemia by transducing hematopoietic stem cells with a car under regulation of cell specific promoter","year":2018,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Chimeric antigen receptor; Haematopoiesis; Cytotoxic T cell; Cancer research; Stem cell; Transgene; Biology; Immunotherapy; Leukemia; Hematopoietic stem cell; Genetic enhancement; Immunology; Cell biology; In vitro; Immune system; Gene; Genetics","score_opus":0.017139491358313403,"score_gpt":0.24890907844705087,"score_spread":0.23176958708873746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802900288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83594775,0.01443373,0.13411792,0.0013392047,0.00043954424,0.00039694464,0.00035086396,0.0012221095,0.011751872],"genre_scores_gemma":[0.96562517,0.0039359718,0.023673473,0.00026179457,0.00007373897,0.00018519243,0.00026942743,0.000049519596,0.005925734],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988055,0.000019379424,0.0000062491567,0.000034522527,0.00003203041,0.000027297538],"domain_scores_gemma":[0.99996364,0.000009415963,0.000007695895,0.000006568783,0.0000058519377,0.000006822004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021348863,0.00043463797,0.00031217383,0.00047184786,0.00019483022,0.0004601192,0.00031265724,0.00039756388,0.00096483895],"category_scores_gemma":[0.000081469276,0.00015437811,0.00034446793,0.00026272732,0.00035937296,0.00035613004,0.00029092177,0.000954789,0.000261895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011252764,0.00016500804,0.00044295183,0.00012726124,0.000018376044,0.0001713897,0.00007573504,0.00047405416,0.9725594,0.0049971472,0.00037584803,0.020480277],"study_design_scores_gemma":[0.000111220266,0.0008351745,0.0010388895,0.000013560545,0.000122417,0.0010332413,0.00003402654,0.002938976,0.9689794,0.00081562507,0.024063764,0.000013666823],"about_ca_topic_score_codex":0.00030440136,"about_ca_topic_score_gemma":0.00031522586,"teacher_disagreement_score":0.00096483895,"about_ca_system_score_codex":0.00029259437,"about_ca_system_score_gemma":0.00039222927,"threshold_uncertainty_score":0.0032277703},"labels":[],"label_agreement":null},{"id":"W2805523469","doi":"10.1158/2159-8290.cd-17-1319","title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":924,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Emerald Foundation; Parker Institute for Cancer Immunotherapy; Alberta Emerald Foundation; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; Juno Therapeutics; Leukemia and Lymphoma Society; American Society of Hematology","keywords":"Lymphoblastic Leukemia; Neurotoxicity; Medicine; Leukemia; Cell; Cancer research; Oncology; Immunology; Biology; Internal medicine; Toxicity; Genetics","score_opus":0.026596257846077314,"score_gpt":0.3056077702695786,"score_spread":0.27901151242350125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805523469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99832445,0.0005706447,0.000059086793,0.000045482637,0.0000044017006,0.0000090396925,0.00015679131,0.0000051867482,0.0008248757],"genre_scores_gemma":[0.9995683,0.00015003949,0.0000357761,0.00001755407,0.0000087258695,0.000005458864,0.00014683693,0.0000010171774,0.00006621893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998241,0.000056025485,0.000022665417,0.000026923859,0.000035403977,0.000034884553],"domain_scores_gemma":[0.99923503,0.00015653389,0.0003224161,0.000029227915,0.00008387169,0.00017286501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026702927,0.00019465253,0.00025809227,0.00058909226,0.0003523222,0.00040476597,0.00018029254,0.00026022465,0.0009257262],"category_scores_gemma":[0.0012909595,0.00011966748,0.00012928013,0.00076720613,0.00033224045,0.0002705697,0.00025777626,0.0003816434,0.00020401788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049044844,0.00004841792,0.9948795,0.000011946803,0.00002270021,0.0007954569,0.000036188383,0.00009469378,0.000963413,0.000019362802,0.00012502643,0.0025129025],"study_design_scores_gemma":[0.000018243376,0.00031725824,0.99557847,0.0000063244524,0.00003327939,0.0031915614,0.00009624661,0.00017884794,0.00031349124,0.00005170645,0.00021043574,0.000004122242],"about_ca_topic_score_codex":0.0014667719,"about_ca_topic_score_gemma":0.0016974056,"teacher_disagreement_score":0.0014667719,"about_ca_system_score_codex":0.00030598976,"about_ca_system_score_gemma":0.00027328462,"threshold_uncertainty_score":0.003096819},"labels":[],"label_agreement":null},{"id":"W2807637103","doi":"10.1200/jco.2018.77.8084","title":"T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":791,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"NIH Clinical Center; National Cancer Institute; National Institutes of Health; Kite Pharma; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Chimeric antigen receptor; Multiple myeloma; Minimal residual disease; Cytokine release syndrome; Antigen; Cyclophosphamide; Bone marrow; Fludarabine; Immunology; Regimen; Cancer research; Internal medicine; T cell; Oncology; Chemotherapy; Immune system","score_opus":0.1424856689320132,"score_gpt":0.4582241318970513,"score_spread":0.3157384629650381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807637103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981799,0.0006519293,0.0004833538,0.00007275089,0.000026563794,0.000050072675,0.00004901912,0.00005368644,0.00043273976],"genre_scores_gemma":[0.99861634,0.00023978252,0.00036449425,0.0000759878,0.000020769,0.000036160443,0.00012471077,0.0000071992094,0.0005146086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987566,0.00002536248,0.000008835351,0.000026042399,0.000025363157,0.00003876053],"domain_scores_gemma":[0.99988186,0.000022014667,0.00003576119,0.000015533396,0.0000061614637,0.000038647595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021021377,0.00032834534,0.00039610724,0.00011753527,0.00016744026,0.00018909777,0.00017038404,0.000299945,0.0011771607],"category_scores_gemma":[0.00021691437,0.00012006043,0.00024838658,0.00007995683,0.00036693746,0.00014158608,0.000119505894,0.00078916404,0.00033629796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072756396,0.0022799002,0.012306428,0.00023019998,0.00013443988,0.0010461829,0.000127741,0.0018184347,0.92439383,0.00045138548,0.001232221,0.04870358],"study_design_scores_gemma":[0.015604068,0.14742522,0.089755714,0.00008322821,0.0006788663,0.018091094,0.00018264104,0.008536153,0.6895587,0.0006784301,0.029338252,0.00006764154],"about_ca_topic_score_codex":0.00024393026,"about_ca_topic_score_gemma":0.0003049152,"teacher_disagreement_score":0.0011771607,"about_ca_system_score_codex":0.00021637668,"about_ca_system_score_gemma":0.00012643864,"threshold_uncertainty_score":0.0039380193},"labels":[],"label_agreement":null},{"id":"W2809223047","doi":"10.1016/bs.ircmb.2018.05.010","title":"T Lymphocyte–Based Cancer Immunotherapeutics","year":2018,"lang":"en","type":"review","venue":"International review of cell and molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Oncolytic virus; Chimeric antigen receptor; Biology; Immunotherapy; Cancer immunotherapy; Immune system; Immune checkpoint; Cancer; Cancer research; Antigen; Immunology","score_opus":0.044694708807888735,"score_gpt":0.43338938753530215,"score_spread":0.3886946787274134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809223047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020416186,0.99786025,0.0002388201,0.00036363243,0.00032550475,0.0000074456007,0.000020623234,0.000009378244,0.00097006845],"genre_scores_gemma":[0.0017788603,0.99650097,0.0002605051,0.00036325346,0.0002855691,0.00001153189,0.000033652515,0.0000015308958,0.00076404406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998864,0.000021678237,0.000012825227,0.000022378195,0.000039609884,0.000017073979],"domain_scores_gemma":[0.9998466,0.00007209457,0.000025981111,0.0000052088,0.000035650042,0.000014470517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041025778,0.0006077503,0.0010166087,0.0013291257,0.0001785874,0.0007629407,0.00066836184,0.000785985,0.0032516688],"category_scores_gemma":[0.00048767577,0.00018241131,0.00036140828,0.001385507,0.0003947624,0.0009244776,0.00058933295,0.0015479545,0.0013604836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009530134,0.00011170368,0.00017456381,0.01240073,0.000076130775,0.00016366146,0.000033644672,0.00039583552,0.0039834245,0.0042010928,0.033255424,0.9451085],"study_design_scores_gemma":[0.00003283724,0.00012741564,0.00036831142,0.0015245758,0.00010804687,0.0008199789,0.000033645527,0.00013718546,0.0012306154,0.0016534277,0.9939499,0.0000141766395],"about_ca_topic_score_codex":0.0004526357,"about_ca_topic_score_gemma":0.00091352116,"teacher_disagreement_score":0.0032516688,"about_ca_system_score_codex":0.00037318625,"about_ca_system_score_gemma":0.00071648293,"threshold_uncertainty_score":0.010877907},"labels":[],"label_agreement":null},{"id":"W2809614382","doi":"10.1007/s12032-018-1167-7","title":"Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting","year":2018,"lang":"en","type":"article","venue":"Medical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Occupational Cancer Research Centre; University of Calgary","funders":"Mach-Gaensslen Foundation of Canada","keywords":"Medicine; Ipilimumab; Clinical trial; Cohort; Internal medicine; Population; Vemurafenib; Cancer; Oncology; Metastatic melanoma; Immunotherapy","score_opus":0.17206039468019826,"score_gpt":0.5487670947428749,"score_spread":0.3767067000626766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809614382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5101606,0.14487268,0.09837159,0.048300385,0.017544348,0.031274736,0.032708257,0.0016289033,0.11513845],"genre_scores_gemma":[0.9605175,0.0040230365,0.007792748,0.013909774,0.001771111,0.006575627,0.0032805062,0.00022083799,0.001908852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.6154156,0.30542874,0.03941398,0.022761019,0.014668635,0.0023120784],"domain_scores_gemma":[0.44859356,0.40850657,0.042026293,0.07906803,0.018051274,0.0037543366],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.27634552,0.001741821,0.0044517596,0.0026229525,0.0016301995,0.005685856,0.0031561193,0.0036222828,0.014097545],"category_scores_gemma":[0.5082989,0.001032653,0.0075992863,0.0034922946,0.0045681777,0.0043643913,0.0032029382,0.0040512276,0.0018525822],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06305824,0.002477617,0.48352563,0.024651561,0.103537634,0.0015677146,0.0042327326,0.010317512,0.0035600378,0.011933498,0.048038136,0.24309967],"study_design_scores_gemma":[0.05375594,0.032273326,0.6341776,0.00912403,0.067587405,0.0028866772,0.0039235773,0.012222566,0.0043558665,0.047209322,0.13208161,0.00040209087],"about_ca_topic_score_codex":0.003677223,"about_ca_topic_score_gemma":0.0038468556,"teacher_disagreement_score":0.27634552,"about_ca_system_score_codex":0.003083638,"about_ca_system_score_gemma":0.003094535,"threshold_uncertainty_score":0.8923948},"labels":[],"label_agreement":null},{"id":"W2809695328","doi":"10.1158/1078-0432.ccr-18-1552","title":"Two Weeks' Notice from Allogeneic Sources","year":2018,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"T-cell receptor; Human leukocyte antigen; Medicine; Notice; Cancer; Immunology; T cell; Antigen; Biology; Internal medicine; Immune system; Political science","score_opus":0.34897601776317844,"score_gpt":0.565567767512028,"score_spread":0.21659174974884954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809695328","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007832678,0.007474154,0.002822211,0.8467809,0.10061497,0.00014814598,0.00033683737,0.0005800825,0.033409998],"genre_scores_gemma":[0.066750646,0.0043768375,0.0015106593,0.7045979,0.08169313,0.00018191956,0.0003632537,0.00014929954,0.14037637],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991054,0.00026784552,0.00007075101,0.0001403099,0.0002686014,0.00014713524],"domain_scores_gemma":[0.99868625,0.000649678,0.00008223307,0.00013070142,0.00020671342,0.0002444373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091178186,0.00053307635,0.00036989243,0.00026116343,0.0010780329,0.0011481675,0.00057040405,0.0070532784,0.0138814105],"category_scores_gemma":[0.007483651,0.00018107229,0.00070605864,0.00013538981,0.0006310338,0.0010696785,0.0008361154,0.012948818,0.010937766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032204305,0.00020443612,0.0013527339,0.0000864027,0.000037451944,0.028440021,0.00020889932,0.00015450791,0.0021197181,0.004362144,0.9112084,0.051503245],"study_design_scores_gemma":[0.00008078188,0.00030043494,0.0013001348,0.00008046157,0.000018670848,0.018648243,0.00017807497,0.00032420666,0.0008070357,0.0046227034,0.97361404,0.000025226553],"about_ca_topic_score_codex":0.0007606804,"about_ca_topic_score_gemma":0.0010769095,"teacher_disagreement_score":0.0138814105,"about_ca_system_score_codex":0.0010223677,"about_ca_system_score_gemma":0.00040106944,"threshold_uncertainty_score":0.04643798},"labels":[],"label_agreement":null},{"id":"W2810960090","doi":"10.1093/annonc/mdy225","title":"Early-drug development in the era of immuno-oncology: are we ready to face the challenges?","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Drug development; Dosing; Clinical trial; Drug; Face (sociological concept); Intensive care medicine; Immunotherapy; Competition (biology); Toxicity; Maximum tolerated dose; Pharmacology; Oncology; Medical physics; Risk analysis (engineering); Immune system; Internal medicine; Immunology","score_opus":0.3627134592304156,"score_gpt":0.5024936264408392,"score_spread":0.13978016721042358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810960090","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000076145516,0.99476105,0.00017844581,0.0038610392,0.00056964555,0.0000033590632,0.000013878983,0.000009511933,0.0005268956],"genre_scores_gemma":[0.0010322571,0.99513644,0.0003499649,0.0021977217,0.000801912,0.0000070175374,0.00002095741,0.000003396069,0.0004503048],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993716,0.00021452225,0.00007086577,0.00007491901,0.0001904145,0.000077739736],"domain_scores_gemma":[0.99650913,0.0022674613,0.00029972958,0.00007946968,0.0006048555,0.00023934525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002820458,0.0006970007,0.0021430962,0.0011363195,0.00043083835,0.0024798114,0.001491974,0.0027207588,0.0067454306],"category_scores_gemma":[0.0037568305,0.00029536488,0.00071581104,0.0011614513,0.0012529817,0.0049042976,0.0010649866,0.005677018,0.0024126607],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011992845,0.0001148636,0.00025960238,0.013062732,0.00009974623,0.0001769661,0.0000926107,0.00033019867,0.0008055828,0.014113126,0.07221131,0.89861345],"study_design_scores_gemma":[0.000043971635,0.00013449842,0.0003481408,0.0063259583,0.000102263635,0.00068271795,0.00012804722,0.00010975693,0.00027652396,0.006958966,0.984866,0.000023175446],"about_ca_topic_score_codex":0.00094498135,"about_ca_topic_score_gemma":0.0029435123,"teacher_disagreement_score":0.0067454306,"about_ca_system_score_codex":0.0009916864,"about_ca_system_score_gemma":0.0027706916,"threshold_uncertainty_score":0.022565722},"labels":[],"label_agreement":null},{"id":"W2811326314","doi":"10.1097/ccm.0000000000003258","title":"Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective","year":2018,"lang":"en","type":"review","venue":"Critical Care Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital","funders":"National Cancer Institute","keywords":"Medicine; Critically ill; Perspective (graphical); Chimeric antigen receptor; Intensive care medicine; Critical illness; Cell therapy; Immunology; Immunotherapy; Immune system; Cell","score_opus":0.04671614563417579,"score_gpt":0.40520449036306533,"score_spread":0.3584883447288895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811326314","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056098463,0.9985996,0.000041064475,0.00084240834,0.0001763745,0.000006965788,0.000008569406,0.0000019069937,0.00026694304],"genre_scores_gemma":[0.0010467215,0.9976412,0.00019650477,0.00065502536,0.00032199148,0.000016604721,0.00001150464,4.898654e-7,0.00010988986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993129,0.00025297335,0.00017015604,0.000051717732,0.00017375134,0.000038475748],"domain_scores_gemma":[0.9984738,0.0007907308,0.00040266704,0.000020939384,0.00025046337,0.00006139333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012310375,0.0008685696,0.0017921106,0.0026578608,0.0003794757,0.0012783349,0.001094178,0.0020590983,0.0022063819],"category_scores_gemma":[0.0029296596,0.00018296158,0.00078183383,0.0020997499,0.00048349108,0.001746175,0.00055556995,0.0017208403,0.0005804736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019028029,0.000086188484,0.0005673822,0.24673541,0.0006140513,0.0012933483,0.0002645597,0.00032923027,0.001638784,0.0038964865,0.059600495,0.6847838],"study_design_scores_gemma":[0.00014869391,0.00038863122,0.0038693175,0.22669256,0.0021008526,0.0111811645,0.00092229265,0.00021751165,0.0010137529,0.004935947,0.748452,0.00007727731],"about_ca_topic_score_codex":0.001146284,"about_ca_topic_score_gemma":0.0022841208,"teacher_disagreement_score":0.0026578608,"about_ca_system_score_codex":0.0010040624,"about_ca_system_score_gemma":0.002759779,"threshold_uncertainty_score":0.0073810816},"labels":[],"label_agreement":null},{"id":"W2883138099","doi":"10.1097/01.tp.0000542905.98105.1f","title":"Humanization and Pre-Clinical Validation of an Anti-HLA-A*02","year":2018,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development; BC Children's Hospital; University of British Columbia","funders":"","keywords":"Immunogenicity; Polyclonal antibodies; Human leukocyte antigen; Antigen; Immunology; Humanized mouse; Chimeric antigen receptor; Antibody; Biology; Immunotherapy; Computational biology; Immune system","score_opus":0.06023133680711768,"score_gpt":0.4084449172840989,"score_spread":0.3482135804769812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883138099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9224853,0.005780681,0.041589472,0.0019752758,0.0004785984,0.004153975,0.0022022938,0.00036563646,0.02096877],"genre_scores_gemma":[0.9683239,0.0020447057,0.01575836,0.0016716212,0.00014437849,0.0013149147,0.0032591925,0.00005596088,0.007427002],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986572,0.0005593345,0.00011587707,0.00018915374,0.00029634102,0.00018208547],"domain_scores_gemma":[0.9991998,0.000145038,0.00009093322,0.00015754029,0.00026432698,0.00014245615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033847373,0.0004918198,0.00018152728,0.00027651622,0.00025016887,0.0008853084,0.0006195729,0.00069960684,0.004403245],"category_scores_gemma":[0.0012783854,0.0001477453,0.00032864913,0.0001784902,0.0005765411,0.00035502648,0.00039508243,0.0007733038,0.0013118209],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003044801,0.0038151995,0.01758116,0.00055759586,0.000116944764,0.00066953467,0.00034219224,0.0013343794,0.8052052,0.003151273,0.006005277,0.15817638],"study_design_scores_gemma":[0.0012029484,0.050556183,0.02504031,0.00025916778,0.00017217634,0.005220842,0.00032114147,0.0026655144,0.73614454,0.0010776673,0.17730126,0.000038202652],"about_ca_topic_score_codex":0.0004627959,"about_ca_topic_score_gemma":0.00035643522,"teacher_disagreement_score":0.004403245,"about_ca_system_score_codex":0.00043010054,"about_ca_system_score_gemma":0.0010318874,"threshold_uncertainty_score":0.017900407},"labels":[],"label_agreement":null},{"id":"W2884280196","doi":"10.1016/j.celrep.2018.06.040","title":"HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants","year":2018,"lang":"en","type":"article","venue":"Cell Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Ontario Institute for Cancer Research","keywords":"Myeloid; Tumor microenvironment; Cancer research; Cytotoxic T cell; Antigen; Immune system; Biology; CD8; Oncolytic virus; Immunology; In vitro","score_opus":0.023877029503952322,"score_gpt":0.29881351260138017,"score_spread":0.27493648309742785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884280196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921183,0.00076378835,0.0032426848,0.00014047114,0.00006389726,0.000053443127,0.0005827694,0.00016703056,0.0028676435],"genre_scores_gemma":[0.9948415,0.00046846186,0.0011831629,0.000041561467,0.000011807617,0.000018594441,0.00027779068,0.000027414524,0.003129585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987626,0.000012493344,0.000010232746,0.000028167105,0.00002795857,0.000044768214],"domain_scores_gemma":[0.999946,0.000007453006,0.000016129843,0.000007642303,0.0000043915115,0.000018359879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009477914,0.0004053494,0.00022816923,0.00021527328,0.00010557797,0.00032855952,0.00019046689,0.00020047723,0.002150064],"category_scores_gemma":[0.00004711309,0.00012480131,0.00022112715,0.00015685309,0.00032752307,0.00016643698,0.00013149504,0.0006261965,0.0005579657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008722403,0.000022089638,0.000110020956,0.00001921716,0.000003741952,0.00002603627,0.000011949855,0.0000699706,0.9980849,0.00015107568,0.00004347089,0.0013704381],"study_design_scores_gemma":[0.00001609551,0.00016127,0.00084389065,0.0000017609204,0.000011219826,0.00008890985,0.000020198651,0.00035190696,0.99693006,0.000022019389,0.0015509444,0.0000018395862],"about_ca_topic_score_codex":0.00096654607,"about_ca_topic_score_gemma":0.0016467057,"teacher_disagreement_score":0.002150064,"about_ca_system_score_codex":0.00033405653,"about_ca_system_score_gemma":0.0002820857,"threshold_uncertainty_score":0.0071926713},"labels":[],"label_agreement":null},{"id":"W2885193471","doi":"10.1158/1538-7445.am2018-ct110","title":"Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Cmax; Medicine; Diffuse large B-cell lymphoma; Internal medicine; Pharmacokinetics; Cytokine release syndrome; CD19; Oncology; Logistic regression; Lymphoma; Immunotherapy; Immunology; Gastroenterology; Pharmacology; Cancer; Peripheral blood","score_opus":0.08152018180211967,"score_gpt":0.4497604693759716,"score_spread":0.3682402875738519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885193471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855735,0.008271321,0.0005497978,0.00050016993,0.0000620967,0.00023493209,0.001011161,0.00013199952,0.0036649427],"genre_scores_gemma":[0.99562955,0.001523594,0.00037793993,0.000320261,0.0000393872,0.00009238588,0.0009257188,0.000009051775,0.0010820712],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980706,0.00009889016,0.000015436233,0.000028391254,0.000032564738,0.000017703029],"domain_scores_gemma":[0.99965286,0.00009820243,0.00010900653,0.000019367713,0.000031224077,0.00008935867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004794334,0.00026977016,0.0005742126,0.00017601557,0.00011338867,0.00045041068,0.000248615,0.00030720868,0.003104712],"category_scores_gemma":[0.0008232249,0.00011355748,0.000397204,0.000263693,0.00017683145,0.00027170297,0.0001609006,0.0010044718,0.0006325286],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22741207,0.006594791,0.06891029,0.0022833173,0.0014253481,0.00077698927,0.00026966742,0.0037851746,0.07817367,0.00045182486,0.011768436,0.5981485],"study_design_scores_gemma":[0.07982412,0.46541446,0.3713227,0.0006064995,0.0017896395,0.0038210591,0.00033384096,0.008762845,0.029174022,0.00066528504,0.038186394,0.000099086625],"about_ca_topic_score_codex":0.00043717396,"about_ca_topic_score_gemma":0.0012552441,"teacher_disagreement_score":0.003104712,"about_ca_system_score_codex":0.00046421593,"about_ca_system_score_gemma":0.00049872056,"threshold_uncertainty_score":0.010386288},"labels":[],"label_agreement":null},{"id":"W2885524635","doi":"10.1158/1538-7445.am2018-3563","title":"Abstract 3563: Impact of the affinity of chimeric antigen receptor on immune activation profiles of T cells","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Chimeric antigen receptor; Epitope; Antigen; Chemistry; Human leukocyte antigen; Antibody; Molecular biology; Immune system; T cell; Cell biology; Biology; Immunology","score_opus":0.10411668772737546,"score_gpt":0.4527555669926724,"score_spread":0.3486388792652969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885524635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977678,0.00053130975,0.0008761518,0.000025827074,0.000009042695,0.000008056541,0.000063059924,0.000018980576,0.0006998484],"genre_scores_gemma":[0.9988691,0.0001153546,0.0004605189,0.000027481577,0.000005567302,0.000006381227,0.000110458896,0.0000075795206,0.00039751193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997081,0.000069428665,0.000027448297,0.00004620176,0.00006669291,0.00008207836],"domain_scores_gemma":[0.9997533,0.00010567718,0.000031827265,0.00002065773,0.000034639816,0.00005384388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020578539,0.0002466671,0.00022597412,0.00015343184,0.00010238368,0.00036019785,0.00012086486,0.00028095357,0.002425009],"category_scores_gemma":[0.00025719983,0.00010500116,0.00017722171,0.00013790399,0.00013526129,0.0001624925,0.00019391376,0.0004949039,0.0005391057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021198014,0.00003411018,0.00024423975,0.00001983264,0.000003940715,0.000018991801,0.000010225063,0.000131199,0.9983542,0.000042938915,0.000022357206,0.0009060409],"study_design_scores_gemma":[0.000025777586,0.00077658385,0.0045031034,0.0000064065694,0.000024534522,0.00024291771,0.000021610525,0.0012821787,0.99215794,0.000049058774,0.0009043836,0.0000055195806],"about_ca_topic_score_codex":0.00023910549,"about_ca_topic_score_gemma":0.00017823443,"teacher_disagreement_score":0.002425009,"about_ca_system_score_codex":0.00018553472,"about_ca_system_score_gemma":0.00011212948,"threshold_uncertainty_score":0.00811249},"labels":[],"label_agreement":null},{"id":"W2885654872","doi":"10.1158/1538-7445.am2018-1763","title":"Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; Immunotherapy; Cytotoxic T cell; Cancer research; Brain tumor; Antibody; Monoclonal antibody; Glioma; T cell; Tumor antigen; Immunology; Biology; Medicine; Immune system; Pathology; In vitro","score_opus":0.18447562576547308,"score_gpt":0.49285059538041026,"score_spread":0.30837496961493716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885654872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873253,0.0015305924,0.003895783,0.00036834582,0.00019578461,0.0007415228,0.0012597528,0.00026710457,0.004415812],"genre_scores_gemma":[0.9864276,0.0012422365,0.0040327,0.00020361625,0.000038613733,0.0005360262,0.0011926107,0.0000501206,0.0062765307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998233,0.00002674475,0.000013117689,0.00002841791,0.000047857888,0.000060560502],"domain_scores_gemma":[0.9999347,0.000008735805,0.000013059669,0.000006585026,0.00000803829,0.000028880897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029015116,0.0006657198,0.000517957,0.00040319527,0.00020280686,0.00035496047,0.0003837585,0.0007363994,0.0034649395],"category_scores_gemma":[0.00010044976,0.00019212527,0.00036860653,0.00025143454,0.00036800362,0.00029022008,0.00019159894,0.001800297,0.0006654457],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028091914,0.0028022234,0.00015952175,0.00017105685,0.000033802957,0.00009058771,0.000057787343,0.001029855,0.9820179,0.0008152475,0.0010979224,0.008914799],"study_design_scores_gemma":[0.00051632174,0.017897004,0.0007999755,0.000012779049,0.00005822941,0.00014965456,0.000028972016,0.0017855399,0.9734115,0.0001478697,0.00518017,0.000011934556],"about_ca_topic_score_codex":0.0008730486,"about_ca_topic_score_gemma":0.0007798203,"teacher_disagreement_score":0.0034649395,"about_ca_system_score_codex":0.00032660295,"about_ca_system_score_gemma":0.0005816915,"threshold_uncertainty_score":0.011591375},"labels":[],"label_agreement":null},{"id":"W2886321703","doi":"10.1038/s41467-018-05395-y","title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University","funders":"Terry Fox Foundation","keywords":"Chimeric antigen receptor; Cytotoxic T cell; CD28; Cancer research; Cytokine release syndrome; Cytokine; Antigen; CD8; Cytotoxicity; T-cell receptor; Immunotherapy; T cell; In vitro; Chemistry; Biology; Immunology; Immune system; Biochemistry","score_opus":0.04732461507935709,"score_gpt":0.3628452382667252,"score_spread":0.3155206231873681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886321703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96351,0.001998638,0.026034553,0.00040706844,0.00012231471,0.00008513711,0.0002742382,0.0004640376,0.0071040597],"genre_scores_gemma":[0.9860547,0.0005515744,0.009524095,0.00011117043,0.000019191088,0.000027146849,0.0002451895,0.00003740443,0.0034295816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978703,0.00003216037,0.000018800923,0.00004595676,0.000064461274,0.0000515089],"domain_scores_gemma":[0.9998622,0.000022791828,0.000037935213,0.000022657765,0.000029388879,0.000025030302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019635237,0.00035023136,0.00022327156,0.00020597561,0.00013374572,0.0006030018,0.0002352596,0.0006611868,0.0011184184],"category_scores_gemma":[0.00015917001,0.00015167466,0.0002537046,0.00016832277,0.00019953118,0.00033092572,0.00018773977,0.0006903368,0.0005364507],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043593296,0.000020739275,0.00005181865,0.000016027994,0.0000033958927,0.00003095948,0.0000037652717,0.00009402342,0.9982147,0.00018381471,0.00008655674,0.0012506995],"study_design_scores_gemma":[0.00001301762,0.00014913884,0.0002518945,0.0000015885907,0.000011050882,0.00025118852,0.000005170008,0.0010599158,0.99607843,0.000025133599,0.0021505975,0.00000289074],"about_ca_topic_score_codex":0.000498348,"about_ca_topic_score_gemma":0.00054608623,"teacher_disagreement_score":0.0011184184,"about_ca_system_score_codex":0.00033891806,"about_ca_system_score_gemma":0.00024280952,"threshold_uncertainty_score":0.0037415028},"labels":[],"label_agreement":null},{"id":"W2886489059","doi":"10.1111/cei.13145","title":"Infusion of<i>ex-vivo</i>expanded human TCR-αβ+ double-negative regulatory T cells delays onset of xenogeneic graft-<i>versus</i>-host disease","year":2018,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Ex vivo; In vivo; Immunology; T cell; Immune system; T-cell receptor; Humanized mouse; Regulatory T cell; Graft-versus-host disease; Biology; Medicine; Cancer research; Stem cell; Cell biology; IL-2 receptor","score_opus":0.07825711958929048,"score_gpt":0.42539361532358083,"score_spread":0.34713649573429034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886489059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925672,0.00093393534,0.0038164293,0.00008925851,0.00007724003,0.000041764306,0.0001657175,0.00016755983,0.0021408668],"genre_scores_gemma":[0.9944273,0.00039738524,0.0027710088,0.00007623228,0.0000325456,0.00002752682,0.00021245482,0.00003170654,0.002023811],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991727,0.00001593662,0.0000075300795,0.000020790483,0.000015886571,0.0000225834],"domain_scores_gemma":[0.999938,0.000013108626,0.000015879466,0.000007720126,0.000003866888,0.000021506132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015958838,0.00028906026,0.00020022392,0.00011422669,0.00006714262,0.00019177915,0.000097835684,0.00012669728,0.0011820608],"category_scores_gemma":[0.0000728797,0.00007758418,0.00011404058,0.000049533242,0.00016358288,0.00015624314,0.00006824399,0.00070854183,0.00019103673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062485307,0.00022239021,0.0001548348,0.00002644895,0.0000040170626,0.00003322672,0.000015735432,0.00014399222,0.9932306,0.00009906875,0.000103597056,0.005341283],"study_design_scores_gemma":[0.00006232084,0.0019676008,0.0013681916,0.000007842191,0.000015831874,0.00025535733,0.0000145546865,0.0010987784,0.99301845,0.000046227047,0.0021409243,0.000003810307],"about_ca_topic_score_codex":0.0001340547,"about_ca_topic_score_gemma":0.00024333817,"teacher_disagreement_score":0.0011820608,"about_ca_system_score_codex":0.0000849676,"about_ca_system_score_gemma":0.0001643496,"threshold_uncertainty_score":0.003954351},"labels":[],"label_agreement":null},{"id":"W2887634491","doi":"10.1097/mot.0000000000000566","title":"Taking regulatory T-cell therapy one step further","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Organ Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cell therapy; Alloimmunity; Immunology; Homing (biology); Autoimmunity; Genetic enhancement; Antigen; In vivo; Ex vivo; Adoptive cell transfer; T cell; Biology; Medicine; Cancer research; Stem cell; Immune system; Cell biology; Gene; Biotechnology","score_opus":0.17448715471353066,"score_gpt":0.422205049717559,"score_spread":0.24771789500402835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887634491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000113822614,0.9927797,0.00035230588,0.0022929779,0.0025491142,0.00001098881,0.000018618955,0.000022242486,0.0018602611],"genre_scores_gemma":[0.00127154,0.99144167,0.0004412868,0.0026587772,0.0020124258,0.00002030167,0.00004328021,0.0000081372,0.0021025268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997106,0.000061925966,0.000034696197,0.00005432833,0.00010446186,0.0000338774],"domain_scores_gemma":[0.99954444,0.00020727339,0.00005228641,0.000016733684,0.0001235146,0.000055620174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008352363,0.0009352575,0.0011681069,0.0011696216,0.00028169627,0.0012665415,0.0008528059,0.0018325548,0.0060985563],"category_scores_gemma":[0.000937153,0.00017972682,0.00055740174,0.0008937169,0.0006789908,0.0018892582,0.00082043116,0.0031102072,0.0038019815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009111825,0.00007398768,0.00011520811,0.016874153,0.00007589205,0.00028716138,0.00008432913,0.00030550087,0.0031061736,0.008553272,0.096652515,0.87378067],"study_design_scores_gemma":[0.000017149303,0.000053329844,0.00015011053,0.002243715,0.000042506133,0.0006494504,0.00003914232,0.000059559534,0.00048612672,0.002244461,0.99400383,0.000010666009],"about_ca_topic_score_codex":0.0004394431,"about_ca_topic_score_gemma":0.00064318185,"teacher_disagreement_score":0.0060985563,"about_ca_system_score_codex":0.00064629014,"about_ca_system_score_gemma":0.0013464214,"threshold_uncertainty_score":0.020401716},"labels":[],"label_agreement":null},{"id":"W2887911630","doi":"10.1093/intimm/dxy051","title":"Producing proT cells to promote immunotherapies","year":2018,"lang":"en","type":"review","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Canada First Research Excellence Fund; Ontario Institute for Regenerative Medicine; Krembil Foundation; University of Toronto","keywords":"Immunotherapy; Chimeric antigen receptor; Cancer immunotherapy; Induced pluripotent stem cell; Immune system; T cell; Cell therapy; Immunology; Progenitor cell; Antigen-presenting cell; Antigen; Biology; Major histocompatibility complex; Cancer research; Stem cell; Cell biology; Embryonic stem cell","score_opus":0.06643699078101255,"score_gpt":0.4047386559700356,"score_spread":0.33830166518902305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887911630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021504592,0.98800176,0.002214527,0.00046018258,0.00045944433,0.000034222496,0.00003939237,0.000035769226,0.006604198],"genre_scores_gemma":[0.01159281,0.9815964,0.0020986132,0.000389147,0.00024820215,0.000046565623,0.00007860104,0.000009523265,0.00394011],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985754,0.000027893328,0.000011882543,0.000023463037,0.00006218762,0.000016890204],"domain_scores_gemma":[0.9999293,0.000030046287,0.000011683194,0.0000043245427,0.000017697716,0.000007011598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037167463,0.00045224253,0.00047231474,0.0011096537,0.00013499187,0.0007092218,0.0004237771,0.0007494529,0.0018603392],"category_scores_gemma":[0.00029971206,0.00014206128,0.00027891825,0.0006125791,0.00031973905,0.0006717488,0.00045754705,0.0009727474,0.0017296474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007443856,0.000114428876,0.00029578668,0.012473077,0.00006093835,0.0005726477,0.00017425038,0.0005734603,0.049742665,0.01872469,0.0157667,0.901427],"study_design_scores_gemma":[0.000012636097,0.00011138536,0.0003912941,0.0010700702,0.000043691867,0.0015019755,0.000044418786,0.00012018009,0.012925581,0.0021242937,0.98164326,0.000011046402],"about_ca_topic_score_codex":0.00021868302,"about_ca_topic_score_gemma":0.00030064673,"teacher_disagreement_score":0.0018603392,"about_ca_system_score_codex":0.00032272373,"about_ca_system_score_gemma":0.00035963889,"threshold_uncertainty_score":0.0062235},"labels":[],"label_agreement":null},{"id":"W2889810537","doi":"10.1093/annonc/mdy398","title":"Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"European Society for Medical Oncology; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Clinical trial; Task force; Immunotherapy; Medical physics; Drug development; Inefficiency; Intensive care medicine; Risk analysis (engineering); Cancer; Internal medicine; Pharmacology; Drug","score_opus":0.83767867545436,"score_gpt":0.6555024798137091,"score_spread":0.1821761956406509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889810537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010289038,0.90663475,0.032208085,0.027039625,0.0057401434,0.020915123,0.0018069613,0.00019578768,0.0044306293],"genre_scores_gemma":[0.012820895,0.67394257,0.25360945,0.020636808,0.0031309018,0.03223829,0.001571999,0.00014567823,0.001903458],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.89423484,0.075019516,0.015217945,0.0029044412,0.011209324,0.001413865],"domain_scores_gemma":[0.7549596,0.17526278,0.025359612,0.0082361335,0.032123785,0.0040581655],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.2123679,0.0034411114,0.013312772,0.00434124,0.0011065439,0.009869659,0.0074533727,0.006847123,0.0055972403],"category_scores_gemma":[0.18118651,0.0018655306,0.011266636,0.0031544918,0.0037338054,0.006543089,0.0037390527,0.010836277,0.0025778408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004675196,0.0006849409,0.0014643719,0.10759286,0.0031669687,0.00021706554,0.0004008145,0.0009736389,0.002140953,0.012140231,0.037407734,0.82913524],"study_design_scores_gemma":[0.011917572,0.004592144,0.00683718,0.2746066,0.017203854,0.00085181295,0.0006592245,0.0014140031,0.0058140783,0.033553056,0.64221287,0.00033765653],"about_ca_topic_score_codex":0.0034821962,"about_ca_topic_score_gemma":0.007408149,"teacher_disagreement_score":0.2123679,"about_ca_system_score_codex":0.0046282155,"about_ca_system_score_gemma":0.041535866,"threshold_uncertainty_score":0.9712906},"labels":[],"label_agreement":null},{"id":"W2890616344","doi":"10.1038/s41586-018-0499-y","title":"A homing system targets therapeutic T cells to brain cancer","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"ALCAM; Homing (biology); Cytotoxic T cell; Extravasation; Cancer cell; Immune system; Cancer research; Cell adhesion molecule; Cell adhesion; Immunotherapy; Cancer immunotherapy; Cell biology; Chemistry; Cancer; Immunology; Cell; Biology; Medicine; In vitro; Internal medicine; Biochemistry","score_opus":0.017823140015528424,"score_gpt":0.3489033750336359,"score_spread":0.33108023501810746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890616344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.857797,0.03616192,0.054971315,0.008735197,0.0019179191,0.00049390487,0.00048189706,0.0018264855,0.037614282],"genre_scores_gemma":[0.97395927,0.006397506,0.009695886,0.0008519203,0.00025554295,0.00013258822,0.00019600202,0.000060929622,0.0084503675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983203,0.00003890589,0.000007850116,0.00004157831,0.000030832824,0.00004875357],"domain_scores_gemma":[0.9999269,0.00001450159,0.000014951009,0.000013874871,0.000011775495,0.00001800487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031631443,0.0004912941,0.00027268444,0.0004388629,0.0003814248,0.0010191231,0.00043900183,0.0009014141,0.0036859016],"category_scores_gemma":[0.00025049012,0.00019377681,0.00034407031,0.00018943596,0.00044135202,0.0007336302,0.0005119611,0.0013241317,0.0010746951],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033920503,0.0003351881,0.00054982083,0.00029218956,0.000053255182,0.00043714934,0.00013031089,0.0008158135,0.885155,0.009280069,0.0049393144,0.09767263],"study_design_scores_gemma":[0.00034303407,0.004395594,0.0027213925,0.0001033506,0.00028057164,0.00301098,0.00025357306,0.0044137784,0.88478655,0.0055352496,0.09411883,0.000037167418],"about_ca_topic_score_codex":0.00035446556,"about_ca_topic_score_gemma":0.00044545953,"teacher_disagreement_score":0.0036859016,"about_ca_system_score_codex":0.00044104832,"about_ca_system_score_gemma":0.00044322017,"threshold_uncertainty_score":0.012330532},"labels":[],"label_agreement":null},{"id":"W2890672884","doi":"10.1200/jco.2018.36.15_suppl.tps9600","title":"A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; Ottawa Hospital; CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Saskatchewan; Cancer Care Ontario; Queen's University; McMaster University; Horizon Health Network; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Clinical endpoint; Adverse effect; Internal medicine; Clinical trial; Quality of life (healthcare); Population; Randomized controlled trial; Oncology; Melanoma; Phases of clinical research; Surgery","score_opus":0.4135943830261517,"score_gpt":0.6025961119743353,"score_spread":0.18900172894818357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890672884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.832072,0.0136021525,0.0022727717,0.0060965414,0.00166495,0.11287556,0.017338404,0.00046488887,0.013612735],"genre_scores_gemma":[0.83768886,0.0065053315,0.0093781985,0.008767143,0.0009664799,0.10383437,0.011518111,0.000100958525,0.021240545],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984584,0.0008083382,0.000057649046,0.00017792822,0.0002113099,0.00028650332],"domain_scores_gemma":[0.9981729,0.00032723704,0.00030617957,0.00012177518,0.00019221264,0.00087980676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047692955,0.0018724886,0.0029660407,0.00048333462,0.00085757906,0.00088891515,0.0013428401,0.0028118815,0.014308763],"category_scores_gemma":[0.002577158,0.00070665,0.0019950648,0.0007115059,0.0014494088,0.00067918363,0.0004521837,0.003324358,0.0014039456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96689075,0.006619933,0.0008743225,0.00097211957,0.0006747548,0.000053388925,0.000047572437,0.0002446302,0.0016561982,0.0002058141,0.004400214,0.017360318],"study_design_scores_gemma":[0.96802765,0.028552946,0.0016086394,0.00003931731,0.000156008,0.000016519985,0.0000072081457,0.000105919185,0.000084213396,0.00008280356,0.0013110527,0.00000764284],"about_ca_topic_score_codex":0.02071398,"about_ca_topic_score_gemma":0.060416754,"teacher_disagreement_score":0.02071398,"about_ca_system_score_codex":0.0031042327,"about_ca_system_score_gemma":0.01032118,"threshold_uncertainty_score":0.047867537},"labels":[],"label_agreement":null},{"id":"W2891114267","doi":"10.4155/bio-2018-0203","title":"Flow Cytometry in Cell-Based Pharmacokinetics or Cellular Kinetics in Adoptive Cell Therapy","year":2018,"lang":"en","type":"editorial","venue":"Bioanalysis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Flow cytometry; Kinetics; Cell therapy; Pharmacokinetics; Cell; Chemistry; Medicine; Pharmacology; Immunology; Biochemistry; Physics","score_opus":0.026463677672429887,"score_gpt":0.33265494908000975,"score_spread":0.30619127140757985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891114267","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010848993,0.058076113,0.0010131139,0.04366401,0.8953465,0.000044984532,0.00004975408,0.00012234619,0.0015747175],"genre_scores_gemma":[0.0009464743,0.059893407,0.0008543399,0.046358734,0.881158,0.000057163536,0.00004251097,0.00007066392,0.010618737],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996289,0.00090040424,0.0006522021,0.00040901083,0.0015893343,0.00016007002],"domain_scores_gemma":[0.9871278,0.007566333,0.0006058492,0.0003940272,0.0035745,0.00073146645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0103114,0.003648574,0.0026547192,0.0027554806,0.0015696693,0.004752874,0.0038249341,0.013677978,0.0050408994],"category_scores_gemma":[0.013029085,0.001064954,0.0026546032,0.0013121932,0.004468463,0.005559268,0.001729924,0.024756467,0.0055706115],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010540221,0.00004972769,0.00006434045,0.00085800106,0.0000396232,0.00021533488,0.000047089092,0.00012231931,0.00053211785,0.0023001868,0.9557197,0.03994627],"study_design_scores_gemma":[0.00006140641,0.00004534298,0.0001812794,0.0005951447,0.000046137036,0.00031658987,0.000022883007,0.00020677384,0.00028874588,0.0016675335,0.9965479,0.000020262745],"about_ca_topic_score_codex":0.0010266565,"about_ca_topic_score_gemma":0.0020387357,"teacher_disagreement_score":0.013677978,"about_ca_system_score_codex":0.003192636,"about_ca_system_score_gemma":0.0018878155,"threshold_uncertainty_score":0.054532528},"labels":[],"label_agreement":null},{"id":"W2891568037","doi":"10.1200/jco.2017.35.15_suppl.10524","title":"A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Ependymoma; Refractory (planetary science); Internal medicine; Sarcoma; Gastroenterology; Oncology; Cancer; Surgery; Pathology; Nivolumab; Immunotherapy","score_opus":0.07854338184453231,"score_gpt":0.4758854040754624,"score_spread":0.3973420222309301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891568037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204034,0.0019659917,0.00043457496,0.00027929377,0.000086991284,0.0024726884,0.0015759112,0.00004957455,0.0010945768],"genre_scores_gemma":[0.9809775,0.0028251484,0.0028601454,0.0013941906,0.00016602855,0.003873577,0.005486762,0.000027006092,0.0023896394],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997008,0.00012665016,0.000021393322,0.00006050205,0.000033973676,0.00005664632],"domain_scores_gemma":[0.99936455,0.000059803868,0.00012686163,0.00004460679,0.000051994884,0.0003522489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001495634,0.0007928315,0.001223714,0.00021512124,0.00028021497,0.0005240623,0.0004188045,0.00067569636,0.0027756048],"category_scores_gemma":[0.0007504127,0.00044175965,0.00080360257,0.000292776,0.0004862869,0.00043106958,0.0002768568,0.001667179,0.0008509767],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5494474,0.10936753,0.081785336,0.0011743294,0.0021651206,0.0012292034,0.00080963527,0.0021831405,0.07481226,0.00045995973,0.012279304,0.16428673],"study_design_scores_gemma":[0.4362739,0.46788514,0.07808948,0.0000613983,0.0006320651,0.0016147809,0.00018573574,0.0011155948,0.004407187,0.00019051325,0.009513096,0.000031136547],"about_ca_topic_score_codex":0.00090123125,"about_ca_topic_score_gemma":0.0023961894,"teacher_disagreement_score":0.0027756048,"about_ca_system_score_codex":0.00063639984,"about_ca_system_score_gemma":0.00159121,"threshold_uncertainty_score":0.009285331},"labels":[],"label_agreement":null},{"id":"W2892229061","doi":"10.1200/jco.2017.35.15_suppl.e21004","title":"Generalizability of clinical trials in metastatic melanoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Ipilimumab; Clinical trial; Internal medicine; Population; Vemurafenib; Cancer; Cohort; Oncology; Melanoma; Metastatic melanoma; Immunotherapy","score_opus":0.6925201321336265,"score_gpt":0.6835808158821697,"score_spread":0.00893931625145683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892229061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2972663,0.21222703,0.17101902,0.060143214,0.01264288,0.041609906,0.053231608,0.00207563,0.14978439],"genre_scores_gemma":[0.9446985,0.0049077515,0.012922473,0.01732843,0.0017287481,0.010729257,0.004931722,0.00032518897,0.0024279337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.4368582,0.43615127,0.06117024,0.030972462,0.031958956,0.0028889212],"domain_scores_gemma":[0.20393975,0.62236816,0.098773174,0.05942467,0.013275077,0.0022191682],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.42564973,0.0010690973,0.0030051572,0.005061141,0.001019029,0.005558047,0.0026164923,0.003847069,0.019602828],"category_scores_gemma":[0.6879572,0.0008702438,0.0063852523,0.008551698,0.0048521995,0.0059222844,0.0049559367,0.0045841965,0.0020187353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016816478,0.00059424253,0.6240168,0.024333319,0.030869437,0.0017517688,0.0027718025,0.004727474,0.00061253016,0.018305093,0.056838438,0.21836266],"study_design_scores_gemma":[0.012144315,0.0063486816,0.61497873,0.01605984,0.021823626,0.0049805576,0.0026133012,0.016122447,0.0014118942,0.09257879,0.2106211,0.00031672136],"about_ca_topic_score_codex":0.002084849,"about_ca_topic_score_gemma":0.002041481,"teacher_disagreement_score":0.42564973,"about_ca_system_score_codex":0.0028613026,"about_ca_system_score_gemma":0.0031059699,"threshold_uncertainty_score":0.70827615},"labels":[],"label_agreement":null},{"id":"W2892293944","doi":"10.1200/jco.2018.36.15_suppl.3056","title":"Initial safety assessment of MAGE-A10<sup>c796</sup>TCR T-cells in two clinical trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T-cell receptor; Clinical trial; Cancer research; Oncology; Internal medicine; T cell; Immunology; Immune system","score_opus":0.3952715896467518,"score_gpt":0.6543995209197939,"score_spread":0.2591279312730421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892293944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819089,0.0035954427,0.0019626203,0.00097270636,0.00017930324,0.005393056,0.0018165945,0.00014782655,0.004023624],"genre_scores_gemma":[0.9771941,0.002310435,0.0031398744,0.0015423899,0.000181535,0.0074178427,0.0038488493,0.00006168494,0.0043033496],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989384,0.0005950921,0.000058055994,0.0001179212,0.00009999256,0.00019041421],"domain_scores_gemma":[0.9986268,0.0002945887,0.00026078013,0.00013005803,0.00014759702,0.0005400584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036408924,0.0011905568,0.0012792605,0.0002965429,0.0005992499,0.0011139978,0.00086626003,0.0016368352,0.0045530694],"category_scores_gemma":[0.002013749,0.00046124257,0.001145683,0.00036029125,0.0006539863,0.0008171269,0.00042848528,0.003151514,0.0010791282],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6031025,0.07853866,0.0074307797,0.0015080854,0.00179413,0.0007003487,0.000846345,0.004359553,0.11582582,0.0008119683,0.012618594,0.17246315],"study_design_scores_gemma":[0.33148947,0.63402563,0.009489337,0.000098746634,0.00069197925,0.000663508,0.00008336047,0.0012934256,0.011805961,0.00039748583,0.009921343,0.000039751973],"about_ca_topic_score_codex":0.00065992615,"about_ca_topic_score_gemma":0.0015711953,"teacher_disagreement_score":0.0045530694,"about_ca_system_score_codex":0.001244599,"about_ca_system_score_gemma":0.0016760174,"threshold_uncertainty_score":0.019255102},"labels":[],"label_agreement":null},{"id":"W2892758519","doi":"10.1038/s41591-018-0146-z","title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":567,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"CD19; Chimeric antigen receptor; Loss of heterozygosity; Biology; Antigen; Cancer research; Mutation; Immunology; Gene; Genetics; T cell; Allele; Immune system","score_opus":0.011473866223421164,"score_gpt":0.3115330090825917,"score_spread":0.3000591428591705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892758519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97258615,0.0070664617,0.009126071,0.0010568653,0.00011436565,0.00014421837,0.00036959478,0.0003854176,0.009150853],"genre_scores_gemma":[0.9956535,0.0016427246,0.00083674554,0.00009373479,0.00002126177,0.000036713158,0.00012218943,0.000033223005,0.0015599246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996413,0.000098998506,0.000022406834,0.00003419959,0.000099231496,0.000103835155],"domain_scores_gemma":[0.99988055,0.000038589722,0.00003679207,0.000021312448,0.000009142832,0.00001355097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046142988,0.0003134311,0.00035353363,0.00051303144,0.00023495138,0.00073971885,0.0005342817,0.00046039867,0.0023905823],"category_scores_gemma":[0.0003151916,0.00019539204,0.00027650248,0.00028390987,0.00054271286,0.00041610084,0.0003763341,0.0010580004,0.00048261508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011499876,0.00055239134,0.0018498142,0.00017725959,0.00006028446,0.00049999054,0.00008684482,0.003014097,0.93157136,0.01876248,0.0012165712,0.041058954],"study_design_scores_gemma":[0.00035505585,0.0025001094,0.004415281,0.000020991862,0.00016531277,0.0016989169,0.000083475534,0.005058692,0.96061355,0.0028280832,0.022245448,0.000014952315],"about_ca_topic_score_codex":0.0004646292,"about_ca_topic_score_gemma":0.0004767151,"teacher_disagreement_score":0.0023905823,"about_ca_system_score_codex":0.0007456246,"about_ca_system_score_gemma":0.00031443618,"threshold_uncertainty_score":0.007997334},"labels":[],"label_agreement":null},{"id":"W2894424410","doi":"10.1080/2162402x.2018.1502905","title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","year":2018,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Anticancer Fund; Kræftens Bekæmpelse","keywords":"Medicine; Tumor-infiltrating lymphocytes; Tolerability; Ovarian cancer; Melanoma; Oncology; Immunotherapy; Internal medicine; Cancer; Immune system; Aldesleukin; Progressive disease; T cell; Chemotherapy; Immunology; Cancer research; Adverse effect","score_opus":0.03149604510729136,"score_gpt":0.3048349407159007,"score_spread":0.27333889560860936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894424410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854857,0.00041394657,0.0002423213,0.00004394143,0.000013575057,0.00023893059,0.000040807652,0.0000119654915,0.00044588288],"genre_scores_gemma":[0.9983552,0.00041959586,0.00035819307,0.00007442559,0.0000611016,0.00027824726,0.0001540451,0.0000035117334,0.00029575315],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997875,0.00009005361,0.000012668513,0.000032432934,0.000028222572,0.00004914243],"domain_scores_gemma":[0.9997156,0.00007617876,0.000038404247,0.000046642832,0.00002246666,0.00010062148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006861198,0.00051482016,0.00063331675,0.00018141256,0.00029295165,0.00032349137,0.0002522868,0.0003800622,0.0012209358],"category_scores_gemma":[0.0006406371,0.00013246066,0.0005329052,0.000183834,0.00039019022,0.00022309324,0.00029867433,0.0007520399,0.00027529223],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13217308,0.120951936,0.08260926,0.001204304,0.00079386786,0.005520438,0.0019975528,0.0042371354,0.37366036,0.0005270098,0.0019168992,0.2744082],"study_design_scores_gemma":[0.022871053,0.8890985,0.058995694,0.000039956918,0.00030623545,0.0025452625,0.00016402065,0.001539748,0.019164301,0.00009349109,0.005165738,0.00001607144],"about_ca_topic_score_codex":0.00048264008,"about_ca_topic_score_gemma":0.0004138742,"teacher_disagreement_score":0.0012209358,"about_ca_system_score_codex":0.00023434486,"about_ca_system_score_gemma":0.00045835483,"threshold_uncertainty_score":0.004084468},"labels":[],"label_agreement":null},{"id":"W2894501339","doi":"10.4049/jimmunol.198.supp.198.9","title":"Characterisation of gene-modified CD3-enhanced CD4+ T cells for cancer immunotherapy","year":2017,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"T-cell receptor; CD3; CD8; Cytotoxic T cell; Antigen; Biology; Adoptive cell transfer; Cancer research; T cell; Molecular biology; Immunotherapy; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.04585417149622763,"score_gpt":0.3626579439399351,"score_spread":0.3168037724437075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894501339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98565125,0.0009661984,0.010551168,0.00007001948,0.000038675735,0.00020683485,0.0004981393,0.00011576874,0.0019018492],"genre_scores_gemma":[0.98619556,0.00041567048,0.0090222275,0.00007857612,0.000013975944,0.00017953129,0.0010455411,0.000066274966,0.0029826001],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987566,0.000022392815,0.000009105389,0.000018825951,0.00003470464,0.000039323484],"domain_scores_gemma":[0.9999187,0.00001778027,0.000011892577,0.000010387571,0.000020754458,0.0000204469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014584033,0.0003239259,0.00021276883,0.00019303989,0.00012728907,0.00029152763,0.00019260158,0.000424901,0.0016279736],"category_scores_gemma":[0.00015567434,0.00011232907,0.0002245418,0.00022973878,0.00012346756,0.00011386596,0.00014426606,0.0005033058,0.00068274816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055585107,0.000017961967,0.00005772434,0.000014439358,0.0000014905636,0.000017916613,0.0000075410862,0.000106273525,0.9990171,0.000020749967,0.000013866979,0.00066926517],"study_design_scores_gemma":[0.000029100684,0.00045632446,0.0019726935,0.0000062050353,0.000014801403,0.00014452181,0.000018027871,0.0017512543,0.9926354,0.00006283764,0.0029044321,0.0000043905975],"about_ca_topic_score_codex":0.00031137545,"about_ca_topic_score_gemma":0.0002807458,"teacher_disagreement_score":0.0016279736,"about_ca_system_score_codex":0.00018722136,"about_ca_system_score_gemma":0.0001178612,"threshold_uncertainty_score":0.005446136},"labels":[],"label_agreement":null},{"id":"W2895872316","doi":"10.1093/annonc/mdy281.157","title":"Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; European Regional Development Fund; Engineering and Physical Sciences Research Council; Agència de Gestió d'Ajuts Universitaris i de Recerca; Canadian Institutes of Health Research; Knut och Alice Wallenbergs Stiftelse; Koning Boudewijnstichting; Cancer Research Foundation in Northern Sweden; Generalitat de Catalunya; Umeå Universitet; Vetenskapsrådet; Fondation contre le Cancer; Cancerfonden; McGill University","keywords":"Medicine; Chimeric antigen receptor; NKG2D; FOLFOX; Colorectal cancer; Oncology; Internal medicine; Clinical trial; Context (archaeology); Tumor microenvironment; Bevacizumab; Immunotherapy; Cancer; Chemotherapy; Oxaliplatin; Cytotoxic T cell","score_opus":0.335728840455008,"score_gpt":0.5838037167005191,"score_spread":0.2480748762455111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895872316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908535,0.0023151613,0.0009733881,0.00034990942,0.00010102169,0.0019613912,0.0011559571,0.00011756118,0.0021722084],"genre_scores_gemma":[0.9882742,0.002144552,0.0017629176,0.00041108087,0.000101637735,0.0024968784,0.0021421595,0.000041141247,0.0026253457],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996177,0.00015987421,0.000021698552,0.000076885655,0.000036201294,0.000087581866],"domain_scores_gemma":[0.9991703,0.00014691261,0.00020852873,0.000084832755,0.000058401816,0.0003310967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015507857,0.0010609557,0.0012490192,0.00045735668,0.00037747054,0.0009646859,0.00078319653,0.0010097779,0.0030958813],"category_scores_gemma":[0.00078363135,0.00035646785,0.00099814,0.00044894553,0.0009590655,0.0006997142,0.00031073816,0.0031124551,0.00063378346],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5967369,0.08305816,0.008442653,0.0017508495,0.0016386156,0.00038351872,0.00041897898,0.0072790943,0.13731286,0.0009321519,0.006244755,0.15580137],"study_design_scores_gemma":[0.24055052,0.7251713,0.0069755767,0.000055031698,0.00055199483,0.00043384312,0.000067806766,0.0012970816,0.020651484,0.00023475253,0.0039842525,0.000026320979],"about_ca_topic_score_codex":0.0011123911,"about_ca_topic_score_gemma":0.0024266567,"teacher_disagreement_score":0.0030958813,"about_ca_system_score_codex":0.0011442363,"about_ca_system_score_gemma":0.0019648355,"threshold_uncertainty_score":0.010356784},"labels":[],"label_agreement":null},{"id":"W2896410911","doi":"10.1093/annonc/mdy288.113","title":"Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer research; T-cell receptor; Cytotoxic T cell; Immunology; Epitope; Viral vector; Antigen; Cancer immunotherapy; Genetic enhancement; T cell; Immunotherapy; Immune system; Biology; Gene; In vitro","score_opus":0.0837797317816706,"score_gpt":0.3920301412292962,"score_spread":0.3082504094476256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896410911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974136,0.00088906835,0.00016647487,0.000061860796,0.0000121921075,0.0000981493,0.00013848137,0.000010229283,0.0012099508],"genre_scores_gemma":[0.99843985,0.00034176593,0.00015300525,0.00009920632,0.000025593139,0.00006992583,0.00032081784,0.0000040563336,0.00054567517],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998795,0.000024119116,0.000009644909,0.000039016682,0.000018679908,0.000028977904],"domain_scores_gemma":[0.99980074,0.00004577289,0.000033067347,0.000008699661,0.00002041166,0.00009138499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030062094,0.00022444974,0.00056492584,0.00019058952,0.0002950266,0.00032162384,0.00016054184,0.00034775617,0.0013934671],"category_scores_gemma":[0.00028226568,0.00008827859,0.0002364456,0.0002277443,0.00018471957,0.0002190547,0.0001106212,0.00054501527,0.00041428948],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11134038,0.015937824,0.50912887,0.001019093,0.0004354861,0.012221506,0.0013996102,0.0015696357,0.158981,0.0006609582,0.0028863358,0.18441936],"study_design_scores_gemma":[0.007841362,0.3222741,0.58318347,0.000103631166,0.00073764496,0.031442672,0.000631188,0.0023367112,0.030017119,0.00035925646,0.021021945,0.000050915027],"about_ca_topic_score_codex":0.00031159996,"about_ca_topic_score_gemma":0.00025606574,"teacher_disagreement_score":0.0013934671,"about_ca_system_score_codex":0.0003669609,"about_ca_system_score_gemma":0.00032052555,"threshold_uncertainty_score":0.0046616197},"labels":[],"label_agreement":null},{"id":"W2896839095","doi":"10.1002/jcp.27519","title":"Predictive and therapeutic biomarkers in chimeric antigen receptor T‐cell therapy: A clinical perspective","year":2018,"lang":"en","type":"review","venue":"Journal of Cellular Physiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute for Medical Research Development; Tehran University of Medical Sciences and Health Services","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Biomarker; Clinical trial; Cell therapy; Adverse effect; Cancer; Immunology; Oncology; Cell; Pharmacology; Internal medicine; Biology","score_opus":0.08719668679768336,"score_gpt":0.4173001961641955,"score_spread":0.3301035093665121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896839095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005319474,0.9986713,0.00015492404,0.00062874646,0.00019026619,0.0000029726993,0.000004856653,0.0000033870451,0.00029035515],"genre_scores_gemma":[0.000871516,0.99758816,0.00036299007,0.0004978414,0.00037665328,0.0000104876,0.000013593519,0.0000016499287,0.00027716724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994235,0.00018330144,0.00008368032,0.000080469064,0.00018349453,0.000045649973],"domain_scores_gemma":[0.9982286,0.0011854279,0.00012529608,0.00004341061,0.00033715216,0.00008019644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002877612,0.0011096754,0.002198422,0.0029517834,0.0002953108,0.0018209411,0.0014302506,0.0026584347,0.0016884337],"category_scores_gemma":[0.0023351726,0.00039799258,0.0008334927,0.002370687,0.0014171799,0.0028348742,0.00100217,0.004339818,0.0011333709],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017002085,0.00014246203,0.0003352689,0.0115505345,0.00012634261,0.0003130265,0.000103709084,0.0006107483,0.0016390408,0.014738558,0.024677826,0.94559246],"study_design_scores_gemma":[0.000042145057,0.00022372602,0.00079031446,0.006232801,0.00016358329,0.0016822971,0.00010851718,0.0003019868,0.00075931416,0.00729032,0.9823667,0.00003820918],"about_ca_topic_score_codex":0.0008717174,"about_ca_topic_score_gemma":0.0011301958,"teacher_disagreement_score":0.0029517834,"about_ca_system_score_codex":0.001104304,"about_ca_system_score_gemma":0.0015231951,"threshold_uncertainty_score":0.015218437},"labels":[],"label_agreement":null},{"id":"W2897377013","doi":"10.3389/fimmu.2018.02380","title":"CAR T Cell Therapy for Neuroblastoma","year":2018,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hyundai Hope On Wheels; Sarcoma Alliance for Research through Collaboration; American Association for Cancer Research; Children's Health Research Institute; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Chimeric antigen receptor; Neuroblastoma; Medicine; Cell therapy; Immunotherapy; Clinical trial; Monoclonal antibody; Targeted therapy; Oncology; T cell; Immunology; Cell; Internal medicine; Antibody; Immune system; Cancer; Biology; Cell culture","score_opus":0.04147406529802984,"score_gpt":0.34212395765616954,"score_spread":0.3006498923581397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897377013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015854152,0.9983302,0.000106805695,0.00022883165,0.00020356008,0.000005107485,0.000011085163,0.0000064258506,0.00094939984],"genre_scores_gemma":[0.0008211366,0.9980118,0.00013834945,0.00019730726,0.00013052364,0.0000065402246,0.00002221668,0.0000012348469,0.00067082484],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998896,0.000019428157,0.00001408513,0.000019703566,0.000044619457,0.000012543987],"domain_scores_gemma":[0.99987555,0.000063035135,0.000016173544,0.0000036757215,0.000028940036,0.000012600655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039972758,0.0005814623,0.0007548181,0.001622991,0.00024593042,0.0006047866,0.00054758287,0.0009947721,0.002953753],"category_scores_gemma":[0.00041771555,0.0001630183,0.00042403105,0.0011403293,0.00033023235,0.00093010115,0.0005328773,0.0016064384,0.0017098752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070926806,0.000082689185,0.00013688784,0.011412947,0.00005588732,0.00023931246,0.000051563107,0.00033143625,0.0028425131,0.0032938903,0.030268552,0.95121336],"study_design_scores_gemma":[0.000022143522,0.00011750924,0.00045018303,0.0022594512,0.00006355607,0.0013860636,0.000037218582,0.000085518164,0.0008145824,0.0014243592,0.9933281,0.000011322668],"about_ca_topic_score_codex":0.0007819378,"about_ca_topic_score_gemma":0.0014715357,"teacher_disagreement_score":0.002953753,"about_ca_system_score_codex":0.0004895425,"about_ca_system_score_gemma":0.000759553,"threshold_uncertainty_score":0.009881318},"labels":[],"label_agreement":null},{"id":"W2897385169","doi":"10.2147/ott.s184898","title":"Novel EXO-T vaccine using polyclonal CD4&lt;sup&gt;+&lt;/sup&gt; T cells armed with HER2-specific exosomes for HER2-positive breast cancer","year":2018,"lang":"en","type":"review","venue":"OncoTargets and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Microvesicles; Polyclonal antibodies; Breast cancer; Medicine; Trastuzumab; Cancer research; Virology; Cancer; Immunology; Antibody; Chemistry; Internal medicine; microRNA; Biochemistry","score_opus":0.05716456505432307,"score_gpt":0.35005826712262816,"score_spread":0.2928937020683051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897385169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009975706,0.9956922,0.0005311208,0.0004806429,0.00045094537,0.000016532375,0.000029758532,0.000014453855,0.0017868952],"genre_scores_gemma":[0.0053163823,0.9911164,0.0006156132,0.0004199803,0.00018777703,0.000031362586,0.000057428293,0.0000033314898,0.002251812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992645,0.000012010088,0.000010068086,0.000016513935,0.0000257683,0.000009224161],"domain_scores_gemma":[0.9999386,0.00002369058,0.000010564763,0.0000021531746,0.00001825833,0.000006732153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024903656,0.00047975843,0.00049476454,0.001065809,0.00015093785,0.00046493218,0.00037333532,0.0007860943,0.0016065716],"category_scores_gemma":[0.00024082972,0.00014550085,0.0003175206,0.00083949196,0.00022995772,0.00072807714,0.0003187985,0.0010709419,0.0008356957],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013472165,0.000162472,0.00021082968,0.013168765,0.000079275844,0.00033167624,0.000059870057,0.00046518148,0.012099508,0.006285447,0.025622103,0.9413802],"study_design_scores_gemma":[0.000035732413,0.00033345885,0.00062627945,0.0016177727,0.00009172306,0.0019368686,0.000048792932,0.00028171463,0.0059812604,0.0012151018,0.9878088,0.000022572156],"about_ca_topic_score_codex":0.00039043726,"about_ca_topic_score_gemma":0.00060535525,"teacher_disagreement_score":0.0016065716,"about_ca_system_score_codex":0.0003475901,"about_ca_system_score_gemma":0.00048507878,"threshold_uncertainty_score":0.005374551},"labels":[],"label_agreement":null},{"id":"W2898156792","doi":"10.1093/annonc/mdy424.048","title":"Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Fludarabine; Gastroenterology; Leukopenia; Context (archaeology); Cyclophosphamide; Oncology; Surgery; Chemotherapy","score_opus":0.21175907972974456,"score_gpt":0.5512415840560463,"score_spread":0.3394825043263017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898156792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865645,0.0056843176,0.0010530466,0.0010577302,0.00024792246,0.0012582894,0.00075714284,0.00007644451,0.0033004996],"genre_scores_gemma":[0.98961383,0.003272932,0.0009007369,0.0007486217,0.00015896086,0.0011625262,0.0011306286,0.000030070352,0.00298174],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99918395,0.00040130052,0.00005883193,0.00012062806,0.00007437224,0.00016097835],"domain_scores_gemma":[0.9989004,0.00039577956,0.00017985383,0.00013675421,0.00010276643,0.00028451948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022780178,0.00089452526,0.0015371932,0.00030614645,0.0004625531,0.0009628012,0.000552697,0.0017913551,0.0027905023],"category_scores_gemma":[0.0016506315,0.00034055562,0.0013857208,0.00035645853,0.00089481636,0.00076685235,0.0002784469,0.0032340966,0.000673461],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62605673,0.04234121,0.0055318107,0.0017969019,0.0024850406,0.00094468327,0.00055428525,0.003780878,0.101600215,0.001287335,0.005865378,0.20775554],"study_design_scores_gemma":[0.40116575,0.54554623,0.009176771,0.00013392184,0.0018285867,0.0008574424,0.00015677177,0.0014151888,0.024004014,0.0009151269,0.014735953,0.000064340406],"about_ca_topic_score_codex":0.0004479309,"about_ca_topic_score_gemma":0.0009892894,"teacher_disagreement_score":0.0027905023,"about_ca_system_score_codex":0.0008435839,"about_ca_system_score_gemma":0.0008454762,"threshold_uncertainty_score":0.01204741},"labels":[],"label_agreement":null},{"id":"W2898361810","doi":"10.1093/annonc/mdy288.029","title":"Initial safety assessment of MAGE-A4 SPEAR T-cells","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Context (archaeology); Internal medicine; Radioimmunotherapy; Oncology; Gastroenterology; Adverse effect; Immunology; Antibody","score_opus":0.1546058658359326,"score_gpt":0.5108487402034521,"score_spread":0.35624287436751945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898361810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037665,0.0010496434,0.0020716651,0.00027132162,0.00005074273,0.0015808183,0.0015022967,0.0001170223,0.0029797272],"genre_scores_gemma":[0.9892887,0.0007091874,0.0021353667,0.00046150788,0.00008903558,0.0016504361,0.0029317564,0.00005610666,0.002678068],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990109,0.0005303265,0.0000506903,0.00009705764,0.00017321696,0.00013782101],"domain_scores_gemma":[0.9990765,0.00022144389,0.00022844343,0.000113413975,0.00015379193,0.00020644777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027941228,0.0006508404,0.0010026442,0.0001756737,0.00033419413,0.00084090413,0.00082925765,0.0009389593,0.00473585],"category_scores_gemma":[0.0012915295,0.00019164408,0.0009211685,0.00028718027,0.0003685336,0.00045900542,0.00026020902,0.002333507,0.0010285807],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23370293,0.062092938,0.022501424,0.001429617,0.0014903722,0.0009916013,0.00089721306,0.012754543,0.41187254,0.0008607198,0.011458214,0.23994781],"study_design_scores_gemma":[0.028049223,0.8541659,0.017234728,0.00007985319,0.00090114534,0.0011800821,0.0001502706,0.0028042602,0.07712386,0.00035667815,0.017914519,0.000039518396],"about_ca_topic_score_codex":0.0005291061,"about_ca_topic_score_gemma":0.0009779694,"teacher_disagreement_score":0.00473585,"about_ca_system_score_codex":0.00084500347,"about_ca_system_score_gemma":0.0012117034,"threshold_uncertainty_score":0.015843034},"labels":[],"label_agreement":null},{"id":"W2899452213","doi":"10.1158/1557-3125.advbc17-a25","title":"Abstract A25: TEM8 specific CAR T cells induce regression of patient-derived xenograft and metastatic models of triple-negative breast cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Triple-negative breast cancer; Cancer research; Cancer; Metastasis; Breast cancer; Flow cytometry; Chimeric antigen receptor; In vivo; Biology; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.08494532212698017,"score_gpt":0.3960223410974566,"score_spread":0.31107701897047646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899452213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199283,0.00086765736,0.0018972819,0.00020961127,0.000113566035,0.000085597516,0.0007939919,0.00027103449,0.0037684718],"genre_scores_gemma":[0.98535824,0.0004725404,0.0016896391,0.00008613252,0.000023680188,0.00008169419,0.0011695264,0.000044511347,0.011073915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987054,0.000016629467,0.00001037148,0.00002967745,0.000032162563,0.00004053008],"domain_scores_gemma":[0.9999199,0.0000120257,0.000011304276,0.000008978274,0.000010895192,0.00003691565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012131414,0.000359797,0.0003174534,0.00025285943,0.00013277895,0.00022002574,0.00017314547,0.000329266,0.003798611],"category_scores_gemma":[0.00008864537,0.00011790616,0.00025489996,0.00010335796,0.00014365999,0.00014370479,0.00012546008,0.00083134434,0.00068657834],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006664491,0.00035572166,0.00012132062,0.000040596104,0.000010094594,0.000102072125,0.000021754804,0.00014339204,0.99448013,0.000114434246,0.0008032623,0.0031406444],"study_design_scores_gemma":[0.00016212283,0.0050717434,0.004398369,0.000009152269,0.000027805097,0.0006753038,0.00003736072,0.0017405885,0.9827071,0.000053352775,0.0051098666,0.000007245525],"about_ca_topic_score_codex":0.0008833291,"about_ca_topic_score_gemma":0.00093702134,"teacher_disagreement_score":0.003798611,"about_ca_system_score_codex":0.00023875172,"about_ca_system_score_gemma":0.00022196067,"threshold_uncertainty_score":0.012707591},"labels":[],"label_agreement":null},{"id":"W2900183696","doi":"10.1182/blood-2018-99-119086","title":"Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; Stem cell; Internal medicine; Immune system; Transplantation; Immunology; T cell; Leukemia; Gastroenterology; Biology","score_opus":0.03347189124600687,"score_gpt":0.3430399669022948,"score_spread":0.30956807565628797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900183696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94450915,0.04555956,0.00363409,0.00021883074,0.00019804716,0.0020566005,0.0019501298,0.000121561505,0.0017519997],"genre_scores_gemma":[0.99241346,0.003795121,0.0010954759,0.00024189407,0.0001521643,0.0006707807,0.0011785121,0.000019366564,0.00043331616],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9967146,0.0018398141,0.00044072073,0.0005073008,0.000339034,0.00015864476],"domain_scores_gemma":[0.99675316,0.0011569072,0.0010769543,0.0004043415,0.0003299554,0.00027857596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066162106,0.0014736686,0.0037980352,0.00092351314,0.00025770772,0.0013328075,0.00046622945,0.0008818758,0.0018434513],"category_scores_gemma":[0.004651735,0.0005425975,0.005736673,0.00078110024,0.0004720755,0.00068847224,0.00045101863,0.0011301769,0.00028743502],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69917774,0.0048207357,0.023877202,0.00486319,0.11658304,0.0001913102,0.00015705323,0.0027367491,0.033854116,0.000132091,0.001596173,0.112010635],"study_design_scores_gemma":[0.21214658,0.46785602,0.11349298,0.00061976054,0.17733072,0.00081024034,0.00021620971,0.00294399,0.018105356,0.0004339742,0.0058737877,0.00017036004],"about_ca_topic_score_codex":0.00028375862,"about_ca_topic_score_gemma":0.00060398964,"teacher_disagreement_score":0.0066162106,"about_ca_system_score_codex":0.0005971421,"about_ca_system_score_gemma":0.0008267424,"threshold_uncertainty_score":0.03499025},"labels":[],"label_agreement":null},{"id":"W2900391822","doi":"10.2147/dddt.s138765","title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","year":2018,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Context (archaeology); Medicine; Oncology; Internal medicine; Immunotherapy; Cancer; Biology","score_opus":0.06862769789823206,"score_gpt":0.32885039219268575,"score_spread":0.26022269429445366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900391822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021794873,0.9982305,0.00011583375,0.00016896405,0.00013579894,0.000005981772,0.000017096187,0.0000101332025,0.0010978362],"genre_scores_gemma":[0.0013642724,0.9972721,0.0001690154,0.00021583556,0.00010441616,0.000009082476,0.000037192647,0.0000018283779,0.00082632684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998771,0.000019959545,0.000021392483,0.000023409297,0.000047583755,0.00001064643],"domain_scores_gemma":[0.99988484,0.000049080656,0.000023635735,0.0000034338027,0.000025933265,0.000013088567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030466268,0.0005444229,0.00074117666,0.002014415,0.00022156084,0.00048816905,0.0005689201,0.00062226696,0.0025653495],"category_scores_gemma":[0.00036663606,0.00015828568,0.00032311564,0.0015560373,0.00027922905,0.0007257316,0.00044985025,0.0014205012,0.0017590224],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000657866,0.000060720864,0.00008092352,0.009007316,0.00005142875,0.00014042185,0.000038138063,0.00024563028,0.0015123185,0.0019173605,0.021499433,0.9653806],"study_design_scores_gemma":[0.00002645664,0.00012568162,0.00052635244,0.0019902599,0.00007740385,0.0018696191,0.000031736105,0.00007751118,0.00067216,0.00073637825,0.99385494,0.000011460638],"about_ca_topic_score_codex":0.0006869108,"about_ca_topic_score_gemma":0.0012229,"teacher_disagreement_score":0.0025653495,"about_ca_system_score_codex":0.0003449367,"about_ca_system_score_gemma":0.0005334413,"threshold_uncertainty_score":0.008581936},"labels":[],"label_agreement":null},{"id":"W2900662379","doi":"10.1182/blood-2018-99-112572","title":"Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Cytokine release syndrome; Medicine; Chimeric antigen receptor; CD19; T cell; Internal medicine; Immunology; B cell; Blinatumomab; Pembrolizumab; Oncology; Immunotherapy; Antigen; Immune system; Cancer; Antibody","score_opus":0.013840445879683815,"score_gpt":0.26218224226146203,"score_spread":0.24834179638177822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900662379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986727,0.0005682412,0.00019183573,0.000034735123,0.0000049335786,0.000021752881,0.0000377139,0.000024699695,0.00044341697],"genre_scores_gemma":[0.99892277,0.0003172493,0.00029850772,0.000035796867,0.000010926531,0.000021575092,0.00012846055,0.0000068954055,0.00025770327],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986815,0.000047062345,0.000012158311,0.000021463631,0.000016850483,0.000034298886],"domain_scores_gemma":[0.9998565,0.000043729793,0.000029766774,0.000011652834,0.000008132398,0.000050219525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022572174,0.00024405844,0.00039796127,0.00020475216,0.00021561015,0.00026958014,0.00020345704,0.0001713144,0.0008429347],"category_scores_gemma":[0.00035639957,0.00010574663,0.00019497462,0.00016335095,0.00017970405,0.000131389,0.00016130276,0.000465613,0.0002764909],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022885108,0.00850075,0.31388822,0.0006990083,0.0006654738,0.015182873,0.0012273367,0.0055880523,0.22703357,0.0004509237,0.0041969647,0.39968172],"study_design_scores_gemma":[0.011394464,0.12598206,0.53624266,0.00014846132,0.0011848843,0.059476744,0.0005230171,0.008783582,0.2250465,0.00031132792,0.0308536,0.000052687865],"about_ca_topic_score_codex":0.0005471999,"about_ca_topic_score_gemma":0.001176455,"teacher_disagreement_score":0.0008429347,"about_ca_system_score_codex":0.00034914256,"about_ca_system_score_gemma":0.00021854482,"threshold_uncertainty_score":0.0028198957},"labels":[],"label_agreement":null},{"id":"W2900733038","doi":"10.1182/blood-2018-99-118344","title":"Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Mantle cell lymphoma; Internal medicine; Follicular lymphoma; CD20; Lymphoma; Gastroenterology; Rituximab; Refractory (planetary science); Adverse effect; Biology","score_opus":0.04516121939774342,"score_gpt":0.3896615740049443,"score_spread":0.34450035460720085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900733038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520266,0.00178535,0.00046620943,0.00014811823,0.000017084167,0.0005141317,0.00048979605,0.00006166277,0.0013149307],"genre_scores_gemma":[0.99538785,0.0007722969,0.0008902071,0.00023644435,0.000045921537,0.00037720441,0.0013874174,0.000018136036,0.00088451314],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997124,0.00013568302,0.000019572286,0.000040729676,0.000038102175,0.000053481912],"domain_scores_gemma":[0.99964476,0.000074688636,0.00008081214,0.000026622165,0.000040006245,0.0001330895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014529341,0.0005972699,0.0007211974,0.00022108456,0.00032445102,0.0005596048,0.00041303312,0.0006203726,0.0015528381],"category_scores_gemma":[0.00047229178,0.00020500261,0.00040565926,0.00019705476,0.00032152174,0.00039724357,0.00013107591,0.0013349857,0.0004097926],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19849187,0.041341078,0.028371017,0.00081269926,0.0012055258,0.0005887601,0.00040238228,0.0031145453,0.47540587,0.0002789892,0.0060205944,0.24396664],"study_design_scores_gemma":[0.13285922,0.65470296,0.111440584,0.00007809805,0.0011365183,0.0015669053,0.000097033066,0.003217349,0.084724806,0.00027453323,0.009849535,0.00005243385],"about_ca_topic_score_codex":0.00062842004,"about_ca_topic_score_gemma":0.0018113669,"teacher_disagreement_score":0.0015528381,"about_ca_system_score_codex":0.00055586523,"about_ca_system_score_gemma":0.0006465221,"threshold_uncertainty_score":0.007683933},"labels":[],"label_agreement":null},{"id":"W2900935567","doi":"10.1007/978-1-4939-8885-3_2","title":"An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood","year":2018,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Rosetrees Trust; National Institute for Health and Care Research; Cancer Research UK; Francis Crick Institute","keywords":"Biology; Complementary DNA; T-cell receptor; Computational biology; Receptor; DNA sequencing; Immune system; DNA; T cell; Gene; Immunology; Genetics","score_opus":0.12476649692176618,"score_gpt":0.48898686531799096,"score_spread":0.3642203683962248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900935567","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070302133,0.00036570049,0.9854146,0.00026635107,0.00019403803,0.0015489474,0.0013485141,0.0018905221,0.0019410753],"genre_scores_gemma":[0.037374485,0.0009263578,0.9396332,0.00080515794,0.00016399934,0.0066044265,0.004775435,0.0009479989,0.008768974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970571,0.0008260829,0.0002650034,0.0006649401,0.0009782994,0.00020852791],"domain_scores_gemma":[0.9983955,0.00057410466,0.00015322756,0.00043339725,0.0003017369,0.00014207119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028396216,0.0019426312,0.0011547299,0.0018080471,0.0011860116,0.0012035203,0.0017479572,0.0015785467,0.0054833973],"category_scores_gemma":[0.0032255258,0.0015455943,0.0010487414,0.00090687076,0.0011440957,0.0009802618,0.0012964723,0.0037964566,0.0070311017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100798046,0.00009918168,0.00020047635,0.00014511237,0.00003084042,0.00006541432,0.000054736458,0.00044227514,0.9785508,0.0014006114,0.0030639523,0.015845984],"study_design_scores_gemma":[0.00011768419,0.00038091844,0.0014301372,0.00006306014,0.00009349169,0.0006088261,0.000051125997,0.0090505835,0.94337463,0.0033937667,0.04133545,0.00010036501],"about_ca_topic_score_codex":0.0006435359,"about_ca_topic_score_gemma":0.0029592179,"teacher_disagreement_score":0.0054833973,"about_ca_system_score_codex":0.00062141,"about_ca_system_score_gemma":0.0021671392,"threshold_uncertainty_score":0.018343747},"labels":[],"label_agreement":null},{"id":"W2901026782","doi":"10.1182/blood-2018-99-111061","title":"Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ibrutinib; Medicine; Fludarabine; Internal medicine; Leukapheresis; Neutropenia; Chronic lymphocytic leukemia; Cyclophosphamide; Immunology; Leukemia; Gastroenterology; Toxicity; Chemotherapy; Stem cell; Biology","score_opus":0.05115529306873292,"score_gpt":0.34419640482197367,"score_spread":0.29304111175324077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901026782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957638,0.0030237683,0.00017042014,0.000071113405,0.00004928315,0.00016433453,0.00014888599,0.000022434944,0.00058595365],"genre_scores_gemma":[0.99806994,0.00087643927,0.00023672696,0.000048164227,0.00008436141,0.00013442362,0.0002108819,0.000008045896,0.00033103972],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99930096,0.0003941781,0.00005416409,0.000089607674,0.00006857733,0.00009245106],"domain_scores_gemma":[0.999366,0.00020482905,0.00012602097,0.000048097198,0.000029503524,0.00022548993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014036314,0.00071099354,0.0019095059,0.00056432904,0.0002053618,0.0006649782,0.0006546083,0.00051509653,0.0012065305],"category_scores_gemma":[0.0008473542,0.00031584434,0.000893607,0.0003762724,0.00051914575,0.00042585735,0.00025805956,0.0013492659,0.0002370277],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62588793,0.030875118,0.015523904,0.0010812912,0.0023846407,0.00038327114,0.0003313025,0.007086529,0.1283373,0.00034196555,0.0012995816,0.18646722],"study_design_scores_gemma":[0.090499714,0.84776086,0.024023391,0.00008577064,0.0022543569,0.00039870394,0.00008857789,0.0031698737,0.029219253,0.00015699674,0.0022966387,0.000045886078],"about_ca_topic_score_codex":0.00085127115,"about_ca_topic_score_gemma":0.0021934072,"teacher_disagreement_score":0.0019095059,"about_ca_system_score_codex":0.0006631359,"about_ca_system_score_gemma":0.00070543215,"threshold_uncertainty_score":0.007423222},"labels":[],"label_agreement":null},{"id":"W2901228410","doi":"10.1182/blood-2018-99-110561","title":"Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Minimal residual disease; Bone marrow; Internal medicine; Fludarabine; Chimeric antigen receptor; Leukemia; Immunotherapy; Oncology; Immunology; Chemotherapy; Cancer; Cyclophosphamide","score_opus":0.030691553626037777,"score_gpt":0.2904626950089509,"score_spread":0.25977114138291313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901228410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949486,0.0002554024,0.002639789,0.0002657166,0.000022974604,0.000032848486,0.0015359115,0.00004312593,0.00025559883],"genre_scores_gemma":[0.99789643,0.00005531937,0.00041640637,0.000021306538,0.000020057603,0.000028949129,0.0011383118,0.000010347657,0.00041287558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865013,0.0006448933,0.00005998311,0.00029540638,0.00010332306,0.0002462105],"domain_scores_gemma":[0.9960051,0.0025523112,0.0005502185,0.00023992057,0.00020354301,0.00044890013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030086522,0.00063610845,0.0007799623,0.0007874986,0.00028211178,0.00095963356,0.0008743569,0.00062100415,0.0038990837],"category_scores_gemma":[0.0039725658,0.00031049416,0.0023349582,0.0007844196,0.0002506729,0.00032837412,0.00063326483,0.0010698548,0.00035837907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031128621,0.00033724366,0.9575727,0.00003675937,0.0016621782,0.00018985395,0.0000624494,0.028326113,0.00068756775,0.0002997065,0.0012752246,0.006437421],"study_design_scores_gemma":[0.00020377619,0.0015734199,0.6014499,0.000023326555,0.0011383797,0.00026483435,0.00023256976,0.3919287,0.00052792154,0.00080332195,0.0018188637,0.000034883353],"about_ca_topic_score_codex":0.009598471,"about_ca_topic_score_gemma":0.004239682,"teacher_disagreement_score":0.009598471,"about_ca_system_score_codex":0.00055866333,"about_ca_system_score_gemma":0.00087516615,"threshold_uncertainty_score":0.019085169},"labels":[],"label_agreement":null},{"id":"W2901850955","doi":"10.1038/s41591-018-0266-5","title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":579,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Horizon 2020 Framework Programme; BC Cancer Foundation; Krebsliga Beider Basel","keywords":"T-cell receptor; CD8; Immune system; Tumor-infiltrating lymphocytes; Cancer research; Cytotoxic T cell; Infiltration (HVAC); Repertoire; T cell; Biology; Pathology; Immunology; Medicine; In vitro","score_opus":0.011790611396794251,"score_gpt":0.3190317624480587,"score_spread":0.3072411510512644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901850955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634933,0.00090754486,0.0006525508,0.000039556548,0.0000046988202,0.0000035914654,0.00011851951,0.000031182924,0.0018928485],"genre_scores_gemma":[0.99905545,0.00017362111,0.0001114735,0.000021870737,0.0000045913166,0.0000045339466,0.0001174666,0.000013334297,0.00049766945],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999818,0.000038979146,0.000010390132,0.00005276569,0.00003051029,0.000049352508],"domain_scores_gemma":[0.9997929,0.00007361555,0.000028587476,0.000045955145,0.000027109683,0.00003187117],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016109034,0.00012496923,0.00013173863,0.00046264942,0.00018882085,0.00047766714,0.00013753433,0.00028852143,0.0026061758],"category_scores_gemma":[0.0004627412,0.00012210495,0.000102111655,0.0002388419,0.00018805527,0.00018149527,0.0002270938,0.00035953074,0.00042764714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034771452,0.000032214586,0.020858765,0.000038144943,0.00002440294,0.00014199922,0.0001502035,0.00022533986,0.9669185,0.0003524352,0.00014467057,0.010765502],"study_design_scores_gemma":[0.00004590425,0.00089238543,0.6273758,0.000044512504,0.00023362244,0.012156805,0.0010393775,0.0029931432,0.3371024,0.0016542006,0.016428271,0.00003360852],"about_ca_topic_score_codex":0.00025250023,"about_ca_topic_score_gemma":0.00027413928,"teacher_disagreement_score":0.0026061758,"about_ca_system_score_codex":0.00015368851,"about_ca_system_score_gemma":0.00008737875,"threshold_uncertainty_score":0.00871855},"labels":[],"label_agreement":null},{"id":"W2902954276","doi":"10.1182/blood-2018-99-119740","title":"Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Immune system; Medicine; Adoptive cell transfer; Immunology; Cytokine release syndrome; T cell; Bone marrow; Cancer research; Myeloid; Haematopoiesis; Cell therapy; Tumor microenvironment; Transplantation; Stem cell; Chimeric antigen receptor; Internal medicine; Biology","score_opus":0.029191515712546977,"score_gpt":0.3330513123574293,"score_spread":0.30385979664488233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902954276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9294943,0.0013347005,0.06439545,0.000148144,0.000042106312,0.00015269885,0.0002702678,0.00019006469,0.0039722556],"genre_scores_gemma":[0.9871546,0.00046563192,0.010822081,0.00002436026,0.000004233946,0.000065449894,0.00010173979,0.00001327559,0.00134857],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99996793,0.000005696435,0.0000010441482,0.0000096207,0.000008222141,0.000007510644],"domain_scores_gemma":[0.9999789,0.000006311802,0.00000744729,0.0000016287123,0.0000021108465,0.0000036290382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000059295675,0.00020850444,0.000107064145,0.000101864236,0.00006677851,0.0002535634,0.00021579136,0.00017146918,0.0010100809],"category_scores_gemma":[0.000066168206,0.00008285983,0.00013725016,0.00008685821,0.0000934617,0.00012176113,0.00008394432,0.00020384637,0.0001880144],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002628364,0.00028853776,0.0008251107,0.00010418372,0.000012658171,0.000107286345,0.000023667822,0.10998552,0.8790529,0.0012205485,0.00022317808,0.007893663],"study_design_scores_gemma":[0.000065074455,0.0016684285,0.0013682885,0.000012201548,0.00003616506,0.000095798874,0.000018921788,0.3383366,0.6543279,0.00037006807,0.0036901345,0.000010397714],"about_ca_topic_score_codex":0.00092145114,"about_ca_topic_score_gemma":0.00077894103,"teacher_disagreement_score":0.0010100809,"about_ca_system_score_codex":0.00028293763,"about_ca_system_score_gemma":0.0002029974,"threshold_uncertainty_score":0.0033791065},"labels":[],"label_agreement":null},{"id":"W2903062212","doi":"10.1056/nejmoa1804980","title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4044,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Neutropenia; Internal medicine; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Lymphoma; Refractory (planetary science); Transplantation; Gastroenterology; Febrile neutropenia; Rituximab; Clinical endpoint; Oncology; Phases of clinical research; Salvage therapy; Immunology; Immunotherapy; Chimeric antigen receptor; Chemotherapy; Clinical trial; Cancer","score_opus":0.026080307824309687,"score_gpt":0.31679131502515506,"score_spread":0.29071100720084536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903062212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908443,0.0075352928,0.00024683177,0.00011079965,0.00001669981,0.00012694512,0.00008198217,0.000035544097,0.0010015969],"genre_scores_gemma":[0.9971814,0.001834823,0.0003535141,0.00013672984,0.00003650991,0.0000611486,0.00019694709,0.000004376681,0.00019449765],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997131,0.00015899858,0.000025522246,0.00003211386,0.000041291205,0.00002899694],"domain_scores_gemma":[0.9996327,0.00011041038,0.00010566342,0.000019456482,0.000029043948,0.00010264717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088512356,0.0003306315,0.0006732082,0.00023846007,0.00012211181,0.00028087618,0.000277382,0.00028852254,0.0009996521],"category_scores_gemma":[0.0005745145,0.00009088591,0.00024050869,0.00028571373,0.0002635889,0.00018991342,0.00021176843,0.00045154814,0.00023029385],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09165528,0.0073115965,0.14037614,0.0027103657,0.0009462834,0.0049042306,0.00068956206,0.004727624,0.09867002,0.00051716936,0.0047212215,0.6427705],"study_design_scores_gemma":[0.06452425,0.4703822,0.3783335,0.00043929106,0.0011742637,0.017725088,0.0004215865,0.0063156253,0.029384239,0.00047790277,0.030752454,0.00006968524],"about_ca_topic_score_codex":0.00032319882,"about_ca_topic_score_gemma":0.0008329755,"teacher_disagreement_score":0.0009996521,"about_ca_system_score_codex":0.00030628077,"about_ca_system_score_gemma":0.00035842773,"threshold_uncertainty_score":0.004681051},"labels":[],"label_agreement":null},{"id":"W2903610511","doi":"10.1016/j.ymthe.2018.12.003","title":"The Bumpy Road to CAR Activation","year":2018,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Scopus; CD28; T cell; Cancer immunotherapy; Cancer research; Biology; T-cell receptor; Cell biology; Immunology; Immune system; Biochemistry; MEDLINE","score_opus":0.0272269844559087,"score_gpt":0.3419275600672362,"score_spread":0.31470057561132747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903610511","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063025737,0.5437046,0.025263255,0.33686873,0.023935912,0.000088352324,0.0008145592,0.0011755206,0.06184657],"genre_scores_gemma":[0.12275207,0.58157635,0.022466954,0.15069553,0.02161682,0.00045849878,0.0015685294,0.0008566016,0.09800866],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804175,0.00050179823,0.000068321686,0.00035318694,0.0006284016,0.00040655272],"domain_scores_gemma":[0.9963457,0.0016384576,0.00012144473,0.00027856647,0.00090103137,0.00071484875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042788284,0.0008151174,0.0013008385,0.001225627,0.001275707,0.0046102395,0.0016441216,0.0054447595,0.028260853],"category_scores_gemma":[0.0077930735,0.00057745184,0.00093636167,0.0008710893,0.0040470758,0.010971793,0.0036048016,0.015610128,0.0129838055],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050450815,0.0001697092,0.00055760145,0.0016324589,0.000057044115,0.0004196095,0.0004705642,0.0007583205,0.0072807446,0.26994923,0.3922594,0.32594085],"study_design_scores_gemma":[0.00003120311,0.00016195011,0.00018600443,0.00042094328,0.00001279388,0.00031707782,0.0002186824,0.0004384483,0.0028960311,0.067758694,0.9275232,0.000034909022],"about_ca_topic_score_codex":0.0012468951,"about_ca_topic_score_gemma":0.0013542771,"teacher_disagreement_score":0.028260853,"about_ca_system_score_codex":0.0020361915,"about_ca_system_score_gemma":0.0023439194,"threshold_uncertainty_score":0.09454197},"labels":[],"label_agreement":null},{"id":"W2903752946","doi":"10.3390/vaccines7010001","title":"The Modified Vaccination Technique","year":2018,"lang":"en","type":"article","venue":"Vaccines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Immune system; Antigen; Immunization; Vaccination; Immunology; Antibody; Virology; Medicine","score_opus":0.03333662805329284,"score_gpt":0.34464637864826364,"score_spread":0.3113097505949708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903752946","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16008997,0.041008603,0.68493354,0.0036516897,0.00956293,0.0026665574,0.0009312043,0.0041577914,0.09299774],"genre_scores_gemma":[0.49503863,0.022583935,0.29269746,0.005838021,0.0014058539,0.0022893243,0.0011881401,0.00047440876,0.17848419],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99933076,0.00012568552,0.00003256832,0.00016663065,0.00025926743,0.00008522363],"domain_scores_gemma":[0.9997762,0.00004595898,0.000038748614,0.00007102494,0.000038385777,0.000029693843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005229092,0.00046514743,0.0005556981,0.00083249545,0.00036143977,0.0004958622,0.00095286826,0.0012640577,0.008328308],"category_scores_gemma":[0.0007447391,0.00024958662,0.00069679983,0.00036840784,0.0006956112,0.00073513726,0.0008536365,0.0019162311,0.0041206838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011442562,0.0005118809,0.0010573999,0.0007828765,0.00013435756,0.0013775019,0.00029409965,0.0007293072,0.523676,0.031708535,0.020951012,0.41763285],"study_design_scores_gemma":[0.00033612287,0.0039624996,0.0042621936,0.00027884002,0.00025590663,0.025070827,0.00008711436,0.00443216,0.29598874,0.008733926,0.6564398,0.00015198348],"about_ca_topic_score_codex":0.0003572597,"about_ca_topic_score_gemma":0.0003141045,"teacher_disagreement_score":0.008328308,"about_ca_system_score_codex":0.00032409673,"about_ca_system_score_gemma":0.0004911754,"threshold_uncertainty_score":0.027861},"labels":[],"label_agreement":null},{"id":"W2904192212","doi":"10.1182/blood-2018-99-115252","title":"Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Clinical trial; Internal medicine; Disease; Biology","score_opus":0.010535377818389088,"score_gpt":0.30110402064912417,"score_spread":0.2905686428307351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904192212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.936169,0.03569546,0.0019881213,0.0012079553,0.0001567124,0.0014026773,0.015872277,0.00017118151,0.0073366603],"genre_scores_gemma":[0.953501,0.0061192825,0.0024743879,0.001869327,0.00035429792,0.0013205856,0.032554124,0.00011437809,0.0016926402],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99735177,0.0013067025,0.00020793293,0.00039013423,0.0005351551,0.00020832614],"domain_scores_gemma":[0.99571604,0.0011677423,0.0015536881,0.00041541373,0.0006368234,0.0005102844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065304637,0.0005540433,0.001551816,0.00072683516,0.0002363536,0.0017371649,0.0007671111,0.0004785248,0.0020496743],"category_scores_gemma":[0.0053580813,0.00025645545,0.0015108464,0.001206241,0.00030959054,0.0010022603,0.00067850854,0.0012366781,0.00033923905],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40214688,0.0029424792,0.17944686,0.005225918,0.02384669,0.00042712575,0.0004692638,0.00607384,0.018793415,0.0013180537,0.031498257,0.32781115],"study_design_scores_gemma":[0.1621158,0.094670676,0.58794576,0.0007814553,0.028788358,0.0021233256,0.00031614475,0.0062139127,0.006049741,0.0018516011,0.10890721,0.00023599245],"about_ca_topic_score_codex":0.00071670045,"about_ca_topic_score_gemma":0.0026402925,"teacher_disagreement_score":0.0065304637,"about_ca_system_score_codex":0.0008673576,"about_ca_system_score_gemma":0.0010473337,"threshold_uncertainty_score":0.03453678},"labels":[],"label_agreement":null},{"id":"W2904522373","doi":"10.1182/bloodadvances.2017014639","title":"CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling","year":2018,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Calgary Laboratory Services; University of Calgary; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; Ontario Ministry of Research and Innovation; Canada Research Chairs; Princess Margaret Cancer Foundation","keywords":"T-cell receptor; Biology; Sanger sequencing; Polymerase chain reaction; Molecular biology; Locus (genetics); Gene; DNA sequencing; genomic DNA; Population; Gene rearrangement; Genetics; T cell","score_opus":0.019576549644762124,"score_gpt":0.3100120321077201,"score_spread":0.290435482462958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904522373","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28377953,0.0023726202,0.66877437,0.00031640695,0.00024297202,0.00098525,0.022188405,0.0112379175,0.010102582],"genre_scores_gemma":[0.46625426,0.0012001931,0.4885032,0.0015785007,0.00016797884,0.0019548074,0.029305542,0.0018408464,0.0091946125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906474,0.00014247425,0.000033545693,0.00033739756,0.00032639658,0.000095338226],"domain_scores_gemma":[0.99939084,0.00020173869,0.00006255375,0.00009755547,0.00017678025,0.000070488335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010116262,0.000897796,0.00074857887,0.00091299164,0.00056202564,0.0009854115,0.0011778157,0.0008308855,0.0045750085],"category_scores_gemma":[0.0007917925,0.00041299712,0.00049809605,0.0006693077,0.00036089527,0.0003620433,0.00060818635,0.00094815507,0.002697922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010189849,0.000034336288,0.0010995045,0.000106261854,0.00005276854,0.00004125671,0.000029631961,0.0006776326,0.98841256,0.00015359928,0.001405112,0.007885452],"study_design_scores_gemma":[0.000035520898,0.00024749138,0.011954459,0.000021148791,0.00010985853,0.00044878887,0.00006339741,0.0443183,0.9263421,0.0004888096,0.015903955,0.00006609196],"about_ca_topic_score_codex":0.0011427837,"about_ca_topic_score_gemma":0.0035639973,"teacher_disagreement_score":0.0045750085,"about_ca_system_score_codex":0.00042156086,"about_ca_system_score_gemma":0.00036574813,"threshold_uncertainty_score":0.015304923},"labels":[],"label_agreement":null},{"id":"W2905241205","doi":"10.1182/blood-2018-99-112599","title":"Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Blinatumomab; Peripheral blood mononuclear cell; Oncology; Phases of clinical research; Cytokine release syndrome; Chimeric antigen receptor; Gastroenterology; Clinical trial; Leukemia; Immunotherapy; Lymphoblastic Leukemia; Biology; Cancer","score_opus":0.006299406194958854,"score_gpt":0.23970613893982043,"score_spread":0.23340673274486157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905241205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96969026,0.013545145,0.0009443279,0.00034209964,0.000041517986,0.0002903398,0.011369611,0.00008383921,0.0036928288],"genre_scores_gemma":[0.97214407,0.0036762,0.0014279549,0.00057941815,0.00010072744,0.0003080758,0.020958835,0.000025984464,0.0007787694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999226,0.00023966384,0.00013943891,0.0001250633,0.00021495952,0.000054756187],"domain_scores_gemma":[0.996902,0.0006426232,0.0013149551,0.00020099577,0.0006421727,0.00029723413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016026,0.00027324556,0.0008850351,0.0006589043,0.00015823859,0.00075608835,0.0005008741,0.00028659301,0.0014455011],"category_scores_gemma":[0.0024780675,0.00016826822,0.0008336866,0.0014017252,0.00015660636,0.00045682053,0.00027824866,0.00058546575,0.00032834787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043315813,0.00082950364,0.719847,0.0015192542,0.0032870155,0.00066974526,0.00029223613,0.0022914067,0.009133203,0.00040662487,0.010076053,0.2083321],"study_design_scores_gemma":[0.0038708802,0.0150835905,0.9333989,0.00023321943,0.004888058,0.0027217285,0.0001650441,0.0017215656,0.003917587,0.00025398724,0.033698373,0.000047126287],"about_ca_topic_score_codex":0.001274747,"about_ca_topic_score_gemma":0.0020193213,"teacher_disagreement_score":0.0016026,"about_ca_system_score_codex":0.0008143228,"about_ca_system_score_gemma":0.00067683775,"threshold_uncertainty_score":0.008475482},"labels":[],"label_agreement":null},{"id":"W2905385734","doi":"10.1007/978-1-4939-8958-4_4","title":"Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies","year":2018,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada; University of British Columbia","funders":"","keywords":"Ipilimumab; Nivolumab; Monoclonal antibody; Pembrolizumab; Medicine; Melanoma; Antibody; Adverse effect; Immunotherapy; TIGIT; Immunology; Monoclonal; Oncology; Immune system; Internal medicine; Cancer research","score_opus":0.1160249317433525,"score_gpt":0.5236938188093235,"score_spread":0.40766888706597104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905385734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008978097,0.998638,0.00016892167,0.00037790462,0.00022184227,0.0000032616847,0.000010256551,0.0000066315815,0.00048343037],"genre_scores_gemma":[0.0007190443,0.99790937,0.00022499707,0.00033161015,0.0002975098,0.000005833943,0.00001941777,0.0000014222117,0.00049068383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998447,0.000027609367,0.000016980026,0.000026751088,0.000061680395,0.000022410793],"domain_scores_gemma":[0.99965334,0.00018647913,0.000042514235,0.000009156914,0.00007191694,0.00003666704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007594932,0.0007977001,0.001109697,0.0015523193,0.00019465755,0.0009400563,0.00089798943,0.0011356376,0.0034122195],"category_scores_gemma":[0.00074166455,0.00025049085,0.00045032997,0.0010759712,0.0005663,0.001495686,0.0006386184,0.002594426,0.0015501265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120480516,0.00010630969,0.00012663282,0.008726007,0.00007541974,0.00015311064,0.000037482354,0.0003575764,0.002861333,0.005815702,0.03383013,0.9477898],"study_design_scores_gemma":[0.00004802328,0.00013068816,0.00039104937,0.0018053044,0.000118939955,0.00075510924,0.00003095882,0.0001429966,0.00071727333,0.0028310565,0.9930114,0.000017160239],"about_ca_topic_score_codex":0.0006988981,"about_ca_topic_score_gemma":0.0017322164,"teacher_disagreement_score":0.0034122195,"about_ca_system_score_codex":0.0005087575,"about_ca_system_score_gemma":0.0008264076,"threshold_uncertainty_score":0.011415005},"labels":[],"label_agreement":null},{"id":"W2905496875","doi":"10.1016/j.biotechadv.2018.12.002","title":"Standardizing CAR-T therapy: Getting it scaled up","year":2018,"lang":"en","type":"review","venue":"Biotechnology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Jiangnan University; National Natural Science Foundation of China; Six Talent Peaks Project in Jiangsu Province; Natural Science Foundation of Jiangsu Province; Government of Jiangsu Province; University of Pennsylvania; Gilead Sciences","keywords":"CAR T-cell therapy; Production (economics); Cancer therapy; Monoclonal antibody; Key (lock); Computer science; Medicine; Business; Cancer; Immunotherapy; Antibody; Immunology; Internal medicine; Chimeric antigen receptor; Economics","score_opus":0.0709283191270123,"score_gpt":0.4124309006885732,"score_spread":0.3415025815615609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905496875","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006959212,0.9959662,0.00031881614,0.0020424372,0.0007666765,0.000006395149,0.000017394033,0.000012677656,0.00079987716],"genre_scores_gemma":[0.00098775,0.9950412,0.00061097404,0.0017883558,0.0007593071,0.000012123606,0.000038312373,0.0000052329838,0.0007567293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994672,0.00011270956,0.000061338,0.00008963574,0.00020372236,0.00006537309],"domain_scores_gemma":[0.99847883,0.0008929668,0.00012854901,0.000045834866,0.00034408132,0.00010975862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021916516,0.00096818066,0.0016621099,0.0017275985,0.0003219828,0.0019000509,0.0013264101,0.0024137134,0.0052026855],"category_scores_gemma":[0.002627542,0.0003254551,0.00072373863,0.0014758187,0.0009703425,0.0030525445,0.0012460777,0.004146933,0.0022029034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008189506,0.00007097911,0.00012648737,0.012538001,0.00008175211,0.00009848235,0.000050759536,0.00041033534,0.0012384432,0.01026083,0.050789706,0.9242524],"study_design_scores_gemma":[0.000028413197,0.000082722494,0.00023438923,0.0038683189,0.00009262784,0.00030859403,0.000060985796,0.00011417228,0.00043449123,0.0048289243,0.98992854,0.000017762119],"about_ca_topic_score_codex":0.0011281574,"about_ca_topic_score_gemma":0.0023109787,"teacher_disagreement_score":0.0052026855,"about_ca_system_score_codex":0.0011903782,"about_ca_system_score_gemma":0.0028820196,"threshold_uncertainty_score":0.017404675},"labels":[],"label_agreement":null},{"id":"W2905623501","doi":"10.1016/j.jval.2018.09.154","title":"PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Cytokine release syndrome; Diffuse large B-cell lymphoma; Gemcitabine; Rituximab; Hematopoietic stem cell transplantation; Oncology; Salvage therapy; Internal medicine; Lymphoma; Immunotherapy; Transplantation; Chemotherapy; Cancer; Chimeric antigen receptor","score_opus":0.03206869418140544,"score_gpt":0.34377035954052426,"score_spread":0.3117016653591188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905623501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9159272,0.015257744,0.0022720958,0.009326476,0.000278746,0.001667367,0.03364946,0.00011948492,0.021501431],"genre_scores_gemma":[0.9884935,0.002116709,0.000907535,0.0007286927,0.000043468513,0.00038698842,0.005003358,0.00002321367,0.0022964973],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.99445903,0.0034150102,0.00025775243,0.00019199285,0.00070778397,0.0009685384],"domain_scores_gemma":[0.9948549,0.0021529263,0.0011117882,0.00013829613,0.00062128156,0.0011206609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004594718,0.0006732582,0.001433851,0.001216771,0.00024372361,0.0014519148,0.0010537605,0.0008612128,0.005051133],"category_scores_gemma":[0.013028606,0.00046668676,0.0025555964,0.0017939311,0.0005217427,0.0007501385,0.00139148,0.0013936881,0.0002774341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09984998,0.0021985462,0.09345225,0.0050326856,0.008585611,0.0010623685,0.00033555584,0.52671677,0.002478655,0.0107712485,0.02963517,0.21988119],"study_design_scores_gemma":[0.035787184,0.037526794,0.6501165,0.0032013417,0.012613635,0.0011740654,0.0022845643,0.17008124,0.003132838,0.006394076,0.07733492,0.0003528857],"about_ca_topic_score_codex":0.17840157,"about_ca_topic_score_gemma":0.16300309,"teacher_disagreement_score":0.17840157,"about_ca_system_score_codex":0.015766082,"about_ca_system_score_gemma":0.012170645,"threshold_uncertainty_score":0.35472637},"labels":[],"label_agreement":null},{"id":"W2905662036","doi":"10.1016/j.jval.2018.09.253","title":"PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CANADIAN SOCIETAL PERSPECTIVE","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Salvage therapy; Oncology; Refractory (planetary science); Young adult; Pediatrics; Chemotherapy; Internal medicine","score_opus":0.024353770187356884,"score_gpt":0.31183947846377785,"score_spread":0.28748570827642095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905662036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6680303,0.1599821,0.0016011096,0.058115393,0.0008439448,0.0005482253,0.027745493,0.000108016786,0.08302536],"genre_scores_gemma":[0.9689849,0.02061095,0.0010860972,0.0018474404,0.0001881671,0.00006286708,0.004694435,0.000017099353,0.0025080263],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99873406,0.00035403497,0.00006251031,0.00008097285,0.0003601645,0.00040823058],"domain_scores_gemma":[0.9986827,0.00029451807,0.00020428181,0.000019392532,0.00031569856,0.00048335083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014355704,0.0005324523,0.00093752984,0.0009354602,0.0005493459,0.0022464637,0.00096359226,0.0008644933,0.006134905],"category_scores_gemma":[0.0043147984,0.0001910562,0.002209651,0.0019912082,0.0005582631,0.0006397274,0.00057363464,0.0014930648,0.00027242512],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02506843,0.0013316536,0.19561477,0.004029257,0.009261008,0.0015197514,0.00048346748,0.0678112,0.0017035259,0.033106945,0.07162381,0.5884462],"study_design_scores_gemma":[0.00930253,0.008138824,0.7515778,0.0054133954,0.01767705,0.00217147,0.0035089676,0.044875376,0.0015896331,0.013121355,0.14220282,0.00042071982],"about_ca_topic_score_codex":0.8296653,"about_ca_topic_score_gemma":0.9001409,"teacher_disagreement_score":0.1703347,"about_ca_system_score_codex":0.037736196,"about_ca_system_score_gemma":0.03976057,"threshold_uncertainty_score":0.34267563},"labels":[],"label_agreement":null},{"id":"W2906002519","doi":"10.1016/j.jval.2018.09.260","title":"PCN177 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL FOR ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA : A CANADIAN SOCIETAL PERSPECTIVE","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Oncology; Salvage therapy; Refractory (planetary science); Quality-adjusted life year; Internal medicine; Cost effectiveness; Chemotherapy; Biology","score_opus":0.05165991619322524,"score_gpt":0.3583497100789593,"score_spread":0.3066897938857341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906002519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4700578,0.289247,0.0017295928,0.10439184,0.0015778963,0.0006343918,0.03528892,0.00012538087,0.09694727],"genre_scores_gemma":[0.9523441,0.033956062,0.0012285175,0.003324814,0.00043693662,0.0000778123,0.005820737,0.000025691214,0.0027851628],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981527,0.00053322315,0.000108447464,0.00012316303,0.00056121964,0.00052121846],"domain_scores_gemma":[0.9976642,0.00055828877,0.0003416095,0.000037496306,0.00069299503,0.00070545217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023280005,0.0006719909,0.0012732933,0.0012898828,0.0006459311,0.0027057119,0.0011391297,0.0011962405,0.0067433],"category_scores_gemma":[0.0072392784,0.00023680273,0.0028628812,0.002552365,0.0007407548,0.0008330342,0.0006942843,0.0020274373,0.00035354847],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030582871,0.0012117327,0.1738154,0.006565325,0.0153246075,0.0013841403,0.0006159702,0.049966965,0.0015721611,0.033541065,0.10021536,0.58520436],"study_design_scores_gemma":[0.014182581,0.006602282,0.7003078,0.009775908,0.031303186,0.0017454795,0.0032973527,0.03986443,0.0012493558,0.016632853,0.17446652,0.00057230453],"about_ca_topic_score_codex":0.8537583,"about_ca_topic_score_gemma":0.91075903,"teacher_disagreement_score":0.14624172,"about_ca_system_score_codex":0.044723127,"about_ca_system_score_gemma":0.048334073,"threshold_uncertainty_score":0.3244905},"labels":[],"label_agreement":null},{"id":"W2906423725","doi":"10.1016/j.jval.2018.09.150","title":"PCN68 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLAND","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Blinatumomab; Medicine; Fludarabine; Population; Leukapheresis; Pediatrics; Internal medicine; Chemotherapy; CD19; Cyclophosphamide; Stem cell","score_opus":0.022785619237043562,"score_gpt":0.32269402317777024,"score_spread":0.29990840394072665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906423725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9029527,0.017324623,0.0021431097,0.014014856,0.00036375245,0.0018540568,0.036447827,0.00011726165,0.02478196],"genre_scores_gemma":[0.9867736,0.0027554065,0.000973389,0.0010204888,0.000047996058,0.0004770084,0.0052579828,0.000024126546,0.0026700369],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99268407,0.0043875044,0.00035159817,0.00021486923,0.0008925298,0.0014694924],"domain_scores_gemma":[0.9931804,0.00290177,0.0013766144,0.00015604471,0.0008082391,0.0015769775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004850123,0.00064023153,0.0014753325,0.0012533715,0.00027718322,0.0016305883,0.0011064754,0.0010812058,0.0057115615],"category_scores_gemma":[0.018267425,0.000584729,0.0024537144,0.0019806742,0.0005464056,0.00092013256,0.00170081,0.0016399184,0.00028640236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0658298,0.0020808938,0.11348339,0.007096206,0.008660458,0.0016932621,0.00057245215,0.51908,0.0020739972,0.016592918,0.04309151,0.21974505],"study_design_scores_gemma":[0.02684185,0.028619744,0.631864,0.0052561355,0.01024394,0.0018272701,0.003918617,0.16912188,0.0025500813,0.009112873,0.11022653,0.0004171151],"about_ca_topic_score_codex":0.22561069,"about_ca_topic_score_gemma":0.21213923,"teacher_disagreement_score":0.22561069,"about_ca_system_score_codex":0.01866228,"about_ca_system_score_gemma":0.015719792,"threshold_uncertainty_score":0.44859493},"labels":[],"label_agreement":null},{"id":"W2906996236","doi":"10.1182/blood-2018-99-116745","title":"Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Durvalumab; Medicine; Fludarabine; Cyclophosphamide; Internal medicine; Tolerability; Combination therapy; Refractory (planetary science); Immunotherapy; Oncology; Gastroenterology; Immunology; Pharmacology; Chemotherapy; Adverse effect; Cancer; Nivolumab; Biology","score_opus":0.01234072366315731,"score_gpt":0.26925204596260044,"score_spread":0.25691132229944313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906996236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996564,0.0022323693,0.00013394981,0.000087706976,0.00002461348,0.00011569441,0.00008892867,0.000023053552,0.00072983],"genre_scores_gemma":[0.99839586,0.00062820176,0.0002725798,0.00006471529,0.00003646604,0.00006186676,0.00014908405,0.0000034359166,0.0003877256],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99983454,0.000070719245,0.000013763248,0.00002132757,0.0000267374,0.000033024095],"domain_scores_gemma":[0.99981743,0.000041223902,0.000038403065,0.000015990898,0.000009487701,0.00007743375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004819749,0.00035765753,0.0011267435,0.00025715007,0.00018698338,0.00038377714,0.0003214963,0.00028756796,0.0008510456],"category_scores_gemma":[0.0003462856,0.00015344501,0.00040005828,0.0001897923,0.00019653182,0.00021184456,0.00015335622,0.00064251834,0.0001706066],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24956281,0.021476991,0.047528103,0.0007909027,0.0022459666,0.001202704,0.00034584367,0.004238871,0.15270586,0.00029734737,0.0024514229,0.5171531],"study_design_scores_gemma":[0.12914462,0.60463965,0.20427732,0.00014381629,0.0024206382,0.0026416937,0.00021328621,0.0065716426,0.03826516,0.0002876807,0.011329462,0.00006505297],"about_ca_topic_score_codex":0.00061285537,"about_ca_topic_score_gemma":0.0022406825,"teacher_disagreement_score":0.0011267435,"about_ca_system_score_codex":0.00048494543,"about_ca_system_score_gemma":0.00039035708,"threshold_uncertainty_score":0.0035185218},"labels":[],"label_agreement":null},{"id":"W2907052423","doi":"10.1182/blood-2018-99-111528","title":"Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Fludarabine; Medicine; Cyclophosphamide; Bone marrow; Immunology; CD8; Leukemia; Antigen; Chimeric antigen receptor; Immunotherapy; Lymphoma; Cancer research; Internal medicine; Immune system; Chemotherapy","score_opus":0.012418857225724647,"score_gpt":0.24743296599175882,"score_spread":0.23501410876603418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907052423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982243,0.00041754826,0.00021323675,0.00005834312,0.00001761137,0.0002274997,0.00009825588,0.000034984798,0.00070818485],"genre_scores_gemma":[0.9978928,0.00028534356,0.0005569826,0.000092940834,0.000024912768,0.00020398888,0.00027670353,0.0000064900146,0.0006599521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984074,0.000045055298,0.000009846431,0.000031656225,0.000021787526,0.000050877272],"domain_scores_gemma":[0.99987936,0.000018442957,0.000022193222,0.00001138889,0.000007517381,0.000061120394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031745643,0.0003506911,0.0006111577,0.00023219374,0.00019210657,0.0003964654,0.00037271442,0.00040152043,0.0015341443],"category_scores_gemma":[0.0001557171,0.00014662942,0.0002737937,0.00016145896,0.0003155187,0.00021638842,0.00023171293,0.00098535,0.00038137188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0434444,0.026577704,0.018091202,0.0006167808,0.00028856454,0.0011104849,0.0002679106,0.0039647687,0.8006519,0.00055812387,0.0032191656,0.10120901],"study_design_scores_gemma":[0.054097835,0.5725151,0.07001733,0.0000734096,0.0007789783,0.0039925682,0.0001941172,0.008314428,0.2713428,0.0003323981,0.018286359,0.00005461517],"about_ca_topic_score_codex":0.000585943,"about_ca_topic_score_gemma":0.0009593689,"teacher_disagreement_score":0.0015341443,"about_ca_system_score_codex":0.0004634022,"about_ca_system_score_gemma":0.00045471778,"threshold_uncertainty_score":0.0051321983},"labels":[],"label_agreement":null},{"id":"W2907079093","doi":"10.1182/blood-2018-99-110429","title":"Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University Health Network","funders":"","keywords":"CHOP; Medicine; Alemtuzumab; Internal medicine; Clinical endpoint; Interim analysis; Peripheral T-cell lymphoma; Lymphoma; Randomized controlled trial; Surgery; Oncology; Transplantation; Immunology; Immune system; T cell","score_opus":0.011782559397960343,"score_gpt":0.2600723246321082,"score_spread":0.24828976523414786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907079093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97232854,0.004052367,0.0029237124,0.0012209095,0.000500964,0.0074760895,0.007158872,0.00011994292,0.004218616],"genre_scores_gemma":[0.9737587,0.0008133563,0.0040149963,0.0011562759,0.00038304477,0.0053451736,0.011153018,0.00006252509,0.003312939],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958289,0.0031189038,0.00019079901,0.0003651654,0.00026475525,0.0002315093],"domain_scores_gemma":[0.9967924,0.0011751316,0.0006898881,0.00038994444,0.00037122346,0.0005813785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0090712635,0.001379532,0.0020878946,0.00034708614,0.0003600058,0.0012964223,0.0007929576,0.0009846006,0.005662136],"category_scores_gemma":[0.0057730465,0.00040764714,0.003040307,0.00039433985,0.00066169054,0.000861636,0.0004760437,0.00203747,0.0008873592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9709466,0.002218551,0.003741423,0.00041314878,0.0038962094,0.00007315157,0.00006464074,0.0012768084,0.0026428637,0.00031877548,0.0033382908,0.011069628],"study_design_scores_gemma":[0.83989775,0.11931084,0.021624628,0.0001022692,0.0068119518,0.00017957896,0.000064697764,0.0028523488,0.0017148387,0.0007812243,0.0066062366,0.000053787695],"about_ca_topic_score_codex":0.0005082812,"about_ca_topic_score_gemma":0.0012530365,"teacher_disagreement_score":0.0090712635,"about_ca_system_score_codex":0.00093870255,"about_ca_system_score_gemma":0.0014319521,"threshold_uncertainty_score":0.04797399},"labels":[],"label_agreement":null},{"id":"W2907883664","doi":"10.1182/blood-2018-99-117333","title":"Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; BC Cancer Agency; Simon Fraser University; Princess Margaret Cancer Centre","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Internal medicine; Oncology; Salvage therapy; Follicular lymphoma; Gemcitabine; Chemotherapy regimen; Autologous stem-cell transplantation; Regimen; Aggressive lymphoma; Lymphoma; Chemotherapy; Surgery","score_opus":0.01397642299068248,"score_gpt":0.27317063032083616,"score_spread":0.2591942073301537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907883664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971933,0.0014378511,0.00017027235,0.00007897961,0.000033900003,0.00044651685,0.00008956018,0.000023208895,0.00052647677],"genre_scores_gemma":[0.9979128,0.00067636766,0.00038654916,0.00012451527,0.000039357536,0.00026907588,0.00016757743,0.000004118971,0.00041954155],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975806,0.000118009295,0.000019715559,0.00003941339,0.000023156572,0.00004176121],"domain_scores_gemma":[0.9995844,0.000064165,0.00008839683,0.00003396645,0.000018539853,0.00021047823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071000424,0.0005764903,0.0013340324,0.00037556855,0.0002834485,0.000783188,0.0006047497,0.00057767425,0.0014780606],"category_scores_gemma":[0.000463226,0.00026776985,0.00056298997,0.0004446335,0.00045604957,0.00043996584,0.00036345888,0.0017104392,0.0003332448],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72080606,0.0459141,0.008738728,0.0009949711,0.00094572245,0.00047651204,0.00031596966,0.0030880922,0.039391074,0.00024883213,0.0010243111,0.17805567],"study_design_scores_gemma":[0.38073388,0.5938985,0.013274338,0.00010193154,0.0004942491,0.00052786485,0.000069094756,0.001443482,0.006955331,0.00021324454,0.0022623334,0.000025755915],"about_ca_topic_score_codex":0.00071091624,"about_ca_topic_score_gemma":0.0018934447,"teacher_disagreement_score":0.0014780606,"about_ca_system_score_codex":0.00065718626,"about_ca_system_score_gemma":0.0009300347,"threshold_uncertainty_score":0.004944563},"labels":[],"label_agreement":null},{"id":"W2908110248","doi":"10.1016/j.imbio.2018.12.003","title":"Enhancing the pro-inflammatory anti-cancer T cell response via biomanufactured, secretome-based, immunotherapeutics","year":2018,"lang":"en","type":"article","venue":"Immunobiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; Canadian Blood Services","keywords":"CD8; Peripheral blood mononuclear cell; Biology; Cancer research; Cancer; HeLa; Cell growth; T cell; Immunology; Cancer cell; Cytotoxic T cell; Melanoma; Cell; In vitro; Immune system; Biochemistry","score_opus":0.021087395476401625,"score_gpt":0.3203290674038167,"score_spread":0.2992416719274151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908110248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871357,0.00188469,0.008339567,0.0001181193,0.000097096614,0.00005289276,0.00022144984,0.0001199857,0.0020304914],"genre_scores_gemma":[0.9912832,0.0006065654,0.0051638563,0.000050061597,0.000020889645,0.000036281846,0.00016025089,0.00001749021,0.0026612515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999076,0.00001495534,0.000008816913,0.000019877292,0.00003143346,0.000017305074],"domain_scores_gemma":[0.9999546,0.000009376012,0.00001331411,0.0000072391285,0.0000070976894,0.000008260109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119951146,0.00029224696,0.00014055702,0.00014100055,0.00008593662,0.0003308945,0.0001011743,0.00026769584,0.0012728355],"category_scores_gemma":[0.00011100668,0.00009359575,0.00015954077,0.000075876895,0.00015390805,0.00016563619,0.00017898837,0.00042709554,0.00045048087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001994707,0.000011323239,0.000044866825,0.000017803919,0.0000017936635,0.000017492926,0.0000072643097,0.00007174466,0.99883765,0.00004355993,0.000021795913,0.0009046678],"study_design_scores_gemma":[0.000003701399,0.00008470919,0.00034589853,0.0000016276895,0.0000046470773,0.00006471656,0.0000057088337,0.0003401962,0.9977101,0.000016909054,0.0014205027,0.000001295563],"about_ca_topic_score_codex":0.00013284342,"about_ca_topic_score_gemma":0.00032089793,"teacher_disagreement_score":0.0012728355,"about_ca_system_score_codex":0.00015803232,"about_ca_system_score_gemma":0.00013191035,"threshold_uncertainty_score":0.0042580366},"labels":[],"label_agreement":null},{"id":"W2908201785","doi":"10.1182/blood-2018-99-115123","title":"Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Blinatumomab; Medicine; Internal medicine; Minimal residual disease; Chemotherapy; Gastroenterology; Oncology; Leukemia; Immunology; Surgery; Lymphoblastic Leukemia","score_opus":0.04176677496032077,"score_gpt":0.36662445671732125,"score_spread":0.32485768175700047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908201785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940065,0.0037728352,0.0002174659,0.00023076849,0.00014384712,0.00042419368,0.0007332265,0.000017028357,0.00045410794],"genre_scores_gemma":[0.9969959,0.00054320943,0.00030058753,0.00034017934,0.00010241411,0.00063227926,0.0007108561,0.0000052869177,0.00036929993],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99909544,0.0004763972,0.000082769,0.00015767488,0.00009160767,0.0000961266],"domain_scores_gemma":[0.9990103,0.00026254027,0.00030865346,0.0001024124,0.00007885024,0.00023720392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019050583,0.0008043166,0.0021407288,0.0003189338,0.00027127072,0.0007340379,0.00046635882,0.0009291733,0.0030106422],"category_scores_gemma":[0.0015979216,0.0003058285,0.0038449832,0.00034078184,0.0003384878,0.0006482759,0.0004579498,0.0015567406,0.0002498559],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95373666,0.0031596818,0.0154479835,0.0005592867,0.008227848,0.000056494137,0.00006753047,0.00041077417,0.0028247004,0.000085315885,0.000849505,0.014574172],"study_design_scores_gemma":[0.54359823,0.25653055,0.17212337,0.00016847604,0.019363403,0.00018271914,0.00020123117,0.0025390019,0.0018691695,0.00061149197,0.0027208629,0.00009145341],"about_ca_topic_score_codex":0.00046322952,"about_ca_topic_score_gemma":0.0013970508,"teacher_disagreement_score":0.0030106422,"about_ca_system_score_codex":0.00057930493,"about_ca_system_score_gemma":0.0005670754,"threshold_uncertainty_score":0.010075033},"labels":[],"label_agreement":null},{"id":"W2908342487","doi":"10.1182/blood-2018-99-118569","title":"T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Cancer research; Immunotherapy; In vivo; T cell; Medicine; Cytokine; Immunology; Biology; Immune system","score_opus":0.013051482795145466,"score_gpt":0.2546756408468227,"score_spread":0.24162415805167725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908342487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947161,0.0010145154,0.0026847192,0.00006625251,0.000032442917,0.0000464929,0.00021282297,0.00011479625,0.0011118717],"genre_scores_gemma":[0.9966485,0.00038547776,0.0011461444,0.00003849324,0.000007414061,0.000023815674,0.00026044998,0.000013418885,0.0014763708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988246,0.000013549885,0.000008879674,0.000028546581,0.000028922579,0.00003767646],"domain_scores_gemma":[0.99993503,0.000010198497,0.000020402316,0.0000100219595,0.000009572135,0.000014780213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011987408,0.00032124046,0.00021523265,0.00015190711,0.00007361057,0.00027281838,0.00020291653,0.0003731786,0.0008135193],"category_scores_gemma":[0.00008093313,0.00009974049,0.0002215902,0.000116260955,0.00012351818,0.00014017583,0.00011960667,0.0007126684,0.00030611377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007304471,0.000068605674,0.000060580973,0.000016117829,0.0000048343577,0.000020942913,0.000009026016,0.0001424417,0.99847347,0.000041070336,0.00005763804,0.0010321246],"study_design_scores_gemma":[0.00006099918,0.0012489159,0.0010592438,0.0000050690005,0.00003439529,0.00017886746,0.000012300223,0.0014475379,0.99415475,0.000021773441,0.0017720854,0.000004168263],"about_ca_topic_score_codex":0.0010052751,"about_ca_topic_score_gemma":0.0005977699,"teacher_disagreement_score":0.0010052751,"about_ca_system_score_codex":0.00022767592,"about_ca_system_score_gemma":0.00015741795,"threshold_uncertainty_score":0.0027214885},"labels":[],"label_agreement":null},{"id":"W2908403203","doi":"10.1182/blood-2018-99-115593","title":"High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; London Health Sciences Centre; McMaster University; McMaster Children's Hospital; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Chimeric antigen receptor; Population; Chemotherapy regimen; Neutropenia; Regimen; Contraindication; Internal medicine; Pediatrics; Cytokine release syndrome; Chemotherapy; Immunotherapy; Cancer; Pathology","score_opus":0.007779938623790587,"score_gpt":0.22598578685935888,"score_spread":0.2182058482355683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908403203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685055,0.00040144633,0.000053285647,0.00017237898,0.000008469866,0.000063680855,0.0013326191,0.000004412102,0.0011131142],"genre_scores_gemma":[0.99829715,0.0003037631,0.00008814058,0.00017980265,0.000009867252,0.000038539565,0.0007081747,0.0000060214597,0.000368572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99825007,0.00015477011,0.00012535183,0.00032086275,0.00050575216,0.00064323365],"domain_scores_gemma":[0.99694866,0.00025014734,0.0010239773,0.000106585394,0.00081990287,0.0008507906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074939075,0.00048147043,0.0007795462,0.00094599207,0.0026989433,0.0015108192,0.0012522629,0.0007481613,0.0018853005],"category_scores_gemma":[0.0023832028,0.0005092184,0.0008686583,0.0038283407,0.0010715077,0.00046258813,0.0008436293,0.0010419849,0.00026962307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016093242,0.00005472417,0.99727315,0.000028854143,0.000054031607,0.000120960496,0.00067995494,0.000038071892,0.00016348576,0.000043898403,0.00039690483,0.0009851089],"study_design_scores_gemma":[0.000038740007,0.00016843916,0.9959973,0.000039011284,0.000066999455,0.00019905766,0.0022904952,0.00017814865,0.000044719494,0.00002111376,0.0009395736,0.000016450738],"about_ca_topic_score_codex":0.9579326,"about_ca_topic_score_gemma":0.9734284,"teacher_disagreement_score":0.04206741,"about_ca_system_score_codex":0.022353187,"about_ca_system_score_gemma":0.02013384,"threshold_uncertainty_score":0.16218448},"labels":[],"label_agreement":null},{"id":"W2908417681","doi":"10.1182/blood-2018-99-115126","title":"Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Cyclophosphamide; Oncology; Non-Hodgkin's lymphoma; Lymphoma; Aggressive lymphoma; Immunology; Chemotherapy; Gastroenterology; Rituximab","score_opus":0.03312583949626026,"score_gpt":0.3160237853105035,"score_spread":0.28289794581424327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908417681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992323,0.00031909684,0.0001940018,0.000026475498,0.0000031542259,0.000017785935,0.000090610345,0.0000059779045,0.0001106698],"genre_scores_gemma":[0.9995346,0.000063034735,0.00010324478,0.000014095647,0.000005905208,0.00001885445,0.00013325135,0.0000013773093,0.00012561504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997353,0.00013780552,0.000016035305,0.00003670546,0.000035816556,0.00003822942],"domain_scores_gemma":[0.9987482,0.00067339157,0.00033410237,0.00003069103,0.0000369664,0.00017666927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010502912,0.00020346169,0.00038064562,0.00017078417,0.000105926985,0.00038371055,0.00017097757,0.00022779535,0.0011623402],"category_scores_gemma":[0.0013396421,0.00009318644,0.00035780162,0.00017356218,0.00014769954,0.00024674492,0.00016755382,0.00041687166,0.00016002695],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.121298276,0.0047386624,0.7397573,0.00025684005,0.00059557846,0.00034618343,0.00017986396,0.0076665627,0.016501576,0.00016105521,0.0007983227,0.10769973],"study_design_scores_gemma":[0.0041790553,0.068031736,0.89626014,0.0000382707,0.00070099486,0.0005622852,0.00013490868,0.019467207,0.0081598135,0.00040877596,0.0020275798,0.000029185312],"about_ca_topic_score_codex":0.00040242384,"about_ca_topic_score_gemma":0.00041553754,"teacher_disagreement_score":0.0011623402,"about_ca_system_score_codex":0.0002480387,"about_ca_system_score_gemma":0.0003361837,"threshold_uncertainty_score":0.005554557},"labels":[],"label_agreement":null},{"id":"W2908444719","doi":"10.1111/trf.15121","title":"Leukoreduction system chambers are a reliable cellular source for the manufacturing of T‐cell therapeutics","year":2018,"lang":"en","type":"article","venue":"Transfusion","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Montréal; Héma-Québec; Hôpital Maisonneuve-Rosemont","funders":"Canadian Donation and Transplantation Research Program","keywords":"Leukoreduction; Peripheral blood mononuclear cell; Leukapheresis; Immunology; T cell; Medicine; Immune system; Cytotoxic T cell; Transplantation; Immunotherapy; Biology; CD34; Blood transfusion; Stem cell; In vitro; Internal medicine","score_opus":0.03251321626058433,"score_gpt":0.27810157513417905,"score_spread":0.2455883588735947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908444719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7008603,0.02002634,0.24636607,0.00070099416,0.00062616577,0.00089357415,0.004821039,0.0028913575,0.022814091],"genre_scores_gemma":[0.91064245,0.0041821464,0.07256136,0.00018740578,0.00015610537,0.00063323445,0.003816304,0.00035966246,0.007461272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989932,0.00021885827,0.0000873577,0.00016936414,0.00046784434,0.0000632719],"domain_scores_gemma":[0.9992415,0.00017676986,0.00028319194,0.00013698342,0.00011414066,0.00004759071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074253866,0.0006396591,0.00031401016,0.0003322943,0.00027007537,0.00079241605,0.00044439628,0.00048520273,0.0051925126],"category_scores_gemma":[0.0007155372,0.0002158782,0.00039337584,0.00020625447,0.0002555543,0.0003599241,0.00035012452,0.00044801398,0.0024676144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007361876,0.000022607195,0.00035076792,0.00017068266,0.000010892767,0.00008207583,0.00003592469,0.00022871511,0.9915563,0.00025087793,0.000320106,0.0068973573],"study_design_scores_gemma":[0.000019919522,0.0003296753,0.0019678848,0.00003026908,0.000031419564,0.00045785855,0.000023133818,0.0005459144,0.97643673,0.00008173634,0.02006467,0.000010797859],"about_ca_topic_score_codex":0.00017741039,"about_ca_topic_score_gemma":0.00026228107,"teacher_disagreement_score":0.0051925126,"about_ca_system_score_codex":0.00025897496,"about_ca_system_score_gemma":0.0003312695,"threshold_uncertainty_score":0.0173707},"labels":[],"label_agreement":null},{"id":"W2908870872","doi":"10.1016/j.bulcan.2018.12.001","title":"Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l’adulte et l’enfant : recommandation de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)","year":2019,"lang":"fr","type":"review","venue":"Bulletin du Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Sanofi Pasteur; Gilead Sciences; Meso Scale Diagnostics; Sanofi; Astellas Pharma; Astellas Pharma US; Pfizer","keywords":"Medicine","score_opus":0.017368712495199064,"score_gpt":0.3293118334841755,"score_spread":0.3119431209889764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908870872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103409955,0.99883825,0.00007651349,0.00048596982,0.00025288286,0.0000038117046,0.000013938141,0.0000037570387,0.00022145992],"genre_scores_gemma":[0.0014739519,0.9965102,0.00031660235,0.00071092503,0.00049776485,0.000013618981,0.00004175862,0.0000013291444,0.00043376008],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973065,0.000069308706,0.000057119156,0.00003511299,0.000078743964,0.000029045133],"domain_scores_gemma":[0.999356,0.00040849668,0.000097026365,0.0000110070705,0.000095987016,0.000031519627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010299016,0.0005514564,0.0013857854,0.001156982,0.00024906575,0.0009939881,0.00054982863,0.0011980634,0.0020318532],"category_scores_gemma":[0.0013192804,0.00022145333,0.00067220227,0.0005885314,0.00037760712,0.0007599863,0.0004711238,0.0019312376,0.0006742676],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021122622,0.000057308127,0.00041343897,0.020009533,0.0001943748,0.00025883186,0.00008090069,0.0001956301,0.002189371,0.0024078672,0.040759385,0.9332222],"study_design_scores_gemma":[0.00017267595,0.00023613374,0.0018277664,0.010607602,0.000546491,0.0018934762,0.0001129156,0.00011801132,0.0010590509,0.0014749327,0.9819228,0.000028093249],"about_ca_topic_score_codex":0.001496042,"about_ca_topic_score_gemma":0.0032773598,"teacher_disagreement_score":0.0020318532,"about_ca_system_score_codex":0.0005323992,"about_ca_system_score_gemma":0.0014569119,"threshold_uncertainty_score":0.006797254},"labels":[],"label_agreement":null},{"id":"W2910040477","doi":"10.1038/s41408-018-0168-2","title":"Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxicity; Cancer research; Antibody; Monoclonal antibody; Cell culture; Chemistry; Biology; Immunology; In vitro","score_opus":0.015420752743249182,"score_gpt":0.30757546229849314,"score_spread":0.292154709555244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910040477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964096,0.0009126313,0.0015903547,0.000050425504,0.000016587323,0.000025587104,0.0001406377,0.00006773014,0.0007864418],"genre_scores_gemma":[0.9975114,0.00033127345,0.0009515682,0.000023748707,0.0000079053225,0.000020554635,0.00020336751,0.00000790242,0.00094235846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998735,0.000030007071,0.000011976147,0.000021995093,0.00002830306,0.00003424896],"domain_scores_gemma":[0.999964,0.000006819729,0.000007708495,0.0000058394353,0.0000046763666,0.000010981107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010851287,0.00029714286,0.00025763377,0.000115589304,0.00007313814,0.0002264974,0.00014277274,0.00016890863,0.0013763391],"category_scores_gemma":[0.000075713186,0.000082237806,0.00018845753,0.000087744476,0.00014227128,0.0001728624,0.00021360163,0.00038671962,0.00038545718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001704015,0.00003478301,0.00009188641,0.000034215285,0.0000036575707,0.000024196645,0.000008725367,0.00006114712,0.99844366,0.000050615057,0.000035066278,0.00104157],"study_design_scores_gemma":[0.000026012054,0.00037548615,0.0008281741,0.0000022850747,0.000008954001,0.00015692844,0.000006175954,0.00059652736,0.9966175,0.000014660569,0.0013655968,0.0000017461327],"about_ca_topic_score_codex":0.00022154456,"about_ca_topic_score_gemma":0.00021706684,"teacher_disagreement_score":0.0013763391,"about_ca_system_score_codex":0.00017626751,"about_ca_system_score_gemma":0.00012338987,"threshold_uncertainty_score":0.00460428},"labels":[],"label_agreement":null},{"id":"W2910164268","doi":"10.1158/1078-0432.ccr-18-0432","title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":672,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Deutsche Krebshilfe","keywords":"Cancer; Antigen; Medicine; Cancer research; Solid tumor; Pathology; Immunology; Internal medicine","score_opus":0.14806278979406062,"score_gpt":0.49720794026348103,"score_spread":0.3491451504694204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910164268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859831,0.004484355,0.0045570084,0.00020163793,0.000043218584,0.00017372532,0.00052407995,0.00027707455,0.0037558377],"genre_scores_gemma":[0.9912225,0.0028848045,0.002790626,0.000083179555,0.000019435036,0.00008900474,0.00090416404,0.000037461297,0.001968863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998981,0.000016033662,0.0000065910804,0.00001547682,0.000027060434,0.000036791273],"domain_scores_gemma":[0.9999119,0.000013801735,0.000019882536,0.0000076425395,0.000013948907,0.000032795426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024110726,0.00038121123,0.00027724268,0.00019955686,0.00013180435,0.00024201607,0.00023873782,0.0003650309,0.0022796427],"category_scores_gemma":[0.00009307357,0.00011334489,0.00025048127,0.00011976932,0.00023153979,0.00025397303,0.00011381006,0.0008258408,0.00055298815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069859426,0.0006971121,0.0010868916,0.00018751876,0.00003554148,0.00012999342,0.000052616895,0.00068739697,0.98262423,0.00038757455,0.0005919692,0.012820522],"study_design_scores_gemma":[0.00025954688,0.009905544,0.0038144086,0.00001799394,0.00007550609,0.0005836009,0.000034643166,0.0013039884,0.9790908,0.00006437361,0.004844186,0.000005344748],"about_ca_topic_score_codex":0.0014014989,"about_ca_topic_score_gemma":0.0018382532,"teacher_disagreement_score":0.0022796427,"about_ca_system_score_codex":0.00027157218,"about_ca_system_score_gemma":0.000528319,"threshold_uncertainty_score":0.007626176},"labels":[],"label_agreement":null},{"id":"W2910406726","doi":"10.1182/blood-2018-99-113516","title":"Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Oncology; Population; Internal medicine; Biology; Immunology; Cancer research; Medicine","score_opus":0.013721261010528483,"score_gpt":0.26497802880941534,"score_spread":0.25125676779888684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910406726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99967194,0.00009466958,0.00006715422,0.0000067945393,6.4717904e-7,0.0000016922594,0.000073652634,0.00000354738,0.0000800115],"genre_scores_gemma":[0.9997904,0.000024405554,0.000037777216,0.0000034538627,0.0000020875145,0.0000015330589,0.000094362236,0.0000010809761,0.000044866898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99986315,0.000031372558,0.000015218104,0.000042208056,0.000025762101,0.00002220819],"domain_scores_gemma":[0.99922824,0.00015091909,0.00039730646,0.000055201508,0.00005932602,0.00010906929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022894306,0.00018140738,0.0002257676,0.00059471594,0.0001541348,0.00033019081,0.00021751974,0.00025810016,0.0012520398],"category_scores_gemma":[0.0010564247,0.00015145412,0.00011431211,0.00042247062,0.00021939141,0.00016251605,0.00024745998,0.00025535264,0.00019047053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007086877,0.00003381571,0.98353666,0.000014792289,0.00004755373,0.0005550051,0.0000459379,0.00010944364,0.011905764,0.000014900873,0.000058011334,0.0029692554],"study_design_scores_gemma":[0.000012988265,0.00012878534,0.99610573,0.000002126955,0.000025553236,0.0023473157,0.000053854168,0.00024610767,0.00090064685,0.000024574494,0.00014971437,0.0000024873834],"about_ca_topic_score_codex":0.00047137763,"about_ca_topic_score_gemma":0.0005102151,"teacher_disagreement_score":0.0012520398,"about_ca_system_score_codex":0.00013079212,"about_ca_system_score_gemma":0.00009259844,"threshold_uncertainty_score":0.0041884184},"labels":[],"label_agreement":null},{"id":"W2910482049","doi":"10.1080/13696998.2019.1569446","title":"Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Metastatic melanoma; Cohort; Oncology; Internal medicine; Melanoma; Overall survival; Cancer","score_opus":0.14165245733668508,"score_gpt":0.4049893729289035,"score_spread":0.26333691559221845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910482049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5239168,0.0020873363,0.44827902,0.00443601,0.00025772792,0.0011229032,0.0024406973,0.00036544408,0.017094022],"genre_scores_gemma":[0.9595191,0.0005892847,0.03663727,0.00028910153,0.000045530334,0.00066040165,0.0005142649,0.000039106162,0.001705887],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9963731,0.003093024,0.00007450144,0.00016313195,0.0001617413,0.00013441667],"domain_scores_gemma":[0.9614375,0.03568821,0.0011948433,0.0004001369,0.0008311002,0.0004482218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012382502,0.00081690704,0.0009932185,0.0008743111,0.00041940634,0.0013242548,0.0012097665,0.0013906348,0.0047169565],"category_scores_gemma":[0.029370314,0.0006620829,0.0017667448,0.00082451745,0.00064291706,0.0012661766,0.0012552405,0.0020718577,0.00021186151],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029589038,0.00003585722,0.001472827,0.000044419234,0.00007134169,0.000026454692,0.000024971336,0.9886346,0.000050431747,0.0070091146,0.00020762597,0.0021265966],"study_design_scores_gemma":[0.000056133766,0.000105111285,0.0002808833,0.000026809574,0.000027224469,0.000007033171,0.000012970001,0.99438643,0.00005709294,0.0047426056,0.0002900699,0.000007689237],"about_ca_topic_score_codex":0.018585972,"about_ca_topic_score_gemma":0.013925252,"teacher_disagreement_score":0.018585972,"about_ca_system_score_codex":0.003267266,"about_ca_system_score_gemma":0.002839268,"threshold_uncertainty_score":0.065485716},"labels":[],"label_agreement":null},{"id":"W2910585122","doi":"10.1111/imcb.12231","title":"<i>In vitro</i>‐generated <scp>MART</scp>‐1‐specific <scp>CD</scp>8 T cells display a broader T‐cell receptor repertoire than <i>ex vivo</i> naïve and tumor‐infiltrating lymphocytes","year":2019,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Krembil Foundation; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"T-cell receptor; Biology; Antigen; Repertoire; Cytotoxic T cell; Cell biology; CD8; Ex vivo; In vitro; Major histocompatibility complex; Molecular biology; Antigen-presenting cell; Immunology; T cell; Immune system; Genetics","score_opus":0.008317179847681978,"score_gpt":0.23267884798335517,"score_spread":0.22436166813567318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910585122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868036,0.0003545705,0.006574499,0.00005799936,0.000026649075,0.000036042617,0.0005129719,0.00010769146,0.0036492145],"genre_scores_gemma":[0.98937726,0.00025161714,0.0059737163,0.00007249061,0.000020612533,0.00003988648,0.0015314649,0.00005458573,0.0026783447],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987733,0.000024937948,0.0000112058,0.000033180193,0.000024356124,0.000029070346],"domain_scores_gemma":[0.9999137,0.000025927757,0.000019449091,0.000015009155,0.000010377251,0.000015519927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014070468,0.0002636231,0.00015452462,0.0001334746,0.00009867781,0.00036184228,0.00010166463,0.00018408886,0.001478342],"category_scores_gemma":[0.00010911926,0.00008339347,0.00012556576,0.00010328831,0.0001323035,0.00013500512,0.00012710011,0.00052018644,0.00058887026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024602645,0.000012908991,0.00015468107,0.000009278412,0.0000014045416,0.000014264974,0.000007023874,0.000035140005,0.9991002,0.00003491233,0.000022845375,0.0005825676],"study_design_scores_gemma":[0.0000048016236,0.00009655306,0.0009844732,0.0000013859358,0.0000052106075,0.000111374444,0.000008062308,0.00031044782,0.99725807,0.000020135702,0.0011983026,0.0000011473169],"about_ca_topic_score_codex":0.00025094862,"about_ca_topic_score_gemma":0.00042045634,"teacher_disagreement_score":0.001478342,"about_ca_system_score_codex":0.00012877445,"about_ca_system_score_gemma":0.000108525586,"threshold_uncertainty_score":0.004945576},"labels":[],"label_agreement":null},{"id":"W2910852524","doi":"10.1158/1078-0432.ccr-18-2291","title":"Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Adoptive cell transfer; Cancer; Medicine; Cancer therapy; Cell therapy; Cancer research; Immunology; Biology; Immune system; T cell; Internal medicine; Stem cell; Cell biology","score_opus":0.36519421318107037,"score_gpt":0.542524949221723,"score_spread":0.17733073604065264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910852524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97460055,0.0030010515,0.01880452,0.00011701519,0.00007233048,0.00031734185,0.0002146188,0.00012509545,0.0027474915],"genre_scores_gemma":[0.9875777,0.000998549,0.009096685,0.000101211626,0.000024181301,0.00012958578,0.00035479627,0.000016235192,0.001701201],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998599,0.000027753773,0.000013592133,0.000034727404,0.000046458168,0.000017527285],"domain_scores_gemma":[0.9999273,0.00001611283,0.000015163304,0.00001536556,0.000011691596,0.00001447243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021423944,0.00031871887,0.0002127575,0.00020853405,0.000073095885,0.00030319966,0.00023650873,0.0002629965,0.00097654434],"category_scores_gemma":[0.00017695576,0.00008521541,0.00013416405,0.00011454561,0.0001512489,0.00017620834,0.00020446577,0.00047077305,0.00029955493],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016451643,0.00017858924,0.00064510584,0.000058525307,0.000009189861,0.00010540324,0.000033830394,0.000405317,0.9845552,0.0002877929,0.00012906542,0.013427517],"study_design_scores_gemma":[0.000117677635,0.002958984,0.0024464244,0.000018610128,0.00007899983,0.0012887996,0.000026402415,0.0030593418,0.9791753,0.00015920112,0.010663569,0.000006645487],"about_ca_topic_score_codex":0.000074133975,"about_ca_topic_score_gemma":0.0001543697,"teacher_disagreement_score":0.00097654434,"about_ca_system_score_codex":0.00011366635,"about_ca_system_score_gemma":0.00012772629,"threshold_uncertainty_score":0.0032668114},"labels":[],"label_agreement":null},{"id":"W2911247197","doi":"10.1158/2326-6074.cricimteatiaacr18-b052","title":"Abstract B052: Immunotherapy for melanoma by adenovirus-mediated full-length antibody, nivolumab","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Nivolumab; Melanoma; Immunotherapy; Medicine; Antibody; Cancer research; Cancer immunotherapy; Cancer; Immunology; Immune system; Monoclonal antibody; Virology; Oncology; Internal medicine","score_opus":0.04798463207347491,"score_gpt":0.4053823627487281,"score_spread":0.35739773067525316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911247197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560928,0.011308091,0.022655198,0.00047134003,0.00071396877,0.0002965818,0.0012962638,0.00033689284,0.006828954],"genre_scores_gemma":[0.9639993,0.002851974,0.019096892,0.00020773409,0.00006804635,0.00010072214,0.0025390366,0.000047832134,0.011088548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989295,0.000014212662,0.000012291286,0.000028789385,0.000030482968,0.000021237844],"domain_scores_gemma":[0.9999784,0.0000023768953,0.0000048271536,0.000002726442,0.0000034006114,0.000008235506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011718119,0.00044925077,0.0001723867,0.00029324586,0.00015450342,0.0003262948,0.00023889882,0.00041063226,0.0014098817],"category_scores_gemma":[0.00006528883,0.00011340684,0.0003628724,0.00014946853,0.0001969988,0.00023665557,0.00017031908,0.00055112777,0.00066838885],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018087664,0.00010621199,0.0003489259,0.00009625663,0.000015099417,0.00007125434,0.000013857986,0.00017362418,0.9907548,0.00047390632,0.0004125763,0.007352664],"study_design_scores_gemma":[0.00012115187,0.0010186265,0.0030432695,0.000019380712,0.000060463015,0.000997615,0.000024946323,0.0025681679,0.9629217,0.00016617352,0.029042019,0.000016481705],"about_ca_topic_score_codex":0.0010107105,"about_ca_topic_score_gemma":0.0007253036,"teacher_disagreement_score":0.0014098817,"about_ca_system_score_codex":0.00048184098,"about_ca_system_score_gemma":0.0002800123,"threshold_uncertainty_score":0.004716575},"labels":[],"label_agreement":null},{"id":"W2911426225","doi":"10.1038/s42003-019-0296-7","title":"On-demand serum-free media formulations for human hematopoietic cell expansion using a high dimensional search algorithm","year":2019,"lang":"en","type":"article","venue":"Communications Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Haematopoiesis; Process (computing); Set (abstract data type); Mathematical optimization; Reagent; Substitution (logic); Computer science; Free space; Algorithm; Mathematics; Chemistry; Stem cell; Biology; Physics","score_opus":0.08002752794135846,"score_gpt":0.38401909444580423,"score_spread":0.30399156650444575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911426225","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25845066,0.00042164227,0.7268726,0.0004557508,0.00005493072,0.00025690216,0.00014334571,0.00065385125,0.012690369],"genre_scores_gemma":[0.61876816,0.00012948608,0.37615195,0.00018595687,0.000015599078,0.0004434165,0.00016759142,0.00010563409,0.004032295],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986875,0.000044202327,0.000006926795,0.000019295416,0.000042936113,0.000017960709],"domain_scores_gemma":[0.9996,0.00027116592,0.00003186718,0.00001648405,0.000060710776,0.000019916826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006570316,0.00062157674,0.00054300186,0.00045945676,0.00027849496,0.0006285087,0.0007306841,0.00099532,0.0020400097],"category_scores_gemma":[0.0011732302,0.00035330988,0.00054918573,0.00027843233,0.0004383501,0.0003638295,0.0005772813,0.0005166981,0.00025200742],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005734362,0.00008488119,0.00045517788,0.000036896086,0.000018424986,0.000032841857,0.0000229745,0.9785377,0.0039667105,0.0021879491,0.00035622038,0.014242879],"study_design_scores_gemma":[0.00001111798,0.000022807479,0.00003669383,0.0000017015601,0.000002256481,0.0000029193739,0.0000037536188,0.9991794,0.00041633422,0.00019522313,0.00012609494,0.0000016853087],"about_ca_topic_score_codex":0.0036753437,"about_ca_topic_score_gemma":0.0048249364,"teacher_disagreement_score":0.0036753437,"about_ca_system_score_codex":0.00071164937,"about_ca_system_score_gemma":0.0009931831,"threshold_uncertainty_score":0.007307887},"labels":[],"label_agreement":null},{"id":"W2911451382","doi":"10.1016/j.tmrv.2019.01.005","title":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Transfusion Medicine Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Institute for Clinical Evaluative Sciences; Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Simon Fraser University; BC Cancer Agency; Ottawa Hospital; University of Manitoba; University of British Columbia; University of Ottawa","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Internal medicine; Oncology; Cancer; Meta-analysis; Clinical trial; Immunotherapy","score_opus":0.3217246896835683,"score_gpt":0.4496143182220625,"score_spread":0.12788962853849417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911451382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003065512,0.9953881,0.00046703086,0.00018213058,0.00010197735,0.00022119182,0.00035963324,0.000018875213,0.00019565453],"genre_scores_gemma":[0.14499827,0.84918857,0.0022787116,0.0009423027,0.00023414531,0.0013513253,0.0006469663,0.00003693302,0.00032284914],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9880288,0.005977178,0.003440527,0.0010248981,0.0012258847,0.00030263647],"domain_scores_gemma":[0.97529095,0.018965095,0.0033619385,0.0006152868,0.001492246,0.0002745743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015329289,0.002840502,0.020592181,0.007844317,0.0006833799,0.0034088355,0.002372492,0.0023752216,0.0036887708],"category_scores_gemma":[0.035232432,0.0018597045,0.03509994,0.00831623,0.00083103904,0.0019269234,0.0017085115,0.0020534405,0.0003251989],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012215932,0.000017036706,0.0022017404,0.42935973,0.5570577,0.00009759459,0.000078010475,0.00042578607,0.00014121656,0.00015704328,0.00052209833,0.008720468],"study_design_scores_gemma":[0.00040284282,0.000109191016,0.0019867553,0.031196585,0.9643743,0.00007487625,0.00004500373,0.00016787526,0.00007764498,0.00023102341,0.0013120398,0.000021857579],"about_ca_topic_score_codex":0.0071898587,"about_ca_topic_score_gemma":0.014940355,"teacher_disagreement_score":0.020592181,"about_ca_system_score_codex":0.003235411,"about_ca_system_score_gemma":0.0037841182,"threshold_uncertainty_score":0.081070006},"labels":[],"label_agreement":null},{"id":"W2911474691","doi":"10.1080/13696998.2019.1582059","title":"CAR T-cells: costs, comparisons, and commentary","year":2019,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Intensive care medicine; Actuarial science; Economics","score_opus":0.033320510649939156,"score_gpt":0.3124527859559872,"score_spread":0.279132275306048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911474691","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001296392,0.001105024,0.000030020225,0.9919293,0.0057115313,0.0000027658234,0.000040934367,0.0000035006324,0.0010473373],"genre_scores_gemma":[0.0056092353,0.0017397775,0.00014029394,0.94848746,0.04199433,0.00002198469,0.00003239739,0.000013640896,0.0019608405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9839749,0.006541175,0.0017297735,0.0015574116,0.005107652,0.0010890678],"domain_scores_gemma":[0.8875842,0.08945348,0.0033614645,0.0014016946,0.014112191,0.0040870104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018262636,0.00077512546,0.0017779607,0.0018424428,0.0035786526,0.0057788054,0.003850755,0.05288355,0.012395768],"category_scores_gemma":[0.138107,0.0006858955,0.0014603741,0.0026306505,0.0057354625,0.0070078922,0.001990219,0.04121503,0.0064538205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012930868,0.000019413355,0.00023877119,0.000099322424,0.000018687757,0.00049905246,0.00010468212,0.0001089524,0.00005571616,0.012935099,0.9763257,0.009465295],"study_design_scores_gemma":[0.0002851999,0.0000853397,0.0009515508,0.0013591057,0.00007532308,0.0015687955,0.00080348074,0.0007478536,0.00031831735,0.063156575,0.9305331,0.000115370814],"about_ca_topic_score_codex":0.009271184,"about_ca_topic_score_gemma":0.008660207,"teacher_disagreement_score":0.05288355,"about_ca_system_score_codex":0.012724534,"about_ca_system_score_gemma":0.010795393,"threshold_uncertainty_score":0.09658325},"labels":[],"label_agreement":null},{"id":"W2911503195","doi":"10.1016/j.bbmt.2018.12.464","title":"A New Specific Promoter Allow Hematopoietic Stem Cell Immunotherapy Approach Against Acute Lymphoblastic Leukemia Using Chimeric Antigen Receptor","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Chimeric antigen receptor; Jurkat cells; Biology; Cytotoxic T cell; Haematopoiesis; Interleukin 21; Molecular biology; Stem cell; Transfection; T cell; Nucleofection; Cancer research; Cell biology; Cell culture; Immunology; In vitro; Immune system","score_opus":0.015719189403738665,"score_gpt":0.24827979397620228,"score_spread":0.2325606045724636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911503195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8129627,0.01139893,0.16757539,0.00076806045,0.00022500797,0.00031622456,0.00059228245,0.0009348566,0.005226523],"genre_scores_gemma":[0.93368727,0.0056058555,0.052669402,0.00017102886,0.00004837917,0.00024228258,0.0010211904,0.00010016513,0.0064544543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998411,0.000025947518,0.000014075087,0.000035318717,0.00006059613,0.00002302893],"domain_scores_gemma":[0.9999503,0.000006726623,0.000018485049,0.0000052658675,0.000009202274,0.000010032144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017325464,0.00034495033,0.00026608666,0.00020137767,0.00009909932,0.00029265322,0.00024395421,0.00027803122,0.0008788456],"category_scores_gemma":[0.00011644858,0.00015218866,0.00030705787,0.00015848185,0.00018138385,0.00023970514,0.00025662643,0.00058789534,0.0005009424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050986662,0.000030175084,0.00018552791,0.00009713494,0.0000057380184,0.00006147609,0.000019322499,0.00033784518,0.992945,0.0004931052,0.00009785019,0.0056758495],"study_design_scores_gemma":[0.000048240985,0.000471054,0.0005408893,0.000016053718,0.000057402707,0.0008013376,0.000016509732,0.003401118,0.9784928,0.00016505946,0.015980052,0.000009455369],"about_ca_topic_score_codex":0.00020185635,"about_ca_topic_score_gemma":0.00024673977,"teacher_disagreement_score":0.0008788456,"about_ca_system_score_codex":0.00021708361,"about_ca_system_score_gemma":0.0003393741,"threshold_uncertainty_score":0.002939999},"labels":[],"label_agreement":null},{"id":"W2911504656","doi":"10.1182/blood-2018-11-883710","title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Juno Therapeutics; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Celgene","keywords":"Medicine; CAR T-cell therapy; CD19; Internal medicine; Oncology; Immunology; T cell; Chimeric antigen receptor; Antibody; Immune system","score_opus":0.019104211371907664,"score_gpt":0.2534960935338183,"score_spread":0.23439188216191065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911504656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993814,0.00016839207,0.0001759222,0.000047140034,0.0000027108567,0.0000027614517,0.00006936971,0.0000072868997,0.00014497832],"genre_scores_gemma":[0.99970824,0.000022232043,0.00007579601,0.00001476079,0.000007019045,0.0000021071598,0.00011355217,0.0000017556517,0.000054417338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996376,0.00014901445,0.00003625934,0.000059084614,0.000049698843,0.00006835703],"domain_scores_gemma":[0.99867153,0.00041133462,0.0005265397,0.00008527893,0.00008029862,0.0002251208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063027436,0.0002230324,0.00035232893,0.00031911477,0.00020012469,0.000517432,0.00023120403,0.00033939836,0.0012497718],"category_scores_gemma":[0.0019605937,0.0001322446,0.00044472108,0.00036185904,0.00020047113,0.00029040358,0.00023219196,0.0005886921,0.00024702246],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006486556,0.00006571302,0.9934104,0.000007485788,0.00006219568,0.00011476261,0.00002481887,0.0002954224,0.0010163478,0.000029727822,0.00014526333,0.00417904],"study_design_scores_gemma":[0.00004958656,0.000695013,0.99390775,0.0000065813956,0.00012978647,0.00078161305,0.00008323691,0.0030279995,0.00072345353,0.00012110911,0.0004660175,0.000007794097],"about_ca_topic_score_codex":0.0006481598,"about_ca_topic_score_gemma":0.0007465578,"teacher_disagreement_score":0.0012497718,"about_ca_system_score_codex":0.0001679116,"about_ca_system_score_gemma":0.00022996144,"threshold_uncertainty_score":0.0041808486},"labels":[],"label_agreement":null},{"id":"W2911843886","doi":"10.1016/j.bbmt.2018.12.783","title":"Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy or CAR-T","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Radioimmunotherapy; Conditioning; Regimen; Conditioning regimen; Oncology; Internal medicine; Immunology; Cyclophosphamide; Chemotherapy; Monoclonal antibody","score_opus":0.012069016687963181,"score_gpt":0.2685406101849105,"score_spread":0.2564715934969473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911843886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632276,0.0037629197,0.016627831,0.00037725782,0.0009251795,0.0016974005,0.0010382133,0.0010178994,0.011325763],"genre_scores_gemma":[0.98557633,0.0010970775,0.006575839,0.00027477427,0.00014377349,0.00077455904,0.0007103962,0.00009775352,0.004749408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999608,0.0000591411,0.000028209864,0.00011240993,0.00006326938,0.00012894452],"domain_scores_gemma":[0.99986756,0.000022250688,0.00002067635,0.000036903017,0.000007751658,0.0000448996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002861679,0.0007787061,0.0007094017,0.00068197586,0.00050867966,0.0006307644,0.000670867,0.0005021641,0.004244075],"category_scores_gemma":[0.00020961651,0.00021621662,0.00036336674,0.0005037001,0.00040592867,0.00032540015,0.00042668107,0.0020600667,0.00084382633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002755383,0.0030384155,0.0010604333,0.00017906283,0.00008238127,0.00022039456,0.00014413318,0.0011273224,0.9523971,0.0029581499,0.001779192,0.03425798],"study_design_scores_gemma":[0.0006429082,0.0063027553,0.005563215,0.000027215787,0.00018617303,0.00077521434,0.00004406522,0.0022345972,0.96394,0.00040420593,0.019858757,0.000020886222],"about_ca_topic_score_codex":0.00095709006,"about_ca_topic_score_gemma":0.0024006274,"teacher_disagreement_score":0.004244075,"about_ca_system_score_codex":0.0004407306,"about_ca_system_score_gemma":0.00082784524,"threshold_uncertainty_score":0.014197886},"labels":[],"label_agreement":null},{"id":"W2911882091","doi":"10.1007/s00262-019-02307-x","title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Medicine; Melanoma; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Aldesleukin; Population; Adverse effect; Chemotherapy; Interleukin 2; Immune system; Internal medicine; Oncology; Immunotherapy; Gastroenterology; Phases of clinical research; Clinical trial; Immunology; Cancer research","score_opus":0.03161818977587048,"score_gpt":0.3569993678410537,"score_spread":0.3253811780651832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911882091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97775877,0.001020118,0.0018283945,0.00075788173,0.00027442558,0.014854682,0.0012563094,0.00018119422,0.0020683769],"genre_scores_gemma":[0.9595522,0.0013363084,0.0067212395,0.0014079934,0.00029664524,0.021984767,0.0032382768,0.000057289108,0.0054052947],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993849,0.00030277655,0.000025634472,0.00009725059,0.00006171233,0.00012776219],"domain_scores_gemma":[0.9990522,0.00013641767,0.00014296219,0.00012726772,0.00007684377,0.0004643195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024452659,0.002725467,0.0023711629,0.00060584093,0.0005672608,0.0010746471,0.0014388874,0.0016782273,0.003141093],"category_scores_gemma":[0.0013509007,0.0007001254,0.0009321701,0.0005373929,0.001370307,0.00079892745,0.0004864251,0.0045317304,0.00080354477],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5972289,0.22953305,0.0056697945,0.000695929,0.0009656725,0.00047766205,0.00045732138,0.005367614,0.07391715,0.0008490198,0.0058226953,0.07901511],"study_design_scores_gemma":[0.5423082,0.44493148,0.004223921,0.000020785534,0.00014325448,0.00016144676,0.000039098926,0.0017100747,0.0041798837,0.0002540545,0.002008334,0.000019381601],"about_ca_topic_score_codex":0.00093501114,"about_ca_topic_score_gemma":0.0018761142,"teacher_disagreement_score":0.003141093,"about_ca_system_score_codex":0.0011272781,"about_ca_system_score_gemma":0.0026567779,"threshold_uncertainty_score":0.012931943},"labels":[],"label_agreement":null},{"id":"W2912271788","doi":"","title":"Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma","year":2014,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ipilimumab; Medicine; Refractory (planetary science); Monoclonal antibody; Melanoma; Oncology; Internal medicine; Monoclonal; Antibody; Immunology; Immunotherapy; Cancer research; Cancer; Biology","score_opus":0.047287008811841814,"score_gpt":0.3897588026719732,"score_spread":0.3424717938601314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912271788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903439,0.0028949236,0.0007068659,0.0005300723,0.0009074494,0.0021942516,0.00053615496,0.000076605305,0.0018098821],"genre_scores_gemma":[0.9935488,0.0009131394,0.00093193306,0.00049228943,0.00042038353,0.0015842635,0.00036782675,0.000021513139,0.0017199026],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984616,0.0007175935,0.0001135309,0.00029509468,0.00011481309,0.00029736944],"domain_scores_gemma":[0.9981092,0.00075056765,0.0003481086,0.00018617634,0.00008731804,0.0005185542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018844851,0.0016873627,0.0043524727,0.00071053865,0.0004893363,0.0015305579,0.0016958785,0.0023435026,0.008248673],"category_scores_gemma":[0.0031099054,0.0012002765,0.0022579385,0.0005868602,0.0022144418,0.0016548746,0.0007056157,0.003974223,0.0011153319],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.99067956,0.0026531685,0.00010931948,0.000112723195,0.00031002238,0.0000115221,0.000014489019,0.00016986285,0.00090821506,0.000069124166,0.00011740612,0.004844689],"study_design_scores_gemma":[0.90659106,0.09030918,0.0011093207,0.000022257726,0.00056916126,0.000013038876,0.000019270208,0.00046046718,0.0003487729,0.00021611115,0.00032226072,0.000019162213],"about_ca_topic_score_codex":0.0018336986,"about_ca_topic_score_gemma":0.0028875358,"teacher_disagreement_score":0.008248673,"about_ca_system_score_codex":0.0021053655,"about_ca_system_score_gemma":0.0013441925,"threshold_uncertainty_score":0.027594626},"labels":[],"label_agreement":null},{"id":"W2912829588","doi":"10.1158/2326-6074.cricimteatiaacr18-b035","title":"Abstract B035: Enhancing antitumoral activity of cell-based immunotherapies by modulating the JAK-STAT axis","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Priming (agriculture); Chimeric antigen receptor; Adoptive cell transfer; CD40; Immunology; Antigen; Cytotoxic T cell; T cell; Cancer research; Medicine; Immunotherapy; Interleukin 21; Antigen-presenting cell; Immune system; Biology; In vitro","score_opus":0.050236515303171025,"score_gpt":0.3845353745239244,"score_spread":0.33429885922075336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912829588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95860165,0.020955961,0.0060097747,0.00076128234,0.0005748045,0.00017271124,0.0015743343,0.0005303084,0.010819163],"genre_scores_gemma":[0.98869926,0.003943007,0.0021857526,0.00023071971,0.000054608387,0.000070753136,0.000855875,0.000026480504,0.0039335717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992204,0.000010791742,0.000005499769,0.000010281107,0.00002495122,0.000026438047],"domain_scores_gemma":[0.99997294,0.0000030203012,0.000005126815,0.0000016914295,0.0000026374505,0.000014628677],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011179414,0.00033306342,0.00020782601,0.0002490197,0.000111048175,0.0003218321,0.00019958598,0.00026128523,0.0057136766],"category_scores_gemma":[0.00004371698,0.00008857879,0.00022709186,0.00015327013,0.00015328999,0.0001363358,0.00012435016,0.0007832712,0.0011483894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017053485,0.0006142821,0.00018345294,0.0002876719,0.000027485143,0.000066722845,0.000014308689,0.0006499538,0.97288245,0.0006824338,0.001255868,0.021630038],"study_design_scores_gemma":[0.00071272644,0.006201341,0.0032104503,0.00005754574,0.00010754702,0.0004499291,0.000030225383,0.0049777115,0.9633718,0.000328635,0.020534359,0.000017794258],"about_ca_topic_score_codex":0.00039226588,"about_ca_topic_score_gemma":0.00054205756,"teacher_disagreement_score":0.0057136766,"about_ca_system_score_codex":0.00024121025,"about_ca_system_score_gemma":0.00025823186,"threshold_uncertainty_score":0.019114137},"labels":[],"label_agreement":null},{"id":"W2913199767","doi":"10.1182/blood-2018-99-119045","title":"T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada); McMaster University","funders":"","keywords":"Chimeric antigen receptor; Cytotoxic T cell; Antigen; Cancer research; T-cell receptor; Immunology; Biology; T cell; Cytokine; CD19; Antigen-presenting cell; Molecular biology; Immune system; In vitro; Biochemistry","score_opus":0.025981840969429938,"score_gpt":0.2740505944299949,"score_spread":0.24806875346056498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913199767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990162,0.0011796067,0.006573143,0.000097099924,0.000038528247,0.00012811007,0.00023323447,0.00014344581,0.0014449109],"genre_scores_gemma":[0.993274,0.0007298485,0.0039461954,0.0001016782,0.000027149157,0.00008719886,0.0004642946,0.000020290909,0.0013494745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982053,0.000031160824,0.000022006978,0.000037293277,0.000050626935,0.00003835136],"domain_scores_gemma":[0.99987984,0.000023239108,0.000038934704,0.000016198544,0.000020553944,0.000021240685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001539628,0.000321295,0.00016605778,0.00025263964,0.00009709003,0.000359237,0.0001834451,0.00040653473,0.0013228573],"category_scores_gemma":[0.00016552993,0.00007350788,0.00019289399,0.00015670956,0.000155409,0.00015611031,0.00016592309,0.0006084171,0.00051815505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014241839,0.00006992249,0.00043634526,0.00004111456,0.000007960569,0.00011698181,0.000018312005,0.00012163976,0.99658847,0.00011352765,0.000094739014,0.002248597],"study_design_scores_gemma":[0.00008158982,0.0009952808,0.002750435,0.000009339783,0.00006276312,0.0014434169,0.000020345853,0.0012978252,0.98774743,0.000075376534,0.005508949,0.0000072844377],"about_ca_topic_score_codex":0.00016370679,"about_ca_topic_score_gemma":0.00013366718,"teacher_disagreement_score":0.0013228573,"about_ca_system_score_codex":0.00016964547,"about_ca_system_score_gemma":0.00011207678,"threshold_uncertainty_score":0.0044254065},"labels":[],"label_agreement":null},{"id":"W2913763056","doi":"10.1007/s11899-019-0498-6","title":"Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy","year":2019,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"NIH Clinical Center; Novartis Pharmaceuticals Corporation; University of Pennsylvania","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Hematology; Cytokine release syndrome; Internal medicine; Clinical trial; Oncology; Cancer","score_opus":0.09754620024724776,"score_gpt":0.37582670228071946,"score_spread":0.2782805020334717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913763056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010327539,0.9978173,0.00013157816,0.0005760335,0.00043407106,0.0000047544477,0.000013967157,0.000008661808,0.000910276],"genre_scores_gemma":[0.0010608342,0.9972542,0.00017850654,0.000647438,0.00027579846,0.000007316799,0.000024691419,0.0000025725074,0.0005485247],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996026,0.00009018898,0.000044705583,0.000060769617,0.00015667363,0.000045018718],"domain_scores_gemma":[0.9994006,0.0003099338,0.00007611976,0.000016920898,0.00015712627,0.000039296705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009058719,0.00060908234,0.0009170316,0.0018790318,0.00023740677,0.001210035,0.0005870937,0.0012240182,0.0037220994],"category_scores_gemma":[0.0013193872,0.00021062544,0.0006642105,0.0016111034,0.00047498578,0.00145928,0.0007112083,0.00207705,0.0017794736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008290498,0.00005304264,0.00013614405,0.03239457,0.00011869532,0.00020523937,0.0000908441,0.00047998747,0.0028596083,0.009821719,0.055732705,0.89802456],"study_design_scores_gemma":[0.000013019042,0.000058598744,0.00021051723,0.0038161215,0.00008614944,0.000449374,0.00004335718,0.000055407945,0.0005714915,0.0014165461,0.9932702,0.000009231742],"about_ca_topic_score_codex":0.00092534075,"about_ca_topic_score_gemma":0.0012454257,"teacher_disagreement_score":0.0037220994,"about_ca_system_score_codex":0.000645876,"about_ca_system_score_gemma":0.0017114711,"threshold_uncertainty_score":0.012451649},"labels":[],"label_agreement":null},{"id":"W2913828923","doi":"10.1172/jci.insight.123672","title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells","year":2019,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia; Centre for Drug Research and Development; BC Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Receptor; Computational biology; Antigen; Cell biology; Biology; Immunology; Chemistry; Genetics; Immunotherapy; Immune system","score_opus":0.04166199188990639,"score_gpt":0.2625196182458322,"score_spread":0.22085762635592582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913828923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96353775,0.00052572385,0.03404802,0.000044972494,0.000011265555,0.00029491785,0.0002677032,0.00014649938,0.001123086],"genre_scores_gemma":[0.9768187,0.00034952804,0.021516794,0.00005857958,0.0000050282856,0.00019551288,0.00034761426,0.00003351134,0.0006747888],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893373,0.00039946957,0.000084895866,0.00019361933,0.00021368764,0.00017459632],"domain_scores_gemma":[0.99960965,0.00012537051,0.000082683044,0.00007731163,0.000074154355,0.000030882813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097513816,0.0006637394,0.000297582,0.00029076013,0.00014990887,0.00036189405,0.00030784283,0.00041906626,0.00056524633],"category_scores_gemma":[0.0005745227,0.00021353218,0.0002723459,0.0002264389,0.00034600514,0.00026394753,0.00040250612,0.000434599,0.00018616274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035544257,0.000041730946,0.00018665307,0.000015602835,0.0000037068637,0.000015250568,0.000013030218,0.00035289102,0.99795085,0.00006103946,0.000011662525,0.0013119853],"study_design_scores_gemma":[0.000009753078,0.0005647769,0.0005691028,0.0000020154541,0.000008821606,0.00007029205,0.000012193895,0.0009732173,0.997341,0.000031686675,0.00041430607,0.0000028507563],"about_ca_topic_score_codex":0.000448027,"about_ca_topic_score_gemma":0.00066597236,"teacher_disagreement_score":0.00097513816,"about_ca_system_score_codex":0.0003188608,"about_ca_system_score_gemma":0.00030682026,"threshold_uncertainty_score":0.0051570535},"labels":[],"label_agreement":null},{"id":"W2914888321","doi":"10.3389/fimmu.2019.00111","title":"Is There a Positive Side to T Cell Exhaustion?","year":2019,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Immunosurveillance; Receptor; Autoimmunity; Immunology; Biology; Cell; Cell biology; Senescence; Immunotherapy; Immune system","score_opus":0.03726496116236359,"score_gpt":0.3517307754025052,"score_spread":0.3144658142401416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914888321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008664691,0.9964805,0.000100208585,0.0012093436,0.0007574449,0.000001645686,0.0000066100274,0.000007560444,0.0013500532],"genre_scores_gemma":[0.00087193865,0.9956424,0.00013394318,0.0010673221,0.00074820546,0.000003881692,0.000013653449,0.00000223794,0.0015163803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985397,0.000029182775,0.000013746789,0.000030165267,0.000050003822,0.0000229359],"domain_scores_gemma":[0.9997892,0.00010917986,0.000021070964,0.0000067571114,0.00004745025,0.000026375908],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052463514,0.0005761275,0.0008730636,0.0011031743,0.00032530678,0.0011505756,0.00066641514,0.0014228813,0.003266479],"category_scores_gemma":[0.0006844286,0.00018924785,0.00031565077,0.0010409222,0.0009164233,0.0021328502,0.0006268839,0.002691873,0.002662128],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095018746,0.00005288933,0.00014881737,0.009659832,0.00004259052,0.00023502075,0.0001265309,0.00022726742,0.0027101035,0.020486182,0.083267406,0.88294834],"study_design_scores_gemma":[0.0000070394876,0.00006192295,0.00020591948,0.0015247702,0.000019257566,0.0006776417,0.00008466342,0.000039806593,0.00027153388,0.0043275943,0.9927711,0.000008771367],"about_ca_topic_score_codex":0.00063519186,"about_ca_topic_score_gemma":0.0012802242,"teacher_disagreement_score":0.003266479,"about_ca_system_score_codex":0.0007218757,"about_ca_system_score_gemma":0.0009630508,"threshold_uncertainty_score":0.010927498},"labels":[],"label_agreement":null},{"id":"W2915025135","doi":"10.1038/s41551-019-0359-6","title":"Cancer immunotherapies repurposed for use in autoimmunity","year":2019,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Cancer; Autoimmunity; Medicine; Immunotherapy; Immunology; Cancer immunotherapy; Immune system; Internal medicine","score_opus":0.014626808452377293,"score_gpt":0.30752249056818587,"score_spread":0.2928956821158086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915025135","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82340574,0.06457414,0.05871227,0.0034024816,0.001661214,0.00077852193,0.0007737939,0.00097032415,0.04572151],"genre_scores_gemma":[0.9592136,0.018024473,0.008435832,0.0007363552,0.00021995847,0.00020894042,0.00030384594,0.000066077024,0.012790835],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99986744,0.000026466269,0.000005437094,0.000022098004,0.000038731974,0.000039753653],"domain_scores_gemma":[0.99994266,0.000013039687,0.000013326324,0.000011545396,0.000008561656,0.000010780639],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002580731,0.00040098224,0.00026828147,0.0005044085,0.0002979414,0.0004440122,0.0003375621,0.0006164969,0.0045279954],"category_scores_gemma":[0.00017059212,0.00014351527,0.00037874695,0.00021567759,0.0003306359,0.00032939317,0.00033739928,0.0012011463,0.0010310762],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027206182,0.00026781094,0.00014651618,0.0002443463,0.000035110636,0.00034974367,0.000115905044,0.0007728709,0.94336975,0.003929839,0.0010642158,0.04943178],"study_design_scores_gemma":[0.0001593467,0.0022864556,0.0011004547,0.00006538472,0.00011244281,0.0011815183,0.00006803072,0.00093103404,0.9241924,0.0014429436,0.06844323,0.000016719143],"about_ca_topic_score_codex":0.00031068278,"about_ca_topic_score_gemma":0.00042653995,"teacher_disagreement_score":0.0045279954,"about_ca_system_score_codex":0.0002498292,"about_ca_system_score_gemma":0.00023354654,"threshold_uncertainty_score":0.015147626},"labels":[],"label_agreement":null},{"id":"W2915478666","doi":"10.1182/blood-2018-99-113642","title":"CAR-Modified Th1/Tc1-Polarized T-Rapa Cells Dissociate Inflammatory Cytokine Secretion from Anti-Tumor Cytotoxicity","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunology; Cytokine release syndrome; Chimeric antigen receptor; Cytokine; Interleukin 21; Interleukin 12; Cancer research; Biology; Medicine; Immunotherapy; Cytotoxic T cell; T cell; Immune system; In vitro","score_opus":0.018173105808239463,"score_gpt":0.2748453735791264,"score_spread":0.256672267770887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915478666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049044,0.0012603544,0.003620353,0.00013855353,0.000056059114,0.00010440253,0.00066272763,0.00021320672,0.003453913],"genre_scores_gemma":[0.99001825,0.0005553493,0.0040603396,0.00009769222,0.000031652835,0.00012408494,0.0010098333,0.00004858346,0.0040541682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999798,0.00002773951,0.000019187313,0.00004480063,0.00004099266,0.00006924122],"domain_scores_gemma":[0.9998572,0.000027665881,0.000031193365,0.000026795442,0.000019531446,0.000037572707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013711595,0.0004506675,0.0003429186,0.0001601492,0.00017258455,0.00037241325,0.00020725276,0.0003669964,0.0037957681],"category_scores_gemma":[0.000081668324,0.00014855633,0.00031314383,0.00012418722,0.0001805902,0.00018962174,0.00015940041,0.0010488629,0.0015220207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011463713,0.0000428248,0.00008879557,0.000029644443,0.0000034421407,0.000035754816,0.000009817808,0.000057907535,0.99870324,0.00005436051,0.00006438341,0.0007951606],"study_design_scores_gemma":[0.00003247381,0.00038129074,0.0013496836,0.0000056167673,0.000012254957,0.0002654026,0.000014960544,0.00066079624,0.99492973,0.00002005194,0.0023252121,0.0000026027842],"about_ca_topic_score_codex":0.000300329,"about_ca_topic_score_gemma":0.00034096866,"teacher_disagreement_score":0.0037957681,"about_ca_system_score_codex":0.00016789381,"about_ca_system_score_gemma":0.00023045047,"threshold_uncertainty_score":0.012698114},"labels":[],"label_agreement":null},{"id":"W2915844515","doi":"10.1038/s41586-019-0967-z","title":"Retraction Note: A homing system targets therapeutic T cells to brain cancer","year":2019,"lang":"en","type":"retraction","venue":"Nature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Homing (biology); Brain cancer; Neuroscience; Cognitive science; Biology; Psychology; Cancer; Ecology; Genetics","score_opus":0.019744595819964437,"score_gpt":0.3627102256696908,"score_spread":0.34296562984972634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915844515","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000078543235,0.002092305,0.00020211248,0.097803146,0.89727265,0.000024342187,0.00017545607,0.00006835326,0.002283063],"genre_scores_gemma":[0.0030251297,0.0069144317,0.0010571224,0.12582369,0.75256145,0.0002393177,0.00047745285,0.00025380784,0.10964758],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99329233,0.0010115958,0.0013080065,0.00060449116,0.0029697951,0.00081379176],"domain_scores_gemma":[0.97325605,0.011525823,0.0016526213,0.0013580996,0.010068118,0.0021393567],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0067355367,0.0026733023,0.0023749694,0.0031500102,0.0036989087,0.004492061,0.0046342714,0.023505129,0.016961744],"category_scores_gemma":[0.051455647,0.0013472923,0.0025503035,0.0016221636,0.003187107,0.0028833011,0.0031158081,0.030814558,0.018875893],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013017973,0.000002893546,0.000011525434,0.000055842396,0.0000054751786,0.00017706999,0.000012654169,0.000011353752,0.000056788365,0.00034112556,0.9959145,0.0033977376],"study_design_scores_gemma":[0.00002444006,0.000014441698,0.00026960182,0.00018687066,0.000023194598,0.0004451573,0.000036253037,0.00009109433,0.00020412872,0.00056678196,0.9981199,0.000018082534],"about_ca_topic_score_codex":0.008143263,"about_ca_topic_score_gemma":0.010095942,"teacher_disagreement_score":0.97649485,"about_ca_system_score_codex":0.006456946,"about_ca_system_score_gemma":0.006063396,"threshold_uncertainty_score":0.056742728},"labels":[{"model":"gemma","categories":["research_integrity"],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["research_integrity"],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2917009888","doi":"10.1016/j.blre.2019.02.001","title":"Cellular immunotherapy for acute myeloid leukemia: How specific should it be?","year":2019,"lang":"en","type":"review","venue":"Blood Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Leukemia and Lymphoma Society","keywords":"Chimeric antigen receptor; Medicine; Myeloid leukemia; Immunotherapy; Cytokine release syndrome; Immunology; Leukemia; Immune system; Hematopoietic stem cell transplantation; Antigen; Myeloid; Cell therapy; Cancer; T cell; Lymphoma; Cancer research; Stem cell; Transplantation; Internal medicine; Biology","score_opus":0.21423503775867625,"score_gpt":0.4130453928163727,"score_spread":0.19881035505769645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917009888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024933555,0.99847406,0.00004365409,0.0007139852,0.0004993415,0.0000022130232,0.000009008789,0.0000042336364,0.00022850304],"genre_scores_gemma":[0.00035300976,0.9973013,0.00010154515,0.0012864139,0.0005627772,0.00000606682,0.00002109792,0.0000014577735,0.0003662999],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997048,0.00007717239,0.000038272607,0.000050220002,0.00009273696,0.00003688002],"domain_scores_gemma":[0.99936515,0.0003292771,0.00006639098,0.000016844866,0.00015739063,0.000064993714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013513736,0.0009588636,0.0022086126,0.0014019281,0.00029701684,0.0013707001,0.0010770715,0.0022249625,0.003721392],"category_scores_gemma":[0.0015789864,0.00030858393,0.0008070759,0.0013991499,0.00069118704,0.0018837415,0.0007707099,0.0039824685,0.0022151677],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021021745,0.00007112972,0.00010474344,0.0155798495,0.00016539828,0.000104570565,0.000036365836,0.0003069487,0.0012012022,0.0037614098,0.118054174,0.86040395],"study_design_scores_gemma":[0.00011511162,0.0001805755,0.00031215383,0.005053961,0.00022136416,0.00034771988,0.00003609723,0.000075302356,0.00018604127,0.001692082,0.99176145,0.000018209708],"about_ca_topic_score_codex":0.0012657209,"about_ca_topic_score_gemma":0.0030018461,"teacher_disagreement_score":0.003721392,"about_ca_system_score_codex":0.0009189638,"about_ca_system_score_gemma":0.0015704788,"threshold_uncertainty_score":0.0124492645},"labels":[],"label_agreement":null},{"id":"W2917035693","doi":"10.1001/jamanetworkopen.2019.0035","title":"Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Spark Therapeutics; Genentech; Regeneron Pharmaceuticals; AstraZeneca; Laura and John Arnold Foundation; Kaiser Permanente; GlaxoSmithKline; Blue Shield of California Foundation; Sanofi; National Pharmaceutical Council; Mallinckrodt Pharmaceuticals; Alnylam Pharmaceuticals; California Health Care Foundation","keywords":"Medicine; Oncology; Lymphoma; Survival analysis; Internal medicine; Cost effectiveness; Quality-adjusted life year; Cohort","score_opus":0.04220927045853014,"score_gpt":0.3345751585168903,"score_spread":0.29236588805836017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917035693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97763777,0.0124652,0.0045170486,0.0012007116,0.000086937296,0.0006648677,0.001210121,0.000032828557,0.0021844844],"genre_scores_gemma":[0.99692255,0.001041697,0.0010879432,0.00009859828,0.00001655004,0.00016901016,0.0004406254,0.000005046202,0.0002179153],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99380684,0.0047903536,0.00027468553,0.0003507309,0.0004252508,0.0003521698],"domain_scores_gemma":[0.9853576,0.011408717,0.0021705998,0.00024942396,0.00031395807,0.00049967895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014217727,0.00092346687,0.0014173513,0.0012149266,0.00023636645,0.0020334008,0.00088701985,0.0013178958,0.0026762637],"category_scores_gemma":[0.037889175,0.00040439935,0.0042326567,0.0010346496,0.0008517535,0.0020163138,0.0011852675,0.0019962206,0.00012768136],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19504325,0.004021118,0.10145327,0.004193809,0.016383845,0.00055472035,0.0003257096,0.5541105,0.0016352722,0.011511893,0.0016433868,0.1091232],"study_design_scores_gemma":[0.021149928,0.0535058,0.099054255,0.0028472065,0.021819567,0.0011106093,0.00076071155,0.7714258,0.003448585,0.02020248,0.004359885,0.00031514125],"about_ca_topic_score_codex":0.0035261,"about_ca_topic_score_gemma":0.0027214563,"teacher_disagreement_score":0.014217727,"about_ca_system_score_codex":0.005366459,"about_ca_system_score_gemma":0.0017735857,"threshold_uncertainty_score":0.07519138},"labels":[],"label_agreement":null},{"id":"W2917127842","doi":"10.1182/blood-2018-11-887067","title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; Juno Therapeutics; University of British Columbia; Celgene; Fred Hutchinson Cancer Research Center","keywords":"Medicine; Fludarabine; Cyclophosphamide; Cytokine release syndrome; Cytokine; Immunology; Internal medicine; Immunotherapy; Gastroenterology; Chemotherapy; Immune system; Chimeric antigen receptor","score_opus":0.005690642519163778,"score_gpt":0.24280284708367725,"score_spread":0.23711220456451346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917127842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99942565,0.00019631613,0.0001599873,0.000033324814,0.0000024998424,0.0000024467915,0.000038391205,0.0000042446845,0.00013715471],"genre_scores_gemma":[0.99983215,0.000023514142,0.000030271436,0.000011646906,0.0000052954447,0.0000015748401,0.000040373252,8.6124345e-7,0.00005437402],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998416,0.00006358318,0.000009184694,0.000020800193,0.000023708802,0.000041135117],"domain_scores_gemma":[0.9996195,0.00015516907,0.000110119836,0.000016534485,0.000019889863,0.00007878989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029043568,0.00012203697,0.00023187647,0.00013009954,0.00011943254,0.0003530254,0.00008529028,0.00015940012,0.000791696],"category_scores_gemma":[0.0007267912,0.000082108825,0.00039402512,0.00013850254,0.00009847918,0.00023325546,0.00017240495,0.00033815025,0.00008149802],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035230652,0.00019512245,0.96792835,0.000019859788,0.00023953483,0.00018475109,0.00006178586,0.0010903699,0.010426111,0.000042570424,0.00020532667,0.016083302],"study_design_scores_gemma":[0.00006436938,0.0017794452,0.99253285,0.000004247127,0.00017254418,0.0003609199,0.000054450396,0.0025075097,0.0018421104,0.00009019806,0.00058717607,0.0000042021125],"about_ca_topic_score_codex":0.00059864024,"about_ca_topic_score_gemma":0.0007501877,"teacher_disagreement_score":0.000791696,"about_ca_system_score_codex":0.00015711773,"about_ca_system_score_gemma":0.00017355174,"threshold_uncertainty_score":0.0026484728},"labels":[],"label_agreement":null},{"id":"W2921590257","doi":"10.1016/j.jcyt.2019.02.003","title":"Advancing cellular therapies towards standard of care: a focus on testing of cellular therapy products","year":2019,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Chimeric antigen receptor; Cell therapy; Genetic enhancement; Medicine; Cell; Intensive care medicine; Business; Immunology; Gene; Immunotherapy; Biology; Immune system; Genetics","score_opus":0.025992854661869104,"score_gpt":0.2952986005582571,"score_spread":0.26930574589638795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921590257","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030869557,0.54594564,0.22426529,0.14489949,0.00685565,0.0013091664,0.0006486669,0.00085698365,0.0443495],"genre_scores_gemma":[0.28566557,0.42017213,0.21416958,0.05884363,0.007869782,0.0015398678,0.0014011539,0.0005496771,0.009788708],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9708702,0.012833206,0.0015618026,0.0021395083,0.011488937,0.0011064119],"domain_scores_gemma":[0.9669154,0.015368171,0.0031601314,0.0028006344,0.010193774,0.0015619649],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04188754,0.00162218,0.0029247066,0.0025726242,0.0008550464,0.010634976,0.003937808,0.0051181684,0.0071347286],"category_scores_gemma":[0.034130115,0.00040510856,0.0012467911,0.001470086,0.009723796,0.008599915,0.004337414,0.008396906,0.0020718793],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009588885,0.0012792565,0.0049203453,0.007246707,0.0001970795,0.00029186788,0.00076325994,0.0050131413,0.111449525,0.24310057,0.027506305,0.59727305],"study_design_scores_gemma":[0.00029477887,0.009694826,0.005039139,0.0074245273,0.00026815667,0.0018940483,0.0018619568,0.0075655784,0.16802068,0.18221673,0.61546546,0.0002541371],"about_ca_topic_score_codex":0.0016993006,"about_ca_topic_score_gemma":0.0016340759,"teacher_disagreement_score":0.04188754,"about_ca_system_score_codex":0.0063909483,"about_ca_system_score_gemma":0.009936714,"threshold_uncertainty_score":0.22152513},"labels":[],"label_agreement":null},{"id":"W2921870084","doi":"10.1016/j.stem.2019.02.013","title":"Close Quarters Can Be a Good Fit for Stem Cells to Become T Cells","year":2019,"lang":"en","type":"letter","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Biology; Mesoderm; Stem cell; Induced pluripotent stem cell; Cell biology; Haematopoiesis; Stromal cell; Mesenchymal stem cell; Organoid; Embryonic stem cell; Cell; Immunology; Genetics; Cancer research; Gene","score_opus":0.04010783111700474,"score_gpt":0.28767264997784114,"score_spread":0.2475648188608364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921870084","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008085696,0.005080459,0.00047677298,0.9648129,0.018943327,0.000008337722,0.000018082605,0.000043694294,0.009807804],"genre_scores_gemma":[0.022007437,0.0034957768,0.00082738634,0.9151982,0.024416042,0.000039584127,0.000026463385,0.000072855524,0.033916157],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976604,0.0007733234,0.00013936499,0.00029374333,0.00081229303,0.00032082185],"domain_scores_gemma":[0.9963085,0.0024743672,0.00028197805,0.00021938054,0.00030756547,0.0004081262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002200538,0.00075045234,0.0008292102,0.00027426815,0.0031842766,0.004250236,0.00079123396,0.031721804,0.009807372],"category_scores_gemma":[0.014527685,0.00039837864,0.000762828,0.0002819174,0.0041822502,0.005528997,0.0022272523,0.02374085,0.0076082167],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015935572,0.00005412589,0.0003728594,0.000085916465,0.000018278302,0.003974954,0.00035515096,0.00010093963,0.0012401295,0.026303297,0.94185656,0.02547844],"study_design_scores_gemma":[0.000064034895,0.000089092595,0.00015676208,0.00007526959,0.000008372672,0.0026275213,0.00069153315,0.00013940607,0.0005474846,0.035366412,0.9602078,0.000026204194],"about_ca_topic_score_codex":0.0010658843,"about_ca_topic_score_gemma":0.0025966035,"teacher_disagreement_score":0.031721804,"about_ca_system_score_codex":0.0019771436,"about_ca_system_score_gemma":0.0011945394,"threshold_uncertainty_score":0.03280896},"labels":[],"label_agreement":null},{"id":"W2922063178","doi":"10.1093/annonc/mdx440.048","title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Hazard ratio; Clinical endpoint; Population; Melanoma; Stage (stratigraphy); Randomized controlled trial; Oncology; Gastroenterology; Surgery; Cancer; Confidence interval; Immunotherapy","score_opus":0.24749111930518156,"score_gpt":0.4682165581798732,"score_spread":0.22072543887469162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922063178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915087,0.003118745,0.0005493683,0.0005015828,0.0004798629,0.0013479731,0.0007175775,0.00014424423,0.001631954],"genre_scores_gemma":[0.9886614,0.0021075122,0.0014143353,0.00085955905,0.0003284424,0.0020157504,0.0010251397,0.000039642,0.0035481763],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997218,0.00012163055,0.000012244447,0.00006677872,0.000016682823,0.00006084274],"domain_scores_gemma":[0.99943155,0.00015756917,0.000110665795,0.000048460694,0.00002256623,0.00022916953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011486658,0.0012970738,0.0023058974,0.00033586912,0.0003291709,0.00087452226,0.00081289746,0.0012811341,0.005194264],"category_scores_gemma":[0.0009683496,0.00052019884,0.0015539335,0.00030129982,0.00090937,0.0008851662,0.00034563654,0.0029622992,0.0009514594],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9635579,0.0064038755,0.0004678897,0.00048477625,0.0005765572,0.000022324039,0.000045900404,0.0006217032,0.0034894205,0.0001044147,0.0010869891,0.023138333],"study_design_scores_gemma":[0.9255592,0.07091315,0.0013179352,0.000030066616,0.00034904678,0.00002410765,0.000017649532,0.000588269,0.00053098256,0.00013838218,0.00051740446,0.000013783629],"about_ca_topic_score_codex":0.001169019,"about_ca_topic_score_gemma":0.002857303,"teacher_disagreement_score":0.005194264,"about_ca_system_score_codex":0.00072869804,"about_ca_system_score_gemma":0.0011063588,"threshold_uncertainty_score":0.017376602},"labels":[],"label_agreement":null},{"id":"W2923979336","doi":"10.1111/cei.13297","title":"Methods to manufacture regulatory T cells for cell therapy","year":2019,"lang":"en","type":"review","venue":"Clinical & Experimental Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Networks of Centres of Excellence of Canada; Canadian Institutes of Health Research; BC Children’s Hospital Foundation; Canadian Donation and Transplantation Research Program","keywords":"Clinical trial; Cell therapy; Medicine; Genome editing; Disease; Genetic enhancement; Regulatory T cell; Immunology; T cell; Cell; Immune system; Computational biology; Genome; Biology; Gene; Internal medicine; Genetics","score_opus":0.26687176563560006,"score_gpt":0.5797990509666617,"score_spread":0.3129272853310617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923979336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051934464,0.98623985,0.004068059,0.00044438956,0.0007489054,0.00006448251,0.00010242553,0.00005764003,0.007754975],"genre_scores_gemma":[0.0024757527,0.98833126,0.004523766,0.00042055393,0.0003148332,0.000084816485,0.00019643299,0.000017088485,0.0036354335],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995685,0.00007212106,0.000050918556,0.00006664119,0.00021493378,0.000026837748],"domain_scores_gemma":[0.9997527,0.00012376676,0.000031676536,0.000014117383,0.000066705106,0.000010969619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008707257,0.000955178,0.0011003761,0.0025785877,0.00024101348,0.0010781562,0.00069773546,0.0009097418,0.0046723443],"category_scores_gemma":[0.00058696425,0.00031189717,0.0006186928,0.001376815,0.0004762936,0.0010328621,0.00057525776,0.0019887488,0.005165216],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055363616,0.000103820246,0.000112044676,0.023594253,0.00008128547,0.00023607924,0.00008841353,0.00069038774,0.028682303,0.016460255,0.025510473,0.9043852],"study_design_scores_gemma":[0.000010859931,0.000080040496,0.00017902804,0.0013780196,0.00004637299,0.000536553,0.000023222068,0.00009458646,0.0063389926,0.00220956,0.9890859,0.000016938506],"about_ca_topic_score_codex":0.0005499369,"about_ca_topic_score_gemma":0.0005810158,"teacher_disagreement_score":0.0046723443,"about_ca_system_score_codex":0.00047289726,"about_ca_system_score_gemma":0.0007582306,"threshold_uncertainty_score":0.015630543},"labels":[],"label_agreement":null},{"id":"W2924424204","doi":"10.1126/scitranslmed.aar5012","title":"Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy","year":2019,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"H2020 European Research Council; Instituto de Salud Carlos III; Fonds de Recherche du Québec - Santé; Fundación Fero; Ministerio de Economía y Competitividad; Worldwide Cancer Research; Fundación BBVA","keywords":"Proof of concept; Cell; Medicine; Chemistry; Cancer research; Computer science; Biochemistry","score_opus":0.04406228012434552,"score_gpt":0.337331160789339,"score_spread":0.29326888066499346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924424204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7627163,0.016627025,0.2028325,0.0020575149,0.0005146255,0.0006086656,0.001324328,0.0009085036,0.01241048],"genre_scores_gemma":[0.95665276,0.0048890514,0.03290699,0.00029014444,0.00005416367,0.00016048778,0.00058707653,0.000057308218,0.004401869],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982786,0.000043606935,0.000009510585,0.000030109957,0.00005826095,0.000030571286],"domain_scores_gemma":[0.9998841,0.00003013561,0.000029772593,0.00001459878,0.000015361438,0.000025993539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038290577,0.00043562308,0.00033675018,0.00016733987,0.00013153566,0.00059603417,0.00031885473,0.00078889105,0.0014308786],"category_scores_gemma":[0.0002470797,0.0001348569,0.00027612998,0.00011412173,0.0004094853,0.00047658535,0.00032055,0.0013027976,0.00057134783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009742443,0.000043851738,0.000055636745,0.0001012338,0.000006898462,0.00009655386,0.000022929373,0.00014263613,0.99241525,0.0016599264,0.00021288748,0.005144758],"study_design_scores_gemma":[0.000026554962,0.0007825744,0.00037914747,0.000018787687,0.000020196421,0.000543185,0.000017170389,0.00090332865,0.98085016,0.00036364223,0.01608817,0.000007032789],"about_ca_topic_score_codex":0.000111906345,"about_ca_topic_score_gemma":0.00016020541,"teacher_disagreement_score":0.0014308786,"about_ca_system_score_codex":0.0002653899,"about_ca_system_score_gemma":0.00020199342,"threshold_uncertainty_score":0.00478673},"labels":[],"label_agreement":null},{"id":"W2926447864","doi":"10.1097/hs9.0000000000000185","title":"CAR‐T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Therakos; Celgene; Mallinckrodt Pharmaceuticals; Gilead Sciences; Sanofi; AOP Orphan; GlaxoSmithKline; Amgen","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Lymphoma; Hematopoietic stem cell transplantation; Cell therapy; Clinical trial; Oncology; Transplantation; Immunotherapy; Adverse effect; Blinatumomab; Immunology; Internal medicine; Stem cell; CD19; Antigen; Immune system; Biology","score_opus":0.05290399143292113,"score_gpt":0.3387629218292847,"score_spread":0.28585893039636356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926447864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00054494804,0.99716455,0.00019519565,0.0009317731,0.00037243636,0.000008053875,0.000024561748,0.000009031231,0.0007494072],"genre_scores_gemma":[0.0033741947,0.99228644,0.00037058862,0.0017882236,0.0010188578,0.000021749356,0.000072158626,0.000005498396,0.0010622666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977726,0.00006647305,0.000036527083,0.000028422646,0.00006678141,0.00002464706],"domain_scores_gemma":[0.99959606,0.00021816322,0.00006142728,0.000012497313,0.00007483287,0.000037114016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009646487,0.00045804447,0.0007584846,0.0008357821,0.00014585533,0.0007922639,0.00045754464,0.0009757585,0.0021012393],"category_scores_gemma":[0.00077812007,0.00012849811,0.0005470763,0.00070965046,0.00030396,0.0012517984,0.0003676786,0.0015012245,0.0009123477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032279638,0.000118544,0.00020988662,0.008602524,0.00011516017,0.0002415285,0.000064091706,0.0004683675,0.0025748168,0.0020668518,0.030550335,0.9546651],"study_design_scores_gemma":[0.00022705585,0.0012767045,0.0017900325,0.005510658,0.00039573078,0.0021182117,0.00009336259,0.00036239123,0.0012406236,0.0032493959,0.98370117,0.0000346627],"about_ca_topic_score_codex":0.00027624692,"about_ca_topic_score_gemma":0.0006772778,"teacher_disagreement_score":0.0021012393,"about_ca_system_score_codex":0.00026361027,"about_ca_system_score_gemma":0.00041819387,"threshold_uncertainty_score":0.0070293546},"labels":[],"label_agreement":null},{"id":"W2928326859","doi":"10.1158/2326-6066.cir-18-0013","title":"Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institutes of Health; Oncolytics Biotech; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Phenotype; Immunotherapy; Cancer research; Cell culture; Cell; Biology; Immunology; Medicine; Cancer; Genetics; Gene","score_opus":0.0742356342109851,"score_gpt":0.36868867120983173,"score_spread":0.2944530369988466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928326859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960765,0.00036213908,0.0025201489,0.000049119455,0.000013685376,0.000035863774,0.00011163561,0.000098382036,0.0007324583],"genre_scores_gemma":[0.9971624,0.00014588708,0.0016802707,0.000031139218,0.0000053891526,0.000024725692,0.00013394182,0.000032325912,0.00078394666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997613,0.000047633996,0.000036819474,0.00004432446,0.000054167085,0.000055871715],"domain_scores_gemma":[0.99972075,0.00008239797,0.000077614706,0.000040504303,0.000024106916,0.000054635435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017106108,0.00028020056,0.0004271916,0.00016658193,0.00009775819,0.00033426203,0.00020040078,0.00034023874,0.0010624491],"category_scores_gemma":[0.00021812244,0.00012947332,0.00017001355,0.000102870945,0.00016978123,0.00013778871,0.00020607165,0.0007364643,0.0004355527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034928544,0.000022657407,0.000087230255,0.000008693033,0.000002073259,0.0000125768165,0.000004453452,0.000083266415,0.9993173,0.00004426005,0.000017638657,0.0003650029],"study_design_scores_gemma":[0.000013671237,0.00032184387,0.0012364764,0.0000036714348,0.00000788369,0.0001576266,0.0000090337135,0.0018612228,0.9956938,0.000028833325,0.0006631937,0.000002738796],"about_ca_topic_score_codex":0.0003723071,"about_ca_topic_score_gemma":0.00044527082,"teacher_disagreement_score":0.0010624491,"about_ca_system_score_codex":0.00037978822,"about_ca_system_score_gemma":0.00015960862,"threshold_uncertainty_score":0.0035542846},"labels":[],"label_agreement":null},{"id":"W2936379593","doi":"10.1016/j.joca.2019.02.011","title":"Safe cell and gene therapy combination: are we there yet in arthritis?","year":2019,"lang":"en","type":"article","venue":"Osteoarthritis and Cartilage","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Arthritis; Induced pluripotent stem cell; Medicine; Genetic enhancement; Disease; Computational biology; Bioinformatics; Cell; Cancer research; Gene; Immunology; Biology; Internal medicine; Genetics; Embryonic stem cell","score_opus":0.015076649275773466,"score_gpt":0.2535215225541983,"score_spread":0.23844487327842484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936379593","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028086124,0.75077,0.016507749,0.18245722,0.007472793,0.00028705527,0.0005868629,0.0004541218,0.013378126],"genre_scores_gemma":[0.28655702,0.5170769,0.04040818,0.10712176,0.018487424,0.001213882,0.0011560927,0.00031086005,0.02766784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965766,0.0013645326,0.0003411587,0.0003252625,0.000880717,0.00051175],"domain_scores_gemma":[0.9912407,0.005175,0.0011114646,0.00044183584,0.001211374,0.00081958284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012306071,0.0010625594,0.005053104,0.0009642623,0.00094137783,0.0062733493,0.0021039725,0.0056080176,0.026785612],"category_scores_gemma":[0.007923021,0.0006368497,0.0018314203,0.0009241359,0.0031467522,0.010963082,0.0016076281,0.0075871083,0.0049194284],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072140973,0.00241978,0.005751646,0.0054497463,0.0014328848,0.0008007763,0.00039929853,0.0012731161,0.016992977,0.026147546,0.07608921,0.856029],"study_design_scores_gemma":[0.004378122,0.01900927,0.010859537,0.010367095,0.0043295706,0.0045625116,0.0037427654,0.0033421745,0.022102617,0.0768989,0.83989865,0.00050884276],"about_ca_topic_score_codex":0.0010042976,"about_ca_topic_score_gemma":0.00469543,"teacher_disagreement_score":0.026785612,"about_ca_system_score_codex":0.0012697768,"about_ca_system_score_gemma":0.004726902,"threshold_uncertainty_score":0.08960682},"labels":[],"label_agreement":null},{"id":"W2936424103","doi":"10.1007/978-3-030-11769-6_26","title":"Novel Therapies in Paediatric NHL","year":2019,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Chimeric antigen receptor; Immunotherapy; Refractory (planetary science); Disease; Oncology; Clinical trial; Intensive care medicine; Internal medicine; Cancer","score_opus":0.04353536456719345,"score_gpt":0.2996625126831642,"score_spread":0.2561271481159707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936424103","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014572751,0.55484456,0.0072525996,0.0106037045,0.005845793,0.00006166729,0.00022590476,0.00020907086,0.4194994],"genre_scores_gemma":[0.01269456,0.36778936,0.0077128,0.009514323,0.0039372207,0.00013105458,0.0003471725,0.00013884655,0.59773463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991655,0.000022514227,0.0000035944586,0.000009181845,0.00003725267,0.000010821777],"domain_scores_gemma":[0.9999118,0.000054928332,0.0000055869973,0.0000051184265,0.000010869459,0.00001170699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030049513,0.00037123624,0.0002920882,0.00061153434,0.00026705422,0.00093754765,0.0004364654,0.0008108381,0.030478388],"category_scores_gemma":[0.00037336204,0.00017544554,0.0002249811,0.0003741989,0.00038271453,0.0009489151,0.00078702666,0.0020842557,0.009754917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003954706,0.00006585895,0.000074106625,0.0007916701,0.000010282716,0.000343343,0.00013992064,0.0007520855,0.0027256366,0.061019998,0.32214236,0.61189514],"study_design_scores_gemma":[0.0000040820955,0.000013573947,0.000055427485,0.00018734488,0.0000022122965,0.00039746024,0.000012539466,0.000056046145,0.00029088827,0.005289654,0.99368876,0.000001967777],"about_ca_topic_score_codex":0.00050259964,"about_ca_topic_score_gemma":0.0018786177,"teacher_disagreement_score":0.030478388,"about_ca_system_score_codex":0.0007020208,"about_ca_system_score_gemma":0.0004418936,"threshold_uncertainty_score":0.10196036},"labels":[],"label_agreement":null},{"id":"W2936882789","doi":"10.1186/s13046-019-1126-y","title":"Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade","year":2019,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; Toronto General Hospital; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research; University Health Network; People's Government of Jilin Province; Canadian Cancer Society; National Natural Science Foundation of China","keywords":"Blockade; Immune checkpoint; Stage (stratigraphy); Medicine; Cancer research; PD-L1; Oncology; Apoptosis; Lung cancer; Pharmacology; Cancer; Internal medicine; Chemistry; Biology; Receptor; Immunotherapy; Biochemistry","score_opus":0.10535085609553471,"score_gpt":0.4687386574166479,"score_spread":0.36338780132111315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936882789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878421,0.0046923743,0.005139971,0.00013438365,0.00004602179,0.000113251874,0.00009468019,0.000067183646,0.0018700698],"genre_scores_gemma":[0.99446917,0.0016340318,0.0028610853,0.00006375743,0.000025630794,0.000058639995,0.00015841528,0.0000044065177,0.0007248991],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999312,0.000011083263,0.000006748636,0.000016205959,0.000019088076,0.000015666319],"domain_scores_gemma":[0.9999645,0.0000070011533,0.000007942507,0.0000051519005,0.0000033900533,0.0000119899905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012684234,0.0003296162,0.00029863615,0.00021060878,0.00009125159,0.00029944585,0.00018072438,0.00018945006,0.0005916094],"category_scores_gemma":[0.00006986091,0.00006222103,0.00019592691,0.00012431815,0.00014117437,0.00014247315,0.00017359859,0.00032781236,0.00013285481],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068183383,0.00082435005,0.0033202951,0.0002599744,0.00004331084,0.00028898125,0.000036813286,0.0012958146,0.94585884,0.000428779,0.00034447774,0.046616577],"study_design_scores_gemma":[0.0006134565,0.012955282,0.015933529,0.0000552498,0.00022530946,0.005680654,0.000059296155,0.007101299,0.9380535,0.00034208302,0.018962739,0.000017541253],"about_ca_topic_score_codex":0.00015355756,"about_ca_topic_score_gemma":0.0004990746,"teacher_disagreement_score":0.0005916094,"about_ca_system_score_codex":0.00020866471,"about_ca_system_score_gemma":0.00020492579,"threshold_uncertainty_score":0.0019791126},"labels":[],"label_agreement":null},{"id":"W2936913202","doi":"10.1182/bloodadvances.2018030577","title":"Targeting CD47 in Sézary syndrome with SIRPαFc","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"National Cancer Institute","keywords":"CD47; Phagocytosis; Lymphoma; Decoy; Medicine; Cutaneous T-cell lymphoma; Cancer research; Immunology; Receptor; Internal medicine; Mycosis fungoides","score_opus":0.009672638446286328,"score_gpt":0.2801466938646356,"score_spread":0.27047405541834924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936913202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786699,0.015467654,0.0013131427,0.00066712114,0.00007806088,0.00014639265,0.00010106686,0.00008646471,0.0034702714],"genre_scores_gemma":[0.99374855,0.004094777,0.00062465563,0.00019568093,0.00003223688,0.000078755285,0.0001678548,0.000005732873,0.0010517196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992895,0.000023899005,0.000005192415,0.0000069628986,0.000012596931,0.000022262986],"domain_scores_gemma":[0.99996316,0.0000080937425,0.000010536657,0.000004468293,0.0000024936035,0.000011270018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025453517,0.00023818329,0.00042864625,0.00015146192,0.00008690552,0.00030016585,0.00017182285,0.00034053857,0.0012073732],"category_scores_gemma":[0.00012713573,0.00007717326,0.0002441639,0.00017083873,0.00024600243,0.00019344414,0.00018268371,0.00055073627,0.00039116654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026685718,0.0021147502,0.011784825,0.0009914967,0.00030702897,0.0045138835,0.00025440974,0.0024199968,0.626995,0.0030692369,0.005591069,0.31527248],"study_design_scores_gemma":[0.032379147,0.10710883,0.07037658,0.00039272368,0.0013376962,0.034230504,0.00060724246,0.01793138,0.55987257,0.002838822,0.1728495,0.00007493658],"about_ca_topic_score_codex":0.00031545223,"about_ca_topic_score_gemma":0.0006782034,"teacher_disagreement_score":0.0012073732,"about_ca_system_score_codex":0.00024223884,"about_ca_system_score_gemma":0.00022805177,"threshold_uncertainty_score":0.0040391088},"labels":[],"label_agreement":null},{"id":"W2939487002","doi":"10.1080/14712598.2019.1608179","title":"Facing the future: challenges and opportunities in adoptive T cell therapy in cancer","year":2019,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Chimeric antigen receptor; T cell; Cancer immunotherapy; Context (archaeology); Medicine; Adoptive cell transfer; Cell therapy; Cancer; Cancer research; Immune system; Immunology; Cell; Biology; Internal medicine","score_opus":0.5050365452917507,"score_gpt":0.4602758091893972,"score_spread":0.04476073610235348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939487002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007765097,0.994409,0.00023195014,0.003588838,0.00080086815,0.000003814096,0.000012623598,0.000009354171,0.0008658545],"genre_scores_gemma":[0.0007705252,0.99551195,0.00026030783,0.001877766,0.0009224653,0.000008083235,0.000022431388,0.0000020966988,0.0006243508],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99963164,0.000111097004,0.000028244502,0.000047776397,0.00013676967,0.00004444264],"domain_scores_gemma":[0.99931586,0.00036112673,0.000056127355,0.000015477755,0.00019518017,0.00005631694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013585996,0.00053429726,0.0009612504,0.0009939602,0.00025523992,0.0011857225,0.0008615169,0.0021326025,0.003995888],"category_scores_gemma":[0.0010584681,0.00017749803,0.0006399375,0.0009643096,0.00074982404,0.0022651798,0.00068862183,0.0037794132,0.0022996014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008374517,0.000063506086,0.00009480092,0.012746504,0.0000636496,0.00020224253,0.0000934736,0.00052239804,0.0021721825,0.0112078935,0.08845168,0.8842978],"study_design_scores_gemma":[0.000021056721,0.000092052884,0.00021764608,0.002970124,0.000042911288,0.00047795664,0.00007973095,0.00013483701,0.00025813002,0.0055573396,0.9901335,0.000014706186],"about_ca_topic_score_codex":0.0008627915,"about_ca_topic_score_gemma":0.0018686125,"teacher_disagreement_score":0.003995888,"about_ca_system_score_codex":0.00085470185,"about_ca_system_score_gemma":0.0014431565,"threshold_uncertainty_score":0.013367593},"labels":[],"label_agreement":null},{"id":"W2942462405","doi":"10.1093/neuonc/noz036.126","title":"IMMU-05. COMBINATIONAL CAR T-CELL AND EPIGENETIC MODIFIER THERAPY TO TARGET POSTERIOR FOSSA TUMORS","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Medicine; Oncology; Internal medicine; Ependymoma; Cancer research; Gastroenterology; Surgery","score_opus":0.02445736219046114,"score_gpt":0.31455335705601534,"score_spread":0.2900959948655542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942462405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90055454,0.026410533,0.009814645,0.002302946,0.0010312089,0.0014542114,0.003832793,0.002193756,0.052405283],"genre_scores_gemma":[0.9540852,0.0078029903,0.009804771,0.0011475227,0.0002478487,0.0011767313,0.005651015,0.00009994978,0.019983929],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99964094,0.00007291855,0.000016597149,0.000076900644,0.000102016216,0.00009070603],"domain_scores_gemma":[0.9998473,0.000028810593,0.000021692567,0.000022309987,0.000015221331,0.00006465368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072306686,0.00067992357,0.00075954205,0.0006326727,0.00028754713,0.0010105608,0.0007284279,0.0011379849,0.0049061924],"category_scores_gemma":[0.00024239825,0.00024007178,0.0006962217,0.00041217526,0.0005425597,0.0004334042,0.00046030132,0.0026834346,0.0016188287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014412663,0.012959274,0.0042578657,0.0015450673,0.00063521287,0.0008082217,0.00035445567,0.005325963,0.63461566,0.007733541,0.020911988,0.29644006],"study_design_scores_gemma":[0.009270172,0.08537929,0.012994375,0.00018301436,0.00085276423,0.0036227289,0.00017684224,0.01029748,0.7194744,0.0015846747,0.15609048,0.000073813724],"about_ca_topic_score_codex":0.001368377,"about_ca_topic_score_gemma":0.0032949804,"teacher_disagreement_score":0.0049061924,"about_ca_system_score_codex":0.0010988185,"about_ca_system_score_gemma":0.0011188564,"threshold_uncertainty_score":0.016412914},"labels":[],"label_agreement":null},{"id":"W2943387000","doi":"10.1101/625285","title":"Efficient and robust NK-Cell transduction with Baboon Envelope pseudotyped lentivector: a major tool for immunotherapy","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation ARC pour la Recherche sur le Cancer; Institut National de la Santé et de la Recherche Médicale","keywords":"Biology; Vesicular stomatitis virus; Transduction (biophysics); Baboon; CD19; Virology; Measles virus; Cell culture; Molecular biology; Antigen; Immunology; Virus; Genetics","score_opus":0.017089277477769473,"score_gpt":0.2381834091941415,"score_spread":0.22109413171637202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943387000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87527305,0.0049581816,0.112360105,0.0004058046,0.00019115237,0.00046127624,0.001123226,0.0012661486,0.0039611356],"genre_scores_gemma":[0.9648101,0.0017879881,0.026601736,0.000102274,0.000034362405,0.00022337268,0.001170618,0.00016129843,0.005108081],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99960023,0.00008533382,0.000050957384,0.00007296205,0.000121217665,0.000069317706],"domain_scores_gemma":[0.9998796,0.000022157106,0.00002478503,0.000027324912,0.00001905888,0.000027012544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046655265,0.00047210586,0.00047952277,0.0002364528,0.00013995825,0.0006211826,0.00029233782,0.00031985398,0.0011868039],"category_scores_gemma":[0.00018866465,0.00017141113,0.00020997156,0.0001813337,0.00029190417,0.00031413234,0.00042306588,0.0012365167,0.0008498354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026803615,0.000020668424,0.0000681767,0.000028218099,0.0000037609962,0.000018052697,0.000008669314,0.000061398045,0.9978727,0.000107729385,0.00005582779,0.0017280597],"study_design_scores_gemma":[0.000020164394,0.00024500734,0.0012490972,0.00000983835,0.000018803405,0.0003427813,0.000013024252,0.0015845685,0.9910453,0.00007213438,0.0053935274,0.000005737017],"about_ca_topic_score_codex":0.00026153494,"about_ca_topic_score_gemma":0.0002544527,"teacher_disagreement_score":0.0011868039,"about_ca_system_score_codex":0.00020529424,"about_ca_system_score_gemma":0.00017557088,"threshold_uncertainty_score":0.003970325},"labels":[],"label_agreement":null},{"id":"W2947005140","doi":"10.1200/jco.2019.37.15_suppl.e14220","title":"MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada); Université de Montréal","funders":"","keywords":"IL-2 receptor; Cytotoxic T cell; Cancer research; CD8; Interleukin 2; Cytokine; Immunotherapy; Tumor microenvironment; Medicine; T cell; In vivo; Immune system; Immunology; Molecular biology; Biology; In vitro; Biochemistry","score_opus":0.0849344890506948,"score_gpt":0.4362207527314609,"score_spread":0.3512862636807661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947005140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972537,0.00070149964,0.0007685833,0.00004663205,0.000022736922,0.00002726043,0.00014337352,0.00004400162,0.0009921737],"genre_scores_gemma":[0.9970836,0.00021697949,0.0012811726,0.000026891936,0.000005365845,0.000023339397,0.00021976237,0.000009161298,0.0011336897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999292,0.000017145901,0.000006392789,0.00001480874,0.000016309417,0.000016033886],"domain_scores_gemma":[0.9999312,0.000016255786,0.000018475954,0.0000046987975,0.000004967749,0.000024330462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092329785,0.00024251059,0.0001022702,0.00007026452,0.000047917627,0.00013149729,0.000116550116,0.00019725157,0.0010847884],"category_scores_gemma":[0.000085717526,0.00005103655,0.00008304588,0.000051567215,0.000102204685,0.0001031815,0.000097179785,0.00033424897,0.00021452397],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015931892,0.000050207807,0.000051402374,0.000019768155,0.0000016368606,0.000018248811,0.000004789439,0.00006233755,0.9988456,0.000025031099,0.000025460417,0.00073614356],"study_design_scores_gemma":[0.000033232507,0.0007370139,0.0007009889,0.0000020784146,0.0000052275313,0.000104474486,0.0000049513765,0.0005548815,0.99685043,0.000008064471,0.000996719,0.0000018750483],"about_ca_topic_score_codex":0.00023122212,"about_ca_topic_score_gemma":0.0002641993,"teacher_disagreement_score":0.0010847884,"about_ca_system_score_codex":0.0001617727,"about_ca_system_score_gemma":0.00009725349,"threshold_uncertainty_score":0.0036289096},"labels":[],"label_agreement":null},{"id":"W2947087421","doi":"10.1200/jco.2019.37.15_suppl.2537","title":"Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fludarabine; Immunology; Cyclophosphamide; Adoptive cell transfer; Cytokine release syndrome; Internal medicine; T cell; Immune system; Chemotherapy; Chimeric antigen receptor","score_opus":0.09368089686190016,"score_gpt":0.47088243630873095,"score_spread":0.37720153944683077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947087421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979152,0.0006273561,0.00018143882,0.00006257168,0.00004999575,0.00008555774,0.00012975061,0.000033930337,0.0009142466],"genre_scores_gemma":[0.9982418,0.00024654838,0.00037689414,0.00006226222,0.00002804005,0.00008066617,0.00034033897,0.000008111418,0.0006153004],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99981385,0.000062163606,0.000016297463,0.00002828092,0.000024902,0.000054534845],"domain_scores_gemma":[0.99962234,0.00012874117,0.00006445674,0.000029407143,0.000016036673,0.00013889726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037913688,0.0003855055,0.0004404062,0.00020454278,0.00016742111,0.0003372038,0.000357452,0.00046324078,0.0022375728],"category_scores_gemma":[0.00045005104,0.00013764517,0.00024601415,0.00013063346,0.00039425507,0.00029751903,0.00018317453,0.0011550362,0.0003925504],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08309458,0.025029821,0.0033213063,0.00045186086,0.00014208951,0.00033493145,0.0002933997,0.0019464808,0.8136306,0.000577986,0.0017196168,0.069457345],"study_design_scores_gemma":[0.010651829,0.3618646,0.027226921,0.00007967202,0.00032995906,0.0010508241,0.00013028366,0.003914596,0.5881476,0.00015648239,0.006408113,0.000039161696],"about_ca_topic_score_codex":0.00046336488,"about_ca_topic_score_gemma":0.0010055687,"teacher_disagreement_score":0.0022375728,"about_ca_system_score_codex":0.0002533278,"about_ca_system_score_gemma":0.00046243207,"threshold_uncertainty_score":0.0074853897},"labels":[],"label_agreement":null},{"id":"W2947759305","doi":"10.1200/jco.2019.37.15_suppl.9504","title":"United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Discontinuation; Ipilimumab; Adverse effect; Placebo; Adjuvant; Hazard ratio; Randomized controlled trial; Intention-to-treat analysis; Oncology; Gastroenterology; Surgery; Cancer; Confidence interval; Immunotherapy; Pathology","score_opus":0.1243248276908649,"score_gpt":0.49600989343293717,"score_spread":0.3716850657420723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947759305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9565325,0.0060916566,0.0015739953,0.002108614,0.00079320604,0.015817003,0.008081375,0.0002708574,0.00873086],"genre_scores_gemma":[0.9520124,0.0040387986,0.004673858,0.004366139,0.0005458494,0.015365542,0.0068776617,0.00008937955,0.012030265],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99903655,0.0006934475,0.000041102314,0.00008482278,0.00006132099,0.000082840954],"domain_scores_gemma":[0.999215,0.00016835022,0.00019417131,0.00006545253,0.000044497297,0.00031247374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040643876,0.0015967549,0.0012882561,0.00059326185,0.0004280409,0.0007888437,0.0010146628,0.0014812689,0.009976569],"category_scores_gemma":[0.0015226993,0.000748992,0.0014010399,0.0004930045,0.000817669,0.0007065204,0.00053560105,0.0033678878,0.001782518],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9274067,0.023777857,0.0027311519,0.0006924819,0.0012839942,0.00008190455,0.00008970235,0.00058178004,0.007260405,0.0004193091,0.0066625634,0.029012145],"study_design_scores_gemma":[0.9255773,0.066058986,0.0033064927,0.000051014806,0.0004998524,0.000077693825,0.000025590256,0.0004481227,0.000839171,0.00015372643,0.0029459628,0.000016089609],"about_ca_topic_score_codex":0.00095507153,"about_ca_topic_score_gemma":0.002933484,"teacher_disagreement_score":0.009976569,"about_ca_system_score_codex":0.0008461342,"about_ca_system_score_gemma":0.0015504026,"threshold_uncertainty_score":0.033374965},"labels":[],"label_agreement":null},{"id":"W2949444368","doi":"10.1097/01.hs9.0000561592.51072.9b","title":"S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM‐151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Essential thrombocythemia; Internal medicine; Randomization; Bone marrow; Polycythemia vera; Gastroenterology; Randomized controlled trial; Anemia","score_opus":0.031235462883460782,"score_gpt":0.3296657506900283,"score_spread":0.2984302878065675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949444368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98987365,0.0010830576,0.00057176634,0.00046043468,0.00024159989,0.0051385364,0.0010204874,0.00013105715,0.0014794919],"genre_scores_gemma":[0.98484194,0.00080403866,0.0017730896,0.0012104902,0.00032051757,0.0071387645,0.001354693,0.000025585992,0.0025308814],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994228,0.00029048804,0.00003364215,0.000112772184,0.00003488765,0.00010547241],"domain_scores_gemma":[0.99922717,0.00015965347,0.0001399707,0.00008431653,0.000058973677,0.00032994983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015705192,0.0017453642,0.0030082348,0.0005097334,0.00046063287,0.0009571794,0.00094891014,0.001861845,0.006899923],"category_scores_gemma":[0.001225181,0.00096250913,0.0016232537,0.00036252956,0.0012484258,0.0011613707,0.00035658816,0.0025815377,0.0011916097],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9515601,0.023455534,0.0008619227,0.00030258743,0.00038917223,0.00006606379,0.00006832489,0.00043762778,0.009153022,0.000120018245,0.0008467349,0.012738872],"study_design_scores_gemma":[0.8812168,0.116400115,0.0012595614,0.000009096157,0.000105298575,0.000031653264,0.0000102421745,0.00021626377,0.00033344215,0.000059739363,0.0003450116,0.0000127888425],"about_ca_topic_score_codex":0.0005090269,"about_ca_topic_score_gemma":0.0013945651,"teacher_disagreement_score":0.006899923,"about_ca_system_score_codex":0.00063763256,"about_ca_system_score_gemma":0.0013893686,"threshold_uncertainty_score":0.023082554},"labels":[],"label_agreement":null},{"id":"W2949669015","doi":"10.1097/01.hs9.0000562584.48238.c8","title":"PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Mycosis fungoides; Internal medicine; Refractory (planetary science); Adverse effect; Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma; Brentuximab vedotin; Oncology; Gastroenterology; T cell; Immunology; Hodgkin lymphoma; Immune system","score_opus":0.010926125519944384,"score_gpt":0.2491841757747903,"score_spread":0.23825805025484592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949669015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217623,0.0025936684,0.00055025064,0.00035524176,0.000045658704,0.00033133177,0.0008194439,0.00012847538,0.002999776],"genre_scores_gemma":[0.99401337,0.0013974565,0.0004375358,0.000328511,0.000043814915,0.00019556422,0.0016279086,0.000027884422,0.0019279283],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997795,0.0000965584,0.000017427092,0.000025101428,0.000034098728,0.000047342754],"domain_scores_gemma":[0.99975437,0.00006565195,0.00004187416,0.000027471722,0.00002243693,0.00008824802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005692388,0.000681816,0.00077856367,0.00024836574,0.00024024765,0.0005147549,0.00043117424,0.0005371942,0.0031938155],"category_scores_gemma":[0.0003892046,0.00019619499,0.0006159821,0.00024524273,0.00034981474,0.0004083704,0.00021340375,0.0019059622,0.0008079696],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15082107,0.03384028,0.0070021194,0.0016830844,0.0011167729,0.0020029137,0.00082983525,0.007481488,0.5258268,0.0004716585,0.009499411,0.25942463],"study_design_scores_gemma":[0.08429776,0.7341218,0.044955153,0.00009066195,0.0010543216,0.0030298147,0.0002649533,0.0048983754,0.1128092,0.00041602727,0.0140049495,0.000056955658],"about_ca_topic_score_codex":0.00091375574,"about_ca_topic_score_gemma":0.0018383091,"teacher_disagreement_score":0.0031938155,"about_ca_system_score_codex":0.0005152595,"about_ca_system_score_gemma":0.00047212187,"threshold_uncertainty_score":0.010684431},"labels":[],"label_agreement":null},{"id":"W2949814266","doi":"10.1002/hon.118_2630","title":"CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Cytokine release syndrome; Medicine; Internal medicine; Refractory (planetary science); Gastroenterology; Clinical endpoint; Lymphoma; Diffuse large B-cell lymphoma; Phases of clinical research; Cytokine; Peripheral T-cell lymphoma; Clinical trial; Immunotherapy; Immunology; T cell; Immune system; Cancer; Biology","score_opus":0.03648638014391697,"score_gpt":0.33761168354361193,"score_spread":0.30112530339969495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949814266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975726,0.0014027699,0.00016418681,0.00004864061,0.000006358623,0.000053786567,0.00025637314,0.000010721528,0.00048466164],"genre_scores_gemma":[0.99848026,0.00032520885,0.00022539002,0.00009734174,0.000018348917,0.000048857986,0.0006620369,0.0000031793481,0.0001394098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994797,0.00023876187,0.00006038216,0.000075196345,0.000095650816,0.000050261584],"domain_scores_gemma":[0.99870455,0.0003051658,0.0005845233,0.00006364433,0.00017193986,0.00017020968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013555565,0.00022331839,0.00055412564,0.00034156375,0.00014945684,0.00045668337,0.00026408874,0.00020891098,0.0006612779],"category_scores_gemma":[0.0012744981,0.00010347817,0.00028137094,0.0004120431,0.0001682151,0.00024977085,0.00023226677,0.00046873806,0.00015517474],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032449823,0.0012248899,0.8463849,0.0003743767,0.00072779873,0.0010136141,0.00027108367,0.0010178405,0.027745126,0.000078777,0.0012417396,0.08746991],"study_design_scores_gemma":[0.0023317204,0.026870696,0.95525867,0.000045437326,0.00057474215,0.0022509224,0.00013821208,0.0017684634,0.006742098,0.000092250586,0.0039015543,0.000025089164],"about_ca_topic_score_codex":0.00035142738,"about_ca_topic_score_gemma":0.00073891215,"teacher_disagreement_score":0.0013555565,"about_ca_system_score_codex":0.00046101527,"about_ca_system_score_gemma":0.00030352213,"threshold_uncertainty_score":0.0071689487},"labels":[],"label_agreement":null},{"id":"W2950210042","doi":"10.1002/hon.119_2630","title":"MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Dosing; Cytokine release syndrome; Adverse effect; Gastroenterology; Chills; Internal medicine; Refractory (planetary science); Toxicity; Lymphoma; Neurotoxicity; Anesthesia; Immunotherapy; Cancer; Chimeric antigen receptor","score_opus":0.021715764776681783,"score_gpt":0.2974048794280057,"score_spread":0.2756891146513239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950210042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99676585,0.0018389834,0.00042886427,0.00005603231,0.0000060892107,0.00012936976,0.00006294429,0.000035458637,0.0006765077],"genre_scores_gemma":[0.99793386,0.00084494747,0.0006791426,0.00006970793,0.000013418033,0.000060731843,0.000119217846,0.000003819954,0.00027518065],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99991727,0.000026330426,0.000009572148,0.000010553451,0.000021407506,0.000014853287],"domain_scores_gemma":[0.999869,0.000033786997,0.000052491974,0.000011894515,0.000011940808,0.000020968584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033162464,0.00022998995,0.00035142372,0.00014514748,0.00013137597,0.00018416964,0.00026374805,0.00017044417,0.00068713765],"category_scores_gemma":[0.00041477985,0.000072961404,0.0001769895,0.00011673241,0.00011501692,0.00018225779,0.00013915557,0.0005175805,0.00015048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014821008,0.0048788236,0.051441018,0.00080208894,0.00038680766,0.001100776,0.00030190643,0.0037038678,0.14747013,0.00012911485,0.002310493,0.772654],"study_design_scores_gemma":[0.01868344,0.26592156,0.5279108,0.00036466419,0.0009510884,0.014059443,0.00022666658,0.010018654,0.1450713,0.0005296821,0.016205467,0.000057217505],"about_ca_topic_score_codex":0.0003023781,"about_ca_topic_score_gemma":0.0011545742,"teacher_disagreement_score":0.00068713765,"about_ca_system_score_codex":0.00024663156,"about_ca_system_score_gemma":0.00022810526,"threshold_uncertainty_score":0.0022987723},"labels":[],"label_agreement":null},{"id":"W2950542774","doi":"10.1097/01.hs9.0000559388.41193.da","title":"PF294 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"","keywords":"Medicine; International Prognostic Index; Internal medicine; Diffuse large B-cell lymphoma; Clinical endpoint; CHOP; Rituximab; Oncology; Lymphoma; Regimen; Gastroenterology; Randomized controlled trial","score_opus":0.01167698582169717,"score_gpt":0.27383872382028873,"score_spread":0.26216173799859155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950542774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975076,0.00140645,0.000058688773,0.00010456829,0.000024376479,0.000053196432,0.00030401474,0.000023840408,0.0005172376],"genre_scores_gemma":[0.99831104,0.00042582085,0.000121617006,0.00012642863,0.000030383178,0.000036080055,0.00058354845,0.0000038940275,0.00036133587],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99985075,0.000069955495,0.000007974967,0.000030517196,0.00001649246,0.000024344588],"domain_scores_gemma":[0.99974734,0.000058500274,0.00008174248,0.000017387769,0.00001670216,0.0000783594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056907034,0.00030702833,0.0006802881,0.00012390286,0.00014162672,0.00045617236,0.00019829629,0.00034957172,0.001371667],"category_scores_gemma":[0.0006641785,0.00012573542,0.00045977635,0.00021442394,0.0001727866,0.00027487366,0.00018159549,0.0007031213,0.00019635557],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5193148,0.010658678,0.21558253,0.0006899952,0.002458662,0.0004670611,0.00022790195,0.0030418418,0.02876607,0.000152125,0.0064723394,0.21216795],"study_design_scores_gemma":[0.07960902,0.26554343,0.6365509,0.00008721602,0.0022366717,0.0011870936,0.00015316234,0.0034888757,0.0042439005,0.0002970643,0.0065614986,0.00004114249],"about_ca_topic_score_codex":0.00056631514,"about_ca_topic_score_gemma":0.0012272368,"teacher_disagreement_score":0.001371667,"about_ca_system_score_codex":0.00032307438,"about_ca_system_score_gemma":0.00032828553,"threshold_uncertainty_score":0.004588723},"labels":[],"label_agreement":null},{"id":"W2950731790","doi":"10.1097/01.hs9.0000562564.17744.e5","title":"PS1067 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF EARLIER STEROID USE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Refractory (planetary science); Cohort; Tocilizumab; Lymphoma; Gastroenterology; Clinical endpoint; Surgery; Oncology; Chimeric antigen receptor; Cancer; Disease; Randomized controlled trial; Immunotherapy","score_opus":0.012470315148255274,"score_gpt":0.23937852626221545,"score_spread":0.22690821111396017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950731790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971499,0.0016100156,0.000078846126,0.00009334038,0.000016987038,0.00007694236,0.00014396031,0.000015500575,0.00081466325],"genre_scores_gemma":[0.99790275,0.00093097147,0.00017884286,0.00014938206,0.0000466261,0.000061017083,0.00032789438,0.0000038632006,0.00039863714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997328,0.00012057996,0.000019570778,0.000036426598,0.000045813278,0.00004493544],"domain_scores_gemma":[0.99961543,0.00010776696,0.000085877204,0.000033969838,0.00002713803,0.00012972625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067823834,0.0003297111,0.00060457626,0.00018720976,0.00014824573,0.0004611722,0.00022138897,0.00020658414,0.00178096],"category_scores_gemma":[0.0007524284,0.00009672511,0.0005429415,0.00027634966,0.00020495999,0.00031288268,0.00020338973,0.00079077086,0.00029532544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31422105,0.023603097,0.11875269,0.0009709466,0.0017102216,0.0007555061,0.00050116744,0.0024151274,0.0332862,0.00013379761,0.0021496324,0.50150055],"study_design_scores_gemma":[0.07884208,0.509132,0.38872644,0.00013295331,0.0022219198,0.0011129774,0.00027496638,0.002348111,0.008233839,0.00021295967,0.008716748,0.00004496966],"about_ca_topic_score_codex":0.00073697895,"about_ca_topic_score_gemma":0.0019364782,"teacher_disagreement_score":0.00178096,"about_ca_system_score_codex":0.00042159337,"about_ca_system_score_gemma":0.00047412748,"threshold_uncertainty_score":0.0059579015},"labels":[],"label_agreement":null},{"id":"W2951090524","doi":"10.1097/01.hs9.0000564792.15111.43","title":"S1636 FRACTIONATED DOSING OF ARI‐0001 CELLS (A3B1:CD8:4–1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Apheresis Group","funders":"","keywords":"Medicine; Cytokine release syndrome; Cyclophosphamide; Fludarabine; Internal medicine; Cohort; Cytokine; CD8; Toxicity; Immunology; Dosing; Gastroenterology; Immune system; Cancer; Chemotherapy; Immunotherapy","score_opus":0.012196298858509851,"score_gpt":0.25969541848738176,"score_spread":0.24749911962887192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951090524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898595,0.00030769283,0.00022685337,0.000027736733,0.000010681701,0.000019574167,0.000045968092,0.000033179396,0.00034228433],"genre_scores_gemma":[0.99889225,0.000101606405,0.00051245675,0.000031821273,0.000012747441,0.000016036029,0.00011714562,0.000004235474,0.00031174545],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999659,0.000006462285,0.000002269813,0.000007778177,0.000005346041,0.0000122331485],"domain_scores_gemma":[0.9998977,0.000014694352,0.000023516648,0.000009983419,0.0000038476373,0.000050347287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117125106,0.00018745643,0.0003599713,0.00009029985,0.00006663031,0.00019095768,0.00018519485,0.0001517616,0.0025323746],"category_scores_gemma":[0.00019230395,0.000057946476,0.00021032161,0.000072464936,0.00013304244,0.00015510936,0.000102274396,0.00046048342,0.00029097366],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05273275,0.013525266,0.035455998,0.0002625931,0.00035864595,0.00036727372,0.00026603887,0.0041608224,0.53439933,0.00046838497,0.003102622,0.35490033],"study_design_scores_gemma":[0.017157096,0.317003,0.41069284,0.00008710782,0.0006902223,0.0032594302,0.00022229383,0.010869404,0.22562788,0.00057894347,0.013755971,0.000055889483],"about_ca_topic_score_codex":0.00035217043,"about_ca_topic_score_gemma":0.00079424813,"teacher_disagreement_score":0.0025323746,"about_ca_system_score_codex":0.00016137322,"about_ca_system_score_gemma":0.0002062653,"threshold_uncertainty_score":0.008471608},"labels":[],"label_agreement":null},{"id":"W2951165653","doi":"10.1097/01.hs9.0000559032.62059.eb","title":"PF204 TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"CD34; CD38; Haematopoiesis; Stem cell; Biology; Cancer research; Myeloid leukemia; Leukemia; Cytotoxic T cell; Cord blood; T-cell receptor; Hematopoietic stem cell; Immunology; T cell; Immune system; Cell biology; In vitro","score_opus":0.02690869596386572,"score_gpt":0.3173762327065463,"score_spread":0.29046753674268055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951165653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920636,0.0020838573,0.0028864443,0.00012152858,0.000028463237,0.000041296786,0.0010963086,0.00015989157,0.0015186373],"genre_scores_gemma":[0.99164647,0.0009859079,0.0034686634,0.0000806525,0.000012853402,0.00007475444,0.0021620314,0.000028106719,0.0015406118],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999012,0.000010281049,0.0000043007644,0.000022391421,0.000033865897,0.00002800765],"domain_scores_gemma":[0.9999683,0.0000074777495,0.000007961206,0.000003098467,0.000006400909,0.0000067397405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000989056,0.00026334325,0.00022589075,0.00026697657,0.00013727516,0.00022583627,0.00014166374,0.00021347478,0.001769394],"category_scores_gemma":[0.00009132742,0.00007629758,0.0001824221,0.0002053336,0.0001247404,0.0001245968,0.00015783038,0.0003810697,0.00046779067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029008457,0.000032234657,0.0004654147,0.000059724163,0.0000058402084,0.00005277837,0.000009391026,0.00035092267,0.994118,0.00006364356,0.00016535204,0.0043865945],"study_design_scores_gemma":[0.000029988953,0.00065741985,0.0043062014,0.000008206001,0.00003293039,0.00036924754,0.000026827012,0.0025820816,0.98710155,0.00009523746,0.00478572,0.000004589802],"about_ca_topic_score_codex":0.00029681018,"about_ca_topic_score_gemma":0.00038006002,"teacher_disagreement_score":0.001769394,"about_ca_system_score_codex":0.00030640632,"about_ca_system_score_gemma":0.00018542279,"threshold_uncertainty_score":0.005919218},"labels":[],"label_agreement":null},{"id":"W2951473081","doi":"10.1002/hon.127_2629","title":"HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Chemoimmunotherapy; Fludarabine; Internal medicine; Lymphoma; Cyclophosphamide; Gastroenterology; Immunotherapy; Oncology; Rituximab; Immunology; Surgery; Chemotherapy; Cancer","score_opus":0.025236009386087662,"score_gpt":0.31089935114862133,"score_spread":0.28566334176253366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951473081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951657,0.0023345924,0.000686977,0.00010712345,0.000009931398,0.00006237364,0.00018763101,0.000039679475,0.0014060669],"genre_scores_gemma":[0.99910396,0.000206156,0.00008181992,0.00007054879,0.000016326105,0.00001869979,0.00024461088,0.0000037803245,0.0002540918],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99961406,0.00013498295,0.0000296984,0.00006731897,0.00008781011,0.00006611992],"domain_scores_gemma":[0.99903464,0.00036396197,0.00025795025,0.00012846648,0.00006151175,0.00015359567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092795154,0.00009687123,0.00036134987,0.00017511529,0.00018133872,0.00023965008,0.00017974585,0.00039225694,0.0020824494],"category_scores_gemma":[0.0017026447,0.0000786416,0.00018164692,0.00018663728,0.00016340424,0.00022755895,0.0002043882,0.00031241262,0.0003429232],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014802517,0.0014884267,0.58115375,0.00039207656,0.000293135,0.003196138,0.00039011694,0.0010366198,0.042941593,0.0002890233,0.0040386617,0.34997788],"study_design_scores_gemma":[0.002211636,0.024981072,0.9237553,0.00006187442,0.00029634623,0.020069692,0.00015319385,0.0021179821,0.014096442,0.0004339207,0.011803791,0.000018719462],"about_ca_topic_score_codex":0.00048680682,"about_ca_topic_score_gemma":0.0004894814,"teacher_disagreement_score":0.0020824494,"about_ca_system_score_codex":0.0002646231,"about_ca_system_score_gemma":0.00021471715,"threshold_uncertainty_score":0.0069664717},"labels":[],"label_agreement":null},{"id":"W2951525681","doi":"10.1016/j.bulcan.2019.05.001","title":"Prise en charge pratique d’une encéphalopathie liée au traitement par cellules CAR-T chez l’adulte et l’enfant : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)","year":2019,"lang":"fr","type":"article","venue":"Bulletin du Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Medicine","score_opus":0.00974675718258218,"score_gpt":0.30659144753831247,"score_spread":0.2968446903557303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951525681","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23010941,0.4695354,0.011824183,0.2236528,0.009034874,0.0003825652,0.0005842684,0.00037233703,0.054504156],"genre_scores_gemma":[0.7654287,0.13689585,0.016191201,0.051382504,0.012373394,0.00036996204,0.0007360272,0.00009609381,0.016526196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99937505,0.00023566787,0.00010826738,0.000049288177,0.000120853685,0.000110937755],"domain_scores_gemma":[0.9969458,0.001257499,0.0006262072,0.00007770139,0.0006590643,0.0004337019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001903474,0.00031594074,0.00064856856,0.00044597793,0.00084720645,0.0016050738,0.00032175664,0.001969414,0.002263202],"category_scores_gemma":[0.0061107855,0.00011513169,0.0005466922,0.00027481915,0.0006221093,0.0009881594,0.00046163556,0.0026212388,0.0005008947],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025376095,0.0006150536,0.06468319,0.0030505056,0.00039403618,0.016381105,0.002328517,0.0006089478,0.019503374,0.005467855,0.09991435,0.7845155],"study_design_scores_gemma":[0.0009849645,0.0041858996,0.13265279,0.011389469,0.0011085465,0.052655343,0.004127103,0.0011911072,0.015254003,0.0067904405,0.76948243,0.00017789188],"about_ca_topic_score_codex":0.0038815252,"about_ca_topic_score_gemma":0.0073951585,"teacher_disagreement_score":0.0038815252,"about_ca_system_score_codex":0.0008655471,"about_ca_system_score_gemma":0.0023562675,"threshold_uncertainty_score":0.010066628},"labels":[],"label_agreement":null},{"id":"W2952255623","doi":"10.1016/j.retram.2019.05.002","title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","year":2019,"lang":"en","type":"article","venue":"Current Research in Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Menzies Centre for Australian Studies, King's College London, University of London; Universitätsklinikum Köln; Hospices Civils de Lyon; King's College London; Vanderbilt University; Moffitt Cancer Center; Knight Cancer Institute, Oregon Health and Science University; Mayo Clinic; King's University College; Centre hospitalier régional universitaire de Lille; Zhejiang University; King Faisal Specialist Hospital and Research Centre; University of Washington; Washington University in St. Louis; Oregon Health and Science University; Memorial Sloan-Kettering Cancer Center; University of Chicago; Fred Hutchinson Cancer Research Center; King’s College Hospital Charity; Vanderbilt University Medical Center","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.21277346737826647,"score_gpt":0.4289146426200575,"score_spread":0.21614117524179105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952255623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925074,0.000248844,0.0001522356,0.000851986,0.00001945099,0.0001323995,0.0030657868,0.0000070695964,0.0030147866],"genre_scores_gemma":[0.99632746,0.00041787312,0.0001879271,0.00067434326,0.000027683847,0.00015251724,0.0014348719,0.0000046193636,0.00077274477],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822956,0.0007962424,0.0003489716,0.00013230699,0.00024704833,0.0002457941],"domain_scores_gemma":[0.99272585,0.001574025,0.0039417446,0.00019741106,0.000663388,0.00089757895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021572136,0.00015466305,0.00021058106,0.0008511714,0.0003245197,0.00057365024,0.00026490304,0.00060264324,0.003921186],"category_scores_gemma":[0.0046316525,0.00017489468,0.00024402264,0.0013116435,0.00031950622,0.00084126246,0.0006790788,0.0006491736,0.0006715716],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003501665,0.00008091835,0.9948251,0.00005079726,0.000012473991,0.00003911765,0.00091969245,0.00002419565,0.00014120003,0.000033290286,0.0010664505,0.0027716875],"study_design_scores_gemma":[0.0000064012665,0.00016111649,0.9954085,0.00003909788,0.000005230075,0.00012255821,0.002339145,0.00008288592,0.000039382958,0.000010226777,0.0017809717,0.0000043801892],"about_ca_topic_score_codex":0.0031846594,"about_ca_topic_score_gemma":0.0024049617,"teacher_disagreement_score":0.003921186,"about_ca_system_score_codex":0.00037224518,"about_ca_system_score_gemma":0.00044068776,"threshold_uncertainty_score":0.013117671},"labels":[],"label_agreement":null},{"id":"W2952294434","doi":"10.1097/01.hs9.0000561352.05716.6c","title":"PF767 PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ONE OR TWO DOSES OF DONOR LYMPHOCYTES DEPLETED OF HOST ALLOREACTIVE T‐CELLS (ATIR101) FOLLOWING T‐CELL‐DEPLETED HAPLOIDENTICAL HSCT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; Immunosuppression; Immune system; T cell; Immunology; Ex vivo; CD34; Stem cell; Transplantation; Haematopoiesis; Clinical endpoint; Internal medicine; Gastroenterology; In vivo; Clinical trial; Biology","score_opus":0.05400656725039787,"score_gpt":0.3857418889832553,"score_spread":0.3317353217328574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952294434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99380165,0.0008726553,0.0006143051,0.00028587398,0.000111551475,0.0021301915,0.00082165725,0.00009296071,0.0012690716],"genre_scores_gemma":[0.9874462,0.0010169635,0.0016929619,0.0006565503,0.00015169621,0.003617674,0.0026090287,0.000026392872,0.0027825166],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995937,0.00018867088,0.000016416563,0.00007491901,0.00003543689,0.000090870395],"domain_scores_gemma":[0.9993253,0.00013368353,0.00013300484,0.00006331485,0.00003939212,0.00030532898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016742535,0.0017773854,0.001637231,0.00048954017,0.0003524695,0.0008934567,0.00080485555,0.0016064508,0.0031219176],"category_scores_gemma":[0.00093966455,0.00048573813,0.00082972087,0.0003444433,0.0012502958,0.000772709,0.0002795239,0.003188834,0.0008597649],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68445545,0.13096468,0.004360229,0.0007758406,0.00090678665,0.00059917656,0.00033807388,0.0066247354,0.089232616,0.00062108226,0.004543105,0.076578245],"study_design_scores_gemma":[0.2880372,0.6986648,0.0037717407,0.000025414067,0.00023688051,0.00033346907,0.00004199997,0.0010359979,0.005924508,0.0001829703,0.0017188501,0.000026119416],"about_ca_topic_score_codex":0.0006178304,"about_ca_topic_score_gemma":0.001295855,"teacher_disagreement_score":0.0031219176,"about_ca_system_score_codex":0.000932864,"about_ca_system_score_gemma":0.0018199432,"threshold_uncertainty_score":0.010443866},"labels":[],"label_agreement":null},{"id":"W2952644065","doi":"10.1097/01.hs9.0000559996.44290.19","title":"PF446 EVALUATING EX VIVO EXPANSION OF FUNCTIONALLY COMPETENT MULTI-SPECIFIC T LYMPHOCYTES TO MINOR HISTOCOMPATIBILITY ANTIGEN FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Minor histocompatibility antigen; Immunology; CD8; T cell; Cytotoxic T cell; Stem cell; Priming (agriculture); Antigen; Haematopoiesis; Major histocompatibility complex; Biology; Cancer research; Immune system; Medicine; In vitro; Cell biology","score_opus":0.12491271604417466,"score_gpt":0.36601823181520166,"score_spread":0.241105515771027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952644065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917413,0.0014790074,0.004573967,0.00008645649,0.000052482945,0.00016950363,0.00018039987,0.0000664383,0.001650477],"genre_scores_gemma":[0.99034506,0.0008847757,0.0059739966,0.00006763826,0.000037080885,0.00018503489,0.0006081534,0.000019282825,0.0018790513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991846,0.000024516976,0.000006107946,0.000011284247,0.000019348507,0.000020390775],"domain_scores_gemma":[0.99995375,0.000012781254,0.000009143344,0.0000050305252,0.00000704851,0.000012188702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016606397,0.00030817554,0.00015254402,0.00014432674,0.0000784985,0.00014704133,0.00015435071,0.00025196033,0.0023545094],"category_scores_gemma":[0.00010658273,0.000049045633,0.00015613533,0.00008135779,0.00008291342,0.00013389501,0.00012739617,0.000519595,0.0004269956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004207897,0.0005261432,0.00023361649,0.00008717214,0.000006054328,0.000060678285,0.00001957803,0.00049959385,0.9897231,0.00010724648,0.00013804277,0.008178038],"study_design_scores_gemma":[0.00022782653,0.009842036,0.0015833189,0.000014118044,0.000050074585,0.00048899493,0.000013806502,0.0019691421,0.98120433,0.00007921337,0.0045222943,0.000004860206],"about_ca_topic_score_codex":0.00007734056,"about_ca_topic_score_gemma":0.00009393739,"teacher_disagreement_score":0.0023545094,"about_ca_system_score_codex":0.000093609306,"about_ca_system_score_gemma":0.00011340121,"threshold_uncertainty_score":0.007876575},"labels":[],"label_agreement":null},{"id":"W2952842269","doi":"10.1182/blood.2019000905","title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Follicular lymphoma; Complete remission; Medicine; Immunotherapy; CD19; Lymphoma; Oncology; Internal medicine; Cancer research; Immunology; Chemotherapy; Cancer; Peripheral blood","score_opus":0.01127728596737254,"score_gpt":0.24931235077624367,"score_spread":0.23803506480887113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952842269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940195,0.0036951783,0.00068165467,0.00011868636,0.000010704921,0.00008001586,0.00017833083,0.000054010812,0.0011619623],"genre_scores_gemma":[0.99872977,0.00030459723,0.0001400059,0.00013185771,0.000020530148,0.000029396833,0.00038242943,0.0000064252354,0.00025499368],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.999585,0.00016180529,0.00003398938,0.00007056922,0.0000742924,0.00007450603],"domain_scores_gemma":[0.99913293,0.00029589888,0.00025274648,0.000109595836,0.00004739356,0.0001614994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010510419,0.00014330373,0.0008046087,0.00019465791,0.00019026705,0.00028957028,0.00017045262,0.00042603503,0.00072371657],"category_scores_gemma":[0.0011888054,0.000087272834,0.00027171284,0.00020873337,0.00019197911,0.00022389468,0.00019321666,0.0004445386,0.00022139086],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039997954,0.0026736488,0.24140114,0.0006769826,0.0006537751,0.002923929,0.0005974667,0.002571843,0.15298018,0.00029031996,0.0042368853,0.55099595],"study_design_scores_gemma":[0.0098687615,0.12555419,0.7845032,0.00010030885,0.00095179374,0.016069673,0.00016246678,0.004357455,0.040864635,0.00043472563,0.01707817,0.000054665074],"about_ca_topic_score_codex":0.000494843,"about_ca_topic_score_gemma":0.00065376103,"teacher_disagreement_score":0.0010510419,"about_ca_system_score_codex":0.00033003028,"about_ca_system_score_gemma":0.00022833353,"threshold_uncertainty_score":0.0055584908},"labels":[],"label_agreement":null},{"id":"W2953056004","doi":"10.1073/pnas.1817255116","title":"A cell topography-based mechanism for ligand discrimination by the T cell receptor","year":2019,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Receptor; Biology; Major histocompatibility complex; Cell biology; T cell; Phosphatase; Cell; Antigen-presenting cell; Phosphorylation; Antigen; Immunology; Immune system; Biochemistry","score_opus":0.03935295177217326,"score_gpt":0.3236934151292771,"score_spread":0.28434046335710383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953056004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8734488,0.0013972071,0.12081388,0.0006071256,0.00008808601,0.000053063697,0.00023789713,0.000367717,0.0029862258],"genre_scores_gemma":[0.99103034,0.00060329057,0.007376935,0.00005883464,0.000010184573,0.000028424372,0.000067433604,0.000018141945,0.00080643484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998859,0.000014551491,0.000004621031,0.0000262524,0.00004812608,0.000020511245],"domain_scores_gemma":[0.9999256,0.000029365612,0.000012775142,0.000014561536,0.0000079912015,0.000009700204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011441822,0.0003626466,0.00029017634,0.0001064381,0.00021431808,0.00040987934,0.00040036178,0.0004897331,0.00080118485],"category_scores_gemma":[0.0003382776,0.0002089064,0.00029703553,0.000120520395,0.0004835881,0.00054916897,0.00022356959,0.00062028895,0.0003008331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043646072,0.000022538492,0.00026988387,0.000044280456,0.000007640706,0.00011125843,0.000020654139,0.011674683,0.9814321,0.0028642693,0.00010745769,0.0034016522],"study_design_scores_gemma":[0.00003745131,0.0002491765,0.0019086458,0.0000046210203,0.000023267381,0.00032572044,0.000027742997,0.23708622,0.75540704,0.0024086542,0.0024864774,0.000035036068],"about_ca_topic_score_codex":0.00046020935,"about_ca_topic_score_gemma":0.00052838045,"teacher_disagreement_score":0.00080118485,"about_ca_system_score_codex":0.00046936807,"about_ca_system_score_gemma":0.00020787814,"threshold_uncertainty_score":0.003405571},"labels":[],"label_agreement":null},{"id":"W2953165127","doi":"10.1002/hon.11_2630","title":"REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Diffuse large B-cell lymphoma; Gene expression profiling; Immunohistochemistry; Germinal center; Concordance; Lymphoma; Gene expression; Biology; Pathology; Medicine; B cell; Gene; Internal medicine; Genetics; Antibody","score_opus":0.06360683452695104,"score_gpt":0.3626921888921254,"score_spread":0.29908535436517436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953165127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895543,0.001177992,0.0062586046,0.00011115695,0.000037662398,0.00009899864,0.00035780686,0.0001474313,0.0022561443],"genre_scores_gemma":[0.9910114,0.00016252667,0.0073571852,0.00005793746,0.000014760101,0.00009829784,0.0006861703,0.000028183598,0.00058353407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990796,0.0002524061,0.00010958476,0.00025005598,0.0001632201,0.00014522593],"domain_scores_gemma":[0.99930716,0.00025918643,0.00015721904,0.0001082243,0.000112709895,0.000055480898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018690092,0.00042046356,0.00054688624,0.001321622,0.00042653971,0.0010275514,0.00045300173,0.00049281074,0.002144715],"category_scores_gemma":[0.0021160287,0.00023761578,0.00052642636,0.0005315613,0.00036882405,0.00040132913,0.00060272054,0.00069775607,0.0006185156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020798007,0.00014357988,0.833488,0.00029758018,0.00017921095,0.00043425336,0.0004894449,0.0017880303,0.106705494,0.000522721,0.0013773585,0.052494604],"study_design_scores_gemma":[0.00010063922,0.0006746293,0.91349846,0.00006840207,0.0002566141,0.0027789553,0.00050591136,0.013929844,0.061297696,0.00060098694,0.0062479526,0.000039828472],"about_ca_topic_score_codex":0.0011599356,"about_ca_topic_score_gemma":0.0018691587,"teacher_disagreement_score":0.002144715,"about_ca_system_score_codex":0.00037906333,"about_ca_system_score_gemma":0.00025800444,"threshold_uncertainty_score":0.009884357},"labels":[],"label_agreement":null},{"id":"W2953176543","doi":"10.71781/26312","title":"Les chambres de leucoréduction sont une nouvelle source de cellules pour la génération de lignées de lymphocytes T en immunothérapie","year":2018,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Université de Montréal; Astellas Pharma; Mitacs","keywords":"Molecular biology; Medicine; Biology","score_opus":0.007830240858498209,"score_gpt":0.21390317420068927,"score_spread":0.20607293334219107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953176543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.908298,0.042090077,0.03421182,0.0010994136,0.0003814468,0.00080050627,0.0011320023,0.00038900523,0.011597764],"genre_scores_gemma":[0.95490265,0.010156255,0.013297819,0.00094536395,0.00013673364,0.0008446,0.0015211025,0.000097149525,0.0180983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926025,0.0002404328,0.00003888264,0.00013208158,0.00023082452,0.000097482836],"domain_scores_gemma":[0.9993948,0.00020911254,0.00008052447,0.00009018029,0.0001447566,0.00008069145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009237671,0.0005102523,0.0007771134,0.00036671644,0.0005926967,0.0010409277,0.00047355492,0.0005467145,0.0065368866],"category_scores_gemma":[0.00080792885,0.00023046035,0.000491911,0.0003366868,0.00042364295,0.000505268,0.00044292156,0.0011337666,0.001718604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022250381,0.0005479563,0.0039688093,0.0010838718,0.00014541567,0.0001434727,0.00039835842,0.0016341052,0.91328067,0.0008180222,0.0013849902,0.074369326],"study_design_scores_gemma":[0.00036055167,0.015249091,0.022376541,0.00030727827,0.0004403418,0.0007216569,0.00048059347,0.002186962,0.8637766,0.0007057341,0.09333751,0.000057118166],"about_ca_topic_score_codex":0.003845619,"about_ca_topic_score_gemma":0.007284127,"teacher_disagreement_score":0.0065368866,"about_ca_system_score_codex":0.0006616372,"about_ca_system_score_gemma":0.00086574303,"threshold_uncertainty_score":0.02186811},"labels":[],"label_agreement":null},{"id":"W2953229874","doi":"10.1002/hon.95_2629","title":"IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Clinical endpoint; Diffuse large B-cell lymphoma; CHOP; Rituximab; Ven; Oncology; Gastroenterology; Venetoclax; Regimen; Lymphoma; Randomized controlled trial; Chronic lymphocytic leukemia; Leukemia","score_opus":0.022662026207577096,"score_gpt":0.32456376199109754,"score_spread":0.3019017357835204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953229874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99772996,0.001355164,0.000061487284,0.00006708816,0.00001590106,0.000062339044,0.0003229338,0.000011646073,0.00037341204],"genre_scores_gemma":[0.99787486,0.0004818327,0.00014749066,0.00014336596,0.000051230723,0.000059847214,0.000969721,0.0000035203088,0.0002680716],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99973243,0.00013227032,0.000014801675,0.00005362481,0.00003193231,0.000034997178],"domain_scores_gemma":[0.9996427,0.000069181435,0.00012494196,0.000035607678,0.000020808791,0.00010667872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008503177,0.00032976453,0.0007053031,0.00014285214,0.0001649918,0.0005446183,0.00027591395,0.00039245046,0.00093784614],"category_scores_gemma":[0.00062697736,0.00019268958,0.00063076,0.00028597342,0.0002642031,0.00033531847,0.000262913,0.00084014895,0.00018522734],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44918746,0.0097320415,0.39948034,0.000789247,0.004071545,0.0004877564,0.0003384285,0.0020019144,0.024826435,0.0001660079,0.0047528623,0.10416606],"study_design_scores_gemma":[0.06321925,0.14332883,0.7817535,0.00007946232,0.0021679967,0.0008473952,0.00016612052,0.0014573026,0.0023519378,0.00016637656,0.0044252127,0.000036591468],"about_ca_topic_score_codex":0.00065128686,"about_ca_topic_score_gemma":0.0015168107,"teacher_disagreement_score":0.00093784614,"about_ca_system_score_codex":0.00037575423,"about_ca_system_score_gemma":0.00033239694,"threshold_uncertainty_score":0.0044969916},"labels":[],"label_agreement":null},{"id":"W2953537665","doi":"10.1200/jco.2019.37.15_suppl.7558","title":"Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Tocilizumab; Internal medicine; Cohort; Clinical endpoint; Transplantation; Surgery; Gastroenterology; Oncology; Chimeric antigen receptor; Cancer; Disease; Randomized controlled trial; Immunotherapy","score_opus":0.05713734364355888,"score_gpt":0.37900502988949414,"score_spread":0.32186768624593526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953537665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507767,0.0023153692,0.00018795002,0.00018152471,0.0000418402,0.00016386571,0.00036005117,0.00003848399,0.0016331357],"genre_scores_gemma":[0.997207,0.0008190527,0.00030141656,0.00026152458,0.000057617937,0.00008381257,0.0005609393,0.0000076254273,0.0007009879],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99966335,0.00015064767,0.000027624059,0.0000547882,0.000047144968,0.000056394907],"domain_scores_gemma":[0.99933654,0.00022208532,0.00013765416,0.0000785111,0.00004293708,0.0001823298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007778268,0.00032785267,0.000652043,0.00017886503,0.0001780542,0.0005322618,0.00027914732,0.00028391532,0.0031513253],"category_scores_gemma":[0.0014474157,0.00011174928,0.0006223613,0.00021429335,0.00024906767,0.00032371044,0.0002374018,0.0008401729,0.0004925346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3708479,0.023191936,0.088063285,0.00096538325,0.0019684418,0.0007090254,0.000477867,0.0015686259,0.03790096,0.00013568,0.0024750652,0.4716959],"study_design_scores_gemma":[0.06989464,0.5907894,0.3080085,0.00015508503,0.0024881023,0.0013143226,0.000309162,0.0018477825,0.011047272,0.0002275126,0.013870041,0.000048249407],"about_ca_topic_score_codex":0.00070888834,"about_ca_topic_score_gemma":0.0019235436,"teacher_disagreement_score":0.0031513253,"about_ca_system_score_codex":0.00040745366,"about_ca_system_score_gemma":0.00042985278,"threshold_uncertainty_score":0.010542214},"labels":[],"label_agreement":null},{"id":"W2954202342","doi":"10.1200/jco.2019.37.15_suppl.7518","title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Dosing; Gastroenterology; Chills; Internal medicine; Refractory (planetary science); Lymphoma; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.045135116611655604,"score_gpt":0.3907390396098182,"score_spread":0.3456039229981626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954202342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962684,0.002281997,0.0005420965,0.00006744894,0.0000069043544,0.00012283746,0.00005755344,0.000030286938,0.0006223955],"genre_scores_gemma":[0.9982291,0.0007380181,0.00062612887,0.00006997797,0.000014398635,0.00004584674,0.000094438874,0.000003547916,0.00017867304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999181,0.000025395266,0.000009117819,0.000010709291,0.000019314797,0.000017449333],"domain_scores_gemma":[0.99985194,0.000031843403,0.000065736545,0.000012686182,0.000010356966,0.00002737815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034832006,0.00028296895,0.0003704938,0.00016296467,0.000143781,0.00017904009,0.0003057075,0.00018522626,0.0005577195],"category_scores_gemma":[0.0004030508,0.000077955956,0.00021914954,0.00012333153,0.00013661037,0.00019455902,0.0001520739,0.0005291248,0.00013888793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018156106,0.0045686373,0.0612283,0.00094247423,0.00052722223,0.0016487462,0.0004132556,0.0043611373,0.1659347,0.00018261917,0.002176096,0.7398607],"study_design_scores_gemma":[0.018766973,0.29880622,0.52112955,0.00032002118,0.0009965955,0.019217603,0.00025729756,0.009851281,0.11236124,0.00057329406,0.017665152,0.000054854216],"about_ca_topic_score_codex":0.00041836812,"about_ca_topic_score_gemma":0.0014560998,"teacher_disagreement_score":0.0005577195,"about_ca_system_score_codex":0.00033162528,"about_ca_system_score_gemma":0.0002673426,"threshold_uncertainty_score":0.0024061203},"labels":[],"label_agreement":null},{"id":"W2954364011","doi":"10.1158/1538-7445.am2019-ct225","title":"Abstract CT225: A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Oncology; Chemotherapy; Immunotherapy; Lung cancer; Phases of clinical research; Cancer; Adverse effect","score_opus":0.03804803893179919,"score_gpt":0.36638646646468603,"score_spread":0.32833842753288683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954364011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819993,0.0014237465,0.00091104215,0.0006667405,0.00026052105,0.009244051,0.0025955553,0.00017472634,0.002724371],"genre_scores_gemma":[0.97706056,0.0010763785,0.0020537742,0.0015749574,0.0003412859,0.010105446,0.0033581858,0.00004421378,0.0043851496],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9992987,0.0003723086,0.000037873284,0.000104959145,0.00004960889,0.00013653985],"domain_scores_gemma":[0.99896765,0.00013761515,0.0001915746,0.00008528111,0.00006304472,0.00055485865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002413393,0.0025266476,0.0019776234,0.00042775317,0.00058142847,0.0013332182,0.0010777566,0.0017829015,0.009973983],"category_scores_gemma":[0.0011593534,0.0007488714,0.0012980063,0.00053858815,0.0013979963,0.0013618317,0.0004979047,0.0034997049,0.0021571429],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91562027,0.044950895,0.0017460806,0.0005317229,0.0008837544,0.00014333316,0.00008930921,0.0007042918,0.018962132,0.00016719098,0.0025357928,0.013665168],"study_design_scores_gemma":[0.7345347,0.26032808,0.0022647611,0.000017996425,0.00029002296,0.000083389874,0.00003089881,0.0003695767,0.001032528,0.000097668046,0.00093398994,0.000016287497],"about_ca_topic_score_codex":0.0014017125,"about_ca_topic_score_gemma":0.0031253013,"teacher_disagreement_score":0.009973983,"about_ca_system_score_codex":0.0012577304,"about_ca_system_score_gemma":0.0021321806,"threshold_uncertainty_score":0.033366263},"labels":[],"label_agreement":null},{"id":"W2955729565","doi":"10.1161/circulationaha.118.034497","title":"Myocarditis in the Setting of Cancer Therapeutics","year":2019,"lang":"en","type":"review","venue":"Circulation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ted Rogers Centre for Heart Research; Canada Research Chairs; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research","keywords":"Medicine; Myocarditis; Clinical trial; Cancer; Incidence (geometry); Disease; Internal medicine; Intensive care medicine; Oncology; Immunology","score_opus":0.151932586011727,"score_gpt":0.439782482553563,"score_spread":0.287849896541836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955729565","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000062159714,0.9990583,0.00004003719,0.0002671062,0.00017172786,0.0000021986878,0.0000032772944,0.0000020051875,0.0003931953],"genre_scores_gemma":[0.0010229923,0.99799013,0.0000792955,0.00036308923,0.00036343443,0.0000045632974,0.00000897043,8.113832e-7,0.00016673672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994286,0.00020426171,0.00009939438,0.00006229749,0.0001660929,0.000039362996],"domain_scores_gemma":[0.99881893,0.00080183934,0.00017026796,0.000025132593,0.00014024439,0.000043526266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097614195,0.0006586635,0.0013968959,0.002048286,0.00028100153,0.0013869889,0.00063339673,0.0014221836,0.0022597646],"category_scores_gemma":[0.0019252974,0.00018981133,0.00072530325,0.0013937048,0.00065558194,0.001354143,0.000741243,0.0022498919,0.0006690619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013205863,0.000057469533,0.00043411544,0.051397376,0.0002599557,0.00074816606,0.00017547597,0.0003915721,0.001020406,0.008609853,0.042921584,0.893852],"study_design_scores_gemma":[0.000059725713,0.00014882318,0.0020643321,0.030742198,0.0003685911,0.007162962,0.0002559387,0.00019816775,0.00046374844,0.0070783296,0.95142084,0.000036372323],"about_ca_topic_score_codex":0.00075952907,"about_ca_topic_score_gemma":0.0014136375,"teacher_disagreement_score":0.0022597646,"about_ca_system_score_codex":0.0006523472,"about_ca_system_score_gemma":0.0012685915,"threshold_uncertainty_score":0.007559657},"labels":[],"label_agreement":null},{"id":"W2955755622","doi":"10.3747/co.26.4381","title":"Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Myocarditis; Melanoma; Internal medicine; Stage (stratigraphy); Metastatic melanoma; Oncology; Dermatology; Immunotherapy; Cancer research; Cancer","score_opus":0.028679980725852698,"score_gpt":0.32285662470990045,"score_spread":0.29417664398404775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955755622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795474,0.0018289812,0.0019195363,0.0015306337,0.00013239545,0.000109016204,0.00009078266,0.0001133293,0.0063206665],"genre_scores_gemma":[0.9980101,0.00040076525,0.0003795954,0.00046322515,0.0001408021,0.000010372292,0.00003863983,0.0000083267605,0.00054836815],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99965024,0.00007460625,0.00003960468,0.00008285375,0.000044720247,0.000108079075],"domain_scores_gemma":[0.99930775,0.00018615973,0.00012214313,0.0000524162,0.000035952915,0.0002955668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036497627,0.0011202305,0.0007622554,0.00079696113,0.0017797245,0.0007500048,0.00054992037,0.0023870037,0.0007848843],"category_scores_gemma":[0.001418308,0.0007717663,0.0010507947,0.00037186922,0.0008694838,0.0005759724,0.00065454503,0.0017171279,0.00031193285],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033495852,0.00014863934,0.026057051,0.00005001986,0.000063823965,0.964999,0.0003008103,0.00038074196,0.004290862,0.00017868867,0.00031726752,0.0028782054],"study_design_scores_gemma":[0.00012923001,0.001132754,0.03671503,0.000041043084,0.00011165277,0.95598197,0.00018567714,0.0019439963,0.002585376,0.00021844817,0.00092605693,0.000028667886],"about_ca_topic_score_codex":0.0017999387,"about_ca_topic_score_gemma":0.0031460912,"teacher_disagreement_score":0.0023870037,"about_ca_system_score_codex":0.0011405032,"about_ca_system_score_gemma":0.0005198298,"threshold_uncertainty_score":0.008274972},"labels":[],"label_agreement":null},{"id":"W2955853802","doi":"10.1158/1538-7445.am2019-7","title":"Abstract 7: Discovery of OICR-10268: A potent and selective BCL6 inhibitor","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"BCL6; Lymphoma; Cancer; Cancer research; Germinal center; Medicine; Internal medicine; Immunology; B cell; Antibody","score_opus":0.05675449112698437,"score_gpt":0.4118218250370835,"score_spread":0.3550673339100991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955853802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8724298,0.034983806,0.018314734,0.0038138244,0.0014015231,0.0011727219,0.004544934,0.0012108057,0.06212782],"genre_scores_gemma":[0.927145,0.01684038,0.009822208,0.0013443996,0.0001388545,0.00019078044,0.004461788,0.000065488406,0.039990958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999337,0.0000058384235,0.0000039609736,0.000010449967,0.00002643369,0.000019648252],"domain_scores_gemma":[0.99996126,0.000001927962,0.0000049573255,0.0000018306368,0.000009995877,0.000019976802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010535671,0.00047313466,0.00037390538,0.00028874294,0.00017185758,0.00043087592,0.00040700645,0.00041310853,0.004137409],"category_scores_gemma":[0.000113224974,0.0001286007,0.00019832049,0.00022465829,0.00011415372,0.00023088064,0.00028738595,0.0006948053,0.0016761147],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008818282,0.00073487824,0.0006916584,0.0006801395,0.000055948105,0.0010624819,0.00006210018,0.0018825624,0.889585,0.0024478275,0.0128462585,0.08906934],"study_design_scores_gemma":[0.0017181428,0.007664436,0.0034363463,0.0001842603,0.00015894171,0.0034634562,0.00007964753,0.0076930877,0.84745,0.0007253453,0.12735663,0.0000697294],"about_ca_topic_score_codex":0.00064747327,"about_ca_topic_score_gemma":0.0011798082,"teacher_disagreement_score":0.004137409,"about_ca_system_score_codex":0.00025835595,"about_ca_system_score_gemma":0.00032530216,"threshold_uncertainty_score":0.013840973},"labels":[],"label_agreement":null},{"id":"W2955937053","doi":"10.1158/1538-7445.am2019-1424","title":"Abstract 1424: Preclinical development of TAC01-CD19, a CD19 specific T-cell Antigen Coupler (TAC) therapy for the treatment of CD19-positive B cell malignancies","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"CD19; Chimeric antigen receptor; T cell; Cancer research; Antigen; Medicine; Immunology; B cell; Antibody; Immune system","score_opus":0.17306072651144228,"score_gpt":0.4446102306505628,"score_spread":0.27154950413912055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955937053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827727,0.0031099396,0.00457186,0.0002820368,0.0001714723,0.0011209195,0.0018960995,0.00026215066,0.0058127893],"genre_scores_gemma":[0.977833,0.0027356853,0.0037350615,0.00019622501,0.00007918067,0.001032954,0.004722143,0.000057899986,0.009607982],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998596,0.000030934258,0.000011568826,0.0000227059,0.000039148486,0.000036143676],"domain_scores_gemma":[0.9998666,0.000016396509,0.000025887695,0.000016292013,0.00002299118,0.0000517612],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041332105,0.00058769865,0.00039430545,0.00037475076,0.00019414113,0.00039181477,0.0004527906,0.00055533886,0.003966036],"category_scores_gemma":[0.00017390875,0.00017549105,0.0003409531,0.0001963286,0.00020680527,0.00032342816,0.00013655021,0.0011698835,0.0011267993],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040818783,0.006815859,0.0005602399,0.00027069077,0.00006720416,0.00016256717,0.0000694089,0.0008435213,0.9640537,0.00034931526,0.0016782866,0.02104735],"study_design_scores_gemma":[0.0028908616,0.09190958,0.0042398903,0.000041885934,0.00022566339,0.00077114603,0.00003506814,0.0016627519,0.8824459,0.000149179,0.015613393,0.000014742732],"about_ca_topic_score_codex":0.00057367375,"about_ca_topic_score_gemma":0.000675144,"teacher_disagreement_score":0.003966036,"about_ca_system_score_codex":0.0003102187,"about_ca_system_score_gemma":0.0006209731,"threshold_uncertainty_score":0.013267696},"labels":[],"label_agreement":null},{"id":"W2956407203","doi":"10.1186/s40425-019-0673-2","title":"Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Cancer Research UK; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research; Hyundai Hope On Wheels; Mayo Clinic","keywords":"Medicine; Immunotherapy; Toxicity; Oncolytic virus; Immunology; Immune system; Brainstem; Cancer research; Internal medicine","score_opus":0.022841207930643707,"score_gpt":0.34046279427430043,"score_spread":0.3176215863436567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956407203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9687959,0.0069283242,0.01979491,0.00021187238,0.00007693096,0.00025828613,0.00031537778,0.00026094547,0.0033574547],"genre_scores_gemma":[0.98635525,0.0039764084,0.008054988,0.00009252349,0.000013582088,0.00013346999,0.000320344,0.000030310435,0.001023086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991214,0.000010127736,0.0000066687844,0.000019995834,0.000026932523,0.000024122848],"domain_scores_gemma":[0.9999521,0.000006797092,0.000015984602,0.000007504804,0.000006268448,0.000011366194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001497283,0.00053312315,0.00027106647,0.00034660602,0.00009464304,0.0002634148,0.0002747039,0.00030064702,0.00059739745],"category_scores_gemma":[0.00008122066,0.00008587519,0.00021121287,0.00017191429,0.00023491959,0.00024105805,0.00018763776,0.0006461944,0.00024524273],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007793381,0.00011962513,0.00021251017,0.000121215446,0.000015437821,0.00006317535,0.000017852426,0.00061506574,0.9896243,0.0002705003,0.00013492364,0.008727372],"study_design_scores_gemma":[0.00007652849,0.00232221,0.0036158608,0.000032015996,0.00008380735,0.00092397747,0.000045220848,0.002266238,0.9831049,0.00025940512,0.0072618052,0.0000081080925],"about_ca_topic_score_codex":0.00024200292,"about_ca_topic_score_gemma":0.0007905972,"teacher_disagreement_score":0.00059739745,"about_ca_system_score_codex":0.0002812827,"about_ca_system_score_gemma":0.00024482334,"threshold_uncertainty_score":0.0020409226},"labels":[],"label_agreement":null},{"id":"W2956632142","doi":"10.1200/jco.2019.37.15_suppl.tps7574","title":"ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Surgery; Lymphoma","score_opus":0.06626956772329211,"score_gpt":0.43779992131585477,"score_spread":0.37153035359256265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956632142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98160845,0.0031484147,0.0011348495,0.0012445508,0.0002626349,0.0067227534,0.0030079593,0.00033926062,0.0025311264],"genre_scores_gemma":[0.9638835,0.003247304,0.0052527417,0.0026660645,0.00033117743,0.011403502,0.006877365,0.00012599697,0.0062123938],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957746,0.00021221861,0.000013568585,0.00007174941,0.000039335944,0.00008570327],"domain_scores_gemma":[0.9992638,0.00009484389,0.00014388353,0.000055004042,0.000058250076,0.00038413718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026469927,0.0020516396,0.0015037998,0.0005247734,0.00043899656,0.0012300689,0.0011256401,0.0016348487,0.0061687874],"category_scores_gemma":[0.0011341793,0.00082251686,0.0012345674,0.0003914814,0.0008501196,0.0010565721,0.00048482575,0.0034857707,0.0018232265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6364984,0.16233896,0.0095222,0.0014908023,0.0018055,0.0004799524,0.0005110504,0.0032101355,0.052544575,0.0005720727,0.013578549,0.1174479],"study_design_scores_gemma":[0.7028253,0.27764583,0.009545287,0.000057395973,0.0005665492,0.00052497047,0.000083620784,0.0015586383,0.0024831288,0.00030399757,0.004370607,0.00003464701],"about_ca_topic_score_codex":0.0008976921,"about_ca_topic_score_gemma":0.0023470405,"teacher_disagreement_score":0.0061687874,"about_ca_system_score_codex":0.00093626225,"about_ca_system_score_gemma":0.0019783794,"threshold_uncertainty_score":0.020636618},"labels":[],"label_agreement":null},{"id":"W2960897154","doi":"10.1182/blood-2018-99-115592","title":"Outcomes of T-Cell Depleted Haploidentical Peripheral Blood Stem Cell Transplantation for Adult Acute Leukemia: A Meta-Analysis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Transplantation; Hematopoietic stem cell transplantation; Internal medicine; Acute leukemia; Leukemia; Meta-analysis; Stem cell; CD34; Oncology; Gastroenterology; Immunology; Biology","score_opus":0.04250206580678483,"score_gpt":0.31770761034001443,"score_spread":0.2752055445332296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960897154","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013809025,0.98360413,0.00084297586,0.00030223603,0.00019320373,0.00022307942,0.0006847247,0.000030244,0.00031025373],"genre_scores_gemma":[0.47935697,0.5127639,0.0028923368,0.0013060055,0.00040216447,0.0013326243,0.0014047638,0.000055372708,0.00048591205],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99025154,0.0051047034,0.0023167762,0.0011798866,0.00078338024,0.00036366258],"domain_scores_gemma":[0.98590577,0.010150818,0.0021425965,0.00052758364,0.0010396112,0.0002335416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012773713,0.0031392407,0.017069837,0.005268086,0.00059879944,0.0033779654,0.0021745833,0.0024433553,0.0030973419],"category_scores_gemma":[0.02545017,0.0014415913,0.057343002,0.006000924,0.0005782868,0.0016796364,0.0013574912,0.0021849212,0.00026205438],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025673981,0.000029599927,0.0051839575,0.12536508,0.8603592,0.00012367884,0.00005052072,0.00078991504,0.0001813013,0.00009652947,0.00035132703,0.0049015237],"study_design_scores_gemma":[0.00038761323,0.00015560872,0.0029159125,0.0063494984,0.9891773,0.00005260022,0.000024729452,0.00021283128,0.000071688395,0.0001332399,0.0005039888,0.000015014927],"about_ca_topic_score_codex":0.0060834875,"about_ca_topic_score_gemma":0.0094808,"teacher_disagreement_score":0.017069837,"about_ca_system_score_codex":0.0023817567,"about_ca_system_score_gemma":0.0022631148,"threshold_uncertainty_score":0.06755465},"labels":[],"label_agreement":null},{"id":"W2961898921","doi":"10.1158/2326-6066.cir-18-0691","title":"TGFβ Programs Central Memory Differentiation in <i>Ex Vivo</i> –Stimulated Human T Cells","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; BC Children's Hospital; University of British Columbia; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Cytotoxic T cell; Adoptive cell transfer; Ex vivo; Biology; Immunology; T cell; CD8; Memory T cell; Cell biology; Immunotherapy; Cancer research; In vivo; Immune system; In vitro","score_opus":0.06344752022462088,"score_gpt":0.39404221541498,"score_spread":0.3305946951903591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961898921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941907,0.001228479,0.0023705636,0.00006086581,0.000032369175,0.000034786357,0.00022344427,0.000066773915,0.0017920911],"genre_scores_gemma":[0.99730945,0.0003604439,0.0009768456,0.000053997614,0.000020842052,0.000025146477,0.00028443066,0.000014706216,0.000954196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999255,0.000021605689,0.000008611215,0.000013342143,0.000011438094,0.000019492625],"domain_scores_gemma":[0.9999379,0.000015510535,0.00001395933,0.0000127328485,0.000008441316,0.000011479193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000137447,0.00029797407,0.0001689043,0.00012228788,0.00007333193,0.000280075,0.000085360254,0.00013668009,0.0012759726],"category_scores_gemma":[0.0000864355,0.000082635415,0.00016670093,0.00008924894,0.000115185496,0.00010551316,0.00011453818,0.00053813076,0.0004674051],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001482415,0.000031460233,0.00017057889,0.00002311764,0.0000016999295,0.000035615947,0.000017474391,0.00004314263,0.9983942,0.000028761478,0.000027270036,0.0010784516],"study_design_scores_gemma":[0.00003892532,0.0008349813,0.0031817437,0.000010784737,0.000017665936,0.00030464516,0.000039349845,0.0006615462,0.9924482,0.000055464716,0.0024036847,0.0000030025233],"about_ca_topic_score_codex":0.00014873093,"about_ca_topic_score_gemma":0.00018232942,"teacher_disagreement_score":0.0012759726,"about_ca_system_score_codex":0.00008848634,"about_ca_system_score_gemma":0.00009754531,"threshold_uncertainty_score":0.0042685866},"labels":[],"label_agreement":null},{"id":"W2963496214","doi":"10.1182/bloodadvances.2019000151","title":"Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Medicine; Internal medicine; Oncology; Cancer research; Biology","score_opus":0.010419713182177843,"score_gpt":0.26191942435312415,"score_spread":0.2514997111709463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963496214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481034,0.0026576533,0.0002413681,0.00015115194,0.000023618493,0.00013652016,0.00010665022,0.00003750511,0.0018351673],"genre_scores_gemma":[0.9966634,0.0012946513,0.00039134888,0.00017276344,0.000032853426,0.0001314023,0.00037198956,0.000009721972,0.0009317726],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99987113,0.00006167932,0.00000857702,0.000013461517,0.00001821515,0.000026837017],"domain_scores_gemma":[0.999851,0.00003182151,0.000036469908,0.000013059012,0.000012898391,0.000054724063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047097952,0.00017971106,0.0004729696,0.00014366739,0.0000998404,0.00032333043,0.00023769918,0.00020234541,0.0010858813],"category_scores_gemma":[0.0003602133,0.00006523972,0.00019434393,0.00016917363,0.0001888185,0.00022540259,0.00020168934,0.00052125036,0.00021535024],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15741222,0.011165132,0.02619288,0.001290683,0.000798255,0.001111699,0.00046388895,0.0038443685,0.19325566,0.0013068833,0.00854225,0.59461606],"study_design_scores_gemma":[0.18333586,0.5352891,0.12919737,0.00027793003,0.0011969078,0.0042841644,0.00054034643,0.015117846,0.06574743,0.0011126901,0.06382173,0.00007867196],"about_ca_topic_score_codex":0.0003760705,"about_ca_topic_score_gemma":0.0014650187,"teacher_disagreement_score":0.0010858813,"about_ca_system_score_codex":0.0003478213,"about_ca_system_score_gemma":0.00030118035,"threshold_uncertainty_score":0.003632605},"labels":[],"label_agreement":null},{"id":"W2965636153","doi":"10.1016/j.jbior.2019.100638","title":"The TCR/CD3 complex in leukemogenesis and as a therapeutic target in T-cell acute lymphoblastic leukemia","year":2019,"lang":"en","type":"review","venue":"Advances in Biological Regulation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Fundação para a Ciência e a Tecnologia; Programa Operacional Temático Factores de Competitividade; Institut National de la Santé et de la Recherche Médicale; Conseil National de la Recherche Scientifique; Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer; Institut Curie; University of Pittsburgh","keywords":"T-cell receptor; Biology; CD3; Thymocyte; T cell; Leukemia; Antigen; Major histocompatibility complex; Immunology; T-cell leukemia; Cell biology; Cancer research; Immune system; CD8","score_opus":0.08073849367163725,"score_gpt":0.3894962577697001,"score_spread":0.3087577640980628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965636153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008221928,0.99871886,0.00011082274,0.00018735352,0.00018719869,0.0000034586803,0.000016114276,0.0000067112624,0.0006873175],"genre_scores_gemma":[0.0005439601,0.99848986,0.00013294107,0.0001971683,0.00014620855,0.000004878431,0.000024925344,0.0000013961393,0.00045867337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987674,0.00002167319,0.00001536194,0.000023029266,0.000043790522,0.000019457315],"domain_scores_gemma":[0.9998198,0.000081648745,0.000028137645,0.000005626643,0.00004444142,0.000020378888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005679019,0.0008127178,0.0014330926,0.0015582355,0.00019328816,0.0010655365,0.0007610335,0.000956977,0.0031923174],"category_scores_gemma":[0.00059135427,0.00025592005,0.0003716369,0.002051742,0.00043525096,0.0010623311,0.0006294214,0.0019769554,0.0022243084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015634847,0.00008500186,0.00009702649,0.012861966,0.00007608372,0.00015323027,0.00003063261,0.0005234454,0.0027035186,0.0042536985,0.032048944,0.9470101],"study_design_scores_gemma":[0.000049564653,0.00013419212,0.00035945096,0.0021222176,0.00013916162,0.0004957628,0.000029075154,0.00012769397,0.00058938365,0.0017263727,0.9942116,0.00001548743],"about_ca_topic_score_codex":0.0008086294,"about_ca_topic_score_gemma":0.0015362976,"teacher_disagreement_score":0.0031923174,"about_ca_system_score_codex":0.0006036869,"about_ca_system_score_gemma":0.0008872963,"threshold_uncertainty_score":0.010679305},"labels":[],"label_agreement":null},{"id":"W2967592537","doi":"10.1055/s-0039-1692977","title":"Innovative Molecular Testing Strategies for Adjunctive Investigations in Hemostasis and Thrombosis","year":2019,"lang":"en","type":"review","venue":"Seminars in Thrombosis and Hemostasis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute","keywords":"Hemostasis; Context (archaeology); Medicine; Thrombosis; Bioinformatics; Cancer; Computational biology; Biology; Internal medicine","score_opus":0.2072553937303359,"score_gpt":0.4296916293429816,"score_spread":0.2224362356126457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967592537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007490197,0.99705005,0.0005264222,0.000643397,0.00039589126,0.000010683382,0.000015239055,0.000011607169,0.0012717515],"genre_scores_gemma":[0.0010979312,0.9954145,0.0010463847,0.0008198478,0.00056527543,0.000024583214,0.000043518914,0.0000039187235,0.0009840097],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992879,0.00019300499,0.00008955678,0.00012125863,0.00025953635,0.00004870274],"domain_scores_gemma":[0.99867237,0.00090116356,0.000100041274,0.000042593958,0.00022342597,0.000060379203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017918821,0.0012112043,0.0017934351,0.00364191,0.00032354228,0.0013763799,0.0013511453,0.002525314,0.0042551183],"category_scores_gemma":[0.002121312,0.0004255962,0.0010385534,0.0017775521,0.0014113487,0.0021278334,0.0009435531,0.0043207086,0.0030743186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006805682,0.00008926503,0.00025525334,0.009328516,0.00009107321,0.00039949326,0.00006417163,0.00027637472,0.0020255898,0.0102274865,0.026540784,0.9506339],"study_design_scores_gemma":[0.00003182511,0.00013183431,0.00089523965,0.004081736,0.00013661498,0.0035003766,0.00006949573,0.00013853151,0.0009250451,0.006247766,0.9838059,0.00003556617],"about_ca_topic_score_codex":0.00074788294,"about_ca_topic_score_gemma":0.0009665512,"teacher_disagreement_score":0.0042551183,"about_ca_system_score_codex":0.0010030135,"about_ca_system_score_gemma":0.0011916085,"threshold_uncertainty_score":0.014234781},"labels":[],"label_agreement":null},{"id":"W2967929847","doi":"10.1016/j.cellimm.2019.103963","title":"Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy","year":2019,"lang":"en","type":"review","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Tabriz; Tehran University of Medical Sciences and Health Services; Tabriz University of Medical Sciences; Northeastern States Research Cooperative","keywords":"Chimeric antigen receptor; Immunotherapy; Immune system; Cancer immunotherapy; Cancer research; T cell; Cancer; Biology; Cell; Immunology","score_opus":0.06636408974079762,"score_gpt":0.35277819138116534,"score_spread":0.28641410164036774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967929847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042235988,0.99039865,0.0016746687,0.0013939186,0.0018812491,0.000020492129,0.00004816126,0.000038599544,0.0041218637],"genre_scores_gemma":[0.0043602586,0.9832145,0.0017384166,0.0019946315,0.0011703857,0.000050171715,0.00010311016,0.000008555386,0.00735994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998913,0.00002162977,0.000009193529,0.00002239086,0.00003772691,0.000017749422],"domain_scores_gemma":[0.99991107,0.000038601538,0.000010689359,0.000004030056,0.000023094897,0.000012458311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046120715,0.0010135632,0.0009423663,0.00092527334,0.00020033009,0.00079925306,0.0006406878,0.0013278428,0.004608078],"category_scores_gemma":[0.00032937745,0.00026332893,0.00034734447,0.0006812526,0.00050801627,0.0014576063,0.00063787843,0.0028684596,0.002466692],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018705739,0.00015003416,0.000061308696,0.009216666,0.0000618281,0.0002692255,0.000048496582,0.00055533805,0.014070112,0.015916105,0.07183495,0.8876288],"study_design_scores_gemma":[0.000050857027,0.00022689631,0.0001515352,0.00094436144,0.000066610184,0.0005640699,0.000020482457,0.00023299316,0.0030637854,0.00475137,0.9899104,0.000016557406],"about_ca_topic_score_codex":0.00037051833,"about_ca_topic_score_gemma":0.0008234199,"teacher_disagreement_score":0.004608078,"about_ca_system_score_codex":0.0005756425,"about_ca_system_score_gemma":0.00083164463,"threshold_uncertainty_score":0.01541549},"labels":[],"label_agreement":null},{"id":"W2969042755","doi":"10.1038/s41577-019-0200-1","title":"Engineering universal cells that evade immune detection","year":2019,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Astellas Pharma; Universal","keywords":"Immune system; CRISPR; Biology; Transplantation; Induced pluripotent stem cell; Immunology; Computational biology; Cell biology; Cancer research; Gene; Medicine; Embryonic stem cell; Genetics","score_opus":0.04236399632393917,"score_gpt":0.34716134679134275,"score_spread":0.3047973504674036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969042755","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015757045,0.9956649,0.0006357288,0.0006360472,0.0008541843,0.0000063637663,0.000028022854,0.000024340801,0.001992838],"genre_scores_gemma":[0.0013910715,0.99477106,0.00042154142,0.00069297245,0.00035073017,0.00001585115,0.00007022743,0.000005682016,0.0022808153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977034,0.00003481787,0.000018795588,0.000039544637,0.000094858755,0.00004164817],"domain_scores_gemma":[0.99976236,0.00010882153,0.000029311466,0.0000123956415,0.00005837648,0.000028658857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007929217,0.0013884552,0.0012001706,0.0013498269,0.00023095022,0.0011145677,0.001206808,0.0016345442,0.0033162283],"category_scores_gemma":[0.00064334006,0.0003818914,0.0004536912,0.0012322089,0.0010164042,0.0015001612,0.0010826756,0.0029891247,0.0032317347],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108836735,0.0000849404,0.000093475086,0.006238226,0.00005375307,0.00010194131,0.000031880947,0.0005890317,0.006813789,0.016421553,0.059190683,0.9102719],"study_design_scores_gemma":[0.000019016354,0.000069079986,0.00015465592,0.0008135071,0.00003091384,0.0002900429,0.000015872538,0.000097302596,0.0015958453,0.00321754,0.99368334,0.000012791496],"about_ca_topic_score_codex":0.0005588561,"about_ca_topic_score_gemma":0.0010815108,"teacher_disagreement_score":0.0033162283,"about_ca_system_score_codex":0.0008603049,"about_ca_system_score_gemma":0.00057615276,"threshold_uncertainty_score":0.011093855},"labels":[],"label_agreement":null},{"id":"W2969682556","doi":"10.1038/s41467-018-04262-0","title":"DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; European Federation of Pharmaceutical Industries and Associations; University of Toronto; Ministero dello Sviluppo Economico; Genome Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Ontario Ministry of Economic Development and Innovation; Novartis Pharma; Ontario Genomics Institute; Wellcome Trust; Pfizer; Princess Margaret Cancer Foundation; Canada First Research Excellence Fund; Ontario Genomics","keywords":"T cell; Adoptive cell transfer; Immunotherapy; Cancer research; Immunology; Avidity; Priming (agriculture); Cancer immunotherapy; Immune system; Medicine; Biology; Antigen","score_opus":0.03867886273269115,"score_gpt":0.34681252955423375,"score_spread":0.3081336668215426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969682556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900253,0.0021364596,0.004738458,0.00022908441,0.000107512125,0.00006683364,0.00034325325,0.00028278006,0.002070319],"genre_scores_gemma":[0.9909321,0.0015176157,0.0030455843,0.00008391919,0.000030162515,0.00008668519,0.0005492521,0.000035172867,0.0037195315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981385,0.000031394655,0.000019001476,0.000035232846,0.000050606952,0.000049903727],"domain_scores_gemma":[0.9998976,0.000012309291,0.000038452767,0.000010241517,0.000010496222,0.00003089631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020503563,0.00067702093,0.00047170534,0.000356476,0.0001705326,0.00028225276,0.00027398433,0.0003164357,0.0010583693],"category_scores_gemma":[0.00009139668,0.00013463925,0.00022043205,0.00017375808,0.0002852842,0.00028338606,0.00018637285,0.0011778275,0.00032110943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003093462,0.00026367008,0.000111975285,0.000068335765,0.000008528852,0.000032102944,0.000018011362,0.0001394483,0.9957486,0.00012471105,0.00010714195,0.0030681186],"study_design_scores_gemma":[0.000041273415,0.0011930838,0.001051872,0.000004657691,0.000022010136,0.00011671177,0.000015086746,0.00092480297,0.994913,0.000045077915,0.0016689557,0.0000033621309],"about_ca_topic_score_codex":0.00029351245,"about_ca_topic_score_gemma":0.00070249505,"teacher_disagreement_score":0.0010583693,"about_ca_system_score_codex":0.00025765193,"about_ca_system_score_gemma":0.00029311032,"threshold_uncertainty_score":0.0035405755},"labels":[],"label_agreement":null},{"id":"W2969967730","doi":"10.1101/746685","title":"Engineering “self-homing” circulating tumour cells as novel cancer theranostics","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Homing (biology); Metastatic breast cancer; Medicine; Bioluminescence imaging; Circulating tumor cell; Primary tumor; Cancer research; Breast cancer; Genetic enhancement; Metastasis; CA15-3; Cancer; Oncology; Pathology; Internal medicine; Gene; Biology; Luciferase","score_opus":0.01899425600140162,"score_gpt":0.25724522877555583,"score_spread":0.23825097277415422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969967730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.913176,0.0070890584,0.07215584,0.0006100383,0.00018345394,0.00023740479,0.00027224515,0.0005668713,0.0057091597],"genre_scores_gemma":[0.96585363,0.0023011698,0.025162715,0.00018710598,0.000032417327,0.00011066702,0.00019878674,0.000052892206,0.0061005643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999063,0.000018017656,0.000006191821,0.000022258171,0.000030218242,0.000016913209],"domain_scores_gemma":[0.99994135,0.000009795962,0.000015876745,0.0000075566336,0.000011281687,0.000014105431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018376198,0.00023680883,0.00022383448,0.00014242168,0.000083011124,0.00036956638,0.00019413725,0.00035921196,0.0010951218],"category_scores_gemma":[0.000116105075,0.000090928035,0.00015624108,0.00011497788,0.00021673512,0.0001953438,0.00021015502,0.0004629373,0.00034609932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034791985,0.00004609286,0.00016981318,0.00007863259,0.0000053117888,0.000056647143,0.000018003635,0.0005020617,0.98921096,0.00074968697,0.00025254145,0.00887552],"study_design_scores_gemma":[0.000052096864,0.00041387283,0.0006719504,0.000010631748,0.000018611865,0.00020477007,0.000012500254,0.0051326756,0.983257,0.00019766188,0.010021059,0.000007120854],"about_ca_topic_score_codex":0.00035061705,"about_ca_topic_score_gemma":0.00041663327,"teacher_disagreement_score":0.0010951218,"about_ca_system_score_codex":0.000322677,"about_ca_system_score_gemma":0.0002119395,"threshold_uncertainty_score":0.00366354},"labels":[],"label_agreement":null},{"id":"W2969992885","doi":"10.3324/haematol.2019.224204","title":"Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network","year":2019,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Medicine; Cell therapy; Clinical trial; Antigen; Daratumumab; Monoclonal antibody; Immunology; Targeted therapy; Bortezomib; Cancer research; Immunotherapy; Oncology; Cancer; Internal medicine; Antibody; Cell; Biology","score_opus":0.04202163171986532,"score_gpt":0.2957468530958976,"score_spread":0.25372522137603226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969992885","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020381792,0.4795946,0.008488391,0.4610085,0.031712838,0.0005402317,0.0009527625,0.00019959372,0.015464956],"genre_scores_gemma":[0.023059113,0.60440326,0.03544489,0.27574128,0.023841295,0.0014471291,0.0038008296,0.00021550791,0.03204675],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948331,0.0012234816,0.0010135109,0.00035329338,0.0021261035,0.00045042823],"domain_scores_gemma":[0.99254274,0.001725065,0.0010717701,0.00019153609,0.0033394457,0.0011294538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015779918,0.00080894027,0.0016393001,0.0013381534,0.0009113946,0.0024596995,0.003338909,0.0085886475,0.0015056961],"category_scores_gemma":[0.0062754694,0.0004007247,0.0015100188,0.0017729788,0.0016521605,0.0018591796,0.0019763515,0.009386226,0.0022544402],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031257657,0.0002765604,0.0009674721,0.0041643726,0.00012734518,0.00059883686,0.0001743486,0.0009567302,0.005102194,0.011345328,0.60026735,0.3757069],"study_design_scores_gemma":[0.00010105225,0.00012976406,0.0013129504,0.0024910918,0.000095086914,0.0005685005,0.00008404694,0.00022602479,0.0012865099,0.0028642283,0.99081296,0.000027660575],"about_ca_topic_score_codex":0.0042231954,"about_ca_topic_score_gemma":0.0055818385,"teacher_disagreement_score":0.015779918,"about_ca_system_score_codex":0.0025645567,"about_ca_system_score_gemma":0.012707413,"threshold_uncertainty_score":0.08345318},"labels":[],"label_agreement":null},{"id":"W2970149384","doi":"10.1007/978-1-4939-9728-2_3","title":"Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; T-cell receptor; Antigen; T cell; Transduction (biophysics); Adoptive cell transfer; Cancer immunotherapy; Receptor; Antigen-presenting cell; Immunology; Cytotoxic T cell; Biology; Cancer research; Immune system; In vitro","score_opus":0.1313057769871186,"score_gpt":0.462946372630096,"score_spread":0.33164059564297743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970149384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88375807,0.0031558755,0.10706153,0.0004666562,0.00007880105,0.00017067761,0.00045493542,0.0003103408,0.0045431238],"genre_scores_gemma":[0.9595058,0.002040638,0.034457427,0.00012659896,0.000024687562,0.00008487698,0.0005417891,0.000060972212,0.0031573377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998547,0.000027851784,0.000008574172,0.00002825067,0.000042975244,0.000037544243],"domain_scores_gemma":[0.9999176,0.000022724225,0.000022877895,0.000014450196,0.000012777332,0.000009568099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023310451,0.0003945378,0.00018613097,0.00040358174,0.00017951138,0.00034053435,0.00028833278,0.00040247373,0.0010239347],"category_scores_gemma":[0.00023333644,0.00017292274,0.00036686243,0.00022381252,0.000475039,0.00033378182,0.00017952747,0.00084973936,0.00031377317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006019777,0.000028640428,0.0001143444,0.000024902987,0.000003162764,0.00003368243,0.000011262668,0.00023018928,0.99618906,0.0012161635,0.00002907711,0.0020592634],"study_design_scores_gemma":[0.000010433798,0.00012234095,0.0004225018,0.0000019777688,0.0000114723525,0.00012600089,0.000008766378,0.0008886661,0.99604046,0.00034167207,0.002021032,0.0000046324653],"about_ca_topic_score_codex":0.00034705005,"about_ca_topic_score_gemma":0.00031863106,"teacher_disagreement_score":0.0010239347,"about_ca_system_score_codex":0.00028660093,"about_ca_system_score_gemma":0.00026351804,"threshold_uncertainty_score":0.0034254193},"labels":[],"label_agreement":null},{"id":"W2970263617","doi":"10.1016/j.clml.2019.07.158","title":"Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Cytokine release syndrome; Lymphoma; Medicine; Refractory (planetary science); Cytokine; Diffuse large B-cell lymphoma; Immunology; Immunotherapy; Oncology; Biology; Immune system; Chimeric antigen receptor","score_opus":0.03538236938760417,"score_gpt":0.3367846881046666,"score_spread":0.30140231871706247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970263617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99867934,0.00032344772,0.000057624093,0.000021828297,0.0000041990056,0.000010904123,0.00014707183,0.0000043290916,0.0007513692],"genre_scores_gemma":[0.999516,0.00007524542,0.000039189636,0.000025131767,0.0000083953255,0.0000074723143,0.0001849353,0.0000013040782,0.00014244295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998331,0.00004255117,0.000023798899,0.000032667955,0.00003076002,0.000037084494],"domain_scores_gemma":[0.9996056,0.00009549288,0.00013573581,0.000019975487,0.000053682375,0.00008956338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019282797,0.00016564471,0.00028797978,0.00062267366,0.00025541033,0.00036539437,0.0001802499,0.0002210464,0.0010821864],"category_scores_gemma":[0.00071215414,0.00007197809,0.00015963831,0.00040591104,0.00018339245,0.00016778117,0.00016578946,0.00031195607,0.00018105572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057743373,0.00026146552,0.95334667,0.000057083707,0.00012084033,0.0069400906,0.00028604065,0.0001622749,0.020443445,0.00007808074,0.00024884797,0.012280681],"study_design_scores_gemma":[0.00007608567,0.0015836384,0.988536,0.000010152295,0.00009299364,0.0060902275,0.0003157341,0.00036376866,0.002272141,0.000063540196,0.0005856021,0.000010174511],"about_ca_topic_score_codex":0.0010518949,"about_ca_topic_score_gemma":0.0013329186,"teacher_disagreement_score":0.0010821864,"about_ca_system_score_codex":0.000270685,"about_ca_system_score_gemma":0.00020433089,"threshold_uncertainty_score":0.003620267},"labels":[],"label_agreement":null},{"id":"W2970435909","doi":"10.1101/749721","title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human Tregs","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD28; Receptor; CD80; Immunology; Antigen; Biology; T-cell receptor; Signal transduction; In vitro; Cell biology; Cancer research; T cell; Immune system; Genetics; CD40; CD8; Cytotoxic T cell","score_opus":0.018686740861283517,"score_gpt":0.2689512575339827,"score_spread":0.25026451667269917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970435909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964631,0.0009023209,0.0017298822,0.000040485364,0.000020038346,0.000023122268,0.00013205523,0.00003304269,0.0006558273],"genre_scores_gemma":[0.9982673,0.00018088888,0.00084932934,0.000024065603,0.000004780836,0.000013940633,0.00017760617,0.0000116554575,0.00047036112],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996891,0.00013604393,0.000019510404,0.000047018126,0.000046116187,0.000062137246],"domain_scores_gemma":[0.99986243,0.00006963581,0.000012734731,0.000017229793,0.000016318101,0.000021540858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056350423,0.00022259222,0.00024482593,0.00014123334,0.000097851254,0.00030821463,0.00011083217,0.00023281643,0.0011935505],"category_scores_gemma":[0.00025673557,0.00006467887,0.00020017983,0.000105928,0.00019926803,0.000104707506,0.00013505688,0.00044756624,0.00023330463],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073191803,0.00015393026,0.00050007884,0.000048486774,0.000015690048,0.00007602592,0.000052290583,0.0010733834,0.99279904,0.00028584493,0.00013628793,0.004126967],"study_design_scores_gemma":[0.000057030888,0.0012447756,0.0008258224,0.0000052308064,0.000031295716,0.0002219098,0.000029416346,0.0020689683,0.9926277,0.00005465638,0.0028285298,0.000004755455],"about_ca_topic_score_codex":0.000795352,"about_ca_topic_score_gemma":0.00051513506,"teacher_disagreement_score":0.0011935505,"about_ca_system_score_codex":0.00028061733,"about_ca_system_score_gemma":0.00020054719,"threshold_uncertainty_score":0.0039928555},"labels":[],"label_agreement":null},{"id":"W2971382867","doi":"10.1186/s12874-019-0823-8","title":"Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia","year":2019,"lang":"en","type":"article","venue":"BMC Medical Research Methodology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Pediatrics; Expert opinion; Young adult; Clinical trial; Term (time); Leukemia; Oncology; Intensive care medicine; Internal medicine","score_opus":0.5060217933686972,"score_gpt":0.5783941496880564,"score_spread":0.07237235631935912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971382867","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8976694,0.0031353747,0.05890909,0.022663476,0.000076805736,0.0012617769,0.00042573054,0.000074340016,0.015784008],"genre_scores_gemma":[0.9648703,0.0012209535,0.031205598,0.0016054858,0.00008303386,0.00026715844,0.00013702796,0.000025468147,0.0005849745],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.94870615,0.04458725,0.0021059818,0.0009852941,0.002510263,0.0011050958],"domain_scores_gemma":[0.76747024,0.21145226,0.010585922,0.002855687,0.0055117137,0.0021242094],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.056434296,0.00047597048,0.0005047613,0.0010428886,0.0018718785,0.0020688442,0.0012642954,0.004030324,0.0026383672],"category_scores_gemma":[0.12483666,0.0004158193,0.00093346497,0.0011311199,0.0014188639,0.0020252457,0.0018894324,0.0024802312,0.00029910548],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032685858,0.0033203147,0.24300835,0.0047480534,0.00074799795,0.152075,0.107956715,0.070494324,0.0044458653,0.033468887,0.016928189,0.3595378],"study_design_scores_gemma":[0.0020119196,0.008056566,0.122096546,0.0067868573,0.001404301,0.1209523,0.17478804,0.27411157,0.01699553,0.082294695,0.18975866,0.0007430896],"about_ca_topic_score_codex":0.0040657157,"about_ca_topic_score_gemma":0.009688724,"teacher_disagreement_score":0.9435657,"about_ca_system_score_codex":0.003774461,"about_ca_system_score_gemma":0.0032139213,"threshold_uncertainty_score":0.2984566},"labels":[],"label_agreement":null},{"id":"W2972212812","doi":"10.1101/760355","title":"The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for detection of neoantigen-specific T cells in PBMC","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science, Technology and Innovation Commission of Shenzhen Municipality; Government of Jiangxi Province; National Natural Science Foundation of China","keywords":"ELISPOT; CD28; Immunology; Peripheral blood mononuclear cell; Immune system; T cell; Medicine; Stimulation; Antigen; Cancer research; Biology; In vitro; Internal medicine; Biochemistry","score_opus":0.023848419906066655,"score_gpt":0.27234450423348716,"score_spread":0.2484960843274205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972212812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7224201,0.011232091,0.25459942,0.00088362576,0.0006230448,0.0005268655,0.0011585376,0.0015321565,0.0070241257],"genre_scores_gemma":[0.80194044,0.0034410956,0.18505903,0.0008856786,0.00030851355,0.000829236,0.0013396349,0.00019674885,0.005999666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971623,0.001046721,0.00023329457,0.0006657429,0.0006046355,0.00028730414],"domain_scores_gemma":[0.9992409,0.0004089138,0.00007455202,0.000087146174,0.000138481,0.000050003717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015642062,0.001102272,0.0006628642,0.00061559095,0.0002596316,0.0007598831,0.00041870464,0.0009789426,0.0022849774],"category_scores_gemma":[0.0010811167,0.00040896647,0.00038694736,0.0004998415,0.0003903965,0.000493853,0.00059742446,0.0015901764,0.0014079557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046896435,0.0000433909,0.0001459069,0.000084406674,0.0000066317957,0.000020856065,0.000019202515,0.00010917733,0.99759835,0.00003783896,0.00010391251,0.0017834129],"study_design_scores_gemma":[0.000010265324,0.00013307821,0.000911597,0.000012657502,0.000011507028,0.00013585523,0.000014298428,0.0018278946,0.99520916,0.000067814304,0.001657785,0.000008014269],"about_ca_topic_score_codex":0.00017950402,"about_ca_topic_score_gemma":0.00049431925,"teacher_disagreement_score":0.0022849774,"about_ca_system_score_codex":0.00022949577,"about_ca_system_score_gemma":0.00025236062,"threshold_uncertainty_score":0.008272409},"labels":[],"label_agreement":null},{"id":"W2973137482","doi":"10.1016/j.bbmt.2019.09.013","title":"Dual T Cell Depletion with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide Results in Low Rates of Cytokine Release Syndrome in Peripheral Blood Haplo-Hematopoietic Stem Cell Transplantation","year":2019,"lang":"en","type":"letter","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Anti-thymocyte globulin; Haematopoiesis; Hematopoietic stem cell transplantation; Stem cell; Immunology; Cytokine; Cyclophosphamide; Transplantation; Peripheral blood; Globulin; Internal medicine; Chemotherapy; Cell biology; Biology","score_opus":0.008808940330552397,"score_gpt":0.23145738300894086,"score_spread":0.22264844267838846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973137482","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24629444,0.005819692,0.004293618,0.68276876,0.018177213,0.0001312962,0.00029545027,0.00057262677,0.041647006],"genre_scores_gemma":[0.7485122,0.0031312907,0.0021740482,0.19831932,0.021031886,0.000112478716,0.00019371425,0.00014762422,0.026377318],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99940646,0.0002307073,0.00006604651,0.00006789125,0.00013278029,0.00009611701],"domain_scores_gemma":[0.9977822,0.0016122638,0.00016957424,0.00010835594,0.00011911824,0.00020850929],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007816602,0.00046972634,0.0006567849,0.00028706554,0.0007354421,0.0011118535,0.0005186539,0.0075828223,0.0013840675],"category_scores_gemma":[0.0040848465,0.00025581784,0.000492313,0.00022877219,0.00080306485,0.00057135976,0.00023091522,0.0043550176,0.0008453489],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059071807,0.001436575,0.03612174,0.00022590054,0.00025430432,0.5768312,0.00046979185,0.0013309518,0.02684276,0.01233511,0.24922915,0.089015365],"study_design_scores_gemma":[0.0022343902,0.0042476295,0.05396304,0.00032504063,0.0003602246,0.593835,0.0004892018,0.01528563,0.033807,0.015295367,0.2799667,0.0001908537],"about_ca_topic_score_codex":0.0006225034,"about_ca_topic_score_gemma":0.0010338904,"teacher_disagreement_score":0.0075828223,"about_ca_system_score_codex":0.0011237732,"about_ca_system_score_gemma":0.0004291747,"threshold_uncertainty_score":0.008153558},"labels":[],"label_agreement":null},{"id":"W2973520315","doi":"10.1177/2472630319846878","title":"Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications","year":2019,"lang":"en","type":"review","venue":"SLAS TECHNOLOGY","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"Ontario Ministry of Research and Innovation; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science; Cancer Research Society","keywords":"Clinical trial; Drug development; Personalized medicine; Medicine; Drug; Drug discovery; Cancer; Intensive care medicine; Pharmacology; Bioinformatics; Biology; Pathology; Internal medicine","score_opus":0.3349991428916382,"score_gpt":0.5699769598246596,"score_spread":0.2349778169330214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973520315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014324978,0.9979346,0.00034787145,0.00026948832,0.00026264903,0.000007485864,0.000023572273,0.000011683084,0.0009994187],"genre_scores_gemma":[0.0012581324,0.9965071,0.0004199676,0.00028385158,0.00019267929,0.000014507077,0.000041630297,0.0000023823095,0.001279727],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998392,0.000025446738,0.000016858192,0.000028151559,0.000066504996,0.000023852304],"domain_scores_gemma":[0.99975854,0.00012069512,0.00003661914,0.0000067218443,0.000054665543,0.0000227934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066812866,0.001156386,0.0011639057,0.0022575262,0.00022457968,0.0009129098,0.00054741715,0.0011052955,0.0040581655],"category_scores_gemma":[0.0006887945,0.00032051178,0.00043921862,0.0016797874,0.0004889612,0.0010567553,0.00093069236,0.0016209579,0.0016237329],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000779365,0.000072004455,0.000080772865,0.0119216535,0.000051637915,0.00009647436,0.000030805546,0.00036898605,0.0050831675,0.0033006328,0.023190437,0.9557255],"study_design_scores_gemma":[0.00003454161,0.00014974957,0.00031016226,0.0021051385,0.00011559672,0.00044020353,0.00003892984,0.00019367244,0.0024132808,0.0017451021,0.9924319,0.000021738837],"about_ca_topic_score_codex":0.0011978465,"about_ca_topic_score_gemma":0.0025615909,"teacher_disagreement_score":0.0040581655,"about_ca_system_score_codex":0.0005949317,"about_ca_system_score_gemma":0.0014419656,"threshold_uncertainty_score":0.013575852},"labels":[],"label_agreement":null},{"id":"W2977427874","doi":"10.1093/annonc/mdz283.003","title":"ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Sarcoma; Dermatology; Internal medicine; Oncology; Pathology","score_opus":0.053423593404045094,"score_gpt":0.38545028891373545,"score_spread":0.33202669550969033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977427874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247605,0.0024752505,0.0001393506,0.0004076663,0.000043436317,0.000010719475,0.00016661215,0.000011362694,0.0042695077],"genre_scores_gemma":[0.9991522,0.00034847966,0.00004774902,0.00008093015,0.000034081888,0.00000389739,0.00011043468,0.0000012727704,0.00022091813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997446,0.000058720565,0.000027533824,0.000048188158,0.00004664752,0.000074315954],"domain_scores_gemma":[0.999655,0.0001152523,0.00008798522,0.000020372381,0.00003056443,0.00009092096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026727913,0.00026216582,0.0003043303,0.00059769157,0.0003911041,0.0006085142,0.00031746004,0.0006559967,0.0021581796],"category_scores_gemma":[0.001397647,0.00020605691,0.00033267468,0.0007728184,0.00034883714,0.0005603854,0.00027646584,0.00051703834,0.00028087432],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017616522,0.00012303305,0.96118635,0.00006158835,0.00011200321,0.014118811,0.000089880974,0.0003916222,0.0039460585,0.0002512355,0.0008713569,0.017086305],"study_design_scores_gemma":[0.00026579073,0.0012740963,0.914089,0.000077526835,0.0004076552,0.072093636,0.001048381,0.0023287102,0.0019924857,0.0010579642,0.0053329444,0.00003173222],"about_ca_topic_score_codex":0.0016561183,"about_ca_topic_score_gemma":0.0015478816,"teacher_disagreement_score":0.0021581796,"about_ca_system_score_codex":0.00040904657,"about_ca_system_score_gemma":0.00038465954,"threshold_uncertainty_score":0.0072197914},"labels":[],"label_agreement":null},{"id":"W2977598599","doi":"10.1182/blood-2018-99-116264","title":"A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Interleukin-3 receptor; CD3; CD19; Cmax; Cytokine release syndrome; Cytokine; Chemistry; Immunology; Pharmacology; Antigen; Medicine; Cancer research; T cell; Biology; Pharmacokinetics; Immune system; CD8","score_opus":0.059474206092329174,"score_gpt":0.31518270128561837,"score_spread":0.2557084951932892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977598599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97677225,0.0027577016,0.016050033,0.0002495995,0.00005913719,0.00027299268,0.00052869326,0.00019058668,0.0031189574],"genre_scores_gemma":[0.98148257,0.0011459916,0.013908995,0.00019406535,0.000019524197,0.00016333029,0.00069618074,0.000038455455,0.0023508593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988484,0.000014351556,0.000005782505,0.000023647775,0.000041332896,0.000029978264],"domain_scores_gemma":[0.99993634,0.000006668202,0.00001609203,0.0000052716578,0.000008314103,0.000027317734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018288693,0.00041212555,0.00016629831,0.00017078221,0.00009460459,0.00039022832,0.0003103651,0.00039907344,0.0010776606],"category_scores_gemma":[0.00018001342,0.00009301741,0.00023901639,0.0001157072,0.00015032783,0.00021500517,0.00020679442,0.00067873654,0.00046679733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009620502,0.00013208752,0.00009999056,0.00004826184,0.000008841264,0.000102208425,0.00002370456,0.00056796026,0.99314874,0.00026161538,0.00024293594,0.005267314],"study_design_scores_gemma":[0.00012520255,0.0021089152,0.0012223375,0.0000095875685,0.000035720554,0.000994953,0.000013271092,0.0036353192,0.9814301,0.000113105154,0.010289329,0.000022270855],"about_ca_topic_score_codex":0.00026092574,"about_ca_topic_score_gemma":0.00026966547,"teacher_disagreement_score":0.0010776606,"about_ca_system_score_codex":0.00036245977,"about_ca_system_score_gemma":0.00020336571,"threshold_uncertainty_score":0.0036051273},"labels":[],"label_agreement":null},{"id":"W2977758416","doi":"10.1097/01.hs9.0000564720.36943.22","title":"S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH‐RISK CYTOGENETIC ABNORMALITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical endpoint; Gastroenterology; Clinical trial","score_opus":0.0034592202711760155,"score_gpt":0.20954569199890194,"score_spread":0.20608647172772593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977758416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98661834,0.0064658076,0.00069019804,0.00042008038,0.00007230116,0.0003753495,0.0014480533,0.00024712604,0.0036627678],"genre_scores_gemma":[0.9927154,0.001995046,0.00084252335,0.0004932446,0.000076668584,0.0002560228,0.0019252034,0.000030691357,0.0016651644],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998437,0.000075492586,0.000012944607,0.000021981792,0.000018855355,0.00002698459],"domain_scores_gemma":[0.999718,0.000044868873,0.00009136287,0.000018425813,0.000014751464,0.0001125359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026744916,0.0003348859,0.0010019052,0.00023846143,0.000104291175,0.00036739878,0.00031411168,0.00047018618,0.004682467],"category_scores_gemma":[0.00043313572,0.0001172733,0.00045396635,0.0003516529,0.00022306538,0.00034457914,0.00019829854,0.00068768865,0.0006569739],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21611947,0.011511633,0.028973259,0.0019369386,0.0015535549,0.0015389298,0.00028269787,0.003212565,0.04476912,0.00085737207,0.012169456,0.67707497],"study_design_scores_gemma":[0.27743733,0.41638985,0.18947695,0.0005274823,0.0014857784,0.008582087,0.00033991502,0.0058824066,0.020192869,0.0013264434,0.078245945,0.000112984904],"about_ca_topic_score_codex":0.00039222438,"about_ca_topic_score_gemma":0.0012706418,"teacher_disagreement_score":0.004682467,"about_ca_system_score_codex":0.0003238231,"about_ca_system_score_gemma":0.0006282404,"threshold_uncertainty_score":0.015664458},"labels":[],"label_agreement":null},{"id":"W2977941468","doi":"10.1093/annonc/mdz253.009","title":"Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Persistence (discontinuity); Cancer research; Genetic enhancement; Immunology; Gene; Genetics; Biology","score_opus":0.058004277633815986,"score_gpt":0.3346907633724914,"score_spread":0.2766864857386754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977941468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802506,0.00029964698,0.00034608232,0.00008914742,0.000016108026,0.000026711241,0.00010710931,0.000046694116,0.0010434831],"genre_scores_gemma":[0.99888843,0.00008919901,0.00014808013,0.00004530926,0.000008402138,0.00001612073,0.0001711009,0.0000067189603,0.0006266557],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99991286,0.000013038975,0.0000045009992,0.000019451338,0.000013166907,0.000037052025],"domain_scores_gemma":[0.9999088,0.000028042447,0.000016039921,0.000013125244,0.0000053490708,0.000028538077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017509826,0.00022248783,0.00039730288,0.00014513296,0.00017094074,0.00033419862,0.00013357314,0.00031461637,0.001222585],"category_scores_gemma":[0.00016958709,0.00010904655,0.00021016024,0.00011875536,0.00032354012,0.00023696331,0.00011467348,0.00083846465,0.00030494598],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076288446,0.0036394626,0.0065392083,0.000081062266,0.000065270055,0.0007241827,0.0002086386,0.0010116693,0.9426834,0.00043831544,0.0009922211,0.035987705],"study_design_scores_gemma":[0.0038087287,0.1209114,0.11583924,0.000027619559,0.0004125568,0.009163118,0.00031261696,0.008427194,0.72451615,0.00056578283,0.015969647,0.00004594315],"about_ca_topic_score_codex":0.0005512389,"about_ca_topic_score_gemma":0.0004580377,"teacher_disagreement_score":0.001222585,"about_ca_system_score_codex":0.00022537485,"about_ca_system_score_gemma":0.0002473878,"threshold_uncertainty_score":0.0040899515},"labels":[],"label_agreement":null},{"id":"W2978051080","doi":"10.1016/j.cll.2019.07.011","title":"Laboratory Testing in the Context of Biologics and Cellular Therapies","year":2019,"lang":"en","type":"review","venue":"Clinics in Laboratory Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Monoclonal antibody; Context (archaeology); Computational biology; Medicine; Biology; Immunology; Antibody","score_opus":0.2069582118324191,"score_gpt":0.4468126421681005,"score_spread":0.2398544303356814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978051080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025731528,0.99882513,0.00010564604,0.0003999297,0.00018609165,0.000002269157,0.000008061543,0.000003728997,0.0004434637],"genre_scores_gemma":[0.000606629,0.9977449,0.0002370576,0.0005790262,0.0005636072,0.000005456842,0.000020101928,0.0000014838915,0.00024165037],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988481,0.00039098345,0.0001397245,0.00016709663,0.00037708637,0.000077061784],"domain_scores_gemma":[0.99602807,0.0027755008,0.00034991105,0.00007266256,0.0006325969,0.00014125757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024989268,0.0013902163,0.0028752473,0.0039292346,0.0003711688,0.0022120494,0.0017466389,0.0025668044,0.0038341603],"category_scores_gemma":[0.0045594065,0.00040954346,0.0010341953,0.003229054,0.0015690723,0.0019997586,0.0013075081,0.003730912,0.0015516785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011788353,0.00006448694,0.00037736868,0.014845024,0.0001357156,0.00022835477,0.000059515165,0.00035409065,0.0005836957,0.007588213,0.030721039,0.9449247],"study_design_scores_gemma":[0.00004360627,0.00012026238,0.0011984797,0.014411407,0.00023390415,0.0017143134,0.00012246254,0.00016821234,0.00030593324,0.0075273495,0.9741097,0.00004436247],"about_ca_topic_score_codex":0.002110435,"about_ca_topic_score_gemma":0.0038342585,"teacher_disagreement_score":0.0039292346,"about_ca_system_score_codex":0.001493635,"about_ca_system_score_gemma":0.0024682106,"threshold_uncertainty_score":0.013215721},"labels":[],"label_agreement":null},{"id":"W2978587517","doi":"10.1038/s41467-019-12441-w","title":"Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Blood Cancer UK; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Effector; Cell biology; T cell; Antigen; Biology; Adoptive cell transfer; Function (biology); Receptor; Chemistry; Immune system; Immunology; Biochemistry","score_opus":0.017009512821761677,"score_gpt":0.29945195658022306,"score_spread":0.2824424437584614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978587517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9371855,0.0019426127,0.057150595,0.0001230296,0.00005829191,0.00012211969,0.0002735475,0.0003768952,0.0027673652],"genre_scores_gemma":[0.9777874,0.00091996585,0.019617854,0.00004731707,0.000010722491,0.00003420944,0.00019689968,0.0000682029,0.0013174359],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984205,0.00002930525,0.000009606324,0.000028506796,0.000050595158,0.00003995191],"domain_scores_gemma":[0.99992156,0.0000134167085,0.000032555425,0.000009538199,0.000008120017,0.000014885654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015618908,0.00047954672,0.00020668896,0.00020546952,0.00010590406,0.0002934092,0.000240619,0.00030647966,0.0007378676],"category_scores_gemma":[0.00016156228,0.00015356869,0.00022770371,0.00018442284,0.0001864587,0.00015191898,0.00026897195,0.00047313827,0.00028412355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017861597,0.000009880936,0.000036580794,0.000019419467,0.000004757488,0.00003914917,0.000008536375,0.00030712408,0.9983145,0.0002282348,0.000021776252,0.0009922382],"study_design_scores_gemma":[0.0000157806,0.00019697807,0.00029179154,0.000003114356,0.000020292415,0.00030673272,0.0000071030786,0.0013048114,0.9936698,0.0000742517,0.0041050017,0.000004396095],"about_ca_topic_score_codex":0.00036186766,"about_ca_topic_score_gemma":0.0006476476,"teacher_disagreement_score":0.0007378676,"about_ca_system_score_codex":0.0002541702,"about_ca_system_score_gemma":0.00020663832,"threshold_uncertainty_score":0.0024684668},"labels":[],"label_agreement":null},{"id":"W2978615859","doi":"10.1093/annonc/mdz260.112","title":"Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Receptor; Cancer research; Immunology; Pharmacology; Immunotherapy; Internal medicine; Adverse effect; Immune system","score_opus":0.03664897699676808,"score_gpt":0.3661601596427191,"score_spread":0.32951118264595103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978615859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652207,0.0017304177,0.00023255986,0.00010928527,0.0000689149,0.00037422532,0.00031635832,0.000027892243,0.00061829825],"genre_scores_gemma":[0.996837,0.00091383554,0.00023808038,0.00014450142,0.00011438779,0.0004405956,0.0004414473,0.00001138362,0.000858702],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993086,0.00033631717,0.000034222132,0.00010722742,0.00006393988,0.00014969241],"domain_scores_gemma":[0.9993724,0.00017823756,0.00013677892,0.000061395745,0.000031308995,0.00021983348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015025616,0.0012559061,0.00188744,0.00039944323,0.0002967983,0.0009687421,0.00076360075,0.0012828881,0.002595191],"category_scores_gemma":[0.0008832171,0.0005686036,0.0017052923,0.00038215745,0.0013219966,0.0011549774,0.00025640387,0.0027873802,0.0007761247],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8909056,0.02769583,0.0024219216,0.00046900814,0.0010944074,0.0001128444,0.000121021425,0.0016857873,0.034642223,0.00015995745,0.00084502576,0.039846297],"study_design_scores_gemma":[0.33134744,0.65364826,0.008205402,0.000023920506,0.0008640115,0.00012282956,0.00005892746,0.000850908,0.003849102,0.00016341709,0.00083877874,0.000027113265],"about_ca_topic_score_codex":0.00082971767,"about_ca_topic_score_gemma":0.0012886439,"teacher_disagreement_score":0.002595191,"about_ca_system_score_codex":0.0008754456,"about_ca_system_score_gemma":0.0007585193,"threshold_uncertainty_score":0.008681774},"labels":[],"label_agreement":null},{"id":"W2978880457","doi":"10.1093/annonc/mdz394.065","title":"5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Nivolumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.08452269851717625,"score_gpt":0.42905341939770825,"score_spread":0.344530720880532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978880457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98891,0.005130837,0.00018332506,0.00045152506,0.00017866075,0.00019165198,0.0020113103,0.000033598986,0.0029090983],"genre_scores_gemma":[0.9911345,0.001599413,0.00025538163,0.00069075066,0.000188585,0.00023702272,0.0034987053,0.000016985345,0.0023786],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9994941,0.00024232673,0.00002445929,0.00008668578,0.000055658336,0.000096797616],"domain_scores_gemma":[0.99927133,0.00017769953,0.00017862758,0.00006008927,0.000042007036,0.00027019717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017131959,0.0006899817,0.0011305931,0.00035007115,0.0003298894,0.0011818497,0.0005845201,0.0008918861,0.0025617627],"category_scores_gemma":[0.001100645,0.00023773,0.0020375347,0.0003289077,0.0004341814,0.0007066648,0.00035228493,0.0021244031,0.0004641668],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80669034,0.010058474,0.033019725,0.00099419,0.0074423836,0.00015639424,0.00015996903,0.008709624,0.010412571,0.0006249133,0.011714751,0.11001672],"study_design_scores_gemma":[0.37937516,0.35083067,0.22555907,0.0003163596,0.013587383,0.0006143392,0.0002592892,0.010021338,0.004501309,0.0015702997,0.013226924,0.00013784909],"about_ca_topic_score_codex":0.0012331383,"about_ca_topic_score_gemma":0.0035777194,"teacher_disagreement_score":0.0025617627,"about_ca_system_score_codex":0.0008917145,"about_ca_system_score_gemma":0.00068396924,"threshold_uncertainty_score":0.009060383},"labels":[],"label_agreement":null},{"id":"W2979129329","doi":"10.1093/annonc/mdz398","title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Centre Hospitalier Universitaire Vaudois; Université de Lausanne; National Cancer Institute; Ludwig Institute for Cancer Research","keywords":"Medicine; Meta-analysis; Melanoma; Internal medicine; Oncology; Confidence interval; Interleukin 2; Immunotherapy; Clinical endpoint; Aldesleukin; Surgery; Gastroenterology; Clinical trial; Cancer; Cytokine; Cancer research","score_opus":0.1985229517320195,"score_gpt":0.4500510520698057,"score_spread":0.2515281003377862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979129329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00899989,0.98966426,0.000348669,0.0001120082,0.0001377944,0.00015883271,0.00033957793,0.000020698284,0.00021830233],"genre_scores_gemma":[0.2756205,0.7197627,0.0014938252,0.0012790282,0.00023584804,0.0004629096,0.00059562305,0.000029778737,0.0005197884],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99708194,0.0011478163,0.00089668925,0.0004103794,0.00031341478,0.0001496917],"domain_scores_gemma":[0.9945807,0.0035704002,0.0012361793,0.00018502379,0.00031475048,0.00011289823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004828496,0.0019374422,0.013631327,0.0022390808,0.0003594305,0.0021519074,0.0018414259,0.00204262,0.0036289592],"category_scores_gemma":[0.010484163,0.0011464674,0.023872085,0.0032261438,0.0006064773,0.001322637,0.0011296028,0.0018044886,0.00032316492],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006035838,0.00007232203,0.00398865,0.34928524,0.62343,0.000118431504,0.000104825485,0.00052482093,0.00046639002,0.000120386394,0.0006427053,0.015210417],"study_design_scores_gemma":[0.0014836438,0.00037584562,0.0033156418,0.010065409,0.9830615,0.00005876669,0.00004803722,0.00013266335,0.000093735325,0.00010407406,0.0012382815,0.000022454253],"about_ca_topic_score_codex":0.0047342097,"about_ca_topic_score_gemma":0.013438138,"teacher_disagreement_score":0.013631327,"about_ca_system_score_codex":0.0015471479,"about_ca_system_score_gemma":0.001707479,"threshold_uncertainty_score":0.025535822},"labels":[],"label_agreement":null},{"id":"W2979548369","doi":"10.1016/s1470-2045(19)30493-0","title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Novartis","keywords":"Medicine; Refractory (planetary science); Quality of life (healthcare); Young adult; Pediatrics; Oncology; Internal medicine; Biology","score_opus":0.03486376564826552,"score_gpt":0.34536738574798603,"score_spread":0.3105036200997205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979548369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590355,0.0022145638,0.00010285736,0.0003407612,0.00006118217,0.0002475122,0.0006440788,0.000031248375,0.00045420855],"genre_scores_gemma":[0.9945673,0.0015877344,0.00034122434,0.0005831297,0.000093011484,0.0008419272,0.001159238,0.000011688677,0.00081477256],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99950874,0.00024594017,0.000020697,0.00008651296,0.00003426792,0.00010371411],"domain_scores_gemma":[0.9993278,0.00012473833,0.00018368215,0.00003536265,0.00002598346,0.00030248336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009309913,0.0013794682,0.002090033,0.0002568455,0.0002544386,0.0010084978,0.00064269867,0.001198532,0.0023196219],"category_scores_gemma":[0.000870003,0.0003348789,0.0019523723,0.0003899472,0.0010609905,0.0007895973,0.0005760089,0.0030796912,0.00045622938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91516566,0.010222602,0.012708868,0.00093064393,0.003507338,0.00018810562,0.0002521569,0.0011765956,0.0040281494,0.0002341597,0.002437134,0.049148545],"study_design_scores_gemma":[0.7866395,0.16103023,0.04670837,0.00009702931,0.0015208968,0.0002698981,0.00015467092,0.00081708166,0.00079843035,0.0002634039,0.0016559765,0.00004447459],"about_ca_topic_score_codex":0.0011101412,"about_ca_topic_score_gemma":0.002393512,"teacher_disagreement_score":0.0023196219,"about_ca_system_score_codex":0.0009107757,"about_ca_system_score_gemma":0.00083749404,"threshold_uncertainty_score":0.0077599287},"labels":[],"label_agreement":null},{"id":"W2979816540","doi":"10.1182/blood.v118.21.167.167","title":"B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Adoptive cell transfer; CD19; Immunology; Fludarabine; Chronic lymphocytic leukemia; Lymphoma; Antigen; Leukemia; Cyclophosphamide; T cell; Cancer research; Internal medicine; Chemotherapy; Immune system","score_opus":0.05633769417147613,"score_gpt":0.326840488072401,"score_spread":0.2705027939009249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979816540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947654,0.0012401944,0.00051367946,0.0003971613,0.00012723946,0.00076815306,0.0001661718,0.000059379752,0.0019625279],"genre_scores_gemma":[0.9950597,0.0006541415,0.00059161213,0.0005431999,0.00011305219,0.0011224877,0.000495974,0.000015897996,0.0014038819],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994203,0.0003107372,0.000030110888,0.00005008582,0.000053448082,0.00013531311],"domain_scores_gemma":[0.99927765,0.0002153969,0.00008282137,0.0000567575,0.000040092174,0.0003272239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015675745,0.0011305365,0.0015016405,0.0004102908,0.00052512414,0.00084811467,0.0006647051,0.0015321311,0.0015482657],"category_scores_gemma":[0.0010456722,0.0003372573,0.00058893004,0.00027803893,0.0009089153,0.0005605192,0.0003149645,0.0025181188,0.0004488773],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6169543,0.092217274,0.009163387,0.0010553423,0.0010238498,0.0023957745,0.0006419443,0.005581595,0.080289945,0.0020489625,0.0066805175,0.18194711],"study_design_scores_gemma":[0.2719093,0.7020459,0.00763339,0.000054608106,0.0001716811,0.00097372726,0.00005831009,0.0024949156,0.010009273,0.00029010983,0.0043238075,0.00003490971],"about_ca_topic_score_codex":0.00054337824,"about_ca_topic_score_gemma":0.0009287099,"teacher_disagreement_score":0.0015675745,"about_ca_system_score_codex":0.00066339696,"about_ca_system_score_gemma":0.0010072034,"threshold_uncertainty_score":0.008290231},"labels":[],"label_agreement":null},{"id":"W2979850125","doi":"10.1182/blood.v120.21.3729.3729","title":"Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Immunology; Immunotherapy; NKG2D; K562 cells; Peripheral blood mononuclear cell; Medicine; Immunophenotyping; Cytotoxic T cell; Interferon gamma; Leukemia; Myeloid leukemia; Immune system; Biology; In vitro; Antigen","score_opus":0.018237107019923933,"score_gpt":0.27089205772571906,"score_spread":0.25265495070579513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979850125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876773,0.00014478515,0.0001401777,0.0000090227295,0.000003258508,0.000010378445,0.00006241205,0.000007323991,0.0008548534],"genre_scores_gemma":[0.998892,0.000079268895,0.00016414844,0.00003020095,0.0000071453264,0.000016759035,0.00020653411,0.000003262107,0.0006007841],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999224,0.000013312285,0.000010821944,0.000018017532,0.0000147696,0.000020631884],"domain_scores_gemma":[0.99986327,0.00003602787,0.000032117092,0.000018584544,0.00001440497,0.000035615223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000995102,0.00016074341,0.0002228445,0.00019201537,0.00013279718,0.00020534906,0.000057090056,0.00015981453,0.0020323696],"category_scores_gemma":[0.0002539113,0.0000782127,0.00006642983,0.000115472205,0.000117882664,0.000103348015,0.000090205445,0.0002039564,0.00041086323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00277413,0.00025174321,0.16164312,0.000055553366,0.000031892574,0.0017056791,0.0004008989,0.00014559431,0.8075356,0.0001098069,0.00023942212,0.025106572],"study_design_scores_gemma":[0.00012320714,0.003226196,0.91719896,0.000020183434,0.000049628732,0.0079673445,0.00024283436,0.00072007586,0.06749721,0.00012998359,0.0028129844,0.0000114308605],"about_ca_topic_score_codex":0.0003013165,"about_ca_topic_score_gemma":0.0003652951,"teacher_disagreement_score":0.0020323696,"about_ca_system_score_codex":0.00009841122,"about_ca_system_score_gemma":0.00006528627,"threshold_uncertainty_score":0.0067989826},"labels":[],"label_agreement":null},{"id":"W2980176712","doi":"10.1182/blood.v124.21.3841.3841","title":"TGF-Beta Signaling Favors Central Memory Phenotype Expression By Ex-Vivo Stimulated Human T Cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD28; Ex vivo; T cell; Biology; Cell biology; Cytotoxic T cell; CD8; Homing (biology); Adoptive cell transfer; Transforming growth factor beta; IL-2 receptor; Cytokine; Immunology; Cancer research; Transforming growth factor; In vivo; Immune system; In vitro","score_opus":0.01853857482162006,"score_gpt":0.2808982350244735,"score_spread":0.2623596602028534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980176712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711084,0.0008251951,0.0007921019,0.000033590808,0.000019190367,0.000013549424,0.00015822591,0.00004079509,0.0010065732],"genre_scores_gemma":[0.9977029,0.00024352985,0.00055412366,0.000038868126,0.000020501333,0.000019490517,0.00030597064,0.000009630653,0.0011049751],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990153,0.000028931325,0.000009351279,0.000018049352,0.000013468359,0.000028726827],"domain_scores_gemma":[0.99989784,0.000037131063,0.0000142645495,0.00001360794,0.0000128405,0.000024284747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012552302,0.00028738266,0.00021982129,0.00014841672,0.0000788618,0.00024100403,0.000085097905,0.00017124532,0.0020587523],"category_scores_gemma":[0.00008790955,0.000080868864,0.00013085375,0.00009165022,0.00008787586,0.00010159863,0.00012900196,0.0004696211,0.00050107396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051250466,0.0000708332,0.0003125713,0.000030179968,0.000002775862,0.00005825308,0.000023161907,0.000046396122,0.9975681,0.00003380573,0.000052643234,0.0012887573],"study_design_scores_gemma":[0.000055372337,0.0010946371,0.00359299,0.0000088753795,0.000017894203,0.00033778924,0.00003082605,0.00086222263,0.99246913,0.000031170744,0.0014960052,0.0000031661111],"about_ca_topic_score_codex":0.00019250429,"about_ca_topic_score_gemma":0.00016958627,"teacher_disagreement_score":0.0020587523,"about_ca_system_score_codex":0.0000843497,"about_ca_system_score_gemma":0.00008772047,"threshold_uncertainty_score":0.0068871975},"labels":[],"label_agreement":null},{"id":"W2980189653","doi":"10.1016/j.smim.2019.101281","title":"Advances in T-cell co-receptor biology and cancer immunotherapy","year":2019,"lang":"en","type":"editorial","venue":"Seminars in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Cancer; Cancer research; Biology; Computational biology; Genetics","score_opus":0.008781475914867378,"score_gpt":0.34932376429446316,"score_spread":0.34054228837959577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980189653","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003386624,0.016955987,0.00017205472,0.0246775,0.956821,0.000012951064,0.00002201582,0.000035297897,0.0012692657],"genre_scores_gemma":[0.00042477107,0.009650206,0.00009810081,0.0097125415,0.9726308,0.00001362219,0.000015195375,0.00001536315,0.0074394643],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99634117,0.00082799146,0.00041095403,0.00038906676,0.0017213604,0.0003094261],"domain_scores_gemma":[0.9885455,0.005723379,0.00067580293,0.00025649276,0.0030041786,0.0017946359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007752642,0.004330303,0.0030355195,0.0031351517,0.0017639156,0.0056576356,0.003110414,0.013006343,0.012780215],"category_scores_gemma":[0.013017715,0.0011602399,0.0020795946,0.0010872517,0.0023470582,0.004515767,0.0017237664,0.018145269,0.0080365855],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102245525,0.000022519214,0.000022912527,0.00046299037,0.000026444084,0.00013366716,0.000011652015,0.000041525247,0.00019340606,0.0008544848,0.98584914,0.01227905],"study_design_scores_gemma":[0.00010193945,0.000053059317,0.0001814799,0.00027267248,0.00006828439,0.00028976714,0.000026092126,0.00021006411,0.00022228577,0.0021814746,0.996375,0.000017701888],"about_ca_topic_score_codex":0.00082859304,"about_ca_topic_score_gemma":0.0024098929,"teacher_disagreement_score":0.013006343,"about_ca_system_score_codex":0.003148319,"about_ca_system_score_gemma":0.0022948869,"threshold_uncertainty_score":0.042754114},"labels":[],"label_agreement":null},{"id":"W2980338073","doi":"10.1182/blood-2018-99-116879","title":"Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; Leukemia & Lymphoma Society of Canada; Ottawa Hospital","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Cohort; Retrospective cohort study; Chimeric antigen receptor; Surgery; Pediatrics; Cancer; Immunotherapy","score_opus":0.04342856139981292,"score_gpt":0.30487345148900186,"score_spread":0.2614448900891889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980338073","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6038259,0.025090476,0.0020792652,0.3329944,0.0014431438,0.00095792615,0.0062462427,0.00043450587,0.026928049],"genre_scores_gemma":[0.96838224,0.013168746,0.0034849255,0.008478952,0.00076818326,0.00025540468,0.0027798482,0.000058856003,0.0026228596],"study_design_codex":"observational","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9983291,0.00031259502,0.00009055849,0.00009692335,0.00046499298,0.0007059001],"domain_scores_gemma":[0.989805,0.0009491941,0.0012656942,0.0003620336,0.0031194221,0.0044986494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024777243,0.0002915212,0.0004942434,0.0012347967,0.00324448,0.0042242683,0.002484663,0.00078492175,0.0073040323],"category_scores_gemma":[0.010620146,0.00018936374,0.0005330281,0.0013191465,0.0018739089,0.0022610324,0.0020069536,0.0015463223,0.0010917182],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032129118,0.00037021036,0.466682,0.0011641929,0.00015335948,0.0013271513,0.0044111717,0.0010762932,0.0012817595,0.004374065,0.18983038,0.32900816],"study_design_scores_gemma":[0.00013101846,0.00082897634,0.70586824,0.00452862,0.00021130462,0.001259304,0.03989694,0.0014699873,0.0018061185,0.004874465,0.23892127,0.00020378643],"about_ca_topic_score_codex":0.5169918,"about_ca_topic_score_gemma":0.6622507,"teacher_disagreement_score":0.5169918,"about_ca_system_score_codex":0.014634574,"about_ca_system_score_gemma":0.06192117,"threshold_uncertainty_score":0.9717055},"labels":[],"label_agreement":null},{"id":"W2980440810","doi":"10.1182/blood.v104.11.4194.4194","title":"Transgenic Blimp-1 Promoter Directs Hematopoietic Specific Gene Expression in Mice.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Biology; Molecular biology; Promoter; Transfection; Transgene; clone (Java method); Gene; Repressor; Gene expression; Genetics","score_opus":0.02726622442150989,"score_gpt":0.28361040690557887,"score_spread":0.256344182484069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980440810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76594025,0.016298559,0.14751059,0.0023396462,0.0011904275,0.0030154947,0.032513704,0.008354248,0.022837121],"genre_scores_gemma":[0.8069841,0.010072559,0.0895002,0.00085574866,0.00026704773,0.0034962073,0.02131333,0.002054165,0.06545664],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988938,0.00012872442,0.00010599432,0.0003635213,0.00027721946,0.0002308191],"domain_scores_gemma":[0.99934965,0.00009204252,0.00027060517,0.00007928155,0.00004496931,0.0001635912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010405668,0.0013035671,0.0006560611,0.0024156142,0.0005465801,0.0010128306,0.0015133244,0.0020555807,0.006870718],"category_scores_gemma":[0.00027174753,0.0012987575,0.0010780452,0.00087275996,0.0008226477,0.0008199704,0.00071088306,0.003984476,0.004502052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026189446,0.00017359944,0.00011568794,0.00010756249,0.000011688001,0.00014142759,0.00004127889,0.00009974579,0.9957872,0.0006078872,0.00029872684,0.0023533476],"study_design_scores_gemma":[0.00022429445,0.00070749363,0.0018351881,0.00006867447,0.000062740684,0.0011624459,0.00003660497,0.0016336346,0.9763302,0.00025450406,0.01766355,0.000020676585],"about_ca_topic_score_codex":0.0005435554,"about_ca_topic_score_gemma":0.0007757461,"teacher_disagreement_score":0.006870718,"about_ca_system_score_codex":0.0008272321,"about_ca_system_score_gemma":0.00042226652,"threshold_uncertainty_score":0.022984862},"labels":[],"label_agreement":null},{"id":"W2981117365","doi":"10.1182/blood-2018-99-120120","title":"Synthetic De Novo Modeling of Human T-Cell Acute Lymphoblastic Leukemia Reveals HOXB Genes Drive Expansion of Leukemia Cells-of-Origin and Established Tumor Clones","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; Leukemia; Cancer research; Progenitor cell; Haematopoiesis; Context (archaeology); Transcriptome; Stem cell; Immunology; Molecular biology; Gene; Genetics; Gene expression","score_opus":0.021214119919132746,"score_gpt":0.2869788202060972,"score_spread":0.2657647002869645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981117365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760741,0.00025355897,0.020414233,0.00004894172,0.00002047508,0.00011397278,0.0009968961,0.00017395287,0.0019039253],"genre_scores_gemma":[0.98456013,0.00032690034,0.011764776,0.000017579245,0.0000035671849,0.000088873974,0.0009957824,0.000058689195,0.0021837386],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9999182,0.0000110932915,0.000006593564,0.000019089302,0.00003094333,0.000013985544],"domain_scores_gemma":[0.9999521,0.000008161583,0.000016793148,0.000007916092,0.0000052683636,0.000009775144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001280966,0.00020626764,0.000115750125,0.00013028762,0.000095052754,0.000293079,0.0001707145,0.00013270503,0.00082930666],"category_scores_gemma":[0.00007276512,0.000105620755,0.00015114654,0.00009780742,0.00012559905,0.00006992462,0.00017672947,0.000333342,0.00027081746],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034354503,0.00001677178,0.00013567088,0.00001273903,0.0000020633688,0.000031201267,0.000011628402,0.0010407909,0.997783,0.00025944912,0.000026428326,0.0006458514],"study_design_scores_gemma":[0.000009542118,0.00019938046,0.0007280612,0.00000239098,0.0000068833338,0.00008018249,0.000014519858,0.0077026896,0.9880278,0.00006392517,0.0031620169,0.0000026058653],"about_ca_topic_score_codex":0.0004555731,"about_ca_topic_score_gemma":0.0005465658,"teacher_disagreement_score":0.00082930666,"about_ca_system_score_codex":0.00024112701,"about_ca_system_score_gemma":0.00013102342,"threshold_uncertainty_score":0.0027742982},"labels":[],"label_agreement":null},{"id":"W2981248828","doi":"10.2174/1389450120666191017113051","title":"Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Current Drug Targets","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Radiation therapy; Chimeric antigen receptor; Renal cell carcinoma; Immunotherapy; Immune checkpoint; Cancer research; Immune system; Oncology; Cancer; Antigen; Cytotoxic T cell; Kidney cancer; Internal medicine; Immunology; Biology; In vitro","score_opus":0.019738252917048088,"score_gpt":0.2927848299684734,"score_spread":0.2730465770514253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981248828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031124678,0.96034205,0.0017374121,0.00055471295,0.0002478889,0.00004632621,0.000087715816,0.00005608156,0.005803114],"genre_scores_gemma":[0.23717499,0.75595695,0.0023166053,0.0005575562,0.00033918992,0.00006276493,0.00024321732,0.000015164304,0.0033336522],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999231,0.000020170883,0.00000730704,0.000012868678,0.00002304088,0.000013583844],"domain_scores_gemma":[0.99995434,0.000020851818,0.000010462887,0.0000026649604,0.000007075305,0.000004583066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025696773,0.00018044544,0.00037807773,0.0003761913,0.00009434369,0.00033074152,0.00024143136,0.00027928627,0.0014125691],"category_scores_gemma":[0.00016340999,0.00006986158,0.00029049022,0.00030763482,0.00015852206,0.0002717258,0.00018068045,0.00042647283,0.0004044466],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011621007,0.00037069523,0.0013159462,0.0093912445,0.00024075048,0.001019337,0.00015024228,0.002361792,0.073727004,0.004613925,0.007526309,0.8981206],"study_design_scores_gemma":[0.0005733987,0.0097274035,0.010114027,0.0023347093,0.0011022614,0.010704058,0.00016516025,0.0025801996,0.1790399,0.0032148685,0.7803718,0.00007227892],"about_ca_topic_score_codex":0.0003686348,"about_ca_topic_score_gemma":0.0009208864,"teacher_disagreement_score":0.0014125691,"about_ca_system_score_codex":0.00027397362,"about_ca_system_score_gemma":0.00026342663,"threshold_uncertainty_score":0.004725516},"labels":[],"label_agreement":null},{"id":"W2981261950","doi":"10.1182/bloodadvances.2018026575","title":"Generation and function of progenitor T cells from StemRegenin-1–expanded CD34+ human hematopoietic progenitor cells","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; Canadian Institutes of Health Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Canada First Research Excellence Fund; National Cancer Institute; National Institutes of Health; Children's Cancer Research Fund; Ontario Institute for Regenerative Medicine; Krembil Foundation; University of Toronto","keywords":"Progenitor cell; CD34; Haematopoiesis; Progenitor; Cell biology; Function (biology); Interleukin 3; Stem cell; Biology; Immunology; T cell; Antigen-presenting cell","score_opus":0.02414054077781971,"score_gpt":0.2921499308567681,"score_spread":0.2680093900789484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981261950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99210984,0.0014152015,0.004272296,0.00003682464,0.0000115385155,0.00013578688,0.0004088579,0.00004781692,0.0015617568],"genre_scores_gemma":[0.9925627,0.00084992946,0.0034763212,0.000034075405,0.0000131426905,0.00010034803,0.0011663411,0.000016232183,0.0017810131],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989927,0.000020912901,0.0000128952015,0.000021015505,0.000026005066,0.000019975756],"domain_scores_gemma":[0.9999552,0.0000068378517,0.000007798177,0.000009324787,0.000006075184,0.000014873171],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018789773,0.00030064816,0.00018251222,0.00020552732,0.00013386348,0.00028175805,0.00014298229,0.00019502427,0.0012819653],"category_scores_gemma":[0.00009549092,0.000095550124,0.0001887269,0.00013077466,0.00011899556,0.00011789548,0.00016224696,0.00046458578,0.00047312383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002348241,0.00008392449,0.00044349782,0.00004487397,0.000005545898,0.0000658621,0.000040673902,0.00017655993,0.99225336,0.00014899008,0.000057946927,0.006443963],"study_design_scores_gemma":[0.000059702168,0.0015945698,0.007058704,0.000011615779,0.000034062818,0.0006038896,0.00002762553,0.0015317068,0.98582286,0.000076940865,0.0031733871,0.000004967777],"about_ca_topic_score_codex":0.00031989027,"about_ca_topic_score_gemma":0.0003169085,"teacher_disagreement_score":0.0012819653,"about_ca_system_score_codex":0.000099572666,"about_ca_system_score_gemma":0.00014026943,"threshold_uncertainty_score":0.004288614},"labels":[],"label_agreement":null},{"id":"W2981355057","doi":"10.14288/1.0383301","title":"Engineered antigen-specific regulatory T cells","year":2019,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Antigen; Cell biology; Computational biology; Chemistry; Biology; Immunology","score_opus":0.010564851257838587,"score_gpt":0.1899268816691796,"score_spread":0.179362030411341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981355057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7278559,0.009396401,0.23130609,0.00042202402,0.0008777176,0.0004739553,0.0011176058,0.002385703,0.026164522],"genre_scores_gemma":[0.89745724,0.0038428614,0.07793158,0.0003913333,0.000082853636,0.00024275797,0.0010019904,0.00010965535,0.018939847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998784,0.000016986414,0.000008663922,0.000026200905,0.00004427034,0.00002545162],"domain_scores_gemma":[0.99997103,0.000005064168,0.0000069202797,0.000004184484,0.000006376586,0.0000064837886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014284656,0.00031420632,0.00015565385,0.00015533848,0.00006667849,0.0003034258,0.00032166246,0.0002887105,0.0014786483],"category_scores_gemma":[0.00009524946,0.00009805675,0.00019572956,0.00009421316,0.00008984883,0.00015025403,0.00016630831,0.00049344974,0.0005740287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007719645,0.00007401429,0.00010083526,0.000110469184,0.000006232495,0.00008833119,0.000015465725,0.000928837,0.9797554,0.0013994491,0.0003073664,0.017136453],"study_design_scores_gemma":[0.000057588833,0.00075076165,0.00033747178,0.000016464504,0.000026388225,0.00037509293,0.000010803835,0.0034500733,0.9592271,0.0004086412,0.035331115,0.000008429472],"about_ca_topic_score_codex":0.00007270893,"about_ca_topic_score_gemma":0.00016782261,"teacher_disagreement_score":0.0014786483,"about_ca_system_score_codex":0.00011205648,"about_ca_system_score_gemma":0.00015501252,"threshold_uncertainty_score":0.00494653},"labels":[],"label_agreement":null},{"id":"W2981371759","doi":"10.1200/cci.19.00086","title":"Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model","year":2019,"lang":"en","type":"article","venue":"JCO Clinical Cancer Informatics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Guelph; University of Waterloo","funders":"","keywords":"Chimeric antigen receptor; Medicine; Lymphoma; Refractory (planetary science); Chemotherapy; Internal medicine; Oncology; Immunotherapy; Cancer; Biology","score_opus":0.06868740518263323,"score_gpt":0.4467243361099316,"score_spread":0.3780369309272984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981371759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94705695,0.0003691467,0.041810613,0.001193799,0.000086076354,0.00019386473,0.0015383394,0.00015561286,0.007595692],"genre_scores_gemma":[0.9933696,0.00016228275,0.00390814,0.00009126395,0.000012134964,0.00015332435,0.00045435177,0.000009772399,0.0018393255],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99930215,0.0003244362,0.00002749816,0.00009340814,0.00006377881,0.00018879726],"domain_scores_gemma":[0.99432594,0.004292058,0.00055393594,0.00009219684,0.0003666517,0.00036932653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016662906,0.0009913921,0.001204302,0.0008547674,0.00060052495,0.0013884552,0.0014511885,0.0019426913,0.0034716919],"category_scores_gemma":[0.0048532705,0.00055094156,0.0016253354,0.000605711,0.0010149489,0.00065936794,0.0010088197,0.001571054,0.00019936325],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008361757,0.000052244613,0.0020879118,0.000011016072,0.000021015408,0.000045596164,0.000010437099,0.99658847,0.00008844756,0.00060774223,0.0000805235,0.00032305415],"study_design_scores_gemma":[0.000047851936,0.00005234129,0.0003774938,0.0000035122105,0.00001917941,0.000005518773,0.000019342524,0.99906796,0.000066286666,0.00027526438,0.000060210165,0.0000050528292],"about_ca_topic_score_codex":0.05389485,"about_ca_topic_score_gemma":0.01914341,"teacher_disagreement_score":0.05389485,"about_ca_system_score_codex":0.0024614402,"about_ca_system_score_gemma":0.0025150569,"threshold_uncertainty_score":0.1071623},"labels":[],"label_agreement":null},{"id":"W2981595408","doi":"10.1186/s40425-019-0762-2","title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; EMD Serono; Eisai; Servier; Amgen; Pfizer; Daiichi Sankyo Europe; Eli Lilly and Company; Eurostars; GlaxoSmithKline","keywords":"Medicine; T cell; Immunology; Fludarabine; Tumor microenvironment; Progressive disease; Synovial sarcoma; Cytotoxic T cell; Immune system; Cancer research; Internal medicine; Pathology; Sarcoma; Biology; Disease; Chemotherapy","score_opus":0.018535859971319776,"score_gpt":0.3255511113769634,"score_spread":0.3070152514056436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981595408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99941945,0.00014821878,0.00015030873,0.000011635528,0.000005415706,0.00001385424,0.000028227794,0.000009555647,0.0002134153],"genre_scores_gemma":[0.9994355,0.00007825813,0.000110835856,0.000020206318,0.000008473102,0.000017935523,0.0000930958,0.0000027467006,0.00023291435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998747,0.000029520796,0.000009058523,0.000024183537,0.00002479401,0.00003766194],"domain_scores_gemma":[0.99988115,0.000023524199,0.00002698668,0.000015977892,0.0000064046317,0.000045929974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021629148,0.00022970789,0.00033420496,0.0001393574,0.00010059537,0.00016463775,0.000107881955,0.00015671241,0.0006482766],"category_scores_gemma":[0.00018799253,0.00009354417,0.00018393411,0.000098855904,0.0002139918,0.00014930443,0.00015756903,0.0004849665,0.00017136145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011510734,0.0025837747,0.014624357,0.00010383191,0.00005811337,0.0005418268,0.00019529626,0.0013771591,0.9300939,0.0001034563,0.00045218246,0.038355503],"study_design_scores_gemma":[0.0017987012,0.14307064,0.21944879,0.00003221348,0.00032533932,0.0038811765,0.00044054972,0.006317065,0.6208394,0.00026132603,0.003554866,0.00002982566],"about_ca_topic_score_codex":0.00028451442,"about_ca_topic_score_gemma":0.0004487594,"teacher_disagreement_score":0.0006482766,"about_ca_system_score_codex":0.00015931365,"about_ca_system_score_gemma":0.00015836312,"threshold_uncertainty_score":0.0021687746},"labels":[],"label_agreement":null},{"id":"W2981626013","doi":"10.1182/bloodadvances.2019000593","title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Hematopoietic cell; CAR T-cell therapy; CD19; Medicine; Cell therapy; Hematopoietic stem cell transplantation; Genetic enhancement; Haematopoiesis; Oncology; Toxicity; Chimeric antigen receptor; Internal medicine; Immunology; Transplantation; Stem cell; T cell; Peripheral blood; Biology; Gene; Immune system","score_opus":0.006991509777375879,"score_gpt":0.24902891076368824,"score_spread":0.24203740098631238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981626013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763394,0.00865138,0.0013373859,0.0002329198,0.000034743545,0.000019548408,0.00014603618,0.000028627652,0.0019154592],"genre_scores_gemma":[0.9982962,0.0009837946,0.00023403745,0.00013974828,0.00004768869,0.000008118174,0.0001645827,0.0000047380904,0.00012108563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994429,0.00024782086,0.000086381784,0.000049607675,0.00011922448,0.000054017895],"domain_scores_gemma":[0.9979107,0.00075673213,0.0007959417,0.00009453434,0.00019918384,0.00024296065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012060513,0.00012774578,0.00034059118,0.0001531842,0.00017591055,0.0004521671,0.00013240812,0.00026538814,0.0005627533],"category_scores_gemma":[0.0029576567,0.000046781744,0.00023413895,0.0002244947,0.00018105227,0.00021695014,0.00018784648,0.00031764715,0.00020359014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006141093,0.00023453606,0.7048656,0.0003898328,0.00018333521,0.005097098,0.00058750133,0.0013748975,0.013720813,0.00061981654,0.0014912534,0.26529434],"study_design_scores_gemma":[0.0004821836,0.042089947,0.84681374,0.00043612995,0.00064133614,0.04831869,0.0007932982,0.004318224,0.026521003,0.0009941567,0.028558232,0.00003308175],"about_ca_topic_score_codex":0.00022457776,"about_ca_topic_score_gemma":0.00026661865,"teacher_disagreement_score":0.0012060513,"about_ca_system_score_codex":0.00027437593,"about_ca_system_score_gemma":0.00026461147,"threshold_uncertainty_score":0.006378293},"labels":[],"label_agreement":null},{"id":"W2981778203","doi":"10.1002/biot.201900286","title":"Adeno‐Associated Viral Vectors for Homology‐Directed Generation of CAR‐T Cells","year":2019,"lang":"en","type":"review","venue":"Biotechnology Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Homology (biology); Computational biology; Virology; Biology; Genetics; Cell biology; Gene","score_opus":0.10365879055873038,"score_gpt":0.3755942421227358,"score_spread":0.2719354515640054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981778203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007762282,0.9906453,0.0028802347,0.00024971121,0.00043932558,0.00003576182,0.00007545261,0.000073793584,0.004824277],"genre_scores_gemma":[0.0036242527,0.9903189,0.002466328,0.00021378524,0.00013362897,0.00003278181,0.0002038652,0.0000087227745,0.0029977292],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998745,0.000016119355,0.0000131916895,0.000018733048,0.000064769236,0.000012658432],"domain_scores_gemma":[0.9999378,0.000024703051,0.000012261502,0.000003393731,0.000014232342,0.0000076344395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025270757,0.00055736216,0.0006749768,0.0017511001,0.000121924255,0.0005674103,0.0005730835,0.0005461783,0.0038190666],"category_scores_gemma":[0.00018735601,0.0002328879,0.00038160704,0.0012886991,0.00025373776,0.0006587354,0.0003009731,0.0013574103,0.003540363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005830061,0.00012058045,0.00013312107,0.012744273,0.000075250144,0.0003474208,0.000056209454,0.0005769031,0.038863428,0.009921209,0.021641226,0.9154621],"study_design_scores_gemma":[0.00001437151,0.00009650595,0.00034485175,0.00065334415,0.000050437942,0.0011188306,0.000020256797,0.00014477385,0.00806216,0.0011555379,0.98832333,0.00001566081],"about_ca_topic_score_codex":0.00033468165,"about_ca_topic_score_gemma":0.00048309693,"teacher_disagreement_score":0.0038190666,"about_ca_system_score_codex":0.0003944906,"about_ca_system_score_gemma":0.0005066229,"threshold_uncertainty_score":0.012776077},"labels":[],"label_agreement":null},{"id":"W2982435333","doi":"10.3390/cells8111341","title":"MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?","year":2019,"lang":"en","type":"review","venue":"Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"","keywords":"Leukemia; Chromosomal translocation; Myeloid leukemia; Acute leukemia; Medicine; Oncology; Cancer research; Fusion gene; Internal medicine; Immunology; Biology; Gene; Genetics","score_opus":0.08670962398240774,"score_gpt":0.3794430066666013,"score_spread":0.2927333826841936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982435333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008561636,0.9984856,0.000109517314,0.0003705598,0.00015759877,0.000004526281,0.000024208903,0.000012503042,0.00074986566],"genre_scores_gemma":[0.00040364248,0.99866676,0.0001518537,0.00027878516,0.0001221379,0.0000071108784,0.00003757356,0.0000017780062,0.00033029547],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986506,0.000022748507,0.000021811655,0.000027633585,0.000048073336,0.000014752353],"domain_scores_gemma":[0.99978894,0.000099424535,0.000029798219,0.000005756773,0.00005087202,0.000025231075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040838672,0.00060250337,0.0012708524,0.0014854097,0.00023586937,0.0008616894,0.00082695,0.0009870393,0.0036792674],"category_scores_gemma":[0.00056144316,0.00021485804,0.0004289199,0.001564537,0.00033070083,0.0012666,0.00057549635,0.0015960656,0.0024870737],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055785655,0.000043755816,0.00009683961,0.01110167,0.000054934768,0.00017079855,0.000038599566,0.00023750962,0.0010459607,0.0016187831,0.0313758,0.95415956],"study_design_scores_gemma":[0.000017050357,0.00008725667,0.00045653977,0.0031764468,0.00011654694,0.0013222655,0.000055140834,0.00007415695,0.0003042158,0.0013612951,0.9930153,0.000013727341],"about_ca_topic_score_codex":0.00077577756,"about_ca_topic_score_gemma":0.0013897562,"teacher_disagreement_score":0.0036792674,"about_ca_system_score_codex":0.0005110094,"about_ca_system_score_gemma":0.00078382855,"threshold_uncertainty_score":0.012308419},"labels":[],"label_agreement":null},{"id":"W2982903806","doi":"10.1182/blood-2019-122781","title":"An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Univariate analysis; Transplantation; Oncology; Surgery; Multivariate analysis; Lymphoma; CD30","score_opus":0.015816124630601492,"score_gpt":0.27362272216319433,"score_spread":0.25780659753259283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982903806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981139,0.0006062468,0.0001816935,0.000046570894,0.0000058236974,0.00009212152,0.0005872537,0.000004240941,0.00036212994],"genre_scores_gemma":[0.9984547,0.0001404052,0.00020625161,0.00005749735,0.00001968075,0.000060042737,0.00089454,0.0000028342672,0.00016407705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875045,0.00049877446,0.00010863169,0.00021238567,0.00024450198,0.00018529837],"domain_scores_gemma":[0.9983852,0.0006022467,0.00055069296,0.0000766261,0.00010789373,0.00027727179],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016548022,0.0003616864,0.00079663354,0.00048509016,0.00019115662,0.0006667458,0.00041028726,0.0003028325,0.0012827525],"category_scores_gemma":[0.0017674016,0.000119892495,0.0018846106,0.0005397427,0.00025634153,0.00037832707,0.00060959306,0.00060368865,0.00012890973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12626804,0.0023641724,0.7931106,0.0007648819,0.0047110403,0.0017578012,0.0003608408,0.0038540834,0.013056343,0.00038272172,0.0015473203,0.051822152],"study_design_scores_gemma":[0.0029306093,0.060496736,0.9184128,0.00011064782,0.0038280683,0.0018464314,0.00040112357,0.00436277,0.0042996886,0.0004217267,0.0028512145,0.000038205697],"about_ca_topic_score_codex":0.0004997851,"about_ca_topic_score_gemma":0.0008603927,"teacher_disagreement_score":0.0016548022,"about_ca_system_score_codex":0.0006741741,"about_ca_system_score_gemma":0.00063560123,"threshold_uncertainty_score":0.008751571},"labels":[],"label_agreement":null},{"id":"W2983303687","doi":"10.1182/blood-2019-125792","title":"A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Refractory (planetary science); Salvage therapy; Internal medicine; Fludarabine; Oncology; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.015596657079155847,"score_gpt":0.3028233139120027,"score_spread":0.2872266568328468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983303687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963427,0.0021810313,0.00010053988,0.00006886939,0.00002725595,0.000057496945,0.0005330876,0.0000056631475,0.0006833517],"genre_scores_gemma":[0.99727637,0.00041118564,0.000103430684,0.00010369794,0.00006354799,0.00008488606,0.0016577215,0.0000031737436,0.00029593724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989693,0.00041874306,0.000103213155,0.00023481631,0.00014967068,0.00012418602],"domain_scores_gemma":[0.99679995,0.0010564864,0.0012425864,0.0002359192,0.00020596755,0.00045913304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002618311,0.00039475807,0.0008962742,0.0007946176,0.00021650628,0.00081282813,0.0004841397,0.00080344296,0.0017847465],"category_scores_gemma":[0.0033264742,0.00019613288,0.0016540965,0.00050481304,0.0003694114,0.0010517662,0.00070885825,0.0009237407,0.00028714084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38542712,0.003604501,0.5084883,0.0011082202,0.008396003,0.0002772834,0.00041043034,0.002338363,0.004862217,0.00039806875,0.0019488776,0.082740694],"study_design_scores_gemma":[0.025633352,0.13276793,0.82800305,0.0001790973,0.0050290124,0.0007626684,0.00046807114,0.0022937115,0.0015013434,0.00048150893,0.0027885654,0.00009173796],"about_ca_topic_score_codex":0.00047298832,"about_ca_topic_score_gemma":0.00089868746,"teacher_disagreement_score":0.002618311,"about_ca_system_score_codex":0.0008390017,"about_ca_system_score_gemma":0.00043428614,"threshold_uncertainty_score":0.013847113},"labels":[],"label_agreement":null},{"id":"W2983333809","doi":"10.1182/blood-2019-126670","title":"A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; CD20; Mantle cell lymphoma; Rituximab; Lymphoma; Tolerability; B cell; Internal medicine; Oncology; Immunology; Gastroenterology; Antibody; Adverse effect","score_opus":0.015190308065964065,"score_gpt":0.30043175066022454,"score_spread":0.2852414425942605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983333809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847348,0.0018610823,0.001067795,0.0005597042,0.00022235866,0.0064328425,0.0022590177,0.00021499659,0.002647496],"genre_scores_gemma":[0.97402644,0.0024240345,0.004242992,0.0018511829,0.000254648,0.005643552,0.005808743,0.00006971609,0.0056785797],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997285,0.000109075096,0.000010385209,0.000062730716,0.000028946737,0.000060298546],"domain_scores_gemma":[0.9996363,0.00004866766,0.000045176097,0.000032524942,0.000031097796,0.00020619953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001264823,0.0016274119,0.0016638753,0.0004180707,0.0003227062,0.00059463945,0.00094261736,0.0011292789,0.0035850008],"category_scores_gemma":[0.000513527,0.00055663986,0.0009789038,0.0002576652,0.0007160027,0.0006714538,0.00035507523,0.00239796,0.0009791781],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5357176,0.19927403,0.008042418,0.0014841557,0.0014919387,0.0008757926,0.00052122393,0.0044180052,0.09664381,0.0005118679,0.011236861,0.13978231],"study_design_scores_gemma":[0.51989484,0.45944327,0.008436512,0.00002501033,0.00038633603,0.00048554927,0.00006308269,0.0016986284,0.0048085456,0.00023322231,0.0044923574,0.000032645385],"about_ca_topic_score_codex":0.0016976657,"about_ca_topic_score_gemma":0.0043882513,"teacher_disagreement_score":0.0035850008,"about_ca_system_score_codex":0.00084962766,"about_ca_system_score_gemma":0.0018883528,"threshold_uncertainty_score":0.011993051},"labels":[],"label_agreement":null},{"id":"W2983410311","doi":"10.1182/blood-2019-124492","title":"Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Hamilton Health Sciences","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Blinatumomab; Refractory (planetary science); Chemotherapy regimen; Lymphoma; Chemotherapy; Internal medicine; Oncology; Rituximab; Leukemia; Biology","score_opus":0.011000794699848876,"score_gpt":0.2645559058655236,"score_spread":0.2535551111656747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983410311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989221,0.00032850142,0.000042848158,0.000039641636,0.000004074969,0.00001890139,0.00012699679,0.000003933939,0.00051311246],"genre_scores_gemma":[0.9993857,0.000055053315,0.000043490865,0.000047240326,0.000011072252,0.000016818503,0.0003362642,0.0000014128151,0.000102852646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997899,0.000056119286,0.000024171894,0.000050376057,0.00003470107,0.000044691275],"domain_scores_gemma":[0.99917525,0.00015782077,0.00031774555,0.00003226944,0.000066826666,0.0002500525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047965534,0.00015521028,0.00032276742,0.0002581846,0.00019402825,0.0004957297,0.00017076822,0.00025627727,0.00091859873],"category_scores_gemma":[0.001059159,0.00006649885,0.00021192274,0.00030738444,0.00016112092,0.0002880539,0.00019717468,0.00041539123,0.00019859165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015494152,0.0007656411,0.9517339,0.00006561782,0.00016984702,0.00044202464,0.00012211835,0.0006754398,0.004890847,0.00006414254,0.0005368055,0.02503955],"study_design_scores_gemma":[0.0007668723,0.011059423,0.983082,0.00002065716,0.00015177266,0.0013698749,0.00012862856,0.0011158064,0.0007425052,0.000119158634,0.0014317594,0.000011431361],"about_ca_topic_score_codex":0.00032670976,"about_ca_topic_score_gemma":0.0005660977,"teacher_disagreement_score":0.00091859873,"about_ca_system_score_codex":0.0004193608,"about_ca_system_score_gemma":0.00023159145,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2983477569","doi":"10.1182/blood-2019-127664","title":"Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Oncology; Brentuximab vedotin; Cochrane Library; Follicular lymphoma; Systematic review; Lymphoma; Salvage therapy; Diffuse large B-cell lymphoma; MEDLINE; Randomized controlled trial; Chemotherapy; Hodgkin lymphoma","score_opus":0.03832518770159279,"score_gpt":0.35417166811200146,"score_spread":0.3158464804104087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983477569","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013099842,0.99383646,0.00035413657,0.0004169572,0.0002002839,0.0014148065,0.0017829296,0.00001898288,0.0006654352],"genre_scores_gemma":[0.016552972,0.9778035,0.0011450289,0.0010100864,0.00011012858,0.0022370417,0.00089597836,0.000012290517,0.00023289108],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98725164,0.004231464,0.005199657,0.00101498,0.0019494123,0.00035289078],"domain_scores_gemma":[0.9673926,0.02127469,0.006704333,0.00054883136,0.0036817132,0.00039781243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0108022895,0.0019903972,0.012464284,0.015888995,0.0009161827,0.0035552245,0.0027218072,0.0021965024,0.008499409],"category_scores_gemma":[0.048043326,0.0012950413,0.009568772,0.014915273,0.0012170699,0.0029691304,0.0021683688,0.0015954252,0.00068610144],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012396908,0.000009160057,0.0003194713,0.98224974,0.005979776,0.00006774888,0.00008594952,0.00005212232,0.00008844964,0.00014348718,0.00080814445,0.010072024],"study_design_scores_gemma":[0.00024222066,0.000140483,0.001863752,0.9229935,0.06184599,0.0002058425,0.00017699807,0.000051488605,0.000102352016,0.00026331298,0.012087443,0.000026608584],"about_ca_topic_score_codex":0.0110786315,"about_ca_topic_score_gemma":0.02842063,"teacher_disagreement_score":0.015888995,"about_ca_system_score_codex":0.00534682,"about_ca_system_score_gemma":0.018410541,"threshold_uncertainty_score":0.05712861},"labels":[],"label_agreement":null},{"id":"W2983803118","doi":"10.1182/blood-2019-128302","title":"Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Hamilton Health Sciences","funders":"","keywords":"Chimeric antigen receptor; Diffuse large B-cell lymphoma; Medicine; Refractory (planetary science); Lymphoma; Cytokine release syndrome; Internal medicine; Oncology; Cancer research; Immunotherapy; Immunology; Biology; Cancer","score_opus":0.03243113997427867,"score_gpt":0.3346661829572612,"score_spread":0.30223504298298254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983803118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99900764,0.0004633575,0.0001394945,0.000024252833,0.0000023707187,0.000013387812,0.0001361445,0.0000052139926,0.00020810979],"genre_scores_gemma":[0.99937373,0.000084699015,0.00016162939,0.000019613162,0.0000045066026,0.000008938122,0.00025652492,0.000002157778,0.0000881558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994141,0.00023994409,0.00005357523,0.00009606486,0.00014927624,0.000046967638],"domain_scores_gemma":[0.9983041,0.0006401562,0.0007365227,0.00007445926,0.000095490395,0.00014924844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014972228,0.00022793874,0.00031591332,0.0002715784,0.00008761513,0.0005240054,0.00017614805,0.00021520248,0.0011158143],"category_scores_gemma":[0.0017698853,0.000060941868,0.00042997205,0.00024204676,0.00019004456,0.00033525328,0.00018707005,0.00040210556,0.0001767325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05027685,0.0017169355,0.82541764,0.00017551682,0.00072449294,0.00022664512,0.000116493815,0.0025448324,0.015912784,0.00007109046,0.0005773275,0.10223947],"study_design_scores_gemma":[0.00068106066,0.038987875,0.9399131,0.000026513306,0.0006956132,0.00079538784,0.00011697337,0.0054559177,0.011533321,0.00012543717,0.0016537436,0.000015066942],"about_ca_topic_score_codex":0.00021662585,"about_ca_topic_score_gemma":0.0002944421,"teacher_disagreement_score":0.0014972228,"about_ca_system_score_codex":0.00024038558,"about_ca_system_score_gemma":0.00015767182,"threshold_uncertainty_score":0.007918179},"labels":[],"label_agreement":null},{"id":"W2984531433","doi":"10.6004/jnccn.2019.0029","title":"NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019","year":2019,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Amgen (Canada)","funders":"National Comprehensive Cancer Network","keywords":"Medicine; Follicular lymphoma; Oncology; Lymphoma; Internal medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Cancer research; Biology","score_opus":0.054509489926656274,"score_gpt":0.3547670538761647,"score_spread":0.3002575639495084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984531433","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046227495,0.109100066,0.019443324,0.25533497,0.02640546,0.0063328887,0.087904096,0.009672017,0.4811844],"genre_scores_gemma":[0.030412236,0.1281034,0.10223055,0.18275245,0.012879738,0.012760629,0.22129707,0.006036832,0.30352712],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99338067,0.0021381816,0.0014575243,0.0001945321,0.0023956124,0.00043352015],"domain_scores_gemma":[0.98036605,0.004578357,0.002532393,0.0007242821,0.010117765,0.0016810548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062482837,0.0008450848,0.0012562355,0.0036459835,0.0009404195,0.0033128478,0.0035451471,0.0051309066,0.03280199],"category_scores_gemma":[0.030429557,0.0009990341,0.0013087833,0.00420522,0.0010702228,0.0018959399,0.0020001307,0.0045554256,0.025554419],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000640828,0.00003716252,0.00045496342,0.00062928343,0.000014778453,0.00013178878,0.000045370838,0.0002865169,0.00020030355,0.0016073238,0.94505525,0.0514732],"study_design_scores_gemma":[0.00013218194,0.000041261428,0.001817093,0.0020792107,0.00003311587,0.00043629928,0.000055761793,0.00033435386,0.00020082356,0.0015754503,0.9932637,0.000030720843],"about_ca_topic_score_codex":0.03211144,"about_ca_topic_score_gemma":0.08486043,"teacher_disagreement_score":0.03280199,"about_ca_system_score_codex":0.0034343794,"about_ca_system_score_gemma":0.013043655,"threshold_uncertainty_score":0.10973358},"labels":[],"label_agreement":null},{"id":"W2985184701","doi":"10.1182/blood-2019-129730","title":"PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Tumor microenvironment; Mantle cell lymphoma; Diffuse large B-cell lymphoma; Cancer research; Lymphoma; Follicular lymphoma; Medicine; Oncology; Internal medicine; Cancer; Biology","score_opus":0.014522705365294505,"score_gpt":0.2547452761588659,"score_spread":0.24022257079357137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985184701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99931026,0.00022859649,0.0001382565,0.000008581917,0.0000011424643,0.000002822079,0.00009996188,0.000005644457,0.00020460755],"genre_scores_gemma":[0.99962735,0.000045641216,0.0001028572,0.000006631862,0.0000032811379,0.0000038165094,0.00014504166,0.0000015628457,0.00006370897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99989176,0.000023903518,0.000011159336,0.000028930599,0.000021800653,0.000022387114],"domain_scores_gemma":[0.9994802,0.00015962402,0.00020718813,0.000036475023,0.00004818998,0.00006844782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029192006,0.00009241249,0.00014412307,0.00040247836,0.0001051292,0.00027174313,0.000113023045,0.00016686521,0.0010770172],"category_scores_gemma":[0.00073848275,0.000074129806,0.00010008806,0.00026460618,0.00017212078,0.00020632468,0.00021830304,0.00021423657,0.00015689048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000886492,0.000036712197,0.9521786,0.0000335019,0.000049386308,0.00015681349,0.00007486667,0.00017091141,0.039784282,0.000033192842,0.000104671526,0.006490538],"study_design_scores_gemma":[0.00000663741,0.00011672132,0.99563414,0.0000023513212,0.00002550183,0.0006062706,0.00007618851,0.0003006339,0.0029304207,0.000044534765,0.00025388328,0.0000027025394],"about_ca_topic_score_codex":0.00014885154,"about_ca_topic_score_gemma":0.0002788252,"teacher_disagreement_score":0.0010770172,"about_ca_system_score_codex":0.00011364283,"about_ca_system_score_gemma":0.00005027813,"threshold_uncertainty_score":0.0036029816},"labels":[],"label_agreement":null},{"id":"W2985774506","doi":"10.1007/978-1-0716-0146-4_6","title":"Lentiviral Vector Production in Suspension Culture Using Serum-Free Medium for the Transduction of CAR-T Cells","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Transduction (biophysics); Transfection; HEK 293 cells; Cell culture; Viral vector; Cell biology; Embryonic stem cell; Suspension culture; Molecular biology; Biology; Chemistry; Recombinant DNA; Gene; Genetics; Biophysics","score_opus":0.047780012112679175,"score_gpt":0.41883066683315656,"score_spread":0.3710506547204774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985774506","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5103524,0.005500407,0.42215607,0.00086771464,0.0015396945,0.005079289,0.016262246,0.00616379,0.032078497],"genre_scores_gemma":[0.71708095,0.0044103814,0.17893736,0.00053250085,0.00040462147,0.0030828442,0.032879125,0.0012708895,0.061401382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991135,0.000104836065,0.00012562859,0.00018879744,0.00031215607,0.00015503551],"domain_scores_gemma":[0.99963534,0.000084873456,0.00004712216,0.00007926959,0.00009376635,0.00005959709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010522753,0.0007709427,0.0009631843,0.0010298344,0.00069541135,0.0015105889,0.0012106576,0.0010391264,0.003617144],"category_scores_gemma":[0.0005395154,0.0005624378,0.000601448,0.00096059573,0.0004915485,0.00062822993,0.0005458242,0.0024777988,0.0037444474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009712692,0.00009403546,0.00015779908,0.000111683396,0.000015041139,0.00007423587,0.00010795056,0.00012988382,0.9914665,0.0014214573,0.0008019064,0.005522395],"study_design_scores_gemma":[0.00004541095,0.00016798134,0.00057226594,0.000022639819,0.0000422021,0.00022844785,0.00002573806,0.0023582887,0.9755229,0.00023145616,0.02076541,0.000017326085],"about_ca_topic_score_codex":0.0011807042,"about_ca_topic_score_gemma":0.0012636496,"teacher_disagreement_score":0.003617144,"about_ca_system_score_codex":0.0006208695,"about_ca_system_score_gemma":0.00060845737,"threshold_uncertainty_score":0.012100518},"labels":[],"label_agreement":null},{"id":"W2985861192","doi":"10.1182/blood-2019-129107","title":"Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Diffuse large B-cell lymphoma; Univariate analysis; Refractory (planetary science); Oncology; Gastroenterology; Salvage therapy; Chemotherapy regimen; Lymphoma; Chemotherapy; Immunotherapy; Multivariate analysis; Cancer; Chimeric antigen receptor; Biology","score_opus":0.03230198785502725,"score_gpt":0.3277322746081032,"score_spread":0.295430286753076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985861192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991794,0.00026451197,0.00005248029,0.00002216927,0.0000024963156,0.00003608008,0.00016284816,0.0000034803975,0.0002764609],"genre_scores_gemma":[0.9982545,0.00009508609,0.00017583546,0.000044475895,0.00001155917,0.00006474316,0.0011767454,0.000004019003,0.0001730051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993668,0.00032475532,0.000048463284,0.00009821554,0.00009368602,0.00006806806],"domain_scores_gemma":[0.9983866,0.00043000202,0.00065680564,0.000114401606,0.00014100038,0.00027111277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022107572,0.00023234433,0.0006449211,0.00024291557,0.0001518082,0.0007562991,0.00029569227,0.00026203488,0.0009096248],"category_scores_gemma":[0.0018572516,0.00010913872,0.00034566422,0.00038486402,0.00022477398,0.00030081128,0.00030661002,0.00049234775,0.00014337317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.185383,0.0023570813,0.74482054,0.00022954316,0.001907716,0.00020388907,0.0002327929,0.0016950077,0.01613648,0.00015031299,0.0013966269,0.045487016],"study_design_scores_gemma":[0.014100911,0.043664154,0.9304238,0.000028159142,0.0012027235,0.0005674733,0.00013561721,0.0028539507,0.003477661,0.00015500915,0.0033617914,0.000028667631],"about_ca_topic_score_codex":0.0002814764,"about_ca_topic_score_gemma":0.0006877627,"teacher_disagreement_score":0.0022107572,"about_ca_system_score_codex":0.00041067158,"about_ca_system_score_gemma":0.00038198315,"threshold_uncertainty_score":0.0116916895},"labels":[],"label_agreement":null},{"id":"W2986196170","doi":"10.1182/blood-2019-123742","title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Follicular lymphoma; Lymphoma; Gastroenterology; Rituximab; Dosing; Oncology; Immunology; Adverse effect","score_opus":0.04627110153982159,"score_gpt":0.3115243581487076,"score_spread":0.265253256608886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986196170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925492,0.002860769,0.0006396167,0.00012879568,0.00003562747,0.00020466269,0.0004023093,0.00021068646,0.0029683034],"genre_scores_gemma":[0.9975968,0.00068639935,0.0002690656,0.00009639905,0.000022673426,0.00006394318,0.00043811946,0.000008357753,0.0008182],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999393,0.000014173998,0.0000038382063,0.000009621783,0.000011577167,0.00002155026],"domain_scores_gemma":[0.99991596,0.000014132918,0.000020593143,0.0000087665885,0.000004442949,0.000036086607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019016258,0.00028589656,0.00037262044,0.00019397183,0.00015009078,0.00016980505,0.00015769302,0.00022989546,0.0020755087],"category_scores_gemma":[0.00015368618,0.000090840076,0.00018809616,0.00012350288,0.00013425938,0.0001538589,0.000118095755,0.0008054924,0.00045036987],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02819557,0.010557673,0.009711547,0.000793003,0.0003869426,0.00051873416,0.00019402023,0.0015700016,0.46277627,0.00033643987,0.008796498,0.47616324],"study_design_scores_gemma":[0.058439087,0.3257422,0.34807563,0.00022909978,0.0006487277,0.005843516,0.00020816212,0.005685899,0.19796851,0.00071034196,0.056392748,0.00005607241],"about_ca_topic_score_codex":0.0003557127,"about_ca_topic_score_gemma":0.0019112481,"teacher_disagreement_score":0.0020755087,"about_ca_system_score_codex":0.00021174076,"about_ca_system_score_gemma":0.00017291647,"threshold_uncertainty_score":0.006943345},"labels":[],"label_agreement":null},{"id":"W2986356453","doi":"10.1172/jci126199","title":"Endogenous T cells prevent tumor immune escape following adoptive T cell therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Government of Ontario; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Endogeny; Oncolytic virus; Immune system; Adoptive cell transfer; Blockade; Immune checkpoint; Cancer research; Immunology; Antigen; Biology; Cytotoxic T cell; T cell; Tumor antigen; Immunotherapy; Receptor; In vitro","score_opus":0.11018993887874642,"score_gpt":0.3819456765103028,"score_spread":0.27175573763155636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986356453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97726876,0.003723035,0.015807047,0.0001566523,0.00011847729,0.00017696283,0.000086559405,0.0004063914,0.0022561601],"genre_scores_gemma":[0.9945258,0.0008325302,0.003168707,0.0000711211,0.000049657163,0.00009330843,0.000057950885,0.00001791585,0.0011831168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969435,0.00006330973,0.000023277313,0.00004693647,0.00006422079,0.00010800502],"domain_scores_gemma":[0.99984825,0.00004043467,0.000040910403,0.00003308646,0.000011853819,0.000025488938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026708195,0.00048817045,0.00040318954,0.00027001204,0.000116254974,0.00041169205,0.00030606563,0.00041914915,0.00092483836],"category_scores_gemma":[0.00029914,0.00015005916,0.00021901604,0.000109444074,0.00035575763,0.00026774433,0.0002939314,0.0012832028,0.00025627727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048501318,0.00058484206,0.00044075327,0.0001530773,0.000023580598,0.00013208261,0.000060066966,0.0008558774,0.9777077,0.0013266283,0.0002509071,0.017979562],"study_design_scores_gemma":[0.00026135636,0.005028003,0.0016375529,0.000028096685,0.00007632898,0.0007538172,0.000030259995,0.004944161,0.97988373,0.0005093956,0.0068384167,0.00000910057],"about_ca_topic_score_codex":0.0001438888,"about_ca_topic_score_gemma":0.00026842553,"teacher_disagreement_score":0.00092483836,"about_ca_system_score_codex":0.0001858669,"about_ca_system_score_gemma":0.00029746458,"threshold_uncertainty_score":0.0030938387},"labels":[],"label_agreement":null},{"id":"W2987620291","doi":"10.1182/blood-2019-124352","title":"Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Gene expression profiling; Germinal center; Cancer research; Oncology; Biopsy; Biology; Internal medicine; B cell; Medicine; Gene; Pathology; Gene expression; Immunology; Antibody; Genetics","score_opus":0.033768194364330206,"score_gpt":0.2893187856528634,"score_spread":0.2555505912885332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987620291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990907,0.00026307296,0.00023015653,0.000014082601,0.0000014448791,0.0000049260457,0.00020300417,0.000006855508,0.00018578925],"genre_scores_gemma":[0.9989191,0.00008553696,0.0003240639,0.000021188305,0.0000025955192,0.000009297722,0.00047909233,0.0000029394178,0.00015609672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981123,0.00003213469,0.000020150035,0.00006222044,0.000039364997,0.00003500661],"domain_scores_gemma":[0.99961555,0.00005973953,0.00016422867,0.00003775674,0.000066493165,0.000056217483],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031648096,0.00013837767,0.00018345227,0.0005972861,0.00021590207,0.0003445875,0.00016519944,0.00023326748,0.0010014152],"category_scores_gemma":[0.00039112158,0.00011716399,0.00014027585,0.00039875478,0.00019146544,0.00018160639,0.0002603142,0.00021863592,0.00030025258],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004322797,0.000028842333,0.94237536,0.000025487347,0.00003363932,0.0004348343,0.00014687012,0.00005158843,0.0510026,0.000021684491,0.00011386744,0.005332973],"study_design_scores_gemma":[0.0000041941616,0.00013982921,0.9915803,0.0000044596873,0.000029033623,0.002053965,0.00016641115,0.00015330952,0.005316665,0.00002559832,0.0005238015,0.0000023875427],"about_ca_topic_score_codex":0.00052636943,"about_ca_topic_score_gemma":0.0013865194,"teacher_disagreement_score":0.0010014152,"about_ca_system_score_codex":0.0001714144,"about_ca_system_score_gemma":0.00007452168,"threshold_uncertainty_score":0.003350079},"labels":[],"label_agreement":null},{"id":"W2987742353","doi":"10.1182/blood-2019-129120","title":"Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Salvage therapy; Fludarabine; Diffuse large B-cell lymphoma; Lymphoma; Cyclophosphamide; Immunotherapy; Chemotherapy; Cancer","score_opus":0.014852087663057753,"score_gpt":0.30483676064559595,"score_spread":0.2899846729825382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987742353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98369724,0.0037455584,0.0008914082,0.0006994912,0.00019533583,0.004352472,0.0024015324,0.00022560082,0.0037913148],"genre_scores_gemma":[0.979154,0.0019573723,0.0030725875,0.001541931,0.0002607762,0.0056223245,0.0052401577,0.00005427726,0.0030966199],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99942553,0.0002942844,0.000034849505,0.00010409986,0.00006314945,0.000078107325],"domain_scores_gemma":[0.99915636,0.00013063806,0.0002057963,0.00009508373,0.00006452562,0.00034758294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021646472,0.0013006576,0.0017664144,0.00043011937,0.00034868554,0.001070821,0.0010719437,0.00084232085,0.005805443],"category_scores_gemma":[0.001317272,0.00057493657,0.0016188525,0.00039939277,0.00074752525,0.0008912724,0.0005891139,0.0037405218,0.0012546381],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76908034,0.06714534,0.012911049,0.0013697667,0.0028225505,0.00037488536,0.00022660449,0.0016692384,0.034683418,0.00037647196,0.005908119,0.103432305],"study_design_scores_gemma":[0.6733771,0.2935374,0.019541083,0.00006301682,0.0015215091,0.0006343153,0.000063548876,0.0013441581,0.0032721849,0.0002600995,0.006348675,0.00003692167],"about_ca_topic_score_codex":0.00039094008,"about_ca_topic_score_gemma":0.001018062,"teacher_disagreement_score":0.005805443,"about_ca_system_score_codex":0.0008603045,"about_ca_system_score_gemma":0.0014026279,"threshold_uncertainty_score":0.0194211},"labels":[],"label_agreement":null},{"id":"W2987812087","doi":"10.1016/j.mayocp.2019.09.006","title":"Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement","year":2019,"lang":"en","type":"letter","venue":"Mayo Clinic Proceedings","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chimeric antigen receptor; Central nervous system; Lymphoma; Antigen; Immunology; Immunotherapy; Virology; Internal medicine; Immune system","score_opus":0.030461654889877114,"score_gpt":0.27369918975763846,"score_spread":0.24323753486776134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987812087","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057219144,0.016079223,0.0010748751,0.8247964,0.016415367,0.00012279599,0.00031462582,0.00024544177,0.08373223],"genre_scores_gemma":[0.57016134,0.0124488445,0.0020129413,0.30746275,0.04996195,0.00015698474,0.00038363363,0.00010188359,0.05730962],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99962044,0.000087935885,0.000038141126,0.000042753574,0.00007410702,0.00013656245],"domain_scores_gemma":[0.99946374,0.00021678799,0.00005896239,0.000021746622,0.00005513806,0.00018363952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043465683,0.0004477177,0.0006855864,0.0005563717,0.0016469738,0.0013552648,0.0007388389,0.010730956,0.0044699283],"category_scores_gemma":[0.0016765089,0.0003105208,0.00066570647,0.00042001068,0.0009794561,0.00080142234,0.00047492806,0.006300993,0.0017868503],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009652004,0.0003857423,0.011689497,0.00027366632,0.000110297166,0.43640837,0.0001896795,0.0007140726,0.003709688,0.006229167,0.48768425,0.051640417],"study_design_scores_gemma":[0.0013644148,0.0009789403,0.018874248,0.00047993773,0.00024229618,0.45702922,0.00035209567,0.005725571,0.004279128,0.011306727,0.4992932,0.000074214535],"about_ca_topic_score_codex":0.0032170974,"about_ca_topic_score_gemma":0.00975288,"teacher_disagreement_score":0.010730956,"about_ca_system_score_codex":0.0031479627,"about_ca_system_score_gemma":0.0013168764,"threshold_uncertainty_score":0.022840142},"labels":[],"label_agreement":null},{"id":"W2988075996","doi":"10.1182/blood-2019-125963","title":"Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Ottawa Hospital; Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Cyclophosphamide; Oncology; Pembrolizumab; Refractory (planetary science); Gastroenterology; Chemotherapy; Cancer; Immunotherapy","score_opus":0.0162301028643446,"score_gpt":0.29289021987244734,"score_spread":0.2766601170081027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988075996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98421466,0.010457055,0.00036847955,0.0006126144,0.00016641447,0.0006019343,0.0005330194,0.00009827822,0.002947616],"genre_scores_gemma":[0.988196,0.005160104,0.00082940224,0.0011011255,0.00020793523,0.0006938535,0.0012910579,0.000022382894,0.0024982],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995432,0.00023845687,0.000027322232,0.000063765125,0.00007297597,0.00005437334],"domain_scores_gemma":[0.9996076,0.00006889688,0.00007769108,0.000047883037,0.00003590534,0.00016201062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020580648,0.0012072277,0.0018388588,0.00042705663,0.00022013822,0.0009540633,0.0009013205,0.0009145749,0.002844159],"category_scores_gemma":[0.0006625275,0.00042588948,0.0017207429,0.00029828018,0.00064801617,0.0007979593,0.00046852857,0.0020073547,0.000892827],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62578297,0.047755595,0.010272939,0.0033957295,0.009923821,0.0005383179,0.00044096957,0.0036575885,0.042954635,0.0007476527,0.0054961173,0.24903369],"study_design_scores_gemma":[0.38934645,0.57374984,0.01999675,0.00018562403,0.0032260993,0.00054179796,0.00016832432,0.001373123,0.0029674424,0.00031781298,0.008056511,0.000070305396],"about_ca_topic_score_codex":0.00038578323,"about_ca_topic_score_gemma":0.0008745123,"teacher_disagreement_score":0.002844159,"about_ca_system_score_codex":0.00057154393,"about_ca_system_score_gemma":0.0006852931,"threshold_uncertainty_score":0.010884166},"labels":[],"label_agreement":null},{"id":"W2988183880","doi":"10.1182/blood-2019-123949","title":"Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Obinutuzumab; Medicine; CD20; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Rituximab; Internal medicine; Clinical trial; Cancer research; Biology","score_opus":0.03937115457596355,"score_gpt":0.3341516338312315,"score_spread":0.2947804792552679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988183880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866904,0.008874878,0.0009870459,0.00041354203,0.00008356985,0.00044143846,0.00039803548,0.00015367448,0.0019574577],"genre_scores_gemma":[0.9914486,0.0034868792,0.0012443278,0.00043465366,0.00006950821,0.00034395594,0.001398201,0.000031466316,0.0015424874],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997985,0.000053358235,0.00001263653,0.000041298827,0.00003763103,0.000056600442],"domain_scores_gemma":[0.99976104,0.000033591714,0.000039440056,0.000020904386,0.000018441022,0.0001265635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076993246,0.0007182909,0.0013836082,0.00026113505,0.00020470023,0.0007976214,0.0005673084,0.00066492334,0.0014843874],"category_scores_gemma":[0.00039002358,0.0002199144,0.0006332699,0.00035607113,0.00048724897,0.00054913986,0.00034653084,0.002151722,0.00044063758],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21168655,0.04004325,0.0066457423,0.0014194208,0.0015698347,0.0008788632,0.0005479167,0.0036196748,0.22458318,0.0007510343,0.006351295,0.50190324],"study_design_scores_gemma":[0.29204243,0.54313767,0.029154355,0.0002421249,0.0017938077,0.0030990255,0.00021073893,0.0068943594,0.093578145,0.0009378184,0.02881519,0.00009440553],"about_ca_topic_score_codex":0.0008089939,"about_ca_topic_score_gemma":0.002090542,"teacher_disagreement_score":0.0014843874,"about_ca_system_score_codex":0.00077893765,"about_ca_system_score_gemma":0.0006599535,"threshold_uncertainty_score":0.005651653},"labels":[],"label_agreement":null},{"id":"W2989357527","doi":"10.1182/blood-2019-122207","title":"Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Diffuse large B-cell lymphoma; Tumor microenvironment; Immune system; CD8; Lymphoma; Cancer research; Medicine; Immune checkpoint; Biology; Oncology; Pathology; Immunology; Immunotherapy","score_opus":0.024342179237805326,"score_gpt":0.2834009129939009,"score_spread":0.25905873375609556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989357527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987452,0.0007847823,0.00010383423,0.000005857999,0.000003627888,0.00001223748,0.000080080004,0.000004013826,0.00026039823],"genre_scores_gemma":[0.9993412,0.00016593984,0.00012832685,0.000014896208,0.000016401575,0.000017645203,0.00019699793,0.0000024215058,0.00011618856],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997429,0.000056070698,0.00002392692,0.00009070058,0.000034906217,0.000051475847],"domain_scores_gemma":[0.99975294,0.00005643235,0.000054905362,0.000022693175,0.000027471971,0.000085499276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041166286,0.00015795216,0.00041851093,0.00075774017,0.00017936747,0.00038501833,0.00017966241,0.00028447455,0.0012124493],"category_scores_gemma":[0.00040243537,0.000083283485,0.00025364925,0.00037988945,0.0003097665,0.00024769508,0.00031037518,0.0001967782,0.00023852989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020376919,0.0013747752,0.8201369,0.00031419017,0.00024773262,0.002549534,0.000655423,0.0002465078,0.11641633,0.00014334013,0.00018414296,0.037354197],"study_design_scores_gemma":[0.00012469565,0.0070585,0.97891474,0.000014609721,0.00015172138,0.006168252,0.0004479065,0.00037976532,0.0053680907,0.00007162506,0.001288816,0.000011452678],"about_ca_topic_score_codex":0.00024241119,"about_ca_topic_score_gemma":0.00022362842,"teacher_disagreement_score":0.0012124493,"about_ca_system_score_codex":0.00025610506,"about_ca_system_score_gemma":0.000106536194,"threshold_uncertainty_score":0.0040560365},"labels":[],"label_agreement":null},{"id":"W2989833047","doi":"10.1038/s41598-019-53756-4","title":"Single variable domains from the T cell receptor β chain function as mono- and bifunctional CARs and TCRs","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Targeting Solutions (Canada)","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Jurkat cells; Computational biology; Receptor; Recombinant DNA; T cell; Cell biology; Computer science; Biology; Chemistry; Immunology; Gene; Genetics; Immune system","score_opus":0.014532922560182893,"score_gpt":0.2399776815054008,"score_spread":0.2254447589452179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989833047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91153365,0.008387252,0.06972251,0.00034074564,0.00019052293,0.000108661094,0.0003323549,0.0006450196,0.008739305],"genre_scores_gemma":[0.9755558,0.0020991208,0.018085377,0.00012635131,0.000021986527,0.000041160823,0.00027174075,0.00006005886,0.0037384103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996588,0.000056763613,0.000025729682,0.00007986942,0.00010426316,0.00007457026],"domain_scores_gemma":[0.9998667,0.00002967312,0.000026713587,0.000023671351,0.000019914543,0.00003336843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033743904,0.00033708726,0.0002562169,0.0003751563,0.00013204789,0.0007014835,0.00039897757,0.0005242522,0.0010713143],"category_scores_gemma":[0.00027799013,0.00018431808,0.0002849667,0.0002407303,0.00042841546,0.00041942994,0.000357203,0.00067602,0.00056825683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008920728,0.000024430701,0.00023749552,0.000048871767,0.000006201207,0.00006914441,0.00002526913,0.00028187723,0.99088365,0.0014457382,0.0001232898,0.0067649693],"study_design_scores_gemma":[0.000026841715,0.00020222185,0.0005666349,0.000009898558,0.000019966346,0.0006454726,0.000027507847,0.0021705122,0.988664,0.0002602267,0.007398362,0.000008383796],"about_ca_topic_score_codex":0.00028184857,"about_ca_topic_score_gemma":0.00035840637,"teacher_disagreement_score":0.0010713143,"about_ca_system_score_codex":0.00034383617,"about_ca_system_score_gemma":0.00019288516,"threshold_uncertainty_score":0.0035838485},"labels":[],"label_agreement":null},{"id":"W2990184116","doi":"10.1182/bloodadvances.2019000717","title":"Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"CD19; Immunology; Antibody; Chimeric antigen receptor; Immunotherapy; Medicine; Antigen; Receptor; Immunity; Virology; Virus; Immune system; Internal medicine","score_opus":0.009515221250823522,"score_gpt":0.2747866744039755,"score_spread":0.2652714531531519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990184116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989938,0.0003648799,0.0003508502,0.000017172406,0.0000034026389,0.000012443002,0.000051733183,0.000016141861,0.00018945821],"genre_scores_gemma":[0.99962604,0.000040509734,0.00012121432,0.000018901044,0.0000047548283,0.0000050702142,0.000067568566,0.000001850924,0.00011400505],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992874,0.00021943024,0.00003970904,0.00013888317,0.00015644896,0.00015816034],"domain_scores_gemma":[0.9989661,0.00037614728,0.0003601846,0.0001377197,0.000067155845,0.00009262126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001444976,0.0002267552,0.00066489424,0.0001346042,0.00013457134,0.00033882292,0.00023530493,0.00027076402,0.00046923364],"category_scores_gemma":[0.0014050042,0.00014477441,0.00037322697,0.00013475228,0.00024853725,0.0003050158,0.00024339199,0.00045222984,0.000118481395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023145888,0.0026690573,0.4374122,0.00033929886,0.0007816909,0.0009408696,0.000634882,0.004839491,0.3692357,0.00034690546,0.0003859602,0.15926805],"study_design_scores_gemma":[0.00054918247,0.062243097,0.8211466,0.000025547577,0.00055766694,0.00176423,0.00013187419,0.0077755745,0.10320852,0.0002649768,0.0023095724,0.00002313834],"about_ca_topic_score_codex":0.00065138243,"about_ca_topic_score_gemma":0.00077664375,"teacher_disagreement_score":0.001444976,"about_ca_system_score_codex":0.00032419746,"about_ca_system_score_gemma":0.00022755288,"threshold_uncertainty_score":0.007641852},"labels":[],"label_agreement":null},{"id":"W2991263669","doi":"10.1182/blood-2019-128344","title":"Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Oncology; Gastroenterology; Immunology","score_opus":0.02022450016857597,"score_gpt":0.2773847017286881,"score_spread":0.25716020156011216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991263669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681962,0.02045698,0.002216953,0.0005402523,0.00019322774,0.00042687554,0.005186454,0.00013149231,0.002651661],"genre_scores_gemma":[0.9866774,0.0027566333,0.0015693093,0.0005053544,0.00014691595,0.0003768106,0.007315233,0.000012469883,0.0006398051],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9989918,0.00037224824,0.00015520197,0.00026011848,0.00014469118,0.00007603472],"domain_scores_gemma":[0.99886996,0.00031189044,0.0005275461,0.00013099839,0.000073834744,0.00008586122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015591639,0.0003361712,0.0010086189,0.00044617182,0.00015370097,0.0006801118,0.00038039513,0.00030475826,0.0027037028],"category_scores_gemma":[0.0024737103,0.00009930109,0.0017052045,0.000813515,0.00014881464,0.00035434123,0.00035880654,0.00062327157,0.00026853327],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.094224095,0.0027008378,0.2508189,0.004218042,0.019044472,0.00038598475,0.00015180568,0.0045252675,0.025252167,0.00059437845,0.009343429,0.5887407],"study_design_scores_gemma":[0.01169779,0.04333552,0.87970084,0.00079076324,0.017961508,0.0013797476,0.00020331578,0.0034512482,0.013019552,0.0014573401,0.02691041,0.000091957474],"about_ca_topic_score_codex":0.00055086805,"about_ca_topic_score_gemma":0.0017798049,"teacher_disagreement_score":0.0027037028,"about_ca_system_score_codex":0.00041663446,"about_ca_system_score_gemma":0.00061817525,"threshold_uncertainty_score":0.009044766},"labels":[],"label_agreement":null},{"id":"W2991564346","doi":"10.1136/jnnp-2019-abn-2.169","title":"200 AFFINITY: opicinumab in a targeted population of MS patients","year":2019,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"","keywords":"Natalizumab; Expanded Disability Status Scale; Multiple sclerosis; Medicine; Placebo; Internal medicine; Population; Clinical endpoint; Stock options; Surrogate endpoint; Physical therapy; Oncology; Clinical trial; Immunology; Pathology","score_opus":0.012793294768442452,"score_gpt":0.2765837377508704,"score_spread":0.263790442982428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991564346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696601,0.0057606813,0.00086972036,0.0027658455,0.00025454038,0.00089535315,0.003732966,0.00023966971,0.0158211],"genre_scores_gemma":[0.98763764,0.0012629582,0.00079936103,0.0024218266,0.00041805702,0.0005979477,0.0016136814,0.000020150444,0.0052283574],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971265,0.000088762994,0.00001999793,0.000071254064,0.000057560566,0.000049687693],"domain_scores_gemma":[0.99960047,0.000077637495,0.00007358833,0.00001677217,0.000058956568,0.00017254011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000605252,0.00024284194,0.0004431591,0.0001939156,0.00025088544,0.00046093928,0.00021848545,0.0004748425,0.008678431],"category_scores_gemma":[0.00090754835,0.00008129172,0.00020905225,0.00015994198,0.00011505169,0.00022711956,0.00029049383,0.00035059865,0.0017408271],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09334713,0.004789899,0.2281551,0.0012102328,0.0007636738,0.0016397358,0.00040780086,0.0007813541,0.04594697,0.00059774244,0.05839455,0.5639658],"study_design_scores_gemma":[0.032478217,0.083809204,0.77793115,0.0005205008,0.0014827221,0.006517293,0.00047276216,0.0035305948,0.0104363635,0.0013582854,0.081370816,0.00009214912],"about_ca_topic_score_codex":0.0008257838,"about_ca_topic_score_gemma":0.0014045922,"teacher_disagreement_score":0.008678431,"about_ca_system_score_codex":0.0003898381,"about_ca_system_score_gemma":0.00044072492,"threshold_uncertainty_score":0.02903229},"labels":[],"label_agreement":null},{"id":"W2991566266","doi":"10.1182/blood-2019-126081","title":"Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Lymphoma; Refractory (planetary science); Internal medicine; Oncology; Cancer research; Biology","score_opus":0.010129602824365593,"score_gpt":0.2240935531776961,"score_spread":0.21396395035333052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991566266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99663264,0.0021794678,0.00009320428,0.00010823544,0.00002793066,0.000069838214,0.00025675204,0.000017221619,0.0006147566],"genre_scores_gemma":[0.99805236,0.0005673361,0.00018040225,0.00017715877,0.000054953915,0.00007465092,0.00055335433,0.000003781189,0.00033598344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951255,0.00014468808,0.00004293662,0.00011068733,0.00009937639,0.00008985729],"domain_scores_gemma":[0.9993369,0.00016360659,0.00025350446,0.000050898216,0.000034312125,0.0001607123],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008375891,0.00032532788,0.000776141,0.00038243132,0.00026041426,0.0006894926,0.00038506786,0.0003942312,0.0018852117],"category_scores_gemma":[0.001280965,0.0001832575,0.0007177308,0.0004947796,0.00025888215,0.00042278427,0.0003194243,0.0009712152,0.0002717491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19667774,0.0066281706,0.5868968,0.000830052,0.0026020147,0.0008830387,0.00038423188,0.0016131919,0.015676813,0.00017310596,0.0019372219,0.18569763],"study_design_scores_gemma":[0.02473535,0.12541053,0.8229624,0.00019217709,0.0030335581,0.0017706674,0.00033903273,0.0017937107,0.005298658,0.0003384448,0.014062223,0.00006323774],"about_ca_topic_score_codex":0.0007063373,"about_ca_topic_score_gemma":0.0017604488,"teacher_disagreement_score":0.0018852117,"about_ca_system_score_codex":0.00071217923,"about_ca_system_score_gemma":0.000743631,"threshold_uncertainty_score":0.0063066483},"labels":[],"label_agreement":null},{"id":"W2992423763","doi":"10.1182/blood.v108.11.773.773","title":"LMO2 and TAL1 Cooperate in a Model of Human T−Cell Leukemogenesis.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Biology; Lymphopoiesis; CD8; Population; Haematopoiesis; T cell; Cytotoxic T cell; Cancer research; Cell biology; Molecular biology; Immunology; Stem cell; Genetics; Antigen; Immune system; Medicine; In vitro","score_opus":0.02752861885774754,"score_gpt":0.2839941180286129,"score_spread":0.25646549917086536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992423763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928929,0.0009253648,0.0024349585,0.00016502956,0.00005917468,0.00007766379,0.0004941889,0.00014972215,0.0028010502],"genre_scores_gemma":[0.9926166,0.00042653258,0.0016421754,0.000043788918,0.000010373934,0.00009824303,0.0005029604,0.000014574126,0.0046446305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998338,0.000040335643,0.000011366172,0.00003062096,0.000048099893,0.00003573308],"domain_scores_gemma":[0.9999285,0.000013197385,0.000017146333,0.000009378879,0.000003527964,0.000028248336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019865624,0.00049129763,0.0002253783,0.00042639457,0.00018608838,0.0003103855,0.00044663905,0.00043743924,0.0022676867],"category_scores_gemma":[0.00006292699,0.0001490454,0.00023659397,0.00021749464,0.00027758916,0.00015076883,0.0002757509,0.00055465195,0.00044216472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039516666,0.00015164033,0.0001571446,0.000041126445,0.0000053927224,0.00018553792,0.000019940224,0.00045744752,0.99698585,0.0005957689,0.00013499458,0.0008700633],"study_design_scores_gemma":[0.00016275048,0.0020923999,0.0014723234,0.000007643192,0.000029561688,0.0005817626,0.000040467894,0.008601806,0.9810625,0.00023887571,0.005702318,0.000007596676],"about_ca_topic_score_codex":0.0010140946,"about_ca_topic_score_gemma":0.000704446,"teacher_disagreement_score":0.0022676867,"about_ca_system_score_codex":0.0004188334,"about_ca_system_score_gemma":0.0001989544,"threshold_uncertainty_score":0.007586181},"labels":[],"label_agreement":null},{"id":"W2993613817","doi":"10.1158/1535-7163.targ-19-c048","title":"Abstract C048: Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer research; In vivo; Immune system; Immunotherapy; Medicine; Hepatocellular carcinoma; Cancer; Immunology; Pharmacology; Biology; Internal medicine","score_opus":0.034315951275988264,"score_gpt":0.280333360489796,"score_spread":0.24601740921380774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993613817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868805,0.0019435083,0.004182242,0.0003090624,0.00013567143,0.00014928856,0.0009844977,0.0003727547,0.003234959],"genre_scores_gemma":[0.9877973,0.00095515733,0.0037455403,0.00009283213,0.000023353878,0.00017862523,0.0010233226,0.00002966346,0.006154219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998907,0.000012850073,0.0000093865065,0.000023783798,0.000037489775,0.000025757356],"domain_scores_gemma":[0.9999472,0.000004440444,0.000012253352,0.000006796132,0.0000087799135,0.000020521678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017341232,0.0005380456,0.00038525916,0.0003512706,0.00015700466,0.00023333466,0.000295129,0.00039493668,0.0020468],"category_scores_gemma":[0.00005210841,0.000111224945,0.00023369245,0.00015999537,0.00024188713,0.00023061357,0.000110231915,0.00091673195,0.00052787777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057663047,0.0002614165,0.00006152916,0.000070536466,0.000008194795,0.000036842244,0.000011182693,0.00010575971,0.99498665,0.00010372165,0.00031252153,0.0034650648],"study_design_scores_gemma":[0.000117101175,0.001640662,0.0007566236,0.000004534854,0.000023394652,0.00015342595,0.000009373943,0.0006535978,0.9944564,0.00002252319,0.0021580332,0.0000043500772],"about_ca_topic_score_codex":0.0009769097,"about_ca_topic_score_gemma":0.001276347,"teacher_disagreement_score":0.0020468,"about_ca_system_score_codex":0.00041578125,"about_ca_system_score_gemma":0.00039829526,"threshold_uncertainty_score":0.006847203},"labels":[],"label_agreement":null},{"id":"W2994926825","doi":"10.1016/j.jval.2019.09.637","title":"PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Leukapheresis; Population; Internal medicine; Adverse effect; Oncology; Refractory (planetary science); Clinical trial; Surgery; Gastroenterology; Stem cell","score_opus":0.08268486209824036,"score_gpt":0.36535704509718864,"score_spread":0.28267218299894825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994926825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875886,0.007738826,0.00025556458,0.0002709751,0.00023042559,0.00016192147,0.0005583417,0.000053948115,0.0031415273],"genre_scores_gemma":[0.9936306,0.002008965,0.0003862874,0.00017579754,0.00012769361,0.00014022648,0.00056043593,0.000010189797,0.002959813],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99962986,0.00016099,0.000022882525,0.0000672574,0.00004032503,0.00007866307],"domain_scores_gemma":[0.9996605,0.00008825471,0.000061826264,0.00002768023,0.000016874028,0.00014479826],"candidate_categories":["metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0005859955,0.00065416086,0.0018941783,0.00040263336,0.00014615495,0.000633824,0.0006068904,0.0006161771,0.009682838],"category_scores_gemma":[0.0005287696,0.0002610305,0.0010285631,0.00033279776,0.0005221382,0.0005981979,0.00033857106,0.0017468052,0.0008469594],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9010169,0.007447477,0.0011095909,0.0006357483,0.0015635643,0.00003960198,0.000046298606,0.0008983235,0.010401226,0.0002492974,0.000835062,0.0757569],"study_design_scores_gemma":[0.3923373,0.5617599,0.023149969,0.00019401137,0.0044622743,0.00018353813,0.00013035299,0.0028683937,0.009413607,0.0004235545,0.0050147427,0.00006227312],"about_ca_topic_score_codex":0.0012215362,"about_ca_topic_score_gemma":0.003375446,"teacher_disagreement_score":0.9981058,"about_ca_system_score_codex":0.00057769846,"about_ca_system_score_gemma":0.0006616628,"threshold_uncertainty_score":0.032392323},"labels":[],"label_agreement":null},{"id":"W2995869139","doi":"","title":"Gene Therapy: An Overview of Approved and Pipeline Technologies","year":2018,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Genetic enhancement; Intensive care medicine; Health care; Business; Gene; Economic growth","score_opus":0.12727747790170948,"score_gpt":0.38835526221496025,"score_spread":0.2610777843132508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995869139","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015060755,0.96010494,0.0093302475,0.0072747283,0.0009960347,0.00013036384,0.00031259956,0.00021958056,0.020125419],"genre_scores_gemma":[0.003999677,0.9771388,0.010455894,0.0019460133,0.00067552313,0.00014527228,0.00042574733,0.000064671825,0.00514841],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99847203,0.0003141719,0.00019131637,0.00016117215,0.00071102654,0.0001502261],"domain_scores_gemma":[0.99772066,0.00096309534,0.00025479845,0.00009787401,0.0006951299,0.00026846636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004341304,0.001110515,0.00094742497,0.0055134217,0.00060228264,0.0040736166,0.0015327053,0.002669072,0.006482303],"category_scores_gemma":[0.0030707899,0.0005993682,0.000912172,0.0039153816,0.0010575777,0.004684098,0.0012346591,0.004143622,0.0045619304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020603016,0.0003457787,0.0006206442,0.0060783857,0.000038512706,0.00045239247,0.00014343156,0.0008512197,0.00634243,0.020031007,0.046177406,0.91871274],"study_design_scores_gemma":[0.000027980228,0.00036480793,0.0005903484,0.0026919153,0.000045709257,0.0016055516,0.00009996529,0.00045007747,0.003499729,0.0063317055,0.9842582,0.0000341909],"about_ca_topic_score_codex":0.001295309,"about_ca_topic_score_gemma":0.0017905306,"teacher_disagreement_score":0.006482303,"about_ca_system_score_codex":0.0019106396,"about_ca_system_score_gemma":0.0031428973,"threshold_uncertainty_score":0.022959292},"labels":[],"label_agreement":null},{"id":"W2996166277","doi":"10.1016/j.jval.2019.09.332","title":"PCN136 ECONOMIC VIABILITY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH ADVANCED LEUKEMIA: EVIDENCE FROM AN EARLY ECONOMIC MODELLING","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Blinatumomab; Chimeric antigen receptor; Oncology; Immunotherapy; Salvage therapy; Internal medicine; Leukemia; Chemotherapy; Cancer; Lymphoblastic Leukemia","score_opus":0.04991998451427404,"score_gpt":0.33051687973485416,"score_spread":0.2805968952205801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996166277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85689867,0.029059064,0.029099742,0.0096127875,0.0005490181,0.0012681052,0.010674297,0.00015206535,0.062686145],"genre_scores_gemma":[0.9900746,0.0035864413,0.0016133739,0.00022848597,0.00004652815,0.00018677118,0.0007049242,0.000020498008,0.0035383909],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9968442,0.0023496302,0.00007589435,0.00012709378,0.0002743896,0.00032881284],"domain_scores_gemma":[0.9750811,0.023066582,0.00078324514,0.00034440428,0.0004248135,0.00029988497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075040185,0.0011950817,0.0015739421,0.0007640273,0.0002636299,0.0018763703,0.0014686862,0.0012820514,0.007166503],"category_scores_gemma":[0.02041693,0.0005160681,0.0026943947,0.0009265049,0.0008675638,0.0012281348,0.00086991105,0.002731202,0.00039547094],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030288542,0.0012024055,0.009571586,0.0022113028,0.0028241044,0.0003031316,0.00016480082,0.80719197,0.00048250332,0.04754155,0.007879164,0.090338804],"study_design_scores_gemma":[0.013441343,0.010992213,0.016763546,0.0017006539,0.009431546,0.0002856041,0.00041158576,0.8251567,0.0026514106,0.089131854,0.029820863,0.00021270101],"about_ca_topic_score_codex":0.024949526,"about_ca_topic_score_gemma":0.011231383,"teacher_disagreement_score":0.024949526,"about_ca_system_score_codex":0.0053724563,"about_ca_system_score_gemma":0.0041555176,"threshold_uncertainty_score":0.04960859},"labels":[],"label_agreement":null},{"id":"W2996286256","doi":"10.3389/fimmu.2019.02873","title":"Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector","year":2019,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation ARC pour la Recherche sur le Cancer; Warren H. and Clara Cole Foundation","keywords":"Vesicular stomatitis virus; Baboon; Biology; Transduction (biophysics); Measles virus; Virology; Cell culture; CD19; Molecular biology; Virus; Immunology; Immune system; Genetics; Endocrinology","score_opus":0.010132946156941651,"score_gpt":0.2284956239988109,"score_spread":0.21836267784186925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996286256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9047928,0.0026913239,0.08344388,0.00019957605,0.00020367817,0.00062536163,0.00172685,0.0011499528,0.0051665404],"genre_scores_gemma":[0.95082176,0.0016860388,0.033187434,0.00011766658,0.00004007545,0.00068766234,0.0033908668,0.00026481802,0.009803717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993079,0.00011061074,0.00010878441,0.00013866604,0.00020540651,0.00012876574],"domain_scores_gemma":[0.9998159,0.000040014922,0.00002958797,0.0000453875,0.00003361769,0.000035580033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007246542,0.0005411431,0.00070342084,0.00025787533,0.00021585288,0.0009180165,0.0004063654,0.00042728873,0.0019060748],"category_scores_gemma":[0.00029516275,0.0002609546,0.0002989709,0.00021934164,0.00032907928,0.0003925792,0.00054214,0.0017403773,0.0012991186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053964326,0.00003939441,0.00012791915,0.000047679016,0.000007469172,0.000041744242,0.000033236152,0.00010985323,0.99692553,0.00021244407,0.00010715356,0.0022935166],"study_design_scores_gemma":[0.000030014275,0.00026084008,0.0013143071,0.000012877366,0.000026544252,0.00042207257,0.000026009198,0.002122795,0.98721176,0.00007296534,0.008491197,0.0000086042055],"about_ca_topic_score_codex":0.00038766788,"about_ca_topic_score_gemma":0.0005055139,"teacher_disagreement_score":0.0019060748,"about_ca_system_score_codex":0.00027880236,"about_ca_system_score_gemma":0.0002720996,"threshold_uncertainty_score":0.0063764453},"labels":[],"label_agreement":null},{"id":"W2996520276","doi":"10.1016/j.jacc.2019.10.049","title":"Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart","year":2019,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Chimeric antigen receptor; Cardiogenic shock; Internal medicine; Adverse effect; Cell therapy; Myocarditis; Cardiology; Cytokine release syndrome; Troponin; Heart failure; Population; Troponin T; Oncology; Cancer; Immunotherapy; Cell; Myocardial infarction","score_opus":0.058436975556238314,"score_gpt":0.3875977864110855,"score_spread":0.32916081085484716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996520276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013261253,0.9970734,0.00018613538,0.0005720688,0.0006815725,0.0000064978967,0.00002108984,0.000012774067,0.0013138755],"genre_scores_gemma":[0.0016138091,0.99433017,0.0003289368,0.0009293905,0.00061685883,0.000018341985,0.000059543072,0.0000029006208,0.0021000039],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998591,0.000025380838,0.000013311848,0.000029140205,0.00005154923,0.00002153378],"domain_scores_gemma":[0.99978167,0.00009780047,0.000039903047,0.000006642014,0.000048126658,0.000025862351],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006620053,0.0007961072,0.0012705511,0.0010736611,0.00023847734,0.0007600768,0.00070615247,0.0013792168,0.0043593408],"category_scores_gemma":[0.00051992247,0.00021446607,0.00041681703,0.0009507793,0.00046276854,0.0007495139,0.00055865984,0.002353916,0.0023159843],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017571838,0.00015363673,0.00008946771,0.0069697993,0.0000986652,0.000107901564,0.00002395551,0.000316701,0.0027802042,0.0052630054,0.088440545,0.8955804],"study_design_scores_gemma":[0.00008619319,0.0002129771,0.00033800802,0.0013971269,0.00012522296,0.0003272927,0.000016562288,0.00011074361,0.0005314355,0.0010796804,0.995764,0.000010769941],"about_ca_topic_score_codex":0.00064229296,"about_ca_topic_score_gemma":0.0017548441,"teacher_disagreement_score":0.0043593408,"about_ca_system_score_codex":0.0005302884,"about_ca_system_score_gemma":0.0007867732,"threshold_uncertainty_score":0.014583409},"labels":[],"label_agreement":null},{"id":"W2996718802","doi":"10.1016/j.jval.2019.09.632","title":"PCN439 DEVELOPING A DISCRETE-EVENT SIMULATION TO STUDY THE INFLUENCE OF WAITING TIMES ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Guelph; University of Waterloo","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cost-effectiveness analysis; Cost effectiveness; Oncology; Lymphoma; Internal medicine; Immunotherapy; Cancer","score_opus":0.04619662143292034,"score_gpt":0.37127889652554735,"score_spread":0.325082275092627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996718802","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35577685,0.00050224,0.61322236,0.0013694548,0.0003361163,0.0005694803,0.0015417485,0.0019986362,0.024683146],"genre_scores_gemma":[0.8871943,0.00022048727,0.10627868,0.00021913582,0.000043646054,0.00039566398,0.00073671754,0.00015890026,0.0047525004],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99950254,0.0002688071,0.000018151119,0.000056920824,0.00008498722,0.0000686942],"domain_scores_gemma":[0.9925011,0.006649003,0.00016457756,0.0001289507,0.00039758306,0.00015887035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018600638,0.00062258524,0.00093638897,0.00048361946,0.00038494787,0.00086495024,0.0011854232,0.0012794702,0.0062982705],"category_scores_gemma":[0.0065251044,0.0005863947,0.001032556,0.00041250917,0.0004271983,0.00045706445,0.0005992068,0.0011911812,0.000295641],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004925944,0.000044136174,0.00034165056,0.00001796262,0.000022062795,0.000013379297,0.000005924579,0.99671894,0.000108149055,0.0010450041,0.00017133163,0.0014621009],"study_design_scores_gemma":[0.000022179,0.000010969406,0.000031327498,0.0000012429864,0.0000038819758,0.0000012375974,0.0000017960546,0.99958175,0.00005794576,0.00020067628,0.00008571362,0.0000013082722],"about_ca_topic_score_codex":0.04703997,"about_ca_topic_score_gemma":0.019739648,"teacher_disagreement_score":0.04703997,"about_ca_system_score_codex":0.0011095089,"about_ca_system_score_gemma":0.0026223212,"threshold_uncertainty_score":0.09353238},"labels":[],"label_agreement":null},{"id":"W2997394796","doi":"10.1016/j.jns.2019.10.313","title":"Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis","year":2019,"lang":"en","type":"article","venue":"Journal of the Neurological Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Population; Clinical trial; Internal medicine; Adverse effect; Phases of clinical research; Immunology; Environmental health","score_opus":0.03989489549209315,"score_gpt":0.26384960430142973,"score_spread":0.22395470880933657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997394796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651899,0.028202634,0.0005600657,0.00044903043,0.00007275663,0.00007841894,0.0033512157,0.000047177826,0.0020488119],"genre_scores_gemma":[0.9898346,0.0040826215,0.0004982483,0.0005164006,0.00021349962,0.000047078713,0.0043555084,0.000015488118,0.00043661424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862313,0.0003188969,0.00025088314,0.0002670866,0.00041774815,0.00012230649],"domain_scores_gemma":[0.9953998,0.0014328964,0.0019009667,0.00031357637,0.000743474,0.000209239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029587199,0.0005032559,0.0014306348,0.0009669882,0.00021197509,0.0011379459,0.0005437995,0.00057152944,0.0007791177],"category_scores_gemma":[0.0045941863,0.00024637094,0.001834245,0.0014251391,0.00024975775,0.0009664803,0.00042202044,0.0008673708,0.00017635677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020038335,0.00026890976,0.8331559,0.0009769691,0.010461292,0.0003820654,0.00011797873,0.0012569596,0.0040580886,0.00012862076,0.0025284116,0.12662655],"study_design_scores_gemma":[0.0024377836,0.002549749,0.9788143,0.00015033258,0.006742919,0.0013216424,0.000076901524,0.0011368674,0.0010052923,0.00017913952,0.005549245,0.00003574599],"about_ca_topic_score_codex":0.0014838687,"about_ca_topic_score_gemma":0.0023061025,"teacher_disagreement_score":0.0029587199,"about_ca_system_score_codex":0.00062387955,"about_ca_system_score_gemma":0.0006563675,"threshold_uncertainty_score":0.015647352},"labels":[],"label_agreement":null},{"id":"W2998937323","doi":"10.1038/s41596-019-0249-0","title":"Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds","year":2020,"lang":"en","type":"article","venue":"Nature Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration; National Institutes of Health; Government of Canada; U.S. Department of Health and Human Services","keywords":"Cell biology; Antigen-presenting cell; T cell; Antigen; Chimeric antigen receptor; Chemistry; Cell; Cell culture; Cell therapy; Ex vivo; Biology; Molecular biology; In vitro; Stem cell; Immunology; Biochemistry; Immune system","score_opus":0.07538587506011594,"score_gpt":0.40112151878599217,"score_spread":0.3257356437258762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998937323","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96269894,0.001579835,0.02560338,0.00013103383,0.00018337743,0.00021627099,0.00056703785,0.0002923265,0.008727819],"genre_scores_gemma":[0.9824117,0.0006428429,0.012741084,0.000048996568,0.000034192068,0.00024152861,0.00047045655,0.000043017215,0.0033662103],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998559,0.00002350934,0.000012871655,0.000032163844,0.000039201164,0.000036309062],"domain_scores_gemma":[0.9999194,0.000033195458,0.000009558139,0.000011841511,0.000012311555,0.000013719766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023920128,0.00029398742,0.00016783492,0.00021882172,0.00016487118,0.0005416676,0.00019799267,0.00032170175,0.0018366718],"category_scores_gemma":[0.00019561799,0.000106105515,0.00019418055,0.00019641398,0.00012715733,0.00022043542,0.00021412363,0.00035703325,0.0005258577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015940695,0.00008368364,0.00020601346,0.0000622842,0.000004695908,0.00007898097,0.00008720945,0.0010071332,0.9924913,0.0005834727,0.00030642303,0.004929422],"study_design_scores_gemma":[0.000021728238,0.00020228034,0.00038829734,0.000006330325,0.000010719034,0.000079967765,0.00002899886,0.003360791,0.9897189,0.00010245518,0.0060757417,0.0000038834582],"about_ca_topic_score_codex":0.00014421833,"about_ca_topic_score_gemma":0.00036158954,"teacher_disagreement_score":0.0018366718,"about_ca_system_score_codex":0.0001434176,"about_ca_system_score_gemma":0.00017200496,"threshold_uncertainty_score":0.0061442256},"labels":[],"label_agreement":null},{"id":"W2999883306","doi":"10.1097/01.cot.0000653352.65501.9d","title":"Dual-Targeted Antibody Offers Positive Outcomes for Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphoma; Medicine; B cell; CD20; Oncology; Cancer; Antibody; Rituximab; Internal medicine; Cancer research; Immunology","score_opus":0.028664672571640435,"score_gpt":0.37234676236506004,"score_spread":0.3436820897934196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999883306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75580615,0.12721783,0.0032167556,0.05172054,0.0047850683,0.0003104358,0.0017428971,0.00066878216,0.054531496],"genre_scores_gemma":[0.9465974,0.020626886,0.0021572467,0.012858422,0.0019329126,0.00015410075,0.001390635,0.000056121586,0.014226277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99968815,0.000078987454,0.000022173239,0.00003868273,0.00008897702,0.00008302719],"domain_scores_gemma":[0.99954236,0.00009807403,0.00007858451,0.00002278821,0.000068370086,0.00018974037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088821194,0.0001948579,0.00032738323,0.0003295012,0.00024678258,0.00096171355,0.00018038781,0.0005262658,0.006002355],"category_scores_gemma":[0.0011504019,0.00007440629,0.00060069584,0.00015351629,0.00021888183,0.0006571703,0.000588574,0.00094824453,0.0008577675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008468226,0.0013206225,0.022904135,0.00066744746,0.00035509447,0.00035261046,0.00010045563,0.0001780859,0.01062037,0.002538369,0.055546943,0.89694756],"study_design_scores_gemma":[0.012897087,0.034667097,0.20062584,0.0015232167,0.0026565904,0.012104086,0.00063409976,0.002795635,0.035254102,0.011688284,0.6850017,0.00015224419],"about_ca_topic_score_codex":0.0003851167,"about_ca_topic_score_gemma":0.0014138543,"teacher_disagreement_score":0.006002355,"about_ca_system_score_codex":0.00073604507,"about_ca_system_score_gemma":0.00034202187,"threshold_uncertainty_score":0.02007991},"labels":[],"label_agreement":null},{"id":"W2999920020","doi":"10.1002/eji.201948309","title":"CD5 blockade enhances ex vivo CD8 <sup>+</sup> T cell activation and tumour cell cytotoxicity","year":2020,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Institute of Cancer Research; Canadian Institutes of Health Research","keywords":"CD5; Cytotoxic T cell; Biology; Ex vivo; CD8; T cell; Cancer research; T-cell receptor; In vivo; Molecular biology; Antigen; Cell biology; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.022525415814308287,"score_gpt":0.2578561671743148,"score_spread":0.23533075136000653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999920020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963425,0.0008827861,0.0009920738,0.000059732294,0.000031373464,0.000026983502,0.00013374354,0.00007108907,0.0014597182],"genre_scores_gemma":[0.9965874,0.00031659185,0.0006100204,0.000036954945,0.000019729012,0.000026423912,0.00021958808,0.00001324725,0.0021700694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997694,0.000055450426,0.00001668171,0.000026213444,0.00003845825,0.00009379672],"domain_scores_gemma":[0.99986744,0.000038726732,0.000027923496,0.000015743019,0.000009198072,0.00004103306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015649977,0.0005788082,0.00031463857,0.00020709848,0.00008264425,0.00028720408,0.00016612778,0.00027581293,0.0020480014],"category_scores_gemma":[0.00010655804,0.00010312287,0.00019334439,0.00009142484,0.0001701514,0.0001676553,0.00016376877,0.00095849636,0.0005293392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042516922,0.00027021984,0.00007615688,0.000045303117,0.0000062633503,0.000034315046,0.000010624081,0.00017482632,0.9971865,0.000076140685,0.000055680808,0.0016387686],"study_design_scores_gemma":[0.00005602726,0.0019135592,0.0010468707,0.0000050417652,0.000013721314,0.00010732953,0.000007674779,0.0008648562,0.9948841,0.0000220528,0.0010768998,0.0000018503928],"about_ca_topic_score_codex":0.00026237412,"about_ca_topic_score_gemma":0.0004272926,"teacher_disagreement_score":0.0020480014,"about_ca_system_score_codex":0.00022712671,"about_ca_system_score_gemma":0.00014845493,"threshold_uncertainty_score":0.0068513155},"labels":[],"label_agreement":null},{"id":"W3001787418","doi":"10.1158/2326-6066.cir-19-0521","title":"IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada); Vector Institute; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"CD8; Cytotoxic T cell; Biology; Chimeric antigen receptor; T-cell receptor; Cancer research; Cytokine; Immunology; Immunotherapy; T cell; Cell biology; Antigen; Immune system; Genetics","score_opus":0.13213537955766047,"score_gpt":0.39498686672623684,"score_spread":0.26285148716857637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001787418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598324,0.0005710776,0.0014956945,0.000063657135,0.00001961263,0.00004102217,0.000173705,0.00007071554,0.0015813722],"genre_scores_gemma":[0.9969597,0.00018814609,0.0009650628,0.00005217926,0.00002002372,0.000031929656,0.00023277385,0.000016248907,0.0015339131],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998971,0.000022725255,0.000008652969,0.000018935616,0.000017153776,0.00003535244],"domain_scores_gemma":[0.99992025,0.000010569255,0.000013397204,0.000013581006,0.0000124652,0.000029758736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000803189,0.00030799198,0.00017531945,0.00012000321,0.0000902377,0.00026053545,0.00005771827,0.0001455161,0.0016637571],"category_scores_gemma":[0.00006748102,0.00006231413,0.00013551097,0.000073581374,0.000077449055,0.00008491042,0.00011875184,0.00037796603,0.00061400654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010384034,0.000037633774,0.00037182914,0.000017351756,0.0000020305606,0.000035961635,0.000007055441,0.00004711545,0.997733,0.000025467029,0.000047638787,0.0015710797],"study_design_scores_gemma":[0.000055609285,0.001429217,0.009418011,0.000008791,0.000020697198,0.0006660796,0.000054663775,0.001144773,0.9824226,0.00005126814,0.004724358,0.000003837047],"about_ca_topic_score_codex":0.00009328514,"about_ca_topic_score_gemma":0.00020928538,"teacher_disagreement_score":0.0016637571,"about_ca_system_score_codex":0.00008903482,"about_ca_system_score_gemma":0.000083323204,"threshold_uncertainty_score":0.0055657625},"labels":[],"label_agreement":null},{"id":"W3003231717","doi":"10.1016/j.omtm.2020.01.012","title":"A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; National Research Council Canada","funders":"National Research Council Canada","keywords":"Jurkat cells; Chimeric antigen receptor; Antigen; Monoclonal antibody; Biology; Cell biology; Electroporation; Computational biology; T cell; Molecular biology; Chemistry; Antibody; Immunology; Immune system; Genetics; Gene","score_opus":0.16504406304242386,"score_gpt":0.4849395707982245,"score_spread":0.3198955077558006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003231717","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14240085,0.0020126821,0.8346857,0.00038718083,0.00023276034,0.0014923094,0.007369254,0.0037823273,0.0076369266],"genre_scores_gemma":[0.41933918,0.0033431516,0.5429101,0.000574858,0.00012172482,0.0052678864,0.011365914,0.00053122896,0.016545998],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989423,0.0002135978,0.000094736635,0.00029165886,0.0003413848,0.000116270625],"domain_scores_gemma":[0.99969995,0.000111253896,0.000037580165,0.00006331926,0.000060929495,0.00002701619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075148285,0.0009276311,0.00078010134,0.0009860209,0.0005313671,0.00084066985,0.000752032,0.000718205,0.0031626157],"category_scores_gemma":[0.00044697084,0.00040111053,0.00070674636,0.0010442884,0.0002944104,0.00046215663,0.00046563477,0.0016828824,0.0041521015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004322232,0.00006732723,0.0002182299,0.00007048173,0.000013492543,0.000034372726,0.0000368984,0.00019268495,0.9943131,0.00030254794,0.00033396928,0.004373611],"study_design_scores_gemma":[0.000024960298,0.00021920582,0.001513728,0.000012684826,0.000034702127,0.00019399292,0.000032550106,0.0045940657,0.9859308,0.00030695822,0.0071126022,0.000023811306],"about_ca_topic_score_codex":0.00064958894,"about_ca_topic_score_gemma":0.0016944814,"teacher_disagreement_score":0.0031626157,"about_ca_system_score_codex":0.00054487603,"about_ca_system_score_gemma":0.0005278783,"threshold_uncertainty_score":0.010580003},"labels":[],"label_agreement":null},{"id":"W3006233208","doi":"10.1182/bloodadvances.2019000525","title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Legend Biotech; Novartis Pharmaceuticals Corporation","keywords":"Cytokine release syndrome; Immunogenicity; Immunology; Medicine; CD19; Hazard ratio; Internal medicine; Tocilizumab; Oncology; Biology; Immunotherapy; Flow cytometry; Cancer; Antibody; Confidence interval; Chimeric antigen receptor","score_opus":0.0500624111526647,"score_gpt":0.3459240145316899,"score_spread":0.29586160337902523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006233208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995297,0.00026108287,0.00006131792,0.000007947954,6.230183e-7,0.0000071697723,0.000030063911,0.000004607567,0.00009742306],"genre_scores_gemma":[0.99962854,0.00006230544,0.00008548253,0.000018794555,0.0000025673348,0.000007759271,0.0001030827,0.0000024063568,0.00008906281],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997446,0.00009936193,0.000023562228,0.000047430123,0.000053445136,0.000031599615],"domain_scores_gemma":[0.9992362,0.00022606867,0.000322127,0.000053048123,0.00005525409,0.00010726926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064707256,0.00014102046,0.00035156374,0.00021215138,0.000091942326,0.00038725772,0.0001490454,0.00018541624,0.0003813021],"category_scores_gemma":[0.00089984847,0.00010965477,0.00018893938,0.00020312422,0.00016243674,0.00019470246,0.00018614251,0.00029910033,0.00011275726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020624738,0.00070051244,0.8352957,0.00013491706,0.00028785228,0.00053537736,0.00021372474,0.0022362696,0.077531055,0.00006604046,0.00026717733,0.062106773],"study_design_scores_gemma":[0.00048752982,0.016353065,0.9664915,0.000009593711,0.00019169279,0.0012213419,0.00012669443,0.00368258,0.010069309,0.00005981757,0.0012930278,0.0000138137975],"about_ca_topic_score_codex":0.00048783736,"about_ca_topic_score_gemma":0.000649549,"teacher_disagreement_score":0.00064707256,"about_ca_system_score_codex":0.00042951526,"about_ca_system_score_gemma":0.00014265082,"threshold_uncertainty_score":0.0034220815},"labels":[],"label_agreement":null},{"id":"W3006716329","doi":"10.1002/advs.201903164","title":"Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer","year":2020,"lang":"en","type":"review","venue":"Advanced Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Key Research and Development Program of China; China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Chimeric antigen receptor; Cancer therapy; Cell therapy; Immunotherapy; Cancer immunotherapy; T cell; Cancer; Computational biology; Nanotechnology; Cell; Medicine; Immune system; Biology; Immunology; Materials science; Genetics","score_opus":0.084066710822694,"score_gpt":0.38719439308852854,"score_spread":0.30312768226583453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006716329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007132586,0.9944067,0.0010678949,0.0002510129,0.00023989905,0.000012281628,0.00001420839,0.000020778714,0.0032738864],"genre_scores_gemma":[0.0050717294,0.9917686,0.0009087964,0.0002596255,0.00016067928,0.000019923524,0.000029228846,0.0000037617065,0.0017775994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998698,0.000029707106,0.000008906107,0.000021821952,0.000054464923,0.000015182038],"domain_scores_gemma":[0.9999224,0.000037589096,0.000013742146,0.0000035617552,0.000016361839,0.0000064594406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039543436,0.00069534045,0.00054215704,0.0014161674,0.00015312682,0.0005401027,0.0004135733,0.00086905685,0.0016438703],"category_scores_gemma":[0.00024366712,0.00020842293,0.00033671406,0.00088627136,0.00050207175,0.0006424246,0.00049324613,0.0012354401,0.0010417303],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007194724,0.00010531667,0.00013912411,0.010013989,0.00006621766,0.0002742759,0.00007294572,0.0012081672,0.03725178,0.021173839,0.01270029,0.91692203],"study_design_scores_gemma":[0.000022021608,0.00018420452,0.0004567862,0.0012259723,0.00004673397,0.0010280577,0.000028896548,0.00029620103,0.009889333,0.0037820581,0.98302126,0.000018471652],"about_ca_topic_score_codex":0.00052077457,"about_ca_topic_score_gemma":0.000982466,"teacher_disagreement_score":0.0016438703,"about_ca_system_score_codex":0.0004817324,"about_ca_system_score_gemma":0.00056287996,"threshold_uncertainty_score":0.0054993033},"labels":[],"label_agreement":null},{"id":"W3006968198","doi":"10.1158/1078-0432.ccr-19-3136","title":"Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Society for Medical Oncology; Merck; AstraZeneca","keywords":"Clinical trial; Drug development; Task force; Medicine; Immunotherapy; Task (project management); Cancer; Test (biology); Intensive care medicine; Drug; Pharmacology; Internal medicine; Political science; Management","score_opus":0.8178733737580474,"score_gpt":0.6530636985540562,"score_spread":0.16480967520399115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006968198","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035138226,0.245515,0.46149147,0.12438999,0.019544626,0.1198761,0.004861438,0.0015030231,0.019304488],"genre_scores_gemma":[0.014983729,0.080355056,0.7579317,0.033575904,0.0047440846,0.10210624,0.0019930245,0.00036744846,0.0039428067],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.4271775,0.45603594,0.05957606,0.0071648657,0.046453886,0.0035917833],"domain_scores_gemma":[0.303733,0.42087612,0.08359907,0.043492474,0.13822354,0.0100759715],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.5962295,0.003878527,0.007469543,0.0058145104,0.0022507035,0.012222603,0.008908575,0.013275031,0.005066431],"category_scores_gemma":[0.4969041,0.0032293317,0.0088433465,0.004336152,0.007913597,0.0062743216,0.0056728986,0.01526902,0.005771574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061039235,0.0010999544,0.0046575353,0.05872922,0.0020118807,0.00047255692,0.0013739894,0.0031288918,0.00498284,0.037687086,0.115222804,0.7645293],"study_design_scores_gemma":[0.007050555,0.0060388576,0.011984039,0.13985506,0.0050225407,0.0010337791,0.0009005945,0.0034844992,0.012321742,0.050583597,0.7612045,0.0005202944],"about_ca_topic_score_codex":0.003447221,"about_ca_topic_score_gemma":0.0045890887,"teacher_disagreement_score":0.5962295,"about_ca_system_score_codex":0.00680681,"about_ca_system_score_gemma":0.076275796,"threshold_uncertainty_score":0.497921},"labels":[],"label_agreement":null},{"id":"W3007071335","doi":"10.1182/blood.v130.suppl_1.2553.2553","title":"Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacodynamics; Medicine; Cytokine release syndrome; Pharmacokinetics; Tocilizumab; Internal medicine; Pharmacology; Oncology; Cancer; Immunotherapy","score_opus":0.009843819103986807,"score_gpt":0.2545859916300531,"score_spread":0.24474217252606628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007071335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973985,0.0011724759,0.0004680071,0.00006847732,0.00000922854,0.000056249162,0.0003291322,0.000032760192,0.00046517042],"genre_scores_gemma":[0.9984169,0.00027985964,0.0004594112,0.000095700125,0.000013234209,0.000052921238,0.0003564374,0.000008962762,0.0003166381],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997446,0.000091696915,0.000017801332,0.000049016242,0.00005945378,0.000037517384],"domain_scores_gemma":[0.9996031,0.0000975414,0.00014490764,0.000027617625,0.000027960687,0.00009881372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005401176,0.00020220925,0.00041502193,0.00016862509,0.00011117448,0.0005168552,0.00018017052,0.0003014702,0.0007247543],"category_scores_gemma":[0.00095149525,0.00016650934,0.0003029757,0.00017618768,0.00019732138,0.00027590606,0.00012463209,0.0007468673,0.00022462723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12910068,0.00502919,0.20400332,0.0005336555,0.0012517008,0.0011770254,0.00089308544,0.012175186,0.4287759,0.000638537,0.0044055185,0.21201614],"study_design_scores_gemma":[0.0071002934,0.16493021,0.66665447,0.00010127836,0.0013670597,0.0037755307,0.0004070593,0.024433514,0.11758589,0.00033094268,0.0132146925,0.00009907444],"about_ca_topic_score_codex":0.0005056204,"about_ca_topic_score_gemma":0.0010950222,"teacher_disagreement_score":0.0007247543,"about_ca_system_score_codex":0.00049867894,"about_ca_system_score_gemma":0.00037298547,"threshold_uncertainty_score":0.0036181808},"labels":[],"label_agreement":null},{"id":"W3007405904","doi":"10.1038/s41375-020-0777-1","title":"CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Agence Nationale de la Recherche","keywords":"Interleukin-3 receptor; CD28; Plasmacytoid dendritic cell; Cancer research; Biology; Effector; Immunotherapy; Immunology; T cell; Immune system; Antigen; Dendritic cell","score_opus":0.021698490980137833,"score_gpt":0.26845814996873685,"score_spread":0.24675965898859903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007405904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95113635,0.004313431,0.005634726,0.0013420354,0.00012243874,0.00022049001,0.00022742231,0.00045025712,0.036552813],"genre_scores_gemma":[0.99514127,0.00046278554,0.0012372824,0.00008487502,0.00004038992,0.00002715033,0.000092570175,0.00001463408,0.0028991138],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986947,0.000028189646,0.000012086857,0.000022334154,0.000030350619,0.000037528367],"domain_scores_gemma":[0.99990106,0.000027932396,0.000011895669,0.000024042425,0.000010340706,0.000024613984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025956254,0.00020693523,0.00023486314,0.00046130214,0.00035224314,0.0005254729,0.00023643386,0.0007862063,0.0029457018],"category_scores_gemma":[0.00025228364,0.00017723827,0.00010635065,0.00018639542,0.0003404326,0.00041709465,0.0002893622,0.0008003608,0.0009544138],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056481953,0.0014402973,0.030438758,0.0009170558,0.00008811013,0.11656822,0.0005727209,0.0021705665,0.6947669,0.024271196,0.008641549,0.11447652],"study_design_scores_gemma":[0.0013277292,0.0030327735,0.048173234,0.00007823315,0.00021851716,0.28876543,0.0005880573,0.019940276,0.51221055,0.01025943,0.11537031,0.000035498495],"about_ca_topic_score_codex":0.0004722247,"about_ca_topic_score_gemma":0.0006123407,"teacher_disagreement_score":0.0029457018,"about_ca_system_score_codex":0.0005480387,"about_ca_system_score_gemma":0.00025881428,"threshold_uncertainty_score":0.009854317},"labels":[],"label_agreement":null},{"id":"W3007507981","doi":"10.1182/bloodadvances.2019001026","title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Kite Pharma; MorphoSys; BeiGene; Novartis Pharmaceuticals Corporation; Celgene; Gilead Sciences; Chugai Pharmaceutical; Servier; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Medicine; Lymphoma; Quality of life (healthcare); Term (time); Oncology; Internal medicine; Biology","score_opus":0.03035533187023569,"score_gpt":0.3139951859388295,"score_spread":0.2836398540685938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007507981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987703,0.00085581414,0.000045928857,0.000032493048,0.000006673613,0.000046127927,0.00006140991,0.000005732072,0.00017544716],"genre_scores_gemma":[0.99900573,0.00034447765,0.000120608034,0.000057119778,0.000013398132,0.00006548608,0.0002222175,0.0000013211104,0.00016960903],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9997403,0.00014725699,0.000016144728,0.000024790701,0.000032675704,0.000038856273],"domain_scores_gemma":[0.99971694,0.00005867399,0.00009885871,0.000015013186,0.000016018044,0.00009450398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007933253,0.00026688827,0.0005571348,0.00016945874,0.000118062315,0.00034116278,0.00024719376,0.00024758434,0.00069407426],"category_scores_gemma":[0.0005174436,0.000100079465,0.0004528556,0.00020012794,0.00019968495,0.00022092441,0.00022066,0.00059339247,0.00011348754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4650547,0.02108153,0.17740175,0.00079863565,0.002548374,0.0003879325,0.0003093584,0.004913539,0.036199786,0.00022532097,0.0019497569,0.28912935],"study_design_scores_gemma":[0.11598294,0.4538583,0.41198778,0.00008505631,0.001249425,0.0006886523,0.00019272856,0.006037012,0.0060332823,0.00018896553,0.0036487475,0.0000471225],"about_ca_topic_score_codex":0.00046351622,"about_ca_topic_score_gemma":0.0011254878,"teacher_disagreement_score":0.0007933253,"about_ca_system_score_codex":0.00037100434,"about_ca_system_score_gemma":0.00026818554,"threshold_uncertainty_score":0.004195571},"labels":[],"label_agreement":null},{"id":"W3007691816","doi":"10.3389/fimmu.2020.00276","title":"T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé","keywords":"Minor histocompatibility antigen; Antigen; Immunology; Immunotherapy; Major histocompatibility complex; Biology; Chimeric antigen receptor; Histocompatibility; Cancer immunotherapy; Cancer research; Human leukocyte antigen; Immune system","score_opus":0.034286764600403946,"score_gpt":0.3136169474172623,"score_spread":0.2793301828168584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007691816","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035026728,0.9905731,0.0020521672,0.0005499269,0.00038997273,0.000028442815,0.000039469436,0.000038256694,0.0028259947],"genre_scores_gemma":[0.017129308,0.97683495,0.0023408602,0.000690808,0.0005794941,0.000051506315,0.00010131972,0.000011307348,0.0022605523],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998692,0.00003307466,0.000014216174,0.000018474457,0.000043349963,0.000021621085],"domain_scores_gemma":[0.9999268,0.000034688812,0.000013496254,0.000002822175,0.000012858838,0.000009316079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040920704,0.0003397067,0.0005616519,0.0006552072,0.00012742265,0.0004981632,0.00038836495,0.0007896804,0.001468963],"category_scores_gemma":[0.00022625977,0.00011649312,0.0003803502,0.0005108626,0.00025881254,0.0005432397,0.00027953935,0.0009129681,0.0009576662],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026869628,0.00022005163,0.0004139404,0.012328619,0.00011274822,0.0009790328,0.00015727656,0.001735646,0.077801436,0.013785293,0.017901614,0.87429565],"study_design_scores_gemma":[0.00007922188,0.0006995892,0.0014335082,0.0012799532,0.0001939618,0.004859183,0.00007408316,0.00060955074,0.02591583,0.0050542327,0.95977145,0.000029284938],"about_ca_topic_score_codex":0.00027035514,"about_ca_topic_score_gemma":0.0005240796,"teacher_disagreement_score":0.001468963,"about_ca_system_score_codex":0.000370298,"about_ca_system_score_gemma":0.00032303896,"threshold_uncertainty_score":0.0049141645},"labels":[],"label_agreement":null},{"id":"W3009044390","doi":"10.3389/fimmu.2020.00326","title":"Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Computational biology; Computer science; Biology","score_opus":0.05796822622788738,"score_gpt":0.3303832482385775,"score_spread":0.2724150220106901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009044390","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015950427,0.9974131,0.00047597295,0.00024637498,0.0003643121,0.000008901941,0.000020148322,0.000012581184,0.0012991179],"genre_scores_gemma":[0.000729281,0.997656,0.0004805588,0.00019158819,0.00025297407,0.000014138329,0.000033810873,0.000002394779,0.00063925004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983263,0.000027141572,0.000019641338,0.000029887693,0.00006888998,0.000021728607],"domain_scores_gemma":[0.99975497,0.0001262086,0.000030030853,0.0000074380146,0.000059299073,0.000022026048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006580141,0.000898149,0.0008904333,0.00176793,0.00020408188,0.00089451374,0.0007291544,0.0010029385,0.0034193275],"category_scores_gemma":[0.00051059434,0.0003125538,0.0004303544,0.0013220948,0.00043506347,0.0015218896,0.0005564799,0.0018549884,0.0021410547],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006927314,0.00010975389,0.00009225764,0.017892798,0.000054523076,0.00016989745,0.000059900904,0.00056553655,0.006611399,0.008759846,0.029515544,0.93609923],"study_design_scores_gemma":[0.000011551946,0.00013649782,0.0002608382,0.0015720238,0.00006651396,0.0005508532,0.000035268073,0.00013812762,0.0015322696,0.0018601086,0.99381894,0.000016964303],"about_ca_topic_score_codex":0.00045903082,"about_ca_topic_score_gemma":0.0006719278,"teacher_disagreement_score":0.0034193275,"about_ca_system_score_codex":0.0005394017,"about_ca_system_score_gemma":0.00083260733,"threshold_uncertainty_score":0.011438847},"labels":[],"label_agreement":null},{"id":"W3010357077","doi":"10.1016/j.bbmt.2020.03.002","title":"Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Transplantation; Cell therapy; Clinical trial; Intensive care medicine; Observational study; Stem cell; Internal medicine","score_opus":0.035550017240259954,"score_gpt":0.30326553556949226,"score_spread":0.2677155183292323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010357077","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009652123,0.5380564,0.047173142,0.24655405,0.026887093,0.0017618092,0.010078103,0.0019007074,0.11793657],"genre_scores_gemma":[0.0537409,0.3955217,0.20619732,0.2005104,0.021111494,0.006387917,0.027289804,0.0017249128,0.08751553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967969,0.0009591876,0.0009062907,0.00016474255,0.00096623035,0.00020665968],"domain_scores_gemma":[0.9931552,0.0020393324,0.0011382864,0.000294696,0.0025584751,0.0008141071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050725183,0.0012742954,0.0019003781,0.0029496022,0.0011338984,0.0021173824,0.002228063,0.004587691,0.0070151035],"category_scores_gemma":[0.007187663,0.0005827959,0.0027161143,0.002708374,0.0014201527,0.0012469213,0.0012600392,0.00915727,0.0068310876],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045986683,0.0003632147,0.0033086075,0.0013698993,0.00010961929,0.00031198782,0.00012450833,0.0013438528,0.0033089246,0.005917116,0.73309535,0.2502869],"study_design_scores_gemma":[0.00028131326,0.00020393965,0.008758283,0.0035252701,0.00019407699,0.0016408913,0.00020328719,0.0007289439,0.0013385477,0.0050056814,0.9780477,0.00007189078],"about_ca_topic_score_codex":0.0061510997,"about_ca_topic_score_gemma":0.016279973,"teacher_disagreement_score":0.0070151035,"about_ca_system_score_codex":0.0020886897,"about_ca_system_score_gemma":0.0077342237,"threshold_uncertainty_score":0.026826382},"labels":[],"label_agreement":null},{"id":"W3011481633","doi":"10.7554/elife.49900.sa2","title":"Author response: The naive T-cell receptor repertoire has an extremely broad distribution of clone sizes","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Repertoire; Biology; clone (Java method); Computational biology; Evolutionary biology; Genetics; Physics; Gene","score_opus":0.1098761402091364,"score_gpt":0.37682350319440466,"score_spread":0.2669473629852683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011481633","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034572282,0.0026988985,0.0029713176,0.8022315,0.14694706,0.0001906167,0.0009502737,0.0006318933,0.03992134],"genre_scores_gemma":[0.04389081,0.004029509,0.0034642178,0.44167998,0.06263188,0.00031620142,0.0012259583,0.0007257697,0.44203568],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994076,0.0018101654,0.0003242048,0.0006255919,0.002588443,0.0005755665],"domain_scores_gemma":[0.9628039,0.013160695,0.0016579317,0.0019300547,0.016978102,0.0034692849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061525954,0.0004434205,0.0006098967,0.00074040756,0.0011587407,0.00232547,0.0008282338,0.00496399,0.113615625],"category_scores_gemma":[0.04968675,0.00026723172,0.00041617343,0.00034185467,0.0012088992,0.00096859824,0.0014460449,0.004379616,0.05108565],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016810033,0.00001793874,0.00042061793,0.00018586226,0.000014074318,0.00023295391,0.00008019416,0.000054587097,0.0011552178,0.0012284968,0.97102904,0.025412835],"study_design_scores_gemma":[0.00007014259,0.00006498021,0.0008616951,0.00009682253,0.000012003977,0.0004592868,0.00027746405,0.00010961327,0.0012400583,0.0020892387,0.9946995,0.000019190571],"about_ca_topic_score_codex":0.00086260115,"about_ca_topic_score_gemma":0.00173992,"teacher_disagreement_score":0.113615625,"about_ca_system_score_codex":0.0011522477,"about_ca_system_score_gemma":0.0024928404,"threshold_uncertainty_score":0.38008213},"labels":[],"label_agreement":null},{"id":"W3011596849","doi":"10.1080/0284186x.2020.1741680","title":"Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas","year":2020,"lang":"en","type":"review","venue":"Acta Oncologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Chimeric antigen receptor; Chemoimmunotherapy; Lymphoma; Immunology; Oncology; Diffuse large B-cell lymphoma; Immunotherapy; Cell therapy; Internal medicine; Cancer research; Rituximab; Immune system; Stem cell; Biology","score_opus":0.07575368936951236,"score_gpt":0.36169467324318155,"score_spread":0.2859409838736692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011596849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016722836,0.89597654,0.0045639747,0.06677456,0.001960823,0.00006267582,0.00016986225,0.00013887652,0.013629878],"genre_scores_gemma":[0.16216315,0.79373515,0.00960972,0.020008715,0.006761475,0.00028889635,0.00037661262,0.00006529061,0.0069910195],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892646,0.00049265823,0.0000698697,0.00008488496,0.00025318153,0.00017293675],"domain_scores_gemma":[0.9975358,0.0013333114,0.00016629185,0.00006612728,0.0004816842,0.00041676633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008897115,0.00050512666,0.0006909717,0.0006238474,0.00041410467,0.0023084974,0.0008963857,0.0029605604,0.0053009796],"category_scores_gemma":[0.0034018122,0.00016766458,0.000675829,0.00041434,0.0019379966,0.0031413082,0.00087316666,0.0024266369,0.0013015759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022437107,0.00068227074,0.0020821977,0.002664588,0.00010584332,0.0012225811,0.00028308775,0.004211251,0.0070097577,0.035606723,0.04847587,0.8954121],"study_design_scores_gemma":[0.0011906534,0.007165906,0.0052825734,0.0048670173,0.0002432288,0.005352504,0.0012090288,0.0077117383,0.005473951,0.07597033,0.8853897,0.00014336246],"about_ca_topic_score_codex":0.0006819369,"about_ca_topic_score_gemma":0.0015423732,"teacher_disagreement_score":0.008897115,"about_ca_system_score_codex":0.0013791043,"about_ca_system_score_gemma":0.002718753,"threshold_uncertainty_score":0.04705298},"labels":[],"label_agreement":null},{"id":"W3011747051","doi":"10.3389/fimmu.2020.00361","title":"Advances in Developing CAR T-Cell Therapy for HIV Cure","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); Medicine; Cell therapy; Virology; Intensive care medicine; Biology; Cell; Viral load; Genetics","score_opus":0.0393279410448842,"score_gpt":0.3567973900772711,"score_spread":0.31746944903238694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011747051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022310572,0.9963444,0.00044797987,0.0005605824,0.00042188232,0.000009452933,0.000017859447,0.000016254482,0.0019584477],"genre_scores_gemma":[0.0010725796,0.99698275,0.00045875565,0.00035204238,0.00021729713,0.000013864925,0.000026296904,0.0000025670433,0.0008738113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998672,0.000027003785,0.000013157093,0.000025156496,0.00004756595,0.000019902744],"domain_scores_gemma":[0.9998449,0.00007892755,0.000014180677,0.000005036506,0.00003928955,0.000017641947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005383029,0.0006685408,0.0007903463,0.001285532,0.0002264808,0.0008378373,0.0006073337,0.0011547282,0.0045340047],"category_scores_gemma":[0.00044558142,0.0001893854,0.00049565005,0.0008308958,0.00036475624,0.0012901672,0.00055140833,0.0022884489,0.0021371036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075765354,0.00011936262,0.000098098804,0.010955336,0.000057089164,0.00018990815,0.000065292144,0.0004612223,0.0053111333,0.010412939,0.0317041,0.9405496],"study_design_scores_gemma":[0.000022922955,0.00014236195,0.00019866176,0.0015164239,0.00006206174,0.00054747175,0.000033386597,0.00014236468,0.0010341138,0.002174795,0.99411315,0.000012347883],"about_ca_topic_score_codex":0.0005322843,"about_ca_topic_score_gemma":0.00087998895,"teacher_disagreement_score":0.0045340047,"about_ca_system_score_codex":0.00042813827,"about_ca_system_score_gemma":0.000706205,"threshold_uncertainty_score":0.015167773},"labels":[],"label_agreement":null},{"id":"W3013325302","doi":"10.1101/2020.03.23.004325","title":"Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; Danmarks Grundforskningsfond; National Research Foundation","keywords":"CD22; Selectin; Sialyl-Lewis X; Cancer research; Chemistry; Lymphoma; Antigen; Immunology; B cell; Molecular biology; Antibody; Biology; Cell adhesion molecule","score_opus":0.017511600526523896,"score_gpt":0.23798411222752086,"score_spread":0.22047251170099696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013325302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96630347,0.0042186575,0.02048349,0.00054938317,0.00011827455,0.00010978394,0.0001944851,0.0002175983,0.0078048036],"genre_scores_gemma":[0.98379725,0.0014903074,0.0072820676,0.00010645197,0.000022770571,0.000040347542,0.00014525677,0.000034781297,0.007080776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995327,0.000009428634,0.0000021281246,0.0000062082604,0.000018570234,0.000010401987],"domain_scores_gemma":[0.9999865,0.000001909737,0.000003411885,0.0000020386667,0.000001929477,0.000004214096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011214594,0.00023590244,0.00012323301,0.000114082235,0.00009305724,0.00023756188,0.000097557684,0.00022398797,0.0015922709],"category_scores_gemma":[0.00006693823,0.00007501879,0.000111618174,0.00007514545,0.00013428344,0.00013208165,0.00019085556,0.00032769865,0.00043770246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051864215,0.000021935552,0.00009028784,0.000026724741,0.000004572077,0.000049966642,0.000014662873,0.00021595688,0.9957765,0.0005145309,0.00020064117,0.003032426],"study_design_scores_gemma":[0.000015742839,0.000075257885,0.00026637103,0.000002679167,0.000005828046,0.00014485807,0.000006221425,0.00093604194,0.9916495,0.00006699681,0.0068285703,0.0000020112702],"about_ca_topic_score_codex":0.00036736374,"about_ca_topic_score_gemma":0.0004132267,"teacher_disagreement_score":0.0015922709,"about_ca_system_score_codex":0.00020731876,"about_ca_system_score_gemma":0.00013360154,"threshold_uncertainty_score":0.0053266883},"labels":[],"label_agreement":null},{"id":"W3013453726","doi":"10.1158/2326-6074.tumimm19-b62","title":"Abstract B62: Development of novel chimeric antigen receptor T cells for immunotherapy of hepatocellular carcinoma","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Epitope; Monoclonal antibody; Antigen; Immunotherapy; Effector; Cancer immunotherapy; Immunohistochemistry; Cancer research; Hepatocellular carcinoma; Antibody; Adoptive cell transfer; Molecular biology; T cell; Biology; Immunology; Immune system","score_opus":0.1458943262138125,"score_gpt":0.39103270112138505,"score_spread":0.24513837490757256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013453726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890266,0.0024379345,0.0057367496,0.00014854367,0.000063361644,0.00010559947,0.00014071359,0.00012717723,0.002213382],"genre_scores_gemma":[0.9880165,0.0011210226,0.0072007296,0.00011570353,0.00003569751,0.000071146096,0.00045500486,0.000012369423,0.002971858],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993694,0.000012147812,0.000004199733,0.00001250656,0.000017471542,0.000016754726],"domain_scores_gemma":[0.9999733,0.0000029997718,0.0000051023358,0.000002746491,0.0000061043675,0.000009769424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009492757,0.00026991835,0.0001731108,0.00012801905,0.000071125876,0.00014929032,0.0001388756,0.00032909404,0.0010832162],"category_scores_gemma":[0.000070888746,0.000072520445,0.00015860067,0.00007317518,0.00007107055,0.00011815466,0.000117850956,0.00039598983,0.00042729932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002093569,0.000114826915,0.00027878696,0.000060244263,0.0000094573525,0.00009132651,0.00001643251,0.00048094857,0.98860407,0.000116793126,0.00020118225,0.009816638],"study_design_scores_gemma":[0.00063051196,0.007102307,0.008304023,0.000036367845,0.00011625287,0.0017722753,0.000040253617,0.010849567,0.94873977,0.00023088642,0.022156643,0.000021109809],"about_ca_topic_score_codex":0.0002455293,"about_ca_topic_score_gemma":0.00026153072,"teacher_disagreement_score":0.0010832162,"about_ca_system_score_codex":0.00013397241,"about_ca_system_score_gemma":0.00013619014,"threshold_uncertainty_score":0.003623724},"labels":[],"label_agreement":null},{"id":"W3013906244","doi":"10.3389/fonc.2020.00448","title":"CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model","year":2020,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Medical Research Council; Wellcome Trust; Bloodwise; Blood Cancer UK; University of Oxford; Cancer Research UK","keywords":"Cancer research; Immune system; Biology; Diffuse large B-cell lymphoma; Lymphoma; Immunology; T cell; Major histocompatibility complex","score_opus":0.03935570422577517,"score_gpt":0.33131085790410014,"score_spread":0.291955153678325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013906244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847435,0.0010027307,0.008351624,0.00022886819,0.00011691484,0.00012000376,0.001402645,0.00070616335,0.0033276144],"genre_scores_gemma":[0.9884292,0.00052359,0.002951792,0.00012171236,0.000013277794,0.00011096198,0.0011161655,0.000102542144,0.006630609],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976116,0.000024685243,0.000026265427,0.000069858215,0.00006539495,0.000052663407],"domain_scores_gemma":[0.9997452,0.000029895456,0.00007261343,0.000025624888,0.000019000734,0.000107699365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023695044,0.0005069516,0.00029496272,0.00056563626,0.00019055173,0.0004261041,0.0003292522,0.00057674694,0.0023466572],"category_scores_gemma":[0.00015528577,0.00017405025,0.0003291458,0.00015850634,0.0003120432,0.00025830447,0.00022945464,0.0009385617,0.00070753106],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001419024,0.00009314941,0.00011560768,0.0000253604,0.000007508175,0.00011955695,0.000024589333,0.00011598758,0.9979437,0.00020364279,0.00012218469,0.0010867844],"study_design_scores_gemma":[0.000097597214,0.0010831443,0.0027488305,0.00001793576,0.000033979715,0.0007306806,0.00006441696,0.0042463862,0.98414314,0.00018682094,0.0066316887,0.000015296866],"about_ca_topic_score_codex":0.0011104309,"about_ca_topic_score_gemma":0.0011265198,"teacher_disagreement_score":0.0023466572,"about_ca_system_score_codex":0.00035360508,"about_ca_system_score_gemma":0.00020080685,"threshold_uncertainty_score":0.007850349},"labels":[],"label_agreement":null},{"id":"W3014563464","doi":"10.1038/s41375-020-0808-y","title":"H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Canadian Institutes of Health Research; Blood Cancer UK; University of Oxford; Research Councils UK; Bloodwise; Wellcome Trust; Lady Tata Memorial Trust; Ministerio de Economía y Competitividad; Cancer Research UK; Leukaemia UK; Medical Research Foundation; National Institute for Health and Care Research; European Hematology Association","keywords":"Leukemia; Biology; Stem cell; Cancer research; Enhancer; Cancer stem cell; Cancer; Genetics; Gene; Transcription factor","score_opus":0.025357778417561753,"score_gpt":0.2960044509883657,"score_spread":0.27064667257080394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014563464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957151,0.0005941352,0.0015486908,0.00005531306,0.000012714992,0.000011428459,0.00049491646,0.00011010748,0.0014575846],"genre_scores_gemma":[0.9960496,0.00021268961,0.00064240757,0.00002685457,0.000003620485,0.000018138906,0.0006246072,0.000021254209,0.0024008497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982196,0.00001686345,0.000010753701,0.000050101746,0.000053178785,0.000047239453],"domain_scores_gemma":[0.99993217,0.0000061576557,0.000021725135,0.000008884554,0.000007172543,0.000023931198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000084036976,0.00018864757,0.00021403198,0.00026770504,0.000228825,0.00031970764,0.00019721399,0.00014129422,0.0018694656],"category_scores_gemma":[0.00009362735,0.00017711596,0.00018066546,0.00019337682,0.00023705054,0.0001499639,0.00037991768,0.00034155592,0.0005697944],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008134859,0.0000118661055,0.00041169784,0.000009741644,0.000001984232,0.000024319866,0.000013818678,0.0000308662,0.99865156,0.00007669123,0.000030868403,0.00065525115],"study_design_scores_gemma":[0.000021190184,0.00010813339,0.02319366,0.00000301503,0.000008227291,0.0002021886,0.000047475234,0.0013335041,0.9719935,0.00008546651,0.0029984678,0.0000051311504],"about_ca_topic_score_codex":0.0013714945,"about_ca_topic_score_gemma":0.002288354,"teacher_disagreement_score":0.0018694656,"about_ca_system_score_codex":0.0003905577,"about_ca_system_score_gemma":0.00022310387,"threshold_uncertainty_score":0.0062540174},"labels":[],"label_agreement":null},{"id":"W3016228284","doi":"10.1016/j.omto.2020.03.018","title":"Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Ben and Catherine Ivy Foundation; Canary Foundation","keywords":"Chimeric antigen receptor; Oncolytic virus; Antigen; CD19; Cancer research; Cell therapy; Melanoma; Cell; Biology; Immunotherapy; Immunology; Virology; Immune system; Tumor cells","score_opus":0.01980434138450807,"score_gpt":0.3008079975698722,"score_spread":0.2810036561853641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016228284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550328,0.0045764777,0.03208218,0.00045818053,0.00017173775,0.00021845721,0.00040851888,0.0005591128,0.006492568],"genre_scores_gemma":[0.98617005,0.0011828769,0.008144386,0.000048420374,0.000023895282,0.000051796353,0.0001951799,0.000059241982,0.0041242563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976796,0.000043038777,0.000012667346,0.000047374004,0.00006599131,0.00006294834],"domain_scores_gemma":[0.9998865,0.000029859617,0.000023452265,0.000019034524,0.000010218885,0.00003079436],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002141365,0.00043756687,0.00029691745,0.00036703298,0.00021633376,0.0006809498,0.00020991491,0.00045937972,0.001801882],"category_scores_gemma":[0.00016864167,0.0001651851,0.00021752826,0.00019803536,0.00040057307,0.0002934895,0.0002673997,0.00077025243,0.0005801224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006424227,0.00008414888,0.00013836478,0.00006006713,0.000011631459,0.00007577926,0.000028519873,0.0002882796,0.99173003,0.0013274001,0.00018546602,0.0060061635],"study_design_scores_gemma":[0.000025056053,0.00047419674,0.000355051,0.000004921245,0.000016947259,0.00022967054,0.0000117858335,0.0016896861,0.99097496,0.000081959675,0.006131827,0.000003999341],"about_ca_topic_score_codex":0.0010570674,"about_ca_topic_score_gemma":0.001917355,"teacher_disagreement_score":0.001801882,"about_ca_system_score_codex":0.000496522,"about_ca_system_score_gemma":0.00044229897,"threshold_uncertainty_score":0.0060278773},"labels":[],"label_agreement":null},{"id":"W3016525618","doi":"10.1016/j.ymthe.2020.04.013","title":"Check and Checkmate: Battling Cancer with Multiplex Immunotherapy","year":2020,"lang":"en","type":"letter","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Oncolytic virus; Cancer; Cancer immunotherapy; Immunotherapy; Tumor microenvironment; Cancer immunology; Medicine; Immune system; Immune checkpoint; Cancer research; Immunology; Internal medicine","score_opus":0.03190717010889309,"score_gpt":0.30537625195003276,"score_spread":0.27346908184113966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016525618","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046186127,0.47219986,0.18777737,0.13633761,0.039103456,0.0007058347,0.001571798,0.008874995,0.1072429],"genre_scores_gemma":[0.36424989,0.2945715,0.13138628,0.065586954,0.01566381,0.00079056964,0.001954162,0.0016179358,0.124178976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993148,0.0001371701,0.000027126274,0.00009249856,0.0003090106,0.00011932146],"domain_scores_gemma":[0.9993206,0.00022102322,0.00008054315,0.00007844578,0.00009797955,0.00020141943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013624539,0.0007053098,0.0006629021,0.0013981903,0.00070250104,0.003223365,0.0009984743,0.0014883908,0.013224279],"category_scores_gemma":[0.0017233479,0.00034546736,0.00077233766,0.0007145283,0.0012991014,0.0043660575,0.0020074274,0.0035325193,0.004346154],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006412811,0.00036313848,0.0008061037,0.0013792288,0.00019182793,0.00045843207,0.00020907172,0.0014912549,0.028067797,0.046288237,0.2077422,0.7123614],"study_design_scores_gemma":[0.00016677173,0.0006171223,0.000588568,0.00044456005,0.00012946101,0.0011383679,0.0001521029,0.0036978638,0.030158516,0.031857263,0.9309587,0.000090777685],"about_ca_topic_score_codex":0.00052143424,"about_ca_topic_score_gemma":0.001617077,"teacher_disagreement_score":0.013224279,"about_ca_system_score_codex":0.0010197574,"about_ca_system_score_gemma":0.0008840793,"threshold_uncertainty_score":0.04423958},"labels":[],"label_agreement":null},{"id":"W3016572530","doi":"10.7554/elife.53244","title":"Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma","year":2020,"lang":"en","type":"article","venue":"eLife","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; Princess Margaret Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Mitacs; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Epitope; Human leukocyte antigen; Antigen; Biology; Allele; Immunotherapy; Tumor-infiltrating lymphocytes; Immunology; Cancer immunotherapy; T-cell receptor; Melanoma; T cell; Immune system; Gene; Cancer research; Genetics","score_opus":0.036163672755717906,"score_gpt":0.2761645601904363,"score_spread":0.24000088743471837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016572530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982463,0.00019045566,0.0012098522,0.000007795883,8.255988e-7,0.0000036740955,0.000037005517,0.000008595687,0.00029542268],"genre_scores_gemma":[0.9984036,0.00008644566,0.0012774403,0.000010493411,0.000001124141,0.000004519267,0.000054565695,0.0000038646276,0.00015794708],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99994063,0.000012765567,0.0000031620625,0.000018653778,0.000011320198,0.000013418858],"domain_scores_gemma":[0.9999646,0.00000886738,0.0000090822,0.0000049939267,0.000003911294,0.000008534494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000088859066,0.00010878129,0.00013303141,0.00027758654,0.00012119377,0.0001845634,0.00007242342,0.00012479072,0.000594325],"category_scores_gemma":[0.00012036341,0.00008243252,0.00009528225,0.00016126,0.00008374491,0.00010319182,0.00014339572,0.00016571439,0.000096345386],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081498154,0.000011482613,0.0059262933,0.000016235557,0.000010084627,0.000055809705,0.000046506935,0.00026015393,0.9893467,0.000054614655,0.000014996274,0.0041756015],"study_design_scores_gemma":[0.000042078485,0.0009623666,0.32653922,0.000024636185,0.00014815666,0.004159008,0.0006352398,0.011015641,0.651873,0.0009686962,0.0036152496,0.000016707729],"about_ca_topic_score_codex":0.00021287739,"about_ca_topic_score_gemma":0.00058672234,"teacher_disagreement_score":0.000594325,"about_ca_system_score_codex":0.00008494378,"about_ca_system_score_gemma":0.0000598305,"threshold_uncertainty_score":0.0019881725},"labels":[],"label_agreement":null},{"id":"W3016844795","doi":"10.3747/co.27.5283","title":"Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Cell therapy; Cancer; Leukemia; T cell; Cancer immunotherapy; Immunology; Cancer research; Immune system; Cell; Internal medicine; Biology","score_opus":0.46528233005644404,"score_gpt":0.6140640395132099,"score_spread":0.14878170945676583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016844795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000119464974,0.9942987,0.00031884195,0.0018099641,0.000864173,0.000009258583,0.000014578247,0.000020103846,0.0025449027],"genre_scores_gemma":[0.0009464468,0.9949351,0.00040453,0.0018217282,0.0006083147,0.000012213149,0.000027398886,0.000004934093,0.0012393796],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996308,0.000072936935,0.000036686153,0.00006558389,0.00015622118,0.000037734964],"domain_scores_gemma":[0.9994634,0.00026996987,0.000045700843,0.000018527304,0.00015160094,0.00005077259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012506649,0.0008838873,0.001082921,0.0013760031,0.00033968597,0.0018194512,0.0008847826,0.0022505438,0.0051752967],"category_scores_gemma":[0.0013436275,0.0002700424,0.00050453935,0.0014614891,0.0009971438,0.003141396,0.0009854748,0.0046518324,0.0035860294],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007877898,0.00006432587,0.0000869031,0.006798337,0.00003190964,0.00018119383,0.00007013854,0.00030081678,0.0019205367,0.012678528,0.056120288,0.9216683],"study_design_scores_gemma":[0.000013047619,0.0000764572,0.00014132341,0.0019665372,0.000023944976,0.00052760175,0.00003356255,0.000053610656,0.00029895178,0.0028718386,0.99398476,0.000008393398],"about_ca_topic_score_codex":0.0009073158,"about_ca_topic_score_gemma":0.0011308861,"teacher_disagreement_score":0.0051752967,"about_ca_system_score_codex":0.0011251186,"about_ca_system_score_gemma":0.0015738889,"threshold_uncertainty_score":0.017313063},"labels":[],"label_agreement":null},{"id":"W3016877653","doi":"10.1016/j.omto.2020.04.001","title":"A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Cancer Society","keywords":"CD28; Chimeric antigen receptor; T cell; Peripheral blood mononuclear cell; Toxicity; CD8; Cytokine release syndrome; Cytotoxic T cell; Adoptive cell transfer; Cancer research; Cytokine; T-cell receptor; Cell; Immunology; Medicine; Antigen; Pharmacology; Biology; Chemistry; Immune system; Internal medicine; In vitro; Biochemistry","score_opus":0.05817557353079079,"score_gpt":0.3426282375479575,"score_spread":0.28445266401716673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016877653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624368,0.0019218817,0.03217401,0.00014671613,0.00005011498,0.000085092994,0.0001415153,0.000084402614,0.0029594444],"genre_scores_gemma":[0.9932827,0.00047715084,0.0046352334,0.000065053275,0.0000074528584,0.00003168763,0.00017142981,0.000012208329,0.0013170412],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999144,0.000027786056,0.0000041228823,0.0000200166,0.000018671602,0.000014934234],"domain_scores_gemma":[0.99989974,0.000039845618,0.000019902669,0.000014160778,0.00001104968,0.000015270096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021024341,0.00033441978,0.00019590526,0.00013875066,0.00015229217,0.00021804344,0.00031763926,0.00038859088,0.0012497951],"category_scores_gemma":[0.00015301793,0.00008150977,0.00024509217,0.00008792825,0.00033445135,0.00030761576,0.00014003155,0.00064950105,0.00019757176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008731257,0.00008425548,0.0003005906,0.000035584744,0.00001069245,0.00011043766,0.00001013444,0.0007848268,0.9953928,0.0017174429,0.000042442185,0.0014235494],"study_design_scores_gemma":[0.000017396515,0.00072239945,0.0010699978,0.0000054696775,0.00002069851,0.00041262497,0.000015953057,0.006844026,0.98782504,0.0005948329,0.0024661142,0.000005435104],"about_ca_topic_score_codex":0.0005509279,"about_ca_topic_score_gemma":0.00042758454,"teacher_disagreement_score":0.0012497951,"about_ca_system_score_codex":0.0004973967,"about_ca_system_score_gemma":0.00023342678,"threshold_uncertainty_score":0.004180968},"labels":[],"label_agreement":null},{"id":"W3017464623","doi":"10.1158/2326-6066.cir-18-0508","title":"Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Institute for Cancer Research","keywords":"Chimeric antigen receptor; T cell; Immunology; Immunotherapy; Adoptive cell transfer; Cytotoxic T cell; Cell therapy; Biology; T-cell receptor; Cancer research; Medicine; Immune system; Stem cell; Cell biology; In vitro","score_opus":0.09584839896265963,"score_gpt":0.3678044325559333,"score_spread":0.2719560335932737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017464623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9663385,0.0014013662,0.028156098,0.0000827086,0.00009821954,0.00009646386,0.00046634796,0.0002787486,0.0030814991],"genre_scores_gemma":[0.99232364,0.00046884414,0.0047650044,0.000045748002,0.000011565538,0.00005021614,0.0003489501,0.000030133977,0.0019558193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988914,0.0000144177675,0.000014379978,0.000028313574,0.000028472925,0.0000252571],"domain_scores_gemma":[0.9999366,0.000006194584,0.000020072366,0.00001561399,0.0000064252613,0.000015096536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009373919,0.0003315497,0.00018817438,0.00013642643,0.00009837303,0.0003405941,0.00016330907,0.00022824387,0.0012529918],"category_scores_gemma":[0.00007016904,0.00009514081,0.00016580622,0.00010609509,0.00015798665,0.00016841332,0.00020080093,0.00052663847,0.0005295524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021842918,0.000014082767,0.00010861827,0.000013073861,0.0000023043133,0.000020486475,0.0000036602455,0.000037261125,0.9988166,0.00009096287,0.000030019322,0.00084121013],"study_design_scores_gemma":[0.000010022028,0.00019391454,0.0008318916,0.00000428756,0.00002173071,0.00023110336,0.000011840228,0.0006482202,0.9939738,0.000048478545,0.004021925,0.0000026847604],"about_ca_topic_score_codex":0.00015485252,"about_ca_topic_score_gemma":0.00017756778,"teacher_disagreement_score":0.0012529918,"about_ca_system_score_codex":0.0001053092,"about_ca_system_score_gemma":0.00012898215,"threshold_uncertainty_score":0.004191637},"labels":[],"label_agreement":null},{"id":"W3019060111","doi":"10.1038/s41591-020-0827-2","title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","year":2020,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of Calgary; McGill University Health Centre; BC Children's Hospital; University of Toronto; SickKids Foundation; University of British Columbia; Hospital for Sick Children","funders":"Programme Development Grants; Canadian Institutes of Health Research; National Cancer Institute; Stand Up To Cancer; National Institutes of Health","keywords":"Medulloblastoma; Ependymoma; Chimeric antigen receptor; Medicine; Cerebrospinal fluid; Cancer research; Pathology; Oncology; Immunotherapy; Internal medicine; Cancer","score_opus":0.03507500143968219,"score_gpt":0.32943180603661787,"score_spread":0.2943568045969357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019060111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683764,0.017628424,0.007111456,0.0010476292,0.0003405565,0.00014958122,0.00022784629,0.0002536808,0.004864479],"genre_scores_gemma":[0.99373287,0.00316492,0.0012881552,0.000120700875,0.000047196285,0.00005192518,0.000087658715,0.000020676383,0.0014859629],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999472,0.0000060258467,0.000002361489,0.000009181207,0.000009636818,0.000025551359],"domain_scores_gemma":[0.99997246,0.000005073316,0.0000078836165,0.0000032962962,0.0000024574258,0.000008839527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000922176,0.00026694906,0.0003014561,0.00023162943,0.00027718057,0.00037976252,0.00030379865,0.00026556608,0.0009658368],"category_scores_gemma":[0.0001324378,0.000087431516,0.0003392198,0.00018925074,0.00036114219,0.00030388086,0.00022140583,0.00065220427,0.00021738642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055342554,0.0014373813,0.0024711357,0.0011227941,0.00025549132,0.0071008536,0.00046257436,0.004981407,0.71411055,0.0032157472,0.0050154305,0.25429237],"study_design_scores_gemma":[0.0028853512,0.023590157,0.016475813,0.0001797258,0.00087814045,0.012818214,0.0004921081,0.01119823,0.86073923,0.0016130672,0.06904318,0.00008672335],"about_ca_topic_score_codex":0.002439631,"about_ca_topic_score_gemma":0.0037520952,"teacher_disagreement_score":0.002439631,"about_ca_system_score_codex":0.0005509418,"about_ca_system_score_gemma":0.0005047772,"threshold_uncertainty_score":0.0048508644},"labels":[],"label_agreement":null},{"id":"W3019602056","doi":"10.1634/theoncologist.2020-0194","title":"Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Blockade; Tocilizumab; Melanoma; Immunotherapy; Oncology; Immune checkpoint; Immune system; Adverse effect; Cytokine; Chimeric antigen receptor; Internal medicine; Immunology; Cancer research; Receptor; Disease","score_opus":0.038032293583396076,"score_gpt":0.3468623536365209,"score_spread":0.30883006005312486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019602056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015348342,0.9962083,0.0003897615,0.000447063,0.00029868764,0.000008453366,0.00001886907,0.000012356383,0.0010816351],"genre_scores_gemma":[0.012091812,0.98553663,0.0004978613,0.0006769053,0.0006045834,0.000010089381,0.000047769,0.000005423537,0.00052885426],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9998246,0.000026398233,0.000048112983,0.000041120697,0.000041207688,0.000018527691],"domain_scores_gemma":[0.99971145,0.00016166181,0.00005677418,0.000010091555,0.000032543336,0.00002748797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023326925,0.00066467945,0.001326801,0.0021238998,0.00033091687,0.00062886614,0.0007884571,0.0010807228,0.0012796457],"category_scores_gemma":[0.0005994473,0.00021928665,0.0006493249,0.0017929844,0.00054621376,0.0010365912,0.0003258245,0.0013051082,0.0007228884],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013954764,0.00017477758,0.0026615337,0.027629605,0.00041993125,0.10171306,0.00031684974,0.000672333,0.00563491,0.0020452216,0.034981396,0.82361084],"study_design_scores_gemma":[0.000052733398,0.00022618502,0.005913771,0.0071988157,0.0006652101,0.60749,0.00045647463,0.00042103097,0.002479852,0.0018149136,0.3731724,0.0001086512],"about_ca_topic_score_codex":0.0006025712,"about_ca_topic_score_gemma":0.0011715076,"teacher_disagreement_score":0.0021238998,"about_ca_system_score_codex":0.00040659864,"about_ca_system_score_gemma":0.0005743653,"threshold_uncertainty_score":0.004280865},"labels":[],"label_agreement":null},{"id":"W3025149699","doi":"10.1101/2020.05.15.098335","title":"Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"CD19; Population; B cell; Transgene; Lentivirus; Immune system; Cell; Genetic enhancement; T cell","score_opus":0.021856212706054253,"score_gpt":0.25883849812451076,"score_spread":0.2369822854184565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025149699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909995,0.0011116002,0.004677601,0.000057255173,0.00003456123,0.00015039682,0.0003817967,0.00039728434,0.002189859],"genre_scores_gemma":[0.99010134,0.00056447636,0.005009551,0.00008557627,0.000021528063,0.00020647251,0.00058761134,0.00007998761,0.0033434022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997894,0.00002894312,0.000014127006,0.00003712488,0.000050411883,0.00007996926],"domain_scores_gemma":[0.9998424,0.00003531196,0.000037324407,0.000026992944,0.000014086749,0.000043847776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025513823,0.00034211058,0.00030101615,0.000354142,0.00013688003,0.00033121865,0.0002703232,0.0002770564,0.00099287],"category_scores_gemma":[0.00014371288,0.0001538972,0.00017832588,0.00012301769,0.00023120335,0.00017292505,0.00016383218,0.0008461697,0.00044238378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012092808,0.000119358614,0.0001666595,0.000019115598,0.0000037017012,0.000037316182,0.000019292165,0.00006436458,0.996503,0.00009151124,0.000080402424,0.0027744153],"study_design_scores_gemma":[0.000051799634,0.00089350704,0.0024952248,0.000007904012,0.000015084647,0.00020218387,0.000008439832,0.0014410217,0.9929188,0.00004329247,0.001919,0.0000037320744],"about_ca_topic_score_codex":0.0003483272,"about_ca_topic_score_gemma":0.00045252888,"teacher_disagreement_score":0.00099287,"about_ca_system_score_codex":0.00021772993,"about_ca_system_score_gemma":0.00019719498,"threshold_uncertainty_score":0.0033214688},"labels":[],"label_agreement":null},{"id":"W3026980848","doi":"10.1038/s41375-020-0874-1","title":"Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Terry Fox Foundation; U.S. Department of Health and Human Services","keywords":"Chimeric antigen receptor; Immune system; Immunology; Cytokine; Antigen; T cell; Autocrine signalling; Cancer research; Immunotherapy; Biology; Interleukin 2; Endogeny; Medicine; Receptor; Internal medicine; Endocrinology","score_opus":0.05250146682893192,"score_gpt":0.2856146705085528,"score_spread":0.2331132036796209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026980848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874586,0.003085325,0.003481276,0.0004833653,0.000185988,0.000080744096,0.0010311606,0.00064294675,0.0035505744],"genre_scores_gemma":[0.9950074,0.00062600937,0.00089995115,0.00008917894,0.0000351129,0.00003473557,0.0004958557,0.000038148908,0.0027735997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999579,0.00008929729,0.000036364218,0.00006917676,0.00008624274,0.00013985983],"domain_scores_gemma":[0.99985564,0.000027980932,0.000026384505,0.000031308777,0.000014309345,0.000044449378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020200825,0.00073682657,0.00051981275,0.00045640746,0.00021336388,0.0005502019,0.00024510644,0.00044925333,0.0036477835],"category_scores_gemma":[0.0001728329,0.00014623454,0.00030476725,0.00022963979,0.0003809758,0.00033338842,0.0002957436,0.0024385834,0.0011373828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013074131,0.00029648302,0.0002097541,0.000097918564,0.000012501832,0.0000777675,0.000048671693,0.00057342934,0.9908387,0.0003793389,0.0004529898,0.005704925],"study_design_scores_gemma":[0.00014015615,0.001002498,0.00083252956,0.00000822623,0.000034124885,0.0002321455,0.000036971698,0.00072192895,0.9912369,0.0001509246,0.0055979863,0.000005622313],"about_ca_topic_score_codex":0.00044521372,"about_ca_topic_score_gemma":0.00047453004,"teacher_disagreement_score":0.0036477835,"about_ca_system_score_codex":0.00038772827,"about_ca_system_score_gemma":0.00043825316,"threshold_uncertainty_score":0.012203038},"labels":[],"label_agreement":null},{"id":"W3027155039","doi":"10.3390/cancers12051321","title":"Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma","year":2020,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Melanoma; Medicine; Immune system; Metastatic melanoma; Cancer; Disease; Immunotherapy; Skin cancer; Adverse effect; Immune surveillance; Metastasis; Immunology; Cancer research; Dermatology; Internal medicine","score_opus":0.03532092597537828,"score_gpt":0.3543734595694293,"score_spread":0.319052533594051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027155039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029574498,0.9979925,0.00020989007,0.00021584054,0.00011157303,0.000007080629,0.000021185797,0.0000073614256,0.0011388016],"genre_scores_gemma":[0.0015542904,0.99738723,0.00020557283,0.00017807599,0.000087825814,0.000010234546,0.00003231686,0.0000014585737,0.0005430086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999114,0.000016506741,0.000010708832,0.000016655335,0.00003213512,0.0000125289225],"domain_scores_gemma":[0.9998834,0.00005875589,0.000016148735,0.000003788433,0.000027232973,0.000010712474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034433889,0.00046358004,0.00068281975,0.0013050453,0.0001780357,0.00067989377,0.0004321855,0.00067092985,0.003178408],"category_scores_gemma":[0.0003402139,0.00016998469,0.00045359606,0.000796113,0.00027234879,0.0008260655,0.00037909715,0.0013735167,0.0014141358],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009714537,0.00012922222,0.00016045688,0.017891534,0.000085464446,0.00024260751,0.000075689655,0.00046845034,0.008730561,0.005621507,0.015640216,0.9508571],"study_design_scores_gemma":[0.000027614335,0.00026899623,0.0008957414,0.0037106634,0.00015877682,0.0016026703,0.00005591948,0.00016124998,0.0024608765,0.0024850487,0.9881534,0.000019055553],"about_ca_topic_score_codex":0.0004677505,"about_ca_topic_score_gemma":0.0011085533,"teacher_disagreement_score":0.003178408,"about_ca_system_score_codex":0.00032723192,"about_ca_system_score_gemma":0.00049642875,"threshold_uncertainty_score":0.010632873},"labels":[],"label_agreement":null},{"id":"W3027248509","doi":"10.1016/j.jcyt.2020.03.252","title":"Strategies for successful monitoring of CAR T-cells by flow cytometry","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Chimeric antigen receptor; Flow cytometry; Context (archaeology); Cell therapy; Medicine; Cytometry; Cell; T cell; Immunology; Computational biology; Chemistry; Biology; Immune system","score_opus":0.043059149088054804,"score_gpt":0.3402613225430027,"score_spread":0.29720217345494787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027248509","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05960021,0.0046046074,0.92371744,0.0012600927,0.00029975685,0.0015219505,0.00044962196,0.0018827567,0.0066634873],"genre_scores_gemma":[0.30792484,0.0055397404,0.67188704,0.0012786143,0.00024839852,0.0043780394,0.00084567,0.0004704486,0.0074272337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981329,0.0006416278,0.00012744803,0.00036608914,0.0005270769,0.00020492291],"domain_scores_gemma":[0.99858487,0.00073428114,0.00011008594,0.00025424425,0.00025081178,0.00006570084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029364328,0.0017700132,0.0010113284,0.0016577471,0.0008908165,0.002477372,0.0015147561,0.0018686604,0.004426886],"category_scores_gemma":[0.0028612346,0.00083123543,0.0006199574,0.0005665079,0.0014110262,0.0017929664,0.0012335529,0.0034880487,0.0025174206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012057237,0.00015323581,0.00044262706,0.0002528982,0.000023545035,0.0000660245,0.0001718248,0.0007388884,0.9645175,0.006741335,0.0009589756,0.02581264],"study_design_scores_gemma":[0.000042229138,0.00021385396,0.0005229376,0.000043774886,0.000040826657,0.0002489186,0.000066796616,0.008704481,0.9740899,0.0044540083,0.011540155,0.000032136595],"about_ca_topic_score_codex":0.000646756,"about_ca_topic_score_gemma":0.0010817632,"teacher_disagreement_score":0.004426886,"about_ca_system_score_codex":0.0010275372,"about_ca_system_score_gemma":0.0008638078,"threshold_uncertainty_score":0.015529573},"labels":[],"label_agreement":null},{"id":"W3027422757","doi":"10.1016/j.jcyt.2020.03.218","title":"Non-toxic cross-reactivity with healthy tissues supports in vivo expansion and therapeutic efficacy of T cells engineered with synthetic antigen receptors","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; In vivo; Antibody; Monoclonal antibody; CD28; In vitro; T cell; Cancer research; Molecular biology; Chemistry; Immunology; Biology; Immune system; Biochemistry; CD8","score_opus":0.021188320311956707,"score_gpt":0.30961075462553417,"score_spread":0.28842243431357745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027422757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860218,0.0011903427,0.008931041,0.00007189081,0.000037196864,0.00008858691,0.00019323472,0.00013550947,0.00333049],"genre_scores_gemma":[0.9958021,0.0003103347,0.0021417988,0.00003018993,0.0000124822045,0.000039118262,0.00024206261,0.00003675476,0.0013851491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996625,0.00009694855,0.000026880667,0.000062861254,0.00007976169,0.000071029186],"domain_scores_gemma":[0.9996599,0.00016493742,0.000048359238,0.00006258819,0.000027741125,0.000036391062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042208115,0.00041634208,0.00024316444,0.00035047403,0.00013196105,0.0004443482,0.00025408855,0.0004544136,0.0018812224],"category_scores_gemma":[0.0003206105,0.00013725959,0.00021211155,0.0001432021,0.00028168366,0.00025647454,0.0002383821,0.0007280011,0.0005821502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000977723,0.00006300428,0.0000746641,0.000022900058,0.0000028770794,0.000027566637,0.000023338742,0.00008724124,0.9986191,0.000110987334,0.000032681135,0.00083787786],"study_design_scores_gemma":[0.000009941947,0.0003042777,0.0003763033,0.0000035809442,0.000011248792,0.00010561464,0.0000091764705,0.00041577773,0.99785334,0.000021243026,0.0008879653,0.0000013917845],"about_ca_topic_score_codex":0.00023290391,"about_ca_topic_score_gemma":0.00030885322,"teacher_disagreement_score":0.0018812224,"about_ca_system_score_codex":0.00014065047,"about_ca_system_score_gemma":0.00015231526,"threshold_uncertainty_score":0.006293297},"labels":[],"label_agreement":null},{"id":"W3027950647","doi":"10.1016/j.jcyt.2020.03.179","title":"Effect of cryopreservation of mesenchymal stromal cells after non-viral transfection on cell viability and transgene expression","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Transfection; Cryopreservation; Mesenchymal stem cell; Transgene; Stromal cell; Viability assay; Cell biology; Biology; Molecular biology; Cell; Cell culture; Embryo; Cancer research; Gene; Genetics","score_opus":0.012644679609469084,"score_gpt":0.282261100820444,"score_spread":0.2696164212109749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027950647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98856163,0.0048401994,0.002870673,0.0001460545,0.00022983032,0.00010228416,0.00052791147,0.00006697846,0.002654531],"genre_scores_gemma":[0.98943603,0.0018450231,0.002535102,0.000075514756,0.000045824338,0.000109882334,0.00084014423,0.000062288775,0.0050502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996908,0.00006742977,0.000044474018,0.00006602152,0.00005395642,0.00007739964],"domain_scores_gemma":[0.9995011,0.0002558983,0.000064971435,0.00006604962,0.00007549847,0.00003646869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005470787,0.00056483323,0.00055602926,0.0002455979,0.00044690695,0.00047352043,0.00039741633,0.00036029678,0.0033800805],"category_scores_gemma":[0.0004205201,0.0001563339,0.00046146332,0.0003432892,0.00036090385,0.00038395813,0.00022652787,0.0006507012,0.00045184055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007841156,0.0001393799,0.000429167,0.00009188907,0.000030021894,0.00010637587,0.00015141323,0.00022307367,0.9951407,0.00011756535,0.00008986676,0.0026964245],"study_design_scores_gemma":[0.000012410053,0.00044465897,0.0023598673,0.00000855526,0.000043909935,0.00004718681,0.000045660898,0.00043717318,0.99564856,0.000024405113,0.0009203054,0.0000071970003],"about_ca_topic_score_codex":0.0028720964,"about_ca_topic_score_gemma":0.0044698417,"teacher_disagreement_score":0.0033800805,"about_ca_system_score_codex":0.00048540934,"about_ca_system_score_gemma":0.00044689266,"threshold_uncertainty_score":0.011307538},"labels":[],"label_agreement":null},{"id":"W3028020071","doi":"10.1016/j.jval.2020.04.1540","title":"PCN34 COMPATIBILITY OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY STUDIES IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) FOR INDIRECT TREATMENT COMPARISON (ITC) ANALYSES","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Clinical trial; Population; Refractory (planetary science); Chimeric antigen receptor; Transplantation; Salvage therapy; Immunotherapy; Cancer; Chemotherapy","score_opus":0.2432661122207745,"score_gpt":0.42804879365365917,"score_spread":0.18478268143288468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028020071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880547,0.0072109383,0.0005996258,0.0001428062,0.00007713984,0.00026605593,0.00036772294,0.00001158959,0.0032693374],"genre_scores_gemma":[0.9981988,0.0005223417,0.00034038798,0.00007037137,0.000056083543,0.00012499707,0.00030209147,0.00000520092,0.00037984195],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9952217,0.0038992062,0.00018517481,0.0002202355,0.00022961314,0.00024415957],"domain_scores_gemma":[0.9979055,0.001249012,0.00026844238,0.0002122074,0.0001432624,0.00022155125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049922625,0.0006072396,0.001188087,0.0005473408,0.00024652554,0.0007746392,0.000455508,0.00051853847,0.0027786489],"category_scores_gemma":[0.0037866246,0.0001570611,0.0012025011,0.0005567876,0.00059646944,0.00066335587,0.00048205187,0.0012058635,0.00022304771],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81054115,0.0030942743,0.054289393,0.001002422,0.0057735736,0.000111347086,0.00026120554,0.0011592353,0.010200506,0.0012216502,0.000585237,0.11176006],"study_design_scores_gemma":[0.1347491,0.61055374,0.20846124,0.00023550335,0.016796546,0.0003933457,0.0004978854,0.003162432,0.014185827,0.0015962872,0.009297937,0.00007009919],"about_ca_topic_score_codex":0.00081935484,"about_ca_topic_score_gemma":0.0013699327,"teacher_disagreement_score":0.0049922625,"about_ca_system_score_codex":0.00090552674,"about_ca_system_score_gemma":0.00067208795,"threshold_uncertainty_score":0.026401937},"labels":[],"label_agreement":null},{"id":"W3029082024","doi":"10.1200/jco.2020.38.15_suppl.tps3160","title":"A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Nap; Medicine; Immunotherapy; Antigen; Cancer research; Immune system; Immune checkpoint; Oncology; Immunology; Nivolumab; Biology","score_opus":0.1893348622942087,"score_gpt":0.5145610612842015,"score_spread":0.32522619898999283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029082024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866895,0.002117746,0.00065100694,0.00075150107,0.00020324092,0.0037797398,0.002415974,0.0001440886,0.0032471938],"genre_scores_gemma":[0.9817139,0.0019552729,0.001489654,0.0011942853,0.00015453363,0.0038233786,0.0038339456,0.000029090279,0.005806034],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976224,0.00007565826,0.000009582208,0.000047053683,0.000026193215,0.00007935188],"domain_scores_gemma":[0.9996107,0.000043818847,0.00006890912,0.000029911509,0.000018992834,0.00022774507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000877809,0.0016622047,0.0013079509,0.0004145826,0.00044562438,0.0007959028,0.0009613878,0.0013100947,0.00594032],"category_scores_gemma":[0.0004840878,0.00047487442,0.00084469386,0.00031488793,0.00081644586,0.0010571339,0.00030784108,0.0032108463,0.0014306995],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7035984,0.10965303,0.004452566,0.0010590128,0.0010390186,0.00045713093,0.00037909808,0.002554482,0.06350032,0.00052691693,0.0076604723,0.105119534],"study_design_scores_gemma":[0.49628025,0.47952777,0.011196938,0.000042059182,0.00033715973,0.00038640297,0.00008274985,0.0012435368,0.004976299,0.00041355932,0.005484854,0.000028412891],"about_ca_topic_score_codex":0.0010581395,"about_ca_topic_score_gemma":0.0031297079,"teacher_disagreement_score":0.00594032,"about_ca_system_score_codex":0.0010316382,"about_ca_system_score_gemma":0.0010972876,"threshold_uncertainty_score":0.019872367},"labels":[],"label_agreement":null},{"id":"W3029558061","doi":"10.1200/jco.2020.38.15_suppl.10518","title":"Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis","keywords":"Medicine; Refractory (planetary science); Internal medicine; Blinatumomab; Gastroenterology; Surgery; Lymphoblastic Leukemia; Leukemia","score_opus":0.15579777345609733,"score_gpt":0.46880294045502197,"score_spread":0.31300516699892467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029558061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935521,0.0019233789,0.0001960109,0.0002746439,0.000037266942,0.0003767221,0.0013055211,0.000047356534,0.0022868414],"genre_scores_gemma":[0.99193525,0.0010990873,0.00033473436,0.00058240746,0.00007280722,0.00031474666,0.0036060822,0.00001834514,0.0020364535],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9996575,0.00017619398,0.000020456693,0.000048351885,0.000044439978,0.000052989624],"domain_scores_gemma":[0.9995813,0.00006209968,0.00009332665,0.000024112773,0.000016078124,0.00022315275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011538804,0.0004321659,0.0005840979,0.00025629852,0.00019893658,0.0006303669,0.0003904248,0.00045617216,0.0045858463],"category_scores_gemma":[0.0004035085,0.00018671808,0.00046381343,0.00034288818,0.00028920168,0.00036060793,0.00043181484,0.0010385618,0.0010560554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4379686,0.043624796,0.1354979,0.001563182,0.0022334189,0.0005262358,0.00054405496,0.0018731405,0.058239873,0.0008981103,0.016500408,0.30053023],"study_design_scores_gemma":[0.18590873,0.49322006,0.27395815,0.00025325853,0.0019932317,0.0014277531,0.0002503476,0.0014234623,0.008427894,0.00040093623,0.032703497,0.00003258052],"about_ca_topic_score_codex":0.00070016546,"about_ca_topic_score_gemma":0.002698475,"teacher_disagreement_score":0.0045858463,"about_ca_system_score_codex":0.0005912241,"about_ca_system_score_gemma":0.00068586745,"threshold_uncertainty_score":0.015341163},"labels":[],"label_agreement":null},{"id":"W3029703953","doi":"10.1200/jco.2020.38.15_suppl.tps11569","title":"SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Fludarabine; Context (archaeology); Internal medicine; Synovial sarcoma; Myxoid liposarcoma; Phases of clinical research; Sarcoma; Oncology; Clinical trial; Liposarcoma; Surgery; Cyclophosphamide; Chemotherapy; Pathology; Adverse effect","score_opus":0.12720236253995762,"score_gpt":0.47421580929525387,"score_spread":0.3470134467552962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029703953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834825,0.0034710614,0.0008369044,0.0011176739,0.00023521882,0.0036044258,0.0018921744,0.00024778373,0.0051122094],"genre_scores_gemma":[0.97775465,0.0025002088,0.0021737732,0.0018388553,0.00032057008,0.0037072871,0.0042322096,0.000047956026,0.0074244803],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959916,0.00017819404,0.00001823703,0.00006378833,0.00004636922,0.00009432646],"domain_scores_gemma":[0.9995166,0.00008633256,0.00009496193,0.000028430848,0.000021171601,0.0002524626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014593968,0.0017695753,0.001301038,0.00048489228,0.00043656965,0.000999058,0.0011129344,0.0017185229,0.008290582],"category_scores_gemma":[0.00067682326,0.0005519097,0.0011680769,0.00039424005,0.00091431785,0.0010392729,0.00045827596,0.0039964747,0.0014007038],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6582374,0.0679272,0.005508912,0.0018133958,0.0013426637,0.0009035398,0.0006500715,0.0046827584,0.07059181,0.0014917534,0.020055031,0.1667955],"study_design_scores_gemma":[0.52602065,0.45788258,0.004743036,0.00005638169,0.00025890674,0.0005502012,0.000069367736,0.0013530988,0.0038772565,0.00037228246,0.004779265,0.00003695934],"about_ca_topic_score_codex":0.0008009284,"about_ca_topic_score_gemma":0.0025943937,"teacher_disagreement_score":0.008290582,"about_ca_system_score_codex":0.00092023605,"about_ca_system_score_gemma":0.0013323766,"threshold_uncertainty_score":0.027734756},"labels":[],"label_agreement":null},{"id":"W3030062209","doi":"10.1200/jco.2020.38.15_suppl.tps11571","title":"Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02<sup>+</sup> previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"GlaxoSmithKline","keywords":"Medicine; Synovial sarcoma; Soft tissue sarcoma; Internal medicine; Oncology; Progressive disease; Chemotherapy; Sarcoma; Immunology; Cancer research; Pathology","score_opus":0.08339887970369389,"score_gpt":0.39242614807332304,"score_spread":0.3090272683696291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030062209","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308187,0.00059313525,0.00065876334,0.00012580719,0.00007314143,0.00391617,0.000639499,0.000034323977,0.0008773732],"genre_scores_gemma":[0.98699796,0.00049587473,0.001480222,0.00035209628,0.00014814825,0.008363423,0.0010168228,0.000020271655,0.001125209],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9980007,0.001285881,0.00012447969,0.00019682244,0.00014242463,0.0002497831],"domain_scores_gemma":[0.9981717,0.00043626723,0.0005060057,0.00031014543,0.00012455399,0.00045135815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041937563,0.0013141481,0.0017041041,0.00052846223,0.00039974778,0.0008848672,0.0010177536,0.0015887499,0.0031918138],"category_scores_gemma":[0.0020803628,0.00065383763,0.0012663702,0.00053151447,0.0014428777,0.0010081341,0.0005026397,0.002619761,0.0006613286],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84914255,0.061486617,0.0063953726,0.00061219407,0.0010294756,0.00018137647,0.0003431799,0.002678912,0.038618773,0.0004795635,0.0019877127,0.03704428],"study_design_scores_gemma":[0.21844333,0.7692885,0.00520679,0.000020587015,0.0003096735,0.00008273733,0.000047654543,0.00077472173,0.004422619,0.00016890604,0.0012147742,0.00001964796],"about_ca_topic_score_codex":0.0005659868,"about_ca_topic_score_gemma":0.0010992289,"teacher_disagreement_score":0.0041937563,"about_ca_system_score_codex":0.0011883066,"about_ca_system_score_gemma":0.0020252138,"threshold_uncertainty_score":0.022178948},"labels":[],"label_agreement":null},{"id":"W3030083314","doi":"10.1200/jco.2020.38.15_suppl.102","title":"Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Neutropenia; Leukopenia; Cyclophosphamide; Internal medicine; Febrile neutropenia; Regimen; Gastroenterology; Chemotherapy; Oncology; Surgery","score_opus":0.20372602864825018,"score_gpt":0.5361714243604768,"score_spread":0.33244539571222664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030083314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942742,0.0006289578,0.00041888512,0.00034667764,0.00007012156,0.0019546952,0.0005754411,0.00007004937,0.0016609285],"genre_scores_gemma":[0.9908264,0.00042674647,0.0014935256,0.00060664443,0.00008859815,0.0024110926,0.0015970778,0.00001850776,0.002531323],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996542,0.00016473274,0.000015655332,0.000046791218,0.000040311865,0.00007839709],"domain_scores_gemma":[0.9994481,0.00009797729,0.00012963936,0.000048203146,0.000030958174,0.000245106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013979098,0.0012267231,0.0009915554,0.00035058195,0.00031755422,0.0006503301,0.00073734496,0.0009914119,0.004738867],"category_scores_gemma":[0.0006785202,0.00038189578,0.00058803795,0.00029121008,0.0005990866,0.00065003143,0.00036176626,0.0032545896,0.0008602045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5743747,0.1450182,0.011574192,0.0006641409,0.00086118723,0.0007779544,0.0005546566,0.006386844,0.10154466,0.00088781497,0.011098893,0.14625677],"study_design_scores_gemma":[0.45208287,0.5221417,0.009851132,0.000030743868,0.00018785278,0.00065175025,0.000053267457,0.0025874965,0.008419239,0.00043721966,0.0035346756,0.000022184033],"about_ca_topic_score_codex":0.00044392672,"about_ca_topic_score_gemma":0.0008373201,"teacher_disagreement_score":0.004738867,"about_ca_system_score_codex":0.0008059722,"about_ca_system_score_gemma":0.00086321746,"threshold_uncertainty_score":0.015853107},"labels":[],"label_agreement":null},{"id":"W3030734898","doi":"10.1200/jco.2020.38.15_suppl.3035","title":"Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"CD19; CD22; Medicine; Flow cytometry; T cell; CD8; Immunology; Internal medicine; Molecular biology; Antigen; Biology; Immune system","score_opus":0.3304972255175948,"score_gpt":0.501662195559655,"score_spread":0.17116497004206016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030734898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958903,0.0012102963,0.00070115214,0.000055575827,0.000012492672,0.00028408226,0.00017527824,0.00008651675,0.0015844783],"genre_scores_gemma":[0.9976649,0.00032060003,0.00043724317,0.000054454176,0.000015486261,0.00014249978,0.0004382514,0.000012722578,0.00091391057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979204,0.000074658405,0.000012222055,0.000033098517,0.00004683303,0.00004107667],"domain_scores_gemma":[0.9998203,0.000035017983,0.00005106211,0.000017691755,0.000013400849,0.00006264792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005898724,0.00047067163,0.00046697227,0.00023053221,0.00020942274,0.00051498803,0.00029586712,0.0005771412,0.0023673533],"category_scores_gemma":[0.00029177146,0.00015255276,0.0002552475,0.00012875948,0.00030190943,0.00026147012,0.00017785348,0.000827906,0.0006175519],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04641941,0.018458342,0.007026363,0.0007548236,0.00023279947,0.001275926,0.00031628087,0.0016565296,0.77459097,0.0004528931,0.002549461,0.1462663],"study_design_scores_gemma":[0.019500028,0.5907093,0.030910583,0.000063028485,0.0005080813,0.0044048456,0.00007725593,0.002794967,0.33832297,0.00017575899,0.012504808,0.000028298136],"about_ca_topic_score_codex":0.00034539576,"about_ca_topic_score_gemma":0.00057643367,"teacher_disagreement_score":0.0023673533,"about_ca_system_score_codex":0.00035128603,"about_ca_system_score_gemma":0.00040345383,"threshold_uncertainty_score":0.00791955},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W3031522008","doi":"10.1089/jpm.2020.0138","title":"Chimeric Antigen Receptor T Cell Immunotherapy: What You Need to Know #393","year":2020,"lang":"en","type":"article","venue":"Journal of Palliative Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Microsemi (Canada)","funders":"National Institute on Aging","keywords":"Chimeric antigen receptor; Immunotherapy; Medicine; Antigen; Associate editor; Oncology; Immunology; Library science; Immune system; Computer science","score_opus":0.04554858171906813,"score_gpt":0.3492327811530041,"score_spread":0.303684199433936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031522008","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017492407,0.38424596,0.0024983105,0.548278,0.0429676,0.00009441437,0.00032233054,0.00024928947,0.019594872],"genre_scores_gemma":[0.024722029,0.38201287,0.010085894,0.41005963,0.09213297,0.0003324108,0.0005933735,0.00014774066,0.07991308],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991301,0.0002775935,0.00009678036,0.00007326611,0.00030039527,0.0001219259],"domain_scores_gemma":[0.995076,0.0019750192,0.00031058467,0.0001677949,0.0015628822,0.00090785394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035599761,0.0006733724,0.0012025875,0.00063444255,0.0012190639,0.0037266642,0.0011973692,0.006581645,0.020616613],"category_scores_gemma":[0.0045106644,0.0003623088,0.00093983463,0.00050515553,0.0018971189,0.006218398,0.0010997332,0.007580928,0.008743499],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041008604,0.0001921408,0.0008087589,0.0012521867,0.000057317175,0.00047546002,0.00011112295,0.00012566627,0.0021883536,0.00612459,0.635053,0.35320124],"study_design_scores_gemma":[0.00014065547,0.00029806714,0.0010870392,0.0020322565,0.00008843923,0.0010473707,0.0005892306,0.00027877127,0.00071139,0.0109261535,0.98273563,0.00006494964],"about_ca_topic_score_codex":0.0027380798,"about_ca_topic_score_gemma":0.008877038,"teacher_disagreement_score":0.020616613,"about_ca_system_score_codex":0.0015339624,"about_ca_system_score_gemma":0.003765723,"threshold_uncertainty_score":0.06896949},"labels":[],"label_agreement":null},{"id":"W3031718783","doi":"10.1200/jco.2020.38.15_suppl.e22504","title":"Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis","keywords":"Medicine; Internal medicine; Lymphoma; Refractory (planetary science); Cytokine release syndrome; Gastroenterology; Surgery; Oncology; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.08639205978262311,"score_gpt":0.4210383654333999,"score_spread":0.3346463056507768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031718783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966228,0.013285641,0.0010777914,0.0016758576,0.00024174905,0.0023089636,0.004953344,0.0005992443,0.009629475],"genre_scores_gemma":[0.96470237,0.0055909404,0.0051326305,0.0022801312,0.00020292493,0.0031940455,0.010858475,0.00012880133,0.007909678],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995919,0.00024073957,0.000013997457,0.00005451951,0.000041633033,0.000057379497],"domain_scores_gemma":[0.99953496,0.000063972475,0.00012322847,0.00003419687,0.000033323016,0.00021035685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015051148,0.001251238,0.0010531618,0.00049403805,0.00029759307,0.0011853577,0.0008739375,0.0009431119,0.0065267934],"category_scores_gemma":[0.0007328839,0.00038725603,0.0006836782,0.00045337473,0.0007294046,0.00092853175,0.0006876237,0.0023735443,0.001652148],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77504534,0.021108972,0.008115524,0.002632923,0.0017640679,0.0003267646,0.0002694834,0.0032231845,0.034309477,0.0014704913,0.020264665,0.13146919],"study_design_scores_gemma":[0.73478425,0.21381375,0.02164559,0.00020742316,0.0009364942,0.001219261,0.00012107264,0.0028371236,0.0040927567,0.0006795023,0.01960106,0.0000617265],"about_ca_topic_score_codex":0.0012542837,"about_ca_topic_score_gemma":0.003499196,"teacher_disagreement_score":0.0065267934,"about_ca_system_score_codex":0.0011770104,"about_ca_system_score_gemma":0.0012173002,"threshold_uncertainty_score":0.021834314},"labels":[],"label_agreement":null},{"id":"W3032561883","doi":"10.1200/jco.2020.38.15_suppl.tps8074","title":"A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; CD20; Lymphoma; Adverse effect; Ofatumumab; Oncology; Internal medicine; Pharmacodynamics; Rituximab; Pharmacology; Cancer research; Pharmacokinetics","score_opus":0.10107067104318164,"score_gpt":0.4645030107838141,"score_spread":0.3634323397406325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032561883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900012,0.0022276053,0.0009814264,0.00031831817,0.000088445464,0.0036831722,0.0010292198,0.00013743281,0.0015331799],"genre_scores_gemma":[0.9870942,0.0019247566,0.0021150932,0.0006480392,0.00013621521,0.0032014574,0.0019522156,0.00004389407,0.0028840748],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996226,0.00018393094,0.000013445458,0.000062139916,0.000042575,0.00007528337],"domain_scores_gemma":[0.9994547,0.0000860805,0.00011888515,0.000050119797,0.000046340418,0.00024384554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014459195,0.0017174501,0.0017491017,0.000561876,0.00028513436,0.00073329045,0.00090765476,0.0012005108,0.0032531822],"category_scores_gemma":[0.00070532324,0.0005593808,0.0007855716,0.00041166515,0.00090772053,0.00072089676,0.0002815894,0.0019583493,0.00083797704],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5956139,0.11792362,0.008201552,0.001326678,0.0014629214,0.00058101607,0.0004999332,0.004432575,0.15177745,0.0005993605,0.0045861667,0.11299483],"study_design_scores_gemma":[0.37103444,0.6093521,0.00821606,0.000033929293,0.00042212906,0.00035124828,0.0000627175,0.0013268333,0.00611828,0.00020848266,0.002847265,0.00002658033],"about_ca_topic_score_codex":0.0014611051,"about_ca_topic_score_gemma":0.0030180097,"teacher_disagreement_score":0.0032531822,"about_ca_system_score_codex":0.0011354738,"about_ca_system_score_gemma":0.001738237,"threshold_uncertainty_score":0.010883033},"labels":[],"label_agreement":null},{"id":"W3033356285","doi":"10.1016/s1470-2045(20)30275-8","title":"Developing anti-CD19 antibody-based combinations in lymphoma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blinatumomab; Antibody-drug conjugate; Medicine; Lymphoma; Refractory (planetary science); Antibody; CD19; Cancer research; Internal medicine; Oncology; Immunology; Monoclonal antibody; Biology","score_opus":0.11330106448099528,"score_gpt":0.40981677696904834,"score_spread":0.2965157124880531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033356285","genre_codex":"commentary","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009794325,0.006614527,0.000362172,0.9700721,0.015946113,0.000026514017,0.00005847156,0.00003349002,0.005907136],"genre_scores_gemma":[0.013082841,0.005288651,0.00079378544,0.9188402,0.05029854,0.00009618576,0.000058350855,0.00004105327,0.011500309],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977702,0.0008035,0.00020503704,0.00021596623,0.0007012153,0.00030417572],"domain_scores_gemma":[0.994426,0.003921155,0.00026070423,0.00009480122,0.00051408,0.00078320655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003377866,0.00069553003,0.0011423575,0.00055035716,0.001702503,0.0027871232,0.0011596747,0.027826423,0.005917399],"category_scores_gemma":[0.01220105,0.000571491,0.000985966,0.00046831023,0.0021186338,0.003507058,0.0013625952,0.021763358,0.0042324294],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003377724,0.00010775282,0.0009580989,0.0001487894,0.000039027273,0.002393538,0.00012248516,0.00032125454,0.0009814431,0.007140832,0.9348008,0.052648213],"study_design_scores_gemma":[0.0005450504,0.0002871385,0.0006794274,0.00021164333,0.000053115993,0.0020469802,0.00018737368,0.0010153465,0.000680881,0.018295586,0.975963,0.000034328525],"about_ca_topic_score_codex":0.0023297144,"about_ca_topic_score_gemma":0.0062635476,"teacher_disagreement_score":0.027826423,"about_ca_system_score_codex":0.0033023972,"about_ca_system_score_gemma":0.0020879414,"threshold_uncertainty_score":0.02396065},"labels":[],"label_agreement":null},{"id":"W3035321276","doi":"10.1101/2020.06.15.149021","title":"Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutations","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital; Simon Fraser University; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; University of British Columbia; Pancreas Centre (Canada); Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; National Institutes of Health; University of Melbourne; Cancer Research Institute; American Association for Cancer Research","keywords":"T-cell receptor; KRAS; CD8; Biology; T cell; Molecular biology; CD3; Cancer research; Cytotoxic T cell; Antigen; Genetics; Gene; Mutation; Immune system","score_opus":0.04324980804223668,"score_gpt":0.2753075742134235,"score_spread":0.2320577661711868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035321276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938969,0.00028788194,0.0040338975,0.000043654472,0.000028499308,0.000075893855,0.0002531154,0.00008315794,0.0012969243],"genre_scores_gemma":[0.99109507,0.00032004347,0.0041422904,0.000069044625,0.000018381521,0.00009653776,0.0009865045,0.00003165546,0.0032403818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997743,0.000039149323,0.000025641035,0.000045364624,0.000048182334,0.000067450776],"domain_scores_gemma":[0.99987376,0.00003197379,0.00002703442,0.000027888993,0.000016918144,0.000022361062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010648725,0.00036771293,0.00021684758,0.0001589807,0.00008169006,0.00027372167,0.00019159858,0.00026664053,0.0020482703],"category_scores_gemma":[0.00015886797,0.00017500261,0.00021181769,0.0001798079,0.00009630176,0.00011193431,0.00017338023,0.0007837356,0.001013612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048900187,0.000023867895,0.00015874166,0.000009401854,0.0000017179278,0.000033591943,0.000007161734,0.000042540803,0.99912447,0.00002352658,0.000025152247,0.00050091033],"study_design_scores_gemma":[0.00007607627,0.0008709267,0.0038949153,0.000009194249,0.00003405526,0.0014194227,0.000043820706,0.0020756316,0.9872994,0.00005615422,0.0042150705,0.0000054631973],"about_ca_topic_score_codex":0.0001929683,"about_ca_topic_score_gemma":0.00015634553,"teacher_disagreement_score":0.0020482703,"about_ca_system_score_codex":0.00013903421,"about_ca_system_score_gemma":0.0000925589,"threshold_uncertainty_score":0.0068522096},"labels":[],"label_agreement":null},{"id":"W3035762342","doi":"10.1172/jci.insight.136012","title":"A rational mouse model to detect on-target, off-tumor CAR T cell toxicity","year":2020,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; Breast Cancer Society of Canada; University of Pennsylvania","keywords":"Toxicity; In vivo; Potency; Cancer research; Antigen; Downregulation and upregulation; Cell; Chimeric antigen receptor; Biology; Immunology; Chemistry; Pharmacology; In vitro; T cell; Medicine; Immune system; Internal medicine; Biochemistry; Gene","score_opus":0.05259355392620244,"score_gpt":0.29972067114915346,"score_spread":0.24712711722295103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035762342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87587065,0.0045009544,0.089050695,0.0016239674,0.0006517647,0.0016708416,0.008955853,0.0029688259,0.014706519],"genre_scores_gemma":[0.9131981,0.0033963493,0.050163876,0.0008202307,0.00008726453,0.0024918108,0.0050058234,0.0005249361,0.02431154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999158,0.00013975159,0.000086438245,0.00023695182,0.0001986657,0.0001800892],"domain_scores_gemma":[0.99954,0.00007274796,0.0001273177,0.00008622449,0.00006536801,0.00010831014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008668383,0.0016817028,0.0006728643,0.0018461752,0.00048423317,0.0008998982,0.0008708979,0.0017565315,0.0044235326],"category_scores_gemma":[0.0002685192,0.00055895286,0.0006278633,0.000507565,0.0007740935,0.000988789,0.00040058699,0.0037667663,0.001378962],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003242177,0.00051283743,0.00035820797,0.00008258083,0.00002201541,0.00011903894,0.000040463277,0.00046371983,0.99336594,0.00095848256,0.0007969501,0.0029554076],"study_design_scores_gemma":[0.00016480341,0.002236648,0.0014121336,0.00003761798,0.000067525674,0.0005885234,0.00005634153,0.0044229305,0.98006743,0.00034879765,0.010572893,0.000024256791],"about_ca_topic_score_codex":0.0013009532,"about_ca_topic_score_gemma":0.002267268,"teacher_disagreement_score":0.0044235326,"about_ca_system_score_codex":0.0008482323,"about_ca_system_score_gemma":0.000491863,"threshold_uncertainty_score":0.014798164},"labels":[],"label_agreement":null},{"id":"W3035910414","doi":"10.1073/pnas.1911154117","title":"A conformation-specific ON-switch for controlling CAR T cells with an orally available drug","year":2020,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bundesministerium für Digitalisierung und Wirtschaftsstandort; Universität für Bodenkultur Wien; Austrian Science Fund; École Polytechnique Fédérale de Lausanne; Florida State University; University of Alberta; Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung; Christian Doppler Forschungsgesellschaft; Cancer Research Institute","keywords":"Small molecule; Molecular switch; Lipocalin; Chemistry; Drug discovery; In vitro; Drug; Function (biology); Plasma protein binding; Biophysics; Molecule; Cell biology; Biochemistry; Biology; Pharmacology","score_opus":0.08111563383848584,"score_gpt":0.3256952133817829,"score_spread":0.24457957954329707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035910414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867932,0.0006428559,0.009476308,0.00012166027,0.00006238244,0.00006004801,0.00011429448,0.00018240706,0.0025468362],"genre_scores_gemma":[0.9918772,0.00027202672,0.0049802302,0.000119795506,0.000012877277,0.000039255225,0.000111590576,0.000025413623,0.0025615902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990094,0.000015768579,0.000004224253,0.000021370563,0.000028802686,0.000028903867],"domain_scores_gemma":[0.99994075,0.000010509406,0.000019651015,0.0000061265055,0.0000056615054,0.000017314296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014095471,0.00031178063,0.00015881586,0.00011471724,0.00008843927,0.0002891085,0.00029246576,0.00025701697,0.0013526388],"category_scores_gemma":[0.00010866964,0.00011649534,0.0001791439,0.00006777794,0.00018694451,0.00022465872,0.00022423906,0.00042101403,0.00020144487],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005810659,0.000031967265,0.00007918844,0.000017338185,0.0000036488009,0.000015082867,0.000006981351,0.00007047257,0.99787426,0.0001915234,0.000049763,0.0016016723],"study_design_scores_gemma":[0.00001506383,0.00018432942,0.00037255738,0.0000016669377,0.000005996368,0.00005718226,0.000006311413,0.0008592572,0.9962613,0.00003027188,0.0022023988,0.0000036701306],"about_ca_topic_score_codex":0.00023352985,"about_ca_topic_score_gemma":0.00033816718,"teacher_disagreement_score":0.0013526388,"about_ca_system_score_codex":0.0003910217,"about_ca_system_score_gemma":0.0001109287,"threshold_uncertainty_score":0.004525006},"labels":[],"label_agreement":null},{"id":"W3037220537","doi":"10.1101/2020.06.27.175158","title":"Repeated stimulation or tonic-signaling chimeric antigen receptors drive regulatory T cell exhaustion","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Children's Hospital","keywords":"Chimeric antigen receptor; Stimulation; Immunology; Autoimmunity; Cell therapy; Regulatory T cell; Biology; Receptor; T-cell receptor; Immune system; T cell; Immunotherapy; Cell biology; Neuroscience; Stem cell; IL-2 receptor","score_opus":0.030598613288052367,"score_gpt":0.2725001237228235,"score_spread":0.24190151043477115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037220537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945738,0.00056906167,0.0030720162,0.000088497254,0.000029913706,0.000013823458,0.00012898557,0.00006929919,0.0014547507],"genre_scores_gemma":[0.9967181,0.00018129255,0.001345566,0.000055123524,0.000012864809,0.000012081555,0.00015253485,0.000015031637,0.0015074972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998487,0.000031303785,0.000009943346,0.00003030504,0.00003255364,0.00004717692],"domain_scores_gemma":[0.99992025,0.000021343358,0.00001828762,0.00001599097,0.0000060122065,0.000018246856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021979678,0.00018820865,0.0001967225,0.000109185974,0.0000814807,0.00026331237,0.00012379258,0.00023056497,0.0018324171],"category_scores_gemma":[0.00010615987,0.000080164566,0.00016376955,0.00009668905,0.00020915731,0.00012736264,0.00017359329,0.0004891936,0.00038076268],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013439066,0.00002923264,0.00025957893,0.00001583404,0.000003571645,0.00003579664,0.000009855244,0.00009872736,0.99795747,0.00018137488,0.000061339226,0.0012128194],"study_design_scores_gemma":[0.00003338006,0.00049126265,0.0017571363,0.0000046050536,0.000014096612,0.0002583965,0.000025373103,0.0014553653,0.99361056,0.00014887421,0.002198084,0.000002832671],"about_ca_topic_score_codex":0.00019800288,"about_ca_topic_score_gemma":0.00020792433,"teacher_disagreement_score":0.0018324171,"about_ca_system_score_codex":0.0001289728,"about_ca_system_score_gemma":0.00015355127,"threshold_uncertainty_score":0.0061300993},"labels":[],"label_agreement":null},{"id":"W3037602706","doi":"10.1038/s41467-020-17011-z","title":"Oncolytic virus-derived type I interferon restricts CAR T cell therapy","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research; Oncolytics Biotech","keywords":"Chimeric antigen receptor; Oncolytic virus; Interferon; T cell; Tumor microenvironment; Cancer research; Immune system; Immunotherapy; Chemokine; Biology; Immunology","score_opus":0.0890405139596509,"score_gpt":0.3763875587926741,"score_spread":0.2873470448330232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037602706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745343,0.0031201586,0.01682892,0.0001347585,0.000059387607,0.00008121946,0.00016257678,0.00018047461,0.00489824],"genre_scores_gemma":[0.9955058,0.00043277655,0.0029196958,0.000036501122,0.000010628898,0.000032426033,0.00006510499,0.000014040505,0.0009829468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971,0.00006394239,0.000019494892,0.00006113085,0.00007526613,0.00007000263],"domain_scores_gemma":[0.99986553,0.000042323314,0.0000356396,0.000022935947,0.000014527996,0.000019007062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001996621,0.00021595498,0.0002915407,0.00014759043,0.00012193263,0.0005197919,0.00017802737,0.00033667698,0.0009063861],"category_scores_gemma":[0.00021858212,0.00010305258,0.00015737563,0.000101831414,0.0003127619,0.00022420615,0.00026440065,0.0006701816,0.00031527033],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012685618,0.0000295318,0.0004136226,0.000035218458,0.000004957671,0.000039780633,0.000021105003,0.00025527622,0.99542373,0.00065466977,0.00008550821,0.0029096948],"study_design_scores_gemma":[0.000016453208,0.00035005462,0.00085233274,0.000007957762,0.000016175003,0.0003598573,0.000027006701,0.0026784004,0.9914801,0.00015474937,0.004053703,0.0000031706334],"about_ca_topic_score_codex":0.00049404416,"about_ca_topic_score_gemma":0.0006272999,"teacher_disagreement_score":0.0009063861,"about_ca_system_score_codex":0.0003166989,"about_ca_system_score_gemma":0.00036267735,"threshold_uncertainty_score":0.003032148},"labels":[],"label_agreement":null},{"id":"W3037613484","doi":"10.1080/2162402x.2020.1782574","title":"Generation of highly activated, antigen-specific tumor-infiltrating CD8 <sup>+</sup> T cells induced by a novel T cell-targeted immunotherapy","year":2020,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute","keywords":"Cytotoxic T cell; CD8; Cancer research; Immunotherapy; Tumor antigen; Antigen; T cell; Immunology; Medicine; Population; Biology; Immune system; In vitro","score_opus":0.05836458485133783,"score_gpt":0.29136447492183964,"score_spread":0.23299989007050181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037613484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181753,0.0005445411,0.006009381,0.00006441193,0.000034279983,0.00014146746,0.00016751233,0.00013562082,0.0010853242],"genre_scores_gemma":[0.991234,0.00035627105,0.0063830665,0.00006036047,0.000030818355,0.00016200771,0.00024640426,0.000015396861,0.0015116514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998964,0.000015924314,0.000010802339,0.000021835147,0.000025087968,0.000029900604],"domain_scores_gemma":[0.99994934,0.000006524605,0.000015367965,0.000007701321,0.000005228342,0.000015810303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010673255,0.00041833168,0.00031482973,0.00018810172,0.00007729861,0.0002047594,0.00016958757,0.000251779,0.0007898475],"category_scores_gemma":[0.000053986627,0.000103081285,0.00020231608,0.000103121594,0.00014598097,0.00012902643,0.00013972065,0.0006753091,0.0002677219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010746061,0.000075922515,0.00008093394,0.000025946807,0.0000026816633,0.000030272524,0.0000069044063,0.000109515735,0.99766785,0.000059014998,0.000032742333,0.0018005966],"study_design_scores_gemma":[0.00010571288,0.0016041838,0.0013060847,0.000005045295,0.000019288887,0.0003069684,0.000007774367,0.00200066,0.9929028,0.000051413932,0.0016861389,0.0000038491303],"about_ca_topic_score_codex":0.00009554575,"about_ca_topic_score_gemma":0.00013598356,"teacher_disagreement_score":0.0007898475,"about_ca_system_score_codex":0.0001069977,"about_ca_system_score_gemma":0.00013606487,"threshold_uncertainty_score":0.0026423335},"labels":[],"label_agreement":null},{"id":"W3037719485","doi":"10.1111/bjh.16961","title":"Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"International Collaboration On Repair Discoveries; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"Vancouver Coastal Health Research Institute","keywords":"Cytokine release syndrome; Cytokine storm; Chimeric antigen receptor; Cytokine; Coronavirus disease 2019 (COVID-19); Immunology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cytokine receptor; Medicine; Receptor; 2019-20 coronavirus outbreak; Virology; Immunotherapy; Immune system; Internal medicine; Infectious disease (medical specialty); Disease","score_opus":0.025521533568235832,"score_gpt":0.2938366043423085,"score_spread":0.2683150707740727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037719485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052787,0.0034864529,0.002400797,0.00023086755,0.000094856696,0.00076428836,0.0002420528,0.00012359793,0.0021292309],"genre_scores_gemma":[0.9957438,0.0010255073,0.0017599855,0.00023319588,0.000106695945,0.00020488698,0.00032134692,0.000013624778,0.00059092906],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9996731,0.000095896045,0.000039362563,0.00003013138,0.00006718313,0.0000943285],"domain_scores_gemma":[0.99954104,0.0000911058,0.00010001063,0.000051124436,0.000046222507,0.00017053721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007101944,0.0006716803,0.0008459412,0.0003515904,0.00016326469,0.00025189837,0.0003631391,0.0005933515,0.0015658292],"category_scores_gemma":[0.0005346197,0.00011604387,0.0005070828,0.00017023578,0.00046344966,0.00039370204,0.00025196993,0.0012490097,0.00026040708],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022883492,0.008594643,0.007108795,0.00092167896,0.00012509509,0.0026983304,0.00013641166,0.0010012117,0.8822197,0.000541552,0.00046071858,0.073308475],"study_design_scores_gemma":[0.0057151318,0.505106,0.12635036,0.000100569334,0.00040200693,0.011810995,0.00015237945,0.003625233,0.33765507,0.00052254036,0.008507448,0.00005234663],"about_ca_topic_score_codex":0.00024492468,"about_ca_topic_score_gemma":0.00044928095,"teacher_disagreement_score":0.0015658292,"about_ca_system_score_codex":0.0002282336,"about_ca_system_score_gemma":0.0003826505,"threshold_uncertainty_score":0.0052382946},"labels":[],"label_agreement":null},{"id":"W3037829129","doi":"10.1038/s41409-020-0982-6","title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells","year":2020,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Agriculture","funders":"","keywords":"Medicine; Haematopoiesis; Stem cell; Transplantation; Acute lymphocytic leukemia; Chimeric antigen receptor; CD19; Philadelphia chromosome; Immunology; Refractory (planetary science); Leukemia; Hematopoietic stem cell transplantation; Acute leukemia; Lymphoblastic Leukemia; Internal medicine; Antigen; Oncology; Cancer research; T cell; Chromosomal translocation; Biology; Immune system; Genetics","score_opus":0.013609995006849932,"score_gpt":0.24787438519349161,"score_spread":0.2342643901866417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037829129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982279,0.00068823446,0.00008421326,0.00008185833,0.000023967244,0.0000121537605,0.00006854388,0.000016235555,0.0007968753],"genre_scores_gemma":[0.99915385,0.00030346675,0.00005224714,0.00005722596,0.000025628813,0.0000051483225,0.00017525528,0.0000026524606,0.00022448736],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999616,0.000010541506,0.0000038663416,0.0000054778498,0.000005026853,0.000013574873],"domain_scores_gemma":[0.9998976,0.000018399654,0.000024043857,0.000009255917,0.000005303231,0.000045423596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014543816,0.0001700223,0.00034107288,0.000101592916,0.00010225889,0.00017895612,0.000099275436,0.00013134265,0.0010780061],"category_scores_gemma":[0.00036266024,0.000039609076,0.00014253703,0.0001203401,0.00012374937,0.00013411032,0.000102381346,0.00032568537,0.00022501116],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12892736,0.006019865,0.22637697,0.0004502176,0.0006016243,0.006478551,0.0008948917,0.0020196845,0.109334074,0.0004957313,0.00541353,0.51298755],"study_design_scores_gemma":[0.005738076,0.09137703,0.866927,0.00009182876,0.00091748557,0.009194541,0.0004546426,0.0015326017,0.014882755,0.00047131724,0.008393149,0.000019572293],"about_ca_topic_score_codex":0.00029954064,"about_ca_topic_score_gemma":0.00066629675,"teacher_disagreement_score":0.0010780061,"about_ca_system_score_codex":0.00009064893,"about_ca_system_score_gemma":0.000099111894,"threshold_uncertainty_score":0.0036063194},"labels":[],"label_agreement":null},{"id":"W3037884364","doi":"10.1016/j.jpha.2020.06.003","title":"Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Analysis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; European Regional Development Fund; Universidad de Granada; Instituto de Salud Carlos III; Ministerio de Economía y Competitividad","keywords":"Tocilizumab; Coronavirus disease 2019 (COVID-19); Pandemic; Economic shortage; Cytokine release syndrome; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Intensive care medicine; Pharmacology; Disease; Internal medicine","score_opus":0.4388270827938437,"score_gpt":0.5219379613527586,"score_spread":0.08311087855891491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037884364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99217296,0.0030863455,0.0030214319,0.00007628859,0.00008702008,0.00013193912,0.00026170976,0.00003395415,0.0011284075],"genre_scores_gemma":[0.98958147,0.0024834133,0.006253935,0.00013469013,0.000059779384,0.00012170897,0.00042242272,0.000035000834,0.0009074922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992594,0.00023261562,0.00006872087,0.0001294501,0.0002313559,0.000078489626],"domain_scores_gemma":[0.9992409,0.00021327281,0.0002239364,0.00006869914,0.00016706546,0.00008613467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007126246,0.00038515637,0.00030736276,0.0005727322,0.00022609695,0.0005223991,0.00019721416,0.00037831155,0.0009942955],"category_scores_gemma":[0.0015873868,0.00013169229,0.00048424237,0.0004506054,0.00027843655,0.00048490893,0.00030644285,0.00060377095,0.00024049127],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039410847,0.0011504994,0.0037375996,0.000394181,0.0001285227,0.00013815904,0.00025342917,0.00046193707,0.9567727,0.00013552519,0.0002432579,0.032643],"study_design_scores_gemma":[0.00015802286,0.022718458,0.027106036,0.000047652033,0.0003061808,0.00055903057,0.00034566026,0.0020098172,0.9415258,0.000120698896,0.0050500063,0.00005260669],"about_ca_topic_score_codex":0.00034984693,"about_ca_topic_score_gemma":0.00030226223,"teacher_disagreement_score":0.0009942955,"about_ca_system_score_codex":0.00015564139,"about_ca_system_score_gemma":0.0003023781,"threshold_uncertainty_score":0.003768742},"labels":[],"label_agreement":null},{"id":"W3039382149","doi":"10.1016/j.cell.2020.05.049","title":"TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate","year":2020,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"Memorial Sloan-Kettering Cancer Center; Leukemia and Lymphoma Society; National Cancer Institute; Chemotherapy Foundation","keywords":"Biology; Germinal center; BCL6; Reprogramming; Transcription factor; Phenotype; Somatic hypermutation; Cancer research; Cell fate determination; Somatic cell; Lymphoma; B cell; Cell; Cell biology; Gene; Genetics; Immunology; Antibody","score_opus":0.033491065504405976,"score_gpt":0.2937743776601731,"score_spread":0.26028331215576717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039382149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079543,0.0007864517,0.002735364,0.00023496458,0.00006133955,0.000042330892,0.0007792123,0.0004531109,0.004111786],"genre_scores_gemma":[0.9951343,0.00011523277,0.0005598604,0.000051375795,0.000008200857,0.000022875272,0.00031244333,0.000070122405,0.003725699],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99968266,0.000044485023,0.000031130334,0.0000822729,0.000057400033,0.000102102815],"domain_scores_gemma":[0.9996997,0.000057465262,0.00009325051,0.000049062302,0.00001595876,0.000084618354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000171557,0.0004309786,0.0002369344,0.0004386822,0.0002642585,0.000715271,0.0003530621,0.00058873725,0.0057804957],"category_scores_gemma":[0.00014992544,0.00027445753,0.00029461086,0.00017013842,0.00039585264,0.00029259548,0.0004347173,0.0016827593,0.0014231835],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011662607,0.00006712407,0.00042932658,0.000025624942,0.000007671803,0.0001518828,0.000024422874,0.00012606906,0.9970794,0.00042139748,0.00016405962,0.0013863683],"study_design_scores_gemma":[0.00006361092,0.00035994826,0.0038320827,0.000008775506,0.000020584019,0.0011057178,0.000114223934,0.0015126608,0.98859197,0.000119613105,0.0042641563,0.0000066133684],"about_ca_topic_score_codex":0.0005282966,"about_ca_topic_score_gemma":0.0010149973,"teacher_disagreement_score":0.0057804957,"about_ca_system_score_codex":0.0004075226,"about_ca_system_score_gemma":0.00017358303,"threshold_uncertainty_score":0.019337654},"labels":[],"label_agreement":null},{"id":"W3039452644","doi":"10.7150/thno.44259","title":"Engineering Circulating Tumor Cells as Novel Cancer Theranostics","year":2020,"lang":"en","type":"article","venue":"Theranostics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Circulating tumor cell; Metastatic breast cancer; Homing (biology); Medicine; Bioluminescence imaging; Primary tumor; Cancer research; Breast cancer; Cancer; Metastatic tumor; Genetic enhancement; Metastasis; CA15-3; Oncology; Pathology; Internal medicine; Gene; Biology; Transfection","score_opus":0.04401718092130154,"score_gpt":0.30375917950547193,"score_spread":0.2597419985841704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039452644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81714773,0.01719409,0.15038477,0.0014889156,0.0005067283,0.00050590985,0.0007192682,0.00091847294,0.011134179],"genre_scores_gemma":[0.9420854,0.004218947,0.043564446,0.00032898347,0.000058767713,0.00021419574,0.0003461632,0.000102276324,0.009080874],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987054,0.000023986135,0.000005997328,0.000030944248,0.000042091193,0.000026514756],"domain_scores_gemma":[0.9999316,0.000014859946,0.000014605516,0.0000062274507,0.000013076203,0.000019519903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002176077,0.00030370304,0.00031847923,0.00019034126,0.00012212357,0.0006228995,0.00024052038,0.00051023456,0.0016397224],"category_scores_gemma":[0.00019576315,0.00013113004,0.00015994259,0.00015470818,0.00025142616,0.00031532624,0.00027373055,0.00067764847,0.00051017303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006376719,0.00006465535,0.00014278713,0.00011513934,0.000005844208,0.00009198594,0.00003677408,0.00068320055,0.9833451,0.0018270549,0.00042993278,0.01319387],"study_design_scores_gemma":[0.00009797318,0.00057118596,0.0004514918,0.000018435267,0.000029853642,0.00028491448,0.000021961489,0.0066101886,0.96690035,0.00047268713,0.02453064,0.000010335754],"about_ca_topic_score_codex":0.00059588166,"about_ca_topic_score_gemma":0.000912565,"teacher_disagreement_score":0.0016397224,"about_ca_system_score_codex":0.0005129119,"about_ca_system_score_gemma":0.00037327307,"threshold_uncertainty_score":0.0054854155},"labels":[],"label_agreement":null},{"id":"W3040607731","doi":"10.1016/j.cytogfr.2020.07.003","title":"A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy","year":2020,"lang":"en","type":"review","venue":"Cytokine & Growth Factor Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Terry Fox Foundation; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; Immune system; Tumor microenvironment; Immunology; Adoptive cell transfer; T cell; Antigen; Cancer research; Biology; Medicine","score_opus":0.2295780936670554,"score_gpt":0.4285131004444376,"score_spread":0.19893500677738218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040607731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018597016,0.9941906,0.0009760704,0.0015431936,0.0010495962,0.000012693612,0.00002581951,0.000027515778,0.0019886424],"genre_scores_gemma":[0.0019395157,0.9922724,0.0011445816,0.0015313186,0.00060974475,0.000026920417,0.000055319142,0.000007719894,0.0024125038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973494,0.00006186963,0.00001960127,0.00003749434,0.00010460806,0.0000415055],"domain_scores_gemma":[0.9997309,0.00015351418,0.000026499927,0.000008719268,0.00005362381,0.000026813172],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011906248,0.0011954545,0.0010862956,0.0012793032,0.0003104036,0.0018941135,0.0011676613,0.0017762741,0.0037848337],"category_scores_gemma":[0.0008827434,0.00032430165,0.00046934703,0.0011991988,0.0010460892,0.0030120055,0.0010598318,0.0046981247,0.002947764],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015840199,0.00011745791,0.00007031224,0.0067773443,0.00009295248,0.00020048213,0.0000707017,0.000844397,0.0070035527,0.047515243,0.10385853,0.83329076],"study_design_scores_gemma":[0.000043416818,0.00010587565,0.00009792766,0.0009351209,0.000042923646,0.000260564,0.00002935004,0.0001652259,0.0007701277,0.006881479,0.9906501,0.00001792292],"about_ca_topic_score_codex":0.0009228825,"about_ca_topic_score_gemma":0.0019966348,"teacher_disagreement_score":0.0037848337,"about_ca_system_score_codex":0.0011571335,"about_ca_system_score_gemma":0.0012431281,"threshold_uncertainty_score":0.012661517},"labels":[],"label_agreement":null},{"id":"W3041665519","doi":"10.1080/2162402x.2020.1792058","title":"Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination","year":2020,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Cancerföreningen i Stockholm; Medicinska Forskningsrådet; Knut och Alice Wallenbergs Stiftelse; Kommunfullmäktige, Stockholms Stad; Stiftelsen för Strategisk Forskning","keywords":"Medicine; Immunotherapy; Melanoma; Cohort; T cell; Internal medicine; Adoptive cell transfer; Vaccination; Oncology; Immune system; Immunology; Surgery; Cancer research","score_opus":0.052239993790942296,"score_gpt":0.31734485816633023,"score_spread":0.26510486437538794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041665519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980831,0.00057056005,0.00038654543,0.00005034937,0.000012279246,0.000060493734,0.000050770843,0.000023609035,0.0007623285],"genre_scores_gemma":[0.9990784,0.00012745301,0.0002687302,0.000041878862,0.000019848198,0.00003104258,0.00011837606,0.000005199073,0.00030910075],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9998516,0.00004381436,0.00001801691,0.000027938795,0.000019311854,0.000039284867],"domain_scores_gemma":[0.99981207,0.000064728396,0.000027857555,0.000025744526,0.000012264662,0.000057285124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040224512,0.0003158317,0.0006257956,0.00020638961,0.00019255935,0.00023059334,0.00014157515,0.00022775431,0.00056604826],"category_scores_gemma":[0.0004133218,0.00012216899,0.00027163562,0.00009904688,0.00017555348,0.00015624896,0.00012575688,0.00050653116,0.0001448556],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026872171,0.0059724306,0.13616477,0.00049377215,0.000512076,0.010315567,0.0006345417,0.0043606902,0.5900256,0.0002433991,0.0020318087,0.22237319],"study_design_scores_gemma":[0.00629827,0.2221924,0.5118693,0.000061735496,0.0008776489,0.031498898,0.00022123876,0.0110239675,0.203027,0.00023480617,0.012639656,0.00005511582],"about_ca_topic_score_codex":0.0002978241,"about_ca_topic_score_gemma":0.0006163263,"teacher_disagreement_score":0.0006257956,"about_ca_system_score_codex":0.00025939554,"about_ca_system_score_gemma":0.00014328117,"threshold_uncertainty_score":0.0021272898},"labels":[],"label_agreement":null},{"id":"W3041971789","doi":"10.1111/sji.12929","title":"Metabolic optimization of adoptive T cell transfer cancer immunotherapy: A historical overview","year":2020,"lang":"en","type":"article","venue":"Scandinavian Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Adoptive cell transfer; Cytotoxic T cell; Immunotherapy; Cancer immunotherapy; Cancer research; Biology; CD8; T cell; Immunology; Cell biology; Antigen; Biochemistry; In vitro; Immune system","score_opus":0.04227273855186823,"score_gpt":0.30494933091690224,"score_spread":0.262676592365034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041971789","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026943868,0.98246574,0.0060636397,0.00087699795,0.00035929764,0.00002539136,0.000047260924,0.000030214096,0.0074370746],"genre_scores_gemma":[0.016404185,0.97418857,0.0060294815,0.0006589724,0.0006707223,0.000058055055,0.00007688933,0.000030050169,0.0018830813],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99956554,0.00011048216,0.00004843378,0.00010771657,0.00012532301,0.00004253029],"domain_scores_gemma":[0.99954444,0.00020415043,0.000062304825,0.000030198147,0.00012278632,0.000036155478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013230894,0.0009921442,0.0008110366,0.0020355696,0.00037200376,0.0022318263,0.0008767646,0.0013072111,0.0019634229],"category_scores_gemma":[0.00086378725,0.00050187437,0.0006489315,0.002400406,0.0011124075,0.0019868456,0.001104574,0.0022148518,0.0011093825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035042476,0.0005635315,0.0013203897,0.011947524,0.00014601075,0.0005442415,0.00029403254,0.00826068,0.018590778,0.067421325,0.012706332,0.87785476],"study_design_scores_gemma":[0.000030330091,0.0010383456,0.0018358486,0.002556515,0.00011406269,0.0012617517,0.00018521442,0.0031358912,0.017334882,0.017740333,0.9546688,0.00009810095],"about_ca_topic_score_codex":0.00092728244,"about_ca_topic_score_gemma":0.00061183167,"teacher_disagreement_score":0.0022318263,"about_ca_system_score_codex":0.0015340106,"about_ca_system_score_gemma":0.0007262445,"threshold_uncertainty_score":0.0111300945},"labels":[],"label_agreement":null},{"id":"W3045194329","doi":"10.1111/bjh.16940","title":"Building Canadian capacity for CAR‐T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study","year":2020,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Ottawa Hospital; University of Manitoba; Ottawa Public Health; Canada's Michael Smith Genome Sciences Centre; University of Ottawa","funders":"","keywords":"Medicine; Chimeric antigen receptor; Malignancy; Progenitor cell; Hematopoietic stem cell transplantation; Stem cell; Internal medicine; Immunology; Haematopoiesis; Oncology; Transplantation; Immunotherapy; Cancer; Biology","score_opus":0.02159558664857928,"score_gpt":0.2844037094014702,"score_spread":0.2628081227528909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045194329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440832,0.03310212,0.0007798868,0.0006058989,0.00013243624,0.0002314353,0.017191742,0.000034591543,0.0038386201],"genre_scores_gemma":[0.9908382,0.0028696386,0.00033108762,0.00035989296,0.00006437196,0.00012204136,0.0049165105,0.000021754804,0.00047652776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99609995,0.00089832046,0.0005353936,0.0012179116,0.0008164559,0.0004319245],"domain_scores_gemma":[0.99440163,0.0010467164,0.0020524373,0.0011553495,0.000924247,0.00041957735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044618705,0.00051846384,0.0013414213,0.0011329898,0.0007656592,0.0014977205,0.0014849544,0.0010753768,0.0044198995],"category_scores_gemma":[0.008256256,0.00059478346,0.003807443,0.0036391683,0.00031146896,0.0011779178,0.00094213017,0.0018328303,0.00062852155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021787132,0.00007424956,0.98003834,0.0005891247,0.00892329,0.00015682202,0.0001812488,0.00017508364,0.00017197269,0.00023492187,0.002147154,0.0051291473],"study_design_scores_gemma":[0.0003958367,0.00045659044,0.98138255,0.00032965717,0.010371135,0.00054801354,0.0004846573,0.00062579894,0.000086175045,0.00022019784,0.005043896,0.00005542109],"about_ca_topic_score_codex":0.040320273,"about_ca_topic_score_gemma":0.052304726,"teacher_disagreement_score":0.9596797,"about_ca_system_score_codex":0.001713231,"about_ca_system_score_gemma":0.0014912524,"threshold_uncertainty_score":0.08017117},"labels":[],"label_agreement":null},{"id":"W3045469676","doi":"10.1158/1538-7445.pedca19-pr05","title":"Abstract PR05: T-cell receptor (TCR)-based immunotherapy in pediatric malignancy: Addressing the challenge of early metastasis and low immunogenicity","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"T-cell receptor; Cancer research; Metastasis; Immunotherapy; Biology; Immunogenicity; CD8; T cell; Cancer; Cancer immunotherapy; Immunology; Immune system; Genetics","score_opus":0.16093607519239192,"score_gpt":0.4025395723156677,"score_spread":0.2416034971232758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045469676","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723143,0.0035469795,0.005198507,0.00064863515,0.00007107472,0.00005199486,0.0002676521,0.00014216428,0.0028415872],"genre_scores_gemma":[0.9907515,0.0016408993,0.0038001044,0.00017016688,0.000049466726,0.000026980139,0.00043939592,0.000021180549,0.003100338],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989355,0.000018894998,0.000008741971,0.000017669443,0.000027290866,0.00003384833],"domain_scores_gemma":[0.99993134,0.000010001061,0.000016906504,0.000006137769,0.000008870712,0.000026814303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018922258,0.00025123372,0.00019521196,0.00016935405,0.00010466677,0.00027188307,0.00026469523,0.00028759922,0.002011721],"category_scores_gemma":[0.000088523644,0.00006375371,0.00013628874,0.0001226306,0.00018840634,0.00018748987,0.00012584084,0.0007368325,0.0005880584],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063023245,0.00018033083,0.0009873752,0.000089308975,0.000011463896,0.00025524438,0.0000179045,0.00027516423,0.98156744,0.0004186856,0.0008837839,0.014683105],"study_design_scores_gemma":[0.0002306617,0.0036379986,0.01131357,0.000022953827,0.00006356683,0.0034457678,0.000041612082,0.0020600494,0.966162,0.00023364366,0.012781438,0.0000067121605],"about_ca_topic_score_codex":0.00022227751,"about_ca_topic_score_gemma":0.00025020607,"teacher_disagreement_score":0.002011721,"about_ca_system_score_codex":0.0003093362,"about_ca_system_score_gemma":0.00024605778,"threshold_uncertainty_score":0.006729841},"labels":[],"label_agreement":null},{"id":"W3046293265","doi":"10.1016/j.omto.2020.07.008","title":"Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Biotechnology and Biological Sciences Research Council; University of Bristol; Engineering and Physical Sciences Research Council; University of Bath; Canolfan Ymchwil Canser Cymru; Cancer Research UK; Wellcome Trust","keywords":"Underpinning; Receptor; Immunotherapy; Cell biology; Chemistry; Cell; Computational biology; Biology; Biochemistry; Immunology; Immune system; Engineering","score_opus":0.04400329613346489,"score_gpt":0.32832955590108875,"score_spread":0.2843262597676239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046293265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983196,0.00043410636,0.012446196,0.00011029706,0.000016169326,0.000025410765,0.000053576794,0.00006626788,0.0036519167],"genre_scores_gemma":[0.99690163,0.00026833554,0.002324812,0.000033529806,0.0000026008217,0.00001584567,0.000042982763,0.000012511119,0.00039779392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987555,0.000019372397,0.0000073657416,0.000022202792,0.000041673215,0.000033733966],"domain_scores_gemma":[0.9999398,0.000023864282,0.000015210245,0.000004136468,0.0000074372047,0.000009588755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015994074,0.00023017774,0.00022027215,0.00012887483,0.0002742823,0.00050376134,0.00031815813,0.00036561303,0.0013612754],"category_scores_gemma":[0.00034999673,0.00024320224,0.00015682884,0.00008063824,0.00045169605,0.0004693692,0.0002510702,0.00057562994,0.00024410337],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020583264,0.00010367845,0.0015318124,0.00011296794,0.000027004773,0.00049489306,0.00008963539,0.050088264,0.9193168,0.023819579,0.00034975566,0.0038597614],"study_design_scores_gemma":[0.00017023065,0.0003411407,0.005560568,0.000027520377,0.000057219055,0.0008326781,0.00029748946,0.36137912,0.6087361,0.01636199,0.0061711716,0.000064813205],"about_ca_topic_score_codex":0.0006865675,"about_ca_topic_score_gemma":0.0011156028,"teacher_disagreement_score":0.0013612754,"about_ca_system_score_codex":0.00041058546,"about_ca_system_score_gemma":0.00032751405,"threshold_uncertainty_score":0.004553914},"labels":[],"label_agreement":null},{"id":"W3046625345","doi":"10.1016/j.jim.2020.112831","title":"The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for detection of neoantigen-specific T cells in PBMC","year":2020,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science, Technology and Innovation Commission of Shenzhen Municipality; National Natural Science Foundation of China","keywords":"ELISPOT; CD28; Immunology; Peripheral blood mononuclear cell; T cell; Immune system; Medicine; Cytotoxic T cell; Antigen; Immunotherapy; Stimulation; Cancer research; Biology; In vitro; Internal medicine; Biochemistry","score_opus":0.09686982993115063,"score_gpt":0.4119008292073958,"score_spread":0.31503099927624517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046625345","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8995912,0.00775665,0.08150451,0.0006001991,0.00060414086,0.0004267128,0.00083622115,0.00069765956,0.007982592],"genre_scores_gemma":[0.9399876,0.0025000547,0.046829693,0.000640928,0.00042821316,0.00065263396,0.0016663804,0.00016077446,0.007133753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971974,0.0010648726,0.00020702762,0.00044424122,0.00062117557,0.00046532816],"domain_scores_gemma":[0.9982784,0.001195902,0.00005670118,0.00017753126,0.00017860059,0.00011288954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017692972,0.0012547958,0.0011474458,0.00061031943,0.0002888787,0.001165252,0.00048141103,0.0012459084,0.0037277194],"category_scores_gemma":[0.0020847449,0.00055050745,0.0005208548,0.00041909638,0.00032375488,0.0005733854,0.0006897653,0.0026506535,0.0021640325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014059833,0.00009471851,0.0002866002,0.00008756223,0.000011027931,0.000032332373,0.000031625106,0.00014476276,0.99667895,0.000051158,0.000089100984,0.0023516123],"study_design_scores_gemma":[0.000021742315,0.00032663165,0.0027642925,0.000024461797,0.000030222249,0.00032497002,0.000023406386,0.0021461085,0.992195,0.00011825879,0.002016493,0.000008422153],"about_ca_topic_score_codex":0.0002859039,"about_ca_topic_score_gemma":0.00066492683,"teacher_disagreement_score":0.0037277194,"about_ca_system_score_codex":0.00032135658,"about_ca_system_score_gemma":0.00049070624,"threshold_uncertainty_score":0.012470484},"labels":[],"label_agreement":null},{"id":"W3046948275","doi":"10.1038/s42255-020-0256-z","title":"Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy","year":2020,"lang":"en","type":"article","venue":"Nature Metabolism","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Institute of Allergy and Infectious Diseases; U.S. Department of Health and Human Services; National Cancer Institute; National Institutes of Health; Max-Planck-Gesellschaft; Deutsche Forschungsgemeinschaft","keywords":"Effector; Conditioning; Cytotoxic T cell; CD8; Adoptive cell transfer; Cell therapy; Immunology; Biology; Cell; T cell; Immune system; Biochemistry; Mathematics","score_opus":0.020843282511545394,"score_gpt":0.3125214294409055,"score_spread":0.2916781469293601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046948275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561935,0.004337493,0.02923932,0.00041636155,0.00024739213,0.00031871104,0.0004644501,0.00033170078,0.008451141],"genre_scores_gemma":[0.9913346,0.0010972904,0.0044009797,0.00010179829,0.00004376933,0.00016164218,0.0002318493,0.00006900884,0.0025591063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998265,0.000041422896,0.000010306511,0.000031163745,0.000034373097,0.000056331213],"domain_scores_gemma":[0.99994016,0.000013293111,0.000014736263,0.000012403179,0.000007689596,0.00001165959],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023128385,0.0004019766,0.00031921698,0.0002469961,0.00021415386,0.00044854087,0.00028634557,0.00033886422,0.005071924],"category_scores_gemma":[0.0001845546,0.00015725743,0.00024605167,0.00019884139,0.000223887,0.00031765958,0.00033187354,0.0010839036,0.0007138528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044779613,0.000097575445,0.00011377554,0.00007309388,0.000009260305,0.00003324682,0.000021326252,0.00074098236,0.9905744,0.00087871443,0.00018233493,0.00682762],"study_design_scores_gemma":[0.000047046622,0.0007246934,0.000667151,0.000010462878,0.000021747695,0.00010576045,0.000013980931,0.001140193,0.99237716,0.00023052824,0.0046549826,0.000006203409],"about_ca_topic_score_codex":0.00031015658,"about_ca_topic_score_gemma":0.00065537426,"teacher_disagreement_score":0.005071924,"about_ca_system_score_codex":0.00027041804,"about_ca_system_score_gemma":0.00021944038,"threshold_uncertainty_score":0.016967297},"labels":[],"label_agreement":null},{"id":"W3047019788","doi":"10.1158/1538-7445.pedca19-a13","title":"Abstract A13: Immunogenomic approaches to optimize immunotherapeutic targeting of neuroblastoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Antigen; Immunotherapy; Medicine; Cancer research; Cancer; Neuroblastoma; Lymphoma; Cancer immunotherapy; Immunology; T cell; Immune system; Internal medicine; Cell culture; Biology","score_opus":0.3185861517142442,"score_gpt":0.3984366831874055,"score_spread":0.07985053147316129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047019788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93478703,0.0054492005,0.050645456,0.00032049307,0.00011878108,0.00053966325,0.0009564725,0.00030789434,0.006875014],"genre_scores_gemma":[0.9376839,0.0039225374,0.050596345,0.0002537683,0.000038134807,0.00032714926,0.000997727,0.00007395558,0.0061065285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998312,0.000027821343,0.000013417953,0.000031997075,0.00004913169,0.00004639405],"domain_scores_gemma":[0.999948,0.00000668254,0.000012039165,0.000006129413,0.000015071175,0.000012074212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025167008,0.00042317115,0.00026640802,0.00038759268,0.00015971747,0.00040551947,0.00029134535,0.0003802891,0.0018654766],"category_scores_gemma":[0.00010869928,0.00016877743,0.00033133233,0.00033824454,0.0001599621,0.00023352561,0.00032206016,0.0005569466,0.000643314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005402079,0.00008559677,0.00015369467,0.00007332723,0.000007649715,0.00003772079,0.000014966965,0.00091486255,0.9914498,0.00038852447,0.00016907108,0.0066507445],"study_design_scores_gemma":[0.000030046307,0.0006527653,0.001269383,0.000013176554,0.00002824361,0.00016464262,0.00001793088,0.0027055452,0.98607177,0.00016287211,0.008874179,0.000009483315],"about_ca_topic_score_codex":0.00049770926,"about_ca_topic_score_gemma":0.00072729774,"teacher_disagreement_score":0.0018654766,"about_ca_system_score_codex":0.0004964912,"about_ca_system_score_gemma":0.00033667567,"threshold_uncertainty_score":0.006240666},"labels":[],"label_agreement":null},{"id":"W3047022674","doi":"10.1158/1538-7445.pedca19-a11","title":"Abstract A11: A comprehensive and integrative omic analysis of multiply relapsed refractory pediatric pre-B cell acute lymphoblastic leukemia predicts response to CD19 CAR T-cell therapy","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; KRAS; Targeted therapy; CD19; Cancer; Cancer research; Immunology; Colorectal cancer","score_opus":0.05515896922623703,"score_gpt":0.37477869149320675,"score_spread":0.3196197222669697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047022674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730108,0.00096374494,0.0017333825,0.00025703298,0.000024785599,0.00006044522,0.021935321,0.00015926136,0.0018552187],"genre_scores_gemma":[0.96378607,0.00048550207,0.0039021883,0.00023958324,0.000029754818,0.000076689634,0.030031614,0.00007099655,0.001377649],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997749,0.000020020185,0.000017868153,0.00008275896,0.000056861663,0.00004759423],"domain_scores_gemma":[0.9997459,0.00005239909,0.000088539535,0.000022581102,0.00003824667,0.00005232229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031064602,0.0004471498,0.0005158765,0.0012458871,0.000496266,0.00072081434,0.00028332366,0.0003395338,0.0034626764],"category_scores_gemma":[0.00035481143,0.0001486222,0.00047251445,0.001252345,0.00020564397,0.00018818423,0.00058324373,0.00043217064,0.0007249978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017474466,0.00020545896,0.43996787,0.00035058858,0.0005597903,0.001088791,0.00020625042,0.0013126808,0.51612353,0.0003140759,0.004583555,0.03354008],"study_design_scores_gemma":[0.000043441232,0.00033904886,0.9611169,0.000035887366,0.00036594286,0.0019667654,0.00029833484,0.0029273937,0.02335034,0.0002926382,0.0092439605,0.000019440797],"about_ca_topic_score_codex":0.001688547,"about_ca_topic_score_gemma":0.0044050496,"teacher_disagreement_score":0.0034626764,"about_ca_system_score_codex":0.0003100602,"about_ca_system_score_gemma":0.00040114456,"threshold_uncertainty_score":0.011583805},"labels":[],"label_agreement":null},{"id":"W3047046898","doi":"10.1158/1538-7445.pedca19-a09","title":"Abstract A09: Glypican-2 targeted CAR T cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neuroblastoma; In vivo; Cancer research; Antigen; Single-chain variable fragment; In vitro; Pediatric cancer; Biology; Cell culture; Chemistry; Molecular biology; Cancer; Antibody; Immunology; Biochemistry; Monoclonal antibody","score_opus":0.10088848235893828,"score_gpt":0.3809940487510608,"score_spread":0.28010556639212253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047046898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911753,0.00038658874,0.0041567776,0.00007943494,0.000030078274,0.00008885505,0.0006420674,0.00013553676,0.003305296],"genre_scores_gemma":[0.98831123,0.0002534261,0.004131656,0.00008073778,0.000010486914,0.00007197491,0.0011202658,0.000037922324,0.0059822826],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999089,0.000008443801,0.0000055951127,0.000020861948,0.000029904886,0.00002629964],"domain_scores_gemma":[0.9999641,0.0000034344646,0.000007357049,0.00000335002,0.000007998631,0.000013734374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000797469,0.00037886648,0.00016551715,0.00015690275,0.00012015767,0.00034334272,0.00023965328,0.00038737064,0.002665192],"category_scores_gemma":[0.00006103836,0.00009862165,0.00016371117,0.00014627402,0.00014596025,0.00014634781,0.00016393673,0.000657528,0.00079415884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010601754,0.000048785998,0.00011159518,0.000021392665,0.0000038114897,0.000028986346,0.0000091060965,0.0001739793,0.99825734,0.000100545156,0.00016665607,0.00097174733],"study_design_scores_gemma":[0.000034451456,0.0004933764,0.0010651674,0.0000031608267,0.000015240926,0.0002310099,0.000011523164,0.0015075321,0.9933994,0.000024119949,0.003211353,0.0000036429776],"about_ca_topic_score_codex":0.0007638984,"about_ca_topic_score_gemma":0.0007039248,"teacher_disagreement_score":0.002665192,"about_ca_system_score_codex":0.00037108568,"about_ca_system_score_gemma":0.00020526686,"threshold_uncertainty_score":0.008915961},"labels":[],"label_agreement":null},{"id":"W3047089095","doi":"10.1158/1538-7445.pedca19-b49","title":"Abstract B49: Modeling a pathogenic <i>SAMD9</i> mutation in human induced pluripotent stem cells","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Induced pluripotent stem cell; Cancer research; Biology; Myeloid; Stem cell; Haematopoiesis; Chromosome 7 (human); Progenitor cell; Genetics; Embryonic stem cell; Gene; Chromosome","score_opus":0.2254322174262751,"score_gpt":0.4319023045431385,"score_spread":0.2064700871168634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047089095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86799794,0.00029449046,0.11028669,0.00027292204,0.00016221189,0.00020699864,0.003194701,0.0009175393,0.01666648],"genre_scores_gemma":[0.9626856,0.00018989683,0.031346027,0.00005007294,0.000007655163,0.00012274666,0.0013528207,0.0000865484,0.004158605],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99992347,0.000010223621,0.000005946331,0.000013103211,0.000036063175,0.000011139934],"domain_scores_gemma":[0.9999336,0.00001552654,0.000014382208,0.000010744793,0.000012610812,0.000013051661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016797452,0.0002036156,0.00015033572,0.00019032421,0.00014638493,0.0003644415,0.00043273336,0.00047827928,0.002842146],"category_scores_gemma":[0.00016811425,0.000117588075,0.00025115398,0.00012824142,0.0001589798,0.00009488132,0.00022206779,0.00034189265,0.00054492644],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010273218,0.00010286237,0.0012531619,0.00008625955,0.000020508416,0.0006539187,0.00004553846,0.09380083,0.891452,0.005710128,0.0006541392,0.006117876],"study_design_scores_gemma":[0.00005135121,0.00040791952,0.0021742184,0.000016422318,0.00003772941,0.0003842371,0.000046647354,0.34455916,0.63667333,0.0010611706,0.014566415,0.000021384005],"about_ca_topic_score_codex":0.0015659805,"about_ca_topic_score_gemma":0.0006842202,"teacher_disagreement_score":0.002842146,"about_ca_system_score_codex":0.00026203212,"about_ca_system_score_gemma":0.00020212482,"threshold_uncertainty_score":0.009507954},"labels":[],"label_agreement":null},{"id":"W3047123472","doi":"10.1158/1538-7445.pedca19-a48","title":"Abstract A48: YB-1-based oncolytic virotherapy in combination with CDK4/6-inhibitors against Ewing sarcoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oncolytic virus; Cancer research; Immune checkpoint; Immune system; Retinoblastoma; Retinoblastoma protein; Viral replication; Biology; Cell cycle; Oncolytic adenovirus; Medicine; Immunotherapy; Virology; Immunology; Cancer; Virus; Internal medicine","score_opus":0.09914652753803432,"score_gpt":0.4084362448651844,"score_spread":0.30928971732715005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047123472","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949897,0.0023032713,0.0009310665,0.000051513347,0.000046320492,0.000053301697,0.00021899301,0.000087149456,0.0013185737],"genre_scores_gemma":[0.99688846,0.00067165773,0.0010371421,0.0000122345955,0.000013813607,0.000025498455,0.00018889383,0.000011861433,0.001150481],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99991107,0.000015497433,0.000010278818,0.000015211417,0.000022910232,0.000025109326],"domain_scores_gemma":[0.99995935,0.000007235588,0.000009758933,0.0000066723824,0.0000043957307,0.0000125025945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010445121,0.0003180438,0.0004330191,0.00026906066,0.000106562715,0.00021179547,0.00016602692,0.00016925995,0.0011509889],"category_scores_gemma":[0.00007912883,0.00008919126,0.00019277172,0.0001510068,0.00015300086,0.00014567298,0.00012680086,0.00040545315,0.00024367875],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052572315,0.00018141704,0.00019055871,0.000062530344,0.000013695781,0.000036002315,0.000013578213,0.0003253719,0.99301285,0.000106673375,0.00011029997,0.0054213316],"study_design_scores_gemma":[0.000057706093,0.0016607218,0.0011477777,0.0000037971124,0.00002487626,0.00010579546,0.000005463943,0.0008813779,0.99438184,0.000018542403,0.0017091825,0.000002991254],"about_ca_topic_score_codex":0.0009512442,"about_ca_topic_score_gemma":0.0010785814,"teacher_disagreement_score":0.0011509889,"about_ca_system_score_codex":0.00025814617,"about_ca_system_score_gemma":0.00022264422,"threshold_uncertainty_score":0.00385046},"labels":[],"label_agreement":null},{"id":"W3047156703","doi":"10.1158/1538-7445.pedca19-ia09","title":"Abstract IA09: Immunotherapeutic approaches for pediatric solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Immunotherapy; Rhabdomyosarcoma; Neuroblastoma; Transplantation; Oncology; Immune system; Chemotherapy; Cytokine release syndrome; Immunology; Cancer research; Sarcoma; Internal medicine; Pathology; Biology; Cell culture","score_opus":0.3021584727594122,"score_gpt":0.45402061226202023,"score_spread":0.15186213950260802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047156703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78426653,0.15851726,0.023518374,0.004393684,0.001050879,0.0007706307,0.0008068495,0.00037208412,0.026303794],"genre_scores_gemma":[0.92119235,0.054305695,0.016333038,0.0010127298,0.00039683908,0.0003940262,0.0009355271,0.00005813544,0.005371545],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999918,0.000032197113,0.0000067087362,0.000010404805,0.000011752144,0.000020949643],"domain_scores_gemma":[0.99994814,0.000012500881,0.000010055984,0.0000062762415,0.000006987592,0.00001607774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031785012,0.00031181157,0.00024603808,0.0003499385,0.00017460277,0.00020680543,0.00028237337,0.00021477939,0.001766728],"category_scores_gemma":[0.00010557132,0.000068178364,0.0002877399,0.00026005774,0.0002084925,0.00018529853,0.00027876513,0.0007381661,0.00052686536],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027080684,0.0022956668,0.0060623297,0.0013726976,0.00014170034,0.0010834427,0.00018837738,0.003220241,0.3804099,0.006393468,0.009592626,0.5865315],"study_design_scores_gemma":[0.0035394093,0.03460985,0.08271421,0.00074685056,0.0005390152,0.012866443,0.00024608677,0.00657706,0.4451701,0.0040267208,0.40890634,0.000058015838],"about_ca_topic_score_codex":0.00043379996,"about_ca_topic_score_gemma":0.0005319557,"teacher_disagreement_score":0.001766728,"about_ca_system_score_codex":0.00027664885,"about_ca_system_score_gemma":0.00032601654,"threshold_uncertainty_score":0.005910337},"labels":[],"label_agreement":null},{"id":"W3047209647","doi":"10.1158/1538-7445.pedca19-a08","title":"Abstract A08: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Monoclonal antibody; In vivo; Immunotherapy; In vitro; Alveolar rhabdomyosarcoma; Antibody; T cell; Medicine; Molecular biology; Biology; Immunology; Rhabdomyosarcoma; Immune system; Pathology; Biochemistry; Sarcoma","score_opus":0.11237093703901149,"score_gpt":0.3963435076616698,"score_spread":0.28397257062265835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047209647","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9637956,0.0022840707,0.0240711,0.00033290204,0.000102524675,0.0005819535,0.0009291652,0.0004774126,0.007425362],"genre_scores_gemma":[0.9670097,0.0012430386,0.02073109,0.00017274356,0.00002458746,0.00027976226,0.0021245643,0.000043391356,0.008371125],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997923,0.000024745788,0.000016504508,0.00004224932,0.00007554705,0.000048769627],"domain_scores_gemma":[0.9999325,0.000005457053,0.000014049525,0.000006284936,0.000017527238,0.000024165662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002509211,0.00052900176,0.00025800493,0.00036461247,0.00014390732,0.0003553568,0.00044928267,0.000628559,0.002434141],"category_scores_gemma":[0.00012377155,0.00015343008,0.00042287091,0.00020067576,0.00014442089,0.00029179954,0.00036721706,0.000620052,0.0009940758],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001477203,0.00023666701,0.0005241122,0.000096405085,0.0000184557,0.00012286534,0.000031923522,0.00062755775,0.9859449,0.00038024917,0.00052022794,0.011348804],"study_design_scores_gemma":[0.00009813741,0.0027462763,0.0017352938,0.000010642393,0.000048764054,0.0006742995,0.000023811213,0.003009876,0.98084474,0.00010688637,0.010688801,0.000012475368],"about_ca_topic_score_codex":0.0002860937,"about_ca_topic_score_gemma":0.00032122672,"teacher_disagreement_score":0.002434141,"about_ca_system_score_codex":0.00033635553,"about_ca_system_score_gemma":0.00028338228,"threshold_uncertainty_score":0.008143008},"labels":[],"label_agreement":null},{"id":"W3047210705","doi":"10.1158/1538-7445.pedca19-pr04","title":"Abstract PR04: Locoregionally administered B7H3-targeting CAR T cells mediate potent antitumor effects in atypical teratoid/rhabdoid tumor","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atypical teratoid rhabdoid tumor; Medicine; Cancer research; Immune system; Brain tumor; Immunology; Pharmacology; Pathology; Medulloblastoma","score_opus":0.07927072980989242,"score_gpt":0.39065753962015737,"score_spread":0.31138680981026495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047210705","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958663,0.0007739672,0.0012657885,0.000058656165,0.000030356185,0.000040855764,0.00035981563,0.00018735688,0.0014169231],"genre_scores_gemma":[0.99601954,0.00035261892,0.0009105721,0.000034277436,0.000015614054,0.000042461656,0.000547703,0.00003106179,0.002046005],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998683,0.000015434442,0.000008232659,0.000025470932,0.000021907494,0.000060611757],"domain_scores_gemma":[0.99991167,0.000015525431,0.000018784,0.000012792202,0.000009231909,0.000032002823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009979519,0.00039271865,0.0004174592,0.00022509803,0.00012200892,0.00025945864,0.00023602236,0.000277877,0.001718725],"category_scores_gemma":[0.00007906993,0.00009881029,0.0002580069,0.00014215046,0.00023114451,0.00022538043,0.00010723365,0.001144313,0.000522417],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064060325,0.00046297093,0.00022673453,0.00005601032,0.000010686434,0.00006641692,0.00003043022,0.0002604624,0.9930981,0.00009530512,0.00025621505,0.0047961427],"study_design_scores_gemma":[0.00012992026,0.006903376,0.0028166845,0.0000067728192,0.000041580286,0.00023632396,0.00004214005,0.0011297627,0.9871313,0.000032338194,0.0015252134,0.0000046950377],"about_ca_topic_score_codex":0.0014162213,"about_ca_topic_score_gemma":0.0011483944,"teacher_disagreement_score":0.001718725,"about_ca_system_score_codex":0.00022862,"about_ca_system_score_gemma":0.00032382217,"threshold_uncertainty_score":0.0057497025},"labels":[],"label_agreement":null},{"id":"W3047276503","doi":"10.1158/1538-7445.pedca19-ia30","title":"Abstract IA30: Using single-cell, high-dimensional approaches to unravel tumor heterogeneity in pediatric cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mass cytometry; Bone marrow; Cancer; Leukemia; B cell; Oncology; Immunology; Cancer research; Internal medicine; Antibody; Biology; Phenotype","score_opus":0.4101916416728193,"score_gpt":0.4161850809966296,"score_spread":0.005993439323810301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047276503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6771728,0.0030887465,0.3127333,0.0005754861,0.00005865009,0.00010845094,0.003425432,0.0011079533,0.0017291032],"genre_scores_gemma":[0.80420417,0.0012294264,0.19055207,0.00010023524,0.000062071456,0.00014044734,0.0028144305,0.00015037051,0.0007468359],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998915,0.000020640633,0.000006108871,0.000042099546,0.000025738913,0.000013879752],"domain_scores_gemma":[0.9997551,0.0000870526,0.00004516359,0.000031993237,0.000038191363,0.000042558237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048331296,0.00034637807,0.00037298191,0.0008491101,0.00021254722,0.0007155573,0.0003103213,0.00036202552,0.0010214993],"category_scores_gemma":[0.0006372696,0.00021055597,0.00027216083,0.00066696765,0.0003075621,0.0004015788,0.00046184883,0.00053627405,0.0002945662],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034754994,0.0001042795,0.049206197,0.00033638184,0.00012648627,0.00023009426,0.00026768536,0.042837027,0.7759187,0.0023566461,0.0028565447,0.12541252],"study_design_scores_gemma":[0.000042945183,0.00021931317,0.13568123,0.000049637507,0.0001071522,0.0008367476,0.00040450392,0.64456755,0.19697087,0.008079635,0.012966432,0.000074101365],"about_ca_topic_score_codex":0.0013957461,"about_ca_topic_score_gemma":0.0019224726,"teacher_disagreement_score":0.0013957461,"about_ca_system_score_codex":0.0004265308,"about_ca_system_score_gemma":0.00035121906,"threshold_uncertainty_score":0.0034172535},"labels":[],"label_agreement":null},{"id":"W3047410483","doi":"10.1158/1538-7445.pedca19-b67","title":"Abstract B67: EGFR as a target in pediatric solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epidermal growth factor receptor; Desmoplastic small-round-cell tumor; Cancer research; Immunohistochemistry; Cancer; Epitope; Tissue microarray; Monoclonal antibody; Malignancy; Medicine; Biology; Pathology; Antibody; Immunology; Internal medicine","score_opus":0.11407814438250664,"score_gpt":0.4558578506241235,"score_spread":0.34177970624161685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047410483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6382743,0.3352266,0.0039805965,0.0039471304,0.00036849573,0.00029295875,0.0021185211,0.00012297145,0.015668515],"genre_scores_gemma":[0.87763196,0.113971494,0.002921961,0.0012033128,0.00034723425,0.00015849479,0.0016667594,0.00002092248,0.002077925],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987507,0.000038447866,0.000013831612,0.00001549596,0.000038985196,0.000018153865],"domain_scores_gemma":[0.9998031,0.00005526841,0.00006918,0.000004513929,0.000036491332,0.000031490992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030994433,0.00018764724,0.00033784992,0.00042853574,0.00012749727,0.00025144438,0.00017562513,0.00027969107,0.0016774087],"category_scores_gemma":[0.0003657847,0.00006875317,0.00027433172,0.00079885934,0.00013805082,0.00024338247,0.00013197954,0.00038424003,0.00050536357],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004278685,0.00058888673,0.12535478,0.009517656,0.00022270296,0.0063707726,0.00030935407,0.0019556815,0.09892795,0.002917658,0.020894524,0.7286613],"study_design_scores_gemma":[0.0013753227,0.014635928,0.36016685,0.0036321594,0.0017118233,0.061075382,0.00096951245,0.002982432,0.138124,0.0025979914,0.4126691,0.00005938026],"about_ca_topic_score_codex":0.000934654,"about_ca_topic_score_gemma":0.001126451,"teacher_disagreement_score":0.0016774087,"about_ca_system_score_codex":0.00037506263,"about_ca_system_score_gemma":0.00064637884,"threshold_uncertainty_score":0.0056114197},"labels":[],"label_agreement":null},{"id":"W3047711886","doi":"10.1158/2326-6074.tumimm18-pr15","title":"Abstract PR15: A novel NK cell-targeted therapeutic strategy against pancreatic cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Pancreatic cancer; Cancer research; Immunotherapy; Cytotoxic T cell; Tumor microenvironment; Immune system; Immunology; Cancer immunotherapy; CD8; Memory T cell; Medicine; Biology; Cancer; Internal medicine; In vitro","score_opus":0.14931097674022706,"score_gpt":0.4141424449200402,"score_spread":0.2648314681798132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047711886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600317,0.018385835,0.01192813,0.000725446,0.00039838447,0.0004437655,0.0005942476,0.00036675634,0.007125665],"genre_scores_gemma":[0.9789283,0.0071441764,0.0070766686,0.00034513228,0.000055334818,0.00020522159,0.0007377765,0.000020787993,0.005486657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999254,0.000008924321,0.000008182626,0.000020089377,0.000015799025,0.000021540221],"domain_scores_gemma":[0.99997926,0.0000013429304,0.000004405147,0.0000024140818,0.0000031339907,0.000009428772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010772868,0.00038735,0.0004554333,0.00024661442,0.00010341288,0.00033054512,0.00042239027,0.0003506854,0.0012469016],"category_scores_gemma":[0.000045311062,0.000106178486,0.00036899326,0.0001854431,0.0001855848,0.000287904,0.00028218387,0.00068751496,0.00047350916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014645101,0.001003056,0.00047007686,0.0005905192,0.00006734523,0.0004993376,0.00005759706,0.0012544831,0.91870075,0.00085169787,0.0014435619,0.07359713],"study_design_scores_gemma":[0.0014897906,0.018067017,0.004334941,0.00008316813,0.0003580558,0.0032844562,0.00006667622,0.0045817727,0.91986614,0.00040311698,0.047423705,0.00004115441],"about_ca_topic_score_codex":0.00037884768,"about_ca_topic_score_gemma":0.0005327914,"teacher_disagreement_score":0.0012469016,"about_ca_system_score_codex":0.00019889067,"about_ca_system_score_gemma":0.0003095755,"threshold_uncertainty_score":0.004171312},"labels":[],"label_agreement":null},{"id":"W3048618685","doi":"10.1016/j.jid.2020.04.004","title":"The Melanoma JID Connector Collection: An Introduction","year":2020,"lang":"en","type":"letter","venue":"Journal of Investigative Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hidradenitis Suppurativa Foundation; Bausch Health; Celgene; Pfizer","keywords":"Narrative review; Perspective (graphical); Narrative; Field (mathematics); Computer science; Medicine; Data science; Artificial intelligence; Philosophy","score_opus":0.04442278249054914,"score_gpt":0.3070852920150112,"score_spread":0.2626625095244621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048618685","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00049325277,0.0030766635,0.0008154384,0.836831,0.13850689,0.00014008346,0.00012239662,0.00013390895,0.019880485],"genre_scores_gemma":[0.0045717945,0.0027561735,0.0013545703,0.7622483,0.14981559,0.00019636555,0.00013104989,0.00015397395,0.07877222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943184,0.00151473,0.0006633515,0.00045425282,0.002277938,0.0007713498],"domain_scores_gemma":[0.98924434,0.004077168,0.0007453934,0.0005088365,0.0029790723,0.0024451327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004244357,0.001087243,0.00080517196,0.0011267397,0.0049318857,0.006443836,0.0018772315,0.030734425,0.025740007],"category_scores_gemma":[0.020997243,0.0007509506,0.0012317648,0.000526227,0.0016748323,0.003344278,0.0026096585,0.027205281,0.01622429],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016544429,0.000022605616,0.00016862447,0.000023917493,0.0000030397186,0.0011685885,0.000033929166,0.00001950846,0.00020107742,0.0009790133,0.992153,0.0052100886],"study_design_scores_gemma":[0.00003109807,0.000037127942,0.00039418545,0.00014228131,0.000007572327,0.0010582862,0.0001524765,0.00010079283,0.00014773752,0.0015735565,0.996333,0.000021819607],"about_ca_topic_score_codex":0.003832365,"about_ca_topic_score_gemma":0.010052549,"teacher_disagreement_score":0.030734425,"about_ca_system_score_codex":0.0038984425,"about_ca_system_score_gemma":0.004060988,"threshold_uncertainty_score":0.08610886},"labels":[],"label_agreement":null},{"id":"W3072963690","doi":"10.1126/scitranslmed.aaz3866","title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","year":2020,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Receptor; Cell biology; Co-receptor; Signal transduction; Biology; Chemistry; Immunology; Immune system; T cell; Genetics","score_opus":0.03626150120858345,"score_gpt":0.32659367669072864,"score_spread":0.2903321754821452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3072963690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984591,0.00042720995,0.0005556283,0.000026402966,0.000011747584,0.000013439853,0.00009713233,0.000020944148,0.00038833116],"genre_scores_gemma":[0.99842644,0.0001345549,0.0006510417,0.000022214339,0.0000049313603,0.000012016146,0.00027381507,0.00000932853,0.00046580064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995486,0.00016234828,0.00003632408,0.00006073412,0.00007330252,0.00011864544],"domain_scores_gemma":[0.9997954,0.000099940524,0.000020540745,0.00002278635,0.000020822492,0.00004057723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004895313,0.0003467139,0.00024869654,0.00015871838,0.000109177025,0.00033106015,0.00017137469,0.00037873015,0.0014691387],"category_scores_gemma":[0.00029810393,0.00011440219,0.00021229062,0.0001303991,0.00026025466,0.00013591394,0.00011336889,0.00050364924,0.000287341],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004698338,0.00006389858,0.000121825695,0.000017657869,0.000005308137,0.00003390218,0.000015543148,0.0001679999,0.9983146,0.000066296714,0.00002600268,0.00069706043],"study_design_scores_gemma":[0.000056252557,0.0010632762,0.0010431302,0.0000027515036,0.000018754974,0.00017294915,0.00001745537,0.00091728114,0.9959027,0.000017974357,0.0007842836,0.0000030711228],"about_ca_topic_score_codex":0.00093686284,"about_ca_topic_score_gemma":0.0008471544,"teacher_disagreement_score":0.0014691387,"about_ca_system_score_codex":0.00033882825,"about_ca_system_score_gemma":0.0002661346,"threshold_uncertainty_score":0.0049147606},"labels":[],"label_agreement":null},{"id":"W3074819526","doi":"10.1158/1538-7445.am2020-6600","title":"Abstract 6600: Rapid generation of TCR-engineered T lymphocytes by linking the single cell transcriptome to its corresponding T cell receptor in antigen specific T cells","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"T-cell receptor; Biology; clone (Java method); Transcriptome; CD8; T cell; Cytotoxic T cell; Molecular biology; Cell biology; Population; Cell; Antigen; Immunology; In vitro; Gene expression; Gene; Immune system; Genetics","score_opus":0.1487216237679269,"score_gpt":0.3563254740094948,"score_spread":0.2076038502415679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3074819526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95564437,0.00044893697,0.040557325,0.00006360707,0.00006654404,0.00007552346,0.0012199439,0.00040163661,0.0015221126],"genre_scores_gemma":[0.9575938,0.00056515564,0.032292306,0.00011779276,0.000025377673,0.00015139928,0.0031416842,0.00024536895,0.0058671497],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985874,0.000012297596,0.000009534327,0.000043902593,0.000049065336,0.000026428406],"domain_scores_gemma":[0.9999448,0.000007549745,0.000018067734,0.00000850432,0.000008418599,0.000012566221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015332522,0.00025796067,0.00020082793,0.00012553319,0.00009332179,0.0003358747,0.00015278348,0.00022301773,0.0012292038],"category_scores_gemma":[0.00009428137,0.00014325058,0.00017453419,0.0001736678,0.00012460441,0.00013010995,0.00022928338,0.000537345,0.0008750311],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015641092,0.0000041507656,0.00006124915,0.000007700169,9.674295e-7,0.0000069691137,0.0000037511315,0.00003682146,0.99934036,0.00002261689,0.000019370913,0.00048042013],"study_design_scores_gemma":[0.000010865334,0.00014414183,0.002493612,0.000004192424,0.000011456964,0.00011901316,0.000015251563,0.002503368,0.99192786,0.000063639265,0.0027023565,0.0000041349635],"about_ca_topic_score_codex":0.000097153745,"about_ca_topic_score_gemma":0.00015281583,"teacher_disagreement_score":0.0012292038,"about_ca_system_score_codex":0.00008654305,"about_ca_system_score_gemma":0.00009359271,"threshold_uncertainty_score":0.004112065},"labels":[],"label_agreement":null},{"id":"W3075607378","doi":"10.3389/fimmu.2020.01850","title":"Thymic Engraftment by in vitro-Derived Progenitor T Cells in Young and Aged Mice","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"Medical Research Council; Canadian Institutes of Health Research; Ontario Institute for Regenerative Medicine; National Institutes of Health; Canada First Research Excellence Fund; National Heart, Lung, and Blood Institute; Krembil Foundation; University of Toronto","keywords":"Progenitor cell; Immunology; Biology; Stem cell; Immune system; Thymic involution; Bone marrow; Haematopoiesis; T cell; Cancer research; Cytotoxic T cell; Medicine; In vitro; Cell biology","score_opus":0.01808105124600049,"score_gpt":0.2942019284216223,"score_spread":0.2761208771756218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3075607378","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981072,0.0041545792,0.0056017567,0.00035587922,0.00020025416,0.00019765533,0.0030847504,0.00042812282,0.0049050576],"genre_scores_gemma":[0.9732686,0.0037867643,0.0049874606,0.0004357716,0.00011046554,0.00041490272,0.0034216128,0.00021994146,0.013354464],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99925977,0.00009083155,0.00012406088,0.00020398936,0.00013050513,0.00019084767],"domain_scores_gemma":[0.99914825,0.00006566497,0.0002641911,0.00009861091,0.000046526824,0.00037667164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063658366,0.00066869723,0.000546402,0.0019489625,0.0004105551,0.00080761634,0.000700011,0.0011348163,0.0023504873],"category_scores_gemma":[0.0002714037,0.00055628055,0.0008794613,0.00040981564,0.0006754176,0.0008715488,0.0005819977,0.0023363805,0.0011613661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010654284,0.00064014224,0.00080930936,0.00008995834,0.00003328154,0.00038832717,0.000175717,0.00028584886,0.9907318,0.00073388434,0.00022321455,0.0048230924],"study_design_scores_gemma":[0.00044324162,0.010276151,0.025651855,0.0001448672,0.00022541534,0.0026257904,0.00038630574,0.0035410076,0.93942565,0.0009978293,0.016208738,0.00007313798],"about_ca_topic_score_codex":0.000805945,"about_ca_topic_score_gemma":0.0009650481,"teacher_disagreement_score":0.0023504873,"about_ca_system_score_codex":0.00050696323,"about_ca_system_score_gemma":0.00033802856,"threshold_uncertainty_score":0.007863164},"labels":[],"label_agreement":null},{"id":"W3081207055","doi":"10.1016/s2152-2650(20)30443-2","title":"How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Blinatumomab; Medicine; Cog; Tolerability; Oncology; Chemotherapy; Immunotherapy; Internal medicine; Clinical trial; Refractory (planetary science); Calicheamicin; Intensive care medicine; Lymphoblastic Leukemia; Leukemia; Adverse effect; Cancer; Myeloid leukemia","score_opus":0.04984465424495905,"score_gpt":0.3120130129867003,"score_spread":0.26216835874174127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081207055","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021809408,0.019273443,0.0072917305,0.9083083,0.006951659,0.000109591296,0.00012095568,0.00036264822,0.03577235],"genre_scores_gemma":[0.44613612,0.053891186,0.046376232,0.4140634,0.021934189,0.00031604027,0.00043543012,0.0006196313,0.016227918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955568,0.0021067774,0.0002296773,0.0003701339,0.0009358514,0.000800746],"domain_scores_gemma":[0.99240065,0.0018688043,0.00040675493,0.0002714859,0.0012910112,0.0037612566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006884296,0.00067134405,0.0008588143,0.0008320616,0.0032752934,0.009040322,0.0015687548,0.005649106,0.004466446],"category_scores_gemma":[0.016739037,0.00044017198,0.0010330628,0.0004995812,0.0036661725,0.006537921,0.0050997455,0.017401336,0.002466712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069603976,0.0009614077,0.023444511,0.0006372317,0.0003570236,0.0019279503,0.003308832,0.0034086362,0.0021341443,0.029570822,0.33634344,0.59721],"study_design_scores_gemma":[0.00031313137,0.001961465,0.017831484,0.0024781022,0.0005164661,0.004895091,0.011146006,0.003113755,0.0019950925,0.15750563,0.79800135,0.00024242375],"about_ca_topic_score_codex":0.0078106844,"about_ca_topic_score_gemma":0.02117755,"teacher_disagreement_score":0.009040322,"about_ca_system_score_codex":0.0055037225,"about_ca_system_score_gemma":0.013643231,"threshold_uncertainty_score":0.03993255},"labels":[],"label_agreement":null},{"id":"W3081590106","doi":"10.1158/1538-7445.am2020-ct162","title":"Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Pembrolizumab; Adverse effect; Cohort; Internal medicine; Neutropenia; Refractory (planetary science); Clinical trial; Oncology; Cancer; Toxicity; Immunotherapy","score_opus":0.04802705472500542,"score_gpt":0.3721562432470194,"score_spread":0.324129188522014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081590106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98472667,0.002938041,0.00063736894,0.000660125,0.00011929108,0.0029057853,0.0044534774,0.00016867157,0.0033906288],"genre_scores_gemma":[0.9673129,0.0025000125,0.0026559287,0.0012541454,0.00032639457,0.004082472,0.013892529,0.00009711283,0.007878561],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995617,0.00022884992,0.000025657058,0.00007410202,0.000055110664,0.000054528788],"domain_scores_gemma":[0.99925274,0.00008778901,0.0001943758,0.00008353766,0.0000559266,0.00032559488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017482826,0.002118535,0.0016190677,0.0004112925,0.00040873807,0.001243907,0.0011594307,0.0010217655,0.00628725],"category_scores_gemma":[0.0010143308,0.00059569796,0.0013604785,0.00042067523,0.0007788742,0.0007365605,0.0004799725,0.004036831,0.0019018766],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76206326,0.049501974,0.014174609,0.0012867729,0.0019804027,0.00047980875,0.00022901074,0.0022657171,0.08754824,0.0002855515,0.0095418645,0.07064278],"study_design_scores_gemma":[0.6363786,0.32063118,0.022531386,0.00008148142,0.0011007074,0.0009782607,0.000049167356,0.001224024,0.0104423305,0.00018811894,0.0063438495,0.000050840164],"about_ca_topic_score_codex":0.0008302725,"about_ca_topic_score_gemma":0.0018094348,"teacher_disagreement_score":0.00628725,"about_ca_system_score_codex":0.000991761,"about_ca_system_score_gemma":0.0016910294,"threshold_uncertainty_score":0.02103293},"labels":[],"label_agreement":null},{"id":"W3082159235","doi":"10.1158/2326-6074.tumimm18-b60","title":"Abstract B60: Functional genomic landscape of T-cell mediated cytotoxicity","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Biology; CTL*; Cancer immunotherapy; Immunotherapy; CRISPR; Cytotoxic T cell; Computational biology; Gene; Cancer; Genetics","score_opus":0.10345025057284551,"score_gpt":0.3694555785910577,"score_spread":0.2660053280182122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082159235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97092956,0.003187138,0.0127001405,0.00030128413,0.00006000222,0.000038874543,0.0056934766,0.000657589,0.006432034],"genre_scores_gemma":[0.9831042,0.001136971,0.0048357854,0.00023470202,0.000015588199,0.000040528066,0.0062148934,0.00018435363,0.0042330166],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971586,0.000021535132,0.000014234125,0.000106036445,0.00008943276,0.000052981854],"domain_scores_gemma":[0.99982685,0.000027296854,0.00004982881,0.000017707447,0.000022115764,0.000056212204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016633623,0.0003386698,0.000395284,0.00056464213,0.00021318614,0.00068720937,0.0002976748,0.00047545123,0.004903209],"category_scores_gemma":[0.0002447832,0.00018457958,0.00033119842,0.0004743896,0.00032734234,0.00016778645,0.0004941612,0.00052872824,0.0018645135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011950978,0.000009861099,0.0008064803,0.00003840623,0.000008026564,0.0000533087,0.000011225325,0.00025500136,0.99526274,0.00032223697,0.0001431382,0.0029699693],"study_design_scores_gemma":[0.00011692428,0.0011238961,0.089079104,0.00009720525,0.00013573289,0.0018111144,0.00019124892,0.0075456947,0.86532706,0.0035000483,0.031011011,0.000060958762],"about_ca_topic_score_codex":0.0006715162,"about_ca_topic_score_gemma":0.0008237031,"teacher_disagreement_score":0.004903209,"about_ca_system_score_codex":0.0003407765,"about_ca_system_score_gemma":0.00025779297,"threshold_uncertainty_score":0.01640284},"labels":[],"label_agreement":null},{"id":"W3083070660","doi":"10.1158/1538-7445.am2020-ct147","title":"Abstract CT147: Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Tumor microenvironment; Adverse effect; Oncology; Radioimmunotherapy; Cancer; Monoclonal antibody; Antibody; Immunology; Toxicity","score_opus":0.08106162704801605,"score_gpt":0.45675539334713555,"score_spread":0.3756937662991195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083070660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99451244,0.0007281592,0.00048357915,0.00017033653,0.00003288674,0.0020376798,0.0007514876,0.00008136503,0.0012020551],"genre_scores_gemma":[0.9904683,0.00058067654,0.002223996,0.00043126958,0.00006019077,0.002547464,0.0018153337,0.000026070173,0.0018466478],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967825,0.00014461385,0.000016362885,0.00004505197,0.00004326998,0.000072548355],"domain_scores_gemma":[0.9997279,0.000041733634,0.000054100332,0.000031705462,0.000024740275,0.000119721364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092690927,0.0009587566,0.0012823744,0.00049845653,0.00027390596,0.0006719864,0.0005547675,0.0006458413,0.0030449112],"category_scores_gemma":[0.00057219365,0.00031240756,0.0006916489,0.00037503778,0.00045137733,0.00034548287,0.0003235031,0.0021480517,0.0005798037],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39398792,0.079712085,0.024020165,0.0009632877,0.0010189007,0.00055016915,0.00063377,0.009561439,0.22323361,0.0011599493,0.010374985,0.25478372],"study_design_scores_gemma":[0.19252062,0.74736524,0.02646725,0.000063968815,0.00037146363,0.0005686323,0.000078042394,0.0038511932,0.021936042,0.00036648425,0.0063795256,0.00003153372],"about_ca_topic_score_codex":0.00081239716,"about_ca_topic_score_gemma":0.0015995648,"teacher_disagreement_score":0.0030449112,"about_ca_system_score_codex":0.00094645284,"about_ca_system_score_gemma":0.0012853966,"threshold_uncertainty_score":0.010186195},"labels":[],"label_agreement":null},{"id":"W3083401631","doi":"10.1158/1538-7445.am2020-3233","title":"Abstract 3233: Reduced inflammatory cytokine production by CAR-modified Th1/Tc1-polarized T-Rapa cells is not sufficient to reduce monocyte-driven production of IL-6","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytokine; Immunology; Biology; Chimeric antigen receptor; T cell; Interleukin 12; Interleukin 21; Cancer research; Cytotoxic T cell; Immune system; In vitro","score_opus":0.10256261673285785,"score_gpt":0.3899393690030996,"score_spread":0.28737675227024173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083401631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937634,0.0010173552,0.0018416295,0.00017179483,0.000069088244,0.00007658728,0.0009505131,0.00014443691,0.0019652762],"genre_scores_gemma":[0.9917646,0.00043709754,0.0018883729,0.00009181861,0.000032400127,0.00011483634,0.0014688751,0.000038050697,0.0041640154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997477,0.000034894663,0.00002538222,0.000048411435,0.000056403536,0.000087193795],"domain_scores_gemma":[0.9998605,0.000027567603,0.000031996977,0.000019468023,0.0000192012,0.000041293595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014828275,0.0004587091,0.0004870361,0.00017520247,0.00018204589,0.0003732745,0.000193911,0.0004173118,0.00418682],"category_scores_gemma":[0.000087745735,0.00015464211,0.00034425405,0.00014117814,0.00022981522,0.00016124941,0.00011741015,0.0012089952,0.0012658372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029212286,0.000071158356,0.00008989093,0.00004193429,0.000005384297,0.00005478006,0.0000099238305,0.00006257751,0.9986078,0.00004565371,0.00010701691,0.0006118304],"study_design_scores_gemma":[0.00007779907,0.00080997543,0.0019879595,0.000007568818,0.000025294758,0.00034166002,0.00002025923,0.0007777941,0.99354917,0.000021410418,0.0023771983,0.000003935116],"about_ca_topic_score_codex":0.0006266019,"about_ca_topic_score_gemma":0.00047144957,"teacher_disagreement_score":0.00418682,"about_ca_system_score_codex":0.00020389515,"about_ca_system_score_gemma":0.0002961855,"threshold_uncertainty_score":0.014006257},"labels":[],"label_agreement":null},{"id":"W3087314845","doi":"10.1097/moh.0000000000000614","title":"Advances in chimeric antigen receptor T cells","year":2020,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Medicine; Lymphoma; Clinical trial; Oncology; Immunology; Internal medicine; Immunotherapy; Cancer","score_opus":0.13340152786659926,"score_gpt":0.46622023946035557,"score_spread":0.3328187115937563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087314845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011132275,0.99762636,0.00019302267,0.0003668506,0.0005314445,0.000010058941,0.000029551795,0.000014824571,0.0011166226],"genre_scores_gemma":[0.001172455,0.9962054,0.0002597316,0.00078664965,0.0004430548,0.000016374763,0.0000881941,0.000004476479,0.0010236048],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997807,0.00003598431,0.000028659382,0.00004345465,0.00007936599,0.00003189541],"domain_scores_gemma":[0.9997105,0.0001271717,0.00004866417,0.000008798822,0.000075917924,0.000029025996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007460834,0.000783294,0.0010977497,0.0013341792,0.00016555614,0.0009160828,0.00081859244,0.0011534155,0.005773676],"category_scores_gemma":[0.0008469942,0.00023600439,0.00068305305,0.0011183859,0.00030106207,0.0011453666,0.0006361557,0.002355493,0.0036033753],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013124553,0.00006590961,0.00007939124,0.020348629,0.00009444286,0.00017495941,0.00003388862,0.00046545672,0.002845212,0.0048555643,0.04476465,0.92614067],"study_design_scores_gemma":[0.000031783264,0.00009590579,0.00018569955,0.0019065341,0.00009176966,0.00065530365,0.000014322904,0.00006539177,0.0006769191,0.0007881494,0.9954781,0.000010191253],"about_ca_topic_score_codex":0.0006647786,"about_ca_topic_score_gemma":0.00074273645,"teacher_disagreement_score":0.005773676,"about_ca_system_score_codex":0.0005692922,"about_ca_system_score_gemma":0.0008871771,"threshold_uncertainty_score":0.019314826},"labels":[],"label_agreement":null},{"id":"W3088012427","doi":"10.1016/j.annonc.2020.08.1206","title":"1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Regimen; Oncology; Cancer; Immunotherapy","score_opus":0.08697317739299981,"score_gpt":0.3589568587274751,"score_spread":0.2719836813344753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088012427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997863,0.00031230133,0.00010494568,0.000027215216,0.000010210272,0.00002204912,0.000338346,0.000009103298,0.0013127523],"genre_scores_gemma":[0.9985121,0.00004847229,0.000074560194,0.00003920654,0.000011821394,0.000025319006,0.0005787117,0.0000015880648,0.00070821337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998559,0.00003374463,0.000009997484,0.000029698249,0.000020276024,0.0000503423],"domain_scores_gemma":[0.9996977,0.00009423084,0.000060263807,0.000023819015,0.000031647436,0.00009224931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043416445,0.00017553891,0.00034330637,0.00033764806,0.00017684544,0.00031804413,0.00011307975,0.0002844854,0.0015566696],"category_scores_gemma":[0.0005340511,0.00008105733,0.00033556746,0.00014658285,0.000099079574,0.00032253642,0.00015803127,0.0003273458,0.00023051816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05048638,0.0018537432,0.82258314,0.00012064567,0.00039205793,0.00077071396,0.00023136428,0.0019237187,0.039211787,0.00015396565,0.001910879,0.08036168],"study_design_scores_gemma":[0.00046144432,0.014702536,0.97533673,0.000010448611,0.00015770472,0.0007318569,0.00010362145,0.0019636378,0.0039335666,0.000052358973,0.0025328698,0.000013159197],"about_ca_topic_score_codex":0.0006070368,"about_ca_topic_score_gemma":0.0010166861,"teacher_disagreement_score":0.0015566696,"about_ca_system_score_codex":0.00022161471,"about_ca_system_score_gemma":0.000118049924,"threshold_uncertainty_score":0.0052075386},"labels":[],"label_agreement":null},{"id":"W3088510493","doi":"10.1016/j.annonc.2020.08.638","title":"524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Tolerability; Internal medicine; Neutropenia; Phases of clinical research; Pharmacokinetics; Pharmacology; Pharmacodynamics; Pembrolizumab; Oncology; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy","score_opus":0.08599711741859951,"score_gpt":0.4161967174254941,"score_spread":0.3301996000068946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088510493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880762,0.0017421986,0.0009565183,0.00084947096,0.00015631419,0.0010952728,0.0021384668,0.00008226087,0.0049032196],"genre_scores_gemma":[0.9835386,0.0012196444,0.002104874,0.001080061,0.00016214632,0.0009508086,0.006203827,0.000049675316,0.0046903943],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997011,0.00013389027,0.000013891754,0.000043757325,0.000027822287,0.00007958856],"domain_scores_gemma":[0.9995914,0.00013242633,0.000035890927,0.00003407314,0.000037814603,0.00016841396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085510133,0.0009537502,0.0013909474,0.00018430823,0.00031657392,0.0006547487,0.00035854668,0.00059967075,0.00386841],"category_scores_gemma":[0.00082017906,0.0002877706,0.00087611354,0.00022411914,0.00042434383,0.00034874238,0.00020616913,0.002026148,0.0010012267],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39414993,0.056237824,0.024513213,0.0008145052,0.0017068619,0.00091971306,0.0004591333,0.0059333337,0.26329952,0.00045896758,0.011189269,0.24031773],"study_design_scores_gemma":[0.2256587,0.6167495,0.082791954,0.000054038435,0.0018378079,0.0012069547,0.00014772956,0.0030461305,0.047102958,0.00044873005,0.020871738,0.000083782696],"about_ca_topic_score_codex":0.0015842437,"about_ca_topic_score_gemma":0.0030650205,"teacher_disagreement_score":0.00386841,"about_ca_system_score_codex":0.0005583546,"about_ca_system_score_gemma":0.00065052346,"threshold_uncertainty_score":0.012941062},"labels":[],"label_agreement":null},{"id":"W3089028786","doi":"10.18632/aging.104058","title":"A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy","year":2020,"lang":"en","type":"article","venue":"Aging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cytokine release syndrome; Clinical trial; CD19; Adverse effect; Chimeric antigen receptor; Pharmacovigilance; Incidence (geometry); CAR T-cell therapy; Cause of death; Internal medicine; Mortality rate; Immunology; Immunotherapy; Antigen; Disease; Cancer","score_opus":0.028867188077289684,"score_gpt":0.2903957712011006,"score_spread":0.26152858312381094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089028786","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.059581526,0.9328469,0.0027417967,0.00034778658,0.00013233375,0.00023670642,0.0030870438,0.000060587674,0.00096531864],"genre_scores_gemma":[0.80488074,0.1858174,0.0031903833,0.0012150676,0.00035348072,0.00039462897,0.0036301394,0.00008047585,0.00043757903],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9917653,0.0036512709,0.0024220005,0.0009610455,0.0009774761,0.00022282987],"domain_scores_gemma":[0.97491145,0.017300857,0.0049291193,0.0013416419,0.0012655423,0.00025135992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015189383,0.00097105413,0.005203915,0.0031874627,0.00027671218,0.0015510012,0.0006854237,0.0007046561,0.001563863],"category_scores_gemma":[0.017173247,0.0005681192,0.017462501,0.004131162,0.00032619125,0.00075419503,0.0007755466,0.0008344611,0.00016300881],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080540525,0.00006963371,0.04537456,0.0675478,0.8312491,0.00028259566,0.00006432405,0.002447275,0.001126199,0.0002743068,0.0016086943,0.041901384],"study_design_scores_gemma":[0.0011051539,0.0012519887,0.060323406,0.0051595317,0.92233425,0.00051349896,0.00004896004,0.0009734791,0.0008335149,0.0006468963,0.006767303,0.00004193801],"about_ca_topic_score_codex":0.0013425645,"about_ca_topic_score_gemma":0.0027342038,"teacher_disagreement_score":0.015189383,"about_ca_system_score_codex":0.0010356407,"about_ca_system_score_gemma":0.0009396837,"threshold_uncertainty_score":0.080330074},"labels":[],"label_agreement":null},{"id":"W3090525098","doi":"10.1136/jitc-2020-001180","title":"Regulation of tumor growth by leukocyte-specific protein 1 in T cells","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Ministry of Education, Science and Technology; National Research Foundation of Korea; National Research Foundation","keywords":"Cancer research; Immunology; Computational biology; Biology; Medicine","score_opus":0.032812834537790075,"score_gpt":0.32360810513992944,"score_spread":0.2907952706021394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090525098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840973,0.009347242,0.0033804332,0.00030466187,0.00007847148,0.00006454795,0.00043477167,0.00017143834,0.0021211035],"genre_scores_gemma":[0.9923943,0.0038680076,0.0015321131,0.00011828028,0.000055582965,0.000107451364,0.0003308321,0.000018428838,0.0015749783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985695,0.000028629278,0.000009553487,0.000036557525,0.000024849222,0.00004349304],"domain_scores_gemma":[0.9998913,0.000019052704,0.0000451622,0.00000870181,0.000010981398,0.00002483451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014286672,0.000541773,0.0002235131,0.00021869116,0.0001254285,0.00026553846,0.00015946077,0.0003174098,0.0012123488],"category_scores_gemma":[0.00011400948,0.0000957907,0.0002241777,0.00013476782,0.00026096555,0.00014967618,0.00021684341,0.0006809267,0.00042462224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025251575,0.000050793053,0.00033004093,0.00014171861,0.0000035336468,0.000064738444,0.000015852072,0.00013740608,0.9956566,0.00016366906,0.000104367886,0.0030787808],"study_design_scores_gemma":[0.00012934353,0.0019543401,0.009430868,0.000043867305,0.000043778917,0.0005490753,0.000053064512,0.0020927412,0.97672576,0.00033736922,0.008631485,0.000008380019],"about_ca_topic_score_codex":0.00014590069,"about_ca_topic_score_gemma":0.00014848806,"teacher_disagreement_score":0.0012123488,"about_ca_system_score_codex":0.00028259744,"about_ca_system_score_gemma":0.00016370742,"threshold_uncertainty_score":0.0040557384},"labels":[],"label_agreement":null},{"id":"W3091048385","doi":"10.3390/ijms21197222","title":"Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting","year":2020,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Western Economic Diversification Canada","keywords":"Chimeric antigen receptor; Modular design; Antigen; Cancer immunotherapy; T cell; Immunotherapy; Computer science; Retargeting; Biology; Cell biology; Immune system; Immunology; Artificial intelligence","score_opus":0.054215576442851354,"score_gpt":0.37178662607069096,"score_spread":0.3175710496278396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091048385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050088787,0.97636604,0.008867871,0.00036403787,0.00054661464,0.000090731286,0.00012059015,0.00015918964,0.008476017],"genre_scores_gemma":[0.024937069,0.96135205,0.006802884,0.00046330178,0.00016784639,0.00011819835,0.0002765955,0.000022020246,0.0058600525],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998679,0.000018896784,0.000009130222,0.00003186636,0.000051507766,0.00002063631],"domain_scores_gemma":[0.99994576,0.00001640131,0.000012462213,0.000003127219,0.000014336781,0.000007917961],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031929216,0.00061867596,0.0006394638,0.0010856485,0.00013063819,0.00043948356,0.00052492647,0.0006554842,0.0025893508],"category_scores_gemma":[0.00022185213,0.00019990955,0.00043221537,0.000871005,0.00025751637,0.0007104587,0.00041897176,0.0011734504,0.0019021282],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013950148,0.00019314852,0.00014276475,0.012554896,0.00009414367,0.00039345445,0.00010312814,0.001742772,0.0937245,0.020612976,0.016836723,0.8534619],"study_design_scores_gemma":[0.000035922705,0.00046155154,0.00037818373,0.0007415828,0.00009512059,0.0012343309,0.000032018765,0.00065894047,0.027654164,0.0020414991,0.9666296,0.000036978778],"about_ca_topic_score_codex":0.00039027783,"about_ca_topic_score_gemma":0.00038172724,"teacher_disagreement_score":0.0025893508,"about_ca_system_score_codex":0.0003882637,"about_ca_system_score_gemma":0.0004291731,"threshold_uncertainty_score":0.008662224},"labels":[],"label_agreement":null},{"id":"W3091049434","doi":"10.1016/j.cellimm.2020.104220","title":"Building a CAR-Treg: Going from the basic to the luxury model","year":2020,"lang":"en","type":"review","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; University of British Columbia; BC Children's Hospital; Health Research","keywords":"Chimeric antigen receptor; Biology; Context (archaeology); Immunology; Autoimmunity; Immune system; Transplantation; Cell therapy; Function (biology); T cell; Stem cell; Cell biology; Medicine","score_opus":0.0708255561848193,"score_gpt":0.3463474842095065,"score_spread":0.2755219280246872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091049434","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000076603894,0.99436766,0.00053359795,0.002863998,0.0010646235,0.0000048101138,0.000015435802,0.000015685071,0.0010575532],"genre_scores_gemma":[0.0016892216,0.990311,0.00083282095,0.0042237346,0.0013811522,0.000021178806,0.00004362721,0.000008916001,0.0014884378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960667,0.00011909491,0.00002976223,0.000061405444,0.00012501921,0.00005811439],"domain_scores_gemma":[0.9993057,0.00043219494,0.000042595293,0.000020245665,0.00011072977,0.00008835011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001967665,0.0010273908,0.0017129235,0.0011555495,0.0004230036,0.002312162,0.0013521172,0.0026737803,0.0045953267],"category_scores_gemma":[0.0013220387,0.00033365327,0.000512996,0.0008873246,0.0014497103,0.0040715835,0.0013328387,0.0073275114,0.0027195094],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016983566,0.00011409058,0.0001466056,0.010618051,0.00008156143,0.00020005977,0.00008238108,0.00062809716,0.0023819555,0.04483478,0.106612355,0.8341301],"study_design_scores_gemma":[0.00003138486,0.00008465989,0.00011659223,0.0018277471,0.00003858604,0.00034129492,0.000053083037,0.00012655328,0.00030913777,0.011807897,0.98524946,0.0000135089185],"about_ca_topic_score_codex":0.0007557297,"about_ca_topic_score_gemma":0.0019899008,"teacher_disagreement_score":0.0045953267,"about_ca_system_score_codex":0.0012791211,"about_ca_system_score_gemma":0.0017207741,"threshold_uncertainty_score":0.015372932},"labels":[],"label_agreement":null},{"id":"W3091908596","doi":"10.1016/j.xpro.2020.100124","title":"Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis","year":2020,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Immunotherapy; Haematopoiesis; Medicine; Toxicity; Cancer research; Bioinformatics; Computational biology; Immunology; Stem cell; Biology; Immune system; Internal medicine","score_opus":0.14491704303306321,"score_gpt":0.4368326941525873,"score_spread":0.2919156511195241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091908596","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95225805,0.0023845073,0.03890192,0.00025171912,0.00014239296,0.0011217024,0.0015481632,0.000248119,0.0031434058],"genre_scores_gemma":[0.9673826,0.0028468876,0.023335172,0.00022912325,0.000045246394,0.00088260067,0.001743767,0.00008628992,0.0034483774],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993474,0.0002229929,0.000063337626,0.0001191849,0.00017760818,0.000069476126],"domain_scores_gemma":[0.99961877,0.000093900635,0.00009823093,0.00009363255,0.00005864854,0.000036827747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016320484,0.000748074,0.00049060734,0.0005938686,0.0002602162,0.00065827166,0.00055266434,0.00070804707,0.0021506688],"category_scores_gemma":[0.00048264008,0.00020013211,0.00041220651,0.00030513882,0.0006286423,0.0005320956,0.00025347446,0.0013639773,0.00036843334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013294928,0.0009981267,0.0008222888,0.000113469454,0.000045801447,0.00007603274,0.000064659354,0.0014496745,0.98853624,0.00065549725,0.00031649505,0.0055921897],"study_design_scores_gemma":[0.00011633795,0.009904539,0.0013827251,0.000016538086,0.000089831294,0.00020964291,0.00003903871,0.0032881773,0.98108417,0.00024520798,0.0036052484,0.000018445628],"about_ca_topic_score_codex":0.0011005496,"about_ca_topic_score_gemma":0.0009971552,"teacher_disagreement_score":0.0021506688,"about_ca_system_score_codex":0.00045834962,"about_ca_system_score_gemma":0.0007120031,"threshold_uncertainty_score":0.008631229},"labels":[],"label_agreement":null},{"id":"W3094515317","doi":"10.1002/ijc.33357","title":"Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Sunnybrook Health Science Centre; St. Michael's Hospital; Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Institute for Clinical Evaluative Sciences; Queen's University; Cancer Care Ontario; University of Toronto","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Ipilimumab; Medicine; Internal medicine; Population; Cohort; Odds ratio; Surgery; Cancer; Immunotherapy","score_opus":0.0578104382998427,"score_gpt":0.3695072463203986,"score_spread":0.3116968080205559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094515317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9872672,0.00083993113,0.0001675766,0.00037858268,0.000017786157,0.000094711126,0.010204204,0.000010258352,0.0010197517],"genre_scores_gemma":[0.9972696,0.0002764479,0.00012266553,0.00008902949,0.000008706225,0.000029062936,0.001901379,0.0000032491644,0.00029997833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998691,0.00013223111,0.00012821132,0.00030056553,0.0003702114,0.00037773428],"domain_scores_gemma":[0.99700254,0.00015836963,0.001144686,0.00022924089,0.0008684154,0.00059673935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093018933,0.00041745644,0.0005730576,0.0008049246,0.0015386891,0.0009936062,0.0012723857,0.0005110886,0.0017264673],"category_scores_gemma":[0.0026698122,0.00056188076,0.0009952845,0.0034485727,0.00061382836,0.0004068377,0.0007644872,0.0009217102,0.000183082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010326342,0.00002419243,0.9976968,0.000031570307,0.00013357303,0.000059427195,0.00019504131,0.000091357455,0.000112594505,0.000053919666,0.000784772,0.00071348145],"study_design_scores_gemma":[0.000018222438,0.000026610613,0.99861276,0.000020465191,0.000047709815,0.000052755637,0.0003066927,0.000387146,0.000021289445,0.000014322229,0.00048122136,0.000010845787],"about_ca_topic_score_codex":0.9815969,"about_ca_topic_score_gemma":0.9838234,"teacher_disagreement_score":0.022519983,"about_ca_system_score_codex":0.022519983,"about_ca_system_score_gemma":0.017039422,"threshold_uncertainty_score":0.16339469},"labels":[],"label_agreement":null},{"id":"W3094639681","doi":"10.1182/blood-2020-134319","title":"Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Refractory (planetary science); Pomalidomide; Lenalidomide; Oncology; Hematologic Neoplasms; Transplantation; Biology","score_opus":0.056192869041160075,"score_gpt":0.3303340735496066,"score_spread":0.27414120450844653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094639681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996942,0.0015374491,0.000097138865,0.00006925227,0.000008019828,0.0001021494,0.0008010977,0.000009840607,0.0004330778],"genre_scores_gemma":[0.9972203,0.00032113784,0.00034321623,0.00013557445,0.000033993023,0.00022022115,0.0014734549,0.000008746748,0.00024331758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990386,0.0005048378,0.00007351106,0.00017157337,0.00013431319,0.00007721001],"domain_scores_gemma":[0.99887663,0.00022722193,0.0004538607,0.00015469323,0.000072536655,0.00021496986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024053198,0.0005416607,0.000762214,0.00049080356,0.00030387973,0.0007275035,0.0005501072,0.00041180314,0.0012189524],"category_scores_gemma":[0.0015060173,0.00025413846,0.001133441,0.0006119588,0.00021077952,0.00040029385,0.0007796658,0.0007663939,0.0003129677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11765143,0.001266485,0.8315541,0.00045146115,0.005301857,0.00028139894,0.00031403176,0.00075667683,0.015365737,0.000112074034,0.0017959023,0.025148869],"study_design_scores_gemma":[0.0102443425,0.009101953,0.9723387,0.000032313306,0.0023541346,0.0006706362,0.00019380571,0.0006163834,0.0013325402,0.00011428618,0.002971971,0.000029020013],"about_ca_topic_score_codex":0.0006353956,"about_ca_topic_score_gemma":0.0013074465,"teacher_disagreement_score":0.0024053198,"about_ca_system_score_codex":0.00035481062,"about_ca_system_score_gemma":0.0004765588,"threshold_uncertainty_score":0.012720704},"labels":[],"label_agreement":null},{"id":"W3094642003","doi":"10.1182/blood-2020-136255","title":"Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chemotherapy regimen; Diffuse large B-cell lymphoma; Chemotherapy; Regimen; Lymphoma; Internal medicine; Surgery; Oncology","score_opus":0.015391288486337012,"score_gpt":0.2378056077934872,"score_spread":0.2224143193071502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094642003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95206946,0.035038758,0.0022866668,0.0014886833,0.00018848832,0.0004512358,0.00086734607,0.00031566247,0.007293715],"genre_scores_gemma":[0.98676586,0.0070126085,0.001656444,0.00086506945,0.000094039286,0.00017574131,0.0011784314,0.000012293169,0.0022394368],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99996746,0.0000073096085,0.000002731771,0.000006164601,0.0000070528895,0.000009312487],"domain_scores_gemma":[0.9999641,0.0000038928088,0.000009473062,0.0000023939594,0.0000026536904,0.000017576334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012146079,0.00019194893,0.00033874763,0.00016252846,0.00013351877,0.00020632173,0.00018184829,0.00022104326,0.0022792045],"category_scores_gemma":[0.00010181684,0.000072916475,0.00018626644,0.00010686178,0.00012131483,0.00023915226,0.0001447181,0.0005203496,0.0004338198],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01593181,0.0030523653,0.008366783,0.00085461244,0.00024237653,0.0006709484,0.0000902793,0.0011794,0.09814888,0.00056134415,0.012659361,0.8582418],"study_design_scores_gemma":[0.097373016,0.19425309,0.277564,0.0012072205,0.0015511155,0.011772069,0.00031470673,0.016908836,0.07745691,0.002483898,0.31896397,0.00015126631],"about_ca_topic_score_codex":0.00027003392,"about_ca_topic_score_gemma":0.0021199682,"teacher_disagreement_score":0.0022792045,"about_ca_system_score_codex":0.00023425014,"about_ca_system_score_gemma":0.00020242087,"threshold_uncertainty_score":0.0076246858},"labels":[],"label_agreement":null},{"id":"W3094679970","doi":"10.1182/blood-2020-137650","title":"Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Bone marrow; T cell; Immunology; CD8; Immune system; Immunotherapy; Antigen; Peripheral blood mononuclear cell; Cell therapy; Medicine; CD19; Biology; Cell","score_opus":0.030619094088624794,"score_gpt":0.27625283518110105,"score_spread":0.24563374109247627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094679970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841398,0.0011816948,0.0028863498,0.00009848709,0.000033338176,0.000038656664,0.010555005,0.00008163045,0.0009851214],"genre_scores_gemma":[0.9762666,0.0008790367,0.004630974,0.0004053259,0.00005481317,0.0001759483,0.014996403,0.00005877864,0.002532053],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99982244,0.000015575355,0.000011414708,0.00006697564,0.000043632117,0.00003991529],"domain_scores_gemma":[0.99981266,0.00005196257,0.00004251051,0.000013244522,0.00004943562,0.000030115243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015433467,0.00018162146,0.00054777105,0.00040437622,0.00024124913,0.0005058805,0.0001455186,0.0003841904,0.0013230477],"category_scores_gemma":[0.0003099331,0.00010831953,0.00028757754,0.00058433483,0.00018131158,0.00010952101,0.0002537944,0.00045481423,0.00036556544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00196223,0.0000971636,0.10457766,0.00038634325,0.00016258018,0.0005878098,0.00065938995,0.0012142208,0.8638343,0.00012999657,0.0014038666,0.024984362],"study_design_scores_gemma":[0.000043748743,0.00087717804,0.8516246,0.00007350036,0.00037328343,0.0022699493,0.0016415976,0.006749431,0.12357135,0.00039101936,0.012331742,0.000052589392],"about_ca_topic_score_codex":0.0007094344,"about_ca_topic_score_gemma":0.0013867967,"teacher_disagreement_score":0.0013230477,"about_ca_system_score_codex":0.00013470244,"about_ca_system_score_gemma":0.00014085784,"threshold_uncertainty_score":0.0044260025},"labels":[],"label_agreement":null},{"id":"W3094684455","doi":"10.1038/s42003-020-01362-w","title":"De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Communications Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; University of Guelph","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; McMaster University","keywords":"Oncolytic virus; Necroptosis; Cancer research; Medicine; Melanoma; Cytotoxic T cell; Immune system; Immunotherapy; Breast cancer; Cancer; Immune checkpoint; Proinflammatory cytokine; Immunology; Inflammation; Biology; Apoptosis; Programmed cell death; Internal medicine","score_opus":0.05195242251619331,"score_gpt":0.33456894772452134,"score_spread":0.28261652520832803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094684455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954372,0.00093796366,0.0017393385,0.00006894986,0.000019147106,0.000025901662,0.00006448328,0.000051167066,0.0016558624],"genre_scores_gemma":[0.997801,0.00036028144,0.000806459,0.000026822274,0.0000084711855,0.000015805972,0.000049748003,0.0000063821713,0.0009250622],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998801,0.000025646928,0.000007971277,0.000022814289,0.000025816917,0.000037619353],"domain_scores_gemma":[0.999925,0.00001377241,0.00002132039,0.000012570408,0.0000048018774,0.000022516886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010151515,0.00018335994,0.00017937022,0.0001248856,0.00011115984,0.00028074955,0.000081058955,0.00020305374,0.001294569],"category_scores_gemma":[0.00008048805,0.00008942579,0.00013114855,0.000054826083,0.00017264365,0.00018941864,0.00019035759,0.00050622685,0.00021674215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014858747,0.00003207578,0.00024352972,0.000016751326,0.000002556035,0.000070329654,0.000010102338,0.000060822484,0.998204,0.00012765176,0.000029333005,0.0010542615],"study_design_scores_gemma":[0.00003779468,0.00074602285,0.0047738175,0.0000063025386,0.000013464881,0.00074163254,0.00003691973,0.00090752234,0.9903082,0.0001099964,0.0023158179,0.00000246842],"about_ca_topic_score_codex":0.000114001865,"about_ca_topic_score_gemma":0.00023943813,"teacher_disagreement_score":0.001294569,"about_ca_system_score_codex":0.00015732042,"about_ca_system_score_gemma":0.00015079557,"threshold_uncertainty_score":0.004330814},"labels":[],"label_agreement":null},{"id":"W3094831999","doi":"10.1182/blood-2020-141126","title":"<i>TRAF3</i> Loss Drives Alternative NF-κB Pathway Activation in Diffuse Large B-Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Diffuse large B-cell lymphoma; Cancer research; Germinal center; Biology; Vincristine; BCL6; B cell; Lymphoma; Immunology; Cyclophosphamide; Genetics","score_opus":0.021239539836986662,"score_gpt":0.27185099652879907,"score_spread":0.2506114566918124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094831999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986094,0.00019390103,0.00041517688,0.000021912761,0.0000021086573,0.000004178579,0.0003154052,0.000038208367,0.00039958314],"genre_scores_gemma":[0.99912614,0.00006554421,0.00018957909,0.000017343042,0.0000019793183,0.000003970223,0.00034467477,0.000008679624,0.00024204192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998721,0.000012972311,0.00001078322,0.000037886923,0.000039154762,0.000027175305],"domain_scores_gemma":[0.99988484,0.00001813072,0.000054853987,0.0000124979315,0.000009622828,0.000020039235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010019644,0.00015623601,0.00014228308,0.00029495038,0.00014118527,0.000292274,0.00015575586,0.00017542412,0.0016144017],"category_scores_gemma":[0.00015787447,0.00010308777,0.00014244625,0.0002748957,0.0001771288,0.00006541777,0.00016510558,0.00023252204,0.00047346624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027251113,0.000029087705,0.021600427,0.00002948171,0.000024663732,0.0005100764,0.000042638523,0.00012651787,0.97413844,0.00004755909,0.00012582168,0.0030527527],"study_design_scores_gemma":[0.00005995355,0.00047754825,0.6005657,0.000014334531,0.0000996499,0.014379085,0.00021830376,0.0022500965,0.37796995,0.00020357018,0.0037483142,0.000013542351],"about_ca_topic_score_codex":0.0009363676,"about_ca_topic_score_gemma":0.0013109827,"teacher_disagreement_score":0.0016144017,"about_ca_system_score_codex":0.00028338336,"about_ca_system_score_gemma":0.000121719575,"threshold_uncertainty_score":0.0054006577},"labels":[],"label_agreement":null},{"id":"W3094939491","doi":"10.1182/blood-2020-139850","title":"Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Population; Salvage therapy; Oncology; Chemotherapy","score_opus":0.012937358606757236,"score_gpt":0.25605602392409893,"score_spread":0.2431186653173417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094939491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990798,0.000102118924,0.00002202894,0.000050313593,0.0000012039677,0.000007816222,0.00020802085,0.0000017417843,0.0005269004],"genre_scores_gemma":[0.9995234,0.0001174702,0.000027026002,0.000021561851,0.0000025507413,0.0000029076175,0.00022666113,0.0000010822666,0.00007749023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99973446,0.000051683928,0.000022409606,0.00003999343,0.00007256358,0.00007883616],"domain_scores_gemma":[0.99913687,0.00007686714,0.00031752043,0.000044898632,0.00014327744,0.00028058758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032497634,0.00011490302,0.00017052382,0.00048521406,0.00061547564,0.000688741,0.00032511054,0.00020783355,0.0009181848],"category_scores_gemma":[0.0012404084,0.00014406233,0.00013065313,0.0012208179,0.0004599675,0.00027008308,0.00055942935,0.00029772473,0.00018691903],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007901562,0.00004317185,0.99635196,0.0000096698695,0.00000946132,0.00046825677,0.0005499109,0.00006924482,0.00017728365,0.00001949591,0.00015208613,0.0020704435],"study_design_scores_gemma":[0.000019023855,0.00016848632,0.99574333,0.000014715168,0.000012596901,0.0014270825,0.0018496073,0.00016428414,0.00008609307,0.000023992374,0.00048260568,0.000008034507],"about_ca_topic_score_codex":0.22812368,"about_ca_topic_score_gemma":0.29031524,"teacher_disagreement_score":0.22812368,"about_ca_system_score_codex":0.003062022,"about_ca_system_score_gemma":0.0020734842,"threshold_uncertainty_score":0.4535917},"labels":[],"label_agreement":null},{"id":"W3095264723","doi":"10.1182/blood-2020-136465","title":"A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Angioimmunoblastic T-cell lymphoma; Lymphoma; Peripheral T-cell lymphoma; Germinal center; Mycosis fungoides; T cell; Neutropenia; Follicular lymphoma; Internal medicine; Antibody; Cancer research; Oncology; Immunology; Immune system; Chemotherapy; B cell","score_opus":0.023257575199438947,"score_gpt":0.3046426809321946,"score_spread":0.28138510573275566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095264723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923153,0.0010155638,0.00054204644,0.00014979896,0.000044669512,0.002904225,0.00073082076,0.00011506742,0.002182494],"genre_scores_gemma":[0.98881537,0.0015294335,0.0017802137,0.00040248447,0.000082150495,0.00258144,0.0020030213,0.000029424764,0.0027764796],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998147,0.00006620425,0.0000105211275,0.000034502547,0.000028071727,0.00004599701],"domain_scores_gemma":[0.99962556,0.000047411453,0.00006559142,0.00003836514,0.000030060086,0.0001930949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082617457,0.001125224,0.0011652452,0.00045913452,0.00035270702,0.0005572546,0.001040042,0.00084890664,0.0033825934],"category_scores_gemma":[0.000397229,0.0004695032,0.0006189794,0.00033850133,0.00067944586,0.00047527315,0.00023378227,0.0020581784,0.0009807873],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4344998,0.14112705,0.010683999,0.0017332733,0.0011668928,0.0010029469,0.00054935156,0.005251452,0.24473102,0.00093090325,0.0058929995,0.15243043],"study_design_scores_gemma":[0.2154765,0.7505108,0.0121331895,0.00004655869,0.00040892427,0.0007959091,0.00009034136,0.0016477172,0.014581912,0.00017409769,0.004108377,0.000025640062],"about_ca_topic_score_codex":0.0014853546,"about_ca_topic_score_gemma":0.003399065,"teacher_disagreement_score":0.0033825934,"about_ca_system_score_codex":0.00074730837,"about_ca_system_score_gemma":0.0014735998,"threshold_uncertainty_score":0.011315882},"labels":[],"label_agreement":null},{"id":"W3095376160","doi":"10.1182/blood-2020-136571","title":"Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"CD137; Cancer research; T cell; CD19; Antibody-dependent cell-mediated cytotoxicity; Immunotherapy; Immunology; Antigen; Medicine; Antibody; Immune system; Monoclonal antibody","score_opus":0.01726297855213852,"score_gpt":0.29514716114275996,"score_spread":0.2778841825906214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095376160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98431844,0.0032364787,0.0015474672,0.0005800628,0.00015933179,0.004764153,0.0024498722,0.00020846922,0.002735806],"genre_scores_gemma":[0.97475106,0.0040097083,0.002770991,0.001322554,0.00016820771,0.0058496483,0.0047731944,0.00009693075,0.0062576877],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967456,0.000105061124,0.000009960215,0.000073449206,0.00003737035,0.000099488476],"domain_scores_gemma":[0.99971706,0.000029813415,0.00004709169,0.000026172256,0.000029596335,0.00015026373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010682849,0.0017694514,0.0017412952,0.0004751633,0.00046152493,0.001173986,0.0009927026,0.0015971017,0.0033291297],"category_scores_gemma":[0.00045348195,0.0007224174,0.0010791838,0.0002958262,0.0006596089,0.00067195215,0.00035364472,0.002892311,0.0013181833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35621667,0.22086309,0.006755688,0.0015272371,0.0021806632,0.00096092396,0.0007721193,0.00622081,0.2558398,0.0009763807,0.016358102,0.1313286],"study_design_scores_gemma":[0.26730293,0.6964649,0.007957948,0.000063100015,0.00062653143,0.00069952314,0.00008923139,0.0016324866,0.016471,0.00049987325,0.008150259,0.00004227073],"about_ca_topic_score_codex":0.0013323963,"about_ca_topic_score_gemma":0.0027851346,"teacher_disagreement_score":0.0033291297,"about_ca_system_score_codex":0.0010338943,"about_ca_system_score_gemma":0.0018135338,"threshold_uncertainty_score":0.011137068},"labels":[],"label_agreement":null},{"id":"W3095414066","doi":"10.1182/blood-2020-136044","title":"Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dosing; Medicine; Cytokine release syndrome; Tolerability; Pharmacokinetics; Obinutuzumab; Internal medicine; Refractory (planetary science); Lymphoma; Cmax; Pharmacology; Oncology; Gastroenterology; Rituximab; Cancer; Immunotherapy; Adverse effect","score_opus":0.025872373302044626,"score_gpt":0.2845159869658392,"score_spread":0.25864361366379457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095414066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680954,0.0011219294,0.00025448325,0.00010294976,0.000020814308,0.00012847739,0.00019692755,0.000103702696,0.0012611822],"genre_scores_gemma":[0.99855953,0.00021122856,0.00018833266,0.00016280347,0.000011511243,0.000044746368,0.00029312423,0.000008923732,0.0005197612],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99986005,0.000031800017,0.000010392273,0.00003442792,0.000033999382,0.00002939117],"domain_scores_gemma":[0.99978215,0.00005518188,0.0000594901,0.00003076326,0.000016785107,0.00005564821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029719982,0.00018228161,0.00046091905,0.00015065559,0.000098127566,0.000298355,0.00015808988,0.0002441688,0.0018895963],"category_scores_gemma":[0.0005870446,0.000098612814,0.0002961448,0.0001408068,0.000110486784,0.00021574178,0.0001555233,0.0007101968,0.0005705574],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050061613,0.008426837,0.06502231,0.00038419294,0.00041912237,0.0006035221,0.0003167471,0.0019555348,0.20093797,0.00015303353,0.0063402303,0.66537887],"study_design_scores_gemma":[0.015578465,0.1821036,0.6953449,0.0000846922,0.0006174804,0.0047928873,0.00023083678,0.004677246,0.07368444,0.00034720305,0.022478508,0.000059633086],"about_ca_topic_score_codex":0.00022350032,"about_ca_topic_score_gemma":0.00053770497,"teacher_disagreement_score":0.0018895963,"about_ca_system_score_codex":0.000287526,"about_ca_system_score_gemma":0.00014851865,"threshold_uncertainty_score":0.006321311},"labels":[],"label_agreement":null},{"id":"W3095419444","doi":"10.1182/blood-2020-141505","title":"Safety and Efficacy of Ex Vivo Expanded Healthy Donor-Derived Double Negative T Cells for the Treatment of AML Relapsed after Allogeneic Stem Cell Transplantation: A First in-Human Phase I/IIa Clinical Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Clinical trial; Hematopoietic stem cell transplantation; Oncology; Donor lymphocyte infusion; Stem cell; Immunology","score_opus":0.0826160488270848,"score_gpt":0.38051433505101945,"score_spread":0.29789828622393466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095419444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678255,0.0046208007,0.0008679781,0.00043454792,0.0002695312,0.0041132225,0.0011514024,0.00011309071,0.0016468385],"genre_scores_gemma":[0.98651624,0.0027484305,0.0016705572,0.0010054089,0.00023341182,0.003942538,0.0017388342,0.000028304887,0.002116276],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994136,0.0002916646,0.00003990251,0.00010052079,0.00004594775,0.00010835584],"domain_scores_gemma":[0.99950445,0.00006518478,0.0000893305,0.00007076375,0.00003314221,0.00023706473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019793813,0.0015459608,0.002088454,0.00049236487,0.00043698208,0.0012071535,0.0009016053,0.0015311103,0.0021627378],"category_scores_gemma":[0.0006837858,0.0004930287,0.001264537,0.0003523674,0.0010937679,0.00077442324,0.00041450356,0.0031057142,0.00057306717],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68164515,0.10764388,0.0029368845,0.0014555324,0.0009809405,0.00048637268,0.00043110966,0.0025534523,0.06634172,0.0005646995,0.00375649,0.13120374],"study_design_scores_gemma":[0.48881388,0.49538946,0.0031094702,0.00005594257,0.00033365516,0.00028869652,0.000045529072,0.0008334199,0.0068746,0.0002530055,0.0039694607,0.000032847132],"about_ca_topic_score_codex":0.00030947957,"about_ca_topic_score_gemma":0.00062820566,"teacher_disagreement_score":0.0021627378,"about_ca_system_score_codex":0.0006843256,"about_ca_system_score_gemma":0.0011638319,"threshold_uncertainty_score":0.010468066},"labels":[],"label_agreement":null},{"id":"W3095453737","doi":"10.1182/blood-2020-137719","title":"Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Population; Cytokine release syndrome; Cytopenia; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.03325975986869781,"score_gpt":0.2778990979638786,"score_spread":0.24463933809518082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095453737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676723,0.008223679,0.009363334,0.00044312238,0.0016935617,0.0049517155,0.0031935922,0.00025475904,0.0042040097],"genre_scores_gemma":[0.97977495,0.0008439,0.008662804,0.00050115807,0.00020055914,0.006537481,0.0010714164,0.00005454391,0.0023531981],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98529714,0.010931971,0.00073419604,0.0016879736,0.0007326027,0.0006161402],"domain_scores_gemma":[0.99269205,0.004725778,0.001162601,0.0007983265,0.00027209808,0.0003492946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010142129,0.0024289836,0.0043842345,0.0009906334,0.0003928435,0.0010777526,0.0015250448,0.0018218341,0.008788068],"category_scores_gemma":[0.018517457,0.0006999296,0.007377804,0.0006305066,0.001073225,0.0012217532,0.0014676319,0.0033538805,0.00059782004],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91478217,0.0017253017,0.005348453,0.0020219567,0.04576731,0.00007526485,0.00013323779,0.002627792,0.0013224827,0.0011603315,0.0012214542,0.023814294],"study_design_scores_gemma":[0.4984194,0.28448287,0.04691555,0.0007125073,0.1117696,0.00034601876,0.0002877788,0.031851415,0.0069662267,0.009434738,0.008557006,0.0002568981],"about_ca_topic_score_codex":0.0013416792,"about_ca_topic_score_gemma":0.0020202182,"teacher_disagreement_score":0.010142129,"about_ca_system_score_codex":0.0012645532,"about_ca_system_score_gemma":0.0012016051,"threshold_uncertainty_score":0.053637385},"labels":[],"label_agreement":null},{"id":"W3095487872","doi":"10.1182/blood-2020-136751","title":"Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; London Health Sciences Centre; Western University; Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Health Sciences Centre; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Pembrolizumab; Population; Immunotherapy; Regimen; Chemotherapy regimen; Chimeric antigen receptor; Cyclophosphamide; Immunology; Cancer; Chemotherapy","score_opus":0.03329050655822488,"score_gpt":0.35096961056598397,"score_spread":0.3176791040077591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095487872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281573,0.0035362695,0.00019607569,0.00026279775,0.000076725424,0.00030609636,0.00045325237,0.00006794158,0.0022851257],"genre_scores_gemma":[0.9955734,0.0011806184,0.00037802887,0.00024836796,0.00010172948,0.0002717387,0.00091402815,0.000011543736,0.001320513],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993494,0.00036071375,0.000040151954,0.00009530165,0.00009003862,0.00006432659],"domain_scores_gemma":[0.9994273,0.000109123896,0.00011633296,0.000064988024,0.000048300015,0.00023405385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019764362,0.0011243883,0.0017614907,0.0004702525,0.0002129521,0.00080874376,0.0007947005,0.0007725128,0.0026261078],"category_scores_gemma":[0.00069926324,0.00033906815,0.0012095291,0.00026426784,0.00059504196,0.00070119783,0.00055834156,0.0015266357,0.0006503202],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64153516,0.04388338,0.013135749,0.0015606676,0.006805992,0.00035082034,0.00033393627,0.0044412203,0.05582415,0.00034987048,0.00418589,0.22759321],"study_design_scores_gemma":[0.20368521,0.75175697,0.029524626,0.00008644873,0.0020980525,0.00037633895,0.00012103058,0.0016009139,0.0058266288,0.00016151766,0.0047083152,0.000053981712],"about_ca_topic_score_codex":0.00041584444,"about_ca_topic_score_gemma":0.0009928496,"teacher_disagreement_score":0.0026261078,"about_ca_system_score_codex":0.00081881636,"about_ca_system_score_gemma":0.0007481267,"threshold_uncertainty_score":0.010452509},"labels":[],"label_agreement":null},{"id":"W3095670265","doi":"10.1182/blood-2020-136360","title":"Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytokine release syndrome; Medicine; Cytokine; Multiple myeloma; Refractory (planetary science); Internal medicine; Lenalidomide; Oncology; Gastroenterology; Immunology; Cancer; Immunotherapy; Biology; Chimeric antigen receptor","score_opus":0.021718242585585707,"score_gpt":0.27168531104383725,"score_spread":0.24996706845825153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095670265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988281,0.0005117502,0.00008032217,0.000031267653,0.000008671691,0.00006460281,0.00024904832,0.00000749366,0.00021872153],"genre_scores_gemma":[0.99845684,0.00012060191,0.00016667094,0.000100788675,0.0000349274,0.000066386514,0.00089153595,0.0000033371705,0.0001589236],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996878,0.00010831324,0.00003277704,0.00007726497,0.000047377613,0.000046455396],"domain_scores_gemma":[0.9994429,0.00011346033,0.00018491138,0.000038408238,0.000034864206,0.00018538424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000922366,0.00038341383,0.00066623325,0.00030926897,0.00023074156,0.00053594675,0.0002561024,0.00042443647,0.0009914057],"category_scores_gemma":[0.0007077051,0.00016952581,0.00045713046,0.00033960358,0.00016278126,0.000278058,0.00026480027,0.0005580572,0.00019070477],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068925165,0.0031459867,0.85796785,0.00028093444,0.0006472498,0.0024949862,0.00029559786,0.0006659654,0.03511919,0.00010640569,0.0013502567,0.029000401],"study_design_scores_gemma":[0.0060962774,0.026573362,0.9566338,0.00002708064,0.00032374813,0.003911701,0.000117445736,0.0012538697,0.0022462066,0.00005022836,0.0027464621,0.000019835023],"about_ca_topic_score_codex":0.0002658503,"about_ca_topic_score_gemma":0.00048412097,"teacher_disagreement_score":0.0009914057,"about_ca_system_score_codex":0.0002731601,"about_ca_system_score_gemma":0.0002973883,"threshold_uncertainty_score":0.0048779845},"labels":[],"label_agreement":null},{"id":"W3095914190","doi":"10.1182/blood-2020-139496","title":"Preclinical Characterization of Cell-Based IL12 Immunotherapy Against Murine Acute Lymphoblastic Leukemia Using Intravital Imaging","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Interleukin 12; Bone marrow; Immunotherapy; Cancer research; Ex vivo; Immune system; Immunology; Leukemia; Medicine; Tumor microenvironment; In vivo; Biology; In vitro","score_opus":0.024411600747359298,"score_gpt":0.30081970413357145,"score_spread":0.27640810338621213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095914190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97418857,0.0017908083,0.020500578,0.00012735993,0.00004254591,0.0004448136,0.00081282575,0.00029761984,0.0017948938],"genre_scores_gemma":[0.9712678,0.0015355696,0.0233247,0.000061232306,0.00001120292,0.00047433525,0.0006836531,0.000054162803,0.002587293],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984944,0.00002051255,0.000010241541,0.000031220803,0.000047036698,0.00004148323],"domain_scores_gemma":[0.99989164,0.000018387651,0.000037725844,0.000011579418,0.000016113823,0.00002449545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031279708,0.0004049724,0.00027561552,0.00025174397,0.00011336056,0.00026193197,0.0003127747,0.00037815055,0.0007728464],"category_scores_gemma":[0.00010644673,0.00013158898,0.00020920299,0.00015149354,0.00018723244,0.00022179903,0.00011146214,0.00074240915,0.0002443467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103189945,0.00013288105,0.00014579536,0.000027706003,0.0000026503885,0.000014527757,0.000015739231,0.00028693548,0.997804,0.00008807048,0.000040590872,0.0013379221],"study_design_scores_gemma":[0.000017379974,0.0012981459,0.00093765766,0.0000033103079,0.000012409069,0.000037876485,0.000008102018,0.0018342879,0.9945655,0.000015585223,0.0012665382,0.000003112589],"about_ca_topic_score_codex":0.001436969,"about_ca_topic_score_gemma":0.00167301,"teacher_disagreement_score":0.001436969,"about_ca_system_score_codex":0.00035251994,"about_ca_system_score_gemma":0.00032795648,"threshold_uncertainty_score":0.0028571486},"labels":[],"label_agreement":null},{"id":"W3096145151","doi":"10.1182/blood-2020-133988","title":"Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Progenitor cell; Myeloid leukemia; Haematopoiesis; Leukemia; Bone marrow; CD33; Antigen; Stem cell; Myeloid; Immunology; Immunotherapy; Medicine; Biology; CD34; Immune system; Cell biology","score_opus":0.020402313932488324,"score_gpt":0.2702720288376731,"score_spread":0.24986971490518478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096145151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9464784,0.0031847171,0.046372645,0.0003264405,0.000020384326,0.00012206243,0.00027990455,0.00017526757,0.003040093],"genre_scores_gemma":[0.9836322,0.0013694096,0.013593359,0.0001187228,0.000010806397,0.00006167527,0.00032164942,0.00002510244,0.000867068],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99974424,0.000060987248,0.000021926407,0.00004866368,0.000086051914,0.000038183633],"domain_scores_gemma":[0.9998604,0.000032711185,0.000035703477,0.000027156257,0.000024235045,0.000019767169],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034073263,0.00024559558,0.0002634638,0.0001984092,0.00012536932,0.0006600781,0.00024792875,0.00020588057,0.0006770006],"category_scores_gemma":[0.0002932484,0.000105649764,0.00015290883,0.00019938775,0.0002657715,0.0003129116,0.00033131053,0.0005703907,0.00023378315],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009410155,0.00005180462,0.0014528328,0.00005852133,0.000014672293,0.00012243965,0.000025937252,0.0012415828,0.9844358,0.0010812478,0.00011947554,0.011301592],"study_design_scores_gemma":[0.000015733274,0.00033274118,0.0030160162,0.000011740268,0.000030037605,0.00085412274,0.0000552039,0.002807326,0.98456013,0.0005181746,0.00779192,0.0000067572532],"about_ca_topic_score_codex":0.00028364963,"about_ca_topic_score_gemma":0.00051312847,"teacher_disagreement_score":0.0006770006,"about_ca_system_score_codex":0.0003704837,"about_ca_system_score_gemma":0.00020453751,"threshold_uncertainty_score":0.0026881099},"labels":[],"label_agreement":null},{"id":"W3096179361","doi":"10.1016/j.yrtph.2020.104813","title":"Considerations for setting occupational exposure limits for novel pharmaceutical modalities","year":2020,"lang":"en","type":"review","venue":"Regulatory Toxicology and Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Modalities; Risk analysis (engineering); Biosafety; Identification (biology); Medicine; Biological hazard; Hazard; Computer science; Biology; Environmental health; Pathology","score_opus":0.2235312005008402,"score_gpt":0.4734867151995026,"score_spread":0.2499555146986624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096179361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000461082,0.97375566,0.004440075,0.01035316,0.0014559894,0.000039053077,0.000097943484,0.00007489418,0.009322114],"genre_scores_gemma":[0.009839422,0.96271485,0.010382456,0.007886168,0.002702334,0.00017304736,0.00016710762,0.000031555286,0.0061030914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974948,0.0008652646,0.0003173625,0.0003104137,0.0008579057,0.00015421855],"domain_scores_gemma":[0.9938019,0.004140817,0.0006199925,0.0001979727,0.0010714313,0.00016794933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008205863,0.0011655045,0.0019091553,0.0019810728,0.0006909766,0.0033973034,0.002452349,0.0048247213,0.0075532254],"category_scores_gemma":[0.0075236834,0.00042716254,0.0013662701,0.0009802604,0.0024686474,0.0036973662,0.0019933898,0.0062662936,0.0024718775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020210276,0.00021537273,0.0004690152,0.011987419,0.000095951895,0.0004960257,0.00020492707,0.0016397465,0.0044972417,0.036373973,0.04375102,0.90006715],"study_design_scores_gemma":[0.0000445423,0.00029476665,0.0007492102,0.011983671,0.00016171561,0.0012781838,0.0003161368,0.00035306346,0.0018255532,0.025372336,0.957569,0.00005190313],"about_ca_topic_score_codex":0.00249906,"about_ca_topic_score_gemma":0.005186287,"teacher_disagreement_score":0.008205863,"about_ca_system_score_codex":0.0015933743,"about_ca_system_score_gemma":0.0053671435,"threshold_uncertainty_score":0.043397248},"labels":[],"label_agreement":null},{"id":"W3096607082","doi":"10.1182/blood-2020-134449","title":"Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Interim; Medicine; Internal medicine; Lymphoma; Oncology; Political science","score_opus":0.025071458830441692,"score_gpt":0.29942498192249317,"score_spread":0.27435352309205147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096607082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702495,0.00435668,0.0038166181,0.000990882,0.00034726647,0.0042588697,0.008317716,0.0005417657,0.0071207825],"genre_scores_gemma":[0.96553135,0.001378512,0.006479195,0.0016011359,0.00018354409,0.0060230307,0.013868986,0.00013410403,0.004800136],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99917835,0.00041381543,0.000039211158,0.00010566627,0.0001106595,0.00015232814],"domain_scores_gemma":[0.99868494,0.00027462823,0.0003601454,0.0001975102,0.00012120153,0.0003615822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004437069,0.0011321969,0.0016759424,0.0004227097,0.00041697102,0.0012661978,0.00071273796,0.0009169744,0.0054489053],"category_scores_gemma":[0.0027175003,0.0004944788,0.0021249903,0.0003428766,0.0004731633,0.00083276205,0.00047988282,0.0031278147,0.00120897],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7922246,0.01923831,0.02157374,0.0012315776,0.0050104777,0.0005296449,0.00023883897,0.0059185615,0.028720504,0.0008528985,0.015488516,0.1089724],"study_design_scores_gemma":[0.39392203,0.4933528,0.062226728,0.0001670889,0.006788137,0.0016328827,0.00017608127,0.0068501253,0.011615899,0.001909505,0.021255309,0.00010329993],"about_ca_topic_score_codex":0.00026700558,"about_ca_topic_score_gemma":0.0007339249,"teacher_disagreement_score":0.0054489053,"about_ca_system_score_codex":0.0005231041,"about_ca_system_score_gemma":0.0013443327,"threshold_uncertainty_score":0.023465753},"labels":[],"label_agreement":null},{"id":"W3096624409","doi":"10.1182/blood-2020-136368","title":"Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Pomalidomide; Quality of life (healthcare); Internal medicine; Lenalidomide; Oncology; Gerontology; Family medicine; Nursing","score_opus":0.10097725679551099,"score_gpt":0.36493475699181815,"score_spread":0.26395750019630715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096624409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99826705,0.00047360186,0.000051855084,0.00008148867,0.000022251967,0.00019940038,0.00046986272,0.0000066450375,0.0004278367],"genre_scores_gemma":[0.9967964,0.00019619631,0.00016413981,0.0002488878,0.0000751153,0.00029923813,0.0014898091,0.0000034816596,0.0007267321],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994862,0.00025205844,0.000029585237,0.00008206476,0.000069770846,0.000080226295],"domain_scores_gemma":[0.9989998,0.00011463574,0.000270806,0.00006253917,0.00006905641,0.0004831945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019368605,0.00085193856,0.0009387728,0.0002750013,0.00036636004,0.00060050463,0.00052895764,0.0008192397,0.0020799756],"category_scores_gemma":[0.0007717163,0.00033556778,0.0010276493,0.00033298912,0.0003993606,0.0006183087,0.00054247706,0.00165507,0.00035185262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56624275,0.04739689,0.32602528,0.0005577497,0.003255889,0.00034460312,0.0004780788,0.0013989862,0.016880058,0.00015544395,0.0027266557,0.034537602],"study_design_scores_gemma":[0.078339115,0.24669223,0.6682522,0.00004713247,0.0010280476,0.0003322459,0.00013220607,0.0014069861,0.001352296,0.000100289835,0.0022620275,0.000055101074],"about_ca_topic_score_codex":0.000900557,"about_ca_topic_score_gemma":0.0016662872,"teacher_disagreement_score":0.0020799756,"about_ca_system_score_codex":0.0004883456,"about_ca_system_score_gemma":0.00056476274,"threshold_uncertainty_score":0.010243237},"labels":[],"label_agreement":null},{"id":"W3096697285","doi":"10.1182/blood-2020-136344","title":"A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Tolerability; CD20; Lymphoma; Internal medicine; Refractory (planetary science); Oncology; Follicular lymphoma; Antibody; Phases of clinical research; Gastroenterology; Chemotherapy; Adverse effect; Immunology; Biology","score_opus":0.020780815090792402,"score_gpt":0.2958991003380819,"score_spread":0.27511828524728954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096697285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946956,0.0006822133,0.00047836397,0.00018445158,0.00006266403,0.0017586115,0.0011450697,0.00006801941,0.0009251615],"genre_scores_gemma":[0.9881583,0.0010592516,0.0018927339,0.0006816854,0.00012202542,0.0019993684,0.003867842,0.00003950908,0.0021793698],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995709,0.00020895341,0.000017093334,0.000085549684,0.000037846767,0.00007960993],"domain_scores_gemma":[0.9994293,0.000076831064,0.00008413541,0.00006297432,0.00003836126,0.00030843797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018140355,0.0017768802,0.0014688014,0.0003628221,0.00036185764,0.000710168,0.00078817015,0.0008598574,0.0029954338],"category_scores_gemma":[0.00069691945,0.0005288062,0.0010479884,0.0003042337,0.0008209043,0.00077019853,0.00046094824,0.002537758,0.0007652671],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5997104,0.16931957,0.022646429,0.000935108,0.00198605,0.00064125645,0.00068481325,0.0034148896,0.09333499,0.00027501877,0.0053574513,0.10169398],"study_design_scores_gemma":[0.43048522,0.5308731,0.02774989,0.000022017077,0.00059496623,0.0005172055,0.00011795907,0.0011906289,0.0049463725,0.00014950166,0.0033178616,0.000035293688],"about_ca_topic_score_codex":0.0014840503,"about_ca_topic_score_gemma":0.0036410969,"teacher_disagreement_score":0.0029954338,"about_ca_system_score_codex":0.00077509554,"about_ca_system_score_gemma":0.0014536185,"threshold_uncertainty_score":0.010020733},"labels":[],"label_agreement":null},{"id":"W3096717600","doi":"10.1182/blood-2020-137233","title":"ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Lymphoma; Mantle cell lymphoma; Internal medicine; Lymphoblastic lymphoma; Refractory (planetary science); Malignancy; Oncology; Gastroenterology; Immunology; T cell","score_opus":0.014890253295505787,"score_gpt":0.2722694317291154,"score_spread":0.2573791784336096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096717600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98567826,0.00400884,0.00073884556,0.0011754285,0.00012007713,0.0036394089,0.0023522633,0.00016440215,0.002122398],"genre_scores_gemma":[0.9725577,0.0050862143,0.0044266772,0.0024060782,0.0001902988,0.006348365,0.006091763,0.00008520767,0.0028076128],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994905,0.00028375242,0.000020968286,0.00006164414,0.000049708262,0.00009338103],"domain_scores_gemma":[0.99915075,0.0000939378,0.00017028766,0.000056968005,0.00007230547,0.00045572952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023212193,0.0013323538,0.0013546222,0.000359665,0.0004522555,0.00095278746,0.0010871787,0.0010037232,0.0035549572],"category_scores_gemma":[0.0009631252,0.0005883233,0.0010748529,0.00037576247,0.0008217593,0.00084255566,0.0005205237,0.0036849962,0.000982159],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42441884,0.15706652,0.06388804,0.0026060028,0.0054695,0.0015740012,0.0014717206,0.004943113,0.08739791,0.0013269078,0.026499707,0.22333771],"study_design_scores_gemma":[0.56712395,0.35672706,0.045534417,0.00016319955,0.0017018025,0.0018331424,0.00033213725,0.0019814011,0.0060884985,0.00068267324,0.0177698,0.00006195017],"about_ca_topic_score_codex":0.0010975039,"about_ca_topic_score_gemma":0.003860135,"teacher_disagreement_score":0.0035549572,"about_ca_system_score_codex":0.0010232409,"about_ca_system_score_gemma":0.0026186921,"threshold_uncertainty_score":0.012275875},"labels":[],"label_agreement":null},{"id":"W3096959229","doi":"10.1182/blood-2020-141168","title":"The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Spinal Cord Injury BC","funders":"Medical Research Council","keywords":"Diffuse large B-cell lymphoma; Biology; Tumor microenvironment; Cancer research; Immune system; Antigen; Context (archaeology); Immunotherapy; Lymphoma; Immunology","score_opus":0.030470672176324858,"score_gpt":0.2646939371310036,"score_spread":0.23422326495467874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096959229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99822277,0.00058585324,0.0006515607,0.000015985657,0.0000015434917,0.0000054793236,0.00022028596,0.000020558273,0.0002759187],"genre_scores_gemma":[0.99903464,0.00012941258,0.00030162963,0.000014068672,0.0000015925458,0.0000058019273,0.0003140196,0.000003847551,0.00019511035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999198,0.000009882733,0.000004253374,0.000027819191,0.00002164673,0.000016530448],"domain_scores_gemma":[0.99990904,0.000018643284,0.000031822205,0.000012240599,0.000010222859,0.000017973582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098924465,0.00012281784,0.0001840206,0.00029478112,0.00009698491,0.00025402656,0.00012579838,0.00019538385,0.00082944264],"category_scores_gemma":[0.00014325003,0.000092068396,0.00012242416,0.00020155862,0.0001845437,0.00014069716,0.00018366563,0.00024855716,0.00022177579],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028501375,0.000021896834,0.012035005,0.0000340414,0.000017605022,0.00009303221,0.00002416357,0.00012771793,0.98377234,0.00003254666,0.000027620332,0.003529048],"study_design_scores_gemma":[0.000053212763,0.0008494035,0.5331152,0.0000057324396,0.00011343215,0.0040240125,0.00015728232,0.0018305414,0.4561405,0.00016386248,0.0035345114,0.0000122605825],"about_ca_topic_score_codex":0.00018158734,"about_ca_topic_score_gemma":0.00031825705,"teacher_disagreement_score":0.00082944264,"about_ca_system_score_codex":0.00015405224,"about_ca_system_score_gemma":0.00006083317,"threshold_uncertainty_score":0.0027747154},"labels":[],"label_agreement":null},{"id":"W3097588851","doi":"10.1182/blood-2020-136730","title":"A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Internal medicine; Population; Progression-free survival; Oncology; Immunology; Chemotherapy","score_opus":0.06832235787039867,"score_gpt":0.3291427218745771,"score_spread":0.2608203640041784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097588851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9643212,0.022441577,0.004230247,0.00041773822,0.0009007179,0.00072348845,0.004420798,0.00009933684,0.0024450521],"genre_scores_gemma":[0.9950653,0.0011318785,0.0011364948,0.00028664994,0.00012724237,0.0005287914,0.0010747948,0.000017168677,0.0006316311],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98298347,0.011805377,0.0012393484,0.0021621725,0.0010002867,0.0008094622],"domain_scores_gemma":[0.97974753,0.013138174,0.0043937084,0.001650278,0.0005822111,0.00048810252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0144336745,0.0013021263,0.003014419,0.0012163352,0.00031415658,0.0013674424,0.0014905091,0.0018776612,0.0058933003],"category_scores_gemma":[0.025351167,0.0006250958,0.013312766,0.0011280021,0.00070796855,0.0011458494,0.0013102907,0.0021097441,0.00047864162],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58042437,0.0013975517,0.114109516,0.006973502,0.2461065,0.00023318909,0.0002468748,0.0043643373,0.0012432329,0.0010764154,0.0025608188,0.041263703],"study_design_scores_gemma":[0.1358779,0.08838934,0.37836987,0.0013937127,0.35420784,0.00064717705,0.00047510798,0.027000967,0.0029287213,0.00420744,0.0062317047,0.00027024385],"about_ca_topic_score_codex":0.0028239512,"about_ca_topic_score_gemma":0.0018185594,"teacher_disagreement_score":0.0144336745,"about_ca_system_score_codex":0.0012397316,"about_ca_system_score_gemma":0.0008267234,"threshold_uncertainty_score":0.07633346},"labels":[],"label_agreement":null},{"id":"W3097603276","doi":"10.1182/blood-2020-138700","title":"Autologous Stem Cell Transplantation (ASCT) for T-Cell Non Hodgkin Lymphoma (T-NHL) Patients Who Achieve Complete Remission with First-Line Treatment: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Autologous stem-cell transplantation; Hazard ratio; Transplantation; Meta-analysis; Chemotherapy regimen; Progression-free survival; Surgery; Chemotherapy; Confidence interval","score_opus":0.07641804720976893,"score_gpt":0.3250659612966761,"score_spread":0.24864791408690717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097603276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003865801,0.9943849,0.0004809473,0.000164515,0.0000934916,0.00032939468,0.0004629256,0.000021711126,0.00019627345],"genre_scores_gemma":[0.11490909,0.8793252,0.0022605346,0.0007753658,0.00016579569,0.0013918942,0.0008436205,0.000025892672,0.00030262565],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9936511,0.0027487346,0.0019604454,0.00067062734,0.00075242884,0.00021675984],"domain_scores_gemma":[0.9897642,0.007132495,0.0017924567,0.00028938483,0.00084945495,0.0001720043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010494101,0.0024115832,0.019233376,0.0072564343,0.0005199849,0.002793363,0.0020316008,0.0020079403,0.0033723998],"category_scores_gemma":[0.021186538,0.0011976509,0.03431446,0.008030444,0.0006502436,0.0018784256,0.0014163111,0.0013174709,0.0002889517],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014426345,0.000032194715,0.0021504175,0.5837845,0.39729172,0.0001228328,0.00008914111,0.00058486074,0.00023434992,0.00015613735,0.00061106053,0.013500055],"study_design_scores_gemma":[0.00041735556,0.00020897712,0.0023821902,0.04086528,0.9538481,0.000099510886,0.000047351834,0.00018657953,0.000096606396,0.00018574423,0.0016404233,0.000021906451],"about_ca_topic_score_codex":0.0062662554,"about_ca_topic_score_gemma":0.013517103,"teacher_disagreement_score":0.019233376,"about_ca_system_score_codex":0.0025992882,"about_ca_system_score_gemma":0.0038441997,"threshold_uncertainty_score":0.05549878},"labels":[],"label_agreement":null},{"id":"W3097838507","doi":"10.1182/blood-2020-141925","title":"Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Cell biology; T cell; Antigen; Cytotoxic T cell; Receptor; Antigen-presenting cell; Molecular biology; Biology; Chemistry; Immunology; Immune system; Biochemistry; In vitro","score_opus":0.020323630542912162,"score_gpt":0.24080840056362807,"score_spread":0.2204847700207159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097838507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030894,0.0005228955,0.00628636,0.000059303573,0.000033108703,0.000023582674,0.00010227213,0.00014531144,0.002518319],"genre_scores_gemma":[0.99584347,0.00023914431,0.001519259,0.00007440646,0.00000923766,0.00001884472,0.00020141562,0.00003873129,0.0020555446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971265,0.000036926765,0.000023491853,0.000049492093,0.00007710841,0.00010038338],"domain_scores_gemma":[0.99983346,0.00003404611,0.000044854027,0.00002404277,0.000019985187,0.00004361313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016083311,0.000378214,0.0002577394,0.00018764134,0.00008826319,0.0004391067,0.00020308241,0.00038821378,0.0009348753],"category_scores_gemma":[0.0001833949,0.00018722063,0.0002443339,0.00012407335,0.00017590485,0.00022978566,0.00025928058,0.00070513034,0.0005187896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003059617,0.000014989201,0.00006088107,0.000010228739,0.0000023220277,0.000033642373,0.0000071308955,0.000058729664,0.9990797,0.00011941917,0.000028208455,0.0005541622],"study_design_scores_gemma":[0.00002060833,0.00034324033,0.0012166791,0.0000052883533,0.000021034823,0.00046835616,0.000014021035,0.002151961,0.99340504,0.000076030185,0.0022732099,0.00000455589],"about_ca_topic_score_codex":0.00025103573,"about_ca_topic_score_gemma":0.0003018533,"teacher_disagreement_score":0.0009348753,"about_ca_system_score_codex":0.00019377217,"about_ca_system_score_gemma":0.00012749595,"threshold_uncertainty_score":0.0031274557},"labels":[],"label_agreement":null},{"id":"W3097912792","doi":"10.1182/blood-2020-136307","title":"CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Internal medicine; Antigen; Population; Fludarabine; Immunology; Oncology; Gastroenterology; Cyclophosphamide; Immunotherapy; Chemotherapy; Cancer","score_opus":0.032698462280976295,"score_gpt":0.29832936063552745,"score_spread":0.26563089835455117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097912792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98978055,0.0017358286,0.0005280724,0.00046401244,0.00008601641,0.002999446,0.0021278032,0.00018877134,0.0020895172],"genre_scores_gemma":[0.9803013,0.0016367484,0.0023257583,0.0012414742,0.00016598278,0.0034383005,0.006928037,0.00006844349,0.0038940709],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997117,0.00010531171,0.000014984928,0.000050987273,0.000035586847,0.000081330545],"domain_scores_gemma":[0.9996414,0.000034317636,0.00005915334,0.000025663803,0.000023783312,0.00021562043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013358442,0.001270827,0.0010722379,0.00044704645,0.00032193615,0.0007126949,0.0008603893,0.00097050343,0.0045964853],"category_scores_gemma":[0.00046494463,0.0004578162,0.00076195976,0.0003337675,0.00053549337,0.00069253676,0.0003723453,0.002649665,0.0008191742],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4582846,0.16588181,0.016144916,0.001529268,0.0011791082,0.0007807437,0.0005166241,0.0045697307,0.16375637,0.0005898328,0.014019849,0.1727471],"study_design_scores_gemma":[0.48725283,0.4680027,0.020869803,0.000055258373,0.00049832667,0.00069128955,0.000055365243,0.0017013766,0.012988051,0.00020752971,0.007637122,0.000040381034],"about_ca_topic_score_codex":0.00097375846,"about_ca_topic_score_gemma":0.0025570968,"teacher_disagreement_score":0.0045964853,"about_ca_system_score_codex":0.00093161955,"about_ca_system_score_gemma":0.0015502681,"threshold_uncertainty_score":0.015376747},"labels":[],"label_agreement":null},{"id":"W3099091492","doi":"10.1101/759167","title":"Quantifying the Limits of Immunotherapies in Mice and Men","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Engineering and Physical Sciences Research Council","keywords":"Immune system; Cart; Immunotherapy; Homing (biology); Clinical trial; Dosing; Medicine; Perfusion; Immunology; Biology; Oncology; Cancer research; Internal medicine","score_opus":0.04537657949138461,"score_gpt":0.29562579236115194,"score_spread":0.2502492128697673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099091492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.705457,0.00904741,0.27003387,0.00050825597,0.00018489113,0.0004412624,0.0037249187,0.0015062588,0.009096083],"genre_scores_gemma":[0.94376117,0.0024984316,0.044211585,0.00046867965,0.00004183016,0.0009846104,0.0015508826,0.00045485006,0.006027865],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998844,0.00032604078,0.00007592022,0.0003592804,0.00026900484,0.00012570748],"domain_scores_gemma":[0.99873954,0.00059989403,0.00028771197,0.00018830609,0.000094855895,0.000089609784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026128318,0.00061772706,0.00042486397,0.0007744362,0.00022196215,0.00080696784,0.00054122874,0.0007217086,0.0020819393],"category_scores_gemma":[0.0013394272,0.00040554328,0.00044868584,0.0002228462,0.0005311045,0.0006110461,0.000368797,0.0011431146,0.0006254179],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000759867,0.00010439154,0.0015379877,0.00016031823,0.00006579184,0.000072998344,0.00014143801,0.0029692273,0.98380786,0.0020639803,0.0005052673,0.007810945],"study_design_scores_gemma":[0.00002393571,0.0010051439,0.002530193,0.000040681236,0.00006408772,0.00019080202,0.00004061096,0.0070638843,0.98117054,0.0006220595,0.0072308406,0.000017202947],"about_ca_topic_score_codex":0.00056523096,"about_ca_topic_score_gemma":0.0005431191,"teacher_disagreement_score":0.0026128318,"about_ca_system_score_codex":0.0005019978,"about_ca_system_score_gemma":0.00025051425,"threshold_uncertainty_score":0.013818145},"labels":[],"label_agreement":null},{"id":"W3099890097","doi":"10.1053/j.seminhematol.2020.11.006","title":"Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity","year":2020,"lang":"en","type":"article","venue":"Seminars in Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Epigenetics; Immunotherapy; Biology; Immune system; Chimeric antigen receptor; Cytotoxic T cell; Immunology; Gene delivery; Cancer research; Cancer immunotherapy; Genetic enhancement; Gene; Genetics","score_opus":0.040520900348912564,"score_gpt":0.33916994809733997,"score_spread":0.2986490477484274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099890097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945155,0.00063846103,0.0026898263,0.000085635824,0.00006103417,0.000058363483,0.00026107105,0.00008749973,0.0016026129],"genre_scores_gemma":[0.99760747,0.0001607049,0.0005879443,0.000021177784,0.0000045231113,0.000022350458,0.0001743612,0.000012313185,0.0014091257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988043,0.000017003482,0.000009887718,0.000026504602,0.000025988633,0.00004014487],"domain_scores_gemma":[0.9999504,0.00001276781,0.0000073564224,0.000013356964,0.0000062912613,0.000009790466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001497837,0.00016521693,0.0002594747,0.0001056395,0.00012863835,0.00029492928,0.00015760283,0.0001786436,0.004580169],"category_scores_gemma":[0.00012653659,0.00010812243,0.00020442094,0.00007776062,0.00016589636,0.0001055537,0.00016756852,0.0005619006,0.0006070348],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021407964,0.00007842168,0.00017193549,0.00001939622,0.0000055758765,0.00002689285,0.000012130798,0.00016977105,0.99672395,0.000120357574,0.000069786554,0.0023876869],"study_design_scores_gemma":[0.00006223777,0.00050137646,0.001926325,0.0000030547708,0.000023266095,0.0001696993,0.000018789167,0.00068835466,0.99446964,0.00004396146,0.0020909323,0.0000024583678],"about_ca_topic_score_codex":0.00031574952,"about_ca_topic_score_gemma":0.0006618191,"teacher_disagreement_score":0.004580169,"about_ca_system_score_codex":0.00020590903,"about_ca_system_score_gemma":0.00023377445,"threshold_uncertainty_score":0.015322208},"labels":[],"label_agreement":null},{"id":"W3099922800","doi":"10.3390/cancers12113329","title":"Current Advances and Hurdles in Chimeric Antigen Receptor Technology","year":2020,"lang":"en","type":"editorial","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Current (fluid); Antigen; Medicine; Computational biology; Immunology; Computer science; Biology; Immunotherapy; Engineering; Immune system","score_opus":0.01630392485573216,"score_gpt":0.3498964100311231,"score_spread":0.3335924851753909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099922800","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006197156,0.101251535,0.00048279864,0.052964613,0.84234804,0.00001895638,0.000042642783,0.00010049503,0.002728839],"genre_scores_gemma":[0.0006058629,0.096061885,0.0004278299,0.043755554,0.85015655,0.000026042348,0.000046916706,0.00005509796,0.008864267],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99521506,0.0008722287,0.0005628461,0.00042411892,0.002692774,0.00023305761],"domain_scores_gemma":[0.98077893,0.010013158,0.0008500161,0.0003284416,0.005925905,0.0021036414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01091847,0.0023703543,0.0021743164,0.002008655,0.0017159056,0.0057969205,0.0028434058,0.009930561,0.004968394],"category_scores_gemma":[0.018717628,0.0010770598,0.0020108244,0.001307906,0.003178287,0.006380921,0.0015218453,0.021720449,0.0061580297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008347274,0.000020419582,0.000019983177,0.0007115749,0.000024958399,0.00011902706,0.000025577845,0.000054356908,0.0002168472,0.0017800234,0.9653072,0.031636525],"study_design_scores_gemma":[0.000030664538,0.000043382224,0.00006007388,0.00030663708,0.000021208563,0.00019171096,0.00002506677,0.000064462714,0.00012104073,0.0016496797,0.9974722,0.000013828065],"about_ca_topic_score_codex":0.0012772602,"about_ca_topic_score_gemma":0.0033454292,"teacher_disagreement_score":0.01091847,"about_ca_system_score_codex":0.0024233689,"about_ca_system_score_gemma":0.0028293394,"threshold_uncertainty_score":0.057743073},"labels":[],"label_agreement":null},{"id":"W3100358566","doi":"10.1136/jitc-2020-sitc2020.0806","title":"806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer","year":2020,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Cohort; Breast cancer; Internal medicine; Clinical endpoint; Letrozole; Trastuzumab; Oncolytic virus; Cancer; Immunotherapy; Clinical trial; Pembrolizumab","score_opus":0.052522123886921686,"score_gpt":0.3335384184004536,"score_spread":0.28101629451353194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100358566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998906,0.0002081956,0.00009707263,0.000026034219,0.00001629071,0.0002401013,0.000114604656,0.0000060652574,0.00038559115],"genre_scores_gemma":[0.9974214,0.0001800102,0.0003093008,0.0001359273,0.00006881185,0.0003774117,0.00036476285,0.000006084216,0.001136318],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99967015,0.00013624689,0.000018670762,0.000061176004,0.000047756555,0.00006599782],"domain_scores_gemma":[0.999468,0.000117212134,0.000076070166,0.00008571376,0.00003494517,0.00021816064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010213553,0.0004042026,0.0006112864,0.0002477527,0.00031358356,0.00054149964,0.00035076233,0.0006414002,0.0016334294],"category_scores_gemma":[0.00046730667,0.00032094936,0.0005415249,0.00014418244,0.0003794191,0.00042875882,0.00028070272,0.0012659952,0.00030119988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32040334,0.10717281,0.101485305,0.00036241225,0.0006180496,0.0014145448,0.0008673119,0.00079807837,0.40036196,0.00041538427,0.0016313911,0.06446941],"study_design_scores_gemma":[0.023617478,0.74553776,0.17591073,0.000018398594,0.00053580815,0.001046178,0.00036111215,0.0007472032,0.04726144,0.0002122126,0.004702798,0.00004890157],"about_ca_topic_score_codex":0.00048676276,"about_ca_topic_score_gemma":0.000934939,"teacher_disagreement_score":0.0016334294,"about_ca_system_score_codex":0.00031293608,"about_ca_system_score_gemma":0.0005407314,"threshold_uncertainty_score":0.005464375},"labels":[],"label_agreement":null},{"id":"W3100538981","doi":"10.1136/jitc-2020-sitc2020.0379","title":"379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CD8; Medicine; T-cell receptor; Internal medicine; Antigen; Cancer; T cell; Gastroenterology; Oncology; Immunology; Immune system","score_opus":0.05083607555745884,"score_gpt":0.29174663320772787,"score_spread":0.24091055765026903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100538981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96535105,0.0025182539,0.0010505336,0.00063585176,0.000117331525,0.0017677891,0.010713454,0.000095116695,0.017750686],"genre_scores_gemma":[0.9671536,0.0014386288,0.0012874188,0.0009462998,0.00010018093,0.0010238178,0.018060522,0.000062185725,0.009927367],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996426,0.00011582924,0.00003203085,0.000047544658,0.00009497879,0.00006699381],"domain_scores_gemma":[0.99963105,0.00008760576,0.00005712142,0.000027911994,0.00003724193,0.0001590084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008312513,0.00040397936,0.000607916,0.00017873103,0.00028498872,0.0008003062,0.00024567146,0.00054710265,0.009161918],"category_scores_gemma":[0.0006825455,0.00013114454,0.00071763544,0.00024449982,0.00026235185,0.0003737135,0.00021290561,0.0011786596,0.0013788254],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4685028,0.018756106,0.023940397,0.0011039054,0.0011872537,0.0010025171,0.0002449608,0.006661091,0.12305488,0.0012950259,0.028872149,0.32537887],"study_design_scores_gemma":[0.09476595,0.62967765,0.09426986,0.000189366,0.0017791641,0.002306387,0.00016435233,0.0035016115,0.06646082,0.0015914913,0.10517959,0.00011377808],"about_ca_topic_score_codex":0.0008434701,"about_ca_topic_score_gemma":0.002052281,"teacher_disagreement_score":0.009161918,"about_ca_system_score_codex":0.0007850422,"about_ca_system_score_gemma":0.0008189744,"threshold_uncertainty_score":0.030649662},"labels":[],"label_agreement":null},{"id":"W3101174158","doi":"10.1016/j.jid.2020.09.020","title":"Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cutaneous Lymphoma Foundation","keywords":"Medicine; Clinical trial; Targeted therapy; Combination therapy; Prioritization; Drug; Malignancy; Drug development; In vivo; Cancer; Pharmacology; Oncology; Internal medicine; Biology; Biotechnology","score_opus":0.1451068651535191,"score_gpt":0.4251670234765556,"score_spread":0.28006015832303655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101174158","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69706863,0.08698193,0.16237037,0.0072947866,0.005169644,0.0027995314,0.0015117578,0.0014384863,0.035364985],"genre_scores_gemma":[0.8497722,0.046232093,0.08648696,0.0010511338,0.00086892175,0.0009376671,0.0008055565,0.00018305011,0.013662396],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99900264,0.00032261483,0.00006591904,0.00014069489,0.00032689932,0.0001411657],"domain_scores_gemma":[0.99932206,0.00018673546,0.00013531375,0.00014792348,0.000106922926,0.000101019265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023707785,0.0008549555,0.00061759696,0.00093981845,0.00049191876,0.0011813855,0.00069796154,0.0009531838,0.005116869],"category_scores_gemma":[0.0011393538,0.000544774,0.00069481414,0.00042214236,0.0009654868,0.0015796451,0.00052304904,0.0041827504,0.0010691065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013614929,0.0020170351,0.000517634,0.0006765629,0.000096323354,0.00023876528,0.00014856891,0.0009278981,0.91466105,0.005378632,0.0022836167,0.0716924],"study_design_scores_gemma":[0.0009695277,0.02330708,0.002779829,0.00018132015,0.00034384837,0.0018364728,0.0001686845,0.0020190934,0.90496796,0.003000482,0.060371533,0.00005411922],"about_ca_topic_score_codex":0.00047828772,"about_ca_topic_score_gemma":0.0008932435,"teacher_disagreement_score":0.005116869,"about_ca_system_score_codex":0.00043399853,"about_ca_system_score_gemma":0.0009909015,"threshold_uncertainty_score":0.01711768},"labels":[],"label_agreement":null},{"id":"W3102155626","doi":"10.3389/fimmu.2020.599253","title":"Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Terry Fox Research Institute","keywords":"Central nervous system; Medicine; Neuroscience; Biology","score_opus":0.027567218939237494,"score_gpt":0.3396758244206966,"score_spread":0.31210860548145913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102155626","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032023023,0.9965969,0.00037111682,0.00031350588,0.0002263007,0.000014371583,0.000023647644,0.000014481745,0.002119442],"genre_scores_gemma":[0.0014779591,0.9967534,0.00046411206,0.00027348765,0.00013181445,0.000017745668,0.000035387224,0.0000022284887,0.00084392016],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990237,0.000019338528,0.000011687136,0.000016500282,0.000037384896,0.000012729385],"domain_scores_gemma":[0.99988854,0.000054356868,0.000016647222,0.0000031679406,0.000026327336,0.0000108509785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048528047,0.00064323674,0.00077942514,0.00159827,0.00016833383,0.0006603109,0.0005210765,0.0008575141,0.0031395243],"category_scores_gemma":[0.00036225872,0.00017017119,0.00044164155,0.0008672758,0.00032282036,0.00090457813,0.00047925249,0.0015475339,0.0016995401],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080343925,0.0001334133,0.00008453256,0.015162267,0.000074764175,0.0001782892,0.00004934683,0.00064816826,0.00767559,0.0075531797,0.01805889,0.9503012],"study_design_scores_gemma":[0.000043767483,0.00028284173,0.00054209057,0.002557605,0.000089502966,0.00079437764,0.00004364939,0.00015972329,0.0017637623,0.0022893157,0.99141663,0.000016831613],"about_ca_topic_score_codex":0.0005891361,"about_ca_topic_score_gemma":0.0012425404,"teacher_disagreement_score":0.0031395243,"about_ca_system_score_codex":0.00043145564,"about_ca_system_score_gemma":0.00073029037,"threshold_uncertainty_score":0.010502756},"labels":[],"label_agreement":null},{"id":"W3103755750","doi":"10.1101/109785","title":"A cell-topography based mechanism for ligand discrimination by the T-cell receptor","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of California, San Francisco; Medical Research Council; Royal Society; Directorate for Biological Sciences; University of Oxford; Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Major histocompatibility complex; Receptor; Cell biology; Biology; Phosphatase; T cell; Cell; Agonist; Phosphorylation; Antigen; Immunology; Immune system; Biochemistry","score_opus":0.023857386497256914,"score_gpt":0.2668557185427346,"score_spread":0.2429983320454777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103755750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89292216,0.00065084826,0.102895245,0.00037693672,0.000066134075,0.000035472825,0.00018176217,0.000278569,0.0025928714],"genre_scores_gemma":[0.996798,0.00012303764,0.0025392552,0.000020673844,0.0000047835615,0.000012290212,0.000028195695,0.000009389672,0.00046439495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999033,0.00001204515,0.000004288617,0.000023136294,0.00003623544,0.000020905289],"domain_scores_gemma":[0.99989283,0.00004296205,0.00002084129,0.000017902654,0.000012237855,0.000013125484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010786931,0.00028958352,0.00029118068,0.00011905775,0.0002014182,0.0003585431,0.0005253499,0.00047227603,0.0016944751],"category_scores_gemma":[0.00033756642,0.00015465582,0.00028513547,0.00010036359,0.0004803114,0.000508556,0.00023789077,0.0004389696,0.00036499609],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071024035,0.000051242925,0.00057565473,0.00007129739,0.00001111468,0.00017617956,0.000022332257,0.028765697,0.96041846,0.006772474,0.00016251364,0.0029021185],"study_design_scores_gemma":[0.000037836246,0.0002706691,0.002150398,0.0000053757967,0.00002252636,0.00033139042,0.000041151936,0.59591466,0.39478222,0.004992151,0.0014144692,0.000037129135],"about_ca_topic_score_codex":0.00037711122,"about_ca_topic_score_gemma":0.00025915727,"teacher_disagreement_score":0.0016944751,"about_ca_system_score_codex":0.0003937371,"about_ca_system_score_gemma":0.00014751458,"threshold_uncertainty_score":0.0056685805},"labels":[],"label_agreement":null},{"id":"W3103926827","doi":"10.1136/jitc-2020-sitc2020.0155","title":"155 iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytotoxic T cell; Cancer research; Immunotherapy; Adoptive cell transfer; NK-92; Cytotoxicity; Perforin; Biology; Immunology; Interleukin 21; Immune system; CD8; T cell; In vitro","score_opus":0.03077527250515736,"score_gpt":0.25573247412130745,"score_spread":0.2249572016161501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103926827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844677,0.0019517643,0.003820289,0.00020036305,0.0001574003,0.0001346957,0.0021110007,0.00024760957,0.006909154],"genre_scores_gemma":[0.9887078,0.0010757162,0.0028883773,0.0002525201,0.000035371388,0.00013965288,0.0031159644,0.000057732654,0.0037268926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981374,0.000020976027,0.00004092487,0.000028631346,0.00005451903,0.000041278272],"domain_scores_gemma":[0.99993217,0.000013463866,0.000015873635,0.000011072392,0.000012498476,0.000014977631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014087073,0.00038362772,0.0003214347,0.00023448387,0.00009909988,0.0003509896,0.00024168861,0.0003430211,0.002957201],"category_scores_gemma":[0.00013417543,0.00012386766,0.00031553104,0.0001808935,0.00016864696,0.00017745946,0.00022612434,0.0008301246,0.0013083172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002797088,0.00013448659,0.00020189233,0.00010392159,0.000010613293,0.00006497085,0.000026759562,0.00025249252,0.9936168,0.00017253292,0.0004679258,0.0046678907],"study_design_scores_gemma":[0.00005377324,0.0004408228,0.0021060777,0.000014334478,0.00002677599,0.00014995331,0.000028534821,0.0006693749,0.9913258,0.00007615848,0.0051021627,0.0000061626547],"about_ca_topic_score_codex":0.000320225,"about_ca_topic_score_gemma":0.00036377262,"teacher_disagreement_score":0.002957201,"about_ca_system_score_codex":0.00022359964,"about_ca_system_score_gemma":0.00023876173,"threshold_uncertainty_score":0.009892821},"labels":[],"label_agreement":null},{"id":"W3103985965","doi":"10.1172/jci.insight.141293","title":"A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells","year":2020,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital","funders":"Canadian Institutes of Health Research","keywords":"CD28; Ex vivo; Cytotoxic T cell; T cell; CD8; Chemistry; Population; Cell biology; Molecular biology; Biology; Immunology; In vitro; Immune system; Biochemistry; Medicine","score_opus":0.06198926715532612,"score_gpt":0.3009758882724902,"score_spread":0.2389866211171641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103985965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683387,0.0027546373,0.023557376,0.00021571315,0.00007069155,0.00015331258,0.0004237151,0.00029045017,0.00419551],"genre_scores_gemma":[0.9754853,0.0015761183,0.01853855,0.000075101816,0.000045637298,0.00009534607,0.0005184892,0.000049792125,0.0036156652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986815,0.00002834694,0.000009660706,0.00003195322,0.000038584203,0.000023313556],"domain_scores_gemma":[0.99991405,0.000023805593,0.000020356429,0.000008429177,0.000008043653,0.000025356974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012025808,0.00031336478,0.00017820792,0.00017576701,0.000098738994,0.0003131399,0.00012461806,0.00022562643,0.0019565774],"category_scores_gemma":[0.000095034804,0.000093987845,0.0001648369,0.00014136497,0.00015645695,0.0001439032,0.00015759082,0.0006363167,0.00055485027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026135864,0.000022709115,0.00003056516,0.00001647028,0.0000013113237,0.000011664462,0.0000054055986,0.000041722873,0.9989203,0.000057421006,0.000025693025,0.0008406871],"study_design_scores_gemma":[0.000016365095,0.00027431044,0.00027194302,0.000002794653,0.000008838482,0.00014210981,0.000005525693,0.00034639225,0.99631053,0.000017432054,0.002601991,0.0000017486257],"about_ca_topic_score_codex":0.00019818515,"about_ca_topic_score_gemma":0.0005661986,"teacher_disagreement_score":0.0019565774,"about_ca_system_score_codex":0.00017502815,"about_ca_system_score_gemma":0.0002843151,"threshold_uncertainty_score":0.0065454245},"labels":[],"label_agreement":null},{"id":"W3105835028","doi":"10.1158/2326-6066.cir-20-0138","title":"A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Academisch Medisch Centrum; Vrije Universiteit Amsterdam","keywords":"CD40; Cancer research; T cell; Chronic lymphocytic leukemia; B cell; Jurkat cells; Antibody; Cytotoxic T cell; Immunology; Biology; Leukemia; Medicine; In vitro; Immune system","score_opus":0.10189720866426633,"score_gpt":0.402953893935271,"score_spread":0.30105668527100465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105835028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672925,0.0006619387,0.0010383654,0.000033060398,0.0000143715315,0.00004110386,0.00012862677,0.000053079344,0.0013000828],"genre_scores_gemma":[0.99749017,0.00030318025,0.00070670433,0.000029451292,0.000009391015,0.000038709488,0.00033529132,0.000009575661,0.001077509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985576,0.000033768865,0.000012262519,0.000023671817,0.000026079035,0.000048381586],"domain_scores_gemma":[0.99995553,0.000012237748,0.00000563312,0.0000075668227,0.00000543096,0.000013601135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016382655,0.00041458104,0.00021202845,0.00020862452,0.00012268394,0.0002266631,0.00019021174,0.00023794205,0.0013214478],"category_scores_gemma":[0.00009213945,0.000107409054,0.00015737354,0.00010417796,0.00010664475,0.00010023849,0.00013640602,0.0005487258,0.00038132264],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023785087,0.00014792981,0.00010149959,0.000026227613,0.0000058068567,0.0000349704,0.000012792854,0.00014839468,0.9977488,0.00007246263,0.000055314245,0.0014079135],"study_design_scores_gemma":[0.000101680394,0.0014632945,0.0025833831,0.0000065605764,0.000019274994,0.00034920205,0.000013362863,0.002043179,0.9914055,0.000038258,0.0019734895,0.0000029497521],"about_ca_topic_score_codex":0.00058968074,"about_ca_topic_score_gemma":0.00055760867,"teacher_disagreement_score":0.0013214478,"about_ca_system_score_codex":0.00019450781,"about_ca_system_score_gemma":0.00015902772,"threshold_uncertainty_score":0.004420638},"labels":[],"label_agreement":null},{"id":"W3106718898","doi":"10.1101/2020.12.03.410043","title":"CRISPR-mediated deletion of the Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) improves human T cell function for adoptive T cell therapy","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Research UK; Wellcome Trust","keywords":"T cell; Adoptive cell transfer; T-cell receptor; Cancer research; Biology; PTPN22; Cancer immunotherapy; Protein tyrosine phosphatase; Immunotherapy; Immunology; Cell biology; Molecular biology; Immune system; Signal transduction; Biochemistry","score_opus":0.02312781428940109,"score_gpt":0.2578207005970101,"score_spread":0.23469288630760904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106718898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93833786,0.0023163618,0.05062452,0.00046460013,0.00029702406,0.00011244685,0.0016968851,0.00073705177,0.005413324],"genre_scores_gemma":[0.981065,0.0006963777,0.011044408,0.00010222749,0.000021472846,0.000052943353,0.000838207,0.00007940436,0.00609997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986804,0.000022752653,0.000011619544,0.00003633881,0.000038282073,0.000023047744],"domain_scores_gemma":[0.99995184,0.000010294306,0.000011589529,0.000009465785,0.000005102767,0.000011666133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016659654,0.00032886662,0.00021373018,0.0001391053,0.00010113023,0.00034652257,0.000118831595,0.0003112757,0.0024650102],"category_scores_gemma":[0.00011359732,0.0001029046,0.0001657054,0.000097349795,0.00018720834,0.000121012694,0.00019667728,0.00059314875,0.0007128511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005320658,0.000012321995,0.000111158326,0.000023515851,0.000004616291,0.00004744487,0.0000068068052,0.00016729049,0.9978339,0.00010087335,0.0001789612,0.0014598902],"study_design_scores_gemma":[0.000013668166,0.000094514544,0.00066064775,0.00000339876,0.000010697982,0.00024007843,0.0000075467087,0.0012018641,0.99185306,0.00004848702,0.0058633895,0.0000026832893],"about_ca_topic_score_codex":0.00041593524,"about_ca_topic_score_gemma":0.00041447332,"teacher_disagreement_score":0.0024650102,"about_ca_system_score_codex":0.00014491723,"about_ca_system_score_gemma":0.0001530855,"threshold_uncertainty_score":0.008246303},"labels":[],"label_agreement":null},{"id":"W3107015789","doi":"10.1016/j.cellimm.2020.104253","title":"Novel T regulatory cells come of age: The curious incident of a mouse in Tennessee, delayed thymectomy and chimeric receptors!","year":2020,"lang":"en","type":"article","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Heart, Lung, and Blood Institute","keywords":"Thymectomy; Biology; Receptor; Cell biology; Immunology; Neuroscience; Genetics; Myasthenia gravis","score_opus":0.0188192193285635,"score_gpt":0.2558864227575448,"score_spread":0.2370672034289813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107015789","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10899533,0.11879638,0.009553609,0.7248242,0.026598658,0.000102952756,0.0008219048,0.00068835,0.009618605],"genre_scores_gemma":[0.38263837,0.09218149,0.018064657,0.42404845,0.011548209,0.00020427127,0.00070936524,0.00047019217,0.070135],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99896145,0.00021762794,0.00008993983,0.00020023201,0.0003144656,0.00021625892],"domain_scores_gemma":[0.9982901,0.0005227419,0.0001814568,0.00013087653,0.00045305444,0.00042175004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006894204,0.00062701444,0.0005633324,0.00042978986,0.0012187556,0.001740267,0.0007915112,0.0035630083,0.002987576],"category_scores_gemma":[0.0033136287,0.00026180514,0.00049735,0.0002304296,0.0025511526,0.0020477304,0.000918713,0.0073529263,0.0005034495],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035073822,0.0005414049,0.017260648,0.0006448021,0.00025024664,0.007595648,0.0028157018,0.00095496315,0.18885587,0.04703465,0.4522191,0.2783196],"study_design_scores_gemma":[0.00024985123,0.0015152488,0.00814652,0.00047537603,0.00018797451,0.005030867,0.003107955,0.0005059693,0.02459484,0.010046527,0.9459872,0.00015156844],"about_ca_topic_score_codex":0.011064081,"about_ca_topic_score_gemma":0.025647061,"teacher_disagreement_score":0.011064081,"about_ca_system_score_codex":0.0018291075,"about_ca_system_score_gemma":0.002469149,"threshold_uncertainty_score":0.03646046},"labels":[],"label_agreement":null},{"id":"W3107336455","doi":"10.1101/2020.12.03.410316","title":"Augmented expansion of Treg cells from healthy and autoimmune subjects via adult progenitor cell co-culture","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"FOXP3; Cell therapy; Immunology; Progenitor cell; Adoptive cell transfer; Biology; Transplantation; Autoimmunity; Regulatory T cell; T cell; Immune system; Cancer research; Cell biology; Stem cell; Medicine; IL-2 receptor; Internal medicine","score_opus":0.01656281229336875,"score_gpt":0.2598523381040351,"score_spread":0.24328952581066632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107336455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985802,0.0012946799,0.008574598,0.000056607132,0.00006484459,0.0002596697,0.00079071586,0.0002284906,0.0029284125],"genre_scores_gemma":[0.98453957,0.0006923728,0.008227978,0.00010704098,0.000076560995,0.0003010763,0.0018696331,0.000048830396,0.0041369144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983335,0.000030233045,0.00001867333,0.00003669236,0.00005241632,0.000028486165],"domain_scores_gemma":[0.99988306,0.000025027295,0.000010744526,0.000025858511,0.000022190807,0.000033094584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026916256,0.00028977988,0.00029490987,0.0003980421,0.00013504362,0.00028398432,0.00020423839,0.00019545651,0.002801264],"category_scores_gemma":[0.00015817673,0.00007995904,0.000178798,0.00020615596,0.00011119208,0.0001033902,0.00035807802,0.0006125213,0.0008359832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003807255,0.00014166391,0.0009286117,0.000038021568,0.0000065043882,0.00015393157,0.000050465933,0.00011460057,0.99117273,0.000066731904,0.00015321553,0.0067928643],"study_design_scores_gemma":[0.00009460333,0.0032852124,0.011716026,0.000032121905,0.00007461278,0.0016157242,0.00005560499,0.0019145634,0.9718655,0.00009036053,0.009243093,0.000012494316],"about_ca_topic_score_codex":0.00016788294,"about_ca_topic_score_gemma":0.00023196358,"teacher_disagreement_score":0.002801264,"about_ca_system_score_codex":0.00005358803,"about_ca_system_score_gemma":0.0001037581,"threshold_uncertainty_score":0.009371161},"labels":[],"label_agreement":null},{"id":"W3107906372","doi":"10.1016/j.drudis.2020.11.028","title":"Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays","year":2020,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; BC Cancer Foundation","keywords":"Immunotherapy; Cancer immunotherapy; Immune system; Chimeric antigen receptor; Cancer; Cancer research; Tumor microenvironment; Immune checkpoint; Cancer cell; Immunology; Biology","score_opus":0.04302134812861547,"score_gpt":0.3330761081072176,"score_spread":0.29005475997860214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107906372","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003967646,0.995689,0.0017289009,0.00018325994,0.00020800857,0.000027581438,0.00007122867,0.000022173723,0.0016731493],"genre_scores_gemma":[0.0023580657,0.99449193,0.0015161354,0.00017136488,0.00007849601,0.00003496225,0.00015528327,0.0000050311824,0.0011887172],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997868,0.000038172657,0.000018282477,0.000033118962,0.000098115794,0.000025659336],"domain_scores_gemma":[0.9997528,0.00011601481,0.000040016825,0.0000135915325,0.000058764635,0.000018783774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007988471,0.001187095,0.0014796208,0.001959895,0.00016233795,0.001130116,0.0009422603,0.0010490273,0.0026467736],"category_scores_gemma":[0.00044383426,0.00035476917,0.0005762387,0.0015035414,0.0004921962,0.0011858478,0.00055587135,0.0019307019,0.0019466068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107951644,0.0002073072,0.0001600588,0.01821184,0.000103293656,0.0002856548,0.000052034058,0.0013756099,0.051193725,0.012309645,0.017241197,0.89875174],"study_design_scores_gemma":[0.000036292757,0.00027032223,0.0006942757,0.0021340114,0.00017111331,0.0012498084,0.0000562693,0.0004455343,0.017581442,0.003177376,0.97413427,0.000049219383],"about_ca_topic_score_codex":0.0009489698,"about_ca_topic_score_gemma":0.0020102006,"teacher_disagreement_score":0.0026467736,"about_ca_system_score_codex":0.0006401712,"about_ca_system_score_gemma":0.00072841544,"threshold_uncertainty_score":0.00885433},"labels":[],"label_agreement":null},{"id":"W3107960404","doi":"10.1097/cmr.0000000000000708","title":"Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)","year":2020,"lang":"en","type":"article","venue":"Melanoma Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Expanded access; Internal medicine; Melanoma; Adverse effect; Oncology; Gastroenterology; Immunotherapy; Cancer; Cancer research","score_opus":0.04357598447339473,"score_gpt":0.35743983192359097,"score_spread":0.31386384745019624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107960404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738437,0.0015552067,0.00012270972,0.0000603072,0.000008061945,0.00009566472,0.0002201167,0.000021379281,0.00053219724],"genre_scores_gemma":[0.99776244,0.0007000322,0.0004134458,0.00013709292,0.00004686534,0.00007751943,0.0005405505,0.0000045128772,0.00031743612],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995646,0.00021582293,0.00002650482,0.00006053074,0.00010067683,0.000031896576],"domain_scores_gemma":[0.99939036,0.00017396014,0.00016720538,0.000039938812,0.00007432207,0.00015417364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012284186,0.00026171256,0.0005768487,0.00025588344,0.0001933265,0.00033217616,0.00025329905,0.0002588708,0.00053995266],"category_scores_gemma":[0.00085570087,0.00015271809,0.00044520674,0.00030232128,0.00017197119,0.00019741734,0.00016380874,0.0005208637,0.00012289915],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17628177,0.012839524,0.32563767,0.00071869127,0.0025749994,0.00058585807,0.00031259473,0.004063521,0.05740731,0.0000854677,0.0038256121,0.4156669],"study_design_scores_gemma":[0.0360758,0.20775886,0.7370343,0.0000862277,0.0015793043,0.0010257885,0.000066041364,0.0034748425,0.006963687,0.000065970984,0.0058320947,0.000037045138],"about_ca_topic_score_codex":0.002167529,"about_ca_topic_score_gemma":0.005269801,"teacher_disagreement_score":0.002167529,"about_ca_system_score_codex":0.00065472967,"about_ca_system_score_gemma":0.00064165547,"threshold_uncertainty_score":0.0064966083},"labels":[],"label_agreement":null},{"id":"W3109522219","doi":"10.1016/j.jcyt.2020.11.005","title":"Cell and gene therapy: a snapshot of investor perspectives","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Commercialization; Investment (military); Business; Health care; Finance; Public relations; Marketing; Economic growth; Political science; Economics","score_opus":0.05545039414905898,"score_gpt":0.3086664867644414,"score_spread":0.2532160926153824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109522219","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021262125,0.3707858,0.0032749488,0.5565731,0.014681889,0.000020438321,0.00014156492,0.00006522001,0.052330814],"genre_scores_gemma":[0.0979398,0.56797487,0.005481787,0.2487445,0.03809621,0.00008832482,0.0001778587,0.0002487961,0.041247852],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99447745,0.0020369506,0.00022910994,0.0005386616,0.0017361549,0.0009816459],"domain_scores_gemma":[0.98824817,0.0064733676,0.0005543439,0.00041606472,0.002268585,0.0020395324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020116523,0.0012336829,0.0013351942,0.0020969023,0.002248828,0.019223327,0.0016055316,0.012865521,0.01600443],"category_scores_gemma":[0.014862225,0.00048093355,0.0007534985,0.001911461,0.0064461753,0.025188627,0.0057109627,0.01800745,0.0025762317],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030138023,0.00034015716,0.00075990875,0.0007623164,0.000042153122,0.00040204576,0.0012124821,0.00039548945,0.0014187978,0.6291205,0.23277749,0.13246723],"study_design_scores_gemma":[0.00006134958,0.00019359819,0.0004617025,0.0012846215,0.000021409174,0.00023895198,0.0015102879,0.00024453018,0.00040743838,0.09454677,0.9009871,0.000042221844],"about_ca_topic_score_codex":0.0031268515,"about_ca_topic_score_gemma":0.006142748,"teacher_disagreement_score":0.020116523,"about_ca_system_score_codex":0.0059911194,"about_ca_system_score_gemma":0.008521425,"threshold_uncertainty_score":0.106387615},"labels":[],"label_agreement":null},{"id":"W3109845612","doi":"10.1016/j.xpro.2020.100174","title":"Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma","year":2020,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; McMaster University","keywords":"Chimeric antigen receptor; Glioblastoma; Peripheral blood mononuclear cell; Medicine; Chemoradiotherapy; Cancer research; Antigen; Brain tumor; Immunotherapy; Immunology; Cancer; Pathology; Biology; Immune system; Internal medicine; In vitro","score_opus":0.1256574991849608,"score_gpt":0.38675527411642496,"score_spread":0.26109777493146413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109845612","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96130455,0.0033983327,0.016596986,0.000843274,0.0008193693,0.002430324,0.006058507,0.0009880031,0.0075605595],"genre_scores_gemma":[0.959995,0.004317234,0.014165334,0.000523307,0.000092516224,0.0031584655,0.00815868,0.00016416224,0.009425475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996499,0.00007193795,0.000036559857,0.00006398783,0.000088465546,0.00008917834],"domain_scores_gemma":[0.9997745,0.00003834982,0.000028583543,0.000033998545,0.000058176225,0.00006633753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010260693,0.00092319516,0.0007244159,0.00042917943,0.00025988845,0.00043822476,0.0006153701,0.0007399361,0.0025957082],"category_scores_gemma":[0.00027832986,0.00035479473,0.0005233984,0.00027075858,0.00028567994,0.00035267978,0.00022563008,0.0021753449,0.0008512569],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031122854,0.007124979,0.00057572534,0.000363892,0.00010233892,0.0002471389,0.00019639358,0.0026984618,0.9680131,0.00091293146,0.005853371,0.010799397],"study_design_scores_gemma":[0.0011523629,0.062399864,0.0026305711,0.000075447846,0.00025439134,0.0006383461,0.00013770476,0.006549849,0.90656585,0.0004577322,0.019100107,0.000037776652],"about_ca_topic_score_codex":0.002529862,"about_ca_topic_score_gemma":0.0037022666,"teacher_disagreement_score":0.0025957082,"about_ca_system_score_codex":0.00050820713,"about_ca_system_score_gemma":0.0009296205,"threshold_uncertainty_score":0.008683562},"labels":[],"label_agreement":null},{"id":"W3109958337","doi":"10.1016/j.drudis.2020.11.024","title":"Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions","year":2020,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fonds Wetenschappelijk Onderzoek; Canadian Armed Forces; Vlaamse regering; McMaster University","keywords":"Market access; Drug discovery; Computational biology; Business; Biology; Bioinformatics; Ecology","score_opus":0.08096664045937163,"score_gpt":0.3571380909215697,"score_spread":0.27617145046219804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109958337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000695726,0.98798823,0.00023090586,0.005413837,0.00023399117,0.000016792199,0.00011388972,0.0000145461645,0.0052920626],"genre_scores_gemma":[0.004138393,0.992935,0.00044564612,0.001177319,0.00009396929,0.000012807488,0.00011386051,0.0000043438567,0.0010787188],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99891543,0.00013646757,0.00009801682,0.00009812101,0.00054814114,0.0002038096],"domain_scores_gemma":[0.9972198,0.0010164895,0.00032130527,0.00003180589,0.0011697224,0.00024078175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002617879,0.00043875622,0.00082422997,0.002810375,0.00061586616,0.002847623,0.00091471605,0.0013400664,0.005419081],"category_scores_gemma":[0.0032797018,0.00021066723,0.0008786718,0.0040833955,0.00081046065,0.0019405918,0.00090893777,0.0021186026,0.00075159996],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007326486,0.000062708365,0.0011833943,0.016393853,0.0001292963,0.00024450148,0.0002628123,0.000624092,0.0011779071,0.018716129,0.047258716,0.91387326],"study_design_scores_gemma":[0.000017137283,0.00007569989,0.002829237,0.009627711,0.00017530881,0.0004740053,0.00046633085,0.00023654764,0.0005129138,0.0032592716,0.982294,0.00003190179],"about_ca_topic_score_codex":0.09107076,"about_ca_topic_score_gemma":0.17290315,"teacher_disagreement_score":0.9089292,"about_ca_system_score_codex":0.0066028917,"about_ca_system_score_gemma":0.02370006,"threshold_uncertainty_score":0.18108135},"labels":[],"label_agreement":null},{"id":"W3110516422","doi":"10.1158/2643-3249.lymphoma20-po-42","title":"Abstract PO-42: TBL1XR1 mutations drive extranodal lymphomagenesis by inducing a protumorigenic memory B-cell fate","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto","funders":"","keywords":"Germinal center; BCL6; Biology; Transcription factor; Cancer research; Phenotype; Cell fate determination; Lymphoma; Reprogramming; B cell; Immune system; Cell; Gene; Immunology; Genetics; Antibody","score_opus":0.02507749552767352,"score_gpt":0.2904823327413624,"score_spread":0.2654048372136889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110516422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98625594,0.0008482364,0.0037013316,0.00033961973,0.000120111305,0.000041311814,0.0009626464,0.00061369117,0.0071169804],"genre_scores_gemma":[0.97948486,0.00052563084,0.0017950577,0.00010704063,0.000020349806,0.000031175565,0.00074190716,0.00010818554,0.017185854],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998491,0.000021764761,0.00001638603,0.000038137703,0.000045189205,0.000029544457],"domain_scores_gemma":[0.99991465,0.000011586204,0.000024487183,0.00001304059,0.0000064891015,0.000029885045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009780863,0.00030640545,0.00017322804,0.00023977166,0.00017398222,0.00040475128,0.0002317454,0.0003271221,0.007924083],"category_scores_gemma":[0.00007302788,0.00016135337,0.00017442273,0.0001204045,0.0003017566,0.0001643261,0.0003059437,0.0006265189,0.0017590367],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054085333,0.000014898139,0.00019827884,0.00002142535,0.000002661754,0.00012986502,0.000012963938,0.00004298456,0.99812764,0.00018053115,0.00014443001,0.0010702995],"study_design_scores_gemma":[0.000030185756,0.0002295193,0.0050453763,0.000007377653,0.000011827836,0.0013097555,0.0000571523,0.00056664296,0.9848156,0.00011943265,0.0078016166,0.000005448164],"about_ca_topic_score_codex":0.0004890542,"about_ca_topic_score_gemma":0.0006829394,"teacher_disagreement_score":0.007924083,"about_ca_system_score_codex":0.00021953393,"about_ca_system_score_gemma":0.00016793705,"threshold_uncertainty_score":0.026508689},"labels":[],"label_agreement":null},{"id":"W3110898018","doi":"10.1111/tan.14168","title":"A one‐step assay for sorted <scp>CD3</scp><sup>+</sup> cell purity and chimerism after hematopoietic stem cell transplantation","year":2020,"lang":"en","type":"article","venue":"HLA","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Flow cytometry; Molecular biology; CD3; Biology; Haematopoiesis; Transplantation; Hematopoietic stem cell transplantation; Stem cell; Polymerase chain reaction; Immunology; Antigen; CD8; Medicine; Genetics; Gene","score_opus":0.025073789143125337,"score_gpt":0.26415380728179283,"score_spread":0.2390800181386675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110898018","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1686335,0.0023078334,0.8140769,0.00022841473,0.00036824617,0.0016351121,0.0028907103,0.003692007,0.0061673187],"genre_scores_gemma":[0.3347199,0.0027398707,0.61893904,0.000786741,0.00022144138,0.005903803,0.012085943,0.0017978839,0.022805426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9916579,0.0014484219,0.0007161,0.0020144847,0.0036517496,0.00051126827],"domain_scores_gemma":[0.99696654,0.0010561049,0.00039546398,0.00043599846,0.0009939882,0.00015189806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037065428,0.0019127704,0.0010222464,0.0016832142,0.00083122874,0.0011427233,0.0013278143,0.0011854351,0.004464555],"category_scores_gemma":[0.0033727796,0.00080790574,0.0011944193,0.0010911236,0.0011945133,0.00065225404,0.0011475874,0.0027725485,0.0033548386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103567654,0.00013096261,0.0014391711,0.00015012934,0.00003408534,0.00005237763,0.00016415838,0.00024678718,0.9860919,0.00044277558,0.00056006515,0.010583963],"study_design_scores_gemma":[0.000021683321,0.000281879,0.004378487,0.000046708887,0.000083505685,0.00022018996,0.000051298066,0.0026576475,0.98640114,0.0002808666,0.0055361083,0.00004041974],"about_ca_topic_score_codex":0.0006795938,"about_ca_topic_score_gemma":0.0016798002,"teacher_disagreement_score":0.004464555,"about_ca_system_score_codex":0.000596043,"about_ca_system_score_gemma":0.0011188841,"threshold_uncertainty_score":0.019602299},"labels":[],"label_agreement":null},{"id":"W3111908765","doi":"10.1038/s41418-020-00666-y","title":"From the T-cell receptor to cancer therapy: an interview with Tak W. Mak","year":2020,"lang":"en","type":"article","venue":"Cell Death and Differentiation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Stand Up To Cancer; Cancer Research Institute","keywords":"Cancer; Receptor; Cancer research; Medicine; Biology; Internal medicine","score_opus":0.05989008136160202,"score_gpt":0.3039498188343187,"score_spread":0.2440597374727167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111908765","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029107154,0.07983401,0.00040464656,0.89016914,0.02801243,0.00001303721,0.000029302744,0.000021266156,0.0012250259],"genre_scores_gemma":[0.010763886,0.10303735,0.0016794091,0.80726236,0.060207833,0.00011672988,0.000054175518,0.000116393625,0.016761933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99483204,0.0024859915,0.0003096291,0.0005399692,0.0014404247,0.00039189824],"domain_scores_gemma":[0.98756427,0.007468811,0.00033251964,0.00018285397,0.0015314748,0.0029199494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014141002,0.0013908109,0.0024046574,0.001270896,0.0036924598,0.005224835,0.001722623,0.009921573,0.0027303747],"category_scores_gemma":[0.016442886,0.0010556987,0.0011192609,0.0012212122,0.0070510576,0.0121941725,0.0038168794,0.047004595,0.0014779718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000984262,0.000050798175,0.000153314,0.00017977154,0.000016405837,0.00026981888,0.0019217243,0.00010525325,0.00034383143,0.005857715,0.9737902,0.017212678],"study_design_scores_gemma":[0.000045775723,0.0001218082,0.00029496924,0.00053305604,0.0000137610605,0.0012240018,0.0028482082,0.00017095655,0.00022826564,0.0070541846,0.9873904,0.000074559284],"about_ca_topic_score_codex":0.0039164936,"about_ca_topic_score_gemma":0.0063834107,"teacher_disagreement_score":0.014141002,"about_ca_system_score_codex":0.005151968,"about_ca_system_score_gemma":0.005319787,"threshold_uncertainty_score":0.07478571},"labels":[],"label_agreement":null},{"id":"W3112058853","doi":"10.1016/j.jval.2020.08.393","title":"PCN256 Health Technology Assessment for Chimeric Antigen Receptor (CAR) T-CELL Therapies for Cancer in Europe, US, and Canada","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Nice; Medicine; Clinical trial; Lymphoma; Cancer; Oncology; Immunotherapy; Intensive care medicine; Internal medicine","score_opus":0.06356303064571747,"score_gpt":0.37776048199218754,"score_spread":0.31419745134647004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112058853","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17787927,0.063372016,0.011744845,0.08772066,0.0039458266,0.005471693,0.15004249,0.0008643071,0.49895892],"genre_scores_gemma":[0.6488966,0.060508456,0.026712958,0.019356357,0.0008254519,0.0024947464,0.07254766,0.00037766955,0.16828015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98844856,0.0013354506,0.0003311789,0.0004173315,0.007976244,0.0014911012],"domain_scores_gemma":[0.9832903,0.0012599125,0.0007285527,0.00015905368,0.011935064,0.0026270968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011325858,0.0007116327,0.0007403684,0.0036751148,0.0016796867,0.0043649506,0.0015757775,0.0017404841,0.0058679027],"category_scores_gemma":[0.013179651,0.00031699036,0.001653355,0.0037553012,0.00078725367,0.00068271987,0.00113155,0.0014899501,0.0010327538],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059750434,0.00073153776,0.10060061,0.0026119405,0.00088899815,0.0005550389,0.0004085343,0.01332241,0.0075947065,0.03608696,0.3905024,0.44072175],"study_design_scores_gemma":[0.0006064654,0.0018132953,0.19617978,0.0018467904,0.00076654536,0.0002414629,0.00077797397,0.0055903336,0.006505006,0.0022230407,0.78332055,0.00012880993],"about_ca_topic_score_codex":0.9414508,"about_ca_topic_score_gemma":0.9376905,"teacher_disagreement_score":0.06188728,"about_ca_system_score_codex":0.06188728,"about_ca_system_score_gemma":0.23955463,"threshold_uncertainty_score":0.44902575},"labels":[],"label_agreement":null},{"id":"W3112202821","doi":"10.1016/j.ygyno.2020.12.005","title":"Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of Victoria; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Medicine; Ovarian cancer; Antigen; Cancer research; Immunology; Cancer; Internal medicine; T cell; Immune system","score_opus":0.03555750875034905,"score_gpt":0.3374122596685919,"score_spread":0.3018547509182429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112202821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981254,0.0006380232,0.00012455937,0.000016342483,0.0000051290444,0.0000053789,0.00007233502,0.0000064502306,0.0010063404],"genre_scores_gemma":[0.998938,0.00015947186,0.00010266392,0.000008926195,0.0000036182078,0.000006639182,0.000115520874,0.0000032814844,0.0006620079],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997162,0.00003661679,0.000020762369,0.000032733176,0.00006116949,0.00013252754],"domain_scores_gemma":[0.99963844,0.00009775839,0.00006228704,0.000029043977,0.000087861095,0.00008465716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000194133,0.00009174579,0.00023405637,0.00070048845,0.00022255848,0.0004301122,0.00013301022,0.00025142974,0.0020652667],"category_scores_gemma":[0.0006474643,0.000111705805,0.00017864004,0.0005042528,0.00025761436,0.00020292988,0.00026717797,0.00022392969,0.00029484072],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028675776,0.00011627431,0.09475354,0.00012085613,0.00006308529,0.001408116,0.00043124793,0.00029602286,0.88936293,0.00040264538,0.00027383227,0.009903985],"study_design_scores_gemma":[0.00005325178,0.0011787837,0.7559957,0.000015561769,0.00020214786,0.006535911,0.0016058969,0.002661914,0.22510546,0.0001855367,0.0064423517,0.00001755416],"about_ca_topic_score_codex":0.0023204852,"about_ca_topic_score_gemma":0.0022102126,"teacher_disagreement_score":0.0023204852,"about_ca_system_score_codex":0.00032729525,"about_ca_system_score_gemma":0.00022545074,"threshold_uncertainty_score":0.006909013},"labels":[],"label_agreement":null},{"id":"W3112510814","doi":"10.1016/j.jval.2020.08.259","title":"PCN122 Cost-Effectiveness of Brentuximab Vedotin for the Frontline Treatment of Peripheral T-Cell Lymphomas in Canada","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Brentuximab vedotin; Medicine; CHOP; Vincristine; Anaplastic large-cell lymphoma; Internal medicine; Oncology; Population; Prednisone; Lymphoma; CD30; Cyclophosphamide; Chemotherapy; Environmental health","score_opus":0.09055864429809313,"score_gpt":0.34746410205941075,"score_spread":0.2569054577613176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112510814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94067484,0.018830417,0.00043405106,0.00844406,0.00022178232,0.00026847745,0.010255008,0.000086910695,0.02078451],"genre_scores_gemma":[0.99175406,0.0030068785,0.0003204689,0.0005022912,0.000042963442,0.000025085319,0.0019067669,0.00001372173,0.0024277682],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9992587,0.0001289211,0.000035755744,0.00006707802,0.00025651083,0.0002530933],"domain_scores_gemma":[0.9983504,0.00020410908,0.0001902796,0.000022021213,0.000605718,0.0006274295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005076668,0.00028347634,0.00056496036,0.00055890036,0.0005253209,0.0013680141,0.0007779044,0.00043294195,0.004476994],"category_scores_gemma":[0.00258237,0.0001633653,0.00078450073,0.0010476685,0.0003576603,0.00029634338,0.0003211618,0.0008346201,0.00020061032],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055962782,0.0018722499,0.26808152,0.0018554357,0.0023796894,0.0012851198,0.0003981968,0.04728764,0.005541482,0.0070214164,0.07473371,0.53358084],"study_design_scores_gemma":[0.007078694,0.0062053176,0.88996375,0.00078498013,0.0036438133,0.0010840488,0.0013399229,0.039257705,0.0025484683,0.0009536494,0.046977345,0.00016234613],"about_ca_topic_score_codex":0.96354616,"about_ca_topic_score_gemma":0.9779733,"teacher_disagreement_score":0.054118533,"about_ca_system_score_codex":0.054118533,"about_ca_system_score_gemma":0.03936168,"threshold_uncertainty_score":0.39265925},"labels":[],"label_agreement":null},{"id":"W3112725336","doi":"10.2196/17005","title":"Developing a Blockchain-Based Supply Chain System for Advanced Therapies: Protocol for a Feasibility Study","year":2020,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Supply chain; Risk analysis (engineering); Process management; Blockchain; Computer science; Business; Computer security","score_opus":0.42012488071286963,"score_gpt":0.5784966818765379,"score_spread":0.15837180116366828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112725336","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013081556,0.0009261751,0.08808007,0.00375553,0.0010387299,0.8482191,0.0055867117,0.000581512,0.038730513],"genre_scores_gemma":[0.028195618,0.0010129198,0.084127106,0.0016160207,0.00013142222,0.87594944,0.0019394552,0.00006311513,0.006964983],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96966875,0.019804984,0.002969568,0.0012444434,0.004423373,0.0018888173],"domain_scores_gemma":[0.9593899,0.0136260325,0.0034493003,0.00638914,0.014828989,0.0023165878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04669699,0.0010838081,0.000891593,0.001633502,0.0035547684,0.0034154626,0.0021203735,0.0038179876,0.0776246],"category_scores_gemma":[0.050441287,0.00071434793,0.0015868254,0.0015118683,0.0031206668,0.002886257,0.0037938391,0.003414841,0.01834843],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02885548,0.009985134,0.005021729,0.03747889,0.00054959074,0.004154664,0.008005674,0.013787799,0.034731213,0.17818983,0.19513561,0.48410442],"study_design_scores_gemma":[0.017100418,0.019261247,0.0063114376,0.014492042,0.00062173983,0.0015031735,0.0047014398,0.007317563,0.025946379,0.03288417,0.8694863,0.0003742405],"about_ca_topic_score_codex":0.0024480915,"about_ca_topic_score_gemma":0.003103185,"teacher_disagreement_score":0.0776246,"about_ca_system_score_codex":0.004666688,"about_ca_system_score_gemma":0.018725587,"threshold_uncertainty_score":0.2596801},"labels":[],"label_agreement":null},{"id":"W3112738960","doi":"10.1177/1078155220979047","title":"Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Blinatumomab; Medicine; Food and drug administration; Toxicity; Pharmacy; Minimal residual disease; Pharmacology; Monoclonal antibody; CD19; Oncology; Intensive care medicine; Immunology; Antibody; Internal medicine; Family medicine; Leukemia","score_opus":0.23883833877160415,"score_gpt":0.4993435177847658,"score_spread":0.26050517901316167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112738960","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13678235,0.61649436,0.037707154,0.17216827,0.0021621448,0.0003659258,0.00025450162,0.0005982084,0.033467073],"genre_scores_gemma":[0.58673275,0.33234704,0.039043754,0.03136687,0.003734443,0.00034461048,0.00019636417,0.00027360895,0.0059606554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852705,0.00066383975,0.00018622639,0.00011108893,0.00040400287,0.00010786996],"domain_scores_gemma":[0.99737775,0.0010835552,0.00080447877,0.00012184747,0.00034289615,0.00026951905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026579797,0.00023986357,0.00074468367,0.0003492739,0.0006710632,0.0016184134,0.0005199282,0.0011168491,0.0018292965],"category_scores_gemma":[0.005190326,0.00017891586,0.00051262596,0.0003864587,0.0008269858,0.0017628293,0.0010884524,0.0032136007,0.0006554405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045579876,0.00031265465,0.013882504,0.0023320357,0.000090091184,0.0041355663,0.0011729756,0.0006681107,0.008593442,0.0060426965,0.026131887,0.9361822],"study_design_scores_gemma":[0.0002499792,0.0039605186,0.02666714,0.0056390185,0.00031321964,0.047470465,0.0032711804,0.0018756177,0.02673896,0.01298406,0.87074405,0.00008579042],"about_ca_topic_score_codex":0.0009491167,"about_ca_topic_score_gemma":0.0023605174,"teacher_disagreement_score":0.0026579797,"about_ca_system_score_codex":0.0009139956,"about_ca_system_score_gemma":0.0018063963,"threshold_uncertainty_score":0.014056921},"labels":[],"label_agreement":null},{"id":"W3113017727","doi":"10.1002/anie.202005934","title":"Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy","year":2020,"lang":"en","type":"article","venue":"Angewandte Chemie International Edition","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institutes of Health; Danmarks Grundforskningsfond; National Research Foundation","keywords":"Glycan; CD22; Selectin; Lymphoma; B-cell lymphoma; Chemistry; Cancer research; Virology; Immunology; Biology; Biochemistry; Glycoprotein; CD20; Cell adhesion molecule","score_opus":0.020694405815921222,"score_gpt":0.2679587866707847,"score_spread":0.2472643808548635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113017727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96296924,0.009049744,0.019967908,0.0003526132,0.000099041885,0.00010804466,0.00012821691,0.0001784295,0.007146818],"genre_scores_gemma":[0.98946035,0.0032520748,0.0043610195,0.0000772389,0.0000130037215,0.00003744666,0.00007018545,0.000010648407,0.0027179343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999573,0.000008813887,0.0000021196827,0.000005486447,0.000013681479,0.00001255294],"domain_scores_gemma":[0.99998677,0.0000013533416,0.0000046110367,0.0000017954015,0.0000019046192,0.0000035143305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008109205,0.00023199013,0.00011049754,0.000114222,0.000073716925,0.00020000985,0.00011037022,0.00019288588,0.00064296887],"category_scores_gemma":[0.000054414075,0.00006932079,0.00012822467,0.000103924554,0.00011256583,0.00015386344,0.00019472287,0.00033145113,0.00015845979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051772615,0.000027909791,0.00008647663,0.00003653151,0.0000062225477,0.00005577444,0.0000149595235,0.00023037948,0.99271613,0.0005138341,0.00014947494,0.0061105355],"study_design_scores_gemma":[0.000021559092,0.0002771847,0.0005368438,0.0000058318487,0.000016255553,0.00030432682,0.000012206447,0.0014060942,0.9888427,0.00009489838,0.008477222,0.000004823719],"about_ca_topic_score_codex":0.0004128103,"about_ca_topic_score_gemma":0.00051399006,"teacher_disagreement_score":0.00064296887,"about_ca_system_score_codex":0.0002199171,"about_ca_system_score_gemma":0.0001349036,"threshold_uncertainty_score":0.0021508932},"labels":[],"label_agreement":null},{"id":"W3113178349","doi":"10.1093/neuonc/noaa215.463","title":"IMMU-33. MULTI-ANTIGEN RECOGNITION CIRCUITS OVERCOME CHALLENGES OF SPECIFICITY, HETEROGENEITY, AND DURABILITY IN T-CELL THERAPY FOR GLIOBLASTOMA","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Antigen; Epidermal growth factor receptor; Cancer research; Glioma; Tumor antigen; Brain tumor; Immunotherapy; Receptor; Priming (agriculture); Biology; Immunology; Medicine; Immune system; Pathology; Internal medicine","score_opus":0.12878803851665777,"score_gpt":0.35772822192127884,"score_spread":0.22894018340462108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113178349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750543,0.0030057062,0.017974429,0.00019438333,0.000054406224,0.00015580338,0.00013990254,0.00021230827,0.003208694],"genre_scores_gemma":[0.99204016,0.000593755,0.0051337997,0.00006904643,0.000010346574,0.000055142616,0.00009275888,0.0000135726905,0.0019915234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990594,0.000012531315,0.0000045818915,0.000018974939,0.000024269224,0.000033665674],"domain_scores_gemma":[0.9999728,0.0000032667515,0.000008419645,0.0000029749674,0.0000058939477,0.000006627009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011144109,0.00028515828,0.00019906562,0.00012952444,0.000092116614,0.00029317543,0.00021405137,0.00022449705,0.00097116426],"category_scores_gemma":[0.000053701548,0.00008413625,0.00013747768,0.000075713404,0.00012418603,0.00018593,0.00018613417,0.00040106673,0.00027462823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010322651,0.00007103524,0.00012353454,0.000060168957,0.0000061412848,0.000041446146,0.000017571809,0.0007004527,0.98918355,0.00070623093,0.00014902289,0.008837739],"study_design_scores_gemma":[0.00003730436,0.0011124212,0.00066791347,0.0000060184307,0.000030875923,0.00021951056,0.000012586734,0.005969495,0.98553574,0.00012564735,0.006277187,0.0000052098044],"about_ca_topic_score_codex":0.00059924764,"about_ca_topic_score_gemma":0.0009613444,"teacher_disagreement_score":0.00097116426,"about_ca_system_score_codex":0.00045102657,"about_ca_system_score_gemma":0.00024105461,"threshold_uncertainty_score":0.0032724738},"labels":[],"label_agreement":null},{"id":"W3114165421","doi":"10.14740/gr1340","title":"Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"Gastroenterology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Immunotherapy; Intensive care medicine; Cancer; Oncology; Diarrhea; Radiation therapy; Cancer immunotherapy; Gastrointestinal cancer; Internal medicine; Colorectal cancer","score_opus":0.09862064302158133,"score_gpt":0.43164132366320884,"score_spread":0.3330206806416275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114165421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00060252444,0.99819607,0.00007467939,0.0001664284,0.000054102966,0.00013840613,0.00043728846,0.000006110336,0.00032446306],"genre_scores_gemma":[0.0061501195,0.99252045,0.00026941547,0.0004333096,0.00006188258,0.00020082317,0.00022257883,0.000003434174,0.00013803848],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972554,0.00069814274,0.0011492434,0.00019130681,0.0006132993,0.000092623624],"domain_scores_gemma":[0.98849875,0.007763817,0.0025096722,0.00013050919,0.0009740521,0.00012311805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028586902,0.0010048504,0.0047095655,0.0061525926,0.00045669774,0.0014783505,0.0010104178,0.0012370828,0.0059505105],"category_scores_gemma":[0.013102008,0.0004697611,0.0051473556,0.0078583835,0.00052768557,0.0012744854,0.0009862164,0.00077639916,0.00035605687],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020821588,0.000014429454,0.0006262757,0.9475319,0.0042966506,0.0001183885,0.00008571329,0.00007251645,0.00014729824,0.0001359751,0.0026717442,0.044090852],"study_design_scores_gemma":[0.00031739633,0.00034107428,0.006017139,0.87582856,0.06701794,0.00095764315,0.00019872517,0.000090753376,0.00028100295,0.0003826229,0.048527695,0.000039494564],"about_ca_topic_score_codex":0.0044761077,"about_ca_topic_score_gemma":0.014603903,"teacher_disagreement_score":0.0061525926,"about_ca_system_score_codex":0.0019365455,"about_ca_system_score_gemma":0.0052266396,"threshold_uncertainty_score":0.019906461},"labels":[],"label_agreement":null},{"id":"W3115448914","doi":"10.14740/jocmr3964","title":"Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of West Attica","keywords":"Medicine; License; Authorization; European union; Product (mathematics); Clinical trial; Regenerative medicine; Heart Rhythm; Risk analysis (engineering); Health care; Business; Computer security; Law; Pathology","score_opus":0.7289437483623789,"score_gpt":0.6436852727129203,"score_spread":0.08525847564945854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115448914","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013808688,0.91216743,0.0031316096,0.06365061,0.0025945322,0.00003700019,0.00010671152,0.0000442516,0.016887017],"genre_scores_gemma":[0.023019703,0.937579,0.0059624272,0.021835914,0.0056940806,0.000103710954,0.0001596505,0.000038201295,0.0056073503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99542725,0.0019096403,0.00034333896,0.00047714743,0.0014765495,0.00036611737],"domain_scores_gemma":[0.988076,0.00871254,0.0005852065,0.00039374654,0.0017259,0.0005066569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010086911,0.0007936247,0.0017218442,0.0021626924,0.0011226786,0.006859898,0.0018154071,0.006490719,0.013708407],"category_scores_gemma":[0.007154611,0.00038908256,0.0013494266,0.002174127,0.0058213477,0.010121909,0.0035816245,0.008114256,0.0033566202],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025952808,0.0002680049,0.00053426897,0.012751105,0.00008722828,0.001060793,0.0010099324,0.0009873129,0.0036415083,0.36319613,0.06899714,0.54720706],"study_design_scores_gemma":[0.000025242745,0.00022454566,0.0004538768,0.0041006193,0.00003559363,0.0010207837,0.0006945235,0.00027083667,0.00092295086,0.07891547,0.91329986,0.000035674922],"about_ca_topic_score_codex":0.0010506805,"about_ca_topic_score_gemma":0.0017759275,"teacher_disagreement_score":0.013708407,"about_ca_system_score_codex":0.0027652886,"about_ca_system_score_gemma":0.0051446874,"threshold_uncertainty_score":0.053345323},"labels":[],"label_agreement":null},{"id":"W3115517794","doi":"10.7554/elife.57063.sa2","title":"Author response: Functionally specialized human CD4+ T-cell subsets express physicochemically distinct TCRs","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Biology; Cell biology; Evolutionary biology; Computational biology","score_opus":0.0847407228311366,"score_gpt":0.3872247588021638,"score_spread":0.3024840359710272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115517794","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039261794,0.0025644104,0.0014058459,0.74132746,0.21822704,0.00019846081,0.0009377335,0.0005250941,0.030887712],"genre_scores_gemma":[0.039055824,0.003681001,0.0017559808,0.3297896,0.084328555,0.00020841077,0.0013470488,0.00043196298,0.5394016],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955928,0.0013245881,0.00022106794,0.00045038803,0.0018509907,0.0005601146],"domain_scores_gemma":[0.9787523,0.007038039,0.0009059897,0.0009277281,0.009354704,0.0030211972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046574925,0.0005833363,0.0005936456,0.00078216166,0.0010225046,0.002867265,0.0007537747,0.006994996,0.13545084],"category_scores_gemma":[0.027205717,0.00026621606,0.0005220452,0.00032200737,0.0010859852,0.0009443784,0.0013708775,0.0041522295,0.044824705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018340297,0.000024157935,0.00030018206,0.00013525906,0.000015728236,0.00016398421,0.000047896665,0.0000513384,0.00091487914,0.0007675253,0.9825379,0.014857739],"study_design_scores_gemma":[0.00010303467,0.00009481268,0.0007822998,0.00007386392,0.000015728921,0.00023650593,0.0002763798,0.00014135496,0.0013577191,0.0016887147,0.9952123,0.00001725482],"about_ca_topic_score_codex":0.0008431997,"about_ca_topic_score_gemma":0.0020776629,"teacher_disagreement_score":0.13545084,"about_ca_system_score_codex":0.0011882694,"about_ca_system_score_gemma":0.0027470877,"threshold_uncertainty_score":0.45312822},"labels":[],"label_agreement":null},{"id":"W3116281132","doi":"10.20944/preprints202012.0795.v1","title":"Advances in Cellular Immunotherapy: Understanding and Preventing T-cell Dysfunction","year":2020,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé","keywords":"Immune system; Immunotherapy; Immune Dysfunction; Adoptive cell transfer; Cell therapy; Cell; Immunology; T cell; Biology; Cancer research; Cell biology; Biochemistry","score_opus":0.16282657015144283,"score_gpt":0.3709396698169554,"score_spread":0.20811309966551259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116281132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013841299,0.88985074,0.06722384,0.009748499,0.002449402,0.00011168786,0.0002410358,0.00037387083,0.016159672],"genre_scores_gemma":[0.1179999,0.8337853,0.03209249,0.0040779454,0.0026489578,0.00018220348,0.00036954082,0.0001359501,0.008707759],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9994735,0.00013540461,0.00003224735,0.00008430138,0.00020873886,0.00006571217],"domain_scores_gemma":[0.99971074,0.00011601424,0.000040604766,0.00003468919,0.000062837615,0.000035069388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011750304,0.00076927245,0.0010601206,0.0008067026,0.00034252834,0.0019126276,0.00063341664,0.0015220686,0.0026285844],"category_scores_gemma":[0.00075402437,0.00027898583,0.0004980851,0.00061180396,0.0011508628,0.0018836941,0.0010674396,0.0030596328,0.0015617954],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023400123,0.00022245597,0.0010039182,0.0076956307,0.000120448465,0.0006620372,0.00054417923,0.0035134917,0.20546754,0.091331415,0.017959107,0.67124575],"study_design_scores_gemma":[0.000055702752,0.0005708408,0.0014809328,0.0011537229,0.00014440026,0.0026342121,0.00020344484,0.0030874596,0.13779841,0.06707885,0.78573644,0.000055562745],"about_ca_topic_score_codex":0.0002474274,"about_ca_topic_score_gemma":0.00024835984,"teacher_disagreement_score":0.0026285844,"about_ca_system_score_codex":0.0007004814,"about_ca_system_score_gemma":0.0010535221,"threshold_uncertainty_score":0.008793533},"labels":[],"label_agreement":null},{"id":"W3117204159","doi":"10.1002/cyto.b.21985","title":"Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses","year":2020,"lang":"en","type":"review","venue":"Cytometry Part B Clinical Cytometry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"Genentech; Navigate BioPharma; Dana-Farber Cancer Institute; American Association of Pharmaceutical Scientists","keywords":"Flow cytometry; Chimeric antigen receptor; Computational biology; Immunology; Medicine; Computer science; Biology; Immunotherapy; Immune system","score_opus":0.6283747946379605,"score_gpt":0.680735279101053,"score_spread":0.052360484463092494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117204159","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004388763,0.96934086,0.015115078,0.0048228772,0.0015544225,0.00025850438,0.0001740464,0.00013827207,0.00815715],"genre_scores_gemma":[0.00278079,0.964618,0.027567312,0.0014540313,0.0005153794,0.00035137814,0.0003118722,0.000040413932,0.0023607584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956483,0.0012385247,0.00067292864,0.0004740825,0.0017218644,0.00024423678],"domain_scores_gemma":[0.99271786,0.0029221245,0.0007459142,0.0005145814,0.00286321,0.00023624297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012553246,0.0016672163,0.0015886432,0.0054472177,0.00057668047,0.002735819,0.0032686265,0.003309447,0.004409274],"category_scores_gemma":[0.009445141,0.0008222371,0.001422731,0.0029915173,0.001805017,0.003487449,0.0016615703,0.0047593312,0.005736414],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069581714,0.00019356533,0.00021555052,0.01787305,0.000077826226,0.00026055213,0.00019565344,0.0008438488,0.005522913,0.02225995,0.029338503,0.92314893],"study_design_scores_gemma":[0.000025831154,0.00012614296,0.0004331639,0.008898173,0.00009661888,0.00062967086,0.00010708676,0.00023525378,0.0050355513,0.00554706,0.97881705,0.00004840308],"about_ca_topic_score_codex":0.0021990852,"about_ca_topic_score_gemma":0.002269323,"teacher_disagreement_score":0.012553246,"about_ca_system_score_codex":0.0022392343,"about_ca_system_score_gemma":0.0069813137,"threshold_uncertainty_score":0.066388726},"labels":[],"label_agreement":null},{"id":"W3118887409","doi":"10.1016/j.xpro.2020.100264","title":"An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells","year":2021,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Taiwan University; Toronto General Hospital Research Institute, University Health Network; National Institutes of Health; National Cancer Institute; National Taiwan University Hospital","keywords":"Induced pluripotent stem cell; Cytotoxic T cell; Virology; Immunotherapy; CD8; Antigen; Hepatitis B virus; Cancer immunotherapy; Adoptive cell transfer; Immunology; Biology; Cancer research; T cell; Medicine; Virus; Immune system; Embryonic stem cell; In vitro","score_opus":0.12216559699626964,"score_gpt":0.3892626040598666,"score_spread":0.26709700706359696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118887409","genre_codex":"methods","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.080634765,0.0052628214,0.83029866,0.0005218607,0.0011090592,0.017281488,0.027318245,0.005140636,0.032432333],"genre_scores_gemma":[0.18706995,0.007824656,0.6808408,0.00071801705,0.00015008042,0.03497112,0.044360258,0.0013583635,0.042706687],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99876606,0.00023163742,0.00024034348,0.00023309821,0.0004068113,0.000122009886],"domain_scores_gemma":[0.9996697,0.00007534022,0.000035090226,0.00011201513,0.00007653592,0.000031409352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011634135,0.0012627472,0.0006597812,0.0012709856,0.0008012963,0.00045150728,0.0009133883,0.00086327584,0.010618683],"category_scores_gemma":[0.0005572705,0.00063973566,0.0006493992,0.0012068436,0.000344748,0.00032583476,0.0005920914,0.0018526643,0.008480867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000113648435,0.00011780716,0.00013872645,0.0004880329,0.000018736648,0.00029686195,0.00013025074,0.0007949834,0.9722695,0.0014296878,0.0023253944,0.021876322],"study_design_scores_gemma":[0.000088048335,0.0005189863,0.001739416,0.00009936143,0.000108510954,0.0009711914,0.000044709406,0.002405594,0.8520488,0.00094863,0.14095218,0.000074569885],"about_ca_topic_score_codex":0.0004906071,"about_ca_topic_score_gemma":0.001713621,"teacher_disagreement_score":0.010618683,"about_ca_system_score_codex":0.0003156225,"about_ca_system_score_gemma":0.0008163541,"threshold_uncertainty_score":0.035523057},"labels":[],"label_agreement":null},{"id":"W3119440760","doi":"10.1097/mph.0000000000002051","title":"Precursor B-Cell Acute Lymphoblastic Leukemia With MYC and BCL2 Rearrangements Presenting as Extensive Extranodal Disease in an Adolescent","year":2021,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Immunophenotyping; Pathology; Medicine; Gene rearrangement; Infiltration (HVAC); Fluorescence in situ hybridization; Precursor cell; Disease; B cell; Lymphoblastic Leukemia; Cancer research; Leukemia; Gene; Cell; Biology; Immunology; Flow cytometry; Antibody","score_opus":0.021604649807720654,"score_gpt":0.33180630222145324,"score_spread":0.3102016524137326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119440760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778,0.00044994545,0.00032128228,0.0001290365,0.000014409023,0.00002397912,0.00009066669,0.000018352059,0.0011723177],"genre_scores_gemma":[0.9989121,0.0004459678,0.0002407831,0.000055420107,0.0000219082,0.000006548278,0.000076513155,0.000007163176,0.00023347806],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99983335,0.000024708788,0.000018147708,0.00003593147,0.000033161974,0.00005479198],"domain_scores_gemma":[0.99960893,0.0000932818,0.00008673734,0.000017193324,0.000029470199,0.00016447694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013773696,0.0006036153,0.0005194472,0.0009757464,0.0006798895,0.000742215,0.0003169487,0.0009419588,0.0014645228],"category_scores_gemma":[0.00088060123,0.0005128503,0.00020894603,0.00055105606,0.0004859334,0.0006326284,0.0005095893,0.000677837,0.00043513067],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018484757,0.00018380654,0.24876688,0.00008830302,0.00002230775,0.73140407,0.00067293586,0.0001608192,0.009835529,0.00032316914,0.0005732247,0.0077840253],"study_design_scores_gemma":[0.000023251205,0.0002557402,0.08563617,0.000028981416,0.000030088031,0.9111181,0.00042533345,0.00027032808,0.0008682563,0.00015183698,0.0011835495,0.000008235264],"about_ca_topic_score_codex":0.0010172907,"about_ca_topic_score_gemma":0.0016031907,"teacher_disagreement_score":0.0014645228,"about_ca_system_score_codex":0.00026397422,"about_ca_system_score_gemma":0.00032213356,"threshold_uncertainty_score":0.004899323},"labels":[],"label_agreement":null},{"id":"W3120167422","doi":"10.1101/2021.01.07.425632","title":"Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T cell therapy for glioblastoma","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Antigen; Chimeric antigen receptor; Glioblastoma; Priming (agriculture); Cancer research; In vivo; T-cell receptor; Homogeneous; Biology; Immunotherapy; Immunology; T cell; Immune system; Genetics","score_opus":0.06637538692330446,"score_gpt":0.29362866579162844,"score_spread":0.22725327886832397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120167422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9475359,0.005115846,0.043453757,0.00046283143,0.00012654664,0.000098853016,0.000086014006,0.00038299293,0.002737366],"genre_scores_gemma":[0.98639005,0.0006904754,0.010912829,0.00012813913,0.000026343127,0.00003765527,0.000044478227,0.000032086915,0.0017379263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998653,0.000020148724,0.000009563603,0.000028507297,0.000038982842,0.000037489364],"domain_scores_gemma":[0.99993885,0.000013363537,0.00001892285,0.000006304101,0.000011197985,0.000011366565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018269538,0.00029613945,0.00027615528,0.00017345365,0.000112086185,0.0004251443,0.0002506368,0.00038982512,0.0010481328],"category_scores_gemma":[0.00015879603,0.000110802255,0.0001612537,0.00009412785,0.00017863799,0.00034125033,0.00024164507,0.00044880924,0.00021423637],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005907662,0.000034060846,0.000099305274,0.000057377805,0.000005261647,0.000036205372,0.000013430501,0.00067672995,0.99023193,0.0005888718,0.00013787093,0.008059872],"study_design_scores_gemma":[0.000019468373,0.0002787178,0.00030626345,0.0000044095705,0.00001697989,0.00013902484,0.0000058018736,0.0033183654,0.9932647,0.00013561512,0.002506437,0.0000042978013],"about_ca_topic_score_codex":0.0002603058,"about_ca_topic_score_gemma":0.00035329373,"teacher_disagreement_score":0.0010481328,"about_ca_system_score_codex":0.00034562696,"about_ca_system_score_gemma":0.00017732228,"threshold_uncertainty_score":0.0035063028},"labels":[],"label_agreement":null},{"id":"W3122370131","doi":"10.1073/pnas.2018861118","title":"Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy","year":2021,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institute of General Medical Sciences; Government of Canada","keywords":"Cell; Biology; Cell culture; Cancer research; Proteome; Cell type; Immunotherapy; Cell biology; Cell growth; Immune system; Immunology; Bioinformatics; Biochemistry; Genetics","score_opus":0.1104301587127117,"score_gpt":0.345920969728454,"score_spread":0.2354908110157423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122370131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896401,0.001865272,0.005920054,0.00017383105,0.000026785885,0.000018597197,0.00023263894,0.00009710013,0.002025562],"genre_scores_gemma":[0.9945285,0.00080902135,0.0026191063,0.000092225906,0.000009349935,0.000017750453,0.00031157667,0.00002492182,0.0015875066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999021,0.000016419655,0.0000051974525,0.000020939982,0.000032175543,0.000023056156],"domain_scores_gemma":[0.99993753,0.000008917028,0.000015747573,0.000011993349,0.000007633025,0.000018135343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001000205,0.00018400954,0.0001467567,0.00011597319,0.00011380853,0.0003207389,0.000110568886,0.00023017838,0.0011474895],"category_scores_gemma":[0.00006133407,0.00011542739,0.00021637688,0.00010875112,0.00015193348,0.0002335677,0.00020514436,0.0005667706,0.00033971627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019855397,0.000004984917,0.000126735,0.000006923453,0.0000014381748,0.00001310202,0.0000029736848,0.000020020403,0.9991548,0.000066715904,0.0000114888035,0.0005709557],"study_design_scores_gemma":[0.000009782171,0.00020908962,0.006822586,0.0000034896939,0.000009802875,0.00047812573,0.000029404182,0.00063940644,0.9876659,0.00013559427,0.0039929016,0.0000039132024],"about_ca_topic_score_codex":0.00013972346,"about_ca_topic_score_gemma":0.00017915262,"teacher_disagreement_score":0.0011474895,"about_ca_system_score_codex":0.00017840225,"about_ca_system_score_gemma":0.00011349144,"threshold_uncertainty_score":0.003838718},"labels":[],"label_agreement":null},{"id":"W3123145316","doi":"10.1186/s13643-021-01588-7","title":"Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Terry Fox Research Institute; University of Ottawa; BC Hydro (Canada); Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Medicine; Chimeric antigen receptor; Clinical trial; Oncology; Adverse effect; Antigen; Targeted therapy; Internal medicine; CD19; Immunology; Immunotherapy; Cancer","score_opus":0.1225571030559747,"score_gpt":0.4045806960754301,"score_spread":0.28202359301945545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123145316","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009299686,0.3688004,0.014709114,0.0034085158,0.0014505766,0.56072307,0.03753532,0.0007558788,0.0033173615],"genre_scores_gemma":[0.025588846,0.11196311,0.020148175,0.0026768222,0.00022854895,0.831289,0.0062773395,0.000112600865,0.0017155793],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9753983,0.009753721,0.009425121,0.002008815,0.0026290717,0.00078491383],"domain_scores_gemma":[0.9784505,0.0098261675,0.006102058,0.0014484456,0.003622651,0.0005502658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.032636456,0.0041342922,0.026089372,0.0146710705,0.0015378542,0.004695162,0.0042639463,0.0038687387,0.018607793],"category_scores_gemma":[0.055747025,0.0025315422,0.03742217,0.012480663,0.0017221285,0.0040889103,0.0041446667,0.0025250607,0.0015083841],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013252529,0.00003011249,0.0006188757,0.94818306,0.03805159,0.00010849034,0.00017395799,0.0004429425,0.00031555406,0.00046809984,0.0025308928,0.007751112],"study_design_scores_gemma":[0.0088578835,0.0008603018,0.00501271,0.4992066,0.44228855,0.00027716864,0.00040395814,0.0009818726,0.0007439854,0.0028750238,0.03825535,0.00023654848],"about_ca_topic_score_codex":0.0063304394,"about_ca_topic_score_gemma":0.012269415,"teacher_disagreement_score":0.032636456,"about_ca_system_score_codex":0.0085634105,"about_ca_system_score_gemma":0.02119222,"threshold_uncertainty_score":0.17260009},"labels":[],"label_agreement":null},{"id":"W3124365819","doi":"10.1111/pcmr.12960","title":"First‐line atezolizumab monotherapy in patients with advanced <i>BRAF</i><sup>V600</sup> wild‐type melanoma","year":2021,"lang":"en","type":"article","venue":"Pigment Cell & Melanoma Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Pembrolizumab; Adverse effect; Melanoma; Oncology; Gastroenterology; Cohort; Response Evaluation Criteria in Solid Tumors; Surgery; Progressive disease; Cancer; Disease; Cancer research; Immunotherapy","score_opus":0.03026515582306657,"score_gpt":0.31727203411469357,"score_spread":0.287006878291627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124365819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925015,0.004330847,0.00021168352,0.00034647595,0.00005939045,0.00015347902,0.0008792575,0.00003259298,0.001484796],"genre_scores_gemma":[0.9973801,0.0009005461,0.00022831908,0.00031879955,0.000044154625,0.000082924176,0.00070590293,0.000004121239,0.00033519865],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998473,0.00005715884,0.000012692997,0.000034593326,0.000021403313,0.000026824835],"domain_scores_gemma":[0.999701,0.00007706457,0.00007677504,0.000013362219,0.00002613647,0.000105757856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000460289,0.00023406686,0.0008032033,0.00015327391,0.00017187087,0.0003986687,0.00017131098,0.0003700056,0.0011658447],"category_scores_gemma":[0.0006483736,0.00016645792,0.00048695903,0.0002151438,0.00009938257,0.00030629506,0.00012014415,0.0007703365,0.000260416],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1496258,0.008571572,0.4837663,0.0012563884,0.001968707,0.001351596,0.0004317332,0.0029834853,0.047210395,0.0002622444,0.020272722,0.28229916],"study_design_scores_gemma":[0.056911223,0.15153489,0.7550085,0.00037667996,0.0017191459,0.002935127,0.0003505917,0.0077808583,0.0063010617,0.00046461518,0.016533986,0.00008336222],"about_ca_topic_score_codex":0.0007901577,"about_ca_topic_score_gemma":0.0024603782,"teacher_disagreement_score":0.0011658447,"about_ca_system_score_codex":0.00042023777,"about_ca_system_score_gemma":0.0005812525,"threshold_uncertainty_score":0.0039001107},"labels":[],"label_agreement":null},{"id":"W3124724032","doi":"10.1101/2021.01.18.427186","title":"Inflammatory Cytokines Regulate T-Cell Development from Blood Progenitor Cells in a Stage and Dose-Specifc Manner","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of Toronto; University of British Columbia","funders":"","keywords":"Stem cell factor; Progenitor cell; Cell biology; T cell; Stem cell; Haematopoiesis; Biology; Cytokine; CD38; Cellular differentiation; CD8; CD34; Immunology; Immune system; Biochemistry","score_opus":0.018035552275513053,"score_gpt":0.2333788489039971,"score_spread":0.21534329662848406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124724032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887742,0.004410914,0.003142852,0.00008082377,0.000060752176,0.000084487416,0.00056886015,0.00007354078,0.0028035305],"genre_scores_gemma":[0.9922139,0.0023488242,0.0022077253,0.000104100975,0.00003550291,0.00007310964,0.00048347068,0.00001556226,0.0025177381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977404,0.00005405373,0.00002390376,0.000030798303,0.00004851365,0.0000686911],"domain_scores_gemma":[0.9998697,0.000026983336,0.000032480395,0.000010489144,0.000025488416,0.00003473589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014960842,0.0003033983,0.000223612,0.00025615146,0.00010159922,0.0003497809,0.000086020336,0.00013943929,0.0015753186],"category_scores_gemma":[0.0001210845,0.0001121252,0.00026118782,0.0001688848,0.00013564309,0.00012894883,0.00016994045,0.0004145854,0.0004687805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025905564,0.00004174069,0.00033848258,0.000038184808,0.0000034996913,0.000042681917,0.000010317948,0.000036127658,0.99771094,0.00003797226,0.000043296546,0.0014377062],"study_design_scores_gemma":[0.000037190126,0.0006510245,0.009563406,0.000015822801,0.000027007181,0.00019266561,0.00004507174,0.00048211767,0.9868536,0.000043544147,0.0020851123,0.000003368043],"about_ca_topic_score_codex":0.00019380951,"about_ca_topic_score_gemma":0.00038750883,"teacher_disagreement_score":0.0015753186,"about_ca_system_score_codex":0.00013490797,"about_ca_system_score_gemma":0.00013923441,"threshold_uncertainty_score":0.0052699447},"labels":[],"label_agreement":null},{"id":"W3125616552","doi":"10.1007/s00270-020-02736-7","title":"Ex Vivo Study of Experimental Method Toward Future In Vivo Tissue Processing for Self-Anti-Tumoral Vaccinations","year":2021,"lang":"en","type":"article","venue":"CardioVascular and Interventional Radiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital; McGill University","funders":"","keywords":"Ex vivo; Medicine; In vivo; Vaccination; Pathology; Medical physics; Biotechnology","score_opus":0.03706627292735521,"score_gpt":0.3793830316774757,"score_spread":0.3423167587501205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125616552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62390494,0.00298261,0.36389568,0.00023727686,0.00040805445,0.00053117145,0.0005473234,0.0005701437,0.0069228387],"genre_scores_gemma":[0.83102834,0.0025017231,0.15358083,0.00028512528,0.00014456075,0.00093543023,0.00090062595,0.0002879129,0.010335436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99962425,0.00006657065,0.000031280106,0.00011964572,0.00011386229,0.0000443839],"domain_scores_gemma":[0.9996649,0.000083196464,0.0000858063,0.00007467127,0.00006395133,0.000027485565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008265644,0.00048844784,0.00022817815,0.00024885262,0.00020420081,0.0004025829,0.00029713125,0.00042955088,0.0029158525],"category_scores_gemma":[0.00036192854,0.00025533608,0.0002912662,0.00012932131,0.00021832468,0.00045918114,0.0001904716,0.0006314113,0.00086274964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005547079,0.000058296664,0.000091994465,0.00004901638,0.0000032228959,0.00003114055,0.00001661141,0.000091646034,0.99792993,0.0001820464,0.000041275456,0.0014493514],"study_design_scores_gemma":[0.000014002025,0.00039526782,0.0007942657,0.000009006156,0.000022026723,0.0002456313,0.000019006122,0.0013226406,0.9941816,0.0000996834,0.0028908513,0.0000061156024],"about_ca_topic_score_codex":0.00013822825,"about_ca_topic_score_gemma":0.00019330088,"teacher_disagreement_score":0.0029158525,"about_ca_system_score_codex":0.00014096801,"about_ca_system_score_gemma":0.00019788323,"threshold_uncertainty_score":0.009754539},"labels":[],"label_agreement":null},{"id":"W3126199907","doi":"10.1158/2326-6074.tumimm20-po081","title":"Abstract PO081: Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Medicine; Population; Haematopoiesis; Immune system; Progenitor cell; Chimeric antigen receptor; Stem cell; Chemoradiotherapy; Oncology; Immunotherapy; Cancer research; Cancer; Immunology; Internal medicine; Biology","score_opus":0.13009358589491676,"score_gpt":0.41780739091948677,"score_spread":0.28771380502457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126199907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96123993,0.0032239119,0.023871856,0.00022783605,0.00017666252,0.00080801395,0.0010196647,0.00032859494,0.009103466],"genre_scores_gemma":[0.9846447,0.0014593148,0.008660423,0.00013447463,0.00002261473,0.0004540484,0.0006421705,0.000059744154,0.003922392],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999175,0.000010912803,0.0000052086675,0.000022171327,0.000023489163,0.000020659545],"domain_scores_gemma":[0.9999778,0.0000022472605,0.000006423088,0.0000039470037,0.000003566426,0.0000060061625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013333543,0.00031493118,0.00018949505,0.00035737857,0.00010885965,0.00021586398,0.00024166743,0.00022700419,0.002191889],"category_scores_gemma":[0.00007579655,0.000093989096,0.00021632326,0.0001580391,0.00014137132,0.00015396663,0.00028230174,0.0004252892,0.00048687292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034951724,0.00040711527,0.00030283208,0.00017234244,0.00002063148,0.00014307954,0.000030480418,0.0007394649,0.965998,0.0010692347,0.0008964262,0.029870845],"study_design_scores_gemma":[0.00018598857,0.00418224,0.0018296536,0.000021858985,0.000088059285,0.0006085421,0.000025004583,0.0029552002,0.97158706,0.00024421499,0.018261483,0.000010678913],"about_ca_topic_score_codex":0.00020129052,"about_ca_topic_score_gemma":0.0002817868,"teacher_disagreement_score":0.002191889,"about_ca_system_score_codex":0.0001376562,"about_ca_system_score_gemma":0.00022000792,"threshold_uncertainty_score":0.007332623},"labels":[],"label_agreement":null},{"id":"W3126604828","doi":"10.3389/fimmu.2020.618387","title":"Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy","year":2021,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"BC Cancer Foundation; VGH and UBC Hospital Foundation","keywords":"Chimeric antigen receptor; Tumor microenvironment; Cytokine release syndrome; T cell; Immunotherapy; Cancer research; Immunology; Medicine; Immune system","score_opus":0.02858909250573865,"score_gpt":0.3102956589479955,"score_spread":0.28170656644225683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126604828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0928526,0.80374295,0.05676281,0.02294202,0.0029083844,0.0001948038,0.00006935611,0.00027334513,0.020253735],"genre_scores_gemma":[0.54804516,0.40561193,0.022569593,0.007241947,0.0036690112,0.00022447345,0.00007235975,0.00006391147,0.012501697],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997477,0.00010310167,0.000012814377,0.000025910304,0.00006459462,0.0000457647],"domain_scores_gemma":[0.9999224,0.000031221443,0.000015410329,0.000006620888,0.000009455284,0.00001502011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069989485,0.00031343353,0.00039130007,0.00026984425,0.00025078835,0.00085119164,0.00034650325,0.0009804117,0.00078377366],"category_scores_gemma":[0.00020965129,0.00016050234,0.00030748823,0.00014246526,0.0009077494,0.0009728465,0.0006777931,0.0019134798,0.00030840805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006926109,0.0006987732,0.0022820826,0.0029717237,0.0001181262,0.0032903943,0.00066461175,0.008451041,0.28651217,0.13340203,0.02051586,0.54040056],"study_design_scores_gemma":[0.00025516126,0.003043787,0.002063595,0.0006468087,0.00018168584,0.010834027,0.00042525603,0.01069402,0.1524705,0.03880762,0.78048205,0.000095431584],"about_ca_topic_score_codex":0.00019633197,"about_ca_topic_score_gemma":0.00053471123,"teacher_disagreement_score":0.0009804117,"about_ca_system_score_codex":0.00039944128,"about_ca_system_score_gemma":0.00045495102,"threshold_uncertainty_score":0.0037014484},"labels":[],"label_agreement":null},{"id":"W3127194872","doi":"10.3390/cancers13040598","title":"T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Leukemia and Lymphoma Society of Canada","keywords":"Immune system; Immunotherapy; Adoptive cell transfer; Immune Dysfunction; Cell therapy; T cell; Immunology; Cell; Cancer research; Biology; Medicine; Cell biology; Stem cell","score_opus":0.0672659571575848,"score_gpt":0.40845473268434346,"score_spread":0.34118877552675864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127194872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001328775,0.99816185,0.00022684681,0.00038396468,0.0001699654,0.000006375364,0.00001027094,0.000008826577,0.0008989523],"genre_scores_gemma":[0.000863696,0.9980399,0.0002620752,0.00025473564,0.00015658826,0.000013200642,0.000017928456,0.000001629063,0.00039024558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997588,0.000047873837,0.000032460008,0.000041897547,0.00009159561,0.000027338918],"domain_scores_gemma":[0.99960667,0.00023048345,0.000044774883,0.000012464261,0.00007720942,0.000028408313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010654005,0.0008210943,0.0013055439,0.0015880376,0.00028311007,0.0013695492,0.0011652291,0.0014451479,0.0029777016],"category_scores_gemma":[0.00079093967,0.0002875208,0.000493752,0.0010625321,0.0006735021,0.0015901808,0.00081303064,0.0022049618,0.0015249816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007804511,0.00009495685,0.00013771387,0.01619205,0.00007087064,0.00016183851,0.00007780396,0.00047360713,0.0024080118,0.009916689,0.015427151,0.95496124],"study_design_scores_gemma":[0.000023562183,0.00018181565,0.00041411998,0.0048594847,0.00011986387,0.0009809214,0.00008843848,0.00016229479,0.0009259691,0.004880429,0.98734075,0.000022366872],"about_ca_topic_score_codex":0.00057918346,"about_ca_topic_score_gemma":0.000972998,"teacher_disagreement_score":0.0029777016,"about_ca_system_score_codex":0.0006153182,"about_ca_system_score_gemma":0.0011824646,"threshold_uncertainty_score":0.009961367},"labels":[],"label_agreement":null},{"id":"W3128717951","doi":"10.2139/ssrn.3640763","title":"A Reservoir of Stem-Like CD8 T Cells in the Tumor-Draining Lymph Node Maintains the Ongoing Anti-Tumor Immune Response","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mila - Quebec Artificial Intelligence Institute","funders":"","keywords":"Immune system; Lymph node; Cytotoxic T cell; Stem cell; Cancer research; Immunology; Biology; Cell biology","score_opus":0.025652277156658607,"score_gpt":0.2926424039016663,"score_spread":0.26699012674500766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128717951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820609,0.003677716,0.008895478,0.00061958417,0.00013123789,0.000057868743,0.00024526138,0.00045573452,0.0038561933],"genre_scores_gemma":[0.9927099,0.00035601598,0.0026243024,0.00013885101,0.0000862408,0.00004399316,0.0002297595,0.000043208674,0.0037677519],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998472,0.000028504415,0.000010906812,0.000037176233,0.00003230679,0.00004384715],"domain_scores_gemma":[0.99975485,0.00004441837,0.000037437992,0.00004458465,0.00004167971,0.00007706682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018652788,0.00023583499,0.00043583784,0.00041844352,0.00027243266,0.0008504875,0.00033418747,0.0004337115,0.0035324018],"category_scores_gemma":[0.0003404519,0.00017375674,0.00017770972,0.00012073665,0.0002636809,0.0009030303,0.00049533666,0.0012991324,0.0014957921],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005243113,0.000185144,0.0055653043,0.00015361674,0.000029246386,0.00053363544,0.0002007566,0.00080406363,0.95243746,0.0028263673,0.00084371894,0.035896275],"study_design_scores_gemma":[0.00034446263,0.0042982264,0.026938379,0.00015713871,0.00020706694,0.0034746109,0.0011764516,0.017385572,0.9000702,0.0058156135,0.040088482,0.000043950997],"about_ca_topic_score_codex":0.00017273588,"about_ca_topic_score_gemma":0.0003092675,"teacher_disagreement_score":0.0035324018,"about_ca_system_score_codex":0.0002609852,"about_ca_system_score_gemma":0.00036042643,"threshold_uncertainty_score":0.011817098},"labels":[],"label_agreement":null},{"id":"W3129688332","doi":"10.1097/hs9.0000000000000540","title":"Hemophilia Gene Therapy: Approaching the First Licensed Product","year":2021,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Genetic enhancement; Clinical trial; Medicine; Intensive care medicine; Gene; Biology; Internal medicine; Genetics","score_opus":0.10629999907020828,"score_gpt":0.35996604074005584,"score_spread":0.2536660416698476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129688332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012379093,0.9967955,0.00022632896,0.0006459289,0.00030010953,0.0000055612786,0.000017334725,0.000009516717,0.0018759432],"genre_scores_gemma":[0.0006113619,0.99765944,0.00027101245,0.00041713368,0.00018226785,0.000007220557,0.000021130347,0.0000028011468,0.00082760776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99971217,0.000058209887,0.000034303084,0.000041322568,0.00013080561,0.000023048173],"domain_scores_gemma":[0.999585,0.00023712474,0.00004609485,0.00001084276,0.000088530265,0.000032447682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010824951,0.0006602662,0.0010578058,0.0018102094,0.00027013948,0.0015159977,0.0007700256,0.0018297109,0.0050288597],"category_scores_gemma":[0.0010148465,0.00027695895,0.00046914237,0.0012218683,0.00060932204,0.0026522824,0.00069980416,0.003017546,0.0030027765],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084705425,0.0000689865,0.000095153075,0.018101754,0.00004541809,0.0003154666,0.00012364864,0.00036431887,0.0043257955,0.015215093,0.04918533,0.91207427],"study_design_scores_gemma":[0.000010556612,0.000078881574,0.00016085885,0.0031010187,0.00003332696,0.00080013054,0.000048368333,0.00006507534,0.0004685226,0.0022911076,0.9929329,0.000009231741],"about_ca_topic_score_codex":0.00083870237,"about_ca_topic_score_gemma":0.0013230457,"teacher_disagreement_score":0.0050288597,"about_ca_system_score_codex":0.0007487126,"about_ca_system_score_gemma":0.0013727602,"threshold_uncertainty_score":0.016823232},"labels":[],"label_agreement":null},{"id":"W3130326316","doi":"10.1080/2162402x.2021.1885778","title":"Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Deutsche Krebshilfe","keywords":"Oncolytic virus; Cancer research; Tumor microenvironment; Immune system; Medicine; Cytotoxic T cell; Immunotherapy; Immune checkpoint; Lung cancer; Cancer; Immunology; Oncolytic adenovirus; Biology; Oncology; Internal medicine","score_opus":0.026666207144907386,"score_gpt":0.32993254255462107,"score_spread":0.3032663354097137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130326316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99602544,0.0018321429,0.0006019038,0.000047801117,0.000039635244,0.000051320687,0.00012117967,0.000048015674,0.0012324314],"genre_scores_gemma":[0.9973475,0.0008737651,0.00074469,0.000036208436,0.0000160598,0.00004410996,0.00014768541,0.0000071516833,0.0007827806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998635,0.000026686868,0.000012964334,0.00001664298,0.00002527539,0.000054872227],"domain_scores_gemma":[0.99994624,0.000009998845,0.000010677347,0.0000067801993,0.0000052025225,0.000020964184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018616683,0.0003906543,0.00045130157,0.00023264534,0.000098284516,0.00023041532,0.00022682872,0.0002782646,0.0007152734],"category_scores_gemma":[0.000065778026,0.00011833755,0.00033113244,0.00012795559,0.0001737642,0.00017792657,0.00019500866,0.0006250118,0.00015477354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009824606,0.00038565588,0.00021166162,0.00009072815,0.00003002639,0.00005153497,0.000023740145,0.00030185375,0.99145097,0.00013961684,0.00010937841,0.006222387],"study_design_scores_gemma":[0.00016233532,0.005523715,0.003002721,0.000009421827,0.00007697844,0.00021652563,0.000029269147,0.0016574631,0.9872472,0.000040665498,0.0020270243,0.0000067918495],"about_ca_topic_score_codex":0.00047977624,"about_ca_topic_score_gemma":0.00097307126,"teacher_disagreement_score":0.0007152734,"about_ca_system_score_codex":0.00016308328,"about_ca_system_score_gemma":0.00023327571,"threshold_uncertainty_score":0.002392888},"labels":[],"label_agreement":null},{"id":"W3130683366","doi":"10.1158/1078-0432.ccr-20-3365","title":"Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Children's Hospital of Eastern Ontario; McGill University; McGill University Health Centre","funders":"Terry Fox Research Institute; Canadian Cancer Society","keywords":"Oncolytic virus; Melanoma; Cancer research; Vesicular stomatitis virus; Herpes simplex virus; Biology; Immune checkpoint; RNA interference; Virology; Immune system; Immunology; Medicine; Virus; Immunotherapy; Gene; RNA","score_opus":0.18968747413423104,"score_gpt":0.5040336254214045,"score_spread":0.31434615128717347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130683366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977187,0.0004269845,0.00086696306,0.000026775337,0.000008083682,0.000020641814,0.00024555778,0.00004705734,0.0006393207],"genre_scores_gemma":[0.9987503,0.00013822055,0.00055735995,0.00001513617,0.000001705852,0.0000074773147,0.00016300021,0.000007032639,0.0003598178],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998926,0.000013564348,0.0000129802,0.000028814206,0.000034599605,0.000017400911],"domain_scores_gemma":[0.9998865,0.000029536915,0.000038181384,0.000012833915,0.000012856432,0.0000200714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114358656,0.00020796101,0.00021975508,0.00028183783,0.00010455226,0.00024819103,0.00009971737,0.00022933543,0.0016259484],"category_scores_gemma":[0.0001683894,0.000106924366,0.00024928767,0.00013259272,0.000120524885,0.000093399954,0.000115658106,0.00033244895,0.0002992926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012204819,0.000034468572,0.0038569595,0.000023982022,0.00001274079,0.00012326895,0.000010166789,0.00019988556,0.9935195,0.000043274238,0.000041868614,0.0020118507],"study_design_scores_gemma":[0.000034645207,0.0006523081,0.07231785,0.000013994632,0.0000619256,0.0034462237,0.00004995518,0.003352542,0.91798276,0.0001011424,0.0019796113,0.0000070591577],"about_ca_topic_score_codex":0.00042586753,"about_ca_topic_score_gemma":0.0005549359,"teacher_disagreement_score":0.0016259484,"about_ca_system_score_codex":0.00022038457,"about_ca_system_score_gemma":0.000115702,"threshold_uncertainty_score":0.005439341},"labels":[],"label_agreement":null},{"id":"W3133229959","doi":"10.1056/nejmoa2024850","title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2424,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Chimeric antigen receptor; Refractory (planetary science); Multiple myeloma; Antigen; Cancer research; Medicine; Receptor; T cell; Internal medicine; Immunology; Biology; Immune system","score_opus":0.03150045003787461,"score_gpt":0.31717604504497804,"score_spread":0.28567559500710343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133229959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874155,0.010643439,0.0004066946,0.00027851443,0.0000321496,0.00005368596,0.000083084735,0.000042854834,0.0010441082],"genre_scores_gemma":[0.99687696,0.0022427663,0.00025063584,0.000151026,0.00006348213,0.000021683389,0.0001521307,0.000006244292,0.00023504448],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997472,0.000096764896,0.000022911416,0.000033165215,0.000057853194,0.000042203403],"domain_scores_gemma":[0.99974996,0.00007003549,0.00007089023,0.000017902965,0.000016233165,0.00007501467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006921369,0.0003559992,0.00067963457,0.00029838033,0.0002766763,0.0002232356,0.0003232839,0.00033269468,0.00056191615],"category_scores_gemma":[0.00069756294,0.00010841822,0.00031430638,0.00036400577,0.00026352482,0.00017269271,0.0001929328,0.00043347196,0.00018964453],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03665624,0.002548259,0.25201777,0.0018390875,0.0012526897,0.023234956,0.00092310924,0.0068807746,0.07311712,0.0005091048,0.009560953,0.59146],"study_design_scores_gemma":[0.013565951,0.07855368,0.71400505,0.00039654176,0.0014031066,0.11306387,0.00038510497,0.013475543,0.03512811,0.0009876608,0.028958756,0.00007673557],"about_ca_topic_score_codex":0.0011337595,"about_ca_topic_score_gemma":0.0020159099,"teacher_disagreement_score":0.0011337595,"about_ca_system_score_codex":0.0005873148,"about_ca_system_score_gemma":0.0003430394,"threshold_uncertainty_score":0.0042612553},"labels":[],"label_agreement":null},{"id":"W3133720646","doi":"10.1172/jci140752","title":"Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; McGill University; Jewish General Hospital","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; H2020 European Research Council; Réseau de cancérologie Rossy; Narodowe Centrum Badań i Rozwoju; McGill University","keywords":"Melanoma; Cancer research; Immunotherapy; CD8; EIF4E; Immune system; Immune checkpoint; Phenotype; Tumor microenvironment; Immunology; Biology; Medicine; Gene","score_opus":0.08551406362731641,"score_gpt":0.39733535910964496,"score_spread":0.31182129548232856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133720646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960963,0.00084472145,0.0011249334,0.00009322789,0.00004572035,0.000040430725,0.0002908268,0.00012766728,0.0013360884],"genre_scores_gemma":[0.99656457,0.00047585933,0.0009284303,0.000040994044,0.0000103136435,0.00005133025,0.00022051459,0.000014050399,0.0016939534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980754,0.000032950717,0.000024018978,0.000029942574,0.000042627165,0.000062840816],"domain_scores_gemma":[0.99989235,0.000019181587,0.000029644887,0.000012759449,0.000005552745,0.000040370945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017224031,0.00050893036,0.00032817698,0.00029295834,0.00010284359,0.00024447814,0.00018538088,0.00027950417,0.00114585],"category_scores_gemma":[0.000095387615,0.00016845507,0.0002001989,0.00011168897,0.00020504776,0.00017816102,0.00019530655,0.00087298086,0.0002362509],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003702115,0.00013382226,0.00013911612,0.000030553198,0.0000062759855,0.00001845264,0.000008523374,0.00015306714,0.9975376,0.00007626192,0.000046476587,0.0014797109],"study_design_scores_gemma":[0.000060680875,0.0015373233,0.0030096865,0.0000075454313,0.000021858636,0.00008962554,0.000016467884,0.0014326628,0.99194056,0.00004635331,0.0018323488,0.0000049625924],"about_ca_topic_score_codex":0.00029130172,"about_ca_topic_score_gemma":0.0006103555,"teacher_disagreement_score":0.00114585,"about_ca_system_score_codex":0.00023414163,"about_ca_system_score_gemma":0.0002055775,"threshold_uncertainty_score":0.0038332343},"labels":[],"label_agreement":null},{"id":"W3134407748","doi":"10.12927/hcpol.2021.26430","title":"Understanding the Feasibility of Implementing Car T-Cell Therapies from a Canadian Perspective","year":2021,"lang":"en","type":"article","venue":"Healthcare policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo","funders":"","keywords":"Chimeric antigen receptor; Perspective (graphical); CAR T-cell therapy; Qualitative research; Medicine; Engineering ethics; Computer science; Engineering; Sociology; T cell; Immunology; Artificial intelligence","score_opus":0.23635135559261253,"score_gpt":0.44775107770208117,"score_spread":0.21139972210946864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134407748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5601026,0.0060562617,0.003859258,0.3101671,0.00027986596,0.00048492965,0.00047658634,0.00005134694,0.118522026],"genre_scores_gemma":[0.984883,0.0028069627,0.0017920884,0.007695124,0.000019623687,0.0000793864,0.00005398699,0.000014408034,0.002655457],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.97451276,0.009404368,0.00060644967,0.0010673902,0.004766547,0.00964256],"domain_scores_gemma":[0.9784933,0.008579689,0.0018424658,0.0002743974,0.0058559915,0.004954285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01804542,0.0004443346,0.0004087696,0.0013268131,0.03142865,0.013089307,0.0028945135,0.00373021,0.0042812787],"category_scores_gemma":[0.025691211,0.0005187209,0.00052650116,0.002494476,0.014405532,0.004430033,0.005569035,0.0052134986,0.00021068589],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0001655547,0.00019192048,0.050437145,0.0012329015,0.00006353957,0.003124697,0.6962763,0.0021897648,0.002842228,0.16755949,0.018768866,0.05714762],"study_design_scores_gemma":[0.000019887602,0.00010635756,0.014924745,0.000907788,0.00005090017,0.00025588856,0.8645937,0.00090753305,0.00088647957,0.0063527455,0.11089038,0.00010357238],"about_ca_topic_score_codex":0.98068076,"about_ca_topic_score_gemma":0.9828203,"teacher_disagreement_score":0.98068076,"about_ca_system_score_codex":0.23143508,"about_ca_system_score_gemma":0.47093448,"threshold_uncertainty_score":0.8914264},"labels":[],"label_agreement":null},{"id":"W3134659811","doi":"10.1038/s41573-021-00155-y","title":"Beyond immune checkpoint blockade: emerging immunological strategies","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":477,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Immune checkpoint; Blockade; Cancer immunotherapy; Medicine; T cell; Immune system; Immunology; Cancer research; Receptor; Internal medicine","score_opus":0.04113483083086296,"score_gpt":0.3922663755111197,"score_spread":0.35113154468025676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134659811","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005404339,0.99760866,0.00019811452,0.00083524274,0.00045448187,0.0000049901787,0.000018267803,0.000009552863,0.00081655127],"genre_scores_gemma":[0.00048832747,0.99712116,0.00021781554,0.0009928808,0.00047404453,0.000010238376,0.000035387755,0.0000022764088,0.0006578454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997502,0.00006175143,0.000021622553,0.000038719605,0.000088121255,0.000039691982],"domain_scores_gemma":[0.99939096,0.0003645332,0.000048859194,0.000015914487,0.00011188932,0.000067893554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012633601,0.0012052567,0.0020830592,0.0016415931,0.00025247014,0.0016089389,0.0014601523,0.001812638,0.005682999],"category_scores_gemma":[0.0013122938,0.00027038454,0.00067163043,0.0012622091,0.0008470967,0.0022838025,0.0010908232,0.0046963547,0.002800502],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021837313,0.000112789094,0.00009052587,0.012289196,0.00012293838,0.00016622142,0.000030689513,0.0004884522,0.0019597972,0.009399078,0.075225584,0.8998964],"study_design_scores_gemma":[0.000085929554,0.00015114223,0.00024563124,0.0036342298,0.00011396939,0.00041339672,0.000032537326,0.00015049499,0.00033480537,0.0046851,0.9901343,0.000018400884],"about_ca_topic_score_codex":0.00088630343,"about_ca_topic_score_gemma":0.0025597822,"teacher_disagreement_score":0.005682999,"about_ca_system_score_codex":0.00087398244,"about_ca_system_score_gemma":0.0012966847,"threshold_uncertainty_score":0.019011557},"labels":[],"label_agreement":null},{"id":"W3134794845","doi":"10.3390/cancers13051106","title":"Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Oncolytic virus; Chimeric antigen receptor; T cell; Tumor microenvironment; Immune system; CD8; Biology; Cytotoxic T cell; Context (archaeology); Immunology; Antigen; Cancer research","score_opus":0.14316046081578548,"score_gpt":0.444017945416965,"score_spread":0.3008574846011795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134794845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14857806,0.77186126,0.050261226,0.0046240324,0.001572075,0.00011301207,0.00016225962,0.0005325938,0.022295604],"genre_scores_gemma":[0.49822935,0.44660744,0.020675905,0.0030195727,0.0014503517,0.00012053567,0.00029012843,0.00013770346,0.02946895],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988127,0.00003326511,0.000010501407,0.000018572937,0.00003666571,0.000019716126],"domain_scores_gemma":[0.9999497,0.00001741909,0.000010169947,0.0000044183375,0.00000951402,0.000008749402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031134134,0.00025695792,0.00035048154,0.00035274078,0.00012831249,0.0009874555,0.00033748648,0.00053350464,0.0008371115],"category_scores_gemma":[0.00019323398,0.00017068633,0.0002417693,0.00022953252,0.00052969425,0.0012255767,0.0003491592,0.0008121653,0.0006028653],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079765427,0.00016887701,0.0009852407,0.0046083424,0.00008390994,0.0011797182,0.00050455576,0.0023135147,0.54354936,0.037676986,0.0060535553,0.40207827],"study_design_scores_gemma":[0.000092834525,0.0024125292,0.001523099,0.00037969378,0.00015975913,0.0048917797,0.000499758,0.003170233,0.3778942,0.015641324,0.5932465,0.00008837364],"about_ca_topic_score_codex":0.0001583835,"about_ca_topic_score_gemma":0.00035950416,"teacher_disagreement_score":0.0009874555,"about_ca_system_score_codex":0.00031194746,"about_ca_system_score_gemma":0.00023464445,"threshold_uncertainty_score":0.0028004646},"labels":[],"label_agreement":null},{"id":"W3136339776","doi":"10.1097/ppo.0000000000000515","title":"Cytokine Release Syndrome Biology and Management","year":2021,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Immunosuppression; Immunotherapy; Immunology; Cytokine; Immune system; Medicine; Biology; Bioinformatics; Cancer research","score_opus":0.0882306754738781,"score_gpt":0.43499388329341665,"score_spread":0.34676320781953857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136339776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018155709,0.9983942,0.00014649125,0.00034785,0.00020733521,0.000004431341,0.000009626762,0.0000066308353,0.0007019219],"genre_scores_gemma":[0.0027388255,0.9955759,0.00025390837,0.00034084456,0.00048008168,0.000010677215,0.00003506514,0.000001596514,0.0005631538],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998184,0.00003803019,0.000030990235,0.000028766764,0.00006346994,0.000020378237],"domain_scores_gemma":[0.9997757,0.00009590616,0.000041440628,0.0000063671864,0.00005924372,0.000021320011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043484496,0.0006422128,0.0010251527,0.0014390697,0.00022571313,0.00083196844,0.0005928899,0.00087962806,0.0019075822],"category_scores_gemma":[0.00066034455,0.00016793208,0.00040187236,0.0007949193,0.00038505998,0.0007237759,0.0004347753,0.0017705247,0.0010725504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010162852,0.00006897968,0.0004551743,0.010748575,0.000084886764,0.00062751,0.000041990024,0.00034829997,0.0015718833,0.0035561377,0.023961162,0.95843375],"study_design_scores_gemma":[0.00005560954,0.00021083734,0.0022269299,0.0072698877,0.00019371783,0.013713097,0.000103250175,0.00034527516,0.0017542824,0.003325321,0.97076946,0.00003236825],"about_ca_topic_score_codex":0.00060345227,"about_ca_topic_score_gemma":0.00078698585,"teacher_disagreement_score":0.0019075822,"about_ca_system_score_codex":0.00047253387,"about_ca_system_score_gemma":0.00083678256,"threshold_uncertainty_score":0.0063815117},"labels":[],"label_agreement":null},{"id":"W3137447968","doi":"10.1200/jco.20.03175","title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Gastroenterology; Refractory (planetary science); Follicular lymphoma; Lymphoma; Rituximab; Adverse effect; CD20; Alemtuzumab; Oncology; T cell; Immunology; Immune system; Transplantation","score_opus":0.26594447380813624,"score_gpt":0.5123547411190288,"score_spread":0.24641026731089255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137447968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939306,0.0026663567,0.00053659215,0.00020296995,0.000038695624,0.00083586015,0.00036054067,0.00012814335,0.0013001609],"genre_scores_gemma":[0.9937006,0.0018395928,0.00087110914,0.00055543217,0.00006918159,0.0006508533,0.0009957072,0.000020745969,0.0012967888],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997851,0.00007963238,0.0000149771995,0.0000426256,0.000023870241,0.000053789445],"domain_scores_gemma":[0.99969363,0.00003874815,0.00006432004,0.000029814992,0.000014142785,0.00015925695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010320132,0.0008501643,0.0009096049,0.00022854371,0.0001938792,0.00057240686,0.0006674856,0.0007621218,0.0016381651],"category_scores_gemma":[0.00034771438,0.0002372027,0.0007505503,0.00019419167,0.0005784379,0.0005797319,0.00027567492,0.0018095701,0.00043813288],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3861126,0.039992828,0.012835074,0.0013377292,0.0020066674,0.0005407575,0.00060619,0.0054094912,0.1849914,0.00075119425,0.007773397,0.35764268],"study_design_scores_gemma":[0.39517856,0.5458966,0.021042418,0.00008165481,0.0006994148,0.0011919228,0.000114444294,0.0035822473,0.023129307,0.00040170795,0.008628532,0.000053178006],"about_ca_topic_score_codex":0.00040729018,"about_ca_topic_score_gemma":0.0010601686,"teacher_disagreement_score":0.0016381651,"about_ca_system_score_codex":0.0005311701,"about_ca_system_score_gemma":0.0004887287,"threshold_uncertainty_score":0.00548023},"labels":[],"label_agreement":null},{"id":"W3137935396","doi":"10.1371/journal.pone.0248118","title":"Establishing CD19 B-cell reference control materials for comparable and quantitative cytometric expression analysis","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fluidigm (Canada)","funders":"National Institute of Standards and Technology","keywords":"CD19; Flow cytometry; Peripheral blood mononuclear cell; Calibration; Computational biology; Computer science; Biology; Immunology; Mathematics; In vitro; Statistics; Biochemistry","score_opus":0.17049444200458552,"score_gpt":0.34852562364445133,"score_spread":0.1780311816398658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137935396","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22589213,0.0069482876,0.7312018,0.0005970442,0.0013686459,0.010221638,0.003329121,0.0031145748,0.017326634],"genre_scores_gemma":[0.27122664,0.004060436,0.67857903,0.00097056373,0.000320332,0.01963515,0.013615483,0.0011754136,0.010416974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9844095,0.0036402156,0.0014577403,0.00239376,0.007318943,0.0007798906],"domain_scores_gemma":[0.99325925,0.0011836898,0.0006636986,0.0013083927,0.0033900784,0.00019485274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009572388,0.0014496787,0.0008189833,0.0033788597,0.0011752817,0.001975965,0.0022232113,0.0018924734,0.005674515],"category_scores_gemma":[0.010858205,0.0008091666,0.00087339885,0.002184911,0.0014790489,0.000852193,0.0014429512,0.0018876833,0.0039159283],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044523622,0.0004027333,0.0016206234,0.00044136264,0.00004144957,0.00011313159,0.00034528942,0.00073844264,0.9685301,0.001921651,0.0016858961,0.023714118],"study_design_scores_gemma":[0.00007294575,0.0007421963,0.0027724118,0.00013798663,0.000087823966,0.00028482932,0.00009982824,0.0029252458,0.9615564,0.0005370743,0.030744014,0.00003938902],"about_ca_topic_score_codex":0.0010585624,"about_ca_topic_score_gemma":0.0016480365,"teacher_disagreement_score":0.009572388,"about_ca_system_score_codex":0.0010744403,"about_ca_system_score_gemma":0.0011507553,"threshold_uncertainty_score":0.05062425},"labels":[],"label_agreement":null},{"id":"W3138645123","doi":"10.1136/bmjopen-2020-043929","title":"Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Institute for Clinical Evaluative Sciences; Genome British Columbia; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Chimeric antigen receptor; Qualitative research; Clinical trial; Knowledge translation; Family medicine; Cancer; Internal medicine; Immunotherapy; Knowledge management","score_opus":0.23405634589597232,"score_gpt":0.5237100543812765,"score_spread":0.28965370848530414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138645123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94938725,0.000948569,0.022827478,0.0119193895,0.00019697682,0.0033025814,0.00052215694,0.00006416074,0.010831469],"genre_scores_gemma":[0.9805156,0.0007918862,0.010788366,0.0024514243,0.000029891826,0.0028572325,0.00013129733,0.000035038127,0.0023992476],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9584596,0.035016146,0.0005830059,0.0012658406,0.0014720714,0.0032032623],"domain_scores_gemma":[0.9174199,0.07045044,0.0031344604,0.0015113936,0.0040056864,0.0034780437],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03825024,0.0011291874,0.00093569775,0.0021940959,0.013279748,0.006198292,0.0036377027,0.003128753,0.0033673022],"category_scores_gemma":[0.051281303,0.0009770938,0.0008630974,0.0020270757,0.02086227,0.005657354,0.010105467,0.0057107843,0.00038814917],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004764599,0.00003575694,0.0010410445,0.00014506913,0.0000044922513,0.00032991223,0.9929806,0.00007882271,0.0003289477,0.0015339255,0.00045470693,0.0030191194],"study_design_scores_gemma":[0.000018675983,0.000040865103,0.0003510479,0.0001607866,0.00000508401,0.00009951536,0.9926137,0.0002493263,0.00019278628,0.0013600005,0.0048888773,0.000019309438],"about_ca_topic_score_codex":0.052438654,"about_ca_topic_score_gemma":0.06731534,"teacher_disagreement_score":0.052438654,"about_ca_system_score_codex":0.016955558,"about_ca_system_score_gemma":0.024839742,"threshold_uncertainty_score":0.20228899},"labels":[],"label_agreement":null},{"id":"W3138818958","doi":"10.1182/blood.2020009081","title":"Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Venetoclax; Cancer research; Medicine; Leukemia; Immunology; Chronic lymphocytic leukemia","score_opus":0.01551792651846018,"score_gpt":0.28204364045300373,"score_spread":0.26652571393454355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138818958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928227,0.003918592,0.000795089,0.00007439777,0.000033043576,0.0000349472,0.00011507622,0.00009961343,0.0021066174],"genre_scores_gemma":[0.9969795,0.0011362003,0.0008270125,0.000024211353,0.00002425503,0.000014258199,0.0001222578,0.000004024226,0.00086836587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993706,0.000019901894,0.000004689764,0.0000108900285,0.000012136523,0.000015385593],"domain_scores_gemma":[0.9999448,0.000017967866,0.000013074606,0.0000059616755,0.000004034418,0.000014124298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008836003,0.00020736859,0.00016358633,0.00020143125,0.000084783875,0.00018103776,0.0001182719,0.00015444375,0.0015316338],"category_scores_gemma":[0.00012089713,0.00006157293,0.000114373936,0.00013893098,0.00012357922,0.00015560414,0.00011422396,0.0005178383,0.00016510763],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000749712,0.00019796295,0.0003940047,0.000074191164,0.000009086758,0.000049750102,0.000022633154,0.00013837041,0.98399323,0.00008922727,0.00012185076,0.014160011],"study_design_scores_gemma":[0.00022887443,0.007573323,0.01014539,0.000011063903,0.00005244524,0.00049850804,0.000021290833,0.0010979263,0.97500956,0.0000571705,0.005298093,0.0000063597086],"about_ca_topic_score_codex":0.00031975243,"about_ca_topic_score_gemma":0.00060325617,"teacher_disagreement_score":0.0015316338,"about_ca_system_score_codex":0.0001273312,"about_ca_system_score_gemma":0.000121485115,"threshold_uncertainty_score":0.005123794},"labels":[],"label_agreement":null},{"id":"W3139314280","doi":"10.1186/s13063-021-05121-y","title":"Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Trials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Institute for Clinical Evaluative Sciences; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Context (archaeology); Workload; Clinical trial; Pathology","score_opus":0.22463829307743308,"score_gpt":0.4329605518670708,"score_spread":0.2083222587896377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139314280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932459,0.0001812265,0.0020805697,0.002242078,0.000019909388,0.0006821854,0.00008261189,0.0000063899065,0.0014592388],"genre_scores_gemma":[0.9931486,0.00040861458,0.0034059857,0.0014611094,0.000013742127,0.0008276091,0.00006492749,0.0000063968046,0.00066295825],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9794049,0.014951582,0.0007779529,0.0007806764,0.0010508065,0.003034102],"domain_scores_gemma":[0.92659795,0.05885378,0.004561938,0.0009777751,0.0042957817,0.0047127362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035586726,0.00058068446,0.00054527324,0.0021954053,0.008100152,0.004416235,0.0015827571,0.0022616326,0.0016679126],"category_scores_gemma":[0.044166572,0.0009669191,0.0006267718,0.0018377816,0.0071749585,0.0030426306,0.005031769,0.00502389,0.00024158311],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004942669,0.00024975205,0.018710015,0.00014187905,0.000006954925,0.00038932162,0.9739255,0.00015625685,0.00025928425,0.0009937355,0.0005354353,0.0045824177],"study_design_scores_gemma":[0.000032110427,0.00013881877,0.004996441,0.00015581562,0.0000068207232,0.00009179096,0.9906872,0.00061298703,0.00017410461,0.00043010793,0.0026540784,0.00001976503],"about_ca_topic_score_codex":0.03698728,"about_ca_topic_score_gemma":0.04688985,"teacher_disagreement_score":0.03698728,"about_ca_system_score_codex":0.015159904,"about_ca_system_score_gemma":0.024982793,"threshold_uncertainty_score":0.18820286},"labels":[],"label_agreement":null},{"id":"W3139471115","doi":"10.1038/s41417-021-00320-w","title":"Engineered cells as glioblastoma therapeutics","year":2021,"lang":"en","type":"review","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Canadian Cancer Society Research Institute","keywords":"Glioblastoma; Genetically engineered; Mesenchymal stem cell; Stem cell; Cancer research; Neural stem cell; Computational biology; Cell; Biology; Medicine; Gene; Cell biology; Genetics","score_opus":0.10004991932952766,"score_gpt":0.41356606844291516,"score_spread":0.3135161491133875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139471115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015771983,0.9976071,0.00022755405,0.00019264656,0.00020546075,0.00000824255,0.000016887454,0.0000075533944,0.0015768922],"genre_scores_gemma":[0.0009392997,0.99749327,0.00027039423,0.00025276258,0.00010052245,0.0000129211985,0.000030859337,0.000002676501,0.00089733937],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998054,0.000038674654,0.000020322816,0.000035796427,0.00008034565,0.000019396233],"domain_scores_gemma":[0.99983275,0.00009572677,0.00001992112,0.0000060049074,0.000033626082,0.0000120152745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058487087,0.0007883628,0.0008509208,0.001912289,0.00023298718,0.0010692343,0.0005422514,0.0012578748,0.0029404128],"category_scores_gemma":[0.0005045792,0.00022525112,0.00044566853,0.0011857966,0.0005042309,0.001333831,0.00067308435,0.0019774672,0.0021381532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054358017,0.00010139476,0.000102648584,0.0116625,0.00005119697,0.00020511137,0.0000714306,0.00045733416,0.0061099925,0.017379042,0.024305722,0.9394993],"study_design_scores_gemma":[0.00001331337,0.000085059466,0.00019922378,0.002093896,0.000043596985,0.00078826176,0.000028062586,0.00006615707,0.0018869074,0.0025779912,0.99220484,0.000012789285],"about_ca_topic_score_codex":0.000739863,"about_ca_topic_score_gemma":0.0012500195,"teacher_disagreement_score":0.0029404128,"about_ca_system_score_codex":0.00063168793,"about_ca_system_score_gemma":0.0006898104,"threshold_uncertainty_score":0.009836674},"labels":[],"label_agreement":null},{"id":"W3140219234","doi":"10.1016/j.jval.2017.08.637","title":"Resource Utilization And Disaggregated Cost Analysis For Initial Treatment Of Melanoma","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Melanoma; Resource (disambiguation); Computer science; Resource use; Natural resource economics; Economics; Medicine; Cancer research; Computer network","score_opus":0.22265516802860844,"score_gpt":0.4504007556636089,"score_spread":0.22774558763500044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140219234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981979,0.0009765938,0.0018408373,0.000492468,0.000021912414,0.000059135313,0.012414667,0.00004192226,0.0021734657],"genre_scores_gemma":[0.9950664,0.00014645355,0.000666987,0.00004206277,0.000008253523,0.000032381504,0.0034952268,0.000009850122,0.00053236994],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99916625,0.00043131897,0.000054844997,0.00008035917,0.000105622574,0.00016159075],"domain_scores_gemma":[0.9982023,0.0010042812,0.00031993137,0.0001366855,0.00022064394,0.00011610353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009656634,0.00038183515,0.00078752526,0.0014084097,0.00016995147,0.000992649,0.0006322655,0.00048811088,0.004002492],"category_scores_gemma":[0.005188123,0.0003526359,0.001973825,0.0028311952,0.00018726011,0.00062225125,0.00048010747,0.0006382664,0.00024989853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003643666,0.00049160316,0.18469058,0.00027716308,0.0025147588,0.00025088387,0.00012436314,0.7698327,0.0008898703,0.005579026,0.0052374527,0.026468018],"study_design_scores_gemma":[0.00020005171,0.0006785945,0.3951833,0.00009362286,0.0010682615,0.00037003303,0.00060172455,0.5923458,0.0009208163,0.0039943582,0.004480298,0.00006316627],"about_ca_topic_score_codex":0.052271817,"about_ca_topic_score_gemma":0.037838947,"teacher_disagreement_score":0.052271817,"about_ca_system_score_codex":0.0028588548,"about_ca_system_score_gemma":0.0013307724,"threshold_uncertainty_score":0.10393512},"labels":[],"label_agreement":null},{"id":"W3141144532","doi":"10.1158/0008-5472.can-20-2701","title":"Mesothelin-Specific CAR T Cells Target Ovarian Cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"Mesothelin; Ovarian cancer; Cancer research; CD28; Tumor microenvironment; T cell; Cytotoxic T cell; CD8; Immune system; Medicine; Ovarian tumor; Antigen; Cancer; Immunology; Biology; Internal medicine; In vitro","score_opus":0.11573063686289073,"score_gpt":0.42826269920093607,"score_spread":0.3125320623380453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141144532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99379855,0.0020393569,0.002199643,0.00013251927,0.000032382803,0.000083404004,0.00015347514,0.000088688656,0.0014720474],"genre_scores_gemma":[0.9974795,0.00044026927,0.00084329554,0.000036520756,0.000013509395,0.000028152748,0.00012596218,0.000005777811,0.0010269578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999118,0.000019208977,0.0000053896624,0.000017609977,0.000016824757,0.000029190029],"domain_scores_gemma":[0.9999541,0.0000086597365,0.000011582771,0.0000058727856,0.000004252733,0.000015449195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000097431715,0.00020145506,0.00020865815,0.00012975834,0.00008689864,0.00028414873,0.000076671815,0.00022482908,0.0012968262],"category_scores_gemma":[0.00007255614,0.000057872647,0.00015303325,0.000076534634,0.00012559223,0.00013298688,0.00013593391,0.0005136259,0.00025868625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035046265,0.0001385276,0.0010552513,0.00007673537,0.000011115543,0.000071706905,0.000025087684,0.00032261538,0.9921361,0.0002119924,0.00021701261,0.005383417],"study_design_scores_gemma":[0.00020458622,0.0042776223,0.009190169,0.000012991307,0.000064173146,0.00096884125,0.00006886743,0.004017703,0.9695015,0.00012905059,0.0115592275,0.000005314574],"about_ca_topic_score_codex":0.00031742404,"about_ca_topic_score_gemma":0.0005183126,"teacher_disagreement_score":0.0012968262,"about_ca_system_score_codex":0.00019857044,"about_ca_system_score_gemma":0.00021105948,"threshold_uncertainty_score":0.0043382645},"labels":[],"label_agreement":null},{"id":"W3145845511","doi":"10.1101/2021.04.02.437733","title":"Autologous humanized mouse models of iPSC-derived tumors allow for the evaluation and modulation of cancer-immune cell interactions","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Immune system; Humanized mouse; Cancer research; Nivolumab; Tumor microenvironment; Cell; Cancer cell; Immunology; Cancer; Biology; Immunotherapy; Medicine","score_opus":0.054378189449212674,"score_gpt":0.32127396295963195,"score_spread":0.26689577351041927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145845511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84090185,0.0045977575,0.12843612,0.0007004965,0.00059034716,0.00055818685,0.007084905,0.0016441884,0.015486151],"genre_scores_gemma":[0.9315668,0.0029926004,0.041466463,0.00020332658,0.0000637069,0.00045627638,0.004060831,0.00030752944,0.018882383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973065,0.00004295844,0.000027988533,0.0000694799,0.00009540777,0.000033395598],"domain_scores_gemma":[0.99983156,0.000031078427,0.000047472357,0.00004262055,0.000015483438,0.000031770072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004687019,0.00071615493,0.00033969228,0.00059181947,0.00019203936,0.0005930575,0.00027480762,0.00056748796,0.0047035464],"category_scores_gemma":[0.00011205807,0.00019055627,0.00038317707,0.00020889663,0.00042794587,0.00037670575,0.0002851496,0.001479468,0.0011896658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011429641,0.00008401857,0.00019106996,0.000056864552,0.00001270619,0.000090415386,0.00002395006,0.00021638018,0.9956086,0.0007730346,0.00026149288,0.0025671276],"study_design_scores_gemma":[0.000016783999,0.00014848323,0.00046092505,0.000009452251,0.000019166211,0.0002878958,0.000012692022,0.0008322751,0.99206114,0.00012041591,0.0060273022,0.0000035108742],"about_ca_topic_score_codex":0.00028976277,"about_ca_topic_score_gemma":0.00041022687,"teacher_disagreement_score":0.0047035464,"about_ca_system_score_codex":0.00028895997,"about_ca_system_score_gemma":0.00029981896,"threshold_uncertainty_score":0.01573497},"labels":[],"label_agreement":null},{"id":"W3145970345","doi":"10.21203/rs.3.rs-355230/v1","title":"Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran)","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Medical Research Council; National Institute for Health and Care Research; Royal Marsden NHS Foundation Trust; Wellcome Trust; Francis Crick Institute; Cancer Research UK; Royal Marsden Cancer Charity","keywords":"Vaccination; Colorectal cancer; Medicine; Cancer; Cytokine; Immunology; Internal medicine","score_opus":0.03231096816779156,"score_gpt":0.3727008006689854,"score_spread":0.34038983250119387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145970345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407154,0.0009118111,0.0009564838,0.00081705843,0.000086345986,0.000060257717,0.00009710103,0.00007170017,0.002927583],"genre_scores_gemma":[0.99873954,0.00021716251,0.0001992417,0.00027082427,0.00008925447,0.000008352912,0.000047075308,0.000004175857,0.00042427724],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998186,0.00003243939,0.000017719027,0.00004435618,0.00002343319,0.00006342119],"domain_scores_gemma":[0.99950516,0.00017024153,0.00010291185,0.000030311332,0.000026936788,0.00016435137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016917249,0.0006263798,0.00054733007,0.0005659331,0.000823786,0.00046639348,0.00022577599,0.0016621525,0.0010615557],"category_scores_gemma":[0.0010038854,0.00027267876,0.0004887254,0.00028335635,0.00046611973,0.00031564807,0.0003861834,0.0012497754,0.00031560566],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063148484,0.000089564324,0.037732136,0.000048965794,0.000027510498,0.95124227,0.00032875646,0.00014766984,0.006261423,0.0001424083,0.0003496687,0.0029981302],"study_design_scores_gemma":[0.00010000681,0.0011705625,0.044231277,0.000021925734,0.000056408546,0.94833034,0.00019070049,0.0008128112,0.0034533984,0.00013151465,0.0014801107,0.000020967964],"about_ca_topic_score_codex":0.0010750459,"about_ca_topic_score_gemma":0.0008347092,"teacher_disagreement_score":0.0016621525,"about_ca_system_score_codex":0.00045234433,"about_ca_system_score_gemma":0.00025533314,"threshold_uncertainty_score":0.0035512447},"labels":[],"label_agreement":null},{"id":"W3151543485","doi":"10.1158/2159-8290.cd-20-1677","title":"Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; European Hematology Association; National Heart, Lung, and Blood Institute; Stand Up To Cancer; Doris Duke Charitable Foundation","keywords":"Persistence (discontinuity); Profiling (computer programming); Cell; Computational biology; Term (time); Biology; Cell biology; Genetics; Computer science; Physics; Engineering","score_opus":0.07317010384896924,"score_gpt":0.32719381558736893,"score_spread":0.25402371173839966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151543485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940791,0.00054110854,0.004032799,0.000035781617,0.000007026077,0.00002322451,0.00073710794,0.000055555385,0.0004883571],"genre_scores_gemma":[0.99680907,0.00015171281,0.0014044133,0.000050807244,0.000007691419,0.000032907086,0.0009515981,0.00001885443,0.00057282817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99984884,0.000017437013,0.000009368147,0.00004263759,0.000043151627,0.000038480164],"domain_scores_gemma":[0.9998559,0.000033258555,0.00003280857,0.000017253786,0.00003592296,0.000024984975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018548217,0.00012881278,0.00025080773,0.0002819596,0.00018084384,0.0005069867,0.00011494236,0.0002215697,0.0012013477],"category_scores_gemma":[0.00022726622,0.00008249204,0.00017706108,0.00018492626,0.00015456988,0.00015086877,0.00017196954,0.00040939316,0.0004349345],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022654922,0.000026589607,0.012544906,0.00003062355,0.00001530737,0.000040280156,0.00007436275,0.00034199236,0.97977704,0.000065928834,0.00009798459,0.006758365],"study_design_scores_gemma":[0.000029374254,0.0012893261,0.27871788,0.000017214401,0.00011467946,0.00093355594,0.0007266943,0.008333018,0.70437104,0.0004976145,0.0049455594,0.000024101178],"about_ca_topic_score_codex":0.00034102215,"about_ca_topic_score_gemma":0.00047338143,"teacher_disagreement_score":0.0012013477,"about_ca_system_score_codex":0.00018030647,"about_ca_system_score_gemma":0.00014559591,"threshold_uncertainty_score":0.0040189624},"labels":[],"label_agreement":null},{"id":"W3153996944","doi":"10.1002/cjce.24141","title":"Process evolution in cell and gene therapy from discovery to commercialization","year":2021,"lang":"en","type":"article","venue":"The Canadian Journal of Chemical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Hatch (Canada)","funders":"","keywords":"Commercialization; Computer science; New product development; Process (computing); Quality by Design; Process management; Quality (philosophy); Modular design; Risk analysis (engineering); Engineering; Business","score_opus":0.01445276828322336,"score_gpt":0.2507932958868911,"score_spread":0.23634052760366772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153996944","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14278443,0.0047649336,0.82163537,0.003687253,0.0001555005,0.0014355924,0.00021566697,0.00089749217,0.02442371],"genre_scores_gemma":[0.5528178,0.0027414344,0.43879887,0.00055361044,0.000044877073,0.0006356897,0.0002676328,0.00019956536,0.0039405073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899946,0.004939793,0.00053100486,0.0009787948,0.003017283,0.00053857174],"domain_scores_gemma":[0.9860297,0.006949427,0.001443078,0.0022946203,0.0028588376,0.00042441476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023593932,0.0007567602,0.0005522612,0.0016649298,0.0009070344,0.004923924,0.0015890532,0.0011906419,0.0022807058],"category_scores_gemma":[0.016213076,0.0006477309,0.0010863743,0.0011146484,0.0025446946,0.0033333662,0.0026331174,0.0018396754,0.00072307925],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063600956,0.000919576,0.012606057,0.001476928,0.00021342104,0.00051374885,0.0018999494,0.10270772,0.1370146,0.29541484,0.0023124155,0.4442848],"study_design_scores_gemma":[0.00040135157,0.005510224,0.00921337,0.0007340096,0.00037954602,0.0010256957,0.0017623163,0.2493898,0.2920267,0.27868137,0.16061547,0.00026020096],"about_ca_topic_score_codex":0.0025277706,"about_ca_topic_score_gemma":0.0015307546,"teacher_disagreement_score":0.023593932,"about_ca_system_score_codex":0.004032076,"about_ca_system_score_gemma":0.0068922224,"threshold_uncertainty_score":0.12477815},"labels":[],"label_agreement":null},{"id":"W3155195921","doi":"10.1016/s2352-3026(21)00060-0","title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Canada Research Chairs; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Intensive care; Intensive care unit; Cytokine release syndrome; Cohort study; Cohort; Observational study; Proportional hazards model; Internal medicine; Retrospective cohort study; Emergency medicine; Chimeric antigen receptor; Pediatrics; Intensive care medicine; Confidence interval; Immunotherapy","score_opus":0.05996188039825393,"score_gpt":0.35537644755280046,"score_spread":0.2954145671545465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155195921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856454,0.00026389176,0.00004823062,0.000076225406,0.000024552804,0.00001336922,0.0007492812,0.000002300002,0.00025764995],"genre_scores_gemma":[0.9984118,0.00020635745,0.0000451208,0.000104545456,0.000036458,0.000021951297,0.0010327742,0.000003074283,0.00013805399],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992467,0.00016914317,0.00006202061,0.00021677605,0.00007545795,0.00022993007],"domain_scores_gemma":[0.99836606,0.00021370007,0.00075222715,0.00015850413,0.00010434046,0.0004052253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062787224,0.0005370447,0.00076413614,0.0005466723,0.000689419,0.001727221,0.000728387,0.0011737909,0.0019627102],"category_scores_gemma":[0.002181564,0.00057191006,0.0013523251,0.0014709998,0.0004854637,0.001008641,0.0009223656,0.0017568609,0.00029422858],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017328083,0.00018270651,0.9953497,0.000029359857,0.00051305024,0.00026511183,0.00015141818,0.000081537044,0.0004004329,0.000069887006,0.00054208393,0.00068194576],"study_design_scores_gemma":[0.00020769802,0.0004853712,0.997361,0.000023983524,0.00026007378,0.0003896485,0.0006053688,0.00025481766,0.000046688776,0.000075737844,0.00026787329,0.000021646098],"about_ca_topic_score_codex":0.009317999,"about_ca_topic_score_gemma":0.008105292,"teacher_disagreement_score":0.009317999,"about_ca_system_score_codex":0.0007418904,"about_ca_system_score_gemma":0.0006633821,"threshold_uncertainty_score":0.018527508},"labels":[],"label_agreement":null},{"id":"W3155376846","doi":"10.1109/jsen.2021.3072578","title":"Miniature Fiber-Spectrophotometer for Real-Time Biomarkers Detection","year":2021,"lang":"en","type":"article","venue":"IEEE Sensors Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Canada First Research Excellence Fund","keywords":"Notation; Spectrometer; Analytical Chemistry (journal); Computer science; Physics; Mathematics; Chromatography; Chemistry; Optics","score_opus":0.021185925962318834,"score_gpt":0.30918506312054483,"score_spread":0.287999137158226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155376846","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.082794905,0.008324166,0.8919641,0.00069753267,0.0012034791,0.0006909816,0.001176126,0.005763271,0.0073855277],"genre_scores_gemma":[0.23767006,0.004133852,0.74552834,0.0006762302,0.00043897177,0.0008197202,0.0008137081,0.00023462565,0.009684448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789894,0.00027231788,0.00007680449,0.000577572,0.0010913605,0.000083000086],"domain_scores_gemma":[0.99935144,0.00021824028,0.000105136605,0.00008193858,0.00020019291,0.000043059594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001033719,0.0012566665,0.0010198088,0.0011296032,0.00049874454,0.0005715706,0.0017599192,0.0015613746,0.0035386395],"category_scores_gemma":[0.0010572502,0.00057830557,0.0007013485,0.0007744488,0.0004076405,0.0013064991,0.0006895238,0.0010163733,0.0025346882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015809524,0.00015393068,0.0012603225,0.00040796536,0.00005672035,0.00009818659,0.00006429435,0.0006203838,0.927119,0.0010376343,0.002413983,0.06660959],"study_design_scores_gemma":[0.000043101903,0.0007152704,0.003499308,0.00003829901,0.00013033522,0.0011829163,0.000054525,0.022697942,0.9300846,0.000506893,0.040937386,0.00010923314],"about_ca_topic_score_codex":0.0005294308,"about_ca_topic_score_gemma":0.0010524156,"teacher_disagreement_score":0.0035386395,"about_ca_system_score_codex":0.0007696651,"about_ca_system_score_gemma":0.0004065671,"threshold_uncertainty_score":0.0118379},"labels":[],"label_agreement":null},{"id":"W3157151159","doi":"10.15173/sciential.v1i4.2435","title":"Review on Anti-CD19 CAR T Therapy against B-Cell Malignancies and Future Implications","year":2020,"lang":"en","type":"article","venue":"Sciential - McMaster Undergraduate Science Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Medicine; CD19; Immunotherapy; Clinical trial; Cell therapy; Targeted therapy; Oncology; Immune system; Immunology; Cancer; Internal medicine; Cell; Biology","score_opus":0.048298990145938074,"score_gpt":0.32278358628384246,"score_spread":0.2744845961379044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157151159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023793011,0.9961993,0.00018155832,0.0005217899,0.00055775704,0.000012858088,0.000032927255,0.000011560548,0.0022443153],"genre_scores_gemma":[0.0007833022,0.99647754,0.00020093241,0.0007465463,0.00039423018,0.000014686159,0.000048822712,0.000002805165,0.001331102],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998658,0.000028199032,0.000019517242,0.000022042126,0.000046841575,0.000017616792],"domain_scores_gemma":[0.9997099,0.00015097627,0.000041934512,0.000006540815,0.0000637822,0.000026844871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003774702,0.00047383152,0.00079335895,0.0015261503,0.00022213704,0.0008406242,0.0006606615,0.0010158815,0.005760913],"category_scores_gemma":[0.0005694366,0.00022292015,0.00056361244,0.001551748,0.00023538033,0.0009904423,0.0003383102,0.0010784223,0.0024615221],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016248139,0.000117982476,0.00013550243,0.017987847,0.0001074344,0.00032452252,0.000066495464,0.00068620685,0.0035403133,0.0028577098,0.09206765,0.8819458],"study_design_scores_gemma":[0.000022735354,0.00021707048,0.00038661493,0.0036471505,0.00009397122,0.0006915302,0.00003272736,0.00005674493,0.00065521576,0.0006073623,0.9935796,0.000009369108],"about_ca_topic_score_codex":0.0008872088,"about_ca_topic_score_gemma":0.0017694202,"teacher_disagreement_score":0.005760913,"about_ca_system_score_codex":0.00058947026,"about_ca_system_score_gemma":0.0009367209,"threshold_uncertainty_score":0.019272149},"labels":[],"label_agreement":null},{"id":"W3157520262","doi":"10.1126/scitranslmed.abe7378","title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","year":2021,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":495,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"UCSF Foundation; National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Institutes of Health; University of California, San Francisco; Parker Institute for Cancer Immunotherapy; Howard Hughes Medical Institute","keywords":"Antigen; Chimeric antigen receptor; Cancer research; Priming (agriculture); Biology; Cytotoxic T cell; Immunology; T cell; Glioma; Medicine; Immune system; In vitro","score_opus":0.0760524279981797,"score_gpt":0.33984175030018243,"score_spread":0.26378932230200275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157520262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911169,0.0027667163,0.0046448237,0.00017236278,0.000037538164,0.000071388415,0.00004837227,0.00009511663,0.0010468164],"genre_scores_gemma":[0.9965513,0.0010788165,0.0014804925,0.000079570425,0.000016936141,0.000025540905,0.000067657464,0.000010079881,0.00068956305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993396,0.00000988441,0.0000056498975,0.00001175129,0.000015477819,0.000023261586],"domain_scores_gemma":[0.9999734,0.0000036016838,0.0000074938434,0.0000038601165,0.0000059024615,0.000005603008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011051312,0.00026300902,0.00021697188,0.00014396566,0.00007214439,0.00023732125,0.00018261091,0.00021809209,0.00047446447],"category_scores_gemma":[0.00006863623,0.000074515716,0.0001429249,0.00007996316,0.00015119223,0.0002282049,0.00018444342,0.00040199363,0.00010589537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002656707,0.00012002534,0.00044650893,0.00014440808,0.000018917126,0.00012427286,0.00004927155,0.0012225888,0.9721934,0.00071698026,0.0002704565,0.024427507],"study_design_scores_gemma":[0.00019416289,0.0048654294,0.0049041044,0.000026646943,0.00016533375,0.0012851565,0.00007076407,0.0060321623,0.96714,0.0003900351,0.014909982,0.000016216954],"about_ca_topic_score_codex":0.00039938002,"about_ca_topic_score_gemma":0.0009878442,"teacher_disagreement_score":0.00047446447,"about_ca_system_score_codex":0.00018790041,"about_ca_system_score_gemma":0.0002293256,"threshold_uncertainty_score":0.0015872121},"labels":[],"label_agreement":null},{"id":"W3157757987","doi":"10.1097/01.cot.0000752008.06679.fd","title":"Overcoming Challenges to Broaden Adoptive T-Cell Therapy in Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); League; Library science; Medicine; Sociology; Biology; Computer science","score_opus":0.04854358197461878,"score_gpt":0.3835921928836314,"score_spread":0.3350486109090126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157757987","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054848916,0.25314203,0.020627331,0.6785795,0.015490131,0.00042580717,0.00013461767,0.0005182812,0.025597373],"genre_scores_gemma":[0.11534236,0.371474,0.03518153,0.40710953,0.046755545,0.0015492141,0.00033885532,0.00044783365,0.021801176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9894811,0.0043941378,0.00077911204,0.0008476536,0.0033121184,0.0011859145],"domain_scores_gemma":[0.98189086,0.009533316,0.0007853316,0.0010063319,0.00383717,0.0029470616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04093062,0.0006461667,0.0012049938,0.0012566155,0.0018748001,0.006330313,0.0027259688,0.0058227824,0.007457325],"category_scores_gemma":[0.018763216,0.00042559885,0.000990397,0.0006151168,0.005469625,0.007528713,0.007929929,0.02010481,0.003502262],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021589425,0.0006012524,0.0014164693,0.0017362743,0.00010185904,0.00038857668,0.0016283961,0.00090387027,0.0038460598,0.041994628,0.29997286,0.64719385],"study_design_scores_gemma":[0.00019243317,0.0007229928,0.0008875963,0.0020717639,0.000059754624,0.0006957637,0.0011718337,0.0005945475,0.0016276091,0.034269363,0.95765615,0.000050142546],"about_ca_topic_score_codex":0.0036639695,"about_ca_topic_score_gemma":0.011121656,"teacher_disagreement_score":0.04093062,"about_ca_system_score_codex":0.0038820233,"about_ca_system_score_gemma":0.00887604,"threshold_uncertainty_score":0.21646434},"labels":[],"label_agreement":null},{"id":"W3158014403","doi":"10.4049/jimmunol.2100141","title":"Cutting Edge: TCR-β Selection Is Required at the CD4+CD8+ Stage of Human T Cell Development","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; Beijing Municipal Natural Science Foundation; Canadian Institute for Telecommunications Research; Canada First Research Excellence Fund; Krembil Foundation; University of Toronto; National Natural Science Foundation of China; National Institutes of Health; Government of Canada; Canadian Cancer Society Research Institute; Sunnybrook Research Institute","keywords":"T-cell receptor; Biology; CD8; RAG2; Negative selection; T cell; Gene rearrangement; Cell biology; Lineage (genetic); Gene; Molecular biology; Genetics; Antigen; Recombination; Genome; Immune system","score_opus":0.04041199063807256,"score_gpt":0.3296500912389186,"score_spread":0.28923810060084604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158014403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882973,0.0024293705,0.0049271453,0.00028341028,0.00006206088,0.000033067394,0.00069825316,0.00020645965,0.003062983],"genre_scores_gemma":[0.99506503,0.0004647997,0.0016732286,0.00013565172,0.00001639173,0.000014677795,0.00054246094,0.000027685392,0.0020600474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998566,0.00001798032,0.000014328339,0.000043526794,0.00003410796,0.000033510067],"domain_scores_gemma":[0.99989223,0.000016824555,0.000031117266,0.000014061438,0.000014977347,0.000030744417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010220088,0.00017876033,0.0001687652,0.000117681506,0.000109488436,0.00043611112,0.00013631421,0.00026765448,0.0033563902],"category_scores_gemma":[0.000107474836,0.00009795778,0.00012299669,0.0000864942,0.00014921106,0.00019219323,0.00019174843,0.00060462666,0.0007934338],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055802077,0.0000074975724,0.00022816162,0.00001848154,0.0000014333516,0.000052425847,0.000005927178,0.00001780749,0.9984989,0.00007001545,0.00005307297,0.0009904387],"study_design_scores_gemma":[0.000013466878,0.00017580786,0.007861898,0.000010805008,0.000014897535,0.00080469256,0.000035949502,0.0004304636,0.98515517,0.00007810249,0.0054154084,0.000003198679],"about_ca_topic_score_codex":0.00022661235,"about_ca_topic_score_gemma":0.00022695158,"teacher_disagreement_score":0.0033563902,"about_ca_system_score_codex":0.00014043124,"about_ca_system_score_gemma":0.00017353818,"threshold_uncertainty_score":0.011228263},"labels":[],"label_agreement":null},{"id":"W3158771720","doi":"10.1016/j.ebiom.2021.103354","title":"Delivery technologies for T cell gene editing: Applications in cancer immunotherapy","year":2021,"lang":"en","type":"review","venue":"EBioMedicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Canadian Aeronautics and Space Institute; Institute for Translational Medicine and Therapeutics; Burroughs Wellcome Fund","keywords":"Immunotherapy; Cancer immunotherapy; Cancer; Genome editing; Computational biology; Gene; Medicine; Biology; Cancer research; Genome; Genetics","score_opus":0.07313519721810581,"score_gpt":0.4149902454000573,"score_spread":0.3418550481819515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158771720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002789871,0.9972156,0.0006866532,0.00014770955,0.00013671862,0.000010487454,0.000018742663,0.000013391787,0.001491687],"genre_scores_gemma":[0.0010771086,0.9974361,0.0005754662,0.00013095888,0.000068483634,0.000013172275,0.000028077067,0.0000029082107,0.0006676735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983764,0.000027420192,0.00001631119,0.000029904551,0.000069501264,0.000019214516],"domain_scores_gemma":[0.99985266,0.00008900117,0.000018843693,0.0000046056894,0.000024611667,0.000010321871],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004817558,0.00066808035,0.00086301274,0.0022600514,0.00023073584,0.00077362225,0.00054437877,0.0010233115,0.0023806863],"category_scores_gemma":[0.00037171732,0.00025818407,0.00049825344,0.001730195,0.0004022273,0.0010146691,0.000512389,0.001632053,0.0015933583],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058292077,0.00010807994,0.000112623115,0.017259995,0.00006532177,0.00034362086,0.00008973105,0.0006596982,0.018310854,0.007874435,0.014438798,0.94067854],"study_design_scores_gemma":[0.000020520614,0.00016493851,0.0004241645,0.0023526028,0.0000850878,0.0017399087,0.000048609112,0.0001817992,0.004991244,0.0024097199,0.9875547,0.000026634478],"about_ca_topic_score_codex":0.0005819527,"about_ca_topic_score_gemma":0.0006865161,"teacher_disagreement_score":0.0023806863,"about_ca_system_score_codex":0.0004512786,"about_ca_system_score_gemma":0.00053692237,"threshold_uncertainty_score":0.007964253},"labels":[],"label_agreement":null},{"id":"W3158886261","doi":"10.1007/978-1-0716-1311-5_19","title":"Transduction of Human T Cell Subsets with Lentivirus","year":2021,"lang":"en","type":"book-chapter","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Transduction (biophysics); Lentivirus; CD8; Chimeric antigen receptor; Cytotoxic T cell; Biology; T cell; Transgene; Gene; Molecular biology; Cell biology; Antigen; Virology; Immunology; Genetics; Human immunodeficiency virus (HIV); Immune system; In vitro; Biochemistry","score_opus":0.05896044766884998,"score_gpt":0.42310302526023563,"score_spread":0.36414257759138563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158886261","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24449244,0.035828207,0.43687525,0.0010633911,0.0019562438,0.0008693061,0.004632538,0.0038983445,0.27038416],"genre_scores_gemma":[0.5037633,0.03184119,0.09886868,0.0010534456,0.0003401743,0.0008432726,0.006816365,0.0010042351,0.35546932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991643,0.000009517469,0.0000062594013,0.000015458725,0.000034050398,0.000018217037],"domain_scores_gemma":[0.99997246,0.000010218673,0.0000030498577,0.000006209694,0.0000044922795,0.000003476861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019315424,0.00050648046,0.00024108494,0.00025342903,0.0001474343,0.00072274654,0.00036595023,0.00021369247,0.0040003047],"category_scores_gemma":[0.00008499369,0.00019058152,0.0003292905,0.00021670683,0.00017532379,0.00036470912,0.00030592032,0.0008873576,0.0017714512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054284046,0.00003427079,0.00006497477,0.00010504136,0.0000064282704,0.00009071494,0.000054936452,0.00023378996,0.9498019,0.005846034,0.0020082612,0.041699287],"study_design_scores_gemma":[0.000024234112,0.00016975342,0.00045137433,0.000032102686,0.000021061913,0.00047594451,0.000024370762,0.0011346489,0.86806244,0.0019916375,0.1276041,0.000008351477],"about_ca_topic_score_codex":0.0003687448,"about_ca_topic_score_gemma":0.0003903807,"teacher_disagreement_score":0.0040003047,"about_ca_system_score_codex":0.00023388995,"about_ca_system_score_gemma":0.00017753747,"threshold_uncertainty_score":0.013382375},"labels":[],"label_agreement":null},{"id":"W3159827603","doi":"10.3390/ijms22094590","title":"State-of-Art of Cellular Therapy for Acute Leukemia","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Immune system; Medicine; Immunotherapy; Leukemia; Disease; Cancer; Pillar; Cell therapy; Immunology; Cell; Biology; Internal medicine","score_opus":0.06919861862279716,"score_gpt":0.43671047141343383,"score_spread":0.3675118527906367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159827603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014428688,0.99741995,0.00023051283,0.00029002703,0.0002105485,0.000009071063,0.000020173955,0.000009328373,0.0016660873],"genre_scores_gemma":[0.0007516413,0.9980482,0.00023414227,0.00016376519,0.00016942433,0.00001157688,0.000029279745,0.000001479605,0.00059052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980325,0.00003540277,0.00002295189,0.000032267068,0.00008527077,0.000020942065],"domain_scores_gemma":[0.9997186,0.00015777112,0.000029450926,0.000010805715,0.000062165156,0.000021109681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006542962,0.0006678925,0.0008976519,0.0017276116,0.00027397336,0.0009194162,0.00071527675,0.000849703,0.0046843584],"category_scores_gemma":[0.00053187937,0.00023532019,0.0004897094,0.0012739829,0.00040735948,0.0011042367,0.0006435166,0.0019712679,0.0026407924],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062086045,0.00008734578,0.00009093393,0.011848298,0.000044894146,0.00011222204,0.00005251341,0.00036590325,0.0035762847,0.0071582193,0.020304129,0.95629716],"study_design_scores_gemma":[0.000011277593,0.00010412333,0.00027497933,0.0016357406,0.000044283614,0.000456687,0.000021777885,0.00009300156,0.0009673593,0.0017374282,0.99464226,0.000011075771],"about_ca_topic_score_codex":0.00066052144,"about_ca_topic_score_gemma":0.0010221968,"teacher_disagreement_score":0.0046843584,"about_ca_system_score_codex":0.00050563295,"about_ca_system_score_gemma":0.00087978685,"threshold_uncertainty_score":0.015670717},"labels":[],"label_agreement":null},{"id":"W3161556153","doi":"10.26685/urncst.227","title":"Efficacy of CRISPR-Cas9 CAR T-Cell Therapy vs. Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; McMaster University","funders":"","keywords":"CRISPR; Chimeric antigen receptor; Medicine; Blinatumomab; Immunology; T cell; Cell therapy; Leukemia; Immunotherapy; Genetic enhancement; Cancer research; Immune system; Oncology; Internal medicine; Cell; Biology; Lymphoblastic Leukemia; Gene","score_opus":0.06254274169820717,"score_gpt":0.4265186770455801,"score_spread":0.36397593534737294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161556153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411917,0.0032662,0.00048715877,0.00012859261,0.00007028059,0.00013335783,0.00031106165,0.00008559043,0.0013985147],"genre_scores_gemma":[0.99657744,0.001545956,0.00054667407,0.00005064636,0.000028872071,0.000114486764,0.00030906624,0.000012313264,0.00081451406],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997588,0.000066316876,0.000022941986,0.000046746245,0.000050997412,0.000054224627],"domain_scores_gemma":[0.99984324,0.000032929656,0.00003697039,0.000018000752,0.000009143843,0.00005966647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043837327,0.00043483666,0.00097481767,0.00042121115,0.00017119144,0.00047431546,0.0003179847,0.0004538318,0.0020250566],"category_scores_gemma":[0.0001802788,0.0001221337,0.00031430367,0.00026872638,0.00035800226,0.000293658,0.00019061513,0.00085254153,0.00029396333],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055682704,0.012438629,0.002407966,0.00082634384,0.0002921768,0.0001717134,0.00015996919,0.0022200416,0.8074585,0.0005856912,0.001576865,0.11617949],"study_design_scores_gemma":[0.007599674,0.19672947,0.018892737,0.000086430744,0.0006444435,0.00079330144,0.00012772223,0.004525591,0.7621424,0.00025355004,0.008165244,0.00003940124],"about_ca_topic_score_codex":0.00072554796,"about_ca_topic_score_gemma":0.0010587439,"teacher_disagreement_score":0.0020250566,"about_ca_system_score_codex":0.00033119653,"about_ca_system_score_gemma":0.0004233713,"threshold_uncertainty_score":0.0067745447},"labels":[],"label_agreement":null},{"id":"W3162743464","doi":"10.1007/s12325-021-01756-0","title":"Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Confidence interval; Salvage therapy; Oncology; Refractory (planetary science); Chemotherapy","score_opus":0.025367968608400935,"score_gpt":0.35202477845148494,"score_spread":0.326656809843084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162743464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97195834,0.015807629,0.0028034723,0.00024855637,0.0005378693,0.0018129136,0.0018325255,0.000049698232,0.004949041],"genre_scores_gemma":[0.99197114,0.0016854092,0.0018167794,0.000284342,0.0001879712,0.0014324775,0.0012318329,0.000021354488,0.0013685145],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9900988,0.0075081186,0.0007137955,0.0007576147,0.00064978807,0.00027192355],"domain_scores_gemma":[0.9897377,0.0071133315,0.0016382388,0.0007885,0.0003995756,0.00032261817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00930664,0.0012829395,0.0029062706,0.0009387781,0.0001630587,0.0011495223,0.0009548723,0.0010241859,0.0052229073],"category_scores_gemma":[0.013719609,0.00037792875,0.0049241595,0.0005797855,0.000705837,0.0008152949,0.0010850898,0.0018805884,0.00043208065],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8864289,0.0022047434,0.010616824,0.0048789233,0.046349905,0.00009751292,0.00022659943,0.0024809563,0.0034658734,0.0011883812,0.0008497288,0.041211702],"study_design_scores_gemma":[0.30972436,0.46607986,0.068706356,0.0012800057,0.11404098,0.0004813475,0.00063839386,0.009702752,0.01243359,0.0048648585,0.011857732,0.00018981691],"about_ca_topic_score_codex":0.0003755818,"about_ca_topic_score_gemma":0.00073218264,"teacher_disagreement_score":0.00930664,"about_ca_system_score_codex":0.0006769561,"about_ca_system_score_gemma":0.00057080976,"threshold_uncertainty_score":0.049218774},"labels":[],"label_agreement":null},{"id":"W3163013904","doi":"10.2139/ssrn.3824765","title":"A First-in-Human Phase I/IIa Study of Allogeneic Double Negative T Cell for the Treatment of Relapsed AML Post Allo-HSCT","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Complete remission; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; CD8; Gastroenterology; Transplantation; Disease; Minimal residual disease; Chemotherapy; Oncology; Leukemia; Surgery; Immunology; Immune system","score_opus":0.029445402952557816,"score_gpt":0.3511902579164156,"score_spread":0.3217448549638578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163013904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874626,0.0015923693,0.0011995558,0.0007620086,0.0002617522,0.0044342335,0.0019838838,0.000112610534,0.0021908856],"genre_scores_gemma":[0.9802556,0.0022800318,0.0024203653,0.0018216308,0.0002930647,0.0041948264,0.0033101216,0.00008176745,0.0053425026],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991943,0.00035602791,0.00003295137,0.00012211261,0.000047622012,0.00024692915],"domain_scores_gemma":[0.9989071,0.00014614541,0.00010408784,0.00014986991,0.000051404906,0.0006413213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025580456,0.0021009552,0.002973456,0.00072793284,0.0010402234,0.0018849946,0.0014948088,0.0022932845,0.0042448347],"category_scores_gemma":[0.0010019543,0.0007564581,0.0020109764,0.000556202,0.0018212707,0.0010741052,0.00053729146,0.0058364985,0.0015407423],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59399235,0.22503543,0.0048194635,0.0009325575,0.0014047626,0.0009768553,0.0007840982,0.0044018924,0.07532665,0.00093842886,0.0057647773,0.08562279],"study_design_scores_gemma":[0.2990764,0.68641806,0.0042905826,0.00003679239,0.00036551166,0.00032286145,0.00012102605,0.0006403566,0.005490906,0.00030678386,0.0028974072,0.000033307984],"about_ca_topic_score_codex":0.0023452512,"about_ca_topic_score_gemma":0.0046235584,"teacher_disagreement_score":0.0042448347,"about_ca_system_score_codex":0.0011389375,"about_ca_system_score_gemma":0.0027709194,"threshold_uncertainty_score":0.014200389},"labels":[],"label_agreement":null},{"id":"W3163117957","doi":"10.21203/rs.3.rs-505891/v1","title":"Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Persistence (discontinuity); Leukemia; Cancer research; Medicine; Immunology; Engineering; Geotechnical engineering","score_opus":0.07782501017433613,"score_gpt":0.4025255716442589,"score_spread":0.32470056146992277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163117957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835278,0.009133107,0.0018680912,0.0006407686,0.00017025741,0.000038426268,0.00091077486,0.00021211825,0.003498725],"genre_scores_gemma":[0.9943178,0.0007508643,0.00016787538,0.00023190145,0.000055627952,0.000016583375,0.0008785369,0.000018901295,0.0035619347],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.99977714,0.000029030809,0.000014877685,0.000044579985,0.000030996463,0.00010334343],"domain_scores_gemma":[0.99948335,0.00011522262,0.000117530704,0.00010890275,0.000036162444,0.00013879905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041323595,0.00017864327,0.0004958712,0.00029145172,0.00031332087,0.0006091601,0.0002865064,0.00071863865,0.0026840076],"category_scores_gemma":[0.0006619027,0.00013216631,0.00035215396,0.00032924747,0.00026278093,0.00039545188,0.00027703104,0.001179511,0.0009520298],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027313363,0.0031848934,0.03272052,0.00041194854,0.00062599784,0.0058218427,0.0006880797,0.0020537053,0.6852067,0.004815783,0.0075766733,0.22958054],"study_design_scores_gemma":[0.003617511,0.05217054,0.29154748,0.00025432897,0.0017281286,0.031892713,0.0009255959,0.006939606,0.47122115,0.009433086,0.13008034,0.00018954059],"about_ca_topic_score_codex":0.0005109678,"about_ca_topic_score_gemma":0.0006532889,"teacher_disagreement_score":0.0026840076,"about_ca_system_score_codex":0.00038949374,"about_ca_system_score_gemma":0.00027966866,"threshold_uncertainty_score":0.008978844},"labels":[],"label_agreement":null},{"id":"W3163431319","doi":"10.1016/s1465324921005934","title":"A novel high-permeability fep bag for gmp-compliant, scalable expansion of t cells in a fully closed system","year":2021,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint-Gobain (Canada)","funders":"","keywords":"Cyclic gmp; Scalability; Computer science; Chemistry; Biochemistry; Operating system","score_opus":0.038566476367271944,"score_gpt":0.3109121678063043,"score_spread":0.27234569143903237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163431319","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66369116,0.003549184,0.31441984,0.00084052206,0.0006477885,0.00034614385,0.0010166973,0.0033271427,0.01216155],"genre_scores_gemma":[0.9134281,0.00068835594,0.07868589,0.00028497746,0.000062299994,0.00026599705,0.00044069256,0.00015298936,0.0059905956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983525,0.00002168908,0.000008630249,0.000048348862,0.00005822883,0.00002775756],"domain_scores_gemma":[0.99989367,0.000022234639,0.000031100313,0.000014686518,0.00001612823,0.000022229211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021214633,0.00034628084,0.0002138998,0.00013021298,0.00023236225,0.00035314626,0.00044607866,0.00075229286,0.0011606313],"category_scores_gemma":[0.00022977099,0.0001936392,0.0001316083,0.000101344056,0.00021010294,0.0006341717,0.00035165914,0.00057390536,0.00073064433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059125705,0.00003614995,0.000054554825,0.000081892824,0.0000044239014,0.000120895806,0.000033838864,0.00044913276,0.9910234,0.0007670368,0.0006900514,0.006679587],"study_design_scores_gemma":[0.000019533338,0.00021202156,0.00038912904,0.000014020059,0.0000089845435,0.0003127937,0.00001675805,0.0063613295,0.97580874,0.00022008941,0.01661517,0.000021419852],"about_ca_topic_score_codex":0.00017740819,"about_ca_topic_score_gemma":0.00038355333,"teacher_disagreement_score":0.0011606313,"about_ca_system_score_codex":0.00022078713,"about_ca_system_score_gemma":0.00021119496,"threshold_uncertainty_score":0.0038826466},"labels":[],"label_agreement":null},{"id":"W3164508064","doi":"10.1038/s41591-021-01362-1","title":"Author Correction: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","year":2021,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of Calgary; McGill University Health Centre; BC Children's Hospital; University of Toronto; SickKids Foundation; University of British Columbia; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medulloblastoma; Ependymoma; Cerebrospinal fluid; Medicine; Pathology","score_opus":0.0291656323447384,"score_gpt":0.34143536405897384,"score_spread":0.31226973171423544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164508064","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000093380106,0.0009549183,0.0003689203,0.040759403,0.9564354,0.000011625781,0.0001743547,0.000105879735,0.0010961605],"genre_scores_gemma":[0.0127017945,0.014246471,0.004363809,0.14305632,0.6662765,0.00016567706,0.000659771,0.0009899113,0.15753977],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666214,0.00049990247,0.0005615344,0.0004514225,0.0015230151,0.00030207174],"domain_scores_gemma":[0.9833862,0.005976917,0.0010102673,0.0007839052,0.007852539,0.0009900733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033847596,0.002037781,0.0018406808,0.0033329576,0.0027001204,0.003075718,0.003232881,0.010403075,0.015263078],"category_scores_gemma":[0.039643142,0.0012506198,0.0018556126,0.0014174471,0.0025610426,0.001746008,0.0012921393,0.015407109,0.010786983],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037252834,0.0000078730445,0.00005046729,0.00010966564,0.000014535993,0.0011120237,0.00002632879,0.000055980647,0.000065839275,0.0006051269,0.9930548,0.0048601544],"study_design_scores_gemma":[0.00006732871,0.000036460868,0.0004675161,0.00032706402,0.000071749,0.0026079037,0.00007866907,0.0003414803,0.0006696258,0.001167568,0.9941187,0.000045973426],"about_ca_topic_score_codex":0.013139498,"about_ca_topic_score_gemma":0.018065631,"teacher_disagreement_score":0.015263078,"about_ca_system_score_codex":0.004376172,"about_ca_system_score_gemma":0.004479634,"threshold_uncertainty_score":0.05106008},"labels":[],"label_agreement":null},{"id":"W3165141334","doi":"10.1111/bjh.17551","title":"Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR‐T‐cell therapies","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mass cytometry; Immune system; Medicine; Immunology; Cytometry; Flow cytometry; Immunotherapy; Cancer research; Biology","score_opus":0.06295627033005305,"score_gpt":0.3147752223489589,"score_spread":0.2518189520189058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165141334","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.071768224,0.006690813,0.9022849,0.00084037124,0.00029856706,0.0013235202,0.00381633,0.0074689696,0.005508297],"genre_scores_gemma":[0.25968605,0.0052251983,0.7145454,0.0009953197,0.0005996838,0.00371562,0.005336728,0.00085011247,0.009045892],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997792,0.00043125884,0.0001252832,0.00055730215,0.0009482534,0.00014595984],"domain_scores_gemma":[0.9994141,0.0001576629,0.00011647973,0.000120572564,0.00011080633,0.00008042487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021144685,0.0014783272,0.0010380795,0.0024500045,0.00056348334,0.0014869063,0.0016223043,0.0013991845,0.0048069665],"category_scores_gemma":[0.0013603956,0.00065881235,0.0004628881,0.0007924515,0.00077700685,0.001128754,0.0015190301,0.0016729899,0.0035673787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001428464,0.00008856754,0.0005435931,0.00015504766,0.000027482722,0.00007837944,0.000056736608,0.00062542845,0.96026474,0.0015384892,0.0028084356,0.03367017],"study_design_scores_gemma":[0.000060107915,0.0003942562,0.0019066028,0.000036905512,0.000042091982,0.0004929561,0.00002050578,0.013042227,0.9558898,0.0012051082,0.026852004,0.00005747589],"about_ca_topic_score_codex":0.00029562463,"about_ca_topic_score_gemma":0.00040472543,"teacher_disagreement_score":0.0048069665,"about_ca_system_score_codex":0.0007215349,"about_ca_system_score_gemma":0.00057139713,"threshold_uncertainty_score":0.016080916},"labels":[],"label_agreement":null},{"id":"W3165634478","doi":"10.1016/j.isci.2021.102619","title":"Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors","year":2021,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cytotoxic T cell; Cytotoxicity; Cancer research; Interleukin 12; Immunology; Context (archaeology); Immunotherapy; NK-92; Biology; Immune system; In vitro","score_opus":0.029172594835564905,"score_gpt":0.3102768838393014,"score_spread":0.2811042890037365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165634478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921727,0.0017829324,0.0037527408,0.00006499055,0.000037806447,0.000042599942,0.00010845098,0.00011490364,0.0019228201],"genre_scores_gemma":[0.99566734,0.00042881572,0.0014888818,0.000035574067,0.000008944388,0.000025058427,0.00021968495,0.000016277958,0.002109374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998708,0.000029656832,0.000010480947,0.000023188884,0.0000316413,0.000034259483],"domain_scores_gemma":[0.99994373,0.000014244649,0.00000886001,0.000012216253,0.00000892681,0.000011983763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010856865,0.00024288917,0.0003389846,0.000113000635,0.00007104765,0.00030059688,0.00014482591,0.00020161206,0.0015131925],"category_scores_gemma":[0.00011353679,0.00007444163,0.00012374039,0.00008103948,0.00017164927,0.00021804051,0.00022959361,0.00045928993,0.00040619422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031594114,0.00010500046,0.00024631884,0.00005322098,0.000008337254,0.00007229871,0.000034243036,0.00034916622,0.9927328,0.0002555109,0.00012351741,0.005703734],"study_design_scores_gemma":[0.000108431224,0.00085715734,0.0014215691,0.000007810242,0.000027516448,0.00045351664,0.000024099401,0.0018776528,0.990607,0.00008846912,0.004521716,0.0000049774485],"about_ca_topic_score_codex":0.00031410987,"about_ca_topic_score_gemma":0.00047918735,"teacher_disagreement_score":0.0015131925,"about_ca_system_score_codex":0.00014081728,"about_ca_system_score_gemma":0.00021307784,"threshold_uncertainty_score":0.0050621033},"labels":[],"label_agreement":null},{"id":"W3165951116","doi":"10.1002/sstr.202100026","title":"Improving the Delivery of Drugs and Nucleic Acids to T Cells Using Nanotechnology","year":2021,"lang":"en","type":"article","venue":"Small Structures","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Waterloo; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Drug delivery; Immune system; In vivo; Immunotherapy; Chemistry; Biology; Nanotechnology; Immunology; Materials science; Biotechnology","score_opus":0.01967499877309157,"score_gpt":0.27178763999702976,"score_spread":0.25211264122393817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165951116","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20991641,0.3162567,0.413125,0.004257904,0.0011334261,0.0004943406,0.00030329666,0.0013468666,0.05316602],"genre_scores_gemma":[0.51364857,0.20222126,0.25443882,0.0013448802,0.00043035895,0.00035317513,0.00033379198,0.00018303447,0.027046202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985945,0.00003062671,0.000010463112,0.00002968935,0.000047490797,0.000022274246],"domain_scores_gemma":[0.9999461,0.000021385942,0.000012108344,0.0000044105414,0.000010642637,0.000005269744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028563885,0.00050903787,0.0003178171,0.00043634497,0.00022245706,0.00066628534,0.00023626554,0.0006403676,0.0008186295],"category_scores_gemma":[0.00019719441,0.00021225701,0.0004048084,0.00023368442,0.00036434023,0.000726831,0.00040231855,0.0006665886,0.00049810053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039756636,0.000051495248,0.00014358619,0.0009460327,0.000021615844,0.00016762226,0.000088012544,0.0015583273,0.9246536,0.0098562,0.0013053053,0.06116843],"study_design_scores_gemma":[0.000016060874,0.000467477,0.00032803748,0.00011906193,0.00005193708,0.0007932608,0.00005309364,0.004682427,0.88374346,0.0028051082,0.10691233,0.000027729324],"about_ca_topic_score_codex":0.00045796306,"about_ca_topic_score_gemma":0.00089015847,"teacher_disagreement_score":0.0008186295,"about_ca_system_score_codex":0.0005524647,"about_ca_system_score_gemma":0.00042301425,"threshold_uncertainty_score":0.0040084124},"labels":[],"label_agreement":null},{"id":"W3166095776","doi":"10.71781/32239","title":"Exploitation du potentiel thérapeutique des cellules Natural Killer pour traiter les cancers","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Mitacs","keywords":"Chemistry; Medicine","score_opus":0.013231079135965516,"score_gpt":0.2167114447801617,"score_spread":0.20348036564419617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166095776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9192163,0.024513574,0.04587652,0.00076529785,0.00026398106,0.00027961787,0.00043659096,0.00040937608,0.008238826],"genre_scores_gemma":[0.965827,0.00928545,0.01634401,0.0002177662,0.000042660122,0.00014183269,0.00050786405,0.00004230707,0.007590983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969244,0.00006784154,0.00002104521,0.00006368262,0.00010849828,0.000046479545],"domain_scores_gemma":[0.9998528,0.000043721706,0.000029972272,0.000028915349,0.000026430314,0.000018168685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039302727,0.00040072185,0.00036710818,0.00030854097,0.00018693418,0.00088853826,0.00025237096,0.0006000515,0.0015066931],"category_scores_gemma":[0.00029392127,0.00014994845,0.0005200491,0.00020289814,0.0003827412,0.00047243678,0.00031791104,0.0010416384,0.00042539404],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014791786,0.000063057836,0.0004751,0.00016558416,0.000022358703,0.00008100632,0.000053436772,0.0004910553,0.97993374,0.00067339663,0.00012773127,0.017765649],"study_design_scores_gemma":[0.00006913452,0.0016341092,0.0019686641,0.00003948486,0.000112796115,0.0007577129,0.00007657984,0.0019603411,0.9701858,0.00026366216,0.022916023,0.00001570267],"about_ca_topic_score_codex":0.00083679333,"about_ca_topic_score_gemma":0.00074146496,"teacher_disagreement_score":0.0015066931,"about_ca_system_score_codex":0.0004505322,"about_ca_system_score_gemma":0.00035584447,"threshold_uncertainty_score":0.0050403476},"labels":[],"label_agreement":null},{"id":"W3166810068","doi":"10.1200/jco.2021.39.15_suppl.tps2661","title":"Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; T-cell receptor; T cell; CD8; Tolerability; Response Evaluation Criteria in Solid Tumors; Synovial sarcoma; Immunology; Cancer; Cancer research; Progressive disease; Sarcoma; Immune system; Pathology; Chemotherapy; Adverse effect","score_opus":0.2679764927034616,"score_gpt":0.49486231230405103,"score_spread":0.22688581960058946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166810068","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15214771,0.0045229816,0.017645137,0.005528703,0.0013034972,0.6870852,0.06325724,0.0018750196,0.06663448],"genre_scores_gemma":[0.12073747,0.002456098,0.024208903,0.008065807,0.00054353767,0.77011204,0.04671691,0.00036785455,0.026791373],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9970559,0.001922217,0.00021337789,0.00023115348,0.00028123424,0.00029623572],"domain_scores_gemma":[0.9952003,0.00061554613,0.0011914456,0.0008296954,0.0009649697,0.00119794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006213591,0.0014687385,0.0019271594,0.0005632336,0.0011255671,0.0012911661,0.0023343095,0.0031049983,0.048279084],"category_scores_gemma":[0.005131077,0.00091511454,0.0021782315,0.0006819522,0.0005420155,0.0011561475,0.0011535287,0.0042322907,0.011213213],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53323287,0.032910984,0.0066034617,0.0043384917,0.0016989541,0.00043486612,0.0004043514,0.004906497,0.052074242,0.0034203595,0.17219768,0.18777731],"study_design_scores_gemma":[0.29501197,0.28213558,0.034117885,0.0013175047,0.0011519141,0.0006764076,0.00026377777,0.003240908,0.014821059,0.0031648332,0.36397186,0.00012636415],"about_ca_topic_score_codex":0.0017917568,"about_ca_topic_score_gemma":0.0059928517,"teacher_disagreement_score":0.048279084,"about_ca_system_score_codex":0.0027325947,"about_ca_system_score_gemma":0.0051578046,"threshold_uncertainty_score":0.16150957},"labels":[],"label_agreement":null},{"id":"W3167481271","doi":"10.1200/jco.2021.39.15_suppl.e19537","title":"Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Neutropenia; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Oncology; Toxicity","score_opus":0.04626106429265371,"score_gpt":0.4152705730423476,"score_spread":0.3690095087496939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167481271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699516,0.007701804,0.0004148091,0.00038200212,0.00004454568,0.00037738393,0.0021117034,0.000066871944,0.0019057558],"genre_scores_gemma":[0.9907026,0.002243931,0.0007007561,0.00061525113,0.00009558527,0.00023048496,0.0046276506,0.000016905013,0.0007670057],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994393,0.00028886762,0.000046803158,0.00006617692,0.00010846015,0.000050416824],"domain_scores_gemma":[0.9990049,0.00024394604,0.00039554833,0.000072394476,0.00007074984,0.00021258286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023322306,0.00046449964,0.0007773515,0.00043384734,0.00015086589,0.0010520127,0.0006341702,0.0004938043,0.0014751569],"category_scores_gemma":[0.0015563567,0.00028947118,0.0010719574,0.0004885172,0.00031467367,0.0006374974,0.00033501335,0.0014333943,0.0003109044],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39143544,0.011881873,0.18753175,0.0019819846,0.008663439,0.00065191655,0.00033686237,0.0041925497,0.043545634,0.0002884387,0.010166641,0.33932343],"study_design_scores_gemma":[0.14739138,0.23559746,0.5641279,0.00029457413,0.011069905,0.002460914,0.00016018971,0.004805549,0.010764772,0.0004280787,0.02279872,0.000100617784],"about_ca_topic_score_codex":0.0005773685,"about_ca_topic_score_gemma":0.002103382,"teacher_disagreement_score":0.0023322306,"about_ca_system_score_codex":0.00084952894,"about_ca_system_score_gemma":0.00071851065,"threshold_uncertainty_score":0.012334108},"labels":[],"label_agreement":null},{"id":"W3167507808","doi":"10.1200/jco.2021.39.15_suppl.9546","title":"KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Discontinuation; Quality of life (healthcare); Cohort; Interim; Interim analysis; Pembrolizumab; Population; Clinical endpoint; Cancer; Clinical trial; Internal medicine; Gerontology; Oncology","score_opus":0.12768831402553285,"score_gpt":0.4580371891146894,"score_spread":0.33034887508915656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167507808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926644,0.002384408,0.00028274974,0.00022520212,0.000032045806,0.00041517385,0.0015458524,0.000044963646,0.0024051727],"genre_scores_gemma":[0.995902,0.0006806935,0.00047252126,0.00017991554,0.00003696265,0.00031757238,0.0015528953,0.0000036407805,0.0008538843],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99974185,0.00009959485,0.000020990485,0.000050924955,0.000037172318,0.00004950076],"domain_scores_gemma":[0.9997626,0.000026729564,0.00009520295,0.000013351717,0.000016746342,0.00008532098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008475738,0.00041228568,0.00054194836,0.00017865417,0.00015200593,0.00054437126,0.00032317973,0.00035781303,0.004358116],"category_scores_gemma":[0.0005195732,0.00013850821,0.0006561952,0.00039091308,0.00017925394,0.00046228376,0.00044357328,0.00093048636,0.00046053476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46673456,0.022606071,0.088786244,0.0019439233,0.002067468,0.00033918873,0.00026602062,0.0050535286,0.035980698,0.00032418934,0.009937863,0.36596027],"study_design_scores_gemma":[0.13004747,0.38332438,0.4517349,0.00022706368,0.002020572,0.0011475773,0.00020307886,0.0051011923,0.011474255,0.00038418244,0.014271021,0.0000643587],"about_ca_topic_score_codex":0.0005434489,"about_ca_topic_score_gemma":0.001070099,"teacher_disagreement_score":0.004358116,"about_ca_system_score_codex":0.0005942627,"about_ca_system_score_gemma":0.0004916626,"threshold_uncertainty_score":0.014579356},"labels":[],"label_agreement":null},{"id":"W3168253197","doi":"10.1016/j.jval.2021.04.282","title":"PCN191 Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada.","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Health care; Leukapheresis; Audit; Chimeric antigen receptor; Medicine; Cost driver; Unit (ring theory); Business; Operations management; Medical emergency; Immunotherapy; Cancer; Internal medicine; Stem cell; CD34","score_opus":0.07457973308357888,"score_gpt":0.3793339968645089,"score_spread":0.30475426378093007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168253197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8185087,0.012341167,0.00109231,0.061317377,0.00068460597,0.000570385,0.048495665,0.00017416527,0.05681565],"genre_scores_gemma":[0.9697304,0.005318226,0.00081720273,0.0039738864,0.00018001861,0.000098605575,0.008798948,0.00004045819,0.011042331],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970204,0.00031728932,0.00012399197,0.00014347755,0.001170894,0.0012238853],"domain_scores_gemma":[0.99414647,0.0005384872,0.0011145995,0.000076659046,0.0019787985,0.0021449307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006322342,0.00022557222,0.00031358117,0.00092340796,0.0013208519,0.0015547541,0.0012608285,0.00088384637,0.007921624],"category_scores_gemma":[0.007022484,0.00024401028,0.0009000782,0.0020881363,0.00054790004,0.00043485453,0.0010242859,0.002017822,0.00034468132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025293543,0.0006190179,0.7025302,0.000641234,0.0006260358,0.0009738431,0.0005352274,0.00738349,0.0007516271,0.009734889,0.12132726,0.15234788],"study_design_scores_gemma":[0.00019901695,0.00042263523,0.9420372,0.00043805095,0.00039159268,0.00062911236,0.002094405,0.007542531,0.00051275356,0.00079012854,0.04488069,0.000061900486],"about_ca_topic_score_codex":0.9885141,"about_ca_topic_score_gemma":0.99202853,"teacher_disagreement_score":0.08393676,"about_ca_system_score_codex":0.08393676,"about_ca_system_score_gemma":0.10028286,"threshold_uncertainty_score":0.60900664},"labels":[],"label_agreement":null},{"id":"W3168407158","doi":"10.1200/jco.2021.39.15_suppl.8006","title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Neutropenia; Internal medicine; Multiple myeloma; Gastroenterology; Anemia; Toxicity; Chimeric antigen receptor; Oncology; Immunology; Cancer; Immunotherapy","score_opus":0.06914840343259031,"score_gpt":0.42732675216882743,"score_spread":0.3581783487362371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168407158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947832,0.0037075551,0.00025683123,0.00012373523,0.000017271937,0.00010848215,0.00021152449,0.000034685247,0.00075671705],"genre_scores_gemma":[0.99817765,0.00067268894,0.00020116451,0.00011585092,0.000034738277,0.0000520861,0.00035972343,0.000004460149,0.00038156426],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997501,0.00008835004,0.00001852723,0.000052107836,0.000052538013,0.000038481136],"domain_scores_gemma":[0.99975914,0.00005196078,0.00008404904,0.00002058675,0.000014670628,0.0000696512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073402806,0.00038823168,0.000682511,0.00025713904,0.00019563046,0.0003935827,0.00023590469,0.00040025095,0.0011285486],"category_scores_gemma":[0.0005174672,0.0001947251,0.0006091903,0.00026444878,0.00033554857,0.00037782785,0.00019148132,0.0011090793,0.00036398735],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30365452,0.016027154,0.09290612,0.0009655376,0.0013019688,0.00075974135,0.0005277899,0.0050734826,0.121252716,0.00022190153,0.0025604642,0.45474854],"study_design_scores_gemma":[0.06826403,0.57869226,0.3063849,0.000092039314,0.001739814,0.0030334967,0.000092265436,0.0044145808,0.027048042,0.000329304,0.009854856,0.00005447628],"about_ca_topic_score_codex":0.0004280028,"about_ca_topic_score_gemma":0.00054809905,"teacher_disagreement_score":0.0011285486,"about_ca_system_score_codex":0.0006260701,"about_ca_system_score_gemma":0.00037706937,"threshold_uncertainty_score":0.00454247},"labels":[],"label_agreement":null},{"id":"W3168412060","doi":"10.1200/jco.2021.39.15_suppl.11504","title":"SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Tolerability; Internal medicine; Sarcoma; Progressive disease; Phases of clinical research; Leukapheresis; Surgery; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Oncology; Gastroenterology; Clinical trial; Pathology; Adverse effect; Stem cell; CD34","score_opus":0.10599834406556526,"score_gpt":0.48494079997412204,"score_spread":0.3789424559085568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168412060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98906565,0.003466041,0.0005667743,0.00047521252,0.00009503698,0.0019019382,0.001055689,0.0001372367,0.0032363858],"genre_scores_gemma":[0.9854639,0.0018995954,0.0016211843,0.0010291581,0.00018559444,0.0019808363,0.0034179988,0.000024655537,0.0043770554],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996933,0.00014902501,0.000015681393,0.00004688587,0.000033646986,0.00006146749],"domain_scores_gemma":[0.99963295,0.00008168886,0.00009003883,0.000024110961,0.00001591998,0.00015513462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011757911,0.0009448207,0.0008269709,0.00035225032,0.00023020033,0.0005497144,0.00064460735,0.00095561444,0.0069312924],"category_scores_gemma":[0.00053785637,0.00028587176,0.00079552253,0.0002618191,0.0005518713,0.0006002972,0.00034029584,0.001966625,0.0010763089],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6697754,0.03980571,0.009215882,0.0018975843,0.0011997044,0.0005517856,0.00038435138,0.0028841726,0.070580706,0.00085450115,0.014643545,0.18820657],"study_design_scores_gemma":[0.5828626,0.38973314,0.012011865,0.0000791024,0.00046211694,0.0007775303,0.0000564515,0.0014598254,0.006353905,0.000263111,0.005904256,0.000036069436],"about_ca_topic_score_codex":0.00047387733,"about_ca_topic_score_gemma":0.001560867,"teacher_disagreement_score":0.0069312924,"about_ca_system_score_codex":0.000528686,"about_ca_system_score_gemma":0.00082422764,"threshold_uncertainty_score":0.023187518},"labels":[],"label_agreement":null},{"id":"W3168509201","doi":"10.1101/2020.10.30.360925","title":"Antigenic Sensitivity of Membrane-Proximal Targeting Chimeric Antigen Receptors can be Fine-Tuned through Hinge Truncation","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; National Research Council Canada; University of Ottawa","funders":"","keywords":"Epitope; Antigen; Chimeric antigen receptor; Receptor; In vivo; Truncation (statistics); T-cell receptor; Hinge; Cancer research; Chemistry; Biology; Cell biology; Molecular biology; Immunotherapy; Immunology; T cell; Immune system; Biochemistry; Computer science; Genetics; Physics","score_opus":0.03233509677387081,"score_gpt":0.2715262690409532,"score_spread":0.23919117226708242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168509201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838173,0.000116717834,0.0011415089,0.000010603008,0.0000031581358,0.000009687924,0.00007242705,0.000017057928,0.00024705182],"genre_scores_gemma":[0.9987531,0.00008501045,0.0007124942,0.000016902583,0.0000014031486,0.0000095965215,0.00013941944,0.0000071862282,0.0002749486],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998454,0.00002606653,0.000021788834,0.00002704193,0.00003664772,0.000043071304],"domain_scores_gemma":[0.9998254,0.000064082116,0.00004481596,0.000025259826,0.000019186045,0.000021305137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026217257,0.0002503557,0.0001658138,0.000113053444,0.000066525805,0.00019848885,0.0002063174,0.00021969537,0.00078848004],"category_scores_gemma":[0.00023527462,0.00009558894,0.00019081244,0.000093152594,0.0001560862,0.00014705324,0.00015646068,0.00035636508,0.00018960277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043441236,0.000008337742,0.0000999005,0.000006059835,0.0000021334208,0.0000118589705,0.0000038917024,0.00009625495,0.9995408,0.0000118851585,0.0000049404907,0.00017036276],"study_design_scores_gemma":[0.000003526453,0.00013877767,0.0009072717,9.0105374e-7,0.000004671479,0.000077007884,0.0000042173283,0.00052554545,0.998159,0.000006049415,0.00017149378,0.000001590892],"about_ca_topic_score_codex":0.0002312188,"about_ca_topic_score_gemma":0.00020558925,"teacher_disagreement_score":0.00078848004,"about_ca_system_score_codex":0.00021184595,"about_ca_system_score_gemma":0.0000800496,"threshold_uncertainty_score":0.002637744},"labels":[],"label_agreement":null},{"id":"W3168836567","doi":"10.1200/jco.2021.39.15_suppl.7519","title":"Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dosing; Refractory (planetary science); Internal medicine; Cytokine release syndrome; Gastroenterology; Rituximab; Neutropenia; Lymphoma; Surgery; Chemotherapy; Cancer; Immunotherapy","score_opus":0.15882958560774624,"score_gpt":0.4813478106215453,"score_spread":0.32251822501379906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168836567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881315,0.004352105,0.00060554856,0.00012890206,0.000016541164,0.00024131345,0.0042697554,0.000084226944,0.00217011],"genre_scores_gemma":[0.99241155,0.000748684,0.00045034816,0.00015691681,0.000020185338,0.00009705118,0.005750581,0.000012252686,0.00035228793],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996152,0.00012887747,0.00004933685,0.00008012141,0.00008445682,0.00004197231],"domain_scores_gemma":[0.9988147,0.00030549182,0.00053570303,0.00011609059,0.00008677867,0.00014120215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015376001,0.00024440122,0.00045857226,0.0003531976,0.00012309384,0.0005332225,0.000336703,0.00027052997,0.0011953117],"category_scores_gemma":[0.0013070923,0.00015479347,0.00052807754,0.00042614326,0.00013810875,0.00034291547,0.00026229257,0.0006199689,0.00027392583],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082652055,0.0018221253,0.4986355,0.000861847,0.0025270483,0.00027696142,0.00034462885,0.004247207,0.040784515,0.00019612067,0.008418125,0.35923383],"study_design_scores_gemma":[0.0045471173,0.029496452,0.94041765,0.00008314071,0.0015990916,0.0012852905,0.00007119864,0.0018139904,0.008846629,0.000096640564,0.011707453,0.00003532402],"about_ca_topic_score_codex":0.0007291746,"about_ca_topic_score_gemma":0.0016615165,"teacher_disagreement_score":0.0015376001,"about_ca_system_score_codex":0.0004899052,"about_ca_system_score_gemma":0.0002488163,"threshold_uncertainty_score":0.0081317425},"labels":[],"label_agreement":null},{"id":"W3168841030","doi":"10.1200/jco.2021.39.15_suppl.e19568","title":"Association of PET/CT response assessment prior to CAR T-cell infusion with outcomes after CAR T-cell therapy in aggressive B-cell lymphomas.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Gastroenterology; CAR T-cell therapy; Nuclear medicine; Surgery; Immunotherapy; Cancer","score_opus":0.05233808995743192,"score_gpt":0.45334641170646206,"score_spread":0.4010083217490301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168841030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990921,0.00024271091,0.000092135684,0.000021099511,0.0000024891583,0.0000069084763,0.00024764249,0.000002719413,0.000292172],"genre_scores_gemma":[0.99945146,0.00004217326,0.000038680028,0.000011015515,0.000006206494,0.0000047683784,0.00036870094,0.0000015686416,0.00007546147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99957293,0.00012663408,0.00005945486,0.00010309328,0.00006432712,0.00007355907],"domain_scores_gemma":[0.9977513,0.0006540919,0.0011480536,0.00009974009,0.00015316054,0.00019369875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090582354,0.0001381762,0.00020302375,0.00048174843,0.00013458573,0.0005162014,0.00023828029,0.00030080817,0.0013239672],"category_scores_gemma":[0.0021453255,0.000097655226,0.00022467884,0.00047933197,0.00018816827,0.00029571963,0.00028602796,0.00039456133,0.00028186472],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065016764,0.000034424414,0.9962624,0.000009330317,0.00002591804,0.000096483534,0.000020235411,0.00006034579,0.00036686944,0.000009080154,0.0000776225,0.002387164],"study_design_scores_gemma":[0.000017926168,0.00040476726,0.9973028,0.000006990493,0.00005062062,0.00078437827,0.00007807519,0.00048251817,0.00042767907,0.00002125282,0.00041987683,0.0000030323256],"about_ca_topic_score_codex":0.00060575636,"about_ca_topic_score_gemma":0.0008253492,"teacher_disagreement_score":0.0013239672,"about_ca_system_score_codex":0.0002480548,"about_ca_system_score_gemma":0.00016854248,"threshold_uncertainty_score":0.0047905445},"labels":[],"label_agreement":null},{"id":"W3170764582","doi":"10.1200/jco.2021.39.15_suppl.tps9138","title":"An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Chemotherapy; Immunotherapy; Immunology; Cancer research; Internal medicine","score_opus":0.15880713877515426,"score_gpt":0.5660918804300211,"score_spread":0.40728474165486683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170764582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98758984,0.0019403889,0.0008169728,0.0004628245,0.0002029913,0.004237955,0.0017167137,0.000114228234,0.0029182157],"genre_scores_gemma":[0.9782632,0.0019431099,0.0022487831,0.0014315957,0.00019474277,0.0064554284,0.0045201825,0.000047428486,0.0048955553],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997032,0.00013107706,0.000011863114,0.00005964611,0.00003430415,0.000059816608],"domain_scores_gemma":[0.99949646,0.00007941731,0.000096732416,0.000049511127,0.000042751817,0.00023509195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00138351,0.0010172868,0.0011016489,0.00031838997,0.00037658348,0.000690607,0.000775224,0.0011825282,0.0063004494],"category_scores_gemma":[0.0007210084,0.0003841342,0.0008187153,0.0004041683,0.0008528373,0.0007216316,0.0003182237,0.0026996622,0.0011929384],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61599296,0.10116602,0.008076598,0.0015730235,0.001207331,0.0004880483,0.00052075216,0.0037703614,0.074013576,0.00060169207,0.011317941,0.18127175],"study_design_scores_gemma":[0.34869617,0.6351807,0.008099672,0.00005090126,0.00024049729,0.0003153527,0.00007826002,0.0007816484,0.0021390284,0.00022676469,0.0041728886,0.000017994207],"about_ca_topic_score_codex":0.0008201267,"about_ca_topic_score_gemma":0.0017952961,"teacher_disagreement_score":0.0063004494,"about_ca_system_score_codex":0.0008318884,"about_ca_system_score_gemma":0.0013443097,"threshold_uncertainty_score":0.021077096},"labels":[],"label_agreement":null},{"id":"W3170891449","doi":"10.1093/neuonc/noab090.121","title":"IMMU-14. COMPUTATIONAL DECONVOLUTION OF TUMOR-INFILTRATING IMMUNE COMPONENTS IN PEDIATRIC NERVOUS SYSTEM TUMORS","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Cancer research; CD8; Medicine; T cell; Immune checkpoint; Immunology; Biology","score_opus":0.033518168114641644,"score_gpt":0.3120968245030121,"score_spread":0.2785786563883705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170891449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8156189,0.002765528,0.13463597,0.0012651038,0.00034740556,0.00020712648,0.027808918,0.009001064,0.008350092],"genre_scores_gemma":[0.8682836,0.0006429512,0.096609406,0.00056175096,0.00009208419,0.000449685,0.029082203,0.0009241035,0.0033541843],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998796,0.00003640458,0.0000046879563,0.000038485825,0.000018253146,0.00002260317],"domain_scores_gemma":[0.9996542,0.00024304997,0.000027767808,0.00001563446,0.00003339613,0.000025951053],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050834107,0.00079174276,0.00053846557,0.0005986163,0.00038333106,0.0006804733,0.00076605624,0.0010237371,0.0029741628],"category_scores_gemma":[0.0013585867,0.00045121426,0.0014320395,0.000475725,0.00035235597,0.00020985269,0.00047020367,0.0007778736,0.0005923384],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004554166,0.00013053286,0.020119656,0.00038187607,0.00034682814,0.00021708399,0.0001062145,0.94374156,0.005214122,0.0022330564,0.007772398,0.019281277],"study_design_scores_gemma":[0.00003197307,0.000037368623,0.0020893214,0.000011698739,0.000023730456,0.000033011107,0.00003203619,0.9939266,0.001040978,0.0010909725,0.001673039,0.00000923196],"about_ca_topic_score_codex":0.017380046,"about_ca_topic_score_gemma":0.016481781,"teacher_disagreement_score":0.017380046,"about_ca_system_score_codex":0.0006832399,"about_ca_system_score_gemma":0.0012158094,"threshold_uncertainty_score":0.03455782},"labels":[],"label_agreement":null},{"id":"W3171042113","doi":"10.1200/jco.2021.39.15_suppl.tps11582","title":"IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Hôpital Maisonneuve-Rosemont","funders":"GlaxoSmithKline","keywords":"Oncology; Medicine; Internal medicine; Anthracycline; Cancer research; Cancer; Breast cancer","score_opus":0.1751760736806835,"score_gpt":0.4692052168953547,"score_spread":0.2940291432146712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171042113","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34429935,0.0045684567,0.017081067,0.0022794474,0.0009844584,0.56129706,0.031611618,0.0010383752,0.036840186],"genre_scores_gemma":[0.28657806,0.001840058,0.021665864,0.0026671388,0.0003306517,0.659362,0.017103171,0.00018608455,0.010266887],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9955707,0.0029722175,0.00025521312,0.00037251046,0.00045066528,0.00037881426],"domain_scores_gemma":[0.9965653,0.0005956289,0.00082536007,0.0008208947,0.00044471983,0.00074829115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010340189,0.0014000068,0.0017319451,0.00065932365,0.0008242072,0.0012638092,0.001998073,0.0020902795,0.026692627],"category_scores_gemma":[0.005708218,0.0009684866,0.0013970886,0.0007963652,0.0011348953,0.001226768,0.0010773224,0.003973919,0.004608017],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7674121,0.026150486,0.0069269887,0.0031574492,0.0011222578,0.00032927963,0.00037241593,0.0032134159,0.039682444,0.0042995354,0.0404465,0.10688713],"study_design_scores_gemma":[0.48035705,0.37532037,0.017660957,0.0006868326,0.001006956,0.00046937476,0.00019494945,0.0022346547,0.013321184,0.0021547303,0.1064981,0.00009484122],"about_ca_topic_score_codex":0.00069661596,"about_ca_topic_score_gemma":0.0021790564,"teacher_disagreement_score":0.026692627,"about_ca_system_score_codex":0.0021631308,"about_ca_system_score_gemma":0.0061220736,"threshold_uncertainty_score":0.089295745},"labels":[],"label_agreement":null},{"id":"W3171232767","doi":"10.1200/jco.2021.39.15_suppl.11557","title":"Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Sarcoma; Internal medicine; Combination therapy; Cancer; Dosing; Oncology; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Pharmacology; Immunotherapy; Pathology","score_opus":0.08994067627134944,"score_gpt":0.4523935307635861,"score_spread":0.3624528544922367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171232767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040437,0.004593343,0.0006103627,0.00015714415,0.000057534282,0.00061744027,0.00067991787,0.000066171735,0.0028137248],"genre_scores_gemma":[0.99523205,0.0011164766,0.000540544,0.00016355213,0.000048337715,0.0002725491,0.0009478834,0.000015332942,0.0016632089],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996697,0.00014139904,0.000016886515,0.0000633293,0.000049463448,0.000059214224],"domain_scores_gemma":[0.9995338,0.00010110669,0.00008221515,0.00003802437,0.00005036853,0.00019449407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001054877,0.00055913744,0.0009018845,0.0002976331,0.00021802762,0.00044654368,0.000237585,0.00049623457,0.0034151785],"category_scores_gemma":[0.0005918564,0.0002120325,0.0006209174,0.00022179798,0.00032363762,0.00040689277,0.00019259148,0.0008878891,0.00095626747],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44134572,0.04206919,0.038925555,0.0013395906,0.0013691685,0.00049322774,0.0003915093,0.0015666614,0.17250465,0.00019171636,0.004864345,0.29493862],"study_design_scores_gemma":[0.014919943,0.8477799,0.08252185,0.00007741785,0.0016302057,0.00074578833,0.00016232424,0.0015730147,0.0430565,0.00011500965,0.007388275,0.000029769573],"about_ca_topic_score_codex":0.0006367948,"about_ca_topic_score_gemma":0.0011692457,"teacher_disagreement_score":0.0034151785,"about_ca_system_score_codex":0.00047347412,"about_ca_system_score_gemma":0.00043477947,"threshold_uncertainty_score":0.011424899},"labels":[],"label_agreement":null},{"id":"W3171665778","doi":"10.1136/jitc-2020-002140","title":"Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Medical Research Council; Breast Cancer Now; Academy of Medical Sciences; Cancer Research UK","keywords":"Immunotherapy; Medicine; Antigen; Immunoglobulin E; Cancer immunotherapy; Immunology; Cancer research; Immune system; Antibody","score_opus":0.0655862087547177,"score_gpt":0.4044719527983389,"score_spread":0.3388857440436212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171665778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97182953,0.004786654,0.0178535,0.00039492492,0.00008358284,0.00016513646,0.0004815396,0.0005763532,0.0038287858],"genre_scores_gemma":[0.9896142,0.001515114,0.006027693,0.00019460126,0.000025089099,0.00007541212,0.00048485122,0.000030078882,0.0020328842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998758,0.000013342752,0.0000066119733,0.00003443582,0.000034437657,0.00003538407],"domain_scores_gemma":[0.9999627,0.0000064376964,0.000012566206,0.0000046717114,0.000005896727,0.000007834463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001344377,0.00037472005,0.00021181688,0.00019895763,0.00008882671,0.0003048425,0.00019259864,0.0004565206,0.0016571458],"category_scores_gemma":[0.000083220846,0.00008373596,0.00038681438,0.000118002885,0.00022695486,0.0001434102,0.00018451836,0.0005601534,0.00036989382],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009268602,0.00004723274,0.00042033734,0.000085973785,0.000021054462,0.00010765085,0.000012915828,0.00031740262,0.9936367,0.0002135815,0.00023433636,0.0048101214],"study_design_scores_gemma":[0.000078228964,0.0008281014,0.0021271706,0.000016359445,0.000102261554,0.00092916394,0.00002128948,0.0024082228,0.9841511,0.00015049348,0.009178704,0.000008879076],"about_ca_topic_score_codex":0.00032150428,"about_ca_topic_score_gemma":0.00041320897,"teacher_disagreement_score":0.0016571458,"about_ca_system_score_codex":0.00029611573,"about_ca_system_score_gemma":0.00021197651,"threshold_uncertainty_score":0.0055437684},"labels":[],"label_agreement":null},{"id":"W3171995199","doi":"10.1200/jco.2021.39.15_suppl.2593","title":"Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Fludarabine; Nivolumab; Neutropenia; Internal medicine; Cyclophosphamide; Progressive disease; Chemotherapy; Refractory (planetary science); Oncology; Gastroenterology; Immunotherapy; Cancer; Biology","score_opus":0.09142502707162185,"score_gpt":0.4643852496822118,"score_spread":0.3729602226105899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171995199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99722725,0.0008292172,0.00023825266,0.0000742462,0.000037322407,0.00046796427,0.00019631875,0.00003631071,0.00089302025],"genre_scores_gemma":[0.99827814,0.00025731995,0.00031323527,0.00012066199,0.000026982168,0.00024181895,0.00037768774,0.000004843771,0.00037925062],"study_design_codex":"randomized_trial","study_design_gemma":"case_report","domain_scores_codex":[0.9997832,0.00006976582,0.000013693259,0.000040129828,0.000020134468,0.00007299746],"domain_scores_gemma":[0.9997949,0.000029906752,0.0000239142,0.000021010786,0.0000074540267,0.0001227232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008120118,0.0005865076,0.0007558135,0.00020870291,0.0002644314,0.00050751417,0.00046324407,0.0006001942,0.0014366283],"category_scores_gemma":[0.00023492181,0.00024573493,0.00043862223,0.0002397616,0.000538962,0.00041102487,0.00021875477,0.0018599285,0.00043156915],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41633886,0.13738467,0.034862746,0.0009736914,0.00063898304,0.0017453736,0.0004324043,0.0034357817,0.22340472,0.0005835608,0.0035792736,0.1766199],"study_design_scores_gemma":[0.08882101,0.80700845,0.051956754,0.00005292065,0.00043638938,0.002172106,0.000110870875,0.0032835423,0.04009961,0.0002345154,0.005791929,0.000031972617],"about_ca_topic_score_codex":0.00080330094,"about_ca_topic_score_gemma":0.001725759,"teacher_disagreement_score":0.0014366283,"about_ca_system_score_codex":0.00080585014,"about_ca_system_score_gemma":0.0009944703,"threshold_uncertainty_score":0.0058469176},"labels":[],"label_agreement":null},{"id":"W3172804543","doi":"10.1200/jco.2021.39.15_suppl.9568","title":"Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Oncology; Internal medicine; Melanoma; Progression-free survival; Prospective cohort study; Chemotherapy; Cancer research","score_opus":0.15827150236902757,"score_gpt":0.48052849117317575,"score_spread":0.3222569888041482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172804543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987437,0.00026948232,0.000064982036,0.00003102712,0.000004405356,0.000053244123,0.00066447916,0.0000052191117,0.00016351898],"genre_scores_gemma":[0.9977683,0.00007479525,0.0002187021,0.000060244514,0.000018607609,0.00006917338,0.0015811092,0.0000051434786,0.00020393716],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999556,0.00015550971,0.000019383337,0.00015864462,0.000039312712,0.00007108233],"domain_scores_gemma":[0.99930024,0.00007786484,0.00020839817,0.00009302711,0.00005584606,0.00026466686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015035077,0.00058863766,0.0005623909,0.0004371777,0.0003738687,0.00055028585,0.00036420932,0.0004448555,0.0009472327],"category_scores_gemma":[0.00086970214,0.0003547614,0.00041493805,0.00047786385,0.0003318593,0.0003007941,0.00045051976,0.00045723375,0.0003385239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011044182,0.0007662789,0.9771344,0.000050226467,0.00025058544,0.00015448549,0.000114479146,0.00019631685,0.004472094,0.000028973584,0.0006625033,0.005125347],"study_design_scores_gemma":[0.001049712,0.0033882726,0.99297404,0.000014792184,0.00021075837,0.00044337043,0.000087392786,0.000388277,0.00041901556,0.000025188474,0.000989206,0.000009947979],"about_ca_topic_score_codex":0.0020242783,"about_ca_topic_score_gemma":0.0029344258,"teacher_disagreement_score":0.0020242783,"about_ca_system_score_codex":0.0006171062,"about_ca_system_score_gemma":0.0005675813,"threshold_uncertainty_score":0.007951438},"labels":[],"label_agreement":null},{"id":"W3173461290","doi":"10.1073/pnas.2025930118","title":"Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic","year":2021,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Ministerio de Ciencia e Innovación","keywords":"CD137; Agonist; Pharmacology; Cancer research; Chemistry; Cytotoxic T cell; Antibody; Monoclonal antibody; Prodrug; Proteases; Immunotherapy; Medicine; Immunology; Receptor; Immune system; In vitro; Biochemistry","score_opus":0.13419463122903236,"score_gpt":0.4037151791293229,"score_spread":0.26952054790029056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173461290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98967147,0.0015748545,0.005354793,0.00015044789,0.00004011253,0.00008339806,0.00016082788,0.00012637065,0.0028377334],"genre_scores_gemma":[0.9947389,0.00054411124,0.0028598998,0.00005176755,0.000013460719,0.000047440735,0.0002067531,0.000012866879,0.0015247781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998504,0.000025386136,0.00000978971,0.000029931582,0.000037689268,0.000046865876],"domain_scores_gemma":[0.99994814,0.00000946132,0.000013029478,0.000008192026,0.000006152254,0.000014958628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017357376,0.00041878552,0.00034757456,0.00023168686,0.000093644405,0.0003878335,0.00023517864,0.0003257633,0.0012122425],"category_scores_gemma":[0.00012482547,0.00009709096,0.00017526413,0.00012784851,0.00021933789,0.00028627052,0.00018178414,0.00086593814,0.00022370392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044952906,0.0003316142,0.00014459049,0.00007138477,0.000011589902,0.000063684376,0.000020317879,0.000493428,0.98726183,0.0005708922,0.00012638351,0.010454794],"study_design_scores_gemma":[0.00019869326,0.0041494034,0.00085798744,0.0000069594107,0.000043537868,0.00042765716,0.0000101114565,0.0017557889,0.98942685,0.00009916958,0.0030190374,0.0000048410066],"about_ca_topic_score_codex":0.00026166192,"about_ca_topic_score_gemma":0.0004453449,"teacher_disagreement_score":0.0012122425,"about_ca_system_score_codex":0.00031101587,"about_ca_system_score_gemma":0.00035574098,"threshold_uncertainty_score":0.004055321},"labels":[],"label_agreement":null},{"id":"W3174028996","doi":"10.1007/s40273-021-01051-4","title":"Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Cost effectiveness; MEDLINE; EconLit; CINAHL; Health economics; Systematic review; Economic evaluation; Quality-adjusted life year; Cost–benefit analysis; Intensive care medicine; Public health; Actuarial science; Psychological intervention; Psychiatry; Pathology; Risk analysis (engineering)","score_opus":0.12902176028496853,"score_gpt":0.45309648081650333,"score_spread":0.3240747205315348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174028996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042429453,0.9984012,0.00008017627,0.00032073632,0.00008098162,0.000069856134,0.00037832904,0.0000027619153,0.00024165788],"genre_scores_gemma":[0.0073250025,0.99154705,0.00024803038,0.0005252859,0.000064304455,0.00009887602,0.00012583144,0.0000024467708,0.00006308272],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962202,0.0014740613,0.001119756,0.0002733763,0.00073571946,0.00017697069],"domain_scores_gemma":[0.97861093,0.01716559,0.0030958338,0.00016893742,0.0007776018,0.00018110982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064386483,0.0011332219,0.0065104966,0.006502516,0.0003094312,0.002521507,0.0013162555,0.0018460382,0.010726563],"category_scores_gemma":[0.024808453,0.0007469887,0.006231631,0.0074804393,0.0007553246,0.001650498,0.0012161273,0.0016373675,0.00042306952],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000694707,0.00003405082,0.00059979217,0.9135306,0.017352166,0.00009360383,0.000048587663,0.00024953877,0.00012855217,0.0006094912,0.0033075754,0.06335136],"study_design_scores_gemma":[0.0013921519,0.00025344704,0.0046346243,0.7996284,0.15624051,0.0003296144,0.00020019179,0.00017285663,0.00016455869,0.0013791752,0.035554364,0.000050158036],"about_ca_topic_score_codex":0.0059846034,"about_ca_topic_score_gemma":0.017417707,"teacher_disagreement_score":0.010726563,"about_ca_system_score_codex":0.0029447037,"about_ca_system_score_gemma":0.0066573583,"threshold_uncertainty_score":0.035883963},"labels":[],"label_agreement":null},{"id":"W3176532045","doi":"10.1016/s0140-6736(21)00933-8","title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1664,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Chimeric antigen receptor; Antigen; Refractory (planetary science); Medicine; Open label; Multiple myeloma; Receptor; Immunology; Cell; Immunotherapy; Cancer research; Biology; Internal medicine; Immune system; Clinical trial","score_opus":0.06200547005268376,"score_gpt":0.34697997397806435,"score_spread":0.2849745039253806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176532045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996454,0.0049901097,0.00045599113,0.00067382347,0.00022001934,0.00080383697,0.000910017,0.00013852092,0.0018432275],"genre_scores_gemma":[0.98805594,0.0036900498,0.0009773467,0.0012035168,0.00021440843,0.00089243223,0.0018143211,0.0000422532,0.0031098],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967766,0.000121636076,0.000011465801,0.00005744498,0.00003291579,0.00009897756],"domain_scores_gemma":[0.9996269,0.000088017834,0.000055067285,0.000030037258,0.000019720303,0.00018038071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011135378,0.0013946851,0.0019433987,0.000445864,0.00032662475,0.0012659644,0.0007750682,0.0015043805,0.0027840766],"category_scores_gemma":[0.00052020035,0.00043191307,0.0013368777,0.00044170467,0.0008975335,0.0010214078,0.00024693276,0.0028643382,0.0007474512],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72959125,0.045741502,0.005399034,0.0012722693,0.0018202504,0.0002488703,0.00026099448,0.0023308562,0.038342323,0.0006114084,0.006060163,0.16832109],"study_design_scores_gemma":[0.64768416,0.3369334,0.0068382192,0.00004473209,0.0006659163,0.00020323772,0.000065280496,0.0011757932,0.0029674114,0.00024652772,0.0031365869,0.00003869446],"about_ca_topic_score_codex":0.0015241359,"about_ca_topic_score_gemma":0.0035223588,"teacher_disagreement_score":0.0027840766,"about_ca_system_score_codex":0.00095656636,"about_ca_system_score_gemma":0.0011939853,"threshold_uncertainty_score":0.009313643},"labels":[],"label_agreement":null},{"id":"W3176850572","doi":"10.1080/19420862.2021.1933690","title":"A T cell redirection platform for co-targeting dual antigens on solid tumors","year":2021,"lang":"en","type":"article","venue":"mAbs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Terry Fox Research Institute; Genome Canada","keywords":"Antigen; Cancer research; Cytotoxic T cell; Cytotoxicity; Antibody; Chemistry; Biology; Computational biology; In vitro; Immunology; Biochemistry","score_opus":0.04228322408717676,"score_gpt":0.34601758597425425,"score_spread":0.3037343618870775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176850572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8845378,0.001812377,0.10662517,0.00025931545,0.00011226608,0.00022768545,0.00031480278,0.00070670515,0.0054037194],"genre_scores_gemma":[0.96499676,0.00067299645,0.0304146,0.00009226468,0.000014564906,0.00008471222,0.00018252873,0.000039287086,0.0035023133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998758,0.000022138478,0.0000053851427,0.00003313395,0.00003239645,0.000031150754],"domain_scores_gemma":[0.9999614,0.000005768863,0.000009418133,0.000004844712,0.0000048699158,0.000013649058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012545625,0.000470856,0.00019275866,0.0002754033,0.000109580775,0.00031642185,0.00027124537,0.00039132056,0.0009598113],"category_scores_gemma":[0.000088666166,0.00015861428,0.00020914736,0.00012391835,0.0001609956,0.00025375397,0.0003187125,0.0005345242,0.00044255247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000047623515,0.00003423291,0.000037798643,0.000019437693,0.0000034772079,0.00005585228,0.000010593823,0.0002904992,0.995992,0.00042691454,0.00007904125,0.0030026527],"study_design_scores_gemma":[0.000022959168,0.0003189671,0.00017139279,0.0000019339616,0.000012365809,0.00028297617,0.0000074439404,0.0025015608,0.99274147,0.00007358202,0.003859007,0.0000062877293],"about_ca_topic_score_codex":0.0002340595,"about_ca_topic_score_gemma":0.0003897781,"teacher_disagreement_score":0.0009598113,"about_ca_system_score_codex":0.00020481447,"about_ca_system_score_gemma":0.00014865381,"threshold_uncertainty_score":0.0032109022},"labels":[],"label_agreement":null},{"id":"W3178189790","doi":"10.1158/1538-7445.am2021-ct219","title":"Abstract CT219: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Tolerability; T-cell receptor; Oncology; CD8; Internal medicine; T cell; Immunology; Tumor microenvironment; Cancer; Adverse effect; Antigen; Immune system","score_opus":0.1512024054731531,"score_gpt":0.4203069724784636,"score_spread":0.2691045670053105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178189790","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23485048,0.006126694,0.016456146,0.0060287067,0.0012975376,0.5540907,0.10617443,0.001751984,0.07322336],"genre_scores_gemma":[0.24557282,0.0028619252,0.022599855,0.00951546,0.0006795608,0.6141666,0.07656522,0.0005450739,0.02749344],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9955781,0.002972937,0.0003225771,0.00033665547,0.00041708883,0.00037269198],"domain_scores_gemma":[0.99370426,0.0008832221,0.001713065,0.0010290076,0.001095232,0.0015752256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007651173,0.0016537461,0.002144759,0.0006388333,0.0012007654,0.0015349187,0.002585954,0.0036238094,0.03249354],"category_scores_gemma":[0.0063454877,0.0009364818,0.0026997982,0.0009784522,0.00076024345,0.0011867802,0.0009871522,0.004443572,0.008505498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64776725,0.019842526,0.008419264,0.0039425497,0.0023471953,0.00045252172,0.00033871856,0.0058836443,0.04669724,0.003010595,0.13864122,0.12265729],"study_design_scores_gemma":[0.38413993,0.29858023,0.04464101,0.0014785173,0.0016158285,0.0007110859,0.00022537654,0.0034381575,0.016093079,0.003175951,0.245769,0.0001318624],"about_ca_topic_score_codex":0.002165927,"about_ca_topic_score_gemma":0.0064997165,"teacher_disagreement_score":0.03249354,"about_ca_system_score_codex":0.004058736,"about_ca_system_score_gemma":0.005900204,"threshold_uncertainty_score":0.108701706},"labels":[],"label_agreement":null},{"id":"W3179219421","doi":"10.1158/1538-7445.am2021-1546","title":"Abstract 1546: Defining the immune microenvironment in Ewing's sarcoma to potentiate IL1RAP-targeted CAR-T immunotherapy","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Stromal cell; Cancer research; T cell; Tumor microenvironment; Medicine; Immunotherapy; Immune system; Cytokine; Biology; Immunology","score_opus":0.04865885854201953,"score_gpt":0.37405951825854866,"score_spread":0.32540065971652915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179219421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075186,0.0015009469,0.0043453714,0.00014161713,0.000032496573,0.00010496867,0.00021725862,0.00008658467,0.0028189821],"genre_scores_gemma":[0.994148,0.00061987666,0.0029289545,0.00005075766,0.000017428838,0.00005465496,0.00019525526,0.000015403795,0.0019696401],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999242,0.000016569267,0.0000053024664,0.000011008487,0.000018231098,0.000024694826],"domain_scores_gemma":[0.9999702,0.000006565181,0.00000492947,0.0000032794194,0.000004415918,0.000010624417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012454987,0.0002769357,0.00024823082,0.000160254,0.00008624621,0.00021586873,0.0001230252,0.0002552796,0.0015520164],"category_scores_gemma":[0.00006263675,0.000078075806,0.00013242832,0.00008918598,0.00016167694,0.00016403101,0.00015463577,0.00046627098,0.000451923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007434147,0.000049571994,0.000085367144,0.000027193691,0.0000016548756,0.000044675875,0.000010015359,0.00013576257,0.9978643,0.00013758028,0.00006822302,0.0015013488],"study_design_scores_gemma":[0.000048643342,0.00093732314,0.0015032934,0.0000060772895,0.000014664668,0.00039266533,0.0000178181,0.001597755,0.9919704,0.00006900709,0.0034400802,0.0000023102498],"about_ca_topic_score_codex":0.00032413844,"about_ca_topic_score_gemma":0.00045775992,"teacher_disagreement_score":0.0015520164,"about_ca_system_score_codex":0.00016483723,"about_ca_system_score_gemma":0.00015734757,"threshold_uncertainty_score":0.005191982},"labels":[],"label_agreement":null},{"id":"W3180458932","doi":"10.1016/j.jcyt.2021.05.007","title":"Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; McMaster University Medical Centre","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Receptor; T-cell receptor; Antigen; Cell biology; T cell; Chimeric antigen receptor; Cancer research; Biology; Monoclonal antibody; Immunology; Chemistry; Antibody; Immune system; Biochemistry","score_opus":0.04379794141137245,"score_gpt":0.30325912682563294,"score_spread":0.2594611854142605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180458932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95730203,0.0031351608,0.035141196,0.00036501457,0.00010574903,0.00028067068,0.00025202453,0.00036035525,0.003057848],"genre_scores_gemma":[0.9632674,0.0017608565,0.03068188,0.0002504162,0.000026714546,0.00011244584,0.0005919411,0.00004938531,0.0032590546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977666,0.000027093814,0.000018710722,0.00004240043,0.0000913847,0.000043767814],"domain_scores_gemma":[0.99992204,0.000008395918,0.000021264728,0.000008878925,0.00001991363,0.000019579937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002865526,0.00031995217,0.0002084758,0.00022059395,0.000109040826,0.00035373794,0.00049092545,0.0006959646,0.0008990844],"category_scores_gemma":[0.00018438433,0.00018513606,0.00046536344,0.00011928581,0.00012820645,0.00022886819,0.00031047995,0.0007184364,0.00062574015],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044311702,0.000061017563,0.00017387225,0.000041520223,0.000011690314,0.000056642944,0.0000124003245,0.0003111867,0.99500644,0.00021252118,0.0001042676,0.0039641038],"study_design_scores_gemma":[0.00006203461,0.00066279253,0.000741418,0.000006184419,0.000037799822,0.00046671275,0.000009886501,0.0027438905,0.98714906,0.000049276146,0.008060856,0.000010198172],"about_ca_topic_score_codex":0.00027141455,"about_ca_topic_score_gemma":0.00020544796,"teacher_disagreement_score":0.0008990844,"about_ca_system_score_codex":0.00046398255,"about_ca_system_score_gemma":0.00019998982,"threshold_uncertainty_score":0.0033664107},"labels":[],"label_agreement":null},{"id":"W3180594295","doi":"10.1136/jitc-2021-002642","title":"Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Human Genome Research Institute; Swim Across America; International Association for the Study of Lung Cancer; Mark Foundation For Cancer Research; LUNGevity Foundation; Commonwealth Foundation; National Cancer Institute; National Institutes of Health; Bloomberg Philanthropies","keywords":"Blockade; T-cell receptor; Immune system; Confounding; Immune checkpoint; T cell; Medicine; Cell; Immunology; Immunotherapy; Cancer research; Biology; Receptor; Internal medicine; Genetics","score_opus":0.0552863817777128,"score_gpt":0.405616804043211,"score_spread":0.3503304222654982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180594295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70296586,0.0068924488,0.27698794,0.0018037527,0.0007914913,0.0008114624,0.0008562439,0.00042770585,0.008463155],"genre_scores_gemma":[0.94701964,0.0005273036,0.049505293,0.00093012647,0.00023464476,0.00065525,0.00029901075,0.00018166869,0.0006471561],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.8911146,0.07420375,0.011415106,0.008510675,0.013084832,0.0016710156],"domain_scores_gemma":[0.78256816,0.15602666,0.01779204,0.032593183,0.009838474,0.0011813805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11498759,0.00095564267,0.001375215,0.0025471784,0.0013640735,0.002703474,0.0016135651,0.0010356545,0.0013798875],"category_scores_gemma":[0.1677028,0.0006120909,0.0010020522,0.0019802877,0.0035543207,0.0015918093,0.0026466867,0.002116956,0.0002766032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030673943,0.00025632823,0.76492184,0.0020725762,0.0033310729,0.0022633858,0.0056810933,0.0049679466,0.06548403,0.008380724,0.0023873344,0.1371863],"study_design_scores_gemma":[0.00013841139,0.0018489308,0.8147697,0.00089697976,0.001887355,0.00633289,0.0036597769,0.0299183,0.090034686,0.027527152,0.022845864,0.0001399145],"about_ca_topic_score_codex":0.0019727207,"about_ca_topic_score_gemma":0.003611165,"teacher_disagreement_score":0.11498759,"about_ca_system_score_codex":0.0007523001,"about_ca_system_score_gemma":0.001151998,"threshold_uncertainty_score":0.6081197},"labels":[],"label_agreement":null},{"id":"W3181502328","doi":"10.1158/1538-7445.am2021-lb105","title":"Abstract LB105: In vivo CAR T therapy: targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Cytotoxic T cell; CD8; Ex vivo; Biology; Transduction (biophysics); T cell; Cancer research; Gene delivery; Viral vector; Cell therapy; CD19; In vivo; Genetic enhancement; Cell biology; Immunology; Antigen; Immune system; In vitro; Stem cell; Biochemistry; Gene; Genetics; Recombinant DNA","score_opus":0.12560361493496577,"score_gpt":0.4004026008070786,"score_spread":0.2747989858721128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181502328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9610867,0.0034654692,0.023170466,0.0004286858,0.00014403614,0.00012959068,0.0009360172,0.0011112813,0.009527787],"genre_scores_gemma":[0.98411983,0.00082478335,0.005631302,0.00010364896,0.000024918107,0.000044336477,0.001020256,0.000068671965,0.008162233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998797,0.00002004322,0.000008951001,0.000026800544,0.0000383098,0.000026208138],"domain_scores_gemma":[0.9999689,0.0000054641464,0.000009436139,0.0000041193416,0.000003458521,0.000008703448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012755979,0.00047320905,0.00024391772,0.00031247933,0.00012296539,0.00030612195,0.00022522728,0.00048083684,0.002213736],"category_scores_gemma":[0.00006707651,0.00010197902,0.00019299221,0.00014363149,0.00019357275,0.00019582271,0.0001233053,0.00065184943,0.00069696223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009622196,0.000084428095,0.00006276827,0.000025607596,0.0000036258277,0.000050188475,0.0000069668595,0.000109053835,0.9961677,0.00017929118,0.0003292685,0.0028848054],"study_design_scores_gemma":[0.00002287973,0.0005796414,0.00057878334,0.0000031396107,0.000011623226,0.00026746045,0.0000040601035,0.0008983588,0.99429035,0.000026292379,0.0033147968,0.0000026200153],"about_ca_topic_score_codex":0.0007834742,"about_ca_topic_score_gemma":0.00045367563,"teacher_disagreement_score":0.002213736,"about_ca_system_score_codex":0.00036609083,"about_ca_system_score_gemma":0.00014292367,"threshold_uncertainty_score":0.0074056983},"labels":[],"label_agreement":null},{"id":"W3181611529","doi":"10.2196/29912","title":"First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?","year":2021,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Intensive care medicine; Adverse effect; Melanoma; Immunotherapy; Randomized controlled trial; Scarcity; Surgery; Cancer; Internal medicine; Cancer research","score_opus":0.024440085063184718,"score_gpt":0.3555394913036441,"score_spread":0.33109940624045936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181611529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00096476334,0.89493674,0.0004279805,0.09685228,0.003841009,0.000020687328,0.0000858632,0.000023024084,0.0028476645],"genre_scores_gemma":[0.017035056,0.92774,0.0020793073,0.040562205,0.010447804,0.000059024464,0.00017207947,0.000029414128,0.0018750738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741685,0.0013423614,0.00034696492,0.0002352126,0.000515057,0.00014347042],"domain_scores_gemma":[0.985726,0.008081946,0.0015007529,0.00029282284,0.0034256715,0.0009727643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063660126,0.0005400785,0.0016977482,0.0014866748,0.0012095586,0.0046036444,0.0013431944,0.0036258881,0.007148371],"category_scores_gemma":[0.012907757,0.00021916835,0.0009323005,0.0014316618,0.0014155821,0.008371269,0.0012318341,0.005848372,0.0022771745],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005850902,0.00027013366,0.0023994027,0.014745853,0.00019188403,0.00029184524,0.0007559274,0.00018675851,0.00045603473,0.01159782,0.096570425,0.8719487],"study_design_scores_gemma":[0.00020447925,0.0014342084,0.006683186,0.058844242,0.0006261566,0.0013688692,0.006419849,0.0003305604,0.0004169181,0.025593264,0.8979632,0.00011510604],"about_ca_topic_score_codex":0.0033085712,"about_ca_topic_score_gemma":0.010346778,"teacher_disagreement_score":0.007148371,"about_ca_system_score_codex":0.0017326577,"about_ca_system_score_gemma":0.0052932035,"threshold_uncertainty_score":0.033667088},"labels":[],"label_agreement":null},{"id":"W3181940780","doi":"10.1101/2021.07.09.451642","title":"Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institutes of Health; Augusta University","keywords":"Avidity; Cart; Effector; Cancer research; Antigen; Hepatocellular carcinoma; Antibody; Chimeric antigen receptor; Epitope; In vivo; Immunology; Biology; Medicine; Immunotherapy; Immune system","score_opus":0.021013534483304605,"score_gpt":0.23492681345557095,"score_spread":0.21391327897226636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181940780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99822646,0.00036714165,0.0006781105,0.000032179727,0.0000106286325,0.000023416385,0.00007827534,0.00004123641,0.00054258597],"genre_scores_gemma":[0.99778336,0.00016942686,0.0009002377,0.000051386607,0.000006635683,0.000024763633,0.00017220002,0.0000061183146,0.0008858959],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999454,0.000009079576,0.0000032374473,0.000006991399,0.000011282744,0.000023989485],"domain_scores_gemma":[0.99996173,0.000005913447,0.000008730387,0.0000040492955,0.000004426168,0.000015145586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060133032,0.00026811476,0.0001564101,0.00009781133,0.0000684294,0.00012857802,0.00014636121,0.00019527323,0.0006835076],"category_scores_gemma":[0.00006339432,0.00006550279,0.00012831566,0.00006121504,0.00008007792,0.00009486423,0.00008759709,0.0004284706,0.00021881006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017833478,0.00012582325,0.0001667687,0.000033140477,0.0000074028603,0.000043394615,0.000011009894,0.00035145448,0.99517316,0.00007492577,0.0001344502,0.0037002235],"study_design_scores_gemma":[0.00017797579,0.003874881,0.0061968653,0.000009407936,0.000046614005,0.00049614935,0.000026654354,0.0050756778,0.9790477,0.00007191736,0.0049653677,0.000010805114],"about_ca_topic_score_codex":0.00039838432,"about_ca_topic_score_gemma":0.0005363643,"teacher_disagreement_score":0.0006835076,"about_ca_system_score_codex":0.00018469049,"about_ca_system_score_gemma":0.00011194123,"threshold_uncertainty_score":0.002286613},"labels":[],"label_agreement":null},{"id":"W3182197846","doi":"10.1016/j.jbc.2021.100966","title":"Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22","year":2021,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"Western Economic Diversification Canada; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canada Research Chairs; National Research Council Canada; Canada Foundation for Innovation; University of Saskatchewan; Canadian Light Source","keywords":"CD22; Epitope; Antibody; SIGLEC; Antigen; Sialic acid; Paratope; Monoclonal antibody; Chemistry; B cell; Molecular biology; Receptor; Biology; Cell biology; Biochemistry; Immunology","score_opus":0.051466291394493956,"score_gpt":0.32593683824821845,"score_spread":0.2744705468537245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182197846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98791724,0.0030615774,0.0041124546,0.0003042929,0.00005952748,0.000028858422,0.0005799274,0.00010928114,0.0038269134],"genre_scores_gemma":[0.99023974,0.0018155051,0.0035858527,0.00018416987,0.000017617198,0.000021112632,0.0019762039,0.000020536847,0.0021392512],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989116,0.000014484113,0.0000049161795,0.000016681195,0.000045613353,0.000027138605],"domain_scores_gemma":[0.99994576,0.000011367889,0.000012358017,0.0000038522207,0.000011262473,0.000015429589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009660472,0.0002963035,0.00025538745,0.00015771211,0.0002790563,0.00027748678,0.000594293,0.00033526702,0.0017531785],"category_scores_gemma":[0.00016740386,0.00017367094,0.0002182587,0.00019432373,0.00015253763,0.00016673018,0.00020246505,0.0007118101,0.00053729664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046751348,0.00018011587,0.0021915534,0.00019521544,0.000050384046,0.0010763012,0.0001389035,0.004692359,0.97813076,0.0025299175,0.0020666514,0.0082804365],"study_design_scores_gemma":[0.0002794054,0.00082462764,0.018075222,0.000071577895,0.00017729863,0.0024937305,0.00033877188,0.059009496,0.86176974,0.0014261482,0.05545466,0.000079284764],"about_ca_topic_score_codex":0.0030565218,"about_ca_topic_score_gemma":0.0021680726,"teacher_disagreement_score":0.0030565218,"about_ca_system_score_codex":0.00062588125,"about_ca_system_score_gemma":0.00033706686,"threshold_uncertainty_score":0.0060774684},"labels":[],"label_agreement":null},{"id":"W3182840620","doi":"10.1371/journal.pone.0253864","title":"The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Alberta Children's Hospital Foundation; Alberta Cancer Foundation; Children's Hospital Foundation; Cancer Research Society","keywords":"Immune system; Sarcoma; Biology; Cancer research; Immunology; Macrophage; Lymphocyte; Immune checkpoint; Pathology; Immunotherapy; Medicine","score_opus":0.053299864276414255,"score_gpt":0.2691362608044228,"score_spread":0.21583639652800857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182840620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98548996,0.0007116833,0.0070630056,0.00029138124,0.00007167751,0.00017511683,0.0024110747,0.00032499075,0.0034610808],"genre_scores_gemma":[0.971961,0.0009151523,0.00961414,0.00012655799,0.000026272905,0.0002729386,0.0018727453,0.00009906245,0.015111993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966705,0.000049535116,0.00004386455,0.00007470455,0.00010197559,0.00006291257],"domain_scores_gemma":[0.9996598,0.000036784048,0.000117918724,0.000058817473,0.0000236035,0.00010302803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026124436,0.0006830472,0.00026165144,0.0011441256,0.0003303341,0.00042808885,0.0004692052,0.0008190079,0.0039343364],"category_scores_gemma":[0.00014752767,0.0004047303,0.0003674244,0.0002898277,0.0006048457,0.00049025676,0.00030639963,0.0012163625,0.0009556395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030768334,0.00020617322,0.00066189386,0.00009059246,0.00000926969,0.00034919693,0.00006392921,0.00028781052,0.99424475,0.00090975617,0.00022328366,0.0026456069],"study_design_scores_gemma":[0.00015670704,0.0021144217,0.011195776,0.000069310045,0.00004383988,0.0038660993,0.00014432785,0.0034162726,0.96374613,0.00048179808,0.014736865,0.0000284245],"about_ca_topic_score_codex":0.00053170347,"about_ca_topic_score_gemma":0.0013833533,"teacher_disagreement_score":0.0039343364,"about_ca_system_score_codex":0.00039348684,"about_ca_system_score_gemma":0.00022453794,"threshold_uncertainty_score":0.0131616},"labels":[],"label_agreement":null},{"id":"W3187322562","doi":"10.3389/fimmu.2021.698565","title":"p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells","year":2021,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Senescence; Cell biology; Downregulation and upregulation; T cell; Immunotherapy; Biology; Ex vivo; Cell; Cell cycle; DNA damage; In vivo; Cancer research; Immune system; Immunology; DNA; Genetics; Gene","score_opus":0.016589656623439412,"score_gpt":0.27872685458128643,"score_spread":0.262137197957847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187322562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965643,0.0013419865,0.0012157141,0.000044504122,0.000012524647,0.000014194869,0.00012547453,0.000054241445,0.00062714296],"genre_scores_gemma":[0.9982704,0.0004190008,0.00048265987,0.00001663701,0.000005885036,0.000017003307,0.0001368392,0.000008326081,0.0006431833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998654,0.000035906174,0.000017328388,0.000028480343,0.000020878953,0.000032024884],"domain_scores_gemma":[0.999897,0.000023931565,0.000031869447,0.000016932836,0.00001117114,0.000019147205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021092047,0.00023304984,0.00018791619,0.00028334284,0.00016724001,0.00040695968,0.00011349403,0.00024088827,0.001121327],"category_scores_gemma":[0.00019737612,0.00012864658,0.00019011072,0.00016946036,0.00023928225,0.00022524728,0.00016250598,0.0004861611,0.00044556378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003065856,0.00006189365,0.0005143998,0.000025654801,0.000003467093,0.000061613784,0.000025892683,0.00013139787,0.99701667,0.000084919,0.000030536135,0.001736886],"study_design_scores_gemma":[0.00003863072,0.00068986206,0.0072827865,0.0000043694067,0.000012874382,0.00044777838,0.000038040584,0.0015098015,0.98802364,0.00014589512,0.0018023221,0.0000040627265],"about_ca_topic_score_codex":0.00020208494,"about_ca_topic_score_gemma":0.00014189762,"teacher_disagreement_score":0.001121327,"about_ca_system_score_codex":0.00020756066,"about_ca_system_score_gemma":0.00017352444,"threshold_uncertainty_score":0.0037511587},"labels":[],"label_agreement":null},{"id":"W3190177153","doi":"10.1136/jitc-2020-002287","title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Tocilizumab; Leukopenia; Internal medicine; Neutropenia; Gastroenterology; Chimeric antigen receptor; Immunotherapy; Chemotherapy","score_opus":0.006887365602533204,"score_gpt":0.2905556143615081,"score_spread":0.2836682487589749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190177153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7845014,0.17129359,0.0066488576,0.0005932175,0.00024764804,0.002931622,0.028411135,0.0003090451,0.0050634015],"genre_scores_gemma":[0.972439,0.014020217,0.0019173902,0.0005201336,0.00020596622,0.0011137477,0.009064429,0.000040861065,0.00067822944],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9918138,0.0043476024,0.0013899829,0.00091090036,0.0012771206,0.0002606674],"domain_scores_gemma":[0.988203,0.0046414956,0.0051502096,0.00069047866,0.0010648028,0.0002499513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013815867,0.0009690717,0.0028093783,0.0017053466,0.00022694336,0.0009878635,0.00048859103,0.0006991639,0.0033469717],"category_scores_gemma":[0.015634289,0.00041366613,0.007751953,0.0019331622,0.00026247447,0.0005567505,0.00066697365,0.00069528946,0.00038674305],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20332968,0.00067652884,0.17480257,0.019345552,0.43355143,0.00080710254,0.0002940018,0.005246392,0.006246969,0.00043250096,0.008347505,0.14691979],"study_design_scores_gemma":[0.038387116,0.042843778,0.50384605,0.0021142312,0.37030664,0.0025106736,0.00029830926,0.0048759645,0.0050256853,0.0008327654,0.028812174,0.00014664102],"about_ca_topic_score_codex":0.0012579022,"about_ca_topic_score_gemma":0.0020767308,"teacher_disagreement_score":0.013815867,"about_ca_system_score_codex":0.0010511295,"about_ca_system_score_gemma":0.0011951649,"threshold_uncertainty_score":0.073066175},"labels":[],"label_agreement":null},{"id":"W3193753748","doi":"10.1101/2021.08.24.457536","title":"Clinically-relevant T cell expansion protocols activate distinct cellular metabolic programs and phenotypes","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of Victoria","funders":"Canadian Institutes of Health Research","keywords":"Ex vivo; Phenotype; In vivo; Glutamine; Function (biology); Biology; Cell biology; Cell; Metabolism; Cell growth; T cell; Carbohydrate metabolism; Immunotherapy; Cancer research; Biochemistry; Immunology; Immune system; Genetics; Gene","score_opus":0.03399406325955247,"score_gpt":0.29830460958641086,"score_spread":0.2643105463268584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193753748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788988,0.0019465906,0.01258753,0.00020241145,0.00008246518,0.00030700135,0.0010378791,0.00021855651,0.0047187214],"genre_scores_gemma":[0.982644,0.0012062388,0.011562585,0.00016821518,0.000040440773,0.00052742375,0.0015322383,0.00011316807,0.0022056322],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99968326,0.000110568115,0.000036800844,0.000051716284,0.000063269435,0.000054333686],"domain_scores_gemma":[0.99982196,0.00007131775,0.00003121575,0.000024849158,0.000025887332,0.000024749921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005309011,0.00045487343,0.00024693253,0.00029464345,0.0001892271,0.0005793565,0.00016417434,0.00036748234,0.0024114465],"category_scores_gemma":[0.00038419408,0.00013377849,0.00016810719,0.00024015558,0.0002504586,0.0002646261,0.0002997489,0.0007492533,0.000689723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036944926,0.000115447125,0.00043633927,0.00008225823,0.000006083905,0.000050003026,0.000056248602,0.00031082085,0.9945069,0.00017804535,0.00020337936,0.0036851238],"study_design_scores_gemma":[0.0000444441,0.0007919875,0.0020116686,0.000013266247,0.000021805843,0.00018759657,0.00005492559,0.0005692972,0.99328125,0.0000950007,0.0029224197,0.000006420175],"about_ca_topic_score_codex":0.00014976297,"about_ca_topic_score_gemma":0.00025109842,"teacher_disagreement_score":0.0024114465,"about_ca_system_score_codex":0.00019788623,"about_ca_system_score_gemma":0.00018538546,"threshold_uncertainty_score":0.008067131},"labels":[],"label_agreement":null},{"id":"W3194238275","doi":"10.1126/scisignal.abe2606","title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","year":2021,"lang":"en","type":"article","venue":"Science Signaling","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Lorentz Center; University of Washington; Fred Hutchinson Cancer Research Center; National Multiple Sclerosis Society Michigan Chapter; Takeda Canada; American Cancer Society","keywords":"T-cell receptor; Chimeric antigen receptor; Antigen; T cell; CD3; Biology; Cancer research; Cell biology; Immunology; Immune system; CD8","score_opus":0.04897694173428213,"score_gpt":0.32589205340288135,"score_spread":0.2769151116685992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194238275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97751576,0.0014295868,0.017808734,0.0001083466,0.000016672711,0.000046969657,0.00029482908,0.00008841963,0.0026906738],"genre_scores_gemma":[0.99258864,0.0008346337,0.0050166147,0.00005019469,0.0000048985257,0.000044887678,0.00034000774,0.000026558673,0.0010935892],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996922,0.000058235266,0.000019441408,0.000055453445,0.00008000663,0.00009475885],"domain_scores_gemma":[0.9998337,0.000045036853,0.000040283816,0.00001854982,0.000033862772,0.000028587361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044895193,0.00036883165,0.00022099013,0.000248281,0.0001257991,0.0005480124,0.00022487389,0.00037213785,0.0014788919],"category_scores_gemma":[0.000355074,0.00018230453,0.00019999781,0.0001846044,0.00020738973,0.00039407454,0.00013141707,0.00055395195,0.00029931913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020042175,0.00004525212,0.00018027888,0.00002637726,0.000005094433,0.000018366623,0.000009463395,0.00069370866,0.9959519,0.00051070517,0.000026496007,0.00233198],"study_design_scores_gemma":[0.000013262898,0.00046910677,0.0005898277,0.000002388521,0.000016983706,0.00008135179,0.000011830358,0.0022572444,0.99512285,0.0000835902,0.0013483939,0.0000031824704],"about_ca_topic_score_codex":0.00030754303,"about_ca_topic_score_gemma":0.0003896154,"teacher_disagreement_score":0.0014788919,"about_ca_system_score_codex":0.0005215888,"about_ca_system_score_gemma":0.0002710223,"threshold_uncertainty_score":0.0049473643},"labels":[],"label_agreement":null},{"id":"W3194271452","doi":"10.1097/ppo.0000000000000532","title":"Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?","year":2021,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Chronic lymphocytic leukemia; Chimeric antigen receptor; Medicine; Immunology; Hematopoietic cell; Leukemia; Disease; Transplantation; Hematopoietic stem cell transplantation; Cell therapy; Haematopoiesis; Cancer research; T cell; Cell; Biology; Stem cell; Immune system; Internal medicine","score_opus":0.1016404066681494,"score_gpt":0.4152514179338117,"score_spread":0.3136110112656623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194271452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000044235734,0.99855584,0.00005255263,0.0006166143,0.000288338,0.0000023095677,0.000008345014,0.0000039920137,0.00042781315],"genre_scores_gemma":[0.0004164439,0.998171,0.0001131108,0.00057978043,0.00030096734,0.0000056208314,0.000017231578,0.0000012772826,0.0003945832],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998017,0.000053997108,0.000023758783,0.000032120442,0.000067001085,0.000021539692],"domain_scores_gemma":[0.99957913,0.00023432614,0.000038929895,0.000012651313,0.00009835996,0.00003660667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008782746,0.0005459314,0.0012537732,0.0011252429,0.00025228172,0.0010581692,0.00081663305,0.0014246671,0.0040297154],"category_scores_gemma":[0.0009341211,0.00016133982,0.0004993482,0.0010519922,0.00056634727,0.0015605028,0.0005808848,0.0027641803,0.0024555332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012664123,0.00006275853,0.00008797853,0.01072395,0.000076833254,0.00011982116,0.00003492809,0.00023793607,0.0012196904,0.0059098895,0.039612718,0.9417869],"study_design_scores_gemma":[0.00004247329,0.00015812422,0.00030308808,0.0046394765,0.000086187865,0.0005867832,0.000046817007,0.000059599333,0.00029879605,0.0025259266,0.99123913,0.000013645448],"about_ca_topic_score_codex":0.0007238925,"about_ca_topic_score_gemma":0.0013110976,"teacher_disagreement_score":0.0040297154,"about_ca_system_score_codex":0.00063699996,"about_ca_system_score_gemma":0.0010350548,"threshold_uncertainty_score":0.0134807825},"labels":[],"label_agreement":null},{"id":"W3194367680","doi":"10.1182/bloodadvances.2020003844","title":"Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Cytokine release syndrome; Immunogenicity; Antibody; Immunology; Medicine; Diffuse large B-cell lymphoma; Lymphoma; Internal medicine; B cell; Immunotherapy; Immune system; Oncology; Chimeric antigen receptor","score_opus":0.010106057027941427,"score_gpt":0.2702827667122035,"score_spread":0.2601767096842621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194367680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971096,0.0018593987,0.00008326815,0.0000674539,0.000012310233,0.000053425807,0.00009158196,0.00001123776,0.0007117218],"genre_scores_gemma":[0.9986223,0.00054702343,0.0001133461,0.00013308569,0.000017454431,0.00004916175,0.000301548,0.0000034098828,0.00021262105],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99962246,0.00019438783,0.0000297061,0.000030423324,0.00007855349,0.000044524022],"domain_scores_gemma":[0.999608,0.00009844699,0.0001407592,0.000024448573,0.000027461649,0.00010105964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010723767,0.00014907299,0.00046421477,0.00020467448,0.000087929,0.00032091202,0.0001655083,0.00023295054,0.0009849792],"category_scores_gemma":[0.00066011964,0.00011612291,0.0002713284,0.00027275126,0.00024586503,0.0002698239,0.00017046303,0.0004886823,0.0002163967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19345371,0.010448253,0.2208621,0.0014842746,0.0013023631,0.0012628161,0.0004543602,0.002526385,0.1715962,0.00066763384,0.0046074092,0.39133453],"study_design_scores_gemma":[0.027347611,0.29231837,0.6244161,0.00014917675,0.00093240006,0.0032629145,0.0003551388,0.0037566626,0.027662491,0.00046516815,0.019279953,0.000054035194],"about_ca_topic_score_codex":0.000396503,"about_ca_topic_score_gemma":0.000953708,"teacher_disagreement_score":0.0010723767,"about_ca_system_score_codex":0.000379773,"about_ca_system_score_gemma":0.0003240547,"threshold_uncertainty_score":0.0056713223},"labels":[],"label_agreement":null},{"id":"W3195202932","doi":"10.1503/cmaj.202907","title":"Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)","year":2021,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; Leukemia & Lymphoma Society of Canada; Canadian Blood Services; Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Cell therapy; Medicine; Cancer immunotherapy; Immunology; Antigen; T cell; CAR T-cell therapy; Cancer; Immune system; Cancer research; Cell; Biology; Internal medicine","score_opus":0.04552432751642645,"score_gpt":0.3670496104793084,"score_spread":0.32152528296288196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195202932","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059586175,0.9970837,0.00024998042,0.0008063059,0.0005642063,0.0000064732853,0.000013580595,0.0000112768585,0.001205016],"genre_scores_gemma":[0.00076609076,0.9966594,0.00027653578,0.00077426754,0.0004601345,0.000009068779,0.00003105277,0.0000028583383,0.00102063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996699,0.000060704428,0.000026824171,0.000057605877,0.00014953519,0.000035396188],"domain_scores_gemma":[0.99952805,0.000225867,0.00004059669,0.000014400058,0.00014411414,0.000046972546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009892079,0.0008570036,0.0011340113,0.0025727027,0.00031779465,0.0011128305,0.0007754036,0.0014403152,0.004767241],"category_scores_gemma":[0.0009933931,0.0002902721,0.00074880855,0.002122567,0.0007621101,0.0015757642,0.000718375,0.004559865,0.0028248054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008187208,0.00008068861,0.00009395735,0.008964277,0.000069664675,0.00013938577,0.000039431063,0.00043492074,0.0019712008,0.010589677,0.08108569,0.8964492],"study_design_scores_gemma":[0.000029447227,0.00007224427,0.00023405493,0.0021284793,0.000048678878,0.0008117353,0.000020748352,0.00009478072,0.0004834206,0.0028938192,0.99316955,0.000013096907],"about_ca_topic_score_codex":0.001479368,"about_ca_topic_score_gemma":0.002022721,"teacher_disagreement_score":0.004767241,"about_ca_system_score_codex":0.001272421,"about_ca_system_score_gemma":0.0012214308,"threshold_uncertainty_score":0.015947998},"labels":[],"label_agreement":null},{"id":"W3195519455","doi":"10.1097/cji.0000000000000386","title":"Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers","year":2021,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Targeting Solutions (Canada)","funders":"","keywords":"Medicine; Cancer research","score_opus":0.019090535158918856,"score_gpt":0.32822564717479075,"score_spread":0.3091351120158719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195519455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8674471,0.042521466,0.07104365,0.0012750675,0.00018392052,0.0008731577,0.0007427833,0.0009576325,0.014955092],"genre_scores_gemma":[0.951042,0.012385572,0.029541371,0.00036986082,0.000050572202,0.0001954939,0.000536181,0.000077843266,0.0058011496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969256,0.000090767564,0.00001688977,0.00004561965,0.000089809815,0.00006433309],"domain_scores_gemma":[0.99989665,0.000034940225,0.000014624603,0.000010421356,0.00002424769,0.000019106139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006123372,0.0004670183,0.00033381235,0.00042874596,0.00017939074,0.000996857,0.0003151925,0.0005333981,0.0016548141],"category_scores_gemma":[0.00038355018,0.0002274789,0.00023490032,0.00026207286,0.0003396157,0.0006567852,0.00040697987,0.0007106463,0.00071000087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020395087,0.00019076128,0.00058005523,0.00019649805,0.000016542068,0.00013998996,0.00009558893,0.0036263086,0.95176077,0.00366236,0.0007548933,0.038772292],"study_design_scores_gemma":[0.00007151898,0.0012526853,0.00095332356,0.000040236526,0.00004993858,0.00045103813,0.00007458119,0.0069229156,0.96658576,0.00100027,0.022574712,0.000022977125],"about_ca_topic_score_codex":0.00059076055,"about_ca_topic_score_gemma":0.0012932146,"teacher_disagreement_score":0.0016548141,"about_ca_system_score_codex":0.0006584304,"about_ca_system_score_gemma":0.00033925328,"threshold_uncertainty_score":0.005535841},"labels":[],"label_agreement":null},{"id":"W3195992586","doi":"10.1038/s41467-021-25245-8","title":"DL4-μbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canada First Research Excellence Fund; National Heart, Lung, and Blood Institute; Krembil Foundation; University of Toronto; National Institutes of Health; Government of Canada; Ontario Institute for Regenerative Medicine; Stem Cell Network","keywords":"Biology; Cell biology; Stem cell; Progenitor cell; Stromal cell; CD34; Haematopoiesis; Cellular differentiation; Immunology; T cell; Immune system; Cancer research","score_opus":0.03241476712848236,"score_gpt":0.3110137377167796,"score_spread":0.27859897058829725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195992586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96109277,0.0010581062,0.030659804,0.000116532334,0.00006644158,0.00013800403,0.0010024915,0.0004354963,0.0054303547],"genre_scores_gemma":[0.9788517,0.00076050445,0.010988419,0.00007281945,0.000014395987,0.00008721858,0.001236674,0.00007197541,0.00791636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989367,0.000018586597,0.000009264517,0.000019386445,0.000038790142,0.000020288531],"domain_scores_gemma":[0.9999211,0.000022179212,0.000019023588,0.000008937518,0.0000092713635,0.000019433919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013901817,0.0002602467,0.00013679756,0.0002587632,0.000119341465,0.00033186472,0.00016114626,0.00016984617,0.001577782],"category_scores_gemma":[0.00006943558,0.00014298242,0.00013588906,0.00013911723,0.00015484764,0.00012971653,0.00025556746,0.00042095405,0.0007241433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024632009,0.000010202487,0.00004684647,0.000017567008,0.0000014506292,0.00001541895,0.000007856939,0.000060623377,0.9990552,0.00011803085,0.000040494637,0.00060170965],"study_design_scores_gemma":[0.0000045996635,0.000044000204,0.00022885935,0.0000019153197,0.000002854942,0.000032063715,0.000005577378,0.00028165005,0.9969325,0.000018766814,0.0024462142,9.897288e-7],"about_ca_topic_score_codex":0.00044451698,"about_ca_topic_score_gemma":0.0007857842,"teacher_disagreement_score":0.001577782,"about_ca_system_score_codex":0.00024361695,"about_ca_system_score_gemma":0.00018759645,"threshold_uncertainty_score":0.0052782297},"labels":[],"label_agreement":null},{"id":"W3197049258","doi":"10.1182/bloodadvances.2020003534","title":"Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"University of Oxford; University of Bristol; National Institute for Health and Care Research","keywords":"CD19; Minimal residual disease; CD34; Medicine; Leukemia; Immunology; Cancer research; Transplantation; Stem cell; Antigen; Oncology; Internal medicine; Biology","score_opus":0.01476344073809838,"score_gpt":0.3032942440092108,"score_spread":0.2885308032711124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197049258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99016017,0.0035004397,0.00441652,0.00008861265,0.000019082472,0.000067051194,0.0001781503,0.00017191943,0.0013979856],"genre_scores_gemma":[0.9899356,0.0032295885,0.0045918715,0.0000876367,0.000013347837,0.00006776277,0.00050328707,0.00001440094,0.0015565844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999651,0.0000044386775,0.000002283485,0.000006381427,0.000012450503,0.000009424897],"domain_scores_gemma":[0.999985,0.0000024294568,0.000004887162,0.0000016446664,0.0000017024221,0.0000043411433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005137245,0.00020631406,0.00019032747,0.0001531065,0.00006834637,0.00022866685,0.00013874721,0.000174247,0.0005583296],"category_scores_gemma":[0.000035100624,0.000053631586,0.000104410676,0.00011755746,0.000056617395,0.00008985954,0.0001288538,0.00032729493,0.00021008932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000843972,0.00008349521,0.00049062894,0.000051397048,0.000007309282,0.000052140953,0.000013655342,0.00028295885,0.9828839,0.00015977773,0.00017235396,0.01571805],"study_design_scores_gemma":[0.000063219646,0.001224643,0.006135376,0.000010667645,0.000054677883,0.0007185836,0.000023488086,0.0027106223,0.9739629,0.0000896367,0.0150015205,0.000004643818],"about_ca_topic_score_codex":0.0002519709,"about_ca_topic_score_gemma":0.00058710494,"teacher_disagreement_score":0.0005583296,"about_ca_system_score_codex":0.00017374383,"about_ca_system_score_gemma":0.000108776316,"threshold_uncertainty_score":0.0018677711},"labels":[],"label_agreement":null},{"id":"W3197223132","doi":"10.1186/s13045-021-01144-9","title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Oncology; Confidence interval; Surgery","score_opus":0.07529656742620855,"score_gpt":0.4012486531152399,"score_spread":0.32595208568903133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197223132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97057706,0.008646814,0.012719349,0.0003076138,0.00033688152,0.002569799,0.0018581996,0.00013356714,0.0028507558],"genre_scores_gemma":[0.9929103,0.00045856956,0.0041728,0.000161417,0.000062171945,0.0013090918,0.00055713445,0.0000137940615,0.00035468102],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9819067,0.01456074,0.0009248659,0.0011551302,0.0011111798,0.00034134745],"domain_scores_gemma":[0.9831808,0.011350202,0.0034643176,0.0011898353,0.0005057096,0.00030911242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017303776,0.0011569776,0.0021900816,0.00089310214,0.00023935779,0.00076485047,0.0009724286,0.0006226467,0.004908989],"category_scores_gemma":[0.025701718,0.00032267114,0.0047622165,0.00074551336,0.0006765128,0.00072477676,0.000990415,0.0015259135,0.00026288294],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7601354,0.0020877274,0.035262816,0.0049754474,0.07105759,0.00009562168,0.00030462706,0.010212207,0.0024410672,0.0023348671,0.0013268827,0.109765664],"study_design_scores_gemma":[0.2875185,0.33521515,0.16147791,0.0011845736,0.116055496,0.00061224157,0.0004926523,0.053926606,0.01506913,0.015925184,0.012209749,0.00031270745],"about_ca_topic_score_codex":0.0006250675,"about_ca_topic_score_gemma":0.0007383821,"teacher_disagreement_score":0.017303776,"about_ca_system_score_codex":0.0008982359,"about_ca_system_score_gemma":0.00094428164,"threshold_uncertainty_score":0.0915122},"labels":[],"label_agreement":null},{"id":"W3197432291","doi":"10.1016/j.jcpo.2021.100303","title":"Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; Canadian Centre for Applied Research in Cancer Control; British Columbia Centre of Excellence for Women's Health","funders":"Michael Smith Health Research BC","keywords":"Chimeric antigen receptor; Qualitative research; Inclusion (mineral); Medicine; Social media; Family medicine; Cancer; Psychology; Social psychology; Sociology; Immunotherapy; Internal medicine; World Wide Web; Computer science","score_opus":0.08440601087932618,"score_gpt":0.4918759082904122,"score_spread":0.407469897411086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197432291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97213364,0.00085587363,0.0016221907,0.008349458,0.00027669192,0.00024934293,0.0004912394,0.000028698607,0.0159928],"genre_scores_gemma":[0.98834014,0.00073092885,0.00069400994,0.0029369825,0.0000760252,0.00043407464,0.0001597797,0.00007391038,0.0065541165],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9790592,0.015538541,0.0005317957,0.00088648684,0.0009920998,0.0029918675],"domain_scores_gemma":[0.9355547,0.054149617,0.0025646617,0.00077182293,0.0025837363,0.0043754694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01517727,0.0007021216,0.0010362531,0.0022168146,0.017824898,0.009423479,0.0023435892,0.003959076,0.0077523487],"category_scores_gemma":[0.035844587,0.0007915312,0.000499125,0.003378879,0.010971823,0.008637112,0.012411704,0.007649333,0.00085073675],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025747238,0.000018720244,0.0006932161,0.000044336455,0.0000018354389,0.00015326105,0.9969989,0.0000068502363,0.0001226912,0.00061038084,0.0002885764,0.0010355397],"study_design_scores_gemma":[0.0000027626954,0.0000103163875,0.00044055682,0.00005233296,0.0000018827769,0.000038661612,0.9950374,0.000011704422,0.00006240254,0.00014031041,0.0041959463,0.0000057160914],"about_ca_topic_score_codex":0.012151335,"about_ca_topic_score_gemma":0.015032521,"teacher_disagreement_score":0.017824898,"about_ca_system_score_codex":0.007373842,"about_ca_system_score_gemma":0.0074513946,"threshold_uncertainty_score":0.080266},"labels":[],"label_agreement":null},{"id":"W3197920680","doi":"10.1016/j.jcpo.2021.100304","title":"Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia; Canadian Centre for Applied Research in Cancer Control; Simon Fraser University","funders":"Janssen Pharmaceuticals; Michael Smith Health Research BC; Teva Pharmaceutical Industries; Roche","keywords":"Chimeric antigen receptor; Clinical trial; Cell therapy; Medicine; Quality of life (healthcare); Receptor; Immunology; Immunotherapy; Cell; Biology; Internal medicine; Immune system; Nursing; Genetics","score_opus":0.40261342603305206,"score_gpt":0.5768524217763609,"score_spread":0.1742389957433088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197920680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8129547,0.017455503,0.003196356,0.0034777166,0.00022178963,0.0017184771,0.1479636,0.000087394976,0.012924482],"genre_scores_gemma":[0.91673523,0.0027078616,0.0016113356,0.0018422247,0.00011512643,0.002391629,0.07379157,0.000035691926,0.00076934416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.93473005,0.037936218,0.015184136,0.003094934,0.006785722,0.0022688326],"domain_scores_gemma":[0.8738007,0.049529202,0.06064659,0.0045676283,0.008429927,0.0030259967],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033328712,0.0004710767,0.0015308609,0.0035747068,0.00066907017,0.0031869006,0.0007391724,0.0010884731,0.0030714308],"category_scores_gemma":[0.08142591,0.00042954512,0.0017832384,0.010562478,0.0009252689,0.001981075,0.0011798813,0.001615555,0.0008212626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010684731,0.0008186504,0.94549346,0.0018822182,0.0025379504,0.000102943064,0.00031213288,0.0014745387,0.0006323428,0.0007227152,0.0076097175,0.027728599],"study_design_scores_gemma":[0.0011148237,0.0026517492,0.9765379,0.0006422931,0.0010513668,0.0002513613,0.0003309628,0.0008350735,0.0010392445,0.0005946106,0.014880251,0.000070330534],"about_ca_topic_score_codex":0.0024136582,"about_ca_topic_score_gemma":0.003987278,"teacher_disagreement_score":0.9666713,"about_ca_system_score_codex":0.0019555292,"about_ca_system_score_gemma":0.0026924452,"threshold_uncertainty_score":0.17626119},"labels":[],"label_agreement":null},{"id":"W3198124923","doi":"10.1182/bloodadvances.2020003848","title":"Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Lymphoma; Oncology; Fludarabine; Chemotherapy; Survival rate; Surgery; Cyclophosphamide","score_opus":0.015949554239113296,"score_gpt":0.32829919814359676,"score_spread":0.31234964390448344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198124923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99936956,0.000299178,0.000052406944,0.000017335575,0.0000061452824,0.000019546624,0.000045774406,0.0000026095167,0.00018742609],"genre_scores_gemma":[0.99906987,0.00021578548,0.00007637156,0.000038354414,0.000026180542,0.000032081938,0.0003765665,0.0000019916129,0.00016281755],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994825,0.00023973246,0.000036661648,0.00010480209,0.00006344244,0.000072836105],"domain_scores_gemma":[0.99898225,0.00033655734,0.0003529749,0.00008727997,0.000035860678,0.00020509258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015094235,0.00026519867,0.0006802308,0.0003947643,0.00011469416,0.0004529436,0.00030090282,0.00044113095,0.00070802076],"category_scores_gemma":[0.0016668235,0.00011855916,0.00060093746,0.00029204032,0.00025872226,0.0004627434,0.00036698204,0.0004590026,0.00013089144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4621298,0.009216563,0.31916246,0.00048041745,0.0025425416,0.0005947741,0.0003796195,0.01057973,0.019900126,0.0006904305,0.0014121587,0.17291142],"study_design_scores_gemma":[0.023575634,0.37520188,0.580587,0.00006501632,0.0016638234,0.0008360711,0.0002793267,0.009300534,0.0057144105,0.0007633134,0.001961473,0.00005153383],"about_ca_topic_score_codex":0.00031045004,"about_ca_topic_score_gemma":0.00071337575,"teacher_disagreement_score":0.0015094235,"about_ca_system_score_codex":0.0005299465,"about_ca_system_score_gemma":0.000357869,"threshold_uncertainty_score":0.007982731},"labels":[],"label_agreement":null},{"id":"W3198342545","doi":"10.1101/2021.08.30.21262835","title":"Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Antigen; Cytotoxic T cell; Biology; Immune system; T cell; Antigen-presenting cell; Cancer immunotherapy; CD8; Immunotherapy; Immunology; Cancer research; Streptamer; Cell biology; In vitro","score_opus":0.05006156664017174,"score_gpt":0.3238584902247554,"score_spread":0.27379692358458363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198342545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421257,0.0010237973,0.0032230567,0.000065444874,0.000033216616,0.000049483275,0.00017710301,0.00012776158,0.0010875679],"genre_scores_gemma":[0.9959812,0.00034691187,0.002234667,0.00005267988,0.000014101006,0.00005028298,0.00018971476,0.000017101169,0.0011133096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999188,0.000012624031,0.0000070753167,0.0000148945865,0.00002100814,0.000025635645],"domain_scores_gemma":[0.99995947,0.000007968285,0.000008611195,0.000005853303,0.0000050695257,0.00001295847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001068894,0.00028777527,0.0002431058,0.00016573463,0.00006767699,0.0002794237,0.00014793732,0.00021433647,0.0011899343],"category_scores_gemma":[0.00007993342,0.0000665272,0.00013308825,0.00008003853,0.000090822316,0.00014026034,0.00013411095,0.0006053775,0.0003095743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021186791,0.00017981835,0.00013969108,0.000028782051,0.000005205604,0.000017503473,0.000008544679,0.00026718987,0.9937848,0.00005121759,0.00011941962,0.005186024],"study_design_scores_gemma":[0.000054182372,0.0012271152,0.0013104916,0.000004449405,0.00002435151,0.00012196931,0.000007872441,0.0018848748,0.99315286,0.00004210056,0.002166738,0.0000028693923],"about_ca_topic_score_codex":0.00011721751,"about_ca_topic_score_gemma":0.00019172924,"teacher_disagreement_score":0.0011899343,"about_ca_system_score_codex":0.00012165413,"about_ca_system_score_gemma":0.00012605258,"threshold_uncertainty_score":0.003980756},"labels":[],"label_agreement":null},{"id":"W3199446885","doi":"10.1158/2326-6066.cir-21-0519","title":"Supporting the Next Generation of Scientists to Lead Cancer Immunology Research","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Engineering ethics; Field (mathematics); Cancer immunotherapy; Publishing; Political science; Immunology; Medicine; Immunotherapy; Engineering; Immune system","score_opus":0.3417155636439009,"score_gpt":0.5241351132805301,"score_spread":0.1824195496366292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199446885","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003934534,0.011397049,0.0103348745,0.9231038,0.021599563,0.0001353247,0.000030107723,0.00017673417,0.029288048],"genre_scores_gemma":[0.26260734,0.033636965,0.059320513,0.5150094,0.03722242,0.0010219209,0.0002910623,0.00039755242,0.09049289],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.937866,0.038322866,0.0014757634,0.003070506,0.009975216,0.009289663],"domain_scores_gemma":[0.85726625,0.022276118,0.0052537983,0.003935202,0.018282754,0.09298598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06649777,0.00083002134,0.000973983,0.0015603557,0.016595902,0.027046572,0.0030479408,0.013079319,0.022169359],"category_scores_gemma":[0.06845948,0.00069449935,0.001205504,0.0010161782,0.016012572,0.017896673,0.023996603,0.024433106,0.00927726],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000191604,0.0004672202,0.005263777,0.00073148706,0.00005430675,0.0010538924,0.031241389,0.00035792656,0.0024291284,0.2625078,0.49556112,0.20014034],"study_design_scores_gemma":[0.000056019093,0.00013218059,0.0004540098,0.00056171365,0.000015089732,0.00034170924,0.016432315,0.00023074284,0.0003144933,0.064176634,0.9172385,0.000046584733],"about_ca_topic_score_codex":0.0018684996,"about_ca_topic_score_gemma":0.0050302893,"teacher_disagreement_score":0.06649777,"about_ca_system_score_codex":0.0060640424,"about_ca_system_score_gemma":0.062104397,"threshold_uncertainty_score":0.351678},"labels":[],"label_agreement":null},{"id":"W3199514812","doi":"10.1007/s00262-021-03051-x","title":"The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"Drs Martin and Dorothy Spatz Charitable Foundation","keywords":"CD47; Cytotoxic T cell; Cancer research; Mycosis fungoides; Immunotherapy; Immunology; Cutaneous T-cell lymphoma; Lymphoma; Medicine; Antibody; Biology; Immune system; In vitro","score_opus":0.015303673055613896,"score_gpt":0.30924680586576947,"score_spread":0.29394313281015555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199514812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93384147,0.048510518,0.0022371276,0.0010280522,0.00024869756,0.00007283244,0.00007317484,0.000053054126,0.01393509],"genre_scores_gemma":[0.9928731,0.0050131395,0.00047662668,0.00008712693,0.00009275764,0.000028603357,0.000022427128,0.000005127693,0.0014011002],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979657,0.00008292042,0.000014947663,0.0000148436775,0.000030461955,0.000060216622],"domain_scores_gemma":[0.99988496,0.000040993884,0.000023635375,0.000015240497,0.000013289106,0.000021944537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000378223,0.00027920853,0.00033722725,0.00020399102,0.00027988444,0.00059893075,0.00014843413,0.00046272483,0.002334647],"category_scores_gemma":[0.0002931486,0.00010627705,0.00017795085,0.00006797335,0.00034267153,0.00056407816,0.00033198335,0.0006168792,0.0003992388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044307373,0.0004141979,0.005957227,0.0009445526,0.000040117593,0.0024947391,0.00026900013,0.0010893861,0.8212089,0.010386899,0.0013730518,0.15139115],"study_design_scores_gemma":[0.0012587716,0.008534375,0.06322734,0.00056188204,0.00038622413,0.019876035,0.0010989761,0.008378381,0.8048502,0.007881632,0.08389525,0.00005087961],"about_ca_topic_score_codex":0.00020597206,"about_ca_topic_score_gemma":0.00020050036,"teacher_disagreement_score":0.002334647,"about_ca_system_score_codex":0.00024087446,"about_ca_system_score_gemma":0.00035131484,"threshold_uncertainty_score":0.0078101754},"labels":[],"label_agreement":null},{"id":"W3200299117","doi":"10.1038/s41598-021-97739-w","title":"In vivo generation of collagen specific Tregs with AAV8 suppresses autoimmune responses and arthritis in DBA1 mice through IL10 production","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Université Laval","keywords":"Immunology; Immune system; Arthritis; Epitope; Autoimmune disease; Medicine; Adeno-associated virus; T cell; Antibody; Biology; Vector (molecular biology); Recombinant DNA","score_opus":0.040079469435824765,"score_gpt":0.30136350408658213,"score_spread":0.2612840346507574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200299117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98863655,0.0010798796,0.0066703437,0.0002659523,0.0001823726,0.0001009336,0.00043627212,0.00037930522,0.002248414],"genre_scores_gemma":[0.9854106,0.0007567457,0.006892887,0.00012938111,0.000068284724,0.0001374321,0.0004951584,0.00008897535,0.006020615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996928,0.000051615374,0.000036085883,0.00007409641,0.000070179296,0.00007516677],"domain_scores_gemma":[0.9997768,0.000027529617,0.00007519245,0.000020863985,0.000015415848,0.00008425357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003345971,0.00063350325,0.0003505786,0.0004534171,0.00017086708,0.0003517086,0.00026879378,0.00048980035,0.0016376629],"category_scores_gemma":[0.00011931574,0.00022552274,0.00033380694,0.00011778075,0.00033455307,0.00019691541,0.00014019855,0.001574346,0.00043553257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015618809,0.00015541057,0.00010530468,0.00002734089,0.0000037876996,0.00003224452,0.000015841435,0.00006043011,0.99834836,0.000097008444,0.00003666894,0.0009614939],"study_design_scores_gemma":[0.00017185193,0.002009971,0.0014223811,0.000013554649,0.000029730654,0.00033552464,0.000034806686,0.001478572,0.99188906,0.00009441059,0.0025129684,0.000007323176],"about_ca_topic_score_codex":0.00048579305,"about_ca_topic_score_gemma":0.00083967956,"teacher_disagreement_score":0.0016376629,"about_ca_system_score_codex":0.00018303853,"about_ca_system_score_gemma":0.0003234189,"threshold_uncertainty_score":0.005478561},"labels":[],"label_agreement":null},{"id":"W3200480347","doi":"10.1158/2643-3230.bcd-20-0208","title":"NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Parker Institute for Cancer Immunotherapy; Entertainment Industry Foundation; Cancer Research Institute; Burroughs Wellcome Fund; Stanford Maternal and Child Health Research Institute; American Association for Cancer Research","keywords":"Haematopoiesis; Progenitor cell; Proinflammatory cytokine; Cancer research; CD34; Endothelial stem cell; Stem cell; Bone marrow; Myeloid; Immunology; Biology; In vitro; Cell biology; Inflammation","score_opus":0.016251784645069246,"score_gpt":0.3011283694173624,"score_spread":0.2848765847722931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200480347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81970966,0.027363498,0.10439965,0.010232835,0.0024645706,0.00046509068,0.0020938816,0.002024947,0.031245757],"genre_scores_gemma":[0.9487843,0.009594048,0.013887117,0.0026032797,0.0003306145,0.00014890512,0.00074829406,0.00019099184,0.023712503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997516,0.00003649704,0.000011202446,0.00005620862,0.000098324876,0.00004616664],"domain_scores_gemma":[0.99993026,0.000016242302,0.000013374947,0.000007877068,0.000018016677,0.000014289015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017701836,0.00031045717,0.00032280775,0.00013452618,0.00017873663,0.0006536199,0.00032526368,0.0005224058,0.0018794377],"category_scores_gemma":[0.0001668299,0.00011726457,0.00014520077,0.00016844287,0.00036711222,0.0002917698,0.00029270232,0.0012341177,0.00063091563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024140468,0.00006279108,0.00012364067,0.00007962579,0.0000102484855,0.00012240573,0.000021076108,0.0005985804,0.97967476,0.0021877054,0.003804065,0.013073737],"study_design_scores_gemma":[0.00004389708,0.00032729623,0.0006271623,0.000009807531,0.000027386934,0.00025502307,0.000025285475,0.001900604,0.9554324,0.00075949955,0.040580466,0.000011204098],"about_ca_topic_score_codex":0.0004016535,"about_ca_topic_score_gemma":0.00087486894,"teacher_disagreement_score":0.0018794377,"about_ca_system_score_codex":0.00046581725,"about_ca_system_score_gemma":0.0002897926,"threshold_uncertainty_score":0.0062872767},"labels":[],"label_agreement":null},{"id":"W3201000277","doi":"10.1016/j.isci.2021.103295","title":"Effective chimeric antigen receptor T cells against SARS-CoV-2","year":2021,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Perforin; Chimeric antigen receptor; Granzyme B; Antigen; Cytolysis; Biology; Granzyme; Virology; Cell biology; Receptor; Cytotoxic T cell; Chemistry; Molecular biology; Immune system; In vitro; T cell; Immunology; CD8; Biochemistry","score_opus":0.029966945812853685,"score_gpt":0.3397855715107883,"score_spread":0.3098186256979346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201000277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812889,0.0018764784,0.008837864,0.0004279815,0.00012708003,0.00013028123,0.00063429767,0.0003771632,0.006299971],"genre_scores_gemma":[0.99038005,0.0006295223,0.0023241004,0.00013485964,0.000035138328,0.00008176298,0.0006729716,0.000026110794,0.005715465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980015,0.00004046235,0.000010410298,0.00003290356,0.00004358141,0.00007254094],"domain_scores_gemma":[0.9999478,0.000011659435,0.000011852151,0.0000065536988,0.000007731813,0.000014494744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023871918,0.00042620828,0.00027251526,0.0002021466,0.000110216664,0.00032163918,0.00018392115,0.00043889618,0.0026826716],"category_scores_gemma":[0.00014582128,0.00013707609,0.00023968138,0.0000871186,0.00018713997,0.00022060995,0.00016163179,0.00092124357,0.0005464517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032756702,0.00020887038,0.00011700042,0.000046726556,0.000011245227,0.00006456732,0.000045939916,0.00076328526,0.99114007,0.00083488534,0.00067460653,0.005765221],"study_design_scores_gemma":[0.00074937526,0.0032441497,0.0020274215,0.000024536082,0.000058950623,0.00062083424,0.00004934042,0.0053530745,0.9642016,0.00045790352,0.023199014,0.00001368563],"about_ca_topic_score_codex":0.00030876137,"about_ca_topic_score_gemma":0.00051391684,"teacher_disagreement_score":0.0026826716,"about_ca_system_score_codex":0.00024855952,"about_ca_system_score_gemma":0.00036712099,"threshold_uncertainty_score":0.008974493},"labels":[],"label_agreement":null},{"id":"W3201013983","doi":"10.1016/s1470-2045(21)00375-2","title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Cytokine release syndrome; Oncology; Hematopoietic stem cell transplantation; Chimeric antigen receptor; Cohort; Transplantation; Clinical trial; Immunotherapy; Cancer; Biology","score_opus":0.14921257768924856,"score_gpt":0.4590593045005727,"score_spread":0.30984672681132414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201013983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978138,0.0010289988,0.00009132609,0.000118724274,0.00004101679,0.00016980959,0.00028683516,0.000021448599,0.00042802436],"genre_scores_gemma":[0.9940514,0.0011226771,0.00040109231,0.0005440929,0.00015168026,0.00061434606,0.0012514188,0.0000220552,0.0018412982],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957126,0.0001631793,0.000020067233,0.00007013123,0.000047047386,0.0001283362],"domain_scores_gemma":[0.9992084,0.00013305322,0.00017466265,0.00008073412,0.00004612611,0.00035710132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013848171,0.0011032027,0.0018989632,0.00034493802,0.0003494171,0.0013178437,0.0006822866,0.0013528649,0.0017738094],"category_scores_gemma":[0.000795852,0.00032904383,0.0015334273,0.0003285827,0.000790326,0.00092915783,0.00041069466,0.0021833002,0.00064690824],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84206504,0.04095067,0.013788629,0.00069241435,0.0026373859,0.0002062283,0.00027331992,0.0015467146,0.017409569,0.00019763452,0.0022364096,0.077996105],"study_design_scores_gemma":[0.4275003,0.51585174,0.048363853,0.00006888903,0.0017295072,0.0002402611,0.00016438348,0.0012623658,0.0018452351,0.00029057654,0.002617574,0.00006529762],"about_ca_topic_score_codex":0.00062019465,"about_ca_topic_score_gemma":0.001300397,"teacher_disagreement_score":0.0018989632,"about_ca_system_score_codex":0.0006552793,"about_ca_system_score_gemma":0.000744865,"threshold_uncertainty_score":0.0073236823},"labels":[],"label_agreement":null},{"id":"W3201609934","doi":"10.1182/blood.2022019117","title":"Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Agence Nationale de la Recherche","keywords":"Wiskott–Aldrich syndrome protein; Autoimmunity; Immunology; Wiskott–Aldrich syndrome; Genetic enhancement; Stem cell; Transplantation; Fludarabine; Hematopoietic stem cell transplantation; Biology; Medicine; Immune system; Cyclophosphamide; Internal medicine; Cell; Gene; Actin cytoskeleton; Cell biology; Genetics","score_opus":0.0410312759080021,"score_gpt":0.3152371416997443,"score_spread":0.2742058657917422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201609934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945851,0.0028380738,0.0005856322,0.00015970347,0.00003508477,0.000100198595,0.00026475184,0.000028368384,0.0014032251],"genre_scores_gemma":[0.99817586,0.00044440493,0.00015539216,0.00012979466,0.00002133121,0.000049705934,0.0006037077,0.0000039588967,0.0004159002],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99968255,0.000117963704,0.000036431855,0.00003279419,0.00006434743,0.000065873],"domain_scores_gemma":[0.9995795,0.00007154497,0.00011554655,0.00003062549,0.000035985162,0.00016674444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007630516,0.00036589842,0.0006018204,0.00018205613,0.00020358589,0.00038382417,0.00015313717,0.00041805417,0.0006163959],"category_scores_gemma":[0.0005230979,0.000050187733,0.00062710204,0.00014386808,0.00025168734,0.00021531062,0.00019846918,0.0005287477,0.00016117161],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15252395,0.010010667,0.1556737,0.0009894276,0.002562667,0.006122244,0.00047477824,0.009180555,0.11007761,0.001547398,0.006006807,0.5448302],"study_design_scores_gemma":[0.017399337,0.39994735,0.50419027,0.0002724857,0.0025281387,0.011615644,0.00022499256,0.007672308,0.04194281,0.0012463621,0.012874999,0.00008536758],"about_ca_topic_score_codex":0.00042608214,"about_ca_topic_score_gemma":0.0004971649,"teacher_disagreement_score":0.0007630516,"about_ca_system_score_codex":0.0003527428,"about_ca_system_score_gemma":0.00028035635,"threshold_uncertainty_score":0.004035473},"labels":[],"label_agreement":null},{"id":"W3202055454","doi":"10.3390/ijms221910828","title":"Improving CAR T-Cell Persistence","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"T cell; Chimeric antigen receptor; Adoptive cell transfer; Medicine; Persistence (discontinuity); Mechanism (biology); Immunotherapy; Immunology; Bioinformatics; Cancer research; Biology; Immune system","score_opus":0.08065189329571965,"score_gpt":0.3996040435973274,"score_spread":0.31895215030160773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202055454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001429643,0.9954098,0.00082353014,0.00026019473,0.00016189915,0.0000148756635,0.00003383289,0.00002590962,0.0018403676],"genre_scores_gemma":[0.011169267,0.985038,0.0008550378,0.00037820832,0.00018919299,0.000033472345,0.00011706519,0.0000063166954,0.0022134453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985397,0.000026916628,0.00001538634,0.000030415282,0.000047203495,0.00002608267],"domain_scores_gemma":[0.999846,0.00007236482,0.000024093619,0.000005328065,0.00004057716,0.000011723392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047342858,0.00059241685,0.0008107268,0.0011381914,0.00013783207,0.00065891404,0.0004999592,0.0007558661,0.002642731],"category_scores_gemma":[0.0004338978,0.00016408169,0.00048055072,0.0006004265,0.0002257211,0.0007982521,0.0004382557,0.0011706237,0.0011329651],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018632099,0.00013343194,0.00029509194,0.017217914,0.000090796944,0.00019062308,0.000060213304,0.0006944724,0.020925876,0.005001117,0.013493066,0.94171107],"study_design_scores_gemma":[0.000069943344,0.000691444,0.0011944888,0.0019940916,0.0002498014,0.002162653,0.00005921517,0.00043363255,0.020252863,0.0019842375,0.9708821,0.000025483894],"about_ca_topic_score_codex":0.00047763824,"about_ca_topic_score_gemma":0.0006108738,"teacher_disagreement_score":0.002642731,"about_ca_system_score_codex":0.0004173649,"about_ca_system_score_gemma":0.00060834025,"threshold_uncertainty_score":0.008840799},"labels":[],"label_agreement":null},{"id":"W3202152517","doi":"10.1111/bjh.17845","title":"Guidelines: the same evidence but different conclusions — relaxation of indications for irradiation of cellular blood components?","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Transplantation; Stem cell; Total body irradiation; Fludarabine; Hematology; Internal medicine; Graft-versus-host disease; Surgery; Chemotherapy","score_opus":0.10102457520370553,"score_gpt":0.35122052373425006,"score_spread":0.2501959485305445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202152517","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010961832,0.18114273,0.004895667,0.71018356,0.08623493,0.0013517368,0.0034366832,0.00023032732,0.011428189],"genre_scores_gemma":[0.012955694,0.10838193,0.047200084,0.7753272,0.035970807,0.0036975825,0.0057356046,0.00047115545,0.010259824],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.94060415,0.02557114,0.017565927,0.0034240887,0.011203865,0.001630707],"domain_scores_gemma":[0.844739,0.060152296,0.014778024,0.006454476,0.068934664,0.0049415487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.049738303,0.0014283701,0.0051864204,0.005466635,0.0018068305,0.0074801026,0.00663949,0.016005032,0.008518449],"category_scores_gemma":[0.14896247,0.0013754352,0.0049964897,0.004879866,0.0038739573,0.007503021,0.0032822574,0.0149209695,0.0055242926],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048256246,0.000114518814,0.0010247384,0.022741353,0.0009829939,0.00018699614,0.0004081906,0.0002934382,0.000477887,0.010967302,0.78945726,0.17286275],"study_design_scores_gemma":[0.0008886606,0.000115891744,0.0023069135,0.09707803,0.0017311294,0.00046881445,0.00047766406,0.00037012642,0.00033693036,0.020436011,0.87561995,0.00016985263],"about_ca_topic_score_codex":0.013170736,"about_ca_topic_score_gemma":0.012395536,"teacher_disagreement_score":0.049738303,"about_ca_system_score_codex":0.006692312,"about_ca_system_score_gemma":0.01605403,"threshold_uncertainty_score":0.26304442},"labels":[],"label_agreement":null},{"id":"W3202237143","doi":"10.1016/j.annonc.2021.08.878","title":"1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Antagonist; Sarcoma; Oncology; Internal medicine; Phases of clinical research; Pharmacology; Chemotherapy; Pathology; Receptor","score_opus":0.07771101551057516,"score_gpt":0.43856233399941363,"score_spread":0.36085131848883845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202237143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244034,0.0010218112,0.00042283925,0.00069902604,0.00012561133,0.0010655784,0.00088149536,0.0001216912,0.0032215836],"genre_scores_gemma":[0.98722655,0.0011662333,0.0017323297,0.00078088214,0.00012309734,0.0013876717,0.0022039094,0.000046963218,0.005332352],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99977106,0.00008782366,0.0000100681245,0.000040724026,0.0000238733,0.00006652457],"domain_scores_gemma":[0.9997869,0.000031102034,0.00002574864,0.00002113018,0.000014995907,0.00012013229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005320404,0.0010336909,0.0015559915,0.0003744808,0.00037422992,0.00073324086,0.00058719644,0.00086668186,0.005819314],"category_scores_gemma":[0.0005122247,0.00051142287,0.00063143356,0.00032429548,0.00061108486,0.0006007356,0.0002969432,0.0028768813,0.0017445883],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4412044,0.067561954,0.009435628,0.0008952761,0.00114327,0.00076909945,0.00047694985,0.005942032,0.17497252,0.0008331304,0.016318068,0.28044766],"study_design_scores_gemma":[0.37843424,0.5776887,0.019378917,0.000058670303,0.0005004203,0.000720009,0.00013560343,0.0025749458,0.008659076,0.0005006494,0.011297913,0.000050847648],"about_ca_topic_score_codex":0.0012705668,"about_ca_topic_score_gemma":0.0027382816,"teacher_disagreement_score":0.005819314,"about_ca_system_score_codex":0.0006615918,"about_ca_system_score_gemma":0.0009474096,"threshold_uncertainty_score":0.019467592},"labels":[],"label_agreement":null},{"id":"W3203163864","doi":"10.1016/j.annonc.2021.08.1062","title":"540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T-cell receptor; Spear; CD8; Receptor; Oncology; Pharmacology; Immunology; Internal medicine; T cell; Antigen; Immune system","score_opus":0.09642382633896207,"score_gpt":0.39833374095669943,"score_spread":0.30190991461773736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203163864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.969522,0.0053406404,0.0016821754,0.0020456335,0.000379047,0.00045790875,0.0054421155,0.00029978596,0.01483065],"genre_scores_gemma":[0.9753829,0.0026126343,0.0006755136,0.0013177176,0.00016632851,0.0003411336,0.005761222,0.00009720249,0.013645424],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997478,0.00006975078,0.000011507808,0.000052201078,0.000042005227,0.00007668139],"domain_scores_gemma":[0.9996809,0.000078598096,0.000042487925,0.000038352297,0.000021248085,0.00013844753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007692182,0.00080367416,0.0011865157,0.00019836606,0.00025702873,0.0013436831,0.00030847185,0.000900753,0.008119945],"category_scores_gemma":[0.0007092425,0.00025541204,0.0010785521,0.00019143002,0.00051548355,0.000775697,0.00025555943,0.0031663373,0.0018307841],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6375088,0.006582603,0.0038905789,0.00112987,0.002226494,0.0004991954,0.00023858642,0.0053445394,0.07068389,0.0031758419,0.023055308,0.2456643],"study_design_scores_gemma":[0.40319625,0.42555076,0.04335782,0.0002805909,0.0032074926,0.0024264948,0.00020397971,0.0056949346,0.03379084,0.004982171,0.077122286,0.0001863976],"about_ca_topic_score_codex":0.0009916561,"about_ca_topic_score_gemma":0.0018301631,"teacher_disagreement_score":0.008119945,"about_ca_system_score_codex":0.0008563918,"about_ca_system_score_gemma":0.00075053243,"threshold_uncertainty_score":0.027163923},"labels":[],"label_agreement":null},{"id":"W3203462303","doi":"10.1038/s41434-021-00295-1","title":"Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-DΔNΔC gene therapy eight-year follow-up of phase I KAT301 study","year":2021,"lang":"en","type":"article","venue":"Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Kuopion Yliopistollinen Sairaala","keywords":"Mace; Medicine; Hazard ratio; Internal medicine; Adverse effect; Genetic enhancement; Angina; Confidence interval; Incidence (geometry); Randomized controlled trial; Surgery; Myocardial infarction; Percutaneous coronary intervention; Biology","score_opus":0.03771391769886721,"score_gpt":0.33723897960194077,"score_spread":0.29952506190307354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203462303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980108,0.0009485975,0.0003540749,0.000046120684,0.000016574257,0.00010386084,0.00018604583,0.000020947067,0.00031306],"genre_scores_gemma":[0.9983664,0.00038670274,0.00022384075,0.0001326205,0.000026637459,0.00010867258,0.00043412778,0.0000048359466,0.0003162488],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996605,0.0001411893,0.000028567203,0.000052251402,0.00005179832,0.00006565962],"domain_scores_gemma":[0.9993166,0.00014146548,0.00020523246,0.000094352596,0.00006790094,0.00017443867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015916737,0.00041456503,0.0010471536,0.0001363111,0.00020081853,0.00039896258,0.0003045201,0.0005323295,0.00063195615],"category_scores_gemma":[0.0006844345,0.00013159325,0.0006320809,0.00012832925,0.00036021607,0.00031189065,0.00014681199,0.0008893306,0.00018388851],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3753217,0.038953643,0.07183456,0.0008631647,0.0020962048,0.00081726856,0.0003188798,0.0027952755,0.29785332,0.0002453356,0.0021422638,0.20675842],"study_design_scores_gemma":[0.054042257,0.7646571,0.14748904,0.000045499528,0.0009003646,0.0007974271,0.00007896358,0.0019470153,0.027452221,0.00016436122,0.0023847597,0.0000410131],"about_ca_topic_score_codex":0.00022063329,"about_ca_topic_score_gemma":0.00032362496,"teacher_disagreement_score":0.0015916737,"about_ca_system_score_codex":0.00030435843,"about_ca_system_score_gemma":0.00033972872,"threshold_uncertainty_score":0.008417666},"labels":[],"label_agreement":null},{"id":"W3204177860","doi":"10.1111/bjh.17673","title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Gilead Sciences","keywords":"Medicine; Cytokine release syndrome; Tocilizumab; Adverse effect; Internal medicine; Corticosteroid; Lymphoma; Gastroenterology; Surgery; Oncology; Chimeric antigen receptor; Cancer; Immunotherapy; Rheumatoid arthritis","score_opus":0.02358306920221175,"score_gpt":0.29881096608573343,"score_spread":0.27522789688352167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204177860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889608,0.0076368097,0.00027934115,0.0005552409,0.00006906955,0.00013496079,0.00035577617,0.000026177271,0.0019817976],"genre_scores_gemma":[0.9978759,0.00083455787,0.0002863613,0.00034191672,0.00007219662,0.000059441038,0.000268523,0.0000023097166,0.000258773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996829,0.00013591223,0.000037537397,0.000044080713,0.00005835303,0.00004117117],"domain_scores_gemma":[0.9990847,0.0002991421,0.00036642552,0.000028801964,0.00007458766,0.00014632761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008133399,0.0001917499,0.0005084467,0.0001654949,0.00021710906,0.00037012732,0.00015325799,0.0001702788,0.001659801],"category_scores_gemma":[0.0010953471,0.000055289318,0.00056091684,0.00018680251,0.00010578566,0.00018740908,0.00012739957,0.000589211,0.00013293985],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041500088,0.0022061616,0.6544932,0.00088290026,0.0013238124,0.0013369402,0.00022122357,0.0014026592,0.020812562,0.00019752655,0.0054073394,0.2702156],"study_design_scores_gemma":[0.0064103096,0.042560376,0.9167764,0.00032485652,0.0018292237,0.0029122103,0.00022852347,0.0025096694,0.0076662414,0.00027511723,0.018457325,0.000049643306],"about_ca_topic_score_codex":0.0006943141,"about_ca_topic_score_gemma":0.0024511698,"teacher_disagreement_score":0.001659801,"about_ca_system_score_codex":0.00046388904,"about_ca_system_score_gemma":0.000701983,"threshold_uncertainty_score":0.00555259},"labels":[],"label_agreement":null},{"id":"W3206372141","doi":"10.1016/j.ejca.2021.09.016","title":"Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb Canada; Astellas Pharma Canada; International Studies Association; Novartis; Celgene; Bayer; AstraZeneca; Amgen; Pfizer; Meso Scale Diagnostics; AbbVie; Merck","keywords":"Maximum tolerated dose; Medicine; Clinical trial; Therapeutic window; Intensive care medicine; Medical physics; Computer science; Pharmacology; Internal medicine","score_opus":0.4579977353478128,"score_gpt":0.597604700362081,"score_spread":0.13960696501426823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206372141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003676187,0.99591917,0.0014365386,0.0007897554,0.00018668869,0.000057246747,0.000066719134,0.000029359457,0.0011470371],"genre_scores_gemma":[0.005276639,0.98721826,0.004145936,0.0014667804,0.0003774476,0.00018689406,0.00020399177,0.000030162997,0.001093855],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99913627,0.00033282404,0.00008763475,0.00015645617,0.00022419436,0.00006260668],"domain_scores_gemma":[0.99710673,0.0021311324,0.00027386,0.00009914069,0.0003025716,0.000086466025],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0040494176,0.001066856,0.003055342,0.0015112443,0.00025877357,0.0021044181,0.0023089007,0.0014795772,0.007457671],"category_scores_gemma":[0.0043743504,0.00039888974,0.0015777315,0.001661923,0.0008972278,0.0018346824,0.00082596124,0.0045661097,0.0018725814],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043176624,0.00015391341,0.00015941869,0.012570838,0.0002155111,0.000051761155,0.000048941554,0.0012711731,0.0014256422,0.0048203887,0.01134683,0.96750367],"study_design_scores_gemma":[0.0009335815,0.0012315023,0.0022921215,0.0126874065,0.0009549109,0.0016135119,0.00010008081,0.001170412,0.0019467756,0.011183897,0.9658093,0.00007651116],"about_ca_topic_score_codex":0.0011195211,"about_ca_topic_score_gemma":0.002032159,"teacher_disagreement_score":0.9959506,"about_ca_system_score_codex":0.0014673301,"about_ca_system_score_gemma":0.0017558277,"threshold_uncertainty_score":0.024948418},"labels":[],"label_agreement":null},{"id":"W3206590901","doi":"10.1007/s00262-021-03073-5","title":"Molecular imaging of cellular immunotherapies in experimental and therapeutic settings","year":2021,"lang":"en","type":"review","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"","keywords":"Immune system; Ex vivo; Medicine; Cancer; Biodistribution; Immunotherapy; Cancer research; Bioinformatics; In vivo; Immunology; Biology; Internal medicine","score_opus":0.03297253149538901,"score_gpt":0.37100936070885276,"score_spread":0.3380368292134638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206590901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019612357,0.806784,0.13041691,0.003794462,0.0014154981,0.00025014588,0.00094650174,0.000865284,0.035914905],"genre_scores_gemma":[0.11759239,0.7515276,0.11015689,0.003705848,0.0011669807,0.0008824047,0.0014902491,0.00030642658,0.01317134],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993493,0.00020933466,0.00003809204,0.000117922464,0.0002163986,0.00006896985],"domain_scores_gemma":[0.99963737,0.0001680376,0.00005370661,0.000032029002,0.000079939855,0.000028801796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014954475,0.00067260116,0.0007680773,0.0012283091,0.00028096698,0.001394539,0.00083116064,0.0016724261,0.0026625644],"category_scores_gemma":[0.00090787275,0.00040879103,0.00055593497,0.000959879,0.0007787926,0.0015494352,0.000675174,0.0020406526,0.0014954366],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003451883,0.00014776671,0.000548698,0.008729581,0.00014100576,0.0005681714,0.00024232455,0.0019789303,0.70313776,0.022413427,0.021067722,0.2406795],"study_design_scores_gemma":[0.000045579392,0.0005991266,0.002108218,0.0011562597,0.0001694218,0.003361516,0.00015247506,0.004256848,0.45430052,0.0054566218,0.52827215,0.00012126312],"about_ca_topic_score_codex":0.0006781165,"about_ca_topic_score_gemma":0.000622836,"teacher_disagreement_score":0.0026625644,"about_ca_system_score_codex":0.0009908727,"about_ca_system_score_gemma":0.0006011337,"threshold_uncertainty_score":0.008907199},"labels":[],"label_agreement":null},{"id":"W3206790308","doi":"10.3390/cancers13205039","title":"Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Cancer Society; Leukemia and Lymphoma Society","keywords":"Idelalisib; Myeloid leukemia; Cancer research; Haematopoiesis; Transplantation; Myeloid; Hematopoietic stem cell transplantation; Leukemia; Medicine; Stem cell; Chemistry; Immunology; Biology; Internal medicine; Cell biology; Ibrutinib; Chronic lymphocytic leukemia","score_opus":0.04518843191315285,"score_gpt":0.3454976100233685,"score_spread":0.3003091781102156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206790308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994121,0.0014740876,0.0018457198,0.00009499248,0.000045338667,0.00006203288,0.00015458096,0.00007545855,0.0021267883],"genre_scores_gemma":[0.99734867,0.00061738584,0.00097257027,0.000049265233,0.000013770346,0.000048830454,0.0001909796,0.000006502127,0.0007519391],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999057,0.000018251325,0.000007540628,0.000015819716,0.000018465407,0.00003424346],"domain_scores_gemma":[0.9999647,0.0000053221,0.000010540683,0.0000038079509,0.0000030001522,0.000012741645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014632032,0.00031398234,0.00027589212,0.00023327037,0.00010279711,0.0003109791,0.0001618852,0.00018979341,0.00069075805],"category_scores_gemma":[0.0000967824,0.00006740519,0.00013999177,0.000111203844,0.00014815062,0.00019259039,0.00014564798,0.0005797192,0.00018262745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011756021,0.0007363314,0.0007385833,0.00013803548,0.000022753178,0.00010807903,0.000044911365,0.0009276933,0.9568227,0.0005717154,0.0006204883,0.038093124],"study_design_scores_gemma":[0.00055791717,0.013209073,0.0045454456,0.00002169846,0.00008928114,0.0009609916,0.000043628745,0.0049991845,0.9645349,0.00020515507,0.010819005,0.000013816525],"about_ca_topic_score_codex":0.0001473775,"about_ca_topic_score_gemma":0.0003553617,"teacher_disagreement_score":0.00069075805,"about_ca_system_score_codex":0.00018898242,"about_ca_system_score_gemma":0.00021807899,"threshold_uncertainty_score":0.0023108125},"labels":[],"label_agreement":null},{"id":"W3208468707","doi":"10.1182/blood-2021-146200","title":"Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Clinical trial; Clinical endpoint; Oncology; Lenalidomide","score_opus":0.11321306732251128,"score_gpt":0.3950350964076225,"score_spread":0.2818220290851112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208468707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993105,0.0014290232,0.00068662653,0.00008497392,0.000032034295,0.0000808219,0.0040505193,0.000011836876,0.0005190967],"genre_scores_gemma":[0.99614346,0.0001089034,0.00030859563,0.000058745893,0.000020367099,0.00007435468,0.0031365135,0.0000054867405,0.00014342397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947891,0.002998849,0.00044153997,0.0010402029,0.0005164405,0.00021392872],"domain_scores_gemma":[0.9902811,0.0032124554,0.003910275,0.0014248375,0.00048189147,0.0006894422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072015226,0.000546157,0.0006833015,0.0005050532,0.00023495138,0.0007864112,0.0008477709,0.00047391688,0.0020475306],"category_scores_gemma":[0.008005096,0.0002224923,0.0022035954,0.0010535783,0.00030147913,0.00047545962,0.00077089533,0.0008598448,0.00014547184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07545284,0.00035645728,0.89301765,0.00050964113,0.015887968,0.00010028015,0.00014757486,0.0014399149,0.0008189371,0.00027768972,0.0015833672,0.010407747],"study_design_scores_gemma":[0.004549258,0.008383397,0.97605354,0.0000760859,0.00566045,0.00020508759,0.0001539508,0.002304755,0.00043949703,0.00020082512,0.0019334042,0.00003980938],"about_ca_topic_score_codex":0.0026835164,"about_ca_topic_score_gemma":0.0034907365,"teacher_disagreement_score":0.0072015226,"about_ca_system_score_codex":0.000580558,"about_ca_system_score_gemma":0.00054788153,"threshold_uncertainty_score":0.03808576},"labels":[],"label_agreement":null},{"id":"W3208635967","doi":"10.1016/j.htct.2021.10.331","title":"EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2021,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Multiple myeloma; Neutropenia; Internal medicine; Gastroenterology; Oncology; Toxicity; Chimeric antigen receptor; Immunology; Immunotherapy; Cancer","score_opus":0.014867424124680827,"score_gpt":0.2713815356584001,"score_spread":0.2565141115337193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208635967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938232,0.0038947202,0.00034680817,0.00016573379,0.00003323041,0.00017758305,0.000356029,0.000050910476,0.0011518691],"genre_scores_gemma":[0.99756795,0.000922756,0.0002676934,0.00017703057,0.000049513717,0.0000886013,0.00043920538,0.000006367915,0.0004809666],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999663,0.0001285756,0.000026183172,0.00006454923,0.00006229291,0.000055306326],"domain_scores_gemma":[0.9996946,0.00005951451,0.00008738286,0.00002727404,0.000016963284,0.000114346294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088226586,0.00050696393,0.001242754,0.0002877152,0.00025002199,0.00043763887,0.00028549237,0.00045851388,0.0009483411],"category_scores_gemma":[0.00064919284,0.00026248847,0.0010220362,0.00030472892,0.0004822352,0.0005338811,0.00023580914,0.0015053764,0.0003382997],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3999779,0.022571541,0.04110073,0.0008674325,0.0014420778,0.0006848095,0.0004489014,0.007232124,0.07838609,0.000284369,0.003192133,0.44381192],"study_design_scores_gemma":[0.11275141,0.6477837,0.20658812,0.00009498882,0.0015761255,0.0015848345,0.00009395786,0.0064930324,0.014948804,0.0004097452,0.007582033,0.00009325272],"about_ca_topic_score_codex":0.0007336927,"about_ca_topic_score_gemma":0.0011066324,"teacher_disagreement_score":0.001242754,"about_ca_system_score_codex":0.0007866106,"about_ca_system_score_gemma":0.000584682,"threshold_uncertainty_score":0.0057073236},"labels":[],"label_agreement":null},{"id":"W3208814858","doi":"10.1182/blood-2021-148039","title":"Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Oncology; Lymphoma; Biology","score_opus":0.015746695104493107,"score_gpt":0.293887349007926,"score_spread":0.2781406539034329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208814858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9631447,0.007345107,0.0017400199,0.001671152,0.0007911478,0.013171758,0.0059424853,0.0003708608,0.005822664],"genre_scores_gemma":[0.97469974,0.0018979555,0.0020520587,0.0018647903,0.00045146435,0.0110979555,0.0035930602,0.00007455739,0.0042685154],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99898905,0.00061795785,0.00003756583,0.00015209187,0.00006257811,0.00014087382],"domain_scores_gemma":[0.9989662,0.0002603595,0.00022718468,0.000080139755,0.00008595601,0.0003801095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003187075,0.0021884546,0.0024826957,0.00043154575,0.0005332281,0.0013945139,0.0010612044,0.0015236521,0.010544055],"category_scores_gemma":[0.0018661283,0.00063556095,0.0031754633,0.000409297,0.0011074651,0.000964685,0.00063317036,0.0036467805,0.0015968842],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9790437,0.0047773467,0.00095143885,0.0006865271,0.0020233581,0.00005053651,0.000038047958,0.0004504932,0.0021433746,0.00013727491,0.0017437192,0.007954111],"study_design_scores_gemma":[0.9411035,0.052629188,0.0023950157,0.00004149245,0.0013311246,0.000052182844,0.000029946576,0.00068517704,0.0004236381,0.00032728002,0.0009665798,0.000014869869],"about_ca_topic_score_codex":0.0009614167,"about_ca_topic_score_gemma":0.0024165646,"teacher_disagreement_score":0.010544055,"about_ca_system_score_codex":0.0011130112,"about_ca_system_score_gemma":0.0017095763,"threshold_uncertainty_score":0.035273373},"labels":[],"label_agreement":null},{"id":"W3209556083","doi":"10.1503/cmaj.202907-f","title":"Innovations en immunothérapie anticancéreuse: thérapie par lymphocytes T porteurs de récepteurs antigéniques chimériques (cellules CAR-T)","year":2021,"lang":"fr","type":"letter","venue":"Canadian Medical Association Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of Manitoba; British Columbia Institute of Technology","funders":"","keywords":"Medicine; Molecular biology; Biology","score_opus":0.012899327291608498,"score_gpt":0.27415624710980874,"score_spread":0.26125691981820026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209556083","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002316729,0.046649907,0.0008080278,0.91647565,0.021672513,0.000023042156,0.000057452733,0.00004308953,0.011953567],"genre_scores_gemma":[0.045825247,0.08373815,0.0024350919,0.7013845,0.13749768,0.00006011147,0.00010040334,0.000048870606,0.028910022],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987386,0.00037396996,0.00012005588,0.00021723023,0.0003913039,0.00015888843],"domain_scores_gemma":[0.99748695,0.0016423309,0.00014635325,0.00008185625,0.00040411315,0.00023844882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014143721,0.00041780216,0.0007112642,0.0004740373,0.0014038881,0.0018740633,0.00085017306,0.009816193,0.0037190611],"category_scores_gemma":[0.0059774537,0.00025566787,0.0006911756,0.0004626212,0.0023468672,0.002021579,0.0004139691,0.013640748,0.0029672948],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048025558,0.00018834489,0.0029682312,0.00064793247,0.000059577247,0.018366672,0.00031481127,0.0003877511,0.0037222365,0.021794392,0.78276545,0.16830431],"study_design_scores_gemma":[0.000120365956,0.00020155044,0.0012992396,0.00041227366,0.00003790084,0.02306208,0.00019386946,0.00046702696,0.0010465487,0.011656722,0.9614642,0.000038182443],"about_ca_topic_score_codex":0.004478433,"about_ca_topic_score_gemma":0.0064221453,"teacher_disagreement_score":0.009816193,"about_ca_system_score_codex":0.0032344626,"about_ca_system_score_gemma":0.0014288347,"threshold_uncertainty_score":0.02346778},"labels":[],"label_agreement":null},{"id":"W3210549609","doi":"10.1182/blood-2021-146060","title":"Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Antigen; Medicine; Multiple myeloma; Immunology; Refractory (planetary science); Immunotherapy; Cancer research; Biology; Immune system","score_opus":0.014589790550367214,"score_gpt":0.25885141836574355,"score_spread":0.24426162781537633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210549609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8683551,0.040039726,0.0022483035,0.002271177,0.00038612916,0.001728839,0.076116,0.00042940365,0.0084254155],"genre_scores_gemma":[0.8505046,0.009216304,0.00473568,0.003534731,0.0006948818,0.0011740761,0.12692283,0.0001797632,0.003037221],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9978727,0.0009005021,0.0002638302,0.00021455338,0.00058151374,0.00016693985],"domain_scores_gemma":[0.99333584,0.001743547,0.002354387,0.0005344713,0.0013019259,0.0007297447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060206214,0.0008697656,0.0015719606,0.0007123995,0.00026009095,0.0011695687,0.0007360094,0.00068812555,0.0018973175],"category_scores_gemma":[0.0045855744,0.000392963,0.0015830811,0.0011094608,0.00018339421,0.00063427776,0.000617947,0.001111288,0.00039030067],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18952988,0.005395602,0.19060427,0.005282703,0.013895071,0.000939872,0.00075279444,0.00549288,0.05578537,0.00026724424,0.06735234,0.46470195],"study_design_scores_gemma":[0.033875544,0.0496614,0.8122616,0.00037235644,0.015109521,0.0024470065,0.00012615825,0.0015805662,0.013143209,0.00016520097,0.07112845,0.0001290039],"about_ca_topic_score_codex":0.0026354666,"about_ca_topic_score_gemma":0.006157189,"teacher_disagreement_score":0.0060206214,"about_ca_system_score_codex":0.0009640312,"about_ca_system_score_gemma":0.0011058537,"threshold_uncertainty_score":0.031840444},"labels":[],"label_agreement":null},{"id":"W3210901280","doi":"10.1016/j.xpro.2021.100920","title":"In vitro evaluation of CAR-T cells in patient-derived glioblastoma models","year":2021,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; McMaster University","keywords":"Chimeric antigen receptor; Glioblastoma; In vitro; Cancer research; Immunotherapy; Protocol (science); Cytotoxicity; Medicine; Cancer; Biology; Pathology; Internal medicine","score_opus":0.06394935725016467,"score_gpt":0.37811261911016775,"score_spread":0.3141632618600031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210901280","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86930805,0.015350798,0.07333007,0.0011392236,0.0011135581,0.0035667478,0.01616398,0.0018598165,0.018167717],"genre_scores_gemma":[0.92378014,0.009049729,0.037630808,0.0005726536,0.00014997805,0.0041542556,0.014049171,0.00021983075,0.010393586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99899155,0.00032409388,0.00012234226,0.0001329153,0.00027332624,0.0001558284],"domain_scores_gemma":[0.9997423,0.000053956734,0.000031446674,0.00005237098,0.00007556156,0.00004435466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013912614,0.0008919065,0.0011459116,0.0005838719,0.00036291755,0.0008155253,0.0006099795,0.00069689314,0.0030387307],"category_scores_gemma":[0.0003775015,0.0003494396,0.0005807752,0.00053625746,0.0002516084,0.00030843215,0.00031216937,0.0017546964,0.00214466],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013496698,0.0014466441,0.0007277989,0.0006833906,0.00008641486,0.00041216437,0.00030820147,0.002245645,0.9788616,0.0010606856,0.0037546484,0.009063057],"study_design_scores_gemma":[0.0002224022,0.005678067,0.0022874668,0.000059023976,0.00019317276,0.00080906966,0.00010843267,0.005106275,0.9691955,0.00025561915,0.016057359,0.000027622957],"about_ca_topic_score_codex":0.0025017944,"about_ca_topic_score_gemma":0.0038977007,"teacher_disagreement_score":0.0030387307,"about_ca_system_score_codex":0.00069124467,"about_ca_system_score_gemma":0.0008166941,"threshold_uncertainty_score":0.010165572},"labels":[],"label_agreement":null},{"id":"W3211360047","doi":"10.1182/blood-2021-153166","title":"Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fludarabine; Population; Internal medicine; Cyclophosphamide; Refractory (planetary science); CAR T-cell therapy; Immunology; Gastroenterology; T cell; Chemotherapy; Chimeric antigen receptor; Biology; Immune system","score_opus":0.017393008910047605,"score_gpt":0.2749539471231319,"score_spread":0.25756093821308434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211360047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973226,0.0006204516,0.00034075763,0.00010080725,0.000018260895,0.00011829251,0.000199829,0.000039747054,0.0012391441],"genre_scores_gemma":[0.99862945,0.0002094214,0.00017772194,0.00008789496,0.000033973927,0.00006294799,0.00037200993,0.0000057678476,0.0004207956],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998093,0.00010246313,0.000016954167,0.000020041121,0.000020254362,0.000031009615],"domain_scores_gemma":[0.9995146,0.00021629222,0.00007788971,0.000053781296,0.000031782787,0.000105601575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075242587,0.0004047382,0.0004329023,0.00013264216,0.00025325222,0.000339057,0.00017684577,0.00036578786,0.0015080199],"category_scores_gemma":[0.00068410224,0.00014111892,0.000333186,0.00008720761,0.00034730986,0.00025457062,0.00013040545,0.0008933417,0.0004554487],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25078365,0.03157227,0.07723471,0.00073013443,0.0005079509,0.0026471373,0.000989662,0.0026074671,0.37068915,0.00025572279,0.0046971706,0.25728494],"study_design_scores_gemma":[0.02809115,0.7258185,0.14403415,0.00007476217,0.00074349716,0.004055162,0.0001648668,0.0019358341,0.085327566,0.00016947472,0.00954977,0.000035261302],"about_ca_topic_score_codex":0.0003303583,"about_ca_topic_score_gemma":0.0004809998,"teacher_disagreement_score":0.0015080199,"about_ca_system_score_codex":0.0002339959,"about_ca_system_score_gemma":0.00028249074,"threshold_uncertainty_score":0.0050448775},"labels":[],"label_agreement":null},{"id":"W3211480515","doi":"10.1182/blood-2021-148709","title":"<i>In Vivo</i> Delivery of a CD20 CAR Using a CD8-Targeted Fusosome in Southern Pig-Tail Macaques (<i>M. nemestrina</i>) Results in B Cell Depletion","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; CD8; Ex vivo; In vivo; Chimeric antigen receptor; Gene delivery; T cell; Immunology; Transduction (biophysics); B cell; Cell biology; Genetic enhancement; Molecular biology; Antigen; Immune system; Antibody; Biochemistry","score_opus":0.02224595986032634,"score_gpt":0.27137122919723045,"score_spread":0.2491252693369041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211480515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911828,0.0009395357,0.0042757615,0.00014653466,0.000046848647,0.000094452575,0.00047565784,0.00019939338,0.0026390834],"genre_scores_gemma":[0.98951715,0.00051684194,0.004108702,0.00009874976,0.000019381589,0.00013780649,0.0005905642,0.000053691365,0.004957161],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985015,0.00001920763,0.000009636848,0.00005520148,0.00002435709,0.00004139742],"domain_scores_gemma":[0.9998838,0.000018112349,0.00004448532,0.000017514956,0.000012694768,0.000023400882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020255522,0.00045483068,0.00022800264,0.0002683472,0.00021954041,0.0002668964,0.00027575958,0.0005001268,0.0010283515],"category_scores_gemma":[0.0000858584,0.00014158392,0.00026930604,0.00007586792,0.00031125467,0.0002258188,0.00016523882,0.00062826223,0.00040453914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010167975,0.000058937083,0.00012474733,0.00001597768,0.0000031793427,0.00003479806,0.000023945455,0.000020998277,0.998889,0.00006439201,0.00004471028,0.00061764236],"study_design_scores_gemma":[0.000016818118,0.0007880397,0.0024349447,0.00000633419,0.000017048233,0.00023559197,0.00002491832,0.0003406957,0.9943111,0.000028689044,0.0017926748,0.0000031640263],"about_ca_topic_score_codex":0.0014320483,"about_ca_topic_score_gemma":0.0016152797,"teacher_disagreement_score":0.0014320483,"about_ca_system_score_codex":0.0002822183,"about_ca_system_score_gemma":0.00015734111,"threshold_uncertainty_score":0.0034402013},"labels":[],"label_agreement":null},{"id":"W3211621704","doi":"10.1182/blood-2021-146393","title":"Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Single Center; Clinical trial; Refractory (planetary science); Hematopoietic stem cell transplantation; Oncology; Pediatrics; Immunotherapy; Transplantation; Chimeric antigen receptor","score_opus":0.0201699544481447,"score_gpt":0.2896246359916098,"score_spread":0.26945468154346514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211621704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9315338,0.007918399,0.0007441119,0.00068728166,0.000057014036,0.00016043245,0.05569102,0.000061587176,0.0031464668],"genre_scores_gemma":[0.942414,0.003162888,0.0009445985,0.0004090455,0.00008829279,0.0003013533,0.052324913,0.000026144939,0.0003286729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805,0.0006560641,0.00034506075,0.0003057984,0.00048117148,0.00016200209],"domain_scores_gemma":[0.99062574,0.0012621263,0.005834238,0.000500328,0.0010692325,0.00070839265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027403214,0.00029921412,0.0006969895,0.0011352375,0.0002801864,0.0012889047,0.000702402,0.00043496356,0.0011800661],"category_scores_gemma":[0.005803693,0.00022344897,0.00083273544,0.002561386,0.00033671327,0.0009313897,0.0007317296,0.0008324918,0.000384498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014572435,0.00007828026,0.9838108,0.00021631751,0.00056444464,0.000068751106,0.00010775923,0.00020951343,0.000121936486,0.000119812605,0.003952806,0.009292377],"study_design_scores_gemma":[0.00020482417,0.0004050148,0.99341196,0.00010936767,0.00046474166,0.0004453993,0.00021412618,0.00022521123,0.00015669005,0.000087646375,0.004251996,0.00002307443],"about_ca_topic_score_codex":0.0043553566,"about_ca_topic_score_gemma":0.007364211,"teacher_disagreement_score":0.0043553566,"about_ca_system_score_codex":0.0009652104,"about_ca_system_score_gemma":0.00079677015,"threshold_uncertainty_score":0.014492393},"labels":[],"label_agreement":null},{"id":"W3211778366","doi":"10.1182/blood-2021-149049","title":"Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Salvage therapy; Oncology; Lymphoma; Population; Diffuse large B-cell lymphoma; Transplantation; Cancer; Chemotherapy","score_opus":0.014850131788839791,"score_gpt":0.2707231962552273,"score_spread":0.25587306446638747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211778366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986468,0.00016733022,0.00010743801,0.000032460473,0.0000023287018,0.000029059749,0.00037554986,0.0000057888774,0.0006332653],"genre_scores_gemma":[0.9990103,0.00008203969,0.00008890932,0.00004908325,0.0000078435305,0.000025192581,0.0005496485,0.0000015266899,0.0001853708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998216,0.000029112392,0.000022329956,0.00004610998,0.000030054858,0.000050876835],"domain_scores_gemma":[0.9997584,0.000016686807,0.00012154432,0.000011241521,0.000020024285,0.00007202066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001811607,0.00013392119,0.00027137264,0.00046737236,0.00039054672,0.00052419223,0.00021351589,0.00015042118,0.002127127],"category_scores_gemma":[0.00037180717,0.0000720871,0.0001848764,0.0006243313,0.00023353097,0.0002623031,0.0003865044,0.00018711446,0.00036331426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016875933,0.0000682731,0.9943973,0.000018495502,0.000015479736,0.00031389185,0.000041275045,0.000036547197,0.0012445081,0.000025966016,0.00016602622,0.0035034637],"study_design_scores_gemma":[0.000028852279,0.00035883262,0.99472576,0.00001170828,0.000027979018,0.0029024407,0.00027702295,0.00015659067,0.00044333562,0.000052931293,0.0010115785,0.0000029721812],"about_ca_topic_score_codex":0.0016688647,"about_ca_topic_score_gemma":0.0040046424,"teacher_disagreement_score":0.002127127,"about_ca_system_score_codex":0.00032616733,"about_ca_system_score_gemma":0.00027757065,"threshold_uncertainty_score":0.0071160197},"labels":[],"label_agreement":null},{"id":"W3211920496","doi":"10.1016/s2152-2650(21)02092-9","title":"OAB-018: A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence in multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; CD28; TIGIT; T cell; CAR T-cell therapy; CD19; Cancer research; Biology; Immunology; Cell biology; Antigen; Medicine; Immune system","score_opus":0.05083502320690806,"score_gpt":0.34308830516624084,"score_spread":0.29225328195933276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211920496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880639,0.0041705295,0.0021124494,0.00073829456,0.00016871428,0.00010613789,0.00039101712,0.00033147237,0.0039175767],"genre_scores_gemma":[0.9946332,0.0008503913,0.001000729,0.00013265485,0.000023830295,0.000073220275,0.00047182705,0.000029787781,0.0027843677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997694,0.000030216033,0.000012980805,0.000030836127,0.00004338823,0.00011317779],"domain_scores_gemma":[0.99992406,0.000010286442,0.0000101695705,0.000010235851,0.000010144869,0.00003520361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033356517,0.00031159935,0.00042504826,0.00040251092,0.0003618142,0.0010009535,0.0006419041,0.0005145494,0.0028541936],"category_scores_gemma":[0.00020244035,0.00019994406,0.0002582348,0.00047460923,0.00033747137,0.0004918986,0.00037695974,0.0019231205,0.0006827169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038631842,0.002100567,0.0015244738,0.00034824508,0.00010895162,0.0002082469,0.0001821545,0.0023836065,0.8939233,0.0024571274,0.004392784,0.08850745],"study_design_scores_gemma":[0.0033563557,0.0161794,0.010813365,0.00006025251,0.0003196394,0.0015853802,0.00021484893,0.01091855,0.8902097,0.0008092956,0.06546549,0.00006766378],"about_ca_topic_score_codex":0.0015124889,"about_ca_topic_score_gemma":0.002570287,"teacher_disagreement_score":0.0028541936,"about_ca_system_score_codex":0.0008694615,"about_ca_system_score_gemma":0.0007116334,"threshold_uncertainty_score":0.009548247},"labels":[],"label_agreement":null},{"id":"W3211997738","doi":"10.1182/blood-2021-147937","title":"Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); BC Cancer Agency; Jewish General Hospital","funders":"","keywords":"Tolerability; Dosing; Medicine; Pharmacokinetics; Refractory (planetary science); Internal medicine; Neutropenia; Cytokine release syndrome; Gastroenterology; Toxicity; Adverse effect; Pharmacology; Immunotherapy; Cancer","score_opus":0.013300032276117554,"score_gpt":0.2837511359260015,"score_spread":0.27045110364988395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211997738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733365,0.001142639,0.00031522976,0.000052297688,0.000020022102,0.00030229663,0.00014660369,0.000050433388,0.0006369881],"genre_scores_gemma":[0.997995,0.00046938562,0.00053130864,0.000114015784,0.000022003678,0.00020003392,0.00023788825,0.0000075681087,0.00042282735],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99984753,0.00004560023,0.000011434301,0.000033095148,0.000026500189,0.000035887322],"domain_scores_gemma":[0.9997868,0.000037408565,0.0000493488,0.000028831606,0.000010963959,0.000086729204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003626165,0.0004216631,0.0007424817,0.00023758048,0.0002014011,0.00044630643,0.00039768426,0.00039178453,0.0019148253],"category_scores_gemma":[0.0003248639,0.00020299296,0.0004268627,0.00023536842,0.00033553736,0.0003266886,0.00016910104,0.0014187131,0.00040922497],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19862556,0.06919606,0.017392056,0.0010714092,0.00096790656,0.00031938375,0.00038225265,0.003271461,0.25399953,0.00028578308,0.0038684283,0.4506201],"study_design_scores_gemma":[0.08928229,0.82239354,0.052013088,0.00007449059,0.00054356444,0.000539266,0.000097631084,0.003219986,0.027625259,0.00019525108,0.003977551,0.000037991827],"about_ca_topic_score_codex":0.00043394993,"about_ca_topic_score_gemma":0.0015132164,"teacher_disagreement_score":0.0019148253,"about_ca_system_score_codex":0.00035665193,"about_ca_system_score_gemma":0.00046368875,"threshold_uncertainty_score":0.006405771},"labels":[],"label_agreement":null},{"id":"W3212504456","doi":"10.1007/s11307-021-01672-3","title":"Visualizing CAR-T cell Immunotherapy Using 3 Tesla Fluorine-19 MRI","year":2021,"lang":"en","type":"article","venue":"Molecular Imaging and Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"","keywords":"Chimeric antigen receptor; CD19; Immunotherapy; Cancer research; Medicine; Magnetic resonance imaging; Bioluminescence imaging; Cancer cell; Antigen; T cell; Leukemia; Cancer; Chemistry; Pathology; Immunology; Internal medicine; Luciferase; Immune system; Radiology; Biochemistry","score_opus":0.030186354002142077,"score_gpt":0.36014957719990087,"score_spread":0.3299632231977588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212504456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84141046,0.006126343,0.1406637,0.00073139434,0.00008455191,0.0002193459,0.0005337718,0.0011275304,0.009102835],"genre_scores_gemma":[0.87114555,0.0032890057,0.11954673,0.00033918553,0.000051626255,0.00015828502,0.0003764432,0.000102344944,0.0049908184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999409,0.000016356307,0.000003874581,0.00001390211,0.000011367877,0.000013644484],"domain_scores_gemma":[0.9999213,0.000019419436,0.00002586135,0.000005471849,0.000010073384,0.000017734119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023963592,0.00034547297,0.00015329935,0.00035894787,0.00014519261,0.0003042792,0.00021727453,0.0005041574,0.0015570326],"category_scores_gemma":[0.00011471308,0.00019984953,0.00019458795,0.0001339452,0.00025240539,0.00030794324,0.00015269202,0.00043888632,0.00041930383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007035368,0.000015241407,0.00019849151,0.00003942255,0.0000033199635,0.00009873358,0.000011575684,0.00017922658,0.9973884,0.00012385829,0.000101652564,0.0017696943],"study_design_scores_gemma":[0.00004662898,0.0007608503,0.0031704577,0.000024655428,0.000036507612,0.0021383013,0.00004459819,0.0041313176,0.9824399,0.000302794,0.0068902425,0.000013695135],"about_ca_topic_score_codex":0.00084672065,"about_ca_topic_score_gemma":0.0008385106,"teacher_disagreement_score":0.0015570326,"about_ca_system_score_codex":0.000214082,"about_ca_system_score_gemma":0.0002531426,"threshold_uncertainty_score":0.0052087307},"labels":[],"label_agreement":null},{"id":"W3212697406","doi":"10.1021/acsptsci.1c00188","title":"Enhancing CAR-T Cell Therapy with Functional Nucleic Acids","year":2021,"lang":"en","type":"review","venue":"ACS Pharmacology & Translational Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Nucleic acid; Chimeric antigen receptor; Ribozyme; Immunotherapy; Aptamer; Computational biology; Cell therapy; Cancer therapy; Biology; Cell; Medicine; RNA; Cancer; Immunology; Immune system; Biochemistry; Molecular biology; Genetics","score_opus":0.07385786044451662,"score_gpt":0.3975091195383652,"score_spread":0.3236512590938486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212697406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007218231,0.99229395,0.0011523385,0.0004559787,0.00040490986,0.000020105947,0.000027190015,0.000028583292,0.004895132],"genre_scores_gemma":[0.003632314,0.9915466,0.0009316862,0.00041396174,0.00017921621,0.000027564227,0.000047416517,0.000004940678,0.0032163702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998925,0.00001945996,0.0000071152895,0.000020458983,0.00004380738,0.000016529508],"domain_scores_gemma":[0.9999392,0.000026039135,0.000008166835,0.0000022122942,0.0000170473,0.0000072442176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038825074,0.00066378113,0.00058701937,0.0011819127,0.00018686395,0.00068614597,0.00045498356,0.00081174873,0.0023069058],"category_scores_gemma":[0.000246397,0.0002032021,0.00031725917,0.0007476367,0.00030670327,0.00093064766,0.00053190294,0.00140626,0.0017985335],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005615913,0.00012703164,0.000090777714,0.011006708,0.00004949418,0.00026834547,0.00008938458,0.0008177564,0.022499952,0.017480494,0.025345154,0.9221687],"study_design_scores_gemma":[0.000013104764,0.00014370366,0.000160173,0.0008011508,0.000031163152,0.00059381215,0.000026358786,0.00018329668,0.0061144917,0.0016578673,0.99026114,0.000013755159],"about_ca_topic_score_codex":0.0005215938,"about_ca_topic_score_gemma":0.0009638871,"teacher_disagreement_score":0.0023069058,"about_ca_system_score_codex":0.0004887634,"about_ca_system_score_gemma":0.00050278776,"threshold_uncertainty_score":0.007717371},"labels":[],"label_agreement":null},{"id":"W3212730017","doi":"10.1182/blood-2021-149327","title":"Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Retrospective cohort study; Follicular lymphoma; Refractory (planetary science); Cohort; Clinical trial; Lymphoma","score_opus":0.02377851177416539,"score_gpt":0.3142376873177308,"score_spread":0.2904591755435654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212730017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873639,0.0095379865,0.00024022897,0.00027785366,0.00012514176,0.00039339764,0.00033721267,0.000031532854,0.001692812],"genre_scores_gemma":[0.99820065,0.0006296808,0.0002461358,0.00019727215,0.00007792639,0.00018726043,0.00029619428,0.0000023436771,0.0001624511],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9981115,0.0012693278,0.00012823044,0.00024151335,0.00014678997,0.00010261811],"domain_scores_gemma":[0.9983047,0.0006333117,0.00051085895,0.00008782558,0.00011954158,0.000343754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024824988,0.00045199218,0.0016137148,0.00044724188,0.00021984248,0.000725883,0.0006518122,0.0007250935,0.0026372217],"category_scores_gemma":[0.0029604745,0.00016998728,0.001476021,0.00040386483,0.0005230358,0.0007103447,0.00046315466,0.0011409161,0.0002657611],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8655205,0.0073691825,0.010963387,0.0014383366,0.0038289435,0.000049584858,0.0001327514,0.0010756489,0.0019900664,0.00022697543,0.0010478011,0.10635676],"study_design_scores_gemma":[0.34069368,0.5891532,0.05945122,0.00030699075,0.0033714797,0.00017514724,0.00017530449,0.0028257472,0.00105482,0.00038166216,0.0023668015,0.000043928518],"about_ca_topic_score_codex":0.0007034004,"about_ca_topic_score_gemma":0.0014998649,"teacher_disagreement_score":0.0026372217,"about_ca_system_score_codex":0.0009967644,"about_ca_system_score_gemma":0.00065162766,"threshold_uncertainty_score":0.013128877},"labels":[],"label_agreement":null},{"id":"W3212910936","doi":"10.1182/blood-2021-152149","title":"Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Immune system; Chimeric antigen receptor; Bone marrow; Immunotherapy; T cell; Medicine; Multiple myeloma; Antigen; Cancer research; Immunology","score_opus":0.028813889938514223,"score_gpt":0.2679662286620868,"score_spread":0.23915233872357258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212910936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974197,0.00025802,0.0016026451,0.00002074898,0.0000037113555,0.000010398237,0.00029013155,0.000022395341,0.0003722371],"genre_scores_gemma":[0.99812657,0.00011155439,0.0008784484,0.000030437594,0.0000031650525,0.000019426961,0.00033984048,0.0000073746905,0.00048306715],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998815,0.000017109898,0.000006296926,0.000041838564,0.000025102576,0.000028065946],"domain_scores_gemma":[0.99995005,0.000010957417,0.00001145311,0.000007631134,0.000009972713,0.000009882731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010802679,0.00012357638,0.0002000253,0.00018164812,0.00012722742,0.00026607473,0.000087894965,0.00017637762,0.0010795298],"category_scores_gemma":[0.000114564515,0.00008947305,0.00013769376,0.00017866796,0.00013367418,0.000093035145,0.00015729462,0.00030718406,0.00023254065],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011997037,0.000010418212,0.002298496,0.000010172508,0.0000053549247,0.00001083827,0.000024974694,0.000112335074,0.99580437,0.000018072767,0.0000135585005,0.0015714141],"study_design_scores_gemma":[0.000019275734,0.000901717,0.16417845,0.0000066781936,0.0000437139,0.00036984376,0.00023629212,0.00458145,0.8277361,0.00014617272,0.0017730463,0.0000073381984],"about_ca_topic_score_codex":0.00044782952,"about_ca_topic_score_gemma":0.00049888744,"teacher_disagreement_score":0.0010795298,"about_ca_system_score_codex":0.00012266044,"about_ca_system_score_gemma":0.00007206339,"threshold_uncertainty_score":0.0036113858},"labels":[],"label_agreement":null},{"id":"W3212994588","doi":"10.1016/j.htct.2021.09.002","title":"Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Medicine; CD19; Hematology; Lymphoblastic Leukemia; CAR T-cell therapy; Cell therapy; Oncology; Leukemia; T cell; Internal medicine; Immunology; Disease; Acute lymphocytic leukemia; Cancer research; Antigen; Cell; Immune system; Biology","score_opus":0.015864145573632197,"score_gpt":0.2614555756327584,"score_spread":0.2455914300591262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212994588","genre_codex":"review","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.076755054,0.54812247,0.019497273,0.14410855,0.02976998,0.0010544201,0.008426228,0.00062916655,0.17163682],"genre_scores_gemma":[0.4524049,0.4226773,0.029005658,0.020113958,0.01462269,0.0010824269,0.007676329,0.00038402624,0.05203271],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977424,0.00048313895,0.0004448224,0.0003444189,0.00076322217,0.00022200655],"domain_scores_gemma":[0.9945582,0.00087811134,0.0013962351,0.0003726537,0.0021178694,0.0006769647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037596102,0.00041750917,0.0006957382,0.003408515,0.0006573732,0.0011879632,0.0006974204,0.0013393066,0.007975365],"category_scores_gemma":[0.0065774783,0.00023848236,0.0006192824,0.0050285757,0.0008840507,0.00045503062,0.0008593628,0.0016617189,0.0023907016],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008097919,0.0002181789,0.06646766,0.004675743,0.00025087694,0.0011123617,0.00043973973,0.00066761597,0.018274363,0.019522404,0.17938308,0.70817816],"study_design_scores_gemma":[0.000088525165,0.00017206215,0.06295064,0.002702386,0.00028792655,0.0040044603,0.00023383721,0.00041112726,0.004043538,0.002183927,0.92287815,0.000043479737],"about_ca_topic_score_codex":0.008606462,"about_ca_topic_score_gemma":0.010418171,"teacher_disagreement_score":0.008606462,"about_ca_system_score_codex":0.0017176863,"about_ca_system_score_gemma":0.004109475,"threshold_uncertainty_score":0.02668029},"labels":[],"label_agreement":null},{"id":"W3213141384","doi":"10.1182/blood-2021-148881","title":"SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"CD22; CD19; Antigen; Population; Medicine; Immunology; Chimeric antigen receptor; T cell; Biology; Immune system","score_opus":0.05609788024173643,"score_gpt":0.3150073002991131,"score_spread":0.25890942005737666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213141384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990112,0.0014849504,0.0025179067,0.000093418654,0.000019552057,0.00014936304,0.0002442899,0.00020215585,0.005176337],"genre_scores_gemma":[0.9947155,0.00048608106,0.0013977257,0.000049451966,0.0000166808,0.00006729912,0.00058073405,0.000029008055,0.0026575131],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998889,0.000027467664,0.0000072268717,0.000021618625,0.000028901508,0.000025928275],"domain_scores_gemma":[0.99993587,0.000011462083,0.000010152868,0.000009694791,0.000009342615,0.000023564648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024878475,0.0003118309,0.00026862547,0.00025075965,0.00014585617,0.0003597905,0.0002049508,0.00030898754,0.0034377659],"category_scores_gemma":[0.00012252225,0.0001090607,0.00015548163,0.00012619991,0.00011383501,0.00015044355,0.00015314389,0.00061505055,0.0009793553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008567806,0.0009676332,0.0005264087,0.0000830621,0.000014871648,0.000116876894,0.000053940323,0.00034284234,0.97857,0.00020944735,0.00044664714,0.017811488],"study_design_scores_gemma":[0.0007832872,0.019850854,0.00796142,0.00002045049,0.00009921522,0.0014943418,0.0000333632,0.0021361562,0.9554167,0.000120974924,0.012075092,0.00000819907],"about_ca_topic_score_codex":0.0005049555,"about_ca_topic_score_gemma":0.0006998622,"teacher_disagreement_score":0.0034377659,"about_ca_system_score_codex":0.00022004505,"about_ca_system_score_gemma":0.00023870575,"threshold_uncertainty_score":0.011500418},"labels":[],"label_agreement":null},{"id":"W3213192832","doi":"10.1182/blood-2021-146397","title":"Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); McMaster University; Juravinski Hospital","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Diffuse large B-cell lymphoma; Single Center; Oncology; Adverse effect; Aggressive lymphoma; Lymphoma; Surgery; Immunotherapy; Rituximab; Cancer; Chimeric antigen receptor","score_opus":0.02530467328569276,"score_gpt":0.31217945976276346,"score_spread":0.2868747864770707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213192832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94581074,0.00886224,0.00092205725,0.0009129451,0.00005640179,0.00024827677,0.036211055,0.00007272163,0.0069036772],"genre_scores_gemma":[0.9563122,0.0023075205,0.0008700061,0.0005945756,0.00009416042,0.00029676248,0.038966753,0.000022398102,0.0005356978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860567,0.00047835338,0.00022189031,0.00020172943,0.00038050284,0.00011188289],"domain_scores_gemma":[0.992027,0.0014537029,0.0042332048,0.0004862469,0.0010999265,0.0006999224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029030475,0.0001901593,0.00057573064,0.00060074305,0.00029759962,0.0013481594,0.0005549843,0.00034826444,0.0013255249],"category_scores_gemma":[0.0046922956,0.00013962887,0.00070918805,0.0014558993,0.00032671102,0.0007483695,0.00047348836,0.0006385977,0.00047041438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00828708,0.00025377487,0.9317304,0.00046639502,0.0009964284,0.00010358221,0.00015297366,0.00064291153,0.00064669526,0.0002959375,0.00891895,0.0475049],"study_design_scores_gemma":[0.0010784118,0.0017121462,0.98170817,0.00017559198,0.0011052227,0.00063806766,0.00025169933,0.0008216472,0.0006271105,0.00033202392,0.011505516,0.000044213102],"about_ca_topic_score_codex":0.0028159195,"about_ca_topic_score_gemma":0.0063418536,"teacher_disagreement_score":0.0029030475,"about_ca_system_score_codex":0.0011952827,"about_ca_system_score_gemma":0.00084721606,"threshold_uncertainty_score":0.015352964},"labels":[],"label_agreement":null},{"id":"W3213274906","doi":"10.1080/2162402x.2021.1995168","title":"Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University; TRIUMF","funders":"Canada Research Chairs","keywords":"Cryopreservation; Bioreactor; Cell; Cell culture; Chemistry; Cell biology; Biotechnology; Biology; Biochemistry; Embryo","score_opus":0.02288096904731359,"score_gpt":0.2790658329351818,"score_spread":0.2561848638878682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213274906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9697683,0.00057432347,0.027588684,0.00017116829,0.000040779167,0.000047096917,0.00020456896,0.00019896071,0.0014061127],"genre_scores_gemma":[0.96830654,0.0003647456,0.029874068,0.000078412544,0.000012126411,0.00004680584,0.00017897123,0.00005519906,0.0010830372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975485,0.000049323324,0.000024536283,0.000060453294,0.00006482093,0.000045944544],"domain_scores_gemma":[0.9997807,0.000054344164,0.00007776517,0.000031132677,0.000035093053,0.000021035792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035778165,0.00026881223,0.00015893372,0.00012219975,0.00013024526,0.00038397312,0.00022889482,0.0003193759,0.0006423968],"category_scores_gemma":[0.00032988747,0.00010647547,0.00030127857,0.000094644754,0.00023300473,0.00031625445,0.00022912386,0.00049828144,0.0003622917],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024763489,0.000008619291,0.000096639946,0.000010821276,0.0000015725649,0.000015806592,0.00001044752,0.00011983324,0.9989458,0.000048239144,0.000013878438,0.0007035649],"study_design_scores_gemma":[0.0000026040334,0.00008212888,0.0003255824,0.0000019062055,0.000003068951,0.000047838737,0.000007890431,0.0005196027,0.998343,0.000021975819,0.0006416457,0.0000027932858],"about_ca_topic_score_codex":0.0004104714,"about_ca_topic_score_gemma":0.00064575387,"teacher_disagreement_score":0.0006423968,"about_ca_system_score_codex":0.00023551792,"about_ca_system_score_gemma":0.00019404008,"threshold_uncertainty_score":0.0021489859},"labels":[],"label_agreement":null},{"id":"W3213324499","doi":"10.1016/j.xpro.2021.100956","title":"Production of human CAR-NK cells with lentiviral vectors and functional assessment in vitro","year":2021,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Flow cytometry; Cell biology; Ex vivo; Transgene; Transduction (biophysics); Janus kinase 3; Biology; In vitro; Immune system; Effector; Interleukin 21; T cell; Immunology; Gene; Genetics","score_opus":0.04441661667281394,"score_gpt":0.36506743946083814,"score_spread":0.3206508227880242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213324499","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6520012,0.011444372,0.25792074,0.0010945085,0.0010429933,0.005665286,0.02732311,0.004411231,0.039096568],"genre_scores_gemma":[0.7966559,0.0062503666,0.118802905,0.0005557203,0.0001562517,0.0050290255,0.0385272,0.00077742164,0.033245288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845695,0.00029325348,0.00027054088,0.00021213503,0.0005084785,0.00025857743],"domain_scores_gemma":[0.9995402,0.00011934747,0.000039906572,0.00013432399,0.00011328768,0.000052960568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00176544,0.0010226166,0.00095886714,0.00070471654,0.0004676493,0.0015485582,0.0009752946,0.0008044001,0.004947127],"category_scores_gemma":[0.00065547513,0.0006607264,0.0006372639,0.0006760548,0.00045103754,0.00063165056,0.0006378268,0.0026277932,0.004607715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001716118,0.00025918294,0.00025200198,0.00025068747,0.000021547688,0.00009621108,0.00017887623,0.000810991,0.9881557,0.001439472,0.0014984509,0.0068653105],"study_design_scores_gemma":[0.00007140166,0.0003120005,0.0006803737,0.000030752755,0.00003698141,0.00022968689,0.000033583194,0.003474038,0.97406965,0.00020115414,0.020838022,0.000022435668],"about_ca_topic_score_codex":0.0015870588,"about_ca_topic_score_gemma":0.0017451356,"teacher_disagreement_score":0.004947127,"about_ca_system_score_codex":0.00093441975,"about_ca_system_score_gemma":0.0006906445,"threshold_uncertainty_score":0.016549766},"labels":[],"label_agreement":null},{"id":"W3213532983","doi":"10.1182/blood-2021-151683","title":"Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2 nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; London Health Sciences Centre; Western University; Vancouver General Hospital; Saskatchewan Cancer Agency; University of Saskatchewan; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prednisone; Ruxolitinib; Internal medicine; Rituximab; Salvage therapy; Retrospective cohort study; Propensity score matching; Corticosteroid; Surgery; Gastroenterology; Chemotherapy; Myelofibrosis; Lymphoma","score_opus":0.07654796442627441,"score_gpt":0.32601916825522376,"score_spread":0.24947120382894933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213532983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958177,0.0003840147,0.002897367,0.000046441168,0.000046478475,0.00014381077,0.00034872326,0.000013798994,0.0003015704],"genre_scores_gemma":[0.9989447,0.000037383867,0.00043564496,0.000029508557,0.000015893249,0.00006780916,0.00031031042,0.0000022662366,0.00015657305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965953,0.0015415075,0.00038639866,0.00085605786,0.00037779094,0.00024298149],"domain_scores_gemma":[0.99707246,0.0009434888,0.0011690928,0.00048078047,0.00015333889,0.00018087839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003963925,0.00040657658,0.00073537865,0.0012003913,0.00040453547,0.0005614686,0.00068126066,0.0005963342,0.0025747311],"category_scores_gemma":[0.006618392,0.00017396263,0.001982,0.00094111107,0.00036266528,0.00039971957,0.00047497763,0.00041787108,0.00022175233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027996752,0.000932716,0.9336431,0.00012721372,0.004036702,0.00025241895,0.0001341257,0.002936016,0.0017321925,0.0007910338,0.001379279,0.026038341],"study_design_scores_gemma":[0.0013448676,0.0081510125,0.9327949,0.000043935463,0.0024821067,0.0005029711,0.00024396992,0.049381327,0.0013094873,0.0013046906,0.002402227,0.00003846685],"about_ca_topic_score_codex":0.0013170594,"about_ca_topic_score_gemma":0.0006329715,"teacher_disagreement_score":0.003963925,"about_ca_system_score_codex":0.0004912768,"about_ca_system_score_gemma":0.0004211407,"threshold_uncertainty_score":0.02096355},"labels":[],"label_agreement":null},{"id":"W3213571777","doi":"10.1182/blood-2021-147598","title":"Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Hôpital de l'Enfant-Jésus; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Refractory (planetary science); Randomization; Randomized controlled trial; Oncology","score_opus":0.04728086257192918,"score_gpt":0.3732617414523252,"score_spread":0.32598087888039606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213571777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932318,0.001841834,0.0003041156,0.00024335858,0.00016120494,0.0022499177,0.0011434931,0.000035747365,0.0007885638],"genre_scores_gemma":[0.9905419,0.0008058644,0.0010900474,0.0006845429,0.00027188472,0.0043838015,0.0015510105,0.000012921384,0.0006580991],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99790984,0.001418656,0.0000931363,0.00023485333,0.00017104889,0.00017236562],"domain_scores_gemma":[0.9973469,0.0006657585,0.00087040954,0.00017815507,0.00021490733,0.0007238307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004317342,0.0015644536,0.0021302812,0.00047191692,0.00052406604,0.0010108058,0.0011448496,0.0018210227,0.003952992],"category_scores_gemma":[0.0023139997,0.0005599524,0.002637888,0.000504865,0.0012239243,0.0010872248,0.00062082335,0.003458577,0.0006449297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96576405,0.019455522,0.0020696907,0.00032244454,0.0013022068,0.000025211122,0.000039393017,0.00039909955,0.0020540173,0.000046477533,0.0005035009,0.008018381],"study_design_scores_gemma":[0.78934085,0.20092314,0.007144972,0.00002376864,0.00082846265,0.000041609772,0.00003109125,0.000657466,0.000524689,0.00008270878,0.00038484274,0.000016465548],"about_ca_topic_score_codex":0.0006961706,"about_ca_topic_score_gemma":0.0015452964,"teacher_disagreement_score":0.004317342,"about_ca_system_score_codex":0.0010624045,"about_ca_system_score_gemma":0.0013061732,"threshold_uncertainty_score":0.022832572},"labels":[],"label_agreement":null},{"id":"W3213746728","doi":"10.1182/blood-2021-147568","title":"Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network","funders":"","keywords":"Medicine; Interquartile range; Internal medicine; CAR T-cell therapy; Cumulative incidence; Population; Cohort; Oncology; Cytokine release syndrome; Minimal residual disease; Lymphoma; Cancer; Chimeric antigen receptor; Immunotherapy; Leukemia","score_opus":0.09814892694299518,"score_gpt":0.3666650623625426,"score_spread":0.26851613541954744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213746728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976242,0.0012375658,0.00009858076,0.00012005227,0.000015233122,0.000039034447,0.00049855094,0.0000025358408,0.00036426462],"genre_scores_gemma":[0.99884146,0.0003127265,0.00007254005,0.00012477362,0.000046315603,0.000037420916,0.00043583638,0.000002589436,0.00012637692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990484,0.0003937458,0.000107726984,0.00024437462,0.00008234971,0.0001233347],"domain_scores_gemma":[0.9960025,0.0006678631,0.0024999327,0.00018975754,0.00016181613,0.00047812716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012828697,0.00024680636,0.00054123235,0.00028370967,0.00051602407,0.000842754,0.00038313432,0.0007847194,0.002702835],"category_scores_gemma":[0.0039084083,0.00021039482,0.0007963835,0.00078539195,0.00030288156,0.00059126836,0.00033318857,0.0011977998,0.0003742945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0127569735,0.0012857995,0.97838783,0.00013907124,0.000755461,0.00014535703,0.00012666156,0.00012318198,0.00054895034,0.00008585222,0.0006736703,0.004971262],"study_design_scores_gemma":[0.0020535872,0.009750005,0.9814348,0.00011111082,0.00090704695,0.00067063485,0.00050634384,0.00077491294,0.00033578015,0.00018117226,0.0032457984,0.000028768807],"about_ca_topic_score_codex":0.0016860892,"about_ca_topic_score_gemma":0.0016486768,"teacher_disagreement_score":0.002702835,"about_ca_system_score_codex":0.0005260933,"about_ca_system_score_gemma":0.000538092,"threshold_uncertainty_score":0.009041846},"labels":[],"label_agreement":null},{"id":"W3213817406","doi":"10.1182/blood-2021-148652","title":"Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Hematopoietic cell; Medicine; Hematopoietic stem cell transplantation; Transplantation; Hematologic Neoplasms; Acute lymphocytic leukemia; CD19; Immunology; Cancer research; Antigen; Lymphoblastic Leukemia; Leukemia; Oncology; Haematopoiesis; Stem cell; Internal medicine; T cell; Biology; Immune system","score_opus":0.01989192779643441,"score_gpt":0.3112064418056722,"score_spread":0.2913145140092378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213817406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99835265,0.0008369149,0.00015881748,0.00009081922,0.000009613894,0.000011173411,0.00010973774,0.00000618732,0.0004240162],"genre_scores_gemma":[0.99953175,0.00015710297,0.00006556645,0.000023635592,0.0000099033205,0.0000037512666,0.00013676225,9.736715e-7,0.0000705658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996107,0.0001831165,0.000032001462,0.000051885036,0.00007184437,0.000050358864],"domain_scores_gemma":[0.9990318,0.00027607253,0.00044863974,0.00003746926,0.000045060122,0.00016100235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070771924,0.000117737065,0.00018020626,0.00015959433,0.00012074978,0.0003915878,0.000196739,0.00010061062,0.00094246824],"category_scores_gemma":[0.0013758471,0.00004768651,0.000289189,0.0002266869,0.0001700544,0.00017904042,0.0002907712,0.00034497684,0.00007487935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006017032,0.0005218365,0.91611046,0.00010019677,0.0003289555,0.00027795538,0.000060108974,0.0019011224,0.002184135,0.00024390101,0.0006254402,0.07162899],"study_design_scores_gemma":[0.0002999317,0.0065238005,0.98299164,0.00006300073,0.00058012345,0.0008481714,0.00013624338,0.0039724926,0.0026508581,0.00011919235,0.001808392,0.0000061553433],"about_ca_topic_score_codex":0.0010033739,"about_ca_topic_score_gemma":0.0019934343,"teacher_disagreement_score":0.0010033739,"about_ca_system_score_codex":0.00047177478,"about_ca_system_score_gemma":0.00064886967,"threshold_uncertainty_score":0.003742814},"labels":[],"label_agreement":null},{"id":"W3213879987","doi":"10.1182/blood-2021-148302","title":"Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Propensity score matching; Lenalidomide; Cohort; Population; Diffuse large B-cell lymphoma; Chemotherapy regimen; Retrospective cohort study; Regimen; Oncology; Surgery; Cancer; Lymphoma; Multiple myeloma","score_opus":0.0768311610291272,"score_gpt":0.3310662052840418,"score_spread":0.2542350442549146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213879987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99825615,0.00052569737,0.00012654702,0.000032272117,0.00001697445,0.000042092663,0.00080241234,0.0000021699445,0.00019562022],"genre_scores_gemma":[0.9978369,0.00015795983,0.000101257254,0.00007058434,0.000037359187,0.00005093317,0.0016427848,0.000001925021,0.00010029351],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991061,0.0002783158,0.000113062044,0.00030443544,0.00010452441,0.00009353938],"domain_scores_gemma":[0.9982008,0.00024993756,0.0009013722,0.00019901138,0.00011187869,0.00033706127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001334143,0.00035887584,0.0005769347,0.0003922257,0.0003459438,0.000689652,0.00051353435,0.00040123117,0.0010719993],"category_scores_gemma":[0.0021608472,0.00028364637,0.0012604401,0.00048144662,0.00029735258,0.0004538774,0.0005565247,0.0007500273,0.00022728463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034222938,0.0009803785,0.9538837,0.00015490943,0.0028797896,0.00015280071,0.00011575602,0.0002741595,0.0010690893,0.00009239979,0.00084803195,0.005325963],"study_design_scores_gemma":[0.0041791247,0.010903229,0.9764593,0.00007451782,0.0027888794,0.0007322466,0.00042869186,0.0016309868,0.00060297386,0.00021343006,0.0019534603,0.000033102042],"about_ca_topic_score_codex":0.0015788617,"about_ca_topic_score_gemma":0.0021112936,"teacher_disagreement_score":0.0015788617,"about_ca_system_score_codex":0.00050974794,"about_ca_system_score_gemma":0.0005115009,"threshold_uncertainty_score":0.0070557},"labels":[],"label_agreement":null},{"id":"W3213899689","doi":"10.1016/s2152-2650(21)02101-7","title":"OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Pomalidomide; Fludarabine; Internal medicine; Bortezomib; Carfilzomib; Rituximab; Daratumumab; Regimen; Multiple myeloma; Refractory (planetary science); Clinical endpoint; Oncology; Cyclophosphamide; Gastroenterology; Surgery; Clinical trial; Chemotherapy; Lymphoma","score_opus":0.03591386775633376,"score_gpt":0.310774505472544,"score_spread":0.2748606377162102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213899689","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.083122425,0.85558534,0.0036210483,0.011700499,0.0024183055,0.000807429,0.0147195775,0.00080017315,0.027225276],"genre_scores_gemma":[0.20895995,0.6863752,0.013371405,0.016334375,0.0022145694,0.0011356462,0.049919818,0.00032019056,0.021368831],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99933136,0.00014828773,0.00008020483,0.0000785952,0.00026303346,0.00009856157],"domain_scores_gemma":[0.99921083,0.0002011873,0.00023193403,0.000036492223,0.00018596795,0.00013356387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024832734,0.0008240682,0.0015850918,0.0012831411,0.00019509532,0.0015507628,0.0010721122,0.0009684003,0.004464169],"category_scores_gemma":[0.0013701081,0.00028162886,0.001222589,0.0016197707,0.00031518287,0.0008332042,0.00048543638,0.0016549503,0.0019976224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008845086,0.0007092827,0.0030483897,0.0027884622,0.0011199864,0.0002674711,0.000055979555,0.00079647836,0.011619928,0.0004653085,0.055665817,0.91461784],"study_design_scores_gemma":[0.013996501,0.009978224,0.03727027,0.0018419875,0.0068778642,0.0025968174,0.00009153974,0.0010084262,0.016180502,0.0007269999,0.90929663,0.00013438019],"about_ca_topic_score_codex":0.0031338509,"about_ca_topic_score_gemma":0.008295297,"teacher_disagreement_score":0.004464169,"about_ca_system_score_codex":0.0013141449,"about_ca_system_score_gemma":0.001816529,"threshold_uncertainty_score":0.014934182},"labels":[],"label_agreement":null},{"id":"W3214093033","doi":"10.1101/2021.05.07.443194","title":"Decade-long remissions of leukemia sustained by the persistence of activated CD4 <sup>+</sup> CAR T-cells","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Chimeric antigen receptor; T-cell receptor; Adoptive cell transfer; Population; Immunology; Leukemia; Cytotoxic T cell; Biology; Cancer research; CD19; Molecular biology; Antigen; T cell; Medicine; Genetics; Immune system","score_opus":0.02179808866004319,"score_gpt":0.2587078643610088,"score_spread":0.2369097757009656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214093033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570614,0.0016610672,0.0013582632,0.00008464577,0.000009034411,0.0000062902286,0.00031556314,0.00007424934,0.0007847131],"genre_scores_gemma":[0.997447,0.00032962128,0.00038493014,0.000070327755,0.000007423951,0.000010086699,0.0005741988,0.000017471471,0.0011591321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998878,0.000011725516,0.00000775186,0.000031581934,0.000024161585,0.00003687288],"domain_scores_gemma":[0.99987996,0.000018974883,0.000043523167,0.000016672371,0.000010847894,0.00003004595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001727538,0.00010569985,0.0002397913,0.0001479778,0.00014167184,0.00046686607,0.00009829024,0.00029721737,0.0012353713],"category_scores_gemma":[0.0001982753,0.0000871692,0.00013289714,0.00015947066,0.00014689207,0.00020140417,0.00022248764,0.00047941445,0.0005379356],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007098797,0.00005902962,0.012659997,0.000047464076,0.000022471924,0.0003290884,0.000139572,0.00031276472,0.96744674,0.00029016577,0.00024926386,0.017733566],"study_design_scores_gemma":[0.00011590604,0.0024412563,0.22128236,0.0000312936,0.00013118942,0.005986146,0.00033461847,0.0028456014,0.74445355,0.00092097645,0.021426389,0.00003078142],"about_ca_topic_score_codex":0.00024477622,"about_ca_topic_score_gemma":0.0003320251,"teacher_disagreement_score":0.0012353713,"about_ca_system_score_codex":0.00021865321,"about_ca_system_score_gemma":0.00012818798,"threshold_uncertainty_score":0.004132688},"labels":[],"label_agreement":null},{"id":"W3214408062","doi":"10.1182/blood-2021-144939","title":"Tisagenlecleucel Leukapheresis and Manufacturing Outcomes in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Leukapheresis; Medicine; Blinatumomab; Internal medicine; Leukemia; Lymphoblastic Leukemia; Stem cell; Biology","score_opus":0.014969082656810635,"score_gpt":0.2531213890440729,"score_spread":0.23815230638726226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214408062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962059,0.00054130517,0.0001115789,0.00009200296,0.000011362794,0.000020636126,0.0017361854,0.0000066899916,0.0012742053],"genre_scores_gemma":[0.9961414,0.00021534694,0.000098693854,0.0001406087,0.000027522196,0.00003083683,0.002951034,0.0000062417434,0.00038826416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996,0.00006417347,0.000054624772,0.00008181862,0.00009628765,0.00010319189],"domain_scores_gemma":[0.9981292,0.00022333812,0.001180276,0.00006269048,0.00012532112,0.0002792432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006001939,0.00020366686,0.00034108115,0.00054946746,0.00032515702,0.00088300003,0.00027644107,0.0003925038,0.0032935007],"category_scores_gemma":[0.001826615,0.000106593914,0.0006946983,0.0008179371,0.00017170592,0.0006288155,0.00056003564,0.00076039555,0.00069951214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048043467,0.00027445034,0.9775729,0.00007152375,0.00017166084,0.00064748176,0.00020828865,0.00035908722,0.00090312713,0.00016213788,0.0022713917,0.0125536835],"study_design_scores_gemma":[0.00024543257,0.002190643,0.9889846,0.000045243607,0.00019720798,0.0023230433,0.00031131218,0.00060582004,0.0006223765,0.00017715905,0.0042802817,0.000016758553],"about_ca_topic_score_codex":0.0022110834,"about_ca_topic_score_gemma":0.002395821,"teacher_disagreement_score":0.0032935007,"about_ca_system_score_codex":0.0007193763,"about_ca_system_score_gemma":0.0005252896,"threshold_uncertainty_score":0.011017919},"labels":[],"label_agreement":null},{"id":"W3214517671","doi":"10.1182/blood-2021-145278","title":"A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells <i>in Vitro</i> and <i>In Vivo</i>","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"CD34; Myeloid leukemia; Cancer research; Stem cell; Leukemia; Haematopoiesis; Antigen; T cell; Biology; Immunology; Molecular biology; Chemistry; Cell biology; Immune system","score_opus":0.01639355764875683,"score_gpt":0.23852785130132656,"score_spread":0.22213429365256973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214517671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767662,0.0014721907,0.01724555,0.0002017589,0.0000879807,0.00021282407,0.0005704018,0.0005145009,0.002928555],"genre_scores_gemma":[0.9830609,0.0006952358,0.009157744,0.00018070583,0.000030612347,0.00011308249,0.0016693689,0.00003975608,0.005052696],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998548,0.000017910854,0.000010304129,0.000033124215,0.0000461292,0.000037756057],"domain_scores_gemma":[0.9999567,0.00000616904,0.000008966078,0.000006483906,0.000005896017,0.00001588967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011130845,0.00044356333,0.00027263194,0.00019754634,0.00010620472,0.0002776466,0.00026530062,0.00035417257,0.0019436273],"category_scores_gemma":[0.00009682717,0.00012628309,0.0002843677,0.00012439214,0.00012572702,0.00014343442,0.00020384208,0.0006463564,0.0006587762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016539363,0.00011839454,0.00009079087,0.000026278965,0.0000063960033,0.00002230941,0.000006181956,0.00010239814,0.9960632,0.000082230974,0.00017062004,0.0031457308],"study_design_scores_gemma":[0.000073205556,0.0010061804,0.0011586297,0.0000046525906,0.00002563263,0.0002450661,0.00000752932,0.0017516481,0.99249566,0.000033743618,0.0031930136,0.00000492039],"about_ca_topic_score_codex":0.00023116037,"about_ca_topic_score_gemma":0.00035759105,"teacher_disagreement_score":0.0019436273,"about_ca_system_score_codex":0.00017233627,"about_ca_system_score_gemma":0.00016016419,"threshold_uncertainty_score":0.0065020323},"labels":[],"label_agreement":null},{"id":"W3214889415","doi":"10.1101/2021.11.26.470145","title":"DLL4 and VCAM1 enhance the emergence of T cell-competent hematopoietic progenitors from human pluripotent stem cells","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Université de Montréal; University of Toronto; Institute for Research in Immunology and Cancer; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Michael Smith Health Research BC; Stem Cell Network; Universities Space Research Association","keywords":"Progenitor cell; Haematopoiesis; Cell biology; Stem cell; Biology; Induced pluripotent stem cell; CD8; T cell; Immunology; Immune system; Embryonic stem cell; Biochemistry","score_opus":0.01911877460398272,"score_gpt":0.2551806227516626,"score_spread":0.23606184814767986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214889415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870252,0.00066907884,0.008903891,0.0001375683,0.000028053188,0.0000502218,0.00069307175,0.00013900101,0.0023539474],"genre_scores_gemma":[0.98497355,0.00033636345,0.0083517395,0.00008033217,0.0000074915993,0.000044086206,0.00078062434,0.000060919487,0.0053648045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998672,0.000025669158,0.000015035776,0.00002396175,0.000041884436,0.000026331169],"domain_scores_gemma":[0.9999045,0.00003120264,0.00002097553,0.000009056305,0.000011887702,0.000022316455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023265867,0.00020043194,0.00012604405,0.00023218464,0.0000854197,0.00034456284,0.00013780974,0.00017577625,0.0016848264],"category_scores_gemma":[0.00013622547,0.00010709835,0.00012866939,0.00013859264,0.00017225854,0.00011623314,0.00028532854,0.0004396895,0.00039890324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023694127,0.0000075874977,0.00007486014,0.000013287335,0.0000015758791,0.000014208065,0.0000071828704,0.0000748221,0.9989711,0.00007041909,0.00003289635,0.000708412],"study_design_scores_gemma":[0.0000040680925,0.000025943378,0.00035029458,0.0000012986765,0.0000020843872,0.000016913198,0.0000047572294,0.00050139136,0.9981269,0.000018170686,0.00094722887,8.1566793e-7],"about_ca_topic_score_codex":0.00038601868,"about_ca_topic_score_gemma":0.0005046278,"teacher_disagreement_score":0.0016848264,"about_ca_system_score_codex":0.00024892096,"about_ca_system_score_gemma":0.00015579864,"threshold_uncertainty_score":0.005636275},"labels":[],"label_agreement":null},{"id":"W3215434289","doi":"10.3390/cancers13235982","title":"Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"University of California, Davis; Drs Martin and Dorothy Spatz Charitable Foundation","keywords":"Mycosis fungoides; Tumor microenvironment; Cancer research; BTLA; Cytotoxic T cell; Immunotherapy; CD8; Immunology; Medicine; Immune system; T cell; Cutaneous T-cell lymphoma; Cancer; Lymphoma; Biology; Internal medicine","score_opus":0.03334650611139613,"score_gpt":0.32991351711785083,"score_spread":0.2965670110064547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215434289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759585,0.0011258789,0.00031461814,0.000063276515,0.000021098014,0.00001911553,0.000059413305,0.000042721174,0.00075814046],"genre_scores_gemma":[0.99895084,0.00018311362,0.00015124511,0.000040335086,0.00001317782,0.0000198063,0.00009257605,0.0000041744784,0.0005447369],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999231,0.000013217416,0.000008069034,0.000013564024,0.00001611144,0.000025932057],"domain_scores_gemma":[0.9998715,0.000025887897,0.00003223857,0.000012525722,0.000013310236,0.00004454926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012648555,0.00014376633,0.00029578333,0.00015161175,0.00010493641,0.00019609924,0.00008351117,0.0002784026,0.0014597496],"category_scores_gemma":[0.00020922393,0.000090901594,0.00012098189,0.00006715581,0.00014450919,0.00013771516,0.00009801375,0.00060458836,0.00026100985],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031143725,0.00034489087,0.005361886,0.00008963645,0.0000147531555,0.00037796848,0.000056392248,0.0001964935,0.9745967,0.000068661466,0.00027269498,0.0155055765],"study_design_scores_gemma":[0.0005359531,0.020077793,0.3199213,0.000046046327,0.00013153632,0.0074137235,0.00025045668,0.0040186155,0.6344809,0.00035218542,0.012744994,0.000026536965],"about_ca_topic_score_codex":0.00009862485,"about_ca_topic_score_gemma":0.000108186265,"teacher_disagreement_score":0.0014597496,"about_ca_system_score_codex":0.00013086884,"about_ca_system_score_gemma":0.00011214103,"threshold_uncertainty_score":0.004883349},"labels":[],"label_agreement":null},{"id":"W3215641558","doi":"10.1182/blood-2021-153262","title":"Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; Centre Hospitalier Universitaire Sainte-Justine; London Health Sciences Centre; Montreal Children's Hospital; Izaak Walton Killam Health Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Population; Blinatumomab; Hematopoietic stem cell transplantation; Pediatrics; Cumulative incidence; Chimeric antigen receptor; Transplantation; Cytokine release syndrome; Incidence (geometry); Internal medicine; Oncology; Leukemia; Lymphoblastic Leukemia; Immunotherapy; Cancer","score_opus":0.015171049975039468,"score_gpt":0.2743083153968002,"score_spread":0.2591372654217607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215641558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896109,0.004087489,0.0002912244,0.00032724856,0.000022395243,0.000069167574,0.00057903246,0.00007122571,0.0049413745],"genre_scores_gemma":[0.9976538,0.0008220774,0.0003162986,0.00012500105,0.0000093366225,0.000014483906,0.0004485431,0.0000049238515,0.00060551823],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99992824,0.000009343453,0.0000062017434,0.000009393181,0.00002350537,0.000023328612],"domain_scores_gemma":[0.9998234,0.000026738964,0.000052041087,0.000007983896,0.000018195948,0.00007161199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009074847,0.00011397546,0.0002701274,0.00016332978,0.00021212612,0.000237544,0.00016057966,0.000121566,0.0011698757],"category_scores_gemma":[0.00036451832,0.000036753274,0.00017199267,0.00017306492,0.00015668312,0.00008191675,0.000120490404,0.00033342213,0.00013146407],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053331675,0.0012243395,0.47338128,0.0007301313,0.00026936497,0.0129918335,0.00079656154,0.000981936,0.030207837,0.0005414611,0.010759758,0.4627822],"study_design_scores_gemma":[0.0008617133,0.006771646,0.93293965,0.00024049298,0.00023382806,0.022479126,0.00036442914,0.0007375455,0.008792548,0.00014704041,0.02641019,0.000021637741],"about_ca_topic_score_codex":0.016576137,"about_ca_topic_score_gemma":0.05181792,"teacher_disagreement_score":0.016576137,"about_ca_system_score_codex":0.00097245903,"about_ca_system_score_gemma":0.001320689,"threshold_uncertainty_score":0.032959342},"labels":[],"label_agreement":null},{"id":"W3216096981","doi":"10.1182/blood-2021-153595","title":"Efficacy and Safety of Chimeric Antigen Receptor T Cell Therapy in Chronic Lymphocytic Leukemia: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Chimeric antigen receptor; Internal medicine; Cytokine release syndrome; Ibrutinib; Oncology; Adverse effect; Immunotherapy; Leukemia; Idelalisib; Immunology; Cancer","score_opus":0.03877698807722168,"score_gpt":0.34124428812178104,"score_spread":0.30246730004455935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216096981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017884129,0.99698323,0.00011633613,0.00016999668,0.00007573082,0.00028202106,0.00037549288,0.00000619747,0.00020267781],"genre_scores_gemma":[0.034295972,0.963428,0.0004858545,0.00057008665,0.00010943482,0.0006619932,0.00031609292,0.0000048376296,0.0001277255],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99522865,0.0016631604,0.0018238914,0.00039506628,0.000737124,0.0001521308],"domain_scores_gemma":[0.98446447,0.010261318,0.0033639374,0.00018304861,0.0015346686,0.00019254205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057383836,0.001267723,0.009496732,0.005880818,0.00046454303,0.0020237148,0.0015631395,0.0016782609,0.003937832],"category_scores_gemma":[0.019826826,0.00077239756,0.008854571,0.0067304065,0.00075656443,0.0015887098,0.0010652783,0.00087994576,0.0002255322],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034010486,0.0000137967945,0.0006314745,0.96576226,0.019189734,0.00006400164,0.00006516426,0.00008236443,0.00014300738,0.000096193085,0.0005718274,0.013040151],"study_design_scores_gemma":[0.00078836596,0.0005852292,0.0058034803,0.6685833,0.31065553,0.00040797392,0.00021076511,0.00017479292,0.00029516043,0.00032439295,0.012121195,0.000049845243],"about_ca_topic_score_codex":0.0050142272,"about_ca_topic_score_gemma":0.011742259,"teacher_disagreement_score":0.009496732,"about_ca_system_score_codex":0.0026235788,"about_ca_system_score_gemma":0.0069229505,"threshold_uncertainty_score":0.030347824},"labels":[],"label_agreement":null},{"id":"W3216151293","doi":"10.1093/neuonc/noab196.692","title":"EXTH-53. ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McMaster University","funders":"","keywords":"Downregulation and upregulation; Cancer research; Chimeric antigen receptor; Glioma; Cancer; Degranulation; Medicine; Antigen; Antibody; Brain tumor; Cancer cell; Immunology; Immunotherapy; Biology; Receptor; Pathology; Internal medicine; Gene","score_opus":0.02928900314783732,"score_gpt":0.3489784364317776,"score_spread":0.3196894332839403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216151293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817615,0.0034607651,0.00461399,0.000453951,0.00011339298,0.00015448102,0.00068575615,0.00046539915,0.008290784],"genre_scores_gemma":[0.9919247,0.0010055293,0.0014159877,0.000114720104,0.00002025645,0.000086292064,0.00043385642,0.000025008461,0.0049736574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999211,0.000006533393,0.0000040046148,0.000015127561,0.000013089404,0.000040103187],"domain_scores_gemma":[0.9999714,0.0000049726127,0.000004691902,0.0000036136323,0.0000033728693,0.000011996524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006845948,0.0003620999,0.00029185074,0.00019471286,0.000118907985,0.00033437228,0.00013752567,0.0002694974,0.002241125],"category_scores_gemma":[0.000054059783,0.00007895435,0.00018674837,0.00010152609,0.00017408609,0.00017845651,0.00013079686,0.0006354628,0.0005762436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003652396,0.00033184365,0.00046773918,0.00010230935,0.000020128506,0.00015677375,0.00004104281,0.00053150766,0.9793985,0.00055514823,0.0014040236,0.0166259],"study_design_scores_gemma":[0.00015543272,0.0024099294,0.004480383,0.000016019661,0.00006123186,0.0007236007,0.00004572416,0.0026387312,0.97332,0.00016522262,0.015975237,0.000008441446],"about_ca_topic_score_codex":0.0010253545,"about_ca_topic_score_gemma":0.0016037128,"teacher_disagreement_score":0.002241125,"about_ca_system_score_codex":0.00027332007,"about_ca_system_score_gemma":0.00028500255,"threshold_uncertainty_score":0.0074973702},"labels":[],"label_agreement":null},{"id":"W3216590746","doi":"10.1016/j.jcyt.2021.09.009","title":"ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products","year":2021,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; International Society for Cellular Therapy","funders":"","keywords":"Pharmacy; Genetic enhancement; Apheresis; Medicine; Chimeric antigen receptor; Cell therapy; Product (mathematics); Pharmacology; Cell; Gene; Internal medicine; Immunotherapy; Family medicine; Chemistry","score_opus":0.078084679215216,"score_gpt":0.35575757478656456,"score_spread":0.27767289557134855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216590746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8973752,0.010024041,0.0015432426,0.015424968,0.0003317237,0.000492616,0.022899654,0.00023609764,0.051672406],"genre_scores_gemma":[0.95965683,0.00840596,0.0020865444,0.009104514,0.000199091,0.00030420758,0.008924516,0.00012372716,0.011194616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943197,0.001251687,0.0011823887,0.00043617244,0.0019133238,0.0008967209],"domain_scores_gemma":[0.9213079,0.011019593,0.040370673,0.0014137595,0.016336193,0.009551931],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026980988,0.00019718427,0.00027488754,0.003195662,0.0007946285,0.0024554024,0.0007857441,0.0007835761,0.012022152],"category_scores_gemma":[0.017743602,0.00027081175,0.0004959497,0.00630885,0.0006615297,0.000691032,0.0013994684,0.0009213476,0.0018707544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027880503,0.00013569613,0.94862086,0.00052055676,0.00006778077,0.0004294436,0.0012421529,0.00022131395,0.0013036651,0.00042678282,0.014095452,0.032657553],"study_design_scores_gemma":[0.000017013226,0.00022476261,0.9593413,0.00074245554,0.000050229624,0.0007582332,0.0062025907,0.00018575811,0.00060408167,0.000046829784,0.031801797,0.000025040088],"about_ca_topic_score_codex":0.042575214,"about_ca_topic_score_gemma":0.042380244,"teacher_disagreement_score":0.9973019,"about_ca_system_score_codex":0.0047394806,"about_ca_system_score_gemma":0.0121460995,"threshold_uncertainty_score":0.08465481},"labels":[],"label_agreement":null},{"id":"W3217304519","doi":"10.1182/blood-2021-149261","title":"A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blinatumomab; Minimal residual disease; Medicine; Internal medicine; Oncology; Salvage therapy; Hematopoietic stem cell transplantation; Philadelphia chromosome; Transplantation; Maintenance therapy; Donor lymphocyte infusion; Lymphoblastic Leukemia; Leukemia; Immunology; Gastroenterology; Chemotherapy; Chromosomal translocation; Biology","score_opus":0.031048777727325987,"score_gpt":0.32337302358971287,"score_spread":0.29232424586238687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217304519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887706,0.0026288095,0.0010604272,0.0005899709,0.00016938234,0.00421431,0.0009561586,0.00014272076,0.0014677153],"genre_scores_gemma":[0.9833361,0.0029135696,0.0026205801,0.0009481713,0.00017133415,0.0047334856,0.0025212595,0.0000487875,0.002706647],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995105,0.00027841996,0.00002062915,0.000065378175,0.00004526351,0.000079820864],"domain_scores_gemma":[0.99927956,0.0001279759,0.000116223506,0.00007231397,0.000055813063,0.0003480348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002155221,0.0016222664,0.001667072,0.00049126317,0.00042523854,0.0011415135,0.0011144844,0.0013785812,0.0035842683],"category_scores_gemma":[0.00085083116,0.0006261494,0.0009658916,0.0005044045,0.0008995489,0.00069257536,0.00039571946,0.00390666,0.0010311464],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6550878,0.16205478,0.0041209967,0.0017385226,0.0013300185,0.00045944267,0.0005067883,0.0028260495,0.07192371,0.00045612428,0.0040714093,0.09542435],"study_design_scores_gemma":[0.58681875,0.40117118,0.0041423463,0.00004536235,0.0002844778,0.00025925107,0.000054398803,0.00077648106,0.0038246831,0.00016194317,0.0024446605,0.00001643536],"about_ca_topic_score_codex":0.0008540978,"about_ca_topic_score_gemma":0.001443908,"teacher_disagreement_score":0.0035842683,"about_ca_system_score_codex":0.0007470898,"about_ca_system_score_gemma":0.0016630373,"threshold_uncertainty_score":0.011990547},"labels":[],"label_agreement":null},{"id":"W3217363670","doi":"10.1182/blood-2021-146237","title":"Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Clinical trial; Internal medicine; Chimeric antigen receptor; Cost effectiveness; Immunotherapy; Cancer","score_opus":0.09148170366789479,"score_gpt":0.378496741030424,"score_spread":0.2870150373625292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217363670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75744957,0.013845685,0.17528063,0.006346527,0.00044154905,0.0073496834,0.021301534,0.00059553643,0.017389169],"genre_scores_gemma":[0.9750895,0.00087513495,0.016652675,0.0005131467,0.000082001665,0.0013681687,0.0028779788,0.00007035612,0.0024711792],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.98854476,0.009128486,0.00035796207,0.0006182724,0.0007682067,0.0005822923],"domain_scores_gemma":[0.9603113,0.033901684,0.002833415,0.0011210393,0.0011569359,0.0006756159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020042954,0.0014198532,0.002535672,0.0031280082,0.00029065728,0.0020318232,0.0027036397,0.0018619542,0.008963613],"category_scores_gemma":[0.03558053,0.0008634622,0.006942467,0.002448817,0.0006837248,0.0017310855,0.0015507024,0.0026821245,0.0005183003],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005938382,0.00080160855,0.021593282,0.00076351763,0.0033304,0.00020925073,0.000052913434,0.9175212,0.00044444413,0.013555537,0.0027450055,0.033044465],"study_design_scores_gemma":[0.00091297424,0.0020821618,0.008995698,0.00017505849,0.0018335024,0.0001711173,0.000096327494,0.9741784,0.00052155566,0.008008269,0.0029694866,0.000055494715],"about_ca_topic_score_codex":0.011350081,"about_ca_topic_score_gemma":0.004180963,"teacher_disagreement_score":0.020042954,"about_ca_system_score_codex":0.008358955,"about_ca_system_score_gemma":0.0036386652,"threshold_uncertainty_score":0.105998576},"labels":[],"label_agreement":null},{"id":"W3217474359","doi":"10.1016/j.prp.2021.153723","title":"Cancer immunotherapy: Challenges and limitations","year":2021,"lang":"en","type":"review","venue":"Pathology - Research and Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Immunosurveillance; Immunotherapy; Oncolytic virus; Cancer; Cancer immunotherapy; Medicine; Acquired resistance; Cancer research; Oncology; Immunology; Internal medicine","score_opus":0.503183840981943,"score_gpt":0.5564164942590247,"score_spread":0.05323265327708171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217474359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000195656,0.9958793,0.00011523065,0.0030507776,0.0005144889,0.000003239941,0.000011357097,0.000006877636,0.00039913005],"genre_scores_gemma":[0.000505908,0.995139,0.00036282217,0.0023467524,0.0013069344,0.000015721225,0.000020815842,0.0000034992456,0.0002984083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979627,0.0007899406,0.00024583435,0.00024526226,0.00058843446,0.00016793731],"domain_scores_gemma":[0.9878149,0.008483227,0.0006551858,0.00024687726,0.0022135542,0.0005862387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011095465,0.0014101597,0.004380704,0.0030670976,0.00085453334,0.0051480466,0.002458662,0.004272249,0.0077070347],"category_scores_gemma":[0.009821672,0.0006345777,0.001183455,0.0032082119,0.0031940888,0.007393706,0.0036671215,0.0075545595,0.003095459],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001416533,0.00007129687,0.00019944471,0.027736235,0.00014364834,0.00009065716,0.00012134242,0.00047117274,0.00038866917,0.019632788,0.089172535,0.8618306],"study_design_scores_gemma":[0.000050130566,0.00010247283,0.00034370384,0.020763747,0.00016215422,0.00030190306,0.00021957945,0.00020369054,0.00011351907,0.010781036,0.96692824,0.000029791532],"about_ca_topic_score_codex":0.0024469364,"about_ca_topic_score_gemma":0.006672382,"teacher_disagreement_score":0.011095465,"about_ca_system_score_codex":0.0029145929,"about_ca_system_score_gemma":0.008007686,"threshold_uncertainty_score":0.058679104},"labels":[],"label_agreement":null},{"id":"W3217544539","doi":"10.1016/j.cell.2021.11.016","title":"An NK-like CAR T cell transition in CAR T cell dysfunction","year":2021,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Stand Up To Cancer; National Cancer Institute; National Institutes of Health; Incyte; Parker Institute for Cancer Immunotherapy; Bayer Fund; American Cancer Society; Stand Up To Cancer Canada; AstraZeneca; Celgene; GlaxoSmithKline","keywords":"Chimeric antigen receptor; Biology; T cell; CD8; Cancer research; Mesothelin; T-cell receptor; Immunology; Cell biology; Antigen; Immune system","score_opus":0.019103117811009353,"score_gpt":0.2763343176554929,"score_spread":0.2572311998444835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217544539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647284,0.004941882,0.010631542,0.0019382869,0.00032500757,0.000102682934,0.0002973806,0.00067080144,0.016363991],"genre_scores_gemma":[0.99637103,0.00027427086,0.00056855835,0.00019087501,0.000038520637,0.000018546676,0.00006327909,0.000022714912,0.0024522026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996445,0.0000767281,0.000030071322,0.000074801595,0.000064344604,0.00010957115],"domain_scores_gemma":[0.9997583,0.000050305618,0.00005583863,0.00003986248,0.000029786224,0.00006581375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030834542,0.000452365,0.00034526637,0.00039527175,0.00045873143,0.0012455864,0.0005244976,0.0011332715,0.007077738],"category_scores_gemma":[0.00056147826,0.00018713623,0.00030639025,0.00014319007,0.00088243186,0.0010443024,0.0006517647,0.0017869541,0.0011379166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024906513,0.00040515396,0.009015167,0.00044378202,0.0000758636,0.010726373,0.0005545654,0.0011563554,0.8964615,0.039426662,0.0036995045,0.03554449],"study_design_scores_gemma":[0.00027775753,0.0022983127,0.026137093,0.000118202166,0.0001996153,0.07524692,0.0012453584,0.008654436,0.8014239,0.02106133,0.06328539,0.00005178063],"about_ca_topic_score_codex":0.00033082574,"about_ca_topic_score_gemma":0.00024574946,"teacher_disagreement_score":0.007077738,"about_ca_system_score_codex":0.00065657677,"about_ca_system_score_gemma":0.00042994536,"threshold_uncertainty_score":0.02367735},"labels":[],"label_agreement":null},{"id":"W3217693816","doi":"10.1007/978-3-030-81261-4_3","title":"Radioimaging of Activated T Cells in Preclinical and Clinical Cancer Investigations","year":2021,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; Immune system; Function (biology); Medicine; Cancer; Psychology; Cancer research; Computational biology; Immunology; Biology; Internal medicine; Cell biology","score_opus":0.15679950858505728,"score_gpt":0.4406685808928341,"score_spread":0.2838690723077768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217693816","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007129675,0.52642024,0.10771506,0.0027271926,0.0029058128,0.00017888394,0.00035889714,0.00080561946,0.3517585],"genre_scores_gemma":[0.03862978,0.31986275,0.05476682,0.0031732263,0.0011842981,0.0002883681,0.00046013552,0.00047506246,0.58115965],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998734,0.000023902534,0.0000040808422,0.000023005703,0.00006089673,0.000014752293],"domain_scores_gemma":[0.9998883,0.00007447486,0.000005692745,0.0000070011947,0.000016622342,0.0000079058855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052175863,0.0007201082,0.00057019776,0.00072996924,0.00024135887,0.0014262974,0.0009405921,0.0009789612,0.01119702],"category_scores_gemma":[0.0002392761,0.00036325696,0.00028411378,0.00066407665,0.0007187647,0.0014451713,0.00062275026,0.0016696285,0.0061277044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021138924,0.00021100877,0.00010718966,0.0023135815,0.000023461893,0.00039115277,0.00034428205,0.0024618271,0.18736081,0.15025671,0.09046363,0.5658549],"study_design_scores_gemma":[0.00001571076,0.00015784462,0.0001352849,0.00031192016,0.000021255888,0.0011655472,0.00006779839,0.0010667592,0.041759394,0.018166594,0.9371119,0.000020041794],"about_ca_topic_score_codex":0.0005702309,"about_ca_topic_score_gemma":0.0010798065,"teacher_disagreement_score":0.01119702,"about_ca_system_score_codex":0.000775911,"about_ca_system_score_gemma":0.00043004498,"threshold_uncertainty_score":0.037457824},"labels":[],"label_agreement":null},{"id":"W4200100973","doi":"10.1182/blood-2021-148009","title":"Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; B-cell lymphoma; Oncology; Lymphoma","score_opus":0.013679287038108634,"score_gpt":0.27678842652890645,"score_spread":0.26310913949079784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200100973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747517,0.0036934363,0.0017846874,0.0006083938,0.00017163866,0.010353541,0.005237565,0.00034531948,0.0030536652],"genre_scores_gemma":[0.97233385,0.0015394966,0.0033684948,0.0011208181,0.00022825004,0.010021394,0.006558069,0.000112196394,0.0047174976],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99912196,0.0004723527,0.000032982753,0.00016936641,0.000067430236,0.00013591503],"domain_scores_gemma":[0.9990159,0.00015035323,0.00017930208,0.000111825146,0.00010376376,0.00043875023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00372089,0.0019538242,0.002290236,0.0005070741,0.00051441276,0.0013206864,0.00095346995,0.0013249953,0.006066417],"category_scores_gemma":[0.0012344851,0.0008160213,0.0017905972,0.00041703816,0.00077872205,0.0007263792,0.00051734643,0.0026395104,0.001471612],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7982421,0.05537308,0.012718111,0.0016946837,0.003787706,0.0003220101,0.0002872864,0.0030772607,0.05344718,0.00035047362,0.007726452,0.06297371],"study_design_scores_gemma":[0.5703482,0.38676372,0.023609266,0.00007263374,0.0023027845,0.0004481897,0.00008003264,0.0017149822,0.0073764096,0.00034470818,0.0068964623,0.000042624557],"about_ca_topic_score_codex":0.0005835854,"about_ca_topic_score_gemma":0.0019519634,"teacher_disagreement_score":0.006066417,"about_ca_system_score_codex":0.0009793843,"about_ca_system_score_gemma":0.0020753003,"threshold_uncertainty_score":0.02029419},"labels":[],"label_agreement":null},{"id":"W4200266275","doi":"10.1002/hep.32279","title":"Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC","year":2021,"lang":"en","type":"article","venue":"Hepatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Genentech; National Cancer Institute; Eisai; Bristol-Myers Squibb","keywords":"Avidity; Cancer research; Monoclonal antibody; Epitope; Antigen; In vivo; Immunology; In vitro; Biology; Antibody; Biochemistry","score_opus":0.026228972041253212,"score_gpt":0.2889072019440803,"score_spread":0.2626782299028271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200266275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99783903,0.00042588502,0.00091739424,0.000032576816,0.000009454175,0.000020272344,0.00007532398,0.00004192727,0.0006382305],"genre_scores_gemma":[0.9970386,0.00020651433,0.0012546709,0.000057812063,0.000008926401,0.00002725928,0.00023075564,0.000008191483,0.0011672422],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999298,0.0000120832065,0.0000044814287,0.000010700096,0.000014613279,0.000028229173],"domain_scores_gemma":[0.9999491,0.000009851012,0.000011309017,0.0000060986567,0.0000074766785,0.000016114225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006186326,0.00031464276,0.0001590479,0.000106805644,0.00008556727,0.00016326655,0.00017404575,0.00021657978,0.00075560936],"category_scores_gemma":[0.00007773118,0.00007534665,0.00014008551,0.000060128903,0.000089050685,0.000117931566,0.00009261293,0.00046790217,0.00020520871],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011036992,0.000075750875,0.00020637285,0.000023584651,0.000005939013,0.000034280885,0.000009391405,0.00022168166,0.9960496,0.00007927064,0.00011195168,0.0030718264],"study_design_scores_gemma":[0.00012924512,0.0023258927,0.0067796917,0.0000077859995,0.000051801555,0.00054465776,0.000024360239,0.003568303,0.9814352,0.00006574525,0.0050583654,0.000008941741],"about_ca_topic_score_codex":0.00039115627,"about_ca_topic_score_gemma":0.00053836725,"teacher_disagreement_score":0.00075560936,"about_ca_system_score_codex":0.0002498964,"about_ca_system_score_gemma":0.00011663805,"threshold_uncertainty_score":0.0025277734},"labels":[],"label_agreement":null},{"id":"W4200335416","doi":"10.1182/blood-2021-153871","title":"A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; CD28; TIGIT; CD19; T cell; Antigen; Immunology; Cancer research; Biology; Medicine; Immune system","score_opus":0.025327477432969377,"score_gpt":0.2788545808456693,"score_spread":0.2535271034126999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200335416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981633,0.00046481134,0.0008879226,0.000046052955,0.000007902248,0.00001638021,0.00010177608,0.000053076034,0.00025896975],"genre_scores_gemma":[0.9982691,0.00011854069,0.00057530124,0.000031907624,0.0000035188057,0.000019380639,0.00019834591,0.000007502405,0.0007763494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990535,0.000011814047,0.0000050883255,0.000020556998,0.000026081,0.00003104914],"domain_scores_gemma":[0.99993896,0.000010586038,0.000010370192,0.000008868007,0.000008703893,0.000022524331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012802186,0.00015378572,0.00026382852,0.00015537627,0.0001617559,0.00028359712,0.0001652475,0.00019150796,0.0009737914],"category_scores_gemma":[0.00009540245,0.00008114209,0.0001421274,0.00012979063,0.00013299526,0.00011583967,0.00017769124,0.0005762881,0.00018711286],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002517676,0.00011058843,0.0008319971,0.00002457599,0.000007900569,0.000041173644,0.00002406631,0.0002005286,0.9942141,0.000041360898,0.00009075353,0.0041611046],"study_design_scores_gemma":[0.00012249075,0.004276465,0.019168552,0.000009008843,0.000062578394,0.0006834795,0.000058381007,0.00653309,0.9644313,0.000100293764,0.004547281,0.0000071155864],"about_ca_topic_score_codex":0.0006734273,"about_ca_topic_score_gemma":0.0010261739,"teacher_disagreement_score":0.0009737914,"about_ca_system_score_codex":0.00024914983,"about_ca_system_score_gemma":0.00017645046,"threshold_uncertainty_score":0.0032576323},"labels":[],"label_agreement":null},{"id":"W4200349633","doi":"10.1016/j.ccell.2021.12.005","title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","year":2021,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"Christian Doppler Forschungsgesellschaft; Deutsche Krebshilfe; National Cancer Institute; Entertainment Industry Foundation; Damon Runyon Cancer Research Foundation; Virginia and D.K. Ludwig Fund for Cancer Research; Stanford University; Canadian Institute for Advanced Research; Cancer Research Institute; Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung; Alex's Lemonade Stand Foundation for Childhood Cancer; Burroughs Wellcome Fund; National Institutes of Health; Canada Research Chairs; Howard Hughes Medical Institute","keywords":"Chimeric antigen receptor; Neuroblastoma; Antigen; Cancer research; Biology; Immune system; Cell culture; Cell biology; Immunology; T cell; Genetics","score_opus":0.02552886023817936,"score_gpt":0.30407623545582546,"score_spread":0.2785473752176461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200349633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98518544,0.0017341567,0.0058859386,0.00013595982,0.00006304007,0.00010060861,0.0005793066,0.00040226482,0.0059132604],"genre_scores_gemma":[0.99338716,0.0005972857,0.0016790942,0.00005882155,0.000013160835,0.000053985823,0.00048049312,0.000045754823,0.0036841582],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997812,0.000020966623,0.000010143071,0.00005359614,0.000052169427,0.0000818917],"domain_scores_gemma":[0.99992764,0.000020294252,0.000009293131,0.000013022514,0.000010464264,0.00001922939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016533953,0.0004309433,0.00038629756,0.00023076049,0.00019506109,0.00047766263,0.00027949136,0.00052885956,0.0023840917],"category_scores_gemma":[0.00012479644,0.00015408234,0.00023765114,0.000215567,0.00027571828,0.00030910273,0.00027492296,0.0012247127,0.00071298704],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005232601,0.000029167699,0.000046078912,0.000019004905,0.0000037005518,0.000019095563,0.000014378803,0.0000796435,0.99869627,0.000072891824,0.00010305504,0.0008643971],"study_design_scores_gemma":[0.000019593408,0.00029067314,0.0007076049,0.0000023685889,0.000013867133,0.00010515553,0.000018422881,0.0004399644,0.9964419,0.000022892842,0.0019344972,0.0000029578941],"about_ca_topic_score_codex":0.0016264925,"about_ca_topic_score_gemma":0.0023108074,"teacher_disagreement_score":0.0023840917,"about_ca_system_score_codex":0.00038588,"about_ca_system_score_gemma":0.00030169362,"threshold_uncertainty_score":0.007975578},"labels":[],"label_agreement":null},{"id":"W4200379562","doi":"10.1002/jha2.286","title":"Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma","year":2021,"lang":"en","type":"article","venue":"eJHaem","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; North York General Hospital; University Health Network","funders":"","keywords":"Medicine; Vincristine; Cytokine release syndrome; Rituximab; Internal medicine; Lymphoma; Oncology; Gastroenterology; Cyclophosphamide; Surgery; Chimeric antigen receptor; Chemotherapy; Immunotherapy; Cancer","score_opus":0.01654318805029646,"score_gpt":0.2790110379962011,"score_spread":0.2624678499459046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200379562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771459,0.007513004,0.0020978248,0.0019515518,0.0002198167,0.0001906485,0.00018102523,0.00026073,0.010439635],"genre_scores_gemma":[0.9963313,0.0011500397,0.00048035523,0.00080537936,0.00016770673,0.00001802601,0.000099305835,0.000010663185,0.0009373041],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998292,0.000024935107,0.000017380818,0.000029395731,0.000030465126,0.00006851955],"domain_scores_gemma":[0.99956316,0.0000921589,0.00011873319,0.000038000362,0.000028869945,0.00015921111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022940563,0.0005246596,0.0005782452,0.00040097712,0.00071772194,0.00041091733,0.0003607095,0.00091838295,0.0012010228],"category_scores_gemma":[0.00075289066,0.00024317094,0.0005468855,0.00030175547,0.0005256026,0.00046455167,0.00034080536,0.0013938001,0.00047724866],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000707235,0.00016963985,0.028459452,0.00010375328,0.000036801357,0.9489528,0.00018472136,0.00023789165,0.006737208,0.00018127295,0.0009181023,0.01331113],"study_design_scores_gemma":[0.00016674223,0.0021277585,0.058491282,0.00010052032,0.00009857383,0.9290488,0.00018323779,0.0015052087,0.004181056,0.00023212563,0.0038469215,0.000017726266],"about_ca_topic_score_codex":0.0014637902,"about_ca_topic_score_gemma":0.003583921,"teacher_disagreement_score":0.0014637902,"about_ca_system_score_codex":0.001115503,"about_ca_system_score_gemma":0.00059812266,"threshold_uncertainty_score":0.008093536},"labels":[],"label_agreement":null},{"id":"W4200426158","doi":"10.1101/2021.12.20.473538","title":"Delivery of CAR-T Cells in a Transient Injectable Stimulatory Hydrogel Niche Improves Treatment of Solid Tumors","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Bill and Melinda Gates Foundation; National Cancer Institute; National Science Foundation; National Institutes of Health; American Cancer Society","keywords":"Cancer research; Drug delivery; Cell; Medicine; Cell therapy; Materials science; Chemistry; Nanotechnology","score_opus":0.019270274563547917,"score_gpt":0.2598169713100371,"score_spread":0.2405466967464892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200426158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886115,0.0012094775,0.0074622235,0.00012803687,0.00005547162,0.00003718432,0.0002073338,0.0002377502,0.0020509379],"genre_scores_gemma":[0.99188966,0.00037173033,0.0049621207,0.000046414898,0.000015636735,0.000023403289,0.000116095965,0.00004493699,0.002530159],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999231,0.000008975325,0.000005606671,0.000016640479,0.000022237924,0.000023409435],"domain_scores_gemma":[0.99994946,0.000009771717,0.00001470187,0.000003247956,0.0000050007525,0.000017849234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012448148,0.00029611486,0.00017293691,0.00021048871,0.000081989194,0.0002249749,0.00010711458,0.00022034989,0.0016174815],"category_scores_gemma":[0.00006133892,0.000069657544,0.00014401069,0.00009592296,0.00017184955,0.00018350614,0.00012822356,0.00033935418,0.00027829086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053170945,0.000037921367,0.00006219563,0.000018716844,0.0000020745008,0.00001640506,0.000006067158,0.00013579722,0.99835986,0.00005156853,0.000048589205,0.001207634],"study_design_scores_gemma":[0.0000068472636,0.00011733776,0.00019698635,0.00000102817,0.0000035112494,0.000022893973,0.000003176136,0.00057098066,0.99869365,0.000007877546,0.00037473603,9.584842e-7],"about_ca_topic_score_codex":0.0003482724,"about_ca_topic_score_gemma":0.00040022001,"teacher_disagreement_score":0.0016174815,"about_ca_system_score_codex":0.00014961282,"about_ca_system_score_gemma":0.00017926627,"threshold_uncertainty_score":0.005411029},"labels":[],"label_agreement":null},{"id":"W4200449197","doi":"10.1182/blood-2021-146177","title":"Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Pomalidomide; Multiple myeloma; Medicine; Refractory (planetary science); Lenalidomide; Internal medicine; Thalidomide; Oncology; Surgery","score_opus":0.08879304162732031,"score_gpt":0.3271464727081697,"score_spread":0.2383534310808494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200449197","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09964076,0.8820576,0.0054130126,0.0014942571,0.0015393738,0.0006411764,0.0067071947,0.00023253482,0.0022740525],"genre_scores_gemma":[0.9343351,0.055442486,0.0030940345,0.0016991635,0.00051628926,0.00093743426,0.0029101851,0.00010252574,0.0009627486],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98098606,0.013673716,0.0017749026,0.0021140026,0.0010121736,0.0004391382],"domain_scores_gemma":[0.97710323,0.018414523,0.002140403,0.0011494267,0.0007771389,0.00041520622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0206029,0.0025973173,0.0128303245,0.0031864098,0.0005251361,0.0029863138,0.0022227764,0.0024680747,0.0041803536],"category_scores_gemma":[0.028596366,0.0011324729,0.05955345,0.00391868,0.00059917854,0.0013709337,0.001472942,0.003143381,0.0003994851],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011045903,0.00003127203,0.0049203727,0.015618633,0.9632815,0.000053636053,0.000027474784,0.001198503,0.00017391016,0.00010825775,0.0004578063,0.003082806],"study_design_scores_gemma":[0.002067141,0.00046584988,0.0047998847,0.00095764885,0.9896975,0.00003776525,0.000023459312,0.00074173725,0.00009617363,0.00032034586,0.0007757174,0.000016762608],"about_ca_topic_score_codex":0.007283594,"about_ca_topic_score_gemma":0.008580191,"teacher_disagreement_score":0.0206029,"about_ca_system_score_codex":0.001736202,"about_ca_system_score_gemma":0.0013817402,"threshold_uncertainty_score":0.10895985},"labels":[],"label_agreement":null},{"id":"W4205148539","doi":"10.1111/nyas.14724","title":"Strategies to overcome the side effects of chimeric antigen receptor T cell therapy","year":2022,"lang":"en","type":"review","venue":"Annals of the New York Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Chimeric antigen receptor; Cell therapy; Antigen; Receptor; Cytokine release syndrome; Cell; Immunotherapy; Immunology; T cell; Genetic enhancement; Immune system; Cancer research; Medicine; Biology; Gene; Internal medicine; Genetics","score_opus":0.19587190234869334,"score_gpt":0.43507989860712987,"score_spread":0.23920799625843653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205148539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021808386,0.9966439,0.0005615033,0.00043958405,0.00024425797,0.000008131363,0.000013386867,0.000014954083,0.001856271],"genre_scores_gemma":[0.0013416532,0.9964851,0.00055794447,0.0003708992,0.00018028443,0.00001322234,0.000029326764,0.0000029826072,0.0010186984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998642,0.000028580382,0.00001454958,0.00002288396,0.000055258664,0.000014427463],"domain_scores_gemma":[0.9998565,0.00007231867,0.000017876686,0.000006029646,0.000035025794,0.00001224208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046162677,0.0006959116,0.00084476755,0.0018000553,0.00018892747,0.0006542915,0.00063697965,0.0009649723,0.0037381344],"category_scores_gemma":[0.0004409987,0.00016918653,0.000565578,0.0009868112,0.00043986915,0.0010018793,0.0005231004,0.0021806343,0.0018305532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049437032,0.000119302145,0.00011582917,0.014095475,0.00007894999,0.00030213236,0.000056953904,0.00044745326,0.005333777,0.00875255,0.025346352,0.9453018],"study_design_scores_gemma":[0.000023078144,0.00011105137,0.00037793617,0.0018679362,0.000086858854,0.0017312357,0.000039217284,0.00012528281,0.0014753577,0.0024845856,0.99166346,0.000014017131],"about_ca_topic_score_codex":0.00048634253,"about_ca_topic_score_gemma":0.0009454925,"teacher_disagreement_score":0.0037381344,"about_ca_system_score_codex":0.00043552843,"about_ca_system_score_gemma":0.0006742612,"threshold_uncertainty_score":0.012505293},"labels":[],"label_agreement":null},{"id":"W4205454814","doi":"10.1200/jco.2022.40.4_suppl.tps363","title":"SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Internal medicine; Oncology; Gastroenterology; Adverse effect; Antigen; Phases of clinical research; Chemotherapy; Immunology","score_opus":0.3690196111746434,"score_gpt":0.5659463194330353,"score_spread":0.19692670825839192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205454814","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97834694,0.0028333047,0.0013369335,0.0009659924,0.0003763941,0.008065921,0.0020739876,0.00029925135,0.005701307],"genre_scores_gemma":[0.9633199,0.0022983004,0.0035749879,0.0019448388,0.00043596711,0.012359471,0.0034710264,0.000081639475,0.012513907],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999551,0.00020182933,0.000018290562,0.00009504892,0.000045498622,0.000088243534],"domain_scores_gemma":[0.9995902,0.00006052756,0.00007952624,0.000027809623,0.000022351203,0.00021962907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015247886,0.0023826587,0.0015845544,0.00044504952,0.00033557272,0.0012657709,0.0010854645,0.0016801833,0.01039384],"category_scores_gemma":[0.00076405855,0.0005808458,0.0008692067,0.00034513522,0.00085783284,0.0014669494,0.00041983713,0.003081261,0.0016233185],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81505436,0.05756874,0.0027498049,0.0017024498,0.000865616,0.00044204682,0.00036407338,0.002527598,0.033748828,0.0017591937,0.0066305758,0.076586634],"study_design_scores_gemma":[0.64241767,0.34513414,0.0024510017,0.00004536014,0.00021725782,0.00031658463,0.00007166549,0.0016032336,0.0021626146,0.0004184501,0.005128637,0.000033344968],"about_ca_topic_score_codex":0.00050795916,"about_ca_topic_score_gemma":0.0017589704,"teacher_disagreement_score":0.01039384,"about_ca_system_score_codex":0.00097002916,"about_ca_system_score_gemma":0.0013113299,"threshold_uncertainty_score":0.034770846},"labels":[],"label_agreement":null},{"id":"W4205468989","doi":"10.1007/s00262-021-03088-y","title":"Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; National Cancer Institute; Fundação para a Ciência e a Tecnologia; U.S. Food and Drug Administration; Swim Across America","keywords":"Oncolytic virus; Medicine; Cancer research; Melanoma; Immunotherapy; Immune system; FOXP3; Cytotoxic T cell; Immune checkpoint; Tumor microenvironment; Combination therapy; CD8; Immunology; Pharmacology; Biology","score_opus":0.026589077853391038,"score_gpt":0.3032453718668765,"score_spread":0.27665629401348546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205468989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996005,0.0002724044,0.0018377322,0.000087773304,0.00005603334,0.00004492232,0.00019220184,0.000093278926,0.0014106852],"genre_scores_gemma":[0.9957419,0.000119780736,0.0015935703,0.000030026798,0.000018228526,0.000047829773,0.0001554399,0.000024138259,0.0022689598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997824,0.000027172424,0.000013369271,0.000041993902,0.00006721918,0.00006787728],"domain_scores_gemma":[0.9999255,0.000008186451,0.000021639487,0.000007874162,0.0000054767643,0.000031287174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012234725,0.00035502226,0.00023428186,0.00030910567,0.0002035952,0.0002365234,0.00014106618,0.00036390702,0.0014045413],"category_scores_gemma":[0.000065292814,0.00013706824,0.00022912255,0.00012760176,0.00022935204,0.00024786472,0.00017757303,0.00080715393,0.00024396634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002238075,0.00009474464,0.000114178285,0.0000111451955,0.0000027380938,0.000045062217,0.000012305996,0.0000996544,0.9983524,0.0001418111,0.00006346457,0.00083863485],"study_design_scores_gemma":[0.000050804265,0.0009561665,0.0013720408,0.0000026637051,0.00001558469,0.00030760918,0.000032790027,0.0011044416,0.99396634,0.000075135904,0.0021121216,0.000004244966],"about_ca_topic_score_codex":0.0005764408,"about_ca_topic_score_gemma":0.00097140163,"teacher_disagreement_score":0.0014045413,"about_ca_system_score_codex":0.000204909,"about_ca_system_score_gemma":0.00023732008,"threshold_uncertainty_score":0.0046986938},"labels":[],"label_agreement":null},{"id":"W4205484767","doi":"10.1158/1078-0432.ccr-21-3261","title":"Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Neutropenia; Lymphoma; Internal medicine; Adverse effect; Phases of clinical research; Diffuse large B-cell lymphoma; Rituximab; Nausea; Gastroenterology; Pharmacokinetics; Oncology; Chemotherapy","score_opus":0.11104047886958199,"score_gpt":0.516506773739555,"score_spread":0.405466294869973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205484767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983475,0.00071180356,0.00011590953,0.000083204504,0.000012644574,0.00030237055,0.00009182991,0.000020703692,0.00031390568],"genre_scores_gemma":[0.99719846,0.0006407814,0.00055886596,0.00029212792,0.000042187283,0.00035284058,0.00041458575,0.000007625594,0.00049251405],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996697,0.00014250424,0.000020187514,0.000050963597,0.00005011614,0.00006651802],"domain_scores_gemma":[0.9996495,0.00006792434,0.00007530063,0.000033119908,0.000030361076,0.00014367547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010248345,0.0008585929,0.0013352978,0.00031860406,0.00023608605,0.0005159729,0.00048423134,0.00059798476,0.0012451813],"category_scores_gemma":[0.0006160805,0.00037064392,0.00058602536,0.00027764952,0.00049569446,0.0004741783,0.00024773265,0.0015196146,0.0004435179],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29221296,0.14596018,0.06768222,0.0013004956,0.0023430865,0.00078724796,0.0011309978,0.0067466493,0.12620644,0.00032669303,0.0042175176,0.35108548],"study_design_scores_gemma":[0.24457173,0.6785772,0.05808839,0.000051121006,0.0005843218,0.0008019781,0.00009801421,0.002807346,0.01018591,0.00016984006,0.004028152,0.0000360011],"about_ca_topic_score_codex":0.0005625855,"about_ca_topic_score_gemma":0.0010958597,"teacher_disagreement_score":0.0013352978,"about_ca_system_score_codex":0.0007261369,"about_ca_system_score_gemma":0.0007937786,"threshold_uncertainty_score":0.0054198503},"labels":[],"label_agreement":null},{"id":"W4205632133","doi":"10.51731/cjht.2021.187","title":"Brexucabtagene Autoleucel (Tecartus)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Mantle cell lymphoma; Chimeric antigen receptor; Bruton's tyrosine kinase; Medicine; CD19; Lymphoma; Drug; Immunotherapy; Cell therapy; Oncology; Tyrosine kinase; Pharmacology; Immunology; Internal medicine; Cell; Antigen; Receptor; Cancer; Biology; Health care; Political science","score_opus":0.05133370576819875,"score_gpt":0.3399551668119211,"score_spread":0.2886214610437224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205632133","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0151214935,0.95621204,0.0010340156,0.0016958023,0.00024306666,0.0001356416,0.00092231407,0.00007161627,0.024564035],"genre_scores_gemma":[0.19172241,0.77681714,0.0038842203,0.0022938787,0.0002452254,0.00019562579,0.002190762,0.000039347426,0.022611322],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945194,0.00012832528,0.00003532262,0.00003705502,0.00030465674,0.00004274135],"domain_scores_gemma":[0.9995004,0.00017680554,0.00012083772,0.000014356069,0.00014540507,0.000042245487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009652477,0.00017277984,0.00038259962,0.0010045575,0.0001924241,0.0007809853,0.00030666965,0.00037701902,0.0038076872],"category_scores_gemma":[0.0009814225,0.000057266454,0.00042884328,0.00082192296,0.00024122128,0.0002754209,0.0001609474,0.00052983715,0.00056299934],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055378623,0.00008313233,0.0012284192,0.0056184665,0.00023595987,0.00021928137,0.000048241258,0.00046235262,0.008193943,0.0038216172,0.026860477,0.95267445],"study_design_scores_gemma":[0.00024248796,0.0010191619,0.007440902,0.002721509,0.00032567087,0.0014884947,0.00007103351,0.00023886607,0.008046385,0.00036371427,0.97802246,0.000019368914],"about_ca_topic_score_codex":0.014800473,"about_ca_topic_score_gemma":0.054793444,"teacher_disagreement_score":0.9851995,"about_ca_system_score_codex":0.0022415004,"about_ca_system_score_gemma":0.0019845804,"threshold_uncertainty_score":0.029428601},"labels":[],"label_agreement":null},{"id":"W4205646931","doi":"10.1186/s42466-021-00166-5","title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","year":2022,"lang":"en","type":"article","venue":"Neurological Research and Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Cytokine release syndrome; Neurological examination; Post-concussion syndrome; Internal medicine; Oncology; Surgery; Concussion; Chimeric antigen receptor; Poison control; Immunotherapy; Toxicity; Emergency medicine; Injury prevention","score_opus":0.14597740654451466,"score_gpt":0.39636067233731453,"score_spread":0.2503832657927999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205646931","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979165,0.00061456335,0.0002468969,0.00004378068,0.00000534047,0.000023730681,0.00006867165,0.000006727259,0.0010737834],"genre_scores_gemma":[0.9993667,0.00024449234,0.00012483483,0.00004023034,0.00001623623,0.000008542815,0.00012063194,0.000001104448,0.00007727206],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973685,0.000064643944,0.000049864444,0.00004259831,0.00005303094,0.000053109892],"domain_scores_gemma":[0.9994535,0.00008405331,0.00023529559,0.000020228992,0.00008615727,0.00012076997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045789868,0.00025761855,0.00039765905,0.0007304633,0.00043519394,0.00037473862,0.00023911326,0.00030652934,0.0007145464],"category_scores_gemma":[0.001025632,0.00009514234,0.00022243969,0.00039121817,0.00030970626,0.00025016864,0.0002381915,0.00031301606,0.0001491536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030538157,0.00007729876,0.9781252,0.000030900355,0.00003197069,0.0108367745,0.00012141426,0.00011384417,0.0015836161,0.000017827917,0.00016952607,0.008586218],"study_design_scores_gemma":[0.000028691546,0.0010183816,0.9499738,0.0000458195,0.00006448639,0.046020985,0.00028100415,0.0004538407,0.0014815705,0.000061346494,0.0005569132,0.000013149609],"about_ca_topic_score_codex":0.0015079187,"about_ca_topic_score_gemma":0.0019258086,"teacher_disagreement_score":0.0015079187,"about_ca_system_score_codex":0.00040254567,"about_ca_system_score_gemma":0.0005579367,"threshold_uncertainty_score":0.0029982924},"labels":[],"label_agreement":null},{"id":"W4206052126","doi":"10.1016/j.jcyt.2021.10.010","title":"Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies","year":2022,"lang":"en","type":"review","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Canadian Blood Services; Ottawa Hospital","funders":"Canadian Blood Services","keywords":"Chimeric antigen receptor; CRISPR; Genome editing; Genetic enhancement; Cas9; Biology; Immune system; Cancer; Melanoma; Leukemia; Immunotherapy; Cancer research; Immunology; Gene; Computational biology; Medicine; Genetics","score_opus":0.40247571748708266,"score_gpt":0.48758415601826116,"score_spread":0.0851084385311785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206052126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014995813,0.99722195,0.00032685517,0.0001375485,0.00007548314,0.00010598579,0.00042522306,0.000010713876,0.0001966775],"genre_scores_gemma":[0.041442703,0.955437,0.0011692572,0.0008821876,0.00009094802,0.00023227623,0.00051286275,0.000019951669,0.00021281718],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996543,0.0012193106,0.00114976,0.00049100135,0.00047183214,0.0001251543],"domain_scores_gemma":[0.9898004,0.007619629,0.0017054793,0.00022426045,0.00054385985,0.00010641989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064690895,0.0016273389,0.010665006,0.0036508439,0.00029850806,0.002351534,0.001687553,0.0014982888,0.003739456],"category_scores_gemma":[0.015463059,0.0006718292,0.014917074,0.00467028,0.000565856,0.0011363443,0.0010539879,0.0013238316,0.00033041628],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001941375,0.000042435968,0.0020232522,0.7103111,0.22831519,0.000118026626,0.000097392636,0.0005569558,0.00082029414,0.00031201955,0.0018160043,0.05364582],"study_design_scores_gemma":[0.0010776636,0.00041312294,0.005231346,0.082049824,0.8974287,0.00021936178,0.00009764785,0.0001852928,0.00040070812,0.000562458,0.01227935,0.000054466007],"about_ca_topic_score_codex":0.0038824566,"about_ca_topic_score_gemma":0.010690722,"teacher_disagreement_score":0.010665006,"about_ca_system_score_codex":0.001457519,"about_ca_system_score_gemma":0.0028726112,"threshold_uncertainty_score":0.03421223},"labels":[],"label_agreement":null},{"id":"W4206063127","doi":"10.1016/j.jaci.2021.11.007","title":"Emerging strategies for treating autoimmune disorders with genetically modified Treg cells","year":2022,"lang":"en","type":"review","venue":"Journal of Allergy and Clinical Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cell therapy; Immunotherapy; Medicine; Immunology; Treg cell; Genetic enhancement; Genome editing; Clinical trial; T cell; Computational biology; Cell; Biology; Immune system; Bioinformatics; Gene; IL-2 receptor; CRISPR","score_opus":0.07861406624080433,"score_gpt":0.41250920472064845,"score_spread":0.3338951384798441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206063127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024996814,0.9974618,0.00061061676,0.00047023245,0.000425487,0.000010757605,0.000022595546,0.00002107509,0.00072753144],"genre_scores_gemma":[0.0023742898,0.9941251,0.001062926,0.00085911155,0.00054442964,0.000031967906,0.00007455742,0.0000047724093,0.00092274405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998636,0.000028795735,0.000013411044,0.00002394227,0.000047840196,0.000022299055],"domain_scores_gemma":[0.99981207,0.000104022496,0.000022261043,0.000008019181,0.00003519611,0.000018488628],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072378863,0.0009703171,0.0013797232,0.001034614,0.00019133934,0.0008917306,0.0010294087,0.0011158325,0.0029733784],"category_scores_gemma":[0.00056736113,0.0001933372,0.00061196904,0.0006655996,0.00047083697,0.0010066379,0.0005419535,0.0031019934,0.0012495446],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019270579,0.00017938446,0.00014444716,0.00754032,0.00012727884,0.00019820707,0.000026890699,0.00053391757,0.0054992978,0.0049731624,0.025019644,0.9555647],"study_design_scores_gemma":[0.00026613194,0.0005569013,0.0007611999,0.0027027188,0.00034686553,0.0013455718,0.000042534353,0.00033439306,0.0023220014,0.0041705263,0.9871199,0.000031274132],"about_ca_topic_score_codex":0.0004802464,"about_ca_topic_score_gemma":0.0011729643,"teacher_disagreement_score":0.0029733784,"about_ca_system_score_codex":0.00037641983,"about_ca_system_score_gemma":0.00057058595,"threshold_uncertainty_score":0.009946942},"labels":[],"label_agreement":null},{"id":"W4206319885","doi":"10.1002/jha2.375","title":"Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Celgene; Bristol-Myers Squibb","keywords":"Medicine; Rituximab; Internal medicine; Tolerability; Refractory (planetary science); Adverse effect; Diffuse large B-cell lymphoma; Gastroenterology; Clinical endpoint; Neutropenia; Phases of clinical research; Lymphoma; Pharmacodynamics; Oncology; Toxicity; Pharmacology; Clinical trial; Pharmacokinetics","score_opus":0.014674722346112092,"score_gpt":0.2874215979630838,"score_spread":0.2727468756169717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206319885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541086,0.0014349328,0.00030275402,0.00018480493,0.00005242255,0.0010650796,0.00036381316,0.000046658763,0.0011386528],"genre_scores_gemma":[0.99541336,0.0011767874,0.00092710933,0.00027397773,0.00006593727,0.0005930662,0.0007843439,0.000013468112,0.0007519411],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999655,0.00017147782,0.00002245677,0.000051866155,0.000036169826,0.000063063315],"domain_scores_gemma":[0.999567,0.000052890722,0.00007812136,0.000035963818,0.000028540568,0.00023737637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001207425,0.00096946885,0.0013372162,0.00036209336,0.00030895276,0.00080807897,0.00073482597,0.00065093656,0.0018647449],"category_scores_gemma":[0.0006115373,0.0005332197,0.00082529255,0.00037437282,0.0006188278,0.0006238385,0.00028280792,0.0020556953,0.00048051018],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49726954,0.14021166,0.019320954,0.0009026931,0.0023620827,0.0006381392,0.00063115056,0.006636684,0.14219809,0.0006036517,0.0048066513,0.18441866],"study_design_scores_gemma":[0.26963273,0.69881904,0.015289854,0.000037722653,0.00059672823,0.00048484612,0.00013664983,0.002187366,0.009267236,0.00019218739,0.0033177487,0.000037871632],"about_ca_topic_score_codex":0.0012508121,"about_ca_topic_score_gemma":0.0036076151,"teacher_disagreement_score":0.0018647449,"about_ca_system_score_codex":0.0009037895,"about_ca_system_score_gemma":0.0012204843,"threshold_uncertainty_score":0.0065574646},"labels":[],"label_agreement":null},{"id":"W4206716689","doi":"10.1126/science.abm0594","title":"CAR T cells produced in vivo to treat cardiac injury","year":2022,"lang":"en","type":"article","venue":"Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1241,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute","keywords":"In vivo; Chimeric antigen receptor; Cardiac fibrosis; Fibrosis; Cardiac function curve; Ex vivo; Antigen; Messenger RNA","score_opus":0.02245622904933814,"score_gpt":0.33541629015949165,"score_spread":0.3129600611101535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206716689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88850355,0.018843515,0.070072636,0.0020723667,0.0013887057,0.0009473208,0.00068659923,0.0017178573,0.015767578],"genre_scores_gemma":[0.9741232,0.0035803532,0.012915234,0.00069489283,0.00017263375,0.00037769444,0.0006516969,0.00007324455,0.0074110976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997726,0.000051018396,0.00001488974,0.000052448086,0.00005289908,0.000056174966],"domain_scores_gemma":[0.999897,0.000022864031,0.000024641999,0.000014383245,0.000015356509,0.000025741165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003869208,0.0005097278,0.00035599733,0.00032363422,0.00015698551,0.0003944936,0.00021652525,0.0007118596,0.0028986807],"category_scores_gemma":[0.00024250272,0.00016564503,0.00030232765,0.00015237393,0.00025672358,0.00024752534,0.00023747199,0.0015403191,0.00080293935],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023429465,0.0003021111,0.00025017263,0.00017426915,0.000027219392,0.00019999921,0.00006948243,0.0002944102,0.9839648,0.0010326047,0.0009101196,0.012540614],"study_design_scores_gemma":[0.00027972652,0.00341113,0.00088380405,0.0000320422,0.00012970027,0.0011547056,0.00005272492,0.0017065346,0.96237475,0.00033609895,0.02962886,0.00000996739],"about_ca_topic_score_codex":0.00026120676,"about_ca_topic_score_gemma":0.00028414547,"teacher_disagreement_score":0.0028986807,"about_ca_system_score_codex":0.00017899997,"about_ca_system_score_gemma":0.00027050727,"threshold_uncertainty_score":0.00969708},"labels":[],"label_agreement":null},{"id":"W4206737391","doi":"10.3390/cancers14030503","title":"Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Partenariat Canadien Contre Le Cancer; Australian Government; PA Research Foundation","keywords":"Prostate cancer; Medicine; Chimeric antigen receptor; Immunotherapy; Cancer; Clinical trial; Oncology; Targeted therapy; Prostate; Antigen; Internal medicine; Immunology","score_opus":0.1092525452124946,"score_gpt":0.4015275827211105,"score_spread":0.2922750375086159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206737391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016843237,0.99882585,0.000077279525,0.00009505716,0.000089512294,0.0000052167934,0.000009435948,0.0000065779936,0.00072259776],"genre_scores_gemma":[0.0011217733,0.99801105,0.00010836116,0.00014858793,0.000046869867,0.000006708611,0.000020911386,0.0000012525514,0.0005346607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999,0.000024758887,0.00001006829,0.000013426556,0.000040616946,0.00001117195],"domain_scores_gemma":[0.9999145,0.00004066994,0.000014419606,0.0000025428533,0.000019365081,0.000008487955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039452576,0.0004932019,0.0009452218,0.0012668987,0.00014347586,0.00050169264,0.00051378214,0.00074380176,0.0022841915],"category_scores_gemma":[0.00030016358,0.00016065149,0.0004988812,0.0010558888,0.0002406578,0.00050905946,0.00035431172,0.0012780519,0.0011586131],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014539015,0.00009600781,0.00009209816,0.02295722,0.00012881825,0.00018734134,0.000055010638,0.0007060216,0.0033531229,0.0038618783,0.026857262,0.94155985],"study_design_scores_gemma":[0.000064989756,0.00027264553,0.00065832725,0.00471987,0.00016322458,0.0011505684,0.000035655965,0.00018618004,0.00095008523,0.0014557403,0.99032754,0.000015160506],"about_ca_topic_score_codex":0.0009889803,"about_ca_topic_score_gemma":0.0017606826,"teacher_disagreement_score":0.0022841915,"about_ca_system_score_codex":0.00039967863,"about_ca_system_score_gemma":0.00057853933,"threshold_uncertainty_score":0.0076414347},"labels":[],"label_agreement":null},{"id":"W4207068215","doi":"","title":"CAR T Cells Produced in vivo to Treat Cardiac Injury","year":2023,"lang":"en","type":"article","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":940,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"In vivo; Spleen; Chimeric antigen receptor; Messenger RNA; Fibrosis; Ex vivo; Antigen; Cardiac fibrosis; Immunology; Cell biology; Cancer research; Biology; Medicine; T cell; Pathology; Immune system; Gene","score_opus":0.019403636445179194,"score_gpt":0.2824189550589764,"score_spread":0.26301531861379723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207068215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91553485,0.0145978965,0.03577019,0.0024000958,0.002008917,0.00095076836,0.0009105692,0.0010099086,0.026816897],"genre_scores_gemma":[0.9724897,0.003271064,0.00605404,0.000511161,0.0003941055,0.00035422458,0.00059611787,0.00012386896,0.016205592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99962807,0.00008151469,0.000025085996,0.00007810006,0.000060098566,0.0001271017],"domain_scores_gemma":[0.9997694,0.000080199825,0.000033828575,0.00002532817,0.00003286529,0.00005832542],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075301295,0.00080789416,0.0006699408,0.000580478,0.00031846343,0.0010649561,0.00040763684,0.0014188017,0.009441729],"category_scores_gemma":[0.00035582494,0.00022979573,0.00062623894,0.00021549239,0.0005296405,0.00045197472,0.00028981885,0.0027439923,0.002083642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001104539,0.00074504357,0.00011003246,0.00020571498,0.000030134148,0.0002921085,0.00011017422,0.00042494663,0.98735064,0.001211624,0.0006343082,0.0077808285],"study_design_scores_gemma":[0.0008325111,0.0056862277,0.000661848,0.000048549617,0.00017658649,0.000514007,0.00012196389,0.0012991802,0.97605103,0.0003851971,0.014212553,0.000010303711],"about_ca_topic_score_codex":0.0004587712,"about_ca_topic_score_gemma":0.00036557694,"teacher_disagreement_score":0.009441729,"about_ca_system_score_codex":0.00030653254,"about_ca_system_score_gemma":0.0004618684,"threshold_uncertainty_score":0.031585753},"labels":[],"label_agreement":null},{"id":"W4210288800","doi":"10.1016/j.crmeth.2021.100153","title":"Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions","year":2022,"lang":"en","type":"article","venue":"Cell Reports Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation Charles-Bruneau","keywords":"Immune system; Humanized mouse; Nivolumab; Cancer research; Cell; Induced pluripotent stem cell; Cancer cell; Biology; Immunology; Immunotherapy; Cancer; Embryonic stem cell","score_opus":0.053789948680657215,"score_gpt":0.37606945984131085,"score_spread":0.3222795111606536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210288800","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84701675,0.0042819656,0.13160792,0.0005658618,0.0004531797,0.00082789746,0.0046016946,0.0014303108,0.009214428],"genre_scores_gemma":[0.9444755,0.003428233,0.03767266,0.0001619482,0.000048773923,0.00065005914,0.0029279052,0.0001971909,0.010437827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99968934,0.000054310185,0.00003764684,0.00007991193,0.000098933415,0.000039919305],"domain_scores_gemma":[0.99971205,0.000055109278,0.00008650127,0.00007632021,0.000022001632,0.00004788717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000523904,0.0008741232,0.0003902209,0.0007848761,0.00021635191,0.00066420954,0.0004386358,0.00069010106,0.0038280133],"category_scores_gemma":[0.0001687726,0.00025238012,0.00044419698,0.00023757797,0.0004871183,0.00051183667,0.0003175436,0.0018218047,0.00090687326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015413499,0.00015946256,0.00031181859,0.0000913197,0.000017841707,0.00014736771,0.000041512063,0.00031706993,0.99355185,0.0011409919,0.00023180369,0.0038349167],"study_design_scores_gemma":[0.000027495604,0.00038016753,0.00070409314,0.000017320483,0.000036876467,0.0005191249,0.00002396156,0.0013098443,0.9894224,0.000176465,0.0073761772,0.000006054169],"about_ca_topic_score_codex":0.00026891349,"about_ca_topic_score_gemma":0.0005388403,"teacher_disagreement_score":0.0038280133,"about_ca_system_score_codex":0.00028385493,"about_ca_system_score_gemma":0.00035423992,"threshold_uncertainty_score":0.012805998},"labels":[],"label_agreement":null},{"id":"W4210397134","doi":"10.1038/s41551-021-00820-y","title":"Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting","year":2022,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Cell sorting; Immunomagnetic separation; Flow cytometry; Cell; Tumor-infiltrating lymphocytes; Cancer research; Potency; T cell; Chemistry; Immunology; Biology; Molecular biology; Immunotherapy; In vitro; Immune system; Biochemistry","score_opus":0.01051781438049039,"score_gpt":0.2729824301814051,"score_spread":0.26246461580091474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210397134","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6862692,0.0033046594,0.29607022,0.0011106962,0.00023589657,0.0006128929,0.0013013496,0.002353923,0.008741144],"genre_scores_gemma":[0.9340148,0.0012897935,0.053767458,0.00030489097,0.00006878334,0.00033919237,0.0010286814,0.0002176895,0.008968657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99944526,0.0000880198,0.00003044852,0.000075290125,0.00023180687,0.00012903559],"domain_scores_gemma":[0.99984515,0.000052391802,0.000021328284,0.00002848683,0.000029598854,0.000023112454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005298907,0.00049908884,0.00043258053,0.00036852044,0.00021722958,0.00087607105,0.0004421445,0.000561669,0.0021102892],"category_scores_gemma":[0.0003489604,0.00019519652,0.00023126774,0.0002712614,0.00034013594,0.0003258792,0.0006379851,0.0013177478,0.001416284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005947581,0.000029036602,0.00005114906,0.00003249496,0.0000031496052,0.000013605834,0.000021202606,0.00014498516,0.994918,0.00043515008,0.00021273506,0.0040790676],"study_design_scores_gemma":[0.000016657388,0.0000640491,0.00023886985,0.0000035188157,0.0000062613,0.00006353945,0.000008658172,0.002277781,0.99405,0.000113898284,0.003152631,0.0000040644404],"about_ca_topic_score_codex":0.0003606007,"about_ca_topic_score_gemma":0.0008194974,"teacher_disagreement_score":0.0021102892,"about_ca_system_score_codex":0.00033625867,"about_ca_system_score_gemma":0.00028266018,"threshold_uncertainty_score":0.0070596933},"labels":[],"label_agreement":null},{"id":"W4210408999","doi":"10.51731/cjht.2022.250","title":"Idecabtagene Vicleucel (Abecma)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Drug; Pharmacology; Intensive care medicine; Health care; Political science","score_opus":0.0544646208570626,"score_gpt":0.33944166122287556,"score_spread":0.28497704036581295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210408999","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0126437135,0.67641604,0.0030150427,0.010198402,0.0029041157,0.0005730009,0.005502223,0.00052139256,0.2882261],"genre_scores_gemma":[0.1929424,0.4996087,0.015288592,0.0206231,0.0017903715,0.0006595145,0.01143513,0.00017783362,0.25747436],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960726,0.00007311203,0.000028950515,0.00004262058,0.00019282637,0.00005530704],"domain_scores_gemma":[0.99935263,0.00013575907,0.00013541071,0.00002028891,0.00023173587,0.00012415147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009470729,0.00031098918,0.00035138702,0.00091825303,0.00030623958,0.0010274579,0.00051012344,0.0007020891,0.019218937],"category_scores_gemma":[0.001232985,0.00010342243,0.00048805622,0.00055690913,0.0003743441,0.00040544235,0.00024445623,0.00074779993,0.004141448],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093716197,0.00009923067,0.00086912484,0.002647056,0.00011788598,0.00021679966,0.000029405437,0.00017571528,0.0059358287,0.005387638,0.17018437,0.81339985],"study_design_scores_gemma":[0.0004320502,0.0006191546,0.0029023911,0.0008867826,0.00010101413,0.0005996101,0.000023661,0.000121413046,0.004237904,0.00037310983,0.9896876,0.00001521915],"about_ca_topic_score_codex":0.029685428,"about_ca_topic_score_gemma":0.11255678,"teacher_disagreement_score":0.029685428,"about_ca_system_score_codex":0.0026568107,"about_ca_system_score_gemma":0.004702015,"threshold_uncertainty_score":0.0642938},"labels":[],"label_agreement":null},{"id":"W4210794959","doi":"10.1016/j.jtct.2022.01.024","title":"Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Chemoimmunotherapy; Population; Oncology; Internal medicine; Autologous stem-cell transplantation; Chimeric antigen receptor; Transplantation; Lymphoma; Surgery; Rituximab; Cancer; Immunotherapy","score_opus":0.024267220530368058,"score_gpt":0.31477420058418687,"score_spread":0.2905069800538188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210794959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997747,0.0002186061,0.0003304381,0.000072857474,0.0000058367664,0.00002087561,0.0011594481,0.000008237968,0.00043678525],"genre_scores_gemma":[0.9986683,0.00004999857,0.00009154318,0.00003802363,0.0000070093433,0.000019540284,0.0010240766,0.0000075705857,0.00009389961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99551696,0.0022635611,0.0003451813,0.000973616,0.00044594333,0.0004546245],"domain_scores_gemma":[0.9836369,0.007275123,0.00613768,0.0009624765,0.00096661714,0.0010212185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041060084,0.000319294,0.0007010641,0.0012425026,0.0004777206,0.001628683,0.001073628,0.0012967853,0.0026414683],"category_scores_gemma":[0.013108953,0.00031454352,0.0010987713,0.0015549072,0.00079459336,0.001473052,0.0011743328,0.0012380129,0.0006685402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011759682,0.00012278675,0.99438137,0.00002153788,0.00037820713,0.00009460017,0.000121888166,0.00063013996,0.00020091898,0.00010686909,0.00042589896,0.002339842],"study_design_scores_gemma":[0.00005635439,0.0006283686,0.9931717,0.000013335167,0.00025818063,0.00052106497,0.0006576406,0.003480948,0.00013599212,0.0001807952,0.00086406444,0.00003157212],"about_ca_topic_score_codex":0.0030622461,"about_ca_topic_score_gemma":0.0032081997,"teacher_disagreement_score":0.0041060084,"about_ca_system_score_codex":0.0008897523,"about_ca_system_score_gemma":0.00039611573,"threshold_uncertainty_score":0.021714926},"labels":[],"label_agreement":null},{"id":"W4210799906","doi":"10.3389/fonc.2022.815726","title":"The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunogenicity; Adverse effect; Radiation therapy; Chemotherapy; Central nervous system; Immunotherapy; Cancer; Oncology; Bioinformatics; Antigen; Immunology; Internal medicine; Biology","score_opus":0.029027235051284062,"score_gpt":0.32304472279875185,"score_spread":0.2940174877474678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210799906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009716588,0.8247145,0.012698159,0.14187902,0.0024478266,0.00010902811,0.00022597419,0.00024524963,0.007963753],"genre_scores_gemma":[0.05577538,0.87740016,0.02320171,0.030641466,0.0069478387,0.00035361008,0.00033578346,0.00014148996,0.0052025495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988175,0.00043769737,0.000089306566,0.0001383223,0.0002773966,0.00023976839],"domain_scores_gemma":[0.9965252,0.002051941,0.00024504334,0.00011736381,0.00054054585,0.0005198329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054571005,0.000637126,0.0012903983,0.0009081937,0.00072330394,0.00381798,0.0010723895,0.0030882573,0.008646826],"category_scores_gemma":[0.0032491833,0.0003405001,0.0010243981,0.00058933464,0.0025783768,0.007844584,0.0017328802,0.0077134734,0.0025029453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008249951,0.0007819371,0.0019753592,0.004249539,0.00014219356,0.0012509144,0.00055338955,0.00362466,0.016341848,0.07400239,0.115001686,0.78125113],"study_design_scores_gemma":[0.00025364998,0.0021891526,0.0018699473,0.0027005782,0.00017478039,0.002849099,0.0013013287,0.0037424834,0.0077295713,0.049493987,0.9276094,0.000086117056],"about_ca_topic_score_codex":0.0010827638,"about_ca_topic_score_gemma":0.0031972453,"teacher_disagreement_score":0.008646826,"about_ca_system_score_codex":0.0013354224,"about_ca_system_score_gemma":0.0033006538,"threshold_uncertainty_score":0.028926492},"labels":[],"label_agreement":null},{"id":"W4211196581","doi":"10.23977/misbp.2021036","title":"Universal CAR T cell: engineering of universal T cell, modular CAR system, and applications","year":2021,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Modular design; Computer science; Immunogenicity; T cell; Antigen; Biology; Immune system; Immunology; Operating system","score_opus":0.009362667109904795,"score_gpt":0.2306318754622036,"score_spread":0.2212692083522988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211196581","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26197276,0.021567456,0.66680187,0.0013534026,0.0010707825,0.00063373864,0.0006085748,0.0022212772,0.043770183],"genre_scores_gemma":[0.73453635,0.009392362,0.23134683,0.00055925245,0.00018858236,0.00051535416,0.0006790804,0.00020527662,0.022576861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997136,0.000036917012,0.000017266013,0.00007194501,0.000100203,0.000060051687],"domain_scores_gemma":[0.9999176,0.00000826677,0.000017499218,0.000010375975,0.000025960346,0.000020168964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035904898,0.00045601916,0.00027457427,0.00055672816,0.00032510186,0.00058927166,0.00043971295,0.00072339486,0.0020285076],"category_scores_gemma":[0.0002263286,0.00024174902,0.00043560023,0.00042839197,0.00033984293,0.0006561164,0.00056667364,0.00064673746,0.00087527005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015202753,0.00009420745,0.0009273952,0.00057398726,0.000023843008,0.00047199344,0.00025052365,0.00481872,0.8525769,0.033779956,0.0039002683,0.10243016],"study_design_scores_gemma":[0.000044924378,0.0010606903,0.00107872,0.000060131402,0.00006541291,0.0025600547,0.00012749524,0.019250272,0.76728445,0.004041286,0.20435923,0.00006737732],"about_ca_topic_score_codex":0.00052261696,"about_ca_topic_score_gemma":0.00043235155,"teacher_disagreement_score":0.0020285076,"about_ca_system_score_codex":0.00044731563,"about_ca_system_score_gemma":0.00055460574,"threshold_uncertainty_score":0.006785989},"labels":[],"label_agreement":null},{"id":"W4211260249","doi":"10.3324/haematol.2021.279486","title":"A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"David och Astrid Hageléns Stiftelse; Barncancerfonden; Vetenskapsrådet; Cancerfonden","keywords":"CD34; Stem cell; CD38; Myeloid leukemia; Cancer research; Haematopoiesis; Leukemia; In vivo; Myeloid; Ex vivo; Transplantation; Immunology; Biology; Medicine; Cell biology; Internal medicine","score_opus":0.024029043832638153,"score_gpt":0.25015882293189984,"score_spread":0.22612977909926169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211260249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713897,0.0014944075,0.023545481,0.00016468877,0.000032697484,0.00017272538,0.0003166039,0.00041216312,0.0024715522],"genre_scores_gemma":[0.98699737,0.0006279593,0.008896175,0.00012552192,0.000010564015,0.00008162261,0.0005495167,0.000028151422,0.0026830581],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998411,0.000024834235,0.000010551379,0.000032694617,0.000052311305,0.00003837593],"domain_scores_gemma":[0.9999591,0.0000051655006,0.0000136657,0.000004072809,0.0000041868298,0.000013778819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011012138,0.000433367,0.00017840597,0.00017585,0.000072200135,0.00018215738,0.00021864966,0.00030597224,0.0009346526],"category_scores_gemma":[0.00010789049,0.00011815218,0.00015283856,0.00013161835,0.00012518653,0.0001454921,0.00024169647,0.0005284653,0.00032017037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000075758675,0.000064814354,0.00007339247,0.00002489613,0.000004664164,0.00003205103,0.000006553732,0.00024295105,0.995815,0.00011159852,0.00009430199,0.0034540584],"study_design_scores_gemma":[0.000046309673,0.00097112346,0.0010840963,0.0000040083783,0.00001880886,0.00036054614,0.0000071738314,0.0028732857,0.99051636,0.000052081024,0.0040598325,0.000006425891],"about_ca_topic_score_codex":0.00022536711,"about_ca_topic_score_gemma":0.0003939981,"teacher_disagreement_score":0.0009346526,"about_ca_system_score_codex":0.00015384937,"about_ca_system_score_gemma":0.000153181,"threshold_uncertainty_score":0.0031267405},"labels":[],"label_agreement":null},{"id":"W4213184823","doi":"10.1016/j.omtm.2022.02.004","title":"Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular function","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of Victoria","funders":"National Human Genome Research Institute; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Victoria University; Cancer Prevention and Research Institute of Texas","keywords":"Ex vivo; Glutamine; In vivo; Phenotype; Function (biology); Cell biology; Cell growth; Biology; Cell; T cell; Carbohydrate metabolism; Metabolism; Cancer research; Biochemistry; Immunology; Immune system; Genetics","score_opus":0.09640898408945156,"score_gpt":0.41555566239564085,"score_spread":0.31914667830618926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213184823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827691,0.003336612,0.009027463,0.00014474023,0.00008281089,0.00016866857,0.00048571013,0.00016624549,0.003818807],"genre_scores_gemma":[0.98263204,0.0022906226,0.011417835,0.00012418242,0.000041739517,0.00030099833,0.00083424913,0.000064743916,0.0022936284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997595,0.00008578234,0.000025109543,0.000036553545,0.00006126526,0.00003179197],"domain_scores_gemma":[0.9998281,0.000072054194,0.000037039423,0.000015420857,0.000023681187,0.000023600292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029274085,0.00047986864,0.00022474398,0.00028171748,0.00013789177,0.0005429209,0.00015650902,0.0002541811,0.0017242702],"category_scores_gemma":[0.00034642548,0.0001146912,0.0001549843,0.00019836606,0.00025052475,0.0002779748,0.00031909434,0.0005616875,0.0003941878],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056172104,0.00012488381,0.00048360135,0.000106373926,0.0000066146617,0.00006432939,0.000050177092,0.00023847668,0.9929848,0.00017438727,0.000110074914,0.005094623],"study_design_scores_gemma":[0.00002723206,0.00067243597,0.0013110765,0.000012874891,0.000020881735,0.00013672463,0.000034966186,0.0003674772,0.99519026,0.00003999213,0.0021807223,0.000005210043],"about_ca_topic_score_codex":0.00015032124,"about_ca_topic_score_gemma":0.00031305754,"teacher_disagreement_score":0.0017242702,"about_ca_system_score_codex":0.00018133438,"about_ca_system_score_gemma":0.00023248834,"threshold_uncertainty_score":0.0057682395},"labels":[],"label_agreement":null},{"id":"W4213272099","doi":"10.1097/01.cot.0000290089.84253.32","title":"SHOP TALK","year":2005,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.032047386799668884,"score_gpt":0.37364294097034956,"score_spread":0.34159555417068066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213272099","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006687526,0.0022013858,0.0021277696,0.01869001,0.0556355,0.00027140626,0.0024408053,0.0029847205,0.9149797],"genre_scores_gemma":[0.001787989,0.00092206686,0.00053530466,0.0062478175,0.0058744466,0.00008002828,0.0012466466,0.000685486,0.9826203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99905556,0.00011498498,0.000042575943,0.0001990299,0.00043551094,0.00015234255],"domain_scores_gemma":[0.9965636,0.00028764285,0.000088766625,0.00022897306,0.0012313753,0.0015996373],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009188845,0.0012268528,0.0008790026,0.001298925,0.0019985475,0.006112515,0.0015484218,0.0032151085,0.85443544],"category_scores_gemma":[0.0049702358,0.00038571906,0.00081823254,0.0008259432,0.00045750386,0.0031782705,0.0037413093,0.0032929152,0.7800617],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021498348,0.000018347539,0.000050732328,0.000037719157,0.000001600291,0.00004667708,0.000018457404,0.000013957619,0.00008849327,0.00084671215,0.96346086,0.03539479],"study_design_scores_gemma":[0.000005088925,0.000008489662,0.000104278886,0.000026790101,0.0000010333721,0.00006328218,0.00004826654,0.000016683332,0.000032221113,0.0003633942,0.9993272,0.000003349876],"about_ca_topic_score_codex":0.0011429486,"about_ca_topic_score_gemma":0.0024635307,"teacher_disagreement_score":0.14556456,"about_ca_system_score_codex":0.0010663494,"about_ca_system_score_gemma":0.0016794564,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4214859401","doi":"10.1182/blood.2022015789","title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","year":2022,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Chimeric antigen receptor; Oncology; Lymphoma; Internal medicine; Chemotherapy; Autologous stem-cell transplantation; Transplantation; Refractory (planetary science); Cell therapy; Surgery; Stem cell; Immunotherapy; Cancer; Biology","score_opus":0.058664802153939176,"score_gpt":0.3534623504236394,"score_spread":0.2947975482697002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214859401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007531463,0.99892235,0.000044770484,0.00043527494,0.00019328392,0.000004464907,0.000009534613,0.000002909535,0.00031213355],"genre_scores_gemma":[0.0005027739,0.99855286,0.00011457485,0.0004946342,0.0001175266,0.00000927654,0.000015139573,0.0000012056439,0.0001920179],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978393,0.000067670175,0.00003310327,0.000035443663,0.00006035114,0.000019508907],"domain_scores_gemma":[0.99957556,0.00025154257,0.000054467175,0.000010176511,0.00008462858,0.000023676424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011766483,0.0006003693,0.0018457709,0.001341036,0.00016714293,0.0010848076,0.0010788799,0.0014037223,0.0029105118],"category_scores_gemma":[0.0011267838,0.00021775422,0.00075767335,0.0013252564,0.00043631427,0.0014123524,0.0004379546,0.0023011807,0.0013725511],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022155588,0.0000695501,0.00009414616,0.04522893,0.00025165812,0.00014498319,0.00005494153,0.0003191721,0.0011622821,0.005052886,0.029392542,0.91800725],"study_design_scores_gemma":[0.00020037264,0.00033698685,0.00067838613,0.020812403,0.0006206965,0.0012553353,0.000094416464,0.00013290385,0.00041175287,0.002841855,0.97258943,0.000025575227],"about_ca_topic_score_codex":0.00081326044,"about_ca_topic_score_gemma":0.0018362367,"teacher_disagreement_score":0.0029105118,"about_ca_system_score_codex":0.00056559284,"about_ca_system_score_gemma":0.0012130367,"threshold_uncertainty_score":0.009736657},"labels":[],"label_agreement":null},{"id":"W4220688343","doi":"10.1080/10428194.2022.2043299","title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; National Cancer Institute; Celgene; CLL Global Research Foundation","keywords":"Lenalidomide; Chronic lymphocytic leukemia; Chimeric antigen receptor; CD23; Cancer research; T cell; Antigen; Immunology; Leukemia; Medicine; Immune system; Multiple myeloma; Immunoglobulin E; Antibody","score_opus":0.01615558200279773,"score_gpt":0.26819361320453683,"score_spread":0.2520380312017391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220688343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864694,0.006606616,0.0017206715,0.00015618849,0.000058140657,0.00012548757,0.00024012994,0.00014312065,0.004480258],"genre_scores_gemma":[0.9948782,0.0017700666,0.0012511305,0.0000464635,0.000019977455,0.000040251023,0.00017414754,0.000017291504,0.0018024158],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998555,0.000033022898,0.000009212999,0.000018493152,0.00003333886,0.00005044465],"domain_scores_gemma":[0.99996316,0.000005404959,0.000007402175,0.00000475999,0.0000037560258,0.000015488045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000153552,0.00032599416,0.00034343684,0.0003118377,0.00014849528,0.0004922403,0.0002463923,0.00023580574,0.0009982445],"category_scores_gemma":[0.00007178041,0.000101730286,0.00019051047,0.00021877229,0.00018341729,0.0002116019,0.00022843653,0.0005197793,0.00031235188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001713488,0.001023106,0.0011260629,0.00019953198,0.000043411856,0.00022917613,0.00009513479,0.0017386617,0.94568545,0.0009378119,0.0008484569,0.04635976],"study_design_scores_gemma":[0.0006635954,0.0087771695,0.007602838,0.000018725894,0.0001391079,0.0014079437,0.000055010965,0.0037666617,0.94625723,0.0001929604,0.031097008,0.000021846447],"about_ca_topic_score_codex":0.0018732053,"about_ca_topic_score_gemma":0.0036904276,"teacher_disagreement_score":0.0018732053,"about_ca_system_score_codex":0.0005162371,"about_ca_system_score_gemma":0.00037159317,"threshold_uncertainty_score":0.0037455559},"labels":[],"label_agreement":null},{"id":"W4220744522","doi":"10.1016/s2666-6367(22)00583-8","title":"Cost-Effectiveness of Brexucabtagene Autoleucel Versus Best Supportive Care for the Treatment of Relapsed/ Refractory Mantle Cell Lymphoma Following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mantle cell lymphoma; Refractory (planetary science); Bruton's tyrosine kinase; Ibrutinib; Internal medicine; Lymphoma; Oncology; Cancer research; Tyrosine kinase; Leukemia; Metallurgy","score_opus":0.033842856003265726,"score_gpt":0.2919828620676587,"score_spread":0.258140006064393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220744522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98503995,0.009413732,0.00013380132,0.0016749133,0.000077471654,0.00018159689,0.00083574606,0.00001443162,0.0026283513],"genre_scores_gemma":[0.99668676,0.0020113883,0.00016341379,0.00018619739,0.000022540384,0.000026089017,0.0003224018,0.0000030608458,0.0005781672],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99930584,0.00022827066,0.000048490932,0.00006366723,0.0001266418,0.00022710983],"domain_scores_gemma":[0.9988201,0.00019724404,0.00019883484,0.000017654851,0.00014825483,0.0006178876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056799874,0.00031502967,0.00076588575,0.000523727,0.00045559226,0.0010005897,0.0007502382,0.00070054486,0.0029179854],"category_scores_gemma":[0.002220878,0.0001824534,0.00130334,0.00085036264,0.00060912117,0.0003769046,0.0004997537,0.0008897866,0.00009899061],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4042801,0.0067432234,0.14755455,0.0028485467,0.0057291086,0.001601187,0.0005712743,0.035782095,0.0043530883,0.0039830008,0.010576509,0.3759775],"study_design_scores_gemma":[0.055834297,0.06732212,0.7999786,0.0014620216,0.011555252,0.0017003685,0.0024738044,0.04073844,0.0021804105,0.0013283571,0.015137968,0.00028837606],"about_ca_topic_score_codex":0.72335654,"about_ca_topic_score_gemma":0.852797,"teacher_disagreement_score":0.27664346,"about_ca_system_score_codex":0.030666297,"about_ca_system_score_gemma":0.020174269,"threshold_uncertainty_score":0.5565453},"labels":[],"label_agreement":null},{"id":"W4220805673","doi":"10.3389/fonc.2022.818679","title":"Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Moonshot Research and Development Program; National Institutes of Health","keywords":"Medicine; Fludarabine; Neutropenia; Internal medicine; Melanoma; Leukopenia; Gastroenterology; Context (archaeology); Oncology; Cyclophosphamide; Cancer research; Chemotherapy","score_opus":0.06616726927313714,"score_gpt":0.4223646722286237,"score_spread":0.3561974029554866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220805673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866304,0.0016602683,0.00089363183,0.0005941409,0.00023994339,0.004575107,0.0020852757,0.00012613129,0.003195071],"genre_scores_gemma":[0.979859,0.0013412281,0.0020794922,0.0012689546,0.00018710663,0.005630466,0.003576228,0.00003547125,0.0060220123],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997378,0.000099909994,0.000010988669,0.00006552508,0.000022414168,0.00006337996],"domain_scores_gemma":[0.99958616,0.000063799365,0.000076697,0.00003133358,0.000031739444,0.00021032972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009480945,0.0012370452,0.0013215931,0.00022471657,0.0003916113,0.00094238424,0.00058946945,0.0013003356,0.0060570682],"category_scores_gemma":[0.0006763996,0.0004146923,0.0007450773,0.00026205587,0.0006077972,0.0006851318,0.00024755814,0.0029358016,0.0010941509],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6798859,0.10821188,0.0068582064,0.0011497231,0.0009971269,0.00065334205,0.00035869633,0.004304925,0.08779568,0.0010710891,0.014413866,0.094299525],"study_design_scores_gemma":[0.44593033,0.53112125,0.0059721963,0.00005113054,0.00030842138,0.0005709279,0.000074425865,0.0015146461,0.007011592,0.0006217826,0.006794601,0.000028683222],"about_ca_topic_score_codex":0.0004224048,"about_ca_topic_score_gemma":0.0014268842,"teacher_disagreement_score":0.0060570682,"about_ca_system_score_codex":0.0007332426,"about_ca_system_score_gemma":0.0013429022,"threshold_uncertainty_score":0.020262837},"labels":[],"label_agreement":null},{"id":"W4220860149","doi":"10.15252/emmm.202114297","title":"Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders","year":2022,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Western University; McMaster University; University of Toronto","funders":"Midwest Athletes Against Childhood Cancer; Hope Foundation","keywords":"Ex vivo; Lentivirus; In vivo; Immunology; Biology; Cancer research; Medicine; Pharmacology; Biotechnology; Virus","score_opus":0.022566141087701778,"score_gpt":0.3137677057689892,"score_spread":0.29120156468128744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220860149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738133,0.0027387673,0.01852929,0.00018262584,0.00011109761,0.00014997085,0.0005203665,0.00034178203,0.0036128361],"genre_scores_gemma":[0.9885485,0.00070169236,0.007608203,0.00004983815,0.000018674731,0.00007034736,0.000317619,0.00002541239,0.0026597225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998969,0.000019912597,0.000011537109,0.000021903608,0.000030387768,0.00001937815],"domain_scores_gemma":[0.99994195,0.000011471558,0.000019172478,0.000009827886,0.0000059626313,0.000011609083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014160578,0.0002825228,0.00016102231,0.00023593911,0.00016058485,0.00034245793,0.00017365422,0.0003547176,0.0015815491],"category_scores_gemma":[0.0000866847,0.0000859517,0.00018316598,0.000102733306,0.00018834525,0.00020794614,0.00013744373,0.0005816075,0.0004963382],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092776514,0.000079280166,0.00013681647,0.00004152076,0.000006925719,0.00007550183,0.000016246711,0.00028784917,0.9950157,0.00036472455,0.00017269015,0.0037100893],"study_design_scores_gemma":[0.000013564658,0.00032647082,0.0004335616,0.0000034521377,0.0000151860895,0.00029134445,0.000005427123,0.0010803349,0.99469864,0.000040024293,0.0030889334,0.0000030845001],"about_ca_topic_score_codex":0.0003132265,"about_ca_topic_score_gemma":0.00029466004,"teacher_disagreement_score":0.0015815491,"about_ca_system_score_codex":0.00022302347,"about_ca_system_score_gemma":0.00016216112,"threshold_uncertainty_score":0.0052908063},"labels":[],"label_agreement":null},{"id":"W4220932718","doi":"10.1186/s40164-022-00268-z","title":"Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel","year":2022,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; EVERSANA (Canada)","funders":"Bristol-Myers Squibb; American Society of Hematology","keywords":"Medicine; Oncology; Hazard ratio; Internal medicine; Confidence interval; Cytokine release syndrome; Odds ratio; Chimeric antigen receptor; Immunology; Immunotherapy; Cancer","score_opus":0.07916506812500414,"score_gpt":0.3910096793426737,"score_spread":0.3118446112176696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220932718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9223936,0.026200332,0.022766173,0.0009880112,0.0021024414,0.010003606,0.0052188593,0.00025432953,0.010072662],"genre_scores_gemma":[0.98042667,0.0015240207,0.009025177,0.0005799931,0.00023212416,0.0050019515,0.001573855,0.000037063965,0.0015992475],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9729647,0.021895118,0.0015733243,0.0014234366,0.0015524282,0.0005908798],"domain_scores_gemma":[0.9832323,0.010075664,0.0038100989,0.0015369875,0.0008611337,0.0004838544],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017897671,0.0013714143,0.0027223998,0.0010465592,0.0003042473,0.0013303821,0.0012190371,0.0012067747,0.008711941],"category_scores_gemma":[0.026100302,0.00040345272,0.007217424,0.0007192649,0.00072861434,0.0008643035,0.0012484399,0.0020754416,0.0005241782],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84743726,0.0017029186,0.009275045,0.0048640305,0.059871875,0.000065743174,0.00021794901,0.0029319956,0.002485525,0.0022023516,0.0018419639,0.06710333],"study_design_scores_gemma":[0.47178313,0.27262944,0.06845101,0.0013892769,0.12559022,0.00038548486,0.00044291627,0.019480642,0.010749385,0.009322727,0.019473258,0.0003024958],"about_ca_topic_score_codex":0.00076253543,"about_ca_topic_score_gemma":0.0009839189,"teacher_disagreement_score":0.017897671,"about_ca_system_score_codex":0.0011204851,"about_ca_system_score_gemma":0.0010959562,"threshold_uncertainty_score":0.09465301},"labels":[],"label_agreement":null},{"id":"W4220946387","doi":"10.21203/rs.3.rs-1466429/v1","title":"Application of blood brain barrier models in pre-clinical assessment of glioblastoma- targeting CAR-T based immunotherapies","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Extravasation; Chimeric antigen receptor; Cancer research; Blood–brain barrier; Immunotherapy; Flow cytometry; Viability assay; Cell therapy; Cytotoxicity; Medicine; Cell; Immunology; Biology; In vitro; Stem cell; Central nervous system; Immune system; Cell biology; Internal medicine","score_opus":0.06286738231336,"score_gpt":0.4625168596422706,"score_spread":0.39964947732891054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220946387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94968784,0.011998018,0.032807503,0.00022655034,0.00016588692,0.0005627494,0.0006456468,0.00048530867,0.003420601],"genre_scores_gemma":[0.98605436,0.0035582178,0.00856644,0.000069925976,0.000011981878,0.00026279988,0.0004039465,0.000031148415,0.0010412603],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997824,0.00006474734,0.000016484964,0.000026025518,0.00007075245,0.000039662005],"domain_scores_gemma":[0.99987936,0.000017284594,0.000030189029,0.00001062404,0.000041284606,0.000021358856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044128954,0.0004301032,0.00034186832,0.0004310616,0.00013242454,0.0003414044,0.00020668776,0.00035300016,0.0008167723],"category_scores_gemma":[0.0001876052,0.00013735058,0.00025568687,0.00020168992,0.00018036665,0.0002766578,0.00017989331,0.00057400006,0.0002169516],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038738034,0.0002468582,0.0006568809,0.00019638802,0.000022230588,0.00015614682,0.000040131014,0.00068085734,0.9884057,0.00018046895,0.0002312931,0.008795569],"study_design_scores_gemma":[0.000032639742,0.0050860546,0.006710933,0.000027086306,0.000107004256,0.0005800865,0.00006885659,0.0067367745,0.97646356,0.00017093541,0.0039992253,0.000017008893],"about_ca_topic_score_codex":0.0011318662,"about_ca_topic_score_gemma":0.0012339079,"teacher_disagreement_score":0.0011318662,"about_ca_system_score_codex":0.00029632048,"about_ca_system_score_gemma":0.00032788207,"threshold_uncertainty_score":0.0027323365},"labels":[],"label_agreement":null},{"id":"W4220949287","doi":"10.1021/acssynbio.1c00236","title":"Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation","year":2022,"lang":"en","type":"article","venue":"ACS Synthetic Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Natural Sciences and Engineering Research Council of Canada; U.S. Department of Defense","keywords":"NFAT; Chimeric antigen receptor; Cancer research; Antigen; Biology; Reporter gene; T cell; Cell biology; Promoter; Molecular biology; Immunology; Immune system; Gene expression; Gene; Transcription factor; Biochemistry","score_opus":0.049114026046286,"score_gpt":0.3148034801829102,"score_spread":0.2656894541366242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220949287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9129911,0.0011951545,0.081933305,0.00025983131,0.000063174484,0.00010626229,0.0003055025,0.00069585146,0.002449903],"genre_scores_gemma":[0.9734076,0.00062068127,0.022265587,0.000057584,0.00001841538,0.00006837068,0.0003008015,0.000093487666,0.003167365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997291,0.000038175407,0.000022753982,0.00007628382,0.00008534937,0.000048326627],"domain_scores_gemma":[0.99982685,0.000032372376,0.00006885168,0.000018718158,0.000025446376,0.000027775783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026887684,0.0004085417,0.00028026977,0.00016339708,0.00010133024,0.00034610459,0.00024533976,0.00036056133,0.0011222477],"category_scores_gemma":[0.0002303448,0.00014173359,0.00024568784,0.00010908305,0.00031579947,0.000334577,0.00030070866,0.0005441811,0.0004584562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024629817,0.000012020649,0.000046279227,0.000017231481,0.0000012805491,0.000020308355,0.0000070534056,0.00012253744,0.9988501,0.00013400141,0.000021250664,0.00074329023],"study_design_scores_gemma":[0.0000065317413,0.00008970707,0.00010455363,0.0000013272418,0.0000046550795,0.00008123177,0.0000045144534,0.0010840368,0.9973839,0.0000246935,0.0012125906,0.0000022292418],"about_ca_topic_score_codex":0.00033931376,"about_ca_topic_score_gemma":0.00038354527,"teacher_disagreement_score":0.0011222477,"about_ca_system_score_codex":0.00035628455,"about_ca_system_score_gemma":0.00039213875,"threshold_uncertainty_score":0.0037542582},"labels":[],"label_agreement":null},{"id":"W4220986427","doi":"10.3389/fped.2022.796994","title":"Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?","year":2022,"lang":"en","type":"review","venue":"Frontiers in Pediatrics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Children's Hospital; University of British Columbia","funders":"Cancer Research Institute","keywords":"Medicine; Leukemia; Graft-versus-host disease; Hematopoietic stem cell transplantation; Lymphoblastic Leukemia; Disease; Immunology; Ex vivo; Transplantation; Haematopoiesis; Minimal residual disease; Stem cell; Hematopoietic stem cell; In vivo; Internal medicine; Biology","score_opus":0.022812519924215634,"score_gpt":0.30437206352000057,"score_spread":0.28155954359578494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220986427","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010995913,0.99865,0.000074655174,0.0004569016,0.00015817075,0.0000027856493,0.000012317943,0.0000030371864,0.0005323184],"genre_scores_gemma":[0.0006352251,0.9986355,0.00011957914,0.00024979777,0.00008739057,0.000004639417,0.000014873116,9.24206e-7,0.00025210413],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988055,0.00003187992,0.000015597698,0.00001960315,0.00003607425,0.000016229327],"domain_scores_gemma":[0.99974424,0.00015305866,0.000034582303,0.0000061469536,0.000046495916,0.000015475856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004986825,0.00039404954,0.0010352002,0.0008979517,0.00016477295,0.00084619963,0.0005834213,0.0010600782,0.0039348374],"category_scores_gemma":[0.0008311717,0.00016171903,0.0005586058,0.00081415445,0.00037488798,0.0012779752,0.00040804563,0.001405276,0.0014397646],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012412114,0.000051505715,0.00013903361,0.03235405,0.00012294014,0.00015101502,0.000055386987,0.00017331765,0.0019576708,0.005387732,0.018940082,0.94054323],"study_design_scores_gemma":[0.000042080337,0.00016572837,0.0007938743,0.011682058,0.00024337224,0.0009888504,0.000111791676,0.000060435934,0.000553797,0.0028166664,0.9825256,0.000015816151],"about_ca_topic_score_codex":0.00070370216,"about_ca_topic_score_gemma":0.0013578073,"teacher_disagreement_score":0.0039348374,"about_ca_system_score_codex":0.00036802277,"about_ca_system_score_gemma":0.0010317597,"threshold_uncertainty_score":0.013163328},"labels":[],"label_agreement":null},{"id":"W4221044986","doi":"10.1038/s41591-022-01731-4","title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemoimmunotherapy; Oncology; Cytokine release syndrome; Phases of clinical research; Lymphoma; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer; Rituximab","score_opus":0.021470399588103366,"score_gpt":0.34156739811469566,"score_spread":0.3200969985265923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221044986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97765356,0.012449506,0.0007143207,0.0010768601,0.00027869828,0.001713491,0.0012896075,0.00026628168,0.0045576976],"genre_scores_gemma":[0.97866184,0.0056410437,0.0020074353,0.0014480636,0.00032397834,0.0026446036,0.0029759314,0.00004952214,0.006247613],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997396,0.00014921666,0.000007326756,0.00002913261,0.000030683783,0.000044125947],"domain_scores_gemma":[0.99971896,0.000054315627,0.000056268786,0.000019092453,0.000014282399,0.00013706443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014055644,0.0008408501,0.0010593423,0.00039011674,0.00019794606,0.00079691183,0.0005400062,0.00096960226,0.0039049904],"category_scores_gemma":[0.0006648717,0.00026490883,0.0006375393,0.00027621002,0.00047536648,0.00053927785,0.00030809798,0.0018314822,0.00075680454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.677249,0.030389315,0.0057781925,0.0020714707,0.0014051436,0.00035201854,0.00020596846,0.0032987203,0.02457438,0.00083009887,0.013641729,0.2402039],"study_design_scores_gemma":[0.772118,0.20073949,0.009929328,0.00015235362,0.0006071234,0.0004783198,0.000056358374,0.002763385,0.0037605409,0.0004703526,0.008894653,0.00003009962],"about_ca_topic_score_codex":0.00047767695,"about_ca_topic_score_gemma":0.0013766381,"teacher_disagreement_score":0.0039049904,"about_ca_system_score_codex":0.000504662,"about_ca_system_score_gemma":0.00068194047,"threshold_uncertainty_score":0.01306355},"labels":[],"label_agreement":null},{"id":"W4221068958","doi":"10.3390/curroncol29030164","title":"Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Blood Services; University of British Columbia; Université Laval; Gilead Sciences (Canada)","funders":"","keywords":"Mantle cell lymphoma; Medicine; Ibrutinib; Internal medicine; Oncology; Cost effectiveness; Quality-adjusted life year; Quality of life (healthcare); Lymphoma; Leukemia","score_opus":0.09165952177948525,"score_gpt":0.38581303641357056,"score_spread":0.29415351463408534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221068958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95177317,0.018051017,0.004639978,0.0035723634,0.00010907782,0.00095936627,0.005155708,0.000109898516,0.015629537],"genre_scores_gemma":[0.9941221,0.0021582204,0.0013332661,0.00017761377,0.000008618349,0.0000686466,0.00081422966,0.000010477218,0.0013067729],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9990392,0.0004239092,0.000038774808,0.00007446635,0.0001655338,0.00025807053],"domain_scores_gemma":[0.9982431,0.001012953,0.00015495556,0.000030153195,0.00028809378,0.00027072526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002055124,0.00078951044,0.0012510355,0.00093845394,0.00055961625,0.0018805704,0.0013563416,0.0008003192,0.0032785656],"category_scores_gemma":[0.007059649,0.00040874895,0.0018041923,0.0009692846,0.00063535955,0.00062428316,0.0008949106,0.0010588146,0.00012535114],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008677507,0.00042646372,0.014684213,0.0010706767,0.0013944774,0.00030774763,0.00010822974,0.91024286,0.0007338323,0.0069133095,0.0034221373,0.052018516],"study_design_scores_gemma":[0.0038930771,0.0023547134,0.02370552,0.0007252976,0.003252321,0.00026466334,0.0005007771,0.95373094,0.001106834,0.0041690315,0.0061659846,0.00013084554],"about_ca_topic_score_codex":0.8538924,"about_ca_topic_score_gemma":0.8447644,"teacher_disagreement_score":0.14610761,"about_ca_system_score_codex":0.0380861,"about_ca_system_score_gemma":0.028865652,"threshold_uncertainty_score":0.29393607},"labels":[],"label_agreement":null},{"id":"W4221073412","doi":"10.1111/trf.16820","title":"Cryopreserved hematopoietic stem/progenitor cells stability program‐development, current status and recommendations: A brief report from the AABB‐ISCT joint working group cellular therapy product stability project team","year":2022,"lang":"en","type":"article","venue":"Transfusion","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec; Canadian Blood Services","funders":"","keywords":"Cryopreservation; Standardization; Progenitor cell; Apheresis; Haematopoiesis; Scope (computer science); Medicine; Stem cell; Computer science; Immunology; Biology","score_opus":0.10775657440442783,"score_gpt":0.3267183771694353,"score_spread":0.21896180276500748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221073412","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040963627,0.18787089,0.033984043,0.6366336,0.018836169,0.007740595,0.010643947,0.0022802297,0.061046913],"genre_scores_gemma":[0.13660295,0.4832239,0.16574591,0.10658408,0.0067176665,0.010100471,0.036752634,0.000798554,0.053473823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.977931,0.0055597434,0.0041621593,0.0010326274,0.009117379,0.002197068],"domain_scores_gemma":[0.91515785,0.013392425,0.0071735396,0.0012189692,0.050075777,0.012981411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.058912795,0.0009738675,0.0006919644,0.0034388802,0.0019168357,0.0058223745,0.003822083,0.0041520935,0.0051856795],"category_scores_gemma":[0.038028173,0.0006871177,0.0011905533,0.0047238744,0.0008248739,0.004163092,0.0030634825,0.005269323,0.0026480388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015494041,0.0008516426,0.01943485,0.005620217,0.000055909237,0.00037624655,0.0019798412,0.0010696416,0.002440361,0.002161399,0.4775707,0.48828435],"study_design_scores_gemma":[0.00005221019,0.00064369675,0.031118507,0.012376086,0.000107580876,0.00040516414,0.007081107,0.0012966619,0.002531525,0.00096056075,0.9433062,0.00012063825],"about_ca_topic_score_codex":0.020173421,"about_ca_topic_score_gemma":0.016202902,"teacher_disagreement_score":0.058912795,"about_ca_system_score_codex":0.0051234686,"about_ca_system_score_gemma":0.052742545,"threshold_uncertainty_score":0.3115644},"labels":[],"label_agreement":null},{"id":"W4221137077","doi":"10.1016/j.jcyt.2022.03.001","title":"Cryopreserved hematopoietic stem/progenitor cells stability program-development, current status and recommendations: A brief report from the AABB-ISCT joint working group cellular therapy product stability project team","year":2022,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec; Canadian Blood Services","funders":"","keywords":"Progenitor cell; Haematopoiesis; Stem cell; Apheresis; Medicine; Immunology; Biology; Cell biology","score_opus":0.12208440870288015,"score_gpt":0.33785075553347627,"score_spread":0.21576634683059612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221137077","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051955186,0.44235107,0.10138249,0.25087106,0.024977183,0.007084967,0.010166085,0.0023249274,0.10888706],"genre_scores_gemma":[0.112316795,0.49953052,0.17668568,0.041615244,0.0070905536,0.004999775,0.023260983,0.0010246905,0.13347583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932939,0.0012248001,0.00079509243,0.00044741182,0.0036163114,0.0006224341],"domain_scores_gemma":[0.98180777,0.0029734995,0.00191653,0.00040167978,0.010566333,0.0023342092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029800428,0.000867099,0.0006311869,0.0019054881,0.0011850868,0.0051969285,0.0023777685,0.0034381333,0.005698578],"category_scores_gemma":[0.010063145,0.00041577846,0.0009853336,0.0015769897,0.0008662653,0.0024692817,0.0019864228,0.0041443324,0.002633458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000751822,0.0013545599,0.006492884,0.0028893831,0.00009284693,0.0003904039,0.0005426428,0.0025576397,0.026598409,0.0059260856,0.2513011,0.7011022],"study_design_scores_gemma":[0.00009200252,0.0015186679,0.0054748957,0.0022126422,0.00018053858,0.00047107108,0.00081097335,0.0010314909,0.034896135,0.001689229,0.9515459,0.000076482036],"about_ca_topic_score_codex":0.0063748537,"about_ca_topic_score_gemma":0.010004338,"teacher_disagreement_score":0.029800428,"about_ca_system_score_codex":0.0025438634,"about_ca_system_score_gemma":0.01951239,"threshold_uncertainty_score":0.1576016},"labels":[],"label_agreement":null},{"id":"W4223991603","doi":"10.1038/s41375-022-01550-z","title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Cytokine release syndrome; Minimal residual disease; Blinatumomab; Internal medicine; Refractory (planetary science); Hematopoietic stem cell transplantation; Acute lymphocytic leukemia; Chemotherapy; Pediatrics; Gastroenterology; Leukemia; Lymphoblastic Leukemia; Cancer; Disease; Immunotherapy","score_opus":0.007083279023805119,"score_gpt":0.23065583200335218,"score_spread":0.22357255297954706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223991603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976489,0.00095323264,0.00003913094,0.000094775445,0.000008242493,0.0000058036785,0.000119645025,0.0000062203962,0.0011240987],"genre_scores_gemma":[0.99925095,0.00036515307,0.0000337866,0.000055515357,0.000014004658,0.000002958108,0.00013374691,0.0000017667242,0.00014210508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998548,0.000028414714,0.00001686177,0.000023423781,0.000024819872,0.00005170148],"domain_scores_gemma":[0.9996718,0.00009174027,0.00010366241,0.000007762419,0.000018069177,0.00010687878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014814906,0.00021608433,0.00036938163,0.0004821403,0.00031992077,0.00045465125,0.00016995115,0.00037833842,0.0012551263],"category_scores_gemma":[0.00096338947,0.00012308774,0.00017138565,0.0005000069,0.0002617702,0.0003785067,0.00021806255,0.0003970673,0.00014010101],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069497037,0.0000628397,0.97026116,0.00002939485,0.000023515297,0.020880343,0.00015110573,0.00008030631,0.0011976938,0.00006662302,0.00029453175,0.006257648],"study_design_scores_gemma":[0.000056475204,0.00085715874,0.9314049,0.00002993118,0.00008442303,0.064395696,0.0009391454,0.00037860288,0.00039280223,0.00011270438,0.0013373948,0.000010816355],"about_ca_topic_score_codex":0.0026510162,"about_ca_topic_score_gemma":0.0031719075,"teacher_disagreement_score":0.0026510162,"about_ca_system_score_codex":0.00031459625,"about_ca_system_score_gemma":0.0003988175,"threshold_uncertainty_score":0.0052711964},"labels":[],"label_agreement":null},{"id":"W4224050212","doi":"10.1126/scitranslmed.abn2231","title":"Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","year":2022,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of Allergy and Infectious Diseases; Rosetrees Trust; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Chimeric antigen receptor; Oncolytic virus; Cancer research; T-cell receptor; T cell; Antigen; Biology; Vesicular stomatitis virus; Glioma; Immunotherapy; Immunology; Melanoma; Virology; Immune system; Virus","score_opus":0.03534674777181349,"score_gpt":0.3319631336615451,"score_spread":0.2966163858897316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224050212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98922485,0.0013281256,0.006199313,0.00015065445,0.000060383532,0.00008915388,0.00031933354,0.00034562024,0.0022825855],"genre_scores_gemma":[0.99121714,0.0007646048,0.0042022555,0.000060809183,0.00003124719,0.000061627936,0.00035047112,0.000066289605,0.0032456475],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997577,0.000039625942,0.000020754816,0.00005652774,0.00005207371,0.000073292416],"domain_scores_gemma":[0.9998441,0.000029074092,0.00004269423,0.000022636621,0.000016080588,0.00004542108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027483696,0.0005468446,0.00045551342,0.00047946264,0.00011953416,0.00041369806,0.00022249609,0.00037670197,0.0012107361],"category_scores_gemma":[0.00014219139,0.00019952166,0.0002648894,0.00017143336,0.00029280112,0.00034693992,0.00022276165,0.0013078357,0.00039098554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016052109,0.00011539429,0.0000792397,0.000022639142,0.000004873766,0.0000145309505,0.000016819811,0.00014464607,0.996897,0.0001342851,0.00006440016,0.0023456486],"study_design_scores_gemma":[0.00006494378,0.0013650032,0.00071314716,0.0000066529383,0.00002400348,0.00012032867,0.000011911948,0.0013796454,0.9943439,0.000042251584,0.001924653,0.000003550393],"about_ca_topic_score_codex":0.0004079037,"about_ca_topic_score_gemma":0.00066740444,"teacher_disagreement_score":0.0012107361,"about_ca_system_score_codex":0.00024044128,"about_ca_system_score_gemma":0.00027082028,"threshold_uncertainty_score":0.004050374},"labels":[],"label_agreement":null},{"id":"W4224279567","doi":"10.1126/sciimmunol.abl3642","title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","year":2022,"lang":"en","type":"article","venue":"Science Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Biology; CD8; Immunology; Antigen; Cytotoxic T cell; Cancer research; CD19","score_opus":0.02468566003903046,"score_gpt":0.3016648611999601,"score_spread":0.27697920116092967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224279567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98239094,0.0020269842,0.010744344,0.00007446642,0.000042692707,0.00012483392,0.00030744466,0.0003529078,0.003935194],"genre_scores_gemma":[0.99430794,0.0007691593,0.002291075,0.00003827681,0.000007250653,0.000076343895,0.00032391417,0.00002343841,0.0021625531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998388,0.00002012929,0.000010866158,0.000030953,0.000049747643,0.00004955199],"domain_scores_gemma":[0.9999404,0.000011529207,0.000014381633,0.000012949242,0.000008035254,0.000012653303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010903096,0.0004155518,0.00027511248,0.00017418074,0.00007839385,0.00021910878,0.00020067306,0.00029116872,0.0012792477],"category_scores_gemma":[0.000088693814,0.00010346091,0.00019314741,0.000108475106,0.00016612478,0.00017825038,0.00014964979,0.00072415743,0.00042471537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010956274,0.00011141032,0.00020859654,0.000060910574,0.0000055822584,0.00005128505,0.000014802158,0.0002815738,0.99334997,0.00029768635,0.00017956833,0.0053291516],"study_design_scores_gemma":[0.000027339336,0.0007060079,0.00093045936,0.000004789062,0.000018993765,0.00034260043,0.000013984103,0.001281231,0.9926146,0.000054211963,0.0040030507,0.0000027318943],"about_ca_topic_score_codex":0.0002497942,"about_ca_topic_score_gemma":0.00040365526,"teacher_disagreement_score":0.0012792477,"about_ca_system_score_codex":0.00014651411,"about_ca_system_score_gemma":0.00019822085,"threshold_uncertainty_score":0.0042794943},"labels":[],"label_agreement":null},{"id":"W4224311696","doi":"10.1212/nxi.0000000000001173","title":"Programmed Cell Death Protein 1–Positive CD8 <sup>+</sup> T Cells in Multiple Sclerosis","year":2022,"lang":"en","type":"letter","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Multiple sclerosis; Programmed cell death; CD8; Cytotoxic T cell; Cell; Cell biology; Chemistry; Biology; Immunology; Apoptosis; Biochemistry; Immune system; In vitro","score_opus":0.036903279635318836,"score_gpt":0.24930107587053896,"score_spread":0.21239779623522012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224311696","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011486059,0.005308462,0.00044314066,0.9445149,0.02186089,0.00003699711,0.00007930677,0.000083871426,0.01618638],"genre_scores_gemma":[0.16108869,0.0053245514,0.0011661786,0.66434604,0.14076024,0.00013222646,0.00011249485,0.000067532674,0.02700202],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9993272,0.00022605907,0.00008952392,0.0000678691,0.00016366321,0.00012571887],"domain_scores_gemma":[0.99745816,0.0016157216,0.00015502682,0.000110698995,0.0003777587,0.0002825806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096845283,0.0006572743,0.0010466464,0.0004982924,0.0021946607,0.0014621259,0.0009565208,0.024707826,0.0029960333],"category_scores_gemma":[0.005809039,0.0004048823,0.0005794698,0.00035285985,0.0016149968,0.0013560059,0.0005426717,0.0108115,0.0018780313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006182341,0.00012589149,0.004450186,0.00023853716,0.00004890879,0.11491483,0.00024422837,0.00026906095,0.0027600257,0.005684034,0.84034914,0.030296877],"study_design_scores_gemma":[0.0014889402,0.0007243637,0.010441368,0.0007799257,0.00022363495,0.18450049,0.0008647658,0.006027865,0.00418817,0.040198553,0.75044054,0.000121361736],"about_ca_topic_score_codex":0.0023100872,"about_ca_topic_score_gemma":0.0029791286,"teacher_disagreement_score":0.024707826,"about_ca_system_score_codex":0.002743846,"about_ca_system_score_gemma":0.0011289787,"threshold_uncertainty_score":0.01990807},"labels":[],"label_agreement":null},{"id":"W4224909487","doi":"10.1016/j.ekir.2022.04.003","title":"Chimeric Antigen Receptor Regulatory T Cell in Transplantation: The Future of Cell Therapy?","year":2022,"lang":"en","type":"editorial","venue":"Kidney International Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cell therapy; Transplantation; Receptor; Immunology; Cell; Antigen; Cancer research; Immunotherapy; Internal medicine; Immune system; Genetics; Biology","score_opus":0.009161559648392438,"score_gpt":0.28586576617202436,"score_spread":0.2767042065236319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224909487","genre_codex":"review","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00052304944,0.8888955,0.0018709091,0.074668236,0.017750034,0.00006014658,0.00013936622,0.00016925861,0.015923494],"genre_scores_gemma":[0.0077851275,0.8556748,0.003981481,0.07272957,0.031418957,0.0001492444,0.0004097182,0.00012861427,0.027722513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993832,0.00016795404,0.00004647713,0.00007215303,0.00025306767,0.0000771099],"domain_scores_gemma":[0.9985178,0.00066369335,0.00013617577,0.0000558925,0.00039870222,0.00022769965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024449527,0.00061980705,0.0013847669,0.0010171487,0.0003686935,0.0020821316,0.00097261945,0.0043244828,0.021024978],"category_scores_gemma":[0.0021003066,0.00019501218,0.0007970185,0.0009352436,0.0012815392,0.003547481,0.00084428437,0.005679729,0.01003801],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041865543,0.00015148285,0.0002142365,0.0019357074,0.00004159911,0.00029570924,0.000040971514,0.00018969462,0.0016982474,0.0145535255,0.3253449,0.65511537],"study_design_scores_gemma":[0.0001553601,0.00028482484,0.00029607836,0.0016451379,0.000042819316,0.0007041179,0.000040148876,0.00019245708,0.0005443526,0.010225522,0.9858439,0.000025342764],"about_ca_topic_score_codex":0.00076222094,"about_ca_topic_score_gemma":0.0016530685,"teacher_disagreement_score":0.021024978,"about_ca_system_score_codex":0.0011878755,"about_ca_system_score_gemma":0.0013055084,"threshold_uncertainty_score":0.07033557},"labels":[],"label_agreement":null},{"id":"W4225319387","doi":"","title":"Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies","year":2022,"lang":"en","type":"review","venue":"White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; AstraZeneca (Canada); Spinal Cord Injury BC; University of British Columbia; Immunovaccine (Canada)","funders":"","keywords":"Medicine; Adverse effect; Context (archaeology); Intensive care medicine; Clinical trial; Cancer; Hematology; Oncology; Internal medicine","score_opus":0.16223791260157028,"score_gpt":0.3898527533791697,"score_spread":0.22761484077759941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225319387","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005298195,0.9937406,0.00031495406,0.0043663597,0.0005456726,0.000017629156,0.000017198932,0.000014809307,0.00092974864],"genre_scores_gemma":[0.0010972737,0.99328446,0.001156405,0.0032291766,0.00070339255,0.000027554954,0.000052366515,0.000008068934,0.00044126582],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928059,0.003002927,0.0013542115,0.00045535198,0.0021457276,0.00023600113],"domain_scores_gemma":[0.96198267,0.024274645,0.0041199448,0.0009194998,0.007876491,0.0008268094],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018522857,0.00082960934,0.0026421766,0.0039643142,0.0005047933,0.0040402203,0.0027437352,0.0034993226,0.004633112],"category_scores_gemma":[0.025084173,0.00049401826,0.002240869,0.0035114284,0.0022616694,0.0069804178,0.0020210596,0.007895536,0.0016618123],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007520155,0.000053838616,0.00019282593,0.019536689,0.00007986732,0.000058058788,0.00014381933,0.00019067051,0.00033132258,0.011169332,0.040839765,0.9273286],"study_design_scores_gemma":[0.000041323732,0.000115303046,0.0007662249,0.02636752,0.0001735628,0.00036800772,0.0001398516,0.00010710427,0.00025969202,0.0063753813,0.9652454,0.00004068633],"about_ca_topic_score_codex":0.0052871536,"about_ca_topic_score_gemma":0.0071486556,"teacher_disagreement_score":0.98147714,"about_ca_system_score_codex":0.0029689656,"about_ca_system_score_gemma":0.0077873166,"threshold_uncertainty_score":0.0979594},"labels":[],"label_agreement":null},{"id":"W4225533228","doi":"10.3389/fimmu.2022.875580","title":"Editorial: T-Cell Signaling Networks in Health and Disease","year":2022,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Biology; Computational biology; Immunology","score_opus":0.008365074513652421,"score_gpt":0.2810487425875146,"score_spread":0.2726836680738622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225533228","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003617726,0.0033230814,0.000107896434,0.021336945,0.973381,0.000014128739,0.000061256316,0.00007591694,0.0016636051],"genre_scores_gemma":[0.00048023713,0.0030801108,0.00009708817,0.014276128,0.97000915,0.000018431574,0.00004744247,0.0000370471,0.011954344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99741805,0.00041783016,0.0002472893,0.00032975475,0.0013411738,0.00024589195],"domain_scores_gemma":[0.9912683,0.0023876145,0.0005527684,0.00023230897,0.0033554018,0.0022035367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00494012,0.0042984732,0.0030023255,0.002796687,0.002616633,0.005166964,0.002848372,0.009497329,0.025669456],"category_scores_gemma":[0.011746848,0.0009951784,0.0023719831,0.00082855235,0.0017304799,0.0035961955,0.0014284478,0.012737437,0.019486947],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004708656,0.000008515772,0.000014187776,0.00009738176,0.000009171576,0.0000618989,0.0000046857012,0.000021012454,0.00006246011,0.00021460807,0.99555165,0.0039073755],"study_design_scores_gemma":[0.00007498087,0.000038645794,0.00018268556,0.00022993298,0.00003918036,0.0002435769,0.000027359238,0.00014823505,0.00015416669,0.0013099276,0.99753416,0.000017251998],"about_ca_topic_score_codex":0.0009921296,"about_ca_topic_score_gemma":0.0027321787,"teacher_disagreement_score":0.025669456,"about_ca_system_score_codex":0.0023838775,"about_ca_system_score_gemma":0.002305508,"threshold_uncertainty_score":0.08587289},"labels":[],"label_agreement":null},{"id":"W4225543978","doi":"10.1007/s11033-022-07147-0","title":"RETRACTED ARTICLE: Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy","year":2022,"lang":"en","type":"article","venue":"Molecular Biology Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"CRISPR; Genome editing; T-cell receptor; Immunotherapy; Cas9; Cancer immunotherapy; Computational biology; T cell; Cell therapy; Biology; Genetic enhancement; Chimeric antigen receptor; Immune system; Transcription activator-like effector nuclease; Cancer research; Immunology; Gene; Cell; Genetics","score_opus":0.013453884977379761,"score_gpt":0.31841823792421714,"score_spread":0.3049643529468374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225543978","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02133164,0.02418295,0.026497712,0.23650818,0.67146367,0.00019695137,0.002203252,0.0022722457,0.015343322],"genre_scores_gemma":[0.22712414,0.04354852,0.0608378,0.17169948,0.18257359,0.00039104334,0.0066131665,0.0018057141,0.30540657],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975546,0.00029457256,0.00036768863,0.0002968042,0.0011343984,0.00035202448],"domain_scores_gemma":[0.9936102,0.0021706775,0.0004248001,0.0004012735,0.0025803256,0.00081268424],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002848143,0.0009235581,0.0009780467,0.0013983658,0.0015619657,0.0020047114,0.0024205719,0.0078039654,0.016110733],"category_scores_gemma":[0.012270877,0.00039660922,0.0009267742,0.0007600004,0.0014152209,0.0018427637,0.0014671079,0.0045817494,0.006870246],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007644996,0.00016499188,0.0018303817,0.001340048,0.00012198279,0.012697971,0.0003714203,0.00042775867,0.041641846,0.008132016,0.76204264,0.17046446],"study_design_scores_gemma":[0.00006159551,0.00026251806,0.0019240661,0.0001544171,0.0001689138,0.013391926,0.00023056226,0.0010492423,0.05817652,0.0038303507,0.92066616,0.00008372916],"about_ca_topic_score_codex":0.0020416996,"about_ca_topic_score_gemma":0.0024015845,"teacher_disagreement_score":0.992196,"about_ca_system_score_codex":0.0016788082,"about_ca_system_score_gemma":0.0027056746,"threshold_uncertainty_score":0.05389583},"labels":[],"label_agreement":null},{"id":"W4226022053","doi":"10.1016/j.clml.2021.12.003","title":"An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy","year":2021,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Medicine; Malignancy; Plasma cell; Antigen; Cancer research; Antibody; Clinical trial; Cancer; Immunology; Oncology; Immunotherapy; Internal medicine","score_opus":0.17085119738957352,"score_gpt":0.4525105370994986,"score_spread":0.28165933970992507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226022053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007941661,0.9985663,0.00016987641,0.0002084611,0.00018963266,0.000008834171,0.000024312085,0.000009258468,0.0007438842],"genre_scores_gemma":[0.00055291306,0.9980433,0.0002696202,0.00031897717,0.00018738328,0.000013149961,0.00005101824,0.0000020290681,0.00056150235],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979264,0.000043002998,0.000026767662,0.00004003606,0.00006491296,0.000032620057],"domain_scores_gemma":[0.99969447,0.00016518458,0.000037475882,0.000008053398,0.000064126056,0.00003073752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008530461,0.001088317,0.0018849497,0.0024117287,0.00026381644,0.0012826548,0.0011453971,0.0013006558,0.004586591],"category_scores_gemma":[0.0007389914,0.0004026779,0.0008223084,0.0021949795,0.0004500429,0.0013130733,0.000718245,0.0026370084,0.0023789757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017203751,0.0001663079,0.00011497597,0.019396082,0.00012389175,0.00015589663,0.00003177549,0.00055631815,0.0021745618,0.0038221441,0.04477119,0.9285147],"study_design_scores_gemma":[0.00009177069,0.00034421362,0.0004184077,0.0036101881,0.00021790208,0.000732441,0.000025880177,0.00018198328,0.0006496839,0.0011592365,0.9925487,0.000019584253],"about_ca_topic_score_codex":0.0012850809,"about_ca_topic_score_gemma":0.0026209836,"teacher_disagreement_score":0.004586591,"about_ca_system_score_codex":0.0008917515,"about_ca_system_score_gemma":0.0013080431,"threshold_uncertainty_score":0.0153436065},"labels":[],"label_agreement":null},{"id":"W4226068368","doi":"10.1038/s41568-022-00466-1","title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","year":2022,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":513,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Immunotherapy; Immunology; Immune system; Cancer immunotherapy; Biology; T cell; Immune checkpoint; Antigen; Cancer research; Context (archaeology); Autoimmunity","score_opus":0.3309784990381246,"score_gpt":0.5148692975168264,"score_spread":0.18389079847870182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226068368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000052765878,0.99890375,0.00005997169,0.00038801978,0.00017323042,0.0000018668043,0.000010102306,0.000004363647,0.0004058958],"genre_scores_gemma":[0.00041727012,0.99871504,0.00005616662,0.00025874004,0.000177519,0.0000041982994,0.000019621182,8.7615757e-7,0.00035052033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979395,0.000047472156,0.000018227698,0.000031272884,0.000076769065,0.00003234107],"domain_scores_gemma":[0.99953127,0.00024110773,0.000051523137,0.000013264556,0.00010734023,0.00005557724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089837576,0.00082657504,0.0016158004,0.0015402267,0.00022489509,0.0013899932,0.0010703239,0.0014830629,0.0041752476],"category_scores_gemma":[0.0008411682,0.00028167345,0.00042313966,0.0015570763,0.0007283821,0.0012948514,0.00078747235,0.0027487068,0.0026672995],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017629989,0.000051826188,0.00013964184,0.011347362,0.00007411061,0.00014402892,0.00003494553,0.00042712246,0.0026438427,0.0049074227,0.050015498,0.9300379],"study_design_scores_gemma":[0.00004464357,0.000104657025,0.00056811544,0.0029447395,0.00008174214,0.00093242433,0.000043076187,0.00008663945,0.00041482682,0.0023764025,0.992388,0.000014804673],"about_ca_topic_score_codex":0.0007700036,"about_ca_topic_score_gemma":0.001520995,"teacher_disagreement_score":0.0041752476,"about_ca_system_score_codex":0.00073982845,"about_ca_system_score_gemma":0.0009438607,"threshold_uncertainty_score":0.013967574},"labels":[],"label_agreement":null},{"id":"W4226242673","doi":"10.1038/s41536-022-00210-1","title":"Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development","year":2022,"lang":"en","type":"article","venue":"npj Regenerative Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Wellcome Trust; Hospital for Sick Children; Michael Smith Health Research BC; University of Toronto; BC Children's Hospital","keywords":"Stem cell; Biology; T cell; Cell biology; Stem cell factor; Progenitor cell; Haematopoiesis; Immunology; CD8; Cytotoxic T cell; Cytokine; Cancer research; Immune system; In vitro","score_opus":0.030168865504003477,"score_gpt":0.2855176232633859,"score_spread":0.2553487577593824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226242673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86425096,0.00037612335,0.13338289,0.000063957705,0.000012700302,0.000046294743,0.00010456508,0.00022832316,0.0015342832],"genre_scores_gemma":[0.96744597,0.000085684136,0.031519756,0.000015919748,0.0000020212835,0.000047606067,0.0000760774,0.00003621941,0.0007706269],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988985,0.000030352625,0.0000053499593,0.000024235344,0.000026283593,0.000023787677],"domain_scores_gemma":[0.9998135,0.00010130672,0.000040475934,0.000007883461,0.000025095027,0.000011651399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005324787,0.0005456109,0.00032992274,0.00026304866,0.00008403907,0.0002475617,0.00021992423,0.00022889461,0.0006270685],"category_scores_gemma":[0.00037002942,0.00018204295,0.00034726004,0.0001686119,0.00019077804,0.00010513541,0.000195991,0.00027759527,0.0000772891],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021482032,0.00009917236,0.0009644579,0.000064715234,0.000035990815,0.00003617726,0.000019535646,0.8458671,0.1391114,0.00038605166,0.00012627659,0.013074172],"study_design_scores_gemma":[0.0000096931035,0.00019517938,0.00071103853,0.0000025193012,0.000009835941,0.000008133001,0.0000061807855,0.9443617,0.05443199,0.00008639048,0.00017210464,0.0000052466553],"about_ca_topic_score_codex":0.0014127224,"about_ca_topic_score_gemma":0.0017304157,"teacher_disagreement_score":0.0014127224,"about_ca_system_score_codex":0.00039801493,"about_ca_system_score_gemma":0.00032513004,"threshold_uncertainty_score":0.0028877854},"labels":[],"label_agreement":null},{"id":"W4226374363","doi":"","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"EUR Research Repository (Erasmus University Rotterdam)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Tolerability; Nivolumab; Medicine; Adverse effect; Internal medicine; Dosing; Phases of clinical research; Pharmacology; Gastroenterology; Mesothelin; Pharmacodynamics; Oncology; Clinical trial; Cancer; Pharmacokinetics; Immunotherapy","score_opus":0.02240105381484284,"score_gpt":0.32797840933215977,"score_spread":0.3055773555173169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226374363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555589,0.016635522,0.0009863917,0.0020651517,0.0009263558,0.004394675,0.0049474644,0.00036794055,0.01411761],"genre_scores_gemma":[0.96748203,0.008063614,0.0015369165,0.0016691856,0.00044534815,0.002208238,0.0057756575,0.00006882498,0.012750245],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997819,0.00008179942,0.000014443799,0.000044395263,0.000022994998,0.00005446917],"domain_scores_gemma":[0.9997446,0.000030441495,0.00005410732,0.000019711008,0.000014901013,0.00013626729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083051063,0.0015548103,0.0020377329,0.00047206116,0.00034925592,0.0012257933,0.0006117445,0.00095489086,0.0075892624],"category_scores_gemma":[0.0005536814,0.000521683,0.0015133396,0.0004454513,0.00071879826,0.00090402504,0.00030753657,0.002092187,0.002169857],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7920401,0.014413429,0.0031211874,0.0028388086,0.0030049877,0.00024649265,0.00019651919,0.0024606343,0.026517736,0.0005542497,0.013351841,0.14125401],"study_design_scores_gemma":[0.78224355,0.19488238,0.009693765,0.00016469596,0.0012348769,0.0002553073,0.00008092556,0.0011605358,0.0025194143,0.0005285179,0.007202795,0.000033101045],"about_ca_topic_score_codex":0.0009787556,"about_ca_topic_score_gemma":0.002819127,"teacher_disagreement_score":0.0075892624,"about_ca_system_score_codex":0.0009077508,"about_ca_system_score_gemma":0.0010054441,"threshold_uncertainty_score":0.025388598},"labels":[],"label_agreement":null},{"id":"W4230910528","doi":"10.3410/f.1022661.260651","title":"Faculty Opinions recommendation of Dynamic molecular interactions linking the T cell antigen receptor to the actin cytoskeleton.","year":2004,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cytoskeleton; Actin cytoskeleton; Actin; Cell biology; Antigen; Chemistry; Receptor; Computational biology; Biology; Cell; Immunology; Biochemistry","score_opus":0.030247848886077316,"score_gpt":0.3890143738921009,"score_spread":0.3587665250060236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230910528","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019834429,0.00018309207,0.000118950906,0.00010857834,0.000031534848,0.0000136528,0.997924,0.000540261,0.0008816163],"genre_scores_gemma":[0.0005909323,0.00013179197,0.0003816252,0.000060172686,0.000008590417,0.000038213344,0.997775,0.000053314623,0.00096037186],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880004,0.00016924209,0.00013347904,0.0003463514,0.00040779856,0.00014307065],"domain_scores_gemma":[0.9975751,0.00067235855,0.00034074934,0.00051270385,0.0005630147,0.00033615105],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0009898442,0.0029543906,0.0018122224,0.0045396034,0.0006758816,0.002681168,0.0033197287,0.0033494318,0.058748875],"category_scores_gemma":[0.006359878,0.00084141514,0.002116257,0.00602429,0.00030598044,0.0014595663,0.0013230684,0.0018451957,0.06014883],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000117818716,0.00003525384,0.0008816896,0.0010032566,0.000066119566,0.00003410022,0.0000090546955,0.00043462147,0.00024322719,0.000304876,0.99280244,0.004067482],"study_design_scores_gemma":[0.0004029147,0.000033387656,0.0070327464,0.00031006976,0.00013256037,0.00012069,0.000031941963,0.0017380761,0.001105822,0.001078266,0.9879758,0.00003770333],"about_ca_topic_score_codex":0.027484223,"about_ca_topic_score_gemma":0.05441925,"teacher_disagreement_score":0.99901015,"about_ca_system_score_codex":0.0018158453,"about_ca_system_score_gemma":0.0032687539,"threshold_uncertainty_score":0.19653457},"labels":[],"label_agreement":null},{"id":"W4233173587","doi":"10.1182/blood-2019-131818","title":"Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Simon Fraser University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Obinutuzumab; Salvage therapy; Internal medicine; Rituximab; Gemcitabine; Oncology; Chemotherapy regimen; Regimen; Autologous stem-cell transplantation; Transplantation; Chemotherapy; Surgery; Lymphoma","score_opus":0.010714106517421475,"score_gpt":0.2580992509205724,"score_spread":0.24738514440315093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233173587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99805355,0.0008856757,0.00016792232,0.000044479162,0.000023979426,0.00044219536,0.00004967918,0.000014802221,0.00031762628],"genre_scores_gemma":[0.9981086,0.0005560473,0.0004243723,0.00008709435,0.00004419535,0.00035580862,0.00011084938,0.0000045635175,0.0003084831],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996182,0.00017966442,0.000029641846,0.00006532276,0.000040864263,0.00006631672],"domain_scores_gemma":[0.9993912,0.00008158021,0.00014988164,0.000062134844,0.00002642749,0.00028880168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009543342,0.00072727137,0.0016361666,0.00044852355,0.00027696078,0.0007191882,0.0008210951,0.0007114205,0.0012910044],"category_scores_gemma":[0.00058320625,0.0003248952,0.0006304369,0.0004712011,0.00070872315,0.00055406993,0.00040328735,0.0017571067,0.00033366852],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6362781,0.09308343,0.011847107,0.0013343955,0.00086902356,0.000845792,0.0005776272,0.0051815165,0.084537156,0.00032508702,0.00095296453,0.16416779],"study_design_scores_gemma":[0.13381809,0.84332496,0.010719331,0.00007016222,0.00038877828,0.00053979014,0.000067728935,0.0012169447,0.008398244,0.00013467197,0.0012961475,0.00002509886],"about_ca_topic_score_codex":0.00059932104,"about_ca_topic_score_gemma":0.0016894073,"teacher_disagreement_score":0.0016361666,"about_ca_system_score_codex":0.00076540274,"about_ca_system_score_gemma":0.0010449697,"threshold_uncertainty_score":0.0055533648},"labels":[],"label_agreement":null},{"id":"W4235546527","doi":"10.1200/jco.2017.77.0446","title":"Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Chimeric antigen receptor; Clinical trial; Immunotherapy; Cancer immunotherapy; Oncology; Clinical Oncology; Internal medicine; Immunology; Family medicine","score_opus":0.24770995579533853,"score_gpt":0.6188850474531973,"score_spread":0.3711750916578588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235546527","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010378165,0.09183058,0.0032049569,0.23382366,0.36540344,0.0016720573,0.00630838,0.0024414859,0.2942776],"genre_scores_gemma":[0.008291806,0.14635774,0.010001508,0.14857288,0.19524121,0.0029051774,0.02458152,0.0016019559,0.46244633],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99165404,0.0009148346,0.00052341475,0.00060988864,0.005159134,0.0011386495],"domain_scores_gemma":[0.978795,0.0012977817,0.0010830392,0.00080323726,0.010142388,0.007878474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008713373,0.0019644138,0.0015521388,0.0029665087,0.0021275815,0.0086988015,0.0025886565,0.008475152,0.07464841],"category_scores_gemma":[0.012422556,0.0008023484,0.0012589127,0.0023566172,0.0012653057,0.0042837146,0.0052641346,0.013346186,0.08648952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002151361,0.000036452308,0.000058078993,0.00009943307,0.0000036843655,0.00001907049,0.0000067803926,0.000016743234,0.00013099017,0.0005211472,0.96995866,0.029127376],"study_design_scores_gemma":[0.000017554308,0.000022268632,0.00020426906,0.00010838007,0.0000032376188,0.00003150889,0.000010361299,0.000018617658,0.000055340082,0.0001974999,0.99932444,0.0000065397585],"about_ca_topic_score_codex":0.002460033,"about_ca_topic_score_gemma":0.0044436264,"teacher_disagreement_score":0.07464841,"about_ca_system_score_codex":0.0030655174,"about_ca_system_score_gemma":0.013502665,"threshold_uncertainty_score":0.24972379},"labels":[],"label_agreement":null},{"id":"W4235632004","doi":"10.4324/9780203427835_chapter_12","title":"Mammalian cell products","year":2010,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Cell; Biology; Genetics","score_opus":0.03569124969875622,"score_gpt":0.28870132549110894,"score_spread":0.25301007579235274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235632004","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009305942,0.14079511,0.10410523,0.0023463664,0.008118052,0.002248735,0.057676435,0.0064234026,0.6689808],"genre_scores_gemma":[0.02292866,0.055482406,0.08116981,0.0022624389,0.00062536664,0.0018731214,0.10577691,0.0017861532,0.7280951],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992907,0.00008145688,0.000058270198,0.00012909193,0.00038614785,0.000054312506],"domain_scores_gemma":[0.99979573,0.000052702504,0.000018788718,0.00004156709,0.00006541679,0.000025701567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063966285,0.0014632967,0.0013226956,0.0013764211,0.00090036524,0.002433721,0.0018105308,0.0012205163,0.06449629],"category_scores_gemma":[0.00072575646,0.00062004605,0.00086082314,0.0017355079,0.00046760368,0.0009758487,0.0012114017,0.0021542432,0.11247085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041237345,0.00036036674,0.00036370856,0.0059667197,0.000080649304,0.0017967151,0.00059013854,0.0008793094,0.34707752,0.045749377,0.31075737,0.28596577],"study_design_scores_gemma":[0.000011098867,0.000044699816,0.00013218466,0.000110883026,0.000013031472,0.00042917902,0.000018714205,0.00006434374,0.012354263,0.0012260044,0.9855871,0.000008507304],"about_ca_topic_score_codex":0.00082964776,"about_ca_topic_score_gemma":0.0015270414,"teacher_disagreement_score":0.06449629,"about_ca_system_score_codex":0.00079793,"about_ca_system_score_gemma":0.0006562346,"threshold_uncertainty_score":0.2157616},"labels":[],"label_agreement":null},{"id":"W4236849491","doi":"10.3410/f.726494315.793524865","title":"Faculty Opinions recommendation of Treatment of ongoing autoimmune encephalomyelitis with activated B-cell progenitors maturing into regulatory B cells.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Experimental autoimmune encephalomyelitis; Progenitor cell; Regulatory B cells; B cell; Encephalomyelitis; Immunology; Biology; Medicine; Cell biology; Stem cell; Multiple sclerosis","score_opus":0.02630271096871737,"score_gpt":0.3435737069009207,"score_spread":0.3172709959322033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236849491","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015391933,0.0005038174,0.00007670441,0.00021027747,0.00005846065,0.00003890117,0.9971245,0.00015428395,0.0016791832],"genre_scores_gemma":[0.0013808392,0.000680281,0.0005650021,0.00048648854,0.000059613263,0.00018094764,0.99443096,0.00008446758,0.0021314032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982822,0.00036956783,0.0003749805,0.00043913999,0.00038340717,0.000150652],"domain_scores_gemma":[0.9934043,0.0022575462,0.0015362025,0.00089978013,0.0012677468,0.0006344222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016733062,0.001583112,0.0020957254,0.0025352982,0.000493733,0.0021877945,0.0022538193,0.0026305267,0.112140045],"category_scores_gemma":[0.01743924,0.0005319237,0.0025899236,0.0037910126,0.00025450994,0.0014867774,0.0012297356,0.0014499355,0.060050532],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042533892,0.000032658427,0.0022741656,0.0041456493,0.00021318301,0.000025458261,0.000008671797,0.00023756713,0.0001561831,0.0002325014,0.9829064,0.009342218],"study_design_scores_gemma":[0.0015651382,0.00008581953,0.0097227255,0.0029490155,0.0005026664,0.000118535456,0.00002940457,0.0006074247,0.00060865394,0.0012285355,0.98253435,0.00004774699],"about_ca_topic_score_codex":0.014029301,"about_ca_topic_score_gemma":0.037005574,"teacher_disagreement_score":0.112140045,"about_ca_system_score_codex":0.0015015834,"about_ca_system_score_gemma":0.0030840382,"threshold_uncertainty_score":0.3751458},"labels":[],"label_agreement":null},{"id":"W4237314469","doi":"10.3410/f.726930282.793525784","title":"Faculty Opinions recommendation of Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Regeneration (biology); Niche; Biology; CD8; Ecological niche; Cell biology; Immunology; Ecology; Immune system","score_opus":0.04013321062593555,"score_gpt":0.36599733623305264,"score_spread":0.3258641256071171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237314469","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020697764,0.00027793486,0.00005522344,0.000117740135,0.000029783594,0.000013442736,0.9985,0.00016490369,0.0006340151],"genre_scores_gemma":[0.0010551485,0.00025097886,0.0003024982,0.00014177116,0.000018771429,0.00008337365,0.9971834,0.000043658743,0.0009203112],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984547,0.00024992792,0.0002617754,0.00048521327,0.00034698925,0.00020140811],"domain_scores_gemma":[0.99652267,0.0010722934,0.0007283098,0.00060020667,0.00068557233,0.00039098848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013804204,0.0020415783,0.0018281265,0.0033851136,0.0005716338,0.0025125616,0.0025928777,0.0026364732,0.059562534],"category_scores_gemma":[0.011252463,0.00057138025,0.0025925387,0.0046544713,0.0003471743,0.0012846397,0.001752295,0.0014711118,0.05356649],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002956409,0.000033726676,0.0042383014,0.0030988385,0.0002060553,0.000042794116,0.000017614064,0.00035828922,0.00022407122,0.00036305995,0.9848935,0.0062280577],"study_design_scores_gemma":[0.0010079802,0.000051828927,0.013473166,0.0015879729,0.00037389447,0.00017047065,0.000059541737,0.0008772052,0.00077717745,0.0015089,0.98006296,0.000048842896],"about_ca_topic_score_codex":0.019462384,"about_ca_topic_score_gemma":0.050285116,"teacher_disagreement_score":0.059562534,"about_ca_system_score_codex":0.0014188003,"about_ca_system_score_gemma":0.0031010292,"threshold_uncertainty_score":0.19925654},"labels":[],"label_agreement":null},{"id":"W4237457482","doi":"10.21203/rs.3.rs-59510/v1","title":"Efficacy and Safety of CD22 Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With B-cell Malignancies: A Protocol for a Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Meta-analysis; CD22; Medicine; Protocol (science); B cell; Immunotherapy; Oncology; Immunology; Internal medicine; Cancer; Antibody; Pathology; Alternative medicine","score_opus":0.13489594269038976,"score_gpt":0.44548884738199357,"score_spread":0.31059290469160383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237457482","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008634687,0.2958743,0.013744409,0.003107736,0.0014305963,0.63836855,0.0353799,0.00066421094,0.0027955621],"genre_scores_gemma":[0.019444833,0.07952755,0.014798767,0.00228982,0.00019585635,0.87691855,0.005197711,0.00008913184,0.0015378359],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9765223,0.008782897,0.009262467,0.0020695827,0.0026007395,0.00076204626],"domain_scores_gemma":[0.9799349,0.008938708,0.0056966604,0.0014347329,0.0034747135,0.0005202347],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.033640157,0.004095162,0.027077366,0.013427238,0.0017371958,0.0050432794,0.0042830007,0.004043036,0.021585736],"category_scores_gemma":[0.054176345,0.0026594035,0.03769725,0.011585846,0.0019245635,0.0044125114,0.0042101527,0.0025986827,0.0018258527],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013303666,0.0000350654,0.0005883979,0.95430446,0.032251984,0.00010729183,0.00018127897,0.00040866892,0.0003393412,0.00050278427,0.0025116566,0.0074388166],"study_design_scores_gemma":[0.010028414,0.00094281917,0.0050142016,0.5260462,0.41288087,0.00026768562,0.0004483741,0.00091484323,0.00082919316,0.0030180714,0.039351895,0.00025739198],"about_ca_topic_score_codex":0.005809846,"about_ca_topic_score_gemma":0.011638647,"teacher_disagreement_score":0.033640157,"about_ca_system_score_codex":0.008854366,"about_ca_system_score_gemma":0.02230005,"threshold_uncertainty_score":0.1779083},"labels":[],"label_agreement":null},{"id":"W4237606309","doi":"10.1515/iupac.84.1187","title":"T Cell, Drug-Specific","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Medicine; Immune system; Philosophy; Linguistics","score_opus":0.024827768472563374,"score_gpt":0.42363980525136774,"score_spread":0.3988120367788044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237606309","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014961063,0.00049764354,0.00009979484,0.000111399175,0.000040220482,0.000026140713,0.9975299,0.00014966186,0.0013956234],"genre_scores_gemma":[0.0014520581,0.0006223232,0.00060476287,0.00047578855,0.00003177326,0.0001867655,0.9948468,0.000059662198,0.0017200797],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99823207,0.00024242223,0.00036635273,0.000615131,0.00034523988,0.00019879568],"domain_scores_gemma":[0.99534565,0.0016366703,0.0010107326,0.0010406116,0.00070739357,0.00025895832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001285737,0.0015239045,0.0016653523,0.0034002766,0.0007094168,0.0030231318,0.0024518848,0.0025978053,0.10558812],"category_scores_gemma":[0.013970902,0.0006263631,0.0021423022,0.0059751538,0.00041676295,0.0017399937,0.0015870808,0.0023358124,0.06882025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000501008,0.000044350032,0.004065979,0.0058605843,0.00022760886,0.00006847876,0.0000201198,0.0007880865,0.00025003235,0.0010619572,0.97472304,0.012388897],"study_design_scores_gemma":[0.0005977576,0.000055947447,0.006317674,0.0014172319,0.00026275072,0.00023399931,0.000031334,0.0004138323,0.00037151008,0.0026145407,0.98764765,0.00003580701],"about_ca_topic_score_codex":0.013089609,"about_ca_topic_score_gemma":0.026513584,"teacher_disagreement_score":0.10558812,"about_ca_system_score_codex":0.0016247297,"about_ca_system_score_gemma":0.0035451136,"threshold_uncertainty_score":0.35322744},"labels":[],"label_agreement":null},{"id":"W4238786266","doi":"10.3410/f.7192959.7437055","title":"Faculty Opinions recommendation of Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation.","year":2010,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transcriptome; Diversification (marketing strategy); Signature (topology); CD8; Cytotoxic T cell; Stimulation; Antigen; Biology; Computational biology; Cell biology; Computer science; Immunology; Neuroscience; Gene; Genetics; In vitro; Business; Gene expression; Mathematics; Marketing","score_opus":0.05796864483014669,"score_gpt":0.36773873441947896,"score_spread":0.3097700895893323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238786266","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018149017,0.00032684515,0.00017340794,0.00023397162,0.00005981507,0.00002521756,0.99561214,0.00034161293,0.0014120148],"genre_scores_gemma":[0.0022001623,0.0001374389,0.00047311286,0.00009573283,0.000011405647,0.000053526233,0.9958573,0.00003396878,0.001137413],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989404,0.00021331667,0.000120377,0.00034572117,0.00025051448,0.00012956918],"domain_scores_gemma":[0.998406,0.0004487525,0.00023808541,0.0003685904,0.00034882166,0.00018984466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012549835,0.0015758955,0.0011853729,0.0020365044,0.0004884751,0.0017762369,0.0016619666,0.0017338184,0.022015339],"category_scores_gemma":[0.0048517413,0.00044001758,0.0012973011,0.0031052213,0.00035209308,0.00066519657,0.00094622053,0.0012422807,0.023593975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062157324,0.00009605958,0.005784808,0.0016176844,0.0002050831,0.00006357881,0.000029324048,0.000816455,0.0016246176,0.00036526943,0.9743079,0.014467677],"study_design_scores_gemma":[0.000998302,0.00014846494,0.039248947,0.00047720363,0.00035975577,0.00031632886,0.00010279316,0.0024230077,0.0041649938,0.001216596,0.95047486,0.00006869268],"about_ca_topic_score_codex":0.016495887,"about_ca_topic_score_gemma":0.041964885,"teacher_disagreement_score":0.022015339,"about_ca_system_score_codex":0.001198907,"about_ca_system_score_gemma":0.0024561873,"threshold_uncertainty_score":0.07364863},"labels":[],"label_agreement":null},{"id":"W4241026090","doi":"10.21203/rs.2.21605/v2","title":"Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Health Sciences Centre; Canadian Partnership Against Cancer; Canadian Agency for Drugs and Technologies in Health; Sunnybrook Health Science Centre; Queen's University; Cancer Care Ontario","funders":"Canadian Institutes of Health Research; Government of Ontario; Canadian Centre for Applied Research in Cancer Control; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Ipilimumab; Medicine; Internal medicine; Cohort; Population; Clinical trial; Oncology; Proportional hazards model; Cancer registry; Cancer; Immunotherapy","score_opus":0.12475419090019918,"score_gpt":0.4402671681884053,"score_spread":0.3155129772882061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241026090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912606,0.0013095386,0.00017850637,0.00039097594,0.00001600886,0.00010199727,0.005708628,0.00000693977,0.0010269221],"genre_scores_gemma":[0.99785584,0.00031882175,0.00013770894,0.00011135155,0.000010240361,0.00003216232,0.0012769506,0.0000030019276,0.00025382303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976235,0.000413376,0.0002209549,0.0005580331,0.00064061914,0.00054348394],"domain_scores_gemma":[0.99478513,0.00045594355,0.002036027,0.00036847594,0.0013791326,0.0009752245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018512848,0.00039286877,0.0007141165,0.00082312134,0.0017954363,0.0011552068,0.0013513165,0.0005013907,0.0015389175],"category_scores_gemma":[0.0039859843,0.0003773955,0.0012056207,0.0032165104,0.00089587725,0.0003374149,0.0006933655,0.0006919727,0.00012534768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034554163,0.000040121333,0.9958407,0.00006905733,0.00037551083,0.000090305715,0.00030034175,0.00015535351,0.00014248346,0.000118051204,0.0008765612,0.0016458776],"study_design_scores_gemma":[0.0000976758,0.00008396261,0.99758875,0.000044290235,0.00021316073,0.0000844127,0.00039932283,0.00048122142,0.000053104955,0.00003630614,0.00090303266,0.00001489751],"about_ca_topic_score_codex":0.9815639,"about_ca_topic_score_gemma":0.9849305,"teacher_disagreement_score":0.034329258,"about_ca_system_score_codex":0.034329258,"about_ca_system_score_gemma":0.02611709,"threshold_uncertainty_score":0.24907738},"labels":[],"label_agreement":null},{"id":"W4241442457","doi":"10.1093/annonc/mdw589.007","title":"410P Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Ipilimumab; Metastatic melanoma; Oncology; Internal medicine; Melanoma; Safety profile; Adverse effect; Cancer research; Cancer; Immunotherapy","score_opus":0.08230944959589033,"score_gpt":0.40613393726275415,"score_spread":0.32382448766686384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241442457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307936,0.00045404362,0.00011720362,0.00040247064,0.000012103962,0.000072123374,0.0010470047,0.000016659766,0.0047990214],"genre_scores_gemma":[0.9931994,0.0008152015,0.00017036768,0.00047624233,0.000008411758,0.00007232655,0.0010730112,0.000009126855,0.00417581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976593,0.000042114814,0.000016134123,0.000041496303,0.000062632396,0.0000716268],"domain_scores_gemma":[0.9996308,0.000047907666,0.000048176516,0.00002591758,0.0001288625,0.0001183907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004850035,0.00021346826,0.00023371942,0.00039606646,0.0005381805,0.0006018153,0.0004029113,0.00022565869,0.0021751772],"category_scores_gemma":[0.00052366935,0.00017385567,0.00022533425,0.0008240337,0.00027389007,0.00025240297,0.00033087019,0.0006196024,0.0006344017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021609848,0.0035870147,0.5437259,0.0002889702,0.0006148478,0.0024845982,0.0011626845,0.003704767,0.15227678,0.00089813164,0.012951617,0.25669476],"study_design_scores_gemma":[0.0013714967,0.0060475194,0.96830064,0.000058074344,0.00032666247,0.0007945589,0.0009988786,0.0018013349,0.010848092,0.00020500796,0.009192855,0.00005486567],"about_ca_topic_score_codex":0.4296563,"about_ca_topic_score_gemma":0.6617926,"teacher_disagreement_score":0.57034373,"about_ca_system_score_codex":0.005210458,"about_ca_system_score_gemma":0.0058361306,"threshold_uncertainty_score":0.85431087},"labels":[],"label_agreement":null},{"id":"W4242295440","doi":"10.5206/uwomj.v89i1.9469","title":"Building the fourth pillar","year":2021,"lang":"en","type":"article","venue":"University of Western Ontario Medical Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Oncolytic virus; Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; Medicine; Blockade; Cancer; Internal medicine; Receptor","score_opus":0.025012670425371218,"score_gpt":0.27311117658764145,"score_spread":0.24809850616227022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242295440","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033271436,0.04798299,0.024202289,0.53542674,0.062540196,0.00014452715,0.00047037876,0.0013865737,0.32451913],"genre_scores_gemma":[0.09555857,0.05814644,0.02243779,0.390742,0.029403059,0.00042681585,0.0008120645,0.002126625,0.4003466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99361366,0.001771305,0.00022372471,0.0011348526,0.001981973,0.0012745061],"domain_scores_gemma":[0.99034286,0.0021960996,0.00030869784,0.001437066,0.0021716272,0.003543585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012264452,0.0013066634,0.0010457046,0.0014300075,0.006679566,0.015597515,0.0027657868,0.008724163,0.07840969],"category_scores_gemma":[0.016989242,0.00063360506,0.0008237463,0.0009082616,0.013308913,0.01963816,0.01277838,0.015188748,0.034654826],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007286143,0.00007133887,0.0004660267,0.0002783006,0.0000235423,0.0001569046,0.0014887141,0.00017299781,0.00038519042,0.34582856,0.5500385,0.101017006],"study_design_scores_gemma":[0.0000070996116,0.00003152488,0.00008261901,0.0001967404,0.000004164966,0.0000832859,0.00051772833,0.00006752222,0.00014995925,0.036838092,0.96200913,0.000012092185],"about_ca_topic_score_codex":0.0052951346,"about_ca_topic_score_gemma":0.006392293,"teacher_disagreement_score":0.07840969,"about_ca_system_score_codex":0.005994457,"about_ca_system_score_gemma":0.012600869,"threshold_uncertainty_score":0.2623065},"labels":[],"label_agreement":null},{"id":"W4243255191","doi":"10.1515/iupac.84.0743","title":"Immunophilin","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Medicine; Immunology; Immune system; Philosophy; Linguistics","score_opus":0.024057115433931606,"score_gpt":0.4479425839081203,"score_spread":0.4238854684741887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243255191","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017997502,0.0002755589,0.000068245245,0.000102434955,0.000024525003,0.000015868423,0.9980951,0.0001822374,0.001055957],"genre_scores_gemma":[0.00063502253,0.0002639347,0.00031487757,0.00014743539,0.000010630514,0.00010185094,0.9976827,0.000050950075,0.0007925055],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99878365,0.00020490286,0.00023057497,0.00036427574,0.0002620725,0.00015448435],"domain_scores_gemma":[0.99760216,0.0008075788,0.00042226285,0.000473119,0.0004723053,0.00022251965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010585387,0.0014502385,0.0013295448,0.0038295228,0.0008309389,0.002834226,0.0020868618,0.0019151069,0.06848196],"category_scores_gemma":[0.007041116,0.0005905998,0.0014355349,0.0058883745,0.0003354,0.0014448685,0.0019248383,0.002018988,0.06592],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026777235,0.000031052114,0.0030462258,0.003064554,0.00009561021,0.000052900523,0.000039516774,0.000298926,0.00026578284,0.0013055867,0.984259,0.00727317],"study_design_scores_gemma":[0.00026888403,0.000025356425,0.006611964,0.00083885144,0.00007788654,0.00013220144,0.000052029693,0.00020447523,0.0003404539,0.0013970961,0.99002624,0.000024552723],"about_ca_topic_score_codex":0.011652534,"about_ca_topic_score_gemma":0.023316965,"teacher_disagreement_score":0.06848196,"about_ca_system_score_codex":0.0013943486,"about_ca_system_score_gemma":0.002970774,"threshold_uncertainty_score":0.22909492},"labels":[],"label_agreement":null},{"id":"W4245501240","doi":"10.1158/1538-7445.sabcs18-1449","title":"Abstract 1449: MG1 Maraba boost following adenovirus prime generates tumor antigen-specific T cells which are potentiated by anti-PD-1 antibody combination","year":2019,"lang":"en","type":"article","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interface Biologics (Canada)","funders":"","keywords":"Antigen; Antibody; Prime (order theory); Cancer research; Molecular biology; Virology; Chemistry; Immunology; Medicine; Biology; Mathematics","score_opus":0.014153524167485184,"score_gpt":0.2842191339901131,"score_spread":0.27006560982262795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245501240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577194,0.0005632249,0.0014265466,0.000057970294,0.00005327451,0.00008250862,0.00029926744,0.0000922898,0.0016529011],"genre_scores_gemma":[0.9947883,0.00034476325,0.0015318354,0.000036151436,0.000019085783,0.00004660624,0.00037162556,0.000010793829,0.0028508783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999094,0.000011049566,0.000006171437,0.000023608829,0.00002284657,0.00002679771],"domain_scores_gemma":[0.9999454,0.000009762082,0.000013494922,0.00000794825,0.000005592068,0.000017812346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008356709,0.0004064793,0.00030379978,0.00016286789,0.00009086528,0.0002142815,0.00015099457,0.00024350201,0.002041005],"category_scores_gemma":[0.00007618271,0.00009535679,0.00019407726,0.00008519152,0.00016273564,0.00015097397,0.00011472752,0.0007057771,0.00040831897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007803216,0.00023498337,0.00023432968,0.000051735842,0.0000068384934,0.00005098838,0.000017132166,0.00020187559,0.9946038,0.00011302399,0.00012048853,0.0035844953],"study_design_scores_gemma":[0.00008836678,0.0032615627,0.0018246032,0.0000049384184,0.00002064564,0.00018931192,0.0000092666905,0.0007164508,0.99150336,0.000024879992,0.0023538733,0.000002728271],"about_ca_topic_score_codex":0.000462234,"about_ca_topic_score_gemma":0.00046242544,"teacher_disagreement_score":0.002041005,"about_ca_system_score_codex":0.0002127157,"about_ca_system_score_gemma":0.0001964906,"threshold_uncertainty_score":0.006827891},"labels":[],"label_agreement":null},{"id":"W4246631325","doi":"10.3410/f.13355957.14725146","title":"Faculty Opinions recommendation of Increased sensitivity of antigen-experienced T cells through the enrichment of oligomeric T cell receptor complexes.","year":2011,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sensitivity (control systems); Antigen; Receptor; Chemistry; Molecular biology; Medicine; Biochemistry; Immunology; Biology; Engineering","score_opus":0.04953735841943186,"score_gpt":0.3701097629927112,"score_spread":0.32057240457327935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246631325","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005600421,0.0003353501,0.00017807116,0.00021363507,0.00007114621,0.000035170156,0.9969104,0.00063824287,0.0010579914],"genre_scores_gemma":[0.0016658105,0.00018615386,0.00083321036,0.00018762624,0.000020346435,0.000097427444,0.99550676,0.000074578624,0.0014280789],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986022,0.00024342064,0.00014409066,0.00048193982,0.0003810284,0.00014736736],"domain_scores_gemma":[0.9974004,0.0008156902,0.00035765654,0.0005550482,0.000619727,0.0002515166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016959897,0.0023355559,0.0017246642,0.0025901082,0.00054238393,0.0022587413,0.0025056575,0.0029042484,0.04018975],"category_scores_gemma":[0.008647734,0.00061848905,0.0021670628,0.0028619624,0.00029755422,0.0010829046,0.0011878698,0.0015788828,0.038823884],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027924072,0.000060062255,0.002457772,0.0019922352,0.00015082868,0.000024944937,0.000010518503,0.00053188694,0.00057170633,0.00023263138,0.98655397,0.0071343007],"study_design_scores_gemma":[0.0013441953,0.00011665687,0.015855988,0.0006029838,0.0004475422,0.00017539767,0.000047323665,0.003460608,0.0032076421,0.0015240943,0.97315097,0.00006657426],"about_ca_topic_score_codex":0.016061971,"about_ca_topic_score_gemma":0.040541507,"teacher_disagreement_score":0.04018975,"about_ca_system_score_codex":0.0013964217,"about_ca_system_score_gemma":0.0022403607,"threshold_uncertainty_score":0.13444811},"labels":[],"label_agreement":null},{"id":"W4246976359","doi":"10.1158/1538-7445.sabcs18-568","title":"Abstract 568: Decoding shared antigenic epitopes and their cognate TCR genes in melanoma TILs using a library of paired human cell-based pHLA multimers and artificial APCs","year":2019,"lang":"en","type":"article","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T-cell receptor; Epitope; Decoding methods; Gene; Computer science; Computational biology; Antigen; T cell; Biology; Genetics; Algorithm","score_opus":0.043211539481999385,"score_gpt":0.3006870073738447,"score_spread":0.2574754678918453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246976359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922536,0.00027741815,0.0063421484,0.000032922686,0.000012421781,0.000034003577,0.00018109016,0.000054118136,0.0008122317],"genre_scores_gemma":[0.9919654,0.00018444033,0.00586569,0.000036439986,0.000007426561,0.00003542639,0.0005146373,0.000020473854,0.0013699405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998994,0.000020474467,0.000009107255,0.000024277166,0.000025329387,0.000021504295],"domain_scores_gemma":[0.99995637,0.0000118231255,0.0000074472855,0.0000086461405,0.0000060866623,0.000009712879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011433533,0.00023881822,0.00019467591,0.00014980369,0.00009013407,0.00024130549,0.00010127653,0.0001828768,0.0013445934],"category_scores_gemma":[0.00015120665,0.00011198907,0.00016467542,0.00014285922,0.00008299237,0.00014934316,0.00020480741,0.0003833106,0.00050540117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008493383,0.000024911607,0.00034071133,0.000010684187,0.0000025287538,0.000027924512,0.000007883948,0.0002555073,0.997013,0.000027688791,0.000020822645,0.002183396],"study_design_scores_gemma":[0.000018806268,0.0003538196,0.002034485,0.0000028357929,0.000016120022,0.0002405481,0.0000140606435,0.0033508684,0.9926237,0.00003539794,0.001307129,0.000002217405],"about_ca_topic_score_codex":0.00014847645,"about_ca_topic_score_gemma":0.00019100102,"teacher_disagreement_score":0.0013445934,"about_ca_system_score_codex":0.00013752081,"about_ca_system_score_gemma":0.00013634957,"threshold_uncertainty_score":0.004498124},"labels":[],"label_agreement":null},{"id":"W4247287852","doi":"10.3410/f.735264826.793577575","title":"Faculty Opinions recommendation of Challenges of driving CD30-directed CAR-T cells to the clinic.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CD30; Medical education; Psychology; World Wide Web; Computer science; Medicine; Tumor cells; Cancer research","score_opus":0.07238136927602407,"score_gpt":0.4035608972835963,"score_spread":0.3311795280075722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247287852","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018855519,0.00024021271,0.000096278665,0.00047416647,0.000111591304,0.00002199187,0.99647444,0.0004598482,0.0019328131],"genre_scores_gemma":[0.0009533705,0.00019390225,0.000450504,0.00044024547,0.000038336104,0.00008526757,0.99521303,0.00009301402,0.0025322854],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982674,0.00038922572,0.0001911251,0.00043247445,0.0005209002,0.00019887781],"domain_scores_gemma":[0.9940216,0.002294228,0.0006103142,0.0009568942,0.0014395958,0.0006773593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022213939,0.0018045185,0.0013223201,0.0021345264,0.00077008037,0.002985056,0.0025591382,0.0031668174,0.095843025],"category_scores_gemma":[0.014656635,0.00055406726,0.0018984646,0.0028827665,0.00035775916,0.0015906813,0.0018289272,0.0018500754,0.10989514],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006348532,0.000016228583,0.00062746025,0.00046571135,0.00002002398,0.000008130028,0.000005919941,0.00012634852,0.00003903467,0.00014846447,0.99596053,0.0025186338],"study_design_scores_gemma":[0.00048561452,0.000039240524,0.0039420533,0.0005722423,0.00006733733,0.0000615073,0.000047996447,0.00095812813,0.00039092315,0.0011813906,0.99222285,0.00003060897],"about_ca_topic_score_codex":0.024817707,"about_ca_topic_score_gemma":0.0723203,"teacher_disagreement_score":0.095843025,"about_ca_system_score_codex":0.0018380755,"about_ca_system_score_gemma":0.003070292,"threshold_uncertainty_score":0.32062685},"labels":[],"label_agreement":null},{"id":"W4248028975","doi":"10.1002/ange.202005934","title":"Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy","year":2020,"lang":"en","type":"article","venue":"Angewandte Chemie","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; Danmarks Grundforskningsfond","keywords":"CD22; Selectin; Chemistry; Sialyl-Lewis X; Cancer research; Natural killer cell; Glycan; Lymphoma; Antigen; Immunology; Molecular biology; In vitro; Biology; CD20; Biochemistry; Cytotoxic T cell; Cell adhesion molecule; Glycoprotein","score_opus":0.02412454907267412,"score_gpt":0.257451623438061,"score_spread":0.23332707436538688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248028975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813297,0.003725927,0.010476907,0.00020388048,0.000055960238,0.00007010905,0.00008230503,0.000109307664,0.003946072],"genre_scores_gemma":[0.9948285,0.0011140609,0.0024197132,0.000043497443,0.0000075453263,0.000024085639,0.0000386441,0.0000064543215,0.0015174819],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999584,0.000009492398,0.000002106315,0.0000052666082,0.000012000819,0.0000125997285],"domain_scores_gemma":[0.99998486,0.0000015610417,0.000004966879,0.0000019360227,0.0000020557857,0.000004569433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007929403,0.0002268988,0.000098569,0.00010915515,0.000072334864,0.00017902012,0.00010576518,0.00018441353,0.0006926776],"category_scores_gemma":[0.000051576855,0.000059763952,0.00011129306,0.0000823871,0.00011385218,0.00013573171,0.00017436469,0.00027662484,0.00014594285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052128125,0.000030466064,0.00008830205,0.000029188988,0.000005416579,0.000046950965,0.000012232797,0.00023432315,0.99543864,0.00040871513,0.00009787297,0.0035557926],"study_design_scores_gemma":[0.000018841958,0.00025473646,0.00042417322,0.000003601202,0.0000112785165,0.00020393456,0.000009370313,0.0012754416,0.99338996,0.000054394917,0.0043509626,0.0000034265163],"about_ca_topic_score_codex":0.00041088558,"about_ca_topic_score_gemma":0.00050081895,"teacher_disagreement_score":0.0006926776,"about_ca_system_score_codex":0.00021460273,"about_ca_system_score_gemma":0.0001184369,"threshold_uncertainty_score":0.0023171902},"labels":[],"label_agreement":null},{"id":"W4248620541","doi":"10.3410/f.726113687.793527799","title":"Faculty Opinions recommendation of Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Antigen; Electronic circuit; Computer science; Engineering; Medicine; Immunology; Electrical engineering","score_opus":0.04817298631447522,"score_gpt":0.37806546270042246,"score_spread":0.32989247638594726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248620541","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006708987,0.00073912856,0.00022318674,0.0003983134,0.00011340353,0.000049807484,0.9952207,0.00096606364,0.0016185198],"genre_scores_gemma":[0.0011878314,0.00026229193,0.00067762355,0.00018901892,0.000024992874,0.00009329706,0.9962024,0.00005885749,0.0013036374],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998587,0.00022050594,0.00012238536,0.00048421777,0.00037699845,0.00020889967],"domain_scores_gemma":[0.9981589,0.00053256965,0.00021666978,0.0004229141,0.00039611442,0.00027279332],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0013587388,0.0037658343,0.0021373883,0.0027818005,0.0008008239,0.0026935032,0.0040186327,0.004169003,0.038807455],"category_scores_gemma":[0.0064673186,0.0007407375,0.0028203616,0.0034356115,0.00048607306,0.0013656444,0.001787028,0.0020333931,0.059947267],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020504785,0.00007090902,0.0014656032,0.001292336,0.00011214019,0.000035916953,0.000010679453,0.00080649584,0.00035294401,0.00030501268,0.9889121,0.0064307153],"study_design_scores_gemma":[0.0011431397,0.00013490194,0.006582645,0.00078146014,0.00032146802,0.00020680574,0.00007402471,0.005879249,0.002659053,0.0027500317,0.9793962,0.000071046976],"about_ca_topic_score_codex":0.026410466,"about_ca_topic_score_gemma":0.06155096,"teacher_disagreement_score":0.99864125,"about_ca_system_score_codex":0.002131666,"about_ca_system_score_gemma":0.0031760475,"threshold_uncertainty_score":0.12982386},"labels":[],"label_agreement":null},{"id":"W4249102396","doi":"10.3410/f.727097373.793532853","title":"Faculty Opinions recommendation of The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"CX3CR1; Chemokine receptor; CD8; Immunology; Immune system; Chemokine; Receptor; Antigen; Biology; Genetics","score_opus":0.03127407615262493,"score_gpt":0.3564286586257713,"score_spread":0.3251545824731463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249102396","genre_codex":"dataset","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000795165,0.00032275502,0.00009490012,0.00018483443,0.00003657438,0.000016659118,0.997324,0.00015193064,0.0010732492],"genre_scores_gemma":[0.0019357122,0.00022061865,0.00027423908,0.00012560094,0.000017204433,0.00006563109,0.9964275,0.000034174696,0.00089928275],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998804,0.00018098007,0.00016020956,0.00036196862,0.00031016464,0.00018261396],"domain_scores_gemma":[0.9979146,0.00059450173,0.00039281318,0.0003727915,0.00045761655,0.00026768915],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0010696199,0.0014673908,0.0013611121,0.0025166147,0.0005681282,0.0021172634,0.0018933141,0.0018526476,0.031264745],"category_scores_gemma":[0.0065058316,0.0004353574,0.0017175351,0.003503908,0.0003537285,0.00077171926,0.0014236904,0.0014050511,0.030751862],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041206725,0.00004492782,0.009692941,0.0018930631,0.00021455623,0.0000647896,0.000028991955,0.00044784194,0.00044597196,0.0007133201,0.97687596,0.009165515],"study_design_scores_gemma":[0.00085137214,0.00006248587,0.029485732,0.0009811857,0.00037474436,0.00029633922,0.00009391948,0.0010949891,0.0013359933,0.001544305,0.9638286,0.000050361785],"about_ca_topic_score_codex":0.020127984,"about_ca_topic_score_gemma":0.045042045,"teacher_disagreement_score":0.9989304,"about_ca_system_score_codex":0.001309607,"about_ca_system_score_gemma":0.0032649795,"threshold_uncertainty_score":0.10459101},"labels":[],"label_agreement":null},{"id":"W4251215396","doi":"10.1142/s021903031400069x","title":"EYE ON CHINA","year":2014,"lang":"en","type":"article","venue":"Asia-Pacific Biotech News","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Milestone; China; General partnership; License; Joint venture; Engineering; Business; Management; Political science; Geography; Finance; Economics; Commerce; Cartography","score_opus":0.019729551572275232,"score_gpt":0.30149630768308666,"score_spread":0.2817667561108114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251215396","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013907676,0.010601654,0.00038291182,0.064666785,0.032410182,0.00005566971,0.0015157216,0.0006347693,0.8883415],"genre_scores_gemma":[0.006023787,0.002935545,0.00015419297,0.020588564,0.0018812912,0.000025989857,0.00054979854,0.00013889397,0.9677019],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996338,0.00003222196,0.000012607969,0.00007105492,0.00013952004,0.00011080289],"domain_scores_gemma":[0.9995845,0.00004314911,0.000019992427,0.000053619126,0.00015743585,0.00014134627],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003842179,0.0008772823,0.0005615119,0.0008905738,0.003082974,0.0046274774,0.00051865337,0.003064601,0.41723615],"category_scores_gemma":[0.0014509514,0.0001976671,0.0005424354,0.00081638363,0.0009523845,0.0024476803,0.0021200902,0.0038955829,0.1502562],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037469148,0.000009533892,0.00020066417,0.000040874966,0.000004218512,0.00017473487,0.000079372054,0.000013245137,0.00018518625,0.012277205,0.952592,0.034385543],"study_design_scores_gemma":[0.000005171633,0.0000056220647,0.00024484508,0.000031967138,0.0000011480025,0.000063481726,0.00007149399,0.000008131901,0.00004367182,0.0008164484,0.99870515,0.0000026845232],"about_ca_topic_score_codex":0.020803086,"about_ca_topic_score_gemma":0.041664865,"teacher_disagreement_score":0.41723615,"about_ca_system_score_codex":0.0021149262,"about_ca_system_score_gemma":0.0031048052,"threshold_uncertainty_score":0.8312419},"labels":[],"label_agreement":null},{"id":"W4251633200","doi":"10.21037/tcr.2016.05.29","title":"Innate immunosurveillance: the next frontier in the cancer immunotherapy toolbox","year":2016,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Immunosurveillance; Frontier; Cancer immunotherapy; Immunotherapy; Cancer; Medicine; Toolbox; Immunology; Computer science; Geography; Internal medicine; Programming language","score_opus":0.14147887814801577,"score_gpt":0.4386822039420392,"score_spread":0.2972033257940234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251633200","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04328795,0.7535739,0.036047757,0.13569316,0.0039550867,0.000102010854,0.00043179735,0.0006300222,0.02627824],"genre_scores_gemma":[0.5700681,0.36065623,0.019667065,0.025218878,0.010452484,0.00020863539,0.0003521292,0.000106588275,0.013269947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99881834,0.0004606291,0.000045814868,0.00017868492,0.00027869508,0.000217778],"domain_scores_gemma":[0.99762064,0.0010433309,0.0002685104,0.00021436953,0.0003155488,0.00053757033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041559595,0.00067210104,0.0015916418,0.00086738734,0.0008382043,0.004831076,0.0010428777,0.0023043763,0.008355992],"category_scores_gemma":[0.002309774,0.00018253797,0.0005047835,0.0005356812,0.005040014,0.0054601887,0.002522109,0.0064682686,0.0014615504],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009842594,0.00050196843,0.004307954,0.0025715579,0.0001291145,0.00076652365,0.00068216544,0.0019254459,0.0783883,0.24747778,0.047572397,0.6146925],"study_design_scores_gemma":[0.00022812327,0.0022119337,0.004894765,0.001785495,0.00013482835,0.003874922,0.0029735311,0.005793699,0.03866107,0.3287127,0.61058545,0.00014348052],"about_ca_topic_score_codex":0.00035058128,"about_ca_topic_score_gemma":0.0006154962,"teacher_disagreement_score":0.008355992,"about_ca_system_score_codex":0.0015654885,"about_ca_system_score_gemma":0.0032502227,"threshold_uncertainty_score":0.027953625},"labels":[],"label_agreement":null},{"id":"W4253005829","doi":"10.1007/978-1-4939-9597-4_1","title":"Introduction to the Immune System","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Multicellular organism; Immune system; Organism; Biology; Acquired immune system; Innate immune system; Immunity; Mechanism (biology); Autoimmunity; Immunology; Cell; Genetics; Philosophy","score_opus":0.02499319325832197,"score_gpt":0.4248316836432698,"score_spread":0.39983849038494784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253005829","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025240907,0.50940216,0.13861558,0.059638828,0.06595786,0.00023415672,0.0014481867,0.001072221,0.22110693],"genre_scores_gemma":[0.04378364,0.32161903,0.09176821,0.062442742,0.072524615,0.0008724591,0.0014551826,0.0007071577,0.404827],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993217,0.00022017711,0.000039443028,0.00017100314,0.00017494822,0.00007268582],"domain_scores_gemma":[0.99914193,0.0004194974,0.00004037698,0.00010995948,0.00016220192,0.00012595141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012152281,0.0013114074,0.0007739526,0.0016735443,0.0009178043,0.0026389821,0.0013746801,0.0020354367,0.028570052],"category_scores_gemma":[0.001327853,0.0005072895,0.0009619013,0.00072738604,0.0032823947,0.0024950255,0.002152023,0.0060211695,0.016205113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008435452,0.000104903935,0.00035869054,0.0012050219,0.000029696626,0.0002087062,0.0004062923,0.00043204078,0.0043282397,0.47905162,0.29423672,0.21955359],"study_design_scores_gemma":[0.0000051382444,0.000025939658,0.00013100568,0.00016871492,0.0000042230913,0.00015227203,0.000026157446,0.00007715424,0.0003204385,0.04910916,0.94997156,0.000008227587],"about_ca_topic_score_codex":0.00062539644,"about_ca_topic_score_gemma":0.0007212005,"teacher_disagreement_score":0.028570052,"about_ca_system_score_codex":0.0011904627,"about_ca_system_score_gemma":0.0011765363,"threshold_uncertainty_score":0.095576346},"labels":[],"label_agreement":null},{"id":"W4254214995","doi":"10.3410/f.717972360.793471504","title":"Faculty Opinions recommendation of Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.","year":2013,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Amphiregulin; Epidermal growth factor receptor; Function (biology); Cancer research; Factor (programming language); Cell biology; TGF alpha; Epidermal growth factor; Biology; Chemistry; Receptor; Internal medicine; Medicine; Computer science","score_opus":0.03395499331498569,"score_gpt":0.3458721974259459,"score_spread":0.3119172041109602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254214995","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045644026,0.00039421866,0.00007154117,0.00018414245,0.000040434836,0.000020697305,0.9976046,0.00021597322,0.0010118621],"genre_scores_gemma":[0.0016008187,0.00031239763,0.00037811222,0.00019175358,0.000019748713,0.000085131054,0.99597424,0.00005003193,0.0013876252],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888045,0.0001947293,0.00014624161,0.0003162288,0.00033025464,0.00013222062],"domain_scores_gemma":[0.9978783,0.000647921,0.00038336794,0.0003511238,0.0004885473,0.00025074696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011133994,0.001680773,0.0014390025,0.0021350607,0.00054417487,0.0018891509,0.0018765205,0.0021254597,0.04568257],"category_scores_gemma":[0.0069371467,0.00045996532,0.0019874582,0.003609978,0.00026220133,0.00094314554,0.0011324546,0.001315768,0.039035466],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044781083,0.00005542732,0.003050376,0.0019259269,0.0001747117,0.000031938547,0.000012682378,0.0003553743,0.00040082558,0.00026284726,0.9858655,0.007416603],"study_design_scores_gemma":[0.0016117793,0.000113157395,0.017190913,0.0009193203,0.0004890143,0.00016930686,0.00005390738,0.0015131602,0.0019859315,0.0012236796,0.97467077,0.000059164922],"about_ca_topic_score_codex":0.023922037,"about_ca_topic_score_gemma":0.05417561,"teacher_disagreement_score":0.04568257,"about_ca_system_score_codex":0.0015044708,"about_ca_system_score_gemma":0.0028637825,"threshold_uncertainty_score":0.15282345},"labels":[],"label_agreement":null},{"id":"W4256455700","doi":"10.3410/f.737287958.793573609","title":"Faculty Opinions recommendation of THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Priming (agriculture); Chimeric antigen receptor; Antigen; Cell biology; Computer science; T cell; Immunology; Biology; Immune system","score_opus":0.0693913031097337,"score_gpt":0.3837607891048951,"score_spread":0.3143694859951614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256455700","genre_codex":"dataset","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002867767,0.00030330094,0.000043545468,0.00013961618,0.000033953922,0.000012447391,0.99834895,0.00021861767,0.00061284367],"genre_scores_gemma":[0.0010500589,0.00021573566,0.0002472049,0.00013491113,0.000012710506,0.00007328146,0.9973858,0.000045936147,0.0008343922],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988279,0.00022257684,0.00013718774,0.0003977249,0.00025142296,0.00016320606],"domain_scores_gemma":[0.99760675,0.0009452561,0.00035599657,0.00037209442,0.00042077902,0.000299128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013929338,0.00196415,0.0016431223,0.0024043978,0.0006882518,0.0025841997,0.002311754,0.0024705764,0.06448503],"category_scores_gemma":[0.0076567503,0.0005773379,0.0023341107,0.0034081032,0.0003380115,0.001085114,0.0016386969,0.001605165,0.05405733],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034729342,0.000046738292,0.0028070724,0.0026490754,0.00019585967,0.000030340098,0.00001963211,0.00045692408,0.00030511423,0.00033515936,0.9870645,0.0057423003],"study_design_scores_gemma":[0.0014858058,0.00009441362,0.013812638,0.0012731121,0.00042629137,0.00012233538,0.00007785444,0.0014074802,0.0012197349,0.001545225,0.97847694,0.000058065674],"about_ca_topic_score_codex":0.022076575,"about_ca_topic_score_gemma":0.04947091,"teacher_disagreement_score":0.06448503,"about_ca_system_score_codex":0.0015550449,"about_ca_system_score_gemma":0.0025855335,"threshold_uncertainty_score":0.21572393},"labels":[],"label_agreement":null},{"id":"W4280488168","doi":"10.1136/jitc-2021-003487","title":"Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"T-cell receptor; Cancer immunotherapy; Medicine; Immunotherapy; Translational research; Chimeric antigen receptor; T cell; Cancer research; Immune system; Computational biology; Immunology; Bioinformatics; Biology; Pathology","score_opus":0.05417610846829858,"score_gpt":0.3756960139525929,"score_spread":0.3215199054842943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083939725,0.9935348,0.0028328428,0.00089485385,0.0003193779,0.000030356165,0.00011544905,0.000051693944,0.0013812035],"genre_scores_gemma":[0.00839194,0.98402643,0.004518548,0.001002088,0.0003436732,0.00008753078,0.00024818146,0.00003158205,0.0013500091],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993088,0.00020746498,0.00005964135,0.00011029747,0.00026671897,0.000046998448],"domain_scores_gemma":[0.99832195,0.0010951508,0.00019265042,0.0000437586,0.00030133457,0.000045075627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027079335,0.0010863267,0.0023207334,0.0013566408,0.00012473897,0.0016855003,0.001263909,0.0016717513,0.0020054223],"category_scores_gemma":[0.003207402,0.00036583998,0.0009181031,0.0008654675,0.0005018507,0.0018321048,0.00044254126,0.002214877,0.0018585878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024042031,0.000111766385,0.0009364074,0.013644863,0.00028477362,0.000110628935,0.00005298728,0.0024220012,0.007580895,0.006830416,0.016699439,0.95108545],"study_design_scores_gemma":[0.00013772407,0.0019064692,0.0041240477,0.009285229,0.0011689377,0.0022232234,0.00018729347,0.0051423227,0.018491127,0.01399641,0.94311905,0.00021827771],"about_ca_topic_score_codex":0.0009178647,"about_ca_topic_score_gemma":0.0011107902,"teacher_disagreement_score":0.0027079335,"about_ca_system_score_codex":0.0007770672,"about_ca_system_score_gemma":0.0011905682,"threshold_uncertainty_score":0.014321089},"labels":[],"label_agreement":null},{"id":"W4280509433","doi":"10.3390/curroncol29050293","title":"CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja","keywords":"Chimeric antigen receptor; Chronic lymphocytic leukemia; Medicine; CAR T-cell therapy; Leukemia; Lymphoma; Cancer research; T cell; Cell therapy; Immunology; Cell; Immune system; Biology","score_opus":0.22125683590318834,"score_gpt":0.4845948981931005,"score_spread":0.26333806228991213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280509433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013743303,0.99892235,0.000072669245,0.00019432117,0.000104315106,0.000002473016,0.000011501509,0.0000045074894,0.00055034197],"genre_scores_gemma":[0.00059068,0.9988386,0.00008420766,0.00014050848,0.00007669717,0.0000036929137,0.000015981368,0.0000010358322,0.00024863964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984765,0.000033647593,0.000023074586,0.000027626622,0.000052968473,0.000014956011],"domain_scores_gemma":[0.9997315,0.00015036999,0.0000281706,0.000007645767,0.00006303844,0.000019378273],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005592945,0.00049995567,0.0009797356,0.0013390955,0.00018635472,0.0007368578,0.00058893283,0.0007492212,0.0026904219],"category_scores_gemma":[0.0006767259,0.0001679015,0.00043623018,0.0013901739,0.00032099924,0.00096576416,0.00043098518,0.0013939084,0.0013118533],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009112119,0.000056111694,0.0001136864,0.01631542,0.00006349229,0.00017243398,0.00006069071,0.0003163312,0.001989322,0.0027283202,0.018954305,0.9591387],"study_design_scores_gemma":[0.00002638269,0.00019420982,0.0005823265,0.0044261534,0.00017178147,0.00149868,0.00006765566,0.00009556567,0.0008960555,0.0017091647,0.9903144,0.000017481352],"about_ca_topic_score_codex":0.0005327833,"about_ca_topic_score_gemma":0.001125578,"teacher_disagreement_score":0.0026904219,"about_ca_system_score_codex":0.00040293147,"about_ca_system_score_gemma":0.0007764613,"threshold_uncertainty_score":0.009000421},"labels":[],"label_agreement":null},{"id":"W4280604259","doi":"10.1016/j.cjca.2022.05.013","title":"A New Era: Immunotherapy Applied to Contemporary Cardiovascular Practice","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; McGill University; Jewish General Hospital; Université de Montréal; McGill University Health Centre","funders":"Sanofi; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Medicine; Proprotein convertase; Immunotherapy; Monoclonal antibody; Immune system; Kexin; Immunology; Chimeric antigen receptor; Antibody; Internal medicine; LDL receptor","score_opus":0.030902647651151,"score_gpt":0.28718040020412156,"score_spread":0.2562777525529706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280604259","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039003054,0.5990747,0.004136527,0.34321263,0.028444963,0.000039432904,0.00011636745,0.00019778035,0.020877266],"genre_scores_gemma":[0.09478435,0.56104994,0.0126811545,0.16896906,0.14915647,0.00014113766,0.00017162197,0.00013590264,0.012910424],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99787414,0.0008366323,0.00017645677,0.00028304753,0.00053976465,0.00028991987],"domain_scores_gemma":[0.99059063,0.0049308673,0.0004926679,0.00040058396,0.0019551232,0.0016300566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005899108,0.00087297295,0.001564946,0.0022285169,0.0017742409,0.0077696075,0.0015689527,0.0068151476,0.01570107],"category_scores_gemma":[0.007714631,0.00031844855,0.0008935993,0.0015541007,0.005548404,0.0094119,0.002644193,0.007665628,0.0027372793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004524214,0.000399968,0.0028203826,0.0026572426,0.0000957614,0.00079300563,0.0009810746,0.0005472042,0.0035981252,0.104868084,0.2455373,0.63724947],"study_design_scores_gemma":[0.00016999945,0.00045558988,0.00322836,0.0039324374,0.000107863736,0.0013977767,0.0020030485,0.0012951124,0.00052064046,0.12327619,0.8635134,0.00009955046],"about_ca_topic_score_codex":0.0025041874,"about_ca_topic_score_gemma":0.007148774,"teacher_disagreement_score":0.01570107,"about_ca_system_score_codex":0.0037660752,"about_ca_system_score_gemma":0.0071760225,"threshold_uncertainty_score":0.05252534},"labels":[],"label_agreement":null},{"id":"W4280617218","doi":"10.1097/01.cot.0000832072.72279.6e","title":"Shop talk","year":2022,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.03439930018503596,"score_gpt":0.3662236639485787,"score_spread":0.33182436376354274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280617218","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008558584,0.0031869628,0.0019202704,0.046881624,0.067694835,0.00025464877,0.0026799703,0.0030434495,0.8734824],"genre_scores_gemma":[0.003025708,0.0013791486,0.00062804145,0.016738178,0.0072659394,0.00009888534,0.0012356006,0.000772841,0.96885574],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998613,0.00022377861,0.000062862666,0.0002726708,0.0005784377,0.0002492967],"domain_scores_gemma":[0.9956814,0.00046796887,0.00012552582,0.0002891898,0.0014657894,0.0019701081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012942788,0.0012448106,0.00082810957,0.0013981129,0.0030349728,0.0077629276,0.0017315816,0.003950875,0.80873156],"category_scores_gemma":[0.007749279,0.00044879343,0.00089620677,0.00083693326,0.00071675575,0.004351051,0.0046979594,0.004527228,0.67642546],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001835215,0.000016400103,0.000064513006,0.000030677373,0.0000015180138,0.00006067879,0.00003609356,0.000009793191,0.00004831294,0.0012882701,0.97430986,0.0241156],"study_design_scores_gemma":[0.000004478455,0.000007304309,0.00009688831,0.000029358425,9.49232e-7,0.00007742813,0.0000940767,0.000013181931,0.00002208931,0.00045400092,0.9991967,0.0000036096346],"about_ca_topic_score_codex":0.0017176684,"about_ca_topic_score_gemma":0.003597549,"teacher_disagreement_score":0.80873156,"about_ca_system_score_codex":0.0015254028,"about_ca_system_score_gemma":0.0023830894,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4281263083","doi":"10.1016/j.jtct.2022.05.026","title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Legend Biotech; Pharmacyclics; Kite Pharma; MorphoSys; Daiichi-Sankyo; Miltenyi Biotec; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Tessa Therapeutics; BeiGene; Atara Biotherapeutics; Kyowa Kirin Pharmaceutical Development; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Servier; Gilead Sciences; Celgene; Novartis; AbbVie; Merck; Bristol-Myers Squibb; Cidara Therapeutics; AstraZeneca; Amgen; Seagen; Sierra Oncology; Astellas Pharma US","keywords":"Medicine; Internal medicine; Cohort; Odds ratio; Confidence interval; Oncology","score_opus":0.05882848758754067,"score_gpt":0.3396543056612309,"score_spread":0.2808258180736902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281263083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72583145,0.22046478,0.0012134545,0.027855892,0.00086915714,0.0003056485,0.00470937,0.00006558033,0.018684687],"genre_scores_gemma":[0.9737176,0.018354828,0.00056533684,0.0051395292,0.0003911042,0.00006121955,0.0014058317,0.000011364465,0.00035324864],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9895867,0.007954013,0.00087182125,0.00039587388,0.0009388774,0.00025262986],"domain_scores_gemma":[0.95286876,0.027431417,0.013876975,0.0015303459,0.0024998286,0.0017926919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015362022,0.00023025763,0.00048091594,0.0004984646,0.0002874224,0.0018006285,0.00059728127,0.0007996811,0.0034402038],"category_scores_gemma":[0.03246662,0.0001851703,0.0010679328,0.0006639488,0.0009626504,0.0008341244,0.0007637038,0.0012023699,0.0003170877],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09459931,0.003094844,0.40724495,0.009751281,0.011151142,0.00050447,0.00063898676,0.0031263807,0.001845469,0.0048220446,0.026952147,0.43626907],"study_design_scores_gemma":[0.026539298,0.045279738,0.74937713,0.012025766,0.014353448,0.0017352472,0.001959604,0.005482653,0.0024106174,0.0043320637,0.13632272,0.00018167977],"about_ca_topic_score_codex":0.0020690379,"about_ca_topic_score_gemma":0.0053967424,"teacher_disagreement_score":0.015362022,"about_ca_system_score_codex":0.0010371617,"about_ca_system_score_gemma":0.0015551309,"threshold_uncertainty_score":0.0812431},"labels":[],"label_agreement":null},{"id":"W4281564783","doi":"10.1089/jir.2021.0236","title":"The Role of Chemokine IL-7 in Tumor and Its Potential Antitumor Immunity","year":2022,"lang":"en","type":"review","venue":"Journal of Interferon & Cytokine Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chemokine; Biology; Immunology; Cancer research; Cytokine; Lymphoma; Immunity; Tumor microenvironment; Acquired immune system; Immune system","score_opus":0.09748215922676258,"score_gpt":0.42247065406219686,"score_spread":0.3249884948354343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281564783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012626871,0.99891555,0.00006022389,0.00022216121,0.00017278006,0.0000018467954,0.000008907431,0.000002761033,0.0004893934],"genre_scores_gemma":[0.0006855985,0.9985482,0.00007360318,0.00014958778,0.00020232682,0.0000036505828,0.000015166859,6.007304e-7,0.0003211083],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998853,0.000019468023,0.000016019641,0.000020137906,0.000045213,0.0000139378035],"domain_scores_gemma":[0.9998566,0.00006068485,0.000019006056,0.0000038971666,0.000043934626,0.000015821533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034322162,0.0004942128,0.0007877268,0.0014486491,0.00020739665,0.0007789395,0.00045007508,0.00080452504,0.0019499552],"category_scores_gemma":[0.00040096027,0.00016128292,0.00033718965,0.0013941495,0.00031258244,0.00095107424,0.00042105358,0.0012676162,0.00094461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009546679,0.00006220288,0.00029691446,0.015243494,0.000072027426,0.00031537967,0.00008020119,0.0004386987,0.0033673688,0.0066449605,0.036602274,0.93678105],"study_design_scores_gemma":[0.000020453013,0.00011175804,0.0010474848,0.003005709,0.0001003665,0.0023589325,0.00007708867,0.00013333124,0.00066961464,0.0028816594,0.98957217,0.00002136918],"about_ca_topic_score_codex":0.00056344626,"about_ca_topic_score_gemma":0.00094387634,"teacher_disagreement_score":0.0019499552,"about_ca_system_score_codex":0.00042067765,"about_ca_system_score_gemma":0.0010015544,"threshold_uncertainty_score":0.006523311},"labels":[],"label_agreement":null},{"id":"W4281631797","doi":"10.1200/jco.2022.40.16_suppl.8006","title":"Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Toxicity; Cohort; Antibody; Oncology; Immunology; Cancer; Chimeric antigen receptor; Immunotherapy","score_opus":0.09750823413975031,"score_gpt":0.4644746690344346,"score_spread":0.3669664348946843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281631797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98827934,0.0016775602,0.00090795907,0.0007426974,0.00007525203,0.0030563665,0.0028132398,0.00011477278,0.002332776],"genre_scores_gemma":[0.98391205,0.0011989437,0.0021481237,0.0015754094,0.00019987371,0.0032853757,0.0057695913,0.00006800815,0.0018424927],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991009,0.0005409258,0.00003917231,0.00012212856,0.00007855235,0.00011828507],"domain_scores_gemma":[0.9988305,0.00024370279,0.00023055698,0.000099659424,0.00008938288,0.0005061594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029556016,0.0017952345,0.0016915448,0.00040623543,0.00068296224,0.001070467,0.0009600121,0.0016125491,0.0032448126],"category_scores_gemma":[0.001895891,0.0005231887,0.001268304,0.0004175738,0.0008854788,0.0010252657,0.00051143946,0.003330826,0.000927491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76942426,0.0570309,0.013701884,0.00065397425,0.0014404438,0.0007230929,0.00052588317,0.0035852268,0.049273986,0.00029807247,0.009091565,0.094250716],"study_design_scores_gemma":[0.52437407,0.43568006,0.025025241,0.00006137854,0.0008531975,0.000809231,0.00006726991,0.0020861838,0.006273051,0.0004199453,0.004301486,0.000048890826],"about_ca_topic_score_codex":0.0009983706,"about_ca_topic_score_gemma":0.002400196,"teacher_disagreement_score":0.0032448126,"about_ca_system_score_codex":0.0012643231,"about_ca_system_score_gemma":0.0019470822,"threshold_uncertainty_score":0.0156309},"labels":[],"label_agreement":null},{"id":"W4281636766","doi":"10.1182/bloodadvances.2021006193","title":"Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"Kite Pharma; Chugai Pharmaceutical; Genentech; MorphoSys; SymBio Pharmaceuticals Limited; Ono Pharmaceutical; Teijin Pharma; TG Therapeutics; Kiadis Pharma; Japan Science and Technology Agency; Juno Therapeutics; Astellas Pharma; Eisai; Daiichi-Sankyo; Omeros Corporation; Pfizer; Incyte; BeiGene; Loxo Oncology; Astex Pharmaceuticals; Nippon Shinyaku; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Karyopharm Therapeutics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Amgen; Fuji Pharma; Japan Society for the Promotion of Science; GlaxoSmithKline","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Medicine; Term (time); Oncology; Internal medicine; Cancer research; Biology; Physics","score_opus":0.009813489538978077,"score_gpt":0.2651330121369403,"score_spread":0.2553195225979622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281636766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95698225,0.031366136,0.0014077388,0.0015586544,0.00029451717,0.00014379874,0.0018624564,0.00018545832,0.00619887],"genre_scores_gemma":[0.9933107,0.0026401866,0.0002154398,0.0007940355,0.00011719371,0.00006650834,0.0012023151,0.000019297822,0.0016343642],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997876,0.00008795503,0.000013861023,0.000027302187,0.00003290202,0.000050362538],"domain_scores_gemma":[0.9995486,0.00014394801,0.00011619571,0.000043376334,0.00004534059,0.00010246094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005614656,0.00021807794,0.0007785815,0.00014616566,0.00022990596,0.00053610187,0.0002947834,0.00037199934,0.002649087],"category_scores_gemma":[0.0008770892,0.00007285628,0.0006889845,0.00021627065,0.00021713949,0.0004103745,0.00017099763,0.0014712757,0.00069195416],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14231974,0.0029756867,0.0434302,0.001697639,0.0024768705,0.0009105818,0.00028982223,0.0018176949,0.030097397,0.00084912917,0.010115308,0.76301986],"study_design_scores_gemma":[0.08167632,0.32657075,0.40294537,0.0012478831,0.0060282396,0.009821385,0.0008282955,0.009010178,0.026222076,0.0035435085,0.13193908,0.00016692509],"about_ca_topic_score_codex":0.00033097115,"about_ca_topic_score_gemma":0.00093430665,"teacher_disagreement_score":0.002649087,"about_ca_system_score_codex":0.00040677702,"about_ca_system_score_gemma":0.0003816765,"threshold_uncertainty_score":0.008862138},"labels":[],"label_agreement":null},{"id":"W4281649068","doi":"10.1007/s12094-022-02847-2","title":"Overcome tumor relapse in CAR T cell therapy","year":2022,"lang":"en","type":"review","venue":"Clinical & Translational Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundamental Research Funds for the Central Universities; Ministry of Economic Development and Trade, Government of Alberta; Innovation and Entrepreneurship Talent Project of Lanzhou","keywords":"Chimeric antigen receptor; Medicine; CAR T-cell therapy; Cell therapy; Genetic enhancement; T cell; Immunotherapy; Antigen; Cancer research; Immune system; Cell; Immunology; Bioinformatics; Gene; Biology; Genetics","score_opus":0.2979011158614083,"score_gpt":0.5288572603495724,"score_spread":0.23095614448816404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281649068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011603082,0.9979578,0.00016902859,0.0004993778,0.00026613928,0.000010762288,0.000021305634,0.000010543021,0.0009490869],"genre_scores_gemma":[0.0013870087,0.9964978,0.0002121934,0.0007585185,0.00028563684,0.000022756944,0.00004300737,0.0000027747249,0.0007902432],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998134,0.000049798684,0.000019762168,0.000032075204,0.000049439757,0.00003553742],"domain_scores_gemma":[0.99973327,0.00015864309,0.000035585374,0.000007964348,0.000044230324,0.00002021072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010529602,0.001160618,0.0020129497,0.0014723382,0.00025836803,0.001139674,0.0009726273,0.0015681194,0.0055564605],"category_scores_gemma":[0.0009232237,0.00036732122,0.0007597755,0.0013760352,0.0006105074,0.0014852019,0.0008267266,0.0032016994,0.0020950432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025408692,0.00014347835,0.000067973095,0.016205026,0.00014274287,0.00009676249,0.000036529087,0.00066771056,0.0014787433,0.0042944136,0.044546727,0.9320659],"study_design_scores_gemma":[0.00027286535,0.0004963422,0.00045139506,0.005761331,0.00038679704,0.0006046991,0.000036544538,0.00032051987,0.00088164327,0.0028481989,0.9879118,0.00002781971],"about_ca_topic_score_codex":0.001026304,"about_ca_topic_score_gemma":0.0028123641,"teacher_disagreement_score":0.0055564605,"about_ca_system_score_codex":0.00091485505,"about_ca_system_score_gemma":0.0012833268,"threshold_uncertainty_score":0.018588245},"labels":[],"label_agreement":null},{"id":"W4281674079","doi":"10.1200/jco.2022.40.16_suppl.8032","title":"A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Oncology; Population; Cytokine release syndrome; Lenalidomide; Multiple myeloma; Gastroenterology; Immunotherapy; Cancer","score_opus":0.1389415827981114,"score_gpt":0.46661091116697845,"score_spread":0.3276693283688671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281674079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8576802,0.11914899,0.0040540257,0.0034069598,0.00043777737,0.003631734,0.0049736616,0.00037737004,0.006289321],"genre_scores_gemma":[0.91295254,0.04883646,0.014783886,0.0050891363,0.00049662637,0.0024890013,0.012249961,0.000106756524,0.0029956403],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99943715,0.00023136726,0.000052024057,0.00006690401,0.00013010847,0.000082377504],"domain_scores_gemma":[0.99941707,0.000104075254,0.0002296243,0.000040452247,0.0000805885,0.00012824863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027822768,0.0007623109,0.0012679633,0.0005433891,0.00026672852,0.00089772383,0.00092856627,0.0007763599,0.0020605125],"category_scores_gemma":[0.00088035536,0.0003058786,0.0012095706,0.0005240623,0.00030867718,0.0007885412,0.00046245081,0.0015869598,0.00049815257],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059017204,0.011947446,0.020130958,0.004378679,0.0028164955,0.00059249485,0.00033621053,0.0037772015,0.111086085,0.00045357682,0.014520123,0.7709435],"study_design_scores_gemma":[0.16337508,0.38126945,0.20398085,0.0013628238,0.010543211,0.007043608,0.00025899653,0.0062801493,0.057924338,0.0006459971,0.16713089,0.00018470235],"about_ca_topic_score_codex":0.0010031058,"about_ca_topic_score_gemma":0.003588653,"teacher_disagreement_score":0.0027822768,"about_ca_system_score_codex":0.00085957564,"about_ca_system_score_gemma":0.0011111108,"threshold_uncertainty_score":0.014714241},"labels":[],"label_agreement":null},{"id":"W4281714381","doi":"10.1200/jco.22.00842","title":"Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Gastroenterology; Cytokine release syndrome; Progression-free survival; Oncology; Chimeric antigen receptor; Surgery; Immunotherapy; Chemotherapy; Cancer","score_opus":0.10538137358338813,"score_gpt":0.42759963328509365,"score_spread":0.32221825970170553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281714381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921091,0.003406422,0.00070555886,0.00018886049,0.000027932258,0.00016416213,0.0014713996,0.00006503437,0.0018615575],"genre_scores_gemma":[0.99508387,0.0005209596,0.0002251183,0.0002629704,0.00003178474,0.00005930514,0.003024408,0.000007514979,0.0007839283],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995184,0.000101509955,0.00004758066,0.00009119987,0.00014135394,0.00010001132],"domain_scores_gemma":[0.99893266,0.0001585203,0.0004192084,0.00010928427,0.00015705163,0.0002233438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021259796,0.0002525361,0.0007208618,0.0004187041,0.00035739492,0.0006041339,0.00032532882,0.0003671922,0.0009895703],"category_scores_gemma":[0.0009834751,0.00012527741,0.0007283398,0.00037139375,0.00017506136,0.00046584496,0.0002589819,0.00083413674,0.00027221377],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05525481,0.003997788,0.628896,0.00047894643,0.002564041,0.0011698724,0.00040285912,0.0022107977,0.032195736,0.00014956167,0.004664783,0.26801473],"study_design_scores_gemma":[0.003911899,0.038640555,0.9336798,0.000067067056,0.0019927532,0.0020392006,0.00009214793,0.0020227076,0.009924969,0.000098778015,0.0075039053,0.000026102753],"about_ca_topic_score_codex":0.0011204494,"about_ca_topic_score_gemma":0.0016317958,"teacher_disagreement_score":0.0021259796,"about_ca_system_score_codex":0.00062929594,"about_ca_system_score_gemma":0.00053144153,"threshold_uncertainty_score":0.011243403},"labels":[],"label_agreement":null},{"id":"W4281719775","doi":"10.1200/jco.2022.40.16_suppl.11562","title":"Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Internal medicine; Synovial sarcoma; Clinical endpoint; Oncology; Phases of clinical research; Sarcoma; Surgery; Chemotherapy; Clinical trial; Pathology","score_opus":0.3094605390236914,"score_gpt":0.5609863222026947,"score_spread":0.2515257831790033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281719775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.884076,0.08011723,0.01702966,0.0006865113,0.0004705738,0.0015818231,0.012194029,0.00043488128,0.0034092679],"genre_scores_gemma":[0.989571,0.0018372115,0.0026306477,0.00024191583,0.0001871971,0.0007387412,0.0042619505,0.00006268357,0.00046869292],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9661773,0.025815438,0.0027096062,0.0029154064,0.0016346541,0.00074749364],"domain_scores_gemma":[0.96829355,0.020991014,0.0056939265,0.003444581,0.0011252895,0.00045157803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0423542,0.0020781613,0.00484687,0.0025817538,0.00025962593,0.0018222452,0.0009679631,0.0013818396,0.0025136145],"category_scores_gemma":[0.034364633,0.0007010224,0.019036131,0.0019792758,0.0004521469,0.0013369381,0.0013476061,0.0013484225,0.00041041736],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17645736,0.00034880123,0.14010708,0.0047703492,0.6182615,0.00015413458,0.00020652608,0.0052966336,0.0046642614,0.00031314712,0.0023496295,0.047070615],"study_design_scores_gemma":[0.015753213,0.019939182,0.36738753,0.0005224668,0.57314026,0.00037304865,0.00021109486,0.011963434,0.0033333935,0.001322959,0.0058690133,0.00018433103],"about_ca_topic_score_codex":0.00067777565,"about_ca_topic_score_gemma":0.0011326553,"teacher_disagreement_score":0.0423542,"about_ca_system_score_codex":0.0005992433,"about_ca_system_score_gemma":0.00060469756,"threshold_uncertainty_score":0.22399306},"labels":[],"label_agreement":null},{"id":"W4281758080","doi":"10.1186/s12987-022-00342-y","title":"Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies","year":2022,"lang":"en","type":"article","venue":"Fluids and Barriers of the CNS","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Sciences and Engineering Research Council of Canada; University of Ottawa; National Research Council Canada","funders":"","keywords":"Chimeric antigen receptor; Extravasation; Cancer research; Immunotherapy; Medicine; Blood–brain barrier; Induced pluripotent stem cell; Cytotoxicity; Antigen; Immunology; In vitro; Biology; Central nervous system; Immune system; Internal medicine; Embryonic stem cell","score_opus":0.014948959537499607,"score_gpt":0.32211808775327105,"score_spread":0.30716912821577147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281758080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9166565,0.019191086,0.056458835,0.00036725728,0.0002642394,0.00086507114,0.0007867752,0.00063075323,0.00477958],"genre_scores_gemma":[0.97337806,0.008178545,0.01577519,0.00013239087,0.000026078857,0.00049637654,0.00061685307,0.000054421573,0.0013420489],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996816,0.000092550166,0.0000264005,0.000041220108,0.00010383211,0.0000544339],"domain_scores_gemma":[0.9998491,0.000022432318,0.00003932709,0.000012671564,0.000049000566,0.000027429976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005627901,0.00054983044,0.00043218362,0.0005130945,0.0001714551,0.00040137407,0.000269427,0.00043156775,0.00086016924],"category_scores_gemma":[0.00025885671,0.00017487534,0.0003038186,0.00025627165,0.00022191348,0.00042092014,0.00025729134,0.0008106893,0.00025565567],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039718192,0.00029191148,0.0005266683,0.00027302327,0.000024512645,0.00019147072,0.000056751,0.00052983325,0.9884412,0.00022137717,0.0002493515,0.008796715],"study_design_scores_gemma":[0.000040548188,0.0061251083,0.006090936,0.000035612273,0.00013744041,0.0007690377,0.00009572439,0.0057798666,0.9754783,0.0002349227,0.005189381,0.00002306034],"about_ca_topic_score_codex":0.00086178,"about_ca_topic_score_gemma":0.0011884709,"teacher_disagreement_score":0.00086178,"about_ca_system_score_codex":0.0002895192,"about_ca_system_score_gemma":0.0004029705,"threshold_uncertainty_score":0.002976358},"labels":[],"label_agreement":null},{"id":"W4281843434","doi":"10.1200/jco.2022.40.16_suppl.2539","title":"The addition of fludarabine to cyclophosphamide for lymphodepleting chemotherapy enhances the persistence of infused NY-ESO-1 TCR anticancer therapy TBI-1301.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Fludarabine; Medicine; Cyclophosphamide; Internal medicine; Cohort; Immunology; Gastroenterology; Chemotherapy; Oncology","score_opus":0.1395545426387361,"score_gpt":0.4665839838991759,"score_spread":0.32702944126043976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281843434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99909985,0.00016619399,0.00016081627,0.000017144954,0.00000784344,0.000035249548,0.00004726777,0.000011134133,0.00045446504],"genre_scores_gemma":[0.9987179,0.00011037931,0.00033988376,0.00002759604,0.000008134208,0.000043342807,0.00017039856,0.0000039469774,0.0005784897],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9999256,0.000013259707,0.000004995733,0.000016941494,0.000013041055,0.000026186504],"domain_scores_gemma":[0.9999012,0.0000210763,0.000025561663,0.000009102591,0.0000053306767,0.00003772167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013899378,0.00019639489,0.00019050867,0.00010629671,0.000098449695,0.00020808278,0.00013915078,0.00017288054,0.001840476],"category_scores_gemma":[0.00011219012,0.0000680652,0.00011938937,0.00006491175,0.00015105086,0.00012640236,0.00010551073,0.00060130074,0.00024575042],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049966406,0.0022462616,0.004678315,0.00008708376,0.000026731945,0.00013533112,0.00007305051,0.0003100012,0.9686367,0.00011329401,0.00038374163,0.018312825],"study_design_scores_gemma":[0.0010626456,0.060880262,0.0488375,0.000028609214,0.00013979133,0.0015560169,0.00010138592,0.0020674611,0.879728,0.000058972302,0.0055284244,0.000010832519],"about_ca_topic_score_codex":0.00023931284,"about_ca_topic_score_gemma":0.0006494874,"teacher_disagreement_score":0.001840476,"about_ca_system_score_codex":0.00022325857,"about_ca_system_score_gemma":0.00019906029,"threshold_uncertainty_score":0.006156981},"labels":[],"label_agreement":null},{"id":"W4281865532","doi":"10.1016/j.omtm.2022.05.006","title":"Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Agency","keywords":"CD19; Population; Transduction (biophysics); Transgene; Biology; Chimeric antigen receptor; Genetic enhancement; Virology; Vesicular stomatitis virus; B cell; Viral vector; Molecular biology; Immunology; T cell; Immune system; Virus; Medicine; Antibody; Gene; Genetics; Recombinant DNA","score_opus":0.07497779339291938,"score_gpt":0.4288613776569801,"score_spread":0.35388358426406075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281865532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890772,0.001363139,0.005449083,0.00008014366,0.000046216468,0.00027211074,0.000529123,0.00052535825,0.002657674],"genre_scores_gemma":[0.98506194,0.00091530697,0.0075976434,0.00013155173,0.000031574127,0.00039401735,0.00082106725,0.00011184173,0.0049350862],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997179,0.00003564501,0.000018791001,0.0000593881,0.00006244253,0.000105833285],"domain_scores_gemma":[0.99981695,0.000034031975,0.00004569931,0.000031965512,0.000016314138,0.000055153127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029454683,0.00045378073,0.00042488097,0.0004807294,0.00018615635,0.0004014016,0.00037185734,0.00035582783,0.0011257683],"category_scores_gemma":[0.00014485078,0.00020922277,0.00023867094,0.00018696411,0.00031214705,0.00024145577,0.00021943828,0.0013139885,0.0005267607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015588563,0.0001512741,0.00017009031,0.000027282662,0.0000044208405,0.000035311168,0.000028236947,0.00006431412,0.99619746,0.00009557613,0.000087615124,0.0029825785],"study_design_scores_gemma":[0.00006440539,0.0009811157,0.0028385178,0.0000103795255,0.000017933338,0.00019976316,0.000011164389,0.0013426059,0.992098,0.000052449566,0.0023787844,0.0000047984295],"about_ca_topic_score_codex":0.00039521107,"about_ca_topic_score_gemma":0.00068783347,"teacher_disagreement_score":0.0011257683,"about_ca_system_score_codex":0.00027790057,"about_ca_system_score_gemma":0.00027682906,"threshold_uncertainty_score":0.0037661195},"labels":[],"label_agreement":null},{"id":"W4281946301","doi":"10.1200/jco.2022.40.16_suppl.8013","title":"Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Cohort; Oncology; Clinical endpoint; Gastroenterology; Chimeric antigen receptor; Surgery; Clinical trial; Immunotherapy; Cancer","score_opus":0.05040499462910015,"score_gpt":0.38968772971000076,"score_spread":0.3392827350809006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281946301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780923,0.0010038001,0.00012835089,0.00006628939,0.000010748769,0.00013961911,0.0003266474,0.000015751717,0.0004997278],"genre_scores_gemma":[0.99859077,0.00034996538,0.00012830866,0.00008048372,0.000024370576,0.00008204943,0.00046603993,0.000003126981,0.0002748224],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997321,0.000114896495,0.000020167414,0.000048756876,0.00003912401,0.00004501566],"domain_scores_gemma":[0.9994809,0.00008982137,0.00018193158,0.000036920068,0.000032584394,0.00017791521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085024926,0.0003336768,0.0006817046,0.00026418973,0.00020616029,0.0005101611,0.00023422469,0.0004362456,0.00096698315],"category_scores_gemma":[0.0008983587,0.00017689283,0.00079304865,0.00029171194,0.0003412799,0.00040804938,0.00026792055,0.00093895616,0.00028096858],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.598027,0.015780192,0.11481638,0.00058313383,0.0013076446,0.0005044854,0.00045246258,0.004828445,0.050008986,0.0001468692,0.0019560575,0.2115883],"study_design_scores_gemma":[0.053910486,0.6472001,0.28143275,0.00005976877,0.0012364758,0.0009797161,0.00011989689,0.0030408034,0.0077318954,0.00015424177,0.00410027,0.00003360333],"about_ca_topic_score_codex":0.00093928224,"about_ca_topic_score_gemma":0.001457514,"teacher_disagreement_score":0.00096698315,"about_ca_system_score_codex":0.0008275325,"about_ca_system_score_gemma":0.0007193067,"threshold_uncertainty_score":0.0060042143},"labels":[],"label_agreement":null},{"id":"W4281974331","doi":"10.1016/j.jconrel.2022.05.040","title":"Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures","year":2022,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre; McMaster University","funders":"","keywords":"Spheroid; In vitro; Fluorescence microscope; Self-healing hydrogels; Biophysics; Cell biology; Cancer research; Chemistry; Biology; Fluorescence; Biochemistry; Physics","score_opus":0.02925505119544184,"score_gpt":0.3522589941114541,"score_spread":0.32300394291601225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281974331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821316,0.0011976968,0.014898201,0.00007382544,0.00006478764,0.000107626816,0.00039980529,0.00013349524,0.000992937],"genre_scores_gemma":[0.9807577,0.00083482615,0.014809266,0.0000359128,0.000017428447,0.00013588331,0.0002773974,0.000049104492,0.0030824477],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998246,0.000026292608,0.000015924401,0.000049771515,0.000046507015,0.000036887817],"domain_scores_gemma":[0.999798,0.00007947841,0.0000436145,0.000017288628,0.000039843915,0.000021765289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034364645,0.0003341932,0.00029774377,0.00015505924,0.00015140184,0.00041171696,0.00019318388,0.0003365353,0.00084910524],"category_scores_gemma":[0.00019566389,0.00014057016,0.00022098974,0.00020522613,0.00025512656,0.00037551307,0.00013356983,0.00032559567,0.00021565887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007514061,0.000019775374,0.000050105446,0.000029730862,0.000002447408,0.00002850409,0.00002759496,0.00011020082,0.9989065,0.00002979842,0.000013065241,0.0007070634],"study_design_scores_gemma":[0.000006850378,0.00013668952,0.00040471813,0.00000177945,0.000007628962,0.000023349188,0.000019175293,0.0014575495,0.99760264,0.000008064032,0.000327883,0.0000036339572],"about_ca_topic_score_codex":0.0011076286,"about_ca_topic_score_gemma":0.0015048283,"teacher_disagreement_score":0.0011076286,"about_ca_system_score_codex":0.0004157507,"about_ca_system_score_gemma":0.0002652968,"threshold_uncertainty_score":0.0030165315},"labels":[],"label_agreement":null},{"id":"W4282018957","doi":"10.1200/jco.2022.40.16_suppl.7548","title":"Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Phases of clinical research; Chemoimmunotherapy; Adverse effect; Refractory (planetary science); Oncology; Clinical trial; Cancer; Immunotherapy","score_opus":0.21426952189194884,"score_gpt":0.5364124915908745,"score_spread":0.32214296969892564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282018957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952825,0.0012440815,0.0002334736,0.00017337863,0.00008396758,0.0013332575,0.0009389051,0.000019073423,0.00069138815],"genre_scores_gemma":[0.99447966,0.00049860973,0.00059013715,0.0003738667,0.00015264608,0.0024062572,0.0009331305,0.0000070071433,0.00055861985],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998406,0.0010751772,0.00007963903,0.00017686798,0.000110743655,0.0001516125],"domain_scores_gemma":[0.9980987,0.00049501954,0.0006618198,0.00011600714,0.00009334619,0.0005351306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035888455,0.0014323278,0.0015786295,0.00037253025,0.00036110985,0.0008372985,0.000770313,0.0013334329,0.004068561],"category_scores_gemma":[0.002173404,0.0004864211,0.0026269436,0.00043451326,0.0008947077,0.00088252354,0.0006133845,0.0023283227,0.000511976],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9801119,0.0065245824,0.0029513324,0.00023347962,0.0011958854,0.000023131683,0.000031887736,0.00040618185,0.0014024043,0.00003985165,0.00030220792,0.0067772623],"study_design_scores_gemma":[0.7265476,0.2501394,0.018879738,0.000036872025,0.0017704297,0.00005642348,0.000045013898,0.0010753124,0.0006616675,0.0001348477,0.00062848936,0.000024215211],"about_ca_topic_score_codex":0.00061393925,"about_ca_topic_score_gemma":0.0015752172,"teacher_disagreement_score":0.004068561,"about_ca_system_score_codex":0.0009550046,"about_ca_system_score_gemma":0.00097292947,"threshold_uncertainty_score":0.018979847},"labels":[],"label_agreement":null},{"id":"W4282927325","doi":"10.1158/1538-7445.am2022-ct126","title":"Abstract CT126: A phase 2 trial of first-line AZD0171 + durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell infiltration","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Tumor microenvironment; Response Evaluation Criteria in Solid Tumors; CD8; Oncology; Cancer research; Immune system; Internal medicine; Immunotherapy; Phases of clinical research; Cancer; Chemotherapy; Immunology; Nivolumab","score_opus":0.0599190100686973,"score_gpt":0.38013565412632844,"score_spread":0.3202166440576311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282927325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851046,0.003356415,0.00058399385,0.0010156212,0.0002842063,0.002659456,0.0029314954,0.00021401237,0.0038502247],"genre_scores_gemma":[0.98092103,0.0020743343,0.0015438359,0.0010362986,0.00025159944,0.0022837638,0.005896284,0.00004000924,0.00595277],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996531,0.00016970727,0.000015836487,0.000059371912,0.000036408972,0.000065533204],"domain_scores_gemma":[0.999564,0.000052927146,0.00006989469,0.00003139256,0.000030199371,0.0002515761],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010944314,0.0015703577,0.0017454454,0.00039702858,0.0003894518,0.0010086216,0.0009767564,0.001296455,0.0058036107],"category_scores_gemma":[0.00075085403,0.0005607174,0.001176575,0.00043183402,0.00090289046,0.00073246955,0.0003482233,0.003349968,0.0011423897],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7710804,0.03434161,0.006205587,0.0014215484,0.0019450594,0.00039712767,0.00023205466,0.0036568108,0.07727586,0.0005522823,0.012160905,0.09073084],"study_design_scores_gemma":[0.64518315,0.32910484,0.010404686,0.00006770816,0.00068290805,0.00052313757,0.000050213515,0.0019506982,0.0060879374,0.00018869716,0.0057095895,0.00004640932],"about_ca_topic_score_codex":0.001358313,"about_ca_topic_score_gemma":0.0053198426,"teacher_disagreement_score":0.0058036107,"about_ca_system_score_codex":0.0015205337,"about_ca_system_score_gemma":0.0016992812,"threshold_uncertainty_score":0.019415021},"labels":[],"label_agreement":null},{"id":"W4282947107","doi":"10.1158/1538-7445.am2022-lb001","title":"Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Human leukocyte antigen; Antigen; Medicine; Cancer; Oncology; Immunology; Cancer research; Internal medicine","score_opus":0.1094098929922035,"score_gpt":0.4386398053673828,"score_spread":0.3292299123751793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282947107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93999326,0.0044661704,0.0034515639,0.0038700756,0.00028104548,0.0025446026,0.009918686,0.00070876896,0.034765795],"genre_scores_gemma":[0.96838444,0.0012395189,0.004731394,0.003837714,0.00028864853,0.0013188684,0.012773923,0.00012422459,0.007301346],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997793,0.000070949325,0.000022250084,0.000042138276,0.000034444878,0.000050908755],"domain_scores_gemma":[0.9995468,0.000098010896,0.0000531306,0.000023133383,0.00004888378,0.0002300206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063040835,0.0002867808,0.00047259105,0.00027677813,0.00033880933,0.0007653977,0.0003860579,0.0006443028,0.00890209],"category_scores_gemma":[0.000977206,0.000118713004,0.00040043867,0.0003085245,0.00021191667,0.0004287578,0.0003437059,0.00078078214,0.0033410105],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06487145,0.0058353967,0.3418787,0.00070894056,0.00025067685,0.00675291,0.00030485858,0.0014150923,0.062027913,0.0014126227,0.10814784,0.4063937],"study_design_scores_gemma":[0.019602222,0.07472549,0.64916486,0.0006931718,0.0006997145,0.022171125,0.0006181523,0.008412979,0.043312404,0.0034972685,0.17692855,0.00017414233],"about_ca_topic_score_codex":0.00082045177,"about_ca_topic_score_gemma":0.0011974684,"teacher_disagreement_score":0.00890209,"about_ca_system_score_codex":0.0007055619,"about_ca_system_score_gemma":0.00072320504,"threshold_uncertainty_score":0.029780507},"labels":[],"label_agreement":null},{"id":"W4282959799","doi":"10.1158/1538-7445.am2022-564","title":"Abstract 564: Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McMaster University","funders":"","keywords":"Cancer; Medicine; Cancer research; Downregulation and upregulation; Glioma; Brain tumor; Chimeric antigen receptor; Cancer cell; Lung cancer; Immunotherapy; Internal medicine; Pathology; Biology; Gene","score_opus":0.1485057133815752,"score_gpt":0.43740882860226404,"score_spread":0.28890311522068884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282959799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8704398,0.042743534,0.03706959,0.006712386,0.0013327834,0.00044383213,0.00086076686,0.0012129144,0.03918434],"genre_scores_gemma":[0.91831285,0.023347333,0.010286826,0.0011238888,0.00029422092,0.00018712705,0.00047160342,0.0000670438,0.04590908],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999573,0.0000040436353,0.0000024833012,0.000008891255,0.00001261395,0.000014615506],"domain_scores_gemma":[0.9999784,0.000001924171,0.000004751038,0.0000015385223,0.000004862462,0.000008471781],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007793008,0.000367334,0.00024206984,0.00029334766,0.00015780493,0.00044651836,0.00024103047,0.00042455707,0.0034468297],"category_scores_gemma":[0.00004572866,0.0000949416,0.00022272173,0.00015102897,0.00021570022,0.00025966726,0.0002133596,0.00070410594,0.0009942391],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003729155,0.0002234807,0.00041040193,0.000388344,0.000021942473,0.00056475005,0.00007833323,0.0005485744,0.9246404,0.0027109736,0.006181399,0.06385854],"study_design_scores_gemma":[0.00017023728,0.0017294659,0.0028816117,0.000047358153,0.00009676729,0.002644328,0.000057513167,0.002536568,0.89912695,0.0006817396,0.0900018,0.000025686571],"about_ca_topic_score_codex":0.00062061247,"about_ca_topic_score_gemma":0.0007277525,"teacher_disagreement_score":0.0034468297,"about_ca_system_score_codex":0.00032508172,"about_ca_system_score_gemma":0.00035963923,"threshold_uncertainty_score":0.011530757},"labels":[],"label_agreement":null},{"id":"W4282959999","doi":"10.1158/1538-7445.am2022-559","title":"Abstract 559: Targeting hematological malignancies and solid tumors with switchable chimeric antigen receptor-engineered iPSC-derived natural killer cells","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Cancer research; CD19; Induced pluripotent stem cell; CD33; NKG2D; Immunotherapy; Biology; Antigen; Immunology; Stem cell; Cell biology; CD34; Cytotoxic T cell; Immune system; Embryonic stem cell; Gene","score_opus":0.042511637850397604,"score_gpt":0.34551406794819167,"score_spread":0.30300243009779404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282959999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96550035,0.0013476801,0.025519775,0.00013777072,0.00009283318,0.00019395538,0.0008533435,0.00047418915,0.005880082],"genre_scores_gemma":[0.9847341,0.00069833983,0.0090155015,0.00008439133,0.000017523558,0.000101356265,0.0009298748,0.000045913846,0.004373145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991405,0.00000740232,0.000010646296,0.000017330221,0.00003109362,0.000019467247],"domain_scores_gemma":[0.999969,0.000005367933,0.000008272305,0.0000047773906,0.0000053559984,0.0000072765406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010872726,0.00027233525,0.00019880327,0.00018949396,0.000077296994,0.00025438864,0.00017931122,0.00026166416,0.0017982757],"category_scores_gemma":[0.00006874026,0.00007765421,0.00019412836,0.000120588906,0.00011882072,0.0001340951,0.00017337197,0.0004053438,0.0005131402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000058847505,0.000041060244,0.00028522994,0.00006168,0.0000067244523,0.000096272495,0.00001537095,0.00038008194,0.9920036,0.00034926945,0.00018993074,0.0065118065],"study_design_scores_gemma":[0.000022012664,0.00012814153,0.0007469296,0.0000044001445,0.000022673052,0.0002978815,0.0000069441458,0.0014912316,0.99189407,0.0000511182,0.0053320895,0.0000025172874],"about_ca_topic_score_codex":0.00022827063,"about_ca_topic_score_gemma":0.00023642079,"teacher_disagreement_score":0.0017982757,"about_ca_system_score_codex":0.00018068872,"about_ca_system_score_gemma":0.00015395856,"threshold_uncertainty_score":0.006015837},"labels":[],"label_agreement":null},{"id":"W4282962127","doi":"10.1158/1538-7445.am2022-572","title":"Abstract 572: Pre-clinical evaluation of Claudin 18.2 TAC T cells for the treatment of gastric cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cancer research; Cancer; Claudin; Tight junction; In vivo; Immunotherapy; Cytotoxic T cell; Medicine; Cancer cell; Immunology; In vitro; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.3995313886288464,"score_gpt":0.5792230089990879,"score_spread":0.17969162037024144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282962127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933855,0.0024113941,0.0007488007,0.00023381865,0.00010943841,0.0005459523,0.00032795803,0.00007137958,0.0021658137],"genre_scores_gemma":[0.99295276,0.0015929911,0.0010218928,0.00022310304,0.00007385396,0.0004160048,0.0009278402,0.000021099728,0.0027704763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998671,0.00003524864,0.000009645949,0.000017339657,0.000031131323,0.000039603412],"domain_scores_gemma":[0.99985766,0.000019724781,0.000019006515,0.000011672869,0.000025004327,0.000066881235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004315941,0.0005056922,0.0005515305,0.00026888476,0.00019568365,0.00053954695,0.00035702166,0.0005509473,0.0032473],"category_scores_gemma":[0.00023354965,0.00013438324,0.0003612794,0.00018689211,0.00027254358,0.0002716592,0.00016517329,0.0012834473,0.0005856401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031758517,0.020967605,0.0023647055,0.0009347228,0.000213782,0.00068079424,0.0002339601,0.001334729,0.8599783,0.0004319191,0.0030467582,0.078054115],"study_design_scores_gemma":[0.019279126,0.47041273,0.012974569,0.00007917779,0.0005611439,0.0013560756,0.0001794861,0.002670302,0.47157064,0.00014365018,0.020743674,0.000029461875],"about_ca_topic_score_codex":0.00057548814,"about_ca_topic_score_gemma":0.00067424704,"teacher_disagreement_score":0.0032473,"about_ca_system_score_codex":0.00035244785,"about_ca_system_score_gemma":0.00053232134,"threshold_uncertainty_score":0.0108632445},"labels":[],"label_agreement":null},{"id":"W4282969370","doi":"10.1158/1538-7445.am2022-ct247","title":"Abstract CT247: A phase I/II trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Leukapheresis; Cancer research; T cell; Immunohistochemistry; Breast cancer; Antigen; Cancer; T-cell receptor; Immunotherapy; Oncology; Immunology; Internal medicine; Immune system; Biology; CD34; Stem cell","score_opus":0.10108806075607954,"score_gpt":0.4461038510280492,"score_spread":0.3450157902719697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282969370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836262,0.0033814178,0.00076759723,0.00078713754,0.00018701793,0.0042341393,0.0030267418,0.00025459653,0.0037351327],"genre_scores_gemma":[0.9780959,0.0021423202,0.0015493169,0.0012827952,0.00021775294,0.0047819586,0.0057886625,0.00004980174,0.006091403],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996902,0.00013935317,0.00001660625,0.000052654545,0.00003191872,0.00006930477],"domain_scores_gemma":[0.9995307,0.000047910635,0.00007301885,0.000034974437,0.00002935424,0.00028415353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010258714,0.0015027848,0.0014029278,0.00037792025,0.00040154686,0.0010268271,0.00095233513,0.0015852577,0.0060000513],"category_scores_gemma":[0.00057599245,0.00039561876,0.000895285,0.00044824425,0.0008338344,0.00067056133,0.0002972477,0.0034006047,0.0017983383],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7041024,0.062391166,0.006604589,0.0018771898,0.001770514,0.0010010637,0.00026177766,0.0038448034,0.104582556,0.00059518305,0.01387254,0.09909622],"study_design_scores_gemma":[0.5068506,0.47251195,0.0054396368,0.000072305585,0.000499486,0.00069783826,0.000053913012,0.0011115335,0.0078243,0.00024663022,0.0046591866,0.00003254856],"about_ca_topic_score_codex":0.00076464895,"about_ca_topic_score_gemma":0.0016431091,"teacher_disagreement_score":0.0060000513,"about_ca_system_score_codex":0.00089416874,"about_ca_system_score_gemma":0.0015499997,"threshold_uncertainty_score":0.020072162},"labels":[],"label_agreement":null},{"id":"W4282983643","doi":"10.1158/1538-7445.am2022-385","title":"Abstract 385: iRGD mediated delivery of neoantigens to enable immunotherapy in integrin b5-rich tumors","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Cancer research; Pancreatic cancer; Immunotherapy; Tumor microenvironment; Integrin; Stromal cell; Stroma; Immune system; Immunosurveillance; Medicine; Immunology; Cancer; Immunohistochemistry; Internal medicine; Receptor","score_opus":0.07954352637616002,"score_gpt":0.40651290960471126,"score_spread":0.32696938322855124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282983643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901923,0.0013486346,0.005306413,0.00012252068,0.000035303692,0.000057905974,0.00026101174,0.00010097412,0.0025748755],"genre_scores_gemma":[0.9879921,0.0005947919,0.0067079156,0.000067088906,0.0000065836516,0.000034011166,0.00028685172,0.000021606775,0.0042891353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999416,0.000007848147,0.0000038762137,0.000012836789,0.000017213813,0.000016656471],"domain_scores_gemma":[0.99997747,0.000002634109,0.000007431012,0.0000019987217,0.0000027473488,0.000007749021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007644214,0.0002257536,0.00015323154,0.000145937,0.00007756746,0.00016474043,0.00013184785,0.000256267,0.0012021924],"category_scores_gemma":[0.0000374835,0.00006857278,0.00017059653,0.000092565075,0.00010889256,0.00012594636,0.00011980312,0.00030319273,0.00032511208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042054766,0.000023321216,0.00005517035,0.000029367502,0.0000027990036,0.000031197713,0.0000073623137,0.000102557016,0.9986118,0.000070846,0.000059257203,0.00096418953],"study_design_scores_gemma":[0.000008337086,0.00019212566,0.00054310146,0.000002409104,0.0000059123977,0.000083948624,0.0000041745166,0.00043221272,0.9970488,0.000010974037,0.0016661179,0.0000019736085],"about_ca_topic_score_codex":0.00069314026,"about_ca_topic_score_gemma":0.0005716918,"teacher_disagreement_score":0.0012021924,"about_ca_system_score_codex":0.000272718,"about_ca_system_score_gemma":0.00011202934,"threshold_uncertainty_score":0.004021764},"labels":[],"label_agreement":null},{"id":"W4283019343","doi":"10.1038/s43018-022-00398-7","title":"Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy","year":2022,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Nationales Centrum für Tumorerkrankungen Heidelberg; Deutsches Krebsforschungszentrum","keywords":"Medicine; Vaccination; Adverse effect; Common Terminology Criteria for Adverse Events; Cancer; Immune system; Immunology; Immunotherapy; Internal medicine; Cohort; Cytokine release syndrome; Cytokine","score_opus":0.031341642417978655,"score_gpt":0.39124105103857426,"score_spread":0.3598994086205956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283019343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789727,0.00075089076,0.00058490306,0.000029533106,0.000010526127,0.000026496493,0.00013397855,0.000014958074,0.00055145466],"genre_scores_gemma":[0.9993414,0.0001511642,0.0001503787,0.000032475775,0.0000114968025,0.000008495882,0.00019030146,0.0000027532158,0.00011139073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995369,0.00014043531,0.00005639175,0.00009674085,0.00009874113,0.00007084371],"domain_scores_gemma":[0.9983902,0.00031780067,0.000947354,0.00009312162,0.00011372618,0.00013776115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046031136,0.00020593553,0.00037923234,0.00020802548,0.00016638477,0.00026003318,0.000086267755,0.00017377365,0.0007827217],"category_scores_gemma":[0.0012044315,0.00007394031,0.00028827204,0.00023177789,0.00018855513,0.00016398221,0.00021367209,0.00032578755,0.00012381676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026608852,0.00009187025,0.93239534,0.00011053201,0.0001431126,0.0021587864,0.00016692924,0.00019373237,0.03996679,0.000064293585,0.00024224445,0.021805465],"study_design_scores_gemma":[0.00003512165,0.0025278237,0.98102516,0.000018318548,0.000081044825,0.0063920706,0.00010415108,0.0003333038,0.008393886,0.000048994094,0.0010323582,0.000007695583],"about_ca_topic_score_codex":0.00024906124,"about_ca_topic_score_gemma":0.0004108419,"teacher_disagreement_score":0.0007827217,"about_ca_system_score_codex":0.0001426232,"about_ca_system_score_gemma":0.00013526464,"threshold_uncertainty_score":0.0026184916},"labels":[],"label_agreement":null},{"id":"W4283270985","doi":"10.1126/scitranslmed.abn3353","title":"B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?","year":2022,"lang":"en","type":"review","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; CD19; CAR T-cell therapy; T cell; Cell; B cell; Cancer research; Cell therapy; Medicine; Antigen; Immunology; Biology; Immune system; Antibody; Genetics","score_opus":0.06806536564021057,"score_gpt":0.3772436598798643,"score_spread":0.3091782942396537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283270985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007802568,0.9982285,0.00016973812,0.0006339549,0.00026009206,0.0000033689241,0.000008841312,0.000005970362,0.00061149796],"genre_scores_gemma":[0.0005839403,0.99778795,0.00020209452,0.000619828,0.00025098308,0.000008228931,0.000015848327,0.0000024585297,0.0005286264],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997354,0.00007898177,0.000027729759,0.000039831848,0.000086958455,0.000031010986],"domain_scores_gemma":[0.99956626,0.00025265676,0.00004114168,0.000015630938,0.00008965198,0.00003471217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014236389,0.00077662594,0.0017829727,0.0013263375,0.00025186833,0.0011701871,0.0013967102,0.0020398893,0.0035444414],"category_scores_gemma":[0.0009983544,0.0003485617,0.00058007566,0.0012409023,0.0010077116,0.0021746205,0.0006912648,0.003813378,0.0024660304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001270725,0.00008442738,0.00009870947,0.013757448,0.00008544882,0.0002571919,0.00006693849,0.0005226643,0.0028090763,0.012166788,0.041636184,0.92838794],"study_design_scores_gemma":[0.000046000154,0.00014569174,0.00022852515,0.0036528022,0.00008502922,0.001261409,0.000045616896,0.00010264007,0.0006649443,0.003896813,0.98985064,0.000019723175],"about_ca_topic_score_codex":0.00095440156,"about_ca_topic_score_gemma":0.0017614488,"teacher_disagreement_score":0.0035444414,"about_ca_system_score_codex":0.0007667756,"about_ca_system_score_gemma":0.0008915165,"threshold_uncertainty_score":0.01185739},"labels":[],"label_agreement":null},{"id":"W4283312353","doi":"10.1097/01.hs9.0000843628.63947.e4","title":"S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Chimeric antigen receptor; Cohort; Oncology; Antigen; Gastroenterology; Immunology; Cancer; Immunotherapy","score_opus":0.025269656908133178,"score_gpt":0.2987480830311138,"score_spread":0.2734784261229806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283312353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970092,0.0010325564,0.00014481625,0.00009823347,0.000019041881,0.00038991545,0.00047440242,0.000021307336,0.00081053056],"genre_scores_gemma":[0.9973636,0.0004984549,0.00033234002,0.00017696444,0.000051835435,0.00022670798,0.0008741764,0.0000047010926,0.00047119008],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972564,0.00011674117,0.000027527842,0.000049722563,0.0000402674,0.00004012434],"domain_scores_gemma":[0.99957556,0.000076520395,0.00014773216,0.000021567623,0.00004347122,0.00013509506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009796255,0.00047585226,0.0010252735,0.00029845742,0.00025789795,0.00047878036,0.00029808347,0.00044083776,0.0020692842],"category_scores_gemma":[0.0007949213,0.00018622843,0.001116102,0.000364121,0.00019534996,0.00031899064,0.00022679043,0.0005338361,0.00041264133],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.506559,0.009209551,0.20126747,0.0016314827,0.0036581047,0.0015731512,0.00039852798,0.004566552,0.059068598,0.00018118398,0.0029337967,0.2089526],"study_design_scores_gemma":[0.08369102,0.56707424,0.3145383,0.00015033114,0.0035512713,0.0023584268,0.00017847057,0.003906579,0.013687513,0.0001758773,0.010644373,0.000043493845],"about_ca_topic_score_codex":0.00074446015,"about_ca_topic_score_gemma":0.001858533,"teacher_disagreement_score":0.0020692842,"about_ca_system_score_codex":0.0008131186,"about_ca_system_score_gemma":0.0011213815,"threshold_uncertainty_score":0.0069224834},"labels":[],"label_agreement":null},{"id":"W4283325455","doi":"10.1097/01.hs9.0000843736.56298.a7","title":"S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Internal medicine; Oncology; Refractory (planetary science); Phases of clinical research; Surgery; Clinical trial; Lymphoma; Confidence interval; Rituximab","score_opus":0.02406320880621695,"score_gpt":0.3345384065848873,"score_spread":0.3104751977786704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283325455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939546,0.0020215858,0.00013474558,0.00029613893,0.00009907216,0.00073671766,0.0018661395,0.000024676348,0.0008662643],"genre_scores_gemma":[0.989472,0.0010377504,0.00062479905,0.0010018207,0.00027383707,0.0015759461,0.004884773,0.000018486391,0.0011104923],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99861157,0.00083699264,0.00007927175,0.00014899315,0.0001287396,0.00019441156],"domain_scores_gemma":[0.9981603,0.00039938686,0.00048625635,0.00018137594,0.00014788812,0.00062468176],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0043355282,0.001311516,0.0019095333,0.00040687242,0.00046997398,0.0012922746,0.0009079774,0.0014331207,0.0046376023],"category_scores_gemma":[0.0019959374,0.00043555564,0.004557779,0.00052447384,0.0008769279,0.00083837676,0.00065941096,0.0027401978,0.0008612079],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9449495,0.016977666,0.010597807,0.0004896653,0.0036702317,0.00006964085,0.00008519671,0.000675293,0.003400285,0.0000853623,0.001539778,0.017459633],"study_design_scores_gemma":[0.629186,0.31953642,0.042918034,0.0000638088,0.0036061103,0.00019435112,0.00010252372,0.0010102172,0.0014801283,0.00020846873,0.0016409976,0.00005307359],"about_ca_topic_score_codex":0.0008502436,"about_ca_topic_score_gemma":0.0025509961,"teacher_disagreement_score":0.0046376023,"about_ca_system_score_codex":0.0010875646,"about_ca_system_score_gemma":0.0015059278,"threshold_uncertainty_score":0.022928715},"labels":[],"label_agreement":null},{"id":"W4283331887","doi":"10.1097/01.hs9.0000843912.35755.7f","title":"S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Phases of clinical research; Lymphoma; Clinical endpoint; Refractory (planetary science); Oncology; Cyclophosphamide; Gastroenterology; Surgery; Chemotherapy; Clinical trial","score_opus":0.01166383156354024,"score_gpt":0.2766023768999559,"score_spread":0.2649385453364157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283331887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945087,0.0020966716,0.00016080606,0.00022456158,0.00004741239,0.00050773384,0.0007168448,0.000064739084,0.0016725857],"genre_scores_gemma":[0.9947431,0.00086854456,0.00045212955,0.00034837268,0.000047705216,0.0003785055,0.0015389625,0.0000113747765,0.0016113514],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998241,0.00008216064,0.0000132660625,0.000028247785,0.00002344161,0.000028833729],"domain_scores_gemma":[0.99977666,0.000026067895,0.00005087678,0.000010390316,0.000012438734,0.00012363275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006628582,0.0004884921,0.0007778436,0.00017940442,0.00019961852,0.00060798146,0.0004496713,0.00054893974,0.0043846173],"category_scores_gemma":[0.0003924095,0.00016138876,0.0003730306,0.00018288883,0.00040108626,0.00040344556,0.0002449296,0.0010319592,0.0008577176],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64990664,0.033455983,0.016017923,0.0016301738,0.0014176533,0.00058739557,0.00034654586,0.0034391417,0.08075123,0.0008080488,0.00901533,0.20262396],"study_design_scores_gemma":[0.31223834,0.62487435,0.034124393,0.00011610324,0.00069335254,0.0010342348,0.00012466195,0.0024225388,0.011953407,0.0002598208,0.012109458,0.000049324863],"about_ca_topic_score_codex":0.00074372906,"about_ca_topic_score_gemma":0.0019556056,"teacher_disagreement_score":0.0043846173,"about_ca_system_score_codex":0.0005410861,"about_ca_system_score_gemma":0.0008747431,"threshold_uncertainty_score":0.014667988},"labels":[],"label_agreement":null},{"id":"W4283369873","doi":"10.1111/bjh.18333","title":"Sequential loss of B‐cell target antigens in multiply relapsed high‐grade B‐cell lymphoma treated with targeted therapies","year":2022,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Lymphoma; Medicine; B cell; Antigen; B-cell lymphoma; Oncology; Immunology; Cancer research; Internal medicine; Antibody","score_opus":0.016211989628227813,"score_gpt":0.25931032101338936,"score_spread":0.24309833138516154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283369873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76784027,0.01763687,0.0024347364,0.14898,0.0075661787,0.00024128958,0.00050069945,0.00028406252,0.054515917],"genre_scores_gemma":[0.94180584,0.0030761561,0.0008084953,0.036553383,0.005769196,0.000056907644,0.00028028587,0.00003976994,0.011609945],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9996549,0.00010406766,0.000035097335,0.00003908821,0.000079415506,0.0000874923],"domain_scores_gemma":[0.9989311,0.0005150674,0.00009695942,0.00006511509,0.00010445998,0.0002873037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045109214,0.0002817199,0.000788867,0.0003781976,0.0006738764,0.0007601503,0.00044373763,0.003919529,0.0013509787],"category_scores_gemma":[0.0024994034,0.00020236528,0.0004078944,0.00041675742,0.00043686607,0.00043850724,0.00031112027,0.0020349051,0.0007258927],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012845788,0.0007249992,0.042194266,0.00045748637,0.00023426898,0.6447912,0.0008242439,0.0015229736,0.024697635,0.0030792768,0.115891166,0.15273668],"study_design_scores_gemma":[0.002384212,0.0058442145,0.14143454,0.0002849347,0.00035142017,0.656536,0.00069319777,0.007539902,0.010955511,0.0074908137,0.16636972,0.00011559687],"about_ca_topic_score_codex":0.0013888382,"about_ca_topic_score_gemma":0.0027243854,"teacher_disagreement_score":0.003919529,"about_ca_system_score_codex":0.0014619081,"about_ca_system_score_gemma":0.00039420792,"threshold_uncertainty_score":0.010606945},"labels":[],"label_agreement":null},{"id":"W4283392950","doi":"10.1097/01.hs9.0000847476.69621.cd","title":"P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Antibody-drug conjugate; Internal medicine; Cmax; Refractory (planetary science); Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Antibody; Pharmacology; Toxicity; Adverse effect; Monoclonal antibody; Immunology","score_opus":0.012692541623903398,"score_gpt":0.29003734080215277,"score_spread":0.2773447991782494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283392950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666995,0.00073685165,0.0008077049,0.000104765946,0.000017953327,0.00043122438,0.00044175843,0.00008194449,0.00070792716],"genre_scores_gemma":[0.99540013,0.00048066347,0.0009383716,0.00025549275,0.000048851944,0.00030728386,0.0015820675,0.00003428449,0.0009528016],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967515,0.00014672118,0.000017950279,0.000060136488,0.000044754514,0.000055254804],"domain_scores_gemma":[0.9994943,0.00009530266,0.00010053389,0.000052950563,0.000038793663,0.00021802328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011315871,0.0009287666,0.00096989097,0.00025762245,0.00030694986,0.00089821743,0.0004795006,0.00063563307,0.0014746338],"category_scores_gemma":[0.00074627146,0.00031637657,0.00061525253,0.0002773019,0.0006629403,0.00055511,0.00023695608,0.001821731,0.0005246271],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26452464,0.12117778,0.031637553,0.000864737,0.0017889458,0.001589726,0.0011624219,0.007560436,0.33435908,0.00035901586,0.006223222,0.2287525],"study_design_scores_gemma":[0.12156254,0.7594804,0.056605693,0.00003571452,0.0010746388,0.0019010036,0.0001722202,0.0047878018,0.048580624,0.00021943828,0.0055120424,0.00006788293],"about_ca_topic_score_codex":0.0008074985,"about_ca_topic_score_gemma":0.0012844494,"teacher_disagreement_score":0.0014746338,"about_ca_system_score_codex":0.0007082948,"about_ca_system_score_gemma":0.00078272616,"threshold_uncertainty_score":0.005984485},"labels":[],"label_agreement":null},{"id":"W4283516611","doi":"10.1016/j.jval.2022.04.416","title":"EE167 Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Confidence interval; Internal medicine; Multiple myeloma; Hazard ratio; Adverse effect; Oncology; Pembrolizumab; Immunotherapy","score_opus":0.19992756430541408,"score_gpt":0.38641269888520613,"score_spread":0.18648513457979204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283516611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5136211,0.010927997,0.33931017,0.007897815,0.001182989,0.0022956624,0.024519723,0.0017375839,0.09850693],"genre_scores_gemma":[0.9374598,0.0015269859,0.03942024,0.0005462748,0.00012138967,0.00076750125,0.0033970338,0.0003707463,0.016390098],"study_design_codex":"simulation_or_modeling","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964616,0.0028074752,0.000087076514,0.00018444595,0.000289151,0.00017028929],"domain_scores_gemma":[0.9858623,0.01239767,0.00043802118,0.0004822761,0.0006370278,0.00018268096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008594894,0.0010269681,0.001568887,0.0012961457,0.0003371231,0.0023839297,0.0018917162,0.0013099862,0.015459799],"category_scores_gemma":[0.022124954,0.00058163994,0.0031686106,0.0013228568,0.00031987653,0.0015605564,0.00074279204,0.0018804577,0.00090121786],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023764384,0.00044427384,0.0060457955,0.0004766967,0.0009032812,0.00015364063,0.00007041255,0.8946137,0.00028445377,0.023145765,0.0065154014,0.064970195],"study_design_scores_gemma":[0.00022479388,0.00038977384,0.0020620045,0.00016248887,0.00039713897,0.00006169818,0.000074867545,0.9783409,0.00036193518,0.012708181,0.0051856735,0.000030582305],"about_ca_topic_score_codex":0.023704512,"about_ca_topic_score_gemma":0.01598488,"teacher_disagreement_score":0.023704512,"about_ca_system_score_codex":0.00367479,"about_ca_system_score_gemma":0.0025636116,"threshold_uncertainty_score":0.051718175},"labels":[],"label_agreement":null},{"id":"W4283662383","doi":"10.1080/2162402x.2022.2093426","title":"Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality","year":2022,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cancerföreningen i Stockholm; Vetenskapsrådet; Karolinska Institutet; Cancerfonden","keywords":"Mesothelin; Chimeric antigen receptor; Cancer research; T cell; Antigen; CD28; Tumor microenvironment; Immunology; Medicine; Immune system; Tumor cells","score_opus":0.024159371536268178,"score_gpt":0.29159067560473584,"score_spread":0.26743130406846766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283662383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234563,0.00097321626,0.0052437903,0.0000887064,0.000008204365,0.000035113637,0.00009795895,0.0000729133,0.0011346216],"genre_scores_gemma":[0.99732035,0.00030303703,0.0013596482,0.00003071662,0.000002464284,0.000022220942,0.00007438681,0.00001086579,0.000876182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981445,0.000043373137,0.000015087799,0.000028465913,0.000051745614,0.00004685195],"domain_scores_gemma":[0.99988616,0.000041081086,0.00003142017,0.000013791564,0.000012269642,0.000015249907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014922999,0.0002614953,0.00025480933,0.00013850677,0.00012512962,0.0003605122,0.00015479156,0.00032998438,0.0012591651],"category_scores_gemma":[0.0001424093,0.000116446805,0.00016468689,0.00009636027,0.00030188062,0.00027517468,0.00022648447,0.0006052981,0.00032673997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004351768,0.000013845956,0.00015283962,0.000022212838,0.0000028126174,0.000033972276,0.000012091179,0.00015967962,0.99855334,0.0001537473,0.000023063141,0.0008288278],"study_design_scores_gemma":[0.000006985133,0.00013385784,0.0011827347,0.0000030315293,0.0000054202965,0.00023793385,0.000017128412,0.0013064585,0.9958587,0.00004201036,0.0012038121,0.0000019084528],"about_ca_topic_score_codex":0.0006740148,"about_ca_topic_score_gemma":0.0011111097,"teacher_disagreement_score":0.0012591651,"about_ca_system_score_codex":0.0003105513,"about_ca_system_score_gemma":0.000286354,"threshold_uncertainty_score":0.0042123795},"labels":[],"label_agreement":null},{"id":"W4283825879","doi":"10.3389/fimmu.2022.905768","title":"Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Discovery Centre","funders":"Mitacs; Terry Fox Research Institute; University of Toronto; McMaster University","keywords":"Antigen; Medicine; Immunotherapy; Modality (human–computer interaction); Immunology; Cancer research; Immune system; Computer science; Artificial intelligence","score_opus":0.01385012627138225,"score_gpt":0.30272764837600397,"score_spread":0.2888775221046217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283825879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667897,0.0065124626,0.019559504,0.00044827038,0.0001436624,0.0002202707,0.00028792568,0.00020536578,0.0058327145],"genre_scores_gemma":[0.9903542,0.0017813141,0.0054225177,0.00011459146,0.000022216982,0.000070457514,0.0001374897,0.00000848739,0.0020886825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999181,0.00001499031,0.0000041120556,0.000018012594,0.000019375291,0.000025373622],"domain_scores_gemma":[0.9999801,0.0000033550996,0.000005205021,0.0000019855572,0.0000026388152,0.000006707899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010426691,0.0003017641,0.0002127242,0.0001457765,0.000090505535,0.00031127987,0.00015916166,0.00039701606,0.0008244338],"category_scores_gemma":[0.000068776906,0.00008794317,0.00018750489,0.0001042519,0.00015549616,0.00021953371,0.00017020575,0.0006244167,0.0002156854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013899707,0.000120462646,0.00014872414,0.0000700198,0.000009915665,0.000109357345,0.000022518278,0.00054208894,0.9902839,0.0005410353,0.0002777425,0.007735312],"study_design_scores_gemma":[0.00007805161,0.0018614514,0.0008570789,0.000012800024,0.000044386157,0.0006758854,0.000026603608,0.004384475,0.98061544,0.00015174746,0.011281883,0.000010044976],"about_ca_topic_score_codex":0.00019525926,"about_ca_topic_score_gemma":0.00043617428,"teacher_disagreement_score":0.0008244338,"about_ca_system_score_codex":0.00022490518,"about_ca_system_score_gemma":0.00013361977,"threshold_uncertainty_score":0.0027579665},"labels":[],"label_agreement":null},{"id":"W4284976473","doi":"10.1038/s41467-022-31510-1","title":"Multi-modal molecular programs regulate melanoma cell state","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"American Cancer Society; AIM at Melanoma; National Health and Medical Research Council; National Institutes of Health; Cancer Prevention and Research Institute of Texas; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Medical Research Council; National Cancer Institute; Melanoma Research Alliance; University of Texas System; University of Texas MD Anderson Cancer Center; Lyda Hill Foundation","keywords":"Melanoma; Transcriptome; Biology; Computational biology; Phenotype; microRNA; Immune checkpoint; DNA methylation; Cancer research; Genetics; Cancer; Gene; Immunotherapy; Gene expression","score_opus":0.03237812463030771,"score_gpt":0.3478284844333382,"score_spread":0.3154503598030305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284976473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99395376,0.00067196786,0.0037815375,0.000025220155,0.0000050748054,0.000010653628,0.0006932003,0.000059393467,0.0007991663],"genre_scores_gemma":[0.9956728,0.00040181514,0.0019583507,0.000024608198,0.000004554743,0.00001843475,0.001065934,0.000023495712,0.0008300453],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99990463,0.000011103831,0.0000058727524,0.000033710796,0.000028110475,0.00001661659],"domain_scores_gemma":[0.9998472,0.000027751697,0.000056722678,0.000023923869,0.00002764701,0.00001672723],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010674741,0.0001519068,0.00015670584,0.00030395767,0.00013922565,0.0004319812,0.00010715126,0.00014050168,0.0005518316],"category_scores_gemma":[0.00014492731,0.000098018136,0.00016193211,0.00022483229,0.00017595114,0.00025304535,0.00032592515,0.00030858305,0.0002321707],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028743261,0.0000038976605,0.003050813,0.00001222072,0.00000400092,0.000017084689,0.00002531707,0.000052322288,0.99536395,0.000070149166,0.000010787423,0.0013606191],"study_design_scores_gemma":[0.000005003908,0.00025324957,0.28662217,0.000012294461,0.00004482278,0.0005013789,0.00026178305,0.0026910256,0.70609415,0.00029732232,0.003200816,0.000016057893],"about_ca_topic_score_codex":0.0002824797,"about_ca_topic_score_gemma":0.0008045596,"teacher_disagreement_score":0.0005518316,"about_ca_system_score_codex":0.00013791503,"about_ca_system_score_gemma":0.00011134189,"threshold_uncertainty_score":0.0018460155},"labels":[],"label_agreement":null},{"id":"W4284987950","doi":"10.1016/s1470-2045(22)00335-7","title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Clinical endpoint; Progressive disease; CD20; Follicular phase; Lymphoma; Oncology; Rituximab; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial; Biology","score_opus":0.04388713937975811,"score_gpt":0.36045103446850474,"score_spread":0.3165638950887466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284987950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967098,0.0019445018,0.00018219807,0.00015621084,0.000043126114,0.00024603694,0.00022806121,0.000025898047,0.0004640493],"genre_scores_gemma":[0.996846,0.0008206821,0.00032490457,0.0003508392,0.000100561505,0.00035252335,0.00052972964,0.000011406882,0.00066327763],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994055,0.00027585414,0.000027777054,0.00010233924,0.00006612322,0.00012239155],"domain_scores_gemma":[0.99936646,0.00012456116,0.00014728786,0.00007073354,0.000037716534,0.00025325923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017414503,0.001374853,0.002215523,0.00038116472,0.0003289322,0.0010534057,0.00068206165,0.0013185737,0.0012798693],"category_scores_gemma":[0.001053321,0.0005213505,0.0014562322,0.00036405603,0.0009343183,0.0009476592,0.0002826699,0.0022287206,0.00043594066],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83275163,0.017551301,0.01241836,0.000722836,0.0024643827,0.00020683219,0.0002940323,0.0020585367,0.039742485,0.00018186014,0.0016915251,0.08991622],"study_design_scores_gemma":[0.56335264,0.39055857,0.037382726,0.000041480107,0.00138873,0.00033536225,0.0000819516,0.0016507044,0.0028550597,0.00022091372,0.0020768922,0.00005507403],"about_ca_topic_score_codex":0.0007775979,"about_ca_topic_score_gemma":0.0013358429,"teacher_disagreement_score":0.002215523,"about_ca_system_score_codex":0.0010862786,"about_ca_system_score_gemma":0.00083550886,"threshold_uncertainty_score":0.009209812},"labels":[],"label_agreement":null},{"id":"W4285019712","doi":"10.1016/j.ymthe.2022.07.006","title":"Targeting glycans for CAR therapy: The advent of sweet CARs","year":2022,"lang":"en","type":"review","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Chimeric antigen receptor; Glycan; Cancer research; Antigen; Stromal cell; Cancer; Glycoprotein; Cancer cell; Targeted therapy; Glycosylation; Immunology; Chemistry; Biology; Immunotherapy; Biochemistry; Genetics","score_opus":0.0856352043509047,"score_gpt":0.3865383807675735,"score_spread":0.3009031764166688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285019712","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016421036,0.99749976,0.00030785307,0.0005792166,0.0003374372,0.0000047184485,0.000016776905,0.000010199705,0.0010797939],"genre_scores_gemma":[0.0014087104,0.9962663,0.00041036724,0.00066979945,0.00027443017,0.000008379547,0.000031569747,0.0000033448493,0.00092705904],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983096,0.00003811636,0.000012672265,0.000026237569,0.00006486223,0.000027127166],"domain_scores_gemma":[0.9997193,0.00015410883,0.000025927908,0.000008040951,0.000062781844,0.000029690766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007921815,0.0008296758,0.001218123,0.0013216019,0.00021611275,0.00125951,0.0006615792,0.001384221,0.0029093025],"category_scores_gemma":[0.0007739684,0.0002267001,0.00058860687,0.0010094023,0.0005547466,0.0018749823,0.00080806745,0.0037804423,0.0012899357],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017669593,0.00012091264,0.00011047746,0.009156214,0.00008879577,0.00024120188,0.0000657711,0.0007009238,0.0056417333,0.016644105,0.04597176,0.9210813],"study_design_scores_gemma":[0.00004147128,0.00015678916,0.0002083557,0.0015739818,0.00006837426,0.0006389483,0.000040225183,0.00026264304,0.0011408499,0.0041297786,0.99171865,0.000020003185],"about_ca_topic_score_codex":0.0007548155,"about_ca_topic_score_gemma":0.001512193,"teacher_disagreement_score":0.0029093025,"about_ca_system_score_codex":0.00066922576,"about_ca_system_score_gemma":0.00064654485,"threshold_uncertainty_score":0.009732604},"labels":[],"label_agreement":null},{"id":"W4285337318","doi":"10.30699/mmlj17.4.2.19","title":"Chimeric antigen receptor (CAR) T cell therapy in hepatocellular carcinoma; a review of recent advances","year":2021,"lang":"en","type":"review","venue":"Modern Medical Laboratory Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Hepatocellular carcinoma; Cancer research; Antigen; Receptor; Medicine; Immunotherapy; Immunology; Biology; Internal medicine; Immune system","score_opus":0.0593628573079132,"score_gpt":0.3705468490452738,"score_spread":0.3111839917373606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285337318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012427832,0.99872166,0.00012002043,0.00021867633,0.0001555019,0.0000052033215,0.000015793781,0.0000074654217,0.0006314345],"genre_scores_gemma":[0.0004709841,0.998868,0.00014113133,0.000109113396,0.00012347494,0.0000054094767,0.000020308235,0.0000010389186,0.00026058377],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988294,0.00002260788,0.000019328454,0.00002277305,0.00004093586,0.000011426268],"domain_scores_gemma":[0.9997855,0.00010832062,0.000026941441,0.000005545695,0.00005201401,0.000021765329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000506641,0.00065531273,0.0009898476,0.0023565623,0.00023625336,0.00071088166,0.0006329375,0.00079085445,0.0032730275],"category_scores_gemma":[0.00052117783,0.00023269949,0.00046994557,0.0021432012,0.0002878277,0.0010143676,0.00047984213,0.0012524149,0.001439899],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083642546,0.000103391096,0.00015934234,0.020556694,0.00007432515,0.00020113352,0.000062780775,0.00045961174,0.0017655547,0.0023597977,0.026744425,0.94742936],"study_design_scores_gemma":[0.000023424249,0.00018397506,0.00074096007,0.004023976,0.000178978,0.0013534451,0.00006197939,0.00015208493,0.00056660577,0.0012840223,0.99140793,0.00002269873],"about_ca_topic_score_codex":0.0009608823,"about_ca_topic_score_gemma":0.0013479892,"teacher_disagreement_score":0.0032730275,"about_ca_system_score_codex":0.00036489277,"about_ca_system_score_gemma":0.000858658,"threshold_uncertainty_score":0.010949433},"labels":[],"label_agreement":null},{"id":"W4285389858","doi":"10.1080/10428194.2022.2092853","title":"Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Myeloid leukemia; Refractory (planetary science); Pharmacokinetics; Antibody; Oncology; Pharmacology; Internal medicine; Immunology; Cancer; Immunotherapy; Nivolumab","score_opus":0.039697565353864255,"score_gpt":0.3630186783913506,"score_spread":0.32332111303748634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285389858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710764,0.005140556,0.0016517453,0.009909914,0.0015404646,0.0017827608,0.0021885012,0.00017156941,0.0065380335],"genre_scores_gemma":[0.9784985,0.001577684,0.0019815783,0.009156489,0.00092301297,0.0010998799,0.0016460575,0.00004309174,0.0050737085],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996712,0.00016062935,0.000016577782,0.000063335916,0.000033796237,0.000054472282],"domain_scores_gemma":[0.9993445,0.00022025585,0.00009169677,0.00004358295,0.00004105226,0.00025875575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009668483,0.00080595195,0.0018241649,0.00017686399,0.0004235735,0.00094975537,0.0006809014,0.0024965426,0.002908799],"category_scores_gemma":[0.0011450223,0.0003976721,0.00084007287,0.0002751933,0.0005881461,0.0007809001,0.00017337032,0.004352326,0.00091979775],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6620615,0.044204343,0.012068452,0.0008306926,0.0016365163,0.0038300809,0.00045142786,0.0036864665,0.047320258,0.0012845108,0.032259073,0.19036667],"study_design_scores_gemma":[0.65626085,0.2911764,0.016569467,0.000063796026,0.0005058127,0.0023291206,0.000106598156,0.0048098397,0.0048000906,0.0010515464,0.022270888,0.000055518838],"about_ca_topic_score_codex":0.0007541444,"about_ca_topic_score_gemma":0.0022055935,"teacher_disagreement_score":0.002908799,"about_ca_system_score_codex":0.0013674241,"about_ca_system_score_gemma":0.00091058906,"threshold_uncertainty_score":0.009921372},"labels":[],"label_agreement":null},{"id":"W4285492548","doi":"10.1182/blood.2022015478","title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Royal Victoria Regional Health Centre; Hôpital de l'Enfant-Jésus; Royal Victoria Hospital; Dalhousie University","funders":"Gilead Sciences","keywords":"Medicine; Quality of life (healthcare); Confidence interval; Visual analogue scale; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Physical therapy","score_opus":0.029688413766771723,"score_gpt":0.32612921224861646,"score_spread":0.29644079848184474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285492548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950181,0.0027165944,0.00029216212,0.00012836835,0.000056521872,0.0004909842,0.0006191871,0.000018091096,0.00065982307],"genre_scores_gemma":[0.9947344,0.0010814406,0.0007805093,0.00031239167,0.00012583927,0.0010840269,0.0013873464,0.000008876959,0.00048511452],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99832755,0.0012026557,0.00006627981,0.00009626795,0.00017981636,0.0001274306],"domain_scores_gemma":[0.99816173,0.0006852888,0.00056114554,0.000118901895,0.00011617855,0.0003567671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003908518,0.0006723445,0.0012107204,0.00035328802,0.00024779854,0.0005246471,0.00046672503,0.0007425064,0.001990579],"category_scores_gemma":[0.0019268594,0.00019563682,0.0017165076,0.00026724703,0.00041864204,0.0004472555,0.00033249045,0.0016078034,0.00034435006],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8330327,0.028472472,0.016843934,0.0010067604,0.003169978,0.00008384715,0.00013373881,0.001825176,0.013054125,0.00017047233,0.001299389,0.1009073],"study_design_scores_gemma":[0.23832269,0.6979412,0.05499633,0.00005586729,0.002072293,0.0002424907,0.000073742296,0.0016632408,0.0026440604,0.00017710638,0.0017824777,0.00002845091],"about_ca_topic_score_codex":0.00035169302,"about_ca_topic_score_gemma":0.00088080595,"teacher_disagreement_score":0.003908518,"about_ca_system_score_codex":0.0004630858,"about_ca_system_score_gemma":0.00072163326,"threshold_uncertainty_score":0.020670474},"labels":[],"label_agreement":null},{"id":"W4285604187","doi":"10.1097/cco.0000000000000843","title":"Immunotherapy of sarcomas with modified T cells","year":2022,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cancer research; Immunotherapy; Synovial sarcoma; Immune system; Antigen; T cell; Cell therapy; Immunology; T-cell receptor; Sarcoma; Cell; Pathology; Biology","score_opus":0.23424564148982915,"score_gpt":0.48614584247148124,"score_spread":0.2519002009816521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285604187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016582053,0.99835217,0.00013843425,0.00019098098,0.0003361722,0.000012665099,0.000030462506,0.000010899085,0.0007625283],"genre_scores_gemma":[0.0007808843,0.9979086,0.00017856475,0.00024132243,0.00020508817,0.000014380292,0.00006599106,0.0000023385712,0.00060289685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998903,0.000017896295,0.000014756117,0.000019976738,0.0000441531,0.000012932994],"domain_scores_gemma":[0.9998698,0.000049700622,0.000028457283,0.0000034185023,0.000034699737,0.000013828215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031939082,0.00086955505,0.0011483616,0.0013161954,0.00013380082,0.0006733387,0.0005498517,0.00078809244,0.003894277],"category_scores_gemma":[0.00044425862,0.00018352996,0.00043413174,0.0012020264,0.00021019892,0.0006896858,0.00045799167,0.0010798208,0.0029991928],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009519426,0.00006744486,0.00009727948,0.02641694,0.00010965249,0.00016489823,0.000027675038,0.00042380072,0.003961305,0.0013559393,0.03318742,0.93409246],"study_design_scores_gemma":[0.000057082092,0.00020008054,0.00072492677,0.005413103,0.00020834687,0.001495357,0.000034829485,0.000121711266,0.0015167233,0.00085793197,0.98935014,0.000019713012],"about_ca_topic_score_codex":0.00048254424,"about_ca_topic_score_gemma":0.0006946847,"teacher_disagreement_score":0.003894277,"about_ca_system_score_codex":0.0003479568,"about_ca_system_score_gemma":0.00064078154,"threshold_uncertainty_score":0.013027608},"labels":[],"label_agreement":null},{"id":"W4285726954","doi":"10.1007/s40273-022-01169-z","title":"The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada); McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Aggressive lymphoma; Cost effectiveness; Quality of life (healthcare); Quality-adjusted life year; Health care; Health economics; Public health; Lymphoma; Health administration; Quality of Life Research; Rituximab; Cost-effectiveness analysis; Intensive care medicine; Oncology; Internal medicine; Risk analysis (engineering); Nursing","score_opus":0.021292195897557455,"score_gpt":0.32236795008721936,"score_spread":0.3010757541896619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285726954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97620493,0.013677868,0.00010854433,0.0040209563,0.00008954827,0.00009996483,0.0011135926,0.000016045813,0.004668661],"genre_scores_gemma":[0.99670666,0.001972671,0.00012501047,0.00034837343,0.000032334443,0.00001368132,0.00033230707,0.0000027964759,0.00046628434],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99938726,0.00023647698,0.000044075663,0.00004950274,0.00011749453,0.00016522771],"domain_scores_gemma":[0.99888974,0.00026993896,0.00021739991,0.000018298555,0.0001203717,0.0004841692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005356215,0.00017275513,0.00045238138,0.00037849514,0.0003363225,0.00090103416,0.00050296914,0.00044953113,0.0022360606],"category_scores_gemma":[0.00282848,0.00010035143,0.00076651806,0.00069475494,0.00043476664,0.00033373758,0.0003730409,0.00082398497,0.00007977458],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20415367,0.0034184682,0.2469201,0.002036227,0.0034305833,0.0009608159,0.00041868456,0.022471638,0.0024243554,0.0027326706,0.015951797,0.495081],"study_design_scores_gemma":[0.020466784,0.02344937,0.9082101,0.00086401263,0.0050748866,0.00090420636,0.0016069799,0.024323557,0.0011782474,0.00080366887,0.012998128,0.000120141915],"about_ca_topic_score_codex":0.56439126,"about_ca_topic_score_gemma":0.7747763,"teacher_disagreement_score":0.43560874,"about_ca_system_score_codex":0.019802904,"about_ca_system_score_gemma":0.01097129,"threshold_uncertainty_score":0.87634826},"labels":[],"label_agreement":null},{"id":"W4286298413","doi":"10.1200/jco.2022.40.16_suppl.11515","title":"INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer; Internal medicine; Nausea; Combination therapy; Gastroenterology; Adverse effect; Vomiting; Common Terminology Criteria for Adverse Events; Oncology","score_opus":0.09199061574928084,"score_gpt":0.4698823754610562,"score_spread":0.37789175971177535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99692446,0.0013894684,0.00024675688,0.000042748976,0.000017912125,0.00014512466,0.00020463167,0.000029784876,0.0009990653],"genre_scores_gemma":[0.9968604,0.0009061263,0.0003410891,0.00006845853,0.000018597311,0.00012890442,0.0003705143,0.000008153912,0.0012977439],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99991846,0.000011985609,0.0000054184043,0.000021505424,0.000014727599,0.000027895081],"domain_scores_gemma":[0.99993,0.0000060119446,0.000012395687,0.0000057431293,0.0000051278807,0.000040743358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021586976,0.00041736252,0.0005870775,0.00030547965,0.00023033337,0.00025924967,0.0001925836,0.00019834923,0.002124935],"category_scores_gemma":[0.000087669374,0.00015452655,0.00030455756,0.00030202573,0.00023413739,0.0002575272,0.0001427605,0.0005367942,0.00055858056],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06145524,0.029135698,0.025776923,0.000984697,0.0005636406,0.0016567789,0.00041994368,0.0033019094,0.63135934,0.00041210998,0.004105376,0.24082841],"study_design_scores_gemma":[0.0138611095,0.61350673,0.16354759,0.000120862445,0.0012848778,0.0070108436,0.00047434683,0.004209,0.17062923,0.0003632874,0.024914807,0.00007729171],"about_ca_topic_score_codex":0.0007643638,"about_ca_topic_score_gemma":0.0025780322,"teacher_disagreement_score":0.002124935,"about_ca_system_score_codex":0.00034167123,"about_ca_system_score_gemma":0.00042386635,"threshold_uncertainty_score":0.0071086287},"labels":[],"label_agreement":null},{"id":"W4286487914","doi":"10.3389/fimmu.2022.864868","title":"Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"National Research Council Canada","keywords":"Epitope; Jurkat cells; Antigen; Chimeric antigen receptor; Cancer research; Epidermal growth factor receptor; Molecular biology; Biology; Chemistry; Receptor; Cell biology; Immunotherapy; Immunology; T cell; Immune system; Biochemistry","score_opus":0.0204181923470274,"score_gpt":0.29256436696106125,"score_spread":0.27214617461403384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286487914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958884,0.00027022557,0.003190931,0.000026809439,0.000010778604,0.000022640968,0.00009741535,0.00004498359,0.00044771034],"genre_scores_gemma":[0.9971603,0.00018150121,0.001873579,0.000038258695,0.000003430575,0.00002215929,0.0001529347,0.000015032628,0.0005526926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991274,0.000011498671,0.00001103985,0.000020783034,0.000023256234,0.000020645326],"domain_scores_gemma":[0.9999113,0.000020490554,0.000031091284,0.0000132737005,0.000011728296,0.000012138815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014198586,0.00021862674,0.00016912362,0.00008227106,0.00006832676,0.00017106482,0.00019512395,0.00020099325,0.00053807534],"category_scores_gemma":[0.000095485186,0.000070908085,0.00023382663,0.00006110743,0.00014424391,0.00014555316,0.00012945542,0.00038304264,0.00015178953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019110368,0.000009547228,0.00003295514,0.000008018109,0.0000017004514,0.000009939785,0.000004456077,0.000052155407,0.99959546,0.000025600339,0.0000058807655,0.00023529469],"study_design_scores_gemma":[0.00000446966,0.0001374562,0.00038291787,8.4304367e-7,0.0000046046734,0.00006997635,0.0000031557647,0.00038412868,0.9986382,0.000006775833,0.00036605695,0.0000012718016],"about_ca_topic_score_codex":0.00017603573,"about_ca_topic_score_gemma":0.00023982815,"teacher_disagreement_score":0.00053807534,"about_ca_system_score_codex":0.0002192557,"about_ca_system_score_gemma":0.000101507314,"threshold_uncertainty_score":0.0018000603},"labels":[],"label_agreement":null},{"id":"W4286539391","doi":"10.2139/ssrn.4163142","title":"CD137 (4-1BB) Signaling Drives a TcR-Independent Exhaustion Program in CD8 T Cells","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CD137; Immunosurveillance; CD8; T cell; Cancer immunotherapy; Cancer research; Immunotherapy; T-cell receptor; TIGIT; Cytotoxic T cell; Naive T cell; Biology; Cell biology; Immune system; Immunology; Genetics","score_opus":0.015279837366658883,"score_gpt":0.3058047767977226,"score_spread":0.2905249394310637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286539391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963439,0.00035299422,0.00094013865,0.00008288071,0.000021910073,0.000016627373,0.00018136643,0.00007035926,0.0019898734],"genre_scores_gemma":[0.9959901,0.000099571254,0.00043628315,0.00005102829,0.000011797588,0.000016113308,0.0002559723,0.000025862173,0.0031133979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996092,0.000044040906,0.00002254892,0.00007408999,0.00007435536,0.00017578468],"domain_scores_gemma":[0.999859,0.000019682866,0.00003163848,0.000020376945,0.000020790281,0.00004860164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014203353,0.0003591024,0.0002819537,0.00029143007,0.00027776312,0.00066683476,0.00025698537,0.0004058536,0.0034783431],"category_scores_gemma":[0.00018776054,0.00018886461,0.00025859353,0.0001380857,0.00021255147,0.00037110655,0.00044977522,0.0017801861,0.0012142614],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003469073,0.000087514214,0.00088440947,0.000039167713,0.000007275647,0.00009107747,0.000046410678,0.000145401,0.9946174,0.00038871914,0.00017169619,0.003173974],"study_design_scores_gemma":[0.00014765449,0.001013119,0.019025402,0.000041228497,0.00004787787,0.0007200613,0.00038253618,0.0037299134,0.96842146,0.00063948607,0.005815592,0.000015692209],"about_ca_topic_score_codex":0.00033024652,"about_ca_topic_score_gemma":0.0008570155,"teacher_disagreement_score":0.0034783431,"about_ca_system_score_codex":0.00033244956,"about_ca_system_score_gemma":0.00033606112,"threshold_uncertainty_score":0.011636257},"labels":[],"label_agreement":null},{"id":"W4288796560","doi":"10.26443/msurj.v15i1.14","title":"Delivering the “Living Drug”: T Cell Immunotherapy","year":2020,"lang":"en","type":"article","venue":"McGill Science Undergraduate Research Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Nanocarriers; Immunotherapy; Medicine; Drug delivery; Drug; Immune system; Chimeric antigen receptor; Cancer; Cancer immunotherapy; Chemotherapy; Cancer research; Immunology; Pharmacology; Nanotechnology; Internal medicine","score_opus":0.08844678524879877,"score_gpt":0.3765944185495841,"score_spread":0.2881476333007853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288796560","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029553885,0.8639768,0.052795388,0.014674344,0.004496239,0.00017409818,0.00016718,0.00040015607,0.03376196],"genre_scores_gemma":[0.24199066,0.6688672,0.03208346,0.010171599,0.003896425,0.0001656054,0.00022122168,0.00006712627,0.04253682],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986994,0.000029061152,0.0000068859936,0.000029441315,0.00004778774,0.000016834387],"domain_scores_gemma":[0.999925,0.000026040478,0.000016485774,0.0000035381543,0.00001775019,0.0000111901545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030166772,0.00035695685,0.0003387422,0.00048407374,0.00015698161,0.0007939992,0.00029967175,0.0009657826,0.0034418947],"category_scores_gemma":[0.00017691577,0.00008357865,0.00027886083,0.00027856533,0.00070197234,0.0006902013,0.00024065228,0.00083104975,0.0013076395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003478484,0.0002721381,0.00070988154,0.007826497,0.00008520036,0.0008570633,0.00018225388,0.0014810532,0.30650592,0.05851384,0.034283765,0.5889345],"study_design_scores_gemma":[0.00012658884,0.0017329908,0.0010433585,0.0008850572,0.000175581,0.0038016005,0.00013678682,0.0028638695,0.2441776,0.017018411,0.7279828,0.000055365097],"about_ca_topic_score_codex":0.00031578806,"about_ca_topic_score_gemma":0.00039498432,"teacher_disagreement_score":0.0034418947,"about_ca_system_score_codex":0.0005378923,"about_ca_system_score_gemma":0.00049194245,"threshold_uncertainty_score":0.011514306},"labels":[],"label_agreement":null},{"id":"W4289878670","doi":"10.1093/noajnl/vdac078.094","title":"SYST-15 TARGETING AXONAL GUIDANCE WITH ANTI-ROBO1 CAR T CELLS: A NEW THERAPEUTIC STRATEGY FOR MALIGNANT BRAIN CANCER","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; McMaster University","funders":"","keywords":"Cancer research; Cancer; Brain metastasis; Medicine; Metastasis; Population; Pathology; Internal medicine","score_opus":0.04391509565129528,"score_gpt":0.36081792638833643,"score_spread":0.3169028307370412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289878670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428376,0.024223648,0.022141246,0.0013844274,0.00021259452,0.00030300612,0.0004857824,0.00058438885,0.007827363],"genre_scores_gemma":[0.9805683,0.007814954,0.006475751,0.00025107065,0.000038369108,0.00013505422,0.00035036547,0.000022173004,0.0043439367],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999441,0.000007980976,0.000003273169,0.000010245744,0.000013205473,0.000021247519],"domain_scores_gemma":[0.9999745,0.0000025550535,0.000005935139,0.0000022603663,0.0000048355205,0.000009893289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114236376,0.00035011818,0.00026266495,0.00030759026,0.00012668243,0.00043692376,0.0002424179,0.00031308437,0.0010899538],"category_scores_gemma":[0.000051453942,0.000098197386,0.00024272365,0.00014329511,0.00022404222,0.0002308617,0.000204253,0.00061380706,0.0003558687],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033452237,0.0002556905,0.00045843114,0.0002713153,0.0000307043,0.00022336931,0.00006712355,0.0007642935,0.96684945,0.0016217262,0.0011513138,0.027972216],"study_design_scores_gemma":[0.00021196694,0.0030867918,0.0030492195,0.00003985271,0.00012747991,0.0017442486,0.00005725294,0.00452145,0.9384107,0.0005440785,0.048182286,0.000024530847],"about_ca_topic_score_codex":0.00065266195,"about_ca_topic_score_gemma":0.0011863692,"teacher_disagreement_score":0.0010899538,"about_ca_system_score_codex":0.0003639556,"about_ca_system_score_gemma":0.00031021336,"threshold_uncertainty_score":0.0036462545},"labels":[],"label_agreement":null},{"id":"W4289918643","doi":"10.1038/s41434-022-00358-x","title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","year":2022,"lang":"en","type":"article","venue":"Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Sangamo Therapeutics","keywords":"Immunosuppression; Immunology; Transplantation; Antigen; Human leukocyte antigen; Biology; Immune system; Tacrolimus; Peripheral blood mononuclear cell; Proinflammatory cytokine; Humanized mouse; Medicine; In vitro; Inflammation; Internal medicine","score_opus":0.08355808030394156,"score_gpt":0.3849365013374286,"score_spread":0.30137842103348705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289918643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798693,0.0015980242,0.013629433,0.00010198009,0.00012245128,0.0013886716,0.000534601,0.0002105519,0.002544979],"genre_scores_gemma":[0.988331,0.0013644799,0.0064172964,0.00008307846,0.00005306464,0.00064648624,0.0011925838,0.000035866862,0.001876085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99953544,0.00014115467,0.000041046318,0.000046531713,0.00012082814,0.0001150976],"domain_scores_gemma":[0.9996946,0.00007085312,0.000062229745,0.000043234802,0.00006424133,0.00006485425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011906935,0.0007302329,0.0004048157,0.00030508934,0.00017663545,0.0005972927,0.00051509845,0.0006572498,0.0013966677],"category_scores_gemma":[0.00047200936,0.00014521932,0.000398085,0.00016965598,0.00025011378,0.00038333144,0.0001638528,0.0012845747,0.00041102344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091577426,0.0029916423,0.00034007264,0.000109445056,0.000020669899,0.000071508955,0.000057375277,0.0012573082,0.9871127,0.00021468723,0.0001389676,0.0067697833],"study_design_scores_gemma":[0.00034217554,0.06980128,0.0012158864,0.000019066916,0.000099674435,0.0002222408,0.000041380994,0.0023840421,0.9229024,0.00012684207,0.0028339566,0.000010970646],"about_ca_topic_score_codex":0.00029043845,"about_ca_topic_score_gemma":0.00034519806,"teacher_disagreement_score":0.0013966677,"about_ca_system_score_codex":0.00023679166,"about_ca_system_score_gemma":0.00047683853,"threshold_uncertainty_score":0.006297052},"labels":[],"label_agreement":null},{"id":"W4290851731","doi":"10.1016/j.jtct.2022.08.010","title":"The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; Miltenyi Biotec; Kite Pharma; Division of Cancer Prevention, National Cancer Institute; Gilead Sciences; AstraZeneca; Bristol-Myers Squibb; National Cancer Institute; AbbVie; Merck; Roche; Astellas Pharma US; Amgen","keywords":"Medicine; Chemoimmunotherapy; Cost effectiveness; Quality-adjusted life year; Clinical trial; Oncology; Internal medicine; Lymphoma; Rituximab","score_opus":0.041125326873381204,"score_gpt":0.3165985277671497,"score_spread":0.2754732008937685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290851731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547879,0.026613547,0.0043973587,0.0034457035,0.00023697934,0.000950626,0.0034957991,0.000068973604,0.0060030725],"genre_scores_gemma":[0.99613696,0.0014784861,0.0007824403,0.00025761029,0.000018719997,0.00021602272,0.000797944,0.000005941364,0.00030575064],"study_design_codex":"simulation_or_modeling","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973437,0.0022781934,0.00006933293,0.00009798783,0.0001049532,0.00010586255],"domain_scores_gemma":[0.996768,0.0024770482,0.0003638383,0.00006336071,0.00008796756,0.0002398718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00597906,0.0009553559,0.0013342281,0.00060353073,0.00018533014,0.0015871353,0.0008307247,0.0011255554,0.0026201445],"category_scores_gemma":[0.010956714,0.0003703432,0.0031575973,0.0006065192,0.00046413494,0.0010658782,0.00069829955,0.0016886202,0.00013605463],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19002087,0.0026062,0.026707845,0.00423786,0.0140900165,0.0007786154,0.0001654864,0.65892905,0.0013436197,0.010355346,0.007168497,0.083596684],"study_design_scores_gemma":[0.06574977,0.027156122,0.019743832,0.0022144213,0.016444236,0.0007384432,0.0003926183,0.8459519,0.0014464946,0.011471851,0.008525525,0.00016481169],"about_ca_topic_score_codex":0.005329265,"about_ca_topic_score_gemma":0.0040908176,"teacher_disagreement_score":0.00597906,"about_ca_system_score_codex":0.0033222493,"about_ca_system_score_gemma":0.0018205929,"threshold_uncertainty_score":0.03162068},"labels":[],"label_agreement":null},{"id":"W4292018553","doi":"10.1182/bloodadvances.2022008150","title":"Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Refractory (planetary science); Confidence interval; Odds ratio; Oncology","score_opus":0.0166545374254523,"score_gpt":0.31204105543230126,"score_spread":0.29538651800684895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292018553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212706,0.006223519,0.0001411963,0.00019656011,0.00007472857,0.00017020175,0.00021949458,0.000020406676,0.00082676887],"genre_scores_gemma":[0.9982514,0.0007623189,0.00017363035,0.0001682079,0.000069754926,0.00013641757,0.00027473294,0.0000019539234,0.00016162981],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985372,0.0009390345,0.00012832161,0.00019118878,0.000103241444,0.00010105666],"domain_scores_gemma":[0.99861026,0.0006016043,0.0003532926,0.00008581376,0.000060811737,0.00028813543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001856648,0.00039413353,0.0015372649,0.00043955728,0.00018076488,0.00048463605,0.00061307324,0.0007498197,0.002392837],"category_scores_gemma":[0.0025789728,0.00015831993,0.001536629,0.00038450057,0.0004096155,0.0005823355,0.0003656852,0.00087567413,0.00024259502],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8731907,0.007332949,0.012847561,0.0013297644,0.0036178126,0.00006780133,0.00012393319,0.0011011956,0.0013668914,0.00025501568,0.0008148463,0.09795145],"study_design_scores_gemma":[0.4213047,0.4764995,0.089355364,0.00034424273,0.004717048,0.00021787673,0.00019321723,0.0038153103,0.000937854,0.00070705457,0.0018561968,0.000051588984],"about_ca_topic_score_codex":0.00069606677,"about_ca_topic_score_gemma":0.0013323887,"teacher_disagreement_score":0.002392837,"about_ca_system_score_codex":0.0006985668,"about_ca_system_score_gemma":0.00037701614,"threshold_uncertainty_score":0.009819031},"labels":[],"label_agreement":null},{"id":"W4292302487","doi":"10.7759/cureus.28162","title":"Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Cureus","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Systematic review; Cochrane Library; Chimeric antigen receptor; Cardiotoxicity; Randomized controlled trial; MEDLINE; Clinical trial; Adverse effect; Intensive care medicine; Narrative review; Internal medicine; Cancer; Immunotherapy; Chemotherapy","score_opus":0.09833758926295857,"score_gpt":0.364639551080973,"score_spread":0.26630196181801447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292302487","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014081163,0.99730885,0.00013005335,0.0002131493,0.00007938751,0.00033579944,0.0003212154,0.0000062875024,0.00019716246],"genre_scores_gemma":[0.01757798,0.98015565,0.00043506417,0.000627757,0.00012453455,0.00070472824,0.00024344576,0.000005226097,0.0001256803],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9937138,0.0017754234,0.0026954976,0.0004889176,0.001140493,0.00018575357],"domain_scores_gemma":[0.97603536,0.016298488,0.0049045193,0.0003239021,0.0022069567,0.00023075943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007113392,0.0014528871,0.007522127,0.008038103,0.0006251158,0.0023162796,0.001358524,0.001819388,0.0038354918],"category_scores_gemma":[0.029861487,0.00088210986,0.01016364,0.0076606926,0.00074915437,0.0018646884,0.0013878696,0.0011001041,0.00024443687],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020905155,0.0000137056795,0.0008759998,0.96875674,0.01231135,0.00009123323,0.0001094566,0.000077223485,0.00012993273,0.00009933637,0.00089214003,0.016433787],"study_design_scores_gemma":[0.00029665726,0.00032433934,0.0052708895,0.80393946,0.17685443,0.00059007073,0.00023320774,0.000110169625,0.00023431012,0.00030701538,0.011792285,0.00004711759],"about_ca_topic_score_codex":0.0061973,"about_ca_topic_score_gemma":0.01602866,"teacher_disagreement_score":0.008038103,"about_ca_system_score_codex":0.0035511272,"about_ca_system_score_gemma":0.00938271,"threshold_uncertainty_score":0.03761971},"labels":[],"label_agreement":null},{"id":"W4292999428","doi":"10.54097/hset.v8i.1182","title":"T Recent advances of FDA-approved CAR-T therapies in multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Multiple myeloma; Clinical trial; Intensive care medicine; Drug; Cytokine release syndrome; Adverse effect; Refractory (planetary science); Cancer; Oncology; Chimeric antigen receptor; Internal medicine; Pharmacology; Immunotherapy","score_opus":0.014804054338159572,"score_gpt":0.26465415265699166,"score_spread":0.2498500983188321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292999428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037963358,0.9737607,0.0027320299,0.00881462,0.0016291271,0.000030439653,0.00013472502,0.00010808356,0.008993879],"genre_scores_gemma":[0.03774774,0.9430567,0.0033070163,0.0075212047,0.0030961467,0.000056381636,0.00034172807,0.00002176695,0.0048512896],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996126,0.000084314954,0.00003877199,0.00006552756,0.0001324553,0.00006636272],"domain_scores_gemma":[0.99919635,0.00025782082,0.00012272333,0.00004016572,0.00025173338,0.00013123993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018427969,0.00054333394,0.0006069382,0.00092642277,0.00034464168,0.0011668324,0.00063315284,0.0014010218,0.004940388],"category_scores_gemma":[0.001401108,0.00021517416,0.00062013237,0.0009938073,0.00060929975,0.0014337458,0.00060177717,0.0023911167,0.0017880762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005178886,0.0003083251,0.0008325184,0.0032268101,0.000093144445,0.00041214985,0.00009642487,0.0007967348,0.008910923,0.0089906035,0.053989694,0.92182475],"study_design_scores_gemma":[0.00014679616,0.0009853066,0.0013577793,0.0008092796,0.00017881242,0.0014313747,0.000100355675,0.0009774183,0.009529162,0.004060122,0.98039,0.000033510532],"about_ca_topic_score_codex":0.0008703653,"about_ca_topic_score_gemma":0.0013796588,"teacher_disagreement_score":0.004940388,"about_ca_system_score_codex":0.0007963956,"about_ca_system_score_gemma":0.001245928,"threshold_uncertainty_score":0.016527236},"labels":[],"label_agreement":null},{"id":"W4293105725","doi":"10.1126/sciadv.abn5522","title":"DLL4 and VCAM1 enhance the emergence of T cell–competent hematopoietic progenitors from human pluripotent stem cells","year":2022,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Université de Montréal; University of Toronto; Institute for Research in Immunology and Cancer; University of British Columbia","funders":"","keywords":"Progenitor cell; Haematopoiesis; Cell biology; Induced pluripotent stem cell; Stem cell; Biology; CD8; T cell; Immunology; Antigen; Immune system; Embryonic stem cell; Biochemistry","score_opus":0.019063850418005956,"score_gpt":0.3141233819719036,"score_spread":0.29505953155389764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293105725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891634,0.0010140842,0.0067613446,0.00011656791,0.000021719914,0.000044735636,0.00034295244,0.00013496914,0.002400375],"genre_scores_gemma":[0.9899753,0.0005097051,0.005626503,0.000065086264,0.000007241192,0.000036701673,0.00043003744,0.000031621836,0.0033179908],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983656,0.00003556927,0.000016964335,0.000023597295,0.000051005027,0.00003626759],"domain_scores_gemma":[0.99991834,0.000018130706,0.000022327302,0.000006843406,0.000009503176,0.000024859897],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015575689,0.00025574808,0.000117799056,0.000305841,0.00008909511,0.0003458666,0.0001644714,0.00018968068,0.0015157674],"category_scores_gemma":[0.00012533608,0.00010155088,0.0001594638,0.00015617286,0.0001335706,0.00016313118,0.0003242639,0.00043536568,0.00026787253],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002577801,0.000016716518,0.00010031537,0.000022353368,0.0000029807134,0.000024731906,0.00000852722,0.00011843249,0.99808383,0.0001283255,0.00004048769,0.0014275601],"study_design_scores_gemma":[0.000004942738,0.00004840903,0.00033470645,0.0000020493303,0.0000048681227,0.00003623087,0.000005094233,0.00058563706,0.9974316,0.00002067813,0.0015245092,0.0000012363575],"about_ca_topic_score_codex":0.00038735868,"about_ca_topic_score_gemma":0.00077210215,"teacher_disagreement_score":0.0015157674,"about_ca_system_score_codex":0.00029287735,"about_ca_system_score_gemma":0.00019519318,"threshold_uncertainty_score":0.005070746},"labels":[],"label_agreement":null},{"id":"W4293240917","doi":"10.21203/rs.3.rs-1587568/v1","title":"Safety and efficacy of allogeneic hematopoietic stem cell transplantation in R/R B-NHL patients with disease progression after CAR-T therapy","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University","keywords":"Medicine; Lymphoma; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Gastroenterology; Regimen; Lymphoblastic lymphoma; Chemotherapy; Surgery; Oncology; T cell; Immunology","score_opus":0.029394059129100415,"score_gpt":0.3602616442129119,"score_spread":0.3308675850838115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293240917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977163,0.0013659238,0.0001151628,0.000049803257,0.000010372009,0.000015384956,0.000088223635,0.0000069642606,0.00063194707],"genre_scores_gemma":[0.99942905,0.0001853691,0.00003688919,0.00003855722,0.000023542822,0.000010400421,0.00020029843,0.0000013452837,0.00007445649],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99966323,0.00013300542,0.000038102626,0.00004752805,0.00007300402,0.00004505813],"domain_scores_gemma":[0.9990814,0.0002197942,0.00036486977,0.000054829772,0.000078837795,0.00020017795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008315187,0.00011821721,0.0003636856,0.00024754775,0.00016990108,0.00038234604,0.00017313308,0.00022013257,0.00045973822],"category_scores_gemma":[0.0013813443,0.000043644915,0.000318325,0.00022539162,0.00017288515,0.00024849508,0.00017445482,0.00043459923,0.00013282048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027025443,0.0013717787,0.818388,0.00021978967,0.000344227,0.001291201,0.0002302627,0.0012505152,0.0058325287,0.00018684908,0.0007245997,0.14313488],"study_design_scores_gemma":[0.0016907596,0.045116942,0.9360511,0.00010179921,0.00057054433,0.0046092477,0.00020115092,0.0033147533,0.004651443,0.00037312924,0.0032961313,0.000022918512],"about_ca_topic_score_codex":0.00017572143,"about_ca_topic_score_gemma":0.00019918976,"teacher_disagreement_score":0.0008315187,"about_ca_system_score_codex":0.0002549245,"about_ca_system_score_gemma":0.00024804933,"threshold_uncertainty_score":0.0043975115},"labels":[],"label_agreement":null},{"id":"W4293786422","doi":"10.1182/bloodadvances.2022007779","title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Immunotherapy","score_opus":0.014657238399119334,"score_gpt":0.31693442509164627,"score_spread":0.30227718669252696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293786422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266243,0.0022570253,0.00048039792,0.00037737802,0.00005662376,0.00074034056,0.00096030254,0.000120001765,0.002345381],"genre_scores_gemma":[0.99108374,0.0013108618,0.0013851845,0.0006439735,0.000111331516,0.0009135834,0.0026204924,0.000040808343,0.0018901475],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995969,0.0002062872,0.000023141294,0.000060889874,0.000055711113,0.00005700301],"domain_scores_gemma":[0.9995944,0.00006054386,0.00010487412,0.000042053012,0.000041516094,0.00015665157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014753971,0.0008879259,0.0010252768,0.0003022821,0.00022632515,0.0009395432,0.0006638656,0.0005552846,0.001993718],"category_scores_gemma":[0.00080864393,0.00030785546,0.0008970337,0.00022866839,0.00044739732,0.0005254922,0.00034371408,0.002274827,0.0005380551],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58046526,0.061776128,0.019155791,0.0010423725,0.0023065617,0.00046248033,0.00026090283,0.0050053927,0.12829207,0.00048606572,0.008863429,0.19188358],"study_design_scores_gemma":[0.37362558,0.5192383,0.059611443,0.0000917502,0.0018129029,0.0011185872,0.00008736899,0.005654324,0.023285411,0.00037736836,0.015014393,0.00008260019],"about_ca_topic_score_codex":0.0005415352,"about_ca_topic_score_gemma":0.0010620008,"teacher_disagreement_score":0.001993718,"about_ca_system_score_codex":0.00080857007,"about_ca_system_score_gemma":0.00087982835,"threshold_uncertainty_score":0.007802725},"labels":[],"label_agreement":null},{"id":"W4295452672","doi":"10.1007/978-1-0716-2712-9_12","title":"A High-Throughput Strategy for T-Cell Receptor Cloning and Expression","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute of Allergy and Infectious Diseases","keywords":"T-cell receptor; Cloning (programming); clone (Java method); Biology; Gene; Plasmid; Computational biology; Expression cloning; Molecular biology; Genetics; T cell; Computer science; Peptide sequence; Immune system","score_opus":0.060910807934350865,"score_gpt":0.4576712093672733,"score_spread":0.3967604014329224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295452672","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057027742,0.0030417042,0.91879606,0.0011707734,0.000504045,0.0016628591,0.004833712,0.003512466,0.009450565],"genre_scores_gemma":[0.23405688,0.0049050557,0.7143107,0.00084835495,0.00022837716,0.0029818444,0.01845186,0.0011217034,0.023095164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837744,0.00031409418,0.00010710779,0.00031705253,0.00065918925,0.00022506011],"domain_scores_gemma":[0.9995148,0.00018786118,0.00003961061,0.00013297553,0.00007385268,0.000050904266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011955951,0.0014252132,0.0015516061,0.0011389408,0.0009455388,0.0019931023,0.0016636763,0.0010294984,0.0042361026],"category_scores_gemma":[0.00097427214,0.0010891006,0.001364616,0.0010568484,0.00057477003,0.0007560127,0.0013393933,0.0030350303,0.0069695585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001556133,0.00020400748,0.00016610365,0.00016053722,0.0000621044,0.0001230608,0.00008196375,0.00060057733,0.9635465,0.002312433,0.0047530057,0.027834056],"study_design_scores_gemma":[0.000070604736,0.00028564638,0.00088473514,0.000023743136,0.00010325339,0.0006047913,0.00005080495,0.0055069393,0.9497574,0.0017176352,0.040936697,0.000057739777],"about_ca_topic_score_codex":0.0014091495,"about_ca_topic_score_gemma":0.003207111,"teacher_disagreement_score":0.0042361026,"about_ca_system_score_codex":0.0007932826,"about_ca_system_score_gemma":0.0011112505,"threshold_uncertainty_score":0.014171183},"labels":[],"label_agreement":null},{"id":"W4295817567","doi":"10.1016/j.annonc.2022.07.861","title":"735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; CD8; Cancer; Adverse effect; Leukapheresis; Immunotherapy; Antigen; Immunology; CD34","score_opus":0.11352274174321512,"score_gpt":0.37618225927644733,"score_spread":0.2626595175332322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46477237,0.12670033,0.007700359,0.07162297,0.008834513,0.002440678,0.08863335,0.0024890937,0.22680631],"genre_scores_gemma":[0.7582375,0.039405428,0.00819924,0.043543853,0.005010121,0.0010731559,0.058439676,0.00045822642,0.08563283],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994998,0.00014468525,0.000034437777,0.00006793398,0.0001800845,0.000073085495],"domain_scores_gemma":[0.99899405,0.00034372133,0.00016245841,0.000087277,0.00018724402,0.00022535033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015215143,0.00035370098,0.00071726553,0.00045341038,0.00034902856,0.0013427429,0.0005073751,0.0007733646,0.01246071],"category_scores_gemma":[0.0023104919,0.00019226929,0.00089871144,0.00041445834,0.00023265822,0.0007324528,0.0002958189,0.0018435032,0.0021429544],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041634083,0.0016302334,0.009238733,0.0013448925,0.0013614836,0.00040629905,0.00009357665,0.0018314144,0.020903038,0.0026114322,0.18927659,0.72966814],"study_design_scores_gemma":[0.03812483,0.027898435,0.05444176,0.0006928123,0.00391655,0.0016591412,0.00008540217,0.0029207973,0.01668175,0.00333311,0.85014415,0.00010119876],"about_ca_topic_score_codex":0.0017109751,"about_ca_topic_score_gemma":0.007270614,"teacher_disagreement_score":0.01246071,"about_ca_system_score_codex":0.0010081447,"about_ca_system_score_gemma":0.0013903673,"threshold_uncertainty_score":0.041685224},"labels":[],"label_agreement":null},{"id":"W4295819067","doi":"10.1016/j.annonc.2022.07.904","title":"778TiP A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Cancer research; Immunotherapy; T cell; Cancer; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.10486761897001701,"score_gpt":0.43402916207023273,"score_spread":0.3291615431002157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837024,0.0020838515,0.0007331748,0.00081690145,0.0002571458,0.0022894118,0.002069586,0.00026365588,0.0077838483],"genre_scores_gemma":[0.98100406,0.0013802027,0.0018614256,0.0013991989,0.00023721001,0.002672683,0.0043354607,0.000066285174,0.007043435],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999699,0.000114031754,0.000012743959,0.000054124357,0.000025059438,0.00009505184],"domain_scores_gemma":[0.9996855,0.00006668593,0.00003631846,0.000033238433,0.00001685364,0.00016139388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007479456,0.0010654178,0.0014206797,0.00034647863,0.00032555373,0.00089346996,0.00064711424,0.0010775323,0.00860708],"category_scores_gemma":[0.0005680995,0.00030177244,0.00075190194,0.00025116428,0.000783092,0.0006629536,0.00032177442,0.0028075273,0.001978321],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.70875114,0.032463193,0.00445781,0.0010428288,0.0013848823,0.00048040628,0.0001594702,0.0034155154,0.05911928,0.0011021192,0.010922443,0.17670089],"study_design_scores_gemma":[0.5851622,0.39282915,0.0055648,0.00006131686,0.0005457966,0.0003044016,0.000056454348,0.0019474123,0.00664103,0.0006223683,0.0062368587,0.000028272636],"about_ca_topic_score_codex":0.0008837857,"about_ca_topic_score_gemma":0.0018494759,"teacher_disagreement_score":0.00860708,"about_ca_system_score_codex":0.00072826765,"about_ca_system_score_gemma":0.0011872562,"threshold_uncertainty_score":0.028793573},"labels":[],"label_agreement":null},{"id":"W4295899536","doi":"10.1111/imcb.12587","title":"Training the next generation of Sudanese immunologists: a case for mentorship","year":2022,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Mentorship; Medical education; Training (meteorology); Quality (philosophy); Medicine; Psychology; Philosophy","score_opus":0.15324307596501782,"score_gpt":0.34724715435146725,"score_spread":0.19400407838644942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295899536","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010857391,0.0074020466,0.0035036975,0.9498641,0.010813258,0.00011996554,0.000028158745,0.00016398143,0.017247407],"genre_scores_gemma":[0.49300197,0.013517105,0.014839995,0.4184989,0.01604604,0.0009989393,0.00015827417,0.0007211536,0.042217687],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8603525,0.09244547,0.0028195465,0.005237501,0.013934153,0.025210833],"domain_scores_gemma":[0.724352,0.071271256,0.010915296,0.012116811,0.026184931,0.15515973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11432342,0.0014943115,0.00087472313,0.0022657476,0.03191111,0.03522601,0.009040304,0.020914273,0.013341595],"category_scores_gemma":[0.13002251,0.000932047,0.0020548278,0.0014577988,0.028917268,0.029773885,0.038628742,0.044669945,0.0051868535],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024012655,0.0010430884,0.008250797,0.00094905565,0.00014536928,0.011037546,0.08948831,0.0005766602,0.0007072133,0.20523596,0.5226168,0.15970905],"study_design_scores_gemma":[0.00014279912,0.0004337925,0.0021073942,0.0032440592,0.000039764196,0.0044300305,0.0970498,0.0009429669,0.00046504868,0.07933,0.8115759,0.00023853923],"about_ca_topic_score_codex":0.0042349743,"about_ca_topic_score_gemma":0.0060269427,"teacher_disagreement_score":0.11432342,"about_ca_system_score_codex":0.012157977,"about_ca_system_score_gemma":0.052326623,"threshold_uncertainty_score":0.6046073},"labels":[],"label_agreement":null},{"id":"W4295941831","doi":"10.1158/1557-3265.sarcomas22-pr005","title":"Abstract PR005: PRC2 inactivating mutations amplify cell death in response to DNMT1-targeted therapy through enhanced viral mimicry in malignant peripheral nerve sheath tumor","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PRC2; Cancer research; Biology; Context (archaeology); EZH2; Cancer; Epigenetics; Genetics","score_opus":0.1878447620197086,"score_gpt":0.5002895845280105,"score_spread":0.31244482250830197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295941831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986668,0.0014496793,0.0051316223,0.00021361042,0.000094239396,0.00014514188,0.0012790496,0.00040530568,0.004613462],"genre_scores_gemma":[0.9915105,0.00037324618,0.0022899306,0.000057781024,0.000008671499,0.00007023757,0.0008542794,0.000032684507,0.0048028454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982184,0.000021313146,0.000016993456,0.00003960079,0.000063860745,0.00003630402],"domain_scores_gemma":[0.9999274,0.0000137907255,0.00001858095,0.000009821062,0.000007892062,0.000022562552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018802301,0.000344505,0.00031171227,0.00023615046,0.0001291521,0.0002999722,0.0002503144,0.0002936426,0.0031747902],"category_scores_gemma":[0.00011960986,0.00011616665,0.00022722267,0.00016881332,0.00022592349,0.00020886994,0.00020064857,0.0008479381,0.00055556756],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001586547,0.00006357852,0.0001249411,0.000031784697,0.000006847163,0.000034135075,0.000011179355,0.00011621592,0.9966904,0.00016272173,0.00017107087,0.0024285074],"study_design_scores_gemma":[0.000026233827,0.0007707801,0.0011199629,0.000002432744,0.000016849654,0.00017613961,0.000009118411,0.0011892498,0.9943988,0.000029640198,0.0022582689,0.00000265409],"about_ca_topic_score_codex":0.00090540375,"about_ca_topic_score_gemma":0.0009013793,"teacher_disagreement_score":0.0031747902,"about_ca_system_score_codex":0.00039280005,"about_ca_system_score_gemma":0.00022785224,"threshold_uncertainty_score":0.010620713},"labels":[],"label_agreement":null},{"id":"W4296130327","doi":"10.1158/1557-3265.sarcomas22-pr001","title":"Abstract PR001: Oncogene-induced matrix reorganization controls CD8+ T cell immunity in the UPS microenvironment","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; YAP1; Cancer research; Cell biology; T cell; CD8; Biology; Extracellular matrix; Cytotoxic T cell; Immunology; Immune system","score_opus":0.19123344588355604,"score_gpt":0.507720672679515,"score_spread":0.316487226795959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953621,0.0004992518,0.0012068456,0.0001681033,0.000041352854,0.000029018109,0.00066881324,0.00012220925,0.0019023512],"genre_scores_gemma":[0.9938823,0.00020833289,0.0008770214,0.00006450719,0.000013126859,0.00004788632,0.00065327366,0.000031286716,0.004222267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999853,0.000017263317,0.000010991853,0.000037963306,0.0000323006,0.00004845321],"domain_scores_gemma":[0.9998994,0.0000095456135,0.00003210943,0.000010008661,0.000008184239,0.000040702304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000690985,0.0003241369,0.00017709467,0.00024000839,0.00017288383,0.00028971248,0.00019061241,0.00027768288,0.0038122549],"category_scores_gemma":[0.00008260343,0.00011802179,0.00019188743,0.00014157678,0.00038308412,0.00019527043,0.00024630822,0.00094344164,0.0009128324],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025182503,0.000056573506,0.00016375551,0.000030990293,0.0000017424004,0.00004386801,0.00001008941,0.000055425015,0.9980445,0.00009668119,0.00009988327,0.001144581],"study_design_scores_gemma":[0.000050137172,0.0007625717,0.007939434,0.000010003326,0.000015006949,0.00022228203,0.00009740027,0.0015840026,0.9859278,0.00009804742,0.0032879412,0.0000052786263],"about_ca_topic_score_codex":0.00032914957,"about_ca_topic_score_gemma":0.0005097108,"teacher_disagreement_score":0.0038122549,"about_ca_system_score_codex":0.0003049521,"about_ca_system_score_gemma":0.00018766013,"threshold_uncertainty_score":0.012753248},"labels":[],"label_agreement":null},{"id":"W4296130403","doi":"10.1158/1557-3265.sarcomas22-ia011","title":"Abstract IA011: Identifying tumor-restricted target antigens for adoptive cellular immunotherapy to treat Ewing Sarcoma using multi-omic discovery platforms","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Major histocompatibility complex; Immunotherapy; Antigen; Biology; Transcriptome; Cancer research; Sarcoma; Computational biology; Immunology; Medicine; Immune system; Gene; Gene expression; Genetics; Pathology","score_opus":0.3662698473752391,"score_gpt":0.5264424264069669,"score_spread":0.16017257903172782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8964517,0.015375212,0.060099956,0.0011456433,0.0003886895,0.0005294479,0.015285475,0.0017365592,0.0089873625],"genre_scores_gemma":[0.83671594,0.009883233,0.094232075,0.0009349344,0.00017034981,0.00052462023,0.04357495,0.00028531515,0.01367853],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999757,0.000021323882,0.000020978378,0.00006579427,0.0000949441,0.00003996985],"domain_scores_gemma":[0.9998833,0.0000145601425,0.000029464853,0.00001447345,0.00003106463,0.000027137201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042614207,0.0006392584,0.00055860373,0.000787684,0.0002860157,0.0010984705,0.0003312862,0.0003742433,0.002092942],"category_scores_gemma":[0.00025105558,0.0001920119,0.00052636064,0.0007122872,0.00024207537,0.0004889682,0.0005522449,0.00079983776,0.0011759553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024108929,0.00005081837,0.0013863196,0.00017225981,0.000020954583,0.00004637579,0.000013655955,0.00035663715,0.9821072,0.00023470471,0.0010109143,0.014359072],"study_design_scores_gemma":[0.00007890503,0.001018703,0.0153654255,0.00004883259,0.00022346969,0.00070820184,0.00008413827,0.010282817,0.9401337,0.0006469968,0.03137697,0.00003181063],"about_ca_topic_score_codex":0.00025707972,"about_ca_topic_score_gemma":0.00041577686,"teacher_disagreement_score":0.002092942,"about_ca_system_score_codex":0.00043992803,"about_ca_system_score_gemma":0.0005320074,"threshold_uncertainty_score":0.007001519},"labels":[],"label_agreement":null},{"id":"W4296130421","doi":"10.1158/1557-3265.sarcomas22-a023","title":"Abstract A023: Identifying new therapeutic indications for afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4]) in adult and pediatric sarcomas using MAGE-A4 immunohistochemistry","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Leiomyosarcoma; Sarcoma; Medicine; Immunohistochemistry; Synovial sarcoma; Undifferentiated Pleomorphic Sarcoma; Liposarcoma; Tissue microarray; Pathology; Cancer; Dermatofibrosarcoma protuberans; Cancer research; Soft tissue sarcoma; Internal medicine","score_opus":0.2983232906111273,"score_gpt":0.5464183236075497,"score_spread":0.24809503299642244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953685,0.0014549388,0.0005238761,0.00009765435,0.000008643262,0.000040589337,0.0010458733,0.000017559443,0.001442351],"genre_scores_gemma":[0.99496484,0.0008170096,0.0018133752,0.000076651515,0.000014916877,0.000048328333,0.0015569729,0.000005609027,0.0007022457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998672,0.000019967269,0.0000148461695,0.00003497213,0.00003575193,0.000027225626],"domain_scores_gemma":[0.99973196,0.000041567928,0.000097259406,0.000011396696,0.00006988637,0.000047984264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000420803,0.00013349573,0.00015317091,0.0006029294,0.00020320113,0.00037032182,0.00019665065,0.00027270993,0.0014011794],"category_scores_gemma":[0.00043631336,0.0001102193,0.00015513333,0.0005244061,0.0001517713,0.00028489335,0.00013682053,0.00017406583,0.00034477003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026284761,0.0001507625,0.76070476,0.00023306237,0.000060590035,0.0017693221,0.00017751208,0.0006052582,0.1862152,0.00016035244,0.0018134331,0.04548138],"study_design_scores_gemma":[0.000063797874,0.00087265455,0.9190988,0.000045904624,0.000103669874,0.0057696467,0.0004436558,0.0019083563,0.06256181,0.000091147485,0.009028848,0.000011758045],"about_ca_topic_score_codex":0.0020811388,"about_ca_topic_score_gemma":0.0036228488,"teacher_disagreement_score":0.0020811388,"about_ca_system_score_codex":0.00062534335,"about_ca_system_score_gemma":0.0005644183,"threshold_uncertainty_score":0.0046874285},"labels":[],"label_agreement":null},{"id":"W4296130477","doi":"10.1158/1557-3265.sarcomas22-a038","title":"Abstract A038: Enrollment of pediatric and adolescent patients with MAGE-A4+ advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4])","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Sarcoma; Cohort; Internal medicine; Soft tissue sarcoma; Oncology; Surgery; Pathology","score_opus":0.0989514237550265,"score_gpt":0.48197742497487267,"score_spread":0.3830260012198462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97467065,0.0011563216,0.00075175794,0.0009999995,0.0001871834,0.008946642,0.009346068,0.000088017194,0.0038533933],"genre_scores_gemma":[0.9701791,0.0009072522,0.0024825837,0.0019574158,0.00025747874,0.010707619,0.00991598,0.0000405526,0.0035520156],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99945754,0.0002292695,0.000039867366,0.00014109872,0.000050082912,0.00008208699],"domain_scores_gemma":[0.9992218,0.00008011013,0.00013933585,0.000047115605,0.000050778424,0.00046084635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011960834,0.00054709485,0.0007255424,0.00023005532,0.00053013826,0.0006993558,0.0005553497,0.0007606536,0.013739923],"category_scores_gemma":[0.0012829963,0.00034575537,0.0010261295,0.0003339263,0.00033428942,0.00056741305,0.0004481964,0.0016348391,0.0019653647],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57517195,0.03422591,0.19360991,0.0009904589,0.0019177232,0.0013734292,0.000946463,0.001132384,0.021925414,0.0009767682,0.038290855,0.12943879],"study_design_scores_gemma":[0.41838974,0.2702828,0.2540416,0.0003571137,0.001731812,0.0022149598,0.00073443574,0.0023030466,0.006550513,0.0012618506,0.042051308,0.000080793674],"about_ca_topic_score_codex":0.0016937,"about_ca_topic_score_gemma":0.0043630283,"teacher_disagreement_score":0.013739923,"about_ca_system_score_codex":0.00094193185,"about_ca_system_score_gemma":0.0026881606,"threshold_uncertainty_score":0.0459646},"labels":[],"label_agreement":null},{"id":"W4296131175","doi":"10.1158/1557-3265.sarcomas22-a007","title":"Abstract A007: Resident memory T cells express PD-1 in high grade liposarcoma","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD8; Liposarcoma; Population; Cancer research; Pembrolizumab; Immunotherapy; Immune system; Medicine; Immunology; Biology; Pathology; Sarcoma","score_opus":0.25340882664836867,"score_gpt":0.5239702194661223,"score_spread":0.27056139281775365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296131175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99898165,0.0001742994,0.00028738595,0.000017518554,0.0000032532034,0.000011310808,0.00006166013,0.000013947244,0.0004489376],"genre_scores_gemma":[0.9991885,0.00003463564,0.00023214702,0.000018728395,0.00001023602,0.000012114987,0.00017683633,0.000002986304,0.00032374196],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999416,0.000011656138,0.000008471953,0.000014806297,0.000011037789,0.000012388763],"domain_scores_gemma":[0.99983585,0.00005595411,0.000032392032,0.000019593863,0.000020334757,0.00003571622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018488748,0.0001666218,0.00013739498,0.0004414576,0.00012727329,0.00024032188,0.00009945461,0.0002347154,0.0034539537],"category_scores_gemma":[0.00031564388,0.000090435664,0.00009793583,0.00017298342,0.00017208717,0.00017951566,0.00017461707,0.00029611177,0.00058710435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039319056,0.0004052584,0.22834213,0.00022079014,0.000033019198,0.0045751925,0.00027964765,0.0003330222,0.7342319,0.00021513201,0.00082506676,0.02660698],"study_design_scores_gemma":[0.0005630072,0.005703717,0.7426865,0.000051095372,0.00013310117,0.04980117,0.0008288296,0.0036699295,0.18981886,0.0006674527,0.006052382,0.000023910608],"about_ca_topic_score_codex":0.000118931224,"about_ca_topic_score_gemma":0.00009527835,"teacher_disagreement_score":0.0034539537,"about_ca_system_score_codex":0.000118480835,"about_ca_system_score_gemma":0.00007724696,"threshold_uncertainty_score":0.011554599},"labels":[],"label_agreement":null},{"id":"W4296131450","doi":"10.1158/1557-3265.sarcomas22-a021","title":"Abstract A021: Chimeric antigen receptor armored natural killer cell immunotherapy for osteosarcoma","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; NK-92; Immunology; Antibody-dependent cell-mediated cytotoxicity; Cancer immunotherapy; Cancer research; Antigen; Biology; Immune system; Natural killer T cell; T cell; Antibody; Medicine; Monoclonal antibody","score_opus":0.17991780428112386,"score_gpt":0.5114094580274091,"score_spread":0.33149165374628525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296131450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8759744,0.05591014,0.021244824,0.0033075304,0.0017319837,0.0007426782,0.00089068187,0.0008455855,0.03935208],"genre_scores_gemma":[0.942437,0.014131505,0.006661365,0.0006178692,0.00022172046,0.00019678687,0.0014270211,0.000054456374,0.034252226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991286,0.000011984902,0.0000057280213,0.000012192436,0.000038229424,0.000018997342],"domain_scores_gemma":[0.9999745,0.0000028538088,0.00000491328,0.0000020782998,0.0000070629485,0.000008713371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025460435,0.00027015546,0.00019510089,0.00033706316,0.00011024336,0.0002753668,0.00023085972,0.0005097876,0.0035481974],"category_scores_gemma":[0.00007004021,0.00007198963,0.0003372454,0.00019426909,0.0001315028,0.00021136881,0.00020760123,0.00041661205,0.0009378234],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022211124,0.0014084838,0.0010785768,0.0008929282,0.000074237556,0.0009671905,0.000069913134,0.0014550062,0.7888167,0.0038881362,0.009327105,0.18980065],"study_design_scores_gemma":[0.0034790167,0.025042411,0.011311428,0.00022887003,0.00036410213,0.009208508,0.00010950234,0.0109888315,0.6769788,0.0030110849,0.25921416,0.00006323527],"about_ca_topic_score_codex":0.00051268114,"about_ca_topic_score_gemma":0.0005445558,"teacher_disagreement_score":0.0035481974,"about_ca_system_score_codex":0.00028078113,"about_ca_system_score_gemma":0.00047695212,"threshold_uncertainty_score":0.011869907},"labels":[],"label_agreement":null},{"id":"W4296301767","doi":"10.1158/2326-6066.cir-22-0434","title":"Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deutschen Konsortium für Translationale Krebsforschung; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft","keywords":"Bone marrow; Immune system; Antigen; Multiple myeloma; Immunology; Phenotype; Immunotherapy; Medicine; Cancer research; Biology; Gene; Genetics","score_opus":0.05314186102276201,"score_gpt":0.3621803626410768,"score_spread":0.30903850161831475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296301767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991942,0.00029362258,0.00012468205,0.000007034617,0.0000014914734,0.000008363332,0.000023600362,0.000005941042,0.00034103185],"genre_scores_gemma":[0.99951994,0.00010097502,0.00012564794,0.000020769223,0.0000032801597,0.000008005271,0.00007697453,0.000002354302,0.0001418703],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99989045,0.000019792285,0.000011431226,0.000030436182,0.000025061967,0.00002284919],"domain_scores_gemma":[0.99989545,0.000029798124,0.000023333945,0.000010246653,0.000016157586,0.000024860181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011381168,0.00020206065,0.00025367778,0.00030243144,0.00016921831,0.0002545973,0.00012744598,0.0003014225,0.0009255004],"category_scores_gemma":[0.00029663366,0.00011898568,0.00013460561,0.00015114178,0.00013874973,0.00013101756,0.00012075472,0.00024383445,0.00015476691],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011834394,0.00021525976,0.099522986,0.00008908508,0.00004149642,0.002738773,0.0004736539,0.00034200907,0.8796766,0.000109115805,0.00013784997,0.015469775],"study_design_scores_gemma":[0.00020531226,0.004447727,0.78543377,0.00003066231,0.00026071738,0.025588416,0.0003665912,0.002137747,0.178023,0.0002101731,0.0032717648,0.000024069532],"about_ca_topic_score_codex":0.0005902596,"about_ca_topic_score_gemma":0.0006381068,"teacher_disagreement_score":0.0009255004,"about_ca_system_score_codex":0.00021945628,"about_ca_system_score_gemma":0.000087629596,"threshold_uncertainty_score":0.0030961633},"labels":[],"label_agreement":null},{"id":"W4297141578","doi":"10.1136/jitc-2022-004725","title":"TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; University of Minnesota","keywords":"Stromal cell; Tumor microenvironment; Cancer research; Lymphokine-activated killer cell; Biology; Interleukin 21; Degranulation; Cytokine; T cell; Immunology; Immune system; Tumor cells; Receptor","score_opus":0.03057813303820549,"score_gpt":0.3280423464682694,"score_spread":0.2974642134300639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297141578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002075,0.0008686694,0.0058410103,0.00008271466,0.000019163599,0.00006591155,0.00021911362,0.000108998895,0.0027738342],"genre_scores_gemma":[0.9921151,0.00030971866,0.004506799,0.000061650826,0.0000086034515,0.000053419513,0.00054556533,0.000014492588,0.0023846903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979097,0.000030099714,0.000018464698,0.000050504546,0.000053802123,0.000056219516],"domain_scores_gemma":[0.99991095,0.000012371773,0.000032734995,0.000013964573,0.000008714438,0.000021183872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013928647,0.00040130157,0.00024493193,0.00012851796,0.00008446705,0.00025355423,0.00023177943,0.00033753715,0.0030792376],"category_scores_gemma":[0.000104324194,0.00011466737,0.00026135173,0.00010220079,0.0001416093,0.00018532856,0.00027831527,0.0005764164,0.001070591],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009463586,0.000029323644,0.00025786468,0.000028907236,0.0000054999746,0.00003626032,0.000008992691,0.000090086265,0.9980453,0.00008936382,0.00006185772,0.0012519491],"study_design_scores_gemma":[0.000036411064,0.00046884498,0.0015746519,0.000007637504,0.000016581125,0.0007249563,0.000017410708,0.0015981552,0.9916244,0.000035674067,0.003891212,0.000004017771],"about_ca_topic_score_codex":0.000091796726,"about_ca_topic_score_gemma":0.00015339688,"teacher_disagreement_score":0.0030792376,"about_ca_system_score_codex":0.0002481234,"about_ca_system_score_gemma":0.0001273669,"threshold_uncertainty_score":0.0103010535},"labels":[],"label_agreement":null},{"id":"W4297312817","doi":"10.1016/j.jcyt.2022.07.014","title":"Particulates are everywhere, but are they harmful in cell and gene therapies?","year":2022,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Particulates; Gene; Biology; Genetics; Ecology","score_opus":0.03025804853908798,"score_gpt":0.2890486513950343,"score_spread":0.2587906028559463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297312817","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014999521,0.5270014,0.016588928,0.38601214,0.023831706,0.000060297003,0.0004201923,0.00032728136,0.030758614],"genre_scores_gemma":[0.19556332,0.568173,0.009530432,0.14409019,0.021009015,0.00017281433,0.0005340018,0.0004899295,0.060437415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973508,0.00065626943,0.00015254407,0.00033296325,0.0012493181,0.00025802385],"domain_scores_gemma":[0.99538285,0.0018447107,0.00072666234,0.00046413564,0.0011913733,0.0003903318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033073905,0.0006427633,0.0015503125,0.000829949,0.0018038496,0.0045897593,0.0008534628,0.0047840206,0.010952467],"category_scores_gemma":[0.0073892213,0.00042245025,0.0008189705,0.0007090989,0.007388623,0.00876147,0.0017851332,0.0058826804,0.006095825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007437423,0.0003602579,0.0074478574,0.0056291614,0.00039823403,0.002488385,0.0019885155,0.0005529871,0.035445612,0.16351128,0.23197281,0.5494611],"study_design_scores_gemma":[0.00003496365,0.00031247758,0.0014459541,0.0016026759,0.000119057324,0.0028554497,0.0027006108,0.00011132151,0.012481302,0.06401047,0.91426617,0.000059564467],"about_ca_topic_score_codex":0.0014910159,"about_ca_topic_score_gemma":0.0014927108,"teacher_disagreement_score":0.010952467,"about_ca_system_score_codex":0.0012281125,"about_ca_system_score_gemma":0.0018299365,"threshold_uncertainty_score":0.03663969},"labels":[],"label_agreement":null},{"id":"W4297322118","doi":"10.1136/jitc-2021-004450","title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Hyundai Hope On Wheels; National Cancer Institute; American Association for Cancer Research; Children's Hospital of Philadelphia; Alex's Lemonade Stand Foundation for Childhood Cancer; Damon Runyon Cancer Research Foundation; Kortney Rose Foundation","keywords":"Chimeric antigen receptor; Medulloblastoma; Neuroblastoma; Cancer research; Glioma; Pediatric cancer; Medicine; Flow cytometry; Brain tumor; Cancer; Immunotherapy; Cell culture; Biology; Immunology; Pathology; Internal medicine","score_opus":0.046226171553148024,"score_gpt":0.37651339021005625,"score_spread":0.33028721865690824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297322118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96832174,0.001703657,0.02590356,0.00017987133,0.00005159975,0.00047854093,0.0008339119,0.00026310913,0.0022639632],"genre_scores_gemma":[0.96985877,0.002085279,0.024470538,0.00012886507,0.00002175494,0.0003053599,0.0015205091,0.00007763731,0.001531385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975675,0.00003551413,0.000018662555,0.000053455984,0.00007535044,0.000060212904],"domain_scores_gemma":[0.99983966,0.000030184088,0.000044034176,0.00001913906,0.000044998524,0.000022008555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002865668,0.00043317763,0.00027945542,0.0002764532,0.0001199301,0.00040738413,0.00031402573,0.00038254526,0.0012827703],"category_scores_gemma":[0.00029786528,0.00015633272,0.00030389914,0.00022446281,0.0002752337,0.00023733005,0.00022113495,0.0007144677,0.0004967502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065025146,0.00004329696,0.00042786193,0.00006299881,0.000011969156,0.00007619172,0.000036888137,0.0007926101,0.9941958,0.00021687166,0.00014885554,0.0039215726],"study_design_scores_gemma":[0.000037611317,0.0009947566,0.0011862526,0.0000103999655,0.000053047133,0.0004026911,0.000037832593,0.002376885,0.9877166,0.000039652074,0.0071348865,0.0000093842755],"about_ca_topic_score_codex":0.0008857323,"about_ca_topic_score_gemma":0.0009761021,"teacher_disagreement_score":0.0012827703,"about_ca_system_score_codex":0.0005489008,"about_ca_system_score_gemma":0.0004819728,"threshold_uncertainty_score":0.0042913556},"labels":[],"label_agreement":null},{"id":"W4297387081","doi":"10.1136/jitc-2022-005187","title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Mark Hughes Foundation; Medical Research Council; Flinders Foundation; Tour de Cure; Australian Cancer Research Foundation; Fay Fuller Foundation; Cancer Australia; Cancer Council South Australia; Neurosurgical Research Foundation; National Health and Medical Research Council; Hospital Research Foundation","keywords":"Chimeric antigen receptor; Medicine; Glioma; Flow cytometry; Cancer research; Brain tumor; Antigen; Immune system; Immunotherapy; Tumor antigen; Pathology; Oncology; Immunology","score_opus":0.02121667910910916,"score_gpt":0.3714376681463423,"score_spread":0.35022098903723314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297387081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979837,0.0049810405,0.011356483,0.00028383115,0.000049381008,0.00016486131,0.000636415,0.00039408382,0.0022969043],"genre_scores_gemma":[0.986278,0.0022037758,0.008277621,0.00016757674,0.000014187203,0.00008337925,0.0011039848,0.000038787603,0.001832643],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999107,0.000009883474,0.000008228597,0.000017680466,0.00003309673,0.000020399448],"domain_scores_gemma":[0.999966,0.0000039783386,0.000010248451,0.0000050186172,0.0000066019716,0.000008116754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015434514,0.00028197005,0.00019340302,0.00031563907,0.00008488945,0.0002685115,0.00016455927,0.00019774289,0.0008463617],"category_scores_gemma":[0.00009214885,0.00008709044,0.0002123815,0.00020731361,0.00021576048,0.00012294287,0.00014129248,0.00030958463,0.00023428052],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017699259,0.00005275425,0.0008241292,0.00006267585,0.000012796832,0.00007016069,0.000019142182,0.00023191891,0.98852575,0.00012805642,0.00026086438,0.009634698],"study_design_scores_gemma":[0.000058650436,0.00088842225,0.0057591535,0.000012666277,0.00006598373,0.00044322768,0.00002072622,0.0009190247,0.9840178,0.00012008332,0.007688397,0.0000058180167],"about_ca_topic_score_codex":0.0005362291,"about_ca_topic_score_gemma":0.0011035663,"teacher_disagreement_score":0.0008463617,"about_ca_system_score_codex":0.00025895424,"about_ca_system_score_gemma":0.000355413,"threshold_uncertainty_score":0.0028313398},"labels":[],"label_agreement":null},{"id":"W4298109903","doi":"10.3389/fimmu.2022.995191","title":"Pathogenic variant c.1052T&gt;A (p.Leu351Gln) in adenosine deaminase 2 impairs secretion and elevates type I IFN responsive gene expression","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Janeway Children's Health and Rehabilitation Centre; BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Centre for Blood Research, University of British Columbia","keywords":"Biology; Secretion; Glycosylation; Extracellular; Gene; AMP deaminase; Gene expression; Molecular biology; Adenosine; Adenosine deaminase; Cell biology; Genetics; Biochemistry","score_opus":0.010984163337729343,"score_gpt":0.25871640892333697,"score_spread":0.24773224558560764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298109903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885768,0.00094404124,0.0046640467,0.00030675725,0.00018828805,0.00006710077,0.0029468026,0.00026025288,0.002045975],"genre_scores_gemma":[0.9938824,0.00027707833,0.002009631,0.00016835424,0.000030644525,0.00006070175,0.0013448888,0.000053646,0.0021725595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99958366,0.00005202216,0.00005867641,0.00017909832,0.000078701305,0.00004791976],"domain_scores_gemma":[0.9998895,0.00002401206,0.00003452702,0.000012068254,0.0000062763643,0.00003351737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018825565,0.00082628755,0.0004346005,0.00031485915,0.00027184628,0.00030472165,0.00032832468,0.001013487,0.0037541224],"category_scores_gemma":[0.00017675862,0.0001356524,0.00055890274,0.0002784926,0.000499012,0.00013202285,0.00023862335,0.00069297676,0.00095557445],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038375033,0.000081401755,0.00086916075,0.00005530805,0.000022287666,0.002439761,0.000039156643,0.00011560468,0.994341,0.000115848256,0.000223687,0.0013130934],"study_design_scores_gemma":[0.00026482984,0.0012360922,0.03330846,0.000043748234,0.0001641594,0.023906397,0.00014759904,0.0031403003,0.92597455,0.0003751756,0.011393336,0.0000453411],"about_ca_topic_score_codex":0.00090065825,"about_ca_topic_score_gemma":0.0009514259,"teacher_disagreement_score":0.0037541224,"about_ca_system_score_codex":0.00037318125,"about_ca_system_score_gemma":0.00016600269,"threshold_uncertainty_score":0.012558758},"labels":[],"label_agreement":null},{"id":"W4299407510","doi":"","title":"CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via na&iuml;ve T-cell anergy","year":2017,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytotoxic T cell; CD8; T cell; Cell mediated immunity; Cell; Immunology; Immunity; Biology; Immune system; Genetics","score_opus":0.20175693623943394,"score_gpt":0.510866178176193,"score_spread":0.30910924193675904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299407510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723864,0.00039300518,0.0012460768,0.00008437696,0.000027593347,0.000027192558,0.00006892809,0.00014509622,0.00076903985],"genre_scores_gemma":[0.99749786,0.00018357552,0.0006604731,0.000053899093,0.000016607562,0.00003962534,0.00009715096,0.000023181534,0.0014277046],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99972945,0.000054785865,0.0000332326,0.0000529899,0.0000515194,0.00007798622],"domain_scores_gemma":[0.9997429,0.000059574235,0.0000746148,0.000040516057,0.000013099133,0.000069320784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002217591,0.0005441907,0.00039102283,0.00027204046,0.00016146526,0.0003277708,0.00030122776,0.00043211793,0.0014825255],"category_scores_gemma":[0.0002219372,0.00021879796,0.00020753988,0.0000960786,0.00034015052,0.00033354323,0.0002766267,0.0011522933,0.00036087586],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048163848,0.00016755654,0.00040758628,0.000043568856,0.000006406697,0.00022818308,0.00003416838,0.0001356129,0.99602294,0.00023534152,0.000096886375,0.002140155],"study_design_scores_gemma":[0.00021807001,0.0026281332,0.009801199,0.000028713997,0.00006865275,0.0025347944,0.000115315306,0.004607844,0.97611266,0.00034587944,0.0035187316,0.00001997027],"about_ca_topic_score_codex":0.00017657805,"about_ca_topic_score_gemma":0.00030813264,"teacher_disagreement_score":0.0014825255,"about_ca_system_score_codex":0.00021586295,"about_ca_system_score_gemma":0.00020136443,"threshold_uncertainty_score":0.0049595237},"labels":[],"label_agreement":null},{"id":"W4300606952","doi":"","title":"Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia","year":2011,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Identification (biology); Leukemia; Pharmacology; Oncology; Computational biology; Internal medicine; Biology","score_opus":0.39942835403016363,"score_gpt":0.5738789530236104,"score_spread":0.17445059899344673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300606952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94154507,0.020467363,0.010864715,0.00090471184,0.00020290138,0.0020331037,0.011877298,0.0002763438,0.011828465],"genre_scores_gemma":[0.9107742,0.01651632,0.0340241,0.001021901,0.00008794014,0.0012426226,0.029998574,0.0001252029,0.006209133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829334,0.0006359656,0.00016553648,0.00016144695,0.00060255785,0.00014120761],"domain_scores_gemma":[0.9989662,0.0003307438,0.00015053456,0.00015241101,0.00034418132,0.000055917335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014370175,0.0007733971,0.00077238766,0.0014231395,0.00054635014,0.0013204167,0.00059553847,0.00042892725,0.003050802],"category_scores_gemma":[0.0016158259,0.0003050911,0.0005660944,0.0014803128,0.00044358004,0.00052864687,0.00064994843,0.0008122203,0.0009094086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014441917,0.0019341148,0.007854754,0.0006394243,0.00017000629,0.0001615092,0.00010893817,0.004101423,0.93090063,0.0004285837,0.0026122567,0.049644105],"study_design_scores_gemma":[0.00022046134,0.010028246,0.011866645,0.00010182472,0.00037314228,0.00070682185,0.00023639466,0.006063818,0.94580024,0.00024051336,0.024317505,0.00004435734],"about_ca_topic_score_codex":0.0010399236,"about_ca_topic_score_gemma":0.0039885524,"teacher_disagreement_score":0.003050802,"about_ca_system_score_codex":0.0008480165,"about_ca_system_score_gemma":0.0013913222,"threshold_uncertainty_score":0.010205984},"labels":[],"label_agreement":null},{"id":"W4300816588","doi":"10.1016/j.omtm.2022.09.016","title":"Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Cytotoxic T cell; Immunotherapy; T-cell receptor; T cell; Antigen; Blockade; CD8; Adoptive cell transfer; Biology; Cancer immunotherapy; Immunology; Streptamer; Ex vivo; Cancer research; Immune system; Receptor; In vivo; In vitro","score_opus":0.12668086104690285,"score_gpt":0.45474196063212075,"score_spread":0.3280610995852179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300816588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706476,0.002118693,0.020805,0.00028138945,0.00011345734,0.00022864959,0.0006025254,0.0006263908,0.0045762355],"genre_scores_gemma":[0.9855546,0.00070553017,0.010145833,0.00012388316,0.000041741427,0.0001539114,0.00048370296,0.00005693234,0.002733893],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974436,0.00004986796,0.000020867508,0.000039337898,0.000072354705,0.00007323679],"domain_scores_gemma":[0.99991846,0.00001754522,0.000014327955,0.000013490762,0.000009390832,0.000026734417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035937005,0.0005033819,0.00043678237,0.0003595719,0.00015861262,0.0006002803,0.00031301874,0.00044110615,0.002644934],"category_scores_gemma":[0.00018865278,0.00015721019,0.0002774833,0.00018779135,0.0001455998,0.00036751162,0.00031807992,0.0012969447,0.000776912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003291859,0.00034915566,0.00024616029,0.000040702038,0.00001099852,0.000023048733,0.000019767265,0.000369457,0.9873498,0.00014306651,0.000373545,0.010745115],"study_design_scores_gemma":[0.00010449295,0.0012497966,0.001617782,0.000007282567,0.00004610188,0.00015213236,0.000015669766,0.0020097625,0.9910165,0.000101709644,0.003670681,0.000008147732],"about_ca_topic_score_codex":0.00027089674,"about_ca_topic_score_gemma":0.00062597607,"teacher_disagreement_score":0.002644934,"about_ca_system_score_codex":0.00021558364,"about_ca_system_score_gemma":0.0002573988,"threshold_uncertainty_score":0.008848131},"labels":[],"label_agreement":null},{"id":"W4301397008","doi":"10.51731/cjht.2022.461","title":"Lisocabtagene Maraleucel (Breyanzi)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Lymphoma; Follicular lymphoma; Medicine; Drug; Chimeric antigen receptor; Diffuse large B-cell lymphoma; Oncology; Internal medicine; Cancer research; Cancer; Immunotherapy; Pharmacology; Political science","score_opus":0.05164566627031014,"score_gpt":0.3287784616090058,"score_spread":0.27713279533869567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301397008","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022146089,0.5468979,0.003987518,0.011406234,0.0023999882,0.00061769877,0.004692677,0.0019989233,0.40585294],"genre_scores_gemma":[0.18136524,0.2102684,0.006808868,0.0092667,0.00093938544,0.00043206103,0.0063844156,0.00028066407,0.58425426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997311,0.00004880731,0.0000133287795,0.000050093706,0.000117444986,0.000039231207],"domain_scores_gemma":[0.9997272,0.00005174115,0.00005084589,0.000012459965,0.000088574365,0.000069192356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005045843,0.0004557197,0.00048087924,0.0011219756,0.00043123093,0.000976918,0.00057472923,0.0010149876,0.06617518],"category_scores_gemma":[0.0006866801,0.00013317978,0.00043478986,0.0006340704,0.00050245,0.00045039458,0.0005165455,0.0012481272,0.018895486],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014944801,0.00021507965,0.0006552803,0.002963968,0.00006588926,0.0005785087,0.00009560882,0.00021705781,0.01677796,0.0053071682,0.13066663,0.84096235],"study_design_scores_gemma":[0.00034842268,0.00068806316,0.001602395,0.0004921191,0.000048400663,0.001015506,0.000036311114,0.00010946169,0.0049175886,0.00027288945,0.9904558,0.000012990352],"about_ca_topic_score_codex":0.016639858,"about_ca_topic_score_gemma":0.047255155,"teacher_disagreement_score":0.06617518,"about_ca_system_score_codex":0.0018038814,"about_ca_system_score_gemma":0.0022579944,"threshold_uncertainty_score":0.22137803},"labels":[],"label_agreement":null},{"id":"W4303446442","doi":"10.1101/2022.10.03.509766","title":"Enhanced STAT5a activation rewires exhausted CD8 T cells during chronic stimulation to acquire a hybrid durable effector like state","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health; Parker Institute for Cancer Immunotherapy; University of Pennsylvania","keywords":"Effector; CD8; Cytotoxic T cell; Biology; Ex vivo; T cell; Cell biology; Epigenetics; Cancer research; Immune system; Immunology; Genetics","score_opus":0.01501151024700386,"score_gpt":0.2642740642277319,"score_spread":0.24926255398072805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303446442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632347,0.0005802384,0.0015700224,0.000053398453,0.000033532386,0.000020206277,0.00022672547,0.000082142564,0.0011102384],"genre_scores_gemma":[0.99816185,0.000111358284,0.0004864953,0.000043715794,0.0000059528847,0.00001693285,0.00013851919,0.000007323982,0.0010278932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998847,0.000014201571,0.00001059029,0.00002648152,0.000020064608,0.000043976943],"domain_scores_gemma":[0.99994695,0.000007873558,0.00001228841,0.0000059278645,0.0000047511467,0.000022255257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009481449,0.00022516352,0.00014729421,0.00008834428,0.00007865353,0.00024569698,0.0001150846,0.00015047353,0.0017156049],"category_scores_gemma":[0.00006401182,0.00006692291,0.00015368618,0.000062956824,0.00014980555,0.00013614184,0.00016543164,0.00060459843,0.0003033584],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029752206,0.000046735797,0.0003575191,0.00003723527,0.000004246471,0.000027726666,0.000012579861,0.00013111254,0.99708754,0.00010154643,0.000064525295,0.0018316268],"study_design_scores_gemma":[0.000038556358,0.0010763684,0.0035688526,0.000008913843,0.000019738729,0.00010536617,0.00004323662,0.001696899,0.99082774,0.00008901105,0.002520733,0.000004688716],"about_ca_topic_score_codex":0.00014885623,"about_ca_topic_score_gemma":0.00037449936,"teacher_disagreement_score":0.0017156049,"about_ca_system_score_codex":0.00015585613,"about_ca_system_score_gemma":0.00013301276,"threshold_uncertainty_score":0.0057392716},"labels":[],"label_agreement":null},{"id":"W4303473194","doi":"10.1016/s2352-3026(22)00284-8","title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Multiple myeloma; Quality of life (healthcare); Refractory (planetary science); Clinical trial; Cancer; Chimeric antigen receptor; Oncology; Immunotherapy","score_opus":0.19861245780340173,"score_gpt":0.447965213090437,"score_spread":0.2493527552870353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303473194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997773,0.0009363822,0.00010101236,0.00013965827,0.00005680249,0.00029151255,0.00033771445,0.000016429758,0.0003472969],"genre_scores_gemma":[0.99556476,0.00070415396,0.00036665154,0.00056029065,0.00018539453,0.0007020448,0.0010432706,0.0000072387465,0.0008661121],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955124,0.00020613598,0.000019632458,0.000077255085,0.000044213582,0.0001014887],"domain_scores_gemma":[0.99932194,0.00014057299,0.00016990835,0.00006071936,0.000037521128,0.0002694039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013555075,0.0012430298,0.001925508,0.0003106348,0.00038351273,0.00085130235,0.0006341904,0.0013277467,0.002656318],"category_scores_gemma":[0.0006639669,0.00043027438,0.0019199774,0.0004008546,0.00093864306,0.0008419721,0.00038272602,0.0028097255,0.0005135752],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.89837366,0.034948237,0.012045609,0.0005827651,0.0017821756,0.00010433885,0.0001401269,0.0007261273,0.0107960375,0.00008048238,0.0011791195,0.0392413],"study_design_scores_gemma":[0.5009291,0.44538197,0.049080882,0.000040847804,0.0011074417,0.000113115966,0.00006731358,0.00079827075,0.0012238366,0.0001119997,0.0011004076,0.00004496298],"about_ca_topic_score_codex":0.0007332192,"about_ca_topic_score_gemma":0.0013158728,"teacher_disagreement_score":0.002656318,"about_ca_system_score_codex":0.00069828564,"about_ca_system_score_gemma":0.00063319,"threshold_uncertainty_score":0.008886218},"labels":[],"label_agreement":null},{"id":"W4304165954","doi":"10.1038/s41467-022-33720-z","title":"Evolution and modulation of antigen-specific T cell responses in melanoma patients","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Cancer Institute; Syöpäsäätiö; K. Albin Johanssons Stiftelse; Emil Aaltosen Säätiö; Signe ja Ane Gyllenbergin Säätiö; Suomen Lääketieteen Säätiö; KAUTE-Säätiö; Blood Disease Research Foundation; Biomedicum Helsinki-säätiö; Howard Hughes Medical Institute","keywords":"Repertoire; Melanoma; T-cell receptor; Antigen; Immunology; Biology; Phenotype; TIGIT; T cell; Cancer research; Medicine; Genetics; Gene; Immune system; CD8","score_opus":0.03372958040194517,"score_gpt":0.3277208938570633,"score_spread":0.29399131345511814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304165954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996333,0.00007177442,0.000047315563,0.000009644724,0.0000011215674,0.0000014472225,0.000057905163,0.000002282479,0.00017522922],"genre_scores_gemma":[0.99977595,0.00002210808,0.0000313899,0.000008049148,0.0000019186018,0.0000013514779,0.00008934479,0.000001186128,0.00006880735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99978477,0.00004733542,0.00001585098,0.000080864316,0.000027554739,0.00004370719],"domain_scores_gemma":[0.9997273,0.000063558335,0.00010609643,0.00002577172,0.000024711022,0.000052657706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020099075,0.00012651739,0.0001803553,0.0007045537,0.0002022505,0.00034250904,0.00013542378,0.0003513384,0.0009541679],"category_scores_gemma":[0.00070000935,0.00009797955,0.00014996904,0.0004177622,0.00014364766,0.0002387663,0.00017920064,0.00023722462,0.00023445438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041209138,0.00003330631,0.9816243,0.000009121206,0.000039910406,0.00040607993,0.00016259369,0.00019465112,0.010487812,0.0000466357,0.000105769446,0.006477688],"study_design_scores_gemma":[0.0000036909312,0.00012438581,0.9968953,0.0000025790698,0.00001392745,0.0012178204,0.0001463912,0.0004065352,0.00089357997,0.00006168965,0.00023101202,0.000003129401],"about_ca_topic_score_codex":0.00054250576,"about_ca_topic_score_gemma":0.0004824534,"teacher_disagreement_score":0.0009541679,"about_ca_system_score_codex":0.00016431215,"about_ca_system_score_gemma":0.0000613281,"threshold_uncertainty_score":0.0031920671},"labels":[],"label_agreement":null},{"id":"W4304588337","doi":"10.1101/2022.10.10.511511","title":"Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of California, San Francisco; Canadian Institutes of Health Research; Bristol-Myers Squibb; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Myeloid leukemia; Chimeric antigen receptor; Immunotherapy; Cancer research; Haematopoiesis; Antigen; Glycoprotein; Cancer; Malignancy; Computational biology; Chemistry; Biology; Cell biology; Immunology; Molecular biology; Stem cell; Genetics","score_opus":0.0336624225361303,"score_gpt":0.2859849146145093,"score_spread":0.25232249207837903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304588337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820165,0.00045089508,0.013731965,0.0003989965,0.000022554968,0.0000140399225,0.00033944278,0.00013379425,0.0028916968],"genre_scores_gemma":[0.99350774,0.00024495364,0.0037105375,0.00012567463,0.00000848861,0.000008117472,0.00033603294,0.000024666902,0.0020338302],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993443,0.000008300516,0.0000023452437,0.000017673672,0.000021734635,0.000015532656],"domain_scores_gemma":[0.9999689,0.000006398221,0.000009132817,0.000003561921,0.000005565194,0.0000063698863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013790371,0.00019499284,0.00010550209,0.00012164821,0.0000951575,0.00036560482,0.00012443306,0.0002737154,0.0014379908],"category_scores_gemma":[0.00010594385,0.00007913699,0.00012440638,0.0001059082,0.00017843439,0.00018364935,0.0001697487,0.00042321713,0.0003275262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043439235,0.000010074888,0.0005598095,0.000009237746,0.000003586339,0.00003537248,0.000011011172,0.00026952996,0.99736387,0.000360006,0.00012339404,0.0012107036],"study_design_scores_gemma":[0.000014457146,0.000100560275,0.0040690885,0.0000023834518,0.000008373652,0.00027346355,0.000035850673,0.008646323,0.98363656,0.00038676176,0.002821874,0.0000043773634],"about_ca_topic_score_codex":0.0005057539,"about_ca_topic_score_gemma":0.000585945,"teacher_disagreement_score":0.0014379908,"about_ca_system_score_codex":0.00027017272,"about_ca_system_score_gemma":0.00012826355,"threshold_uncertainty_score":0.0048105717},"labels":[],"label_agreement":null},{"id":"W4306179806","doi":"10.1038/s41467-022-33597-y","title":"Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Johns Hopkins Bloomberg School of Public Health; Department of Pathology, Johns Hopkins University; Newfoundland and Labrador; National Institute of Biomedical Imaging and Bioengineering; Sidney Kimmel Comprehensive Cancer Center; Emerson Collective; Maryland Stem Cell Research Fund; Johns Hopkins University; U.S. Department of Health and Human Services; National Institutes of Health; National Science Foundation; U.S. Department of Defense","keywords":"Cytotoxic T cell; Biology; Cell biology; Antigen-presenting cell; CD8; Major histocompatibility complex; T cell; Streptamer; Immunotherapy; Antigen; Immunology; Effector; MHC class II; Cancer research; Immune system; In vitro; Biochemistry","score_opus":0.02181179341991284,"score_gpt":0.31997203293867593,"score_spread":0.2981602395187631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306179806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9846066,0.0011586831,0.009536296,0.00010779201,0.000082156395,0.000053935004,0.00007499304,0.0002311634,0.0041483636],"genre_scores_gemma":[0.99353194,0.00033722282,0.0038215818,0.00003948244,0.000016659666,0.000027845941,0.000046931742,0.00001811419,0.002160024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989843,0.000019717763,0.0000074648724,0.000019067818,0.000026702082,0.00002861035],"domain_scores_gemma":[0.9999527,0.0000131956285,0.0000093556555,0.000005676305,0.000007647298,0.000011583329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010507017,0.00031685442,0.0001451843,0.00017871194,0.000088026405,0.0002834128,0.00013954383,0.00030476027,0.0009786615],"category_scores_gemma":[0.00010313152,0.00010343082,0.00014107909,0.00007248692,0.00015215875,0.00019493,0.00016990189,0.0003352702,0.00023966971],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063708234,0.000044109423,0.000043374865,0.000027928745,0.00000237359,0.000018085198,0.0000068508357,0.0001682622,0.99720407,0.0001357495,0.000055891778,0.0022296254],"study_design_scores_gemma":[0.000011866854,0.0002628962,0.00020198805,0.0000020774203,0.000007664887,0.00003086844,0.0000046794767,0.001293052,0.9967393,0.000034256147,0.0014096695,0.0000016002647],"about_ca_topic_score_codex":0.00023162922,"about_ca_topic_score_gemma":0.00035427406,"teacher_disagreement_score":0.0009786615,"about_ca_system_score_codex":0.00019953346,"about_ca_system_score_gemma":0.0001421346,"threshold_uncertainty_score":0.0032739043},"labels":[],"label_agreement":null},{"id":"W4306319940","doi":"10.1016/j.htct.2022.09.415","title":"A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3","year":2022,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Multiple myeloma; Cohort; Refractory (planetary science); Antibody; Oncology; Immunology; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.022036251958436188,"score_gpt":0.307113675771095,"score_spread":0.2850774238126588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306319940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905571,0.0011690767,0.0006437475,0.0005627273,0.000121309095,0.0031230906,0.0014891534,0.00011041801,0.0022233578],"genre_scores_gemma":[0.982819,0.0013424263,0.0022694615,0.0012952928,0.0002641061,0.0043994808,0.0038226596,0.00005332879,0.003734293],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996556,0.00018093911,0.0000123272785,0.00006537956,0.000027734925,0.000058040307],"domain_scores_gemma":[0.9995635,0.00006774228,0.00008252325,0.000040911586,0.00002533049,0.00021988832],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322023,0.0017517663,0.001405302,0.00040659442,0.00042936564,0.0008296699,0.00081452535,0.0011054913,0.004210011],"category_scores_gemma":[0.00090952683,0.0005283492,0.00092580996,0.00033236592,0.0007446968,0.00082871306,0.00039820283,0.0026527238,0.0009981674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84436405,0.05105413,0.0039933985,0.00044462044,0.00068306096,0.00028150642,0.00023926323,0.001722245,0.033482753,0.00031558238,0.004590668,0.05882876],"study_design_scores_gemma":[0.7627808,0.22411634,0.006586759,0.000019578658,0.00026395445,0.00024022006,0.00003259276,0.0012693221,0.002322755,0.00026915202,0.002077669,0.00002080402],"about_ca_topic_score_codex":0.00092188106,"about_ca_topic_score_gemma":0.0021564355,"teacher_disagreement_score":0.004210011,"about_ca_system_score_codex":0.0008460085,"about_ca_system_score_gemma":0.0014073015,"threshold_uncertainty_score":0.014083922},"labels":[],"label_agreement":null},{"id":"W4306721717","doi":"10.1158/2326-6066.cir-22-0095","title":"Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; American Association for Cancer Research; Children's Hospital of Philadelphia; Stand Up To Cancer; Entertainment Industry Foundation; Doris Duke Charitable Foundation","keywords":"CD19; Chimeric antigen receptor; Medicine; Context (archaeology); Immunotherapy; Immunology; Oncology; Cancer research; Antigen; Biology; Immune system","score_opus":0.07989112111024521,"score_gpt":0.3691113198757585,"score_spread":0.2892201987655133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306721717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99655163,0.00018967848,0.0024719976,0.000026739732,0.0000015750668,0.000017879182,0.00025253117,0.00003415315,0.00045375855],"genre_scores_gemma":[0.99773896,0.00011453114,0.0013977803,0.000039362014,0.0000016042944,0.000015334768,0.00044650584,0.000011326381,0.00023468932],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99987864,0.000019256928,0.000008849351,0.00003210999,0.000039105646,0.000022083042],"domain_scores_gemma":[0.99989057,0.00003742865,0.000027077294,0.000015090156,0.00001527447,0.000014608399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015642933,0.00012146912,0.00020939736,0.00024822133,0.00007191785,0.0002538733,0.00013783143,0.00021131501,0.00051218196],"category_scores_gemma":[0.0004272081,0.00008703779,0.00009828555,0.00016068427,0.00012624565,0.000090105714,0.00015020877,0.00021717345,0.00012592548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002823247,0.000051660358,0.021007435,0.000025901849,0.000029686229,0.00022241665,0.00008617416,0.001470848,0.96234685,0.0002008547,0.0000997673,0.014176109],"study_design_scores_gemma":[0.000059179816,0.0014289308,0.17619321,0.000010340282,0.00014115716,0.0051276493,0.00014724427,0.03365571,0.77837616,0.00054985634,0.0042963405,0.000014240807],"about_ca_topic_score_codex":0.0004398299,"about_ca_topic_score_gemma":0.0005580766,"teacher_disagreement_score":0.00051218196,"about_ca_system_score_codex":0.0001404824,"about_ca_system_score_gemma":0.00008864453,"threshold_uncertainty_score":0.0017133951},"labels":[],"label_agreement":null},{"id":"W4306867618","doi":"10.3324/haematol.2022.280678","title":"Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Gastroenterology; Internal medicine; Cytokine release syndrome; Adverse effect; Anemia; Incidence (geometry); Surgery; Chimeric antigen receptor; Immunotherapy","score_opus":0.03940613311196696,"score_gpt":0.3146591669903849,"score_spread":0.27525303387841793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306867618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99203813,0.0040573096,0.0011377899,0.00016462039,0.00002649,0.00030331704,0.000922916,0.0000746844,0.0012747741],"genre_scores_gemma":[0.9893444,0.0024202624,0.0014626937,0.00037602033,0.000050352624,0.0003617161,0.0042481953,0.000040396044,0.001695972],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995401,0.00018435126,0.000035551093,0.0000448709,0.00007273298,0.00012250566],"domain_scores_gemma":[0.99908745,0.00021749313,0.00025703415,0.00009230429,0.00009719717,0.0002485973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024767679,0.0006795465,0.0011573794,0.000342948,0.0004413377,0.00069203397,0.00036501122,0.0004852203,0.001005413],"category_scores_gemma":[0.00091293117,0.00016537201,0.00085785775,0.00024032805,0.00030177587,0.00041525005,0.0003353599,0.0013491574,0.0003139443],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13345951,0.042785697,0.10433478,0.0011970011,0.0026548866,0.0013963211,0.0011081673,0.015005554,0.20273565,0.0005133575,0.009308071,0.48550102],"study_design_scores_gemma":[0.034244016,0.5867185,0.2622934,0.00014381998,0.0028524783,0.00295885,0.00042720794,0.0058041024,0.0803152,0.0005183661,0.023641346,0.00008269922],"about_ca_topic_score_codex":0.0008964498,"about_ca_topic_score_gemma":0.0016936928,"teacher_disagreement_score":0.0024767679,"about_ca_system_score_codex":0.0005892012,"about_ca_system_score_gemma":0.0005515103,"threshold_uncertainty_score":0.013098538},"labels":[],"label_agreement":null},{"id":"W4307450117","doi":"10.1136/ijgc-2022-esgo.1019","title":"2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ovarian cancer; Medicine; Leukapheresis; Internal medicine; Oncology; CD8; Cancer; Population; Immunotherapy; Chemotherapy; Immunology; Antigen; Gastroenterology; Biology; Stem cell","score_opus":0.0713958216413929,"score_gpt":0.3759185532703714,"score_spread":0.30452273162897847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307450117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99031186,0.0021835,0.00033726371,0.0003407987,0.00010822022,0.00014515591,0.0007073525,0.000049912625,0.0058158105],"genre_scores_gemma":[0.99590504,0.0005339148,0.00018475848,0.00027244794,0.0000497293,0.00006788955,0.0011790036,0.000009083521,0.0017981798],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998969,0.00003658002,0.0000053407343,0.000012971322,0.000011319119,0.000036870824],"domain_scores_gemma":[0.99986494,0.00003406693,0.000011010093,0.000017625483,0.000010379031,0.000061994266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003491349,0.00031101648,0.00058035884,0.00016644142,0.00016313694,0.0003897911,0.00015769408,0.00050082686,0.002044918],"category_scores_gemma":[0.00032498347,0.00009478808,0.00043690833,0.00015731771,0.00029587024,0.00028555686,0.00015789796,0.000794065,0.0004388579],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3152545,0.023665901,0.03449986,0.0010971187,0.0010585855,0.00451932,0.0005219004,0.007444358,0.2076277,0.00093348866,0.008244513,0.3951327],"study_design_scores_gemma":[0.04859155,0.6198582,0.20793837,0.00011978368,0.0016296369,0.005773527,0.00042427634,0.00751154,0.07110933,0.0009651025,0.035993844,0.00008486615],"about_ca_topic_score_codex":0.0006631526,"about_ca_topic_score_gemma":0.0014334065,"teacher_disagreement_score":0.002044918,"about_ca_system_score_codex":0.00025778462,"about_ca_system_score_gemma":0.00028656324,"threshold_uncertainty_score":0.0068409443},"labels":[],"label_agreement":null},{"id":"W4307842003","doi":"10.1200/jco.22.00478","title":"Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Prednisone; Vincristine; Cyclophosphamide; Oncology; Internal medicine; Lymphoma; Chemotherapy","score_opus":0.05108753602228596,"score_gpt":0.4074900151700494,"score_spread":0.35640247914776346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307842003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795384,0.005855838,0.0073183174,0.0009925995,0.0001487885,0.0012805612,0.0014461451,0.00009407898,0.0033254216],"genre_scores_gemma":[0.9972082,0.0004970771,0.0012540583,0.00013073494,0.000014820308,0.00030225166,0.00031967246,0.0000057684556,0.00026751138],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.997479,0.0018870875,0.00007778871,0.00016907162,0.00012198961,0.00026509888],"domain_scores_gemma":[0.9938425,0.0045510293,0.0007918869,0.0001336647,0.00017156733,0.00050939614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048506386,0.0017149323,0.0021573675,0.0010906823,0.00027665173,0.0011208337,0.0013268933,0.001490016,0.0048848675],"category_scores_gemma":[0.010448764,0.0008195341,0.0057677478,0.0005847338,0.00067300606,0.0012828081,0.00083306874,0.0016311372,0.00017786332],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13155197,0.0028305151,0.009238171,0.0014762871,0.008089409,0.00021736199,0.00007483172,0.8088485,0.0010564267,0.0030674872,0.0009710342,0.03257802],"study_design_scores_gemma":[0.040867932,0.043207515,0.014320528,0.0007176075,0.0149384355,0.00032459348,0.00017511555,0.8769598,0.0014467883,0.00572477,0.0011819089,0.00013502491],"about_ca_topic_score_codex":0.0103056785,"about_ca_topic_score_gemma":0.006252439,"teacher_disagreement_score":0.0103056785,"about_ca_system_score_codex":0.006890982,"about_ca_system_score_gemma":0.003610681,"threshold_uncertainty_score":0.049997807},"labels":[],"label_agreement":null},{"id":"W4307945544","doi":"10.3390/ijms232113217","title":"What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?","year":2022,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Harm; Medicine; Intensive care medicine; Cancer; Cancer therapy; Psychology; Internal medicine","score_opus":0.15974574582348178,"score_gpt":0.4538704750003089,"score_spread":0.29412472917682714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307945544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01195607,0.64116853,0.030935002,0.2937868,0.008539351,0.00017577273,0.0003783534,0.0005396624,0.012520459],"genre_scores_gemma":[0.19140537,0.579072,0.032760963,0.1687839,0.015566618,0.0005182593,0.00049605354,0.0005262641,0.010870493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98384315,0.007886271,0.0014080252,0.0015426953,0.004611448,0.00070845947],"domain_scores_gemma":[0.93868655,0.03861872,0.008302817,0.0043713963,0.008722825,0.0012976888],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.04456173,0.0010068369,0.0024121327,0.0016600476,0.0016556563,0.005403862,0.0027798992,0.0055882554,0.0030978185],"category_scores_gemma":[0.04309764,0.00062952243,0.0012269054,0.0014920045,0.010534269,0.0068401387,0.0017899164,0.008606137,0.0030852873],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010720228,0.00034931707,0.018988455,0.01219169,0.0005387689,0.003153046,0.0021078694,0.0018111453,0.023687677,0.095499344,0.14549176,0.69510895],"study_design_scores_gemma":[0.00014055845,0.0015382384,0.008119979,0.005525881,0.00046917942,0.013717279,0.0031585998,0.0015979765,0.029192299,0.14756894,0.78862023,0.0003508826],"about_ca_topic_score_codex":0.0009270855,"about_ca_topic_score_gemma":0.0012885849,"teacher_disagreement_score":0.95543826,"about_ca_system_score_codex":0.00369186,"about_ca_system_score_gemma":0.0028451628,"threshold_uncertainty_score":0.23566777},"labels":[],"label_agreement":null},{"id":"W4307957799","doi":"10.1016/j.copbio.2022.102822","title":"Manufacturing next-generation regulatory T-cell therapies","year":2022,"lang":"en","type":"review","venue":"Current Opinion in Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"FOXP3; Induced pluripotent stem cell; Genome editing; Cell therapy; Genetic enhancement; Immunology; Transduction (biophysics); Computational biology; Biology; Cell; Regulatory T cell; T cell; Bioinformatics; Medicine; Gene; Immune system; Genetics; Genome; Embryonic stem cell; IL-2 receptor","score_opus":0.24502948170256564,"score_gpt":0.4107519284894123,"score_spread":0.16572244678684664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307957799","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024174336,0.99337405,0.0016342121,0.0007172366,0.0010823692,0.000021697973,0.000030609113,0.000023463563,0.0028745844],"genre_scores_gemma":[0.0021479374,0.99218434,0.0015481418,0.0009296122,0.00054080953,0.000031604806,0.00010766668,0.000007987632,0.0025019804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995969,0.000068666624,0.000025224352,0.0000653549,0.00019071552,0.00005320876],"domain_scores_gemma":[0.99969757,0.00015462586,0.00004570196,0.000012447077,0.00006434471,0.000025423245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012894849,0.0013194726,0.0015505014,0.001143583,0.00020385862,0.001650707,0.0015576496,0.0018034443,0.0055071614],"category_scores_gemma":[0.00093267864,0.0004122863,0.0007317809,0.0009942609,0.00068383466,0.0020826606,0.0010641823,0.0031400481,0.003513805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109237466,0.000094890784,0.00006410193,0.010063658,0.00006555602,0.00016865724,0.00003036399,0.0008606364,0.006814911,0.0133609725,0.030938055,0.937429],"study_design_scores_gemma":[0.000064434294,0.00014723271,0.00015896835,0.0019167034,0.00006960893,0.00042641492,0.000022336257,0.00032183313,0.002291855,0.0051798047,0.9893812,0.000019662148],"about_ca_topic_score_codex":0.0005915223,"about_ca_topic_score_gemma":0.0011405167,"teacher_disagreement_score":0.0055071614,"about_ca_system_score_codex":0.00074638386,"about_ca_system_score_gemma":0.0008180883,"threshold_uncertainty_score":0.018423319},"labels":[],"label_agreement":null},{"id":"W4308200450","doi":"10.1101/2022.11.02.514865","title":"Apoptotic contraction drives target cell release by cytotoxic T cells","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Ludwig Institute for Cancer Research; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute","keywords":"Cytotoxic T cell; CTL*; Cell biology; Contraction (grammar); Immunological synapse; Contractility; Apoptosis; Cytoskeleton; Stimulation; Cell; Biology; Immune system; Chemistry; T cell; Neuroscience; Immunology; T-cell receptor; Biochemistry","score_opus":0.012931866222210547,"score_gpt":0.24784975927627814,"score_spread":0.2349178930540676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308200450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960854,0.0005186836,0.0019845306,0.00009627734,0.000019566363,0.00000925345,0.000061434956,0.000027290962,0.001197481],"genre_scores_gemma":[0.99775237,0.00015193516,0.0006949933,0.00005686246,0.000011709593,0.000011138667,0.00007329239,0.000009852597,0.0012378953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998822,0.000012106092,0.0000052693267,0.000024792895,0.00003986472,0.000035757923],"domain_scores_gemma":[0.99992275,0.000018656363,0.000018700735,0.000009172056,0.000010333507,0.000020340482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000098962584,0.00014371054,0.00021446262,0.000100073354,0.00010963616,0.00031823735,0.00015225151,0.00021201854,0.0013478423],"category_scores_gemma":[0.000121782614,0.00010340518,0.00011584796,0.00008061378,0.00017037951,0.00015532946,0.00027215385,0.00052434014,0.0003466921],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005164746,0.000011706756,0.00016436321,0.000012889093,0.0000014913778,0.00003939942,0.000012806352,0.000059990718,0.99838436,0.000103025406,0.00004074689,0.0011175626],"study_design_scores_gemma":[0.000028500539,0.00020456944,0.007393493,0.000007858132,0.000005566424,0.00019621798,0.00006444464,0.0045276475,0.98579687,0.00015739276,0.0016132486,0.0000041831895],"about_ca_topic_score_codex":0.0001873828,"about_ca_topic_score_gemma":0.00023112049,"teacher_disagreement_score":0.0013478423,"about_ca_system_score_codex":0.0002506435,"about_ca_system_score_gemma":0.00009799254,"threshold_uncertainty_score":0.004508972},"labels":[],"label_agreement":null},{"id":"W4308294796","doi":"10.1016/j.jconrel.2022.10.043","title":"The past, present, and future of chemotherapy with a focus on individualization of drug dosing","year":2022,"lang":"en","type":"review","venue":"Journal of Controlled Release","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Department of Mechanical Engineering, University of Alberta; National Science Foundation","keywords":"Dosing; Medicine; Pharmacokinetics; Drug; Therapeutic drug monitoring; Pharmacology; Chemotherapy; Intensive care medicine; Distribution (mathematics); Therapeutic index; Oncology; Internal medicine","score_opus":0.021915109450048192,"score_gpt":0.3276433204012992,"score_spread":0.30572821095125097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308294796","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000083982995,0.99861646,0.00018789363,0.00044004535,0.0001959433,0.0000034747231,0.000008477226,0.000005305368,0.00045838364],"genre_scores_gemma":[0.0009528294,0.99773383,0.000279919,0.0003171335,0.0003263341,0.000006278848,0.000012653683,0.0000016560329,0.00036929632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99966896,0.000081330254,0.0000420149,0.000061108294,0.0001176565,0.000028966333],"domain_scores_gemma":[0.99928683,0.00040930914,0.00010948798,0.000021724285,0.00012767098,0.00004495769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013634585,0.0007829499,0.0013563068,0.001723174,0.00021999785,0.001282681,0.0011420633,0.0012706431,0.0027490386],"category_scores_gemma":[0.0014309331,0.00036538165,0.00057528575,0.0014500591,0.00095862825,0.0021131882,0.0006292045,0.0028169453,0.0010892063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015853763,0.000080343576,0.0001424331,0.0115293665,0.000077660225,0.0001118095,0.00005665149,0.00072898663,0.0022908873,0.009784222,0.024642369,0.9503968],"study_design_scores_gemma":[0.00005311068,0.00025958774,0.00086286606,0.003822928,0.00011064404,0.00092796434,0.00005768102,0.00045782328,0.0006623377,0.0037679079,0.988981,0.000036116486],"about_ca_topic_score_codex":0.0010639294,"about_ca_topic_score_gemma":0.0026472784,"teacher_disagreement_score":0.0027490386,"about_ca_system_score_codex":0.0008083659,"about_ca_system_score_gemma":0.0010833534,"threshold_uncertainty_score":0.009196401},"labels":[],"label_agreement":null},{"id":"W4308378248","doi":"10.1136/jitc-2022-sitc2022.0234","title":"234 Bead-bound antibody-activation of T cells provides sub-optimal metabolic programming and tumour control compared to dendritic cell-activated T cells","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CD28; T cell; Biology; Cell biology; Cytotoxic T cell; Antigen; Dendritic cell; Cancer research; CD8; Molecular biology; Immunology; Biochemistry; Immune system; In vitro","score_opus":0.018158421451222675,"score_gpt":0.27313632410871636,"score_spread":0.2549779026574937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308378248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537635,0.00055827055,0.0022097742,0.00006109359,0.000022871413,0.000017579623,0.0002760318,0.00005660783,0.0014213995],"genre_scores_gemma":[0.99650395,0.0002509799,0.0017618431,0.000056469915,0.000008473587,0.000020423651,0.00032292202,0.000022891776,0.0010520632],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998387,0.000022862305,0.000011991696,0.00003223155,0.000036001948,0.000058087982],"domain_scores_gemma":[0.99994075,0.000011986322,0.000018091283,0.0000048221127,0.000008188848,0.000016134574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008476149,0.00022038582,0.00019982609,0.00007598624,0.00008679413,0.0003738598,0.00014050007,0.00023828325,0.0015235584],"category_scores_gemma":[0.00007587813,0.00009618805,0.00018582791,0.00013215296,0.0001630895,0.00011802044,0.00011189535,0.00051222934,0.0004824458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028041276,0.000029441608,0.00013775159,0.00002499866,0.0000025267454,0.000011836029,0.0000059284625,0.000102425416,0.9983535,0.000037727314,0.00004344006,0.00097014866],"study_design_scores_gemma":[0.00001928007,0.0003403804,0.0014292803,0.0000022902977,0.000009135854,0.000057487796,0.000012311833,0.0006504518,0.9965833,0.000024296038,0.0008688171,0.0000030189951],"about_ca_topic_score_codex":0.00035000005,"about_ca_topic_score_gemma":0.000718523,"teacher_disagreement_score":0.0015235584,"about_ca_system_score_codex":0.00018922331,"about_ca_system_score_gemma":0.00017168789,"threshold_uncertainty_score":0.005096793},"labels":[],"label_agreement":null},{"id":"W4308398717","doi":"10.1136/jitc-2022-sitc2022.0261","title":"261 Evidence for durable anti-tumor responses by TAC-T cells in preclinical models of solid tumors","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cancer research; Flow cytometry; T cell; Antigen; Bone marrow; Immune system; Cytotoxic T cell; Biology; Molecular biology; Immunology; In vitro","score_opus":0.09622014376030799,"score_gpt":0.36606365320160206,"score_spread":0.2698435094412941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308398717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805846,0.0036521894,0.004717647,0.0004323013,0.00022682679,0.00021521168,0.0021229289,0.00037698797,0.007671359],"genre_scores_gemma":[0.9840747,0.0017020277,0.0026798625,0.00031521422,0.00008267493,0.00022694006,0.0035270299,0.000080074766,0.007311456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997477,0.00004274475,0.000022511498,0.000052305422,0.000069443595,0.000065247295],"domain_scores_gemma":[0.9997484,0.000037821734,0.000062785766,0.000041086045,0.000044096174,0.0000657414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030308694,0.000450033,0.00035764236,0.00032806935,0.00017787093,0.0003647764,0.00023920742,0.00041122548,0.0033850006],"category_scores_gemma":[0.00020882694,0.00014549043,0.0003176405,0.00018342708,0.0002892855,0.00023055685,0.00011418607,0.0015492884,0.0011987773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014281094,0.00093156676,0.00043400365,0.00012537812,0.000019559538,0.00012063914,0.000039157578,0.00023715835,0.9896912,0.00018181637,0.00083884236,0.005952386],"study_design_scores_gemma":[0.0002568985,0.016790336,0.0064789983,0.00003409955,0.00007569748,0.001027522,0.000081675855,0.0016647062,0.9645748,0.00019206488,0.008809433,0.0000137821435],"about_ca_topic_score_codex":0.00051990413,"about_ca_topic_score_gemma":0.00057687506,"teacher_disagreement_score":0.0033850006,"about_ca_system_score_codex":0.00021450147,"about_ca_system_score_gemma":0.00028636606,"threshold_uncertainty_score":0.011323988},"labels":[],"label_agreement":null},{"id":"W4308399396","doi":"10.1136/jitc-2022-sitc2022.0558","title":"558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Renal cell carcinoma; Fludarabine; Medicine; Clear cell renal cell carcinoma; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Oncology; Gastroenterology; Cyclophosphamide; Cancer research; Immunotherapy; Chemotherapy; Cancer; Biology","score_opus":0.01358275220468149,"score_gpt":0.24546656095012168,"score_spread":0.23188380874544018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308399396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957711,0.0016062056,0.00023895777,0.00023170811,0.0000321668,0.0002206254,0.0006107881,0.0000371854,0.0012512943],"genre_scores_gemma":[0.99659735,0.0006320971,0.0002890032,0.00027469316,0.000034365556,0.000104701576,0.0014080829,0.000011085654,0.0006486274],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99983716,0.000051855677,0.0000094035195,0.000037427006,0.00003076666,0.00003332213],"domain_scores_gemma":[0.99976975,0.000040431878,0.00004317423,0.000021404756,0.000027673197,0.00009762598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005973821,0.00035984433,0.00069941184,0.00010800907,0.00018610044,0.0005120121,0.00023402713,0.00035599867,0.001107798],"category_scores_gemma":[0.00025826704,0.00013968429,0.000545935,0.00017274293,0.00026926497,0.00023231507,0.00014378087,0.000823627,0.00031489998],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33404627,0.0246348,0.11744768,0.0009689358,0.0025947716,0.0005869261,0.00066522445,0.008614424,0.18147501,0.0004981194,0.017038262,0.31142965],"study_design_scores_gemma":[0.198688,0.44016665,0.2935479,0.00010194037,0.0029041287,0.0012086944,0.00024696512,0.008079917,0.03081806,0.00044994286,0.02369869,0.00008919492],"about_ca_topic_score_codex":0.0016485521,"about_ca_topic_score_gemma":0.003364159,"teacher_disagreement_score":0.0016485521,"about_ca_system_score_codex":0.00068855623,"about_ca_system_score_gemma":0.00072074775,"threshold_uncertainty_score":0.004995823},"labels":[],"label_agreement":null},{"id":"W4308415196","doi":"10.3389/fimmu.2022.1029269","title":"Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Interface Biologics (Canada); Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Research Institute; Canadian Cancer Society","keywords":"Oncolytic virus; Colorectal cancer; Cancer research; Tumor microenvironment; Medicine; Immune system; Immunotherapy; Cancer; Immunogenic cell death; Cancer cell; CD8; Cytotoxic T cell; Immunology; Biology; In vitro; Internal medicine","score_opus":0.01721192061402348,"score_gpt":0.2975827241361198,"score_spread":0.2803708035220963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308415196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680397,0.006867728,0.019893246,0.00020770314,0.00014579968,0.00022425232,0.00053942314,0.00033601557,0.003746112],"genre_scores_gemma":[0.9872938,0.0016014457,0.007743432,0.00007988922,0.000018165334,0.00012752424,0.00042368678,0.000022160095,0.0026899998],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999025,0.000012150637,0.000005874163,0.000022659457,0.000030030415,0.000026784443],"domain_scores_gemma":[0.9999764,0.0000027471992,0.000006630617,0.0000035432458,0.000003839165,0.000006799072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008089887,0.00030772254,0.00024255316,0.00016767225,0.000077009536,0.00024146405,0.00017230502,0.00030241124,0.00076266046],"category_scores_gemma":[0.00006774369,0.00010028724,0.00018975775,0.00010513541,0.000100297104,0.00016790953,0.00018425148,0.0005520073,0.00028243716],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012327898,0.000058372145,0.000099940575,0.000061543135,0.000009007759,0.000043491582,0.000010600715,0.00038686366,0.99334925,0.000151028,0.00018314342,0.005523503],"study_design_scores_gemma":[0.00006013407,0.0014986867,0.0011968837,0.000008175788,0.00005029366,0.0005318494,0.000013382875,0.005811308,0.97864974,0.00010077614,0.012068188,0.000010655776],"about_ca_topic_score_codex":0.0003491259,"about_ca_topic_score_gemma":0.00053922314,"teacher_disagreement_score":0.00076266046,"about_ca_system_score_codex":0.00023763732,"about_ca_system_score_gemma":0.00018073576,"threshold_uncertainty_score":0.0025513768},"labels":[],"label_agreement":null},{"id":"W4308495428","doi":"10.51731/cjht.2022.491","title":"Mogamulizumab (Poteligeo)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Refractory (planetary science); Drug; Vial; Intensive care medicine; Family medicine; Pharmacology; Political science; Health care","score_opus":0.04859463929211724,"score_gpt":0.333019264260428,"score_spread":0.2844246249683108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308495428","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016834568,0.7963225,0.0027774642,0.011373205,0.0021936335,0.0003604109,0.002318308,0.0004979356,0.16732194],"genre_scores_gemma":[0.19679262,0.6053106,0.01059316,0.016473826,0.0011941497,0.0004322287,0.0044474443,0.000109563676,0.16464639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99966824,0.000053835087,0.000028036342,0.000044560726,0.00015115208,0.000054226854],"domain_scores_gemma":[0.99972695,0.00004751295,0.000074615884,0.000011496983,0.00009475021,0.000044696048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000628453,0.00036344296,0.00033846908,0.00093766704,0.00029473365,0.0008417584,0.00042432197,0.00067689124,0.012272466],"category_scores_gemma":[0.00074088183,0.000104605206,0.0004472726,0.0005477964,0.0004010377,0.00048461548,0.00043266983,0.00069457316,0.003452593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059950247,0.000069591304,0.0006991996,0.0030308135,0.00010234499,0.00029292188,0.000036953104,0.00011687384,0.009329427,0.0040236427,0.09295922,0.8887395],"study_design_scores_gemma":[0.00032816033,0.0006968361,0.0062590707,0.0017790787,0.00018582978,0.0012947635,0.000040773295,0.00012776122,0.006984162,0.0006062786,0.9816761,0.000021181108],"about_ca_topic_score_codex":0.020854853,"about_ca_topic_score_gemma":0.06495436,"teacher_disagreement_score":0.020854853,"about_ca_system_score_codex":0.0019280023,"about_ca_system_score_gemma":0.0030580114,"threshold_uncertainty_score":0.04146695},"labels":[],"label_agreement":null},{"id":"W4308545220","doi":"10.1016/j.anai.2022.10.025","title":"Interleukin-6 and cytokine release syndrome","year":2022,"lang":"en","type":"review","venue":"Annals of Allergy Asthma & Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; Queen's University; University of Toronto; Kingston General Hospital; St. Michael's Hospital","funders":"","keywords":"Tryptase; Drug allergy; Medicine; Angioedema; Desensitization (medicine); Drug; Biomarker; Pharmacology; Immunology; Mast cell; Internal medicine; Chemistry","score_opus":0.0930446162973759,"score_gpt":0.37749135255415905,"score_spread":0.2844467362567832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308545220","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000043435288,0.9987903,0.000050400955,0.0002806832,0.00044063834,0.0000033096067,0.000009190651,0.0000035016772,0.00037843696],"genre_scores_gemma":[0.0005668226,0.9968329,0.00009114039,0.0005168985,0.0014159819,0.000011492216,0.000026357675,0.0000011763306,0.00053722505],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973685,0.000058904472,0.000055008568,0.000039753504,0.00008219861,0.000027187882],"domain_scores_gemma":[0.9995167,0.0002356015,0.000112135,0.000012613636,0.00007969996,0.000043270586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006935235,0.001422319,0.0025092533,0.0025890898,0.00025477022,0.0011691076,0.0007837576,0.0015825205,0.004683783],"category_scores_gemma":[0.0011327843,0.0003584732,0.0006375317,0.0020413345,0.00060520147,0.0014296924,0.00087268394,0.0027000115,0.0024652563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033309308,0.00010944498,0.00024970106,0.022429194,0.00020595222,0.00042578028,0.000034158762,0.00024481863,0.0011374603,0.0021228842,0.073969424,0.898738],"study_design_scores_gemma":[0.0003451907,0.00034394412,0.0016917145,0.009392956,0.0006264408,0.003443017,0.000064309446,0.00018852344,0.0005052988,0.0025069858,0.9808473,0.000044366985],"about_ca_topic_score_codex":0.00059357804,"about_ca_topic_score_gemma":0.0014311983,"teacher_disagreement_score":0.004683783,"about_ca_system_score_codex":0.0005437922,"about_ca_system_score_gemma":0.0011462906,"threshold_uncertainty_score":0.015668869},"labels":[],"label_agreement":null},{"id":"W4308722894","doi":"10.3390/cancers14225485","title":"T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"China Scholarship Council; Deutsche Forschungsgemeinschaft; St. Baldrick's Foundation","keywords":"CRISPR; Genome editing; Chimeric antigen receptor; Adoptive cell transfer; Cancer research; Cytotoxic T cell; Viral vector; Genetic enhancement; T-cell receptor; Cas9; Immunotherapy; T cell; Transduction (biophysics); Biology; Immunology; Gene; Immune system; Genetics; Recombinant DNA","score_opus":0.03485692058424868,"score_gpt":0.2863379827032491,"score_spread":0.25148106211900045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308722894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98696786,0.0015851897,0.008882883,0.00007147992,0.000059744158,0.00011297848,0.00020009316,0.00011683948,0.0020028434],"genre_scores_gemma":[0.99225885,0.00096555037,0.004773817,0.00004878512,0.000014230272,0.00008919378,0.00023834303,0.000025601354,0.0015856451],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999629,0.00006686517,0.00004413104,0.000090858885,0.00009698349,0.00007214669],"domain_scores_gemma":[0.9999089,0.000018310902,0.000026542995,0.00000970365,0.000013336388,0.000023063834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028151827,0.00039410646,0.0003335906,0.00033261505,0.00015828642,0.00042841546,0.00029349228,0.00046111224,0.0010898608],"category_scores_gemma":[0.00014790644,0.00014475881,0.00029552713,0.00017136635,0.00029204198,0.00030323866,0.00020641815,0.0006992032,0.00033778502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014251626,0.00007826185,0.00007341512,0.000041566105,0.000006095234,0.000028010923,0.000015212234,0.00012271803,0.99801636,0.000111810565,0.000023540257,0.0013404472],"study_design_scores_gemma":[0.00004110935,0.0011319215,0.0007598673,0.0000047573462,0.000051332958,0.00030177136,0.0000186459,0.00089019706,0.9950539,0.000044624587,0.00169576,0.0000060351067],"about_ca_topic_score_codex":0.00061175734,"about_ca_topic_score_gemma":0.0005906927,"teacher_disagreement_score":0.0010898608,"about_ca_system_score_codex":0.00026030405,"about_ca_system_score_gemma":0.00021098182,"threshold_uncertainty_score":0.0036459565},"labels":[],"label_agreement":null},{"id":"W4308840323","doi":"10.1101/2022.11.10.516049","title":"Integration of exogenous and endogenous co-stimulatory signals by CAR-Tregs","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Michael Smith Health Research BC; BC Children's Hospital; Bristol-Myers Squibb; U.S. Department of Defense","keywords":"CD28; Chimeric antigen receptor; In vivo; Immunology; In vitro; Antigen; Biology; Cytokine; Cancer research; Cell biology; T cell; Immune system; Genetics","score_opus":0.03846649051790115,"score_gpt":0.2797519642242023,"score_spread":0.24128547370630113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308840323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96849513,0.0015218651,0.024580358,0.00013447773,0.0001175204,0.000047739206,0.00020402546,0.00026329583,0.004635563],"genre_scores_gemma":[0.98996943,0.00028965526,0.0063358215,0.00004184456,0.00002020457,0.000024793004,0.00024979585,0.00006086739,0.0030075235],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975675,0.000050115726,0.000013942646,0.000043784643,0.000068629284,0.00006678813],"domain_scores_gemma":[0.9999161,0.00002732875,0.000010602688,0.000017872773,0.00000961105,0.000018398361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028062833,0.00028327288,0.00023303807,0.00021533383,0.00009923351,0.00038457318,0.00017154767,0.0002678973,0.0014848921],"category_scores_gemma":[0.00015191769,0.00009090168,0.00019790247,0.00011104406,0.00023245532,0.00016661354,0.0002526994,0.0006557357,0.0005134162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017494845,0.000050566152,0.0002617571,0.000036677342,0.000006780461,0.00010174364,0.000017326605,0.00025312076,0.9947942,0.0010123885,0.00006710065,0.003223506],"study_design_scores_gemma":[0.000019013716,0.000115960305,0.0002969113,0.0000030842048,0.000011848657,0.00015794954,0.000012218618,0.0020776852,0.9939843,0.00009229428,0.0032268649,0.0000019142813],"about_ca_topic_score_codex":0.00030147366,"about_ca_topic_score_gemma":0.00026466622,"teacher_disagreement_score":0.0014848921,"about_ca_system_score_codex":0.00019679603,"about_ca_system_score_gemma":0.00023116081,"threshold_uncertainty_score":0.0049675107},"labels":[],"label_agreement":null},{"id":"W4309014062","doi":"10.1007/978-1-0716-2740-2_15","title":"Induction of Human T Cell Development In Vitro with OP9-DL4-7FS Cells Expressing Human Cytokines","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital","funders":"Canadian Institutes of Health Research","keywords":"Cell biology; Biology; Haematopoiesis; Stromal cell; Stem cell; Cancer research","score_opus":0.05628862039573744,"score_gpt":0.42594063827114825,"score_spread":0.3696520178754108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309014062","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8989666,0.0043345266,0.05544476,0.00036587118,0.0006401172,0.0013246395,0.0059795137,0.001427155,0.03151682],"genre_scores_gemma":[0.9553356,0.0016152896,0.019547282,0.00015955341,0.00012832426,0.0005517725,0.005406896,0.00024138876,0.017013814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992411,0.00015350718,0.00009305728,0.00012282682,0.00017397263,0.00021567348],"domain_scores_gemma":[0.9994862,0.00022602304,0.00005490857,0.000099218094,0.000056186196,0.00007737599],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007386161,0.0010235572,0.00055008836,0.0006728788,0.0002832937,0.00068187516,0.00042757316,0.0005318517,0.0051703183],"category_scores_gemma":[0.00030379195,0.0002838068,0.0006881419,0.00036667328,0.00033159935,0.0003175451,0.00044389055,0.0021840513,0.0024873673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035786958,0.00008215872,0.00017271494,0.00006973704,0.000008512555,0.00010147434,0.00008072021,0.00014764641,0.9960377,0.0004997985,0.00024318925,0.0021982894],"study_design_scores_gemma":[0.000022978467,0.00013521935,0.00037923353,0.000005517068,0.000009483076,0.00006326752,0.000011844884,0.00043792403,0.9943836,0.00003695874,0.004511843,0.0000020748914],"about_ca_topic_score_codex":0.0008917974,"about_ca_topic_score_gemma":0.0008845039,"teacher_disagreement_score":0.0051703183,"about_ca_system_score_codex":0.0003564573,"about_ca_system_score_gemma":0.00033851233,"threshold_uncertainty_score":0.017296433},"labels":[],"label_agreement":null},{"id":"W4309153013","doi":"10.3390/ijms232214122","title":"Inflammatory Cytokines That Enhance Antigen Responsiveness of Naïve CD8+ T Lymphocytes Modulate Chromatin Accessibility of Genes Impacted by Antigen Stimulation","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Faculty of Medicine and Health, University of Sydney; Natural Sciences and Engineering Research Council of Canada; Université de Sherbrooke","keywords":"Priming (agriculture); Antigen; Biology; Cytokine; Cytotoxic T cell; Chromatin; Cell biology; CD8; Immunology; Antigen-presenting cell; Immune system; T cell; Molecular biology; Gene; In vitro; Genetics","score_opus":0.025427066133956285,"score_gpt":0.35879840258692147,"score_spread":0.3333713364529652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309153013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974082,0.00083970075,0.00085068366,0.000026489266,0.000012232035,0.000012706259,0.00010037498,0.000021002612,0.0007285403],"genre_scores_gemma":[0.9980971,0.00034390285,0.0007110108,0.000029178098,0.0000099498675,0.000017949842,0.00013043884,0.0000058102637,0.0006546913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998764,0.000025853902,0.000008817327,0.000029193616,0.00002359099,0.00003611255],"domain_scores_gemma":[0.99989927,0.000024376366,0.000027274264,0.0000086871705,0.000013651413,0.00002664388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011229277,0.00018556586,0.00015412834,0.00016095323,0.00009232151,0.00029193563,0.00007983995,0.00015959417,0.0018302596],"category_scores_gemma":[0.00014919485,0.000086229025,0.00010254714,0.000105741485,0.00017065232,0.00017259065,0.00015282136,0.00027920774,0.00028121352],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008835647,0.000008432436,0.00042061898,0.000016878363,0.0000010762834,0.000020208154,0.000014517625,0.00001639812,0.9987907,0.000019442854,0.0000075277094,0.0005958971],"study_design_scores_gemma":[0.00002531758,0.00051471556,0.0414802,0.000013518248,0.000016693604,0.0002700344,0.0001287981,0.00059127744,0.9555158,0.000119458586,0.001319199,0.000004965181],"about_ca_topic_score_codex":0.00006508363,"about_ca_topic_score_gemma":0.00016250987,"teacher_disagreement_score":0.0018302596,"about_ca_system_score_codex":0.000077923774,"about_ca_system_score_gemma":0.00007896052,"threshold_uncertainty_score":0.006122768},"labels":[],"label_agreement":null},{"id":"W4309407667","doi":"10.1101/2022.11.17.516906","title":"Adaptation to <i>ex vivo</i> culture drives human haematopoietic stem cell loss of repopulation capacity in a cell cycle independent manner","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Blood Cancer UK; Cancer Research UK Cambridge Institute, University of Cambridge; National Institute for Health and Care Research; Cancer Research UK","keywords":"Haematopoiesis; Biology; Ex vivo; Stem cell; Cell biology; Cell cycle; Regeneration (biology); Immunology; Cancer research; In vivo; Gene; Genetics","score_opus":0.03236226140086407,"score_gpt":0.2654378159602654,"score_spread":0.23307555455940132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309407667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98739547,0.0007110375,0.007841204,0.00012558718,0.00003588127,0.000029107625,0.0010377091,0.00021539009,0.0026085041],"genre_scores_gemma":[0.9919412,0.00038350967,0.0026898144,0.00008765661,0.0000102211325,0.00003639305,0.0011265253,0.00008806198,0.0036365814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989593,0.000014717523,0.000007702071,0.000035568733,0.00002474866,0.000021175414],"domain_scores_gemma":[0.9999249,0.000019072615,0.000018547476,0.000016589645,0.000009486252,0.00001134888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012686301,0.00016198478,0.00016021704,0.00007768176,0.00010263971,0.00043879994,0.00013712994,0.00013329653,0.0019036025],"category_scores_gemma":[0.00011331852,0.00010275869,0.00012863186,0.00009271383,0.00020899405,0.00014127308,0.00019844723,0.00042018312,0.0006329513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050243347,0.000009544851,0.00015433668,0.000015394146,0.0000018151255,0.000014573828,0.0000145804315,0.00007350323,0.9985189,0.000055992805,0.000080377824,0.0010108387],"study_design_scores_gemma":[0.0000032674325,0.000050161972,0.0033235291,0.0000027585768,0.0000036898703,0.0000459644,0.00001591778,0.0007554855,0.99404305,0.000024144785,0.0017297498,0.0000022517768],"about_ca_topic_score_codex":0.00046365845,"about_ca_topic_score_gemma":0.00079008506,"teacher_disagreement_score":0.0019036025,"about_ca_system_score_codex":0.00018469086,"about_ca_system_score_gemma":0.00012481655,"threshold_uncertainty_score":0.0063681602},"labels":[],"label_agreement":null},{"id":"W4309411030","doi":"10.1200/jco.22.00642","title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Lymphoblastic Leukemia; Refractory (planetary science); Oncology; Young adult; Pediatrics; Internal medicine; Leukemia","score_opus":0.04583295466574167,"score_gpt":0.38603387227293473,"score_spread":0.34020091760719307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309411030","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37089658,0.3712206,0.015318275,0.066660896,0.013562157,0.008940985,0.08869516,0.002521893,0.062183544],"genre_scores_gemma":[0.6053449,0.13080727,0.028227981,0.073565006,0.009149277,0.019031182,0.12065221,0.0009430236,0.012279197],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99326646,0.0037267401,0.0008967104,0.00021430706,0.0015549179,0.00034086837],"domain_scores_gemma":[0.98485476,0.005703292,0.0036711555,0.0009252616,0.0032172792,0.0016282011],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019879157,0.0005407234,0.0026809436,0.0010942629,0.0005174167,0.00318406,0.0009974227,0.0016849082,0.0022650408],"category_scores_gemma":[0.016901549,0.00032923179,0.0020241693,0.0015370738,0.00036328865,0.0016503031,0.0012486974,0.0038378283,0.0008153186],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06550924,0.0019283344,0.024105852,0.010350251,0.006498794,0.00064569374,0.0008525868,0.0019091767,0.0058529885,0.0029527566,0.23445253,0.64494175],"study_design_scores_gemma":[0.061081387,0.02721763,0.108006746,0.007166064,0.010158804,0.0023542554,0.00032936534,0.0026551215,0.0044611376,0.003666326,0.77261424,0.00028893162],"about_ca_topic_score_codex":0.0007809894,"about_ca_topic_score_gemma":0.0019983258,"teacher_disagreement_score":0.019879157,"about_ca_system_score_codex":0.001090246,"about_ca_system_score_gemma":0.0021449723,"threshold_uncertainty_score":0.10513234},"labels":[],"label_agreement":null},{"id":"W4309778403","doi":"10.3389/fimmu.2022.1018786","title":"CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil","year":2022,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Triple-negative breast cancer; Chimeric antigen receptor; Breast cancer; Medicine; Cancer; Targeted therapy; Radiation therapy; Estrogen receptor; Cancer research; Oncology; Immunotherapy; Antigen; Immunology; Internal medicine","score_opus":0.04445785183428317,"score_gpt":0.33926570727339384,"score_spread":0.29480785543911064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309778403","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017877323,0.9982938,0.00014069902,0.0002835303,0.0001875528,0.000004431014,0.000011516174,0.00000657501,0.0008930994],"genre_scores_gemma":[0.0010455784,0.99759007,0.00016665016,0.00032011222,0.00015335399,0.000009104593,0.000024666731,0.0000018851729,0.00068847125],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998946,0.00002389037,0.000010349549,0.000019372712,0.000038352926,0.000013321388],"domain_scores_gemma":[0.9998598,0.00007580684,0.000013185685,0.0000042576557,0.000031967156,0.00001493339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042287394,0.0004929249,0.00080441235,0.0012511469,0.00020929698,0.00067532033,0.0006016633,0.0009811658,0.0018917162],"category_scores_gemma":[0.00041754456,0.00016646157,0.00036702334,0.0010815338,0.0003402765,0.0010342125,0.00044570657,0.0017325167,0.0012821944],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009611614,0.00009970945,0.00012037135,0.009108299,0.00004961243,0.00019796677,0.00005328137,0.0003729754,0.0024040774,0.0048135114,0.030343832,0.95234036],"study_design_scores_gemma":[0.000028812112,0.00019857487,0.00048248103,0.002104439,0.00007308631,0.0013016514,0.000043661774,0.00014351316,0.0009665932,0.0019104737,0.992733,0.000013697146],"about_ca_topic_score_codex":0.00056091975,"about_ca_topic_score_gemma":0.0010536707,"teacher_disagreement_score":0.0018917162,"about_ca_system_score_codex":0.00045233118,"about_ca_system_score_gemma":0.000616042,"threshold_uncertainty_score":0.006328404},"labels":[],"label_agreement":null},{"id":"W4310096555","doi":"10.1182/blood-2022-167804","title":"High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Chimeric antigen receptor; Internal medicine; Oncology; Lenalidomide; Cohort; Chemotherapy; Cancer; Immunotherapy","score_opus":0.018692912816314654,"score_gpt":0.25275916974395557,"score_spread":0.2340662569276409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310096555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988237,0.0003888084,0.00023287813,0.000016598358,0.0000015392627,0.0000063252746,0.00016378258,0.000008975208,0.0003574653],"genre_scores_gemma":[0.99948275,0.000073947005,0.00017636575,0.0000069671228,0.0000043987843,0.0000067094943,0.00017893495,0.000003995258,0.00006585833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99976903,0.00004635022,0.000027106218,0.000044337357,0.0000817398,0.000031506257],"domain_scores_gemma":[0.9994056,0.00009311113,0.0003625765,0.000030410545,0.000040395575,0.00006792902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032810532,0.00016736987,0.00030090282,0.0006674366,0.00021642167,0.0004302853,0.00017747434,0.00016316836,0.0009446343],"category_scores_gemma":[0.0009177414,0.000108525375,0.00021593666,0.000763089,0.0001684191,0.0002235246,0.00030510244,0.0002049684,0.00012466477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005303403,0.000025079062,0.98501116,0.000018972058,0.000037237773,0.00030863972,0.000033732893,0.000281952,0.0062355683,0.000032781245,0.00008504616,0.007399661],"study_design_scores_gemma":[0.000006101374,0.00017964766,0.9963509,0.000002654906,0.000026590504,0.0015247959,0.00003146827,0.00047046167,0.0010942557,0.00004087268,0.00026944577,0.000002808652],"about_ca_topic_score_codex":0.0006158084,"about_ca_topic_score_gemma":0.00085847225,"teacher_disagreement_score":0.0009446343,"about_ca_system_score_codex":0.00029104468,"about_ca_system_score_gemma":0.00014625225,"threshold_uncertainty_score":0.0031601787},"labels":[],"label_agreement":null},{"id":"W4310096775","doi":"10.1182/blood-2022-168374","title":"Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine; Immunology; Medicine","score_opus":0.022189981912104303,"score_gpt":0.28224858206499914,"score_spread":0.26005860015289484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310096775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983335,0.0005150028,0.00035800107,0.000021407504,0.000007482931,0.000018203833,0.0003468016,0.000013768836,0.00038586408],"genre_scores_gemma":[0.99761486,0.00021238042,0.0005274493,0.00006243717,0.000008599217,0.00003074967,0.0009963041,0.000005220382,0.00054210826],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998784,0.00002170421,0.000008354522,0.000028180435,0.000036105666,0.000027190486],"domain_scores_gemma":[0.9998173,0.000025551135,0.00006842196,0.000009799604,0.000030652358,0.000048283673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018588656,0.000191573,0.00023942465,0.00036860685,0.000117605,0.00043039274,0.000107773885,0.00020085627,0.0008302207],"category_scores_gemma":[0.00030006,0.00008228268,0.0001839704,0.00024095946,0.00013986141,0.00016763723,0.00017472317,0.00030404318,0.00027836836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089979395,0.00023754641,0.051875703,0.00007807093,0.00008971043,0.00087497977,0.00015899242,0.00021689905,0.92318916,0.00007378,0.00026680768,0.013940549],"study_design_scores_gemma":[0.000217041,0.006681547,0.5692254,0.000024034525,0.00017076098,0.004166523,0.0004702562,0.0030620357,0.4105812,0.00011167839,0.005262385,0.000027078413],"about_ca_topic_score_codex":0.00026176072,"about_ca_topic_score_gemma":0.00025639677,"teacher_disagreement_score":0.0008302207,"about_ca_system_score_codex":0.00016877147,"about_ca_system_score_gemma":0.00012115275,"threshold_uncertainty_score":0.0027773976},"labels":[],"label_agreement":null},{"id":"W4310104788","doi":"10.1182/blood-2022-171228","title":"<i>DNMT3A</i> Limits Myeloid Signaling Responses in Committed T Cells during Normal and Leukemic Development","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; Progenitor cell; Epigenetics; Myeloid; Haematopoiesis; Cellular differentiation; Stem cell; Cell biology; T cell; Cancer research; Genetics; Gene; Immune system","score_opus":0.02326314419817613,"score_gpt":0.2615291274510778,"score_spread":0.2382659832529017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310104788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956174,0.0020975696,0.004603884,0.00012072602,0.000017684832,0.00006223684,0.0005459541,0.00017708838,0.0028131518],"genre_scores_gemma":[0.9945832,0.00057416235,0.0029129356,0.000048629157,0.0000076222673,0.0000500902,0.00034905074,0.000039339502,0.0014349879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999814,0.00003304953,0.00002328856,0.000039029797,0.000047327227,0.000043407385],"domain_scores_gemma":[0.99987173,0.00002309401,0.0000390627,0.00001690777,0.000011180407,0.00003793658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020102698,0.00018036735,0.0002496268,0.00018737746,0.00014754484,0.00050887413,0.00025210908,0.00020342368,0.0013542578],"category_scores_gemma":[0.00018090523,0.00013322296,0.00015322861,0.000107414686,0.00020472443,0.00020732371,0.00028055822,0.0005783246,0.00041553596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009732132,0.00001620649,0.00022422627,0.000016572423,0.0000018568563,0.000012031001,0.000011014239,0.000075677344,0.9980385,0.00012050746,0.000026324098,0.0013598448],"study_design_scores_gemma":[0.0000120361365,0.00025350478,0.0034345954,0.000007100001,0.000010570206,0.00010369246,0.000018661856,0.0011930565,0.99155176,0.00007770051,0.0033345385,0.0000028546103],"about_ca_topic_score_codex":0.00087685394,"about_ca_topic_score_gemma":0.0023086753,"teacher_disagreement_score":0.0013542578,"about_ca_system_score_codex":0.0003969088,"about_ca_system_score_gemma":0.00042534008,"threshold_uncertainty_score":0.00453043},"labels":[],"label_agreement":null},{"id":"W4310109630","doi":"10.1182/blood-2022-165887","title":"Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Stollery Children's Hospital; Alberta Children's Hospital; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Fludarabine; Chimeric antigen receptor; Blinatumomab; Internal medicine; Immunotherapy; Oncology; Cyclophosphamide; Clinical trial; CD19; Immunology; Antigen; Chemotherapy; Cancer","score_opus":0.010782009342702245,"score_gpt":0.24570286404493302,"score_spread":0.23492085470223079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310109630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8998974,0.010367656,0.012327852,0.0021421013,0.00052116066,0.008445493,0.008559596,0.0009019494,0.056836843],"genre_scores_gemma":[0.93968856,0.004078003,0.013019149,0.0011769054,0.0002635768,0.0019603465,0.013462155,0.0000976853,0.026253533],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994721,0.00014219864,0.000012792994,0.00008836575,0.0001960964,0.00008849579],"domain_scores_gemma":[0.9995289,0.00004192976,0.00006989783,0.00004697223,0.00008495341,0.00022734537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001277708,0.00065302814,0.00033910503,0.00050264614,0.0004955834,0.0008170891,0.00068268925,0.000619327,0.002762908],"category_scores_gemma":[0.00045769403,0.00019611382,0.00037174462,0.0003118178,0.0005915031,0.00017697735,0.00042548246,0.0011492431,0.0005467273],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033406418,0.01812532,0.016421797,0.0009204822,0.00035577585,0.0013370457,0.0003921866,0.010880833,0.49374035,0.006265376,0.056334008,0.36182046],"study_design_scores_gemma":[0.052921686,0.20888083,0.11791392,0.00017249817,0.00085013325,0.0031641922,0.00018540642,0.008428433,0.31826144,0.0016033191,0.28752413,0.0000940451],"about_ca_topic_score_codex":0.027396856,"about_ca_topic_score_gemma":0.063915364,"teacher_disagreement_score":0.027396856,"about_ca_system_score_codex":0.0026817995,"about_ca_system_score_gemma":0.004965097,"threshold_uncertainty_score":0.05447477},"labels":[],"label_agreement":null},{"id":"W4310120142","doi":"10.1182/blood-2022-157691","title":"Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Follicular lymphoma; Medicine; Refractory (planetary science); Safety profile; Oncology; Internal medicine; Rituximab; Lymphoma; Phases of clinical research; Follicular phase; Clinical trial; Adverse effect","score_opus":0.01069748530457965,"score_gpt":0.2509131653512022,"score_spread":0.24021568004662258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310120142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902142,0.006946214,0.0002954181,0.00020096853,0.000028860379,0.00023462706,0.0005214552,0.000037946604,0.0015202878],"genre_scores_gemma":[0.9951858,0.0022865084,0.00039652493,0.00030175466,0.000052385712,0.00016138259,0.0011857618,0.000009641875,0.0004202221],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975735,0.00008034324,0.000022888935,0.000041184685,0.000045759734,0.000052533185],"domain_scores_gemma":[0.9995541,0.00009794339,0.00015365722,0.00003463457,0.000048148802,0.00011149841],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010942589,0.0004349343,0.001009308,0.00017448625,0.00017140622,0.00070619764,0.00030490413,0.0002830032,0.0011211353],"category_scores_gemma":[0.0006846315,0.00018048639,0.0006547799,0.0003018274,0.00020996196,0.00034936616,0.00014892351,0.00085079996,0.00030909007],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19164746,0.009031726,0.114924185,0.001708135,0.0037705584,0.00084969227,0.0005430676,0.0031363014,0.105211265,0.0002535983,0.012073956,0.5568501],"study_design_scores_gemma":[0.12627931,0.28289595,0.51060414,0.00036473083,0.005785786,0.004907936,0.0003178779,0.005755082,0.021201655,0.0004381238,0.04133948,0.00010995241],"about_ca_topic_score_codex":0.00054356165,"about_ca_topic_score_gemma":0.001941195,"teacher_disagreement_score":0.0011211353,"about_ca_system_score_codex":0.00062397175,"about_ca_system_score_gemma":0.0004387627,"threshold_uncertainty_score":0.005787015},"labels":[],"label_agreement":null},{"id":"W4310126163","doi":"10.1182/blood-2022-162738","title":"Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Lenalidomide; Oncology; Internal medicine; Cohort; Refractory (planetary science); Materials science","score_opus":0.016252222328361206,"score_gpt":0.27809086817263956,"score_spread":0.26183864584427835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310126163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98851264,0.0028183502,0.000508067,0.0005531953,0.00008222973,0.0012652898,0.0047816476,0.00009646664,0.001382178],"genre_scores_gemma":[0.9836072,0.0018072703,0.0014850175,0.0012130071,0.00018537535,0.0009876963,0.009330108,0.000034037635,0.0013503365],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99928516,0.00032485358,0.000048448605,0.00012993903,0.00011391314,0.00009766961],"domain_scores_gemma":[0.99917954,0.00010376878,0.00023608444,0.00007957595,0.00007720809,0.00032388017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022909096,0.0010471551,0.0015208501,0.00037396833,0.00052443886,0.0011255603,0.00064164045,0.0008103498,0.0023824242],"category_scores_gemma":[0.0012031335,0.0005011671,0.0018621172,0.00046290155,0.0004025384,0.00064416794,0.0005219581,0.001994183,0.0007778877],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6347368,0.040162824,0.09320074,0.0010394998,0.00616987,0.0006360327,0.000632099,0.0033759093,0.032697603,0.00027900035,0.016631985,0.1704376],"study_design_scores_gemma":[0.4165189,0.33411595,0.21215323,0.00015048003,0.006606571,0.0014268165,0.00021504186,0.0031472682,0.0072751925,0.00042790573,0.017854756,0.00010790691],"about_ca_topic_score_codex":0.0015159812,"about_ca_topic_score_gemma":0.0044555715,"teacher_disagreement_score":0.0023824242,"about_ca_system_score_codex":0.001165258,"about_ca_system_score_gemma":0.0017119029,"threshold_uncertainty_score":0.012115598},"labels":[],"label_agreement":null},{"id":"W4310142579","doi":"10.3390/curroncol29120725","title":"Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Population; Neuroblastoma RAS viral oncogene homolog; Cohort; Sequence (biology); Oncology; Melanoma; Internal medicine; Pediatrics; Cancer; KRAS; Genetics; Cancer research; Biology","score_opus":0.19956944273886637,"score_gpt":0.5002350967732713,"score_spread":0.30066565403440493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310142579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9685342,0.006057822,0.014233196,0.0024790189,0.00007558735,0.00055275206,0.0030323288,0.00015554488,0.004879637],"genre_scores_gemma":[0.99326843,0.0008972553,0.0034497003,0.00020975854,0.000021599006,0.00027059918,0.0009475816,0.000015508564,0.0009194885],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9964142,0.0024827127,0.00009734991,0.0002663746,0.00019860367,0.0005407202],"domain_scores_gemma":[0.9890787,0.008984457,0.00080657634,0.0001859098,0.00051415,0.00043010138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006756695,0.0016680531,0.0022405921,0.0018158763,0.00039748225,0.0022809913,0.0013914302,0.0018541066,0.004339884],"category_scores_gemma":[0.012874082,0.0007865345,0.0034338115,0.001172851,0.00072312064,0.0012484293,0.0010996127,0.0015081011,0.00021600131],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011919156,0.0003290883,0.00699435,0.00021429689,0.0005739889,0.00011000403,0.00003554479,0.98131,0.00015543785,0.0020078183,0.00059809274,0.0064794593],"study_design_scores_gemma":[0.0009673886,0.0023411307,0.011823346,0.00017377039,0.00085369457,0.00015314456,0.00016840298,0.9789811,0.00022733763,0.0027851507,0.0014680485,0.00005749673],"about_ca_topic_score_codex":0.084933095,"about_ca_topic_score_gemma":0.02981102,"teacher_disagreement_score":0.084933095,"about_ca_system_score_codex":0.011932488,"about_ca_system_score_gemma":0.0052871564,"threshold_uncertainty_score":0.16887748},"labels":[],"label_agreement":null},{"id":"W4310159202","doi":"10.1182/blood-2022-158492","title":"Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Refractory (planetary science); Oncology; Lymphoma; Internal medicine; Physics","score_opus":0.026009783173247546,"score_gpt":0.3245871880200717,"score_spread":0.29857740484682416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310159202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990872,0.00040545536,0.000024666202,0.000049327347,0.000012193316,0.0000067245223,0.00009498216,0.0000033037873,0.0003160452],"genre_scores_gemma":[0.99923277,0.00010454624,0.000016998418,0.000039908988,0.00001998364,0.000010714206,0.00026367555,0.000001012468,0.000310373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998678,0.00003299365,0.000008304571,0.000029137793,0.000014947315,0.000046753838],"domain_scores_gemma":[0.99963486,0.00006311072,0.000093105846,0.000017984374,0.000015787342,0.00017528262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030788127,0.00016017548,0.0003623658,0.00016921622,0.0001356286,0.00048757007,0.00020112589,0.000294039,0.0018215983],"category_scores_gemma":[0.0005243049,0.000076558346,0.00035742047,0.0001703392,0.00015195606,0.0003271745,0.00021399872,0.0005957516,0.00021547206],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17195818,0.004093575,0.738092,0.00015153532,0.00092526217,0.0004068575,0.00014676792,0.0008271146,0.008703767,0.00020267458,0.0015959853,0.07289632],"study_design_scores_gemma":[0.0025555508,0.037280574,0.95363516,0.000034428827,0.00073460804,0.0004823921,0.00022194932,0.0018692672,0.0013375572,0.00023620189,0.0015903953,0.000022027618],"about_ca_topic_score_codex":0.00047715043,"about_ca_topic_score_gemma":0.00083723676,"teacher_disagreement_score":0.0018215983,"about_ca_system_score_codex":0.00030981435,"about_ca_system_score_gemma":0.00023742601,"threshold_uncertainty_score":0.0060938597},"labels":[],"label_agreement":null},{"id":"W4310163262","doi":"10.1182/blood-2022-160319","title":"A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Internal medicine; Phases of clinical research; Lymphoma; Oncology; Gastroenterology; Multiple myeloma; Clinical trial; Materials science","score_opus":0.018524220612302716,"score_gpt":0.2875345803979591,"score_spread":0.26901035978565635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310163262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850723,0.0042316588,0.0005768168,0.00078569126,0.00032747956,0.0044882437,0.0017108937,0.00015869483,0.0026481624],"genre_scores_gemma":[0.98125994,0.002962556,0.0025182555,0.0021698244,0.0002496213,0.004775934,0.0031465285,0.00005167129,0.0028656367],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957496,0.0001649259,0.00002249175,0.00008992763,0.000044708606,0.000102934435],"domain_scores_gemma":[0.99926716,0.000083724066,0.00009464325,0.000059461952,0.00006284772,0.00043203647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015457689,0.0015532558,0.0026155144,0.00048170847,0.00050876406,0.0016164121,0.001221314,0.001311235,0.0048663043],"category_scores_gemma":[0.0008881866,0.0007905083,0.002139737,0.00046476716,0.000860792,0.0009918744,0.0004925773,0.004120993,0.0014545026],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7706175,0.102546014,0.0051954505,0.0010671881,0.0030955034,0.00029005116,0.000376425,0.0018708268,0.021430448,0.00028656027,0.004940375,0.08828369],"study_design_scores_gemma":[0.71760553,0.2690905,0.0070400164,0.000049834183,0.0006366226,0.0002231846,0.00007992788,0.00083036505,0.000979099,0.00023864674,0.0031905773,0.00003567791],"about_ca_topic_score_codex":0.0019937095,"about_ca_topic_score_gemma":0.005015329,"teacher_disagreement_score":0.0048663043,"about_ca_system_score_codex":0.001778985,"about_ca_system_score_gemma":0.0021725325,"threshold_uncertainty_score":0.0162794},"labels":[],"label_agreement":null},{"id":"W4310603204","doi":"10.1016/j.ymthe.2022.11.010","title":"Cellular therapy: Great promise, but at what cost?","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"","keywords":"Chimeric antigen receptor; Medicine; Mantle cell lymphoma; Lymphoma; Follicular lymphoma; Cancer research; Oncology; Immunotherapy; Immunology; Internal medicine; Cancer","score_opus":0.0356913478571717,"score_gpt":0.29700168404124355,"score_spread":0.26131033618407185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310603204","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033400701,0.36915147,0.0039578653,0.6007433,0.008232141,0.000069911155,0.00040416874,0.00025598056,0.013845133],"genre_scores_gemma":[0.09318137,0.634298,0.014742271,0.18035218,0.046936274,0.00038959613,0.00084290514,0.00021512648,0.029042326],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99595404,0.0018186632,0.00020846575,0.00043538702,0.001016337,0.0005671066],"domain_scores_gemma":[0.98316836,0.010247501,0.0008308597,0.00076255464,0.002750001,0.0022406252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014545548,0.0014371386,0.002835311,0.0011788561,0.0012659241,0.007272372,0.0022208674,0.009121909,0.03900239],"category_scores_gemma":[0.013534855,0.00045210376,0.0017635798,0.0008663991,0.006666553,0.012471311,0.0021407674,0.009531634,0.007970982],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023404264,0.00069664937,0.0021201316,0.0044268025,0.000449529,0.0011303341,0.0003212555,0.0012108191,0.0066819144,0.10137382,0.32683352,0.5524148],"study_design_scores_gemma":[0.00069639226,0.0018219142,0.0032448887,0.0053688562,0.00054645597,0.002433199,0.0027614755,0.0014465543,0.003873089,0.12143504,0.8561856,0.00018650726],"about_ca_topic_score_codex":0.0023901842,"about_ca_topic_score_gemma":0.0053586382,"teacher_disagreement_score":0.03900239,"about_ca_system_score_codex":0.0028189393,"about_ca_system_score_gemma":0.0073714233,"threshold_uncertainty_score":0.130476},"labels":[],"label_agreement":null},{"id":"W4310747261","doi":"10.1136/jitc-2022-005360","title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Chemical, Bioengineering, Environmental, and Transport Systems; York University; New York University; Leukemia and Lymphoma Society; AstraZeneca; National Institute of General Medical Sciences; Cancer Research Institute; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Chimeric antigen receptor; CD19; Medicine; T cell; Immunotherapy; Clinical trial; Leukemia; Oncology; Internal medicine; Antigen; Immunology; Cancer; Immune system","score_opus":0.020053779762780204,"score_gpt":0.31615903936231066,"score_spread":0.29610525959953043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310747261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92835516,0.00026994455,0.065092996,0.00065366476,0.000046472825,0.00009879687,0.0012089986,0.00019904257,0.004074897],"genre_scores_gemma":[0.9935197,0.00010133023,0.00462694,0.00006561692,0.000008332459,0.00014492935,0.0004635621,0.000014161938,0.0010553749],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99984956,0.000055429442,0.000008125009,0.000035781384,0.000018702453,0.000032398257],"domain_scores_gemma":[0.9993882,0.0004281522,0.000069120695,0.00002596462,0.000045121444,0.000043454285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043304305,0.00046830665,0.0006157192,0.00032641806,0.00024061855,0.0005111392,0.00061989954,0.00076133665,0.0015117422],"category_scores_gemma":[0.0015401322,0.0003325339,0.00071228476,0.00026701068,0.0003825172,0.00025643516,0.00032962783,0.00043698415,0.00012507188],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035474415,0.000014574757,0.0015933068,0.0000065620316,0.000008432117,0.000026000556,0.0000050928056,0.9973348,0.00016260921,0.0002281918,0.000068160356,0.00051674835],"study_design_scores_gemma":[0.000008318849,0.000015765669,0.00030278836,0.0000010410772,0.0000065824465,0.0000068036215,0.000003004532,0.99928373,0.00011059003,0.00020507761,0.000054457556,0.0000018249914],"about_ca_topic_score_codex":0.012936166,"about_ca_topic_score_gemma":0.0072893295,"teacher_disagreement_score":0.012936166,"about_ca_system_score_codex":0.000763857,"about_ca_system_score_gemma":0.0011985872,"threshold_uncertainty_score":0.025721729},"labels":[],"label_agreement":null},{"id":"W4311504925","doi":"10.3389/fonc.2022.1062592","title":"Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Medicine; Personalized medicine; Scale (ratio); Precision medicine; Medical physics; Computer science; Bioinformatics; Pathology; Biology","score_opus":0.0407797552147476,"score_gpt":0.37007987908496026,"score_spread":0.3293001238702127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311504925","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016795717,0.005253136,0.9618053,0.0041780546,0.0004032356,0.00007683221,0.00014717728,0.00057574507,0.010764775],"genre_scores_gemma":[0.32360163,0.009985949,0.65467453,0.0010772803,0.00038900846,0.00020961571,0.0003489135,0.00034627863,0.00936674],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995228,0.00019543571,0.00002030599,0.000085118816,0.0001477362,0.000028593739],"domain_scores_gemma":[0.9989907,0.0005413132,0.00008966481,0.000197019,0.00010147485,0.000079804304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015514924,0.00054039265,0.0008596093,0.00089556316,0.00037158412,0.0026548705,0.0011129737,0.0009382456,0.0037920193],"category_scores_gemma":[0.0029565361,0.0004100435,0.00097431993,0.0005568643,0.0017206562,0.002457147,0.002715976,0.0017624655,0.0007276828],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026863138,0.00013879736,0.003440535,0.0008141836,0.00017645248,0.0004131535,0.00041121812,0.28447634,0.02146738,0.34782112,0.009824137,0.33074805],"study_design_scores_gemma":[0.000030366202,0.00012636835,0.00059869146,0.000122060614,0.000057258116,0.0004578686,0.00015011967,0.70782745,0.006723705,0.23572816,0.04811773,0.000060220857],"about_ca_topic_score_codex":0.0010232496,"about_ca_topic_score_gemma":0.0011233509,"teacher_disagreement_score":0.0037920193,"about_ca_system_score_codex":0.0009982241,"about_ca_system_score_gemma":0.00094769034,"threshold_uncertainty_score":0.012685537},"labels":[],"label_agreement":null},{"id":"W4312079433","doi":"10.21203/rs.3.rs-2378631/v1","title":"Harnessing CD3 diversity to optimise CAR T cells","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Commission; Deutsche Forschungsgemeinschaft; European Federation of Pharmaceutical Industries and Associations; McGill University","keywords":"Diversity (politics); Business; Computer science; Sociology; Anthropology","score_opus":0.13631357775516698,"score_gpt":0.43488102919819493,"score_spread":0.298567451443028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312079433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96994597,0.0018960206,0.023014242,0.00026927964,0.000061436804,0.00005743341,0.0003305782,0.00031207505,0.004113022],"genre_scores_gemma":[0.99159485,0.00054142403,0.0062424983,0.00006761044,0.000009711509,0.000026203827,0.0001771815,0.000041787465,0.0012987915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987805,0.000018190347,0.0000066334496,0.000025668312,0.000026980551,0.000044416174],"domain_scores_gemma":[0.9999385,0.000013415632,0.000011547253,0.00000789057,0.000011039975,0.000017506245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019342458,0.00027912844,0.00019001412,0.00016967604,0.0001382355,0.00055332424,0.00018823304,0.0002618643,0.0015652172],"category_scores_gemma":[0.00016933065,0.000103884224,0.0001598025,0.00021073692,0.00021339621,0.0002604587,0.00037063262,0.0005528643,0.0007067103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011679322,0.000035107903,0.00022616483,0.000046427413,0.000005425174,0.000058481233,0.000019308914,0.0014773828,0.99221766,0.00066112005,0.00015266608,0.0049834694],"study_design_scores_gemma":[0.000020819942,0.00022403002,0.00031996056,0.0000038636254,0.000011504949,0.00013160415,0.000019373292,0.0036418445,0.98906904,0.00031205066,0.0062399725,0.0000059008735],"about_ca_topic_score_codex":0.00027759763,"about_ca_topic_score_gemma":0.00039581434,"teacher_disagreement_score":0.0015652172,"about_ca_system_score_codex":0.0003181973,"about_ca_system_score_gemma":0.00018257835,"threshold_uncertainty_score":0.005236149},"labels":[],"label_agreement":null},{"id":"W4312137408","doi":"10.21203/rs.3.rs-2355585/v1","title":"Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ- PBMC-HPV) in HLA-A*02+ patients with HPV16+ Solid Tumors","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Peripheral blood mononuclear cell; Medicine; Pharmacodynamics; Tolerability; CD8; Immune system; Antigen; Immunotherapy; Immunology; Human leukocyte antigen; Internal medicine; Adverse effect; Pharmacokinetics; Biology; In vitro","score_opus":0.08236097604119805,"score_gpt":0.4336529150774708,"score_spread":0.35129193903627276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312137408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973756,0.00025542258,0.0006017276,0.00006978784,0.00003649471,0.0009915465,0.00020353172,0.000023899349,0.00044193523],"genre_scores_gemma":[0.99460214,0.0001968865,0.001720956,0.0002562778,0.000062913525,0.0013119528,0.00040407848,0.000011403487,0.001433343],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975175,0.00011108451,0.0000100653,0.00005446825,0.000031193616,0.000041499905],"domain_scores_gemma":[0.9996824,0.00007644944,0.00008912641,0.000036166475,0.000024813722,0.000091025744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007796316,0.0005702842,0.0007550267,0.00014028094,0.00020002587,0.00038933134,0.00025590663,0.0005514459,0.0025073003],"category_scores_gemma":[0.00045868094,0.00024960111,0.00038754227,0.00010793619,0.0003761467,0.00030455174,0.00015638133,0.0012530355,0.0004175643],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21721707,0.1014133,0.019092293,0.00048598362,0.00036869364,0.0003876475,0.00046789082,0.0048294887,0.51925147,0.0005304917,0.0027967296,0.13315903],"study_design_scores_gemma":[0.034056537,0.92377615,0.009240122,0.00001081776,0.0000885917,0.00025970498,0.000046663758,0.0013504223,0.028623141,0.00014071615,0.0023961987,0.00001101699],"about_ca_topic_score_codex":0.00014801873,"about_ca_topic_score_gemma":0.00030625594,"teacher_disagreement_score":0.0025073003,"about_ca_system_score_codex":0.00032333596,"about_ca_system_score_gemma":0.000512505,"threshold_uncertainty_score":0.008387744},"labels":[],"label_agreement":null},{"id":"W4313201618","doi":"10.1016/j.clml.2022.12.011","title":"SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia","year":2022,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Blinatumomab; Medicine; Hematopoietic stem cell transplantation; CD19; Minimal residual disease; Chemotherapy; Lymphoblastic Leukemia; Oncology; Leukemia; Internal medicine; Transplantation; Immunology; Antibody","score_opus":0.10113126277775292,"score_gpt":0.40438592425702263,"score_spread":0.3032546614792697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313201618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007795568,0.9979171,0.000068909896,0.00071220374,0.0004437475,0.0000070786423,0.00004841777,0.0000076265655,0.0007169376],"genre_scores_gemma":[0.0008951737,0.99676704,0.00017592647,0.0010200309,0.00051874726,0.00001062719,0.00008221072,0.0000041174294,0.00052623847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996302,0.00009917222,0.000068419526,0.00006324737,0.000098559176,0.0000404055],"domain_scores_gemma":[0.9990658,0.00054026104,0.00015062898,0.000017167698,0.0001741981,0.00005185927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001227995,0.0005771957,0.0019733168,0.0010883933,0.0001943797,0.0017714419,0.0010969599,0.0010898603,0.0076494743],"category_scores_gemma":[0.0023186887,0.00029273526,0.0010558531,0.0010992289,0.0003944393,0.0015172354,0.0005677452,0.0025192439,0.0027447217],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003026569,0.00005102608,0.00012863336,0.020476839,0.00015341636,0.00006849162,0.00002894111,0.00028817792,0.00067990867,0.0023779636,0.05353338,0.9219106],"study_design_scores_gemma":[0.00015527384,0.00019881847,0.00054037245,0.01046241,0.00043905663,0.00047109608,0.000039216113,0.00013663303,0.00026919408,0.0017190812,0.9855473,0.000021636655],"about_ca_topic_score_codex":0.0015298715,"about_ca_topic_score_gemma":0.0033874922,"teacher_disagreement_score":0.0076494743,"about_ca_system_score_codex":0.0008333391,"about_ca_system_score_gemma":0.0014668922,"threshold_uncertainty_score":0.025590062},"labels":[],"label_agreement":null},{"id":"W4313245350","doi":"10.3390/cancers15010094","title":"Adoptive Cell Therapy for T-Cell Malignancies","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Cell therapy; Adoptive cell transfer; Medicine; Cell; T cell; Immunology; Immune system; Biology","score_opus":0.12192030993947205,"score_gpt":0.38934349601605395,"score_spread":0.2674231860765819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313245350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025850092,0.9976713,0.00038285935,0.0001417402,0.00017832422,0.00001097242,0.000018016719,0.000014962419,0.0013233058],"genre_scores_gemma":[0.0014182342,0.9972138,0.000302846,0.00014690767,0.00011165248,0.000014913684,0.000036500198,0.0000019703596,0.00075336976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998814,0.000020823329,0.000012068756,0.000020636193,0.000051771098,0.0000133852545],"domain_scores_gemma":[0.99990857,0.000045868026,0.000013301377,0.000003764194,0.00001977521,0.000008690764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003246122,0.0006462843,0.0007998656,0.0015006434,0.00018979903,0.0005331859,0.00050878513,0.00071150187,0.0028545463],"category_scores_gemma":[0.00027296616,0.0001533552,0.00047338707,0.00088109396,0.00027973103,0.00067777466,0.00048270015,0.0014737507,0.0015512886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063606574,0.00012442889,0.00013726538,0.015018254,0.00007374629,0.00022005828,0.000056679564,0.0003524737,0.008172447,0.003556477,0.019063402,0.9531611],"study_design_scores_gemma":[0.0000252073,0.00022686314,0.000639111,0.0025231123,0.00012033279,0.0020098079,0.000039168106,0.00011960389,0.0026853846,0.0014711964,0.99012345,0.000016762306],"about_ca_topic_score_codex":0.0003925573,"about_ca_topic_score_gemma":0.0006812214,"teacher_disagreement_score":0.0028545463,"about_ca_system_score_codex":0.00029246605,"about_ca_system_score_gemma":0.00044848165,"threshold_uncertainty_score":0.009549439},"labels":[],"label_agreement":null},{"id":"W4313334167","doi":"10.1016/j.clml.2022.12.015","title":"CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Lymphoma; Retrospective cohort study; Cohort; Population; Oncology; Clinical trial; Gastroenterology; Immunotherapy; Cancer","score_opus":0.057318149621745584,"score_gpt":0.3451042323808731,"score_spread":0.28778608275912754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313334167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891072,0.0049344054,0.00026066208,0.0002474552,0.000027411817,0.00023516091,0.0020582785,0.000013544182,0.0031158724],"genre_scores_gemma":[0.9937405,0.0027615181,0.00033408872,0.0004238307,0.000044232158,0.00006703278,0.0017856197,0.000028096425,0.0008151845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843997,0.00023062294,0.00009042165,0.00031740277,0.00040844464,0.0005130847],"domain_scores_gemma":[0.9981223,0.00022128092,0.00040063256,0.00015219631,0.00066687044,0.00043666916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011775347,0.0009065186,0.0012583517,0.0010047714,0.002204345,0.0015908759,0.0013797719,0.0011574952,0.0023241662],"category_scores_gemma":[0.0022106764,0.00078001583,0.0015723822,0.0033591746,0.0012115309,0.000617516,0.00062433607,0.0011707229,0.0003563632],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013170495,0.0009359929,0.9499208,0.00050005596,0.0014722827,0.0017461411,0.0012238626,0.00067469943,0.005011815,0.00060300523,0.0025123649,0.022228522],"study_design_scores_gemma":[0.0019914305,0.002547303,0.98117894,0.00016880874,0.002046914,0.0021305964,0.0015330347,0.0005593806,0.00059815915,0.00013794466,0.006988575,0.00011887615],"about_ca_topic_score_codex":0.8475724,"about_ca_topic_score_gemma":0.89718896,"teacher_disagreement_score":0.8475724,"about_ca_system_score_codex":0.018189015,"about_ca_system_score_gemma":0.020401157,"threshold_uncertainty_score":0.30665052},"labels":[],"label_agreement":null},{"id":"W4313349575","doi":"10.4049/jimmunol.190.supp.205.12","title":"Enhancing adoptively transferred T cells by stimulating with dendritic cell stimulation: exploring novel therapies (P4405)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Adoptive cell transfer; Lymphocytic choriomeningitis; Cancer research; In vivo; Immunology; Immunotherapy; T cell; Medicine; Antigen; Biology; Immune system; CD8","score_opus":0.043483782953671106,"score_gpt":0.27548226060323716,"score_spread":0.23199847764956605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313349575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96035933,0.016574949,0.014129572,0.00058974506,0.00029735407,0.00033383621,0.00025531344,0.00027945713,0.007180589],"genre_scores_gemma":[0.97810954,0.007254948,0.00847362,0.0002896782,0.00014281849,0.00024369286,0.00031162341,0.000019089466,0.005155036],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993384,0.000012493146,0.000003916907,0.000011986216,0.00001933567,0.000018409693],"domain_scores_gemma":[0.9999802,0.0000028681166,0.0000040753116,0.0000022295371,0.0000026647597,0.00000803241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011203307,0.00041906664,0.00021048912,0.00026332468,0.00008106003,0.00023973736,0.00019026596,0.00033830598,0.0012944629],"category_scores_gemma":[0.000045891342,0.00006333396,0.000221728,0.00014657517,0.00013980527,0.00013724389,0.00015386858,0.00061581866,0.00033934595],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036892932,0.0006869265,0.0002948205,0.00028589077,0.00001561821,0.00010173636,0.000025140243,0.00038874763,0.9519825,0.0005051282,0.000574774,0.044769797],"study_design_scores_gemma":[0.00036810042,0.0063010333,0.0023546163,0.000032363794,0.00010425613,0.0006043407,0.000021436581,0.0032033972,0.96543646,0.0004024071,0.021162312,0.000009368709],"about_ca_topic_score_codex":0.000120677716,"about_ca_topic_score_gemma":0.00015331236,"teacher_disagreement_score":0.0012944629,"about_ca_system_score_codex":0.00012648338,"about_ca_system_score_gemma":0.00015665623,"threshold_uncertainty_score":0.0043303967},"labels":[],"label_agreement":null},{"id":"W4313350039","doi":"10.4049/jimmunol.186.supp.100.38","title":"A new dynamic model of three cell interactions by CD4+ T-licensed DCs and DC-primed CD4+ T cells (100.38)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"","keywords":"Cytotoxic T cell; CTL*; Priming (agriculture); CD8; Biology; T cell; Cell biology; Immunology; Interleukin 21; Immune system; In vitro","score_opus":0.04139728557869283,"score_gpt":0.29965992901136135,"score_spread":0.2582626434326685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313350039","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32101202,0.0030404932,0.5940232,0.0027150363,0.00060573197,0.0002248125,0.000388109,0.0006264912,0.077364065],"genre_scores_gemma":[0.93156946,0.0018091633,0.029305737,0.00042003614,0.00020372216,0.00043815796,0.00021294954,0.00011175601,0.03592914],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997497,0.000048595262,0.000010301396,0.00007083724,0.00006421283,0.000056384448],"domain_scores_gemma":[0.9998642,0.000029512043,0.000023940778,0.000013880803,0.000021238164,0.000047159298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002477957,0.0005218952,0.0005282077,0.00050883216,0.0006469391,0.0011702429,0.0013438213,0.0010136453,0.0056706583],"category_scores_gemma":[0.00027597498,0.00049458933,0.00072574057,0.0002708668,0.00091000966,0.002336276,0.0008789268,0.0008416104,0.0011464445],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019407365,0.00016979733,0.00111445,0.00024231485,0.00007652606,0.00100903,0.00032283788,0.29056498,0.13553263,0.5561686,0.0026948804,0.011909872],"study_design_scores_gemma":[0.000069224865,0.00013175291,0.000471216,0.000019402185,0.000028276545,0.00023149326,0.000080352045,0.915775,0.006213112,0.06573353,0.011211906,0.000034732682],"about_ca_topic_score_codex":0.0020462761,"about_ca_topic_score_gemma":0.00083448924,"teacher_disagreement_score":0.0056706583,"about_ca_system_score_codex":0.0012615516,"about_ca_system_score_gemma":0.00089608296,"threshold_uncertainty_score":0.018970251},"labels":[],"label_agreement":null},{"id":"W4313350059","doi":"10.4049/jimmunol.186.supp.153.42","title":"Instructional role of ligand in γδ T cell lineage commitment (153.42)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T-cell receptor; Lineage (genetic); Biology; Cell fate determination; T cell; Cell biology; Ligand (biochemistry); Negative selection; Immunology; Gene; Receptor; Genetics; Transcription factor; Immune system","score_opus":0.02898959373728102,"score_gpt":0.2802784944135813,"score_spread":0.25128890067630033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313350059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879462,0.0021328356,0.0021382025,0.00011251741,0.000029909004,0.000013335605,0.00021460309,0.000074616044,0.007337697],"genre_scores_gemma":[0.9949124,0.00041607718,0.0013473408,0.000040711973,0.000008997926,0.0000072654952,0.00012914298,0.00002363351,0.003114429],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99981195,0.00004603805,0.000014347759,0.00003540311,0.000043258522,0.000049040962],"domain_scores_gemma":[0.9997836,0.00006666932,0.00004099215,0.000019926678,0.000024880785,0.000063927946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015405047,0.00017799732,0.00015463798,0.00019294769,0.00020820585,0.00074743904,0.00015712088,0.00022422838,0.0051506627],"category_scores_gemma":[0.00023984848,0.00015140878,0.000102872225,0.000106575215,0.00017251843,0.00023360355,0.0003111437,0.00051977334,0.0012745564],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012002547,0.000020911773,0.00034800463,0.000022800532,0.0000012442621,0.000068242385,0.000013287567,0.000085310225,0.9960556,0.00032347502,0.0000314524,0.0029096126],"study_design_scores_gemma":[0.000021176245,0.00024670042,0.005174699,0.000019764953,0.000012532423,0.00035359612,0.00008100717,0.0011913645,0.98873436,0.0002364095,0.0039223353,0.0000060891693],"about_ca_topic_score_codex":0.00032399912,"about_ca_topic_score_gemma":0.00063813594,"teacher_disagreement_score":0.0051506627,"about_ca_system_score_codex":0.00029447774,"about_ca_system_score_gemma":0.00023925077,"threshold_uncertainty_score":0.01723075},"labels":[],"label_agreement":null},{"id":"W4313351792","doi":"10.4049/jimmunol.186.supp.63.29","title":"Embryonic stem cell-derived factors inhibit T effector activation and induce T regulatory cells by modulating PKC-θ activation. (63.29)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Cell biology; Ionomycin; CD28; T cell; Transcription factor; Protein kinase C; Biology; Embryonic stem cell; Immune system; Western blot; FOXP3; Molecular biology; Chemistry; Phosphorylation; Immunology; Biochemistry; Intracellular","score_opus":0.032320520923024114,"score_gpt":0.2620367731275391,"score_spread":0.22971625220451497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313351792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97275114,0.00895397,0.01043493,0.00020547821,0.00023228994,0.00009787856,0.001130701,0.00028910552,0.0059045446],"genre_scores_gemma":[0.983709,0.0047971383,0.004085072,0.00012954343,0.000055906217,0.00008058054,0.0014230881,0.00003469257,0.0056850226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984264,0.000028860508,0.000025326839,0.00002380253,0.00004540521,0.000033966968],"domain_scores_gemma":[0.9999126,0.000018281917,0.0000256907,0.000013873879,0.00001235855,0.000017099277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014615606,0.0005052162,0.0002053013,0.00023721921,0.00008757387,0.00025801847,0.0001284839,0.00020142777,0.0027816775],"category_scores_gemma":[0.00011878039,0.000098733435,0.00032578784,0.00017270689,0.00016149221,0.00014295925,0.00012524755,0.000572647,0.00072618295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008366185,0.00003455178,0.00015519644,0.000073604606,0.000007571937,0.000049154743,0.000005634858,0.000027086764,0.9970079,0.00009429258,0.00007897442,0.002382332],"study_design_scores_gemma":[0.000014047095,0.00019267008,0.0023513054,0.000007438766,0.000020102008,0.00013309819,0.000007942621,0.00017681984,0.9935075,0.00002786946,0.003559453,0.0000016637432],"about_ca_topic_score_codex":0.00018087869,"about_ca_topic_score_gemma":0.00028675373,"teacher_disagreement_score":0.0027816775,"about_ca_system_score_codex":0.000118504555,"about_ca_system_score_gemma":0.00014121745,"threshold_uncertainty_score":0.009305656},"labels":[],"label_agreement":null},{"id":"W4313354752","doi":"10.4049/jimmunol.190.supp.177.6","title":"Discovering optimal targets for adoptive T-cell immunotherapy of leukemia (P4346)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Immunogenicity; Antigen; CD8; Leukemia; Immunology; Biology; Immunotherapy; Adoptive cell transfer; Cytotoxic T cell; T cell; Cancer research; Major histocompatibility complex; Minor histocompatibility antigen; Immune system; In vitro","score_opus":0.017583604569491557,"score_gpt":0.28744322223252067,"score_spread":0.2698596176630291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313354752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97505176,0.007901387,0.014117922,0.0002986781,0.00004496988,0.00015554555,0.00021944959,0.00017279535,0.0020375196],"genre_scores_gemma":[0.987045,0.002294343,0.008900474,0.00008074546,0.000020376476,0.00010763962,0.00023126893,0.000023768684,0.0012963964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981016,0.00005580873,0.000013816239,0.000027646776,0.000047414058,0.000045197616],"domain_scores_gemma":[0.99994075,0.000012644767,0.000019855652,0.0000057296506,0.0000070882156,0.000013899749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024411012,0.000447328,0.00038666453,0.00032515917,0.00012226257,0.0005829014,0.00023308383,0.00047758862,0.0013069223],"category_scores_gemma":[0.00012968424,0.00016958093,0.00017135557,0.00021219449,0.00016688956,0.00041886774,0.00028427553,0.0006838835,0.0007682472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018649428,0.00016499047,0.0003399761,0.000070313,0.0000074179925,0.000043294673,0.000017035003,0.0010129355,0.9896169,0.00031629583,0.00012852278,0.008095767],"study_design_scores_gemma":[0.0001507565,0.0025367509,0.0024236843,0.00002428184,0.000049048143,0.00030195515,0.000047318266,0.006486685,0.97993124,0.00043453975,0.0076040355,0.000009774478],"about_ca_topic_score_codex":0.00015137659,"about_ca_topic_score_gemma":0.00021808708,"teacher_disagreement_score":0.0013069223,"about_ca_system_score_codex":0.00021930924,"about_ca_system_score_gemma":0.0002058256,"threshold_uncertainty_score":0.0043720603},"labels":[],"label_agreement":null},{"id":"W4313365647","doi":"10.4049/jimmunol.202.supp.71.3","title":"Optimization of human T cell activation and expansion protocols improves efficiency of genetic modification and overall cell yield","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Stemcell Technologies","funders":"","keywords":"Transfection; T cell; Cell biology; Cell; T-cell receptor; Cell culture; Cell growth; Molecular biology; Chemistry; Biology; Immunology; Biochemistry; Immune system; Genetics","score_opus":0.02783875306635918,"score_gpt":0.30995969897452896,"score_spread":0.2821209459081698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313365647","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7973772,0.0035450645,0.18535592,0.0003840247,0.00020266674,0.00083462213,0.0018549867,0.0019303043,0.008515082],"genre_scores_gemma":[0.8407396,0.0033499717,0.1403207,0.0002338793,0.000040154307,0.0007794757,0.0032181968,0.0009935473,0.010324466],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999318,0.00012836268,0.0000940351,0.00016569183,0.00021484448,0.00007921132],"domain_scores_gemma":[0.9996594,0.00010670797,0.00006928421,0.000051377043,0.00008355198,0.000029743596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011109224,0.00075931556,0.0003906463,0.00045322263,0.00023102929,0.0008767324,0.0004123753,0.00046189636,0.0030794425],"category_scores_gemma":[0.00070437876,0.00023578799,0.00038614072,0.00037560862,0.00026735506,0.00031217115,0.00041804538,0.0006077914,0.0018805608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007275883,0.000043331333,0.00018489012,0.00007278381,0.000008722167,0.00004745356,0.000042331158,0.0006384786,0.9938053,0.00015154325,0.00025801838,0.0046743695],"study_design_scores_gemma":[0.0000054817356,0.000073886506,0.00035148795,0.000008757349,0.000015101558,0.000069824906,0.000009067466,0.0009165269,0.99379116,0.000039877756,0.004711815,0.0000070687906],"about_ca_topic_score_codex":0.00049091515,"about_ca_topic_score_gemma":0.00075059646,"teacher_disagreement_score":0.0030794425,"about_ca_system_score_codex":0.00034143956,"about_ca_system_score_gemma":0.00033138477,"threshold_uncertainty_score":0.010301769},"labels":[],"label_agreement":null},{"id":"W4313369002","doi":"10.4049/jimmunol.204.supp.159.23","title":"Deep characterization of <i>in vitro</i> chronically stimulated T cells via single-cell multiomic analysis","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"CD28; Downregulation and upregulation; Effector; Cell; Transcriptome; Biology; Cell biology; In vitro; T cell; Flow cytometry; Stimulation; Molecular biology; Phenotype; Gene; Gene expression; Immunology; Genetics; Immune system; Neuroscience","score_opus":0.018544745343717157,"score_gpt":0.2646893594496181,"score_spread":0.2461446141059009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313369002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93946826,0.00060239277,0.05601263,0.00008969162,0.000023786999,0.00007418951,0.002156471,0.00029389965,0.0012787109],"genre_scores_gemma":[0.96566755,0.0005263636,0.029501954,0.00014856581,0.000018220822,0.0001812869,0.0023421417,0.0001132631,0.0015006583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999019,0.000010910218,0.000007831454,0.000029210569,0.000030059853,0.000020125606],"domain_scores_gemma":[0.9998871,0.000023049237,0.000024703308,0.000015962922,0.000031424875,0.000017762995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016148713,0.00028807204,0.00028300023,0.00036540325,0.00014571327,0.00047126715,0.00015331221,0.00023385894,0.0007608232],"category_scores_gemma":[0.00015621947,0.000117371754,0.00025284087,0.00028326397,0.00017788196,0.00024212523,0.00029819718,0.00042891907,0.00042279492],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024876199,0.000004106603,0.00041560386,0.000014654383,0.0000029013395,0.000015362833,0.00001006843,0.00012758514,0.9982712,0.000031681462,0.000021467233,0.001060491],"study_design_scores_gemma":[0.0000044962558,0.00017140206,0.019447228,0.000010085404,0.000032262826,0.00024209172,0.00006934727,0.009476891,0.96837574,0.0003160089,0.0018417067,0.000012887843],"about_ca_topic_score_codex":0.00020475178,"about_ca_topic_score_gemma":0.00032340502,"teacher_disagreement_score":0.0007608232,"about_ca_system_score_codex":0.00014490563,"about_ca_system_score_gemma":0.00014054979,"threshold_uncertainty_score":0.0025452375},"labels":[],"label_agreement":null},{"id":"W4313369028","doi":"10.4049/jimmunol.204.supp.153.16","title":"Robust serum-free expansion of human B cells with an animal component-free cell culture supplement","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Stemcell Technologies","funders":"","keywords":"Antibody; Biology; Population; Peripheral blood mononuclear cell; In vitro; Cell culture; Immunology; Cell; Andrology; Molecular biology; Biochemistry; Medicine; Genetics","score_opus":0.04059105518603894,"score_gpt":0.2878682473164423,"score_spread":0.24727719213040333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313369028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80992776,0.012796854,0.14990765,0.0007152158,0.0005192539,0.0013861118,0.0072622634,0.0018936148,0.015591254],"genre_scores_gemma":[0.84068865,0.0047793165,0.12260902,0.0004933109,0.00010171525,0.001482667,0.015678918,0.00029769598,0.01386869],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996375,0.00007816936,0.000046557907,0.000061342136,0.00014626147,0.000030225334],"domain_scores_gemma":[0.99977964,0.000046225337,0.000028253105,0.00004511803,0.00006952096,0.000031299474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005311876,0.00047646728,0.00038974,0.00038749017,0.00017480382,0.0005168959,0.0004620868,0.0004689517,0.001857119],"category_scores_gemma":[0.00038238722,0.00016388483,0.0003075659,0.000335389,0.00016152115,0.00014399695,0.00041832027,0.0006508339,0.0022535676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073776006,0.000044463548,0.0001731318,0.00008065433,0.000008071315,0.00006231063,0.0000418268,0.00014268924,0.9957118,0.00008686383,0.00044464227,0.0031297188],"study_design_scores_gemma":[0.000024530105,0.00028872717,0.0020290106,0.00006197307,0.00004550009,0.0004136003,0.000022376491,0.0011968344,0.96655166,0.000054638236,0.029298468,0.0000126954565],"about_ca_topic_score_codex":0.0010273844,"about_ca_topic_score_gemma":0.0013179109,"teacher_disagreement_score":0.001857119,"about_ca_system_score_codex":0.00023289303,"about_ca_system_score_gemma":0.0002489924,"threshold_uncertainty_score":0.0062127113},"labels":[],"label_agreement":null},{"id":"W4313373373","doi":"10.4049/jimmunol.204.supp.239.22","title":"Modulating extracellular TCR-CD3 interaction to identify new immunotherapy targets against cancer","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"T-cell receptor; CD3; T cell; Antigen; Biology; Cell biology; Signal transduction; Immune system; CD8; Molecular biology; Immunology","score_opus":0.05120867103629202,"score_gpt":0.36974372431066893,"score_spread":0.3185350532743769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313373373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852717,0.0020851106,0.009741801,0.00016799253,0.00003440144,0.000043806882,0.0002369427,0.00018850139,0.002229728],"genre_scores_gemma":[0.9936186,0.00045978243,0.0047323974,0.00007090338,0.0000062862123,0.000017140432,0.00017146424,0.000020886468,0.0009026234],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993074,0.000011467207,0.0000040511245,0.000012639191,0.000020797943,0.000020313464],"domain_scores_gemma":[0.9999695,0.0000052292157,0.000008949756,0.0000028264546,0.0000045271277,0.000008952983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009624851,0.00025136143,0.00024522495,0.00013494451,0.00010474875,0.00020086872,0.00014930543,0.00019571239,0.0017630871],"category_scores_gemma":[0.00007221411,0.0000789417,0.00012786656,0.00013012237,0.00009900374,0.0001289744,0.00016536444,0.00037484744,0.00045890396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004754774,0.000029874518,0.00014112053,0.000020003945,0.0000026350103,0.000019769572,0.0000030000094,0.00032093577,0.99734855,0.000081932674,0.000050957056,0.00193359],"study_design_scores_gemma":[0.000028863184,0.00021461339,0.0009328175,0.0000040077744,0.000017448003,0.00010558772,0.000009188334,0.003566336,0.9920781,0.000071057315,0.0029684585,0.0000034712984],"about_ca_topic_score_codex":0.00027725377,"about_ca_topic_score_gemma":0.00041417632,"teacher_disagreement_score":0.0017630871,"about_ca_system_score_codex":0.0002646907,"about_ca_system_score_gemma":0.00012973756,"threshold_uncertainty_score":0.0058980584},"labels":[],"label_agreement":null},{"id":"W4313381166","doi":"10.4049/jimmunol.202.supp.195.21","title":"CD73-dependent tumor resistance to agonistic anti-4-1BB therapy through TGF-β","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"CD137; Downregulation and upregulation; Effector; CD8; T cell; Immune system; Cancer research; Antigen; Antibody; Agonist; Immunotherapy; Immunology; Biology; Receptor; Biochemistry","score_opus":0.027851278586259666,"score_gpt":0.3216469051581989,"score_spread":0.2937956265719392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947536,0.0016039776,0.0012210043,0.0001463941,0.000041128194,0.00003758837,0.00008926025,0.00007546337,0.00203158],"genre_scores_gemma":[0.9975957,0.00038536827,0.0003216033,0.000036728266,0.000010093486,0.000019361267,0.00009838128,0.000005954708,0.0015266952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988437,0.000019857242,0.000006615833,0.000014491171,0.000028671977,0.000045822188],"domain_scores_gemma":[0.9999465,0.000010234831,0.000015165213,0.000007038343,0.0000065559284,0.000014543035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107017906,0.00023114386,0.00019793776,0.00014026475,0.00010616483,0.00025387644,0.00015650468,0.00019473216,0.0016108748],"category_scores_gemma":[0.00009003734,0.000075177486,0.000117136726,0.0000908425,0.00016563003,0.00012248581,0.00009405177,0.0007043291,0.00026589088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034391426,0.00018455093,0.0002676525,0.000036760215,0.0000066517864,0.000076372824,0.000014335994,0.00014774017,0.993602,0.00020338912,0.00015925146,0.0049573653],"study_design_scores_gemma":[0.00011188685,0.0019748204,0.0038532754,0.0000067481037,0.000038415397,0.00084343983,0.000026487809,0.0018747174,0.98615414,0.00013399778,0.004977577,0.000004359135],"about_ca_topic_score_codex":0.00046936425,"about_ca_topic_score_gemma":0.0005875903,"teacher_disagreement_score":0.0016108748,"about_ca_system_score_codex":0.00018308163,"about_ca_system_score_gemma":0.00024930693,"threshold_uncertainty_score":0.0053889155},"labels":[],"label_agreement":null},{"id":"W4313381876","doi":"10.4049/jimmunol.200.supp.174.38","title":"Fast and easy immunomagnetic isolation of untouched human naïve T cells in less than 15 minutes","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Antigen; Immunomagnetic separation; Leukapheresis; Antibody; Molecular biology; IL-2 receptor; T cell; Transplantation; Peripheral blood mononuclear cell; CD3; CD8; Chemistry; Biology; Immunology; Immune system; Cell biology; Medicine; In vitro; Biochemistry; Stem cell; CD34; Internal medicine","score_opus":0.026350125166852503,"score_gpt":0.2995187577404267,"score_spread":0.2731686325735742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381876","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45560142,0.011700022,0.5004311,0.00058996346,0.0014044408,0.0045334217,0.0065772887,0.0028891966,0.016272988],"genre_scores_gemma":[0.59341043,0.0048223697,0.3513566,0.0008552034,0.0005046562,0.004960612,0.013971082,0.00054056785,0.029578473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994524,0.00006960911,0.00006169266,0.00012667802,0.00021896137,0.00007054917],"domain_scores_gemma":[0.99981683,0.00004876036,0.000013950399,0.000043609576,0.000051712243,0.000025177262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003411145,0.0007600804,0.0005112053,0.00033884877,0.00031675867,0.00045295054,0.0005222355,0.00035557995,0.0036634423],"category_scores_gemma":[0.00041953794,0.00025221918,0.00034147306,0.00024052522,0.00018373376,0.00020485975,0.0004688641,0.0007458946,0.003702203],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011927669,0.000045015513,0.00018150234,0.00005824241,0.0000063577145,0.00004738896,0.000027287986,0.000069452624,0.99058014,0.00010094606,0.00060405885,0.0081602335],"study_design_scores_gemma":[0.00011790141,0.0007936536,0.0061046546,0.000040392708,0.00005444834,0.0005272553,0.000037495996,0.0024555733,0.95930916,0.0003046161,0.030228771,0.000026057267],"about_ca_topic_score_codex":0.00050289003,"about_ca_topic_score_gemma":0.0012529686,"teacher_disagreement_score":0.0036634423,"about_ca_system_score_codex":0.00012821917,"about_ca_system_score_gemma":0.00027529354,"threshold_uncertainty_score":0.01225549},"labels":[],"label_agreement":null},{"id":"W4313383005","doi":"10.4049/jimmunol.202.supp.134.16","title":"Ex Vivo Phenotyping and Potency Monitoring of CD19 CAR T Cells With a combined Flow Cytometry and Impedance-based Real-Time Cell Analysis Workflow","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"CD19; T cell; Flow cytometry; CD8; Antigen; Immunophenotyping; Molecular biology; CD28; HEK 293 cells; Ex vivo; Cytotoxic T cell; Biology; Immunology; Cancer research; Chemistry; Immune system; Receptor; In vitro; Biochemistry","score_opus":0.00887441052586603,"score_gpt":0.25225519664789686,"score_spread":0.24338078612203085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313383005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82633865,0.00078256044,0.16759108,0.00011989033,0.00005346723,0.0001954553,0.0018070163,0.0014074391,0.0017044387],"genre_scores_gemma":[0.90088946,0.0007074146,0.09237074,0.00012009559,0.000038315226,0.00051629747,0.0014622528,0.000146964,0.0037484737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994698,0.00006409282,0.000045889108,0.000166224,0.00019325214,0.000060762646],"domain_scores_gemma":[0.99969125,0.00007001661,0.00007317168,0.000041272233,0.000098785866,0.00002555776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043459152,0.00050219713,0.00039044526,0.00062256743,0.0001307678,0.00058980717,0.0003037407,0.0004074803,0.0015317898],"category_scores_gemma":[0.00030925748,0.00017331263,0.00027501548,0.0003464365,0.00018942513,0.00034811872,0.0002814316,0.00050769973,0.00066120067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007472986,0.000029293084,0.0006459129,0.000023776416,0.000004475691,0.000015729645,0.000023367871,0.0002506112,0.99551255,0.00004031527,0.0000467429,0.0033323872],"study_design_scores_gemma":[0.000004593841,0.00015256938,0.002264747,0.00000300597,0.000012868911,0.00006475294,0.000014003845,0.00743595,0.98938924,0.00005858817,0.00059041777,0.000009299667],"about_ca_topic_score_codex":0.0002003662,"about_ca_topic_score_gemma":0.00020980225,"teacher_disagreement_score":0.0015317898,"about_ca_system_score_codex":0.00023329795,"about_ca_system_score_gemma":0.00014823428,"threshold_uncertainty_score":0.0051243305},"labels":[],"label_agreement":null},{"id":"W4313383207","doi":"10.4049/jimmunol.204.supp.165.35","title":"CD28 and glycogen synthase kinase-3 (GSK-3) inhibitor combination therapy generates tumor infiltrating T-cells (TILs) with a reversal of markers for T-cell exhaustion","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD28; GSK-3; Cancer research; CD8; Immunotherapy; Immune checkpoint; T cell; Biology; Chemistry; Immune system; Kinase; Immunology; Biochemistry","score_opus":0.023303757006828945,"score_gpt":0.26703558174669445,"score_spread":0.24373182473986552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313383207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945253,0.0007126266,0.0011621834,0.00022230433,0.000113429276,0.000098424054,0.00032162038,0.00019348942,0.002650555],"genre_scores_gemma":[0.9965863,0.00028921477,0.0008388156,0.00007357551,0.000022632603,0.00006855206,0.00020914627,0.000014244694,0.0018973456],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998605,0.000020559428,0.000010272066,0.000022565006,0.00004214753,0.000043945063],"domain_scores_gemma":[0.9999198,0.000008836802,0.00002120761,0.000008745369,0.0000036854879,0.00003767129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011353983,0.0003930366,0.00051310455,0.00028970616,0.000087397835,0.00024490882,0.00016158787,0.00023361135,0.0014108724],"category_scores_gemma":[0.00006851617,0.00013110679,0.0003087331,0.00013007957,0.0002520348,0.00014298595,0.0001491597,0.001125816,0.0004217146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018009932,0.0008030648,0.0002785407,0.00007518157,0.000027459955,0.00010600511,0.000025448991,0.0007529692,0.9854124,0.00022320774,0.0006331732,0.009861554],"study_design_scores_gemma":[0.0012172911,0.019752359,0.0055656573,0.000020194746,0.00009526327,0.0006813768,0.000041933006,0.0037662983,0.96284884,0.00024113161,0.005752199,0.000017427265],"about_ca_topic_score_codex":0.00033642896,"about_ca_topic_score_gemma":0.0008103804,"teacher_disagreement_score":0.0014108724,"about_ca_system_score_codex":0.00020443418,"about_ca_system_score_gemma":0.00027424516,"threshold_uncertainty_score":0.0047198534},"labels":[],"label_agreement":null},{"id":"W4313388441","doi":"10.4049/jimmunol.178.supp.b151","title":"Interleukin-12 initiates an immune response that leads to tumour rejection (B151)","year":2007,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Immune system; Immunotherapy; Immunology; CD8; Cancer research; Biology; Cancer immunotherapy; T cell; Tumor microenvironment; Interleukin 15; Acquired immune system; Cytotoxic T cell; Cytokine; Interleukin","score_opus":0.045586214021727856,"score_gpt":0.34862286851025076,"score_spread":0.3030366544885229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313388441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886905,0.0012282755,0.004710345,0.0001951599,0.00008917025,0.000050339742,0.00016555535,0.00016757414,0.004702977],"genre_scores_gemma":[0.99457043,0.0003082353,0.001178266,0.00009545461,0.000016389335,0.0000284436,0.00015016388,0.000017361574,0.0036352712],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998202,0.000040818024,0.000013390934,0.000025179028,0.00003767009,0.000062841435],"domain_scores_gemma":[0.9998895,0.00002090853,0.000028658402,0.000010905152,0.0000101476635,0.000039919643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019342349,0.00035460872,0.00018140391,0.00023113702,0.000119041404,0.00034810326,0.0000925168,0.00040462342,0.0034816372],"category_scores_gemma":[0.0001184648,0.00010258646,0.00024882983,0.00007734241,0.00021841632,0.00013010326,0.00021206625,0.0007701618,0.0011622172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021897788,0.000063494525,0.00025284872,0.00003434071,0.000004972066,0.0000977264,0.0000132892355,0.000060431954,0.99733007,0.00044601414,0.00011176502,0.0013660293],"study_design_scores_gemma":[0.00014891593,0.0012888314,0.0033774578,0.000020552308,0.000019806812,0.0011686656,0.0000495705,0.0016458925,0.985113,0.00035756975,0.0068044197,0.0000052353057],"about_ca_topic_score_codex":0.00020759093,"about_ca_topic_score_gemma":0.0001794852,"teacher_disagreement_score":0.0034816372,"about_ca_system_score_codex":0.00021049734,"about_ca_system_score_gemma":0.00012506174,"threshold_uncertainty_score":0.011647224},"labels":[],"label_agreement":null},{"id":"W4313389535","doi":"10.3389/fimmu.2022.1074740","title":"CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Terry Fox Research Institute; Vancouver General Hospital; University of British Columbia; Simon Fraser University; Ottawa Hospital","funders":"Ottawa Hospital Foundation; BC Cancer Foundation","keywords":"Medicine; Fludarabine; Cytokine release syndrome; CD34; Cyclophosphamide; CD19; Internal medicine; Lymphoma; Gastroenterology; Oncology; Immunology; Cancer; Antigen; Chimeric antigen receptor; Stem cell; Immunotherapy; Chemotherapy; Biology","score_opus":0.007283874523590764,"score_gpt":0.23820834050241368,"score_spread":0.23092446597882293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313389535","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670954,0.00093769433,0.0037699346,0.00013223363,0.000026192836,0.0027800563,0.0010952115,0.0002178279,0.004331129],"genre_scores_gemma":[0.99013937,0.00034788708,0.0043355227,0.00019568556,0.00003443113,0.0008407018,0.0011838283,0.000041669777,0.0028808485],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942267,0.00014904393,0.000023831888,0.0001252787,0.00018770077,0.00009154124],"domain_scores_gemma":[0.99947006,0.0000927357,0.000112450165,0.00010056214,0.00007031901,0.00015385001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011597316,0.0002465723,0.00025458398,0.0003060983,0.0006190499,0.0007321464,0.00085127476,0.00046755993,0.0059500025],"category_scores_gemma":[0.000928495,0.00020897771,0.00018614304,0.00030117345,0.00063361134,0.00024893164,0.0003999782,0.00061684835,0.0014706643],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046020493,0.011856475,0.06412653,0.00081790093,0.00013347619,0.001436038,0.0023978036,0.0021537181,0.5269035,0.0010775544,0.00975347,0.33332303],"study_design_scores_gemma":[0.018142456,0.20270872,0.26322076,0.00018697444,0.0004189685,0.0065649142,0.001482136,0.005032529,0.3790023,0.00038173425,0.122730434,0.00012813241],"about_ca_topic_score_codex":0.016235687,"about_ca_topic_score_gemma":0.027091453,"teacher_disagreement_score":0.016235687,"about_ca_system_score_codex":0.0019117594,"about_ca_system_score_gemma":0.0025754403,"threshold_uncertainty_score":0.032282352},"labels":[],"label_agreement":null},{"id":"W4313405848","doi":"10.4049/jimmunol.208.supp.117.15","title":"CD28: A roadblock to designing long-lasting CARs?","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; CD28; CD86; Medicine; CD80; T cell; Immunology; Cancer research; Biology; Cytotoxic T cell; In vitro; Immune system; CD40; Genetics","score_opus":0.0373835636982445,"score_gpt":0.3178649326347742,"score_spread":0.28048136893652975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313405848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48492488,0.14206246,0.30359352,0.034396112,0.0026211573,0.0008084447,0.00084214873,0.0017257578,0.029025497],"genre_scores_gemma":[0.881078,0.028519988,0.066804364,0.0044983355,0.00036380268,0.0006648387,0.00050203764,0.00016714164,0.017401442],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9997632,0.00007151091,0.000014776208,0.000043732427,0.000056135235,0.000050669918],"domain_scores_gemma":[0.9997092,0.000082148224,0.00003870081,0.000027163183,0.00007946042,0.00006328266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072831096,0.00035018963,0.00032624972,0.00013055737,0.00019105693,0.00060527213,0.00047784363,0.0008611193,0.0036122634],"category_scores_gemma":[0.0006952927,0.00016849459,0.00023199964,0.00010273165,0.00038734297,0.00089269766,0.00047864753,0.0016873828,0.0018540659],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051277597,0.00049726997,0.0008644839,0.0013306227,0.00007577037,0.00045133304,0.00022480247,0.005503839,0.79280615,0.03555342,0.014752325,0.14742719],"study_design_scores_gemma":[0.00024960347,0.0030356455,0.0010946373,0.00024037508,0.00009039134,0.0010926151,0.00022515285,0.014069045,0.6851913,0.021999469,0.27265078,0.000060940187],"about_ca_topic_score_codex":0.0003377285,"about_ca_topic_score_gemma":0.00041845592,"teacher_disagreement_score":0.0036122634,"about_ca_system_score_codex":0.0006099272,"about_ca_system_score_gemma":0.00035770118,"threshold_uncertainty_score":0.012084186},"labels":[],"label_agreement":null},{"id":"W4313405910","doi":"10.4049/jimmunol.208.supp.121.13","title":"Sushi domain containing 2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Effector; CD8; T cell; Cytotoxic T cell; Cell biology; Biology; Cancer immunotherapy; Chimeric antigen receptor; CD19; Cytokine; Tumor microenvironment; Cancer research; Adoptive cell transfer; Immunotherapy; Immune system; Immunology; Biochemistry","score_opus":0.017446326755908147,"score_gpt":0.2807663160608957,"score_spread":0.26331998930498757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313405910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99632496,0.00087719236,0.0012193887,0.00014367451,0.000047788366,0.0000209838,0.0002532589,0.00009802769,0.0010147889],"genre_scores_gemma":[0.9971148,0.00023883088,0.00090970536,0.00006347736,0.000018666564,0.000023530547,0.00031629181,0.000010884072,0.0013037777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984145,0.00004145948,0.000014560699,0.000020631178,0.000043441578,0.00003853838],"domain_scores_gemma":[0.99988115,0.000022121585,0.000031529573,0.000015775035,0.000006532235,0.000042798383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014871293,0.00039003123,0.00026637857,0.000183871,0.00011855792,0.0002619577,0.00016966004,0.00025275772,0.0012421865],"category_scores_gemma":[0.000096037,0.00011311987,0.00014068777,0.0000944319,0.00025985896,0.00012937015,0.00013586872,0.0006813296,0.00030279552],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015203681,0.000054546912,0.0001354103,0.000018632638,0.0000036223817,0.00003082685,0.000003278406,0.000050315706,0.9989446,0.000057470723,0.00006601989,0.00048331553],"study_design_scores_gemma":[0.00007268535,0.0008931302,0.003184932,0.0000040798395,0.00001496836,0.00035654142,0.000019960107,0.0018426839,0.9908077,0.000046939927,0.0027523416,0.000004045265],"about_ca_topic_score_codex":0.00012917908,"about_ca_topic_score_gemma":0.0002495671,"teacher_disagreement_score":0.0012421865,"about_ca_system_score_codex":0.00015640324,"about_ca_system_score_gemma":0.00015378746,"threshold_uncertainty_score":0.0041555166},"labels":[],"label_agreement":null},{"id":"W4313423565","doi":"10.4049/jimmunol.208.supp.66.10","title":"Sex differences in the pre-treatment cytokine signatures associated with response and survival in B cell lymphoma patients treated with anti-CD19 CAR T-cell therapy","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Internal medicine; Lymphoma; Cytokine; CD19; Oncology; Chemokine; Immunology; Immune system; Lactate dehydrogenase; Biology","score_opus":0.015642742634212944,"score_gpt":0.2561343330318531,"score_spread":0.24049159039764018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313423565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980556,0.0009591209,0.00009353338,0.000048674556,0.000013277019,0.000008154094,0.00022429727,0.000004345355,0.00059302105],"genre_scores_gemma":[0.9993549,0.00011525912,0.00004065629,0.000046361693,0.000014657356,0.0000082232555,0.00014293079,0.0000020053988,0.0002749834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99984014,0.000031954794,0.000013481025,0.000029135985,0.00003388829,0.00005140363],"domain_scores_gemma":[0.9996704,0.00006360141,0.0001520588,0.000015920972,0.00003599873,0.00006204631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000173995,0.0001196126,0.00030712085,0.0002711466,0.000119224525,0.00033316758,0.00007330704,0.00017299976,0.0016651368],"category_scores_gemma":[0.00054282666,0.00005976293,0.00015448441,0.0002773791,0.00010651446,0.00013856225,0.00011678719,0.00026920516,0.00029035786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050049606,0.0001830996,0.948917,0.000049838105,0.00010694976,0.00044677974,0.00015787152,0.00015022643,0.020361666,0.000049467664,0.00040083012,0.024171408],"study_design_scores_gemma":[0.000030860134,0.0011664538,0.99537694,0.000009343527,0.00004414195,0.00063094683,0.00012680775,0.00020447015,0.0014712139,0.00004257569,0.0008906644,0.0000054928496],"about_ca_topic_score_codex":0.000227125,"about_ca_topic_score_gemma":0.00033908724,"teacher_disagreement_score":0.0016651368,"about_ca_system_score_codex":0.00014443012,"about_ca_system_score_gemma":0.00011033623,"threshold_uncertainty_score":0.0055704713},"labels":[],"label_agreement":null},{"id":"W4313430064","doi":"10.4049/jimmunol.208.supp.122.22","title":"Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Avidity; Hepatocellular carcinoma; Cancer research; Monoclonal antibody; In vivo; Antigen; Epitope; In vitro; Apoptosis; Antibody; Immunology; Biology; Biochemistry","score_opus":0.021495530233803357,"score_gpt":0.25363454232783395,"score_spread":0.2321390120940306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313430064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977717,0.00044820807,0.0009101519,0.00004138471,0.0000118481,0.000023624367,0.00008815427,0.00005289854,0.0006519709],"genre_scores_gemma":[0.99698216,0.00022114982,0.0011752478,0.00006724605,0.000009541266,0.000029550938,0.00024420363,0.0000085563415,0.0012623621],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993026,0.000011080293,0.0000043845207,0.000010366622,0.000014357054,0.000029593753],"domain_scores_gemma":[0.9999491,0.000008438111,0.000011612898,0.000005961707,0.000007395509,0.000017539367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006805481,0.0002998781,0.0001601379,0.00010930254,0.000081854356,0.00015066924,0.00018024133,0.0002052649,0.0008145661],"category_scores_gemma":[0.00007404425,0.000070200695,0.00014491806,0.00006489869,0.00008502563,0.00011476221,0.00009362583,0.00045515207,0.0002426776],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012751948,0.00010322254,0.00023075232,0.00003183123,0.0000074540126,0.000042409094,0.000011439818,0.00024077034,0.99524105,0.00008357877,0.00016203219,0.0037178777],"study_design_scores_gemma":[0.00013846037,0.0028082982,0.0069267265,0.000009391001,0.000058829657,0.0005652386,0.000030439816,0.0038487962,0.9798687,0.000073320065,0.0056614685,0.000010331855],"about_ca_topic_score_codex":0.00037582856,"about_ca_topic_score_gemma":0.0005157765,"teacher_disagreement_score":0.0008145661,"about_ca_system_score_codex":0.0002196298,"about_ca_system_score_gemma":0.00012284888,"threshold_uncertainty_score":0.0027249455},"labels":[],"label_agreement":null},{"id":"W4313430181","doi":"10.4049/jimmunol.208.supp.173.06","title":"Quick and Easy Isolation of Immune Cells From Large-Volume Samples","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Stemcell Technologies","funders":"","keywords":"Cell; Lysis; Chromatography; Cell culture; Isolation (microbiology); CD8; T cell; Chemistry; Antigen; Biology; Immune system; Immunology; Bioinformatics; Biochemistry","score_opus":0.02122845244858797,"score_gpt":0.28193452933073737,"score_spread":0.2607060768821494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313430181","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20278108,0.010725895,0.75245845,0.0012144108,0.001251587,0.0031218615,0.005397806,0.004869106,0.018179791],"genre_scores_gemma":[0.34126762,0.006374511,0.6108033,0.001736208,0.00054279534,0.0029329387,0.013251866,0.0009137881,0.022176879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991736,0.00012834951,0.0000906083,0.00016829316,0.00034355774,0.00009563921],"domain_scores_gemma":[0.99951875,0.00011457558,0.000060887844,0.000076556265,0.0001486147,0.0000807113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084651774,0.0009191731,0.0004721579,0.0010844287,0.00044795655,0.0010361356,0.00073943345,0.00053191767,0.004189827],"category_scores_gemma":[0.00067652564,0.00032136973,0.0004639319,0.00036026997,0.00040429085,0.00053911726,0.0011571777,0.0013638216,0.0061133],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006817001,0.00005503513,0.00057737075,0.00017017128,0.000013127006,0.00008649089,0.000038669794,0.00011644327,0.9758389,0.00046299674,0.0021107646,0.020461863],"study_design_scores_gemma":[0.00009018566,0.0004048519,0.0067147957,0.00011075922,0.00005722237,0.0010240452,0.0000723404,0.00222769,0.9353354,0.0011337515,0.052788317,0.00004055747],"about_ca_topic_score_codex":0.000298202,"about_ca_topic_score_gemma":0.00081630825,"teacher_disagreement_score":0.004189827,"about_ca_system_score_codex":0.00019763508,"about_ca_system_score_gemma":0.0005305467,"threshold_uncertainty_score":0.01401633},"labels":[],"label_agreement":null},{"id":"W4313562093","doi":"10.1007/978-3-030-80962-1_188-1","title":"Targeting CAR T Cells’ Metabolic Pathways to Boost Their Effectiveness Against Tumors","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Tumor microenvironment; Cancer research; Biology; T cell; Reprogramming; Effector; Antigen; Metabolic pathway; Cell biology; Metabolism; Immune system; Tumor cells; Cell; Immunology; Biochemistry","score_opus":0.040327275887623984,"score_gpt":0.27968821890623513,"score_spread":0.23936094301861116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313562093","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009748329,0.13056745,0.070449375,0.005405591,0.0046968525,0.0001445494,0.00070457935,0.001190107,0.7770931],"genre_scores_gemma":[0.03343991,0.06846302,0.020228304,0.002575393,0.0005288059,0.00011868281,0.00039822538,0.00032292854,0.87392473],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9999585,0.0000040617206,0.0000010347757,0.000007662761,0.000021883849,0.0000067247342],"domain_scores_gemma":[0.9999764,0.000009939876,0.0000015593293,0.00000210972,0.0000065916593,0.0000034790303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013026626,0.00048328395,0.00022347836,0.00039630345,0.0002172333,0.0010028817,0.00035198868,0.00048282882,0.025254207],"category_scores_gemma":[0.00009953478,0.00019027322,0.00022424442,0.0002931053,0.00027054854,0.0009576671,0.0003825387,0.0014053951,0.010930005],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012220445,0.00015902906,0.000070629525,0.0007779271,0.00001845015,0.00014707126,0.00013450197,0.0021936647,0.1260555,0.16534218,0.15596628,0.5490126],"study_design_scores_gemma":[0.000010751846,0.000055439345,0.000080256475,0.000079857025,0.0000086707905,0.00021691476,0.000027920129,0.0007976124,0.03136621,0.012109298,0.95523876,0.000008207478],"about_ca_topic_score_codex":0.0005567958,"about_ca_topic_score_gemma":0.0012952763,"teacher_disagreement_score":0.025254207,"about_ca_system_score_codex":0.0005950607,"about_ca_system_score_gemma":0.0003148144,"threshold_uncertainty_score":0.0844838},"labels":[],"label_agreement":null},{"id":"W4313887581","doi":"10.1016/j.jtct.2023.01.004","title":"Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Health Resources and Services Administration; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; Medac; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Anxiety; Family medicine; Health care; Psychology; Psychiatry","score_opus":0.2083465041368138,"score_gpt":0.38663325994693726,"score_spread":0.17828675581012346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313887581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8982477,0.0014167764,0.056786794,0.012804984,0.00041166088,0.006226716,0.0020208692,0.00014895377,0.021935612],"genre_scores_gemma":[0.9611932,0.0010412156,0.021389024,0.0026196446,0.000074417745,0.008656482,0.0004360642,0.000072016264,0.004518019],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.96038693,0.033896066,0.000981606,0.0010967245,0.00109165,0.0025470855],"domain_scores_gemma":[0.93541574,0.05416581,0.0026073486,0.0014553716,0.0042515686,0.0021042656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.035552505,0.001176274,0.0007740536,0.002045212,0.0081197,0.0035196103,0.0021118664,0.0025251147,0.0049289004],"category_scores_gemma":[0.038026065,0.00069915655,0.0005948645,0.0021128464,0.008689144,0.0049530948,0.007755177,0.004175779,0.00075272744],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006204782,0.000044206554,0.000845344,0.00026300838,0.0000037158525,0.00043122098,0.9896651,0.0001060796,0.00094229996,0.0019673738,0.0009995209,0.004670076],"study_design_scores_gemma":[0.000020350297,0.00006170498,0.0006820427,0.0002677264,0.0000037228303,0.00015148874,0.98332536,0.00032886374,0.00053766364,0.0017691804,0.012833151,0.000018840146],"about_ca_topic_score_codex":0.0047092596,"about_ca_topic_score_gemma":0.007233863,"teacher_disagreement_score":0.035552505,"about_ca_system_score_codex":0.0063807373,"about_ca_system_score_gemma":0.0061229956,"threshold_uncertainty_score":0.18802184},"labels":[],"label_agreement":null},{"id":"W4313893438","doi":"10.1038/s41591-022-02128-z","title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Oncology; Cancer; Antigen; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Immunotherapy; Melanoma; Clinical trial; Gastroenterology; Phases of clinical research; Immunology; Cancer research","score_opus":0.033600660203183974,"score_gpt":0.41502600831845066,"score_spread":0.3814253481152667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313893438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941267,0.0018022588,0.0005658593,0.0003748057,0.000083735955,0.0014085909,0.00047489695,0.00005952215,0.0011035647],"genre_scores_gemma":[0.99004,0.0016676661,0.001773443,0.0008247504,0.0001395485,0.0022949541,0.0010919344,0.000021585773,0.0021462622],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999744,0.0001285344,0.000011170282,0.000041126397,0.000023042949,0.000052189032],"domain_scores_gemma":[0.9997317,0.000055218527,0.000054918128,0.0000215303,0.00001999936,0.00011656487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011858416,0.0010880294,0.0010117906,0.00021011136,0.0002475652,0.00067919435,0.00049623643,0.0009530422,0.0023091775],"category_scores_gemma":[0.00053164625,0.00025955983,0.0006577182,0.00022370668,0.00046121576,0.0004982589,0.00023147774,0.0018858147,0.0005091303],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5133145,0.089133345,0.007679853,0.0015731322,0.0011159409,0.00078897475,0.0005632687,0.0076773446,0.13355578,0.00096354,0.009661443,0.23397294],"study_design_scores_gemma":[0.4451798,0.5346681,0.005440606,0.000043409207,0.00023947877,0.0005472499,0.00005074547,0.0024789767,0.006491739,0.00040490014,0.0044328766,0.000022050637],"about_ca_topic_score_codex":0.00034096724,"about_ca_topic_score_gemma":0.00061033544,"teacher_disagreement_score":0.0023091775,"about_ca_system_score_codex":0.0005076929,"about_ca_system_score_gemma":0.0008173963,"threshold_uncertainty_score":0.007724941},"labels":[],"label_agreement":null},{"id":"W4313906308","doi":"10.35493/medu.39.22","title":"CARs on the road: Who gets a seat?","year":2021,"lang":"en","type":"article","venue":"The Meducator","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Medicine; Cancer research; Oncology; Immunology; Immune system","score_opus":0.04646088158447804,"score_gpt":0.34686494150690766,"score_spread":0.30040405992242963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313906308","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002519039,0.79411465,0.0014045335,0.16202737,0.010064498,0.000030017465,0.00009262427,0.000072472496,0.029674789],"genre_scores_gemma":[0.025561556,0.8857482,0.0014418996,0.0413502,0.005619279,0.00004060513,0.0001504088,0.000046468715,0.040041313],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99906534,0.0003411609,0.000049356102,0.00013299029,0.00025866987,0.00015260081],"domain_scores_gemma":[0.9992835,0.00023091598,0.000064335974,0.000018684164,0.0002856889,0.00011696038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016220085,0.0004967192,0.0007274578,0.00080629415,0.0017291248,0.0041095526,0.0007272145,0.0034791946,0.013289847],"category_scores_gemma":[0.0023600894,0.00022618967,0.0004284077,0.00083568454,0.0020335924,0.0064465934,0.0012834662,0.0043218085,0.00702455],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018075602,0.00009409822,0.0013398315,0.0025425607,0.000038547292,0.0005652722,0.0012184858,0.00014597765,0.0016038925,0.033018764,0.2750113,0.68424046],"study_design_scores_gemma":[0.0000064501533,0.00007605964,0.00042704144,0.0011357977,0.000019708837,0.0007161593,0.0022248384,0.00003830089,0.00049540197,0.0050680027,0.98977286,0.000019511332],"about_ca_topic_score_codex":0.0040518874,"about_ca_topic_score_gemma":0.007132857,"teacher_disagreement_score":0.013289847,"about_ca_system_score_codex":0.0017155601,"about_ca_system_score_gemma":0.0026835278,"threshold_uncertainty_score":0.044458926},"labels":[],"label_agreement":null},{"id":"W4315864638","doi":"10.3390/curroncol30010087","title":"Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"clone (Java method); Cytopenia; Medicine; Context (archaeology); Karyotype; CD19; Somatic evolution in cancer; Lymphoma; Oncology; Cancer research; Immunology; Internal medicine; Biology; Genetics; Gene; Cancer; Bone marrow; Chromosome; Flow cytometry","score_opus":0.12223144844620364,"score_gpt":0.45520251926029737,"score_spread":0.3329710708140937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315864638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909787,0.0014433849,0.0016257517,0.00075569993,0.00005989554,0.000049731585,0.00011190024,0.00015389234,0.0048209876],"genre_scores_gemma":[0.9984864,0.00028374325,0.00028970902,0.00024387384,0.00006179442,0.0000067683322,0.00005715218,0.000010188668,0.00056041876],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998542,0.00003146012,0.000010993251,0.000024940891,0.00002635017,0.000052120122],"domain_scores_gemma":[0.99940085,0.00019374903,0.000103775536,0.00006121887,0.000029651064,0.00021080112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019975539,0.00046594001,0.00039777657,0.0004170752,0.0006226929,0.0004883017,0.0003095442,0.0014371353,0.0009695556],"category_scores_gemma":[0.0009143536,0.00018720406,0.00032328357,0.00022692845,0.00046611347,0.00027698244,0.00045318247,0.0011556101,0.00040976508],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034838522,0.00008185351,0.012469119,0.0000402433,0.00001963937,0.9664609,0.00019398621,0.000521678,0.012334879,0.00046939295,0.00051576755,0.006544083],"study_design_scores_gemma":[0.00008263385,0.0007277624,0.014994771,0.000019049627,0.000041706695,0.9684955,0.00007009607,0.0028646202,0.00991003,0.0005334228,0.002246089,0.000014352381],"about_ca_topic_score_codex":0.00073441677,"about_ca_topic_score_gemma":0.0009108485,"teacher_disagreement_score":0.0014371353,"about_ca_system_score_codex":0.0005555384,"about_ca_system_score_gemma":0.00023695562,"threshold_uncertainty_score":0.004030764},"labels":[],"label_agreement":null},{"id":"W4316925850","doi":"10.1007/s12032-022-01930-6","title":"RETRACTED ARTICLE: Molecular and therapeutic effect of CRISPR in treating cancer","year":2023,"lang":"en","type":"review","venue":"Medical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"CRISPR; Genome editing; Biology; Epigenetics; Gene; Cancer; Genome; Computational biology; DNA repair; Genetics; Cancer cell; Cancer research","score_opus":0.07365655161423457,"score_gpt":0.4941140225092025,"score_spread":0.42045747089496793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316925850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00082355936,0.7637119,0.0011927007,0.019901516,0.2002711,0.000058352896,0.00032692033,0.00015207035,0.013561783],"genre_scores_gemma":[0.005446935,0.8729063,0.0011134542,0.023374181,0.04952928,0.000049896604,0.00061037985,0.0000797049,0.046889782],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994529,0.00007946756,0.00007492683,0.000077913355,0.0002281989,0.000086610315],"domain_scores_gemma":[0.99884135,0.00031978864,0.000099010926,0.000029642717,0.00053128373,0.00017894263],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010176688,0.00094277854,0.0010101276,0.0016720649,0.00059976993,0.0013846112,0.0015450007,0.0032862832,0.016402641],"category_scores_gemma":[0.0028226075,0.00022189085,0.00078848714,0.0013551571,0.0006815146,0.0018618203,0.0011651547,0.0035477083,0.008830721],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016012478,0.00005213066,0.00014233211,0.0060419915,0.000056960023,0.0007815444,0.00008023326,0.00022710794,0.0022891513,0.003139814,0.60649025,0.38053837],"study_design_scores_gemma":[0.00001849387,0.00007715854,0.00022320922,0.0008270076,0.000042470056,0.0015325497,0.000026705156,0.000054267523,0.0007342263,0.00062817306,0.9958223,0.000013423779],"about_ca_topic_score_codex":0.0010853466,"about_ca_topic_score_gemma":0.0018488228,"teacher_disagreement_score":0.9967137,"about_ca_system_score_codex":0.00075707433,"about_ca_system_score_gemma":0.0013516073,"threshold_uncertainty_score":0.054872274},"labels":[],"label_agreement":null},{"id":"W4317372334","doi":"10.1186/s13643-022-02158-1","title":"Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Meta-analysis; Chimeric antigen receptor; Clinical trial; MEDLINE; Systematic review; Oncology; Intensive care medicine; Internal medicine; Immunotherapy; Cancer","score_opus":0.5115059957136703,"score_gpt":0.5026597038941844,"score_spread":0.00884629181948593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317372334","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051963255,0.036169287,0.012221561,0.0015966672,0.00073116197,0.9155749,0.02613939,0.0005848415,0.001785985],"genre_scores_gemma":[0.007404853,0.0051969877,0.007370123,0.0005943844,0.00004729872,0.9764206,0.0023066895,0.000036724876,0.0006223217],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9688761,0.017437207,0.006635174,0.0035214417,0.002448469,0.0010816028],"domain_scores_gemma":[0.97389245,0.012911393,0.0055341413,0.00294114,0.003983702,0.00073711603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.058752,0.0056268596,0.022579487,0.010058249,0.0016875016,0.0051045236,0.005559341,0.006381723,0.033906005],"category_scores_gemma":[0.079828374,0.0041217757,0.035761174,0.008231834,0.0026882845,0.004439224,0.004031511,0.004275727,0.0035969731],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009016699,0.00014451599,0.001889964,0.871109,0.087902464,0.00028739506,0.00045901802,0.0019735417,0.0005387563,0.0018939181,0.0105062965,0.014278468],"study_design_scores_gemma":[0.060794745,0.0026995428,0.011326152,0.25865299,0.57354355,0.00050366233,0.000665061,0.0057982793,0.0018765053,0.0106973965,0.07285824,0.0005839106],"about_ca_topic_score_codex":0.0066178753,"about_ca_topic_score_gemma":0.009352059,"teacher_disagreement_score":0.058752,"about_ca_system_score_codex":0.007861481,"about_ca_system_score_gemma":0.02247539,"threshold_uncertainty_score":0.310714},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4317863112","doi":"10.1200/jco.2023.41.4_suppl.349","title":"Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Internal medicine; Cancer; Gastroenterology; Oncology; Esophageal cancer; Adverse effect; Antigen; Immunology","score_opus":0.14423713882392886,"score_gpt":0.4446103898628588,"score_spread":0.3003732510389299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98924047,0.0024818769,0.00048656928,0.0004910713,0.000083464605,0.0006923007,0.0027211206,0.00008777625,0.0037152753],"genre_scores_gemma":[0.98342437,0.0017045012,0.00077420566,0.0011047444,0.00012021779,0.0007166968,0.0076348716,0.00003777867,0.0044826074],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99963915,0.00015910101,0.000016824099,0.00007300532,0.000046644738,0.00006527557],"domain_scores_gemma":[0.999522,0.00009634269,0.00010807985,0.000045261528,0.000027258357,0.0002010815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011068955,0.0009283021,0.0008127406,0.00022430085,0.00024987423,0.0012077234,0.00040505832,0.0009401499,0.004390635],"category_scores_gemma":[0.0007248112,0.00027637125,0.0008629411,0.00019637466,0.00043311325,0.00087391876,0.00034536544,0.001907426,0.00073390425],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68474036,0.023741603,0.018079806,0.0014052718,0.0024611526,0.0005645146,0.0004722563,0.0069919173,0.055753812,0.001347052,0.019660866,0.18478131],"study_design_scores_gemma":[0.33646542,0.5697284,0.049919557,0.00012719045,0.0018591247,0.0019095349,0.00018992374,0.004595454,0.012743668,0.0014773844,0.020888533,0.00009578322],"about_ca_topic_score_codex":0.00048542736,"about_ca_topic_score_gemma":0.0014046317,"teacher_disagreement_score":0.004390635,"about_ca_system_score_codex":0.00076133816,"about_ca_system_score_gemma":0.0006406701,"threshold_uncertainty_score":0.014688134},"labels":[],"label_agreement":null},{"id":"W4317891402","doi":"10.1200/jco.2023.41.4_suppl.tps816","title":"A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; T cell; Tolerability; Cancer; Immunotherapy; Clinical trial; Cancer research; Oncology; Internal medicine; Immune system; Immunology; Adverse effect","score_opus":0.16911744821216934,"score_gpt":0.5104959826276299,"score_spread":0.3413785344154605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317891402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844726,0.0026211943,0.0010331434,0.00088088535,0.00029078132,0.004309252,0.002056976,0.00020136128,0.0041338704],"genre_scores_gemma":[0.98335797,0.0016763803,0.0014326299,0.0011738185,0.00019121444,0.004007247,0.0038514682,0.00004276547,0.0042665424],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997087,0.00011349841,0.000014720101,0.00005537451,0.000029658106,0.00007795753],"domain_scores_gemma":[0.9994825,0.00007083444,0.000087324006,0.000049185146,0.000033114437,0.00027695356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011504869,0.0012774372,0.0013004873,0.00037876028,0.00035789303,0.0008672725,0.0007547199,0.0014398133,0.0058435663],"category_scores_gemma":[0.0007397608,0.00040472217,0.0010558622,0.0003794077,0.0009000349,0.00083835196,0.00030238615,0.0034761687,0.0015114228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80094594,0.04261069,0.0032133867,0.0009796772,0.0010682445,0.00056107243,0.00024452954,0.0027868615,0.036512323,0.0006939969,0.008145347,0.10223806],"study_design_scores_gemma":[0.59314495,0.395591,0.003164548,0.00004081001,0.0002934974,0.00041285635,0.00004914549,0.0010704087,0.0030827639,0.0003838068,0.0027508182,0.00001540467],"about_ca_topic_score_codex":0.0007814085,"about_ca_topic_score_gemma":0.0011938865,"teacher_disagreement_score":0.0058435663,"about_ca_system_score_codex":0.0007583408,"about_ca_system_score_gemma":0.0013852417,"threshold_uncertainty_score":0.019548714},"labels":[],"label_agreement":null},{"id":"W4318263697","doi":"10.1080/13696998.2023.2173466","title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Surgery","score_opus":0.030366608140798463,"score_gpt":0.2906257714463823,"score_spread":0.26025916330558385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318263697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98581845,0.006214034,0.00043726797,0.0014299108,0.000045844015,0.00018628959,0.002590338,0.0000376002,0.0032402514],"genre_scores_gemma":[0.99713093,0.00071803544,0.00034003842,0.0001832878,0.000009531938,0.000045234843,0.001082895,0.000006181977,0.00048394257],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99877673,0.00051395426,0.00004117,0.00013951694,0.00016975039,0.00035881947],"domain_scores_gemma":[0.99820626,0.0006151702,0.00027837852,0.00003748338,0.00031568974,0.00054703833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016774222,0.00072879985,0.0010410631,0.0007453532,0.00067427306,0.0018375654,0.0011425638,0.0008943259,0.0032010572],"category_scores_gemma":[0.004168251,0.00021812598,0.0021754971,0.0010696317,0.00059837213,0.00046318027,0.00086958654,0.0008907312,0.0001261792],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08418471,0.0037606556,0.30787605,0.0018842097,0.007695786,0.0013365698,0.0005416273,0.41303712,0.0015817316,0.008863342,0.01671185,0.1525263],"study_design_scores_gemma":[0.015932625,0.015652688,0.5224686,0.0012771179,0.0060680658,0.0010671595,0.0026379297,0.41679752,0.0016078022,0.002759235,0.013353779,0.00037745413],"about_ca_topic_score_codex":0.86777246,"about_ca_topic_score_gemma":0.8426271,"teacher_disagreement_score":0.13222754,"about_ca_system_score_codex":0.05613078,"about_ca_system_score_gemma":0.025321094,"threshold_uncertainty_score":0.40725923},"labels":[],"label_agreement":null},{"id":"W4318616170","doi":"10.1038/s41467-023-36126-7","title":"Enhancing CAR-T cell functionality in a patient-specific manner","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration; Dana-Farber Cancer Institute; National Cancer Institute; National Science Foundation; U.S. Department of Health and Human Services; National Institutes of Health; Hansjörg Wyss Institute for Biologically Inspired Engineering, Harvard University; Harvard University","keywords":"Chimeric antigen receptor; CD28; CD19; T cell; Stimulation; Cell; Antigen; Co-stimulation; Chronic lymphocytic leukemia; Medicine; Immunology; Computational biology; Biology; Leukemia; Immune system; Internal medicine; Genetics","score_opus":0.04717086020109685,"score_gpt":0.3482251953717439,"score_spread":0.30105433517064706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318616170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91962445,0.00043871332,0.076152734,0.00013094376,0.00001641323,0.000059203736,0.0005406035,0.00030723182,0.0027297256],"genre_scores_gemma":[0.992735,0.00024588822,0.00593394,0.000029076557,0.0000034968266,0.000037698508,0.00022543862,0.000015488562,0.00077379326],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982554,0.000050541657,0.0000070199426,0.000047500784,0.00003565286,0.000033783857],"domain_scores_gemma":[0.9998621,0.000058328544,0.000030342924,0.000016466449,0.000019138175,0.0000135738455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029047803,0.00045501348,0.00033679963,0.00013711072,0.00007998962,0.00061642966,0.00029415116,0.00047737124,0.0011401306],"category_scores_gemma":[0.0005478617,0.00015254636,0.0003120108,0.00014212674,0.00018661094,0.00030415363,0.00015183614,0.00028756823,0.00043568475],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00056154554,0.00025115488,0.007509632,0.0001419107,0.00004313494,0.00025326994,0.00008371151,0.3044237,0.66330546,0.0028567654,0.00063675764,0.019932922],"study_design_scores_gemma":[0.000042709275,0.00091275014,0.0024986835,0.00001019141,0.000064459135,0.0003466666,0.000043376225,0.6755763,0.31646574,0.0011692692,0.0028468806,0.000022935354],"about_ca_topic_score_codex":0.00047447963,"about_ca_topic_score_gemma":0.00067470444,"teacher_disagreement_score":0.0011401306,"about_ca_system_score_codex":0.0003011169,"about_ca_system_score_gemma":0.00043005974,"threshold_uncertainty_score":0.0038141012},"labels":[],"label_agreement":null},{"id":"W4319316777","doi":"10.1136/jitc-2022-005691","title":"Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"CD28; Mesothelin; Cancer research; T cell; Ovarian cancer; Flow cytometry; Tumor microenvironment; Chimeric antigen receptor; CD19; Immunotherapy; Cytotoxic T cell; Cancer; Biology; Immune system; Immunology; Medicine; In vitro; Antibody; Tumor cells; Internal medicine","score_opus":0.07222553027337288,"score_gpt":0.39572200909368005,"score_spread":0.3234964788203072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319316777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808455,0.00027807578,0.00096186844,0.000025823178,0.0000072414223,0.000024766407,0.00009445852,0.000046111774,0.00047707756],"genre_scores_gemma":[0.9981846,0.00020296984,0.00068914343,0.00001799981,0.0000061682754,0.000033702625,0.0001519991,0.0000082999895,0.0007050532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998894,0.000014043105,0.0000110190595,0.000022158254,0.00002642584,0.0000370264],"domain_scores_gemma":[0.99990964,0.00001727467,0.000027165623,0.000011686207,0.0000094782845,0.000024700637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001237397,0.0002738138,0.00021020774,0.00023268085,0.00006790313,0.0001959667,0.0001043642,0.00022551199,0.0008107697],"category_scores_gemma":[0.00008283969,0.00006712283,0.00014296074,0.00011276791,0.00015674469,0.000120034565,0.00013062336,0.000530874,0.00017062611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019071023,0.00012071105,0.00023631596,0.000029442705,0.000003153316,0.000020197673,0.000021397136,0.00019494312,0.99780244,0.00004668281,0.000037237172,0.0012966971],"study_design_scores_gemma":[0.000034930887,0.0012845747,0.0013982138,0.0000036153015,0.000014966813,0.00008958951,0.000017809416,0.0009326548,0.9952537,0.000019177693,0.0009490632,0.0000018940251],"about_ca_topic_score_codex":0.00021129023,"about_ca_topic_score_gemma":0.0003419518,"teacher_disagreement_score":0.0008107697,"about_ca_system_score_codex":0.0002025143,"about_ca_system_score_gemma":0.00015021936,"threshold_uncertainty_score":0.0027123094},"labels":[],"label_agreement":null},{"id":"W4319432270","doi":"10.4049/jimmunol.206.supp.58.07","title":"Lack of stem-like exhausted T cells and increased inhibitory receptor expression distinguishes diffuse large B cell lymphomas from Hodgkin lymphoma","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Lymphoma; Cancer research; CD8; Diffuse large B-cell lymphoma; Immunophenotyping; Medicine; Follicular lymphoma; Oncology; Internal medicine; Immunology; Immune system; Flow cytometry","score_opus":0.02556787508587118,"score_gpt":0.2769564302286834,"score_spread":0.2513885551428122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987697,0.00028094815,0.00030626563,0.000008394707,0.0000016698651,0.0000065028953,0.000093459465,0.000011901443,0.00052114384],"genre_scores_gemma":[0.9993825,0.00006628933,0.00013345832,0.0000132228,0.0000038084092,0.0000060177413,0.00021127507,0.0000023706675,0.0001809085],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99991,0.000009673687,0.000014519875,0.000020460826,0.00001760333,0.000027721722],"domain_scores_gemma":[0.9998698,0.000028466133,0.00003339104,0.000015010442,0.000015157139,0.000038117185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012723665,0.00015055866,0.00015648693,0.0004993934,0.00009827927,0.00034044703,0.00007734772,0.00015813783,0.0016613702],"category_scores_gemma":[0.00014565728,0.000104526436,0.00008943373,0.00019088523,0.0001948252,0.00014818537,0.00018629912,0.00020959493,0.00026955266],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006360415,0.00006502203,0.09153237,0.000070186135,0.000025381049,0.00063826516,0.00011218782,0.000066845285,0.9004838,0.00015496854,0.00007644433,0.0061384845],"study_design_scores_gemma":[0.00013119972,0.0011787083,0.79466707,0.000032894943,0.000083072235,0.013490727,0.0008219083,0.001453632,0.18359208,0.00041886888,0.004117244,0.000012594986],"about_ca_topic_score_codex":0.0002967307,"about_ca_topic_score_gemma":0.00030819906,"teacher_disagreement_score":0.0016613702,"about_ca_system_score_codex":0.000107543834,"about_ca_system_score_gemma":0.00006707632,"threshold_uncertainty_score":0.0055577755},"labels":[],"label_agreement":null},{"id":"W4319432308","doi":"10.4049/jimmunol.206.supp.27.15","title":"Automated Large-Scale T Cell Isolation in a New Closed Cell Separation System","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency; Stemcell Technologies","funders":"","keywords":"Immunomagnetic separation; Isolation (microbiology); Cell; CD8; T cell; Lysis; Cell culture; Computer science; Chromatography; Biology; Chemistry; Immunology; Bioinformatics; Antigen; Biochemistry; Genetics","score_opus":0.01621767350831087,"score_gpt":0.3092339558984663,"score_spread":0.2930162823901554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432308","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23226687,0.00087227277,0.7463237,0.00061793707,0.0007250789,0.0020125932,0.0017427247,0.01181754,0.0036213296],"genre_scores_gemma":[0.24465042,0.0005249518,0.7364072,0.0010200943,0.000359335,0.0023563462,0.006576924,0.00048759975,0.0076171737],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834776,0.00020836857,0.0001336482,0.00046168713,0.00073280575,0.000115810784],"domain_scores_gemma":[0.9990607,0.00020708004,0.00008748608,0.00014386636,0.0003395612,0.00016129085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010916913,0.00076236797,0.0010012544,0.0009064846,0.00083858054,0.0012877396,0.0012872736,0.0010550532,0.002709857],"category_scores_gemma":[0.0010598949,0.0004504184,0.0005867019,0.0004695782,0.0005604391,0.00076104514,0.0010735911,0.0015448638,0.002770979],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018421025,0.00026602097,0.0007262618,0.000102847895,0.000024748102,0.000082479906,0.00008001869,0.00069388875,0.97528446,0.0004926134,0.0027302445,0.019332236],"study_design_scores_gemma":[0.00036286024,0.0016082344,0.0078366455,0.000054532193,0.0001448097,0.0011097018,0.000057133828,0.05592248,0.88334554,0.0008128448,0.048514042,0.00023115403],"about_ca_topic_score_codex":0.0012926968,"about_ca_topic_score_gemma":0.0011760085,"teacher_disagreement_score":0.002709857,"about_ca_system_score_codex":0.0005184403,"about_ca_system_score_gemma":0.0014526,"threshold_uncertainty_score":0.00906539},"labels":[],"label_agreement":null},{"id":"W4319432320","doi":"10.4049/jimmunol.206.supp.58.06","title":"Inhibition of JAK/STAT signaling sustain stem-like exhausted CD8+ T lymphocytes with enhanced antitumor effects","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cytotoxic T cell; Adoptive cell transfer; CD8; T cell; Biology; Cancer research; JAK-STAT signaling pathway; Progenitor cell; Ex vivo; Interleukin 21; Cytokine; Immunology; Stem cell; Cell biology; In vivo; Signal transduction; Immune system; In vitro; Tyrosine kinase","score_opus":0.012987012272306276,"score_gpt":0.2742844501923555,"score_spread":0.2612974379200492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518245,0.0013433647,0.0014696294,0.000086483305,0.00005130895,0.000033296685,0.0005395823,0.00010030459,0.0011936306],"genre_scores_gemma":[0.99629116,0.00046456803,0.0008710746,0.000061299324,0.000011460279,0.000038102367,0.00058980094,0.000013611352,0.0016590232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999256,0.000008724178,0.0000083175755,0.000010216537,0.000021990829,0.000025123323],"domain_scores_gemma":[0.99995303,0.00000904787,0.000010987419,0.0000042016354,0.0000054356406,0.000017276572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080277714,0.00025526207,0.0001997693,0.00013387676,0.0000611568,0.00022870633,0.000115096685,0.00013848154,0.0014817195],"category_scores_gemma":[0.00005619868,0.000065605374,0.00014604419,0.00008329166,0.00010620117,0.000105371684,0.000088035384,0.0006338061,0.00033717536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035689116,0.00010183009,0.00013157864,0.00005310466,0.0000061691053,0.00001595533,0.0000066060607,0.00024406602,0.996675,0.000050733506,0.00009773395,0.0022602004],"study_design_scores_gemma":[0.00006417659,0.0010427837,0.0016492674,0.0000073339324,0.000022255874,0.00006752274,0.000011379489,0.0019502806,0.99313,0.000046520785,0.002005312,0.000003171557],"about_ca_topic_score_codex":0.00016317022,"about_ca_topic_score_gemma":0.00035265606,"teacher_disagreement_score":0.0014817195,"about_ca_system_score_codex":0.00011741541,"about_ca_system_score_gemma":0.00017016436,"threshold_uncertainty_score":0.0049568415},"labels":[],"label_agreement":null},{"id":"W4319433798","doi":"10.4049/jimmunol.206.supp.25.02","title":"Engineering T cells with improved TCR-CD3 interaction for optimal tumor killing","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"T-cell receptor; CD3; T cell; Extracellular; Biology; Jurkat cells; Cell biology; Immune system; Signal transduction; CD8; Molecular biology; Genetics","score_opus":0.015902051448910753,"score_gpt":0.28349811059690866,"score_spread":0.2675960591479979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319433798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918291,0.00022957471,0.0068844636,0.000047658505,0.000016096907,0.000036225054,0.00017897361,0.00007007197,0.0007078004],"genre_scores_gemma":[0.99443156,0.00012585375,0.004335707,0.000032930817,0.000004732278,0.000025527324,0.00018664001,0.000025420772,0.00083160505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998722,0.000021221935,0.000015049207,0.000020363208,0.00003147095,0.0000396969],"domain_scores_gemma":[0.9999236,0.000014287599,0.000024336217,0.000008312023,0.0000109515795,0.000018578363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095151685,0.000321664,0.0001694387,0.00013128167,0.000098480494,0.0002942746,0.00017341578,0.00026310157,0.0008934797],"category_scores_gemma":[0.00009891192,0.00009641386,0.00017836601,0.00015699942,0.00011221976,0.0000961333,0.00016978545,0.00043134173,0.00040044804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027402533,0.000017112714,0.000048358357,0.00000555799,0.0000016101168,0.0000140663215,0.0000044871194,0.00013043577,0.99931467,0.000038654747,0.000010259842,0.00038735213],"study_design_scores_gemma":[0.000013430547,0.00012819412,0.00044357197,0.0000015570342,0.000009036746,0.00007963968,0.0000061920396,0.0010015348,0.9974558,0.000017773624,0.00084101956,0.0000022934005],"about_ca_topic_score_codex":0.0003685705,"about_ca_topic_score_gemma":0.00033242197,"teacher_disagreement_score":0.0008934797,"about_ca_system_score_codex":0.00020768023,"about_ca_system_score_gemma":0.000120776254,"threshold_uncertainty_score":0.0029889941},"labels":[],"label_agreement":null},{"id":"W4319812103","doi":"10.1056/nejmoa2213614","title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":705,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Celgene; Bristol-Myers Squibb","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Oncology; Internal medicine; Lenalidomide; Materials science; Metallurgy","score_opus":0.0453368430261291,"score_gpt":0.3410931074954077,"score_spread":0.2957562644692786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319812103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958742,0.0025302141,0.00015419161,0.00014741311,0.00005716184,0.00009062539,0.00011992548,0.000022323906,0.0010040097],"genre_scores_gemma":[0.9971078,0.0014435492,0.00028012003,0.00026415393,0.000083716775,0.00010146263,0.0002315916,0.000004626055,0.00048307484],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999824,0.00007623157,0.000014214067,0.000027712784,0.000026617035,0.000031333657],"domain_scores_gemma":[0.9996847,0.00011218422,0.00006789564,0.000028217732,0.000008386196,0.000098659715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074200286,0.0001989546,0.00091337226,0.00022095644,0.00014947864,0.00025864088,0.00020637899,0.0003087396,0.0022114706],"category_scores_gemma":[0.00069653755,0.0001366079,0.00043793497,0.00018379456,0.00023239416,0.00025279,0.00018099738,0.0005588956,0.00028168366],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5477128,0.009558047,0.02646869,0.0006748788,0.000862721,0.00048672967,0.00016902752,0.0020581954,0.025236037,0.0004941365,0.0051949876,0.38108373],"study_design_scores_gemma":[0.25630718,0.5034445,0.2039045,0.0002968027,0.0013417396,0.0024249386,0.00018457341,0.0058793,0.009324622,0.0018629754,0.0149617,0.000067226145],"about_ca_topic_score_codex":0.00014708396,"about_ca_topic_score_gemma":0.00046109525,"teacher_disagreement_score":0.0022114706,"about_ca_system_score_codex":0.00019720927,"about_ca_system_score_gemma":0.0002551808,"threshold_uncertainty_score":0.0073981285},"labels":[],"label_agreement":null},{"id":"W4319984037","doi":"10.9734/bpi/mono/978-81-19039-63-0/ch19","title":"CAR T Cells Produced in vivo to Treat Cardiac Injury","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"In vivo; Spleen; Chimeric antigen receptor; Messenger RNA; Fibrosis; Ex vivo; Antigen; Cardiac fibrosis; Immunology; Medicine; Cancer research; Cell biology; Biology; T cell; Pathology; Immune system; Gene","score_opus":0.0384824907537155,"score_gpt":0.3167556968768568,"score_spread":0.27827320612314127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319984037","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1256022,0.3025345,0.16048962,0.0063110995,0.0065165884,0.00079515285,0.0011221063,0.0031212338,0.39350748],"genre_scores_gemma":[0.365414,0.15501013,0.07730801,0.008959175,0.0014574331,0.0006975662,0.0018470387,0.0004924509,0.3888142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999567,0.000006041342,0.0000021424883,0.000011546913,0.000015942782,0.0000075931157],"domain_scores_gemma":[0.99997795,0.0000070575725,0.000003578726,0.0000017166805,0.0000048681763,0.000004780865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015293974,0.00052247103,0.00018303067,0.0003020891,0.000101489786,0.000431046,0.00025492086,0.00051491294,0.0057678814],"category_scores_gemma":[0.000072236355,0.00012739714,0.00021452109,0.00016205895,0.000196971,0.00034511436,0.00024621523,0.0011580802,0.0024358565],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013264616,0.00026102012,0.00019897077,0.0007415072,0.000022135626,0.0006298914,0.00023327999,0.0007013647,0.7692803,0.021701716,0.02679046,0.17930676],"study_design_scores_gemma":[0.00010499285,0.0007363947,0.0004755465,0.00017961464,0.00006207441,0.0024989722,0.00006809287,0.0013949762,0.30278635,0.0033525869,0.6883237,0.000016764685],"about_ca_topic_score_codex":0.0002316513,"about_ca_topic_score_gemma":0.00033490316,"teacher_disagreement_score":0.0057678814,"about_ca_system_score_codex":0.00019323564,"about_ca_system_score_gemma":0.00017013776,"threshold_uncertainty_score":0.019295514},"labels":[],"label_agreement":null},{"id":"W4320034434","doi":"10.1016/j.jcyt.2023.01.002","title":"T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; TRAC; Multiple myeloma; Receptor; Immunology; Cancer research; T cell; Medicine; Internal medicine; Computer science; Immune system","score_opus":0.019670174701244204,"score_gpt":0.2607613006876543,"score_spread":0.24109112598641008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320034434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835902,0.0010120258,0.01147851,0.00010721541,0.00006490144,0.000084298124,0.00027095652,0.00024123881,0.003150637],"genre_scores_gemma":[0.99429566,0.0002949579,0.0030404339,0.000041722524,0.000009272057,0.000022489032,0.00020029924,0.000027758651,0.0020675648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998666,0.000019081546,0.000009409879,0.000032441843,0.000034648863,0.000037762624],"domain_scores_gemma":[0.9999522,0.000010602182,0.000012940815,0.0000072155253,0.0000073953415,0.000009647579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011810454,0.00026728577,0.00020097713,0.00016896534,0.00011585835,0.00039915924,0.00022758586,0.0003774155,0.001348262],"category_scores_gemma":[0.00009799328,0.00010570157,0.00016235915,0.00014384229,0.00015841688,0.00018484889,0.00018478175,0.0006925731,0.0004554053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007354374,0.00004499027,0.00009328061,0.000016865366,0.0000068537192,0.000039894916,0.000014075812,0.00020140849,0.9974963,0.00042025244,0.00009995034,0.0014926235],"study_design_scores_gemma":[0.00003153499,0.00023074474,0.0005283522,0.0000022293423,0.000023990922,0.00017107802,0.000010394138,0.0017734417,0.99300134,0.00006854626,0.004154937,0.0000034707334],"about_ca_topic_score_codex":0.00064048695,"about_ca_topic_score_gemma":0.0004915047,"teacher_disagreement_score":0.001348262,"about_ca_system_score_codex":0.0002979312,"about_ca_system_score_gemma":0.00018389097,"threshold_uncertainty_score":0.004510343},"labels":[],"label_agreement":null},{"id":"W4321203706","doi":"10.1016/j.lrr.2023.100364","title":"Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Cart; Chimeric antigen receptor; Lymphoblastic Leukemia; Internal medicine; Leukemia; Oncology; Immunology; Cancer; Immunotherapy","score_opus":0.02381273821878506,"score_gpt":0.3316124645774158,"score_spread":0.30779972635863073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321203706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988715,0.0005210394,0.000028807355,0.000034193796,0.0000055841133,0.000006559807,0.00011508412,0.000001404263,0.00041584964],"genre_scores_gemma":[0.99942577,0.00026086732,0.000045238747,0.000038557017,0.000012870069,0.0000059435074,0.00012814741,4.6051437e-7,0.000082260936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999782,0.000053305015,0.000030247122,0.000028918983,0.000044329565,0.000061157414],"domain_scores_gemma":[0.9992009,0.00008441698,0.0005000065,0.000011777307,0.000040621344,0.00016226163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002610793,0.00020611272,0.00027057383,0.00043183315,0.00032702668,0.00045816545,0.00013401227,0.00027491845,0.0011448408],"category_scores_gemma":[0.0010256129,0.00014001687,0.00025603475,0.0005060671,0.00014634347,0.0003177226,0.00026211783,0.00044545616,0.00015425774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007934009,0.000035241184,0.9986494,0.000006172148,0.000013883706,0.00017736197,0.000018294117,0.000010262108,0.000057108333,0.0000061743385,0.000041019906,0.00090561155],"study_design_scores_gemma":[0.000009748965,0.0002170102,0.9975575,0.000010973941,0.000027126855,0.0017202909,0.00018111693,0.000075365955,0.0000386191,0.000018423027,0.00014149174,0.000002246159],"about_ca_topic_score_codex":0.0021127576,"about_ca_topic_score_gemma":0.0030961125,"teacher_disagreement_score":0.0021127576,"about_ca_system_score_codex":0.00022992899,"about_ca_system_score_gemma":0.00030982497,"threshold_uncertainty_score":0.0042008758},"labels":[],"label_agreement":null},{"id":"W4321604791","doi":"10.1101/2023.02.23.529741","title":"Human A2-CAR T cells reject HLA-A2+ human islets transplanted into mice without inducing graft versus host disease","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Alberta","funders":"National Institutes of Health; Manpei Suzuki Diabetes Foundation; University of British Columbia; BC Children's Hospital; Juvenile Diabetes Research Foundation Canada","keywords":"Human leukocyte antigen; Graft-versus-host disease; Host (biology); Islet; Human disease; Immunology; Disease; Biology; Medicine; Diabetes mellitus; Antigen; Genetics; Internal medicine; Endocrinology","score_opus":0.041150980030911874,"score_gpt":0.3020467307956627,"score_spread":0.2608957507647508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321604791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954976,0.00069011457,0.0023387622,0.000043284497,0.00006711224,0.000033553286,0.0002220773,0.0001268241,0.0009807298],"genre_scores_gemma":[0.9948521,0.00029562126,0.0015122225,0.000100233345,0.000029571784,0.00005504552,0.00037134366,0.00003760098,0.0027463334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996519,0.00005957966,0.000034064473,0.00010355274,0.000060859555,0.000089967405],"domain_scores_gemma":[0.99976987,0.00005908798,0.000041074465,0.000050112845,0.00002048031,0.00005931155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035755066,0.0005457969,0.00040158784,0.00019143002,0.000107348336,0.0004534212,0.00017127309,0.00050849566,0.0019912925],"category_scores_gemma":[0.00017625322,0.00014595536,0.0003063085,0.00010753778,0.00021872703,0.0002705689,0.00017835292,0.0009115109,0.00044607103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005110323,0.00017130101,0.00021161023,0.000030045845,0.000012243819,0.000042848373,0.000026168142,0.00012604194,0.9975344,0.000062473286,0.00007785633,0.0011940601],"study_design_scores_gemma":[0.0000945216,0.003187442,0.0023840142,0.000010925976,0.000033705768,0.00028677323,0.000043959477,0.002412473,0.9895801,0.000053390908,0.001905487,0.0000072816506],"about_ca_topic_score_codex":0.0003857533,"about_ca_topic_score_gemma":0.00026533552,"teacher_disagreement_score":0.0019912925,"about_ca_system_score_codex":0.00014818918,"about_ca_system_score_gemma":0.00017981835,"threshold_uncertainty_score":0.006661594},"labels":[],"label_agreement":null},{"id":"W4321748193","doi":"10.1158/1078-0432.ccr-22-2955","title":"Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Lymphoma; Follicular lymphoma; Angioimmunoblastic T-cell lymphoma; T cell; Internal medicine; Adverse effect; Oncology; Peripheral T-cell lymphoma; Refractory (planetary science); Pharmacodynamics; Gastroenterology; Immunology; Pharmacokinetics; Immune system","score_opus":0.07551008948559883,"score_gpt":0.395376646050156,"score_spread":0.31986655656455715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321748193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982368,0.0010085497,0.00013082165,0.000036455083,0.0000031131458,0.000038843187,0.000043674278,0.000013327311,0.0004885421],"genre_scores_gemma":[0.9991366,0.00033132054,0.0002007333,0.000060766488,0.000010858579,0.000019266508,0.00010551786,0.0000015367992,0.00013334524],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999925,0.000026595899,0.0000074528216,0.000011015396,0.000012899777,0.000016977618],"domain_scores_gemma":[0.99988043,0.00003100446,0.00003198651,0.000008402577,0.000007669167,0.00004058084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027414763,0.00020774559,0.00039629402,0.00012309372,0.00013417249,0.00021146375,0.00018262031,0.0001576452,0.00063116645],"category_scores_gemma":[0.00031110662,0.00008518714,0.00013764203,0.00016995941,0.00018498182,0.00016224942,0.00010007087,0.00035733325,0.00018913746],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049491156,0.0037513142,0.44717932,0.0007912091,0.00044686114,0.0043679993,0.00073735864,0.0036259224,0.16633818,0.0003229508,0.0025301808,0.32041752],"study_design_scores_gemma":[0.01520859,0.21376427,0.6879058,0.00014063164,0.001130738,0.01482206,0.00053257216,0.0070556775,0.045325782,0.0003902175,0.013686524,0.00003714949],"about_ca_topic_score_codex":0.0003749561,"about_ca_topic_score_gemma":0.0009273907,"teacher_disagreement_score":0.00063116645,"about_ca_system_score_codex":0.00028949132,"about_ca_system_score_gemma":0.0002592655,"threshold_uncertainty_score":0.002111435},"labels":[],"label_agreement":null},{"id":"W4322011926","doi":"10.1016/j.msard.2023.104590","title":"Are we ready for CD19-targeted CAR T-cell therapies in MS?","year":2023,"lang":"en","type":"editorial","venue":"Multiple Sclerosis and Related Disorders","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; CD19; Medicine; Immunology; B cell; Antigen; T cell; Cancer research","score_opus":0.0493028518859097,"score_gpt":0.29498792866946655,"score_spread":0.24568507678355683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322011926","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045621444,0.015165872,0.00016550219,0.047656547,0.9355238,0.000024122339,0.000046099736,0.000052088206,0.0013204257],"genre_scores_gemma":[0.00057520065,0.011200273,0.00018433447,0.049318902,0.93129045,0.000038678198,0.00003213497,0.000032975076,0.007327111],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962775,0.00088134233,0.0004572132,0.00035730362,0.0017211724,0.00030545803],"domain_scores_gemma":[0.9854976,0.0073679853,0.0007133693,0.00029912128,0.0037502097,0.0023717724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009979367,0.0030074597,0.0034972513,0.0021583254,0.0023650776,0.0057103755,0.0031777842,0.01934572,0.008862408],"category_scores_gemma":[0.018684788,0.0010543654,0.0025064382,0.0009260155,0.0021999488,0.004721707,0.001289771,0.02471867,0.006173671],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009382545,0.00002144337,0.0000176577,0.00028983108,0.000026474027,0.00008743751,0.000008322711,0.000030195642,0.0000835125,0.00041745286,0.9902907,0.008633112],"study_design_scores_gemma":[0.00021646444,0.0001040794,0.00021825978,0.00046200972,0.00012298934,0.00021906452,0.000033317654,0.0002504197,0.00017386027,0.0018673282,0.99630415,0.000027987919],"about_ca_topic_score_codex":0.0018936817,"about_ca_topic_score_gemma":0.0050192946,"teacher_disagreement_score":0.01934572,"about_ca_system_score_codex":0.002768916,"about_ca_system_score_gemma":0.0031312138,"threshold_uncertainty_score":0.052776575},"labels":[],"label_agreement":null},{"id":"W4322494886","doi":"10.1038/s41587-023-01687-x","title":"Deconvolution of clinical variance in CAR-T cell pharmacology and response","year":2023,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Hatch (Canada)","funders":"","keywords":"Chimeric antigen receptor; Effector; Immunophenotyping; Cytotoxic T cell; T cell; Antigen; Computational biology; Biology; Immunology; Neuroscience; Immune system; In vitro; Genetics","score_opus":0.028769687787816578,"score_gpt":0.41537531063099037,"score_spread":0.3866056228431738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322494886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68221,0.00029477887,0.3140482,0.0005429477,0.000028493088,0.0000710134,0.00068817683,0.0006099817,0.0015064286],"genre_scores_gemma":[0.9915147,0.00008313428,0.0071293353,0.00009462063,0.0000074828986,0.000042347925,0.00026699703,0.00003124548,0.00083007483],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99949384,0.00016978821,0.000019412764,0.00017902246,0.000087044384,0.00005078721],"domain_scores_gemma":[0.99864286,0.000851969,0.00018694022,0.00017623838,0.000088436536,0.000053536136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024733394,0.0004998258,0.000564665,0.0002051291,0.00010739738,0.00074433535,0.0004952517,0.0006155954,0.00090839877],"category_scores_gemma":[0.004602766,0.00035540812,0.0006225767,0.0001880897,0.00046170535,0.000598699,0.00034967723,0.00096907123,0.00028019896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008184368,0.00016558541,0.03556913,0.00007425005,0.00014397949,0.00021646969,0.0000991581,0.88900703,0.034677126,0.0046744593,0.0006132761,0.0339411],"study_design_scores_gemma":[0.000013555804,0.00010760973,0.005271563,0.0000021453143,0.000019143768,0.000052193773,0.000007753629,0.98603153,0.00645591,0.0018076501,0.00021934135,0.000011608514],"about_ca_topic_score_codex":0.001694287,"about_ca_topic_score_gemma":0.0010342909,"teacher_disagreement_score":0.0024733394,"about_ca_system_score_codex":0.0008277573,"about_ca_system_score_gemma":0.00087643723,"threshold_uncertainty_score":0.013080418},"labels":[],"label_agreement":null},{"id":"W4323036146","doi":"10.1007/s10637-023-01342-x","title":"Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Peripheral blood mononuclear cell; Medicine; CD8; Tolerability; Immune system; Antigen; Pharmacodynamics; Immunotherapy; Immunology; Human leukocyte antigen; Pharmacology; Adverse effect; Internal medicine; Pharmacokinetics; Biology","score_opus":0.04542277026582583,"score_gpt":0.3424850493680232,"score_spread":0.2970622791021974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323036146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736184,0.00023864754,0.0005995529,0.00008056202,0.000036977806,0.001036141,0.00021795186,0.000024947858,0.00040336925],"genre_scores_gemma":[0.9938883,0.00022335861,0.001853558,0.00030827985,0.00007400495,0.0016168207,0.00052573095,0.000013520673,0.0014963252],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99971396,0.00013132446,0.000012016001,0.00005803539,0.000033189997,0.000051520765],"domain_scores_gemma":[0.999624,0.00009076437,0.00009671247,0.00004642179,0.000030581556,0.00011140161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009643101,0.00065088447,0.000896086,0.00017726008,0.00023595891,0.0004308868,0.0003294817,0.0006314643,0.0023612136],"category_scores_gemma":[0.0005027372,0.00028728158,0.00048289855,0.00012267541,0.0004280401,0.00034236102,0.00018670618,0.0015340501,0.00043437537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24667434,0.14131479,0.021116743,0.0005019706,0.0004583591,0.00050226366,0.00062804396,0.0055120564,0.4517749,0.0006157174,0.0033659597,0.12753484],"study_design_scores_gemma":[0.038700268,0.9266506,0.008471669,0.000010306341,0.00009187239,0.0002456849,0.00004823702,0.0013862888,0.022050316,0.00015301941,0.0021796948,0.000012017821],"about_ca_topic_score_codex":0.00017952968,"about_ca_topic_score_gemma":0.00035100666,"teacher_disagreement_score":0.0023612136,"about_ca_system_score_codex":0.00036818194,"about_ca_system_score_gemma":0.0006109186,"threshold_uncertainty_score":0.007899046},"labels":[],"label_agreement":null},{"id":"W4323353350","doi":"10.1016/j.clml.2023.03.002","title":"Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; National Cancer Institute; Gilead Sciences; Servier; Alexion Pharmaceuticals; Apellis Pharmaceuticals; BeiGene; Pfizer; Incyte; Innovent Biologics; Adaptive Biotechnologies; Sierra Oncology; CTI Biopharma; bluebird bio; TG Therapeutics; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Cidara Therapeutics; MorphoSys; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Vaccination; Seroconversion; Lymphoma; Immunology; Multiple myeloma; Antibody; Cancer; Chimeric antigen receptor; Immune system; Immunotherapy; Virology; Internal medicine","score_opus":0.03695353903935361,"score_gpt":0.3572703254441805,"score_spread":0.3203167864048269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323353350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99792385,0.00055188366,0.000034387416,0.00015309501,0.000028623894,0.000015153544,0.00014399801,0.000005692006,0.001143228],"genre_scores_gemma":[0.9992918,0.000075537384,0.000019120456,0.0001329967,0.000030436906,0.000010641375,0.00018519451,0.0000011745249,0.00025301363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951935,0.00013013977,0.000036250585,0.0000869949,0.000056820136,0.00017046343],"domain_scores_gemma":[0.9990257,0.00039203296,0.00020348192,0.00003402678,0.00008143286,0.00026321647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004631198,0.0002567216,0.00055880315,0.00032427444,0.00036259112,0.00052593666,0.00024901069,0.00070436666,0.0018248325],"category_scores_gemma":[0.002279836,0.00016111584,0.0004830548,0.00037074534,0.00023987202,0.0004810429,0.00028806296,0.0007767992,0.0003105797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009157254,0.00049956754,0.97217697,0.000055338365,0.00016117482,0.0007184517,0.00021631595,0.00026930406,0.0021710803,0.000033743316,0.00060433964,0.013936352],"study_design_scores_gemma":[0.00018738245,0.0036883457,0.993258,0.000017077147,0.0001217001,0.00077867776,0.00028140654,0.000479282,0.00033161967,0.000043237684,0.0008021612,0.0000110003975],"about_ca_topic_score_codex":0.0017433389,"about_ca_topic_score_gemma":0.002342059,"teacher_disagreement_score":0.0018248325,"about_ca_system_score_codex":0.0005482665,"about_ca_system_score_gemma":0.00029743425,"threshold_uncertainty_score":0.006104648},"labels":[],"label_agreement":null},{"id":"W4323652962","doi":"10.1002/eji.202250002","title":"Targeting regulatory T cell metabolism in disease: Novel therapeutic opportunities","year":2023,"lang":"en","type":"review","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Biology; Autoimmunity; Cell metabolism; Immune system; Adoptive cell transfer; Function (biology); Cancer research; Regulatory T cell; Cancer; Immunology; Transplant rejection; T cell; Cell; Cell biology; Genetics; IL-2 receptor","score_opus":0.16259025924903045,"score_gpt":0.3537250928782405,"score_spread":0.19113483362921005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323652962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016452152,0.99782133,0.0002611061,0.0005250554,0.0003193877,0.0000045315246,0.000012744332,0.000012647145,0.00087870716],"genre_scores_gemma":[0.0010225555,0.9971908,0.00032958752,0.00045228438,0.00030239028,0.000011037908,0.00002925568,0.0000024326212,0.00065970863],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987197,0.000026522834,0.000013624639,0.000021989501,0.000046961202,0.000019004103],"domain_scores_gemma":[0.999848,0.000073354066,0.000017066517,0.000005631242,0.000033562264,0.000022366201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005882527,0.0007281236,0.0010898083,0.0011148762,0.00021697476,0.0008909183,0.00073270896,0.0012740417,0.0026328608],"category_scores_gemma":[0.00039138476,0.00021326076,0.00042962396,0.0008738143,0.00043194805,0.001193023,0.0005986234,0.002554302,0.001581162],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001312687,0.000111892885,0.00010810582,0.009050213,0.0000738833,0.00021725368,0.00005165023,0.0004897438,0.0049481336,0.0075466363,0.02781225,0.9494589],"study_design_scores_gemma":[0.000035651585,0.00017389627,0.0003858361,0.0017862485,0.00007320793,0.00091177196,0.00003666967,0.0001353474,0.0006932811,0.0030825704,0.99266994,0.000015474348],"about_ca_topic_score_codex":0.00035546778,"about_ca_topic_score_gemma":0.0008157884,"teacher_disagreement_score":0.0026328608,"about_ca_system_score_codex":0.0004928154,"about_ca_system_score_gemma":0.00064597826,"threshold_uncertainty_score":0.008807778},"labels":[],"label_agreement":null},{"id":"W4323656441","doi":"10.1016/j.ccell.2023.02.008","title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","year":2023,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"José Carreras Leukämie-Stiftung; Terry Fox Research Institute; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; International Myeloma Society; Else Kröner-Fresenius-Stiftung; Deutsche Krebshilfe; Pfizer","keywords":"CD8; Major histocompatibility complex; Immunotherapy; Multiple myeloma; Immune system; MHC class I; Immunology; T cell; Repertoire; Cytotoxic T cell; Biology; Mechanism (biology); Cancer research; Computational biology; Medicine; Genetics; In vitro","score_opus":0.04948049454371408,"score_gpt":0.3285578656138817,"score_spread":0.27907737107016767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323656441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99890685,0.00029573997,0.00010935349,0.000031189204,0.0000018002074,0.0000062020654,0.000055302768,0.00001247082,0.0005811197],"genre_scores_gemma":[0.9995957,0.000065896056,0.00006114013,0.000029391023,0.0000031929326,0.0000051247393,0.000067493675,0.000002784774,0.00016932006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998628,0.000024484816,0.000011265383,0.000033618082,0.000026509997,0.00004127691],"domain_scores_gemma":[0.9998653,0.000029127106,0.000041302334,0.000009833591,0.000015230869,0.000039097293],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015108558,0.00013424363,0.0002368497,0.0003786128,0.00019169724,0.0003430425,0.00012147666,0.0002562333,0.0013150363],"category_scores_gemma":[0.0003990552,0.000100439225,0.000095845615,0.00026727736,0.0001687203,0.00021919886,0.00017527348,0.00038871108,0.00021674628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039652586,0.0002463192,0.47946563,0.00006496963,0.00007305791,0.0018346773,0.00050427334,0.00060548045,0.47080976,0.0003911823,0.00050375884,0.041535553],"study_design_scores_gemma":[0.000037893344,0.0011552684,0.9645412,0.000014398678,0.000058314537,0.003991871,0.00028743717,0.0012234867,0.026342379,0.00029132367,0.002046909,0.000009576113],"about_ca_topic_score_codex":0.0005890165,"about_ca_topic_score_gemma":0.00079485844,"teacher_disagreement_score":0.0013150363,"about_ca_system_score_codex":0.00032430008,"about_ca_system_score_gemma":0.00012900995,"threshold_uncertainty_score":0.0043991804},"labels":[],"label_agreement":null},{"id":"W4323656721","doi":"10.1073/pnas.2216901120","title":"Visualizing cell–cell communication using synthetic notch activated MRI","year":2023,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Institute of Cancer Research; Ontario Institute for Cancer Research; Robarts Clinical Trials; Western University","funders":"Canadian Institutes of Health Research","keywords":"Cancer cell; CD19; Biology; Cell biology; Cell; Antigen; Immune system; Reporter gene; Cancer research; Bioluminescence imaging; Cell culture; Cancer; Immunology; Gene expression; Gene; Biochemistry; Genetics; Transfection","score_opus":0.11779834927070305,"score_gpt":0.4075851612719628,"score_spread":0.2897868120012598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323656721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8873402,0.0022043304,0.099050924,0.0005911427,0.00010250486,0.00012416048,0.00038809606,0.00043311805,0.009765555],"genre_scores_gemma":[0.92850447,0.001390436,0.064674295,0.00026882772,0.000035977257,0.00015114494,0.00028579196,0.0000459387,0.004643179],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998957,0.00002402882,0.00000483347,0.000030601834,0.000026394546,0.000018495482],"domain_scores_gemma":[0.99988675,0.00004272302,0.000035597423,0.000009357707,0.000010207842,0.000015228931],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020589332,0.00028966056,0.00011809981,0.00018882878,0.0000934609,0.00029772616,0.0003685826,0.0004874002,0.0013515044],"category_scores_gemma":[0.00019053137,0.000145878,0.00012827077,0.00012616598,0.00024764834,0.0003014475,0.000327255,0.00042470216,0.0003217496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025547357,0.000006389752,0.000022548089,0.000030103234,0.0000015948806,0.000039077564,0.000011518468,0.00024370731,0.99821764,0.00030735243,0.00004858497,0.0010458381],"study_design_scores_gemma":[0.00002357346,0.00021967612,0.00040883335,0.000008445551,0.0000067333553,0.00022039798,0.000026148595,0.008111848,0.9862884,0.00030260682,0.0043739695,0.000009422412],"about_ca_topic_score_codex":0.00021720723,"about_ca_topic_score_gemma":0.00031363705,"teacher_disagreement_score":0.0013515044,"about_ca_system_score_codex":0.00024857966,"about_ca_system_score_gemma":0.0001311568,"threshold_uncertainty_score":0.0045212507},"labels":[],"label_agreement":null},{"id":"W4323663940","doi":"10.1016/j.jtct.2023.03.005","title":"Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Children's Hospital; Wellcome Trust; National Cancer Institute; Bill and Melinda Gates Foundation","keywords":"Medicine; Immunology; Immunogenicity; Vaccination; Internal medicine; Population; Interquartile range; Antibody","score_opus":0.03830271334259059,"score_gpt":0.3009766478217383,"score_spread":0.26267393447914766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323663940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993594,0.00005155517,0.00014928957,0.000023697641,0.00001922719,0.000016672864,0.000022525128,0.000004469792,0.00035318796],"genre_scores_gemma":[0.99944144,0.00003225459,0.000031325042,0.00004399838,0.000019153782,0.000014107606,0.000051689425,0.00000228027,0.0003636793],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99967575,0.00008912854,0.000020436084,0.00005347888,0.000036275527,0.00012507569],"domain_scores_gemma":[0.99971277,0.00007417524,0.00005074996,0.000041205163,0.000036817197,0.00008417894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064679945,0.00035355688,0.00031779226,0.00024489223,0.00025147793,0.00045193182,0.00016923557,0.0004962495,0.001502704],"category_scores_gemma":[0.0006791561,0.00016171287,0.00025308155,0.0001011826,0.00026263765,0.00048710505,0.00017551129,0.0008482004,0.00032002054],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023993237,0.0075898822,0.042648837,0.00009772331,0.000127074,0.0014480669,0.0006621241,0.00068647024,0.8987408,0.0010523534,0.000824734,0.022128696],"study_design_scores_gemma":[0.0044308677,0.16566232,0.35675064,0.00007887771,0.0008512228,0.0077483393,0.0018623301,0.0141991675,0.43793848,0.0018753503,0.008488114,0.00011430915],"about_ca_topic_score_codex":0.00028322186,"about_ca_topic_score_gemma":0.00014744935,"teacher_disagreement_score":0.001502704,"about_ca_system_score_codex":0.00021506014,"about_ca_system_score_gemma":0.00021425454,"threshold_uncertainty_score":0.005026996},"labels":[],"label_agreement":null},{"id":"W4323783949","doi":"10.1039/d2bm01795d","title":"T cell-loaded injectable chitosan scaffold shows short-term efficacy in localised cancer immunotherapy in mice","year":2023,"lang":"en","type":"article","venue":"Biomaterials Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; École de Technologie Supérieure; Centre Hospitalier de l’Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Flow cytometry; Chemistry; In vitro; Immunotherapy; Biocompatibility; Chitosan; Immune system; Pharmacology; Immunology; Medicine; Pathology; Biochemistry","score_opus":0.04078009132063916,"score_gpt":0.3488355255666527,"score_spread":0.30805543424601356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323783949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99255437,0.0015159693,0.0039052009,0.000076549935,0.000059469337,0.00006630666,0.0004292705,0.00017405156,0.001218772],"genre_scores_gemma":[0.99141943,0.0010021338,0.0036813114,0.00004496669,0.000027320693,0.000117524614,0.00046194028,0.000040900253,0.003204517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998481,0.000017236696,0.000013370177,0.000036198628,0.00004031507,0.000044722532],"domain_scores_gemma":[0.9998216,0.000041783664,0.000066844455,0.000014998601,0.000018490251,0.000036299578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023717577,0.00043430974,0.00028074151,0.00032816947,0.0000900905,0.00023618355,0.00019795209,0.00048424868,0.00084653916],"category_scores_gemma":[0.000116251984,0.0001325204,0.0002382853,0.0001947058,0.00027169674,0.00028334823,0.00009274134,0.0006266605,0.00027113134],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013238293,0.00006293945,0.00003898946,0.000026939631,0.0000028360823,0.000014849921,0.000010633386,0.000079845224,0.9987778,0.000017877746,0.000020962647,0.0008138572],"study_design_scores_gemma":[0.000018346473,0.0015902887,0.0011207368,0.0000037793889,0.00002431716,0.00005331651,0.000009677099,0.00070395187,0.996079,0.000010365025,0.00038156813,0.0000046172913],"about_ca_topic_score_codex":0.0007591936,"about_ca_topic_score_gemma":0.00095782394,"teacher_disagreement_score":0.00084653916,"about_ca_system_score_codex":0.0002422684,"about_ca_system_score_gemma":0.00022350415,"threshold_uncertainty_score":0.0028319359},"labels":[],"label_agreement":null},{"id":"W4324044824","doi":"10.1038/s41591-023-02234-6","title":"A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Deutschen Konsortium für Translationale Krebsforschung; Nationales Centrum für Tumorerkrankungen Heidelberg; Deutsche Krebshilfe; National Cancer Institute; Weizmann Institute of Science; Ministry of Science and Technology, Israel; Wellcome Trust; Wilhelm Sander-Stiftung; Moffitt Cancer Center; Deutsche Forschungsgemeinschaft; Deutsches Krebsforschungszentrum; Canadian Institute for Advanced Research; Bill and Melinda Gates Foundation; IDSA Foundation; Baden-Württemberg Stiftung; Infectious Diseases Society of America; Universität Heidelberg; Howard Hughes Medical Institute","keywords":"Akkermansia; Microbiome; Antibiotics; Immunology; Medicine; Cancer; Cohort; Population; Gut flora; Internal medicine; Biology; Oncology; Bioinformatics; Bacteroides; Microbiology","score_opus":0.03393981037234582,"score_gpt":0.4145805644084198,"score_spread":0.38064075403607395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324044824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99641633,0.001626286,0.00028681642,0.0003379325,0.000052084513,0.000015674548,0.00023515287,0.00001871582,0.0010110534],"genre_scores_gemma":[0.9989987,0.00020525054,0.00017116091,0.00012179982,0.000025228304,0.000009627888,0.0001640827,0.0000057238435,0.00029843478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995498,0.00010838053,0.0000324731,0.000088447065,0.000077655925,0.0001430795],"domain_scores_gemma":[0.99859387,0.0001963942,0.00076329894,0.00007778657,0.00010272549,0.00026588282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029319947,0.00019392524,0.00033077496,0.0002538602,0.0003128552,0.00065209833,0.00014351965,0.0004893232,0.0022858623],"category_scores_gemma":[0.0012382877,0.00013305614,0.00024956922,0.00033377353,0.00038789635,0.00033349684,0.00032865163,0.0007405212,0.00025566568],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019616028,0.00080070755,0.6847108,0.00033430575,0.00063375774,0.0016203577,0.0002067448,0.00030262006,0.2410664,0.00042354784,0.0019094939,0.048375152],"study_design_scores_gemma":[0.00011547541,0.0021431793,0.9785041,0.000050526964,0.00022806488,0.0022970515,0.00032143816,0.00056092,0.0110090105,0.00040730814,0.004344431,0.00001854086],"about_ca_topic_score_codex":0.00037858664,"about_ca_topic_score_gemma":0.00064907374,"teacher_disagreement_score":0.0022858623,"about_ca_system_score_codex":0.00029675275,"about_ca_system_score_gemma":0.00030486056,"threshold_uncertainty_score":0.007646978},"labels":[],"label_agreement":null},{"id":"W4324342851","doi":"10.1016/j.omtm.2023.03.006","title":"Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Ottawa Hospital; Institute of Infection and Immunity; University of Ottawa","funders":"National Cancer Institute; National Research Council Canada; Ottawa Hospital Research Institute; Canadian Institutes of Health Research; University of Ottawa","keywords":"CRISPR; Transgenesis; Biology; Cas9; Genetics; Computational biology; Gene; Reproductive technology","score_opus":0.11891240073928173,"score_gpt":0.4657807527445325,"score_spread":0.3468683520052508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324342851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7751472,0.0016826486,0.21448784,0.00027991543,0.0003237821,0.001242497,0.000930334,0.0014103949,0.004495362],"genre_scores_gemma":[0.92198867,0.0008069264,0.0682231,0.000107313805,0.00002454165,0.0005834915,0.0009711119,0.00018337365,0.0071115517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99920136,0.00009300124,0.000115998155,0.0002061177,0.00027504234,0.000108542554],"domain_scores_gemma":[0.9996879,0.000069100024,0.00009562513,0.0000650735,0.000033508728,0.000048878283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058741786,0.0006332953,0.00055106444,0.00039669528,0.00025539426,0.00068924594,0.000568851,0.0007935555,0.0013844214],"category_scores_gemma":[0.00030141906,0.00037854206,0.0005072102,0.00018495468,0.0004994903,0.00039560423,0.00060618547,0.0013575436,0.0007339511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004407306,0.000041479198,0.00013381022,0.00004458105,0.000010373905,0.000086322216,0.00003440905,0.00016404058,0.9966395,0.00045880704,0.000056474848,0.0022862207],"study_design_scores_gemma":[0.000017968148,0.00013589476,0.0003358139,0.000005213757,0.00002206992,0.00032494732,0.000012123434,0.0014517236,0.9938047,0.000058914724,0.003822939,0.000007717229],"about_ca_topic_score_codex":0.0003581798,"about_ca_topic_score_gemma":0.000661253,"teacher_disagreement_score":0.0013844214,"about_ca_system_score_codex":0.00036805135,"about_ca_system_score_gemma":0.0004660204,"threshold_uncertainty_score":0.004631281},"labels":[],"label_agreement":null},{"id":"W4327940554","doi":"10.1016/j.cell.2023.02.027","title":"Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing","year":2023,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation; National Human Genome Research Institute; Howard Hughes Medical Institute","keywords":"Biology; Human immunodeficiency virus (HIV); Base (topology); Virology; CD3; Severe combined immunodeficiency; Immunodeficiency; Cell biology; Genetics; Computational biology; Immunology; Gene; Immune system; CD8","score_opus":0.06127085463604074,"score_gpt":0.32833108210947287,"score_spread":0.2670602274734321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327940554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98041224,0.0010663897,0.008401322,0.00027636826,0.00017361678,0.00010796634,0.0019972948,0.0009171614,0.0066475905],"genre_scores_gemma":[0.993701,0.0002627758,0.0020781066,0.00007228438,0.000016001903,0.000038171267,0.0007331746,0.00009413967,0.003004435],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997273,0.00006198171,0.00003236582,0.00005727557,0.000049802948,0.00007120505],"domain_scores_gemma":[0.9998228,0.000039923336,0.000041073,0.00004363588,0.000012397668,0.00004019895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000336247,0.00044600086,0.00032570216,0.0004540328,0.00031570587,0.0005481121,0.0003581055,0.000638967,0.004107325],"category_scores_gemma":[0.00020166204,0.00018431192,0.0003357524,0.00026033656,0.00047739813,0.00019184902,0.00029519707,0.0012147588,0.00095178135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003008753,0.00004185085,0.00017292025,0.000029661134,0.000010608956,0.00020976656,0.000038568414,0.00013374454,0.9960402,0.000670483,0.00027757185,0.0020737324],"study_design_scores_gemma":[0.000089586196,0.00023226964,0.0014002931,0.000007755476,0.000029848552,0.0008502117,0.000036649242,0.0012116885,0.9860707,0.0002484609,0.009812988,0.000009622838],"about_ca_topic_score_codex":0.00064293185,"about_ca_topic_score_gemma":0.0005837982,"teacher_disagreement_score":0.004107325,"about_ca_system_score_codex":0.00020574633,"about_ca_system_score_gemma":0.00026770352,"threshold_uncertainty_score":0.013740361},"labels":[],"label_agreement":null},{"id":"W4328048068","doi":"10.1016/j.jcyt.2023.02.007","title":"International Society for Cell &amp; Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant","year":2023,"lang":"en","type":"review","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Stem cell; Genetic enhancement; Hematopoietic stem cell; Graft-versus-host disease; Disease; Hematopoietic stem cell transplantation; Cell; Haematopoiesis; Cell therapy; Stem-cell therapy; Medicine; Gene; Cancer research; Immunology; Biology; Internal medicine; Cell biology; Genetics","score_opus":0.08540012506480056,"score_gpt":0.33491598721822236,"score_spread":0.2495158621534218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328048068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016560053,0.9837631,0.00043789623,0.0016862572,0.0031747613,0.000048746537,0.000117903815,0.000042443025,0.010563187],"genre_scores_gemma":[0.0009803243,0.9797203,0.00074787077,0.0014856268,0.00093312346,0.000052482763,0.00025772926,0.0000125290835,0.015810085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997074,0.000029283705,0.000026853639,0.00004135805,0.00015629425,0.000038928803],"domain_scores_gemma":[0.9994123,0.00013381724,0.00007697967,0.000015748103,0.00026461048,0.00009652606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010256598,0.0011042409,0.0012189936,0.0025107528,0.00041109417,0.0014800464,0.0009051938,0.0018247197,0.008855893],"category_scores_gemma":[0.00067292625,0.00028547383,0.0004639958,0.0023958702,0.00049161946,0.001242247,0.0009366768,0.0025997704,0.009121822],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010042498,0.0001041297,0.00006244908,0.004626588,0.000026743355,0.00008139591,0.000025409532,0.00014177353,0.0040830816,0.0036460545,0.16429149,0.8228106],"study_design_scores_gemma":[0.000027192245,0.00005877156,0.00020636416,0.00095329364,0.000030074569,0.00016326616,0.000010666097,0.00004005709,0.00089076103,0.0004396972,0.99717194,0.000007890215],"about_ca_topic_score_codex":0.0020340057,"about_ca_topic_score_gemma":0.0039893272,"teacher_disagreement_score":0.008855893,"about_ca_system_score_codex":0.00090671866,"about_ca_system_score_gemma":0.0031858934,"threshold_uncertainty_score":0.029625893},"labels":[],"label_agreement":null},{"id":"W4353086070","doi":"10.54097/hset.v36i.5706","title":"Comprehensive Overview of CAR-T Cell Therapy, Engineering Process and Future Prospects","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Chimeric antigen receptor; Immune system; Antigen; Cancer research; Cell therapy; Antigen-presenting cell; Immunology; Immunotherapy; Cytotoxic T cell; T cell; Medicine; Biology; Stem cell; Cell biology","score_opus":0.019460927381170234,"score_gpt":0.28982051849732815,"score_spread":0.2703595911161579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353086070","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012767378,0.97863275,0.0068083624,0.0012629896,0.00076184154,0.00007062971,0.00011951709,0.00011610139,0.01095118],"genre_scores_gemma":[0.00544817,0.9820011,0.0044966377,0.0009811916,0.00068520405,0.000104356746,0.00028266647,0.000024697802,0.005976017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969256,0.00004959835,0.000032558306,0.00006820144,0.00011348261,0.000043664662],"domain_scores_gemma":[0.999813,0.00006528418,0.000021326949,0.000009857527,0.00006615693,0.000024411718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083350943,0.00080613856,0.00086276315,0.0018770967,0.000341595,0.0014834943,0.0008636683,0.0013794585,0.0053671002],"category_scores_gemma":[0.0004506357,0.0004177602,0.0008102348,0.0016848344,0.0003553878,0.0021408908,0.00062477804,0.001713518,0.003150593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015019915,0.0002460839,0.0004910808,0.0094822245,0.000053070115,0.00033011322,0.00010657135,0.0015824655,0.013726584,0.02145813,0.036697205,0.91567624],"study_design_scores_gemma":[0.000014858369,0.0002943749,0.00039809934,0.00072482857,0.000058357564,0.0012720246,0.00004193024,0.00074106513,0.005418518,0.0037687102,0.987237,0.000030182615],"about_ca_topic_score_codex":0.0009971561,"about_ca_topic_score_gemma":0.00091561244,"teacher_disagreement_score":0.0053671002,"about_ca_system_score_codex":0.0009535044,"about_ca_system_score_gemma":0.0010575781,"threshold_uncertainty_score":0.017954767},"labels":[],"label_agreement":null},{"id":"W4353087883","doi":"10.54097/hset.v36i.5685","title":"Advantages and Disadvantages of Car-T Therapy in the Clinical Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; CAR T-cell therapy; Medicine; Lymphoma; Cell therapy; Oncology; Chemotherapy; T cell; Cancer; Internal medicine; Immunotherapy; Immunology; Cell; Immune system; Biology","score_opus":0.024159055362451828,"score_gpt":0.3423455755452983,"score_spread":0.3181865201828465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353087883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.051302407,0.8506987,0.041276634,0.026327753,0.0010718141,0.00007076125,0.000084688756,0.00017126648,0.028995954],"genre_scores_gemma":[0.49177793,0.46118155,0.027495531,0.0085579865,0.0038587812,0.00014749813,0.00014057438,0.00009081983,0.006749344],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885523,0.00048084243,0.00008047363,0.00011730885,0.0003798274,0.0000863142],"domain_scores_gemma":[0.9992242,0.00044525368,0.000105618325,0.000037437752,0.00012698324,0.00006042472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030582992,0.0003162255,0.00045765648,0.00064915576,0.00038131519,0.0011613192,0.00043666168,0.0011169704,0.0015409917],"category_scores_gemma":[0.0013217856,0.0001223266,0.0005132601,0.00050736347,0.00091011764,0.0012686078,0.00066238706,0.0018263515,0.000408732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070427987,0.00020484555,0.0047746855,0.0016841453,0.00009760475,0.0014695423,0.00028260463,0.0018216467,0.022466501,0.031748034,0.00849862,0.9262474],"study_design_scores_gemma":[0.00033402565,0.004264507,0.013564419,0.0011918432,0.0005468382,0.041729216,0.0006998518,0.007896764,0.06801697,0.047942914,0.8136325,0.00018005968],"about_ca_topic_score_codex":0.00041242267,"about_ca_topic_score_gemma":0.0007067106,"teacher_disagreement_score":0.0030582992,"about_ca_system_score_codex":0.00069461454,"about_ca_system_score_gemma":0.00081540446,"threshold_uncertainty_score":0.016174018},"labels":[],"label_agreement":null},{"id":"W4360825288","doi":"10.1117/12.2669343","title":"Design of a novel CAR T system targeting glioblastoma","year":2023,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Glioblastoma; Limiting; Cancer research; Immune system; Glioma; Antigen; Cytotoxicity; Receptor; T-cell receptor; Immunotherapy; T cell; Biology; Medicine; Immunology; In vitro; Internal medicine; Engineering","score_opus":0.05674340200660939,"score_gpt":0.3215453981473689,"score_spread":0.2648019961407595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360825288","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8593471,0.005139209,0.12076564,0.00086613855,0.00025751596,0.0014007746,0.00050378183,0.00085751957,0.010862371],"genre_scores_gemma":[0.96251047,0.0017628665,0.029586798,0.00043992,0.000046688085,0.0006145071,0.00036287608,0.000034023848,0.0046417667],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999144,0.000011976454,0.0000067540345,0.000022843418,0.000015516134,0.000028458227],"domain_scores_gemma":[0.9999697,0.0000020383256,0.000008208492,0.000001577468,0.0000060960847,0.000012416316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116276366,0.00033471864,0.0002627514,0.00027539596,0.00022396384,0.00029077535,0.0003271742,0.00040746937,0.0012497177],"category_scores_gemma":[0.00009376361,0.00018272744,0.00026047562,0.0001455873,0.000145647,0.00026134352,0.00027049874,0.00034274618,0.00047829727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022090842,0.00014463563,0.0002621309,0.00022347193,0.0000184642,0.00024031877,0.000062138344,0.0012680944,0.979752,0.0023489064,0.0007006543,0.01475842],"study_design_scores_gemma":[0.00026295788,0.0041885143,0.0011423575,0.00002549294,0.00010267964,0.001021101,0.000049039543,0.012447655,0.95088226,0.00042642065,0.029394299,0.000057163674],"about_ca_topic_score_codex":0.00061186956,"about_ca_topic_score_gemma":0.0005394015,"teacher_disagreement_score":0.0012497177,"about_ca_system_score_codex":0.00034586692,"about_ca_system_score_gemma":0.0005365591,"threshold_uncertainty_score":0.004180789},"labels":[],"label_agreement":null},{"id":"W4360992847","doi":"10.1073/pnas.2219086120","title":"Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion","year":2023,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"Canadian Institutes of Health Research; Government of Canada; BC Children's Hospital","keywords":"Chimeric antigen receptor; Biology; Downregulation and upregulation; Immunology; Transcription factor; Chromatin; T cell; CD8; Receptor; Cell biology; Immune system; Cell therapy; Stem cell; Genetics; Gene","score_opus":0.06730328592337548,"score_gpt":0.36110241886607736,"score_spread":0.2937991329427019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360992847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960387,0.00051202433,0.002276801,0.00003848418,0.000013512788,0.000031801228,0.00016705833,0.0000815412,0.000840079],"genre_scores_gemma":[0.99724126,0.0002589154,0.0010258943,0.000058818543,0.000008021279,0.000028044717,0.0004337057,0.000016366188,0.0009289912],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984205,0.00002636991,0.00001226414,0.00003438973,0.000030927433,0.000054051427],"domain_scores_gemma":[0.99994314,0.000015472766,0.000011862996,0.000012779338,0.000006213238,0.000010450963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020940755,0.00020604707,0.00019225446,0.00013267518,0.00007793886,0.00021971045,0.00014489553,0.00016113381,0.0013119577],"category_scores_gemma":[0.00011107328,0.0000902779,0.0001966861,0.0000985378,0.0001404544,0.00010775714,0.00017173914,0.0004446077,0.00030179115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019234589,0.000060903283,0.00037372718,0.00001895475,0.0000050967287,0.000045249115,0.000017708118,0.00014532426,0.9965642,0.00016748476,0.00007884221,0.0023300739],"study_design_scores_gemma":[0.000102672784,0.0019570729,0.0060492093,0.000008402752,0.000047274796,0.0007079283,0.00005112448,0.003500985,0.98207283,0.00020981213,0.005283162,0.000009415833],"about_ca_topic_score_codex":0.0002612217,"about_ca_topic_score_gemma":0.00029718594,"teacher_disagreement_score":0.0013119577,"about_ca_system_score_codex":0.00015978237,"about_ca_system_score_gemma":0.00018983358,"threshold_uncertainty_score":0.0043889284},"labels":[],"label_agreement":null},{"id":"W4361279352","doi":"10.1182/bloodadvances.2022009117","title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Leukemia and Lymphoma Society","keywords":"Chimeric antigen receptor; Medicine; Receptor; Antigen; Cell therapy; Immunology; Internal medicine; Cell; Immunotherapy; Biology; Immune system; Genetics","score_opus":0.028434535764571875,"score_gpt":0.31652089862229865,"score_spread":0.28808636285772676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361279352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99930537,0.00015910357,0.00007548448,0.00005541264,0.0000041614294,0.000010384566,0.00026511055,0.0000026194068,0.00012237672],"genre_scores_gemma":[0.9990608,0.000062648294,0.00006820008,0.000053498512,0.00000768271,0.000024067764,0.00063710316,0.0000012018846,0.0000847599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998803,0.000543043,0.000114433395,0.00017995553,0.00013882219,0.00022072702],"domain_scores_gemma":[0.9963766,0.0006148102,0.00180535,0.00021915944,0.0003257429,0.0006584318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002864537,0.00026603517,0.0005988517,0.00050845015,0.00057543354,0.0010140255,0.00039366583,0.0005892891,0.000777659],"category_scores_gemma":[0.005825566,0.00027509153,0.0009105557,0.0008672176,0.00023899176,0.00078652176,0.0007320176,0.0013224292,0.0002159558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004771009,0.00016475811,0.9972922,0.0000065435293,0.000098387376,0.000035715133,0.000105913525,0.00009269995,0.000097807075,0.000012905788,0.00008990633,0.0015260576],"study_design_scores_gemma":[0.000048739465,0.00090555596,0.99783033,0.000008751357,0.00007500105,0.00010443526,0.00015870093,0.0005432121,0.000082531624,0.000040436313,0.00019136818,0.000010911835],"about_ca_topic_score_codex":0.003475239,"about_ca_topic_score_gemma":0.0039238613,"teacher_disagreement_score":0.003475239,"about_ca_system_score_codex":0.0006341137,"about_ca_system_score_gemma":0.0005249395,"threshold_uncertainty_score":0.015149295},"labels":[],"label_agreement":null},{"id":"W4361817155","doi":"10.1158/1078-0432.c.6528245.v1","title":"Data from Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Social Innovation; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"CD8; Cancer research; Cytotoxicity; In vitro; In vivo; Transplantation; Cytotoxic T cell; Flow cytometry; Immunology; Chemistry; Molecular biology; Immune system; Biology; Medicine; Biochemistry; Internal medicine","score_opus":0.2841065190242599,"score_gpt":0.4189088756336146,"score_spread":0.13480235660935475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361817155","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9153493,0.018288333,0.02883351,0.0011425639,0.0003839717,0.0008645582,0.0033000403,0.00028388892,0.03155376],"genre_scores_gemma":[0.96397835,0.01110209,0.008436183,0.0010440749,0.00010469553,0.00041865214,0.005231341,0.000078195575,0.009606427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996259,0.00009256566,0.000059201582,0.000062447325,0.00012490258,0.000034901794],"domain_scores_gemma":[0.9996049,0.00012950164,0.0000515118,0.00006498029,0.00009801593,0.00005112985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008397147,0.0005548301,0.00025953708,0.000276041,0.0001325285,0.00053595856,0.0003962638,0.00044265922,0.003566909],"category_scores_gemma":[0.00045157853,0.000098176984,0.0002470305,0.00019367538,0.00026288893,0.00034170103,0.00020124369,0.0010422996,0.0009357607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015924636,0.0010453127,0.0019427672,0.0005687133,0.00005989548,0.0002105315,0.00010710394,0.0008676482,0.9344883,0.0012367795,0.0024173746,0.055463128],"study_design_scores_gemma":[0.00017541507,0.007322005,0.004929441,0.00005066525,0.0001743407,0.00086644926,0.0000703416,0.000979991,0.95382094,0.00024149564,0.031358175,0.000010751082],"about_ca_topic_score_codex":0.00026226483,"about_ca_topic_score_gemma":0.00042464756,"teacher_disagreement_score":0.003566909,"about_ca_system_score_codex":0.0002295925,"about_ca_system_score_gemma":0.00028479885,"threshold_uncertainty_score":0.011932552},"labels":[],"label_agreement":null},{"id":"W4361817253","doi":"10.1158/1078-0432.c.6528245","title":"Data from Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Social Innovation; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"CD8; Cytotoxicity; Cancer research; In vitro; Transplantation; Cytotoxic T cell; In vivo; Flow cytometry; Immunology; Chemistry; Molecular biology; Immune system; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.2841065190242599,"score_gpt":0.4189088756336146,"score_spread":0.13480235660935475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361817253","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9153493,0.018288333,0.02883351,0.0011425639,0.0003839717,0.0008645582,0.0033000403,0.00028388892,0.03155376],"genre_scores_gemma":[0.96397835,0.01110209,0.008436183,0.0010440749,0.00010469553,0.00041865214,0.005231341,0.000078195575,0.009606427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996259,0.00009256566,0.000059201582,0.000062447325,0.00012490258,0.000034901794],"domain_scores_gemma":[0.9996049,0.00012950164,0.0000515118,0.00006498029,0.00009801593,0.00005112985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008397147,0.0005548301,0.00025953708,0.000276041,0.0001325285,0.00053595856,0.0003962638,0.00044265922,0.003566909],"category_scores_gemma":[0.00045157853,0.000098176984,0.0002470305,0.00019367538,0.00026288893,0.00034170103,0.00020124369,0.0010422996,0.0009357607],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015924636,0.0010453127,0.0019427672,0.0005687133,0.00005989548,0.0002105315,0.00010710394,0.0008676482,0.9344883,0.0012367795,0.0024173746,0.055463128],"study_design_scores_gemma":[0.00017541507,0.007322005,0.004929441,0.00005066525,0.0001743407,0.00086644926,0.0000703416,0.000979991,0.95382094,0.00024149564,0.031358175,0.000010751082],"about_ca_topic_score_codex":0.00026226483,"about_ca_topic_score_gemma":0.00042464756,"teacher_disagreement_score":0.003566909,"about_ca_system_score_codex":0.0002295925,"about_ca_system_score_gemma":0.00028479885,"threshold_uncertainty_score":0.011932552},"labels":[],"label_agreement":null},{"id":"W4361822960","doi":"10.1158/0008-5472.c.6513447.v1","title":"Data from Mesothelin-Specific CAR T Cells Target Ovarian Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"Mesothelin; Ovarian cancer; Cancer research; CD28; Tumor microenvironment; T cell; CD8; Immune system; Cytotoxic T cell; Medicine; Antigen; Immunology; Cancer; Chemistry; Internal medicine; Tumor cells; In vitro","score_opus":0.1848458817025429,"score_gpt":0.38904224535881604,"score_spread":0.20419636365627314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361822960","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97364503,0.008858681,0.00477335,0.0007250649,0.00014987488,0.00016188223,0.0029202548,0.00025799425,0.00850783],"genre_scores_gemma":[0.9863424,0.0033121484,0.0013071791,0.00032614561,0.000059600992,0.00012749653,0.0034072972,0.00005904588,0.0050587286],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999676,0.00007395784,0.000046516383,0.000054785654,0.00009436224,0.00005439042],"domain_scores_gemma":[0.9996971,0.000091987284,0.000046509645,0.00005520761,0.00005048478,0.00005879056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003946411,0.00032015936,0.00037693421,0.00028801328,0.00014733705,0.00039362512,0.0001713626,0.0003267381,0.0035872597],"category_scores_gemma":[0.00028101922,0.00009975285,0.000381754,0.00021404526,0.0001970294,0.000283767,0.00018524959,0.0009774212,0.00075759896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001099963,0.0002611227,0.0022620119,0.00048439554,0.000052830474,0.00011122413,0.000104155595,0.00036493863,0.9786428,0.0003411698,0.0011895022,0.015085776],"study_design_scores_gemma":[0.00015410231,0.004499939,0.017058436,0.000026740865,0.00018245107,0.0011044529,0.00012082406,0.0013140768,0.9453152,0.00012561245,0.030086718,0.000011559779],"about_ca_topic_score_codex":0.00040692653,"about_ca_topic_score_gemma":0.00063498423,"teacher_disagreement_score":0.0035872597,"about_ca_system_score_codex":0.00023553366,"about_ca_system_score_gemma":0.00023122586,"threshold_uncertainty_score":0.012000561},"labels":[],"label_agreement":null},{"id":"W4361942601","doi":"10.1158/1078-0432.c.6516061","title":"Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Gilead Sciences","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Adverse effect; Clinical endpoint; Refractory (planetary science); Cytokine release syndrome; Oncology; Gastroenterology; Randomized controlled trial; Lymphoma; Surgery; Immunotherapy; Rituximab; Chimeric antigen receptor; Cancer","score_opus":0.04952137718723923,"score_gpt":0.32935372489378223,"score_spread":0.27983234770654297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361942601","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247533,0.003652573,0.00013440833,0.00032177297,0.000057498422,0.00027955882,0.0015335508,0.000013804321,0.0015314806],"genre_scores_gemma":[0.9963632,0.0010412157,0.00012981423,0.00047458173,0.00008839173,0.00021569172,0.001232646,0.000005597942,0.0004489091],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988953,0.00064253755,0.00012379207,0.00010216805,0.00013344797,0.00010267833],"domain_scores_gemma":[0.99752134,0.0009770377,0.000806886,0.00022214901,0.00010134734,0.00037126013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021388433,0.00042772092,0.0011352726,0.00033466984,0.0002424586,0.00069042237,0.00042133706,0.0007641573,0.0029150096],"category_scores_gemma":[0.002841877,0.00021515858,0.0021906735,0.00049529254,0.0005427589,0.0005989507,0.00032216025,0.0010894124,0.00039738772],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9133152,0.0036333392,0.021347793,0.0010676746,0.0038309118,0.00016068971,0.00011945228,0.00093744736,0.0056110006,0.00011954402,0.0018343162,0.0480227],"study_design_scores_gemma":[0.44246602,0.3533703,0.1785961,0.00036775394,0.010204543,0.0005978921,0.00028752445,0.0014429848,0.0050629578,0.00047013033,0.0070535056,0.00008034388],"about_ca_topic_score_codex":0.00068087125,"about_ca_topic_score_gemma":0.0018347235,"teacher_disagreement_score":0.0029150096,"about_ca_system_score_codex":0.0006118118,"about_ca_system_score_gemma":0.00066428044,"threshold_uncertainty_score":0.011311412},"labels":[],"label_agreement":null},{"id":"W4361943767","doi":"10.1158/1078-0432.c.6519491","title":"Data from Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Antagonist; Regimen; Internal medicine; Lymphoma; Pharmacology; Adverse effect; Gastroenterology; Receptor","score_opus":0.17987563151021402,"score_gpt":0.41832344583255215,"score_spread":0.23844781432233814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361943767","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95440304,0.016892327,0.003148953,0.0018291065,0.00027921906,0.0037391835,0.009868833,0.0003055161,0.009533854],"genre_scores_gemma":[0.96371,0.0091473535,0.0024695299,0.003174661,0.00018241996,0.0025515016,0.015137215,0.000073756775,0.0035536005],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990715,0.0005491398,0.00009769986,0.00008595998,0.0001238029,0.000071965755],"domain_scores_gemma":[0.9972097,0.00110069,0.0005818489,0.00031492885,0.00021638203,0.00057639065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029485028,0.0011589117,0.0017324266,0.00036381857,0.00036512973,0.0008301693,0.000770426,0.0009824267,0.003701396],"category_scores_gemma":[0.0025887156,0.00038452807,0.0015912168,0.00058589753,0.0006222361,0.0008144738,0.00028263676,0.0023129762,0.00087211904],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5816397,0.023400873,0.017231587,0.0036229163,0.005094673,0.0005369779,0.0004086377,0.006018931,0.0963063,0.00072520995,0.022009306,0.24300487],"study_design_scores_gemma":[0.41559923,0.4853208,0.051425908,0.000321023,0.0034872333,0.0010070355,0.00015218962,0.0015179586,0.01743909,0.0005821341,0.023061302,0.00008606261],"about_ca_topic_score_codex":0.0008880465,"about_ca_topic_score_gemma":0.0021062344,"teacher_disagreement_score":0.003701396,"about_ca_system_score_codex":0.00074652606,"about_ca_system_score_gemma":0.0014148746,"threshold_uncertainty_score":0.01559341},"labels":[],"label_agreement":null},{"id":"W4361947401","doi":"10.1158/1078-0432.c.6530741","title":"Data from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"Leukemia and Lymphoma Society; Canadian Institutes of Health Research; BC Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation; Gilead Sciences","keywords":"Lenalidomide; Cancer research; Diffuse large B-cell lymphoma; EZH2; Medicine; Lymphoma; Biology; Epigenetics; Immunology; Multiple myeloma; Gene","score_opus":0.08134297010076623,"score_gpt":0.3518199541938775,"score_spread":0.2704769840931113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9510361,0.007936721,0.0043816315,0.00095387356,0.00019417457,0.00007041328,0.026569122,0.0010895765,0.0077684205],"genre_scores_gemma":[0.96860194,0.0029307653,0.0018305479,0.00064345205,0.000026471942,0.000088237786,0.01970342,0.00011327752,0.0060619074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997085,0.000023780212,0.00002937621,0.000054896325,0.00013808202,0.000045326047],"domain_scores_gemma":[0.99982834,0.000032639586,0.00003202037,0.000023250723,0.000036714126,0.00004694111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027021856,0.0003117337,0.00054275064,0.00043700353,0.00016796956,0.0004539484,0.00023434486,0.00036567522,0.00453113],"category_scores_gemma":[0.00019717749,0.00017933823,0.00046946647,0.00037419872,0.00018434234,0.00020915791,0.00021234689,0.0010506931,0.0012338732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001360111,0.00017847428,0.0025111185,0.0003127214,0.00009300736,0.0001357815,0.000026955866,0.0005175526,0.98156893,0.00013555534,0.0026907697,0.010468928],"study_design_scores_gemma":[0.0002655506,0.001509936,0.048695054,0.000024632516,0.0002305729,0.0010605323,0.00012779931,0.0022779836,0.9220742,0.00018446133,0.023519522,0.000029671713],"about_ca_topic_score_codex":0.0011542086,"about_ca_topic_score_gemma":0.001951421,"teacher_disagreement_score":0.00453113,"about_ca_system_score_codex":0.00041854326,"about_ca_system_score_gemma":0.00033673845,"threshold_uncertainty_score":0.015158117},"labels":[],"label_agreement":null},{"id":"W4361947402","doi":"10.1158/1078-0432.c.6530591","title":"Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Adverse effect; Antibody; Melanoma; Gastroenterology; Colorectal cancer; Cancer; Lung cancer; Oncology; Immunology; Cancer research","score_opus":0.18471333416550853,"score_gpt":0.510112216982763,"score_spread":0.3253988828172545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7887553,0.015832806,0.0087752165,0.0037315406,0.0006596326,0.008146323,0.13844885,0.00071516423,0.034935106],"genre_scores_gemma":[0.8606202,0.0046969308,0.004187944,0.0041196323,0.00027585367,0.0058582327,0.111473314,0.00018411812,0.008583774],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99809283,0.0009779448,0.00020854756,0.00021906177,0.00035856658,0.00014298367],"domain_scores_gemma":[0.9937218,0.0025617336,0.0013377592,0.00071982003,0.0006511192,0.0010077767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005540112,0.0012617866,0.0020949477,0.0004406298,0.0005953075,0.0013896384,0.00077732344,0.0012260292,0.0069934265],"category_scores_gemma":[0.0051629455,0.0004848186,0.0021346076,0.0007868437,0.00054974976,0.0012949519,0.00039708932,0.002862168,0.0020027051],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64076984,0.01777681,0.031599373,0.0044432255,0.007562291,0.00043098186,0.00029934268,0.018152453,0.02188111,0.0009660867,0.06850594,0.18761256],"study_design_scores_gemma":[0.49169454,0.25779268,0.117882214,0.0008095805,0.009756879,0.0018132073,0.0002375203,0.00962444,0.019129975,0.002619205,0.08841737,0.00022231361],"about_ca_topic_score_codex":0.0012118523,"about_ca_topic_score_gemma":0.0023763583,"teacher_disagreement_score":0.0069934265,"about_ca_system_score_codex":0.00093128893,"about_ca_system_score_gemma":0.0019253395,"threshold_uncertainty_score":0.029299319},"labels":[],"label_agreement":null},{"id":"W4361948700","doi":"10.1158/1078-0432.c.6516061.v1","title":"Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Gilead Sciences","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Adverse effect; Clinical endpoint; Refractory (planetary science); Oncology; Cytokine release syndrome; Gastroenterology; Randomized controlled trial; Lymphoma; Surgery; Rituximab; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.04952137718723923,"score_gpt":0.32935372489378223,"score_spread":0.27983234770654297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361948700","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247533,0.003652573,0.00013440833,0.00032177297,0.000057498422,0.00027955882,0.0015335508,0.000013804321,0.0015314806],"genre_scores_gemma":[0.9963632,0.0010412157,0.00012981423,0.00047458173,0.00008839173,0.00021569172,0.001232646,0.000005597942,0.0004489091],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988953,0.00064253755,0.00012379207,0.00010216805,0.00013344797,0.00010267833],"domain_scores_gemma":[0.99752134,0.0009770377,0.000806886,0.00022214901,0.00010134734,0.00037126013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021388433,0.00042772092,0.0011352726,0.00033466984,0.0002424586,0.00069042237,0.00042133706,0.0007641573,0.0029150096],"category_scores_gemma":[0.002841877,0.00021515858,0.0021906735,0.00049529254,0.0005427589,0.0005989507,0.00032216025,0.0010894124,0.00039738772],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9133152,0.0036333392,0.021347793,0.0010676746,0.0038309118,0.00016068971,0.00011945228,0.00093744736,0.0056110006,0.00011954402,0.0018343162,0.0480227],"study_design_scores_gemma":[0.44246602,0.3533703,0.1785961,0.00036775394,0.010204543,0.0005978921,0.00028752445,0.0014429848,0.0050629578,0.00047013033,0.0070535056,0.00008034388],"about_ca_topic_score_codex":0.00068087125,"about_ca_topic_score_gemma":0.0018347235,"teacher_disagreement_score":0.0029150096,"about_ca_system_score_codex":0.0006118118,"about_ca_system_score_gemma":0.00066428044,"threshold_uncertainty_score":0.011311412},"labels":[],"label_agreement":null},{"id":"W4361949487","doi":"10.1158/1078-0432.c.6519491.v1","title":"Data from Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Antagonist; Regimen; Lymphoma; Pharmacology; Internal medicine; Adverse effect; Gastroenterology; Receptor","score_opus":0.17987563151021402,"score_gpt":0.41832344583255215,"score_spread":0.23844781432233814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361949487","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95440304,0.016892327,0.003148953,0.0018291065,0.00027921906,0.0037391835,0.009868833,0.0003055161,0.009533854],"genre_scores_gemma":[0.96371,0.0091473535,0.0024695299,0.003174661,0.00018241996,0.0025515016,0.015137215,0.000073756775,0.0035536005],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9990715,0.0005491398,0.00009769986,0.00008595998,0.0001238029,0.000071965755],"domain_scores_gemma":[0.9972097,0.00110069,0.0005818489,0.00031492885,0.00021638203,0.00057639065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029485028,0.0011589117,0.0017324266,0.00036381857,0.00036512973,0.0008301693,0.000770426,0.0009824267,0.003701396],"category_scores_gemma":[0.0025887156,0.00038452807,0.0015912168,0.00058589753,0.0006222361,0.0008144738,0.00028263676,0.0023129762,0.00087211904],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5816397,0.023400873,0.017231587,0.0036229163,0.005094673,0.0005369779,0.0004086377,0.006018931,0.0963063,0.00072520995,0.022009306,0.24300487],"study_design_scores_gemma":[0.41559923,0.4853208,0.051425908,0.000321023,0.0034872333,0.0010070355,0.00015218962,0.0015179586,0.01743909,0.0005821341,0.023061302,0.00008606261],"about_ca_topic_score_codex":0.0008880465,"about_ca_topic_score_gemma":0.0021062344,"teacher_disagreement_score":0.003701396,"about_ca_system_score_codex":0.00074652606,"about_ca_system_score_gemma":0.0014148746,"threshold_uncertainty_score":0.01559341},"labels":[],"label_agreement":null},{"id":"W4361953633","doi":"10.1158/1078-0432.c.6530078.v1","title":"Data from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Cancer Research UK; Pancreatic Cancer UK; Johns Hopkins University; Canary Foundation","keywords":"Cancer research; Pancreatic cancer; In vivo; Pancreas; Adenocarcinoma; Cell culture; Pancreatic ductal adenocarcinoma; Cancer; Medicine; Biology; Internal medicine","score_opus":0.13886998638167972,"score_gpt":0.3811469021155344,"score_spread":0.2422769157338547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953633","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92067873,0.01438701,0.008900388,0.0018018063,0.00034611343,0.0004059947,0.010373753,0.000690719,0.04241544],"genre_scores_gemma":[0.9566109,0.0070258146,0.0035759246,0.0011059415,0.00009411737,0.00030674986,0.012511366,0.00015601571,0.018613236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99972695,0.000046443973,0.000034977933,0.00004252329,0.00011106311,0.000038095677],"domain_scores_gemma":[0.9997781,0.000061265986,0.000023611763,0.000036299312,0.00005074471,0.000049963513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002949861,0.00031630028,0.00044231713,0.00039616256,0.00016667377,0.000465952,0.00029691122,0.00043234188,0.008719319],"category_scores_gemma":[0.00023227632,0.00013939448,0.00040188694,0.00029674964,0.00020578127,0.00023471742,0.00014629075,0.0009012832,0.001918652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016043398,0.00041927767,0.001296935,0.00047782675,0.0000574996,0.00022324931,0.000038982907,0.0002718521,0.9739388,0.00036807626,0.0035800356,0.017723257],"study_design_scores_gemma":[0.0002853075,0.0038130155,0.010297857,0.00003478519,0.00018399996,0.0011298603,0.00007159573,0.0010550552,0.94560844,0.00016578793,0.037341777,0.000012588777],"about_ca_topic_score_codex":0.0008492238,"about_ca_topic_score_gemma":0.0010425036,"teacher_disagreement_score":0.008719319,"about_ca_system_score_codex":0.00036199362,"about_ca_system_score_gemma":0.00033218693,"threshold_uncertainty_score":0.029169023},"labels":[],"label_agreement":null},{"id":"W4361958335","doi":"10.1158/1078-0432.c.6530741.v1","title":"Data from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"Leukemia and Lymphoma Society; Canadian Institutes of Health Research; BC Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation; Gilead Sciences","keywords":"Lenalidomide; Cancer research; Diffuse large B-cell lymphoma; EZH2; Medicine; Lymphoma; Biology; Epigenetics; Immunology; Multiple myeloma; Gene","score_opus":0.08134297010076623,"score_gpt":0.3518199541938775,"score_spread":0.2704769840931113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958335","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9510361,0.007936721,0.0043816315,0.00095387356,0.00019417457,0.00007041328,0.026569122,0.0010895765,0.0077684205],"genre_scores_gemma":[0.96860194,0.0029307653,0.0018305479,0.00064345205,0.000026471942,0.000088237786,0.01970342,0.00011327752,0.0060619074],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997085,0.000023780212,0.00002937621,0.000054896325,0.00013808202,0.000045326047],"domain_scores_gemma":[0.99982834,0.000032639586,0.00003202037,0.000023250723,0.000036714126,0.00004694111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027021856,0.0003117337,0.00054275064,0.00043700353,0.00016796956,0.0004539484,0.00023434486,0.00036567522,0.00453113],"category_scores_gemma":[0.00019717749,0.00017933823,0.00046946647,0.00037419872,0.00018434234,0.00020915791,0.00021234689,0.0010506931,0.0012338732],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001360111,0.00017847428,0.0025111185,0.0003127214,0.00009300736,0.0001357815,0.000026955866,0.0005175526,0.98156893,0.00013555534,0.0026907697,0.010468928],"study_design_scores_gemma":[0.0002655506,0.001509936,0.048695054,0.000024632516,0.0002305729,0.0010605323,0.00012779931,0.0022779836,0.9220742,0.00018446133,0.023519522,0.000029671713],"about_ca_topic_score_codex":0.0011542086,"about_ca_topic_score_gemma":0.001951421,"teacher_disagreement_score":0.00453113,"about_ca_system_score_codex":0.00041854326,"about_ca_system_score_gemma":0.00033673845,"threshold_uncertainty_score":0.015158117},"labels":[],"label_agreement":null},{"id":"W4361958339","doi":"10.1158/1078-0432.c.6530591.v1","title":"Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Adverse effect; Antibody; Melanoma; Gastroenterology; Colorectal cancer; Cancer; Oncology; Immunology; Cancer research","score_opus":0.18471333416550853,"score_gpt":0.510112216982763,"score_spread":0.3253988828172545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958339","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7887553,0.015832806,0.0087752165,0.0037315406,0.0006596326,0.008146323,0.13844885,0.00071516423,0.034935106],"genre_scores_gemma":[0.8606202,0.0046969308,0.004187944,0.0041196323,0.00027585367,0.0058582327,0.111473314,0.00018411812,0.008583774],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99809283,0.0009779448,0.00020854756,0.00021906177,0.00035856658,0.00014298367],"domain_scores_gemma":[0.9937218,0.0025617336,0.0013377592,0.00071982003,0.0006511192,0.0010077767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005540112,0.0012617866,0.0020949477,0.0004406298,0.0005953075,0.0013896384,0.00077732344,0.0012260292,0.0069934265],"category_scores_gemma":[0.0051629455,0.0004848186,0.0021346076,0.0007868437,0.00054974976,0.0012949519,0.00039708932,0.002862168,0.0020027051],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64076984,0.01777681,0.031599373,0.0044432255,0.007562291,0.00043098186,0.00029934268,0.018152453,0.02188111,0.0009660867,0.06850594,0.18761256],"study_design_scores_gemma":[0.49169454,0.25779268,0.117882214,0.0008095805,0.009756879,0.0018132073,0.0002375203,0.00962444,0.019129975,0.002619205,0.08841737,0.00022231361],"about_ca_topic_score_codex":0.0012118523,"about_ca_topic_score_gemma":0.0023763583,"teacher_disagreement_score":0.0069934265,"about_ca_system_score_codex":0.00093128893,"about_ca_system_score_gemma":0.0019253395,"threshold_uncertainty_score":0.029299319},"labels":[],"label_agreement":null},{"id":"W4361959681","doi":"10.1158/1078-0432.c.6530078","title":"Data from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Cancer Research UK; Pancreatic Cancer UK; Johns Hopkins University; Canary Foundation","keywords":"Cancer research; Pancreatic cancer; In vivo; Adenocarcinoma; Pancreas; Cell culture; Pancreatic ductal adenocarcinoma; In vitro; Cancer; Medicine; Biology; Internal medicine","score_opus":0.13886998638167972,"score_gpt":0.3811469021155344,"score_spread":0.2422769157338547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361959681","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92067873,0.01438701,0.008900388,0.0018018063,0.00034611343,0.0004059947,0.010373753,0.000690719,0.04241544],"genre_scores_gemma":[0.9566109,0.0070258146,0.0035759246,0.0011059415,0.00009411737,0.00030674986,0.012511366,0.00015601571,0.018613236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99972695,0.000046443973,0.000034977933,0.00004252329,0.00011106311,0.000038095677],"domain_scores_gemma":[0.9997781,0.000061265986,0.000023611763,0.000036299312,0.00005074471,0.000049963513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002949861,0.00031630028,0.00044231713,0.00039616256,0.00016667377,0.000465952,0.00029691122,0.00043234188,0.008719319],"category_scores_gemma":[0.00023227632,0.00013939448,0.00040188694,0.00029674964,0.00020578127,0.00023471742,0.00014629075,0.0009012832,0.001918652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016043398,0.00041927767,0.001296935,0.00047782675,0.0000574996,0.00022324931,0.000038982907,0.0002718521,0.9739388,0.00036807626,0.0035800356,0.017723257],"study_design_scores_gemma":[0.0002853075,0.0038130155,0.010297857,0.00003478519,0.00018399996,0.0011298603,0.00007159573,0.0010550552,0.94560844,0.00016578793,0.037341777,0.000012588777],"about_ca_topic_score_codex":0.0008492238,"about_ca_topic_score_gemma":0.0010425036,"teacher_disagreement_score":0.008719319,"about_ca_system_score_codex":0.00036199362,"about_ca_system_score_gemma":0.00033218693,"threshold_uncertainty_score":0.029169023},"labels":[],"label_agreement":null},{"id":"W4362451642","doi":"10.1158/1078-0432.ccr-22-3136","title":"Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Gilead Sciences","keywords":"Medicine; Chemoimmunotherapy; Clinical endpoint; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Surgery; Lymphoma; Rituximab","score_opus":0.10425728756673605,"score_gpt":0.4631420898558782,"score_spread":0.3588848022891421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362451642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99840254,0.0010416552,0.000045978893,0.00007302475,0.000022698385,0.00006713519,0.00008196265,0.000005303954,0.0002596407],"genre_scores_gemma":[0.9991008,0.00032093198,0.000078710116,0.00011839069,0.000042266794,0.00006158468,0.000113841204,0.0000012445385,0.00016216184],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99956447,0.00023195417,0.00003822755,0.0000536468,0.00003897134,0.00007269156],"domain_scores_gemma":[0.9994518,0.00017240096,0.0001722409,0.000036208097,0.000019947669,0.00014738545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010746814,0.00038255804,0.0009987626,0.00028808933,0.00018699265,0.0005077232,0.000270334,0.00048809714,0.0016448795],"category_scores_gemma":[0.0013563088,0.00017993276,0.0011565357,0.00023557183,0.00038464135,0.0003642885,0.00026358917,0.0006969168,0.00018784113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9157548,0.004633712,0.026879525,0.0003399355,0.0014886934,0.00011034127,0.00008687265,0.00073721504,0.0064481883,0.000068674555,0.00037899805,0.043073025],"study_design_scores_gemma":[0.27693364,0.5774661,0.13187759,0.00011684461,0.0037293627,0.00042846947,0.0002774448,0.00311764,0.0036136585,0.00037831382,0.0020170629,0.000043975808],"about_ca_topic_score_codex":0.00045939806,"about_ca_topic_score_gemma":0.0014470099,"teacher_disagreement_score":0.0016448795,"about_ca_system_score_codex":0.00047647452,"about_ca_system_score_gemma":0.00047728393,"threshold_uncertainty_score":0.0056835413},"labels":[],"label_agreement":null},{"id":"W4362525380","doi":"10.1158/2326-6066.c.6550763","title":"Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Stand Up To Cancer; University of Texas MD Anderson Cancer Center; National Cancer Institute; National Institutes of Health; Parker Institute for Cancer Immunotherapy; Cycle for Survival; Geoffrey Beene Cancer Research Center; Memorial Sloan-Kettering Cancer Center; University of Pittsburgh; Melanoma Research Alliance","keywords":"CD8; Melanoma; Tumor-infiltrating lymphocytes; Immunotherapy; Medicine; T cell; Cancer; Cancer research; MHC class I; Immunology; Antigen; Internal medicine; Immune system","score_opus":0.11932743449809381,"score_gpt":0.37568513062343856,"score_spread":0.25635769612534476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362525380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782604,0.0004159908,0.0006100844,0.000049328264,0.000005750821,0.000006972576,0.0005340373,0.000022039054,0.0005296793],"genre_scores_gemma":[0.9983553,0.00012116742,0.00029159454,0.000040576637,0.0000071159866,0.000012153943,0.0007453026,0.000010684583,0.00041602773],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99989593,0.000014451068,0.000008328298,0.000036214165,0.00002503709,0.000020021462],"domain_scores_gemma":[0.99981385,0.000031208085,0.000060284605,0.0000283139,0.000024897136,0.000041411473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013287534,0.0001664757,0.00014639387,0.0003795696,0.00013001483,0.00026250875,0.00010398006,0.0002175301,0.0021794995],"category_scores_gemma":[0.00018304604,0.000088926456,0.00014083876,0.00020750407,0.00017024032,0.00013714681,0.00016583878,0.00034113176,0.0004512115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095586345,0.000061577426,0.053062785,0.000042398224,0.000027533957,0.00011267701,0.00007060062,0.00009459904,0.94113404,0.00003217898,0.00018298425,0.0042227437],"study_design_scores_gemma":[0.00004420077,0.0008265382,0.7156632,0.000010563211,0.000066490546,0.0024305468,0.00027523964,0.0013052019,0.27623722,0.00012215275,0.003007337,0.000011376625],"about_ca_topic_score_codex":0.00024836266,"about_ca_topic_score_gemma":0.0003398682,"teacher_disagreement_score":0.0021794995,"about_ca_system_score_codex":0.000096031144,"about_ca_system_score_gemma":0.00004864124,"threshold_uncertainty_score":0.007291138},"labels":[],"label_agreement":null},{"id":"W4362525603","doi":"10.1158/2326-6066.c.6551154","title":"Data from Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stand Up To Cancer; National Institutes of Health; Children's Hospital of Philadelphia; Canadian Institutes of Health Research; American Association for Cancer Research","keywords":"CD19; Context (archaeology); B cell; Medicine; Molecular biology; Antigen; Biology; Cancer research; Immunology; Antibody","score_opus":0.14527647862626242,"score_gpt":0.35043282589172875,"score_spread":0.20515634726546633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362525603","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745184,0.00089334464,0.009897811,0.00022188763,0.000019716648,0.000072249655,0.010043698,0.00017519812,0.0041574985],"genre_scores_gemma":[0.97634184,0.00051293825,0.00573139,0.00031775696,0.000013729935,0.00012487874,0.0154369995,0.00008498603,0.0014355961],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.999577,0.00005083098,0.000038255894,0.00012705993,0.00014567355,0.000061101564],"domain_scores_gemma":[0.999382,0.00020852518,0.00008258912,0.00012096569,0.00012972638,0.00007617586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040563894,0.0002648389,0.00038588716,0.00045414554,0.00019184683,0.00052533916,0.00024304508,0.00043073852,0.002059302],"category_scores_gemma":[0.0011149739,0.00013397049,0.00027480762,0.00044190246,0.00027832534,0.00016837285,0.0003925255,0.00046129507,0.0006574387],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001800303,0.00019632073,0.19234404,0.00026300448,0.00028399812,0.0012047937,0.0004957717,0.00479703,0.7091847,0.0011312269,0.003830709,0.084468156],"study_design_scores_gemma":[0.00021282377,0.001623651,0.47608033,0.000057446945,0.0005212928,0.011810413,0.0004002887,0.01731858,0.43702826,0.0017757224,0.053109348,0.000061753475],"about_ca_topic_score_codex":0.0009085537,"about_ca_topic_score_gemma":0.0012693275,"teacher_disagreement_score":0.002059302,"about_ca_system_score_codex":0.0002667224,"about_ca_system_score_gemma":0.00019664073,"threshold_uncertainty_score":0.006889105},"labels":[],"label_agreement":null},{"id":"W4362540776","doi":"10.1158/1538-7445.am2023-3188","title":"Abstract 3188: Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"In vivo; CD8; In vitro; Population; Cancer research; T cell; Cytotoxic T cell; Medicine; Chimeric antigen receptor; Antigen; Molecular biology; Chemistry; Immunology; Biology; Immune system; Biochemistry","score_opus":0.14977035715370438,"score_gpt":0.40363075826807926,"score_spread":0.2538604011143749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362540776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983304,0.0012705962,0.008140886,0.00012768354,0.000113903814,0.00012851389,0.0009283721,0.0003432585,0.0056428523],"genre_scores_gemma":[0.989734,0.00030787702,0.0024218946,0.00008554338,0.000033576252,0.00009187124,0.0015605536,0.00006530409,0.005699331],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997149,0.000053133346,0.000018590046,0.00007141819,0.000080854734,0.000061096645],"domain_scores_gemma":[0.9998566,0.00003306658,0.000027925882,0.000024864574,0.000020875324,0.000036713973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022899391,0.0005680507,0.00029194233,0.0002048248,0.0001239986,0.00040381073,0.00018077593,0.00045032334,0.004712141],"category_scores_gemma":[0.00015174902,0.000118400094,0.00025200023,0.00018476817,0.00013409893,0.00021038076,0.00018189859,0.0011760264,0.00156032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021449955,0.0001283348,0.00014664682,0.000031344098,0.000005559165,0.0000912157,0.00002016787,0.00012693487,0.9972351,0.00007705842,0.00023590452,0.00168718],"study_design_scores_gemma":[0.000094514726,0.001986627,0.0024829712,0.000012614914,0.00004340732,0.0010257291,0.000025964919,0.0029762583,0.98461413,0.00006441375,0.0066677523,0.0000056170857],"about_ca_topic_score_codex":0.00038536606,"about_ca_topic_score_gemma":0.00023523963,"teacher_disagreement_score":0.004712141,"about_ca_system_score_codex":0.00018043013,"about_ca_system_score_gemma":0.0001709753,"threshold_uncertainty_score":0.01576364},"labels":[],"label_agreement":null},{"id":"W4362540965","doi":"10.1158/1538-7445.am2023-1154","title":"Abstract 1154: Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University of Toronto; McMaster University","funders":"","keywords":"Cancer research; Flow cytometry; Tumor microenvironment; Tissue microarray; Immunotherapy; Glioma; Immune system; Immunohistochemistry; Biology; Medicine; Immunology; Tumor cells","score_opus":0.06544406792514754,"score_gpt":0.3587911702735495,"score_spread":0.293347102348402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362540965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953561,0.0009680743,0.0018131853,0.00012426214,0.000018403507,0.000029147654,0.00058508513,0.00007227687,0.0010334543],"genre_scores_gemma":[0.99176216,0.0008644418,0.0018852932,0.00010002871,0.0000075509124,0.00005372877,0.0015804216,0.000033375083,0.00371295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992657,0.000006200988,0.0000039201714,0.000013985661,0.000025973974,0.000023362592],"domain_scores_gemma":[0.9999683,0.000003083901,0.0000060906655,0.0000029720104,0.0000068285835,0.000012719984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011603115,0.0002122052,0.00020482403,0.00018425306,0.00015446483,0.00031389613,0.00015747681,0.00026289898,0.0017422324],"category_scores_gemma":[0.000063239146,0.00008190894,0.000210322,0.00015675036,0.00016775653,0.00017527064,0.000137743,0.00046238775,0.0005099064],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095177566,0.00002846659,0.0003138861,0.000036477093,0.000004501647,0.000026973456,0.000013922177,0.000046825455,0.9978759,0.000053455857,0.0000977343,0.0014067016],"study_design_scores_gemma":[0.000017455255,0.00061449944,0.011337752,0.0000075997987,0.000027465136,0.00028521838,0.000057464982,0.0012850793,0.9827863,0.00005443815,0.0035230822,0.0000035938501],"about_ca_topic_score_codex":0.001418189,"about_ca_topic_score_gemma":0.001252749,"teacher_disagreement_score":0.0017422324,"about_ca_system_score_codex":0.00036627287,"about_ca_system_score_gemma":0.00025223722,"threshold_uncertainty_score":0.0058283806},"labels":[],"label_agreement":null},{"id":"W4362541229","doi":"10.1158/1538-7445.am2023-4052","title":"Abstract 4052: Direct selection of PD1+ CD39+ tumor infiltrating lymphocytes (TIL) from tumor dissociates enrich for functional tumor-reactive cells","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Tumor-infiltrating lymphocytes; Cancer research; Cell sorting; Population; Adoptive cell transfer; Antigen; Cancer; Immunotherapy; Medicine; T cell; Immunology; Biology; Flow cytometry; CD8; Immune system; Internal medicine","score_opus":0.08352439900389312,"score_gpt":0.39616652613189246,"score_spread":0.3126421271279993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362541229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98441666,0.00073314866,0.00905953,0.000091890724,0.000026848513,0.00021038268,0.0008284418,0.00014501717,0.0044880616],"genre_scores_gemma":[0.9807966,0.00038849557,0.008890408,0.00010569649,0.000025542107,0.00018475013,0.0017929178,0.000058621572,0.0077570295],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988365,0.000016512127,0.000010308457,0.000028495126,0.00003354074,0.000027627144],"domain_scores_gemma":[0.9999454,0.00001490928,0.0000074641976,0.000008783977,0.000008817751,0.000014620992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001487464,0.00030560026,0.00018329438,0.00018820057,0.00015232789,0.00029752302,0.00014852431,0.00023710208,0.004415705],"category_scores_gemma":[0.00009398058,0.00008254295,0.00015219953,0.00015283258,0.00010075915,0.00012126301,0.00022460625,0.00044478552,0.0017783011],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008357209,0.00003448986,0.00036537426,0.000020438663,0.0000020716861,0.0000519462,0.000010696411,0.000047907502,0.9975865,0.000050799175,0.00009948804,0.0016467232],"study_design_scores_gemma":[0.000033077988,0.0004017257,0.0036502534,0.0000076176075,0.000015179373,0.0006890344,0.00001635059,0.00074821874,0.98889685,0.00005766252,0.0054806494,0.0000033700603],"about_ca_topic_score_codex":0.00016122141,"about_ca_topic_score_gemma":0.00023193994,"teacher_disagreement_score":0.004415705,"about_ca_system_score_codex":0.00011574031,"about_ca_system_score_gemma":0.00018330697,"threshold_uncertainty_score":0.014771938},"labels":[],"label_agreement":null},{"id":"W4362541661","doi":"10.1158/1538-7445.am2023-1785","title":"Abstract 1785: Multi-step engineering of gene-edited CAR T cells using RNA lipid nanoparticles","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"CD19; Chimeric antigen receptor; Molecular biology; Transfection; Gene expression; Biology; Cell biology; Chemistry; Flow cytometry; T cell; Gene; Immune system; Immunology; Biochemistry","score_opus":0.1706561909875915,"score_gpt":0.43312415718407987,"score_spread":0.2624679661964884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362541661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94501054,0.0005195629,0.047675934,0.00013446697,0.000101662394,0.00016568706,0.00040538382,0.0003135881,0.005673267],"genre_scores_gemma":[0.9531037,0.00028278198,0.035817638,0.000065415006,0.000012734578,0.00011994292,0.00038040537,0.00008775529,0.010129531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998995,0.000010813649,0.000008736923,0.000024062596,0.00003785567,0.000018951669],"domain_scores_gemma":[0.9999609,0.000006148567,0.000012362588,0.000003792584,0.000008791974,0.0000078928615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000102459664,0.00028169708,0.00015135667,0.00014133491,0.00009492159,0.0002497287,0.00020358764,0.00031103988,0.0012383142],"category_scores_gemma":[0.00006952595,0.000099632314,0.00019788851,0.000077853285,0.000111090114,0.00013274237,0.00019490602,0.00029750456,0.0006196804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019919358,0.00001343484,0.000030706586,0.000019005809,0.0000021366898,0.000034603418,0.000008884952,0.00019107609,0.998279,0.00013340687,0.000058403104,0.0012095433],"study_design_scores_gemma":[0.0000049241357,0.00006707783,0.00008966978,0.0000011940252,0.0000030001104,0.00004123707,0.0000027258598,0.0009351068,0.9975001,0.000013928219,0.00133943,0.0000016886038],"about_ca_topic_score_codex":0.00028756575,"about_ca_topic_score_gemma":0.00037356123,"teacher_disagreement_score":0.0012383142,"about_ca_system_score_codex":0.00023049155,"about_ca_system_score_gemma":0.00016023291,"threshold_uncertainty_score":0.0041425824},"labels":[],"label_agreement":null},{"id":"W4362543748","doi":"10.1158/1538-7445.am2023-892","title":"Abstract 892: Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4) demonstrates durable clinical responses by inducing broad immune engagement with anti-tumor activity","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Tumor microenvironment; Medicine; CD8; Cancer research; FOXP3; Immunotherapy; Immunology; T cell; Internal medicine; Oncology","score_opus":0.1878490284929845,"score_gpt":0.4787060654354717,"score_spread":0.2908570369424872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362543748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98994935,0.0023301267,0.0019713305,0.00023803333,0.000058570604,0.00010472553,0.0011532493,0.0001294666,0.0040650805],"genre_scores_gemma":[0.9909067,0.00048040214,0.0012668534,0.00024986884,0.00007516998,0.00006418944,0.0027743233,0.000026240037,0.0041562775],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998708,0.00002410713,0.000008801475,0.00003196967,0.000033933018,0.00003030172],"domain_scores_gemma":[0.9999269,0.000019388308,0.00001596639,0.000006283307,0.000009255164,0.000022182281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002216014,0.00028361255,0.00034027605,0.00018844997,0.00013930773,0.00033024716,0.00017731129,0.0002342524,0.0054054614],"category_scores_gemma":[0.00017268497,0.00007631519,0.0001787726,0.00015458815,0.00015931623,0.00014623733,0.00011557729,0.00051812764,0.0012612537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009435878,0.0012566295,0.007453353,0.00014052921,0.000065630025,0.0006036511,0.00005424543,0.00036318836,0.90958446,0.00015808655,0.003228403,0.06765606],"study_design_scores_gemma":[0.0028132359,0.033352755,0.085884936,0.000022363778,0.00014759954,0.007793731,0.000057165613,0.0023440963,0.84473634,0.00016012062,0.02266429,0.000023256312],"about_ca_topic_score_codex":0.00024079709,"about_ca_topic_score_gemma":0.00023590695,"teacher_disagreement_score":0.0054054614,"about_ca_system_score_codex":0.00021005969,"about_ca_system_score_gemma":0.00017024876,"threshold_uncertainty_score":0.018083036},"labels":[],"label_agreement":null},{"id":"W4362546428","doi":"10.1158/2159-8290.c.6549640.v1","title":"Data from Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"National Institutes of Health; Moffitt Cancer Center","keywords":"Cancer research; Biology; Immune system; Mantle cell lymphoma; Downregulation and upregulation; T cell; Transcriptome; Lymphoma; Immunology; Genetics; Gene; Gene expression","score_opus":0.09745959639451734,"score_gpt":0.308177417878479,"score_spread":0.21071782148396168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362546428","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841606,0.001458032,0.006000893,0.00023631263,0.000014800812,0.00002114132,0.0061387434,0.00020583227,0.0017635225],"genre_scores_gemma":[0.99106467,0.0006897673,0.0026081717,0.00016089418,0.00001485944,0.00002631369,0.0047874935,0.000069469505,0.00057828514],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998621,0.000012702801,0.000009240708,0.000052245992,0.000041842937,0.000021778123],"domain_scores_gemma":[0.99976295,0.00005568,0.00007358933,0.000038186383,0.0000376707,0.000031936943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018919373,0.00019449483,0.00027169002,0.00061490136,0.00014569687,0.00059707725,0.00014485575,0.00025973213,0.0016680205],"category_scores_gemma":[0.0004293132,0.00012416532,0.00022010483,0.0005338361,0.00019093892,0.00027225426,0.00037105472,0.00033552985,0.00035917325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042340718,0.00004162813,0.08642531,0.0001911278,0.000145643,0.0006752324,0.0001588875,0.0015364838,0.8660128,0.000415851,0.001135722,0.042837992],"study_design_scores_gemma":[0.000027511926,0.00035797618,0.740736,0.0000639044,0.00032881164,0.00576482,0.000576892,0.008433657,0.22457196,0.0025761249,0.016526414,0.000035836525],"about_ca_topic_score_codex":0.00029260243,"about_ca_topic_score_gemma":0.00063182577,"teacher_disagreement_score":0.0016680205,"about_ca_system_score_codex":0.00020796439,"about_ca_system_score_gemma":0.00013200635,"threshold_uncertainty_score":0.005580008},"labels":[],"label_agreement":null},{"id":"W4362547126","doi":"10.1158/2326-6066.c.6550763.v1","title":"Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Stand Up To Cancer; University of Texas MD Anderson Cancer Center; National Cancer Institute; National Institutes of Health; Parker Institute for Cancer Immunotherapy; Cycle for Survival; Geoffrey Beene Cancer Research Center; Memorial Sloan-Kettering Cancer Center; University of Pittsburgh; Melanoma Research Alliance","keywords":"CD8; Melanoma; Tumor-infiltrating lymphocytes; Immunotherapy; T cell; Cancer research; Medicine; MHC class I; Cancer; Immunology; Antigen; Immune system; Internal medicine","score_opus":0.11932743449809381,"score_gpt":0.37568513062343856,"score_spread":0.25635769612534476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362547126","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99782604,0.0004159908,0.0006100844,0.000049328264,0.000005750821,0.000006972576,0.0005340373,0.000022039054,0.0005296793],"genre_scores_gemma":[0.9983553,0.00012116742,0.00029159454,0.000040576637,0.0000071159866,0.000012153943,0.0007453026,0.000010684583,0.00041602773],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99989593,0.000014451068,0.000008328298,0.000036214165,0.00002503709,0.000020021462],"domain_scores_gemma":[0.99981385,0.000031208085,0.000060284605,0.0000283139,0.000024897136,0.000041411473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013287534,0.0001664757,0.00014639387,0.0003795696,0.00013001483,0.00026250875,0.00010398006,0.0002175301,0.0021794995],"category_scores_gemma":[0.00018304604,0.000088926456,0.00014083876,0.00020750407,0.00017024032,0.00013714681,0.00016583878,0.00034113176,0.0004512115],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095586345,0.000061577426,0.053062785,0.000042398224,0.000027533957,0.00011267701,0.00007060062,0.00009459904,0.94113404,0.00003217898,0.00018298425,0.0042227437],"study_design_scores_gemma":[0.00004420077,0.0008265382,0.7156632,0.000010563211,0.000066490546,0.0024305468,0.00027523964,0.0013052019,0.27623722,0.00012215275,0.003007337,0.000011376625],"about_ca_topic_score_codex":0.00024836266,"about_ca_topic_score_gemma":0.0003398682,"teacher_disagreement_score":0.0021794995,"about_ca_system_score_codex":0.000096031144,"about_ca_system_score_gemma":0.00004864124,"threshold_uncertainty_score":0.007291138},"labels":[],"label_agreement":null},{"id":"W4362552710","doi":"10.1158/2326-6066.22537889","title":"Supplementary Table 1, Figures 1 - 3 from Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy","year":2023,"lang":"en","type":"supplementary-materials","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Institutes of Health; Universiteit Leiden; Princess Margaret Cancer Foundation","keywords":"T-cell receptor; Jurkat cells; CD3; CD8; Molecular biology; Tetramer; Chemistry; T cell; Gene; Biology; Antigen; Genetics; Biochemistry; Immune system; Enzyme","score_opus":0.025513284541075404,"score_gpt":0.2993980960641245,"score_spread":0.2738848115230491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362552710","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00235188,0.0009229136,0.012176756,0.0005639398,0.0014051851,0.0007789245,0.9318094,0.0042482903,0.045742664],"genre_scores_gemma":[0.0076801656,0.0013735201,0.012837673,0.000531107,0.0001538634,0.0013327564,0.91937757,0.0016236095,0.055089638],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992711,0.00009453926,0.00008257539,0.00016480865,0.00028139362,0.00010567054],"domain_scores_gemma":[0.99808455,0.00067934487,0.00012557379,0.00034262246,0.0004605862,0.0003074164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012632946,0.001973146,0.0010777608,0.0020525693,0.001597853,0.0020697983,0.0024244275,0.0012204918,0.78039217],"category_scores_gemma":[0.0032499603,0.0011673138,0.0008615444,0.002137306,0.00036864198,0.0012268061,0.001004769,0.0020167439,0.38607618],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007686801,0.0003991604,0.0005972604,0.0018107354,0.000047760514,0.00020632001,0.00004659576,0.0006567916,0.032399192,0.003593859,0.9182258,0.041247815],"study_design_scores_gemma":[0.0002935752,0.00027888364,0.0017293614,0.0001760327,0.000039658964,0.00034170417,0.000046678106,0.0007377679,0.02177194,0.0025015343,0.97204494,0.000037931302],"about_ca_topic_score_codex":0.0022344114,"about_ca_topic_score_gemma":0.0067676674,"teacher_disagreement_score":0.78039217,"about_ca_system_score_codex":0.0011675034,"about_ca_system_score_gemma":0.0023629304,"threshold_uncertainty_score":0.31324387},"labels":[],"label_agreement":null},{"id":"W4362557284","doi":"10.3390/curroncol30040305","title":"CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Reimbursement; Chimeric antigen receptor; Medicine; Health care; Health technology; Agency (philosophy); Business; T cell; Immunology; Political science","score_opus":0.112304222274775,"score_gpt":0.4254165059810915,"score_spread":0.3131122837063165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362557284","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013270931,0.033121057,0.00055659865,0.9368218,0.0036845508,0.00004919638,0.00024660482,0.000035041503,0.02415801],"genre_scores_gemma":[0.10210941,0.1509552,0.010048455,0.691794,0.004855342,0.00012038353,0.0006319677,0.0001464339,0.039338805],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97758454,0.0029612794,0.0012092947,0.0012518605,0.0116479825,0.005345063],"domain_scores_gemma":[0.9421643,0.007185429,0.0017062642,0.0005661439,0.03577188,0.012605896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01665258,0.0009623529,0.001068296,0.0029557406,0.013260262,0.018143935,0.0045974674,0.018193785,0.00896918],"category_scores_gemma":[0.042511333,0.00072711613,0.0014271723,0.0045873336,0.011241301,0.0076550436,0.0041826214,0.016275506,0.0012907984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006373063,0.0000816164,0.0029200893,0.0007447946,0.00006744006,0.0009149295,0.001629774,0.0009295929,0.00060299574,0.18649931,0.7199321,0.08561371],"study_design_scores_gemma":[0.000034592253,0.000052528576,0.0030628224,0.001347207,0.000046963927,0.00029669635,0.0024413595,0.00041260265,0.00027886798,0.016152853,0.97573686,0.0001365249],"about_ca_topic_score_codex":0.98105216,"about_ca_topic_score_gemma":0.9861152,"teacher_disagreement_score":0.8336953,"about_ca_system_score_codex":0.16630474,"about_ca_system_score_gemma":0.5482651,"threshold_uncertainty_score":0.96696836},"labels":[],"label_agreement":null},{"id":"W4362593403","doi":"10.1158/1538-7445.am2023-ng14","title":"Abstract NG14: Dissecting immune microenvironment of T-cell acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University Health Network","funders":"","keywords":"Immune system; Leukemia; Immunology; Immunotherapy; Medicine; Tumor microenvironment; Biology; Cancer research","score_opus":0.056896164349953204,"score_gpt":0.3906074047209294,"score_spread":0.3337112403709762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362593403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8998461,0.0023106253,0.08437295,0.00047965377,0.00021773126,0.00015741543,0.0057622823,0.0013810354,0.005472182],"genre_scores_gemma":[0.8731706,0.0018560456,0.106939964,0.0010352393,0.0000713315,0.00026832774,0.010992664,0.00050481496,0.0051609534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977094,0.000028973267,0.000012076644,0.00006796829,0.00008324942,0.000036821097],"domain_scores_gemma":[0.999861,0.00002783929,0.000022194106,0.000015710355,0.00003934646,0.00003393103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031263637,0.000313415,0.00029811927,0.0002948891,0.00032446894,0.0004511459,0.00026343038,0.00032247955,0.0013454906],"category_scores_gemma":[0.00022336163,0.00016880028,0.00029214862,0.0002672287,0.00023582418,0.00025003415,0.0005716651,0.0005427033,0.0007180164],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053494496,0.00001697415,0.0020457422,0.000077528886,0.000009783326,0.000036051635,0.000033710414,0.00097085576,0.9910501,0.00022417173,0.00058003055,0.004901461],"study_design_scores_gemma":[0.00002365234,0.00024501915,0.021044614,0.00003311774,0.000049330603,0.0002966576,0.00018391368,0.03063175,0.92233294,0.00094285596,0.024182964,0.000033108518],"about_ca_topic_score_codex":0.0007216178,"about_ca_topic_score_gemma":0.0018170021,"teacher_disagreement_score":0.0013454906,"about_ca_system_score_codex":0.00035966668,"about_ca_system_score_gemma":0.00032127817,"threshold_uncertainty_score":0.0045011044},"labels":[],"label_agreement":null},{"id":"W4362595669","doi":"10.1158/1538-7445.am2023-1128","title":"Abstract 1128: Lineage tracing of CAR T cells in patients with B cell malignancies","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Chimeric antigen receptor; Immunology; T cell; Medicine; Immunotherapy; CD19; Cancer research; T-cell receptor; Cancer immunotherapy; Biology; Antigen; Immune system","score_opus":0.06974373913961528,"score_gpt":0.38487324908452086,"score_spread":0.3151295099449056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362595669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516666,0.00061138556,0.0014011322,0.00007599806,0.0000053392814,0.000024063285,0.0012356719,0.00007291133,0.0014067792],"genre_scores_gemma":[0.99553865,0.00023668051,0.0017402567,0.00011477816,0.0000054230572,0.000041027055,0.0016497008,0.000025201129,0.00064824364],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998565,0.000026840335,0.000009261309,0.000039631366,0.000042642754,0.000025094983],"domain_scores_gemma":[0.9998895,0.000026513715,0.000029533538,0.000013405816,0.000024394454,0.000016547423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024879925,0.00009435755,0.00018290506,0.00040131478,0.00018029084,0.0003946264,0.00015400465,0.00024738096,0.0017373346],"category_scores_gemma":[0.00035888152,0.00011260029,0.00009937195,0.00037934008,0.00010890138,0.00017741343,0.0001642567,0.000278246,0.0006766081],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034969999,0.00015117587,0.5999271,0.00014343734,0.000046618745,0.0007504701,0.000682494,0.0008474883,0.31590897,0.000240752,0.0023701068,0.07543427],"study_design_scores_gemma":[0.00009754856,0.0013578653,0.87431306,0.000050638373,0.00009655157,0.0043085264,0.000597426,0.004680534,0.0986874,0.00040487119,0.015386895,0.000018668246],"about_ca_topic_score_codex":0.0013205134,"about_ca_topic_score_gemma":0.001833751,"teacher_disagreement_score":0.0017373346,"about_ca_system_score_codex":0.00024344027,"about_ca_system_score_gemma":0.0001352502,"threshold_uncertainty_score":0.0058119297},"labels":[],"label_agreement":null},{"id":"W4362614405","doi":"10.1038/s41408-023-00820-y","title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; Minimal residual disease; Gastroenterology","score_opus":0.036904548148674894,"score_gpt":0.3457851510166651,"score_spread":0.30888060286799024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362614405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980286,0.0013216925,0.0000714814,0.00007640685,0.0000059096355,0.000006556422,0.000076678116,0.000005740781,0.0004069374],"genre_scores_gemma":[0.9996383,0.000118140524,0.000044799286,0.000022533455,0.000009373216,0.0000023962514,0.00008103488,9.460764e-7,0.000082292005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996001,0.00016408836,0.000038354756,0.000044864308,0.000074819174,0.000077718585],"domain_scores_gemma":[0.9985593,0.00042894282,0.00059833634,0.000047475656,0.0000866133,0.00027932893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007699578,0.00016498708,0.000371921,0.00032573508,0.00021752305,0.00050396903,0.00021370388,0.00044739517,0.00067383016],"category_scores_gemma":[0.0019102758,0.00011898966,0.00025811073,0.00028905584,0.00022258288,0.00029294437,0.00023397246,0.0005236741,0.000186831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028800569,0.00011257602,0.98173714,0.00002098892,0.00004585114,0.0001939018,0.000049190763,0.00021540586,0.0021341648,0.000017661061,0.00013223017,0.01246087],"study_design_scores_gemma":[0.000037199665,0.0012697516,0.99634594,0.000008473535,0.000057678863,0.0006729899,0.000028805855,0.00049474835,0.0006690026,0.000031169464,0.00037894258,0.0000053212552],"about_ca_topic_score_codex":0.0008440599,"about_ca_topic_score_gemma":0.0014790412,"teacher_disagreement_score":0.0008440599,"about_ca_system_score_codex":0.00031617156,"about_ca_system_score_gemma":0.00021749838,"threshold_uncertainty_score":0.004071951},"labels":[],"label_agreement":null},{"id":"W4365512087","doi":"10.1158/1538-7445.am2023-ct234","title":"Abstract CT234: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Breast cancer; Cancer; Leukapheresis; Immunotherapy; T cell; Clinical trial; Oncology; Cancer research; Internal medicine; Immunology; Immune system; Stem cell; CD34","score_opus":0.16290501504143873,"score_gpt":0.48638303389157284,"score_spread":0.3234780188501341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98651046,0.0017024631,0.00068377506,0.00063220976,0.0001450227,0.0027544168,0.0031229153,0.00018951757,0.004259321],"genre_scores_gemma":[0.98373324,0.001396774,0.0011457942,0.00074690976,0.00014188916,0.0023208011,0.00548418,0.000037011563,0.004993382],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974066,0.00011997366,0.000014207936,0.00004248038,0.00002928412,0.00005333658],"domain_scores_gemma":[0.9995993,0.000045128047,0.00006005404,0.00003436725,0.000022808315,0.00023838224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007161679,0.0014479967,0.0011509554,0.00036940718,0.00037500364,0.0010111295,0.00088528806,0.000918516,0.007315611],"category_scores_gemma":[0.0005844143,0.00029198962,0.0008451508,0.00044225514,0.000899887,0.0005818687,0.00031060015,0.0028348134,0.0018379452],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69372576,0.042238504,0.007051181,0.0019491292,0.001588234,0.001191351,0.00027293555,0.0046621426,0.12869795,0.0008994106,0.011523792,0.10619962],"study_design_scores_gemma":[0.49534482,0.4704454,0.008156619,0.000098595076,0.0005253946,0.0012878351,0.000081456965,0.0013717185,0.015250164,0.0004025525,0.0069842846,0.000051181392],"about_ca_topic_score_codex":0.0010418746,"about_ca_topic_score_gemma":0.001642406,"teacher_disagreement_score":0.007315611,"about_ca_system_score_codex":0.0009100938,"about_ca_system_score_gemma":0.0016850189,"threshold_uncertainty_score":0.02447313},"labels":[],"label_agreement":null},{"id":"W4365513888","doi":"10.3410/f.742552675.793598330","title":"Faculty Opinions recommendation of T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lymphatic system; Control (management); Antigen; Computer science; Medicine; Pathology; Immunology; Artificial intelligence","score_opus":0.031630965820291526,"score_gpt":0.364255964363549,"score_spread":0.3326249985432575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365513888","genre_codex":"dataset","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042634242,0.0004275156,0.000099338184,0.0002885344,0.000067006295,0.000016846447,0.9970523,0.00036431075,0.001257799],"genre_scores_gemma":[0.0013477994,0.00023012809,0.00044145295,0.00018620548,0.000022820626,0.0000636252,0.99617696,0.00005673165,0.0014743445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983771,0.0002969152,0.0001749768,0.0005144529,0.0004048159,0.00023180504],"domain_scores_gemma":[0.9969765,0.0010527283,0.00042701472,0.0005871095,0.000630577,0.00032607085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015898395,0.0022817685,0.0015164866,0.002885701,0.0008431495,0.0030124937,0.0026768234,0.0033223585,0.051427446],"category_scores_gemma":[0.010021326,0.00060216873,0.0022468807,0.0041072955,0.00044806738,0.001250537,0.0017094819,0.0018552727,0.07242857],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016764914,0.000038609676,0.002999617,0.0012117294,0.00010817803,0.00002870032,0.000016162525,0.0003605068,0.0001945328,0.00033099885,0.9889142,0.0056291358],"study_design_scores_gemma":[0.0005712178,0.000057376394,0.010652252,0.0008417384,0.00023280585,0.00016039377,0.00007869004,0.0015136704,0.000885017,0.0018720584,0.9830837,0.00005112608],"about_ca_topic_score_codex":0.024692694,"about_ca_topic_score_gemma":0.062620625,"teacher_disagreement_score":0.051427446,"about_ca_system_score_codex":0.0016817517,"about_ca_system_score_gemma":0.002878894,"threshold_uncertainty_score":0.17204195},"labels":[],"label_agreement":null},{"id":"W4365813711","doi":"10.1007/s00262-023-03442-2","title":"Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Leukemia; Adoptive cell transfer; Granzyme B; Immunology; Biology; CD8; Immune system; Interleukin 21; Cytotoxic T cell; IL-2 receptor; Granzyme; Cancer research; Molecular biology; T cell; Perforin","score_opus":0.027116800034224724,"score_gpt":0.30158481317946384,"score_spread":0.2744680131452391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365813711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884769,0.0009123934,0.006730734,0.00014152267,0.00013176566,0.000117138035,0.00059488567,0.00039027992,0.0025045134],"genre_scores_gemma":[0.99146956,0.00039801712,0.00280797,0.0000617018,0.000029870918,0.000066607914,0.00072733796,0.000049432,0.004389514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997234,0.000034186745,0.000039201575,0.00004527315,0.0000766271,0.00008131072],"domain_scores_gemma":[0.9997838,0.000034130535,0.0000709431,0.00003653429,0.000015788957,0.000058843227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016701166,0.0006641482,0.00032749373,0.00043378217,0.00018889,0.00050727086,0.00022088882,0.0004912578,0.0014880798],"category_scores_gemma":[0.000119567114,0.00019616375,0.00042013606,0.00022200386,0.0002353534,0.0002791247,0.00027097578,0.001314841,0.000869437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017946685,0.00009460847,0.00012322125,0.000018293333,0.000006422035,0.0000454882,0.000015902833,0.00018428416,0.9979658,0.00015328801,0.000049836337,0.0011633486],"study_design_scores_gemma":[0.00004358329,0.00030053465,0.00061658584,0.000002774652,0.000013511302,0.00011606494,0.000008516996,0.0008120075,0.9965496,0.000053400894,0.0014803369,0.0000030145231],"about_ca_topic_score_codex":0.00028004326,"about_ca_topic_score_gemma":0.00041681938,"teacher_disagreement_score":0.0014880798,"about_ca_system_score_codex":0.000373809,"about_ca_system_score_gemma":0.0002357882,"threshold_uncertainty_score":0.00497818},"labels":[],"label_agreement":null},{"id":"W4366083620","doi":"10.1182/bloodadvances.2022009260","title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; MorphoSys; Juno Therapeutics; Adaptive Biotechnologies; Celltrion; Celgene; Alimera Sciences; BeiGene; MEI Pharma; Sunesis; TG Therapeutics; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Pfizer; Incyte; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Yuhan; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Internal medicine; Medicine; Oncology; Cancer research; Gastroenterology; Biology","score_opus":0.008757305009623545,"score_gpt":0.261308908155294,"score_spread":0.2525516031456705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366083620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99884003,0.0005001005,0.00009914052,0.000036094254,0.0000051880515,0.000082640036,0.00006615592,0.000014700944,0.00035587774],"genre_scores_gemma":[0.99912566,0.0002318499,0.00019015117,0.00007109118,0.000020390275,0.000052320454,0.00015669942,0.0000021654876,0.0001497331],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997563,0.00010653467,0.000015468282,0.000037407066,0.000035834597,0.000048420574],"domain_scores_gemma":[0.9997967,0.000044336008,0.000041075964,0.000017797947,0.000012228863,0.000087857574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074517884,0.00029992528,0.0008473457,0.00022272386,0.00022656265,0.00033198396,0.0001688605,0.00021321826,0.00061160314],"category_scores_gemma":[0.00053906714,0.00017230405,0.00023437457,0.00018987467,0.00023506183,0.00027018096,0.0001556114,0.00053516653,0.00022555933],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119916,0.0131117,0.28009364,0.00047813405,0.0007203787,0.0025310507,0.00081439596,0.002389657,0.20937468,0.00021201442,0.0034856622,0.3668727],"study_design_scores_gemma":[0.029395707,0.262567,0.67899793,0.000052005387,0.0004836263,0.0042511434,0.00020256905,0.0046436493,0.012138814,0.00017780185,0.0070453836,0.000044330955],"about_ca_topic_score_codex":0.00035436254,"about_ca_topic_score_gemma":0.0011875973,"teacher_disagreement_score":0.0008473457,"about_ca_system_score_codex":0.000261146,"about_ca_system_score_gemma":0.00027346524,"threshold_uncertainty_score":0.00394094},"labels":[],"label_agreement":null},{"id":"W4366161256","doi":"10.1016/j.xpro.2023.102224","title":"A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line","year":2023,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"HORIZON EUROPE Marie Sklodowska-Curie Actions; H2020 Marie Skłodowska-Curie Actions; Horizon 2020; Medical Research Council; Horizon 2020 Framework Programme; Ministero della Salute; Natural Sciences and Engineering Research Council of Canada; European Commission; Weston Brain Institute; Canadian Institutes of Health Research; Alzheimer Society; National Institute for Health and Care Research; Alzheimer's Society","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxicity; CD16; Peripheral blood mononuclear cell; Immune system; Cell culture; Immunology; Jurkat cells; Cancer; Antibody; Cancer research; Natural killer cell; Flow cytometry; Biology; Cancer cell; In vitro; T cell; CD3; Biochemistry","score_opus":0.06271952799619793,"score_gpt":0.41222800101806994,"score_spread":0.34950847302187205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366161256","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37468198,0.0046328264,0.59538156,0.0006036012,0.00063985854,0.003511555,0.0053785313,0.0025983504,0.012571597],"genre_scores_gemma":[0.54905987,0.004499051,0.4049868,0.0008524706,0.000144969,0.008210793,0.011271311,0.0005266147,0.020448167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751186,0.00041107353,0.00025468197,0.00062080345,0.0010373621,0.0001641635],"domain_scores_gemma":[0.999201,0.00012737581,0.00012963092,0.0001870117,0.00027529735,0.000079799036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011380943,0.0008983446,0.0007239573,0.0006339832,0.00065235223,0.0008868732,0.00088415004,0.0008675527,0.0021735716],"category_scores_gemma":[0.0005225644,0.00034958404,0.00056644576,0.00069647486,0.00044275308,0.000487272,0.0007261812,0.0016753863,0.001983266],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118529926,0.00015432629,0.00066191563,0.00019024193,0.000033377146,0.00007399242,0.0000970942,0.00053969235,0.9927832,0.0005128405,0.0009458045,0.0038889658],"study_design_scores_gemma":[0.000017953813,0.00037768972,0.0010438556,0.00001784957,0.000046998346,0.0002095001,0.00003435097,0.0025234018,0.98633444,0.00010390529,0.009270893,0.000019047724],"about_ca_topic_score_codex":0.0017310953,"about_ca_topic_score_gemma":0.0038253064,"teacher_disagreement_score":0.0021735716,"about_ca_system_score_codex":0.0007155055,"about_ca_system_score_gemma":0.0009952816,"threshold_uncertainty_score":0.0072713494},"labels":[],"label_agreement":null},{"id":"W4366222007","doi":"10.3389/fimmu.2023.1179827","title":"LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; University of Ottawa; McMaster University; Children's Hospital of Eastern Ontario; Discovery Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer research","score_opus":0.016899903624781262,"score_gpt":0.27137088684261357,"score_spread":0.2544709832178323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366222007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970817,0.0007068132,0.0008056951,0.00007341115,0.000014540629,0.000031549305,0.00022544511,0.00007286391,0.0009880149],"genre_scores_gemma":[0.99559265,0.00032494013,0.0014514707,0.000042150812,0.000010725074,0.000044662076,0.0004368398,0.000025793268,0.0020708076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998062,0.000029633178,0.000023674347,0.000032058462,0.000052591447,0.00005584466],"domain_scores_gemma":[0.9997336,0.00004371825,0.00010210695,0.0000280196,0.000019678486,0.00007280787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001834472,0.00044733123,0.00028126474,0.00023942647,0.00009930773,0.00029814514,0.00022021044,0.00033510436,0.0015203006],"category_scores_gemma":[0.00010842722,0.00010978975,0.00022872988,0.00016710038,0.00022351692,0.00020804192,0.00020378205,0.0008251321,0.0005987963],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017035395,0.00006857533,0.00011924399,0.000022984692,0.0000027471729,0.000027422611,0.000012263238,0.00006824827,0.9987507,0.000040512416,0.000025383282,0.00069154974],"study_design_scores_gemma":[0.00002113399,0.00057132257,0.00083576585,0.0000037133052,0.0000082780125,0.000111401714,0.000007221953,0.00045945693,0.997059,0.000013876197,0.00090724597,0.0000015428262],"about_ca_topic_score_codex":0.00022792352,"about_ca_topic_score_gemma":0.0003769486,"teacher_disagreement_score":0.0015203006,"about_ca_system_score_codex":0.00032444758,"about_ca_system_score_gemma":0.0002171453,"threshold_uncertainty_score":0.005085945},"labels":[],"label_agreement":null},{"id":"W4366405937","doi":"10.1089/genbio.2023.0008","title":"Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies","year":2023,"lang":"en","type":"review","venue":"GEN Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of Manitoba; CancerCare Manitoba; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC; Stem Cell Network","keywords":"Induced pluripotent stem cell; Stem cell; Cell therapy; Immunotherapy; T cell; Computer science; Medicine; Computational biology; Biology; Immunology; Immune system; Cell biology; Embryonic stem cell","score_opus":0.17443680802377695,"score_gpt":0.3386897575866703,"score_spread":0.16425294956289335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366405937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004797743,0.99573284,0.0010556388,0.00039271908,0.00025204953,0.000012302031,0.000019741254,0.000018534636,0.002036287],"genre_scores_gemma":[0.0019990448,0.9955095,0.00089347793,0.00028891195,0.0001410033,0.000016999318,0.000040306997,0.0000036624817,0.0011072044],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998485,0.000024638992,0.000013522522,0.00002199685,0.00007187009,0.000019563862],"domain_scores_gemma":[0.99986315,0.00006630331,0.000018296449,0.0000047627555,0.00003236022,0.000015102353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005789685,0.00060956605,0.00065084785,0.0011942845,0.00016066113,0.0007708512,0.0005732043,0.0009833946,0.002814933],"category_scores_gemma":[0.00037050067,0.00020861658,0.0003699714,0.0008503914,0.00036220692,0.0010604786,0.0005295905,0.0016693398,0.0018946733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005969312,0.0001040086,0.00011717299,0.009028763,0.00004623918,0.00021743964,0.00004966174,0.0008137436,0.014264421,0.0131779965,0.015532562,0.94658846],"study_design_scores_gemma":[0.000019590605,0.00014318523,0.0002749913,0.0013560288,0.000046664176,0.00079689844,0.00003222957,0.00023069588,0.0041158414,0.0031861668,0.9897838,0.000013869488],"about_ca_topic_score_codex":0.00040158423,"about_ca_topic_score_gemma":0.00078531675,"teacher_disagreement_score":0.002814933,"about_ca_system_score_codex":0.000517024,"about_ca_system_score_gemma":0.0007344833,"threshold_uncertainty_score":0.009416819},"labels":[],"label_agreement":null},{"id":"W4366412976","doi":"10.3410/f.742510058.793598333","title":"Faculty Opinions recommendation of Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lineage (genetic); Transmembrane protein; Cell; Tumor necrosis factor alpha; Cell biology; Biology; Immunology; Genetics; Gene; Receptor","score_opus":0.060017073427398766,"score_gpt":0.3873674926003697,"score_spread":0.3273504191729709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366412976","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039824704,0.00026563302,0.00006836557,0.0001719474,0.000043227716,0.000013007183,0.99797815,0.00017640315,0.00088504236],"genre_scores_gemma":[0.0014288333,0.00016697537,0.0003227962,0.0001495626,0.000016178059,0.000061108774,0.9966222,0.000044595887,0.0011877802],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845195,0.00031802166,0.00018344732,0.00047454052,0.00037559727,0.00019641912],"domain_scores_gemma":[0.996636,0.0013051018,0.00047185866,0.00056289067,0.00070657977,0.00031760798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015961918,0.001600213,0.0013075959,0.0021759276,0.00071017037,0.0024802503,0.0017638718,0.002279132,0.059155915],"category_scores_gemma":[0.010066139,0.00049778016,0.0017692257,0.0031642881,0.00032933443,0.0009141598,0.0013299399,0.0015905397,0.06252489],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029359735,0.000041134444,0.0033497512,0.0015896977,0.0001220126,0.000029431854,0.000019358327,0.00034655278,0.0003589256,0.00034011912,0.9881165,0.00539298],"study_design_scores_gemma":[0.0010172353,0.00007949811,0.01486982,0.0009394709,0.0002963035,0.00015104662,0.00009653165,0.0010656093,0.0014941928,0.0013207543,0.9786218,0.00004782721],"about_ca_topic_score_codex":0.01675617,"about_ca_topic_score_gemma":0.039827477,"teacher_disagreement_score":0.059155915,"about_ca_system_score_codex":0.0013003189,"about_ca_system_score_gemma":0.0025435572,"threshold_uncertainty_score":0.19789624},"labels":[],"label_agreement":null},{"id":"W4366596010","doi":"10.1016/j.bbrc.2023.04.067","title":"Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells","year":2023,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Canadian Internet Registration Authority; Japan Agency for Medical Research and Development","keywords":"Human leukocyte antigen; Biology; Induced pluripotent stem cell; Humanized mouse; Immunology; Haematopoiesis; Janus kinase 3; Stem cell; Interleukin 12; Interleukin 21; Cancer research; Cell biology; Antigen; Cytotoxic T cell; T cell; Immune system; In vitro; Embryonic stem cell; Gene; Genetics","score_opus":0.1809811898549389,"score_gpt":0.38739321125058657,"score_spread":0.20641202139564765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366596010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.928827,0.0020414945,0.056184623,0.00037082715,0.00078441174,0.0011238393,0.0033451114,0.0011100525,0.00621261],"genre_scores_gemma":[0.9584496,0.0018906028,0.020042924,0.0002780839,0.00007321558,0.0014315278,0.00261755,0.00026170345,0.014954637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993906,0.00007266595,0.00007283017,0.00018147416,0.00016840533,0.00011395429],"domain_scores_gemma":[0.99962723,0.000075891694,0.00009714243,0.00008699152,0.00004835282,0.00006433589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093393377,0.0009965673,0.0005312777,0.0007791533,0.00028326423,0.0007610165,0.0006674977,0.001147007,0.005688072],"category_scores_gemma":[0.0002709851,0.00028363906,0.00055864075,0.0002902599,0.00066035555,0.0007181242,0.00028630462,0.002729692,0.0016011571],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005652095,0.00051044335,0.00016976647,0.00009329604,0.000020184307,0.0001930521,0.00007851813,0.00040325863,0.99403536,0.0010173732,0.0003256973,0.0025878274],"study_design_scores_gemma":[0.00010697192,0.0013761474,0.0004643211,0.00002223158,0.00006853473,0.00043346587,0.000052127933,0.0016351899,0.98888165,0.00020932023,0.006739532,0.0000106205725],"about_ca_topic_score_codex":0.00033020938,"about_ca_topic_score_gemma":0.00037292327,"teacher_disagreement_score":0.005688072,"about_ca_system_score_codex":0.00036864498,"about_ca_system_score_gemma":0.0004006206,"threshold_uncertainty_score":0.019028485},"labels":[],"label_agreement":null},{"id":"W4366683885","doi":"10.3389/fimmu.2023.1192636","title":"Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis","year":2023,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Bundesministerium für Bildung und Forschung; Berlin-Brandenburg School for Regenerative Therapies; Deutsche Forschungsgemeinschaft; European Commission","keywords":"Mechanism (biology); Mechanism of action; Medicine; Chemistry; Philosophy; Biochemistry","score_opus":0.03072550979996148,"score_gpt":0.30999577243667575,"score_spread":0.2792702626367143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366683885","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008145538,0.003997074,0.00026640092,0.0236901,0.9692488,0.00003149935,0.000110738125,0.000109058616,0.0024649021],"genre_scores_gemma":[0.0008463307,0.004167999,0.00021023546,0.017891696,0.9590748,0.00002832203,0.000077461766,0.00006125165,0.017642008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975988,0.0002759514,0.00028347806,0.00030243033,0.0013513216,0.00018793574],"domain_scores_gemma":[0.9924891,0.0022327404,0.0005849361,0.00020389268,0.0031335093,0.0013557425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045989226,0.003163703,0.0023943982,0.0020684178,0.0017501944,0.0040736767,0.0020413927,0.008429817,0.020021038],"category_scores_gemma":[0.009558645,0.0007989027,0.0020585624,0.0006637726,0.001384823,0.0028530674,0.0009085507,0.010776157,0.015808707],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006400521,0.0000147569,0.000019467372,0.0001314576,0.000011384603,0.000085286694,0.0000051383377,0.000031056894,0.00016120014,0.00023802965,0.99361426,0.00562408],"study_design_scores_gemma":[0.000091946196,0.00005163502,0.00017886695,0.00018760476,0.00004204821,0.0002854758,0.000020053929,0.00018783768,0.00044235453,0.0010296087,0.9974654,0.000017158383],"about_ca_topic_score_codex":0.0006740129,"about_ca_topic_score_gemma":0.0017055391,"teacher_disagreement_score":0.020021038,"about_ca_system_score_codex":0.0018374948,"about_ca_system_score_gemma":0.0017712758,"threshold_uncertainty_score":0.06697708},"labels":[],"label_agreement":null},{"id":"W4366782404","doi":"10.1111/pde.15310","title":"Proceedings of the 10th Pediatric Dermatology Research Alliance (<scp>PeDRA</scp>) Annual Conference","year":2023,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Sanofi; Pfizer; Eli Lilly and Company; Amryt Pharma; U.S. Department of Health and Human Services","keywords":"Alliance; Session (web analytics); Medicine; Coronavirus disease 2019 (COVID-19); Panel discussion; Theme (computing); Medical education; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Library science; Family medicine; World Wide Web; Computer science; Pathology; History","score_opus":0.0550134225719476,"score_gpt":0.35165486111866956,"score_spread":0.296641438546722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366782404","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015609405,0.07268479,0.0047386824,0.11903248,0.2429383,0.00083573174,0.0022393663,0.00086330244,0.54105794],"genre_scores_gemma":[0.057276778,0.050490845,0.0069752373,0.016789004,0.05641317,0.00095670525,0.0024339757,0.00055281376,0.8081115],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987062,0.00036670803,0.00005800316,0.00011299222,0.00054237765,0.00021367852],"domain_scores_gemma":[0.99755645,0.00020339862,0.000114266375,0.000050423972,0.00080546126,0.0012699999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002852488,0.00079238776,0.00036506742,0.0008115418,0.0012859324,0.0031241695,0.000784614,0.001301038,0.0770856],"category_scores_gemma":[0.0028144484,0.00021701862,0.000604737,0.00034383568,0.00039897475,0.0007187507,0.0014159798,0.0028467823,0.020702023],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013524771,0.00011016321,0.00051114045,0.00018401704,0.000012135897,0.00023278268,0.00010333186,0.0000858728,0.00066319306,0.0010419843,0.9377168,0.059203416],"study_design_scores_gemma":[0.000015878719,0.000045906563,0.0012365469,0.0001947143,0.0000071270883,0.00019971943,0.00016197868,0.00006327358,0.0003583507,0.00026336403,0.9974462,0.000007089141],"about_ca_topic_score_codex":0.0022918938,"about_ca_topic_score_gemma":0.007312415,"teacher_disagreement_score":0.0770856,"about_ca_system_score_codex":0.0021945836,"about_ca_system_score_gemma":0.00326367,"threshold_uncertainty_score":0.257877},"labels":[],"label_agreement":null},{"id":"W4366984296","doi":"10.1158/1078-0432.c.6615932.v1","title":"Data from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"Pharmacyclics; Genentech; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Adjuvant; Radiation therapy; Melanoma; Adjuvant therapy; Gastroenterology; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.22064895977477625,"score_gpt":0.4054649721142443,"score_spread":0.18481601233946807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366984296","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9682875,0.01036423,0.0005649358,0.0033641777,0.0007932111,0.0017769753,0.0058814264,0.0001164353,0.008851078],"genre_scores_gemma":[0.97720224,0.0035205805,0.00096544117,0.002424368,0.0006368133,0.0020759376,0.0065048747,0.000052792668,0.0066168173],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99932563,0.00040364946,0.00005105788,0.000084559826,0.000064710104,0.000070430244],"domain_scores_gemma":[0.9987436,0.0003036863,0.00030946758,0.0001432354,0.00008264112,0.00041746514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001945316,0.0008868424,0.0013672411,0.00021518832,0.00037718387,0.0009225708,0.000513763,0.00090262294,0.0053476472],"category_scores_gemma":[0.00190133,0.00030246025,0.0019817208,0.00020831922,0.0005931508,0.0008397871,0.00035735828,0.0018485949,0.0008531847],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94202286,0.0027350837,0.0037604496,0.001207347,0.002816965,0.00012631167,0.00011150539,0.0006126892,0.0056750453,0.00024775337,0.009378318,0.031305663],"study_design_scores_gemma":[0.8812086,0.08581947,0.016653717,0.0002222595,0.0029680803,0.0001770102,0.00007195987,0.0008856046,0.0018203573,0.0004585497,0.009673669,0.000040729356],"about_ca_topic_score_codex":0.00068902655,"about_ca_topic_score_gemma":0.00232855,"teacher_disagreement_score":0.0053476472,"about_ca_system_score_codex":0.0005815917,"about_ca_system_score_gemma":0.0009869369,"threshold_uncertainty_score":0.017889619},"labels":[],"label_agreement":null},{"id":"W4366997604","doi":"10.1101/2023.04.21.537841","title":"NR4A3 deficiency in CD8 <sup>+</sup> T cells improves adoptive T cell therapy of cancer","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Effector; Cytotoxic T cell; CD8; Biology; Cancer research; Adoptive cell transfer; T cell; Cell biology; Immunology; Antigen; Immune system; Genetics","score_opus":0.030103347123966125,"score_gpt":0.2822207896416499,"score_spread":0.2521174425176838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366997604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913693,0.0021488855,0.0023800903,0.00028259287,0.000172143,0.00005888766,0.0012924232,0.00046142048,0.0018342317],"genre_scores_gemma":[0.99418396,0.0004208509,0.0016417125,0.00016782667,0.000022687393,0.00005774883,0.000808406,0.00006879565,0.002628138],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971205,0.00004049785,0.000043259977,0.000053134867,0.00008048423,0.00007062971],"domain_scores_gemma":[0.99980205,0.000018380411,0.000055143788,0.000023213222,0.00002361625,0.000077604585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018582278,0.00047392136,0.00063271343,0.00020290587,0.0001405593,0.00039689703,0.0003241001,0.00038707184,0.0031614525],"category_scores_gemma":[0.00014659893,0.0001236201,0.00032514214,0.0001338474,0.00029690642,0.00019531214,0.0001852118,0.0013250861,0.0009925611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047104893,0.000083556944,0.00014122798,0.000051305673,0.000007866809,0.000022185766,0.0000066730877,0.00009798253,0.9970187,0.000029711686,0.0001402284,0.0019296601],"study_design_scores_gemma":[0.00015594615,0.002577342,0.0047050565,0.000015339223,0.00006490699,0.00033723583,0.000058351507,0.0014828093,0.9853851,0.00010392276,0.0051022368,0.000011682562],"about_ca_topic_score_codex":0.0004905795,"about_ca_topic_score_gemma":0.00064479973,"teacher_disagreement_score":0.0031614525,"about_ca_system_score_codex":0.0002561158,"about_ca_system_score_gemma":0.0002497087,"threshold_uncertainty_score":0.010576129},"labels":[],"label_agreement":null},{"id":"W4367052591","doi":"10.3410/f.742323959.793598362","title":"Faculty Opinions recommendation of Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Refractory (planetary science); CD19; Medicine; Systemic therapy; Immunology; Dermatology; Internal medicine; Antibody; Biology","score_opus":0.054283156519615856,"score_gpt":0.3868330823229618,"score_spread":0.33254992580334597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367052591","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014143155,0.00031241088,0.00006883692,0.0002578234,0.000057096935,0.000020522244,0.99749076,0.0002608086,0.001390371],"genre_scores_gemma":[0.00096325076,0.0003395754,0.00043600495,0.00038355592,0.00003643221,0.00009853579,0.995833,0.00007907839,0.001830528],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988507,0.00024144248,0.00015033469,0.0003304836,0.00029039875,0.00013655635],"domain_scores_gemma":[0.9963116,0.0014016839,0.0005037952,0.0005661416,0.0006995675,0.000517226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014318745,0.0017159136,0.0016074996,0.002173003,0.00052758906,0.002326061,0.0023865032,0.0027851888,0.10175479],"category_scores_gemma":[0.009942923,0.00051321386,0.0018899172,0.003042956,0.00025945937,0.0010532,0.0012993217,0.0016338876,0.076586396],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012629542,0.000022219876,0.0007578282,0.0009103427,0.000052535917,0.0000135344935,0.000004560442,0.00015181632,0.00006848506,0.00015256932,0.993899,0.0038409277],"study_design_scores_gemma":[0.0009099783,0.00005452694,0.0057669342,0.00085133576,0.0001816615,0.000081252794,0.0000225678,0.0007550988,0.00048387266,0.0011833184,0.9896774,0.000032048465],"about_ca_topic_score_codex":0.01581183,"about_ca_topic_score_gemma":0.044071004,"teacher_disagreement_score":0.10175479,"about_ca_system_score_codex":0.0015250585,"about_ca_system_score_gemma":0.0027717801,"threshold_uncertainty_score":0.34040368},"labels":[],"label_agreement":null},{"id":"W4367185145","doi":"10.3389/fimmu.2023.1178403","title":"A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Terry Fox Research Institute; University of Ottawa; University of British Columbia; Ottawa Hospital; University of Toronto","funders":"","keywords":"CD22; Medicine; Chimeric antigen receptor; CD19; Internal medicine; Oncology; Lymphoma; Immunology; Antigen; Immunotherapy; Cancer","score_opus":0.06912131729448169,"score_gpt":0.35192005123113446,"score_spread":0.2827987339366528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367185145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030647267,0.99462974,0.0005072707,0.00021463785,0.00015824877,0.0003538159,0.00075107155,0.00002020562,0.00030016055],"genre_scores_gemma":[0.09876423,0.89478,0.0020113634,0.0010193365,0.00023576804,0.0017408427,0.001008541,0.000035626315,0.0004044015],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98708004,0.0061827046,0.0037661712,0.0013315949,0.0012586156,0.0003809626],"domain_scores_gemma":[0.9812299,0.013741085,0.0027384167,0.00047848118,0.0015277995,0.0002843493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013315434,0.003068394,0.023781454,0.009343784,0.00081696146,0.0036948202,0.0023814405,0.002378592,0.004972726],"category_scores_gemma":[0.030977804,0.0016368827,0.036590453,0.011631591,0.0008818671,0.0023072504,0.001663701,0.0019137439,0.00047983325],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00125351,0.000019280886,0.0015197785,0.5846746,0.40250504,0.00011565686,0.00007477651,0.00042754595,0.0001934892,0.00015028096,0.00074017874,0.008325947],"study_design_scores_gemma":[0.00047166515,0.0001402297,0.0018866328,0.03963776,0.9554824,0.00007361908,0.000044035565,0.00012756619,0.00008757167,0.00017323821,0.0018546404,0.00002057634],"about_ca_topic_score_codex":0.009563373,"about_ca_topic_score_gemma":0.020084543,"teacher_disagreement_score":0.023781454,"about_ca_system_score_codex":0.003635522,"about_ca_system_score_gemma":0.0058710133,"threshold_uncertainty_score":0.07041961},"labels":[],"label_agreement":null},{"id":"W4367310554","doi":"10.1177/19418744231167290","title":"Chimeric Antigen Receptor-T Cell Mediated Bilateral Facial Nerve Palsy: A Case Report","year":2023,"lang":"en","type":"article","venue":"The Neurohospitalist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; Ontario Brain Institute; University of Calgary","funders":"","keywords":"Medicine; Chimeric antigen receptor; Encephalopathy; Leukocytosis; Diplopia; Neurotoxicity; Facial nerve; Pathology; Immunotherapy; Internal medicine; Immune system; Immunology; Surgery; Toxicity","score_opus":0.029800700448282792,"score_gpt":0.30647724603038273,"score_spread":0.2766765455820999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367310554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95286435,0.010053676,0.0076819165,0.006287902,0.000842628,0.00039770926,0.00044828717,0.00043020095,0.020993322],"genre_scores_gemma":[0.9898289,0.0030112264,0.0020949729,0.0011934547,0.0010966524,0.00006198267,0.000109829976,0.0000331031,0.0025699006],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99875236,0.00012275773,0.00012407737,0.00034380713,0.00021218888,0.00044489998],"domain_scores_gemma":[0.9985209,0.00037605333,0.0003720066,0.0001854474,0.000102209466,0.0004433608],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005506712,0.0030694955,0.0018998357,0.0028634365,0.0037148793,0.002500977,0.0019451502,0.0075395014,0.0031061647],"category_scores_gemma":[0.0024164026,0.0015418658,0.0016533715,0.0019653095,0.002693147,0.0031033,0.0022399866,0.0048491703,0.0014113702],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000010057942,0.000041499756,0.0009416358,0.000017538034,0.0000056996278,0.9977422,0.000075611744,0.000033408443,0.00027523644,0.00011175129,0.00014535456,0.00060016237],"study_design_scores_gemma":[0.0000066840594,0.000031258485,0.00073234277,0.0000073628507,0.000006812388,0.9985952,0.00005438683,0.000108977314,0.00017934847,0.000072592054,0.00019883632,0.0000063151615],"about_ca_topic_score_codex":0.00423078,"about_ca_topic_score_gemma":0.004994603,"teacher_disagreement_score":0.0075395014,"about_ca_system_score_codex":0.002750328,"about_ca_system_score_gemma":0.0017419338,"threshold_uncertainty_score":0.019955099},"labels":[],"label_agreement":null},{"id":"W4367396590","doi":"10.1016/j.blre.2023.101095","title":"Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need","year":2023,"lang":"en","type":"review","venue":"Blood Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Champlain Regional College","funders":"","keywords":"Chimeric antigen receptor; Medicine; Multiple myeloma; Lymphoma; Salvage therapy; CAR T-cell therapy; Refractory (planetary science); Oncology; Internal medicine; Intensive care medicine; Cancer; Immunotherapy; Chemotherapy","score_opus":0.07481768095768547,"score_gpt":0.3531875806208339,"score_spread":0.2783698996631484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367396590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045318546,0.9987664,0.000058741654,0.0006337402,0.00028089524,0.0000016099426,0.000010917197,0.000006400897,0.00019581504],"genre_scores_gemma":[0.000657252,0.9972716,0.00014459158,0.0011300759,0.00051962625,0.0000052017654,0.00003433084,0.000002491283,0.00023469618],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996623,0.00009379105,0.00004830538,0.000052079762,0.00010456066,0.000039045837],"domain_scores_gemma":[0.9991949,0.00043791078,0.00012142092,0.000015990972,0.00016232612,0.0000674551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014451294,0.00078231783,0.0031836394,0.0012378212,0.00021155772,0.0014146913,0.001041145,0.0016404245,0.0039386065],"category_scores_gemma":[0.001601658,0.00025455776,0.0009151067,0.0012659084,0.0004794279,0.0014467301,0.00070525333,0.0031124833,0.0019692557],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023799736,0.000053577936,0.00016213658,0.013060995,0.00019137161,0.0001679613,0.000026778125,0.00031322613,0.0008061035,0.0020343116,0.074702814,0.9082428],"study_design_scores_gemma":[0.00022239838,0.00032683837,0.0008565595,0.007895181,0.00054132944,0.0011007057,0.000057248977,0.00021345276,0.00023232031,0.0019061605,0.986616,0.000031690237],"about_ca_topic_score_codex":0.0010021157,"about_ca_topic_score_gemma":0.0027802652,"teacher_disagreement_score":0.0039386065,"about_ca_system_score_codex":0.0007833574,"about_ca_system_score_gemma":0.0015736462,"threshold_uncertainty_score":0.013175964},"labels":[],"label_agreement":null},{"id":"W4367602086","doi":"10.1016/j.leukres.2023.107274","title":"Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation – Post-transplantation treatment: IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS WHO UNDERGO MATCHED UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Transplantation; Hematopoietic cell; Medicine; Hematopoietic stem cell transplantation; Haematopoiesis; Intensive care medicine; Stem cell; Internal medicine; Biology","score_opus":0.024924774068694554,"score_gpt":0.3027709996817769,"score_spread":0.27784622561308236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367602086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6225916,0.21631186,0.0032756932,0.058843445,0.028802976,0.0020667934,0.0048802844,0.00088617596,0.062341172],"genre_scores_gemma":[0.75480556,0.094589636,0.0049176496,0.03519827,0.038206305,0.0014918768,0.0059026266,0.00014829804,0.06473979],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998698,0.000039471663,0.000015394655,0.000023251112,0.000025786754,0.000026276399],"domain_scores_gemma":[0.99981767,0.00004106022,0.000044116012,0.000008604523,0.000028510425,0.00006011438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047236923,0.0003044957,0.00068078004,0.00023471203,0.00029598788,0.0006061609,0.00028013272,0.0011370406,0.010576256],"category_scores_gemma":[0.00030350045,0.0000758863,0.00055417954,0.00017827556,0.00029010055,0.00023513986,0.00018705364,0.000886216,0.0020380283],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051771324,0.006569915,0.006682521,0.0045827385,0.00059467234,0.00061231153,0.000099881305,0.0004326113,0.04521575,0.0018617881,0.20000574,0.68157077],"study_design_scores_gemma":[0.048761535,0.07021258,0.07376672,0.0023820384,0.0031800396,0.004954914,0.00047768332,0.0015852368,0.09623332,0.0026129894,0.69571793,0.00011494988],"about_ca_topic_score_codex":0.00022641127,"about_ca_topic_score_gemma":0.00065402273,"teacher_disagreement_score":0.010576256,"about_ca_system_score_codex":0.0002886978,"about_ca_system_score_gemma":0.00072117435,"threshold_uncertainty_score":0.03538108},"labels":[],"label_agreement":null},{"id":"W4367681764","doi":"10.3410/f.741237310.793598365","title":"Faculty Opinions recommendation of Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia","funders":"","keywords":"Breast cancer; Suppressor; Cancer; Cancer research; Oncology; Receptor; Cell; Medicine; Internal medicine; Chemistry; Biochemistry","score_opus":0.04610169381906,"score_gpt":0.4034897243944212,"score_spread":0.3573880305753612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367681764","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024492014,0.00031878758,0.000049297032,0.00022931122,0.000040857332,0.000022208029,0.9980848,0.00016160453,0.00084836053],"genre_scores_gemma":[0.00118733,0.00030095762,0.00037265982,0.00027994235,0.00002410803,0.00012815668,0.9963052,0.00004480966,0.0013567727],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988576,0.00023686115,0.0001397946,0.00031651152,0.0002950209,0.00015419113],"domain_scores_gemma":[0.9967794,0.0012068704,0.00050234405,0.00044248454,0.0006483164,0.0004206245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015185392,0.0015859561,0.0015693763,0.002285262,0.00056054885,0.0021206855,0.0024677776,0.0025344999,0.06857157],"category_scores_gemma":[0.008651896,0.00046997398,0.0022709223,0.0033202497,0.00028200125,0.0008852266,0.0013397225,0.0014993751,0.04358493],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030716535,0.000044390505,0.001723814,0.0021533726,0.00015627919,0.000022549691,0.000009447698,0.0002689922,0.00019445253,0.0002344682,0.9894908,0.005394394],"study_design_scores_gemma":[0.0021548728,0.00011034784,0.010853393,0.0011607236,0.00048683336,0.00009968193,0.000045530123,0.0010129531,0.00096734805,0.0012415143,0.9818174,0.000049338185],"about_ca_topic_score_codex":0.020376977,"about_ca_topic_score_gemma":0.054840647,"teacher_disagreement_score":0.06857157,"about_ca_system_score_codex":0.0015280029,"about_ca_system_score_gemma":0.003017354,"threshold_uncertainty_score":0.22939473},"labels":[],"label_agreement":null},{"id":"W4367834504","doi":"10.1017/erm.2023.13","title":"Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia","year":2023,"lang":"en","type":"review","venue":"Expert Reviews in Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Centre for the Replacement, Refinement and Reduction of Animals in Research; Children's Cancer and Leukaemia Group","keywords":"Bone marrow; Cancer research; Cadherin; Tumor microenvironment; Medicine; Immunology; Cell; Biology; Tumor cells; Genetics","score_opus":0.05423215016981911,"score_gpt":0.37903037800590894,"score_spread":0.3247982278360898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367834504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036094055,0.9975822,0.00017546337,0.0002434414,0.00019292672,0.000008477367,0.00002218324,0.00001090547,0.0014034901],"genre_scores_gemma":[0.001328376,0.99701834,0.00021210752,0.00020213248,0.00011748427,0.00001054218,0.00004832266,0.0000017857889,0.0010608346],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998983,0.000016704365,0.000011324512,0.000015765156,0.00004181402,0.000016042339],"domain_scores_gemma":[0.9999018,0.000046132245,0.000016208867,0.0000023245414,0.000022086164,0.00001145496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002904235,0.00047116025,0.000884276,0.0011639977,0.00015805145,0.0007112036,0.00051397656,0.00093752856,0.0033701037],"category_scores_gemma":[0.00031992962,0.00017497675,0.00038109638,0.0008072808,0.00021183325,0.0007319643,0.0004342818,0.001225446,0.0018280778],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009505238,0.00006984401,0.0001395697,0.016988017,0.000080713995,0.0003390317,0.00006171206,0.00048114487,0.007850243,0.0032820085,0.022837725,0.94777495],"study_design_scores_gemma":[0.00002121367,0.00018200064,0.0005967469,0.0020495001,0.00010351163,0.001622312,0.00004085019,0.00011712146,0.0013928117,0.0008948605,0.99296534,0.000013812689],"about_ca_topic_score_codex":0.0005764892,"about_ca_topic_score_gemma":0.0012779593,"teacher_disagreement_score":0.0033701037,"about_ca_system_score_codex":0.0003962353,"about_ca_system_score_gemma":0.0005512315,"threshold_uncertainty_score":0.011274099},"labels":[],"label_agreement":null},{"id":"W4367852216","doi":"10.3389/fimmu.2023.1166038","title":"Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa; Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cell therapy; CAR T-cell therapy; Immunotherapy; Medicine; Immunology; Bioinformatics; Biology; Immune system; Cell","score_opus":0.15477535705814865,"score_gpt":0.4157809578509788,"score_spread":0.26100560079283014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367852216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010893733,0.99759585,0.00024946706,0.000906912,0.0003337872,0.0000035604287,0.0000117038935,0.000008132341,0.0007817094],"genre_scores_gemma":[0.00075265596,0.99753916,0.00032235179,0.0005834616,0.00024939177,0.0000064851906,0.000020677877,0.0000027920298,0.00052301405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969697,0.00006800657,0.000037782367,0.000055552322,0.00010602635,0.000035599085],"domain_scores_gemma":[0.99935824,0.00039092058,0.00004021182,0.000018378842,0.00013621645,0.000056080724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00124628,0.00066500827,0.0011927543,0.0014258479,0.00026396892,0.0012105284,0.00077212346,0.0014856311,0.003486811],"category_scores_gemma":[0.0012485314,0.00025899522,0.0008366844,0.0012858467,0.0006431196,0.0023604857,0.0006493961,0.004086036,0.0014992752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011210535,0.0001101255,0.00014474386,0.016260788,0.00008990779,0.00022286392,0.00009346568,0.0007290863,0.0024357173,0.012666058,0.038633034,0.9285021],"study_design_scores_gemma":[0.000021944037,0.0001349077,0.00028034495,0.0030984047,0.00006537705,0.00072150654,0.00005909755,0.00013014792,0.0006374342,0.0038676963,0.99096733,0.000015812393],"about_ca_topic_score_codex":0.0011217775,"about_ca_topic_score_gemma":0.0018820703,"teacher_disagreement_score":0.003486811,"about_ca_system_score_codex":0.0008374378,"about_ca_system_score_gemma":0.0014447937,"threshold_uncertainty_score":0.011664569},"labels":[],"label_agreement":null},{"id":"W4368371666","doi":"10.3410/f.733111646.793598355","title":"Faculty Opinions recommendation of Universal chimeric antigen receptors for multiplexed and logical control of T cell responses.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Multiplexing; Receptor; Control (management); Computational biology; Antigen; Computer science; Chemistry; Cell biology; Biology; Immunology; T cell; Genetics; Artificial intelligence; Telecommunications; Immune system","score_opus":0.05238407062758756,"score_gpt":0.3816209964834639,"score_spread":0.3292369258558764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368371666","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014228343,0.00017951115,0.000110194065,0.00012718434,0.000038613383,0.000020424035,0.9980702,0.00053329405,0.0007782605],"genre_scores_gemma":[0.00053947634,0.00012749693,0.00044410766,0.00013939921,0.000010997951,0.00008290853,0.99780554,0.00006868517,0.0007814283],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976882,0.0004594703,0.00026142178,0.00067375804,0.00061448925,0.00030269029],"domain_scores_gemma":[0.9952651,0.0015996157,0.0005655345,0.0011072446,0.00089831895,0.0005641432],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002545116,0.002710281,0.0020635838,0.0034612697,0.00086945447,0.003436822,0.0035040397,0.00373105,0.076085046],"category_scores_gemma":[0.011919951,0.0008704412,0.0024385971,0.0045402437,0.00047666422,0.0014333063,0.0022089405,0.0022793303,0.10128886],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018143268,0.0000442949,0.0013402231,0.0014457469,0.000079634614,0.000020778783,0.000012434966,0.0003673115,0.00024740156,0.00034786036,0.9913999,0.0045130565],"study_design_scores_gemma":[0.0007692747,0.00005775902,0.004905043,0.00069944834,0.00014689483,0.0000731794,0.000042101412,0.0013098913,0.0011067503,0.0016956945,0.98915184,0.000042029078],"about_ca_topic_score_codex":0.019811934,"about_ca_topic_score_gemma":0.040740382,"teacher_disagreement_score":0.076085046,"about_ca_system_score_codex":0.0018363302,"about_ca_system_score_gemma":0.0035445527,"threshold_uncertainty_score":0.25452983},"labels":[],"label_agreement":null},{"id":"W4368373774","doi":"10.1016/j.ymthe.2023.04.021","title":"A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Akebia Therapeutics; Canadian Institute of Steel Construction; Children’s Hospital of Wisconsin Research Institute; Seattle Children's Research Institute; Leona M. and Harry B. Helmsley Charitable Trust","keywords":"In vivo; Cell biology; Biology; T-cell receptor; FOXP3; CD19; Chimeric antigen receptor; In vitro; T cell; Cancer research; Immunology; Antigen; Immune system; Genetics","score_opus":0.023745303880693867,"score_gpt":0.3002096828997834,"score_spread":0.27646437901908955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368373774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91747785,0.00085515756,0.069816865,0.0004078073,0.00024147432,0.0004519033,0.0020327633,0.0010784924,0.007637682],"genre_scores_gemma":[0.9469697,0.0003541264,0.039055735,0.00021894746,0.00005678575,0.00031160848,0.0022148725,0.00041891175,0.010399304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993787,0.00010279917,0.00005572042,0.00014159887,0.0001687068,0.00015241944],"domain_scores_gemma":[0.9997131,0.0000652224,0.00008506466,0.00004209974,0.000027848955,0.00006654065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034585738,0.00078666233,0.0003285642,0.0005641997,0.0002492418,0.0008945547,0.0004807601,0.0006944583,0.003316433],"category_scores_gemma":[0.00020146485,0.00035401288,0.00031224763,0.00029088932,0.0003046737,0.00033018985,0.00047639353,0.001555956,0.0012745999],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004117236,0.00003559839,0.00004422022,0.0000106269,0.0000027469305,0.000013743985,0.000007723724,0.000071866234,0.9989999,0.00021248998,0.000056661964,0.0005032627],"study_design_scores_gemma":[0.000016936492,0.000067236324,0.0003002715,0.0000024395956,0.000009867537,0.00008687835,0.0000058104483,0.0007184187,0.9961985,0.00002074944,0.0025694093,0.0000034402333],"about_ca_topic_score_codex":0.0006021271,"about_ca_topic_score_gemma":0.0014496917,"teacher_disagreement_score":0.003316433,"about_ca_system_score_codex":0.0005545632,"about_ca_system_score_gemma":0.00044763702,"threshold_uncertainty_score":0.01109457},"labels":[],"label_agreement":null},{"id":"W4368377442","doi":"10.14740/wjon1575","title":"Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy","year":2023,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Adverse effect; Antigen; Immune system; Immunology; Immunotherapy; Receptor; Pharmacology; Internal medicine","score_opus":0.05445517049777401,"score_gpt":0.38029507042618693,"score_spread":0.32583989992841295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368377442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015950315,0.99856144,0.00007747659,0.000121460995,0.000099175835,0.0000065853524,0.000018501745,0.0000061280925,0.000949742],"genre_scores_gemma":[0.0009813898,0.99809986,0.00011714884,0.00016218922,0.00008828954,0.000009409516,0.000032223765,0.0000011488987,0.00050828326],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997385,0.000050844283,0.000048716942,0.00003498598,0.000103173996,0.000023688643],"domain_scores_gemma":[0.9996735,0.00016509891,0.0000717678,0.000006863355,0.00006466377,0.000018079447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049184443,0.00067179976,0.0014099275,0.0018233698,0.0002480872,0.0008823108,0.00072317227,0.00089506665,0.0042745294],"category_scores_gemma":[0.00072850706,0.00019846596,0.00086390454,0.0012855766,0.000246308,0.0006437381,0.00049654423,0.0011027666,0.0011702441],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008889324,0.000060607323,0.00017199748,0.029657071,0.00019645352,0.0002607901,0.000041003765,0.0002859254,0.0013164729,0.0017019797,0.019447774,0.94677114],"study_design_scores_gemma":[0.00006642763,0.00020053191,0.0012818673,0.011308803,0.00050238246,0.0043772156,0.0000683477,0.00013367672,0.0010483748,0.0013979286,0.9795887,0.00002572241],"about_ca_topic_score_codex":0.00083552004,"about_ca_topic_score_gemma":0.0019460919,"teacher_disagreement_score":0.0042745294,"about_ca_system_score_codex":0.0005134585,"about_ca_system_score_gemma":0.0009681013,"threshold_uncertainty_score":0.014299691},"labels":[],"label_agreement":null},{"id":"W4375844599","doi":"10.2174/1573404820666230505110617","title":"Recent Developments in Combinatorial Immunotherapy towards OvarianCancer","year":2023,"lang":"en","type":"article","venue":"Current Women s Health Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"","keywords":"Immunotherapy; Medicine; Ovarian cancer; Oncolytic virus; Disease; Radiation therapy; Cancer immunotherapy; Cancer; Oncology; Immunology; Internal medicine","score_opus":0.16371118422226963,"score_gpt":0.46338862633506683,"score_spread":0.29967744211279723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375844599","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.019654527,0.9592153,0.008517234,0.0022234789,0.0007634693,0.00008700101,0.00008002719,0.00011550762,0.0093434295],"genre_scores_gemma":[0.096513994,0.8842073,0.010172868,0.0021840313,0.0010333407,0.00014591868,0.00025707897,0.000030508289,0.0054549384],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986327,0.000035358968,0.000009976661,0.000030566363,0.00003665418,0.000024094492],"domain_scores_gemma":[0.99985003,0.00005156533,0.00002701195,0.000010102295,0.00003677393,0.000024441648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061617,0.0005396385,0.00043937255,0.00083895255,0.00021502507,0.0009321505,0.00042552038,0.00066372135,0.0021312311],"category_scores_gemma":[0.0003046432,0.00019607175,0.00045922777,0.0006451864,0.00040562113,0.0008075847,0.00059255207,0.0013266236,0.00062305183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031679103,0.00073251897,0.00069512054,0.0071949437,0.00015947387,0.00051289104,0.0002511639,0.0046280622,0.102314524,0.024240524,0.015145106,0.8438088],"study_design_scores_gemma":[0.00016879947,0.0031581204,0.0017282922,0.0011254689,0.00022832012,0.0021941697,0.00016463532,0.003822565,0.08563929,0.008811193,0.8928987,0.00006050337],"about_ca_topic_score_codex":0.00025218,"about_ca_topic_score_gemma":0.0005717518,"teacher_disagreement_score":0.0021312311,"about_ca_system_score_codex":0.0004964179,"about_ca_system_score_gemma":0.00034507815,"threshold_uncertainty_score":0.007129669},"labels":[],"label_agreement":null},{"id":"W4375864821","doi":"10.1080/10428194.2023.2203790","title":"Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Etoposide; Oncology; Carmustine; Febrile neutropenia; Melphalan; Cytarabine; Autologous stem-cell transplantation; Follicular lymphoma; Mucositis; Hematopoietic stem cell transplantation; Regimen; Transplantation; Surgery; Neutropenia; Lymphoma; Chemotherapy; Rituximab","score_opus":0.01950455767052423,"score_gpt":0.2957316072068995,"score_spread":0.2762270495363753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375864821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991518,0.00037723,0.000098660086,0.00000997954,0.00000521561,0.00005520934,0.00008849443,0.000002187628,0.00021112117],"genre_scores_gemma":[0.999416,0.000104485865,0.00008771631,0.00004941139,0.000016281163,0.000035045978,0.00022392931,0.000001983877,0.00006503521],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99904734,0.00030558687,0.00016751295,0.0002569964,0.0001223093,0.00010017394],"domain_scores_gemma":[0.99796873,0.00052503403,0.0006665072,0.00023566482,0.0002076841,0.00039631705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00130535,0.00032623604,0.0007359199,0.0005553394,0.00057360734,0.00067493756,0.00025315132,0.00046010784,0.0013980943],"category_scores_gemma":[0.0022393675,0.00033997916,0.0006138576,0.000855663,0.0004582037,0.00040846967,0.0003202714,0.00038426352,0.00030768442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002756284,0.0006902532,0.99161536,0.000055208064,0.0003118802,0.000575848,0.0001420522,0.00006105016,0.0008981277,0.00003350209,0.00010044203,0.0027599204],"study_design_scores_gemma":[0.00097643904,0.015677653,0.97594815,0.00003491714,0.00053074886,0.0036408966,0.00048806358,0.000425229,0.00069951796,0.000059001257,0.0014900778,0.000029358152],"about_ca_topic_score_codex":0.0011627388,"about_ca_topic_score_gemma":0.001328994,"teacher_disagreement_score":0.0013980943,"about_ca_system_score_codex":0.00045119366,"about_ca_system_score_gemma":0.00065945025,"threshold_uncertainty_score":0.0069034696},"labels":[],"label_agreement":null},{"id":"W4375955180","doi":"10.1111/ejh.13982","title":"<scp>PD‐L1</scp> expression predicts efficacy in the phase <scp>II SPiReL</scp> trial with <scp>MVP‐S</scp>, pembrolizumab, and low‐dose <scp>CPA</scp> in R/R <scp>DLBCL</scp>","year":2023,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Baker Hughes (Canada); McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Oncology; Discontinuation; Gastroenterology; Immunotherapy; Cancer","score_opus":0.034535795403372906,"score_gpt":0.31449901093513066,"score_spread":0.27996321553175774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375955180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987079,0.00035308936,0.00007670696,0.0001197437,0.000008546372,0.000066691144,0.00026732715,0.000013213533,0.00038672803],"genre_scores_gemma":[0.99853826,0.00008355455,0.0001599041,0.00007187551,0.000023855551,0.000059188846,0.000845229,0.0000035991018,0.0002146621],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99958366,0.00023887372,0.000021833897,0.000056856214,0.000042394266,0.000056340796],"domain_scores_gemma":[0.99905807,0.0002868214,0.00024581217,0.000048169764,0.00004760594,0.00031349194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002023996,0.00052375696,0.00053448573,0.00024083292,0.00021449797,0.00095251016,0.00033489932,0.00043774775,0.002016984],"category_scores_gemma":[0.0012813275,0.00021840233,0.0005555493,0.00017844731,0.00037352456,0.00043496682,0.0002929296,0.0011200871,0.00036686996],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3460158,0.0067664315,0.54100156,0.00048076728,0.0019753205,0.00026747352,0.00019559468,0.005552483,0.023113392,0.00020139574,0.005250867,0.069178924],"study_design_scores_gemma":[0.054471843,0.09079499,0.8186034,0.000089994675,0.0020037438,0.0011322831,0.00014454064,0.018710721,0.009933057,0.00034731245,0.0037101253,0.000058077007],"about_ca_topic_score_codex":0.00033710833,"about_ca_topic_score_gemma":0.00071050174,"teacher_disagreement_score":0.002023996,"about_ca_system_score_codex":0.00051128084,"about_ca_system_score_gemma":0.0006021524,"threshold_uncertainty_score":0.0107040405},"labels":[],"label_agreement":null},{"id":"W4376107823","doi":"10.1200/edbk_390778","title":"COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies","year":2023,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tocilizumab; Chimeric antigen receptor; Immunology; Population; Disease; Immune system; Internal medicine; Immunotherapy","score_opus":0.08741768583104755,"score_gpt":0.4779941578406663,"score_spread":0.39057647200961876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376107823","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.879652,0.06709034,0.0009886152,0.004406016,0.00036365615,0.00017867931,0.0022404944,0.00007812266,0.045002006],"genre_scores_gemma":[0.9860481,0.008735283,0.0004460381,0.0012327415,0.00037382657,0.00005148728,0.0010337306,0.000009033477,0.0020698],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965537,0.000075347765,0.00004408307,0.00004894796,0.00009470504,0.00008151536],"domain_scores_gemma":[0.99953175,0.000079131765,0.00019939765,0.000017093545,0.00004320151,0.00012941884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023255861,0.00016799328,0.00029713352,0.00046327122,0.00053657166,0.0004529229,0.00015621679,0.0004167844,0.0035496405],"category_scores_gemma":[0.0011037987,0.000107737,0.00023721921,0.0009505968,0.00019428946,0.00045455634,0.00037211212,0.00083993917,0.0004282078],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032529834,0.00009640327,0.9534042,0.00018349742,0.000045434175,0.0035814506,0.00018281097,0.00008702617,0.00073977397,0.00035198912,0.0045209364,0.036481246],"study_design_scores_gemma":[0.000045129276,0.00036378048,0.94591844,0.0004322545,0.00009714746,0.026714556,0.00076892786,0.00034736498,0.00033855,0.00076243444,0.02418668,0.000024688556],"about_ca_topic_score_codex":0.0023573022,"about_ca_topic_score_gemma":0.0024596353,"teacher_disagreement_score":0.0035496405,"about_ca_system_score_codex":0.0003420866,"about_ca_system_score_gemma":0.0004711607,"threshold_uncertainty_score":0.011874735},"labels":[],"label_agreement":null},{"id":"W4376225548","doi":"10.1007/s00277-023-05196-4","title":"RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"National Cancer Institute; MorphoSys","keywords":"Lenalidomide; Medicine; Rituximab; Internal medicine; Bendamustine; Oncology; Clinical endpoint; Surgery; Multiple myeloma; Lymphoma; Clinical trial","score_opus":0.0815092479124416,"score_gpt":0.3680034390507228,"score_spread":0.28649419113828123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376225548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700874,0.0011525879,0.00021527398,0.00009709943,0.000052954812,0.0003173634,0.00048084644,0.000013229591,0.0006618532],"genre_scores_gemma":[0.997358,0.00040510113,0.00043415377,0.00014105189,0.00008603954,0.0002494007,0.0009400501,0.0000049687073,0.0003812095],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99916625,0.00053324876,0.000063203915,0.00011916727,0.00005469149,0.00006347549],"domain_scores_gemma":[0.9987218,0.00042213188,0.00043001925,0.000118759686,0.00004608699,0.00026117402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021441479,0.0007989789,0.0011109307,0.00030634177,0.00012260044,0.0006969848,0.0007558996,0.00060222094,0.001622512],"category_scores_gemma":[0.0019678972,0.00034319088,0.0021840534,0.00023185568,0.00046293047,0.0006073837,0.0005021038,0.0014145956,0.0002245131],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9532242,0.0049781944,0.008596424,0.00033735333,0.0029264265,0.00004188895,0.000057600108,0.0018193788,0.0042765928,0.00012182693,0.0003822599,0.023237858],"study_design_scores_gemma":[0.4595904,0.4721213,0.050117124,0.00008140953,0.0053469706,0.00031933896,0.00010707799,0.0055257133,0.0037950461,0.00054541306,0.0023835704,0.00006666274],"about_ca_topic_score_codex":0.00056680304,"about_ca_topic_score_gemma":0.0014252316,"teacher_disagreement_score":0.0021441479,"about_ca_system_score_codex":0.00088332023,"about_ca_system_score_gemma":0.0005540079,"threshold_uncertainty_score":0.011339426},"labels":[],"label_agreement":null},{"id":"W4376226544","doi":"10.1182/bloodadvances.2022007059","title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Incyte; Andrew McDonough B+ Foundation; American Society of Clinical Oncology; American Association for Cancer Research; St. Baldrick's Foundation; Stand Up To Cancer; National Cancer Institute; Entertainment Industry Foundation; Gilead Sciences; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Chimeric antigen receptor; CD38; Cart; Haematopoiesis; Antigen; Cancer research; Medicine; Immunology; Myeloid leukemia; Immunotherapy; T cell; Myeloid; Leukemia; Stem cell; Biology; CD34; Immune system; Cell biology","score_opus":0.026737103991852498,"score_gpt":0.3417820071623222,"score_spread":0.31504490317046974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376226544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9284977,0.015663562,0.035034414,0.0013707413,0.0002315216,0.0005760207,0.0006441431,0.0007445519,0.01723726],"genre_scores_gemma":[0.9746713,0.0029379756,0.016118666,0.00019083389,0.000031387888,0.00019708811,0.00039553357,0.000037411864,0.0054197577],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999806,0.00004402228,0.000007192007,0.000045125762,0.000048514925,0.00004925703],"domain_scores_gemma":[0.99995685,0.0000071749637,0.0000072390485,0.0000073717724,0.000006995834,0.000014265636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022760082,0.0004950527,0.00020662785,0.00028247433,0.00020190098,0.00038714512,0.00038622686,0.0005107299,0.0024426559],"category_scores_gemma":[0.00012294533,0.00014719648,0.0002243214,0.00018014322,0.00022676754,0.00037361943,0.00039290398,0.0009960762,0.00052208797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021249335,0.00017118487,0.00023178461,0.000109500565,0.0000128383035,0.00019246596,0.0000616258,0.00082520954,0.97764343,0.0027510314,0.00084723916,0.01694127],"study_design_scores_gemma":[0.00014471417,0.0015327625,0.00092297693,0.000024288775,0.000042449632,0.0017381747,0.000036509056,0.005143602,0.9382507,0.00042516663,0.05172478,0.000013769422],"about_ca_topic_score_codex":0.0010557561,"about_ca_topic_score_gemma":0.0013429213,"teacher_disagreement_score":0.0024426559,"about_ca_system_score_codex":0.00074576744,"about_ca_system_score_gemma":0.00039447125,"threshold_uncertainty_score":0.008171499},"labels":[],"label_agreement":null},{"id":"W4376608471","doi":"10.1038/s41587-023-01816-6","title":"Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response","year":2023,"lang":"en","type":"erratum","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Hatch (Canada)","funders":"","keywords":"Deconvolution; Variance (accounting); Computational biology; Pharmacology; Clinical pharmacology; Mathematics; Biology; Statistics; Economics","score_opus":0.03218830129564559,"score_gpt":0.4115892689948476,"score_spread":0.379400967699202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376608471","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050309685,0.0015187212,0.028128065,0.0361382,0.91701543,0.00007972517,0.007223547,0.0027429664,0.006650266],"genre_scores_gemma":[0.051875293,0.008008651,0.10330759,0.05166597,0.16089186,0.00072702294,0.016982622,0.016069094,0.59047204],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99209434,0.0015683899,0.0011965223,0.0013250629,0.0035108966,0.00030488378],"domain_scores_gemma":[0.93529326,0.01975488,0.0021246972,0.0068036593,0.034815222,0.0012083022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008944644,0.002743905,0.0019570142,0.003380032,0.002272042,0.003532756,0.0035875873,0.00439154,0.11395914],"category_scores_gemma":[0.12593089,0.0014095495,0.0021826439,0.0032124952,0.0016632352,0.0023181636,0.0025629678,0.007659852,0.055374198],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006158547,0.000006679416,0.0001543404,0.00015871724,0.000025875432,0.00016678836,0.000031619238,0.00034921078,0.00011841536,0.0031892804,0.9804817,0.015255815],"study_design_scores_gemma":[0.00008692918,0.000024048006,0.0008219862,0.00046652363,0.00009572531,0.0010094543,0.000071042836,0.004574255,0.0019847262,0.0123396795,0.9784289,0.00009685414],"about_ca_topic_score_codex":0.015314398,"about_ca_topic_score_gemma":0.021790953,"teacher_disagreement_score":0.11395914,"about_ca_system_score_codex":0.0037604694,"about_ca_system_score_gemma":0.0069091134,"threshold_uncertainty_score":0.3812313},"labels":[],"label_agreement":null},{"id":"W4376611005","doi":"10.1158/1078-0432.c.6516061.v2","title":"Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Gilead Sciences","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Adverse effect; Clinical endpoint; Cytokine release syndrome; Refractory (planetary science); Oncology; Gastroenterology; Randomized controlled trial; Lymphoma; Surgery; Rituximab; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.04952137718723923,"score_gpt":0.32935372489378223,"score_spread":0.27983234770654297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376611005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247533,0.003652573,0.00013440833,0.00032177297,0.000057498422,0.00027955882,0.0015335508,0.000013804321,0.0015314806],"genre_scores_gemma":[0.9963632,0.0010412157,0.00012981423,0.00047458173,0.00008839173,0.00021569172,0.001232646,0.000005597942,0.0004489091],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9988953,0.00064253755,0.00012379207,0.00010216805,0.00013344797,0.00010267833],"domain_scores_gemma":[0.99752134,0.0009770377,0.000806886,0.00022214901,0.00010134734,0.00037126013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021388433,0.00042772092,0.0011352726,0.00033466984,0.0002424586,0.00069042237,0.00042133706,0.0007641573,0.0029150096],"category_scores_gemma":[0.002841877,0.00021515858,0.0021906735,0.00049529254,0.0005427589,0.0005989507,0.00032216025,0.0010894124,0.00039738772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9133152,0.0036333392,0.021347793,0.0010676746,0.0038309118,0.00016068971,0.00011945228,0.00093744736,0.0056110006,0.00011954402,0.0018343162,0.0480227],"study_design_scores_gemma":[0.44246602,0.3533703,0.1785961,0.00036775394,0.010204543,0.0005978921,0.00028752445,0.0014429848,0.0050629578,0.00047013033,0.0070535056,0.00008034388],"about_ca_topic_score_codex":0.00068087125,"about_ca_topic_score_gemma":0.0018347235,"teacher_disagreement_score":0.0029150096,"about_ca_system_score_codex":0.0006118118,"about_ca_system_score_gemma":0.00066428044,"threshold_uncertainty_score":0.011311412},"labels":[],"label_agreement":null},{"id":"W4376645275","doi":"10.3390/curroncol30050378","title":"Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine; Memorial Sloan-Kettering Cancer Center","keywords":"Chimeric antigen receptor; Medicine; Cytokine release syndrome; Toxicity; Immunotherapy; Cytokine; Targeted therapy; Immunology; Oncology; Cancer research; Cancer; Internal medicine; Immune system","score_opus":0.28521256016160845,"score_gpt":0.49256499436315554,"score_spread":0.2073524342015471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376645275","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029154323,0.9979018,0.00022633073,0.00026027413,0.00012388165,0.000007742877,0.000025173556,0.000010113176,0.0011531424],"genre_scores_gemma":[0.001678979,0.99715924,0.0002955141,0.00018370355,0.00013922749,0.000010168655,0.000045417943,0.0000021681888,0.00048550445],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981695,0.000042109816,0.000033966222,0.000031844225,0.00005767796,0.000017496073],"domain_scores_gemma":[0.99976546,0.000111093665,0.000041031846,0.000007627135,0.0000605328,0.000014281443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036761686,0.00056977913,0.00083477003,0.0017616526,0.00019731969,0.0007035899,0.0005478342,0.00071989617,0.0024519279],"category_scores_gemma":[0.00066516455,0.00014383804,0.00052810804,0.0012797597,0.00025745426,0.0007658059,0.00041045927,0.0010521751,0.0010653975],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006480726,0.00006215033,0.00029841403,0.013662887,0.00007490971,0.00020842435,0.00004583884,0.00036331586,0.0014101816,0.001494447,0.014420147,0.9678945],"study_design_scores_gemma":[0.00002190157,0.00021582106,0.002144116,0.008467931,0.00025595946,0.0049516177,0.00009805413,0.00019335616,0.0014214513,0.0018577501,0.9803508,0.000021092423],"about_ca_topic_score_codex":0.0006561471,"about_ca_topic_score_gemma":0.0011160137,"teacher_disagreement_score":0.0024519279,"about_ca_system_score_codex":0.0004689483,"about_ca_system_score_gemma":0.0007584608,"threshold_uncertainty_score":0.008202493},"labels":[],"label_agreement":null},{"id":"W4377077805","doi":"10.1007/978-1-0716-3056-3_1","title":"Cancer Cell Culture: The Basics and Two-Dimensional Cultures","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Psychological intervention; Cancer; Computer science; Engineering ethics; Intervention (counseling); Medicine; Engineering","score_opus":0.04481828783222981,"score_gpt":0.477577311979164,"score_spread":0.4327590241469342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377077805","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037771046,0.07086247,0.80951864,0.0082995,0.003405971,0.0024642604,0.011426722,0.0019895777,0.054261796],"genre_scores_gemma":[0.18096589,0.118589275,0.5949758,0.0031574098,0.00211709,0.0078030885,0.01611399,0.0010846654,0.07519289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917334,0.00019635343,0.00010970212,0.00009904393,0.00034685046,0.00007465911],"domain_scores_gemma":[0.9994753,0.00018920851,0.000024799994,0.00016013662,0.00008234939,0.00006822689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013418276,0.00076274184,0.000987051,0.0011877794,0.0009135576,0.0013854707,0.0015516365,0.000832918,0.0037907013],"category_scores_gemma":[0.0005804811,0.00069350866,0.0006956464,0.0009772787,0.0010587707,0.0011693209,0.0010311946,0.0032087623,0.0037215548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047986076,0.0004359108,0.00092065806,0.0018838611,0.000037995782,0.00066507835,0.0010372078,0.0014672722,0.80552626,0.06738113,0.027349364,0.0928154],"study_design_scores_gemma":[0.000098228484,0.00034090542,0.0023260352,0.000256909,0.000056749694,0.0021382242,0.00013831962,0.0045026178,0.45556486,0.014233874,0.52022153,0.00012174518],"about_ca_topic_score_codex":0.0016105138,"about_ca_topic_score_gemma":0.0031139632,"teacher_disagreement_score":0.0037907013,"about_ca_system_score_codex":0.0004933865,"about_ca_system_score_gemma":0.0007276072,"threshold_uncertainty_score":0.012681186},"labels":[],"label_agreement":null},{"id":"W4377087306","doi":"10.21203/rs.3.rs-2907146/v1","title":"Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Cart; Medicine; Chimeric antigen receptor; Quality of life (healthcare); Internal medicine; Cohort; Refractory (planetary science); Oncology; Disease; Prospective cohort study; Lymphoma; Immunotherapy; Cancer","score_opus":0.1485487459625802,"score_gpt":0.4187385744424377,"score_spread":0.2701898284798575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377087306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99865925,0.000042731284,0.00031636716,0.00004099055,0.000005730123,0.00028528154,0.0003498861,0.00000547441,0.00029431883],"genre_scores_gemma":[0.99728763,0.000045371573,0.0009959795,0.00007855881,0.000018291974,0.0007484565,0.0006692327,0.0000020896116,0.00015433539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978398,0.0012908344,0.00024001434,0.00019534012,0.00023640823,0.00019764593],"domain_scores_gemma":[0.99601823,0.0008972844,0.0014568594,0.00033615096,0.0006723965,0.00061903737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005243192,0.00034941343,0.00040350866,0.00072091015,0.00075907353,0.00070317223,0.00036949327,0.0004738911,0.00077279593],"category_scores_gemma":[0.007465316,0.00023239793,0.0004517473,0.0005377495,0.00026781225,0.00066531415,0.000681562,0.00064735964,0.00040358887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008419794,0.0006536351,0.9910046,0.000020703359,0.000040600593,0.00010370168,0.00030410342,0.00012331695,0.00069360767,0.000020327543,0.00017713565,0.0060164146],"study_design_scores_gemma":[0.0001640922,0.004979341,0.9920175,0.00001662146,0.000044833025,0.00026783778,0.000555879,0.00069738255,0.00055312424,0.000040554398,0.0006489564,0.000013844877],"about_ca_topic_score_codex":0.001318003,"about_ca_topic_score_gemma":0.0021182944,"teacher_disagreement_score":0.005243192,"about_ca_system_score_codex":0.0003924404,"about_ca_system_score_gemma":0.00066085765,"threshold_uncertainty_score":0.027729034},"labels":[],"label_agreement":null},{"id":"W4377141625","doi":"10.1016/j.canlet.2023.216242","title":"A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7","year":2023,"lang":"en","type":"article","venue":"Cancer Letters","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"T-cell receptor; Cytotoxic T cell; Antigen; Chimeric antigen receptor; Biology; Adoptive cell transfer; CD8; Cancer research; T cell; CD28; Cancer immunotherapy; Immunotherapy; CD3; Immunology; Immune system","score_opus":0.035026598577599696,"score_gpt":0.3340917778599455,"score_spread":0.29906517928234577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377141625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974692,0.0003170373,0.00030493367,0.000038017184,0.000018421677,0.000011881198,0.000035987632,0.000026694379,0.0017779493],"genre_scores_gemma":[0.9979493,0.00016270492,0.000257078,0.000034601788,0.0000136830095,0.000010349982,0.00008148597,0.000010039414,0.0014807663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976724,0.00006027283,0.000014221586,0.000023698587,0.00003846594,0.00009613932],"domain_scores_gemma":[0.9998209,0.00008450577,0.000017330092,0.000022195036,0.000015704392,0.00003942004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019838574,0.0003956953,0.00043022743,0.00018249359,0.00015569363,0.0004629737,0.00019401679,0.0003991612,0.0022050333],"category_scores_gemma":[0.00022979641,0.0001557477,0.00023672124,0.0000952639,0.00022063055,0.0003363613,0.00023106675,0.0007597828,0.0005547096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005376126,0.00010216756,0.00021334834,0.000027024118,0.000004821249,0.00012078922,0.000021280282,0.00016983239,0.99729425,0.00010450316,0.000061229744,0.0013430704],"study_design_scores_gemma":[0.00015499494,0.0018564324,0.0044040596,0.000007541581,0.00002676889,0.00075207924,0.00005954335,0.002017768,0.98872644,0.000059921655,0.0019265001,0.00000808418],"about_ca_topic_score_codex":0.000336043,"about_ca_topic_score_gemma":0.0004092804,"teacher_disagreement_score":0.0022050333,"about_ca_system_score_codex":0.00023663459,"about_ca_system_score_gemma":0.00022067978,"threshold_uncertainty_score":0.007376611},"labels":[],"label_agreement":null},{"id":"W4377195778","doi":"10.1111/bjh.18863","title":"Granulocyte transfusion during cord blood transplant for relapsed, refractory <scp>AML</scp> is associated with massive <scp>CD8</scp><sup>+</sup> T‐cell expansion, significant cytokine release syndrome and induction of disease remission","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Children's Cancer and Leukaemia Group","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Immunology; Hematopoietic stem cell transplantation; Gastroenterology; Transplantation; T cell; Immune system","score_opus":0.015426651381661008,"score_gpt":0.24959361001121064,"score_spread":0.23416695862954962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377195778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989581,0.00043704858,0.00023523325,0.000050511877,0.000013890037,0.00003282366,0.000025694439,0.000021417974,0.00022518735],"genre_scores_gemma":[0.9994161,0.00013821328,0.00020274441,0.000051875522,0.00001746016,0.000015981932,0.00007323894,0.000003442729,0.00008091896],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9997428,0.0001315747,0.000027549562,0.000022538581,0.000043651118,0.000031924785],"domain_scores_gemma":[0.99951386,0.0001281323,0.00019606926,0.000044811477,0.000014996572,0.00010204109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051510043,0.00017715749,0.00042653852,0.000084807325,0.00013025035,0.0002821683,0.00021142463,0.00020812567,0.0006333083],"category_scores_gemma":[0.00091537036,0.00007014763,0.00018767624,0.00013262812,0.00027947567,0.00016268846,0.0001424915,0.00063722464,0.00012333435],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14779048,0.0073184324,0.102058955,0.0012076225,0.0008269257,0.0074922876,0.0007714321,0.004403159,0.25394243,0.0009821939,0.006861992,0.46634415],"study_design_scores_gemma":[0.021237608,0.34301263,0.40771952,0.0002836262,0.0010789847,0.031998385,0.0003270728,0.018859046,0.1650255,0.0008489616,0.009545285,0.00006346675],"about_ca_topic_score_codex":0.00038636476,"about_ca_topic_score_gemma":0.000712664,"teacher_disagreement_score":0.0006333083,"about_ca_system_score_codex":0.00032560155,"about_ca_system_score_gemma":0.00028943448,"threshold_uncertainty_score":0.0027241707},"labels":[],"label_agreement":null},{"id":"W4377861121","doi":"10.1016/j.jaut.2023.103057","title":"Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application","year":2023,"lang":"en","type":"article","venue":"Journal of Autoimmunity","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"FOXP3; Regulatory T cell; Immunology; Immune system; Autoimmunity; Effector; Biology; Cancer research; T cell; IL-2 receptor","score_opus":0.10417332569156208,"score_gpt":0.41640065756241457,"score_spread":0.3122273318708525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377861121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96031773,0.006341098,0.029298907,0.00023681748,0.00012584215,0.0002240091,0.00039791854,0.0007571701,0.0023004],"genre_scores_gemma":[0.989771,0.00096049096,0.0066868174,0.000072303315,0.000040234874,0.00010597304,0.00059685245,0.0000831949,0.0016832515],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996619,0.000064501786,0.000023955483,0.0000742239,0.00010148232,0.00007390153],"domain_scores_gemma":[0.9998648,0.000033794917,0.00002963983,0.00002349682,0.000022073638,0.000026129883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005223712,0.0004392938,0.0004079171,0.00028736156,0.00014309795,0.00045020206,0.00021492914,0.0003656449,0.0026237185],"category_scores_gemma":[0.00029046394,0.00013736564,0.00030482246,0.00019170785,0.0003550984,0.00021969096,0.00015953393,0.0009545762,0.00070205535],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031991545,0.0001186566,0.00012268063,0.000052506723,0.0000070021847,0.000052907286,0.00002363749,0.00012888652,0.99253136,0.00012672797,0.0000975902,0.0064182356],"study_design_scores_gemma":[0.00012852711,0.0012812046,0.0013486615,0.000009568486,0.00005896343,0.0005051786,0.000016766076,0.0015297977,0.9898136,0.00006962487,0.0052307798,0.000007306585],"about_ca_topic_score_codex":0.00036864867,"about_ca_topic_score_gemma":0.00034884363,"teacher_disagreement_score":0.0026237185,"about_ca_system_score_codex":0.00022110502,"about_ca_system_score_gemma":0.00037318355,"threshold_uncertainty_score":0.008777201},"labels":[],"label_agreement":null},{"id":"W4378952773","doi":"10.1111/bjh.18900","title":"Genome‐wide <scp>CRISPR</scp> screening uncovers potential targets and mechanisms of vincristine resistance in <scp>DLBCL</scp>","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Vincristine; CRISPR; Drug resistance; Cancer research; Biology; Medicine; Cell cycle checkpoint; Computational biology; Apoptosis; Bioinformatics; Cell cycle; Internal medicine; Genetics; Chemotherapy; Gene","score_opus":0.015495743719001967,"score_gpt":0.27458812039269387,"score_spread":0.2590923766736919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378952773","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018654554,0.012327432,0.0013759296,0.74995977,0.23002245,0.00005925849,0.00065259956,0.00038917764,0.0033479633],"genre_scores_gemma":[0.015821392,0.022125784,0.0019058187,0.6107071,0.32330796,0.00011571125,0.00054768566,0.0001915769,0.025277013],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986929,0.00020766522,0.00013186567,0.00019665548,0.00057507673,0.00019584657],"domain_scores_gemma":[0.99397814,0.0032240888,0.00032869462,0.00018360975,0.0015733585,0.0007121089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002852408,0.00090056506,0.0011285272,0.0005964632,0.001424669,0.0024292471,0.0023693047,0.01378228,0.005403219],"category_scores_gemma":[0.0075460444,0.0004942295,0.0010103051,0.00038370615,0.0016583202,0.0015148701,0.0010161864,0.0147820255,0.0027476405],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001225004,0.000024947658,0.00025134566,0.00012253756,0.000020646785,0.000384776,0.000042962252,0.00008273905,0.0012086552,0.0009604519,0.98129404,0.015484352],"study_design_scores_gemma":[0.00015652,0.00014513236,0.0017012007,0.00019145565,0.00008090213,0.0007877421,0.00016947056,0.00055144005,0.002114136,0.0050453222,0.9890036,0.000053144122],"about_ca_topic_score_codex":0.0023535844,"about_ca_topic_score_gemma":0.006959194,"teacher_disagreement_score":0.01378228,"about_ca_system_score_codex":0.0016166598,"about_ca_system_score_gemma":0.0020002592,"threshold_uncertainty_score":0.018075585},"labels":[],"label_agreement":null},{"id":"W4379185221","doi":"10.2196/45872","title":"Creating an Innovative Artificial Intelligence–Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial","year":2023,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund","keywords":"T-cell receptor; Immunotherapy; Medicine; Observational study; Colorectal cancer; Cancer immunotherapy; Clinical trial; Oncology; Cancer; Internal medicine; Bioinformatics; Immune system; Immunology; T cell; Biology","score_opus":0.6942350076305847,"score_gpt":0.624114053398265,"score_spread":0.07012095423231968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379185221","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0047889138,0.00017186925,0.008228548,0.0004259476,0.00030604194,0.98307323,0.0014644763,0.00007430503,0.0014665414],"genre_scores_gemma":[0.0032870686,0.0001061933,0.008665146,0.0002629766,0.000052105755,0.9869811,0.00029637327,0.000006154974,0.0003428591],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9725823,0.019421123,0.0029457503,0.0014627614,0.0024444126,0.001143696],"domain_scores_gemma":[0.9701099,0.007060341,0.0049141063,0.0070876935,0.007708021,0.0031199018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.051812556,0.0024135767,0.0023758,0.0014991023,0.0028073243,0.0020479457,0.0023416881,0.0032868423,0.023611663],"category_scores_gemma":[0.04597016,0.0013553222,0.002735205,0.0018665201,0.002289724,0.0015369377,0.0030140122,0.00417634,0.006667361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5909763,0.05949647,0.012821549,0.013578393,0.002353978,0.0011185821,0.0014273202,0.014664262,0.016154265,0.019587595,0.05648268,0.2113387],"study_design_scores_gemma":[0.5093434,0.18834461,0.02179261,0.004240772,0.001708879,0.00047746976,0.0005420644,0.006706253,0.009152354,0.014803795,0.24247585,0.0004120636],"about_ca_topic_score_codex":0.001208216,"about_ca_topic_score_gemma":0.0015328579,"teacher_disagreement_score":0.051812556,"about_ca_system_score_codex":0.0031213374,"about_ca_system_score_gemma":0.017511813,"threshold_uncertainty_score":0.2740143},"labels":[],"label_agreement":null},{"id":"W4379281047","doi":"10.1200/jco.2023.41.16_suppl.8537","title":"Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Mesothelin; Medicine; Mesothelioma; Cancer research; Oncology; Ovarian cancer; Internal medicine; Cancer; Gastroenterology; Immunology; Pathology","score_opus":0.1679472589828233,"score_gpt":0.5078129524008199,"score_spread":0.3398656934179966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995025,0.0010430401,0.00037148877,0.00024345059,0.000045124503,0.0011935732,0.0006042286,0.00007225468,0.0014019157],"genre_scores_gemma":[0.9925914,0.0008420659,0.000818702,0.00044554012,0.000058789006,0.0012504446,0.0014377562,0.000020772612,0.0025345376],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998925,0.00004292104,0.0000042708334,0.0000208591,0.000010773696,0.000028714843],"domain_scores_gemma":[0.99979705,0.000033385742,0.000039401886,0.000015854213,0.000009608347,0.000104647486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005467419,0.0007837199,0.0007223881,0.00020670274,0.00024953258,0.00055715843,0.00044469858,0.0007494518,0.0030820419],"category_scores_gemma":[0.00029237824,0.00027594893,0.00052116264,0.00020582521,0.0005145496,0.0003901794,0.00021976534,0.0014775011,0.000777752],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5318642,0.06725105,0.025574548,0.0012445272,0.0009449637,0.0009969196,0.0007915964,0.005512488,0.19341363,0.00092884497,0.011642457,0.15983476],"study_design_scores_gemma":[0.30423447,0.6388807,0.026596295,0.000066257744,0.00042782788,0.0011579379,0.00016175468,0.0024012842,0.015119564,0.00040620856,0.010520661,0.000027025655],"about_ca_topic_score_codex":0.00086637435,"about_ca_topic_score_gemma":0.0023873877,"teacher_disagreement_score":0.0030820419,"about_ca_system_score_codex":0.0006799868,"about_ca_system_score_gemma":0.0009342257,"threshold_uncertainty_score":0.010310411},"labels":[],"label_agreement":null},{"id":"W4379281157","doi":"10.1200/jco.2023.41.16_suppl.8003","title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"Janssen Research and Development","keywords":"Medicine; Daratumumab; Internal medicine; Refractory (planetary science); CD38; Oncology; Tolerability; Gastroenterology; Proteasome inhibitor; Lenalidomide; Multiple myeloma; Adverse effect; CD34","score_opus":0.1027499321914212,"score_gpt":0.4408975407525841,"score_spread":0.3381476085611629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8420865,0.13535306,0.0011055454,0.0019944438,0.00028313298,0.00078067015,0.009833295,0.0001799738,0.008383519],"genre_scores_gemma":[0.94792145,0.031418987,0.002039267,0.0021612088,0.00040205917,0.0003631211,0.014128358,0.000037341553,0.0015282298],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994646,0.00018223908,0.000089673464,0.00007993755,0.00012402667,0.00005951909],"domain_scores_gemma":[0.99899536,0.0002731248,0.00040056644,0.0000413917,0.00013547388,0.00015396405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020528906,0.00052021944,0.001050648,0.0005862779,0.00016619368,0.0008703392,0.00043643903,0.00046690524,0.0016260287],"category_scores_gemma":[0.001311165,0.0002130817,0.00163136,0.0009180567,0.00013664438,0.000515413,0.00035662233,0.0006230661,0.00046778886],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083229356,0.0018075213,0.25833607,0.00502997,0.010267447,0.00064031093,0.0003428663,0.0030600538,0.008747048,0.0001792606,0.019061094,0.609299],"study_design_scores_gemma":[0.023034565,0.05283329,0.8305169,0.0018117513,0.025224866,0.0039634965,0.00031749817,0.0031053845,0.004998214,0.00037551438,0.053700466,0.0001181052],"about_ca_topic_score_codex":0.0019121469,"about_ca_topic_score_gemma":0.0054280707,"teacher_disagreement_score":0.0020528906,"about_ca_system_score_codex":0.00067637704,"about_ca_system_score_gemma":0.0005925433,"threshold_uncertainty_score":0.010856867},"labels":[],"label_agreement":null},{"id":"W4379281765","doi":"10.1200/jco.2023.41.16_suppl.7550","title":"Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Post-hoc analysis; Regimen; Phases of clinical research; Nuclear medicine; Clinical endpoint; Internal medicine; Toxicity; Urology; Surgery; Clinical trial","score_opus":0.14952030056499643,"score_gpt":0.5083827260818493,"score_spread":0.3588624255168529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898986,0.0041374103,0.00054691505,0.00025516175,0.00003629456,0.0010892275,0.0025670845,0.0000596227,0.0014095294],"genre_scores_gemma":[0.9880376,0.001573152,0.0010204598,0.00046293766,0.00007492752,0.00083936856,0.0068308683,0.00002224207,0.0011384519],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99951494,0.00024383071,0.000031187865,0.000072179886,0.000058185866,0.00007972809],"domain_scores_gemma":[0.99929476,0.00012507167,0.00022633519,0.00006934312,0.00004453006,0.00023987838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001990667,0.0007986028,0.0010933003,0.00030770054,0.0002469252,0.0008375344,0.0005960112,0.00052572484,0.001810442],"category_scores_gemma":[0.00095419335,0.00030787045,0.0010516569,0.0004918529,0.00034252717,0.0006242132,0.00047479043,0.0013762619,0.00046921193],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7450705,0.014965285,0.063855276,0.001540774,0.0046499646,0.00062760216,0.00049242977,0.003716617,0.039163575,0.00022828068,0.008517098,0.117172666],"study_design_scores_gemma":[0.30570552,0.4137486,0.25305465,0.00017691517,0.0039163544,0.0013482443,0.00021702972,0.0024318208,0.0065607303,0.0003023167,0.0124385115,0.00009936391],"about_ca_topic_score_codex":0.0008865082,"about_ca_topic_score_gemma":0.0028036532,"teacher_disagreement_score":0.001990667,"about_ca_system_score_codex":0.00089231844,"about_ca_system_score_gemma":0.00078329764,"threshold_uncertainty_score":0.01052773},"labels":[],"label_agreement":null},{"id":"W4379281880","doi":"10.1200/jco.2023.41.16_suppl.tps7586","title":"SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Gemcitabine; Phases of clinical research; Antibody-drug conjugate; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Lymphoma; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Antibody; Immunology; Monoclonal antibody; Colorectal cancer","score_opus":0.0704012691811073,"score_gpt":0.44661518105052217,"score_spread":0.3762139118694149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895391,0.003961349,0.00032353777,0.00070259784,0.000259049,0.0015132785,0.0012612458,0.00011769548,0.0023221446],"genre_scores_gemma":[0.9884397,0.0027120356,0.0010351,0.0010788639,0.00019325224,0.0017576455,0.0019572692,0.000024740912,0.0028014535],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997681,0.00009850698,0.000010488408,0.000045728728,0.000023129105,0.000054123353],"domain_scores_gemma":[0.9996507,0.00005572134,0.000066546316,0.000021906195,0.000015494463,0.0001896383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092320744,0.0010275753,0.001497488,0.0003132967,0.00028482624,0.00097629457,0.00073037075,0.0009998598,0.0050242236],"category_scores_gemma":[0.0006158315,0.00046417475,0.0014457434,0.00030474633,0.00063244393,0.0006856615,0.00034008778,0.0026774844,0.0009123342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84317756,0.01970548,0.0037656706,0.0014781756,0.002009046,0.0001798113,0.00026575525,0.0017778059,0.021407275,0.00040675252,0.0041836738,0.10164303],"study_design_scores_gemma":[0.74600214,0.23663846,0.009757944,0.00009131528,0.00077846914,0.00024542032,0.00006765634,0.0013235194,0.0014726119,0.00030526717,0.0032881615,0.000029062217],"about_ca_topic_score_codex":0.0009986968,"about_ca_topic_score_gemma":0.003319483,"teacher_disagreement_score":0.0050242236,"about_ca_system_score_codex":0.0009974426,"about_ca_system_score_gemma":0.0009820056,"threshold_uncertainty_score":0.016807735},"labels":[],"label_agreement":null},{"id":"W4379283040","doi":"10.1200/jco.2023.41.16_suppl.2519","title":"A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Chimeric antigen receptor; Breast cancer; Immunotherapy; Cancer; Cancer research; Leukapheresis; T cell; Oncology; Internal medicine; Immunology; Immune system; Stem cell; CD34","score_opus":0.2245488059784758,"score_gpt":0.54106261968792,"score_spread":0.3165138137094442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857383,0.0020429974,0.00077601214,0.0006404553,0.00021206506,0.004914061,0.0020156894,0.00016063526,0.0034997899],"genre_scores_gemma":[0.98272187,0.0013029971,0.0015528679,0.0012395405,0.00019898491,0.004216225,0.004473663,0.000039918923,0.004253892],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996132,0.00018441417,0.0000181128,0.00006257399,0.000037166756,0.00008446438],"domain_scores_gemma":[0.9993845,0.0000956273,0.00011535602,0.00007016636,0.000035030072,0.0002993149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015366948,0.0012856378,0.0011552959,0.0003886092,0.0003462592,0.0009453826,0.00094804086,0.0015298089,0.0050496454],"category_scores_gemma":[0.00072398316,0.00043722708,0.0008183378,0.0004033604,0.0010061063,0.00081672287,0.00031326205,0.0029517554,0.0014918334],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7491771,0.09143061,0.004963918,0.00093917537,0.00094175304,0.0007228098,0.00024914593,0.0028656223,0.059274487,0.0006480514,0.0078423945,0.080944985],"study_design_scores_gemma":[0.56247044,0.4235146,0.0040093195,0.00003162158,0.00024831583,0.0004491113,0.00004184096,0.001163075,0.004761019,0.0002855812,0.0030085342,0.000016598739],"about_ca_topic_score_codex":0.0007370903,"about_ca_topic_score_gemma":0.0012619513,"teacher_disagreement_score":0.0050496454,"about_ca_system_score_codex":0.0008488141,"about_ca_system_score_gemma":0.0016991381,"threshold_uncertainty_score":0.016892731},"labels":[],"label_agreement":null},{"id":"W4379283399","doi":"10.1200/jco.2023.41.16_suppl.tps2671","title":"Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; T-cell receptor; CD8; Antigen; Immunology; Cytokine release syndrome; Cancer research; T cell; Pharmacology; Oncology; Internal medicine; Immune system; Chimeric antigen receptor; Adverse effect","score_opus":0.057827630948723535,"score_gpt":0.43414341595895894,"score_spread":0.37631578501023544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727338,0.005534462,0.0023186705,0.0017558275,0.00031419515,0.0049436414,0.005431561,0.00051303057,0.0064547807],"genre_scores_gemma":[0.9557824,0.004853173,0.004516686,0.003127673,0.000252337,0.0062918537,0.012413109,0.00015764977,0.012604925],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997688,0.00009745045,0.000008222911,0.00004471455,0.000022123973,0.000058684815],"domain_scores_gemma":[0.9996718,0.000051204566,0.000058188947,0.00002100087,0.00002834013,0.00016943553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010797586,0.001716417,0.0011502634,0.00036946792,0.00033791465,0.0011891316,0.0007717027,0.001645148,0.005112934],"category_scores_gemma":[0.00054703385,0.00042499925,0.00087960373,0.0003169239,0.00075562554,0.00094962004,0.00033204223,0.0030298147,0.0014361817],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.612881,0.07206125,0.0059749573,0.0020331151,0.0013971537,0.0009010858,0.0004994952,0.005228182,0.12237704,0.0023018548,0.027370248,0.14697458],"study_design_scores_gemma":[0.49058908,0.47791407,0.0048141205,0.0000861256,0.0004065487,0.0009373101,0.00010273467,0.0023384814,0.011969824,0.0006976277,0.010100548,0.000043547083],"about_ca_topic_score_codex":0.0005856287,"about_ca_topic_score_gemma":0.0016191509,"teacher_disagreement_score":0.005112934,"about_ca_system_score_codex":0.0007280161,"about_ca_system_score_gemma":0.0013755673,"threshold_uncertainty_score":0.017104506},"labels":[],"label_agreement":null},{"id":"W4379283750","doi":"10.1200/jco.2023.41.16_suppl.2062","title":"Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Chimeric antigen receptor; Oncolytic virus; Cancer research; Medicine; Glioma; Immunotherapy; Immune system; Antigen; Population; T cell; CD8; Cytotoxic T cell; Epitope; Tumor microenvironment; Immunology; Biology; In vitro","score_opus":0.12369999698428902,"score_gpt":0.4475433971989874,"score_spread":0.3238434002146984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654526,0.0011135233,0.001111145,0.000047647423,0.000056182933,0.000048399885,0.00010751295,0.00007931879,0.0008911207],"genre_scores_gemma":[0.99755543,0.00038779675,0.0006965722,0.000026634407,0.0000144524,0.00003454238,0.00018418221,0.000014353709,0.001086114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998834,0.000016566144,0.0000066358266,0.00002423833,0.000025537332,0.00004356659],"domain_scores_gemma":[0.9999429,0.000012812821,0.00001397617,0.0000068276418,0.000006920164,0.000016569642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014414464,0.0004660266,0.00032727153,0.00019197693,0.000093725874,0.0003337395,0.00032699958,0.0005347762,0.0009503573],"category_scores_gemma":[0.00010604857,0.00012428947,0.00025936737,0.00010869119,0.0002324161,0.0002943694,0.00013163856,0.00084941153,0.0003370439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078454625,0.0005686034,0.00015011875,0.00010156216,0.00001604564,0.000048827842,0.000039634793,0.00034413853,0.9920855,0.00011420814,0.0001611807,0.005585549],"study_design_scores_gemma":[0.00017738127,0.0052708252,0.00124177,0.00000734613,0.00006206139,0.00016827114,0.000017525812,0.0018658426,0.98967385,0.000031120086,0.0014772345,0.000006805246],"about_ca_topic_score_codex":0.00077497074,"about_ca_topic_score_gemma":0.00063794624,"teacher_disagreement_score":0.0009503573,"about_ca_system_score_codex":0.00026602476,"about_ca_system_score_gemma":0.00025546952,"threshold_uncertainty_score":0.0031793118},"labels":[],"label_agreement":null},{"id":"W4379330790","doi":"10.1200/jco.2023.41.16_suppl.tps7592","title":"Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Rituximab; Diffuse large B-cell lymphoma; Internal medicine; Vincristine; Cytokine release syndrome; CHOP; Oncology; Prednisone; Phases of clinical research; International Prognostic Index; Cyclophosphamide; Lymphoma; Gastroenterology; Discontinuation; CD20; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.10362165935719093,"score_gpt":0.45996181553981313,"score_spread":0.3563401561826222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862211,0.0020477197,0.00074206304,0.00095696026,0.00045994474,0.0040298468,0.0018848941,0.00027794158,0.0033797289],"genre_scores_gemma":[0.9824554,0.0014460608,0.0018799277,0.0018806953,0.00035143972,0.0042683007,0.003535628,0.000051885232,0.004130575],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996697,0.00016986715,0.000010474651,0.00005622803,0.00002724154,0.00006647191],"domain_scores_gemma":[0.9993538,0.00012876625,0.0001158751,0.000063186126,0.000032421467,0.0003058681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016074214,0.0020061906,0.0018518937,0.00030994613,0.0003098037,0.001010657,0.0010277976,0.0012525127,0.0059749465],"category_scores_gemma":[0.0011153276,0.0005908591,0.0013237162,0.00034247737,0.0009734849,0.00087802653,0.0004309057,0.004409473,0.0015079762],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92219007,0.025436644,0.0013247981,0.00047119227,0.00070286193,0.00013290659,0.00011602117,0.001255752,0.009434543,0.00020456944,0.0032145302,0.035516057],"study_design_scores_gemma":[0.8422967,0.15157312,0.0030054285,0.000022983557,0.00022224724,0.00012872758,0.000029986988,0.0009772982,0.0005641639,0.00020508046,0.0009600119,0.000014240265],"about_ca_topic_score_codex":0.0011749727,"about_ca_topic_score_gemma":0.002859487,"teacher_disagreement_score":0.0059749465,"about_ca_system_score_codex":0.00092882366,"about_ca_system_score_gemma":0.0012124105,"threshold_uncertainty_score":0.01998818},"labels":[],"label_agreement":null},{"id":"W4379334167","doi":"10.1200/jco.2023.41.16_suppl.e14531","title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Cohort; Internal medicine; Sarcoma; Cytokine release syndrome; Fludarabine; Gastroenterology; Oncology; Surgery; Cyclophosphamide; Chemotherapy; Cancer; Pathology; Immunotherapy; Chimeric antigen receptor","score_opus":0.060239172461123786,"score_gpt":0.4539872028012736,"score_spread":0.3937480303401498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920638,0.0042590233,0.00040661922,0.0001365832,0.000055104396,0.00071593106,0.0015158047,0.00003798566,0.0008091032],"genre_scores_gemma":[0.9941977,0.0009961878,0.000494697,0.0002202287,0.00010412843,0.00059932086,0.0025591576,0.000010328336,0.00081808306],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9987569,0.00074595085,0.00007101487,0.00021567426,0.00010096849,0.00010960465],"domain_scores_gemma":[0.99902666,0.0002846529,0.00029480644,0.00011691258,0.00005687777,0.00022012008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029265732,0.001072623,0.0015027004,0.00045196866,0.00022528012,0.00065148453,0.00045300362,0.0006050726,0.0026229648],"category_scores_gemma":[0.0019793392,0.00035292984,0.001924864,0.00040783433,0.00034733771,0.00056204473,0.00048113003,0.00086943334,0.00027707408],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.912245,0.0022892435,0.029009113,0.00060211547,0.011975547,0.000102654114,0.00009151587,0.000839993,0.007623858,0.00009700336,0.0015950082,0.03352895],"study_design_scores_gemma":[0.536847,0.2595036,0.17644437,0.00013174965,0.01663435,0.0005593416,0.00014398246,0.0021829365,0.0032556504,0.0004280974,0.0037865527,0.000082438484],"about_ca_topic_score_codex":0.00055178924,"about_ca_topic_score_gemma":0.0015991033,"teacher_disagreement_score":0.0029265732,"about_ca_system_score_codex":0.0004606059,"about_ca_system_score_gemma":0.0007408829,"threshold_uncertainty_score":0.015477359},"labels":[],"label_agreement":null},{"id":"W4379341611","doi":"10.1200/jco.2023.41.16_suppl.8008","title":"Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Adverse effect; Surgery; Gastroenterology; Oncology","score_opus":0.05691125985349645,"score_gpt":0.40425127325656196,"score_spread":0.34734001340306553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341611","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4559986,0.52970624,0.0025015008,0.00040377222,0.00020387402,0.0009278612,0.0076367287,0.00013110615,0.0024903705],"genre_scores_gemma":[0.96084917,0.03376783,0.0009951988,0.00033747905,0.00019167607,0.000503856,0.0029229869,0.000022702725,0.00040931528],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955987,0.002466081,0.0008896067,0.00047997662,0.0004003425,0.00016521958],"domain_scores_gemma":[0.99576294,0.0017070629,0.0018100902,0.00022771182,0.00034921756,0.00014292919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009701716,0.0015292795,0.004950898,0.002967134,0.00026709598,0.0018280491,0.0006182056,0.0009902753,0.0022947262],"category_scores_gemma":[0.0076017887,0.00082293514,0.015061928,0.0025004798,0.0003263247,0.00081817294,0.00095909147,0.00060502184,0.00032384097],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09238087,0.00023056075,0.058163106,0.022196826,0.7717158,0.00016998037,0.000121111065,0.0015769573,0.003684876,0.000084144944,0.0013785189,0.048297238],"study_design_scores_gemma":[0.017814284,0.011174865,0.13380747,0.0019163354,0.82852685,0.000483889,0.00012393447,0.00084184506,0.0012062599,0.00021950684,0.0038213478,0.00006338041],"about_ca_topic_score_codex":0.0010521275,"about_ca_topic_score_gemma":0.0030023884,"teacher_disagreement_score":0.009701716,"about_ca_system_score_codex":0.00081554585,"about_ca_system_score_gemma":0.0007153558,"threshold_uncertainty_score":0.051308155},"labels":[],"label_agreement":null},{"id":"W4379345563","doi":"10.1200/jco.2023.41.16_suppl.11563","title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Internal medicine; Cohort; Oncology; Sarcoma; Interim analysis; Clinical endpoint; Fludarabine; Progression-free survival; Surgery; Gastroenterology; Cyclophosphamide; Chemotherapy; Clinical trial; Pathology","score_opus":0.1710643192867094,"score_gpt":0.5202117515068317,"score_spread":0.34914743222012234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99181503,0.0035396928,0.00028212307,0.0002939236,0.000064659616,0.00086827617,0.0014697498,0.000041096628,0.0016255077],"genre_scores_gemma":[0.9875551,0.0022344575,0.00093214074,0.0005055073,0.00017611719,0.0012258064,0.0044853617,0.000015829488,0.002869676],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99960774,0.00023335851,0.000016140217,0.000057761772,0.000033143075,0.000051989387],"domain_scores_gemma":[0.99950206,0.00011398309,0.00012500066,0.00003454891,0.00002240115,0.00020206653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013243229,0.00097474887,0.0009060019,0.00029607536,0.00020977326,0.00053435506,0.00056940893,0.0006988019,0.0037165529],"category_scores_gemma":[0.00076304976,0.00026500179,0.0012151124,0.0002645663,0.00045108914,0.00050296966,0.00032211543,0.0014535161,0.00047175033],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90307367,0.0073302025,0.009817833,0.000881278,0.0017358401,0.0001698775,0.00015450186,0.0015283684,0.013840209,0.00028252942,0.0040851715,0.057100628],"study_design_scores_gemma":[0.67103595,0.27686244,0.03869084,0.00012507926,0.0018993072,0.0005055137,0.00007158804,0.0019469865,0.003876717,0.00040077345,0.0045422013,0.000042687243],"about_ca_topic_score_codex":0.0008280618,"about_ca_topic_score_gemma":0.0025653157,"teacher_disagreement_score":0.0037165529,"about_ca_system_score_codex":0.00068160455,"about_ca_system_score_gemma":0.00090804364,"threshold_uncertainty_score":0.012433112},"labels":[],"label_agreement":null},{"id":"W4379375856","doi":"10.1056/nejmoa2301665","title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Gilead Sciences","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Internal medicine; Confidence interval; Lymphoma; Oncology; Transplantation; Autologous stem-cell transplantation; Survival analysis; Surgery; Rituximab","score_opus":0.03199120473262039,"score_gpt":0.31318210441992306,"score_spread":0.28119089968730265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379375856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973936,0.0017276906,0.00014491049,0.00011591668,0.000023249248,0.00007899314,0.00008180833,0.000016479851,0.00041716834],"genre_scores_gemma":[0.9985434,0.0004976608,0.00019529469,0.00013075203,0.00004054277,0.00012720218,0.0002500257,0.000002866307,0.0002122995],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995359,0.0002836249,0.000020848955,0.000053817494,0.000047397665,0.000058418107],"domain_scores_gemma":[0.99937266,0.00021011019,0.00016315466,0.00003907646,0.000024233852,0.00019085467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013579528,0.00030317335,0.0006190021,0.00027908426,0.00014285391,0.00033305294,0.00027525445,0.00042013483,0.001733584],"category_scores_gemma":[0.0010986584,0.000106675056,0.0005639564,0.00019441379,0.00038768598,0.00025080293,0.000251883,0.00070951384,0.00015223335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76195896,0.009122637,0.035930675,0.0005950919,0.0010625661,0.00015554027,0.00010137543,0.0038772202,0.018123822,0.0002227009,0.0017159047,0.16713351],"study_design_scores_gemma":[0.33506894,0.51851845,0.12751555,0.00011955352,0.0013629341,0.0005406724,0.00006706748,0.0040415865,0.008328169,0.00058849674,0.0038127264,0.00003583009],"about_ca_topic_score_codex":0.00027046292,"about_ca_topic_score_gemma":0.0005993142,"teacher_disagreement_score":0.001733584,"about_ca_system_score_codex":0.00054127077,"about_ca_system_score_gemma":0.0004878111,"threshold_uncertainty_score":0.0071816444},"labels":[],"label_agreement":null},{"id":"W4379375986","doi":"10.1056/nejmoa2303379","title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":733,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Lenalidomide; Multiple myeloma; Refractory (planetary science); Standard of care; Medicine; Internal medicine; Oncology; Biology; Astrobiology","score_opus":0.0463347515928686,"score_gpt":0.3503627163535822,"score_spread":0.3040279647607136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379375986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942788,0.004428365,0.00013829095,0.00028771887,0.0000735387,0.00026247514,0.000062828025,0.000017996186,0.00045001888],"genre_scores_gemma":[0.99746716,0.0012807326,0.00039540563,0.0002850451,0.00009685038,0.00023051846,0.000085907355,0.0000020482214,0.00015624473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99944836,0.00032387927,0.000045314166,0.000070387854,0.00004920129,0.00006283945],"domain_scores_gemma":[0.9991154,0.0003453688,0.00027048652,0.000035336496,0.000026144933,0.00020721603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013057081,0.0003563,0.0008290396,0.0003778806,0.0002103529,0.00037878935,0.00049360923,0.00074776076,0.002126109],"category_scores_gemma":[0.0013930942,0.0001828742,0.0007486448,0.00028862982,0.00053724844,0.00034214303,0.00028314785,0.0011025853,0.00013069862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85055345,0.012362998,0.009540437,0.00063622964,0.00093925494,0.000082183644,0.00009483993,0.0011529512,0.0045635183,0.00021962673,0.00069488824,0.11915964],"study_design_scores_gemma":[0.62072927,0.3419081,0.02904822,0.00017438889,0.0011891415,0.00017474515,0.0000574841,0.0020382567,0.0022951183,0.00037166433,0.0019923046,0.000021370475],"about_ca_topic_score_codex":0.00065085036,"about_ca_topic_score_gemma":0.0014595267,"teacher_disagreement_score":0.002126109,"about_ca_system_score_codex":0.0006849585,"about_ca_system_score_gemma":0.000721735,"threshold_uncertainty_score":0.007112503},"labels":[],"label_agreement":null},{"id":"W4379662243","doi":"10.1200/jco.2023.41.17_suppl.lba107","title":"Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Interim analysis; Refractory (planetary science); Intention-to-treat analysis; Censoring (clinical trials); Oncology; Survival analysis; Cumulative incidence; Confidence interval; Proportional hazards model; Randomized controlled trial; Surgery; Cohort","score_opus":0.13418231096971184,"score_gpt":0.4891123781802256,"score_spread":0.3549300672105138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9497756,0.010263569,0.0024297407,0.0017080386,0.0008485657,0.009508262,0.015637303,0.00039247028,0.009436365],"genre_scores_gemma":[0.97033656,0.0019429933,0.0023607693,0.00216327,0.00052170374,0.0077485535,0.010719759,0.000116097515,0.0040903487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99595296,0.0029132306,0.00012204822,0.0003770653,0.00027875716,0.00035592704],"domain_scores_gemma":[0.9967049,0.0010445252,0.00084424217,0.00034864686,0.00025945666,0.0007983122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008940777,0.0023459976,0.0032180285,0.00094006606,0.00048792505,0.0013779012,0.0013621742,0.0017574632,0.008993734],"category_scores_gemma":[0.004836758,0.000795645,0.006183213,0.00060525286,0.0010941254,0.0012576861,0.000903585,0.005146316,0.0013905128],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9528187,0.006426875,0.0027824533,0.0014745281,0.00789673,0.00006903383,0.00007655864,0.0016610628,0.0032743723,0.00026483845,0.0046674977,0.018587368],"study_design_scores_gemma":[0.80004287,0.16465244,0.017162357,0.00018306944,0.008760368,0.000176452,0.000065584914,0.0022052862,0.002092898,0.00091656664,0.0036910626,0.000051089082],"about_ca_topic_score_codex":0.0007160587,"about_ca_topic_score_gemma":0.0025982661,"teacher_disagreement_score":0.008993734,"about_ca_system_score_codex":0.0015622696,"about_ca_system_score_gemma":0.0019631502,"threshold_uncertainty_score":0.047283888},"labels":[],"label_agreement":null},{"id":"W4379979795","doi":"10.1002/hon.3164_325","title":"Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Post-hoc analysis; Clinical endpoint; Oncology; Autologous stem-cell transplantation; Cohort; Refractory (planetary science); Transplantation; Clinical trial; Multiple myeloma","score_opus":0.04577710757521213,"score_gpt":0.38758623869763525,"score_spread":0.3418091311224231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917944,0.0010360464,0.0007638402,0.0003475738,0.0002305863,0.0013993051,0.0019834968,0.00008273437,0.0023619658],"genre_scores_gemma":[0.9905606,0.00025407725,0.0013059751,0.0007666896,0.00024409825,0.0017071475,0.0032047776,0.00004030332,0.0019163146],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9971879,0.0015927684,0.000110591034,0.00045602862,0.00022085464,0.0004319182],"domain_scores_gemma":[0.99677914,0.0010600016,0.00081470684,0.0004537684,0.00022145997,0.0006709458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005530468,0.0014326089,0.0028402482,0.000510026,0.0003280165,0.0015954123,0.0012247693,0.00087608106,0.0044289436],"category_scores_gemma":[0.0038933742,0.0005421307,0.00691363,0.0004058002,0.001082725,0.0011837719,0.0010399979,0.0027765264,0.0007254018],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9575631,0.003873294,0.009537829,0.00035084365,0.006534435,0.000045190332,0.00010979193,0.0016948186,0.00365825,0.00020981263,0.0015797492,0.014842868],"study_design_scores_gemma":[0.37188506,0.4919531,0.0949945,0.00015503902,0.015837895,0.00021137147,0.00023284368,0.009537471,0.006922046,0.0010500948,0.0070997267,0.00012084805],"about_ca_topic_score_codex":0.00090232625,"about_ca_topic_score_gemma":0.0021499668,"teacher_disagreement_score":0.005530468,"about_ca_system_score_codex":0.0020431126,"about_ca_system_score_gemma":0.0021603054,"threshold_uncertainty_score":0.029248238},"labels":[],"label_agreement":null},{"id":"W4379981406","doi":"10.1002/hon.3163_22","title":"PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"Helsingin Yliopisto","keywords":"Medicine; Refractory (planetary science); Internal medicine; Lymphoma; Gastroenterology; Biology","score_opus":0.04697189223102332,"score_gpt":0.3827252295165396,"score_spread":0.33575333728551626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955296,0.009141831,0.002839986,0.0015144048,0.00053674006,0.009163033,0.011832125,0.000328071,0.009347831],"genre_scores_gemma":[0.97162074,0.0019765985,0.0026746758,0.001654869,0.0004128267,0.008671923,0.009123532,0.000092644004,0.0037722192],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961283,0.0027707606,0.00013548671,0.00037590164,0.00031850146,0.00027104],"domain_scores_gemma":[0.9964424,0.001228652,0.0009069418,0.0003535954,0.00033652238,0.00073188654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009726225,0.0018330171,0.0026852295,0.00071472686,0.00043273994,0.0012562105,0.001120902,0.001277747,0.008582195],"category_scores_gemma":[0.0051400843,0.0006279593,0.004870185,0.00058049243,0.0009398794,0.0010332292,0.0007003666,0.0041824663,0.0011596665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9487206,0.0059150723,0.0031845078,0.0015258511,0.007581198,0.000061112434,0.000068771194,0.0014739627,0.0034645724,0.0003178035,0.003765484,0.023921082],"study_design_scores_gemma":[0.78067744,0.17847417,0.021936135,0.00020122464,0.009139999,0.00014681935,0.00005421339,0.0019727896,0.0025627322,0.0010487963,0.0037338505,0.000051812684],"about_ca_topic_score_codex":0.0005140809,"about_ca_topic_score_gemma":0.0018512513,"teacher_disagreement_score":0.009726225,"about_ca_system_score_codex":0.001218271,"about_ca_system_score_gemma":0.001957262,"threshold_uncertainty_score":0.051437795},"labels":[],"label_agreement":null},{"id":"W4379981428","doi":"10.1002/hon.3163_t05","title":"SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Rituximab; Brentuximab vedotin; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Chimeric antigen receptor; Phases of clinical research; Clinical trial; Immunotherapy; Cancer; CD30","score_opus":0.0644506952634808,"score_gpt":0.3914333370511365,"score_spread":0.3269826417876557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831308,0.008000476,0.00032947538,0.0010264278,0.0003761748,0.0014083537,0.0016150858,0.00018618966,0.003926974],"genre_scores_gemma":[0.9834426,0.004976696,0.0010478694,0.0013881497,0.00019516073,0.0014700552,0.0020837362,0.000025350955,0.0053703766],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99982786,0.00007517958,0.000008873043,0.00003109853,0.000019655317,0.00003734213],"domain_scores_gemma":[0.99977297,0.00003401679,0.000047241097,0.000015533347,0.0000117874,0.000118495765],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007879268,0.0008074136,0.0010616285,0.00023828348,0.00024493496,0.0010304649,0.0006852503,0.0008187387,0.005052322],"category_scores_gemma":[0.00043752874,0.00039351013,0.001133387,0.00021836715,0.0004927135,0.0005431098,0.00030230227,0.0021454573,0.00088178343],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69732445,0.016412206,0.004407679,0.002967837,0.002864332,0.00021373051,0.00038061655,0.0026674117,0.028278284,0.0008629233,0.010231331,0.23338927],"study_design_scores_gemma":[0.7705871,0.197984,0.015955305,0.00024380283,0.00088945974,0.00042788527,0.00010385829,0.0018184725,0.0024311594,0.00053696614,0.008977949,0.000043997676],"about_ca_topic_score_codex":0.0010939623,"about_ca_topic_score_gemma":0.0042484445,"teacher_disagreement_score":0.005052322,"about_ca_system_score_codex":0.0009748928,"about_ca_system_score_gemma":0.0008175117,"threshold_uncertainty_score":0.016901731},"labels":[],"label_agreement":null},{"id":"W4379981707","doi":"10.1002/hon.3164_398","title":"Neurotoxicity in patients with CNS lymphomas treated with CAR‐T cell therapy. A LOC network study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Lymphoma; Encephalopathy; Internal medicine; Toxicity; Gastroenterology; Pediatrics; Oncology","score_opus":0.04181337863293949,"score_gpt":0.3220643908578386,"score_spread":0.2802510122248991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99794835,0.00062121695,0.00006275543,0.000044794273,0.000004601519,0.000043380795,0.00040969555,0.000002655721,0.00086259854],"genre_scores_gemma":[0.9984249,0.00032258508,0.000046601494,0.000057374196,0.000019559235,0.000044034394,0.00084546884,0.0000021593055,0.0002375055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996588,0.00010295123,0.000046971836,0.000067545014,0.000073303054,0.000050473172],"domain_scores_gemma":[0.99931324,0.00007049146,0.00031397628,0.000042242493,0.000087076216,0.00017290638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000496169,0.00028412545,0.00033658536,0.00067467033,0.00049181515,0.00056633324,0.0003426433,0.00032467474,0.0012849835],"category_scores_gemma":[0.00081694516,0.00018419052,0.00040291366,0.00086684834,0.00022152915,0.00040934223,0.0004281991,0.00030922357,0.00028763348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001630509,0.00020111109,0.9926731,0.000059337704,0.00016771824,0.000612466,0.00010417518,0.00009114414,0.00038043605,0.000024780567,0.00021448258,0.0038408448],"study_design_scores_gemma":[0.00036411698,0.00229337,0.99200433,0.00003282351,0.00026737203,0.0028860199,0.00024640677,0.00024778626,0.00023607159,0.000054993576,0.0013545847,0.000012080945],"about_ca_topic_score_codex":0.0045667575,"about_ca_topic_score_gemma":0.0059928517,"teacher_disagreement_score":0.0045667575,"about_ca_system_score_codex":0.0008260994,"about_ca_system_score_gemma":0.00062041695,"threshold_uncertainty_score":0.00908035},"labels":[],"label_agreement":null},{"id":"W4379981730","doi":"10.1002/hon.3165_637","title":"COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Takeda Pharmaceuticals International","keywords":"Internal medicine; Oncology; Medicine; Etoposide; Gemcitabine; Carboplatin; Regimen; Ifosfamide; Cytarabine; Rituximab; Chemotherapy; Cisplatin; Lymphoma","score_opus":0.1821421503594694,"score_gpt":0.4575280083319074,"score_spread":0.275385857972438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009815348,0.9872485,0.00078384375,0.00036344666,0.00019859454,0.0006313133,0.0005766633,0.00002916225,0.00035315746],"genre_scores_gemma":[0.34369105,0.6466543,0.0038504105,0.0012379392,0.00030965218,0.0028668616,0.00092911115,0.000040412975,0.0004202367],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.980891,0.012530408,0.0036532362,0.0012768009,0.0012721841,0.0003763809],"domain_scores_gemma":[0.9619123,0.030397108,0.0048824754,0.00073374325,0.0017111108,0.00036334532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019775702,0.0023874047,0.017853621,0.0067729615,0.00051664567,0.0029698366,0.0022261017,0.0022953039,0.0031804044],"category_scores_gemma":[0.04911949,0.0014247219,0.031493388,0.0064003696,0.00079785514,0.0016949824,0.0015565116,0.0019048051,0.00026540837],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032981068,0.00003191811,0.002554546,0.32237765,0.6608575,0.000105492574,0.000082676524,0.0007782716,0.00016939647,0.00018560841,0.00051283353,0.009046018],"study_design_scores_gemma":[0.0015226377,0.00028911082,0.0024743008,0.023232326,0.97036374,0.00006265066,0.000051720548,0.00038242032,0.000097633405,0.0002850409,0.0012137627,0.00002466634],"about_ca_topic_score_codex":0.007520654,"about_ca_topic_score_gemma":0.013265434,"teacher_disagreement_score":0.019775702,"about_ca_system_score_codex":0.0036134284,"about_ca_system_score_gemma":0.0034270608,"threshold_uncertainty_score":0.10458517},"labels":[],"label_agreement":null},{"id":"W4379981852","doi":"10.1002/hon.3166_ot28","title":"PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Rituximab; Diffuse large B-cell lymphoma; Vincristine; Cytokine release syndrome; Oncology; Prednisone; CHOP; International Prognostic Index; Cyclophosphamide; Phases of clinical research; CD20; Lymphoma; Discontinuation; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04596949735079359,"score_gpt":0.36019912368922496,"score_spread":0.3142296263384314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98719215,0.002012041,0.0006604421,0.00090654736,0.00040897407,0.0033914472,0.001707352,0.00024607682,0.00347505],"genre_scores_gemma":[0.98358005,0.0014538622,0.0017278761,0.0016096225,0.00029996247,0.003863232,0.0032709949,0.000049059894,0.0041452716],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996784,0.00016950257,0.000010562709,0.000054624994,0.000024832822,0.000062113766],"domain_scores_gemma":[0.999428,0.00011533573,0.000103867664,0.00005487726,0.00003025516,0.0002676332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001542606,0.0019405558,0.0017750999,0.00028564726,0.00031881948,0.0010314471,0.00096394354,0.001190194,0.0055427374],"category_scores_gemma":[0.0010310034,0.0005843755,0.00132476,0.00033141952,0.0009241509,0.00083705445,0.00040095052,0.0044496045,0.0014898628],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9219002,0.023587532,0.0015375841,0.0004901231,0.00076120504,0.00012391155,0.00012548952,0.0013158421,0.009798429,0.000224059,0.0034337533,0.036701914],"study_design_scores_gemma":[0.8509995,0.14242502,0.0032636547,0.000026067175,0.00024187543,0.00012385393,0.000029371406,0.0009786002,0.0006384714,0.00021485865,0.001042964,0.000015894235],"about_ca_topic_score_codex":0.001120435,"about_ca_topic_score_gemma":0.0028462345,"teacher_disagreement_score":0.0055427374,"about_ca_system_score_codex":0.0008989691,"about_ca_system_score_gemma":0.0012865401,"threshold_uncertainty_score":0.01854229},"labels":[],"label_agreement":null},{"id":"W4379981884","doi":"10.1002/hon.3163_83","title":"MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Follicular phase; Gastroenterology; Phases of clinical research; Clinical endpoint; Dosing; Lymphoma; Urology; Oncology; Surgery; Clinical trial; Materials science","score_opus":0.030225123102663037,"score_gpt":0.34757183728010405,"score_spread":0.317346714177441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97036785,0.024147918,0.000637074,0.00043606557,0.000051006784,0.000316045,0.0010649362,0.000065748456,0.0029133956],"genre_scores_gemma":[0.99263823,0.004165224,0.0005077012,0.0003733583,0.00009230916,0.00010050997,0.0017173317,0.000012779896,0.00039262552],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994816,0.00020361885,0.000057338926,0.00009143879,0.00009741781,0.00006855585],"domain_scores_gemma":[0.998618,0.00041765158,0.00047090751,0.00010248021,0.00017137673,0.00021948681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026956329,0.00039239734,0.0010289159,0.00029060102,0.00015452626,0.00087778305,0.00041549676,0.00032238886,0.0010133586],"category_scores_gemma":[0.0016198115,0.00018616382,0.00077438937,0.00040375435,0.00017973762,0.000439024,0.00019933589,0.0008015812,0.0002292482],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09324777,0.00238162,0.2775575,0.0019407005,0.0045558643,0.000526399,0.00033237744,0.002279098,0.06741115,0.00028998827,0.008889238,0.5405884],"study_design_scores_gemma":[0.029176196,0.08601815,0.8265858,0.00037664743,0.006304344,0.0035959645,0.00016088736,0.0037151368,0.012208819,0.00027394603,0.031508554,0.00007538273],"about_ca_topic_score_codex":0.0006313671,"about_ca_topic_score_gemma":0.0021158413,"teacher_disagreement_score":0.0026956329,"about_ca_system_score_codex":0.00062358886,"about_ca_system_score_gemma":0.00044743315,"threshold_uncertainty_score":0.01425606},"labels":[],"label_agreement":null},{"id":"W4379981988","doi":"10.1002/hon.3164_394","title":"Developing CAR‐T‐sparing Radiotherapy ‐ early dosimetric results","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Nuclear medicine; Radiation therapy; Surgery","score_opus":0.12701227083581387,"score_gpt":0.412145902536441,"score_spread":0.2851336317006271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7734767,0.0031346795,0.21271883,0.00019940891,0.000043066222,0.0010997214,0.0008758873,0.0008942599,0.007557493],"genre_scores_gemma":[0.86653554,0.0004415143,0.13006589,0.00004550887,0.000018440984,0.0003726821,0.0006739837,0.0002961289,0.0015502844],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99938273,0.00024959497,0.000039196555,0.00008268738,0.00018972329,0.000056097608],"domain_scores_gemma":[0.9992994,0.00027287722,0.00010031147,0.00016326862,0.00012729046,0.000036742815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019278866,0.0005295587,0.0002715124,0.00036195322,0.00013338668,0.0004660102,0.00067704805,0.00040879456,0.0029246828],"category_scores_gemma":[0.0016772761,0.000224645,0.00098004,0.00029716836,0.00029475192,0.00024712706,0.00041850473,0.00044945872,0.00042063493],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043114717,0.0014234316,0.023958817,0.00084443146,0.00037480277,0.0001702038,0.00034398807,0.33306602,0.22983718,0.003187574,0.0015989022,0.40088314],"study_design_scores_gemma":[0.0017031633,0.019866636,0.0881918,0.00009638804,0.0008757031,0.0017063557,0.00009716393,0.11007954,0.7584057,0.0030179175,0.015835634,0.00012399872],"about_ca_topic_score_codex":0.0007163416,"about_ca_topic_score_gemma":0.00062076864,"teacher_disagreement_score":0.0029246828,"about_ca_system_score_codex":0.00069846096,"about_ca_system_score_gemma":0.00065630063,"threshold_uncertainty_score":0.010195732},"labels":[],"label_agreement":null},{"id":"W4380083458","doi":"10.1002/hon.3164_446","title":"Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Obinutuzumab; Internal medicine; Rituximab; CHOP; Refractory (planetary science); Gastroenterology; Lymphoma; CD20; Oncology; Dosing; Phases of clinical research; Immunology; Adverse effect; Chemotherapy; Biology","score_opus":0.036268815423270026,"score_gpt":0.3635415401709561,"score_spread":0.32727272474768604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96360075,0.027549528,0.0008008377,0.0007779972,0.000113721944,0.00079383334,0.0011193232,0.00019487555,0.0050490773],"genre_scores_gemma":[0.975087,0.016291725,0.0015023103,0.0016387769,0.00018614552,0.00064750126,0.0030282899,0.00006312058,0.0015553159],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996934,0.00012260862,0.000035594545,0.0000322943,0.00004899298,0.000067105466],"domain_scores_gemma":[0.99944025,0.00013009646,0.00015041337,0.0000708726,0.00007968109,0.00012868555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001990455,0.00047401965,0.0010748571,0.00024273824,0.00018809705,0.0011322718,0.0005998236,0.0005718109,0.0020683056],"category_scores_gemma":[0.0007110707,0.00022517682,0.0009581284,0.0003837594,0.00035976837,0.0006404973,0.00020438079,0.0012988669,0.0005819605],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10533602,0.01415274,0.020186858,0.0024140617,0.002120767,0.00036985724,0.0006435444,0.0020428835,0.090050206,0.00048058524,0.010464273,0.75173825],"study_design_scores_gemma":[0.14850366,0.5831884,0.12720104,0.0009851069,0.0049868333,0.003928518,0.00041439224,0.002906046,0.039838135,0.0006635247,0.08723628,0.0001481016],"about_ca_topic_score_codex":0.00066087686,"about_ca_topic_score_gemma":0.0017126641,"teacher_disagreement_score":0.0020683056,"about_ca_system_score_codex":0.000690608,"about_ca_system_score_gemma":0.0007244719,"threshold_uncertainty_score":0.010526657},"labels":[],"label_agreement":null},{"id":"W4380083530","doi":"10.1002/hon.3164_386","title":"Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Raincoast Conservation Foundation","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Fludarabine; Clinical trial; Alemtuzumab; Progression-free survival; Refractory (planetary science); Lymphoma; Overall survival; Confidence interval; Chemotherapy; Transplantation; Cyclophosphamide","score_opus":0.06551910042501254,"score_gpt":0.36349055388389534,"score_spread":0.2979714534588828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8815107,0.09433398,0.0053989305,0.0006433828,0.0013851498,0.0045650895,0.006146296,0.00014101766,0.005875546],"genre_scores_gemma":[0.9904694,0.0035686453,0.0016926277,0.0004014064,0.00013377603,0.0016139456,0.0012725551,0.000014084543,0.00083360303],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99084646,0.006571564,0.00090672745,0.0008328335,0.00052439765,0.00031808479],"domain_scores_gemma":[0.9915332,0.0056179073,0.001751053,0.00043899406,0.00037995138,0.00027902165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009124917,0.0016444691,0.004803366,0.0009538147,0.00026089215,0.0014387963,0.0013114904,0.0015011344,0.0077540623],"category_scores_gemma":[0.015448468,0.00052922394,0.01370782,0.0007488892,0.00061731477,0.0010470573,0.0011643415,0.0019084376,0.0004908913],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73510313,0.0012064233,0.007932047,0.018008772,0.20401612,0.0000998627,0.00014771466,0.003545025,0.0011550139,0.0007753288,0.00071440666,0.027296232],"study_design_scores_gemma":[0.34472087,0.11597731,0.03816256,0.002887339,0.47418544,0.0002650319,0.00025723578,0.011570386,0.0022105675,0.0038654755,0.005716746,0.00018104029],"about_ca_topic_score_codex":0.0016722415,"about_ca_topic_score_gemma":0.0019771003,"teacher_disagreement_score":0.009124917,"about_ca_system_score_codex":0.0012631833,"about_ca_system_score_gemma":0.0010627214,"threshold_uncertainty_score":0.04825777},"labels":[],"label_agreement":null},{"id":"W4380084938","doi":"10.1002/hon.3163_95","title":"GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (<i>R</i>/<i>R</i>) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Kite Pharma; F. Hoffmann-La Roche; Genentech; Celgene; Gilead Sciences; Pharmacyclics; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Medicine; Lymphoma; Oncology; Internal medicine; Physics","score_opus":0.046888727290113154,"score_gpt":0.37710057351762066,"score_spread":0.3302118462275075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493116,0.0032557743,0.00018318089,0.0001625092,0.000023245324,0.00016382594,0.00048740415,0.00003557442,0.00075724185],"genre_scores_gemma":[0.99647164,0.0011566638,0.00035751506,0.00022643396,0.0000432936,0.00012535187,0.0012237845,0.000008024159,0.000387342],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997485,0.00011030129,0.00002297893,0.000044429446,0.000033792243,0.000039940936],"domain_scores_gemma":[0.9995328,0.00008211133,0.00016789157,0.000043047614,0.000027901588,0.00014628214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009010204,0.00043176464,0.0009886416,0.00021993576,0.00016582155,0.00067014963,0.00041237706,0.000397276,0.0010037831],"category_scores_gemma":[0.0007291725,0.00022003413,0.00068336487,0.00031921334,0.00021697972,0.0005251792,0.00023975018,0.0009929239,0.0003147199],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4746427,0.010137434,0.13686581,0.0013230579,0.0030079596,0.00088094536,0.0006795295,0.005144469,0.070633784,0.00021878247,0.007032433,0.2894332],"study_design_scores_gemma":[0.12838127,0.3847013,0.45153442,0.00024673672,0.0027055435,0.0022978585,0.0002893141,0.0037678909,0.010732497,0.0003750537,0.014852205,0.00011591368],"about_ca_topic_score_codex":0.0004362001,"about_ca_topic_score_gemma":0.0015958233,"teacher_disagreement_score":0.0010037831,"about_ca_system_score_codex":0.0006624802,"about_ca_system_score_gemma":0.00045172617,"threshold_uncertainty_score":0.0048066378},"labels":[],"label_agreement":null},{"id":"W4380148586","doi":"10.1016/j.jcyt.2023.05.004","title":"Constitutive expression of interleukin-27 diminishes proinflammatory cytokine production without impairing effector function of engineered T cells","year":2023,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Discovery Centre","funders":"","keywords":"Cytokine; Tumor necrosis factor alpha; Immunology; Proinflammatory cytokine; Immunotherapy; Cancer research; Biology; Immune system; Inflammation","score_opus":0.02125419104203506,"score_gpt":0.2889989854898254,"score_spread":0.2677447944477903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380148586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111605,0.00042673753,0.0061192513,0.00008800131,0.000056698293,0.0000471764,0.00027260772,0.0001424816,0.0017309815],"genre_scores_gemma":[0.9954112,0.00025025752,0.002272425,0.000038416354,0.000010302965,0.000034294615,0.00029718562,0.00003542342,0.0016504691],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997086,0.000051726223,0.00002772965,0.00004651568,0.000071410446,0.000093990435],"domain_scores_gemma":[0.9997608,0.0000788735,0.000051501367,0.000030975098,0.000021390078,0.000056496767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022927858,0.00052391796,0.00031123447,0.0002448222,0.00013548293,0.00042941573,0.00021508944,0.00031572362,0.0016324796],"category_scores_gemma":[0.00014731906,0.0001468365,0.00024169279,0.00015346387,0.00036162505,0.00016551431,0.00019923136,0.0012239884,0.0005404936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013966215,0.000068959525,0.00007905909,0.000019136114,0.0000038873995,0.00004166797,0.000010790089,0.00015678532,0.9988281,0.00012260416,0.00003260849,0.00049670914],"study_design_scores_gemma":[0.000015870382,0.00015634361,0.0003277554,0.0000022552845,0.000008404079,0.00007796174,0.000009990719,0.0006055405,0.99809176,0.000017674813,0.00068487396,0.0000015702587],"about_ca_topic_score_codex":0.00028242852,"about_ca_topic_score_gemma":0.00040869732,"teacher_disagreement_score":0.0016324796,"about_ca_system_score_codex":0.00020772181,"about_ca_system_score_gemma":0.00030506085,"threshold_uncertainty_score":0.005461216},"labels":[],"label_agreement":null},{"id":"W4380150346","doi":"10.1016/j.jval.2023.03.356","title":"EE51 A Cost-Consequence Analysis of Adopting Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma in Saudi Arabia: a Multi-Center Comparison","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Lymphoma; Medicine; Referral; Oncology; Immunotherapy; Internal medicine; Family medicine; Cancer; Biology","score_opus":0.08135585999482925,"score_gpt":0.36770681570183034,"score_spread":0.2863509557070011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380150346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976041,0.0008585071,0.0001937666,0.00012260934,0.000019915235,0.00007560719,0.00053706305,0.0000033303447,0.00058521825],"genre_scores_gemma":[0.9989195,0.00019624029,0.000106442974,0.000083536885,0.000015941028,0.000032727898,0.00044858397,0.0000018289041,0.0001952308],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979711,0.0012727563,0.00013343302,0.00016722913,0.00015923595,0.0002962352],"domain_scores_gemma":[0.9956867,0.0023691785,0.00087555475,0.00021031094,0.00034805312,0.0005101866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003442199,0.00071691355,0.001150955,0.00065391464,0.00031137042,0.0011710058,0.00072640204,0.0010253472,0.0044047004],"category_scores_gemma":[0.0058549987,0.00028022274,0.00387575,0.00090122945,0.00044519125,0.0009392993,0.00082258385,0.0010541119,0.00024197201],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5136086,0.004481369,0.3248053,0.0015487588,0.020133913,0.0006154967,0.0005067143,0.039959926,0.003644399,0.0022980357,0.0021277836,0.086269654],"study_design_scores_gemma":[0.038164932,0.19364288,0.6900181,0.00037889296,0.02731351,0.00091124995,0.0023639542,0.037783995,0.0030224305,0.0013329186,0.0048324657,0.00023458283],"about_ca_topic_score_codex":0.007816141,"about_ca_topic_score_gemma":0.006392048,"teacher_disagreement_score":0.007816141,"about_ca_system_score_codex":0.003363956,"about_ca_system_score_gemma":0.001105235,"threshold_uncertainty_score":0.024407268},"labels":[],"label_agreement":null},{"id":"W4380152961","doi":"10.51731/cjht.2023.668","title":"Brexucabtagene Autoleucel (Tecartus)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Refractory (planetary science); Chimeric antigen receptor; Drug; Intensive care medicine; Family medicine; Pharmacology; Internal medicine; Political science; Cancer; Immunotherapy","score_opus":0.06782205487796064,"score_gpt":0.3562780262120117,"score_spread":0.2884559713340511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380152961","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03366643,0.78830564,0.0051005334,0.008229233,0.0014661908,0.00045529802,0.003827197,0.0005154727,0.15843394],"genre_scores_gemma":[0.3317381,0.47033408,0.011590282,0.008847881,0.0007620734,0.00046340554,0.007683232,0.0001817344,0.16839913],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995426,0.000099164376,0.000027875582,0.00003991653,0.00024250238,0.000048030197],"domain_scores_gemma":[0.99962366,0.00009933579,0.00008718305,0.00001876282,0.00012370653,0.000047264373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000878014,0.00020603609,0.00028528203,0.00076749164,0.00023332464,0.00078425073,0.0004021431,0.00055851345,0.011610133],"category_scores_gemma":[0.0008554698,0.000069767906,0.00037709164,0.0005483041,0.0003591517,0.00033190107,0.00024185899,0.0006347743,0.0023118628],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071276695,0.00011366083,0.0014299297,0.0034316725,0.00012996553,0.00036929562,0.00006296355,0.00031810615,0.02668967,0.0073019145,0.1077146,0.8517255],"study_design_scores_gemma":[0.00019980944,0.00088049774,0.0064611323,0.000955706,0.00008821585,0.001480499,0.00005224802,0.00020503173,0.01960579,0.0003248387,0.96972704,0.000019175604],"about_ca_topic_score_codex":0.025039934,"about_ca_topic_score_gemma":0.060665347,"teacher_disagreement_score":0.025039934,"about_ca_system_score_codex":0.001876574,"about_ca_system_score_gemma":0.0019645465,"threshold_uncertainty_score":0.049788356},"labels":[],"label_agreement":null},{"id":"W4380203508","doi":"10.51731/cjht.2023.667","title":"Axicabtagene Ciloleucel (Yescarta)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Reimbursement; Medicine; Lymphoma; Drug; Refractory (planetary science); Oncology; Intensive care medicine; Internal medicine; Pharmacology; Health care; Rituximab; Political science","score_opus":0.07583853752595779,"score_gpt":0.35787496221602544,"score_spread":0.2820364246900676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380203508","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02543784,0.6080985,0.0023223169,0.01387976,0.002517675,0.0007423409,0.0063083153,0.00071452896,0.33997875],"genre_scores_gemma":[0.23760776,0.40428025,0.008284527,0.019846264,0.0011994023,0.0007027326,0.010562005,0.00016267557,0.31735447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99974805,0.000042076645,0.000020933123,0.000031953376,0.00012326203,0.00003365567],"domain_scores_gemma":[0.9997236,0.000055268076,0.000060375703,0.000009357965,0.00009760946,0.00005376762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045756227,0.00024541252,0.00026580138,0.00074231083,0.00025133218,0.0007425893,0.00044436427,0.0006175428,0.028777955],"category_scores_gemma":[0.0006955131,0.00008204261,0.00038629866,0.0004545841,0.00032280435,0.0003923416,0.00028666764,0.000595799,0.0046975026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012112554,0.00013653786,0.000973531,0.0037165717,0.00009383831,0.00023924182,0.000034177883,0.0001580746,0.010785496,0.004084606,0.16161945,0.81694716],"study_design_scores_gemma":[0.0006023819,0.0011440938,0.004467091,0.000878264,0.00011195612,0.00062576396,0.00004101624,0.00017076236,0.0060115866,0.00034680223,0.9855834,0.000016960652],"about_ca_topic_score_codex":0.017206743,"about_ca_topic_score_gemma":0.07261575,"teacher_disagreement_score":0.028777955,"about_ca_system_score_codex":0.001557321,"about_ca_system_score_gemma":0.002465878,"threshold_uncertainty_score":0.09627187},"labels":[],"label_agreement":null},{"id":"W4380234055","doi":"10.1016/j.jtct.2023.06.007","title":"Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age &lt;3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Leukapheresis; Medicine; Blinatumomab; Leukemia; Lymphoblastic Leukemia; Immunology; Stem cell","score_opus":0.01585269188541878,"score_gpt":0.25388425744362353,"score_spread":0.23803156555820476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380234055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99822,0.0005157842,0.000084493426,0.000053305597,0.0000042030024,0.000012601766,0.0005675448,0.000006015611,0.0005360331],"genre_scores_gemma":[0.9984012,0.00014706296,0.0000880481,0.000073963354,0.000008712092,0.000010252575,0.0011368081,0.000004471592,0.00012944936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992805,0.00015104015,0.00011564096,0.0001334297,0.00020279057,0.000116589516],"domain_scores_gemma":[0.99632734,0.00055541046,0.002499452,0.00013165573,0.00023100043,0.00025509013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001313635,0.00014630944,0.00026654446,0.0006210509,0.00026229332,0.0007971954,0.00020112706,0.00032616607,0.0013167321],"category_scores_gemma":[0.0031651305,0.00010291294,0.0005107869,0.0010783657,0.00023347774,0.00054439617,0.0004248518,0.0006313921,0.0003295694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002690002,0.00011367148,0.98560417,0.000031721476,0.00008655161,0.0002432786,0.00017208478,0.00026212633,0.0011544707,0.00008482237,0.0004918308,0.009065291],"study_design_scores_gemma":[0.00006746095,0.0013266404,0.9947101,0.000015462057,0.00008102976,0.00083602406,0.0001734522,0.00041506943,0.00094956125,0.00006245077,0.0013542891,0.000008418625],"about_ca_topic_score_codex":0.0019918848,"about_ca_topic_score_gemma":0.0020959966,"teacher_disagreement_score":0.0019918848,"about_ca_system_score_codex":0.00071192713,"about_ca_system_score_gemma":0.00039216943,"threshold_uncertainty_score":0.006947279},"labels":[],"label_agreement":null},{"id":"W4380606669","doi":"10.1101/2023.06.14.545014","title":"Predicting T cell activation based on intracellular calcium fluctuations","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de recherche du Québec – Nature et technologies; Natural Sciences and Engineering Research Council of Canada; Fonds de Recherche du Québec - Santé; Radboud Universiteit","keywords":"T-cell receptor; Antigen; Cytotoxic T cell; Biology; T cell; Cell biology; Polyclonal antibodies; Streptamer; Intracellular; Molecular biology; In vitro; Immunology; Immune system; Biochemistry","score_opus":0.03854715687238681,"score_gpt":0.2796330752602993,"score_spread":0.2410859183879125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380606669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91204274,0.00027203618,0.08444043,0.00022835654,0.000049398564,0.000039363695,0.0007025262,0.000990802,0.001234425],"genre_scores_gemma":[0.99104893,0.000073135445,0.008196744,0.000024312554,0.000009269779,0.000014234666,0.00019740414,0.000013224055,0.00042280104],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99990916,0.000007568233,0.000005752547,0.000040844552,0.000020913747,0.00001579788],"domain_scores_gemma":[0.99979,0.000068718735,0.000052285293,0.000012817192,0.000044620887,0.000031524865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021095024,0.00059509417,0.00029422378,0.0006239798,0.00014437917,0.00050034205,0.00025301738,0.0005805417,0.0008031747],"category_scores_gemma":[0.0008352419,0.00014360686,0.00019079442,0.0003088385,0.00017727951,0.0003078681,0.00022689858,0.0004882954,0.00022889482],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001014733,0.00018533738,0.06863388,0.00012577696,0.000086450105,0.00020938502,0.00003952735,0.42458123,0.42641672,0.0007732952,0.0015790559,0.07635455],"study_design_scores_gemma":[0.000005653959,0.000035602512,0.0050016455,0.0000027183619,0.000006688308,0.000021957281,0.0000055117353,0.96896535,0.025607947,0.00023640657,0.00010473924,0.000005887081],"about_ca_topic_score_codex":0.0025632214,"about_ca_topic_score_gemma":0.0027225476,"teacher_disagreement_score":0.0025632214,"about_ca_system_score_codex":0.0004742583,"about_ca_system_score_gemma":0.0003503997,"threshold_uncertainty_score":0.0050966144},"labels":[],"label_agreement":null},{"id":"W4381309016","doi":"10.1080/10428194.2023.2226278","title":"Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma","year":2023,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Bendamustine; Medicine; Internal medicine; Lymphoma","score_opus":0.03402183222211579,"score_gpt":0.3065968196357071,"score_spread":0.2725749874135913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381309016","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39363313,0.0063255522,0.003982971,0.5269083,0.006073103,0.00016922662,0.0015777997,0.00025494746,0.061074976],"genre_scores_gemma":[0.9149874,0.0023350974,0.0030844337,0.06500543,0.0070745745,0.000075911834,0.00044770198,0.000073665586,0.006915821],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992482,0.00027400698,0.000095464646,0.00006674162,0.00018224117,0.00013330913],"domain_scores_gemma":[0.99184084,0.005996272,0.0003831689,0.00021645453,0.0010459024,0.0005172746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001380521,0.00023888107,0.00037750328,0.0005801371,0.00043874266,0.0009266417,0.00045060928,0.003181543,0.00329282],"category_scores_gemma":[0.011491259,0.00022064612,0.00039917085,0.00040000604,0.00032578537,0.0005273683,0.00022523504,0.002892003,0.0015143869],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063725896,0.000515065,0.4773626,0.0002518982,0.00017952887,0.057135105,0.00044297794,0.004901276,0.007504522,0.0027652031,0.23299575,0.20957345],"study_design_scores_gemma":[0.0013116379,0.0069800257,0.5309995,0.0007957888,0.0009653236,0.14880128,0.0025329918,0.0510026,0.015594576,0.020154806,0.22058257,0.00027897782],"about_ca_topic_score_codex":0.004775753,"about_ca_topic_score_gemma":0.0065798406,"teacher_disagreement_score":0.004775753,"about_ca_system_score_codex":0.0023237173,"about_ca_system_score_gemma":0.00076204113,"threshold_uncertainty_score":0.01685983},"labels":[],"label_agreement":null},{"id":"W4381429777","doi":"10.3390/curroncol30060440","title":"Neurologic Complications of Cancer Immunotherapy","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Immunotherapy; Intensive care medicine; Cancer; Clinical Practice; Cancer immunotherapy; Cancer treatment; Internal medicine; Physical therapy","score_opus":0.4827665994145928,"score_gpt":0.5875342349185801,"score_spread":0.10476763550398732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381429777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031428045,0.9962599,0.00017017836,0.0004817184,0.00033071902,0.000006985335,0.00002051241,0.000009267224,0.0024064828],"genre_scores_gemma":[0.0021204029,0.99622715,0.00015979988,0.00040030538,0.00033708304,0.000008723358,0.000030540774,0.0000012474029,0.00071479095],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997801,0.000049932558,0.00003239656,0.000028940723,0.000079305035,0.00002931126],"domain_scores_gemma":[0.9997334,0.00012646613,0.00004686826,0.000008070858,0.00006923866,0.00001597972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037246846,0.00065017707,0.0008725222,0.0012903394,0.0003875042,0.0010078321,0.00055166485,0.0010230367,0.0027127282],"category_scores_gemma":[0.0007321558,0.00013149992,0.00055702886,0.0010652737,0.00040572308,0.00074994727,0.00062332593,0.0014654847,0.00080550043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078440455,0.00006055712,0.00045073938,0.017520193,0.00013387528,0.00093799277,0.000088459325,0.00036940046,0.0020001105,0.0056706723,0.03901933,0.9336702],"study_design_scores_gemma":[0.000025472804,0.00015518816,0.0017162845,0.0073731067,0.00025486766,0.011376049,0.00011875686,0.00014977911,0.0016120757,0.003946579,0.9732466,0.000025211284],"about_ca_topic_score_codex":0.0011887001,"about_ca_topic_score_gemma":0.0026718075,"teacher_disagreement_score":0.0027127282,"about_ca_system_score_codex":0.0007086344,"about_ca_system_score_gemma":0.0011773452,"threshold_uncertainty_score":0.009074986},"labels":[],"label_agreement":null},{"id":"W4381890138","doi":"10.1101/2023.06.20.545790","title":"Engineered CD47 protects T cells for enhanced antitumor immunity","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"School of Medicine, Stanford University; Virginia and D.K. Ludwig Fund for Cancer Research; Alliance Nationale pour les Sciences de la Vie et de la Santé; Parker Institute for Cancer Immunotherapy; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"CD47; Chimeric antigen receptor; Macrophage; Immune system; T cell; Cancer research; Adoptive cell transfer; Immunology; Cell biology; Biology; In vitro; Biochemistry","score_opus":0.03349499980653457,"score_gpt":0.27783762579723853,"score_spread":0.24434262599070394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381890138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98221314,0.0009891252,0.011833528,0.00030667425,0.00007917746,0.000049803766,0.00039706207,0.00029258235,0.0038388928],"genre_scores_gemma":[0.9927008,0.00025244048,0.0030085766,0.000097663564,0.00001837175,0.000027269265,0.00028078986,0.000046480996,0.00356754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985385,0.000031586012,0.000012122292,0.000022980606,0.00003570995,0.000043663378],"domain_scores_gemma":[0.99990284,0.000022150607,0.000020962376,0.000020227915,0.000012134523,0.000021625916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022878246,0.0003094324,0.00022423478,0.00019793643,0.00010232297,0.00032607402,0.0001154011,0.00033106995,0.0022742709],"category_scores_gemma":[0.000104039864,0.00012316206,0.00019682043,0.00010372259,0.000229961,0.00015089639,0.000166513,0.00064964965,0.0009216483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015578629,0.000039101164,0.00010604055,0.000014965448,0.0000041547564,0.000037914164,0.000007897888,0.00014017563,0.99773055,0.00034567397,0.00011932002,0.0012983936],"study_design_scores_gemma":[0.000029948023,0.00016609373,0.0002840658,0.0000019044484,0.0000042897764,0.0001033571,0.000005218918,0.000735476,0.9962011,0.0000665306,0.0024006472,0.000001358974],"about_ca_topic_score_codex":0.00020235794,"about_ca_topic_score_gemma":0.00012699774,"teacher_disagreement_score":0.0022742709,"about_ca_system_score_codex":0.00017530807,"about_ca_system_score_gemma":0.00019057153,"threshold_uncertainty_score":0.007608235},"labels":[],"label_agreement":null},{"id":"W4382240403","doi":"10.1158/2326-6066.cir-23-0189","title":"A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Landsteiner Foundation for Blood Transfusion Research","keywords":"Cancer research; CD8; T cell; Cytotoxic T cell; Immune system; Immunotherapy; In vivo; Effector; Peripheral blood mononuclear cell; CD3; Antibody; Ex vivo; Immunology; Biology; In vitro","score_opus":0.07868281163372867,"score_gpt":0.3782674942303921,"score_spread":0.2995846825966634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382240403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552935,0.0003961286,0.0028271293,0.00002420622,0.0000110591045,0.00006353026,0.00012105477,0.00003031135,0.0009972301],"genre_scores_gemma":[0.9972356,0.00022581883,0.0012723733,0.000041467887,0.0000058183177,0.000042888758,0.00022215782,0.000004751862,0.0009491343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998386,0.000029867073,0.000012717388,0.000039450184,0.0000362315,0.000043028274],"domain_scores_gemma":[0.9999639,0.000008236336,0.000009552806,0.000006862835,0.000005014421,0.000006531205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016924995,0.00045754138,0.00020377427,0.00013852592,0.00006598403,0.00026820347,0.00018465245,0.00029323384,0.00071289425],"category_scores_gemma":[0.00010098442,0.00009460081,0.0001754094,0.00009502121,0.00009092006,0.00015226414,0.0001611206,0.0006138965,0.00020510073],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000106563435,0.00006772519,0.00020358997,0.00002964015,0.0000053230424,0.000031066404,0.000014389687,0.00020675977,0.9973024,0.00005462681,0.000030225354,0.0019476247],"study_design_scores_gemma":[0.00004249696,0.0016328911,0.0018093938,0.000008975177,0.000020236428,0.0005127219,0.000025480878,0.0014795895,0.9926876,0.00005479574,0.0017225473,0.0000033320903],"about_ca_topic_score_codex":0.00016603214,"about_ca_topic_score_gemma":0.00029909235,"teacher_disagreement_score":0.00071289425,"about_ca_system_score_codex":0.00016709736,"about_ca_system_score_gemma":0.00012132594,"threshold_uncertainty_score":0.002384901},"labels":[],"label_agreement":null},{"id":"W4382700748","doi":"10.1016/j.jtct.2023.06.019","title":"Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"Coins for Alzheimer's Research Trust; Swedish Orphan Biovitrum; Government of South Australia; Juno Therapeutics; Novartis; NIH Clinical Center; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Cart; Chimeric antigen receptor; Medicine; CD19; Internal medicine; Antigen; T cell; Immunology; Oncology; Immune system","score_opus":0.020929212730782583,"score_gpt":0.28457628878529995,"score_spread":0.26364707605451737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382700748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9426932,0.046587836,0.0048175603,0.0004223753,0.0001332178,0.00013644919,0.00045342138,0.00012391015,0.004632146],"genre_scores_gemma":[0.99384886,0.0045105955,0.0005843257,0.00017870452,0.000075076314,0.000043356464,0.00028275928,0.000009098952,0.00046719267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998067,0.00006933308,0.000021740045,0.000031715434,0.000037181857,0.00003334566],"domain_scores_gemma":[0.9995956,0.00012168016,0.00017144521,0.000032791086,0.000031633826,0.000046889334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005864663,0.0001552517,0.00045667685,0.00039048155,0.00015216108,0.00047038254,0.00027679343,0.00025657064,0.001305981],"category_scores_gemma":[0.000663834,0.000045175027,0.00047962653,0.0003090273,0.00017154211,0.00021110494,0.00017838369,0.0003272784,0.0002771885],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064838445,0.000623934,0.18857755,0.0015878484,0.00064761227,0.009423926,0.00032804967,0.0034488202,0.030853242,0.0025680284,0.008196082,0.74726105],"study_design_scores_gemma":[0.0024662314,0.041235052,0.58824825,0.0024375548,0.0025738247,0.121460825,0.0009185573,0.017066265,0.08990443,0.006120142,0.12746516,0.00010367617],"about_ca_topic_score_codex":0.00029054674,"about_ca_topic_score_gemma":0.00040782848,"teacher_disagreement_score":0.001305981,"about_ca_system_score_codex":0.0003659141,"about_ca_system_score_gemma":0.00036395647,"threshold_uncertainty_score":0.0043689013},"labels":[],"label_agreement":null},{"id":"W4382786855","doi":"10.1016/j.immuni.2023.06.007","title":"TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation","year":2023,"lang":"en","type":"article","venue":"Immunity","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; Institut National Du Cancer; Ligue Contre le Cancer; Bristol-Myers Squibb; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Fondation Toulouse Cancer Santé; Cancer Research Institute","keywords":"CD137; Biology; CD8; T cell; T-cell receptor; Cancer research; Cell biology; Immune system; Cytotoxic T cell; Cell growth; Cancer immunotherapy; Immunotherapy; Immunology; Biochemistry","score_opus":0.04049820537544255,"score_gpt":0.3159927071436563,"score_spread":0.2754945017682138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382786855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928358,0.0017345037,0.002724911,0.00008378217,0.000025472511,0.000027675474,0.00017785162,0.000092144226,0.002297834],"genre_scores_gemma":[0.9962625,0.00046493715,0.0010010409,0.00003314535,0.000008500675,0.00001189008,0.00016237724,0.000009000441,0.0020465336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987364,0.000023709881,0.000008684263,0.0000228451,0.00002885667,0.000042270094],"domain_scores_gemma":[0.9999484,0.000007464106,0.000014106014,0.000004668433,0.0000063841812,0.000018920846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011370896,0.00029180152,0.00022410676,0.00016737978,0.00008928316,0.00035369123,0.000103795806,0.00019845403,0.0017020426],"category_scores_gemma":[0.00010535078,0.00007801255,0.00013743404,0.000086974076,0.00015274649,0.00021653972,0.00022672753,0.0006829385,0.00041272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001324209,0.000034558583,0.00020180455,0.000037277438,0.0000025433915,0.00004327138,0.000012492332,0.00008459876,0.9963354,0.00022786272,0.000052687257,0.0028351285],"study_design_scores_gemma":[0.000048683814,0.0007264134,0.002464273,0.000012556524,0.000018402883,0.00039733516,0.00004039307,0.001232156,0.99055827,0.0001863483,0.0043118605,0.0000033567048],"about_ca_topic_score_codex":0.00020866354,"about_ca_topic_score_gemma":0.0004389016,"teacher_disagreement_score":0.0017020426,"about_ca_system_score_codex":0.00020901517,"about_ca_system_score_gemma":0.0002676239,"threshold_uncertainty_score":0.0056939125},"labels":[],"label_agreement":null},{"id":"W4382807727","doi":"10.1016/j.annonc.2023.04.087","title":"P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medac; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Ipsen; Servier; Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung; National Center for Global Health and Medicine; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celgene; MacroGenics; Sanofi; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Chimeric antigen receptor; Leukapheresis; Response Evaluation Criteria in Solid Tumors; T cell; Chemotherapy; Clinical trial; Internal medicine; Oncology; Immunotherapy; Phases of clinical research; Cancer research; Pharmacology; Cancer; Immunology; Immune system; CD34; Stem cell","score_opus":0.16540892445874333,"score_gpt":0.4750678984302584,"score_spread":0.30965897397151504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382807727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092954,0.0019094445,0.00046410828,0.0006856656,0.00013463086,0.001652644,0.0010371647,0.00009756036,0.0030891448],"genre_scores_gemma":[0.9892452,0.0015952797,0.001030244,0.0007124126,0.00010771414,0.0014665414,0.0021253566,0.000031631982,0.0036856858],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964654,0.00017970876,0.000013465065,0.000057124373,0.000024355406,0.00007885246],"domain_scores_gemma":[0.999458,0.00013533681,0.000073751224,0.00006100329,0.000021268708,0.00025051952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013461398,0.0009970906,0.0012941948,0.0003152042,0.00036698522,0.0008521342,0.00061295234,0.0009484112,0.0041222963],"category_scores_gemma":[0.00086706394,0.0003354478,0.0009221503,0.0002847899,0.001108989,0.00079251,0.00040240792,0.003301815,0.0009906254],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75936705,0.031963903,0.004506564,0.0010855832,0.0014179747,0.0006444635,0.00031168145,0.0071741273,0.050419424,0.0011380779,0.0081350515,0.13383614],"study_design_scores_gemma":[0.58808535,0.38799992,0.007928399,0.00006272583,0.00047955636,0.0006563879,0.00008688469,0.0025921718,0.0067348126,0.0010657489,0.004271438,0.000036638245],"about_ca_topic_score_codex":0.0010121443,"about_ca_topic_score_gemma":0.002320184,"teacher_disagreement_score":0.0041222963,"about_ca_system_score_codex":0.0007548458,"about_ca_system_score_gemma":0.0015451883,"threshold_uncertainty_score":0.013790429},"labels":[],"label_agreement":null},{"id":"W4382983620","doi":"10.3390/curroncol30070467","title":"Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Bispecific antibody; Multiple myeloma; Adverse effect; Malignancy; Immunology; Immunotherapy; Clinical trial; Antigen; Cytokine release syndrome; Antibody; Intensive care medicine; Immune system; Monoclonal antibody; Internal medicine","score_opus":0.18569027681698777,"score_gpt":0.4573332689036392,"score_spread":0.27164299208665144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382983620","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026778446,0.9988109,0.00007689858,0.00018802576,0.000071661016,0.000004688853,0.000019409938,0.000003836688,0.00055693305],"genre_scores_gemma":[0.0015228884,0.9976914,0.00012441383,0.00020083692,0.00008855118,0.000007649822,0.00003811362,0.0000012415886,0.00032497518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99975914,0.000059113892,0.000042372765,0.000031712985,0.00008890709,0.000018722887],"domain_scores_gemma":[0.9996861,0.00015124174,0.000058886937,0.000006511296,0.00008292683,0.000014308419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070073316,0.0005229715,0.0011196192,0.0011963972,0.00017764501,0.00067584607,0.00061214285,0.00072717847,0.0019657277],"category_scores_gemma":[0.0007689166,0.00016893732,0.00069846696,0.0011569037,0.00020555514,0.00059413555,0.0003882652,0.0009479097,0.0006010729],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014370904,0.00006432143,0.00028805155,0.02274951,0.00020557667,0.00018960136,0.00004906377,0.00055030285,0.0020003733,0.0015019435,0.01625985,0.95599777],"study_design_scores_gemma":[0.0000769191,0.0005163398,0.002443222,0.009883459,0.0007471829,0.0032810287,0.0000869658,0.00027607568,0.0019105521,0.0017550127,0.97899044,0.00003280664],"about_ca_topic_score_codex":0.00089727994,"about_ca_topic_score_gemma":0.0016931574,"teacher_disagreement_score":0.0019657277,"about_ca_system_score_codex":0.0005716613,"about_ca_system_score_gemma":0.00086655177,"threshold_uncertainty_score":0.0065760016},"labels":[],"label_agreement":null},{"id":"W4383226811","doi":"10.1016/j.jtct.2023.06.012","title":"ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Transplantation; ThioTEPA; Oncology; Lymphoma; Rituximab; Hematopoietic cell; Chimeric antigen receptor; Salvage therapy; Internal medicine; CHOP; Chemotherapy; Cancer; Haematopoiesis; Immunotherapy; Stem cell; Cyclophosphamide","score_opus":0.06321421224880473,"score_gpt":0.3757907171074914,"score_spread":0.31257650485868665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383226811","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016495105,0.028206438,0.097018525,0.62503797,0.016983042,0.05293284,0.0053541665,0.0012550474,0.15671693],"genre_scores_gemma":[0.07086072,0.025225325,0.71734947,0.09170793,0.002708365,0.052360617,0.009752016,0.00042216684,0.029613374],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.8566849,0.083392546,0.0331417,0.0022393358,0.020872718,0.0036688067],"domain_scores_gemma":[0.73231906,0.07650037,0.028188912,0.0065581826,0.1400151,0.016418394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11588137,0.0011030886,0.001360503,0.0072393753,0.0035875398,0.0053652884,0.00487427,0.009440868,0.008577015],"category_scores_gemma":[0.16026449,0.00089053,0.0040971497,0.006575852,0.0036891708,0.003204041,0.006862049,0.009038866,0.006150141],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018175232,0.0008347508,0.007222503,0.007864084,0.000120087076,0.0012206918,0.008932246,0.0020049664,0.0016992496,0.023407685,0.6227655,0.3237464],"study_design_scores_gemma":[0.00046548859,0.00039283733,0.007073881,0.023858862,0.0001754585,0.0012148179,0.008263086,0.0025180078,0.0009940856,0.020649921,0.93421656,0.00017711242],"about_ca_topic_score_codex":0.010031162,"about_ca_topic_score_gemma":0.015707357,"teacher_disagreement_score":0.11588137,"about_ca_system_score_codex":0.008736381,"about_ca_system_score_gemma":0.069884196,"threshold_uncertainty_score":0.6128466},"labels":[],"label_agreement":null},{"id":"W4383342546","doi":"10.22541/au.168864332.23180439/v1","title":"Children’s Oncology Group’s 2023 Blueprint for Research: Cellular Therapy and Stem Cell Transplantation","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Transplantation; Oncology; Umbilical cord; Stem cell; Minimal residual disease; Leukemia; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Cell therapy; Immunology; Biology","score_opus":0.24032965839095258,"score_gpt":0.41958628601329256,"score_spread":0.17925662762234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383342546","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025361157,0.038972963,0.005074031,0.4712697,0.22830258,0.00033461262,0.007947842,0.0023168281,0.24324521],"genre_scores_gemma":[0.019981692,0.029573182,0.01609491,0.073774695,0.06964814,0.0003725233,0.012916121,0.0021254665,0.7755133],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99690396,0.0004226697,0.00010402167,0.00032207524,0.0017420234,0.00050520524],"domain_scores_gemma":[0.993505,0.00087919936,0.00027731352,0.000556543,0.0016239972,0.0031580261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004652952,0.001093658,0.0007927242,0.0013762651,0.0013138365,0.0041306145,0.000804496,0.0052010072,0.10400676],"category_scores_gemma":[0.008039806,0.00048745575,0.00077634735,0.0012939594,0.0011446777,0.0015428389,0.0019290827,0.005834645,0.05813047],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052948966,0.000015133718,0.000088255896,0.000021023156,0.0000062692566,0.000037989605,0.000004971295,0.000027342958,0.00019565194,0.0028504666,0.97598946,0.020710336],"study_design_scores_gemma":[0.000051148603,0.000029674391,0.0002939755,0.000039108945,0.0000034703748,0.000094813804,0.0000067284786,0.00005935283,0.00048368901,0.0015771649,0.9973544,0.0000063848775],"about_ca_topic_score_codex":0.002878039,"about_ca_topic_score_gemma":0.004701453,"teacher_disagreement_score":0.10400676,"about_ca_system_score_codex":0.0050465893,"about_ca_system_score_gemma":0.00870595,"threshold_uncertainty_score":0.3479373},"labels":[],"label_agreement":null},{"id":"W4383561245","doi":"10.1136/jitc-2023-006863","title":"BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Ovarian Cancer Research Alliance; McMaster University; Roswell Park Cancer Institute","keywords":"Cancer research; T cell; Medicine; Tumor microenvironment; Ovarian cancer; Adoptive cell transfer; Chimeric antigen receptor; Cytotoxic T cell; Immunology; Cancer; Biology; Immune system; Internal medicine; In vitro","score_opus":0.026223649595796015,"score_gpt":0.3397886489431468,"score_spread":0.31356499934735077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99534,0.00092306227,0.0019037888,0.00009501775,0.00003845722,0.000049791888,0.0001733308,0.00013893451,0.0013376368],"genre_scores_gemma":[0.9971615,0.0004027415,0.00079498166,0.000047148722,0.0000143488205,0.000027140328,0.00022148513,0.00001253318,0.0013181983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991214,0.000009453601,0.000007899705,0.000018229712,0.00002806033,0.00002429156],"domain_scores_gemma":[0.9999366,0.0000089431815,0.000022704055,0.000008003188,0.0000067709652,0.000016987662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010123095,0.00030683752,0.00020891914,0.00017494506,0.000069822076,0.000301253,0.00012990182,0.00023259189,0.0011714647],"category_scores_gemma":[0.00010064113,0.00007525143,0.00018202906,0.00012010314,0.00016425342,0.00013570803,0.00012038751,0.00068989623,0.00027239343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039915176,0.00018470659,0.000487253,0.00006199109,0.00001038242,0.000038544888,0.000039714687,0.0003989042,0.9866448,0.00009068287,0.00018153075,0.011462329],"study_design_scores_gemma":[0.00018654902,0.0048817475,0.0044745784,0.000015144972,0.00006177742,0.0003060178,0.000067380446,0.0023062434,0.98027235,0.000079869795,0.0073428378,0.000005592951],"about_ca_topic_score_codex":0.0003111686,"about_ca_topic_score_gemma":0.0003577223,"teacher_disagreement_score":0.0011714647,"about_ca_system_score_codex":0.0001546573,"about_ca_system_score_gemma":0.00014254679,"threshold_uncertainty_score":0.003918946},"labels":[],"label_agreement":null},{"id":"W4383907732","doi":"10.1002/adtp.202300124","title":"A Modular Antibody‐Oligomer T Cell Engager for Applications in Local Therapies","year":2023,"lang":"en","type":"article","venue":"Advanced Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Cytotoxicity; Antibody; Cancer research; Antigen; Immunotherapy; Cancer; Cancer immunotherapy; CTL*; Medicine; Chemistry; Pharmacology; In vitro; Immunology; Internal medicine; CD8; Biochemistry","score_opus":0.04357636839134153,"score_gpt":0.3795854253508251,"score_spread":0.3360090569594836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383907732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690521,0.0017604042,0.025889603,0.00011750951,0.000036778747,0.00007626556,0.000107499596,0.00023718587,0.002722706],"genre_scores_gemma":[0.9903234,0.00035851143,0.0075422423,0.00003970614,0.000005718597,0.00003009642,0.000056995443,0.000008750376,0.0016345493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999547,0.000007190978,0.0000028555546,0.0000116359,0.0000133446065,0.000010207709],"domain_scores_gemma":[0.9999609,0.0000055058454,0.000015414937,0.0000045450934,0.000005248686,0.000008417795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095668736,0.00026874125,0.000095934854,0.00008580168,0.000051942206,0.00016208258,0.00013286382,0.00027572672,0.0011747277],"category_scores_gemma":[0.000061871404,0.00006922685,0.0001422295,0.0000638865,0.0000971632,0.00015856558,0.00015608636,0.00030079583,0.00031113866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002165179,0.000017300927,0.000052388117,0.000021449268,0.0000021045587,0.000020237521,0.0000048959673,0.0002585289,0.9976271,0.00013971057,0.000042501928,0.0017921161],"study_design_scores_gemma":[0.000014204304,0.0005046851,0.00071310095,0.000003975905,0.000010189601,0.00017255603,0.0000073070087,0.0025737393,0.9928832,0.00005147174,0.0030612668,0.000004359853],"about_ca_topic_score_codex":0.00013477026,"about_ca_topic_score_gemma":0.00019421057,"teacher_disagreement_score":0.0011747277,"about_ca_system_score_codex":0.0001516411,"about_ca_system_score_gemma":0.00009738749,"threshold_uncertainty_score":0.0039298534},"labels":[],"label_agreement":null},{"id":"W4383998685","doi":"10.1002/hon.3202","title":"Diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; Vincristine; Lymphoma; CHOP; Prednisone; Oncology; Clinical trial; Internal medicine; Intensive care medicine; Cyclophosphamide; Chemotherapy","score_opus":0.1736930225114751,"score_gpt":0.45716910312321773,"score_spread":0.2834760806117427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383998685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005785324,0.9983523,0.000050421724,0.00020019658,0.00016245022,0.000004491348,0.000019141049,0.000006984455,0.0011461996],"genre_scores_gemma":[0.0004634386,0.9985247,0.00006135946,0.00024428335,0.00013047742,0.0000048044953,0.000043882923,0.000001015363,0.00052603695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985695,0.00002205478,0.000019673033,0.000029463965,0.000055166274,0.000016643822],"domain_scores_gemma":[0.99982387,0.00007155878,0.000030291862,0.00000535802,0.00004822573,0.000020666675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039254027,0.0006701937,0.0012402318,0.0018432997,0.00023954318,0.0008451552,0.00067131396,0.00065143616,0.004694193],"category_scores_gemma":[0.0005925267,0.0001800462,0.00040956613,0.0017009217,0.0002850395,0.00084076996,0.000544406,0.001281604,0.0029391032],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004903743,0.000027376416,0.00012366584,0.01347077,0.00007052835,0.00011754193,0.000022318593,0.000117403695,0.0006153817,0.0013004051,0.05467763,0.9294079],"study_design_scores_gemma":[0.000025140173,0.00004997256,0.0007581347,0.005364583,0.00011889911,0.0018565996,0.000027953525,0.00003617103,0.00020080929,0.00085732364,0.99069196,0.000012412479],"about_ca_topic_score_codex":0.0012173592,"about_ca_topic_score_gemma":0.0025879117,"teacher_disagreement_score":0.004694193,"about_ca_system_score_codex":0.00061440404,"about_ca_system_score_gemma":0.0010000574,"threshold_uncertainty_score":0.015703619},"labels":[],"label_agreement":null},{"id":"W4384069921","doi":"10.1093/noajnl/vdad071.009","title":"ROBO1 CAR-T CELL THERAPY FOR TREATMENT REFRACTORY BRAIN CANCER","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cancer research; Medulloblastoma; Brain tumor; Medicine; In vivo; Cancer; Immunology; Pathology; Biology; Internal medicine","score_opus":0.056414335125963715,"score_gpt":0.4091929817051589,"score_spread":0.35277864657919517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384069921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97286844,0.013415598,0.005266963,0.00056688895,0.00019160392,0.00030481815,0.000595189,0.0003204077,0.006469958],"genre_scores_gemma":[0.98536694,0.0053626015,0.0023580599,0.00020027964,0.000042485794,0.00018214776,0.0009330204,0.00002727209,0.005527077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999368,0.000010333219,0.0000038412136,0.000008637862,0.000019369945,0.000021071262],"domain_scores_gemma":[0.9999726,0.0000029182158,0.000006332188,0.0000026191817,0.000005425979,0.000010023339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001235831,0.00028145654,0.00039870915,0.00030791564,0.00013703687,0.00030726724,0.00018254545,0.00026270203,0.0013876428],"category_scores_gemma":[0.000064023,0.000056460125,0.00020056976,0.00015161218,0.00012520075,0.00012778147,0.00012875494,0.00046175852,0.00034955403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008394043,0.0004745086,0.00089155283,0.00031848706,0.00004802167,0.00067893416,0.00009284303,0.00059215236,0.9552437,0.00057935435,0.0027275558,0.037513543],"study_design_scores_gemma":[0.00044526032,0.009069539,0.008722909,0.00006555269,0.0002175915,0.0046818405,0.000113449314,0.004193314,0.91344815,0.00034803798,0.058669545,0.000024926547],"about_ca_topic_score_codex":0.0013447765,"about_ca_topic_score_gemma":0.0021904882,"teacher_disagreement_score":0.0013876428,"about_ca_system_score_codex":0.00032553513,"about_ca_system_score_gemma":0.00031117426,"threshold_uncertainty_score":0.0046421885},"labels":[],"label_agreement":null},{"id":"W4384070397","doi":"10.1093/noajnl/vdad071.024","title":"AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Clinical trial; Immune system; Antigen; Glioblastoma; Brain tumor; Cell therapy; Cancer research; Oncology; Immunology; Internal medicine; Cell; Pathology; Biology","score_opus":0.03225344404747963,"score_gpt":0.32698748482459494,"score_spread":0.2947340407771153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384070397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99672925,0.00045474665,0.0012455069,0.000054181088,0.000028195176,0.000021957378,0.00048047196,0.00006669773,0.00091905816],"genre_scores_gemma":[0.99682057,0.00027076184,0.0004434821,0.000044280736,0.0000051605157,0.000026099066,0.00097014057,0.000012733395,0.0014068867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988365,0.000015595675,0.000014228995,0.000026258625,0.000028723576,0.000031546344],"domain_scores_gemma":[0.99993575,0.000013146757,0.000009901854,0.000012035804,0.000012837583,0.000016267644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014162874,0.00025790362,0.00025398054,0.00012098534,0.000082041435,0.00023295189,0.00012408968,0.00021307946,0.0025921257],"category_scores_gemma":[0.000104500825,0.00006274789,0.00019537398,0.00009928765,0.00012224358,0.00011827302,0.00013338453,0.00064038136,0.00053504156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004661954,0.00027768407,0.0004717785,0.000077944074,0.000020984087,0.00007888941,0.00005081577,0.00028688918,0.9929255,0.00015173563,0.00039021706,0.0048012785],"study_design_scores_gemma":[0.000052737018,0.0035589698,0.0059030335,0.000011870486,0.00006603346,0.0005855853,0.000064974185,0.0016779571,0.9837082,0.000097644006,0.004266505,0.0000065138875],"about_ca_topic_score_codex":0.000608891,"about_ca_topic_score_gemma":0.0004779896,"teacher_disagreement_score":0.0025921257,"about_ca_system_score_codex":0.00013590694,"about_ca_system_score_gemma":0.00016358492,"threshold_uncertainty_score":0.008671522},"labels":[],"label_agreement":null},{"id":"W4384131434","doi":"10.1186/s41231-023-00150-y","title":"Feasibility of manufacture of chimeric antigen receptor-regulatory T cells from patients with end-stage renal disease","year":2023,"lang":"en","type":"article","venue":"Translational Medicine Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; Etablissement Français du Sang; Sangamo Therapeutics","keywords":"Transplantation; Human leukocyte antigen; Chimeric antigen receptor; Population; Medicine; End stage renal disease; Immunology; Cell therapy; Antigen; FOXP3; Kidney transplantation; T cell; Biology; Cell; Internal medicine; Disease; Immune system","score_opus":0.06671789336631592,"score_gpt":0.3459377385188726,"score_spread":0.2792198451525567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384131434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933717,0.00032285426,0.00397002,0.00006909936,0.00003364199,0.0003459119,0.00014255823,0.00007218892,0.0016719041],"genre_scores_gemma":[0.9956648,0.00006976666,0.0029751954,0.00012819894,0.000022937968,0.00014087206,0.00037698512,0.000015265472,0.0006059974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99951565,0.00019651084,0.000040886694,0.0000919,0.000104250925,0.000050795876],"domain_scores_gemma":[0.9993118,0.0002774508,0.00006148858,0.00011962578,0.00010318467,0.00012647515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001649216,0.0002347586,0.00026417008,0.00024932664,0.00026192173,0.0006096259,0.00026032166,0.00025984086,0.0025678826],"category_scores_gemma":[0.0021598244,0.00014383091,0.00025312355,0.00012421008,0.00018899323,0.00019645895,0.00031949984,0.00039050687,0.0007488132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021798354,0.003183873,0.12990381,0.0003124789,0.00011458811,0.0026294487,0.0013247925,0.0019222116,0.6683969,0.0009580091,0.0026557692,0.16679984],"study_design_scores_gemma":[0.0049102013,0.10541966,0.28679326,0.00015853105,0.00046214013,0.0103856465,0.0011450335,0.013802655,0.5409089,0.00078806235,0.03515781,0.00006814461],"about_ca_topic_score_codex":0.00021861444,"about_ca_topic_score_gemma":0.00023861541,"teacher_disagreement_score":0.0025678826,"about_ca_system_score_codex":0.00018984155,"about_ca_system_score_gemma":0.0003561129,"threshold_uncertainty_score":0.008722007},"labels":[],"label_agreement":null},{"id":"W4384134344","doi":"10.58931/cht.2023.2232","title":"Cellular therapy in CLL/iNHL: Therapeutic agents in the pipeline","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Chimeric antigen receptor; Mantle cell lymphoma; Lymphoma; Chronic lymphocytic leukemia; Oncology; Refractory (planetary science); Immunology; Internal medicine; Immunotherapy; Leukemia; Immune system","score_opus":0.07791951657750991,"score_gpt":0.3436069837462599,"score_spread":0.26568746716875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134344","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051408345,0.8152458,0.0021959667,0.11585601,0.004329436,0.0001601872,0.0005457999,0.00030260498,0.05622338],"genre_scores_gemma":[0.03454001,0.89258915,0.0056520714,0.029721877,0.0030762956,0.00013731056,0.0008785458,0.00008752588,0.033317294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991442,0.00012726779,0.00003494238,0.00006056746,0.000369912,0.00026309758],"domain_scores_gemma":[0.99797136,0.00027531618,0.00011105474,0.000043746775,0.0008669734,0.0007316086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021054307,0.0005748144,0.00064133754,0.0014621608,0.0012991404,0.0031189674,0.0008040755,0.0019376249,0.019941771],"category_scores_gemma":[0.0019037557,0.00017799038,0.00050101976,0.0014118925,0.001595154,0.0019158464,0.0017479914,0.0045581535,0.0039774105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004547047,0.00033338685,0.0008138428,0.0011863713,0.000034293676,0.00043309637,0.00024861834,0.0006137103,0.0057792766,0.030889483,0.19604768,0.76316553],"study_design_scores_gemma":[0.00010123897,0.0002966922,0.0006616182,0.00061772804,0.00002719685,0.00028077824,0.000121901656,0.00021097355,0.0011585489,0.0026542814,0.9938543,0.00001476887],"about_ca_topic_score_codex":0.10318743,"about_ca_topic_score_gemma":0.25966838,"teacher_disagreement_score":0.10318743,"about_ca_system_score_codex":0.011087515,"about_ca_system_score_gemma":0.020291248,"threshold_uncertainty_score":0.20517367},"labels":[],"label_agreement":null},{"id":"W4384463921","doi":"10.58931/cht.2022.1214","title":"Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Medicine; Rituximab; Lymphoma; Vincristine; Internal medicine; Oncology; Cyclophosphamide; Chemotherapy; Refractory (planetary science); Salvage therapy; Prednisone; CHOP; Autologous stem-cell transplantation","score_opus":0.01717987800143865,"score_gpt":0.27041674975359287,"score_spread":0.2532368717521542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463921","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6749475,0.1622351,0.009782253,0.013224996,0.0024444438,0.000964988,0.0009816404,0.0016374685,0.1337817],"genre_scores_gemma":[0.9499873,0.026174454,0.0027775113,0.002986321,0.00040544785,0.00016269211,0.001077275,0.000055236243,0.016373804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999274,0.000013176469,0.000002643061,0.0000060063007,0.000024063567,0.000026677631],"domain_scores_gemma":[0.9999436,0.000006935352,0.0000071368368,0.0000045084284,0.000011241813,0.000026613672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022415568,0.00018215511,0.00032516418,0.00030492072,0.0003100327,0.00025972148,0.00033782364,0.00036327148,0.003961583],"category_scores_gemma":[0.00018154165,0.000046147325,0.00026176768,0.00026806566,0.00020021303,0.0001769917,0.00016624363,0.00070970826,0.0010548403],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036482783,0.0015226457,0.0034427107,0.0005499033,0.00020455007,0.0036859224,0.00019407383,0.0016703849,0.031152664,0.0030104127,0.06705559,0.883863],"study_design_scores_gemma":[0.014419912,0.021555496,0.08560919,0.0005322147,0.00047253797,0.024822649,0.00037014665,0.010846474,0.028156227,0.00473971,0.8083688,0.000106626845],"about_ca_topic_score_codex":0.011695055,"about_ca_topic_score_gemma":0.028996771,"teacher_disagreement_score":0.011695055,"about_ca_system_score_codex":0.0014040907,"about_ca_system_score_gemma":0.0008051996,"threshold_uncertainty_score":0.023253977},"labels":[],"label_agreement":null},{"id":"W4384925159","doi":"10.1186/s12967-023-04329-7","title":"Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)","year":2023,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; National Institutes of Health; Eisai; MacroGenics; Moderna; Apellis Pharmaceuticals; Incyte; Sanofi; Exelixis; Regeneron Pharmaceuticals; Gilead Sciences; BeiGene; Bristol-Myers Squibb; AstraZeneca; Celldex Therapeutics; Amgen; University of Texas MD Anderson Cancer Center; Pfizer; National Cancer Institute; Emory University","keywords":"Immunotherapy; Medicine; Immune system; Cancer immunotherapy; Melanoma; Adoptive immunotherapy; Immunology; Cancer research","score_opus":0.05524501084084582,"score_gpt":0.36268935682250625,"score_spread":0.3074443459816604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384925159","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002091323,0.21036184,0.0013072282,0.25519022,0.4743738,0.00040661733,0.0014927386,0.00021265387,0.054563556],"genre_scores_gemma":[0.012191964,0.14107527,0.0026428057,0.120386004,0.34315717,0.00042792142,0.0026906338,0.00021407899,0.37721413],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988943,0.00015785918,0.00006194187,0.00017955282,0.00041181935,0.000294678],"domain_scores_gemma":[0.99818856,0.00013678637,0.00008956761,0.000030854535,0.00051270076,0.0010414026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002857697,0.0017092997,0.00062375085,0.0008347171,0.000781956,0.003015474,0.0009608329,0.005997026,0.032491494],"category_scores_gemma":[0.0014240647,0.00036540255,0.0010039556,0.00043107435,0.0003965514,0.0017938559,0.0016317966,0.0054992433,0.019851774],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012897832,0.00006187303,0.00014082484,0.00022244304,0.0000080420405,0.00016115588,0.000013159539,0.00005667093,0.00073307496,0.00044367538,0.9630303,0.034999743],"study_design_scores_gemma":[0.000034380173,0.000072094765,0.0007779767,0.00014361556,0.000009176632,0.00014846267,0.00003146342,0.000051865405,0.00028249403,0.00030391265,0.99813545,0.000009223036],"about_ca_topic_score_codex":0.0014747208,"about_ca_topic_score_gemma":0.0032597245,"teacher_disagreement_score":0.032491494,"about_ca_system_score_codex":0.0014048463,"about_ca_system_score_gemma":0.0031050472,"threshold_uncertainty_score":0.10869491},"labels":[],"label_agreement":null},{"id":"W4385063875","doi":"10.1002/pbc.30577","title":"Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation","year":2023,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Transplantation; Oncology; Stem cell; Umbilical cord; Minimal residual disease; Leukemia; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Immunology","score_opus":0.10202665111422239,"score_gpt":0.3807347684414044,"score_spread":0.27870811732718204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385063875","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014630131,0.056917492,0.0026302035,0.6210781,0.18593383,0.00031283702,0.0018310193,0.00069593696,0.12913767],"genre_scores_gemma":[0.017360743,0.093088746,0.015622273,0.30349234,0.11067606,0.0007162408,0.0045807394,0.0010097786,0.45345312],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99407345,0.0009317571,0.00028138678,0.0005582439,0.0030293448,0.0011258285],"domain_scores_gemma":[0.9837796,0.0024877125,0.0007898382,0.00086142274,0.0049143774,0.007167062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0069224685,0.0012155003,0.00092302624,0.0020124959,0.001801719,0.0049381587,0.0014617975,0.008548452,0.043300863],"category_scores_gemma":[0.010597713,0.0006185631,0.0010265689,0.0015060495,0.0020505278,0.0023157473,0.0030707696,0.013198145,0.018986853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005177745,0.000022004555,0.00013582387,0.000045415745,0.0000072906196,0.000059223818,0.000008138914,0.000035529658,0.0002067329,0.003387257,0.9589809,0.037059873],"study_design_scores_gemma":[0.000042593292,0.00003559091,0.0003458292,0.000120920326,0.00000477143,0.00011960187,0.000010584599,0.00003590767,0.00018908404,0.0008441684,0.99824345,0.00000752464],"about_ca_topic_score_codex":0.006336435,"about_ca_topic_score_gemma":0.017631615,"teacher_disagreement_score":0.043300863,"about_ca_system_score_codex":0.0066890293,"about_ca_system_score_gemma":0.01982672,"threshold_uncertainty_score":0.14485586},"labels":[],"label_agreement":null},{"id":"W4385302690","doi":"10.1038/s41591-023-02452-y","title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health","keywords":"Mesothelin; Medicine; Internal medicine; Pneumonitis; Interim analysis; Pembrolizumab; Oncology; Cytokine release syndrome; Clinical endpoint; Refractory (planetary science); Gastroenterology; Cancer; Clinical trial; Chimeric antigen receptor; Immunotherapy; Lung","score_opus":0.03486724585317036,"score_gpt":0.3866904057862175,"score_spread":0.35182315993304714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385302690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97589695,0.0038575109,0.0030531872,0.0019515133,0.00032666745,0.005618799,0.0045200274,0.00036881803,0.004406584],"genre_scores_gemma":[0.9680811,0.0026385544,0.0044838395,0.0025260525,0.00031344203,0.0072473115,0.0076167,0.0001031986,0.0069898227],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955255,0.00020039082,0.000022436017,0.00004653158,0.00006341108,0.00011471744],"domain_scores_gemma":[0.9994629,0.00012371413,0.00009103561,0.000047372014,0.000050428687,0.00022461762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002408781,0.0012288111,0.0012842036,0.00026272156,0.0003824315,0.0010988866,0.0006107381,0.0016833801,0.00251979],"category_scores_gemma":[0.00085218175,0.00027787275,0.00087626884,0.0001807373,0.000562686,0.00068861106,0.00027598394,0.0019557637,0.00074055995],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4074588,0.0588406,0.014407076,0.0024477586,0.0020383014,0.0020075645,0.0009234366,0.009969996,0.2382058,0.0019171439,0.039725453,0.22205806],"study_design_scores_gemma":[0.33943266,0.5868815,0.01839442,0.00014929054,0.0005985662,0.001077731,0.00010757815,0.0058117583,0.028219791,0.00096863747,0.01829672,0.00006133396],"about_ca_topic_score_codex":0.00049839925,"about_ca_topic_score_gemma":0.0010996908,"teacher_disagreement_score":0.00251979,"about_ca_system_score_codex":0.00055600354,"about_ca_system_score_gemma":0.0010967901,"threshold_uncertainty_score":0.012739062},"labels":[],"label_agreement":null},{"id":"W4385406834","doi":"10.1111/imr.13254","title":"Eras of designer Tregs: Harnessing synthetic biology for immune suppression","year":2023,"lang":"en","type":"review","venue":"Immunological Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Breakthrough T1D Canada; Canadian Institutes of Health Research; Juvenile Diabetes Research Foundation Canada","keywords":"FOXP3; Biology; Genome editing; Immunology; Autoimmunity; Chimeric antigen receptor; Immune system; Immune tolerance; Antigen; Immunotherapy; Computational biology; CRISPR; Genetics","score_opus":0.3221200108650642,"score_gpt":0.4857176525348458,"score_spread":0.16359764166978158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385406834","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036057286,0.99616265,0.00086626416,0.00042246984,0.0003662774,0.0000059592107,0.000009944942,0.0000185658,0.0017873576],"genre_scores_gemma":[0.0030054473,0.9938558,0.0008934235,0.0004920315,0.0002808866,0.000015357586,0.00002584042,0.000005046603,0.0014260457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997706,0.000052433374,0.000016910752,0.000035149573,0.00009645326,0.000028532773],"domain_scores_gemma":[0.9998512,0.000081757986,0.000017652425,0.000006332615,0.000027284661,0.000015679203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006629381,0.0006697939,0.0007630414,0.0011820084,0.0002239158,0.00080384495,0.0005934374,0.0009631559,0.0019024498],"category_scores_gemma":[0.00046034492,0.00023929958,0.00041282564,0.00081088673,0.0005916212,0.0014153004,0.00063670287,0.0020047256,0.0014062084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011998214,0.00012774955,0.0001361296,0.01223445,0.00007403067,0.0003586664,0.00017391062,0.00096563174,0.021552451,0.044591103,0.028484713,0.8911812],"study_design_scores_gemma":[0.000015494747,0.0001216152,0.00015866167,0.0010040377,0.000029195138,0.0007174702,0.000043887485,0.00015873158,0.003282485,0.0050491528,0.989403,0.000016335463],"about_ca_topic_score_codex":0.00039743545,"about_ca_topic_score_gemma":0.00061202416,"teacher_disagreement_score":0.0019024498,"about_ca_system_score_codex":0.00061327167,"about_ca_system_score_gemma":0.00068122114,"threshold_uncertainty_score":0.0063643456},"labels":[],"label_agreement":null},{"id":"W4385477467","doi":"10.1097/tp.0000000000004709","title":"Human A2-CAR T Cells Reject HLA-A2+ Human Islets Transplanted Into Mice Without Inducing Graft-versus-host Disease","year":2023,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Alberta","funders":"Breakthrough T1D Canada; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Manpei Suzuki Diabetes Foundation; Genome British Columbia; Stem Cell Network; BC Children's Hospital; Juvenile Diabetes Research Foundation Canada","keywords":"Graft-versus-host disease; Host (biology); Islet; Human leukocyte antigen; Immunology; Human disease; Disease; Transplantation; Biology; Graft vs Host Reaction; Virology; Medicine; Diabetes mellitus; Antigen; Pathology; Genetics; Surgery; Bone marrow transplantation; Endocrinology","score_opus":0.04540071783670685,"score_gpt":0.35078925815447654,"score_spread":0.3053885403177697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385477467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950537,0.0007718812,0.002827876,0.000052905685,0.000059519443,0.000042058986,0.00018615114,0.00015662647,0.00084925763],"genre_scores_gemma":[0.99523675,0.0003417185,0.0017832781,0.00012058866,0.000030821524,0.0000633879,0.0004016932,0.000044676694,0.0019768875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996592,0.00004913748,0.000033245768,0.00010817738,0.000068156514,0.000082102604],"domain_scores_gemma":[0.9997243,0.00007068502,0.00006121825,0.000058368583,0.00002097329,0.000064386695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004502162,0.0006267581,0.00040929543,0.00019056462,0.000119344986,0.00046308312,0.00018963496,0.0005724871,0.0020189984],"category_scores_gemma":[0.00022936385,0.00015330505,0.00032749158,0.000111036316,0.00026505688,0.0003150417,0.00020260624,0.0010739865,0.00046383176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005261612,0.00019566981,0.0003314063,0.00003807414,0.000017061684,0.000056174922,0.000035859353,0.00016571712,0.9970239,0.00007136111,0.000105026455,0.0014334909],"study_design_scores_gemma":[0.000116691794,0.0032060132,0.00297552,0.000013559657,0.000044664648,0.00043142567,0.00004415212,0.0027934997,0.98826176,0.00005851616,0.0020460556,0.000008077437],"about_ca_topic_score_codex":0.0003359368,"about_ca_topic_score_gemma":0.0002749088,"teacher_disagreement_score":0.0020189984,"about_ca_system_score_codex":0.00018409536,"about_ca_system_score_gemma":0.00022672016,"threshold_uncertainty_score":0.00675416},"labels":[],"label_agreement":null},{"id":"W4385552853","doi":"10.51731/cjht.2023.706","title":"Ciltacabtagene Autoleucel (Carvykti)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Drug; Refractory (planetary science); Antibody therapy; Intensive care medicine; Pharmacology; Antibody; Immunology; Health care; Monoclonal antibody; Political science","score_opus":0.0766381167478992,"score_gpt":0.36080694697566534,"score_spread":0.2841688302277662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385552853","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018585175,0.690366,0.0028883668,0.010292054,0.003669745,0.00054488593,0.0053563034,0.0009243153,0.26737309],"genre_scores_gemma":[0.1997112,0.46771485,0.008570236,0.01835847,0.0013946462,0.0005422614,0.012068679,0.00020458808,0.29143506],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973935,0.0000291045,0.000019705341,0.000035215544,0.00013368475,0.000042951193],"domain_scores_gemma":[0.9996985,0.000047874462,0.00006134998,0.000010537305,0.0001133455,0.000068347836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004344468,0.0002780262,0.00030996266,0.00090940984,0.00026426103,0.0010235992,0.0004810968,0.00064900535,0.02075148],"category_scores_gemma":[0.0005149517,0.00008253541,0.00040805148,0.00058178883,0.00033375475,0.0004546324,0.00031181067,0.00066109456,0.004216927],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074123655,0.00009624154,0.0008865274,0.0032720347,0.000079680285,0.00023434487,0.000036471178,0.00015636331,0.010525295,0.004538561,0.1609277,0.8185055],"study_design_scores_gemma":[0.00030277707,0.0006605342,0.003339732,0.00069472764,0.00007540269,0.0006150668,0.00003135859,0.0001412139,0.0050633545,0.0002588345,0.98880184,0.0000151598315],"about_ca_topic_score_codex":0.024794914,"about_ca_topic_score_gemma":0.08992351,"teacher_disagreement_score":0.97520506,"about_ca_system_score_codex":0.0022713696,"about_ca_system_score_gemma":0.0033143405,"threshold_uncertainty_score":0.069420576},"labels":[],"label_agreement":null},{"id":"W4385578304","doi":"10.1093/noajnl/vdad070.128","title":"SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Calgary; University of Toronto; McMaster University","funders":"","keywords":"Cancer research; Downregulation and upregulation; Immune system; Biology; Glioma; Immunotherapy; Tumor microenvironment; Cell culture; In vivo; Immunology","score_opus":0.01791703292439036,"score_gpt":0.283449173471124,"score_spread":0.2655321405467337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385578304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93737006,0.001880495,0.034126617,0.00033697928,0.00016069246,0.0002496044,0.0138074625,0.0033207985,0.008747394],"genre_scores_gemma":[0.9500874,0.0010826073,0.024094334,0.00021456987,0.00002682933,0.00076183904,0.012439641,0.00039097044,0.010901768],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999747,0.000025588452,0.000018872455,0.00008380749,0.000069470574,0.000055250763],"domain_scores_gemma":[0.9999027,0.00001393519,0.000024294526,0.0000116509955,0.000021126098,0.000026223343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040549782,0.0003150633,0.00046314628,0.00036225078,0.00024173173,0.00072874076,0.00033919569,0.00042821458,0.0068032513],"category_scores_gemma":[0.00016563288,0.00018786387,0.00036693554,0.0003363268,0.00023096387,0.00025205454,0.00022633681,0.0005808204,0.0021304574],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082369643,0.000090227724,0.0021441074,0.00023044871,0.000027815573,0.00007054256,0.0000884031,0.0006153642,0.9822527,0.0007214863,0.0017032339,0.011231893],"study_design_scores_gemma":[0.00015078128,0.0013089458,0.014320875,0.000022461405,0.00010659871,0.00027813786,0.00007128566,0.015867857,0.94813955,0.0004001203,0.01930405,0.000029356246],"about_ca_topic_score_codex":0.0009952234,"about_ca_topic_score_gemma":0.0013278333,"teacher_disagreement_score":0.0068032513,"about_ca_system_score_codex":0.0004203137,"about_ca_system_score_gemma":0.00045377857,"threshold_uncertainty_score":0.02275914},"labels":[],"label_agreement":null},{"id":"W4385578484","doi":"10.1093/noajnl/vdad070.133","title":"SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Clinical trial; Immunotherapy; Immune system; Antigen; T cell; Cell therapy; Cancer research; Immunology; Oncology; Internal medicine; Cell; Biology","score_opus":0.05064917220828051,"score_gpt":0.33389486940954705,"score_spread":0.2832456972012665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385578484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862586,0.0006787689,0.009877599,0.00011181721,0.000054276687,0.000115483344,0.0007149231,0.0002128452,0.0019755366],"genre_scores_gemma":[0.99268085,0.0003483735,0.0035038765,0.00006658837,0.0000069826388,0.00007806344,0.00105834,0.000045779358,0.002211133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987805,0.000017973385,0.000012127859,0.000025576923,0.00003955346,0.000026685197],"domain_scores_gemma":[0.9999454,0.000008040346,0.000013483834,0.000008629743,0.000011859359,0.000012662614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015963131,0.00024990592,0.00022535854,0.00016897728,0.00009968477,0.00034932853,0.00016861223,0.0002791021,0.0025448836],"category_scores_gemma":[0.00012303834,0.00009010064,0.0002121166,0.00011886027,0.00014235826,0.00012385762,0.00020155362,0.00059508707,0.00063546555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001941783,0.00009896673,0.00029483635,0.000057044235,0.000010087936,0.000092696006,0.000029831815,0.00033040767,0.99370015,0.00033795627,0.0003011651,0.0045527867],"study_design_scores_gemma":[0.00003936732,0.0010600276,0.0015421648,0.000008865799,0.000047106674,0.0005573371,0.000023011642,0.0021291994,0.98478556,0.00009044606,0.009710278,0.0000067289584],"about_ca_topic_score_codex":0.0004281066,"about_ca_topic_score_gemma":0.00040815517,"teacher_disagreement_score":0.0025448836,"about_ca_system_score_codex":0.00017039005,"about_ca_system_score_gemma":0.00023116126,"threshold_uncertainty_score":0.008513451},"labels":[],"label_agreement":null},{"id":"W4385620600","doi":"10.1080/10428194.2023.2234528","title":"Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Rituximab; Gemcitabine; Chimeric antigen receptor; Salvage therapy; Regimen; Clinical trial; Diffuse large B-cell lymphoma; Lymphoma; Chemotherapy regimen; Chemotherapy; Refractory (planetary science); Immunotherapy; Cancer; Biology","score_opus":0.1039930813529429,"score_gpt":0.3912292872957763,"score_spread":0.2872362059428334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385620600","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07481768,0.9185145,0.0025727903,0.00066229946,0.00060883106,0.0004934246,0.001300354,0.000098442724,0.00093174144],"genre_scores_gemma":[0.8678625,0.124591485,0.0030101324,0.0011212261,0.0003992384,0.0008608339,0.0016064201,0.00007879506,0.0004692637],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98388577,0.011492503,0.002063015,0.001435741,0.0007924882,0.000330449],"domain_scores_gemma":[0.9800326,0.015380502,0.002697954,0.00092271867,0.0005828234,0.00038336773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021147287,0.0026494775,0.013202126,0.0031459702,0.0003649265,0.0029923138,0.0018555076,0.0019021066,0.002342359],"category_scores_gemma":[0.025763936,0.001118085,0.036044654,0.0035042695,0.0006885592,0.0017232939,0.0013052294,0.0022608538,0.00024383588],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017357493,0.000034493874,0.0046581263,0.022141954,0.94933975,0.000051756113,0.000026609388,0.0011051659,0.00022736298,0.00008217024,0.00026951835,0.0047056666],"study_design_scores_gemma":[0.0037959374,0.00057733885,0.004162691,0.0012330724,0.9883597,0.000040021936,0.000024937694,0.00072306924,0.00013099267,0.00027371998,0.00066240405,0.0000162056],"about_ca_topic_score_codex":0.0027419613,"about_ca_topic_score_gemma":0.004002572,"teacher_disagreement_score":0.021147287,"about_ca_system_score_codex":0.0017433986,"about_ca_system_score_gemma":0.00093502627,"threshold_uncertainty_score":0.11183888},"labels":[],"label_agreement":null},{"id":"W4385644673","doi":"10.1097/01.hs9.0000967692.36989.7b","title":"S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Refractory (planetary science); Lenalidomide; Population; Multiple myeloma","score_opus":0.012653030857564059,"score_gpt":0.2517735670351252,"score_spread":0.23912053617756115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969709,0.0016941513,0.00008261615,0.00009850362,0.000038624086,0.00005409446,0.0003715641,0.000010582392,0.00067889463],"genre_scores_gemma":[0.99816257,0.0003512096,0.00015131585,0.00020359462,0.000057569563,0.000058850823,0.0005580704,0.0000033407396,0.00045347222],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995957,0.00016504688,0.000028452087,0.000073974974,0.00005007765,0.00008680943],"domain_scores_gemma":[0.9995018,0.00014733676,0.00014036236,0.000042559954,0.000019412437,0.00014851768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009986203,0.00025436585,0.00077227835,0.00028721255,0.00015713615,0.00075461133,0.00034023807,0.0005077471,0.0026831387],"category_scores_gemma":[0.0007418784,0.00012517889,0.001680365,0.00026546937,0.00026031173,0.00041036238,0.00030613333,0.0007980045,0.0002749924],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7308421,0.003788345,0.14108609,0.0005218867,0.005555495,0.00027057485,0.00018804254,0.0016868373,0.010397964,0.000314715,0.0025208734,0.10282699],"study_design_scores_gemma":[0.09424422,0.27508214,0.59825104,0.0002577814,0.0073288893,0.0013375875,0.00034431688,0.006508693,0.0053318883,0.0009261846,0.010314992,0.00007218052],"about_ca_topic_score_codex":0.00056869705,"about_ca_topic_score_gemma":0.0020196624,"teacher_disagreement_score":0.0026831387,"about_ca_system_score_codex":0.0007484676,"about_ca_system_score_gemma":0.0005034157,"threshold_uncertainty_score":0.008975983},"labels":[],"label_agreement":null},{"id":"W4385644849","doi":"10.1097/01.hs9.0000967680.90062.ca","title":"S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); CD38; Gastroenterology; Lenalidomide; Multiple myeloma; CD34","score_opus":0.020957787947047585,"score_gpt":0.2764088675186831,"score_spread":0.2554510795716355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8545604,0.092835225,0.00157151,0.0045668366,0.0006554187,0.0010372095,0.023702806,0.0003548721,0.020715766],"genre_scores_gemma":[0.9265093,0.022858618,0.0034125787,0.004272564,0.0007700464,0.0005630814,0.03732314,0.000112474176,0.00417812],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992716,0.00025570343,0.000099027595,0.000101270445,0.00018651229,0.00008595694],"domain_scores_gemma":[0.9989599,0.00021896015,0.0003398661,0.000044558885,0.00024683872,0.00018979824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021981942,0.00049312646,0.0012319244,0.00053721544,0.00019303143,0.0010437135,0.0005906485,0.0005495831,0.0037299197],"category_scores_gemma":[0.0015103228,0.00018046575,0.0018489602,0.0007991669,0.00014453277,0.0005455309,0.0004033104,0.000696841,0.0009927833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08775925,0.0017386881,0.16806154,0.0065392884,0.01016088,0.0008684214,0.0003329404,0.0038888038,0.014620711,0.00032453137,0.0538687,0.6518363],"study_design_scores_gemma":[0.028010279,0.05936745,0.6817443,0.002762839,0.023878472,0.0054462166,0.0003678967,0.004639166,0.01358001,0.0006906331,0.17932566,0.00018715407],"about_ca_topic_score_codex":0.001797965,"about_ca_topic_score_gemma":0.004624998,"teacher_disagreement_score":0.0037299197,"about_ca_system_score_codex":0.0010061393,"about_ca_system_score_gemma":0.00077120133,"threshold_uncertainty_score":0.012477815},"labels":[],"label_agreement":null},{"id":"W4385666327","doi":"10.1097/01.hs9.0000967372.19440.62","title":"S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Blinatumomab; Internal medicine; Minimal residual disease; Oncology; Rituximab; Induction chemotherapy; Chemotherapy; Acute lymphocytic leukemia; Chemotherapy regimen; Lymphoblastic Leukemia; Leukemia; Lymphoma","score_opus":0.017448307798226627,"score_gpt":0.27229854191145964,"score_spread":0.254850234113233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99408036,0.0033606743,0.00010065272,0.0003297564,0.00010594915,0.00019546926,0.0005117249,0.00004976484,0.0012656766],"genre_scores_gemma":[0.9955729,0.0012766247,0.00021547808,0.0003742984,0.00010627005,0.00011942749,0.001115606,0.000010547678,0.0012087433],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9998441,0.00006374582,0.000017755154,0.000020534831,0.00002094286,0.000032924756],"domain_scores_gemma":[0.99973613,0.00005460945,0.0000751127,0.000018867067,0.00001561321,0.00009973124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000525539,0.0004313341,0.0011851292,0.00021803199,0.00013707308,0.0005476145,0.00036082044,0.0006404848,0.0070863627],"category_scores_gemma":[0.0005680359,0.0001442186,0.0010022512,0.00031975,0.00020745026,0.00038781535,0.00023920857,0.0008452592,0.00077017973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6499733,0.008477923,0.02607103,0.0015176128,0.002100201,0.00026583776,0.0001737018,0.0017797932,0.028782537,0.0002343615,0.004517182,0.2761065],"study_design_scores_gemma":[0.25154993,0.46127862,0.24344282,0.0005441529,0.0060308664,0.0012567397,0.0002451787,0.0035651168,0.017679997,0.00045929986,0.01386318,0.00008420184],"about_ca_topic_score_codex":0.00061917206,"about_ca_topic_score_gemma":0.0017750807,"teacher_disagreement_score":0.0070863627,"about_ca_system_score_codex":0.00039241285,"about_ca_system_score_gemma":0.00054225937,"threshold_uncertainty_score":0.023706257},"labels":[],"label_agreement":null},{"id":"W4385667275","doi":"10.1097/01.hs9.0000972412.18474.98","title":"P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Medicine; Immunotherapy; Cytokine; Lymphoma; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.03743959570515347,"score_gpt":0.32109295928812887,"score_spread":0.2836533635829754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983596,0.00044544152,0.0002092255,0.00004721514,0.000017715878,0.000016073245,0.00033976152,0.000013409836,0.00055149733],"genre_scores_gemma":[0.997106,0.00019601184,0.00028887647,0.00008206538,0.0000103200455,0.000021300953,0.0010405823,0.0000144228325,0.0012403496],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999337,0.000008901954,0.000003297945,0.000015629976,0.000017212857,0.000021280903],"domain_scores_gemma":[0.9999275,0.000010392161,0.000018650331,0.0000035818643,0.000009075233,0.00003090183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000083789884,0.0002520699,0.00027058466,0.00015971992,0.00008734227,0.0002289387,0.00011477314,0.00021458429,0.00374295],"category_scores_gemma":[0.00018279871,0.00006497901,0.00021046745,0.00011982026,0.00014008365,0.00015682467,0.000094082985,0.000339651,0.0005941672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008452142,0.00032573976,0.004410076,0.00008057044,0.000041889823,0.00028000138,0.000029513787,0.0001544705,0.9689612,0.000061762126,0.00042634815,0.01677626],"study_design_scores_gemma":[0.0010462874,0.024360064,0.20898041,0.0000336068,0.00018821897,0.004189143,0.00027541825,0.0032710985,0.7450936,0.00023414135,0.012290926,0.000037013662],"about_ca_topic_score_codex":0.00029786388,"about_ca_topic_score_gemma":0.0003035783,"teacher_disagreement_score":0.00374295,"about_ca_system_score_codex":0.00016781891,"about_ca_system_score_gemma":0.00012968635,"threshold_uncertainty_score":0.012521446},"labels":[],"label_agreement":null},{"id":"W4385667651","doi":"10.1097/01.hs9.0000971208.36694.eb","title":"P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Clinical endpoint; Phases of clinical research; Surrogate endpoint; Lymphoma; Clinical trial; Oncology; Surgery; Gastroenterology","score_opus":0.021690606153916586,"score_gpt":0.3096533414890721,"score_spread":0.2879627353351555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857211,0.010551569,0.00035225163,0.00036626976,0.000045521472,0.00021898893,0.0006188751,0.00007677088,0.0020487693],"genre_scores_gemma":[0.9939395,0.0031815767,0.00042902608,0.00032079645,0.00006644619,0.0001116257,0.0012019129,0.000012271915,0.0007366924],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99976975,0.00007722718,0.000023722072,0.00004076131,0.000042514443,0.000046038345],"domain_scores_gemma":[0.999666,0.00008095586,0.00011953085,0.000022863369,0.000031130738,0.000079552905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009771009,0.00033929874,0.0009290543,0.00021142322,0.00013781131,0.00067476387,0.00034911177,0.00035102258,0.0016820865],"category_scores_gemma":[0.00065671856,0.00015874214,0.0005641244,0.00025795918,0.0001842831,0.00041705032,0.00017995833,0.0009061952,0.0003898736],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13315257,0.0048009567,0.0704414,0.001964914,0.0025867708,0.0007763781,0.00034245494,0.0022472958,0.07938879,0.00027767595,0.011256655,0.6927641],"study_design_scores_gemma":[0.1414912,0.3087443,0.44946727,0.00056307897,0.0063619195,0.007853323,0.00035121205,0.007099793,0.027454505,0.00050900714,0.04998707,0.000117351934],"about_ca_topic_score_codex":0.0004422988,"about_ca_topic_score_gemma":0.0017336146,"teacher_disagreement_score":0.0016820865,"about_ca_system_score_codex":0.0005865012,"about_ca_system_score_gemma":0.0004383852,"threshold_uncertainty_score":0.0056270957},"labels":[],"label_agreement":null},{"id":"W4385667659","doi":"10.1097/01.hs9.0000972428.19857.ae","title":"P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Oncology; Chimeric antigen receptor; Internal medicine; Immunotherapy; Immunology; Cytokine; Immune system","score_opus":0.04156970555081718,"score_gpt":0.32604922160139255,"score_spread":0.28447951605057537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99886775,0.00020005157,0.00014818671,0.000029577704,0.0000049471364,0.000016869624,0.00018213844,0.000009132247,0.0005413145],"genre_scores_gemma":[0.9986638,0.000049458748,0.00010035288,0.000040732688,0.0000063040115,0.000019793886,0.00058954005,0.000004635011,0.0005253551],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998646,0.000018094544,0.000010343298,0.000040951392,0.000030492338,0.000035524972],"domain_scores_gemma":[0.9997093,0.00005990443,0.00008787194,0.00002701969,0.000026207546,0.00008967481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018713051,0.0001488714,0.00024681928,0.00016336156,0.00012991519,0.00029335942,0.0001788171,0.0002953812,0.0029396426],"category_scores_gemma":[0.00046705303,0.00008270905,0.0002214679,0.00015025488,0.00018264557,0.0002369972,0.00018421265,0.0005672446,0.0005371476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032059345,0.002290258,0.37407845,0.00020203186,0.00020944297,0.0046197134,0.00043246336,0.0009484086,0.45841217,0.0005831086,0.0027488086,0.12341573],"study_design_scores_gemma":[0.0008469788,0.021635968,0.8740679,0.000021751084,0.00014171022,0.0113204345,0.00032988228,0.0022042948,0.08257015,0.00033543463,0.0064995573,0.000025935202],"about_ca_topic_score_codex":0.00037697336,"about_ca_topic_score_gemma":0.0004321968,"teacher_disagreement_score":0.0029396426,"about_ca_system_score_codex":0.00036516227,"about_ca_system_score_gemma":0.00018646564,"threshold_uncertainty_score":0.009834051},"labels":[],"label_agreement":null},{"id":"W4385686800","doi":"10.4049/jimmunol.210.supp.226.07","title":"What did the T cell see? A deep-learning model of CD8+ T cell activation reveals sharp antigen discrimination at the single cell level","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Antigenicity; Antigen; Flow cytometry; Cytotoxic T cell; CD8; T cell; Cancer research; Cell; Biology; Immunology; Immune system; In vitro","score_opus":0.07770327271561742,"score_gpt":0.3163797734850131,"score_spread":0.2386765007693957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385686800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8091647,0.000498678,0.18238541,0.0022686936,0.000111430774,0.000041618787,0.0005786664,0.0002892099,0.0046616164],"genre_scores_gemma":[0.99187005,0.00007611583,0.005486953,0.00014266942,0.000014523747,0.000025182073,0.00009585518,0.000012253653,0.002276324],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9999155,0.00001619194,0.0000024258845,0.0000288682,0.000008413432,0.000028642724],"domain_scores_gemma":[0.99985325,0.000068329995,0.00001842992,0.000009195476,0.000026825815,0.00002392431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003235441,0.00040901126,0.00044958582,0.00020773608,0.000189998,0.0007455535,0.00056198816,0.0011037419,0.0017199968],"category_scores_gemma":[0.0007186592,0.00022828457,0.00042918697,0.00021107074,0.0005220392,0.00059340434,0.00031122915,0.0010179295,0.00028664822],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016015476,0.00006124678,0.005603727,0.000028788034,0.000023786906,0.00011624914,0.00005166613,0.96971446,0.007418169,0.0025592304,0.0009213484,0.013341121],"study_design_scores_gemma":[0.000002631684,0.000009247137,0.00025662413,0.0000012985125,0.0000022226318,0.000006119001,0.000003529807,0.99838734,0.00031801563,0.0009522003,0.000058546797,0.0000021787903],"about_ca_topic_score_codex":0.0069978815,"about_ca_topic_score_gemma":0.0044052294,"teacher_disagreement_score":0.0069978815,"about_ca_system_score_codex":0.00079062127,"about_ca_system_score_gemma":0.0005261297,"threshold_uncertainty_score":0.013914287},"labels":[],"label_agreement":null},{"id":"W4385686994","doi":"10.4049/jimmunol.210.supp.142.09","title":"TCR/Chimeric Antigen Receptor (CAR) Cross-Antagonism to Fine-Tune CAR-T cell Immunotherapy","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Cancer immunotherapy; Immunotherapy; Receptor; T cell; Antigen; Cell biology; Biology; Cancer research; Immunology; Immune system; Biochemistry","score_opus":0.028197414559190212,"score_gpt":0.338542726784412,"score_spread":0.31034531222522177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385686994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8972416,0.0020665906,0.09397467,0.0002850848,0.00006761994,0.00007394611,0.000089987385,0.00033274083,0.0058676996],"genre_scores_gemma":[0.9920677,0.00021623516,0.0064019565,0.000059355836,0.000006913318,0.000014058652,0.000026075788,0.000018077577,0.0011896865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981445,0.000046697874,0.000010154616,0.0000363587,0.000051914667,0.000040478943],"domain_scores_gemma":[0.9999212,0.00002559999,0.000025091245,0.000009773257,0.0000071087316,0.000011278825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027494025,0.00031853508,0.00021989195,0.00021125456,0.00011252934,0.00033663507,0.0002557688,0.00036007547,0.0015628887],"category_scores_gemma":[0.00019374467,0.000116463794,0.00028515965,0.00011560507,0.00029554262,0.00021783792,0.00023114451,0.0006373841,0.0003350424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043047185,0.00006414084,0.00025298522,0.00004021046,0.00001071387,0.000047859838,0.0000087931,0.0052368958,0.9898375,0.0017972592,0.00012928764,0.0025312833],"study_design_scores_gemma":[0.00003662025,0.00032982623,0.0007840541,0.000008407081,0.000030153144,0.00035899502,0.0000139773065,0.07691947,0.9173002,0.0008061151,0.0034037833,0.000008300288],"about_ca_topic_score_codex":0.000439472,"about_ca_topic_score_gemma":0.00050870026,"teacher_disagreement_score":0.0015628887,"about_ca_system_score_codex":0.00035028328,"about_ca_system_score_gemma":0.00017073043,"threshold_uncertainty_score":0.0052284},"labels":[],"label_agreement":null},{"id":"W4385687833","doi":"10.4049/jimmunol.210.supp.145.13","title":"Can Engineering IL-2Rα Expression Improve NK Cell Immunotherapy?","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; Interleukin 21; Interleukin 12; Cancer research; Lymphokine-activated killer cell; Immunology; Cell therapy; Adoptive cell transfer; Interleukin 15; Cell; Janus kinase 3; Biology; T cell; Cell biology; Cytotoxic T cell; Cytokine; Stem cell; Immune system; In vitro; Interleukin","score_opus":0.014909143872700986,"score_gpt":0.2754549711733745,"score_spread":0.2605458273006735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385687833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93349516,0.01321345,0.043928523,0.003987914,0.000654954,0.00020101418,0.00030485188,0.0004798262,0.0037341972],"genre_scores_gemma":[0.9759,0.0050077955,0.015023474,0.0006512184,0.00009704556,0.00007483211,0.00020237878,0.00006154359,0.0029816816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971694,0.00008080741,0.000032230175,0.00004360156,0.00006110551,0.00006530144],"domain_scores_gemma":[0.99983144,0.0000377899,0.00004857917,0.000026386635,0.000031677067,0.000023985356],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049020606,0.0004313354,0.00038146388,0.00015698551,0.000106896325,0.00065768126,0.00033573495,0.00052140193,0.0014428893],"category_scores_gemma":[0.00036375356,0.00012362211,0.00033697288,0.00012415122,0.0003483038,0.00050565583,0.0001803173,0.00071945926,0.0006295596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001959158,0.00017978672,0.0004997044,0.0001572895,0.000016233404,0.00006769236,0.000021124046,0.0011727213,0.9878192,0.00055325794,0.00023551949,0.009081498],"study_design_scores_gemma":[0.00007832547,0.00079675333,0.0010058586,0.000029433184,0.000056660683,0.0002235816,0.00002856233,0.0018168606,0.9856285,0.0004276932,0.009897569,0.000010209476],"about_ca_topic_score_codex":0.00024152116,"about_ca_topic_score_gemma":0.00031111552,"teacher_disagreement_score":0.0014428893,"about_ca_system_score_codex":0.0003585542,"about_ca_system_score_gemma":0.00022263723,"threshold_uncertainty_score":0.0048269033},"labels":[],"label_agreement":null},{"id":"W4385697656","doi":"10.1097/01.hs9.0000970368.33859.48","title":"P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Multiple myeloma; Lenalidomide; Hazard ratio; Confidence interval","score_opus":0.016896486216187306,"score_gpt":0.26855701842140345,"score_spread":0.2516605322052161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723166,0.0016531863,0.00008773319,0.00010067316,0.000037888018,0.00008430847,0.0003136649,0.000008874217,0.0004819779],"genre_scores_gemma":[0.99864846,0.00030659843,0.00009157768,0.000120876095,0.000059869228,0.0000745536,0.000393836,0.0000031877023,0.00030102805],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995926,0.00016088669,0.0000376348,0.00007809134,0.000048137383,0.00008265262],"domain_scores_gemma":[0.9994025,0.00020202696,0.00016811914,0.000052942774,0.000024844398,0.00014949775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010071986,0.0002922297,0.0011344219,0.00024793702,0.00013803555,0.00066028076,0.0003436576,0.00054490357,0.002111801],"category_scores_gemma":[0.0009539151,0.00015155553,0.0021293103,0.00031137012,0.00023566373,0.00043387813,0.00031677468,0.0010239576,0.00023381192],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84997475,0.0024021575,0.07040853,0.00063757884,0.006838814,0.0001272934,0.00012798897,0.0017019104,0.0074618226,0.00014987892,0.0016224394,0.058546875],"study_design_scores_gemma":[0.17276296,0.2918625,0.50272876,0.00027160902,0.012587169,0.0009779129,0.00034871732,0.0072133224,0.0045068134,0.0009751116,0.005683422,0.00008170495],"about_ca_topic_score_codex":0.0004300575,"about_ca_topic_score_gemma":0.0011680902,"teacher_disagreement_score":0.002111801,"about_ca_system_score_codex":0.000481034,"about_ca_system_score_gemma":0.0004431405,"threshold_uncertainty_score":0.0070646405},"labels":[],"label_agreement":null},{"id":"W4385716931","doi":"10.1158/1078-0432.ccr-22-2181","title":"HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Cancer research; Reprogramming; Biology; Tumor microenvironment; Immunotherapy; T cell; CD8; Cell; Cytotoxic T cell; Transcriptome; Immunology; Immune system","score_opus":0.2326283083407908,"score_gpt":0.5135318852890013,"score_spread":0.2809035769482105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385716931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439937,0.00090347085,0.0027679843,0.000070268565,0.000039907452,0.000049109574,0.00035081967,0.00017599062,0.0012430499],"genre_scores_gemma":[0.9963814,0.0005200216,0.0011046171,0.000038636856,0.000014611292,0.000041873012,0.00033170765,0.000028061746,0.001539033],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999094,0.000006631254,0.0000063801467,0.000022406473,0.000024330533,0.000030765594],"domain_scores_gemma":[0.9999429,0.0000054883517,0.00002336977,0.000006998599,0.0000049038563,0.000016302893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000071238144,0.0004383708,0.00026379558,0.00019328135,0.00009843496,0.0002250384,0.00020859888,0.00012227459,0.0012925435],"category_scores_gemma":[0.00005423426,0.00009096247,0.0002162288,0.00012656277,0.00027065485,0.00015326485,0.00017946346,0.0005511698,0.00026314094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011385099,0.00005688846,0.00016495054,0.000034192843,0.000004488274,0.000014451909,0.0000071045324,0.00013721976,0.9971705,0.00006254413,0.000043479056,0.0021903578],"study_design_scores_gemma":[0.000029149234,0.0008582279,0.002916827,0.0000046280907,0.0000244059,0.00008545298,0.000022362881,0.0009530347,0.9934934,0.00003103666,0.0015779478,0.0000035098926],"about_ca_topic_score_codex":0.00032700362,"about_ca_topic_score_gemma":0.00088815734,"teacher_disagreement_score":0.0012925435,"about_ca_system_score_codex":0.0002585965,"about_ca_system_score_gemma":0.00023881822,"threshold_uncertainty_score":0.004324019},"labels":[],"label_agreement":null},{"id":"W4385751197","doi":"10.1158/1078-0432.ccr-23-1137","title":"Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Olaparib; Immunotherapy; Response Evaluation Criteria in Solid Tumors; Immune system; Internal medicine; Oncology; Tumor microenvironment; Toxicity; Immunology; Phases of clinical research; Nivolumab; Biology","score_opus":0.3288032443135986,"score_gpt":0.5626271940113787,"score_spread":0.23382394969778014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385751197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637514,0.0019495642,0.0001286597,0.00017808388,0.000027556101,0.00021329649,0.00038520154,0.000020485104,0.0007220129],"genre_scores_gemma":[0.9965887,0.00099611,0.00038415482,0.00024437468,0.00006321057,0.00027469287,0.0007210013,0.0000060898014,0.00072176114],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99973506,0.00014327084,0.000015868718,0.00003625568,0.000026827862,0.000042742166],"domain_scores_gemma":[0.99955636,0.000086213,0.00012891831,0.0000326662,0.00001608343,0.00017970352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011054634,0.00084443885,0.001112971,0.00019884024,0.00016610387,0.0006339707,0.00046712495,0.0005326632,0.0014864242],"category_scores_gemma":[0.000667097,0.0002681756,0.0005276345,0.00021836655,0.0005055727,0.00042462934,0.00018827936,0.0012619182,0.00027892838],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8357794,0.011617848,0.0113123,0.0007241069,0.0015415892,0.0002904362,0.00013671783,0.0019928757,0.0349219,0.00018887062,0.0024594937,0.09903438],"study_design_scores_gemma":[0.6355096,0.31776205,0.03234283,0.000056508074,0.0010799031,0.0007077296,0.00006692209,0.0021062612,0.007041107,0.00029626614,0.0029983965,0.00003242888],"about_ca_topic_score_codex":0.00042144913,"about_ca_topic_score_gemma":0.0012103751,"teacher_disagreement_score":0.0014864242,"about_ca_system_score_codex":0.0006051957,"about_ca_system_score_gemma":0.0005523596,"threshold_uncertainty_score":0.005846262},"labels":[],"label_agreement":null},{"id":"W4385839652","doi":"10.3389/fimmu.2023.1225610","title":"Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institutes of Health; UVA Cancer Center; Midwest Athletes Against Childhood Cancer; University of Virginia","keywords":"CD30; Monoclonal antibody; Antibody; Ex vivo; Immunotherapy; Epitope; Antigen; CD3; T cell; Cancer research; In vivo; Molecular biology; Chemistry; In vitro; Biology; Immunology; Immune system; Biochemistry; CD8; Tumor cells","score_opus":0.030501788103333448,"score_gpt":0.29899380660267594,"score_spread":0.2684920184993425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385839652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98590547,0.0025455146,0.007998269,0.000063704385,0.000014768798,0.00010600253,0.00018523932,0.00011912254,0.0030618287],"genre_scores_gemma":[0.9931681,0.00091496616,0.0041796467,0.00008006193,0.0000073963765,0.000051369047,0.00024879485,0.0000071897307,0.0013424285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998977,0.000018646148,0.0000069862663,0.000015694459,0.00003117542,0.000029684938],"domain_scores_gemma":[0.99996674,0.0000066196667,0.0000073916062,0.0000038068183,0.000006547526,0.000008875901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010188688,0.00027295027,0.00010917567,0.00014238515,0.000067968365,0.0001486999,0.0001323955,0.00019041204,0.00091071095],"category_scores_gemma":[0.00009024363,0.00007626194,0.0001211449,0.0001193764,0.00006427552,0.00009050865,0.00012845891,0.0003413956,0.00030427513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008990238,0.00004343276,0.00019288313,0.000027040767,0.0000036121155,0.000041748484,0.000012568901,0.00016620224,0.9939812,0.00010419573,0.000076398916,0.0052607954],"study_design_scores_gemma":[0.000032810003,0.0005937106,0.0024128342,0.000005065404,0.000013550063,0.0004121905,0.000009153265,0.0015008369,0.99025035,0.000044154556,0.004722269,0.0000030782708],"about_ca_topic_score_codex":0.00037623505,"about_ca_topic_score_gemma":0.0005778466,"teacher_disagreement_score":0.00091071095,"about_ca_system_score_codex":0.00019759436,"about_ca_system_score_gemma":0.00015031866,"threshold_uncertainty_score":0.0030465722},"labels":[],"label_agreement":null},{"id":"W4385856058","doi":"10.1097/01.hs9.0000971412.45898.1a","title":"P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Regimen; Post-hoc analysis; Internal medicine; Phases of clinical research; Clinical endpoint; Toxicity; Oncology; Nuclear medicine; Clinical trial; Surgery","score_opus":0.027672898584496907,"score_gpt":0.33315772246846176,"score_spread":0.30548482388396486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385856058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930957,0.0025685984,0.00036254284,0.00031825973,0.000053024018,0.00041923,0.0016505455,0.00008432665,0.0014477165],"genre_scores_gemma":[0.9920501,0.0010073328,0.00062109705,0.00031411045,0.00008692231,0.00032722586,0.0043925834,0.000022529457,0.0011780851],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961865,0.00019934996,0.000023884917,0.00006570504,0.00004324084,0.000049150676],"domain_scores_gemma":[0.9994609,0.000102777325,0.00015257842,0.00005503966,0.000041250016,0.00018741426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011823091,0.00054588687,0.0012379775,0.00019271199,0.00019943378,0.0008937253,0.00046569866,0.00052772835,0.0022517026],"category_scores_gemma":[0.00088169397,0.00023842392,0.0008675432,0.00035372746,0.00030432246,0.0006280054,0.00041277628,0.0015951002,0.0005710688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7068452,0.011394773,0.04691231,0.0014539339,0.003013877,0.00058042246,0.00033716773,0.0035882334,0.042889778,0.00020696112,0.010490611,0.17228672],"study_design_scores_gemma":[0.34340787,0.40607035,0.22247422,0.00015433818,0.0027863963,0.001261194,0.00014590695,0.0030426346,0.0060933465,0.00032392875,0.014151987,0.00008781362],"about_ca_topic_score_codex":0.00041079492,"about_ca_topic_score_gemma":0.0013255986,"teacher_disagreement_score":0.0022517026,"about_ca_system_score_codex":0.0005052126,"about_ca_system_score_gemma":0.0005181632,"threshold_uncertainty_score":0.007532716},"labels":[],"label_agreement":null},{"id":"W4385878518","doi":"10.3390/curroncol30080554","title":"Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Perioperative; Immunotherapy; Cancer; Intensive care medicine; Immune system; Immunology; Internal medicine; Surgery","score_opus":0.3280185255880636,"score_gpt":0.5092924379160871,"score_spread":0.18127391232802353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385878518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006538837,0.9984687,0.00007410264,0.00040094025,0.00033697332,0.0000028672382,0.0000076113165,0.0000038847156,0.0006395807],"genre_scores_gemma":[0.00050020625,0.9979619,0.00012563527,0.00041466343,0.00034152347,0.0000061225155,0.000017437398,0.000001462051,0.0006310591],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99972445,0.000054975633,0.00003446234,0.00004121995,0.000112129965,0.000032759865],"domain_scores_gemma":[0.9994715,0.00027760997,0.00005119333,0.000017660805,0.0001415738,0.000040466253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089801895,0.0008620314,0.0011932668,0.0018377738,0.00034025154,0.0013955542,0.00095813617,0.0014969733,0.003728093],"category_scores_gemma":[0.0011128024,0.0002968781,0.00061088393,0.0016756728,0.00073732814,0.0019584554,0.00076463405,0.002923739,0.0017495988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063030624,0.0000722507,0.00012287048,0.009718697,0.00005101636,0.00014961859,0.00006133428,0.00033655483,0.0013691821,0.0063769207,0.03940722,0.9422713],"study_design_scores_gemma":[0.000014751507,0.00008108386,0.00032588074,0.0031806724,0.000045954115,0.00086575444,0.000058794765,0.000075828124,0.00035337568,0.0027037032,0.9922816,0.0000125415],"about_ca_topic_score_codex":0.00089195545,"about_ca_topic_score_gemma":0.0018949981,"teacher_disagreement_score":0.003728093,"about_ca_system_score_codex":0.00080141507,"about_ca_system_score_gemma":0.0012011554,"threshold_uncertainty_score":0.0124717355},"labels":[],"label_agreement":null},{"id":"W4385955561","doi":"10.1097/01.hs9.0000972472.24418.bc","title":"P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; CD33; Plerixafor; Fludarabine; CD34; Myeloid; Hematopoietic stem cell transplantation; Stem cell; Melphalan; Busulfan; Haematopoiesis; Internal medicine; Immunology; Transplantation; Oncology; Chemotherapy; Immune system; CXCR4; Cyclophosphamide; Biology; Chemokine","score_opus":0.013684587279929656,"score_gpt":0.2551828161038957,"score_spread":0.24149822882396604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991763,0.0009778084,0.0012354092,0.00040357496,0.000101409925,0.00016588796,0.0023142828,0.00020325951,0.0028354495],"genre_scores_gemma":[0.987745,0.0006463497,0.0009434434,0.00022888658,0.000029558058,0.0001494088,0.0045321104,0.000057494766,0.0056678266],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99990225,0.000009014123,0.00000907399,0.000021264712,0.00003194645,0.00002649368],"domain_scores_gemma":[0.9999244,0.000008051534,0.00001831321,0.0000071906506,0.0000059953636,0.00003605881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014734604,0.0003649641,0.00037951153,0.00017335328,0.0002005388,0.0003107038,0.0002459079,0.0003978452,0.008228538],"category_scores_gemma":[0.00011682484,0.000118355165,0.00022055862,0.00016638571,0.00029848644,0.00024474773,0.0002603708,0.0012635299,0.0013874037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035346977,0.0010338865,0.0013661807,0.00014021157,0.000037097456,0.0004992651,0.000043595664,0.00037627682,0.968113,0.00052126526,0.0026791843,0.02165546],"study_design_scores_gemma":[0.0033271634,0.030203583,0.03890249,0.000051933835,0.00019524926,0.0084052095,0.00014567746,0.003080641,0.8652996,0.0006976249,0.04965017,0.00004068896],"about_ca_topic_score_codex":0.00042293177,"about_ca_topic_score_gemma":0.0005671935,"teacher_disagreement_score":0.008228538,"about_ca_system_score_codex":0.00028320265,"about_ca_system_score_gemma":0.0003037404,"threshold_uncertainty_score":0.027527213},"labels":[],"label_agreement":null},{"id":"W4386229155","doi":"10.33844/cjm.2023.6029","title":"Simulation-Based Software Modeling of CAR T Cell Therapy Efficacy Against Solid Malignant Tumors","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia","funders":"","keywords":"Cytotoxic T cell; CD8; Chimeric antigen receptor; Immunotherapy; Immunology; Innate immune system; Cancer research; Biology; Population; Antigen; Immune system; T cell; Medicine; In vitro","score_opus":0.059056928970759204,"score_gpt":0.33031022973351853,"score_spread":0.27125330076275933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386229155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68992054,0.0006852356,0.27528784,0.00053477014,0.000094033145,0.00022544517,0.0009973486,0.0011561427,0.031098736],"genre_scores_gemma":[0.9701866,0.00036523008,0.024588862,0.0000399989,0.00000845016,0.00022687603,0.00027976042,0.00007558227,0.0042285356],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998559,0.000045324865,0.000007549959,0.000020098327,0.000045373992,0.000025726114],"domain_scores_gemma":[0.99960047,0.00023493667,0.000047292448,0.000017259254,0.000071437185,0.00002864804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002759234,0.00051007874,0.00047940188,0.00040066798,0.0003436535,0.0006002797,0.00063074613,0.0007924892,0.0022191089],"category_scores_gemma":[0.0008769609,0.00026193322,0.00060320814,0.00033990774,0.00038182517,0.00028432297,0.00039094768,0.0003668196,0.00024578674],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016855669,0.000012870335,0.00039350003,0.000011977336,0.0000050939266,0.000017488639,0.000012863353,0.9968706,0.0009327078,0.0009361311,0.000053629774,0.00073636166],"study_design_scores_gemma":[0.000005237514,0.000010494731,0.00008017623,0.0000014470323,0.000002783135,0.0000034770283,0.0000032374435,0.9991474,0.00034312607,0.00019831018,0.00020251313,0.0000017428428],"about_ca_topic_score_codex":0.021311283,"about_ca_topic_score_gemma":0.01016567,"teacher_disagreement_score":0.021311283,"about_ca_system_score_codex":0.0010478182,"about_ca_system_score_gemma":0.0011013492,"threshold_uncertainty_score":0.04237449},"labels":[],"label_agreement":null},{"id":"W4386270762","doi":"10.1016/s2152-2650(23)00862-5","title":"POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Refractory (planetary science); Medicine; Multiple myeloma; Phase (matter); Phases of clinical research; Internal medicine; Nuclear medicine; Materials science; Chemistry; Clinical trial; Metallurgy; Organic chemistry","score_opus":0.06028986609263801,"score_gpt":0.36688599263435107,"score_spread":0.30659612654171303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93436766,0.009965156,0.0020951866,0.00854413,0.0021170897,0.007121711,0.011241559,0.0010958698,0.023451636],"genre_scores_gemma":[0.93686396,0.004860158,0.004124869,0.007003001,0.0011086583,0.0032396545,0.010095984,0.0003101057,0.032393593],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996487,0.00012696742,0.000014392913,0.00005124466,0.000038374917,0.00012027134],"domain_scores_gemma":[0.9995097,0.000070178496,0.000045945064,0.00002765893,0.000029241302,0.00031725352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013143034,0.0016487145,0.0016771109,0.00037222443,0.0006871239,0.0011578503,0.00083858095,0.0016080881,0.012850046],"category_scores_gemma":[0.00056513643,0.0004820732,0.0015813465,0.00022192512,0.0006257998,0.0006460019,0.0004548411,0.0038136027,0.0025888535],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44981143,0.061667796,0.006895874,0.0015678174,0.0027108695,0.0006745906,0.0004339886,0.0049729096,0.07991031,0.0010343096,0.104139365,0.28618076],"study_design_scores_gemma":[0.5476069,0.38200736,0.02472993,0.00013285865,0.0008573677,0.00045045489,0.00008565443,0.0021665962,0.0106133325,0.0005809661,0.030691108,0.00007748992],"about_ca_topic_score_codex":0.0021716913,"about_ca_topic_score_gemma":0.00528066,"teacher_disagreement_score":0.012850046,"about_ca_system_score_codex":0.0010920116,"about_ca_system_score_gemma":0.0016361106,"threshold_uncertainty_score":0.042987704},"labels":[],"label_agreement":null},{"id":"W4386280311","doi":"10.14740/jh1112","title":"Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma","year":2023,"lang":"en","type":"review","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of South Florida","keywords":"Rituximab; Medicine; Diffuse large B-cell lymphoma; Lymphoma; Chimeric antigen receptor; Tumor microenvironment; Immunology; Monoclonal antibody; Oncology; Immune system; Cancer research; Immunotherapy; Antibody","score_opus":0.04144877747681473,"score_gpt":0.3732354573810576,"score_spread":0.3317866799042429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386280311","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007705979,0.99959224,0.00002561623,0.00008683306,0.000039665694,0.000006032699,0.000006603117,0.0000018541033,0.00016406736],"genre_scores_gemma":[0.00065288576,0.998934,0.00011725871,0.00015079825,0.000045357585,0.000010048246,0.000010778108,5.340613e-7,0.00007841529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996637,0.00007769115,0.00008712047,0.000038601156,0.00010950504,0.00002333512],"domain_scores_gemma":[0.99966717,0.000184425,0.00007491652,0.0000062689514,0.00004987847,0.000017250266],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000661403,0.00074525794,0.00240632,0.0042770933,0.00032852602,0.0010501257,0.00089624134,0.0014182127,0.0033494302],"category_scores_gemma":[0.001103098,0.00025823037,0.0011581215,0.0033070196,0.00035837447,0.0013830246,0.0005305515,0.0010409154,0.0007593036],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015836202,0.00008427541,0.00022868703,0.18607013,0.0005884732,0.00040028393,0.00008665523,0.00016121646,0.0013881202,0.0013645503,0.01404086,0.7954284],"study_design_scores_gemma":[0.00036209056,0.00047036353,0.0030531834,0.13904639,0.0054630106,0.005785369,0.00036512036,0.00018933642,0.001498549,0.0022896398,0.84142,0.00005692251],"about_ca_topic_score_codex":0.0011487035,"about_ca_topic_score_gemma":0.002519222,"teacher_disagreement_score":0.0042770933,"about_ca_system_score_codex":0.0006422232,"about_ca_system_score_gemma":0.0013368675,"threshold_uncertainty_score":0.011204958},"labels":[],"label_agreement":null},{"id":"W4386282299","doi":"10.1016/s2152-2650(23)00880-7","title":"POSTER: CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axicel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Chimeric antigen receptor; Lymphoma; Medicine; B-cell lymphoma; Cancer research; Virology; Immunology; Internal medicine; Immunotherapy; Cancer","score_opus":0.058699882457818923,"score_gpt":0.36835500546202554,"score_spread":0.3096551230042066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93471897,0.019781157,0.00090714707,0.0054086936,0.0021738284,0.0006746111,0.009592163,0.00033307247,0.026410352],"genre_scores_gemma":[0.9733828,0.0033790418,0.00083834474,0.000989328,0.00057318417,0.0002449862,0.0040864074,0.00004760879,0.016458368],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996717,0.00016695604,0.000017567876,0.00003522992,0.0000433247,0.00006527969],"domain_scores_gemma":[0.99937505,0.0002827831,0.00008240743,0.00002499414,0.0000364796,0.00019830637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005141645,0.0004797173,0.00083495426,0.00026288017,0.00016458782,0.0006321736,0.0003686615,0.00089119596,0.03678532],"category_scores_gemma":[0.0013181374,0.00016812515,0.0014271954,0.00020666154,0.000319343,0.00039623224,0.0002134534,0.0015596709,0.0019230455],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7803095,0.005839325,0.002489518,0.0009271914,0.0011954649,0.00024305277,0.000031751446,0.0049415464,0.016053408,0.0009570202,0.024911268,0.16210084],"study_design_scores_gemma":[0.28088585,0.45252436,0.11011597,0.000891388,0.010415821,0.001979378,0.0002539977,0.018058151,0.06112285,0.0023110698,0.06125854,0.00018269011],"about_ca_topic_score_codex":0.0018343839,"about_ca_topic_score_gemma":0.0021013252,"teacher_disagreement_score":0.03678532,"about_ca_system_score_codex":0.0008962435,"about_ca_system_score_gemma":0.0009995474,"threshold_uncertainty_score":0.12305921},"labels":[],"label_agreement":null},{"id":"W4386455160","doi":"10.4049/jimmunol.2300049","title":"Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches","year":2023,"lang":"en","type":"review","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute of Allergy and Infectious Diseases; Princess Margaret Cancer Foundation; Ministry of Health, Ontario","keywords":"Cancer; Immune system; Medicine; Cancer research; Cancer cell; T cell; Immunology; Internal medicine","score_opus":0.15850057831339184,"score_gpt":0.3948356683118157,"score_spread":0.23633508999842387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386455160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015408103,0.99809116,0.00020425448,0.00041461096,0.00021877809,0.000005464069,0.000009414972,0.0000080747695,0.0008940795],"genre_scores_gemma":[0.00093865785,0.9975981,0.0002709635,0.00032317857,0.00019498017,0.000011889886,0.000016248136,0.0000021384421,0.00064381363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983037,0.000039244605,0.000016964474,0.000029818444,0.000060185186,0.000023451417],"domain_scores_gemma":[0.9997503,0.00013257832,0.000022237495,0.000008635271,0.00006024261,0.000025986938],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081033213,0.0006924166,0.0012828954,0.0018158186,0.0002570878,0.0012025177,0.0009083793,0.0015679597,0.0029306433],"category_scores_gemma":[0.0005520791,0.0002786073,0.00046066608,0.0013271158,0.0006382671,0.0016910577,0.0007456612,0.0029257399,0.0020726267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010031518,0.00010569185,0.00011058868,0.010694017,0.000059666367,0.00016189068,0.000092188966,0.0004489745,0.003991967,0.012303633,0.020324415,0.9516066],"study_design_scores_gemma":[0.000025362768,0.00019566472,0.00037779694,0.0027471515,0.000059116544,0.00072021544,0.00007431917,0.00011394013,0.00083574385,0.0039835023,0.9908501,0.000017129423],"about_ca_topic_score_codex":0.00052676344,"about_ca_topic_score_gemma":0.0009368784,"teacher_disagreement_score":0.0029306433,"about_ca_system_score_codex":0.00057449314,"about_ca_system_score_gemma":0.00078893884,"threshold_uncertainty_score":0.009803951},"labels":[],"label_agreement":null},{"id":"W4386465406","doi":"10.1172/jci.insight.167215","title":"Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection","year":2023,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Michael Smith Health Research BC; BC Children's Hospital; Canadian Institutes of Health Research; Bristol-Myers Squibb; U.S. Department of Defense","keywords":"Control (management); Computer science; Chemistry; Immunology; Cancer research; Medicine; Artificial intelligence","score_opus":0.037498196540220886,"score_gpt":0.3300835142629037,"score_spread":0.2925853177226828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386465406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95905656,0.0060921754,0.02750754,0.00021628565,0.00009764567,0.00007406265,0.00017858506,0.0004591759,0.0063180695],"genre_scores_gemma":[0.9899233,0.0012618571,0.006202714,0.00006271743,0.000031449024,0.000030053405,0.0001096414,0.000030003177,0.0023483962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980587,0.00003140003,0.00000999157,0.00003303814,0.00005659045,0.00006312019],"domain_scores_gemma":[0.99993896,0.000015264595,0.000011909218,0.000009332324,0.0000092199125,0.000015340978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028633958,0.00023921908,0.00017540874,0.00028853878,0.00009057435,0.00037576782,0.00022812115,0.00023545505,0.001116203],"category_scores_gemma":[0.00010555029,0.00009458647,0.00015284205,0.0001007261,0.00028310737,0.0002517843,0.00020148657,0.00045047977,0.00024741516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001945082,0.00007231065,0.00046432638,0.000059503134,0.0000062090376,0.00008993089,0.000032867865,0.00028499166,0.98356944,0.002264642,0.00013490522,0.012826357],"study_design_scores_gemma":[0.00009037398,0.0007456821,0.0024128659,0.000012413766,0.000039759754,0.00092417886,0.00004673456,0.0059511457,0.9754674,0.0005077817,0.013792938,0.000008680714],"about_ca_topic_score_codex":0.00027603735,"about_ca_topic_score_gemma":0.00042624446,"teacher_disagreement_score":0.001116203,"about_ca_system_score_codex":0.0002688312,"about_ca_system_score_gemma":0.0002806979,"threshold_uncertainty_score":0.0037341118},"labels":[],"label_agreement":null},{"id":"W4386476688","doi":"10.3389/fimmu.2023.1248867","title":"The future of affordable cancer immunotherapy","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"HORIZON EUROPE Framework Programme; Deutsche Forschungsgemeinschaft; Friedrich-Alexander-Universität Erlangen-Nürnberg; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","keywords":"Immunotherapy; Chimeric antigen receptor; Medicine; Cancer immunotherapy; Cancer; Antigen; Cancer research; Immune system; Immunology; Oncology; Internal medicine","score_opus":0.03481279846192579,"score_gpt":0.3630841210880556,"score_spread":0.3282713226261298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386476688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044233454,0.78698176,0.017699735,0.10936324,0.009237088,0.000110969704,0.00036044786,0.00021676005,0.07160663],"genre_scores_gemma":[0.07572853,0.82366437,0.016992807,0.03664789,0.008059414,0.00042960834,0.00076146016,0.00015051347,0.037565514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986344,0.00043163734,0.00005112348,0.0001405678,0.0005235304,0.00021873879],"domain_scores_gemma":[0.9989355,0.00042929905,0.00011955223,0.000063052554,0.00028192997,0.00017058758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024140647,0.0005804075,0.00079175783,0.0008117804,0.0005331971,0.0022762257,0.0010370807,0.0036067686,0.021434665],"category_scores_gemma":[0.003042576,0.00026207737,0.00066605833,0.0008172928,0.0015186535,0.0053788857,0.0019150048,0.0045292056,0.0045372667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000213501,0.0001660228,0.0003259854,0.0033816802,0.000067967085,0.00032557466,0.00017953794,0.0018079868,0.0061761537,0.37053224,0.13502301,0.48180032],"study_design_scores_gemma":[0.000028783232,0.00013754255,0.00021377942,0.0007005327,0.000015761654,0.00018678405,0.00008986928,0.00041102918,0.0007330934,0.05561706,0.9418509,0.000014963436],"about_ca_topic_score_codex":0.00068491214,"about_ca_topic_score_gemma":0.00069355255,"teacher_disagreement_score":0.021434665,"about_ca_system_score_codex":0.0022419463,"about_ca_system_score_gemma":0.0024159304,"threshold_uncertainty_score":0.071706116},"labels":[],"label_agreement":null},{"id":"W4386496099","doi":"10.1136/jitc-2023-007277","title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; T cell; Cancer research; Immunology; Immune system","score_opus":0.06099437135282873,"score_gpt":0.3805189673241266,"score_spread":0.3195245959712979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386496099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97576773,0.0043492946,0.013954065,0.00013794401,0.000051733146,0.00025223652,0.0003102737,0.00028890805,0.004887619],"genre_scores_gemma":[0.99168265,0.0014099409,0.0049133627,0.000069113696,0.000020009156,0.00010051918,0.00035632862,0.000015840234,0.0014321613],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984574,0.000020860154,0.000013285557,0.000041698688,0.000040841183,0.000037597405],"domain_scores_gemma":[0.999931,0.000013041872,0.00001962962,0.000014052893,0.000007907098,0.000014429567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012754336,0.0003540716,0.00022183014,0.0002556808,0.00009466325,0.000304921,0.00023018387,0.0003264778,0.0011904252],"category_scores_gemma":[0.00010578506,0.000078373814,0.00019962137,0.00016454577,0.00020449793,0.0001795992,0.00021632593,0.00050439703,0.00038988306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020120105,0.00018602272,0.0010781067,0.00014713041,0.000015701979,0.00016496675,0.000025654846,0.00047966946,0.9840702,0.00045912352,0.00025882173,0.012913404],"study_design_scores_gemma":[0.00010384752,0.002086429,0.0023946282,0.000017961467,0.000078674835,0.002282704,0.00003204889,0.0025737043,0.9756737,0.0001830419,0.014566067,0.0000072410226],"about_ca_topic_score_codex":0.00022399097,"about_ca_topic_score_gemma":0.0002554666,"teacher_disagreement_score":0.0011904252,"about_ca_system_score_codex":0.00022103691,"about_ca_system_score_gemma":0.00020559886,"threshold_uncertainty_score":0.003982365},"labels":[],"label_agreement":null},{"id":"W4386527000","doi":"10.1186/s13073-023-01219-x","title":"Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours","year":2023,"lang":"en","type":"article","venue":"Genome Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; SickKids Foundation; University Health Network; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre; Hospital for Sick Children; University of British Columbia","funders":"NHLBI Division of Intramural Research; Stanford Cancer Institute; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Deutsche Krebshilfe; Terry Fox Research Institute; University of Toronto; Parker Institute for Cancer Immunotherapy","keywords":"Human genetics; Medicine; Central nervous system; Nervous system; Systems biology; Computational biology; Immunology; Biology; Bioinformatics; Neuroscience; Genetics; Internal medicine; Gene","score_opus":0.03392925098274058,"score_gpt":0.2945778025462837,"score_spread":0.2606485515635431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386527000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98391724,0.0014768986,0.0034869935,0.00012645726,0.0000135723385,0.000025056108,0.009942984,0.00007023856,0.0009406235],"genre_scores_gemma":[0.98001915,0.0007687765,0.0032056835,0.00016013581,0.000016193746,0.00006940698,0.015191227,0.00005473595,0.0005146745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995347,0.000055355158,0.000033576427,0.00018194901,0.00009936002,0.00009501112],"domain_scores_gemma":[0.99937844,0.00020991794,0.00022045772,0.000050523784,0.00008677053,0.000053999884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039011062,0.00016023505,0.00030047365,0.0008146341,0.0002722187,0.0006009014,0.00019134919,0.00024504078,0.0012297806],"category_scores_gemma":[0.0011224444,0.00011547099,0.00035538696,0.00094614667,0.00036509283,0.0002144859,0.0006212335,0.00037264373,0.00036284458],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010173446,0.00005806999,0.6244343,0.00068576424,0.00033861524,0.0005906763,0.0010633847,0.0025653662,0.3256031,0.00072827365,0.0024720663,0.04044302],"study_design_scores_gemma":[0.00001573962,0.00013323927,0.96263087,0.0000703709,0.00018308959,0.001228059,0.0007736973,0.003157752,0.021134004,0.000854055,0.009794993,0.000024062989],"about_ca_topic_score_codex":0.0012975353,"about_ca_topic_score_gemma":0.0028658216,"teacher_disagreement_score":0.0012975353,"about_ca_system_score_codex":0.00038056236,"about_ca_system_score_gemma":0.000340368,"threshold_uncertainty_score":0.0041140914},"labels":[],"label_agreement":null},{"id":"W4386537550","doi":"10.1093/neuonc/noad137.155","title":"P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Fibroblast activation protein, alpha; Chimeric antigen receptor; Cancer research; Stromal cell; Medicine; Glioma; Antigen; U87; Immunology; Immunotherapy; Cancer; Internal medicine; Immune system","score_opus":0.05777059559807561,"score_gpt":0.3468138788377503,"score_spread":0.28904328323967465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386537550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96973455,0.009038177,0.01102782,0.00052977196,0.00026498435,0.00032634658,0.0006843046,0.0003705716,0.008023568],"genre_scores_gemma":[0.9848363,0.0024734726,0.0058017126,0.00016278878,0.000042383534,0.0002151127,0.0007234667,0.000027635997,0.0057171197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999379,0.000008577503,0.0000039055762,0.000011976929,0.00001582368,0.00002173846],"domain_scores_gemma":[0.9999776,0.0000022498589,0.000004929676,0.0000023053049,0.0000038687267,0.000009117319],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001423421,0.0002654567,0.00033052752,0.00022939949,0.00014025111,0.00029261332,0.00027307443,0.0004910635,0.0019660587],"category_scores_gemma":[0.00005491629,0.00007743414,0.00023127878,0.00014834032,0.0001625421,0.00013701506,0.00013533587,0.00045781993,0.0006214248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00102387,0.0006154059,0.000537818,0.00029114747,0.000026917225,0.0007361396,0.0000658666,0.0011509352,0.955191,0.0011405697,0.0021640246,0.037056334],"study_design_scores_gemma":[0.0004284528,0.006277317,0.0040758387,0.000052532116,0.00011585708,0.004133146,0.000056323435,0.009589239,0.9326175,0.0004258546,0.042207655,0.000020369253],"about_ca_topic_score_codex":0.00064990664,"about_ca_topic_score_gemma":0.0005199956,"teacher_disagreement_score":0.0019660587,"about_ca_system_score_codex":0.00022197275,"about_ca_system_score_gemma":0.00031809567,"threshold_uncertainty_score":0.006577134},"labels":[],"label_agreement":null},{"id":"W4386537716","doi":"10.1093/neuonc/noad137.019","title":"JS03.6.A NEUROTOXICITY IN PATIENTS WITH CNS LYMPHOMAS TREATED WITH CAR T CELL THERAPY. A LOC NETWORK STUDY","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Lymphoma; Encephalopathy; Internal medicine; Toxicity; Gastroenterology; Pediatrics; Oncology","score_opus":0.026686438841491265,"score_gpt":0.3005137498712934,"score_spread":0.2738273110298022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386537716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976815,0.00077714276,0.000057541376,0.00004127077,0.0000070912865,0.00005100685,0.00050395005,0.0000032688445,0.0008771411],"genre_scores_gemma":[0.9977538,0.0003979635,0.00006258382,0.00007728211,0.0000324767,0.00006274799,0.0011260324,0.0000035329506,0.00048359873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996631,0.000105987274,0.000045896755,0.00007002919,0.000060110935,0.000054906453],"domain_scores_gemma":[0.99935955,0.00006332958,0.00025376928,0.000038124846,0.00008033548,0.00020498248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053121493,0.00035759126,0.00035304844,0.0007775219,0.00043869996,0.0006284261,0.00038667463,0.00038945978,0.0018973923],"category_scores_gemma":[0.0006341258,0.0002098733,0.0006025754,0.0009595242,0.00023494176,0.00042223852,0.0003862353,0.0003381109,0.00046801925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00472248,0.0006190011,0.9845579,0.00012754957,0.00036838476,0.0007529766,0.00012996212,0.00010895484,0.0008679867,0.00004354722,0.00036406482,0.007337225],"study_design_scores_gemma":[0.00082966965,0.0051719993,0.98798394,0.000042143718,0.000550447,0.002500294,0.00030905794,0.0003582715,0.0003405035,0.000073529045,0.0018246118,0.000015573665],"about_ca_topic_score_codex":0.0033904377,"about_ca_topic_score_gemma":0.0041469582,"teacher_disagreement_score":0.0033904377,"about_ca_system_score_codex":0.0006400671,"about_ca_system_score_gemma":0.0005246916,"threshold_uncertainty_score":0.0067414045},"labels":[],"label_agreement":null},{"id":"W4386574738","doi":"10.1016/j.jcyt.2023.07.012","title":"Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform","year":2023,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Octane (Canada)","funders":"National Cancer Institute; McMaster University","keywords":"Chimeric antigen receptor; Cell therapy; Medicine; Process (computing); Clinical trial; Manufacturing process; T cell; Computer science; Immunology; Cell; Immune system; Biology; Internal medicine","score_opus":0.07365111325701204,"score_gpt":0.3572147562017875,"score_spread":0.28356364294477543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386574738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.635942,0.0021631056,0.34796724,0.00026345224,0.00040256712,0.00062131515,0.0009148733,0.0019752672,0.009750235],"genre_scores_gemma":[0.8669729,0.001153839,0.12679207,0.000107523214,0.00003421553,0.00028552357,0.0008366051,0.00020730504,0.0036100568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997311,0.00003883395,0.0000192763,0.00007650874,0.000095167095,0.00003901365],"domain_scores_gemma":[0.99981624,0.000045586366,0.000046819114,0.000032575408,0.000029036513,0.000029706927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027836728,0.0005166686,0.00025760158,0.00036953346,0.00018069043,0.00055056176,0.00029516444,0.00038345953,0.0014149724],"category_scores_gemma":[0.00033427603,0.00015785731,0.00037638465,0.00030149234,0.0003024738,0.00027245056,0.00038583475,0.00055139756,0.00079984154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063484986,0.000037531157,0.00013356641,0.000042089505,0.0000039534543,0.00013868869,0.000029348397,0.00066668313,0.9923988,0.00034292863,0.00016485591,0.0059780213],"study_design_scores_gemma":[0.000017036586,0.00022021838,0.0004398531,0.0000066764856,0.000011227693,0.00016962635,0.000013647022,0.0064349757,0.9874386,0.00006598995,0.0051732203,0.00000886579],"about_ca_topic_score_codex":0.00083466945,"about_ca_topic_score_gemma":0.0009052516,"teacher_disagreement_score":0.0014149724,"about_ca_system_score_codex":0.0002798871,"about_ca_system_score_gemma":0.00028024946,"threshold_uncertainty_score":0.004733622},"labels":[],"label_agreement":null},{"id":"W4386590486","doi":"10.22192/ttdls.2023.010","title":"Immunotherapy: breakthrough in Cancer Treatment","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society of Microbiologists","funders":"","keywords":"Scope (computer science); Population; Engineering; Engineering ethics; Business; Management science; Computer science; Engineering management; Medicine","score_opus":0.08348273814235774,"score_gpt":0.37140108342471717,"score_spread":0.28791834528235943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386590486","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007744327,0.66682684,0.0049948706,0.04655184,0.032729987,0.00008042414,0.0005028207,0.00050666917,0.24703206],"genre_scores_gemma":[0.0076187304,0.46676618,0.00779224,0.039585024,0.017900415,0.00012810722,0.0007404703,0.0002834758,0.45918542],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995524,0.000081874365,0.000017619403,0.00006547838,0.00024158676,0.000040993968],"domain_scores_gemma":[0.9997023,0.000096031814,0.000022185484,0.000021243739,0.00008589588,0.00007229021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006622501,0.00080102537,0.0007118165,0.0010184326,0.00064231415,0.0032772229,0.0009261303,0.002134639,0.038416736],"category_scores_gemma":[0.0009301472,0.0002811484,0.0006349334,0.0009318965,0.0009095125,0.0034746758,0.0015207212,0.0051383725,0.024320152],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037439448,0.000057151363,0.00007326185,0.00090305205,0.00001666575,0.00009254438,0.0001118229,0.0001887322,0.0012225654,0.036136877,0.7067423,0.2544176],"study_design_scores_gemma":[0.0000047133617,0.000016314896,0.00006797336,0.0002509546,0.000003469037,0.00024028792,0.000022511229,0.000048993235,0.00009670808,0.0056099296,0.99363446,0.000003614973],"about_ca_topic_score_codex":0.0006145539,"about_ca_topic_score_gemma":0.0018328156,"teacher_disagreement_score":0.038416736,"about_ca_system_score_codex":0.001221332,"about_ca_system_score_gemma":0.0011248629,"threshold_uncertainty_score":0.1285168},"labels":[],"label_agreement":null},{"id":"W4386709546","doi":"10.18609/vac.2023.045","title":"Establishing a B cell and T cell receptor data commons using next-generation sequencing","year":2023,"lang":"en","type":"article","venue":"Vaccine Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Commons; Computational biology; Cell; Biology; Genetics; Ecology","score_opus":0.2321827372040129,"score_gpt":0.34205045087419433,"score_spread":0.10986771367018144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386709546","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013035382,0.03240668,0.090258814,0.4749547,0.39352745,0.00037273587,0.0006785815,0.0015153247,0.0049822098],"genre_scores_gemma":[0.012636819,0.06652766,0.12129324,0.27098536,0.4937393,0.0006621453,0.001543016,0.0019530436,0.030659402],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9840395,0.0045796176,0.0026701032,0.0014102886,0.0068440614,0.000456489],"domain_scores_gemma":[0.88657147,0.062573455,0.0043818057,0.0044144923,0.034289286,0.0077694664],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.051858127,0.000768539,0.0010277751,0.0033832109,0.0014773118,0.008634618,0.0030380345,0.0061082724,0.003940369],"category_scores_gemma":[0.06554932,0.0009876352,0.0012296851,0.0011756847,0.003197479,0.008367427,0.002597925,0.015885185,0.0038693687],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014142998,0.00004465439,0.0007125718,0.0005342986,0.00007535368,0.0005503307,0.00039617837,0.00037661445,0.0038764826,0.007899156,0.79282475,0.19256827],"study_design_scores_gemma":[0.000018659734,0.000046973237,0.0003689485,0.00043294646,0.000028996006,0.0005240698,0.00015980993,0.0010015545,0.0014020363,0.008802689,0.9871782,0.000035110737],"about_ca_topic_score_codex":0.0012973783,"about_ca_topic_score_gemma":0.0027637754,"teacher_disagreement_score":0.99696195,"about_ca_system_score_codex":0.0015123528,"about_ca_system_score_gemma":0.006802623,"threshold_uncertainty_score":0.27425528},"labels":[],"label_agreement":null},{"id":"W4386815771","doi":"10.1101/2023.09.14.557485","title":"Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec; University of Victoria; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Mitacs","keywords":"CRISPR; Resistance (ecology); Control (management); Biology; Chemistry; Computational biology; Computer science; Genetics; Gene; Ecology; Artificial intelligence","score_opus":0.041734087164700596,"score_gpt":0.30705475359160783,"score_spread":0.2653206664269072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386815771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8696681,0.0024120277,0.1133705,0.00060125464,0.00020684623,0.00028249406,0.0016962166,0.0022783007,0.009484301],"genre_scores_gemma":[0.9631259,0.0005815708,0.02923145,0.000144906,0.000028386114,0.00013854733,0.00048582145,0.00020220246,0.006061254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969196,0.000056037105,0.000029270634,0.00008982432,0.00007482798,0.000058059908],"domain_scores_gemma":[0.99989676,0.000024037303,0.000032355165,0.00001770889,0.000010141738,0.000019041727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023932355,0.0003931091,0.00026178066,0.00026343766,0.00016533842,0.00053548237,0.0002808154,0.0003885342,0.0017053589],"category_scores_gemma":[0.0001558065,0.00017850025,0.00022238518,0.00012343859,0.00035991555,0.00015228504,0.00028285457,0.00066325563,0.0008198403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036297548,0.000011447855,0.00005965661,0.000023319439,0.0000046110645,0.000035468554,0.00001164771,0.00017104861,0.9975714,0.0004060706,0.00013934245,0.0015296726],"study_design_scores_gemma":[0.000007565042,0.000037661754,0.00012516035,0.0000012897756,0.0000045036822,0.00007874861,0.0000041636927,0.0008577889,0.995458,0.000034438734,0.0033883834,0.0000023614616],"about_ca_topic_score_codex":0.00043001157,"about_ca_topic_score_gemma":0.0006570851,"teacher_disagreement_score":0.0017053589,"about_ca_system_score_codex":0.00031838298,"about_ca_system_score_gemma":0.00024294476,"threshold_uncertainty_score":0.0057049394},"labels":[],"label_agreement":null},{"id":"W4386817435","doi":"10.1002/ajh.27098","title":"Bone marrow fibrosis is associated with non‐response to <scp>CD19 CAR T</scp>‐cell therapy in <scp>B</scp>‐acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"CURE Childhood Cancer Association","keywords":"Stromal cell; Bone marrow; Medicine; CD19; Fibrosis; T cell; Cancer research; B cell; Myelofibrosis; Cell therapy; Immunology; Pathology; Cell; Flow cytometry; Biology; Immune system; Antibody","score_opus":0.012103395241732408,"score_gpt":0.2796308972548362,"score_spread":0.26752750201310377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386817435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993892,0.00022368466,0.000098278826,0.00001102086,9.0432206e-7,0.0000053130398,0.00014381048,0.0000072686607,0.00012045037],"genre_scores_gemma":[0.9992306,0.00011981151,0.00013563481,0.000017205068,0.0000032529033,0.000011106204,0.00029333105,0.0000026884625,0.00018637379],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999895,0.000026012965,0.00000986631,0.000024728086,0.000022546808,0.000021839136],"domain_scores_gemma":[0.99971586,0.000054321466,0.00015300528,0.00001428914,0.000017910757,0.000044586057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015630142,0.00012691517,0.00020407779,0.00032961398,0.00011621607,0.00021958353,0.00006261942,0.00014818467,0.0009042571],"category_scores_gemma":[0.00024154581,0.00009090359,0.00013129757,0.00024435416,0.00017519595,0.000071654504,0.00011798365,0.00022843065,0.00016411157],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035843113,0.00011329419,0.3489747,0.00010880568,0.00006828928,0.0008396758,0.00016898292,0.00026048583,0.633908,0.00005100091,0.000243218,0.011679278],"study_design_scores_gemma":[0.000011511312,0.00031282203,0.9837847,0.0000047315143,0.00003654148,0.0011737591,0.000063559404,0.0002716207,0.014006447,0.000031260774,0.00030021233,0.0000027961312],"about_ca_topic_score_codex":0.00034894206,"about_ca_topic_score_gemma":0.0006380766,"teacher_disagreement_score":0.0009042571,"about_ca_system_score_codex":0.00011395536,"about_ca_system_score_gemma":0.00009171229,"threshold_uncertainty_score":0.003025055},"labels":[],"label_agreement":null},{"id":"W4386837057","doi":"10.3390/curroncol30090619","title":"Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Medicine; Cart; Glioblastoma; Radiation therapy; Antigen; Immunotherapy; Clinical trial; Tumor microenvironment; Brain tumor; CD8; Cancer research; T cell; Oncology; Cancer; Immunology; Internal medicine; Immune system; Tumor cells; Pathology","score_opus":0.20809332928761784,"score_gpt":0.46269867400889053,"score_spread":0.2546053447212727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386837057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000115870294,0.99840075,0.00009794129,0.00028144039,0.00026096165,0.00000597876,0.000019020277,0.000008576128,0.0008094572],"genre_scores_gemma":[0.0003704801,0.9985827,0.00015008295,0.00024873985,0.00013512521,0.000007377773,0.000029847512,0.0000013964248,0.00047425678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985397,0.000026307527,0.000021275207,0.000022296033,0.000057242964,0.000018973953],"domain_scores_gemma":[0.9997209,0.0001438648,0.00003539539,0.000005672592,0.00006749589,0.000026759564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005916187,0.00081619626,0.0010973085,0.0021471574,0.00022554706,0.0009953893,0.0007747953,0.0012339912,0.0035145415],"category_scores_gemma":[0.0006180616,0.00028559225,0.00056919537,0.0020680143,0.00031296114,0.0013394743,0.0005425344,0.0020264063,0.0019184648],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088451154,0.000112079855,0.000108097745,0.017855765,0.000086579035,0.00017440527,0.00005796787,0.00040699542,0.0018579195,0.003321784,0.04542862,0.9305014],"study_design_scores_gemma":[0.00002168348,0.00013293691,0.00034210493,0.0035670393,0.00012345599,0.0006676992,0.000035347097,0.00009246074,0.00032173417,0.000994535,0.99368805,0.0000130963235],"about_ca_topic_score_codex":0.001027683,"about_ca_topic_score_gemma":0.002416974,"teacher_disagreement_score":0.0035145415,"about_ca_system_score_codex":0.0005944536,"about_ca_system_score_gemma":0.0010407794,"threshold_uncertainty_score":0.011757255},"labels":[],"label_agreement":null},{"id":"W4386871562","doi":"10.5220/0012015600003633","title":"Cancer Immunology: CAR T-Cell Therapy on Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Renal cell carcinoma; Cancer; Medicine; Cancer research; Immunology; Oncology; Internal medicine","score_opus":0.03307022250846871,"score_gpt":0.3088625909861549,"score_spread":0.2757923684776862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386871562","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25305507,0.47012007,0.008923675,0.059951194,0.011553888,0.00031228925,0.00081788225,0.0007996004,0.1944664],"genre_scores_gemma":[0.7344932,0.12833613,0.0043558464,0.008356519,0.0064997994,0.000156966,0.00052169233,0.000088844856,0.117190994],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979454,0.00004624437,0.000009154199,0.000028136343,0.000051770552,0.000070233975],"domain_scores_gemma":[0.99987054,0.000029116094,0.000016582891,0.00000951139,0.000037045484,0.000037140246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050359784,0.00047921273,0.00040942087,0.0007652606,0.0005023573,0.001107273,0.000399235,0.0009751762,0.01581419],"category_scores_gemma":[0.00029046836,0.00016696882,0.000401061,0.00055540894,0.00052046095,0.00079926406,0.0004514552,0.0016046071,0.0022217215],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015894428,0.0019576696,0.0040674023,0.0025078286,0.00014807898,0.0013388434,0.00027536842,0.0017067444,0.14910242,0.07222535,0.08501076,0.68007004],"study_design_scores_gemma":[0.00064170826,0.0032560816,0.008098669,0.00045839133,0.00022071473,0.003456147,0.00024421437,0.002171977,0.13772161,0.008847702,0.834839,0.00004373673],"about_ca_topic_score_codex":0.0013860962,"about_ca_topic_score_gemma":0.0022383449,"teacher_disagreement_score":0.01581419,"about_ca_system_score_codex":0.00089979824,"about_ca_system_score_gemma":0.0015346352,"threshold_uncertainty_score":0.05290371},"labels":[],"label_agreement":null},{"id":"W4386977179","doi":"10.3390/cimb45100486","title":"Targeted Delivery of Chimeric Antigen Receptor into T Cells via CRISPR-Mediated Homology-Directed Repair with a Dual-AAV6 Transduction System","year":2023,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds de Recherche du Québec - Santé; Canada Research Chairs","keywords":"Chimeric antigen receptor; CRISPR; Insertional mutagenesis; Transduction (biophysics); Biology; Homology directed repair; Cell biology; T cell; Molecular biology; Genetics; Gene; DNA repair; Immune system; Genome","score_opus":0.03301138151884226,"score_gpt":0.37404577756489915,"score_spread":0.3410343960460569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386977179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017235568,0.9913317,0.0029615061,0.00027755558,0.00026113374,0.00003050918,0.000044057073,0.000081596976,0.0032883883],"genre_scores_gemma":[0.008139582,0.9858416,0.0025496231,0.00028083898,0.00013873029,0.00003426184,0.00012792372,0.000008004761,0.0028793395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989605,0.000015555837,0.000008931415,0.000020685558,0.000044946293,0.000013818426],"domain_scores_gemma":[0.99996173,0.000011414948,0.000007969542,0.000001970293,0.000010877313,0.0000060918514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002716675,0.0005690484,0.00066462305,0.0010964966,0.000085591826,0.00044272293,0.0005416896,0.0005735882,0.0013637604],"category_scores_gemma":[0.00012705819,0.0001814636,0.00031181125,0.0006734472,0.00020184806,0.00046275483,0.00029209905,0.0009113624,0.0012802783],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010553817,0.0001449417,0.00014758618,0.010968328,0.0001289598,0.00048172145,0.000048517544,0.00078875537,0.08244697,0.0052212765,0.018201986,0.88131535],"study_design_scores_gemma":[0.000069851245,0.00034483918,0.0010550825,0.0009801745,0.00016801906,0.0039391094,0.000036027737,0.0005249211,0.030870019,0.0012806655,0.960694,0.000037314305],"about_ca_topic_score_codex":0.00042184463,"about_ca_topic_score_gemma":0.00054808595,"teacher_disagreement_score":0.0013637604,"about_ca_system_score_codex":0.00036851992,"about_ca_system_score_gemma":0.0003680766,"threshold_uncertainty_score":0.004562199},"labels":[],"label_agreement":null},{"id":"W4387003976","doi":"10.1016/s2152-2650(23)01646-4","title":"P-028 Canadian-made single domain antibody (sdAb) BCMA CAR-T cells for multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Single-domain antibody; Multiple myeloma; Antibody; Domain (mathematical analysis); Medicine; Immunology; Mathematics","score_opus":0.05718393129945083,"score_gpt":0.3656824003563769,"score_spread":0.3084984690569261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8345505,0.021697216,0.008138586,0.0064680395,0.0016113564,0.0006488402,0.0022848456,0.0011532924,0.1234472],"genre_scores_gemma":[0.97039783,0.0035298176,0.0042681596,0.00047360835,0.000089700734,0.00006636826,0.0011628908,0.000046162706,0.019965565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998099,0.000018250932,0.000005561667,0.000022796201,0.000081007216,0.00006241631],"domain_scores_gemma":[0.99989367,0.000011053924,0.000007962936,0.000011149347,0.00003844924,0.00003757766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003282702,0.00017889947,0.000166476,0.0004290023,0.0004509294,0.00049679895,0.00052755984,0.00041573288,0.005910472],"category_scores_gemma":[0.0003371305,0.00011502108,0.0002165713,0.00037915495,0.0003045166,0.00018229151,0.0002912731,0.00098341,0.0012799809],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004027068,0.001343929,0.0067154462,0.00032892838,0.00010997765,0.0015043828,0.00026942688,0.002072371,0.6035838,0.011690793,0.050572395,0.3177815],"study_design_scores_gemma":[0.0013982066,0.0039050998,0.019335026,0.00006719915,0.00020754874,0.004603492,0.00021906575,0.004359373,0.42476854,0.001587464,0.53949726,0.00005165952],"about_ca_topic_score_codex":0.03244086,"about_ca_topic_score_gemma":0.05480215,"teacher_disagreement_score":0.96755916,"about_ca_system_score_codex":0.0018583835,"about_ca_system_score_gemma":0.002705209,"threshold_uncertainty_score":0.06450409},"labels":[],"label_agreement":null},{"id":"W4387004108","doi":"10.1016/s2152-2650(23)01644-0","title":"P-026 Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Terry Fox Research Institute; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Cart; Multiple myeloma; Refractory (planetary science); Medicine; Antigen; Receptor; Cancer research; Virology; Immunotherapy; Immunology; Internal medicine; Biology; Immune system","score_opus":0.04908132357785517,"score_gpt":0.34190956089097674,"score_spread":0.2928282373131216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387004108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502784,0.002055499,0.00041402155,0.00017571331,0.000056975845,0.00009088274,0.00023320095,0.00007911157,0.001866865],"genre_scores_gemma":[0.99764365,0.000516152,0.00021265775,0.00008430889,0.00003465409,0.00004283999,0.00033169801,0.000010996974,0.0011230374],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99988306,0.000039069437,0.00000543973,0.000018148316,0.000019418027,0.000034746892],"domain_scores_gemma":[0.99989533,0.000022577844,0.000015384598,0.000015092819,0.0000067523597,0.00004486592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027149712,0.0002541976,0.0006322101,0.00020355698,0.00020057092,0.00053102756,0.00038795586,0.0004891197,0.0021197705],"category_scores_gemma":[0.0002789712,0.00012556816,0.0003484104,0.00022238518,0.00042231358,0.00032065972,0.00012007772,0.0015053019,0.0005237577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16617787,0.025990186,0.0059863566,0.00069091294,0.00057456887,0.0014509667,0.0003772384,0.005075959,0.37081102,0.0014005178,0.004144306,0.4173201],"study_design_scores_gemma":[0.072104976,0.65040797,0.046488807,0.00009642989,0.0009866089,0.0042359834,0.0002105911,0.012311877,0.19381844,0.0005763594,0.018665442,0.00009659178],"about_ca_topic_score_codex":0.0015521004,"about_ca_topic_score_gemma":0.0015720302,"teacher_disagreement_score":0.0021197705,"about_ca_system_score_codex":0.00043620798,"about_ca_system_score_gemma":0.00053890556,"threshold_uncertainty_score":0.0070913434},"labels":[],"label_agreement":null},{"id":"W4387104794","doi":"10.1101/2023.09.26.559329","title":"A synthetic Notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"Canadian Institutes of Health Research","keywords":"CD19; Immune system; Cancer research; Jurkat cells; Chimeric antigen receptor; Cancer cell; Immunotherapy; Antigen; Cancer immunotherapy; Cancer; Immunology; Biology; T cell; Molecular biology; Medicine; Internal medicine","score_opus":0.031465955752841425,"score_gpt":0.2769455545566925,"score_spread":0.2454795988038511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387104794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95972115,0.00045333122,0.036625072,0.000121339996,0.000048692775,0.0001078641,0.00052510964,0.00018007713,0.0022172034],"genre_scores_gemma":[0.9764757,0.00028583195,0.01943135,0.00006919746,0.00001084949,0.00007559887,0.0005433469,0.000016718259,0.0030913628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978465,0.0000430319,0.000020141084,0.000053059677,0.00007071309,0.000028445336],"domain_scores_gemma":[0.9998379,0.000023860826,0.00007260868,0.000019617331,0.000018439518,0.0000275261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023170299,0.00029755762,0.00009891352,0.0001953805,0.000068832545,0.00024432153,0.00029263314,0.0003294299,0.00095303543],"category_scores_gemma":[0.00012832104,0.000105036714,0.00013913726,0.00013824578,0.00019414502,0.00016885196,0.0002192442,0.0002669949,0.0002789728],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003395967,0.000010267961,0.00008008553,0.0000148428435,0.0000017097495,0.000017964587,0.0000038065953,0.000109699286,0.9990675,0.00014137641,0.000022457833,0.0004963934],"study_design_scores_gemma":[0.0000056507165,0.00010629215,0.00020819133,0.0000013426313,0.000003626626,0.00006181493,0.000004748339,0.0007630767,0.9979771,0.00002173487,0.0008444234,0.0000021185315],"about_ca_topic_score_codex":0.00026193896,"about_ca_topic_score_gemma":0.0003297611,"teacher_disagreement_score":0.00095303543,"about_ca_system_score_codex":0.0003758336,"about_ca_system_score_gemma":0.00019527899,"threshold_uncertainty_score":0.0031882524},"labels":[],"label_agreement":null},{"id":"W4387115637","doi":"10.1111/ejh.14100","title":"Long‐term survivorship care after <scp>CAR‐T</scp> cell therapy","year":2023,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Medicine; Tocilizumab; Survivorship curve; Population; CAR T-cell therapy; Immune system; Disease; Immunology; Intensive care medicine; Immunotherapy; Cell therapy; T cell; Bioinformatics; Cell; Internal medicine; Biology","score_opus":0.10031656807501967,"score_gpt":0.36828685148472,"score_spread":0.26797028340970036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387115637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017907686,0.9981304,0.00011445965,0.00027172075,0.0001925229,0.0000071786117,0.000016194972,0.000005937208,0.0010825108],"genre_scores_gemma":[0.0012075448,0.9977774,0.0001545526,0.00023333964,0.00015725094,0.000010385174,0.00003190423,0.0000013068487,0.00042631326],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998306,0.00004238218,0.00002343653,0.000020696045,0.00006044975,0.000022321574],"domain_scores_gemma":[0.9997296,0.00014633662,0.000045979457,0.0000065301733,0.00005104565,0.000020589363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005818878,0.00041453043,0.0008499188,0.0009793806,0.00020381663,0.00069346005,0.00057131785,0.00087400246,0.0026888764],"category_scores_gemma":[0.00089482754,0.00011197733,0.00046625326,0.00088043464,0.00022990903,0.000585895,0.00052466535,0.0011875808,0.0011719419],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064945925,0.00003905087,0.00014205802,0.015411211,0.00008804673,0.00025608414,0.000049268885,0.00020517077,0.0006326947,0.0017879618,0.021470157,0.9598534],"study_design_scores_gemma":[0.000036555783,0.00015256711,0.0012388317,0.011492305,0.0001856369,0.002731033,0.00008241312,0.00006542634,0.00043812086,0.0012580669,0.9823046,0.000014509122],"about_ca_topic_score_codex":0.00074781064,"about_ca_topic_score_gemma":0.0014974403,"teacher_disagreement_score":0.0026888764,"about_ca_system_score_codex":0.00046951236,"about_ca_system_score_gemma":0.0010703722,"threshold_uncertainty_score":0.008995235},"labels":[],"label_agreement":null},{"id":"W4387135433","doi":"10.1136/ijgc-2023-esgo.866","title":"#24 A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Oncology; Ovarian cancer; Nivolumab; Medicine; Internal medicine; Population; Ovarian carcinoma; Debulking; CD8; Immunotherapy; Cancer; Immunology; Antigen","score_opus":0.04904749363744676,"score_gpt":0.37701556038881845,"score_spread":0.3279680667513717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387135433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815351,0.004094839,0.0006941795,0.0023818612,0.000617831,0.003120165,0.0024426768,0.0002837783,0.0048296466],"genre_scores_gemma":[0.9735069,0.0023324643,0.0024038784,0.0033356284,0.00030800438,0.0027156353,0.0028785535,0.000071251736,0.012447642],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997807,0.00009196384,0.000009923044,0.00004452101,0.000015507447,0.00005738629],"domain_scores_gemma":[0.99976534,0.000033553857,0.000026936505,0.000020374182,0.000018652392,0.00013508709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007929769,0.00094600243,0.0015653758,0.00025916367,0.00041378423,0.0008204534,0.0005574402,0.0012239873,0.0053488393],"category_scores_gemma":[0.00042273087,0.00039894204,0.001395602,0.00019562042,0.00058333966,0.0004727359,0.00020898928,0.0028039734,0.0012953898],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57213914,0.04745108,0.0069743027,0.0018932283,0.0035025594,0.00075837004,0.0003768633,0.004674354,0.081516005,0.00087481696,0.028817812,0.2510214],"study_design_scores_gemma":[0.6857179,0.2914577,0.0074252533,0.000052044812,0.0005700248,0.00034842073,0.00006863059,0.0011935163,0.0035329584,0.0003272662,0.009264662,0.000041682728],"about_ca_topic_score_codex":0.0016139123,"about_ca_topic_score_gemma":0.00538703,"teacher_disagreement_score":0.0053488393,"about_ca_system_score_codex":0.000790326,"about_ca_system_score_gemma":0.0009709098,"threshold_uncertainty_score":0.017893612},"labels":[],"label_agreement":null},{"id":"W4387209890","doi":"10.1111/cas.15985","title":"Intratumoral administration of unconjugated Accum™ impairs the growth of pre‐established solid lymphoma tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada; Centre Hospitalier Universitaire Sainte-Justine; Université de Sherbrooke; Université de Montréal","funders":"Cancer Research Society","keywords":"Cancer research; Immune system; Programmed cell death; Immunogenic cell death; Endosome; Lymphoma; Pharmacology; Biology; CD8; Cell biology; Immunotherapy; Immunology; Apoptosis; Biochemistry; Intracellular","score_opus":0.033036508945736405,"score_gpt":0.36102301747985954,"score_spread":0.32798650853412314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387209890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962119,0.0011506573,0.0013113138,0.000062612075,0.00003445062,0.000017139537,0.00012284631,0.00009542422,0.0009937526],"genre_scores_gemma":[0.99433607,0.00082695624,0.0009974049,0.00003881466,0.000012592481,0.000022282347,0.00024743672,0.00001621148,0.0035021543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998579,0.000021050499,0.000011932467,0.00002567923,0.000036654474,0.000046758414],"domain_scores_gemma":[0.9999163,0.00001687764,0.000023921506,0.000010438172,0.000007721055,0.000024711593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001264782,0.00035775115,0.0002799605,0.00024655563,0.000071175,0.00023107689,0.00022809482,0.00025985227,0.0006599312],"category_scores_gemma":[0.00007493071,0.00012036604,0.00015401567,0.00013743849,0.00023401753,0.00021229424,0.00011395872,0.000616849,0.00017432313],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025517438,0.00010722857,0.000068993766,0.000032994016,0.0000066323482,0.00002797363,0.000015185202,0.000091677495,0.99782324,0.00006842768,0.000038835875,0.0014636511],"study_design_scores_gemma":[0.000012093868,0.0010321302,0.0006427766,0.0000027892795,0.000014775298,0.000043731114,0.000010420616,0.00043224415,0.99683607,0.00001646296,0.00095354207,0.00000295513],"about_ca_topic_score_codex":0.00052539504,"about_ca_topic_score_gemma":0.00078205066,"teacher_disagreement_score":0.0006599312,"about_ca_system_score_codex":0.00023193572,"about_ca_system_score_gemma":0.00020445192,"threshold_uncertainty_score":0.002207756},"labels":[],"label_agreement":null},{"id":"W4387267794","doi":"10.1038/s43018-023-00634-8","title":"Immunotargeting of a recurrent AML-specific neoantigen","year":2023,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Myeloid leukemia; Human leukocyte antigen; Medicine; Immunology; Myeloid; Cancer research; Oncology; Antigen","score_opus":0.03267180719695787,"score_gpt":0.373176615773337,"score_spread":0.3405048085763791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387267794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98630697,0.0012378322,0.006050412,0.00041304322,0.000085832,0.000077508594,0.0001200788,0.0001544699,0.0055538546],"genre_scores_gemma":[0.9954869,0.00034220333,0.0013743606,0.000063719286,0.000016282132,0.000021515732,0.00008540638,0.000015910071,0.002593629],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976045,0.0000306507,0.000009286651,0.000046659472,0.000053046508,0.00009995247],"domain_scores_gemma":[0.99993265,0.00001394353,0.000013166276,0.000013860218,0.0000075740495,0.000018800756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002126127,0.00031572935,0.00035024105,0.00027613525,0.00021244511,0.00047112495,0.00035272818,0.0006043,0.002482024],"category_scores_gemma":[0.00021354643,0.00013964008,0.00027086237,0.00017229239,0.00023911326,0.00027460567,0.00050548714,0.00086189056,0.000591954],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023769628,0.0001596982,0.00051981176,0.000060930237,0.000023927776,0.00037502265,0.000074916745,0.0010604003,0.9799683,0.0024694097,0.00050010433,0.014549745],"study_design_scores_gemma":[0.00012954618,0.0013484026,0.0024145527,0.000010982782,0.00006448996,0.0020209546,0.00008085691,0.0057498906,0.9759562,0.0005591111,0.011655677,0.000009494025],"about_ca_topic_score_codex":0.00065232214,"about_ca_topic_score_gemma":0.0010724084,"teacher_disagreement_score":0.002482024,"about_ca_system_score_codex":0.00056723,"about_ca_system_score_gemma":0.00033107752,"threshold_uncertainty_score":0.008303225},"labels":[],"label_agreement":null},{"id":"W4387296735","doi":"10.1158/1078-0432.ccr-23-1735","title":"Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canada Foundation for Innovation; Mitacs; Canada Research Chairs","keywords":"Chimeric antigen receptor; Medicine; Antigen; Population; Cancer research; Cancer stem cell; Metastasis; Immunotherapy; Immunology; Oncology; Cancer; Internal medicine; Immune system","score_opus":0.20659055628028922,"score_gpt":0.5196007385964388,"score_spread":0.31301018231614963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387296735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.727414,0.1549716,0.015815137,0.05758972,0.0066021094,0.0004358446,0.00046681904,0.0012878033,0.035417046],"genre_scores_gemma":[0.8972518,0.06719448,0.004800412,0.010709283,0.0031134982,0.00020146849,0.0002486326,0.00012544454,0.016354939],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992406,0.00001742029,0.000003344539,0.000015433625,0.000023794619,0.000015943446],"domain_scores_gemma":[0.999936,0.000026301204,0.000010345684,0.0000042679244,0.000011500757,0.000011629003],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023118751,0.00024740738,0.00022962841,0.00018619363,0.0001221873,0.0003368325,0.00023748215,0.00057590706,0.0006306355],"category_scores_gemma":[0.0001748972,0.00006433752,0.0001594299,0.00014219113,0.0006028133,0.0002498292,0.0001487471,0.0014216724,0.00029872442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017350116,0.0005953649,0.00074983283,0.0008414338,0.00006537298,0.0010918444,0.000132177,0.0011206943,0.7497582,0.0053476095,0.041975062,0.19658744],"study_design_scores_gemma":[0.0014503791,0.005856609,0.0066815303,0.00020622833,0.00022029756,0.0035443334,0.00022383184,0.0039415862,0.6846535,0.0021221025,0.29104382,0.000055785],"about_ca_topic_score_codex":0.0005053807,"about_ca_topic_score_gemma":0.0013169735,"teacher_disagreement_score":0.0006306355,"about_ca_system_score_codex":0.00043580582,"about_ca_system_score_gemma":0.00047211605,"threshold_uncertainty_score":0.0031619668},"labels":[],"label_agreement":null},{"id":"W4387398407","doi":"10.1016/j.actbio.2023.10.002","title":"Injectable hydrogels for personalized cancer immunotherapies","year":2023,"lang":"en","type":"review","venue":"Acta Biomaterialia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"Terasaki Institute for Biomedical Innovation; National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Foundation for the National Institutes of Health","keywords":"Self-healing hydrogels; Materials science; Cancer; Cancer immunotherapy; Immunotherapy; Biomedical engineering; Medicine; Internal medicine; Polymer chemistry","score_opus":0.1338811687094837,"score_gpt":0.4307899513428981,"score_spread":0.2969087826334144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387398407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025159746,0.9972824,0.00042158115,0.00016689838,0.00034918886,0.000010535805,0.000031745876,0.000013572825,0.0014724622],"genre_scores_gemma":[0.0020726584,0.99474007,0.0005170781,0.00028473954,0.0002532364,0.000022109178,0.0000533052,0.0000043352297,0.0020524692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998827,0.000019219962,0.000010513448,0.000019566547,0.000048447397,0.000019662659],"domain_scores_gemma":[0.9998815,0.000058392518,0.000024259074,0.0000046465348,0.000020215952,0.000010898764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055348297,0.0011160239,0.0010785178,0.0015723498,0.00014999264,0.0008417752,0.00060028944,0.0010108646,0.0048733708],"category_scores_gemma":[0.0004306574,0.00033556792,0.00047441045,0.0010564785,0.00036989595,0.0010736765,0.0006412618,0.0016529771,0.0018655662],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001406536,0.00014375326,0.000053955562,0.014884764,0.00009210049,0.00017471469,0.000036204397,0.0004983516,0.011669722,0.005345775,0.027338248,0.9396218],"study_design_scores_gemma":[0.000081074795,0.0002030936,0.0003161183,0.002633979,0.00017026767,0.000695866,0.000029964309,0.00025842173,0.0045782323,0.0021073048,0.9888993,0.000026443811],"about_ca_topic_score_codex":0.000456612,"about_ca_topic_score_gemma":0.0010991493,"teacher_disagreement_score":0.0048733708,"about_ca_system_score_codex":0.00040519313,"about_ca_system_score_gemma":0.0005206843,"threshold_uncertainty_score":0.016303003},"labels":[],"label_agreement":null},{"id":"W4387500323","doi":"10.21203/rs.3.rs-3366592/v1","title":"CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different amplitude.","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; University of Toronto; Cancerfonden; Stiftelsen Tornspiran","keywords":"Glucocorticoid; Phenotype; Function (biology); Amplitude; Cell biology; Biology; Chemistry; Physics; Endocrinology; Genetics; Gene; Optics","score_opus":0.05723631142787739,"score_gpt":0.3549740242073337,"score_spread":0.2977377127794563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387500323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993893,0.0021994023,0.001485551,0.0000863794,0.000048185706,0.00002518547,0.00072481914,0.00008317331,0.0014542764],"genre_scores_gemma":[0.99726796,0.0005245095,0.0004576769,0.000051705854,0.000009166882,0.00002652763,0.0004516519,0.0000124547305,0.0011983796],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997408,0.000046591013,0.0000166794,0.00005209856,0.000060112627,0.00008371688],"domain_scores_gemma":[0.9998946,0.000017702047,0.000030531315,0.000013283204,0.000013620517,0.000030243145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009743784,0.00030642736,0.00018924531,0.00014200184,0.00009756699,0.0004030564,0.00015443037,0.00034169745,0.0023780908],"category_scores_gemma":[0.00013441054,0.000097829055,0.0002872531,0.00013001918,0.00021418264,0.00016837736,0.0001436185,0.00065158855,0.00047017992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036600535,0.00003397697,0.00053448946,0.000051963172,0.000008403973,0.00007080868,0.000025890848,0.000098898854,0.9969831,0.0000690029,0.00007025912,0.0016870891],"study_design_scores_gemma":[0.00003108412,0.001298892,0.013321586,0.000012289394,0.00006823722,0.00064383936,0.00012695117,0.0006647257,0.97943795,0.00008554132,0.0042993235,0.000009711129],"about_ca_topic_score_codex":0.00044596434,"about_ca_topic_score_gemma":0.00039134332,"teacher_disagreement_score":0.0023780908,"about_ca_system_score_codex":0.0002320578,"about_ca_system_score_gemma":0.00013217867,"threshold_uncertainty_score":0.007955432},"labels":[],"label_agreement":null},{"id":"W4387540453","doi":"10.1080/17474086.2023.2268273","title":"Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?","year":2023,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Immunotherapy; Myeloid leukemia; Clinical trial; Immunology; Myelodysplastic syndromes; Myeloid; Tolerability; T cell; Immune system; Oncology; Cancer research; Internal medicine; Bone marrow; Adverse effect","score_opus":0.049156869697557774,"score_gpt":0.40672588013009886,"score_spread":0.3575690104325411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387540453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004837978,0.99790466,0.00004934429,0.00095080736,0.0005124527,0.0000031373559,0.000011980513,0.0000054171855,0.0005138813],"genre_scores_gemma":[0.000386998,0.9974607,0.00009427119,0.0009102384,0.00053465145,0.0000058490477,0.000024856972,0.0000014741889,0.0005809309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99979097,0.00005296987,0.000023458142,0.000029567009,0.00008295578,0.000020138503],"domain_scores_gemma":[0.99963355,0.000158102,0.00005572756,0.000007715464,0.00011389561,0.00003097951],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006627085,0.00057846814,0.0011507395,0.0009849089,0.00018786907,0.0008196946,0.0007234263,0.0012081761,0.003917729],"category_scores_gemma":[0.0009095359,0.00014553928,0.00050846057,0.0011237196,0.0002989501,0.0011490844,0.00044193908,0.0019911542,0.0021440051],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008672138,0.000033479122,0.0000778439,0.014036565,0.00009115353,0.000091300644,0.000034635646,0.00021526702,0.00074100407,0.0021733292,0.08664247,0.8957763],"study_design_scores_gemma":[0.00004020913,0.000091425565,0.0004149316,0.0071267695,0.00011864295,0.00064860337,0.000041216197,0.000065781,0.00013408336,0.0017150006,0.9895914,0.000012085929],"about_ca_topic_score_codex":0.0008753564,"about_ca_topic_score_gemma":0.0017072164,"teacher_disagreement_score":0.003917729,"about_ca_system_score_codex":0.00048230763,"about_ca_system_score_gemma":0.0009151947,"threshold_uncertainty_score":0.013106108},"labels":[],"label_agreement":null},{"id":"W4387576459","doi":"10.1038/s41467-023-42010-1","title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China; Chinese Academy of Sciences; Institute of Genetics; National Natural Science Foundation of China","keywords":"KRAS; T-cell receptor; Cancer research; T cell; Immunotherapy; Context (archaeology); Mutant; Biology; Mutation; Molecular biology; Immunology; Immune system; Genetics; Gene","score_opus":0.06662169282579858,"score_gpt":0.3603754140301149,"score_spread":0.2937537212043163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387576459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.954457,0.0107648205,0.019837743,0.00064076297,0.00024917722,0.00037712598,0.00039472946,0.00063589594,0.012642709],"genre_scores_gemma":[0.9875102,0.0025856113,0.005501004,0.00012398086,0.000028165188,0.00010916468,0.000260274,0.000020587942,0.0038611267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987006,0.000030634277,0.0000069365483,0.00002015939,0.000038385973,0.000033868073],"domain_scores_gemma":[0.99997544,0.0000033146177,0.000006811403,0.0000041936673,0.0000029794185,0.000007249505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000099234356,0.00031855697,0.00020196666,0.00022651708,0.00009129912,0.00029531674,0.0002262298,0.00035988688,0.0019992113],"category_scores_gemma":[0.00006771185,0.00011304493,0.00019131397,0.00014206806,0.00013954863,0.00015929072,0.000166098,0.0009372499,0.00074581325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026556975,0.0002751675,0.00030932392,0.000119675526,0.000015980857,0.00018752734,0.000030551717,0.0005476227,0.97410005,0.0007684636,0.00077301165,0.022606904],"study_design_scores_gemma":[0.000286582,0.003929335,0.0024558534,0.000036699992,0.00009454808,0.0029401449,0.00004089357,0.0058848113,0.9515171,0.00039692278,0.032399092,0.000017932005],"about_ca_topic_score_codex":0.00023352719,"about_ca_topic_score_gemma":0.00047784156,"teacher_disagreement_score":0.0019992113,"about_ca_system_score_codex":0.00022192807,"about_ca_system_score_gemma":0.0001989252,"threshold_uncertainty_score":0.006687999},"labels":[],"label_agreement":null},{"id":"W4387581273","doi":"10.3389/fmolb.2023.1267762","title":"Unlocking the potential of Tregs: innovations in CAR technology","year":2023,"lang":"en","type":"review","venue":"Frontiers in Molecular Biosciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Kidney Foundation of Canada","keywords":"Chimeric antigen receptor; Homing (biology); Antigen; Immunology; Receptor; Immunotherapy; FOXP3; Immune system; Cell therapy; Biology; Computational biology; Cell biology; Stem cell; Genetics","score_opus":0.03796710047597518,"score_gpt":0.3643147626166985,"score_spread":0.3263476621407233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387581273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029448727,0.87790114,0.068191595,0.004176959,0.001055045,0.000118431504,0.00012135987,0.0003659107,0.018620856],"genre_scores_gemma":[0.182853,0.75881976,0.040242154,0.0036059301,0.001295312,0.00026149646,0.00027330391,0.000083547806,0.012565537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999708,0.000061831975,0.0000142405715,0.000058742782,0.00010745878,0.00004968329],"domain_scores_gemma":[0.9998456,0.00006822477,0.000018940149,0.000008358567,0.00004174651,0.000017117398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007387523,0.00048759583,0.00047233797,0.00071018015,0.00018723833,0.000860209,0.0005888178,0.0008758061,0.0015686966],"category_scores_gemma":[0.00043137177,0.00022289592,0.0005568356,0.0003891785,0.0004724122,0.001417271,0.00058810547,0.0021826625,0.000755478],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027682085,0.00024345345,0.0006056142,0.005371934,0.00009044953,0.0008822936,0.00031817867,0.0028291056,0.24546126,0.07943383,0.009963749,0.6545233],"study_design_scores_gemma":[0.00009034887,0.0014741342,0.0007315771,0.00072020275,0.00018843004,0.0027539153,0.00015847482,0.004270333,0.1753884,0.014285802,0.7998447,0.00009374265],"about_ca_topic_score_codex":0.0004789499,"about_ca_topic_score_gemma":0.00038893384,"teacher_disagreement_score":0.0015686966,"about_ca_system_score_codex":0.0005691018,"about_ca_system_score_gemma":0.0005388922,"threshold_uncertainty_score":0.0052478313},"labels":[],"label_agreement":null},{"id":"W4387747059","doi":"10.1016/j.omtm.2023.101139","title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"Bundesministerium für Bildung und Forschung","keywords":"Electroporation; Chimeric antigen receptor; In vitro; In vivo; Messenger RNA; Cell; Ex vivo; T cell; Cell biology; Chemistry; Biology; Immunology; Immune system; Biotechnology; Gene; Biochemistry","score_opus":0.09062217181834831,"score_gpt":0.4393684752559198,"score_spread":0.3487463034375715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387747059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96600026,0.0044132625,0.023026355,0.00028424288,0.000098623605,0.000082442966,0.000135339,0.00024258894,0.005716908],"genre_scores_gemma":[0.98792124,0.001428145,0.0063216095,0.00007117358,0.000016721293,0.000036224235,0.00012306841,0.000040745836,0.00404101],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998354,0.00004060162,0.000014402425,0.000045973884,0.00003658314,0.000027068621],"domain_scores_gemma":[0.99985635,0.00005679075,0.000034540994,0.000009699199,0.000030205785,0.000012423697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020465556,0.00030652,0.00019358657,0.00015336864,0.00009341982,0.00040023678,0.000110671215,0.00035098975,0.001084261],"category_scores_gemma":[0.000385448,0.000105477025,0.0001738033,0.000095607356,0.00021236065,0.00035322522,0.00024529066,0.00032543862,0.0003861777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001428212,0.000022723107,0.0001123405,0.00007463221,0.000004905867,0.000048956343,0.00002467085,0.00034119506,0.9933977,0.00021874023,0.000055928886,0.005555433],"study_design_scores_gemma":[0.000007974358,0.00027641663,0.00037857937,0.000005341939,0.000022420632,0.000085873166,0.000012844573,0.0013465612,0.9956145,0.000063479616,0.002182142,0.000003769328],"about_ca_topic_score_codex":0.00052984577,"about_ca_topic_score_gemma":0.00063381036,"teacher_disagreement_score":0.001084261,"about_ca_system_score_codex":0.00027037502,"about_ca_system_score_gemma":0.00021987075,"threshold_uncertainty_score":0.0036272407},"labels":[],"label_agreement":null},{"id":"W4387809673","doi":"10.1016/j.annonc.2023.10.029","title":"LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"Ipsen; Astellas Pharma; Eisai; AstraZeneca; University College London; Boston Scientific Corporation; Seagen; Pfizer","keywords":"Medicine; Open label; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Open label study; Surgery; Randomized controlled trial","score_opus":0.3080902739800833,"score_gpt":0.5448928587729979,"score_spread":0.23680258479291455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794207,0.0056772754,0.001271282,0.0016115422,0.0008069947,0.0031053564,0.0026531632,0.00033161786,0.0051221135],"genre_scores_gemma":[0.98215485,0.0025653285,0.002373127,0.0021771223,0.00033263306,0.00270686,0.0024616513,0.0000928688,0.00513553],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993894,0.00030369236,0.000017780776,0.00010820865,0.00004644113,0.00013448278],"domain_scores_gemma":[0.9993747,0.00014959043,0.00011815849,0.000046159137,0.000036322785,0.00027508748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020076195,0.0015136277,0.0023108337,0.000495732,0.0004062653,0.0012455656,0.0011820507,0.001811666,0.008069461],"category_scores_gemma":[0.0010692817,0.0006173192,0.0019184913,0.00047524823,0.0014596712,0.0012761179,0.0004553771,0.004873838,0.0016172657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9131043,0.016517105,0.0012323679,0.00078455976,0.0014805554,0.000040410352,0.00010482017,0.001094514,0.0057882452,0.00040794755,0.004552074,0.054893132],"study_design_scores_gemma":[0.8999537,0.09366112,0.0022187491,0.00005121295,0.00054871716,0.000038496462,0.00005737882,0.000921519,0.00060281577,0.00028936824,0.0016292293,0.000027638278],"about_ca_topic_score_codex":0.0025080317,"about_ca_topic_score_gemma":0.008248091,"teacher_disagreement_score":0.008069461,"about_ca_system_score_codex":0.0013541604,"about_ca_system_score_gemma":0.001760883,"threshold_uncertainty_score":0.026995003},"labels":[],"label_agreement":null},{"id":"W4387811091","doi":"10.1016/j.annonc.2023.09.2185","title":"1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"PharmaMar; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; European Society for Medical Oncology; American Society of Clinical Oncology; BeiGene; Sanofi","keywords":"Medicine; Cytokine release syndrome; Glypican 3; Pharmacokinetics; Oncology; Adverse effect; T cell; Internal medicine; Biomarker; Gastroenterology; Cancer; Cancer research; Immunotherapy; Immunology; Chimeric antigen receptor; Immune system","score_opus":0.1514363011465199,"score_gpt":0.47915271221053296,"score_spread":0.32771641106401306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98347324,0.0021005615,0.0017357494,0.0014029421,0.00022367557,0.0022145403,0.0031278622,0.0003901436,0.0053311945],"genre_scores_gemma":[0.97162,0.002636281,0.0046502496,0.0019506557,0.00019769958,0.0023405333,0.0064605367,0.00016770579,0.009976289],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996437,0.00016064361,0.000010646503,0.000048556387,0.00004162372,0.00009489958],"domain_scores_gemma":[0.9994973,0.00009915828,0.00006494356,0.000046204794,0.0000335752,0.00025881798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012886365,0.0019864049,0.0016521321,0.0005343976,0.00046374951,0.0012076831,0.00078096415,0.0014273131,0.0047196527],"category_scores_gemma":[0.00070857763,0.0005270284,0.0015854193,0.00045783276,0.00091229554,0.0007958289,0.00033020088,0.004790866,0.0012900204],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41647178,0.12084534,0.0069362195,0.0012719355,0.0025460955,0.00048635295,0.0007048812,0.01471408,0.113686144,0.0011587081,0.0234291,0.29774937],"study_design_scores_gemma":[0.4103569,0.54564667,0.016917136,0.00006977668,0.0008170781,0.00044452545,0.00015773636,0.00521435,0.009709037,0.0009903142,0.009608478,0.000067938934],"about_ca_topic_score_codex":0.0018247267,"about_ca_topic_score_gemma":0.0040299604,"teacher_disagreement_score":0.0047196527,"about_ca_system_score_codex":0.00096430734,"about_ca_system_score_gemma":0.0014233176,"threshold_uncertainty_score":0.015788794},"labels":[],"label_agreement":null},{"id":"W4387811241","doi":"10.1016/j.annonc.2023.09.2158","title":"1019O Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Chugai Pharmaceutical; Astellas Pharma; Eisai; Daiichi-Sankyo; Svenska Forskningsrådet Formas; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; BeiGene; Pfizer; INOVIO Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Nivolumab; Internal medicine; Neutropenia; Oncology; CD8; Pembrolizumab; Cytokine release syndrome; Melanoma; Immunotherapy; Immunology; Antigen; Chimeric antigen receptor; Chemotherapy; Cancer; Cancer research","score_opus":0.3242130588186991,"score_gpt":0.5044721720448572,"score_spread":0.18025911322615806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9354749,0.011880049,0.0013317381,0.0052907453,0.0009737361,0.0012869238,0.009491091,0.00021182818,0.03405894],"genre_scores_gemma":[0.9541185,0.0051028114,0.0022159757,0.0039386484,0.0004238381,0.0007577798,0.01672582,0.000091615184,0.016625082],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99964523,0.00013326661,0.00002264568,0.00005195,0.000058997342,0.000087937144],"domain_scores_gemma":[0.9994783,0.00013475973,0.00005742476,0.000052701653,0.000054646724,0.00022210709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011622926,0.0006176941,0.0009199691,0.0001996069,0.00043257538,0.0012088249,0.0003180126,0.0006789477,0.011095319],"category_scores_gemma":[0.000725974,0.0002007454,0.00071137474,0.00026799692,0.00046080965,0.0006565696,0.00027829324,0.0021085879,0.0021134082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35929912,0.021126948,0.012383967,0.0014435054,0.002538322,0.00039831284,0.00020572488,0.0026232125,0.09744065,0.0016849028,0.041977156,0.45887813],"study_design_scores_gemma":[0.27673718,0.39871016,0.080749996,0.0003064059,0.0031333251,0.0016494794,0.00039042137,0.003596108,0.047065295,0.0025123092,0.18503495,0.000114485316],"about_ca_topic_score_codex":0.0011304375,"about_ca_topic_score_gemma":0.0040944424,"teacher_disagreement_score":0.011095319,"about_ca_system_score_codex":0.0007628153,"about_ca_system_score_gemma":0.0008695319,"threshold_uncertainty_score":0.03711754},"labels":[],"label_agreement":null},{"id":"W4387812409","doi":"10.1016/j.annonc.2023.09.1440","title":"1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Pneumonitis; Chimeric antigen receptor; Internal medicine; Oncology; Refractory (planetary science); Chemotherapy; Leukapheresis; Immunotherapy; Gastroenterology; Cancer; Stem cell; Lung","score_opus":0.1673751192360413,"score_gpt":0.47712884700499364,"score_spread":0.3097537277689524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893505,0.0014441542,0.000554455,0.00067626074,0.00019253478,0.0015267163,0.0017061679,0.00018155907,0.0043676794],"genre_scores_gemma":[0.9842716,0.0012732919,0.0015763533,0.0011244533,0.00016751487,0.0018810201,0.004340908,0.0000616462,0.005303147],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999678,0.00015428245,0.000013287243,0.000061878614,0.000024007533,0.000068668596],"domain_scores_gemma":[0.99965024,0.00008359704,0.00004954983,0.00004095449,0.000017760483,0.00015791583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010497925,0.0010431554,0.0014691792,0.00035968228,0.00027433067,0.0008044166,0.00064715056,0.0010724022,0.0061481064],"category_scores_gemma":[0.000705462,0.00035774175,0.0007441832,0.0002945794,0.0007470175,0.00064031733,0.00028468887,0.0026048187,0.0013382827],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6860974,0.03485161,0.0056369393,0.0010640107,0.0015531601,0.0006401008,0.00021483575,0.004021428,0.08410626,0.0011833796,0.013521263,0.16710958],"study_design_scores_gemma":[0.6246495,0.35118747,0.007646518,0.000050930543,0.0005349053,0.0006488203,0.000070205235,0.0019816002,0.0065581887,0.0005876716,0.00605338,0.000030828047],"about_ca_topic_score_codex":0.00090604846,"about_ca_topic_score_gemma":0.001912695,"teacher_disagreement_score":0.0061481064,"about_ca_system_score_codex":0.00068035006,"about_ca_system_score_gemma":0.0010171144,"threshold_uncertainty_score":0.020567417},"labels":[],"label_agreement":null},{"id":"W4387824968","doi":"10.1016/j.annonc.2023.09.2005","title":"859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Adverse effect; Head and neck squamous-cell carcinoma; Refractory (planetary science); Phases of clinical research; Cohort; Surgery; Oncology; Clinical trial; Head and neck cancer; Cancer","score_opus":0.06312735777555628,"score_gpt":0.3723666057780799,"score_spread":0.3092392480025236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387824968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276286,0.003157177,0.00011467336,0.0004589341,0.00009589691,0.00020390049,0.000821998,0.00007007937,0.0023145124],"genre_scores_gemma":[0.99076486,0.0028458051,0.00033944743,0.0007958964,0.00009853682,0.00016789499,0.002433891,0.000022913062,0.0025308547],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998765,0.00004074767,0.000005392248,0.000023754488,0.000013482364,0.000040140272],"domain_scores_gemma":[0.99986446,0.000017823939,0.000025448255,0.000009672535,0.000008287162,0.00007421444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000496001,0.00055540795,0.0010133219,0.00020259038,0.0001817138,0.00073226326,0.0003621061,0.00049095217,0.0027199697],"category_scores_gemma":[0.00031325937,0.00019470451,0.00068548054,0.00036992293,0.00039634202,0.0005267514,0.00024343099,0.0013443667,0.0008613006],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5761712,0.009702847,0.028113525,0.0012570682,0.002806967,0.00033871725,0.0003571843,0.0056335656,0.035365295,0.00084164325,0.015390989,0.32402107],"study_design_scores_gemma":[0.5560367,0.2962067,0.10819214,0.00026860993,0.0030706467,0.0010031818,0.00041982753,0.004832994,0.0053986516,0.0017120477,0.022789208,0.000069341964],"about_ca_topic_score_codex":0.0015823541,"about_ca_topic_score_gemma":0.006751203,"teacher_disagreement_score":0.0027199697,"about_ca_system_score_codex":0.00056644256,"about_ca_system_score_gemma":0.0007027954,"threshold_uncertainty_score":0.0090991855},"labels":[],"label_agreement":null},{"id":"W4387866461","doi":"10.1139/bcb-2023-0207","title":"BioCanRx Summit for Cancer Immunotherapy 2022 Proceedings","year":2023,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Terry Fox Research Institute; University of Calgary; Beatrice Hunter Cancer Research Institute; University of British Columbia; Ottawa Hospital; Canadian Patient Safety Institute; Dalhousie University","funders":"Canadian Institutes of Health Research; Killam Trusts; BC Children's Hospital; BC Cancer Foundation; Children's Hospital Foundation; Beatrice Hunter Cancer Research Institute; Alberta Children's Hospital Research Institute; Cancer Research Institute","keywords":"Summit; Event (particle physics); Session (web analytics); Medicine; Plenary session; Pandemic; Medical education; Panel discussion; Cancer; Public relations; Coronavirus disease 2019 (COVID-19); Political science; Library science; Disease; Pathology; Internal medicine; Computer science; Business","score_opus":0.02352348168894332,"score_gpt":0.3223409686032118,"score_spread":0.2988174869142685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387866461","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049386965,0.08509253,0.0032902912,0.23858227,0.36829507,0.00093037315,0.00686877,0.0017441397,0.29025787],"genre_scores_gemma":[0.024386313,0.03464595,0.0029628875,0.06107648,0.09890352,0.0009740854,0.013318449,0.00080466346,0.76292753],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970055,0.0005025333,0.00008092557,0.0002243155,0.0017653038,0.00042138677],"domain_scores_gemma":[0.9965224,0.00031843642,0.00014084921,0.00010165491,0.0014350624,0.0014815611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061392905,0.0011888128,0.0007206701,0.0010183763,0.0024399047,0.005942295,0.0015517132,0.004666832,0.10853795],"category_scores_gemma":[0.004688404,0.00030916228,0.0010237527,0.00053742365,0.0006703943,0.0016010908,0.0041275285,0.00644404,0.06271024],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007617498,0.000021782247,0.000030011435,0.000098004835,0.00000698778,0.000037437276,0.000023314868,0.000030883737,0.00046745146,0.00068255473,0.98767674,0.010848643],"study_design_scores_gemma":[0.000018937611,0.000041642907,0.00021525525,0.00005877516,0.0000056238623,0.000027465598,0.00004229098,0.00003746509,0.0003160926,0.00028875214,0.9989416,0.0000059985027],"about_ca_topic_score_codex":0.0042658355,"about_ca_topic_score_gemma":0.0107208565,"teacher_disagreement_score":0.10853795,"about_ca_system_score_codex":0.0041463915,"about_ca_system_score_gemma":0.005744225,"threshold_uncertainty_score":0.36309558},"labels":[],"label_agreement":null},{"id":"W4387955394","doi":"10.1016/j.intimp.2023.111093","title":"Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer","year":2023,"lang":"en","type":"review","venue":"International Immunopharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Tabriz University of Medical Sciences","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Toxicity; Suicide gene; Antigen; Cell therapy; Immunotherapy; Cancer; Cancer research; Adverse effect; Monoclonal antibody; Immunology; Immune system; Genetic enhancement; Medicine; T cell; Biology; Cell; Pharmacology; Antibody; Internal medicine; Gene","score_opus":0.10877761384237111,"score_gpt":0.4661448907634555,"score_spread":0.3573672769210844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387955394","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023427956,0.99735427,0.0005155891,0.0002993645,0.0002449041,0.000010391983,0.000021064137,0.000012319478,0.0013078154],"genre_scores_gemma":[0.0013424028,0.99666685,0.00057768216,0.00026490804,0.00013075098,0.000014429974,0.00003721807,0.0000023747468,0.0009634434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998803,0.000021936714,0.000010306133,0.000020815822,0.00004751322,0.000019130164],"domain_scores_gemma":[0.99985373,0.00007409568,0.000021275526,0.0000055005366,0.000033439323,0.0000119421165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066998677,0.00092360994,0.001098785,0.0011714079,0.00020534046,0.00082307827,0.0008839887,0.0010485701,0.0038340257],"category_scores_gemma":[0.0004960038,0.000238897,0.0005629816,0.0011143193,0.00045649603,0.001043133,0.00054428977,0.002088323,0.0017100313],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012565967,0.00015580273,0.00007381877,0.012023824,0.000093250004,0.00014155338,0.000037013528,0.00086337246,0.007958434,0.009041627,0.024740096,0.9447456],"study_design_scores_gemma":[0.000067673485,0.00023337724,0.00034727872,0.0018668827,0.00014693182,0.0005119946,0.000029237232,0.00022155851,0.0023166446,0.0029604097,0.9912776,0.00002039811],"about_ca_topic_score_codex":0.0010885228,"about_ca_topic_score_gemma":0.0019041606,"teacher_disagreement_score":0.0038340257,"about_ca_system_score_codex":0.0006371059,"about_ca_system_score_gemma":0.00080000854,"threshold_uncertainty_score":0.012826145},"labels":[],"label_agreement":null},{"id":"W4387966068","doi":"10.1038/s41591-023-02591-2","title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Sunnybrook Hospital; McMaster University; University of Toronto","funders":"Fondation ARC pour la Recherche sur le Cancer; Direction Générale de l’offre de Soins; Deutsche Forschungsgemeinschaft; Bundesministerium für Bildung und Forschung; Foundation for the National Institutes of Health","keywords":"Myocarditis; Thymoma; Medicine; Myasthenia gravis; Myositis; Nivolumab; Autoimmunity; Pembrolizumab; Immunology; Internal medicine; Immune system; Immunotherapy","score_opus":0.01963470711067283,"score_gpt":0.3438438234289383,"score_spread":0.3242091163182655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387966068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828583,0.00064227404,0.00016231537,0.00004270867,0.000011963735,0.0000046318164,0.000043516975,0.000012167095,0.0007944664],"genre_scores_gemma":[0.9993594,0.00013334546,0.00006410432,0.000016128562,0.000022898685,0.000002607515,0.000032891443,0.0000033346937,0.00036520843],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998336,0.000046635123,0.000009837303,0.00004088597,0.000027517637,0.000041407948],"domain_scores_gemma":[0.99921405,0.00008707588,0.0003895907,0.000059798396,0.000032641503,0.00021684132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025874865,0.0002879183,0.00021508554,0.00076061586,0.00018618564,0.00040578088,0.00021310768,0.00037602047,0.002937375],"category_scores_gemma":[0.0006909029,0.0001956094,0.00017483465,0.00022431303,0.0002344973,0.00028468238,0.00027730296,0.00053757883,0.00022341912],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015194468,0.0008822484,0.410998,0.00014270018,0.0003587715,0.0042642592,0.00018934403,0.0002713374,0.54394644,0.00063739705,0.0003603178,0.022754744],"study_design_scores_gemma":[0.00012277688,0.0017640779,0.9715926,0.00002477231,0.0001673893,0.005828362,0.00021849491,0.00047945016,0.018507717,0.00034847826,0.00092971674,0.000016169224],"about_ca_topic_score_codex":0.0002467019,"about_ca_topic_score_gemma":0.0002634452,"teacher_disagreement_score":0.002937375,"about_ca_system_score_codex":0.00015631974,"about_ca_system_score_gemma":0.00011369247,"threshold_uncertainty_score":0.009826481},"labels":[],"label_agreement":null},{"id":"W4387998434","doi":"10.3389/fimmu.2023.1239132","title":"Mediport use as an acceptable standard for CAR T cell infusion","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Sidney Kimmel Comprehensive Cancer Center; University of Florida Health; University of California, San Francisco; Winship Cancer Institute; Hospital for Sick Children; City of Hope; Johns Hopkins University; University of Minnesota; University of California, Los Angeles; Yale University; Cincinnati Children's Hospital Medical Center; Emory University; Children's National Hospital; Florida Department of Health","keywords":"Medicine; Chimeric antigen receptor; Clinical Practice; Cell therapy; T cell; Cell; Immunology; Immune system; Physical therapy","score_opus":0.027608934302303417,"score_gpt":0.3232360501654752,"score_spread":0.29562711586317175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387998434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96681523,0.00386313,0.0110004945,0.002845329,0.00011809965,0.00025179674,0.0028469237,0.00022602404,0.012032891],"genre_scores_gemma":[0.9900186,0.0016679331,0.0059262933,0.0006812143,0.00007861562,0.00014251615,0.0010184156,0.00004414515,0.00042228238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9880733,0.0042533353,0.0021063148,0.0012991829,0.0038577144,0.0004102208],"domain_scores_gemma":[0.94211817,0.012340257,0.035836626,0.0032612863,0.0046652285,0.0017783702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005631106,0.00017533734,0.00024582914,0.0010994211,0.000533685,0.0019663405,0.0008073624,0.00050604134,0.0043272614],"category_scores_gemma":[0.035686,0.00015031923,0.00035193865,0.0018427796,0.000943831,0.0016190677,0.0009804476,0.0007849165,0.0008280614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026077175,0.00014208462,0.9100445,0.0004958508,0.00007567419,0.0002932562,0.001389327,0.00026634953,0.0016732045,0.0010718694,0.0046937615,0.07959324],"study_design_scores_gemma":[0.000032954675,0.0012161549,0.94110954,0.0012185116,0.00014124572,0.0067204386,0.004313589,0.001620049,0.006439048,0.00082654017,0.03629854,0.000063497806],"about_ca_topic_score_codex":0.0013612482,"about_ca_topic_score_gemma":0.0015867476,"teacher_disagreement_score":0.005631106,"about_ca_system_score_codex":0.0009653704,"about_ca_system_score_gemma":0.001714974,"threshold_uncertainty_score":0.029780507},"labels":[],"label_agreement":null},{"id":"W4388035612","doi":"10.1038/s43018-023-00652-6","title":"Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target","year":2023,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Waterloo","funders":"National Institute of General Medical Sciences; American Society of Hematology; University of California, San Francisco; NIH Office of the Director; National Science Foundation; Canadian Institutes of Health Research; Michelson Prize and Grants; Bristol-Myers Squibb; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Government of Canada","keywords":"Myeloid leukemia; Chimeric antigen receptor; Cancer research; Immunotherapy; Haematopoiesis; Cancer; Glycoprotein; Antigen; Computational biology; Malignancy; Biology; Chemistry; Cell biology; Immunology; Molecular biology; Stem cell; Genetics","score_opus":0.03415566916516265,"score_gpt":0.3550307940967016,"score_spread":0.3208751249315389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388035612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825294,0.00038664657,0.013839983,0.00027685997,0.0000146076145,0.000013945849,0.00016029249,0.000107358195,0.0026708944],"genre_scores_gemma":[0.99533135,0.00019407683,0.0030195208,0.00011850731,0.0000052516107,0.000008322138,0.0001480429,0.000015377924,0.0011595573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993277,0.000008612286,0.0000021538808,0.000016744369,0.00002225339,0.000017404318],"domain_scores_gemma":[0.99996126,0.000007446499,0.0000123092295,0.0000040357463,0.0000075323715,0.0000074484587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116066556,0.00017827556,0.00009672243,0.00012206327,0.00009969817,0.0003450987,0.00014499172,0.0002769286,0.0012018821],"category_scores_gemma":[0.00010433514,0.00008343452,0.00013088582,0.00009831649,0.00016857043,0.00018486299,0.00015691007,0.00042794645,0.00024191987],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026490774,0.00000829895,0.00033196865,0.0000060907396,0.000002361662,0.000020307596,0.0000075044804,0.00022063911,0.9980007,0.00026710116,0.00006578049,0.0010427603],"study_design_scores_gemma":[0.000011190273,0.00016459519,0.003504135,0.0000023812336,0.000009105716,0.00024743422,0.000038901835,0.0086083645,0.9850462,0.00028534964,0.0020775544,0.000004797177],"about_ca_topic_score_codex":0.00053604564,"about_ca_topic_score_gemma":0.0006484162,"teacher_disagreement_score":0.0012018821,"about_ca_system_score_codex":0.00028474562,"about_ca_system_score_gemma":0.00013794607,"threshold_uncertainty_score":0.0040206313},"labels":[],"label_agreement":null},{"id":"W4388042528","doi":"10.1136/jitc-2023-sitc2023.0689","title":"689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; CD38; Pharmacodynamics; Internal medicine; Multiple myeloma; CD8; Oncology; Refractory (planetary science); Antibody; Monoclonal antibody; Pharmacology; Immunology; Gastroenterology; Bortezomib; Immune system; Pharmacokinetics; Stem cell; Biology; CD34","score_opus":0.014267462257194538,"score_gpt":0.255296573393422,"score_spread":0.24102911113622744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388042528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963462,0.0018226426,0.00014241962,0.00019530514,0.000025684289,0.000074785865,0.00032233744,0.00003386717,0.0010367199],"genre_scores_gemma":[0.99842227,0.0003003159,0.0001962339,0.0002282997,0.000044032935,0.000038671198,0.00042995298,0.000008713138,0.00033159714],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980885,0.00006736035,0.000013898711,0.00003722891,0.000032275617,0.00004037558],"domain_scores_gemma":[0.9997305,0.000063002786,0.0000645959,0.0000142625295,0.000016955466,0.00011073079],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004677588,0.00029714854,0.0009248331,0.00024839962,0.0001976313,0.00055489625,0.00019058006,0.00039470164,0.0018980056],"category_scores_gemma":[0.0006584134,0.00014935085,0.0008220193,0.00024103852,0.0001903919,0.0003240371,0.00018300833,0.0009819252,0.0003948915],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4267815,0.013247508,0.11348892,0.00070157845,0.0034808675,0.001563194,0.00045936875,0.00687431,0.15931757,0.0003056841,0.005835525,0.26794398],"study_design_scores_gemma":[0.08382152,0.3303176,0.50128543,0.000101225916,0.0042376444,0.0041640894,0.0003096949,0.015428062,0.040259335,0.00070480077,0.019223325,0.00014724521],"about_ca_topic_score_codex":0.0005999689,"about_ca_topic_score_gemma":0.0012500178,"teacher_disagreement_score":0.0018980056,"about_ca_system_score_codex":0.00052263937,"about_ca_system_score_gemma":0.00033916387,"threshold_uncertainty_score":0.006349504},"labels":[],"label_agreement":null},{"id":"W4388042588","doi":"10.1136/jitc-2023-sitc2023.0347","title":"347 Functional characterization of GUCY2C-TAC T cells for the treatment of colorectal cancer using preclinical models","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vivo; Cancer research; Receptor; In vitro; Antigen; Cancer; Cancer cell; Colorectal cancer; Cytotoxic T cell; Chemistry; Cell biology; Biology; Medicine; Immunology; Internal medicine; Biochemistry","score_opus":0.11431374849587565,"score_gpt":0.34841567456806927,"score_spread":0.2341019260721936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388042588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867661,0.0013170197,0.0068857903,0.00019653363,0.000059187634,0.00028778004,0.0015002604,0.00012124679,0.0028661273],"genre_scores_gemma":[0.9866194,0.0008341388,0.0060490803,0.00014400185,0.00002038405,0.00029192222,0.002588159,0.000034255634,0.0034187231],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986815,0.000025372694,0.000010629313,0.00001952898,0.0000397425,0.000036592366],"domain_scores_gemma":[0.9999279,0.000012770591,0.000012982057,0.0000075504668,0.000018956762,0.000019892148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020612215,0.00037403108,0.000249584,0.00019426871,0.00011865936,0.00022976265,0.00018488042,0.00036612278,0.0014396809],"category_scores_gemma":[0.00011814869,0.000087142274,0.0002564975,0.00015203231,0.00012212334,0.00011197593,0.000065607506,0.00055653264,0.00061385904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018197422,0.00013725253,0.00008109306,0.000033016906,0.000004835875,0.000040177183,0.000013429708,0.000267396,0.99761415,0.00009100181,0.00013119204,0.0014044234],"study_design_scores_gemma":[0.000060585717,0.0026410324,0.0012505712,0.0000052318755,0.000021572032,0.00019213268,0.000019144069,0.0022832192,0.9906741,0.00003229214,0.002814224,0.0000058891246],"about_ca_topic_score_codex":0.0012381338,"about_ca_topic_score_gemma":0.0007165109,"teacher_disagreement_score":0.0014396809,"about_ca_system_score_codex":0.00027740977,"about_ca_system_score_gemma":0.00019417722,"threshold_uncertainty_score":0.004816234},"labels":[],"label_agreement":null},{"id":"W4388047619","doi":"10.1136/jitc-2023-sitc2023.0778","title":"778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Cancer; Internal medicine; Oncology; Surgery; Immunotherapy; Cancer research","score_opus":0.04680987990646559,"score_gpt":0.31675635918176015,"score_spread":0.2699464792752946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848316,0.0013900612,0.00050728675,0.000800342,0.00041236047,0.00640967,0.0018893855,0.00015457929,0.0036049618],"genre_scores_gemma":[0.975836,0.0015465039,0.002499647,0.0021922775,0.0004957932,0.0072920676,0.0033179808,0.000073361094,0.0067465208],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995036,0.00025261633,0.000021969245,0.000069895934,0.00005552431,0.000096416006],"domain_scores_gemma":[0.99903595,0.00016633638,0.00016956903,0.000059507074,0.00005371962,0.0005148712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017346926,0.0015330433,0.0018169952,0.00044353312,0.00058727956,0.0010723236,0.0010675809,0.0020025498,0.005738661],"category_scores_gemma":[0.0008730602,0.000657143,0.0016081915,0.00027705135,0.0010586961,0.0009372074,0.00032967023,0.004107145,0.0013321108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8323248,0.08862117,0.0017749707,0.00053219066,0.0006606335,0.00014579916,0.00012133904,0.0012078527,0.037780218,0.00027000386,0.0046970565,0.03186406],"study_design_scores_gemma":[0.60545295,0.3863767,0.003297207,0.000022439239,0.0002446652,0.00008001075,0.00002873207,0.00071339606,0.0022710005,0.0001581345,0.0013284519,0.000026233127],"about_ca_topic_score_codex":0.0015313778,"about_ca_topic_score_gemma":0.005009654,"teacher_disagreement_score":0.005738661,"about_ca_system_score_codex":0.0011029027,"about_ca_system_score_gemma":0.0025114778,"threshold_uncertainty_score":0.019197762},"labels":[],"label_agreement":null},{"id":"W4388047658","doi":"10.1136/jitc-2023-sitc2023.0654","title":"654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Adverse effect; Refractory (planetary science); Internal medicine; Pharmacokinetics; Immunotherapy; Leukapheresis; T cell; Chemotherapy; Oncology; Gastroenterology; Immunology; Immune system; Cancer; Stem cell","score_opus":0.044519737722509396,"score_gpt":0.3424634879703385,"score_spread":0.2979437502478291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897323,0.00087035197,0.00051438593,0.00043546842,0.000124735,0.0034915304,0.0014931281,0.000084042986,0.0032540779],"genre_scores_gemma":[0.98310167,0.000950674,0.0018223353,0.0013661652,0.00018565347,0.0030984841,0.0040045828,0.00003815133,0.0054323697],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970466,0.00014097488,0.000013952122,0.00004038963,0.000030400477,0.00006961851],"domain_scores_gemma":[0.9995747,0.00006686435,0.000057939826,0.000040343195,0.00002904592,0.00023109939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012599186,0.0008492024,0.0008601312,0.00031760323,0.0003645744,0.0006279638,0.00059043657,0.0008152665,0.005233837],"category_scores_gemma":[0.00045929383,0.0003293357,0.0008644147,0.00027124202,0.0006021079,0.0003729842,0.00020723735,0.0020341403,0.0009908547],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.713187,0.09907936,0.0065657194,0.000632363,0.0010722065,0.00047718425,0.00023076951,0.003205817,0.075433545,0.0005961795,0.0100383395,0.08948157],"study_design_scores_gemma":[0.5176327,0.46264553,0.0058963173,0.000029710034,0.00030286176,0.00019612514,0.000044085187,0.0016166297,0.00784044,0.00033467807,0.0034419147,0.000018975854],"about_ca_topic_score_codex":0.0015895783,"about_ca_topic_score_gemma":0.0025384524,"teacher_disagreement_score":0.005233837,"about_ca_system_score_codex":0.0007367258,"about_ca_system_score_gemma":0.0018346284,"threshold_uncertainty_score":0.017508864},"labels":[],"label_agreement":null},{"id":"W4388047947","doi":"10.1136/jitc-2023-sitc2023.0400","title":"400 Preclinical characterization and modelling of allogeneic Vγ9Vδ2 TAC T cells for the treatment of solid tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Antigen; T cell; Cytotoxic T cell; Cell therapy; Immunotherapy; Chimeric antigen receptor; Immunology; In vivo; Antigen-presenting cell; Biology; Medicine; In vitro; Immune system; Cell biology; Stem cell","score_opus":0.08392283671548659,"score_gpt":0.3301677903857863,"score_spread":0.24624495367029972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876773,0.0008683377,0.0069045103,0.000060645903,0.000026112848,0.00017678521,0.00092993624,0.000052376756,0.0033040033],"genre_scores_gemma":[0.99408555,0.00050342886,0.002815529,0.000024858795,0.000006454349,0.00009964839,0.00096533494,0.000013181698,0.0014860615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990284,0.0000148347535,0.000004986547,0.00001433797,0.00003965491,0.000023256294],"domain_scores_gemma":[0.9999466,0.000009105089,0.000012599436,0.000006051436,0.000010844884,0.000014796321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016826804,0.0002538106,0.000145221,0.0001523507,0.00009796498,0.00030057653,0.0002488958,0.0003131232,0.0013756722],"category_scores_gemma":[0.000085974905,0.000081752085,0.00020100281,0.00013789913,0.00010399633,0.00010477652,0.00006497641,0.00036558651,0.00044642642],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038273117,0.000477376,0.00055654533,0.00005544041,0.000006913585,0.00010811336,0.00002292398,0.013254603,0.9815974,0.00033147063,0.00018723654,0.0030191755],"study_design_scores_gemma":[0.00008188057,0.0056486875,0.0017837997,0.0000108345475,0.000023848248,0.00022674305,0.000042383424,0.0334063,0.95434415,0.00016266854,0.004260083,0.000008542833],"about_ca_topic_score_codex":0.0015129197,"about_ca_topic_score_gemma":0.00064505544,"teacher_disagreement_score":0.0015129197,"about_ca_system_score_codex":0.00027993086,"about_ca_system_score_gemma":0.00024193648,"threshold_uncertainty_score":0.0046020746},"labels":[],"label_agreement":null},{"id":"W4388048003","doi":"10.1136/jitc-2023-sitc2023.0312","title":"312 IL7 increases targeted lipid nanoparticle-mediated mRNA protein expression in T cells<i> in vitro</i> and<i> in situ</i> by enhancing T cell translation","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"Molecular biology; Biology; T cell; mCherry; CD28; CD8; Cell biology; Antigen; Immune system; Green fluorescent protein; Immunology; Biochemistry","score_opus":0.014291793481288098,"score_gpt":0.24408714815614044,"score_spread":0.22979535467485235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98243606,0.0013426507,0.008297984,0.0002227225,0.000115745985,0.00008980636,0.00090497214,0.00023425478,0.0063558505],"genre_scores_gemma":[0.98314697,0.0007691023,0.0064334795,0.00018896293,0.00002360018,0.00013853108,0.0015866383,0.00008279447,0.007630022],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997937,0.000040691637,0.000024339275,0.000040849576,0.000050024562,0.000050419745],"domain_scores_gemma":[0.9999001,0.00002841099,0.00002080363,0.0000074030077,0.000021526823,0.000021686557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018306068,0.0003317375,0.00017902165,0.0001961273,0.00011736873,0.0003224694,0.00014432742,0.00038137537,0.003971794],"category_scores_gemma":[0.0000975069,0.00013177143,0.00030405156,0.00015140069,0.00021198862,0.00019262564,0.00014026409,0.0007464202,0.0013252673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014263288,0.000051169896,0.000062292565,0.00004021929,0.0000024332323,0.000023505792,0.000014640693,0.00005447059,0.9988016,0.000054549244,0.000096250944,0.0006561945],"study_design_scores_gemma":[0.000012483025,0.00022660225,0.00046295088,0.0000041448075,0.000004824923,0.000029880575,0.000019877267,0.00047855955,0.99780494,0.0000166109,0.00093686685,0.0000023048678],"about_ca_topic_score_codex":0.0005104985,"about_ca_topic_score_gemma":0.0006718712,"teacher_disagreement_score":0.003971794,"about_ca_system_score_codex":0.0003016062,"about_ca_system_score_gemma":0.00021539051,"threshold_uncertainty_score":0.013286948},"labels":[],"label_agreement":null},{"id":"W4388048115","doi":"10.1136/jitc-2023-sitc2023.0372","title":"372 TAC-T cells persist and remain functional during and after repeated tumor exposure <i>in vitro</i> and <i>in vivo</i>","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytotoxic T cell; Cancer research; In vivo; T cell; Antigen; Flow cytometry; In vitro; Tumor antigen; Biology; Immune system; Immunotherapy; Molecular biology; Immunology; Biochemistry","score_opus":0.012901209380400826,"score_gpt":0.22928253968148246,"score_spread":0.21638133030108164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99196166,0.0011514853,0.0026805152,0.00009761756,0.00004557675,0.00003589824,0.00095121417,0.00012805864,0.0029480313],"genre_scores_gemma":[0.9916391,0.00032982486,0.001174497,0.00011788846,0.0000156668,0.0000639413,0.0020090027,0.00003641931,0.004613731],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995523,0.00006792155,0.000039883053,0.000084614025,0.00010782769,0.00014735192],"domain_scores_gemma":[0.9997657,0.000035997633,0.000050885974,0.000062577084,0.00004077448,0.000044053682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021967609,0.00037325418,0.00026751368,0.00017941845,0.00017524374,0.0004954897,0.0002104823,0.00035582512,0.0015663577],"category_scores_gemma":[0.0001504909,0.000130697,0.000241239,0.00015463798,0.00024873353,0.00019345539,0.000165795,0.00094926235,0.0010465932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022479586,0.000073959345,0.00039013257,0.000017047498,0.000005434302,0.00005199325,0.000025502546,0.00008458417,0.9976914,0.000080301405,0.00013009059,0.0012247645],"study_design_scores_gemma":[0.000015145518,0.0009954774,0.0052396753,0.0000066327475,0.0000211487,0.0003108176,0.000055682,0.0009254324,0.99025655,0.00005215498,0.0021129788,0.00000831457],"about_ca_topic_score_codex":0.0010464994,"about_ca_topic_score_gemma":0.001143424,"teacher_disagreement_score":0.0015663577,"about_ca_system_score_codex":0.00032025826,"about_ca_system_score_gemma":0.00020853068,"threshold_uncertainty_score":0.0052399635},"labels":[],"label_agreement":null},{"id":"W4388048122","doi":"10.1136/jitc-2023-sitc2023.0738","title":"738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Immunotherapy; Leukapheresis; Chimeric antigen receptor; Cancer research; Radioimmunotherapy; Stem cell; Immunology; Immune system; Antibody; Biology; CD34","score_opus":0.037706947430035526,"score_gpt":0.3355257030615537,"score_spread":0.29781875563151816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904306,0.00076403224,0.0009835535,0.0003111175,0.00013859247,0.0051907687,0.001391572,0.00009868419,0.0020786484],"genre_scores_gemma":[0.98204744,0.0009226039,0.002446706,0.0010804771,0.00023019302,0.005413456,0.0021531095,0.000042859487,0.005663169],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996537,0.00014259916,0.000014706354,0.000063012376,0.000036682162,0.00008934792],"domain_scores_gemma":[0.9995009,0.00007492206,0.000072348674,0.000044333967,0.00005415308,0.00025349652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012645761,0.0010716986,0.0012897495,0.00031890487,0.00047981855,0.0006466552,0.0006037928,0.0010663632,0.0049258773],"category_scores_gemma":[0.0004736913,0.0004351817,0.0009904238,0.00025845846,0.0007681729,0.000492639,0.00018244557,0.002252894,0.0010637788],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54652065,0.20308593,0.007923618,0.0008074374,0.000826515,0.00072441506,0.00037305147,0.0021072957,0.15447558,0.00044427058,0.008071602,0.074639685],"study_design_scores_gemma":[0.12102784,0.8638402,0.0049416726,0.000014620768,0.0002433411,0.00020248936,0.00005152919,0.00066287833,0.006134918,0.00013917102,0.0027249833,0.000016509553],"about_ca_topic_score_codex":0.0013329408,"about_ca_topic_score_gemma":0.0023293067,"teacher_disagreement_score":0.0049258773,"about_ca_system_score_codex":0.00067994493,"about_ca_system_score_gemma":0.0018130575,"threshold_uncertainty_score":0.016478717},"labels":[],"label_agreement":null},{"id":"W4388048274","doi":"10.1136/jitc-2023-sitc2023.0277","title":"277 SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cancer research; Glioma; Immunotherapy; Chimeric antigen receptor; Tumor microenvironment; Flow cytometry; Immune system; Epidermal growth factor receptor; Antigen; Cytotoxic T cell; Brain tumor; Biology; Immunology; Medicine; Receptor; Pathology; Internal medicine; In vitro","score_opus":0.04880684535185395,"score_gpt":0.3212046304507716,"score_spread":0.27239778509891766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99040985,0.0009409403,0.0037044077,0.00022298377,0.00011243358,0.0001620984,0.0013409158,0.00029898115,0.0028074267],"genre_scores_gemma":[0.98832524,0.00087378186,0.0030846745,0.00018210283,0.00003097666,0.00019661602,0.0014400396,0.00008790009,0.0057786983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997069,0.00003589104,0.000032280426,0.000057858368,0.000068051304,0.000098951576],"domain_scores_gemma":[0.9998449,0.000020257692,0.000046510668,0.00002092573,0.000021963713,0.000045409684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028503544,0.00089183176,0.00045261043,0.0005932152,0.00017295901,0.00033964662,0.00038218132,0.0006743068,0.001841175],"category_scores_gemma":[0.00011369497,0.00026547062,0.0004554298,0.00022051804,0.00032110943,0.00035442805,0.00014146867,0.001495068,0.0007522388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048112698,0.00038997442,0.00010839727,0.00004431732,0.000008956926,0.00006887561,0.000035636705,0.0002514886,0.99691653,0.0001810413,0.00021288224,0.0013009621],"study_design_scores_gemma":[0.000077481,0.0023542994,0.0009030725,0.0000071925397,0.000019643865,0.00015587451,0.000027907503,0.0013494635,0.9937542,0.000046256668,0.0012985461,0.0000060813245],"about_ca_topic_score_codex":0.0015236977,"about_ca_topic_score_gemma":0.0017586966,"teacher_disagreement_score":0.001841175,"about_ca_system_score_codex":0.00042943028,"about_ca_system_score_gemma":0.00034704673,"threshold_uncertainty_score":0.006159365},"labels":[],"label_agreement":null},{"id":"W4388048378","doi":"10.1136/jitc-2023-sitc2023.0619","title":"619 First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: updated phase 1 results","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network","funders":"","keywords":"Tolerability; Medicine; Internal medicine; Oncology; Cancer; Cohort; Toxicity; Adverse effect","score_opus":0.016204629377014217,"score_gpt":0.300082005965044,"score_spread":0.28387737658802975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8603175,0.06598837,0.004162358,0.0035639647,0.0005980948,0.0048410953,0.03310403,0.00065616396,0.026768398],"genre_scores_gemma":[0.90773666,0.024008147,0.008597219,0.006275372,0.00050475297,0.002496092,0.043603733,0.00017573468,0.0066022896],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99952304,0.0001976394,0.00003618023,0.000047804886,0.00013095797,0.000064344706],"domain_scores_gemma":[0.99896395,0.00025601484,0.00032475198,0.00006648811,0.00016755775,0.00022126718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023045582,0.00043680612,0.0008292174,0.0003359293,0.00022116237,0.00095649477,0.0004997491,0.0005439972,0.0033904454],"category_scores_gemma":[0.0013425158,0.00019845877,0.00097248086,0.00039926657,0.00014253375,0.00043823122,0.0002719593,0.001235176,0.00081616506],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.090412945,0.009034786,0.03719029,0.003216835,0.0049442095,0.00039995293,0.00026617467,0.005976182,0.044623222,0.0005802096,0.06232107,0.74103415],"study_design_scores_gemma":[0.122760884,0.25983602,0.2878995,0.0012752443,0.010872952,0.0033769088,0.00023318698,0.006716371,0.03270818,0.0022109537,0.27188617,0.00022362926],"about_ca_topic_score_codex":0.00082191126,"about_ca_topic_score_gemma":0.0032697266,"teacher_disagreement_score":0.0033904454,"about_ca_system_score_codex":0.0006015268,"about_ca_system_score_gemma":0.0010259623,"threshold_uncertainty_score":0.012187779},"labels":[],"label_agreement":null},{"id":"W4388048473","doi":"10.1136/jitc-2023-sitc2023.0442-a","title":"442-A Optimization and validation of novel chimeric antigen receptor (CARs) architectures for the treatment of leukemia and beyond","year":2023,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Chimeric antigen receptor; Leukemia; Computer science; Computational biology; Cancer research; Medicine; Biology; Immunology; Immunotherapy; Immune system","score_opus":0.03970991027185679,"score_gpt":0.3268304874268504,"score_spread":0.2871205771549936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97963583,0.0016670895,0.012314395,0.000279019,0.00005896608,0.00025464836,0.00075547444,0.00021728613,0.004817252],"genre_scores_gemma":[0.97678775,0.0012163942,0.016943868,0.00010041695,0.000012717951,0.00010725713,0.0010993284,0.000059147213,0.003673126],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971896,0.000048409765,0.000012891893,0.00003502068,0.00012190693,0.00006277116],"domain_scores_gemma":[0.99988055,0.000010857361,0.00001999898,0.000011436794,0.00004998055,0.000027192515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004895038,0.0003592952,0.00015640951,0.00019694245,0.00014990244,0.00038710856,0.00023954225,0.000346318,0.0013017018],"category_scores_gemma":[0.00025045144,0.0001147818,0.00029575516,0.00012647723,0.00016747523,0.00021042973,0.00015471807,0.00036902755,0.0004028213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013083813,0.00012070007,0.00028993236,0.000048425998,0.000009173523,0.000030795884,0.000016856962,0.0022863504,0.99093634,0.0005311325,0.00032816126,0.0052712387],"study_design_scores_gemma":[0.000024865245,0.0010259937,0.00073630444,0.0000057491097,0.000010293554,0.000067905006,0.000013796659,0.0050546164,0.9863665,0.000045879002,0.0066385716,0.000009566223],"about_ca_topic_score_codex":0.0014343781,"about_ca_topic_score_gemma":0.001343701,"teacher_disagreement_score":0.0014343781,"about_ca_system_score_codex":0.00062711304,"about_ca_system_score_gemma":0.00043882715,"threshold_uncertainty_score":0.00455004},"labels":[],"label_agreement":null},{"id":"W4388048531","doi":"10.1136/jitc-2023-sitc2023.1372","title":"1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"CD28; Cancer research; T cell; CD3; Cytokine; In vivo; Antibody; Immunotherapy; Immunology; Chemistry; Immune system; Medicine; Biology; CD8","score_opus":0.05746762826388186,"score_gpt":0.3030686027193463,"score_spread":0.24560097445546447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665179,0.0010998811,0.022263823,0.00021916583,0.000063666215,0.00009344692,0.000913644,0.00039592638,0.00843251],"genre_scores_gemma":[0.97824806,0.00054612674,0.01199345,0.00017077469,0.00001263764,0.00008668233,0.0009511195,0.00006533349,0.007925996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990547,0.000009367392,0.00000655838,0.000018906938,0.00003756467,0.000022191136],"domain_scores_gemma":[0.9999666,0.0000046241107,0.000011201704,0.000003160975,0.0000065489303,0.000007885391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000911914,0.0002640185,0.00009906058,0.00012579047,0.00010042112,0.00020747975,0.00017635005,0.00027593446,0.0030609886],"category_scores_gemma":[0.000059663453,0.0000961355,0.000117747506,0.000105631836,0.00012835764,0.00018811517,0.00017962609,0.00036273786,0.0009632706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004544304,0.0000157207,0.00011946723,0.000025423891,0.0000024624376,0.000029676465,0.000008169633,0.00015976971,0.9970284,0.000214594,0.00017794133,0.0021729758],"study_design_scores_gemma":[0.000005916839,0.00011318912,0.00030652015,0.0000011320908,0.000003403891,0.00012629374,0.0000060689836,0.0007382787,0.99600464,0.0000181618,0.0026737433,0.0000025856843],"about_ca_topic_score_codex":0.0003246153,"about_ca_topic_score_gemma":0.00062269473,"teacher_disagreement_score":0.0030609886,"about_ca_system_score_codex":0.00023142854,"about_ca_system_score_gemma":0.00021832199,"threshold_uncertainty_score":0.010240078},"labels":[],"label_agreement":null},{"id":"W4388074720","doi":"10.1136/jitc-2023-sitc2023.1396","title":"1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Cancer research; Tumor microenvironment; PD-L1; T cell; Immunotherapy; Immune checkpoint; Cytotoxicity; Cytotoxic T cell; Immune system; Chemistry; Cancer immunotherapy; In vitro; Biology; Immunology; Tumor cells; Biochemistry","score_opus":0.040494279708013003,"score_gpt":0.2694589960541106,"score_spread":0.2289647163460976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388074720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96478635,0.0013977695,0.019170009,0.000249883,0.00010079794,0.00023768019,0.0010053475,0.0005150784,0.012537175],"genre_scores_gemma":[0.9817939,0.0005203951,0.010236787,0.00017337863,0.000014595245,0.00013020901,0.0007947025,0.00004423413,0.0062917215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986684,0.000012860483,0.000008346103,0.000027392607,0.000052623585,0.000031975276],"domain_scores_gemma":[0.9999435,0.000005253763,0.000018674837,0.0000054681786,0.000010174598,0.000016904081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011526604,0.00033134085,0.00012962453,0.00019524549,0.0000961157,0.00028649904,0.00031701606,0.00041946615,0.0024436146],"category_scores_gemma":[0.00010142323,0.00013235358,0.00017121251,0.00014776546,0.0001244949,0.00020963831,0.00020799176,0.0006331378,0.00085062854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100040284,0.00010982991,0.00010539177,0.00003774798,0.0000073694373,0.00006455582,0.000014787047,0.00039173706,0.9935782,0.00033169746,0.00044679875,0.0048117465],"study_design_scores_gemma":[0.000024534165,0.00067829766,0.00038119053,0.0000027698527,0.000006621019,0.00018725735,0.000008190734,0.0019803725,0.9928619,0.000036340913,0.0038245812,0.000008050732],"about_ca_topic_score_codex":0.00035274166,"about_ca_topic_score_gemma":0.000585804,"teacher_disagreement_score":0.0024436146,"about_ca_system_score_codex":0.00028349686,"about_ca_system_score_gemma":0.000182885,"threshold_uncertainty_score":0.008174717},"labels":[],"label_agreement":null},{"id":"W4388081144","doi":"10.1136/jitc-2023-sitc2023.0178","title":"178 Tumor neoantigen prioritization from liquid biopsy whole exome sequencing for selected tumor-infiltrating lymphocyte therapy","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Liquid biopsy; Exome sequencing; Tumor-infiltrating lymphocytes; Biopsy; Exome; Transcriptome; Cancer research; Deep sequencing; Medicine; Cancer; Pathology; Computational biology; Immunotherapy; Biology; Mutation; Internal medicine; Gene; Gene expression; Genome; Genetics","score_opus":0.03762420379382995,"score_gpt":0.28809596548987787,"score_spread":0.2504717616960479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388081144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9125157,0.002594127,0.06809771,0.0006908416,0.00018502536,0.0003781792,0.009040282,0.0010398446,0.005458246],"genre_scores_gemma":[0.90876293,0.0011535193,0.072491735,0.0010602018,0.000088583205,0.00046742795,0.011250333,0.00043508975,0.004290199],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997569,0.000044425786,0.000019320894,0.00008361568,0.00006710096,0.000028668868],"domain_scores_gemma":[0.9998274,0.000053514952,0.000030588802,0.00002132343,0.000046064102,0.000021145872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048252582,0.00035337763,0.00034226652,0.00044828164,0.00020881518,0.0007887013,0.00026748996,0.00037114407,0.002689272],"category_scores_gemma":[0.0006044901,0.0001519939,0.00033501367,0.00029515938,0.00015826922,0.00016686379,0.00032745596,0.0004622873,0.00095170515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007972396,0.0001100611,0.021300195,0.0002612315,0.000094216404,0.00034996882,0.000091309834,0.003368544,0.8850806,0.00044091707,0.004650076,0.08345564],"study_design_scores_gemma":[0.00016813522,0.0008743749,0.084979154,0.0001130596,0.00025291118,0.0020348933,0.0002787377,0.054546107,0.82105595,0.0022301895,0.033398654,0.00006786996],"about_ca_topic_score_codex":0.00058879843,"about_ca_topic_score_gemma":0.0014637511,"teacher_disagreement_score":0.002689272,"about_ca_system_score_codex":0.0002471841,"about_ca_system_score_gemma":0.00034714982,"threshold_uncertainty_score":0.008996487},"labels":[],"label_agreement":null},{"id":"W4388087237","doi":"10.1136/jitc-2023-sitc2023.0839","title":"839 TALL<sup>TM</sup> (Targeted Antigen Loaded Liposomes) immunotherapy exploits recall immunity to form an excellent co-therapy option for immune checkpoint inhibitors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oncolytic virus; Immunotherapy; Adoptive cell transfer; Tumor microenvironment; Medicine; Cancer research; Chimeric antigen receptor; Cancer; Immune system; Tumor-infiltrating lymphocytes; Antigen; Immunology; T cell; Internal medicine","score_opus":0.046547665589573975,"score_gpt":0.31310218700715103,"score_spread":0.2665545214175771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388087237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9330011,0.0041526686,0.04671487,0.0007693254,0.0002080196,0.0002970216,0.0023772179,0.0009230123,0.011556756],"genre_scores_gemma":[0.95531166,0.0018942415,0.025174664,0.0003741109,0.000038447666,0.00019636424,0.0024715138,0.00013323911,0.0144056715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991894,0.000010076107,0.000006780163,0.000016194434,0.000025798894,0.000022273189],"domain_scores_gemma":[0.9999615,0.000004295244,0.00001173487,0.0000047333915,0.000008243892,0.000009561595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012930737,0.00033366823,0.0001502288,0.00019406802,0.00013023397,0.00035805092,0.0001875494,0.00034223194,0.0032620013],"category_scores_gemma":[0.00005786685,0.00013521049,0.00023385025,0.00009956032,0.00016212417,0.00027810782,0.0002468247,0.0004957632,0.0013651216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009997965,0.000034631936,0.0001952705,0.000042858766,0.000004715145,0.000034136014,0.000006739374,0.00013270756,0.99462503,0.00026567836,0.00032633927,0.004231885],"study_design_scores_gemma":[0.000012030399,0.00023093015,0.00084191305,0.000005688018,0.0000078058465,0.00013946733,0.000007781661,0.0007259887,0.99154234,0.00007174824,0.0064099235,0.0000043140135],"about_ca_topic_score_codex":0.0003912801,"about_ca_topic_score_gemma":0.0006156904,"teacher_disagreement_score":0.0032620013,"about_ca_system_score_codex":0.00028329313,"about_ca_system_score_gemma":0.00021821605,"threshold_uncertainty_score":0.010912538},"labels":[],"label_agreement":null},{"id":"W4388231839","doi":"10.51731/cjht.2023.774","title":"Tisagenlecleucel (Kymriah)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Refractory (planetary science); Food and drug administration; Drug; Intensive care medicine; Medical emergency; Pharmacology; Political science; Health care","score_opus":0.07828658743759795,"score_gpt":0.36425421196518165,"score_spread":0.28596762452758373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388231839","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014067245,0.33823773,0.0032805745,0.010416052,0.004746808,0.00064870465,0.0086155385,0.0017597083,0.61822766],"genre_scores_gemma":[0.11850852,0.168533,0.0061429734,0.013692148,0.0009957114,0.00039393522,0.014177531,0.00028897403,0.6772672],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99966717,0.00003955877,0.000020865142,0.000047267513,0.00017139684,0.00005379331],"domain_scores_gemma":[0.9996693,0.000042770058,0.00005015361,0.000013843755,0.00013111635,0.00009278419],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046308272,0.00042676646,0.00036483555,0.0009656188,0.00042563438,0.0009840417,0.0005521125,0.0009908029,0.085346214],"category_scores_gemma":[0.0006122584,0.00011527406,0.0004140867,0.0006092367,0.0004292459,0.0005466494,0.00054929906,0.0010041139,0.024126116],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005218528,0.000109966226,0.0004958573,0.002366894,0.000053142834,0.00026485816,0.00005427612,0.00018803867,0.010849454,0.0062664878,0.29684013,0.681989],"study_design_scores_gemma":[0.0001348192,0.000326807,0.0009821949,0.00034724668,0.000023996574,0.00033361567,0.000023225959,0.000079291574,0.0030346839,0.00027208502,0.9944332,0.000008810351],"about_ca_topic_score_codex":0.021731531,"about_ca_topic_score_gemma":0.061742887,"teacher_disagreement_score":0.085346214,"about_ca_system_score_codex":0.0017012585,"about_ca_system_score_gemma":0.0030555062,"threshold_uncertainty_score":0.28551155},"labels":[],"label_agreement":null},{"id":"W4388425287","doi":"10.1038/s41590-023-01658-z","title":"Harnessing CD3 diversity to optimize CAR T cells","year":2023,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"FP7 Health; European Commission; Horizon 2020 Framework Programme; FAZIT Stiftung; Deutsche Forschungsgemeinschaft; University of Oxford; European Federation of Pharmaceutical Industries and Associations; McGill University","keywords":"T-cell receptor; CD3; Chimeric antigen receptor; Cell biology; T cell; Intracellular; Biology; Antigen; Chemistry; Immune system; CD8; Immunology","score_opus":0.021956186225114697,"score_gpt":0.31829253788031536,"score_spread":0.29633635165520067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388425287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97633433,0.0011808671,0.019492887,0.0001588378,0.000029586177,0.0000517027,0.00023284183,0.00019734306,0.0023217509],"genre_scores_gemma":[0.9902705,0.0005730947,0.007746875,0.00007529269,0.000007992786,0.000028183487,0.00022853445,0.000037410013,0.001032156],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987113,0.000020490197,0.000008467269,0.000027131515,0.000029238461,0.000043530334],"domain_scores_gemma":[0.9999485,0.000009295222,0.00001194309,0.000006274125,0.000010896189,0.000013158715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015405209,0.00028150994,0.0001610822,0.00018852185,0.00012586568,0.00043358727,0.00020367131,0.00023189172,0.0007873196],"category_scores_gemma":[0.0001327182,0.00010417469,0.00016707346,0.00022298776,0.00018177723,0.00024399563,0.00030190882,0.0005127987,0.00041812152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049841703,0.000019062949,0.00015084977,0.000023409199,0.000003622696,0.000039058465,0.000015663762,0.00060550944,0.9957526,0.0003703801,0.00005718125,0.002912879],"study_design_scores_gemma":[0.000013200852,0.00016013917,0.0003734403,0.000002633672,0.000012453365,0.00013383613,0.000018816345,0.002394259,0.99247384,0.00013934949,0.004273386,0.0000047067647],"about_ca_topic_score_codex":0.00034618957,"about_ca_topic_score_gemma":0.0007329083,"teacher_disagreement_score":0.0007873196,"about_ca_system_score_codex":0.0003520172,"about_ca_system_score_gemma":0.00019451856,"threshold_uncertainty_score":0.0026338696},"labels":[],"label_agreement":null},{"id":"W4388541004","doi":"10.1038/s41590-023-01663-2","title":"CD3ζ ITAMs enable ligand discrimination and antagonism by inhibiting TCR signaling in response to low-affinity peptides","year":2023,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mila - Quebec Artificial Intelligence Institute; Université de Montréal; McGill University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Immunoreceptor tyrosine-based activation motif; T-cell receptor; CD3; Biology; Cell biology; T cell; Signal transduction; CD8; Antigen; Immune system; Immunology","score_opus":0.015363571418819543,"score_gpt":0.3140258550961627,"score_spread":0.29866228367734315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388541004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810736,0.0013419605,0.008320135,0.00036526046,0.00012647283,0.000057925576,0.000353397,0.000396967,0.007964331],"genre_scores_gemma":[0.9939851,0.00041671324,0.0020250846,0.0001301105,0.000020521586,0.000028512657,0.00020885357,0.0000494446,0.0031356553],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996669,0.000023165616,0.000012562514,0.00004825192,0.000059507984,0.00018967988],"domain_scores_gemma":[0.9998858,0.000022921193,0.000022312739,0.00002124458,0.000011019566,0.00003681848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022229571,0.0005936168,0.00021763529,0.00021618986,0.00036693673,0.00076285994,0.00046440004,0.0004916778,0.004981329],"category_scores_gemma":[0.00022337909,0.00022719169,0.00028686668,0.00015177188,0.00036108383,0.00032761178,0.0004690105,0.0018439472,0.0012728489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020388434,0.000053043557,0.0001278826,0.000023304636,0.0000051716193,0.000027189995,0.000012632577,0.00013636991,0.9963793,0.0005349506,0.00019125981,0.0023049864],"study_design_scores_gemma":[0.000053022617,0.0001356385,0.00095065136,0.0000044000512,0.000014372583,0.000107516964,0.000019271529,0.00141042,0.9936293,0.00022850362,0.003442655,0.0000041752114],"about_ca_topic_score_codex":0.000885967,"about_ca_topic_score_gemma":0.0014677654,"teacher_disagreement_score":0.004981329,"about_ca_system_score_codex":0.0007164174,"about_ca_system_score_gemma":0.00043951138,"threshold_uncertainty_score":0.016664267},"labels":[],"label_agreement":null},{"id":"W4388590696","doi":"10.1093/neuonc/noad179.0862","title":"EXTH-08. IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Fibroblast activation protein, alpha; Chimeric antigen receptor; Cancer research; U87; Medicine; Stromal cell; Glioma; Antigen; Immunotherapy; Immunology; Cancer; Internal medicine; Immune system","score_opus":0.05985623119210558,"score_gpt":0.3477529791566311,"score_spread":0.2878967479645255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388590696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820067,0.005247014,0.0059199138,0.00047352625,0.00018697925,0.00039136264,0.00067032943,0.00026358775,0.004840663],"genre_scores_gemma":[0.9872765,0.002077461,0.0040759672,0.0002568029,0.000036857637,0.00027066274,0.001079768,0.000028791448,0.004897233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992883,0.000010746862,0.0000043985115,0.00001316084,0.000014948699,0.000027912136],"domain_scores_gemma":[0.9999734,0.0000031233774,0.000004391242,0.0000033248875,0.000004384371,0.000011307976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001628106,0.0002888294,0.00036290634,0.0002214284,0.00012820461,0.00023184154,0.0002858682,0.00043921047,0.0016583124],"category_scores_gemma":[0.00006177872,0.0000810163,0.00027613368,0.00014316605,0.00015967607,0.000151067,0.00015927355,0.00049660413,0.000508066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015175502,0.0012896513,0.0012358581,0.00048242477,0.000060986506,0.00096821727,0.0001350411,0.0017311987,0.9179544,0.0011335952,0.0032035594,0.070287555],"study_design_scores_gemma":[0.0011408399,0.014140079,0.0073677297,0.000053084063,0.00021168319,0.0037443708,0.00007637393,0.009254313,0.9264969,0.00039460693,0.03708878,0.000031177864],"about_ca_topic_score_codex":0.0010526588,"about_ca_topic_score_gemma":0.0012386846,"teacher_disagreement_score":0.0016583124,"about_ca_system_score_codex":0.00025777135,"about_ca_system_score_gemma":0.00034427192,"threshold_uncertainty_score":0.0055476427},"labels":[],"label_agreement":null},{"id":"W4388824359","doi":"10.21203/rs.3.rs-3576281/v1","title":"Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Hyundai Hope On Wheels; National Institutes of Health; University of Minnesota; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research","keywords":"Oncolytic virus; Blockade; Virotherapy; CD8; Viral therapy; T cell; Cytotoxic T cell; Immunotherapy; Medicine; Virology; Cancer research; Immunology; Biology; Coronavirus disease 2019 (COVID-19); Virus; Immune system; Receptor; Internal medicine; In vitro","score_opus":0.047605455395248665,"score_gpt":0.3637150472437093,"score_spread":0.3161095918484606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388824359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870697,0.0005025973,0.007325725,0.00030909927,0.000075662625,0.00007649423,0.0005464683,0.00036551524,0.0037287087],"genre_scores_gemma":[0.99416757,0.00011728463,0.0023808512,0.00009463739,0.000011188863,0.000040326668,0.00023385951,0.00006391876,0.0028903848],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997582,0.000038297512,0.000013189954,0.00005856985,0.000047583813,0.000084170635],"domain_scores_gemma":[0.9998801,0.000028957036,0.000023015467,0.000020143505,0.000007722278,0.00004002135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019353158,0.0004281515,0.00030062898,0.00021881964,0.00014440685,0.0004498627,0.000297643,0.0005644121,0.0033924489],"category_scores_gemma":[0.00018549155,0.00021153937,0.0002834804,0.00011609589,0.0002739564,0.0002083677,0.00033793092,0.0018940188,0.0007222515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033355612,0.00008515343,0.00009518187,0.000023566716,0.000011669965,0.000034846096,0.000013663923,0.0007277658,0.9959122,0.0007998151,0.00018287777,0.0017797092],"study_design_scores_gemma":[0.0001116415,0.0003896699,0.0006635969,0.000004765326,0.00001973294,0.00018321318,0.000015388823,0.0036928635,0.9896722,0.00017513195,0.0050658523,0.0000060485054],"about_ca_topic_score_codex":0.00045561872,"about_ca_topic_score_gemma":0.00041161786,"teacher_disagreement_score":0.0033924489,"about_ca_system_score_codex":0.00045095044,"about_ca_system_score_gemma":0.00032561645,"threshold_uncertainty_score":0.011348903},"labels":[],"label_agreement":null},{"id":"W4388850548","doi":"10.1101/2023.11.20.567960","title":"A Synthetic Cytotoxic T cell Platform for Rapidly Prototyping TCR Function","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital; Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; Genome British Columbia; National Institutes of Health; Michael Smith Health Research BC","keywords":"Cytotoxic T cell; T-cell receptor; Function (biology); Rapid prototyping; T cell; Chemistry; Computer science; Cell biology; Biology; Engineering; Immunology; In vitro; Biochemistry; Immune system","score_opus":0.04006224446447281,"score_gpt":0.2740619521043875,"score_spread":0.23399970763991468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388850548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90029347,0.00053710054,0.09596566,0.00008444497,0.00007240375,0.00013870379,0.00023504297,0.0004682061,0.0022049847],"genre_scores_gemma":[0.9437019,0.00037156302,0.052968208,0.000045338933,0.000011286259,0.00010633774,0.00024510088,0.000054836055,0.0024954032],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997212,0.000042502365,0.000020192021,0.000054795764,0.00011041267,0.000050981973],"domain_scores_gemma":[0.9997936,0.00003575448,0.00006519947,0.000038220052,0.000030548643,0.000036709836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029242338,0.00036953538,0.00019445366,0.0001584403,0.000105781735,0.0003716794,0.00045941625,0.00031840635,0.0011063019],"category_scores_gemma":[0.00030630207,0.00014232921,0.0001870203,0.00010056545,0.00023883504,0.0002416248,0.00039429794,0.00043104868,0.00038943806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018937739,0.0000074852824,0.000038159964,0.000016774275,0.0000013279018,0.00003759318,0.000007717113,0.00039240092,0.9982768,0.00011940357,0.000018290797,0.0010651392],"study_design_scores_gemma":[0.000005616211,0.00015006022,0.00013587513,0.0000021532842,0.0000028587328,0.00015529507,0.000005798336,0.0016103156,0.9967533,0.00003505134,0.0011396687,0.0000040544737],"about_ca_topic_score_codex":0.00013427538,"about_ca_topic_score_gemma":0.00013331878,"teacher_disagreement_score":0.0011063019,"about_ca_system_score_codex":0.0002128435,"about_ca_system_score_gemma":0.00017518009,"threshold_uncertainty_score":0.003700912},"labels":[],"label_agreement":null},{"id":"W4388921302","doi":"10.1016/j.intimp.2023.111249","title":"Comparative evaluation of antitumor effects of TNF superfamily costimulatory ligands delivered by mesenchymal stem cells","year":2023,"lang":"en","type":"article","venue":"International Immunopharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Higher Education Discipline Innovation Project; Shanghai Jiao Tong University; Science and Technology Commission of Shanghai Municipality; Major Projects of Special Development Funds in Zhangjiang National Independent Innovation Demonstration Zone, Shanghai; Shanghai Municipal Education Commission; Ministry of Education of the People's Republic of China; Shanghai Municipal Health Commission","keywords":"Mesenchymal stem cell; Cancer research; Tumor necrosis factor alpha; Immune system; Immunology; Biology; Pharmacology; Cell biology","score_opus":0.05454021726798623,"score_gpt":0.40266281108958685,"score_spread":0.3481225938216006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388921302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974209,0.0010174816,0.0005468071,0.00002499337,0.00003002842,0.000017679416,0.000078978126,0.000015372467,0.00084762933],"genre_scores_gemma":[0.9980489,0.00058125326,0.00039037492,0.0000143367115,0.000018606986,0.000019741145,0.000108003034,0.0000051460443,0.00081370474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998161,0.000051496652,0.000017631968,0.000020516896,0.00003655011,0.000057654262],"domain_scores_gemma":[0.9998337,0.000077797784,0.000021977547,0.0000121022495,0.000023955714,0.000030485697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026299848,0.00027839278,0.00029403844,0.0002919707,0.00011816504,0.00026078697,0.00015408087,0.0002839337,0.0012655316],"category_scores_gemma":[0.00019587929,0.000082492275,0.00022378606,0.0002479155,0.00021969978,0.00032664122,0.000092882416,0.0004747692,0.00016861546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00289167,0.0004961902,0.0002568784,0.0001073489,0.000015079018,0.00006129321,0.00006138516,0.0005031599,0.98967487,0.00020975563,0.00005050109,0.005671829],"study_design_scores_gemma":[0.00008917205,0.006577437,0.0015575251,0.0000045012534,0.0000555121,0.0000728854,0.0000463465,0.0011398048,0.98959816,0.000039260536,0.0008155982,0.0000037732102],"about_ca_topic_score_codex":0.0003689697,"about_ca_topic_score_gemma":0.0003129674,"teacher_disagreement_score":0.0012655316,"about_ca_system_score_codex":0.00015905485,"about_ca_system_score_gemma":0.00019878411,"threshold_uncertainty_score":0.0042335987},"labels":[],"label_agreement":null},{"id":"W4388943550","doi":"10.3389/fimmu.2023.1166059","title":"Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Immunity; Immune system; Cellular immunity; Clinical trial; Immunology; Vaccine efficacy; Pandemic; Medicine; Risk analysis (engineering); Coronavirus disease 2019 (COVID-19); Biology; Bioinformatics; Disease; Infectious disease (medical specialty)","score_opus":0.05603285182762251,"score_gpt":0.3420147387486446,"score_spread":0.28598188692102205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388943550","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16189851,0.18052532,0.5731834,0.022402257,0.0026638792,0.004046307,0.00917764,0.003976306,0.042126298],"genre_scores_gemma":[0.5568055,0.059393097,0.34842417,0.010978516,0.0025139283,0.0030511178,0.0046157404,0.00042177297,0.01379606],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9935929,0.0027616834,0.00046660868,0.0006812393,0.0021617792,0.00033589866],"domain_scores_gemma":[0.9899789,0.004213515,0.002086444,0.0011652577,0.0021558676,0.00039991186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011912613,0.0011318022,0.001914479,0.00219469,0.0005539068,0.0036509288,0.0010576305,0.002334623,0.0046756407],"category_scores_gemma":[0.008969037,0.00067763875,0.0009730417,0.0014712176,0.0015914645,0.0040579806,0.001235539,0.0038156246,0.0024851866],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013703889,0.00086339016,0.043004513,0.0034141766,0.00038523375,0.00031152225,0.00044524754,0.0043149916,0.3443325,0.017660052,0.013688608,0.57020944],"study_design_scores_gemma":[0.00023724193,0.010250092,0.09672899,0.002556923,0.0011126694,0.0042415173,0.0015555923,0.015472403,0.47357118,0.0526383,0.34121293,0.000422258],"about_ca_topic_score_codex":0.0010226332,"about_ca_topic_score_gemma":0.0012012521,"teacher_disagreement_score":0.011912613,"about_ca_system_score_codex":0.0011853351,"about_ca_system_score_gemma":0.0021249691,"threshold_uncertainty_score":0.06300068},"labels":[],"label_agreement":null},{"id":"W4389166429","doi":"10.21203/rs.3.rs-3661193/v1","title":"A Synthetic Cytotoxic T cell Platform for Rapidly Prototyping TCR Function","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genome British Columbia; National Institutes of Health; Michael Smith Health Research BC","keywords":"T-cell receptor; Cytotoxic T cell; Major histocompatibility complex; Antigen; Biology; T cell; Granzyme; Computational biology; Cell biology; Human leukocyte antigen; Granzyme B; CD8; Immunology; Immune system; In vitro; Genetics; Perforin","score_opus":0.14656178462797836,"score_gpt":0.4190089896662709,"score_spread":0.27244720503829256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389166429","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90029347,0.00053710054,0.09596566,0.00008444497,0.00007240375,0.00013870379,0.00023504297,0.0004682061,0.0022049847],"genre_scores_gemma":[0.9437019,0.00037156302,0.052968208,0.000045338933,0.000011286259,0.00010633774,0.00024510088,0.000054836055,0.0024954032],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997212,0.000042502365,0.000020192021,0.000054795764,0.00011041267,0.000050981973],"domain_scores_gemma":[0.9997936,0.00003575448,0.00006519947,0.000038220052,0.000030548643,0.000036709836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029242338,0.00036953538,0.00019445366,0.0001584403,0.000105781735,0.0003716794,0.00045941625,0.00031840635,0.0011063019],"category_scores_gemma":[0.00030630207,0.00014232921,0.0001870203,0.00010056545,0.00023883504,0.0002416248,0.00039429794,0.00043104868,0.00038943806],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018937739,0.0000074852824,0.000038159964,0.000016774275,0.0000013279018,0.00003759318,0.000007717113,0.00039240092,0.9982768,0.00011940357,0.000018290797,0.0010651392],"study_design_scores_gemma":[0.000005616211,0.00015006022,0.00013587513,0.0000021532842,0.0000028587328,0.00015529507,0.000005798336,0.0016103156,0.9967533,0.00003505134,0.0011396687,0.0000040544737],"about_ca_topic_score_codex":0.00013427538,"about_ca_topic_score_gemma":0.00013331878,"teacher_disagreement_score":0.0011063019,"about_ca_system_score_codex":0.0002128435,"about_ca_system_score_gemma":0.00017518009,"threshold_uncertainty_score":0.003700912},"labels":[],"label_agreement":null},{"id":"W4389218826","doi":"10.1182/blood-2023-173873","title":"Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Subgroup analysis; Oncology; Chemoimmunotherapy; Aggressive lymphoma; Intention-to-treat analysis; Lymphoma; Randomized controlled trial; Surgery; Confidence interval; Rituximab","score_opus":0.01250162557583315,"score_gpt":0.2699300756294732,"score_spread":0.25742845005364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389218826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943242,0.0039992956,0.00014192067,0.00014966783,0.00005446186,0.00013175014,0.00067069364,0.0000095916785,0.0005185102],"genre_scores_gemma":[0.9972778,0.00076533563,0.0001544543,0.00022805389,0.00009286647,0.00015755712,0.0010792498,0.0000059723257,0.00023878245],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99938583,0.00021382513,0.000088070236,0.00012191549,0.000086759756,0.00010361388],"domain_scores_gemma":[0.9993325,0.00019782646,0.00018687281,0.00008610923,0.00005577941,0.00014084567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015545875,0.00057601056,0.001604206,0.00059822446,0.00024039153,0.00092876394,0.00037975036,0.0005599801,0.0015716539],"category_scores_gemma":[0.0014683148,0.00018759607,0.0041975193,0.0005637285,0.00023479667,0.00048328278,0.0004545306,0.0007504334,0.0002488175],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3942699,0.0022614175,0.47220647,0.001597241,0.03238131,0.0006532452,0.00027197428,0.001244113,0.010742531,0.00023298392,0.0032365515,0.080902345],"study_design_scores_gemma":[0.046049587,0.05247543,0.8541902,0.0003275185,0.03224759,0.0012679315,0.0005763649,0.003911729,0.0022100215,0.00084746134,0.0057938998,0.00010232416],"about_ca_topic_score_codex":0.000657513,"about_ca_topic_score_gemma":0.0020219907,"teacher_disagreement_score":0.001604206,"about_ca_system_score_codex":0.0004415073,"about_ca_system_score_gemma":0.0005075741,"threshold_uncertainty_score":0.008221567},"labels":[],"label_agreement":null},{"id":"W4389219761","doi":"10.1182/blood-2023-173949","title":"Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Premedication; Cytokine release syndrome; Prednisolone; Dexamethasone; Corticosteroid; Internal medicine; Methylprednisolone; Prednisone; Follicular lymphoma; Gastroenterology; Surgery; Lymphoma; Cancer","score_opus":0.013440384799756854,"score_gpt":0.2531730764839318,"score_spread":0.23973269168417494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389219761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960239,0.002602452,0.00021583532,0.00013339003,0.000029855444,0.00008430021,0.0001957405,0.000022275197,0.00069231575],"genre_scores_gemma":[0.9990326,0.00037107107,0.00016085086,0.000084103856,0.000018484949,0.000026038313,0.00015250141,0.0000025948561,0.00015183112],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9996841,0.000120875266,0.000036285237,0.000053969547,0.00006996064,0.000034853634],"domain_scores_gemma":[0.99916804,0.00018921134,0.0003551592,0.000051773055,0.000042816337,0.00019307554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047881136,0.00018061379,0.00050668494,0.00011958307,0.00011260414,0.00037126298,0.00017363534,0.00021633295,0.0009439462],"category_scores_gemma":[0.0012099544,0.000070799775,0.00032399045,0.00018435252,0.00015048846,0.0002593649,0.00017672897,0.0006906007,0.00015943036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19415922,0.0055270134,0.21501529,0.0010277391,0.0017387191,0.0012616717,0.00053561904,0.002359759,0.15805946,0.00017822318,0.0030444835,0.4170927],"study_design_scores_gemma":[0.017263088,0.31787014,0.60862976,0.00017209748,0.0013196721,0.0055546947,0.00047230622,0.003196727,0.032596525,0.00019623847,0.012670025,0.000058705034],"about_ca_topic_score_codex":0.00025111975,"about_ca_topic_score_gemma":0.000966688,"teacher_disagreement_score":0.0009439462,"about_ca_system_score_codex":0.00031055723,"about_ca_system_score_gemma":0.00037428932,"threshold_uncertainty_score":0.003157854},"labels":[],"label_agreement":null},{"id":"W4389220343","doi":"10.1182/blood-2023-189200","title":"Intensity of Survivin Expression Correlates with Clinical and Biological Markers of Aggressive R/R DLBCL","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Calgary; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Survivin; Medicine; Immunohistochemistry; Oncology; Internal medicine; Pathology; Cancer","score_opus":0.05891360144423264,"score_gpt":0.3468215963229426,"score_spread":0.28790799487871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998376,0.0003987806,0.0001725947,0.000027952185,0.0000025724137,0.000021822414,0.00017208421,0.000012534666,0.0008156452],"genre_scores_gemma":[0.9992624,0.00006455304,0.00013776436,0.000017936674,0.00000855624,0.000014181325,0.00030410697,0.0000020147954,0.00018851053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997259,0.00009711265,0.000025930945,0.00005726189,0.00006020645,0.000033607324],"domain_scores_gemma":[0.99919003,0.00011601444,0.0004364363,0.000050629813,0.000085218795,0.00012172397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011303653,0.0002330943,0.00024591517,0.0003762964,0.000100692014,0.0004427571,0.00022278397,0.00019904226,0.0014823943],"category_scores_gemma":[0.0010031603,0.0001325256,0.00015650036,0.00027352863,0.00022413454,0.00022166711,0.00026256332,0.0003413315,0.00027266782],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040832236,0.00019666133,0.96511745,0.000045107052,0.00012354991,0.00010895965,0.000050327562,0.0003043343,0.017203534,0.000034165296,0.0003093649,0.012423319],"study_design_scores_gemma":[0.00013314739,0.0016910664,0.99525476,0.0000064653927,0.00006638163,0.0004463783,0.00003812689,0.00031940397,0.001593169,0.000030514693,0.00041582598,0.0000048295897],"about_ca_topic_score_codex":0.00026995694,"about_ca_topic_score_gemma":0.00044005175,"teacher_disagreement_score":0.0014823943,"about_ca_system_score_codex":0.00022084858,"about_ca_system_score_gemma":0.00014229433,"threshold_uncertainty_score":0.005978048},"labels":[],"label_agreement":null},{"id":"W4389220356","doi":"10.1182/blood-2023-178738","title":"A Systematic Literature Review (SLR) and Meta-Analysis of Clinical Evidence of Second Line or Later (2L+) Treatments for Follicular Lymphoma (FL) in Adult Patients","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Oncology; Follicular lymphoma; Internal medicine; Pembrolizumab; Population; MEDLINE; Cochrane Library; Meta-analysis; Systematic review; Lymphoma; Immunotherapy; Cancer","score_opus":0.12261468838760457,"score_gpt":0.4252385404789309,"score_spread":0.3026238520913263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220356","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0061445194,0.98980975,0.00067100424,0.00026801226,0.00019005347,0.0012005194,0.0012120653,0.000033975615,0.0004701931],"genre_scores_gemma":[0.16982983,0.8170754,0.0040664407,0.001563143,0.00028505403,0.0052327085,0.0013928395,0.000044803848,0.0005098963],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97993726,0.010094742,0.006182847,0.0016505275,0.0016653163,0.0004692953],"domain_scores_gemma":[0.9713974,0.019956484,0.0055800877,0.000679752,0.0020141096,0.00037229736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.019136809,0.0031194687,0.022818277,0.012054007,0.00080102764,0.0039227973,0.0024407287,0.0026568663,0.0054178014],"category_scores_gemma":[0.04627241,0.001654829,0.038203504,0.0116122775,0.0009384123,0.0024379382,0.0022140215,0.0020076833,0.00046943384],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019019131,0.000024099789,0.001607649,0.5726368,0.41431555,0.000111234986,0.00008378891,0.00033677416,0.0001570386,0.00010828179,0.0005176954,0.008199185],"study_design_scores_gemma":[0.00087375095,0.00025203126,0.0022192663,0.053569898,0.9407928,0.00008829193,0.00005480973,0.000119398945,0.00008450504,0.00015440487,0.0017682603,0.000022596061],"about_ca_topic_score_codex":0.008851629,"about_ca_topic_score_gemma":0.019994797,"teacher_disagreement_score":0.022818277,"about_ca_system_score_codex":0.004745335,"about_ca_system_score_gemma":0.0061372304,"threshold_uncertainty_score":0.1012063},"labels":[],"label_agreement":null},{"id":"W4389220803","doi":"10.1182/blood-2023-174510","title":"3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Fludarabine; Chemotherapy regimen; Phases of clinical research; International Prognostic Index; Regimen; Diffuse large B-cell lymphoma; Interim analysis; Surgery; Oncology; Lymphoma; Cyclophosphamide; Chemotherapy; Clinical trial","score_opus":0.01785151884795993,"score_gpt":0.2935026324855429,"score_spread":0.275651113637583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96683615,0.010944993,0.0016888375,0.00083735544,0.00012679546,0.0014381002,0.014177429,0.00021166008,0.0037386888],"genre_scores_gemma":[0.96171135,0.0027558205,0.0013936502,0.001592558,0.00015631714,0.0012510077,0.028294818,0.00007952696,0.0027650555],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99802494,0.00085074914,0.00011598806,0.0003476529,0.0003693574,0.0002912735],"domain_scores_gemma":[0.99594706,0.00074163795,0.0013596723,0.000345201,0.00044229682,0.001164246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007988826,0.0010544886,0.0020753567,0.0008314846,0.00051461137,0.0019072264,0.0009935654,0.0014786752,0.0036365744],"category_scores_gemma":[0.0035504587,0.0005546427,0.0033404946,0.00090211997,0.00055850577,0.0013235947,0.00072575716,0.0032043771,0.0008941304],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6332192,0.015412338,0.15107825,0.0021032323,0.022960478,0.0006957148,0.00042653253,0.008225963,0.017558321,0.0006049368,0.016322494,0.13139257],"study_design_scores_gemma":[0.2005998,0.19650885,0.54864794,0.00029099907,0.021347914,0.0015925419,0.00024639204,0.007318661,0.0048839073,0.0009718919,0.017409973,0.00018106907],"about_ca_topic_score_codex":0.0013971445,"about_ca_topic_score_gemma":0.003250107,"teacher_disagreement_score":0.007988826,"about_ca_system_score_codex":0.0013216346,"about_ca_system_score_gemma":0.0016652192,"threshold_uncertainty_score":0.04224944},"labels":[],"label_agreement":null},{"id":"W4389220841","doi":"10.1182/blood-2023-174929","title":"A Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of Glofitamab As Monotherapy and in Combination with R-ICE Chemoimmunotherapy in Children and Young Adults with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Chemoimmunotherapy; Medicine; Tumor lysis syndrome; Neutropenia; Internal medicine; Population; Febrile neutropenia; Rituximab; Cytokine release syndrome; Oncology; Tolerability; Lymphoma; Gastroenterology; Cancer; Adverse effect; Chemotherapy; Immunotherapy; Chimeric antigen receptor","score_opus":0.010659493861115539,"score_gpt":0.30349722035288157,"score_spread":0.29283772649176604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838925,0.0027332753,0.00055782584,0.0008100211,0.00021956702,0.003263643,0.0019024655,0.0001034871,0.0020204792],"genre_scores_gemma":[0.9803068,0.00201734,0.0024667985,0.0020822727,0.00022885947,0.0057149436,0.0034576235,0.000039644547,0.003685721],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996228,0.00015046952,0.00001743101,0.00008635129,0.000030850253,0.00009211898],"domain_scores_gemma":[0.99890256,0.00013678608,0.00020054853,0.0001006184,0.0000683529,0.00059110776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014154831,0.0012181307,0.0016728473,0.00031257202,0.0003139814,0.00101198,0.0007481477,0.0014792292,0.005612692],"category_scores_gemma":[0.0010554589,0.00049941265,0.0012969589,0.00029904416,0.00099607,0.0011316625,0.00043944878,0.0032978863,0.0015375519],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83622754,0.059093174,0.0071419203,0.0007244945,0.0014825545,0.00028280925,0.00033158116,0.0013648381,0.017109927,0.00046961554,0.00476962,0.07100194],"study_design_scores_gemma":[0.62558097,0.36127344,0.0070974934,0.00004638108,0.00038184942,0.00035947852,0.00007137172,0.0007111776,0.0011350672,0.00035951863,0.0029595164,0.00002370629],"about_ca_topic_score_codex":0.0006977395,"about_ca_topic_score_gemma":0.0013750095,"teacher_disagreement_score":0.005612692,"about_ca_system_score_codex":0.0010618789,"about_ca_system_score_gemma":0.0012504518,"threshold_uncertainty_score":0.018776357},"labels":[],"label_agreement":null},{"id":"W4389220971","doi":"10.1182/blood-2023-174209","title":"Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Cytokine release syndrome; Regimen; Lymphoma; Interim analysis; Clinical endpoint; Refractory (planetary science); Gastroenterology; Diffuse large B-cell lymphoma; Oncology; Clinical trial; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.015396412424737509,"score_gpt":0.28835124940416645,"score_spread":0.27295483697942896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967764,0.0012018378,0.00029233974,0.00009761869,0.00001691017,0.0003210938,0.00029962818,0.00004425944,0.00094985194],"genre_scores_gemma":[0.99783796,0.00048155882,0.00042990837,0.000121450794,0.00002472638,0.00013838579,0.0004445105,0.0000076056667,0.00051382557],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.999796,0.00007614762,0.000017235812,0.00004037614,0.00003077593,0.0000394546],"domain_scores_gemma":[0.9997632,0.000036986967,0.000053739455,0.0000227766,0.000014937074,0.00010845972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070088776,0.00045483027,0.00088395044,0.0002473439,0.00019718577,0.0006694723,0.00031531663,0.00031112588,0.0015585715],"category_scores_gemma":[0.0004248362,0.00023398339,0.0004855389,0.00024815957,0.000299463,0.00040619963,0.00017077441,0.0010565363,0.00042369025],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36616287,0.032747444,0.044784732,0.00094018976,0.0018965648,0.0006181373,0.0004594809,0.0036733644,0.18423043,0.00027293933,0.0043838206,0.35983017],"study_design_scores_gemma":[0.19382788,0.6245148,0.13310482,0.00010024414,0.0016413578,0.0022270752,0.00019046522,0.0042238305,0.027942723,0.00028108148,0.0118908025,0.00005483416],"about_ca_topic_score_codex":0.00045441688,"about_ca_topic_score_gemma":0.0019657137,"teacher_disagreement_score":0.0015585715,"about_ca_system_score_codex":0.0006552853,"about_ca_system_score_gemma":0.0005172978,"threshold_uncertainty_score":0.0052139163},"labels":[],"label_agreement":null},{"id":"W4389222107","doi":"10.1182/blood-2023-173955","title":"A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Cancer research; Antibody-drug conjugate; Radioimmunotherapy; In vivo; Medicine; Lymphoma; Follicular lymphoma; Chemistry; Pharmacology; Antibody; Internal medicine; Immunology; Biology; Monoclonal antibody","score_opus":0.012010767958892821,"score_gpt":0.275547729114953,"score_spread":0.2635369611560602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945787,0.0006853475,0.00045943164,0.00026691493,0.00006722778,0.0014817991,0.00070564693,0.000097626194,0.0016572207],"genre_scores_gemma":[0.9910492,0.00046578725,0.0012577553,0.0006353159,0.000066560126,0.001980846,0.0017179339,0.000031033553,0.0027956795],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997254,0.000085692416,0.000011516147,0.000056406257,0.00003014563,0.000090828995],"domain_scores_gemma":[0.9994741,0.00006506716,0.000091996146,0.00006703083,0.00003820216,0.00026362707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010719013,0.0011730118,0.0010686951,0.0003379369,0.00037613214,0.00078648835,0.00069948076,0.00089257007,0.0043508923],"category_scores_gemma":[0.00053573557,0.0003618868,0.00075911806,0.0003086831,0.00081381085,0.00082473323,0.0003203505,0.0030122374,0.0011279801],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.53769356,0.16106449,0.017241808,0.0005598295,0.0009681432,0.00057255244,0.00091245055,0.0052492484,0.09712919,0.0008694351,0.009486059,0.16825327],"study_design_scores_gemma":[0.288688,0.6789899,0.016021661,0.00003058433,0.00024799586,0.00051829574,0.00011635176,0.0021128121,0.008405829,0.0006412592,0.004196294,0.000031076277],"about_ca_topic_score_codex":0.0007179073,"about_ca_topic_score_gemma":0.0017779422,"teacher_disagreement_score":0.0043508923,"about_ca_system_score_codex":0.0012352867,"about_ca_system_score_gemma":0.001154649,"threshold_uncertainty_score":0.014555216},"labels":[],"label_agreement":null},{"id":"W4389227639","doi":"10.1158/2326-6074.tumimm23-a006","title":"Abstract A006: Understanding the Potential of Human IL-12 and Chimeric IL-15 Combination for Cancer Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Interleukin 15; Cancer immunotherapy; Immunology; Cytotoxic T cell; Chimeric antigen receptor; CD8; T cell; Cancer research; STAT4; Biology; Immune system; Medicine; Cytokine; Interleukin; In vitro; stat; STAT3; Cell biology; Signal transduction","score_opus":0.15433649951523956,"score_gpt":0.4428773898484035,"score_spread":0.288540890333164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8376667,0.07986133,0.0657643,0.0017978543,0.00030468882,0.00030259634,0.0007095877,0.0003216291,0.013271283],"genre_scores_gemma":[0.9784848,0.0070087044,0.010616525,0.00029508478,0.000059121507,0.00006774715,0.00022209791,0.0000115513385,0.0032342835],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99993956,0.00001162134,0.000004056944,0.00001168278,0.000018648298,0.000014511845],"domain_scores_gemma":[0.9999826,0.0000035736266,0.000005159113,0.0000013090864,0.0000029591927,0.0000043874525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001709396,0.00024863085,0.00015323973,0.00016072165,0.00005490812,0.00029067448,0.000209066,0.00028320646,0.0017406108],"category_scores_gemma":[0.000078134646,0.000081997874,0.00022482671,0.00009301368,0.00012728093,0.00028662034,0.000092252696,0.00031801045,0.00046190427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028842597,0.00010009009,0.0005103594,0.00020685262,0.000015665864,0.000091791,0.000012485628,0.0017632799,0.97828513,0.0011816163,0.00045229268,0.017091997],"study_design_scores_gemma":[0.00008235666,0.001732266,0.0024318616,0.000045629295,0.00006280667,0.00071417826,0.000026678912,0.019393014,0.952861,0.0013166842,0.021319326,0.000014132142],"about_ca_topic_score_codex":0.0003847466,"about_ca_topic_score_gemma":0.0003000863,"teacher_disagreement_score":0.0017406108,"about_ca_system_score_codex":0.00030420293,"about_ca_system_score_gemma":0.00019079333,"threshold_uncertainty_score":0.005822897},"labels":[],"label_agreement":null},{"id":"W4389227694","doi":"10.1158/2326-6074.tumimm23-b025","title":"Abstract B025: Neutrophil depletion enhances the anti-tumor activity of CAR-T cells in an autochthonous model of non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; T cell; CD8; Immunotherapy; Medicine; Infiltration (HVAC); Cell; Lung cancer; Cancer immunotherapy; Immune system; Immunology; Pathology; Biology","score_opus":0.08007744742955278,"score_gpt":0.4022435364212251,"score_spread":0.3221660889916723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99548584,0.00078935,0.0011724856,0.00012480233,0.0000615081,0.000097341064,0.0006148716,0.00013747255,0.0015163956],"genre_scores_gemma":[0.99356127,0.0003838471,0.0012621717,0.00007962942,0.000021468604,0.00011928829,0.0007275876,0.000033057026,0.0038118612],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996055,0.00007974003,0.00003293759,0.00007352346,0.000096365526,0.00011198049],"domain_scores_gemma":[0.9997706,0.00004353451,0.000046162055,0.00003356709,0.000019212548,0.000087011955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003492466,0.00047913415,0.0005415161,0.00036140447,0.00015886569,0.0003542933,0.00042769298,0.00054486643,0.002765721],"category_scores_gemma":[0.00012590794,0.00020066446,0.0003652293,0.00016994854,0.0002822627,0.00026901992,0.00020273804,0.0014682359,0.0006838611],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007749476,0.00073334086,0.00010760733,0.0000680994,0.000008531291,0.00007883886,0.00002436154,0.00021409012,0.99548066,0.00016186807,0.00020227104,0.0021453507],"study_design_scores_gemma":[0.0002069881,0.0065747374,0.0022523836,0.000011108988,0.000019335583,0.00021500769,0.000027110436,0.0026644075,0.98638815,0.00004514704,0.0015885053,0.000007117717],"about_ca_topic_score_codex":0.001591235,"about_ca_topic_score_gemma":0.0018858596,"teacher_disagreement_score":0.002765721,"about_ca_system_score_codex":0.00035621034,"about_ca_system_score_gemma":0.00038232215,"threshold_uncertainty_score":0.00925225},"labels":[],"label_agreement":null},{"id":"W4389227770","doi":"10.1158/2326-6074.tumimm23-b003","title":"Abstract B003: Communication is key: Understanding the modulating effect of immune cell crosstalk on T cell therapy function","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Crosstalk; T cell; Immune system; Interactome; CD8; Immunotherapy; Cancer immunotherapy; Cancer research; Cell; Biology; Computational biology; Cell biology; Immunology; Genetics","score_opus":0.15349428235421014,"score_gpt":0.42722960022174505,"score_spread":0.2737353178675349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5840418,0.05942954,0.10869078,0.017460316,0.003869271,0.00037662327,0.013368771,0.004039185,0.20872378],"genre_scores_gemma":[0.8607757,0.01652853,0.020719888,0.001461265,0.00043276054,0.0003169319,0.0038560862,0.00044553058,0.09546335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99969494,0.000033679018,0.000015573516,0.000087336404,0.000094223295,0.000074160824],"domain_scores_gemma":[0.999828,0.000039768503,0.000037940677,0.000014906819,0.000032171014,0.000047251902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027673354,0.00061399397,0.00036572144,0.00043229488,0.00046684628,0.0014107756,0.00034997583,0.0011650964,0.05520948],"category_scores_gemma":[0.00024050569,0.00020613396,0.00034338885,0.00036989807,0.00048196132,0.0010559412,0.00063117273,0.0013670836,0.012681818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023460189,0.000047326725,0.0002384957,0.00031974266,0.000009534989,0.00015637634,0.000025778843,0.00027446865,0.97096485,0.0032462985,0.0031277044,0.021354802],"study_design_scores_gemma":[0.00007820902,0.00038560864,0.0077635744,0.00011687567,0.00004139564,0.0006220314,0.0001389411,0.0052681654,0.8388541,0.0052596843,0.1414466,0.000024812276],"about_ca_topic_score_codex":0.00053961796,"about_ca_topic_score_gemma":0.0003748998,"teacher_disagreement_score":0.05520948,"about_ca_system_score_codex":0.0008115597,"about_ca_system_score_gemma":0.0004936982,"threshold_uncertainty_score":0.18469411},"labels":[],"label_agreement":null},{"id":"W4389227797","doi":"10.1158/2326-6074.tumimm23-a047","title":"Abstract A047: Tumor specific γδ T cells expand and respond to PD-1 blockade","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; TIGIT; T cell; T-cell receptor; Blockade; Immunology; Cancer immunotherapy; Tumor-infiltrating lymphocytes; Immunotherapy; Biology; Cancer research; Medicine; Immune system; Receptor; Internal medicine","score_opus":0.12411425987828946,"score_gpt":0.4345827140921795,"score_spread":0.3104684542138901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944924,0.0006830369,0.0009212723,0.00017743812,0.00003357738,0.000036872334,0.0002609323,0.0000693687,0.0033251948],"genre_scores_gemma":[0.99753416,0.00010185607,0.00047380396,0.0001713106,0.000015759482,0.000022735292,0.00026311312,0.000012431233,0.001404763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999285,0.000010627702,0.0000065789086,0.0000181238,0.000013140806,0.000023123377],"domain_scores_gemma":[0.99991906,0.000021634829,0.000009004987,0.000010377,0.0000149985035,0.000024821418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008163391,0.0002251824,0.00018362606,0.00021468685,0.00020113357,0.00028550078,0.00011288453,0.00033202005,0.0033768083],"category_scores_gemma":[0.00017364495,0.00008257319,0.000175905,0.00008852592,0.00013161471,0.000113172195,0.00015376459,0.0007082543,0.00070094055],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055485906,0.00010472014,0.007906327,0.00003952626,0.000010191769,0.0010668514,0.00010457214,0.00022884217,0.9797355,0.00011867467,0.00086556416,0.009264371],"study_design_scores_gemma":[0.00035032147,0.004181511,0.19613689,0.000051967552,0.00014784496,0.024083309,0.0005453879,0.0061718,0.74181145,0.00068873377,0.025804367,0.000026395539],"about_ca_topic_score_codex":0.0006066238,"about_ca_topic_score_gemma":0.00034898848,"teacher_disagreement_score":0.0033768083,"about_ca_system_score_codex":0.00020499613,"about_ca_system_score_gemma":0.00010416723,"threshold_uncertainty_score":0.01129657},"labels":[],"label_agreement":null},{"id":"W4389227931","doi":"10.1158/2326-6074.tumimm23-b008","title":"Abstract B008: GPR64-targeting single-domain CAR-T cells for immunotherapy in Ewing sarcoma","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Cancer research; Cancer; FLI1; Context (archaeology); Transcriptome; Medicine; Sarcoma; Mesenchymal stem cell; Cancer immunotherapy; Biology; Computational biology; Bioinformatics; Transcription factor; Internal medicine; Pathology; Gene expression; Genetics; Gene","score_opus":0.12010739287825663,"score_gpt":0.42062158504169206,"score_spread":0.30051419216343545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98735213,0.0039957697,0.0040786364,0.00032267126,0.00014245338,0.00013302692,0.0012508986,0.00022738338,0.0024970714],"genre_scores_gemma":[0.9864608,0.0016830802,0.004201008,0.00023081157,0.00003232326,0.00015327228,0.0028246215,0.00003853821,0.004375632],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988747,0.000013901634,0.0000068899244,0.000029665161,0.000030227415,0.000031793003],"domain_scores_gemma":[0.999977,0.0000025282154,0.0000043382447,0.0000024652443,0.0000052165137,0.000008507887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015715968,0.00026169233,0.00034307342,0.0002794927,0.00013472671,0.00030639025,0.00018555224,0.00042171055,0.002801421],"category_scores_gemma":[0.000086247936,0.00008919602,0.00032049287,0.00026007905,0.00013547647,0.00017910189,0.0002494705,0.00058895815,0.0010512072],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033169347,0.00008868966,0.00036479026,0.00009205034,0.000013616405,0.00008485689,0.000015606165,0.00022274815,0.99099606,0.0001322338,0.0005745487,0.007083183],"study_design_scores_gemma":[0.00019016418,0.0026058194,0.009126532,0.000029710334,0.00011830399,0.0012523229,0.00007785648,0.0046539805,0.95536715,0.0002899862,0.026269713,0.00001835608],"about_ca_topic_score_codex":0.00021133173,"about_ca_topic_score_gemma":0.00020231222,"teacher_disagreement_score":0.002801421,"about_ca_system_score_codex":0.00019854015,"about_ca_system_score_gemma":0.00016654396,"threshold_uncertainty_score":0.009371698},"labels":[],"label_agreement":null},{"id":"W4389227987","doi":"10.1158/2326-6074.tumimm23-a010","title":"Abstract A010: Assay development to assess the efficiency and stability of candidate molecules for transcriptional gene silencing of FOXP3, using a human tumor-derived cell line","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gene silencing; Biology; FOXP3; Transcription factor; Cell biology; Transcriptional regulation; Epigenetics; Effector; Cancer research; Therapeutic gene modulation; Gene expression; Immune system; Gene; Immunology; Genetics; Regulator gene","score_opus":0.22277501408679942,"score_gpt":0.4421814979584126,"score_spread":0.21940648387161318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227987","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7352291,0.0043802117,0.24885906,0.0001735248,0.00025914906,0.0009392304,0.0022785584,0.0017928696,0.006088267],"genre_scores_gemma":[0.7588189,0.0024743124,0.21183611,0.00020863845,0.00008414728,0.0022309392,0.0073128096,0.00027840608,0.016755756],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986584,0.00030715283,0.00013092607,0.0003475294,0.00047444494,0.00008152381],"domain_scores_gemma":[0.999368,0.00025439513,0.00009706067,0.00008822991,0.00013250412,0.000059772374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009638669,0.0010434417,0.00046379195,0.00083729177,0.00029819008,0.0005847029,0.0004775749,0.00064769015,0.0027206023],"category_scores_gemma":[0.00066321203,0.00037473883,0.0004867247,0.00054678414,0.00037458487,0.00030989645,0.0003208738,0.0008673692,0.0013247429],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006406212,0.00006031691,0.0003242774,0.000045643235,0.000007655399,0.000012675105,0.00002275046,0.00005287911,0.9972958,0.000048672584,0.000038447924,0.0020268508],"study_design_scores_gemma":[0.000007805432,0.00039875924,0.00094147,0.0000046408195,0.000022784301,0.00006263816,0.000010521251,0.0006989572,0.99671245,0.000025384585,0.0011098009,0.0000046327978],"about_ca_topic_score_codex":0.00043800194,"about_ca_topic_score_gemma":0.00048066795,"teacher_disagreement_score":0.0027206023,"about_ca_system_score_codex":0.00035169834,"about_ca_system_score_gemma":0.00031525863,"threshold_uncertainty_score":0.009101272},"labels":[],"label_agreement":null},{"id":"W4389229518","doi":"10.1182/blood-2023-178724","title":"A Potential Paradigm for the Robust and Systematic Prioritisation of Assets in Academic-Led, Multi-Industry Collaborative Trials in Rare Populations (Glo-BNHL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Clinical trial; Relevance (law); Adverse effect; Intensive care medicine; Medical physics; Pathology; Pharmacology","score_opus":0.143860817377604,"score_gpt":0.40989628892360797,"score_spread":0.26603547154600393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229518","genre_codex":"commentary","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004994696,0.05809643,0.26708692,0.56912476,0.023291366,0.038203623,0.002924274,0.0019723289,0.034305684],"genre_scores_gemma":[0.07325816,0.015221526,0.67864764,0.15784223,0.018034631,0.046430886,0.0027194342,0.0010584954,0.0067870286],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.26292178,0.6392172,0.039479792,0.015171936,0.03764418,0.0055650687],"domain_scores_gemma":[0.15873685,0.5317831,0.05532884,0.093265355,0.13409635,0.026789516],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.7513449,0.002771075,0.0058251903,0.01052698,0.00463479,0.028485628,0.010893127,0.013255969,0.011885037],"category_scores_gemma":[0.6659781,0.0027224454,0.0068023433,0.008454452,0.009165642,0.019184968,0.030670756,0.018885557,0.0053077373],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025478192,0.0004801448,0.0040871976,0.024300529,0.0039794776,0.00042449092,0.007080721,0.0054686414,0.0026945297,0.18894799,0.15484093,0.6051475],"study_design_scores_gemma":[0.004881804,0.0024771935,0.0065677697,0.03582671,0.001853431,0.0003960936,0.0019660946,0.005882139,0.0021503253,0.34027788,0.5971777,0.0005429135],"about_ca_topic_score_codex":0.0046444177,"about_ca_topic_score_gemma":0.007437573,"teacher_disagreement_score":0.24865508,"about_ca_system_score_codex":0.01771498,"about_ca_system_score_gemma":0.16868973,"threshold_uncertainty_score":0.30663604},"labels":[],"label_agreement":null},{"id":"W4389231884","doi":"10.1182/blood-2023-179474","title":"TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Refractory (planetary science); Clinical endpoint; Oncology; Cohort; Phases of clinical research; Lymphoma; Gastroenterology; Surgery; Chemotherapy; Clinical trial; Biology","score_opus":0.020436914417571526,"score_gpt":0.2999379315298334,"score_spread":0.2795010171122619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97293663,0.0050399904,0.0013673297,0.00074989005,0.00017250933,0.007134201,0.0077315276,0.00026809558,0.004599909],"genre_scores_gemma":[0.9726917,0.0021770878,0.0023278724,0.0015753644,0.00029240543,0.005797155,0.01066972,0.0000902924,0.004378321],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994942,0.0002303215,0.000021626294,0.00010946663,0.000059523125,0.00008478276],"domain_scores_gemma":[0.99934274,0.000089785666,0.00017170617,0.00006288713,0.00008073126,0.00025218911],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021609694,0.0014372626,0.0016534778,0.0004083301,0.0003349386,0.0011591271,0.0008895476,0.0009597995,0.0063091815],"category_scores_gemma":[0.0010002762,0.00054053066,0.0016381807,0.0003252941,0.0005347749,0.0007327701,0.0004574777,0.0021966395,0.0011987443],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.75714964,0.043271348,0.019096375,0.0027044723,0.005464007,0.00046967738,0.00034661923,0.0025748827,0.061453205,0.000487305,0.013918085,0.09306437],"study_design_scores_gemma":[0.5820113,0.3545759,0.035300124,0.00014881577,0.0038430383,0.0011459934,0.00013471775,0.001934337,0.008097389,0.00043459143,0.012300174,0.00007362876],"about_ca_topic_score_codex":0.0006056068,"about_ca_topic_score_gemma":0.0022740727,"teacher_disagreement_score":0.0063091815,"about_ca_system_score_codex":0.00093733164,"about_ca_system_score_gemma":0.001538432,"threshold_uncertainty_score":0.021106303},"labels":[],"label_agreement":null},{"id":"W4389231975","doi":"10.1182/blood-2023-178868","title":"WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Immune system; Biology; Cancer research; Cancer immunotherapy; Immunotherapy; Immunology; Cell biology","score_opus":0.025281636456025786,"score_gpt":0.26789262133763597,"score_spread":0.24261098488161018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822167,0.0013621714,0.012113191,0.0001969527,0.00005958416,0.000057212572,0.0006700882,0.00021291827,0.0031111976],"genre_scores_gemma":[0.98245376,0.0006136489,0.009638644,0.00017984057,0.000013136209,0.00008984071,0.0012729776,0.000057212088,0.005680867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999861,0.000018414043,0.00001676445,0.00004292129,0.000036350237,0.000024532992],"domain_scores_gemma":[0.9999274,0.000009923742,0.000021457516,0.000009745917,0.000010838193,0.000020613088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000111355585,0.00020953239,0.00023573406,0.00012487631,0.00013644776,0.00044941335,0.00024115322,0.00026941544,0.00088621094],"category_scores_gemma":[0.00015296132,0.000072053284,0.00016132167,0.000127402,0.00022088565,0.0003021438,0.00028877627,0.0005602612,0.00054350594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105091254,0.00003990214,0.0005348047,0.00003512333,0.000004377862,0.000043924305,0.0000137181405,0.00016576606,0.99420255,0.00015914453,0.00010537888,0.0045901467],"study_design_scores_gemma":[0.000018495872,0.00054822286,0.0023307686,0.000008807471,0.000016074335,0.0005553102,0.000058997884,0.0012192151,0.989364,0.00013105516,0.0057401927,0.000008805405],"about_ca_topic_score_codex":0.00016555408,"about_ca_topic_score_gemma":0.00057666725,"teacher_disagreement_score":0.00088621094,"about_ca_system_score_codex":0.0001446345,"about_ca_system_score_gemma":0.00015723343,"threshold_uncertainty_score":0.0029646158},"labels":[],"label_agreement":null},{"id":"W4389232148","doi":"10.1182/blood-2023-183001","title":"Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Medicine; Internal medicine; Cart; Diffuse large B-cell lymphoma; Progression-free survival; Chemoimmunotherapy; BCL6; Oncology; Gastroenterology; Lymphoma; Rituximab; Immunology; Chemotherapy; B cell","score_opus":0.033491921752018955,"score_gpt":0.2998034567588199,"score_spread":0.26631153500680094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99943095,0.00018603109,0.00006178625,0.00001986096,0.000002009399,0.000002749369,0.000065819695,0.0000026642538,0.00022801769],"genre_scores_gemma":[0.99972624,0.000060783972,0.000029459803,0.000016747714,0.000006836619,0.0000018601561,0.00009186434,6.531456e-7,0.000065532884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985623,0.00004739536,0.000013431834,0.000029654619,0.000022764561,0.000030433514],"domain_scores_gemma":[0.9995653,0.00007755063,0.00023521065,0.000025386402,0.000021458052,0.00007513203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000428662,0.00008403498,0.0002264603,0.0001673102,0.00011745538,0.00031772107,0.000098220815,0.0001440214,0.000989018],"category_scores_gemma":[0.0007287074,0.00005709082,0.00014220549,0.00018694004,0.00012929419,0.00021685728,0.0001664249,0.00015007061,0.00013291957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029854153,0.00015020209,0.9699813,0.000030739495,0.0000901814,0.0006182477,0.00007706697,0.00040977317,0.0034785124,0.000062370396,0.00025372783,0.021862615],"study_design_scores_gemma":[0.00016383668,0.004770087,0.9876346,0.000016248614,0.00013775607,0.0034798763,0.00009962096,0.0011977619,0.0011133227,0.00008399405,0.0012968084,0.0000060060156],"about_ca_topic_score_codex":0.00034353588,"about_ca_topic_score_gemma":0.00052812666,"teacher_disagreement_score":0.000989018,"about_ca_system_score_codex":0.0002339553,"about_ca_system_score_gemma":0.00016643126,"threshold_uncertainty_score":0.0033085942},"labels":[],"label_agreement":null},{"id":"W4389232661","doi":"10.1182/blood-2023-174956","title":"Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Neutropenia; Ibrutinib; Gastroenterology; Population; Adverse effect; Febrile neutropenia; Oncology; Pharmacology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.025440544477267114,"score_gpt":0.2851808303898294,"score_spread":0.25974028591256226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99447894,0.0030730853,0.00045316448,0.00020572952,0.00003134792,0.00034356126,0.00033266787,0.00005283007,0.0010287011],"genre_scores_gemma":[0.9962967,0.0013088024,0.00062352675,0.00026919227,0.000048559963,0.00022126244,0.000588391,0.000013446785,0.00063011126],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997987,0.000060358936,0.000016105443,0.000040968855,0.00003615585,0.00004775058],"domain_scores_gemma":[0.99972004,0.000047128535,0.000054486634,0.000028491415,0.00001730232,0.00013252805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007607337,0.0005739155,0.0010398151,0.00023683751,0.00023605881,0.00074788084,0.00045368104,0.00039083406,0.0018946463],"category_scores_gemma":[0.00046876376,0.00024743073,0.00084003404,0.0002963928,0.00040197544,0.00055481424,0.00020939796,0.0016731276,0.00050141604],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28484184,0.043414474,0.023934634,0.0011990883,0.0022353472,0.00078668987,0.0006068816,0.0037140443,0.1600224,0.00026650546,0.0053911596,0.47358698],"study_design_scores_gemma":[0.1916062,0.6966786,0.080664486,0.00010983331,0.0013414666,0.0020385555,0.00017533646,0.0025469274,0.015273537,0.00027000354,0.009242389,0.00005266383],"about_ca_topic_score_codex":0.0007225626,"about_ca_topic_score_gemma":0.0020422642,"teacher_disagreement_score":0.0018946463,"about_ca_system_score_codex":0.0007810389,"about_ca_system_score_gemma":0.00057117274,"threshold_uncertainty_score":0.0063382387},"labels":[],"label_agreement":null},{"id":"W4389233282","doi":"10.1182/blood-2023-190037","title":"Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD33; Plerixafor; Myeloid leukemia; CD34; Medicine; Hematopoietic stem cell transplantation; Haematopoiesis; Leukemia; Stem cell; Myeloid; Immunology; Cancer research; Transplantation; Internal medicine; Oncology; Biology; CXCR4; Immune system","score_opus":0.00656140965244994,"score_gpt":0.21476699234294463,"score_spread":0.2082055826904947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878692,0.0015305004,0.0049619866,0.00017147324,0.00005188149,0.00018175549,0.0012441836,0.00057466177,0.003414256],"genre_scores_gemma":[0.9933562,0.00060027186,0.0028038728,0.00007587934,0.000006551275,0.00008727797,0.0013602755,0.000032096996,0.0016775894],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998871,0.000020190864,0.000007228582,0.000026219606,0.000035169967,0.000023986897],"domain_scores_gemma":[0.99991953,0.000011902027,0.00003004803,0.000008884798,0.0000065784234,0.000023104962],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022758087,0.0002518376,0.00029063955,0.00018178797,0.00009575891,0.00024027536,0.00023068105,0.00026934943,0.0030459955],"category_scores_gemma":[0.00013777977,0.00009017791,0.00022214318,0.00011065697,0.00021711527,0.00012270079,0.00014200414,0.00058501225,0.0005138267],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041084685,0.0010805731,0.0016776305,0.00028310335,0.0000819982,0.0003878381,0.00003752061,0.0012976736,0.94589144,0.00042883918,0.0021287345,0.042596217],"study_design_scores_gemma":[0.002414152,0.01697747,0.012984587,0.000030470814,0.00017513068,0.003852278,0.000038416623,0.00482403,0.9379446,0.00014916468,0.020581754,0.000027918266],"about_ca_topic_score_codex":0.00030646418,"about_ca_topic_score_gemma":0.00072573987,"teacher_disagreement_score":0.0030459955,"about_ca_system_score_codex":0.00023272476,"about_ca_system_score_gemma":0.00025723418,"threshold_uncertainty_score":0.010189891},"labels":[],"label_agreement":null},{"id":"W4389233418","doi":"10.1182/blood-2023-182447","title":"Harnessing TCR/CAR Antagonism to Enhance Immunotherapeutic Precision","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Antigen; Adoptive cell transfer; Biology; CD19; Immunology; Immunotherapy; T cell; Cancer research; Leukemia; Cell biology; Immune system","score_opus":0.033525931763121374,"score_gpt":0.35828287330636066,"score_spread":0.3247569415432393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73132527,0.0011602903,0.26139042,0.00030303982,0.000042578886,0.00013268008,0.00024120833,0.00047158022,0.0049329437],"genre_scores_gemma":[0.9789402,0.0005402007,0.01931473,0.000079891746,0.000007885333,0.00008439239,0.00006292011,0.000023978291,0.00094588584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99967504,0.000045370285,0.00002013275,0.00008275393,0.00010651738,0.00007018621],"domain_scores_gemma":[0.99983597,0.00006853962,0.000054611985,0.000015338155,0.000014074102,0.000011475648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004093471,0.00057522213,0.0005439605,0.00019118923,0.00013797173,0.0006197586,0.0004590717,0.0006522133,0.00080593926],"category_scores_gemma":[0.0005427638,0.0003232346,0.00039393103,0.00016436497,0.00032881554,0.0006153443,0.00039405856,0.0008955358,0.00027226363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077587116,0.000096291216,0.00059728196,0.00012219258,0.00002075053,0.00009435235,0.000030901723,0.15192175,0.8376434,0.0041527096,0.00014304805,0.005099723],"study_design_scores_gemma":[0.000023469556,0.0003232712,0.00042946267,0.000009500318,0.000025575378,0.000101515754,0.000014452033,0.65965164,0.33661503,0.0011019564,0.0016888834,0.000015248094],"about_ca_topic_score_codex":0.0005529818,"about_ca_topic_score_gemma":0.00073748134,"teacher_disagreement_score":0.00080593926,"about_ca_system_score_codex":0.00066140713,"about_ca_system_score_gemma":0.00044156137,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4389233438","doi":"10.1182/blood-2023-178786","title":"Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Population; Internal medicine; Oncology; Refractory (planetary science); Monoclonal; Monoclonal antibody; Gastroenterology; Immunology; Antibody; Biology","score_opus":0.05250218656409533,"score_gpt":0.32336730339557646,"score_spread":0.2708651168314811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9602776,0.015603062,0.009201119,0.0004022735,0.0014583478,0.0021454885,0.0056484435,0.00017362494,0.0050899517],"genre_scores_gemma":[0.9894917,0.0006345558,0.0041763214,0.00047848615,0.00015368633,0.0018999404,0.0016717715,0.000033496082,0.0014600625],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98349816,0.01172878,0.00089109223,0.0021759418,0.0009903976,0.0007157676],"domain_scores_gemma":[0.9872709,0.008883339,0.0017160194,0.0013437563,0.0003792135,0.00040672463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013119056,0.0014886865,0.0031749744,0.000985934,0.00030216252,0.00093112886,0.0014273328,0.0014799746,0.0069078277],"category_scores_gemma":[0.023083499,0.00047696623,0.007996377,0.00064382085,0.0008494742,0.0011640599,0.0013568883,0.0031001256,0.0004662617],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6658296,0.0014256346,0.061000623,0.0051739365,0.20732795,0.0002562661,0.00024181127,0.006243155,0.002963285,0.0029829154,0.004627711,0.041927084],"study_design_scores_gemma":[0.1717344,0.1995404,0.2412749,0.0011916094,0.27535093,0.0010855742,0.0005808222,0.06698084,0.009099529,0.010985544,0.021803156,0.0003722807],"about_ca_topic_score_codex":0.0015848125,"about_ca_topic_score_gemma":0.0019387557,"teacher_disagreement_score":0.013119056,"about_ca_system_score_codex":0.001006099,"about_ca_system_score_gemma":0.00067573914,"threshold_uncertainty_score":0.06938106},"labels":[],"label_agreement":null},{"id":"W4389233512","doi":"10.1182/blood-2023-177527","title":"Human iPSC-Derived NK Cells with Knock-in of the BCL2 G101V Mutation Are Resistant to Venetoclax and Demonstrate Improved Anti-AML Activity In Vivo","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Venetoclax; Induced pluripotent stem cell; Cancer research; Biology; Immunotherapy; Leukemia; Immunology; Immune system; Embryonic stem cell; Genetics; Gene; Chronic lymphocytic leukemia","score_opus":0.02075981551833654,"score_gpt":0.2862143710152169,"score_spread":0.26545455549688035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97117853,0.001814927,0.013472134,0.00026113534,0.00021290513,0.00019884648,0.0036355096,0.00054094207,0.0086851],"genre_scores_gemma":[0.98416233,0.0008224147,0.004571699,0.00015103118,0.000013083886,0.00014934382,0.0035855526,0.000076507866,0.006467994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999723,0.00002532743,0.000049399805,0.000057949197,0.00010779911,0.000036369245],"domain_scores_gemma":[0.9998374,0.000036609214,0.0000428353,0.000036738766,0.000017276781,0.00002909964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023597645,0.00030676994,0.00032289024,0.00021722462,0.00016509173,0.00044273643,0.00025678257,0.00044679467,0.0025120105],"category_scores_gemma":[0.00016333601,0.00015469536,0.00028493462,0.0001758899,0.00027299323,0.00023290279,0.00016061396,0.0010771361,0.0009122624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009527474,0.00007807664,0.00022923546,0.00004928362,0.00001163602,0.00011475264,0.000028667075,0.00028014262,0.99524623,0.0002627511,0.00025299584,0.0033510511],"study_design_scores_gemma":[0.00006196141,0.00027522875,0.0026439212,0.000011991829,0.000039789895,0.0007396185,0.000028404085,0.0016054694,0.986273,0.00010542403,0.008206025,0.000009206966],"about_ca_topic_score_codex":0.00035263624,"about_ca_topic_score_gemma":0.0005191774,"teacher_disagreement_score":0.0025120105,"about_ca_system_score_codex":0.00017457879,"about_ca_system_score_gemma":0.00017781548,"threshold_uncertainty_score":0.00840348},"labels":[],"label_agreement":null},{"id":"W4389234406","doi":"10.1182/blood-2023-177591","title":"Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"CHOP; Medicine; Rituximab; Oncology; Internal medicine; Lymphoma; Diffuse large B-cell lymphoma; Chemotherapy regimen; Biomarker; Gene signature; Immunology; Chemotherapy; Cancer research; Biology; Gene expression; Gene","score_opus":0.009579933272469627,"score_gpt":0.2652194575617714,"score_spread":0.25563952428930176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994312,0.0002545146,0.00002798039,0.000035344736,0.0000025303248,0.0000070396686,0.0000904449,0.000002693296,0.00014821911],"genre_scores_gemma":[0.999506,0.00006605271,0.000055917782,0.000036871068,0.0000075887956,0.000008772149,0.00020350811,0.0000011703082,0.00011409338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998826,0.000027383325,0.000009221767,0.000031203745,0.000021611933,0.000028080676],"domain_scores_gemma":[0.9996685,0.00009151103,0.0001196937,0.000010566372,0.00002413197,0.00008563085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026429858,0.00011848898,0.0002811095,0.00027286494,0.00015464802,0.0003996906,0.00015185308,0.00025574028,0.0009328337],"category_scores_gemma":[0.00063091086,0.00013116118,0.00017471467,0.0003237283,0.0001312231,0.00017871294,0.00015034518,0.00034018813,0.0002100809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006396008,0.00025622023,0.9668745,0.000043033906,0.000092239025,0.00022525503,0.00008383167,0.00030538364,0.007854375,0.000026117346,0.0004098181,0.01743319],"study_design_scores_gemma":[0.00015616651,0.0016489328,0.99553126,0.000007446174,0.000055639244,0.00036665198,0.00007436072,0.0009238166,0.00079210126,0.000028638608,0.00041028607,0.0000046871874],"about_ca_topic_score_codex":0.00067650276,"about_ca_topic_score_gemma":0.001554256,"teacher_disagreement_score":0.0009328337,"about_ca_system_score_codex":0.00038005298,"about_ca_system_score_gemma":0.00016933662,"threshold_uncertainty_score":0.0031206608},"labels":[],"label_agreement":null},{"id":"W4389240069","doi":"10.1158/2326-6074.tumimm23-a053","title":"Abstract A053: Notch completes CD4 T cell help in CD8 T cells and ensures timely departure","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Priming (agriculture); Cytotoxic T cell; CD8; Antigen-presenting cell; T cell; Cell biology; CD40; IL-2 receptor; Lymph node; Biology; Immunology; Chemistry; Antigen; Immune system; Biochemistry","score_opus":0.10310504523726723,"score_gpt":0.4104980381016099,"score_spread":0.3073929928643427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705038,0.0012578081,0.012631742,0.00037560487,0.00016785967,0.00007752376,0.0013970714,0.00056819775,0.013020351],"genre_scores_gemma":[0.9739396,0.00025807353,0.006884633,0.00016026504,0.000045072717,0.00005443163,0.0010472453,0.00011161245,0.017499123],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998186,0.000020390915,0.00001578651,0.000043294054,0.0000572375,0.000044817232],"domain_scores_gemma":[0.99983644,0.000018151122,0.00003816935,0.000023769171,0.00002651461,0.000057039622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011129178,0.0002334172,0.0001640659,0.00021805736,0.00023400481,0.00045130137,0.0003968834,0.00042014083,0.007948147],"category_scores_gemma":[0.0001331408,0.00014103095,0.00020206739,0.000116952906,0.00019962993,0.00026185007,0.00028795752,0.0007312413,0.003173713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002070777,0.000029339151,0.00016680708,0.000025224099,0.0000021960254,0.00006035081,0.000008980157,0.000069520414,0.99677294,0.00039892131,0.00020868093,0.0020498661],"study_design_scores_gemma":[0.00002758929,0.00016291978,0.0015278786,0.000007630979,0.000007093731,0.0002209463,0.000018961986,0.0009877557,0.98980635,0.00016109175,0.0070678107,0.000003990932],"about_ca_topic_score_codex":0.00044221975,"about_ca_topic_score_gemma":0.00045643924,"teacher_disagreement_score":0.007948147,"about_ca_system_score_codex":0.00048353113,"about_ca_system_score_gemma":0.0003024663,"threshold_uncertainty_score":0.026589274},"labels":[],"label_agreement":null},{"id":"W4389241392","doi":"10.1158/2326-6074.tumimm23-b007","title":"Abstract B007: Phenotypic Signatures of Circulating Neoantigen-Reactive CD8+ T Cells in Patients with Metastatic Cancers","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD8; T-cell receptor; Cytotoxic T cell; Immunotherapy; T cell; Biology; Antigen; Cancer immunotherapy; Immunology; Circulating tumor cell; Cancer research; Phenotype; Cancer; Immune system; Metastasis; Gene; In vitro; Genetics","score_opus":0.06538773514156315,"score_gpt":0.38750745095334577,"score_spread":0.3221197158117826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999209,0.00009898267,0.0001905321,0.000013373689,0.0000019880206,0.000006300125,0.00011062859,0.000009848865,0.00035932],"genre_scores_gemma":[0.999323,0.000029958106,0.00021003344,0.000016040143,0.000004235802,0.000009542231,0.00020375941,0.0000028873235,0.00020065073],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999926,0.000010428889,0.0000060862794,0.00002325956,0.000018007067,0.000016231068],"domain_scores_gemma":[0.99987495,0.000034400568,0.000027031487,0.000007849181,0.000023589539,0.000032172124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008289081,0.0001311383,0.00017084199,0.0002851325,0.00011619203,0.00021483365,0.000078740886,0.00024641628,0.001587597],"category_scores_gemma":[0.000288708,0.00006610306,0.000071810326,0.00020227114,0.000092135844,0.00010465739,0.0001053758,0.00024834136,0.00031641757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017009452,0.00016419205,0.47807187,0.000087245244,0.000026948841,0.0008741131,0.00030211842,0.00033904036,0.49538162,0.000058024212,0.0004429346,0.022551017],"study_design_scores_gemma":[0.00003919645,0.0013926405,0.95191413,0.000010124392,0.00004145082,0.0045990567,0.0002464231,0.0011905326,0.039089542,0.00007845269,0.0013913123,0.000007020509],"about_ca_topic_score_codex":0.00024750645,"about_ca_topic_score_gemma":0.00022695138,"teacher_disagreement_score":0.001587597,"about_ca_system_score_codex":0.000096559874,"about_ca_system_score_gemma":0.000054893568,"threshold_uncertainty_score":0.005311072},"labels":[],"label_agreement":null},{"id":"W4389241834","doi":"10.1158/2326-6074.tumimm23-b005","title":"Abstract B005: Molecular, metabolic and functional CD4 T cell paralysis in lymph node impedes tumor control","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CD8; Biology; T cell; Lymph node; Adoptive cell transfer; Cancer research; Tumor-infiltrating lymphocytes; Epitope; Antigen; Immunology; Cell biology; Immune system","score_opus":0.053916213096303046,"score_gpt":0.3794539962917979,"score_spread":0.3255377831954948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877664,0.0011521673,0.003476763,0.0003430287,0.000074054245,0.00006462317,0.00058724784,0.00018551924,0.0063501545],"genre_scores_gemma":[0.986283,0.00033173276,0.0022470835,0.00008118033,0.000016823082,0.000057502813,0.0005535126,0.000036174755,0.010392907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998889,0.0000109077455,0.0000068066383,0.000021448852,0.000033998385,0.000037991256],"domain_scores_gemma":[0.9999261,0.000011673667,0.000015148195,0.000008179705,0.000010713586,0.000028192855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010361987,0.00032367217,0.00015362304,0.0001841698,0.00013743548,0.00028126047,0.00032073402,0.0003467344,0.005674663],"category_scores_gemma":[0.00009316468,0.00011160093,0.00016007059,0.00008975248,0.00030332137,0.00018609637,0.0002069084,0.001075636,0.0011196748],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038454184,0.00006724746,0.00017400118,0.000053313834,0.0000031440213,0.000035285106,0.000014203911,0.00012335894,0.99613357,0.00039905743,0.00015732158,0.0024550853],"study_design_scores_gemma":[0.00005269516,0.0006259159,0.0023448656,0.000014582682,0.000010987219,0.0001907223,0.000029250641,0.0018872013,0.9898113,0.00014815411,0.004880948,0.0000034314305],"about_ca_topic_score_codex":0.0008180365,"about_ca_topic_score_gemma":0.00064357946,"teacher_disagreement_score":0.005674663,"about_ca_system_score_codex":0.00052102533,"about_ca_system_score_gemma":0.00034362648,"threshold_uncertainty_score":0.018983603},"labels":[],"label_agreement":null},{"id":"W4389241863","doi":"10.1158/1535-7163.targ-23-c028","title":"Abstract C028: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Radioimmunotherapy; Cancer research; Leukapheresis; Immunotherapy; Cancer; Monoclonal antibody; Immunology; Pharmacology; Antibody; Stem cell; Internal medicine; Biology; CD34","score_opus":0.056765147181907914,"score_gpt":0.3818371142617724,"score_spread":0.3250719670798645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98835677,0.00086132076,0.00074640906,0.00042202,0.00015611287,0.0052931383,0.0019223457,0.00016698962,0.0020748626],"genre_scores_gemma":[0.9795681,0.0009567006,0.0021675301,0.0013449299,0.00025745563,0.0060136914,0.003455522,0.00006562862,0.0061703795],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995722,0.00016018789,0.00001981486,0.0000870938,0.000053577372,0.0001070402],"domain_scores_gemma":[0.9991979,0.000100514044,0.000106898326,0.000069121896,0.00008468249,0.00044088354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016014064,0.0016445301,0.0016850284,0.00047015617,0.0006632876,0.00095133344,0.00096732733,0.0019170329,0.004745844],"category_scores_gemma":[0.00071063824,0.0005535212,0.0009966271,0.0003387247,0.00095278845,0.0007146363,0.0002699047,0.0035021254,0.0015178446],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5034016,0.23618758,0.005808079,0.0009135888,0.00080721057,0.00079524826,0.00046366343,0.0020201763,0.1653221,0.00039894538,0.010504571,0.07337738],"study_design_scores_gemma":[0.16083528,0.82529235,0.0045783804,0.000017303915,0.0001748097,0.0002658112,0.000054854496,0.00075655465,0.0055442755,0.000101487894,0.0023586506,0.000020189811],"about_ca_topic_score_codex":0.0015883029,"about_ca_topic_score_gemma":0.0027394877,"teacher_disagreement_score":0.004745844,"about_ca_system_score_codex":0.0009514917,"about_ca_system_score_gemma":0.0020289025,"threshold_uncertainty_score":0.015876412},"labels":[],"label_agreement":null},{"id":"W4389242080","doi":"10.1158/1535-7163.targ-23-b035","title":"Abstract B035: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Chimeric antigen receptor; Pneumonitis; Internal medicine; T cell; Pharmacokinetics; Leukapheresis; Immunotherapy; Refractory (planetary science); Oncology; Gastroenterology; Pharmacology; Cancer; Immunology; Immune system; Lung; Stem cell","score_opus":0.07208883215688347,"score_gpt":0.3961923356484441,"score_spread":0.3241035034915606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98699075,0.0017816757,0.00065016595,0.0007321367,0.00015209026,0.0029303783,0.0028908227,0.0001784016,0.0036936582],"genre_scores_gemma":[0.9827387,0.0012741083,0.0018496827,0.0016744396,0.00016672205,0.002583923,0.0055302405,0.00004810753,0.0041339872],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995906,0.00020681182,0.000022339489,0.00006082327,0.00004108908,0.000078350626],"domain_scores_gemma":[0.9994228,0.00008569917,0.00008238104,0.000045334968,0.000030364004,0.00033355382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016891806,0.0011418402,0.0013280476,0.00038782516,0.00043255519,0.0008860518,0.0008974107,0.0011095924,0.0066430448],"category_scores_gemma":[0.0006468879,0.00040637274,0.00085627876,0.00038144077,0.00077641953,0.0005865576,0.00029816304,0.0027134211,0.0017169596],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73792887,0.07720813,0.0065394454,0.0008637152,0.00129984,0.00052328204,0.00022306756,0.0018445009,0.05884608,0.00056039775,0.011479546,0.10268306],"study_design_scores_gemma":[0.5823302,0.40124145,0.0067500058,0.00004687752,0.0002982868,0.00030353363,0.000053684842,0.0016019929,0.0043450855,0.00024877157,0.0027595572,0.000020547504],"about_ca_topic_score_codex":0.0015726628,"about_ca_topic_score_gemma":0.002617477,"teacher_disagreement_score":0.0066430448,"about_ca_system_score_codex":0.0008861004,"about_ca_system_score_gemma":0.0017753596,"threshold_uncertainty_score":0.022223234},"labels":[],"label_agreement":null},{"id":"W4389242918","doi":"10.1182/blood-2023-179387","title":"Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Oncology; Blinatumomab; Clinical trial; Salvage therapy; Refractory (planetary science); Chimeric antigen receptor; CD19; Immunotherapy; Chemotherapy; Cancer","score_opus":0.011834043048669978,"score_gpt":0.25214075025714483,"score_spread":0.24030670720847486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99913436,0.00021217714,0.000048692516,0.000029266472,0.0000026134048,0.000015322408,0.0002147634,0.0000036975177,0.00033905506],"genre_scores_gemma":[0.99937326,0.000080759295,0.00004437483,0.000042893313,0.000007969152,0.000013613194,0.00038061108,8.49657e-7,0.000055770037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997503,0.00006679668,0.000026067408,0.000042735363,0.000046733992,0.00006734138],"domain_scores_gemma":[0.9993279,0.00008687503,0.00039673308,0.00002102514,0.00003745078,0.00013017294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006338167,0.00012076463,0.00026239737,0.000313254,0.00023573764,0.0006368925,0.00016256704,0.00012831371,0.0006971296],"category_scores_gemma":[0.0010665485,0.00005898149,0.00030546688,0.00037945923,0.000172993,0.00027712586,0.00026297919,0.00028926897,0.00013093188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061840513,0.0006783834,0.966549,0.00005923989,0.00022217554,0.00034499186,0.00016690546,0.00043789888,0.0014672141,0.000038557984,0.0005949679,0.02325658],"study_design_scores_gemma":[0.00046472333,0.0042786235,0.99159056,0.000015610523,0.00015863258,0.00071988156,0.000182785,0.000552015,0.0005592341,0.000039140534,0.0014290971,0.000009755652],"about_ca_topic_score_codex":0.002172879,"about_ca_topic_score_gemma":0.0042799455,"teacher_disagreement_score":0.002172879,"about_ca_system_score_codex":0.00068575895,"about_ca_system_score_gemma":0.0004736423,"threshold_uncertainty_score":0.004975617},"labels":[],"label_agreement":null},{"id":"W4389243266","doi":"10.1182/blood-2023-187295","title":"CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Receiver operating characteristic; Oncology; Internal medicine; Immunology; Area under the curve; Immune system; Pharmacology; Immunotherapy; Chimeric antigen receptor","score_opus":0.012366434127539882,"score_gpt":0.255808980568887,"score_spread":0.24344254644134714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856794,0.000287107,0.00039139137,0.000051551742,0.000009126494,0.000015062292,0.00022095368,0.00001465305,0.00044208838],"genre_scores_gemma":[0.9991586,0.000086464184,0.0003098171,0.000024603309,0.000009867247,0.000010532618,0.00018699878,0.0000029491312,0.00021015014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997818,0.000039546558,0.000029047922,0.000054998975,0.000056357123,0.000038243306],"domain_scores_gemma":[0.99948645,0.00007958073,0.00027219375,0.000020021776,0.000063575695,0.00007815977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003041197,0.0003122197,0.00027494467,0.000717843,0.00019949276,0.00059358624,0.00012814668,0.00031028345,0.0014584215],"category_scores_gemma":[0.0007672083,0.00012325792,0.00022422175,0.00046390248,0.00019679077,0.00022515126,0.0002536328,0.00038887863,0.0002966594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012340238,0.00012888073,0.9642767,0.000037396956,0.0000898191,0.0004932765,0.00007012405,0.00046206173,0.020359324,0.00006050457,0.0003386698,0.012449264],"study_design_scores_gemma":[0.000018021947,0.0006420151,0.9882908,0.0000108617405,0.000054319167,0.0022913506,0.00012712201,0.0027859153,0.0050572953,0.00009778802,0.00061608263,0.000008604414],"about_ca_topic_score_codex":0.00039626702,"about_ca_topic_score_gemma":0.000509149,"teacher_disagreement_score":0.0014584215,"about_ca_system_score_codex":0.00024035946,"about_ca_system_score_gemma":0.00018077264,"threshold_uncertainty_score":0.004878938},"labels":[],"label_agreement":null},{"id":"W4389243316","doi":"10.1182/blood-2023-189747","title":"Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Stimulation; In vivo; Antigen; Biology; Immunology; Medicine; Cancer research; Endocrinology; Genetics","score_opus":0.01847844680771295,"score_gpt":0.2882705134185854,"score_spread":0.26979206661087246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813396,0.0002937906,0.0008622033,0.00003886016,0.0000096431795,0.000019346347,0.00007565745,0.000052946267,0.0005136186],"genre_scores_gemma":[0.9977502,0.00012458525,0.0006064231,0.000030476645,0.000006040885,0.00002437074,0.00019750102,0.000012138784,0.0012481614],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997063,0.00004599479,0.000021341599,0.00004528369,0.000060951446,0.00012009339],"domain_scores_gemma":[0.99984205,0.000029889,0.00003930829,0.000027109234,0.0000143323805,0.000047306403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020729683,0.00033096358,0.00028775362,0.00021552775,0.0001425154,0.00035965125,0.0002823001,0.00034811755,0.001113699],"category_scores_gemma":[0.0001603922,0.00014357071,0.00019853751,0.00017211522,0.00024771848,0.00024286279,0.00023983317,0.000854666,0.00029322435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022981215,0.00016074609,0.00020227964,0.000017787464,0.0000048625348,0.000025900508,0.000026888667,0.00019178886,0.9969139,0.00010044145,0.00006317171,0.002062369],"study_design_scores_gemma":[0.00007379366,0.0018762153,0.002926098,0.0000055146716,0.000020352425,0.00023520268,0.000025447667,0.00249498,0.9900332,0.000049478407,0.0022538777,0.0000058360524],"about_ca_topic_score_codex":0.0009896165,"about_ca_topic_score_gemma":0.0011700613,"teacher_disagreement_score":0.001113699,"about_ca_system_score_codex":0.00033795493,"about_ca_system_score_gemma":0.00024923656,"threshold_uncertainty_score":0.0037257671},"labels":[],"label_agreement":null},{"id":"W4389243379","doi":"10.1182/blood-2023-187663","title":"CAR T Cell Exhaustion but Not <i>Ex Vivo</i> Cytotoxicity Is Predictive of Patient Clinical Response: An Interim Analysis of ACIT001/EXC002, a Phase Ib/II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunophenotyping; Ex vivo; Immunotherapy; Oncology; Immunology; Lymphoma; Internal medicine; Cytotoxic T cell; T cell; Antigen; Immune system; In vivo; Biology; In vitro","score_opus":0.0644916410500575,"score_gpt":0.3929571026369683,"score_spread":0.3284654615869108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970867,0.00046067566,0.00044100176,0.00008803261,0.000009978631,0.00022596175,0.00065161166,0.000023708959,0.0010123755],"genre_scores_gemma":[0.9956304,0.000120845,0.00046151545,0.00027314332,0.000020702671,0.00016043047,0.0025346125,0.000009881078,0.00078861316],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992805,0.00018735774,0.000033041382,0.000120342556,0.0002050261,0.0001737868],"domain_scores_gemma":[0.9986986,0.00032998042,0.00025744134,0.00016254811,0.00015504919,0.0003964825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025921664,0.00052830635,0.0009597689,0.00025036215,0.00028105994,0.00088589475,0.000574609,0.00064531673,0.00082195667],"category_scores_gemma":[0.0015060976,0.00022112545,0.00057787774,0.00031541707,0.0005336834,0.00036828828,0.00022601312,0.0015095192,0.00021372507],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34907416,0.013949514,0.24964519,0.00043971016,0.0010710764,0.00081495324,0.0005693731,0.011850713,0.20927462,0.0005409766,0.0051181964,0.15765157],"study_design_scores_gemma":[0.021571044,0.30188075,0.5876551,0.000045852903,0.0016371215,0.0014085809,0.00022540572,0.015475253,0.060504466,0.0004314016,0.00905005,0.000114812276],"about_ca_topic_score_codex":0.0033487424,"about_ca_topic_score_gemma":0.007203674,"teacher_disagreement_score":0.0033487424,"about_ca_system_score_codex":0.0012852405,"about_ca_system_score_gemma":0.001897339,"threshold_uncertainty_score":0.01370883},"labels":[],"label_agreement":null},{"id":"W4389243535","doi":"10.1182/blood-2023-174432","title":"Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Oncology; Follicular lymphoma; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Lymphoma; Multiple myeloma","score_opus":0.023303801925209075,"score_gpt":0.30396566331727964,"score_spread":0.28066186139207056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722038,0.006272503,0.0019193757,0.0030768146,0.00017647297,0.0042811325,0.0039043943,0.0002526273,0.007912863],"genre_scores_gemma":[0.9796562,0.00280569,0.004073493,0.0025985944,0.00019493695,0.0025053734,0.0053428775,0.000047445094,0.0027754325],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99959046,0.0001923977,0.000026109961,0.000058136735,0.00005043166,0.00008255751],"domain_scores_gemma":[0.99917954,0.00021793053,0.00015173489,0.00005442514,0.00006795219,0.00032839814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021360768,0.0008045611,0.0011230326,0.00021931654,0.00036919187,0.0009523278,0.0004991952,0.0010758605,0.004055929],"category_scores_gemma":[0.0011292627,0.00024232316,0.0010374459,0.00026292328,0.00051777414,0.0006109154,0.00029321175,0.0023654904,0.0009435073],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.37668437,0.055279274,0.025701735,0.002189782,0.0032155435,0.0008842281,0.0005675325,0.0037085195,0.121769294,0.0008330442,0.020160362,0.3890063],"study_design_scores_gemma":[0.3502781,0.55663073,0.03844198,0.00021898032,0.0020858934,0.0014854452,0.00011235479,0.0030676427,0.02296089,0.00074262056,0.023912422,0.00006288226],"about_ca_topic_score_codex":0.0006863968,"about_ca_topic_score_gemma":0.0030863832,"teacher_disagreement_score":0.004055929,"about_ca_system_score_codex":0.0008045377,"about_ca_system_score_gemma":0.0010813227,"threshold_uncertainty_score":0.013568401},"labels":[],"label_agreement":null},{"id":"W4389244101","doi":"10.1182/blood-2023-184864","title":"Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cancer research; Lymphoma; Chimeric antigen receptor; CD19; Immunotherapy; T cell; Medicine; Immunology; Antigen; Cancer; Internal medicine; Immune system","score_opus":0.03353847504303479,"score_gpt":0.2951050653562019,"score_spread":0.2615665903131671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389244101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.728091,0.0072804266,0.009539201,0.00039517833,0.000085731175,0.00026537015,0.24060765,0.0033979318,0.010337506],"genre_scores_gemma":[0.43673593,0.0024072772,0.011050608,0.0003489922,0.000021991558,0.0002722925,0.54537666,0.0001930519,0.0035932057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997522,0.000025824671,0.00001755375,0.00008507375,0.0000650332,0.000054273423],"domain_scores_gemma":[0.9998418,0.000027063763,0.000031037456,0.000024911533,0.00004500566,0.000030136405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021382229,0.00045146683,0.0005038374,0.0013459572,0.00018986652,0.00057131134,0.00045174555,0.00031130124,0.0032124096],"category_scores_gemma":[0.00058671646,0.00008995487,0.00037362266,0.0017396425,0.00012223402,0.00023040082,0.0005080337,0.00031034232,0.0016293515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030047258,0.0005106199,0.08709272,0.0043631783,0.00070037507,0.0019234663,0.00023477062,0.032087978,0.44287032,0.0025647501,0.14521019,0.2794369],"study_design_scores_gemma":[0.00068066485,0.0018141983,0.14377615,0.0003851412,0.00084290863,0.004142983,0.00065802765,0.079107374,0.3504066,0.0025982794,0.41547427,0.00011331401],"about_ca_topic_score_codex":0.011679071,"about_ca_topic_score_gemma":0.014776589,"teacher_disagreement_score":0.011679071,"about_ca_system_score_codex":0.00071008375,"about_ca_system_score_gemma":0.00064807985,"threshold_uncertainty_score":0.023222208},"labels":[],"label_agreement":null},{"id":"W4389246812","doi":"10.1182/blood-2023-173951","title":"Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Oncology; Diffuse large B-cell lymphoma; Phases of clinical research; Lymphoma; Transplantation; Chimeric antigen receptor; Gastroenterology; Immunology; Cancer; Clinical trial; Immunotherapy","score_opus":0.020556797315697723,"score_gpt":0.2984440166044841,"score_spread":0.2778872192887864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939966,0.0029069157,0.000385959,0.00010618074,0.00003567636,0.00047893633,0.0013471954,0.000025531906,0.00071686116],"genre_scores_gemma":[0.9924493,0.0007598968,0.00047502364,0.00031325992,0.00009883781,0.0004779872,0.0048012626,0.000018987088,0.0006055792],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99868613,0.00047831982,0.0001241809,0.00032445492,0.00014832235,0.00023856525],"domain_scores_gemma":[0.99851257,0.00030557215,0.00040019344,0.00025217244,0.00013263634,0.00039691932],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034866983,0.0011013251,0.0023441769,0.0006046042,0.0004970858,0.0012347491,0.0006213813,0.00083267037,0.0019137084],"category_scores_gemma":[0.0016203437,0.0004098844,0.0031892934,0.00073279307,0.00040390296,0.00093577494,0.0005819294,0.0015315732,0.0004147927],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69610155,0.0070971507,0.17348716,0.0009164398,0.014599593,0.0007772296,0.00041484713,0.002006683,0.031266823,0.00014194362,0.0031314471,0.07005916],"study_design_scores_gemma":[0.11885631,0.17537895,0.66905,0.00014852002,0.017609818,0.0016072318,0.00041038168,0.0022373772,0.005841754,0.00037202612,0.008317619,0.0001701047],"about_ca_topic_score_codex":0.00048748477,"about_ca_topic_score_gemma":0.0014124634,"teacher_disagreement_score":0.0034866983,"about_ca_system_score_codex":0.0006686533,"about_ca_system_score_gemma":0.0007643976,"threshold_uncertainty_score":0.01843959},"labels":[],"label_agreement":null},{"id":"W4389247212","doi":"10.1182/blood-2023-179044","title":"CAR-T Therapy for the Treatment of Relapsed/Refractory CD19 Positive Large B Cell Lymphoma: Canadian Real-World Evidence","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Medicine; CAR T-cell therapy; Lymphoma; Clinical trial; Real world data; Refractory (planetary science); Population; Internal medicine; Oncology; Immunotherapy; Cancer; Environmental health","score_opus":0.044600783763291414,"score_gpt":0.3295677116673361,"score_spread":0.2849669279040447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247212","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06119611,0.92183775,0.00024480475,0.0040800693,0.00017136509,0.00017279774,0.001076249,0.000010487666,0.011210367],"genre_scores_gemma":[0.40222782,0.59095603,0.0012763619,0.002849144,0.0005166134,0.00006702049,0.001312727,0.000010673621,0.0007836782],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99710137,0.0011199089,0.0005661086,0.00020844252,0.00086350157,0.00014052425],"domain_scores_gemma":[0.986785,0.004635729,0.0047718296,0.00028386802,0.0029328996,0.0005906756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053775776,0.00025441215,0.0004989259,0.0012309637,0.0004418719,0.0013750657,0.0008053596,0.0007532982,0.004546854],"category_scores_gemma":[0.010637505,0.00015796919,0.00069729076,0.0025967194,0.0009882423,0.00049999834,0.00038541417,0.00067190477,0.00034810792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011706144,0.0005535788,0.09936058,0.052953694,0.00270234,0.0013292076,0.0005970779,0.0009703106,0.002790735,0.0023118572,0.014143189,0.81058115],"study_design_scores_gemma":[0.010201303,0.013678776,0.46866518,0.06261273,0.015425467,0.008768152,0.0022084464,0.0011133003,0.0041320897,0.0006808812,0.4123455,0.00016809073],"about_ca_topic_score_codex":0.07692594,"about_ca_topic_score_gemma":0.15135702,"teacher_disagreement_score":0.07692594,"about_ca_system_score_codex":0.0049943067,"about_ca_system_score_gemma":0.010135998,"threshold_uncertainty_score":0.15295637},"labels":[],"label_agreement":null},{"id":"W4389247484","doi":"10.1182/blood-2023-181181","title":"Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Eurostars; Legend Biotech; Pharmacyclics; Aptitude Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Juno Therapeutics; Astellas Pharma; Swedish Orphan Biovitrum; Omeros Corporation; BeiGene; Incyte; CTI Biopharma; bluebird bio; Jazz Pharmaceuticals; Fred Hutchinson Cancer Research Center; Karyopharm Therapeutics; Atara Biotherapeutics; Massachusetts General Hospital; Leukemia and Lymphoma Society; Kite Pharma; Society for Immunotherapy of Cancer; AstraZeneca; Cidara Therapeutics; MorphoSys; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Proportional hazards model; Oncology; Cancer; Immunotherapy","score_opus":0.01048107823113658,"score_gpt":0.24786097802336715,"score_spread":0.23737989979223056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989349,0.0004036375,0.000068415575,0.000028890514,0.0000036155889,0.0000036052388,0.0001820885,0.000002513835,0.00037225932],"genre_scores_gemma":[0.9996338,0.000072679206,0.00003409539,0.0000071516633,0.000006343876,0.0000028131242,0.00019255895,7.2632974e-7,0.000049831353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975103,0.000059329384,0.00003667608,0.000043347896,0.00005429427,0.000055224595],"domain_scores_gemma":[0.99827015,0.00034970228,0.0009101473,0.00005656029,0.00013150224,0.00028198893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050706347,0.00016152347,0.00022164219,0.00046535343,0.00024081915,0.00041124685,0.00017610942,0.00021575185,0.0012725603],"category_scores_gemma":[0.0016629765,0.000103377875,0.00030579497,0.0006261432,0.00019813735,0.00034607504,0.000281456,0.00043914455,0.0001749267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077817225,0.0000055712435,0.9993228,0.0000017903244,0.000008264501,0.000047788883,0.0000055139567,0.000032852084,0.000049939186,0.0000035762619,0.000018562154,0.00042554564],"study_design_scores_gemma":[0.0000052914156,0.0001265382,0.99849415,0.0000046028063,0.000023033244,0.0007761301,0.00006149361,0.00023848232,0.0000767122,0.000018470455,0.00017279763,0.0000022872061],"about_ca_topic_score_codex":0.00082428777,"about_ca_topic_score_gemma":0.0011351337,"teacher_disagreement_score":0.0012725603,"about_ca_system_score_codex":0.0002151602,"about_ca_system_score_gemma":0.00028970477,"threshold_uncertainty_score":0.0042571425},"labels":[],"label_agreement":null},{"id":"W4389247829","doi":"10.1182/blood-2023-173692","title":"Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Surrogate endpoint; Adverse effect; Regimen; Gastroenterology; Chemotherapy regimen; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy","score_opus":0.016229743080162895,"score_gpt":0.28606857835725663,"score_spread":0.26983883527709374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98170966,0.01174865,0.00062847347,0.000477936,0.000067282795,0.00048406626,0.0015284787,0.00008893569,0.0032665422],"genre_scores_gemma":[0.9922227,0.0020065096,0.00044549888,0.00090632803,0.00008512706,0.00022579187,0.0033145777,0.000021784537,0.0007716398],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9991254,0.0002453783,0.00009451538,0.00014230338,0.00017931199,0.00021311906],"domain_scores_gemma":[0.9982324,0.00037629766,0.0005355204,0.00018342711,0.0002494937,0.00042286058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032761202,0.0005462041,0.001533961,0.00030272568,0.00050507294,0.0013737103,0.00044494157,0.0006619715,0.0016313532],"category_scores_gemma":[0.0016098408,0.0002161037,0.0012617836,0.00043632044,0.0003025266,0.0007428847,0.0002724228,0.0015289889,0.00067404594],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14716053,0.0115284,0.24360456,0.0014825356,0.005301352,0.0013166593,0.000843758,0.0022482965,0.0853565,0.0002903097,0.017704885,0.48316208],"study_design_scores_gemma":[0.041685484,0.19400522,0.69602215,0.00036502804,0.00500667,0.003910253,0.00030989278,0.0025625983,0.018687041,0.0003737031,0.036963955,0.00010796744],"about_ca_topic_score_codex":0.00072045723,"about_ca_topic_score_gemma":0.0017376447,"teacher_disagreement_score":0.0032761202,"about_ca_system_score_codex":0.0007882513,"about_ca_system_score_gemma":0.00061204424,"threshold_uncertainty_score":0.017325997},"labels":[],"label_agreement":null},{"id":"W4389247832","doi":"10.1182/blood-2023-178821","title":"Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; National Research Council Canada; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD28; Multiple myeloma; Antigen; Cancer research; Immunology; Biology; T cell; Medicine; Immune system","score_opus":0.019522833264658066,"score_gpt":0.27105707369461324,"score_spread":0.25153424042995515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99044985,0.00037277365,0.0059482376,0.000079546095,0.000039975937,0.0000884701,0.0007198418,0.00014495784,0.002156277],"genre_scores_gemma":[0.99221987,0.00021912315,0.0029263631,0.0000237688,0.000006392907,0.00006678826,0.00039017052,0.000039420072,0.0041082124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996836,0.000036304744,0.00004148877,0.00007733793,0.000078855686,0.00008244483],"domain_scores_gemma":[0.99980086,0.000053719396,0.00003982686,0.000030177333,0.000017250433,0.00005812147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024760986,0.0003192958,0.00032901435,0.00040190417,0.00020837683,0.00042044854,0.00029747392,0.00041282823,0.0014625381],"category_scores_gemma":[0.0001189572,0.00011835708,0.00025980073,0.00021211944,0.00027763733,0.00022957235,0.00024484438,0.0010984301,0.00036969638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010472339,0.00006083765,0.00010886956,0.00001800384,0.0000030025149,0.000058252113,0.000042355518,0.0001496487,0.9985024,0.00022446747,0.00004697145,0.00068047765],"study_design_scores_gemma":[0.000012075025,0.0003059839,0.0009088165,0.0000028330478,0.000006768664,0.00014768305,0.000021372398,0.0012600567,0.99606067,0.00003087423,0.001240235,0.0000025597358],"about_ca_topic_score_codex":0.0026790015,"about_ca_topic_score_gemma":0.0024751413,"teacher_disagreement_score":0.0026790015,"about_ca_system_score_codex":0.0004901867,"about_ca_system_score_gemma":0.0002652953,"threshold_uncertainty_score":0.0053268075},"labels":[],"label_agreement":null},{"id":"W4389248024","doi":"10.1182/blood-2023-180233","title":"Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood &amp; Marrow Transplant Research (CIBMTR) Analysis","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Aggressive lymphoma; Oncology; Cumulative incidence; Transplantation; Rituximab; Lymphoma; Chimeric antigen receptor; Cancer; Immunotherapy","score_opus":0.06427681933567496,"score_gpt":0.3831817213200614,"score_spread":0.3189049019843864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99498063,0.00025893768,0.00016158108,0.00006767922,0.0000045210895,0.000057632522,0.003914006,0.000011802209,0.00054329634],"genre_scores_gemma":[0.99275005,0.000083677915,0.00018275072,0.000048776,0.000014935557,0.000060792514,0.006764303,0.0000064878004,0.00008816186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984616,0.00055408746,0.00020804166,0.0002923359,0.0002858034,0.00019813361],"domain_scores_gemma":[0.9941551,0.00095959037,0.0028509742,0.0006193791,0.00080833014,0.00060662004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003636726,0.00025677792,0.00039421185,0.001429267,0.0003627541,0.0010626576,0.00055154605,0.00030466702,0.0016428275],"category_scores_gemma":[0.0037084331,0.00017850826,0.0005999814,0.0020659538,0.00028793694,0.0005310896,0.0009267264,0.00049563986,0.00028045097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016171789,0.00010601552,0.9936289,0.00003312407,0.00024842957,0.00007523592,0.000049489987,0.00025858937,0.00013263445,0.00006350169,0.00082294154,0.0029638826],"study_design_scores_gemma":[0.00026204772,0.00069076306,0.99580187,0.000019963458,0.00021692514,0.00034634004,0.00017307451,0.0010029024,0.00016473231,0.000043878645,0.0012633743,0.000014032524],"about_ca_topic_score_codex":0.004688769,"about_ca_topic_score_gemma":0.004099614,"teacher_disagreement_score":0.004688769,"about_ca_system_score_codex":0.0011093566,"about_ca_system_score_gemma":0.0008129625,"threshold_uncertainty_score":0.019233108},"labels":[],"label_agreement":null},{"id":"W4389248242","doi":"10.1182/blood-2023-173302","title":"Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Tolerability; Refractory (planetary science); Leukemia; Oncology; Gastroenterology; Immunology; Adverse effect; Biology","score_opus":0.020594905653847157,"score_gpt":0.31710687491740386,"score_spread":0.2965119692635567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950906,0.001235359,0.00051635684,0.00021369703,0.00005441757,0.0013262039,0.00045705843,0.00011433732,0.0009919509],"genre_scores_gemma":[0.9926386,0.0009839658,0.0015719861,0.0005311516,0.00008194372,0.0018926109,0.00097187556,0.000031744486,0.0012961696],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960595,0.0001854647,0.00002184834,0.00007335289,0.000030246438,0.00008314833],"domain_scores_gemma":[0.99953735,0.00006527029,0.000087533575,0.000058505448,0.000024906085,0.0002264031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011338039,0.0013621236,0.0017766334,0.0005082432,0.0003248354,0.000800439,0.00087285193,0.0007873238,0.0022582782],"category_scores_gemma":[0.0005361777,0.000520488,0.0009011062,0.0004465188,0.0006845898,0.0006447017,0.00034396388,0.0027207977,0.00073943555],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.50664234,0.13050498,0.009074288,0.001116887,0.0015753739,0.0004268362,0.00073774066,0.005431431,0.1490332,0.0005551946,0.004940222,0.18996152],"study_design_scores_gemma":[0.3487173,0.6200122,0.016360216,0.00003731249,0.00042718783,0.00043465104,0.000075239,0.0015720347,0.007949926,0.00026173482,0.004114287,0.00003785008],"about_ca_topic_score_codex":0.00058152905,"about_ca_topic_score_gemma":0.0014997399,"teacher_disagreement_score":0.0022582782,"about_ca_system_score_codex":0.0007654024,"about_ca_system_score_gemma":0.0010047097,"threshold_uncertainty_score":0.0075546503},"labels":[],"label_agreement":null},{"id":"W4389248280","doi":"10.1182/blood-2023-190517","title":"Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cytotoxic T cell; Chimeric antigen receptor; Antigen; Peripheral blood mononuclear cell; Immune system; Medicine; Immunotherapy; Immunology; Cancer research; T cell; Biology; In vitro; Genetics","score_opus":0.014123695186511031,"score_gpt":0.24993359265028006,"score_spread":0.23580989746376904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982141,0.00024550734,0.00016603208,0.000036873593,0.00000188507,0.000008392334,0.00069894886,0.000012737597,0.00061541214],"genre_scores_gemma":[0.99829894,0.00011161963,0.00024038575,0.00005479258,0.000004576055,0.0000123889995,0.0008462329,0.0000051477255,0.00042596637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998611,0.000017427683,0.00001147818,0.00005240423,0.000029575654,0.000027974094],"domain_scores_gemma":[0.99987364,0.000027377255,0.000048431943,0.000009824835,0.000015733869,0.000025016652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000760905,0.00012276269,0.00023574551,0.0005054879,0.00017583591,0.00026669088,0.000094298906,0.00028985753,0.0013963332],"category_scores_gemma":[0.00032113056,0.000085701104,0.00015070429,0.00049960933,0.00011070573,0.00014128331,0.00016592594,0.0002708869,0.00019723298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023577672,0.00015405305,0.8356397,0.000055689543,0.000105496,0.001243642,0.00030900404,0.00042305002,0.12483649,0.00016020908,0.0007579963,0.033956923],"study_design_scores_gemma":[0.000011266367,0.0005127305,0.99197924,0.000004390269,0.000039818526,0.0018229703,0.00009361876,0.0003597534,0.0039885496,0.000056925677,0.0011267253,0.000003920641],"about_ca_topic_score_codex":0.00063352956,"about_ca_topic_score_gemma":0.00074046716,"teacher_disagreement_score":0.0013963332,"about_ca_system_score_codex":0.0001398901,"about_ca_system_score_gemma":0.00008700958,"threshold_uncertainty_score":0.0046711564},"labels":[],"label_agreement":null},{"id":"W4389248467","doi":"10.1182/blood-2023-181710","title":"A New Machine Learning-Based Prognostic Prediction Strategy for Patients with Diffuse-Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Internal medicine; Oncology; Lymphoma; CHOP; ABVD; Rituximab; Chemotherapy; Cyclophosphamide; Vincristine","score_opus":0.01719968098037226,"score_gpt":0.26287813092745027,"score_spread":0.24567844994707802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8087186,0.0012668172,0.17703387,0.0025361534,0.00025750085,0.0004924427,0.0045797275,0.0021136072,0.0030012783],"genre_scores_gemma":[0.960527,0.00013228586,0.0351554,0.00019373886,0.0001722597,0.00022479931,0.0028368044,0.000021431515,0.00073626445],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99948466,0.00014049254,0.000080416976,0.00014508003,0.00008344541,0.00006596726],"domain_scores_gemma":[0.9986009,0.0005912743,0.00020089505,0.00007274375,0.00036568247,0.00016842157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011937472,0.00075519364,0.00097340136,0.0025820618,0.0003766833,0.000918516,0.00076321344,0.00070085505,0.0018616493],"category_scores_gemma":[0.0032275273,0.00018701279,0.000736251,0.0007863408,0.00017684595,0.00066046475,0.00059012265,0.00062618376,0.0006564382],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010424053,0.0009632659,0.606227,0.00011745011,0.00033324424,0.00058964576,0.00009293613,0.054923616,0.003115113,0.00046773267,0.0073059327,0.32482165],"study_design_scores_gemma":[0.000095437994,0.00045765043,0.052770335,0.00003550318,0.00018021821,0.00052953494,0.00007340074,0.94097376,0.0017040984,0.0014679001,0.001678679,0.00003344353],"about_ca_topic_score_codex":0.0025738692,"about_ca_topic_score_gemma":0.0029425314,"teacher_disagreement_score":0.0025820618,"about_ca_system_score_codex":0.00053180865,"about_ca_system_score_gemma":0.00083881425,"threshold_uncertainty_score":0.0063132048},"labels":[],"label_agreement":null},{"id":"W4389259388","doi":"10.1182/blood-2023-187713","title":"Risk of Bleeding and Thrombosis with CAR T-Cell Therapy: A Scoping Review","year":2023,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Chimeric antigen receptor; Thrombosis; Lymphoma; Internal medicine; Venous thrombosis; CAR T-cell therapy; Malignancy; Pediatrics; Oncology; Cancer; Surgery; Immunotherapy","score_opus":0.12163844875201123,"score_gpt":0.40119066190462427,"score_spread":0.279552213152613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078577985,0.9981762,0.00009354764,0.00027132512,0.000080894904,0.00018597393,0.00014579982,0.000004282296,0.00025625396],"genre_scores_gemma":[0.006936756,0.9917402,0.0003238532,0.00035663557,0.0000886506,0.00033400327,0.00014077802,0.0000026124405,0.00007641052],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99069583,0.002274655,0.0046288706,0.0006017983,0.0015421264,0.0002567822],"domain_scores_gemma":[0.94106877,0.043174487,0.0099425195,0.00055071426,0.00490359,0.0003599055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009889222,0.001484552,0.00597534,0.025248641,0.001025146,0.0034775613,0.0017024429,0.0031835106,0.0033665374],"category_scores_gemma":[0.047402762,0.0013590857,0.0068061682,0.02433123,0.0011040426,0.0032162168,0.0016675204,0.0013506152,0.0003513443],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019891381,0.000025750578,0.0021106182,0.9122795,0.0051343422,0.000377628,0.00036566678,0.00014532126,0.00021853264,0.00035316686,0.0025406466,0.076249875],"study_design_scores_gemma":[0.00007002667,0.00012785482,0.003110298,0.9584885,0.02330819,0.00078186125,0.000347094,0.000078993246,0.0001327659,0.00025730202,0.013270167,0.000026989266],"about_ca_topic_score_codex":0.008145751,"about_ca_topic_score_gemma":0.0138729215,"teacher_disagreement_score":0.025248641,"about_ca_system_score_codex":0.004916155,"about_ca_system_score_gemma":0.012261384,"threshold_uncertainty_score":0.052299798},"labels":[],"label_agreement":null},{"id":"W4389261506","doi":"10.1158/2326-6074.tumimm23-a042","title":"Abstract A042: Quantitative multiplex immunoprecipitation reveals distinct protein interaction networks responsible for discrepant <i>in vivo</i> activity exhibited by two second generation CD22-targeted chimeric antigen receptors","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Multiplex; CD19; Antigen; CD22; Immunoprecipitation; In vivo; Cancer research; MUC1; CD28; Immunotherapy; Biology; Computational biology; Immunology; Antibody; CD8; Immune system; Bioinformatics; Genetics","score_opus":0.11106423132623436,"score_gpt":0.43683583407814675,"score_spread":0.3257716027519124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389261506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99027294,0.0006095796,0.00554398,0.0002309466,0.000044488643,0.00003650083,0.0011547738,0.00022590504,0.0018808588],"genre_scores_gemma":[0.99148303,0.00026961914,0.003504067,0.00015950763,0.000027349923,0.000059689715,0.0019377324,0.000049450307,0.0025095763],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997379,0.000035625133,0.000014436801,0.00009670146,0.000060408012,0.000054882446],"domain_scores_gemma":[0.9998772,0.000035615012,0.000026447955,0.000014126079,0.000018702574,0.000027884835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031596815,0.00038188722,0.0002781455,0.00038414518,0.00022387823,0.0007835388,0.0002800115,0.00035568626,0.0033319565],"category_scores_gemma":[0.00027229244,0.00017056936,0.000324225,0.00026962385,0.0001874863,0.00019062367,0.00012567009,0.0006451067,0.0008634166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005943182,0.00009025708,0.0009839479,0.000026826085,0.000021225775,0.00004139003,0.000012043806,0.00015501995,0.99578387,0.0001355073,0.00041929615,0.0017361783],"study_design_scores_gemma":[0.00012379324,0.00052988343,0.02722113,0.0000069384946,0.000060606217,0.00063931476,0.000048689268,0.015167235,0.95260096,0.00023004701,0.003353086,0.000018360712],"about_ca_topic_score_codex":0.00046175395,"about_ca_topic_score_gemma":0.0005751158,"teacher_disagreement_score":0.0033319565,"about_ca_system_score_codex":0.00039375047,"about_ca_system_score_gemma":0.00018830753,"threshold_uncertainty_score":0.011146486},"labels":[],"label_agreement":null},{"id":"W4389374456","doi":"10.1212/wnl.98.18_supplement.2864","title":"Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4) (S23.009)","year":2022,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; McGill University","funders":"","keywords":"Placebo; Art; Medicine; Art history; Pathology; Alternative medicine","score_opus":0.03689167336412621,"score_gpt":0.38009996554715186,"score_spread":0.3432082921830257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389374456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870882,0.0049419235,0.0010962259,0.00036232977,0.00020153058,0.0024309785,0.0014882307,0.0002231819,0.0021673616],"genre_scores_gemma":[0.98816013,0.0017247528,0.0023476589,0.00074249704,0.00017161324,0.002653697,0.0013503737,0.000030078943,0.0028191751],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99967635,0.00015901378,0.000018914652,0.000059671533,0.00003956736,0.000046498655],"domain_scores_gemma":[0.99966717,0.000056625024,0.000092896786,0.000023166904,0.00003967877,0.00012038924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014275848,0.0012865628,0.0014023501,0.00041268519,0.00028275454,0.00046139382,0.0005499072,0.0010677039,0.004228964],"category_scores_gemma":[0.0005724909,0.00039221445,0.0008541682,0.00026003443,0.00054345647,0.00048182832,0.00016793114,0.0014880324,0.000523932],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8720756,0.017315751,0.002427493,0.00090293173,0.0021005457,0.000103037724,0.00007408122,0.0005423491,0.059179027,0.00013561126,0.0015203254,0.04362322],"study_design_scores_gemma":[0.6134102,0.3614222,0.016609002,0.000050872393,0.00087623677,0.00012151648,0.000041585277,0.00071550877,0.005215191,0.00012393741,0.0013853995,0.000028311568],"about_ca_topic_score_codex":0.00061857246,"about_ca_topic_score_gemma":0.0019346958,"teacher_disagreement_score":0.004228964,"about_ca_system_score_codex":0.0004179255,"about_ca_system_score_gemma":0.0005424755,"threshold_uncertainty_score":0.014147222},"labels":[],"label_agreement":null},{"id":"W4389397268","doi":"10.2214/ajr.23.30301","title":"Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts","year":2024,"lang":"en","type":"review","venue":"American Journal of Roentgenology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Lymphoma; Positron emission tomography; Cell therapy; Radiation therapy; Oncology; Immunotherapy; Internal medicine; Radiology; Cell; Cancer","score_opus":0.018739165852069656,"score_gpt":0.3313885973862729,"score_spread":0.31264943153420327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389397268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013582707,0.9991879,0.00008762908,0.00020864636,0.000054367756,0.0000020402583,0.0000047151157,0.0000030804981,0.00031577126],"genre_scores_gemma":[0.0020993124,0.99707603,0.00028401337,0.00018480892,0.00021214227,0.000005557144,0.000017117747,0.0000016195826,0.000119446166],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969304,0.00009957327,0.000053060387,0.000055812838,0.00007977904,0.00001887655],"domain_scores_gemma":[0.9992601,0.00044359022,0.00010660007,0.000014240993,0.0001454099,0.00002997711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009211888,0.00080626685,0.0019130736,0.0019880712,0.0001565481,0.0010237679,0.0008571939,0.0011052687,0.00094392727],"category_scores_gemma":[0.0014676137,0.00028662308,0.0006416552,0.0016904017,0.0005957675,0.0011669763,0.00040760575,0.0016342159,0.00047164375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016896968,0.00003727372,0.0013903973,0.010278727,0.00016881443,0.0004106467,0.00006903252,0.00028278105,0.0008291471,0.0011634773,0.011617127,0.9735835],"study_design_scores_gemma":[0.00018038381,0.00043738188,0.022323698,0.030314999,0.0018806088,0.023210388,0.0004095449,0.0009909583,0.0024169686,0.005280589,0.9124068,0.0001476385],"about_ca_topic_score_codex":0.0014657206,"about_ca_topic_score_gemma":0.0020642371,"teacher_disagreement_score":0.0019880712,"about_ca_system_score_codex":0.0006593745,"about_ca_system_score_gemma":0.0007560743,"threshold_uncertainty_score":0.0048717856},"labels":[],"label_agreement":null},{"id":"W4389443021","doi":"10.3389/fimmu.2023.1302307","title":"CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Medicine; Chimeric antigen receptor; Ovarian cancer; Immunotherapy; Bevacizumab; Context (archaeology); Oncology; Taxane; Cancer; Internal medicine; Immunology; Chemotherapy; Breast cancer; Biology","score_opus":0.0225108172773095,"score_gpt":0.3065004900360217,"score_spread":0.2839896727587122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389443021","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003784727,0.98518753,0.0017973114,0.0042101312,0.0012727913,0.000029783876,0.00004856201,0.00006960939,0.0035994493],"genre_scores_gemma":[0.03457312,0.9492296,0.0017954657,0.004783789,0.0020958006,0.000063298314,0.00017275207,0.000021464934,0.007264715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982363,0.000048103353,0.000016010283,0.000023787601,0.0000561908,0.00003239222],"domain_scores_gemma":[0.9998597,0.00005575925,0.000018180008,0.000006053796,0.000034842604,0.000025429114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006614812,0.00034431164,0.0005040048,0.0005084933,0.00021832595,0.0008610972,0.0003670536,0.0009016559,0.0024011815],"category_scores_gemma":[0.00044344054,0.00013060494,0.00035206048,0.00041527225,0.00047309045,0.0013276044,0.0006019363,0.0020091084,0.0010137709],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028061648,0.00013172264,0.0005963725,0.004295863,0.000069998605,0.0005343209,0.00021634661,0.0005100087,0.018358268,0.017210053,0.04478651,0.9130099],"study_design_scores_gemma":[0.00009908395,0.0008795841,0.0008515791,0.0009057525,0.00008713412,0.0022777643,0.00012893882,0.00044509504,0.00626456,0.0068838894,0.9811508,0.000025779205],"about_ca_topic_score_codex":0.00034023175,"about_ca_topic_score_gemma":0.0007029528,"teacher_disagreement_score":0.0024011815,"about_ca_system_score_codex":0.00043904598,"about_ca_system_score_gemma":0.00059166946,"threshold_uncertainty_score":0.008032739},"labels":[],"label_agreement":null},{"id":"W4389453684","doi":"10.3389/fphar.2023.1304194","title":"A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay","year":2023,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"CD19; Immune system; Cancer research; Jurkat cells; Chimeric antigen receptor; Cancer cell; Immunotherapy; Cancer immunotherapy; Antigen; Cancer; Immunology; Biology; Medicine; T cell; Molecular biology; Internal medicine","score_opus":0.025528909196160816,"score_gpt":0.3345519877506767,"score_spread":0.3090230785545159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389453684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92928135,0.0007512078,0.065172866,0.000177617,0.00006796989,0.00018589426,0.0007541142,0.00030402356,0.003304834],"genre_scores_gemma":[0.9611598,0.0005252768,0.03348518,0.00011626849,0.000016093976,0.00011461655,0.00082811876,0.000027979664,0.003726645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997826,0.00003988026,0.000017808528,0.00005688966,0.000076877586,0.000025945976],"domain_scores_gemma":[0.9998375,0.000024600264,0.00007366681,0.000020248404,0.000017568613,0.000026371776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000253575,0.0003157387,0.00010786673,0.00020200362,0.000073395946,0.00025054553,0.00030748703,0.0003787361,0.0010144192],"category_scores_gemma":[0.00014560146,0.000116739764,0.00016070143,0.00013980795,0.0002111589,0.00019553612,0.00023484211,0.000312527,0.000366312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033682813,0.0000099188055,0.00006770843,0.000018784678,0.0000018868586,0.000020937463,0.0000041541484,0.00010641675,0.9989517,0.00016508547,0.000027170414,0.0005924606],"study_design_scores_gemma":[0.000006220752,0.00012921396,0.00022288389,0.0000018423087,0.000004733067,0.00009683541,0.00000447911,0.00075540924,0.9974452,0.000027885724,0.0013025982,0.000002745032],"about_ca_topic_score_codex":0.00023081263,"about_ca_topic_score_gemma":0.00032213508,"teacher_disagreement_score":0.0010144192,"about_ca_system_score_codex":0.00037418088,"about_ca_system_score_gemma":0.00020589626,"threshold_uncertainty_score":0.0033935308},"labels":[],"label_agreement":null},{"id":"W4389507960","doi":"10.1007/978-1-0716-3593-3_4","title":"Expansion and Retroviral Transduction of Primary Murine T Cells for CAR T-Cell Therapy","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Transduction (biophysics); Chimeric antigen receptor; Antigen; Biology; T cell; Transgene; Cell biology; Viral vector; Molecular biology; Immune system; Immunology; Genetics; Gene; Biochemistry","score_opus":0.04990881097312872,"score_gpt":0.41780008132419694,"score_spread":0.3678912703510682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389507960","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.68700093,0.0061121588,0.24823867,0.00082654064,0.0012220751,0.008754805,0.016167197,0.0027506475,0.028926924],"genre_scores_gemma":[0.83880377,0.0043815933,0.10121954,0.0006032861,0.00032864252,0.0057660383,0.012567976,0.0009104627,0.03541866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99921966,0.00013124825,0.00008739476,0.00012620576,0.0001856301,0.0002498586],"domain_scores_gemma":[0.9995776,0.00013216687,0.00003609246,0.00010377291,0.00007093934,0.000079489524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082512276,0.00076625735,0.00055117003,0.0010455163,0.00054131873,0.0007915847,0.0007349142,0.00077462185,0.007336233],"category_scores_gemma":[0.00045459208,0.0005771811,0.00064701337,0.00052121136,0.00036937228,0.0003920302,0.0005507796,0.0033042324,0.0039241374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012164771,0.00011427887,0.00010226839,0.000042672073,0.0000047920685,0.000058081856,0.00007032021,0.0001608461,0.9960835,0.0006077918,0.00037484284,0.0022590067],"study_design_scores_gemma":[0.00006246559,0.00030751622,0.0008455834,0.000016721737,0.000027960485,0.00021102854,0.00003101219,0.0012949188,0.9798656,0.00012860743,0.017200233,0.000008439869],"about_ca_topic_score_codex":0.000746768,"about_ca_topic_score_gemma":0.0010447168,"teacher_disagreement_score":0.007336233,"about_ca_system_score_codex":0.00044538907,"about_ca_system_score_gemma":0.00043222937,"threshold_uncertainty_score":0.024542153},"labels":[],"label_agreement":null},{"id":"W4389508010","doi":"10.1007/978-1-0716-3593-3_17","title":"Nano-optogenetic CAR-T Cell Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Optogenetics; Immunotherapy; Cancer immunotherapy; Cytokine release syndrome; Cell; Cancer research; Medicine; Immunology; Chemistry; Biology; Immune system; Neuroscience; Biochemistry","score_opus":0.04397838864026288,"score_gpt":0.44872381175964215,"score_spread":0.4047454231193793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389508010","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61391145,0.0146928085,0.27389708,0.0035311973,0.0018775495,0.0004992616,0.0014219532,0.001727965,0.08844079],"genre_scores_gemma":[0.9204846,0.0026525403,0.05058143,0.0008497511,0.00015936018,0.00027363168,0.00027629826,0.00012766871,0.024594845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988246,0.0000121743105,0.0000044862663,0.000028508928,0.0000460046,0.000026245327],"domain_scores_gemma":[0.9999651,0.0000121470175,0.0000081594635,0.000005424841,0.0000041188073,0.0000050589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015279194,0.0002808438,0.00016550752,0.00018551631,0.00013770597,0.00043015892,0.0003007187,0.00044599324,0.0037300899],"category_scores_gemma":[0.000107466636,0.00013989728,0.00023848006,0.00013316846,0.00026360448,0.00039810262,0.00031843368,0.0005088421,0.00073472934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000073266296,0.000044674598,0.00013061853,0.000098024495,0.000009954228,0.0000487547,0.000021038742,0.0008473954,0.9759134,0.006844812,0.001082418,0.014885512],"study_design_scores_gemma":[0.00003225332,0.00014579787,0.00058936153,0.000010546363,0.000021396805,0.00022659967,0.000026874948,0.0071810815,0.9601134,0.0018186261,0.029822182,0.000011802933],"about_ca_topic_score_codex":0.00033920296,"about_ca_topic_score_gemma":0.0006502892,"teacher_disagreement_score":0.0037300899,"about_ca_system_score_codex":0.00034629452,"about_ca_system_score_gemma":0.00025224613,"threshold_uncertainty_score":0.012478411},"labels":[],"label_agreement":null},{"id":"W4389513800","doi":"10.1016/j.msard.2023.105364","title":"Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis","year":2023,"lang":"en","type":"editorial","venue":"Multiple Sclerosis and Related Disorders","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Multiple sclerosis; Medicine; Physical medicine and rehabilitation; Immunology","score_opus":0.051789653677591994,"score_gpt":0.2849057615460464,"score_spread":0.2331161078684544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389513800","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017441377,0.025487496,0.0003452775,0.103912294,0.8676454,0.000054905384,0.0001611231,0.000109973385,0.0021091532],"genre_scores_gemma":[0.0017966736,0.010002804,0.0002532963,0.09847273,0.8853927,0.00006928323,0.00004925339,0.00006368151,0.0038996416],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99058354,0.0038889444,0.001531073,0.00072468584,0.0028081948,0.00046346133],"domain_scores_gemma":[0.9522301,0.03403231,0.0025701395,0.0009053343,0.0063333632,0.003928829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022289421,0.0032790205,0.0064234966,0.0020855137,0.0025372875,0.0063478905,0.005448678,0.027237702,0.0068247756],"category_scores_gemma":[0.059213653,0.0016646397,0.0036446827,0.0016236517,0.002354674,0.004078766,0.0012208709,0.034744155,0.004967057],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004515655,0.000027257749,0.00007461963,0.0007556644,0.00019633405,0.0002582875,0.000022346772,0.000059027134,0.000081461396,0.0005768601,0.98705286,0.010443654],"study_design_scores_gemma":[0.0017492896,0.00036327375,0.0010585019,0.0026912568,0.0012844779,0.0006881389,0.00010091279,0.0010067604,0.00035580652,0.004517378,0.9860799,0.000104426865],"about_ca_topic_score_codex":0.002192901,"about_ca_topic_score_gemma":0.00669444,"teacher_disagreement_score":0.027237702,"about_ca_system_score_codex":0.0041132425,"about_ca_system_score_gemma":0.0035836468,"threshold_uncertainty_score":0.11787915},"labels":[],"label_agreement":null},{"id":"W4389519919","doi":"10.1038/s41591-023-02726-5","title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Saskatchewan Cancer Agency; McGill University; Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche; Roche","keywords":"Refractory (planetary science); Internal medicine; Lymphoma; Medicine; Oncology; Aggressive lymphoma; Brentuximab vedotin; Cancer research; Biology; Hodgkin lymphoma; Rituximab","score_opus":0.022097220259738714,"score_gpt":0.3634544553876059,"score_spread":0.3413572351278672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389519919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939819,0.00274714,0.00030673898,0.0003744296,0.000058835216,0.0009350011,0.00030301997,0.000070316484,0.0012226267],"genre_scores_gemma":[0.9935016,0.0013154433,0.0011599888,0.00058960746,0.00014319742,0.0010174473,0.0008923134,0.000018507359,0.0013618831],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99945825,0.00028687337,0.000029510918,0.00008725962,0.00005675038,0.00008134018],"domain_scores_gemma":[0.99952996,0.00007747877,0.00009939006,0.000039030805,0.000031318883,0.00022285312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018783833,0.00073571026,0.0012446624,0.00031784677,0.000261511,0.0010156826,0.0005432312,0.0008032966,0.0015877541],"category_scores_gemma":[0.0006684771,0.00029457352,0.00073842786,0.00027050005,0.00049966504,0.00064829295,0.00030607698,0.0019612936,0.0003875515],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62087876,0.036021143,0.0100396285,0.00087976805,0.0014136807,0.00041465732,0.0003683037,0.003032687,0.08495679,0.000447007,0.003883318,0.23766424],"study_design_scores_gemma":[0.6464801,0.31750247,0.019221475,0.00007364179,0.00067412376,0.00061127666,0.00006770737,0.0025883773,0.0075544924,0.00030815872,0.0048856284,0.000032596272],"about_ca_topic_score_codex":0.0005280831,"about_ca_topic_score_gemma":0.0013972104,"teacher_disagreement_score":0.0018783833,"about_ca_system_score_codex":0.0007670537,"about_ca_system_score_gemma":0.0008909807,"threshold_uncertainty_score":0.0099339485},"labels":[],"label_agreement":null},{"id":"W4389568253","doi":"10.1016/j.omtm.2023.101171","title":"Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"NIH Clinical Center; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; Australian Government; Center for Cancer Research","keywords":"Cart; CD8; Leukapheresis; Chimeric antigen receptor; Peripheral blood mononuclear cell; Biology; Cytotoxic T cell; T cell; Cytokine; Immunology; Antigen; Cancer research; Cell biology; Immune system; Stem cell; Genetics; In vitro","score_opus":0.07940232075959335,"score_gpt":0.43305341134702346,"score_spread":0.3536510905874301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389568253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97378564,0.00094716734,0.01925768,0.00012926028,0.00007473097,0.00033496373,0.00049774075,0.00024193166,0.0047309324],"genre_scores_gemma":[0.97797304,0.0005506885,0.015167233,0.00014850612,0.000026179185,0.00031338914,0.0010755009,0.00009487357,0.0046505304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99950993,0.00010352174,0.000059438637,0.00010602127,0.00014690075,0.00007418246],"domain_scores_gemma":[0.99983966,0.00003988436,0.00002895788,0.000031971544,0.00003215927,0.000027291631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037665997,0.00041549318,0.00024882462,0.00018650031,0.00013666497,0.0006748224,0.00015762026,0.00028515694,0.0020570662],"category_scores_gemma":[0.00026784546,0.00012522248,0.00017459526,0.00016306929,0.00019608652,0.00016772613,0.00016962831,0.00057399727,0.00093908585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020231062,0.00007192813,0.00026281053,0.000037990856,0.0000058414817,0.00004003705,0.00004006077,0.00009811983,0.9952378,0.00014367123,0.00012443402,0.0037349686],"study_design_scores_gemma":[0.000020194071,0.00043484228,0.00090671575,0.0000042857046,0.000016799946,0.0001963664,0.00001446228,0.0005692394,0.9948426,0.000036658883,0.0029539482,0.0000040114637],"about_ca_topic_score_codex":0.00014251609,"about_ca_topic_score_gemma":0.00023432945,"teacher_disagreement_score":0.0020570662,"about_ca_system_score_codex":0.00011841725,"about_ca_system_score_gemma":0.00016031697,"threshold_uncertainty_score":0.0068815947},"labels":[],"label_agreement":null},{"id":"W4389623269","doi":"10.1016/j.clml.2023.12.005","title":"Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Roche Canada","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Follicular lymphoma; Neutropenia; Lymphoma; Adverse effect; Febrile neutropenia; Gastroenterology; Tumor lysis syndrome; Refractory (planetary science); Rituximab; Cyclophosphamide; Oncology; Surgery; Cancer; Chemotherapy; Immunotherapy","score_opus":0.03510957312794868,"score_gpt":0.3631146871045697,"score_spread":0.328005113976621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389623269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911759,0.0060531143,0.00029542876,0.00039918997,0.0000394744,0.00013911232,0.0004496313,0.000032026295,0.001416154],"genre_scores_gemma":[0.9955735,0.0018964616,0.00032202355,0.0004683061,0.0000651506,0.0001223509,0.0009073984,0.00001459151,0.0006301687],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99973935,0.00011042057,0.000015339509,0.000039410475,0.0000369839,0.000058457983],"domain_scores_gemma":[0.9996283,0.000098477714,0.00009886211,0.00003134473,0.00002922849,0.00011379035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013286953,0.00043588955,0.0010512482,0.00015320742,0.00023378136,0.00088131014,0.00029154762,0.00038210698,0.00096680125],"category_scores_gemma":[0.00088210823,0.00014753752,0.0006103762,0.00023423183,0.00034682167,0.00046321537,0.00015610288,0.0016100982,0.00030389102],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30998528,0.011337582,0.045958735,0.0012938067,0.0039153025,0.0006426129,0.00071755453,0.005227983,0.13203306,0.00076188927,0.011687176,0.47643888],"study_design_scores_gemma":[0.2621295,0.4234248,0.24149899,0.0003339835,0.0052752555,0.003698347,0.00040257047,0.007318409,0.021390717,0.001270333,0.033132438,0.00012468999],"about_ca_topic_score_codex":0.00036545985,"about_ca_topic_score_gemma":0.0011244499,"teacher_disagreement_score":0.0013286953,"about_ca_system_score_codex":0.0005410036,"about_ca_system_score_gemma":0.00048309282,"threshold_uncertainty_score":0.007026851},"labels":[],"label_agreement":null},{"id":"W4389639558","doi":"10.1111/ene.16174","title":"Patterns of neurotoxicity among patients receiving chimeric antigen receptor T‐cell therapy: A single‐centre cohort study","year":2023,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Encephalopathy; Cohort; Internal medicine; Prospective cohort study; Incidence (geometry); Cohort study; Pediatrics; Toxicity","score_opus":0.03049357398452666,"score_gpt":0.2737641118352143,"score_spread":0.24327053785068767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389639558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99964404,0.000055164157,0.000045399433,0.000010035932,0.0000020381242,0.000022899025,0.00011238633,0.0000014819158,0.000106484214],"genre_scores_gemma":[0.9996147,0.00005629748,0.00004909164,0.00001843681,0.0000052680675,0.000018941717,0.00017563501,0.0000017046359,0.000059998463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915457,0.0001675263,0.0001152889,0.00027530504,0.00014062774,0.0001466343],"domain_scores_gemma":[0.99840766,0.00015793914,0.00076619105,0.0001550528,0.00021097298,0.00030214433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000823956,0.00037784877,0.0006234037,0.0007894227,0.0008577789,0.0009891801,0.0004320098,0.00045626043,0.0011943876],"category_scores_gemma":[0.00232886,0.00043153897,0.0006022364,0.0010602125,0.00035637608,0.0007901505,0.0007820626,0.00056604075,0.00028111006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014872356,0.000043802902,0.9986125,0.0000053139865,0.000034872664,0.00021062822,0.00011156061,0.000017512182,0.0001956184,0.0000051839916,0.0000395245,0.0005746968],"study_design_scores_gemma":[0.000025484145,0.00059487554,0.9971047,0.000007934277,0.000048811617,0.00151076,0.00033017693,0.00015481058,0.000077671466,0.00001386937,0.0001222362,0.000008721597],"about_ca_topic_score_codex":0.0070771053,"about_ca_topic_score_gemma":0.0076697026,"teacher_disagreement_score":0.0070771053,"about_ca_system_score_codex":0.0005993564,"about_ca_system_score_gemma":0.00067983544,"threshold_uncertainty_score":0.014071822},"labels":[],"label_agreement":null},{"id":"W4389669358","doi":"10.3390/curroncol30120762","title":"Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Internal medicine; Medicine; Oncology; Diffuse large B-cell lymphoma; Context (archaeology); Cohort; Lymphoma; Immunology; Biology","score_opus":0.08760787529509852,"score_gpt":0.4221598131312722,"score_spread":0.3345519378361737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389669358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99968755,0.00013949402,0.000036259975,0.000007548854,0.0000011666115,0.0000026076798,0.000031200096,0.0000015241652,0.00009262558],"genre_scores_gemma":[0.9998568,0.000028905377,0.000017067008,0.000007822152,0.0000024820715,0.000001538752,0.00004379788,9.789283e-7,0.00004046657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975437,0.000059637157,0.000025144593,0.000059937072,0.000041518302,0.000059484028],"domain_scores_gemma":[0.9995036,0.0001562627,0.00018336266,0.000027460563,0.000029252504,0.00009993224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036528168,0.00014609266,0.0003369766,0.00033462007,0.00020409278,0.00047851162,0.00017069269,0.00030701104,0.00075046415],"category_scores_gemma":[0.0010450786,0.00014189775,0.00026622138,0.00025949944,0.00019269728,0.00019419835,0.00019459109,0.0002568979,0.00017999625],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019596596,0.00017920282,0.96841097,0.00001957898,0.000128843,0.00074202457,0.000119083845,0.00044541966,0.014610244,0.00004058217,0.00015498023,0.013189341],"study_design_scores_gemma":[0.000048931684,0.00097326055,0.9933008,0.0000039324855,0.00008047737,0.0025270607,0.00007971657,0.0009186875,0.0016863813,0.00003894286,0.00033640888,0.0000054102834],"about_ca_topic_score_codex":0.0007284238,"about_ca_topic_score_gemma":0.00093416433,"teacher_disagreement_score":0.00075046415,"about_ca_system_score_codex":0.00031149125,"about_ca_system_score_gemma":0.00015327742,"threshold_uncertainty_score":0.002510488},"labels":[],"label_agreement":null},{"id":"W4389726359","doi":"10.1101/2023.12.13.571465","title":"Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Massively parallel; Base (topology); Primary (astronomy); Computer science; Computational biology; Biology; Parallel computing; Physics","score_opus":0.02803366770179337,"score_gpt":0.26676837820690297,"score_spread":0.23873471050510958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389726359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91646105,0.0011274086,0.07439253,0.00023238671,0.00009139829,0.0006272362,0.002706902,0.001866871,0.0024941515],"genre_scores_gemma":[0.94944996,0.00057606894,0.04548987,0.00016848743,0.000025758842,0.00021043782,0.0018879803,0.00019941531,0.0019920538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993999,0.00009354422,0.000059568843,0.00013770095,0.0002199897,0.00008920648],"domain_scores_gemma":[0.9996227,0.00012536687,0.00006425171,0.00007536349,0.000054391567,0.00005801283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050324324,0.000698096,0.0006401858,0.00045393975,0.00030146074,0.0006094388,0.00040777674,0.0004568327,0.0015944109],"category_scores_gemma":[0.00038851882,0.0002221936,0.00057361746,0.00032305435,0.00028562002,0.00012797,0.0005263627,0.0008468957,0.00038156952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006624743,0.000063006635,0.00031754427,0.000032200656,0.000020916948,0.00007219352,0.000009488442,0.000791167,0.995736,0.00005162155,0.00011266831,0.0027270168],"study_design_scores_gemma":[0.0000339013,0.0005573536,0.0022894063,0.0000028458987,0.000052964064,0.0004078151,0.00001186341,0.0055511557,0.9892105,0.00010261185,0.0017679784,0.0000116618885],"about_ca_topic_score_codex":0.00072435866,"about_ca_topic_score_gemma":0.0013929199,"teacher_disagreement_score":0.0015944109,"about_ca_system_score_codex":0.00040010692,"about_ca_system_score_gemma":0.00032737045,"threshold_uncertainty_score":0.0053339005},"labels":[],"label_agreement":null},{"id":"W4389869854","doi":"10.1002/jcph.2397","title":"Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103)","year":2023,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Pharmacokinetics; TIGIT; Dosing; Medicine; Pharmacology; Chemistry; Internal medicine; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.09254291781798765,"score_gpt":0.4808868178622886,"score_spread":0.38834390004430097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389869854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942908,0.0026440532,0.00072947226,0.00016226033,0.000029073368,0.0002914806,0.00073253346,0.00014826209,0.00097202655],"genre_scores_gemma":[0.99657,0.00053059886,0.0007038929,0.00028665527,0.000029610474,0.0002431362,0.0010378837,0.00002336625,0.00057484646],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99957746,0.00017625449,0.000022176282,0.000078604506,0.000059069396,0.00008643759],"domain_scores_gemma":[0.9995547,0.00009246378,0.00012559947,0.000045026132,0.000036263176,0.00014592682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011443169,0.0007844873,0.0016459635,0.00028876992,0.00030643644,0.0010219981,0.00033190456,0.0006856001,0.0011653467],"category_scores_gemma":[0.0010194285,0.00045146878,0.001201861,0.00032168793,0.0003674098,0.00048317318,0.00023745996,0.0019591742,0.0005961563],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3361274,0.023786008,0.07708941,0.0010301035,0.0036309285,0.0015836913,0.00079767726,0.0052116057,0.32370526,0.00047001668,0.0104015665,0.2161663],"study_design_scores_gemma":[0.060242537,0.6442331,0.20804295,0.00012055753,0.00254509,0.0050692116,0.00022233151,0.010721423,0.04856885,0.00037858114,0.01970131,0.00015403259],"about_ca_topic_score_codex":0.0007737936,"about_ca_topic_score_gemma":0.0010308655,"teacher_disagreement_score":0.0016459635,"about_ca_system_score_codex":0.0010744823,"about_ca_system_score_gemma":0.00091809116,"threshold_uncertainty_score":0.00779593},"labels":[],"label_agreement":null},{"id":"W4389943594","doi":"10.1182/bloodadvances.2023011492","title":"Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pharmacyclics; Genentech; Adaptive Biotechnologies; Juno Therapeutics; Incyte; BeiGene; Loxo Oncology; TG Therapeutics; University of Pennsylvania; Seagen; Kite Pharma; Society for Immunotherapy of Cancer; Mallinckrodt Pharmaceuticals; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; GlaxoSmithKline; Regeneron Pharmaceuticals; Leukemia and Lymphoma Society; Legend Biotech; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Bendamustine; Immunology; Lymphoma; Rituximab","score_opus":0.014826103761929521,"score_gpt":0.2868707754483552,"score_spread":0.2720446716864257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389943594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974577,0.0014458464,0.00027218944,0.000056008404,0.0000070369665,0.00001638142,0.00010554619,0.000017514565,0.00062175654],"genre_scores_gemma":[0.99928206,0.00012351881,0.00018248058,0.000047612342,0.0000040819696,0.000006511334,0.00015792316,0.0000026761736,0.00019308689],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998616,0.000040483672,0.000009686198,0.00003116668,0.00003289209,0.0000241431],"domain_scores_gemma":[0.99983466,0.000046142828,0.00006589314,0.000010883152,0.000013999227,0.000028381806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021542767,0.00012484941,0.00019740323,0.00010959613,0.00009447045,0.00023236935,0.00010889047,0.00013679874,0.0013576348],"category_scores_gemma":[0.0004331147,0.000066152876,0.00012819056,0.00011135941,0.00011793955,0.00013238452,0.00010417587,0.00032039877,0.0001484613],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032778643,0.00095947797,0.20051478,0.00040416472,0.00036117216,0.0005466904,0.0001781138,0.0014583771,0.60449934,0.00013827073,0.0009862821,0.15717466],"study_design_scores_gemma":[0.0023444893,0.047190875,0.7699873,0.00006050451,0.00039889666,0.0042693904,0.0001777216,0.00258623,0.16185553,0.00011244478,0.010999399,0.000017247354],"about_ca_topic_score_codex":0.00053788046,"about_ca_topic_score_gemma":0.0011759531,"teacher_disagreement_score":0.0013576348,"about_ca_system_score_codex":0.00033367204,"about_ca_system_score_gemma":0.00020171818,"threshold_uncertainty_score":0.0045417547},"labels":[],"label_agreement":null},{"id":"W4390030675","doi":"10.54254/2753-8818/24/20231150","title":"Next generation armored CAR-T cells with a drug inducible cytokine circuit","year":2023,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Immune system; Immunotherapy; Tumor microenvironment; Cytokine; Cancer immunotherapy; Cancer research; T cell; Biology; Immunology","score_opus":0.033263182813825634,"score_gpt":0.297694995493518,"score_spread":0.2644318126796924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390030675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5740071,0.0072868527,0.38947162,0.0013077564,0.00073525915,0.00052282,0.00042535196,0.0012276866,0.025015507],"genre_scores_gemma":[0.8967618,0.0018946336,0.088675775,0.00058557506,0.00008316309,0.00023484725,0.00024402257,0.00004249358,0.0114778085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998902,0.000016345824,0.0000072739554,0.000026382197,0.0000393028,0.000020498055],"domain_scores_gemma":[0.99994826,0.000008247526,0.000017507033,0.0000062260347,0.000009956389,0.000009671529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001333123,0.00026501267,0.00018118213,0.00017280603,0.00011247666,0.0003395307,0.000382945,0.000517543,0.0012196074],"category_scores_gemma":[0.00011124914,0.00009822043,0.00030107354,0.0001132753,0.00022858143,0.0003316879,0.00021492504,0.00045637944,0.00042103615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010479777,0.0001213035,0.00028257375,0.00013709132,0.000013745873,0.00016245521,0.000039804298,0.001735087,0.9716385,0.0070150103,0.00041051337,0.018339084],"study_design_scores_gemma":[0.000053386528,0.0010174864,0.0003174341,0.000010315612,0.00003940739,0.0005155556,0.000013022807,0.009717329,0.95629245,0.0006210636,0.031383634,0.000018957868],"about_ca_topic_score_codex":0.00011059926,"about_ca_topic_score_gemma":0.00014492455,"teacher_disagreement_score":0.0012196074,"about_ca_system_score_codex":0.00023652676,"about_ca_system_score_gemma":0.00023603653,"threshold_uncertainty_score":0.0040799975},"labels":[],"label_agreement":null},{"id":"W4390427350","doi":"10.1007/978-3-662-67908-1","title":"Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft","year":2023,"lang":"de","type":"book","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Berlin Institute of Health; Stem Cell Network","keywords":"Philosophy; Art","score_opus":0.07130748548204845,"score_gpt":0.382843740178604,"score_spread":0.31153625469655555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390427350","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037889156,0.093142495,0.0035370304,0.017246673,0.035569575,0.00013074475,0.0016040286,0.00094529364,0.8474452],"genre_scores_gemma":[0.0013977003,0.036278196,0.0016971178,0.0043728463,0.0052508293,0.00006127365,0.00059256225,0.0003980624,0.94995147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995807,0.0000503105,0.000018337005,0.000050795596,0.00026184178,0.00003811921],"domain_scores_gemma":[0.999086,0.00042199733,0.000049327664,0.0000786352,0.00017124672,0.00019273316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007712241,0.0006593764,0.0006080449,0.0012039595,0.00050896924,0.004826704,0.0005946029,0.0018867376,0.20899275],"category_scores_gemma":[0.0016723631,0.0004005784,0.00060093886,0.0014168547,0.0009402847,0.0022689202,0.0012436736,0.003243937,0.1455124],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002157442,0.000018476896,0.00003045721,0.00039146398,0.0000044945,0.000024218567,0.000025207617,0.000093890354,0.00095616764,0.014221633,0.8425096,0.14170285],"study_design_scores_gemma":[0.000002943231,0.00000698342,0.00007140371,0.00011995276,0.0000017606978,0.00006494949,0.000008422898,0.000031491592,0.00012322131,0.0018110662,0.9977551,0.0000026189773],"about_ca_topic_score_codex":0.0015222171,"about_ca_topic_score_gemma":0.004065847,"teacher_disagreement_score":0.20899275,"about_ca_system_score_codex":0.0013785884,"about_ca_system_score_gemma":0.001613082,"threshold_uncertainty_score":0.6991504},"labels":[],"label_agreement":null},{"id":"W4390482949","doi":"10.1002/inmd.20230030","title":"Immune function assessing of TIM3/CD28‐modified CD19 CAR‐T cells and general CD19 CAR‐T cells through a high‐throughput single‐cell microarray platform","year":2024,"lang":"en","type":"article","venue":"Interdisciplinary medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Major Scientific and Technological Innovation Project of Shandong Province; Key Technology Research and Development Program of Shandong; National Natural Science Foundation of China; National Science Foundation","keywords":"CD28; CD19; Chimeric antigen receptor; Immunotherapy; T cell; Immune system; Cancer research; Immunology; Cytotoxic T cell; Biology; Medicine; In vitro","score_opus":0.04251365988367222,"score_gpt":0.3433641136777488,"score_spread":0.30085045379407654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390482949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9278249,0.0013089798,0.06661766,0.00017391804,0.000092281945,0.000101728685,0.0010122781,0.00077122066,0.002096914],"genre_scores_gemma":[0.92706317,0.0008503797,0.066797815,0.00013416252,0.000029903806,0.00028361933,0.0006989525,0.00004927296,0.004092651],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973255,0.000019946005,0.00001624986,0.0000903637,0.00009957863,0.000041302173],"domain_scores_gemma":[0.99990404,0.000016848004,0.000019491908,0.000009684466,0.00003870924,0.000011181653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029008588,0.00041769946,0.00031815178,0.00032493484,0.00016442845,0.00034396848,0.0003143894,0.00045992102,0.0008773144],"category_scores_gemma":[0.00017057503,0.00019329978,0.00028820967,0.00021492032,0.0001574813,0.0003288152,0.00021414895,0.00030812502,0.0003390405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039387312,0.00001924693,0.00023578177,0.000037369195,0.000005114902,0.000013637825,0.000017437125,0.0003271574,0.99652344,0.00009818551,0.00010127019,0.0025818949],"study_design_scores_gemma":[0.000004092894,0.00010627206,0.0009233569,0.0000016500521,0.000012071884,0.000025586663,0.000015781521,0.010629426,0.9874823,0.000035485475,0.00075396744,0.000009872575],"about_ca_topic_score_codex":0.00050984614,"about_ca_topic_score_gemma":0.000845376,"teacher_disagreement_score":0.0008773144,"about_ca_system_score_codex":0.00040046254,"about_ca_system_score_gemma":0.00022543504,"threshold_uncertainty_score":0.0029349327},"labels":[],"label_agreement":null},{"id":"W4390706466","doi":"10.1007/s41669-023-00464-5","title":"A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Quality of life (healthcare); Population; Rituximab; Health care; Systematic review; MEDLINE; Oncology; Family medicine; Lymphoma; Internal medicine; Environmental health; Cancer; Immunotherapy; Nursing","score_opus":0.13180303865277276,"score_gpt":0.47445124690915247,"score_spread":0.3426482082563797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390706466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037516674,0.99208474,0.0003452913,0.00042750733,0.00010916865,0.0010593317,0.0015670165,0.000013196382,0.0006422038],"genre_scores_gemma":[0.046971597,0.946587,0.0019243315,0.00081865006,0.00010058161,0.002528707,0.0008730956,0.000010677444,0.00018542958],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9810884,0.006799482,0.008206544,0.001093741,0.002357218,0.00045460858],"domain_scores_gemma":[0.9416889,0.039835468,0.0123336995,0.0007496375,0.004897078,0.000495336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016370514,0.001763374,0.010176067,0.02314499,0.0008675271,0.0034238477,0.0022121302,0.001995929,0.0045760856],"category_scores_gemma":[0.07320826,0.0010743283,0.008230776,0.022192024,0.0012792837,0.002868574,0.002347104,0.0011301037,0.00030349146],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017303052,0.0000117867285,0.0010681116,0.97230893,0.007348743,0.00013696303,0.00019210465,0.000095812036,0.00008694068,0.00017358671,0.0007204674,0.017683443],"study_design_scores_gemma":[0.00029119232,0.00025779492,0.006001147,0.9090975,0.0733032,0.00043709725,0.00041300067,0.00010427863,0.00014418666,0.00031747262,0.009593158,0.000040068182],"about_ca_topic_score_codex":0.009325678,"about_ca_topic_score_gemma":0.023308445,"teacher_disagreement_score":0.02314499,"about_ca_system_score_codex":0.0069321194,"about_ca_system_score_gemma":0.017687278,"threshold_uncertainty_score":0.08657664},"labels":[],"label_agreement":null},{"id":"W4390912419","doi":"10.1186/s40164-024-00473-y","title":"Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy","year":2024,"lang":"en","type":"letter","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Hematology; Lymphoma; Transplantation; Refractory (planetary science); Surgery; Oncology","score_opus":0.018795935414203605,"score_gpt":0.3165809880801099,"score_spread":0.2977850526659063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390912419","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979481,0.00046273723,0.00009058689,0.000118745804,0.000014822113,0.000009157017,0.00018671934,0.000004844045,0.0011641945],"genre_scores_gemma":[0.9986369,0.0002299217,0.00006205716,0.00011196836,0.00006253243,0.000009560229,0.0005848735,0.0000037678774,0.00029845815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996754,0.0000648874,0.000055958204,0.00004112083,0.00005801107,0.00010456901],"domain_scores_gemma":[0.9991947,0.00017602192,0.0003158764,0.000036019093,0.00006285671,0.00021445769],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003257118,0.00018775607,0.00029652848,0.00059757056,0.00048297376,0.00055556785,0.00017628919,0.00040531735,0.00082864356],"category_scores_gemma":[0.0010906616,0.000111468304,0.00024774327,0.00061965553,0.00027761643,0.0002681168,0.00032917905,0.00033322824,0.00030502595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007778043,0.00010125463,0.9643771,0.000024994515,0.000039325678,0.0222358,0.00013950316,0.00024431018,0.0008572059,0.00006970939,0.00068439136,0.010448714],"study_design_scores_gemma":[0.00010341515,0.0013602088,0.8859026,0.000028928953,0.00008596219,0.106521875,0.00043013037,0.0010751347,0.0010563396,0.0002542527,0.0031572466,0.000023919742],"about_ca_topic_score_codex":0.000690031,"about_ca_topic_score_gemma":0.0010089639,"teacher_disagreement_score":0.00082864356,"about_ca_system_score_codex":0.00048592224,"about_ca_system_score_gemma":0.00028975366,"threshold_uncertainty_score":0.0035256743},"labels":[],"label_agreement":null},{"id":"W4390988643","doi":"10.1017/cjn.2024.7","title":"Frontal Lobe Status Epilepticus Related to CAR T-Cell Therapy Responsive to Anakinra","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Status epilepticus; Content (measure theory); Neuroscience; Medicine; Frontal lobe; Psychology; Epilepsy; Mathematics","score_opus":0.03829667992383834,"score_gpt":0.32054205253323426,"score_spread":0.2822453726093959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390988643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8854321,0.0075158393,0.0041023428,0.013685319,0.00071864494,0.0005374246,0.0012208879,0.00045329295,0.086334296],"genre_scores_gemma":[0.99236155,0.0014269747,0.0002104924,0.0021829067,0.0002418858,0.000022509423,0.00027351678,0.0000139394,0.0032662202],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998386,0.000029433708,0.000015576528,0.000017937331,0.000037452053,0.000061005514],"domain_scores_gemma":[0.9994843,0.00019276881,0.000118791555,0.000042199426,0.000055175493,0.000106761654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014736992,0.00053015945,0.00044781354,0.00044727174,0.0006500677,0.00035540864,0.00028706997,0.0013060283,0.004381113],"category_scores_gemma":[0.0010774743,0.00013867673,0.00037723026,0.00049432466,0.0006649601,0.00043612169,0.00025248458,0.0019684387,0.0007231344],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014378469,0.00023665091,0.022745922,0.00019025609,0.00010568674,0.94020915,0.0002613877,0.00040090206,0.004527546,0.0014472968,0.008107323,0.020330086],"study_design_scores_gemma":[0.00032580062,0.0012634337,0.13019352,0.00013197587,0.00021377392,0.8450994,0.00039887277,0.0019370192,0.004160865,0.0023748218,0.013837847,0.0000626805],"about_ca_topic_score_codex":0.014703038,"about_ca_topic_score_gemma":0.017706875,"teacher_disagreement_score":0.014703038,"about_ca_system_score_codex":0.0013861979,"about_ca_system_score_gemma":0.00080519886,"threshold_uncertainty_score":0.029234886},"labels":[],"label_agreement":null},{"id":"W4391091122","doi":"10.1200/jco.2024.42.3_suppl.tps419","title":"First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Radioimmunotherapy; Cancer research; Oncology; Internal medicine; Monoclonal antibody; Antibody; Immunology","score_opus":0.21684933801765216,"score_gpt":0.5891909108825557,"score_spread":0.37234157286490355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.966504,0.0043231216,0.0021775027,0.0017873775,0.00051521976,0.012067768,0.0055342712,0.00044691196,0.0066438555],"genre_scores_gemma":[0.956959,0.002800882,0.0044263634,0.002989541,0.0004606519,0.010891071,0.008505728,0.00011864719,0.012848204],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99958867,0.00016930046,0.000016434322,0.00006707931,0.000044498705,0.00011405711],"domain_scores_gemma":[0.9992842,0.00009221565,0.00015507413,0.000066016335,0.000051989366,0.00035054004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017142995,0.0022055528,0.0014288124,0.0004648019,0.00051572686,0.0013059592,0.0010707802,0.0020533577,0.008469087],"category_scores_gemma":[0.00073013484,0.00058921333,0.0012352554,0.00036404046,0.0008692725,0.001259612,0.00044402553,0.004016801,0.0019456808],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.58297783,0.14651977,0.006459687,0.002103197,0.0016061722,0.00071309326,0.0004478424,0.0040690587,0.068647146,0.0010680488,0.025023604,0.16036455],"study_design_scores_gemma":[0.47632816,0.4992198,0.0041781855,0.00006120173,0.00035592986,0.00056236825,0.00008819104,0.0015279903,0.007207879,0.00056947226,0.009869172,0.000031649102],"about_ca_topic_score_codex":0.0008096896,"about_ca_topic_score_gemma":0.0026666655,"teacher_disagreement_score":0.008469087,"about_ca_system_score_codex":0.0013375124,"about_ca_system_score_gemma":0.0019655807,"threshold_uncertainty_score":0.028331876},"labels":[],"label_agreement":null},{"id":"W4391091436","doi":"10.1200/jco.2024.42.3_suppl.747","title":"A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Internal medicine; Immunotherapy; Refractory (planetary science); T cell; Oncology; Pharmacokinetics; Chemotherapy; Leukapheresis; Gastroenterology; Immunology; Immune system; Cancer; Stem cell; CD34","score_opus":0.1868673389277022,"score_gpt":0.5374342180194681,"score_spread":0.3505668790917659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884952,0.001503593,0.00050355605,0.0005423416,0.00013863266,0.004147086,0.0017379967,0.00010901729,0.002822702],"genre_scores_gemma":[0.9810321,0.0013061104,0.0017040195,0.001247473,0.00020802619,0.0048739617,0.005231312,0.000037051712,0.004359963],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99960595,0.00019957741,0.000017112918,0.000057576326,0.000037777274,0.00008192999],"domain_scores_gemma":[0.99930274,0.00011957976,0.0001306314,0.00006990008,0.000038745486,0.00033834772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015978676,0.001235459,0.0010365439,0.000387507,0.00036843243,0.00083965715,0.0008756833,0.0012695247,0.0053341025],"category_scores_gemma":[0.00076205964,0.00042345928,0.0007515799,0.00035907875,0.0008730973,0.00069107936,0.000309921,0.0025732878,0.0014533873],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7932594,0.07694533,0.0059690373,0.00072701945,0.00092590856,0.0005665042,0.00022508507,0.0019021598,0.0402423,0.00044650058,0.0069543514,0.07183641],"study_design_scores_gemma":[0.6760928,0.31252968,0.004323229,0.000026177597,0.0002312542,0.00034160604,0.00003536624,0.0008050532,0.0030377032,0.00023960402,0.0023255574,0.000012007606],"about_ca_topic_score_codex":0.0007107798,"about_ca_topic_score_gemma":0.0012051435,"teacher_disagreement_score":0.0053341025,"about_ca_system_score_codex":0.0008248181,"about_ca_system_score_gemma":0.0017645749,"threshold_uncertainty_score":0.017844379},"labels":[],"label_agreement":null},{"id":"W4391103764","doi":"10.1101/2024.01.17.576100","title":"Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"National Cancer Institute; Genentech; Leukemia and Lymphoma Society","keywords":"Immune system; Diffuse large B-cell lymphoma; Lymphoma; Immunotherapy; CD19; Chimeric antigen receptor; Cancer research; Biology; Immunology; T cell; CD20; Medicine","score_opus":0.010102333732425953,"score_gpt":0.24466577801587328,"score_spread":0.23456344428344733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391103764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99427396,0.0005864171,0.0037325367,0.000048222937,0.0000031433337,0.0000115532675,0.0007295897,0.000071941715,0.00054255273],"genre_scores_gemma":[0.9955777,0.0002091136,0.0027909575,0.000053986427,0.0000058684727,0.0000115665525,0.0010455202,0.000026037804,0.0002792446],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99983346,0.000026541094,0.000008309134,0.00006410495,0.00003381355,0.000033666536],"domain_scores_gemma":[0.9998869,0.000028943428,0.000047272577,0.000012988522,0.0000085350675,0.000015248827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000209378,0.00017730148,0.0003100312,0.00085752347,0.00011309356,0.00047857634,0.0001004306,0.00013477965,0.0006529133],"category_scores_gemma":[0.00027975533,0.00012152335,0.00023856788,0.00061115157,0.0002162156,0.000121533434,0.00037846755,0.00023934248,0.000121356476],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004291742,0.000051066963,0.055618007,0.000084096726,0.00009259122,0.00014660157,0.00014663652,0.00081008807,0.9178592,0.0002741831,0.00013472227,0.024353728],"study_design_scores_gemma":[0.000031804302,0.00037124017,0.8934876,0.0000138203295,0.00023847856,0.000900098,0.0003299681,0.0062315366,0.09480273,0.0008083495,0.002766917,0.000017391787],"about_ca_topic_score_codex":0.00053371623,"about_ca_topic_score_gemma":0.0010018484,"teacher_disagreement_score":0.00085752347,"about_ca_system_score_codex":0.00020325228,"about_ca_system_score_gemma":0.00017055115,"threshold_uncertainty_score":0.0021842122},"labels":[],"label_agreement":null},{"id":"W4391134430","doi":"10.51731/cjht.2024.819","title":"Axicabtagene Ciloleucel (Yescarta)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.05406790230311775,"score_gpt":0.35301510937500535,"score_spread":0.2989472070718876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391134430","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017396271,0.6821057,0.0021014048,0.014112054,0.0023572107,0.0005191668,0.004426296,0.00046057565,0.2765212],"genre_scores_gemma":[0.19330707,0.53427756,0.008458857,0.018700326,0.0012858772,0.0005004411,0.007512386,0.00013117035,0.23582639],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958295,0.00007468515,0.000037092796,0.000041307216,0.0002131018,0.0000509618],"domain_scores_gemma":[0.9995365,0.00010106581,0.000097638294,0.000014279453,0.0001870431,0.00006346463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006875222,0.0002383687,0.000282609,0.000906349,0.0002746908,0.0009148219,0.00043855887,0.0006192279,0.026324172],"category_scores_gemma":[0.0010588064,0.00008030305,0.0004567735,0.00055382785,0.00038336831,0.0004964115,0.000334519,0.0005963092,0.004133161],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006851303,0.00009008591,0.00088852394,0.004199779,0.00009456249,0.00020427446,0.000039190974,0.00013122169,0.008354233,0.00460265,0.13950375,0.84120643],"study_design_scores_gemma":[0.00028522982,0.0008157103,0.004593364,0.0012674045,0.00011886791,0.00056865736,0.00005116952,0.00013946589,0.005740189,0.00040034775,0.98600256,0.000017040224],"about_ca_topic_score_codex":0.021341674,"about_ca_topic_score_gemma":0.08744776,"teacher_disagreement_score":0.026324172,"about_ca_system_score_codex":0.0018575151,"about_ca_system_score_gemma":0.003088228,"threshold_uncertainty_score":0.08806318},"labels":[],"label_agreement":null},{"id":"W4391252618","doi":"10.54097/m670m217","title":"CAR T Cell On-Target, Off-Tumor Toxicity in Solid Tumor Treatment: Generation and Management","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Solid tumor; Toxicity; Cancer research; Medicine; Internal medicine; Cancer","score_opus":0.016592828226762536,"score_gpt":0.27271439272603876,"score_spread":0.2561215644992762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391252618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03206089,0.9070504,0.03807912,0.005675699,0.00095272093,0.0002100929,0.00016020445,0.00024348924,0.015567417],"genre_scores_gemma":[0.30165955,0.6606903,0.016638866,0.0031921575,0.0013751526,0.00033270117,0.00039257182,0.00007332917,0.015645342],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996636,0.00008282088,0.00001921894,0.000050854876,0.00011859008,0.00006495449],"domain_scores_gemma":[0.99981993,0.000059282964,0.000037372578,0.000010173379,0.00004943603,0.0000237329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008642314,0.00036845403,0.0005490381,0.0005629127,0.0003411955,0.001082984,0.00059089565,0.0009878601,0.002244449],"category_scores_gemma":[0.00043097697,0.00016029358,0.00048037534,0.00043978784,0.0005072419,0.0010595875,0.00059204875,0.0015301812,0.0007819013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047054002,0.00046142176,0.0025319345,0.008532564,0.00013640629,0.0014870054,0.00045492186,0.0050014695,0.13721325,0.04272792,0.029521413,0.77146125],"study_design_scores_gemma":[0.000098268574,0.0025700445,0.0018580836,0.00089592347,0.00025929115,0.011012888,0.000379923,0.006743262,0.17478028,0.01488736,0.7864367,0.000078051955],"about_ca_topic_score_codex":0.00047046127,"about_ca_topic_score_gemma":0.0006991209,"teacher_disagreement_score":0.002244449,"about_ca_system_score_codex":0.0007986687,"about_ca_system_score_gemma":0.00074838125,"threshold_uncertainty_score":0.007508397},"labels":[],"label_agreement":null},{"id":"W4391309797","doi":"10.1055/s-0043-1777627","title":"Tissue-specific chimeric antigen receptor modified regulatory T cells for the therapy of hepatic inflammation","year":2024,"lang":"de","type":"article","venue":"Zeitschrift für Gastroenterologie","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Associated Medical Services","funders":"","keywords":"Inflammation; Chimeric antigen receptor; Immunology; Antigen; Medicine; Genetic enhancement; Receptor; Cancer research; Biology; Immune system; Immunotherapy; Internal medicine; Gene; Biochemistry","score_opus":0.0448052883331775,"score_gpt":0.32366093961049,"score_spread":0.2788556512773125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391309797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69603336,0.18625149,0.098560646,0.0016578166,0.0013789221,0.0005666494,0.00059844775,0.0010617728,0.013890833],"genre_scores_gemma":[0.94672614,0.02958468,0.016525624,0.00064568827,0.0001920662,0.00025648088,0.000524486,0.000041635783,0.0055032303],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989736,0.000029628925,0.00000479121,0.000015536672,0.000032028624,0.000020648375],"domain_scores_gemma":[0.99997675,0.0000045639167,0.0000074989803,0.0000021049095,0.000004120726,0.0000048592465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017921037,0.00025247157,0.00027381355,0.00017081462,0.000047604368,0.00016009134,0.00017508173,0.00030670912,0.00085198117],"category_scores_gemma":[0.000076341465,0.00005415209,0.00025680877,0.00012360844,0.00011248191,0.000109582026,0.00010109686,0.000767811,0.00023188886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004658533,0.00023360975,0.00018433934,0.0006023338,0.00003588341,0.00027887314,0.00003427423,0.00054300536,0.934436,0.00095481315,0.0009468705,0.06128405],"study_design_scores_gemma":[0.0008679059,0.009774706,0.0028552942,0.000152752,0.000308535,0.0036649015,0.00004861794,0.0062105837,0.871177,0.0009348414,0.1039704,0.000034498044],"about_ca_topic_score_codex":0.000119307995,"about_ca_topic_score_gemma":0.00018334018,"teacher_disagreement_score":0.00085198117,"about_ca_system_score_codex":0.0001345548,"about_ca_system_score_gemma":0.000120877536,"threshold_uncertainty_score":0.002850175},"labels":[],"label_agreement":null},{"id":"W4391596701","doi":"10.1038/d41586-024-00305-3","title":"Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells","year":2024,"lang":"en","type":"article","venue":"Nature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Immune system; Cancer cell; Potency; Cancer; Cancer research; Mutation; Biology; Chemistry; Molecular biology; Immunology; Genetics; In vitro; Gene","score_opus":0.021628801775249538,"score_gpt":0.34378085773068545,"score_spread":0.3221520559554359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391596701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9240224,0.0048388042,0.051837415,0.0019791457,0.0010624988,0.000398092,0.0013619557,0.0031352104,0.011364525],"genre_scores_gemma":[0.9575816,0.0015542184,0.020921296,0.0005319149,0.00016916612,0.00020751666,0.00060981105,0.00064920064,0.017775297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99939215,0.000048894635,0.000035707148,0.00018151476,0.00017211452,0.00016952647],"domain_scores_gemma":[0.9996182,0.00010263178,0.00009725455,0.00007165652,0.000028755958,0.000081587066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000437259,0.0008299802,0.0006743014,0.0007851282,0.00041474274,0.00080998935,0.0007465072,0.0015369575,0.003014124],"category_scores_gemma":[0.00033935663,0.0006029845,0.0010193537,0.0002558893,0.000912652,0.00096075324,0.00061231735,0.003996579,0.001264237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004714974,0.00006477354,0.00014158289,0.00007848048,0.00002993158,0.00009692691,0.000050465893,0.00039913302,0.99272245,0.001404685,0.0004192897,0.004120796],"study_design_scores_gemma":[0.00006959,0.0005776594,0.00043825185,0.000011523197,0.000038260543,0.0003492877,0.000019470717,0.0016133536,0.9915981,0.0003669887,0.004904344,0.000013048281],"about_ca_topic_score_codex":0.00093083165,"about_ca_topic_score_gemma":0.00092337636,"teacher_disagreement_score":0.003014124,"about_ca_system_score_codex":0.00039739907,"about_ca_system_score_gemma":0.00044837626,"threshold_uncertainty_score":0.010083199},"labels":[],"label_agreement":null},{"id":"W4391718044","doi":"10.1016/j.eclinm.2024.102476","title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","year":2024,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Position paper; Position statement; Intensive care medicine; Immunosuppression; Best practice; Harmonization; Immunology; Family medicine; Pathology","score_opus":0.12500705885243496,"score_gpt":0.4946712732144844,"score_spread":0.36966421436204944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391718044","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024110407,0.31309748,0.029697163,0.5778875,0.023728669,0.006857705,0.0036041455,0.00064244313,0.042073824],"genre_scores_gemma":[0.028508361,0.35155126,0.27460927,0.28329608,0.014158228,0.01565553,0.012426288,0.00064952526,0.019145463],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9428093,0.024653712,0.015775762,0.0017326027,0.013041537,0.0019870736],"domain_scores_gemma":[0.89378095,0.033760928,0.01567784,0.0030709275,0.048798196,0.0049110735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07472133,0.0013448001,0.0033238067,0.0058444836,0.0018620117,0.007075665,0.0069441567,0.013477522,0.004897129],"category_scores_gemma":[0.10881338,0.0009705085,0.005327296,0.004348654,0.002763092,0.0036650177,0.005991671,0.011969689,0.0046725613],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028870057,0.00038015895,0.0016569274,0.014668728,0.0005309092,0.00035069964,0.0009021342,0.0013872033,0.0011508038,0.01637792,0.5247608,0.4375451],"study_design_scores_gemma":[0.0005865142,0.00020647285,0.0021084468,0.05282245,0.00078731164,0.0005103069,0.00055344234,0.00091736263,0.0008197191,0.015114048,0.92546517,0.00010870865],"about_ca_topic_score_codex":0.0075361594,"about_ca_topic_score_gemma":0.008166373,"teacher_disagreement_score":0.07472133,"about_ca_system_score_codex":0.005834692,"about_ca_system_score_gemma":0.034675855,"threshold_uncertainty_score":0.3951689},"labels":[],"label_agreement":null},{"id":"W4391774222","doi":"10.1016/j.omton.2024.200775","title":"Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Ottawa Hospital; University of Ottawa; Terry Fox Research Institute; University of British Columbia; Concordia University; National Research Council Canada; Canada's Michael Smith Genome Sciences Centre; Institute of Infection and Immunity","funders":"BC Cancer Agency; National Research Council Canada; Ottawa Hospital Research Institute","keywords":"CD22; Epitope; Antigen; Antibody; Molecular biology; Biology; Immunology; B cell","score_opus":0.0504285465343114,"score_gpt":0.4044585089451424,"score_spread":0.354029962410831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391774222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95030874,0.004766431,0.03425663,0.00056230807,0.00013735093,0.0014039755,0.0013041453,0.00041997334,0.006840437],"genre_scores_gemma":[0.97854596,0.002888897,0.011139262,0.00019912515,0.00003525383,0.0006473961,0.0015046052,0.000037628848,0.0050017377],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986875,0.000019762396,0.000008297755,0.00002267097,0.00003950175,0.000041015897],"domain_scores_gemma":[0.9999099,0.0000064547908,0.000015604284,0.000012459876,0.000017037568,0.000038538998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039518828,0.00046396643,0.00031147434,0.00029511633,0.00015430305,0.00048552037,0.00036027085,0.0004499742,0.0012785059],"category_scores_gemma":[0.00013191625,0.00018875768,0.00039471197,0.00012512902,0.00020520088,0.00028916638,0.00019972779,0.0008391472,0.0005582809],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026457675,0.00072969816,0.00016693937,0.00010456597,0.000016202359,0.00010340866,0.000032330896,0.0010460597,0.9892162,0.00048986654,0.00035826451,0.0074718096],"study_design_scores_gemma":[0.00017725401,0.00992716,0.00094103086,0.000019343652,0.00005533665,0.000389425,0.00002081193,0.0022130862,0.9739248,0.00013935627,0.012183659,0.000008707549],"about_ca_topic_score_codex":0.00038382434,"about_ca_topic_score_gemma":0.0005308864,"teacher_disagreement_score":0.0012785059,"about_ca_system_score_codex":0.00038049088,"about_ca_system_score_gemma":0.00041793045,"threshold_uncertainty_score":0.0042770505},"labels":[],"label_agreement":null},{"id":"W4391838668","doi":"10.1182/bloodadvances.2023012463","title":"Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"bluebird bio; Mallinckrodt Pharmaceuticals; Jazz Pharmaceuticals","keywords":"Extracorporeal Photopheresis; Photopheresis; Graft-versus-host disease; Immunology; Medicine; Hematopoietic stem cell transplantation; T cell; Mixed lymphocyte reaction; CD19; Immune system; CD8; Transplantation; Internal medicine; Lymphoma","score_opus":0.040692693254508416,"score_gpt":0.34950940949916676,"score_spread":0.30881671624465834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391838668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94075066,0.025502857,0.028918035,0.0004366655,0.00017115069,0.00016036772,0.00012236886,0.0004071211,0.003530854],"genre_scores_gemma":[0.9890543,0.0046879547,0.0045687193,0.00014523369,0.000060015085,0.00005161353,0.00012489945,0.000023337525,0.0012838071],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999411,0.00001568736,0.0000027706792,0.000011758201,0.000016807899,0.000011869173],"domain_scores_gemma":[0.9999716,0.0000073617584,0.0000061873793,0.000006228674,0.0000031151258,0.000005499764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001021467,0.00024313362,0.00018449267,0.00020041395,0.00009922622,0.00024289126,0.00019493539,0.00026990497,0.00078439084],"category_scores_gemma":[0.00006883471,0.0000531764,0.00019393262,0.000105849234,0.00019019721,0.00020442036,0.00015730452,0.00055169855,0.00016380797],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046789975,0.00039988855,0.00080754404,0.00023929932,0.000036580965,0.00044734043,0.000040341074,0.00056684494,0.93830013,0.0006986682,0.00051664776,0.057478856],"study_design_scores_gemma":[0.00012662074,0.0020002287,0.006177874,0.0000272224,0.00011611685,0.0023965563,0.000024911997,0.002918427,0.9733474,0.00043319512,0.012420923,0.000010424735],"about_ca_topic_score_codex":0.00011286505,"about_ca_topic_score_gemma":0.0001565108,"teacher_disagreement_score":0.00078439084,"about_ca_system_score_codex":0.00014425958,"about_ca_system_score_gemma":0.00013513869,"threshold_uncertainty_score":0.0026240945},"labels":[],"label_agreement":null},{"id":"W4391886452","doi":"10.1093/intimm/dxae007","title":"Reprogramming T-cell metabolism to enhance adoptive cell therapies","year":2024,"lang":"en","type":"review","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Canada Research Chairs; University Health Network","funders":"National Institutes of Health","keywords":"Reprogramming; Adoptive cell transfer; T cell; Cell metabolism; Cell; Metabolism; Cell biology; Chemistry; Cancer research; Biology; Immunology; Immune system; Biochemistry","score_opus":0.046104247773667534,"score_gpt":0.4189143796292311,"score_spread":0.37281013185556355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391886452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041187808,0.9959214,0.00060216646,0.00035257745,0.0004385885,0.000015800888,0.000027951111,0.00002617079,0.0022034633],"genre_scores_gemma":[0.0022190546,0.9953193,0.0005407574,0.0003336435,0.00018048358,0.000025470024,0.00005528032,0.0000042327993,0.001321701],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998629,0.000024327384,0.000014339366,0.00002299625,0.000053555454,0.000021913082],"domain_scores_gemma":[0.9998895,0.00004611782,0.000016411228,0.0000051830625,0.000030001742,0.00001267152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046744052,0.00076782744,0.0007575019,0.0013913414,0.00017090749,0.0008180202,0.0006596615,0.0010903354,0.0027116383],"category_scores_gemma":[0.00039155397,0.00022174322,0.00050106057,0.00085196574,0.0002886389,0.00089597364,0.0005357118,0.0015281177,0.001821536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000084120125,0.00012992884,0.0001196537,0.012884582,0.0000799838,0.00021479024,0.00005525599,0.00067173596,0.010169552,0.0075681945,0.022389038,0.94563305],"study_design_scores_gemma":[0.000022397473,0.00014705125,0.00038696209,0.0015300452,0.000073078125,0.00083472364,0.000027606116,0.00016796631,0.0030107351,0.001959603,0.9918241,0.000015756124],"about_ca_topic_score_codex":0.00038515654,"about_ca_topic_score_gemma":0.0006082809,"teacher_disagreement_score":0.0027116383,"about_ca_system_score_codex":0.0005006954,"about_ca_system_score_gemma":0.00048877316,"threshold_uncertainty_score":0.0090712905},"labels":[],"label_agreement":null},{"id":"W4391989862","doi":"10.1002/9781119824572.ch18","title":"The Scientific Rationale for Targeting Tumor‐Associated Antigens","year":2024,"lang":"en","type":"other","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Antigen; Tumor associated antigen; Computational biology; Biology; Immunology; Immunotherapy; Immune system","score_opus":0.0393911888289574,"score_gpt":0.34260041206276615,"score_spread":0.3032092232338087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391989862","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015187635,0.16984841,0.071376674,0.46446913,0.024981247,0.00049846485,0.00073910056,0.00027570708,0.25262368],"genre_scores_gemma":[0.29290166,0.20290925,0.058939412,0.2856802,0.027522925,0.0029623217,0.00067225564,0.00036837344,0.12804359],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99793553,0.0006712244,0.00013497712,0.00041487953,0.0006677393,0.00017563922],"domain_scores_gemma":[0.9968573,0.0015335713,0.00023084552,0.00041089213,0.00067685894,0.00029044983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00634283,0.0006225334,0.0006029966,0.0010505229,0.0011507362,0.0025451754,0.0010956028,0.0043361993,0.00792769],"category_scores_gemma":[0.0052808807,0.00033830246,0.000709669,0.00055690913,0.005984728,0.002814479,0.0019286235,0.009879403,0.0028521111],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019146176,0.00019123111,0.00044102423,0.00065184064,0.0000334256,0.00027828687,0.00011712164,0.00050350913,0.004712235,0.89643115,0.035914224,0.06053461],"study_design_scores_gemma":[0.00024752668,0.00027890582,0.00040097165,0.000657442,0.00005861153,0.00096818985,0.00012888531,0.0007180807,0.006497482,0.23591694,0.7540901,0.000036969494],"about_ca_topic_score_codex":0.000680653,"about_ca_topic_score_gemma":0.00068401196,"teacher_disagreement_score":0.00792769,"about_ca_system_score_codex":0.0019282923,"about_ca_system_score_gemma":0.002877244,"threshold_uncertainty_score":0.03354448},"labels":[],"label_agreement":null},{"id":"W4392050283","doi":"10.1038/s42255-024-00976-2","title":"Metabolic engineering for optimized CAR-T cell therapy","year":2024,"lang":"en","type":"article","venue":"Nature Metabolism","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of Victoria","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; University of Victoria; Government of Canada; U.S. Department of Defense","keywords":"Chimeric antigen receptor; Cytotoxicity; Immune system; Metabolic pathway; Biology; T cell; Computational biology; Cell; Immunotherapy; Genome editing; Metabolic engineering; Function (biology); Genetic enhancement; Bioinformatics; Cancer research; Immunology; Gene; Genome; Cell biology; Genetics","score_opus":0.014721376386846024,"score_gpt":0.30953550042048317,"score_spread":0.29481412403363716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392050283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7230866,0.010997252,0.23735324,0.0016457527,0.00046368092,0.00023369223,0.0021075401,0.00097248715,0.023139734],"genre_scores_gemma":[0.9491184,0.0040310984,0.039826497,0.0001477386,0.000022471326,0.00013556053,0.00076821004,0.00017207695,0.005777929],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998418,0.00003122914,0.000009220107,0.000034632383,0.00004324843,0.000039873074],"domain_scores_gemma":[0.99996006,0.000006633171,0.000010453392,0.0000056581116,0.000009075492,0.000008132062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018670171,0.00045341448,0.00036099434,0.00026982726,0.00018693437,0.00068091444,0.0003480034,0.00043153897,0.0019503522],"category_scores_gemma":[0.00016709672,0.00018899755,0.0003695537,0.00038532217,0.00017127585,0.00043281174,0.00041338408,0.00076109264,0.0006444852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025143256,0.00011547179,0.00021141877,0.00019371387,0.000025560808,0.000119039025,0.00002712987,0.004777843,0.96704715,0.0072223097,0.00056780863,0.019441023],"study_design_scores_gemma":[0.000026882099,0.0002896237,0.0003237352,0.000016127451,0.0000317514,0.00018974705,0.000025517638,0.0077458997,0.96927285,0.0014832927,0.02057771,0.000016764716],"about_ca_topic_score_codex":0.0005843407,"about_ca_topic_score_gemma":0.0011797475,"teacher_disagreement_score":0.0019503522,"about_ca_system_score_codex":0.00065533275,"about_ca_system_score_gemma":0.00037831138,"threshold_uncertainty_score":0.006524563},"labels":[],"label_agreement":null},{"id":"W4392131538","doi":"10.1002/cam4.7033","title":"Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Alberta; Janeway Children's Health and Rehabilitation Centre; University of Toronto; Memorial University of Newfoundland; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier Universitaire Sainte-Justine; McMaster Children's Hospital; McGill University Health Centre; CancerCare Manitoba; University of Manitoba; Children's Hospital of Eastern Ontario; Children's Hospital of Western Ontario; London Health Sciences Centre; Montreal Children's Hospital; Hospital for Sick Children; Western University; Saskatoon City Hospital; University of Calgary; Research Institute in Oncology and Hematology; Université Laval; BC Children's Hospital; SickKids Foundation; Stollery Children's Hospital","funders":"Hospital for Sick Children; McGill University Health Centre; BC Children's Hospital; McGill University","keywords":"Medicine; Clinical trial; Context (archaeology); Oncology; Cancer; Everolimus; Internal medicine","score_opus":0.08125349747259299,"score_gpt":0.448215773911411,"score_spread":0.366962276438818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392131538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97535455,0.0043309205,0.000268458,0.0032356922,0.0000525381,0.00015464915,0.004831963,0.000038357277,0.011732857],"genre_scores_gemma":[0.98625934,0.008389032,0.0005746934,0.0012136732,0.00004489437,0.00005063356,0.0018650715,0.000033917535,0.0015687312],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965587,0.00020731,0.0002108413,0.0002947818,0.0014105834,0.0013176193],"domain_scores_gemma":[0.98836434,0.0009285477,0.0036035257,0.0002342866,0.0035518866,0.003317435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011024346,0.00036216015,0.00043076416,0.002122541,0.003612876,0.0022953157,0.0012919528,0.0007373042,0.003245001],"category_scores_gemma":[0.0061030434,0.00041633513,0.0004021276,0.010979681,0.001586836,0.00081504096,0.0016855547,0.0010223356,0.00033695603],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008512367,0.00011049312,0.9593944,0.00019447411,0.00003945096,0.002580326,0.0037466674,0.00019238317,0.00027038885,0.00048440578,0.006748897,0.026152942],"study_design_scores_gemma":[0.000020339148,0.00007382031,0.9625837,0.0002496461,0.0000506486,0.004499151,0.013945985,0.00047658136,0.00027871877,0.00010246384,0.017674638,0.000044189976],"about_ca_topic_score_codex":0.9752746,"about_ca_topic_score_gemma":0.98325896,"teacher_disagreement_score":0.044480674,"about_ca_system_score_codex":0.044480674,"about_ca_system_score_gemma":0.08902314,"threshold_uncertainty_score":0.32273138},"labels":[],"label_agreement":null},{"id":"W4392203306","doi":"10.1016/j.xcrm.2024.101435","title":"Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial","year":2024,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Medical Research Council; Manchester Biomedical Research Centre; Ipsen; NIHR Cambridge Biomedical Research Centre; Rosetrees Trust; Royal Marsden NHS Foundation Trust; Department of Health and Social Care; Cancer Research UK; National Institute for Health and Care Research; National Institutes of Health; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Novartis; Melanoma Research Alliance; Francis Crick Institute; Wellcome Trust; Amgen","keywords":"Medicine","score_opus":0.05398573251415962,"score_gpt":0.35691144629571064,"score_spread":0.30292571378155103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392203306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98090494,0.011369523,0.0004741792,0.0011900396,0.00017956768,0.00047929602,0.001422701,0.00011691691,0.0038627358],"genre_scores_gemma":[0.9868079,0.004468122,0.00088191836,0.0010085324,0.00019819304,0.000669709,0.0029052268,0.000031492058,0.0030288694],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996344,0.00023064156,0.000015049963,0.00003917544,0.000037608243,0.000043133692],"domain_scores_gemma":[0.9995722,0.00008001619,0.0000889645,0.00003129113,0.000040548217,0.00018697417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010285709,0.00058694964,0.0010449637,0.00017264992,0.00015838108,0.0006147628,0.00036937936,0.00045544808,0.0020154237],"category_scores_gemma":[0.00083761016,0.00010528762,0.0005314157,0.00020009778,0.00032775642,0.0005014378,0.00027839994,0.0009877862,0.0004417906],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60391206,0.01276452,0.013782333,0.0026551266,0.0031000483,0.0005728424,0.000340905,0.0040563103,0.037488773,0.0009353977,0.023601182,0.29679042],"study_design_scores_gemma":[0.5910363,0.3074302,0.047898456,0.00038454417,0.0022579567,0.0019753084,0.0002516595,0.0075587076,0.011092796,0.0013175061,0.028685559,0.00011097423],"about_ca_topic_score_codex":0.00029399022,"about_ca_topic_score_gemma":0.0011528137,"teacher_disagreement_score":0.0020154237,"about_ca_system_score_codex":0.0005656707,"about_ca_system_score_gemma":0.000490907,"threshold_uncertainty_score":0.006742239},"labels":[],"label_agreement":null},{"id":"W4392288363","doi":"10.1002/adma.202313226","title":"Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy","year":2024,"lang":"en","type":"article","venue":"Advanced Materials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Pennsylvania; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Perelman School of Medicine, University of Pennsylvania; National Institutes of Health; Canadian Aeronautics and Space Institute; National Center for Advancing Translational Sciences; Division of Chemical, Bioengineering, Environmental, and Transport Systems; National Cancer Institute; National Science Foundation; Emerson Collective","keywords":"Materials science; Cancer immunotherapy; Immunotherapy; Cancer; Cell; Nanoparticle; Nanotechnology; Cancer research; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.02429534248655237,"score_gpt":0.3365589295503751,"score_spread":0.31226358706382273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392288363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85966563,0.003986801,0.123390675,0.00051298004,0.00018914815,0.00029687025,0.000235506,0.0009258913,0.010796342],"genre_scores_gemma":[0.9669185,0.0010262794,0.02729624,0.00012327297,0.000022658183,0.00011685171,0.00012484031,0.000045297464,0.00432597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998919,0.000021729355,0.0000060797606,0.000023375978,0.00003816,0.000018802033],"domain_scores_gemma":[0.99995685,0.0000104058545,0.00001172609,0.0000040418176,0.0000103151615,0.0000066851876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014778675,0.00029368376,0.00013772001,0.00017218104,0.00010391048,0.000288974,0.00017764482,0.00039171043,0.0008364652],"category_scores_gemma":[0.00015401051,0.00011415209,0.00015271314,0.000095962125,0.00013509141,0.00026178118,0.0002484072,0.0003219653,0.0005577259],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042700027,0.000028522607,0.0000483766,0.00005101826,0.0000034039804,0.000053070893,0.00001758298,0.00042505693,0.992459,0.0005078305,0.00017900429,0.006184265],"study_design_scores_gemma":[0.00001239202,0.00016150477,0.00012624079,0.0000037687134,0.000008831297,0.000089453264,0.0000084197,0.0036559077,0.99118364,0.00008811514,0.004657201,0.000004475957],"about_ca_topic_score_codex":0.00025133436,"about_ca_topic_score_gemma":0.00035770118,"teacher_disagreement_score":0.0008364652,"about_ca_system_score_codex":0.00028008438,"about_ca_system_score_gemma":0.0001710314,"threshold_uncertainty_score":0.0027982593},"labels":[],"label_agreement":null},{"id":"W4392303061","doi":"10.1136/jitc-2023-008735","title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iovance Biotherapeutics; Gilead Sciences; Servier; National Cancer Institute; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Pfizer; Moderna; Incyte; Ipsen; BeiGene; Sun Pharma; Sanofi; Moffitt Cancer Center; Exelixis; Seagen; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Context (archaeology); Intensive care medicine; Clinical trial; Cell therapy; Best practice; Internal medicine; Stem cell","score_opus":0.26030052746488336,"score_gpt":0.5246172299582877,"score_spread":0.2643167024934044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392303061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032326195,0.93591833,0.006717581,0.02886121,0.006491673,0.0012203829,0.0013158162,0.00024676934,0.01890493],"genre_scores_gemma":[0.0034754635,0.9397074,0.029322442,0.014276603,0.0014599602,0.0019366727,0.0029183307,0.0000763565,0.0068268534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916067,0.0031827406,0.0021575391,0.00041869763,0.0022567739,0.00037759682],"domain_scores_gemma":[0.98710877,0.0058056135,0.0015223101,0.00036280326,0.0047652125,0.00043524394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012482367,0.0016090124,0.0026823347,0.006370005,0.00090414606,0.0028475933,0.0051698694,0.005077878,0.009746762],"category_scores_gemma":[0.018870173,0.0007039305,0.0042398614,0.0047599114,0.0011502282,0.0024250802,0.0020058947,0.0041377624,0.006097464],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000119523145,0.00012098072,0.00025074434,0.062455866,0.00031234435,0.0005236964,0.00041549405,0.0007775632,0.0007509862,0.010735297,0.30528054,0.618257],"study_design_scores_gemma":[0.00006111836,0.000050656818,0.0003202874,0.05054962,0.0003753318,0.0005580353,0.0001280145,0.00012587066,0.00024062904,0.0037591876,0.9437993,0.00003191423],"about_ca_topic_score_codex":0.0047742524,"about_ca_topic_score_gemma":0.0071826973,"teacher_disagreement_score":0.012482367,"about_ca_system_score_codex":0.0028221887,"about_ca_system_score_gemma":0.013199653,"threshold_uncertainty_score":0.06601381},"labels":[],"label_agreement":null},{"id":"W4392529715","doi":"10.1126/sciadv.adk2298","title":"Machine learning predictions of T cell antigen specificity from intracellular calcium dynamics","year":2024,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"T-cell receptor; Antigen; Cytotoxic T cell; Polyclonal antibodies; T cell; Cell biology; Biology; CD8; Immunology; Biochemistry; Immune system; In vitro","score_opus":0.022950374647809003,"score_gpt":0.32752769963639977,"score_spread":0.30457732498859075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392529715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5202809,0.0011458816,0.47106573,0.0017079993,0.00012219542,0.00006522348,0.0008025262,0.0015108422,0.0032987334],"genre_scores_gemma":[0.9691834,0.00029383446,0.028503304,0.00013742934,0.000041663225,0.000047440073,0.00047976332,0.000031897176,0.0012813004],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9998981,0.000024367784,0.0000066172934,0.000035182795,0.000015435682,0.00002031838],"domain_scores_gemma":[0.9993051,0.00044442725,0.00007362013,0.0000414408,0.0000881226,0.0000471667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005642836,0.0005134915,0.0004857106,0.00041560034,0.00015589717,0.00066807494,0.0004219643,0.00075551146,0.00091226073],"category_scores_gemma":[0.002719032,0.00021239994,0.00030410232,0.0002771729,0.00028388688,0.0005211587,0.00030356264,0.0010642912,0.00035912194],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031294022,0.00014614142,0.011203961,0.000081780585,0.0000512521,0.000092471346,0.000025009886,0.8766208,0.019446103,0.0032984414,0.0022850914,0.086436],"study_design_scores_gemma":[0.0000045476545,0.000010721743,0.00033388322,0.0000019443298,0.0000017591556,0.000005933251,0.0000019536158,0.9968822,0.001186472,0.0014947698,0.00007420225,0.0000017602465],"about_ca_topic_score_codex":0.001609895,"about_ca_topic_score_gemma":0.0021777381,"teacher_disagreement_score":0.001609895,"about_ca_system_score_codex":0.00043688336,"about_ca_system_score_gemma":0.0005487522,"threshold_uncertainty_score":0.003201127},"labels":[],"label_agreement":null},{"id":"W4392561740","doi":"10.1128/jvi.01701-23","title":"The human adenovirus PI3K-Akt activator E4orf1 is targeted by the tumor suppressor p53","year":2024,"lang":"en","type":"article","venue":"Journal of Virology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Deutsche Forschungsgemeinschaft","keywords":"Biology; Suppressor; PI3K/AKT/mTOR pathway; Cancer research; Activator (genetics); Adenoviridae; Protein kinase B; Tumor suppressor gene; Virology; Molecular biology; Cell biology; Carcinogenesis; Genetic enhancement; Gene; Signal transduction; Genetics","score_opus":0.024383124702418966,"score_gpt":0.3449633092336427,"score_spread":0.3205801845312237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392561740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99014485,0.001391625,0.005754653,0.00007885995,0.000044610082,0.000030194335,0.00062316254,0.00013570377,0.0017963648],"genre_scores_gemma":[0.99202067,0.00041451587,0.002696828,0.00002382916,0.0000045713346,0.000019701785,0.0010152821,0.000011386436,0.0037931253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988174,0.000015109881,0.000011344473,0.000032032523,0.000028184615,0.00003166827],"domain_scores_gemma":[0.9999397,0.00000989036,0.000018815812,0.000012335828,0.0000057071497,0.000013489994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012473219,0.00042802215,0.00015352228,0.00022846312,0.00019318462,0.0002545495,0.00015076854,0.0002258268,0.0017321851],"category_scores_gemma":[0.00011736974,0.00016251668,0.00030335897,0.00015055104,0.00017980361,0.00017379054,0.0002038483,0.00033190107,0.00063325034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015931154,0.000021331309,0.00073773076,0.000032757278,0.0000076185506,0.00008535054,0.000012367096,0.00014181914,0.99639326,0.00032677388,0.000078224046,0.0020034276],"study_design_scores_gemma":[0.000021094444,0.00014078067,0.005896367,0.0000055162395,0.000016361419,0.00040042403,0.000021296906,0.0020514207,0.9847798,0.00009696377,0.0065640705,0.0000058657997],"about_ca_topic_score_codex":0.00069629104,"about_ca_topic_score_gemma":0.00058484526,"teacher_disagreement_score":0.0017321851,"about_ca_system_score_codex":0.0005630304,"about_ca_system_score_gemma":0.00020043689,"threshold_uncertainty_score":0.005794704},"labels":[],"label_agreement":null},{"id":"W4392588447","doi":"10.1038/s41467-024-46367-9","title":"Structural basis for self-discrimination by neoantigen-specific TCRs","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Argonne National Laboratory; Biological and Environmental Research; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Melanoma Research Alliance; University of Chicago; National Institute of General Medical Sciences; Cancer Research Institute; York University; U.S. Department of Energy","keywords":"T-cell receptor; Avidity; Major histocompatibility complex; Epitope; Biology; T cell; Cytolysis; Immunogenicity; Computational biology; Antigen presentation; Cell biology; Antigen; Genetics; Cytotoxic T cell; Immune system; In vitro","score_opus":0.050255254777179514,"score_gpt":0.3819615148023472,"score_spread":0.3317062600251677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392588447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99637574,0.00019113605,0.002268417,0.00003390304,0.0000064433593,0.0000075751796,0.000032274213,0.000021994221,0.0010624585],"genre_scores_gemma":[0.99924976,0.000045975627,0.00043284945,0.000012229915,0.0000012811591,0.0000024823394,0.000046524936,0.0000029939072,0.0002058917],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995625,0.000008131519,0.0000022024926,0.0000069039615,0.000014032785,0.000012497788],"domain_scores_gemma":[0.9999497,0.000011516896,0.000012675378,0.0000064082597,0.0000074482164,0.000012407758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000065320775,0.00014017957,0.00009778363,0.00007338657,0.00008228409,0.00016262752,0.00015251887,0.0002171397,0.0013754972],"category_scores_gemma":[0.0000794473,0.00007127695,0.00013959454,0.00004498042,0.00014515566,0.00008139434,0.00012575509,0.00025259895,0.00033891012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006487643,0.00001579456,0.00040334862,0.0000123009095,0.000003133002,0.00008402459,0.000007502419,0.00036677657,0.99803966,0.00035183545,0.00001791307,0.00063286186],"study_design_scores_gemma":[0.000032267228,0.00044446782,0.008371094,0.000007666623,0.000018006991,0.0008478903,0.000058375375,0.00835439,0.9792442,0.0007078489,0.0019074929,0.000006398548],"about_ca_topic_score_codex":0.00019059188,"about_ca_topic_score_gemma":0.0001447925,"teacher_disagreement_score":0.0013754972,"about_ca_system_score_codex":0.0001525622,"about_ca_system_score_gemma":0.0000923496,"threshold_uncertainty_score":0.0046014786},"labels":[],"label_agreement":null},{"id":"W4392600366","doi":"10.1016/j.xcrm.2024.101465","title":"Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy","year":2024,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Cell biology; Ex vivo; Cell therapy; Chemistry; Biophysics; Biology; Stem cell; Biochemistry; In vitro","score_opus":0.030274837885283092,"score_gpt":0.3158685303698254,"score_spread":0.2855936924845423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392600366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921997,0.0015069613,0.0038879574,0.00013060513,0.000047370435,0.00004837688,0.00028201911,0.00009635408,0.0018007323],"genre_scores_gemma":[0.9961278,0.0005564745,0.0019065172,0.00004618343,0.000011787645,0.0000338958,0.0001503983,0.00000940122,0.001157509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999188,0.000019790547,0.000005534003,0.000014453053,0.000021583097,0.000019927056],"domain_scores_gemma":[0.99996495,0.0000057633792,0.00001043651,0.000005161305,0.000002793558,0.000010917254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011001202,0.0003336816,0.00020241814,0.00013553449,0.00007824202,0.00023122145,0.000115814386,0.00023563518,0.0010910742],"category_scores_gemma":[0.00005030393,0.00006816406,0.00015592005,0.000080245176,0.00013713138,0.0001334951,0.0001541467,0.0004603636,0.00018877747],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001320676,0.000027851396,0.000095073934,0.000026992337,0.000003683647,0.000026257101,0.000007783525,0.000116761956,0.99809355,0.000066680324,0.000030787578,0.001372529],"study_design_scores_gemma":[0.000022940947,0.00049284543,0.00097239896,0.000003888149,0.000011950615,0.00012438039,0.000013500764,0.00051847106,0.9956726,0.00003998607,0.0021249005,0.0000021536569],"about_ca_topic_score_codex":0.00013663305,"about_ca_topic_score_gemma":0.00045775512,"teacher_disagreement_score":0.0010910742,"about_ca_system_score_codex":0.00013586626,"about_ca_system_score_gemma":0.000120642624,"threshold_uncertainty_score":0.00364995},"labels":[],"label_agreement":null},{"id":"W4392634220","doi":"10.1136/ijgc-2024-esgo.7","title":"237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Open label; Medicine; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Randomized controlled trial","score_opus":0.19083547522675567,"score_gpt":0.5127291952406223,"score_spread":0.3218937200138666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392634220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708952,0.0069773,0.0017636633,0.0017834302,0.0010447041,0.0054418147,0.003906404,0.00039718376,0.0077902717],"genre_scores_gemma":[0.97803986,0.002672104,0.002746159,0.0026077165,0.00035764303,0.004104389,0.002682465,0.000084280684,0.00670543],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99949324,0.0002521427,0.00001708692,0.000092437294,0.000039810166,0.00010530667],"domain_scores_gemma":[0.9995782,0.00010522015,0.00007326584,0.000032402033,0.000030045592,0.00018092977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013736698,0.0013091674,0.0018722143,0.0004136257,0.00038763942,0.0011621895,0.00077379664,0.0017392915,0.010088353],"category_scores_gemma":[0.00087031064,0.0005882358,0.0020620546,0.0003578434,0.0010868039,0.000926417,0.00035530308,0.004016194,0.0018141598],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9161866,0.011893841,0.0008652578,0.0009737224,0.0017216596,0.00005039667,0.00008609385,0.0008891393,0.0058787274,0.00040626165,0.0049668155,0.056081396],"study_design_scores_gemma":[0.9092934,0.08504485,0.0015874159,0.000052456544,0.0005028977,0.00003803585,0.00003851549,0.0006771205,0.0006271847,0.00027594154,0.0018375694,0.000024636043],"about_ca_topic_score_codex":0.0018435996,"about_ca_topic_score_gemma":0.0053851805,"teacher_disagreement_score":0.010088353,"about_ca_system_score_codex":0.0009834873,"about_ca_system_score_gemma":0.001359571,"threshold_uncertainty_score":0.033748925},"labels":[],"label_agreement":null},{"id":"W4392785337","doi":"10.3791/65887-v","title":"JoVE Video Dataset","year":2024,"lang":"pt","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Computer science; Artificial intelligence","score_opus":0.05829413987748627,"score_gpt":0.392553274354005,"score_spread":0.3342591344765187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392785337","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007599005,0.001105073,0.0029256877,0.0009695335,0.0008966215,0.00033089812,0.87258536,0.008572984,0.11185397],"genre_scores_gemma":[0.007988708,0.0023820915,0.012819593,0.0016402281,0.00045793504,0.0009766141,0.8292126,0.004048903,0.14047328],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996735,0.000038785598,0.00002475304,0.000092111964,0.00012301258,0.00004786724],"domain_scores_gemma":[0.9986137,0.0004179468,0.00008189685,0.00013256684,0.00047455946,0.00027934334],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000456693,0.001392221,0.0009618583,0.0028121583,0.0008583868,0.0026299837,0.0018237212,0.0016204702,0.71769476],"category_scores_gemma":[0.0040416555,0.00031780073,0.00062852603,0.0027369433,0.0002418027,0.00200936,0.0023369552,0.001001376,0.45166686],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006105452,0.000015118294,0.00017454893,0.00036351374,0.000005084134,0.000049234677,0.000018584793,0.00008739127,0.000166477,0.0003353761,0.9761614,0.02256219],"study_design_scores_gemma":[0.000031883657,0.000017691684,0.0011129889,0.0002561651,0.000011060704,0.00015168049,0.000079697995,0.00035628641,0.0003018976,0.0013260288,0.99633265,0.000021961474],"about_ca_topic_score_codex":0.01083383,"about_ca_topic_score_gemma":0.027613688,"teacher_disagreement_score":0.71769476,"about_ca_system_score_codex":0.00077942805,"about_ca_system_score_gemma":0.0013600651,"threshold_uncertainty_score":0.40267414},"labels":[],"label_agreement":null},{"id":"W4392785618","doi":"10.3791/65887","title":"Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells","year":2024,"lang":"en","type":"article","venue":"Journal of Visualized Experiments","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Center for Advancing Translational Sciences; National Institute of Biomedical Imaging and Bioengineering","keywords":"Chimeric antigen receptor; Immune system; Context (archaeology); T cell; Cancer research; Antigen; Tumor microenvironment; Immunology; Biology; Medicine","score_opus":0.06399087211917413,"score_gpt":0.46268778668373856,"score_spread":0.3986969145645644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392785618","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6979686,0.0035212424,0.27729255,0.0004016098,0.0003322153,0.0024370244,0.0052627074,0.0018249127,0.010959081],"genre_scores_gemma":[0.9068878,0.002688692,0.07339971,0.0001638604,0.000065291024,0.0015253249,0.004266478,0.00030723473,0.010695644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99952435,0.000082361905,0.00006336317,0.00010639595,0.00012466652,0.000098932935],"domain_scores_gemma":[0.999819,0.000040427087,0.00003425885,0.000037217575,0.000031913307,0.000037284895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066333474,0.0004660297,0.00035311494,0.0006907969,0.0002877882,0.00059845654,0.00042284472,0.0005309124,0.002426698],"category_scores_gemma":[0.00037483816,0.00025365892,0.0003278505,0.00041752207,0.00024712092,0.00032729807,0.0004964733,0.0011544582,0.0013454651],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012117006,0.0000817144,0.00015979873,0.00007113886,0.000008127354,0.000083831015,0.00006906361,0.0004132494,0.9917571,0.0016221701,0.00048600868,0.0051265284],"study_design_scores_gemma":[0.000041870935,0.00025408546,0.00028287384,0.0000064419273,0.000017840413,0.00023181565,0.000016784408,0.001350923,0.9863777,0.00010507848,0.011308606,0.0000059635277],"about_ca_topic_score_codex":0.00035170827,"about_ca_topic_score_gemma":0.0004201108,"teacher_disagreement_score":0.002426698,"about_ca_system_score_codex":0.00024243245,"about_ca_system_score_gemma":0.00053970027,"threshold_uncertainty_score":0.008118093},"labels":[],"label_agreement":null},{"id":"W4392796921","doi":"10.1073/pnas.2310866121","title":"Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function","year":2024,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; York University; National Cancer Institute; National Institutes of Health; Emerson Collective; Melanoma Research Alliance","keywords":"Ectodomain; Allosteric regulation; Ligand (biochemistry); Cell biology; Receptor; Function (biology); Chemistry; Mutation; Biophysics; Biology; Biochemistry; Gene","score_opus":0.04585850223171072,"score_gpt":0.35700207098395614,"score_spread":0.3111435687522454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392796921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944993,0.001365621,0.0026107912,0.00031393304,0.00001311612,0.000006748201,0.000102909995,0.000073822695,0.0010136628],"genre_scores_gemma":[0.9968054,0.0008068923,0.0017044515,0.00010917299,0.0000062249846,0.0000036341257,0.0001496242,0.000009807874,0.0004048941],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999702,0.000005798185,0.0000014144194,0.000006112877,0.000007607091,0.000008784571],"domain_scores_gemma":[0.9999703,0.0000061158166,0.00000737728,0.0000023252371,0.000002562808,0.000011315309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008890204,0.00034502667,0.00015216893,0.00009028366,0.00014986513,0.00023661382,0.00023518133,0.00029644198,0.0007301223],"category_scores_gemma":[0.000069455105,0.00013140241,0.0001837795,0.00008690651,0.00016939962,0.00029796385,0.00018177636,0.0005636917,0.00018776178],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022630853,0.000049465532,0.001113437,0.000070835296,0.000011757837,0.00028725393,0.000058110647,0.0017057473,0.99331033,0.000899068,0.00021051652,0.0020572452],"study_design_scores_gemma":[0.00023644995,0.0005009987,0.042310804,0.000042375883,0.0001362502,0.0022114841,0.0004868709,0.0963797,0.8400155,0.0032447954,0.014379674,0.00005504638],"about_ca_topic_score_codex":0.0010957082,"about_ca_topic_score_gemma":0.0013502635,"teacher_disagreement_score":0.0010957082,"about_ca_system_score_codex":0.00039507396,"about_ca_system_score_gemma":0.00023194945,"threshold_uncertainty_score":0.0028665066},"labels":[],"label_agreement":null},{"id":"W4392854760","doi":"10.1177/0272989x241234070","title":"CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis","year":2024,"lang":"en","type":"article","venue":"Medical Decision Making","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo; Canadian Centre for Applied Research in Cancer Control; University of Guelph; Toronto General Hospital","funders":"Canadian Institutes of Health Research; Canada First Research Excellence Fund","keywords":"Medicine; Clinical trial; Chimeric antigen receptor; Quality-adjusted life year; Cost-effectiveness analysis; Cost effectiveness; Oncology; Internal medicine; Intensive care medicine; Immunotherapy; Cancer","score_opus":0.03373929135459469,"score_gpt":0.3590436528543052,"score_spread":0.3253043614997105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392854760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90998626,0.0081564635,0.019678432,0.005335272,0.00012783465,0.0026435629,0.028508965,0.00023413084,0.025329137],"genre_scores_gemma":[0.98489887,0.0018803736,0.006385395,0.00032127523,0.000017556185,0.00035038978,0.0041329297,0.000030053987,0.0019832144],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983771,0.0006724712,0.000060836624,0.00016119219,0.00035999232,0.00036837065],"domain_scores_gemma":[0.9955155,0.002373922,0.00030409067,0.000099918005,0.0012829255,0.00042367927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034702288,0.0013305538,0.0012929043,0.0022381947,0.000996507,0.002023395,0.0018486881,0.0011335614,0.004689094],"category_scores_gemma":[0.011361227,0.0007661307,0.0025081127,0.0033838719,0.00071236625,0.000667117,0.00093562686,0.0014134935,0.000214162],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012718543,0.00023446618,0.016812535,0.00042315628,0.0006899847,0.00031554184,0.000056059496,0.95916533,0.00024272698,0.004676433,0.003377825,0.012734157],"study_design_scores_gemma":[0.0009841028,0.00044490144,0.016149541,0.00018487076,0.001054479,0.00015748618,0.00022068391,0.9737734,0.00029928263,0.0025098426,0.004128039,0.00009343347],"about_ca_topic_score_codex":0.94915414,"about_ca_topic_score_gemma":0.90954953,"teacher_disagreement_score":0.91294307,"about_ca_system_score_codex":0.08705695,"about_ca_system_score_gemma":0.054979514,"threshold_uncertainty_score":0.6316453},"labels":[],"label_agreement":null},{"id":"W4392881315","doi":"10.1016/j.jcyt.2024.03.009","title":"Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Genetically engineered; Clinical trial; Cell therapy; Cancer; Medicine; Immune system; Genetically modified organism; Computational biology; Immunotherapy; Bioinformatics; Immunology; Biology; Cell; Internal medicine","score_opus":0.13037486829129202,"score_gpt":0.39490187779802277,"score_spread":0.26452700950673075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392881315","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004924727,0.0031056723,0.9776708,0.007909806,0.00013911437,0.0012409298,0.00032404158,0.00038642608,0.0042985356],"genre_scores_gemma":[0.08753198,0.0034553194,0.9045642,0.0017399841,0.00021494798,0.0015600508,0.000339719,0.000116859395,0.00047702735],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.8306793,0.12362107,0.013156301,0.007445979,0.02407131,0.001025994],"domain_scores_gemma":[0.5978571,0.28529036,0.04277203,0.044715654,0.026648037,0.0027167506],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.26150024,0.0029381756,0.0022883671,0.009706167,0.0014668355,0.010877125,0.0054443977,0.0034897416,0.0023525066],"category_scores_gemma":[0.34167382,0.0015489461,0.0042905053,0.0037092154,0.0075350604,0.009355197,0.009697687,0.0068764044,0.0009116934],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007203704,0.00055485277,0.024731392,0.003215368,0.0015512682,0.0008173007,0.0027649032,0.07789662,0.0038375866,0.41457382,0.0051256726,0.46421078],"study_design_scores_gemma":[0.00018169939,0.0016619079,0.0045281984,0.006141924,0.001036046,0.00075849507,0.0009821049,0.088063955,0.008813818,0.8227795,0.064760104,0.00029222015],"about_ca_topic_score_codex":0.002130575,"about_ca_topic_score_gemma":0.0018170013,"teacher_disagreement_score":0.26150024,"about_ca_system_score_codex":0.0050627934,"about_ca_system_score_gemma":0.020594792,"threshold_uncertainty_score":0.9107017},"labels":[],"label_agreement":null},{"id":"W4392886198","doi":"10.1186/s12967-024-05063-4","title":"CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","year":2024,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Karolinska Institutet; National Cancer Institute; Radiumhemmets Forskningsfonder; Cancerfonden; Stiftelsen Tornspiran; Memorial Sloan-Kettering Cancer Center","keywords":"Chimeric antigen receptor; CD28; Cytokine release syndrome; Cytotoxic T cell; Interleukin 21; T cell; IL-2 receptor; CD19; Cancer research; Interleukin 3; Immune system; Medicine; Immunology; Biology; Chemistry; In vitro","score_opus":0.015910685704372277,"score_gpt":0.27530309591415947,"score_spread":0.2593924102097872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392886198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99273103,0.0029892316,0.0016205623,0.00013174242,0.000056111923,0.00002888609,0.0005304923,0.000078595906,0.0018333279],"genre_scores_gemma":[0.9969501,0.000835463,0.0005426325,0.000079875266,0.000014057349,0.000033275694,0.00038548835,0.000013544669,0.0011456142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996767,0.00005555448,0.00002213065,0.000058001802,0.00008338698,0.00010414579],"domain_scores_gemma":[0.9998785,0.00001936154,0.000034935925,0.000015391559,0.000015894715,0.00003595496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011317975,0.00031352378,0.00021804633,0.00014794168,0.00011023653,0.0004822357,0.00016775732,0.0003931007,0.0023082262],"category_scores_gemma":[0.00015673811,0.00009593129,0.0002941562,0.00013011231,0.00025774457,0.0002147542,0.00016704095,0.000778439,0.00042735532],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039797346,0.000046141096,0.0006001689,0.000070824644,0.000010260576,0.00009200543,0.000038912473,0.00014021035,0.9962631,0.00011110343,0.000082201295,0.0021471605],"study_design_scores_gemma":[0.000038181854,0.0016990886,0.012315021,0.000018579234,0.00007559135,0.0006889274,0.00017050457,0.0006002042,0.9783985,0.0001294781,0.005853058,0.000012841285],"about_ca_topic_score_codex":0.00037467454,"about_ca_topic_score_gemma":0.00037437942,"teacher_disagreement_score":0.0023082262,"about_ca_system_score_codex":0.00027860812,"about_ca_system_score_gemma":0.00015543198,"threshold_uncertainty_score":0.0077217817},"labels":[],"label_agreement":null},{"id":"W4392921484","doi":"10.1038/s41540-024-00355-3","title":"Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics","year":2024,"lang":"en","type":"article","venue":"npj Systems Biology and Applications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Medicine; Systems pharmacology; Immune system; Drug; Translation (biology); Pharmacology; Computational biology; Immunotherapy; Immunology; Biology","score_opus":0.0637748487477591,"score_gpt":0.4028104538280402,"score_spread":0.3390356050802811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392921484","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054763254,0.006694707,0.91683346,0.00421862,0.0002657749,0.00015650809,0.00036503433,0.00037120524,0.016331522],"genre_scores_gemma":[0.84831005,0.010784624,0.13105649,0.001411007,0.00024133534,0.00037189832,0.00025390062,0.00015696249,0.007413754],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99928916,0.00029303532,0.00002574127,0.00012909605,0.00022197167,0.00004100229],"domain_scores_gemma":[0.99891543,0.00071380165,0.00016154342,0.000091607675,0.00008329424,0.00003434561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001417568,0.0005827656,0.0006396857,0.0003396018,0.00025244028,0.0016007372,0.00072201673,0.0009560238,0.0015882174],"category_scores_gemma":[0.0035136614,0.00046915447,0.00069391687,0.0002970324,0.0016053986,0.002297996,0.0006664736,0.0018015673,0.00037080082],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001664433,0.00019802677,0.0016446174,0.0006273201,0.00010715082,0.00014836274,0.00017368377,0.44116595,0.09563574,0.4062595,0.0030176938,0.050855543],"study_design_scores_gemma":[0.00004261397,0.00025351343,0.00041654517,0.00005700656,0.000033522083,0.00008466956,0.000042009236,0.82755077,0.021094745,0.14057836,0.009798901,0.000047408703],"about_ca_topic_score_codex":0.001456502,"about_ca_topic_score_gemma":0.00087767775,"teacher_disagreement_score":0.0016007372,"about_ca_system_score_codex":0.0015678619,"about_ca_system_score_gemma":0.0011191356,"threshold_uncertainty_score":0.011375666},"labels":[],"label_agreement":null},{"id":"W4392955797","doi":"10.1038/s43018-024-00744-x","title":"Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies","year":2024,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Cancer Institute; U.S. Department of Health and Human Services; Government of Canada; Marie-Josée and Henry R. Kravis Center for Molecular Oncology; Servier; Cycle for Survival","keywords":"T-cell receptor; Chimeric antigen receptor; Ectodomain; Antigen; CD28; Receptor; T cell; Biology; Cell biology; CD80; CD3; Cancer research; Immunology; Molecular biology; Cytotoxic T cell; Immune system; CD8; In vitro; Biochemistry; CD40","score_opus":0.012960246948447891,"score_gpt":0.3315731635100779,"score_spread":0.31861291656163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392955797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97228795,0.0067149755,0.011426846,0.0002361426,0.00010050724,0.000074384334,0.000153448,0.00030308185,0.008702679],"genre_scores_gemma":[0.99301106,0.0008880979,0.0034438747,0.00008144264,0.000021989588,0.000030388057,0.00013457172,0.000025131489,0.002363495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996898,0.00005568819,0.000018549663,0.000053509528,0.000099542754,0.00008289631],"domain_scores_gemma":[0.9998722,0.00003420563,0.000025755799,0.000015303907,0.000017058028,0.000035502315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021652425,0.00034653052,0.00040030965,0.00034238712,0.000114139904,0.0005283784,0.0002752715,0.00050514255,0.0019531287],"category_scores_gemma":[0.0002028991,0.00012887003,0.00019905648,0.0002160289,0.00019481145,0.00037762767,0.00041504705,0.00060386764,0.0007726034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019642277,0.00012306425,0.00016416026,0.00006103137,0.000010401728,0.000053852284,0.000017634758,0.0005390354,0.98926055,0.0004961453,0.00015508845,0.0089225415],"study_design_scores_gemma":[0.000034102857,0.0009942258,0.0007018427,0.000005752267,0.000035817622,0.00040400604,0.000013483818,0.0018668085,0.9890376,0.00012213725,0.00677732,0.000006858709],"about_ca_topic_score_codex":0.00016905704,"about_ca_topic_score_gemma":0.00027132322,"teacher_disagreement_score":0.0019531287,"about_ca_system_score_codex":0.0003061771,"about_ca_system_score_gemma":0.00020255407,"threshold_uncertainty_score":0.006533861},"labels":[],"label_agreement":null},{"id":"W4392967953","doi":"10.1101/2024.03.18.584896","title":"Gene editing of <i>CD3 epsilon</i> gene to redirect regulatory T cells for adoptive T cell transfer","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Adoptive cell transfer; Gene; Gene transfer; T cell; Genome editing; CD3; Biology; Cell biology; Genetics; Immune system; CD8; Genome","score_opus":0.020909864188841935,"score_gpt":0.2559609035531854,"score_spread":0.23505103936434346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392967953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92467225,0.0007222113,0.06711283,0.00019538826,0.00022886203,0.00022237435,0.0008845871,0.0011147565,0.0048467866],"genre_scores_gemma":[0.97811997,0.00025556947,0.016722467,0.000092218215,0.000015465228,0.000088667715,0.00040836303,0.00013074517,0.0041665863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998424,0.000019922341,0.00001572183,0.00003943153,0.000041769275,0.000040709223],"domain_scores_gemma":[0.999884,0.000016883758,0.00004586012,0.000017940356,0.000013367188,0.000021895557],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016471703,0.0004275762,0.00016696723,0.00016122527,0.00011092097,0.00030580602,0.00029285974,0.00035423433,0.0017184584],"category_scores_gemma":[0.000100208286,0.0001177282,0.00026893348,0.00010673631,0.00025328193,0.00013017622,0.00019032492,0.00066503807,0.0005257868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025221396,0.000012287731,0.000039357466,0.000019086703,0.0000028789088,0.000030410394,0.000005477952,0.000082689025,0.99869186,0.0001329118,0.00006168036,0.0008960978],"study_design_scores_gemma":[0.000007343789,0.00007100126,0.00028155395,0.0000023180833,0.000006595404,0.000116619034,0.000003829878,0.0007884652,0.99631965,0.000027892747,0.0023710632,0.0000035718142],"about_ca_topic_score_codex":0.00044806377,"about_ca_topic_score_gemma":0.00042946485,"teacher_disagreement_score":0.0017184584,"about_ca_system_score_codex":0.00024740526,"about_ca_system_score_gemma":0.00015365453,"threshold_uncertainty_score":0.0057488084},"labels":[],"label_agreement":null},{"id":"W4392987439","doi":"10.3390/biology13030196","title":"Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy","year":2024,"lang":"en","type":"article","venue":"Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Food Inspection Agency; Leucid Bio","keywords":"Biology; T-cell receptor; Cancer immunotherapy; Cytotoxic T cell; Immunotherapy; Cytolysis; Antigen; Cancer research; T cell; Immunology; Molecular biology; Virology; Immune system; Genetics","score_opus":0.03771093852680156,"score_gpt":0.34493183315043147,"score_spread":0.3072208946236299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392987439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97287446,0.0022278936,0.021852087,0.00012653292,0.000054184045,0.00013585063,0.00012717456,0.00013832672,0.0024635652],"genre_scores_gemma":[0.98820925,0.0007312525,0.00942645,0.00006813809,0.000008421023,0.000037386722,0.00010654134,0.000016662561,0.001395868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980146,0.000041996707,0.000014190871,0.00003163446,0.000052856078,0.00005792838],"domain_scores_gemma":[0.99995697,0.0000068663617,0.00001343539,0.0000060238604,0.000006611135,0.000010161663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013057243,0.0003777823,0.0002263064,0.00017985608,0.000093037546,0.00043665353,0.00030064242,0.000519869,0.0010065823],"category_scores_gemma":[0.000100850375,0.00013421969,0.00019572975,0.00019657623,0.00015869628,0.00023689578,0.00030490037,0.00070847874,0.0006140109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000045446697,0.000034720666,0.00006789197,0.000027917815,0.0000036733845,0.000038233113,0.000011662932,0.00025235565,0.9973482,0.00016098737,0.000028320539,0.0019805853],"study_design_scores_gemma":[0.000038482085,0.00054903014,0.00052028074,0.000006521619,0.000026850406,0.00049369544,0.000021216894,0.0021830758,0.99065965,0.000074788026,0.0054196944,0.00000670967],"about_ca_topic_score_codex":0.00017257387,"about_ca_topic_score_gemma":0.00024762045,"teacher_disagreement_score":0.0010065823,"about_ca_system_score_codex":0.00020962191,"about_ca_system_score_gemma":0.00013012324,"threshold_uncertainty_score":0.0033673048},"labels":[],"label_agreement":null},{"id":"W4393015884","doi":"10.1002/ajh.27283","title":"Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor <scp>ECOG</scp> performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy","year":2024,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; bluebird bio; Pharmacyclics; Daiichi Sankyo Europe; Takeda Oncology; AstraZeneca; Genentech; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Seagen; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; GlaxoSmithKline; Kiadis Pharma; Sanofi; TG Therapeutics; Medac; Ipsen; Jazz Pharmaceuticals; Boston Scientific Corporation; StemCyte; U.S. Navy; Legend Biotech; HistoGenetics; Omeros Corporation; Vertex Pharmaceuticals; Leukemia and Lymphoma Society; U.S. Department of Defense; Celgene; CSL Behring; Bristol-Myers Squibb; Amgen; National Heart, Lung, and Blood Institute; Ascentage Pharma; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Mallinckrodt Pharmaceuticals; Society for Immunotherapy of Cancer; Astellas Pharma US; Atara Biotherapeutics; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Hazard ratio; Refractory (planetary science); Propensity score matching; Lymphoma; Regimen; Salvage therapy; Gastroenterology; Surgery; Oncology; Chemotherapy; Confidence interval; Rituximab","score_opus":0.010061085264894416,"score_gpt":0.2739395781119439,"score_spread":0.2638784928470495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393015884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983767,0.0012098256,0.00003503976,0.000052707117,0.000015039459,0.000011638751,0.0000445333,0.0000027271913,0.0002516658],"genre_scores_gemma":[0.99943846,0.00024619812,0.000038417882,0.000056993544,0.00003201606,0.000008350042,0.000086693035,6.056439e-7,0.00009226506],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99972135,0.00015326813,0.000021024935,0.000041398085,0.0000227445,0.000040187893],"domain_scores_gemma":[0.9994313,0.00016980576,0.00020332338,0.000026938447,0.000013550709,0.0001549809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077444763,0.00016250274,0.00046734075,0.00019390044,0.000101167454,0.0003210773,0.00014261137,0.00022273045,0.0008779308],"category_scores_gemma":[0.0011335582,0.000093854214,0.00052885123,0.00017781007,0.00015904075,0.00028012122,0.00021682028,0.00037122742,0.00007997994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42698866,0.0043175444,0.40732953,0.00043865212,0.0025597909,0.00038099347,0.00014938983,0.0021395453,0.009910084,0.00022849995,0.0010404895,0.14451672],"study_design_scores_gemma":[0.029089885,0.13471445,0.8225567,0.00008068407,0.002714337,0.0006774701,0.00018275931,0.0044984235,0.0022657744,0.00025571455,0.0029305671,0.00003326238],"about_ca_topic_score_codex":0.000449275,"about_ca_topic_score_gemma":0.0014352738,"teacher_disagreement_score":0.0008779308,"about_ca_system_score_codex":0.00032058454,"about_ca_system_score_gemma":0.00023597355,"threshold_uncertainty_score":0.0040956736},"labels":[],"label_agreement":null},{"id":"W4393032832","doi":"10.1073/pnas.2319856121","title":"IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation","year":2024,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"Molecular biology; T cell; mCherry; Biology; CD8; Messenger RNA; In vitro; Cell biology; Immune system; Green fluorescent protein; Immunology; Biochemistry","score_opus":0.024774281273011643,"score_gpt":0.30096348590813754,"score_spread":0.2761892046351259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393032832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905552,0.0021612728,0.0043164613,0.00018141075,0.00008841456,0.000057152603,0.0002790805,0.0001593783,0.0022014915],"genre_scores_gemma":[0.98822194,0.0014359213,0.0054739793,0.00017491968,0.000046902423,0.00013220968,0.00081101636,0.0000709266,0.0036322158],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996773,0.00007023123,0.00003428972,0.000050870072,0.00007788077,0.00008937423],"domain_scores_gemma":[0.9998084,0.0000664961,0.000039233077,0.000013494965,0.000033586868,0.00003882691],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026480784,0.0005723071,0.00039865653,0.0003738227,0.00015776251,0.00039441316,0.00017360969,0.00054806774,0.001501451],"category_scores_gemma":[0.00017709298,0.00017030949,0.00044839294,0.00019417278,0.00025006203,0.00023882822,0.00022428461,0.0010372516,0.0006381682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000108701264,0.000040537005,0.000036493166,0.000036309943,0.0000032185749,0.000018011531,0.000013708006,0.00006919364,0.99910045,0.000028165225,0.00002533576,0.00051986874],"study_design_scores_gemma":[0.00002225593,0.0004731442,0.0004601873,0.0000062612685,0.000014971879,0.000028988392,0.000016420405,0.0007897828,0.99752265,0.000020819487,0.00064191927,0.0000026619043],"about_ca_topic_score_codex":0.00042984867,"about_ca_topic_score_gemma":0.0006378256,"teacher_disagreement_score":0.001501451,"about_ca_system_score_codex":0.00038379963,"about_ca_system_score_gemma":0.00024340267,"threshold_uncertainty_score":0.005022824},"labels":[],"label_agreement":null},{"id":"W4393084941","doi":"10.1158/1538-7445.am2024-6716","title":"Abstract 6716: DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancers","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Cancer research; Medicine; Cell; Cancer; Internal medicine; Biology","score_opus":0.29885606712149465,"score_gpt":0.4732763836450434,"score_spread":0.17442031652354872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393084941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95700353,0.005635891,0.02364799,0.00060331007,0.00017164712,0.00018512247,0.00091312453,0.00059846434,0.011240937],"genre_scores_gemma":[0.97966856,0.0017383379,0.009687583,0.00032640854,0.000023930883,0.00012396267,0.000700894,0.00005584612,0.0076745898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999188,0.000009641223,0.000004738393,0.000014161887,0.000027821021,0.000024793282],"domain_scores_gemma":[0.99997294,0.0000020783918,0.0000075756193,0.0000019420208,0.0000053374283,0.000010095986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009624392,0.00029452718,0.00013601247,0.0001459583,0.00008102556,0.00021080866,0.00023774178,0.00032034592,0.0022386527],"category_scores_gemma":[0.000055442488,0.000086611,0.00019244976,0.00010262815,0.00009654837,0.000147686,0.00026268876,0.00046714875,0.00091416715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013648899,0.000064515516,0.00018268636,0.00006296389,0.0000104886485,0.00007286907,0.000015617163,0.0005188555,0.99104214,0.00026801293,0.00071813096,0.0069072684],"study_design_scores_gemma":[0.00004932347,0.00066873635,0.00083537184,0.000008797888,0.00002254219,0.00042281888,0.00001764078,0.0033388098,0.9812851,0.0000820477,0.013259045,0.000009694359],"about_ca_topic_score_codex":0.000439806,"about_ca_topic_score_gemma":0.00059359585,"teacher_disagreement_score":0.0022386527,"about_ca_system_score_codex":0.00031217028,"about_ca_system_score_gemma":0.00019750961,"threshold_uncertainty_score":0.007489085},"labels":[],"label_agreement":null},{"id":"W4393087951","doi":"10.1158/1538-7445.am2024-6325","title":"Abstract 6325: Lineage tracing defines responding CAR T cells in patients with B cell malignancies","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Lineage (genetic); Cell lineage; Cancer research; Biology; Medicine; Genetics; Gene; Cellular differentiation","score_opus":0.06131275062229219,"score_gpt":0.3844948816443257,"score_spread":0.3231821310220335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393087951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556893,0.0006435557,0.0015755387,0.000046610978,0.0000049699743,0.00002436012,0.00089022773,0.00006784956,0.0011780645],"genre_scores_gemma":[0.99598783,0.00018960352,0.0015432582,0.00009966214,0.0000061583405,0.000042146876,0.0014931319,0.00002922008,0.0006089689],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998559,0.000022885099,0.000009138022,0.00004750168,0.000036421563,0.000028108354],"domain_scores_gemma":[0.9998907,0.000030960517,0.000027279726,0.000012678836,0.000020247318,0.000018109675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021939812,0.00010005771,0.00018474033,0.00044532324,0.00017609766,0.00043997314,0.00014842875,0.00026554937,0.0024402693],"category_scores_gemma":[0.00035339044,0.000108766566,0.00009845909,0.0003398646,0.000121735706,0.0001642791,0.00016315343,0.0002990738,0.000836211],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028486317,0.00015303626,0.37387672,0.00013268874,0.000049392722,0.0006158874,0.00059315684,0.0010723111,0.54621696,0.00029560464,0.0020092567,0.07213642],"study_design_scores_gemma":[0.00010255749,0.0017234584,0.8233186,0.00005586013,0.00011810183,0.004351491,0.00064209633,0.006114082,0.14584799,0.000552631,0.017149907,0.000023195471],"about_ca_topic_score_codex":0.0009402018,"about_ca_topic_score_gemma":0.0012011669,"teacher_disagreement_score":0.0024402693,"about_ca_system_score_codex":0.00021560625,"about_ca_system_score_gemma":0.00015111886,"threshold_uncertainty_score":0.008163512},"labels":[],"label_agreement":null},{"id":"W4393093070","doi":"10.1158/1538-7445.am2024-6740","title":"Abstract 6740: Next-generation LNPs induce effective anti-tumor T cell responses","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Pacific Railway (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer research; Biology","score_opus":0.18236883560364034,"score_gpt":0.46299014508014313,"score_spread":0.28062130947650277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093070","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980292,0.0012910694,0.01189119,0.00021994999,0.00008609021,0.00010187513,0.00044766575,0.0002647553,0.0054052817],"genre_scores_gemma":[0.98231506,0.00071897684,0.0078070103,0.00015790196,0.000023074846,0.0000744689,0.00047769697,0.000043106615,0.0083828475],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999287,0.000008219083,0.0000042458246,0.000013585888,0.000024562818,0.00002058359],"domain_scores_gemma":[0.99996805,0.0000055625414,0.000007454862,0.000002688674,0.000007894099,0.0000082629795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008272901,0.0002577866,0.00012502287,0.000102897335,0.00006232632,0.00020631975,0.000091395465,0.00029467154,0.0024551186],"category_scores_gemma":[0.000067261426,0.00006233262,0.0001237463,0.0000588658,0.00010095863,0.00012229232,0.00014908818,0.0004941572,0.00076151884],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003694617,0.00002317659,0.000043108972,0.000023668399,0.0000016826383,0.000022780354,0.0000070858882,0.00009305421,0.99816054,0.000068956164,0.00009255734,0.0014265456],"study_design_scores_gemma":[0.000017444132,0.00041075543,0.00047740163,0.0000049751725,0.000007895116,0.00009213629,0.00000884653,0.00069049455,0.9942825,0.0000368403,0.0039682356,0.000002410358],"about_ca_topic_score_codex":0.00021293567,"about_ca_topic_score_gemma":0.0002957794,"teacher_disagreement_score":0.0024551186,"about_ca_system_score_codex":0.00019375925,"about_ca_system_score_gemma":0.00012923293,"threshold_uncertainty_score":0.008213162},"labels":[],"label_agreement":null},{"id":"W4393093578","doi":"10.1158/1538-7445.am2024-1868","title":"Abstract 1868: Target-dependent considerations for the design of bispecific T-cell engagers","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Bispecific antibody; Computer science; Medicine; Human–computer interaction; Immunology; Antibody","score_opus":0.27608712638577726,"score_gpt":0.4572063767417708,"score_spread":0.18111925035599352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093578","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9219668,0.003008712,0.06624759,0.00054780254,0.00006736862,0.00017003648,0.00041475226,0.00028675701,0.007290241],"genre_scores_gemma":[0.9696704,0.0011463834,0.02490451,0.00023601162,0.000023067934,0.00012769677,0.00044089454,0.000057031815,0.0033940005],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997167,0.000058215708,0.000024985002,0.00004115996,0.00011283418,0.00004596891],"domain_scores_gemma":[0.99981207,0.000067938105,0.000034570206,0.000021305988,0.00004446389,0.000019741008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044877824,0.00031769348,0.00023708127,0.00018128235,0.00012984015,0.0004657111,0.0003372694,0.0003768724,0.0018745674],"category_scores_gemma":[0.00057656446,0.00010639244,0.00015497718,0.00017864651,0.00021652877,0.00048571342,0.000279485,0.00084434066,0.00061829074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015830499,0.00008603512,0.000384348,0.00009474402,0.000012219819,0.000055852983,0.000043465963,0.0018815909,0.98671573,0.00075784774,0.00021134998,0.009598488],"study_design_scores_gemma":[0.00002011896,0.00041724087,0.0007767662,0.0000052317087,0.000015543525,0.0001730161,0.000016716625,0.0037887786,0.98897076,0.00031867356,0.0054894392,0.000007620916],"about_ca_topic_score_codex":0.00021431317,"about_ca_topic_score_gemma":0.00042738917,"teacher_disagreement_score":0.0018745674,"about_ca_system_score_codex":0.00030961592,"about_ca_system_score_gemma":0.00012706872,"threshold_uncertainty_score":0.0062710643},"labels":[],"label_agreement":null},{"id":"W4393096401","doi":"10.1158/1538-7445.am2024-2373","title":"Abstract 2373: Functional and specific T-cell engagers against a peptide-MHC tumor target","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Major histocompatibility complex; Biology; Computer science; Psychology; Computational biology; Medicine; Antigen; Immunology","score_opus":0.106342958946202,"score_gpt":0.3899743948057807,"score_spread":0.28363143585957873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393096401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98782015,0.0008005345,0.006930947,0.00008725041,0.000028851071,0.00007595202,0.00048714216,0.00012668748,0.003642465],"genre_scores_gemma":[0.988461,0.0003183742,0.0060235667,0.000070257935,0.000014297171,0.00006638706,0.00089596474,0.000035737048,0.004114453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979895,0.000028102007,0.000015933882,0.000029119537,0.00006829078,0.000059623668],"domain_scores_gemma":[0.99993455,0.000014153346,0.0000125052175,0.000008516294,0.000011651011,0.000018587285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001694778,0.00036336746,0.00021288045,0.0001400377,0.00011591791,0.0003784717,0.00024144082,0.00028087298,0.002823684],"category_scores_gemma":[0.00017087538,0.00009805208,0.0001951673,0.00013916114,0.00013162513,0.00020368355,0.00023132774,0.0005146234,0.001045115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000070281116,0.00003599076,0.0001604874,0.000023672208,0.000004074588,0.000045539127,0.000009169442,0.0002485284,0.99719644,0.00010514517,0.00011537876,0.001985296],"study_design_scores_gemma":[0.000016049558,0.00030430188,0.0010429593,0.000003945601,0.000008637905,0.00028602878,0.0000153467,0.0014853816,0.9936498,0.000055039323,0.0031279204,0.0000046438963],"about_ca_topic_score_codex":0.0002639863,"about_ca_topic_score_gemma":0.0003244863,"teacher_disagreement_score":0.002823684,"about_ca_system_score_codex":0.00029165854,"about_ca_system_score_gemma":0.00018340925,"threshold_uncertainty_score":0.009446144},"labels":[],"label_agreement":null},{"id":"W4393096561","doi":"10.1158/1538-7445.am2024-6719","title":"Abstract 6719: TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"CD28; Cancer research; T cell; Medicine; Immune system; Immunology","score_opus":0.17556246383653798,"score_gpt":0.43762412715906307,"score_spread":0.2620616633225251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393096561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96252614,0.0016212635,0.025765521,0.00022548642,0.00008610428,0.00017683464,0.0011675953,0.00047292616,0.007958117],"genre_scores_gemma":[0.9609774,0.00095406815,0.025413765,0.00021062339,0.00002080319,0.00019037857,0.0017582969,0.00010098749,0.010373577],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985623,0.000017130154,0.000010067542,0.000028968525,0.000053411666,0.00003424148],"domain_scores_gemma":[0.999951,0.000005174609,0.000016776323,0.0000037081704,0.000010412067,0.000012883872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014159566,0.00039608325,0.00015357981,0.00020807664,0.00010532296,0.00024891217,0.0002632456,0.0003357364,0.002882728],"category_scores_gemma":[0.000083566454,0.00012714726,0.00015509443,0.00014987556,0.00011760254,0.00021809645,0.00022558535,0.00046898387,0.00096408866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005017144,0.000032205866,0.0001015949,0.00002994517,0.0000043115224,0.00003037992,0.000009339143,0.0002645513,0.99683785,0.00022810117,0.00024837386,0.0021631804],"study_design_scores_gemma":[0.0000097860175,0.00022171065,0.0003096139,0.0000022961444,0.0000070875717,0.00011229997,0.000006370416,0.0012667684,0.994549,0.00002091791,0.0034899598,0.000004112846],"about_ca_topic_score_codex":0.00031464186,"about_ca_topic_score_gemma":0.00053360104,"teacher_disagreement_score":0.002882728,"about_ca_system_score_codex":0.0002777451,"about_ca_system_score_gemma":0.0001837823,"threshold_uncertainty_score":0.009643674},"labels":[],"label_agreement":null},{"id":"W4393096802","doi":"10.1158/1538-7445.am2024-5241","title":"Abstract 5241: Generation of allogeneic CAR-T circumvents functional deficits in patient-derived autologous product for glioblastoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Glioblastoma; Medicine; Product (mathematics); Cancer research; Mathematics","score_opus":0.13576936141394785,"score_gpt":0.4057190539522579,"score_spread":0.26994969253831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393096802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941462,0.0005082824,0.0034053302,0.00006556082,0.000030142894,0.00007684128,0.00050291605,0.00008169453,0.0011830104],"genre_scores_gemma":[0.9943857,0.00028536268,0.0016226792,0.000051261664,0.000007025075,0.000060887676,0.0013515584,0.000022709097,0.0022127884],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998815,0.00002033553,0.000012862131,0.000024496276,0.00003351624,0.00002726442],"domain_scores_gemma":[0.9999523,0.000007241626,0.000012679256,0.000007671862,0.000008690564,0.000011460456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001352671,0.0002597673,0.00020220153,0.00012840367,0.000093045,0.00031406197,0.00016110984,0.00027877232,0.0029444278],"category_scores_gemma":[0.000118092605,0.000071721224,0.00018692011,0.00012295741,0.00012418616,0.00011253664,0.00015563397,0.0005230418,0.0006155581],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002146768,0.000120627716,0.00026937213,0.000047248086,0.000007896626,0.00008487195,0.000022267031,0.00016737361,0.9955771,0.00018046543,0.00018568969,0.0031223854],"study_design_scores_gemma":[0.000049922546,0.0015275242,0.002407086,0.000008457733,0.000036878217,0.00075538835,0.000024423667,0.0009662581,0.98846287,0.000050443286,0.0057061887,0.000004518299],"about_ca_topic_score_codex":0.00028694983,"about_ca_topic_score_gemma":0.0002221203,"teacher_disagreement_score":0.0029444278,"about_ca_system_score_codex":0.00014149187,"about_ca_system_score_gemma":0.00020371094,"threshold_uncertainty_score":0.009850144},"labels":[],"label_agreement":null},{"id":"W4393101183","doi":"10.1158/1538-7445.am2024-6333","title":"Abstract 6333: A high-parameter mass cytometry panel for the functional characterization of CAR T cells","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Integrity Testing Laboratory (Canada)","funders":"","keywords":"TIGIT; Mass cytometry; Flow cytometry; Granzyme B; Cytokine; T cell; Immune system; Cancer research; Immunology; Tumor microenvironment; Cell therapy; Biology; Cell biology; Stem cell; Phenotype","score_opus":0.15866238021223067,"score_gpt":0.41540188587425836,"score_spread":0.2567395056620277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393101183","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19629031,0.002641301,0.7471467,0.00087741396,0.00016319027,0.002339235,0.008047765,0.011823599,0.03067052],"genre_scores_gemma":[0.44175664,0.0029386396,0.48607892,0.0010852227,0.00022304838,0.004889206,0.03109788,0.001881522,0.03004891],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875426,0.00025789064,0.00012708668,0.00018809078,0.00052284024,0.00014992389],"domain_scores_gemma":[0.99919695,0.00020847462,0.00008196249,0.000092317394,0.00033163137,0.00008872153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014251466,0.0017143559,0.000455579,0.002865872,0.00057597016,0.0007571161,0.00070186803,0.0010640819,0.018216297],"category_scores_gemma":[0.0010820723,0.00055551145,0.00057209574,0.0009627467,0.00036035432,0.00063997257,0.00065608794,0.0012390799,0.009678837],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001263615,0.00006390438,0.00051886484,0.000057913785,0.000010509694,0.00005450587,0.000038994658,0.00036240986,0.9807972,0.0006863862,0.0023647142,0.014918226],"study_design_scores_gemma":[0.00009431245,0.00044290218,0.00562088,0.000046773835,0.000056005676,0.0009520484,0.000027988355,0.011471308,0.9443217,0.0008542375,0.036068786,0.000042901993],"about_ca_topic_score_codex":0.0003937696,"about_ca_topic_score_gemma":0.00061985257,"teacher_disagreement_score":0.018216297,"about_ca_system_score_codex":0.000424044,"about_ca_system_score_gemma":0.0005877816,"threshold_uncertainty_score":0.06093955},"labels":[],"label_agreement":null},{"id":"W4393127926","doi":"10.1101/2024.03.21.586084","title":"Endogenous CD28 drives CAR T cell responses in multiple myeloma","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Endogeny; Multiple myeloma; Medicine; Immunology; Internal medicine","score_opus":0.03729499252346495,"score_gpt":0.26746490758465735,"score_spread":0.2301699150611924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393127926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910642,0.0011509334,0.004740882,0.00016038057,0.00004462843,0.00007230836,0.00039578832,0.00022320705,0.0021476303],"genre_scores_gemma":[0.9959566,0.00027802118,0.0016995233,0.000047298836,0.000011898043,0.000056915742,0.00023645043,0.0000235365,0.0016897263],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996209,0.000063333704,0.00002491026,0.000092814116,0.000098319615,0.00009971014],"domain_scores_gemma":[0.99989283,0.00002468082,0.000018048782,0.000017228773,0.000012987347,0.000034235185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030765007,0.00029286728,0.00030618793,0.00028248454,0.00019749472,0.00036871494,0.00021565416,0.00037351833,0.0022862374],"category_scores_gemma":[0.0001653274,0.00019721304,0.00021537079,0.00014379046,0.000248025,0.00016835102,0.0003497224,0.0014607761,0.00073276553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011702447,0.000082093386,0.00011257783,0.000024861709,0.0000027120168,0.000029253355,0.000014689226,0.00019696861,0.9979982,0.00014736167,0.00010041529,0.0011737514],"study_design_scores_gemma":[0.0000640197,0.0006815642,0.0013837267,0.0000055331434,0.000009466801,0.0001760998,0.0000288832,0.003895458,0.99105763,0.000115542054,0.002578093,0.0000039296265],"about_ca_topic_score_codex":0.0006222756,"about_ca_topic_score_gemma":0.0008822957,"teacher_disagreement_score":0.0022862374,"about_ca_system_score_codex":0.0005626906,"about_ca_system_score_gemma":0.00030117345,"threshold_uncertainty_score":0.00764817},"labels":[],"label_agreement":null},{"id":"W4393188520","doi":"10.1038/s41587-024-02205-3","title":"Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","year":2024,"lang":"en","type":"erratum","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Immunotherapy; Major histocompatibility complex; T cell; Immunology; Cancer research; Computational biology; Medicine; Biology; Immune system","score_opus":0.015405665824249445,"score_gpt":0.3433121987524451,"score_spread":0.32790653292819566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393188520","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000101558035,0.0006053805,0.00049527,0.03319238,0.96377057,0.000010535352,0.0002262254,0.00014746789,0.0014505963],"genre_scores_gemma":[0.017186586,0.01026364,0.006698414,0.12670086,0.5081332,0.00020368672,0.001454732,0.0016552588,0.32770365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960239,0.0005251448,0.00053814397,0.0005212128,0.002051018,0.00034053827],"domain_scores_gemma":[0.9790259,0.0062181866,0.00097368343,0.0011158551,0.011490747,0.0011756422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003755708,0.002015536,0.0016841159,0.002847091,0.0030721508,0.003007614,0.0032321173,0.008218627,0.028569829],"category_scores_gemma":[0.037494127,0.0010706547,0.0016365672,0.0012479953,0.0021930044,0.0016576082,0.0016821577,0.012010853,0.019685209],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031780215,0.0000065439735,0.000039890412,0.00008211619,0.000010736298,0.0005241664,0.000019923089,0.000036306854,0.000095087635,0.00058122055,0.99381846,0.0047537587],"study_design_scores_gemma":[0.000039983122,0.000019494153,0.00026153377,0.00015078325,0.00004735894,0.0010384799,0.000046641828,0.00020586287,0.00078707346,0.0010380951,0.9963372,0.000027459328],"about_ca_topic_score_codex":0.009191783,"about_ca_topic_score_gemma":0.011699222,"teacher_disagreement_score":0.028569829,"about_ca_system_score_codex":0.0034383407,"about_ca_system_score_gemma":0.004107964,"threshold_uncertainty_score":0.09557557},"labels":[],"label_agreement":null},{"id":"W4393191154","doi":"10.1007/978-3-031-50399-3_6","title":"The Future of Cell Replacement Therapies","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.021814994944936203,"score_gpt":0.29582436123499994,"score_spread":0.2740093662900637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393191154","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009822099,0.5488944,0.0098164575,0.016345436,0.007886579,0.000040828814,0.00011494313,0.00018228986,0.41573685],"genre_scores_gemma":[0.011523001,0.40846825,0.010438441,0.011038961,0.004612498,0.000109663524,0.00017720033,0.000117368036,0.55351466],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976736,0.000053831136,0.000006044094,0.000021237585,0.00012812803,0.000023324212],"domain_scores_gemma":[0.9997842,0.0001343113,0.0000075055914,0.000012022943,0.00003991829,0.00002204569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005586045,0.0005129363,0.00053719804,0.0006721997,0.00042021216,0.0024553465,0.00076426065,0.0015015161,0.03006933],"category_scores_gemma":[0.00051943754,0.0002122736,0.00031686013,0.0004879869,0.0011231434,0.0025097271,0.000937383,0.002960393,0.012088757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005539735,0.00008045215,0.000060783048,0.0008241341,0.000010445817,0.0001437649,0.00024036206,0.0006843795,0.0040250057,0.2619901,0.29268026,0.4392049],"study_design_scores_gemma":[0.000003895906,0.000010667654,0.000026567152,0.00016316235,0.0000019631664,0.00011487867,0.00003225912,0.00012016321,0.00018852457,0.023100022,0.9762347,0.0000033314332],"about_ca_topic_score_codex":0.0007007449,"about_ca_topic_score_gemma":0.0015214412,"teacher_disagreement_score":0.03006933,"about_ca_system_score_codex":0.0011113177,"about_ca_system_score_gemma":0.00088256015,"threshold_uncertainty_score":0.1005919},"labels":[],"label_agreement":null},{"id":"W4393252428","doi":"10.1200/jco.23.02329","title":"Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Refractory (planetary science); Clinical endpoint; Internal medicine; Phases of clinical research; Clinical trial; Lymphoma; Non-Hodgkin's lymphoma; Oncology","score_opus":0.08335546380125415,"score_gpt":0.4715924011792489,"score_spread":0.38823693737799475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393252428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98434675,0.011424763,0.0011976601,0.00018137877,0.000056010795,0.0003324011,0.00092808955,0.00004682636,0.0014861738],"genre_scores_gemma":[0.9957819,0.0012882618,0.00047206436,0.0002599331,0.00008839654,0.00014550502,0.0014736931,0.000012519015,0.0004778298],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99736315,0.0012698823,0.00028131847,0.00034048792,0.00042644684,0.00031866343],"domain_scores_gemma":[0.9923252,0.0023528687,0.0025397053,0.0012475143,0.00060542865,0.00092938775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013049747,0.00046993748,0.0015797729,0.00057206274,0.00039551672,0.0014366722,0.00045348948,0.00062479294,0.0012009884],"category_scores_gemma":[0.0047003636,0.00022934352,0.0020038206,0.00066171546,0.00045048475,0.001131972,0.00048199922,0.0017151909,0.0003060379],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20172894,0.005376478,0.34609082,0.0019376738,0.01336483,0.00079120055,0.0008440052,0.0034621656,0.035853792,0.0003715038,0.00347778,0.3867008],"study_design_scores_gemma":[0.0148067875,0.14389148,0.8039322,0.00047368187,0.010162799,0.0015604981,0.0002832838,0.00314222,0.008787976,0.0005548083,0.012317739,0.000086600514],"about_ca_topic_score_codex":0.0003637962,"about_ca_topic_score_gemma":0.0008520985,"teacher_disagreement_score":0.013049747,"about_ca_system_score_codex":0.0007580352,"about_ca_system_score_gemma":0.0005990275,"threshold_uncertainty_score":0.06901449},"labels":[],"label_agreement":null},{"id":"W4393257495","doi":"10.3138/cim-2024-2657","title":"A Discussion with Dr. Natasha Kekre, Hematologist and Clinician Scientist","year":2024,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Western University","funders":"","keywords":"Bachelor; Hematologist; Medicine; Transplantation; Family medicine; Medical education; Internal medicine; Political science; Disease","score_opus":0.20757116031735892,"score_gpt":0.44078909034199887,"score_spread":0.23321793002463995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393257495","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014201777,0.0025714675,0.0006422014,0.8915567,0.09827085,0.000057109857,0.000097467215,0.000088134184,0.0065740794],"genre_scores_gemma":[0.0031793204,0.0047892374,0.0011566574,0.87406147,0.061488762,0.00013195325,0.00017179613,0.00011941157,0.05490144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963098,0.001145726,0.00029180548,0.0005872296,0.0011773676,0.00048800884],"domain_scores_gemma":[0.9798743,0.0064371694,0.00070974603,0.000515755,0.005898176,0.006564782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006274087,0.00094819797,0.0007366335,0.0010236055,0.0049166116,0.00478912,0.0022634454,0.015848387,0.060458142],"category_scores_gemma":[0.03659278,0.0005987019,0.0014779284,0.0007176217,0.0022767305,0.0052395076,0.002666479,0.02251662,0.032663506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000073582764,0.0000043607365,0.000060727267,0.000025811843,0.0000017942602,0.00012574298,0.000036292182,0.00001098338,0.000024285844,0.0005972734,0.9953695,0.0037357546],"study_design_scores_gemma":[0.000021292564,0.000013243745,0.00014212605,0.00014005169,0.0000060089947,0.0008568924,0.00020387664,0.000042476167,0.00007084679,0.0010369866,0.9974522,0.000014071902],"about_ca_topic_score_codex":0.0063388795,"about_ca_topic_score_gemma":0.013867972,"teacher_disagreement_score":0.060458142,"about_ca_system_score_codex":0.0052306848,"about_ca_system_score_gemma":0.009669773,"threshold_uncertainty_score":0.20225263},"labels":[],"label_agreement":null},{"id":"W4393280322","doi":"10.1182/bloodadvances.2023011739","title":"Double-negative T cells utilize a TNFα–JAK1–ICAM-1 cytotoxic axis against acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Cytotoxic T cell; Cytotoxicity; Cancer research; Leukemia; Flow cytometry; Tumor necrosis factor alpha; Immunology; Medicine; Chemistry; In vitro; Biochemistry","score_opus":0.022102472702105164,"score_gpt":0.32007254931942475,"score_spread":0.29797007661731956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393280322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947744,0.00090209366,0.002377308,0.00006170864,0.000027790189,0.00006330011,0.00019496358,0.00008083393,0.0015176606],"genre_scores_gemma":[0.9973857,0.0002777645,0.0011820792,0.00003519095,0.00001002569,0.000029700606,0.00020158254,0.000004529525,0.0008735703],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982375,0.000024684057,0.000014897916,0.000042402262,0.000049354767,0.000044975845],"domain_scores_gemma":[0.99994457,0.000007974924,0.000015299864,0.00000830288,0.000006790652,0.000017157976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013560377,0.00039195226,0.00028162403,0.00021574854,0.00014071098,0.00046708866,0.00014983625,0.00021198175,0.0014854973],"category_scores_gemma":[0.00009704709,0.000083277686,0.00014819554,0.00012680098,0.00015881071,0.00021768261,0.00016722677,0.00054184085,0.00038378887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002649055,0.00013660561,0.0007622101,0.00003992178,0.0000065057743,0.000043017706,0.000013159545,0.0001372423,0.9944225,0.00017080359,0.000084999796,0.0039180773],"study_design_scores_gemma":[0.00012758649,0.0018955687,0.0055274363,0.000011271323,0.000038838498,0.0007202202,0.000038323982,0.0026480972,0.98486346,0.00015191233,0.003972163,0.000005006225],"about_ca_topic_score_codex":0.00008570544,"about_ca_topic_score_gemma":0.00019386884,"teacher_disagreement_score":0.0014854973,"about_ca_system_score_codex":0.00018429612,"about_ca_system_score_gemma":0.00013756567,"threshold_uncertainty_score":0.0049694777},"labels":[],"label_agreement":null},{"id":"W4393315734","doi":"10.1111/ejh.14208","title":"Ocular adverse events following <scp>CAR‐T</scp> cell therapy: A pharmacovigilance study and systematic review","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacovigilance; Adverse effect; Medicine; Pharmacology; Intensive care medicine","score_opus":0.02932337168247901,"score_gpt":0.3358748212748156,"score_spread":0.3065514495923366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393315734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00806723,0.98859507,0.00024846045,0.00033417082,0.000060409468,0.00042023716,0.0017621063,0.0000094933475,0.0005027564],"genre_scores_gemma":[0.09056467,0.9048694,0.00094929023,0.0012184298,0.00013703767,0.0007732375,0.0012575313,0.0000106521,0.00021985648],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.992668,0.0019479638,0.0033400597,0.00058781076,0.0012696021,0.00018661754],"domain_scores_gemma":[0.9652736,0.021105625,0.009891944,0.0005568529,0.0028887661,0.0002831342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006540024,0.0006887439,0.0035958316,0.0080104405,0.00036682692,0.0014680666,0.00076638954,0.0011213943,0.002582638],"category_scores_gemma":[0.025408056,0.00044277462,0.006903302,0.007743463,0.000533745,0.00114512,0.0010039911,0.0006559557,0.00020216279],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007587287,0.00004137125,0.011056649,0.90568125,0.024168408,0.00041575776,0.00029500102,0.00015319769,0.0004576003,0.00024210876,0.0023058718,0.0544242],"study_design_scores_gemma":[0.0007833819,0.00077483844,0.045323685,0.69219744,0.22612391,0.002690591,0.000609355,0.00028135153,0.0006266786,0.0006062776,0.029877296,0.00010516036],"about_ca_topic_score_codex":0.004350847,"about_ca_topic_score_gemma":0.013967816,"teacher_disagreement_score":0.0080104405,"about_ca_system_score_codex":0.0017866241,"about_ca_system_score_gemma":0.0052253925,"threshold_uncertainty_score":0.034587383},"labels":[],"label_agreement":null},{"id":"W4393408771","doi":"10.1016/j.jtha.2024.03.021","title":"A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","year":2024,"lang":"en","type":"review","venue":"Journal of Thrombosis and Haemostasis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Incyte; CSL Behring","keywords":"Medicine; Hemostasis; Internal medicine; Malignancy; Thrombosis; Venous thrombosis; Meta-analysis; Incidence (geometry); Chimeric antigen receptor; Gastroenterology; Cancer; Immunotherapy","score_opus":0.34785240354308167,"score_gpt":0.43787012693967725,"score_spread":0.09001772339659558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393408771","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008488163,0.98905444,0.00087138556,0.0003139643,0.00045494238,0.00008855887,0.00039157266,0.000034746034,0.00030222084],"genre_scores_gemma":[0.27370918,0.7182475,0.0025079446,0.002444638,0.00082738267,0.0002755354,0.00091563957,0.00005247353,0.0010197548],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99717367,0.0015778464,0.0004909032,0.00037751894,0.00023172023,0.00014828311],"domain_scores_gemma":[0.9949787,0.0038116954,0.0005786959,0.00021198978,0.00031682805,0.00010210304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00550626,0.0020986113,0.0103149675,0.0014449478,0.0002944362,0.0017844627,0.0012343135,0.0018796748,0.0035450025],"category_scores_gemma":[0.010113049,0.0008814491,0.024949612,0.0020582313,0.00031941425,0.00081518304,0.00082806376,0.0023410476,0.00039469128],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011656222,0.000048486643,0.0027775022,0.08646799,0.87480223,0.00016527908,0.000036142377,0.00068933563,0.0004943063,0.00015156536,0.0016079465,0.021103082],"study_design_scores_gemma":[0.0028586616,0.00040227448,0.0029359125,0.0038864412,0.98707306,0.00009235043,0.000019986359,0.00026600563,0.00010032588,0.0003012905,0.0020365266,0.000027178774],"about_ca_topic_score_codex":0.0045243367,"about_ca_topic_score_gemma":0.009840304,"teacher_disagreement_score":0.0103149675,"about_ca_system_score_codex":0.0010868716,"about_ca_system_score_gemma":0.001279422,"threshold_uncertainty_score":0.029120266},"labels":[],"label_agreement":null},{"id":"W4393771747","doi":"10.5281/zenodo.1154256","title":"Generation Of Fluorescently Labelled Op9 Stromal Cells For Growing Patient Leukemic Cells","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stromal cell; Cancer research; Cell biology; Chemistry; Biology","score_opus":0.0559423750143571,"score_gpt":0.27985903583277755,"score_spread":0.22391666081842043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393771747","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016194558,0.0007264635,0.0005428342,0.00012206458,0.000055522454,0.000057386904,0.9950051,0.001090318,0.0007809525],"genre_scores_gemma":[0.0012909013,0.00019249621,0.0009402046,0.00007988854,0.0000061387373,0.00018089211,0.99685717,0.00008362511,0.00036866672],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99862087,0.00023004894,0.0001752796,0.00046678726,0.00032339667,0.00018364536],"domain_scores_gemma":[0.9986179,0.0004626269,0.0001747095,0.0003710292,0.00023925751,0.00013443163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001761479,0.0028090365,0.0019221855,0.0030122946,0.00060117606,0.0021621594,0.003010286,0.0029902204,0.013205289],"category_scores_gemma":[0.004716686,0.00070938474,0.0018897598,0.003382886,0.00053806894,0.0006518551,0.001537915,0.0017911956,0.024112828],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010383836,0.0002245753,0.0055662305,0.005091621,0.00037565085,0.0002277497,0.00007363635,0.00501427,0.0041129463,0.0012269121,0.95798796,0.019060005],"study_design_scores_gemma":[0.0015026545,0.00018685746,0.007381224,0.0007086032,0.00040024897,0.00041670303,0.00008898125,0.004002799,0.008428806,0.0027821122,0.9740189,0.000082244296],"about_ca_topic_score_codex":0.009665596,"about_ca_topic_score_gemma":0.017731939,"teacher_disagreement_score":0.013205289,"about_ca_system_score_codex":0.0015623308,"about_ca_system_score_gemma":0.0020432286,"threshold_uncertainty_score":0.0441761},"labels":[],"label_agreement":null},{"id":"W4393859316","doi":"10.1101/2024.04.02.587705","title":"Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Oncolytic virus; Biology; Melanoma; Immune system; Immunotherapy; Cytotoxic T cell; Immunology; Cancer research; Immune checkpoint; Tumor microenvironment; Antigen; Virology; In vitro","score_opus":0.018991050941669464,"score_gpt":0.24440508383258935,"score_spread":0.22541403289091988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393859316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979255,0.00040286235,0.0008708966,0.00004944312,0.000030617008,0.000033897373,0.00011435455,0.0000470377,0.0005255042],"genre_scores_gemma":[0.9976058,0.00024480192,0.0008800091,0.00002003429,0.000011191267,0.000030393814,0.00013217387,0.000008346837,0.0010672057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998362,0.000035268935,0.000012023431,0.000032970147,0.000035480727,0.00004801083],"domain_scores_gemma":[0.99990916,0.000016125805,0.000022092774,0.000015943482,0.0000073849806,0.000029318846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001751572,0.00040224378,0.0003790021,0.00021836633,0.00013546097,0.0002657292,0.00025389748,0.00029642248,0.0008725683],"category_scores_gemma":[0.000083082006,0.00010308876,0.0002164359,0.000106919164,0.00023315118,0.00015717214,0.00015114826,0.0009306184,0.00021733234],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038180343,0.00018689885,0.00007646862,0.00002349538,0.0000043534965,0.000033778375,0.000020165968,0.00026928892,0.9978517,0.000073236304,0.000046818695,0.0010319037],"study_design_scores_gemma":[0.00009382181,0.0050942167,0.0018315497,0.0000065008458,0.000017894512,0.00022790514,0.00003225128,0.0040671653,0.9871256,0.00006949482,0.0014273438,0.0000063193465],"about_ca_topic_score_codex":0.0008295892,"about_ca_topic_score_gemma":0.00073901465,"teacher_disagreement_score":0.0008725683,"about_ca_system_score_codex":0.00024082306,"about_ca_system_score_gemma":0.00015515137,"threshold_uncertainty_score":0.0029190779},"labels":[],"label_agreement":null},{"id":"W4393859731","doi":"10.3390/curroncol31040143","title":"A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; St Mary's Hospital Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Personalized medicine; Precision medicine; Microbiome; Cancer; Bioinformatics; Cancer treatment; Computational biology; Immunotherapy; Internal medicine; Biology; Pathology","score_opus":0.32305359300402575,"score_gpt":0.5797166237464436,"score_spread":0.25666303074241786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393859731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038701146,0.9966317,0.000113177026,0.0015526812,0.00075783144,0.000006204805,0.000017800856,0.000006233142,0.0008757582],"genre_scores_gemma":[0.0002951543,0.9975097,0.00018900003,0.0010557577,0.00054531737,0.0000085525135,0.000021301064,0.0000022575384,0.00037294545],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993673,0.00019191242,0.00009967591,0.000082662445,0.00020850878,0.000049928505],"domain_scores_gemma":[0.9980558,0.0012437053,0.00017535123,0.00003239965,0.0003951801,0.00009759105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014599082,0.0007393816,0.0011473087,0.0026099405,0.00041026028,0.0015643239,0.0009843544,0.0018434541,0.0069145863],"category_scores_gemma":[0.0032736466,0.0002990376,0.00075689505,0.0030204467,0.00060937175,0.0020057906,0.00089593825,0.002564708,0.0023639447],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005739213,0.000041420477,0.00010329302,0.041681148,0.00009161857,0.00017079017,0.00016903495,0.0003628559,0.00048365424,0.00876867,0.118450396,0.82961977],"study_design_scores_gemma":[0.000009104986,0.000037575504,0.00023227825,0.013221993,0.00005751714,0.00045333355,0.00006773046,0.000044798835,0.0000562873,0.001692214,0.9841165,0.000010647813],"about_ca_topic_score_codex":0.0015417932,"about_ca_topic_score_gemma":0.0037612678,"teacher_disagreement_score":0.0069145863,"about_ca_system_score_codex":0.0016392074,"about_ca_system_score_gemma":0.0031180468,"threshold_uncertainty_score":0.023131609},"labels":[],"label_agreement":null},{"id":"W4393871903","doi":"10.1038/s41467-024-47012-1","title":"Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Spinal Cord Injury BC; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; WorldQuant Foundation; National Institute of Mental Health; Takeda Oncology; Weill Cornell Medical College; National Institutes of Health; BC Cancer Foundation; Leukemia and Lymphoma Society; Michael Smith Health Research BC; Wilhelm Sander-Stiftung; Deutsche Forschungsgemeinschaft; Else Kröner-Fresenius-Stiftung","keywords":"Biology; Epigenetics; Chromatin; Immune system; Germinal center; Enhancer; Epigenome; B cell; Cancer research; Phenotype; Transcription factor; Genetics; Cell biology; Gene; DNA methylation; Gene expression","score_opus":0.026768234445647573,"score_gpt":0.3250207970556583,"score_spread":0.2982525626100107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393871903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356586,0.00067553634,0.003529105,0.00008921243,0.000033340446,0.000021168622,0.00044800833,0.00021605733,0.0014217487],"genre_scores_gemma":[0.9962709,0.00015235275,0.0011446552,0.000027379345,0.0000072586104,0.000020778238,0.00026411653,0.00004799257,0.0020645957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997836,0.000030420626,0.00001938431,0.000045693603,0.00006380229,0.000057138957],"domain_scores_gemma":[0.9998222,0.000020366346,0.00004944826,0.000025139248,0.000008429496,0.000074369294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001141976,0.00044403865,0.00021490187,0.0003529364,0.00012630898,0.00025917531,0.00029873496,0.00031623305,0.002503418],"category_scores_gemma":[0.00010619367,0.00018705151,0.00020595065,0.00012723252,0.00039207074,0.00014062031,0.00039525292,0.00048085197,0.0005584762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005805784,0.000011222625,0.00016134209,0.000012635964,0.0000026150917,0.000040929437,0.0000032487262,0.000034653676,0.99920076,0.000044563934,0.00001709587,0.00041295483],"study_design_scores_gemma":[0.000018373663,0.00013256214,0.0030644378,0.0000031845404,0.000010620148,0.0005006089,0.000018761173,0.00063363207,0.9941552,0.000033828874,0.0014259476,0.0000027757626],"about_ca_topic_score_codex":0.0004691017,"about_ca_topic_score_gemma":0.0009037477,"teacher_disagreement_score":0.002503418,"about_ca_system_score_codex":0.00026087897,"about_ca_system_score_gemma":0.00017722914,"threshold_uncertainty_score":0.00837481},"labels":[],"label_agreement":null},{"id":"W4393983153","doi":"10.1158/1538-7445.am2024-ct081","title":"Abstract CT081: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Phase (matter); Oncology; Internal medicine; Claudin; Phases of clinical research; Cancer research; Toxicity; Chemistry; Tight junction","score_opus":0.09422062859099477,"score_gpt":0.4516854115260862,"score_spread":0.35746478293509143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393983153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844023,0.0011012938,0.00096656836,0.0005952612,0.0001397288,0.0063286927,0.0033841587,0.00023831065,0.0028435886],"genre_scores_gemma":[0.9733093,0.001042558,0.0027761895,0.0013654736,0.0002233151,0.008118269,0.005561083,0.0000749618,0.007528764],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995228,0.00021547501,0.000022799155,0.00008551164,0.00005267104,0.00010085423],"domain_scores_gemma":[0.999033,0.0001363915,0.00015900453,0.000080140824,0.0000979436,0.0004936728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015794089,0.0018750642,0.0016763653,0.000506237,0.0006471654,0.00088994176,0.0010949814,0.0017878286,0.0064862994],"category_scores_gemma":[0.00090575847,0.0005979554,0.00092487544,0.00043382106,0.0011145232,0.00077644543,0.00029308657,0.0039714267,0.0019951672],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5607215,0.15839124,0.009626304,0.0012625542,0.0010462201,0.0008755346,0.00050163403,0.002662756,0.17917821,0.00049542397,0.014669957,0.07056869],"study_design_scores_gemma":[0.22510494,0.75421184,0.007587499,0.0000340852,0.00028523215,0.00046795004,0.000057664955,0.00078767585,0.008015675,0.00014486106,0.0032775367,0.000024990617],"about_ca_topic_score_codex":0.0015179998,"about_ca_topic_score_gemma":0.0031217532,"teacher_disagreement_score":0.0064862994,"about_ca_system_score_codex":0.0011767244,"about_ca_system_score_gemma":0.0025808476,"threshold_uncertainty_score":0.021698833},"labels":[],"label_agreement":null},{"id":"W4393983476","doi":"10.1158/1538-7445.am2024-ct286","title":"Abstract CT286: TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Tumor-infiltrating lymphocytes; Melanoma; Oncology; Metastatic melanoma; Immunotherapy; Internal medicine; Cancer; Cancer research","score_opus":0.09603221829209885,"score_gpt":0.4251622067439079,"score_spread":0.3291299884518091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393983476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715566,0.0028890294,0.000692259,0.0016913022,0.0005635921,0.010441845,0.005470316,0.00030058017,0.0063944384],"genre_scores_gemma":[0.9646081,0.0018403246,0.0024265612,0.0027636979,0.0004445305,0.008567451,0.0070398087,0.000071159986,0.0122384485],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995746,0.00019789668,0.000025486897,0.00007329213,0.00005434208,0.00007432769],"domain_scores_gemma":[0.9990717,0.00012802861,0.00016398207,0.00006423547,0.000068342386,0.0005036222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016714798,0.0017977272,0.001919209,0.0003494156,0.000772603,0.0012513913,0.0012885869,0.0022607096,0.009298985],"category_scores_gemma":[0.0009424364,0.0007510784,0.0015673223,0.00035219156,0.0009876089,0.0010247725,0.00033950838,0.005543812,0.0020812151],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84569025,0.050195184,0.0028922074,0.0010103238,0.0009075955,0.00025044283,0.00014435807,0.0013064352,0.05075905,0.00031540057,0.009881492,0.036647312],"study_design_scores_gemma":[0.7501282,0.23900943,0.0043436447,0.000043058528,0.00029496104,0.00014606742,0.000027378726,0.0007122618,0.003119447,0.00018913258,0.001962281,0.000024089486],"about_ca_topic_score_codex":0.00158661,"about_ca_topic_score_gemma":0.0042248378,"teacher_disagreement_score":0.009298985,"about_ca_system_score_codex":0.0013704344,"about_ca_system_score_gemma":0.0027587423,"threshold_uncertainty_score":0.0311082},"labels":[],"label_agreement":null},{"id":"W4393988288","doi":"10.1158/1538-7445.am2024-ct002","title":"Abstract CT002: CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chimeric antigen receptor; CRISPR; Renal cell carcinoma; Medicine; Antigen; Cancer research; Immunology; Biology; Oncology; Immunotherapy; Immune system; Gene; Genetics","score_opus":0.07240042123301262,"score_gpt":0.3885031541100254,"score_spread":0.3161027328770128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975592,0.0007158846,0.000312225,0.0001250594,0.000013605833,0.000097644785,0.00044097556,0.00003148048,0.00070396793],"genre_scores_gemma":[0.9979558,0.00019160938,0.00021711836,0.00011711372,0.000013760187,0.000047832684,0.0010024698,0.0000048783613,0.00044934457],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99982005,0.00005273245,0.000011349757,0.000045616023,0.00003828593,0.000032040753],"domain_scores_gemma":[0.9996418,0.000056284298,0.00009839502,0.00003738556,0.00003755755,0.0001285822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006212918,0.00029164687,0.0004162595,0.00011585779,0.00021038298,0.00051512156,0.00030306526,0.00033224205,0.0010315473],"category_scores_gemma":[0.0003880284,0.00010985478,0.00031150316,0.00022565117,0.00027028687,0.00029747878,0.00015442962,0.00086833216,0.00029009223],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16359168,0.017461903,0.19503029,0.0008648357,0.0019733096,0.001170971,0.0006524705,0.009309161,0.34142086,0.0004065998,0.014282955,0.25383502],"study_design_scores_gemma":[0.04840255,0.3871319,0.46892658,0.00008310664,0.0017083994,0.0028334174,0.00031308414,0.010100544,0.06318399,0.00034374843,0.016900036,0.000072668314],"about_ca_topic_score_codex":0.0010507687,"about_ca_topic_score_gemma":0.0016142403,"teacher_disagreement_score":0.0010507687,"about_ca_system_score_codex":0.0005448662,"about_ca_system_score_gemma":0.0005758036,"threshold_uncertainty_score":0.003953278},"labels":[],"label_agreement":null},{"id":"W4394060769","doi":"10.1158/2159-8290.cd-24-0102","title":"CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences","keywords":"Renal cell carcinoma; Cell; Cancer research; Cell therapy; Targeted therapy; Clear cell renal cell carcinoma; Medicine; Oncology; Internal medicine; Biology; Cancer; Genetics","score_opus":0.024328738825237905,"score_gpt":0.3122543425206403,"score_spread":0.28792560369540243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394060769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876681,0.005145716,0.0029560605,0.0002831075,0.000050542843,0.00022146871,0.00013537826,0.00013077563,0.0034088162],"genre_scores_gemma":[0.9953028,0.001732863,0.0015256678,0.000063900756,0.00002298331,0.000046005625,0.000175991,0.000009251243,0.0011205835],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99994075,0.000011886093,0.000003268738,0.000008405488,0.00001855524,0.000017102675],"domain_scores_gemma":[0.99995744,0.000007859536,0.0000061995947,0.0000054506354,0.00000470545,0.000018351144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018471674,0.00021487114,0.00039466197,0.00023668422,0.00021760147,0.0002845212,0.0001610392,0.00025136478,0.0013342872],"category_scores_gemma":[0.000118678596,0.0000706227,0.00017771989,0.00016054796,0.00026637907,0.00018386765,0.00018137951,0.0005847095,0.00035018212],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033693784,0.0028608814,0.003570539,0.00046229007,0.00008571593,0.0013645391,0.00031673835,0.0064241816,0.80914044,0.0020725618,0.0027617877,0.16757101],"study_design_scores_gemma":[0.0055433596,0.056175344,0.032463063,0.000083420484,0.00033225142,0.011057445,0.00015059616,0.020641662,0.81203514,0.001283761,0.060174093,0.000059882903],"about_ca_topic_score_codex":0.0012226455,"about_ca_topic_score_gemma":0.0019545886,"teacher_disagreement_score":0.0013342872,"about_ca_system_score_codex":0.00039708987,"about_ca_system_score_gemma":0.00058925373,"threshold_uncertainty_score":0.004463613},"labels":[],"label_agreement":null},{"id":"W4394312980","doi":"10.6084/m9.figshare.22604309","title":"Additional file 3 of CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL","year":2023,"lang":"en","type":"dataset","venue":"Open MIND","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Stem cell; Hematopoietic stem cell transplantation; Transplantation; Outcome (game theory); Hematopoietic cell; Oncology; Internal medicine; Haematopoiesis; Medicine; Biology; Genetics; Mathematics","score_opus":0.0715829801705885,"score_gpt":0.33448418309124806,"score_spread":0.26290120292065955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394312980","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013400007,0.000031296884,0.00005982627,0.00005684509,0.000011455203,0.000026521075,0.99939954,0.000059268496,0.00022125582],"genre_scores_gemma":[0.0032171307,0.000095664844,0.00064981217,0.00025810226,0.000037551705,0.0006994112,0.99309933,0.00012655475,0.0018164588],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99893874,0.00017020463,0.0002041733,0.0003450702,0.00018511832,0.00015663677],"domain_scores_gemma":[0.9907837,0.0059192525,0.00089510554,0.0010065992,0.0010100789,0.00038523093],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017086482,0.0013774381,0.0017382966,0.0014196748,0.0008164182,0.0022219329,0.0022649018,0.0022477852,0.47514424],"category_scores_gemma":[0.022929592,0.00058871764,0.0014559895,0.0021813833,0.00035707038,0.0016148922,0.0011944154,0.0015839384,0.06864666],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008113777,0.00008385444,0.0046957666,0.0045962245,0.00024853708,0.00008946379,0.00003408478,0.00075297244,0.00020068514,0.0007307193,0.9822089,0.0055475007],"study_design_scores_gemma":[0.012997695,0.0004046722,0.039778847,0.005623627,0.00086970825,0.00085078133,0.00022514467,0.0024712074,0.0011616338,0.009451174,0.92601216,0.00015322785],"about_ca_topic_score_codex":0.008438642,"about_ca_topic_score_gemma":0.015841778,"teacher_disagreement_score":0.47514424,"about_ca_system_score_codex":0.0015679298,"about_ca_system_score_gemma":0.0021474152,"threshold_uncertainty_score":0.74864304},"labels":[],"label_agreement":null},{"id":"W4394407308","doi":"10.6084/m9.figshare.24062570","title":"Additional file 1 of CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Lymphoma; CD38; Cancer research; Chemistry; Biology; Cell biology; Immunology","score_opus":0.040521320665913206,"score_gpt":0.2737361853603297,"score_spread":0.23321486469441646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394407308","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000526468,0.000021279915,0.00003653658,0.000031667754,0.0000047433973,0.000016196473,0.9996099,0.000072884926,0.0001540877],"genre_scores_gemma":[0.0016684923,0.00009358161,0.00056760205,0.00014249801,0.000016184595,0.0006204009,0.99562424,0.00015096359,0.0011161232],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99901664,0.00016308705,0.00017606038,0.0003316057,0.00016835051,0.00014423505],"domain_scores_gemma":[0.9928209,0.0049191336,0.00062243507,0.00062220386,0.00068916206,0.00032613933],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015365083,0.001314811,0.0018053607,0.0019751433,0.0006683061,0.0018527517,0.002056527,0.0016714773,0.52728695],"category_scores_gemma":[0.017798852,0.0005861268,0.0011604688,0.0035853905,0.00029974635,0.001447023,0.0012622608,0.0012353143,0.12133416],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003512861,0.000050902556,0.002506948,0.005489827,0.00009826183,0.000041676765,0.000026059872,0.00049802376,0.00013535158,0.00046791445,0.985775,0.004558774],"study_design_scores_gemma":[0.0046596127,0.00022182129,0.015760703,0.0028145919,0.00029109794,0.0002751351,0.00013381409,0.0012628009,0.0007053515,0.0036250376,0.9701744,0.00007569139],"about_ca_topic_score_codex":0.0063654915,"about_ca_topic_score_gemma":0.013224813,"teacher_disagreement_score":0.52728695,"about_ca_system_score_codex":0.0012257262,"about_ca_system_score_gemma":0.0020039463,"threshold_uncertainty_score":0.67426777},"labels":[],"label_agreement":null},{"id":"W4394567790","doi":"10.1016/j.stem.2024.03.012","title":"Rebuilding and rebooting immunity with stem cells","year":2024,"lang":"en","type":"article","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Genome British Columbia; Natural Sciences and Engineering Research Council of Canada; Wellcome Trust","keywords":"Biology; Reboot; Immune system; Regenerative medicine; Immunity; Immunology; Population; Stem cell; Regeneration (biology); Neuroscience; Computational biology; Computer science; Medicine; Cell biology","score_opus":0.02661360309648523,"score_gpt":0.276535880386647,"score_spread":0.24992227729016178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394567790","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6132993,0.06348299,0.29235893,0.0048158863,0.0014976612,0.0007914479,0.0004418307,0.0017446576,0.021567296],"genre_scores_gemma":[0.90534526,0.016151685,0.07127916,0.001161753,0.00024196472,0.00023983342,0.00019161696,0.00009652286,0.005292109],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99975413,0.000056600147,0.000020258924,0.000038488703,0.00009549877,0.000035050947],"domain_scores_gemma":[0.9997991,0.00007797142,0.00005037676,0.00002400158,0.000024818606,0.000023813116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006868741,0.00040207853,0.00038396395,0.00070009835,0.00019992901,0.0009780215,0.00037733561,0.00046586583,0.0017143226],"category_scores_gemma":[0.00046227625,0.0001429898,0.00037479005,0.00018358456,0.00056469033,0.0006024735,0.00046567802,0.0007829589,0.0005090643],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033823287,0.00022453163,0.001241994,0.0006936888,0.000055395085,0.0002972631,0.00030961185,0.002780497,0.83993423,0.01381428,0.0017335019,0.13857675],"study_design_scores_gemma":[0.00009466275,0.0019227338,0.0012588798,0.00015973327,0.00012213281,0.0007802255,0.00020512818,0.0068726935,0.9244372,0.0040565194,0.0600679,0.000022213164],"about_ca_topic_score_codex":0.00015057085,"about_ca_topic_score_gemma":0.00043032362,"teacher_disagreement_score":0.0017143226,"about_ca_system_score_codex":0.00025648405,"about_ca_system_score_gemma":0.00034602592,"threshold_uncertainty_score":0.00573498},"labels":[],"label_agreement":null},{"id":"W4394598287","doi":"10.1212/wnl.0000000000204493","title":"Safety of CAR T-Cell Therapy in Patients with Active Autoimmune Diseases: A Case Report (P3-14.003)","year":2024,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; CAR T-cell therapy; Immunology; T cell; Chimeric antigen receptor; Immune system","score_opus":0.012123533305530865,"score_gpt":0.28467861039281794,"score_spread":0.2725550770872871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394598287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97466725,0.0032919762,0.0030774297,0.0022410245,0.000090588204,0.000055388235,0.00008428736,0.000099622026,0.016392348],"genre_scores_gemma":[0.9968736,0.00059761974,0.0004933456,0.0005452769,0.00018784407,0.00001113169,0.00005316313,0.000010901217,0.0012270012],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.999757,0.000046878307,0.00003082381,0.000041670857,0.000042907162,0.00008071684],"domain_scores_gemma":[0.99910814,0.00037987286,0.0001918118,0.00007556724,0.000074731586,0.000170007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031591603,0.0004917092,0.00039905537,0.00048722603,0.00092941686,0.00080411806,0.000499165,0.0023309416,0.0014991282],"category_scores_gemma":[0.0015460338,0.00019900089,0.0005356552,0.00038327463,0.0005803118,0.00064135407,0.00035263033,0.0013833111,0.00061594864],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016428348,0.000114222596,0.02410595,0.00004416046,0.000021442458,0.96182704,0.00018439595,0.00019233464,0.002938393,0.0002961604,0.00050274987,0.009608848],"study_design_scores_gemma":[0.000020937627,0.0003733951,0.007576785,0.000011989415,0.00003094416,0.9871339,0.00006401807,0.00049310393,0.0023396262,0.0002370616,0.0017099717,0.000008179206],"about_ca_topic_score_codex":0.00088461814,"about_ca_topic_score_gemma":0.0009321345,"teacher_disagreement_score":0.0023309416,"about_ca_system_score_codex":0.00054990855,"about_ca_system_score_gemma":0.0005086232,"threshold_uncertainty_score":0.0050150156},"labels":[],"label_agreement":null},{"id":"W4394598356","doi":"10.1212/wnl.0000000000204489","title":"Novel Risk Factors for Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS) (P3-14.001)","year":2024,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Neurotoxicity; Medicine; Internal medicine; Toxicity","score_opus":0.027879735570361414,"score_gpt":0.29765352635358416,"score_spread":0.2697737907832227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394598356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494666,0.00040578583,0.0012535146,0.00027359452,0.000040056653,0.000042839725,0.0007616732,0.000027864646,0.0022480204],"genre_scores_gemma":[0.9971219,0.00012593732,0.0011074248,0.00008733388,0.000051191524,0.000029716772,0.0007082232,0.000009779414,0.00075846235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974006,0.00006166095,0.000033439475,0.000051844756,0.000055823024,0.000057105204],"domain_scores_gemma":[0.9990169,0.00019553753,0.0004137501,0.000043397853,0.00012415522,0.000206232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056682975,0.0006436743,0.0003151799,0.00068351865,0.00039356056,0.00060630793,0.00041940514,0.0007041456,0.0028211435],"category_scores_gemma":[0.0018029562,0.00014099074,0.0004654282,0.00071359205,0.0002464675,0.00043634934,0.00042220933,0.0009691825,0.0005831064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004082225,0.00010568702,0.99102914,0.00001256133,0.00006822482,0.0005760435,0.0000206102,0.00021012762,0.0013620282,0.000112231915,0.00048146374,0.0056136535],"study_design_scores_gemma":[0.0000511394,0.00042569434,0.988204,0.000022186745,0.00017654884,0.0042293766,0.00010625616,0.0034757534,0.0012392636,0.00062129344,0.0014340397,0.000014422494],"about_ca_topic_score_codex":0.0019520127,"about_ca_topic_score_gemma":0.002272964,"teacher_disagreement_score":0.0028211435,"about_ca_system_score_codex":0.0003337942,"about_ca_system_score_gemma":0.00092791487,"threshold_uncertainty_score":0.00943768},"labels":[],"label_agreement":null},{"id":"W4394621491","doi":"10.14740/jh1211","title":"Successful Treatment of Refractory Post-Transplant Lymphoproliferative Disorder With Chimeric Antigen Receptor T-Cell Therapy in a Heart Transplant Recipient","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Refractory (planetary science); Post-transplant lymphoproliferative disorder; Immunology; Cell therapy; Heart transplantation; Immunotherapy; Antigen; Transplant rejection; Transplantation; Cell; Lymphoma; Internal medicine; Immune system; Biology; Rituximab","score_opus":0.01534176998527919,"score_gpt":0.29956876746539796,"score_spread":0.28422699748011876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394621491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94344795,0.018585045,0.008936764,0.008941896,0.0011315247,0.00026252685,0.00026101622,0.0003263254,0.018107016],"genre_scores_gemma":[0.9881533,0.003841912,0.0013999349,0.0021449502,0.0007343999,0.000037201586,0.0002167326,0.00003085188,0.0034409096],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9998976,0.000015150654,0.000011667903,0.000017761065,0.00001525318,0.00004259557],"domain_scores_gemma":[0.9997867,0.00003764311,0.000026103507,0.00001354112,0.000013008218,0.00012308308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016858379,0.0004530354,0.00060478254,0.00046444184,0.00091968855,0.00046759314,0.00040987777,0.0012326874,0.0011113156],"category_scores_gemma":[0.0005383485,0.00011861887,0.00052919844,0.00021064331,0.0002959983,0.0005180143,0.00040084354,0.0017264229,0.0005363515],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006169787,0.0010043733,0.016349409,0.0002261221,0.00005793644,0.91715163,0.00040437243,0.0008435025,0.0137031935,0.0009822709,0.003314178,0.045346063],"study_design_scores_gemma":[0.0001546197,0.0023255402,0.024886232,0.00016321176,0.000102352366,0.9479961,0.00022491647,0.0021306793,0.007860606,0.0012267535,0.012886204,0.000042821062],"about_ca_topic_score_codex":0.00043313284,"about_ca_topic_score_gemma":0.0009927129,"teacher_disagreement_score":0.0012326874,"about_ca_system_score_codex":0.00034901945,"about_ca_system_score_gemma":0.0004217025,"threshold_uncertainty_score":0.00371778},"labels":[],"label_agreement":null},{"id":"W4394680557","doi":"10.1016/j.omtm.2024.101249","title":"Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Grainger Institute for Engineering, University of Wisconsin-Madison; College of Engineering, University of Wisconsin-Madison; National Institute of General Medical Sciences; Engineering Research Centers; Government of the United Kingdom; U.S. Department of Health and Human Services; National Institutes of Health; University of Wisconsin Carbone Cancer Center; St. Baldrick's Foundation; Canadian Thoracic Society; Hyundai Hope On Wheels; National Science Foundation; Michigan Council for Arts and Cultural Affairs; University of Wisconsin-Madison; Division of Graduate Education; National Heart, Lung, and Blood Institute; Wisconsin Alumni Research Foundation","keywords":"CRISPR; Chimeric antigen receptor; Priming (agriculture); Persistence (discontinuity); Cas9; Phenotype; Ribonucleoprotein; Biology; Cell biology; Computational biology; T cell; Genetics; Gene; Engineering; Immune system; RNA","score_opus":0.10272237245015799,"score_gpt":0.4156942167703084,"score_spread":0.3129718443201504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394680557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752797,0.00086923304,0.020841502,0.00009622639,0.000024677041,0.00006891893,0.0002446543,0.00031060984,0.0022644731],"genre_scores_gemma":[0.98177576,0.00051437266,0.015528016,0.000053466654,0.000008869548,0.000077419776,0.0002848295,0.00006575664,0.0016915695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998628,0.000025046533,0.00001159951,0.000035145975,0.000035726618,0.000029724832],"domain_scores_gemma":[0.9998903,0.000019086367,0.000042070842,0.000015225863,0.0000178579,0.000015352365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000148233,0.00038270414,0.00019086066,0.0001639805,0.00013532127,0.00044854407,0.00018850678,0.00025229325,0.0011193942],"category_scores_gemma":[0.00014301391,0.00012296585,0.00024915696,0.00015750954,0.00015569526,0.00026922082,0.00027861446,0.0003657727,0.00041408336],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004467531,0.000012275218,0.00013594342,0.000021916421,0.000002258655,0.000024546023,0.000010858617,0.00015153976,0.9975873,0.00007131324,0.000027287291,0.0019100263],"study_design_scores_gemma":[0.0000036967112,0.00011913214,0.00037831406,0.0000019858471,0.0000060545717,0.00006431688,0.0000071632144,0.0003845682,0.9980519,0.000017671648,0.00096247334,0.0000027163537],"about_ca_topic_score_codex":0.00031626198,"about_ca_topic_score_gemma":0.0006448326,"teacher_disagreement_score":0.0011193942,"about_ca_system_score_codex":0.00023908113,"about_ca_system_score_gemma":0.00023069428,"threshold_uncertainty_score":0.003744781},"labels":[],"label_agreement":null},{"id":"W4394770414","doi":"10.1016/j.tips.2024.03.004","title":"Direct in vivo CAR T cell engineering","year":2024,"lang":"en","type":"article","venue":"Trends in Pharmacological Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"BC Cancer Agency; Canadian Institutes of Health Research; BC Cancer Foundation; Michael Smith Health Research BC","keywords":"In vivo; Chimeric antigen receptor; Ex vivo; Cell therapy; Medicine; Immunotherapy; Immunology; Computational biology; Computer science; Biology; Stem cell; Immune system; Biotechnology; Cell biology","score_opus":0.07236072218963159,"score_gpt":0.4097159349219207,"score_spread":0.33735521273228913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394770414","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38737485,0.005462515,0.573166,0.0009538445,0.00066386873,0.000982094,0.0010220746,0.0016640024,0.028710676],"genre_scores_gemma":[0.8362788,0.004115385,0.13781224,0.0004926594,0.00011476175,0.00048820494,0.0006900115,0.00026464986,0.019743199],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9997341,0.00006277511,0.000018923703,0.00006446536,0.00007198445,0.000047707534],"domain_scores_gemma":[0.9998808,0.000031627136,0.000031746258,0.000023648445,0.000018143688,0.0000141114115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003801999,0.00050771615,0.00020146428,0.00021518688,0.00016388748,0.00061326957,0.00030704646,0.0005746407,0.0028567514],"category_scores_gemma":[0.0002352134,0.0002086504,0.00027312755,0.000092977054,0.0002607186,0.00031865234,0.00040928976,0.0010469407,0.0013523946],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004680665,0.000058153513,0.00007087687,0.00007914793,0.0000039719985,0.000098744036,0.00004413639,0.00039223666,0.9908875,0.0021991136,0.0003681816,0.005751061],"study_design_scores_gemma":[0.0000096464055,0.00018257812,0.00007770248,0.000005570424,0.000007939565,0.00027177352,0.000012353081,0.0010951308,0.9848104,0.00019276315,0.013330964,0.0000032085534],"about_ca_topic_score_codex":0.00014720546,"about_ca_topic_score_gemma":0.00030330665,"teacher_disagreement_score":0.0028567514,"about_ca_system_score_codex":0.00017449592,"about_ca_system_score_gemma":0.0002531332,"threshold_uncertainty_score":0.00955683},"labels":[],"label_agreement":null},{"id":"W4394871491","doi":"10.1016/j.cels.2024.03.004","title":"Integrating multiplexed imaging and multiscale modeling identifies tumor phenotype conversion as a critical component of therapeutic T cell efficacy","year":2024,"lang":"en","type":"article","venue":"Cell Systems","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Cancer Institute; National Human Genome Research Institute; Hamilton Health Sciences Foundation; Defence Science and Technology Laboratory; U.S. Food and Drug Administration; U.S. Department of Defense; Silicon Valley Community Foundation; Cancer Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Bill and Melinda Gates Foundation; National Institutes of Health; Cancer Research UK; National Heart, Lung, and Blood Institute","keywords":"Component (thermodynamics); Phenotype; Computational biology; Computer science; Biology; Biological system; Physics; Genetics; Gene","score_opus":0.02971431905540872,"score_gpt":0.3201112536483638,"score_spread":0.29039693459295507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394871491","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45709237,0.00077409256,0.5327321,0.0007242858,0.00011991513,0.00009216581,0.00043245286,0.001961198,0.0060713496],"genre_scores_gemma":[0.8910059,0.00044629464,0.10652805,0.000091649155,0.000018144361,0.000098939425,0.000118051124,0.00020250736,0.0014904258],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9997985,0.000032307187,0.0000091750635,0.000043039596,0.00009017165,0.000026741945],"domain_scores_gemma":[0.9996829,0.00015895374,0.00006087845,0.000036593367,0.00003445059,0.000026235235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062928855,0.00044459625,0.00036651827,0.00034891148,0.00020903352,0.0010402487,0.0003954715,0.0005546575,0.0014769181],"category_scores_gemma":[0.0009988467,0.00028139324,0.0003746772,0.00024603854,0.00038847936,0.000707339,0.0005904734,0.0007659719,0.00018588924],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022189389,0.00021695216,0.0051685986,0.0001706968,0.00007547144,0.0002513064,0.00018993198,0.31878418,0.6033837,0.019875163,0.0015029714,0.05015912],"study_design_scores_gemma":[0.000009783108,0.00008568561,0.00096287765,0.0000073726796,0.000022320135,0.000044265114,0.00002162271,0.8716091,0.12322492,0.0019343327,0.0020557432,0.000022010754],"about_ca_topic_score_codex":0.0018507183,"about_ca_topic_score_gemma":0.0022673965,"teacher_disagreement_score":0.0018507183,"about_ca_system_score_codex":0.0007793913,"about_ca_system_score_gemma":0.00066943053,"threshold_uncertainty_score":0.0056548715},"labels":[],"label_agreement":null},{"id":"W4394884067","doi":"10.1016/j.cjco.2024.04.004","title":"Multimodality Imaging of Acute Myocarditis in Cytokine Release Syndrome (CRS) Following CAR-T Therapy","year":2024,"lang":"en","type":"article","venue":"CJC Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; McGill University","funders":"McGill University Health Centre","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Rituximab; Lymphoma; Radiology; Internal medicine; Immunotherapy; Cancer","score_opus":0.031760034121391535,"score_gpt":0.36586832020449317,"score_spread":0.3341082860831016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394884067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9501926,0.014472816,0.0096381465,0.0033481352,0.00028513532,0.00047171873,0.00028638565,0.00043789417,0.02086727],"genre_scores_gemma":[0.9923867,0.0030059114,0.0021257827,0.0010502824,0.00045611872,0.00005053536,0.0001488249,0.00001856321,0.0007572154],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99959856,0.00007605152,0.000048932397,0.000079562495,0.000049920254,0.00014690847],"domain_scores_gemma":[0.9993679,0.00016262788,0.00010247133,0.00006459772,0.000082022816,0.000220468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045931162,0.0012156427,0.00079355633,0.0017480154,0.00053397426,0.0005173632,0.0006962821,0.0021943715,0.0021719146],"category_scores_gemma":[0.0014550518,0.0005159122,0.00075458176,0.0006631194,0.00071290886,0.0014133184,0.00095338695,0.0018264889,0.00060855196],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005151864,0.00015772182,0.02650379,0.00016828258,0.000048505517,0.9455639,0.00014361762,0.00040462826,0.017456975,0.00021285392,0.0007893364,0.00803513],"study_design_scores_gemma":[0.00018693156,0.0014908864,0.052843448,0.00020460246,0.00023055136,0.9262005,0.00022027832,0.006189591,0.008463638,0.0005695534,0.0033541813,0.000045886725],"about_ca_topic_score_codex":0.0012673603,"about_ca_topic_score_gemma":0.00097311207,"teacher_disagreement_score":0.0021943715,"about_ca_system_score_codex":0.00056655164,"about_ca_system_score_gemma":0.0004104823,"threshold_uncertainty_score":0.0072657466},"labels":[],"label_agreement":null},{"id":"W4394893537","doi":"10.1016/j.jval.2024.04.004","title":"Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Public Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Hematologic Neoplasms; Medicine; Intensive care medicine; Internal medicine; Cancer","score_opus":0.16152575852155565,"score_gpt":0.4577174283364431,"score_spread":0.2961916698148874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394893537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009360213,0.99781126,0.00016604361,0.00020160335,0.00009845849,0.0001837052,0.00034195618,0.000007094225,0.00025392039],"genre_scores_gemma":[0.027304113,0.9706792,0.00064191874,0.0006304717,0.000085979686,0.00030649296,0.00019925741,0.0000068903983,0.0001456302],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9946273,0.0026850326,0.0013083892,0.0003313385,0.0008616605,0.0001863173],"domain_scores_gemma":[0.98053634,0.015091321,0.0031481567,0.00017988612,0.0008464083,0.00019791287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007986744,0.0013981548,0.009351808,0.004094444,0.00030085404,0.0024734149,0.0015818961,0.0017977272,0.006370349],"category_scores_gemma":[0.03142055,0.0008181409,0.009687324,0.004617931,0.0007526324,0.0014782851,0.0011884883,0.0018136175,0.00027045235],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014226218,0.000030328907,0.00046218594,0.90134454,0.049069233,0.000079074576,0.000060161932,0.00037104386,0.00017459756,0.0004513933,0.00209182,0.044442993],"study_design_scores_gemma":[0.0038070262,0.0006750184,0.003770164,0.5519222,0.41204008,0.00032889863,0.0002028754,0.000417179,0.0002657413,0.0014166518,0.025082042,0.00007205344],"about_ca_topic_score_codex":0.0063408916,"about_ca_topic_score_gemma":0.017552339,"teacher_disagreement_score":0.009351808,"about_ca_system_score_codex":0.003527095,"about_ca_system_score_gemma":0.0052341297,"threshold_uncertainty_score":0.042238414},"labels":[],"label_agreement":null},{"id":"W4395007321","doi":"10.1186/s13045-024-01542-9","title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","year":2024,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Incyte; TG Therapeutics; National Cancer Institute; Laffey-McHugh Foundation; Pharmacyclics; Genentech; Celgene; Mallinckrodt Pharmaceuticals; Society for Immunotherapy of Cancer; University of Pennsylvania; Gilead Sciences; Leukemia and Lymphoma Society","keywords":"Bendamustine; Medicine; Cytokine release syndrome; Internal medicine; Fludarabine; Cyclophosphamide; Gastroenterology; Lymphoma; Immunotherapy; Rituximab; Chemotherapy; Cancer; Chimeric antigen receptor","score_opus":0.03244576333228277,"score_gpt":0.3624544389628308,"score_spread":0.33000867563054803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395007321","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829274,0.00070520595,0.00016072605,0.000030494557,0.0000050520684,0.000034823384,0.00007403216,0.000008203663,0.0006886533],"genre_scores_gemma":[0.9990676,0.00020183373,0.00012195096,0.000033636417,0.000010512173,0.00003088353,0.0002619768,0.000002919966,0.00026865044],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976665,0.000092496266,0.000012711332,0.00003689613,0.00005166972,0.000039459763],"domain_scores_gemma":[0.99968123,0.00010805048,0.000086325956,0.000022227458,0.000016262744,0.00008599735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000390398,0.00018403586,0.00042171218,0.00016670252,0.00015483022,0.00033222116,0.000180641,0.00018531848,0.0009456159],"category_scores_gemma":[0.00059298764,0.000111097004,0.00027415,0.00012063468,0.00018343444,0.0002481681,0.00014852331,0.00051814364,0.00028765926],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17603816,0.012135289,0.18651634,0.00029225516,0.00034752063,0.0014159835,0.00049291283,0.0031924993,0.3255162,0.00031470007,0.0013392705,0.2923989],"study_design_scores_gemma":[0.0089041125,0.314194,0.5808529,0.00007958192,0.00039873848,0.004605238,0.00021883819,0.0041930047,0.07609816,0.00019053931,0.010219179,0.0000457157],"about_ca_topic_score_codex":0.00044400647,"about_ca_topic_score_gemma":0.00068795343,"teacher_disagreement_score":0.0009456159,"about_ca_system_score_codex":0.0003746827,"about_ca_system_score_gemma":0.000310337,"threshold_uncertainty_score":0.003163457},"labels":[],"label_agreement":null},{"id":"W4395081939","doi":"10.51731/cjht.2024.873","title":"Glofitamab (Columvi)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Vial; Medicine; Refractory (planetary science); Lymphoma; Follicular lymphoma; Drug; Intensive care medicine; Internal medicine; Pharmacology; Health care; Political science","score_opus":0.05172994418768404,"score_gpt":0.35660408707546454,"score_spread":0.3048741428877805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395081939","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027345715,0.75210005,0.0017292607,0.0063428334,0.0013653941,0.0008916492,0.0051922738,0.00093846506,0.20409432],"genre_scores_gemma":[0.29695743,0.46474087,0.0065418063,0.016894251,0.00078686327,0.00071325933,0.016032495,0.00021023447,0.19712274],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996137,0.00007134697,0.000025134821,0.00006098173,0.00016263346,0.00006623798],"domain_scores_gemma":[0.9997168,0.000035644873,0.00006791194,0.000014186976,0.00009081246,0.00007463051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006521978,0.00044292325,0.00045409662,0.001129004,0.00038544065,0.0015327666,0.0006659254,0.0010685179,0.02430115],"category_scores_gemma":[0.0009182404,0.00013094785,0.00067442184,0.00074717164,0.00032514276,0.00061279896,0.0004863159,0.0011303396,0.0066366256],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001131341,0.00014174182,0.0012555425,0.00327328,0.0001038573,0.00035382117,0.000087389744,0.00021220738,0.007474628,0.0030200253,0.11217333,0.87077296],"study_design_scores_gemma":[0.000657085,0.0009994732,0.0035234208,0.0017308516,0.00011132446,0.001994814,0.000059497004,0.00011744758,0.0026993884,0.00027731166,0.9878099,0.000019549689],"about_ca_topic_score_codex":0.014080331,"about_ca_topic_score_gemma":0.042731863,"teacher_disagreement_score":0.02430115,"about_ca_system_score_codex":0.0019378655,"about_ca_system_score_gemma":0.0022128767,"threshold_uncertainty_score":0.08129543},"labels":[],"label_agreement":null},{"id":"W4395464285","doi":"10.1007/s40487-024-00272-9","title":"Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example","year":2024,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Hospital","funders":"","keywords":"Medicine; Referral; Chimeric antigen receptor; CAR T-cell therapy; CD19; Patient education; Cytokine release syndrome; Intensive care medicine; Medical emergency; Immunotherapy; Internal medicine; Cancer; Family medicine; Immunology; Antigen","score_opus":0.046091410346501216,"score_gpt":0.3533299062937665,"score_spread":0.30723849594726527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395464285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84603775,0.008316015,0.013050472,0.06922789,0.002067801,0.00054541655,0.0006083584,0.0003004359,0.059845734],"genre_scores_gemma":[0.97454256,0.0036719071,0.006113018,0.007775225,0.0016992115,0.000062102314,0.00022235069,0.000092807204,0.005820957],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99950445,0.00009685643,0.00005066642,0.00006916738,0.00007616245,0.00020270975],"domain_scores_gemma":[0.9987778,0.00031966795,0.00016114188,0.00003167285,0.000084245345,0.0006254907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030495966,0.00080255297,0.00061457296,0.0012244269,0.002756909,0.0017027038,0.00083280564,0.0034280056,0.0030533734],"category_scores_gemma":[0.0030665465,0.0004018111,0.00080191315,0.001022153,0.00088518095,0.0014712744,0.0013409314,0.0046006846,0.0009011217],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003783403,0.00009923776,0.006357301,0.000036433656,0.0000048920097,0.98525435,0.0004160251,0.00012001209,0.0004267052,0.00077247433,0.0025481724,0.003926631],"study_design_scores_gemma":[0.0000063153498,0.000045000386,0.0019799152,0.000035831687,0.0000043300493,0.9945088,0.00061507936,0.00026667403,0.00018568635,0.00039846142,0.0019426655,0.000011242075],"about_ca_topic_score_codex":0.0030987316,"about_ca_topic_score_gemma":0.0069138366,"teacher_disagreement_score":0.0034280056,"about_ca_system_score_codex":0.001949648,"about_ca_system_score_gemma":0.00089185475,"threshold_uncertainty_score":0.0141457915},"labels":[],"label_agreement":null},{"id":"W4396578915","doi":"10.1186/s12967-024-05179-7","title":"Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"review","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute of Standards and Technology; United States Pharmacopeia","keywords":"Potency; Mechanism (biology); Action (physics); Medicine; Mechanism of action; Bioinformatics; Pharmacology; Computational biology; Chemistry; Biology; Biochemistry; In vitro","score_opus":0.16554820886852453,"score_gpt":0.43302920294581865,"score_spread":0.2674809940772941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396578915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054283733,0.44411704,0.19608368,0.26443124,0.0108488295,0.0005560552,0.00018861538,0.00035908606,0.07798702],"genre_scores_gemma":[0.16677973,0.32233083,0.35379896,0.10623847,0.016198887,0.0024884543,0.00031981713,0.00059620495,0.031248637],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9731339,0.013608949,0.0023867884,0.0013493601,0.008764404,0.00075651903],"domain_scores_gemma":[0.95969933,0.029865198,0.0025641974,0.0015325561,0.0051117465,0.0012270706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.042892337,0.0024882238,0.0034048948,0.004039681,0.0035218368,0.016030569,0.00448726,0.011151999,0.005848524],"category_scores_gemma":[0.03237248,0.0013465476,0.0026811694,0.0018042576,0.02550687,0.020553144,0.005871564,0.020376392,0.0027251018],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018666618,0.00015014334,0.0007292159,0.0026598293,0.000038460577,0.00079610664,0.0022323902,0.0019996006,0.0038394325,0.86458784,0.019699244,0.10308101],"study_design_scores_gemma":[0.00005465538,0.00070643326,0.0007212903,0.003587985,0.00009498373,0.0021600774,0.0032570595,0.002145572,0.0028247715,0.44974783,0.5345726,0.00012679536],"about_ca_topic_score_codex":0.0035448237,"about_ca_topic_score_gemma":0.0035091597,"teacher_disagreement_score":0.042892337,"about_ca_system_score_codex":0.008230522,"about_ca_system_score_gemma":0.012001011,"threshold_uncertainty_score":0.22683907},"labels":[],"label_agreement":null},{"id":"W4396613915","doi":"10.51731/cjht.2024.884","title":"Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Anakinra; Internal medicine; Oncology; Chimeric antigen receptor; T cell; Immunology; Immune system","score_opus":0.07920129161709988,"score_gpt":0.3448582712694659,"score_spread":0.265656979652366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396613915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037198307,0.916957,0.0028632735,0.04927425,0.010883838,0.0064200317,0.0035825153,0.000109424305,0.0061899014],"genre_scores_gemma":[0.024682047,0.89456445,0.013590331,0.046476122,0.00684467,0.008512113,0.0017907673,0.00010418636,0.00343532],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.95910287,0.009912593,0.02420332,0.0011738342,0.0050020963,0.00060522946],"domain_scores_gemma":[0.7509236,0.15670174,0.04200345,0.0040335865,0.045009993,0.0013276333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04103457,0.0012581779,0.009547204,0.026062392,0.0013556579,0.0049684173,0.0035857912,0.0058169756,0.008201009],"category_scores_gemma":[0.15897566,0.0015285915,0.007190455,0.017167944,0.0024942078,0.0064770593,0.002505673,0.0020018523,0.0017066402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000338737,0.000024849563,0.0011570622,0.8594725,0.0024310772,0.0005604528,0.0008095712,0.00008526668,0.00042862815,0.0011567611,0.030070959,0.10346418],"study_design_scores_gemma":[0.0004670939,0.00018694458,0.0024286755,0.84833974,0.007996143,0.00091598567,0.0010238498,0.000095793504,0.00029139558,0.0026659349,0.1355023,0.00008618132],"about_ca_topic_score_codex":0.005551286,"about_ca_topic_score_gemma":0.016238688,"teacher_disagreement_score":0.04103457,"about_ca_system_score_codex":0.0047604106,"about_ca_system_score_gemma":0.020310406,"threshold_uncertainty_score":0.21701413},"labels":[],"label_agreement":null},{"id":"W4396730858","doi":"10.1126/sciadv.adj1468","title":"Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators","year":2024,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Temerty Faculty of Medicine, University of Toronto; Canadian Institutes of Health Research; University of Toronto","keywords":"CRISPR; Phenotype; Computational biology; Cell growth; Cell sorting; Drug discovery; Phenotypic screening; Microfluidics; Cell; Magnetic nanoparticles; Computer science; Workflow; Biology; Nanotechnology; Cell biology; Bioinformatics; Nanoparticle; Materials science; Genetics; Gene","score_opus":0.023698446217568128,"score_gpt":0.31814994376402145,"score_spread":0.29445149754645333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396730858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7950744,0.0014081085,0.19508618,0.00041390496,0.0001054288,0.00027610932,0.0009744743,0.0010717371,0.0055898065],"genre_scores_gemma":[0.9180818,0.00074271945,0.0761819,0.0001837448,0.000024643092,0.00030566758,0.00055108045,0.000101142046,0.003827382],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99963045,0.00005585311,0.000024928679,0.000091548136,0.00015851216,0.000038700196],"domain_scores_gemma":[0.9997117,0.00011051465,0.000053633878,0.000031510943,0.000068172194,0.000024412873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045255348,0.00033058706,0.0002589009,0.0003866603,0.00022796156,0.00042551875,0.00023174187,0.00033703796,0.0006595294],"category_scores_gemma":[0.00053648243,0.00014730445,0.0001830024,0.0001394361,0.00029433463,0.00021347009,0.00027566624,0.00048604616,0.00024839415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015651609,0.000007661983,0.00008901445,0.000018534934,0.000003006952,0.000013495773,0.0000101047735,0.000104644365,0.9983047,0.000092905895,0.000038058974,0.0013020625],"study_design_scores_gemma":[0.0000033545084,0.000059551567,0.0004731953,0.0000022078664,0.000005034777,0.00004938962,0.000010365954,0.0019228284,0.9961482,0.000045507008,0.0012764705,0.000003994408],"about_ca_topic_score_codex":0.000608867,"about_ca_topic_score_gemma":0.0014385196,"teacher_disagreement_score":0.0006595294,"about_ca_system_score_codex":0.0003718607,"about_ca_system_score_gemma":0.00023598793,"threshold_uncertainty_score":0.0026980639},"labels":[],"label_agreement":null},{"id":"W4396773639","doi":"10.1007/s00259-024-06722-w","title":"Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography","year":2024,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Ontario Institute for Cancer Research; Lawson Health Research Institute; Western University","funders":"Natural Sciences and Engineering Research Council of Canada; National Institutes of Health; National Institute of Biomedical Imaging and Bioengineering; Ontario Institute for Cancer Research","keywords":"Sodium-iodide symporter; Bioluminescence imaging; Chimeric antigen receptor; Ovarian cancer; Cancer research; Reporter gene; Positron emission tomography; Medicine; Chemistry; Cell culture; Cancer; Immunotherapy; Luciferase; Biology; Internal medicine; Symporter; Transfection; Nuclear medicine","score_opus":0.010964798856070922,"score_gpt":0.2805226611097397,"score_spread":0.2695578622536688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396773639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331994,0.0013316203,0.01337931,0.00008792274,0.0000094903135,0.000034140066,0.00010865616,0.00011973992,0.0016090978],"genre_scores_gemma":[0.9864575,0.0008575817,0.010403656,0.000030428273,0.0000048502225,0.000040420666,0.00013571953,0.000022373795,0.002047533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999486,0.000014875499,0.0000024116678,0.000011230651,0.000010922138,0.000011886979],"domain_scores_gemma":[0.9999715,0.000008046462,0.000007953758,0.0000032766382,0.0000047912918,0.000004422818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016403319,0.00022032994,0.0002038868,0.0001420804,0.00005417001,0.0002521776,0.00018869793,0.00027020054,0.00075290643],"category_scores_gemma":[0.00007207075,0.0001435536,0.0001465218,0.000103894825,0.0001259226,0.00023872533,0.00013450361,0.00019686003,0.00016455831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001078344,0.000018476549,0.00039777043,0.00003578597,0.0000055724076,0.00007151208,0.000012112895,0.00046486207,0.99721503,0.00008610322,0.000045929424,0.0015390123],"study_design_scores_gemma":[0.000028528058,0.00038034367,0.0027883744,0.000004694651,0.000025047251,0.0006741531,0.00003262708,0.00917107,0.9845548,0.00004246568,0.0022916878,0.0000062312047],"about_ca_topic_score_codex":0.00092325365,"about_ca_topic_score_gemma":0.00081173866,"teacher_disagreement_score":0.00092325365,"about_ca_system_score_codex":0.00025865814,"about_ca_system_score_gemma":0.00015906745,"threshold_uncertainty_score":0.0025187135},"labels":[],"label_agreement":null},{"id":"W4396839649","doi":"10.17504/protocols.io.rm7vzyb75lx1/v1","title":"AD BONCAT-FCM Screening &amp;amp; Coupled SYBR+ FCM Cell-Counting - 2022 v1","year":2022,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chemistry; Physics; Computer science","score_opus":0.06830435917926243,"score_gpt":0.3558844963020575,"score_spread":0.28758013712279507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396839649","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021258201,0.002770563,0.83812225,0.0010564864,0.0012643981,0.004698149,0.025829326,0.0330831,0.071917504],"genre_scores_gemma":[0.046229567,0.0032395178,0.6901034,0.0010664505,0.00041453828,0.015344816,0.07604941,0.01078308,0.15676916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995581,0.0007908119,0.0003589874,0.0011277626,0.0016143582,0.0005271282],"domain_scores_gemma":[0.9985684,0.00052240613,0.00008985173,0.00039413807,0.00031917298,0.00010600548],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033535634,0.0040726066,0.0023405054,0.004321837,0.0018098525,0.0024100968,0.0032563878,0.002385105,0.0929719],"category_scores_gemma":[0.002191393,0.002844354,0.0012019491,0.0021886076,0.0014653465,0.0015376828,0.001844343,0.005196463,0.074885346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005169878,0.00024733396,0.00038784125,0.0013807367,0.000058971156,0.00019165508,0.00029376,0.00070525095,0.9026947,0.01001404,0.04006506,0.04344372],"study_design_scores_gemma":[0.00008737049,0.0001755125,0.0008365068,0.00015243425,0.000050424,0.00057205954,0.000046350193,0.00460269,0.7604445,0.0025313543,0.2304058,0.00009498894],"about_ca_topic_score_codex":0.001032413,"about_ca_topic_score_gemma":0.0023808912,"teacher_disagreement_score":0.0929719,"about_ca_system_score_codex":0.001171814,"about_ca_system_score_gemma":0.0017596419,"threshold_uncertainty_score":0.31102198},"labels":[],"label_agreement":null},{"id":"W4396847734","doi":"10.1111/bjh.19497","title":"Atrial arrhythmias following <scp>CAR‐chimeric</scp> antigen receptor T‐cell therapy: Incidence, risk factors and biomarker profile","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; Swim Across America; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Chimeric antigen receptor; Atrial fibrillation; Internal medicine; Cardiotoxicity; Cardiology; Cancer; Immunotherapy; Chemotherapy","score_opus":0.02320608738721138,"score_gpt":0.30156380719973097,"score_spread":0.2783577198125196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396847734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998782,0.0005266251,0.00018251385,0.000026285012,0.000002481345,0.0000061587434,0.00010339634,0.0000063779266,0.00036420565],"genre_scores_gemma":[0.999506,0.00015365393,0.00008907355,0.000022007545,0.000011689235,0.0000039090974,0.00015688901,0.0000020510365,0.000054864482],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994548,0.00013920043,0.00008202979,0.000114978495,0.00013950252,0.00006948936],"domain_scores_gemma":[0.99677557,0.0006871004,0.0019455446,0.00015079636,0.00016349973,0.00027754268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058583415,0.00011937389,0.0003082499,0.00036664167,0.00014632926,0.0005662609,0.00016352317,0.00031911902,0.00084709184],"category_scores_gemma":[0.001961418,0.000083446605,0.00028837236,0.00058796,0.0002075838,0.00026320017,0.00021262262,0.00034961954,0.00020062199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031866846,0.00003177797,0.9925236,0.000014299692,0.000038229256,0.000348691,0.000029851986,0.000096701806,0.0013389677,0.000023234365,0.00005325566,0.0051827533],"study_design_scores_gemma":[0.000012302913,0.00048161994,0.9945856,0.000006753119,0.000042642252,0.0035821556,0.0000658293,0.00035843306,0.00056617125,0.000047286907,0.00024617775,0.0000050770914],"about_ca_topic_score_codex":0.00035549505,"about_ca_topic_score_gemma":0.0003359668,"teacher_disagreement_score":0.00084709184,"about_ca_system_score_codex":0.00017575965,"about_ca_system_score_gemma":0.0001996088,"threshold_uncertainty_score":0.0030982494},"labels":[],"label_agreement":null},{"id":"W4396887610","doi":"10.1016/j.omtm.2024.101265","title":"Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"T-cell receptor; Medicine; Human leukocyte antigen; T cell; Oncology; Immunology; Internal medicine; Cancer research; Antigen; Immune system","score_opus":0.11804649378496984,"score_gpt":0.49498310604291246,"score_spread":0.3769366122579426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396887610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557555,0.00093251513,0.0004926662,0.00012887266,0.000019512236,0.00009358319,0.00061836524,0.000012485995,0.00212654],"genre_scores_gemma":[0.9972881,0.00033871862,0.0005425902,0.00028741578,0.00002510664,0.00010513208,0.0009168886,0.0000068032573,0.0004892778],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99945146,0.00016252164,0.00010422783,0.000110814166,0.00008271602,0.000088300745],"domain_scores_gemma":[0.9990146,0.00031199423,0.0003428371,0.00007724586,0.000099264194,0.00015394221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014725598,0.00013117393,0.00029640042,0.0004909594,0.0003846302,0.00072879007,0.00022306814,0.0003090482,0.0022796101],"category_scores_gemma":[0.0019032104,0.0001041724,0.00039170161,0.00061741925,0.00020820327,0.00039102096,0.0003756579,0.00040079022,0.0005836043],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020396796,0.00016567485,0.9691575,0.00008216875,0.000042606684,0.0005441073,0.00011419202,0.00016158314,0.0056243185,0.00012647176,0.0011426104,0.020799054],"study_design_scores_gemma":[0.00023070035,0.0018228114,0.9806908,0.0000875892,0.00012008089,0.0035437818,0.0004931067,0.00096853473,0.0043630996,0.00054812734,0.0071162744,0.000015242174],"about_ca_topic_score_codex":0.00055991346,"about_ca_topic_score_gemma":0.001152582,"teacher_disagreement_score":0.0022796101,"about_ca_system_score_codex":0.00023810769,"about_ca_system_score_gemma":0.0003968231,"threshold_uncertainty_score":0.007787764},"labels":[],"label_agreement":null},{"id":"W4396935974","doi":"10.37766/inplasy2024.5.0069","title":"Metabolic tumor volume and survival of Non-Hodgkin lymphoma on CAR-T","year":2024,"lang":"en","type":"report","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Volume (thermodynamics); Hodgkin lymphoma; Lymphoma; Oncology; Medicine; Internal medicine; Cancer research; Biology; Physics","score_opus":0.040751045214348365,"score_gpt":0.35467243021039013,"score_spread":0.3139213849960418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396935974","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023566125,0.88305944,0.0011877158,0.0016345301,0.00054210675,0.0092954645,0.07463744,0.00013204507,0.0059451065],"genre_scores_gemma":[0.2353056,0.6957804,0.004528224,0.003533885,0.0007676423,0.03058395,0.024106627,0.000097168966,0.0052966056],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.99723583,0.00072718866,0.0012651265,0.00030150145,0.00036673044,0.00010366347],"domain_scores_gemma":[0.9881175,0.00793632,0.0030134725,0.00016268136,0.0005779269,0.00019207635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039451765,0.00077674177,0.0076899654,0.008681614,0.00029054921,0.0016095074,0.0012983048,0.0012784384,0.020386374],"category_scores_gemma":[0.01868832,0.00046413983,0.003986899,0.012323052,0.00041200715,0.0013050261,0.00082528265,0.00063802564,0.0008637325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024907717,0.00002704767,0.0045872657,0.9491409,0.012204352,0.0002053819,0.00011233636,0.00018062201,0.00026218037,0.00046750458,0.008063276,0.022258352],"study_design_scores_gemma":[0.0065869796,0.0012473057,0.065032855,0.73646194,0.1185949,0.0012434676,0.00046187823,0.0008026156,0.00056077715,0.0027445867,0.06612226,0.00014034462],"about_ca_topic_score_codex":0.0074808816,"about_ca_topic_score_gemma":0.012461666,"teacher_disagreement_score":0.020386374,"about_ca_system_score_codex":0.0028317915,"about_ca_system_score_gemma":0.0035431127,"threshold_uncertainty_score":0.06819922},"labels":[],"label_agreement":null},{"id":"W4398191044","doi":"10.1016/j.xpro.2024.103078","title":"Protocol for preclinical evaluation of locoregionally delivered CAR T cells in patient-derived xenograft models of brain tumors","year":2024,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Great Ormond Street Institute of Child Health; Medical Research Council; Stand Up To Cancer; China Agricultural Research System; Great Ormond Street Hospital Charity; Fondation Brain Canada; British Microcirculation Society; St. Baldrick's Foundation; Kids Brain Health Network; Children Neurodevelopmental Disorders Network","keywords":"Protocol (science); Medicine; Cancer research; Pathology; Alternative medicine","score_opus":0.18291787763054887,"score_gpt":0.46657308839439465,"score_spread":0.2836552107638458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398191044","genre_codex":"methods","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07930458,0.007958016,0.6537739,0.0023341877,0.0032250844,0.12526843,0.05934403,0.011358129,0.05743372],"genre_scores_gemma":[0.10348794,0.008642824,0.39646024,0.0029902107,0.00046137875,0.32801896,0.0850229,0.0017708034,0.07314468],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740195,0.00071252784,0.00030542767,0.00039590956,0.00092339865,0.0002608361],"domain_scores_gemma":[0.99810565,0.00037401766,0.00014922346,0.000515337,0.00060423923,0.00025162147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037026082,0.0019211886,0.00136633,0.0017833454,0.001391967,0.0009508473,0.0017073066,0.00166927,0.034715492],"category_scores_gemma":[0.0019628848,0.0010889076,0.0011373569,0.0009264898,0.000778478,0.0008583239,0.00096438406,0.0048557143,0.014535095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054741134,0.0033125482,0.00077487726,0.0015188957,0.00013169987,0.00057405815,0.0003900694,0.0029011657,0.8397597,0.009417749,0.090297215,0.04544783],"study_design_scores_gemma":[0.001428009,0.009404506,0.0030726644,0.00041181134,0.00027526342,0.0012654609,0.00011598459,0.0042218207,0.51867324,0.0027463294,0.45821908,0.00016580896],"about_ca_topic_score_codex":0.0008931367,"about_ca_topic_score_gemma":0.002904584,"teacher_disagreement_score":0.034715492,"about_ca_system_score_codex":0.0010566737,"about_ca_system_score_gemma":0.0027313642,"threshold_uncertainty_score":0.11613494},"labels":[],"label_agreement":null},{"id":"W4398193496","doi":"10.1016/j.jcyt.2024.03.406","title":"UNLOCKING THE POTENTIAL: TME-PRIMING RADIATION STRATEGIES FOR IMPROVING CAR-T CELL EFFICACY IN SOLID TUMOUR TREATMENT","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Priming (agriculture); Cancer research; Medicine; Biology","score_opus":0.03163566684685637,"score_gpt":0.343708207773408,"score_spread":0.3120725409265516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6803452,0.19117612,0.09178577,0.011069472,0.0013022288,0.00049238885,0.00038026227,0.0013665525,0.022081975],"genre_scores_gemma":[0.96180993,0.020744663,0.012152753,0.0008949719,0.00020959107,0.00011994347,0.000071711795,0.00007895418,0.003917462],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998203,0.000049790382,0.000007307292,0.00003786386,0.00003375054,0.000051108786],"domain_scores_gemma":[0.9998733,0.000053510114,0.000023100325,0.000019901421,0.000014060876,0.000016127655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006773256,0.00042785244,0.0004560122,0.00042250045,0.00024365087,0.0009874866,0.00051447505,0.00079662213,0.004165172],"category_scores_gemma":[0.00047144914,0.00020378108,0.00036989985,0.0002459372,0.0008066553,0.0014137614,0.0006095745,0.0017078194,0.0005796454],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009671407,0.00043616042,0.0005636071,0.00081041316,0.00006213431,0.00014095216,0.00019476848,0.0040751803,0.82852674,0.016109668,0.0017365736,0.14637664],"study_design_scores_gemma":[0.00032790969,0.0051244106,0.0029102503,0.00021779718,0.00017426116,0.0006419419,0.00030779128,0.008705571,0.9203541,0.010589295,0.05059609,0.00005061558],"about_ca_topic_score_codex":0.00040395051,"about_ca_topic_score_gemma":0.0005271022,"teacher_disagreement_score":0.004165172,"about_ca_system_score_codex":0.00046513192,"about_ca_system_score_gemma":0.00049823825,"threshold_uncertainty_score":0.013933897},"labels":[],"label_agreement":null},{"id":"W4398193540","doi":"10.1016/j.jcyt.2024.03.385","title":"COMPREHENSIVE ASSESSMENT OF PREMANUFACTURE T CELLS IDENTIFIES FUNCTIONAL DEFECTS AMONG NON-RESPONDERS TO CAR T CELL THERAPY","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Cell therapy; CAR T-cell therapy; T cell; Medicine; Cell; Immunology; Biology; Chimeric antigen receptor; Immune system; Genetics","score_opus":0.03240886436277794,"score_gpt":0.3354163098976238,"score_spread":0.3030074455348458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984518,0.0002688161,0.0003774976,0.000025324141,0.000003249962,0.00002567669,0.00017554635,0.000023353468,0.0006488609],"genre_scores_gemma":[0.9985215,0.00009019838,0.00023368341,0.00003071668,0.0000039086303,0.000033101533,0.0002754822,0.0000075595462,0.0008038681],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999764,0.000036241174,0.000018429682,0.000041321357,0.000071772585,0.000068183166],"domain_scores_gemma":[0.99969494,0.000095479096,0.00007105182,0.000031510353,0.000057885652,0.000049089307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038245268,0.00020054339,0.00028794355,0.0007513819,0.00020857819,0.00044286583,0.00025760478,0.00045673826,0.0021519677],"category_scores_gemma":[0.00070038426,0.000089266476,0.00017158905,0.0002565117,0.00025032612,0.00018556621,0.00017480749,0.00033714127,0.00042971346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027234503,0.00027415325,0.20643593,0.00006948239,0.000038752925,0.0013639417,0.000484204,0.00027285572,0.75830364,0.00017518153,0.00048064647,0.02937766],"study_design_scores_gemma":[0.000042948373,0.003847333,0.82791173,0.000020353069,0.00012107244,0.0063663214,0.0010172188,0.0016193545,0.15489228,0.00018877922,0.0039557014,0.000016876103],"about_ca_topic_score_codex":0.0010029696,"about_ca_topic_score_gemma":0.00086234685,"teacher_disagreement_score":0.0021519677,"about_ca_system_score_codex":0.0002129515,"about_ca_system_score_gemma":0.00012855705,"threshold_uncertainty_score":0.007199049},"labels":[],"label_agreement":null},{"id":"W4398193808","doi":"10.1016/j.jcyt.2024.03.340","title":"MULTIPLEX GENE EDITING IN CAR T CELLS","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Multiplex; Gene; Genome editing; Biology; Computational biology; Genetics; CRISPR","score_opus":0.03450811823970933,"score_gpt":0.33659582609495803,"score_spread":0.3020877078552487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.774909,0.0056666764,0.19067074,0.0007510348,0.000365772,0.0005281311,0.00067130086,0.0017387446,0.024698576],"genre_scores_gemma":[0.9625041,0.00092357426,0.024531353,0.00012734043,0.00004821447,0.0001914573,0.0001773873,0.000108139124,0.0113884425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99943525,0.00009424618,0.000023506667,0.00020141066,0.00013167317,0.00011394047],"domain_scores_gemma":[0.9997564,0.000084354426,0.00004597819,0.000056384717,0.000025635345,0.000031297375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065006333,0.00055148563,0.000476996,0.000385761,0.00030954243,0.0012320094,0.00054732664,0.0008288445,0.0038987796],"category_scores_gemma":[0.00049257587,0.00026207112,0.0002872794,0.0002755133,0.0004960759,0.00057712477,0.0006241115,0.0012171784,0.00068248925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014578301,0.000057545876,0.00015982284,0.000087755354,0.000015840957,0.000096760574,0.00008538756,0.0006549802,0.98189914,0.0044113775,0.00036074384,0.012024892],"study_design_scores_gemma":[0.000020410544,0.00021915232,0.00020123555,0.0000045575052,0.000018314555,0.0001815366,0.000015874068,0.001992937,0.9916821,0.0003726662,0.005283752,0.000007368032],"about_ca_topic_score_codex":0.00047537763,"about_ca_topic_score_gemma":0.0006361327,"teacher_disagreement_score":0.0038987796,"about_ca_system_score_codex":0.0005000641,"about_ca_system_score_gemma":0.00024274472,"threshold_uncertainty_score":0.013042688},"labels":[],"label_agreement":null},{"id":"W4398193887","doi":"10.1016/j.jcyt.2024.03.343","title":"ANTI-TUMOR ACTIVITY OF ENDOGLIN CAR T CELLS AGAINST ADVANCED SARCOMAS","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Endoglin; Cancer research; Medicine; Biology; Cell biology; Stem cell; CD34","score_opus":0.02439211014069121,"score_gpt":0.323605968976175,"score_spread":0.2992138588354838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947665,0.0013015623,0.0008985011,0.00012007929,0.000043034022,0.00004164621,0.0000837658,0.000068090136,0.0026768297],"genre_scores_gemma":[0.9976464,0.00056042563,0.00044243797,0.000032856457,0.000022283455,0.00002581204,0.0001041607,0.000007045947,0.0011586117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998845,0.000024547235,0.000005521619,0.000016744872,0.000022495968,0.00004621348],"domain_scores_gemma":[0.99992967,0.00002477162,0.000008069579,0.000011653287,0.000007034359,0.000018813256],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000168033,0.00023831098,0.00027199637,0.00033179478,0.00013091827,0.0002546568,0.00020122719,0.00027603205,0.0016483025],"category_scores_gemma":[0.00013778411,0.000088018096,0.00018204884,0.00015246433,0.00027419132,0.0001760849,0.00013866891,0.0007551958,0.00026349118],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010304075,0.0005691816,0.00024241494,0.00010101813,0.000021635238,0.00013197455,0.00007512472,0.0010006387,0.9823713,0.00062890246,0.00031176693,0.013515599],"study_design_scores_gemma":[0.0005528542,0.008122902,0.004176472,0.0000139135145,0.00008696701,0.00040010418,0.000077011406,0.002971781,0.97659075,0.00022957662,0.0067695435,0.000008153205],"about_ca_topic_score_codex":0.0010393967,"about_ca_topic_score_gemma":0.00087608275,"teacher_disagreement_score":0.0016483025,"about_ca_system_score_codex":0.00016239678,"about_ca_system_score_gemma":0.00029172917,"threshold_uncertainty_score":0.005514145},"labels":[],"label_agreement":null},{"id":"W4398193905","doi":"10.1016/j.jcyt.2024.03.355","title":"INVESTIGATING THE EFFECT OF INVARIANT NATURAL KILLER T CELL RECEPTOR ON T CELL DEVELOPMENT AND FUNCTION FROM HUMAN PLURIPOTENT Stem Cells","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Cell biology; Biology; Stem cell; Function (biology); Cell; Genetics; Embryonic stem cell; Gene","score_opus":0.020750893923571923,"score_gpt":0.26947251611728706,"score_spread":0.24872162219371513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919906,0.002286819,0.0036282835,0.00007051218,0.00002877418,0.000045844045,0.0001714475,0.000020184014,0.0017574783],"genre_scores_gemma":[0.9969362,0.0008247407,0.0009291074,0.000051656425,0.000007700048,0.000030573996,0.00022887002,0.000006588336,0.0009844699],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999806,0.00006308211,0.000025235451,0.00002354384,0.000047898702,0.000034223856],"domain_scores_gemma":[0.9999006,0.000053988646,0.000013968689,0.000010259612,0.000012802031,0.000008443642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044085144,0.000182412,0.00017325778,0.00015431392,0.000093748764,0.00024811417,0.00017368552,0.00023740518,0.001225662],"category_scores_gemma":[0.00021124934,0.00007540918,0.00022376471,0.00013445168,0.00014781703,0.00020610409,0.000114657414,0.0004009209,0.00016684277],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011631417,0.000031082982,0.00018556966,0.00004491458,0.00000578833,0.000045749675,0.000019470886,0.00008915922,0.99719536,0.00021599748,0.00002293107,0.0020275698],"study_design_scores_gemma":[0.000021062231,0.00050622446,0.001491113,0.0000027313395,0.000028520988,0.0000697354,0.0000146178345,0.00047426895,0.9962431,0.00003585226,0.0011112711,0.0000015875008],"about_ca_topic_score_codex":0.00036639476,"about_ca_topic_score_gemma":0.00039274446,"teacher_disagreement_score":0.001225662,"about_ca_system_score_codex":0.00013251246,"about_ca_system_score_gemma":0.00016389047,"threshold_uncertainty_score":0.0041002035},"labels":[],"label_agreement":null},{"id":"W4398194000","doi":"10.1016/j.jcyt.2024.04.051","title":"ENGINEERING CAR-EXPRESSING INNATE LYMPHOID CELLS (ILCS) FROM HUMAN PLURIPOTENT STEM CELLS (HPSCS) FOR CANCER IMMUNOTHERAPY","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Innate lymphoid cell; Cancer immunotherapy; Biology; Immunotherapy; Cancer research; Immunology; Innate immune system; Immune system; Embryonic stem cell; Genetics; Gene","score_opus":0.028846961111984416,"score_gpt":0.3121160642707506,"score_spread":0.2832691031587662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398194000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8569943,0.00592057,0.12311515,0.000543663,0.00030084583,0.00060048955,0.0012022937,0.0006927113,0.010629894],"genre_scores_gemma":[0.97559035,0.0015346453,0.017302847,0.00022982576,0.00003100707,0.00016639054,0.0005167018,0.000046745354,0.004581513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984646,0.000024496492,0.00001439668,0.000027416276,0.000056255354,0.000030870047],"domain_scores_gemma":[0.9999137,0.000023740651,0.000016767219,0.000010964649,0.00002047228,0.00001427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028737445,0.00020954758,0.00017698866,0.0002888699,0.00012506949,0.00043923393,0.0001597382,0.00037804476,0.0020847397],"category_scores_gemma":[0.00017926557,0.00009553409,0.00024121602,0.00019232872,0.00020221445,0.00017926455,0.00023540319,0.000730691,0.00066427444],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006482322,0.000034806242,0.00034698914,0.0001060941,0.00000733451,0.00009289892,0.00006442879,0.00025098477,0.988987,0.0010713096,0.00022047054,0.008752827],"study_design_scores_gemma":[0.000030788964,0.00021575583,0.0007983179,0.00001652295,0.00003404552,0.00024850544,0.00005911157,0.0017621531,0.982884,0.00023377451,0.013712262,0.00000471219],"about_ca_topic_score_codex":0.00025327128,"about_ca_topic_score_gemma":0.00049900776,"teacher_disagreement_score":0.0020847397,"about_ca_system_score_codex":0.00015292676,"about_ca_system_score_gemma":0.00021940588,"threshold_uncertainty_score":0.006974101},"labels":[],"label_agreement":null},{"id":"W4398194041","doi":"10.1016/j.jcyt.2024.03.389","title":"ACTIVATION, EXPANSION, AND CULTURE OF HUMAN T CELLS INCORPORATING IMMUNOCULTTM CGMP-COMPLIANT ANCILLARY REAGENTS","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Stemcell Technologies","funders":"","keywords":"Reagent; Cell biology; Chemistry; Biology","score_opus":0.03546791324614947,"score_gpt":0.33493439853858703,"score_spread":0.2994664852924376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398194041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.727315,0.0047450527,0.20082304,0.000612043,0.0005569634,0.007205958,0.00798,0.002574281,0.048187587],"genre_scores_gemma":[0.81876504,0.0039948956,0.12220663,0.00045330415,0.00031943698,0.006365022,0.012192711,0.00044083604,0.03526214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992429,0.00021575554,0.000077557044,0.00013858988,0.00018837009,0.00013690657],"domain_scores_gemma":[0.9996141,0.00014519822,0.000028242202,0.00011989329,0.000052516643,0.000040018298],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009134223,0.0011145115,0.0006384063,0.00047747025,0.00039783897,0.00083485997,0.00071450823,0.00073338556,0.0071663675],"category_scores_gemma":[0.00055910763,0.00034662304,0.00040152585,0.0006560895,0.00033053505,0.00029678244,0.00047524413,0.0019044145,0.004916528],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003302458,0.00022841427,0.0003201371,0.00014040344,0.0000075172866,0.00017233822,0.00026748507,0.0005811431,0.9860622,0.00083997473,0.0012606952,0.009789457],"study_design_scores_gemma":[0.000060184437,0.00051828276,0.00070961245,0.00002305015,0.000022952381,0.00021471409,0.000028104872,0.0014579818,0.9789894,0.00013016921,0.017836535,0.000008964363],"about_ca_topic_score_codex":0.00046729512,"about_ca_topic_score_gemma":0.0006275121,"teacher_disagreement_score":0.0071663675,"about_ca_system_score_codex":0.00016743163,"about_ca_system_score_gemma":0.0005150003,"threshold_uncertainty_score":0.023973823},"labels":[],"label_agreement":null},{"id":"W4398198889","doi":"10.1016/j.jcyt.2024.03.374","title":"INCREASED TRANSFECTION OF T AND NK CELLS WITH MRNA LIPID NANOPARTICLES FOR CELLULAR IMMUNOTHERAPIES","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Transfection; Messenger RNA; Cell biology; Chemistry; Molecular biology; Biology; Gene; Biochemistry","score_opus":0.017874712683085398,"score_gpt":0.2813582223888962,"score_spread":0.2634835097058108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398198889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670757,0.0019650443,0.025704866,0.00026155802,0.00014430587,0.000088596105,0.00018330423,0.00030481952,0.004271756],"genre_scores_gemma":[0.9883819,0.0006817282,0.006933748,0.000074396936,0.00001675785,0.00007627591,0.00014718392,0.000053574917,0.003634578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980813,0.000028836017,0.000013889121,0.00004859245,0.000055621796,0.000044808687],"domain_scores_gemma":[0.99991786,0.000025542011,0.000018404275,0.000009626689,0.00001871697,0.000009886184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017989999,0.00031882068,0.00027462613,0.00015504046,0.00016426954,0.00044670398,0.00015332727,0.00043308022,0.0015090391],"category_scores_gemma":[0.00019724181,0.00011362354,0.00021657812,0.00013907345,0.0002888878,0.00031375312,0.00025739733,0.00058602623,0.00044317835],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006251427,0.000019910967,0.00006009026,0.000043813092,0.0000038824633,0.000025065336,0.000022089365,0.00013906375,0.99680173,0.00030877042,0.000050781007,0.002462242],"study_design_scores_gemma":[0.0000067077285,0.000091142625,0.00019286045,0.0000023728232,0.000011531724,0.00003746816,0.000008564577,0.00050637807,0.99763334,0.00003432839,0.0014731842,0.000002116439],"about_ca_topic_score_codex":0.00048901525,"about_ca_topic_score_gemma":0.00060826284,"teacher_disagreement_score":0.0015090391,"about_ca_system_score_codex":0.0004126832,"about_ca_system_score_gemma":0.0002709352,"threshold_uncertainty_score":0.0050482154},"labels":[],"label_agreement":null},{"id":"W4398199060","doi":"10.1016/j.jcyt.2024.03.035","title":"SINGLE-DOSE GLP-1-BASED PANCREATIC GENE THERAPY PRODUCES SUSTAINED LOWERING OF BLOOD GLUCOSE AND BODY WEIGHT IN MURINE MODELS OF DIABETES AND OBESITY","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cell biology; Chemistry; Biology","score_opus":0.020401762166939643,"score_gpt":0.27069350167856093,"score_spread":0.2502917395116213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398199060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790028,0.0017175035,0.0123567,0.00076410174,0.00039821267,0.00016231542,0.0017252314,0.00082301203,0.0030502575],"genre_scores_gemma":[0.9770355,0.0015810458,0.009843745,0.00030116196,0.00010157322,0.00030584185,0.0012140907,0.00026961893,0.009347432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99958235,0.000049827122,0.00003124225,0.00010844486,0.00011325161,0.0001149719],"domain_scores_gemma":[0.99954647,0.000043283595,0.00017165112,0.00004315541,0.000025936308,0.00016933368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043673802,0.0010419367,0.0007378268,0.001403991,0.0003485619,0.00075501413,0.0005863464,0.0011045107,0.0019418806],"category_scores_gemma":[0.00018992339,0.00038443532,0.00076320395,0.0005135973,0.0010075009,0.00065226085,0.00028459146,0.0034311297,0.000530686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011028348,0.00043982602,0.00011347048,0.000046981615,0.000012307446,0.00004097794,0.000028240109,0.00028583774,0.99481356,0.0003551559,0.0001655994,0.002595341],"study_design_scores_gemma":[0.00017532553,0.0020568108,0.000906262,0.000014808824,0.000035508234,0.00007755614,0.00004081998,0.0013558249,0.9938181,0.00013170934,0.0013751691,0.000011973193],"about_ca_topic_score_codex":0.00069521985,"about_ca_topic_score_gemma":0.0014295623,"teacher_disagreement_score":0.0019418806,"about_ca_system_score_codex":0.00059009256,"about_ca_system_score_gemma":0.00053455046,"threshold_uncertainty_score":0.0064962506},"labels":[],"label_agreement":null},{"id":"W4398775452","doi":"10.1016/j.semarthrit.2024.152479","title":"Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions","year":2024,"lang":"en","type":"review","venue":"Seminars in Arthritis and Rheumatism","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Rheumatic disease; Autoimmune disease; Disease; Dermatology; Immunology; Intensive care medicine; Rheumatoid arthritis; Internal medicine","score_opus":0.019721510685513168,"score_gpt":0.32338727582527316,"score_spread":0.30366576513976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398775452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011987307,0.99647814,0.00010704502,0.0024927969,0.0002655739,0.000008881164,0.000016264574,0.0000040038713,0.0005073447],"genre_scores_gemma":[0.0025590644,0.99366343,0.00043132025,0.0021998414,0.00090612355,0.000020312518,0.000035821377,0.000002308266,0.00018183824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756324,0.0010339193,0.0004263433,0.00020965858,0.0006334239,0.00013335151],"domain_scores_gemma":[0.98896176,0.00786436,0.0011852654,0.00017647589,0.0015467497,0.00026534926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006375648,0.00069522415,0.0016735158,0.001957572,0.00033153233,0.002518017,0.0008676412,0.0025102524,0.0057433317],"category_scores_gemma":[0.008110725,0.00028824786,0.0012436848,0.0018160508,0.0009207653,0.0032914882,0.00094242295,0.0026641213,0.00124183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003279804,0.00010169394,0.0005878716,0.0665763,0.00031702305,0.00017228897,0.00010177795,0.00028863404,0.0009711299,0.005893356,0.024319243,0.9003427],"study_design_scores_gemma":[0.0002505731,0.0011035072,0.002191861,0.15631466,0.0020287547,0.0017250815,0.00056470773,0.000490025,0.0010047692,0.014014091,0.82025385,0.00005819976],"about_ca_topic_score_codex":0.0008256791,"about_ca_topic_score_gemma":0.0018945121,"teacher_disagreement_score":0.006375648,"about_ca_system_score_codex":0.0011688999,"about_ca_system_score_gemma":0.0031995014,"threshold_uncertainty_score":0.03371811},"labels":[],"label_agreement":null},{"id":"W4398783795","doi":"10.1080/10428194.2024.2353877","title":"Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Blinatumomab; Refractory (planetary science); Internal medicine; Clinical trial; Lymphoblastic Leukemia; Oncology; Leukemia","score_opus":0.024587027961861088,"score_gpt":0.2825747664574556,"score_spread":0.25798773849559453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398783795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596596,0.0024964414,0.000071760594,0.00007050604,0.000028841976,0.00009417051,0.0004917411,0.000005263445,0.0007752596],"genre_scores_gemma":[0.9961791,0.0010016857,0.00008276212,0.00015335908,0.000048925995,0.00015754317,0.0020867418,0.0000027146511,0.00028716077],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9994148,0.00032593013,0.000044343,0.00007337174,0.000041667125,0.00009992221],"domain_scores_gemma":[0.99921477,0.00015175501,0.00024397379,0.00005464248,0.00003903953,0.0002958224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020023086,0.0003316591,0.00083554833,0.0002628927,0.00033252282,0.0006253628,0.00029580845,0.0004376034,0.0013143464],"category_scores_gemma":[0.0013116916,0.00013205483,0.0010803667,0.00039793475,0.0002643006,0.00055071607,0.0005395971,0.00069819076,0.00023177567],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57300943,0.007195164,0.33130988,0.0006619604,0.0029871988,0.00086467667,0.0005590549,0.0026302568,0.0077741314,0.00051039,0.0031381259,0.069359794],"study_design_scores_gemma":[0.061546348,0.20989871,0.7061316,0.00023757166,0.0027665864,0.001784521,0.0005502103,0.0014901276,0.0030301437,0.000560249,0.011936731,0.00006734921],"about_ca_topic_score_codex":0.00052948575,"about_ca_topic_score_gemma":0.0011429214,"teacher_disagreement_score":0.0020023086,"about_ca_system_score_codex":0.00056846836,"about_ca_system_score_gemma":0.0005137662,"threshold_uncertainty_score":0.010589361},"labels":[],"label_agreement":null},{"id":"W4399032715","doi":"10.1111/bjh.19569","title":"Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A <scp>CIBMTR</scp> analysis","year":2024,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Moonshot; Moonshot Research and Development Program; National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Alexion Pharmaceuticals; bluebird bio; Pharmacyclics; Takeda Oncology; AstraZeneca; Genentech; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Seagen; Pediatric Blood and Marrow Transplant Consortium; Pediatric Transplantation and Cellular Therapy Consortium; CareDx; BeiGene; Juno Therapeutics; Swedish Orphan Biovitrum; Astellas Pharma; GlaxoSmithKline; Kiadis Pharma; Jazz Pharmaceuticals; Medical College of Wisconsin; Gateway for Cancer Research; Celgene; Omeros Corporation; Vertex Pharmaceuticals; Atara Biotherapeutics; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; National Marrow Donor Program; Mallinckrodt Pharmaceuticals; Astellas Pharma US; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Sanofi; HistoGenetics","keywords":"Chimeric antigen receptor; Medicine; Central nervous system; Lymphoma; Antigen; Receptor; Immunology; Oncology; Immunotherapy; Cancer research; Internal medicine; Immune system","score_opus":0.008835141096105326,"score_gpt":0.23265787953333253,"score_spread":0.2238227384372272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399032715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759405,0.0013590899,0.00036000175,0.0012988653,0.00012755966,0.00010487979,0.014549181,0.000019582123,0.0062402603],"genre_scores_gemma":[0.9887143,0.00038590629,0.00011536067,0.00043532142,0.00012900676,0.00012605629,0.008573802,0.000009569734,0.0015106897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99930465,0.0002029762,0.00007815458,0.00010505611,0.00016036478,0.00014884368],"domain_scores_gemma":[0.9983859,0.0004793634,0.0005311937,0.00009897285,0.00022320516,0.0002814652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073603605,0.00019888084,0.00050770334,0.0006505058,0.00028500092,0.0004207344,0.0003165914,0.0004450489,0.0057012835],"category_scores_gemma":[0.0021709441,0.00012418035,0.00085315463,0.001171799,0.00016127585,0.0004620212,0.0003682855,0.00061656657,0.0005801462],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0119152,0.00020935314,0.93017197,0.00028211417,0.0011785299,0.0020104551,0.00018275663,0.0015251419,0.0007804426,0.00039227965,0.021651126,0.029700689],"study_design_scores_gemma":[0.0008857578,0.001569205,0.9873954,0.00009386562,0.000611274,0.002300614,0.00027661462,0.0013189737,0.00021843235,0.0005655539,0.0047298297,0.00003452294],"about_ca_topic_score_codex":0.004031113,"about_ca_topic_score_gemma":0.004815021,"teacher_disagreement_score":0.0057012835,"about_ca_system_score_codex":0.0010202577,"about_ca_system_score_gemma":0.00047742928,"threshold_uncertainty_score":0.019072652},"labels":[],"label_agreement":null},{"id":"W4399040613","doi":"10.1080/14737140.2024.2344647","title":"Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Expert Review of Anticancer Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Medicine; Multiple myeloma; Antibody-drug conjugate; Bispecific antibody; Antibody; Drug; Immunotherapy; Oncology; Refractory (planetary science); Antibody therapy; Internal medicine; Immunology; Cancer research; Monoclonal antibody; Pharmacology; Cancer","score_opus":0.03972425220517079,"score_gpt":0.37765439056616346,"score_spread":0.33793013836099267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399040613","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043918838,0.9935144,0.00045457276,0.0017058928,0.0007015125,0.000016878574,0.000052069357,0.000018113644,0.0030973624],"genre_scores_gemma":[0.0044329064,0.9897489,0.00041762652,0.0017976374,0.0008101428,0.00003090588,0.00011695279,0.0000042645006,0.0026406706],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997603,0.00006545578,0.000019522664,0.000034079316,0.0000892962,0.00003126611],"domain_scores_gemma":[0.9998072,0.00007589819,0.00003817489,0.0000043013733,0.00005748646,0.000017015927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006267014,0.00041858552,0.00062769937,0.0008365473,0.00014958101,0.00067660684,0.00053149625,0.0013829772,0.0063012135],"category_scores_gemma":[0.00055205676,0.00013635725,0.0004895857,0.00064340833,0.0002561197,0.000778468,0.00043442112,0.0013293739,0.0021985937],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018927558,0.000081302445,0.00015854782,0.016847914,0.000125626,0.00032119147,0.00006656774,0.00067442865,0.0053991843,0.0059436727,0.07686753,0.89332473],"study_design_scores_gemma":[0.000056439607,0.00019984481,0.00039988692,0.002595623,0.00010234747,0.0011922301,0.000038323135,0.00018452102,0.0013881654,0.002515548,0.9913135,0.000013664],"about_ca_topic_score_codex":0.00058302865,"about_ca_topic_score_gemma":0.0012628663,"teacher_disagreement_score":0.0063012135,"about_ca_system_score_codex":0.0005345517,"about_ca_system_score_gemma":0.00061012054,"threshold_uncertainty_score":0.021079719},"labels":[],"label_agreement":null},{"id":"W4399052293","doi":"10.1101/2024.05.22.595383","title":"Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Tow Foundation","keywords":"Multiple myeloma; Immunotherapy; Antigen; Immune escape; Immunology; Cancer research; Biology; Immune system","score_opus":0.023750365389989373,"score_gpt":0.2541226220592759,"score_spread":0.2303722566692865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399052293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99748874,0.0007086281,0.0011077024,0.000057394303,0.0000036636648,0.0000075194243,0.00015510787,0.000032217922,0.00043897366],"genre_scores_gemma":[0.99841475,0.00021497684,0.00093976274,0.000029401803,0.0000024492892,0.0000045288184,0.00018188282,0.0000070267233,0.00020521313],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998785,0.000022882956,0.0000055001387,0.00003529344,0.00003526612,0.000022515065],"domain_scores_gemma":[0.99988353,0.000024886025,0.0000495838,0.000011979111,0.000010938437,0.0000190028],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001881279,0.00009269793,0.00027233994,0.00032510745,0.00016181482,0.0003131414,0.000106914275,0.00024468685,0.0006351619],"category_scores_gemma":[0.00049724453,0.000100265344,0.00012328908,0.0004140697,0.00015598697,0.00017184988,0.00020398734,0.00030713135,0.00013539524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031528708,0.00026153066,0.317221,0.0001540828,0.00013547316,0.0016289179,0.00066633796,0.010090915,0.50155073,0.0006722126,0.0009193289,0.16354653],"study_design_scores_gemma":[0.00005988953,0.0021682247,0.8119384,0.000025879455,0.0001322867,0.0038741096,0.00028229106,0.026019095,0.14913681,0.0009978876,0.00533826,0.000026754971],"about_ca_topic_score_codex":0.0015693031,"about_ca_topic_score_gemma":0.0014818854,"teacher_disagreement_score":0.0015693031,"about_ca_system_score_codex":0.00036296775,"about_ca_system_score_gemma":0.00015426449,"threshold_uncertainty_score":0.0031203628},"labels":[],"label_agreement":null},{"id":"W4399122701","doi":"10.1016/j.ejcskn.2024.100143","title":"A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Nivolumab; Medicine; Pharmacokinetics; Safety profile; Metastatic melanoma; Melanoma; Oncology; Pharmacology; Internal medicine; Anesthesia; Adverse effect; Cancer; Immunotherapy; Cancer research","score_opus":0.026175707076226656,"score_gpt":0.35289931568384625,"score_spread":0.3267236086076196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943968,0.0007344535,0.0006138687,0.00028259106,0.00017514863,0.0013557116,0.0011188878,0.000098492834,0.0012240062],"genre_scores_gemma":[0.98867387,0.0009310872,0.0021275878,0.0006949998,0.00022693965,0.0020113392,0.0021048211,0.00008771844,0.0031415892],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99923706,0.00031428997,0.00002218049,0.00016109427,0.00006577637,0.00019963107],"domain_scores_gemma":[0.9989536,0.00018038304,0.00017139525,0.00014038401,0.000053972242,0.0005002953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021243384,0.0020061247,0.003010283,0.0006939989,0.00059552514,0.0015178691,0.0011159127,0.0014524187,0.0040492313],"category_scores_gemma":[0.0012425807,0.00093514123,0.0030031106,0.0006000724,0.0016178649,0.0011668879,0.00039449832,0.0058784373,0.0012733114],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82475317,0.09775673,0.0017963259,0.0002868263,0.0013618274,0.00012177545,0.00025048683,0.0022508744,0.03191299,0.00027221223,0.0021004851,0.037136372],"study_design_scores_gemma":[0.4355563,0.55474645,0.0040478264,0.000013267445,0.00043337946,0.000110114044,0.00005256532,0.0011252034,0.0027644942,0.00018531813,0.0009297109,0.000035494755],"about_ca_topic_score_codex":0.0024716705,"about_ca_topic_score_gemma":0.0038741964,"teacher_disagreement_score":0.0040492313,"about_ca_system_score_codex":0.0014913299,"about_ca_system_score_gemma":0.00255078,"threshold_uncertainty_score":0.01354605},"labels":[],"label_agreement":null},{"id":"W4399154266","doi":"10.29173/eureka28822","title":"How Fundamental Research on T cell Biology Started a Revolution in Cancer Therapy Development","year":2024,"lang":"en","type":"article","venue":"Eureka","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Transformative learning; Cancer immunotherapy; Immune checkpoint; Immunotherapy; Cancer therapy; Cancer; Cornerstone; Cancer cell; Environmental ethics; Biology; Immune system; Cancer research; Immunology; Sociology; Philosophy; History; Genetics","score_opus":0.18498004284897754,"score_gpt":0.44703414907501104,"score_spread":0.26205410622603353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399154266","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007657725,0.36665574,0.025259146,0.49949172,0.035805788,0.00009357326,0.00025875997,0.00041473296,0.064362794],"genre_scores_gemma":[0.27015355,0.36686862,0.029839119,0.22463137,0.03235234,0.000283352,0.00027082307,0.00060274004,0.07499808],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99634993,0.0015645487,0.00013521839,0.00057989813,0.00091397285,0.0004565249],"domain_scores_gemma":[0.99477494,0.0028773495,0.0002670073,0.0005023121,0.000694775,0.0008835378],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.009370459,0.0007364699,0.0010189824,0.0015805509,0.0022970168,0.009514605,0.00086994667,0.0060489723,0.011657839],"category_scores_gemma":[0.012095524,0.00048324454,0.0008647322,0.0008834377,0.013091647,0.014011107,0.003675883,0.01349031,0.00425853],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004807015,0.00017964165,0.00084578496,0.00093804684,0.000089534115,0.0003469453,0.0015725906,0.0011893751,0.0048870426,0.6934052,0.11960178,0.17646337],"study_design_scores_gemma":[0.00007594399,0.00019952233,0.00022387013,0.0006355009,0.000031852956,0.00032368457,0.00066595507,0.0002877292,0.0021365567,0.29128906,0.7040828,0.000047530062],"about_ca_topic_score_codex":0.0021363827,"about_ca_topic_score_gemma":0.0021157688,"teacher_disagreement_score":0.99770296,"about_ca_system_score_codex":0.005110523,"about_ca_system_score_gemma":0.006545904,"threshold_uncertainty_score":0.049556315},"labels":[],"label_agreement":null},{"id":"W4399157658","doi":"10.21203/rs.3.rs-4432372/v1","title":"Limited Immunogenicity of an HLA-A*03:01-restricted Epitope of Erv-k-env in Non-hiv-1 Settings: Implications for Adoptive Cell Therapy in Cancer","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; National Cancer Institute; Children's National Hospital; George Washington University; U.S. Department of Defense","keywords":"Immunogenicity; Epitope; Human leukocyte antigen; Virology; Human immunodeficiency virus (HIV); Cancer; Adoptive cell transfer; Immunology; Medicine; Cancer research; Antibody; Immune system; T cell; Antigen; Internal medicine","score_opus":0.08717692726774202,"score_gpt":0.44479350366338494,"score_spread":0.3576165763956429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399157658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99102473,0.0023812347,0.0028191186,0.00029820824,0.000033821612,0.000027666278,0.00011794842,0.000051530016,0.0032458038],"genre_scores_gemma":[0.99703395,0.0005583521,0.0007347316,0.00008117043,0.000012081466,0.00001589894,0.00010432654,0.0000083878185,0.001451083],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998536,0.000054760698,0.000011177923,0.000017125763,0.000030102465,0.000033141398],"domain_scores_gemma":[0.9998708,0.00005472619,0.000025612813,0.000018387691,0.000012780779,0.000017760996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039597682,0.00016439067,0.00018132714,0.00008823684,0.0000994807,0.00040994678,0.00016129768,0.00030996386,0.0021244143],"category_scores_gemma":[0.0002869769,0.00007065153,0.000101313715,0.00006629636,0.00020076131,0.00019787642,0.00012564841,0.00036524233,0.00040319297],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039795262,0.000091753056,0.0014086866,0.000083428255,0.0000050328977,0.00021979725,0.00003697336,0.0001325659,0.9910149,0.0004781107,0.00016909558,0.0059616636],"study_design_scores_gemma":[0.00006742401,0.0012949272,0.011126118,0.000025949337,0.000032997443,0.0023060974,0.0001306961,0.001247515,0.9775619,0.0004579208,0.0057430007,0.0000054429815],"about_ca_topic_score_codex":0.00016502074,"about_ca_topic_score_gemma":0.00015371665,"teacher_disagreement_score":0.0021244143,"about_ca_system_score_codex":0.00018296768,"about_ca_system_score_gemma":0.00018284525,"threshold_uncertainty_score":0.0071069},"labels":[],"label_agreement":null},{"id":"W4399275929","doi":"10.1101/2024.05.29.596375","title":"Pre-TCR-Targeted Immunotherapy for T-cell Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centro Nacional de Biotecnología; Brigham and Women's Hospital; University of Toronto; Universiteit van Amsterdam; European Regional Development Fund; European Commission; Agencia Estatal de Investigación; Fundación Inocente, Inocente; Centro de Biología Molecular Severo Ochoa; Sunnybrook Research Institute; Comunidad de Madrid; Fundación Ramón Areces","keywords":"T-cell receptor; Lymphoblastic Leukemia; Immunotherapy; Medicine; Cancer research; T cell; Leukemia; Immunology; Immune system","score_opus":0.014531618191342218,"score_gpt":0.26593728888083595,"score_spread":0.2514056706894937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399275929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8305276,0.07635868,0.04723887,0.004969191,0.0012980092,0.0006345121,0.0017829126,0.0016773813,0.035512734],"genre_scores_gemma":[0.9395679,0.022352854,0.016469615,0.0006212133,0.00034888758,0.00016887528,0.0013407047,0.00013394433,0.01899597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999137,0.000017423516,0.0000044936132,0.000012521354,0.000034554898,0.000017280227],"domain_scores_gemma":[0.9999672,0.0000069665725,0.000006253908,0.00000494772,0.0000048926427,0.000009788464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018046936,0.00028773496,0.0002119391,0.0002406034,0.000107182124,0.0003296162,0.0001451255,0.00024611386,0.0028586374],"category_scores_gemma":[0.00009180495,0.000081592276,0.00014895973,0.00014476199,0.00013913022,0.00015584946,0.00020730533,0.000833579,0.0012288726],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005470917,0.00025441762,0.00081698305,0.0003368921,0.000029463732,0.0003071852,0.0000467737,0.0012382303,0.9316206,0.003311632,0.006065027,0.055425763],"study_design_scores_gemma":[0.00017340227,0.00090750906,0.0024894802,0.000033118427,0.000049971673,0.0022256377,0.000026139885,0.0028132724,0.86728567,0.0017181125,0.12226964,0.0000080818345],"about_ca_topic_score_codex":0.00017599628,"about_ca_topic_score_gemma":0.00021652113,"teacher_disagreement_score":0.0028586374,"about_ca_system_score_codex":0.00024742412,"about_ca_system_score_gemma":0.00023606961,"threshold_uncertainty_score":0.009563088},"labels":[],"label_agreement":null},{"id":"W4399281392","doi":"10.1200/jco.2024.42.16_suppl.10016","title":"Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood &amp; Marrow Transplant Research (CIBMTR) registry results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Blinatumomab; Bone marrow transplant; Hematopoietic cell; Acute lymphocytic leukemia; Bone marrow; Oncology; Bone transplantation; Pediatrics; Leukemia; Internal medicine; Bone marrow transplantation; Stem cell; Surgery; Haematopoiesis","score_opus":0.14603389688117718,"score_gpt":0.46044773126579247,"score_spread":0.3144138343846153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833672,0.0016003638,0.0001499001,0.00046319477,0.000022464363,0.000059089947,0.011855072,0.000026219204,0.0024565277],"genre_scores_gemma":[0.98271054,0.0009120473,0.00021152198,0.00039466066,0.000029712903,0.00007207092,0.014989068,0.000016099857,0.00066426105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989197,0.00023974513,0.0001723843,0.00021032203,0.00031795015,0.00013983864],"domain_scores_gemma":[0.9958092,0.0005524978,0.0025912158,0.00017665491,0.00042424645,0.00044624254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018545813,0.00013305742,0.0002944368,0.0006404818,0.00023426198,0.0009653672,0.00045451758,0.00039221335,0.0014406095],"category_scores_gemma":[0.0031275263,0.0001685399,0.00043740173,0.0015073194,0.0001792177,0.000793003,0.0004209099,0.000777333,0.000450631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012284324,0.00015871343,0.98439884,0.0000452134,0.000102113125,0.00009592027,0.00006625385,0.00022051977,0.00029683262,0.00007313616,0.0020373943,0.011276483],"study_design_scores_gemma":[0.0001379808,0.0008185982,0.9920866,0.000048483038,0.00015061078,0.0006673348,0.00024576325,0.0006709832,0.00046399617,0.00005762101,0.004639302,0.000012669166],"about_ca_topic_score_codex":0.0066627967,"about_ca_topic_score_gemma":0.012288973,"teacher_disagreement_score":0.0066627967,"about_ca_system_score_codex":0.0010808783,"about_ca_system_score_gemma":0.0014711266,"threshold_uncertainty_score":0.013248026},"labels":[],"label_agreement":null},{"id":"W4399285742","doi":"10.1038/s41591-024-02986-9","title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"Loxo Oncology; Pharmacyclics; Chugai Pharmaceutical; Genentech; EMD Serono; MorphoSys; SymBio Pharmaceuticals Limited; BeiGene; Mitsubishi Tanabe Pharma Corporation; Seagen; Celgene; Alimera Sciences; Eisai; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Karyopharm Therapeutics; Sanofi; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Follicular phase; Lymphoma; Oncology; Confidence interval; Rituximab; CD20; Clinical endpoint; Gastroenterology; Clinical trial; Biology","score_opus":0.022271693998789203,"score_gpt":0.38543607341103714,"score_spread":0.36316437941224794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399285742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96683216,0.017613031,0.0010153846,0.0012290811,0.00021238126,0.0030560102,0.0024152286,0.00020252635,0.007424158],"genre_scores_gemma":[0.97463566,0.0069144308,0.0021963927,0.0022228046,0.00031848295,0.0030004184,0.005351493,0.000053381584,0.0053069894],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99962366,0.00020205163,0.000014348847,0.00004113918,0.00006339667,0.00005547038],"domain_scores_gemma":[0.99954873,0.00008673385,0.000105393796,0.00004174478,0.00005380181,0.00016340983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019693663,0.00079971197,0.00096124545,0.00035960993,0.00018229186,0.0006594572,0.00071814546,0.0008637037,0.003136626],"category_scores_gemma":[0.0008489398,0.00023686528,0.0011277082,0.00022961485,0.0003450441,0.0005854342,0.00037684082,0.0016432593,0.000737482],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46501926,0.046182178,0.015156153,0.0027815537,0.003194351,0.0005028152,0.00038726124,0.0029486606,0.044371985,0.0010118342,0.016468102,0.40197587],"study_design_scores_gemma":[0.48684806,0.4387142,0.03190991,0.00026141023,0.0021135705,0.00087918923,0.00013235136,0.0019840337,0.0078058685,0.0006386988,0.02865268,0.00006003084],"about_ca_topic_score_codex":0.00042968232,"about_ca_topic_score_gemma":0.0011927605,"teacher_disagreement_score":0.003136626,"about_ca_system_score_codex":0.00054707006,"about_ca_system_score_gemma":0.0006756371,"threshold_uncertainty_score":0.0104931},"labels":[],"label_agreement":null},{"id":"W4399292909","doi":"10.1038/s41551-024-01216-4","title":"Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells","year":2024,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health; Government of Canada; U.S. Department of Health and Human Services","keywords":"T cell; Chimeric antigen receptor; Scaffold; Chemistry; Cytotoxicity; Cell growth; Cell biology; Pharmacology; Cancer research; Immunology; In vitro; Medicine; Immune system; Biology; Biomedical engineering; Biochemistry","score_opus":0.014981513598037401,"score_gpt":0.31167360044932724,"score_spread":0.29669208685128984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399292909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97760713,0.0031785157,0.014885588,0.00012763597,0.00025824495,0.00013799359,0.00040387793,0.00032912838,0.0030718264],"genre_scores_gemma":[0.9890286,0.00097390293,0.005874854,0.000050653463,0.000046929024,0.00009262503,0.00023506643,0.00003963328,0.0036577776],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997842,0.00002117842,0.000012465678,0.000044938093,0.0000607281,0.00007647734],"domain_scores_gemma":[0.99981934,0.0000508529,0.00006064759,0.000019016119,0.000014777954,0.000035367968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028908782,0.0006153232,0.00022937063,0.00035157384,0.00014543843,0.00038263027,0.00022396086,0.00048792057,0.0018008617],"category_scores_gemma":[0.0001825371,0.00014336905,0.00032370363,0.00018298687,0.0002102717,0.00034834282,0.00017701011,0.0006237006,0.0003777085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001223209,0.000071043134,0.00004365435,0.000042244315,0.000003731959,0.00005134746,0.00001654988,0.00012068824,0.997454,0.0000845634,0.00004268236,0.0019472856],"study_design_scores_gemma":[0.00001938266,0.00066370674,0.00043109932,0.0000052228847,0.000019472332,0.00007817106,0.000018545277,0.00063029776,0.99672073,0.000021163218,0.0013889996,0.0000032898788],"about_ca_topic_score_codex":0.00052488944,"about_ca_topic_score_gemma":0.0011032525,"teacher_disagreement_score":0.0018008617,"about_ca_system_score_codex":0.00020613511,"about_ca_system_score_gemma":0.00033412597,"threshold_uncertainty_score":0.00602448},"labels":[],"label_agreement":null},{"id":"W4399296888","doi":"10.1101/2024.05.29.596014","title":"Conditional CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Glycosaminoglycan; Oncofetal antigen; Cell biology; Cancer research; Chemistry; Biology; Biochemistry; Immunology; Immunotherapy; Immune system","score_opus":0.020014724663877652,"score_gpt":0.2707863480388036,"score_spread":0.2507716233749259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399296888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98728895,0.0005994126,0.00833139,0.00014731703,0.00004155315,0.000087615874,0.0005400187,0.00033879248,0.0026249154],"genre_scores_gemma":[0.99309665,0.00015200324,0.0025683632,0.000055003802,0.0000097675065,0.00004990908,0.00048065593,0.00004582186,0.0035417327],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997255,0.000042627493,0.000023360968,0.00006105064,0.00004999444,0.00009749196],"domain_scores_gemma":[0.9998723,0.0000331417,0.000025319861,0.000019293517,0.000016774953,0.00003317573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024467587,0.00041421264,0.00024084968,0.00021545704,0.00013967723,0.00048451227,0.00026751903,0.00044355873,0.0023893055],"category_scores_gemma":[0.00014125474,0.00016754169,0.00022486872,0.00014990543,0.00035130093,0.00019586789,0.00027689873,0.0008028081,0.00070360524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011410652,0.000032403797,0.000105600244,0.00001965609,0.000003484082,0.00004614468,0.000017598715,0.00011479536,0.99836546,0.0002917986,0.00009934341,0.00078955584],"study_design_scores_gemma":[0.000027544578,0.00019897814,0.00050929806,0.0000024354329,0.00001182057,0.00019376435,0.00001725128,0.0011251437,0.99542195,0.00004186282,0.0024466785,0.0000032775083],"about_ca_topic_score_codex":0.00056450895,"about_ca_topic_score_gemma":0.0004477109,"teacher_disagreement_score":0.0023893055,"about_ca_system_score_codex":0.00028618317,"about_ca_system_score_gemma":0.0002081447,"threshold_uncertainty_score":0.0079930425},"labels":[],"label_agreement":null},{"id":"W4399304973","doi":"10.1186/s12967-024-05340-2","title":"Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth","year":2024,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Defence Research and Development Canada; Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Programmed cell death; Cancer cell; Flow cytometry; Apoptosis; Immune system; Cancer; Cell cycle checkpoint; Cell cycle; Biology; Transcriptome; Endosome; Cell culture; Cell; Chemistry; Molecular biology; Immunology; Biochemistry; Gene; Genetics; Gene expression","score_opus":0.02375582300826361,"score_gpt":0.30952036329841026,"score_spread":0.28576454029014664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957059,0.0013722071,0.0014580389,0.000039163006,0.000017229264,0.000039121045,0.00015096129,0.00007917975,0.0011383306],"genre_scores_gemma":[0.9961887,0.00071304565,0.0012845333,0.000024130211,0.0000068081213,0.000036919344,0.00017276352,0.000011469816,0.0015617019],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999442,0.000007355493,0.0000041848393,0.000013100808,0.000017945475,0.000013207187],"domain_scores_gemma":[0.99996257,0.000007166689,0.000011651136,0.0000037212856,0.0000056957583,0.000009154576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000776682,0.00025223338,0.00017977705,0.00016625883,0.000069541995,0.00017477617,0.000121750905,0.00018159827,0.001019211],"category_scores_gemma":[0.000051164174,0.00006727855,0.0001463174,0.000086632135,0.000121660974,0.00011308375,0.00010378986,0.0002702191,0.00017900698],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015394363,0.00004700575,0.000088283596,0.00004906628,0.000004645247,0.000021860975,0.0000071947816,0.00018899434,0.99743503,0.00004996188,0.00006122683,0.0018927582],"study_design_scores_gemma":[0.000016964294,0.0007888339,0.00076320686,0.000004794637,0.000012238491,0.00006577802,0.000008882684,0.00068628776,0.99614704,0.000010871279,0.0014924245,0.0000026769983],"about_ca_topic_score_codex":0.00032397624,"about_ca_topic_score_gemma":0.00048577334,"teacher_disagreement_score":0.001019211,"about_ca_system_score_codex":0.00015856499,"about_ca_system_score_gemma":0.00012429598,"threshold_uncertainty_score":0.003409624},"labels":[],"label_agreement":null},{"id":"W4399379462","doi":"10.1101/2024.06.04.597422","title":"IMMUNOTAR - Integrative prioritization of cell surface targets for cancer immunotherapy","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; Terry Fox Research Institute","funders":"National Cancer Institute; Cancer Research UK; National Institutes of Health; Michael Smith Health Research BC; Mark Foundation For Cancer Research","keywords":"Prioritization; Immunotherapy; Cancer immunotherapy; Cancer; Computational biology; Cancer research; Computer science; Medicine; Biology; Engineering; Internal medicine; Management science","score_opus":0.017139886532822945,"score_gpt":0.2873855314952395,"score_spread":0.27024564496241654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399379462","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32210153,0.002063251,0.5801625,0.0015747627,0.0003246717,0.00053028937,0.03107004,0.049805272,0.012367618],"genre_scores_gemma":[0.5225043,0.0009664316,0.4285972,0.0007438247,0.00011183652,0.000905773,0.040437568,0.003119569,0.0026134495],"study_design_codex":"simulation_or_modeling","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99941134,0.00017437837,0.000044610835,0.00016371337,0.00015030563,0.00005567698],"domain_scores_gemma":[0.99904567,0.00055740145,0.00007753301,0.00011630384,0.00013661741,0.00006641889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019730295,0.0013182962,0.0014696277,0.0018295253,0.0005196465,0.0022187585,0.0011815475,0.000785246,0.004155788],"category_scores_gemma":[0.0032156894,0.000526946,0.0017935769,0.0014058227,0.00039658239,0.0013557167,0.0012112096,0.0010134209,0.001120205],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026902468,0.00089821755,0.039199892,0.0021324612,0.0015162902,0.0007556562,0.00046646554,0.59790564,0.07665491,0.025158796,0.062536195,0.19008526],"study_design_scores_gemma":[0.00017462803,0.00017218945,0.0017493066,0.000027926979,0.00013304691,0.000116347655,0.00006979358,0.9612549,0.016152002,0.011126498,0.008985658,0.000037722122],"about_ca_topic_score_codex":0.002428904,"about_ca_topic_score_gemma":0.0050208876,"teacher_disagreement_score":0.004155788,"about_ca_system_score_codex":0.0008462793,"about_ca_system_score_gemma":0.0021028295,"threshold_uncertainty_score":0.013902485},"labels":[],"label_agreement":null},{"id":"W4399391946","doi":"10.21203/rs.3.rs-4381902/v1","title":"Epithelial Cell Adhesion Molecule (EpCAM)-Targeted CAR-T Cells (IMC001) in Patients with Advanced Gastric Cancer: A Phase I Dose-Escalation Trial","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Medicine; Tolerability; Epithelial cell adhesion molecule; Cancer; Gastroenterology; Internal medicine; Pharmacokinetics; Cmax; Chemotherapy; Oncology; Nuclear medicine; Adverse effect","score_opus":0.034035100479836954,"score_gpt":0.3872638101725909,"score_spread":0.353228709692754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399391946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911573,0.0023903775,0.00044000515,0.00124278,0.00019331179,0.00087851565,0.0009646426,0.0001368693,0.0025961755],"genre_scores_gemma":[0.9817139,0.0028599703,0.0020927244,0.0016996035,0.00020306672,0.0014197307,0.0031248524,0.000069122856,0.0068170764],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997534,0.00009546701,0.000008061404,0.000045968492,0.00002195467,0.00007506431],"domain_scores_gemma":[0.99972504,0.000053868192,0.00003256169,0.00002753602,0.000014616628,0.00014629506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001047194,0.0014736862,0.0015662018,0.00031270584,0.00026969248,0.00096763525,0.0006338508,0.0011009843,0.0040905965],"category_scores_gemma":[0.0005406278,0.00040232274,0.0012130239,0.00037645444,0.00089353713,0.0007686192,0.00036464375,0.0037803825,0.0008970817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6218519,0.050368186,0.006347003,0.0011283307,0.00198712,0.0003126055,0.0003975851,0.006525421,0.04071732,0.0009585461,0.018090786,0.2513152],"study_design_scores_gemma":[0.6998736,0.2735643,0.010654175,0.000054499444,0.0009106052,0.00024085943,0.00011257998,0.0029313609,0.005305031,0.00051905605,0.0057911268,0.00004274611],"about_ca_topic_score_codex":0.0014849763,"about_ca_topic_score_gemma":0.0033404755,"teacher_disagreement_score":0.0040905965,"about_ca_system_score_codex":0.0011199419,"about_ca_system_score_gemma":0.0014603637,"threshold_uncertainty_score":0.013684452},"labels":[],"label_agreement":null},{"id":"W4399452369","doi":"10.1200/jco.2024.42.17_suppl.lba7005","title":"Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Brentuximab vedotin; Rituximab; Population; Oncology; Refractory (planetary science); Clinical endpoint; Placebo; Phases of clinical research; Diffuse large B-cell lymphoma; Interim analysis; Gastroenterology; Surgery; Lymphoma; CD30; Chemotherapy; Randomized controlled trial; Multiple myeloma; Pathology","score_opus":0.05589310246874222,"score_gpt":0.41747220317367334,"score_spread":0.3615791007049311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898201,0.006703234,0.00029655415,0.00037064357,0.0000957456,0.0006073336,0.0008740243,0.000058613132,0.0011737477],"genre_scores_gemma":[0.99292177,0.002178273,0.0006887458,0.0007428803,0.00014419256,0.0005536683,0.0019238433,0.000021431802,0.0008252825],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9993112,0.0004039752,0.00003957411,0.00007788701,0.00007300866,0.000094335446],"domain_scores_gemma":[0.9993678,0.00012376254,0.00016616534,0.00004989778,0.00003239543,0.0002599968],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023960425,0.0010800312,0.0020356297,0.0003783067,0.00025514068,0.0011096246,0.0009119253,0.0009544025,0.001484304],"category_scores_gemma":[0.0010309927,0.00049552677,0.0015831498,0.00046632192,0.00065267034,0.0009261646,0.00039228384,0.002081328,0.00050435925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8255762,0.021065772,0.021505972,0.00086830545,0.004791881,0.00024709987,0.0002287461,0.0023544068,0.014704816,0.00014857379,0.0035980702,0.10491018],"study_design_scores_gemma":[0.68654525,0.2433584,0.05757252,0.00010454436,0.0030766618,0.00043488882,0.00012534822,0.0020310478,0.0018532733,0.00026449357,0.0045862086,0.00004741787],"about_ca_topic_score_codex":0.0013151673,"about_ca_topic_score_gemma":0.0032768473,"teacher_disagreement_score":0.0023960425,"about_ca_system_score_codex":0.001128181,"about_ca_system_score_gemma":0.0010920354,"threshold_uncertainty_score":0.012671649},"labels":[],"label_agreement":null},{"id":"W4399570650","doi":"10.1200/jco.2024.42.16_suppl.tps9602","title":"A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Human leukocyte antigen; Surgery; Immunotherapy; Cancer research; Immunology; Cancer; Antigen","score_opus":0.07968899237102706,"score_gpt":0.47349714728562897,"score_spread":0.3938081549146019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399570650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989985,0.0013681302,0.00052611454,0.0007325668,0.00034960106,0.0034868692,0.0011904178,0.000115542985,0.0022458164],"genre_scores_gemma":[0.9856758,0.0012769734,0.001567279,0.0011589683,0.00024523697,0.0032380098,0.0020815693,0.000040207047,0.004715947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9995881,0.00019217205,0.000012873128,0.00007778112,0.000040447863,0.00008866996],"domain_scores_gemma":[0.99940825,0.00009768006,0.00010186415,0.000040567862,0.000028855453,0.000322872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015162209,0.0018302891,0.0015820053,0.00043128786,0.0004995379,0.0010974418,0.0011377069,0.0015141814,0.005623795],"category_scores_gemma":[0.00086488714,0.00064209226,0.0015408194,0.00037706093,0.0010310481,0.0010025654,0.00041325504,0.005680577,0.0011984977],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86353505,0.06329118,0.0020356502,0.00049603346,0.0007316735,0.0002556016,0.00027093838,0.0018857874,0.023691649,0.00031834652,0.0033310563,0.04015697],"study_design_scores_gemma":[0.5451431,0.44628334,0.003974263,0.000026354859,0.00020842634,0.00015545341,0.000047104553,0.00095393875,0.0014461055,0.00021854957,0.0015183352,0.000025072834],"about_ca_topic_score_codex":0.0012708349,"about_ca_topic_score_gemma":0.0033438713,"teacher_disagreement_score":0.005623795,"about_ca_system_score_codex":0.0012273454,"about_ca_system_score_gemma":0.0016407126,"threshold_uncertainty_score":0.018813431},"labels":[],"label_agreement":null},{"id":"W4399614387","doi":"10.21769/bioprotoc.5021","title":"A Flow Cytometry–Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells","year":2024,"lang":"en","type":"article","venue":"BIO-PROTOCOL","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"","keywords":"Jurkat cells; Flow cytometry; Kinetics; Flow (mathematics); Chemistry; Cell biology; Computer science; Cancer research; Molecular biology; Immunology; Biology; T cell; Physics; Mechanics","score_opus":0.09766097975005007,"score_gpt":0.4541910561190355,"score_spread":0.3565300763689854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399614387","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07072976,0.0023628043,0.903167,0.0006231839,0.0008781474,0.0021847032,0.0044616293,0.008922259,0.0066705276],"genre_scores_gemma":[0.15252657,0.0036684845,0.8142271,0.0008850445,0.00033180244,0.009360053,0.006611808,0.0010800883,0.011309058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99501723,0.00090869947,0.0006299794,0.0015558882,0.0014558198,0.00043247463],"domain_scores_gemma":[0.99771404,0.00087043195,0.00029645726,0.00034756548,0.00064637215,0.0001250595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027317398,0.0025870625,0.0014147041,0.0032173144,0.0013467476,0.0015707486,0.002003808,0.0023983377,0.008129552],"category_scores_gemma":[0.001978303,0.000883481,0.00102335,0.0021126482,0.0009463067,0.0013085104,0.000873148,0.004860788,0.004366004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001236353,0.00017465392,0.0004612196,0.00024863437,0.000031675285,0.00004447357,0.00012622523,0.0002442841,0.9863696,0.00079487544,0.0012830993,0.010097754],"study_design_scores_gemma":[0.000037035228,0.00020888947,0.0016277796,0.000037170605,0.000051889107,0.00027205143,0.00004594245,0.007125835,0.98112136,0.00047834066,0.008917557,0.00007606706],"about_ca_topic_score_codex":0.0009988643,"about_ca_topic_score_gemma":0.0016039937,"teacher_disagreement_score":0.008129552,"about_ca_system_score_codex":0.0012517751,"about_ca_system_score_gemma":0.0012138677,"threshold_uncertainty_score":0.02719611},"labels":[],"label_agreement":null},{"id":"W4399644646","doi":"10.1089/genbio.2024.0010","title":"T-Cell Differentiation from Hematopoietic Progenitor Cells Using 3D Thymic-like Hydrogels","year":2024,"lang":"en","type":"article","venue":"GEN Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada's Michael Smith Genome Sciences Centre; Dalhousie University; University of British Columbia","funders":"","keywords":"Self-healing hydrogels; Haematopoiesis; Progenitor cell; Cell biology; Progenitor; Stem cell; Chemistry; Biology; Polymer chemistry","score_opus":0.021393005669313934,"score_gpt":0.2838438445043288,"score_spread":0.26245083883501485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399644646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96804094,0.0011091494,0.025536526,0.00011186585,0.000056243356,0.00007098133,0.00042222202,0.00026414625,0.004387947],"genre_scores_gemma":[0.9823152,0.0007726399,0.014597802,0.00006175538,0.0000089004325,0.00006111152,0.00019675166,0.00003352917,0.0019523347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995387,0.000005328558,0.000003773962,0.000008982673,0.000017680573,0.000010411809],"domain_scores_gemma":[0.99995446,0.0000075734997,0.000017292636,0.0000036081992,0.000004923604,0.000012194291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000087623324,0.00022375617,0.000086728855,0.00012744647,0.00006658534,0.00028037213,0.00015440975,0.00023801441,0.00060905353],"category_scores_gemma":[0.00006876753,0.000114622315,0.00015168737,0.0000861585,0.00010113505,0.00014752964,0.00015296074,0.00028175832,0.0002278012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013242552,0.000011461063,0.000057148303,0.000031953303,0.0000021383137,0.000046308407,0.000013805998,0.00052713475,0.997759,0.0001651756,0.00004462032,0.0013280438],"study_design_scores_gemma":[0.000010558053,0.000066187116,0.00042144602,0.0000073566707,0.0000073011265,0.000108127766,0.000012530013,0.0032938176,0.99333364,0.000064383836,0.0026689456,0.000005705461],"about_ca_topic_score_codex":0.00019606465,"about_ca_topic_score_gemma":0.0005819325,"teacher_disagreement_score":0.00060905353,"about_ca_system_score_codex":0.00014242805,"about_ca_system_score_gemma":0.00014654078,"threshold_uncertainty_score":0.0020374656},"labels":[],"label_agreement":null},{"id":"W4399672006","doi":"10.1200/jco.2024.42.16_suppl.2055","title":"Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; University of Alberta; Hospital for Sick Children","funders":"","keywords":"Trametinib; Medicine; Dabrafenib; Glioma; Mutant; Oncology; Internal medicine; Cancer research; Cancer; Genetics; Gene; MAPK/ERK pathway; Biology; Phosphorylation; Vemurafenib; Metastatic melanoma","score_opus":0.20529667890765502,"score_gpt":0.5428811047524997,"score_spread":0.3375844258448447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399672006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847868,0.0008346246,0.009573331,0.0007457741,0.00005961719,0.00033180558,0.0012652028,0.000038265996,0.002364568],"genre_scores_gemma":[0.99568695,0.00025619206,0.002516529,0.0001130292,0.000008945128,0.00018835103,0.0004523579,0.000008076319,0.0007694926],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9993192,0.00035265507,0.000023984569,0.000094145216,0.000046999205,0.00016303426],"domain_scores_gemma":[0.9948454,0.0037770835,0.000665758,0.000111706446,0.00022847521,0.00037148086],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002425919,0.0011994861,0.0013764171,0.0007665648,0.00035653447,0.0009757441,0.001679594,0.0014256943,0.004047291],"category_scores_gemma":[0.0072442014,0.0006362789,0.0021022903,0.0005877558,0.0007216546,0.0008750461,0.0008695894,0.0015316505,0.00019286235],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009789239,0.00030977,0.003656775,0.000085037966,0.0001831059,0.00011283215,0.000018280987,0.99043876,0.00032740927,0.0011827262,0.00026931433,0.0024371075],"study_design_scores_gemma":[0.0004767031,0.0015193399,0.0023123075,0.000030678948,0.00032947803,0.000074807205,0.00007154421,0.9933169,0.0005178609,0.0009012987,0.0004275167,0.000021539296],"about_ca_topic_score_codex":0.022675598,"about_ca_topic_score_gemma":0.0110778585,"teacher_disagreement_score":0.022675598,"about_ca_system_score_codex":0.004766994,"about_ca_system_score_gemma":0.0032299059,"threshold_uncertainty_score":0.04508722},"labels":[],"label_agreement":null},{"id":"W4399672190","doi":"10.1200/jco.2024.42.16_suppl.2579","title":"Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pharmacokinetics; Biomarker; Cancer research; Oncology; Internal medicine; Chemistry","score_opus":0.14415824151901102,"score_gpt":0.5316970850717138,"score_spread":0.38753884355270274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399672190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419045,0.00084011303,0.0011667619,0.0001721078,0.00002914594,0.0005134967,0.0016810418,0.000095609976,0.0013112352],"genre_scores_gemma":[0.9913352,0.00048191886,0.0015711,0.00037996573,0.000046446105,0.00046254968,0.0042068963,0.000038635677,0.0014773434],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995695,0.00015959686,0.00002023433,0.000099405275,0.00010066676,0.000050565734],"domain_scores_gemma":[0.9993692,0.0001237011,0.00019818195,0.0000704903,0.00006450867,0.00017391001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012011983,0.0006855374,0.0008743985,0.00027643554,0.00023673252,0.00091361254,0.00033708086,0.00065141876,0.0022300028],"category_scores_gemma":[0.0011547761,0.0003764851,0.0007871782,0.00035189406,0.00037710945,0.000607336,0.0002383871,0.001916273,0.000582865],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27680057,0.03860931,0.06942288,0.00095454074,0.002611054,0.0010651856,0.00075559446,0.014336,0.37486833,0.00056584395,0.013291664,0.206719],"study_design_scores_gemma":[0.08477543,0.59186745,0.1921556,0.00009637493,0.002784006,0.004210904,0.00027859927,0.015341659,0.0768431,0.0009312512,0.030538552,0.00017709252],"about_ca_topic_score_codex":0.0003296071,"about_ca_topic_score_gemma":0.0007437514,"teacher_disagreement_score":0.0022300028,"about_ca_system_score_codex":0.00066176587,"about_ca_system_score_gemma":0.0008024253,"threshold_uncertainty_score":0.0074600577},"labels":[],"label_agreement":null},{"id":"W4399787848","doi":"10.1093/neuonc/noae064.068","title":"DIPG-15. NOVEL CNS SENSING SYNNOTCH-CAR T CELLS FOR TARGETING DIFFUSE MIDLINE GLIOMA","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Toronto","funders":"","keywords":"Glioma; Medicine; Neuroscience; Cancer research; Biology","score_opus":0.04177343121070988,"score_gpt":0.34884445503677874,"score_spread":0.3070710238260689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399787848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268086,0.0020429627,0.010383246,0.00012988156,0.000049478964,0.0001998095,0.0003682504,0.00023759916,0.0039079576],"genre_scores_gemma":[0.99298155,0.00045247958,0.00423089,0.00006067936,0.000006849898,0.000055557855,0.0002434811,0.000008915465,0.0019595197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999429,0.0000064079964,0.0000032767882,0.000014708925,0.000013412364,0.000019235533],"domain_scores_gemma":[0.9999833,0.0000016570367,0.0000036464871,0.000002206185,0.000002575494,0.000006461547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006386184,0.0002967092,0.0001420426,0.00016289926,0.000067753,0.00018561399,0.00020045199,0.00030713194,0.0008801105],"category_scores_gemma":[0.00003634738,0.000074687094,0.00014466581,0.00009606989,0.000109437184,0.000114231814,0.00014395591,0.00033197924,0.000266279],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010440441,0.00005064808,0.00021001538,0.000057674857,0.0000059445333,0.00008600137,0.000014041949,0.00034145568,0.9936522,0.0003357483,0.00015219304,0.0049897255],"study_design_scores_gemma":[0.00008446414,0.0013006626,0.0017140951,0.0000061958713,0.000032510707,0.00062331377,0.000019321675,0.0037792288,0.98644316,0.00008621181,0.005905062,0.000005849742],"about_ca_topic_score_codex":0.00071296486,"about_ca_topic_score_gemma":0.0008018635,"teacher_disagreement_score":0.0008801105,"about_ca_system_score_codex":0.0002603033,"about_ca_system_score_gemma":0.00017435987,"threshold_uncertainty_score":0.0029442906},"labels":[],"label_agreement":null},{"id":"W4400109246","doi":"10.1200/jco.2024.42.16_suppl.7008","title":"Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Refractory (planetary science); Mantle cell lymphoma; Neutropenia; Urology; Tolerability; Progression-free survival; Surgery; Oncology; Nuclear medicine; Adverse effect; Toxicity; Lymphoma; Chemotherapy","score_opus":0.05460563674213853,"score_gpt":0.44120849765124337,"score_spread":0.38660286090910484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96477824,0.024934173,0.0007918324,0.00035333322,0.000038295493,0.00053052674,0.006044346,0.0001010722,0.0024281247],"genre_scores_gemma":[0.97751755,0.00775315,0.0010694598,0.0005906841,0.00008196827,0.00032019784,0.0120220175,0.000022019061,0.00062295963],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99951816,0.00022458548,0.0000549263,0.00006337177,0.00008475472,0.000054253163],"domain_scores_gemma":[0.99910104,0.00022604672,0.00040013838,0.00006714698,0.00007355296,0.00013194156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017343096,0.00042610386,0.0010719376,0.0004407079,0.00013761433,0.00076574815,0.00042691498,0.00041002978,0.00120683],"category_scores_gemma":[0.0010169481,0.0002454144,0.0010978162,0.0008423352,0.00016993008,0.0004528672,0.0002607554,0.000582416,0.00031583983],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22616756,0.002131326,0.34621632,0.0026116369,0.011385704,0.00061953533,0.00030950294,0.004161433,0.042985037,0.00022060213,0.009286804,0.35390455],"study_design_scores_gemma":[0.042134974,0.057726786,0.8572102,0.0003344647,0.0113630295,0.0023351093,0.00015148711,0.0021342419,0.005128383,0.00022790235,0.021169264,0.00008423651],"about_ca_topic_score_codex":0.0008864124,"about_ca_topic_score_gemma":0.003005417,"teacher_disagreement_score":0.0017343096,"about_ca_system_score_codex":0.0004860427,"about_ca_system_score_gemma":0.00045500023,"threshold_uncertainty_score":0.009172022},"labels":[],"label_agreement":null},{"id":"W4400117070","doi":"10.1097/01.cot.0001026288.74302.f6","title":"Shop Talk","year":2024,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Business","score_opus":0.034566600306888844,"score_gpt":0.3869763956953666,"score_spread":0.3524097953884778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400117070","genre_codex":"other","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00062592415,0.0024799623,0.0020470435,0.020351563,0.049464498,0.00025904484,0.0026472819,0.003059127,0.91906554],"genre_scores_gemma":[0.0019174388,0.0011064345,0.00061473856,0.007338544,0.005243693,0.00009089281,0.0014468894,0.00077238516,0.9814689],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99877733,0.0001593006,0.00005930417,0.0002475597,0.00056559057,0.00019099309],"domain_scores_gemma":[0.996265,0.0003794296,0.00010488199,0.00029182187,0.0013560776,0.0016028071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010447014,0.0011788297,0.0009675025,0.0015599278,0.0023163976,0.007235791,0.0018121412,0.003475143,0.846768],"category_scores_gemma":[0.0061168354,0.0004115808,0.00091891916,0.0010231785,0.0005441456,0.0039360765,0.004166288,0.0036489954,0.77583534],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021418084,0.000020778687,0.00006119176,0.00005005937,0.000002110028,0.000057187157,0.000028681288,0.000015896541,0.00008395784,0.0013034868,0.9559255,0.042429633],"study_design_scores_gemma":[0.0000043447785,0.0000071124928,0.00009511383,0.000031959535,0.0000010312198,0.000060561553,0.000056895195,0.000015898784,0.000027011622,0.0004487389,0.99924785,0.0000034209727],"about_ca_topic_score_codex":0.001366887,"about_ca_topic_score_gemma":0.0027954015,"teacher_disagreement_score":0.846768,"about_ca_system_score_codex":0.0012372696,"about_ca_system_score_gemma":0.0020528007,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W4400266836","doi":"10.1007/s00262-024-03740-3","title":"Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Karolinska Institutet; Cancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"Treosulfan; Mesothelin; Fludarabine; Cancer research; Ovarian cancer; Medicine; Immunology; Antigen; Cancer; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.017341642191132958,"score_gpt":0.33033527995686185,"score_spread":0.3129936377657289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400266836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977488,0.0007407733,0.00046708848,0.00002869835,0.0000145828935,0.000023458946,0.00015386521,0.0000146101775,0.0008080338],"genre_scores_gemma":[0.99759823,0.00032447968,0.00058032153,0.00003462378,0.000006796429,0.000023293615,0.00029855064,0.0000052596924,0.0011284916],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989295,0.000028575509,0.000009653579,0.000018733359,0.000023120128,0.000026980977],"domain_scores_gemma":[0.99993956,0.0000140568745,0.000012732786,0.0000086462915,0.000009299625,0.00001565689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000079122125,0.00025944973,0.00021030738,0.00008062831,0.000074208096,0.00014148094,0.000113274335,0.00015871081,0.00092946505],"category_scores_gemma":[0.00009224583,0.000051037332,0.00017269287,0.000067260014,0.00007645009,0.00010859288,0.00009421666,0.00021116213,0.00016395439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043473166,0.000051987292,0.00034460725,0.000033245542,0.000007834713,0.00006105333,0.00001800959,0.00019942682,0.99676114,0.000054934142,0.00004092353,0.0019921404],"study_design_scores_gemma":[0.000026053182,0.0014771152,0.0036421944,0.0000037382313,0.000018493474,0.00018001176,0.000021768206,0.00046355033,0.99236816,0.000015503892,0.0017807956,0.0000026698078],"about_ca_topic_score_codex":0.0010010712,"about_ca_topic_score_gemma":0.0013852154,"teacher_disagreement_score":0.0010010712,"about_ca_system_score_codex":0.00012275345,"about_ca_system_score_gemma":0.00016542344,"threshold_uncertainty_score":0.0031093955},"labels":[],"label_agreement":null},{"id":"W4400428906","doi":"10.1038/s41408-024-01084-w","title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Gateway for Cancer Research; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Medicine; Cumulative incidence; Internal medicine; Univariate analysis; Incidence (geometry); Progression-free survival; Hematopoietic cell; Surgery; Retrospective cohort study; Hematopoietic stem cell transplantation; Transplantation; Multivariate analysis; Chemotherapy; Haematopoiesis","score_opus":0.027509978119901374,"score_gpt":0.29665129241502913,"score_spread":0.2691413142951278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400428906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991702,0.0005683713,0.000037549074,0.000022433213,0.000007485318,0.000009427524,0.00005604595,0.0000015965791,0.00012687239],"genre_scores_gemma":[0.9995789,0.00017555806,0.0000304155,0.000039528695,0.000016480055,0.0000075947073,0.000114528186,5.281529e-7,0.00003652886],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997129,0.00011947469,0.000033417175,0.000058140417,0.000030959847,0.000045143166],"domain_scores_gemma":[0.9992747,0.00023864985,0.0002728692,0.000036929072,0.000021310749,0.00015555002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005718106,0.000105557934,0.0005000486,0.0001833734,0.00012914608,0.0003295835,0.00014626523,0.00023907474,0.000546923],"category_scores_gemma":[0.0010553529,0.00008238395,0.0005893242,0.0002887215,0.00015734983,0.00021728198,0.00016790135,0.00037509424,0.00008564408],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17268652,0.0025541396,0.7464077,0.00031045434,0.001239957,0.0006901239,0.00019969874,0.0011362161,0.006424726,0.00015237463,0.00060895755,0.06758923],"study_design_scores_gemma":[0.007563706,0.07455738,0.9091652,0.000061699204,0.0010959478,0.0017079684,0.00020011619,0.0020737215,0.0016497438,0.00025727155,0.0016479683,0.000019329662],"about_ca_topic_score_codex":0.00053291384,"about_ca_topic_score_gemma":0.00092042505,"teacher_disagreement_score":0.0005718106,"about_ca_system_score_codex":0.00033486134,"about_ca_system_score_gemma":0.0002766193,"threshold_uncertainty_score":0.0030241013},"labels":[],"label_agreement":null},{"id":"W4400443280","doi":"10.3390/curroncol31070292","title":"Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Multiple myeloma; CAR T-cell therapy; Intensive care medicine; Immunotherapy; Immunology; Immune system; Chimeric antigen receptor","score_opus":0.25414509971375804,"score_gpt":0.5056507127003103,"score_spread":0.2515056129865522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400443280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023979002,0.99882716,0.000027054635,0.00036126212,0.00025890357,0.000003315045,0.000018313696,0.000003737086,0.00047630694],"genre_scores_gemma":[0.00017325392,0.99913174,0.000055751134,0.0002571532,0.00011928948,0.0000031487243,0.000020241985,8.3393104e-7,0.00023868763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961334,0.000059506383,0.000058483456,0.00005527099,0.00017054337,0.000042865253],"domain_scores_gemma":[0.9986027,0.0005570729,0.00014054324,0.000024798766,0.0005598849,0.00011503516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010681119,0.0008477228,0.0015662526,0.004155216,0.00048153452,0.0013403913,0.0012824733,0.0015043368,0.005998203],"category_scores_gemma":[0.0022844826,0.00032502812,0.00095578836,0.005194725,0.00048722996,0.001441017,0.0007177079,0.0018916316,0.001823663],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010536155,0.000045141223,0.00013008727,0.052433286,0.00016714851,0.00016624569,0.00009044589,0.00035762507,0.0006734935,0.0030111074,0.11473929,0.8280808],"study_design_scores_gemma":[0.000016215841,0.00004934747,0.00039327593,0.012315667,0.00020505756,0.0003373875,0.000039313672,0.00004296416,0.00009506986,0.0005810919,0.9859115,0.000013170567],"about_ca_topic_score_codex":0.018168533,"about_ca_topic_score_gemma":0.030560603,"teacher_disagreement_score":0.9818315,"about_ca_system_score_codex":0.002499028,"about_ca_system_score_gemma":0.0067428336,"threshold_uncertainty_score":0.0361256},"labels":[],"label_agreement":null},{"id":"W4400684648","doi":"10.1007/s00281-024-01013-w","title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","year":2024,"lang":"en","type":"review","venue":"Seminars in Immunopathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Chimeric antigen receptor; Cytokine storm; Cytokine release syndrome; Immune system; Immunology; Immunotherapy; Cytokine; T cell; Medicine; Biology; Disease; Internal medicine","score_opus":0.04047758097940247,"score_gpt":0.35253288456038623,"score_spread":0.31205530358098377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400684648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001240453,0.99811435,0.00024756722,0.000429171,0.00023423239,0.0000056039853,0.000007771256,0.000008721091,0.0008286017],"genre_scores_gemma":[0.00088269054,0.99754614,0.00034788964,0.00034159218,0.00023397115,0.000010922634,0.000016119162,0.0000024299143,0.0006182293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977106,0.000053484793,0.00002346526,0.000029850304,0.00009896056,0.000023185246],"domain_scores_gemma":[0.99970144,0.00017137494,0.000030132664,0.000008440294,0.00006404381,0.000024623625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008733223,0.0007498233,0.0011565865,0.0017983383,0.00027001795,0.0011183837,0.00092515035,0.0014368984,0.0024110142],"category_scores_gemma":[0.0007154943,0.00025876815,0.0005075485,0.0015248931,0.0007025717,0.0016983941,0.0007328832,0.0033455514,0.0016171132],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007473167,0.0000942868,0.00009467696,0.008735494,0.000058241123,0.00016732725,0.00008357021,0.000709759,0.0017477138,0.007343869,0.029607892,0.9512824],"study_design_scores_gemma":[0.000030420972,0.00014494803,0.00035413058,0.0026122828,0.000056386838,0.0009679642,0.000055509518,0.00022149073,0.00064352935,0.0032529703,0.9916427,0.000017547922],"about_ca_topic_score_codex":0.00077641394,"about_ca_topic_score_gemma":0.001509982,"teacher_disagreement_score":0.0024110142,"about_ca_system_score_codex":0.0008730353,"about_ca_system_score_gemma":0.00084759237,"threshold_uncertainty_score":0.008065641},"labels":[],"label_agreement":null},{"id":"W4400690992","doi":"10.1080/10428194.2024.2371472","title":"Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genmab; AbbVie Canada","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Medicine; Oncology; Internal medicine; Cancer research; Materials science","score_opus":0.015303812571067062,"score_gpt":0.27597024301362166,"score_spread":0.2606664304425546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400690992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971969,0.00074617635,0.0001303023,0.000065099885,0.000004625556,0.000022110646,0.0012676875,0.0000051305324,0.0005619231],"genre_scores_gemma":[0.9979206,0.00020033224,0.00010924031,0.0000520164,0.000011559811,0.000017498578,0.0016190356,0.0000020284008,0.000067800844],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988348,0.0005805479,0.00013615159,0.00015993573,0.00016227798,0.00012633318],"domain_scores_gemma":[0.9966492,0.00064148963,0.0021014498,0.00015520748,0.00019289908,0.00025961048],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014238314,0.00017291745,0.00034091732,0.0007492454,0.00021742644,0.00093537645,0.0002685023,0.00028242936,0.0006010512],"category_scores_gemma":[0.0032015808,0.00009967317,0.0004262607,0.0009622987,0.0003082546,0.00061232055,0.00053450203,0.00034810742,0.00015153125],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024530136,0.0002857733,0.9809006,0.000079951176,0.00034193127,0.00015699802,0.00013440092,0.0012088466,0.00051505043,0.00008923758,0.0005169127,0.013317256],"study_design_scores_gemma":[0.00025799448,0.0018995719,0.99205047,0.00003778189,0.00023029988,0.00071715825,0.00038848948,0.00162659,0.00057894783,0.000109075794,0.0020818773,0.000021760263],"about_ca_topic_score_codex":0.0033084233,"about_ca_topic_score_gemma":0.0073777167,"teacher_disagreement_score":0.0033084233,"about_ca_system_score_codex":0.0011885053,"about_ca_system_score_gemma":0.00053267466,"threshold_uncertainty_score":0.008623242},"labels":[],"label_agreement":null},{"id":"W4401012202","doi":"10.1101/2024.07.26.605251","title":"Identification of a novel myosin antigen activating CD8 <sup>+</sup> T cells in C57BL/6 mice","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"T-cell receptor; Epitope; Antigen; CD8; T cell; Biology; Cell biology; Cytotoxic T cell; Antigen-presenting cell; Molecular biology; Immune system; Immunology; In vitro; Genetics","score_opus":0.026184413956590245,"score_gpt":0.2801596148023852,"score_spread":0.25397520084579495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401012202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668473,0.0012522168,0.019192891,0.0006655916,0.00018588397,0.000106888845,0.0071197418,0.0009395599,0.0036898796],"genre_scores_gemma":[0.9411149,0.0010947367,0.027284127,0.000885402,0.00009238216,0.00027092177,0.009284307,0.0010671008,0.018906241],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996296,0.000033322965,0.000026788397,0.00015763256,0.00008377729,0.00006880345],"domain_scores_gemma":[0.99965954,0.000051429008,0.000088317356,0.000032307995,0.000034950768,0.00013351442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000313827,0.0007146653,0.00036177158,0.00088534586,0.00028013298,0.0006111783,0.00031351807,0.00078167365,0.0038566822],"category_scores_gemma":[0.00015932064,0.00039915164,0.00040700895,0.0001949984,0.00043916272,0.00023456482,0.00028270978,0.0020806775,0.0016743268],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013419012,0.000030681393,0.0001923828,0.000024361352,0.0000048022803,0.000046851947,0.00001351582,0.0000659062,0.9984127,0.000088363726,0.000118694064,0.00086766755],"study_design_scores_gemma":[0.00014237419,0.0004866528,0.0114264535,0.000036691657,0.00005092573,0.00073945965,0.00008118924,0.0027784917,0.9767606,0.00025441503,0.007227149,0.000015519729],"about_ca_topic_score_codex":0.00044643495,"about_ca_topic_score_gemma":0.0007197912,"teacher_disagreement_score":0.0038566822,"about_ca_system_score_codex":0.00029132282,"about_ca_system_score_gemma":0.0001912403,"threshold_uncertainty_score":0.012901902},"labels":[],"label_agreement":null},{"id":"W4401015063","doi":"10.1016/j.jtct.2024.07.011","title":"In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy","year":2024,"lang":"en","type":"editorial","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Accreditation; Quality assurance; Transformative learning; Medicine; Quality (philosophy); Multidisciplinary approach; Process management; Business; Medical education; Psychology; External quality assessment; Political science","score_opus":0.026715483915577723,"score_gpt":0.38192068123047324,"score_spread":0.3552051973148955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401015063","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024116549,0.011095841,0.00073315465,0.19876084,0.78825927,0.000025391195,0.000030252453,0.000051298764,0.0010198544],"genre_scores_gemma":[0.00072375144,0.0056198575,0.00048652512,0.09141545,0.89932907,0.000045704604,0.000013903258,0.00004345168,0.0023222682],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.95855004,0.015920946,0.005999631,0.0028152252,0.015009315,0.0017047437],"domain_scores_gemma":[0.7863056,0.15672489,0.006166232,0.0034429394,0.036815755,0.010544451],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.060049433,0.0043355883,0.0057146032,0.0032746177,0.0047304025,0.019791273,0.007150679,0.052957486,0.0070281625],"category_scores_gemma":[0.15291218,0.0017626634,0.004121889,0.0021431237,0.014508986,0.013804554,0.005304795,0.08064414,0.0042665205],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002944048,0.000015883523,0.000020919377,0.00039542894,0.000052908534,0.00007403962,0.000062055224,0.00006163576,0.000025567968,0.0069698147,0.9837765,0.008515946],"study_design_scores_gemma":[0.00015610168,0.00005625001,0.0002015522,0.0016901497,0.00013674692,0.00015195254,0.00017851718,0.0004636185,0.00011332004,0.025676772,0.97107935,0.000095658215],"about_ca_topic_score_codex":0.0030651123,"about_ca_topic_score_gemma":0.007333296,"teacher_disagreement_score":0.060049433,"about_ca_system_score_codex":0.010018459,"about_ca_system_score_gemma":0.013138479,"threshold_uncertainty_score":0.3175755},"labels":[],"label_agreement":null},{"id":"W4401074395","doi":"10.1038/s44222-024-00219-9","title":"Genetically engineered hypoimmunogenic cell therapy","year":2024,"lang":"en","type":"article","venue":"Nature Reviews Bioengineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Immune system; Cell therapy; Immunotherapy; Transplantation; Stem cell; Genetic enhancement; Computational biology; Medicine; Biology; Immunology; Gene; Genetics","score_opus":0.0235477653437189,"score_gpt":0.3134757730102026,"score_spread":0.2899280076664837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401074395","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5000591,0.19036978,0.22587307,0.008178657,0.005143404,0.00041739582,0.0011234608,0.0032021804,0.0656329],"genre_scores_gemma":[0.8759395,0.062416077,0.033134714,0.0025284206,0.00046454795,0.0002985926,0.00075060234,0.00023447478,0.02423307],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998542,0.000024641908,0.000007094189,0.000026090858,0.00006421734,0.000023702501],"domain_scores_gemma":[0.99993396,0.00001562083,0.000022722796,0.000009994336,0.0000089316,0.000008694865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028518712,0.0004633653,0.00027044487,0.0002963236,0.00009242836,0.00050150976,0.000486241,0.0006572715,0.0018962439],"category_scores_gemma":[0.00015299268,0.000119388686,0.00019620397,0.00015990446,0.0005395516,0.00034300133,0.00036697503,0.001117978,0.00060799596],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013091945,0.00014789266,0.0001684904,0.00042975214,0.000036845777,0.00020059284,0.000038719656,0.0013048009,0.90586394,0.020003531,0.003482847,0.068191804],"study_design_scores_gemma":[0.00012379981,0.0008076065,0.0011410168,0.00015149622,0.00013845618,0.0017628229,0.000042662166,0.0031718968,0.7273363,0.0066407137,0.25865567,0.000027487766],"about_ca_topic_score_codex":0.00016967248,"about_ca_topic_score_gemma":0.00022597324,"teacher_disagreement_score":0.0018962439,"about_ca_system_score_codex":0.00033262014,"about_ca_system_score_gemma":0.00019591159,"threshold_uncertainty_score":0.0063435435},"labels":[],"label_agreement":null},{"id":"W4401113081","doi":"10.1021/acsnano.4c07306","title":"Spiky Gold Nanoparticles, a Nanoscale Approach to Enhanced Ex Vivo T-Cell Activation","year":2024,"lang":"en","type":"article","venue":"ACS Nano","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Colloidal gold; Nanotechnology; Biocompatibility; Ex vivo; Biophysics; Chemistry; Materials science; T cell; Nanoparticle; In vitro; Biology; Biochemistry; Immunology; Immune system","score_opus":0.02627374760426702,"score_gpt":0.29582464125836283,"score_spread":0.2695508936540958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401113081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.878267,0.004979746,0.10510458,0.0006643896,0.00025163736,0.00021367594,0.0002995895,0.0006078606,0.009611559],"genre_scores_gemma":[0.94734347,0.0021095877,0.04626309,0.0002605829,0.000040875573,0.00008050018,0.00012557514,0.000048591988,0.0037276726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999167,0.000011926479,0.000005217214,0.00002753943,0.000025551726,0.000013065575],"domain_scores_gemma":[0.99995387,0.000009694521,0.000013090795,0.000007410427,0.000006213755,0.000009688431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012319096,0.0002975783,0.0001533587,0.00015735762,0.00011578225,0.00024313662,0.0001372003,0.00031403173,0.00037600417],"category_scores_gemma":[0.000114913535,0.00016129306,0.00017434092,0.0001254157,0.0002460111,0.00019724069,0.000309747,0.0003974398,0.00018438065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026675792,0.000013076318,0.000075642296,0.00005325924,0.0000059444983,0.00005280427,0.000022559103,0.00047065614,0.9937781,0.0006982126,0.00016470464,0.004638412],"study_design_scores_gemma":[0.000022079965,0.00032227408,0.0005261592,0.000005188559,0.000010426405,0.00019512045,0.0000196047,0.0040436457,0.9877236,0.00033455942,0.0067861676,0.000011110902],"about_ca_topic_score_codex":0.00026195994,"about_ca_topic_score_gemma":0.0006480477,"teacher_disagreement_score":0.00037600417,"about_ca_system_score_codex":0.00022042911,"about_ca_system_score_gemma":0.00015949119,"threshold_uncertainty_score":0.0015993714},"labels":[],"label_agreement":null},{"id":"W4401155069","doi":"10.1016/j.biomaterials.2024.122731","title":"Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R","year":2024,"lang":"en","type":"article","venue":"Biomaterials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Ludwig Center at Harvard; Merck KGaA","keywords":"Blocking (statistics); Antibody; Cancer research; Materials science; Biomedical engineering; Biology; Immunology; Medicine; Computer science","score_opus":0.06925131991838904,"score_gpt":0.32448015127052077,"score_spread":0.2552288313521317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401155069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778144,0.0022193769,0.01459882,0.00055047864,0.0002587995,0.00022977551,0.0009705287,0.0003003149,0.003057605],"genre_scores_gemma":[0.9918516,0.000684696,0.004116538,0.000113252245,0.0000310524,0.00016150453,0.0005075899,0.000017735932,0.0025158974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975115,0.000059618997,0.000015029817,0.000052418807,0.000049283644,0.00007245034],"domain_scores_gemma":[0.9999064,0.000019274752,0.00002455845,0.000014346611,0.000006918011,0.00002851157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029291143,0.00049449387,0.00042836033,0.00023765408,0.00016894746,0.0005012842,0.00031035978,0.00055245624,0.002132068],"category_scores_gemma":[0.00012634319,0.00019048541,0.00027059446,0.00022479071,0.0001806727,0.00022162845,0.0001701772,0.0012358198,0.00069295004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014136318,0.0006686094,0.0003513647,0.00012440654,0.000030569758,0.0004339201,0.00006950797,0.0005202085,0.99013644,0.0010449155,0.000831017,0.0043754033],"study_design_scores_gemma":[0.00022467008,0.003746761,0.002717382,0.000013843667,0.00009459428,0.0025854646,0.00005875599,0.0057193427,0.97446567,0.00021334438,0.01014686,0.000013235292],"about_ca_topic_score_codex":0.00056484644,"about_ca_topic_score_gemma":0.0006281123,"teacher_disagreement_score":0.002132068,"about_ca_system_score_codex":0.00026963078,"about_ca_system_score_gemma":0.00044497615,"threshold_uncertainty_score":0.0071324706},"labels":[],"label_agreement":null},{"id":"W4401204112","doi":"10.1002/ejhf.3340","title":"Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","year":2024,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Ted Rogers Centre for Heart Research; Toronto General Hospital; University of Toronto; Mount Sinai Hospital","funders":"Ministero della Salute","keywords":"Medicine; Myocarditis; Immune system; Heart failure; Adverse effect; Immunology; Immune dysregulation; Cancer; Rash; Internal medicine","score_opus":0.058690383981007004,"score_gpt":0.33045284640168343,"score_spread":0.2717624624206764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401204112","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020203923,0.42755127,0.002332736,0.4778273,0.078227624,0.00010630257,0.00031193063,0.00014703102,0.011475405],"genre_scores_gemma":[0.02577512,0.425522,0.0060048946,0.27914968,0.24318776,0.0002677221,0.00083004247,0.00013356996,0.019129189],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952062,0.0012925107,0.000822236,0.00034188715,0.002013327,0.00032386347],"domain_scores_gemma":[0.9721805,0.012099107,0.0032843163,0.0007879893,0.009097297,0.002550861],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013012007,0.00073263736,0.0014297393,0.0007111226,0.0013996356,0.003989941,0.001440482,0.009222567,0.002353497],"category_scores_gemma":[0.012393831,0.00030722594,0.0017292612,0.00064933946,0.001957586,0.0022154946,0.0018896421,0.014343022,0.0018948221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001716341,0.00013240802,0.0010730625,0.0011221747,0.00010670244,0.00027207698,0.00008445336,0.00027491734,0.0013573316,0.0062435768,0.6565666,0.33259502],"study_design_scores_gemma":[0.000055888566,0.00022755121,0.001847422,0.0018884144,0.00008998662,0.0007143381,0.00005436012,0.00026831808,0.0004823615,0.0042914967,0.9900476,0.000032229425],"about_ca_topic_score_codex":0.0012711382,"about_ca_topic_score_gemma":0.0024780275,"teacher_disagreement_score":0.013012007,"about_ca_system_score_codex":0.0013394105,"about_ca_system_score_gemma":0.0051979986,"threshold_uncertainty_score":0.06881487},"labels":[],"label_agreement":null},{"id":"W4401219225","doi":"10.1080/14656566.2024.2387673","title":"Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Lymphoblastic Leukemia; Cytokine storm; Immune system; Cytokine; Immunology; Leukemia; Acute lymphocytic leukemia; Receptor; T cell; Adverse effect; Internal medicine; Disease","score_opus":0.027437902744180738,"score_gpt":0.36035886421433105,"score_spread":0.3329209614701503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401219225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015438815,0.99757344,0.00009357946,0.0007904605,0.00038191798,0.0000062035638,0.000029447514,0.000005732157,0.00096492644],"genre_scores_gemma":[0.001376092,0.99672806,0.00012708383,0.00082561106,0.0003411977,0.000009722037,0.00004547682,0.0000020935981,0.0005446215],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999819,0.000049850754,0.000026060623,0.000026922206,0.000060122544,0.000018073662],"domain_scores_gemma":[0.9997397,0.00013776433,0.000046445362,0.000005240773,0.000058172758,0.000012661276],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044039337,0.0003599732,0.0007982894,0.0006101124,0.00014623636,0.0006536439,0.00052388577,0.0008438199,0.0036117174],"category_scores_gemma":[0.00087202387,0.000100978745,0.0005266136,0.0006594446,0.00020781968,0.000611356,0.0003532668,0.0012728694,0.0013241854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013825463,0.0000369251,0.0002014926,0.029342277,0.0001743652,0.00035694768,0.000065266206,0.0002566664,0.0013017079,0.0027967745,0.069708176,0.8956211],"study_design_scores_gemma":[0.00007127805,0.00011920868,0.0009532693,0.011200232,0.0002783138,0.0025527382,0.00007106222,0.00011445276,0.0005596827,0.0018431523,0.9822191,0.000017513843],"about_ca_topic_score_codex":0.0007052846,"about_ca_topic_score_gemma":0.0016049226,"teacher_disagreement_score":0.0036117174,"about_ca_system_score_codex":0.00040256427,"about_ca_system_score_gemma":0.00084220804,"threshold_uncertainty_score":0.012082398},"labels":[],"label_agreement":null},{"id":"W4401219445","doi":"10.1016/j.omton.2024.200851","title":"Minimally modified off-the-shelf allogeneic CAR T cells","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; Canadian Institutes of Health Research; Fonds Léon Fredericq; Terry Fox Research Institute; Michael Smith Health Research BC","keywords":"Chimeric antigen receptor; Cell therapy; Medicine; Cancer research; In vivo; Induced pluripotent stem cell; Immunotherapy; Stem cell; Immunology; Chemistry; Biology; Biotechnology; Immune system; Cell biology","score_opus":0.03441878770243568,"score_gpt":0.343309674273072,"score_spread":0.30889088657063635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401219445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70297104,0.09933576,0.11142134,0.001928047,0.0018916137,0.0020442125,0.009316733,0.0027693177,0.068321936],"genre_scores_gemma":[0.8410843,0.036765277,0.05264643,0.0019337225,0.00025122685,0.0011632344,0.013288735,0.00030093535,0.052566208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979264,0.000025646495,0.000011230675,0.00003895675,0.00010662311,0.000024904892],"domain_scores_gemma":[0.9999238,0.000010975642,0.000018040426,0.000011503184,0.000022150016,0.000013554064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020732112,0.00032358698,0.00025893844,0.00032764487,0.00008456981,0.00049085176,0.00043953402,0.00045345776,0.0042331587],"category_scores_gemma":[0.0002169669,0.00011639296,0.00033421582,0.00022575424,0.00012510372,0.00031650328,0.0003059437,0.0006441416,0.0028862213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005313289,0.0002488106,0.00038335627,0.00072087726,0.00003134978,0.0002731688,0.00004648892,0.00043016407,0.88479495,0.0011204482,0.0048781224,0.10654109],"study_design_scores_gemma":[0.00013460328,0.0027230172,0.0021267335,0.00009990302,0.00013467674,0.0020525097,0.000058243695,0.0012735327,0.7992022,0.00059077935,0.19157429,0.000029497385],"about_ca_topic_score_codex":0.00030211874,"about_ca_topic_score_gemma":0.0005340951,"teacher_disagreement_score":0.0042331587,"about_ca_system_score_codex":0.00020286719,"about_ca_system_score_gemma":0.0003062101,"threshold_uncertainty_score":0.014161289},"labels":[],"label_agreement":null},{"id":"W4401265865","doi":"10.1038/s41591-024-03138-9","title":"Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Ottawa; Princess Margaret Cancer Centre; McMaster University Medical Centre; Hospital for Sick Children; University Health Network; University of Toronto; SickKids Foundation; National Research Council Canada; McMaster University","funders":"Mitacs; Canadian Institutes of Health Research; Terry Fox Research Institute; National Cancer Institute; Government of Canada; Foundation for the National Institutes of Health","keywords":"Glioblastoma; Neuroscience; Cancer research; Computational biology; Computer science; Biology","score_opus":0.01016253600359658,"score_gpt":0.3026076256505932,"score_spread":0.2924450896469966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401265865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829282,0.0032151698,0.006535067,0.00085015333,0.000109275636,0.000079112106,0.0003273834,0.00033031948,0.0056252615],"genre_scores_gemma":[0.9940639,0.0010113472,0.0014199011,0.00011119096,0.000015057319,0.000057841116,0.0001559161,0.000029587747,0.0031352532],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998672,0.00001387342,0.000004807116,0.00002313943,0.000024188523,0.00006684961],"domain_scores_gemma":[0.99994934,0.000007089338,0.000013910517,0.0000055267296,0.0000072293356,0.00001677412],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001588663,0.0003390077,0.00027935684,0.00035063576,0.00029470358,0.0005733706,0.00024730832,0.00040380552,0.001493896],"category_scores_gemma":[0.00012925918,0.0001488311,0.000256214,0.00017950675,0.0002336666,0.00031920266,0.00021876936,0.0008575848,0.00036034055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007853986,0.0003698853,0.0007206398,0.00022780868,0.00005235553,0.00047621023,0.00012606672,0.0017382862,0.9695878,0.0032343701,0.0021219377,0.020559197],"study_design_scores_gemma":[0.00023354155,0.0018942654,0.003552837,0.0000352744,0.00013100605,0.001183399,0.00022613593,0.008144792,0.9627823,0.0011740245,0.02061922,0.000023178101],"about_ca_topic_score_codex":0.0032929997,"about_ca_topic_score_gemma":0.004405116,"teacher_disagreement_score":0.0032929997,"about_ca_system_score_codex":0.00056886126,"about_ca_system_score_gemma":0.00057494483,"threshold_uncertainty_score":0.0065476894},"labels":[],"label_agreement":null},{"id":"W4401357304","doi":"10.3390/curroncol31080323","title":"Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Allegheny Health Network","keywords":"Medicine; Chimeric antigen receptor; Venous thromboembolism; Meta-analysis; Clinical trial; Oncology; Internal medicine; Phases of clinical research; CAR T-cell therapy; Immunology; Immunotherapy; Cancer; Thrombosis","score_opus":0.6163136460934728,"score_gpt":0.6136496854667778,"score_spread":0.00266396062669505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401357304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011344613,0.9862357,0.000843062,0.00024292959,0.00020852378,0.00012018342,0.00062300684,0.000037313446,0.00034471523],"genre_scores_gemma":[0.48170152,0.5114537,0.0023608408,0.001318326,0.00043936868,0.0005796297,0.0013944823,0.00009352353,0.0006585693],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9885606,0.005879687,0.0027770207,0.0013334333,0.0011448757,0.0003043819],"domain_scores_gemma":[0.9765778,0.018010926,0.0030461468,0.0009208946,0.0011323363,0.00031186471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015954532,0.0027711447,0.013660209,0.0059064864,0.00045449592,0.0035556806,0.0016983642,0.0022620491,0.0026499727],"category_scores_gemma":[0.028679956,0.0016152429,0.053751554,0.006525457,0.00061924674,0.0016383241,0.0014929496,0.0025170003,0.0003574026],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025662133,0.000013739356,0.0062888274,0.068059854,0.9171779,0.000086319684,0.000029060957,0.00049544417,0.00018029145,0.00007216904,0.0002850391,0.00474518],"study_design_scores_gemma":[0.0003233101,0.00012577052,0.0034461254,0.0030207273,0.9919946,0.00006598775,0.000015437003,0.00017693422,0.00008879698,0.0001123796,0.0006193967,0.000010525034],"about_ca_topic_score_codex":0.004754947,"about_ca_topic_score_gemma":0.0070960084,"teacher_disagreement_score":0.015954532,"about_ca_system_score_codex":0.001644123,"about_ca_system_score_gemma":0.0015633262,"threshold_uncertainty_score":0.08437669},"labels":[],"label_agreement":null},{"id":"W4401451904","doi":"10.1186/s12885-024-12574-2","title":"Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Institute of Cancer Research; Ontario Clinical Oncology Group; Juravinski Cancer Centre","funders":"","keywords":"Chimeric antigen receptor; Cart; Medicine; Surgical oncology; Refractory (planetary science); Lymphoma; Oncology; Cell therapy; Antigen; Internal medicine; Cell; Immunotherapy; Immunology; Cancer; Biology","score_opus":0.07087076294447868,"score_gpt":0.3612566289399052,"score_spread":0.2903858659954265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401451904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856913,0.000046031982,0.000356393,0.000046382087,0.0000056047525,0.0003049964,0.00033695565,0.000005619396,0.00032874223],"genre_scores_gemma":[0.99699366,0.0000523569,0.0012168492,0.00008139715,0.00001912731,0.00076510664,0.0007299348,0.000002116882,0.00013946109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977984,0.0013574527,0.0002162087,0.00018126835,0.00026463755,0.00018193111],"domain_scores_gemma":[0.99575967,0.000947374,0.0016647589,0.00035562998,0.0006919394,0.00058067817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005713473,0.000346608,0.00039846238,0.00072031753,0.00071714044,0.00068134867,0.00040231357,0.0004741532,0.0007437333],"category_scores_gemma":[0.0076081012,0.0002396311,0.0004408968,0.0005151844,0.00029844634,0.0006471352,0.00070145313,0.00073982985,0.00041019302],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007463824,0.00053226773,0.9915285,0.000020461284,0.000036266607,0.000103599385,0.0003015649,0.000112920876,0.00064497924,0.000017481161,0.00015249006,0.005803167],"study_design_scores_gemma":[0.00015030363,0.0047208644,0.9923254,0.000017745471,0.000040498526,0.00036019605,0.000529644,0.0006296103,0.00052857527,0.000036743637,0.00064804073,0.000012483914],"about_ca_topic_score_codex":0.0012020813,"about_ca_topic_score_gemma":0.0019069975,"teacher_disagreement_score":0.005713473,"about_ca_system_score_codex":0.00039186538,"about_ca_system_score_gemma":0.0006968527,"threshold_uncertainty_score":0.030216098},"labels":[],"label_agreement":null},{"id":"W4401486739","doi":"10.1016/j.jcyt.2024.08.004","title":"CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Béatrice Ederer-Weber Stiftung; Faculty of Medicine, University of Ottawa; Deutsche Krebshilfe; Essity Germany; Baylor College of Medicine","keywords":"Cytotoxic T cell; Interleukin 21; IL-2 receptor; Interleukin 12; Immunology; Natural killer T cell; CD19; Transactivation; Biology; Chemistry; Immune system; T cell; Cell biology; Cancer research; In vitro; Biochemistry; Transcription factor","score_opus":0.020672316952580296,"score_gpt":0.29724832157250997,"score_spread":0.27657600461992965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401486739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912649,0.0018733292,0.0049907346,0.0000618392,0.00005361657,0.00008186403,0.00013473486,0.00013338034,0.0014056261],"genre_scores_gemma":[0.99303234,0.000914289,0.0031684763,0.00007010762,0.000025315641,0.000068486195,0.00030768086,0.000036155518,0.0023770214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99970216,0.000048623548,0.00002693077,0.00005478761,0.000077373814,0.000090085174],"domain_scores_gemma":[0.9999105,0.00001832473,0.000028411825,0.000012842451,0.000011433537,0.0000185499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014083835,0.0004792616,0.00042719505,0.0001949393,0.00008450097,0.00027461984,0.00019461337,0.0002767222,0.0012266517],"category_scores_gemma":[0.00012408495,0.00009235329,0.0002906886,0.00011455522,0.00016068519,0.0002048795,0.00020006973,0.00067140866,0.00032747688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012102173,0.00009112646,0.00013585523,0.0000356643,0.000005713062,0.000035166402,0.000008555801,0.0000780832,0.99708647,0.00006046826,0.000033350654,0.0023085554],"study_design_scores_gemma":[0.00003889538,0.0006335842,0.00093652896,0.0000033293757,0.000018184735,0.00016380144,0.000007450243,0.00058518694,0.99613225,0.000028818196,0.001450245,0.0000017251582],"about_ca_topic_score_codex":0.0001881514,"about_ca_topic_score_gemma":0.0002970763,"teacher_disagreement_score":0.0012266517,"about_ca_system_score_codex":0.00016741728,"about_ca_system_score_gemma":0.00019996539,"threshold_uncertainty_score":0.004103601},"labels":[],"label_agreement":null},{"id":"W4401690600","doi":"10.1101/2024.08.19.608538","title":"Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"Instituto de Salud Carlos III; European Regional Development Fund; Horizon 2020 Framework Programme; National Cancer Institute; National Institutes of Health; Ministerio de Ciencia e Innovación; Memorial Sloan-Kettering Cancer Center; Lietuvos Mokslo Taryba; Austrian Science Fund; Centro de Investigación Biomédica en Red de Cáncer; European Commission","keywords":"Crosstalk; Epigenetics; Metabolite; Immunity; Biology; Chemistry; Cancer research; Computational biology; Cell biology; Genetics; Immune system; Gene; Biochemistry; Engineering; Electronic engineering","score_opus":0.0171991688476267,"score_gpt":0.2696200321042862,"score_spread":0.2524208632566595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401690600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883786,0.0016058433,0.006365899,0.00028946545,0.000064195876,0.00004818823,0.00047741807,0.00012373843,0.0026467121],"genre_scores_gemma":[0.9942688,0.00045454584,0.0019187715,0.00012785643,0.000012871571,0.000028421415,0.00032849138,0.000030595864,0.0028295203],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998684,0.000024690007,0.000007288879,0.000038824837,0.00002777805,0.000033019413],"domain_scores_gemma":[0.9999565,0.0000057349293,0.000010565023,0.0000062854824,0.0000069717944,0.000013976559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012644009,0.00025067097,0.00019229129,0.00012968437,0.000100198726,0.00041330312,0.00009205374,0.00022429466,0.0025843754],"category_scores_gemma":[0.00010964232,0.000111189,0.00019375111,0.00010084315,0.0001454111,0.00016630783,0.00028493165,0.0006554046,0.00065315474],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022766113,0.000032230913,0.0004234882,0.000041119092,0.0000064114265,0.00005407338,0.000027954276,0.00014158967,0.9949281,0.00021069133,0.00010347429,0.0038031703],"study_design_scores_gemma":[0.000025924252,0.000518402,0.0035079697,0.000007531879,0.000022169454,0.00020237068,0.00007779023,0.0015111392,0.9883985,0.00018299518,0.005540429,0.000004839038],"about_ca_topic_score_codex":0.00021506668,"about_ca_topic_score_gemma":0.00046924638,"teacher_disagreement_score":0.0025843754,"about_ca_system_score_codex":0.00017338403,"about_ca_system_score_gemma":0.00018909435,"threshold_uncertainty_score":0.008645594},"labels":[],"label_agreement":null},{"id":"W4401698483","doi":"10.1038/s41698-024-00669-9","title":"A synthetic cytotoxic T cell platform for rapidly prototyping TCR function","year":2024,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; Genome British Columbia; National Institutes of Health; Michael Smith Health Research BC; U.S. Department of Health and Human Services","keywords":"T-cell receptor; Cytotoxic T cell; Major histocompatibility complex; Biology; Antigen; Granzyme; Cell biology; T cell; Granzyme B; Computational biology; Immunology; Immune system; In vitro; Genetics; Perforin","score_opus":0.05179868637115881,"score_gpt":0.3708730042852314,"score_spread":0.3190743179140726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401698483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7983921,0.0011027897,0.19316095,0.00017091964,0.0001290687,0.00030254724,0.00051435584,0.00088054343,0.0053467588],"genre_scores_gemma":[0.8757769,0.0009185675,0.117648035,0.00008988284,0.000021862139,0.0002338462,0.00047102562,0.00009235449,0.0047474937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974936,0.00004301697,0.00001810632,0.00004814787,0.000099169185,0.00004220925],"domain_scores_gemma":[0.99984705,0.000028553302,0.000043139207,0.000026128522,0.000023554734,0.00003150409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027858975,0.00040040282,0.00017755321,0.00018289947,0.00012124578,0.00036791878,0.0004675368,0.00037099991,0.001335687],"category_scores_gemma":[0.0002912509,0.00016643602,0.00020285907,0.00012259238,0.00021376277,0.00028311464,0.00035310385,0.00046185585,0.0004792152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025852727,0.000012989307,0.00004476354,0.00003573356,0.0000017422728,0.00006344574,0.000013210125,0.0006361487,0.9964935,0.00026828554,0.000043180582,0.0023610122],"study_design_scores_gemma":[0.000010559849,0.00030598557,0.00015856304,0.0000042834026,0.000004941143,0.00028875357,0.000008822083,0.0023461834,0.99350077,0.00008827348,0.0032750224,0.000007824412],"about_ca_topic_score_codex":0.00014335525,"about_ca_topic_score_gemma":0.00018181448,"teacher_disagreement_score":0.001335687,"about_ca_system_score_codex":0.00019909901,"about_ca_system_score_gemma":0.00020443751,"threshold_uncertainty_score":0.004468322},"labels":[],"label_agreement":null},{"id":"W4401745029","doi":"10.1002/hem3.130","title":"Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"University of Toronto","keywords":"Chimeric antigen receptor; Chemoimmunotherapy; Medicine; Oncology; Refractory (planetary science); Lymphoma; Internal medicine; CD19; Disease; Immunotherapy; Antigen; Immunology; Rituximab; Cancer; Biology","score_opus":0.06631002535945682,"score_gpt":0.379980524641565,"score_spread":0.3136704992821082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401745029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005491593,0.9989436,0.000054959048,0.00012410338,0.00005498081,0.000004747701,0.00003052125,0.0000028907011,0.00023504237],"genre_scores_gemma":[0.0049580047,0.9943558,0.00017766093,0.00015427457,0.00008824789,0.000019302806,0.0000768303,9.731376e-7,0.00016892972],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9997677,0.00007742672,0.000041519055,0.00003530098,0.000059103688,0.000018932084],"domain_scores_gemma":[0.99949,0.0002921599,0.00010292795,0.0000075703288,0.00009057694,0.000016731448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079003384,0.0006299957,0.0016215822,0.001109736,0.00009974039,0.000535982,0.00044344476,0.0005413794,0.00085515104],"category_scores_gemma":[0.0013356119,0.00014971814,0.00074720825,0.0011032999,0.0001880205,0.000392119,0.0002826947,0.0007852524,0.00031594557],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004338089,0.000066909786,0.0031035005,0.019290859,0.0007436246,0.00009782501,0.00003987136,0.0002833929,0.0010687133,0.0005209886,0.008298965,0.9660515],"study_design_scores_gemma":[0.00070667407,0.0031214731,0.096123986,0.06481999,0.013228524,0.0066297916,0.00040720133,0.0013865681,0.0053847465,0.0041366625,0.80381465,0.00023967233],"about_ca_topic_score_codex":0.00074794283,"about_ca_topic_score_gemma":0.0012646563,"teacher_disagreement_score":0.0016215822,"about_ca_system_score_codex":0.0003572624,"about_ca_system_score_gemma":0.0005877477,"threshold_uncertainty_score":0.004178107},"labels":[],"label_agreement":null},{"id":"W4401876465","doi":"10.1016/s2152-2650(24)01517-9","title":"ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chimeric antigen receptor; Refractory (planetary science); Phases of clinical research; Oncology; Lymphoma; Internal medicine; Cancer research; Immunotherapy; Clinical trial; Cancer","score_opus":0.029723763590510346,"score_gpt":0.34594281705386265,"score_spread":0.31621905346335233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936026,0.0041557024,0.00027585198,0.0001875415,0.00006153299,0.0001960979,0.00095781486,0.000037249858,0.00052575424],"genre_scores_gemma":[0.9952734,0.0010890405,0.00024495387,0.0002795135,0.0000972904,0.00018250688,0.0022909478,0.000016766862,0.0005256496],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988418,0.00051510363,0.00006809943,0.00021735838,0.000102048754,0.0002555552],"domain_scores_gemma":[0.99899155,0.00026868965,0.00025525835,0.00017071287,0.00006399876,0.00024985423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033226886,0.001699838,0.0035931263,0.00059990137,0.00041020202,0.0016002944,0.0007969551,0.0010321735,0.0019710201],"category_scores_gemma":[0.0014593829,0.00062412606,0.0041457457,0.00084405026,0.00063929224,0.0014324582,0.00055172195,0.0020879493,0.00045616436],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8444587,0.0032572367,0.055083133,0.0006270263,0.018328898,0.00031778315,0.00019639268,0.0027202726,0.014606012,0.00015190327,0.0022508826,0.05800173],"study_design_scores_gemma":[0.3740812,0.13441502,0.44639972,0.00014891868,0.029473254,0.00078129827,0.00041722367,0.0039505977,0.0038345351,0.0008251482,0.00544981,0.00022322698],"about_ca_topic_score_codex":0.0010496941,"about_ca_topic_score_gemma":0.0030841583,"teacher_disagreement_score":0.0035931263,"about_ca_system_score_codex":0.00087756483,"about_ca_system_score_gemma":0.0009211084,"threshold_uncertainty_score":0.017572284},"labels":[],"label_agreement":null},{"id":"W4401877474","doi":"10.1016/s2152-2650(24)00811-5","title":"Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chimeric antigen receptor; Oncology; Refractory (planetary science); Internal medicine; Lymphoma; Phases of clinical research; Immunotherapy; Clinical trial; Cancer","score_opus":0.030020297283375175,"score_gpt":0.3461436852849306,"score_spread":0.3161233880015554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933351,0.0044961753,0.00026666583,0.00016648925,0.00006060576,0.00016497118,0.0010174761,0.0000305182,0.00046199103],"genre_scores_gemma":[0.99531317,0.0010133161,0.00022329732,0.00025812513,0.00009554394,0.00016402347,0.002467651,0.00001671789,0.0004481985],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9987348,0.00054487056,0.00007803787,0.0002635949,0.00010923074,0.00026963156],"domain_scores_gemma":[0.99880815,0.00033564962,0.00029950167,0.00020819229,0.0000700414,0.00027852991],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035452126,0.0017344465,0.0038267476,0.0005566059,0.00044664886,0.0017218867,0.0008538154,0.0010604125,0.0018591655],"category_scores_gemma":[0.0016495688,0.0005903561,0.004608502,0.0008119321,0.0006593918,0.0015552442,0.00060982787,0.0020463248,0.0003846293],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8259679,0.0025191172,0.080233745,0.00068982155,0.02444057,0.00034939774,0.00021885685,0.0025269901,0.013023004,0.0001579072,0.002189344,0.04768328],"study_design_scores_gemma":[0.2887262,0.09800944,0.5632176,0.00015310933,0.035736177,0.0008461651,0.00048167954,0.003460342,0.0032336214,0.00085038313,0.005052189,0.00023304587],"about_ca_topic_score_codex":0.0009137427,"about_ca_topic_score_gemma":0.0027819593,"teacher_disagreement_score":0.0038267476,"about_ca_system_score_codex":0.00084933994,"about_ca_system_score_gemma":0.00085989805,"threshold_uncertainty_score":0.018749058},"labels":[],"label_agreement":null},{"id":"W4401892676","doi":"10.1038/s41423-024-01211-4","title":"The emerging roles of B cells in cancer development","year":2024,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hong Kong Government; Innovation and Technology Commission; National Natural Science Foundation of China; McGill University","keywords":"Cancer; Cancer research; Biology; Genetics","score_opus":0.012644560872175874,"score_gpt":0.291482502959603,"score_spread":0.2788379420874271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401892676","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26988953,0.61203974,0.023699576,0.034556374,0.0022661001,0.000075815165,0.0004765695,0.0002662809,0.05673001],"genre_scores_gemma":[0.814022,0.15701438,0.0089115435,0.0048711738,0.0021299,0.00008187555,0.00020994528,0.000050172435,0.012709052],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99973935,0.00009479124,0.000011981553,0.000039819854,0.000050878472,0.000063054504],"domain_scores_gemma":[0.9995802,0.00016913701,0.000042447522,0.0000332336,0.00006827454,0.000106695654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009235532,0.00031241024,0.000283592,0.0009510566,0.00038756663,0.0013788306,0.00041071014,0.0009274755,0.0036863394],"category_scores_gemma":[0.0005991186,0.0001523748,0.00021874705,0.0004122792,0.0012414184,0.0015900143,0.00063646777,0.002115521,0.0007200214],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016535008,0.00031298745,0.01715499,0.001740076,0.00011690067,0.0024822934,0.0007991371,0.0013886908,0.34967566,0.16787326,0.016106376,0.4406961],"study_design_scores_gemma":[0.00034318672,0.0021164818,0.046516098,0.001083266,0.00018147298,0.006328405,0.0027859337,0.0030150677,0.07193305,0.14009589,0.7255262,0.00007494911],"about_ca_topic_score_codex":0.00047071246,"about_ca_topic_score_gemma":0.0007045352,"teacher_disagreement_score":0.0036863394,"about_ca_system_score_codex":0.00044061593,"about_ca_system_score_gemma":0.0005323975,"threshold_uncertainty_score":0.012332022},"labels":[],"label_agreement":null},{"id":"W4402022196","doi":"10.1016/j.exphem.2024.104575","title":"2018 – TET2-MUTANT CLONAL HEMATOPOIESIS REPROGRAMS THE TUMOUR MICROENVIRONMENT TO PROMOTE IMMUNOTHERAPY RESPONSE","year":2024,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University Health Network","funders":"","keywords":"Mutant; Haematopoiesis; Immunotherapy; Cancer research; Biology; Cell biology; Immunology; Stem cell; Genetics; Immune system; Gene","score_opus":0.021688657688170514,"score_gpt":0.34116289999531396,"score_spread":0.31947424230714344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402022196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868999,0.0009334725,0.0032203053,0.00053406524,0.00018122303,0.000048221333,0.0005232533,0.0003314348,0.0073281224],"genre_scores_gemma":[0.9925373,0.00020578854,0.0010528542,0.00013570864,0.000044466116,0.00003296519,0.00038207718,0.000060404862,0.005548415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99975866,0.000038120073,0.00001324127,0.000046098907,0.00007396206,0.000069910835],"domain_scores_gemma":[0.99988055,0.000025598607,0.000022957409,0.000017820043,0.000009147724,0.000043859443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001369773,0.00026702593,0.00017593839,0.0003514331,0.00020986228,0.00047226233,0.00021065657,0.00045113277,0.006738284],"category_scores_gemma":[0.00015454157,0.00016977557,0.00017825005,0.0001675126,0.00031215537,0.00028220244,0.00029036592,0.0014011707,0.0011590283],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023916969,0.000099797886,0.00028043063,0.000022052844,0.0000054048173,0.00009333724,0.000022178187,0.00016496077,0.99433017,0.0006620177,0.0005866595,0.003493697],"study_design_scores_gemma":[0.0000979401,0.0005205398,0.004984348,0.000010253073,0.000024399666,0.00073944835,0.0000803036,0.0032037843,0.97585094,0.0004006383,0.014079616,0.000007676803],"about_ca_topic_score_codex":0.00043039728,"about_ca_topic_score_gemma":0.00090258504,"teacher_disagreement_score":0.006738284,"about_ca_system_score_codex":0.00028385114,"about_ca_system_score_gemma":0.00025933696,"threshold_uncertainty_score":0.022541761},"labels":[],"label_agreement":null},{"id":"W4402184323","doi":"10.1182/blood.2024025679","title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Royal College of Physicians and Surgeons of Canada","keywords":"Cytokine release syndrome; Medicine; Chimeric antigen receptor; Myelopathy; Cell therapy; Pathophysiology; Immunology; Immunotherapy; Intensive care medicine; Myelitis; Immune system; Internal medicine; Cell; Spinal cord; Biology","score_opus":0.055000010301930566,"score_gpt":0.40441695368018465,"score_spread":0.3494169433782541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402184323","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008218049,0.99659914,0.00025933172,0.00043291628,0.00017793222,0.000007168583,0.000017121916,0.000010245534,0.0016744512],"genre_scores_gemma":[0.007502568,0.9910383,0.00031218692,0.00034223942,0.0003319288,0.0000081357275,0.00003606314,0.0000018216232,0.00042682514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998528,0.00003579256,0.000029396817,0.000023219514,0.00004252714,0.000016171294],"domain_scores_gemma":[0.9998142,0.00008937898,0.0000406037,0.0000055325527,0.00003840653,0.000011914889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029561477,0.0005165051,0.00069066556,0.0016439367,0.0002379536,0.000661426,0.00057872053,0.0008757001,0.0011275508],"category_scores_gemma":[0.0007452349,0.00011178444,0.00030274762,0.0010218755,0.0003900959,0.0006104221,0.0003538737,0.0008715247,0.00071940164],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008906743,0.0000614105,0.0016662066,0.01772642,0.0001482005,0.010695947,0.00018698386,0.00046054562,0.0026524935,0.0027269425,0.024061782,0.93952394],"study_design_scores_gemma":[0.00003922959,0.00022225203,0.0090719825,0.021176435,0.00055557734,0.20319726,0.000586159,0.00044255008,0.0028210136,0.005053862,0.75676185,0.0000718687],"about_ca_topic_score_codex":0.00065691915,"about_ca_topic_score_gemma":0.00091965706,"teacher_disagreement_score":0.0016439367,"about_ca_system_score_codex":0.00034368903,"about_ca_system_score_gemma":0.00067286886,"threshold_uncertainty_score":0.0037720203},"labels":[],"label_agreement":null},{"id":"W4402266730","doi":"10.1158/1538-7445.pediatric24-b053","title":"Abstract B053: Tumor-associated macrophages diminishes IL1RAP-targeting CAR-T cell therapy efficacy in Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Chimeric antigen receptor; T cell; Medicine; Immunology; Immune system","score_opus":0.08861207712633722,"score_gpt":0.42057948188926525,"score_spread":0.331967404762928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960496,0.0009782407,0.0012606852,0.00014068562,0.00005348498,0.000061235325,0.00031789127,0.00008240892,0.0010558226],"genre_scores_gemma":[0.99491936,0.00033131536,0.0012700077,0.0000781766,0.000016420794,0.00010006809,0.0004621816,0.000019401656,0.0028030418],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997712,0.000045620192,0.000023463406,0.00003444141,0.000049146827,0.00007617813],"domain_scores_gemma":[0.9998833,0.000023673507,0.000019586461,0.000012389836,0.000014511513,0.000046522477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022698924,0.00029827366,0.00055232336,0.00020946805,0.00014813297,0.0003031806,0.00023964778,0.00042498083,0.0029593925],"category_scores_gemma":[0.00012577402,0.00010963522,0.00026227132,0.00014840171,0.00025779224,0.00021945585,0.00018082453,0.0010435565,0.0007051515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082388235,0.00049756333,0.0001682702,0.000064379165,0.000010400313,0.000046918423,0.000029516417,0.00010581926,0.99519944,0.000128697,0.00023001347,0.00269499],"study_design_scores_gemma":[0.00012923956,0.0034060953,0.0016899122,0.000008975496,0.0000269217,0.00018077728,0.00004087194,0.0010652436,0.9909389,0.000042994707,0.002466149,0.000003929534],"about_ca_topic_score_codex":0.000600248,"about_ca_topic_score_gemma":0.00060270587,"teacher_disagreement_score":0.0029593925,"about_ca_system_score_codex":0.00020742574,"about_ca_system_score_gemma":0.00033198873,"threshold_uncertainty_score":0.009900153},"labels":[],"label_agreement":null},{"id":"W4402267177","doi":"10.1158/1538-7445.pediatric24-ia015","title":"Abstract IA015: GD2-specific CAR T cell therapies for pediatric solid cancers","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Solid tumor; Oncology; Cancer; Cancer research; Internal medicine","score_opus":0.12855894036498683,"score_gpt":0.4531213373343368,"score_spread":0.32456239696934996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74335843,0.112716414,0.035091892,0.0033846663,0.001443552,0.00074168784,0.0036727313,0.0018648475,0.09772573],"genre_scores_gemma":[0.91128963,0.029142497,0.013655948,0.0008021176,0.00022289545,0.00031206265,0.0037990517,0.00011299368,0.04066273],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99994147,0.000009722028,0.0000042926927,0.000010949155,0.000017796925,0.000015754607],"domain_scores_gemma":[0.99996054,0.0000039799256,0.000008279237,0.000003245639,0.000008655053,0.000015247014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001597644,0.00034278195,0.00016639601,0.0003004619,0.000106737025,0.00027381122,0.0002301299,0.00028405283,0.004306755],"category_scores_gemma":[0.000077119774,0.00007004308,0.00020505927,0.00023088856,0.000114444185,0.00018111632,0.0002621226,0.00057497027,0.0015361668],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019498152,0.0006042055,0.0037611641,0.0012242976,0.00008148431,0.0011492085,0.00013328342,0.0018749365,0.5864503,0.0057720896,0.031139586,0.36585966],"study_design_scores_gemma":[0.0007792605,0.005385999,0.01149963,0.0002049324,0.00014261219,0.006686786,0.000076469376,0.0036489344,0.5453723,0.0007306902,0.42544633,0.000025976118],"about_ca_topic_score_codex":0.00074174436,"about_ca_topic_score_gemma":0.00072016,"teacher_disagreement_score":0.004306755,"about_ca_system_score_codex":0.00048224995,"about_ca_system_score_gemma":0.0005060102,"threshold_uncertainty_score":0.014407575},"labels":[],"label_agreement":null},{"id":"W4402267246","doi":"10.1158/1538-7445.pediatric24-b047","title":"Abstract B047: Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Leukemia; CD19; Lymphoblastic Leukemia; Cancer research; Medicine; Biology; Immunology; Antigen","score_opus":0.052705287333144335,"score_gpt":0.3661746427095858,"score_spread":0.31346935537644144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992812,0.00016443133,0.000103797465,0.000013080491,0.0000012993814,0.0000046947357,0.00023587914,0.000008805997,0.00018687874],"genre_scores_gemma":[0.9991385,0.00008609308,0.00014930224,0.000022884475,0.0000039978413,0.00000858858,0.0004124243,0.000007789712,0.00017047746],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980956,0.00001923807,0.00001259551,0.0000505638,0.00004322803,0.000064785665],"domain_scores_gemma":[0.99973816,0.00005269545,0.000115007475,0.00001488687,0.000029910103,0.000049338687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017542229,0.00015357014,0.0002644266,0.0005373604,0.00022456041,0.00042695997,0.00016091563,0.0003290479,0.0012202337],"category_scores_gemma":[0.00040258787,0.00014414133,0.00015086662,0.00047821473,0.0003013047,0.00017720634,0.00021958689,0.0004190307,0.00026691039],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018282867,0.00013741192,0.7689888,0.00008965763,0.00003516445,0.0030111545,0.00083185686,0.00043158102,0.20919722,0.0001852069,0.00043379856,0.014829944],"study_design_scores_gemma":[0.000023247492,0.0009957134,0.97459644,0.000012842746,0.00005122598,0.005739887,0.00052626437,0.00041940276,0.015018782,0.00009713282,0.0025096484,0.000009348947],"about_ca_topic_score_codex":0.0016313934,"about_ca_topic_score_gemma":0.0012041517,"teacher_disagreement_score":0.0016313934,"about_ca_system_score_codex":0.0003492088,"about_ca_system_score_gemma":0.00020357288,"threshold_uncertainty_score":0.0040820837},"labels":[],"label_agreement":null},{"id":"W4402267877","doi":"10.1158/1538-7445.pediatric24-b061","title":"Abstract B061: Dissecting pediatric sarcoma microenvironment using single-cell and spatial multi-omics","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sarcoma; Computational biology; Omics; Medicine; Tumor microenvironment; Cancer; Biology; Cancer research; Bioinformatics; Pathology; Internal medicine","score_opus":0.12593706990709044,"score_gpt":0.4082897044346989,"score_spread":0.2823526345276085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59803104,0.014783139,0.20107129,0.0026109696,0.0008585888,0.0005133255,0.16104071,0.0047319466,0.016358942],"genre_scores_gemma":[0.5919187,0.007856832,0.24942562,0.0023342406,0.00041978856,0.0009384717,0.13692579,0.0019302504,0.008250368],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992866,0.00008970711,0.000039696664,0.00026755352,0.0002190817,0.000097445816],"domain_scores_gemma":[0.99920887,0.00021849653,0.00013963827,0.00009624392,0.00024971753,0.00008715819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010739957,0.00068871735,0.000800867,0.001351014,0.0009099247,0.001414028,0.0004964882,0.0007721169,0.0034205024],"category_scores_gemma":[0.0012308002,0.0003772205,0.00089571933,0.0013742854,0.00044578916,0.0006638966,0.001262817,0.0010440268,0.0015278421],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005272071,0.000084559884,0.051894616,0.0016068767,0.00042024514,0.00047107573,0.0005449778,0.0045191254,0.86229175,0.0024633724,0.013320759,0.061855394],"study_design_scores_gemma":[0.00009096537,0.0005718272,0.42437673,0.00069605524,0.00079514604,0.0021414838,0.0017812236,0.056442853,0.31276882,0.011711685,0.18834358,0.00027969864],"about_ca_topic_score_codex":0.0030142402,"about_ca_topic_score_gemma":0.00702972,"teacher_disagreement_score":0.0034205024,"about_ca_system_score_codex":0.0005175469,"about_ca_system_score_gemma":0.0010672259,"threshold_uncertainty_score":0.011442721},"labels":[],"label_agreement":null},{"id":"W4402267976","doi":"10.1158/1538-7445.pediatric24-pr010","title":"Abstract PR010: Developing a safe and potent tumor-targeting gated CAR-T cell therapy for DIPG: A deadly pediatric brain tumor","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Brain tumor; CAR T-cell therapy; Tumor cells; Cancer; Cancer research; Oncology; Internal medicine; Immunotherapy; Pathology; Chimeric antigen receptor","score_opus":0.07872022883180967,"score_gpt":0.4125548820167345,"score_spread":0.33383465318492483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8739725,0.005955667,0.101081304,0.0014191025,0.00022336424,0.0006016731,0.001119753,0.00093809166,0.014688475],"genre_scores_gemma":[0.9530104,0.0023202363,0.034889217,0.0002927413,0.000021353053,0.00021044479,0.0010161705,0.00006396085,0.0081755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989676,0.000012479583,0.0000049050795,0.000023609162,0.000035356377,0.00002679175],"domain_scores_gemma":[0.9999685,0.0000037016,0.0000062298905,0.000002678837,0.0000065435547,0.000012369688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001465795,0.00035677076,0.00021834322,0.00016589003,0.00012652934,0.00033150802,0.0004272234,0.00040313552,0.0013765738],"category_scores_gemma":[0.00007968373,0.00012277137,0.00022988165,0.00015012271,0.00022125158,0.00022500214,0.00024533836,0.00076056155,0.00052307145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024320128,0.00019010204,0.000740802,0.00025041882,0.00001811839,0.0003857284,0.000040526127,0.002305585,0.96374524,0.0029573557,0.0015411563,0.02758179],"study_design_scores_gemma":[0.000138186,0.0016782165,0.0012994293,0.00001883078,0.000054291617,0.0014464475,0.00002674702,0.01024969,0.96114564,0.00028927388,0.02363994,0.000013286042],"about_ca_topic_score_codex":0.0014014549,"about_ca_topic_score_gemma":0.00095616677,"teacher_disagreement_score":0.0014014549,"about_ca_system_score_codex":0.00048608234,"about_ca_system_score_gemma":0.0007003106,"threshold_uncertainty_score":0.004605055},"labels":[],"label_agreement":null},{"id":"W4402279313","doi":"10.1007/s00262-024-03813-3","title":"Correction to: Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells","year":2024,"lang":"en","type":"erratum","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mesothelin; Treosulfan; Fludarabine; Olaparib; Chimeric antigen receptor; Ovarian cancer; Cancer research; Medicine; Oncology; Antigen; Immunology; Internal medicine; Biology; Immunotherapy; Chemotherapy; Cancer; Gene; Immune system; Poly ADP ribose polymerase; Genetics; Cyclophosphamide","score_opus":0.014802131076722286,"score_gpt":0.3236933696166772,"score_spread":0.3088912385399549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402279313","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012453414,0.0010295514,0.00030290423,0.029439522,0.9672295,0.000013070266,0.00023402921,0.00008811898,0.0015387802],"genre_scores_gemma":[0.01251976,0.010308787,0.003463512,0.09758103,0.6496062,0.00013485861,0.0010645414,0.00086536945,0.22445598],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99748635,0.00037526968,0.0003948567,0.00033007373,0.0011462227,0.0002671757],"domain_scores_gemma":[0.98665327,0.0036803754,0.0006458696,0.00067860936,0.007296462,0.0010454535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028083099,0.0018082552,0.0014529639,0.002604331,0.0020207884,0.0027638227,0.0026863639,0.006367965,0.028336482],"category_scores_gemma":[0.025315246,0.0008623748,0.0014720864,0.0011620075,0.0017689016,0.0013054127,0.0012655514,0.008748067,0.0149357375],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056925313,0.00000777563,0.000055001798,0.0001087956,0.000014341372,0.0004921444,0.000014390558,0.000044672754,0.00008909828,0.00038771352,0.993067,0.005662014],"study_design_scores_gemma":[0.000051732506,0.000021098287,0.00038656004,0.00014485858,0.000046328732,0.0008697187,0.000031376247,0.00018462891,0.00046757466,0.0005636849,0.99721503,0.000017339293],"about_ca_topic_score_codex":0.011723478,"about_ca_topic_score_gemma":0.014008876,"teacher_disagreement_score":0.028336482,"about_ca_system_score_codex":0.0035503763,"about_ca_system_score_gemma":0.0037660308,"threshold_uncertainty_score":0.09479505},"labels":[],"label_agreement":null},{"id":"W4402340874","doi":"10.1101/2024.09.03.611092","title":"A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Concordia University","funders":"","keywords":"Microscale chemistry; Microfluidics; Production (economics); Immune system; Nanotechnology; Computer science; Biology; Materials science; Immunology; Economics; Mathematics","score_opus":0.023196108972669265,"score_gpt":0.24800599691893774,"score_spread":0.22480988794626847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402340874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5889524,0.0055550383,0.38373435,0.0010090662,0.00087479234,0.0007056043,0.0024092402,0.0042197676,0.012539672],"genre_scores_gemma":[0.762297,0.0017710981,0.22877654,0.0002582686,0.00008723447,0.00066217716,0.0006838253,0.000089277535,0.005374575],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998197,0.00001558726,0.000017949382,0.000048909722,0.00007285887,0.000025017833],"domain_scores_gemma":[0.9998728,0.00003481357,0.000044623815,0.000016849905,0.00001604008,0.000014793113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000273114,0.00030251188,0.00016788967,0.00035026475,0.00015984119,0.00038414335,0.00028836305,0.00031939414,0.0013531278],"category_scores_gemma":[0.00021567494,0.00015661963,0.00022096107,0.00015331412,0.00023842278,0.00024186868,0.00036705274,0.00039345477,0.0004996017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018553294,0.00003272823,0.000095469535,0.000059018956,0.000005443626,0.000032630127,0.000014049254,0.0005065061,0.9912816,0.00054295803,0.00046425193,0.0069467556],"study_design_scores_gemma":[0.000013852006,0.00011419287,0.00043552453,0.0000055539035,0.0000068476334,0.00009121475,0.000006186581,0.004572167,0.98690665,0.00009741964,0.007739926,0.000010488111],"about_ca_topic_score_codex":0.00024381402,"about_ca_topic_score_gemma":0.00034847035,"teacher_disagreement_score":0.0013531278,"about_ca_system_score_codex":0.00041516635,"about_ca_system_score_gemma":0.00029418984,"threshold_uncertainty_score":0.004526615},"labels":[],"label_agreement":null},{"id":"W4402363529","doi":"10.4049/immunohorizons.2300095","title":"Improving Reliability of Immunological Assays by Defining Minimal Criteria for Cell Fitness","year":2024,"lang":"en","type":"article","venue":"ImmunoHorizons","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Montreal Heart Institute; BC Children's Hospital; University of British Columbia","funders":"Institute of Nutrition, Metabolism and Diabetes; Institute of Infection and Immunity; Genome Canada; Canadian Institutes of Health Research; Genome British Columbia; Institute of Genetics; Government of Canada","keywords":"Cryopreservation; Peripheral blood mononuclear cell; Flow cytometry; Biology; Biomarker; Viability assay; Immune system; Cell; Immunology; Coefficient of variation; Computational biology; Cell biology; In vitro; Chemistry; Genetics; Embryo","score_opus":0.02550995418780715,"score_gpt":0.3363704938689318,"score_spread":0.31086053968112465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402363529","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32475775,0.006721804,0.6562542,0.0012643972,0.00070510164,0.0016473549,0.0007447386,0.0012187579,0.0066859727],"genre_scores_gemma":[0.6354848,0.001685266,0.35453197,0.000986005,0.0001579476,0.0027617323,0.001378766,0.0004827825,0.0025307722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9546711,0.02219664,0.0054847817,0.0039460384,0.01262733,0.0010742302],"domain_scores_gemma":[0.9396138,0.036594544,0.0047599687,0.007886177,0.010628358,0.00051713904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.031370487,0.0016431106,0.0016196627,0.0021291168,0.0010570276,0.0030186006,0.0018080445,0.002455844,0.00116961],"category_scores_gemma":[0.053597115,0.0007898287,0.0008228112,0.0012477034,0.002645856,0.0015301198,0.002126872,0.0021485577,0.0010250688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010854114,0.00034346292,0.041971423,0.001119856,0.0002088109,0.00023174884,0.0021850632,0.0052954783,0.8846402,0.0043862327,0.0013811716,0.05715115],"study_design_scores_gemma":[0.00004359568,0.0014387754,0.037437897,0.00028953722,0.00020322588,0.0006399969,0.00041669168,0.025088873,0.92226255,0.0029754175,0.009040819,0.00016252194],"about_ca_topic_score_codex":0.00097144244,"about_ca_topic_score_gemma":0.0018067705,"teacher_disagreement_score":0.031370487,"about_ca_system_score_codex":0.0010495535,"about_ca_system_score_gemma":0.0009563408,"threshold_uncertainty_score":0.165905},"labels":[],"label_agreement":null},{"id":"W4402471159","doi":"10.1182/bloodadvances.2024012982","title":"Point-of-care CAR T manufacturing solutions: can 1 model fit all?","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Point (geometry); Computer science; Mathematics","score_opus":0.045130513431129046,"score_gpt":0.33922728022692095,"score_spread":0.2940967667957919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402471159","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074117836,0.0395965,0.0902532,0.7302765,0.013108984,0.00048522858,0.00060569297,0.002722806,0.11553927],"genre_scores_gemma":[0.23051791,0.11115245,0.27591974,0.25553066,0.012351672,0.0016159149,0.0020173765,0.00192263,0.10897156],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9924918,0.0026417533,0.00036982493,0.0005564486,0.0030602717,0.00087984785],"domain_scores_gemma":[0.98898953,0.002301234,0.00094474794,0.0011763343,0.0035636977,0.0030245776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01182418,0.0013651034,0.00083309977,0.0011308048,0.0018770384,0.010510736,0.0036365723,0.008210831,0.027140072],"category_scores_gemma":[0.018067576,0.000508273,0.0013337733,0.00091259985,0.0031503441,0.012992455,0.004821837,0.0083542885,0.015713448],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041029262,0.00064022385,0.002440092,0.0013407534,0.00009485706,0.00072140637,0.0007046093,0.0032787416,0.0023476386,0.31344867,0.41316554,0.26140726],"study_design_scores_gemma":[0.000117479016,0.0008502664,0.00044736636,0.0010428104,0.00007140251,0.0008876289,0.0009162102,0.0023793336,0.0016925733,0.087940514,0.9035547,0.00009978466],"about_ca_topic_score_codex":0.0018684007,"about_ca_topic_score_gemma":0.0034939593,"teacher_disagreement_score":0.027140072,"about_ca_system_score_codex":0.003641154,"about_ca_system_score_gemma":0.008960374,"threshold_uncertainty_score":0.0907926},"labels":[],"label_agreement":null},{"id":"W4402492440","doi":"10.1016/j.healthpol.2024.105153","title":"Availability and financing of CAR-T cell therapies: A cross-country comparative analysis","year":2024,"lang":"en","type":"review","venue":"Health Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; Institute for Work & Health","funders":"European Observatory on Health Systems and Policies","keywords":"Business; Finance","score_opus":0.13948010126114785,"score_gpt":0.5300620829097249,"score_spread":0.39058198164857705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402492440","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010953482,0.9861944,0.00014886275,0.00033618987,0.0000492238,0.00008487454,0.0009402446,0.0000035256428,0.001289195],"genre_scores_gemma":[0.077493675,0.9207806,0.00040574349,0.00024624093,0.000042718864,0.00013756588,0.00070169196,0.0000047475546,0.00018694386],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958215,0.0020437222,0.0008362819,0.0002948293,0.00070350914,0.00030021052],"domain_scores_gemma":[0.9910971,0.005443882,0.0021848364,0.0001369895,0.0009748826,0.00016240252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068363016,0.00056182133,0.0028759965,0.006149634,0.00020753633,0.0015537136,0.00077101873,0.0008994383,0.004607901],"category_scores_gemma":[0.012199452,0.00051902205,0.004245823,0.011736047,0.00035425712,0.0013178412,0.0010744511,0.0009893535,0.0002811811],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047203726,0.000233041,0.015012704,0.48345262,0.028317535,0.000646638,0.0005811611,0.0023046322,0.0006228803,0.0056979978,0.009183163,0.44922724],"study_design_scores_gemma":[0.003841192,0.0047061206,0.19541234,0.35369587,0.1724338,0.004958122,0.003649656,0.001317865,0.0019209541,0.0023669482,0.25542614,0.00027095765],"about_ca_topic_score_codex":0.00872863,"about_ca_topic_score_gemma":0.0124215735,"teacher_disagreement_score":0.00872863,"about_ca_system_score_codex":0.002664798,"about_ca_system_score_gemma":0.004953882,"threshold_uncertainty_score":0.03615421},"labels":[],"label_agreement":null},{"id":"W4402499383","doi":"10.1186/s40364-024-00634-5","title":"Updates on CAR T cell therapy in multiple myeloma","year":2024,"lang":"en","type":"review","venue":"Biomarker Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chimeric antigen receptor; Medicine; Cytokine release syndrome; Immunotherapy; Multiple myeloma; T cell; Cancer research; Immunology; Cancer; Oncology; Internal medicine; Immune system","score_opus":0.30861410387930377,"score_gpt":0.48950730688676003,"score_spread":0.18089320300745626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402499383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051837583,0.9948761,0.0003703577,0.00090455165,0.00087596936,0.000013955982,0.00007150162,0.000029181117,0.0023400006],"genre_scores_gemma":[0.0022816784,0.9927441,0.000562781,0.0014608876,0.001081863,0.000025854088,0.00020224045,0.000009315178,0.0016313723],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997789,0.000048966624,0.000036027643,0.00003374976,0.00007225205,0.000030173935],"domain_scores_gemma":[0.99954575,0.00024336757,0.00004394707,0.00001101502,0.00011592454,0.00003997147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007891723,0.0005045232,0.00081349956,0.0011689067,0.00020177706,0.00091243547,0.00063992373,0.0010401262,0.0045986],"category_scores_gemma":[0.0008921071,0.00021513518,0.00065999693,0.000947559,0.00023826168,0.0011035794,0.00050813326,0.0020910804,0.0019182127],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002050337,0.000107922206,0.00015315422,0.009850327,0.000090354784,0.00022265455,0.00007739422,0.00059455936,0.003992795,0.0028705986,0.0634182,0.9184169],"study_design_scores_gemma":[0.00003273435,0.00024168713,0.00033989278,0.001677474,0.00011511651,0.0005989817,0.00002249385,0.00011396029,0.0009988752,0.0006239952,0.99522215,0.000012593142],"about_ca_topic_score_codex":0.0006224678,"about_ca_topic_score_gemma":0.0011225776,"teacher_disagreement_score":0.0045986,"about_ca_system_score_codex":0.00045434665,"about_ca_system_score_gemma":0.00067328836,"threshold_uncertainty_score":0.01538378},"labels":[],"label_agreement":null},{"id":"W4402558664","doi":"10.1016/j.annonc.2024.08.2144","title":"987TiP First-in-human dose escalation trial of fourth generation chimeric antigen receptor (CAR) T cell therapy (EU307) in patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Glypican 3; Chimeric antigen receptor; Hepatocellular carcinoma; Oncology; Internal medicine; Cancer research; Immunotherapy; Cancer","score_opus":0.06382615843562044,"score_gpt":0.35002115545629187,"score_spread":0.2861949970206714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952989,0.0005263308,0.00020891055,0.0004138497,0.00012292912,0.00047619455,0.0005455569,0.00007851978,0.0023288284],"genre_scores_gemma":[0.9937568,0.00040168283,0.00046326517,0.0006392944,0.00008742397,0.000549343,0.0010972914,0.000023183988,0.0029817673],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99974626,0.000088741595,0.000010228665,0.000035546287,0.00001469448,0.00010458959],"domain_scores_gemma":[0.99972993,0.000043850745,0.00002229431,0.000030098136,0.000009444093,0.00016438488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059397414,0.00094654976,0.0015911865,0.00030243315,0.00036208125,0.0009620673,0.00048160698,0.0011026888,0.005071835],"category_scores_gemma":[0.00042972207,0.00036828898,0.0009064569,0.0002884843,0.00068638107,0.00070459966,0.00033846163,0.0027044965,0.0012482734],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8293446,0.030089818,0.005205882,0.00032661986,0.0007700691,0.0004417915,0.00021787058,0.003152932,0.024273273,0.00062361435,0.0050587347,0.100494795],"study_design_scores_gemma":[0.5033469,0.46757272,0.014086724,0.00003281991,0.0003821638,0.00038211732,0.0001056015,0.0028966519,0.0059700967,0.0004860586,0.004689293,0.000048817506],"about_ca_topic_score_codex":0.0006939456,"about_ca_topic_score_gemma":0.0015037224,"teacher_disagreement_score":0.005071835,"about_ca_system_score_codex":0.0007283065,"about_ca_system_score_gemma":0.00071633887,"threshold_uncertainty_score":0.016966999},"labels":[],"label_agreement":null},{"id":"W4402559898","doi":"10.1016/j.annonc.2024.08.859","title":"808MO Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T cell therapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Wellcome Trust","keywords":"Medicine; Chimeric antigen receptor; Lymphoma; Antigen; Diffuse large B-cell lymphoma; B cell; Nuclear medicine; Cancer research; Oncology; Immunotherapy; Pathology; Internal medicine; Immunology; Cancer; Antibody","score_opus":0.04343359763471496,"score_gpt":0.3659126109900065,"score_spread":0.32247901335529155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977685,0.002949122,0.00016498251,0.0003812459,0.00006234946,0.00001712659,0.0001685265,0.000016486054,0.0064632427],"genre_scores_gemma":[0.99863964,0.0004778658,0.00012664478,0.000103376085,0.000079067846,0.000007038468,0.00016168266,0.000004435061,0.00040028634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998216,0.0000390642,0.000020101932,0.00002636087,0.000032111464,0.000060773426],"domain_scores_gemma":[0.9994199,0.00019921322,0.00009644987,0.000025369083,0.00011902022,0.00013993015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038685882,0.00063897,0.0005039306,0.000994351,0.00036096683,0.00096636196,0.00034832917,0.0010401976,0.001929167],"category_scores_gemma":[0.0016191863,0.00020887193,0.00041347413,0.0004773426,0.0003021879,0.00061986584,0.00023965191,0.00054147403,0.00054361107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002713334,0.00017811057,0.9667162,0.00004718754,0.0000765319,0.009204359,0.000073716605,0.00029960164,0.004800255,0.000066797904,0.00036902362,0.015454828],"study_design_scores_gemma":[0.00009441596,0.0009774391,0.9724283,0.00007520249,0.0005176694,0.015385674,0.0005751463,0.0032084805,0.003308287,0.00029233267,0.003107627,0.000029401872],"about_ca_topic_score_codex":0.0026243923,"about_ca_topic_score_gemma":0.0029720752,"teacher_disagreement_score":0.0026243923,"about_ca_system_score_codex":0.00048693074,"about_ca_system_score_gemma":0.00031492728,"threshold_uncertainty_score":0.006453693},"labels":[],"label_agreement":null},{"id":"W4402560756","doi":"10.1016/j.annonc.2024.08.1149","title":"1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Melanoma; Dermatology; Phase (matter); Oncology; Internal medicine; Cancer research","score_opus":0.05754284482523902,"score_gpt":0.4079441693441884,"score_spread":0.3504013245189494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98378986,0.0056468435,0.00054517266,0.0016039101,0.00043447877,0.001292518,0.0016665292,0.0002356741,0.0047848467],"genre_scores_gemma":[0.97552925,0.005942747,0.0014066139,0.0016287327,0.0002608312,0.0018740726,0.0035905633,0.000075476055,0.009691642],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99969816,0.000113184724,0.000014442891,0.000044906938,0.00003147244,0.00009786601],"domain_scores_gemma":[0.99974614,0.00003751451,0.000041573116,0.000024253499,0.000018114759,0.00013235265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007156187,0.0013281336,0.0021776801,0.00051267113,0.00037420547,0.0011639782,0.0008661915,0.0011287987,0.0059311897],"category_scores_gemma":[0.00040463422,0.00056615024,0.0019136054,0.00042088365,0.0007059937,0.0007965352,0.00035032086,0.0036008593,0.001587491],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5058398,0.054679796,0.007967567,0.002370303,0.0040682806,0.0005325274,0.0004625699,0.005604323,0.07363134,0.00097288226,0.021031292,0.32283932],"study_design_scores_gemma":[0.5322551,0.4325998,0.013558292,0.00012117898,0.0013054135,0.00050496735,0.00018124607,0.002258302,0.0065699187,0.0003435548,0.010243295,0.000058963713],"about_ca_topic_score_codex":0.001981255,"about_ca_topic_score_gemma":0.0064142724,"teacher_disagreement_score":0.0059311897,"about_ca_system_score_codex":0.00097131834,"about_ca_system_score_gemma":0.0013373411,"threshold_uncertainty_score":0.01984185},"labels":[],"label_agreement":null},{"id":"W4402684921","doi":"10.14740/jmc4287","title":"Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ponatinib; Lymphoblastic Leukemia; Refractory (planetary science); Maintenance therapy; Bridge (graph theory); Internal medicine; Oncology; Leukemia; Surgery; Myeloid leukemia; Chemotherapy; Dasatinib","score_opus":0.018904137330430292,"score_gpt":0.30797661611468,"score_spread":0.28907247878424974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402684921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085945,0.0042272485,0.0010873103,0.0011240822,0.00006658921,0.000082622806,0.00005641472,0.000066558045,0.002429712],"genre_scores_gemma":[0.9966106,0.0014190568,0.0006574361,0.00039193485,0.0000796119,0.000020781516,0.00009453551,0.000010638055,0.00071543065],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99989164,0.000016472466,0.000013675076,0.000027783624,0.000018039244,0.00003234001],"domain_scores_gemma":[0.9999069,0.000014149579,0.000014098719,0.000006790513,0.0000044516073,0.000053661803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000114926246,0.00038584045,0.00074542244,0.00031390303,0.0005020471,0.00036350221,0.00034596885,0.00062501716,0.0005189142],"category_scores_gemma":[0.00023665716,0.00020994432,0.0003947726,0.00025000126,0.00028675154,0.00042352185,0.00031894806,0.0011787096,0.00027507055],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067119454,0.0027016927,0.037103064,0.00044058202,0.0003198682,0.67801315,0.0013570557,0.00257452,0.12304726,0.0009845445,0.0033073982,0.14343897],"study_design_scores_gemma":[0.0020631254,0.017709479,0.042483237,0.00006033411,0.00043033872,0.8641574,0.0003816045,0.0062325713,0.04409493,0.00070879847,0.021577578,0.00010064382],"about_ca_topic_score_codex":0.00052283815,"about_ca_topic_score_gemma":0.0012769105,"teacher_disagreement_score":0.00074542244,"about_ca_system_score_codex":0.0004398077,"about_ca_system_score_gemma":0.00025657724,"threshold_uncertainty_score":0.0031910539},"labels":[],"label_agreement":null},{"id":"W4402715623","doi":"10.1101/2024.09.18.613561","title":"Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"","keywords":"Blocking (statistics); Antibody; Blocking antibody; Chemistry; Molecular biology; Biology; Computer science; Immunology","score_opus":0.030285445165221702,"score_gpt":0.2939124376450998,"score_spread":0.2636269924798781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402715623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84510535,0.004688635,0.1327882,0.00057292974,0.0002562838,0.00084904535,0.0015761157,0.0007060899,0.013457365],"genre_scores_gemma":[0.94813013,0.002177617,0.038389817,0.00018142247,0.00006590449,0.00021859907,0.0015193461,0.000078512385,0.0092386855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997081,0.00005271126,0.000028403392,0.000057167457,0.00008499004,0.00006868271],"domain_scores_gemma":[0.9998685,0.00002422027,0.000026950953,0.000022220323,0.00003349599,0.000024579873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042382273,0.00047436843,0.00018062153,0.00047860693,0.00011574162,0.00038359172,0.0004115773,0.00037393463,0.0025267894],"category_scores_gemma":[0.00018052133,0.00012170668,0.00020248088,0.00016620115,0.00018079471,0.00020099343,0.00040498786,0.00042244708,0.0008227077],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003150713,0.000040762603,0.00023308811,0.00006124143,0.0000047569606,0.00004184271,0.000013517463,0.00013957843,0.9934818,0.00060707354,0.00017404446,0.0051707434],"study_design_scores_gemma":[0.000021054408,0.00019446229,0.00094504975,0.000015335168,0.000021239057,0.00033324608,0.00001613057,0.0011553032,0.98539597,0.00009915798,0.011798863,0.0000041946932],"about_ca_topic_score_codex":0.0004346438,"about_ca_topic_score_gemma":0.0005921154,"teacher_disagreement_score":0.0025267894,"about_ca_system_score_codex":0.00037900102,"about_ca_system_score_gemma":0.0003617295,"threshold_uncertainty_score":0.008452952},"labels":[],"label_agreement":null},{"id":"W4402784527","doi":"10.1016/j.omton.2024.200876","title":"Innovative approaches to glioma treatment: Oncolytic foamy virus and CAR T cell therapy","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Oncolytic virus; Glioma; Virology; Virus; Medicine; Cancer research","score_opus":0.12167697695646601,"score_gpt":0.35955457143196046,"score_spread":0.23787759447549445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402784527","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17455326,0.652439,0.10533797,0.030766116,0.0036854714,0.0005082849,0.000332902,0.0005284687,0.03184851],"genre_scores_gemma":[0.7135362,0.23082256,0.03448646,0.004734847,0.0029541182,0.0004052868,0.00029155932,0.00006186062,0.012707069],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980193,0.000052053965,0.0000063300085,0.00003548885,0.000044762066,0.000059385846],"domain_scores_gemma":[0.9998901,0.00003752742,0.000019257313,0.000009851745,0.000020594536,0.000022591985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062571926,0.0005800348,0.00051110785,0.00087939674,0.00029465946,0.0013339956,0.00065497373,0.001219781,0.0021192017],"category_scores_gemma":[0.00034565863,0.00014158365,0.0005722397,0.0004832731,0.0011130802,0.0014751168,0.00069460063,0.0018455322,0.00042323288],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017150227,0.0012068298,0.0012967449,0.0017616877,0.0002274209,0.0010777159,0.000357608,0.0038103187,0.17401944,0.10231978,0.015739882,0.69646746],"study_design_scores_gemma":[0.0020473814,0.012679285,0.0055558197,0.001050528,0.00051711046,0.0077143232,0.000943136,0.019176824,0.26609823,0.11983624,0.5641477,0.00023340045],"about_ca_topic_score_codex":0.001360761,"about_ca_topic_score_gemma":0.001518801,"teacher_disagreement_score":0.0021192017,"about_ca_system_score_codex":0.00089179905,"about_ca_system_score_gemma":0.00095386116,"threshold_uncertainty_score":0.0070894957},"labels":[],"label_agreement":null},{"id":"W4402929046","doi":"10.1002/cpt.3445","title":"A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; Roche","keywords":"Medicine; Regimen; Follicular lymphoma; Neutropenia; Dosing; Internal medicine; Adverse effect; Refractory (planetary science); Population; Pharmacokinetics; Oncology; Lymphoma; Gastroenterology; Pharmacology; Toxicity; Biology","score_opus":0.10287831559075052,"score_gpt":0.4523550682450669,"score_spread":0.3494767526543164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402929046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861247,0.0014446218,0.010040021,0.00016110764,0.000024897134,0.00027178894,0.00014204609,0.00018265484,0.0016082113],"genre_scores_gemma":[0.995555,0.00024004531,0.0036698643,0.000060161346,0.000011032021,0.00007578882,0.00007174768,0.000009420039,0.0003069058],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997782,0.00008057011,0.00001322463,0.00004316393,0.000056321405,0.000028437504],"domain_scores_gemma":[0.99984586,0.000059656097,0.000047234047,0.000015622938,0.000010606069,0.000020973699],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037998526,0.00022973353,0.0004223941,0.00031155423,0.00006721795,0.00035501784,0.00037743026,0.0003034987,0.0013599007],"category_scores_gemma":[0.0009235757,0.00013116031,0.0003000388,0.00014929844,0.00012427986,0.00024448443,0.00021826266,0.0006524001,0.00018281456],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020088464,0.006514977,0.008266068,0.00035100445,0.000539894,0.0002575943,0.00018912106,0.047291093,0.28653252,0.0023949177,0.0023719885,0.6252023],"study_design_scores_gemma":[0.020706894,0.1826151,0.09551319,0.00019104403,0.0025429043,0.001913043,0.00017000415,0.4487567,0.21476433,0.0046826573,0.02788427,0.00025989124],"about_ca_topic_score_codex":0.0004358877,"about_ca_topic_score_gemma":0.00079068,"teacher_disagreement_score":0.0013599007,"about_ca_system_score_codex":0.0003504309,"about_ca_system_score_gemma":0.00026407564,"threshold_uncertainty_score":0.0045493245},"labels":[],"label_agreement":null},{"id":"W4403094942","doi":"10.54194/iowr5712","title":"Government development of ‘made-in-Canada’ CAR-T cell immunotherapies: assessing cost, risk, access, and alternatives","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Business; Risk analysis (engineering)","score_opus":0.05149128024051644,"score_gpt":0.39716694700375493,"score_spread":0.34567566676323846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403094942","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057937037,0.049295798,0.0059953867,0.67758864,0.0041281385,0.0013304156,0.0066425717,0.00031657133,0.19676554],"genre_scores_gemma":[0.7363045,0.038759317,0.020567998,0.15453227,0.0015885992,0.00065683195,0.0032481246,0.0001490005,0.044193216],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.971845,0.0061235027,0.00061202043,0.0011065318,0.01390925,0.0064036483],"domain_scores_gemma":[0.9677802,0.0077613867,0.00180163,0.0007073097,0.01595645,0.005993041],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015841264,0.0008234262,0.0007975081,0.0025534676,0.003953715,0.009011745,0.0039062835,0.0072325272,0.010804965],"category_scores_gemma":[0.029648345,0.000667492,0.0016256905,0.002921981,0.0052250186,0.0025218271,0.0023604801,0.006013837,0.00052483066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015938473,0.0007589128,0.013638906,0.0026317197,0.00052529917,0.0005759475,0.0016387757,0.012586325,0.004722761,0.41133693,0.34314445,0.20684607],"study_design_scores_gemma":[0.0010091049,0.0008668581,0.035369392,0.0032644481,0.00046847874,0.00026752136,0.0026762716,0.0083936965,0.0039433413,0.028200159,0.9152828,0.0002579735],"about_ca_topic_score_codex":0.9741285,"about_ca_topic_score_gemma":0.9828587,"teacher_disagreement_score":0.8196163,"about_ca_system_score_codex":0.18038371,"about_ca_system_score_gemma":0.51526785,"threshold_uncertainty_score":0.9506387},"labels":[],"label_agreement":null},{"id":"W4403251225","doi":"10.1016/j.ygyno.2024.07.417","title":"GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.03270045354597139,"score_gpt":0.34693050096028794,"score_spread":0.31423004741431654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403251225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98824894,0.0035013831,0.00033574205,0.0019350023,0.00042345005,0.0010535595,0.0009635927,0.00025989997,0.003278517],"genre_scores_gemma":[0.9877511,0.0022895152,0.0010330101,0.0015988081,0.00018016635,0.0011030798,0.0017213487,0.000045086195,0.0042777695],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99972194,0.000111872585,0.000010848653,0.000049641927,0.000019303054,0.0000864003],"domain_scores_gemma":[0.99971217,0.000045332094,0.00003321628,0.000019699712,0.000015405196,0.00017409366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008836531,0.0010936559,0.0016837888,0.0004359839,0.00041613317,0.0009658424,0.0007378486,0.0012565922,0.005178868],"category_scores_gemma":[0.0006216777,0.00045716448,0.001076084,0.0004070024,0.0009814402,0.00089484453,0.00038442144,0.0037371065,0.0010323526],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52975917,0.04127525,0.009987711,0.0025654552,0.0031049617,0.0004840739,0.0005705923,0.007814233,0.045704637,0.0014747077,0.023006128,0.33425304],"study_design_scores_gemma":[0.68288684,0.2882922,0.012121033,0.00012477186,0.00089038763,0.0005062437,0.00023255021,0.0023874934,0.0029055392,0.0008547835,0.008744744,0.000053388267],"about_ca_topic_score_codex":0.0017132179,"about_ca_topic_score_gemma":0.0063166656,"teacher_disagreement_score":0.005178868,"about_ca_system_score_codex":0.0010081913,"about_ca_system_score_gemma":0.0011863704,"threshold_uncertainty_score":0.017325044},"labels":[],"label_agreement":null},{"id":"W4403262461","doi":"10.25163/angiotherapy.899889","title":"Real-World Insights into CAR T-Cell Therapy: Efficacy and Safety of Kymriah in B-ALL and NHL","year":2024,"lang":"en","type":"article","venue":"Journal of Angiotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CAR T-cell therapy; Medicine; Internal medicine; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.028834959681595433,"score_gpt":0.34655493619911903,"score_spread":0.3177199765175236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403262461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991699,0.0049719396,0.00078785233,0.0003170402,0.0000057283432,0.00005615171,0.00068994355,0.000010028905,0.0014624811],"genre_scores_gemma":[0.9983714,0.0007458389,0.0002766246,0.00007666759,0.00001231761,0.000021986969,0.00042665456,0.0000024932408,0.00006607383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978707,0.0011625693,0.00019397038,0.00015173148,0.00049175863,0.00012919315],"domain_scores_gemma":[0.995943,0.0015560858,0.0017206126,0.00017646565,0.00046518983,0.00013870749],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005499076,0.00013570143,0.00028742568,0.0005563656,0.00014831373,0.00081777544,0.00027365278,0.00021069012,0.0006651157],"category_scores_gemma":[0.0045724143,0.0000762194,0.00029011493,0.0007487872,0.0006665254,0.00061278057,0.0004058536,0.00035676736,0.00010832037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003581031,0.00036273347,0.9030125,0.00042824744,0.0004765605,0.00016991688,0.0004451279,0.004513308,0.004048142,0.00029882893,0.0005501439,0.08211337],"study_design_scores_gemma":[0.0001894006,0.0045898156,0.98067755,0.0000901836,0.00031975334,0.00092801,0.0005846462,0.0027513183,0.0049645114,0.00032248037,0.0045571993,0.000025140665],"about_ca_topic_score_codex":0.0027882538,"about_ca_topic_score_gemma":0.0052473126,"teacher_disagreement_score":0.005499076,"about_ca_system_score_codex":0.0013222332,"about_ca_system_score_gemma":0.00089598563,"threshold_uncertainty_score":0.029082239},"labels":[],"label_agreement":null},{"id":"W4403429512","doi":"10.1158/2326-6066.cir-24-0138","title":"Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Cancer research; Immunotherapy; Antigen; Chimeric antigen receptor; Cytotoxicity; Immunology; Cytotoxic T cell; In vivo; Medicine; In vitro; Chemistry; Immune system; Biology; Biochemistry","score_opus":0.09737323653413922,"score_gpt":0.4412458670481349,"score_spread":0.3438726305139957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403429512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867683,0.0011378431,0.0067405845,0.00021488922,0.00016543356,0.0015716917,0.00084991386,0.00018820814,0.0023631426],"genre_scores_gemma":[0.9860961,0.0015534784,0.006309843,0.00015909628,0.0000576108,0.0011664386,0.0014458789,0.000042139356,0.0031694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996394,0.000089673245,0.000029392673,0.000060064925,0.000076908735,0.00010459387],"domain_scores_gemma":[0.99977165,0.000032913234,0.00005407113,0.000028480714,0.000040541494,0.000072310744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065961713,0.00081840844,0.0005450722,0.00052645826,0.00027363843,0.00062805664,0.0006044913,0.0008658411,0.0014172737],"category_scores_gemma":[0.00031152926,0.0002931567,0.0004665409,0.00023157576,0.00031592205,0.0004394599,0.00021795489,0.0020300932,0.0005330627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019364597,0.00565931,0.00042378248,0.00014741597,0.000044474116,0.00019284953,0.000120261415,0.0016427437,0.98107177,0.0004836493,0.00059732626,0.00767994],"study_design_scores_gemma":[0.00157486,0.076427534,0.0018324462,0.000027847731,0.00016898924,0.0006011059,0.00008979017,0.0036410084,0.90748763,0.00016838001,0.007963621,0.000016736332],"about_ca_topic_score_codex":0.0006787307,"about_ca_topic_score_gemma":0.00083230034,"teacher_disagreement_score":0.0014172737,"about_ca_system_score_codex":0.00038993955,"about_ca_system_score_gemma":0.0005320074,"threshold_uncertainty_score":0.0047412515},"labels":[],"label_agreement":null},{"id":"W4403431753","doi":"10.1038/s44321-024-00153-8","title":"Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors","year":2024,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"Canadian Institutes of Health Research - Antimicrobial Resistance Research Initiative; Stand Up To Cancer; Novo Nordisk Fonden; National Cancer Institute; National Institutes of Health; Canadian Urological Association Scholarship Fund; Canadian Institutes of Health Research; Canadian Urological Association; American Association for Cancer Research","keywords":"Glycosaminoglycan; Oncofetal antigen; Transient (computer programming); Cell biology; Chemistry; Biology; Medicine; Cancer research; Pathology; Internal medicine; Biochemistry; Cancer; Computer science; Immunotherapy","score_opus":0.018018849299157116,"score_gpt":0.3108578895756146,"score_spread":0.2928390402764575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403431753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820815,0.0013031127,0.0131028555,0.00016933665,0.000049457223,0.00015839674,0.00026908168,0.0003893185,0.0024769176],"genre_scores_gemma":[0.9929671,0.0003678846,0.0037681821,0.000071567534,0.000011700283,0.00009420509,0.00028841084,0.000029473278,0.0024015347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99960715,0.000075537166,0.000030888925,0.00007519203,0.00007231767,0.00013897466],"domain_scores_gemma":[0.99987423,0.00003379459,0.000026948152,0.000019608338,0.00001744519,0.000028063683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026831473,0.00043219392,0.00030912805,0.00021054372,0.00017483649,0.0006304952,0.00033085633,0.0005825706,0.001451592],"category_scores_gemma":[0.00016783332,0.00018625312,0.0002886406,0.00021426352,0.00035975067,0.0002949155,0.0003206203,0.0008780767,0.00051663705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010986035,0.000056020872,0.00010341864,0.00003427856,0.000004910006,0.00005092306,0.000034587036,0.00016953096,0.9975827,0.00030930748,0.000090356596,0.0014541446],"study_design_scores_gemma":[0.00003184979,0.00046745158,0.000377432,0.0000030346114,0.000022146383,0.00020716368,0.000022290298,0.0010655461,0.9951918,0.000032777898,0.0025737816,0.0000047225367],"about_ca_topic_score_codex":0.00043868768,"about_ca_topic_score_gemma":0.0005354056,"teacher_disagreement_score":0.001451592,"about_ca_system_score_codex":0.00037857456,"about_ca_system_score_gemma":0.0002470658,"threshold_uncertainty_score":0.00485605},"labels":[],"label_agreement":null},{"id":"W4403446436","doi":"10.1126/scitranslmed.adj9331","title":"Human OX40L–CAR-T <sub>regs</sub> target activated antigen-presenting cells and control T cell alloreactivity","year":2024,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"FOXP3; Immunology; Adoptive cell transfer; Immune system; Antigen; T cell; Autoimmunity; Alloimmunity; Chimeric antigen receptor; Cytotoxic T cell; Biology; IL-2 receptor; In vitro","score_opus":0.02752573745987304,"score_gpt":0.32877610976273275,"score_spread":0.3012503723028597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403446436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874522,0.0020715122,0.0068090474,0.00014327743,0.000054484142,0.00006783209,0.00026228893,0.00027018113,0.0028691543],"genre_scores_gemma":[0.99161315,0.0008744021,0.0036067734,0.00008861828,0.00002415164,0.00005847309,0.0003255562,0.000031731022,0.0033771282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997689,0.000039805313,0.000020238484,0.000040188963,0.000045453195,0.000085473905],"domain_scores_gemma":[0.99992466,0.000012278367,0.000020941854,0.000011280616,0.000010110992,0.000020709344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017790214,0.00046164502,0.00026252502,0.0002057999,0.00014521809,0.00043185332,0.0001980108,0.00033042574,0.0019448271],"category_scores_gemma":[0.000120299024,0.00014736838,0.00025995236,0.00012316958,0.00033049472,0.00023789212,0.00019074805,0.000901041,0.0006057887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020661458,0.00009045952,0.0002783585,0.00007008354,0.0000071933478,0.00007308372,0.000042756146,0.00034521634,0.99408287,0.0005615188,0.00019065003,0.004051052],"study_design_scores_gemma":[0.00004230982,0.00040014012,0.000884613,0.0000050358008,0.000014538094,0.00036326193,0.00002362481,0.0014364843,0.9906281,0.00008667637,0.006110682,0.000004604851],"about_ca_topic_score_codex":0.0004938196,"about_ca_topic_score_gemma":0.00053941045,"teacher_disagreement_score":0.0019448271,"about_ca_system_score_codex":0.0003697685,"about_ca_system_score_gemma":0.00029036065,"threshold_uncertainty_score":0.006506145},"labels":[],"label_agreement":null},{"id":"W4403520285","doi":"10.1158/2326-6074.tumimm24-b012","title":"Abstract B012: Reviving exhausted T cells in pediatric B-cell acute lymphoblastic leukemia","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Cancer research; Immunology; Leukemia","score_opus":0.05261392441516446,"score_gpt":0.3874645670991617,"score_spread":0.3348506426839973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403520285","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953939,0.0019279994,0.0016537632,0.00004232388,0.000014106836,0.000030897496,0.0002890192,0.00004331071,0.00060463796],"genre_scores_gemma":[0.99558157,0.0012611592,0.001784044,0.00007220546,0.000012042187,0.000046373425,0.00061859045,0.000016486929,0.0006076173],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998373,0.000029645063,0.000012100077,0.000025802863,0.000053485634,0.000041595624],"domain_scores_gemma":[0.99993074,0.000012901241,0.000023857127,0.0000058837986,0.000010007199,0.000016645177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023833413,0.00027238825,0.0003047667,0.0002445898,0.0001090244,0.00033414477,0.00016018799,0.0003094716,0.00080766826],"category_scores_gemma":[0.00015975253,0.00009772491,0.00014321916,0.00030837188,0.00020756027,0.00028771767,0.00022241507,0.0007638304,0.0002846718],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061369705,0.0001002455,0.004041322,0.00012225528,0.000008883839,0.00011034991,0.00006392254,0.00025394632,0.9881493,0.0001337431,0.000112046735,0.0062903673],"study_design_scores_gemma":[0.00007781093,0.0034108406,0.052920364,0.0000280732,0.000051060077,0.0012676278,0.00027573376,0.002395364,0.9322365,0.000181484,0.0071422462,0.000012933114],"about_ca_topic_score_codex":0.00042794686,"about_ca_topic_score_gemma":0.0004771274,"teacher_disagreement_score":0.00080766826,"about_ca_system_score_codex":0.0002585965,"about_ca_system_score_gemma":0.00016621746,"threshold_uncertainty_score":0.0027019382},"labels":[],"label_agreement":null},{"id":"W4403543517","doi":"10.1186/s12951-024-02898-3","title":"Antibody-targeted T cells and natural killer cells for cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Journal of Nanobiotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Cytotoxic T cell; Immune system; Cancer immunotherapy; Immunotherapy; Cancer cell; Chimeric antigen receptor; Antigen; Antibody; Natural killer T cell; Oncolytic virus; Cancer research; Immunology; Biology; T cell; Chemistry; Cancer; Biochemistry; In vitro","score_opus":0.012378514101285069,"score_gpt":0.33326258285996413,"score_spread":0.3208840687586791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403543517","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32206345,0.3486653,0.27775943,0.0048242207,0.002205033,0.00065967446,0.00045832866,0.00082635926,0.04253832],"genre_scores_gemma":[0.77871877,0.106925905,0.08867175,0.00243143,0.0007075294,0.0004563503,0.00054688606,0.00007472626,0.021466559],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985135,0.000035254874,0.000008663985,0.000029412533,0.00005494974,0.000020310747],"domain_scores_gemma":[0.99995315,0.000011987865,0.000011770706,0.000003739426,0.000011347566,0.00000804139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026223608,0.0003184941,0.00020694766,0.0002678194,0.00009035248,0.000325909,0.00031953517,0.0006259854,0.0020026965],"category_scores_gemma":[0.00013018255,0.00007083962,0.0002467546,0.00019195203,0.0003565273,0.00036816084,0.00026867184,0.0006488965,0.0007954396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016356743,0.00016286851,0.00037290363,0.0009535742,0.000026710051,0.00021537881,0.000049181403,0.0011403242,0.8859284,0.01666036,0.0019210104,0.09240569],"study_design_scores_gemma":[0.00019108744,0.0016005437,0.0010494896,0.00014138698,0.0000828046,0.0016375694,0.000054024356,0.005701834,0.82170886,0.009906086,0.15789711,0.000029205083],"about_ca_topic_score_codex":0.0001195614,"about_ca_topic_score_gemma":0.00016939605,"teacher_disagreement_score":0.0020026965,"about_ca_system_score_codex":0.00031935945,"about_ca_system_score_gemma":0.0002635208,"threshold_uncertainty_score":0.0066996813},"labels":[],"label_agreement":null},{"id":"W4403602474","doi":"10.58931/cht.2023.2338","title":"Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Lymphoma; Antibody; Bispecific antibody; Antigen; Medicine; Virology; Immunology; Antibody therapy; Cancer research; Immunotherapy; Monoclonal antibody; Immune system","score_opus":0.0350963459906627,"score_gpt":0.3005168672949186,"score_spread":0.2654205213042559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602474","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4700958,0.4091318,0.014030732,0.007591908,0.0012462328,0.00052101025,0.00068496214,0.00079910515,0.0958985],"genre_scores_gemma":[0.84881157,0.11691049,0.006458211,0.0027003419,0.00047619204,0.00020505037,0.00095834315,0.000043289667,0.02343657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992406,0.000017079816,0.00000359465,0.000007287394,0.000025828766,0.000022141427],"domain_scores_gemma":[0.9999608,0.000008295891,0.000008265008,0.0000024220828,0.000006512998,0.000013706876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021568089,0.00018695682,0.00020283546,0.00046182965,0.00013876124,0.00021456507,0.0002560882,0.00034032145,0.002848529],"category_scores_gemma":[0.00015966267,0.000044359473,0.00016421583,0.00029302706,0.00020928479,0.00019765655,0.0001967996,0.00054003345,0.0007626452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023137135,0.0012377191,0.0027532806,0.00063773355,0.000080087826,0.0011474744,0.00009421258,0.0017888452,0.0582488,0.008206646,0.0195932,0.9038985],"study_design_scores_gemma":[0.0033976806,0.016138393,0.036707398,0.0003760683,0.00031647156,0.010291294,0.00014029573,0.004264766,0.074708514,0.0059197713,0.84767914,0.00006034113],"about_ca_topic_score_codex":0.0033148525,"about_ca_topic_score_gemma":0.0068392097,"teacher_disagreement_score":0.0033148525,"about_ca_system_score_codex":0.0006546823,"about_ca_system_score_gemma":0.0005578128,"threshold_uncertainty_score":0.009529293},"labels":[],"label_agreement":null},{"id":"W4403622162","doi":"10.58931/cht.2023.2342","title":"Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences; Sanofi","keywords":"Chimeric antigen receptor; Multiple myeloma; Antigen; Immunology; Receptor; Medicine; Cancer research; Virology; Biology; Immunotherapy; Internal medicine; Immune system","score_opus":0.027811339048661968,"score_gpt":0.2724164986273658,"score_spread":0.24460515957870382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054283896,0.71270007,0.0016145967,0.2474798,0.0034936992,0.000047762696,0.00034440294,0.00012443193,0.028766925],"genre_scores_gemma":[0.062792145,0.8873407,0.002804045,0.03378167,0.003504518,0.00006161958,0.00038404114,0.000086939806,0.00924418],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99797815,0.00037802372,0.000120168756,0.00023342934,0.0009601635,0.00033000854],"domain_scores_gemma":[0.9927597,0.0012672015,0.00037403766,0.00010568454,0.0040381243,0.0014552783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006274331,0.0004954903,0.00077448343,0.0020908315,0.0022206127,0.0030554147,0.0015865618,0.0022050869,0.010979028],"category_scores_gemma":[0.006724352,0.00021285935,0.00044723868,0.0041116513,0.0034961714,0.002300664,0.0018457253,0.0040402855,0.00163429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061293907,0.00022410939,0.0025084668,0.0021591817,0.00009710116,0.000458862,0.0003851192,0.0012363314,0.001964833,0.055516142,0.18883394,0.7460031],"study_design_scores_gemma":[0.00016745873,0.00028360807,0.0030861103,0.001484023,0.00011261694,0.0006127977,0.00048267937,0.00060020026,0.00075278495,0.006602238,0.9857686,0.00004695047],"about_ca_topic_score_codex":0.42789638,"about_ca_topic_score_gemma":0.6190782,"teacher_disagreement_score":0.5721036,"about_ca_system_score_codex":0.02738625,"about_ca_system_score_gemma":0.049244344,"threshold_uncertainty_score":0.8508115},"labels":[],"label_agreement":null},{"id":"W4403709325","doi":"10.1182/blood.2024025454","title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Jewish General Hospital; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Royal Adelaide Hospital; BeiGene; Incyte; F. Hoffmann-La Roche; Pharmacyclics; Genentech; MEI Pharma; Teva Pharmaceutical Industries; Kite Pharma; Gilead Sciences; TG Therapeutics; Amgen; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Follicular lymphoma; Confidence interval; Refractory (planetary science); Gastroenterology; Adverse effect; Cytokine release syndrome; Surgery; Lymphoma; Immunotherapy; Cancer","score_opus":0.01866792604861877,"score_gpt":0.2919711297431507,"score_spread":0.2733032036945319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403709325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948013,0.0031264499,0.00029529227,0.00010908844,0.000020701458,0.00004900869,0.0006898436,0.000024463425,0.0008838793],"genre_scores_gemma":[0.99823594,0.00026506788,0.00006381937,0.00010495267,0.000021023829,0.000021089594,0.0009929823,0.000003153681,0.0002918696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993895,0.00016182968,0.00006796368,0.000118776436,0.000116539086,0.00014545035],"domain_scores_gemma":[0.9983327,0.000352456,0.000611105,0.00012320404,0.00024145425,0.000339044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002011747,0.0003181891,0.0010283906,0.00045908464,0.00058727816,0.0007650636,0.00032989096,0.0006892501,0.00097513397],"category_scores_gemma":[0.0019795254,0.00017155305,0.0009627045,0.0004226253,0.00021631789,0.00059926935,0.0003388008,0.001062357,0.00040891345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0353028,0.0020970232,0.84657913,0.00020589582,0.0020064625,0.0019178968,0.00046372248,0.0015271658,0.013324465,0.0000893298,0.0021585056,0.094327636],"study_design_scores_gemma":[0.00089424214,0.010237394,0.98017234,0.00004315203,0.0014212378,0.0012961472,0.00010406847,0.0012452586,0.001894636,0.000065831635,0.0025943161,0.000031348085],"about_ca_topic_score_codex":0.0017866079,"about_ca_topic_score_gemma":0.0018306045,"teacher_disagreement_score":0.002011747,"about_ca_system_score_codex":0.0007352865,"about_ca_system_score_gemma":0.00026978969,"threshold_uncertainty_score":0.01063925},"labels":[],"label_agreement":null},{"id":"W4403735421","doi":"10.1111/ejh.14331","title":"Distance to <scp>CAR</scp>‐T Treatment Center Does Not Impede Delivery","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Apheresis; Refractory (planetary science); Internal medicine; Chimeric antigen receptor; Single Center; Referral; Gastroenterology; Surgery; Immunotherapy; Cancer","score_opus":0.02730334715386731,"score_gpt":0.30890125878051883,"score_spread":0.28159791162665154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403735421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98787165,0.002617353,0.002690123,0.0007781408,0.00003932304,0.00007292365,0.00038626252,0.00003075306,0.0055134343],"genre_scores_gemma":[0.99897265,0.0002450319,0.00041245815,0.00007166955,0.000012383382,0.000013569507,0.00009548366,0.0000052888695,0.00017154455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988545,0.0002997545,0.00016630013,0.00015504943,0.0002935309,0.0002308043],"domain_scores_gemma":[0.9957332,0.0013220551,0.0021356714,0.000155344,0.00034319665,0.00031062058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009045997,0.00012564888,0.00024512722,0.00022495193,0.0006132357,0.0010653193,0.00037562117,0.00033079102,0.004105094],"category_scores_gemma":[0.0043813717,0.000099684585,0.00028343307,0.00050473487,0.0007001237,0.0004968143,0.0004974979,0.00036504603,0.00045150684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001092731,0.00006093416,0.94404775,0.0006994659,0.00023507932,0.0022036082,0.0005239197,0.0024387345,0.0051798285,0.00084178,0.0027736293,0.0399026],"study_design_scores_gemma":[0.00016134714,0.0009876692,0.9476233,0.00022478215,0.0004153314,0.012141891,0.0020760067,0.0022378222,0.006366508,0.00062638574,0.027107345,0.000031640546],"about_ca_topic_score_codex":0.032806184,"about_ca_topic_score_gemma":0.05490821,"teacher_disagreement_score":0.032806184,"about_ca_system_score_codex":0.0030799988,"about_ca_system_score_gemma":0.0041996306,"threshold_uncertainty_score":0.06523049},"labels":[],"label_agreement":null},{"id":"W4403859802","doi":"10.1182/bloodadvances.2024014555","title":"Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Janssen Biotech; Genentech; National Institutes of Health; Swedish Orphan Biovitrum; Omeros Corporation; Incyte; BeiGene; Angiocrine Bioscience; Parker Institute for Cancer Immunotherapy; Servier; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Medpace; Celgene; Gilead Sciences; Sanofi; Pfizer; Seres Therapeutics; Amgen","keywords":"Medicine; Weight loss; Cachexia; Internal medicine; Cancer; Lymphoma; Oncology; Obesity","score_opus":0.015093004599438645,"score_gpt":0.30787951075646797,"score_spread":0.29278650615702934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403859802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99934787,0.0002090722,0.00008619755,0.000033562945,0.0000051220322,0.0000031896427,0.00012639987,0.000003143074,0.00018532488],"genre_scores_gemma":[0.99969137,0.00004489434,0.000036432695,0.000011610957,0.00000743857,0.0000020173256,0.00014151409,0.0000012707217,0.00006347519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997665,0.000052858464,0.000029067984,0.000050179202,0.00005182304,0.000049498256],"domain_scores_gemma":[0.9982261,0.00020786747,0.0010230648,0.00010218416,0.000114974784,0.00032591022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038834978,0.00018713051,0.00023413895,0.00041432065,0.00024591305,0.00054575864,0.00021643363,0.00026050466,0.0017372576],"category_scores_gemma":[0.0014800993,0.00013482824,0.00031752454,0.0006109046,0.00023446578,0.0003053041,0.00033566693,0.0005857317,0.00019503485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000146772,0.000017905246,0.9986014,0.0000049198497,0.000034097546,0.000050782863,0.000008706046,0.00003014153,0.00036548273,0.000005124184,0.000048210648,0.0006864617],"study_design_scores_gemma":[0.0000051772968,0.00009162242,0.9989754,0.0000035979383,0.000036689697,0.00032607839,0.00003659479,0.00021033756,0.00017456099,0.000012440909,0.00012528044,0.0000023285443],"about_ca_topic_score_codex":0.0012135064,"about_ca_topic_score_gemma":0.0019295306,"teacher_disagreement_score":0.0017372576,"about_ca_system_score_codex":0.00019208697,"about_ca_system_score_gemma":0.00031912053,"threshold_uncertainty_score":0.005811751},"labels":[],"label_agreement":null},{"id":"W4403931912","doi":"10.36401/jipo-24-23","title":"A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives","year":2024,"lang":"en","type":"review","venue":"Journal of Immunotherapy and Precision Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vitalité Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tumor microenvironment; Engineering ethics; Computer science; Process management; Medicine; Business; Cancer research; Engineering; Tumor cells","score_opus":0.10760450098204283,"score_gpt":0.4100770395047811,"score_spread":0.30247253852273825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403931912","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011202254,0.9982572,0.000166764,0.00051579095,0.00017774518,0.0000051005895,0.000011616922,0.00000663453,0.000747058],"genre_scores_gemma":[0.00066118484,0.9979721,0.00026763714,0.000398395,0.00018832886,0.000009669681,0.000021916261,0.0000018606573,0.00047904684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997881,0.000047331243,0.000027217604,0.00003256353,0.00007655163,0.000028320945],"domain_scores_gemma":[0.99957997,0.00022943625,0.000041633928,0.000012241146,0.00010332453,0.00003342315],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008579219,0.00078154105,0.0017093291,0.001905467,0.00026437317,0.0013168455,0.0008661098,0.0015032981,0.0034539602],"category_scores_gemma":[0.000778885,0.00029841845,0.00065765926,0.0014743493,0.00047790055,0.0022534311,0.00069338863,0.0029575329,0.0017428185],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009933936,0.00012694373,0.00009770034,0.017511271,0.00008051102,0.00028272634,0.0000890378,0.0005503459,0.004179602,0.007492935,0.027209878,0.94227976],"study_design_scores_gemma":[0.000025756468,0.00019281663,0.00033377708,0.0034888803,0.00009377374,0.0011426214,0.00006690442,0.0001573725,0.0007665113,0.0024479635,0.99126476,0.000018817702],"about_ca_topic_score_codex":0.00070881407,"about_ca_topic_score_gemma":0.0016283395,"teacher_disagreement_score":0.0034539602,"about_ca_system_score_codex":0.00059402286,"about_ca_system_score_gemma":0.0012290599,"threshold_uncertainty_score":0.011554658},"labels":[],"label_agreement":null},{"id":"W4403972887","doi":"10.1101/2024.10.30.621196","title":"A novel miniaturized filamentous phagemid as a gene delivery vehicle to target mammalian cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Phagemid; Gene delivery; Gene; Computational biology; Biology; Cell biology; Genetics; Bacteriophage; Genetic enhancement","score_opus":0.018789707945636794,"score_gpt":0.2602479113905176,"score_spread":0.24145820344488084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403972887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71901613,0.0042812624,0.2671116,0.0004564653,0.00032842925,0.00050502975,0.0012498861,0.001991379,0.0050598434],"genre_scores_gemma":[0.81788975,0.0022774613,0.1655561,0.00016588514,0.000067254856,0.00031196387,0.0018203451,0.00014310233,0.011768101],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998919,0.000017004682,0.000006637629,0.000027735474,0.00004163663,0.00001509104],"domain_scores_gemma":[0.9999449,0.000010201205,0.000010737744,0.0000055340684,0.000009000034,0.00001959546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002628298,0.0003211137,0.00021497381,0.00021563792,0.00019094968,0.0003633349,0.00035154936,0.00039959594,0.0007016239],"category_scores_gemma":[0.000114072885,0.00014664227,0.00020166107,0.0001355266,0.00019744897,0.00024280907,0.0002964612,0.00035529802,0.00047616241],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000023985689,0.000016698828,0.00009208906,0.00003595336,0.0000029734226,0.000053722808,0.000012027109,0.00012843519,0.9958818,0.000374656,0.00013810869,0.0032395835],"study_design_scores_gemma":[0.000016022303,0.0002995598,0.0008626976,0.000007241535,0.000013766088,0.0003638978,0.000010115369,0.0022143887,0.9784871,0.00009162233,0.017623097,0.0000105356985],"about_ca_topic_score_codex":0.00052853255,"about_ca_topic_score_gemma":0.0005706101,"teacher_disagreement_score":0.0007016239,"about_ca_system_score_codex":0.000436767,"about_ca_system_score_gemma":0.0003030361,"threshold_uncertainty_score":0.0031690001},"labels":[],"label_agreement":null},{"id":"W4404007927","doi":"10.1002/prp2.70024","title":"Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy","year":2024,"lang":"en","type":"article","venue":"Pharmacology Research & Perspectives","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Ipsen; Flatiron Health; Pharmacyclics; BeiGene; Janssen Scientific Affairs; Servier; TG Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Retrospective cohort study; Tocilizumab; Lasso (programming language); Database; Internal medicine; Emergency medicine; Computer science; Rheumatoid arthritis","score_opus":0.03275787449147814,"score_gpt":0.40947439796442814,"score_spread":0.37671652347295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404007927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948591,0.0005139239,0.0013043258,0.00009743985,0.000007778216,0.00008510055,0.0027761324,0.000016016536,0.00034011062],"genre_scores_gemma":[0.99400264,0.0002096435,0.0018638481,0.00007136368,0.000017252461,0.000098431345,0.0036909927,0.0000040714162,0.000041573498],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9875224,0.0052623143,0.0035291254,0.0015853425,0.001701663,0.00039906224],"domain_scores_gemma":[0.9574126,0.01714809,0.018246887,0.0030236645,0.0035985992,0.0005701565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011811857,0.00035294195,0.00081145565,0.0024113618,0.00030843247,0.0013785851,0.0006571559,0.0006206299,0.0004903301],"category_scores_gemma":[0.041210324,0.0003649853,0.0008734106,0.0037145286,0.00027668895,0.00089877995,0.00093888276,0.0006018689,0.0001395469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018487012,0.000024750403,0.9978677,0.000030095523,0.00007827192,0.000029028799,0.000059248803,0.0002121405,0.00009217506,0.000040082785,0.00010651876,0.001275107],"study_design_scores_gemma":[0.00003382671,0.00024225461,0.98817366,0.000068162146,0.00018456105,0.0004917729,0.0003538907,0.009114243,0.00052891404,0.000112092035,0.0006804061,0.000016255837],"about_ca_topic_score_codex":0.0037042145,"about_ca_topic_score_gemma":0.0027539597,"teacher_disagreement_score":0.011811857,"about_ca_system_score_codex":0.0004910247,"about_ca_system_score_gemma":0.0006675349,"threshold_uncertainty_score":0.062467813},"labels":[],"label_agreement":null},{"id":"W4404016752","doi":"10.1101/2024.10.29.620998","title":"Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Human Induced Pluripotent Stem Cells; Stem cell; Cell biology; CD8; Biology; Embryonic stem cell; Genetics; Immune system; Gene","score_opus":0.021703536406994437,"score_gpt":0.2500414394659735,"score_spread":0.22833790305897908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404016752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93960094,0.0033068536,0.042993885,0.00030062348,0.0001492747,0.00016378725,0.0015488022,0.00040141834,0.0115343565],"genre_scores_gemma":[0.9690878,0.0016891657,0.019424895,0.00016584487,0.000026206157,0.000100758785,0.0013922593,0.00008223269,0.008030928],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990916,0.000016853199,0.000010866446,0.000021111411,0.000026893942,0.000015087717],"domain_scores_gemma":[0.9999608,0.000011110684,0.000007226089,0.000007291603,0.000006384017,0.000007146583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019808993,0.00021892523,0.00010454558,0.00017285944,0.00007444256,0.00024905175,0.00010906329,0.00020274034,0.0021077443],"category_scores_gemma":[0.00013572059,0.000097763776,0.00011799727,0.00015333472,0.00013046403,0.00012886437,0.00022807506,0.0003462107,0.000597529],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054156597,0.000009337831,0.00015804682,0.00004159552,0.000002672903,0.000036148016,0.000018451687,0.00021442526,0.99261135,0.00040995498,0.00016706767,0.0062767537],"study_design_scores_gemma":[0.000017279925,0.00007695205,0.000419174,0.0000071010736,0.000007889393,0.00009396541,0.000011960143,0.0009947605,0.9893476,0.00017097587,0.008849908,0.0000024643002],"about_ca_topic_score_codex":0.000116658746,"about_ca_topic_score_gemma":0.00021533406,"teacher_disagreement_score":0.0021077443,"about_ca_system_score_codex":0.00011266592,"about_ca_system_score_gemma":0.00012016076,"threshold_uncertainty_score":0.0070511103},"labels":[],"label_agreement":null},{"id":"W4404064412","doi":"10.1136/jitc-2024-sitc2024.0361","title":"361 Early differentiation and memory transcription programs drive long-term persistence of NY-ESO-1 specific TCR-T cells in adoptive cell therapy","year":2024,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T-cell receptor; Term (time); Persistence (discontinuity); Biology; Computer science; T cell; Immunology; Physics; Engineering; Immune system","score_opus":0.035798880816205,"score_gpt":0.2570067381479863,"score_spread":0.2212078573317813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404064412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971539,0.0004447937,0.001265734,0.00003407417,0.000010047937,0.000037414236,0.00015474176,0.000049909326,0.0008493361],"genre_scores_gemma":[0.99714774,0.00022200058,0.00088269444,0.00003972216,0.0000058574205,0.000039700346,0.00026064456,0.000009699584,0.0013920465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999915,0.0000100290645,0.0000075277935,0.000016074799,0.000021719,0.000029715387],"domain_scores_gemma":[0.99994576,0.0000071214936,0.000018138639,0.0000088706975,0.000005863285,0.000014338435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011547297,0.00017752121,0.00015107074,0.00009429963,0.00009746563,0.00022199262,0.00012127493,0.00018161489,0.0013429737],"category_scores_gemma":[0.000068694906,0.00007970546,0.00012319881,0.000077580706,0.0001630811,0.00014680275,0.000117377225,0.00058191194,0.00038128774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022316958,0.00014024747,0.0005115771,0.00001660474,0.0000027991225,0.000043335822,0.000023225834,0.000076960314,0.9957223,0.00010343114,0.000105136314,0.003031185],"study_design_scores_gemma":[0.00010986632,0.004738711,0.010947522,0.000009856466,0.000030234944,0.00084031903,0.000059640384,0.0013927233,0.97746974,0.00011139359,0.0042841053,0.0000059724534],"about_ca_topic_score_codex":0.00027909863,"about_ca_topic_score_gemma":0.00048728895,"teacher_disagreement_score":0.0013429737,"about_ca_system_score_codex":0.00014786498,"about_ca_system_score_gemma":0.00015136981,"threshold_uncertainty_score":0.0044927},"labels":[],"label_agreement":null},{"id":"W4404064451","doi":"10.1136/jitc-2024-sitc2024.1291","title":"1291 Profiling bispecific T-cell engagers: strategies for enhancing potency while minimizing cytokine release","year":2024,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Profiling (computer programming); Potency; Computer science; Bispecific antibody; Cytokine; Human–computer interaction; Chemistry; Medicine; Immunology; Antibody; Operating system","score_opus":0.03727982372611302,"score_gpt":0.2903729767150358,"score_spread":0.25309315298892276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404064451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729196,0.00054049713,0.023393407,0.000084899446,0.0000121845305,0.0000970347,0.0002838688,0.00015311074,0.002515351],"genre_scores_gemma":[0.9770562,0.00035773835,0.02040491,0.00012568689,0.000007780767,0.00009826872,0.00027817706,0.000049250302,0.0016218971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997305,0.000050719074,0.000020757776,0.00004227315,0.00009622385,0.000059562135],"domain_scores_gemma":[0.99986315,0.000039365128,0.00003807907,0.000012415254,0.000027805096,0.000019277999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003369795,0.00032979978,0.00021058548,0.00017763856,0.00010894064,0.00046693286,0.00021474762,0.0003030517,0.0010858275],"category_scores_gemma":[0.0002476665,0.00010926544,0.00013788046,0.00017213688,0.00016539978,0.00025938245,0.00020745579,0.00047158232,0.00041194865],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060885908,0.000049522278,0.00025305484,0.00002557848,0.0000038659,0.000016568692,0.000009394097,0.00068071164,0.9960387,0.00013330451,0.00006347432,0.0026648],"study_design_scores_gemma":[0.000009640797,0.00018954804,0.00030738438,0.0000017838972,0.000004347197,0.00003348901,0.0000063287425,0.002041317,0.99654275,0.00004031683,0.00082060887,0.0000025071574],"about_ca_topic_score_codex":0.00031216908,"about_ca_topic_score_gemma":0.0008149492,"teacher_disagreement_score":0.0010858275,"about_ca_system_score_codex":0.00031108645,"about_ca_system_score_gemma":0.0001834946,"threshold_uncertainty_score":0.0036324263},"labels":[],"label_agreement":null},{"id":"W4404133614","doi":"10.1002/cac2.12624","title":"FOXO1 or not FOXO1: that is the question","year":2024,"lang":"en","type":"article","venue":"Cancer Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Ligue Contre le Cancer; Bristol-Myers Squibb","keywords":"FOXO1; Cytotoxic T cell; Granzyme B; Biology; Cell biology; Transcription factor; Cancer research; Chemistry; In vitro; Biochemistry; Gene","score_opus":0.20355240978209913,"score_gpt":0.4773397007046023,"score_spread":0.2737872909225032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404133614","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0262862,0.5476633,0.005752996,0.3879641,0.015502986,0.000035381414,0.0022424045,0.000307498,0.014245119],"genre_scores_gemma":[0.26370043,0.5293312,0.003313212,0.14692464,0.028243637,0.00012972417,0.001791002,0.00026173634,0.026304455],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.999199,0.000092691815,0.00004950725,0.0003188155,0.00013414118,0.00020582057],"domain_scores_gemma":[0.99808705,0.00053396204,0.00029979565,0.00014168935,0.00046713164,0.00047038478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026798295,0.0006174919,0.0018751383,0.00050062785,0.000954522,0.0023178204,0.0013502062,0.0035745762,0.008287341],"category_scores_gemma":[0.0026446145,0.0003061307,0.0005690446,0.0007319786,0.005127948,0.005458195,0.001378719,0.004380731,0.003501182],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023081596,0.0003557431,0.01358234,0.008403336,0.0005317415,0.0012692864,0.0015082603,0.00060725823,0.03695625,0.13199314,0.31396347,0.48852104],"study_design_scores_gemma":[0.00016675881,0.0005014111,0.009005895,0.0024405129,0.00019853645,0.0016686206,0.0030220621,0.0005262808,0.0057296488,0.13041115,0.8461887,0.00014041924],"about_ca_topic_score_codex":0.001316675,"about_ca_topic_score_gemma":0.0014567496,"teacher_disagreement_score":0.008287341,"about_ca_system_score_codex":0.0012813873,"about_ca_system_score_gemma":0.0017347273,"threshold_uncertainty_score":0.027723908},"labels":[],"label_agreement":null},{"id":"W4404167351","doi":"10.4049/jimmunol.212.supp.1545.5087","title":"HLA-A2 Chimeric antigen receptor regulatory T cells promote allograft acceptance in mice","year":2024,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Human leukocyte antigen; Immunology; Receptor; Antigen; Biology; Cell biology; Immunotherapy; Immune system; Genetics","score_opus":0.016811387056162932,"score_gpt":0.299077918084197,"score_spread":0.28226653102803406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404167351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962997,0.000600117,0.001344094,0.00006781601,0.000045910943,0.000036774072,0.00017132914,0.00022223631,0.0012119184],"genre_scores_gemma":[0.9933007,0.00041053692,0.0011631097,0.00008612974,0.0000339172,0.000057716235,0.0002952799,0.000052631076,0.004600149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997409,0.000042590484,0.000020653119,0.00005259067,0.00006388085,0.00007945355],"domain_scores_gemma":[0.9997428,0.000029321182,0.000080857295,0.000028849316,0.000018442057,0.000099691104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003397561,0.0006820276,0.00035338133,0.00042342558,0.00011875161,0.0003396897,0.00020732608,0.00036850496,0.001806969],"category_scores_gemma":[0.00012539884,0.00020952839,0.00032212006,0.00010083411,0.00022207836,0.0003077378,0.0002008128,0.0011668463,0.00064989796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041113666,0.00028443304,0.00020540411,0.000029837209,0.0000056539084,0.000060595226,0.000022024069,0.00009366082,0.99718,0.00008272905,0.00006602274,0.0015583944],"study_design_scores_gemma":[0.00036851954,0.008146931,0.007276931,0.000041864525,0.000056072982,0.00059162185,0.00006315003,0.0026769503,0.9771827,0.0001690371,0.0034121303,0.000014088379],"about_ca_topic_score_codex":0.00016246446,"about_ca_topic_score_gemma":0.00025850354,"teacher_disagreement_score":0.001806969,"about_ca_system_score_codex":0.00017502614,"about_ca_system_score_gemma":0.00020720156,"threshold_uncertainty_score":0.0060449243},"labels":[],"label_agreement":null},{"id":"W4404167771","doi":"10.4049/jimmunol.212.supp.0263.5530","title":"Highly efficient non-viral delivery of macromolecules to unactivated human T cells using microfluidic transfection","year":2024,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Transfection; Macromolecule; Microfluidics; Nanotechnology; Gene delivery; Cell biology; Chemistry; Materials science; Biology; Biochemistry; Gene","score_opus":0.01835528357172901,"score_gpt":0.30085329056671184,"score_spread":0.28249800699498284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404167771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8839517,0.0024720856,0.10728772,0.00029951127,0.00028099585,0.00033036794,0.000997096,0.0009148253,0.0034656425],"genre_scores_gemma":[0.9549256,0.0011080552,0.038210463,0.00013860587,0.000048793285,0.0003065785,0.0006395028,0.00007025174,0.004552105],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997044,0.000034052297,0.000030400759,0.000080011734,0.00008334333,0.00006777096],"domain_scores_gemma":[0.99991214,0.00002234086,0.000030965104,0.000010479432,0.00001496815,0.00000906844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003332432,0.00035688165,0.00028410566,0.00016617056,0.00015740324,0.0005751076,0.00031649755,0.0003434324,0.0007761502],"category_scores_gemma":[0.00020246081,0.00016212618,0.00031235453,0.0001436363,0.00022136046,0.00019186237,0.00025702605,0.00043872197,0.0004066956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026662683,0.0000134736065,0.00005213285,0.000035092286,0.0000036700983,0.000027700622,0.000015057177,0.00015261897,0.9978709,0.00017382739,0.00010845697,0.0015203723],"study_design_scores_gemma":[0.00001055307,0.00007550996,0.00024163142,0.0000029402684,0.00000592322,0.0000492226,0.0000036685103,0.001361873,0.995926,0.000025354568,0.002292688,0.0000046813466],"about_ca_topic_score_codex":0.0005213095,"about_ca_topic_score_gemma":0.00065660966,"teacher_disagreement_score":0.0007761502,"about_ca_system_score_codex":0.00047912064,"about_ca_system_score_gemma":0.00037831732,"threshold_uncertainty_score":0.003476262},"labels":[],"label_agreement":null},{"id":"W4404200734","doi":"10.1016/j.mednuc.2024.10.007","title":"Évaluation en TEP 18F-FDG de la réponse au traitement par CAR T-Cells et anticorps bispécifiques des lymphomes non hodgkiniens agressifs","year":2024,"lang":"fr","type":"article","venue":"Médecine Nucléaire","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Molecular biology; Chemistry; Gynecology; Biology; Medicine","score_opus":0.039029945066124394,"score_gpt":0.357018279699197,"score_spread":0.31798833463307263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404200734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8437392,0.10213271,0.02589408,0.0011380645,0.00028522275,0.00031283885,0.000963204,0.00037734938,0.025157237],"genre_scores_gemma":[0.9584043,0.018720528,0.011482028,0.00054899335,0.0001316419,0.00027471533,0.0011739427,0.00014107444,0.009122817],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994037,0.0002381509,0.00004365288,0.000102952436,0.0001266827,0.00008498271],"domain_scores_gemma":[0.99939597,0.00026806528,0.00009106305,0.000044405813,0.00015873574,0.000041836272],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001516096,0.0005677392,0.00070054823,0.0012530443,0.00023820579,0.0010313626,0.00034905388,0.00090378907,0.0027279933],"category_scores_gemma":[0.0014713234,0.00023352739,0.0006962366,0.0007160761,0.0005449462,0.00090064446,0.00028342227,0.00076233933,0.0006843099],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01055379,0.00046256365,0.11009324,0.003328456,0.0008585896,0.008266178,0.0010925719,0.0038224407,0.46283752,0.0029681672,0.0035641773,0.39215228],"study_design_scores_gemma":[0.00069440034,0.015314443,0.2922565,0.001480496,0.0031124572,0.052051835,0.0021579787,0.011881688,0.4892653,0.006238366,0.1253174,0.00022910141],"about_ca_topic_score_codex":0.0013289592,"about_ca_topic_score_gemma":0.0015877004,"teacher_disagreement_score":0.0027279933,"about_ca_system_score_codex":0.000625313,"about_ca_system_score_gemma":0.00030432825,"threshold_uncertainty_score":0.009126008},"labels":[],"label_agreement":null},{"id":"W4404212319","doi":"10.1016/j.autrev.2024.103687","title":"Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice","year":2024,"lang":"en","type":"review","venue":"Autoimmunity Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Immunology; Medicine; Systemic lupus erythematosus; Lupus nephritis; Chimeric antigen receptor; Antigen; Immune system; CD19; Antibody; T cell; Disease; Internal medicine","score_opus":0.08939971251358837,"score_gpt":0.412783016538474,"score_spread":0.32338330402488563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404212319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004794831,0.9982686,0.00013974177,0.0007549071,0.0003192613,0.000003585709,0.000009898345,0.000007247256,0.00044871576],"genre_scores_gemma":[0.00064337504,0.99752337,0.00023679913,0.0007383404,0.00046409026,0.000010040355,0.000017026692,0.000001774474,0.0003651634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996177,0.000104538856,0.000036328533,0.00006410988,0.0001305276,0.000046744288],"domain_scores_gemma":[0.99903893,0.000628833,0.000076052675,0.000022725766,0.0001621351,0.00007135764],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017039777,0.0010658365,0.0022438853,0.0017062691,0.00031191652,0.0020054555,0.0014220814,0.0023942206,0.0048758364],"category_scores_gemma":[0.0017350172,0.00033142394,0.00074046856,0.00146244,0.0010291914,0.0024909275,0.0010496681,0.0049334606,0.0022460802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020856629,0.00012149297,0.00011810266,0.017975587,0.00013761155,0.00015505422,0.000053248572,0.0006862445,0.001796502,0.012265074,0.052205864,0.9142767],"study_design_scores_gemma":[0.000102159596,0.000217476,0.00029816924,0.006684024,0.00015746901,0.0005611313,0.00006889811,0.00025905416,0.00048249392,0.0076967753,0.9834456,0.000026797024],"about_ca_topic_score_codex":0.0009141197,"about_ca_topic_score_gemma":0.0019022152,"teacher_disagreement_score":0.0048758364,"about_ca_system_score_codex":0.0009935342,"about_ca_system_score_gemma":0.0016041761,"threshold_uncertainty_score":0.016311288},"labels":[],"label_agreement":null},{"id":"W4404236843","doi":"10.1093/neuonc/noae165.0982","title":"EXTH-51. ENHANCING GLIOBLASTOMA TREATMENT: ALLOGENEIC CAR-T CELLS OVERCOMES FUNCTIONAL DEFICITS OF PATIENT-DERIVED AUTOLOGOUS PRODUCTS","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University Medical Centre; University of Toronto; McMaster University","funders":"","keywords":"Glioblastoma; Cancer research; Medicine","score_opus":0.02533520469584187,"score_gpt":0.29759105269736946,"score_spread":0.2722558480015276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404236843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99537754,0.0007790081,0.0019022799,0.00009990767,0.000048146754,0.000057062323,0.00025012568,0.00011895646,0.0013668576],"genre_scores_gemma":[0.9971982,0.00030786186,0.00076254155,0.00006110381,0.000009554781,0.000038038546,0.0003502932,0.00001568438,0.001256722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998803,0.000014398376,0.000009517316,0.000027085618,0.000026109365,0.0000424917],"domain_scores_gemma":[0.999959,0.0000048581496,0.000008735301,0.0000060757866,0.000004845019,0.00001646745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011903233,0.000319679,0.00039987257,0.00016938927,0.00010101591,0.00033516058,0.0001973959,0.0002875345,0.0017953919],"category_scores_gemma":[0.00007256465,0.00007510827,0.0001965097,0.000121751735,0.00019999,0.00016728882,0.00018218099,0.0008035881,0.0003970435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095913844,0.00070473657,0.0006751423,0.00013238004,0.000029079423,0.00016765553,0.00006136261,0.000535969,0.9776708,0.0004328772,0.0005685388,0.018062176],"study_design_scores_gemma":[0.000188039,0.0062615713,0.0042736195,0.000011830478,0.00012624126,0.00079593813,0.000044705197,0.0019612473,0.97858626,0.00011440939,0.0076256674,0.00001038712],"about_ca_topic_score_codex":0.00045536342,"about_ca_topic_score_gemma":0.0006051092,"teacher_disagreement_score":0.0017953919,"about_ca_system_score_codex":0.00015862941,"about_ca_system_score_gemma":0.00026440443,"threshold_uncertainty_score":0.0060061216},"labels":[],"label_agreement":null},{"id":"W4404280348","doi":"10.1101/2024.11.11.623124","title":"TCR-TRANSLATE: Conditional Generation of Real Antigen Specific T-cell Receptor Sequences","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T-cell receptor; Computational biology; Antigen; Receptor; Computer science; Biology; Cell biology; T cell; Immunology; Genetics; Immune system","score_opus":0.04128630541710477,"score_gpt":0.287002876138793,"score_spread":0.24571657072168823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404280348","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32278112,0.0005170151,0.6606192,0.00029095585,0.00013371688,0.00014045158,0.0014804986,0.008207076,0.0058299573],"genre_scores_gemma":[0.8075824,0.00028558914,0.18499362,0.00026742005,0.000028939818,0.00026208893,0.0025900193,0.00081296667,0.0031769765],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99979955,0.000069105175,0.0000080052205,0.00005862531,0.00004292577,0.000021801095],"domain_scores_gemma":[0.99969196,0.00017380284,0.000035956415,0.000039488285,0.000036921036,0.00002187299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079556805,0.00069275656,0.0003444768,0.00014330809,0.00015706156,0.0003753497,0.0007569152,0.00050103385,0.0021290176],"category_scores_gemma":[0.0013016509,0.00025222544,0.0004983095,0.00014233844,0.00032277175,0.00036116838,0.00044844125,0.0008866881,0.00055038754],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004393205,0.00012675182,0.0018129759,0.00019537275,0.000069744856,0.0001536977,0.000051388004,0.89299023,0.06220855,0.006231861,0.0025911531,0.033128895],"study_design_scores_gemma":[0.00002614467,0.00013955991,0.00014495749,0.000005033875,0.0000125744855,0.000035965484,0.000006514604,0.9793026,0.017690666,0.0012009213,0.0014286464,0.00000644058],"about_ca_topic_score_codex":0.0017898626,"about_ca_topic_score_gemma":0.002273769,"teacher_disagreement_score":0.0021290176,"about_ca_system_score_codex":0.0003724207,"about_ca_system_score_gemma":0.00077637064,"threshold_uncertainty_score":0.007122278},"labels":[],"label_agreement":null},{"id":"W4404435807","doi":"10.17615/d5s2-9s76","title":"Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis","year":2024,"lang":"en","type":"article","venue":"UNC Libraries","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; bluebird bio; Alexion Pharmaceuticals; Pharmacyclics; Novavax; Adaptive Biotechnologies; Health Resources and Services Administration; Kite Pharma; Takeda Oncology; AstraZeneca; Genentech; MorphoSys; Syndax Pharmaceuticals; Seagen; CTI Biopharma; CareDx; BeiGene; Juno Therapeutics; Swedish Orphan Biovitrum; Astellas Pharma; Atara Biotherapeutics; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; MEI Pharma; Omeros Corporation; Karyopharm Therapeutics; HistoGenetics; Gateway for Cancer Research; Celgene; Mallinckrodt Pharmaceuticals; Spectrum Pharmaceuticals; Actinium Pharmaceuticals; Gilead Sciences; TG Therapeutics; Sanofi; Kiadis Pharma; GlaxoSmithKline; aTyr; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; Vertex Pharmaceuticals; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation; Incyte; Pfizer","keywords":"Chimeric antigen receptor; Lymphoma; Medicine; Immunology; B cell; Bone marrow; Antigen; T cell; Antibody; Immune system","score_opus":0.044171672301916605,"score_gpt":0.32548263219582957,"score_spread":0.28131095989391297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404435807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9625085,0.0042787776,0.008802326,0.0035448303,0.00015227981,0.0007862416,0.00081337785,0.0003983639,0.01871539],"genre_scores_gemma":[0.98169416,0.0018769893,0.009759136,0.00087711593,0.00011415968,0.00025304232,0.0009567229,0.00012486771,0.0043438906],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9995617,0.00015176933,0.000020114194,0.00007246896,0.00010150787,0.00009230619],"domain_scores_gemma":[0.9996,0.000085192965,0.00003093959,0.00008127154,0.00004529693,0.00015735453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015657524,0.00034370364,0.0004008227,0.0005036293,0.00065912853,0.0010306044,0.0009265,0.00053340115,0.004068464],"category_scores_gemma":[0.00059127226,0.00018300711,0.0002991029,0.00050693325,0.00042818784,0.000686756,0.0004368594,0.0010494896,0.0006018689],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047071155,0.015969355,0.03646065,0.00030322,0.0003676424,0.004264253,0.0004193464,0.0033491359,0.22741838,0.014448733,0.019076768,0.63085145],"study_design_scores_gemma":[0.031280555,0.10546192,0.28109685,0.0002530924,0.0018732753,0.029415784,0.0008684935,0.035486143,0.36481425,0.0065131923,0.14269815,0.00023834879],"about_ca_topic_score_codex":0.0016985129,"about_ca_topic_score_gemma":0.0026109882,"teacher_disagreement_score":0.004068464,"about_ca_system_score_codex":0.0009984965,"about_ca_system_score_gemma":0.0022786323,"threshold_uncertainty_score":0.013610363},"labels":[],"label_agreement":null},{"id":"W4404446714","doi":"10.1016/j.autrev.2024.103692","title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","year":2024,"lang":"en","type":"review","venue":"Autoimmunity Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"National Key Research and Development Program of China","keywords":"Refractory (planetary science); Medicine; CD19; Immunology; Antibody; Biology","score_opus":0.0895292656332639,"score_gpt":0.3761407201750377,"score_spread":0.2866114545417738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404446714","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038122542,0.9460808,0.004879839,0.004320421,0.0011388856,0.00014843764,0.00014882036,0.000107921594,0.0050522755],"genre_scores_gemma":[0.18744221,0.7940958,0.004719658,0.006798443,0.001610508,0.00020244284,0.00057016924,0.000028436123,0.004532334],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9998903,0.00002817271,0.000017501712,0.000016642536,0.000020709876,0.000026536378],"domain_scores_gemma":[0.99986124,0.00006094659,0.000023959665,0.000009138472,0.00001119308,0.0000334953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003777922,0.00075003767,0.0010746333,0.00031642456,0.0002098857,0.0003373007,0.0004944128,0.0011482112,0.00093655224],"category_scores_gemma":[0.00047582504,0.00012542456,0.0006390434,0.00021760169,0.0002584964,0.00030560113,0.00029345285,0.0014524609,0.00040222192],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010496776,0.000475034,0.002000398,0.006669555,0.0003816887,0.034062967,0.00023235127,0.00068213174,0.012811114,0.00216152,0.01863275,0.92084074],"study_design_scores_gemma":[0.002962907,0.0062071593,0.019646456,0.0042492733,0.001772788,0.27360952,0.00030747557,0.0010510185,0.022271777,0.0024955939,0.6652754,0.000150645],"about_ca_topic_score_codex":0.00041732533,"about_ca_topic_score_gemma":0.0010534062,"teacher_disagreement_score":0.0011482112,"about_ca_system_score_codex":0.00026878095,"about_ca_system_score_gemma":0.00033746895,"threshold_uncertainty_score":0.0031330585},"labels":[],"label_agreement":null},{"id":"W4404515472","doi":"10.1016/bs.mcb.2024.10.017","title":"Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research","year":2024,"lang":"en","type":"article","venue":"Methods in cell biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"European Research Council; Hector Stiftung; Elitenetzwerk Bayern; José Carreras Leukämie-Stiftung; Ludwig-Maximilians-Universität München; Deutsche Forschungsgemeinschaft; Fritz-Bender-Stiftung; Bundesministerium für Bildung und Forschung; Deutsche Krebshilfe; Wilhelm Sander-Stiftung; Else Kröner-Fresenius-Stiftung; Bayerische Forschungsstiftung; Melanoma Research Alliance","keywords":"Biology; Retrovirus; Chimeric antigen receptor; Antigen; Cancer therapy; Virology; Cancer; Computational biology; Immunology; Cancer research; Immunotherapy; Genetics; Virus","score_opus":0.21418299738036933,"score_gpt":0.5361122738648615,"score_spread":0.32192927648449216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404515472","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6335426,0.0052690236,0.34903193,0.00043676884,0.0006877455,0.0011953955,0.0014099879,0.0010516552,0.0073748273],"genre_scores_gemma":[0.82133466,0.0023398155,0.16785252,0.00018683246,0.00006943995,0.00043728354,0.001562952,0.00023853433,0.0059779636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9993049,0.00017311846,0.000066912886,0.00010278472,0.00027697432,0.00007525314],"domain_scores_gemma":[0.9996978,0.000086083135,0.00006784144,0.000073243515,0.000044237528,0.00003090363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008801939,0.0005220287,0.000417236,0.0005193346,0.00029012904,0.0010081822,0.0007440598,0.000923335,0.0013416283],"category_scores_gemma":[0.00062473427,0.00044189193,0.0006333928,0.00039473647,0.0003878335,0.0003794303,0.00040613362,0.0015806893,0.0010104703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056340203,0.000029134377,0.000048103502,0.000037768215,0.000008962759,0.00004520742,0.00003187493,0.00032798407,0.99628985,0.0007544936,0.000072338466,0.0022980731],"study_design_scores_gemma":[0.00001937061,0.00015946149,0.00009348572,0.0000046359205,0.000018247278,0.00012425994,0.000009048983,0.00091255445,0.99474066,0.00011447121,0.0037986552,0.0000050983213],"about_ca_topic_score_codex":0.0002717237,"about_ca_topic_score_gemma":0.00037563816,"teacher_disagreement_score":0.0013416283,"about_ca_system_score_codex":0.00041997188,"about_ca_system_score_gemma":0.0003064116,"threshold_uncertainty_score":0.0046550035},"labels":[],"label_agreement":null},{"id":"W4404534527","doi":"10.1016/j.jid.2024.10.449","title":"439 Metabolite-driven regulation of T cells in human keratinocyte-derived skin cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Metabolite; Keratinocyte; Skin cancer; Human skin; Cancer research; Cancer; Biology; Chemistry; Medicine; Cell culture; Internal medicine; Genetics","score_opus":0.04099177613358404,"score_gpt":0.35027749739029723,"score_spread":0.30928572125671316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404534527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960747,0.0008148573,0.0008178321,0.00005474741,0.00002703734,0.00004044003,0.00042131706,0.00005457231,0.0016944137],"genre_scores_gemma":[0.9962392,0.00035140326,0.00062092114,0.000035089677,0.0000074192762,0.000034699195,0.0004439172,0.0000127994235,0.002254661],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997867,0.000065790584,0.000015810654,0.000034914,0.00004303195,0.000053738564],"domain_scores_gemma":[0.9999602,0.000009127703,0.000007467341,0.0000061817113,0.000008720953,0.000008256715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012380177,0.00019661374,0.00019276013,0.00020858158,0.0001836826,0.00037274588,0.00012530442,0.00026488662,0.002082292],"category_scores_gemma":[0.000097000084,0.00012242637,0.0002925787,0.00016826307,0.00012901389,0.00014276063,0.00014098133,0.00036709962,0.0006759604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044060877,0.000085116095,0.00031781444,0.00002405391,0.0000038127075,0.00011112735,0.000025444157,0.000072669085,0.9973732,0.000076517346,0.000060419126,0.0014092],"study_design_scores_gemma":[0.000028254994,0.00061887974,0.0077037695,0.0000033962476,0.000013711754,0.00017311996,0.00007193687,0.00058725855,0.98875976,0.000037221722,0.0019994932,0.000003138653],"about_ca_topic_score_codex":0.0007014885,"about_ca_topic_score_gemma":0.0010747008,"teacher_disagreement_score":0.002082292,"about_ca_system_score_codex":0.00026601335,"about_ca_system_score_gemma":0.00017333544,"threshold_uncertainty_score":0.006965935},"labels":[],"label_agreement":null},{"id":"W4404538329","doi":"10.1080/10428194.2024.2430703","title":"Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"Persistence (discontinuity); Lymphoma; Toxicity; Term (time); Immune system; Immune checkpoint; Cancer research; Biology; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.011446509951488564,"score_gpt":0.2485690102953221,"score_spread":0.23712250034383353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538329","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021153968,0.1241212,0.002197259,0.53372663,0.30929196,0.00005524093,0.00045440256,0.0002115486,0.008787888],"genre_scores_gemma":[0.106756024,0.06094677,0.001053787,0.24525706,0.56544846,0.00005599543,0.00030583912,0.00012876707,0.020047283],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9994165,0.00014040768,0.00011451154,0.00009064225,0.00016351558,0.00007450292],"domain_scores_gemma":[0.9960459,0.0025792145,0.00032911648,0.00012240311,0.0006585099,0.00026483188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001740451,0.0005225373,0.0010454785,0.0003807039,0.00056998094,0.001385928,0.0010051788,0.0034118807,0.0019449467],"category_scores_gemma":[0.006816022,0.00026482574,0.00048792918,0.00035687452,0.0008094531,0.0010730942,0.00021649037,0.005425451,0.0015867074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020190545,0.00013454228,0.0032538685,0.0010647124,0.0002168014,0.013550651,0.00010134054,0.00030500305,0.0031049934,0.0027626827,0.82643,0.14705625],"study_design_scores_gemma":[0.00048386658,0.0009973194,0.010171974,0.00062378077,0.0005564179,0.04122595,0.00016768661,0.0012330388,0.0046525453,0.0036256753,0.93617654,0.00008515727],"about_ca_topic_score_codex":0.0004748975,"about_ca_topic_score_gemma":0.0011678131,"teacher_disagreement_score":0.0034118807,"about_ca_system_score_codex":0.00085684966,"about_ca_system_score_gemma":0.00045675263,"threshold_uncertainty_score":0.009204507},"labels":[],"label_agreement":null},{"id":"W4404564918","doi":"10.51731/cjht.2024.1029","title":"Ciltacabtagene Autoleucel (Carvykti)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Medicine; Chimeric antigen receptor; Drug; Refractory (planetary science); Multiple myeloma; Disease; Thalidomide; Internal medicine; Oncology; Intensive care medicine; Pharmacology; Immunotherapy; Cancer","score_opus":0.05463637822091671,"score_gpt":0.35592399706672717,"score_spread":0.30128761884581046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404564918","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23799032,0.2779853,0.014241963,0.027405253,0.008126028,0.002843891,0.015135355,0.013249358,0.40302256],"genre_scores_gemma":[0.67380327,0.04675014,0.010816937,0.0147055425,0.0014609781,0.00091557164,0.023398722,0.0008035644,0.2273452],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964094,0.000033667435,0.00002217067,0.000058642345,0.00014872348,0.000095882264],"domain_scores_gemma":[0.9996612,0.000037149897,0.000047911868,0.000023938976,0.00006312574,0.00016663216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040589538,0.00036904955,0.00071085594,0.00088725187,0.00041262066,0.0012537105,0.00055272965,0.00082613167,0.025748571],"category_scores_gemma":[0.0007027351,0.00014480452,0.0005225034,0.0005450394,0.00030852275,0.0005389207,0.0007168725,0.002127723,0.010192695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044600465,0.0007968039,0.0030223087,0.0009673725,0.00013199379,0.001325624,0.00008232513,0.0005301689,0.03223934,0.0047937375,0.18623829,0.7654121],"study_design_scores_gemma":[0.005308352,0.002630637,0.008050106,0.00027897017,0.00013009767,0.0051459707,0.000041694093,0.0010911837,0.01636216,0.0009305175,0.9599905,0.000039732873],"about_ca_topic_score_codex":0.0065367627,"about_ca_topic_score_gemma":0.012763808,"teacher_disagreement_score":0.025748571,"about_ca_system_score_codex":0.0015493887,"about_ca_system_score_gemma":0.0022705,"threshold_uncertainty_score":0.08613759},"labels":[],"label_agreement":null},{"id":"W4404573127","doi":"10.1146/annurev-med-070623-045906","title":"CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond","year":2024,"lang":"en","type":"review","venue":"Annual Review of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Immune system; Medicine; Antigen; Renal cell carcinoma; Antibody; Monoclonal antibody; Immunology; Immunotherapy; Oncology","score_opus":0.049437904909689266,"score_gpt":0.42455137488135225,"score_spread":0.375113469971663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404573127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012045939,0.9983198,0.00008629418,0.00029621404,0.00017357005,0.00000385613,0.000013425578,0.000007884396,0.0009785421],"genre_scores_gemma":[0.0006681479,0.9978398,0.00013809008,0.00026350716,0.00016582271,0.000006100791,0.000029658613,0.0000014944458,0.00088740804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989104,0.000018832956,0.000010264251,0.000017645672,0.000044405024,0.000017716915],"domain_scores_gemma":[0.99987257,0.000042800384,0.000019274632,0.00000370325,0.00004012829,0.000021473901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004094693,0.00059683115,0.0010819919,0.0017412904,0.00023196382,0.0008938254,0.0006096686,0.0009775651,0.0040317806],"category_scores_gemma":[0.00030555687,0.00018886244,0.00037469773,0.0016709619,0.00033301895,0.0011881024,0.00059744186,0.0016361239,0.0026667833],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007742704,0.00006599986,0.00009952158,0.009735004,0.00004455718,0.00017228337,0.000047754485,0.0003104113,0.0027153033,0.0042140894,0.032539904,0.9499778],"study_design_scores_gemma":[0.000014120063,0.000093395276,0.0003579082,0.0015186963,0.00004213177,0.00068757014,0.000035207482,0.00006909896,0.00035669887,0.0013339036,0.9954809,0.000010333327],"about_ca_topic_score_codex":0.0008600685,"about_ca_topic_score_gemma":0.0019098296,"teacher_disagreement_score":0.0040317806,"about_ca_system_score_codex":0.00052883464,"about_ca_system_score_gemma":0.0008560503,"threshold_uncertainty_score":0.013487637},"labels":[],"label_agreement":null},{"id":"W4404622765","doi":"10.1142/9789819807024_0028","title":"Understanding TCR T cell knockout behavior using interpretable machine learning","year":2024,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; National Human Genome Research Institute; Parker Institute for Cancer Immunotherapy; Canadian Institute for Advanced Research","keywords":"T-cell receptor; Computer science; Set (abstract data type); Artificial intelligence; T cell; Biology; Immunology","score_opus":0.15273448791244165,"score_gpt":0.37298749876777376,"score_spread":0.2202530108553321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404622765","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14661217,0.0005668693,0.8424259,0.0007313602,0.000083854626,0.00007995148,0.0014880153,0.0048994604,0.003112413],"genre_scores_gemma":[0.7889898,0.0005318536,0.20372413,0.00031926058,0.00003321721,0.00020127218,0.0027239437,0.00032057476,0.0031560427],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99977666,0.000041114094,0.00001144129,0.00008809501,0.000047250196,0.000035553167],"domain_scores_gemma":[0.9993741,0.00028531265,0.0001256603,0.00009799574,0.00009009616,0.000026861459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006117958,0.00094595295,0.0003370082,0.0005512255,0.00022523114,0.0007416189,0.00071326323,0.0007903011,0.0014885602],"category_scores_gemma":[0.0019196869,0.00029050242,0.0008305447,0.0003338515,0.0004304227,0.0006875611,0.00035111426,0.0014552431,0.00039887245],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012935052,0.00015143852,0.012611847,0.00016595003,0.00014108422,0.0001836367,0.000087514265,0.83571243,0.046189085,0.0073250732,0.0029337658,0.09436883],"study_design_scores_gemma":[0.0000021009052,0.000016167121,0.0009134459,0.000004834274,0.000007101905,0.000013361385,0.0000069752036,0.9886503,0.00657408,0.0031975969,0.0006082222,0.000005764136],"about_ca_topic_score_codex":0.0048438325,"about_ca_topic_score_gemma":0.0062034964,"teacher_disagreement_score":0.0048438325,"about_ca_system_score_codex":0.0010075629,"about_ca_system_score_gemma":0.0005679679,"threshold_uncertainty_score":0.009631276},"labels":[],"label_agreement":null},{"id":"W4404728397","doi":"10.3389/fonc.2024.1446995","title":"Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement","year":2024,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; Vancouver General Hospital; Université Laval; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Dr. Everett Chalmers Regional Hospital; Centre hospitalier universitaire de Québec; Ottawa Hospital; BC Cancer Agency; McGill University; Regional Municipality of Durham","funders":"Janssen Canada","keywords":"Statement (logic); Consensus conference; Medicine; MEDLINE; Intensive care medicine; Political science; Internal medicine; Law","score_opus":0.13261888074979708,"score_gpt":0.44220175787301985,"score_spread":0.30958287712322274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404728397","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00080488547,0.052328527,0.014810449,0.87875605,0.020266233,0.0042849653,0.0028493083,0.0004229234,0.025476648],"genre_scores_gemma":[0.029824749,0.16528827,0.28275824,0.4529803,0.008440365,0.010192605,0.01653145,0.0005164464,0.03346766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9242923,0.025376461,0.01387959,0.0028362116,0.02605351,0.007561918],"domain_scores_gemma":[0.6883992,0.03235129,0.011541607,0.0034675328,0.23338507,0.030855393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10162327,0.0026629507,0.003359831,0.00977693,0.008996458,0.009178664,0.014977867,0.021105638,0.010365134],"category_scores_gemma":[0.1391373,0.0019154731,0.008019732,0.00929274,0.0064096944,0.005485631,0.0068787457,0.02093469,0.0057804165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006251085,0.00011184018,0.0012255674,0.0047096377,0.00011501507,0.0003520933,0.0010181029,0.001002923,0.0004834826,0.008000927,0.88296807,0.09994988],"study_design_scores_gemma":[0.00026461546,0.00006346666,0.002847345,0.022337126,0.0003469486,0.00034297977,0.0015449633,0.000795304,0.0004636278,0.0076181935,0.9631366,0.00023876784],"about_ca_topic_score_codex":0.6250286,"about_ca_topic_score_gemma":0.70191747,"teacher_disagreement_score":0.3749714,"about_ca_system_score_codex":0.069890045,"about_ca_system_score_gemma":0.41988084,"threshold_uncertainty_score":0.75435936},"labels":[],"label_agreement":null},{"id":"W4404799289","doi":"10.1016/s1470-2045(24)00508-4","title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"CRISPR; Refractory (planetary science); Open label; Medicine; Cancer research; Internal medicine; Adverse effect; Biology; Genetics; Gene","score_opus":0.0810241588147585,"score_gpt":0.3709479855397072,"score_spread":0.2899238267249487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404799289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99841666,0.00050305977,0.00024040975,0.000048841644,0.000015010628,0.00025245862,0.00015548067,0.00003250463,0.00033560512],"genre_scores_gemma":[0.9982387,0.00029361722,0.00032698066,0.00012444159,0.00002451389,0.00020103066,0.00031358513,0.000010477379,0.00046664156],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997831,0.00008293481,0.000012009546,0.000043179047,0.00003191883,0.00004680234],"domain_scores_gemma":[0.9997415,0.00003999783,0.00006807937,0.000025394169,0.000015310708,0.00010979141],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007015831,0.0005579798,0.00086583867,0.00020245598,0.00023091478,0.0004906871,0.0003789087,0.0006074168,0.0013465323],"category_scores_gemma":[0.00027063186,0.0002435749,0.0006261909,0.00016515581,0.0005631399,0.00044565703,0.00017594075,0.0013287542,0.000319604],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29500127,0.0822172,0.0149738565,0.0007629247,0.0010892858,0.00043429717,0.0005862701,0.005896336,0.42528573,0.00029711716,0.0036318046,0.16982396],"study_design_scores_gemma":[0.074760415,0.8545927,0.023998048,0.00002297075,0.00043600204,0.00057604106,0.0000934763,0.0024654304,0.040359713,0.00014306138,0.0025128892,0.000039365743],"about_ca_topic_score_codex":0.0007200269,"about_ca_topic_score_gemma":0.0014967183,"teacher_disagreement_score":0.0013465323,"about_ca_system_score_codex":0.00054380676,"about_ca_system_score_gemma":0.00073187187,"threshold_uncertainty_score":0.0045045614},"labels":[],"label_agreement":null},{"id":"W4404926477","doi":"10.1136/jitc-2024-009462","title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Cilag; Medac; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; BeiGene; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene","keywords":"Medicine; Chimeric antigen receptor; Immune system; T cell; Immunotherapy; Immunosenescence; Immunology; Multiple myeloma; Naive T cell; Senescence; Cancer research; Internal medicine; T-cell receptor","score_opus":0.03172640834317397,"score_gpt":0.38804858641614765,"score_spread":0.35632217807297367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404926477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021412356,0.9949491,0.00013545442,0.0014624788,0.00024869418,0.0000058079345,0.000030085872,0.000007854597,0.0010191901],"genre_scores_gemma":[0.020753477,0.9756806,0.00029812258,0.0015897771,0.0010192374,0.000020379723,0.000079181984,0.0000026415446,0.00055661803],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976534,0.00008377715,0.000044674074,0.000025396374,0.000055648336,0.000025115964],"domain_scores_gemma":[0.99948055,0.0002530561,0.00012026475,0.000006519289,0.0000950705,0.00004458364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056782825,0.00020802824,0.000431024,0.00047779168,0.00017447611,0.00044398024,0.00017558428,0.0005200139,0.0010280792],"category_scores_gemma":[0.0009875628,0.000051604355,0.00031263698,0.00042421985,0.00017277276,0.0004363402,0.00032220603,0.00062144996,0.00027814496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003761725,0.00005960428,0.004331012,0.009221573,0.00017897398,0.0004725211,0.00012634386,0.00021720573,0.002108866,0.0014024437,0.020769505,0.96073556],"study_design_scores_gemma":[0.000121823745,0.001323985,0.033196043,0.010861685,0.0012690865,0.0067722253,0.00031216425,0.00029840518,0.0021071662,0.002198887,0.9414979,0.00004070809],"about_ca_topic_score_codex":0.00053354277,"about_ca_topic_score_gemma":0.0013131928,"teacher_disagreement_score":0.0010280792,"about_ca_system_score_codex":0.00031959763,"about_ca_system_score_gemma":0.00049959007,"threshold_uncertainty_score":0.0034393072},"labels":[],"label_agreement":null},{"id":"W4404956327","doi":"10.14740/jh1367","title":"A Case of Fulminant Cerebral Edema Leading to Death After Chimeric Antigen Receptor T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Fulminant; Chimeric antigen receptor; Medicine; Refractory (planetary science); Cell therapy; Cerebral edema; T cell; Edema; Immunotherapy; Immune system; Cell; Immunology; Antigen; Oncology; Internal medicine; Biology","score_opus":0.03534010633411582,"score_gpt":0.3499590468036861,"score_spread":0.3146189404695703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404956327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.959559,0.005312075,0.0074545345,0.009097618,0.001061662,0.0003261985,0.0004247012,0.0003048198,0.016459486],"genre_scores_gemma":[0.99379444,0.0011158275,0.0011452086,0.0014767827,0.00067560415,0.000027704307,0.00009794241,0.000024396257,0.0016420531],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9992968,0.00006940578,0.00004697897,0.00013445542,0.000104596926,0.00034779563],"domain_scores_gemma":[0.99799466,0.0006143826,0.00036639086,0.0001736092,0.00012785815,0.0007230358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003828371,0.0017587821,0.0014200939,0.0024592832,0.0027425012,0.0015699989,0.001801418,0.005993931,0.0015625294],"category_scores_gemma":[0.0029910312,0.0008892234,0.0014831221,0.0016277373,0.0016380372,0.001838646,0.0019943176,0.005723068,0.0006420378],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026782427,0.000030196465,0.0013251576,0.000010505617,0.0000064640203,0.99740344,0.00008961689,0.000050663453,0.00024899733,0.00012417833,0.00013438615,0.00054956623],"study_design_scores_gemma":[0.000017350672,0.00009171269,0.0026717968,0.000012348797,0.000013535494,0.99560237,0.00009475952,0.00033314244,0.00041396322,0.00027783643,0.00045840128,0.000012670173],"about_ca_topic_score_codex":0.0036502348,"about_ca_topic_score_gemma":0.004707557,"teacher_disagreement_score":0.005993931,"about_ca_system_score_codex":0.0022013718,"about_ca_system_score_gemma":0.0013251391,"threshold_uncertainty_score":0.015972197},"labels":[],"label_agreement":null},{"id":"W4404959524","doi":"10.1158/1078-0432.ccr-24-2469","title":"The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and Application","year":2024,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Immunotherapy; Cancer; Medicine; Biomarker; Cancer immunotherapy; Precision oncology; Oncology; Biomarker discovery; Clinical Oncology; Perspective (graphical); Cancer research; Internal medicine; Biology; Computer science; Proteomics","score_opus":0.29019097892027956,"score_gpt":0.6372890486359728,"score_spread":0.34709806971569324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404959524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011989894,0.9717755,0.00059681194,0.01141834,0.009934669,0.000027832297,0.00006210436,0.00004592071,0.0060190335],"genre_scores_gemma":[0.0010959051,0.9770129,0.0012073681,0.010534353,0.004018307,0.000045121385,0.000094034585,0.000013860792,0.005978203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990934,0.00019411714,0.00010589515,0.000113371134,0.0003883619,0.00010485016],"domain_scores_gemma":[0.9977621,0.0008187668,0.00018999999,0.00007314067,0.0008846777,0.00027135716],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031235132,0.0010865078,0.0011092885,0.0026438248,0.00045828187,0.0025895406,0.0012123724,0.0033894547,0.005036971],"category_scores_gemma":[0.002398834,0.00033177424,0.0010256832,0.003007198,0.001277747,0.0034137068,0.0015038349,0.009887163,0.0053428174],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009513153,0.00008991056,0.00014186837,0.00485737,0.00006088795,0.00015467798,0.000061815306,0.0002765861,0.0019507059,0.018424204,0.28492728,0.6889595],"study_design_scores_gemma":[0.000011317178,0.0000518712,0.00012173091,0.0008875005,0.000017777138,0.00019607355,0.000011981388,0.000034949375,0.00016197364,0.0014091565,0.99708897,0.0000068311256],"about_ca_topic_score_codex":0.0012853764,"about_ca_topic_score_gemma":0.002797465,"teacher_disagreement_score":0.005036971,"about_ca_system_score_codex":0.001818382,"about_ca_system_score_gemma":0.0040365607,"threshold_uncertainty_score":0.016850352},"labels":[],"label_agreement":null},{"id":"W4404970989","doi":"10.1158/2643-3230.bcd-23-0258","title":"CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Hyundai Hope On Wheels; Saban Research Institute; CureSearch for Children's Cancer; National Cancer Institute; St. Baldrick's Foundation; University of Southern California","keywords":"Interleukin-3 receptor; Cancer research; Haematopoiesis; CD33; Immunotherapy; Progenitor cell; Cytokine release syndrome; Leukemia; T cell; Stem cell; Immunology; Medicine; Biology; CD34; Myeloid; Chimeric antigen receptor; Cell biology; Immune system","score_opus":0.022163457041508895,"score_gpt":0.29113912565701067,"score_spread":0.26897566861550176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404970989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904496,0.00014616187,0.008046769,0.000057246765,0.000011439749,0.00002823082,0.00006325554,0.0001476886,0.0010495492],"genre_scores_gemma":[0.99669856,0.00005239369,0.0024881118,0.000031704334,0.0000038136507,0.000012599873,0.00005978944,0.000018375136,0.00063475413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998907,0.0000129198825,0.0000074491404,0.000023630464,0.00002679864,0.00003856083],"domain_scores_gemma":[0.9999294,0.000008882124,0.000024212693,0.000009415739,0.000013799266,0.000014273382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096196665,0.0003026997,0.00017071872,0.00011506079,0.00009584552,0.00033504367,0.00019784906,0.0002029231,0.0013070437],"category_scores_gemma":[0.00010316418,0.00006891964,0.000106367894,0.000085623586,0.00016354266,0.00018585485,0.00016765049,0.0003398003,0.00018342446],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009248979,0.000027135009,0.00028784684,0.000017311622,0.000002532675,0.000027421715,0.000009271105,0.00029166878,0.9970631,0.00025895605,0.000060628874,0.0018616372],"study_design_scores_gemma":[0.000013514463,0.00024923927,0.0008624982,0.0000017389302,0.000010181318,0.000118661665,0.000008273597,0.0033556086,0.9943427,0.00005070392,0.0009846977,0.000002200823],"about_ca_topic_score_codex":0.000277021,"about_ca_topic_score_gemma":0.00029665034,"teacher_disagreement_score":0.0013070437,"about_ca_system_score_codex":0.00025918073,"about_ca_system_score_gemma":0.00017056464,"threshold_uncertainty_score":0.0043724775},"labels":[],"label_agreement":null},{"id":"W4405038296","doi":"10.1182/blood-2024-197948","title":"Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.06928148602245389,"score_gpt":0.3452610976245043,"score_spread":0.2759796116020504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9343445,0.016623234,0.016691567,0.0010071017,0.0037819606,0.0054688063,0.011406664,0.0003994232,0.010276671],"genre_scores_gemma":[0.9802557,0.00087574264,0.0066603394,0.0007288855,0.00032994297,0.005337708,0.0028838457,0.00005541159,0.0028722987],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9818007,0.013092896,0.0010939868,0.0022673984,0.0010879061,0.0006571603],"domain_scores_gemma":[0.98641706,0.009993364,0.0017120393,0.0010988341,0.00042316705,0.0003555796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012653696,0.0020993983,0.0041846735,0.0013138702,0.0003589814,0.0011306071,0.0015743213,0.0020176433,0.011977469],"category_scores_gemma":[0.02709672,0.0005773324,0.009702385,0.00074626895,0.000936558,0.0016435495,0.0015732027,0.003949978,0.00064939365],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82908285,0.0015098862,0.017600354,0.004477958,0.10258948,0.00016846287,0.00014104974,0.004169585,0.0013064883,0.002346739,0.004486037,0.03212112],"study_design_scores_gemma":[0.3864109,0.20688237,0.11096271,0.0014731067,0.1836588,0.0008429109,0.00057289086,0.067343295,0.006176801,0.018698888,0.016553244,0.00042404234],"about_ca_topic_score_codex":0.0016894564,"about_ca_topic_score_gemma":0.0018891538,"teacher_disagreement_score":0.012653696,"about_ca_system_score_codex":0.0011369907,"about_ca_system_score_gemma":0.0009428369,"threshold_uncertainty_score":0.06691992},"labels":[],"label_agreement":null},{"id":"W4405038423","doi":"10.1182/blood-2024-200937","title":"Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Refractory (planetary science); Medicine; Internal medicine; Second line treatment; Nuclear medicine; Gastroenterology; Oncology; Physics; Chemotherapy","score_opus":0.027326737559294444,"score_gpt":0.28131938889399033,"score_spread":0.2539926513346959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95323175,0.023294475,0.008498666,0.000532028,0.0012520872,0.0025065935,0.0064098155,0.00022249192,0.004052115],"genre_scores_gemma":[0.9907836,0.0010749551,0.0029445766,0.00050543423,0.00015150754,0.0015265878,0.0017256292,0.000031987744,0.0012557991],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9945773,0.0037795785,0.00035393325,0.000683469,0.00037695153,0.00022882178],"domain_scores_gemma":[0.9964394,0.0021143965,0.00073349115,0.00041291962,0.0001333416,0.00016631134],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0064673433,0.0012828605,0.0027791471,0.0005986017,0.00020123408,0.00082420174,0.0008839349,0.0009017092,0.004934067],"category_scores_gemma":[0.010579878,0.00034717267,0.0069600833,0.00046926606,0.0004781008,0.00085174094,0.00088718557,0.002098766,0.00036408176],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8084015,0.0007557738,0.015278936,0.0039286437,0.12100351,0.00010753596,0.00013479762,0.0029043076,0.0021600348,0.0010078604,0.0020256462,0.042291474],"study_design_scores_gemma":[0.3971506,0.17483652,0.11225388,0.0009663633,0.2665882,0.0004634781,0.00025287012,0.020070871,0.0063333577,0.00492795,0.015982976,0.0001728905],"about_ca_topic_score_codex":0.0012964545,"about_ca_topic_score_gemma":0.002361744,"teacher_disagreement_score":0.0064673433,"about_ca_system_score_codex":0.0007945172,"about_ca_system_score_gemma":0.0006310747,"threshold_uncertainty_score":0.034202993},"labels":[],"label_agreement":null},{"id":"W4405038568","doi":"10.1182/blood-2024-212330","title":"Gene Expression Profile of Enriched T-Cells Prior to Chimeric Antigen Receptor (CAR) T-Cell Manufacturing Is Predictive of CAR T-Cell Response","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Antigen; T cell; Receptor; Molecular biology; Cytotoxic T cell; Biology; Immunology; Immune system; Genetics; In vitro","score_opus":0.014504562979752913,"score_gpt":0.27722097428775544,"score_spread":0.26271641130800255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956808,0.00033367076,0.0020836038,0.000025816642,0.000007740193,0.000055396413,0.0010209862,0.000035225403,0.00075680454],"genre_scores_gemma":[0.9961457,0.00017955551,0.0012345549,0.000047818427,0.000007866401,0.000090543566,0.0013501153,0.0000134734455,0.0009302873],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997204,0.00005438433,0.00001884167,0.00006618039,0.00007515573,0.00006494512],"domain_scores_gemma":[0.99977046,0.00008824388,0.000043545093,0.00001814667,0.000038334376,0.00004122676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020577438,0.00015125927,0.00031075146,0.00039657028,0.00014008404,0.00039160028,0.00009536216,0.00021087502,0.0015357499],"category_scores_gemma":[0.00035679727,0.000094318595,0.00017209371,0.00028614362,0.00022142968,0.00014166682,0.00013401406,0.00028555634,0.00044735378],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002358107,0.00019749932,0.101527765,0.000044368764,0.00004527541,0.00017879264,0.0001701815,0.00065183383,0.8819864,0.0000612709,0.0002120162,0.012566409],"study_design_scores_gemma":[0.00004803061,0.0034838864,0.4121003,0.000008810803,0.000113444265,0.00074674626,0.00031742573,0.002476815,0.57812464,0.000118697346,0.0024458866,0.000015268399],"about_ca_topic_score_codex":0.00029495853,"about_ca_topic_score_gemma":0.0004091548,"teacher_disagreement_score":0.0015357499,"about_ca_system_score_codex":0.00013156426,"about_ca_system_score_gemma":0.000117075084,"threshold_uncertainty_score":0.0051375628},"labels":[],"label_agreement":null},{"id":"W4405039315","doi":"10.1182/blood-2024-206375","title":"A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"Ipsen; Eisai; BeiGene; AstraZeneca; Eli Lilly and Company","keywords":"Refractory (planetary science); Medicine; Lymphoma; Standard of care; Chemotherapy regimen; Oncology; Internal medicine; Chemotherapy; Biology","score_opus":0.03787083616924094,"score_gpt":0.3061754718049588,"score_spread":0.2683046356357179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98928493,0.0019291755,0.00027886432,0.0005396175,0.000040318035,0.00046569295,0.0057746917,0.000016367758,0.0016702191],"genre_scores_gemma":[0.9967361,0.00039024156,0.00021061997,0.00020834629,0.000018888577,0.00011624852,0.0019432378,0.0000053116855,0.0003709231],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647707,0.0008443007,0.0002270519,0.0006447703,0.0008841128,0.00092272536],"domain_scores_gemma":[0.9932986,0.0007073958,0.0024487418,0.00028272133,0.0016530252,0.0016095793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024232527,0.00055526395,0.0008265832,0.00068647333,0.0019985095,0.0013254775,0.0016629765,0.00062565843,0.0017342212],"category_scores_gemma":[0.006075169,0.000348377,0.0012848899,0.002075012,0.0014495234,0.00045059316,0.0010747709,0.00072309544,0.00015342452],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019843047,0.0010591708,0.93448067,0.00094525417,0.002545882,0.00034670928,0.0015050889,0.004300211,0.0011814043,0.001130666,0.008093065,0.024568835],"study_design_scores_gemma":[0.002339171,0.0027931298,0.9838811,0.0001935084,0.0009057382,0.00016566984,0.0011360984,0.0034279546,0.00024431956,0.0001785424,0.0046552652,0.00007952755],"about_ca_topic_score_codex":0.9770405,"about_ca_topic_score_gemma":0.98366356,"teacher_disagreement_score":0.06518229,"about_ca_system_score_codex":0.06518229,"about_ca_system_score_gemma":0.048773777,"threshold_uncertainty_score":0.47293282},"labels":[],"label_agreement":null},{"id":"W4405039623","doi":"10.1182/blood-2024-201539","title":"Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Standard of care; Health care; Lymphoma; Internal medicine; Economic growth; Economics","score_opus":0.02531581132739111,"score_gpt":0.2880469772701274,"score_spread":0.26273116594273627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98818445,0.0008243488,0.00007678019,0.00024966765,0.000008030782,0.00009147293,0.0097671775,0.0000065113636,0.0007915636],"genre_scores_gemma":[0.9940882,0.00041389748,0.00010608464,0.00007346166,0.000008846759,0.00003890811,0.0050047985,0.000003389303,0.00026238355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826354,0.00020701428,0.00016636365,0.00024217292,0.0004599993,0.00066099176],"domain_scores_gemma":[0.995891,0.00038358284,0.0015516146,0.000101142425,0.0011185441,0.0009540536],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008899506,0.0006672757,0.00089834066,0.0022249646,0.0015801153,0.0017368491,0.0016418839,0.0006740305,0.0016346134],"category_scores_gemma":[0.003179248,0.00048515608,0.0017980379,0.007614065,0.0009880385,0.0005689798,0.0011190525,0.0007501095,0.00013429766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009179494,0.00009931941,0.99150324,0.00015884204,0.00062814594,0.00022103905,0.00032004612,0.0021868537,0.0001578639,0.0002212335,0.0013031508,0.002282377],"study_design_scores_gemma":[0.000093108116,0.00011416127,0.9950547,0.00004841731,0.00018335677,0.000094524854,0.00077365956,0.0029095123,0.000038782524,0.000042214386,0.000620271,0.000027240349],"about_ca_topic_score_codex":0.9887504,"about_ca_topic_score_gemma":0.9869695,"teacher_disagreement_score":0.06689559,"about_ca_system_score_codex":0.06689559,"about_ca_system_score_gemma":0.026182719,"threshold_uncertainty_score":0.48536372},"labels":[],"label_agreement":null},{"id":"W4405040041","doi":"10.1182/blood-2024-209364","title":"Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Socioeconomic status; Medicine; Refractory (planetary science); B cell; Oncology; Immunology; Environmental health; Population; Antibody; Biology","score_opus":0.052192684676009835,"score_gpt":0.3693888399222971,"score_spread":0.31719615524628725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936194,0.0015837596,0.00007647638,0.0008506473,0.0000136955805,0.00008303467,0.004833394,0.0000048128763,0.003192239],"genre_scores_gemma":[0.99809915,0.0005849946,0.00007677807,0.00009468303,0.0000065728127,0.000028418457,0.0008121153,0.0000025029035,0.000294807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988049,0.00010335524,0.00009131068,0.00010391711,0.00032468326,0.0005717939],"domain_scores_gemma":[0.99614197,0.00022684787,0.0011876925,0.000081298844,0.0013048481,0.0010573937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007917352,0.00021402139,0.0003469121,0.0015887432,0.0023424234,0.0010789899,0.0009807807,0.0002504075,0.0021636288],"category_scores_gemma":[0.0030825504,0.00021030256,0.0005405521,0.0044147135,0.00078054634,0.00035229835,0.0011855153,0.00040668977,0.0001277866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064552456,0.00001737911,0.9943321,0.00007305138,0.00003818134,0.000092194765,0.00088218064,0.000059246777,0.000058020934,0.00010897357,0.0008290451,0.003445192],"study_design_scores_gemma":[0.000006732652,0.000019630814,0.99732697,0.00006130515,0.000022785263,0.0000458085,0.0014740645,0.00012750311,0.000020778432,0.000022296086,0.0008668549,0.000005375586],"about_ca_topic_score_codex":0.9930033,"about_ca_topic_score_gemma":0.995804,"teacher_disagreement_score":0.036530066,"about_ca_system_score_codex":0.036530066,"about_ca_system_score_gemma":0.046236977,"threshold_uncertainty_score":0.2650454},"labels":[],"label_agreement":null},{"id":"W4405040316","doi":"10.1182/blood-2024-201189","title":"Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CD19; Medicine; Chimeric antigen receptor; Lymphoma; Antigen; Refractory (planetary science); Oncology; Immunology; Internal medicine; Virology; Immunotherapy; Biology; Cancer","score_opus":0.03537496092950763,"score_gpt":0.3317406471556205,"score_spread":0.29636568622611287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986204,0.00066528603,0.000034652512,0.0000359577,0.000004006296,0.000007130921,0.0002580534,0.0000017001444,0.0003727184],"genre_scores_gemma":[0.99928325,0.00015954646,0.00001735967,0.000034244804,0.000007702088,0.0000061650962,0.00041963454,0.0000012167055,0.000070835114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981564,0.000038490663,0.000025062265,0.00004043574,0.000037427773,0.000043046002],"domain_scores_gemma":[0.9987154,0.00025784053,0.0006875701,0.000033664317,0.00007559893,0.00022997311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040628714,0.00008083102,0.00026958296,0.00033093424,0.00015396252,0.0004560165,0.00013228571,0.00019489601,0.001581375],"category_scores_gemma":[0.0015010358,0.00004866546,0.00030235187,0.00046019137,0.00015721456,0.00024795192,0.0002472423,0.00021636431,0.00016429712],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033635944,0.000057832513,0.9816389,0.00009959758,0.00009804524,0.00049384404,0.00012878761,0.0001311969,0.0009304832,0.0000329335,0.00031455004,0.012710123],"study_design_scores_gemma":[0.000091970134,0.001152827,0.9951061,0.000042554937,0.00010770029,0.001914995,0.00013694663,0.00016168097,0.00020973317,0.000055352135,0.0010164023,0.0000038243816],"about_ca_topic_score_codex":0.0014000363,"about_ca_topic_score_gemma":0.002221525,"teacher_disagreement_score":0.001581375,"about_ca_system_score_codex":0.0005722424,"about_ca_system_score_gemma":0.00029165548,"threshold_uncertainty_score":0.0052902102},"labels":[],"label_agreement":null},{"id":"W4405040677","doi":"10.1182/blood-2024-209455","title":"A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; CD22; Acute lymphocytic leukemia; Retrospective cohort study; Oncology; Pediatrics; Leukemia; Internal medicine; Immunology; B cell; Antibody","score_opus":0.010560562670765536,"score_gpt":0.2686793725623277,"score_spread":0.25811880989156216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987349,0.0003820426,0.000053457497,0.000022326989,0.0000038229186,0.000021292493,0.00026010862,0.0000018604075,0.00052011653],"genre_scores_gemma":[0.99923015,0.0002361509,0.000096325486,0.000061080245,0.000008524346,0.000017138884,0.00026410795,0.0000019966508,0.00008451055],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994091,0.00009955335,0.00010320721,0.000183536,0.00011267152,0.00009196771],"domain_scores_gemma":[0.998841,0.00017811697,0.0006053664,0.00006754777,0.00011064936,0.0001974488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004427548,0.00022647194,0.00035920664,0.00085305184,0.00053434307,0.00055328227,0.00022708773,0.0002997132,0.0011541998],"category_scores_gemma":[0.0013841769,0.0002531892,0.0002518016,0.0011575051,0.00032834188,0.00039308477,0.00041267398,0.0003939568,0.00023028003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006313985,0.000020126337,0.9980032,0.000011515027,0.000014338735,0.00075821276,0.00011098904,0.000008968537,0.00014321496,0.000017756094,0.00006867598,0.00077987986],"study_design_scores_gemma":[0.000013724459,0.0003044578,0.98927015,0.000023953875,0.00006796839,0.007968731,0.00074681675,0.000082853265,0.00016371236,0.000028378545,0.0013232492,0.0000059051927],"about_ca_topic_score_codex":0.005447776,"about_ca_topic_score_gemma":0.004430077,"teacher_disagreement_score":0.005447776,"about_ca_system_score_codex":0.0004995422,"about_ca_system_score_gemma":0.00058330904,"threshold_uncertainty_score":0.010832131},"labels":[],"label_agreement":null},{"id":"W4405043173","doi":"10.1182/blood-2024-204166","title":"Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Daiichi Sankyo Europe; National Cancer Institute; EMD Serono; Pharmacyclics; Genentech; Incyte; BeiGene; Regeneron Pharmaceuticals; Seagen; Janssen Pharmaceuticals; Gilead Sciences; MorphoSys; Cancer Prevention and Research Institute of Texas; Celgene; AstraZeneca; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Tumor microenvironment; Lymphoma; Medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; CD19; Oncology; Cancer research; Internal medicine; Tumor cells; Biology; Peripheral blood","score_opus":0.008359443956642763,"score_gpt":0.20839313540628784,"score_spread":0.20003369144964508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99872667,0.0002881987,0.00035834857,0.00001940101,0.0000013137993,0.000009251136,0.0002897776,0.000012678034,0.00029429045],"genre_scores_gemma":[0.9987431,0.00007803382,0.0003418417,0.00002682707,0.000004407005,0.000011416432,0.00069384306,0.0000062575446,0.00009434461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998178,0.00003060663,0.000016545888,0.000063789696,0.000034377157,0.000036983445],"domain_scores_gemma":[0.9998658,0.00003421386,0.00003525323,0.000017126185,0.000019692201,0.000027877391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002398238,0.00018894026,0.00033467176,0.0006401644,0.00021521746,0.00042822128,0.00017956598,0.00021721509,0.000679362],"category_scores_gemma":[0.00046633347,0.00010572041,0.00018572411,0.00039696932,0.0001576607,0.00017993945,0.0002926147,0.00019353398,0.00026189053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014156045,0.00008235297,0.82353455,0.00005913418,0.00008036919,0.00063095166,0.00025894254,0.00065384945,0.1437826,0.00011119872,0.00042676102,0.028963553],"study_design_scores_gemma":[0.000030263549,0.00024136709,0.9826173,0.0000115147695,0.00008198321,0.0016190463,0.00027096408,0.0021741134,0.011514156,0.00015310741,0.0012787159,0.0000075018343],"about_ca_topic_score_codex":0.0006703301,"about_ca_topic_score_gemma":0.0012213989,"teacher_disagreement_score":0.000679362,"about_ca_system_score_codex":0.00020254731,"about_ca_system_score_gemma":0.00013559834,"threshold_uncertainty_score":0.002272725},"labels":[],"label_agreement":null},{"id":"W4405045028","doi":"10.1182/blood-2024-202199","title":"Identification of a Novel Function of B2M Involving T-Cell Exhaustion Via P-Selectin Ligand Upregulation in Diffuse Large B-Cell Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Downregulation and upregulation; Identification (biology); Lymphoma; Cancer research; Chemistry; Medicine; Immunology; Biology; Biochemistry","score_opus":0.017036348487291457,"score_gpt":0.27130329152062194,"score_spread":0.2542669430333305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417984,0.0017686166,0.0026585339,0.000091596594,0.00001576431,0.000018980296,0.0002775273,0.000079511614,0.0009095701],"genre_scores_gemma":[0.99726486,0.0004475209,0.0010254588,0.00005553886,0.000012406656,0.000026217467,0.00045835864,0.000012070292,0.0006976259],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999021,0.000012423815,0.000007197488,0.000028041539,0.000026132502,0.000024116993],"domain_scores_gemma":[0.9999237,0.0000063809375,0.000027373535,0.000008159818,0.000009204838,0.000025163916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012286867,0.0002956542,0.00023176684,0.00038739337,0.00014648086,0.00039396298,0.00019909142,0.00032627836,0.001094422],"category_scores_gemma":[0.0000976637,0.000104373845,0.00020422533,0.0001944978,0.0002389781,0.00017022523,0.00026125083,0.00039115816,0.00034682482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001606866,0.000029424,0.0036621382,0.00006669952,0.000008511028,0.0006293391,0.000021117272,0.000033566525,0.9933416,0.00009239255,0.00009628401,0.0018581874],"study_design_scores_gemma":[0.00012333592,0.00096993096,0.19174008,0.000035876583,0.00009615833,0.020080307,0.0002848179,0.0024967191,0.7695977,0.000399815,0.014150678,0.000024590872],"about_ca_topic_score_codex":0.00014934572,"about_ca_topic_score_gemma":0.00021817692,"teacher_disagreement_score":0.001094422,"about_ca_system_score_codex":0.00020185154,"about_ca_system_score_gemma":0.00011917736,"threshold_uncertainty_score":0.0036612153},"labels":[],"label_agreement":null},{"id":"W4405047042","doi":"10.1182/blood-2024-209646","title":"Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Stollery Children's Hospital; University of Calgary; University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Refractory (planetary science); Cancer research; CD19; Blinatumomab; Hematologic Neoplasms; Antigen; Internal medicine; Immunology; Oncology; Cancer; Biology","score_opus":0.010193334808513416,"score_gpt":0.2535019991890671,"score_spread":0.24330866438055365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8165638,0.04774826,0.0127764875,0.005839859,0.00119532,0.009144974,0.041705407,0.0013540108,0.06367174],"genre_scores_gemma":[0.86603063,0.014426803,0.019768132,0.004367918,0.0005744274,0.002192655,0.06751464,0.0002483398,0.024876475],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99864644,0.00046540922,0.000058050762,0.00012809476,0.0005460984,0.00015590951],"domain_scores_gemma":[0.9987832,0.00018800603,0.00024907937,0.00010407056,0.000312269,0.00036332058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032843205,0.00078569737,0.00070098165,0.0008481094,0.00041570276,0.001137041,0.00097624573,0.00089040614,0.0020421855],"category_scores_gemma":[0.0010489809,0.00028890872,0.00051271927,0.000794174,0.00040079615,0.00025832368,0.00036674808,0.0012576826,0.00047848697],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045376115,0.0141877765,0.02463125,0.0015561662,0.0009839584,0.0010413943,0.00032482613,0.013317135,0.26775122,0.0017864861,0.122721694,0.50632197],"study_design_scores_gemma":[0.04652406,0.18566026,0.16791087,0.00025422653,0.0029327394,0.0029375206,0.00017649436,0.0059495033,0.20394212,0.0012813731,0.3822817,0.0001491653],"about_ca_topic_score_codex":0.025280671,"about_ca_topic_score_gemma":0.05319383,"teacher_disagreement_score":0.025280671,"about_ca_system_score_codex":0.0025653034,"about_ca_system_score_gemma":0.00366751,"threshold_uncertainty_score":0.05026704},"labels":[],"label_agreement":null},{"id":"W4405047413","doi":"10.1182/blood-2024-202053","title":"Deciphering Minor Histocompatibility Antigen Immunoreactivity through Optimized T Cell Expansion Strategies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Minor histocompatibility antigen; Immunology; Antigen; Biology; Histocompatibility; Major histocompatibility complex; Human leukocyte antigen","score_opus":0.036205202794188644,"score_gpt":0.3257998966375804,"score_spread":0.28959469384339176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9114235,0.012890189,0.063586175,0.0009138965,0.00024836158,0.0008732687,0.0004111797,0.0003702808,0.009283167],"genre_scores_gemma":[0.9507888,0.004999426,0.039426517,0.0006498555,0.00014003064,0.00061060005,0.00054983987,0.00007694634,0.0027580468],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983406,0.00003836461,0.000013753571,0.00003075225,0.00004295854,0.000040154304],"domain_scores_gemma":[0.9998952,0.000025343972,0.000026382657,0.000009860424,0.000017735989,0.000025471474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045229628,0.00043837226,0.00027856854,0.00034414182,0.00013188833,0.00054153136,0.00033184636,0.00037915786,0.0025100017],"category_scores_gemma":[0.00028252794,0.00011395491,0.00024277202,0.00015013388,0.00017870273,0.00035222212,0.00036015495,0.0011794711,0.00081765774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041882027,0.0005688439,0.00087973964,0.00029660648,0.000020226178,0.00011454321,0.00006893003,0.0027235071,0.9454329,0.0010255995,0.0009235072,0.04752682],"study_design_scores_gemma":[0.0005037412,0.010054044,0.004277739,0.00016608296,0.00026571535,0.0010552823,0.00016511139,0.01906795,0.91439384,0.001862206,0.0481559,0.00003232544],"about_ca_topic_score_codex":0.00009962394,"about_ca_topic_score_gemma":0.00021838839,"teacher_disagreement_score":0.0025100017,"about_ca_system_score_codex":0.0002039463,"about_ca_system_score_gemma":0.00020905124,"threshold_uncertainty_score":0.008396804},"labels":[],"label_agreement":null},{"id":"W4405048123","doi":"10.1182/blood-2024-210635","title":"Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cart; Population; Internal medicine; Salvage therapy; Cohort; Univariate analysis; Retrospective cohort study; Surgery; Multivariate analysis; Chemotherapy","score_opus":0.024248885918860624,"score_gpt":0.2822549505573605,"score_spread":0.25800606463849984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980463,0.0006139321,0.000063971755,0.00006946499,0.0000031799946,0.0000149686275,0.00042170493,0.0000040954274,0.0007623902],"genre_scores_gemma":[0.99946886,0.00012554342,0.00004711966,0.00003570274,0.000006663991,0.000008116928,0.00023089186,8.6324485e-7,0.000076242795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996835,0.00007130515,0.000037888196,0.00004551585,0.00007782787,0.00008399259],"domain_scores_gemma":[0.9978529,0.000337393,0.0013609171,0.000033373522,0.0001738856,0.00024152563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000681487,0.00011968117,0.0002457975,0.0004950697,0.00032653662,0.0005118384,0.00021147465,0.00015461573,0.0020584567],"category_scores_gemma":[0.0012273559,0.000061066305,0.00026152123,0.0007833522,0.00025241022,0.00027466696,0.00031371124,0.0003016062,0.00022896663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008545917,0.000009699741,0.9963768,0.000021670961,0.000013670297,0.0001909131,0.00003641542,0.00002487013,0.00014124099,0.000007294323,0.00013143609,0.0029603355],"study_design_scores_gemma":[0.0000033425365,0.00010498387,0.9984642,0.000014356787,0.000015186902,0.00092727103,0.00010943332,0.00003442205,0.000046935977,0.000010560952,0.0002679781,0.0000013770053],"about_ca_topic_score_codex":0.002664633,"about_ca_topic_score_gemma":0.0077014756,"teacher_disagreement_score":0.002664633,"about_ca_system_score_codex":0.00048757865,"about_ca_system_score_gemma":0.00046129923,"threshold_uncertainty_score":0.006886184},"labels":[],"label_agreement":null},{"id":"W4405048675","doi":"10.1182/blood-2024-210720","title":"Assessing Gender and Racial Inclusion in CAR-T Cell Therapy Clinical Studies: A Scoping Review","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Inclusion (mineral); MEDLINE; Inclusion and exclusion criteria; Family medicine; Demography; Gerontology; Alternative medicine; Psychology; Pathology","score_opus":0.38324976935478167,"score_gpt":0.5774928269549707,"score_spread":0.19424305760018906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015248371,0.9917373,0.0010143927,0.0013983202,0.00045859252,0.0018014592,0.0008473676,0.000017642295,0.0012000077],"genre_scores_gemma":[0.022477299,0.96456635,0.00391484,0.0019810137,0.00034022398,0.005522523,0.00081446534,0.000025736865,0.0003575949],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.92094135,0.027413271,0.038432505,0.0029329215,0.009099429,0.0011806296],"domain_scores_gemma":[0.6891337,0.2489263,0.03514179,0.004521904,0.0212286,0.0010477128],"candidate_categories":["metaresearch","open_science"],"consensus_categories":[],"category_scores_codex":[0.07453972,0.0019095677,0.008465212,0.028988687,0.0022041837,0.006797712,0.0032029445,0.0040693977,0.005563402],"category_scores_gemma":[0.2568299,0.0019427107,0.010203418,0.022623433,0.0024185854,0.0066125668,0.0042056353,0.0019404866,0.0006433627],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024159413,0.000017425593,0.001922893,0.91844004,0.0051001622,0.00020125454,0.001122892,0.000116469186,0.00020931971,0.00087795453,0.003162524,0.06858738],"study_design_scores_gemma":[0.000062724685,0.000051516763,0.0016504492,0.96468383,0.01466738,0.00019438236,0.0005837611,0.000051796676,0.000120552104,0.0005101174,0.017401174,0.000022344284],"about_ca_topic_score_codex":0.007580674,"about_ca_topic_score_gemma":0.017930398,"teacher_disagreement_score":0.9967971,"about_ca_system_score_codex":0.007448743,"about_ca_system_score_gemma":0.027599972,"threshold_uncertainty_score":0.39420843},"labels":[],"label_agreement":null},{"id":"W4405048924","doi":"10.1182/blood-2024-211444","title":"Unwavering Priorities: Global Physician Alignment on Gene Therapy for Hemophilia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Specialty; Family medicine; Demographics; Demography","score_opus":0.029531622374197895,"score_gpt":0.3249777534739233,"score_spread":0.29544613109972545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98037386,0.0008211684,0.0009454169,0.012288041,0.000047096655,0.00006237591,0.00018096158,0.0000142160525,0.005266852],"genre_scores_gemma":[0.99809533,0.00022411333,0.0005896379,0.0008537905,0.000020194337,0.000017434773,0.000055925095,0.0000031190784,0.00014041773],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.9932995,0.0040988354,0.00038760534,0.00033310012,0.0011934089,0.0006875893],"domain_scores_gemma":[0.9718542,0.012953056,0.008700152,0.00042780422,0.0022984159,0.003766331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00869324,0.00012666249,0.0001745618,0.0009835871,0.0017187807,0.0015773847,0.0003651854,0.0005456031,0.0022546516],"category_scores_gemma":[0.033850692,0.00014499656,0.0001895386,0.0013218065,0.0010324214,0.0020786934,0.0019627616,0.0009382287,0.0001477363],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002894468,0.00013005978,0.84611845,0.00035881114,0.00006984501,0.0003928091,0.055293735,0.00053332903,0.00073679455,0.0026275055,0.009617966,0.08383115],"study_design_scores_gemma":[0.000047307894,0.00025140864,0.8462921,0.00034088947,0.00003221021,0.00066450576,0.12779957,0.0015869586,0.00029394473,0.0034629735,0.019186225,0.00004183157],"about_ca_topic_score_codex":0.013903262,"about_ca_topic_score_gemma":0.019782703,"teacher_disagreement_score":0.013903262,"about_ca_system_score_codex":0.00374962,"about_ca_system_score_gemma":0.005170399,"threshold_uncertainty_score":0.04597473},"labels":[],"label_agreement":null},{"id":"W4405049075","doi":"10.1182/blood-2024-210199","title":"A Canadian Cost-Utility Analysis of Epcoritamab Versus Current Therapies in Third-Line or Later Large B-Cell Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lenalidomide; Rituximab; Population; Chemoimmunotherapy; Internal medicine; Oncology; Lymphoma; Multiple myeloma","score_opus":0.041577474496117525,"score_gpt":0.34036101461906393,"score_spread":0.2987835401229464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9097944,0.012367296,0.0075899814,0.0037178625,0.00013688611,0.0012688293,0.040614083,0.00019651797,0.024314048],"genre_scores_gemma":[0.985084,0.0016727949,0.0026011572,0.0002909103,0.000025554675,0.0001915581,0.0077780467,0.000034542252,0.0023213725],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99806124,0.00085505773,0.000059911337,0.00022610345,0.00035104185,0.00044665582],"domain_scores_gemma":[0.99567837,0.0022419377,0.00048265565,0.00015678743,0.00094089506,0.0004993726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0047589764,0.0013420557,0.0013841565,0.0024753497,0.0008316502,0.002099632,0.0022227627,0.00092174404,0.0048001986],"category_scores_gemma":[0.01007656,0.00068918447,0.0033902426,0.0038383808,0.00077771203,0.00060548796,0.0011451151,0.0016662872,0.00023299965],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007668533,0.00050761923,0.06762589,0.0011106821,0.004453077,0.00053899037,0.00019528021,0.8563001,0.0005533538,0.016596168,0.016249618,0.028200697],"study_design_scores_gemma":[0.0020651552,0.0013586361,0.08007591,0.00038605972,0.004049179,0.00033751884,0.0005003661,0.89204466,0.00031491971,0.003301928,0.015357149,0.0002085152],"about_ca_topic_score_codex":0.9457436,"about_ca_topic_score_gemma":0.90132797,"teacher_disagreement_score":0.9291352,"about_ca_system_score_codex":0.07086482,"about_ca_system_score_gemma":0.033585574,"threshold_uncertainty_score":0.51416266},"labels":[],"label_agreement":null},{"id":"W4405049108","doi":"10.1182/blood-2024-205736","title":"Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Apheresis; Medicine; Single Center; CAR T-cell therapy; Internal medicine; Oncology; Surgery; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.02096156753019747,"score_gpt":0.31125163888140317,"score_spread":0.2902900713512057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988537,0.00028191117,0.00026920505,0.000022693443,0.000003414904,0.000041069165,0.00010426348,0.000009487781,0.00041419748],"genre_scores_gemma":[0.9991924,0.00012699967,0.00027110346,0.000020844793,0.000009603526,0.000020836824,0.00024538074,0.0000042220086,0.000108537955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99894494,0.00042995415,0.00009947418,0.00019135242,0.00024357179,0.00009077263],"domain_scores_gemma":[0.9966719,0.0010498252,0.0008477108,0.00025200372,0.0005794786,0.0005991116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018659836,0.00028487976,0.00042304792,0.00045175184,0.0003411067,0.00075263454,0.00029278384,0.0002803764,0.00060824485],"category_scores_gemma":[0.0041768616,0.00018077402,0.00023475457,0.00047721202,0.00030240777,0.00035269404,0.00040092037,0.00041735955,0.00021598628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026786006,0.00076637295,0.9565965,0.000038231876,0.00005044967,0.00063147524,0.00056890905,0.00029465268,0.0026233934,0.000024925335,0.000280608,0.03544583],"study_design_scores_gemma":[0.0002310506,0.009699705,0.9814933,0.000019652789,0.000113879185,0.0019821308,0.000347197,0.0011821381,0.003846149,0.000034435972,0.0010287171,0.000021749338],"about_ca_topic_score_codex":0.0020322797,"about_ca_topic_score_gemma":0.0021691602,"teacher_disagreement_score":0.0020322797,"about_ca_system_score_codex":0.00089714356,"about_ca_system_score_gemma":0.0006655495,"threshold_uncertainty_score":0.009868383},"labels":[],"label_agreement":null},{"id":"W4405049338","doi":"10.1182/blood-2024-206502","title":"Single-Cell Immuno-Metabolic Profiling of Apheresis Samples for Chimeric Antigen T Cell Receptor Therapy Using Cytometry By Time of Flight","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Flow cytometry; Mass cytometry; Chimeric antigen receptor; Antigen; Apheresis; Cell; Cell therapy; Immunology; Medicine; Molecular biology; Biology; Immunotherapy; Immune system; Platelet; Biochemistry","score_opus":0.03654596276350723,"score_gpt":0.2995784964865683,"score_spread":0.26303253372306107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97232676,0.0014661873,0.020678015,0.000115314,0.00003913977,0.00018574945,0.003243819,0.00034273943,0.0016022351],"genre_scores_gemma":[0.9666745,0.0008726702,0.0268522,0.00013454776,0.00002630249,0.00031438694,0.0035473998,0.00007887824,0.0014990782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99982077,0.000023259774,0.000010445778,0.000056790843,0.00006455795,0.000024166324],"domain_scores_gemma":[0.9999305,0.000014235524,0.00001404541,0.0000062728272,0.000021713684,0.000013203378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015467382,0.00031185435,0.0002598877,0.00088280905,0.00020803281,0.0003619356,0.0001459043,0.00026096232,0.0014372995],"category_scores_gemma":[0.00021427068,0.00008415984,0.00017365007,0.0005421974,0.000118088654,0.00012729004,0.00012772362,0.0002670761,0.0004355737],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032018498,0.000036111272,0.0051509626,0.000030966297,0.000014115103,0.00004771978,0.00004542679,0.00024439712,0.9870472,0.00006843546,0.0001326475,0.006861819],"study_design_scores_gemma":[0.000030638726,0.00037530172,0.070925556,0.00001358121,0.000049300856,0.0005822952,0.00009835607,0.0091665145,0.91439843,0.00026651612,0.0040763454,0.000017150092],"about_ca_topic_score_codex":0.00066417287,"about_ca_topic_score_gemma":0.0007991502,"teacher_disagreement_score":0.0014372995,"about_ca_system_score_codex":0.00024669437,"about_ca_system_score_gemma":0.00017909029,"threshold_uncertainty_score":0.004808247},"labels":[],"label_agreement":null},{"id":"W4405049957","doi":"10.1182/blood-2024-204282","title":"Lintuzumab-Ac225 Exerts Mutation Agnostic Antileukemic Activity in Preclinical Models of AML","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Mutation; Cancer research; Leukemia; Medicine; Biology; Genetics; Immunology; Gene","score_opus":0.060134507179108974,"score_gpt":0.37524637745984196,"score_spread":0.315111870280733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127895,0.002277455,0.002546215,0.00015341297,0.00007463422,0.00021981137,0.00080619607,0.00030906126,0.002334222],"genre_scores_gemma":[0.99406284,0.0011296984,0.0015799179,0.00006535699,0.000017776983,0.00017573034,0.0008867114,0.000018488785,0.0020634942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998411,0.000032007007,0.000012124449,0.000026732781,0.000037771602,0.00005021928],"domain_scores_gemma":[0.99991786,0.000010373286,0.000022906564,0.000010928617,0.000009652052,0.00002829692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030947075,0.0005909827,0.00039580092,0.00043240143,0.00016997156,0.00029818524,0.00034571977,0.00039508223,0.0015676633],"category_scores_gemma":[0.000106608044,0.00015063002,0.0002761542,0.00019783493,0.00018661132,0.00022708884,0.000118993055,0.0011048765,0.00037618828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011391292,0.0014537878,0.0003091514,0.00013119288,0.000032859898,0.000052417105,0.000038743427,0.00071599486,0.98840904,0.00020946718,0.0004407605,0.007067438],"study_design_scores_gemma":[0.0004306231,0.02108544,0.0035465138,0.000020448764,0.000091150956,0.00038154479,0.000033779095,0.0021407774,0.96496606,0.000093412884,0.0071990327,0.000011386293],"about_ca_topic_score_codex":0.0008378521,"about_ca_topic_score_gemma":0.0015287916,"teacher_disagreement_score":0.0015676633,"about_ca_system_score_codex":0.00036783755,"about_ca_system_score_gemma":0.0003150348,"threshold_uncertainty_score":0.0052443743},"labels":[],"label_agreement":null},{"id":"W4405050041","doi":"10.1182/blood-2024-201855","title":"Long-Term Outcomes and Adverse Events of CAR T-19 Cell Therapy in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia - a Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Meta-analysis; Lymphoblastic Leukemia; Oncology; Refractory (planetary science); Leukemia; CAR T-cell therapy; Acute lymphocytic leukemia; Internal medicine; Cancer; Chimeric antigen receptor; Biology; Immunotherapy","score_opus":0.08288058284013552,"score_gpt":0.3791185913339176,"score_spread":0.2962380084937821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003221079,0.9951284,0.0003799563,0.00015609317,0.00011490046,0.0002654141,0.0005304382,0.00001857015,0.00018523801],"genre_scores_gemma":[0.114735134,0.8792459,0.0018727697,0.000897462,0.00025404576,0.0017380557,0.00092777936,0.000025690228,0.0003031211],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9909339,0.0043169153,0.0026360475,0.0008664163,0.0009243554,0.00032235045],"domain_scores_gemma":[0.9855129,0.010116082,0.0024517411,0.00045013067,0.0012711935,0.00019798885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011949344,0.0027600771,0.01924201,0.0068616434,0.0006281898,0.0033002147,0.0022219298,0.0025935858,0.0035039063],"category_scores_gemma":[0.03112792,0.0016063902,0.044441495,0.0076471767,0.0006493092,0.0016074467,0.0015059542,0.0016066817,0.00029919043],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012684868,0.000024028588,0.0018928035,0.5005735,0.48617664,0.00012676562,0.00006817615,0.0006447461,0.00018039068,0.00013787179,0.0005703778,0.008336174],"study_design_scores_gemma":[0.00041932298,0.00016348952,0.00202909,0.03273984,0.96266127,0.000083636725,0.000035811547,0.00017533175,0.00009056111,0.00017586832,0.0014008139,0.000025020145],"about_ca_topic_score_codex":0.0083554,"about_ca_topic_score_gemma":0.015479154,"teacher_disagreement_score":0.01924201,"about_ca_system_score_codex":0.0031882566,"about_ca_system_score_gemma":0.004158275,"threshold_uncertainty_score":0.06319493},"labels":[],"label_agreement":null},{"id":"W4405051535","doi":"10.1182/blood-2024-211007","title":"Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"Eisai; BeiGene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Intensive care medicine","score_opus":0.06841936375932402,"score_gpt":0.39594189204138525,"score_spread":0.32752252828206124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405051535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470747,0.0014393354,0.00021747279,0.00023020647,0.000012667745,0.00003823085,0.0006505336,0.000012211694,0.0026918997],"genre_scores_gemma":[0.9993511,0.00019318792,0.00004360174,0.000062260355,0.0000125440365,0.0000135715545,0.00017351356,0.0000032378841,0.00014714169],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987203,0.00029368297,0.00016543867,0.00024239627,0.00029466572,0.0002835202],"domain_scores_gemma":[0.98917353,0.0026646534,0.0066613248,0.00027659815,0.00069055724,0.00053336896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001081108,0.00009788803,0.00034112297,0.0005672165,0.00038488474,0.00091901765,0.00029088822,0.00027030747,0.003460301],"category_scores_gemma":[0.0066907974,0.0001221103,0.0004019994,0.00082023104,0.00032221465,0.00046990794,0.0004147963,0.00044464626,0.00045238575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037156852,0.000017901233,0.9887205,0.00008391632,0.000044130597,0.00047472218,0.00016561012,0.0000732705,0.0003097134,0.00004153743,0.000328494,0.009368589],"study_design_scores_gemma":[0.000018625848,0.00024221517,0.99567163,0.000063831714,0.0000816896,0.0016132393,0.00042728693,0.000083075865,0.00020981615,0.00004727002,0.001537178,0.000004173289],"about_ca_topic_score_codex":0.003295325,"about_ca_topic_score_gemma":0.0064933375,"teacher_disagreement_score":0.003460301,"about_ca_system_score_codex":0.0008682796,"about_ca_system_score_gemma":0.00076336466,"threshold_uncertainty_score":0.011575818},"labels":[],"label_agreement":null},{"id":"W4405052961","doi":"10.1182/blood-2024-194331","title":"Glofitamab in Combination with R-ICE Chemoimmunotherapy or as Monotherapy in Children and Adolescents with Relapsed/Refractory B-cell non-Hodgkin Lymphoma: Initial Safety and Efficacy Results from the Ongoing iMATRIX-GLO Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Rituximab; Cohort; Oncology; Lymphoma","score_opus":0.009643382075257279,"score_gpt":0.2786636109654514,"score_spread":0.2690202288901941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405052961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904303,0.007644198,0.00010367647,0.00025307032,0.000035801655,0.00015866442,0.0005026558,0.000029432793,0.0008422743],"genre_scores_gemma":[0.9930507,0.004268579,0.00041989578,0.00049750856,0.000060917435,0.000201131,0.0011038162,0.000013315116,0.000384093],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9997459,0.00009810617,0.000020260379,0.000043097545,0.000039829607,0.00005276868],"domain_scores_gemma":[0.99937075,0.00011526513,0.0001832881,0.000040782717,0.0000383113,0.0002515503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008005381,0.00036349666,0.0012563817,0.00022159188,0.00015599797,0.00058294414,0.00036920139,0.00043882485,0.0012166348],"category_scores_gemma":[0.00071345124,0.0002259194,0.00097785,0.00027548496,0.00037965988,0.00052742864,0.0002797932,0.001724423,0.0003832083],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3894347,0.018366268,0.15121652,0.0019936727,0.004375053,0.0011552365,0.0008871895,0.0027555905,0.029382538,0.00042826319,0.009235102,0.3907698],"study_design_scores_gemma":[0.22094274,0.4412336,0.29375547,0.0006462131,0.004182797,0.0038627966,0.0006847858,0.0034182146,0.008345926,0.0004778581,0.022359315,0.00009036479],"about_ca_topic_score_codex":0.0008016163,"about_ca_topic_score_gemma":0.0027816591,"teacher_disagreement_score":0.0012563817,"about_ca_system_score_codex":0.0007055115,"about_ca_system_score_gemma":0.00069150695,"threshold_uncertainty_score":0.005118847},"labels":[],"label_agreement":null},{"id":"W4405056347","doi":"10.1126/science.adl4237","title":"Programming tissue-sensing T cells that deliver therapies to the brain","year":2024,"lang":"en","type":"article","venue":"Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Cancer Moonshot; Moonshot Research and Development Program; University of California, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Institute of Neurological Disorders and Stroke; National Cancer Institute; Advanced Research Projects Agency; National Institutes of Health; Multiple Sclerosis Society; Valhalla Foundation; Parker Institute for Cancer Immunotherapy; Emerson Collective; Sandler Foundation","keywords":"Neuroinflammation; Central nervous system; Chimeric antigen receptor; Antigen; Biology; Cell biology; Extracellular; Extracellular matrix; Neuroscience; Clearance; Receptor; Immunology; Immunotherapy; Medicine; Inflammation; Immune system","score_opus":0.04704679087321421,"score_gpt":0.3627700912532719,"score_spread":0.3157233003800577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405056347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93700063,0.0036206087,0.050148822,0.0004512803,0.0002309233,0.00036972138,0.0002727244,0.00035765916,0.007547662],"genre_scores_gemma":[0.9792565,0.0016635525,0.014918874,0.00018868927,0.000030374853,0.00015056264,0.00010171241,0.000036427165,0.0036532755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998779,0.000021719481,0.000008502,0.000028641458,0.000028177386,0.000035049237],"domain_scores_gemma":[0.9999521,0.000009621172,0.000016584463,0.0000041606495,0.000007529968,0.000010037368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015751165,0.00042351458,0.0002110794,0.00024876412,0.00010445997,0.0004129042,0.00019560754,0.00041480892,0.00138798],"category_scores_gemma":[0.00013772961,0.000098622586,0.00018454634,0.00011651578,0.00024880373,0.00020872043,0.0002522538,0.0006491235,0.00040930812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009966756,0.00009160771,0.00023390193,0.00008422453,0.000009170819,0.00014469288,0.00007355399,0.0009385184,0.9853226,0.0018797031,0.00023848293,0.010883822],"study_design_scores_gemma":[0.00009356088,0.000931115,0.00047001752,0.00002086471,0.000038408918,0.00040130256,0.000071857896,0.003939552,0.98032653,0.00056739396,0.013129431,0.000009810647],"about_ca_topic_score_codex":0.00027990737,"about_ca_topic_score_gemma":0.0005098872,"teacher_disagreement_score":0.00138798,"about_ca_system_score_codex":0.00018181813,"about_ca_system_score_gemma":0.0002330563,"threshold_uncertainty_score":0.0046432614},"labels":[],"label_agreement":null},{"id":"W4405062597","doi":"10.26685/urncst.738","title":"Optimizing Chimeric Artificial T Cell Receptor Therapy for Solid Tumour Targeting by Manipulating the Tumour Microenvironment: A Literature Review","year":2024,"lang":"en","type":"review","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Tumor microenvironment; Receptor; Targeted therapy; Computational biology; Medicine; Chemistry; Immunotherapy; Biology; Internal medicine; Cancer; Tumor cells","score_opus":0.09181363673023372,"score_gpt":0.4492578110532317,"score_spread":0.35744417432299797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405062597","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029535123,0.9990152,0.000092356604,0.00011515415,0.00004588998,0.000021606782,0.000041605563,0.0000032629823,0.00036965375],"genre_scores_gemma":[0.0011169832,0.99833786,0.00024008055,0.00011260218,0.000029047436,0.000024401517,0.000039329487,9.084897e-7,0.00009872733],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994735,0.00010501496,0.00017202843,0.0000742929,0.00013799783,0.00003723524],"domain_scores_gemma":[0.99798065,0.0012035387,0.00039121095,0.000022792783,0.00035388969,0.000047885085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012721671,0.00096857146,0.0026320282,0.008985709,0.00035972294,0.0014454232,0.0012136307,0.001335032,0.0032157535],"category_scores_gemma":[0.0025114731,0.00040527407,0.001608402,0.012420702,0.0003952401,0.0015265231,0.00063639344,0.00060113595,0.0006991043],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015189992,0.000080421094,0.00045312755,0.5053816,0.00073044404,0.000551065,0.0002437835,0.00060868275,0.0018813856,0.001471428,0.008464686,0.4799815],"study_design_scores_gemma":[0.00012155808,0.000692414,0.004495274,0.39460883,0.00993223,0.0035074828,0.00069641595,0.0005820163,0.0029171132,0.0019391157,0.5804068,0.000100849604],"about_ca_topic_score_codex":0.0030787897,"about_ca_topic_score_gemma":0.00471684,"teacher_disagreement_score":0.008985709,"about_ca_system_score_codex":0.0010661504,"about_ca_system_score_gemma":0.003860247,"threshold_uncertainty_score":0.010757804},"labels":[],"label_agreement":null},{"id":"W4405064946","doi":"10.1101/2024.11.29.626103","title":"Boosting of CAR-T cells with rhabdovirus is limited by type I interferon and rapid contraction","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Ottawa Hospital; McMaster University","funders":"","keywords":"Boosting (machine learning); Interferon; Contraction (grammar); Virology; Biology; Computer science; Artificial intelligence; Endocrinology","score_opus":0.019376056460681523,"score_gpt":0.255078554392699,"score_spread":0.23570249793201747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405064946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844683,0.0018248347,0.007889863,0.00007874701,0.000032828357,0.000038116665,0.00008346957,0.00007297529,0.0015322872],"genre_scores_gemma":[0.99577373,0.00031443516,0.0025015632,0.000048742608,0.000007409462,0.000037789858,0.00009182004,0.000016281387,0.0012082685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976593,0.00004502448,0.000017840359,0.00004784401,0.000043609147,0.00007966435],"domain_scores_gemma":[0.9998404,0.000046271107,0.000046893663,0.000026440473,0.000014291724,0.000025701072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002558149,0.0003097405,0.0002909265,0.000089872556,0.00006790319,0.00027932462,0.00021085331,0.0003143612,0.0009239162],"category_scores_gemma":[0.0001811025,0.0001589889,0.00023089738,0.00006944372,0.0002458622,0.00022077069,0.00020311319,0.00067794655,0.00023990245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007453585,0.000014856928,0.00012537214,0.000025474588,0.0000028389577,0.000020187816,0.0000057732204,0.00014783019,0.99875367,0.00011309893,0.00002166888,0.00069467735],"study_design_scores_gemma":[0.000016530026,0.00019892913,0.00084545003,0.0000061708793,0.000009845851,0.000137653,0.000009449214,0.0018463148,0.9957302,0.0000472472,0.001150208,0.0000020043813],"about_ca_topic_score_codex":0.00028218227,"about_ca_topic_score_gemma":0.00038220172,"teacher_disagreement_score":0.0009239162,"about_ca_system_score_codex":0.00030762338,"about_ca_system_score_gemma":0.0002296514,"threshold_uncertainty_score":0.0030907393},"labels":[],"label_agreement":null},{"id":"W4405092569","doi":"10.1182/blood-2024-211475","title":"Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Lymphoma; Medicine; CD19; Immunology; Cancer research; Internal medicine; Antibody","score_opus":0.036435702091213884,"score_gpt":0.3426034512495697,"score_spread":0.3061677491583558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405092569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99784577,0.0006126204,0.00014443399,0.0000351595,0.0000058095648,0.000025960817,0.0008769911,0.0000036853537,0.0004495627],"genre_scores_gemma":[0.9982382,0.00014440883,0.00010090066,0.00002683331,0.000015839898,0.000034133747,0.0013671466,0.0000020054226,0.00007043349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982482,0.0007459258,0.00022149805,0.00035587198,0.00025837723,0.00017021628],"domain_scores_gemma":[0.99488103,0.0009069657,0.0032474517,0.00027827473,0.0003476564,0.0003386082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023269774,0.00021759815,0.00031148235,0.0007933582,0.0002655747,0.0009702025,0.00038320138,0.0004318937,0.0017257015],"category_scores_gemma":[0.004516438,0.00013909786,0.0005075398,0.0010180168,0.0003800595,0.0007095615,0.00058225705,0.00031247459,0.00030594165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004789326,0.0002352633,0.9865602,0.000058182126,0.00032161557,0.00011287938,0.000086874345,0.00041052175,0.00038526315,0.000062184314,0.00030529188,0.006672344],"study_design_scores_gemma":[0.00029292575,0.0030369645,0.99287224,0.00003274756,0.0002580632,0.00065073784,0.00023449933,0.0006848678,0.0007140271,0.0000694561,0.0011369187,0.000016456996],"about_ca_topic_score_codex":0.0009618743,"about_ca_topic_score_gemma":0.0010879055,"teacher_disagreement_score":0.0023269774,"about_ca_system_score_codex":0.0009795653,"about_ca_system_score_gemma":0.00037536863,"threshold_uncertainty_score":0.012306392},"labels":[],"label_agreement":null},{"id":"W4405126172","doi":"10.1182/blood-2024-201784","title":"CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Acute lymphocytic leukemia; CD19; Leukemia; Immunology; Internal medicine; Cancer research; Flow cytometry","score_opus":0.02819512710747323,"score_gpt":0.2907933705097839,"score_spread":0.26259824340231064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405126172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461573,0.00084544416,0.00030208062,0.00017721606,0.00005517406,0.0029952452,0.00035732292,0.000037476286,0.00061441585],"genre_scores_gemma":[0.991922,0.0013583122,0.0011880816,0.0005083454,0.00017108303,0.003249396,0.0008021085,0.000012312703,0.0007883768],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9995602,0.00019809435,0.000032551885,0.00007327416,0.000037134636,0.00009877471],"domain_scores_gemma":[0.99919933,0.000120192395,0.0001247254,0.00009524228,0.00004858556,0.0004119887],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016463475,0.0010101652,0.0017601942,0.0003456967,0.00040289562,0.0007969387,0.00085077854,0.0010475183,0.0036347948],"category_scores_gemma":[0.00082074193,0.00042554553,0.0014336577,0.000362975,0.0009074251,0.00078781496,0.0005182499,0.0023016427,0.00080999243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60117567,0.25665477,0.009939415,0.0011228679,0.0012167167,0.0005436812,0.00053503556,0.0015650516,0.032739833,0.00030223024,0.0019483225,0.09225641],"study_design_scores_gemma":[0.14840026,0.8403524,0.007940945,0.000022054677,0.00033232357,0.00018141778,0.000060769602,0.0003066391,0.0010939938,0.00006531869,0.0012333479,0.00001055039],"about_ca_topic_score_codex":0.0010567497,"about_ca_topic_score_gemma":0.0014869331,"teacher_disagreement_score":0.0036347948,"about_ca_system_score_codex":0.0007750201,"about_ca_system_score_gemma":0.0014929709,"threshold_uncertainty_score":0.012159526},"labels":[],"label_agreement":null},{"id":"W4405177856","doi":"10.1182/blood.2024024965","title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Chimeric antigen receptor; Cohort; Internal medicine; Bone marrow; Immunology; Cancer; Immunotherapy","score_opus":0.017851523879817328,"score_gpt":0.28673564636660515,"score_spread":0.26888412248678784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405177856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987527,0.00023739302,0.00023458702,0.0000310185,0.0000025139157,0.0000052130295,0.0003257838,0.00000788813,0.0004029278],"genre_scores_gemma":[0.99959725,0.000021567968,0.00006750118,0.000009578271,0.0000027699407,0.0000035194907,0.00021192976,0.0000014373743,0.00008448752],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99982613,0.0000387947,0.000017211827,0.00004145078,0.00003848325,0.000038033893],"domain_scores_gemma":[0.99957675,0.00009655041,0.000163832,0.000031113505,0.000043750384,0.00008797373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003078584,0.00014872725,0.00023546495,0.00031408772,0.00017260267,0.00049749744,0.0001541279,0.0002484612,0.0014629283],"category_scores_gemma":[0.00085566053,0.00006990096,0.00014398117,0.00042621235,0.00015294368,0.00024103899,0.00022675499,0.0003506217,0.00039787235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008343123,0.000047489488,0.9873734,0.000014482619,0.000039693412,0.000119404394,0.000031467553,0.0002487939,0.0056722034,0.000048399816,0.00021287048,0.005357428],"study_design_scores_gemma":[0.00002253571,0.00047392302,0.9933878,0.000004633096,0.00004260666,0.0008814656,0.000056507888,0.0014366002,0.0030372636,0.000098633114,0.00055347325,0.000004504134],"about_ca_topic_score_codex":0.00074645213,"about_ca_topic_score_gemma":0.00074908906,"teacher_disagreement_score":0.0014629283,"about_ca_system_score_codex":0.00028267744,"about_ca_system_score_gemma":0.00020277282,"threshold_uncertainty_score":0.004894018},"labels":[],"label_agreement":null},{"id":"W4405177945","doi":"10.1182/blood.2024025673","title":"Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"CD19; Chimeric antigen receptor; Antibody; Antigen; Effector; Monoclonal antibody; Biology; Cancer research; Immunology; Chemistry; Cell biology; T cell; Immune system","score_opus":0.022774162309239055,"score_gpt":0.32420242912402375,"score_spread":0.3014282668147847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405177945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99416465,0.0014441733,0.0024210853,0.00006563323,0.000035795925,0.000042149684,0.0002189375,0.00014696161,0.0014606576],"genre_scores_gemma":[0.9940487,0.00054289895,0.0022401283,0.000038521855,0.0000096059275,0.000039002527,0.00029080667,0.000020517027,0.0027697927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998498,0.000025055786,0.000012743596,0.000031150328,0.00003577474,0.00004549452],"domain_scores_gemma":[0.9999294,0.000013044888,0.000016644997,0.00000946273,0.00000927314,0.000022028504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000082771934,0.00033219485,0.00029860457,0.00017358121,0.00008166981,0.00022060405,0.00018389484,0.0002456799,0.0017232307],"category_scores_gemma":[0.00006508977,0.0000847884,0.0001641925,0.000101913305,0.00013010661,0.00014391213,0.00012290008,0.0007686137,0.00040965044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000096525815,0.00007280261,0.00009586914,0.00001781104,0.000004432842,0.000020012412,0.0000060588322,0.00005065988,0.99809724,0.000043492248,0.000059639693,0.0014354852],"study_design_scores_gemma":[0.0000143166535,0.00041008883,0.001547468,0.0000018523124,0.0000105240815,0.00008719367,0.000005447297,0.00059365644,0.99623436,0.0000066302864,0.0010871766,0.0000012618427],"about_ca_topic_score_codex":0.0006329001,"about_ca_topic_score_gemma":0.0012382984,"teacher_disagreement_score":0.0017232307,"about_ca_system_score_codex":0.00025535215,"about_ca_system_score_gemma":0.00018378388,"threshold_uncertainty_score":0.0057647824},"labels":[],"label_agreement":null},{"id":"W4405181441","doi":"10.1158/1538-8514.cancerchem24-ia017","title":"Abstract IA017: Transferrin receptor targeting chimeras (TransTACs) for targeted degradation of membrane and extracellular proteins in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Transferrin receptor; Epidermal growth factor receptor; Cancer cell; Cancer; Cancer research; Targeted therapy; Extracellular; Receptor; Biology; Chemistry; Medicine; Cell biology; Biochemistry; Internal medicine","score_opus":0.04099871369861158,"score_gpt":0.3359801257257002,"score_spread":0.2949814120270886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8346639,0.037618127,0.06936464,0.0030690269,0.0009648495,0.00048273403,0.0034919619,0.0028411767,0.047503587],"genre_scores_gemma":[0.94690096,0.0079079075,0.017933844,0.0003101501,0.00004622322,0.00011801498,0.0022145545,0.00020374659,0.024364645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998534,0.00002408038,0.000011605575,0.000030173562,0.00005252175,0.00002819395],"domain_scores_gemma":[0.9999349,0.000006887597,0.000014989075,0.000008898808,0.000016012524,0.000018307694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002666502,0.00043115573,0.00031125286,0.00049631356,0.00026300026,0.00045986642,0.00041389195,0.00043637952,0.0037601853],"category_scores_gemma":[0.00013098757,0.0001907184,0.0003145384,0.0003949806,0.00027235397,0.00034877646,0.0003365908,0.00070979894,0.001023566],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003685905,0.00005870429,0.0002617889,0.0001361777,0.000023884924,0.0001719339,0.000043913882,0.0004237582,0.97454923,0.0023426367,0.0032985692,0.018320737],"study_design_scores_gemma":[0.00007709318,0.00031235875,0.0011903304,0.000014209259,0.000034780478,0.0017298794,0.00002175266,0.001956599,0.9617902,0.00014978462,0.03270932,0.000013833189],"about_ca_topic_score_codex":0.0021576139,"about_ca_topic_score_gemma":0.0016153705,"teacher_disagreement_score":0.0037601853,"about_ca_system_score_codex":0.00097146514,"about_ca_system_score_gemma":0.0006958191,"threshold_uncertainty_score":0.012579083},"labels":[],"label_agreement":null},{"id":"W4405186265","doi":"10.1016/j.stem.2024.11.010","title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","year":2024,"lang":"en","type":"article","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Institutes of Health; Ontario Institute for Regenerative Medicine; Abramson Cancer Center; University of Pennsylvania; Diabetes Research Center, Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","keywords":"Organoid; Biology; Glioblastoma; Cell therapy; CAR T-cell therapy; Cancer research; Bioinformatics; Neuroscience; Stem cell; Cell biology; Cancer; Immunotherapy; Genetics; Chimeric antigen receptor","score_opus":0.04223789516226863,"score_gpt":0.36520614074426455,"score_spread":0.32296824558199594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405186265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9369929,0.0022711474,0.052092735,0.00023812694,0.0003430922,0.00038556207,0.0016834573,0.00051375024,0.0054791896],"genre_scores_gemma":[0.9831081,0.0005634635,0.012355356,0.00009987153,0.000015085681,0.0003474008,0.0008436845,0.0000574094,0.0026095742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99965084,0.000107298416,0.000020011363,0.00007699195,0.00009293106,0.0000518884],"domain_scores_gemma":[0.99976164,0.0000798534,0.000035727164,0.00004062705,0.000036593177,0.00004552258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008090849,0.0004072692,0.0003364859,0.0003028859,0.00016269328,0.0005231161,0.00026830012,0.00061047653,0.0026122662],"category_scores_gemma":[0.00040002452,0.0002076319,0.00026331664,0.0002203894,0.00026998887,0.0003771578,0.00029716754,0.0011044887,0.0008526654],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014616766,0.00032775739,0.0014364567,0.00018395431,0.000032130658,0.0003505373,0.00039869698,0.0030691011,0.980566,0.00086636114,0.0009840813,0.010323262],"study_design_scores_gemma":[0.00017315224,0.0027921489,0.0037346585,0.000025962694,0.00011420242,0.00096443715,0.00042677135,0.016378926,0.9604565,0.00037778978,0.014524965,0.00003045925],"about_ca_topic_score_codex":0.0007550026,"about_ca_topic_score_gemma":0.0009332093,"teacher_disagreement_score":0.0026122662,"about_ca_system_score_codex":0.0002906268,"about_ca_system_score_gemma":0.0002335381,"threshold_uncertainty_score":0.008738875},"labels":[],"label_agreement":null},{"id":"W4405248118","doi":"10.1002/cpt.3512","title":"Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Chimeric antigen receptor; Clinical trial; Internal medicine; Oncology; Immunotherapy","score_opus":0.2873189533852471,"score_gpt":0.4787642868699958,"score_spread":0.19144533348474868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405248118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99148095,0.001057697,0.0044743917,0.00011187584,0.000004479679,0.00010241622,0.0010008268,0.00004043941,0.0017269755],"genre_scores_gemma":[0.99717784,0.00033019326,0.0012263682,0.000022742262,0.0000048821507,0.00004988083,0.00086370244,0.000014042751,0.00031039826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99498343,0.0019881092,0.0006084534,0.0010266238,0.00094213407,0.0004511752],"domain_scores_gemma":[0.9457866,0.027399385,0.020840816,0.0019958252,0.002519287,0.0014580367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010884011,0.00039334845,0.00039141718,0.0022489813,0.00033209386,0.0017184477,0.00045185882,0.00053469517,0.0030263239],"category_scores_gemma":[0.029740108,0.0003324312,0.0010430212,0.0014418646,0.00067743956,0.0012955916,0.001272776,0.00085927965,0.00076641364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073650625,0.00006113913,0.97248566,0.00005923372,0.00017069456,0.00015338292,0.00015820896,0.005872156,0.000990485,0.0005126415,0.00020501153,0.018594906],"study_design_scores_gemma":[0.00006301029,0.0013564876,0.96311706,0.00006133444,0.00030822796,0.001636984,0.0004927278,0.02373595,0.003541562,0.0015642542,0.0040744008,0.000048000475],"about_ca_topic_score_codex":0.0014904779,"about_ca_topic_score_gemma":0.0012307762,"teacher_disagreement_score":0.010884011,"about_ca_system_score_codex":0.0007688338,"about_ca_system_score_gemma":0.0008874485,"threshold_uncertainty_score":0.05756086},"labels":[],"label_agreement":null},{"id":"W4405264395","doi":"10.3389/fimmu.2024.1347404","title":"Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Deutschen Konsortium für Translationale Krebsforschung; Deutsche Forschungsgemeinschaft; Technische Universität München; Wilhelm Sander-Stiftung","keywords":"CD8; ELISPOT; Tumor necrosis factor alpha; Cytotoxic T cell; Cancer research; Immunology; Major histocompatibility complex; T cell; Cytokine; Biology; Medicine; Antigen; Immune system; In vitro","score_opus":0.015744929768898994,"score_gpt":0.2984258400617035,"score_spread":0.28268091029280445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405264395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935448,0.0029326666,0.0025230225,0.00005922166,0.000023932873,0.00008432071,0.00029138752,0.000035968842,0.00050479604],"genre_scores_gemma":[0.99295795,0.0017688165,0.004033357,0.00005515206,0.000039454888,0.000074473435,0.00052725105,0.000006035855,0.000537624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99985325,0.00003256074,0.000015457954,0.000024425064,0.000035037643,0.00003915089],"domain_scores_gemma":[0.9998796,0.00002977541,0.00004064285,0.000008126245,0.000022306878,0.000019558987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018046593,0.000336056,0.00025443741,0.00025232718,0.00008439225,0.0002722392,0.000101426034,0.00020477989,0.00097400206],"category_scores_gemma":[0.00016701563,0.00007046367,0.00020957756,0.00016908009,0.00008144349,0.00013742958,0.00013030563,0.00029686594,0.0003050242],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025727175,0.00007590758,0.0015258635,0.0000635668,0.000004141436,0.000058022575,0.000008569667,0.00014121145,0.9939487,0.000017887669,0.00003185384,0.0038669768],"study_design_scores_gemma":[0.000044211287,0.0020900622,0.0072914134,0.000013925729,0.000029109895,0.00047904064,0.000025098916,0.00054954056,0.9879952,0.000028190581,0.0014515372,0.0000028095449],"about_ca_topic_score_codex":0.000084464715,"about_ca_topic_score_gemma":0.00014749293,"teacher_disagreement_score":0.00097400206,"about_ca_system_score_codex":0.00012619763,"about_ca_system_score_gemma":0.0001247592,"threshold_uncertainty_score":0.0032583475},"labels":[],"label_agreement":null},{"id":"W4405273291","doi":"10.1182/bloodadvances.2024014903","title":"Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"Cilag; Berlin Institute of Health; Swedish Orphan Biovitrum; Incyte; BeiGene; Agios Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Sanofi; Pfizer; Les Laboratories Pierre Fabre; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Bendamustine; Refractory (planetary science); Cytokine release syndrome; Rituximab; Oncology; Salvage therapy; Gastroenterology; Lymphoma; Surgery; Chemotherapy; Immunotherapy; Cancer; Chimeric antigen receptor; Biology","score_opus":0.016827185534477724,"score_gpt":0.3415337235392444,"score_spread":0.3247065380047667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405273291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99884987,0.0003868527,0.00011249771,0.000065961714,0.000005820638,0.00007983431,0.00024836612,0.000010454222,0.0002403421],"genre_scores_gemma":[0.9985108,0.00014524143,0.00015879341,0.00013348353,0.000016450062,0.000063722895,0.00086209836,0.0000049963246,0.00010442867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990534,0.00054629776,0.000067912835,0.00013872399,0.000103412414,0.00009026124],"domain_scores_gemma":[0.99843746,0.00025977634,0.00061564724,0.00020399183,0.0001278205,0.00035525067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004057815,0.00054891466,0.0006701033,0.00025293682,0.00032869613,0.0009868668,0.00047088834,0.000707638,0.0008410528],"category_scores_gemma":[0.0016758514,0.00022111955,0.0007031799,0.00034353326,0.0006267453,0.000718827,0.0004161504,0.00081403024,0.0003436394],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14384116,0.009880806,0.76620966,0.0002759271,0.0019357852,0.00085068285,0.00047325355,0.0020607465,0.021353781,0.00009498708,0.0013923179,0.05163092],"study_design_scores_gemma":[0.022419114,0.12292169,0.8381042,0.00005106564,0.0013621199,0.001894407,0.00029555356,0.0031391878,0.005060902,0.00010312061,0.0045836824,0.000065001324],"about_ca_topic_score_codex":0.0005820273,"about_ca_topic_score_gemma":0.00078877003,"teacher_disagreement_score":0.004057815,"about_ca_system_score_codex":0.00079822965,"about_ca_system_score_gemma":0.000669747,"threshold_uncertainty_score":0.021459997},"labels":[],"label_agreement":null},{"id":"W4405285852","doi":"10.1177/12034754241303057","title":"Molecular-Guided Therapy for Melanoma in Canada: Overview of Current Practices and Recommendations","year":2024,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Western University; Dalhousie University; University of Toronto; Memorial University of Newfoundland; Nova Scotia Health Authority; University of Calgary","funders":"Memorial University of Newfoundland; University of Toronto; Queen's University; McGill University; University of Ottawa; Université Laval","keywords":"Medicine; Standardization; Biomarker; Cancer; Melanoma; Targeted therapy; Molecular biomarkers; Diagnostic test; Medical physics; Biomarker discovery; Oncology; Internal medicine; Proteomics; Cancer research","score_opus":0.266182314002347,"score_gpt":0.4718297759904469,"score_spread":0.2056474619880999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405285852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000075881755,0.99625117,0.00008804898,0.002048418,0.00017936024,0.000012734826,0.00007744676,0.000010705018,0.0012563245],"genre_scores_gemma":[0.00063416624,0.99821424,0.0002405401,0.00046905817,0.00008773324,0.000008692619,0.00007058189,0.000002089956,0.0002729724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991935,0.00009512009,0.00012564093,0.00008962632,0.0003986757,0.00009748535],"domain_scores_gemma":[0.996549,0.00082420255,0.0003749131,0.000042023366,0.0019052164,0.00030463378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002480905,0.0008303267,0.0013744595,0.006020633,0.00085087446,0.0018448049,0.0020858413,0.0014758116,0.0048125195],"category_scores_gemma":[0.0036647653,0.00041317192,0.0011992891,0.006001601,0.00089056994,0.0012134394,0.0008540648,0.002338146,0.0011267317],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007586236,0.00005476838,0.0007584526,0.020361058,0.00012849519,0.00015514194,0.00010733299,0.00048812738,0.00026517332,0.002834137,0.0777464,0.897025],"study_design_scores_gemma":[0.000035550172,0.00007116971,0.0038402206,0.033919387,0.00041493317,0.00063137774,0.0001747656,0.0002395728,0.00023360901,0.0013171216,0.95907897,0.000043244654],"about_ca_topic_score_codex":0.34423783,"about_ca_topic_score_gemma":0.52286315,"teacher_disagreement_score":0.6557622,"about_ca_system_score_codex":0.01368149,"about_ca_system_score_gemma":0.029602464,"threshold_uncertainty_score":0.68446827},"labels":[],"label_agreement":null},{"id":"W4405310215","doi":"10.1016/j.ymthe.2024.12.012","title":"Tailoring capsid-directed evolution technology for improved AAV-mediated CAR-T generation","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Narodowym Centrum Nauki; Wellcome Trust; National Health and Medical Research Council; Narodowe Centrum Nauki; St. Jude Children's Research Hospital; Children's Hospital of Philadelphia","keywords":"Capsid; Biology; Virology; Computational biology; Cell biology; Virus","score_opus":0.025288169104329787,"score_gpt":0.30766485327587845,"score_spread":0.28237668417154865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405310215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8382568,0.0023510677,0.15460764,0.000142795,0.00008986545,0.00021635226,0.00028946024,0.00062199344,0.0034241206],"genre_scores_gemma":[0.935823,0.0014194923,0.05932107,0.00007334507,0.000015474725,0.000064420004,0.00044083854,0.000118978394,0.0027232673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99971706,0.000034464847,0.000025365325,0.00006350819,0.000100234305,0.000059366816],"domain_scores_gemma":[0.999892,0.000017049373,0.000032441927,0.000011615458,0.000027454053,0.000019494071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027723078,0.00038508972,0.00026935484,0.00026838583,0.00011951204,0.0004407119,0.00023198902,0.00034668003,0.0006197267],"category_scores_gemma":[0.00025398005,0.00019213,0.00028438235,0.0002470606,0.00018888514,0.00023948035,0.0002933868,0.00061956403,0.00028066445],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017737428,0.000018194163,0.00012415634,0.00003060021,0.000004259581,0.00006563021,0.000022514947,0.00033971423,0.9960853,0.00022784855,0.000048361675,0.003015745],"study_design_scores_gemma":[0.000011574751,0.00018420225,0.0006348014,0.0000035595378,0.00001675854,0.00030168725,0.000009190238,0.0029679078,0.9919224,0.000048979487,0.003889277,0.0000097786115],"about_ca_topic_score_codex":0.00093160756,"about_ca_topic_score_gemma":0.0010913085,"teacher_disagreement_score":0.00093160756,"about_ca_system_score_codex":0.00036830388,"about_ca_system_score_gemma":0.00026760067,"threshold_uncertainty_score":0.0026721954},"labels":[],"label_agreement":null},{"id":"W4405737818","doi":"10.3390/curroncol32010002","title":"Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University; Nova Scotia Health Authority; Health Sciences Centre","funders":"","keywords":"Medicine; Cytokine release syndrome; CAR T-cell therapy; Clinical trial; Retrospective cohort study; Internal medicine; Intensive care medicine; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.06510995503037549,"score_gpt":0.3864192310409812,"score_spread":0.3213092760106057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405737818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954809,0.0020050216,0.000037435802,0.00010620491,0.0000038580943,0.000036892936,0.0011864449,0.0000028633515,0.0011403527],"genre_scores_gemma":[0.9981926,0.00086215866,0.000051581137,0.00008265706,0.0000055070327,0.000010161724,0.00062566134,0.0000014923019,0.00016830792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934787,0.000092844886,0.00011974423,0.00007996253,0.00019684565,0.00016278647],"domain_scores_gemma":[0.9968183,0.00035817685,0.0016238906,0.000056119752,0.0007825843,0.00036078802],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060271047,0.00010763719,0.00023090861,0.00089998264,0.0004943961,0.0006206808,0.00030983353,0.00020528818,0.00058091554],"category_scores_gemma":[0.0020682712,0.00012731129,0.00023529529,0.0020895714,0.0003962861,0.00014244855,0.00023468585,0.00019999174,0.00008371345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001188227,0.000013365184,0.99531806,0.00007324945,0.000022725297,0.00035727985,0.00021483023,0.00006996787,0.0003020035,0.00001969864,0.00024279972,0.0032471996],"study_design_scores_gemma":[0.0000037787215,0.00006298146,0.99867463,0.000029362962,0.000013256462,0.0003827511,0.0002763963,0.000042674317,0.000052519397,0.000002569924,0.0004562686,0.0000027751435],"about_ca_topic_score_codex":0.58528095,"about_ca_topic_score_gemma":0.748849,"teacher_disagreement_score":0.41471905,"about_ca_system_score_codex":0.007405443,"about_ca_system_score_gemma":0.0049150093,"threshold_uncertainty_score":0.8343228},"labels":[],"label_agreement":null},{"id":"W4405748254","doi":"10.1016/j.jval.2024.10.642","title":"EE361 Long-Term Remission (LTR) Assumptions in Health Technology Assessments (HTAs) of Bispecific Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Following Two or More Lines of Systemic Therapy (3L+)","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Medicine; Oncology; Term (time); Lymphoma; Internal medicine; Cancer research; Physics","score_opus":0.1088455886547828,"score_gpt":0.4519538653960237,"score_spread":0.3431082767412409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748254","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8522751,0.0031295936,0.10347512,0.006045878,0.000181467,0.00070922705,0.008817875,0.0002989768,0.02506672],"genre_scores_gemma":[0.99282867,0.00011870912,0.0034949945,0.0004715148,0.00002390087,0.000102376995,0.0013290227,0.000018333105,0.0016124629],"study_design_codex":"simulation_or_modeling","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9791564,0.014714164,0.00096446864,0.0021051401,0.0017859688,0.0012738347],"domain_scores_gemma":[0.8888857,0.09688824,0.0068124565,0.0040615536,0.0024743231,0.00087761984],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.047809254,0.0007931303,0.0009990124,0.00096661656,0.0005002014,0.0027194603,0.0016965672,0.00178264,0.0047169095],"category_scores_gemma":[0.08023222,0.00041211082,0.0024644122,0.00067466934,0.0011571462,0.002968288,0.0018020364,0.0030841774,0.0006946943],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010170048,0.0007268347,0.35526624,0.00078995334,0.002945034,0.0012883944,0.0009697938,0.40014288,0.0031909528,0.0814039,0.0063443887,0.1367616],"study_design_scores_gemma":[0.0004217443,0.0038736109,0.15918122,0.00041479222,0.0014279378,0.0008270665,0.0011154152,0.7032614,0.0062196436,0.11380462,0.009298954,0.00015362483],"about_ca_topic_score_codex":0.0041517345,"about_ca_topic_score_gemma":0.003955079,"teacher_disagreement_score":0.95219076,"about_ca_system_score_codex":0.002532041,"about_ca_system_score_gemma":0.0015516039,"threshold_uncertainty_score":0.25284255},"labels":[],"label_agreement":null},{"id":"W4405748558","doi":"10.1016/j.jval.2024.10.297","title":"EE13 A Cost-Consequence Analysis of Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma Across Gulf Cooperation Council Countries","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Medicine; Lymphoma; Oncology; Cancer research; Internal medicine; Immunotherapy; Biology; Cancer","score_opus":0.051855495934935936,"score_gpt":0.33293342912135687,"score_spread":0.28107793318642094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998711,0.00021240867,0.000102328995,0.000075282405,0.0000040316077,0.000028815915,0.00022492177,0.0000029979801,0.00063819514],"genre_scores_gemma":[0.99914443,0.00007797909,0.00008736152,0.00005824373,0.0000043202544,0.000016548202,0.00036083706,0.0000026279845,0.0002476141],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99934465,0.00033031355,0.000044640627,0.00006775181,0.00007149761,0.00014113015],"domain_scores_gemma":[0.9991303,0.00036227063,0.00016461547,0.000056147765,0.0001209185,0.00016578288],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016161937,0.0003043146,0.0005973869,0.00043960544,0.0003015165,0.00079937297,0.00030158059,0.00042443525,0.0018890081],"category_scores_gemma":[0.0017276503,0.00014533778,0.0007072556,0.00085346936,0.00026313443,0.00029663113,0.0003138746,0.0005294212,0.00016002495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17420687,0.003421293,0.644324,0.0002800129,0.0021291361,0.001894708,0.00065382454,0.01990327,0.018353239,0.0012379456,0.0025799305,0.1310158],"study_design_scores_gemma":[0.0042124363,0.030608771,0.946973,0.000051663385,0.0015472609,0.00092746934,0.0007773041,0.006689747,0.003414015,0.00026723754,0.004502505,0.000028520673],"about_ca_topic_score_codex":0.010108831,"about_ca_topic_score_gemma":0.0072043496,"teacher_disagreement_score":0.010108831,"about_ca_system_score_codex":0.0017797821,"about_ca_system_score_gemma":0.0008673465,"threshold_uncertainty_score":0.020099998},"labels":[],"label_agreement":null},{"id":"W4405749862","doi":"10.1016/j.jval.2024.10.3254","title":"PCR11 Patient Reported Symptoms, Functioning, and Quality of Life (QoL) in Patients Treated With Chimeric Antigen Receptor T Cells for Hematologic Malignancy: A Systematic Review and Meta Analysis","year":2024,"lang":"en","type":"review","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Hematologic malignancy; Medicine; Chimeric antigen receptor; Meta-analysis; Quality of life (healthcare); Malignancy; Oncology; Internal medicine; Immunotherapy; Cancer; Nursing","score_opus":0.15851327232871035,"score_gpt":0.39514214647368007,"score_spread":0.23662887414496972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405749862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007590239,0.9913857,0.00017677774,0.000101094265,0.000082150655,0.0000792202,0.00040969448,0.000008945465,0.0001661833],"genre_scores_gemma":[0.19465846,0.80192626,0.0009765314,0.00088875287,0.00018454531,0.0003576312,0.0006646312,0.000011698747,0.00033157752],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975413,0.000961311,0.0007083502,0.00035492252,0.00030687478,0.00012721372],"domain_scores_gemma":[0.9952923,0.0033615371,0.0008853168,0.0001194346,0.00026281262,0.00007862686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0038331917,0.0015275045,0.009996308,0.0020125571,0.0003833009,0.001962189,0.0011327692,0.0015327177,0.0029516488],"category_scores_gemma":[0.009760357,0.00084579014,0.023419447,0.0037318694,0.00047442628,0.0008417363,0.0010403517,0.0017583367,0.00020677764],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040549515,0.000078549645,0.008635479,0.3588032,0.59726614,0.00011530337,0.000091748494,0.0004693853,0.0003409309,0.0001187042,0.0010754578,0.028950179],"study_design_scores_gemma":[0.0014387957,0.00035001585,0.0096406415,0.018681306,0.96730417,0.00010601884,0.000067185225,0.00016208409,0.00010507709,0.00014429318,0.0019636499,0.000036665868],"about_ca_topic_score_codex":0.006630401,"about_ca_topic_score_gemma":0.017682739,"teacher_disagreement_score":0.009996308,"about_ca_system_score_codex":0.0013926572,"about_ca_system_score_gemma":0.0016730473,"threshold_uncertainty_score":0.020272076},"labels":[],"label_agreement":null},{"id":"W4405750051","doi":"10.1016/j.jval.2024.10.3348","title":"PCR105 Impact of CAR T-Cell Therapy on Health Utilities for Patients Diagnosed With Diffuse Large B-Cell Lymphoma in Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Ottawa; Princess Margaret Cancer Centre; University of Waterloo; University of Toronto","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Medicine; Pediatrics; Oncology; Internal medicine","score_opus":0.03961365323178231,"score_gpt":0.3331608637186762,"score_spread":0.2935472104868939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405750051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9383511,0.0044579213,0.00022750894,0.012697673,0.00016207717,0.000087309665,0.027441502,0.000036546375,0.016538247],"genre_scores_gemma":[0.99132055,0.0012898103,0.00015299773,0.00071572565,0.000030318277,0.0000185473,0.0036800737,0.000010205234,0.002781655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99905986,0.00012657004,0.000048360598,0.000080433405,0.0002279089,0.00045679777],"domain_scores_gemma":[0.9970192,0.00029354362,0.00038900343,0.00003435427,0.0011981841,0.0010658109],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004314982,0.00021752367,0.00038086448,0.00054997695,0.0009778673,0.0014988875,0.0008357812,0.00046676956,0.004493625],"category_scores_gemma":[0.0037503254,0.00015662232,0.0009651028,0.0022760415,0.00041585593,0.0003266889,0.00054879277,0.0010890596,0.00026522347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010959512,0.00019481893,0.945717,0.00014572212,0.00032025605,0.00021352377,0.00024949416,0.0021804573,0.00018317538,0.001140252,0.018216504,0.030342873],"study_design_scores_gemma":[0.00015072696,0.00012340906,0.991339,0.00009626307,0.00019303034,0.00006233928,0.001011659,0.0018569125,0.00012416956,0.00016979317,0.0048426646,0.00002989152],"about_ca_topic_score_codex":0.9947976,"about_ca_topic_score_gemma":0.99681723,"teacher_disagreement_score":0.053109597,"about_ca_system_score_codex":0.053109597,"about_ca_system_score_gemma":0.057879433,"threshold_uncertainty_score":0.3853389},"labels":[],"label_agreement":null},{"id":"W4406033308","doi":"10.1186/s12967-024-06035-4","title":"Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells","year":2025,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Guizhou Province","keywords":"Medicine; Adverse effect; Chimeric antigen receptor; Cytokine release syndrome; Internal medicine; Cochrane Library; Randomized controlled trial; Lymphoma; Oncology; Immunotherapy; Cancer","score_opus":0.009864634279171941,"score_gpt":0.26411488638474045,"score_spread":0.2542502521055685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406033308","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23706385,0.7504526,0.0048143575,0.0011232974,0.0002726007,0.0011974921,0.0030624925,0.000044991153,0.001968296],"genre_scores_gemma":[0.94495046,0.0484393,0.003583408,0.00045745194,0.00021974565,0.0009169998,0.0011321158,0.000015014899,0.00028543247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9843307,0.007985424,0.0040695863,0.0011978662,0.0021843608,0.00023211444],"domain_scores_gemma":[0.9425239,0.040193822,0.013768574,0.0009819557,0.0020692495,0.00046243734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014722159,0.000702341,0.0031615351,0.0040083034,0.00027826964,0.0014318867,0.0008411346,0.0012275178,0.0023557362],"category_scores_gemma":[0.03860511,0.0004061625,0.015345493,0.0035117136,0.00037662336,0.0006072411,0.00072816043,0.0011506797,0.00012603047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040169742,0.00023496017,0.48623246,0.11697205,0.25176767,0.0012038252,0.0003882826,0.0027583835,0.0011103842,0.0008142048,0.0018994558,0.09644851],"study_design_scores_gemma":[0.005723668,0.0071752546,0.39726043,0.013311001,0.5533475,0.0038877702,0.00051586184,0.004920781,0.001549419,0.003117163,0.009011203,0.00017995399],"about_ca_topic_score_codex":0.0009953973,"about_ca_topic_score_gemma":0.0010294248,"teacher_disagreement_score":0.014722159,"about_ca_system_score_codex":0.0009404411,"about_ca_system_score_gemma":0.0011909821,"threshold_uncertainty_score":0.0778591},"labels":[],"label_agreement":null},{"id":"W4406080334","doi":"10.1016/s2352-3026(24)00346-6","title":"Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Multiple myeloma; Chimeric antigen receptor; Food and drug administration; Standard of care; Oncology; Overall survival; Progression-free survival; Immunotherapy; Cancer; Confidence interval; Pharmacology","score_opus":0.06945262945612482,"score_gpt":0.31280173439360864,"score_spread":0.24334910493748382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406080334","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.633569,0.039793447,0.0009038647,0.27659026,0.0043035643,0.000058833964,0.0027585865,0.00009534808,0.0419271],"genre_scores_gemma":[0.93893695,0.0049215704,0.00024518458,0.046250436,0.006066089,0.000033102322,0.0010436093,0.000014805783,0.002488268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984699,0.0005188385,0.00017146606,0.00013749622,0.00038297728,0.00031917193],"domain_scores_gemma":[0.99251527,0.003478571,0.0020967086,0.00023856382,0.0006344873,0.0010363283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014895338,0.00016426377,0.00073342293,0.00032164194,0.0005517958,0.0015160152,0.0004950256,0.0029342556,0.0028750845],"category_scores_gemma":[0.008883014,0.000115204275,0.00075439055,0.0011855401,0.0004196493,0.0006697474,0.00046008066,0.0033404452,0.00045544744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009942361,0.0008368475,0.71123064,0.0007556132,0.0011504026,0.025781723,0.0007235585,0.00242926,0.0028148668,0.0031489981,0.08125657,0.15992916],"study_design_scores_gemma":[0.00123128,0.0027953484,0.87182087,0.00055043254,0.0012262494,0.04038063,0.00085283234,0.0026906482,0.0012771172,0.0060115913,0.07099465,0.00016836626],"about_ca_topic_score_codex":0.0022483724,"about_ca_topic_score_gemma":0.003112057,"teacher_disagreement_score":0.0029342556,"about_ca_system_score_codex":0.0020148254,"about_ca_system_score_gemma":0.00075898605,"threshold_uncertainty_score":0.014618695},"labels":[],"label_agreement":null},{"id":"W4406091198","doi":"10.58931/cht.2024.3359","title":"The Evolving Landscape of DLBCL Treatment Beyond the First Line in 2024","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Line (geometry); Environmental planning; Geography","score_opus":0.018070650475495022,"score_gpt":0.29264030940429214,"score_spread":0.27456965892879714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091198","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021790087,0.5661337,0.004602032,0.32206318,0.0070600403,0.00009810105,0.0008789798,0.00028365888,0.07709025],"genre_scores_gemma":[0.1840651,0.57591087,0.012702838,0.17691007,0.015842041,0.00021273189,0.0031896683,0.00030359684,0.03086309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988109,0.00031521742,0.00012355634,0.00013478062,0.00036425944,0.0002513391],"domain_scores_gemma":[0.99758756,0.00044501008,0.00025003447,0.00007621665,0.0007352498,0.00090582663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033906323,0.00036356234,0.0005936204,0.0007825229,0.0009014502,0.003204923,0.0010271221,0.0017480912,0.0096747475],"category_scores_gemma":[0.0030576496,0.00019935376,0.0005743259,0.0008068602,0.0011314852,0.002368509,0.0015749787,0.0033998373,0.002335456],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052656117,0.00015608508,0.002390664,0.0013216775,0.0000550412,0.00059578323,0.0002205258,0.0009124168,0.0034445906,0.02905358,0.124242224,0.83708084],"study_design_scores_gemma":[0.000088565146,0.00039089296,0.002616049,0.0011423626,0.000039219707,0.0013197998,0.00022964492,0.00044284176,0.0009482168,0.006640141,0.98611706,0.000025216834],"about_ca_topic_score_codex":0.009198543,"about_ca_topic_score_gemma":0.026792591,"teacher_disagreement_score":0.0096747475,"about_ca_system_score_codex":0.007645697,"about_ca_system_score_gemma":0.0070643877,"threshold_uncertainty_score":0.055473685},"labels":[],"label_agreement":null},{"id":"W4406127406","doi":"10.1177/10781552241306741","title":"Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba","year":2025,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Daratumumab; Medicine; Tolerability; Retrospective cohort study; Toxicity; Subcutaneous injection; Internal medicine; Emergency medicine; Oncology; Surgery; Multiple myeloma; Adverse effect","score_opus":0.054436104547021545,"score_gpt":0.45732928911255444,"score_spread":0.4028931845655329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406127406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979347,0.00054913183,0.00026746103,0.000028677485,0.000003372548,0.00014501317,0.00043433212,0.0000134648835,0.00062392745],"genre_scores_gemma":[0.9977209,0.0005222408,0.00050464063,0.00005387671,0.0000063339535,0.0000934915,0.00058705296,0.000008373745,0.000503133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990375,0.00040301387,0.000054990745,0.00012660971,0.00025780147,0.0001199849],"domain_scores_gemma":[0.9974903,0.00073520397,0.0007055939,0.00018679445,0.000678224,0.00020385583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017030354,0.00046796683,0.00035840334,0.0012434302,0.0004507257,0.0008094924,0.0006684965,0.00023482955,0.0016512413],"category_scores_gemma":[0.0029264914,0.000259642,0.0007504319,0.0014836009,0.00053996575,0.00020033201,0.00044592962,0.00038207276,0.00028356633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020706352,0.0026814588,0.8832308,0.00056617317,0.0010688136,0.0010395935,0.00095487386,0.013244539,0.032194357,0.00033365248,0.0010665719,0.042912867],"study_design_scores_gemma":[0.00067923014,0.0135604525,0.9624958,0.00006413175,0.00070628966,0.0007208969,0.0007337978,0.0100580035,0.008690337,0.000083903375,0.0021424058,0.00006483402],"about_ca_topic_score_codex":0.19720061,"about_ca_topic_score_gemma":0.18856698,"teacher_disagreement_score":0.8027994,"about_ca_system_score_codex":0.0073177926,"about_ca_system_score_gemma":0.002308669,"threshold_uncertainty_score":0.39210552},"labels":[],"label_agreement":null},{"id":"W4406211672","doi":"10.33540/2707","title":"Clinical Outcome after Cellular Therapies in Children with Acute Leukemia","year":2025,"lang":"en","type":"dissertation","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Intensive care medicine; Disease; Leukemia; Acute leukemia; Transplantation; Hematopoietic stem cell transplantation; Immune system; Oncology; Immunology; Internal medicine","score_opus":0.025660354702896716,"score_gpt":0.3757440132774246,"score_spread":0.3500836585745279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406211672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97235495,0.012165399,0.00031328303,0.0006965707,0.00006387795,0.00005272111,0.00084228895,0.000017995539,0.013492923],"genre_scores_gemma":[0.98742783,0.008577545,0.00032026053,0.00015080716,0.000039754093,0.0000471673,0.0009036728,0.0000058587543,0.0025271468],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9998733,0.00002980585,0.000007715268,0.0000124966555,0.00004038789,0.00003627041],"domain_scores_gemma":[0.9998568,0.000028474557,0.00004408628,0.0000047510666,0.00002383526,0.000041997355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028305178,0.00009629092,0.00015177795,0.00020884945,0.00016354764,0.000340916,0.00007563619,0.00011194337,0.001339854],"category_scores_gemma":[0.0005622459,0.000035240722,0.00015082922,0.0002524516,0.00014584018,0.00010191098,0.00024026893,0.00024490344,0.00032780206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024362546,0.0007971445,0.4650007,0.0008734821,0.0001506023,0.0024891791,0.0018766057,0.0014353467,0.009871925,0.0020936357,0.015854241,0.49712095],"study_design_scores_gemma":[0.00013340422,0.004164567,0.9301241,0.00048113283,0.00018002589,0.005800665,0.0014705432,0.00036011034,0.008008655,0.0008692902,0.048388034,0.000019502108],"about_ca_topic_score_codex":0.00069423,"about_ca_topic_score_gemma":0.0015310541,"teacher_disagreement_score":0.001339854,"about_ca_system_score_codex":0.000424532,"about_ca_system_score_gemma":0.0004970372,"threshold_uncertainty_score":0.0044822693},"labels":[],"label_agreement":null},{"id":"W4406226722","doi":"10.54254/2753-8818/2024.la19836","title":"On-target off-tumor toxicity from HER2-targeting chimeric antigen receptor (CAR) engineered T cell therapy: current solutions","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Toxicity; Current (fluid); Antigen; Cancer research; Receptor; Cell therapy; CAR T-cell therapy; Medicine; Immunotherapy; Cell; Immunology; Biology; Internal medicine; Immune system; Engineering; Biochemistry","score_opus":0.01086847989251262,"score_gpt":0.28991178859551886,"score_spread":0.27904330870300625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406226722","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007016021,0.9707281,0.011384216,0.0037082199,0.0004932256,0.00006367112,0.000065463486,0.0000853261,0.0064557977],"genre_scores_gemma":[0.036806267,0.95266795,0.0055468497,0.0015531606,0.0003582345,0.000098595236,0.00010685624,0.000017599907,0.0028445707],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997477,0.000054750097,0.00002328555,0.00004001063,0.0000917783,0.000042542342],"domain_scores_gemma":[0.9997919,0.00009780576,0.00003927859,0.000009096537,0.000046458907,0.000015436884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008000584,0.0005467544,0.00092236773,0.0006467036,0.00034927775,0.001407268,0.0006689831,0.0011463211,0.0025034775],"category_scores_gemma":[0.00049373624,0.00022827541,0.0006935572,0.000450941,0.00055807445,0.0016272306,0.0006662745,0.0018396633,0.0007026333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029006603,0.00031672008,0.0005964713,0.016164893,0.00015548001,0.0006301422,0.00030766084,0.0027631824,0.07205322,0.032947987,0.01336126,0.86041296],"study_design_scores_gemma":[0.00009505701,0.0016657929,0.0011927306,0.004078878,0.00040423413,0.003026207,0.0005350224,0.0031832142,0.06389952,0.028675217,0.8931451,0.00009916145],"about_ca_topic_score_codex":0.00038732693,"about_ca_topic_score_gemma":0.000871646,"teacher_disagreement_score":0.0025034775,"about_ca_system_score_codex":0.00066773436,"about_ca_system_score_gemma":0.0009391105,"threshold_uncertainty_score":0.008374989},"labels":[],"label_agreement":null},{"id":"W4406226749","doi":"10.54254/2753-8818/2024.la19838","title":"Challenges and innovations in managing cytokine release syndrome in CAR-T therapy: mechanisms, clinical impact, and future directions","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytokine; Cytokine release syndrome; Medicine; Intensive care medicine; Immunology; Immunotherapy; Immune system","score_opus":0.021885036358453975,"score_gpt":0.36297704502978617,"score_spread":0.3410920086713322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406226749","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025789754,0.95027566,0.0067053903,0.035298962,0.0015350935,0.00004159693,0.000037107537,0.000059279864,0.0034678858],"genre_scores_gemma":[0.027050162,0.94454926,0.010298238,0.010481726,0.005954723,0.00014224436,0.00008249676,0.000023899438,0.0014173589],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880135,0.00051388214,0.00014263162,0.0001683176,0.00023366312,0.00014019632],"domain_scores_gemma":[0.99630153,0.0022956468,0.0003211135,0.00013167216,0.0006528563,0.0002970534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005571388,0.00081751635,0.0014750726,0.0011532112,0.00070289953,0.0032251673,0.0014155795,0.0035873808,0.003931346],"category_scores_gemma":[0.003932543,0.0002687579,0.0011472093,0.0008682101,0.002773076,0.005516594,0.0013086917,0.005848663,0.0010914723],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048028308,0.000608909,0.002618844,0.011191624,0.00015705408,0.001583129,0.0005839316,0.0019994148,0.007207225,0.050362665,0.027793232,0.8954137],"study_design_scores_gemma":[0.00027867957,0.002275831,0.0032807726,0.011980693,0.0005976617,0.0089521585,0.0032759937,0.004937483,0.007937748,0.11384351,0.8424393,0.0002001706],"about_ca_topic_score_codex":0.0009223656,"about_ca_topic_score_gemma":0.0018071935,"teacher_disagreement_score":0.005571388,"about_ca_system_score_codex":0.0011787821,"about_ca_system_score_gemma":0.0045183487,"threshold_uncertainty_score":0.029464722},"labels":[],"label_agreement":null},{"id":"W4406226940","doi":"10.1002/mdc3.14335","title":"Parkinsonism and Bilateral Facial Palsy after Chimeric Antigen Receptor T‐Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Movement Disorders Clinical Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Parkinsonism; Plasma cell dyscrasia; Multiple myeloma; Bortezomib; Internal medicine; Immunology; Antibody; Disease","score_opus":0.03227393156992773,"score_gpt":0.3961809974149553,"score_spread":0.3639070658450276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406226940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9490868,0.007894866,0.005554538,0.004438874,0.00033572715,0.00032549445,0.00037305988,0.0007106788,0.03127999],"genre_scores_gemma":[0.9928925,0.0013722196,0.000616767,0.0017403299,0.00015688765,0.0000340135,0.00013600173,0.000020173195,0.0030310976],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99972564,0.000028388074,0.000021250295,0.00005050115,0.000059216745,0.00011505781],"domain_scores_gemma":[0.9994747,0.000109991175,0.00015622897,0.00004706842,0.000051718955,0.00016033562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025934906,0.0010400148,0.0009868541,0.00054880296,0.000916401,0.00043435488,0.0005928328,0.0018718239,0.0013121765],"category_scores_gemma":[0.0008888773,0.00029480306,0.0006518069,0.0004363084,0.00077449373,0.00053800305,0.00054804573,0.002085475,0.0005119755],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021658631,0.00010413265,0.006261532,0.000055303586,0.000032889988,0.982444,0.000067355286,0.0002937416,0.0021802394,0.00025055563,0.0006714787,0.007422137],"study_design_scores_gemma":[0.00009903659,0.0006100877,0.018904349,0.000040077684,0.000042817726,0.97533834,0.000050037273,0.001129564,0.0017295142,0.00039063208,0.0016515083,0.000013991067],"about_ca_topic_score_codex":0.00537995,"about_ca_topic_score_gemma":0.00759237,"teacher_disagreement_score":0.00537995,"about_ca_system_score_codex":0.0024171292,"about_ca_system_score_gemma":0.0010944455,"threshold_uncertainty_score":0.017537594},"labels":[],"label_agreement":null},{"id":"W4406316580","doi":"10.1200/jco-24-02081","title":"Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Tumor microenvironment; Colorectal cancer; T cell; Cancer; Cancer research; Immune system; Oncology; Immunology; Internal medicine","score_opus":0.14160946337063576,"score_gpt":0.5378796703098482,"score_spread":0.39627020693921244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406316580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018039682,0.9984785,0.00020838015,0.00029136695,0.00019508654,0.00000517223,0.000008791307,0.000007159274,0.00062522787],"genre_scores_gemma":[0.0010578674,0.99787164,0.00025375272,0.00024199382,0.00014239602,0.0000067281367,0.000021265227,0.0000015781762,0.0004026355],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99985003,0.0000311248,0.000014363462,0.00002310146,0.000059261463,0.000022051729],"domain_scores_gemma":[0.99980813,0.00009391475,0.000019465851,0.0000055412006,0.000047657402,0.000025295501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007204291,0.00065083976,0.00090702536,0.0014670305,0.00017594661,0.00075021706,0.0006265312,0.00095642835,0.0020245605],"category_scores_gemma":[0.0005564717,0.00023863679,0.00057729497,0.0012363007,0.0004510371,0.0012469111,0.00058458804,0.0025686047,0.00107408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014539131,0.00013014287,0.00014872536,0.014396871,0.000100398815,0.00023318862,0.00007853497,0.00084541144,0.0052467315,0.0086299,0.027913256,0.9421314],"study_design_scores_gemma":[0.000055758475,0.00025892133,0.00045185714,0.0022867147,0.00010473576,0.0008385587,0.000038375892,0.0002042739,0.0012466353,0.00262231,0.9918738,0.000017864359],"about_ca_topic_score_codex":0.0006859785,"about_ca_topic_score_gemma":0.0012992498,"teacher_disagreement_score":0.0020245605,"about_ca_system_score_codex":0.0005074373,"about_ca_system_score_gemma":0.00090299454,"threshold_uncertainty_score":0.006772816},"labels":[],"label_agreement":null},{"id":"W4406400396","doi":"10.54254/2753-8818/2025.gu20456","title":"CRISPR/Cas9-Enhanced CAR-T Cell Therapy for Hematological Malignancies","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"CRISPR; CAR T-cell therapy; Medicine; Cancer research; Biology; Internal medicine; Cancer; Immunotherapy; Chimeric antigen receptor; Genetics; Gene","score_opus":0.013131264166333605,"score_gpt":0.3319525780267485,"score_spread":0.3188213138604149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406400396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6183508,0.059544053,0.2673773,0.0031756775,0.00095500733,0.000792136,0.0014317338,0.0034108858,0.044962402],"genre_scores_gemma":[0.9563884,0.010493798,0.024791695,0.0005598135,0.000057057594,0.00019103965,0.000491326,0.000065597706,0.006961211],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99981135,0.000039002083,0.000016023836,0.000040117986,0.00006334649,0.000030287845],"domain_scores_gemma":[0.9999503,0.000011587434,0.000011951132,0.000007772123,0.000009623274,0.000008790532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021179911,0.00029064593,0.00029942015,0.00035268647,0.00019476931,0.00038151315,0.00031022695,0.00044011176,0.0022317148],"category_scores_gemma":[0.00018655846,0.00010555693,0.00031663428,0.00019842187,0.0002967935,0.00026317406,0.0003219039,0.00075153616,0.00040973263],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034359368,0.00019755328,0.0008963087,0.00070805877,0.000071125345,0.0005506306,0.00008167808,0.0026408273,0.87648624,0.0060031656,0.0040633245,0.10795745],"study_design_scores_gemma":[0.00018683673,0.0010968136,0.0023737957,0.00008515315,0.00014966208,0.0032049739,0.00006978217,0.012314725,0.88988024,0.002079342,0.08852153,0.000037208887],"about_ca_topic_score_codex":0.0008634248,"about_ca_topic_score_gemma":0.0012360853,"teacher_disagreement_score":0.0022317148,"about_ca_system_score_codex":0.00040269017,"about_ca_system_score_gemma":0.0005746763,"threshold_uncertainty_score":0.0074658394},"labels":[],"label_agreement":null},{"id":"W4406447454","doi":"10.1016/j.yonc.2013.08.019","title":"10.1016/j.yonc.2013.08.019","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cytokine; Blinatumomab; Cytokine release syndrome; Macrophage activation syndrome; Immunology; Immunotherapy; CD19; Immune system","score_opus":0.014059187987949388,"score_gpt":0.24606730121849044,"score_spread":0.23200811323054105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406447454","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0055236956,0.0124743115,0.0048090946,0.007627885,0.0026218307,0.00011581934,0.0022055192,0.0017845704,0.9628373],"genre_scores_gemma":[0.013703256,0.0037433566,0.00214604,0.001550003,0.00052813796,0.00007334726,0.0015425325,0.00026931107,0.9764441],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997347,0.000021801136,0.000015886368,0.0000784765,0.000081607,0.00006749901],"domain_scores_gemma":[0.99917346,0.000117085096,0.00008116832,0.000058037323,0.00016368486,0.00040660406],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006072205,0.0010223673,0.0006183323,0.0014579305,0.0010473876,0.0030905043,0.0010051008,0.0030812817,0.8798241],"category_scores_gemma":[0.0011282407,0.00037803233,0.00061340793,0.0006739798,0.0010101468,0.0017450341,0.0012178766,0.0015621769,0.81407356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004011578,0.00027883003,0.0033831007,0.00045561144,0.00004608062,0.00048072365,0.00013690983,0.00031133636,0.003058689,0.008081079,0.28810912,0.6952575],"study_design_scores_gemma":[0.000051353905,0.00011801304,0.00339711,0.0005188849,0.00003416591,0.0024656847,0.00019950944,0.00023913452,0.0009849893,0.003963054,0.9880072,0.000020934574],"about_ca_topic_score_codex":0.0018088311,"about_ca_topic_score_gemma":0.0020662704,"teacher_disagreement_score":0.1201759,"about_ca_system_score_codex":0.00095042156,"about_ca_system_score_gemma":0.0013445063,"threshold_uncertainty_score":0.17141634},"labels":[],"label_agreement":null},{"id":"W4406520193","doi":"10.1016/s0765-2046(98)80225-6","title":"10.1016/s0765-2046(98)80225-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lymphoma; Virology; Medicine; Family medicine; Immunology","score_opus":0.015552041403016987,"score_gpt":0.25098287916850404,"score_spread":0.23543083776548704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406520193","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005257115,0.0005538732,0.0006797969,0.00046543355,0.0003538516,0.00013970373,0.0005903086,0.0007671499,0.99592423],"genre_scores_gemma":[0.0005475305,0.00022661492,0.0003177409,0.00020676131,0.00007429053,0.000074792835,0.00032152957,0.00011585312,0.9981148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930716,0.000042728236,0.00005637691,0.00024627263,0.0001882978,0.00015919522],"domain_scores_gemma":[0.9977704,0.0005897254,0.00015574781,0.00021695839,0.00041718766,0.0008501048],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011911625,0.0031647496,0.002262217,0.0029926766,0.0026460108,0.0040820655,0.0035453949,0.006589398,0.9881242],"category_scores_gemma":[0.0015822547,0.0010464286,0.0018324824,0.0021416233,0.0022694524,0.0051739123,0.0035768696,0.003307782,0.9924206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000613164,0.00033797155,0.0008445853,0.00080988224,0.000050708666,0.00031137685,0.00013418845,0.00049219193,0.0032467742,0.0060607563,0.33178252,0.655316],"study_design_scores_gemma":[0.00008848708,0.00018679304,0.0007651918,0.000330315,0.00001752849,0.00043825904,0.000119643686,0.00020540162,0.00047667898,0.00067812507,0.9966678,0.000025888485],"about_ca_topic_score_codex":0.0030629127,"about_ca_topic_score_gemma":0.0024848804,"teacher_disagreement_score":0.011875808,"about_ca_system_score_codex":0.0011101348,"about_ca_system_score_gemma":0.0011956339,"threshold_uncertainty_score":0.016939402},"labels":[],"label_agreement":null},{"id":"W4406544289","doi":"10.3389/fimmu.2024.1491341","title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"Natural Science Foundation of Tianjin City","keywords":"Myeloid leukemia; Stem cell; Medicine; Haematopoiesis; Hematopoietic stem cell transplantation; Transplantation; Leukemia; Immunology; Cancer research; Internal medicine; Biology","score_opus":0.01739932337425429,"score_gpt":0.28432998280340366,"score_spread":0.2669306594291494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406544289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979426,0.0009560045,0.0005632538,0.00004220005,0.00001645915,0.00007082683,0.00006899952,0.000030120265,0.00030958376],"genre_scores_gemma":[0.99867237,0.00031738976,0.0004262011,0.000053496886,0.000012183581,0.00007752532,0.00020708978,0.000004190472,0.00022970018],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987245,0.000031468197,0.000008836806,0.000024326064,0.000027276732,0.000035657224],"domain_scores_gemma":[0.9999089,0.00001149856,0.000023102468,0.000012762606,0.0000074261247,0.00003624069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030201537,0.00021486501,0.00046662317,0.00016507489,0.00013878215,0.00033560264,0.00023250763,0.00018054269,0.0010990368],"category_scores_gemma":[0.00020301521,0.000061380524,0.00019285279,0.00009531542,0.00019764957,0.000120348595,0.0002579796,0.0005111361,0.00021747223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01601903,0.0048318524,0.040022258,0.0006893566,0.00019245264,0.0012544428,0.0004023204,0.0026481594,0.72855276,0.00080059626,0.0019545325,0.20263231],"study_design_scores_gemma":[0.006614107,0.12989666,0.105915755,0.00013286714,0.0008369183,0.008325706,0.00039803144,0.01018244,0.7110497,0.00081927824,0.0257741,0.00005437392],"about_ca_topic_score_codex":0.00015656948,"about_ca_topic_score_gemma":0.0002942841,"teacher_disagreement_score":0.0010990368,"about_ca_system_score_codex":0.0002483231,"about_ca_system_score_gemma":0.0003317726,"threshold_uncertainty_score":0.0036767125},"labels":[],"label_agreement":null},{"id":"W4406550256","doi":"10.1016/s1541-9800(05)70314-8","title":"10.1016/s1541-9800(05)70314-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computational biology; Business; Computer science; Biology","score_opus":0.014568551095336448,"score_gpt":0.2478379553560473,"score_spread":0.23326940426071086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550256","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059799873,0.0006238404,0.0007655683,0.0005724356,0.00040946587,0.00012432557,0.0006940794,0.0007772034,0.99543506],"genre_scores_gemma":[0.00052354624,0.00020969278,0.00029926762,0.00016709686,0.000070679685,0.00004900982,0.00035176732,0.00009751164,0.99823135],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994821,0.00003217903,0.000038729017,0.00017327766,0.00015470212,0.00011910199],"domain_scores_gemma":[0.9982254,0.00043621106,0.00010995798,0.00015477322,0.0003500845,0.0007235424],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00084938924,0.0025414967,0.0015282102,0.0023021267,0.0019686064,0.0030170628,0.002613285,0.005406887,0.9848555],"category_scores_gemma":[0.0011964958,0.0007683823,0.0014089933,0.0015921065,0.0013508191,0.0036701753,0.0025546777,0.0026304366,0.9883796],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004897387,0.00030975204,0.00069395395,0.0005784116,0.000037320813,0.0002608569,0.00008524418,0.0003743465,0.0035123164,0.004315428,0.3058823,0.68346024],"study_design_scores_gemma":[0.00007815386,0.0001547265,0.0008678406,0.00024449942,0.000014635072,0.00037651163,0.00008716649,0.00018066897,0.0006681582,0.0005426164,0.99676466,0.000020270632],"about_ca_topic_score_codex":0.002878556,"about_ca_topic_score_gemma":0.0024518685,"teacher_disagreement_score":0.015144527,"about_ca_system_score_codex":0.0009244494,"about_ca_system_score_gemma":0.0011371375,"threshold_uncertainty_score":0.021601856},"labels":[],"label_agreement":null},{"id":"W4406571069","doi":"10.1101/2025.01.17.24311574","title":"Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ontario Ministry of Research and Innovation","keywords":"Repertoire; Melanoma; Product (mathematics); Adoptive cell transfer; Cell; Cancer research; Medicine; Biology; T cell; Immunology; Genetics; Mathematics; Art; Immune system","score_opus":0.022419740516605384,"score_gpt":0.29220685984398703,"score_spread":0.26978711932738164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406571069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972651,0.00046071215,0.0017070022,0.00001322406,0.0000074395775,0.000019676021,0.0001490297,0.000028504839,0.00034924442],"genre_scores_gemma":[0.9978555,0.0001600397,0.0012249056,0.000033662025,0.000008440173,0.000035637284,0.00026244443,0.000007692535,0.000411558],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99987614,0.000025105528,0.000005750898,0.000043593907,0.00003130536,0.000018103747],"domain_scores_gemma":[0.9998568,0.00003907553,0.000030698888,0.000017529086,0.00002868251,0.000027084567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021501728,0.00015447573,0.0002670178,0.0002269715,0.000120536824,0.00024118954,0.000096770316,0.00016516511,0.0008665588],"category_scores_gemma":[0.00027848463,0.00008946452,0.00012795461,0.00015038991,0.000121464844,0.00013410239,0.00012249994,0.0003104897,0.0002372495],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013377562,0.00012198547,0.020841714,0.00006347308,0.000021683896,0.00008242882,0.0001100502,0.00066462124,0.9565999,0.000022901535,0.00012572635,0.020007707],"study_design_scores_gemma":[0.00006675313,0.008665834,0.32729995,0.000024594277,0.00014587733,0.0014253828,0.00031281446,0.012054171,0.646948,0.00014900937,0.0028876679,0.000019947141],"about_ca_topic_score_codex":0.00020801039,"about_ca_topic_score_gemma":0.0002455415,"teacher_disagreement_score":0.0008665588,"about_ca_system_score_codex":0.00010287958,"about_ca_system_score_gemma":0.00007408817,"threshold_uncertainty_score":0.0028989315},"labels":[],"label_agreement":null},{"id":"W4406584151","doi":"10.1101/2025.01.17.25320737","title":"WITHDRAWN: Novel Risk Factors for Predicting Immune Effector Cell-Associated Neurotoxicity Syndrome","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Neurotoxicity; Effector; Immune system; Neuroscience; Medicine; Immunology; Psychology; Internal medicine; Toxicity","score_opus":0.02835711639482958,"score_gpt":0.30482327721100133,"score_spread":0.27646616081617176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99361295,0.0012449985,0.00048282812,0.00050082227,0.00007008515,0.000034422275,0.0011370128,0.00003144066,0.002885398],"genre_scores_gemma":[0.9979081,0.00021322287,0.0002453352,0.00011887644,0.0001083163,0.00001119295,0.0007108473,0.0000054079132,0.000678677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99967897,0.00006516322,0.000061196966,0.000059429185,0.000086894026,0.000048348313],"domain_scores_gemma":[0.99846953,0.00024040003,0.00071053434,0.0000636982,0.00028750775,0.00022831748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004394383,0.00043046087,0.00032515702,0.00064452505,0.00041258373,0.00062777835,0.00030859423,0.0004586761,0.0044558574],"category_scores_gemma":[0.0026951956,0.00008604946,0.00030768703,0.00072574575,0.00021123141,0.00032896857,0.00026288745,0.0006364823,0.00070176297],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001637601,0.00002456611,0.9957033,0.000013328014,0.00002647995,0.00036974173,0.000012477634,0.000034685094,0.0003532812,0.000017971272,0.00031730984,0.002963126],"study_design_scores_gemma":[0.000020206075,0.00021847592,0.9951331,0.000018313065,0.000050024588,0.0029476788,0.00006234585,0.00053359533,0.00023445996,0.00008406682,0.0006927382,0.0000049045584],"about_ca_topic_score_codex":0.0019076304,"about_ca_topic_score_gemma":0.0023373745,"teacher_disagreement_score":0.0044558574,"about_ca_system_score_codex":0.0003140524,"about_ca_system_score_gemma":0.0004805924,"threshold_uncertainty_score":0.014906347},"labels":[],"label_agreement":null},{"id":"W4406665586","doi":"10.1158/1078-0432.ccr-24-2753","title":"Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aurinia (Canada)","funders":"","keywords":"Multiple myeloma; Cmax; Population; Medicine; Pharmacokinetics; Oncology; Immunology; Pharmacology; Internal medicine","score_opus":0.08116083786380267,"score_gpt":0.4550818260549206,"score_spread":0.3739209881911179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406665586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99827063,0.00025732466,0.0011695342,0.000028635315,0.0000020034329,0.00003117873,0.000070716516,0.00001935876,0.00015057556],"genre_scores_gemma":[0.99921954,0.00009231473,0.00043846044,0.00003362976,0.0000035292032,0.000020455103,0.00011574102,0.0000038534117,0.00007246322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996729,0.00018257284,0.000011858569,0.000059439255,0.00005152351,0.000021768728],"domain_scores_gemma":[0.9995394,0.0001968475,0.0001586373,0.000044531233,0.00001996508,0.00004065662],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083266443,0.00031734296,0.0005785542,0.000116664974,0.00009557646,0.0004015706,0.00027851065,0.00032546994,0.00038759952],"category_scores_gemma":[0.0016363941,0.00021048992,0.00039629178,0.00016282054,0.00020863388,0.00042368541,0.00022592931,0.0006225568,0.000088494184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117441505,0.005800056,0.31808737,0.00049267994,0.0020475462,0.0007979402,0.0010772825,0.2334445,0.12316291,0.00090176146,0.0014893913,0.19525708],"study_design_scores_gemma":[0.008944551,0.17158534,0.38697496,0.000053954118,0.0017661569,0.0017681976,0.0004137948,0.37321705,0.04805226,0.001211089,0.0058930814,0.000119468765],"about_ca_topic_score_codex":0.0010873486,"about_ca_topic_score_gemma":0.0008188745,"teacher_disagreement_score":0.0010873486,"about_ca_system_score_codex":0.0006000621,"about_ca_system_score_gemma":0.00046520974,"threshold_uncertainty_score":0.004403591},"labels":[],"label_agreement":null},{"id":"W4406683378","doi":"10.1136/jitc-2024-010207","title":"Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Cancer immunotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.12186916104096639,"score_gpt":0.48237948766339306,"score_spread":0.36051032662242666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406683378","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012779688,0.30630845,0.008646892,0.6298445,0.029899066,0.000061283085,0.00011122276,0.00016492899,0.02368563],"genre_scores_gemma":[0.043325227,0.53704476,0.014735572,0.31627932,0.07028754,0.00021503,0.0002159315,0.00023416714,0.017662408],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99622583,0.001446913,0.00024775194,0.00039992132,0.0013017685,0.00037791548],"domain_scores_gemma":[0.99135596,0.004559378,0.00033804018,0.0006186314,0.0020100817,0.0011179327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010075922,0.0006892042,0.0008922576,0.0014271655,0.0016683779,0.0066932095,0.0016815532,0.006831534,0.0062532304],"category_scores_gemma":[0.009915668,0.00031434922,0.00089547614,0.00088592945,0.009074269,0.008931482,0.0036603943,0.02018693,0.002477722],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015706153,0.00018824695,0.00038770842,0.0014728571,0.000051081835,0.00040277577,0.0007517575,0.0009562841,0.001708646,0.30661497,0.3842898,0.30301896],"study_design_scores_gemma":[0.000032832002,0.00013061718,0.00015254451,0.0012154025,0.000018290568,0.00046353298,0.0003120288,0.00027668432,0.0004910171,0.04923882,0.94764227,0.000026041052],"about_ca_topic_score_codex":0.0024293547,"about_ca_topic_score_gemma":0.0047191796,"teacher_disagreement_score":0.010075922,"about_ca_system_score_codex":0.0036985835,"about_ca_system_score_gemma":0.008246149,"threshold_uncertainty_score":0.053287208},"labels":[],"label_agreement":null},{"id":"W4406772134","doi":"10.1002/pbc.31516","title":"Access to CARe: A Narrative of Real‐World Medical Decision‐Making to Access Chimeric Antigen Receptor (CAR) T‐Cell Therapy in Children, Adolescents, and Young Adults","year":2025,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Intramural Research Program; NIH Clinical Center; National Institutes of Health","keywords":"Chimeric antigen receptor; Medicine; Narrative review; Refractory (planetary science); Clinical trial; Oncology; Pediatrics; Immunotherapy; Intensive care medicine; Internal medicine; Cancer","score_opus":0.028568326256725365,"score_gpt":0.4049604464300942,"score_spread":0.37639212017336887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406772134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008030404,0.969884,0.0005152788,0.022903163,0.0007385087,0.000025866686,0.000034881767,0.000006413986,0.0050887633],"genre_scores_gemma":[0.013488204,0.9762907,0.0011907306,0.00734305,0.0007418081,0.000062620624,0.00003744769,0.000005793657,0.0008395512],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9980685,0.0013049776,0.00018121835,0.00008870969,0.0002615262,0.000095096766],"domain_scores_gemma":[0.9944425,0.004586533,0.00040450366,0.000055755077,0.000343124,0.0001676721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036588816,0.0005240488,0.0007075162,0.0010949022,0.0007192468,0.0027625917,0.00076974795,0.0026901313,0.0020506792],"category_scores_gemma":[0.009815882,0.00027299454,0.00058756873,0.0014542172,0.0013046806,0.0031418323,0.0014379648,0.0034345768,0.0004169265],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000107918924,0.000073760064,0.0007568135,0.040057328,0.00023692795,0.0017884441,0.006573191,0.0010273354,0.00036549263,0.09479295,0.12600738,0.72821254],"study_design_scores_gemma":[0.000024287821,0.000056107136,0.00063315756,0.05201186,0.00015541725,0.003208951,0.0031410225,0.00020333154,0.00015860065,0.012388622,0.92797345,0.00004518149],"about_ca_topic_score_codex":0.0031340742,"about_ca_topic_score_gemma":0.008163287,"teacher_disagreement_score":0.0036588816,"about_ca_system_score_codex":0.0028688686,"about_ca_system_score_gemma":0.0055757384,"threshold_uncertainty_score":0.020815253},"labels":[],"label_agreement":null},{"id":"W4406795493","doi":"10.2196/71293","title":"Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)”","year":2025,"lang":"en","type":"article","venue":"JMIRx Med","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Chimeric antigen receptor; Meta-analysis; Glioblastoma; Medicine; Clinical trial; Oncology; Internal medicine; Cancer research; Immunotherapy; Computer science; Cancer; World Wide Web","score_opus":0.2552106420503055,"score_gpt":0.540461303106882,"score_spread":0.2852506610565765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406795493","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07016674,0.28068107,0.03436804,0.25620684,0.17153081,0.014970047,0.14549537,0.002469886,0.024111208],"genre_scores_gemma":[0.63645655,0.060027707,0.030590983,0.076858155,0.094996884,0.010384027,0.05937079,0.0033620785,0.02795279],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.89352953,0.07521375,0.0111936545,0.007863107,0.010738153,0.0014617597],"domain_scores_gemma":[0.61769724,0.2405741,0.034768388,0.026520075,0.076081626,0.0043586106],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.10355299,0.002032361,0.0070444033,0.0030609334,0.001528259,0.0044783545,0.003028722,0.0047851284,0.025868382],"category_scores_gemma":[0.3803183,0.0015899908,0.017987087,0.0044150697,0.0016898626,0.0026192002,0.0022005467,0.0031486289,0.0042778715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030921757,0.00012238805,0.019966055,0.10971936,0.2655373,0.00060898456,0.00061054656,0.0015080535,0.0019144166,0.0016994112,0.4646515,0.102740236],"study_design_scores_gemma":[0.057627447,0.0024609878,0.08335547,0.030236928,0.3995146,0.0011520418,0.00042897067,0.00573084,0.0039836857,0.014160373,0.40071753,0.00063108926],"about_ca_topic_score_codex":0.0050721723,"about_ca_topic_score_gemma":0.0057871314,"teacher_disagreement_score":0.896447,"about_ca_system_score_codex":0.0023208228,"about_ca_system_score_gemma":0.007908747,"threshold_uncertainty_score":0.5476471},"labels":[],"label_agreement":null},{"id":"W4406802045","doi":"10.14309/crj.0000000000001597","title":"Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"ACG Case Reports Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Refractory (planetary science); Lymphoma; Antigen; Complication; Cell therapy; Mantle cell lymphoma; Immunology; Cancer research; Cell; Immune system; Internal medicine","score_opus":0.028581338956687092,"score_gpt":0.3232871997219937,"score_spread":0.29470586076530664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406802045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9465468,0.012736242,0.0077343313,0.0076004807,0.0015948683,0.000398641,0.00064860645,0.00080056547,0.021939557],"genre_scores_gemma":[0.9918657,0.0017933331,0.0011050011,0.0014149457,0.0014792762,0.00004275703,0.00015748711,0.000050124174,0.0020913908],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9991097,0.00010693783,0.00007292742,0.00017953296,0.00012368054,0.0004072702],"domain_scores_gemma":[0.9970253,0.00081053353,0.0005586905,0.00041330664,0.00017161835,0.0010205194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042823254,0.00200595,0.001913374,0.0026379041,0.0025919753,0.0021079318,0.0015611597,0.008220933,0.0029846178],"category_scores_gemma":[0.0035197288,0.0012010954,0.0021138238,0.00216215,0.0019271007,0.0019883078,0.00192642,0.005070478,0.0012249507],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025797985,0.000037076396,0.0017174253,0.000020196305,0.000008287045,0.99682367,0.000091266185,0.000046528316,0.00029444235,0.00014511224,0.00025228356,0.0005379706],"study_design_scores_gemma":[0.000015989972,0.00006332835,0.0021136496,0.000009688526,0.000012341924,0.9968035,0.000052681455,0.00014766428,0.00022193391,0.00009288145,0.00045591936,0.000010257237],"about_ca_topic_score_codex":0.0028360444,"about_ca_topic_score_gemma":0.0029104606,"teacher_disagreement_score":0.008220933,"about_ca_system_score_codex":0.0015626492,"about_ca_system_score_gemma":0.0010271706,"threshold_uncertainty_score":0.011337936},"labels":[],"label_agreement":null},{"id":"W4406848242","doi":"10.1038/s41375-024-02482-6","title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","year":2025,"lang":"en","type":"review","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Multiple myeloma; Medicine; Antigen; Oncology; Immunology; Internal medicine; Immune system","score_opus":0.08323822165411887,"score_gpt":0.3775774111568178,"score_spread":0.29433918950269894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406848242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006291421,0.6717551,0.003933106,0.18703511,0.06471128,0.002060115,0.0055843075,0.0004850567,0.06380679],"genre_scores_gemma":[0.0020362032,0.7899681,0.010120551,0.13125266,0.010380299,0.0012218127,0.006124266,0.0001253495,0.048770756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694014,0.0007493879,0.000541146,0.00020073354,0.0012865111,0.0002822335],"domain_scores_gemma":[0.99210984,0.0013495297,0.0010143945,0.00020078047,0.004637721,0.000687852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007068215,0.0009822227,0.0017801024,0.0035240597,0.0007523374,0.0023148684,0.0030239453,0.005812369,0.012393727],"category_scores_gemma":[0.0072355377,0.0005745613,0.0029926014,0.0039941366,0.0006941371,0.002420763,0.0015648641,0.0057233884,0.01243031],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008142658,0.000056532706,0.00012083184,0.0065345503,0.00008587894,0.00011222068,0.000041674863,0.00011772599,0.0007369778,0.0019796693,0.7901874,0.19994512],"study_design_scores_gemma":[0.00005634635,0.000032955355,0.0002343834,0.004358467,0.00010385634,0.000095521966,0.000016414839,0.000023058277,0.00016364876,0.00085077976,0.99405515,0.0000092711925],"about_ca_topic_score_codex":0.007547866,"about_ca_topic_score_gemma":0.012956121,"teacher_disagreement_score":0.012393727,"about_ca_system_score_codex":0.0024947003,"about_ca_system_score_gemma":0.015370767,"threshold_uncertainty_score":0.04146111},"labels":[],"label_agreement":null},{"id":"W4406854667","doi":"10.1182/blood.2024025355","title":"Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC; BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Diffuse large B-cell lymphoma; Immune system; Germinal center; CD19; Immunotherapy; Chimeric antigen receptor; B cell; T cell; Cancer research; Lymphoma; CD20; Biology; Immunology; Antibody","score_opus":0.013690929479762403,"score_gpt":0.3065875653718829,"score_spread":0.2928966358921205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406854667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972736,0.00019092609,0.0015480412,0.000015465906,0.0000014985145,0.000012753648,0.0007206465,0.000025538246,0.00021151497],"genre_scores_gemma":[0.9973097,0.000051497827,0.0011600872,0.000024881501,0.0000026613718,0.000017523227,0.0013126062,0.000010327853,0.00011081845],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.999746,0.0000406344,0.000014808767,0.00010391152,0.000046922785,0.000047654306],"domain_scores_gemma":[0.9997845,0.000054415836,0.00008130243,0.000022669536,0.000024433402,0.000032734322],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027535626,0.0002079499,0.00036593244,0.0012352166,0.00015799464,0.00042958936,0.00014163091,0.00014420801,0.00080091355],"category_scores_gemma":[0.00041370658,0.000106346386,0.00029027596,0.00086924277,0.00018926735,0.000114897106,0.00047051703,0.00024185714,0.00013127566],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010586187,0.00012300123,0.3084839,0.00009044044,0.00032240877,0.00017155838,0.00021257772,0.0012640721,0.6660628,0.00016944263,0.0001818983,0.021859128],"study_design_scores_gemma":[0.000018616132,0.00022210427,0.9723973,0.0000053689473,0.00014898142,0.00035484988,0.00016098765,0.0042873616,0.021513514,0.00018168104,0.0007013355,0.000007914762],"about_ca_topic_score_codex":0.0009788545,"about_ca_topic_score_gemma":0.0015922056,"teacher_disagreement_score":0.0012352166,"about_ca_system_score_codex":0.00026536512,"about_ca_system_score_gemma":0.00015462191,"threshold_uncertainty_score":0.0026792884},"labels":[],"label_agreement":null},{"id":"W4406919094","doi":"10.1186/s13046-024-03247-w","title":"Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD","year":2025,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Toronto General Hospital; University of Calgary; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Alberta Cancer Foundation","keywords":"Myeloid leukemia; Immunology; CD8; Cancer research; Leukemia; Graft-versus-host disease; Hematopoietic stem cell transplantation; Stem cell; Haematopoiesis; Transplantation; Medicine; Immune system; Biology; Internal medicine; Cell biology","score_opus":0.1471290124295697,"score_gpt":0.5112069163038436,"score_spread":0.36407790387427397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406919094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184906,0.00246996,0.0015441261,0.00008146396,0.00011434197,0.00012051125,0.00022235447,0.00007042463,0.003527746],"genre_scores_gemma":[0.99623007,0.001006048,0.0009087812,0.000080442594,0.000047855778,0.000066351065,0.00026601012,0.0000064374544,0.0013879597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998585,0.000036396523,0.00001242863,0.000019836702,0.000034883957,0.000037889007],"domain_scores_gemma":[0.99994135,0.00001158196,0.000012761145,0.000007930803,0.0000054183633,0.000021004007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011569087,0.00040335962,0.00032782112,0.00022773498,0.00007973458,0.00020422788,0.00014887241,0.00021079922,0.0014791709],"category_scores_gemma":[0.00007731852,0.00007238137,0.0001979136,0.00013377033,0.00016122234,0.00013508419,0.00012671843,0.0005759356,0.00031075178],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018512014,0.0011134354,0.000628833,0.00021892674,0.000021763806,0.0001375507,0.000030262021,0.00048566482,0.97547567,0.00038400662,0.0003491087,0.019303665],"study_design_scores_gemma":[0.0005441175,0.023132734,0.006735359,0.000040561612,0.00013029497,0.0010152024,0.000060585393,0.0022478949,0.9503739,0.00024304683,0.015466251,0.000010143315],"about_ca_topic_score_codex":0.00012159347,"about_ca_topic_score_gemma":0.0002594443,"teacher_disagreement_score":0.0014791709,"about_ca_system_score_codex":0.00009605751,"about_ca_system_score_gemma":0.00017603254,"threshold_uncertainty_score":0.004948318},"labels":[],"label_agreement":null},{"id":"W4406995266","doi":"10.3390/curroncol32020079","title":"Tumor-Associated Extracellular Matrix Obstacles for CAR-T Cell Therapy: Approaches to Overcoming","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Science and Higher Education of the Russian Federation","keywords":"Chimeric antigen receptor; Extracellular matrix; Cancer research; Medicine; Cell therapy; Cytotoxic T cell; T cell; Tumor microenvironment; Infiltration (HVAC); Cell; Immunology; Immune system; Tumor cells; Chemistry; Biology; Cell biology; Materials science","score_opus":0.41884260293245695,"score_gpt":0.4776253732411605,"score_spread":0.05878277030870355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406995266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001755625,0.9981211,0.00037080038,0.00019427181,0.00015585337,0.00000908681,0.000011283629,0.000009833528,0.00095233414],"genre_scores_gemma":[0.00083979155,0.9979157,0.00039170927,0.00013707097,0.00007612737,0.000012383416,0.000022304313,0.0000020043942,0.00060295116],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998591,0.00002871624,0.000014742941,0.000023973053,0.0000581033,0.000015338277],"domain_scores_gemma":[0.99987674,0.000062856794,0.000017843597,0.0000045183274,0.00002668231,0.000011332078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039487515,0.00087860983,0.0010572764,0.0020237775,0.00023744842,0.00093702757,0.0006863219,0.0011646238,0.0029439211],"category_scores_gemma":[0.00032133516,0.00028805117,0.00062365155,0.0014370573,0.00048225175,0.0012697878,0.00062088075,0.001928173,0.0016214001],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006094327,0.00012456327,0.00011203699,0.026385251,0.00010034411,0.00026402983,0.00008387926,0.0007476912,0.010683296,0.008847663,0.020822743,0.93176764],"study_design_scores_gemma":[0.00002111708,0.0001415203,0.0003803662,0.0022489224,0.00010033693,0.0012082797,0.000050927778,0.00017419914,0.0023450772,0.0020648886,0.9912441,0.000020258887],"about_ca_topic_score_codex":0.00073671667,"about_ca_topic_score_gemma":0.001403755,"teacher_disagreement_score":0.0029439211,"about_ca_system_score_codex":0.0005973749,"about_ca_system_score_gemma":0.0008734051,"threshold_uncertainty_score":0.009848416},"labels":[],"label_agreement":null},{"id":"W4407007830","doi":"10.1182/bloodadvances.2024013656","title":"Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel","year":2025,"lang":"en","type":"review","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Odds ratio; Internal medicine; Refractory (planetary science); Leukapheresis; Surgery; Gastroenterology; Confidence interval","score_opus":0.015372867371088561,"score_gpt":0.3482179956828738,"score_spread":0.33284512831178525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407007830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.074549705,0.9212753,0.00042848074,0.00069906446,0.00023288942,0.00012825427,0.001529484,0.000016184702,0.001140525],"genre_scores_gemma":[0.8522301,0.14331761,0.0005718249,0.0015042236,0.0003067979,0.00020006778,0.001391379,0.000021523101,0.0004566041],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717915,0.0012149563,0.0006995796,0.0004682796,0.00031691854,0.0001211829],"domain_scores_gemma":[0.9947319,0.0032238439,0.0014863549,0.00011130336,0.00029782517,0.00014875681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034870629,0.0005626563,0.003446017,0.0011153648,0.00023073475,0.001495278,0.000663604,0.0010545172,0.002044663],"category_scores_gemma":[0.007738463,0.00040035893,0.01195128,0.002001541,0.0002802727,0.0008376349,0.00042315462,0.0015428769,0.0001804599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060362972,0.0003573357,0.086197674,0.17943259,0.572059,0.00025717364,0.00022382916,0.0022327262,0.0014880612,0.000525289,0.003010657,0.093852684],"study_design_scores_gemma":[0.011837883,0.004744621,0.10248076,0.018773815,0.8481037,0.00041275655,0.00021200678,0.0014192811,0.00081107096,0.0011920715,0.009911426,0.00010064527],"about_ca_topic_score_codex":0.0024245912,"about_ca_topic_score_gemma":0.0044111162,"teacher_disagreement_score":0.0034870629,"about_ca_system_score_codex":0.0009482196,"about_ca_system_score_gemma":0.00086834625,"threshold_uncertainty_score":0.018441558},"labels":[],"label_agreement":null},{"id":"W4407036945","doi":"10.20944/preprints202501.1882.v2","title":"Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in Canada","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Bispecific antibody; Lymphoma; Medicine; Antibody; Diffuse large B-cell lymphoma; Refractory (planetary science); Antibody therapy; Chimeric antigen receptor; Oncology; Cancer research; Internal medicine; Immunotherapy; Immunology; Cancer; Monoclonal antibody; Biology","score_opus":0.14617016911375658,"score_gpt":0.3699330324314396,"score_spread":0.22376286331768303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407036945","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4450928,0.30783832,0.03205869,0.05932292,0.0020023833,0.000508007,0.0013326386,0.00093589065,0.15090838],"genre_scores_gemma":[0.9251022,0.04068732,0.018972185,0.0056337323,0.00047145138,0.00010596317,0.00065849617,0.00020093573,0.00816789],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99962926,0.00010477341,0.00003220028,0.000046164736,0.0001056561,0.00008194409],"domain_scores_gemma":[0.9997073,0.000048184986,0.00006151802,0.00002377295,0.00007844426,0.00008087632],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010724565,0.00014912772,0.00026337188,0.0003828683,0.00032358945,0.0012732653,0.00029781333,0.0005727974,0.0029640517],"category_scores_gemma":[0.001416379,0.00010741879,0.0002464696,0.00038853197,0.00042468216,0.00044765003,0.0003865753,0.00081242237,0.0009620476],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003610662,0.00041140115,0.016728975,0.0010801277,0.00011474528,0.0025806613,0.00035812432,0.0024369645,0.062055465,0.010414224,0.036173347,0.8640351],"study_design_scores_gemma":[0.00096156035,0.0024382581,0.059548274,0.00121098,0.00036193736,0.010178849,0.00081115245,0.0035181134,0.088579774,0.010601158,0.82170224,0.00008776142],"about_ca_topic_score_codex":0.009649835,"about_ca_topic_score_gemma":0.016956154,"teacher_disagreement_score":0.9903502,"about_ca_system_score_codex":0.0026268922,"about_ca_system_score_gemma":0.0025249464,"threshold_uncertainty_score":0.019187331},"labels":[],"label_agreement":null},{"id":"W4407171542","doi":"10.26685/urncst.677","title":"Chimeric Antigen Receptor T Cells (CAR T-Cells): A New Frontier in Targeted Cancer Therapy","year":2025,"lang":"en","type":"article","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Queen's University","keywords":"Chimeric antigen receptor; Frontier; Cancer; Antigen; Receptor; Cancer research; Cancer therapy; Immunotherapy; Immunology; Biology; Genetics; Political science","score_opus":0.05283176534618251,"score_gpt":0.4303344833493677,"score_spread":0.3775027180031852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407171542","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011156838,0.8051885,0.0765152,0.06643978,0.00792693,0.00014620706,0.00041994723,0.0007996263,0.031407006],"genre_scores_gemma":[0.12126507,0.7614565,0.03891668,0.03018942,0.009821713,0.00041950296,0.00076710334,0.00018302727,0.036981035],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99943525,0.0001377191,0.000021042906,0.00011659489,0.00021438416,0.00007499671],"domain_scores_gemma":[0.9995307,0.00016917202,0.00005727714,0.00002277895,0.00013321462,0.000086811815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013748457,0.0005142684,0.000754153,0.00077046757,0.00034882035,0.001920534,0.00081149896,0.0026787976,0.0030909197],"category_scores_gemma":[0.00096827105,0.00026205188,0.00046333126,0.00079005305,0.0020836727,0.0025642226,0.0009885026,0.0045817345,0.0016070021],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038988504,0.0001936947,0.00085082935,0.0015153317,0.000048701313,0.00044553494,0.00028718752,0.001518967,0.040694278,0.24471676,0.13289815,0.57644063],"study_design_scores_gemma":[0.00006474765,0.00044168657,0.00037138443,0.00034384348,0.000034943863,0.0015311787,0.00009577116,0.0016207194,0.014302874,0.026698211,0.9544476,0.00004695641],"about_ca_topic_score_codex":0.00092673313,"about_ca_topic_score_gemma":0.00053301366,"teacher_disagreement_score":0.0030909197,"about_ca_system_score_codex":0.0014441527,"about_ca_system_score_gemma":0.0010664079,"threshold_uncertainty_score":0.010478079},"labels":[],"label_agreement":null},{"id":"W4407249781","doi":"10.54097/qqyb3z55","title":"CAR-T cell therapy in treating advanced prostate cancer","year":2024,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakes Environmental (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Oncology; Internal medicine","score_opus":0.009371166423952837,"score_gpt":0.2873681195778401,"score_spread":0.2779969531538872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407249781","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037211825,0.98808205,0.0020135937,0.0006823486,0.00043274026,0.000034993263,0.000053969925,0.00006790993,0.004911235],"genre_scores_gemma":[0.03046261,0.96191174,0.0024326027,0.00087184744,0.00045912556,0.00007991641,0.00014354284,0.000013232321,0.0036253089],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998547,0.000035020556,0.000011034851,0.000026676405,0.00004714365,0.00002527611],"domain_scores_gemma":[0.9999492,0.000015386837,0.000008531433,0.000002561139,0.000015566487,0.000008651819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034130528,0.00041524117,0.00053180155,0.0007418063,0.0002045272,0.0005251502,0.0004612535,0.00068010506,0.0016375771],"category_scores_gemma":[0.00019353564,0.0001443039,0.0004732659,0.0005926806,0.00026628256,0.0005645025,0.0003691539,0.001413995,0.0008829268],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002858199,0.00026997444,0.00061787333,0.0095817875,0.00012488464,0.0008387481,0.0002012312,0.0020996088,0.05138945,0.011777772,0.023384763,0.8994281],"study_design_scores_gemma":[0.000099886616,0.0014662016,0.0012837377,0.00090461323,0.00017494138,0.0033844216,0.000072228184,0.0009912533,0.020422202,0.0026924328,0.96846515,0.000042857744],"about_ca_topic_score_codex":0.0007650393,"about_ca_topic_score_gemma":0.0011532882,"teacher_disagreement_score":0.0016375771,"about_ca_system_score_codex":0.00046598932,"about_ca_system_score_gemma":0.0005046646,"threshold_uncertainty_score":0.005478263},"labels":[],"label_agreement":null},{"id":"W4407280299","doi":"10.1016/bs.mcb.2025.01.004","title":"Evaluating transcriptional tumour microenvironment response to immunotherapy using microarray analysis: From harvesting tumours to data analysis","year":2025,"lang":"en","type":"article","venue":"Methods in cell biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Microarray analysis techniques; Immunotherapy; Computational biology; Microarray; Tumor microenvironment; Cancer research; Immunology; Immune system; Genetics; Gene expression; Gene","score_opus":0.1756769651994756,"score_gpt":0.5031746313922958,"score_spread":0.32749766619282017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407280299","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5887731,0.0020548226,0.3947353,0.0007895129,0.0003049964,0.0007251502,0.0061717266,0.002323738,0.0041217105],"genre_scores_gemma":[0.7161386,0.0024222354,0.26225016,0.0009535546,0.00018109933,0.0022827024,0.007564622,0.00083855126,0.0073685017],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984523,0.00036927036,0.00009959946,0.00033741572,0.0005336865,0.00020771501],"domain_scores_gemma":[0.9989072,0.0005712684,0.00009169956,0.00019567051,0.00018311017,0.00005097793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012453758,0.0006333626,0.0008893099,0.0006516451,0.00048382694,0.0012983301,0.00038930352,0.00054309523,0.0017730355],"category_scores_gemma":[0.0014902629,0.0004533635,0.0006063435,0.0010706567,0.0006146005,0.00043023503,0.00048613557,0.0014526381,0.0010974251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009778328,0.000039315575,0.0013395364,0.00004166305,0.00001376379,0.000012498629,0.00004056637,0.00025668487,0.99269944,0.00008011288,0.00011043353,0.0052683037],"study_design_scores_gemma":[0.0000080773825,0.0002556856,0.019147238,0.0000073691504,0.00005172604,0.00007245108,0.00012762577,0.004576062,0.97325563,0.00039659638,0.0020804037,0.000020975865],"about_ca_topic_score_codex":0.00085612136,"about_ca_topic_score_gemma":0.0021521715,"teacher_disagreement_score":0.0017730355,"about_ca_system_score_codex":0.00046150884,"about_ca_system_score_gemma":0.0005790783,"threshold_uncertainty_score":0.0065862536},"labels":[],"label_agreement":null},{"id":"W4407288611","doi":"10.1136/jitc-2024-009890","title":"Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Iovance Biotherapeutics; Janssen Research and Development; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; bluebird bio; Pharmacyclics; Takeda Oncology; Legend Biotech; U.S. Navy; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; CytoSen Therapeutics; MorphoSys; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; CSL Behring; Kyowa Kirin Pharmaceutical Development; Atara Biotherapeutics; Vertex Pharmaceuticals; Anthem Foundation; GlaxoSmithKline; Kiadis Pharma; Sanofi; TG Therapeutics; Medac; Jazz Pharmaceuticals; Omeros Corporation; U.S. Department of Defense; Medical College of Wisconsin; StemCyte; AbbVie; Actinium Pharmaceuticals; Gilead Sciences; Stanford University; National Marrow Donor Program; Mallinckrodt Pharmaceuticals; Merck; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma US; Be The Match Foundation; Novartis Pharmaceuticals Corporation; Dana-Farber Cancer Institute; Allogene Therapeutics; Incyte; Pfizer; Amgen; Boston Children's Hospital; HistoGenetics","keywords":"Medicine; Cytokine release syndrome; Fludarabine; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Salvage therapy; Cohort; Lymphoma; Transplantation; Chimeric antigen receptor; Immunotherapy; Chemotherapy; Cancer; Cyclophosphamide","score_opus":0.04027750660366552,"score_gpt":0.41093005155627,"score_spread":0.37065254495260447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407288611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346394,0.0022024773,0.0003978655,0.000116687785,0.000022554463,0.0001812434,0.012223622,0.000026166601,0.0013655169],"genre_scores_gemma":[0.9891149,0.00028978108,0.00016602305,0.0000601326,0.00002678725,0.00018734866,0.0100001665,0.000022489849,0.00013243417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940352,0.0021934002,0.0012525943,0.0010158378,0.00091023685,0.0005928229],"domain_scores_gemma":[0.99000835,0.0020965622,0.0049265143,0.0017723481,0.00070555735,0.0004906253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062243026,0.000472587,0.0011759122,0.0025148033,0.00032121077,0.0015152171,0.0008797982,0.0004991129,0.0020553411],"category_scores_gemma":[0.011114768,0.0003048149,0.0032306782,0.003948549,0.00029927347,0.00084791676,0.0013952458,0.00068961154,0.00043963583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004223731,0.00006473072,0.9835556,0.00029172038,0.004303541,0.00020450317,0.00016013061,0.00054923905,0.00020153109,0.000095843956,0.0013777444,0.0049716104],"study_design_scores_gemma":[0.0003949298,0.00045991043,0.99249387,0.000090858935,0.0026184698,0.00057650026,0.00042112853,0.0008045787,0.00014273138,0.00012679184,0.0018378084,0.000032400334],"about_ca_topic_score_codex":0.003958053,"about_ca_topic_score_gemma":0.005978825,"teacher_disagreement_score":0.0062243026,"about_ca_system_score_codex":0.00090189266,"about_ca_system_score_gemma":0.000814334,"threshold_uncertainty_score":0.03291768},"labels":[],"label_agreement":null},{"id":"W4407300113","doi":"10.1097/coc.0000000000001171","title":"Efficacy and Safety of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Patients with Non-Hodgkin Lymphoma","year":2025,"lang":"en","type":"review","venue":"American Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Internal medicine; Lymphoma; Neutropenia; Adverse effect; Nausea; Chimeric antigen receptor; Hazard ratio; Oncology; Incidence (geometry); Gastroenterology; Chemotherapy; Cancer; Immunotherapy; Confidence interval","score_opus":0.055866799719170517,"score_gpt":0.45606727496103683,"score_spread":0.4002004752418663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407300113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01713742,0.9812277,0.00018691557,0.0003395026,0.00014425213,0.00012184898,0.00024625374,0.000009982829,0.0005860879],"genre_scores_gemma":[0.5558293,0.43982074,0.0006992371,0.0016987291,0.0006716499,0.00034926017,0.00052429904,0.000017441618,0.0003894382],"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933062,0.0036912942,0.0015340066,0.00050159654,0.0008125019,0.00015429968],"domain_scores_gemma":[0.9892315,0.0075636012,0.0022958985,0.00020220927,0.0005589458,0.00014783793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009864031,0.0008076594,0.0060296627,0.0018332694,0.00022350841,0.001776164,0.0009007535,0.0016822201,0.002380923],"category_scores_gemma":[0.01735072,0.0005118752,0.012617854,0.0020260226,0.00049315795,0.0012030195,0.00059714384,0.0016289816,0.00021700269],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054729205,0.0004957206,0.013326231,0.35129783,0.39291963,0.00022018678,0.00019029526,0.0016130261,0.0012169052,0.00045728718,0.0017912646,0.18174239],"study_design_scores_gemma":[0.02604082,0.017333139,0.039644152,0.053470932,0.84516746,0.0007559579,0.0002681457,0.0013204116,0.0013353042,0.0015221465,0.013048005,0.00009357897],"about_ca_topic_score_codex":0.0011756803,"about_ca_topic_score_gemma":0.002017702,"teacher_disagreement_score":0.009864031,"about_ca_system_score_codex":0.0011695832,"about_ca_system_score_gemma":0.0010543293,"threshold_uncertainty_score":0.05216664},"labels":[],"label_agreement":null},{"id":"W4407364868","doi":"10.1101/2025.02.10.637482","title":"Precise engineering of chimeric antigen receptor expression levels defines T cell identity and function","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Chimeric antigen receptor; Identity (music); Function (biology); Expression (computer science); Cell biology; Antigen; Receptor; Computational biology; Biology; T cell; Immunology; Computer science; Genetics; Immune system; Physics","score_opus":0.024331975729834997,"score_gpt":0.2612501688721465,"score_spread":0.23691819314231152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407364868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638577,0.0005957738,0.0324646,0.00012350167,0.0000383909,0.0000486003,0.00053490297,0.00030644564,0.0020300383],"genre_scores_gemma":[0.98757476,0.00023406818,0.009726577,0.000049369944,0.000006552807,0.000045745295,0.00028791235,0.0001279492,0.0019469395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996245,0.000073008014,0.000037162496,0.000099965095,0.0000857338,0.00007970483],"domain_scores_gemma":[0.9997751,0.00007473529,0.00005664259,0.00003244426,0.000027529755,0.00003355175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041016645,0.00028202223,0.00026786,0.00022304092,0.0001692514,0.0006326121,0.00021129404,0.00035486894,0.0011827309],"category_scores_gemma":[0.00029296533,0.0001955048,0.00021019229,0.00016525554,0.0004741498,0.00021596094,0.00032549573,0.000756017,0.0005741387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027110342,0.000006642896,0.000054644614,0.000006616701,0.0000010860157,0.0000058491555,0.0000069516236,0.000082463856,0.9992957,0.000121951816,0.000015159001,0.00037576575],"study_design_scores_gemma":[0.000004167571,0.00004777481,0.00033577817,0.0000015134749,0.0000037049617,0.0000249006,0.000007682608,0.0010887692,0.9976927,0.000039920546,0.00075055787,0.0000024649692],"about_ca_topic_score_codex":0.00027279704,"about_ca_topic_score_gemma":0.00034175525,"teacher_disagreement_score":0.0011827309,"about_ca_system_score_codex":0.00040784306,"about_ca_system_score_gemma":0.00019069077,"threshold_uncertainty_score":0.003956616},"labels":[],"label_agreement":null},{"id":"W4407396455","doi":"10.1182/blood.2024027347","title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Lymphoma; Leukapheresis; Fludarabine; Phases of clinical research; Gastroenterology; Chimeric antigen receptor; Surgery; Chemotherapy; Immunotherapy; Cancer; Cyclophosphamide","score_opus":0.021148801557246615,"score_gpt":0.2961322123846648,"score_spread":0.2749834108274182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407396455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960777,0.0012337656,0.0002934869,0.000057716534,0.000013936399,0.00009630148,0.0012345631,0.000026113687,0.000966389],"genre_scores_gemma":[0.9958449,0.00019954414,0.00012940168,0.00010655109,0.000025150315,0.0000708814,0.0029283701,0.0000068767563,0.0006884789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993273,0.0002366191,0.000050799234,0.00012875916,0.00013535576,0.00012130597],"domain_scores_gemma":[0.99800223,0.00041906684,0.00068631035,0.00024988377,0.00022026146,0.00042223244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031647617,0.00050536986,0.0009365563,0.00045092448,0.0002926507,0.0008550814,0.00042619347,0.00072915544,0.001222429],"category_scores_gemma":[0.0021250856,0.00026965418,0.0012139353,0.00038099196,0.00022114084,0.0005918646,0.0003344128,0.0011575613,0.00038042816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.119217016,0.0032847577,0.81031924,0.00031682657,0.0048673428,0.00063329795,0.0002523803,0.0023106649,0.010304105,0.00015539315,0.0028214487,0.045517482],"study_design_scores_gemma":[0.005716937,0.025418412,0.9606368,0.000023901921,0.0019570903,0.0005584744,0.00007071371,0.0016482805,0.0015139802,0.0001209721,0.0023071743,0.00002733671],"about_ca_topic_score_codex":0.0012258535,"about_ca_topic_score_gemma":0.0016398513,"teacher_disagreement_score":0.0031647617,"about_ca_system_score_codex":0.000588723,"about_ca_system_score_gemma":0.000391939,"threshold_uncertainty_score":0.016737103},"labels":[],"label_agreement":null},{"id":"W4407409544","doi":"10.1080/08820139.2025.2462536","title":"Variable Lymphocyte Receptor B Technologies – Are They Ready for Prime Time?","year":2025,"lang":"en","type":"review","venue":"Immunological Investigations","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Sick Kids Foundation","keywords":"Receptor; Common variable immunodeficiency; Lymphocyte; Prime (order theory); Immunology; Biology; Computational biology; Genetics; Chemistry; Antibody; Mathematics; Combinatorics","score_opus":0.12314555125493065,"score_gpt":0.3852417675768454,"score_spread":0.26209621632191477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407409544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000562251,0.98936325,0.00061594177,0.005665673,0.0010060993,0.00002321197,0.00008352577,0.000016484037,0.0026635393],"genre_scores_gemma":[0.0066680633,0.9783956,0.0019909088,0.008806562,0.0019355074,0.00009437768,0.00021594699,0.000023685165,0.0018693797],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825484,0.00074551546,0.00026598098,0.00013012344,0.00046411357,0.00013945121],"domain_scores_gemma":[0.9942525,0.0039882916,0.0006822525,0.0001376103,0.00074141973,0.0001979556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005887905,0.00036524702,0.0010756622,0.0013312052,0.00019171825,0.0024603817,0.001096496,0.0021864616,0.010859726],"category_scores_gemma":[0.009147403,0.0002675754,0.000833197,0.0012442862,0.00083132583,0.0054086647,0.000689151,0.0022448706,0.0047528334],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005148964,0.00007155488,0.00050483295,0.029041024,0.00019417086,0.0002635777,0.00016140201,0.00012703142,0.0021331457,0.015509978,0.041033145,0.9104453],"study_design_scores_gemma":[0.000095603405,0.0003075304,0.0005748767,0.018005483,0.00020225582,0.0011471157,0.0002861506,0.000043815995,0.0011096173,0.009264778,0.9689398,0.000022989983],"about_ca_topic_score_codex":0.0005675009,"about_ca_topic_score_gemma":0.0005882967,"teacher_disagreement_score":0.010859726,"about_ca_system_score_codex":0.0007533747,"about_ca_system_score_gemma":0.0019021997,"threshold_uncertainty_score":0.03632939},"labels":[],"label_agreement":null},{"id":"W4407411156","doi":"10.69645/wsam8047","title":"The regulation of cell therapy","year":2025,"lang":"en","type":"article","venue":"˜The œbiomedical & life sciences collection.","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cell therapy; Cell; Chemistry; Biochemistry","score_opus":0.02775150057847669,"score_gpt":0.3314335778454464,"score_spread":0.3036820772669697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407411156","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13076665,0.29416272,0.034311984,0.03240141,0.011066394,0.00035659887,0.002941119,0.00057209795,0.49342093],"genre_scores_gemma":[0.7317734,0.07324966,0.008907739,0.0060131946,0.002177739,0.00035213862,0.0018534302,0.00015593038,0.17551675],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988858,0.00021906548,0.000044026034,0.00020541003,0.0004888014,0.00015688398],"domain_scores_gemma":[0.99953103,0.00007650495,0.00007158177,0.00009531416,0.00012814379,0.00009752013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010244752,0.00042242752,0.0004508755,0.0006382427,0.00064023153,0.0036079749,0.000543934,0.00085533765,0.006819387],"category_scores_gemma":[0.0007903844,0.00024362208,0.00040932526,0.0004170905,0.0011808077,0.00080910075,0.0010235065,0.0021082847,0.0034420092],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003546095,0.00020287157,0.0016266892,0.0006620247,0.000063853055,0.00033141332,0.00050203153,0.0005845597,0.49673885,0.23586407,0.04689031,0.21617875],"study_design_scores_gemma":[0.000057395326,0.00034536506,0.0063691605,0.000171076,0.000036877092,0.0009069377,0.00025763432,0.0010040744,0.18363726,0.016091133,0.79109395,0.000029195477],"about_ca_topic_score_codex":0.0008711183,"about_ca_topic_score_gemma":0.0010647648,"teacher_disagreement_score":0.006819387,"about_ca_system_score_codex":0.0013542668,"about_ca_system_score_gemma":0.0012532216,"threshold_uncertainty_score":0.022813141},"labels":[],"label_agreement":null},{"id":"W4407669458","doi":"10.1101/2025.02.16.638489","title":"Pooled screening identifies combinatorial CAR signaling domains for next-generation CAR-M immunotherapies","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"Basic and Applied Basic Research Foundation of Guangdong Province; Natural Science Foundation of Jiangsu Province; Peking University; Zhejiang University; Government of Jiangsu Province","keywords":"Computational biology; Computer science; Biology","score_opus":0.04168567242878246,"score_gpt":0.28655238925102466,"score_spread":0.2448667168222422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407669458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91566515,0.001843971,0.077198245,0.00020537373,0.00004997945,0.0004627204,0.00087232614,0.00089183485,0.0028102922],"genre_scores_gemma":[0.94636405,0.00065951364,0.048929375,0.00017413916,0.000017105403,0.00022480117,0.0009215784,0.00011362151,0.0025957709],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992576,0.000154365,0.00003643367,0.00013988634,0.00025717626,0.00015447958],"domain_scores_gemma":[0.9997509,0.00007063709,0.000049638915,0.00003663741,0.00004885088,0.000043305823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010059845,0.0007042835,0.0008360262,0.0008164922,0.00022101964,0.00087064196,0.00054187834,0.0005184937,0.0016094146],"category_scores_gemma":[0.000639936,0.00027060736,0.0005508859,0.00041294395,0.0003298985,0.00038961446,0.0007984567,0.00074439036,0.0008260364],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017610811,0.0001322923,0.00049145316,0.00005088633,0.000026176758,0.00005592086,0.00001731733,0.0013833989,0.9878461,0.000258311,0.00017111408,0.009391098],"study_design_scores_gemma":[0.000019923787,0.0004643495,0.00049351394,0.0000041455473,0.0000314738,0.00009590947,0.000017430368,0.004845451,0.9918858,0.000098375844,0.002033633,0.0000099490435],"about_ca_topic_score_codex":0.00043957887,"about_ca_topic_score_gemma":0.0009473266,"teacher_disagreement_score":0.0016094146,"about_ca_system_score_codex":0.00060164323,"about_ca_system_score_gemma":0.0004131042,"threshold_uncertainty_score":0.005384028},"labels":[],"label_agreement":null},{"id":"W4407734681","doi":"10.1158/0008-5472.can-24-1643","title":"Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR T Cells against Hematologic Malignancies","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Cytotoxic T cell; Granzyme B; Chimeric antigen receptor; Granzyme; Cancer research; Immunology; T cell; CD8; Homing (biology); CD19; Biology; Immune system; Medicine; In vitro; Perforin","score_opus":0.08047372379180479,"score_gpt":0.3951829907347449,"score_spread":0.3147092669429401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407734681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99646556,0.000784456,0.0014466589,0.000044317258,0.000013273274,0.000024687286,0.00009147491,0.00007029219,0.0010592671],"genre_scores_gemma":[0.99757034,0.00032679818,0.0005275133,0.00002474015,0.000007723315,0.000014636764,0.00015026431,0.00000942646,0.001368604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988794,0.00001888311,0.000009860607,0.000018156488,0.000028795557,0.000036275545],"domain_scores_gemma":[0.99996173,0.0000064497717,0.000008925241,0.000005302797,0.0000055771247,0.00001191967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107686676,0.00025724937,0.00017543601,0.00013543565,0.00007105144,0.00024026437,0.00012161098,0.00012233827,0.0012921712],"category_scores_gemma":[0.00008499694,0.00006122105,0.000120999655,0.00008560847,0.00012230374,0.00012540171,0.00013806662,0.00039831162,0.00027531295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012622785,0.00005786323,0.00016846607,0.000020365458,0.000004121053,0.000019933821,0.0000064984115,0.000097781325,0.99758995,0.0000363252,0.000041902655,0.0018305603],"study_design_scores_gemma":[0.000019815676,0.0005230788,0.0021978463,0.0000017191358,0.000017988825,0.000120387704,0.0000069776293,0.00087116833,0.9949569,0.000009908381,0.0012724592,0.0000017468928],"about_ca_topic_score_codex":0.00033017603,"about_ca_topic_score_gemma":0.0007043392,"teacher_disagreement_score":0.0012921712,"about_ca_system_score_codex":0.00015361863,"about_ca_system_score_gemma":0.00017227232,"threshold_uncertainty_score":0.0043227077},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4407776291","doi":"10.1016/j.reth.2025.02.001","title":"Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey","year":2025,"lang":"en","type":"article","venue":"Regenerative Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Experiential learning; Medicine; Psychology; Mathematics education","score_opus":0.04602210248634406,"score_gpt":0.3520961204929508,"score_spread":0.3060740180066067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407776291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794525,0.0064553693,0.006589285,0.0022492625,0.000102081955,0.00045308683,0.00029682156,0.00009532732,0.0043062544],"genre_scores_gemma":[0.9620867,0.009088833,0.022641303,0.0012438693,0.00024465492,0.00027590367,0.0016029194,0.0000808858,0.0027349305],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971289,0.0008889083,0.000374912,0.00024939072,0.0009307758,0.0004271517],"domain_scores_gemma":[0.9957755,0.00066727935,0.0012149643,0.00040681893,0.0010533831,0.0008819994],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007179879,0.0007086786,0.000368723,0.000615612,0.0007811929,0.0016197058,0.00087203307,0.00047051703,0.0017177811],"category_scores_gemma":[0.0057901666,0.00024594145,0.00084397104,0.0008196489,0.00050751586,0.0013566479,0.0016322915,0.00086996076,0.0005649619],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002226057,0.0067052552,0.23022899,0.0009208548,0.0004029871,0.003236112,0.007238161,0.003176713,0.026584672,0.0011184993,0.014912849,0.7032488],"study_design_scores_gemma":[0.0008175115,0.036663387,0.58948135,0.0011217118,0.001183,0.023681123,0.02336332,0.016037697,0.064134836,0.0024509095,0.2405076,0.0005576114],"about_ca_topic_score_codex":0.0021936179,"about_ca_topic_score_gemma":0.003918289,"teacher_disagreement_score":0.007179879,"about_ca_system_score_codex":0.0012914729,"about_ca_system_score_gemma":0.0028475067,"threshold_uncertainty_score":0.037971318},"labels":[],"label_agreement":null},{"id":"W4407863613","doi":"10.1158/2326-6074.io2025-a015","title":"Abstract A015: GPNMB CAR T cells target both Glioblastoma and its immunosuppressive niche to relieve immune evasion","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; McMaster University","funders":"","keywords":"Evasion (ethics); Glioblastoma; Niche; Immune system; Immunotherapy; Immunology; Cancer immunotherapy; Biology; Cancer research; Medicine; Ecology","score_opus":0.03854279659123545,"score_gpt":0.39178252174718603,"score_spread":0.3532397251559506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407863613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776289,0.0036699225,0.006739311,0.0011938476,0.0002713743,0.00012281792,0.000989489,0.00041367087,0.008970781],"genre_scores_gemma":[0.971374,0.0020198277,0.0051826364,0.00052175194,0.0000743956,0.00008438814,0.0008290629,0.000050248604,0.019863809],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999194,0.0000077501445,0.00000495527,0.000019351772,0.000029355657,0.00001914055],"domain_scores_gemma":[0.99995804,0.00000474083,0.000008003803,0.0000029867376,0.000011302704,0.000014948593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104661485,0.00022398094,0.00021084184,0.0002964126,0.00021110657,0.00044158727,0.0002017534,0.00031888543,0.00768352],"category_scores_gemma":[0.00008963556,0.00009658123,0.00018149527,0.00018587576,0.00022352845,0.0002148357,0.00021471715,0.00051399716,0.0012701282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018691488,0.000048261965,0.00089720817,0.00008443929,0.000009442977,0.00016248463,0.000031858406,0.00013142644,0.98682284,0.00046202756,0.0012639281,0.009899106],"study_design_scores_gemma":[0.000059542384,0.0009738352,0.013158184,0.00002636486,0.000043226635,0.0015996466,0.00018539092,0.0021546916,0.9545148,0.00053757726,0.026734065,0.0000127320445],"about_ca_topic_score_codex":0.00068450265,"about_ca_topic_score_gemma":0.0009865754,"teacher_disagreement_score":0.00768352,"about_ca_system_score_codex":0.00028898584,"about_ca_system_score_gemma":0.0003723648,"threshold_uncertainty_score":0.025703907},"labels":[],"label_agreement":null},{"id":"W4407866624","doi":"10.1158/2326-6074.io2025-a016","title":"Abstract A016: Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"","keywords":"Glioblastoma; Cancer research; Medicine; Immunotherapy; Computational biology; Cancer; Biology; Internal medicine","score_opus":0.041151855758443136,"score_gpt":0.38099791652814474,"score_spread":0.3398460607697016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407866624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953967,0.0006755424,0.002216878,0.00009410896,0.000025704388,0.00004760113,0.00041298996,0.00015281585,0.0009776284],"genre_scores_gemma":[0.9952583,0.0003587283,0.0015326219,0.000039362072,0.000006495662,0.00004949787,0.00058079057,0.000024739084,0.0021494366],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990046,0.000009763841,0.000008075541,0.000023832574,0.00002593738,0.00003187971],"domain_scores_gemma":[0.9999571,0.0000042126944,0.000012057326,0.000005121671,0.0000069836237,0.000014484156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010676665,0.00036590715,0.0002755086,0.00025018462,0.00009913845,0.0003352571,0.00020599464,0.0002673426,0.0012907542],"category_scores_gemma":[0.000073789015,0.00011312407,0.00022116721,0.00015782932,0.00017534218,0.0001304619,0.0001476152,0.00056685327,0.00036642168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015085052,0.0000692745,0.00020358247,0.0000349453,0.000008310415,0.000039873867,0.000013527305,0.00017117975,0.9970983,0.000092823015,0.00011465863,0.0020026534],"study_design_scores_gemma":[0.00006521774,0.0015789228,0.0026039437,0.0000055287505,0.000046219808,0.00038796963,0.000029084184,0.0014832587,0.9907092,0.000044629545,0.003040454,0.0000057138677],"about_ca_topic_score_codex":0.001425693,"about_ca_topic_score_gemma":0.0014167724,"teacher_disagreement_score":0.001425693,"about_ca_system_score_codex":0.00026619527,"about_ca_system_score_gemma":0.00026305192,"threshold_uncertainty_score":0.0043180585},"labels":[],"label_agreement":null},{"id":"W4407873167","doi":"10.1186/s12935-025-03697-y","title":"Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies","year":2025,"lang":"en","type":"review","venue":"Cancer Cell International","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chimeric antigen receptor; Antigen; Medicine; Immunology; Receptor; Immunotherapy; Cancer research; Virology; Immune system; Internal medicine","score_opus":0.04052181563804908,"score_gpt":0.3758730317671781,"score_spread":0.33535121612912905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407873167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000304264,0.99717486,0.00028870773,0.00025845828,0.00015948685,0.000006714013,0.00001585045,0.000013493799,0.0017781765],"genre_scores_gemma":[0.0015507755,0.9969897,0.00019378345,0.00020670104,0.00008390179,0.00000967748,0.000024849098,0.0000018500044,0.00093876646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984205,0.000028064385,0.0000139746935,0.000031848067,0.00006109468,0.000022880726],"domain_scores_gemma":[0.9999027,0.000042368665,0.000014435051,0.000003973051,0.000026314781,0.000010123718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000403089,0.0006150916,0.00096012687,0.001672181,0.00020061071,0.00073501084,0.00080073683,0.00093129656,0.002327634],"category_scores_gemma":[0.00033234563,0.00023116611,0.00043483626,0.0012415863,0.00046122714,0.0008128835,0.0004911111,0.0016229663,0.0015300631],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008617946,0.00011068722,0.00014684442,0.015391748,0.00008811804,0.0003744372,0.00010004994,0.00092193147,0.008662516,0.014471943,0.028555095,0.9310904],"study_design_scores_gemma":[0.000021328617,0.00012930966,0.00042389057,0.0013901606,0.00006376482,0.0013821999,0.000041170213,0.00013989283,0.0018724721,0.0025410804,0.9919795,0.000015214004],"about_ca_topic_score_codex":0.0005823408,"about_ca_topic_score_gemma":0.0008924532,"teacher_disagreement_score":0.002327634,"about_ca_system_score_codex":0.00061548245,"about_ca_system_score_gemma":0.0006018534,"threshold_uncertainty_score":0.007786691},"labels":[],"label_agreement":null},{"id":"W4407920322","doi":"10.1038/s41598-025-87944-2","title":"Tuning TCR complex recruitment to the T cell antigen coupler (TAC) enhances TAC-T cell function","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF; University of Toronto","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"T-cell receptor; T cell; Function (biology); Cell biology; Antigen; Cell; Chemistry; Immunology; Biology; Biochemistry; Immune system","score_opus":0.0834483860972458,"score_gpt":0.35297938832979625,"score_spread":0.26953100223255044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407920322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949995,0.00045520018,0.0034693289,0.000052881624,0.000016986074,0.000024771649,0.00004664482,0.000060631624,0.00087400386],"genre_scores_gemma":[0.99674714,0.0002943181,0.002155891,0.000046672856,0.0000068669233,0.000017425078,0.000049421058,0.000018183366,0.00066414446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997937,0.0000426,0.000020547195,0.000040583895,0.000048056423,0.000054578904],"domain_scores_gemma":[0.9998877,0.000029057066,0.0000358349,0.000011416193,0.00001142386,0.0000244518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002178099,0.00031770076,0.00023762486,0.000119078075,0.0001178467,0.00033435444,0.00018282224,0.00025819172,0.001240783],"category_scores_gemma":[0.0002185138,0.00008410561,0.00015355683,0.00011691031,0.00018100652,0.00022657865,0.00022331327,0.00049852784,0.0003203517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034961806,0.000020266398,0.000035164845,0.000013137435,0.0000017050003,0.000014406294,0.000006097415,0.00007323974,0.9991678,0.000054735876,0.000013964045,0.000564447],"study_design_scores_gemma":[0.00001075372,0.00022279455,0.0004330003,0.0000016426429,0.0000073904944,0.00008747571,0.0000053954113,0.0008040183,0.99742967,0.000010743244,0.0009847122,0.000002468711],"about_ca_topic_score_codex":0.00018309857,"about_ca_topic_score_gemma":0.0002592351,"teacher_disagreement_score":0.001240783,"about_ca_system_score_codex":0.00022965424,"about_ca_system_score_gemma":0.00011321959,"threshold_uncertainty_score":0.0041508675},"labels":[],"label_agreement":null},{"id":"W4407954426","doi":"10.3390/curroncol32030135","title":"Influence of Vitamin D and Its Analogues in Type-B Lymphomas","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; In vivo; Lymphoma; Internal medicine; Cancer research; Cancer; Oncology; Metastasis; Clinical trial; Overall survival; In vitro; Disease; Biology","score_opus":0.16598168683163025,"score_gpt":0.4942575303144392,"score_spread":0.3282758434828089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407954426","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52385056,0.4670983,0.0021394365,0.00048778593,0.00026892984,0.0000549658,0.0004899298,0.0000677715,0.005542343],"genre_scores_gemma":[0.9247558,0.07138904,0.0014361276,0.00026274112,0.00010631698,0.000027958737,0.00034617903,0.000022224569,0.0016536388],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998388,0.00007065975,0.000019422945,0.000030476609,0.000028101227,0.00001240456],"domain_scores_gemma":[0.9998522,0.00007612742,0.000023432522,0.000010705032,0.000019030895,0.00001846081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025486594,0.00015299152,0.0002853563,0.0004493285,0.00009935423,0.00042382436,0.00018190657,0.00026271556,0.0010220853],"category_scores_gemma":[0.0004062922,0.00007764295,0.00035344047,0.00030967378,0.00015188407,0.00018892945,0.00017302169,0.0003143031,0.00016923413],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012380248,0.00061504304,0.010584712,0.0042955866,0.0005067531,0.0011591068,0.00016559706,0.0011232505,0.71616787,0.0010382954,0.0014917068,0.25047186],"study_design_scores_gemma":[0.001158235,0.014728961,0.03951752,0.00047664577,0.0015436491,0.005933424,0.0004204816,0.0015060081,0.7362703,0.0014894593,0.19690323,0.000052111576],"about_ca_topic_score_codex":0.00051503687,"about_ca_topic_score_gemma":0.00050057843,"teacher_disagreement_score":0.0010220853,"about_ca_system_score_codex":0.0002385292,"about_ca_system_score_gemma":0.00016336373,"threshold_uncertainty_score":0.0034191608},"labels":[],"label_agreement":null},{"id":"W4407976290","doi":"10.1016/j.jtct.2025.01.355","title":"Cost and Health Service Utilization Differences between Lymphoma Patients Treated with Commercial CAR-T and Made -in-Alberta Therapies","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Alberta Cancer Foundation; Alberta Health; University of Alberta; University of Calgary","funders":"","keywords":"Lymphoma; Medicine; Service (business); Business; Intensive care medicine; Marketing; Internal medicine","score_opus":0.062273573678095516,"score_gpt":0.32116510208155385,"score_spread":0.25889152840345836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981818,0.0002527574,0.000023795852,0.000120078366,0.000007557465,0.000006816202,0.00052068563,0.0000015583281,0.0008848524],"genre_scores_gemma":[0.99912673,0.00008445468,0.000017071796,0.00005096677,0.000007668372,0.000005849611,0.0004432667,0.0000013562084,0.00026271035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995309,0.00011195387,0.000040086583,0.0000569447,0.000063059815,0.00019719022],"domain_scores_gemma":[0.99876225,0.0002967854,0.0005438864,0.00002864652,0.00008919022,0.0002792935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027061743,0.00013730553,0.0002819499,0.0005985547,0.00025962442,0.0007586053,0.0003247676,0.00045177076,0.004087233],"category_scores_gemma":[0.0021110273,0.000122821,0.0009034954,0.0012078288,0.00024098795,0.0004738801,0.00043506367,0.0005332477,0.00020196491],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029585394,0.00029172568,0.98772454,0.0000270188,0.00037403847,0.00011904462,0.00012496703,0.0005749508,0.00041096154,0.00024457515,0.000502622,0.0066471286],"study_design_scores_gemma":[0.000062448846,0.00039213963,0.9971213,0.0000102677495,0.00013375696,0.00013202454,0.00062281714,0.00086996536,0.00009503677,0.00009255148,0.0004590494,0.000008665679],"about_ca_topic_score_codex":0.041449133,"about_ca_topic_score_gemma":0.046139672,"teacher_disagreement_score":0.9585509,"about_ca_system_score_codex":0.0020993624,"about_ca_system_score_gemma":0.0009228192,"threshold_uncertainty_score":0.08241576},"labels":[],"label_agreement":null},{"id":"W4407976601","doi":"10.1016/j.jtct.2025.01.159","title":"Fludarabine during Lymphodepletion Chemotherapy Prior to CAR-T Cell Therapy in Adult Patients with Non-Hodgkin Lymphoma: Evaluation of a Pharmacokinetic Model and Exploration of Optimal Exposure","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Fludarabine; Chemotherapy; Medicine; Pharmacokinetics; Lymphoma; Cyclophosphamide; Oncology; Pharmacology; Internal medicine","score_opus":0.019301962104278456,"score_gpt":0.28665886335044105,"score_spread":0.26735690124616257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916037,0.00090105756,0.0064972457,0.0001454853,0.000011061456,0.000039213275,0.000082267674,0.000052257717,0.00066781737],"genre_scores_gemma":[0.9989518,0.00012302698,0.0007813708,0.000026883212,0.000004105,0.000011349249,0.00003684732,0.000005371686,0.000059304122],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995419,0.00027664134,0.000017031623,0.00005925139,0.000049690865,0.000055518074],"domain_scores_gemma":[0.9993656,0.00042585176,0.00011118901,0.00003105654,0.000023250426,0.000043045013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065083546,0.00030384032,0.000634218,0.0001755168,0.00015124702,0.0008382043,0.00025715987,0.00056108047,0.00039972624],"category_scores_gemma":[0.0026810456,0.00025250504,0.00032279512,0.00023344479,0.00022560729,0.00033301325,0.00015700616,0.000484035,0.00007843557],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06669549,0.002651557,0.1782762,0.0005350411,0.0006682372,0.0025874812,0.0007467646,0.46530825,0.104841,0.0051331623,0.0019172742,0.17063956],"study_design_scores_gemma":[0.0033383344,0.034119796,0.16902024,0.00012966194,0.0014319067,0.0037508747,0.00048094022,0.7016144,0.076517604,0.0026405228,0.006818998,0.00013679001],"about_ca_topic_score_codex":0.0023432171,"about_ca_topic_score_gemma":0.002265584,"teacher_disagreement_score":0.0023432171,"about_ca_system_score_codex":0.00057998614,"about_ca_system_score_gemma":0.00090400566,"threshold_uncertainty_score":0.004659176},"labels":[],"label_agreement":null},{"id":"W4407976889","doi":"10.1016/j.jtct.2025.01.323","title":"Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients with Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Refractory (planetary science); B-cell lymphoma; Standard of care; Lymphoma; Oncology; Internal medicine; Materials science","score_opus":0.011799772427328882,"score_gpt":0.2592529896449002,"score_spread":0.2474532172175713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038213,0.0063314606,0.00015838761,0.00058121805,0.00025384332,0.00009468676,0.0002529236,0.000051555566,0.0018936882],"genre_scores_gemma":[0.9969489,0.0014489569,0.00023661063,0.00035175352,0.00012254635,0.00006274139,0.00027744516,0.000005501923,0.0005456429],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99970645,0.00013246849,0.000018143535,0.000040746763,0.00001854498,0.00008354594],"domain_scores_gemma":[0.99963415,0.00011945536,0.000038927625,0.000017384722,0.000010116223,0.00017987337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075712375,0.0004314863,0.0012244864,0.00033675882,0.00017719028,0.0006469702,0.00037171468,0.00055038,0.002916475],"category_scores_gemma":[0.00093240984,0.00015557461,0.0008088178,0.00032088693,0.0004484532,0.0007190371,0.00028539193,0.001408401,0.00030344806],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8005309,0.006409287,0.008362727,0.00056867645,0.00095073314,0.00023829177,0.00013102192,0.0017819871,0.007984341,0.00040219334,0.0026783012,0.1699615],"study_design_scores_gemma":[0.27164438,0.6099834,0.089729875,0.00028966786,0.0036550113,0.0009975972,0.0004969656,0.007409976,0.005526028,0.0010984585,0.009078771,0.000089938854],"about_ca_topic_score_codex":0.00089331117,"about_ca_topic_score_gemma":0.0032779379,"teacher_disagreement_score":0.002916475,"about_ca_system_score_codex":0.0005677035,"about_ca_system_score_gemma":0.0005954709,"threshold_uncertainty_score":0.009756625},"labels":[],"label_agreement":null},{"id":"W4408006873","doi":"10.1101/2025.02.26.24319604","title":"Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; University of British Columbia; Quest University Canada; University of Calgary","funders":"","keywords":"Pathognomonic; Fusion protein; Fusion; Medicine; Recombinant DNA; Chemistry; Philosophy; Biochemistry; Internal medicine; Disease","score_opus":0.03674016286590534,"score_gpt":0.31214767192650106,"score_spread":0.27540750906059575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408006873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97771454,0.003805857,0.012001517,0.00043030264,0.00008082064,0.00016085325,0.0008502055,0.00026544026,0.004690588],"genre_scores_gemma":[0.98933345,0.0010458216,0.004564727,0.000051766685,0.000014835435,0.000048621947,0.00075924944,0.000023995537,0.004157502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999063,0.000019694387,0.0000047472167,0.00001958396,0.000026849351,0.000022813756],"domain_scores_gemma":[0.9999647,0.0000070589194,0.0000069874877,0.000005601645,0.000004320895,0.00001130888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018535843,0.00023872714,0.00019817513,0.00013896158,0.0001690248,0.00040789804,0.00013473738,0.0002780283,0.0020731536],"category_scores_gemma":[0.00007733371,0.00008785549,0.00016263728,0.00010444274,0.00027074103,0.00015739634,0.00015579775,0.00071649486,0.0006191682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021186401,0.00009215613,0.0005715284,0.00006393856,0.000009998956,0.00009547875,0.0000356876,0.00035066914,0.9911476,0.0005576978,0.0005517447,0.006311603],"study_design_scores_gemma":[0.000039781957,0.0007214414,0.0016795656,0.0000051134825,0.000019512383,0.0006418943,0.000021809736,0.001202009,0.9807202,0.00008928084,0.014856015,0.0000033450076],"about_ca_topic_score_codex":0.00039531506,"about_ca_topic_score_gemma":0.00048421815,"teacher_disagreement_score":0.0020731536,"about_ca_system_score_codex":0.0003474798,"about_ca_system_score_gemma":0.000249456,"threshold_uncertainty_score":0.006935358},"labels":[],"label_agreement":null},{"id":"W4408032428","doi":"10.3390/curroncol32030142","title":"Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; Fluidigm (Canada); University of Ottawa; University of Calgary; Université de Montréal","funders":"AbbVie Canada","keywords":"Bispecific antibody; Medicine; Lymphoma; Antibody; Chimeric antigen receptor; Diffuse large B-cell lymphoma; Oncology; Refractory (planetary science); Cancer research; Internal medicine; Immunotherapy; Immunology; Cancer; Monoclonal antibody; Biology","score_opus":0.2203581579266412,"score_gpt":0.45881313153067205,"score_spread":0.23845497360403084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408032428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007535403,0.99918383,0.000041066443,0.0001873866,0.00007178103,0.000003048877,0.000006428297,0.00000274487,0.0004283834],"genre_scores_gemma":[0.0006947115,0.99864465,0.00010150463,0.00021510488,0.00006195877,0.000004110404,0.000017072904,9.856807e-7,0.00025991007],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998031,0.00003986343,0.000034024495,0.000027453472,0.0000744705,0.000021115737],"domain_scores_gemma":[0.9997516,0.000107103835,0.000046307305,0.00000553645,0.000070219045,0.000019140805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007262193,0.00045579273,0.00091310684,0.0018362426,0.00019378308,0.0007073237,0.00072029076,0.0008688825,0.002637593],"category_scores_gemma":[0.0007305469,0.00023970239,0.0004936968,0.0011976458,0.00032272557,0.0009203885,0.0004336321,0.0014096951,0.0012125722],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103802355,0.000040444105,0.00012989361,0.015710391,0.000088791516,0.00015409676,0.000037266924,0.00020747162,0.0010981358,0.0020598609,0.022371491,0.95799845],"study_design_scores_gemma":[0.00004766222,0.00012702144,0.00071113516,0.00698029,0.00016118064,0.0012696211,0.00004470803,0.00009113934,0.0005026156,0.0010781934,0.9889726,0.000013862112],"about_ca_topic_score_codex":0.0019478598,"about_ca_topic_score_gemma":0.0043530143,"teacher_disagreement_score":0.9980521,"about_ca_system_score_codex":0.0007316114,"about_ca_system_score_gemma":0.0011740223,"threshold_uncertainty_score":0.008823633},"labels":[],"label_agreement":null},{"id":"W4408037706","doi":"10.1101/2025.02.23.639405","title":"Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as potential CAR T cell target for pediatric solid tumors","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"","keywords":"Organoid; Proteomics; Cell; Cancer research; Biology; Computational biology; Cell biology; Genetics; Gene","score_opus":0.009270386752119325,"score_gpt":0.23905950557126165,"score_spread":0.22978911881914232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408037706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97929484,0.001461442,0.015125506,0.00033132997,0.000029574463,0.000073438874,0.0019143303,0.00023590188,0.0015335788],"genre_scores_gemma":[0.98705417,0.00089826656,0.009035436,0.00014842695,0.0000086295695,0.000059114194,0.0016803193,0.000044530247,0.0010712433],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998597,0.000022337494,0.000011021338,0.000037141403,0.000039881128,0.000029921415],"domain_scores_gemma":[0.99992263,0.000016831582,0.000018562087,0.000008128107,0.000014711068,0.000019115438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021617582,0.0002821244,0.00021397995,0.00034386915,0.00022474014,0.0003916154,0.00014498786,0.00027312106,0.0012613594],"category_scores_gemma":[0.0002069449,0.00010725881,0.00020564551,0.00021680314,0.0001677642,0.00017851403,0.0002110464,0.00036087545,0.00046006395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091542206,0.000012690439,0.0024884453,0.000043637847,0.000012828317,0.00021964713,0.000041269133,0.00022895953,0.99486005,0.000074896205,0.00020080934,0.0017252481],"study_design_scores_gemma":[0.000015245879,0.00017819507,0.025436407,0.000008946783,0.000038821345,0.0022204428,0.00024399527,0.0027764258,0.9628943,0.00013657921,0.0060403463,0.000010250263],"about_ca_topic_score_codex":0.0007213362,"about_ca_topic_score_gemma":0.0011319434,"teacher_disagreement_score":0.0012613594,"about_ca_system_score_codex":0.00025088928,"about_ca_system_score_gemma":0.00029887314,"threshold_uncertainty_score":0.004219651},"labels":[],"label_agreement":null},{"id":"W4408098504","doi":"10.1016/j.hlife.2025.02.003","title":"Harnessing allogeneic CAR-T cell therapy for autoimmune conditions","year":2025,"lang":"en","type":"article","venue":"hLife","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Cell therapy; CAR T-cell therapy; Medicine; Immunology; T cell; Cell; Chimeric antigen receptor; Biology; Immune system; Genetics","score_opus":0.0413054508756802,"score_gpt":0.3621299959722013,"score_spread":0.3208245450965211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408098504","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8015719,0.08137932,0.05425646,0.0063731866,0.0022555133,0.00052509387,0.00050510955,0.0009613872,0.052172005],"genre_scores_gemma":[0.9663703,0.017384978,0.006004115,0.0011350481,0.00058635423,0.00014116119,0.00023283357,0.000044872715,0.00810034],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99978155,0.000048636684,0.000009199895,0.000034155106,0.00004737094,0.00007915682],"domain_scores_gemma":[0.99993277,0.00001772575,0.000012836418,0.000012278197,0.000008055963,0.000016232729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040491417,0.00043538708,0.00033866838,0.0005128662,0.00020480761,0.0008423971,0.00034099954,0.00063032337,0.0042401934],"category_scores_gemma":[0.00022518089,0.000117622614,0.0002963513,0.00018685381,0.0004545269,0.0004115106,0.0005865836,0.0013935176,0.0009453591],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087698735,0.0008665841,0.001759244,0.0008702181,0.00012623926,0.001081395,0.00022956938,0.0012321584,0.7623313,0.021443551,0.005917367,0.20326538],"study_design_scores_gemma":[0.0008080369,0.007387939,0.005091787,0.00030750365,0.0004803013,0.006121952,0.0005159846,0.0052891653,0.70521235,0.008986909,0.25976065,0.00003748205],"about_ca_topic_score_codex":0.000248469,"about_ca_topic_score_gemma":0.0004176889,"teacher_disagreement_score":0.0042401934,"about_ca_system_score_codex":0.00025310158,"about_ca_system_score_gemma":0.00033562392,"threshold_uncertainty_score":0.014184833},"labels":[],"label_agreement":null},{"id":"W4408123725","doi":"10.1186/s12967-025-06253-4","title":"Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products","year":2025,"lang":"en","type":"review","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Potency; Medicine; Pharmacology; Drug approval; Medical physics; Drug; Chemistry","score_opus":0.19797502453293553,"score_gpt":0.4324895607580021,"score_spread":0.23451453622506657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408123725","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7415598,0.044572312,0.08790023,0.00186608,0.0010396952,0.003855355,0.04604224,0.002608313,0.07055606],"genre_scores_gemma":[0.9071227,0.01121097,0.04899179,0.0015133783,0.00021370374,0.0019839292,0.021394826,0.0005725989,0.006996199],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9549877,0.007164706,0.004469805,0.0030196356,0.029408311,0.00094984804],"domain_scores_gemma":[0.9248286,0.035589483,0.013589309,0.004654145,0.020498835,0.00083953683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02697809,0.0012555837,0.00094811304,0.007077347,0.0007261609,0.0025990645,0.0008391084,0.00087349664,0.003179718],"category_scores_gemma":[0.056161128,0.0005223911,0.0012784128,0.007882861,0.001335839,0.0011266727,0.0014090905,0.0019393899,0.002163988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024461076,0.000834212,0.4028214,0.0047295573,0.0010776179,0.0011269372,0.0019944669,0.0042958204,0.08435076,0.0036302048,0.020295601,0.4723973],"study_design_scores_gemma":[0.00011107819,0.0038734896,0.5839126,0.0011367856,0.001471316,0.0044856244,0.0025268118,0.00883825,0.24134256,0.0019107504,0.15008534,0.0003053306],"about_ca_topic_score_codex":0.0035048756,"about_ca_topic_score_gemma":0.0033143358,"teacher_disagreement_score":0.02697809,"about_ca_system_score_codex":0.00210923,"about_ca_system_score_gemma":0.0022822658,"threshold_uncertainty_score":0.14267546},"labels":[],"label_agreement":null},{"id":"W4408157999","doi":"10.1186/s40164-025-00610-1","title":"Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma","year":2025,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Follicular lymphoma; Refractory (planetary science); Medicine; Oncology; Follicular phase; Internal medicine; Lymphoma; Second line; First line; Biology","score_opus":0.051390398366162875,"score_gpt":0.39864506947045025,"score_spread":0.34725467110428737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408157999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97935677,0.00579445,0.0048337216,0.00024402524,0.00048737394,0.0024491039,0.003176361,0.000102354374,0.0035557495],"genre_scores_gemma":[0.99350774,0.00040272012,0.0026436055,0.00023288332,0.000083644016,0.0013605363,0.0010533029,0.000012941399,0.0007025999],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9878478,0.008859296,0.000821053,0.0010513371,0.0009335185,0.00048703246],"domain_scores_gemma":[0.99017817,0.005305563,0.002440196,0.0012008821,0.00043987163,0.0004352236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011143614,0.0013229362,0.0024861677,0.000756007,0.00027413457,0.00096244353,0.0012364791,0.0010899703,0.0070380396],"category_scores_gemma":[0.015628632,0.00042898286,0.005833757,0.00051951007,0.00083788834,0.0009170321,0.0011958446,0.0020578376,0.0004480552],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8988897,0.0021464336,0.014855198,0.0017215709,0.037792135,0.000051877334,0.00011483581,0.0039903186,0.002405136,0.0011077618,0.0010809345,0.03584409],"study_design_scores_gemma":[0.37268767,0.36206287,0.1120338,0.00050321606,0.095383056,0.000443091,0.0002708791,0.029080631,0.010385323,0.006173573,0.010735894,0.00024008322],"about_ca_topic_score_codex":0.0009795784,"about_ca_topic_score_gemma":0.0010387573,"teacher_disagreement_score":0.011143614,"about_ca_system_score_codex":0.0012347185,"about_ca_system_score_gemma":0.0010077006,"threshold_uncertainty_score":0.058933735},"labels":[],"label_agreement":null},{"id":"W4408174527","doi":"10.1016/j.isci.2025.112142","title":"DAP12-associated synthetic antigen receptors enable multi-targeting of T cells with independent chimeric receptors in a small genetic payload","year":2025,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Ministry of Colleges and Universities; Mitacs; Canada Research Chairs","keywords":"Chimeric antigen receptor; Receptor; Payload (computing); Computational biology; Antigen; Biology; Chemistry; Cell biology; Immunology; Computer science; Immunotherapy; Genetics; Immune system","score_opus":0.020551267834423972,"score_gpt":0.28104959284969044,"score_spread":0.2604983250152665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408174527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9422348,0.0021979779,0.05210777,0.00018582838,0.000053616404,0.00015338382,0.00022071623,0.0002711764,0.0025747584],"genre_scores_gemma":[0.9697222,0.00083088817,0.026148716,0.000057615,0.000012116446,0.000072727526,0.00021831339,0.00004368479,0.0028936502],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997907,0.000043262473,0.000021182757,0.00003759849,0.000059165057,0.000048090893],"domain_scores_gemma":[0.99985766,0.00002593125,0.000041601073,0.000019963956,0.000016832095,0.00003803292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021207232,0.00046705792,0.00027970117,0.00020301464,0.00010792671,0.00035214928,0.00036329246,0.00036149545,0.00106153],"category_scores_gemma":[0.00018887273,0.00015665637,0.00026644103,0.00016865597,0.00019527863,0.000300547,0.00039167027,0.00078197947,0.0004458523],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009400679,0.000030252242,0.000120226425,0.00004760136,0.000008950183,0.00012241345,0.000017409122,0.00038963027,0.9946385,0.00020576488,0.0000656461,0.004259654],"study_design_scores_gemma":[0.000016958278,0.0004950543,0.00035847168,0.00000426513,0.00002261754,0.00059503893,0.000010630766,0.0011935127,0.9925929,0.00005284143,0.0046512084,0.000006575905],"about_ca_topic_score_codex":0.00013310475,"about_ca_topic_score_gemma":0.00028041808,"teacher_disagreement_score":0.00106153,"about_ca_system_score_codex":0.00026742928,"about_ca_system_score_gemma":0.00014370588,"threshold_uncertainty_score":0.0035511851},"labels":[],"label_agreement":null},{"id":"W4408188213","doi":"10.1016/j.xcrm.2025.101994","title":"Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; HCA Healthcare","keywords":"Cancer research; Medicine","score_opus":0.030108361792868146,"score_gpt":0.3431106570374404,"score_spread":0.3130022952445723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408188213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212366,0.0008066399,0.0009752826,0.00019192853,0.000058322374,0.0021709064,0.0010373922,0.0001159839,0.0025198485],"genre_scores_gemma":[0.9798601,0.0013353083,0.0025515617,0.0006091912,0.000069416375,0.0031821833,0.0048308237,0.000051969146,0.0075094053],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99984694,0.000051504772,0.000004851883,0.00003632162,0.000021255224,0.000039103885],"domain_scores_gemma":[0.9997962,0.00002687073,0.00004126299,0.000018776796,0.00001648928,0.00010048306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064719963,0.0011694641,0.0010074213,0.00031628791,0.00027534107,0.00062419503,0.00056550984,0.0008353967,0.0025066899],"category_scores_gemma":[0.00031759418,0.0003909447,0.00050945044,0.00018696571,0.0004632699,0.00045277484,0.0002498852,0.002092952,0.0005741149],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2888447,0.17043489,0.01364292,0.0011014978,0.00082654937,0.00067192793,0.00061530963,0.011507644,0.3213125,0.0012682879,0.011564631,0.17820911],"study_design_scores_gemma":[0.17249149,0.7632613,0.01684885,0.00005817837,0.00030592555,0.00063437206,0.000097786215,0.0037767903,0.033603717,0.0005093547,0.008370151,0.000042095726],"about_ca_topic_score_codex":0.00062948855,"about_ca_topic_score_gemma":0.0019898138,"teacher_disagreement_score":0.0025066899,"about_ca_system_score_codex":0.00061774737,"about_ca_system_score_gemma":0.0013049558,"threshold_uncertainty_score":0.0083857775},"labels":[],"label_agreement":null},{"id":"W4408238872","doi":"10.3389/fimmu.2025.1533044","title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; National Research Council Canada; University of Ottawa","funders":"National Cancer Institute; National Research Council Canada; National Research Foundation of Korea; Ottawa Hospital Research Institute; Cancer Research Society; Canadian Institutes of Health Research; National Research Foundation","keywords":"Chimeric antigen receptor; Histone deacetylase; Cancer research; Histone deacetylase inhibitor; Immunotherapy; Cancer immunotherapy; Cytotoxic T cell; Immunology; Biology; Immune system; Histone; In vitro","score_opus":0.007671204556374219,"score_gpt":0.2872052454678329,"score_spread":0.27953404091145867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408238872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822291,0.0056914045,0.00592224,0.00014693037,0.00007191446,0.00007536521,0.0005548461,0.00024951712,0.005058669],"genre_scores_gemma":[0.9902029,0.002117496,0.003520751,0.000048777776,0.000014322557,0.000032723343,0.00057987694,0.00002277657,0.0034603868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998864,0.000013674849,0.0000116338615,0.000022570666,0.0000409216,0.000024804991],"domain_scores_gemma":[0.9999609,0.0000061561364,0.000010855811,0.000006028746,0.0000074876275,0.000008565259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008898584,0.00030666526,0.00034058583,0.00018979431,0.00011320501,0.00023758023,0.00023208748,0.00016813028,0.0014846871],"category_scores_gemma":[0.00008501688,0.000073080475,0.00019549734,0.00015923954,0.00014365396,0.00021818255,0.00012532258,0.00043917698,0.00034603383],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012593636,0.000045392466,0.00022023008,0.00007498055,0.0000097203065,0.000041243336,0.000014160803,0.00014436457,0.98981994,0.00012491533,0.000119799035,0.0092594195],"study_design_scores_gemma":[0.000013366265,0.00023347636,0.0014739957,0.0000021564838,0.000015854572,0.0001501269,0.000007968607,0.00047927487,0.9937605,0.000015818025,0.0038450724,0.0000023320106],"about_ca_topic_score_codex":0.0008597788,"about_ca_topic_score_gemma":0.0028418556,"teacher_disagreement_score":0.0014846871,"about_ca_system_score_codex":0.00041148037,"about_ca_system_score_gemma":0.00025802953,"threshold_uncertainty_score":0.0049667954},"labels":[],"label_agreement":null},{"id":"W4408246183","doi":"10.1007/s10637-025-01518-7","title":"First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Medicine; Cmax; Pharmacodynamics; Pharmacokinetics; Adverse effect; Maculopapular rash; Rash; Internal medicine; Gastroenterology; Area under the curve; Lymphoma; Pharmacology; Toxicity","score_opus":0.012745993595768064,"score_gpt":0.30562469083016436,"score_spread":0.2928786972343963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408246183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932365,0.0015261914,0.00063983374,0.00038848334,0.000112573,0.0012546527,0.00080045225,0.00012805128,0.0019133129],"genre_scores_gemma":[0.99283195,0.0010512713,0.0009830412,0.00048629232,0.000077190445,0.00079049874,0.0011179589,0.00003914333,0.0026226437],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996263,0.00013866671,0.000011632721,0.00006354846,0.00003375548,0.00012610911],"domain_scores_gemma":[0.99964094,0.000049348946,0.000039771076,0.000033398683,0.000017633942,0.00021884777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011830667,0.0015790781,0.0020189842,0.0005319752,0.00051318866,0.0011961972,0.0008277099,0.00097978,0.002779989],"category_scores_gemma":[0.0004866073,0.00062936527,0.0010393462,0.00042623386,0.0011403325,0.0008766585,0.00034167757,0.0033919879,0.00082070206],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47126833,0.2055162,0.008011415,0.00092413166,0.0017419792,0.000614096,0.00077265286,0.010016872,0.13539332,0.0008017847,0.009838243,0.15510108],"study_design_scores_gemma":[0.31610987,0.64764744,0.013299733,0.000027186465,0.0005381285,0.00039142236,0.00017005725,0.0032730617,0.013186773,0.00040532852,0.00489739,0.000053629206],"about_ca_topic_score_codex":0.0019125347,"about_ca_topic_score_gemma":0.004564729,"teacher_disagreement_score":0.002779989,"about_ca_system_score_codex":0.0014328498,"about_ca_system_score_gemma":0.0014840334,"threshold_uncertainty_score":0.010396123},"labels":[],"label_agreement":null},{"id":"W4408289832","doi":"10.3390/biomedicines13030664","title":"Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials","year":2025,"lang":"en","type":"review","venue":"Biomedicines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Alberta; Stollery Children's Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Medicine; Immunotherapy; Tumor microenvironment; Chimeric antigen receptor; Metastasis; Immune system; Immunogenicity; Oncology; Cancer; Clinical trial; Osteosarcoma; Immunology; Cancer research; Internal medicine","score_opus":0.5553001008875875,"score_gpt":0.5392191322367651,"score_spread":0.016080968650822425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408289832","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012381322,0.9978644,0.0001369765,0.0008994381,0.0002604481,0.00002214379,0.000051257164,0.0000072045405,0.00063426694],"genre_scores_gemma":[0.0009470352,0.99706393,0.00031083764,0.0010671158,0.00027316174,0.00003893722,0.00007514111,0.0000024968524,0.00022125235],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9994242,0.00016354038,0.00015617281,0.000074670024,0.00013880922,0.000042661937],"domain_scores_gemma":[0.9976495,0.0014045495,0.00036021214,0.000046223027,0.00044939367,0.00009005372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020476398,0.00075585244,0.0016989576,0.002442506,0.00035129656,0.0017098562,0.0010668102,0.0011589587,0.0056005744],"category_scores_gemma":[0.0039771516,0.00029822247,0.0014265691,0.0023691412,0.00046622497,0.0021889275,0.00095172593,0.0017691507,0.0010411514],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002840286,0.00007634483,0.0002841344,0.105785444,0.00034402896,0.00018748677,0.00016825402,0.00036524763,0.0009524729,0.0042378926,0.043060523,0.8442541],"study_design_scores_gemma":[0.00010086029,0.00033533864,0.0010265599,0.06319069,0.0019352455,0.0009821461,0.00019084875,0.00020762104,0.0004042777,0.0026167994,0.9289614,0.000048175076],"about_ca_topic_score_codex":0.0008750553,"about_ca_topic_score_gemma":0.002466549,"teacher_disagreement_score":0.0056005744,"about_ca_system_score_codex":0.00082711305,"about_ca_system_score_gemma":0.002609619,"threshold_uncertainty_score":0.018735766},"labels":[],"label_agreement":null},{"id":"W4408362108","doi":"10.1158/2326-6066.cir-24-0758","title":"IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Amgen (Canada); Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute on Aging; Congressionally Directed Medical Research Programs; National Institute of Allergy and Infectious Diseases; Natural Sciences and Engineering Research Council of Canada; American Cancer Society; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Pancreatic Cancer Action Network","keywords":"CD8; CD40; T cell; Cancer research; Cytotoxic T cell; Biology; Immunology; Antigen; Immune system; Genetics; In vitro","score_opus":0.06724943435714295,"score_gpt":0.39998855345792045,"score_spread":0.33273911910077747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408362108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99899083,0.00026040414,0.00034777753,0.000022139608,0.000012244377,0.0000119837205,0.00003963472,0.000026997079,0.0002879499],"genre_scores_gemma":[0.998596,0.00011649398,0.0005411809,0.000026298821,0.0000066779107,0.00001384882,0.00009905639,0.000007047873,0.00059342507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998173,0.000036281974,0.00002317657,0.000030801042,0.000035808018,0.0000568076],"domain_scores_gemma":[0.99992657,0.0000101711275,0.000014675716,0.000010258959,0.0000066676917,0.000031635456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014342552,0.00019095713,0.00023287191,0.00017110023,0.00008384671,0.00030077173,0.00013007807,0.0001558163,0.0007855832],"category_scores_gemma":[0.00012520098,0.0000913898,0.00017033417,0.00007778627,0.00013191387,0.00014263559,0.0001631245,0.00051069877,0.00018477911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046776177,0.00014089092,0.00068724336,0.000028199069,0.0000075197986,0.000027225413,0.00001889329,0.00014586918,0.9950879,0.000041734587,0.000041513682,0.0033053355],"study_design_scores_gemma":[0.00009285092,0.0026395908,0.0068319966,0.0000064351075,0.000042069558,0.00025366788,0.000029990157,0.0012563472,0.9867007,0.0000365106,0.0021067415,0.0000031233594],"about_ca_topic_score_codex":0.00024507233,"about_ca_topic_score_gemma":0.0005376708,"teacher_disagreement_score":0.0007855832,"about_ca_system_score_codex":0.00020098001,"about_ca_system_score_gemma":0.0001531074,"threshold_uncertainty_score":0.0026280284},"labels":[],"label_agreement":null},{"id":"W4408502164","doi":"10.1038/s43018-025-00921-6","title":"Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Alberta","funders":"Regeneron Pharmaceuticals","keywords":"Refractory (planetary science); Medicine; Internal medicine; Oncology; Diffuse large B-cell lymphoma; Lymphoma; Phases of clinical research; Clinical trial; Primary (astronomy); Materials science; Physics","score_opus":0.0062235947205640406,"score_gpt":0.30842749525276114,"score_spread":0.3022039005321971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408502164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956814,0.002305421,0.00019095858,0.00014092763,0.000029973964,0.00034365992,0.0004316502,0.00004055117,0.00083546084],"genre_scores_gemma":[0.9941685,0.0014506016,0.00060012203,0.0005103842,0.00009288291,0.0005250783,0.0015667133,0.000011981025,0.0010736804],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999728,0.00014865234,0.000014472652,0.000038969018,0.000026979616,0.000043024913],"domain_scores_gemma":[0.9997844,0.000039374005,0.000050361083,0.00001840396,0.000012597224,0.00009480311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012033146,0.0007243414,0.0012227347,0.00021262222,0.00015711968,0.000609469,0.0003787592,0.0005245471,0.0015710427],"category_scores_gemma":[0.00047836156,0.00021419572,0.0006214177,0.00020439364,0.0003154787,0.00051773316,0.000254418,0.0011807908,0.00036493555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.68609333,0.023263242,0.020826597,0.0014239622,0.0018691228,0.0006896452,0.00035614692,0.0032136948,0.05897031,0.00033433415,0.004879487,0.19808017],"study_design_scores_gemma":[0.57579917,0.3534017,0.05078781,0.00011875267,0.00082191505,0.0010605489,0.000107796885,0.0035666376,0.0067401947,0.0003783455,0.0071678595,0.00004930653],"about_ca_topic_score_codex":0.00021375605,"about_ca_topic_score_gemma":0.00088550063,"teacher_disagreement_score":0.0015710427,"about_ca_system_score_codex":0.00047983573,"about_ca_system_score_gemma":0.000449574,"threshold_uncertainty_score":0.006363809},"labels":[],"label_agreement":null},{"id":"W4408502996","doi":"10.3390/ijms26062686","title":"Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"LNCaP; Bombesin; Prostate cancer; In vivo; Immunotherapy; Cancer research; Cancer cell; In vitro; Ex vivo; Cancer immunotherapy; Cancer; Peptide; Chemistry; Biology; Medicine; Receptor; Internal medicine; Biochemistry; Neuropeptide","score_opus":0.011388895319872017,"score_gpt":0.32815359243533093,"score_spread":0.3167646971154589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408502996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97696245,0.007137865,0.012885091,0.00019209267,0.000044685443,0.00009108078,0.00016237557,0.00015695262,0.0023673633],"genre_scores_gemma":[0.9892267,0.0019167084,0.0060410146,0.00009864606,0.000011161556,0.0000481006,0.00020169944,0.000015392243,0.0024404624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999237,0.000014643979,0.000004238631,0.0000176614,0.000019611047,0.00002000986],"domain_scores_gemma":[0.99997973,0.0000024352523,0.000005649531,0.0000024872697,0.0000036743975,0.0000060528596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107793414,0.00028836442,0.00023666528,0.00011341808,0.00007302231,0.0002233629,0.00016766299,0.00036231778,0.0007461779],"category_scores_gemma":[0.000075234646,0.000084416,0.00015279616,0.0001242558,0.00012831444,0.00018334595,0.0002265607,0.0004099743,0.00028346822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000855102,0.000031498028,0.00011021186,0.00007014731,0.000008541545,0.00005121834,0.000016863958,0.00025476556,0.99335396,0.00015192608,0.000107328924,0.0057580895],"study_design_scores_gemma":[0.000025167654,0.0005945662,0.00070999743,0.0000052298324,0.00002545325,0.00037561185,0.00002040492,0.0013934795,0.9901626,0.00004850984,0.006632426,0.0000065287863],"about_ca_topic_score_codex":0.00023926947,"about_ca_topic_score_gemma":0.00040295091,"teacher_disagreement_score":0.0007461779,"about_ca_system_score_codex":0.00020253824,"about_ca_system_score_gemma":0.00008602714,"threshold_uncertainty_score":0.0024962425},"labels":[],"label_agreement":null},{"id":"W4408505554","doi":"10.3390/curroncol32030173","title":"Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Fleurimont; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Cytokine release syndrome; Single Center; Internal medicine; Lymphoma; Refractory (planetary science); Oncology; Progression-free survival; Chimeric antigen receptor; Gastroenterology; Overall survival; Immunotherapy; Cancer","score_opus":0.06359163350671208,"score_gpt":0.40190500971638826,"score_spread":0.33831337620967616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408505554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981305,0.00055189873,0.0006620922,0.000057760848,0.0000055329892,0.0000543765,0.000025970183,0.000016300773,0.00049550267],"genre_scores_gemma":[0.998417,0.00043973475,0.0007018937,0.00007521984,0.00002891257,0.000042986445,0.00010885236,0.00001035112,0.00017501884],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993573,0.00038539508,0.000039585222,0.00008293214,0.00005820177,0.000076577344],"domain_scores_gemma":[0.99931777,0.00025700833,0.000096998425,0.00008624742,0.000044341487,0.00019768476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017977023,0.00047066848,0.00043847525,0.00022498841,0.00037539168,0.00068228244,0.00052864995,0.0005281221,0.0010416087],"category_scores_gemma":[0.001538982,0.00017450622,0.00046153678,0.00024704603,0.00055815984,0.0004514511,0.00051782175,0.0005598814,0.0003776802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042328443,0.048491057,0.2203612,0.0006524213,0.00093872636,0.008792096,0.004204136,0.013292226,0.08846348,0.0006418824,0.0027851951,0.5690491],"study_design_scores_gemma":[0.01877064,0.51632136,0.3231712,0.00013298327,0.00088887865,0.028906982,0.0018296653,0.013814084,0.08045117,0.0007670117,0.014766287,0.00017980114],"about_ca_topic_score_codex":0.00039277272,"about_ca_topic_score_gemma":0.0005534147,"teacher_disagreement_score":0.0017977023,"about_ca_system_score_codex":0.0004968996,"about_ca_system_score_gemma":0.00023266776,"threshold_uncertainty_score":0.0095072985},"labels":[],"label_agreement":null},{"id":"W4408621916","doi":"10.3390/curroncol32030177","title":"The Changing Role of Allogeneic Stem Cell Transplantation in Adult B-ALL in the Era of CAR T Cell Therapy","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Transplantation; Hematopoietic stem cell transplantation; Oncology; Stem cell; Internal medicine; Immunology; Immunotherapy; Cancer","score_opus":0.12400400123635356,"score_gpt":0.44257048758442663,"score_spread":0.31856648634807305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408621916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00040785095,0.99796474,0.0001036451,0.00084765605,0.00020933649,0.0000033508998,0.000010286024,0.0000037064417,0.00044952089],"genre_scores_gemma":[0.0022168697,0.99628145,0.0001810461,0.0008027772,0.00036906838,0.000007676102,0.0000140945795,0.0000015483965,0.00012551142],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996973,0.00011298985,0.00006137431,0.000037001213,0.00007440001,0.00001699416],"domain_scores_gemma":[0.9993518,0.00043655335,0.0000818869,0.00001108595,0.00008797197,0.000030777952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011245662,0.0002626597,0.0008806709,0.0007357204,0.00012603059,0.000720939,0.00044247802,0.0005963365,0.0012456438],"category_scores_gemma":[0.0015072749,0.00012494945,0.0004278916,0.00083249935,0.00042201456,0.0010615218,0.00038396596,0.0011968965,0.00036744153],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021061732,0.00003775833,0.00029288797,0.015694868,0.000118000586,0.00024084469,0.0000835327,0.00036198355,0.0011618999,0.0028273806,0.013116085,0.9658541],"study_design_scores_gemma":[0.000106310916,0.00054842094,0.0024532268,0.013185948,0.00044489102,0.0017030704,0.00015929993,0.00017527274,0.0006375186,0.0033322945,0.97723085,0.000022987753],"about_ca_topic_score_codex":0.00050734996,"about_ca_topic_score_gemma":0.0012823371,"teacher_disagreement_score":0.0012456438,"about_ca_system_score_codex":0.00047054823,"about_ca_system_score_gemma":0.0009309567,"threshold_uncertainty_score":0.005947292},"labels":[],"label_agreement":null},{"id":"W4408770668","doi":"10.1038/s43018-025-00934-1","title":"CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology; Japan Agency for Medical Research and Development; Takeda Science Foundation","keywords":"Myeloid leukemia; Immunology; Human leukocyte antigen; Haematopoiesis; Stem cell; Myeloid; Leukemia; Medicine; Cancer research; Biology; Antigen; Cell biology","score_opus":0.009192645512119011,"score_gpt":0.2921316737030913,"score_spread":0.2829390281909723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408770668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863664,0.004333413,0.0025313846,0.00040468943,0.00020057571,0.00011129512,0.00010797045,0.00012947597,0.0058147595],"genre_scores_gemma":[0.99808276,0.00062958756,0.0004004078,0.000087364366,0.00004011904,0.000026407415,0.00008540212,0.000006918334,0.0006410513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998615,0.00003128004,0.0000122471265,0.000015793421,0.000021145685,0.00005807895],"domain_scores_gemma":[0.99990547,0.00002395387,0.00002031859,0.000017659544,0.0000040480254,0.000028571043],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033278126,0.00019037737,0.00037702944,0.00021378968,0.00020450946,0.0005010742,0.00024013405,0.0003446223,0.001782087],"category_scores_gemma":[0.00026727226,0.0000991828,0.0002484342,0.00018718619,0.00036639895,0.00035693642,0.00023378427,0.00080651697,0.00033332483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047908995,0.0070697786,0.032798357,0.0010161664,0.00041871433,0.011094253,0.000522722,0.008288462,0.5357071,0.015651943,0.009180631,0.3303428],"study_design_scores_gemma":[0.00817778,0.08095226,0.13862744,0.00020693225,0.0013323899,0.053456835,0.0005910838,0.026658524,0.58722866,0.007603913,0.09507719,0.000087084714],"about_ca_topic_score_codex":0.00031617246,"about_ca_topic_score_gemma":0.00056576834,"teacher_disagreement_score":0.001782087,"about_ca_system_score_codex":0.00025501274,"about_ca_system_score_gemma":0.0003081121,"threshold_uncertainty_score":0.0059616566},"labels":[],"label_agreement":null},{"id":"W4408810005","doi":"10.26443/msurj.v1i2.303","title":"Characterizing Signals Associated with the pre-TCR during T Cell Development","year":2025,"lang":"en","type":"article","venue":"McGill Science Undergraduate Research Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"T-cell receptor; T cell; Computer science; Biology; Immunology; Immune system","score_opus":0.05802441424722297,"score_gpt":0.367554316256239,"score_spread":0.30952990200901603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408810005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810416,0.003305447,0.0064901607,0.000060586364,0.000022086344,0.00004551045,0.00056038337,0.00007163076,0.0013399777],"genre_scores_gemma":[0.9857022,0.003894501,0.0068451534,0.000101190846,0.000021147696,0.0001573793,0.0010762449,0.000042486474,0.0021597564],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981934,0.0000150189635,0.000013709865,0.000040214534,0.000065372624,0.000046467227],"domain_scores_gemma":[0.9998437,0.000040616596,0.00003388149,0.000012689321,0.000032841606,0.00003620589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001799597,0.00026353815,0.00025287076,0.00035864394,0.00019906562,0.0005132716,0.0003087334,0.00035692198,0.0011492152],"category_scores_gemma":[0.00020317962,0.00013022638,0.00024546447,0.0003847991,0.00020127899,0.00043723875,0.00023613445,0.0011214461,0.00046051154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007433028,0.0000129186865,0.00029520746,0.00003013822,0.0000017995588,0.000036885962,0.000021368916,0.000028209392,0.99865746,0.00004336007,0.000009699365,0.00078865286],"study_design_scores_gemma":[0.000012050347,0.00031428077,0.02931169,0.000017965858,0.000022345399,0.0003475657,0.00010549882,0.00090412446,0.96714,0.000097018,0.0017201788,0.000007116231],"about_ca_topic_score_codex":0.00040990338,"about_ca_topic_score_gemma":0.0006073745,"teacher_disagreement_score":0.0011492152,"about_ca_system_score_codex":0.00033199505,"about_ca_system_score_gemma":0.00021288512,"threshold_uncertainty_score":0.0038444996},"labels":[],"label_agreement":null},{"id":"W4408824469","doi":"10.1017/cts.2024.996","title":"372 Defining and designing a remote monitoring tool for CAR T-cell therapy patients","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical and Translational Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science; Medicine","score_opus":0.09957007446169311,"score_gpt":0.4425670342879195,"score_spread":0.34299695982622636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408824469","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35692212,0.014208251,0.5141215,0.007657647,0.001375847,0.013771138,0.0023359817,0.0113194985,0.078288004],"genre_scores_gemma":[0.42414284,0.0061034393,0.54166204,0.0028236848,0.0002693263,0.007226383,0.00129982,0.00036251367,0.016109968],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9978248,0.0011242734,0.00025661828,0.00024239843,0.00041734293,0.00013462034],"domain_scores_gemma":[0.99572647,0.0027547816,0.0003161814,0.00019200705,0.0008196204,0.00019088566],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002937818,0.00066679606,0.0003963781,0.000855057,0.0005572843,0.002175087,0.0011687541,0.001398561,0.006733046],"category_scores_gemma":[0.0098144775,0.0003472882,0.0009434201,0.00036133867,0.00047977126,0.0018156861,0.0012054621,0.00063851767,0.0027448065],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007316231,0.0008100794,0.015031308,0.011669599,0.00011118931,0.0024124945,0.012804617,0.0015188323,0.030860864,0.0042807083,0.028836219,0.89093244],"study_design_scores_gemma":[0.0008000055,0.00801651,0.06457505,0.013931271,0.0010966338,0.017307175,0.023199052,0.022460494,0.059191585,0.010551622,0.77805763,0.00081305334],"about_ca_topic_score_codex":0.00059056433,"about_ca_topic_score_gemma":0.0008802685,"teacher_disagreement_score":0.006733046,"about_ca_system_score_codex":0.0004223822,"about_ca_system_score_gemma":0.0013108717,"threshold_uncertainty_score":0.022524357},"labels":[],"label_agreement":null},{"id":"W4408856819","doi":"10.1016/j.omton.2025.200977","title":"Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Miltenyi Biotec; Indian Council of Medical Research","keywords":"CAR T-cell therapy; CD19; Cell therapy; Medicine; Internal medicine; Cell; Chimeric antigen receptor; Immunotherapy; Chemistry","score_opus":0.015318148437875842,"score_gpt":0.3357818229476246,"score_spread":0.3204636745097488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408856819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485636,0.0006845744,0.00037825268,0.0002486385,0.000045549223,0.0009857778,0.00076355966,0.00007307638,0.0019641737],"genre_scores_gemma":[0.9940446,0.00045168735,0.0006256975,0.00034986457,0.000076505865,0.0010536414,0.0013507836,0.00001895138,0.002028223],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996253,0.00018477747,0.0000122323645,0.000037055222,0.00003543078,0.00010517996],"domain_scores_gemma":[0.99956805,0.000093914765,0.00009122989,0.00005640265,0.000019628053,0.00017072733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009957578,0.00086532236,0.0009449179,0.00043006157,0.00031593922,0.0011196149,0.00084486295,0.0010917785,0.004623745],"category_scores_gemma":[0.0006739037,0.0004110078,0.0009657945,0.0005288384,0.00089822855,0.0006385713,0.00037131942,0.0022411826,0.0009704563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.812502,0.043359466,0.012307788,0.00052643166,0.00084550463,0.00047966308,0.0002024761,0.0035462133,0.014219913,0.0006471041,0.0031465234,0.10821698],"study_design_scores_gemma":[0.4985039,0.4604427,0.027271306,0.000058479312,0.00074514205,0.0005733644,0.000119128286,0.0021443325,0.005040079,0.0005184685,0.0045276126,0.000055532357],"about_ca_topic_score_codex":0.00075622887,"about_ca_topic_score_gemma":0.0010712679,"teacher_disagreement_score":0.004623745,"about_ca_system_score_codex":0.0009355882,"about_ca_system_score_gemma":0.0011192141,"threshold_uncertainty_score":0.015467942},"labels":[],"label_agreement":null},{"id":"W4408939564","doi":"10.3390/curroncol32040198","title":"Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Pathogenesis; Disease; Cytokine; Cancer; Intensive care medicine; Immunology; Bioinformatics; Cytokine release syndrome; Infectious disease (medical specialty); Pathology; Internal medicine; Coronavirus disease 2019 (COVID-19); Biology","score_opus":0.07467834341829367,"score_gpt":0.4168006779541516,"score_spread":0.34212233453585794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408939564","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008406483,0.99780935,0.00007367663,0.0008008131,0.00009829103,0.0000061810874,0.000018758794,0.0000018148687,0.00035046125],"genre_scores_gemma":[0.023775924,0.9739083,0.00055741303,0.00091796665,0.0006465885,0.000023898965,0.00005804057,0.0000016812335,0.00011020732],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991353,0.00030183472,0.00024900166,0.00009980513,0.00016585329,0.000048196376],"domain_scores_gemma":[0.99660254,0.0022093845,0.0007123099,0.00003930166,0.00036699453,0.00006941486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013113343,0.00041149667,0.0010268913,0.0023354224,0.00025899324,0.000890441,0.00043416422,0.00096748496,0.00094531005],"category_scores_gemma":[0.0043745604,0.00015712118,0.00082481967,0.0019091744,0.00044394788,0.0012956711,0.00045140766,0.00069251267,0.00016671619],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046499542,0.00009272012,0.031038282,0.15879561,0.0011035234,0.0039392,0.00069539994,0.00056101615,0.0020018972,0.0036213861,0.021799473,0.77588654],"study_design_scores_gemma":[0.00023871858,0.00091475464,0.09111598,0.35967016,0.0051383823,0.06901121,0.0034212524,0.00091968686,0.0019173542,0.007786497,0.45968673,0.00017924028],"about_ca_topic_score_codex":0.0012347925,"about_ca_topic_score_gemma":0.0016759145,"teacher_disagreement_score":0.0023354224,"about_ca_system_score_codex":0.00069996924,"about_ca_system_score_gemma":0.0014565804,"threshold_uncertainty_score":0.00693506},"labels":[],"label_agreement":null},{"id":"W4408957618","doi":"10.1111/bjh.20061","title":"CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Natural Science Foundation of Shandong Province; National Natural Science Foundation of China","keywords":"Chimeric antigen receptor; Immunology; CD19; Antigen; Immune thrombocytopenia; Medicine; Immune system; Receptor; Virology; T cell; Antibody; Internal medicine","score_opus":0.017159117864516304,"score_gpt":0.3131646132022168,"score_spread":0.2960054953377005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408957618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973684,0.0075828875,0.00936171,0.00046001966,0.00029873961,0.00039794017,0.0005946696,0.00054316316,0.007076972],"genre_scores_gemma":[0.99169815,0.002158873,0.0024486578,0.00010652026,0.000045161407,0.00020502634,0.00041316924,0.00003124357,0.0028932476],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997789,0.000067426714,0.000013811117,0.000029758106,0.000048976523,0.000061095554],"domain_scores_gemma":[0.9999056,0.000021900625,0.000023535635,0.000015822912,0.000008879177,0.00002440427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027130562,0.0005668914,0.0004353574,0.0005178299,0.00014512977,0.00029642077,0.0002952759,0.0005888619,0.0015464688],"category_scores_gemma":[0.00012502108,0.000117539756,0.00028399407,0.00016983079,0.00025188323,0.00018020438,0.0001801276,0.00091728684,0.00038272984],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001820377,0.001321004,0.00034552263,0.00031122772,0.00005725694,0.0005146566,0.000074228956,0.0023207206,0.9584009,0.0018392635,0.0011921468,0.03180282],"study_design_scores_gemma":[0.001099376,0.014144405,0.0014686212,0.000032517084,0.00012589211,0.0013036383,0.000021960861,0.005139313,0.9559018,0.00030098332,0.020448992,0.000012404125],"about_ca_topic_score_codex":0.00055054104,"about_ca_topic_score_gemma":0.00049788004,"teacher_disagreement_score":0.0015464688,"about_ca_system_score_codex":0.00034051892,"about_ca_system_score_gemma":0.00026909276,"threshold_uncertainty_score":0.0051734447},"labels":[],"label_agreement":null},{"id":"W4409039889","doi":"10.1038/s41591-025-03532-x","title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Lymphoma; Biomarker; Signature (topology); Medicine; Hodgkin lymphoma; Immunology; Inflammatory response; Inflammation; Oncology; Cancer research; Biology; Genetics; Mathematics","score_opus":0.009917450318926229,"score_gpt":0.33742553321095087,"score_spread":0.32750808289202465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409039889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984073,0.0003784812,0.014688465,0.00009061191,0.000006958433,0.00001944383,0.0003952263,0.00009188642,0.00025593204],"genre_scores_gemma":[0.9970758,0.00007015517,0.002275677,0.00002334941,0.000007831829,0.000012667886,0.00037131837,0.000005080366,0.0001580938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99975806,0.00012076415,0.000012392374,0.000053238207,0.00003373557,0.000021823218],"domain_scores_gemma":[0.9995592,0.0002090277,0.00014260542,0.000035888268,0.000025642661,0.000027650965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090880477,0.0003174077,0.00036284508,0.0003186739,0.00010290146,0.0005271984,0.00017457746,0.00019643403,0.00039351967],"category_scores_gemma":[0.0015898598,0.00011011109,0.00026351455,0.00020423955,0.00017634417,0.00021549588,0.00042790058,0.0003689083,0.00008476754],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027383668,0.00032878865,0.7982845,0.00011793389,0.00040561566,0.00022626673,0.00020505226,0.08970997,0.03588617,0.00062868895,0.0009514046,0.07051721],"study_design_scores_gemma":[0.00006812242,0.0009929958,0.38046157,0.000019856752,0.00020866423,0.00043856792,0.00019421602,0.597011,0.017317686,0.001978128,0.0012692472,0.000039884584],"about_ca_topic_score_codex":0.001071351,"about_ca_topic_score_gemma":0.0014850372,"teacher_disagreement_score":0.001071351,"about_ca_system_score_codex":0.0002672781,"about_ca_system_score_gemma":0.0003435893,"threshold_uncertainty_score":0.00480628},"labels":[],"label_agreement":null},{"id":"W4409040539","doi":"10.51731/cjht.2025.1108","title":"Ciltacabtagene Autoleucel (Carvykti)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.04058088739669979,"score_gpt":0.3538447205249171,"score_spread":0.3132638331282173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409040539","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012030994,0.93568635,0.0009419413,0.0023047926,0.00049378135,0.00021080002,0.0018911883,0.00018140428,0.046258684],"genre_scores_gemma":[0.15208562,0.8050163,0.00447144,0.0034915637,0.00045635286,0.00026308055,0.0040572826,0.000061105064,0.030097356],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995222,0.00007776865,0.000039283124,0.000042038464,0.00026728655,0.000051404637],"domain_scores_gemma":[0.9994746,0.00014307936,0.00013045751,0.000010977304,0.00017808775,0.00006283487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006851475,0.00019115898,0.00040702877,0.0011689807,0.00020151018,0.0010533986,0.00033797877,0.00038166431,0.004977065],"category_scores_gemma":[0.00097311346,0.000073809,0.0004584678,0.0010595658,0.00019954448,0.0003581282,0.00019753994,0.0005223451,0.0008199739],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053619914,0.00006804082,0.00098154,0.0065234643,0.00015758393,0.00013802802,0.000036300276,0.00022207218,0.004195157,0.0021669269,0.050498422,0.9344763],"study_design_scores_gemma":[0.00029681227,0.00063191366,0.0048033977,0.0024923254,0.00029524317,0.00075685035,0.000047002664,0.00014838511,0.0030152162,0.00023682721,0.98725986,0.000016248954],"about_ca_topic_score_codex":0.019168373,"about_ca_topic_score_gemma":0.085715786,"teacher_disagreement_score":0.019168373,"about_ca_system_score_codex":0.002342145,"about_ca_system_score_gemma":0.0031305696,"threshold_uncertainty_score":0.038113594},"labels":[],"label_agreement":null},{"id":"W4409086045","doi":"10.1103/physrevresearch.7.023003","title":"Comparing kinetic proofreading and kinetic segregation for T cell receptor activation","year":2025,"lang":"en","type":"article","venue":"Physical Review Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Natural Sciences and Engineering Research Council of Canada; Advanced Research Projects Agency; Defense Advanced Research Projects Agency; Oncode Institute; Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"Kinetic energy; Proofreading; Biophysics; Chemistry; Computational biology; Cell biology; Computer science; Biology; Physics; Biochemistry; Enzyme; Polymerase","score_opus":0.13784381884062546,"score_gpt":0.46845922590877537,"score_spread":0.3306154070681499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409086045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8340806,0.004204025,0.13988553,0.0012682084,0.0002726875,0.00010398072,0.00021279194,0.00032249704,0.019649586],"genre_scores_gemma":[0.9908179,0.0011313782,0.0063442485,0.000073183764,0.000031027936,0.000057942005,0.00010053081,0.000045947152,0.0013977301],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9995401,0.00013073646,0.000025064657,0.00008593463,0.00011514731,0.000103114675],"domain_scores_gemma":[0.99581665,0.0031598744,0.000381888,0.00024850023,0.00022498413,0.0001681249],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011586231,0.0005936162,0.0008100704,0.00053473515,0.00038460214,0.0014406595,0.0010810652,0.0011396593,0.0029664964],"category_scores_gemma":[0.006994817,0.00028036305,0.0008901202,0.0004446687,0.0008721494,0.0025540253,0.000579483,0.0008559757,0.0005443912],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005295618,0.00027367187,0.0027869495,0.0004012612,0.00005513589,0.00029371094,0.00012592753,0.87582904,0.022013633,0.08018143,0.00085087674,0.016658703],"study_design_scores_gemma":[0.00004023215,0.00015609177,0.00054323405,0.000013912971,0.000023700051,0.000054947577,0.00003254636,0.9815516,0.0050014695,0.012013605,0.0005383249,0.00003029913],"about_ca_topic_score_codex":0.0021320344,"about_ca_topic_score_gemma":0.0009478538,"teacher_disagreement_score":0.0029664964,"about_ca_system_score_codex":0.0014658071,"about_ca_system_score_gemma":0.0010500517,"threshold_uncertainty_score":0.010635257},"labels":[],"label_agreement":null},{"id":"W4409109865","doi":"10.1101/2025.03.28.645991","title":"Mapping cellular targets of covalent cancer drugs in the entire mammalian body","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"In vivo; Computer science; Drug discovery; Click chemistry; Computational biology; Chemistry; Nanotechnology; Biology; Combinatorial chemistry; Materials science; Biochemistry","score_opus":0.02043507199465934,"score_gpt":0.27511920938620515,"score_spread":0.25468413739154583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409109865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7022084,0.0040157987,0.27821037,0.0006066229,0.00008541648,0.00010103991,0.0015152033,0.0013899516,0.011867284],"genre_scores_gemma":[0.90525776,0.002867692,0.08382451,0.00042352424,0.000021344804,0.00013174988,0.0008181703,0.0002210049,0.006434272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999814,0.000019100313,0.0000070236247,0.000067631365,0.00006366085,0.000028699886],"domain_scores_gemma":[0.9999101,0.000025110643,0.000027023108,0.000012214817,0.000013526232,0.000012054057],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026993713,0.00036059503,0.0002801319,0.00041559758,0.00021687115,0.0008316637,0.00027029382,0.0006165848,0.0011100576],"category_scores_gemma":[0.00020845911,0.0002909986,0.0002756907,0.00023854055,0.00038250443,0.00040941974,0.0005123753,0.0005487527,0.00041663964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003930765,0.00000921185,0.00039072963,0.000042138916,0.000011103634,0.000060284354,0.000034447534,0.0010546737,0.99160916,0.00095709553,0.00015886099,0.0056329304],"study_design_scores_gemma":[0.000007551426,0.00010023214,0.0029159316,0.000007946679,0.00001830055,0.00030904484,0.000052033232,0.0055459104,0.985394,0.00049357145,0.0051415334,0.000013861317],"about_ca_topic_score_codex":0.0010422237,"about_ca_topic_score_gemma":0.0015929032,"teacher_disagreement_score":0.0011100576,"about_ca_system_score_codex":0.0004325441,"about_ca_system_score_gemma":0.00044045824,"threshold_uncertainty_score":0.0037134886},"labels":[],"label_agreement":null},{"id":"W4409190862","doi":"10.1101/2025.03.31.646438","title":"Epidermal Resident Memory T Cell Fitness Requires Antigen Encounter in the Skin","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; McGill University; University of Pittsburgh","keywords":"Antigen; Psychology; Computer science; Neuroscience; Biology; Immunology","score_opus":0.022976164435485422,"score_gpt":0.28337344675704423,"score_spread":0.2603972823215588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409190862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99079764,0.0013093284,0.0036386887,0.00014732263,0.000052334588,0.000019039335,0.00054832845,0.00019118404,0.0032961057],"genre_scores_gemma":[0.99298877,0.00029398114,0.0012858085,0.000076594384,0.0000108187,0.000015161056,0.00037418574,0.000048548653,0.004906232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998541,0.000018599372,0.0000060802267,0.000051037794,0.000027712007,0.000042555308],"domain_scores_gemma":[0.9999192,0.00001023914,0.000014962803,0.000011456165,0.000012576425,0.00003148888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013321445,0.00020083443,0.00020636305,0.00016985831,0.00015745412,0.00059634954,0.00011554247,0.00034181,0.0042302012],"category_scores_gemma":[0.000107705055,0.0001322195,0.0001731336,0.00010011029,0.00017065249,0.0002501071,0.00023971518,0.000720415,0.0014271872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000791916,0.0000107894,0.00028667971,0.000020089086,0.0000020523273,0.000036709316,0.000011566927,0.000033741177,0.99799985,0.00007234055,0.00007796453,0.001368987],"study_design_scores_gemma":[0.000015879874,0.00024643305,0.012053786,0.000016737176,0.000015907917,0.00047006944,0.0001206367,0.0012669998,0.9816155,0.00019306665,0.003977867,0.0000070592027],"about_ca_topic_score_codex":0.0002581634,"about_ca_topic_score_gemma":0.0003100123,"teacher_disagreement_score":0.0042302012,"about_ca_system_score_codex":0.00018415786,"about_ca_system_score_gemma":0.00013460997,"threshold_uncertainty_score":0.014151454},"labels":[],"label_agreement":null},{"id":"W4409251014","doi":"10.1016/j.tmrv.2025.150897","title":"Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Transfusion Medicine Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Ottawa Public Health; University of Ottawa; University of British Columbia; Ottawa Hospital","funders":"Networks of Centres of Excellence of Canada; Copenhagen School of Energy Infrastructure; Canadian Institutes of Health Research","keywords":"Meta-analysis; Medicine; Internal medicine","score_opus":0.34744195528740296,"score_gpt":0.4512098839360388,"score_spread":0.10376792864863582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409251014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0065978556,0.9904475,0.0011134826,0.00024708427,0.00015011766,0.000305576,0.00078337797,0.000039936975,0.0003150515],"genre_scores_gemma":[0.33342335,0.65592873,0.004461459,0.001483753,0.00034761353,0.0020273305,0.0016837417,0.00008057071,0.00056353095],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9878149,0.0066292346,0.003089317,0.0012307588,0.00090844504,0.00032729981],"domain_scores_gemma":[0.96904904,0.02497235,0.003470198,0.0009585391,0.0012847469,0.00026518523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017926468,0.002622889,0.019051109,0.0049685827,0.000551961,0.0032166063,0.002113538,0.0024124896,0.0038798887],"category_scores_gemma":[0.03854841,0.0015553256,0.045934923,0.0061835498,0.0008385864,0.0016442484,0.0015470263,0.0021051602,0.00037052415],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018480772,0.000019679754,0.0030031416,0.19661295,0.79005647,0.000083399,0.000047817626,0.00055092474,0.00015998525,0.00011954504,0.00039088566,0.0071070394],"study_design_scores_gemma":[0.0004223445,0.00010973222,0.0017588896,0.008705138,0.98768485,0.000042266824,0.00001813484,0.00015513555,0.000067953304,0.00016713777,0.00085512735,0.000013336248],"about_ca_topic_score_codex":0.0060894554,"about_ca_topic_score_gemma":0.010437951,"teacher_disagreement_score":0.019051109,"about_ca_system_score_codex":0.0023007626,"about_ca_system_score_gemma":0.002892971,"threshold_uncertainty_score":0.09480536},"labels":[],"label_agreement":null},{"id":"W4409256027","doi":"10.1182/blood.2024026216","title":"Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stanford Cancer Institute; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Doris Duke Charitable Foundation; Amgen; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Internal medicine; Multiple myeloma; Clinical trial; Refractory (planetary science); Cohort; Surgery; Oncology","score_opus":0.022124320350807025,"score_gpt":0.3219916211097771,"score_spread":0.29986730075897006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409256027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98944014,0.008224404,0.00049403217,0.0001455319,0.000029973808,0.000083618266,0.00024945644,0.00006603473,0.0012668987],"genre_scores_gemma":[0.9980623,0.00091305113,0.00033681176,0.00011162511,0.000026702584,0.000024220388,0.00031214516,0.0000036234544,0.00020967326],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99975914,0.00008660604,0.000025751313,0.00003287781,0.00006256063,0.00003307496],"domain_scores_gemma":[0.9997172,0.000057356927,0.00010642287,0.000022686954,0.000028180246,0.00006820111],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068592303,0.00021169755,0.0004735132,0.00030535765,0.00014753752,0.00029369074,0.00026915176,0.00018700976,0.00094772433],"category_scores_gemma":[0.00049720943,0.000058180973,0.00032153065,0.00029531334,0.00013880002,0.00016267125,0.00015602892,0.00038147625,0.00021343387],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04754899,0.004505541,0.16511966,0.0010199934,0.00091629336,0.0014892796,0.00013277956,0.002120358,0.03631905,0.00031265226,0.0072774854,0.7332379],"study_design_scores_gemma":[0.025713958,0.15755536,0.7224838,0.00039698085,0.0010955893,0.01279472,0.0002159869,0.010731483,0.041173067,0.0006463736,0.027133368,0.000059260383],"about_ca_topic_score_codex":0.00033488337,"about_ca_topic_score_gemma":0.00083204656,"teacher_disagreement_score":0.00094772433,"about_ca_system_score_codex":0.00045333002,"about_ca_system_score_gemma":0.00037761216,"threshold_uncertainty_score":0.0036275983},"labels":[],"label_agreement":null},{"id":"W4409323048","doi":"10.1016/j.jcyt.2025.04.060","title":"Shaping the future of cell and gene therapy workforce development: training of cell therapy processing personnel - perspectives from the International Society for Cell &amp; Gene Therapy Lab Practices Committee","year":2025,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Alberta; International Society for Cellular Therapy","funders":"","keywords":"Workforce; Genetic enhancement; Cell therapy; Training (meteorology); Workforce development; Business; Cell; Gene; Economic growth; Biology; Genetics; Economics; Geography","score_opus":0.09345781902315406,"score_gpt":0.3510643987199699,"score_spread":0.2576065796968159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409323048","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035324884,0.004476517,0.0011106456,0.9763282,0.0050925864,0.0000835695,0.00005789778,0.000054300013,0.009263805],"genre_scores_gemma":[0.18412305,0.022979135,0.0128540415,0.7102029,0.007995402,0.0007454436,0.00035168737,0.00021208238,0.060536355],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97190505,0.0074451338,0.0011766214,0.0015059662,0.0064867106,0.011480499],"domain_scores_gemma":[0.9002785,0.014174015,0.0035807218,0.0014545013,0.01658445,0.06392791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.063393146,0.0011554292,0.00085062726,0.0015056374,0.0123435445,0.017349875,0.004033627,0.021225242,0.016131101],"category_scores_gemma":[0.026689393,0.00071063376,0.0012548172,0.0010437956,0.008553319,0.007192937,0.013136946,0.024166217,0.002981156],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027216205,0.0011829941,0.010919596,0.0009275262,0.00006646506,0.000515921,0.01341184,0.001858821,0.0058903005,0.064238094,0.7124822,0.1882341],"study_design_scores_gemma":[0.00009044253,0.0005689001,0.011923054,0.002092649,0.000023053113,0.00021212496,0.028582685,0.0009643937,0.0016671671,0.019971093,0.93374485,0.00015952176],"about_ca_topic_score_codex":0.026942566,"about_ca_topic_score_gemma":0.049474657,"teacher_disagreement_score":0.063393146,"about_ca_system_score_codex":0.011797473,"about_ca_system_score_gemma":0.20732805,"threshold_uncertainty_score":0.33525902},"labels":[],"label_agreement":null},{"id":"W4409348483","doi":"10.1016/j.cell.2025.03.017","title":"Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity","year":2025,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Chinese American Medical Society; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Kennedy Trust for Rheumatology Research; Aspen Center for Physics; Fonds Québécois de la Recherche sur la Nature et les Technologies; Kennedy Memorial Trust; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"T-cell receptor; Chimeric antigen receptor; Biology; Antigen; Cancer immunotherapy; Immunotherapy; Cancer research; Crosstalk; T cell; Receptor; Tumor microenvironment; Cell biology; Immunology; Immune system; Tumor cells; Biochemistry","score_opus":0.018741005974053704,"score_gpt":0.28786492790999146,"score_spread":0.26912392193593776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409348483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7929539,0.000563471,0.18484639,0.00030992442,0.0001649318,0.00007000141,0.00010145767,0.00063209207,0.020357836],"genre_scores_gemma":[0.98225176,0.000094363706,0.014409792,0.00006661101,0.000008003713,0.000010310625,0.000029312492,0.000017934797,0.003111929],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988616,0.000013379155,0.0000047598323,0.000024889723,0.000045449124,0.000025388254],"domain_scores_gemma":[0.99990225,0.000027194297,0.000019326595,0.000008223727,0.000029089542,0.000013974629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001190741,0.00022546685,0.00011643093,0.00019530377,0.00015673556,0.0004244045,0.00021798565,0.00034479355,0.0028884644],"category_scores_gemma":[0.000318776,0.0000953447,0.0001524094,0.000120897355,0.0002142096,0.00023095461,0.00015402639,0.00041249127,0.00043065398],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014704553,0.00005401873,0.00023359548,0.000049523453,0.000005899877,0.00011154132,0.00003036966,0.0047942,0.97692525,0.004226551,0.00015809888,0.013263836],"study_design_scores_gemma":[0.00003380937,0.00026592673,0.0004466228,0.000010044654,0.000024654659,0.00031088502,0.000045929857,0.053160384,0.94025254,0.001299153,0.004138028,0.000012016522],"about_ca_topic_score_codex":0.00046713118,"about_ca_topic_score_gemma":0.00060107926,"teacher_disagreement_score":0.0028884644,"about_ca_system_score_codex":0.00023453038,"about_ca_system_score_gemma":0.00019487983,"threshold_uncertainty_score":0.009662926},"labels":[],"label_agreement":null},{"id":"W4409349463","doi":"10.69690/odmj-018-0425-1030","title":"Allogeneic Stem-Cell Transplantation Following Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed/Refractory Hematologic Malignancy in Pediatrics and Young Adults: A Systematic Review and Meta-Analysis of Clinical Studies","year":2025,"lang":"en","type":"review","venue":"OncoDaily Medical Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Medicine; Meta-analysis; Transplantation; Hematopoietic stem cell transplantation; Malignancy; Stem cell; Refractory (planetary science); Oncology; Immunology; Immunotherapy; Pediatrics; Internal medicine; Immune system; Biology","score_opus":0.14252855633730416,"score_gpt":0.45015579189447075,"score_spread":0.3076272355571666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409349463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038359798,0.9949216,0.00031524355,0.00016543806,0.000087052205,0.00021057244,0.00031231696,0.000011178923,0.00014072342],"genre_scores_gemma":[0.12752028,0.8672798,0.002208095,0.00078224065,0.00023802916,0.0011279014,0.0006409955,0.000018771196,0.00018387681],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98882574,0.005238448,0.003346687,0.0010432085,0.0012309883,0.00031495618],"domain_scores_gemma":[0.981062,0.013113731,0.0037564193,0.0005140798,0.0013247897,0.0002289685],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015234944,0.002272417,0.017977923,0.0064248266,0.0005560539,0.003213651,0.0018697939,0.001879757,0.0025333974],"category_scores_gemma":[0.030751422,0.001153865,0.0320544,0.0074116,0.0006881767,0.0016510322,0.0012635425,0.0013219089,0.00019332558],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014793426,0.000031217456,0.0049248952,0.540811,0.43868715,0.0001482084,0.00009641539,0.00039187513,0.00028282497,0.00011329306,0.00044885816,0.012585],"study_design_scores_gemma":[0.00036486157,0.00021923713,0.0035802554,0.04183038,0.9519882,0.00010575763,0.000049833936,0.00012271691,0.000109393455,0.00013610795,0.0014745459,0.000018735283],"about_ca_topic_score_codex":0.0050635645,"about_ca_topic_score_gemma":0.01335388,"teacher_disagreement_score":0.017977923,"about_ca_system_score_codex":0.0022374878,"about_ca_system_score_gemma":0.00480072,"threshold_uncertainty_score":0.080571055},"labels":[],"label_agreement":null},{"id":"W4409377259","doi":"10.18295/2075-0528.1356","title":"A New Cellular Weapon to Kill Leukaemic B-Cells","year":2012,"lang":"en","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine","score_opus":0.018572183402215784,"score_gpt":0.2723575139942364,"score_spread":0.25378533059202063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409377259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59409803,0.16705187,0.044710156,0.023879252,0.008195807,0.00047337415,0.0006695781,0.00070713117,0.16021481],"genre_scores_gemma":[0.85105556,0.03718438,0.01577395,0.0038821523,0.0011476879,0.00021613491,0.0003199547,0.000044314453,0.09037591],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99990916,0.000020620479,0.000004957181,0.000016166656,0.000027973198,0.00002103753],"domain_scores_gemma":[0.99995255,0.000008988402,0.000007983511,0.0000060916213,0.000015616859,0.000008738785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023235273,0.00029887143,0.00023656533,0.00041188637,0.00045958514,0.00080853887,0.00021765417,0.00045598,0.0068945726],"category_scores_gemma":[0.000121783894,0.00010478471,0.00023720745,0.00017401623,0.00047789552,0.00039572737,0.00037142774,0.00055712287,0.0010038175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006960289,0.00033707867,0.002681958,0.0010113247,0.00008626641,0.00083196163,0.00041867266,0.00046901635,0.704889,0.037384976,0.012628588,0.23856507],"study_design_scores_gemma":[0.00028033214,0.0016890261,0.0045303633,0.00023004951,0.00016118167,0.0030910894,0.0006032833,0.001623876,0.38135502,0.0076222783,0.5987819,0.000031630712],"about_ca_topic_score_codex":0.0005627008,"about_ca_topic_score_gemma":0.00090802845,"teacher_disagreement_score":0.0068945726,"about_ca_system_score_codex":0.00043293906,"about_ca_system_score_gemma":0.00052551646,"threshold_uncertainty_score":0.023064613},"labels":[],"label_agreement":null},{"id":"W4409446817","doi":"10.1016/j.xcrm.2025.102076","title":"Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Immune system; CD3; T-cell receptor; Receptor; T cell; Biology; Cancer research; Medicine; Immunology; Internal medicine; CD8","score_opus":0.009998365414937595,"score_gpt":0.2560175750440299,"score_spread":0.2460192096290923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409446817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976115,0.00071179925,0.00043254305,0.00005551754,0.000011507468,0.000022610213,0.00024421336,0.00002237196,0.00088784326],"genre_scores_gemma":[0.9982845,0.00017757433,0.0002692511,0.00007470482,0.000004593715,0.00002621493,0.00041146905,0.0000055273554,0.00074599066],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999094,0.000014181998,0.000003062968,0.000018978299,0.000023748453,0.000030622978],"domain_scores_gemma":[0.99992573,0.000016345954,0.000020386547,0.000005754794,0.0000100635,0.000021784577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012812347,0.00009695459,0.00019927867,0.00014145167,0.00011287722,0.00018884912,0.00006586263,0.00020122161,0.0009937349],"category_scores_gemma":[0.00017966138,0.000060433344,0.00012536057,0.00010941141,0.00011291371,0.00014346177,0.000076853496,0.00045087098,0.0001597836],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005066356,0.00034452183,0.019517563,0.00007121679,0.00004899291,0.00034845868,0.00012057537,0.00070748146,0.9434856,0.000091608184,0.00064322416,0.029554358],"study_design_scores_gemma":[0.00022546024,0.014318653,0.49658984,0.00002923357,0.0001679617,0.0025507677,0.00033169694,0.006848107,0.46825364,0.00041226705,0.010243704,0.000028686738],"about_ca_topic_score_codex":0.00060383714,"about_ca_topic_score_gemma":0.0011521374,"teacher_disagreement_score":0.0009937349,"about_ca_system_score_codex":0.00024925914,"about_ca_system_score_gemma":0.00015515996,"threshold_uncertainty_score":0.0033243299},"labels":[],"label_agreement":null},{"id":"W4409448922","doi":"10.1097/io9.0000000000000062","title":"Revolutionizing treatment for recurrent glioblastoma with intraventricular CARv3-TEAM-E T cells","year":2024,"lang":"en","type":"article","venue":"International Journal of Surgery Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Medicine; Glioblastoma; Internal medicine; Cancer research","score_opus":0.0698043182956191,"score_gpt":0.37001763334817445,"score_spread":0.30021331505255533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409448922","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015640568,0.13404152,0.0033151817,0.434258,0.4043656,0.00018431942,0.00037381344,0.0002986516,0.0075223055],"genre_scores_gemma":[0.05994123,0.10951406,0.0027511222,0.28563643,0.5142407,0.00021508153,0.00027200705,0.00019615264,0.027233237],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99946445,0.00012425231,0.00006984461,0.00007026264,0.00019198123,0.00007922989],"domain_scores_gemma":[0.99786586,0.0010648707,0.0002307668,0.000048542195,0.0004788764,0.00031102088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017186916,0.00056011736,0.00081150356,0.0002624149,0.00043568743,0.0012261957,0.0011955622,0.003576411,0.0027195418],"category_scores_gemma":[0.0043032067,0.00025360257,0.0004648119,0.00020373834,0.00077546376,0.0015281112,0.00043152805,0.0065844613,0.0016724197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001266277,0.00016593926,0.0009474757,0.0013326406,0.00010872511,0.0016946947,0.00017043993,0.00029586442,0.0038413368,0.0031677315,0.8208021,0.16620679],"study_design_scores_gemma":[0.00031763982,0.00057135924,0.0010130396,0.00029692822,0.00014170646,0.0022288146,0.00013825839,0.0006144715,0.0032232148,0.0013669586,0.99005604,0.000031644267],"about_ca_topic_score_codex":0.00027028917,"about_ca_topic_score_gemma":0.0008418843,"teacher_disagreement_score":0.003576411,"about_ca_system_score_codex":0.00044176594,"about_ca_system_score_gemma":0.00067147263,"threshold_uncertainty_score":0.009097815},"labels":[],"label_agreement":null},{"id":"W4409493832","doi":"10.1182/bloodadvances.2024015719","title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"MorphoSys; Swedish Orphan Biovitrum; Incyte; Regeneron Pharmaceuticals; Gilead Sciences; Sanofi; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Bispecific antibody; Refractory (planetary science); Lymphoma; Antibody therapy; Medicine; Antibody; CAR T-cell therapy; Cancer research; Oncology; Internal medicine; Immunology; T cell; Chimeric antigen receptor; Biology; Monoclonal antibody; Immune system","score_opus":0.009952427921185381,"score_gpt":0.3055829094655686,"score_spread":0.2956304815443832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409493832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988954,0.0005905426,0.00009878774,0.00002548394,0.0000043158625,0.00001263344,0.00012503861,0.000005426801,0.00024230586],"genre_scores_gemma":[0.9995703,0.00006506709,0.0000257121,0.000024884803,0.000007756925,0.0000072436933,0.00023876394,0.0000013772744,0.000058889378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996656,0.00013206725,0.000034938686,0.000052458483,0.000039038823,0.00007585959],"domain_scores_gemma":[0.99915457,0.00018553411,0.0003281373,0.000051143776,0.000046273206,0.0002344101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006596536,0.0002136275,0.00045200813,0.00024787273,0.00022971009,0.00052762195,0.00020973726,0.00045009603,0.00071327074],"category_scores_gemma":[0.0011842956,0.00010385422,0.0004547815,0.00028008598,0.00021361098,0.00027941144,0.0002994513,0.00041707672,0.00024575368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0262591,0.0011410523,0.9177153,0.00014168835,0.00051803776,0.0037983677,0.00034378056,0.0019301682,0.01024979,0.0000978469,0.0005550091,0.037249923],"study_design_scores_gemma":[0.000664393,0.017796237,0.9695757,0.000033149012,0.00038756474,0.0052363444,0.00015633053,0.0020023182,0.0026778423,0.00011915114,0.0013287588,0.000022131147],"about_ca_topic_score_codex":0.0006295054,"about_ca_topic_score_gemma":0.0005020359,"teacher_disagreement_score":0.00071327074,"about_ca_system_score_codex":0.00042468414,"about_ca_system_score_gemma":0.00019930149,"threshold_uncertainty_score":0.0034886599},"labels":[],"label_agreement":null},{"id":"W4409535425","doi":"10.1136/jitc-2024-010684","title":"Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Flow cytometry; T cell; Cancer research; Biology; In vivo; Leukemia; Ex vivo; T-cell receptor; Cell; Single-cell analysis; Phenotype; Cancer; RNA; Jurkat cells; Molecular biology; Immunology; Gene; Immune system; Genetics","score_opus":0.055193438543429695,"score_gpt":0.3742840893308047,"score_spread":0.31909065078737503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409535425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97199506,0.00078347384,0.023637325,0.000051199822,0.000021548725,0.00005516973,0.0013654414,0.0001377057,0.001953138],"genre_scores_gemma":[0.9822642,0.00047967266,0.013755399,0.00007015011,0.000014081552,0.00007243714,0.0018300792,0.000052109768,0.0014618777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998399,0.000017658538,0.000010622851,0.00006775785,0.00004381548,0.000020203568],"domain_scores_gemma":[0.99987125,0.000036839367,0.00003148335,0.000019201423,0.000026532327,0.000014695268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001371778,0.00018840937,0.00013272795,0.00020931414,0.0001403014,0.0003250293,0.000089205976,0.00022037742,0.0007464678],"category_scores_gemma":[0.00024700575,0.00007866951,0.00013977662,0.00015587144,0.0001838929,0.00009627219,0.000112704045,0.00019078515,0.00036044896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029807725,0.000003387566,0.00048889656,0.000013701389,0.0000013421417,0.000019749523,0.000012900808,0.0000985665,0.99806505,0.00004755608,0.0000138469495,0.0012051362],"study_design_scores_gemma":[0.000005933362,0.00020103483,0.010155904,0.000006956777,0.000016662549,0.00034877655,0.000054747576,0.001977795,0.9844769,0.00016655156,0.0025845962,0.00000399908],"about_ca_topic_score_codex":0.00014803144,"about_ca_topic_score_gemma":0.000398417,"teacher_disagreement_score":0.0007464678,"about_ca_system_score_codex":0.00013896794,"about_ca_system_score_gemma":0.00014256801,"threshold_uncertainty_score":0.0024971366},"labels":[],"label_agreement":null},{"id":"W4409566964","doi":"10.1002/cpt.3658","title":"Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes","year":2025,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Clinical trial; Drug; Drug development; Clinical pharmacology; Immunotherapy; Pharmacology; Oncology; Cancer; Medical physics; Computational biology; Bioinformatics; Internal medicine; Biology","score_opus":0.4881619744201073,"score_gpt":0.5448352007766311,"score_spread":0.056673226356523776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409566964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029365597,0.9137127,0.06595058,0.0034346206,0.00036733315,0.0001818587,0.00012933745,0.00017457001,0.013112434],"genre_scores_gemma":[0.052909154,0.8876687,0.052400503,0.0021181824,0.0006279125,0.00030823442,0.00023397434,0.00011544415,0.0036179144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99923086,0.0002844478,0.00006980659,0.00012082681,0.0002483564,0.000045731882],"domain_scores_gemma":[0.998923,0.00075134146,0.00013078727,0.00004834448,0.00011962246,0.000026907035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023690555,0.0008952761,0.0013000161,0.0015634521,0.00018871682,0.0014321792,0.0014851437,0.0009776154,0.0032396289],"category_scores_gemma":[0.0029428771,0.00036336988,0.0010798532,0.0009928094,0.0007609258,0.0014647794,0.0010108564,0.0026471727,0.0010249872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013276872,0.00013381834,0.0003807864,0.007401817,0.00017583313,0.00011859176,0.000073385025,0.020297281,0.0041858894,0.04145774,0.006978299,0.91866386],"study_design_scores_gemma":[0.00015981185,0.00088239706,0.0021032,0.007834438,0.0004773135,0.0025789733,0.00015176581,0.018263454,0.010343136,0.06715346,0.88993174,0.000120236065],"about_ca_topic_score_codex":0.0006715936,"about_ca_topic_score_gemma":0.00085107604,"teacher_disagreement_score":0.0032396289,"about_ca_system_score_codex":0.0011790359,"about_ca_system_score_gemma":0.0014708282,"threshold_uncertainty_score":0.012528956},"labels":[],"label_agreement":null},{"id":"W4409584925","doi":"10.3390/curroncol32040238","title":"Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Cégep de Lévis; Jewish General Hospital; Hôpital Charles-Le Moyne; Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Multiple myeloma; Cytokine release syndrome; Immunotherapy; Oncology; T cell; Internal medicine; Intensive care medicine; Immunology; Immune system; Chimeric antigen receptor","score_opus":0.2263227285703102,"score_gpt":0.46895234177489103,"score_spread":0.24262961320458085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409584925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00028413674,0.99666566,0.0002736895,0.0006367217,0.00026357867,0.000008636857,0.000024075984,0.00000985622,0.0018335645],"genre_scores_gemma":[0.0013226254,0.9970439,0.0002979724,0.00043110302,0.00017693435,0.000012372645,0.000035890596,0.0000021745952,0.0006771102],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998479,0.000037482347,0.00001755528,0.000027266517,0.000052379255,0.000017521394],"domain_scores_gemma":[0.9997818,0.00011777307,0.000030562038,0.0000057908655,0.000049048132,0.000015061644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052799174,0.00043317146,0.0005972152,0.0008602668,0.00016634764,0.0007466104,0.00046725987,0.0009098046,0.0038630737],"category_scores_gemma":[0.0004902521,0.0001721597,0.0005162032,0.0007637692,0.00025650044,0.001061527,0.00040728453,0.0016584132,0.0014281669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010844355,0.0001116099,0.00012869715,0.017720906,0.00007167162,0.0002253245,0.000088139524,0.00047243014,0.0049129836,0.0077966885,0.026515985,0.9418471],"study_design_scores_gemma":[0.000025210113,0.00020594631,0.00033309736,0.003085179,0.00007918862,0.0009537426,0.000051139086,0.00011218709,0.0011098958,0.0017425336,0.992289,0.000012949757],"about_ca_topic_score_codex":0.0005509728,"about_ca_topic_score_gemma":0.0012060548,"teacher_disagreement_score":0.0038630737,"about_ca_system_score_codex":0.00037955728,"about_ca_system_score_gemma":0.0006685542,"threshold_uncertainty_score":0.012923241},"labels":[],"label_agreement":null},{"id":"W4409613957","doi":"10.1136/jitc-2025-011829","title":"MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Stem Cell Network; Institute of Infection and Immunity; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Chimeric antigen receptor; Receptor; Immune system; T cell; Cancer immunotherapy; Modular design; Immunotherapy; Cancer research; Antigen; Biology; Immunology; Medicine; Computer science; Internal medicine","score_opus":0.015918664833253077,"score_gpt":0.3158186075849806,"score_spread":0.2998999427517275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409613957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547912,0.0048269616,0.034051932,0.00042993366,0.00012547905,0.00010587306,0.00024076163,0.00048384423,0.0049441117],"genre_scores_gemma":[0.98384905,0.0016180978,0.011628803,0.00013795395,0.000024082146,0.000044184115,0.0001856853,0.000033385775,0.0024788058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999043,0.000013448964,0.0000053037566,0.000023187784,0.000030086052,0.000023806404],"domain_scores_gemma":[0.9999161,0.000007442584,0.000035847228,0.0000075092735,0.000011290044,0.000021766635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000169413,0.00037191494,0.00018581339,0.00020336686,0.00007503661,0.0002693582,0.00027921944,0.00035078573,0.00072778127],"category_scores_gemma":[0.00017774207,0.00009703959,0.0002994447,0.00009503843,0.00020727685,0.00028951507,0.00023358554,0.00042577254,0.00037524823],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006505195,0.000032597603,0.00016057104,0.00006042203,0.0000080775035,0.00007249164,0.000013888957,0.00060344033,0.9927247,0.00082701485,0.00017803468,0.0052536237],"study_design_scores_gemma":[0.000053125932,0.001504497,0.0017004781,0.000013763905,0.00005357223,0.0011075891,0.00002553365,0.0067575164,0.9714955,0.00017723799,0.017081734,0.000029398865],"about_ca_topic_score_codex":0.0001934185,"about_ca_topic_score_gemma":0.00020421189,"teacher_disagreement_score":0.00072778127,"about_ca_system_score_codex":0.0002526459,"about_ca_system_score_gemma":0.00018020938,"threshold_uncertainty_score":0.002434671},"labels":[],"label_agreement":null},{"id":"W4409627226","doi":"10.1158/1538-7445.am2025-3506","title":"Abstract 3506: Clinic enabling development of a TCR-Ab half life extended T cell engager against a novel solid tumor target","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"T-cell receptor; Solid tumor; Cancer research; T cell; Medicine; Chemistry; Cancer; Immunology; Internal medicine; Immune system","score_opus":0.13136231778522853,"score_gpt":0.4501290994282303,"score_spread":0.31876678164300176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409627226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.889081,0.006462069,0.070888296,0.0013098419,0.0003271936,0.00077263615,0.0023019342,0.0025986615,0.02625837],"genre_scores_gemma":[0.94442725,0.002331523,0.030548785,0.00063713937,0.0000641776,0.00034346696,0.0017100818,0.000120373516,0.019817268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984825,0.00001834842,0.0000075001903,0.0000331047,0.00006216593,0.00003054615],"domain_scores_gemma":[0.99993265,0.000010286904,0.000013054138,0.000007110162,0.000013288144,0.000023596976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002581031,0.00036782515,0.00019196705,0.00019043384,0.00014578331,0.00052130746,0.0003424457,0.0006683051,0.0036616207],"category_scores_gemma":[0.0001386044,0.00014395468,0.0001916163,0.000105983556,0.00017846058,0.00023580824,0.00029008812,0.0006921511,0.0014606488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002519653,0.00025571554,0.000276292,0.00010507714,0.000009632719,0.00026927853,0.000039735518,0.0006428928,0.97640616,0.0006034513,0.0019186204,0.019221019],"study_design_scores_gemma":[0.00032288043,0.00472808,0.0015180404,0.000026759686,0.000050206392,0.0025784792,0.00002803081,0.0061708614,0.95195085,0.00034551675,0.032257777,0.000022633332],"about_ca_topic_score_codex":0.0002732966,"about_ca_topic_score_gemma":0.0003495507,"teacher_disagreement_score":0.0036616207,"about_ca_system_score_codex":0.00025603035,"about_ca_system_score_gemma":0.00028536498,"threshold_uncertainty_score":0.01224941},"labels":[],"label_agreement":null},{"id":"W4409629821","doi":"10.1158/1538-7445.am2025-6106","title":"Abstract 6106: A regulated, cell-intrinsic cytokine engineering strategy to enhance the in vitro and in vivo persistence of iPSC-derived CAR-T cell therapies","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"iCo Therapeutics (Canada)","funders":"","keywords":"In vivo; Persistence (discontinuity); Cytokine; In vitro; Cell; Immunology; Cell biology; Biology; Cancer research; Medicine; Genetics; Engineering","score_opus":0.038009788108527766,"score_gpt":0.35332950943719427,"score_spread":0.3153197213286665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409629821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92906207,0.0014231452,0.060555555,0.00024846083,0.00014013867,0.00027681616,0.0009827894,0.00050770014,0.0068033496],"genre_scores_gemma":[0.9700117,0.00074252463,0.021873478,0.0001341426,0.000023652301,0.00016462884,0.00077675964,0.000113736394,0.0061592716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978906,0.000024709627,0.000032573807,0.00003967892,0.000078660894,0.000035330828],"domain_scores_gemma":[0.99988306,0.000019711895,0.000040475312,0.000015661635,0.000020549915,0.000020489779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020870988,0.00039479928,0.00024045527,0.00030673982,0.00012814815,0.00044351642,0.00027210714,0.0005051233,0.0016984402],"category_scores_gemma":[0.0001277414,0.00012814411,0.000278619,0.00020069088,0.00019545038,0.00022020855,0.00020524373,0.00078115764,0.000872321],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020461095,0.000028568033,0.00005129467,0.000023579409,0.0000027058286,0.00003533577,0.000010054158,0.00017519979,0.9975182,0.0002277741,0.000069755486,0.0018370844],"study_design_scores_gemma":[0.000009551783,0.0000980154,0.00022831421,0.0000031218847,0.000010502362,0.000111665955,0.0000047424887,0.0011171469,0.99583817,0.000030096302,0.0025455127,0.000003217662],"about_ca_topic_score_codex":0.00015904287,"about_ca_topic_score_gemma":0.00016927317,"teacher_disagreement_score":0.0016984402,"about_ca_system_score_codex":0.00023568439,"about_ca_system_score_gemma":0.0002476278,"threshold_uncertainty_score":0.0056818128},"labels":[],"label_agreement":null},{"id":"W4409632782","doi":"10.1158/1538-7445.am2025-5815","title":"Abstract 5815: Both CD4 and CD8 T cells mediate antitumor immunity to prevent development of neoantigen-expressing autochthonous sarcomas","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Immunity; CD8; Cytotoxic T cell; Immunology; Cancer research; Biology; Medicine; Immune system; Genetics; In vitro","score_opus":0.07726887156536029,"score_gpt":0.4268249320366299,"score_spread":0.34955606047126964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409632782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96009135,0.0054742075,0.017591164,0.0010547722,0.0004620839,0.00015466465,0.0013322276,0.0010673724,0.012772267],"genre_scores_gemma":[0.9666968,0.0012072161,0.0059682103,0.000330305,0.00012973436,0.00012691038,0.0010734535,0.00009084669,0.024376404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998087,0.000022549293,0.000015615478,0.000045391153,0.00005495327,0.00005282582],"domain_scores_gemma":[0.99989796,0.000011882388,0.000031519397,0.000010616834,0.000013782734,0.000034204913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012939742,0.0004199072,0.0002738916,0.00028109775,0.00011830178,0.00028402847,0.0003014518,0.0004783105,0.0076297405],"category_scores_gemma":[0.00008069539,0.00013233177,0.00026382526,0.00013259587,0.00019970133,0.00020903631,0.0002607937,0.0011604594,0.0020266937],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012184254,0.000047708032,0.00011811365,0.000073515184,0.0000047555336,0.000037463647,0.0000085372885,0.00005590527,0.9961443,0.00015899767,0.00024858885,0.002980267],"study_design_scores_gemma":[0.00009223353,0.0006354761,0.0021094563,0.0000140160855,0.000023047125,0.00030978315,0.000011645891,0.00054904114,0.9841712,0.00010037888,0.011980303,0.000003396949],"about_ca_topic_score_codex":0.00023851897,"about_ca_topic_score_gemma":0.0002762319,"teacher_disagreement_score":0.0076297405,"about_ca_system_score_codex":0.0002632398,"about_ca_system_score_gemma":0.00024135312,"threshold_uncertainty_score":0.02552408},"labels":[],"label_agreement":null},{"id":"W4409633840","doi":"10.1158/1538-7445.am2025-6012","title":"Abstract 6012: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Oncology; Internal medicine; Cancer research","score_opus":0.19960217398232777,"score_gpt":0.5205241300861528,"score_spread":0.32092195610382507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409633840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890687,0.002319349,0.0031825698,0.0003010788,0.00006985963,0.00014213956,0.0007244131,0.00023356357,0.003958346],"genre_scores_gemma":[0.9930748,0.0008853043,0.0018981732,0.00010933795,0.000012306644,0.000059002192,0.000535182,0.000028168739,0.0033977046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987054,0.00001690006,0.0000067708147,0.000019488522,0.000043755816,0.000042463013],"domain_scores_gemma":[0.99991524,0.000012945879,0.000016913682,0.000008223488,0.000015976575,0.00003068259],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020611803,0.00039061654,0.00027752275,0.00024939392,0.00013076157,0.00030752693,0.00020068724,0.00037518438,0.0027807176],"category_scores_gemma":[0.00016176407,0.000110998844,0.00018146378,0.00016002342,0.00016640793,0.00017913537,0.00013271428,0.0009381844,0.0004298048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046062842,0.0005637675,0.00020092721,0.0000519547,0.000016626462,0.000027397611,0.00002231041,0.0005310621,0.9907398,0.00013780397,0.00052414753,0.006723547],"study_design_scores_gemma":[0.00017152159,0.0080093555,0.0026444427,0.0000120696905,0.000038904036,0.00014272067,0.00001737737,0.0017249163,0.9829249,0.000083697676,0.004222502,0.000007638176],"about_ca_topic_score_codex":0.0009912513,"about_ca_topic_score_gemma":0.0015212571,"teacher_disagreement_score":0.0027807176,"about_ca_system_score_codex":0.00032927952,"about_ca_system_score_gemma":0.00029207458,"threshold_uncertainty_score":0.009302378},"labels":[],"label_agreement":null},{"id":"W4409634212","doi":"10.1158/1538-7445.am2025-6114","title":"Abstract 6114: Engineering novel synNotch CAR T cells to precisely and effectively target medulloblastoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medulloblastoma; Cancer research; Neuroscience; Medicine; Biology","score_opus":0.036485709218601246,"score_gpt":0.38557038107882885,"score_spread":0.3490846718602276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409634212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890055,0.0004889131,0.007659062,0.00006966077,0.000025893436,0.00010908397,0.00026117623,0.00009700131,0.0022836719],"genre_scores_gemma":[0.9920731,0.00025936906,0.004865158,0.000034358112,0.0000053347376,0.000048192793,0.00026453665,0.00001398989,0.0024360148],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999254,0.000008807228,0.000005693065,0.000015407202,0.00002328667,0.000021447508],"domain_scores_gemma":[0.999972,0.0000033046797,0.000008457268,0.000003141536,0.0000056543763,0.000007499516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006954014,0.00021568767,0.00010805493,0.00011646079,0.00007592966,0.00021922436,0.00015160699,0.0002563946,0.0012037973],"category_scores_gemma":[0.00005677868,0.000065657885,0.00011095758,0.00008327554,0.00010220897,0.000108264285,0.00013599898,0.00030416495,0.00033296784],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055271637,0.000029255889,0.00016645572,0.000025895635,0.0000030184494,0.000042410335,0.000015108637,0.0004334619,0.9973757,0.0001753113,0.000096245065,0.0015818593],"study_design_scores_gemma":[0.000038049788,0.0005011738,0.0014312821,0.0000051249194,0.00001381451,0.00024900114,0.000025916936,0.003549967,0.9887454,0.00004529323,0.0053913654,0.0000035690223],"about_ca_topic_score_codex":0.00078797224,"about_ca_topic_score_gemma":0.0010415094,"teacher_disagreement_score":0.0012037973,"about_ca_system_score_codex":0.00027028788,"about_ca_system_score_gemma":0.00018321227,"threshold_uncertainty_score":0.004027128},"labels":[],"label_agreement":null},{"id":"W4409645431","doi":"10.1093/gpbjnl/qzaf033","title":"TRAIT: A Comprehensive Database for T-cell Receptor–antigen Interactions","year":2025,"lang":"en","type":"article","venue":"Genomics Proteomics & Bioinformatics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Zhejiang University; Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China","keywords":"T-cell receptor; Antigen; Biology; Trait; Computational biology; T cell; Binding affinities; Chimeric antigen receptor; Database; Immunology; Receptor; Computer science; Immune system; Genetics","score_opus":0.03631192317494432,"score_gpt":0.32680743656705397,"score_spread":0.29049551339210966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409645431","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018231215,0.01433429,0.027834063,0.00039475938,0.00016042624,0.00018699182,0.9074697,0.024994249,0.006394272],"genre_scores_gemma":[0.02337102,0.0042242133,0.02050779,0.00026736426,0.000038583206,0.0002567595,0.94966894,0.0009414057,0.00072396867],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845874,0.0002406814,0.00035407205,0.00044769148,0.00034114826,0.00015764039],"domain_scores_gemma":[0.9981566,0.00059652963,0.00038587555,0.00035506574,0.00025887936,0.0002470338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014425088,0.002598355,0.002829984,0.006919431,0.0008521887,0.0033435442,0.0027392518,0.0019947581,0.011917717],"category_scores_gemma":[0.005829381,0.0009945726,0.001958213,0.0090070795,0.0003619634,0.0028888062,0.0033885385,0.0017681429,0.012932423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040781447,0.0004912747,0.039023302,0.029172681,0.002526331,0.0033599967,0.0009138915,0.014919446,0.07472214,0.01934557,0.60532486,0.20612237],"study_design_scores_gemma":[0.00048726995,0.00031583046,0.024516586,0.0013127439,0.0011430251,0.0026461452,0.0003686489,0.017348003,0.017031804,0.015970424,0.9185391,0.0003203531],"about_ca_topic_score_codex":0.0030584608,"about_ca_topic_score_gemma":0.0038408176,"teacher_disagreement_score":0.011917717,"about_ca_system_score_codex":0.0008745385,"about_ca_system_score_gemma":0.002390374,"threshold_uncertainty_score":0.039868712},"labels":[],"label_agreement":null},{"id":"W4409653495","doi":"10.1007/s13402-025-01056-7","title":"State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment","year":2025,"lang":"en","type":"review","venue":"Cellular Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Wood Council","funders":"","keywords":"In vivo; Cancer therapy; Cancer; Medicine; Production (economics); Cancer treatment; Internal medicine; Biology; Biotechnology","score_opus":0.05204119636552876,"score_gpt":0.38322254731185706,"score_spread":0.3311813509463283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409653495","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001873722,0.99725467,0.00032890995,0.000413823,0.00026247083,0.000006665558,0.000019120369,0.000010431714,0.0015165199],"genre_scores_gemma":[0.0007679878,0.9981345,0.00026174184,0.0002304695,0.00012376597,0.0000074160644,0.00002415303,0.0000020529212,0.00044799],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99969256,0.00006133499,0.00003128439,0.000053172003,0.00012597191,0.000035610745],"domain_scores_gemma":[0.99952567,0.00027310097,0.000045756853,0.00001683588,0.000103804836,0.000034833323],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010577933,0.00077223417,0.0011591596,0.002108958,0.0002738997,0.0012398809,0.000851648,0.0012335924,0.0039000507],"category_scores_gemma":[0.0008452688,0.00037838746,0.00073639624,0.0020310683,0.00062679936,0.0020028814,0.00071319187,0.002651024,0.0018879295],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000083131614,0.00012870852,0.00016005969,0.021456853,0.00008579046,0.00019880146,0.00009397569,0.0007132585,0.005047627,0.012133995,0.028255688,0.9316421],"study_design_scores_gemma":[0.000012678554,0.00013704559,0.00032406268,0.002640895,0.000081318954,0.000570132,0.000045855864,0.00015423005,0.0011574911,0.0022650044,0.9925937,0.000017431517],"about_ca_topic_score_codex":0.00084141555,"about_ca_topic_score_gemma":0.0012980736,"teacher_disagreement_score":0.0039000507,"about_ca_system_score_codex":0.00078417256,"about_ca_system_score_gemma":0.0011217598,"threshold_uncertainty_score":0.01304698},"labels":[],"label_agreement":null},{"id":"W4409656849","doi":"10.14740/jh2046","title":"Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ruxolitinib; Multiple myeloma; Parkinsonism; Bortezomib; Oncology; Internal medicine; Myelofibrosis; Disease; Bone marrow","score_opus":0.035472671785467105,"score_gpt":0.3622998982399766,"score_spread":0.3268272264545095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409656849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94707125,0.034279812,0.0017107163,0.0028003766,0.00015930003,0.00008510063,0.00019776114,0.00031235247,0.013383377],"genre_scores_gemma":[0.9951656,0.0024896546,0.00035634096,0.00040967527,0.00006369587,0.000010045495,0.0001605787,0.000007221973,0.0013372507],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9999342,0.000008719362,0.0000093879535,0.000013835107,0.000013360212,0.000020499876],"domain_scores_gemma":[0.99994695,0.0000114417435,0.000013711131,0.000004773769,0.000005093572,0.000017996921],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081403196,0.00018622576,0.0002963815,0.00024214647,0.0002870984,0.00020300476,0.00015575718,0.00040391987,0.00062581117],"category_scores_gemma":[0.00018712677,0.000064805805,0.00021550286,0.00013504631,0.00012038739,0.00017634517,0.0001366965,0.00044907737,0.00023317942],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036320013,0.001196974,0.071432464,0.0009540451,0.00023779154,0.13943464,0.00045315255,0.0009238689,0.14957939,0.0011843404,0.011392254,0.61957914],"study_design_scores_gemma":[0.0013612554,0.00887073,0.23132406,0.00024014046,0.00049287017,0.57280296,0.00027668892,0.005179073,0.081890695,0.00097148254,0.0965136,0.00007642599],"about_ca_topic_score_codex":0.0003820052,"about_ca_topic_score_gemma":0.0012450668,"teacher_disagreement_score":0.00062581117,"about_ca_system_score_codex":0.00027757118,"about_ca_system_score_gemma":0.00014216441,"threshold_uncertainty_score":0.0020935535},"labels":[],"label_agreement":null},{"id":"W4409690079","doi":"10.1158/1538-7445.am2025-896","title":"Abstract 896: Unleashing the power within: enhancing cancer treatment with invariant natural killer T cells","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Invariant (physics); Cancer; Medicine; Immunology; Mathematics; Internal medicine; Mathematical physics","score_opus":0.05312659537491095,"score_gpt":0.4053088560114074,"score_spread":0.3521822606364965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409690079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727193,0.008913426,0.007923112,0.0007758844,0.00027320677,0.00010973308,0.0005255657,0.0002586487,0.008501119],"genre_scores_gemma":[0.98526853,0.0031703268,0.0043837377,0.0004752833,0.00020665911,0.000052838903,0.00047875,0.000049496593,0.005914399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998883,0.00002011271,0.0000081142425,0.00002183447,0.00003481447,0.000026793618],"domain_scores_gemma":[0.99996114,0.0000070599717,0.00000942229,0.000004529366,0.0000066217253,0.000011124407],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104843784,0.00027331276,0.00031094797,0.0001774422,0.0000982968,0.0004250819,0.00014551998,0.00030361966,0.0036169428],"category_scores_gemma":[0.00013938571,0.00006705489,0.00018431667,0.00016327434,0.00015424685,0.00021086396,0.00023174011,0.0005045422,0.0011219911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057018735,0.0001413918,0.0005650289,0.00015925804,0.000009548513,0.00012556485,0.000017871409,0.00019554654,0.9707437,0.00017081232,0.00056683243,0.026734281],"study_design_scores_gemma":[0.00014734521,0.001923973,0.0052434346,0.00003084273,0.000054241886,0.0014874437,0.000030304242,0.0012037342,0.9721796,0.00032172352,0.017367473,0.000009946158],"about_ca_topic_score_codex":0.00009892833,"about_ca_topic_score_gemma":0.00008575236,"teacher_disagreement_score":0.0036169428,"about_ca_system_score_codex":0.0001122157,"about_ca_system_score_gemma":0.00016574726,"threshold_uncertainty_score":0.012099862},"labels":[],"label_agreement":null},{"id":"W4409704555","doi":"10.21203/rs.3.rs-5828115/v1","title":"ARM-X: an Adaptable Mesenchymal Stromal Cell-based Vaccination Plaftorm Suitable for Solid Tumors","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Université de Montréal","funders":"","keywords":"Mesenchymal stem cell; Stromal cell; Vaccination; Cancer research; Medicine; Computer science; Pathology","score_opus":0.08851009591313151,"score_gpt":0.44381167276783184,"score_spread":0.3553015768547003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409704555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8911194,0.003944619,0.08769857,0.00048411693,0.00043897747,0.00043941007,0.0015809211,0.0026044715,0.01168956],"genre_scores_gemma":[0.95280355,0.0012250775,0.026188387,0.00019501115,0.000055713386,0.00027503315,0.0010601444,0.00014673722,0.018050257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998921,0.0000132441855,0.0000049484242,0.000027503193,0.00003591885,0.000026250587],"domain_scores_gemma":[0.9999559,0.000006604171,0.000011637101,0.0000060309703,0.0000047676062,0.000014961882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018482156,0.00041563122,0.00020396535,0.00024713672,0.00012993056,0.00038370307,0.00030238848,0.0004935017,0.0028752896],"category_scores_gemma":[0.00011625531,0.00012723313,0.0002972568,0.00013779923,0.00019637914,0.0002476193,0.00039827818,0.0005425817,0.0012092545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023295685,0.000086283115,0.00014548776,0.000087041066,0.000015185161,0.000069565416,0.00002976089,0.001283802,0.9797237,0.00038117505,0.0006960172,0.017248916],"study_design_scores_gemma":[0.00008464664,0.0013036589,0.0010440341,0.000010522041,0.000036418016,0.00026524893,0.00001657346,0.0053156037,0.97186714,0.00017863473,0.01985869,0.0000187225],"about_ca_topic_score_codex":0.00040136796,"about_ca_topic_score_gemma":0.00032081964,"teacher_disagreement_score":0.0028752896,"about_ca_system_score_codex":0.00027091586,"about_ca_system_score_gemma":0.00016192393,"threshold_uncertainty_score":0.009618819},"labels":[],"label_agreement":null},{"id":"W4409785815","doi":"10.70962/cis2025abstract.116","title":"Defects in B Cell Differentiation and Antibody Production due to Biallelic TANK Mutation","year":2025,"lang":"en","type":"article","venue":"Journal of Human Immunity","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Mutation; Antibody; Biology; Genetics; Gene","score_opus":0.024144439485877748,"score_gpt":0.35030058888543264,"score_spread":0.3261561493995549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409785815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99750143,0.00026416476,0.0009448472,0.00005626779,0.000009936621,0.000015288468,0.00033192505,0.00004416383,0.0008319347],"genre_scores_gemma":[0.9985228,0.00011533792,0.00053771277,0.000026086153,0.0000060256934,0.000006930651,0.00017738482,0.000014441383,0.00059320027],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9997669,0.000021837775,0.00003345211,0.00008094226,0.000051614865,0.0000452418],"domain_scores_gemma":[0.99975437,0.00005894124,0.0000623389,0.000027186465,0.000016391996,0.00008077046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001521801,0.0007220178,0.0002336383,0.00072107057,0.00031161154,0.00024528272,0.00019978303,0.00064098556,0.0028529873],"category_scores_gemma":[0.00043385188,0.00020315038,0.0003054811,0.00025098067,0.00039422276,0.00019567955,0.00047169812,0.00046133596,0.000492814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004198416,0.00012522141,0.03394289,0.0000919298,0.00005953814,0.06275076,0.00040137174,0.000187878,0.8951042,0.00035489738,0.00032274122,0.006238717],"study_design_scores_gemma":[0.000091996255,0.0008837821,0.2292646,0.0000386061,0.00015938752,0.42934862,0.00042049485,0.0018484164,0.3324575,0.00042374572,0.0050226315,0.000040202183],"about_ca_topic_score_codex":0.00084296236,"about_ca_topic_score_gemma":0.000923372,"teacher_disagreement_score":0.0028529873,"about_ca_system_score_codex":0.00021414834,"about_ca_system_score_gemma":0.00017535122,"threshold_uncertainty_score":0.009544134},"labels":[],"label_agreement":null},{"id":"W4409798211","doi":"10.1016/j.jtct.2025.03.011","title":"Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Cytokine release syndrome; CD19; Neurotoxicity; Lymphoma; Cytokine; Immunology; Medicine; Cancer research; T cell; Antigen; Chimeric antigen receptor; Internal medicine; Toxicity; Immune system","score_opus":0.014777245316883587,"score_gpt":0.2716196132885174,"score_spread":0.25684236797163384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409798211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284995,0.0021469938,0.0011935434,0.00021871428,0.000044682838,0.000053954365,0.00008908815,0.000047558467,0.0033554076],"genre_scores_gemma":[0.9990085,0.0003587371,0.00009588065,0.00008668573,0.000041346597,0.0000138603555,0.000071318726,0.000003961655,0.00031970305],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.9997178,0.00010615938,0.000032415926,0.000025838708,0.000039284925,0.00007841652],"domain_scores_gemma":[0.99924797,0.00030385505,0.00018933948,0.00008485391,0.00006668091,0.00010725047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005546049,0.00065931544,0.00054100645,0.0007286546,0.0004608336,0.00036236734,0.00049466785,0.0012291594,0.0013617377],"category_scores_gemma":[0.0012491334,0.00028847303,0.0004921272,0.00044792134,0.000736158,0.0005711463,0.00041952613,0.0013608101,0.00033892723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03511907,0.0024158745,0.11439343,0.0007704269,0.0005747663,0.6316112,0.00075977953,0.0013280817,0.1660666,0.0022284922,0.0015431088,0.04318923],"study_design_scores_gemma":[0.0017878175,0.01764071,0.3317154,0.000116463205,0.001065281,0.52833456,0.00093051716,0.0038740574,0.10619029,0.0029040542,0.005345623,0.00009515582],"about_ca_topic_score_codex":0.0012220844,"about_ca_topic_score_gemma":0.0012023271,"teacher_disagreement_score":0.0013617377,"about_ca_system_score_codex":0.0005878253,"about_ca_system_score_gemma":0.00040249963,"threshold_uncertainty_score":0.004555404},"labels":[],"label_agreement":null},{"id":"W4409821534","doi":"10.1158/1538-7445.am2025-lb037","title":"Abstract LB037: CD28 drives CAR T cell responses in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Medicine; Cancer research; Internal medicine","score_opus":0.10052210901345007,"score_gpt":0.4490982665798321,"score_spread":0.34857615756638205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409821534","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99332845,0.00090862304,0.0030994772,0.00015930392,0.000045756566,0.00005128736,0.0004454018,0.00016379228,0.0017979931],"genre_scores_gemma":[0.99589443,0.0002744468,0.0011206963,0.000060225837,0.000012091504,0.00004558623,0.00038283828,0.000022403954,0.0021871678],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99967456,0.000049408718,0.000022779468,0.000062848405,0.0000978538,0.00009260584],"domain_scores_gemma":[0.9999248,0.000011337931,0.000014225373,0.000009970701,0.0000116463425,0.000028080844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022934549,0.0003046894,0.00030437062,0.0002581255,0.00017760113,0.00037294405,0.00023986907,0.00043688755,0.0022905446],"category_scores_gemma":[0.000108000015,0.0001736259,0.00028788316,0.0001657885,0.00020126614,0.00016193397,0.000255851,0.0014168418,0.0008894785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013798062,0.00009346444,0.00009757528,0.000020769965,0.000002782995,0.000027321164,0.0000103194925,0.00012652301,0.9981591,0.00007408186,0.000114398674,0.0011356754],"study_design_scores_gemma":[0.000059193637,0.0009826995,0.001748051,0.000005383798,0.00001287524,0.00020471205,0.000029708051,0.0030412197,0.9918508,0.00006838996,0.0019926515,0.0000042878173],"about_ca_topic_score_codex":0.00080298714,"about_ca_topic_score_gemma":0.00077085634,"teacher_disagreement_score":0.0022905446,"about_ca_system_score_codex":0.00046451422,"about_ca_system_score_gemma":0.00028439157,"threshold_uncertainty_score":0.007662654},"labels":[],"label_agreement":null},{"id":"W4409831621","doi":"10.14740/jh2029","title":"A Novel Therapeutic Strategy for Central Nervous System Lymphoma: Integrating Chimeric Antigen Receptor T-Cell Therapy and Gamma Knife Radiation","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Central nervous system; Chimeric antigen receptor; Lymphoma; Radiation therapy; Antigen; Cancer research; Immunology; Immunotherapy; Internal medicine; Immune system","score_opus":0.03339158438928045,"score_gpt":0.31916847033223805,"score_spread":0.2857768859429576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409831621","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.797725,0.087168895,0.076670215,0.00846438,0.00095998094,0.0008652869,0.0001971231,0.0010130208,0.026936077],"genre_scores_gemma":[0.9572821,0.017731128,0.018007796,0.0022992862,0.00092892733,0.0001724194,0.0002125614,0.000043014632,0.0033227343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998975,0.0000139476415,0.000009439895,0.000030207342,0.000013666916,0.00003526659],"domain_scores_gemma":[0.99994373,0.000009873654,0.000011421384,0.000008895068,0.0000037369632,0.000022386801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001542139,0.00048437138,0.0005043809,0.00063274,0.00044768784,0.00049666496,0.0004990308,0.0009528361,0.0011061619],"category_scores_gemma":[0.00019927489,0.00015921326,0.0006768003,0.0003052753,0.00041453616,0.0005081219,0.0004948576,0.0009263191,0.00043892252],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009615673,0.0015952587,0.01586696,0.0012586787,0.00027476632,0.3775439,0.00044699403,0.0027210868,0.19130948,0.006342953,0.004774757,0.39690372],"study_design_scores_gemma":[0.0006983772,0.0035697287,0.010578062,0.00012852359,0.00042335095,0.8991273,0.00013316145,0.0052833017,0.029966881,0.0020871775,0.047950923,0.000053148007],"about_ca_topic_score_codex":0.000624681,"about_ca_topic_score_gemma":0.0015469975,"teacher_disagreement_score":0.0011061619,"about_ca_system_score_codex":0.00043256427,"about_ca_system_score_gemma":0.00037629568,"threshold_uncertainty_score":0.0037004948},"labels":[],"label_agreement":null},{"id":"W4409879933","doi":"10.1016/j.critrevonc.2025.104751","title":"Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering","year":2025,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mount Royal University","keywords":"Chimeric antigen receptor; Immunotherapy; Tumor microenvironment; Cell therapy; Cancer immunotherapy; Medicine; Cytokine release syndrome; Cancer; T cell; Clinical trial; Immunology; Cancer research; Biology; Cell; Immune system; Internal medicine","score_opus":0.09647313472189277,"score_gpt":0.4360006391393491,"score_spread":0.3395275044174563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409879933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059814316,0.99673957,0.00032103143,0.0013013199,0.00067878404,0.0000047050785,0.000014803147,0.000013382434,0.00086651626],"genre_scores_gemma":[0.00061980064,0.99691075,0.00030482575,0.0009929363,0.00049494667,0.000008224818,0.000026099906,0.000002576079,0.00063991453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970406,0.000067928755,0.000020240142,0.000042718348,0.000121768586,0.00004317407],"domain_scores_gemma":[0.9993278,0.00038567692,0.000049543574,0.00001878899,0.00014404679,0.00007425338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012303436,0.000977921,0.0013083296,0.0013543442,0.00028576632,0.0016676275,0.0010360023,0.0017396112,0.0055861464],"category_scores_gemma":[0.0012583865,0.0002465333,0.0006326932,0.00128695,0.000871325,0.002279221,0.0009254709,0.004315651,0.002764752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000103755694,0.00009501873,0.000084885316,0.010804979,0.00007537095,0.00011598254,0.000041309362,0.0004833648,0.0034623083,0.012069608,0.1017046,0.87095875],"study_design_scores_gemma":[0.000027734808,0.00007772191,0.000146676,0.0018486533,0.000055881137,0.00026608753,0.000032691438,0.00011123003,0.00057435205,0.003919723,0.9929264,0.000012782046],"about_ca_topic_score_codex":0.0009836695,"about_ca_topic_score_gemma":0.0019836342,"teacher_disagreement_score":0.0055861464,"about_ca_system_score_codex":0.0009280342,"about_ca_system_score_gemma":0.0016921213,"threshold_uncertainty_score":0.018687546},"labels":[],"label_agreement":null},{"id":"W4409907906","doi":"10.1158/2159-8290.cd-24-1465","title":"Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors","year":2025,"lang":"en","type":"review","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stand Up To Cancer; National Cancer Institute; National Institutes of Health; Stand Up To Cancer Canada; Washington Research Foundation; American Association for Cancer Research","keywords":"Central nervous system; Medicine; Cell; Bioinformatics; Computational biology; Neuroscience; Cancer research; Biology; Genetics","score_opus":0.02895395773494304,"score_gpt":0.3410489312697332,"score_spread":0.31209497353479015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409907906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015053412,0.9972927,0.00021892917,0.0010125557,0.00042130053,0.0000055409337,0.000011739233,0.000010463897,0.0008761882],"genre_scores_gemma":[0.0008687111,0.99718034,0.000291811,0.00073536497,0.00025880727,0.0000076220467,0.000016612443,0.0000022554436,0.00063849846],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997819,0.00005852501,0.000022964012,0.000027814824,0.00008523553,0.000023522807],"domain_scores_gemma":[0.99965024,0.00016997129,0.00003391376,0.000008818428,0.000107226755,0.000029731471],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010560041,0.0005526756,0.0007824472,0.001404845,0.00022649138,0.00089032087,0.0007125377,0.0011880441,0.0029163659],"category_scores_gemma":[0.0008181526,0.0001805239,0.0005057197,0.0009880258,0.0004449916,0.0014501273,0.00059850246,0.0031609535,0.0013067015],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008227508,0.00008767697,0.00009463682,0.01106844,0.00007277319,0.00014606956,0.00007721801,0.0006271231,0.0023493005,0.010101412,0.04826566,0.9270273],"study_design_scores_gemma":[0.000027348666,0.00013537366,0.0002523244,0.0033089146,0.00006685402,0.00049658125,0.000057996098,0.00015090563,0.0004954736,0.0028336458,0.9921639,0.000010698723],"about_ca_topic_score_codex":0.0010482831,"about_ca_topic_score_gemma":0.0022991048,"teacher_disagreement_score":0.0029163659,"about_ca_system_score_codex":0.0007113771,"about_ca_system_score_gemma":0.0011951062,"threshold_uncertainty_score":0.0097562075},"labels":[],"label_agreement":null},{"id":"W4409909460","doi":"10.1016/j.jcyt.2025.03.418","title":"DEVELOPMENT OF ROBUST T CELL MANUFACTURING PROTOCOLS IN BIOREACTORS USING CGMP-COMPLIANT ANCILLARY REAGENTS","year":2025,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Bioreactor; Biochemical engineering; Computer science; Chemistry; Engineering","score_opus":0.09941409715983572,"score_gpt":0.371884300204655,"score_spread":0.2724702030448193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409909460","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10109122,0.0013808548,0.8779563,0.0004923734,0.0004600213,0.0051423935,0.0016150441,0.0027012704,0.009160577],"genre_scores_gemma":[0.16196477,0.001455119,0.8207945,0.0004087783,0.00010514531,0.0041647516,0.003400113,0.0005192832,0.007187397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966313,0.000789627,0.0004811809,0.0006223422,0.0012851452,0.0001903473],"domain_scores_gemma":[0.99725384,0.00065024145,0.00055029313,0.00059042824,0.00076645816,0.00018880851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005254453,0.0012610039,0.00062225515,0.0009230249,0.0007957963,0.0014770644,0.0017161367,0.001227339,0.0030308678],"category_scores_gemma":[0.0039474294,0.0006978911,0.0007841618,0.00057665183,0.00070931274,0.000779072,0.0010748114,0.0022546602,0.0028830117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007577229,0.00011201868,0.00022447247,0.00019366559,0.000012571625,0.000081344224,0.00009648955,0.0009879757,0.9831246,0.0013815251,0.00070372294,0.013005895],"study_design_scores_gemma":[0.000023699806,0.00024678462,0.0003198946,0.00003992919,0.000015562735,0.00010427269,0.000021300848,0.0023207213,0.98547137,0.0003786368,0.011040164,0.000017809529],"about_ca_topic_score_codex":0.0010321504,"about_ca_topic_score_gemma":0.0020187765,"teacher_disagreement_score":0.005254453,"about_ca_system_score_codex":0.00077382836,"about_ca_system_score_gemma":0.0026202532,"threshold_uncertainty_score":0.02778852},"labels":[],"label_agreement":null},{"id":"W4409917909","doi":"10.1101/2025.04.25.650551","title":"Performance of a Modular Robotic Cluster Matches Skilled Human Operators for Complex Cell Therapy Manufacturing Tasks","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Computer science; Manufacturing engineering; Artificial intelligence; Engineering","score_opus":0.03188270739536163,"score_gpt":0.28156022270684755,"score_spread":0.2496775153114859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409917909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91565955,0.0001631502,0.07879624,0.00009831107,0.00012953037,0.0003883309,0.00022628382,0.002178346,0.0023602534],"genre_scores_gemma":[0.93722856,0.00009141329,0.059002087,0.00007052247,0.00002075444,0.0002819791,0.00040511577,0.00014134354,0.0027581688],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926454,0.00008602802,0.000043422104,0.00021431014,0.00024664076,0.00014509748],"domain_scores_gemma":[0.9991604,0.00017736662,0.00013319588,0.0001459092,0.00022165773,0.00016150183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009758854,0.0008994036,0.00048070695,0.00051035086,0.00030961476,0.00054987974,0.0010679471,0.00051885756,0.004138855],"category_scores_gemma":[0.0018080616,0.0003054788,0.00036835426,0.00017785348,0.0003777452,0.00043600652,0.0009610755,0.00030891653,0.0015001183],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017123964,0.0006376228,0.008454686,0.0004756167,0.00008454073,0.00022853116,0.00029942175,0.029462833,0.8526119,0.00045659745,0.002401029,0.10317481],"study_design_scores_gemma":[0.00020141492,0.014557115,0.05812309,0.000068832676,0.0001769413,0.00073191454,0.0003536225,0.18991677,0.7164789,0.00043829202,0.018705735,0.00024740602],"about_ca_topic_score_codex":0.0011616157,"about_ca_topic_score_gemma":0.00094344706,"teacher_disagreement_score":0.004138855,"about_ca_system_score_codex":0.00041226877,"about_ca_system_score_gemma":0.0008799378,"threshold_uncertainty_score":0.013845861},"labels":[],"label_agreement":null},{"id":"W4409980751","doi":"10.4103/abr.abr_531_23","title":"CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges","year":2025,"lang":"en","type":"review","venue":"Advanced Biomedical Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Chimeric antigen receptor; Medicine; Cytokine release syndrome; Side effect (computer science); Clinical trial; Toxicity; Cancer; Intensive care medicine; Immunotherapy; Bioinformatics; Oncology; Internal medicine","score_opus":0.10627265928497447,"score_gpt":0.46237238823262217,"score_spread":0.3560997289476477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409980751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001383032,0.9977429,0.00022278354,0.00058347476,0.0002244692,0.000005664312,0.000011538536,0.000011563939,0.0010593215],"genre_scores_gemma":[0.00077057973,0.9978109,0.00024235807,0.00034069535,0.00016683385,0.0000100171155,0.000023962259,0.000002038422,0.0006327075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997384,0.000057219262,0.000027780212,0.0000349781,0.000112547204,0.000029092098],"domain_scores_gemma":[0.999658,0.00017365973,0.000039685143,0.000010159517,0.00008730153,0.00003120718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088301266,0.00077287026,0.0012339638,0.0019527421,0.0002880476,0.0010558461,0.0010005626,0.001345672,0.003482173],"category_scores_gemma":[0.00079909805,0.0002437666,0.00054683053,0.0014677626,0.00056882744,0.0014325734,0.0006566585,0.0026770963,0.0017520748],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051148392,0.00007772498,0.00009338034,0.01094123,0.000056636578,0.00015552521,0.000053337844,0.00042285206,0.0017573697,0.005833648,0.03076932,0.94978786],"study_design_scores_gemma":[0.000019042784,0.00009259985,0.0002974787,0.00252072,0.000052562016,0.0008353267,0.000047590645,0.00012285529,0.00054129504,0.0022163293,0.9932422,0.0000120456925],"about_ca_topic_score_codex":0.0008303188,"about_ca_topic_score_gemma":0.0015663422,"teacher_disagreement_score":0.003482173,"about_ca_system_score_codex":0.0007472866,"about_ca_system_score_gemma":0.0010737978,"threshold_uncertainty_score":0.011649013},"labels":[],"label_agreement":null},{"id":"W4409987547","doi":"10.58931/cht.2025.4164","title":"Central Nervous System Relapse of Aggressive B-cell Lymphoma: Insights Into Current Treatment Approaches","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Royal College of Pathologists of Australasia","keywords":"Lymphoma; Central nervous system; Medicine; Current (fluid); Aggressive lymphoma; Oncology; Neuroscience; Intensive care medicine; Internal medicine; Biology; Rituximab; Engineering","score_opus":0.02649810773108343,"score_gpt":0.2737271228354629,"score_spread":0.24722901510437947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409987547","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022433437,0.9862307,0.0011042424,0.0076454505,0.00040209526,0.000025981395,0.000052073985,0.000037964706,0.0022581255],"genre_scores_gemma":[0.027350806,0.9617927,0.0036050924,0.0039430466,0.0022082888,0.00011874989,0.00024634454,0.000019816353,0.00071517006],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993229,0.0002131494,0.0001094725,0.00013185601,0.00013250406,0.00009015016],"domain_scores_gemma":[0.99823284,0.000919815,0.00019203234,0.000058399677,0.00042465588,0.00017217099],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023634331,0.00065735914,0.0013977315,0.0016129537,0.00039986972,0.0019583427,0.0015658642,0.0011606202,0.002473835],"category_scores_gemma":[0.0032996142,0.0002771285,0.0009988967,0.0007768391,0.00086114474,0.002202437,0.0009932346,0.0033290505,0.0007820901],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036370885,0.00029792145,0.0024654206,0.0050661205,0.00018223474,0.00040436635,0.00019622175,0.0012226017,0.0008409545,0.006697948,0.016620804,0.96564174],"study_design_scores_gemma":[0.0005552667,0.0026992399,0.011769489,0.03641187,0.0016285533,0.006385266,0.0017040768,0.006697083,0.00170592,0.039015915,0.891223,0.00020423828],"about_ca_topic_score_codex":0.0018076573,"about_ca_topic_score_gemma":0.0041964194,"teacher_disagreement_score":0.002473835,"about_ca_system_score_codex":0.0017077561,"about_ca_system_score_gemma":0.002364688,"threshold_uncertainty_score":0.012499154},"labels":[],"label_agreement":null},{"id":"W4410031891","doi":"10.1080/13696998.2025.2498853","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre","funders":"Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Standard of care; Lymphoma; Oncology; Internal medicine; Pediatrics; Family medicine","score_opus":0.01783357241865267,"score_gpt":0.319916550429289,"score_spread":0.3020829780106363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410031891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93977696,0.031628143,0.0012999146,0.0042189816,0.00022239519,0.0014296857,0.011482383,0.0001405079,0.009801118],"genre_scores_gemma":[0.99089956,0.0035103306,0.0011652816,0.00047229,0.000036553443,0.00023513185,0.0029078457,0.000013789212,0.0007592368],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.998287,0.0011106143,0.000054390945,0.00012195345,0.0002290475,0.00019686879],"domain_scores_gemma":[0.99798644,0.000890844,0.00037348593,0.000071293616,0.000249026,0.00042893126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029726333,0.00133553,0.0016940767,0.0006947165,0.0005739125,0.0013010318,0.0017318503,0.0010394838,0.0039348598],"category_scores_gemma":[0.0069330684,0.00037506563,0.0037257685,0.0011104996,0.0006741378,0.0005489332,0.00068810914,0.0017561419,0.00015271489],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42116868,0.003505577,0.05409101,0.009666891,0.03160273,0.00042639236,0.00029014,0.28277564,0.0014303748,0.007510363,0.02327728,0.16425493],"study_design_scores_gemma":[0.2832828,0.033435114,0.114468,0.0033181652,0.041847706,0.0005418621,0.0006798781,0.49669874,0.001327808,0.006330459,0.01761445,0.00045503603],"about_ca_topic_score_codex":0.7504809,"about_ca_topic_score_gemma":0.78203195,"teacher_disagreement_score":0.24951911,"about_ca_system_score_codex":0.036038063,"about_ca_system_score_gemma":0.025681658,"threshold_uncertainty_score":0.5019771},"labels":[],"label_agreement":null},{"id":"W4410144747","doi":"10.1038/s41423-025-01290-x","title":"Harnessing nutrient scarcity for enhanced CAR-T-cell potency and safety in solid tumors","year":2025,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agence Nationale de la Recherche; Université Laval; Institut National de la Santé et de la Recherche Médicale; Fondation de l'Avenir pour la Recherche Médicale Appliquée","keywords":"Tumor microenvironment; Integrated stress response; ATF4; Cancer research; Chimeric antigen receptor; Transcription factor; T cell; Biology; Cell biology; Immunology; Biochemistry; Immune system; Gene; Tumor cells; Translation (biology)","score_opus":0.008415842849811271,"score_gpt":0.27618887928522157,"score_spread":0.2677730364354103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410144747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713604,0.0028404705,0.022922441,0.00021888228,0.00006067566,0.00006436324,0.00025769,0.00020017423,0.002074973],"genre_scores_gemma":[0.99146867,0.0008391781,0.006392187,0.000060811453,0.000011519297,0.00004668311,0.00019240603,0.000024865054,0.00096379657],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998803,0.000020984084,0.000009717596,0.000025724537,0.000037189027,0.000026028663],"domain_scores_gemma":[0.999926,0.000016030564,0.000021772808,0.000007920189,0.000013736352,0.000014503277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014263313,0.00027270732,0.00028791718,0.0001383526,0.00014051763,0.0003478631,0.0002064518,0.0003099656,0.0008628109],"category_scores_gemma":[0.00010041222,0.00007111516,0.00017992419,0.00011274598,0.00018890026,0.00030051262,0.00026995334,0.0005515855,0.00032041586],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000065629465,0.000033759676,0.00013650548,0.00006362289,0.000003742235,0.000035298886,0.000012442004,0.00038165977,0.99656725,0.00020064431,0.0000570178,0.0024423813],"study_design_scores_gemma":[0.0000082133465,0.0002443093,0.00032433606,0.000004530999,0.000011630182,0.000102127255,0.00001687508,0.0016376008,0.99494994,0.00008597386,0.0026100632,0.000004455506],"about_ca_topic_score_codex":0.00022698168,"about_ca_topic_score_gemma":0.00035349422,"teacher_disagreement_score":0.0008628109,"about_ca_system_score_codex":0.00021272381,"about_ca_system_score_gemma":0.00020978706,"threshold_uncertainty_score":0.002886355},"labels":[],"label_agreement":null},{"id":"W4410186945","doi":"10.1136/jitc-2024-010073","title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario College of Art and Design","funders":"China Postdoctoral Science Foundation; Ministry of Education; National Natural Science Foundation of China","keywords":"Venetoclax; Cancer research; Chimeric antigen receptor; Antigen; In vivo; Medicine; In vitro; Cancer; Immunology; Immunotherapy; Biology; Leukemia; Internal medicine","score_opus":0.01716655082443336,"score_gpt":0.350663301073179,"score_spread":0.33349675024874564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410186945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942173,0.0023778817,0.0009140706,0.00009599199,0.00005602336,0.00011573435,0.00015844902,0.00013028542,0.0019342406],"genre_scores_gemma":[0.99723536,0.0008530878,0.000737205,0.000028958935,0.000022067721,0.000050636027,0.00024820506,0.0000075286207,0.00081695284],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999052,0.000019223182,0.0000064325395,0.000014944669,0.00002356444,0.000030534404],"domain_scores_gemma":[0.999936,0.000013659377,0.000011267971,0.0000073680694,0.000005509206,0.000026204914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016296374,0.00035936816,0.00043579377,0.00030740118,0.00015544724,0.00021279907,0.00026539978,0.00027425378,0.0012622715],"category_scores_gemma":[0.00007647729,0.000104631945,0.00030568213,0.00022707539,0.0001933407,0.00019236539,0.00015732086,0.00068027066,0.00023017202],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017002985,0.0011479697,0.0009831735,0.0002176663,0.00004972579,0.0001360449,0.000045931116,0.0008282062,0.97406036,0.0001682728,0.0005056957,0.020156672],"study_design_scores_gemma":[0.0007696318,0.016843555,0.0097873425,0.000019911964,0.00023196904,0.0009022913,0.00004758082,0.0043446706,0.95995545,0.000079147576,0.007003372,0.0000151138365],"about_ca_topic_score_codex":0.00063481514,"about_ca_topic_score_gemma":0.0011544989,"teacher_disagreement_score":0.0012622715,"about_ca_system_score_codex":0.00019532723,"about_ca_system_score_gemma":0.00038373747,"threshold_uncertainty_score":0.0042227507},"labels":[],"label_agreement":null},{"id":"W4410258234","doi":"10.1016/j.coph.2025.102537","title":"Allogeneic double-negative T-cell therapy for acute myeloid leukemia","year":2025,"lang":"en","type":"review","venue":"Current Opinion in Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Toronto Rehabilitation Institute; University Health Network","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Myeloid leukemia; Medicine; Leukemia; Virology; Immunology; Cancer research","score_opus":0.1592254208433085,"score_gpt":0.5093296194371574,"score_spread":0.3501041985938489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410258234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033193923,0.99671006,0.00031191015,0.00045200187,0.0004928379,0.000013115737,0.00004349024,0.000017778944,0.0016268523],"genre_scores_gemma":[0.0025610104,0.9942772,0.00029397485,0.00078692497,0.00034024916,0.000020350744,0.00010853611,0.0000032584237,0.0016084446],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999231,0.000013381078,0.000008247319,0.000015494546,0.000026887059,0.000012858472],"domain_scores_gemma":[0.9999242,0.000032631073,0.000014119186,0.0000026406562,0.00001695647,0.0000095128435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034869715,0.0005639811,0.0011160685,0.00058966974,0.00012829438,0.00058561,0.0005859966,0.00062507857,0.0045825],"category_scores_gemma":[0.00025328604,0.00013558567,0.00035895573,0.0007256243,0.0002718766,0.0006080351,0.00038814323,0.0017996134,0.00219946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019414916,0.000112390204,0.0000613291,0.0074394327,0.00007548659,0.00007294807,0.000016646294,0.00029707525,0.0033560079,0.0019899446,0.03302313,0.9533615],"study_design_scores_gemma":[0.00026704418,0.00043940346,0.00057998934,0.0018550333,0.0002023741,0.0006194738,0.000021359447,0.00016684126,0.0009403604,0.0014569783,0.9934361,0.000015224405],"about_ca_topic_score_codex":0.00041856695,"about_ca_topic_score_gemma":0.0011450481,"teacher_disagreement_score":0.0045825,"about_ca_system_score_codex":0.00030139636,"about_ca_system_score_gemma":0.00047988424,"threshold_uncertainty_score":0.015329957},"labels":[],"label_agreement":null},{"id":"W4410425696","doi":"10.1182/bloodadvances.2024015634","title":"Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"National Cancer Institute; Centers for Disease Control and Prevention; University of California, San Francisco; University of Southern California; California Department of Public Health","keywords":"Medicine; Logistic regression; Psychological intervention; Socioeconomic status; Internal medicine; CAR T-cell therapy; Disadvantaged; Oncology; Population; Cancer; Environmental health; Nursing","score_opus":0.043124636876642905,"score_gpt":0.36626355476231093,"score_spread":0.323138917885668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410425696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845754,0.0008063297,0.00018101321,0.0006763938,0.00001618099,0.000018308625,0.013049475,0.00000811491,0.0006687998],"genre_scores_gemma":[0.99304765,0.00022523235,0.00011433515,0.00013105763,0.000017908988,0.000020183797,0.006336011,0.000004756465,0.00010300821],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975126,0.00079715304,0.00042269385,0.0004465627,0.00042677927,0.0003942372],"domain_scores_gemma":[0.9923006,0.0012921873,0.004750547,0.0003188759,0.00063169113,0.00070597173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017730404,0.00027171048,0.0004951993,0.001906935,0.00037792532,0.001071403,0.0007203299,0.00051084213,0.0026032436],"category_scores_gemma":[0.0064670974,0.00031306857,0.0013360298,0.004816109,0.00027822718,0.0008117395,0.0013262111,0.0010392437,0.00027363034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008166053,0.000024978222,0.997993,0.000018764036,0.0001742186,0.00002376833,0.000034979825,0.0001490951,0.000021789217,0.00008621041,0.00071909744,0.0006725516],"study_design_scores_gemma":[0.000024249739,0.000040655235,0.9960265,0.000044150293,0.00012992998,0.00009244722,0.00033635498,0.0023658748,0.000041877825,0.00007557133,0.0008139675,0.000008459016],"about_ca_topic_score_codex":0.059697367,"about_ca_topic_score_gemma":0.05133406,"teacher_disagreement_score":0.059697367,"about_ca_system_score_codex":0.0012978158,"about_ca_system_score_gemma":0.0011274875,"threshold_uncertainty_score":0.11869979},"labels":[],"label_agreement":null},{"id":"W4410464105","doi":"10.1186/s40164-025-00662-3","title":"Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines","year":2025,"lang":"en","type":"review","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"National University Health System","keywords":"Cancer immunotherapy; Medicine; Cancer; Immunotherapy; Blood cancer; Immunology; Oncology; Internal medicine","score_opus":0.27417381271174723,"score_gpt":0.4431416177267477,"score_spread":0.16896780501500047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410464105","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018503707,0.9539702,0.017373001,0.0034522773,0.00061014347,0.00008784303,0.00005674586,0.00010169534,0.0058445246],"genre_scores_gemma":[0.11702441,0.8599282,0.014636317,0.0028444144,0.000803966,0.00018433185,0.00014165882,0.00004365324,0.004393153],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997739,0.00006624007,0.000011822029,0.00003895925,0.000056171342,0.00005293367],"domain_scores_gemma":[0.999892,0.000049838804,0.000014217271,0.000005407622,0.000019763418,0.000018774837],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083498965,0.0004560011,0.0006408201,0.00083529,0.00018407553,0.0010644266,0.00044879984,0.0009084677,0.0018264524],"category_scores_gemma":[0.00041312742,0.00022013739,0.0007460887,0.00040568088,0.0004990813,0.002101514,0.00068752246,0.0015732528,0.0006022373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000499541,0.000651396,0.0007964849,0.0065869372,0.00019436766,0.0007116592,0.0002627305,0.004331126,0.12482488,0.048749175,0.011845123,0.8005466],"study_design_scores_gemma":[0.00032171677,0.004147926,0.002012211,0.0020298446,0.00039148278,0.003913219,0.00030838925,0.010494017,0.12841983,0.03194693,0.81590205,0.00011240637],"about_ca_topic_score_codex":0.00042904034,"about_ca_topic_score_gemma":0.00067219394,"teacher_disagreement_score":0.0018264524,"about_ca_system_score_codex":0.0007393774,"about_ca_system_score_gemma":0.0006033168,"threshold_uncertainty_score":0.0061101317},"labels":[],"label_agreement":null},{"id":"W4410513091","doi":"10.3899/jrheum.2025-0390.pv250","title":"POTENT AND SPECIFIC KILLING OF SLE B CELLS WITH ALLONK <sup>®</sup> (AB-101), AN ALLOGENEIC CORD BLOOD-NK CELL THERAPY, IN COMBINATION WITH ANTI-CD19 OR ANTI-CD20 MONOCLONAL ANTIBODIES","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; CD19; Monoclonal antibody; CD20; B cell; Immunology; Antibody; Cord blood; Monoclonal","score_opus":0.022237671196698828,"score_gpt":0.2815528086136822,"score_spread":0.25931513741698337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410513091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913713,0.0024844802,0.0015843901,0.00007919616,0.00005298902,0.00007043161,0.00020000823,0.00008263403,0.0040746015],"genre_scores_gemma":[0.99364084,0.0010567066,0.001340351,0.00006280957,0.000015888625,0.000049071456,0.00042322234,0.0000098249475,0.0034012531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999186,0.000019066492,0.000006004919,0.0000138893565,0.000020030051,0.000022444448],"domain_scores_gemma":[0.9999728,0.00000530829,0.0000058624983,0.0000038202325,0.0000029062908,0.000009383706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011342814,0.00031406706,0.0002389207,0.00013175108,0.00009511631,0.0002230139,0.0001425483,0.00021198802,0.0016434274],"category_scores_gemma":[0.00006092409,0.000067885645,0.0001848644,0.00008415293,0.000096340984,0.00009161798,0.00012055362,0.0003193911,0.0004527319],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046381712,0.00026310768,0.00026091232,0.000065560045,0.000011061886,0.00005832427,0.00001504105,0.00022129176,0.98528683,0.000049362505,0.00018070232,0.013123938],"study_design_scores_gemma":[0.00022818726,0.007902889,0.006313908,0.000014615304,0.000049458973,0.0009498685,0.000018749392,0.0011509858,0.97750664,0.000048706577,0.0058099227,0.000006189099],"about_ca_topic_score_codex":0.00026498386,"about_ca_topic_score_gemma":0.00047211893,"teacher_disagreement_score":0.0016434274,"about_ca_system_score_codex":0.0000897554,"about_ca_system_score_gemma":0.00014854061,"threshold_uncertainty_score":0.005497813},"labels":[],"label_agreement":null},{"id":"W4410513221","doi":"10.3899/jrheum.2025-0390.pv119","title":"A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP)","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); CD19; Open label; Dermatology; Internal medicine; Immunology; Clinical trial; Antibody","score_opus":0.049719025264614955,"score_gpt":0.3411021922081021,"score_spread":0.29138316694348715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410513221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98811674,0.0018658817,0.0016417425,0.0006618624,0.00027640173,0.0030017279,0.0016026995,0.00018072771,0.0026521105],"genre_scores_gemma":[0.98333883,0.0012275233,0.0028259153,0.0013753707,0.00019449116,0.003012939,0.002490052,0.000062537714,0.0054723523],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99962854,0.00010458337,0.000013718863,0.00011963848,0.000043867127,0.00008971264],"domain_scores_gemma":[0.99960774,0.000043258846,0.0000538441,0.000040822935,0.000026525588,0.00022780825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012308535,0.0017118574,0.001555142,0.00036165366,0.0006024448,0.0013757509,0.0007502232,0.001515036,0.003538604],"category_scores_gemma":[0.00048785968,0.000504517,0.0009396094,0.00024435183,0.0010947995,0.00081311597,0.00031362663,0.0035722617,0.001104778],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3715704,0.27424806,0.004996615,0.0014470206,0.001373058,0.0007364614,0.0007311493,0.004163568,0.20027965,0.0011207651,0.011102334,0.12823087],"study_design_scores_gemma":[0.24929278,0.72368157,0.0058869403,0.000051318064,0.00046834332,0.0004978884,0.00011602795,0.0017675252,0.012397969,0.00043801774,0.005343436,0.000058230013],"about_ca_topic_score_codex":0.0007770472,"about_ca_topic_score_gemma":0.0015753268,"teacher_disagreement_score":0.003538604,"about_ca_system_score_codex":0.0010357369,"about_ca_system_score_gemma":0.0014368438,"threshold_uncertainty_score":0.01183784},"labels":[],"label_agreement":null},{"id":"W4410579459","doi":"10.3899/jrheum.2025-0390.pv262","title":"IANALUMAB’S DUAL MODE OF ACTION: TARGETING B CELLS THROUGH ENHANCED B CELL DEPLETION AND BLOCKADE OF B CELL-ACTIVATING FACTOR RECEPTOR SIGNALING","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Receptor; Blockade; Signal transduction; Cell biology; B cell; Mode of action; Cell; Dual (grammatical number); Cancer research; Immunology; Internal medicine; Antibody; Biochemistry; Biology","score_opus":0.02457174578623603,"score_gpt":0.3194643638910647,"score_spread":0.29489261810482864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410579459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581109,0.016257867,0.006880923,0.000711688,0.0002061093,0.00017757044,0.0005445016,0.00026689575,0.01684356],"genre_scores_gemma":[0.98029995,0.00504388,0.0054232692,0.00020995853,0.00010548199,0.00013795587,0.0005169476,0.000024535859,0.008237867],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999038,0.000022102855,0.0000060597927,0.000015132061,0.000021515858,0.00003133308],"domain_scores_gemma":[0.9999777,0.0000023389905,0.0000054410334,0.000002526983,0.0000028475488,0.000009124626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001647717,0.0004171718,0.00032924625,0.000248619,0.00011599133,0.0003171164,0.00029116872,0.0003230011,0.0020115077],"category_scores_gemma":[0.000059020145,0.00010164127,0.00019907794,0.0001438305,0.0001469061,0.00018154857,0.0001308394,0.00080497866,0.00073599775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062089675,0.0002727841,0.00020453903,0.00011718232,0.000014168484,0.00010290549,0.000014673075,0.00015209563,0.981979,0.00028454443,0.000601071,0.015636139],"study_design_scores_gemma":[0.0002650793,0.0042415215,0.003156587,0.000012130422,0.000054830474,0.0017368871,0.000014256645,0.0008420611,0.96975815,0.00010839799,0.019796953,0.00001316092],"about_ca_topic_score_codex":0.00017400544,"about_ca_topic_score_gemma":0.00028018054,"teacher_disagreement_score":0.0020115077,"about_ca_system_score_codex":0.0002157319,"about_ca_system_score_gemma":0.00012863432,"threshold_uncertainty_score":0.0067291856},"labels":[],"label_agreement":null},{"id":"W4410595562","doi":"10.1158/2643-3230.bcd-25-0099","title":"B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with <i>MYC</i> and <i>BCL2</i> Rearrangements","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"H2020 Marie Skłodowska-Curie Actions; Fondazione Beretta; Fondazione Cariplo; American Society of Hematology; Fondazione AIRC per la ricerca sul cancro ETS","keywords":"Gene silencing; B cell; Cancer research; Biology; Cell; Genetics; Gene; Antibody","score_opus":0.013868097935081475,"score_gpt":0.27053676845694474,"score_spread":0.25666867052186326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410595562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971554,0.0003738118,0.00084520556,0.000022647406,0.000004456491,0.000008739059,0.00021883058,0.00006547866,0.0013053829],"genre_scores_gemma":[0.9978988,0.00017624299,0.00033568146,0.000019484418,0.0000028105594,0.000008629263,0.00038573192,0.000021904729,0.0011506843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999897,0.000009546101,0.0000074133914,0.000022305034,0.000026272404,0.000037577927],"domain_scores_gemma":[0.99992836,0.000011685277,0.000020428892,0.000010895409,0.000006895347,0.00002171836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006219,0.00013488636,0.000106067375,0.00015684425,0.0000717479,0.00034738224,0.00013053197,0.00014934073,0.0012083955],"category_scores_gemma":[0.00006639905,0.000103437924,0.00012270418,0.000111942405,0.000104251696,0.00015922922,0.00014690972,0.0004435473,0.00046524857],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006607679,0.000017870932,0.00054937426,0.000005991273,0.0000023106745,0.000024676898,0.000007123259,0.000036172994,0.998343,0.00007860715,0.000024747767,0.0008441258],"study_design_scores_gemma":[0.000012219465,0.00021725408,0.019201137,0.0000028251977,0.000017623723,0.00042441755,0.0000413714,0.0013486855,0.9771254,0.000051132236,0.001554414,0.0000035339265],"about_ca_topic_score_codex":0.0005937101,"about_ca_topic_score_gemma":0.00087739684,"teacher_disagreement_score":0.0012083955,"about_ca_system_score_codex":0.0002349534,"about_ca_system_score_gemma":0.00008997306,"threshold_uncertainty_score":0.004042506},"labels":[],"label_agreement":null},{"id":"W4410635655","doi":"10.1016/j.jcyt.2025.05.003","title":"Artificial intelligence, machine learning, and digitalization systems in the cell and gene therapy sector: a guidance document from the ISCT industry committees","year":2025,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Studies","funders":"","keywords":"Genetic enhancement; Political science; Business; Gene; Artificial intelligence; Computer science; Biology; Genetics","score_opus":0.03359672061384604,"score_gpt":0.3204809349915395,"score_spread":0.28688421437769346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410635655","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032130994,0.05320787,0.017515758,0.59582084,0.016638115,0.0026536768,0.0016555478,0.00065724767,0.3086379],"genre_scores_gemma":[0.03601896,0.10976342,0.0708453,0.15365767,0.021382403,0.0034979573,0.0028377683,0.00078611623,0.6012104],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853124,0.0032709942,0.00093273295,0.0005135668,0.008381326,0.0015889823],"domain_scores_gemma":[0.9568386,0.017296579,0.0021955254,0.0014364586,0.01771773,0.0045151236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02763649,0.0013583039,0.0015195641,0.0031280941,0.0031092432,0.01163805,0.0024518045,0.024841288,0.017074695],"category_scores_gemma":[0.023463719,0.00088030845,0.0015796316,0.0028054442,0.0031524745,0.0037180255,0.0028872394,0.010821613,0.00937207],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010331275,0.00042941378,0.00084361987,0.0004227275,0.000020249568,0.00014215519,0.00022158411,0.002057694,0.002209573,0.03489781,0.87155855,0.08709326],"study_design_scores_gemma":[0.00008497345,0.00016580067,0.0017773047,0.0011149914,0.00003161016,0.00013771666,0.00030887028,0.0014609807,0.0019142105,0.0119647635,0.98098296,0.000055805016],"about_ca_topic_score_codex":0.019306203,"about_ca_topic_score_gemma":0.03365373,"teacher_disagreement_score":0.02763649,"about_ca_system_score_codex":0.0048245746,"about_ca_system_score_gemma":0.044610195,"threshold_uncertainty_score":0.14615744},"labels":[],"label_agreement":null},{"id":"W4410715612","doi":"10.3899/jrheum.2025-0390.o006","title":"DISTINCT MOLECULAR PROFILES OF REMISSION POST-CD19 CAR-T CELL THERAPY VERSUS STANDARD IMMUNOSUPPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunosuppression; Lupus erythematosus; CD19; Immunology; Systemic disease; Immunopathology; Systemic therapy; Internal medicine; Peripheral blood; Antibody","score_opus":0.013104186626562186,"score_gpt":0.30200483415097573,"score_spread":0.2889006475244135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410715612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981298,0.00063443277,0.00025286383,0.000026709942,0.0000032268538,0.0000074412005,0.00066379394,0.000012333151,0.00026939606],"genre_scores_gemma":[0.9969602,0.00036043077,0.00044642633,0.00004373485,0.000007728146,0.000025899539,0.0017872191,0.0000062177505,0.00036207034],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998654,0.000023067649,0.000010566176,0.00003431001,0.00003370147,0.00003289517],"domain_scores_gemma":[0.9998292,0.000046293542,0.000058357004,0.000009405839,0.000018100756,0.0000386313],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000152574,0.00013016904,0.00026618232,0.00062085676,0.00014705339,0.0003390782,0.00007849528,0.0001794785,0.001289076],"category_scores_gemma":[0.00023978837,0.00007028254,0.00022229509,0.00037843562,0.00011653489,0.00012562085,0.0001516589,0.00025438258,0.0002049041],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009406168,0.00026615427,0.11940624,0.00022771503,0.00017973158,0.00039424878,0.00021931199,0.00070886523,0.82746625,0.00020720583,0.00042071714,0.04109738],"study_design_scores_gemma":[0.0000749913,0.0013444386,0.9420705,0.000017153741,0.0001407654,0.0010813066,0.00021649181,0.0017490225,0.051629208,0.0001959853,0.001464998,0.000015231048],"about_ca_topic_score_codex":0.00021834945,"about_ca_topic_score_gemma":0.00031881037,"teacher_disagreement_score":0.001289076,"about_ca_system_score_codex":0.0001699954,"about_ca_system_score_gemma":0.000111247115,"threshold_uncertainty_score":0.004312396},"labels":[],"label_agreement":null},{"id":"W4410715736","doi":"10.3899/jrheum.2025-0390.o029","title":"RESET SLE: CLINICAL TRIAL EVALUATING CABA-201, A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN NONRENAL SLE AND LUPUS NEPHRITIS","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lupus nephritis; CD19; Reset (finance); Internal medicine; Immunology; Antibody","score_opus":0.08434236423360857,"score_gpt":0.43476144804059724,"score_spread":0.35041908380698866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410715736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759267,0.007260491,0.00076165557,0.00092467316,0.00032047345,0.0030225948,0.0032999287,0.00037537137,0.008108152],"genre_scores_gemma":[0.9818287,0.0017780026,0.0014687929,0.0016597487,0.0002491603,0.0028532227,0.003775365,0.000038394068,0.0063487026],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996785,0.00014449145,0.000018862202,0.000056361507,0.000033668963,0.00006814926],"domain_scores_gemma":[0.9994036,0.000099444434,0.00010719406,0.00004583363,0.000029370947,0.0003144182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011956084,0.0007963033,0.0010613272,0.00024717255,0.00032625097,0.0011433776,0.00070543046,0.0011187983,0.0093540475],"category_scores_gemma":[0.0007879024,0.0002936955,0.00093724,0.00020173607,0.00068560994,0.0007378574,0.00039263535,0.0022788295,0.0014134733],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85461366,0.016633948,0.0042149555,0.0020300923,0.0011558362,0.00028598422,0.00022606607,0.0015379471,0.028449053,0.0009734885,0.008734278,0.081144735],"study_design_scores_gemma":[0.7258411,0.25294566,0.007938146,0.00013922802,0.000554237,0.00039554902,0.00006707569,0.0009217368,0.0028105234,0.00037701463,0.007973545,0.000036261794],"about_ca_topic_score_codex":0.00052491546,"about_ca_topic_score_gemma":0.0016479832,"teacher_disagreement_score":0.0093540475,"about_ca_system_score_codex":0.00058173336,"about_ca_system_score_gemma":0.0010761269,"threshold_uncertainty_score":0.03129244},"labels":[],"label_agreement":null},{"id":"W4410799986","doi":"10.1016/s2352-3026(25)00051-1","title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; BeiGene; Eli Lilly and Company; AstraZeneca; Arnold Ventures; Adaptive Biotechnologies; Gilead Sciences; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Seagen; Cidara Therapeutics; National Institute of Allergy and Infectious Diseases; Celgene; GlaxoSmithKline","keywords":"Medicine; Tolerability; Oncology; Immunotherapy; Internal medicine; Intensive care medicine; Adverse effect; Cancer","score_opus":0.09745188310624656,"score_gpt":0.37481295902621686,"score_spread":0.2773610759199703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036764468,0.9972351,0.00037242667,0.00093655917,0.00017210933,0.000016199005,0.000025186073,0.000007623032,0.00086724554],"genre_scores_gemma":[0.012629687,0.983061,0.0009531847,0.0016233156,0.00078725006,0.00005460189,0.00008019156,0.000010228147,0.00080057606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645114,0.00157334,0.00069962174,0.00021834925,0.0009483719,0.00010914896],"domain_scores_gemma":[0.99258024,0.00474507,0.001421989,0.0001842035,0.00094352395,0.00012496146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008595796,0.00062464975,0.002610556,0.0012864065,0.0001930572,0.0021329285,0.0011783027,0.0012812354,0.0022225229],"category_scores_gemma":[0.0076731546,0.00023515825,0.001421994,0.0013035454,0.0010034064,0.002592752,0.0009537793,0.002790364,0.00056960026],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003229744,0.000048892496,0.00033732638,0.026430778,0.00029475996,0.00011227213,0.00015367559,0.0005229376,0.0016154712,0.006237314,0.010051986,0.95387155],"study_design_scores_gemma":[0.00028818136,0.002006077,0.0055674375,0.033944137,0.0014099198,0.0028494243,0.00048241325,0.0006129393,0.0041798614,0.015699508,0.9328183,0.0001418406],"about_ca_topic_score_codex":0.00089369377,"about_ca_topic_score_gemma":0.0013914879,"teacher_disagreement_score":0.008595796,"about_ca_system_score_codex":0.0012618918,"about_ca_system_score_gemma":0.0015385221,"threshold_uncertainty_score":0.04545945},"labels":[],"label_agreement":null},{"id":"W4410801539","doi":"10.1182/bloodadvances.2025016141","title":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Alexion Pharmaceuticals; bluebird bio; Pharmacyclics; Adaptive Biotechnologies; Health Resources and Services Administration; Kite Pharma; Daiichi Sankyo Europe; Takeda Oncology; AstraZeneca; Fundação de Amparo à Pesquisa do Estado de São Paulo; Genentech; MorphoSys; U.S. Navy; Legend Biotech; Sangamo Therapeutics; Seagen; CTI Biopharma; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; U.S. Department of Health and Human Services; GlaxoSmithKline; Kiadis Pharma; Medac; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; HistoGenetics; Children's Hospital of Philadelphia; Gateway for Cancer Research; Celgene; Omeros Corporation; Vertex Pharmaceuticals; U.S. Department of Defense; Sanofi; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Bristol-Myers Squibb; Cidara Therapeutics; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Atara Biotherapeutics; Actinium Pharmaceuticals; Gilead Sciences","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Lymphoma; Internal medicine; Cumulative incidence; Incidence (geometry); CD19; Immunology; Gastroenterology; Transplantation; Antigen; Immunotherapy; Cancer","score_opus":0.010808022390614186,"score_gpt":0.3128229019549339,"score_spread":0.3020148795643197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410801539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985083,0.00027518996,0.00011067877,0.000029083249,0.0000034253624,0.000019724856,0.0008010527,0.0000047182803,0.0002476484],"genre_scores_gemma":[0.99804807,0.0001252076,0.00008061791,0.000036179415,0.000013174337,0.000019764184,0.0015927335,0.000003046977,0.00008112795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989299,0.00041041744,0.000116576404,0.00018452287,0.0002053247,0.00015322451],"domain_scores_gemma":[0.9975914,0.0004138449,0.001257506,0.0002081174,0.00020515696,0.0003240186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012676131,0.00034180545,0.00033463413,0.0008461544,0.00028826407,0.000831697,0.00038510808,0.0004110301,0.0013469864],"category_scores_gemma":[0.0019508111,0.00024709405,0.0006202325,0.0010951823,0.00029242953,0.00046178716,0.000603489,0.0005566796,0.00043889115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076369965,0.00009226175,0.995774,0.000030615807,0.000109659704,0.00019274974,0.000069499845,0.00008890309,0.00023468392,0.000015783582,0.00030485063,0.0023234973],"study_design_scores_gemma":[0.000057029734,0.0003293354,0.99748236,0.00001418903,0.00007558225,0.00077320344,0.00015537783,0.00044735905,0.00016849817,0.000012966038,0.00047442116,0.000009685882],"about_ca_topic_score_codex":0.002947349,"about_ca_topic_score_gemma":0.0023982786,"teacher_disagreement_score":0.002947349,"about_ca_system_score_codex":0.00073994166,"about_ca_system_score_gemma":0.0004201789,"threshold_uncertainty_score":0.0067038536},"labels":[],"label_agreement":null},{"id":"W4410803211","doi":"10.1200/jco.2025.43.16_suppl.tps7091","title":"TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Open label; Refractory (planetary science); CD8; Oncology; Multicenter study; Internal medicine; Cancer research; Clinical trial; Immunology; Antigen; Materials science; Metallurgy; Randomized controlled trial","score_opus":0.15544688119133895,"score_gpt":0.4794816699232975,"score_spread":0.32403478873195857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819389,0.0040299376,0.002964709,0.0008636579,0.00023448662,0.0026431095,0.0030804658,0.00050140114,0.003743332],"genre_scores_gemma":[0.9730723,0.0039673713,0.0041649584,0.0018753139,0.00018545221,0.002567087,0.0070294803,0.0001666548,0.0069713844],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996588,0.00010467034,0.000011867317,0.000087243934,0.000052029838,0.00008527845],"domain_scores_gemma":[0.99976236,0.000026169198,0.000053614298,0.000021951953,0.000018899582,0.000116972136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011970282,0.0017391938,0.0015078146,0.00048103742,0.00036436768,0.0013151041,0.0012181271,0.0015586858,0.004122261],"category_scores_gemma":[0.00038750307,0.0005513823,0.0011206485,0.00040750843,0.00085575023,0.0010391818,0.00045352257,0.0029479547,0.0014701133],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28881258,0.09464691,0.0054492173,0.0016780336,0.002798581,0.00060210435,0.00064186804,0.009850966,0.37577486,0.0012031704,0.017142734,0.20139898],"study_design_scores_gemma":[0.28486082,0.6516029,0.0100165345,0.00007747293,0.0011323872,0.0011980679,0.00021748697,0.0044451025,0.031526744,0.0004909752,0.01434063,0.00009076943],"about_ca_topic_score_codex":0.0013836847,"about_ca_topic_score_gemma":0.0033238905,"teacher_disagreement_score":0.004122261,"about_ca_system_score_codex":0.0010954234,"about_ca_system_score_gemma":0.0012331271,"threshold_uncertainty_score":0.013790309},"labels":[],"label_agreement":null},{"id":"W4410803316","doi":"10.1200/jco.2025.43.16_suppl.2521","title":"Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Biomarker; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.09818264285640337,"score_gpt":0.5118084556203576,"score_spread":0.4136258127639542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868776,0.002561361,0.0012711402,0.0005783919,0.00009166815,0.003520149,0.003109814,0.00017458745,0.0018153124],"genre_scores_gemma":[0.97862405,0.0023186812,0.003478662,0.0014740163,0.0001710405,0.0034444684,0.0065592607,0.00007593787,0.0038538673],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995753,0.00022374894,0.000016218602,0.000059530797,0.00005058084,0.00007461788],"domain_scores_gemma":[0.99939,0.00008571589,0.00018847636,0.00006911581,0.00005544583,0.00021126798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001968953,0.0015680492,0.0013764938,0.000374637,0.00030682582,0.0012405282,0.0006944256,0.0012051999,0.0038292354],"category_scores_gemma":[0.00085960305,0.0006265667,0.0010045824,0.00039569248,0.00066358474,0.0010373781,0.00033456364,0.002729178,0.0009896896],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5612632,0.10854535,0.017182702,0.0016449005,0.0026804213,0.0005400531,0.0005908667,0.005244245,0.13906308,0.0006050699,0.012405528,0.15023461],"study_design_scores_gemma":[0.3598919,0.5881678,0.02295934,0.00006793387,0.0010032468,0.0009024163,0.0001272427,0.0027627663,0.013480962,0.0006491467,0.009925041,0.00006214363],"about_ca_topic_score_codex":0.000426772,"about_ca_topic_score_gemma":0.0015161522,"teacher_disagreement_score":0.0038292354,"about_ca_system_score_codex":0.000804989,"about_ca_system_score_gemma":0.0013157085,"threshold_uncertainty_score":0.012810111},"labels":[],"label_agreement":null},{"id":"W4410803628","doi":"10.1200/jco.2025.43.16_suppl.e24085","title":"Incidence and risk factors for venous thromboembolism after CAR T-cell therapy: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Venous thromboembolism; Meta-analysis; Incidence (geometry); Oncology; Surgery; Internal medicine; Thrombosis","score_opus":0.2845261523703347,"score_gpt":0.5438197238772523,"score_spread":0.2592935715069176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803628","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029771114,0.9946925,0.00052169245,0.0002220353,0.00011277253,0.00031299994,0.0009064982,0.000020679974,0.00023361576],"genre_scores_gemma":[0.12287313,0.8702329,0.0021400352,0.00082974974,0.00019714583,0.0018630766,0.0014135237,0.000030754,0.0004197505],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.992683,0.0031758898,0.0022461254,0.00075068854,0.00087182235,0.00027254724],"domain_scores_gemma":[0.9879551,0.008341437,0.002274332,0.00034641655,0.00091463566,0.0001680717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0105519425,0.0024913265,0.016393095,0.0074304645,0.00053726765,0.002855092,0.0018504187,0.002345435,0.004551579],"category_scores_gemma":[0.025638508,0.001452136,0.041624244,0.009226419,0.00060127233,0.0016683302,0.0013309004,0.0018689425,0.00039411115],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00137812,0.000025438878,0.0035837074,0.48888224,0.49389488,0.000107042746,0.0000698339,0.0005177091,0.00014526982,0.00016293765,0.0009793186,0.010253536],"study_design_scores_gemma":[0.0005658509,0.00015373465,0.0036549342,0.038277812,0.9543573,0.00011720996,0.000048132693,0.00023567822,0.00009543234,0.0002353916,0.0022311544,0.000027269327],"about_ca_topic_score_codex":0.007996614,"about_ca_topic_score_gemma":0.013926528,"teacher_disagreement_score":0.016393095,"about_ca_system_score_codex":0.002373725,"about_ca_system_score_gemma":0.004031503,"threshold_uncertainty_score":0.05580467},"labels":[],"label_agreement":null},{"id":"W4410810027","doi":"10.1200/jco.2025.43.16_suppl.tps2687","title":"Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; T-cell receptor; Bifunctional; Antibody; Receptor; Cancer research; Immunology; Pharmacology; Molecular biology; Internal medicine; T cell; Biochemistry; Biology; Immune system","score_opus":0.03909459737228007,"score_gpt":0.4344524656994455,"score_spread":0.39535786832716546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97859573,0.0016932586,0.0026292466,0.00097465154,0.00021525724,0.0070481524,0.004073169,0.00054026506,0.0042302124],"genre_scores_gemma":[0.94978535,0.0026511492,0.009039625,0.0023690944,0.00020688986,0.01107829,0.014154228,0.00024854712,0.010466785],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9996557,0.00012165777,0.000009831146,0.00006276139,0.000045079665,0.00010505754],"domain_scores_gemma":[0.9996505,0.000040712046,0.000059141526,0.00003544046,0.000039079798,0.00017515486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013699215,0.001987132,0.0011055814,0.0005847329,0.0003703933,0.0011054714,0.0010811775,0.0015662549,0.0048194444],"category_scores_gemma":[0.0006829785,0.00067677523,0.0010028563,0.00036636437,0.0007849931,0.00091913366,0.00047258608,0.0041325763,0.001406659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33522114,0.17642842,0.006264284,0.0010526654,0.0010399104,0.0007258242,0.00090100575,0.009204656,0.24759375,0.0017956248,0.029873785,0.18989886],"study_design_scores_gemma":[0.35061952,0.59553343,0.0087821325,0.00008498919,0.00036535555,0.0008407377,0.00012542562,0.0042267554,0.025775615,0.0008224636,0.012745836,0.00007761916],"about_ca_topic_score_codex":0.00087688357,"about_ca_topic_score_gemma":0.002191953,"teacher_disagreement_score":0.0048194444,"about_ca_system_score_codex":0.0010132891,"about_ca_system_score_gemma":0.0017815493,"threshold_uncertainty_score":0.016122699},"labels":[],"label_agreement":null},{"id":"W4410810149","doi":"10.1200/jco.2025.43.16_suppl.tps2671","title":"ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer research; Solid tumor; Oncology; Internal medicine; Cancer","score_opus":0.1303790071812936,"score_gpt":0.4964741971718948,"score_spread":0.3660951899906012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9729723,0.0037233452,0.0023923018,0.001578149,0.00022759952,0.009097427,0.0047817477,0.00042143473,0.0048056985],"genre_scores_gemma":[0.9649447,0.0028555566,0.0052248924,0.0025252872,0.00019694913,0.007655115,0.008334708,0.00013307131,0.008129795],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.999496,0.00020159432,0.00001615033,0.00009378583,0.00005895029,0.00013346928],"domain_scores_gemma":[0.9993211,0.000109234745,0.00012792935,0.00005771966,0.000047934405,0.00033610652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018093386,0.0018767017,0.0015747412,0.00047494232,0.00047915496,0.0013977668,0.0010874403,0.0020774088,0.005986615],"category_scores_gemma":[0.00084306713,0.00079041335,0.0010822885,0.00042130274,0.00088196655,0.0011511467,0.00049083075,0.0051170443,0.0019747429],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27392966,0.29796022,0.008842151,0.0020107806,0.0016756664,0.0009167444,0.0007468227,0.010736724,0.16977002,0.0013078497,0.024602907,0.20750049],"study_design_scores_gemma":[0.19396502,0.7654549,0.008585576,0.00005605113,0.0004343728,0.0009905121,0.00011190064,0.0028031194,0.01672926,0.00052583177,0.010284379,0.000059069826],"about_ca_topic_score_codex":0.0008976109,"about_ca_topic_score_gemma":0.0022898677,"teacher_disagreement_score":0.005986615,"about_ca_system_score_codex":0.0012344068,"about_ca_system_score_gemma":0.0022790476,"threshold_uncertainty_score":0.02002716},"labels":[],"label_agreement":null},{"id":"W4410821212","doi":"10.1200/jco.2025.43.16_suppl.7028","title":"Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Chimeric antigen receptor; Medicine; Safety profile; Adverse effect; Lymphoma; Adverse Event Reporting System; Postmarketing surveillance; Diffuse large B-cell lymphoma; Pharmacovigilance; Oncology; Antigen; Internal medicine; Cancer research; Immunology; Cancer; Immunotherapy","score_opus":0.06189013748469961,"score_gpt":0.43465728156570516,"score_spread":0.37276714408100553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98737645,0.0033128757,0.0013574709,0.00015707783,0.00001940171,0.0002487394,0.0061314134,0.00004688554,0.0013496613],"genre_scores_gemma":[0.99398744,0.00035273648,0.0005215895,0.00011355134,0.000028638491,0.0001127443,0.0046423064,0.000015039084,0.00022582595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98936427,0.0038482419,0.0018226882,0.0014633195,0.0030855874,0.00041593943],"domain_scores_gemma":[0.95289356,0.013623383,0.027576337,0.0020512843,0.0032493398,0.0006060532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012011163,0.00034968051,0.0004887655,0.0019116912,0.00018776662,0.0008643027,0.00034723242,0.0004364509,0.0018888518],"category_scores_gemma":[0.019546648,0.00017664843,0.0020523474,0.0017512493,0.0004197261,0.0007445811,0.00049301464,0.0007363931,0.0003185354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007049986,0.00038245344,0.95553124,0.0004813515,0.0024138133,0.0002236636,0.00015211597,0.0014863906,0.0024239437,0.00020242391,0.001274406,0.028378308],"study_design_scores_gemma":[0.00020445834,0.0023571579,0.9879233,0.00006887534,0.00079555594,0.0008137668,0.00009149491,0.0029223918,0.0020351387,0.00013033325,0.0026313316,0.000026160636],"about_ca_topic_score_codex":0.0009087819,"about_ca_topic_score_gemma":0.0010882983,"teacher_disagreement_score":0.012011163,"about_ca_system_score_codex":0.00078299735,"about_ca_system_score_gemma":0.000662579,"threshold_uncertainty_score":0.0635218},"labels":[],"label_agreement":null},{"id":"W4410822904","doi":"10.1200/jco.2025.43.16_suppl.e19057","title":"Sex-based differences in complications in patients with diffuse large B cell lymphoma receiving axicabtagene ciloleucel therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Oncology; Surgery","score_opus":0.10030424752009427,"score_gpt":0.4371271288490954,"score_spread":0.3368228813290011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99874485,0.00034328562,0.000043399858,0.000037068094,0.000007381455,0.0000050704043,0.00028242238,0.0000024900426,0.00053394417],"genre_scores_gemma":[0.99960667,0.0000722436,0.000016412849,0.000020704376,0.000008360611,0.0000033723786,0.00018569829,0.0000013153959,0.00008530719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995763,0.000072356204,0.00006537911,0.00009819547,0.000087189226,0.00010049909],"domain_scores_gemma":[0.9983511,0.00027001995,0.0010309623,0.000058333564,0.00008272366,0.0002068503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044445533,0.00015785881,0.00024357911,0.0005537009,0.00020929317,0.00051126105,0.00020814728,0.0003070245,0.002482743],"category_scores_gemma":[0.0020841607,0.00016630007,0.000504167,0.0006807347,0.00016287722,0.00041435342,0.00032902628,0.00039684013,0.00024159162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008282331,0.000010227152,0.9992125,0.0000026775392,0.000018869436,0.000040218496,0.000015779557,0.000008786617,0.000035967594,0.000006414476,0.000035370245,0.0005303023],"study_design_scores_gemma":[0.0000043592413,0.00006622635,0.9993304,0.0000031545326,0.000012433728,0.00028201853,0.00010339315,0.000089259425,0.000018207034,0.000011358976,0.00007740703,0.0000017310289],"about_ca_topic_score_codex":0.0016421825,"about_ca_topic_score_gemma":0.002376553,"teacher_disagreement_score":0.002482743,"about_ca_system_score_codex":0.00022837555,"about_ca_system_score_gemma":0.00019578107,"threshold_uncertainty_score":0.008305609},"labels":[],"label_agreement":null},{"id":"W4410822970","doi":"10.1200/jco.2025.43.16_suppl.e19049","title":"Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Second line; Oncology; Lymphoma; First line","score_opus":0.14789144499785303,"score_gpt":0.4464841575960615,"score_spread":0.2985927125982085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86702317,0.07004241,0.019654766,0.0020124612,0.004258057,0.006177683,0.01601696,0.00045071123,0.014363864],"genre_scores_gemma":[0.9833471,0.0017063239,0.006194556,0.001241296,0.00035422557,0.0023539478,0.0023209234,0.000048092665,0.0024334681],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98876256,0.008419377,0.00071679143,0.0010764665,0.00069377746,0.0003311041],"domain_scores_gemma":[0.9930698,0.0044710045,0.0011466173,0.00081678375,0.00029186992,0.00020389838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010889937,0.001280948,0.002404454,0.000773689,0.00023526611,0.0009320497,0.0010434332,0.001142904,0.0072891326],"category_scores_gemma":[0.021024942,0.00037332022,0.008645841,0.0005773555,0.00046649016,0.0009752436,0.00087992515,0.0025317012,0.00056534575],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66197574,0.0008222847,0.024443408,0.008216571,0.21764703,0.00016648145,0.00021162925,0.0028119383,0.0025371993,0.0029588093,0.006672904,0.071536],"study_design_scores_gemma":[0.35525036,0.099990495,0.10959463,0.0018687823,0.3657116,0.00060108415,0.0002956513,0.015214632,0.006880671,0.00809638,0.0362759,0.0002198171],"about_ca_topic_score_codex":0.0016259414,"about_ca_topic_score_gemma":0.002689122,"teacher_disagreement_score":0.010889937,"about_ca_system_score_codex":0.00080002414,"about_ca_system_score_gemma":0.0006763786,"threshold_uncertainty_score":0.057592154},"labels":[],"label_agreement":null},{"id":"W4410823212","doi":"10.1200/jco.2025.43.16_suppl.tps3160","title":"Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Mesothelin; Medicine; Solid tumor; Cancer research; CD3; Bispecific antibody; Oncology; Nuclear medicine; Internal medicine; Cancer; Monoclonal antibody; Immune system; Immunology; Antibody","score_opus":0.24522242943177328,"score_gpt":0.5255013246005501,"score_spread":0.2802788951687768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89198613,0.0018009952,0.004763385,0.0009887835,0.0009146968,0.089644745,0.0047444566,0.00034201174,0.004814798],"genre_scores_gemma":[0.8688926,0.0013824617,0.009956274,0.0034763075,0.0006764544,0.102604784,0.0031218291,0.000110502726,0.009778775],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9985672,0.00047294618,0.0000567906,0.00037413443,0.00010908054,0.0004198795],"domain_scores_gemma":[0.99853015,0.00017003767,0.00023761934,0.00015324485,0.0001239975,0.0007848655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004726971,0.003127528,0.003201354,0.0005293995,0.0013090401,0.0018500375,0.0015892877,0.0031937761,0.008467562],"category_scores_gemma":[0.0021171395,0.0014987749,0.0013827664,0.00040184057,0.0018271654,0.0020797274,0.00092044333,0.004826979,0.0023691887],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67402196,0.22493272,0.0042992667,0.0009800695,0.0007038646,0.00043736407,0.0005492561,0.0018857011,0.04161385,0.00070006715,0.0056073726,0.044268485],"study_design_scores_gemma":[0.2320164,0.7531652,0.003207899,0.000033993132,0.0002798358,0.00012907771,0.00011720692,0.0006755427,0.003047876,0.00040593295,0.0068790554,0.00004196747],"about_ca_topic_score_codex":0.0009517155,"about_ca_topic_score_gemma":0.0025844972,"teacher_disagreement_score":0.008467562,"about_ca_system_score_codex":0.001590439,"about_ca_system_score_gemma":0.00460552,"threshold_uncertainty_score":0.02832681},"labels":[],"label_agreement":null},{"id":"W4410864172","doi":"10.1038/s41409-025-02637-8","title":"Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Centre hospitalier régional universitaire de Lille","keywords":"Bioproduction; Critical quality attributes; Limulus amebocyte lysate; Medicine; Quality (philosophy); Reliability engineering; Computer science; Biotechnology; Operations management; Engineering; Immunology; Biology","score_opus":0.034395637906422916,"score_gpt":0.32902000727884795,"score_spread":0.29462436937242503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410864172","genre_codex":"methods","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.044511218,0.027184859,0.69657356,0.08263743,0.028191982,0.020125322,0.0055232556,0.0048723132,0.09038014],"genre_scores_gemma":[0.15041414,0.021979231,0.6176928,0.02693535,0.0068233316,0.015471429,0.022282217,0.005345866,0.1330556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.89903224,0.029691115,0.0063876836,0.0059612314,0.054904908,0.0040227645],"domain_scores_gemma":[0.89649695,0.0147147365,0.00817357,0.013812119,0.06181588,0.0049867784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.15390655,0.0025664272,0.0019277941,0.004549229,0.0035676449,0.01406214,0.008444349,0.008788031,0.0081914505],"category_scores_gemma":[0.06836995,0.0014153334,0.0026330873,0.003299492,0.0046145744,0.004651709,0.008377843,0.008026514,0.008429322],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015117794,0.0018584742,0.0050227307,0.0027922576,0.00031671,0.00090435235,0.0025241415,0.009609152,0.13656396,0.05053,0.24440587,0.5439607],"study_design_scores_gemma":[0.00029379892,0.002840676,0.003826631,0.0014016249,0.00012324093,0.0005197016,0.00079401885,0.004878682,0.17780301,0.014382349,0.7928704,0.00026578465],"about_ca_topic_score_codex":0.0047351485,"about_ca_topic_score_gemma":0.0033911595,"teacher_disagreement_score":0.15390655,"about_ca_system_score_codex":0.0068682814,"about_ca_system_score_gemma":0.031444374,"threshold_uncertainty_score":0.8139454},"labels":[],"label_agreement":null},{"id":"W4410870736","doi":"10.14740/jmc5114","title":"High-Sensitivity Flow Cytometric Detection of a Small Circulating Population of Nodal T-Follicular Helper Cell Lymphoma Angioimmunoblastic Type Cells","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; NODAL; Flow cytometry; Follicular lymphoma; Pathology; Lymphoma; Immunology; Internal medicine","score_opus":0.02335803757813309,"score_gpt":0.2972487032172782,"score_spread":0.2738906656391451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410870736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719757,0.0022549042,0.02118612,0.00023894261,0.000049127462,0.00008180164,0.00037515885,0.00031781406,0.0035204785],"genre_scores_gemma":[0.9841032,0.00048857776,0.013901643,0.00016198569,0.00004844458,0.0000516273,0.00046308283,0.000013273903,0.00076805265],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998223,0.00004480851,0.00001615471,0.0000465405,0.000033312102,0.000036923244],"domain_scores_gemma":[0.999818,0.00008360055,0.00001915636,0.000014721485,0.00003702104,0.000027432967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024145092,0.00033018735,0.00018506986,0.00081382087,0.00012359228,0.00026004607,0.00023793658,0.00045192754,0.0010457579],"category_scores_gemma":[0.00036538343,0.000105591556,0.000100964295,0.000231352,0.00013075146,0.0002085629,0.00015796679,0.00028900598,0.0004015641],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021188792,0.00009230103,0.02001595,0.00006330998,0.000016532445,0.002068075,0.00009198749,0.00011283103,0.96415687,0.00017540161,0.00029466947,0.01270017],"study_design_scores_gemma":[0.000112671885,0.001323065,0.17230147,0.00006656314,0.00018334783,0.035366897,0.0003668613,0.025672771,0.7525457,0.0010604768,0.010959864,0.000040308605],"about_ca_topic_score_codex":0.00020812327,"about_ca_topic_score_gemma":0.00024268132,"teacher_disagreement_score":0.0010457579,"about_ca_system_score_codex":0.00014303233,"about_ca_system_score_gemma":0.0000547499,"threshold_uncertainty_score":0.003498435},"labels":[],"label_agreement":null},{"id":"W4410893761","doi":"10.3390/curroncol32060322","title":"CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cytokine release syndrome; CAR T-cell therapy; Myeloid leukemia; Chimeric antigen receptor; Clinical trial; Disease; Population; Oncology; Internal medicine; Intensive care medicine; Immunology; Immunotherapy; Cancer","score_opus":0.14293709924110634,"score_gpt":0.48779391948154843,"score_spread":0.34485682024044206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410893761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021236055,0.95381594,0.0006255426,0.022107767,0.0006088731,0.00006238976,0.00019907342,0.00002129684,0.0013231299],"genre_scores_gemma":[0.114087515,0.86195266,0.003759454,0.015125075,0.0033602836,0.00017158034,0.0004661538,0.00002524215,0.0010520638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983443,0.0007741465,0.0003692294,0.000134861,0.0002693707,0.00010824126],"domain_scores_gemma":[0.99056935,0.006217156,0.0011911495,0.00021347642,0.0012091944,0.00059969],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009220654,0.00027327525,0.0014402672,0.0012742038,0.0002779027,0.0025460797,0.0007052782,0.0012739816,0.0029063828],"category_scores_gemma":[0.0074923085,0.000110838395,0.0006442321,0.0019247064,0.0009047575,0.0040681357,0.0007204322,0.0014580778,0.00063623034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029803796,0.00027983313,0.009880963,0.008448976,0.0003630972,0.00021577827,0.00018702375,0.0005362156,0.002832577,0.0026260843,0.011240297,0.9604087],"study_design_scores_gemma":[0.0030907912,0.030644689,0.03949555,0.06272661,0.0043169935,0.0050281817,0.0032553608,0.0023478072,0.006272007,0.022768233,0.8197671,0.00028667727],"about_ca_topic_score_codex":0.0003723426,"about_ca_topic_score_gemma":0.001051672,"teacher_disagreement_score":0.009220654,"about_ca_system_score_codex":0.00068345707,"about_ca_system_score_gemma":0.002216375,"threshold_uncertainty_score":0.04876411},"labels":[],"label_agreement":null},{"id":"W4410926980","doi":"10.1016/j.soncn.2025.151912","title":"The Experience of Patients with Cancer and Their Informal Caregivers Related to Adoptive Cell Therapy: A Qualitative Systematic Review","year":2025,"lang":"en","type":"review","venue":"Seminars in Oncology Nursing","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Swiss Cancer Research Foundation","keywords":"Medicine; Cancer; Qualitative research; Psychotherapist; Internal medicine","score_opus":0.03261467924982775,"score_gpt":0.42894866331748793,"score_spread":0.3963339840676602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410926980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1462105,0.8184206,0.0048146676,0.0091076605,0.0007092004,0.009824769,0.0034025179,0.000031835105,0.007478312],"genre_scores_gemma":[0.4817544,0.4793869,0.011123924,0.0064707794,0.00013333464,0.018195711,0.0010985433,0.00003962795,0.0017968516],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.974917,0.018527273,0.0035376525,0.0007531537,0.0014991969,0.0007656966],"domain_scores_gemma":[0.9425378,0.048012834,0.0038751194,0.00063030986,0.00412864,0.00081526476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034131695,0.000782788,0.0026524502,0.006177894,0.0025915783,0.0027869814,0.0015566347,0.0014023593,0.0035886478],"category_scores_gemma":[0.06326748,0.000802316,0.0026199764,0.007685207,0.0026065712,0.0038547958,0.0040551256,0.0013858507,0.00022689751],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048984983,0.00009918598,0.0062444597,0.4853521,0.0012704682,0.0025063383,0.38365474,0.00023763048,0.00084255956,0.0031932336,0.0046414137,0.11146804],"study_design_scores_gemma":[0.00017308784,0.00043858995,0.005298529,0.46352333,0.00264129,0.0015961992,0.4597758,0.00011162587,0.00049400225,0.0015798253,0.06423893,0.00012891655],"about_ca_topic_score_codex":0.0118252,"about_ca_topic_score_gemma":0.033601634,"teacher_disagreement_score":0.034131695,"about_ca_system_score_codex":0.008136453,"about_ca_system_score_gemma":0.023463292,"threshold_uncertainty_score":0.18050778},"labels":[],"label_agreement":null},{"id":"W4410955025","doi":"10.1038/s41590-025-02154-2","title":"Regulatory T cell therapies to treat autoimmune diseases and transplant rejection","year":2025,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Immunology; Medicine","score_opus":0.005500535717867823,"score_gpt":0.27628577318921815,"score_spread":0.2707852374713503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410955025","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17635113,0.63710445,0.03730962,0.024838232,0.012742333,0.0004879871,0.00040104525,0.0010442608,0.10972097],"genre_scores_gemma":[0.685522,0.23034725,0.01627617,0.008711839,0.0068006264,0.00046437778,0.00045904206,0.00014014792,0.0512785],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998165,0.000049121223,0.000008356101,0.000025808702,0.000056423232,0.000043859352],"domain_scores_gemma":[0.99987113,0.00003685117,0.000028155195,0.0000124659655,0.000020916521,0.000030539304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007197058,0.00056885235,0.0004514552,0.00055837934,0.00026273384,0.0007195769,0.00041600905,0.0007271258,0.0056974837],"category_scores_gemma":[0.0002855683,0.00010548951,0.0003751876,0.00021872974,0.00058611477,0.0004595893,0.00037606797,0.0024738724,0.0012764686],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014413081,0.0013547263,0.0010326619,0.0015793558,0.00014128625,0.0006807043,0.00016543071,0.0012453152,0.19934759,0.05822909,0.028649129,0.70613337],"study_design_scores_gemma":[0.0020507204,0.007106067,0.0030330783,0.0006098483,0.00037674283,0.0037044822,0.00018498386,0.0022301048,0.13891423,0.025594076,0.8161526,0.000043084317],"about_ca_topic_score_codex":0.00011990301,"about_ca_topic_score_gemma":0.0003415566,"teacher_disagreement_score":0.0056974837,"about_ca_system_score_codex":0.00026485656,"about_ca_system_score_gemma":0.000415744,"threshold_uncertainty_score":0.019060016},"labels":[],"label_agreement":null},{"id":"W4410973309","doi":"10.1111/imcb.70037","title":"Highlights of 2024: unleashing the power of NK cells—cancer's worst nightmare","year":2025,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Children's Hospital Foundation; PA Research Foundation; University of Queensland; National Breast Cancer Foundation; Canadian Institutes of Health Research; Tour de Cure; Cancer Research Society","keywords":"Cytotoxicity; CRISPR; Cancer cell; Cytokine; Cell; Cancer research; Cancer; Biology; Immunology; Gene; In vitro; Biochemistry; Genetics","score_opus":0.01040844026320787,"score_gpt":0.28655691207170775,"score_spread":0.2761484718084999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410973309","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045220223,0.30730176,0.0048136953,0.4054959,0.2228092,0.00007546132,0.00047080478,0.00047438993,0.054036777],"genre_scores_gemma":[0.051826205,0.23902184,0.005912988,0.24697529,0.16991794,0.00012996147,0.00088160817,0.00049883407,0.28483537],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989507,0.0001964959,0.0000540053,0.00014057184,0.00041438726,0.00024369262],"domain_scores_gemma":[0.9978757,0.00043862432,0.000079991834,0.00007359066,0.00047452404,0.001057674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026980669,0.0008483014,0.0005179872,0.00066097354,0.0018365259,0.004226098,0.00100385,0.0039834315,0.015189804],"category_scores_gemma":[0.0028128456,0.00024656692,0.0007147663,0.0004345257,0.001750301,0.0032950006,0.0021414938,0.006975967,0.004900953],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016542527,0.000041722076,0.00026648334,0.000254884,0.000014654656,0.00028115,0.00012606583,0.00011097434,0.002131126,0.00974396,0.88734543,0.099518135],"study_design_scores_gemma":[0.000012508406,0.00008920386,0.00021731584,0.00011567706,0.0000093828485,0.0004246062,0.00017248446,0.000088221954,0.0010598601,0.0029562144,0.9948394,0.000015270472],"about_ca_topic_score_codex":0.0025350342,"about_ca_topic_score_gemma":0.0059199044,"teacher_disagreement_score":0.015189804,"about_ca_system_score_codex":0.0021046684,"about_ca_system_score_gemma":0.0031467315,"threshold_uncertainty_score":0.050814927},"labels":[],"label_agreement":null},{"id":"W4410992159","doi":"10.31219/osf.io/yj5fb_v1","title":"Mid-term neurocognitive outcomes after CAR T cell therapy in central nervous system lymphomas: statistical analysis plan","year":2025,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Term (time); Central nervous system; CAR T-cell therapy; Statistical analysis; Plan (archaeology); Neuroscience; Medicine; T cell; Psychology; Cognition; Immunology; Biology; Immune system; Statistics; Mathematics","score_opus":0.02619972986616645,"score_gpt":0.3192107432866936,"score_spread":0.29301101342052716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410992159","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71465236,0.0051417802,0.23055169,0.0027248722,0.00077281473,0.008137434,0.032900162,0.0015440101,0.0035748887],"genre_scores_gemma":[0.9288775,0.0004023531,0.039117914,0.00040704466,0.00017851467,0.0128690265,0.016177075,0.00017725152,0.0017934475],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.96848184,0.019870486,0.0024347755,0.0041839303,0.003790228,0.0012388687],"domain_scores_gemma":[0.92190254,0.058875285,0.0062248297,0.008640697,0.003111434,0.0012451428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.057994675,0.0010343293,0.0021226208,0.0038942287,0.0005588865,0.0016298898,0.0023393678,0.0013240441,0.006605439],"category_scores_gemma":[0.070997834,0.00031206373,0.007313595,0.0027776395,0.0013451831,0.0014804185,0.0021708815,0.002193335,0.00066362176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018084353,0.0011459524,0.77564806,0.001672912,0.02039136,0.0005090621,0.00059246,0.022727836,0.0012962266,0.0046487395,0.017376564,0.13590653],"study_design_scores_gemma":[0.0009878163,0.012232584,0.6988657,0.00064250734,0.007525166,0.00075756165,0.0010636178,0.24198245,0.0033521357,0.013461345,0.018898169,0.00023098961],"about_ca_topic_score_codex":0.0020218329,"about_ca_topic_score_gemma":0.0010396235,"teacher_disagreement_score":0.057994675,"about_ca_system_score_codex":0.0014894096,"about_ca_system_score_gemma":0.002230545,"threshold_uncertainty_score":0.3067088},"labels":[],"label_agreement":null},{"id":"W4411017159","doi":"10.1200/go-24-00441","title":"Global Access to Multiple Myeloma Therapies","year":2025,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Expanded access; Family medicine; Chimeric antigen receptor; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.04368081239765278,"score_gpt":0.4343898033175966,"score_spread":0.3907089909199438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411017159","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8055787,0.020300092,0.0019276113,0.032657765,0.00020428102,0.00012877246,0.0076497123,0.00019402902,0.13135907],"genre_scores_gemma":[0.989012,0.005736495,0.0005121173,0.0014939636,0.00014650587,0.000039281946,0.0009918279,0.000009210611,0.0020584713],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938107,0.00022351823,0.0000600395,0.000074684605,0.0001262211,0.00013450345],"domain_scores_gemma":[0.99762386,0.00051634095,0.0010757513,0.00008927719,0.00021011168,0.0004845211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008952747,0.00013084775,0.00014817859,0.0005772215,0.00024404474,0.0007093837,0.0002437257,0.00025103043,0.015731808],"category_scores_gemma":[0.0033315893,0.000054430522,0.00018497548,0.0011844486,0.00027920931,0.0009260494,0.0011795694,0.0003527628,0.00071663555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015875361,0.0001057297,0.7822877,0.0011443587,0.00013264068,0.0003106871,0.0015392796,0.0007689751,0.00065101386,0.004321179,0.018030334,0.19054934],"study_design_scores_gemma":[0.000042333973,0.00034648864,0.8532588,0.0011777052,0.000119980636,0.0013802925,0.0033835508,0.00055744505,0.0006312284,0.0022495028,0.13682799,0.000024619307],"about_ca_topic_score_codex":0.0027213956,"about_ca_topic_score_gemma":0.002678939,"teacher_disagreement_score":0.015731808,"about_ca_system_score_codex":0.0004403541,"about_ca_system_score_gemma":0.00087811984,"threshold_uncertainty_score":0.05262816},"labels":[],"label_agreement":null},{"id":"W4411063878","doi":"10.1002/advs.202500181","title":"An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Advanced Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chinese Academy of Sciences; Basic and Applied Basic Research Foundation of Guangdong Province; National Key Research and Development Program of China; Peking Union Medical College; Institute of Genetics; Institute of Microbiology, Chinese Academy of Sciences; National Natural Science Foundation of China","keywords":"T-cell receptor; KRAS; Context (archaeology); T cell; Cancer research; Immunotherapy; Avidity; Antigen; Computational biology; Mutation; Biology; Molecular biology; Chemistry; Immunology; Genetics; Immune system; Gene","score_opus":0.029175162036476313,"score_gpt":0.3437539107347228,"score_spread":0.3145787486982465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411063878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98162156,0.0013192397,0.013874154,0.00013288076,0.000047200327,0.00006748966,0.00018665582,0.00020390592,0.0025468995],"genre_scores_gemma":[0.99095833,0.00049296365,0.0065408014,0.00006343801,0.000010085096,0.000033965673,0.00018247483,0.000014663517,0.0017031687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998963,0.000013113531,0.0000076277693,0.00001848703,0.000039267743,0.00002527668],"domain_scores_gemma":[0.9999628,0.0000029545633,0.000016490363,0.000003451613,0.0000051556563,0.000009200774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006814651,0.00025549048,0.00015477341,0.00009162837,0.000060596944,0.00023374526,0.00016739413,0.00032889453,0.0006281677],"category_scores_gemma":[0.00008160527,0.00009691705,0.00014897108,0.00009095943,0.00008335054,0.00011655867,0.00015528384,0.000430749,0.00035279765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003598884,0.00003043084,0.000075937896,0.000027272099,0.0000038983912,0.00005709909,0.0000073522497,0.0004672771,0.9969254,0.00015480563,0.00008346989,0.0021309927],"study_design_scores_gemma":[0.000027079452,0.00087550073,0.0006316802,0.000005596443,0.000019335175,0.00052968884,0.000014246384,0.0044107977,0.98799884,0.000056215442,0.0054212697,0.000009677647],"about_ca_topic_score_codex":0.0001532707,"about_ca_topic_score_gemma":0.00032507768,"teacher_disagreement_score":0.0006281677,"about_ca_system_score_codex":0.00017117447,"about_ca_system_score_gemma":0.000110697285,"threshold_uncertainty_score":0.0021014214},"labels":[],"label_agreement":null},{"id":"W4411126573","doi":"10.1186/s40644-025-00888-8","title":"Prognostic value of early post-treatment 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Cancer Imaging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Women's College Hospital","funders":"","keywords":"Medicine; Standardized uptake value; Proportional hazards model; Nuclear medicine; Lymphoma; Log-rank test; Univariate analysis; Positron emission tomography; Progression-free survival; Internal medicine; Diffuse large B-cell lymphoma; Multivariate analysis; Oncology; Gastroenterology; Chemotherapy","score_opus":0.01174658242552977,"score_gpt":0.29977397794352556,"score_spread":0.2880273955179958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411126573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9989073,0.00057483214,0.00007377381,0.00002288047,0.000004357466,0.0000034216598,0.000059853974,0.000002551779,0.00035093978],"genre_scores_gemma":[0.9996362,0.000104770734,0.000057062363,0.000010320324,0.000011371231,0.0000021315439,0.000103587954,0.0000010030479,0.00007364979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981517,0.0000477485,0.000021134585,0.0000324684,0.000033326098,0.000050220566],"domain_scores_gemma":[0.998765,0.00030177893,0.0005218344,0.000046328936,0.00012114364,0.00024399375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003589754,0.00018548961,0.00028423461,0.00047671422,0.00020069987,0.00055018644,0.00019700384,0.00045412863,0.0009847132],"category_scores_gemma":[0.0015572114,0.00011038106,0.00021616263,0.00037009188,0.0002564046,0.00034264705,0.00015597358,0.0002944542,0.00022926526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004407724,0.000019061688,0.9956476,0.000007415337,0.000009942103,0.0006606697,0.000016829517,0.000069418624,0.00077680097,0.000007923528,0.000039112565,0.0023043384],"study_design_scores_gemma":[0.00001323503,0.00025556202,0.9938939,0.0000069554662,0.000028614502,0.0044920594,0.00007986191,0.00036801156,0.0005414317,0.000015027891,0.00030028078,0.0000050243602],"about_ca_topic_score_codex":0.00091798016,"about_ca_topic_score_gemma":0.001190711,"teacher_disagreement_score":0.0009847132,"about_ca_system_score_codex":0.00025803692,"about_ca_system_score_gemma":0.00017679857,"threshold_uncertainty_score":0.00329417},"labels":[],"label_agreement":null},{"id":"W4411136134","doi":"10.1101/2025.06.06.658308","title":"Imaging CRISPR-Edited CAR-T Cell Therapies with Optical and Positron Emission Tomography Reporters","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Lawson Health Research Institute; University of Manitoba; Western University","funders":"National Institutes of Health","keywords":"Positron emission tomography; CRISPR; Physics; Medical physics; Psychology; Neuroscience; Biology; Genetics","score_opus":0.010198859144757967,"score_gpt":0.25104817895860093,"score_spread":0.24084931981384297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411136134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78107905,0.004501261,0.20262758,0.0005592235,0.00013757277,0.00024774886,0.0014327349,0.0019049854,0.0075098076],"genre_scores_gemma":[0.9392476,0.0014946603,0.053494055,0.00013653541,0.000022114456,0.00017695167,0.0005910921,0.00009520752,0.0047417833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974984,0.00003712015,0.000017859751,0.000067080466,0.0000808628,0.00004732663],"domain_scores_gemma":[0.9998741,0.000023768484,0.00003414042,0.000016176296,0.000028196175,0.000023644046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025769862,0.00038323004,0.00032204387,0.00029125006,0.00012695378,0.00066167314,0.00042031048,0.00047703512,0.000906672],"category_scores_gemma":[0.0002106632,0.0002002115,0.00025683816,0.00019471266,0.00035348508,0.0002576097,0.0002606572,0.0005474769,0.0004803423],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006847393,0.000018971865,0.00026261408,0.000060587234,0.000007242202,0.00006770155,0.000015011073,0.0010003462,0.9940435,0.00052669435,0.00019077561,0.0037380506],"study_design_scores_gemma":[0.000010842005,0.00011511208,0.00047348416,0.000005348144,0.0000124181925,0.00022661281,0.000012283329,0.0043546464,0.9906849,0.00010556309,0.0039899605,0.000008804305],"about_ca_topic_score_codex":0.00087705115,"about_ca_topic_score_gemma":0.00071372866,"teacher_disagreement_score":0.000906672,"about_ca_system_score_codex":0.0006332114,"about_ca_system_score_gemma":0.00040152774,"threshold_uncertainty_score":0.0045942664},"labels":[],"label_agreement":null},{"id":"W4411148333","doi":"10.1016/j.jiec.2025.06.017","title":"Nanoparticles-Mediated CRISPR-Cas9 systems for CAR T-cell immunotherapy as smart cancer biotherapeutics","year":2025,"lang":"en","type":"article","venue":"Journal of Industrial and Engineering Chemistry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"Umm Al-Qura University","keywords":"CRISPR; Cancer immunotherapy; Immunotherapy; Genome editing; Cas9; Cancer research; Chemistry; Computational biology; Cancer; Biology; Biochemistry; Gene; Genetics","score_opus":0.029488499934878825,"score_gpt":0.30125258237159114,"score_spread":0.2717640824367123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411148333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7594358,0.010072355,0.20107606,0.0011624086,0.00088131113,0.00041691578,0.0015483993,0.004260428,0.021146365],"genre_scores_gemma":[0.9563337,0.0013122521,0.03289075,0.00023894945,0.000029341727,0.00014756572,0.0006163889,0.00014890988,0.008282224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995845,0.000044626053,0.000031566724,0.00013044648,0.00014693456,0.000061889696],"domain_scores_gemma":[0.9998833,0.000029010973,0.000031652617,0.000014954164,0.000024820885,0.00001626918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002493994,0.00046194304,0.00045044717,0.0002900917,0.00023281376,0.0008194677,0.0004825021,0.0008335337,0.0018326419],"category_scores_gemma":[0.00034419104,0.00029079505,0.00037158516,0.00014347163,0.00035903393,0.00048393282,0.0004387163,0.00084378175,0.0009073742],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000064855616,0.00002948504,0.000049408292,0.000091514645,0.000014830336,0.000055107637,0.000023889828,0.00042000695,0.9923805,0.00085138483,0.00037387645,0.005645253],"study_design_scores_gemma":[0.0000083085215,0.00007738484,0.000110033245,0.000004183612,0.000015450245,0.000085247295,0.000008572548,0.0024707867,0.99167025,0.00011836307,0.0054214033,0.000010020164],"about_ca_topic_score_codex":0.00057342584,"about_ca_topic_score_gemma":0.0009853232,"teacher_disagreement_score":0.0018326419,"about_ca_system_score_codex":0.00055453327,"about_ca_system_score_gemma":0.0002713385,"threshold_uncertainty_score":0.006130755},"labels":[],"label_agreement":null},{"id":"W4411150706","doi":"10.58931/crt.2025.2160","title":"The Impact of Chimeric Antigen Receptor (CAR) T Cell Therapy: Its Potential to Reshape Rheumatology Practice","year":2025,"lang":"en","type":"article","venue":"Canadian rheumatology today.","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Rheumatology; Internal medicine; Receptor; Antigen; Medicine; Immunology; Immunotherapy","score_opus":0.01358585037871875,"score_gpt":0.32049053594546567,"score_spread":0.30690468556674694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411150706","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058055314,0.39940894,0.0014809082,0.3675738,0.21973951,0.000028350592,0.000058259473,0.0001254203,0.011004257],"genre_scores_gemma":[0.01032148,0.50754964,0.0027169748,0.1665209,0.2922575,0.000030011695,0.00007536964,0.0001267231,0.020401405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99634093,0.0007450781,0.00030427985,0.00033162965,0.0019643037,0.00031377168],"domain_scores_gemma":[0.9833693,0.006714244,0.00065465504,0.00027586895,0.006821796,0.00216418],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006398135,0.00085900584,0.00077014015,0.0013130002,0.0015386275,0.0035936914,0.0012352702,0.0051223678,0.0057210387],"category_scores_gemma":[0.013204152,0.00032318928,0.0008798523,0.0006642352,0.0032271314,0.003085327,0.0010071986,0.008604225,0.002571373],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011968792,0.000031475593,0.00019714165,0.000995475,0.000034033455,0.00047949547,0.0001646186,0.00016059603,0.0006734715,0.008483596,0.8228448,0.16581559],"study_design_scores_gemma":[0.000025111989,0.000036940302,0.00021368083,0.00033594324,0.000018582545,0.0004060867,0.000078323676,0.00007519941,0.00013081532,0.0022067362,0.9964547,0.000017969096],"about_ca_topic_score_codex":0.018147718,"about_ca_topic_score_gemma":0.05734464,"teacher_disagreement_score":0.018147718,"about_ca_system_score_codex":0.005673025,"about_ca_system_score_gemma":0.008643544,"threshold_uncertainty_score":0.041160822},"labels":[],"label_agreement":null},{"id":"W4411238360","doi":"10.1016/j.ccell.2025.05.013","title":"CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Horizon 2020; European Research Council; Hector Stiftung; Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen; José Carreras Leukämie-Stiftung; Bundesministerium für Bildung und Forschung; Horizon 2020 Framework Programme; Imhoff Stiftung; Else Kröner-Fresenius-Stiftung; Bayerische Forschungsstiftung; Deutsche Forschungsgemeinschaft; Fritz-Bender-Stiftung; Deutsche Krebshilfe; Wilhelm Sander-Stiftung; Universität zu Köln; European Commission; Deutsches Zentrum für Infektionsforschung","keywords":"Lymphoma; Myeloid; Cancer research; Myeloid cells; Cell; Biology; Immunology; Genetics","score_opus":0.0135611302673057,"score_gpt":0.30067887263412796,"score_spread":0.28711774236682225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411238360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998276,0.00042903994,0.0006721428,0.000024353416,0.0000013915378,0.0000205964,0.000093036484,0.000047326408,0.00043602602],"genre_scores_gemma":[0.99868125,0.00015047756,0.00055697287,0.000022538174,0.0000031733687,0.0000145744325,0.00014204398,0.000004800705,0.00042412223],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989986,0.000024397219,0.00000707635,0.000016602335,0.000023313047,0.000028745908],"domain_scores_gemma":[0.9999422,0.000012800867,0.000014612261,0.000009243547,0.0000047949306,0.000016371312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014643645,0.00012745948,0.00017850586,0.00026304688,0.00014549308,0.00032693005,0.00008241546,0.00016438126,0.0010703147],"category_scores_gemma":[0.00011901257,0.00010677825,0.00009937839,0.00014340022,0.00017230405,0.000101720005,0.00015197332,0.00032059278,0.0002849281],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024740284,0.00008962286,0.006464321,0.000028489894,0.000008722086,0.00022324613,0.00006484069,0.00015651582,0.98649687,0.00020099673,0.00012377971,0.0058952156],"study_design_scores_gemma":[0.00019083546,0.0027522284,0.1429873,0.000019175337,0.00008866214,0.0046962495,0.0002964483,0.006109359,0.83319944,0.00049916113,0.009147772,0.000013361468],"about_ca_topic_score_codex":0.0006344861,"about_ca_topic_score_gemma":0.0010590678,"teacher_disagreement_score":0.0010703147,"about_ca_system_score_codex":0.00018168849,"about_ca_system_score_gemma":0.00014330864,"threshold_uncertainty_score":0.0035805702},"labels":[],"label_agreement":null},{"id":"W4411259006","doi":"10.1126/sciadv.adx7845","title":"Armored human CAR T <sub>reg</sub> cells with PD1 promoter-driven IL-10 have enhanced suppressive function","year":2025,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Children's Hospital; AstraZeneca","keywords":"Function (biology); Cell biology; Computational biology; Biology; Molecular biology","score_opus":0.013511176984301787,"score_gpt":0.31620300698714404,"score_spread":0.3026918300028423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411259006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97097856,0.0017111904,0.018635016,0.0003432707,0.00009654207,0.00011094443,0.000901796,0.0008089885,0.006413722],"genre_scores_gemma":[0.9824096,0.0005216191,0.007460525,0.00014854495,0.000018889801,0.00007573292,0.0011327814,0.00008604052,0.008146236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966395,0.000052247495,0.000026342264,0.00007877146,0.00008547414,0.00009321072],"domain_scores_gemma":[0.99986565,0.000030652027,0.000031225154,0.000026827323,0.000017446253,0.000028280067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027640103,0.00047580167,0.0003654238,0.00024686754,0.0001322354,0.00055442576,0.00027169494,0.00045900742,0.003404869],"category_scores_gemma":[0.00013122048,0.00019472546,0.00032678017,0.0001857783,0.00042296344,0.000218717,0.00020975126,0.0010630307,0.0014222554],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000141203,0.00006443239,0.00020344656,0.00004521567,0.000011134813,0.000051395018,0.00003129275,0.00020863494,0.9960061,0.00040203054,0.00028347707,0.0025516308],"study_design_scores_gemma":[0.000031973275,0.00023686644,0.00055805454,0.0000027893054,0.000023310888,0.0002964232,0.000015496134,0.0012567285,0.9903998,0.00004284839,0.007130534,0.0000051716356],"about_ca_topic_score_codex":0.0007171066,"about_ca_topic_score_gemma":0.0009673481,"teacher_disagreement_score":0.003404869,"about_ca_system_score_codex":0.00038049198,"about_ca_system_score_gemma":0.0002935919,"threshold_uncertainty_score":0.011390388},"labels":[],"label_agreement":null},{"id":"W4411287882","doi":"10.1101/2025.06.09.658763","title":"Thermally controlled state switches for macrophage immunotherapy","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; California Institute of Technology; Sontag Foundation; Beckman Institute, California Institute of Technology; National Institutes of Health; National Science Foundation","keywords":"Immunotherapy; Immune system; Cancer immunotherapy; In vivo; Cytokine; Cell biology; Macrophage; Biology; Cancer research; Immunology; In vitro; Genetics","score_opus":0.01857719081642212,"score_gpt":0.2771008792582714,"score_spread":0.2585236884418493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411287882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86836594,0.0044275504,0.10580037,0.001166399,0.0004812474,0.00012082503,0.00027029667,0.0008796838,0.01848772],"genre_scores_gemma":[0.9882004,0.0005562251,0.007798837,0.00011835355,0.000026264632,0.000060135302,0.000042695134,0.00003233946,0.0031648066],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99994063,0.00000913972,0.0000031535221,0.00001590007,0.000019167259,0.000012008128],"domain_scores_gemma":[0.999954,0.000016459358,0.0000114024015,0.0000054752595,0.0000059138924,0.0000067242363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013691593,0.00015550476,0.000110936104,0.00007721639,0.00014125474,0.0003012938,0.00019105822,0.0002517608,0.002353954],"category_scores_gemma":[0.00014826749,0.00009194154,0.00012640742,0.00006444,0.00024540178,0.00025944653,0.00017182072,0.00042765,0.0003777137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005056908,0.000028747409,0.00008069194,0.000047493384,0.0000035844366,0.00003500106,0.000024946426,0.00089764927,0.9877671,0.006279563,0.00037308695,0.0044116015],"study_design_scores_gemma":[0.000020103984,0.00015877733,0.00021177063,0.000006764765,0.000005834541,0.00005952645,0.000015602773,0.009556586,0.9790491,0.00176645,0.009139396,0.000010071774],"about_ca_topic_score_codex":0.00009832164,"about_ca_topic_score_gemma":0.00015510833,"teacher_disagreement_score":0.002353954,"about_ca_system_score_codex":0.0002897517,"about_ca_system_score_gemma":0.00009727779,"threshold_uncertainty_score":0.007874787},"labels":[],"label_agreement":null},{"id":"W4411319666","doi":"10.1136/jitc-2024-011364","title":"Blockade of colon cancer metastasis via single and double silencing of <i>PCSK7</i> / <i>PCSK9</i> : enhanced T cells cytotoxicity in mouse and human","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Montreal Clinical Research Institute","funders":"Canada Research Chairs; Québec Consortium for Drug Discovery; Cancer Research Society","keywords":"Proprotein convertase; Cancer research; T cell; Kexin; Cytotoxic T cell; Immune checkpoint; Biology; Immune system; CD8; Immunotherapy; Immunology; LDL receptor; Endocrinology; Cholesterol","score_opus":0.025767333762424804,"score_gpt":0.360806984194092,"score_spread":0.3350396504316672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411319666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002236,0.0013583957,0.0043065385,0.00024658235,0.00007068712,0.00009507802,0.0011377911,0.00033452437,0.0024280066],"genre_scores_gemma":[0.9916501,0.0008422331,0.0020051643,0.000089444,0.000016928409,0.000113026086,0.0009203058,0.000046581084,0.00431631],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981624,0.000020753776,0.000017798026,0.000052805215,0.000044754128,0.000047773963],"domain_scores_gemma":[0.9999256,0.000009341032,0.000019373369,0.000012803756,0.0000068762183,0.000025906018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014087275,0.00044302858,0.0003034553,0.00030313,0.00012454251,0.00023796697,0.00016516101,0.0003158594,0.0014280608],"category_scores_gemma":[0.00007472919,0.00014925319,0.000306925,0.00014734647,0.00030628484,0.00012726177,0.00013156715,0.0009242482,0.0004196901],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024625007,0.000043723234,0.00010042749,0.00003455858,0.0000079118245,0.000030968804,0.000009052275,0.00009489522,0.9982803,0.00007495892,0.0001115503,0.00096559915],"study_design_scores_gemma":[0.00005671322,0.0007854438,0.0015381615,0.000004097774,0.000026751008,0.00025109918,0.000012754166,0.00084570015,0.9944905,0.000036824786,0.0019483127,0.0000036166211],"about_ca_topic_score_codex":0.001129641,"about_ca_topic_score_gemma":0.0013692362,"teacher_disagreement_score":0.0014280608,"about_ca_system_score_codex":0.00030029955,"about_ca_system_score_gemma":0.0003045497,"threshold_uncertainty_score":0.004777372},"labels":[],"label_agreement":null},{"id":"W4411335183","doi":"10.1002/hon.70093_5","title":"5 | LARGE B‐CELL LYMPHOMA MICROENVIRONMENT ARCHETYPE PROFILES (LYMPHOMAPS) IDENTIFY SUBGROUPS WITH GREATEST BENEFIT FROM CD19 CAR T‐CELL THERAPY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"MorphoSys; Genentech; Incyte; Gilead Sciences; AstraZeneca","keywords":"CD19; Lymphoma; Medicine; B cell; Oncology; Internal medicine; Cancer research; Immunology","score_opus":0.02569170392763857,"score_gpt":0.31176753998727297,"score_spread":0.2860758360596344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411335183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436104,0.0005043979,0.0016496896,0.00010385632,0.0000048087977,0.0000308806,0.001918408,0.000101571306,0.0013252462],"genre_scores_gemma":[0.99616736,0.00008134791,0.00097513327,0.000052900894,0.000008847171,0.000017254271,0.002285215,0.000013316485,0.0003985558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99989176,0.0000160849,0.00000777341,0.00003191986,0.000018788856,0.000033628963],"domain_scores_gemma":[0.9998097,0.00004431832,0.000065849155,0.000011520754,0.000017535685,0.000051238643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019997836,0.00023032833,0.00031008857,0.0007714593,0.00026859448,0.0005830717,0.00017040582,0.0003060586,0.00442883],"category_scores_gemma":[0.00028963902,0.00008918785,0.0002627123,0.0003959866,0.00017693316,0.00024321917,0.0003828417,0.00025184697,0.00059472333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002824359,0.00013419894,0.7325471,0.00020331379,0.00016770662,0.0005292046,0.00018174059,0.0008723095,0.2103878,0.0005550527,0.002615888,0.04898141],"study_design_scores_gemma":[0.0000448967,0.0003311948,0.9707516,0.000019078328,0.00013291079,0.0021626006,0.00022171272,0.0023059414,0.019592255,0.00059876,0.0038285586,0.0000105192685],"about_ca_topic_score_codex":0.0006686246,"about_ca_topic_score_gemma":0.0012757102,"teacher_disagreement_score":0.00442883,"about_ca_system_score_codex":0.00027909383,"about_ca_system_score_gemma":0.00019227131,"threshold_uncertainty_score":0.014815927},"labels":[],"label_agreement":null},{"id":"W4411383594","doi":"10.1080/10428194.2025.2518440","title":"Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Chimeric antigen receptor; Reimbursement; Medicine; Activity-based costing; Cohort; Health care; Retrospective cohort study; Internal medicine; Immunotherapy; Cancer; Business","score_opus":0.010594177255934879,"score_gpt":0.26298161148964,"score_spread":0.25238743423370513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411383594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611269,0.0026900857,0.0005288305,0.0028007075,0.000037923768,0.00010958588,0.027701525,0.000028172397,0.0049763694],"genre_scores_gemma":[0.989516,0.0016130281,0.0004855363,0.00026035038,0.000017156875,0.000029561366,0.007131992,0.000007962201,0.0009384406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989698,0.00016069738,0.00011993398,0.00009875356,0.00034235942,0.00030846146],"domain_scores_gemma":[0.9980338,0.00021993049,0.000666709,0.000044316545,0.00065293413,0.00038223126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005590189,0.00037125073,0.0003730011,0.0013960294,0.0010023993,0.0016507573,0.0008006018,0.0004612652,0.002118649],"category_scores_gemma":[0.004077075,0.0003497022,0.0010966976,0.004155364,0.00039435545,0.00054944697,0.0006395744,0.00085606007,0.0001491684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046821343,0.00008036732,0.956558,0.00018926717,0.00058900827,0.00069716503,0.00025413898,0.017711805,0.00020439169,0.0018740875,0.006660912,0.014712618],"study_design_scores_gemma":[0.0001322205,0.00011536362,0.96842426,0.00020782785,0.00027463355,0.0006136222,0.0011542838,0.022041567,0.00022488464,0.00054871285,0.006175258,0.000087368084],"about_ca_topic_score_codex":0.98640627,"about_ca_topic_score_gemma":0.98728263,"teacher_disagreement_score":0.06511001,"about_ca_system_score_codex":0.06511001,"about_ca_system_score_gemma":0.025017116,"threshold_uncertainty_score":0.4724084},"labels":[],"label_agreement":null},{"id":"W4411401649","doi":"10.1016/j.omtm.2025.101517","title":"Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Defense Science and Engineering Graduate; University of California, Los Angeles; National Institutes of Health; Weston Havens Foundation; University of Toronto; Medizinische Universität Wien; Johns Hopkins University; Lung Cancer Research Foundation; Japan Society for the Promotion of Science; Kyushu University; California Institute for Regenerative Medicine","keywords":"Lung cancer; Cancer research; Medicine; Cell; Oncology; Biology; Genetics","score_opus":0.06819337799728677,"score_gpt":0.4599584104786687,"score_spread":0.39176503248138195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411401649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83287764,0.0042356853,0.12533014,0.0009890972,0.0009283608,0.0014945478,0.0054477234,0.0012776757,0.027419116],"genre_scores_gemma":[0.9617645,0.002177188,0.023323756,0.00042985103,0.00005328048,0.00051927747,0.0030587085,0.00014503136,0.008528304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998673,0.000018998506,0.000020180649,0.000026244703,0.000040834122,0.000026442625],"domain_scores_gemma":[0.99989164,0.000026445965,0.000026204953,0.000017328579,0.00002096276,0.000017339735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028362797,0.00029483903,0.00018966821,0.00028349442,0.00013383527,0.00038552057,0.00028536035,0.0005576908,0.0017564279],"category_scores_gemma":[0.0002270241,0.0001427428,0.00033060912,0.00016432689,0.000181006,0.00021350654,0.00017780531,0.0011819752,0.00079078856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010047449,0.00014668574,0.0003584097,0.00010658676,0.000020287513,0.0003230065,0.000060444647,0.0010235164,0.9833038,0.0015027868,0.0008763684,0.01217763],"study_design_scores_gemma":[0.000069241236,0.00029374688,0.0009880031,0.000019995712,0.00004936382,0.0006258898,0.000023781846,0.002264639,0.97789705,0.00030396495,0.017456472,0.00000783952],"about_ca_topic_score_codex":0.00020769982,"about_ca_topic_score_gemma":0.00030459557,"teacher_disagreement_score":0.0017564279,"about_ca_system_score_codex":0.00015274051,"about_ca_system_score_gemma":0.00029192254,"threshold_uncertainty_score":0.005875826},"labels":[],"label_agreement":null},{"id":"W4411412184","doi":"10.1016/j.ccell.2025.06.002","title":"Large B cell lymphoma microenvironment archetype profiles","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"National Cancer Institute; Leukemia and Lymphoma Society; Lymphoma Research Foundation","keywords":"Lymphoma; Cancer research; Tumor microenvironment; Archetype; Biology; Cell biology; Computational biology; Medicine; Immunology; Tumor cells","score_opus":0.016007983191194113,"score_gpt":0.3006595645842687,"score_spread":0.28465158139307456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411412184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959115,0.00035988548,0.0023325896,0.000013821842,0.0000014578787,0.000023703338,0.00044019133,0.000046365923,0.00087057415],"genre_scores_gemma":[0.9973085,0.0001772766,0.0013301959,0.00002330289,0.000002137222,0.000027602835,0.00062050467,0.000013713322,0.00049671455],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99985635,0.000020304438,0.000008478497,0.000042166852,0.00003530296,0.000037391157],"domain_scores_gemma":[0.9999058,0.000013540177,0.000031583255,0.000014751815,0.000013994123,0.000020365718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011538811,0.00016453901,0.0001522476,0.00076335267,0.00022246683,0.00040884013,0.00010167937,0.00016871693,0.001266424],"category_scores_gemma":[0.00014554552,0.00009474335,0.000120853794,0.00033583658,0.00018877514,0.00018983702,0.0004001521,0.00018684704,0.0003078499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043655495,0.00001867888,0.039118864,0.00004451255,0.000019465799,0.00026026677,0.00016044665,0.00016201686,0.9526717,0.00018989567,0.00007401011,0.006843537],"study_design_scores_gemma":[0.00003515029,0.0004244896,0.54718757,0.00002096167,0.00008512964,0.007646543,0.0010508884,0.0021974358,0.43304348,0.00083549984,0.0074512335,0.000021611642],"about_ca_topic_score_codex":0.0005451353,"about_ca_topic_score_gemma":0.0013744779,"teacher_disagreement_score":0.001266424,"about_ca_system_score_codex":0.00019598521,"about_ca_system_score_gemma":0.00011030593,"threshold_uncertainty_score":0.004236579},"labels":[],"label_agreement":null},{"id":"W4411429251","doi":"10.1080/10428194.2025.2504719","title":"Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Chemoimmunotherapy; CD20; Rituximab; CHOP; Monoclonal antibody; Vincristine; Cancer research; Lymphoma; Medicine; B cell; Antibody-dependent cell-mediated cytotoxicity; Diffuse large B-cell lymphoma; Antibody; Immunology; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.008323771422152333,"score_gpt":0.27149745491985194,"score_spread":0.2631736834976996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411429251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925156,0.0036874507,0.0017617731,0.00005216331,0.000043020962,0.00012061858,0.00005766446,0.000058647387,0.0017029578],"genre_scores_gemma":[0.996702,0.0010004307,0.0013486076,0.000033994093,0.0000146628045,0.00006227055,0.00008277918,0.000008962552,0.0007462735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997985,0.000049763807,0.000014748769,0.00003555428,0.00004764808,0.000053712294],"domain_scores_gemma":[0.99994624,0.00001089843,0.000009539153,0.000011217447,0.000006509786,0.000015529373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002310068,0.0003231095,0.000484877,0.00035431221,0.00010341159,0.00039323448,0.00026759633,0.0002348058,0.0006847431],"category_scores_gemma":[0.00017160835,0.00013263583,0.00022963848,0.00021917294,0.0001516226,0.00020913,0.0002973364,0.00037681294,0.00021844546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015085373,0.001375212,0.0010013261,0.00020906249,0.00013727085,0.0002104279,0.00010718954,0.0028117027,0.92729896,0.0002803671,0.00032347298,0.06473643],"study_design_scores_gemma":[0.0007313026,0.02285114,0.0065871654,0.00002431511,0.0003895225,0.0007762917,0.000066548884,0.008304514,0.9490491,0.00017492176,0.011023628,0.00002163136],"about_ca_topic_score_codex":0.00048813902,"about_ca_topic_score_gemma":0.001270979,"teacher_disagreement_score":0.0006847431,"about_ca_system_score_codex":0.00028822038,"about_ca_system_score_gemma":0.00020170146,"threshold_uncertainty_score":0.002290666},"labels":[],"label_agreement":null},{"id":"W4411431464","doi":"10.1016/j.ard.2025.05.101","title":"OP0079 Clinical, Cellular Kinetics, Pharmacodynamics and Biomarker Data Up to 12 Months After YTB323 (Rapcabtagene Autoleucel), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLE","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacodynamics; Biomarker; Pharmacology; Pharmacokinetics","score_opus":0.1711146996053166,"score_gpt":0.4758479427257691,"score_spread":0.30473324312045247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411431464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904496,0.0029637127,0.00067524007,0.00016763297,0.00003274483,0.00048121638,0.0031147748,0.0000597781,0.002055234],"genre_scores_gemma":[0.98768973,0.0010289272,0.0006705936,0.00041418558,0.000080867896,0.0004372484,0.0077427896,0.000031653464,0.0019039785],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99930584,0.00028356558,0.000052635907,0.00009515936,0.00016260477,0.00010014713],"domain_scores_gemma":[0.9984818,0.00042074305,0.0004569606,0.00012943806,0.00013163201,0.00037946424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018150485,0.000606939,0.001045338,0.0003311719,0.00026946142,0.0007916202,0.0004507081,0.0007572439,0.0032166827],"category_scores_gemma":[0.0010495026,0.00018104588,0.00070469844,0.00042622455,0.0006268854,0.0005720535,0.00030472165,0.0019689277,0.00081989577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5261658,0.029695643,0.06896074,0.0016509882,0.0020666968,0.0015095285,0.00045087325,0.003959014,0.16913345,0.0003029593,0.007598168,0.1885062],"study_design_scores_gemma":[0.05264875,0.6530587,0.23856127,0.000113081434,0.0013826088,0.0027749378,0.00017811901,0.001742655,0.035579022,0.00037452948,0.0134750875,0.000111260764],"about_ca_topic_score_codex":0.00026698472,"about_ca_topic_score_gemma":0.0005316419,"teacher_disagreement_score":0.0032166827,"about_ca_system_score_codex":0.00045809802,"about_ca_system_score_gemma":0.0005902751,"threshold_uncertainty_score":0.010760903},"labels":[],"label_agreement":null},{"id":"W4411516648","doi":"10.1111/ene.70236","title":"Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of <scp>ICANS</scp> in <scp>CAR</scp> T‐Cell Therapy for Aggressive B‐Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Montreal Cognitive Assessment; Cognitive impairment; Disease","score_opus":0.028718000725559318,"score_gpt":0.30248808326568627,"score_spread":0.27377008254012697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411516648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996691,0.00007465612,0.000027764912,0.000009148939,0.0000018967721,0.0000018069634,0.000046900117,0.0000022373365,0.0001665242],"genre_scores_gemma":[0.9998437,0.000018175573,0.000013760618,0.0000050637495,0.0000034586287,0.0000010254856,0.000071250564,7.437898e-7,0.00004278613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99981123,0.000040815867,0.000021703498,0.000035206725,0.000042233285,0.00004883534],"domain_scores_gemma":[0.99863654,0.00021584764,0.0007148969,0.00006047074,0.00007276709,0.00029947306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040914735,0.00016494776,0.00024835108,0.00024667414,0.0001893724,0.00047494122,0.00016278918,0.0001888817,0.0015638393],"category_scores_gemma":[0.0013780737,0.000103817976,0.00040857636,0.00027059548,0.00016966471,0.0002544471,0.00017386796,0.00033296403,0.00021371266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009208426,0.000082486105,0.99595046,0.0000054867555,0.000072033676,0.000110450426,0.000017294382,0.00007918357,0.00059993076,0.0000073533583,0.000051845334,0.0021024693],"study_design_scores_gemma":[0.00001011489,0.0006148216,0.99846494,0.0000020219518,0.00004095597,0.00035802668,0.000017115195,0.00024120406,0.00015747413,0.000010056103,0.000081254075,0.0000019748043],"about_ca_topic_score_codex":0.0015122073,"about_ca_topic_score_gemma":0.0022567508,"teacher_disagreement_score":0.0015638393,"about_ca_system_score_codex":0.0002570775,"about_ca_system_score_gemma":0.000276263,"threshold_uncertainty_score":0.005231619},"labels":[],"label_agreement":null},{"id":"W4411544535","doi":"10.1080/16078454.2025.2519865","title":"Revaccination following CAR-T therapy: a needs assessment","year":2025,"lang":"en","type":"article","venue":"Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; McMaster University; Hamilton Health Sciences; Canadian Sleep Society","funders":"Canadian Hematology Society","keywords":"Medicine; Intensive care medicine; Oncology","score_opus":0.028503807906213013,"score_gpt":0.3848523500138798,"score_spread":0.35634854210766675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411544535","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981574,0.0006279625,0.0014416008,0.009349657,0.0000786501,0.004033991,0.00024255938,0.000041451847,0.002610097],"genre_scores_gemma":[0.98388654,0.0013719945,0.007822103,0.0017327155,0.000053602358,0.004224365,0.00022693258,0.000013487762,0.0006682093],"study_design_codex":"qualitative","study_design_gemma":"not_applicable","domain_scores_codex":[0.9885731,0.0057693888,0.0013191837,0.00030514374,0.0017947966,0.002238373],"domain_scores_gemma":[0.97663134,0.0068768477,0.0044793924,0.0004579878,0.0065689245,0.004985431],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.026954243,0.0005190307,0.0006398689,0.0026206307,0.0039015403,0.0019461329,0.0019069042,0.001721369,0.0016942347],"category_scores_gemma":[0.036461085,0.0006741661,0.0012414776,0.0015980471,0.0012634149,0.0032517246,0.005592916,0.0023495113,0.00030464988],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045223918,0.004155357,0.28583544,0.003683693,0.00009349899,0.003291736,0.46865994,0.0005947107,0.0018069671,0.0011374726,0.008835178,0.2214538],"study_design_scores_gemma":[0.00013525024,0.0047636833,0.24797577,0.0019537646,0.0000764209,0.0017582064,0.7236181,0.0019779173,0.0009644293,0.0009402151,0.015683327,0.00015287862],"about_ca_topic_score_codex":0.007955914,"about_ca_topic_score_gemma":0.014017676,"teacher_disagreement_score":0.026954243,"about_ca_system_score_codex":0.008083622,"about_ca_system_score_gemma":0.016320229,"threshold_uncertainty_score":0.1425494},"labels":[],"label_agreement":null},{"id":"W4411550209","doi":"10.1007/978-1-0716-4654-0_13","title":"Chimeric Antigen Receptor T Cell Production for Brain Cancers","year":2025,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; Cancer research; Neuroscience; Biology; Computational biology; Immunology; Immunotherapy; Immune system","score_opus":0.034395821996669775,"score_gpt":0.4687643660926454,"score_spread":0.4343685440959756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411550209","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8405827,0.010047765,0.12545767,0.0011619189,0.00070421805,0.00096664415,0.0038524095,0.0012757616,0.015950838],"genre_scores_gemma":[0.95703775,0.0036273866,0.026924545,0.00013546387,0.000089924906,0.00034706143,0.0021563398,0.00017543773,0.009506097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980503,0.000034661636,0.000014426471,0.000042348896,0.000042252723,0.0000612843],"domain_scores_gemma":[0.9998455,0.00004768446,0.000022906544,0.000026633863,0.00002814803,0.000029117533],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037964,0.0005785244,0.00038471178,0.0005041067,0.0002838352,0.0006387554,0.0005803262,0.00064327504,0.0035379601],"category_scores_gemma":[0.00030924333,0.0002781378,0.0004151323,0.00026824002,0.00023670655,0.00033978702,0.0003496932,0.001758437,0.001399527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029666317,0.000093905845,0.000073045914,0.000112939626,0.000017437358,0.0001525141,0.000057461108,0.0003999058,0.9916979,0.0012522934,0.0006771028,0.0051689856],"study_design_scores_gemma":[0.0000742424,0.0003032739,0.00020273289,0.0000123242235,0.000045971457,0.0003314084,0.000019899462,0.0014246211,0.98645115,0.00016703364,0.010961752,0.0000056689773],"about_ca_topic_score_codex":0.0009800278,"about_ca_topic_score_gemma":0.00063582964,"teacher_disagreement_score":0.0035379601,"about_ca_system_score_codex":0.0003954464,"about_ca_system_score_gemma":0.0003887613,"threshold_uncertainty_score":0.011835635},"labels":[],"label_agreement":null},{"id":"W4411603000","doi":"10.1182/bloodadvances.2025015881","title":"Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Takeda Oncology; National Institutes of Health; MorphoSys; Health Resources and Services Administration; Syndax Pharmaceuticals; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; University of Pittsburgh; HistoGenetics; U.S. Department of Defense; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Mallinckrodt Pharmaceuticals; Astellas Pharma US; U.S. Navy; Gateway for Cancer Research; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Atara Biotherapeutics; National Cancer Institute; Servier; Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Internal medicine; Gastroenterology; Pediatrics; Biology","score_opus":0.07493340698245726,"score_gpt":0.4053863752245954,"score_spread":0.33045296824213816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411603000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97360873,0.0038236247,0.0006020128,0.0001937676,0.000049170223,0.00011826118,0.020302271,0.000033554756,0.0012685492],"genre_scores_gemma":[0.9866476,0.00028609525,0.00019229851,0.0000786987,0.000039330764,0.00011266695,0.012419461,0.000026221158,0.00019774817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993608,0.0026629188,0.0011431716,0.0012573797,0.0008098689,0.00051876483],"domain_scores_gemma":[0.990694,0.0022367486,0.0040938854,0.0020188221,0.0005661017,0.00039053473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050425427,0.0006179965,0.0012932301,0.0019545169,0.0002697547,0.0015565576,0.00082771864,0.0006780047,0.0025053977],"category_scores_gemma":[0.010083078,0.00040902573,0.0040073534,0.0034446516,0.0003169928,0.0012228586,0.0009864146,0.0008391656,0.0005630017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074032797,0.00009546695,0.9730311,0.00037961366,0.01044705,0.00020755359,0.00012759914,0.0006842437,0.00042727296,0.00012621412,0.0023622205,0.004708412],"study_design_scores_gemma":[0.0007890456,0.0007057744,0.986963,0.00010773984,0.0049020415,0.0005864033,0.00047437096,0.0017318161,0.00031361484,0.00020106544,0.0031646304,0.000060456754],"about_ca_topic_score_codex":0.0019656229,"about_ca_topic_score_gemma":0.0031560608,"teacher_disagreement_score":0.0050425427,"about_ca_system_score_codex":0.0006519936,"about_ca_system_score_gemma":0.00048946176,"threshold_uncertainty_score":0.026667833},"labels":[],"label_agreement":null},{"id":"W4411710914","doi":"10.1016/j.jtct.2025.06.028","title":"Improving Patient Access through Value-Based CAR T Delivery: Examples Using a Micro-costing Tool","year":2025,"lang":"en","type":"review","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Kite Pharma","keywords":"Activity-based costing; Computer science; Operations management; Business; Engineering; Marketing","score_opus":0.1110565043690317,"score_gpt":0.36560730706037725,"score_spread":0.25455080269134556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411710914","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044227322,0.995544,0.000540009,0.0010391029,0.00020770257,0.000017100021,0.000028928907,0.000008252935,0.0021727139],"genre_scores_gemma":[0.004011592,0.9932627,0.000957301,0.0005831101,0.00014482596,0.000031356587,0.000027936214,0.0000034513714,0.0009777002],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996371,0.00013193245,0.000029949637,0.000041264175,0.000118183314,0.000041528325],"domain_scores_gemma":[0.99902785,0.0007517938,0.00007717619,0.000015920255,0.00009979754,0.000027512038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014094951,0.0006028472,0.00090961956,0.001309779,0.00019408895,0.0013384637,0.0007804794,0.0013237321,0.0061710738],"category_scores_gemma":[0.0016038754,0.00015877135,0.00083784055,0.0016353382,0.00046780068,0.0010640849,0.0006106191,0.0017248802,0.0010464465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010758948,0.0001176476,0.00009194923,0.015363124,0.000101022786,0.00012605217,0.000054663808,0.00045958,0.0011052222,0.017534165,0.019225992,0.9457129],"study_design_scores_gemma":[0.00009540944,0.00034872672,0.0008972338,0.011114091,0.0002673977,0.0007597706,0.00015727627,0.00033446334,0.0013793659,0.0068739397,0.97773427,0.000038126396],"about_ca_topic_score_codex":0.0013392136,"about_ca_topic_score_gemma":0.0027898771,"teacher_disagreement_score":0.0061710738,"about_ca_system_score_codex":0.00094775576,"about_ca_system_score_gemma":0.0010464276,"threshold_uncertainty_score":0.020644307},"labels":[],"label_agreement":null},{"id":"W4411872495","doi":"10.1172/jci184043","title":"Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute","keywords":"Blockade; Blocking (statistics); Blocking antibody; Immune system; Immune checkpoint; Antibody; Immunology; Cancer research; Medicine; Chemistry; Immunotherapy; Receptor; Computer science; Internal medicine","score_opus":0.05981472004056149,"score_gpt":0.43013826727697013,"score_spread":0.37032354723640865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411872495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99351513,0.001998887,0.001943843,0.00016360277,0.00007005747,0.0000812732,0.00016616663,0.0002535994,0.0018072989],"genre_scores_gemma":[0.99609804,0.0006751518,0.0012417753,0.00010437921,0.00003226949,0.000056199882,0.00018711726,0.000017717028,0.0015873963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99979895,0.000027724143,0.000012414338,0.000032223936,0.000038300677,0.000090447895],"domain_scores_gemma":[0.99992156,0.000011734391,0.00002085348,0.0000090492595,0.000007057417,0.000029777597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016036085,0.0004792673,0.00062988914,0.00025660955,0.00010588053,0.00026162073,0.00021091363,0.00047447128,0.0013156855],"category_scores_gemma":[0.00009004147,0.00012718957,0.0003321103,0.00011801368,0.00019620548,0.00022158388,0.00014372835,0.0013810219,0.00039873485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048807258,0.0002899277,0.00014487312,0.00007281261,0.0000106848665,0.000034544828,0.00001698689,0.00021125867,0.99418044,0.000079956044,0.00019625909,0.0042742486],"study_design_scores_gemma":[0.00016643979,0.003524527,0.0030898573,0.000010913561,0.00006292557,0.00035602195,0.000026149553,0.0021999166,0.9869042,0.00006944671,0.0035810817,0.0000084168505],"about_ca_topic_score_codex":0.0003870842,"about_ca_topic_score_gemma":0.0005750237,"teacher_disagreement_score":0.0013156855,"about_ca_system_score_codex":0.00025981362,"about_ca_system_score_gemma":0.00029327357,"threshold_uncertainty_score":0.004401386},"labels":[],"label_agreement":null},{"id":"W4411932984","doi":"10.1038/s41584-025-01272-3","title":"CAR T cell therapy for children with rheumatic disease: the time is now","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Medicine; Rheumatic disease; Disease; MEDLINE; Cell therapy; Intensive care medicine; Pediatrics; Cell; Internal medicine","score_opus":0.021762212896210036,"score_gpt":0.35942272931541003,"score_spread":0.3376605164192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411932984","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040522147,0.99790406,0.000068308094,0.0010387256,0.00060393283,0.0000016688205,0.000011234526,0.000008227659,0.00032329743],"genre_scores_gemma":[0.0007810397,0.99564964,0.00017787192,0.0018499652,0.0008097789,0.0000058538103,0.000027767755,0.0000027664523,0.0006953482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997285,0.00005722224,0.00002798746,0.000045847348,0.0000969079,0.000043562664],"domain_scores_gemma":[0.9992943,0.00038446498,0.000072239134,0.000016254635,0.0001485282,0.000084182706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012657745,0.0009252857,0.001966214,0.000849325,0.00027420933,0.0012804363,0.0008387124,0.0019808467,0.0042813336],"category_scores_gemma":[0.0012474331,0.00022364953,0.0006768178,0.00092703296,0.00071447116,0.001815604,0.00088772585,0.00429441,0.0019357502],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023416492,0.000050789135,0.00014173554,0.010224358,0.00012117653,0.00013025636,0.000042892832,0.00032248645,0.0012549608,0.0041530207,0.110164225,0.87316],"study_design_scores_gemma":[0.00009948681,0.00013911113,0.00032787924,0.0036029231,0.00013890432,0.00037538717,0.000043028955,0.00007067823,0.00015170361,0.0017326865,0.993306,0.000012337999],"about_ca_topic_score_codex":0.0014298842,"about_ca_topic_score_gemma":0.0030376504,"teacher_disagreement_score":0.0042813336,"about_ca_system_score_codex":0.0007456132,"about_ca_system_score_gemma":0.0011651341,"threshold_uncertainty_score":0.014322519},"labels":[],"label_agreement":null},{"id":"W4411954611","doi":"10.51643/22562915.688","title":"In-House CAR-T: una revisión","year":2025,"lang":"en","type":"article","venue":"Revista Colombiana de Hematología y Oncología","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"House call; Political science; Law","score_opus":0.019290031417698545,"score_gpt":0.35516031699063955,"score_spread":0.335870285572941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411954611","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009220679,0.92640334,0.0018804589,0.020188386,0.026296053,0.0001439872,0.0006857829,0.00024830355,0.023231588],"genre_scores_gemma":[0.013093043,0.9240405,0.0034489636,0.023979723,0.016264312,0.00025347224,0.0010347675,0.00018870493,0.017696558],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960914,0.0008954994,0.001179331,0.0005475739,0.0010693845,0.00021674788],"domain_scores_gemma":[0.98716265,0.0052194283,0.0018534246,0.001093469,0.004118423,0.0005525673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006154211,0.00072712026,0.0016757444,0.0032532704,0.0007617913,0.0037106941,0.0019432164,0.0029338803,0.028071146],"category_scores_gemma":[0.020667328,0.0004723323,0.0019246845,0.0024668444,0.0028424095,0.0054197027,0.0016088593,0.0039530913,0.011883828],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044022326,0.00008281416,0.00078311923,0.032811753,0.0003128093,0.0019279959,0.00036614685,0.000238973,0.0011409438,0.012761262,0.22802584,0.7211081],"study_design_scores_gemma":[0.000031629177,0.000044613476,0.0004179521,0.0078017307,0.00015387665,0.0025758345,0.00008196414,0.000028070175,0.00043225897,0.0011088031,0.9873065,0.000016817798],"about_ca_topic_score_codex":0.0034678038,"about_ca_topic_score_gemma":0.0034023975,"teacher_disagreement_score":0.028071146,"about_ca_system_score_codex":0.0025141407,"about_ca_system_score_gemma":0.007427624,"threshold_uncertainty_score":0.0939073},"labels":[],"label_agreement":null},{"id":"W4412002759","doi":"10.1016/j.ccell.2025.06.014","title":"Engineering myeloid cells for cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Leukemia and Lymphoma Society of Canada; Parker Institute for Cancer Immunotherapy; Leukemia and Lymphoma Society","keywords":"Myeloid cells; Immunotherapy; Cancer immunotherapy; Myeloid; Cancer; Cancer research; Cancer cell; Immunology; Biology; Medicine; Immune system; Genetics","score_opus":0.01717821939778622,"score_gpt":0.32465989203873363,"score_spread":0.3074816726409474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412002759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74152,0.01384822,0.20743792,0.0032884025,0.0010171245,0.000798811,0.0008450416,0.0006070679,0.030637488],"genre_scores_gemma":[0.9458956,0.0046374663,0.03868421,0.00039101313,0.00010390948,0.00018018992,0.00029822806,0.000070035225,0.009739298],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998568,0.000039923478,0.000008665305,0.000017596218,0.000045228313,0.000031721767],"domain_scores_gemma":[0.99992895,0.000016994209,0.00001689929,0.000012491715,0.000010122805,0.000014474786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029150982,0.00031496963,0.00017840564,0.00029774237,0.000180442,0.00057432865,0.00022870088,0.0003913049,0.0036239882],"category_scores_gemma":[0.00020473263,0.00014743386,0.00020623361,0.00014269285,0.00023807523,0.00035045733,0.00048884493,0.0011484196,0.0013930777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001356507,0.00014814708,0.00040526816,0.00013385367,0.0000149806865,0.0001296555,0.00007663315,0.0010657521,0.96250606,0.012377575,0.0008334859,0.022172978],"study_design_scores_gemma":[0.00009406672,0.0006410146,0.00052925484,0.000032640462,0.000046067362,0.0005354935,0.00008009382,0.0031119238,0.9197379,0.0024957836,0.07268758,0.000008258367],"about_ca_topic_score_codex":0.00012109315,"about_ca_topic_score_gemma":0.0002684736,"teacher_disagreement_score":0.0036239882,"about_ca_system_score_codex":0.00022066926,"about_ca_system_score_gemma":0.00024960493,"threshold_uncertainty_score":0.012123466},"labels":[],"label_agreement":null},{"id":"W4412024111","doi":"10.1101/2025.06.30.660492","title":"Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation; Amgen","keywords":"Allele; Human leukocyte antigen; Class (philosophy); Genetics; Biology; Computational biology; Computer science; Antigen; Gene; Artificial intelligence","score_opus":0.02679706647982766,"score_gpt":0.26427387162972354,"score_spread":0.2374768051498959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412024111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95999676,0.0009429485,0.027128235,0.00033492158,0.00007627426,0.00006625205,0.00039323725,0.00035297227,0.0107085705],"genre_scores_gemma":[0.98220485,0.00056026626,0.0077958605,0.00007787267,0.000015700516,0.000034236193,0.00047783655,0.000033988854,0.008799373],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991715,0.000011291026,0.0000043980826,0.000020179497,0.000021402522,0.000025509324],"domain_scores_gemma":[0.9999715,0.000007168544,0.000005227586,0.000004330532,0.0000038193602,0.000007890981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012193099,0.0002893084,0.00012944556,0.00016566904,0.00013063832,0.00032053408,0.00011475224,0.00026056552,0.0033860337],"category_scores_gemma":[0.00008503009,0.00009446775,0.00011778581,0.000104267405,0.00020713797,0.00015343257,0.00018018943,0.0003980867,0.0010093504],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066777284,0.00002044027,0.0003626033,0.000025523546,0.0000038996504,0.00007907607,0.000024710236,0.00032824106,0.9942456,0.0009039999,0.00035597503,0.0035831872],"study_design_scores_gemma":[0.000019718,0.00012777612,0.0010136148,0.000003890518,0.000007855915,0.00032358436,0.000029522302,0.003400241,0.98416615,0.00023086791,0.010673549,0.0000032471328],"about_ca_topic_score_codex":0.00037995444,"about_ca_topic_score_gemma":0.0003039632,"teacher_disagreement_score":0.0033860337,"about_ca_system_score_codex":0.00015587902,"about_ca_system_score_gemma":0.00013398351,"threshold_uncertainty_score":0.011327386},"labels":[],"label_agreement":null},{"id":"W4412040747","doi":"10.3345/cep.2025.00031","title":"Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Clinical and Experimental Pediatrics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Medicine; Malignancy; Hematologic malignancy; Transplantation; Hematologic Neoplasms; Hematopoietic stem cell transplantation; Meta-analysis; Oncology; Immunology; Immunotherapy; Internal medicine; Immune system; Biology","score_opus":0.07731408315595743,"score_gpt":0.4035482887950692,"score_spread":0.32623420563911176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412040747","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034439145,0.99520063,0.00030865127,0.00014396528,0.00008294547,0.00026353932,0.0003636111,0.000013637594,0.00017915606],"genre_scores_gemma":[0.11027932,0.88545054,0.0015741377,0.00070062425,0.00015459752,0.0009951722,0.0006269051,0.000016529073,0.0002021839],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9932695,0.002906523,0.0021348912,0.00067600474,0.00079077395,0.00022241505],"domain_scores_gemma":[0.98442197,0.010913096,0.0030377507,0.00032770995,0.001054937,0.00024458213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0107782,0.0021672123,0.017828956,0.0075939544,0.0005498139,0.0028241486,0.0022149486,0.0021203514,0.0030642266],"category_scores_gemma":[0.025412388,0.0012302499,0.03134803,0.008904416,0.00067070423,0.001710866,0.0012384652,0.0014499942,0.00025447525],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013481493,0.000033841116,0.0030604347,0.57035404,0.41111568,0.00013937599,0.00009243317,0.00037150344,0.00020470694,0.00011007907,0.00051140855,0.012658324],"study_design_scores_gemma":[0.00043556694,0.00021801403,0.0028274958,0.0461107,0.9483091,0.00011003219,0.000059656424,0.0001419608,0.000090862355,0.00013472122,0.0015391973,0.000022625498],"about_ca_topic_score_codex":0.006706363,"about_ca_topic_score_gemma":0.016445315,"teacher_disagreement_score":0.017828956,"about_ca_system_score_codex":0.0025986999,"about_ca_system_score_gemma":0.0044106473,"threshold_uncertainty_score":0.057001293},"labels":[],"label_agreement":null},{"id":"W4412066586","doi":"10.1186/s12943-025-02386-8","title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","year":2025,"lang":"en","type":"review","venue":"Molecular Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Uppsala Universitet","keywords":"Chimeric antigen receptor; Oncolytic virus; Biology; Tumor microenvironment; Immune system; Immunotherapy; Cancer research; Cell; Immunology","score_opus":0.06666268807641285,"score_gpt":0.3953721075754012,"score_spread":0.32870941949898835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412066586","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013289777,0.9981913,0.00024757025,0.00038092522,0.00017087406,0.000004906081,0.000007563882,0.0000072247853,0.00085675035],"genre_scores_gemma":[0.0005849362,0.9981889,0.00029253014,0.00023378611,0.00011377191,0.000007298633,0.000014810343,0.0000014887329,0.0005625529],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997726,0.000050007766,0.000019140844,0.00003131364,0.00009473936,0.000032099724],"domain_scores_gemma":[0.9997137,0.00013863892,0.0000280656,0.000009074599,0.00007436683,0.00003621696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010386998,0.0008176647,0.0010846514,0.0018625691,0.00027024435,0.0013832011,0.00085311354,0.0014037531,0.0035762275],"category_scores_gemma":[0.0005747569,0.00032311163,0.0005225552,0.0014823377,0.0006366859,0.002209157,0.0008218419,0.0028235002,0.0020894741],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081056176,0.00013746972,0.00008771353,0.017102262,0.000070851944,0.00022381502,0.00011592019,0.0011139243,0.0061939745,0.014135898,0.029767975,0.9309691],"study_design_scores_gemma":[0.000020331616,0.0001665231,0.00024069962,0.0025157104,0.000051021536,0.0006321555,0.00007454628,0.00018443291,0.0009095993,0.00338419,0.9918035,0.000017149667],"about_ca_topic_score_codex":0.0009064867,"about_ca_topic_score_gemma":0.0020330565,"teacher_disagreement_score":0.0035762275,"about_ca_system_score_codex":0.00084224535,"about_ca_system_score_gemma":0.0011361262,"threshold_uncertainty_score":0.0119636655},"labels":[],"label_agreement":null},{"id":"W4412093048","doi":"10.3390/ijtm5030028","title":"Protein Engineering Paving the Way for Next-Generation Therapies in Cancer","year":2025,"lang":"en","type":"article","venue":"International Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Cancer; Medicine; Engineering; Computer science; Computational biology; Biology; Internal medicine","score_opus":0.07552677918434995,"score_gpt":0.3792414076941884,"score_spread":0.30371462850983844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412093048","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029742848,0.79973817,0.12274381,0.016342444,0.0019699782,0.00015366037,0.00023855668,0.00053924153,0.028531281],"genre_scores_gemma":[0.14781985,0.76126975,0.07363635,0.004351771,0.0010970319,0.00014254951,0.00038472886,0.0001661751,0.01113185],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995945,0.00012863657,0.000025930605,0.000055407854,0.00014888671,0.000046668458],"domain_scores_gemma":[0.9997619,0.00010538823,0.000046177156,0.00001935821,0.00004370373,0.000023532724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088806,0.0004238411,0.0004616765,0.0007025385,0.00034798367,0.0015569117,0.00041551914,0.0011409394,0.0019275362],"category_scores_gemma":[0.0007974135,0.00022868693,0.0004936946,0.0005349822,0.0008788619,0.002337697,0.0008707394,0.0015054438,0.0011361479],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025783945,0.0002955752,0.0010089009,0.0056077936,0.00010726904,0.0007138578,0.0005186398,0.0081884535,0.21356317,0.16082458,0.018053656,0.59086025],"study_design_scores_gemma":[0.00004159512,0.00057859556,0.0006046935,0.0008073875,0.00006363747,0.0016436216,0.00021955105,0.004937163,0.08899414,0.045339648,0.85671663,0.000053329546],"about_ca_topic_score_codex":0.00034192525,"about_ca_topic_score_gemma":0.0005337501,"teacher_disagreement_score":0.0019275362,"about_ca_system_score_codex":0.0008766284,"about_ca_system_score_gemma":0.0008094215,"threshold_uncertainty_score":0.0064482093},"labels":[],"label_agreement":null},{"id":"W4412461972","doi":"10.1111/bjh.70012","title":"Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Multiple myeloma; Antigen; Medicine; Cancer research; Refractory (planetary science); Immunology; T cell; Oncology; Biology; Immune system","score_opus":0.019908754751251426,"score_gpt":0.2897263368892645,"score_spread":0.2698175821380131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995939,0.0001419788,0.00003764594,0.000008306968,0.0000011109462,0.0000043090477,0.000042442964,0.0000031373904,0.00016720755],"genre_scores_gemma":[0.99970573,0.000028694756,0.000035707828,0.00001119687,0.0000028836075,0.000004303132,0.000093625065,0.0000015671847,0.00011629347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997366,0.00007548839,0.000029833736,0.000051434934,0.00005248913,0.000054194268],"domain_scores_gemma":[0.9991897,0.00030375095,0.00027525093,0.00005223217,0.000035697256,0.00014332029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058653334,0.00014000204,0.0003926973,0.0002786089,0.00014333337,0.00034760416,0.00014815881,0.000305197,0.0011053965],"category_scores_gemma":[0.0011105705,0.000099375546,0.00022015144,0.00028553916,0.00021549896,0.00024425422,0.00016261108,0.0003854829,0.00016539614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020957991,0.0007908362,0.82399803,0.00007702422,0.00020382185,0.0012830589,0.00032694373,0.0010803987,0.11686478,0.00013072656,0.00026264333,0.03402378],"study_design_scores_gemma":[0.0001019264,0.0062014763,0.9846747,0.0000041092053,0.00008247987,0.0019965728,0.00009617966,0.0007713917,0.0054589515,0.00007511769,0.00052686,0.000010342822],"about_ca_topic_score_codex":0.0002484747,"about_ca_topic_score_gemma":0.0005088312,"teacher_disagreement_score":0.0011053965,"about_ca_system_score_codex":0.00026596594,"about_ca_system_score_gemma":0.00019961793,"threshold_uncertainty_score":0.0036979318},"labels":[],"label_agreement":null},{"id":"W4412492231","doi":"10.1182/bloodadvances.2024015519","title":"In vivo CRISPR screening reveals cooperation of <i>KMT2D</i> and <i>TP53</i> deficiencies in B-cell lymphomagenesis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University","funders":"","keywords":"Biology; Cancer research; CRISPR; YAP1; Diffuse large B-cell lymphoma; Transplantation; Lymphoma; Genetics; Gene; Immunology; Transcription factor; Medicine","score_opus":0.013408603913164462,"score_gpt":0.30233026421181747,"score_spread":0.288921660298653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98741317,0.00040794094,0.008143808,0.000098705896,0.00002477974,0.000040682724,0.001367026,0.00055677776,0.0019470043],"genre_scores_gemma":[0.9946866,0.00014438784,0.0030064827,0.00006336875,0.000003314208,0.000022551876,0.0007655827,0.000082665385,0.0012251274],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983513,0.000020723552,0.000018733583,0.000046689842,0.000052537274,0.000026149251],"domain_scores_gemma":[0.99986494,0.000025381905,0.00005204459,0.000018514485,0.000008196643,0.000030881307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000128909,0.0003253735,0.00023841416,0.00024585094,0.00011569704,0.00031323993,0.0002263912,0.00028170593,0.0016967311],"category_scores_gemma":[0.00010572384,0.00011879953,0.00026011252,0.00014032026,0.00018403764,0.00007009748,0.00025269893,0.00034955237,0.00063913723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033494816,0.000009403196,0.00023642532,0.000014528346,0.0000061476185,0.000057888035,0.000004452418,0.00007678044,0.99882597,0.00003258858,0.000039405797,0.00066285185],"study_design_scores_gemma":[0.000010257137,0.000095088486,0.005549675,0.000004774098,0.000021012984,0.0005618625,0.000014035254,0.0018346416,0.9899539,0.000028376095,0.0019213103,0.000005078028],"about_ca_topic_score_codex":0.00054108404,"about_ca_topic_score_gemma":0.0009976332,"teacher_disagreement_score":0.0016967311,"about_ca_system_score_codex":0.000270063,"about_ca_system_score_gemma":0.00013979914,"threshold_uncertainty_score":0.0056761503},"labels":[],"label_agreement":null},{"id":"W4412552497","doi":"10.1038/s41590-025-02232-5","title":"LARP4-mediated hypertranslation drives T cell dysfunction in tumors","year":2025,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Natural Science Foundation of China","keywords":"Cancer research; Cell biology; Medicine; Biology; Chemistry","score_opus":0.00667346609264948,"score_gpt":0.28099900434285374,"score_spread":0.2743255382502043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412552497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986021,0.0014177868,0.0057320027,0.0010061297,0.00017586374,0.000045124252,0.00075992587,0.0005793204,0.0042629037],"genre_scores_gemma":[0.9961308,0.00025787196,0.0007248491,0.00014886631,0.000017629847,0.000020001138,0.00030730016,0.00005235681,0.0023402923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995198,0.00009835656,0.000025777532,0.00010024158,0.00009582037,0.00015999415],"domain_scores_gemma":[0.99977237,0.000038457118,0.00005793211,0.00003669079,0.000024156698,0.00007039161],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031451383,0.00047976983,0.00030211473,0.00037406315,0.0003747556,0.00083438674,0.00038088756,0.00074860814,0.00456844],"category_scores_gemma":[0.0002611826,0.00026794456,0.00044248183,0.00018064342,0.0006347882,0.0004264271,0.00052442536,0.0018984248,0.0013859306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027972,0.000058414553,0.00032485617,0.00005220789,0.000013326279,0.00018983909,0.000020594469,0.00022463172,0.9959441,0.00051628676,0.00041455773,0.0019615002],"study_design_scores_gemma":[0.000047840767,0.00033231548,0.0021254688,0.000007966651,0.000019131097,0.0006049183,0.00008883861,0.002239089,0.99033713,0.00030434757,0.0038854138,0.0000076152623],"about_ca_topic_score_codex":0.0005402209,"about_ca_topic_score_gemma":0.00059997744,"teacher_disagreement_score":0.00456844,"about_ca_system_score_codex":0.0008997434,"about_ca_system_score_gemma":0.00042533383,"threshold_uncertainty_score":0.015282929},"labels":[],"label_agreement":null},{"id":"W4412620438","doi":"10.1182/bloodadvances.2024015014","title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Pharmacyclics; Eurostars; Genentech; Health Resources and Services Administration; Aptitude Health; Seagen; Incyte; Juno Therapeutics; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Gateway for Cancer Research; Celgene; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Alexion Pharmaceuticals; Spectrum Pharmaceuticals; Mallinckrodt Pharmaceuticals; Kite Pharma; Society for Immunotherapy of Cancer; Astellas Pharma US; Amgen","keywords":"Medicine; Hazard ratio; Internal medicine; Bendamustine; Mantle cell lymphoma; Cumulative incidence; Oncology; Confidence interval; Salvage therapy; Odds ratio; Melphalan; Gastroenterology; Lymphoma; Surgery; Transplantation; Chemotherapy; Rituximab","score_opus":0.02176219910519934,"score_gpt":0.3536270628012587,"score_spread":0.3318648636960594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412620438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971738,0.0006387683,0.00024411015,0.000034841854,0.000004773445,0.000033798045,0.0014557597,0.000005791551,0.00040836533],"genre_scores_gemma":[0.99711454,0.0001140091,0.00008813915,0.000026009395,0.0000107708875,0.00002898311,0.0025278917,0.0000033390404,0.00008632244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976967,0.0010279429,0.00028890237,0.00037496188,0.0003879584,0.00022347992],"domain_scores_gemma":[0.99337196,0.0017442625,0.0032941508,0.0004902016,0.0005567405,0.0005426772],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040818234,0.00035955218,0.0005876281,0.0010302906,0.00023656692,0.001273918,0.0005049353,0.00045189113,0.0015575027],"category_scores_gemma":[0.004249487,0.00019294879,0.0015493163,0.0011203736,0.00036920243,0.00075699814,0.00083816116,0.00059874443,0.00033048654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007857267,0.00028016267,0.97949034,0.00014023685,0.001670491,0.00017667146,0.00009207234,0.0014258015,0.00045204128,0.000069318216,0.00045014924,0.007895414],"study_design_scores_gemma":[0.00041150165,0.0034412842,0.99062365,0.000033688,0.0010442921,0.00066874287,0.00016981616,0.002016514,0.000505257,0.00006289356,0.0009885613,0.000033860004],"about_ca_topic_score_codex":0.00077553286,"about_ca_topic_score_gemma":0.0008563636,"teacher_disagreement_score":0.0040818234,"about_ca_system_score_codex":0.0008366004,"about_ca_system_score_gemma":0.0003839645,"threshold_uncertainty_score":0.021587014},"labels":[],"label_agreement":null},{"id":"W4412654447","doi":"10.1080/10428194.2025.2532674","title":"Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"European Union Studies Association; Kite Pharma; Genmab; Genentech Foundation; Daiichi Sankyo Europe; Janssen Biotech; AbbVie Canada; Pharmacyclics; Seattle Genetics; Genentech; MorphoSys; Seagen; Incyte; TG Therapeutics; bluebird bio; Novartis Portugal; BeiGene; Merck KGaA; Regeneron Pharmaceuticals; Astellas Pharma; Takeda Pharmaceuticals U.S.A.; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Confidence interval; Odds ratio; Refractory (planetary science); Lymphoma; Cytokine release syndrome; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.027151610728664,"score_gpt":0.29862573315635244,"score_spread":0.2714741224276884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412654447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95172447,0.02328562,0.0050658765,0.000809963,0.0012451672,0.0038383435,0.0047851824,0.00022085075,0.009024591],"genre_scores_gemma":[0.99067783,0.0017387838,0.0023566096,0.0005940357,0.00016002616,0.0013759044,0.0013316431,0.000019181329,0.0017461071],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9954294,0.0033773321,0.00028144298,0.00036678198,0.000349556,0.00019540625],"domain_scores_gemma":[0.9975267,0.0011958742,0.00070148654,0.00022635228,0.00015664556,0.00019294211],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042130644,0.0012881751,0.002331361,0.0005494784,0.00018902242,0.00095245714,0.0008580519,0.0010453211,0.008635209],"category_scores_gemma":[0.006742716,0.00042127987,0.005569275,0.00042256972,0.00055559113,0.0007987702,0.00089793076,0.002105014,0.00068741373],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94406897,0.0011796533,0.0018111545,0.0022063062,0.019276233,0.000035155026,0.000056894005,0.0014623272,0.0016664575,0.000636785,0.0008888057,0.026711283],"study_design_scores_gemma":[0.7162392,0.18750603,0.023953712,0.0005496057,0.04831421,0.00020052584,0.00014558643,0.0067536924,0.0038271088,0.003548736,0.008837657,0.00012398537],"about_ca_topic_score_codex":0.0011942772,"about_ca_topic_score_gemma":0.00198486,"teacher_disagreement_score":0.008635209,"about_ca_system_score_codex":0.0008685937,"about_ca_system_score_gemma":0.00090508256,"threshold_uncertainty_score":0.02888769},"labels":[],"label_agreement":null},{"id":"W4412679455","doi":"10.1101/2025.07.25.25332228","title":"International Multi-site Implementation of Local Cell-Free Protein Biomanufacturing to Advance Health and Research Equity","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Emmanuel Bible College; IMPCO Technologies (Canada); University of Toronto","funders":"CHIST-ERA; Canadian Institutes of Health Research; Shastri Indo-Canadian Institute; Agencia Nacional de Investigación y Desarrollo; Indian Institute of Science Education and Research Mohali; Ministry of Colleges and Universities; Indian Institute of Science Education and Research Pune; Agenția Națională pentru Cercetare și Dezvoltare; Conselho Nacional de Desenvolvimento Científico e Tecnológico; National Institutes of Health; Canada Research Chairs; International Development Research Centre; CYTED Ciencia y Tecnología para el Desarrollo; University of Toronto","keywords":"Biomanufacturing; Equity (law); Business; Political science; Biology; Biotechnology","score_opus":0.10420849113128612,"score_gpt":0.4891772292764831,"score_spread":0.384968738145197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412679455","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17200802,0.014665629,0.6155462,0.037035,0.0043699928,0.004056652,0.0023357046,0.005785599,0.14419709],"genre_scores_gemma":[0.67880404,0.006712828,0.26908556,0.0053753383,0.00051232526,0.0021835763,0.0023931242,0.00062260166,0.034310665],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958134,0.0015696364,0.00016287933,0.00083987496,0.000969348,0.0006448327],"domain_scores_gemma":[0.99366814,0.0008820028,0.00083186623,0.0014388788,0.0015948801,0.0015841764],"candidate_categories":["open_science"],"consensus_categories":[],"category_scores_codex":[0.014484433,0.00080120895,0.00042436365,0.0009830091,0.0010970535,0.0026229525,0.0019475373,0.0015023699,0.0114966985],"category_scores_gemma":[0.0041833282,0.00027998345,0.00088026107,0.00079806277,0.0021453071,0.002354075,0.007805354,0.0027997394,0.0023216698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012964956,0.002362139,0.009741496,0.0023727347,0.0003353246,0.0008246794,0.0025080438,0.016738005,0.172701,0.13382119,0.06219741,0.5951015],"study_design_scores_gemma":[0.0007621851,0.005095338,0.014474688,0.00066993467,0.00020252503,0.0010813754,0.0022102373,0.016588785,0.1526802,0.04613688,0.75988126,0.00021655195],"about_ca_topic_score_codex":0.00237722,"about_ca_topic_score_gemma":0.0030928499,"teacher_disagreement_score":0.9980525,"about_ca_system_score_codex":0.002337123,"about_ca_system_score_gemma":0.009901302,"threshold_uncertainty_score":0.07660192},"labels":[],"label_agreement":null},{"id":"W4412693854","doi":"10.1186/s12935-025-03846-3","title":"Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions","year":2025,"lang":"en","type":"review","venue":"Cancer Cell International","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Medicines Canada","funders":"","keywords":"Immunotherapy; Cancer stem cell; Medicine; Tumor microenvironment; Cancer immunotherapy; Cancer; Cancer research; Limiting; Immunology; Tumor cells; Internal medicine","score_opus":0.047690582780398644,"score_gpt":0.39325160684750643,"score_spread":0.34556102406710776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412693854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010775136,0.9988695,0.0000744368,0.00029796764,0.000099676814,0.0000035167907,0.000010472068,0.000005189332,0.0005314165],"genre_scores_gemma":[0.00045909124,0.99898595,0.00011727521,0.00015576452,0.000054550153,0.0000053906165,0.000013722117,8.5049e-7,0.0002074017],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984527,0.000028919461,0.00002119145,0.000025811561,0.000059417594,0.000019334233],"domain_scores_gemma":[0.9995895,0.00022582297,0.00004250309,0.000011045778,0.000096243304,0.000034778186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000913207,0.00067206426,0.001215924,0.0018065863,0.00020720612,0.0011587457,0.00079265016,0.0010657909,0.0034494756],"category_scores_gemma":[0.00075617555,0.00024620118,0.0005297826,0.0015309048,0.0004951667,0.0013308763,0.0005629741,0.0017344623,0.0017258576],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009605951,0.000088820874,0.000121582394,0.016614541,0.000077628836,0.000128787,0.00004321808,0.0003196486,0.0021534436,0.0042931614,0.015739935,0.9603233],"study_design_scores_gemma":[0.00003947802,0.00021127526,0.0006387936,0.0075007235,0.00016558137,0.00088182226,0.000075835866,0.00013637495,0.0010193574,0.0029465142,0.9863631,0.000021139082],"about_ca_topic_score_codex":0.00079794216,"about_ca_topic_score_gemma":0.0016255829,"teacher_disagreement_score":0.0034494756,"about_ca_system_score_codex":0.0006750955,"about_ca_system_score_gemma":0.0013375054,"threshold_uncertainty_score":0.011539638},"labels":[],"label_agreement":null},{"id":"W4412712532","doi":"10.3390/curroncol32080425","title":"Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Single-nucleotide polymorphism; Internal medicine; Oncology; Bioinformatics; Genetics; Computational biology; Biology; Genotype; Gene","score_opus":0.1158453225711534,"score_gpt":0.45693172936193194,"score_spread":0.3410864067907785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412712532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99922884,0.00032755945,0.000029701596,0.000037451995,0.000004254425,0.0000038486255,0.000047943515,0.0000017626594,0.0003185816],"genre_scores_gemma":[0.99977297,0.000048093203,0.00001099089,0.000023230243,0.0000060559387,0.0000022047113,0.00007200709,6.3464444e-7,0.00006384739],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99984074,0.00004658394,0.000015591602,0.000036542784,0.000028072458,0.0000323673],"domain_scores_gemma":[0.99969923,0.00006280639,0.00011645654,0.000010703088,0.000024887942,0.00008595036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019873446,0.000109889246,0.00030644197,0.00024304578,0.00025868058,0.00033115895,0.000118294905,0.00026385745,0.0010465223],"category_scores_gemma":[0.0006687418,0.00007890196,0.00021587078,0.00035783864,0.0001730872,0.0001387066,0.00011713036,0.00033478855,0.00014641034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019868973,0.00013494269,0.98572856,0.000018556435,0.000114089635,0.0008911893,0.000052786796,0.00012278683,0.0025904502,0.000031507963,0.00015722883,0.008171118],"study_design_scores_gemma":[0.00008958042,0.000674276,0.99519724,0.000009295858,0.00013026045,0.00224798,0.000096670716,0.00037704158,0.000550784,0.00007252583,0.00054872467,0.0000055888427],"about_ca_topic_score_codex":0.00083308027,"about_ca_topic_score_gemma":0.0011468328,"teacher_disagreement_score":0.0010465223,"about_ca_system_score_codex":0.00030741552,"about_ca_system_score_gemma":0.0002051117,"threshold_uncertainty_score":0.0035009384},"labels":[],"label_agreement":null},{"id":"W4412727668","doi":"10.1016/j.jprot.2025.105507","title":"Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Proteomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Fundação de Amparo à Pesquisa do Estado de São Paulo; International Union of Biochemistry and Molecular Biology; Royal Society of Chemistry; Biochemical Society; European Association for Cancer Research","keywords":"Jurkat cells; Chimeric antigen receptor; CD28; CD19; Biology; T cell; Cancer immunotherapy; Cell biology; Immunotherapy; Antigen; Immunology; Immune system","score_opus":0.015941541869590813,"score_gpt":0.3349791735705588,"score_spread":0.319037631700968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412727668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99127954,0.0026545662,0.0025350747,0.00018508677,0.000055470457,0.000041218802,0.00038483954,0.00007268168,0.0027916369],"genre_scores_gemma":[0.99361247,0.0009790967,0.001768721,0.00012649113,0.000020895961,0.000024826026,0.00045622376,0.000012759736,0.0029986256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999261,0.0000070129263,0.000004163311,0.000015815647,0.000018296345,0.000028671042],"domain_scores_gemma":[0.9999689,0.0000050279064,0.00000562869,0.0000026651794,0.000008103861,0.000009752606],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010036655,0.00022839167,0.00014921676,0.00031563576,0.00019169944,0.0003199711,0.00014803045,0.0003394312,0.0027638031],"category_scores_gemma":[0.00011011098,0.00011646268,0.00029350683,0.00016975825,0.00008795441,0.00025957517,0.00013329006,0.00035543353,0.0005593029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006339338,0.00008142573,0.0024086726,0.0000676375,0.000028124685,0.00028383912,0.000028366605,0.00008032182,0.9904953,0.0003108866,0.00028177456,0.005299676],"study_design_scores_gemma":[0.000060790055,0.0004594071,0.061633904,0.000012717571,0.00011930754,0.0014816646,0.00012634986,0.0038317295,0.9248434,0.00041618163,0.0070023164,0.0000122861775],"about_ca_topic_score_codex":0.0003041455,"about_ca_topic_score_gemma":0.00042331358,"teacher_disagreement_score":0.0027638031,"about_ca_system_score_codex":0.00021776938,"about_ca_system_score_gemma":0.00015959068,"threshold_uncertainty_score":0.0092458725},"labels":[],"label_agreement":null},{"id":"W4412805889","doi":"10.1093/eurheartjsupp/suaf083.016","title":"Cardiovascular adverse events after CAR-T, BiTEs and TILs therapies: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"European Heart Journal Supplements","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Meta-analysis; Adverse effect; Intensive care medicine; Dermatology; Internal medicine","score_opus":0.056024992447638255,"score_gpt":0.3505701393222382,"score_spread":0.29454514687459993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412805889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0054338123,0.99264514,0.00047207862,0.00016477297,0.00009823133,0.0002891177,0.0006878697,0.000019675534,0.00018929492],"genre_scores_gemma":[0.19024333,0.80368525,0.0022479563,0.000726151,0.0002477558,0.0015148742,0.0010233532,0.0000264388,0.00028485068],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.989002,0.005220443,0.0032928125,0.0010656378,0.0011068296,0.00031230669],"domain_scores_gemma":[0.972147,0.020748623,0.004323538,0.000642791,0.0018415865,0.0002964056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013631609,0.0025751598,0.017999807,0.007606794,0.000605183,0.002980904,0.0020994863,0.0020155897,0.0034161329],"category_scores_gemma":[0.031200599,0.0014480209,0.038144484,0.008624668,0.0006867681,0.0015227478,0.0014287531,0.0015636836,0.000277992],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013238816,0.000022867258,0.004465312,0.3725703,0.6115688,0.00013297058,0.0000624974,0.00055587955,0.00013606547,0.00009045487,0.0005257378,0.008545303],"study_design_scores_gemma":[0.00043224552,0.00017283144,0.0035945377,0.023427565,0.9707244,0.00010228924,0.00004302377,0.0001880214,0.00009300112,0.00013067081,0.0010710199,0.000020385125],"about_ca_topic_score_codex":0.0061696437,"about_ca_topic_score_gemma":0.011835078,"teacher_disagreement_score":0.017999807,"about_ca_system_score_codex":0.0026053155,"about_ca_system_score_gemma":0.0032348575,"threshold_uncertainty_score":0.0720917},"labels":[],"label_agreement":null},{"id":"W4412824780","doi":"10.1038/s41746-025-01809-6","title":"Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies","year":2025,"lang":"en","type":"review","venue":"npj Digital Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"National Cancer Institute; European Commission","keywords":"Immune system; Computer science; Computational biology; Adoptive cell transfer; Psychology; Neuroscience; Human–computer interaction; Medicine; Biology; Immunology; T cell","score_opus":0.12884270219560104,"score_gpt":0.36965207301881325,"score_spread":0.24080937082321222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412824780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008797673,0.6004094,0.3012355,0.0062892716,0.0024601254,0.0008480595,0.0007212395,0.00043969863,0.07879897],"genre_scores_gemma":[0.11053764,0.56355774,0.2858177,0.0061424165,0.0005656293,0.0027802219,0.001204064,0.00021973834,0.029174827],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985568,0.00044792594,0.00017943037,0.00015112232,0.00058841537,0.00007641114],"domain_scores_gemma":[0.99823976,0.0010880097,0.00022411862,0.00011794194,0.00028748682,0.00004266355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036259603,0.0010634201,0.0007064776,0.0009610966,0.00038662786,0.0014701883,0.0015461191,0.002194079,0.0037283837],"category_scores_gemma":[0.0039022183,0.00053902913,0.0009059772,0.00064898713,0.0013294833,0.0015450256,0.0011824105,0.0024363166,0.002133245],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012292211,0.00012020937,0.00029563674,0.013877739,0.00006805452,0.00043803843,0.00033196155,0.009753667,0.02227909,0.48256323,0.015547464,0.45460194],"study_design_scores_gemma":[0.000041205763,0.0003608498,0.00019954453,0.0034498482,0.00010778981,0.001010841,0.00012856377,0.0021442554,0.016069008,0.048296634,0.92814016,0.00005120399],"about_ca_topic_score_codex":0.00076677446,"about_ca_topic_score_gemma":0.00092866266,"teacher_disagreement_score":0.0037283837,"about_ca_system_score_codex":0.001127298,"about_ca_system_score_gemma":0.0016310418,"threshold_uncertainty_score":0.019176126},"labels":[],"label_agreement":null},{"id":"W4412825944","doi":"10.1158/2326-6066.cir-24-0897","title":"Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Sarcoma Foundation of America","keywords":"Chimeric antigen receptor; Cancer research; Metastasis; Sarcoma; Cytotoxic T cell; Stromal cell; Tumor microenvironment; Immunotherapy; Cancer; Antigen; Medicine; Immunology; Biology; Immune system; Pathology; In vitro; Internal medicine","score_opus":0.053936030644522716,"score_gpt":0.4012525384342819,"score_spread":0.34731650778975914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412825944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882448,0.0011452069,0.008113094,0.00013588312,0.000029496934,0.000074648706,0.00017405309,0.0001739628,0.0019088975],"genre_scores_gemma":[0.9937412,0.00065820693,0.0036608542,0.00007542699,0.000012960893,0.000051773663,0.00020670831,0.00001576973,0.0015770429],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999305,0.000009302539,0.000005527711,0.000016280535,0.000017202692,0.000021287431],"domain_scores_gemma":[0.9999628,0.0000065249974,0.000007813235,0.000003910198,0.000004378141,0.000014428844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008507551,0.00025802018,0.00021478572,0.00015621411,0.00006690824,0.00020217648,0.00013135631,0.0002564914,0.0010156323],"category_scores_gemma":[0.000052421463,0.0000853789,0.00018546787,0.000071468814,0.00016792487,0.00013802345,0.00018932547,0.00051187474,0.00033424067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009549011,0.000049450406,0.00024444234,0.000048942948,0.0000056685194,0.00014086842,0.000025514091,0.00078623014,0.99451536,0.00031815926,0.00015938524,0.0036105467],"study_design_scores_gemma":[0.00008102314,0.0009160524,0.0018335468,0.000010147727,0.000045425553,0.00090113765,0.000033729666,0.004187347,0.9838974,0.0001634549,0.007924266,0.0000064101578],"about_ca_topic_score_codex":0.00034451194,"about_ca_topic_score_gemma":0.00047404927,"teacher_disagreement_score":0.0010156323,"about_ca_system_score_codex":0.00016832084,"about_ca_system_score_gemma":0.00021501954,"threshold_uncertainty_score":0.0033976436},"labels":[],"label_agreement":null},{"id":"W4412850991","doi":"10.1016/j.ajt.2025.07.1935","title":"T Cell-Mediated Rejection Produces Unique Patterns of Molecular Injury: An Underestimated Menace","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BP (Canada)","funders":"","keywords":"Medicine; Graft rejection; Immunology; Transplantation; Surgery","score_opus":0.011268260520574187,"score_gpt":0.3203634147639454,"score_spread":0.30909515424337125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412850991","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.077363744,0.48433262,0.05981171,0.32579273,0.013139863,0.00008795533,0.0005177696,0.0006370905,0.038316455],"genre_scores_gemma":[0.55768025,0.2761043,0.033036843,0.07059912,0.045383982,0.00019687842,0.0002515238,0.0002825536,0.016464561],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99814713,0.0008718006,0.00015313628,0.00022946337,0.0004781743,0.00012028336],"domain_scores_gemma":[0.9866899,0.008083274,0.00062187173,0.0024976155,0.0013816908,0.00072560785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011264634,0.0006570898,0.001267769,0.0012799584,0.0010444273,0.0037086357,0.0012657889,0.0029385556,0.0037388732],"category_scores_gemma":[0.010492042,0.00033960192,0.0003685252,0.000668479,0.009746394,0.010203313,0.0019358792,0.0061378395,0.0010470833],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013435025,0.000570168,0.027060369,0.0025788965,0.00038887234,0.0035253637,0.0021499968,0.0014048654,0.03529585,0.24275406,0.07639142,0.6065366],"study_design_scores_gemma":[0.00023035842,0.0014256228,0.03409395,0.0025660247,0.00037326908,0.026120156,0.0076333205,0.0037155368,0.015001385,0.43377265,0.4747459,0.00032181948],"about_ca_topic_score_codex":0.0004761531,"about_ca_topic_score_gemma":0.0007817735,"teacher_disagreement_score":0.011264634,"about_ca_system_score_codex":0.0007545624,"about_ca_system_score_gemma":0.0011244027,"threshold_uncertainty_score":0.05957383},"labels":[],"label_agreement":null},{"id":"W4412852294","doi":"10.1016/j.ajt.2025.07.659","title":"Defining Optimal Cryoprotectant Agent Conditions for Cryopreservation of Regulatory T Cells for Tolerogenic Cell Therapy in Transplant Recipients","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cryopreservation; Medicine; Cryoprotectant; Cell therapy; Transplantation; Cell; Immunology; Surgery; Cell biology; Biology; Biochemistry","score_opus":0.019912428608731977,"score_gpt":0.31912979925128027,"score_spread":0.2992173706425483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412852294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702497,0.008669949,0.017316945,0.00036268943,0.000120848345,0.00027178176,0.0003047718,0.000063436746,0.0026398613],"genre_scores_gemma":[0.981037,0.0034928077,0.013916504,0.00021343643,0.00007404322,0.00023227664,0.00035395197,0.000055361117,0.00062461256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99976164,0.00007175161,0.000027691085,0.000042224103,0.000047167774,0.000049573406],"domain_scores_gemma":[0.99972874,0.00008394835,0.00007827265,0.000018739558,0.0000632316,0.00002702434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009708456,0.0003136652,0.00032202824,0.00030948635,0.0003631621,0.00085776584,0.0003567189,0.00029553502,0.0015620176],"category_scores_gemma":[0.00089358655,0.00013908354,0.00017748195,0.00020047436,0.00033062015,0.00074352784,0.00024270467,0.00057964073,0.00022992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046346875,0.00012959608,0.001869301,0.00016400772,0.000020584668,0.000052376836,0.000086533946,0.0015337017,0.9875329,0.0005201989,0.00028378857,0.00734347],"study_design_scores_gemma":[0.000057832687,0.0010717579,0.010885833,0.00011198497,0.0001117282,0.00020242653,0.0002658493,0.00455725,0.9772107,0.0004976505,0.0050005508,0.000026436304],"about_ca_topic_score_codex":0.0007181547,"about_ca_topic_score_gemma":0.0015887045,"teacher_disagreement_score":0.0015620176,"about_ca_system_score_codex":0.0003574307,"about_ca_system_score_gemma":0.0005250726,"threshold_uncertainty_score":0.0052254796},"labels":[],"label_agreement":null},{"id":"W4412865633","doi":"10.1016/j.ajt.2025.07.1806","title":"Canadian Transplant Pharmacists’ Knowledge and Perspectives on Chimeric Antigen Receptor T Cell Therapy","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Occupational Cancer Research Centre; University of Alberta; BC Children's Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cell therapy; Antigen; Immunology; Intensive care medicine; Immunotherapy; Cell; Immune system; Genetics","score_opus":0.01873298544881717,"score_gpt":0.3185463200908913,"score_spread":0.2998133346420741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412865633","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024308514,0.018163314,0.00033574953,0.87922156,0.0029613606,0.000020338892,0.00017945183,0.000016442089,0.07479329],"genre_scores_gemma":[0.6126642,0.085821114,0.0012776734,0.27310756,0.0039855563,0.00003710107,0.0002481415,0.000038932678,0.022819811],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9890899,0.0026686967,0.0003785966,0.00044220654,0.004661999,0.002758605],"domain_scores_gemma":[0.9541551,0.009039812,0.00303828,0.0003560357,0.016976826,0.016433982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010516074,0.00029732508,0.0004569599,0.0018627633,0.00913033,0.008506511,0.001404934,0.004780371,0.02274751],"category_scores_gemma":[0.025238086,0.00028308821,0.00054184656,0.0026004468,0.006164865,0.0032279508,0.003293997,0.0076416824,0.001256037],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025512002,0.0005216623,0.049770955,0.0011648515,0.00010215332,0.0037341749,0.03163081,0.0008879641,0.0011437329,0.04653156,0.64093065,0.22332637],"study_design_scores_gemma":[0.00012172573,0.00013788124,0.029798424,0.0024102614,0.00007537363,0.0019773524,0.061074313,0.00046558006,0.00041979543,0.009141143,0.8941952,0.0001829939],"about_ca_topic_score_codex":0.7692254,"about_ca_topic_score_gemma":0.85336286,"teacher_disagreement_score":0.23077458,"about_ca_system_score_codex":0.035706345,"about_ca_system_score_gemma":0.12014926,"threshold_uncertainty_score":0.4642673},"labels":[],"label_agreement":null},{"id":"W4412957745","doi":"10.1016/j.jtct.2025.07.021","title":"Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Internal medicine; Cumulative incidence; Oncology; Immunotherapy; Gastroenterology; Immunology; Transplantation; Cancer","score_opus":0.020433082632561664,"score_gpt":0.3003773014187984,"score_spread":0.27994421878623676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412957745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87378305,0.011299819,0.03881189,0.0029658764,0.00027689614,0.0010121594,0.0024965266,0.0011493872,0.06820445],"genre_scores_gemma":[0.973898,0.0039531905,0.009425035,0.00032775867,0.000053964493,0.00015077667,0.0011988798,0.00015759093,0.010834785],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9994954,0.00010990842,0.000031605538,0.000080613485,0.00012981858,0.00015268559],"domain_scores_gemma":[0.9997733,0.000072731986,0.0000333207,0.00004733912,0.000030803563,0.000042451673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00096691825,0.00073108624,0.0007294021,0.0018252514,0.00041922968,0.00079386117,0.0010039294,0.0006372929,0.008438658],"category_scores_gemma":[0.000410229,0.00019370143,0.0005804639,0.00044470414,0.0006254361,0.0006712519,0.00038925378,0.0014324725,0.0012952036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032998847,0.0015668413,0.0018833141,0.00030451725,0.00011216203,0.0014785567,0.0001796316,0.002310431,0.9116903,0.021706417,0.0025432757,0.052924667],"study_design_scores_gemma":[0.00028919743,0.00230555,0.0018976443,0.00002685623,0.00021429028,0.0031844545,0.00008555339,0.0051871333,0.9565267,0.0019407707,0.028316699,0.000025204998],"about_ca_topic_score_codex":0.0015241681,"about_ca_topic_score_gemma":0.0009956828,"teacher_disagreement_score":0.008438658,"about_ca_system_score_codex":0.0009027666,"about_ca_system_score_gemma":0.0008096896,"threshold_uncertainty_score":0.028230071},"labels":[],"label_agreement":null},{"id":"W4413094417","doi":"10.1007/s40264-025-01596-9","title":"Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up","year":2025,"lang":"en","type":"review","venue":"Drug Safety","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kootenay Association for Science & Technology","funders":"","keywords":"Pharmacovigilance; Medicine; Blueprint; Clinical trial; Risk analysis (engineering); Intensive care medicine; Bioinformatics; Adverse effect; Pharmacology; Pathology","score_opus":0.055418353736730035,"score_gpt":0.36289067018476684,"score_spread":0.3074723164480368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413094417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013367548,0.44140184,0.15870543,0.36020333,0.003991888,0.00040550117,0.0010223291,0.0011626516,0.019739527],"genre_scores_gemma":[0.2935682,0.459669,0.13767035,0.09094704,0.010290578,0.0011815366,0.0017169325,0.0004971654,0.004459149],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.95954454,0.024304545,0.0045816544,0.0025893927,0.008127076,0.00085283717],"domain_scores_gemma":[0.84505206,0.11029682,0.013321852,0.006778404,0.020949032,0.0036018395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05706175,0.00082314055,0.0025123705,0.002253026,0.0014438385,0.011576129,0.003715847,0.004453651,0.0028600025],"category_scores_gemma":[0.13005301,0.000488402,0.0018807361,0.002281267,0.0039602383,0.007868866,0.0064825607,0.008815487,0.0012354072],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031380542,0.00014424417,0.014569966,0.0059490623,0.0009047051,0.0011782318,0.0024475458,0.0055424795,0.0009180017,0.09155925,0.059364453,0.8171082],"study_design_scores_gemma":[0.00018256396,0.00085523754,0.007922836,0.025135508,0.0012816897,0.003954113,0.003433773,0.012881299,0.0033561864,0.28707,0.6535908,0.00033591627],"about_ca_topic_score_codex":0.0047544236,"about_ca_topic_score_gemma":0.0042032497,"teacher_disagreement_score":0.05706175,"about_ca_system_score_codex":0.0052005267,"about_ca_system_score_gemma":0.016059643,"threshold_uncertainty_score":0.30177498},"labels":[],"label_agreement":null},{"id":"W4413114150","doi":"10.3390/cells14151223","title":"Exploiting TCR Repertoire Analysis to Select Therapeutic TCRs for Cancer Immunotherapy","year":2025,"lang":"en","type":"review","venue":"Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Chulabhorn Royal Academy","keywords":"T-cell receptor; Immunotherapy; Cancer immunotherapy; Antigen; Cancer; Adoptive cell transfer; T cell; Biology; Computational biology; Immunology; Immune system; Cancer research; Medicine; Genetics","score_opus":0.08142222239966064,"score_gpt":0.4294910818292818,"score_spread":0.3480688594296212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413114150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083622587,0.9961033,0.0010348345,0.00016676115,0.00014199152,0.000015553258,0.000040825053,0.000023829036,0.0016367458],"genre_scores_gemma":[0.003446427,0.99406356,0.0011632284,0.0002029611,0.000082516446,0.000021922662,0.0000971034,0.000005180095,0.00091722194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982136,0.000028897019,0.000019481191,0.000034802848,0.000072906674,0.000022612416],"domain_scores_gemma":[0.9998344,0.00008121729,0.000022018809,0.0000066451776,0.000044867422,0.000010838384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005148982,0.0006747864,0.001079213,0.002054641,0.00012316722,0.00080649817,0.0005527015,0.0006972838,0.0019555162],"category_scores_gemma":[0.00052290544,0.00023207309,0.00048513245,0.0014402589,0.0002623131,0.0007849389,0.00039960013,0.0012349596,0.0015170845],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009836492,0.00010993804,0.00036795618,0.0154201565,0.00010271049,0.00017092942,0.000040458603,0.00081876345,0.021308415,0.0030058173,0.008624974,0.94993144],"study_design_scores_gemma":[0.000051297862,0.0003350388,0.0023437433,0.0035061226,0.00032756713,0.0023266943,0.000066538894,0.00063802727,0.010894706,0.0029921592,0.9764807,0.00003743434],"about_ca_topic_score_codex":0.00040627882,"about_ca_topic_score_gemma":0.0006857406,"teacher_disagreement_score":0.002054641,"about_ca_system_score_codex":0.00043604834,"about_ca_system_score_gemma":0.0005529373,"threshold_uncertainty_score":0.006541848},"labels":[],"label_agreement":null},{"id":"W4413127351","doi":"10.1101/2025.08.08.669387","title":"CART-GPT: A T Cell-Informed AI Linguistic Framework for Interpreting Neurotoxicity and Therapeutic Outcomes in CAR-T Therapy","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; University of Ottawa","funders":"National Cancer Institute; National Research Council Canada; Alliance de recherche numérique du Canada; Comprehensive Cancer Center at Wake Forest Baptist Medical Center","keywords":"Chimeric antigen receptor; Cart; Neurotoxicity; Immunotherapy; T cell; Computational biology; Computer science; Cell; Medicine; Neuroscience; Immune system; Bioinformatics; Artificial intelligence; Biology; Immunology; Internal medicine; Engineering; Toxicity","score_opus":0.027483994754852994,"score_gpt":0.32159501169713206,"score_spread":0.2941110169422791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413127351","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032825794,0.0013802921,0.9498908,0.0016487807,0.00022623362,0.00014797847,0.004816406,0.0042769504,0.0047868383],"genre_scores_gemma":[0.67617005,0.0012983335,0.30272406,0.0020027454,0.00035261648,0.0009288692,0.007857755,0.001062131,0.0076034125],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996587,0.00014095374,0.000018980616,0.00009166735,0.0000570913,0.000032607666],"domain_scores_gemma":[0.9990951,0.0006154902,0.000074486285,0.0000476839,0.0001183461,0.00004893528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001090067,0.00086926384,0.00075631426,0.00078331935,0.00044761784,0.0014327379,0.0013305005,0.0011852182,0.003259875],"category_scores_gemma":[0.003790386,0.0004146753,0.0016204456,0.00055713323,0.0006509756,0.0006654375,0.00094397715,0.0014399841,0.00090505404],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014385203,0.00003561433,0.0024594485,0.00015533507,0.00011637088,0.00020823174,0.00008852465,0.94377106,0.003526483,0.010161982,0.0056012347,0.033731867],"study_design_scores_gemma":[0.000013058651,0.00002867994,0.00017707447,0.0000137998295,0.000025905347,0.00004519925,0.00001094473,0.9797102,0.0007457386,0.016731111,0.0024892897,0.000009008086],"about_ca_topic_score_codex":0.01248312,"about_ca_topic_score_gemma":0.014884833,"teacher_disagreement_score":0.01248312,"about_ca_system_score_codex":0.0013156515,"about_ca_system_score_gemma":0.0019449901,"threshold_uncertainty_score":0.024820924},"labels":[],"label_agreement":null},{"id":"W4413139122","doi":"10.1182/bloodadvances.2024015599","title":"New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Legend Biotech; Pharmacyclics; Eurostars; Genentech; National Institutes of Health; Juno Therapeutics; Astellas Pharma; Swedish Orphan Biovitrum; Omeros Corporation; BeiGene; Pfizer; Incyte; bluebird bio; Jazz Pharmaceuticals; National Cancer Institute; Servier; Gilead Sciences; Moffitt Cancer Center; Society for Immunotherapy of Cancer; Cidara Therapeutics; Celgene; Fred Hutchinson Cancer Research Center; Karyopharm Therapeutics; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Comorbidity; Internal medicine; Hazard ratio; Lymphoma; Diabetes mellitus; Gastroenterology; Confidence interval","score_opus":0.01401590502790424,"score_gpt":0.2952427108687055,"score_spread":0.2812268058408013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413139122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99868935,0.00030772178,0.00020310441,0.000056392477,0.000014624298,0.000008177391,0.00043390595,0.000004578648,0.00028207884],"genre_scores_gemma":[0.9993036,0.00004878872,0.00007731104,0.000011884728,0.000012190678,0.0000048735164,0.0004941057,0.000001094753,0.000046237714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995234,0.0001326036,0.00007524656,0.00008197942,0.000111954956,0.00007476095],"domain_scores_gemma":[0.99748176,0.000428743,0.0013025019,0.00011392911,0.00024834735,0.000424627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006979234,0.00032646535,0.00032387493,0.00060627935,0.00029191838,0.0005418063,0.0002690099,0.00028822644,0.0012762764],"category_scores_gemma":[0.003232177,0.00011163872,0.0005224663,0.00090156874,0.00015756392,0.00033893372,0.0005711896,0.0006441296,0.00014693479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012066435,0.000011671528,0.99882895,0.000004175498,0.00003837432,0.00001524842,0.0000047763697,0.00007297711,0.000083424624,0.00000781537,0.00006767017,0.0007443094],"study_design_scores_gemma":[0.000009451634,0.000063206346,0.9979962,0.0000049575306,0.00005127439,0.00011111959,0.00002399992,0.0015183664,0.00007798276,0.000022636628,0.000117115116,0.000003669579],"about_ca_topic_score_codex":0.0030370757,"about_ca_topic_score_gemma":0.0039870525,"teacher_disagreement_score":0.0030370757,"about_ca_system_score_codex":0.00048232416,"about_ca_system_score_gemma":0.0004227341,"threshold_uncertainty_score":0.006038785},"labels":[],"label_agreement":null},{"id":"W4413148372","doi":"10.18295/2075-0528.1377","title":"Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors : From antigen choice to clinical implementation","year":2012,"lang":"en","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of Saskatchewan; McGill University Health Centre","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Antigen; Receptor; Immunology; Antigen-presenting cell; T cell; Immune system; Internal medicine","score_opus":0.060186006952712354,"score_gpt":0.39417967200392956,"score_spread":0.3339936650512172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413148372","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28357503,0.62121165,0.05725302,0.01779582,0.00044065347,0.0003486265,0.00006820976,0.0002544379,0.019052507],"genre_scores_gemma":[0.65525967,0.2984505,0.035496965,0.0035056397,0.00060689973,0.00019492357,0.000104634106,0.000053509906,0.0063272165],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997955,0.000077559685,0.000011888855,0.000021145197,0.000064722015,0.00002915859],"domain_scores_gemma":[0.9998492,0.00008003951,0.000027031383,0.0000071398044,0.000020048365,0.000016549613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012359481,0.00024984303,0.00037665205,0.0003663897,0.00019327048,0.0008945939,0.0002623696,0.0007868973,0.0016115537],"category_scores_gemma":[0.00043306616,0.00013130972,0.00018695575,0.00026882067,0.0006982819,0.0007896346,0.00035156345,0.0008571306,0.00035013354],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000636376,0.0005999185,0.0035790093,0.0021269019,0.00003433996,0.0008157148,0.00047821878,0.0019326289,0.22914879,0.027322823,0.0031562063,0.7301691],"study_design_scores_gemma":[0.00090605905,0.0130325705,0.0084148655,0.0013839811,0.00020726385,0.012378928,0.000986842,0.0069659865,0.3989942,0.031229919,0.5254003,0.00009912265],"about_ca_topic_score_codex":0.0002573691,"about_ca_topic_score_gemma":0.0004563409,"teacher_disagreement_score":0.0016115537,"about_ca_system_score_codex":0.00048515073,"about_ca_system_score_gemma":0.0007050884,"threshold_uncertainty_score":0.0065363646},"labels":[],"label_agreement":null},{"id":"W4413160413","doi":"10.1016/j.drudis.2025.104453","title":"Commercialization of cell and gene therapy in Canada: Current landscape, challenges and opportunities","year":2025,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Commercialization; Current (fluid); Genetic enhancement; Gene; Biotechnology; Computational biology; Business; Biology; Engineering; Genetics; Marketing","score_opus":0.09829680913850976,"score_gpt":0.3382983723454111,"score_spread":0.24000156320690136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413160413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032576127,0.9899041,0.000099917605,0.0043263067,0.00019444583,0.00000963377,0.000108065535,0.000009600258,0.0050221016],"genre_scores_gemma":[0.002243313,0.99600804,0.00018574615,0.0006829584,0.000047819205,0.0000055043106,0.00007172915,0.0000030404678,0.0007518194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983028,0.00016750148,0.000112757276,0.0001350438,0.0009736767,0.00030824254],"domain_scores_gemma":[0.99517703,0.0013888436,0.00032651945,0.00005749061,0.0026715826,0.00037856263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002842445,0.000705203,0.0011553719,0.0042754165,0.0016610126,0.0048007704,0.0013519311,0.0019813823,0.0067869257],"category_scores_gemma":[0.003989788,0.0003247608,0.00077645876,0.01035864,0.0017898142,0.0021372063,0.0011605959,0.002205562,0.0009347447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008677774,0.000056135905,0.0007226291,0.03232274,0.000108300796,0.00031176995,0.00037733268,0.0005835071,0.00093319954,0.04058014,0.08378542,0.8401321],"study_design_scores_gemma":[0.000014404868,0.000030409896,0.001823692,0.014193584,0.00012842544,0.0002643546,0.00046813575,0.0001388679,0.00034851857,0.002479769,0.9800797,0.000030137584],"about_ca_topic_score_codex":0.6000534,"about_ca_topic_score_gemma":0.7245417,"teacher_disagreement_score":0.97546667,"about_ca_system_score_codex":0.02453332,"about_ca_system_score_gemma":0.10338299,"threshold_uncertainty_score":0.8046039},"labels":[],"label_agreement":null},{"id":"W4413220663","doi":"10.58931/cect.2025.4258","title":"Adverse Events Associated With Novel Cancer Therapies","year":2025,"lang":"en","type":"article","venue":"Canadian Eye Care Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Western University","funders":"","keywords":"Adverse effect; Medicine; Cancer; Intensive care medicine; Bioinformatics; Pharmacology; Biology; Internal medicine","score_opus":0.017739685335443157,"score_gpt":0.3056143570413656,"score_spread":0.2878746717059224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413220663","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22688939,0.5837479,0.01824227,0.01385137,0.0020048332,0.0016913717,0.0070778737,0.0005676716,0.14592735],"genre_scores_gemma":[0.8400402,0.1261968,0.0071485406,0.007293263,0.0019608345,0.00054661615,0.0027104944,0.0000758131,0.014027351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954595,0.0015649269,0.0008155774,0.00020889823,0.001683247,0.00026774558],"domain_scores_gemma":[0.9894208,0.0040751253,0.0039295075,0.00040626153,0.0017544256,0.0004138204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003094809,0.00025329905,0.00073920726,0.0005794805,0.0005934349,0.0008568999,0.00028974316,0.000498386,0.0041288515],"category_scores_gemma":[0.009132854,0.00007632123,0.00097480003,0.0010929618,0.00030360377,0.0003255373,0.00058119994,0.0016050837,0.00053760194],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00498892,0.0004202969,0.111095965,0.008398066,0.0021985418,0.008893737,0.0004885411,0.0017211988,0.0063676257,0.008133147,0.04449648,0.80279756],"study_design_scores_gemma":[0.0006719535,0.0056266556,0.2363073,0.0061323894,0.0036361245,0.06932441,0.000764674,0.0026580875,0.014330404,0.009661616,0.65074146,0.0001449621],"about_ca_topic_score_codex":0.0015135478,"about_ca_topic_score_gemma":0.0032194345,"teacher_disagreement_score":0.0041288515,"about_ca_system_score_codex":0.0012646785,"about_ca_system_score_gemma":0.0008289807,"threshold_uncertainty_score":0.016367078},"labels":[],"label_agreement":null},{"id":"W4413257665","doi":"10.1182/bloodadvances.2025016778","title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Omeros Corporation; Angiocrine Bioscience; Gilead Sciences; Sanofi; Bristol-Myers Squibb; National Cancer Institute; Incyte; Royal College of Physicians and Surgeons of Canada; Amgen","keywords":"CD19; Lymphoma; B cell; Cell; Cancer research; Medicine; Biology; Immunology; Antibody; Genetics","score_opus":0.020859460373952095,"score_gpt":0.3463436107200448,"score_spread":0.32548415034609274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413257665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700326,0.0011777878,0.00020671508,0.000048250826,0.000011125061,0.000028420845,0.0010760427,0.000005277054,0.000443029],"genre_scores_gemma":[0.9981792,0.00013285269,0.000078281264,0.0000281552,0.0000137769775,0.000025523337,0.0014809677,0.0000025327959,0.00005868215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969885,0.00161909,0.00033879615,0.00044570962,0.00038188117,0.00022606729],"domain_scores_gemma":[0.99377114,0.001356388,0.0035286427,0.00043635402,0.00047928412,0.00042810562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033747181,0.00026115795,0.00046495636,0.0005834461,0.00024366086,0.0010735216,0.00042461112,0.00051096146,0.0015588024],"category_scores_gemma":[0.006264542,0.00016405495,0.0009814061,0.00076452654,0.00038477505,0.000761389,0.000604171,0.0004823412,0.00027842674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032869365,0.0007016628,0.943714,0.00020331933,0.0027184559,0.00020908075,0.00013419619,0.002325621,0.001091379,0.00017532171,0.00071839476,0.015139066],"study_design_scores_gemma":[0.0015594052,0.009215276,0.9810883,0.000053560325,0.001135196,0.00067990494,0.00022592749,0.002630661,0.0013702039,0.00015493362,0.0018447307,0.000041961517],"about_ca_topic_score_codex":0.0008354014,"about_ca_topic_score_gemma":0.0010053426,"teacher_disagreement_score":0.0033747181,"about_ca_system_score_codex":0.0011957313,"about_ca_system_score_gemma":0.00041851413,"threshold_uncertainty_score":0.017847419},"labels":[],"label_agreement":null},{"id":"W4413316564","doi":"10.1182/bloodadvances.2024015282","title":"Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; Takeda Oncology; Genentech; National Institutes of Health; Kyowa Hakko Kirin; Memorial Sloan-Kettering Cancer Center; Chugai Pharmaceutical; Celltrion; Seagen; Kite Pharma; Gilead Sciences; Eisai; BeiGene; Daiichi Sankyo Europe; Sanofi; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"CHOP; Medicine; Prednisone; Internal medicine; Vincristine; Anaplastic large-cell lymphoma; Cyclophosphamide; Lymphoma; Oncology; Peripheral T-cell lymphoma; Chemotherapy; Gastroenterology; Immunology; T cell; Immune system","score_opus":0.011150924414558954,"score_gpt":0.3162519335843498,"score_spread":0.3051010091697908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413316564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978757,0.0010306886,0.00009082875,0.00011654292,0.000039481365,0.000092993156,0.0002314029,0.000009236831,0.000513065],"genre_scores_gemma":[0.9984124,0.00020354247,0.00009045918,0.000104270905,0.000076903605,0.00012655799,0.00052616437,0.0000040020823,0.00045574983],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99891627,0.0007861363,0.00004419734,0.00009637663,0.000061842075,0.00009525926],"domain_scores_gemma":[0.9986259,0.0005435026,0.00031134565,0.00011428965,0.000055763576,0.00034934163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024596388,0.0004463783,0.0010278446,0.00014836097,0.00017554025,0.00071255903,0.00047432183,0.0008399508,0.0024490743],"category_scores_gemma":[0.0019996187,0.0001947903,0.00085282867,0.00020907777,0.00045324574,0.000606745,0.0003425525,0.0014398537,0.00031678978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9714651,0.0017310096,0.009577277,0.00012769495,0.000819443,0.000032655924,0.00003234958,0.00064131274,0.002244976,0.000044336008,0.0004060417,0.012877837],"study_design_scores_gemma":[0.4362267,0.3644275,0.180213,0.0001138352,0.0030600883,0.00033219476,0.000114145245,0.0056898477,0.0059857764,0.00096244045,0.0028126526,0.00006180672],"about_ca_topic_score_codex":0.0002708792,"about_ca_topic_score_gemma":0.0005934267,"teacher_disagreement_score":0.0024596388,"about_ca_system_score_codex":0.00047288774,"about_ca_system_score_gemma":0.00039361592,"threshold_uncertainty_score":0.0130079985},"labels":[],"label_agreement":null},{"id":"W4413349976","doi":"10.1126/scitranslmed.adp6519","title":"CAR T <sub>reg</sub> cells mediate linked suppression and infectious tolerance in islet transplantation in mice","year":2025,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Alloimmunity; Immunology; Autoimmunity; Islet; Transplantation; Biology; Adoptive cell transfer; Antigen; Immune system; T cell; Medicine; Diabetes mellitus; Endocrinology; Internal medicine","score_opus":0.015457513228790817,"score_gpt":0.3159360446472166,"score_spread":0.3004785314184258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413349976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769191,0.002263216,0.012270323,0.0002886821,0.0001711323,0.00019407204,0.0010663585,0.0010191818,0.0058080256],"genre_scores_gemma":[0.98099923,0.0015666882,0.0064411582,0.00034708428,0.00009313093,0.0003042463,0.0010899776,0.0003080153,0.008850531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99944025,0.00009323005,0.00008408972,0.000096619384,0.00011919074,0.00016657707],"domain_scores_gemma":[0.9997019,0.000039148134,0.00008714183,0.000057928304,0.000019846917,0.0000939072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061509834,0.0011139426,0.00055296044,0.00085241115,0.0002475945,0.00071429147,0.0005338424,0.00081072556,0.002092906],"category_scores_gemma":[0.00020541408,0.0004653949,0.000771892,0.00022195728,0.00045000535,0.00051994476,0.00035041536,0.0022135687,0.0011590547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035871158,0.00027951825,0.00013197954,0.000050626164,0.000013926405,0.00009991102,0.00003399972,0.000207282,0.9964432,0.0004392387,0.000116264244,0.0018253217],"study_design_scores_gemma":[0.00018860583,0.0015777202,0.001659953,0.00002198446,0.00005021497,0.0005139066,0.00004494686,0.0025341995,0.9899602,0.0001914974,0.0032461705,0.0000104742],"about_ca_topic_score_codex":0.00033762358,"about_ca_topic_score_gemma":0.0003775069,"teacher_disagreement_score":0.002092906,"about_ca_system_score_codex":0.0002957123,"about_ca_system_score_gemma":0.00027325493,"threshold_uncertainty_score":0.0070014596},"labels":[],"label_agreement":null},{"id":"W4413416908","doi":"10.3390/curroncol32080460","title":"Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Université Laval; Université de Montréal; London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; St. John’s Health Sciences Centre; Hôpital Charles-Le Moyne; Université de Sherbrooke; Western University; Southlake Regional Health Center; Occupational Cancer Research Centre; CancerCare Manitoba; Ottawa Hospital; University of Manitoba; University of Calgary","funders":"Roche Canada","keywords":"Medicine; Health care; Health professionals","score_opus":0.21394395431071667,"score_gpt":0.5635384590925364,"score_spread":0.34959450478181975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413416908","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040669918,0.017434793,0.038958438,0.63686764,0.0052847993,0.008839593,0.0063415295,0.0030244442,0.24257886],"genre_scores_gemma":[0.24164419,0.024810169,0.35095954,0.20300002,0.0009938296,0.004910642,0.0060357987,0.0006060501,0.16703983],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9878485,0.0035948504,0.0009022017,0.000492629,0.0040310263,0.0031307829],"domain_scores_gemma":[0.96472853,0.0040732045,0.0014296517,0.0006808766,0.018339945,0.010747886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011755758,0.00081851013,0.0003943455,0.0024457055,0.00595743,0.003896921,0.003836108,0.0049811373,0.011406353],"category_scores_gemma":[0.019384094,0.0006052352,0.0009278287,0.0020859225,0.0025546895,0.0015487227,0.0032777616,0.003420984,0.0022257536],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011029932,0.0004866077,0.014879036,0.001104972,0.00002507977,0.0016081993,0.0048185242,0.0032283717,0.0032203058,0.0114437,0.7646379,0.19443704],"study_design_scores_gemma":[0.00015472937,0.00027300484,0.036865868,0.0026784758,0.000051200197,0.0007354819,0.008962111,0.0018775729,0.0017698815,0.0038629184,0.94259477,0.00017398913],"about_ca_topic_score_codex":0.9435615,"about_ca_topic_score_gemma":0.9752034,"teacher_disagreement_score":0.06793346,"about_ca_system_score_codex":0.06793346,"about_ca_system_score_gemma":0.39870158,"threshold_uncertainty_score":0.49289405},"labels":[],"label_agreement":null},{"id":"W4413494869","doi":"10.1038/s41551-025-01470-0","title":"Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells","year":2025,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Engineering and Applied Science, University of Pennsylvania; National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; Mallinckrodt Pharmaceuticals; Perelman School of Medicine, University of Pennsylvania; National Cancer Institute; Institute for Translational Medicine and Therapeutics; University of Pennsylvania; Massachusetts General Hospital; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Children's Hospital of Philadelphia; National Institutes of Health; National Science Foundation","keywords":"Chimeric antigen receptor; CD19; Cancer research; In vivo; Antigen; T cell; Immunology; Biology; Medicine; Chemistry; Immune system","score_opus":0.005535937912300631,"score_gpt":0.28179288182267503,"score_spread":0.2762569439103744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413494869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94845986,0.001538361,0.047367044,0.00020234461,0.000030327486,0.00017791185,0.00022256614,0.00023121925,0.0017703404],"genre_scores_gemma":[0.9750489,0.00092999835,0.021746315,0.00009348156,0.000011068633,0.00007234347,0.00027022403,0.00004218856,0.0017854972],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988115,0.000030624626,0.000009293496,0.000019705314,0.000031499036,0.000027699678],"domain_scores_gemma":[0.9999392,0.000013045787,0.000018947398,0.000006215928,0.00000937247,0.0000131852485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019402122,0.00037335185,0.00020270246,0.00015791407,0.00007740129,0.0002693646,0.00018383592,0.00028743036,0.00054334715],"category_scores_gemma":[0.00018187119,0.00014621628,0.00017629693,0.000130025,0.00014688045,0.00015268082,0.00025356244,0.00051162817,0.00026265168],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034947418,0.000027402279,0.00006838158,0.00001415502,0.0000030202573,0.000030739975,0.000011377784,0.00048008777,0.9971511,0.00021772258,0.000026897807,0.001934334],"study_design_scores_gemma":[0.00001547593,0.00018842667,0.0002243406,0.0000018363429,0.0000060397756,0.00010051875,0.0000061929136,0.0015632393,0.99636805,0.000027897322,0.0014953294,0.0000026542884],"about_ca_topic_score_codex":0.00026187752,"about_ca_topic_score_gemma":0.00042544227,"teacher_disagreement_score":0.00054334715,"about_ca_system_score_codex":0.00029687528,"about_ca_system_score_gemma":0.00017001192,"threshold_uncertainty_score":0.0021539927},"labels":[],"label_agreement":null},{"id":"W4413505578","doi":"10.1101/2025.08.22.671679","title":"WITHDRAWN: AAV-Mediated CAR-T therapy eradicate HIV reservoirs with augmented safety and persistence","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; A&L Canada Laboratories (Canada); Université de Sherbrooke; Centre Hospitalier Universitaire Sainte-Justine; Institut National de la Recherche Scientifique; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Persistence (discontinuity); Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Virology; Viral load; Engineering; Geotechnical engineering","score_opus":0.02283886266749234,"score_gpt":0.24965152402738072,"score_spread":0.22681266135988837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413505578","genre_codex":"editorial","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028357977,0.023335157,0.021817379,0.2273395,0.56201774,0.0015514009,0.046049837,0.008792253,0.0807388],"genre_scores_gemma":[0.18452133,0.01766257,0.015302717,0.12164396,0.06068111,0.0016703403,0.050535053,0.0060656085,0.54191726],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967372,0.00035346122,0.00059846835,0.00020433213,0.0017789927,0.00032759228],"domain_scores_gemma":[0.9880385,0.0033494069,0.00056439015,0.0012963939,0.005505275,0.0012459512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039368523,0.00066986424,0.0014424956,0.00063863763,0.0012107106,0.003649661,0.0012235402,0.005400025,0.0653241],"category_scores_gemma":[0.022458844,0.00033591216,0.0011202706,0.0005189595,0.0008124398,0.0013383095,0.0008967159,0.003462841,0.04480249],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025718356,0.00011963575,0.00084534177,0.00058294437,0.000102174825,0.0023532817,0.0001315913,0.000115688184,0.019085433,0.00564065,0.8908297,0.07762175],"study_design_scores_gemma":[0.0006068092,0.0003251152,0.0024708929,0.00020761564,0.00008007128,0.003667791,0.00009342828,0.0006233119,0.02213678,0.0039435816,0.9657678,0.000076777505],"about_ca_topic_score_codex":0.0013016274,"about_ca_topic_score_gemma":0.0012142261,"teacher_disagreement_score":0.0653241,"about_ca_system_score_codex":0.0016278357,"about_ca_system_score_gemma":0.0031935726,"threshold_uncertainty_score":0.2185309},"labels":[],"label_agreement":null},{"id":"W4413539704","doi":"10.64628/aam.73wewhtus","title":"All for one, not one for all: The promise and challenges of personalized medicine","year":2024,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Personalized medicine; Precision medicine; Medicine; Internet privacy; Data science; Computer science; Bioinformatics; Biology; Pathology","score_opus":0.2042038018108626,"score_gpt":0.3993359464152614,"score_spread":0.1951321446043988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413539704","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041383463,0.16407678,0.009315081,0.7997217,0.007645806,0.000028133705,0.0002098459,0.00015986265,0.014704503],"genre_scores_gemma":[0.20654581,0.29658833,0.021666227,0.4300194,0.032339137,0.0001946869,0.00036923596,0.00030146766,0.011975734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99161583,0.0044936417,0.00034176398,0.0009757185,0.0019101128,0.0006629392],"domain_scores_gemma":[0.9706727,0.021532683,0.0012062923,0.0018650807,0.001961225,0.0027620168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01772386,0.0007309637,0.0024681203,0.0012332017,0.0034449382,0.009306363,0.0016230458,0.0070691085,0.01040913],"category_scores_gemma":[0.022966282,0.00051192037,0.0012662387,0.0010088581,0.012998064,0.019352505,0.005207819,0.019989882,0.0036096897],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004413074,0.00035660047,0.00443459,0.002025567,0.00033316333,0.0005708865,0.0020672975,0.0009354393,0.0017504614,0.28078297,0.22950971,0.4767919],"study_design_scores_gemma":[0.00010763066,0.0003093495,0.0020766237,0.0019932962,0.00024315437,0.0013801873,0.0031523241,0.0012464895,0.0010232908,0.52162826,0.46668163,0.00015769829],"about_ca_topic_score_codex":0.0016219328,"about_ca_topic_score_gemma":0.0041436395,"teacher_disagreement_score":0.01772386,"about_ca_system_score_codex":0.0033278512,"about_ca_system_score_gemma":0.0070426892,"threshold_uncertainty_score":0.09373385},"labels":[],"label_agreement":null},{"id":"W4413618388","doi":"10.1101/2025.08.18.670666","title":"<i>Sleeping Beauty</i> mutagenesis identifies <i>BACH2</i> and other regulators of CD8 <sup>+</sup> T cell exhaustion, persistence <i>in vivo</i> , and CAR-T function under tumor-associated chronic antigen stimulation","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Adler","funders":"Kite Pharma; Genentech; National Institutes of Health; University of Minnesota","keywords":"Mutagenesis; Persistence (discontinuity); Beauty; Function (biology); CD8; In vivo; Biology; T cell; Genetics; Cancer research; Mutation; Cell biology; Immune system; Philosophy; Gene; Engineering; Epistemology","score_opus":0.01791341842263895,"score_gpt":0.24077072055189255,"score_spread":0.22285730212925361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413618388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98760265,0.0005913325,0.0077438564,0.00012331441,0.000021334785,0.000052582593,0.0020115438,0.00031103226,0.0015424557],"genre_scores_gemma":[0.9899305,0.00030743697,0.0041632373,0.00010910283,0.0000061404444,0.000044954344,0.0022974496,0.00008572952,0.0030554687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981207,0.000016468419,0.000016167522,0.000045383946,0.000059370024,0.000050482304],"domain_scores_gemma":[0.99983144,0.000028146615,0.000066373446,0.000014794278,0.0000148475365,0.00004432567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017500244,0.00038217823,0.00024931808,0.00032424476,0.0001984056,0.00032449895,0.00022813703,0.00026294962,0.001691804],"category_scores_gemma":[0.00012487452,0.00016353611,0.00033599336,0.00025148178,0.00030928783,0.00014302388,0.00030747472,0.0005943975,0.00041130427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004189323,0.0000092087175,0.00047613797,0.000018803994,0.0000030203423,0.00003182722,0.0000071224563,0.00007380514,0.99845994,0.000048179925,0.00005083939,0.0007793195],"study_design_scores_gemma":[0.00001313707,0.00020784714,0.016425997,0.000008780316,0.00002727807,0.0003500969,0.000047010715,0.0019556591,0.9776325,0.000055305274,0.0032668337,0.00000955005],"about_ca_topic_score_codex":0.0010806338,"about_ca_topic_score_gemma":0.0027180407,"teacher_disagreement_score":0.001691804,"about_ca_system_score_codex":0.0003173272,"about_ca_system_score_gemma":0.00027793396,"threshold_uncertainty_score":0.0056596994},"labels":[],"label_agreement":null},{"id":"W4413675912","doi":"10.64628/aap.csrtypcng","title":"La médecine personnalisée est prometteuse, mais ses enjeux, dont son coût, sont nombreux","year":2025,"lang":"fr","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Humanities; Political science; Art; Philosophy","score_opus":0.04815926023584218,"score_gpt":0.35028271963117813,"score_spread":0.30212345939533597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413675912","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02325092,0.051974505,0.06632342,0.43283972,0.030872947,0.00024585772,0.00217111,0.0023407592,0.38998067],"genre_scores_gemma":[0.26745725,0.046993103,0.066227354,0.051399264,0.019388614,0.00070601504,0.0024255107,0.0016982273,0.5437047],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9897675,0.0052022305,0.0003121103,0.0010788284,0.0027644294,0.0008750582],"domain_scores_gemma":[0.98147637,0.0069565233,0.0014655177,0.0028348095,0.0037641395,0.0035025864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010316983,0.000724046,0.0013290542,0.0013081359,0.0030660175,0.008872173,0.0012812512,0.005020116,0.07189868],"category_scores_gemma":[0.023825683,0.00035800243,0.0009380365,0.001670181,0.0046764906,0.004148619,0.004184578,0.0066659846,0.027612437],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064706657,0.00033646953,0.005308752,0.0007923059,0.00013609379,0.0006235937,0.0042448617,0.00068646227,0.0048566363,0.2749438,0.27021196,0.437212],"study_design_scores_gemma":[0.000054239044,0.0001328624,0.003396699,0.0002926877,0.000014908982,0.0008087535,0.0009541207,0.00023258914,0.0009796423,0.020892652,0.9722028,0.000038041948],"about_ca_topic_score_codex":0.0062403185,"about_ca_topic_score_gemma":0.0052140425,"teacher_disagreement_score":0.07189868,"about_ca_system_score_codex":0.0032715767,"about_ca_system_score_gemma":0.009046117,"threshold_uncertainty_score":0.240525},"labels":[],"label_agreement":null},{"id":"W4413734272","doi":"10.33540/3174","title":"Unmet needs in T cell-based cancer therapies: opportunities for translational innovation","year":2025,"lang":"en","type":"dissertation","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Translational science; Translational research; Medicine; Oncology; Cancer research; Pathology","score_opus":0.11400931596028135,"score_gpt":0.3894417403053376,"score_spread":0.27543242434505627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413734272","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035963643,0.46979997,0.0076014563,0.4992332,0.009127791,0.000063274696,0.00023607619,0.00025778436,0.010084077],"genre_scores_gemma":[0.052033264,0.7955051,0.024147997,0.08756777,0.028322924,0.00031314205,0.00057470484,0.0001189888,0.011416032],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9960173,0.0012660292,0.0002864378,0.00041894792,0.0010151046,0.0009962588],"domain_scores_gemma":[0.9871975,0.0056069046,0.0006693338,0.0006174139,0.0021018523,0.0038070267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017555067,0.0011847487,0.0018135391,0.001519279,0.0016746226,0.007791451,0.0019543383,0.01244875,0.022029173],"category_scores_gemma":[0.0067917393,0.0004747484,0.0014426674,0.0015803342,0.0065009,0.013745558,0.004639597,0.010836303,0.005881203],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007983709,0.001060476,0.001041787,0.0072307317,0.00014118335,0.0008500321,0.0012175369,0.0026556868,0.008136913,0.18548542,0.2386801,0.5527018],"study_design_scores_gemma":[0.00029314388,0.0010827861,0.0013101888,0.004012377,0.00007109941,0.0007830067,0.0035456987,0.0023357365,0.0014291286,0.28902268,0.69600606,0.00010806733],"about_ca_topic_score_codex":0.0008260711,"about_ca_topic_score_gemma":0.0018308242,"teacher_disagreement_score":0.022029173,"about_ca_system_score_codex":0.0028832997,"about_ca_system_score_gemma":0.014925042,"threshold_uncertainty_score":0.09284121},"labels":[],"label_agreement":null},{"id":"W4413774493","doi":"10.1016/s2152-2650(25)02385-7","title":"ABCL-1487: Large B-Cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) Clinically Identify Subgroups With Greatest Benefit From CD19 CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; CD19; Lymphoma; Oncology; Internal medicine; Immunology; Antigen","score_opus":0.02548499021004296,"score_gpt":0.3236153303053004,"score_spread":0.2981303400952574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424016,0.00040207818,0.0005851729,0.00025027606,0.000011291034,0.000046183744,0.0006769303,0.000045678826,0.0037421912],"genre_scores_gemma":[0.9975673,0.00008180572,0.00055129756,0.00012701712,0.000019034,0.000024223085,0.0010093083,0.000014573623,0.00060555985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998066,0.000031441796,0.000016116202,0.000041596333,0.00004056728,0.00006377255],"domain_scores_gemma":[0.99973375,0.0000475053,0.00008744139,0.000018736775,0.00003476079,0.000077703335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029852657,0.00030821052,0.00036197063,0.0007820969,0.00040504077,0.0009995693,0.0002806342,0.00038808348,0.0053737178],"category_scores_gemma":[0.0005475213,0.00010156289,0.00029638348,0.0005369131,0.00031462146,0.0005368054,0.0005796979,0.0004627992,0.0012024032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055878656,0.00023955858,0.787665,0.000119625576,0.00024337888,0.0015274765,0.00018371781,0.0006448588,0.11018093,0.0014327004,0.0043693776,0.087805405],"study_design_scores_gemma":[0.00027981636,0.0012003684,0.94373804,0.000042589796,0.00028814276,0.010459155,0.00088766037,0.0042218147,0.024455044,0.0038955223,0.010500883,0.000030968844],"about_ca_topic_score_codex":0.0005877799,"about_ca_topic_score_gemma":0.0013415803,"teacher_disagreement_score":0.0053737178,"about_ca_system_score_codex":0.00045011428,"about_ca_system_score_gemma":0.00026227083,"threshold_uncertainty_score":0.01797688},"labels":[],"label_agreement":null},{"id":"W4413783187","doi":"10.1016/s2152-2650(25)01538-1","title":"ALL-562: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Oncology; Internal medicine; Pediatrics; Leukemia","score_opus":0.02242904538383347,"score_gpt":0.3368691806410551,"score_spread":0.31444013525722164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998139,0.00048402202,0.00004008187,0.00006839935,0.00001408229,0.000008168498,0.00048094074,0.0000041942694,0.0007609908],"genre_scores_gemma":[0.99845755,0.0001658309,0.000020872276,0.000065984685,0.00002058699,0.0000083073755,0.0009034361,0.0000027629114,0.00035462854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99970967,0.000049253787,0.000019726076,0.00006891869,0.000036377434,0.00011598536],"domain_scores_gemma":[0.99964786,0.000037169037,0.00015532493,0.000019874935,0.000015835694,0.00012399702],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027132142,0.00033074437,0.00048404117,0.0002755698,0.00024410756,0.00079484814,0.00034115827,0.00045211974,0.0017922088],"category_scores_gemma":[0.0006660774,0.00019442473,0.0007411569,0.00059354695,0.00022670419,0.00055110623,0.00056009676,0.00074076746,0.00026298093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019102141,0.00025854533,0.96690434,0.000052111838,0.00056896085,0.00033739067,0.00008392682,0.00058568764,0.002627773,0.00015561371,0.0007380715,0.0085854335],"study_design_scores_gemma":[0.0003620743,0.0015189386,0.99480575,0.00001482685,0.00039162562,0.0005221638,0.00021728281,0.00061599136,0.00032990926,0.0001810419,0.001024184,0.000016269269],"about_ca_topic_score_codex":0.0027279607,"about_ca_topic_score_gemma":0.0044246376,"teacher_disagreement_score":0.0027279607,"about_ca_system_score_codex":0.0006303861,"about_ca_system_score_gemma":0.00041633908,"threshold_uncertainty_score":0.0059955716},"labels":[],"label_agreement":null},{"id":"W4413791664","doi":"10.1016/s2152-2650(25)01097-3","title":"POSTER: ABCL-1487 Large B-Cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) Clinically Identify Subgroups With Greatest Benefit From CD19 CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; CD19; Lymphoma; CAR T-cell therapy; Internal medicine; Oncology; Immunology; Immunotherapy; Chimeric antigen receptor; Cancer; Antigen","score_opus":0.024492328462297062,"score_gpt":0.3206075723707601,"score_spread":0.29611524390846305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791664","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40824524,0.02656033,0.004758682,0.098463215,0.021910781,0.0024875118,0.011816458,0.0023431687,0.42341456],"genre_scores_gemma":[0.6391971,0.007449698,0.0046575447,0.018488655,0.012399252,0.00075963984,0.007264253,0.00029426598,0.30948958],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9998266,0.000038021437,0.000008921448,0.00003184095,0.00003489815,0.00005970111],"domain_scores_gemma":[0.9996474,0.00005981857,0.000027337564,0.000014720517,0.000058502013,0.0001922212],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005365676,0.00055844267,0.00035624328,0.00046577482,0.00056700374,0.0011022057,0.00027155562,0.0009902017,0.09352336],"category_scores_gemma":[0.0005790758,0.00013762419,0.00036176748,0.00019143186,0.0003214237,0.00040163644,0.00047075195,0.0011481171,0.024134308],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011712431,0.0011436596,0.017396033,0.0005947181,0.00018973414,0.0012449941,0.00010005745,0.00037656372,0.02915887,0.0022823731,0.56243,0.37337056],"study_design_scores_gemma":[0.0075470963,0.0086713135,0.09921122,0.00050241716,0.00056832464,0.0082541825,0.00049884524,0.0020810866,0.03579895,0.0057986523,0.83097845,0.00008945423],"about_ca_topic_score_codex":0.00038003738,"about_ca_topic_score_gemma":0.0011028831,"teacher_disagreement_score":0.09352336,"about_ca_system_score_codex":0.0005730691,"about_ca_system_score_gemma":0.00050978,"threshold_uncertainty_score":0.3128668},"labels":[],"label_agreement":null},{"id":"W4413792288","doi":"10.1016/s2152-2650(25)02748-x","title":"CT-041: Third-Line (3L) CAR T-Cell Therapy in the Golden Years: A Single-Center Experience on Outcomes for Elderly Patients in Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Single Center; Center (category theory); Aggressive lymphoma; Oncology; Lymphoma; Internal medicine; Rituximab","score_opus":0.04795534734860198,"score_gpt":0.36277100446945076,"score_spread":0.3148156571208488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413792288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99807537,0.0010313039,0.00008496573,0.0000655137,0.000010994245,0.000009590576,0.00012919218,0.0000047651024,0.00058839924],"genre_scores_gemma":[0.9986442,0.0005553228,0.00012783988,0.00009770951,0.000024442363,0.000011156089,0.0003699131,0.00000523262,0.00016425051],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99972445,0.00008894954,0.000019766008,0.00004394072,0.00003722375,0.00008568229],"domain_scores_gemma":[0.9994307,0.00010154617,0.0001218418,0.000027572656,0.00003444959,0.00028380795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010673266,0.00023890885,0.00054420053,0.00019468593,0.0003684542,0.0008102039,0.00020367674,0.00023745703,0.00072787947],"category_scores_gemma":[0.000931454,0.00006797076,0.00040482613,0.00037049924,0.00028373997,0.0004986283,0.00043166504,0.0003526075,0.00014601552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03384277,0.0030465696,0.75653994,0.00016714811,0.00070371246,0.0013426016,0.00086004334,0.0022147761,0.006747617,0.00030422362,0.0037943749,0.19043626],"study_design_scores_gemma":[0.0019205164,0.032716714,0.9516486,0.00008743333,0.0008288484,0.0024503719,0.0008852461,0.0020212936,0.002592414,0.00020982328,0.0046000304,0.00003882747],"about_ca_topic_score_codex":0.0015762232,"about_ca_topic_score_gemma":0.0028399255,"teacher_disagreement_score":0.0015762232,"about_ca_system_score_codex":0.0007612003,"about_ca_system_score_gemma":0.0005573459,"threshold_uncertainty_score":0.0056446195},"labels":[],"label_agreement":null},{"id":"W4413804340","doi":"10.4110/in.2025.25.e29","title":"Adoptive Cellular Therapies in Pediatric Leukemia Patients After Allogeneic-Hematopoietic Stem Cell Transplants","year":2025,"lang":"en","type":"review","venue":"Immune Network","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ontario Institute for Cancer Research","funders":"Alberta Children's Hospital Research Institute; Canadian Institutes of Health Research; Arnie Charbonneau Cancer Institute, University of Calgary","keywords":"Medicine; Stem cell; Hematopoietic stem cell; Haematopoiesis; Hematopoietic stem cell transplantation; Leukemia; Immunology; Cancer research; Transplantation; Internal medicine; Biology; Cell biology","score_opus":0.019952025183029125,"score_gpt":0.2829232855194382,"score_spread":0.26297126033640905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413804340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021738128,0.9988661,0.00007494585,0.00012276667,0.00007886111,0.000006149349,0.000015210005,0.0000046392406,0.0006139431],"genre_scores_gemma":[0.000889111,0.9985769,0.000121137346,0.00012100767,0.000057478886,0.000008214197,0.000024071895,8.962304e-7,0.0002012682],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998841,0.000029507675,0.000022400909,0.00001900776,0.000033579898,0.000011261661],"domain_scores_gemma":[0.9998462,0.0000933481,0.000022099135,0.0000034561579,0.000025482057,0.000009336825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041638772,0.0004441627,0.00084995443,0.0010407626,0.00013997282,0.0005014753,0.00047447375,0.00056928466,0.002058332],"category_scores_gemma":[0.0005101412,0.0001327006,0.0004776355,0.0007746019,0.00018524624,0.00056371215,0.00037204826,0.0009176338,0.00074115477],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011769013,0.000063126696,0.00014535412,0.020836376,0.00010713458,0.00014857958,0.00004722761,0.00023717851,0.0013014872,0.0014740604,0.011032063,0.96448964],"study_design_scores_gemma":[0.00006465563,0.00033231362,0.0013429405,0.010412047,0.0003590697,0.0017996135,0.00006498847,0.00011299837,0.0009767129,0.0011494736,0.9833681,0.000017107383],"about_ca_topic_score_codex":0.0005291485,"about_ca_topic_score_gemma":0.0011549317,"teacher_disagreement_score":0.002058332,"about_ca_system_score_codex":0.00029323247,"about_ca_system_score_gemma":0.00063272216,"threshold_uncertainty_score":0.006885767},"labels":[],"label_agreement":null},{"id":"W4413880346","doi":"10.3389/fimmu.2025.1690655","title":"Editorial: Repurposing cancer immunotherapies for use in autoimmunity and transplantation","year":2025,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"","keywords":"Repurposing; Autoimmunity; Medicine; Transplantation; Cancer; Immunology; Immunotherapy; Cancer immunotherapy; Immune system; Biology; Internal medicine","score_opus":0.014779445130986826,"score_gpt":0.31550982959040474,"score_spread":0.3007303844594179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413880346","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013800112,0.004585647,0.00028712768,0.021886634,0.97097236,0.00004564311,0.00008598104,0.00015824684,0.0018403248],"genre_scores_gemma":[0.00068118644,0.0039832448,0.00014551303,0.018510567,0.9689895,0.000023465156,0.000042982447,0.00004705663,0.0075764484],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606824,0.0004857669,0.00042426717,0.0006312303,0.0020724917,0.00031803307],"domain_scores_gemma":[0.9886418,0.0042205807,0.00091684697,0.00032856216,0.003434642,0.0024575933],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054881866,0.0041739233,0.0029458406,0.0024213686,0.0022852167,0.005246108,0.0037211815,0.011311295,0.019395962],"category_scores_gemma":[0.012849949,0.0010706879,0.0032114782,0.00086347986,0.0023034962,0.004781785,0.0013151485,0.014671607,0.013093718],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013145998,0.00004958408,0.000053866654,0.00044594146,0.000026461365,0.00019697027,0.00001940685,0.00007903152,0.00033692917,0.00048764446,0.98717564,0.010997006],"study_design_scores_gemma":[0.00011008247,0.00012463846,0.00030684768,0.00034765224,0.00005134521,0.00040548996,0.000037114463,0.0002512192,0.000451187,0.00093283824,0.9969529,0.000028611292],"about_ca_topic_score_codex":0.00060481974,"about_ca_topic_score_gemma":0.0012197417,"teacher_disagreement_score":0.019395962,"about_ca_system_score_codex":0.0023948026,"about_ca_system_score_gemma":0.0022484846,"threshold_uncertainty_score":0.06488603},"labels":[],"label_agreement":null},{"id":"W4413883555","doi":"10.1016/j.ymthe.2025.08.046","title":"T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health; King's College London; Mayo Foundation for Medical Education and Research; University of Minnesota; Hyundai Hope On Wheels; National Institute of Allergy and Infectious Diseases; Mayo Clinic","keywords":"Oncolytic virus; Blockade; Immune checkpoint; Immune system; Cancer research; T cell; Immunotherapy; Biology; Cytotoxic T cell; Cell; Immunology; Virology; Receptor","score_opus":0.01066415550059916,"score_gpt":0.2920930423690289,"score_spread":0.2814288868684297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413883555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977539,0.0005009288,0.00065488066,0.000056556655,0.000019957834,0.000012415818,0.0001078829,0.00006169646,0.00083177554],"genre_scores_gemma":[0.99893814,0.00010036887,0.00014020376,0.000017362665,0.0000052946416,0.000011402251,0.00014804796,0.000010666765,0.00062856846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984396,0.000023026887,0.000015133321,0.000018558821,0.000024748979,0.00007444968],"domain_scores_gemma":[0.9998909,0.000019786972,0.000022032364,0.00002487119,0.0000068943386,0.000035434106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014400863,0.0002838119,0.00043891626,0.00022881408,0.00014967631,0.00038640547,0.00017910599,0.0002208307,0.0013665283],"category_scores_gemma":[0.00019541517,0.00013214728,0.00025817816,0.00016051413,0.00024531287,0.00026351403,0.0002401922,0.0008882568,0.00037287222],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006618038,0.0001443941,0.00072755944,0.00003134061,0.000015298741,0.00012066338,0.000024087267,0.00031486066,0.9942602,0.00036152665,0.00015532631,0.0031829916],"study_design_scores_gemma":[0.0001261383,0.0013357371,0.013266733,0.000009667325,0.000041298325,0.00079478347,0.00008222949,0.0034564126,0.97737724,0.00030987954,0.003188411,0.000011364049],"about_ca_topic_score_codex":0.00051267847,"about_ca_topic_score_gemma":0.000503763,"teacher_disagreement_score":0.0013665283,"about_ca_system_score_codex":0.00021223028,"about_ca_system_score_gemma":0.00027560449,"threshold_uncertainty_score":0.0045714974},"labels":[],"label_agreement":null},{"id":"W4413885244","doi":"10.1016/j.bneo.2025.100164","title":"Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"CD19; Refractory (planetary science); Lymphoma; Oncology; Medicine; Internal medicine; CAR T-cell therapy; Cancer research; Chimeric antigen receptor; Biology; Immunotherapy; Cancer","score_opus":0.025083253545016972,"score_gpt":0.320445708459025,"score_spread":0.29536245491400803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413885244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986021,0.0010293322,0.000043894568,0.000038707243,0.0000046024566,0.0000040273103,0.000049183174,0.0000022061693,0.00022589914],"genre_scores_gemma":[0.99957126,0.00018532548,0.00001496563,0.000037681148,0.000007784849,0.0000030852766,0.00012802304,9.299831e-7,0.000050980067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985087,0.000050062834,0.000016401396,0.000024565661,0.000020868418,0.000037126592],"domain_scores_gemma":[0.99931014,0.00020711988,0.00025793578,0.000025486108,0.000032815315,0.00016656666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034747433,0.00008132196,0.00029146118,0.0002450805,0.00014414176,0.00040540486,0.00009739019,0.00023275116,0.0008708253],"category_scores_gemma":[0.0010495831,0.000047766705,0.00039415364,0.00027300496,0.0001753233,0.00022990708,0.00023401286,0.0002651724,0.00013606735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009001714,0.000206294,0.925958,0.00014190676,0.00023616132,0.0011859637,0.00035350496,0.00041449306,0.004423425,0.000102903374,0.00052330986,0.057452306],"study_design_scores_gemma":[0.0002251052,0.003761134,0.9904919,0.000049422368,0.00022912573,0.0026147163,0.0003138792,0.00041670093,0.00061237864,0.00018830248,0.001088655,0.000008685662],"about_ca_topic_score_codex":0.0004033433,"about_ca_topic_score_gemma":0.000731341,"teacher_disagreement_score":0.0008708253,"about_ca_system_score_codex":0.00024089582,"about_ca_system_score_gemma":0.00015148126,"threshold_uncertainty_score":0.002913177},"labels":[],"label_agreement":null},{"id":"W4413924802","doi":"10.1101/2025.08.31.25334789","title":"Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphoblastic Leukemia; Refractory (planetary science); Medicine; Oncology; Leukemia; Meta-analysis; Cancer research; Internal medicine; Biology","score_opus":0.04058267434142196,"score_gpt":0.32124358521947605,"score_spread":0.2806609108780541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413924802","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002919649,0.99557906,0.00033656624,0.00014280577,0.000092625385,0.00025474277,0.00048063594,0.000015532652,0.0001783854],"genre_scores_gemma":[0.11022098,0.88519615,0.0014111034,0.0008216114,0.00020159797,0.0010974634,0.0007743754,0.00002210305,0.00025455587],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9926299,0.0033211664,0.0022445887,0.00074540294,0.00083103945,0.00022787185],"domain_scores_gemma":[0.98384124,0.011545998,0.002751802,0.00037676518,0.001273234,0.00021096593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010542075,0.0023717417,0.021077186,0.0067084786,0.00055518537,0.0031671016,0.0023840454,0.0021405637,0.0041167485],"category_scores_gemma":[0.024443002,0.0012812188,0.03322121,0.007657576,0.0007384592,0.0016463036,0.0013475874,0.0015797527,0.00030299881],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012400737,0.000025603465,0.0015603268,0.5981251,0.38670927,0.0001021019,0.00006250048,0.00041427626,0.00017563297,0.00012266374,0.00050224114,0.010960252],"study_design_scores_gemma":[0.00050575624,0.00019457244,0.002251149,0.043642905,0.9511108,0.00008868014,0.000042095617,0.00015539586,0.000096588024,0.0001804543,0.0017071739,0.000024379344],"about_ca_topic_score_codex":0.006046184,"about_ca_topic_score_gemma":0.010947061,"teacher_disagreement_score":0.021077186,"about_ca_system_score_codex":0.002641942,"about_ca_system_score_gemma":0.0037438374,"threshold_uncertainty_score":0.055752516},"labels":[],"label_agreement":null},{"id":"W4413949817","doi":"10.3390/curroncol32090495","title":"CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Medicine; Multiple myeloma; Social determinants of health; Health equity; Gerontology; Immunology; Pathology; Public health","score_opus":0.23815776165681662,"score_gpt":0.5489496916085798,"score_spread":0.31079192995176314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413949817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98122805,0.0024932616,0.00016512087,0.010981044,0.000053507814,0.000016494609,0.0011651414,0.0000041753215,0.003893198],"genre_scores_gemma":[0.99825925,0.000842885,0.000066447355,0.0005366918,0.00002533677,0.000010349604,0.00013557225,0.0000015166988,0.00012191261],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915767,0.00025198088,0.000036914185,0.000106883825,0.00005946315,0.00038715353],"domain_scores_gemma":[0.9985341,0.00021952258,0.0006338853,0.00003705776,0.00014419452,0.00043133087],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009561759,0.00016879561,0.00021316318,0.00076657545,0.0011570818,0.0012162692,0.0003647841,0.00043838914,0.0032341212],"category_scores_gemma":[0.0026489773,0.00016621967,0.0004955067,0.0011105784,0.0005445593,0.0010722015,0.0015224208,0.0010278486,0.00011436968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039259467,0.00008275795,0.98600465,0.000058096535,0.00008408004,0.00010248053,0.002690438,0.000106357,0.0001114109,0.0008703364,0.0012230331,0.0086272415],"study_design_scores_gemma":[0.0000072200296,0.00007219628,0.9876329,0.00024679623,0.000062510226,0.000090886904,0.008985597,0.00017189601,0.000045155324,0.0005276519,0.0021467255,0.000010348955],"about_ca_topic_score_codex":0.12849428,"about_ca_topic_score_gemma":0.16071855,"teacher_disagreement_score":0.12849428,"about_ca_system_score_codex":0.0019138121,"about_ca_system_score_gemma":0.002439255,"threshold_uncertainty_score":0.2554927},"labels":[],"label_agreement":null},{"id":"W4413969506","doi":"10.3390/biom15081096","title":"CD4/CD8–p56lck Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy","year":2025,"lang":"en","type":"review","venue":"Biomolecules","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Business","score_opus":0.09640532206609212,"score_gpt":0.41620899136199985,"score_spread":0.31980366929590776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413969506","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020232682,0.9978532,0.000141533,0.00024911438,0.0002606902,0.000004419586,0.000018739145,0.000009302162,0.0012606895],"genre_scores_gemma":[0.0008061624,0.9980488,0.00014722461,0.00015979675,0.00014068339,0.0000062750764,0.000027660097,0.0000012886645,0.00066203385],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998975,0.000015353648,0.000013168512,0.000016935364,0.000042959462,0.000014209541],"domain_scores_gemma":[0.9998778,0.0000537633,0.000016028553,0.0000042506044,0.000034242803,0.000013948178],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035050843,0.0005511611,0.00083204336,0.0013894426,0.00016021749,0.000661531,0.0005134291,0.0006794164,0.003267749],"category_scores_gemma":[0.00034014843,0.00020273318,0.0003653705,0.0013060669,0.00029312007,0.0009117746,0.00043827324,0.001493995,0.0018875424],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010357833,0.00009299615,0.00011542211,0.015537226,0.00007499494,0.00019322267,0.00005493035,0.0005118105,0.0051592207,0.004841055,0.024125347,0.9491903],"study_design_scores_gemma":[0.00001819506,0.00013592083,0.00064971653,0.002154131,0.0000702358,0.00089019316,0.000037160706,0.00011082474,0.00087510335,0.0018159229,0.9932288,0.000013773085],"about_ca_topic_score_codex":0.00043976997,"about_ca_topic_score_gemma":0.0008119166,"teacher_disagreement_score":0.003267749,"about_ca_system_score_codex":0.00054150063,"about_ca_system_score_gemma":0.00074585807,"threshold_uncertainty_score":0.010931671},"labels":[],"label_agreement":null},{"id":"W4413998514","doi":"10.3389/fimmu.2025.1649891","title":"FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8+ T cell responses and remodel the tumor microenvironment to enhance anti-tumor efficacy","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Tumor microenvironment; Cancer research; Dendritic cell; Cytotoxic T cell; Follicular dendritic cells; CD8; Tumor cells; Chemistry; Cell biology; Biology; T cell; Immune system; Immunology; Antigen-presenting cell; In vitro; Biochemistry","score_opus":0.009622239950817412,"score_gpt":0.2608458648255901,"score_spread":0.2512236248747727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413998514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97934556,0.0018375515,0.0134463785,0.0003012376,0.00011326031,0.00014098862,0.0018253811,0.0004808319,0.0025088007],"genre_scores_gemma":[0.98568416,0.0005628207,0.0094987815,0.00018484783,0.000025611978,0.00011064495,0.0008806276,0.00007291909,0.0029795938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998447,0.000012937116,0.000012092944,0.000040476,0.00003750368,0.000052272397],"domain_scores_gemma":[0.9999429,0.0000074808336,0.000015471773,0.000005982053,0.000007351339,0.00002076163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012663507,0.0003264031,0.00024917145,0.00021729339,0.0001338562,0.00024734557,0.00019824562,0.0003540446,0.0014444353],"category_scores_gemma":[0.00006462424,0.00010911281,0.00027071938,0.00014550654,0.00019512228,0.00018908444,0.00018970872,0.0008027324,0.00049264234],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005518922,0.000024698324,0.00007825835,0.000034767894,0.000002210691,0.000013937688,0.0000066080474,0.0001119131,0.99846673,0.000080323654,0.0000930737,0.0010322776],"study_design_scores_gemma":[0.000028286955,0.00014057537,0.0006552355,0.0000038645044,0.000012009282,0.000056620414,0.000008965163,0.0014921199,0.9942133,0.000056021105,0.0033295872,0.0000034204231],"about_ca_topic_score_codex":0.0003772101,"about_ca_topic_score_gemma":0.00066486385,"teacher_disagreement_score":0.0014444353,"about_ca_system_score_codex":0.00039002506,"about_ca_system_score_gemma":0.00029055448,"threshold_uncertainty_score":0.004832089},"labels":[],"label_agreement":null},{"id":"W4414029944","doi":"10.1101/2025.08.30.673295","title":"Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignancies","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Discovery Centre","funders":"Common Fund; Nationwide Children's Hospital","keywords":"Polyclonal antibodies; CD38; Cancer research; T cell; Medicine; Immunology; Biology; Stem cell; Cell biology; Antibody; Immune system","score_opus":0.02531008067084267,"score_gpt":0.2674429040765548,"score_spread":0.24213282340571213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414029944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9522142,0.008475166,0.027207872,0.00040743127,0.00017923994,0.00046150648,0.001458669,0.00088327023,0.008712699],"genre_scores_gemma":[0.9838758,0.0022008573,0.008383129,0.00012473475,0.000028523233,0.00016162316,0.0010992188,0.000049550184,0.004076492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991214,0.000010175367,0.000005757109,0.000019344216,0.00003615347,0.00001645073],"domain_scores_gemma":[0.9999608,0.000004388336,0.000008509551,0.000008826417,0.0000047183444,0.000012762952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010817399,0.00026236387,0.00017220256,0.00019737011,0.000107711625,0.00025075176,0.00024177253,0.00025345077,0.0019605937],"category_scores_gemma":[0.00006964486,0.00008958686,0.00016207981,0.000118301905,0.000113293776,0.00013795185,0.00015737937,0.00063048705,0.0008702231],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010596658,0.0001207398,0.00023249515,0.00007282504,0.0000073341807,0.00008196994,0.000021514828,0.00023635356,0.9822971,0.00019901656,0.0006561956,0.015968418],"study_design_scores_gemma":[0.000065175365,0.0010486004,0.0019875753,0.000020529533,0.00004945289,0.0012175033,0.000021250242,0.0014718715,0.96804136,0.00010784583,0.025962671,0.000006074482],"about_ca_topic_score_codex":0.0002864466,"about_ca_topic_score_gemma":0.00045083032,"teacher_disagreement_score":0.0019605937,"about_ca_system_score_codex":0.00017263212,"about_ca_system_score_gemma":0.00021786451,"threshold_uncertainty_score":0.006558895},"labels":[],"label_agreement":null},{"id":"W4414145598","doi":"10.54254/2753-8818/2025.ld26551","title":"CRISPR/Cas9 Applications in T Cell Modifications for Tumor Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Immunotherapy; T cell; Immune system; Cancer immunotherapy; T-cell receptor; Cell; Cytokine; Function (biology)","score_opus":0.011052386314404947,"score_gpt":0.3438042944885486,"score_spread":0.33275190817414363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414145598","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24800113,0.061564315,0.6143826,0.0041672857,0.0017256322,0.0007872534,0.0014420144,0.0051587652,0.062770955],"genre_scores_gemma":[0.7935056,0.032383814,0.14971624,0.0013568995,0.00021650316,0.00040248103,0.001042294,0.00030401177,0.021072155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992724,0.00012748431,0.00007211243,0.00018387617,0.00026448336,0.00007976433],"domain_scores_gemma":[0.9998091,0.000050410712,0.000047051264,0.000029786119,0.000042219745,0.000021458782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005268184,0.00061673345,0.0004343553,0.0006870993,0.0004282799,0.00094955676,0.0004431948,0.0010314254,0.0023649535],"category_scores_gemma":[0.0004565885,0.00029166075,0.0007494143,0.00046073392,0.000631374,0.0006468207,0.00057979295,0.0012767524,0.0008481842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014108776,0.00008193772,0.0008139119,0.00082319474,0.000051328592,0.00046140084,0.00013063588,0.0025814981,0.912304,0.0103450995,0.002531926,0.06973399],"study_design_scores_gemma":[0.000041904354,0.0003794662,0.0013212458,0.0000812933,0.000110123554,0.0014643852,0.000077745026,0.009916225,0.8865487,0.003583205,0.096421555,0.000054140368],"about_ca_topic_score_codex":0.0009811074,"about_ca_topic_score_gemma":0.001087359,"teacher_disagreement_score":0.0023649535,"about_ca_system_score_codex":0.0005810169,"about_ca_system_score_gemma":0.0006853986,"threshold_uncertainty_score":0.007911563},"labels":[],"label_agreement":null},{"id":"W4414179163","doi":"10.3899/jrheum.2024-1301","title":"Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Quality of life (healthcare); CD19; Disease; CAR T-cell therapy; Systemic lupus erythematosus; Lupus erythematosus; T cell; Cell therapy","score_opus":0.019540261994958504,"score_gpt":0.3337058611835677,"score_spread":0.3141655991886092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414179163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99801034,0.001132207,0.00011076915,0.00004033414,0.0000032352955,0.00003425338,0.00033573227,0.0000033209121,0.00032993167],"genre_scores_gemma":[0.9989716,0.0002444176,0.00012311956,0.000022614753,0.000012041433,0.000036562236,0.00045994532,0.0000014476265,0.00012824245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99897015,0.0006018811,0.000079894344,0.000087422355,0.00014434915,0.00011631246],"domain_scores_gemma":[0.9971879,0.0017334658,0.00053295953,0.00010783836,0.0001615203,0.00027629637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015858299,0.0004985385,0.0007726063,0.0005328887,0.00019380212,0.00047652837,0.00024554593,0.00029876916,0.0018894362],"category_scores_gemma":[0.0027603775,0.00013087633,0.0024208538,0.0005037947,0.00026474346,0.00029054092,0.00041872225,0.00044347983,0.0001305621],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.096316986,0.0042917607,0.80502456,0.0005641663,0.0066413437,0.0009668786,0.0002127277,0.008885029,0.0067716874,0.00017340652,0.00064622855,0.06950521],"study_design_scores_gemma":[0.0007573696,0.020928424,0.9724764,0.000024372472,0.0017408024,0.00033219394,0.0000637301,0.0020546399,0.00101847,0.000052404303,0.00053518236,0.000015972704],"about_ca_topic_score_codex":0.0012757533,"about_ca_topic_score_gemma":0.0013709586,"teacher_disagreement_score":0.0018894362,"about_ca_system_score_codex":0.00059644814,"about_ca_system_score_gemma":0.00041849798,"threshold_uncertainty_score":0.008386731},"labels":[],"label_agreement":null},{"id":"W4414249926","doi":"10.1111/hae.70128","title":"The Critical Need to Consolidate All Gene Therapy Data in Haemophilia","year":2025,"lang":"en","type":"letter","venue":"Haemophilia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hemophilia Society","funders":"","keywords":"Haemophilia; Clinical trial; Genetic enhancement; Dosing; Haemophilia A; Haemophilia B; Milestone; Targeted therapy","score_opus":0.10614457363458844,"score_gpt":0.39548131582477275,"score_spread":0.2893367421901843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414249926","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00088021765,0.58568,0.0065863896,0.3694521,0.030162929,0.00009326874,0.0010642409,0.0004330621,0.005647842],"genre_scores_gemma":[0.009970114,0.6458226,0.025427505,0.2258029,0.0853847,0.00024086879,0.0026904088,0.0004597533,0.004201065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98441124,0.0061178524,0.0019950736,0.001411598,0.0054692947,0.00059500383],"domain_scores_gemma":[0.8134681,0.09949957,0.008585831,0.011641917,0.052223608,0.014581082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.046174277,0.0013954698,0.00504868,0.005347487,0.0019008458,0.014420826,0.0044727027,0.011821652,0.022878857],"category_scores_gemma":[0.096993275,0.00093367754,0.0021394945,0.0044427766,0.006109401,0.025364038,0.0069053844,0.024103492,0.010318804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055694435,0.00025050392,0.0011702317,0.007364595,0.00028078223,0.00023537411,0.00027703185,0.00040768762,0.0020646295,0.0344717,0.35988298,0.5930376],"study_design_scores_gemma":[0.00006536684,0.00030151213,0.00074066233,0.0062153623,0.00016442453,0.0004131685,0.00023849023,0.00021476479,0.0005265531,0.018398043,0.97266924,0.000052323947],"about_ca_topic_score_codex":0.0021818131,"about_ca_topic_score_gemma":0.0036481994,"teacher_disagreement_score":0.046174277,"about_ca_system_score_codex":0.004786407,"about_ca_system_score_gemma":0.014658936,"threshold_uncertainty_score":0.24419582},"labels":[],"label_agreement":null},{"id":"W4414308830","doi":"10.1101/2025.09.17.676755","title":"Identifying Distinct Molecular Response of CAR-T cells to Solid Tumors by Synthetic Single-Cell Transcriptomic Analyses","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Transcriptome; CD8; Context (archaeology); Immune system; Solid tumor; Cell; Haematopoiesis; Cell therapy; Antigen","score_opus":0.034055235638650594,"score_gpt":0.306821314338097,"score_spread":0.2727660786994464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414308830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766901,0.00035178795,0.017227145,0.00007329147,0.000027617565,0.000048025075,0.0045870626,0.00015651416,0.00083845214],"genre_scores_gemma":[0.9789039,0.00038280187,0.013368459,0.00008970648,0.000011811408,0.00009950743,0.0053626434,0.000078643316,0.0017025347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989986,0.000010830765,0.000006846426,0.00003058784,0.000030546562,0.000021352591],"domain_scores_gemma":[0.999923,0.000022259755,0.000022955472,0.0000069582106,0.000013363477,0.000011487903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001462089,0.00022152472,0.00019229735,0.00022845963,0.00011543279,0.00031488165,0.00011779254,0.00020372201,0.00090713945],"category_scores_gemma":[0.00012594444,0.00007999259,0.00021796963,0.00018390763,0.00018321785,0.00010774152,0.00012031187,0.0003831104,0.0003831336],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027611317,0.00000320108,0.00018005767,0.000011585458,0.0000017755883,0.00000812328,0.0000051851043,0.000112279246,0.9992556,0.000031449203,0.000011764616,0.00035134214],"study_design_scores_gemma":[0.0000038575777,0.00008285881,0.005788495,0.000002066237,0.000010729759,0.00006568444,0.000035833633,0.0028661045,0.9901292,0.00009298066,0.0009178166,0.0000044176422],"about_ca_topic_score_codex":0.00023946256,"about_ca_topic_score_gemma":0.00031151116,"teacher_disagreement_score":0.00090713945,"about_ca_system_score_codex":0.00018769772,"about_ca_system_score_gemma":0.0001428377,"threshold_uncertainty_score":0.003034711},"labels":[],"label_agreement":null},{"id":"W4414352545","doi":"10.3390/cancers17183068","title":"Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Cell therapy; Synovial sarcoma; Sarcoma; Cell; Cancer therapy; Tumor microenvironment; Breakout","score_opus":0.052632595061025814,"score_gpt":0.37778315722771433,"score_spread":0.32515056216668853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414352545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008143447,0.9952159,0.00013261198,0.0024377569,0.0009823518,0.000007913961,0.000028080907,0.000009945833,0.0011039207],"genre_scores_gemma":[0.0006099992,0.99585354,0.00035453748,0.0017290177,0.00051273085,0.00001183225,0.000051846862,0.0000034778423,0.00087290735],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99957496,0.00007391012,0.00005494168,0.00006675045,0.00017031691,0.000059204664],"domain_scores_gemma":[0.9986614,0.0006380466,0.00011273475,0.000029518624,0.00041168052,0.00014658371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023174128,0.00095776696,0.0010556258,0.002173619,0.00038722155,0.0020984614,0.00075373414,0.0021645136,0.004356068],"category_scores_gemma":[0.0019578012,0.00034816453,0.00079288095,0.002177415,0.00066119217,0.0035743772,0.0012912153,0.004377733,0.0024485956],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014437245,0.000083866835,0.00015198348,0.011570672,0.00006238889,0.00019181828,0.000104109335,0.00045078315,0.0014558758,0.012782685,0.1397636,0.8332379],"study_design_scores_gemma":[0.000021959688,0.00008355686,0.00029316326,0.0036924283,0.000058632537,0.0003297821,0.00007153134,0.00007531806,0.00021753261,0.002056378,0.9930861,0.000013802056],"about_ca_topic_score_codex":0.0017322882,"about_ca_topic_score_gemma":0.0027566315,"teacher_disagreement_score":0.004356068,"about_ca_system_score_codex":0.0015446807,"about_ca_system_score_gemma":0.0037909083,"threshold_uncertainty_score":0.014572442},"labels":[],"label_agreement":null},{"id":"W4414384084","doi":"10.58931/cht.2025.4271","title":"Cellular Therapy and Follicular Lymphoma: Where Do We Stand in 2025?","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Follicular lymphoma; Follicular phase; Adverse effect; Lymphoma; Disease; International Prognostic Index","score_opus":0.01828241181672316,"score_gpt":0.28201133139322987,"score_spread":0.2637289195765067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384084","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019095189,0.98441666,0.000041786618,0.012765128,0.0014863919,0.00000482147,0.000022198124,0.0000054607067,0.0010666195],"genre_scores_gemma":[0.003038062,0.98283845,0.00030594788,0.010219171,0.0023843804,0.000018308197,0.000057425957,0.0000070760775,0.0011311795],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988764,0.00035943036,0.0001823863,0.00010511028,0.0003461632,0.00013050994],"domain_scores_gemma":[0.9959972,0.001817993,0.0003705232,0.000063921434,0.0013490986,0.00040122378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037031972,0.000529718,0.0016144064,0.0013424059,0.0007303335,0.0028089737,0.0010870384,0.002611547,0.0068859914],"category_scores_gemma":[0.0056132427,0.00024491933,0.000764008,0.0018923158,0.0012007813,0.0045583416,0.0010473606,0.0033134052,0.0020597696],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053362455,0.00006687106,0.00079545885,0.011759654,0.00017053974,0.00021229155,0.0002338829,0.00016370206,0.0007321241,0.0077427262,0.09684343,0.8807457],"study_design_scores_gemma":[0.00008855305,0.0002816729,0.0014534644,0.016165076,0.00028168256,0.0003726682,0.0006447505,0.00008788019,0.00011881744,0.0048394143,0.9756309,0.00003508591],"about_ca_topic_score_codex":0.011622723,"about_ca_topic_score_gemma":0.037132036,"teacher_disagreement_score":0.011622723,"about_ca_system_score_codex":0.0026053155,"about_ca_system_score_gemma":0.0073485007,"threshold_uncertainty_score":0.023110151},"labels":[],"label_agreement":null},{"id":"W4414444386","doi":"10.1136/jitc-2024-010792","title":"T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"European Regional Development Fund; Instituto de Salud Carlos III; Generalitat de Catalunya; Agència de Gestió d'Ajuts Universitaris i de Recerca; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; Fundación Científica Asociación Española Contra el Cáncer","keywords":"Immune system; Immunogenicity; Peripheral blood mononuclear cell; Monoclonal antibody; Antigen; Antibody; Chimeric antigen receptor; Immunotherapy","score_opus":0.0330377316831344,"score_gpt":0.38629744154714707,"score_spread":0.35325970986401267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414444386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438125,0.0021153935,0.0004466024,0.00028407114,0.0000078544435,0.000017815863,0.00006271315,0.000019196255,0.0026650957],"genre_scores_gemma":[0.999025,0.00037156203,0.00009822006,0.000086844055,0.00001676411,0.0000066629887,0.00008200733,0.0000030474591,0.00030982465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998186,0.000039755658,0.000020067666,0.000027131462,0.000034747765,0.00005966244],"domain_scores_gemma":[0.99972314,0.00009867725,0.00009504244,0.000017059472,0.000019033883,0.000046998834],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028951067,0.00014443274,0.00023204146,0.00020960553,0.00016701788,0.0004925083,0.0001513568,0.00034529087,0.00093401887],"category_scores_gemma":[0.0005679544,0.000058658236,0.00018808593,0.00012815963,0.00020416867,0.00022877853,0.00013927558,0.000518865,0.00018849778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056583337,0.0009816041,0.51185036,0.00042029255,0.00015266228,0.05580471,0.0013888272,0.0016474637,0.18062256,0.0015981507,0.0023484977,0.23752658],"study_design_scores_gemma":[0.00040385593,0.008805765,0.65845615,0.00014470355,0.00045369967,0.19722869,0.0011464288,0.0055099754,0.103544265,0.0013027549,0.022956612,0.00004711251],"about_ca_topic_score_codex":0.0005135239,"about_ca_topic_score_gemma":0.00051163795,"teacher_disagreement_score":0.00093401887,"about_ca_system_score_codex":0.00034492306,"about_ca_system_score_gemma":0.00013829944,"threshold_uncertainty_score":0.003124535},"labels":[],"label_agreement":null},{"id":"W4414466003","doi":"10.1158/2326-6074.cimm25-b004","title":"Abstract B004: Route dependent T-cell activation by mRNA cluster therapies","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Peripheral blood mononuclear cell; Immunogenicity; Flow cytometry; Messenger RNA; Cell; T cell; Immunotherapy; CD8; Cancer vaccine","score_opus":0.053018574797816256,"score_gpt":0.40494907590402934,"score_spread":0.3519305011062131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414466003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95722985,0.00763617,0.017604798,0.00072365097,0.00038797318,0.00057524943,0.0010421637,0.0008621626,0.013938021],"genre_scores_gemma":[0.970689,0.002492284,0.008854686,0.00027020983,0.00011267416,0.00030783744,0.0012438564,0.00011392147,0.015915446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998549,0.00002580925,0.000007475903,0.00003050836,0.00004664866,0.000034582208],"domain_scores_gemma":[0.9999467,0.000011183901,0.000015233722,0.0000055746746,0.0000103946995,0.000010864335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016874299,0.0005128488,0.00028282922,0.00022917609,0.00010464742,0.00039828845,0.00027400916,0.00048570387,0.0066734846],"category_scores_gemma":[0.00014054644,0.00010791941,0.00025668417,0.000120778444,0.0001759894,0.00023569404,0.00020378456,0.0007854627,0.0024726996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047590793,0.00018190836,0.000087831846,0.00011336472,0.0000067499864,0.000033791028,0.000010220762,0.00022200859,0.98727536,0.00014383906,0.0005043489,0.010944766],"study_design_scores_gemma":[0.00033241673,0.0063738334,0.002054144,0.00003234187,0.0000641144,0.00038921722,0.00002369506,0.0027765601,0.97112983,0.00018936272,0.016623072,0.0000114802115],"about_ca_topic_score_codex":0.0003230057,"about_ca_topic_score_gemma":0.00033175017,"teacher_disagreement_score":0.0066734846,"about_ca_system_score_codex":0.00029701486,"about_ca_system_score_gemma":0.0003339734,"threshold_uncertainty_score":0.022325039},"labels":[],"label_agreement":null},{"id":"W4414490680","doi":"10.1182/bloodadvances.2025017081","title":"Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Bundesamt für Gesundheit; European Commission; European Federation of Pharmaceutical Industries and Associations; Ministerie van Volksgezondheid, Welzijn en Sport; AstraZeneca; Celgene; Gilead Sciences; National Institute for Health and Care Excellence; Eli Lilly and Company; Pulmonary Fibrosis Foundation","keywords":"Quality of life (healthcare); Cohort; Anxiety; Disease; Cohort study; MEDLINE; Depression (economics)","score_opus":0.011472708846043041,"score_gpt":0.2682026959169495,"score_spread":0.25672998707090644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414490680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99845433,0.0004995833,0.000044506272,0.0000667134,0.000005882629,0.00000934243,0.0005615906,0.0000024826186,0.00035567855],"genre_scores_gemma":[0.9990138,0.00013733699,0.00003605408,0.00004983608,0.0000061947308,0.000011670983,0.0006895738,9.109447e-7,0.000054604403],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863845,0.0006153197,0.00021606204,0.00018042418,0.00020964109,0.0001401291],"domain_scores_gemma":[0.997543,0.0005178682,0.0013537315,0.00006090876,0.00023981118,0.00028468046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020606844,0.00020877397,0.00043302838,0.0008400397,0.00025372714,0.00085667416,0.00029751335,0.00055331027,0.00085191824],"category_scores_gemma":[0.0040520686,0.000104616585,0.0005471851,0.0018768606,0.0002726626,0.00054288027,0.0006178842,0.00040106793,0.0001355191],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025669334,0.00007319005,0.9966671,0.0000253536,0.0001234217,0.00006881971,0.000087970635,0.00014964982,0.000054111,0.000017419958,0.0001737308,0.0023026494],"study_design_scores_gemma":[0.000031149844,0.00022282361,0.99878305,0.000016302847,0.000050133473,0.00018291114,0.00017440841,0.000186417,0.000049118582,0.0000147829805,0.00028374145,0.000005200367],"about_ca_topic_score_codex":0.002609872,"about_ca_topic_score_gemma":0.0015779164,"teacher_disagreement_score":0.002609872,"about_ca_system_score_codex":0.00049682806,"about_ca_system_score_gemma":0.00031239117,"threshold_uncertainty_score":0.010898054},"labels":[],"label_agreement":null},{"id":"W4414491793","doi":"10.1158/2326-6074.cimm25-ia08","title":"Abstract IA08: Development and use of Engineered Regulatory T cells to treat Autoimmune Diseases","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Peripheral tolerance; Immune tolerance; Effector; T cell; Population; Immunotherapy; Antigen; Regulatory T cell","score_opus":0.06425826163130895,"score_gpt":0.3799349477968155,"score_spread":0.3156766861655066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414491793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8746755,0.044390693,0.05289419,0.0011673153,0.0010113184,0.00057468645,0.0012551601,0.0011992656,0.022831907],"genre_scores_gemma":[0.93473005,0.013166678,0.0355259,0.0005516445,0.00018223011,0.00042656861,0.0014703717,0.00010827452,0.013838305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998944,0.000018571089,0.000007776612,0.000021016405,0.00003651033,0.000021743672],"domain_scores_gemma":[0.9999522,0.000005223852,0.000012730579,0.000004462457,0.000010453948,0.000014887614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022621425,0.00038874388,0.00017772632,0.0003012501,0.00007826343,0.00032700953,0.0003374519,0.0003704318,0.000927294],"category_scores_gemma":[0.00010598396,0.00007591743,0.00020629635,0.00013102156,0.00017944924,0.00013811138,0.00016026881,0.0007117015,0.0006408008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026703725,0.00019096328,0.00026331376,0.00017023252,0.000015910684,0.00016189464,0.000024670226,0.0006215642,0.9432477,0.0007748047,0.0010891249,0.05317288],"study_design_scores_gemma":[0.00031622787,0.0050305277,0.0016320848,0.00007216227,0.000081249906,0.0013880893,0.000018220459,0.0025931785,0.9243668,0.0002607645,0.06422252,0.00001822402],"about_ca_topic_score_codex":0.00027964197,"about_ca_topic_score_gemma":0.00022210399,"teacher_disagreement_score":0.000927294,"about_ca_system_score_codex":0.00019992977,"about_ca_system_score_gemma":0.0002835374,"threshold_uncertainty_score":0.0031021237},"labels":[],"label_agreement":null},{"id":"W4414508324","doi":"10.1080/2162402x.2025.2562210","title":"IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy","year":2025,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Discovery Centre","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care","keywords":"Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; T cell; Ovarian cancer; Tumor microenvironment; Cell therapy; Antigen; Cancer","score_opus":0.01529819831688233,"score_gpt":0.32126101308457927,"score_spread":0.30596281476769693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414508324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942159,0.00087084464,0.0027899882,0.000043520726,0.000032322183,0.000027665119,0.00020736415,0.00007383284,0.0017385593],"genre_scores_gemma":[0.9957747,0.00048445226,0.0015018506,0.000031509873,0.000006418987,0.000023246666,0.00031131206,0.000012249117,0.0018543488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987054,0.000019033512,0.000013710018,0.000024174027,0.000037571095,0.00003494468],"domain_scores_gemma":[0.9999572,0.0000067755486,0.000012552913,0.000008805754,0.000005213118,0.000009502531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008338695,0.00026979405,0.0001543229,0.00009895786,0.00007609551,0.00030540104,0.00012235506,0.00024672848,0.0012652038],"category_scores_gemma":[0.00008092866,0.000057131725,0.00015602192,0.00009648541,0.00012274655,0.00016993996,0.0001436026,0.00039342046,0.0003788316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006573356,0.000032061165,0.00011754875,0.000024672168,0.0000018805099,0.00003127513,0.000010915755,0.00014862006,0.99750745,0.000077247474,0.000037408234,0.0019451469],"study_design_scores_gemma":[0.0000062730114,0.00021578044,0.001059976,0.0000027458439,0.000006115023,0.00016260274,0.000011480495,0.00055056554,0.9961145,0.000017590612,0.0018507679,0.0000016871301],"about_ca_topic_score_codex":0.000118026524,"about_ca_topic_score_gemma":0.00017914442,"teacher_disagreement_score":0.0012652038,"about_ca_system_score_codex":0.00010707905,"about_ca_system_score_gemma":0.00012417551,"threshold_uncertainty_score":0.004232526},"labels":[],"label_agreement":null},{"id":"W4414542568","doi":"10.1038/s41467-025-63338-w","title":"CD137L promotes immune surveillance in melanoma via HLTF regulation","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; Xiangya Hospital, Central South University; China Postdoctoral Science Foundation; Central South University; National Natural Science Foundation of China","keywords":"Immune system; Melanoma; Transcription factor; Immune checkpoint; Immunotherapy; Regulator; Immunity; Transcriptome; Transcriptional regulation; Mediator","score_opus":0.020476741972426715,"score_gpt":0.3537408475515789,"score_spread":0.3332641055791522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414542568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.867389,0.053280316,0.014195532,0.031102382,0.010206035,0.00036396986,0.0015551205,0.0011026529,0.020804878],"genre_scores_gemma":[0.9666354,0.009688244,0.0027457366,0.0055432776,0.0015284105,0.000097571545,0.00043514438,0.00006947269,0.013256715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998394,0.000036481106,0.0000123818045,0.000027049507,0.00005456943,0.000030062878],"domain_scores_gemma":[0.9998841,0.000021134048,0.000034444776,0.0000069032003,0.000025975449,0.000027433238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003341916,0.00023615721,0.00019935658,0.00015483968,0.0001369381,0.0004361109,0.00014009057,0.0003740771,0.0024273884],"category_scores_gemma":[0.00033375603,0.000093609764,0.00025863052,0.000060213824,0.00017319502,0.00030528053,0.00022622463,0.0006916862,0.00055327755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013754895,0.00016516101,0.0018418463,0.0008167954,0.000049880655,0.00066310895,0.0001164166,0.00027152782,0.91070217,0.0026246083,0.023317317,0.058055744],"study_design_scores_gemma":[0.00070569286,0.0032392137,0.019729462,0.00025087278,0.0002018969,0.003882629,0.00019968562,0.0031873048,0.7693863,0.0025199607,0.19666179,0.000035212266],"about_ca_topic_score_codex":0.00016905398,"about_ca_topic_score_gemma":0.00035819734,"teacher_disagreement_score":0.0024273884,"about_ca_system_score_codex":0.0003429039,"about_ca_system_score_gemma":0.0003072605,"threshold_uncertainty_score":0.008120477},"labels":[],"label_agreement":null},{"id":"W4414582304","doi":"10.1158/1538-7445.pancreatic25-a114","title":"Abstract A114: CCK-B Receptor Blockade with Proglumide Enhances Antitumor Activity and Persistence of CD8+CD161+ CAR-T Cells in Pancreatic Ductal Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"CD8; Immunotherapy; Tumor microenvironment; Immune system; T cell; Receptor; Flow cytometry; Proglumide","score_opus":0.05291562931985745,"score_gpt":0.3681261127798817,"score_spread":0.3152104834600243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414582304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729186,0.0006818001,0.00054277293,0.000069534464,0.00004490244,0.000034885186,0.00021410402,0.000073699535,0.0010464388],"genre_scores_gemma":[0.9954686,0.0003645207,0.000709096,0.000048476082,0.00002027432,0.000076086115,0.00043148862,0.000011225827,0.002870307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998882,0.000019402985,0.000013301753,0.000021106578,0.000019787956,0.00003817522],"domain_scores_gemma":[0.9999385,0.000009650843,0.00001233172,0.000008707674,0.0000052097007,0.000025624222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109036875,0.00027799516,0.00033776183,0.00015907442,0.00009539508,0.00022771761,0.00016876616,0.00022766225,0.002136212],"category_scores_gemma":[0.00008196856,0.0000923658,0.00022453644,0.000107520245,0.00016971973,0.00015742995,0.00012226771,0.00079062086,0.0005009675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009002927,0.00042983814,0.00022029928,0.000059335904,0.0000075298417,0.000056314027,0.00001707807,0.00012445306,0.993664,0.00006110633,0.00017152507,0.0042882296],"study_design_scores_gemma":[0.00027310653,0.0077273985,0.0045905593,0.00000697686,0.000034981076,0.00031300203,0.000030573778,0.0012481473,0.98256505,0.000035113833,0.0031695962,0.000005350135],"about_ca_topic_score_codex":0.00039508485,"about_ca_topic_score_gemma":0.00042478924,"teacher_disagreement_score":0.002136212,"about_ca_system_score_codex":0.00016588213,"about_ca_system_score_gemma":0.00021137566,"threshold_uncertainty_score":0.007146299},"labels":[],"label_agreement":null},{"id":"W4414606164","doi":"10.1038/s41467-025-63579-9","title":"Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Pharmacokinetics; Adverse effect; Clinical trial; Drug; Immunotherapy; Pharmacodynamics","score_opus":0.018662909956790878,"score_gpt":0.3753721925454597,"score_spread":0.35670928258866885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414606164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934088,0.0027629589,0.00055578345,0.00039297942,0.00009874202,0.0011439631,0.0005514865,0.00007858936,0.001006678],"genre_scores_gemma":[0.993782,0.0014695205,0.00090761896,0.0005366178,0.0001122155,0.00096410513,0.0009324998,0.0000136884655,0.0012816959],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9997538,0.0001132287,0.000012619178,0.000038925078,0.000024963396,0.000056484678],"domain_scores_gemma":[0.9995708,0.00009912065,0.000089519526,0.00002961264,0.00002758741,0.00018330241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011565568,0.0009730634,0.0011427832,0.00020243398,0.0002453241,0.0008618716,0.0003929894,0.0010095272,0.0021777817],"category_scores_gemma":[0.0007168521,0.00029060186,0.0008131182,0.00022445338,0.00048340834,0.00066893117,0.00021932033,0.0016617412,0.0005576039],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7278467,0.03082186,0.00736854,0.0012488925,0.0009176294,0.00054735073,0.00046033002,0.0034491464,0.0568743,0.00050547236,0.0041307914,0.16582894],"study_design_scores_gemma":[0.57300806,0.4083965,0.008198553,0.000054234228,0.00024213298,0.0003837536,0.000046208053,0.0020179886,0.004581732,0.00027326203,0.0027719918,0.000025510019],"about_ca_topic_score_codex":0.0002968201,"about_ca_topic_score_gemma":0.0005672716,"teacher_disagreement_score":0.0021777817,"about_ca_system_score_codex":0.00059472077,"about_ca_system_score_gemma":0.00080898544,"threshold_uncertainty_score":0.0072853565},"labels":[],"label_agreement":null},{"id":"W4414800233","doi":"10.1093/neuonc/noaf193.286","title":"P08.18.B PROSPECTIVE EVALUATION OF NEUROLOGICAL SAFETY AFTER ANTI-BCMA CAR T-CELL THERAPY IN A SINGLE-CENTRE COHORT","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Cohort; Prospective cohort study; Neurotoxicity; Cognition; Post-concussion syndrome; Neurological examination; Cohort study","score_opus":0.04003583211486778,"score_gpt":0.350929074696149,"score_spread":0.3108932425812812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414800233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99793625,0.00026804494,0.00016591053,0.000019422554,0.000007346872,0.00011847891,0.0010794038,0.000010287968,0.0003947945],"genre_scores_gemma":[0.9972108,0.00010980108,0.0002425845,0.00005443578,0.000022491107,0.00020147358,0.001858055,0.000007964194,0.00029241582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992919,0.000191805,0.00007700586,0.00026677377,0.00008982752,0.0000827376],"domain_scores_gemma":[0.9982869,0.00015998619,0.00073345995,0.00015865685,0.00030182383,0.00035925268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010190804,0.00044312532,0.0005698438,0.00067233294,0.0006112372,0.00062397565,0.00043527773,0.0003700871,0.0019530635],"category_scores_gemma":[0.0015403595,0.0002757564,0.00062704517,0.00066688407,0.00030927456,0.0004338709,0.000504316,0.00044858942,0.0009990927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037840253,0.0004109656,0.98687416,0.0000878093,0.00027607495,0.0005361901,0.00014216949,0.00010546757,0.0017481077,0.000020402034,0.0006011078,0.005413555],"study_design_scores_gemma":[0.0004302739,0.006576681,0.98846626,0.00002731501,0.00023604176,0.0019498646,0.00013428683,0.00029605845,0.00060148677,0.000030550134,0.001232763,0.000018332641],"about_ca_topic_score_codex":0.0017490983,"about_ca_topic_score_gemma":0.0014358289,"teacher_disagreement_score":0.0019530635,"about_ca_system_score_codex":0.00040237283,"about_ca_system_score_gemma":0.00062440627,"threshold_uncertainty_score":0.0065336823},"labels":[],"label_agreement":null},{"id":"W4414857438","doi":"10.1093/oncolo/oyaf330","title":"Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"Daiichi Sankyo Europe; U.S. Food and Drug Administration; Celgene; MorphoSys; Gilead Sciences; Kite Pharma; Incyte; BeiGene; TG Therapeutics; Seagen; Karyopharm Therapeutics; AstraZeneca","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Standard of care; Salvage therapy; Clinical trial","score_opus":0.02572095470819502,"score_gpt":0.3219684897978651,"score_spread":0.29624753508967006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414857438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904497,0.00068035896,0.00006110823,0.00017670738,0.0000116406745,0.00013732577,0.0073511573,0.000007866767,0.0011239855],"genre_scores_gemma":[0.9885771,0.0006596424,0.00022532405,0.0003461418,0.000026918153,0.000099727535,0.009607273,0.00000837269,0.0004494275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861157,0.0001214665,0.00008801065,0.00028474987,0.00041505723,0.0004791241],"domain_scores_gemma":[0.99771774,0.00011263887,0.00080492796,0.00015715441,0.00073629786,0.00047120097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092805503,0.00078401563,0.0007973504,0.0012373339,0.0022494616,0.0010323796,0.001623631,0.0005412506,0.0014513598],"category_scores_gemma":[0.0018266218,0.0004373315,0.0011149703,0.0041345493,0.00062989636,0.00033908288,0.0010733743,0.0007565648,0.00021795799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008189631,0.00011820936,0.9924777,0.00009986175,0.000305449,0.00016146337,0.00033742786,0.00015118762,0.00031969202,0.000082209466,0.0017153872,0.0034124001],"study_design_scores_gemma":[0.00013280283,0.00017301702,0.9964142,0.00003985996,0.00015558832,0.00020726825,0.00069304585,0.00020792714,0.00008082014,0.000020133866,0.0018527501,0.000022509175],"about_ca_topic_score_codex":0.94813454,"about_ca_topic_score_gemma":0.96847814,"teacher_disagreement_score":0.05186546,"about_ca_system_score_codex":0.025847903,"about_ca_system_score_gemma":0.02577343,"threshold_uncertainty_score":0.18754053},"labels":[],"label_agreement":null},{"id":"W4414913470","doi":"10.1007/978-3-032-00767-4_188","title":"Targeting CAR T Cells’ Metabolic Pathways to Boost Their Effectiveness Against Tumors","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Tumor microenvironment; Metabolic pathway; T cell; Immunotherapy; Immune system; Metabolism; Effector; Antigen","score_opus":0.024557285015834134,"score_gpt":0.2725037007201503,"score_spread":0.24794641570431616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414913470","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009865658,0.13725226,0.0711261,0.005446036,0.0048378306,0.00014469576,0.000701771,0.0011788127,0.76944673],"genre_scores_gemma":[0.034668986,0.07001422,0.020611754,0.0026499478,0.0005487124,0.00011822954,0.00040322036,0.0003165722,0.8706684],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995756,0.000004227458,0.0000010615719,0.000007964258,0.00002227186,0.0000068287186],"domain_scores_gemma":[0.9999759,0.000010224303,0.0000016024768,0.0000021558767,0.000006581756,0.0000036520737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013252029,0.0004901838,0.00022218088,0.000398312,0.00021547411,0.0009933473,0.00035953862,0.0004815292,0.02509331],"category_scores_gemma":[0.00010052795,0.00018978327,0.00022292993,0.00028990646,0.00027372793,0.0009725708,0.00038633327,0.0014155135,0.010745392],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012413322,0.0001597166,0.00006988956,0.00079785375,0.000018710633,0.00014512768,0.0001352562,0.002151684,0.12636535,0.16739918,0.15389298,0.54874015],"study_design_scores_gemma":[0.000010682164,0.00005699298,0.0000801731,0.00008046072,0.000008786875,0.00021421863,0.000027991928,0.0007877661,0.031663124,0.012195128,0.95486635,0.000008293232],"about_ca_topic_score_codex":0.0005285471,"about_ca_topic_score_gemma":0.0012438773,"teacher_disagreement_score":0.02509331,"about_ca_system_score_codex":0.00059564994,"about_ca_system_score_gemma":0.00030771462,"threshold_uncertainty_score":0.08394551},"labels":[],"label_agreement":null},{"id":"W4414925391","doi":"10.3389/fimmu.2025.1675786","title":"Production of functional CD19 CAR T cells under hypoxic manufacturing conditions","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Center for Innovative Medicine; National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden","keywords":"CD19; Phenotype; Hypoxia (environmental); Chimeric antigen receptor; T cell; Cell","score_opus":0.016065437097900395,"score_gpt":0.2731994918521396,"score_spread":0.2571340547542392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414925391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99331665,0.00034352398,0.004076477,0.000041217136,0.000018755862,0.00006875169,0.00037124127,0.00007331126,0.0016901024],"genre_scores_gemma":[0.9910268,0.00022922804,0.004712214,0.00004875676,0.00001668033,0.00009598345,0.0008283588,0.000024399744,0.0030175673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997867,0.0000453699,0.000019942672,0.00004052935,0.000048679856,0.000058930447],"domain_scores_gemma":[0.9998759,0.000023864512,0.000030677988,0.000022723863,0.000020399126,0.000026530934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016418453,0.00032996456,0.0001987887,0.00014082238,0.00012535676,0.00028289424,0.00018045439,0.00027400444,0.002480695],"category_scores_gemma":[0.00014420816,0.00011383252,0.0001708995,0.000093191775,0.00014097661,0.00012668254,0.00030386465,0.00030335697,0.00046269578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007111454,0.000016865155,0.00024735587,0.000021002043,0.0000022596446,0.000038507253,0.000020719686,0.000081592654,0.99859947,0.000033028817,0.000035576693,0.00083258405],"study_design_scores_gemma":[0.000028143764,0.0010788891,0.0033002533,0.000006443539,0.000023838289,0.00044102565,0.000037612746,0.00080003805,0.99017906,0.00003250707,0.0040663686,0.0000058948335],"about_ca_topic_score_codex":0.00031893956,"about_ca_topic_score_gemma":0.00043975492,"teacher_disagreement_score":0.002480695,"about_ca_system_score_codex":0.00013124938,"about_ca_system_score_gemma":0.00012567501,"threshold_uncertainty_score":0.008298695},"labels":[],"label_agreement":null},{"id":"W4415050492","doi":"10.1158/0008-5472.can-25-3596","title":"Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Helen and Martin Kimmel Center for Molecular Design, Weizmann Institute of Science; National Cancer Institute; European Research Council; Azrieli Foundation; Israel Science Foundation; Lotte and John Hecht Memorial Foundation; Elsie and Marvin Dekelboum Family Foundation; Deutsche Forschungsgemeinschaft","keywords":"Lymphoma; Peripheral blood; Immune system; Diffuse large B-cell lymphoma; Peripheral","score_opus":0.02317539412967375,"score_gpt":0.3376043002972652,"score_spread":0.31442890616759145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415050492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99953246,0.00011125244,0.00014012445,0.000009503133,9.681675e-7,0.000003882125,0.0000699942,0.000005058284,0.00012689662],"genre_scores_gemma":[0.9995734,0.000041587817,0.00008729448,0.000015540365,0.000002759868,0.0000065663826,0.00016329858,0.0000024811668,0.000107141845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998204,0.000045213343,0.000017562668,0.00004317596,0.00003525257,0.000038402817],"domain_scores_gemma":[0.9997048,0.00007291847,0.000117838594,0.000026504089,0.000031473483,0.00004639181],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021601965,0.00011844966,0.00021379661,0.00038487298,0.00012982207,0.00035909557,0.000093294206,0.00020957313,0.0009582128],"category_scores_gemma":[0.00068922195,0.00009172908,0.000073732954,0.0003152526,0.00020673744,0.00012660453,0.00015663338,0.0002652265,0.00024606715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029722895,0.00020611323,0.79540026,0.000067399495,0.00007099685,0.0005541971,0.0003342275,0.00038506655,0.17933553,0.00008081539,0.00026073103,0.020332262],"study_design_scores_gemma":[0.000025603502,0.0006555941,0.98178893,0.000007775684,0.00004722909,0.0014230737,0.00023675928,0.0006683789,0.014634009,0.000094476694,0.00041304427,0.0000051196703],"about_ca_topic_score_codex":0.00032272466,"about_ca_topic_score_gemma":0.0005747103,"teacher_disagreement_score":0.0009582128,"about_ca_system_score_codex":0.00012973434,"about_ca_system_score_gemma":0.00010489528,"threshold_uncertainty_score":0.0032055378},"labels":[],"label_agreement":null},{"id":"W4415054617","doi":"10.1016/j.retram.2025.103547","title":"HLA molecules: Another challenge for CAR T cell therapy","year":2025,"lang":"en","type":"review","venue":"Current Research in Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Human leukocyte antigen; Immune system; T cell; Disease; Evasion (ethics); CAR T-cell therapy; Genetic enhancement; Cell therapy","score_opus":0.39991823808502097,"score_gpt":0.5431795299907464,"score_spread":0.1432612919057254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415054617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006908588,0.99360037,0.00039621675,0.0034664,0.0010536955,0.0000041255203,0.000022516768,0.000019324247,0.0013682599],"genre_scores_gemma":[0.0012078641,0.99023473,0.0006091441,0.004077286,0.0015239113,0.000017176053,0.000056205216,0.0000071497134,0.002266451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99960536,0.000115038376,0.000032662003,0.000064443964,0.00013266546,0.000049848186],"domain_scores_gemma":[0.99897385,0.00065761706,0.00005749242,0.000032314885,0.00020041064,0.0000782869],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016050166,0.00093543617,0.0021375,0.0012268838,0.00041219057,0.002342954,0.001337896,0.0031162065,0.0073037767],"category_scores_gemma":[0.00170491,0.00028386415,0.00061599974,0.0010854407,0.0012551831,0.0032936165,0.001250512,0.0056041176,0.0042941184],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012648178,0.00006550178,0.0000947153,0.0059752064,0.00005857459,0.00017989789,0.00004991284,0.00036340614,0.0015478218,0.01910917,0.12475373,0.8476756],"study_design_scores_gemma":[0.000026302738,0.000059483147,0.00008070974,0.0014032108,0.000037342215,0.00031453563,0.000040357005,0.00007905355,0.00017967306,0.004069563,0.9936999,0.000009872232],"about_ca_topic_score_codex":0.0012609318,"about_ca_topic_score_gemma":0.0020091485,"teacher_disagreement_score":0.0073037767,"about_ca_system_score_codex":0.0011821802,"about_ca_system_score_gemma":0.0022175142,"threshold_uncertainty_score":0.024433553},"labels":[],"label_agreement":null},{"id":"W4415071401","doi":"10.1016/j.jtct.2025.10.006","title":"CAR-T for Management of R/R PTLD Following Lung Transplant: A Multi-center Retrospective Study","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Sleep Society; University Health Network; Dalhousie University; Princess Margaret Cancer Centre; Juravinski Hospital; Juravinski Cancer Centre","funders":"","keywords":"Tocilizumab; Immunosuppression; Lung; Retrospective cohort study; Cytokine release syndrome; Lung transplantation; Lymphoproliferative disorders; Malignancy","score_opus":0.026374471961739816,"score_gpt":0.3312877172294737,"score_spread":0.3049132452677339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415071401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680173,0.0018528531,0.0005074119,0.00004614989,0.000013106276,0.00002439252,0.00015644456,0.0000034763498,0.0005943674],"genre_scores_gemma":[0.99916327,0.00037088714,0.000111933936,0.000044607717,0.000016051014,0.000007944473,0.00021199782,0.0000031737532,0.000070033435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992568,0.00017679362,0.00013051867,0.00020527204,0.00010164514,0.00012896856],"domain_scores_gemma":[0.9989723,0.00021785249,0.00046381814,0.00011520534,0.00008196423,0.00014892848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075728854,0.00027626375,0.0005219964,0.0006529108,0.0005473814,0.00091610424,0.00032835035,0.00050258264,0.0014537873],"category_scores_gemma":[0.0013812864,0.00026732704,0.0007939727,0.0010253286,0.00051508227,0.00064347824,0.00043197605,0.000654998,0.00022392155],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007684505,0.00010036113,0.9906731,0.000061341045,0.00027838585,0.0024606332,0.00011041093,0.00011547817,0.00094420166,0.00011641929,0.00013049899,0.0042406796],"study_design_scores_gemma":[0.00010795413,0.0016962631,0.95943093,0.000109584325,0.0010620746,0.030522965,0.0016429978,0.0008303276,0.0010448662,0.00033330952,0.00317037,0.000048271188],"about_ca_topic_score_codex":0.00070070947,"about_ca_topic_score_gemma":0.0010263122,"teacher_disagreement_score":0.0014537873,"about_ca_system_score_codex":0.00039085658,"about_ca_system_score_gemma":0.0005223884,"threshold_uncertainty_score":0.0048633814},"labels":[],"label_agreement":null},{"id":"W4415071610","doi":"10.1101/2025.10.09.681473","title":"Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec; University of Victoria","funders":"Canadian Institutes of Health Research; Ovarian Cancer Canada; Université Laval","keywords":"Autophagy; Cytolysis; Chimeric antigen receptor; Tumor microenvironment; Ovarian cancer; Immunotherapy; Cytotoxicity; Reprogramming; Cell culture","score_opus":0.015645507621628862,"score_gpt":0.2742481101298869,"score_spread":0.25860260250825806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415071610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908235,0.0007210817,0.0050510596,0.00013017768,0.00004357056,0.000031521213,0.0005916789,0.00017676462,0.0024306842],"genre_scores_gemma":[0.9948343,0.00017433593,0.001664355,0.00004343531,0.0000069360026,0.000016935992,0.00035242748,0.000038972496,0.0028682717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991536,0.000011630339,0.0000053741765,0.000022326021,0.000017946359,0.000027261414],"domain_scores_gemma":[0.99996746,0.0000063613725,0.000008088422,0.0000042430665,0.00000405343,0.000009828136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000091496884,0.00019413725,0.00019974151,0.00013102505,0.0001078765,0.00028141603,0.000102326776,0.00023811293,0.0018804023],"category_scores_gemma":[0.000059113707,0.0000785961,0.00014632074,0.00009909828,0.00016589274,0.00013135732,0.00013831473,0.00039417317,0.0004767678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019381638,0.000018230932,0.00009804963,0.000013276005,0.0000025519407,0.000033784047,0.000009283591,0.000107481865,0.9982925,0.00013265773,0.00006107009,0.0010373527],"study_design_scores_gemma":[0.000013230201,0.000085517466,0.00056267163,0.0000011305015,0.0000036235263,0.000075575,0.000009725631,0.00069786777,0.9969025,0.000036782043,0.0016098697,0.0000015080392],"about_ca_topic_score_codex":0.00040535658,"about_ca_topic_score_gemma":0.000383567,"teacher_disagreement_score":0.0018804023,"about_ca_system_score_codex":0.00017572446,"about_ca_system_score_gemma":0.00020167012,"threshold_uncertainty_score":0.0062906146},"labels":[],"label_agreement":null},{"id":"W4415237419","doi":"10.3389/fimmu.2025.1680410","title":"Multiplex engineering and multifunction T cells for precise and effective immunotherapies","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Adoptive cell transfer; Cancer immunotherapy; T cell; Multiplex; Antigen","score_opus":0.006261329684152147,"score_gpt":0.2544441701112436,"score_spread":0.24818284042709146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415237419","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33024764,0.12980568,0.5159558,0.0016687872,0.0011412777,0.0005824875,0.0004979909,0.0012173078,0.018883012],"genre_scores_gemma":[0.77887243,0.04882202,0.16307421,0.0005416085,0.00027133693,0.0004188598,0.00025632375,0.00009145346,0.0076517495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999699,0.000064314496,0.000022094071,0.000072277224,0.0000919386,0.000050498842],"domain_scores_gemma":[0.9999199,0.0000218043,0.0000244896,0.0000092929695,0.000012520501,0.000012094316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005493061,0.0005330769,0.00041500965,0.0003855538,0.00013040968,0.00072386593,0.00035437013,0.00058273034,0.0009989995],"category_scores_gemma":[0.0002684524,0.00019552755,0.00038902325,0.00030254966,0.00038278732,0.0006093958,0.0005581354,0.00090268016,0.00046313833],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008715189,0.00005431776,0.00012854885,0.0005152076,0.000023101256,0.00020381103,0.000065306434,0.0022114755,0.93836945,0.009686773,0.00057270104,0.04808204],"study_design_scores_gemma":[0.000053821164,0.0008213525,0.00045636523,0.00008463238,0.000077188466,0.0008995801,0.000040787414,0.0071826293,0.9112712,0.0036530988,0.07542756,0.000031757154],"about_ca_topic_score_codex":0.00011372241,"about_ca_topic_score_gemma":0.00018219628,"teacher_disagreement_score":0.0009989995,"about_ca_system_score_codex":0.00039288957,"about_ca_system_score_gemma":0.00025272663,"threshold_uncertainty_score":0.0033419728},"labels":[],"label_agreement":null},{"id":"W4415306280","doi":"10.1101/2025.10.17.683068","title":"Engineering human protein switches for functional control of CARs and transcription factors via oral drug administration","year":2025,"lang":"","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"Universität für Bodenkultur Wien; Austrian Science Fund; Christian Doppler Forschungsgesellschaft; Cancer Research Institute; Österreichische Forschungsförderungsgesellschaft; Österreichischen Akademie der Wissenschaften; Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung","keywords":"Transcription factor; Drug; Transcription (linguistics); Transcriptional regulation; Drug administration; Drug discovery","score_opus":0.022791915726199652,"score_gpt":0.2531602087881917,"score_spread":0.23036829306199202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415306280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561341,0.0015390626,0.03620104,0.0003104244,0.00013882297,0.00016375573,0.0005051295,0.0004114295,0.004596256],"genre_scores_gemma":[0.9806042,0.0005092801,0.014470747,0.0001187313,0.000024429703,0.000088938104,0.00024016567,0.00006510035,0.0038783604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984634,0.000029711904,0.000010832912,0.000039750124,0.000044629487,0.00002871886],"domain_scores_gemma":[0.9999193,0.00001929858,0.00003264797,0.000011412178,0.000005459229,0.000011901809],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025503707,0.00029505952,0.00017316428,0.00014422988,0.000091493646,0.00036120487,0.00016544378,0.00025454708,0.0016257804],"category_scores_gemma":[0.00014359452,0.000103265455,0.00018898153,0.00009892871,0.0003536233,0.00014799616,0.00019537659,0.0005437534,0.0003603048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006357917,0.0000267657,0.0000949561,0.000018454995,0.0000035655653,0.000022986766,0.000011465679,0.00012620291,0.9968575,0.0005637037,0.00010925941,0.002101471],"study_design_scores_gemma":[0.00001761939,0.00015973793,0.00021385388,0.0000019950946,0.000005003733,0.000059567607,0.0000048311526,0.00074261165,0.99401915,0.000066291,0.004706051,0.0000033759966],"about_ca_topic_score_codex":0.00029449264,"about_ca_topic_score_gemma":0.00028276612,"teacher_disagreement_score":0.0016257804,"about_ca_system_score_codex":0.00027468477,"about_ca_system_score_gemma":0.00020201306,"threshold_uncertainty_score":0.005438745},"labels":[],"label_agreement":null},{"id":"W4415457678","doi":"10.3389/fimmu.2025.1677548","title":"Reprogramming the tumor microenvironment to boost adoptive T cell therapy","year":2025,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"Reprogramming; Tumor microenvironment; Oncolytic virus; Stromal cell; T cell; Immunotherapy; Immune system; Adoptive cell transfer","score_opus":0.026193884130190866,"score_gpt":0.3185648156557382,"score_spread":0.29237093152554733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415457678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033375566,0.99632543,0.00050500047,0.00034871243,0.0003695129,0.000009658755,0.000022732358,0.000019329167,0.0020657987],"genre_scores_gemma":[0.0017509601,0.99645483,0.0003545691,0.00030176566,0.00015027101,0.000013651044,0.000033316817,0.0000025988406,0.00093809643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989593,0.000018335864,0.000009630234,0.000019407873,0.000041974807,0.000014644535],"domain_scores_gemma":[0.9999074,0.000040644987,0.000012185498,0.000004126511,0.000024769746,0.00001090596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003606067,0.0005907974,0.00065856404,0.0011567412,0.00016141801,0.00071797916,0.0005042146,0.0008451629,0.0026021888],"category_scores_gemma":[0.0003247611,0.00017228384,0.00039768484,0.00080761133,0.00029803262,0.0007412498,0.0004507564,0.0014873318,0.0015479567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007438519,0.00008492002,0.00008712182,0.012714768,0.00007056996,0.00015303867,0.000055019515,0.0007067031,0.010856647,0.008343715,0.02743577,0.93941724],"study_design_scores_gemma":[0.000021027397,0.000109807814,0.00036634156,0.0017950147,0.0000673353,0.0006560899,0.0000314737,0.0001592021,0.0020867356,0.0021695348,0.99252605,0.000011503375],"about_ca_topic_score_codex":0.00048170984,"about_ca_topic_score_gemma":0.00084472325,"teacher_disagreement_score":0.0026021888,"about_ca_system_score_codex":0.00047417192,"about_ca_system_score_gemma":0.0006694838,"threshold_uncertainty_score":0.008705199},"labels":[],"label_agreement":null},{"id":"W4415459514","doi":"10.1002/hon.70144","title":"The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Observational study; Software deployment; Retrospective cohort study; Pharmacy practice; Pharmacist; MEDLINE","score_opus":0.07731557741980553,"score_gpt":0.441086529883501,"score_spread":0.36377095246369545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415459514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949438,0.0013757617,0.00016290492,0.0008485911,0.000020257796,0.000025400608,0.00018398947,0.000009347705,0.0024299016],"genre_scores_gemma":[0.9979498,0.00072623015,0.00009874083,0.00042447512,0.000043541677,0.000015435855,0.00017458595,0.0000064662904,0.0005606284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970854,0.0011329255,0.00013213669,0.00027519694,0.00050687906,0.0008675331],"domain_scores_gemma":[0.99238706,0.0015130808,0.0029079313,0.00020818596,0.0009305668,0.0020532017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024449818,0.00034171354,0.00028889882,0.0013527431,0.0010081289,0.0020945808,0.0003798563,0.00091457664,0.0038325398],"category_scores_gemma":[0.008354586,0.00019631363,0.00045926604,0.0016826614,0.0006234519,0.0010569667,0.0007557901,0.0005551808,0.0006616999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029400302,0.00032942402,0.966554,0.00006478012,0.00006052544,0.0009102019,0.0037577446,0.00013735089,0.0002817768,0.00021049555,0.0020346835,0.025365109],"study_design_scores_gemma":[0.00005224249,0.0013275967,0.969261,0.00008995,0.00005579389,0.0038973824,0.010256531,0.00027710566,0.00023327806,0.000073570714,0.014437972,0.000037608228],"about_ca_topic_score_codex":0.03975927,"about_ca_topic_score_gemma":0.042116612,"teacher_disagreement_score":0.03975927,"about_ca_system_score_codex":0.0032646984,"about_ca_system_score_gemma":0.003960067,"threshold_uncertainty_score":0.07905573},"labels":[],"label_agreement":null},{"id":"W4415469677","doi":"10.54254/2753-8818/2025.au27984","title":"Combined Immunotherapy of Dual-Targeted CAR NK Cells and Modified Oncolytic Virus Against Glioblastoma","year":2025,"lang":"","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oncolytic virus; Immunotherapy; Chimeric antigen receptor; Tumor microenvironment; Chemokine; Immune system; Glioblastoma; Virus","score_opus":0.006806896578322443,"score_gpt":0.28482404955225815,"score_spread":0.2780171529739357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415469677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909288,0.004017841,0.003091114,0.000098154014,0.000057667658,0.000049504655,0.00004205025,0.00005287846,0.0016620851],"genre_scores_gemma":[0.9959202,0.0011870143,0.0016676151,0.000033469303,0.000017056098,0.000036053872,0.000045652665,0.000005495376,0.0010873583],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999907,0.000012863122,0.000005339235,0.000016931359,0.000021884955,0.000035836445],"domain_scores_gemma":[0.999982,0.000001934168,0.0000047034655,0.0000024378976,0.0000022174033,0.0000067285105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010759183,0.00031667986,0.00038204854,0.00021691105,0.00007903276,0.0003226724,0.000248321,0.00022615993,0.0006013428],"category_scores_gemma":[0.00005403504,0.00009540946,0.00019777965,0.000112266745,0.00017377183,0.0002793358,0.0003989911,0.00038877595,0.00014636246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010414161,0.0005229367,0.000717571,0.00021794153,0.00005275785,0.00019020369,0.000056355086,0.0017660842,0.9460881,0.00093901146,0.00035713086,0.04805041],"study_design_scores_gemma":[0.00059440656,0.01026108,0.0046710647,0.00004922071,0.00029366752,0.0016255116,0.00009778229,0.012219046,0.9531427,0.00051159214,0.016510105,0.000023782974],"about_ca_topic_score_codex":0.00043536842,"about_ca_topic_score_gemma":0.0009807779,"teacher_disagreement_score":0.0006013428,"about_ca_system_score_codex":0.00025371212,"about_ca_system_score_gemma":0.0002576195,"threshold_uncertainty_score":0.0020117164},"labels":[],"label_agreement":null},{"id":"W4415516512","doi":"10.1186/s13045-025-01741-y","title":"B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia","year":2025,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"National Cancer Institute; National Institutes of Health; Center for Cancer Research","keywords":"Chimeric antigen receptor; Immunotherapy; Myeloid leukemia; Antigen; Leukemia; B cell; Myeloid; Flow cytometry","score_opus":0.02319117376752284,"score_gpt":0.3493004129627951,"score_spread":0.3261092391952723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415516512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707171,0.011875078,0.013088842,0.00042965717,0.00007667089,0.0001388639,0.00015793028,0.00014640232,0.0033693542],"genre_scores_gemma":[0.9918154,0.00251905,0.003619068,0.000121690326,0.000027865728,0.000052329473,0.00016779386,0.000011798653,0.0016649984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999926,0.000017071037,0.000004213841,0.000014893189,0.000021736729,0.000016203556],"domain_scores_gemma":[0.9999721,0.000004460341,0.0000065783865,0.0000032043865,0.00000569269,0.000007910575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010245215,0.000196253,0.00014775728,0.00016286758,0.00011379237,0.0002879987,0.00013593494,0.00023196844,0.0010163481],"category_scores_gemma":[0.00008888534,0.00006332484,0.000101896294,0.00012559834,0.00014256896,0.00016932048,0.00015865164,0.0005129199,0.00029177757],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007332582,0.000037394275,0.00047018117,0.00006615307,0.0000051802535,0.000037310387,0.000010101014,0.00021731526,0.99018914,0.0003153017,0.00013640415,0.0084422985],"study_design_scores_gemma":[0.00005105417,0.000841773,0.0047590216,0.000019392433,0.00004120503,0.0007764145,0.000031408537,0.003132717,0.9607541,0.0004649304,0.029122524,0.0000055205846],"about_ca_topic_score_codex":0.00025263868,"about_ca_topic_score_gemma":0.00025570102,"teacher_disagreement_score":0.0010163481,"about_ca_system_score_codex":0.00021485926,"about_ca_system_score_gemma":0.00021228028,"threshold_uncertainty_score":0.0034000278},"labels":[],"label_agreement":null},{"id":"W4415524675","doi":"10.1007/978-3-031-97297-3_8","title":"Raw Material Considerations for the Manufacture of Cell-Based Therapies","year":2025,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Commercialization; Raw material; Quality (philosophy); Product (mathematics); Pace; New product development; Clinical trial","score_opus":0.07799450206240785,"score_gpt":0.4580216582267075,"score_spread":0.3800271561642996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415524675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004755368,0.9891356,0.003049042,0.0005724671,0.00084361795,0.000055522734,0.00014277372,0.00003329371,0.0056921057],"genre_scores_gemma":[0.0022347537,0.98960096,0.0040872414,0.00035376864,0.0004139615,0.0000673235,0.0002254516,0.000013723014,0.0030028024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99927026,0.00010663776,0.00007967711,0.00008275222,0.0004008582,0.000059828857],"domain_scores_gemma":[0.9994266,0.00030820837,0.000076720964,0.00003173904,0.00012990512,0.000026930564],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017107397,0.0012350954,0.0017934657,0.0026061558,0.00034879707,0.0021472147,0.0013969423,0.001734966,0.008192314],"category_scores_gemma":[0.0015021261,0.0006313186,0.0009535799,0.002034574,0.0008372714,0.0020262299,0.00093969,0.0033353202,0.006518459],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018599474,0.0001813832,0.00010129192,0.026805373,0.00007460867,0.0005863456,0.00008475275,0.0011358808,0.032075178,0.028803749,0.025869546,0.8840959],"study_design_scores_gemma":[0.000026013508,0.00015315502,0.00024924154,0.0023000187,0.000050195405,0.0005977118,0.00003309908,0.0001282818,0.0072618597,0.0055685835,0.9836093,0.000022520868],"about_ca_topic_score_codex":0.00085197145,"about_ca_topic_score_gemma":0.0013026666,"teacher_disagreement_score":0.008192314,"about_ca_system_score_codex":0.0008162884,"about_ca_system_score_gemma":0.0011768709,"threshold_uncertainty_score":0.027405977},"labels":[],"label_agreement":null},{"id":"W4415534276","doi":"10.1101/2025.10.23.684261","title":"Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Hyundai Hope On Wheels; Albert and Bettie Sacchi Foundation","keywords":"Chimeric antigen receptor; Leukemia; CD19; CAR T-cell therapy; T cell; Bone marrow; PI3K/AKT/mTOR pathway; Cell therapy","score_opus":0.020088476824742154,"score_gpt":0.27924940910928003,"score_spread":0.2591609322845379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415534276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99946254,0.00020428892,0.00009952867,0.000019738605,0.0000013832295,0.0000037232896,0.000045569803,0.000004588389,0.0001585891],"genre_scores_gemma":[0.9995778,0.000065156506,0.000082683015,0.000019935234,0.0000036455751,0.000006033567,0.00012406534,0.0000027491858,0.00011783914],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99989927,0.000028137414,0.00000848479,0.000018771678,0.000016717608,0.000028632947],"domain_scores_gemma":[0.9998343,0.00003169928,0.000057659876,0.000012346343,0.000012431423,0.000051548246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020958734,0.00008866295,0.00023988531,0.00019687974,0.000106549705,0.00028363336,0.00009252104,0.00024384448,0.00077617244],"category_scores_gemma":[0.0003004771,0.00006197457,0.00009739121,0.0001697576,0.00012129968,0.00016171008,0.00017786755,0.0002797417,0.00020346383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012168723,0.00045076024,0.27739435,0.000060012477,0.00007196664,0.0008833764,0.0002825093,0.00079502753,0.6781292,0.00013681166,0.00021479656,0.0294125],"study_design_scores_gemma":[0.00012836044,0.006087391,0.9129138,0.000008647806,0.0000963488,0.00193527,0.0002944272,0.0017682506,0.075319864,0.0001811412,0.001250325,0.000016264428],"about_ca_topic_score_codex":0.00019025416,"about_ca_topic_score_gemma":0.00021951823,"teacher_disagreement_score":0.00077617244,"about_ca_system_score_codex":0.0001746151,"about_ca_system_score_gemma":0.00008330636,"threshold_uncertainty_score":0.0025965571},"labels":[],"label_agreement":null},{"id":"W4415535704","doi":"10.1016/j.jtct.2025.10.024","title":"CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Takeda Oncology; U.S. Public Health Service; Health Resources and Services Administration; National Institutes of Health; Jazz Pharmaceuticals; Medac; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Incyte; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Gateway for Cancer Research; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Clinical trial; Cytokine release syndrome; Safety monitoring; Food and drug administration; Data monitoring committee; Confidence interval","score_opus":0.12455555396610758,"score_gpt":0.4200015351121382,"score_spread":0.29544598114603066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415535704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9191419,0.061545905,0.0037694247,0.0007284762,0.00013404807,0.0008690097,0.004312411,0.000098245684,0.009400725],"genre_scores_gemma":[0.99128175,0.004276382,0.0009573504,0.0004928561,0.00009813814,0.00034085105,0.00206299,0.000015564134,0.0004741776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9885718,0.0061066397,0.0024902686,0.00089696544,0.0015900662,0.0003442257],"domain_scores_gemma":[0.95395476,0.016813869,0.024214713,0.0022951267,0.0020265733,0.00069491914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013615756,0.00034054052,0.0010152744,0.000550919,0.0003042003,0.0015040331,0.00043896356,0.00048773273,0.002108928],"category_scores_gemma":[0.019894818,0.00018076712,0.0015086908,0.0011171965,0.0006399491,0.0009846105,0.00062469085,0.001000921,0.00030331386],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06384961,0.0010156679,0.6531903,0.007927014,0.013788025,0.0011716479,0.000568893,0.002306678,0.007208837,0.001672686,0.0060867732,0.24121384],"study_design_scores_gemma":[0.0100466935,0.02649358,0.89360607,0.0018526744,0.0073248334,0.0073217843,0.0007291977,0.002343952,0.008288396,0.002134798,0.039757505,0.00010060102],"about_ca_topic_score_codex":0.00029111793,"about_ca_topic_score_gemma":0.0011747445,"teacher_disagreement_score":0.013615756,"about_ca_system_score_codex":0.0005358071,"about_ca_system_score_gemma":0.00079036894,"threshold_uncertainty_score":0.072007895},"labels":[],"label_agreement":null},{"id":"W4415567205","doi":"10.3389/fimmu.2025.1664403","title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","year":2025,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Terry Fox Research Institute; Canada Research Chairs; Michael Smith Health Research BC","keywords":"Chimeric antigen receptor; Transmembrane protein; Antigen; Transmembrane domain; Modular design; Immune system; Cytolysis; Cell; Signal transduction","score_opus":0.03990709242569941,"score_gpt":0.3267499709263403,"score_spread":0.2868428785006409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415567205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015662948,0.99569833,0.00034999105,0.0011916424,0.0005261896,0.0000032389694,0.000010549108,0.00000880711,0.0020545973],"genre_scores_gemma":[0.0014653874,0.99522036,0.000383978,0.0009631293,0.00038109432,0.0000073359383,0.000023580144,0.0000028827353,0.0015522601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998504,0.000040858984,0.000012805431,0.000027305774,0.00004937237,0.000019357747],"domain_scores_gemma":[0.99982625,0.00008426681,0.000016737988,0.0000073573888,0.00004895204,0.000016490312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063966616,0.0005508439,0.0006263419,0.0007600623,0.0002141802,0.0011213537,0.0007390917,0.0012130343,0.0022428061],"category_scores_gemma":[0.000609888,0.00017330717,0.00028581425,0.0007701141,0.0008016794,0.0019960762,0.0004995708,0.002428555,0.0018135969],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091275986,0.000058158923,0.00010145873,0.007314151,0.000051548705,0.00018003235,0.00009651621,0.000460537,0.004782285,0.027954035,0.04429401,0.91461605],"study_design_scores_gemma":[0.000009680289,0.000056461744,0.00018585745,0.0012103784,0.00002368424,0.0005430497,0.000050182352,0.000080515085,0.00060482597,0.004462496,0.99276215,0.000010683034],"about_ca_topic_score_codex":0.0008037174,"about_ca_topic_score_gemma":0.0012313401,"teacher_disagreement_score":0.0022428061,"about_ca_system_score_codex":0.00069906464,"about_ca_system_score_gemma":0.000865496,"threshold_uncertainty_score":0.0075029135},"labels":[],"label_agreement":null},{"id":"W4415620886","doi":"10.1002/jha2.70164","title":"Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre; Juravinski Hospital","funders":"Ontario Institute for Cancer Research; Government of Ontario; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Complication; Malignancy; Retrospective cohort study; Clinical trial; Adverse effect; MEDLINE","score_opus":0.01787858321658435,"score_gpt":0.3086770106493665,"score_spread":0.2907984274327821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415620886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983987,0.00057111675,0.00019621807,0.000015113205,0.000004492466,0.000023246814,0.00032875984,0.0000050597796,0.000457229],"genre_scores_gemma":[0.99909306,0.00019508957,0.00008262259,0.000023162587,0.000011893064,0.00001317874,0.0004888949,0.0000031179443,0.00008899363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992324,0.00015268094,0.00013739352,0.00020668922,0.00016716334,0.00010377695],"domain_scores_gemma":[0.9975803,0.00047953008,0.0011360807,0.00025552104,0.00022501234,0.00032360054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080459064,0.00018893162,0.00035301852,0.0009419835,0.0004164822,0.00055244734,0.000307631,0.00029081694,0.0017834711],"category_scores_gemma":[0.0015093251,0.00026483813,0.00049527857,0.0010047628,0.000318745,0.00031934422,0.00044664202,0.0004020542,0.00032196008],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017971272,0.000025380888,0.9970445,0.000017395187,0.00005153395,0.00045510547,0.00003907275,0.000034901554,0.00020704207,0.000015321784,0.00010796989,0.0018220433],"study_design_scores_gemma":[0.000019375539,0.00031924076,0.9923849,0.000017257891,0.000101090634,0.0055618575,0.00013315411,0.00020810017,0.0004768594,0.000021789365,0.0007494633,0.0000068182026],"about_ca_topic_score_codex":0.0012989336,"about_ca_topic_score_gemma":0.0012960427,"teacher_disagreement_score":0.0017834711,"about_ca_system_score_codex":0.00035327353,"about_ca_system_score_gemma":0.0004438554,"threshold_uncertainty_score":0.005966246},"labels":[],"label_agreement":null},{"id":"W4415641374","doi":"10.1016/j.isci.2025.113887","title":"Resource: A compendium of HLA types and expression in pediatric cancer models","year":2025,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Information Technology, Monash University; Medical Research Future Fund; National Cancer Institute; National Health and Medical Research Council; University of California; Children’s Cancer Foundation; Hudson Institute of Medical Research; Institute of Cancer Research; Robert Connor Dawes Foundation; McKenna Claire Foundation; Children's Hospital Los Angeles; St. Jude Children's Research Hospital; Royal Children's Hospital Foundation; Chordoma Foundation; McGill University; Dana-Farber Cancer Institute; Duke University; Johns Hopkins University; Murdoch Children's Research Institute; Deutsches Krebsforschungszentrum; University of Colorado; Victorian Cancer Agency; Children's Hospital of Philadelphia; Swifty Foundation; Children’s Oncology Group; Stanford University; Children's Cancer Foundation","keywords":"Human leukocyte antigen; Immunotherapy; Immune system; Pediatric cancer; Compendium; Cancer immunotherapy; Loss of heterozygosity; Antigen; Cancer; RNA splicing","score_opus":0.031876325645396865,"score_gpt":0.35403362347869244,"score_spread":0.32215729783329555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415641374","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024292136,0.001212146,0.0016372964,0.000100621866,0.000031620737,0.000029825827,0.99088913,0.0017589782,0.0019111646],"genre_scores_gemma":[0.0039656837,0.0008061986,0.002423953,0.00010615599,0.000007337641,0.00014057483,0.99184287,0.00023044873,0.00047680738],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999172,0.00014669921,0.000121346246,0.0002487378,0.00020383824,0.00010740915],"domain_scores_gemma":[0.99751616,0.0010419126,0.0003324105,0.00050319906,0.00033373447,0.0002726143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012018724,0.0013441887,0.001313533,0.0040841037,0.00068156037,0.0018484181,0.002029964,0.0014575641,0.024099523],"category_scores_gemma":[0.0040011597,0.0006704959,0.001212876,0.005518504,0.00030527584,0.00089969026,0.001866504,0.0014595622,0.016376488],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007068441,0.00012156585,0.034785293,0.0081394855,0.00066975196,0.00092229724,0.00030936324,0.0054645846,0.017750403,0.0047264243,0.86654884,0.059855074],"study_design_scores_gemma":[0.00017128476,0.00007129766,0.022349749,0.0007406307,0.00031355445,0.0009056911,0.00014133465,0.0021918155,0.0037907925,0.002967437,0.96628165,0.000074665455],"about_ca_topic_score_codex":0.010615918,"about_ca_topic_score_gemma":0.0210827,"teacher_disagreement_score":0.024099523,"about_ca_system_score_codex":0.0009738374,"about_ca_system_score_gemma":0.0024172808,"threshold_uncertainty_score":0.080620944},"labels":[],"label_agreement":null},{"id":"W4415871413","doi":"10.1136/jitc-2025-sitc2025.1303","title":"1303 Phase I/Ib study of next generation JAK-STAT CAR-T therapy for patients with relapsed or refractory CD19 <sup>+</sup> B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)","year":2025,"lang":"","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Refractory (planetary science); Lymphoma; CD20; Phases of clinical research; CD19; Ibrutinib; Leukemia","score_opus":0.04467810406372259,"score_gpt":0.31022548861920235,"score_spread":0.26554738455547977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415871413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986587,0.0021706608,0.0007560334,0.000669637,0.00017260022,0.002170786,0.0026236407,0.00017331971,0.0046762982],"genre_scores_gemma":[0.98103917,0.0017611217,0.0022829513,0.0012345649,0.00008913893,0.0024014881,0.0058549573,0.000057069698,0.005279567],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99980944,0.000055736462,0.000008302376,0.000027947637,0.0000176594,0.00008086701],"domain_scores_gemma":[0.9997806,0.000029525561,0.000019213383,0.000017796372,0.000014288008,0.00013862835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080988056,0.0009155497,0.0012786302,0.00037980088,0.00044023097,0.0010747423,0.0006179832,0.00091249583,0.0059270253],"category_scores_gemma":[0.0003066521,0.00036468566,0.0011093635,0.00034918252,0.0007076579,0.00053494266,0.00026859037,0.00228654,0.0014921174],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5286797,0.08402587,0.011723942,0.0011288123,0.001917448,0.000519453,0.00057216454,0.010143512,0.12714773,0.0018920688,0.019161798,0.21308751],"study_design_scores_gemma":[0.44301003,0.51084644,0.014659293,0.0000615985,0.0008442042,0.0005665655,0.00013727866,0.0044951327,0.012481405,0.00071251165,0.0121383,0.000047324567],"about_ca_topic_score_codex":0.0023755615,"about_ca_topic_score_gemma":0.0063123154,"teacher_disagreement_score":0.0059270253,"about_ca_system_score_codex":0.00097463554,"about_ca_system_score_gemma":0.0018973796,"threshold_uncertainty_score":0.019827902},"labels":[],"label_agreement":null},{"id":"W4415896981","doi":"10.1136/jitc-2024-011382","title":"Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics and Genomics of Geneva; Université de Genève; Ligue Genevoise Contre le Cancer; University of Pennsylvania; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Fondation ISREC; Institut National Du Cancer; National Science Foundation; McMaster University; Fondation privée des Hôpitaux universitaires de Genève","keywords":"Bystander effect; Glioblastoma; Extracellular matrix; Cytotoxic T cell; Domain (mathematical analysis); T cell; Extracellular","score_opus":0.036324732330809476,"score_gpt":0.3776838244149533,"score_spread":0.34135909208414383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415896981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918249,0.002075505,0.0027791818,0.00017773968,0.00007038364,0.0001999113,0.00055747246,0.0002979252,0.0020169225],"genre_scores_gemma":[0.9915835,0.0019822298,0.0024645696,0.00009319719,0.00003360001,0.00025526548,0.0008406723,0.000042997286,0.002703903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998233,0.000024499543,0.000011614371,0.000026918035,0.000035730693,0.000078009456],"domain_scores_gemma":[0.9998642,0.000014175543,0.000029685076,0.000014387273,0.000022011383,0.000055447705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035869094,0.000868938,0.00051017693,0.0006717725,0.0001571396,0.00034909765,0.0003745606,0.00042873598,0.0012352149],"category_scores_gemma":[0.00012267996,0.00017987101,0.00036567522,0.00025810878,0.0002543821,0.00027187815,0.00017460326,0.0012564403,0.00039957537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012795251,0.0015658131,0.00026755568,0.0001585782,0.000033392844,0.00008727646,0.00006288716,0.00080231915,0.9867732,0.00015303069,0.0005228713,0.00829358],"study_design_scores_gemma":[0.00037100102,0.019806527,0.0029393346,0.000034374676,0.0001450522,0.0002928308,0.00005239493,0.0029083875,0.9699103,0.00009852225,0.003428574,0.000012624987],"about_ca_topic_score_codex":0.001398274,"about_ca_topic_score_gemma":0.0023565623,"teacher_disagreement_score":0.001398274,"about_ca_system_score_codex":0.00042161267,"about_ca_system_score_gemma":0.00056270184,"threshold_uncertainty_score":0.004132211},"labels":[],"label_agreement":null},{"id":"W4415898666","doi":"10.1136/jitc-2025-sitc2025.1196","title":"1196 TriTCE Co-stim: a differentiated T cell engager platform with conditional <i>cis</i> CD28 co-stimulation is transferable to diverse targeting strategies","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"T cell; CD28; Cell; T-cell receptor; Ubiquitin-Protein Ligases","score_opus":0.02448960916072105,"score_gpt":0.2953962097737661,"score_spread":0.27090660061304506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415898666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9493613,0.0016032094,0.023628809,0.0005367188,0.00030046963,0.00020221039,0.003023749,0.0010144642,0.020329108],"genre_scores_gemma":[0.96476626,0.00061907736,0.009608202,0.00025163527,0.000030537973,0.00015604853,0.0031412577,0.00019142014,0.021235546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999521,0.000045219032,0.000030294272,0.00011934859,0.00014515368,0.00013900945],"domain_scores_gemma":[0.9999043,0.000014040382,0.000017010718,0.000015637863,0.000013100285,0.000035836143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002057787,0.00040476304,0.00029407963,0.00027050058,0.0002640973,0.00062801235,0.00033383336,0.0005334614,0.0069517638],"category_scores_gemma":[0.00013021597,0.00024368944,0.00026768973,0.00021552402,0.00024113324,0.0002867163,0.00041482731,0.0014564276,0.0034817527],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009475535,0.000033335044,0.000086580534,0.00002390197,0.000006687398,0.00002981075,0.000011423199,0.000090492016,0.9971008,0.00026385396,0.00044830752,0.0018101683],"study_design_scores_gemma":[0.000017926031,0.00012007574,0.00065675366,0.0000035113283,0.000012243579,0.0001312105,0.000015586842,0.0008879261,0.9920229,0.00004657052,0.0060800323,0.000005240188],"about_ca_topic_score_codex":0.00046859268,"about_ca_topic_score_gemma":0.0012365987,"teacher_disagreement_score":0.0069517638,"about_ca_system_score_codex":0.00036678987,"about_ca_system_score_gemma":0.000363284,"threshold_uncertainty_score":0.023255944},"labels":[],"label_agreement":null},{"id":"W4415898865","doi":"10.1136/jitc-2025-sitc2025.0320","title":"320 Integrated efficacy and safety analysis of letetresgene autoleucel, a T-cell receptor T-cell therapy, across clinical trials of patients with synovial sarcoma and myxoid/round cell liposarcoma","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Clinical trial; Soft tissue sarcoma; Synovial sarcoma; Liposarcoma; Sarcoma; Receptor","score_opus":0.043261942524745856,"score_gpt":0.3526277013207987,"score_spread":0.3093657587960528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415898865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596965,0.001422289,0.0004790251,0.000110933724,0.00004768516,0.0003915704,0.0006334315,0.000043178337,0.00090223964],"genre_scores_gemma":[0.99644214,0.0005308878,0.0005488936,0.00015074476,0.0000546002,0.00031847728,0.0011457012,0.000021819022,0.00078669924],"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99778134,0.0012346271,0.00017412104,0.00027193155,0.0002868398,0.00025105875],"domain_scores_gemma":[0.99875486,0.0003501496,0.00033542377,0.00016888168,0.00014691232,0.00024382777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042284722,0.0006203348,0.001795444,0.0006475158,0.00026130912,0.0012036745,0.00045943816,0.00074835523,0.0020801567],"category_scores_gemma":[0.0023615337,0.00038083037,0.0015706576,0.0005486094,0.00078194105,0.001059319,0.0003615954,0.0015307071,0.0005006729],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7737965,0.016023178,0.012846712,0.0005307731,0.0038756994,0.00010806313,0.00022418593,0.0041468986,0.060787898,0.00040771716,0.0013640639,0.12588832],"study_design_scores_gemma":[0.15969399,0.7545114,0.05866751,0.000054254473,0.0037639658,0.00028224709,0.00014082984,0.003183734,0.014027265,0.0003986788,0.005205862,0.000070308466],"about_ca_topic_score_codex":0.00051167374,"about_ca_topic_score_gemma":0.0008708477,"teacher_disagreement_score":0.0042284722,"about_ca_system_score_codex":0.0010979119,"about_ca_system_score_gemma":0.0009159388,"threshold_uncertainty_score":0.02236259},"labels":[],"label_agreement":null},{"id":"W4415898942","doi":"10.1136/jitc-2025-sitc2025.0283","title":"283 Functional profiling of CAR T cells using high-dimensional CyTOF: integrating cytokine, transcription factor and immune checkpoint marker signatures","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Transcription factor; Profiling (computer programming); Immune system; Immune checkpoint; Transcription (linguistics); Gene expression profiling","score_opus":0.023002610327908395,"score_gpt":0.26604151805324533,"score_spread":0.24303890772533693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415898942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97582924,0.0005831692,0.016849047,0.0001598135,0.000021108895,0.00007810675,0.003198795,0.0002452476,0.003035424],"genre_scores_gemma":[0.9744819,0.00044399,0.017412188,0.000116392184,0.000014564174,0.00012304056,0.0033361202,0.00011432004,0.0039576283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984205,0.000015556896,0.000008229178,0.000032593653,0.000050636092,0.000050903407],"domain_scores_gemma":[0.999918,0.000026166184,0.000009936082,0.00000980463,0.000022056547,0.000014047217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014158405,0.00017608206,0.00023314363,0.00061787275,0.00031068246,0.00088968786,0.00018756978,0.0003725681,0.002188592],"category_scores_gemma":[0.00017845191,0.00013179041,0.00023338028,0.00038909406,0.00018189165,0.00020578224,0.00015425847,0.0005283147,0.0011797942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011928585,0.000021241885,0.0010374477,0.000017349044,0.0000033717956,0.000024929337,0.000037293397,0.00023456622,0.9955318,0.00012793954,0.00008927267,0.0027555344],"study_design_scores_gemma":[0.00001146607,0.00012767907,0.019628197,0.0000054781203,0.000019162448,0.00015442834,0.00016985499,0.0072790813,0.96950454,0.00016040787,0.0029278048,0.000011857263],"about_ca_topic_score_codex":0.001181403,"about_ca_topic_score_gemma":0.0017525486,"teacher_disagreement_score":0.002188592,"about_ca_system_score_codex":0.00027770246,"about_ca_system_score_gemma":0.00018103137,"threshold_uncertainty_score":0.007321596},"labels":[],"label_agreement":null},{"id":"W4415952016","doi":"10.3324/haematol.2025.288838","title":"CD19 directed CAR T therapy for intravascular large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Astellas Pharma US; Health Resources and Services Administration; National Institutes of Health; Gilead Sciences; Actinium Pharmaceuticals; Adaptive Biotechnologies; Moonshot Research and Development Program; AstraZeneca; Gateway for Cancer Research; Astellas Pharma; Alexion Pharmaceuticals; Amgen","keywords":"Lymphoma; CD19; Chimeric antigen receptor; Aggressive lymphoma; CAR T-cell therapy; Antibody therapy","score_opus":0.023826367591453696,"score_gpt":0.3159687436674928,"score_spread":0.2921423760760391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415952016","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23875707,0.34233493,0.010030768,0.037728157,0.0117267035,0.0027067375,0.021928422,0.0011119472,0.33367518],"genre_scores_gemma":[0.74356574,0.11237425,0.0076520336,0.0113985175,0.0022343546,0.0017104308,0.014895888,0.00014722122,0.10602149],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99973005,0.00009951393,0.000023597011,0.000026774205,0.0000531814,0.00006695374],"domain_scores_gemma":[0.9997143,0.00011859451,0.000031622414,0.000034363864,0.000028031513,0.00007305978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004931218,0.00024202044,0.0004304014,0.00027295706,0.00027911272,0.0007172139,0.0007704165,0.0012149336,0.03400837],"category_scores_gemma":[0.0006789484,0.00012794022,0.0004220011,0.0003578772,0.00023609865,0.00071388413,0.00022209043,0.0010589865,0.005534154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021376781,0.0033904337,0.002253462,0.0039236885,0.00069578935,0.0021233442,0.00011335042,0.0010931436,0.037849292,0.006236964,0.17573076,0.74521303],"study_design_scores_gemma":[0.008517837,0.014926378,0.0059605893,0.0009649885,0.00067373284,0.003341764,0.000108702516,0.0008285246,0.025885582,0.0022756967,0.9364857,0.000030463862],"about_ca_topic_score_codex":0.0005537537,"about_ca_topic_score_gemma":0.0016364955,"teacher_disagreement_score":0.03400837,"about_ca_system_score_codex":0.0005688152,"about_ca_system_score_gemma":0.0006419191,"threshold_uncertainty_score":0.11376929},"labels":[],"label_agreement":null},{"id":"W4415987224","doi":"10.1007/s11899-025-00764-z","title":"Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy","year":2025,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Blinatumomab; Chimeric antigen receptor; Ponatinib; Immunotherapy; Hematology; Minimal residual disease; Chemotherapy","score_opus":0.03765103770373049,"score_gpt":0.34985800668731853,"score_spread":0.312206968983588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415987224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000064839456,0.9992436,0.000067461544,0.00013073023,0.00013367669,0.000003224081,0.000007905039,0.0000036415145,0.00034489122],"genre_scores_gemma":[0.0003687852,0.9989728,0.00009861654,0.00017252585,0.00010694561,0.0000034296954,0.00001569604,7.9170434e-7,0.00026052288],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998252,0.00003628067,0.000020597872,0.000027420896,0.00007038661,0.00002011729],"domain_scores_gemma":[0.99975115,0.00012523516,0.000040764633,0.0000062101735,0.00005350536,0.000023119916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006468053,0.0007419452,0.0013965566,0.0016097425,0.00017277374,0.00097546383,0.00090366934,0.0009918171,0.0027296217],"category_scores_gemma":[0.00065481395,0.00022162993,0.00045752001,0.0018641789,0.00043192785,0.0009485951,0.00053558545,0.0020252494,0.0014753395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012658989,0.00009307167,0.00010554763,0.0143931545,0.00008781698,0.00012764591,0.000034705947,0.00044225063,0.0021234641,0.0029506062,0.027058667,0.9524566],"study_design_scores_gemma":[0.00005843212,0.00016600723,0.00047159437,0.002830986,0.00015372763,0.0006571169,0.000036371923,0.000115481525,0.0005544287,0.0011357039,0.99380577,0.000014344105],"about_ca_topic_score_codex":0.0010897149,"about_ca_topic_score_gemma":0.002008271,"teacher_disagreement_score":0.0027296217,"about_ca_system_score_codex":0.0005012531,"about_ca_system_score_gemma":0.00086970377,"threshold_uncertainty_score":0.009131491},"labels":[],"label_agreement":null},{"id":"W4416085335","doi":"10.1093/neuonc/noaf201.1397","title":"EXTH-64. Allogeneic CAR-DNT cell therapy to overcome spatial heterogeneity in glioblastoma","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Fonds Wetenschappelijk Onderzoek","keywords":"Chimeric antigen receptor; Cytotoxicity; Cytotoxic T cell; Cell therapy; In vitro; Glioblastoma; Immunotherapy; CD19; Antigen; Cell","score_opus":0.02928261303002896,"score_gpt":0.35076667718269267,"score_spread":0.32148406415266373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416085335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99456453,0.0014875546,0.0017853321,0.000050381495,0.000033493976,0.00007597077,0.00012728777,0.00007010793,0.0018052524],"genre_scores_gemma":[0.9967225,0.00070699165,0.00072018744,0.000023626639,0.000006851525,0.000032866596,0.00016828939,0.000007788103,0.0016108666],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999522,0.000004425796,0.0000027341166,0.000009930066,0.000011846676,0.0000188599],"domain_scores_gemma":[0.9999833,0.0000018911359,0.000003701178,0.0000026944624,0.000002176765,0.0000062537097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000661105,0.00025251275,0.00026256256,0.00024037824,0.000077244455,0.0001826973,0.00012574345,0.00016007059,0.00088362244],"category_scores_gemma":[0.000030785784,0.000069707385,0.00011364338,0.00015200881,0.00011417354,0.00009056632,0.00016044879,0.000309698,0.00021240966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034151398,0.00028029724,0.00036719785,0.00008603414,0.000011870893,0.00012582453,0.000033502954,0.0006042585,0.9854058,0.00033712617,0.0001993783,0.012207306],"study_design_scores_gemma":[0.00021021802,0.005354339,0.0053479853,0.000018223562,0.00007761144,0.0010813051,0.00004579817,0.0031486608,0.9736495,0.00015398239,0.010905525,0.000006768895],"about_ca_topic_score_codex":0.0011075283,"about_ca_topic_score_gemma":0.0014935924,"teacher_disagreement_score":0.0011075283,"about_ca_system_score_codex":0.0001986746,"about_ca_system_score_gemma":0.00023249321,"threshold_uncertainty_score":0.0029559731},"labels":[],"label_agreement":null},{"id":"W4416086893","doi":"10.1182/bloodadvances.2025016845","title":"A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Ipsen; Mallinckrodt Pharmaceuticals; Seagen; National Institutes of Health; Incyte; BeiGene; Genentech; AstraZeneca","keywords":"Lenalidomide; Blinatumomab; Concomitant; Adverse effect; Phases of clinical research; Toxicity; Lymphoma; Neurotoxicity","score_opus":0.01619469634600543,"score_gpt":0.3483985157154631,"score_spread":0.33220381936945764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416086893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950505,0.0022375197,0.00039270756,0.0001271221,0.000025535954,0.0010017424,0.0005795255,0.000040050745,0.00054540095],"genre_scores_gemma":[0.9935962,0.0011121748,0.0016200747,0.00036140066,0.000075323114,0.00071672245,0.0016909247,0.00001777523,0.0008093528],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9992855,0.00042499832,0.000039649778,0.00009055202,0.00010185242,0.000057473073],"domain_scores_gemma":[0.9990941,0.00018973942,0.00024877017,0.00009700076,0.000090168905,0.00028019934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003097143,0.00077732455,0.0011099835,0.0004811326,0.00031923005,0.0007986968,0.0007614521,0.00075088517,0.001617731],"category_scores_gemma":[0.001015836,0.0004318488,0.00079831673,0.00049047876,0.00061843864,0.00040026408,0.00023707065,0.0018474734,0.00033914414],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46889886,0.09955745,0.05481338,0.0014761044,0.0031021948,0.0012240667,0.00046391907,0.005247677,0.2243632,0.00042867172,0.0038667202,0.13655786],"study_design_scores_gemma":[0.2647393,0.62384844,0.06703521,0.00009142209,0.0017360275,0.0017135374,0.00012957504,0.0040342435,0.03073361,0.00032176953,0.0055588046,0.000058069698],"about_ca_topic_score_codex":0.00068104,"about_ca_topic_score_gemma":0.0014850921,"teacher_disagreement_score":0.003097143,"about_ca_system_score_codex":0.0008467202,"about_ca_system_score_gemma":0.0013292005,"threshold_uncertainty_score":0.016379476},"labels":[],"label_agreement":null},{"id":"W4416114352","doi":"10.1038/s41598-025-23159-9","title":"Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital","funders":"","keywords":"Multivariate analysis; Lymphoma; Retrospective cohort study; Prognostic variable; Diffuse large B-cell lymphoma; Overall survival; Multivariate statistics; Antigen; Predictive value; Survival analysis","score_opus":0.01104840940962449,"score_gpt":0.2823102877517549,"score_spread":0.2712618783421304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416114352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993376,0.0003037716,0.00005959809,0.0000115353405,0.0000025738407,0.000004466797,0.00008370099,0.00000210705,0.00019452268],"genre_scores_gemma":[0.9996797,0.000058210775,0.00006890178,0.000008085739,0.0000070368137,0.0000025287848,0.00013975643,8.4996776e-7,0.000034897083],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998227,0.00005351031,0.000022238615,0.000039710765,0.000030536743,0.000031378167],"domain_scores_gemma":[0.999106,0.00024764566,0.0002766188,0.00006601048,0.00009964718,0.00020395446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043913137,0.00017812943,0.00030630585,0.0005664925,0.00017926781,0.00044414785,0.0002071767,0.00032751652,0.00075302087],"category_scores_gemma":[0.0012996849,0.00010971345,0.00019934861,0.000401858,0.00028284165,0.00026898528,0.00017218842,0.00027973746,0.00017265666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053262286,0.000020864445,0.99570245,0.00000688207,0.000012876775,0.000384153,0.000017994444,0.000080391175,0.0009069851,0.000007288573,0.000026209214,0.0023012205],"study_design_scores_gemma":[0.00001862133,0.00039314432,0.9961965,0.000004074864,0.000038710194,0.0021529335,0.0000690045,0.00039735468,0.00044839268,0.00001791684,0.0002581599,0.0000050819694],"about_ca_topic_score_codex":0.0009289344,"about_ca_topic_score_gemma":0.0014272485,"teacher_disagreement_score":0.0009289344,"about_ca_system_score_codex":0.00025531076,"about_ca_system_score_gemma":0.0001951368,"threshold_uncertainty_score":0.002519071},"labels":[],"label_agreement":null},{"id":"W4416116967","doi":"10.1158/0008-5472.can-24-3329","title":"Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Department of Medicine, University of Toronto; Terry Fox Research Institute; Deutsches Krebsforschungszentrum; Physicians' Services Incorporated Foundation; Princess Margaret Cancer Foundation; Leukemia and Lymphoma Society of Canada; Ministry of Health, Ontario","keywords":"Blockade; Immune checkpoint; Haematopoiesis; Immunotherapy; Immune system; Cancer immunotherapy","score_opus":0.05917256912853262,"score_gpt":0.44006774784438407,"score_spread":0.38089517871585143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416116967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99781644,0.0006350607,0.0006713722,0.00005665624,0.000015771133,0.000012460606,0.00012473429,0.000051782023,0.0006157371],"genre_scores_gemma":[0.9988937,0.0001605332,0.00026581276,0.000030962343,0.000006830222,0.000010117341,0.00011906195,0.000007061143,0.0005060669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998312,0.000028205723,0.0000119765655,0.00003185811,0.000038250957,0.000058525944],"domain_scores_gemma":[0.99986625,0.000018283212,0.000045430315,0.0000148759755,0.000010343127,0.00004478651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012528052,0.00023340787,0.0001777321,0.00019381783,0.00006042908,0.0002307002,0.00008601837,0.0001855013,0.0012809859],"category_scores_gemma":[0.00012095064,0.00007752812,0.00015924394,0.00008005472,0.00016676389,0.00013235082,0.00017727529,0.00067524344,0.00014752331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029773434,0.000046334735,0.0007722806,0.000020726582,0.000006718312,0.000037619466,0.000006122882,0.000048747275,0.99721295,0.000046647358,0.000035405425,0.0014686055],"study_design_scores_gemma":[0.000036663525,0.0014882557,0.019604664,0.000010585209,0.000046084537,0.00045791644,0.00002552521,0.0009516015,0.9760993,0.000058438265,0.0012164798,0.000004452646],"about_ca_topic_score_codex":0.00016286728,"about_ca_topic_score_gemma":0.00031506122,"teacher_disagreement_score":0.0012809859,"about_ca_system_score_codex":0.00018153143,"about_ca_system_score_gemma":0.00011695101,"threshold_uncertainty_score":0.0042853355},"labels":[],"label_agreement":null},{"id":"W4416126817","doi":"10.21203/rs.3.rs-7949545/v1","title":"Engagement of the T cell receptor against an oncolytic virus generates a population of hypereffector CAR T cells with potent antitumor activity","year":2025,"lang":"","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of British Columbia","funders":"National Institutes of Health","keywords":"Oncolytic virus; Chimeric antigen receptor; T cell; Vesicular stomatitis virus; T-cell receptor; Cytotoxic T cell; Population; Streptamer; Antigen","score_opus":0.07020830993468759,"score_gpt":0.38896211950153603,"score_spread":0.31875380956684846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416126817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98645896,0.00047598034,0.010143882,0.00010757582,0.00002542483,0.000051999974,0.0001929901,0.0001257637,0.0024175642],"genre_scores_gemma":[0.9940783,0.00014715007,0.002505424,0.00008756943,0.000028073775,0.000036716443,0.00037619978,0.000045543035,0.002695027],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998159,0.00002353128,0.000010766687,0.000045295223,0.000034883135,0.00006967575],"domain_scores_gemma":[0.9998578,0.000038735667,0.00001670235,0.000029560244,0.000019186667,0.000037983915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024372872,0.00028952528,0.0002582412,0.00032326602,0.00014863299,0.00064597145,0.00019454566,0.00031678917,0.0020572785],"category_scores_gemma":[0.00024382076,0.00015603949,0.00021510174,0.00015382105,0.00017956614,0.00028940383,0.00040334676,0.00084684044,0.00078759843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000085666186,0.000026521673,0.00029205394,0.0000061597057,0.0000043464065,0.000031380918,0.000016733824,0.0001018712,0.9971962,0.00032215062,0.000055244927,0.0018616407],"study_design_scores_gemma":[0.000039561437,0.00028987287,0.0025561573,0.0000028807303,0.000026093187,0.0004071491,0.000035351753,0.0029819158,0.99063104,0.00031514323,0.0027077708,0.0000071216864],"about_ca_topic_score_codex":0.00022436395,"about_ca_topic_score_gemma":0.00020825249,"teacher_disagreement_score":0.0020572785,"about_ca_system_score_codex":0.0002197071,"about_ca_system_score_gemma":0.00015916879,"threshold_uncertainty_score":0.00688231},"labels":[],"label_agreement":null},{"id":"W4416140366","doi":"10.1093/neuonc/noaf201.1473","title":"EXTH-142. Quantitative surfaceome profiling of high-risk medulloblastoma prioritizes the oncofetal antigen GPC2 for potent CAR-T cell therapy","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Children's Hospital; BC Cancer Agency; McMaster University","funders":"","keywords":"Medulloblastoma; Antigen; Potency; Disease; Tumor antigen; Immunotherapy; Cell","score_opus":0.034950985266482486,"score_gpt":0.3582756843886205,"score_spread":0.323324699122138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921108,0.00025019894,0.004416051,0.000044528977,0.000006128439,0.00003944808,0.0020616273,0.00008469857,0.0009864616],"genre_scores_gemma":[0.9908249,0.00019424545,0.0042601777,0.00005372265,0.000003921049,0.00006563558,0.0027266175,0.000032076292,0.0018386714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991035,0.000009900763,0.000004081989,0.000021301501,0.000035537614,0.00001880629],"domain_scores_gemma":[0.9999405,0.000011497871,0.000013686991,0.00000591775,0.000013926788,0.000014464481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014583212,0.0001762092,0.00018020747,0.00028656214,0.00015865044,0.0003598164,0.00009206278,0.00016633829,0.0016096092],"category_scores_gemma":[0.00015434645,0.00008873198,0.00014585492,0.00022237754,0.00014537145,0.00014850193,0.0001750874,0.00024844933,0.00032407913],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010990527,0.000017160835,0.003336692,0.000018499015,0.0000054330126,0.000015653175,0.000017620632,0.0002556817,0.9934088,0.000062102634,0.00011809761,0.0026343965],"study_design_scores_gemma":[0.000017970053,0.00051546184,0.10487822,0.000007029151,0.000033620476,0.00027664797,0.00013363414,0.009460861,0.88036156,0.00017012673,0.004133755,0.000011203197],"about_ca_topic_score_codex":0.0013759546,"about_ca_topic_score_gemma":0.0024322418,"teacher_disagreement_score":0.0016096092,"about_ca_system_score_codex":0.00026038173,"about_ca_system_score_gemma":0.00016817341,"threshold_uncertainty_score":0.005384743},"labels":[],"label_agreement":null},{"id":"W4416296108","doi":"10.5430/jst.v15n1p41","title":"Effectiveness of chimeric antigen receptor-T therapy on prostate cancer: A preclinical and clinical systematic review","year":2025,"lang":"","type":"article","venue":"Journal of Solid Tumors","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Student Research Committee, Tabriz University of Medical Sciences","keywords":"Prostate cancer; Tumor microenvironment; Clinical trial; Prostate; Immune system; Antigen; Immunotherapy; Prostate-specific antigen","score_opus":0.04234880502121697,"score_gpt":0.4446988460932782,"score_spread":0.40235004107206124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416296108","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010960973,0.99798524,0.00010912691,0.00011829414,0.0000766679,0.00018570603,0.00022119444,0.0000063040015,0.00020138215],"genre_scores_gemma":[0.019170154,0.9793292,0.00039121154,0.00037549715,0.00008603946,0.0003423226,0.0001962896,0.000006089749,0.00010315208],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9962586,0.0013346798,0.0013411846,0.00031810356,0.0006253603,0.00012204586],"domain_scores_gemma":[0.98561156,0.009933469,0.002416099,0.00023254949,0.0015832069,0.00022306024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006384632,0.0013628457,0.010320902,0.00541238,0.00046405022,0.001946368,0.001770342,0.0015976864,0.0037283497],"category_scores_gemma":[0.017604694,0.00077807414,0.008605912,0.006439326,0.00068920845,0.0014562801,0.0009799252,0.0008375867,0.00031069727],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000486723,0.000022771796,0.00051328394,0.9456642,0.020495264,0.00007156603,0.00006627182,0.00012096335,0.0002973549,0.00013145858,0.00093844,0.031191679],"study_design_scores_gemma":[0.0008940736,0.00093816314,0.00524926,0.6154403,0.3543675,0.00041710315,0.00018825429,0.00021414924,0.000569992,0.00034047675,0.021323407,0.000057267436],"about_ca_topic_score_codex":0.0048015313,"about_ca_topic_score_gemma":0.0128665585,"teacher_disagreement_score":0.010320902,"about_ca_system_score_codex":0.0024854229,"about_ca_system_score_gemma":0.0063694254,"threshold_uncertainty_score":0.033765554},"labels":[],"label_agreement":null},{"id":"W4416330185","doi":"10.1200/jco-25-00507","title":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University; Juravinski Hospital","funders":"","keywords":"Lymphoma; Lactate dehydrogenase; Refractory (planetary science); Cytokine release syndrome; Clinical trial; Survival analysis; Overall survival; Immunotherapy; Prospective cohort study","score_opus":0.048001974939657285,"score_gpt":0.42936079321755405,"score_spread":0.38135881827789675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416330185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914243,0.004471954,0.0005921365,0.0001727049,0.000035207056,0.00024413687,0.0016179177,0.000026931652,0.0014145751],"genre_scores_gemma":[0.990932,0.00080394454,0.000441677,0.00033431064,0.00007492674,0.00021450453,0.006468815,0.000019535246,0.00071034813],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9979778,0.0011902819,0.00011883532,0.00023013179,0.00023134293,0.00025156766],"domain_scores_gemma":[0.99704236,0.00095461117,0.0009337951,0.00027998147,0.00021502761,0.00057431165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067044445,0.00064368837,0.0015873497,0.00053111766,0.0003239191,0.001420531,0.0006075577,0.00071358075,0.0014476666],"category_scores_gemma":[0.003311985,0.00023429192,0.0020301647,0.0006447045,0.00048751145,0.0008913768,0.0006902029,0.001351756,0.00029652537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59360105,0.0058188494,0.26580653,0.0014829427,0.0174647,0.00084377406,0.00046772062,0.008120972,0.010372933,0.0006790303,0.005083998,0.09025752],"study_design_scores_gemma":[0.08245405,0.23801747,0.63790447,0.00020005424,0.0128968125,0.0011695119,0.0003746302,0.0084575,0.00258976,0.00075582677,0.015044902,0.00013513169],"about_ca_topic_score_codex":0.00081370847,"about_ca_topic_score_gemma":0.0013632735,"teacher_disagreement_score":0.0067044445,"about_ca_system_score_codex":0.0007922212,"about_ca_system_score_gemma":0.0005977659,"threshold_uncertainty_score":0.035456955},"labels":[],"label_agreement":null},{"id":"W4416388565","doi":"10.20944/preprints202511.1469.v1","title":"Assessing Canadaʹs Health System Readiness for Complex Therapies - The Current and Future State of T-Cell Redirecting Therapies","year":2025,"lang":"","type":"preprint","venue":"Preprints.org","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health care; Psychological intervention; Deliberation; Intervention (counseling); Data collection; Flexibility (engineering); Healthcare system; Health informatics","score_opus":0.1900785494135644,"score_gpt":0.43381133449116704,"score_spread":0.24373278507760265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416388565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8749976,0.005377507,0.0027271572,0.042032056,0.00018796588,0.0018550223,0.009748817,0.00015092165,0.06292299],"genre_scores_gemma":[0.98936903,0.0016889027,0.003500094,0.0013264064,0.000021809456,0.00021118534,0.0011502235,0.000009288,0.0027230906],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915004,0.0013345013,0.0003988124,0.00039057032,0.004304706,0.0020710065],"domain_scores_gemma":[0.97682625,0.002919329,0.002164042,0.00029811336,0.013043658,0.004748545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062162266,0.00034187324,0.0003560589,0.0024568478,0.006588011,0.0034218892,0.0021039937,0.00072029006,0.005146228],"category_scores_gemma":[0.017857434,0.00027559215,0.0007747975,0.0033231103,0.0017280894,0.0011029021,0.0019067117,0.0012285934,0.00028098735],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002421254,0.00026952272,0.8126097,0.0015007744,0.00020754391,0.00024958863,0.014756891,0.0014782823,0.00090300024,0.006549189,0.025749525,0.1354838],"study_design_scores_gemma":[0.000037426107,0.00028189737,0.9308677,0.0007831584,0.00012457903,0.00009069881,0.025799725,0.0018303692,0.00065864803,0.00043286284,0.038999952,0.00009301744],"about_ca_topic_score_codex":0.9936005,"about_ca_topic_score_gemma":0.9968072,"teacher_disagreement_score":0.87601674,"about_ca_system_score_codex":0.12398324,"about_ca_system_score_gemma":0.2569216,"threshold_uncertainty_score":0.8995656},"labels":[],"label_agreement":null},{"id":"W4416392126","doi":"10.1177/03009858251391388","title":"Characterization of host immune cell infiltrate in human CAR T cell-mediated xenogeneic graft versus host disease in NSG mice","year":2025,"lang":"en","type":"article","venue":"Veterinary Pathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"University of Pennsylvania","keywords":"Immune system; Graft-versus-host disease; Histiocyte; Antigen; Chimeric antigen receptor; Antigen presentation; Population; Cytotoxic T cell; Immunohistochemistry","score_opus":0.028297569353368465,"score_gpt":0.3133089044087582,"score_spread":0.2850113350553897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416392126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248224,0.0010285354,0.0040397006,0.000046323992,0.00002098552,0.00012648349,0.0006946403,0.00010226752,0.0014588659],"genre_scores_gemma":[0.9929663,0.00056382164,0.0027198372,0.00006743459,0.000013492281,0.00014275697,0.0009834862,0.000027569204,0.0025152813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997868,0.000029194007,0.000016767714,0.00006459362,0.000049018872,0.000053586115],"domain_scores_gemma":[0.99987125,0.00001972456,0.000028254613,0.000019976796,0.0000118571,0.00004903498],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029047113,0.00043901938,0.00032562017,0.0007039155,0.00013983848,0.00023103786,0.000110485205,0.0003696372,0.001530729],"category_scores_gemma":[0.0000895708,0.00014674228,0.0002360442,0.00023875035,0.00024234627,0.00022659785,0.00016985135,0.000653491,0.00042547312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002323158,0.00011942443,0.0005815536,0.000025066069,0.0000046566183,0.00015070368,0.00003921552,0.000084958345,0.99760795,0.000091966365,0.000031658605,0.0010306617],"study_design_scores_gemma":[0.00009868838,0.0028552713,0.029444356,0.000016885104,0.00004681097,0.0020300143,0.0001043263,0.004278443,0.956862,0.00016632277,0.004083626,0.00001340952],"about_ca_topic_score_codex":0.00036950895,"about_ca_topic_score_gemma":0.00041809524,"teacher_disagreement_score":0.001530729,"about_ca_system_score_codex":0.00020264852,"about_ca_system_score_gemma":0.00015772386,"threshold_uncertainty_score":0.005120814},"labels":[],"label_agreement":null},{"id":"W4416394020","doi":"10.1016/j.jgo.2025.102392","title":"Geriatric assessment in patients aged 70 and over considered for CAR-T therapy: A descriptive study","year":2025,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut Universitaire de Gériatrie de Montréal; Quebec - Clinical Research Organization in Cancer; Centres Intégré Universitaires de Santé et de Services Sociaux; Canadian Institute for International Peace and Security","funders":"","keywords":"Descriptive research; Descriptive statistics; Geriatrics; MEDLINE; Cross-sectional study","score_opus":0.03592266160567572,"score_gpt":0.3871580336817469,"score_spread":0.3512353720760712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416394020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990927,0.0002304447,0.000026675501,0.000026607919,0.0000046693694,0.00002363792,0.00020797175,6.885285e-7,0.00038662032],"genre_scores_gemma":[0.9989961,0.00029218098,0.000047014844,0.00007160592,0.000015155107,0.00003384938,0.00038217753,8.206849e-7,0.00016107783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99968255,0.00006148524,0.00006108698,0.000054987486,0.0000453145,0.000094611656],"domain_scores_gemma":[0.9993587,0.00008016161,0.0002603111,0.0000185616,0.000103276245,0.00017898118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003294698,0.00034508936,0.0007462995,0.0012951092,0.000816188,0.0007816517,0.000250073,0.0005882347,0.0012579821],"category_scores_gemma":[0.0014249539,0.0002788914,0.00080108485,0.0015120296,0.0003625612,0.0008466093,0.0006767339,0.00056575757,0.00023125076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002067149,0.00021677652,0.99780613,0.000025933012,0.00003781816,0.00025791454,0.00037824237,0.0000161363,0.00007230595,0.000016426698,0.00008576887,0.00087981945],"study_design_scores_gemma":[0.000018951438,0.0005344117,0.9952181,0.000023508732,0.000050708986,0.0006776746,0.0030935793,0.00006203285,0.000020345171,0.000031420146,0.00025878914,0.000010376591],"about_ca_topic_score_codex":0.009465072,"about_ca_topic_score_gemma":0.012655091,"teacher_disagreement_score":0.009465072,"about_ca_system_score_codex":0.00069008226,"about_ca_system_score_gemma":0.00071540865,"threshold_uncertainty_score":0.018819928},"labels":[],"label_agreement":null},{"id":"W4416426245","doi":"10.1016/j.jtct.2025.11.026","title":"Impact of Chimeric Antigen Receptor T-Cell Therapy on Health Utilities of Patients Diagnosed with Diffuse Large B-Cell Lymphoma in Canada","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Toronto General Hospital; Toronto Public Health","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Chimeric antigen receptor; Lymphoma; Population; Baseline (sea); Cancer; Health care; Clinical trial; Health economics; Disease","score_opus":0.01213776183665281,"score_gpt":0.2695603418211101,"score_spread":0.2574225799844573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416426245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97771025,0.0024146172,0.0001054062,0.005245835,0.00007367555,0.000030875115,0.007868047,0.000011785535,0.0065394794],"genre_scores_gemma":[0.99689376,0.0006962154,0.00006012241,0.0002926562,0.000014336024,0.0000049775895,0.0011783128,0.000003506703,0.00085606147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991912,0.00014003881,0.000051722487,0.00007222466,0.0001780544,0.000366785],"domain_scores_gemma":[0.9974685,0.00022950096,0.0004194427,0.000032902295,0.0009647831,0.000884976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040815986,0.00018832082,0.00032186403,0.0005467401,0.0009447267,0.0013039272,0.00091797224,0.00043350278,0.0029118503],"category_scores_gemma":[0.0026660922,0.00013394775,0.000652222,0.0021907727,0.00049298524,0.00029544233,0.0005991245,0.00085938856,0.00014598097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057302724,0.00009088127,0.9821712,0.00004630315,0.0001383582,0.00024475824,0.00018082919,0.0012582865,0.0001522894,0.0005629684,0.0032673767,0.011313757],"study_design_scores_gemma":[0.000059067075,0.00007188062,0.9952825,0.000043489494,0.00009491988,0.000082210725,0.0010195548,0.0012022863,0.000080940954,0.00009931982,0.0019449539,0.000018905836],"about_ca_topic_score_codex":0.9917297,"about_ca_topic_score_gemma":0.9953343,"teacher_disagreement_score":0.041526955,"about_ca_system_score_codex":0.041526955,"about_ca_system_score_gemma":0.0396716,"threshold_uncertainty_score":0.3013006},"labels":[],"label_agreement":null},{"id":"W4416446307","doi":"10.1093/jimmun/vkaf283.1196","title":"Preclinical development of a single domain mesothelin-specific chimeric antigen receptor (CAR) T cell therapy for ovarian cancer and other solid tumours 3385","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"National Institutes of Health; Multiple Sclerosis Society","keywords":"Chimeric antigen receptor; Ovarian cancer; Antigen; Antibody; T cell; Single-domain antibody; Cancer; Immunotherapy; Adoptive cell transfer","score_opus":0.04909471744990439,"score_gpt":0.3562863423110805,"score_spread":0.30719162486117607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416446307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98445255,0.0014367216,0.009402158,0.00013734747,0.000047824746,0.00053613685,0.0004618288,0.00015779195,0.0033675383],"genre_scores_gemma":[0.9943072,0.00064885983,0.0022862128,0.000031572847,0.000006106473,0.00016741123,0.00034128755,0.00001103423,0.0022003262],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999318,0.000013479059,0.0000035442843,0.000010615137,0.000020524534,0.000020002599],"domain_scores_gemma":[0.9999467,0.0000074827026,0.000009556323,0.0000065963936,0.000010598393,0.000019113366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023899657,0.00022104915,0.00017362922,0.00020612883,0.000102630496,0.00022836597,0.00017200923,0.00022258225,0.001770265],"category_scores_gemma":[0.000086354514,0.00008283495,0.0001788217,0.0000843962,0.00011975972,0.00014306848,0.000096750664,0.00041572753,0.00030513882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000695439,0.00064416515,0.00046951784,0.00009081798,0.0000145860095,0.000057170615,0.00003582911,0.0012756495,0.98447937,0.00029352572,0.0004187669,0.011525226],"study_design_scores_gemma":[0.00038470453,0.017428042,0.0026880626,0.000014204567,0.00004870322,0.00028688804,0.000030545787,0.005384183,0.9648787,0.000087047556,0.008763997,0.000004937966],"about_ca_topic_score_codex":0.0009212826,"about_ca_topic_score_gemma":0.0008197602,"teacher_disagreement_score":0.001770265,"about_ca_system_score_codex":0.00020213367,"about_ca_system_score_gemma":0.00049940223,"threshold_uncertainty_score":0.005922079},"labels":[],"label_agreement":null},{"id":"W4416446808","doi":"10.1093/jimmun/vkaf283.1249","title":"Development and preclinical validation of a therapeutic γδ TCR-engineered cell product for pan-cancer targeting 3442","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"T-cell receptor; Chimeric antigen receptor; Antigen; Population; T cell; Adoptive cell transfer; CRISPR; Cell","score_opus":0.05388783730068482,"score_gpt":0.3671076135907055,"score_spread":0.3132197762900207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416446808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93436223,0.002173179,0.04898415,0.00031667776,0.00018373229,0.0016470379,0.00196378,0.0003714127,0.00999783],"genre_scores_gemma":[0.9569121,0.0013930856,0.027002038,0.00015107436,0.000019120707,0.00058123755,0.002683154,0.00008483173,0.011173343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99943024,0.00008856857,0.000035922396,0.00008146226,0.00030037522,0.00006335387],"domain_scores_gemma":[0.9997533,0.000027363234,0.000035519464,0.000045062658,0.00008951744,0.000049266222],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008070651,0.00039505324,0.0002509534,0.00030955987,0.00021462073,0.000561273,0.00035679288,0.0005257895,0.001742341],"category_scores_gemma":[0.00029768702,0.00017649068,0.00024634696,0.00019205986,0.00022807397,0.00019873712,0.00018081763,0.00073911325,0.0007885044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010350592,0.00018051166,0.00012657355,0.00003858483,0.000007384776,0.000045659435,0.000025442696,0.00079319964,0.9941907,0.00024871822,0.00023377196,0.0040061274],"study_design_scores_gemma":[0.00004489077,0.0019687922,0.00074147515,0.0000105334675,0.000024707342,0.00015804761,0.000017469341,0.0018169115,0.98676354,0.000046985264,0.008401237,0.000005387445],"about_ca_topic_score_codex":0.0013012226,"about_ca_topic_score_gemma":0.0009032665,"teacher_disagreement_score":0.001742341,"about_ca_system_score_codex":0.000454604,"about_ca_system_score_gemma":0.00069911126,"threshold_uncertainty_score":0.0058286786},"labels":[],"label_agreement":null},{"id":"W4416448454","doi":"10.1093/jimmun/vkaf283.2021","title":"Using oncolytic viruses to exploit endogenous TCR signaling for modulation of CAR T phenotype and function against solid tumors 4322","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of British Columbia","funders":"National Institutes of Health","keywords":"Cytotoxic T cell; T-cell receptor; T cell; Granzyme B; Epitope; Phenotype; Vesicular stomatitis virus; Priming (agriculture); Interleukin 21","score_opus":0.09687229563756208,"score_gpt":0.351987154741734,"score_spread":0.25511485910417186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416448454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98728263,0.0009456671,0.008601574,0.00008558211,0.00004131595,0.00017972283,0.00074190804,0.00024226571,0.0018792708],"genre_scores_gemma":[0.98658735,0.000832069,0.007666436,0.00006683985,0.000014735693,0.00023218888,0.00081249076,0.000082708044,0.0037051588],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997439,0.000029760015,0.000019685107,0.000055790555,0.00006283539,0.00008805139],"domain_scores_gemma":[0.9999206,0.000013234185,0.000017402312,0.000014464992,0.000013188953,0.000021034923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017066745,0.00039203544,0.00028791334,0.0002431313,0.00015794374,0.00049548637,0.00021634945,0.00039960243,0.0019391405],"category_scores_gemma":[0.00009800964,0.00018678933,0.00030659774,0.00016083111,0.0001920778,0.00020884763,0.0002264931,0.0011096225,0.0007384496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004484626,0.000035355028,0.00006567163,0.000015958953,0.000002419707,0.000015226774,0.000009384263,0.00007988789,0.99883884,0.00006445003,0.00003741054,0.0007904957],"study_design_scores_gemma":[0.000019315969,0.00045213322,0.0009083019,0.0000044161698,0.000013876847,0.00017661724,0.00001448545,0.0009799673,0.9945017,0.0000333034,0.0028911494,0.000004637571],"about_ca_topic_score_codex":0.00039284967,"about_ca_topic_score_gemma":0.0004960948,"teacher_disagreement_score":0.0019391405,"about_ca_system_score_codex":0.00027306977,"about_ca_system_score_gemma":0.00020955157,"threshold_uncertainty_score":0.0064870715},"labels":[],"label_agreement":null},{"id":"W4416449055","doi":"10.1093/jimmun/vkaf283.844","title":"Development of human ex vivo expanded Vδ1 γδ T cells armed with CAR as a metabolically fit, off-the-shelf cell therapy for solid tumors 2995","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Cytotoxicity; Chimeric antigen receptor; Cytotoxic T cell; Ovarian cancer; Tumor microenvironment; T cell; Antigen; Ex vivo; Cancer cell","score_opus":0.02635398681630415,"score_gpt":0.3300299734459684,"score_spread":0.3036759866296643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416449055","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909636,0.0010290812,0.00562845,0.00007278044,0.0000362725,0.00011675488,0.00030767857,0.000067987145,0.0017774452],"genre_scores_gemma":[0.99332386,0.00043729885,0.003368299,0.000053316642,0.000008813675,0.00008726472,0.00047849308,0.0000127166395,0.0022299495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999174,0.000013657989,0.000006999662,0.000020620726,0.000020188165,0.000021102607],"domain_scores_gemma":[0.9999676,0.000005684532,0.0000057852776,0.000005381663,0.0000067842316,0.000008732686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012256012,0.00026450073,0.00018846722,0.00011624389,0.00007414762,0.00033797105,0.00016881492,0.00033666333,0.001183401],"category_scores_gemma":[0.000074003445,0.00008948602,0.00015578109,0.00009037721,0.000082568156,0.00014067984,0.00012659331,0.00045264215,0.0004665867],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016297874,0.00013596943,0.000208516,0.000034653774,0.000005907443,0.00005302976,0.000038588136,0.0005017117,0.994221,0.00014795364,0.0001347592,0.004354931],"study_design_scores_gemma":[0.000058806418,0.0016918507,0.0013079209,0.00000926758,0.00003060307,0.00028913448,0.00003493401,0.0034289053,0.9877721,0.000051890493,0.0053190496,0.000005616506],"about_ca_topic_score_codex":0.00026951026,"about_ca_topic_score_gemma":0.00019935127,"teacher_disagreement_score":0.001183401,"about_ca_system_score_codex":0.00010959571,"about_ca_system_score_gemma":0.00011695145,"threshold_uncertainty_score":0.0039588213},"labels":[],"label_agreement":null},{"id":"W4416449288","doi":"10.1093/jimmun/vkaf283.736","title":"Engineering Intracellular Signaling Domains to Drive CAR-T Cell Differentiation from Pluripotent Stem Cell 2865","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Chimeric antigen receptor; Progenitor cell; Cellular differentiation; Cell therapy; Stem cell; Signal transduction; Intracellular","score_opus":0.009207760652358715,"score_gpt":0.23789154237939308,"score_spread":0.22868378172703438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416449288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9245041,0.0011581713,0.058988534,0.00023818553,0.000062766725,0.00030156458,0.0014673674,0.00042373987,0.012855624],"genre_scores_gemma":[0.97404397,0.00058886624,0.018140769,0.00008731055,0.0000047819226,0.00009827024,0.0013121805,0.000048118978,0.0056756935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99984944,0.000018671939,0.000021038119,0.000022998614,0.00005752514,0.00003020543],"domain_scores_gemma":[0.9999341,0.000011768079,0.000016381999,0.000008697628,0.000017109316,0.000011927687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018500882,0.00022391067,0.00013417554,0.0002594089,0.00010702606,0.0003164737,0.00017816613,0.00023239416,0.0019105469],"category_scores_gemma":[0.00011326321,0.00011176888,0.00014917665,0.00021951174,0.0001446814,0.00010986567,0.0002043087,0.00048797598,0.0006962652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020700498,0.000017102742,0.00011042703,0.000028511653,0.0000022332372,0.00003634995,0.000011671936,0.00031201704,0.99557805,0.00039617423,0.00009487466,0.003392006],"study_design_scores_gemma":[0.0000094929765,0.000114883595,0.0004405934,0.000005095919,0.000008811545,0.00008948125,0.000015987509,0.0017233264,0.99131596,0.000061549785,0.006211748,0.0000030935557],"about_ca_topic_score_codex":0.0006353135,"about_ca_topic_score_gemma":0.00091025163,"teacher_disagreement_score":0.0019105469,"about_ca_system_score_codex":0.00033288437,"about_ca_system_score_gemma":0.000264826,"threshold_uncertainty_score":0.006391406},"labels":[],"label_agreement":null},{"id":"W4416449582","doi":"10.1093/jimmun/vkaf283.545","title":"Highly efficient engineering of human immune cells and hematopoietic stem and progenitor cells using microfluidic transfection 2651","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Transfection; Haematopoiesis; Electroporation; Stem cell; Nucleofection; Progenitor cell; Cytotoxic T cell","score_opus":0.013274604470746807,"score_gpt":0.2679398683414312,"score_spread":0.2546652638706844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416449582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73010147,0.0021441288,0.2562756,0.00035088288,0.00028438,0.00044481817,0.0015122966,0.0020637808,0.0068226336],"genre_scores_gemma":[0.863817,0.0013897332,0.12599581,0.0001460274,0.000039781204,0.0005055592,0.0012124086,0.00012556456,0.00676814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998275,0.0000150559,0.000018059687,0.000039701412,0.00006900516,0.00003056067],"domain_scores_gemma":[0.9999422,0.00001249573,0.000018991557,0.000006489113,0.00001133776,0.000008600918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002539321,0.00027387048,0.00018414082,0.00022578952,0.00015397514,0.00035525163,0.00019962918,0.00020807763,0.00061120547],"category_scores_gemma":[0.00013929431,0.00015517119,0.00024327438,0.00010688888,0.00018143193,0.000119023345,0.00027856187,0.00031103485,0.00034387223],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014445016,0.000013417576,0.0001296137,0.00003944796,0.0000040055706,0.000036341233,0.000020469275,0.0004229322,0.99474156,0.00040994378,0.00020369563,0.0039640726],"study_design_scores_gemma":[0.0000060171865,0.00005908493,0.00071466086,0.000004789311,0.000006830445,0.000072466486,0.000006554876,0.002414755,0.9893498,0.0000602385,0.007297442,0.0000074359473],"about_ca_topic_score_codex":0.00060738524,"about_ca_topic_score_gemma":0.00074738567,"teacher_disagreement_score":0.00061120547,"about_ca_system_score_codex":0.0004089284,"about_ca_system_score_gemma":0.00030732556,"threshold_uncertainty_score":0.002967},"labels":[],"label_agreement":null},{"id":"W4416548268","doi":"10.1158/2326-6066.cir-25-0445","title":"Phenotypic Characterization and Prognostic Impact of CD103+ Tissue-Resident Memory T Cells in Diffuse Large B-cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Canada's Michael Smith Genome Sciences Centre; Spinal Cord Injury BC; University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"BC Cancer Foundation; Canada Research Chairs; Canadian Cancer Society; Michael Smith Health Research BC; Terry Fox Research Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Flow cytometry; Lymph node; Phenotype; Lymphoma; Cytotoxic T cell; Population; Immunophenotyping; Diffuse large B-cell lymphoma; T cell; Transcriptome","score_opus":0.02971413439104169,"score_gpt":0.38436654717757895,"score_spread":0.35465241278653725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416548268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99774617,0.0007338862,0.00044385495,0.000023311537,0.0000036544614,0.000010810075,0.0006305224,0.000027515052,0.00038022717],"genre_scores_gemma":[0.9978727,0.00018484778,0.00035499997,0.00004079851,0.0000075923795,0.000017076552,0.0013017385,0.000010319926,0.0002099005],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9998332,0.000024764553,0.00001658455,0.000055417066,0.000028653236,0.000041438743],"domain_scores_gemma":[0.9998342,0.000028744622,0.000041163108,0.000020969053,0.000029896806,0.000045026823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023210738,0.00014585603,0.00024785503,0.0005581548,0.00017822439,0.000666513,0.00012978469,0.00023131761,0.00086898473],"category_scores_gemma":[0.0003867659,0.00009669514,0.000118700555,0.00043225515,0.00012797756,0.00015483628,0.00019615983,0.0003225567,0.0003486144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017490473,0.000120519224,0.5814035,0.00019284243,0.000101593396,0.00061786774,0.00043209465,0.00073023804,0.36551696,0.00014481945,0.0010479268,0.04794262],"study_design_scores_gemma":[0.000074267635,0.00052779616,0.9499086,0.000048478927,0.00014014778,0.0035825162,0.00082517276,0.003828301,0.035018243,0.0003199017,0.0057043172,0.000022195312],"about_ca_topic_score_codex":0.000696934,"about_ca_topic_score_gemma":0.0010954646,"teacher_disagreement_score":0.00086898473,"about_ca_system_score_codex":0.00019412707,"about_ca_system_score_gemma":0.000087322864,"threshold_uncertainty_score":0.0029070377},"labels":[],"label_agreement":null},{"id":"W4416734638","doi":"10.1002/hem3.70248","title":"Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Corticosteroid; Hazard ratio; Cumulative dose; Lymphoma; Cytokine release syndrome; Cumulative incidence; Toxicity; Methylprednisolone; Prednisone","score_opus":0.022807049954925034,"score_gpt":0.3072871860336976,"score_spread":0.28448013607877254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416734638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99856573,0.0009619482,0.0000792041,0.00002101147,0.0000023362804,0.000006321561,0.00012265757,0.00000309032,0.00023765412],"genre_scores_gemma":[0.9995165,0.00018611446,0.000039750084,0.000016461292,0.000006911094,0.0000033365918,0.00019580274,0.0000017574827,0.000033369502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860245,0.00034166756,0.00028932354,0.00025593463,0.00034806412,0.00016258021],"domain_scores_gemma":[0.9941446,0.0010942302,0.0038247097,0.00021332823,0.00033988178,0.0003832898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095709006,0.000113680544,0.00037775873,0.00048151912,0.00015397514,0.0006245117,0.00021765896,0.00030871193,0.0004992069],"category_scores_gemma":[0.004017371,0.000118876356,0.00039681702,0.0007729385,0.00037072715,0.00037919127,0.0003005493,0.00043282373,0.00015868993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062920223,0.000023647368,0.99299157,0.00001907389,0.0000667858,0.00016533537,0.00005916205,0.00016492433,0.00074403366,0.000015570296,0.000045123383,0.0050755264],"study_design_scores_gemma":[0.000013880281,0.0004627577,0.9975988,0.000012284319,0.000048472957,0.00079292315,0.000113184156,0.0002469728,0.00043217986,0.0000207928,0.00025137886,0.0000063092752],"about_ca_topic_score_codex":0.0011720998,"about_ca_topic_score_gemma":0.0015849876,"teacher_disagreement_score":0.0011720998,"about_ca_system_score_codex":0.0005612385,"about_ca_system_score_gemma":0.00045182827,"threshold_uncertainty_score":0.0050616264},"labels":[],"label_agreement":null},{"id":"W4416808330","doi":"10.1002/acr2.70139","title":"A Guide for Initiating and Managing Chimeric Antigen Receptor T Cell Therapy Clinical Trials in Autoimmune Rheumatic Diseases","year":2025,"lang":"en","type":"article","venue":"ACR Open Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Clinical trial; Chimeric antigen receptor; Autoimmunity; Translational research; Immune system; Cell therapy; Rheumatology","score_opus":0.128755947908628,"score_gpt":0.4867129642659138,"score_spread":0.35795701635728583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416808330","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024283696,0.09296804,0.3813617,0.27421483,0.01718349,0.014630111,0.009928166,0.028902633,0.17838268],"genre_scores_gemma":[0.00653106,0.066516876,0.7149515,0.09371709,0.009198004,0.018964618,0.005199998,0.00367092,0.08124998],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9791393,0.011915583,0.004039242,0.00087724655,0.0034726907,0.0005557791],"domain_scores_gemma":[0.9436445,0.02947018,0.0066397097,0.003091473,0.010329706,0.006824491],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02537111,0.0024380626,0.0026789655,0.0063078934,0.0013799295,0.009460938,0.0042836377,0.008843722,0.040271018],"category_scores_gemma":[0.052450534,0.002559265,0.0024538564,0.004509726,0.0019686213,0.0062897825,0.003685788,0.013613887,0.055673666],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017286223,0.00040242952,0.0006588113,0.0012811718,0.000073017385,0.0009078079,0.00040175806,0.0011989368,0.0011114314,0.0073836576,0.6271951,0.35921308],"study_design_scores_gemma":[0.00031594522,0.000274925,0.001281946,0.0029647816,0.000055645774,0.0014360243,0.00020240441,0.0011107492,0.00034801036,0.012220276,0.97970724,0.00008222164],"about_ca_topic_score_codex":0.0029872821,"about_ca_topic_score_gemma":0.0097540505,"teacher_disagreement_score":0.040271018,"about_ca_system_score_codex":0.0028049387,"about_ca_system_score_gemma":0.013374578,"threshold_uncertainty_score":0.13471997},"labels":[],"label_agreement":null},{"id":"W4416910450","doi":"10.1136/jitc-2025-013420","title":"The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"School of Medicine, Emory University; National Cancer Institute; National Institutes of Health; University of Connecticut Health Center; Society for Immunotherapy of Cancer; Ohio State University; University of Pittsburgh; Emory University; Massachusetts General Hospital","keywords":"Tumor-infiltrating lymphocytes; T cell; Immunotherapy; Cancer; Immune system; Immune checkpoint; Adoptive cell transfer; Blockade; Clinical trial","score_opus":0.027962384859575633,"score_gpt":0.3661467783282843,"score_spread":0.33818439346870866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416910450","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001041729,0.11339846,0.00072124746,0.78737885,0.0861942,0.000055489636,0.00016190232,0.000074061965,0.010974127],"genre_scores_gemma":[0.017359788,0.25897104,0.0038151287,0.46758768,0.1811772,0.00029034988,0.0006430418,0.00018161074,0.06997417],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960813,0.00088827714,0.00034950615,0.00046043916,0.0016837732,0.0005367503],"domain_scores_gemma":[0.9862422,0.002113098,0.0004946374,0.000468479,0.0057833297,0.0048983116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012565328,0.0014314246,0.00083305134,0.001219827,0.0019155928,0.0059064673,0.0017046916,0.0098987315,0.008021595],"category_scores_gemma":[0.0071659633,0.00035583225,0.0010658574,0.00095669174,0.003578143,0.0043255403,0.002777065,0.017647274,0.0045747827],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011135566,0.00015495953,0.00052412733,0.00022095234,0.000009979015,0.00011830291,0.00007900162,0.00014457956,0.0007112551,0.008397371,0.9132933,0.07623484],"study_design_scores_gemma":[0.000032269236,0.00011794729,0.0005363989,0.00036909746,0.000007565883,0.00015334832,0.00007791283,0.0001184087,0.00022773213,0.0033344445,0.99500495,0.000019926283],"about_ca_topic_score_codex":0.0054201297,"about_ca_topic_score_gemma":0.011592492,"teacher_disagreement_score":0.012565328,"about_ca_system_score_codex":0.003181106,"about_ca_system_score_gemma":0.016994158,"threshold_uncertainty_score":0.06645262},"labels":[],"label_agreement":null},{"id":"W4416931943","doi":"10.1136/jitc-2025-013518","title":"Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Perelman School of Medicine, University of Pennsylvania; Children's Hospital of Philadelphia; Children's National Hospital; Universitat de Barcelona; University of Pennsylvania; Gilead Sciences; Bristol-Myers Squibb","keywords":"Transformative learning; Genetically modified organism; Cancer immunotherapy; Ethical issues; Bridge (graph theory); Translational research; Genetically engineered; Public funding","score_opus":0.15005957271258458,"score_gpt":0.39586612709767544,"score_spread":0.24580655438509086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416931943","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044348463,0.037243366,0.06712032,0.81828773,0.017354472,0.00019690445,0.00024919867,0.00038622896,0.054726895],"genre_scores_gemma":[0.17066988,0.0811791,0.06260555,0.6216132,0.020947041,0.0008632338,0.00038572826,0.00055172987,0.041184507],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.98030764,0.006639079,0.0012873879,0.0022506607,0.0078123575,0.0017029707],"domain_scores_gemma":[0.965976,0.024470458,0.002206882,0.0019442391,0.004511146,0.00089130044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.020588167,0.000806964,0.0008447861,0.0010186217,0.0021894127,0.008379843,0.0052918503,0.012260449,0.008383089],"category_scores_gemma":[0.039069876,0.00063716754,0.0022194996,0.00069891976,0.009668294,0.011234164,0.005142477,0.016354665,0.0016709556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001258542,0.000054721855,0.00031967973,0.00073342194,0.00004537622,0.0003955781,0.0011668792,0.0041505974,0.0031408586,0.7838022,0.14986199,0.056202706],"study_design_scores_gemma":[0.00003639943,0.00009782278,0.00024794726,0.00083588646,0.000026989921,0.00021886131,0.00039762218,0.000957225,0.002108629,0.12481096,0.87019515,0.000066501445],"about_ca_topic_score_codex":0.006619211,"about_ca_topic_score_gemma":0.012987117,"teacher_disagreement_score":0.020588167,"about_ca_system_score_codex":0.007129461,"about_ca_system_score_gemma":0.014525774,"threshold_uncertainty_score":0.10888195},"labels":[],"label_agreement":null},{"id":"W4417001687","doi":"10.1182/blood-2025-62","title":"Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Cancer Research Institute","funders":"","keywords":"Chemoimmunotherapy; Interim analysis; Clinical endpoint; Phases of clinical research; Follicular lymphoma; Cohort; Lymphoma; Regimen; Pharmacokinetics","score_opus":0.013817240001792937,"score_gpt":0.2851206098193621,"score_spread":0.27130336981756914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99102354,0.0036234972,0.00047274254,0.00033767943,0.00009226234,0.00080291193,0.0016963808,0.000065817236,0.0018851488],"genre_scores_gemma":[0.99064386,0.0014814807,0.0012976845,0.0009939278,0.00016538375,0.00083167286,0.0037624664,0.00002075892,0.00080270495],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994161,0.00028904638,0.000043265238,0.00007807666,0.0000645807,0.00010899225],"domain_scores_gemma":[0.99894446,0.0001523057,0.00030614837,0.00011719342,0.000094489886,0.0003854163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024365366,0.0008217127,0.0014985286,0.000226605,0.0003802374,0.0011179205,0.00062094553,0.00066853064,0.0021125537],"category_scores_gemma":[0.00095389615,0.00041944912,0.001759184,0.00030271357,0.0005809374,0.0008189724,0.0003680482,0.0022252917,0.00057886256],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6899714,0.04011634,0.038321696,0.0015192388,0.00527598,0.00037164055,0.00045859124,0.0022916642,0.034376983,0.0004570383,0.011458496,0.17538093],"study_design_scores_gemma":[0.4251585,0.4821959,0.07334295,0.00017460469,0.00273051,0.0007698192,0.00020649938,0.0022633444,0.004129337,0.00045404737,0.008488695,0.00008578151],"about_ca_topic_score_codex":0.0007501438,"about_ca_topic_score_gemma":0.0026340794,"teacher_disagreement_score":0.0024365366,"about_ca_system_score_codex":0.000753807,"about_ca_system_score_gemma":0.0010264037,"threshold_uncertainty_score":0.012885749},"labels":[],"label_agreement":null},{"id":"W4417001848","doi":"10.1182/blood-2025-325","title":"Lipid uptake via FATP2 enhances CAR-t therapy resistance in B-cell acute lymphoblastic leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Leukemia; Chemotherapy regimen; Acute lymphocytic leukemia; Chemotherapy; Antigen; T-cell leukemia; Perforin; T cell; Immunotherapy","score_opus":0.012976977087274388,"score_gpt":0.28214832654264144,"score_spread":0.269171349455367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99468416,0.001571578,0.001336396,0.00020807766,0.000038402133,0.00003323881,0.00021393229,0.00017600997,0.0017381429],"genre_scores_gemma":[0.99664587,0.000757126,0.0004474727,0.000078653335,0.00000845366,0.000033653072,0.0003442358,0.000028235814,0.0016562524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998621,0.000033635984,0.0000050299013,0.000015931118,0.000037044705,0.000046253364],"domain_scores_gemma":[0.9999504,0.00000960721,0.000008892278,0.000008046706,0.0000069313387,0.000016071306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014974485,0.00031179935,0.00035622326,0.00018909869,0.00013184836,0.00056477915,0.0002005539,0.0003376675,0.0028199942],"category_scores_gemma":[0.00014830595,0.00016285485,0.00027902864,0.00020160434,0.00021095063,0.0003033876,0.00030365758,0.00094743946,0.0012780664],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010892528,0.00042617426,0.00051540026,0.000106060856,0.000021113397,0.00018278825,0.00005261145,0.000501192,0.98947144,0.00032524366,0.00072083494,0.006587837],"study_design_scores_gemma":[0.0002945248,0.004770747,0.004989587,0.000016671078,0.00007799495,0.0006626609,0.00012670894,0.006459282,0.97035944,0.0002689293,0.01195987,0.000013571947],"about_ca_topic_score_codex":0.0006832894,"about_ca_topic_score_gemma":0.0005844223,"teacher_disagreement_score":0.0028199942,"about_ca_system_score_codex":0.00039497644,"about_ca_system_score_gemma":0.00018751454,"threshold_uncertainty_score":0.009433806},"labels":[],"label_agreement":null},{"id":"W4417002069","doi":"10.1182/blood-2025-2730","title":"Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Hôtel-Dieu de Québec; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Chimeric antigen receptor; Real world data; Lymphoma; CAR T-cell therapy; Follicular lymphoma; Rituximab; Refractory (planetary science); Apheresis","score_opus":0.01346666025648666,"score_gpt":0.2753726718758079,"score_spread":0.2619060116193212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98093903,0.006229693,0.00019186188,0.0013368157,0.000022940565,0.00009957385,0.0055769747,0.000026740505,0.0055763396],"genre_scores_gemma":[0.9904377,0.0054845684,0.00027996916,0.00060945895,0.00001466753,0.000025828653,0.001711844,0.000017588232,0.0014183878],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998847,0.00008703046,0.00013147085,0.00013789254,0.0004681146,0.000328519],"domain_scores_gemma":[0.9964275,0.00028215378,0.0013488547,0.000053057505,0.0011680136,0.00072046573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046266662,0.00018929802,0.00037068935,0.0010368979,0.002300074,0.0017657469,0.00078400597,0.00038834236,0.0023889588],"category_scores_gemma":[0.0019215022,0.00025561132,0.00036019238,0.004313586,0.00069749117,0.00044191233,0.00079588575,0.0007102794,0.00032087593],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000395124,0.000103460006,0.9517987,0.00061842427,0.00010915348,0.0043116957,0.006074675,0.000302205,0.0008280539,0.00025565922,0.0056193,0.029583603],"study_design_scores_gemma":[0.000023880066,0.0003066795,0.9475407,0.00056530366,0.00013682919,0.008011574,0.020829469,0.00036543814,0.0006180443,0.00005609368,0.021475827,0.000070272945],"about_ca_topic_score_codex":0.9269741,"about_ca_topic_score_gemma":0.9573355,"teacher_disagreement_score":0.07302588,"about_ca_system_score_codex":0.023547176,"about_ca_system_score_gemma":0.032390494,"threshold_uncertainty_score":0.17084748},"labels":[],"label_agreement":null},{"id":"W4417002179","doi":"10.1182/blood-2025-4419","title":"Consensus on cytokine release syndrome (CRS) monitoring practices: A Delphi approach","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agfa-Gevaert (Canada)","funders":"","keywords":"Delphi method; Cytokine release syndrome; Delphi; MEDLINE; Patient safety; Chimeric antigen receptor; Grading (engineering); Health care","score_opus":0.062168909495097215,"score_gpt":0.35368419703172876,"score_spread":0.29151528753663153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6593494,0.004981322,0.15913166,0.053815346,0.0016591197,0.08711669,0.0015259272,0.00029581593,0.032124788],"genre_scores_gemma":[0.77586067,0.0031595689,0.15007387,0.008515393,0.00028320937,0.059276458,0.00065805844,0.00008775811,0.0020850361],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.7120608,0.23381375,0.024451505,0.005995943,0.013789585,0.009888416],"domain_scores_gemma":[0.81750137,0.115090854,0.008240376,0.004311258,0.04729293,0.0075631742],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.23137331,0.0015819346,0.0018864108,0.0073852036,0.005838322,0.0051040803,0.004014249,0.0037844132,0.004943888],"category_scores_gemma":[0.16132218,0.0013542862,0.0023639314,0.0038565483,0.0064587146,0.0056578848,0.018594032,0.0048830044,0.00094771653],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013536467,0.0009815501,0.028481703,0.012434767,0.00049150456,0.0020362672,0.66793936,0.0043613445,0.0075578378,0.032834776,0.022022912,0.21950425],"study_design_scores_gemma":[0.00056063937,0.0020012942,0.015195335,0.012192569,0.00023811158,0.0012924271,0.83870983,0.013724806,0.0027868361,0.036747143,0.07600297,0.0005481418],"about_ca_topic_score_codex":0.0027680655,"about_ca_topic_score_gemma":0.001787689,"teacher_disagreement_score":0.23137331,"about_ca_system_score_codex":0.0092111975,"about_ca_system_score_gemma":0.029191384,"threshold_uncertainty_score":0.94785357},"labels":[],"label_agreement":null},{"id":"W4417004861","doi":"10.1182/blood-2025-652","title":"γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Bone marrow; Immunosurveillance; Cohort; Myeloid leukemia; Interim analysis; Phases of clinical research; Chemotherapy; Dosing; Chemotherapy regimen; Cancer","score_opus":0.01582501349393114,"score_gpt":0.28506090680109153,"score_spread":0.2692358933071604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668056,0.0011058474,0.0003503714,0.00010459465,0.000022589717,0.00018217221,0.0005911889,0.000023901535,0.00093872915],"genre_scores_gemma":[0.99449,0.000689209,0.0006010969,0.00023271842,0.000031075997,0.00018803796,0.0025428329,0.000014693086,0.0012102721],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99962723,0.00018226684,0.000029810055,0.000060421375,0.000046140518,0.000054185137],"domain_scores_gemma":[0.99952805,0.00010393366,0.00009629991,0.00007603992,0.000040940813,0.00015474435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011051471,0.0003608151,0.0006270159,0.00017945301,0.00018742676,0.0006153317,0.00034264557,0.00040040436,0.0012788981],"category_scores_gemma":[0.0004704639,0.00017099518,0.00050674414,0.00026134626,0.00032578662,0.00025018532,0.00027637335,0.0013919948,0.00030447045],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28315052,0.03504845,0.081881024,0.00076448324,0.0023794568,0.000751277,0.0007160615,0.0047844583,0.30688274,0.000480826,0.0071964073,0.2759644],"study_design_scores_gemma":[0.069230735,0.60775524,0.19830418,0.00011864457,0.0024320213,0.0026880899,0.00029908624,0.0023517574,0.09692234,0.00041436957,0.01941166,0.00007185089],"about_ca_topic_score_codex":0.00035699006,"about_ca_topic_score_gemma":0.0010468459,"teacher_disagreement_score":0.0012788981,"about_ca_system_score_codex":0.00038173926,"about_ca_system_score_gemma":0.0004216844,"threshold_uncertainty_score":0.0058446527},"labels":[],"label_agreement":null},{"id":"W4417004910","doi":"10.1182/blood-2025-1031","title":"Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD19; Cell culture; Multiple myeloma; Gene expression; Antigen; Annexin A5; Gene; Chimeric antigen receptor","score_opus":0.04496808679528664,"score_gpt":0.3337368869448775,"score_spread":0.2887688001495909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99039465,0.0009916845,0.0034555374,0.00010213789,0.000018859337,0.00004161983,0.003205445,0.00016421387,0.0016258833],"genre_scores_gemma":[0.98539937,0.00054382876,0.0035175288,0.00012282252,0.000012071008,0.00009317506,0.0050817695,0.00003274625,0.0051966524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998492,0.000005472519,0.000010586257,0.000042450283,0.00005267809,0.000039610073],"domain_scores_gemma":[0.9998196,0.000027895834,0.000053094587,0.000022452823,0.00003695774,0.000040124363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007576822,0.00015539509,0.00016342917,0.00037598802,0.00017712118,0.00036575057,0.0001343316,0.00038038372,0.004582944],"category_scores_gemma":[0.00009505674,0.00009058696,0.00019185012,0.00054780085,0.00016032768,0.00012261295,0.00018115621,0.0005727351,0.001118044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009988023,0.00002241794,0.00271111,0.000019212406,0.0000060295256,0.00009437991,0.000018580997,0.000010753703,0.9960354,0.000035123674,0.000069507405,0.0008776498],"study_design_scores_gemma":[0.000019608655,0.00049778575,0.25751305,0.000009303098,0.000044368167,0.0026602882,0.00018490899,0.00047459645,0.73356986,0.00010295054,0.0049136714,0.0000096335425],"about_ca_topic_score_codex":0.00037855722,"about_ca_topic_score_gemma":0.00054512464,"teacher_disagreement_score":0.004582944,"about_ca_system_score_codex":0.00020886994,"about_ca_system_score_gemma":0.00014761701,"threshold_uncertainty_score":0.015331447},"labels":[],"label_agreement":null},{"id":"W4417005135","doi":"10.1182/blood-2025-4517","title":"The impact of distance to CAR-T centre on CAR-T delivery and CAR-T outcomes: A single centre retrospective cohort study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University Medical Centre","funders":"","keywords":"Retrospective cohort study; Cohort; Cohort study; Young adult; Systemic therapy; Propensity score matching; Log-rank test","score_opus":0.01285999277351518,"score_gpt":0.3074315453285909,"score_spread":0.2945715525550757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417005135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710447,0.00020299494,0.00018552832,0.0000353228,0.0000074349323,0.000064974025,0.001913648,0.0000052107835,0.0004804356],"genre_scores_gemma":[0.9986247,0.000069991685,0.00009714215,0.000038581482,0.000008032982,0.00004299534,0.0009455202,0.0000037371694,0.00016931731],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854726,0.00015520587,0.00017119666,0.0005309696,0.00028624476,0.00030908347],"domain_scores_gemma":[0.9971685,0.00022392273,0.001153988,0.00038808113,0.00058542984,0.00048010462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090004096,0.0003826784,0.0005803326,0.0009847888,0.0011594782,0.001062927,0.0009840524,0.00045367674,0.0020870445],"category_scores_gemma":[0.0020749865,0.00048134036,0.0007857172,0.0019212251,0.0005611874,0.00055887585,0.00091423467,0.00056713104,0.00041532033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000100156365,0.000014849382,0.9989349,0.000011639063,0.000059351834,0.00011852895,0.00011591227,0.000022471604,0.00008679442,0.00001683726,0.00014624959,0.00037238043],"study_design_scores_gemma":[0.000026436035,0.00021736557,0.9975535,0.000020170348,0.00010606937,0.0005050716,0.00060926285,0.00025968233,0.00006563236,0.000028543773,0.0005958211,0.000012605704],"about_ca_topic_score_codex":0.16698453,"about_ca_topic_score_gemma":0.19770715,"teacher_disagreement_score":0.16698453,"about_ca_system_score_codex":0.0026999076,"about_ca_system_score_gemma":0.0026740243,"threshold_uncertainty_score":0.3320251},"labels":[],"label_agreement":null},{"id":"W4417006218","doi":"10.1182/blood-2025-7600","title":"Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Cohort; Multiple myeloma; CAR T-cell therapy; Second line; Overall survival; Second-line therapy; First line therapy","score_opus":0.02281320235758821,"score_gpt":0.32365944172801614,"score_spread":0.3008462393704279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507564,0.0031856126,0.00011589825,0.000112051785,0.000009948643,0.000017602862,0.0007501348,0.0000031379038,0.0007298535],"genre_scores_gemma":[0.9982488,0.00080261304,0.00009247808,0.00010242806,0.000026884592,0.000016021755,0.00060534914,0.0000026297614,0.0001027818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99918514,0.00029492294,0.00011928175,0.00020922245,0.00008688672,0.0001046404],"domain_scores_gemma":[0.9983461,0.00022881609,0.000994825,0.00007570096,0.00015607875,0.00019854971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093402277,0.00017447029,0.00029098697,0.0008714321,0.00026107382,0.00081093766,0.00022669359,0.00038341788,0.0010575474],"category_scores_gemma":[0.0013045333,0.00011123258,0.0004549207,0.0017944324,0.00033179446,0.00048901455,0.00047274132,0.00028259176,0.00016001565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017768109,0.00027673613,0.97465736,0.0002396352,0.0004109103,0.00050716,0.0005206628,0.00023037913,0.00052041264,0.0001384076,0.00085352745,0.019868022],"study_design_scores_gemma":[0.00007922574,0.0007132351,0.99252033,0.0000864576,0.00028426404,0.0009926124,0.0014325265,0.0002345703,0.00022771244,0.00004875067,0.0033660606,0.000014383704],"about_ca_topic_score_codex":0.0017704658,"about_ca_topic_score_gemma":0.0026165894,"teacher_disagreement_score":0.0017704658,"about_ca_system_score_codex":0.0006676007,"about_ca_system_score_gemma":0.000438479,"threshold_uncertainty_score":0.0049396157},"labels":[],"label_agreement":null},{"id":"W4417006357","doi":"10.1182/blood-2025-5728","title":"Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Spinal Cord Injury BC","funders":"","keywords":"Pomalidomide; Multiple myeloma; Cancer; Flow cytometry; Cancer cell; T cell; Tumor microenvironment; Bortezomib","score_opus":0.024890221459246457,"score_gpt":0.2771451017268084,"score_spread":0.25225488026756193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320626,0.0007772821,0.0016140556,0.00018883777,0.00013603589,0.0001269872,0.0011810282,0.0001202957,0.0026493552],"genre_scores_gemma":[0.9934029,0.00033339448,0.0013781572,0.000098637625,0.00003136038,0.0001413416,0.00053492305,0.000015903857,0.0040633697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966085,0.00004500859,0.000036689074,0.00007296953,0.00007411121,0.00011035179],"domain_scores_gemma":[0.9998716,0.000012782251,0.000031218042,0.000020249638,0.000010021143,0.000054154312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024646043,0.0005016785,0.000482175,0.00034288393,0.00021806215,0.00040348462,0.00043375386,0.0005890735,0.0018514143],"category_scores_gemma":[0.00009115697,0.0001829117,0.00039161948,0.00020404121,0.00023948013,0.0002715481,0.00019410819,0.0019657745,0.0005441938],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014332164,0.0008446623,0.0002414042,0.00006630592,0.00001574752,0.00009359458,0.000050203646,0.00040117803,0.99393576,0.00028862501,0.00035091423,0.002278359],"study_design_scores_gemma":[0.00022409728,0.004114149,0.002740588,0.000012942134,0.000042383082,0.00021092103,0.00006148827,0.0042278348,0.9853932,0.00012814191,0.0028331887,0.00001098105],"about_ca_topic_score_codex":0.001160261,"about_ca_topic_score_gemma":0.0015091663,"teacher_disagreement_score":0.0018514143,"about_ca_system_score_codex":0.00057896157,"about_ca_system_score_gemma":0.0003494461,"threshold_uncertainty_score":0.0061935782},"labels":[],"label_agreement":null},{"id":"W4417009527","doi":"10.1182/blood-2025-4079","title":"Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Juravinski Cancer Centre","funders":"","keywords":"Multiple myeloma; Chimeric antigen receptor; Clinical trial; Phases of clinical research; Carfilzomib; Bortezomib; Antigen; Overall survival","score_opus":0.016579407795935888,"score_gpt":0.3164352646403779,"score_spread":0.29985585684444205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749511,0.00734282,0.001214378,0.0021315336,0.00036915537,0.0043015666,0.0043329992,0.0003659551,0.0049904753],"genre_scores_gemma":[0.97769904,0.0027159338,0.0022161806,0.002561206,0.00027577486,0.0032048877,0.004438277,0.000056568464,0.006832146],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993981,0.00033512097,0.000022528084,0.00008980066,0.000049648854,0.00010473501],"domain_scores_gemma":[0.9992673,0.000106602965,0.00013221282,0.00006279501,0.00006613563,0.00036495278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022676177,0.0012612087,0.0016336147,0.00038427117,0.00044995215,0.0012596971,0.0011315887,0.0016087904,0.006566694],"category_scores_gemma":[0.00092484674,0.00045095134,0.0014270324,0.00036723472,0.0008467372,0.0010261168,0.00041007594,0.0037146343,0.0012920777],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7921891,0.04334862,0.006374694,0.0014445935,0.0024987943,0.00029549602,0.00032257443,0.002110773,0.028318068,0.0005507444,0.008495041,0.114051476],"study_design_scores_gemma":[0.7777473,0.20660397,0.0078888545,0.000054528227,0.00037839808,0.00021340362,0.00005295809,0.0009820067,0.0016290125,0.0002459943,0.0041748923,0.00002869134],"about_ca_topic_score_codex":0.0008710382,"about_ca_topic_score_gemma":0.0026255508,"teacher_disagreement_score":0.006566694,"about_ca_system_score_codex":0.00074786256,"about_ca_system_score_gemma":0.0011132456,"threshold_uncertainty_score":0.021967828},"labels":[],"label_agreement":null},{"id":"W4417009678","doi":"10.1182/blood-2025-5339","title":"Stepwise engineering of human germinal center B cells to model dark zone high-grade B cell lymphoma driven by sequential BCL2 and MYC deregulation","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Germinal center; Gene silencing; Lymphoma; Follicular lymphoma; B cell; Gene; Phenotype; Gene rearrangement; B-cell receptor","score_opus":0.011601034071110537,"score_gpt":0.2662502802555481,"score_spread":0.25464924618443757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97691125,0.0014468195,0.015609491,0.00012773051,0.000086471475,0.00048237896,0.0010416618,0.00021904621,0.0040751845],"genre_scores_gemma":[0.9877452,0.00064447644,0.007977345,0.000048107548,0.000009024963,0.00016773179,0.00081237993,0.000043709115,0.0025519093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99978954,0.000044997854,0.000019226642,0.000037372545,0.00006952841,0.000039428243],"domain_scores_gemma":[0.99989176,0.000019138379,0.00003064055,0.000018053928,0.000009292479,0.000031113515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026427337,0.0003464925,0.00022748759,0.00029660793,0.00016638222,0.0005482385,0.00041544228,0.00038308356,0.0013472013],"category_scores_gemma":[0.0001250076,0.00016252752,0.00024507652,0.00018291814,0.00022234957,0.00011741283,0.0003440444,0.00063154195,0.0005657136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013311497,0.00012114489,0.00020310524,0.000038930993,0.000007667107,0.0000635504,0.000029792063,0.00057490537,0.99694437,0.00044724447,0.00006283907,0.0013733002],"study_design_scores_gemma":[0.000099979836,0.0012016,0.0015107767,0.000012729109,0.000038282476,0.00033193786,0.00004115886,0.005425485,0.981136,0.00014417706,0.010050449,0.0000074443924],"about_ca_topic_score_codex":0.0008475383,"about_ca_topic_score_gemma":0.0007841831,"teacher_disagreement_score":0.0013472013,"about_ca_system_score_codex":0.00039980645,"about_ca_system_score_gemma":0.0001987828,"threshold_uncertainty_score":0.004506886},"labels":[],"label_agreement":null},{"id":"W4417009721","doi":"10.1182/blood-2025-5962","title":"Individualizing apheresis processing volumes using a predictive algorithm: Analysis of the CAR T-cell collection protocol utilized in ACIT001/EXC002, a phase lb/ll trial of decentralized production of CAR T-cells for treatment of relapsed/refractory aggressive NHL and ALL","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta","funders":"","keywords":"Apheresis; Leukapheresis; Blood collection; Plateletpheresis; Data collection; Chimeric antigen receptor","score_opus":0.04184067357787266,"score_gpt":0.3720435590733941,"score_spread":0.33020288549552146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778872,0.00031546506,0.02012181,0.000097757,0.000014772562,0.00028758918,0.00017657432,0.00038291322,0.0007157541],"genre_scores_gemma":[0.9792271,0.00008120407,0.019828595,0.00006447652,0.000009667425,0.00014963502,0.00037359874,0.000031234045,0.00023449227],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9988819,0.00053938245,0.00007780767,0.00020764113,0.00024037661,0.00005296326],"domain_scores_gemma":[0.99425524,0.0041207992,0.0006158349,0.00033795307,0.0005122842,0.00015792919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045915465,0.0004924442,0.00050602516,0.0006370109,0.00021678452,0.0009997427,0.0005697881,0.0004157759,0.00046456564],"category_scores_gemma":[0.0088799205,0.00017472533,0.0003390313,0.00053207105,0.0002820174,0.0003703167,0.00029187053,0.0005944561,0.0001302398],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019043349,0.0029256481,0.2831047,0.00024874852,0.0005494617,0.00023668895,0.00038657855,0.28816518,0.030792048,0.0013436219,0.0025648987,0.37063903],"study_design_scores_gemma":[0.0004231322,0.003729449,0.055676043,0.000019748755,0.00018973951,0.00019028132,0.00005918863,0.9223669,0.015962342,0.0004519686,0.0009001125,0.00003106601],"about_ca_topic_score_codex":0.002159334,"about_ca_topic_score_gemma":0.0012940408,"teacher_disagreement_score":0.0045915465,"about_ca_system_score_codex":0.0008729866,"about_ca_system_score_gemma":0.0011917686,"threshold_uncertainty_score":0.024282694},"labels":[],"label_agreement":null},{"id":"W4417009738","doi":"10.1182/blood-2025-5352","title":"Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Follicular lymphoma; Adverse effect; Tolerability; Dosing; Incidence (geometry); Progressive disease; Phases of clinical research; Lymphoma","score_opus":0.013852790504268511,"score_gpt":0.30590820073459446,"score_spread":0.29205541023032594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912062,0.0058010207,0.0003409049,0.0001871588,0.000038460377,0.00027373922,0.0007580813,0.00003676031,0.0013576337],"genre_scores_gemma":[0.99748504,0.00050584285,0.00021364,0.0002470426,0.000048779508,0.00011464798,0.0010740686,0.0000067457645,0.00030432089],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9988801,0.0004217545,0.00010871461,0.00019485035,0.00019983038,0.00019474706],"domain_scores_gemma":[0.99763656,0.00044169626,0.00087025476,0.0002696178,0.0002462164,0.0005356077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039025762,0.00055422995,0.0013842514,0.00033776683,0.00048857846,0.0011060596,0.0005959532,0.0008167618,0.0014966939],"category_scores_gemma":[0.0018992932,0.00027788282,0.0015510841,0.00038290702,0.00040777403,0.0008500334,0.00032704443,0.0018944714,0.00048253525],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42063627,0.017653164,0.21888073,0.0010506683,0.008223908,0.0006088339,0.00052166445,0.0025421968,0.049136966,0.00023875863,0.0058240206,0.2746827],"study_design_scores_gemma":[0.07103239,0.31385392,0.5895642,0.00015829637,0.0052206316,0.0012848718,0.00017808184,0.0022225115,0.009079051,0.00025411995,0.007065488,0.000086427885],"about_ca_topic_score_codex":0.0006431984,"about_ca_topic_score_gemma":0.0012393761,"teacher_disagreement_score":0.0039025762,"about_ca_system_score_codex":0.0007483573,"about_ca_system_score_gemma":0.0005347866,"threshold_uncertainty_score":0.020639002},"labels":[],"label_agreement":null},{"id":"W4417009748","doi":"10.1182/blood-2025-5353","title":"Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"","keywords":"Follicular lymphoma; Refractory (planetary science); Dosing; Complete response; Phases of clinical research; Progressive disease; Follicular phase; Lymphoma","score_opus":0.008669991846502094,"score_gpt":0.2697400038793466,"score_spread":0.2610700120328445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99052024,0.00555075,0.00066516065,0.0001886357,0.000043458473,0.00035132025,0.00074736547,0.00007014266,0.0018628715],"genre_scores_gemma":[0.9970446,0.00068356,0.00025953917,0.00026376918,0.000041502946,0.00011545023,0.001128921,0.000011583209,0.00045100588],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99929214,0.00025845657,0.00006562185,0.00012359064,0.0001193447,0.00014077392],"domain_scores_gemma":[0.9988199,0.0002732816,0.000355658,0.00015809419,0.00012253,0.00027047642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027410605,0.00043993583,0.0010358084,0.00020025276,0.00035221272,0.00093361177,0.00038611735,0.00051717856,0.0015143262],"category_scores_gemma":[0.0013562784,0.00018831097,0.00077381905,0.00029381874,0.00027765692,0.0005879211,0.00021434383,0.0012217101,0.00046448436],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26651886,0.01475294,0.1341462,0.0010768643,0.0033651032,0.0006908251,0.0005245746,0.0025369078,0.11204855,0.00023741316,0.009576322,0.4545254],"study_design_scores_gemma":[0.06389453,0.37188956,0.5141767,0.00015776491,0.002933607,0.0022032405,0.00021775563,0.003421619,0.023880191,0.00028705053,0.016863413,0.000074532814],"about_ca_topic_score_codex":0.00046829143,"about_ca_topic_score_gemma":0.0009552908,"teacher_disagreement_score":0.0027410605,"about_ca_system_score_codex":0.00048564814,"about_ca_system_score_gemma":0.00044046118,"threshold_uncertainty_score":0.014496267},"labels":[],"label_agreement":null},{"id":"W4417009848","doi":"10.1182/blood-2025-5959","title":"Expanding access to haploidentical transplantation : Clinical feasibility of a centralized nationwide distribution model for fresh TCRα/β-depleted grafts in France","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Transplantation; Apheresis; Stem cell; CD19; Hematopoietic stem cell transplantation; Immune system; Interim","score_opus":0.09580000145381803,"score_gpt":0.44903173316484646,"score_spread":0.3532317317110284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93021363,0.0015305338,0.053114504,0.0015001234,0.00029246675,0.0019461772,0.00068107556,0.0011982986,0.009523243],"genre_scores_gemma":[0.9687395,0.0007037771,0.02402541,0.00056781265,0.00020779304,0.0011966744,0.0010977593,0.0001562252,0.0033051404],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99840504,0.0006922769,0.000049912127,0.00033363578,0.00020911812,0.000310073],"domain_scores_gemma":[0.998566,0.00025739783,0.0001764192,0.00019747425,0.00023515012,0.0005677068],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049293987,0.00064931443,0.00040144622,0.0006210923,0.0007910757,0.0017104351,0.0013156252,0.0008575893,0.009623762],"category_scores_gemma":[0.0015383895,0.00025027312,0.0006685249,0.00040760692,0.0008730154,0.0008657768,0.0013882285,0.00094581547,0.0020289894],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027095083,0.027796384,0.087611504,0.0008938717,0.00037746303,0.006035867,0.003274632,0.035082698,0.20044048,0.013823397,0.023780495,0.57378817],"study_design_scores_gemma":[0.025428552,0.15504834,0.30050477,0.0010228045,0.001163202,0.0145237185,0.00406298,0.0775679,0.14578173,0.006500969,0.26782542,0.00056953874],"about_ca_topic_score_codex":0.0060326215,"about_ca_topic_score_gemma":0.004791164,"teacher_disagreement_score":0.009623762,"about_ca_system_score_codex":0.0028689848,"about_ca_system_score_gemma":0.0034737396,"threshold_uncertainty_score":0.032194734},"labels":[],"label_agreement":null},{"id":"W4417010329","doi":"10.1182/blood-2025-925","title":"Initial results of a CRUK phase I/II, first in human trial of the CAR t-cell engager protein aleta-001 in patients who have received anti-CD19 CAR t-cell therapy for the treatment of b-cell malignancies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development","funders":"","keywords":"Tolerability; CD20; CD19; Phases of clinical research; Adverse effect; Refractory (planetary science); Cytokine release syndrome; Antigen; Chimeric antigen receptor","score_opus":0.04077552201564379,"score_gpt":0.3264877264865539,"score_spread":0.2857122044709101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667928,0.005971855,0.0049793688,0.0024773187,0.00035179185,0.00396315,0.007711825,0.00049657206,0.007255355],"genre_scores_gemma":[0.9704179,0.002847103,0.004289208,0.0030148746,0.00020282589,0.002852336,0.008881298,0.00019098703,0.007303533],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99945694,0.0002409165,0.000024498158,0.0000783684,0.00004685905,0.00015236103],"domain_scores_gemma":[0.99888927,0.000255932,0.0001346549,0.00010577633,0.000089496636,0.00052486145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021691632,0.0015693129,0.0015262477,0.00027348794,0.00040186028,0.0016393352,0.000740124,0.0016221575,0.004256852],"category_scores_gemma":[0.001358326,0.00040220944,0.0015276639,0.00026742416,0.0009175617,0.00094666384,0.0004530011,0.004204096,0.0013223353],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42746073,0.103511974,0.008813216,0.0020241013,0.0029085637,0.0011088252,0.00085833535,0.010496607,0.16766694,0.0012206783,0.031958684,0.24197148],"study_design_scores_gemma":[0.2676768,0.65976614,0.017943453,0.00013261531,0.0013590595,0.0012085073,0.00018170691,0.0036259182,0.02720089,0.0014255254,0.019387912,0.00009137608],"about_ca_topic_score_codex":0.00081270066,"about_ca_topic_score_gemma":0.0019922582,"teacher_disagreement_score":0.004256852,"about_ca_system_score_codex":0.0008176332,"about_ca_system_score_gemma":0.001063335,"threshold_uncertainty_score":0.014240563},"labels":[],"label_agreement":null},{"id":"W4417011029","doi":"10.1182/blood-2025-269","title":"Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Multiple myeloma; Clinical trial; Adverse effect; Phases of clinical research; Lenalidomide; Progressive disease; Safety profile","score_opus":0.02062231640243224,"score_gpt":0.30420295861852553,"score_spread":0.2835806422160933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899031,0.0052172826,0.000665449,0.000433037,0.000066416804,0.00037128883,0.001329379,0.00011383177,0.0019000788],"genre_scores_gemma":[0.99516135,0.0011928326,0.0005493478,0.0003929278,0.000047921614,0.00017296846,0.0016343647,0.000018342353,0.0008299652],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9995981,0.00019089808,0.000028579807,0.00006375464,0.000057526147,0.00006107914],"domain_scores_gemma":[0.9996045,0.00007577961,0.000105927,0.00003569352,0.000036990758,0.0001411219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012176011,0.0006185931,0.0009347742,0.000219053,0.00028790784,0.0007993429,0.00056274264,0.00063830445,0.0017812185],"category_scores_gemma":[0.0006719733,0.000206593,0.0007501456,0.00029422352,0.00049109117,0.00044787733,0.00024338478,0.002004489,0.00045768268],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35830635,0.035902016,0.023429273,0.0015477828,0.0023883749,0.00048936636,0.0004730033,0.005083478,0.21481061,0.00053275964,0.0126057705,0.3444312],"study_design_scores_gemma":[0.1621651,0.67792875,0.07416971,0.00013315784,0.0029014717,0.0018398159,0.00022351246,0.006927059,0.052395012,0.00078252517,0.020433687,0.00010018256],"about_ca_topic_score_codex":0.0012849731,"about_ca_topic_score_gemma":0.0033009078,"teacher_disagreement_score":0.0017812185,"about_ca_system_score_codex":0.0010161443,"about_ca_system_score_gemma":0.0009864945,"threshold_uncertainty_score":0.0073726177},"labels":[],"label_agreement":null},{"id":"W4417011298","doi":"10.1182/blood-2025-2369","title":"INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Société de Protection des Forêts contre les Insectes et Maladies","funders":"","keywords":"Blinatumomab; Chimeric antigen receptor; Gemtuzumab ozogamicin; Minimal residual disease; Salvage therapy; Acute lymphocytic leukemia; Cytokine release syndrome; Hematopoietic stem cell transplantation","score_opus":0.011148621871947857,"score_gpt":0.2673398979002521,"score_spread":0.2561912760283042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994293,0.000799662,0.00005578738,0.00015151036,0.000008110412,0.000031847347,0.003930956,0.0000071301206,0.0007220263],"genre_scores_gemma":[0.994547,0.0004194508,0.00010724243,0.00015014145,0.00002141194,0.00003213823,0.0045604943,0.000006059893,0.00015613207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99898976,0.00027436097,0.0001667203,0.00020353612,0.00019906595,0.00016652056],"domain_scores_gemma":[0.9949003,0.0005493168,0.0034453054,0.00015882985,0.00038442892,0.0005619629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011626608,0.00018483901,0.0003505006,0.00071554567,0.0002256632,0.00093926565,0.00048315202,0.0003605306,0.0016306062],"category_scores_gemma":[0.0034202896,0.00020420607,0.0004134359,0.001864131,0.00030454012,0.0004849251,0.00071011455,0.000473478,0.0002745816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023323232,0.00009926615,0.99028087,0.00006342149,0.00009385674,0.00018145704,0.00012450884,0.00018170345,0.00009320861,0.000033067972,0.0014890116,0.0050272024],"study_design_scores_gemma":[0.00025548937,0.00054087327,0.99537355,0.00006815165,0.0000835079,0.000721196,0.0004930372,0.00028933954,0.000103878716,0.00003159634,0.0020259724,0.000013538477],"about_ca_topic_score_codex":0.0176822,"about_ca_topic_score_gemma":0.015541678,"teacher_disagreement_score":0.0176822,"about_ca_system_score_codex":0.0016932454,"about_ca_system_score_gemma":0.0010412183,"threshold_uncertainty_score":0.035158575},"labels":[],"label_agreement":null},{"id":"W4417011616","doi":"10.1182/blood-2025-5807","title":"Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; T cell; Clinical trial; Phases of clinical research; Cytotoxicity; Hematopoietic stem cell transplantation; Antigen; Stem cell","score_opus":0.016471332803316262,"score_gpt":0.3027173890597998,"score_spread":0.2862460562564835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97081447,0.0035956583,0.0018092567,0.0018227731,0.00040720738,0.009019054,0.0065221605,0.00043690394,0.0055724457],"genre_scores_gemma":[0.9513258,0.0034972224,0.0053003607,0.0034275267,0.0005024736,0.013826205,0.011278605,0.00015510255,0.010686651],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99934274,0.00030044746,0.000023847033,0.00013061582,0.00006400155,0.0001384143],"domain_scores_gemma":[0.9989172,0.00013753827,0.00022576212,0.00010432731,0.00008041878,0.0005347238],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024805865,0.0024806384,0.0022945714,0.00040583406,0.00066858577,0.0016661944,0.0014395631,0.0022435372,0.008696293],"category_scores_gemma":[0.0014196822,0.0007194538,0.0014708085,0.00044090752,0.0013423522,0.0015119958,0.0004522857,0.005322167,0.0022159638],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8003838,0.08257333,0.004158088,0.0011082281,0.0015410234,0.0003166856,0.00032446932,0.0020241907,0.040228676,0.00065616023,0.011397942,0.055287413],"study_design_scores_gemma":[0.70633733,0.28139058,0.0040929774,0.00003677435,0.00039212315,0.00027399292,0.00006117061,0.00090961374,0.002215826,0.00038104109,0.0038805392,0.000027918319],"about_ca_topic_score_codex":0.0011435623,"about_ca_topic_score_gemma":0.0025389425,"teacher_disagreement_score":0.008696293,"about_ca_system_score_codex":0.0011844356,"about_ca_system_score_gemma":0.002424182,"threshold_uncertainty_score":0.029091954},"labels":[],"label_agreement":null},{"id":"W4417011724","doi":"10.1182/blood-2025-914","title":"Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Chimera (genetics); CD28; T cell; Multiple myeloma; Immunotherapy; Jurkat cells; Cell culture; Receptor","score_opus":0.025723857366887964,"score_gpt":0.3050658594412568,"score_spread":0.2793420020743688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978987,0.00060444156,0.000585968,0.000034456007,0.000019838511,0.00002777705,0.00017854202,0.000049973904,0.00060031575],"genre_scores_gemma":[0.9982079,0.00020989575,0.00043691054,0.000018291768,0.0000060694465,0.000023097418,0.00017538632,0.000004739624,0.00091755314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998425,0.000022628343,0.000016905196,0.000027635071,0.000037370286,0.00005281647],"domain_scores_gemma":[0.99991906,0.000015851581,0.000013132251,0.000013058631,0.000010314959,0.00002858484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020500552,0.00023227255,0.00035893163,0.00015081656,0.0001264618,0.00032055945,0.00019832845,0.0003538666,0.001029314],"category_scores_gemma":[0.00010707242,0.00007708581,0.00019863047,0.00017078889,0.00015197243,0.0001687887,0.00015334145,0.00079193286,0.00026454992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010805659,0.0003733463,0.00039777352,0.00007395892,0.000017849632,0.00006882391,0.00004163563,0.0007072757,0.9909587,0.00010236911,0.00018187985,0.005995926],"study_design_scores_gemma":[0.00015483928,0.00460216,0.0026555464,0.0000054836423,0.00004529492,0.00020805957,0.000021086424,0.0021758496,0.9884165,0.00003546827,0.0016748289,0.0000049471882],"about_ca_topic_score_codex":0.00090589304,"about_ca_topic_score_gemma":0.00074984255,"teacher_disagreement_score":0.001029314,"about_ca_system_score_codex":0.0002960666,"about_ca_system_score_gemma":0.00030085893,"threshold_uncertainty_score":0.00344342},"labels":[],"label_agreement":null},{"id":"W4417011989","doi":"10.1182/blood-2025-2178","title":"Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Frameshift mutation; Transcriptome; Romidepsin; Multiple myeloma; Exome sequencing; Bone marrow; Exome; Mutation","score_opus":0.02039897027117914,"score_gpt":0.29339179084607436,"score_spread":0.2729928205748952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726164,0.001663716,0.00058684347,0.000041293944,0.0000027661656,0.000010232165,0.00013388404,0.000011516538,0.00028806948],"genre_scores_gemma":[0.99891555,0.00040646576,0.00027141089,0.00003593496,0.000005222818,0.000006859217,0.0001764234,0.0000023616412,0.00017970859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99986553,0.000024084575,0.000006936021,0.000026071008,0.000049620234,0.000027844117],"domain_scores_gemma":[0.99989545,0.000020656687,0.00004754924,0.000010768222,0.000014204744,0.000011384231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022031882,0.00015937017,0.00025740443,0.0003337045,0.00013363735,0.0004758983,0.00014350556,0.00021677128,0.0007164635],"category_scores_gemma":[0.0002703147,0.0001125449,0.00019954657,0.0002290068,0.00016935471,0.00020217897,0.00021374364,0.000324911,0.00009858743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077402213,0.000107874126,0.18569683,0.00015783087,0.00017373869,0.00066657306,0.00019887673,0.001583517,0.77648836,0.00046323403,0.00025800208,0.033431135],"study_design_scores_gemma":[0.000050015427,0.000907797,0.8419216,0.00003246506,0.00012299987,0.0040335804,0.00027221968,0.0060571684,0.14124696,0.00052627624,0.004812507,0.000016455648],"about_ca_topic_score_codex":0.0004445081,"about_ca_topic_score_gemma":0.00067894714,"teacher_disagreement_score":0.0007164635,"about_ca_system_score_codex":0.00034026353,"about_ca_system_score_gemma":0.00013015736,"threshold_uncertainty_score":0.0024688244},"labels":[],"label_agreement":null},{"id":"W4417012274","doi":"10.1182/blood-2025-3735","title":"Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Saskatchewan Cancer Agency; University of Saskatchewan; McGill University; Jewish General Hospital","funders":"","keywords":"Clinical endpoint; Follicular lymphoma; Refractory (planetary science); Regimen; Phases of clinical research; Salvage therapy; Lymphoma; Combination therapy","score_opus":0.011221494668720168,"score_gpt":0.2776723305511716,"score_spread":0.2664508358824514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382955,0.0032603724,0.00041037533,0.00016095268,0.000035580404,0.00030309288,0.0005814407,0.000058256413,0.001360415],"genre_scores_gemma":[0.996801,0.00071993034,0.00028044198,0.00028851887,0.000037565896,0.00015047942,0.0011900576,0.000011412166,0.00052057963],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994816,0.00016252081,0.000045273515,0.000092688584,0.000084862106,0.00013310967],"domain_scores_gemma":[0.99930763,0.0001183601,0.00016202443,0.00008819765,0.00005930794,0.0002645174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017733291,0.00063889544,0.0014431704,0.00031788286,0.00042816027,0.0012243814,0.00050326,0.0005587267,0.0013295246],"category_scores_gemma":[0.0007097705,0.0002770202,0.0009998288,0.00040025395,0.00042727406,0.0006748372,0.00023441772,0.0016300412,0.00049272337],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3160235,0.031679574,0.1100207,0.00084927067,0.0049105557,0.00077467953,0.0005651915,0.0032831067,0.1096434,0.00022442134,0.0076282057,0.4143974],"study_design_scores_gemma":[0.11949051,0.49570602,0.34486058,0.00013614525,0.0035393815,0.0018730694,0.00023827184,0.0033813654,0.017169138,0.00032421117,0.013209893,0.000071404254],"about_ca_topic_score_codex":0.0007080947,"about_ca_topic_score_gemma":0.0018488686,"teacher_disagreement_score":0.0017733291,"about_ca_system_score_codex":0.00085500773,"about_ca_system_score_gemma":0.0006375569,"threshold_uncertainty_score":0.009378374},"labels":[],"label_agreement":null},{"id":"W4417012633","doi":"10.1182/blood-2025-3730","title":"First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lymphoma; Minimal residual disease; Refractory (planetary science); Aggressive lymphoma; Rituximab; Phases of clinical research","score_opus":0.01633925364020866,"score_gpt":0.31334122923914537,"score_spread":0.2970019755989367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98756844,0.009503771,0.00025769934,0.00050394784,0.0001985911,0.0003860703,0.00032556683,0.00007577084,0.0011801065],"genre_scores_gemma":[0.9945531,0.0020637223,0.00029365037,0.00072331325,0.00016594585,0.00025820316,0.00077531976,0.000012747259,0.0011539888],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99973935,0.00011994742,0.000012021786,0.00004278448,0.000027952341,0.0000578154],"domain_scores_gemma":[0.9994143,0.000108167595,0.00011654642,0.000047851227,0.000026662367,0.00028644796],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008695857,0.00069240574,0.0015031183,0.0002706783,0.00024123187,0.0009808097,0.0006084557,0.00093287905,0.003646167],"category_scores_gemma":[0.0005012543,0.00026927344,0.0011757084,0.00029462547,0.0005527768,0.00092479517,0.00031672395,0.0024747998,0.0009808013],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8089926,0.025853096,0.009215208,0.000678675,0.0014045773,0.00014726393,0.00012980019,0.0011938275,0.012115657,0.00018310975,0.003537359,0.13654885],"study_design_scores_gemma":[0.45533413,0.5106126,0.024584753,0.00013517406,0.00092670653,0.0002988353,0.000085585176,0.001510859,0.0024217968,0.00028134408,0.003775111,0.000033035507],"about_ca_topic_score_codex":0.00045703023,"about_ca_topic_score_gemma":0.00086382724,"teacher_disagreement_score":0.003646167,"about_ca_system_score_codex":0.0006056721,"about_ca_system_score_gemma":0.00052644,"threshold_uncertainty_score":0.012197614},"labels":[],"label_agreement":null},{"id":"W4417014679","doi":"10.1182/blood-2025-3921","title":"Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Integrity Testing Laboratory (Canada)","funders":"","keywords":"Multiple myeloma; Bone marrow; Hematologic malignancy; Tumor microenvironment; Immunotherapy; Immunophenotyping; Flow cytometry","score_opus":0.018818863979529792,"score_gpt":0.28286349146779455,"score_spread":0.26404462748826474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99857247,0.0004051398,0.0006450794,0.00001654788,0.0000016501884,0.0000036715894,0.00015614541,0.000015500395,0.00018379888],"genre_scores_gemma":[0.999042,0.00008574351,0.00049688324,0.000014726973,0.0000019162153,0.0000060516836,0.00018244298,0.000004374931,0.00016594492],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987006,0.000022316412,0.000008389286,0.000036388647,0.000027798662,0.00003513088],"domain_scores_gemma":[0.99991465,0.000012498674,0.000028711345,0.000008544621,0.000014837674,0.000020789417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021510645,0.00011796047,0.00017579837,0.0006271406,0.00016857928,0.00036533046,0.00015329746,0.00020250562,0.0010214593],"category_scores_gemma":[0.00018299698,0.00014204584,0.00017586761,0.0003680093,0.00017576736,0.00014956476,0.00023851942,0.00017705448,0.0002457539],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014782095,0.000054669275,0.1464276,0.0000682721,0.000079627716,0.00038711677,0.000216894,0.00059402897,0.83691114,0.00014716793,0.00021157326,0.013423627],"study_design_scores_gemma":[0.000024099609,0.00020896221,0.9252495,0.000006542065,0.000046818666,0.0011070374,0.00041985975,0.004249329,0.06765288,0.00017124675,0.00085532863,0.000008299985],"about_ca_topic_score_codex":0.0011654766,"about_ca_topic_score_gemma":0.0012821173,"teacher_disagreement_score":0.0011654766,"about_ca_system_score_codex":0.00020114987,"about_ca_system_score_gemma":0.000101602986,"threshold_uncertainty_score":0.0034170747},"labels":[],"label_agreement":null},{"id":"W4417014962","doi":"10.1182/blood-2025-5505","title":"Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytopenia; Neutropenia; Rituximab; Febrile neutropenia; Lymphoma; Leukopenia; Salvage therapy; Anemia; Refractory (planetary science)","score_opus":0.006640684584130754,"score_gpt":0.23728001324453102,"score_spread":0.23063932866040027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993957,0.00022608342,0.00006809361,0.0000148762365,0.0000017858217,0.000009512623,0.00008375704,0.000002970473,0.00019712312],"genre_scores_gemma":[0.9996419,0.000057818146,0.000049236452,0.000017561455,0.0000075999533,0.000005504687,0.0001469451,0.0000010753399,0.00007228833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99979585,0.000056961966,0.00002764153,0.000046514775,0.00003565619,0.000037412865],"domain_scores_gemma":[0.999137,0.00015840294,0.00045883737,0.000030090643,0.000059251906,0.00015653658],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042271795,0.00020476426,0.00034445792,0.00044885246,0.00023270237,0.00049336086,0.00024564148,0.0003270086,0.0006774986],"category_scores_gemma":[0.0010301371,0.00016939008,0.00023705303,0.0005781923,0.0002191721,0.00037211017,0.000283724,0.00036968954,0.00016936958],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008184563,0.00008004462,0.99478745,0.000021023936,0.000020733056,0.0009648054,0.00006733596,0.00008193329,0.0007170413,0.000011649707,0.000058510926,0.0023709722],"study_design_scores_gemma":[0.000060726325,0.0018228935,0.9910746,0.0000121799585,0.00005034745,0.005711352,0.00012905995,0.00047725867,0.0003253006,0.000030324807,0.0002993725,0.000006615274],"about_ca_topic_score_codex":0.0009949607,"about_ca_topic_score_gemma":0.0011413145,"teacher_disagreement_score":0.0009949607,"about_ca_system_score_codex":0.00031627706,"about_ca_system_score_gemma":0.00024728637,"threshold_uncertainty_score":0.0022947788},"labels":[],"label_agreement":null},{"id":"W4417016543","doi":"10.1182/blood-2025-5524","title":"A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lymphoma; Follicular lymphoma; Dosing; Macroglobulinemia; In vivo; Antibody; Waldenstrom macroglobulinemia; Chronic lymphocytic leukemia; Toxicity","score_opus":0.019152295503091648,"score_gpt":0.30541245797784644,"score_spread":0.2862601624747548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97541636,0.0038272345,0.0018342907,0.0016446271,0.00029066997,0.0062290267,0.00454113,0.00038503073,0.005831624],"genre_scores_gemma":[0.9633212,0.0028325731,0.0042289807,0.0028673543,0.0002975336,0.0065066917,0.008918427,0.000125261,0.010901964],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99961984,0.00016216116,0.00001362354,0.000066296285,0.000036955007,0.00010114549],"domain_scores_gemma":[0.9995365,0.00006702364,0.00007708504,0.000034031615,0.000033236585,0.00025214953],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001415926,0.0020763138,0.0013587051,0.0003204287,0.00055927684,0.0013617735,0.0009618724,0.001901187,0.0067843585],"category_scores_gemma":[0.00060902804,0.0004969292,0.0009146873,0.00027812057,0.0007776446,0.0012634835,0.00051606464,0.0042160964,0.0016769991],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54252535,0.11662378,0.0064885966,0.0017084082,0.0016853596,0.00078994344,0.0005913647,0.0038957745,0.12113413,0.0012003356,0.028447397,0.1749096],"study_design_scores_gemma":[0.44037727,0.5256809,0.0071469513,0.00007311675,0.00037417302,0.0007308284,0.00009336181,0.0014699519,0.011693142,0.000675315,0.011634742,0.000050294453],"about_ca_topic_score_codex":0.0006608095,"about_ca_topic_score_gemma":0.0020099825,"teacher_disagreement_score":0.0067843585,"about_ca_system_score_codex":0.0010113862,"about_ca_system_score_gemma":0.0015154846,"threshold_uncertainty_score":0.022695899},"labels":[],"label_agreement":null},{"id":"W4417017123","doi":"10.1182/blood-2025-2719","title":"Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prehabilitation; Logistic regression; Rehabilitation; Retrospective cohort study; Prospective cohort study; Minimal clinically important difference; Adverse effect","score_opus":0.012517721578787345,"score_gpt":0.3067540450047023,"score_spread":0.294236323425915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991598,0.00022909281,0.00004598096,0.000021737398,0.000003288216,0.000015926218,0.00022260919,0.0000029503276,0.0002986426],"genre_scores_gemma":[0.9994375,0.000049091643,0.000028625893,0.000020019996,0.000008594773,0.000017313076,0.0003405451,7.927226e-7,0.000097444645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99962115,0.000090874106,0.000045737008,0.00007540873,0.00006704702,0.00009975002],"domain_scores_gemma":[0.99878913,0.00011999603,0.00061004545,0.00003780325,0.00013270574,0.00031020143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004172973,0.00020752345,0.00037295328,0.000556398,0.00038184298,0.0005699277,0.0002382878,0.0003293426,0.0010667782],"category_scores_gemma":[0.0010748237,0.00010607052,0.00035193717,0.00059059815,0.00023319143,0.00033030636,0.00037726568,0.00042831377,0.00014875832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027112992,0.000105921354,0.9976655,0.000011310481,0.000025789652,0.000080154874,0.000020478486,0.000070057016,0.00015883446,0.000003432614,0.00005303636,0.0015343595],"study_design_scores_gemma":[0.000008780052,0.0003553953,0.99920696,0.000004182623,0.000012821928,0.0001440901,0.00004033585,0.000075800424,0.000080394704,0.000006052833,0.00006309182,0.0000020236473],"about_ca_topic_score_codex":0.0034225152,"about_ca_topic_score_gemma":0.0046674344,"teacher_disagreement_score":0.0034225152,"about_ca_system_score_codex":0.00045247196,"about_ca_system_score_gemma":0.00038261534,"threshold_uncertainty_score":0.006805241},"labels":[],"label_agreement":null},{"id":"W4417017792","doi":"10.1182/blood-2025-133","title":"Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cytopenia; Comorbidity; Retrospective cohort study; Transplantation; Cohort; Cohort study; Multiple myeloma; Multivariate analysis","score_opus":0.013317002783837507,"score_gpt":0.30222040276787254,"score_spread":0.288903399984035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713755,0.00042044473,0.00014339811,0.00005272475,0.0000074407685,0.000056240187,0.0017588716,0.0000044626713,0.00041893963],"genre_scores_gemma":[0.99751186,0.00010368554,0.00010208418,0.00006206456,0.000015419799,0.000043480588,0.0020796868,0.0000025093634,0.0000791239],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802196,0.0007505553,0.00026516098,0.00041246347,0.00034819104,0.00020155095],"domain_scores_gemma":[0.9939313,0.0010004984,0.0034791017,0.00050657697,0.00049124693,0.00059131894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036439523,0.0003508832,0.00073573267,0.000898854,0.00039765052,0.0012014981,0.00062009925,0.00042564998,0.0019331218],"category_scores_gemma":[0.005857342,0.00019792852,0.0015166273,0.0011652975,0.00037330564,0.00067916233,0.0008111209,0.0006219566,0.00028632293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008851542,0.0003976639,0.98237336,0.000115645365,0.001561631,0.000086420565,0.00009004735,0.00034624693,0.00031213503,0.00006897075,0.0004871225,0.005309072],"study_design_scores_gemma":[0.0006337529,0.004153923,0.9908494,0.000042532007,0.0009298035,0.00037831205,0.00021976829,0.0014160053,0.00018511093,0.0000708334,0.0010939528,0.000026657206],"about_ca_topic_score_codex":0.0018673039,"about_ca_topic_score_gemma":0.0020541844,"teacher_disagreement_score":0.0036439523,"about_ca_system_score_codex":0.00069078436,"about_ca_system_score_gemma":0.00057912414,"threshold_uncertainty_score":0.019271255},"labels":[],"label_agreement":null},{"id":"W4417017939","doi":"10.1182/blood-2025-803","title":"Deletion of TRAF3 and CYLD and NIK amplification activates NF-kb signalling and drives resistance to T cell based therapies in multiple myeloma by suppressing T cell activity","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"CRISPR; Cas9; Chimeric antigen receptor; T cell; HEK 293 cells; Gene; Genome editing; Multiple myeloma; Cell","score_opus":0.015826011956377666,"score_gpt":0.2684716832338972,"score_spread":0.2526456712775195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420565,0.00047655008,0.0029713623,0.00007331958,0.000014874625,0.00003850942,0.0010695701,0.00012639983,0.0010237322],"genre_scores_gemma":[0.9956684,0.00027809347,0.0016787302,0.000031005802,0.0000037496259,0.000027418635,0.0006607362,0.000029756233,0.0016220321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983966,0.0000223317,0.000027785622,0.000031609914,0.000044071774,0.00003450894],"domain_scores_gemma":[0.9999087,0.000014582663,0.0000348279,0.0000128379825,0.000005128574,0.000024004852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013195563,0.00026281903,0.00021924295,0.00022569913,0.0001578838,0.00030934712,0.00017326983,0.00022591422,0.001766147],"category_scores_gemma":[0.00007794049,0.00011421993,0.0002805007,0.00019449984,0.00024941986,0.00011231225,0.00022830979,0.00048411984,0.00055530894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004987647,0.000017358474,0.00024357732,0.000021956439,0.0000044195244,0.00005385624,0.0000072464613,0.00006115546,0.9987876,0.000057078283,0.00002587219,0.0006700577],"study_design_scores_gemma":[0.000021897358,0.00020285952,0.0053893807,0.000005933845,0.000022682978,0.00060537225,0.000027729735,0.00095910125,0.99000204,0.000032332555,0.0027265626,0.0000040377877],"about_ca_topic_score_codex":0.000645084,"about_ca_topic_score_gemma":0.0008298801,"teacher_disagreement_score":0.001766147,"about_ca_system_score_codex":0.00028387769,"about_ca_system_score_gemma":0.00019660362,"threshold_uncertainty_score":0.00590837},"labels":[],"label_agreement":null},{"id":"W4417018394","doi":"10.1182/blood-2025-5918","title":"Lipid nanoparticle-mediated mRNA transfection enables efficient and safe generation of CAR macrophages.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Transfection; Chimeric antigen receptor; Genetic enhancement; Carcinogenesis; Cytokine; Immune system; Cancer cell; Cancer; Immunotherapy","score_opus":0.01825271170035706,"score_gpt":0.272377285400817,"score_spread":0.25412457370045993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8968423,0.0029960312,0.08843199,0.0005890815,0.00020533912,0.00021037004,0.00047263436,0.00067213975,0.009580074],"genre_scores_gemma":[0.9674841,0.00089511904,0.023798902,0.00017724007,0.000021957027,0.00011845024,0.0003571856,0.00007275604,0.007074245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998554,0.000020663838,0.000010477328,0.000043130927,0.00003854513,0.00003175908],"domain_scores_gemma":[0.99993455,0.000012407239,0.000021115653,0.000008725921,0.000014943925,0.0000082673205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022627768,0.00024921115,0.0001453163,0.00016769367,0.00015948815,0.0002418735,0.0001534879,0.00034855757,0.0010907914],"category_scores_gemma":[0.00013813154,0.00012741913,0.00021896072,0.000093830415,0.00019882868,0.0001913968,0.00026147088,0.0003745899,0.00073861645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035657595,0.000015167938,0.000054441593,0.00002933623,0.0000020672242,0.000050564184,0.0000128628735,0.00006999778,0.9969512,0.0002583148,0.00009916731,0.0024212042],"study_design_scores_gemma":[0.00000875139,0.00011658087,0.00018851452,0.000003479184,0.000007385803,0.000121574325,0.000007835342,0.0010386584,0.99449867,0.000047564536,0.003957625,0.000003390696],"about_ca_topic_score_codex":0.00038544595,"about_ca_topic_score_gemma":0.00054833706,"teacher_disagreement_score":0.0010907914,"about_ca_system_score_codex":0.00029201136,"about_ca_system_score_gemma":0.00029014066,"threshold_uncertainty_score":0.003649056},"labels":[],"label_agreement":null},{"id":"W4417018574","doi":"10.1182/blood-2025-5661","title":"Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Cytotoxicity; CD19; Peripheral blood mononuclear cell; Ex vivo; Chronic lymphocytic leukemia; Immune system; Flow cytometry; Immunotherapy; CD20","score_opus":0.007096418163613456,"score_gpt":0.2436032348991928,"score_spread":0.23650681673557936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9994455,0.00015125608,0.000104621664,0.0000049604137,0.0000015364388,0.0000052807104,0.00008770234,0.0000045909724,0.00019457095],"genre_scores_gemma":[0.99952745,0.00003221703,0.0001050622,0.000010310721,0.0000030356803,0.000005203985,0.00019823661,0.0000013764841,0.00011722626],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981946,0.00004745892,0.000016263706,0.000046703095,0.000038995782,0.000031175656],"domain_scores_gemma":[0.99966836,0.000093086506,0.00010698926,0.000024385432,0.000040015737,0.000067152956],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022203074,0.0001455712,0.00021036253,0.0002863999,0.00017230454,0.00034950173,0.00008910277,0.00019625094,0.0008350867],"category_scores_gemma":[0.00047581238,0.000089360496,0.00010077183,0.00025385755,0.0001343197,0.0001475143,0.000172838,0.0002607467,0.00018626466],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009168857,0.000559548,0.7545881,0.00007143131,0.00009627939,0.0010659358,0.00030627425,0.0009772282,0.20831959,0.00007300728,0.00033231333,0.024441386],"study_design_scores_gemma":[0.00008037671,0.0041410355,0.9604912,0.000005810112,0.00006836489,0.0022279723,0.0001204126,0.0013466352,0.030590631,0.000031148043,0.00088525214,0.000011222291],"about_ca_topic_score_codex":0.0004691232,"about_ca_topic_score_gemma":0.0005725245,"teacher_disagreement_score":0.0008350867,"about_ca_system_score_codex":0.00023035976,"about_ca_system_score_gemma":0.00008689433,"threshold_uncertainty_score":0.0027936697},"labels":[],"label_agreement":null},{"id":"W4417018940","doi":"10.1182/blood-2025-443","title":"CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fludarabine; Minimal residual disease; Chimeric antigen receptor; Tolerability; Cohort; Toxicity; Discontinuation; CAR T-cell therapy; Maintenance therapy","score_opus":0.023340242369378365,"score_gpt":0.3057704639602916,"score_spread":0.28243022159091324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9987452,0.00040613528,0.00014660496,0.000058883208,0.000013141352,0.00013093946,0.000098688055,0.000021314087,0.00037909983],"genre_scores_gemma":[0.9983677,0.00031093348,0.00035108102,0.00012858731,0.000026485914,0.00012733707,0.00025858395,0.000004004575,0.00042510265],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998528,0.000054942695,0.000011917622,0.000030350457,0.000018134479,0.000031909636],"domain_scores_gemma":[0.99978036,0.000025580448,0.000036292262,0.000025831334,0.000013071707,0.000118783],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056362484,0.00030494452,0.00064261997,0.00016329833,0.00023823397,0.00038778156,0.00029130146,0.00036860176,0.0017728589],"category_scores_gemma":[0.0003105735,0.00013384153,0.00029600254,0.00015352872,0.00029079392,0.00031157915,0.00020400154,0.0009672274,0.00037737718],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29844242,0.07588943,0.066669874,0.0006530602,0.0006626056,0.0005227602,0.00059466803,0.00326096,0.18506905,0.00038665792,0.0057722246,0.36207628],"study_design_scores_gemma":[0.054225083,0.8132449,0.09708661,0.000068532376,0.0005432073,0.00087929575,0.0001427082,0.0024566262,0.02365206,0.00022549601,0.0074532586,0.000022254977],"about_ca_topic_score_codex":0.0005626171,"about_ca_topic_score_gemma":0.0013091436,"teacher_disagreement_score":0.0017728589,"about_ca_system_score_codex":0.00033818264,"about_ca_system_score_gemma":0.0004906195,"threshold_uncertainty_score":0.0059307814},"labels":[],"label_agreement":null},{"id":"W4417019591","doi":"10.1182/blood-2025-3567","title":"Single-cell metabolic profiling of T cells identifies a fitness signature associated with early CAR T failure in large B cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Princess Margaret Cancer Centre","funders":"","keywords":"Metabolic pathway; Peripheral blood mononuclear cell; Pentose phosphate pathway; Citric acid cycle; Metabolism; T cell; Leukapheresis; Glycolysis; Lymphoma","score_opus":0.010410907551201793,"score_gpt":0.24733133903413448,"score_spread":0.23692043148293268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99824023,0.00044617304,0.0005401659,0.000018757662,0.0000022182116,0.000009201503,0.0005118903,0.000019590952,0.00021165718],"genre_scores_gemma":[0.99851817,0.00017042899,0.000499631,0.000023237866,0.0000036599058,0.00001847196,0.00055917236,0.0000066503553,0.00020052814],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9999192,0.000012549302,0.0000051243933,0.000026075613,0.000017719745,0.000019363491],"domain_scores_gemma":[0.99991286,0.000014739573,0.000027809132,0.0000065461427,0.000015484371,0.000022619102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000121580255,0.00016566619,0.000291106,0.00062763446,0.00014875179,0.00043675594,0.000103513215,0.00026754555,0.0009187852],"category_scores_gemma":[0.00017534452,0.00008760034,0.00014382364,0.0004896711,0.00012423046,0.00015647574,0.0001625235,0.00020431455,0.00023659578],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015195159,0.00006146224,0.1005843,0.000058547485,0.000034729845,0.00020589933,0.000057391255,0.00035470005,0.88756174,0.000046143592,0.00015436803,0.009361257],"study_design_scores_gemma":[0.00003255644,0.0009337259,0.84388477,0.000014512175,0.00007767159,0.0016809646,0.00026284208,0.003717247,0.14797707,0.0002383815,0.00116619,0.000014046514],"about_ca_topic_score_codex":0.000431091,"about_ca_topic_score_gemma":0.00043290565,"teacher_disagreement_score":0.0009187852,"about_ca_system_score_codex":0.00019510163,"about_ca_system_score_gemma":0.0000793028,"threshold_uncertainty_score":0.0030736327},"labels":[],"label_agreement":null},{"id":"W4417019669","doi":"10.1182/blood-2025-4596","title":"Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Innovative Research Group (Canada)","funders":"","keywords":"Incidence (geometry); Multiple myeloma; Lenalidomide; Medical record; Cohort; Retrospective cohort study; Interim analysis; Chart; Medical diagnosis","score_opus":0.02433128109997328,"score_gpt":0.3200725747195481,"score_spread":0.2957412936195748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082386,0.00044872123,0.000209823,0.0001980881,0.000011788082,0.000046986108,0.0072397287,0.000011623513,0.0010094235],"genre_scores_gemma":[0.99526876,0.00029177402,0.00022726197,0.000097770826,0.00001855618,0.000050852643,0.003879165,0.000005080463,0.00016079334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986261,0.00027696154,0.0002648543,0.00039265637,0.0002555227,0.00018387925],"domain_scores_gemma":[0.99475175,0.00055105827,0.003542437,0.0002231771,0.0005738469,0.00035770575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000952429,0.00016053097,0.00024210261,0.0012266857,0.0005202365,0.0010043312,0.00051405496,0.00030103597,0.0018568875],"category_scores_gemma":[0.0053355223,0.00019355227,0.00035357106,0.00202389,0.0002343261,0.00071819953,0.00082172913,0.00071263814,0.00027910608],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054030188,0.000030076313,0.99705005,0.000022860459,0.000030103776,0.000074806165,0.00010303392,0.000050550152,0.000027045937,0.000042217824,0.0006308957,0.0018843233],"study_design_scores_gemma":[0.000009209195,0.00010859122,0.99630874,0.000087801745,0.00003517552,0.00059105013,0.0008259018,0.0004960513,0.000116173185,0.0000733928,0.0013382974,0.000009510229],"about_ca_topic_score_codex":0.015646923,"about_ca_topic_score_gemma":0.01914929,"teacher_disagreement_score":0.015646923,"about_ca_system_score_codex":0.0011429111,"about_ca_system_score_gemma":0.001221229,"threshold_uncertainty_score":0.031111717},"labels":[],"label_agreement":null},{"id":"W4417020065","doi":"10.1182/blood-2025-2647","title":"Healthcare resource utilization with prophylactic intravenous anakinra following anti-CD19 CAR-T therapy in B-cell lymphoma: A Canadian single-center quality improvement experience.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Anakinra; Population; Cytokine release syndrome; Incidence (geometry); Retrospective cohort study; Adverse effect; Quality management","score_opus":0.041472522109953135,"score_gpt":0.3212215139428803,"score_spread":0.2797489918329272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279237,0.0011456003,0.00027377647,0.0007892771,0.000024078236,0.00020478175,0.0036028996,0.000018599441,0.0011487007],"genre_scores_gemma":[0.9968886,0.00045084392,0.0003511613,0.00019514516,0.000012042619,0.000053041324,0.0019029288,0.0000041239446,0.00014209696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962782,0.00062823266,0.00036295192,0.0004898355,0.0013739743,0.00086678035],"domain_scores_gemma":[0.98689854,0.00074325496,0.0054321643,0.00032175254,0.0037438222,0.0028605354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035926586,0.00030187977,0.0004601098,0.001065057,0.0016481847,0.0016279899,0.0012520506,0.00042339874,0.0007793683],"category_scores_gemma":[0.008129283,0.00022527926,0.00064985245,0.004482804,0.00061851676,0.0005571353,0.0012644732,0.00066919514,0.00008126087],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031136774,0.00021284708,0.98671806,0.000090519214,0.00014949992,0.000051940224,0.0006223407,0.00031006453,0.00017348595,0.00007000254,0.001635935,0.009653932],"study_design_scores_gemma":[0.000049354232,0.0002760337,0.9973169,0.00003628019,0.000052611762,0.00004784858,0.00070334476,0.0005393639,0.00008508645,0.000012746504,0.00086612935,0.00001431164],"about_ca_topic_score_codex":0.8748548,"about_ca_topic_score_gemma":0.89851964,"teacher_disagreement_score":0.1251452,"about_ca_system_score_codex":0.03093615,"about_ca_system_score_gemma":0.040673487,"threshold_uncertainty_score":0.25176436},"labels":[],"label_agreement":null},{"id":"W4417021970","doi":"10.1182/blood-2025-4119","title":"Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Gene isoform; Alternative splicing; Myeloid leukemia; Transcriptome; Protein isoform; Exon; Intron; Chimeric antigen receptor; RNA splicing","score_opus":0.025361823637314998,"score_gpt":0.3108893188318013,"score_spread":0.28552749519448634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93388736,0.0009729973,0.05286713,0.00011880388,0.000089361994,0.000120089615,0.009217347,0.0009361254,0.0017906897],"genre_scores_gemma":[0.891808,0.0008291091,0.081636734,0.00017938635,0.000032269887,0.00021729941,0.022337677,0.00039852498,0.002560965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99974424,0.000021376549,0.000018442048,0.000076802746,0.00011005557,0.00002910581],"domain_scores_gemma":[0.99978167,0.000049430695,0.000072287265,0.000020719046,0.000049580827,0.000026307984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028295437,0.0003524129,0.00039259772,0.0004972331,0.00034144003,0.000573694,0.00020039926,0.00033510532,0.001554179],"category_scores_gemma":[0.00031481622,0.00016617833,0.0005516042,0.00050922274,0.00015764417,0.0002166721,0.00022151902,0.0004946782,0.0010265714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017101913,0.000032566037,0.005615917,0.00010097156,0.000021611038,0.00010750663,0.00003418641,0.0014733052,0.9814803,0.0002404678,0.0004317193,0.010290376],"study_design_scores_gemma":[0.000032552074,0.00033363025,0.050401825,0.000037097823,0.0001364186,0.00089922326,0.00013908918,0.046804488,0.8857488,0.0010467219,0.014388547,0.00003154715],"about_ca_topic_score_codex":0.0005200692,"about_ca_topic_score_gemma":0.000776928,"teacher_disagreement_score":0.001554179,"about_ca_system_score_codex":0.00036704293,"about_ca_system_score_gemma":0.0003248029,"threshold_uncertainty_score":0.005199313},"labels":[],"label_agreement":null},{"id":"W4417034000","doi":"10.15173/m.v1i48.4040","title":"Shifting Gears: CAR NK-Cell Therapy vs. CAR T-cell Therapy","year":2025,"lang":"","type":"article","venue":"The Meducator","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Population health; MEDLINE; Public health; Population; Health care","score_opus":0.033220540556206136,"score_gpt":0.3329429600252085,"score_spread":0.29972241946900235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417034000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.42085323,0.1423918,0.08765011,0.046506196,0.013249138,0.00085719745,0.00064282055,0.0023615467,0.28548795],"genre_scores_gemma":[0.921126,0.016769446,0.01601732,0.004661408,0.0012241394,0.00027927148,0.00011865653,0.0002231476,0.03958061],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923503,0.00018457115,0.000027735101,0.00014655886,0.00022909934,0.00017700606],"domain_scores_gemma":[0.9996722,0.00012116906,0.000055927027,0.00005328874,0.000030090801,0.000067300614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012153926,0.00050999195,0.00085111335,0.00056329346,0.0005665921,0.0015971845,0.00084644556,0.0012100051,0.027232295],"category_scores_gemma":[0.0014378766,0.00020548754,0.0006104445,0.00031688038,0.0011841987,0.0015770926,0.0012050638,0.0020534054,0.0035450477],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051046414,0.00071329734,0.0013484294,0.000877341,0.00011941826,0.00023999948,0.00027555283,0.0018512054,0.04225476,0.04349518,0.015267596,0.8884524],"study_design_scores_gemma":[0.0034531893,0.019153727,0.009188569,0.0013615979,0.0009180738,0.005470496,0.0013344475,0.012344435,0.15775612,0.07781326,0.7109921,0.00021404431],"about_ca_topic_score_codex":0.0005791625,"about_ca_topic_score_gemma":0.00087619125,"teacher_disagreement_score":0.027232295,"about_ca_system_score_codex":0.00079703477,"about_ca_system_score_gemma":0.00079434994,"threshold_uncertainty_score":0.09110111},"labels":[],"label_agreement":null},{"id":"W4417116629","doi":"10.64898/2025.12.01.691479","title":"Cryptic leukemia antigens share homology with microbial epitopes and stimulate T-cell responses in healthy donors","year":2025,"lang":"","type":"article","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Computer Research Institute of Montréal; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Epitope; T-cell receptor; Antigen; Leukemia; Repertoire; Major histocompatibility complex; Homology (biology); Myeloid leukemia","score_opus":0.014099169579146295,"score_gpt":0.2628099371199695,"score_spread":0.24871076754082316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417116629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978332,0.0002659206,0.0008267949,0.00003056365,0.00001223202,0.000037373018,0.00017266777,0.000027917597,0.00079345173],"genre_scores_gemma":[0.998425,0.000120913144,0.0003749653,0.000056309145,0.000008135498,0.00003041071,0.00022363922,0.0000064618343,0.0007541823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99980253,0.000039570466,0.000014112972,0.000059425198,0.000030927156,0.000053536132],"domain_scores_gemma":[0.9998503,0.00003343452,0.00002551022,0.00002307126,0.000013131549,0.00005456097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021318655,0.00024537204,0.00020695517,0.00018270723,0.00013246268,0.00021045882,0.00010145612,0.00021244836,0.0032826304],"category_scores_gemma":[0.00021629829,0.000097900636,0.00014662632,0.00011837695,0.00011950988,0.0001295431,0.0002629155,0.0005025431,0.0005548923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012014426,0.00029243424,0.0054629515,0.000057630252,0.0000134042475,0.00028020248,0.00007241376,0.00015316972,0.9853694,0.00010046458,0.00015861193,0.0068378546],"study_design_scores_gemma":[0.0005132966,0.016968416,0.1380094,0.000058403824,0.00014433597,0.007526958,0.00054400525,0.0051893503,0.8221555,0.000724293,0.00813287,0.000033122353],"about_ca_topic_score_codex":0.00031396587,"about_ca_topic_score_gemma":0.00020969268,"teacher_disagreement_score":0.0032826304,"about_ca_system_score_codex":0.00016471626,"about_ca_system_score_gemma":0.000118989425,"threshold_uncertainty_score":0.0109815},"labels":[],"label_agreement":null},{"id":"W4417129324","doi":"10.1158/2326-6066.cir-25-0070","title":"A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; McMaster University Medical Centre","funders":"Institute of Cancer Research; Terry Fox Foundation; Canada Research Chairs","keywords":"Boosting (machine learning); Antigen; Chimeric antigen receptor; Adoptive cell transfer; Cytotoxic T cell; Epitope; Immunotherapy; Cancer immunotherapy","score_opus":0.1669757946377332,"score_gpt":0.44288927577131776,"score_spread":0.27591348113358455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8438651,0.0047636237,0.147759,0.00017306185,0.00014383622,0.00043814158,0.00012559409,0.00051699055,0.0022146297],"genre_scores_gemma":[0.9544177,0.0010605514,0.04306252,0.00011774429,0.000028890356,0.00011156888,0.00009183464,0.000029233664,0.0010799579],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9996215,0.00006469039,0.00002614471,0.0001120623,0.00006840268,0.00010726775],"domain_scores_gemma":[0.99988997,0.000012644535,0.000032879285,0.00002851526,0.000010890347,0.000025085197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038621307,0.00077832065,0.00057572155,0.0002984796,0.00013591899,0.00041693263,0.00042337392,0.0004930842,0.0008389018],"category_scores_gemma":[0.00016896486,0.00027744047,0.00044971093,0.0001941602,0.00039432576,0.0004574646,0.0005520073,0.0010830691,0.0003084195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016453955,0.00019484365,0.00036597997,0.000116718424,0.00002591086,0.000101130805,0.000028277016,0.0012055561,0.98125136,0.00077611476,0.00011206998,0.01565733],"study_design_scores_gemma":[0.000059804333,0.0024283563,0.00080188696,0.000012550454,0.00010542535,0.00087105413,0.000018070361,0.0071360967,0.9828928,0.00022462639,0.005434834,0.000014471503],"about_ca_topic_score_codex":0.00020792452,"about_ca_topic_score_gemma":0.0003066252,"teacher_disagreement_score":0.0008389018,"about_ca_system_score_codex":0.00027069304,"about_ca_system_score_gemma":0.00039401534,"threshold_uncertainty_score":0.002806425},"labels":[],"label_agreement":null},{"id":"W4417129956","doi":"10.58931/cht.2025.4378","title":"Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Centre Hospitalier Universitaire de Québec; Royal College of Physicians and Surgeons of Canada; Université Laval","keywords":"Chimeric antigen receptor; Lymphoma; Cytokine release syndrome; Bispecific antibody; Blinatumomab; Immunotherapy; Aggressive lymphoma; Antibody","score_opus":0.023746943467071464,"score_gpt":0.3227101856237286,"score_spread":0.29896324215665715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129956","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038621657,0.66663903,0.066167526,0.103792965,0.00348578,0.0006987299,0.00040280184,0.0015108587,0.11868067],"genre_scores_gemma":[0.27506042,0.5487254,0.09837367,0.04293943,0.0070909974,0.00055810553,0.0010100744,0.00024200877,0.025999848],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99964833,0.00006740518,0.000035548564,0.000025116859,0.00014686199,0.00007683713],"domain_scores_gemma":[0.9996805,0.000055692828,0.00004761062,0.000012082441,0.000105935454,0.00009815899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006274491,0.0005405461,0.0006541811,0.0008480456,0.0010272807,0.001032234,0.0007992313,0.0011350639,0.0024525623],"category_scores_gemma":[0.0011858682,0.00019048505,0.0003828459,0.00060494227,0.0006466706,0.00073057157,0.00085372064,0.0025380503,0.0010079953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001935454,0.00013482658,0.0050118384,0.0015403886,0.00005810179,0.028016716,0.00054994534,0.0013721526,0.009086231,0.0061555463,0.14404482,0.803836],"study_design_scores_gemma":[0.00016163784,0.00030324893,0.009619334,0.0016608367,0.0001337433,0.07048607,0.0010508244,0.0012793466,0.0053795897,0.009809367,0.90005016,0.0000657612],"about_ca_topic_score_codex":0.022807518,"about_ca_topic_score_gemma":0.057085343,"teacher_disagreement_score":0.022807518,"about_ca_system_score_codex":0.0022257536,"about_ca_system_score_gemma":0.003716894,"threshold_uncertainty_score":0.04534948},"labels":[],"label_agreement":null},{"id":"W4417240262","doi":"10.1038/s41409-025-02756-2","title":"Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Centre hospitalier régional universitaire de Lille","keywords":"Supply chain; Quality assurance; Consumables; Quality (philosophy); Production (economics); Vendor; Work (physics); Bioproduction; Product (mathematics)","score_opus":0.025242305742883667,"score_gpt":0.31009439351359885,"score_spread":0.2848520877707152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417240262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.50449324,0.025550738,0.3256743,0.042580277,0.001346869,0.0074772877,0.0034534489,0.0026107272,0.08681307],"genre_scores_gemma":[0.731418,0.007936332,0.22995648,0.0046012197,0.0006388971,0.0021664903,0.0048835515,0.00069435046,0.01770461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.96178454,0.018299775,0.0025657185,0.0032295967,0.011529856,0.0025905522],"domain_scores_gemma":[0.943679,0.012473536,0.012812794,0.011546735,0.016508685,0.00297926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04414186,0.0009944646,0.0006912371,0.0042338828,0.004042775,0.012185325,0.0026553795,0.0020662132,0.0068413736],"category_scores_gemma":[0.036529664,0.00045814714,0.0008496888,0.005064127,0.0037155256,0.005340373,0.00456461,0.0016918419,0.0031097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010828618,0.00059303816,0.09575778,0.0024617112,0.00017060373,0.0011590176,0.00793993,0.0061988807,0.03565332,0.035992663,0.017833445,0.79515666],"study_design_scores_gemma":[0.00018900642,0.0030437969,0.15846592,0.0033435433,0.00031676205,0.002720394,0.012401872,0.0096729025,0.11935669,0.016428001,0.6736971,0.00036408115],"about_ca_topic_score_codex":0.02954721,"about_ca_topic_score_gemma":0.023718245,"teacher_disagreement_score":0.04414186,"about_ca_system_score_codex":0.013143977,"about_ca_system_score_gemma":0.040402763,"threshold_uncertainty_score":0.23344725},"labels":[],"label_agreement":null},{"id":"W4417314003","doi":"10.64898/2025.12.08.692978","title":"Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; CD8; Gene; Chimeric antigen receptor; Plasma cell; Immune system; Transcriptome; Antigen; Cell","score_opus":0.022029275944860698,"score_gpt":0.27076268269340675,"score_spread":0.24873340674854605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417314003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958644,0.00057308574,0.0020650653,0.00015461537,0.000014021954,0.000009200796,0.00037894462,0.00007733685,0.00086329394],"genre_scores_gemma":[0.9972314,0.00022128213,0.000869039,0.00007195992,0.0000076091237,0.000007726009,0.00041416593,0.00001746886,0.0011592718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988425,0.000017668823,0.0000052570904,0.000026847836,0.000041903368,0.00002397951],"domain_scores_gemma":[0.9999467,0.000012677383,0.000014339036,0.00000839269,0.0000066075504,0.000011383098],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016791128,0.00013579542,0.0002552981,0.00019659386,0.00012968152,0.00034543214,0.00010467236,0.00028499358,0.0013473808],"category_scores_gemma":[0.00019246648,0.00009208605,0.00015416715,0.00020722965,0.000160619,0.00010566156,0.00017827861,0.000484262,0.00033099292],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026683902,0.000040004157,0.004853287,0.00003309021,0.000021098971,0.00024808288,0.000051372186,0.000627148,0.98681796,0.00026364048,0.00039086316,0.0063867723],"study_design_scores_gemma":[0.000067522924,0.0004972221,0.10940293,0.00001240066,0.00005334117,0.0023530896,0.0001862001,0.014874929,0.86134326,0.0009788083,0.010218641,0.000011692349],"about_ca_topic_score_codex":0.00049578305,"about_ca_topic_score_gemma":0.00047712037,"teacher_disagreement_score":0.0013473808,"about_ca_system_score_codex":0.0002877015,"about_ca_system_score_gemma":0.00013569147,"threshold_uncertainty_score":0.004507482},"labels":[],"label_agreement":null},{"id":"W4417329705","doi":"10.18609/cgti.2025.034","title":"CAR-T manufacturing intensification: the next wave of CAR-T commercialization","year":2025,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Medical Association","funders":"","keywords":"Commercialization; Manufacturing; Manufacturing sector; Advanced manufacturing; Intersection (aeronautics); Health care","score_opus":0.062189352294689616,"score_gpt":0.29876343330783983,"score_spread":0.23657408101315022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417329705","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024193583,0.105223395,0.032342993,0.7448642,0.013341814,0.0004902077,0.00027140393,0.00082461955,0.07844776],"genre_scores_gemma":[0.2667111,0.16227698,0.092111975,0.40612587,0.014597047,0.00044469917,0.0011594415,0.00068675476,0.055886075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941977,0.0013152708,0.00031891782,0.0007143921,0.0026145584,0.00083909987],"domain_scores_gemma":[0.9911765,0.003091418,0.0007063585,0.00031860004,0.003302184,0.0014049613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015796484,0.0007347017,0.0004893692,0.0011753489,0.0019026289,0.010274405,0.0014952167,0.006767126,0.012452978],"category_scores_gemma":[0.009280806,0.000366599,0.0013309568,0.0008195556,0.0026501655,0.011070824,0.0035170654,0.008952674,0.002502894],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037287804,0.0004176952,0.0025953855,0.0013667437,0.000054460656,0.0009734752,0.0012484973,0.001224407,0.023486149,0.18982126,0.30372444,0.4747146],"study_design_scores_gemma":[0.000046234058,0.00048252038,0.0009132039,0.0006939058,0.000030984535,0.0006273465,0.0013627249,0.0011230046,0.008709459,0.02993733,0.9560199,0.000053408174],"about_ca_topic_score_codex":0.0011839382,"about_ca_topic_score_gemma":0.0024909284,"teacher_disagreement_score":0.015796484,"about_ca_system_score_codex":0.0037022524,"about_ca_system_score_gemma":0.010278561,"threshold_uncertainty_score":0.0835408},"labels":[],"label_agreement":null},{"id":"W4417334990","doi":"10.18609/cgti.2025.008","title":"Driving innovation in cell and gene therapy: the role of AI and robotics","year":2025,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"OmniActive Health Technologies (Canada)","funders":"","keywords":"Robotics; Pharmaceutical industry; Field (mathematics); Robot","score_opus":0.017972079512783453,"score_gpt":0.2777696302803272,"score_spread":0.25979755076754374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417334990","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009388037,0.2085883,0.08085614,0.561844,0.014855662,0.000099893354,0.00015782595,0.0005733278,0.12363682],"genre_scores_gemma":[0.46346065,0.23054583,0.08566409,0.15473738,0.018425573,0.00040996063,0.00022604116,0.00038804155,0.046142418],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952721,0.0020284744,0.00014584958,0.0004379681,0.0016225706,0.00049310783],"domain_scores_gemma":[0.9912969,0.005283055,0.00063508307,0.00049427006,0.001238659,0.0010520119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0092331525,0.0006643558,0.0006381615,0.0011827501,0.0016265915,0.0059510944,0.0012724149,0.003906322,0.007542232],"category_scores_gemma":[0.008177646,0.00023260011,0.00060541346,0.0007992743,0.01615275,0.008057669,0.0025792476,0.006298996,0.00220494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012000012,0.000096543525,0.0009307076,0.00094664836,0.0000592598,0.00014461298,0.0009737505,0.001075884,0.0027139445,0.7582294,0.08389616,0.15081307],"study_design_scores_gemma":[0.000042788015,0.00020370974,0.0006897862,0.0006638992,0.00002178315,0.00029664292,0.00087221933,0.001601581,0.0022580593,0.46455416,0.52872247,0.00007299104],"about_ca_topic_score_codex":0.0024549586,"about_ca_topic_score_gemma":0.0023944778,"teacher_disagreement_score":0.0092331525,"about_ca_system_score_codex":0.003181012,"about_ca_system_score_gemma":0.0049091196,"threshold_uncertainty_score":0.04883015},"labels":[],"label_agreement":null},{"id":"W4417360235","doi":"10.1186/s13073-025-01583-w","title":"Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma","year":2025,"lang":"en","type":"article","venue":"Genome Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canada Foundation for Innovation; Princess Margaret Cancer Foundation","keywords":"Repertoire; Peripheral blood mononuclear cell; Adoptive cell transfer; Melanoma; Immunotherapy; T cell; Cancer immunotherapy","score_opus":0.015885862884638263,"score_gpt":0.2818221286523561,"score_spread":0.26593626576771784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417360235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974879,0.00042441,0.0015910132,0.000011593698,0.000005554733,0.000019053916,0.0001113022,0.000024476656,0.000324571],"genre_scores_gemma":[0.9976406,0.00019300167,0.0014565114,0.000032043772,0.00000803729,0.000037852402,0.0002840111,0.000007852596,0.0003399787],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9998833,0.00002067567,0.000005454792,0.00004039307,0.000033887452,0.000016286926],"domain_scores_gemma":[0.9998524,0.000039548144,0.00003612856,0.000017402737,0.000028942015,0.00002554443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023470778,0.00015296994,0.00024423885,0.00022285046,0.00012001591,0.00023253026,0.0001072359,0.00017604361,0.000775306],"category_scores_gemma":[0.0002843189,0.00008847883,0.00012570233,0.00014630778,0.00013652963,0.00014254244,0.0001235256,0.00033833276,0.00023653713],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013444509,0.00012423778,0.023919113,0.00007478359,0.00002249279,0.00009099318,0.00014421981,0.0007269835,0.95181787,0.000023518509,0.00011447155,0.021596879],"study_design_scores_gemma":[0.00007530923,0.008723515,0.33275402,0.000025289843,0.00015755165,0.0016920978,0.0002731875,0.010344261,0.6429426,0.00014199832,0.0028512774,0.000018825225],"about_ca_topic_score_codex":0.00017627171,"about_ca_topic_score_gemma":0.00022847313,"teacher_disagreement_score":0.000775306,"about_ca_system_score_codex":0.00010917035,"about_ca_system_score_gemma":0.00008143758,"threshold_uncertainty_score":0.0025936365},"labels":[],"label_agreement":null},{"id":"W4417412714","doi":"10.33540/3350","title":"Empowering CAR T Cell Therapy","year":2025,"lang":"","type":"dissertation","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Granzyme B; Cytotoxic T cell; T cell; Chimeric antigen receptor; Granzyme; Immune system; Immunotherapy; Effector","score_opus":0.03078821477318786,"score_gpt":0.3795749101656454,"score_spread":0.3487866953924575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417412714","genre_codex":"methods","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18638651,0.23140633,0.32399863,0.013071701,0.0042151366,0.0009909194,0.0014258234,0.0039269165,0.23457816],"genre_scores_gemma":[0.6213543,0.14746892,0.09114518,0.007635757,0.0013742383,0.0010852184,0.0011180536,0.00038575075,0.12843263],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99983096,0.000024540397,0.0000054326765,0.000038582988,0.000055567612,0.000044872315],"domain_scores_gemma":[0.99995565,0.00001122576,0.0000071324926,0.0000047802346,0.000010287326,0.000010898575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022338249,0.0003743291,0.0002637312,0.00027958545,0.0002195959,0.0009804817,0.0003943955,0.00083457166,0.0073577655],"category_scores_gemma":[0.00017538216,0.0002434456,0.0003959368,0.00018444764,0.0003021585,0.00059567555,0.0008211327,0.0014168776,0.0027325999],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021220226,0.00030369186,0.00046872417,0.0014644624,0.000053099862,0.00044783766,0.00033003863,0.0064987876,0.57040423,0.06180232,0.036778167,0.3212364],"study_design_scores_gemma":[0.000088698696,0.000662847,0.0003575018,0.0001296649,0.000050772276,0.00075146515,0.000064115615,0.006801138,0.25717285,0.010521876,0.72336566,0.000033386812],"about_ca_topic_score_codex":0.00026342436,"about_ca_topic_score_gemma":0.00046601307,"teacher_disagreement_score":0.0073577655,"about_ca_system_score_codex":0.00049273483,"about_ca_system_score_gemma":0.0004445524,"threshold_uncertainty_score":0.024614215},"labels":[],"label_agreement":null},{"id":"W4417432359","doi":"10.1080/13696998.2025.2600217","title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Antibody therapy; Immunotherapy; Salvage therapy; Cell therapy; Safety profile","score_opus":0.12464273081717334,"score_gpt":0.41862964772985595,"score_spread":0.29398691691268264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417432359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003202148,0.99485284,0.0004505523,0.00021826239,0.00013040254,0.0003513794,0.0005017326,0.00001916074,0.00027351864],"genre_scores_gemma":[0.11985044,0.8747464,0.0020936655,0.0007549329,0.00021421976,0.0013446305,0.0006645361,0.000026676471,0.00030444228],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99052763,0.004815302,0.0025486446,0.00074969465,0.0010738359,0.00028494955],"domain_scores_gemma":[0.9818841,0.013887145,0.0025035688,0.00033968344,0.0011778766,0.00020761638],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013481334,0.0028249773,0.021605179,0.0080015715,0.0005442714,0.0037157745,0.0021922125,0.0022816556,0.004326828],"category_scores_gemma":[0.032564227,0.0016337904,0.037786536,0.008197008,0.0007316411,0.0018964245,0.0013980643,0.0020400991,0.0002979792],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015180364,0.000028442451,0.0013808697,0.5214433,0.4605494,0.000110143345,0.00004604688,0.0009035596,0.0001394047,0.00019366741,0.00058784644,0.013099234],"study_design_scores_gemma":[0.0007562035,0.00020693208,0.0018509928,0.042714175,0.9520543,0.00010309309,0.000038047332,0.0003381279,0.000105347615,0.00026184373,0.0015468905,0.00002407202],"about_ca_topic_score_codex":0.008408166,"about_ca_topic_score_gemma":0.014774326,"teacher_disagreement_score":0.021605179,"about_ca_system_score_codex":0.004318953,"about_ca_system_score_gemma":0.004406654,"threshold_uncertainty_score":0.07129693},"labels":[],"label_agreement":null},{"id":"W4417524948","doi":"10.1016/j.cels.2025.101458","title":"Harnessing heterogeneity for the rational design of cell manufacturing","year":2025,"lang":"en","type":"article","venue":"Cell Systems","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Research Council Canada; Natural Sciences and Engineering Research Council of Canada; Juvenile Diabetes Research Foundation Canada; Killam Trusts; Canadian Institutes of Health Research; Breakthrough T1D Canada; Sick Kids Foundation; Michael Smith Health Research BC; Stem Cell Network; Hospital for Sick Children; University of British Columbia; Paul G. Allen Frontiers Group; Canada Research Chairs","keywords":"Robustness (evolution); Multicellular organism; Quality by Design; Synthetic biology; Quality (philosophy); Bioprocess; Macro; Systems biology; Rational design","score_opus":0.05901936482559499,"score_gpt":0.3237736670058372,"score_spread":0.2647543021802422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417524948","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27126744,0.008014824,0.6956312,0.0016136093,0.0004195712,0.00035779263,0.00030450197,0.00071970077,0.021671258],"genre_scores_gemma":[0.8865818,0.0033183096,0.10678506,0.00030737938,0.00006889392,0.0003165568,0.00022305288,0.000102203085,0.0022967544],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9996049,0.00009177666,0.000028829907,0.000082133076,0.00012570056,0.00006671922],"domain_scores_gemma":[0.9996026,0.00016385812,0.00006356817,0.00008806456,0.000047016256,0.00003494941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008705997,0.0005818978,0.0007209167,0.0004557156,0.00047098758,0.001385327,0.00097482227,0.0006992099,0.0016888275],"category_scores_gemma":[0.0013249365,0.00044231207,0.00050009484,0.00044534597,0.0008652531,0.0014769039,0.0011699015,0.0013447745,0.0007319591],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021095625,0.0002772214,0.00092037127,0.00067183614,0.00006513566,0.00035341023,0.00018188044,0.0903657,0.6709994,0.17174384,0.0015074157,0.06270285],"study_design_scores_gemma":[0.0001742798,0.001070651,0.00046779125,0.0000854559,0.000078329795,0.00043005345,0.00015909073,0.22659114,0.6220353,0.10106555,0.047737293,0.000105055726],"about_ca_topic_score_codex":0.00029265153,"about_ca_topic_score_gemma":0.00058678386,"teacher_disagreement_score":0.0016888275,"about_ca_system_score_codex":0.00089046557,"about_ca_system_score_gemma":0.0005993596,"threshold_uncertainty_score":0.006460786},"labels":[],"label_agreement":null},{"id":"W48601634","doi":"10.1182/blood.v122.21.168.168","title":"Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CD19; Antigen; Immunology; Cyclophosphamide; Chimeric antigen receptor; T cell; Internal medicine; Immune system; Chemotherapy","score_opus":0.007627921460208917,"score_gpt":0.2469499303169068,"score_spread":0.23932200885669788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W48601634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939137,0.0029266253,0.0010495852,0.00011131547,0.00003391031,0.00016510506,0.000094256146,0.00005674534,0.0016486471],"genre_scores_gemma":[0.99683553,0.0013676541,0.0007982181,0.0000779779,0.0000371336,0.00007949412,0.0002504978,0.000014068809,0.00053945556],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998647,0.00004372244,0.0000080924665,0.000021950098,0.000024462106,0.000037096383],"domain_scores_gemma":[0.9998746,0.000036668793,0.000018631212,0.000022158898,0.000004289697,0.000043720873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004070955,0.0004384065,0.000757664,0.0003088061,0.00021486888,0.0003678842,0.00029829697,0.0002664042,0.0010408816],"category_scores_gemma":[0.00024758387,0.00015582745,0.00036436267,0.00022005364,0.00036142376,0.00027679792,0.0002509266,0.00059904036,0.00030250236],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024665533,0.01209649,0.01420589,0.000687884,0.0006053153,0.0045112125,0.00059807155,0.0076092966,0.5602908,0.0012977642,0.002731695,0.3707],"study_design_scores_gemma":[0.05773325,0.39901695,0.10734415,0.00014470181,0.0015349847,0.014633069,0.00027675054,0.010626426,0.36878407,0.0010216706,0.038788233,0.00009574309],"about_ca_topic_score_codex":0.00042059465,"about_ca_topic_score_gemma":0.0008906289,"teacher_disagreement_score":0.0010408816,"about_ca_system_score_codex":0.00027734338,"about_ca_system_score_gemma":0.00020528857,"threshold_uncertainty_score":0.0034821033},"labels":[],"label_agreement":null},{"id":"W52169269","doi":"10.12816/0003105","title":"A New Cellular Weapon to Kill Leukaemic B-Cells = سلاح خلوي جديد لقتل خلايا ( ب ) المسببة لإبيضاض الدم","year":2012,"lang":"ar","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pathology","score_opus":0.019287422055067893,"score_gpt":0.27191967702565834,"score_spread":0.25263225497059044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W52169269","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13423257,0.6447387,0.056491807,0.02202192,0.014869878,0.0003972299,0.00071484037,0.0006280455,0.12590505],"genre_scores_gemma":[0.4412758,0.33818334,0.039613802,0.010307971,0.0056972736,0.0004955063,0.0005579969,0.00014983426,0.16371837],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999248,0.000013502612,0.000003597266,0.000013642742,0.000028166349,0.000016330298],"domain_scores_gemma":[0.9999647,0.0000078894,0.000005855623,0.0000024168455,0.0000105725685,0.0000085574775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016875812,0.00025537357,0.00023939225,0.00029644396,0.00023439784,0.00056205783,0.00027643688,0.0005275156,0.011076291],"category_scores_gemma":[0.0001146525,0.000091786824,0.00021197327,0.00018256983,0.00032126255,0.00051201775,0.00038028674,0.00074702787,0.0033004328],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040462436,0.00036745428,0.00076441065,0.002138648,0.0000813212,0.0008014619,0.00019519779,0.0008652603,0.42351136,0.04743081,0.038292244,0.4851473],"study_design_scores_gemma":[0.000078211946,0.00069620926,0.0010382058,0.00022338402,0.000046031215,0.001702585,0.000095907555,0.0009951313,0.14268705,0.0069492464,0.84546334,0.000024625555],"about_ca_topic_score_codex":0.0001956663,"about_ca_topic_score_gemma":0.00028475458,"teacher_disagreement_score":0.011076291,"about_ca_system_score_codex":0.00033159996,"about_ca_system_score_gemma":0.00016690834,"threshold_uncertainty_score":0.037053943},"labels":[],"label_agreement":null},{"id":"W56457892","doi":"10.1182/blood.v122.21.144.144","title":"Co-Administration Of Gene-Modified CD4+ T Cells Targeting HLA Class I-Restricted WT1 Epitope Diversely Enhances The Antitumor Effect Mediated By Redirected T-Cell Based Adoptive Immunotherapy Against Human Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"CD8; Cytotoxic T cell; Biology; T cell; Immunotherapy; Adoptive cell transfer; Epitope; T-cell receptor; Interleukin 21; Cancer research; Immunology; Molecular biology; Antigen; Immune system; In vitro","score_opus":0.012433194291963979,"score_gpt":0.2701206179103804,"score_spread":0.2576874236184164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W56457892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99806064,0.0003539844,0.0010053893,0.000030650255,0.00002025804,0.00002286622,0.000058858615,0.000045905592,0.00040142014],"genre_scores_gemma":[0.99743253,0.0002530757,0.0011484784,0.000023636256,0.000012838731,0.000029149549,0.00010730154,0.000011475817,0.0009815042],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998074,0.00003292546,0.000021268617,0.0000446435,0.000040087234,0.000053775362],"domain_scores_gemma":[0.99993634,0.000008735712,0.000019052763,0.000010334565,0.00000629947,0.000019240693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010923419,0.00046318048,0.00040468283,0.00017247204,0.000090456524,0.0002476422,0.00016327466,0.0002337096,0.0008353402],"category_scores_gemma":[0.000080189566,0.000111778376,0.00019464047,0.00011286634,0.00021660022,0.00017690701,0.00018108074,0.0007718777,0.00023486538],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023440336,0.00010347723,0.0001231334,0.00002654635,0.000006088623,0.000024660078,0.000012245893,0.00014355763,0.99791366,0.000052304054,0.000026462383,0.0013335887],"study_design_scores_gemma":[0.000047382568,0.0014578478,0.0012020726,0.000003237072,0.00003481349,0.00013998749,0.000014613917,0.0012013998,0.9949575,0.000021367487,0.0009162987,0.00000350266],"about_ca_topic_score_codex":0.00022465615,"about_ca_topic_score_gemma":0.00027471673,"teacher_disagreement_score":0.0008353402,"about_ca_system_score_codex":0.000138384,"about_ca_system_score_gemma":0.00016425044,"threshold_uncertainty_score":0.0027944446},"labels":[],"label_agreement":null},{"id":"W6893073646","doi":"10.5281/zenodo.14529586","title":"A guide to selecting high-performing antibodies for hnRNP H2 (UniProt ID: P55795) for use in western blot and immunoprecipitation","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Immunoprecipitation; Western blot; Gene knockdown; Antibody; Blot; Cell culture","score_opus":0.04721923933878736,"score_gpt":0.31920405446804484,"score_spread":0.2719848151292575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6893073646","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013971852,0.013330165,0.65643483,0.0045416686,0.0024786205,0.011627724,0.17586738,0.06427112,0.057476636],"genre_scores_gemma":[0.009497175,0.009903392,0.6866232,0.0023991272,0.0007497134,0.016292868,0.21119732,0.015106267,0.048230838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963229,0.0008971266,0.0005997165,0.0006031801,0.0011281188,0.00044903028],"domain_scores_gemma":[0.99443495,0.0020018944,0.0003085227,0.0013258649,0.001392543,0.00053611747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044926438,0.005274262,0.003956191,0.008120998,0.0032988084,0.0027451473,0.0048562377,0.0026259017,0.13318105],"category_scores_gemma":[0.007460721,0.005921193,0.00240326,0.004521464,0.0010988263,0.0019044626,0.0021241424,0.0048247557,0.17438832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013883733,0.00060689065,0.0014125501,0.0028175167,0.00023636055,0.001321387,0.00027616377,0.0008654726,0.4749127,0.0027459753,0.42404312,0.089373566],"study_design_scores_gemma":[0.0004168588,0.0006345484,0.005491996,0.0004406418,0.00017956576,0.0042776973,0.00012931836,0.0019385624,0.10909582,0.0033296428,0.87381953,0.00024584212],"about_ca_topic_score_codex":0.0018491212,"about_ca_topic_score_gemma":0.007293547,"teacher_disagreement_score":0.13318105,"about_ca_system_score_codex":0.0008245988,"about_ca_system_score_gemma":0.0021117297,"threshold_uncertainty_score":0.445535},"labels":[],"label_agreement":null},{"id":"W6893197593","doi":"10.5281/zenodo.14529585","title":"A guide to selecting high-performing antibodies for hnRNP H2 (UniProt ID: P55795) for use in western blot and immunoprecipitation","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Immunoprecipitation; Western blot; Gene knockdown; Antibody; Blot; Cell culture","score_opus":0.04721923933878736,"score_gpt":0.31920405446804484,"score_spread":0.2719848151292575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6893197593","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013971852,0.013330165,0.65643483,0.0045416686,0.0024786205,0.011627724,0.17586738,0.06427112,0.057476636],"genre_scores_gemma":[0.009497175,0.009903392,0.6866232,0.0023991272,0.0007497134,0.016292868,0.21119732,0.015106267,0.048230838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963229,0.0008971266,0.0005997165,0.0006031801,0.0011281188,0.00044903028],"domain_scores_gemma":[0.99443495,0.0020018944,0.0003085227,0.0013258649,0.001392543,0.00053611747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044926438,0.005274262,0.003956191,0.008120998,0.0032988084,0.0027451473,0.0048562377,0.0026259017,0.13318105],"category_scores_gemma":[0.007460721,0.005921193,0.00240326,0.004521464,0.0010988263,0.0019044626,0.0021241424,0.0048247557,0.17438832],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013883733,0.00060689065,0.0014125501,0.0028175167,0.00023636055,0.001321387,0.00027616377,0.0008654726,0.4749127,0.0027459753,0.42404312,0.089373566],"study_design_scores_gemma":[0.0004168588,0.0006345484,0.005491996,0.0004406418,0.00017956576,0.0042776973,0.00012931836,0.0019385624,0.10909582,0.0033296428,0.87381953,0.00024584212],"about_ca_topic_score_codex":0.0018491212,"about_ca_topic_score_gemma":0.007293547,"teacher_disagreement_score":0.13318105,"about_ca_system_score_codex":0.0008245988,"about_ca_system_score_gemma":0.0021117297,"threshold_uncertainty_score":0.445535},"labels":[],"label_agreement":null},{"id":"W6901869847","doi":"10.6084/m9.figshare.13627439","title":"Additional file 1 of Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa; Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD22; B cell; Immunotherapy; CAR T-cell therapy; T cell; Antigen","score_opus":0.059103660297845015,"score_gpt":0.3460429781788807,"score_spread":0.28693931788103566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901869847","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020006858,0.00961447,0.0022051514,0.0010912633,0.00028058182,0.05220676,0.92819685,0.00048644142,0.003917823],"genre_scores_gemma":[0.032377508,0.01752428,0.029857064,0.0038931214,0.00060880225,0.6707903,0.21765865,0.0005625573,0.026727647],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713635,0.0008456102,0.0011763637,0.00033932336,0.00033960518,0.00016279795],"domain_scores_gemma":[0.9714475,0.020821873,0.0046817395,0.000614978,0.002144019,0.00028974688],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0067321123,0.0023481145,0.0060584433,0.0053420193,0.0007958455,0.001942879,0.0016216927,0.0018409473,0.56053114],"category_scores_gemma":[0.042514157,0.0012891853,0.0070520258,0.006923075,0.00051925436,0.0029999102,0.0013882986,0.0013925465,0.014505276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034906545,0.00009020249,0.0006521728,0.89864045,0.003115979,0.000082311904,0.00013341328,0.00043981127,0.00039401764,0.0010451864,0.07827857,0.013637146],"study_design_scores_gemma":[0.10000319,0.0025483717,0.022629969,0.4604685,0.048501797,0.0006639582,0.00055851566,0.002506745,0.0017110067,0.01069172,0.34921464,0.0005016024],"about_ca_topic_score_codex":0.0047620335,"about_ca_topic_score_gemma":0.013734684,"teacher_disagreement_score":0.56053114,"about_ca_system_score_codex":0.0030881048,"about_ca_system_score_gemma":0.0050819507,"threshold_uncertainty_score":0.62684894},"labels":[],"label_agreement":null},{"id":"W6901903496","doi":"10.6084/m9.figshare.22611196.v1","title":"Additional file 1 of Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Protocol (science); Patient data; MEDLINE; Data collection; Systematic review","score_opus":0.2836596883364506,"score_gpt":0.4036598257093907,"score_spread":0.12000013737294007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901903496","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042492614,0.00060711964,0.0015219236,0.0004041316,0.00011082419,0.0074506835,0.98798066,0.00036079952,0.001138918],"genre_scores_gemma":[0.020975055,0.00309341,0.041955303,0.0036679052,0.00046432068,0.47680578,0.42862138,0.0012211005,0.023195846],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9957825,0.0015337121,0.0013033365,0.0006342317,0.0004957722,0.00025054123],"domain_scores_gemma":[0.9011113,0.08334848,0.006787095,0.0029391684,0.005225796,0.0005881527],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011586899,0.0020115478,0.0033248274,0.00497452,0.0010367399,0.0020956376,0.0024297475,0.0021261354,0.7818535],"category_scores_gemma":[0.10771544,0.0016876294,0.005855995,0.00720332,0.00062545366,0.0027718248,0.0016908951,0.0017793161,0.037157077],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032356188,0.00018689617,0.0021105658,0.3553286,0.0032246634,0.00013523441,0.0002753949,0.0014832354,0.00027947882,0.0039987327,0.6087094,0.021032188],"study_design_scores_gemma":[0.10498367,0.0017092687,0.027529294,0.14813067,0.021045279,0.0008771316,0.00072801183,0.0050955927,0.0016863764,0.042989407,0.6445385,0.0006868437],"about_ca_topic_score_codex":0.0063346163,"about_ca_topic_score_gemma":0.013887379,"teacher_disagreement_score":0.7818535,"about_ca_system_score_codex":0.0023906275,"about_ca_system_score_gemma":0.0073956144,"threshold_uncertainty_score":0.3111595},"labels":[],"label_agreement":null},{"id":"W6901931657","doi":"10.6084/m9.figshare.12284570.v1","title":"Additional file 4 of Effect of flavophospholipol on fecal microbiota in weaned pigs challenged with Salmonella Typhimurium","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Feces; Salmonella; Enterobacteriaceae; Bacteria; Strain (injury); Weaning","score_opus":0.029424589864597814,"score_gpt":0.2664882744342145,"score_spread":0.2370636845696167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901931657","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004084223,0.000019211398,0.00020612168,0.00006662581,0.000027536911,0.00007754904,0.99828255,0.0003495299,0.000562449],"genre_scores_gemma":[0.022584606,0.00020798859,0.0071087405,0.00066021085,0.00012093169,0.003329365,0.9466601,0.0014721086,0.017856061],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99947816,0.000073127965,0.000074309544,0.00013635421,0.00014333664,0.000094737574],"domain_scores_gemma":[0.99038273,0.0070148953,0.00072272465,0.00049179327,0.0010982024,0.0002895447],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013047396,0.0008817145,0.0011580278,0.0012146183,0.0007347297,0.001264696,0.0012723871,0.0009958645,0.86160654],"category_scores_gemma":[0.013713481,0.00043564447,0.0009339939,0.0016764818,0.0002348562,0.0011308689,0.0007167462,0.00067585055,0.128404],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018970463,0.0003468272,0.0057094623,0.0072795884,0.00015209349,0.00013159732,0.00011983775,0.0007710127,0.00089939666,0.0005102105,0.9660583,0.016124647],"study_design_scores_gemma":[0.015699526,0.0021190045,0.10008725,0.0075740707,0.00061413477,0.00082393846,0.00094597455,0.0041641854,0.004244462,0.008478638,0.85494334,0.00030547773],"about_ca_topic_score_codex":0.0052233874,"about_ca_topic_score_gemma":0.010234387,"teacher_disagreement_score":0.86160654,"about_ca_system_score_codex":0.0006375408,"about_ca_system_score_gemma":0.0012434574,"threshold_uncertainty_score":0.19740146},"labels":[],"label_agreement":null},{"id":"W6901999208","doi":"10.6084/m9.figshare.13093610.v1","title":"Additional file 3 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen; Immune system","score_opus":0.10496957802123638,"score_gpt":0.33786207164941817,"score_spread":0.2328924936281818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901999208","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012095219,0.00004582778,0.00029972204,0.00043970763,0.00005953472,0.00031567473,0.99539644,0.00026284586,0.003059317],"genre_scores_gemma":[0.016317924,0.00069296604,0.0077118184,0.004136901,0.0005494798,0.010491113,0.9128126,0.001836032,0.045451272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972554,0.0007708583,0.0006706121,0.0004009368,0.0005635682,0.00033865374],"domain_scores_gemma":[0.90235335,0.07792334,0.0058845305,0.0032521351,0.008548548,0.0020380556],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0054642167,0.00091354985,0.0015728837,0.00274975,0.0009811233,0.002572437,0.0017083805,0.0017923173,0.91422373],"category_scores_gemma":[0.09438513,0.0006532198,0.0013016714,0.0045931377,0.000362127,0.002524578,0.0015326062,0.0012485576,0.17521021],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055774336,0.000056542893,0.001118519,0.0046782345,0.00006070339,0.00004278804,0.000041922085,0.00030183527,0.000039400413,0.0010538286,0.98280877,0.009239666],"study_design_scores_gemma":[0.012952809,0.0004312531,0.01895955,0.010804131,0.00037536462,0.00038952,0.00040547518,0.0015262823,0.0004636958,0.019204956,0.9343232,0.00016382155],"about_ca_topic_score_codex":0.006921154,"about_ca_topic_score_gemma":0.013149464,"teacher_disagreement_score":0.91422373,"about_ca_system_score_codex":0.0020781732,"about_ca_system_score_gemma":0.0034396662,"threshold_uncertainty_score":0.12234944},"labels":[],"label_agreement":null},{"id":"W6902180895","doi":"10.6084/m9.figshare.22611196","title":"Additional file 1 of Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Protocol (science); Patient data; MEDLINE; Data collection; Systematic review","score_opus":0.2836596883364506,"score_gpt":0.4036598257093907,"score_spread":0.12000013737294007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902180895","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042492614,0.00060711964,0.0015219236,0.0004041316,0.00011082419,0.0074506835,0.98798066,0.00036079952,0.001138918],"genre_scores_gemma":[0.020975055,0.00309341,0.041955303,0.0036679052,0.00046432068,0.47680578,0.42862138,0.0012211005,0.023195846],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957825,0.0015337121,0.0013033365,0.0006342317,0.0004957722,0.00025054123],"domain_scores_gemma":[0.9011113,0.08334848,0.006787095,0.0029391684,0.005225796,0.0005881527],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.011586899,0.0020115478,0.0033248274,0.00497452,0.0010367399,0.0020956376,0.0024297475,0.0021261354,0.7818535],"category_scores_gemma":[0.10771544,0.0016876294,0.005855995,0.00720332,0.00062545366,0.0027718248,0.0016908951,0.0017793161,0.037157077],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032356188,0.00018689617,0.0021105658,0.3553286,0.0032246634,0.00013523441,0.0002753949,0.0014832354,0.00027947882,0.0039987327,0.6087094,0.021032188],"study_design_scores_gemma":[0.10498367,0.0017092687,0.027529294,0.14813067,0.021045279,0.0008771316,0.00072801183,0.0050955927,0.0016863764,0.042989407,0.6445385,0.0006868437],"about_ca_topic_score_codex":0.0063346163,"about_ca_topic_score_gemma":0.013887379,"teacher_disagreement_score":0.2181465,"about_ca_system_score_codex":0.0023906275,"about_ca_system_score_gemma":0.0073956144,"threshold_uncertainty_score":0.3111595},"labels":[],"label_agreement":null},{"id":"W6902248215","doi":"10.6084/m9.figshare.28920986.v1","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Refractory (planetary science); Standard of care; Clinical trial; Confidence interval","score_opus":0.03081814673992698,"score_gpt":0.32723172556437974,"score_spread":0.29641357882445274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902248215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93970466,0.03328562,0.0014570773,0.0040429104,0.00022320714,0.0012370519,0.010143013,0.00015046523,0.00975597],"genre_scores_gemma":[0.9912115,0.0035764435,0.0010911314,0.000497571,0.000032134067,0.00018058883,0.0025943276,0.000014843935,0.000801506],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984011,0.001026874,0.000051164407,0.00010537394,0.0002171647,0.00019826395],"domain_scores_gemma":[0.99814343,0.0008792507,0.00030198775,0.00006245732,0.00023142413,0.0003813873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003012213,0.001249213,0.0016753664,0.0006406738,0.00052311434,0.0013028869,0.001688527,0.0010067823,0.0034803653],"category_scores_gemma":[0.0072679603,0.00037544986,0.0034823287,0.0011026018,0.0006659228,0.000553214,0.0006437669,0.001862056,0.0001457989],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3883543,0.0031811108,0.040480264,0.009348815,0.024702271,0.00049723615,0.00029722488,0.32825977,0.0018972543,0.008371062,0.022485685,0.1721251],"study_design_scores_gemma":[0.24470218,0.032575686,0.09911081,0.0029392997,0.03538918,0.00053107226,0.0006310288,0.555658,0.0017158826,0.0064702444,0.019795543,0.00048109534],"about_ca_topic_score_codex":0.779348,"about_ca_topic_score_gemma":0.7961974,"teacher_disagreement_score":0.22065198,"about_ca_system_score_codex":0.034822166,"about_ca_system_score_gemma":0.025343176,"threshold_uncertainty_score":0.44390285},"labels":[],"label_agreement":null},{"id":"W6903021297","doi":"10.7939/r3-wt63-hj84","title":"The Clinical Adoption of anti-CD19 CAR T-cell Therapy in Alberta: A Historical Review and Retrospective Comparative Case Study","year":2022,"lang":"en","type":"dissertation","venue":"University of Alberta Library","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Timeline; Stakeholder; Product (mathematics); Health care; Process (computing); Comparative case; Perspective (graphical); Comparative effectiveness research; Grey literature","score_opus":0.04373236393315394,"score_gpt":0.32866209514437955,"score_spread":0.2849297312112256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6903021297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.79907227,0.15966494,0.0012293592,0.0037548083,0.00016102371,0.00064306404,0.0020129047,0.00003602992,0.033425592],"genre_scores_gemma":[0.888674,0.10359822,0.0017140316,0.0010740558,0.00006745269,0.00017162175,0.00087019603,0.00002469538,0.0038055677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967542,0.0007684805,0.00034456802,0.00026865688,0.0012668403,0.00059712894],"domain_scores_gemma":[0.9918812,0.0029048822,0.0018532624,0.00030286587,0.0023498451,0.0007079442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004750659,0.00028418258,0.00045125946,0.005092355,0.0023928462,0.0026986161,0.0013221584,0.0007762275,0.0021118612],"category_scores_gemma":[0.008397252,0.0003998623,0.00032900242,0.013279753,0.0019716364,0.0007335502,0.0012994008,0.00074874825,0.00029722278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006644215,0.0004234279,0.34122306,0.017091611,0.0002738562,0.04860623,0.24844757,0.000761346,0.0035472682,0.013056825,0.014258783,0.31164563],"study_design_scores_gemma":[0.00003523374,0.00042705957,0.52176297,0.013645207,0.00059926324,0.024739731,0.2215225,0.0002516574,0.0010177245,0.0006515602,0.21520233,0.00014483299],"about_ca_topic_score_codex":0.64449316,"about_ca_topic_score_gemma":0.81217337,"teacher_disagreement_score":0.64449316,"about_ca_system_score_codex":0.026788004,"about_ca_system_score_gemma":0.037510667,"threshold_uncertainty_score":0.71520096},"labels":[],"label_agreement":null},{"id":"W6907653799","doi":"10.25384/sage.c.5104085.v1","title":"Mapping as a Complementary Perspective on the Dynamics of Participation in a City’s Musical Life","year":2020,"lang":"en","type":"other","venue":"Sage Journals Data","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legibility; Musical; Perspective (graphical); Dynamics (music); Attendance; Subject (documents)","score_opus":0.1742411750248867,"score_gpt":0.43432938045346076,"score_spread":0.260088205428574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6907653799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54948694,0.002451196,0.04313654,0.01630491,0.00039046307,0.00048942777,0.0021005636,0.00026010844,0.38537985],"genre_scores_gemma":[0.9729619,0.0010972979,0.010305545,0.00033567322,0.00006759289,0.00030414062,0.00021902373,0.00007353412,0.014635279],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9962553,0.0028927966,0.000072541814,0.00022372855,0.0002695163,0.00028617337],"domain_scores_gemma":[0.99230874,0.0056691356,0.00048052476,0.00062794413,0.000517396,0.00039627173],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045806533,0.000585247,0.00037402197,0.0052930606,0.006954124,0.009010749,0.001044782,0.00096504024,0.011055652],"category_scores_gemma":[0.0061650258,0.0002902217,0.00034208383,0.008013423,0.012494717,0.006926689,0.005538242,0.0015077047,0.00043809906],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003783607,0.000022389653,0.004797517,0.00020822386,0.000011875088,0.00033816093,0.90679765,0.0002716927,0.000650582,0.05688683,0.0031244871,0.026852833],"study_design_scores_gemma":[0.0000055978176,0.00002872944,0.009648163,0.0002322654,0.000011956244,0.00015741575,0.8839021,0.0003604846,0.00032612853,0.012192852,0.093108565,0.000025818272],"about_ca_topic_score_codex":0.047945365,"about_ca_topic_score_gemma":0.0975979,"teacher_disagreement_score":0.047945365,"about_ca_system_score_codex":0.00427204,"about_ca_system_score_gemma":0.004189274,"threshold_uncertainty_score":0.09533262},"labels":[],"label_agreement":null},{"id":"W6907797343","doi":"10.25318/3610028701-eng","title":"Personal income, personal income per person, and personal disposable income, annual, 1926 - 1990","year":2019,"lang":"en","type":"dataset","venue":"Statistics Canada Dissemination","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Personal income; Table (database); Personal account; Personal life; Personal computer; Payment","score_opus":0.012182798874675712,"score_gpt":0.29672873825564255,"score_spread":0.28454593938096684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6907797343","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019421945,0.000039775856,0.000011046863,0.0000302163,0.0000109139155,0.0000038056467,0.999253,0.00002522356,0.0004317956],"genre_scores_gemma":[0.000885421,0.00008163136,0.00006771991,0.0000298546,0.000007750095,0.00003478417,0.99779737,0.000014495443,0.0010809661],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990049,0.0000798953,0.00015463092,0.00022812228,0.00034189638,0.0001906333],"domain_scores_gemma":[0.9966624,0.00048923766,0.00051643373,0.00033908623,0.0017298198,0.00026301935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077122083,0.0010155719,0.0010595708,0.0038441212,0.0005891928,0.001610056,0.001482435,0.0008109694,0.03572414],"category_scores_gemma":[0.0068626083,0.0004884385,0.0006812708,0.013352579,0.00026165193,0.00083581475,0.0008185682,0.0014302261,0.038976885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005636826,0.000017772907,0.0038659517,0.00026347602,0.000025838126,0.000012532858,0.000014677597,0.00019926428,0.0000300057,0.00029624027,0.9934947,0.0017233191],"study_design_scores_gemma":[0.0002485078,0.00002453896,0.0667989,0.00043055922,0.00005469685,0.00006993713,0.00017907593,0.00040758133,0.00024547143,0.00049543806,0.93101084,0.00003436815],"about_ca_topic_score_codex":0.2932952,"about_ca_topic_score_gemma":0.32614696,"teacher_disagreement_score":0.7067048,"about_ca_system_score_codex":0.0033138462,"about_ca_system_score_gemma":0.0046161297,"threshold_uncertainty_score":0.5831761},"labels":[],"label_agreement":null},{"id":"W6908840949","doi":"10.3389/fphys.2022.1059686.s001","title":"Presentation1_Early mechanisms of neutrophil activation and transmigration in acute lung injury.PPTX","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lipopolysaccharide; Lung; Tidal volume; Ventilation (architecture); Selectin; P-selectin; Respiratory system","score_opus":0.0319064628073427,"score_gpt":0.3209760167151325,"score_spread":0.28906955390778977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908840949","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92932254,0.0145552065,0.02172867,0.0016085468,0.00048577794,0.0005617071,0.0049270936,0.0010638939,0.025746604],"genre_scores_gemma":[0.90925753,0.0066164867,0.0070883003,0.0005630289,0.00017650265,0.00045868868,0.0040369355,0.000112381036,0.071690165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997738,0.00002326547,0.000015319965,0.000045146,0.00007137065,0.00007106359],"domain_scores_gemma":[0.9999021,0.00000478416,0.000037619822,0.000006289272,0.00001217404,0.00003695265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021191062,0.00074383005,0.0003362909,0.00054389046,0.00028069146,0.00057107804,0.00040740392,0.0007090623,0.011018803],"category_scores_gemma":[0.00009884827,0.00024810873,0.0003704569,0.00020271231,0.00026913945,0.0006653915,0.00050913566,0.0010129494,0.002986135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000541592,0.00008624953,0.00046662526,0.00032249524,0.000006189797,0.0002576023,0.000039846724,0.00006688686,0.9884184,0.0008350205,0.0006924507,0.00826664],"study_design_scores_gemma":[0.00014601194,0.0020929184,0.0354073,0.00017652323,0.000049128856,0.0029530055,0.00015440125,0.001522349,0.92835826,0.0012664675,0.027847163,0.000026493552],"about_ca_topic_score_codex":0.00030099292,"about_ca_topic_score_gemma":0.0003397781,"teacher_disagreement_score":0.011018803,"about_ca_system_score_codex":0.0004021163,"about_ca_system_score_gemma":0.00023632299,"threshold_uncertainty_score":0.0368616},"labels":[],"label_agreement":null},{"id":"W6911827169","doi":"10.5281/zenodo.15125672","title":"Personalized Medicine in Cancer: An Overview with Chimeric Antigen Receptor Therapy and Health Canada Regulatory Insights","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Personalized medicine; Regulatory science; Chimeric antigen receptor; Precision medicine; MEDLINE; Cancer; Risk management; Good manufacturing practice","score_opus":0.07921043495232297,"score_gpt":0.3295970178244372,"score_spread":0.25038658287211424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911827169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035488713,0.9177187,0.0014648802,0.058152262,0.001614681,0.00005093853,0.00017693266,0.000047238656,0.020419445],"genre_scores_gemma":[0.005000219,0.9757789,0.0014528768,0.012360694,0.001998483,0.00005065214,0.00012829452,0.000025449683,0.0032044738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957659,0.0010310722,0.0002569494,0.00031041077,0.002076315,0.0005593136],"domain_scores_gemma":[0.98833317,0.00527258,0.00056271907,0.00022550102,0.0045081777,0.0010978739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008287161,0.0012448219,0.0012801003,0.006603571,0.0018531088,0.0052311663,0.0023999172,0.0048511773,0.00826642],"category_scores_gemma":[0.009143068,0.0005249157,0.0013525293,0.008703038,0.005144697,0.0037085405,0.0028916385,0.006605811,0.0014306961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019081621,0.0001895345,0.0011259826,0.005641033,0.00013215939,0.00047240575,0.0004237114,0.0021013687,0.00046139385,0.11210284,0.21454193,0.6626168],"study_design_scores_gemma":[0.000033957003,0.00007780466,0.0014549862,0.004756694,0.000056207915,0.00032997664,0.00018223144,0.0004054412,0.0001923632,0.013251061,0.9792101,0.00004926876],"about_ca_topic_score_codex":0.5200412,"about_ca_topic_score_gemma":0.6333421,"teacher_disagreement_score":0.47995877,"about_ca_system_score_codex":0.05408593,"about_ca_system_score_gemma":0.06851025,"threshold_uncertainty_score":0.9655707},"labels":[],"label_agreement":null},{"id":"W6912163997","doi":"10.5281/zenodo.15125673","title":"Personalized Medicine in Cancer: An Overview with Chimeric Antigen Receptor Therapy and Health Canada Regulatory Insights","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Personalized medicine; Regulatory science; Chimeric antigen receptor; Precision medicine; MEDLINE; Cancer; Risk management; Good manufacturing practice","score_opus":0.07921043495232297,"score_gpt":0.3295970178244372,"score_spread":0.25038658287211424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6912163997","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035488713,0.9177187,0.0014648802,0.058152262,0.001614681,0.00005093853,0.00017693266,0.000047238656,0.020419445],"genre_scores_gemma":[0.005000219,0.9757789,0.0014528768,0.012360694,0.001998483,0.00005065214,0.00012829452,0.000025449683,0.0032044738],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957659,0.0010310722,0.0002569494,0.00031041077,0.002076315,0.0005593136],"domain_scores_gemma":[0.98833317,0.00527258,0.00056271907,0.00022550102,0.0045081777,0.0010978739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008287161,0.0012448219,0.0012801003,0.006603571,0.0018531088,0.0052311663,0.0023999172,0.0048511773,0.00826642],"category_scores_gemma":[0.009143068,0.0005249157,0.0013525293,0.008703038,0.005144697,0.0037085405,0.0028916385,0.006605811,0.0014306961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019081621,0.0001895345,0.0011259826,0.005641033,0.00013215939,0.00047240575,0.0004237114,0.0021013687,0.00046139385,0.11210284,0.21454193,0.6626168],"study_design_scores_gemma":[0.000033957003,0.00007780466,0.0014549862,0.004756694,0.000056207915,0.00032997664,0.00018223144,0.0004054412,0.0001923632,0.013251061,0.9792101,0.00004926876],"about_ca_topic_score_codex":0.5200412,"about_ca_topic_score_gemma":0.6333421,"teacher_disagreement_score":0.47995877,"about_ca_system_score_codex":0.05408593,"about_ca_system_score_gemma":0.06851025,"threshold_uncertainty_score":0.9655707},"labels":[],"label_agreement":null},{"id":"W6920673451","doi":"10.6084/m9.figshare.13093610","title":"Additional file 3 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen; Immune system","score_opus":0.10496957802123638,"score_gpt":0.33786207164941817,"score_spread":0.2328924936281818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920673451","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012095219,0.00004582778,0.00029972204,0.00043970763,0.00005953472,0.00031567473,0.99539644,0.00026284586,0.003059317],"genre_scores_gemma":[0.016317924,0.00069296604,0.0077118184,0.004136901,0.0005494798,0.010491113,0.9128126,0.001836032,0.045451272],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972554,0.0007708583,0.0006706121,0.0004009368,0.0005635682,0.00033865374],"domain_scores_gemma":[0.90235335,0.07792334,0.0058845305,0.0032521351,0.008548548,0.0020380556],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0054642167,0.00091354985,0.0015728837,0.00274975,0.0009811233,0.002572437,0.0017083805,0.0017923173,0.91422373],"category_scores_gemma":[0.09438513,0.0006532198,0.0013016714,0.0045931377,0.000362127,0.002524578,0.0015326062,0.0012485576,0.17521021],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055774336,0.000056542893,0.001118519,0.0046782345,0.00006070339,0.00004278804,0.000041922085,0.00030183527,0.000039400413,0.0010538286,0.98280877,0.009239666],"study_design_scores_gemma":[0.012952809,0.0004312531,0.01895955,0.010804131,0.00037536462,0.00038952,0.00040547518,0.0015262823,0.0004636958,0.019204956,0.9343232,0.00016382155],"about_ca_topic_score_codex":0.006921154,"about_ca_topic_score_gemma":0.013149464,"teacher_disagreement_score":0.91422373,"about_ca_system_score_codex":0.0020781732,"about_ca_system_score_gemma":0.0034396662,"threshold_uncertainty_score":0.12234944},"labels":[],"label_agreement":null},{"id":"W6920674398","doi":"10.6084/m9.figshare.13093604.v1","title":"Additional file 1 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10676808617153956,"score_gpt":0.3383602675787483,"score_spread":0.23159218140720877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920674398","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016017615,0.00006212406,0.00049802376,0.0006961432,0.0000706999,0.0007765438,0.99389946,0.00036296606,0.0034739473],"genre_scores_gemma":[0.016500957,0.0010323108,0.013781574,0.0057124095,0.0006474878,0.033481855,0.8809343,0.0024053457,0.045503777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959312,0.0013951025,0.0011137609,0.00045920844,0.00071553845,0.00038520346],"domain_scores_gemma":[0.8569582,0.114429854,0.009228965,0.0046601803,0.012373275,0.0023494193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009269265,0.0010173493,0.0014309931,0.0031592173,0.0010446775,0.002228276,0.0017807106,0.0018101963,0.8849335],"category_scores_gemma":[0.13139388,0.000855103,0.001471598,0.0045747263,0.00040645452,0.002694287,0.0016411924,0.0013540792,0.15575856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039275113,0.000043863365,0.0010434168,0.004429118,0.00004348227,0.000033095912,0.000046949815,0.00019278597,0.000024838168,0.000851926,0.98390085,0.0089969775],"study_design_scores_gemma":[0.011527316,0.00036547976,0.018324537,0.01345172,0.000310417,0.0003907421,0.00042615147,0.0011354734,0.00041246507,0.016738111,0.9367577,0.00015993763],"about_ca_topic_score_codex":0.0062739113,"about_ca_topic_score_gemma":0.012631263,"teacher_disagreement_score":0.8849335,"about_ca_system_score_codex":0.0020778666,"about_ca_system_score_gemma":0.0046385312,"threshold_uncertainty_score":0.16412836},"labels":[],"label_agreement":null},{"id":"W6920886201","doi":"10.6084/m9.figshare.25397536","title":"Additional file 1 of CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CD19; CD8; T cell; Cytotoxic T cell; Interleukin 21; Phenotype; Interleukin 3","score_opus":0.017155511829438915,"score_gpt":0.2405484962564494,"score_spread":0.22339298442701047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920886201","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029505146,0.00003523709,0.00047878065,0.00012298742,0.000051753945,0.00013408739,0.9976597,0.0004039498,0.00081844203],"genre_scores_gemma":[0.014550362,0.00037639888,0.008586102,0.0011340525,0.00016876389,0.0048220353,0.9540792,0.0017928804,0.014490208],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911624,0.00011678043,0.00014406822,0.0002331039,0.00024316068,0.00014650369],"domain_scores_gemma":[0.9864014,0.010296319,0.00063845265,0.00079464976,0.0014291117,0.0004399311],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019323794,0.001430002,0.0017803719,0.0018086109,0.0012538168,0.0021612511,0.002173611,0.0016816491,0.90086365],"category_scores_gemma":[0.024367569,0.00078853936,0.0009968365,0.0029850106,0.00034805582,0.0018247562,0.0011873845,0.0012161238,0.17608261],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009704173,0.00022641121,0.0028676454,0.0069676978,0.00007388955,0.0002289344,0.00012702675,0.0006880951,0.0008786844,0.0010520839,0.97125816,0.014660964],"study_design_scores_gemma":[0.010672475,0.0012335938,0.03260067,0.0072065517,0.00036554862,0.0017806814,0.0008925099,0.004391471,0.0042575407,0.014898357,0.9213609,0.00033958722],"about_ca_topic_score_codex":0.00615934,"about_ca_topic_score_gemma":0.010195168,"teacher_disagreement_score":0.90086365,"about_ca_system_score_codex":0.0009641249,"about_ca_system_score_gemma":0.0024471972,"threshold_uncertainty_score":0.14140588},"labels":[],"label_agreement":null},{"id":"W6921018313","doi":"10.6084/m9.figshare.29387378","title":"Revaccination following CAR-T therapy: a needs assessment","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Focus group; CLARITY; Needs assessment; Audit; Primary care; Qualitative research; Patient education; Schedule","score_opus":0.056052696427784744,"score_gpt":0.3870660347820867,"score_spread":0.3310133383543019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921018313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98693085,0.00044229516,0.001217322,0.006281197,0.00004703928,0.0028120158,0.00022000965,0.000032401018,0.0020169427],"genre_scores_gemma":[0.98572874,0.0012624668,0.0068876105,0.0015473177,0.000044942335,0.0034814153,0.00022131986,0.000013462028,0.0008128043],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9909272,0.004428046,0.001103813,0.00025616944,0.001312335,0.001972543],"domain_scores_gemma":[0.98174083,0.0053236512,0.0034746777,0.000364344,0.005405527,0.0036910425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021055374,0.0004941056,0.0005418672,0.0025943012,0.003785972,0.001838513,0.0016610065,0.0016241991,0.0015769815],"category_scores_gemma":[0.026442934,0.0007084025,0.0011235232,0.001615006,0.0012547707,0.0032556388,0.0052998657,0.0022212234,0.0003443576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045061635,0.0038447864,0.2864618,0.0028437723,0.00007684599,0.0037227653,0.4835693,0.00056413276,0.0025833065,0.0012002068,0.008287405,0.2063951],"study_design_scores_gemma":[0.000096251606,0.004362969,0.22523892,0.0012298408,0.00006173759,0.0017267913,0.74825144,0.0016876945,0.0010744472,0.00086456357,0.015261371,0.00014397633],"about_ca_topic_score_codex":0.009415933,"about_ca_topic_score_gemma":0.018182077,"teacher_disagreement_score":0.021055374,"about_ca_system_score_codex":0.0080400305,"about_ca_system_score_gemma":0.014365488,"threshold_uncertainty_score":0.1113528},"labels":[],"label_agreement":null},{"id":"W6921038188","doi":"10.6084/m9.figshare.14313463.v1","title":"Additional file 1 of Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"CAR T-cell therapy; Chimeric antigen receptor; Immunotherapy; Antibody therapy; T cell; Antigen; MEDLINE","score_opus":0.08753466445652208,"score_gpt":0.33392228397746976,"score_spread":0.24638761952094768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921038188","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034993403,0.00013473422,0.0017979095,0.0035041627,0.00015775899,0.01004878,0.9646743,0.0002437563,0.015939318],"genre_scores_gemma":[0.10536968,0.0014504264,0.033138838,0.012704593,0.0007196876,0.33110678,0.4323714,0.0009010197,0.08223753],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9980909,0.00097235,0.0003300411,0.00018751559,0.00020522701,0.00021384523],"domain_scores_gemma":[0.9235815,0.06405715,0.003543859,0.001398125,0.006016083,0.0014032666],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005701021,0.00057052856,0.0008514524,0.0017452668,0.0018908827,0.0012356114,0.001257994,0.0012537505,0.78070796],"category_scores_gemma":[0.06754684,0.0006391162,0.0005297122,0.002702316,0.0003388738,0.0021327306,0.0010101411,0.0016219722,0.0826432],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038770883,0.0002373389,0.002114489,0.0021304085,0.000015581303,0.000054135715,0.0008539251,0.0002297916,0.000023388791,0.0012768428,0.9791296,0.013546604],"study_design_scores_gemma":[0.019488918,0.0011794999,0.052145984,0.016638173,0.00022002141,0.0007466426,0.015228706,0.0038992062,0.0005912217,0.025580341,0.86401904,0.00026222345],"about_ca_topic_score_codex":0.009723919,"about_ca_topic_score_gemma":0.017623333,"teacher_disagreement_score":0.994299,"about_ca_system_score_codex":0.0023355202,"about_ca_system_score_gemma":0.004655755,"threshold_uncertainty_score":0.31279343},"labels":[],"label_agreement":null},{"id":"W6921051786","doi":"10.6084/m9.figshare.25744470","title":"Additional file 2 of Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Mechanism (biology); Potency; Key (lock); Cell; Mechanism of action","score_opus":0.08141334175345424,"score_gpt":0.32790889355422725,"score_spread":0.246495551800773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921051786","genre_codex":"dataset","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014758605,0.0001384684,0.00076040346,0.0005061866,0.00010015548,0.00035073003,0.9930039,0.00031766115,0.0046748486],"genre_scores_gemma":[0.017699882,0.0015070604,0.012544706,0.004668633,0.00065233593,0.0076436736,0.90787244,0.0021845375,0.04522667],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9978986,0.0006441273,0.000401846,0.000302313,0.00055412186,0.00019899479],"domain_scores_gemma":[0.92535985,0.0615595,0.0028854352,0.002785427,0.0064831777,0.0009265771],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056982595,0.00090992864,0.0014488774,0.0020695638,0.0007703548,0.0022421074,0.0020518426,0.0017037254,0.89843446],"category_scores_gemma":[0.0667479,0.0005869953,0.0014520322,0.0032993443,0.0003888892,0.002628233,0.0011879286,0.0015556382,0.20184894],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057756755,0.00007089141,0.00070041546,0.0045047053,0.000048748785,0.000040687384,0.000034962308,0.00038990105,0.000074836054,0.0019838319,0.9774156,0.014157859],"study_design_scores_gemma":[0.003806364,0.00030919237,0.0059796367,0.006267209,0.00022639989,0.00037892975,0.00018802569,0.0009810401,0.0006075405,0.019308154,0.9618648,0.00008254567],"about_ca_topic_score_codex":0.0039142175,"about_ca_topic_score_gemma":0.0056633097,"teacher_disagreement_score":0.89843446,"about_ca_system_score_codex":0.0019584517,"about_ca_system_score_gemma":0.0030827657,"threshold_uncertainty_score":0.14487094},"labels":[],"label_agreement":null},{"id":"W6923603246","doi":"10.14288/1.0449064","title":"Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference","year":2025,"lang":"en","type":"article","venue":"Open Collections","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Presentation (obstetrics); Transplantation; Cell therapy; MEDLINE","score_opus":0.02356228923068407,"score_gpt":0.2973331447189159,"score_spread":0.2737708554882319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6923603246","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050345366,0.05648726,0.0022400613,0.12276675,0.31986347,0.0013415071,0.01260668,0.00056885026,0.47909087],"genre_scores_gemma":[0.010918272,0.0203642,0.0010900719,0.008472916,0.029198874,0.00040800602,0.005218693,0.00029457582,0.9240344],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964361,0.00021656518,0.00011161469,0.00019339767,0.0026358808,0.00040644794],"domain_scores_gemma":[0.99035245,0.0003004919,0.00025413703,0.0001349323,0.0057577128,0.0032001936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032749493,0.0011475268,0.0007836419,0.002427564,0.004106291,0.0074694087,0.0014864624,0.0025682272,0.24146672],"category_scores_gemma":[0.004939846,0.00034712104,0.0008477059,0.0019572396,0.0009188219,0.0011621475,0.002016307,0.0026813224,0.07108025],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025233872,0.00001230683,0.00006786125,0.000058984853,0.000001844526,0.000034242545,0.000020256368,0.000019698226,0.00015512144,0.00023203975,0.9900477,0.00932466],"study_design_scores_gemma":[0.000007980643,0.000010345661,0.0004922434,0.00007498047,0.0000022627978,0.00003991502,0.00009933611,0.000021307304,0.000102488295,0.00010084069,0.9990416,0.0000066693046],"about_ca_topic_score_codex":0.17120193,"about_ca_topic_score_gemma":0.34071368,"teacher_disagreement_score":0.984218,"about_ca_system_score_codex":0.015782014,"about_ca_system_score_gemma":0.042366825,"threshold_uncertainty_score":0.80778664},"labels":[],"label_agreement":null},{"id":"W6926407573","doi":"10.25316/ir-13003","title":"The Nanaimo Free Press [Thursday, June 13, 1889]","year":2019,"lang":"en","type":"other","venue":"VIUSpace (Vancouver Island University Library)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"","score_opus":0.010036661538751442,"score_gpt":0.214977185860959,"score_spread":0.20494052432220758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6926407573","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000566296,0.013689076,0.00014203778,0.004283074,0.0068770493,0.000034768513,0.0013647708,0.00011479536,0.97292805],"genre_scores_gemma":[0.00089392945,0.0011040024,0.000037127804,0.00019795143,0.00015400985,0.00000867077,0.0001011255,0.000039573035,0.9974636],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.999574,0.000038565533,0.000016827351,0.00007269683,0.00019802965,0.000099837715],"domain_scores_gemma":[0.9997664,0.00003506572,0.000012764706,0.000017066246,0.000107614374,0.00006105785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003773988,0.0009739719,0.0005647005,0.0018798679,0.00574267,0.00652342,0.00074054196,0.0021771197,0.25697765],"category_scores_gemma":[0.0014284743,0.0005342443,0.00035989578,0.0023769587,0.0010413493,0.0018487603,0.0015146731,0.003452188,0.09538151],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026324285,0.000008091931,0.00013129774,0.000072263465,0.0000030246913,0.000095389136,0.00018774398,0.000040717066,0.0000822261,0.016091868,0.95463145,0.028629642],"study_design_scores_gemma":[0.0000013451365,0.0000017038825,0.00019115473,0.00003840555,5.9366477e-7,0.000015339885,0.00004160582,0.0000063056254,0.000022732542,0.0003257555,0.999353,0.000002092051],"about_ca_topic_score_codex":0.13538563,"about_ca_topic_score_gemma":0.51796377,"teacher_disagreement_score":0.86461437,"about_ca_system_score_codex":0.0051942198,"about_ca_system_score_gemma":0.0033673646,"threshold_uncertainty_score":0.8596759},"labels":[],"label_agreement":null},{"id":"W6939276113","doi":"10.6084/m9.figshare.13093604","title":"Additional file 1 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10676808617153956,"score_gpt":0.3383602675787483,"score_spread":0.23159218140720877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939276113","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016017615,0.00006212406,0.00049802376,0.0006961432,0.0000706999,0.0007765438,0.99389946,0.00036296606,0.0034739473],"genre_scores_gemma":[0.016500957,0.0010323108,0.013781574,0.0057124095,0.0006474878,0.033481855,0.8809343,0.0024053457,0.045503777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959312,0.0013951025,0.0011137609,0.00045920844,0.00071553845,0.00038520346],"domain_scores_gemma":[0.8569582,0.114429854,0.009228965,0.0046601803,0.012373275,0.0023494193],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009269265,0.0010173493,0.0014309931,0.0031592173,0.0010446775,0.002228276,0.0017807106,0.0018101963,0.8849335],"category_scores_gemma":[0.13139388,0.000855103,0.001471598,0.0045747263,0.00040645452,0.002694287,0.0016411924,0.0013540792,0.15575856],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039275113,0.000043863365,0.0010434168,0.004429118,0.00004348227,0.000033095912,0.000046949815,0.00019278597,0.000024838168,0.000851926,0.98390085,0.0089969775],"study_design_scores_gemma":[0.011527316,0.00036547976,0.018324537,0.01345172,0.000310417,0.0003907421,0.00042615147,0.0011354734,0.00041246507,0.016738111,0.9367577,0.00015993763],"about_ca_topic_score_codex":0.0062739113,"about_ca_topic_score_gemma":0.012631263,"teacher_disagreement_score":0.8849335,"about_ca_system_score_codex":0.0020778666,"about_ca_system_score_gemma":0.0046385312,"threshold_uncertainty_score":0.16412836},"labels":[],"label_agreement":null},{"id":"W6939335640","doi":"10.6084/m9.figshare.22611199","title":"Additional file 2 of Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Protocol (science); Patient data; Sample (material); Data collection; Identification (biology)","score_opus":0.2762720757223113,"score_gpt":0.4029468743318842,"score_spread":0.12667479860957287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939335640","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00059004576,0.0010222434,0.0010795518,0.0003932007,0.000099811135,0.0033582738,0.9920609,0.0002784158,0.001117585],"genre_scores_gemma":[0.052348867,0.0053103277,0.031175619,0.0048822644,0.0006501666,0.25988266,0.6096642,0.0015353938,0.034550473],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743074,0.000830032,0.00074233173,0.00047841316,0.00028590672,0.00023252165],"domain_scores_gemma":[0.943198,0.048359547,0.0036385893,0.0016589299,0.0026924214,0.00045244556],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006847817,0.0018827816,0.003868952,0.0053952658,0.0009206732,0.0019456093,0.0020639228,0.001948087,0.718142],"category_scores_gemma":[0.07164563,0.001295936,0.0062478962,0.007501665,0.000522982,0.0024634674,0.0015241287,0.0014093334,0.025428774],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003625951,0.00015580594,0.0036700855,0.48331937,0.00606983,0.0002293485,0.0002902879,0.0017221131,0.00048061082,0.003637037,0.47950256,0.01729706],"study_design_scores_gemma":[0.10283697,0.001982564,0.04522661,0.15926418,0.05000213,0.0011888978,0.0008567434,0.006357879,0.0020869884,0.03564818,0.59382796,0.00072087947],"about_ca_topic_score_codex":0.007641696,"about_ca_topic_score_gemma":0.016892677,"teacher_disagreement_score":0.718142,"about_ca_system_score_codex":0.0019280482,"about_ca_system_score_gemma":0.0045658685,"threshold_uncertainty_score":0.40203625},"labels":[],"label_agreement":null},{"id":"W6939411255","doi":"10.6084/m9.figshare.28920986","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Refractory (planetary science); Standard of care; Clinical trial; Confidence interval","score_opus":0.03081814673992698,"score_gpt":0.32723172556437974,"score_spread":0.29641357882445274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939411255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93970466,0.03328562,0.0014570773,0.0040429104,0.00022320714,0.0012370519,0.010143013,0.00015046523,0.00975597],"genre_scores_gemma":[0.9912115,0.0035764435,0.0010911314,0.000497571,0.000032134067,0.00018058883,0.0025943276,0.000014843935,0.000801506],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9984011,0.001026874,0.000051164407,0.00010537394,0.0002171647,0.00019826395],"domain_scores_gemma":[0.99814343,0.0008792507,0.00030198775,0.00006245732,0.00023142413,0.0003813873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003012213,0.001249213,0.0016753664,0.0006406738,0.00052311434,0.0013028869,0.001688527,0.0010067823,0.0034803653],"category_scores_gemma":[0.0072679603,0.00037544986,0.0034823287,0.0011026018,0.0006659228,0.000553214,0.0006437669,0.001862056,0.0001457989],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3883543,0.0031811108,0.040480264,0.009348815,0.024702271,0.00049723615,0.00029722488,0.32825977,0.0018972543,0.008371062,0.022485685,0.1721251],"study_design_scores_gemma":[0.24470218,0.032575686,0.09911081,0.0029392997,0.03538918,0.00053107226,0.0006310288,0.555658,0.0017158826,0.0064702444,0.019795543,0.00048109534],"about_ca_topic_score_codex":0.779348,"about_ca_topic_score_gemma":0.7961974,"teacher_disagreement_score":0.22065198,"about_ca_system_score_codex":0.034822166,"about_ca_system_score_gemma":0.025343176,"threshold_uncertainty_score":0.44390285},"labels":[],"label_agreement":null},{"id":"W6939567774","doi":"10.6084/m9.figshare.25744470.v1","title":"Additional file 2 of Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Mechanism (biology); Potency; Key (lock); Cell; Mechanism of action","score_opus":0.08141334175345424,"score_gpt":0.32790889355422725,"score_spread":0.246495551800773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939567774","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014758605,0.0001384684,0.00076040346,0.0005061866,0.00010015548,0.00035073003,0.9930039,0.00031766115,0.0046748486],"genre_scores_gemma":[0.017699882,0.0015070604,0.012544706,0.004668633,0.00065233593,0.0076436736,0.90787244,0.0021845375,0.04522667],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9978986,0.0006441273,0.000401846,0.000302313,0.00055412186,0.00019899479],"domain_scores_gemma":[0.92535985,0.0615595,0.0028854352,0.002785427,0.0064831777,0.0009265771],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056982595,0.00090992864,0.0014488774,0.0020695638,0.0007703548,0.0022421074,0.0020518426,0.0017037254,0.89843446],"category_scores_gemma":[0.0667479,0.0005869953,0.0014520322,0.0032993443,0.0003888892,0.002628233,0.0011879286,0.0015556382,0.20184894],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057756755,0.00007089141,0.00070041546,0.0045047053,0.000048748785,0.000040687384,0.000034962308,0.00038990105,0.000074836054,0.0019838319,0.9774156,0.014157859],"study_design_scores_gemma":[0.003806364,0.00030919237,0.0059796367,0.006267209,0.00022639989,0.00037892975,0.00018802569,0.0009810401,0.0006075405,0.019308154,0.9618648,0.00008254567],"about_ca_topic_score_codex":0.0039142175,"about_ca_topic_score_gemma":0.0056633097,"teacher_disagreement_score":0.89843446,"about_ca_system_score_codex":0.0019584517,"about_ca_system_score_gemma":0.0030827657,"threshold_uncertainty_score":0.14487094},"labels":[],"label_agreement":null},{"id":"W6939576725","doi":"10.6084/m9.figshare.14313463","title":"Additional file 1 of Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"CAR T-cell therapy; Chimeric antigen receptor; Immunotherapy; Antibody therapy; T cell; Antigen; MEDLINE","score_opus":0.08753466445652208,"score_gpt":0.33392228397746976,"score_spread":0.24638761952094768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939576725","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034993403,0.00013473422,0.0017979095,0.0035041627,0.00015775899,0.01004878,0.9646743,0.0002437563,0.015939318],"genre_scores_gemma":[0.10536968,0.0014504264,0.033138838,0.012704593,0.0007196876,0.33110678,0.4323714,0.0009010197,0.08223753],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9980909,0.00097235,0.0003300411,0.00018751559,0.00020522701,0.00021384523],"domain_scores_gemma":[0.9235815,0.06405715,0.003543859,0.001398125,0.006016083,0.0014032666],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005701021,0.00057052856,0.0008514524,0.0017452668,0.0018908827,0.0012356114,0.001257994,0.0012537505,0.78070796],"category_scores_gemma":[0.06754684,0.0006391162,0.0005297122,0.002702316,0.0003388738,0.0021327306,0.0010101411,0.0016219722,0.0826432],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038770883,0.0002373389,0.002114489,0.0021304085,0.000015581303,0.000054135715,0.0008539251,0.0002297916,0.000023388791,0.0012768428,0.9791296,0.013546604],"study_design_scores_gemma":[0.019488918,0.0011794999,0.052145984,0.016638173,0.00022002141,0.0007466426,0.015228706,0.0038992062,0.0005912217,0.025580341,0.86401904,0.00026222345],"about_ca_topic_score_codex":0.009723919,"about_ca_topic_score_gemma":0.017623333,"teacher_disagreement_score":0.994299,"about_ca_system_score_codex":0.0023355202,"about_ca_system_score_gemma":0.004655755,"threshold_uncertainty_score":0.31279343},"labels":[],"label_agreement":null},{"id":"W6939767888","doi":"10.6084/m9.figshare.25744317","title":"Additional file 1 of Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Potency; Mechanism (biology); Cell; Product (mathematics); Clinical trial","score_opus":0.08471419520195171,"score_gpt":0.3286717834675676,"score_spread":0.24395758826561587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939767888","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018297191,0.00008096543,0.00053058664,0.00059030135,0.00007243954,0.00044569926,0.99276745,0.00024546447,0.0050841947],"genre_scores_gemma":[0.018839743,0.00115886,0.010765673,0.0049036085,0.0006900639,0.009896849,0.9029479,0.0015195321,0.04927775],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99745256,0.000759347,0.0005588785,0.00030035747,0.00068735983,0.00024142527],"domain_scores_gemma":[0.9064169,0.073689155,0.005519771,0.00325992,0.00955359,0.001560611],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0071558505,0.00077537214,0.0012182896,0.0021513002,0.00083748094,0.002042235,0.0017068238,0.0015772149,0.90434366],"category_scores_gemma":[0.07768798,0.0006298435,0.0011220055,0.003698157,0.0003417727,0.0023812617,0.0011852895,0.0014261813,0.22198972],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072285434,0.00009701558,0.00085102976,0.0028780499,0.000036170986,0.00003682296,0.00002735811,0.00027758148,0.000058989517,0.0011970068,0.98131114,0.012505869],"study_design_scores_gemma":[0.0058029476,0.0005090366,0.008536323,0.0045474116,0.00019743186,0.00036128506,0.00017663515,0.00088264706,0.000569292,0.010836888,0.96749985,0.00008029694],"about_ca_topic_score_codex":0.0036235477,"about_ca_topic_score_gemma":0.006339219,"teacher_disagreement_score":0.90434366,"about_ca_system_score_codex":0.0018949964,"about_ca_system_score_gemma":0.0034736062,"threshold_uncertainty_score":0.13644218},"labels":[],"label_agreement":null},{"id":"W6949277524","doi":"10.5281/zenodo.14640141","title":"PREreview of \"Safety and Efficacy of Chimeric Antigen Receptor T-cell Therapy for Recurrent Glioblastoma: An Augmented Meta-analysis of Phase 1 Clinical Trials\"","year":2025,"lang":"en","type":"peer-review","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Adverse effect; Disease; Compassionate Use; CAR T-cell therapy; Progression-free survival; Phases of clinical research; Glioblastoma","score_opus":0.2629647973709968,"score_gpt":0.4665238097959352,"score_spread":0.2035590124249384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6949277524","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009646149,0.7780045,0.009080188,0.06802513,0.0610192,0.017444916,0.042843606,0.0012051961,0.01273114],"genre_scores_gemma":[0.20885742,0.52297336,0.039657965,0.06696106,0.055601057,0.032266174,0.041471835,0.0020874836,0.030123577],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.94989336,0.033257473,0.0064200456,0.002053632,0.0077340705,0.0006414978],"domain_scores_gemma":[0.7475423,0.14942181,0.024362408,0.012131575,0.063205294,0.0033366063],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07471672,0.0019926964,0.0069510727,0.005598883,0.00078304735,0.0047484054,0.0028369615,0.0026119617,0.021902515],"category_scores_gemma":[0.21492437,0.0014539866,0.009543692,0.0046940525,0.0007250782,0.0020089631,0.001951279,0.0030587427,0.003577327],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053814678,0.000089529305,0.0033965616,0.30598816,0.054201767,0.0004204893,0.0002889662,0.0006503914,0.0016031449,0.0011357169,0.51319045,0.11365338],"study_design_scores_gemma":[0.010095053,0.002580147,0.022547785,0.17458515,0.20374544,0.0009278418,0.0003693293,0.0018161567,0.0027655077,0.003979199,0.57620114,0.00038727367],"about_ca_topic_score_codex":0.0019505621,"about_ca_topic_score_gemma":0.006475618,"teacher_disagreement_score":0.9252833,"about_ca_system_score_codex":0.003552195,"about_ca_system_score_gemma":0.0105387475,"threshold_uncertainty_score":0.39514446},"labels":[],"label_agreement":null},{"id":"W6950229199","doi":"10.5281/zenodo.6132564","title":"Homaxinella amphispicula","year":2014,"lang":"pt","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Griffin; Fish <Actinopterygii>; Fish habitat","score_opus":0.03822627206587388,"score_gpt":0.2734444410469378,"score_spread":0.23521816898106396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6950229199","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8083231,0.010878269,0.0036607678,0.00047450225,0.00025899312,0.00016490904,0.0018424965,0.00036395024,0.17403294],"genre_scores_gemma":[0.97443455,0.0023417235,0.0034518098,0.00028556463,0.00006231814,0.000052007308,0.00094990514,0.000018756355,0.018403381],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989176,0.000014722487,0.000010655749,0.000035867353,0.000023176439,0.000023930754],"domain_scores_gemma":[0.99987245,0.000016219477,0.000055300876,0.000014320001,0.000028657912,0.000013104267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016064518,0.0004792216,0.0001342408,0.00084490556,0.00090509595,0.00032731085,0.00027151316,0.0004761288,0.008398626],"category_scores_gemma":[0.0004262804,0.00016080475,0.00015670703,0.0005255395,0.00034660453,0.00062805775,0.0006479272,0.00027857488,0.0025807852],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011342521,0.00014436585,0.14066069,0.0015813335,0.00008563605,0.0037194046,0.0052959444,0.00068799435,0.20123316,0.006584605,0.021175064,0.6176976],"study_design_scores_gemma":[0.000048698686,0.0009384263,0.58536994,0.0013604151,0.000099939134,0.011206841,0.0037193506,0.0007949304,0.017122054,0.0014305343,0.37785277,0.00005607553],"about_ca_topic_score_codex":0.00465147,"about_ca_topic_score_gemma":0.0075808023,"teacher_disagreement_score":0.008398626,"about_ca_system_score_codex":0.00040814176,"about_ca_system_score_gemma":0.00016873029,"threshold_uncertainty_score":0.028096199},"labels":[],"label_agreement":null},{"id":"W6958028467","doi":"10.6084/m9.figshare.13627439.v1","title":"Additional file 1 of Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa; Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD22; B cell; Immunotherapy; CAR T-cell therapy; T cell; Antigen","score_opus":0.05712757881856177,"score_gpt":0.3170791003207258,"score_spread":0.259951521502164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958028467","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016939499,0.008426047,0.0018789257,0.0009845134,0.0002448823,0.040573914,0.94208556,0.00045271963,0.0036593294],"genre_scores_gemma":[0.0335633,0.017945021,0.029608496,0.0040751565,0.0006282872,0.63207865,0.25273877,0.0006356366,0.02872664],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99721414,0.0008088984,0.0011284208,0.00034342334,0.00034006094,0.00016503723],"domain_scores_gemma":[0.9711809,0.021210544,0.0045142225,0.0006195837,0.0021753353,0.00029935676],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0064037517,0.0022839839,0.0059255357,0.0055755116,0.0007889486,0.0019642098,0.0016658955,0.0018199189,0.58785576],"category_scores_gemma":[0.04263057,0.0012752617,0.0069278604,0.0072993976,0.000524166,0.003090679,0.0014373118,0.0013689395,0.016392188],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033010873,0.00008686547,0.0006599603,0.88888305,0.0031160826,0.00008123831,0.00013091764,0.00043763616,0.00036940415,0.0010911525,0.08797376,0.013868857],"study_design_scores_gemma":[0.09787703,0.002459163,0.0233187,0.44746616,0.046268594,0.0006765521,0.0005612062,0.0024686551,0.0016017478,0.01105621,0.3657335,0.0005124561],"about_ca_topic_score_codex":0.0048229266,"about_ca_topic_score_gemma":0.013840141,"teacher_disagreement_score":0.58785576,"about_ca_system_score_codex":0.0030005234,"about_ca_system_score_gemma":0.0049584745,"threshold_uncertainty_score":0.5878737},"labels":[],"label_agreement":null},{"id":"W6958064869","doi":"10.6084/m9.figshare.14313469","title":"Additional file 3 of Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; CAR T-cell therapy; Antibody therapy; Immunotherapy; T cell; Antigen; MEDLINE","score_opus":0.0861324749895752,"score_gpt":0.333462124646558,"score_spread":0.2473296496569828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958064869","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010123978,0.00014390261,0.0017963964,0.0077578686,0.00021350381,0.0077783973,0.94842106,0.00027792025,0.023487],"genre_scores_gemma":[0.1989289,0.0013967936,0.027014798,0.015063578,0.0006306638,0.23107499,0.4235915,0.0009278308,0.10137091],"study_design_codex":"not_applicable","study_design_gemma":"qualitative","domain_scores_codex":[0.9981377,0.00096512196,0.00030021457,0.00014326787,0.00022215425,0.00023158354],"domain_scores_gemma":[0.90044415,0.086415984,0.0037240377,0.0013008039,0.0065719727,0.0015431424],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0059945844,0.00053763704,0.0007218324,0.0019947258,0.0022106932,0.0014283607,0.0013118976,0.0012849853,0.7310627],"category_scores_gemma":[0.072362915,0.0005047772,0.0005195118,0.0028815782,0.00042408824,0.0028147576,0.0014230969,0.0016616825,0.06361326],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003927523,0.0003448601,0.004845539,0.0025079383,0.00001723204,0.00009366928,0.004207106,0.00029846124,0.000036504938,0.0020492321,0.96999747,0.015209246],"study_design_scores_gemma":[0.011110752,0.00086649205,0.07703176,0.015550148,0.00017193437,0.0006196985,0.06370689,0.003676459,0.0007142181,0.028907174,0.7973587,0.0002858892],"about_ca_topic_score_codex":0.012683584,"about_ca_topic_score_gemma":0.020143678,"teacher_disagreement_score":0.7310627,"about_ca_system_score_codex":0.003361604,"about_ca_system_score_gemma":0.00429152,"threshold_uncertainty_score":0.38360637},"labels":[],"label_agreement":null},{"id":"W6958106387","doi":"10.6084/m9.figshare.19424825.v1","title":"Additional file 1 of Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; EVERSANA (Canada)","funders":"","keywords":"Sensitivity (control systems); Table (database); Refractory (planetary science); Immunotherapy; Primary (astronomy); Clinical trial","score_opus":0.10080985751320244,"score_gpt":0.33478981893570675,"score_spread":0.23397996142250432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958106387","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011438889,0.00014338554,0.0007041733,0.00019025466,0.00007608992,0.00069665443,0.9946844,0.0002072742,0.002153897],"genre_scores_gemma":[0.09094075,0.0007683586,0.013351325,0.0025462513,0.00056702964,0.03055056,0.8149731,0.0021599876,0.04414259],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9968823,0.0011711942,0.00050337234,0.0005787264,0.00049095316,0.0003734757],"domain_scores_gemma":[0.95461667,0.036101416,0.0037008305,0.0024138766,0.0025195773,0.00064755103],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004594193,0.0013012096,0.0022244556,0.0015540636,0.00080479804,0.0015086203,0.0021138156,0.0013380176,0.8033909],"category_scores_gemma":[0.05919925,0.0006723586,0.0029709917,0.0030042615,0.00026730308,0.0017597249,0.0009178188,0.0014173749,0.06719785],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012312885,0.0003890847,0.0076135723,0.011875033,0.0013780292,0.00012275203,0.00009924186,0.0018816503,0.00016854503,0.0019001303,0.93963367,0.022625342],"study_design_scores_gemma":[0.114887334,0.005428671,0.12820905,0.014014015,0.0065235323,0.0013296461,0.00071343937,0.009955617,0.0019015472,0.023204265,0.6934219,0.00041091736],"about_ca_topic_score_codex":0.0065243687,"about_ca_topic_score_gemma":0.0090398695,"teacher_disagreement_score":0.8033909,"about_ca_system_score_codex":0.0014967048,"about_ca_system_score_gemma":0.0022945353,"threshold_uncertainty_score":0.28043902},"labels":[],"label_agreement":null},{"id":"W6958268367","doi":"10.6084/m9.figshare.13093607","title":"Additional file 2 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10340761571144173,"score_gpt":0.33772088003794015,"score_spread":0.2343132643264984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958268367","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010337318,0.000037883172,0.00036426578,0.00032202844,0.000055312736,0.00028990093,0.9957349,0.0002914828,0.0028008528],"genre_scores_gemma":[0.012161383,0.000547422,0.00877149,0.0029630458,0.00044190386,0.008577312,0.9289323,0.0018746888,0.035730466],"study_design_codex":"not_applicable","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9970169,0.0008272802,0.000758741,0.00046271164,0.00061659445,0.00031778938],"domain_scores_gemma":[0.90156174,0.078457564,0.0054820585,0.0036041026,0.009177367,0.0017172203],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056859283,0.00096111814,0.0015664786,0.0031625498,0.00094199594,0.0025410496,0.0017947819,0.0016469841,0.90682554],"category_scores_gemma":[0.09473604,0.0006609071,0.0013275272,0.005263056,0.0003521496,0.0024347133,0.0015424598,0.0011746024,0.18507099],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048503233,0.000053261414,0.0010952331,0.0051881275,0.00005950104,0.00004228496,0.00004778645,0.0003362657,0.000044798537,0.0012451785,0.9808147,0.010587834],"study_design_scores_gemma":[0.009215063,0.000356426,0.015672833,0.009930691,0.00034879954,0.00034848484,0.00036176763,0.0014869961,0.00053469156,0.017092466,0.94450897,0.00014282863],"about_ca_topic_score_codex":0.006514881,"about_ca_topic_score_gemma":0.012573299,"teacher_disagreement_score":0.90682554,"about_ca_system_score_codex":0.0020149671,"about_ca_system_score_gemma":0.0034961,"threshold_uncertainty_score":0.13290197},"labels":[],"label_agreement":null},{"id":"W6958323770","doi":"10.6084/m9.figshare.19960075","title":"Additional file 4 of Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada","funders":"","keywords":"Table (database); Antibody; Immune system; Immunotherapy; Monoclonal antibody","score_opus":0.03444660161805825,"score_gpt":0.34538094404969144,"score_spread":0.3109343424316332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958323770","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024628185,0.000044202916,0.0004409198,0.00017274616,0.000039746883,0.00021955078,0.9969476,0.00048705612,0.0014019394],"genre_scores_gemma":[0.014488835,0.0004497629,0.007560651,0.001247483,0.0001924468,0.005691037,0.94844747,0.0016427623,0.020279555],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99906725,0.00016868947,0.00021148736,0.00017858871,0.00026576797,0.000108123335],"domain_scores_gemma":[0.9723998,0.020763287,0.0014705658,0.0012796788,0.0035703364,0.0005163548],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002548973,0.0009785369,0.0012408515,0.0018883395,0.00076860667,0.0017642464,0.0014945583,0.0014144536,0.87197274],"category_scores_gemma":[0.03494003,0.00053672644,0.0010313783,0.002276451,0.00024049445,0.0013383229,0.0009542151,0.00083065155,0.1577856],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009984522,0.0001612929,0.0019062173,0.004398338,0.00006811729,0.00008648328,0.00005189489,0.0005489016,0.000215004,0.00069238734,0.97291994,0.017952964],"study_design_scores_gemma":[0.008378933,0.00059150293,0.022796804,0.005879421,0.00034844465,0.0006351085,0.00035948094,0.0024602734,0.0020042264,0.012556132,0.94382787,0.0001617946],"about_ca_topic_score_codex":0.0043649157,"about_ca_topic_score_gemma":0.0084246285,"teacher_disagreement_score":0.87197274,"about_ca_system_score_codex":0.0012586867,"about_ca_system_score_gemma":0.0018818768,"threshold_uncertainty_score":0.18261534},"labels":[],"label_agreement":null},{"id":"W6958564055","doi":"10.6084/m9.figshare.28920986.v2","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Refractory (planetary science); Standard of care; Clinical trial; Confidence interval","score_opus":0.03081814673992698,"score_gpt":0.32723172556437974,"score_spread":0.29641357882445274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958564055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93970466,0.03328562,0.0014570773,0.0040429104,0.00022320714,0.0012370519,0.010143013,0.00015046523,0.00975597],"genre_scores_gemma":[0.9912115,0.0035764435,0.0010911314,0.000497571,0.000032134067,0.00018058883,0.0025943276,0.000014843935,0.000801506],"study_design_codex":"randomized_trial","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9984011,0.001026874,0.000051164407,0.00010537394,0.0002171647,0.00019826395],"domain_scores_gemma":[0.99814343,0.0008792507,0.00030198775,0.00006245732,0.00023142413,0.0003813873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003012213,0.001249213,0.0016753664,0.0006406738,0.00052311434,0.0013028869,0.001688527,0.0010067823,0.0034803653],"category_scores_gemma":[0.0072679603,0.00037544986,0.0034823287,0.0011026018,0.0006659228,0.000553214,0.0006437669,0.001862056,0.0001457989],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3883543,0.0031811108,0.040480264,0.009348815,0.024702271,0.00049723615,0.00029722488,0.32825977,0.0018972543,0.008371062,0.022485685,0.1721251],"study_design_scores_gemma":[0.24470218,0.032575686,0.09911081,0.0029392997,0.03538918,0.00053107226,0.0006310288,0.555658,0.0017158826,0.0064702444,0.019795543,0.00048109534],"about_ca_topic_score_codex":0.779348,"about_ca_topic_score_gemma":0.7961974,"teacher_disagreement_score":0.22065198,"about_ca_system_score_codex":0.034822166,"about_ca_system_score_gemma":0.025343176,"threshold_uncertainty_score":0.44390285},"labels":[],"label_agreement":null},{"id":"W6968743015","doi":"10.5281/zenodo.15058299","title":"Actualización de Seguridad - Health Canada realizó una evaluación del riesgo potencial de neoplasia maligna secundaria a las terapias CAR-T.","year":2025,"lang":"es","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Cancer; Epidemiology; Disease; Radiation therapy","score_opus":0.021146751330155006,"score_gpt":0.3102873918132703,"score_spread":0.2891406404831153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968743015","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6341673,0.1894712,0.020031694,0.017602935,0.00096574303,0.0039418703,0.035696946,0.0007659572,0.09735633],"genre_scores_gemma":[0.9450793,0.02672121,0.00908178,0.0029772231,0.00020411314,0.00080735935,0.0054882844,0.00010529384,0.009535422],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.98803025,0.0048919553,0.0010453152,0.0008404224,0.0044097626,0.00078231905],"domain_scores_gemma":[0.9707771,0.0057333307,0.004386037,0.0015115739,0.01637189,0.0012201128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018651646,0.00056527485,0.0009977868,0.0027576145,0.0014423756,0.0024135318,0.0012215112,0.0006207269,0.003157159],"category_scores_gemma":[0.021998888,0.00030661555,0.0014237976,0.004959101,0.001209929,0.00070578547,0.0009596198,0.0009201711,0.00044801913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040448285,0.00034819602,0.61385256,0.0032387138,0.0018459532,0.00017024532,0.0011558479,0.00314058,0.002855236,0.004244577,0.013292537,0.3518108],"study_design_scores_gemma":[0.0007081913,0.0034306073,0.78709173,0.0023041905,0.0036674298,0.0005417922,0.001597845,0.002507729,0.014533089,0.0017571987,0.18172267,0.00013760451],"about_ca_topic_score_codex":0.6463964,"about_ca_topic_score_gemma":0.70029044,"teacher_disagreement_score":0.3536036,"about_ca_system_score_codex":0.021110538,"about_ca_system_score_gemma":0.050284345,"threshold_uncertainty_score":0.7113721},"labels":[],"label_agreement":null},{"id":"W6976873748","doi":"10.6084/m9.figshare.29387378.v1","title":"Revaccination following CAR-T therapy: a needs assessment","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Focus group; CLARITY; Needs assessment; Audit; Primary care; Qualitative research; Patient education; Schedule","score_opus":0.056052696427784744,"score_gpt":0.3870660347820867,"score_spread":0.3310133383543019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976873748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98693085,0.00044229516,0.001217322,0.006281197,0.00004703928,0.0028120158,0.00022000965,0.000032401018,0.0020169427],"genre_scores_gemma":[0.98572874,0.0012624668,0.0068876105,0.0015473177,0.000044942335,0.0034814153,0.00022131986,0.000013462028,0.0008128043],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.9909272,0.004428046,0.001103813,0.00025616944,0.001312335,0.001972543],"domain_scores_gemma":[0.98174083,0.0053236512,0.0034746777,0.000364344,0.005405527,0.0036910425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.021055374,0.0004941056,0.0005418672,0.0025943012,0.003785972,0.001838513,0.0016610065,0.0016241991,0.0015769815],"category_scores_gemma":[0.026442934,0.0007084025,0.0011235232,0.001615006,0.0012547707,0.0032556388,0.0052998657,0.0022212234,0.0003443576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045061635,0.0038447864,0.2864618,0.0028437723,0.00007684599,0.0037227653,0.4835693,0.00056413276,0.0025833065,0.0012002068,0.008287405,0.2063951],"study_design_scores_gemma":[0.000096251606,0.004362969,0.22523892,0.0012298408,0.00006173759,0.0017267913,0.74825144,0.0016876945,0.0010744472,0.00086456357,0.015261371,0.00014397633],"about_ca_topic_score_codex":0.009415933,"about_ca_topic_score_gemma":0.018182077,"teacher_disagreement_score":0.021055374,"about_ca_system_score_codex":0.0080400305,"about_ca_system_score_gemma":0.014365488,"threshold_uncertainty_score":0.1113528},"labels":[],"label_agreement":null},{"id":"W6976939000","doi":"10.6084/m9.figshare.25397536.v1","title":"Additional file 1 of CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CD19; CD8; T cell; Cytotoxic T cell; Interleukin 21; Phenotype; Interleukin 3","score_opus":0.017155511829438915,"score_gpt":0.2405484962564494,"score_spread":0.22339298442701047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976939000","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029505146,0.00003523709,0.00047878065,0.00012298742,0.000051753945,0.00013408739,0.9976597,0.0004039498,0.00081844203],"genre_scores_gemma":[0.014550362,0.00037639888,0.008586102,0.0011340525,0.00016876389,0.0048220353,0.9540792,0.0017928804,0.014490208],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99911624,0.00011678043,0.00014406822,0.0002331039,0.00024316068,0.00014650369],"domain_scores_gemma":[0.9864014,0.010296319,0.00063845265,0.00079464976,0.0014291117,0.0004399311],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019323794,0.001430002,0.0017803719,0.0018086109,0.0012538168,0.0021612511,0.002173611,0.0016816491,0.90086365],"category_scores_gemma":[0.024367569,0.00078853936,0.0009968365,0.0029850106,0.00034805582,0.0018247562,0.0011873845,0.0012161238,0.17608261],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009704173,0.00022641121,0.0028676454,0.0069676978,0.00007388955,0.0002289344,0.00012702675,0.0006880951,0.0008786844,0.0010520839,0.97125816,0.014660964],"study_design_scores_gemma":[0.010672475,0.0012335938,0.03260067,0.0072065517,0.00036554862,0.0017806814,0.0008925099,0.004391471,0.0042575407,0.014898357,0.9213609,0.00033958722],"about_ca_topic_score_codex":0.00615934,"about_ca_topic_score_gemma":0.010195168,"teacher_disagreement_score":0.90086365,"about_ca_system_score_codex":0.0009641249,"about_ca_system_score_gemma":0.0024471972,"threshold_uncertainty_score":0.14140588},"labels":[],"label_agreement":null},{"id":"W6976993400","doi":"10.6084/m9.figshare.21968360.v1","title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Population; Clinical trial; Standard of care; Survival analysis; Relative survival","score_opus":0.05145052267298273,"score_gpt":0.29677436454742906,"score_spread":0.24532384187444634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976993400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908975,0.003948055,0.00062756316,0.0009593167,0.000023559633,0.000105082465,0.0013605168,0.000037002133,0.0020415275],"genre_scores_gemma":[0.9975115,0.0006128002,0.0004426419,0.00013568274,0.0000057314464,0.000033533557,0.0007829724,0.000006499964,0.00046861777],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9991653,0.00040848067,0.00002292229,0.00008607256,0.00009481537,0.0002225429],"domain_scores_gemma":[0.998285,0.000876237,0.000198763,0.00004024007,0.00023168753,0.0003680512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014862226,0.00077090744,0.0010283348,0.0006122826,0.000578571,0.001486766,0.001122106,0.0008614316,0.0023390763],"category_scores_gemma":[0.0043519833,0.00026781278,0.001854163,0.0008084856,0.0006616722,0.00047027966,0.0008453014,0.00089354784,0.00011480282],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031576067,0.0015129407,0.0905143,0.00065463403,0.002602472,0.0006872512,0.00025991583,0.7995386,0.00095854397,0.0049843104,0.0053247386,0.061386257],"study_design_scores_gemma":[0.0060792807,0.0075216615,0.13547562,0.0004091836,0.0023851984,0.0005165129,0.0013184124,0.83839977,0.0010919479,0.002085346,0.0045234608,0.00019356437],"about_ca_topic_score_codex":0.81398106,"about_ca_topic_score_gemma":0.7313508,"teacher_disagreement_score":0.18601894,"about_ca_system_score_codex":0.033424407,"about_ca_system_score_gemma":0.015746197,"threshold_uncertainty_score":0.37422884},"labels":[],"label_agreement":null},{"id":"W6977145869","doi":"10.6084/m9.figshare.13093607.v1","title":"Additional file 2 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10340761571144173,"score_gpt":0.33772088003794015,"score_spread":0.2343132643264984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977145869","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010337318,0.000037883172,0.00036426578,0.00032202844,0.000055312736,0.00028990093,0.9957349,0.0002914828,0.0028008528],"genre_scores_gemma":[0.012161383,0.000547422,0.00877149,0.0029630458,0.00044190386,0.008577312,0.9289323,0.0018746888,0.035730466],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970169,0.0008272802,0.000758741,0.00046271164,0.00061659445,0.00031778938],"domain_scores_gemma":[0.90156174,0.078457564,0.0054820585,0.0036041026,0.009177367,0.0017172203],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0056859283,0.00096111814,0.0015664786,0.0031625498,0.00094199594,0.0025410496,0.0017947819,0.0016469841,0.90682554],"category_scores_gemma":[0.09473604,0.0006609071,0.0013275272,0.005263056,0.0003521496,0.0024347133,0.0015424598,0.0011746024,0.18507099],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048503233,0.000053261414,0.0010952331,0.0051881275,0.00005950104,0.00004228496,0.00004778645,0.0003362657,0.000044798537,0.0012451785,0.9808147,0.010587834],"study_design_scores_gemma":[0.009215063,0.000356426,0.015672833,0.009930691,0.00034879954,0.00034848484,0.00036176763,0.0014869961,0.00053469156,0.017092466,0.94450897,0.00014282863],"about_ca_topic_score_codex":0.006514881,"about_ca_topic_score_gemma":0.012573299,"teacher_disagreement_score":0.90682554,"about_ca_system_score_codex":0.0020149671,"about_ca_system_score_gemma":0.0034961,"threshold_uncertainty_score":0.13290197},"labels":[],"label_agreement":null},{"id":"W6977398995","doi":"10.6084/m9.figshare.28301094","title":"Additional file 2 of Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Toronto General Hospital; University of Calgary","funders":"","keywords":"Cell therapy; Cell; Immunotherapy; T cell; Antibody therapy; Transplantation; Cell culture; Disease","score_opus":0.02810389943053269,"score_gpt":0.27530042683255035,"score_spread":0.24719652740201767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977398995","genre_codex":"dataset","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022691581,0.000040393694,0.0007881866,0.00015015507,0.00009069697,0.00013348881,0.9950387,0.0010682248,0.0024632218],"genre_scores_gemma":[0.010467404,0.00032061778,0.007966649,0.0011489672,0.000184375,0.0023729124,0.9573099,0.0030317653,0.017197445],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991543,0.00012394064,0.00010652669,0.0002144836,0.00025924243,0.00014151186],"domain_scores_gemma":[0.98265994,0.013380706,0.0006114708,0.0010427072,0.0015475819,0.00075758685],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016907718,0.0012964439,0.0018460461,0.0020383913,0.0012877929,0.0021895168,0.002026147,0.0017875835,0.9358581],"category_scores_gemma":[0.019920412,0.0010490882,0.0012500511,0.0023703566,0.00041446567,0.0016910448,0.001089333,0.0014239087,0.32776946],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006480101,0.00018558251,0.0014400986,0.0038769674,0.000056037938,0.0001270407,0.000052768526,0.0006827684,0.0008238017,0.0010686417,0.978288,0.012750375],"study_design_scores_gemma":[0.0061292117,0.00071313465,0.01598418,0.0032045767,0.00022197136,0.00088994124,0.00031864867,0.0025545862,0.0048335455,0.01522714,0.9497036,0.00021955131],"about_ca_topic_score_codex":0.0040918128,"about_ca_topic_score_gemma":0.008347032,"teacher_disagreement_score":0.9358581,"about_ca_system_score_codex":0.0012198316,"about_ca_system_score_gemma":0.002095119,"threshold_uncertainty_score":0.091490686},"labels":[],"label_agreement":null},{"id":"W6981320802","doi":"","title":"EDSP 553-01 Assessment and Program Planning for Transition Education and Services","year":2016,"lang":"en","type":"article","venue":"Exhibit - A Showcase of Scholarship, Creativity and Preservation Provided by Xavier University Library (Xavier University)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Program evaluation; Transition (genetics); Program Design Language; Plan (archaeology)","score_opus":0.027443273586005075,"score_gpt":0.29899967708934533,"score_spread":0.27155640350334026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981320802","genre_codex":"other","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14939131,0.0015584386,0.054188114,0.0976154,0.004914222,0.04343988,0.023058884,0.006462981,0.6193709],"genre_scores_gemma":[0.36702552,0.0027878801,0.21811956,0.007748441,0.0003854544,0.03648814,0.015790256,0.0010166048,0.35063803],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965553,0.0014163669,0.0002524635,0.00014002547,0.00093466527,0.0007011718],"domain_scores_gemma":[0.9866536,0.0010700185,0.00045846292,0.00033983024,0.0060849492,0.0053931237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012301168,0.00056255865,0.00043431966,0.0025656498,0.0025301485,0.0027487983,0.0021489635,0.0014578223,0.079582535],"category_scores_gemma":[0.015164076,0.00044237112,0.0008259754,0.000978015,0.00037056653,0.001539778,0.0033656608,0.0020530783,0.018408224],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047334156,0.0024466233,0.024205815,0.00039220872,0.000023292512,0.00042290287,0.0014720176,0.0019133257,0.00073092803,0.0038252869,0.48837948,0.47571477],"study_design_scores_gemma":[0.00054722244,0.0035333338,0.18065287,0.004001502,0.000095125106,0.00078181655,0.016289927,0.007923287,0.004598943,0.007537991,0.7738871,0.00015096685],"about_ca_topic_score_codex":0.037515193,"about_ca_topic_score_gemma":0.092634924,"teacher_disagreement_score":0.079582535,"about_ca_system_score_codex":0.007829349,"about_ca_system_score_gemma":0.04223624,"threshold_uncertainty_score":0.2662301},"labels":[],"label_agreement":null},{"id":"W69901490","doi":"10.4049/jimmunol.182.supp.41.37","title":"Adoptive therapy of a fast growing tumor with reactivated memory T cells combined with anti-4-1BB eliminates tumors through effects of anti-4-1BB on transferred but not host cells (41.37)","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adoptive cell transfer; Immunotherapy; Immunology; CD8; Cancer research; Cytotoxic T cell; Priming (agriculture); Cancer immunotherapy; T cell; Biology; Ex vivo; In vivo; Immune system; In vitro","score_opus":0.013069246956785657,"score_gpt":0.2555432166990163,"score_spread":0.24247396974223065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W69901490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99593204,0.0008308785,0.0019876265,0.000067736895,0.00006524147,0.000087195054,0.00009027663,0.00017189099,0.00076713326],"genre_scores_gemma":[0.9952798,0.00045765092,0.002172623,0.000055651406,0.000049768794,0.00009548699,0.00017620658,0.00002408611,0.0016887689],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99973696,0.000042844233,0.000022326767,0.00005145296,0.00004685609,0.00009960899],"domain_scores_gemma":[0.99983764,0.000039573933,0.000042193096,0.00003738283,0.000009015019,0.000034137316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003303794,0.0009355579,0.00057582225,0.00033138003,0.00014763646,0.0003754547,0.0004121322,0.00040628968,0.0013563489],"category_scores_gemma":[0.0001596514,0.00023523226,0.00039109215,0.00013518792,0.0003368052,0.00022028877,0.00025011617,0.0014072412,0.00035119057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034622723,0.0003833433,0.00015213323,0.00005160148,0.000016415806,0.000050422674,0.00002635337,0.00020236426,0.9951315,0.0001219444,0.000056582303,0.0034610673],"study_design_scores_gemma":[0.00013151675,0.004394782,0.0008259015,0.000009016787,0.00005768117,0.00024058035,0.000008933021,0.0012518773,0.9917216,0.000047789457,0.0013059517,0.0000044256926],"about_ca_topic_score_codex":0.00030877817,"about_ca_topic_score_gemma":0.0004171195,"teacher_disagreement_score":0.0013563489,"about_ca_system_score_codex":0.00021020956,"about_ca_system_score_gemma":0.00030040662,"threshold_uncertainty_score":0.004537463},"labels":[],"label_agreement":null},{"id":"W6996006929","doi":"","title":"Profil d'application québécois de métadonnées pour les opportunités d'étude, d'apprentissage et de formation (v0.7.5)","year":2011,"lang":"fr","type":"other","venue":"Bibliothèque et Archives nationales du Québec (Québec government)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Work (physics); Process (computing); Term (time)","score_opus":0.03026081497946018,"score_gpt":0.2740971606121987,"score_spread":0.2438363456327385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996006929","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46799672,0.18741864,0.034267,0.01622658,0.0033416038,0.005231012,0.016762553,0.0036182087,0.26513776],"genre_scores_gemma":[0.70053077,0.051710747,0.041223355,0.0035904865,0.0003497893,0.0020268972,0.005706577,0.0008385082,0.19402283],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997177,0.0007286007,0.00013310705,0.00033069655,0.0013333631,0.0002971163],"domain_scores_gemma":[0.9952943,0.0011433363,0.00028603207,0.00030851553,0.0025011608,0.000466636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0062946514,0.00065107807,0.0010348724,0.002218809,0.001828331,0.0024289894,0.0005854618,0.0015196638,0.030147878],"category_scores_gemma":[0.0067430506,0.00028890898,0.0008610627,0.0013336177,0.0006524564,0.0007348155,0.00070914376,0.0010240712,0.0044006207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031155122,0.00075739046,0.013306563,0.002775388,0.00020629633,0.00068746565,0.001695523,0.00054942886,0.11614046,0.0022384748,0.044127416,0.81440014],"study_design_scores_gemma":[0.00063206116,0.0082288105,0.06578379,0.0029039648,0.00082064356,0.0021250094,0.0022810518,0.0017365023,0.144143,0.0011022933,0.770045,0.00019795643],"about_ca_topic_score_codex":0.11029081,"about_ca_topic_score_gemma":0.22991975,"teacher_disagreement_score":0.8897092,"about_ca_system_score_codex":0.005219722,"about_ca_system_score_gemma":0.00790203,"threshold_uncertainty_score":0.2192977},"labels":[],"label_agreement":null},{"id":"W7008270954","doi":"","title":"Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial Results","year":2024,"lang":"en","type":"other","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Heron; Stock (firearms); Quarter (Canadian coin); Stock exchange","score_opus":0.038414313554182344,"score_gpt":0.32102282507862245,"score_spread":0.2826085115244401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7008270954","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006709538,0.00096169114,0.00034639981,0.012305943,0.0109354695,0.000096600575,0.00971854,0.001447181,0.9635172],"genre_scores_gemma":[0.0018819162,0.00056855887,0.000159389,0.0025257876,0.0010764526,0.000032605265,0.004106994,0.00023775133,0.98941046],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991279,0.0000498548,0.000028545885,0.00007183816,0.00055548316,0.00016625525],"domain_scores_gemma":[0.9975405,0.00018169044,0.000101636935,0.000100363875,0.0009832487,0.0010926115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010346939,0.0007052943,0.0005197691,0.0011933345,0.0012519783,0.00523829,0.00070518616,0.0029381043,0.64020866],"category_scores_gemma":[0.0032921957,0.00027846708,0.00062798266,0.0007337379,0.00039908942,0.0014980021,0.0009997907,0.0023690367,0.5280618],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029606628,0.000018716113,0.000066605455,0.000014274307,8.3226564e-7,0.000016807091,0.0000020788125,0.000014494672,0.00007460125,0.00063666474,0.9872945,0.011830844],"study_design_scores_gemma":[0.000028989765,0.00003086489,0.00058737205,0.000041535783,0.0000019095419,0.00003670697,0.000017054674,0.00011420701,0.0001911601,0.00047350247,0.99847025,0.0000063896073],"about_ca_topic_score_codex":0.006824369,"about_ca_topic_score_gemma":0.014076189,"teacher_disagreement_score":0.64020866,"about_ca_system_score_codex":0.0015479303,"about_ca_system_score_gemma":0.0036633727,"threshold_uncertainty_score":0.5131986},"labels":[],"label_agreement":null},{"id":"W7008907978","doi":"","title":"Cytokinetics Reports First Quarter 2020 Financial Results","year":2020,"lang":"en","type":"other","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Payment; Government (linguistics)","score_opus":0.018847881570827358,"score_gpt":0.28743966741341825,"score_spread":0.2685917858425909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7008907978","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021027138,0.0060033677,0.0014478931,0.029330574,0.04560517,0.00040327734,0.03713563,0.002365728,0.8756055],"genre_scores_gemma":[0.00619572,0.0033746392,0.0012247844,0.006764825,0.0057089617,0.00020254392,0.020199245,0.00069009396,0.95563924],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99758196,0.00022313777,0.0000934833,0.00015020014,0.0015507839,0.00040048637],"domain_scores_gemma":[0.9941174,0.00055606395,0.00040096196,0.00019734063,0.001992,0.0027363498],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029029094,0.001254208,0.0007181334,0.0019035275,0.00091546593,0.0064749825,0.00097194134,0.003196905,0.4491675],"category_scores_gemma":[0.007323395,0.00041267322,0.0011502102,0.0010951927,0.00062079437,0.0015263224,0.0014340967,0.0030608068,0.38181907],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017386793,0.000069179936,0.00015929992,0.00006667998,0.0000051853344,0.000035337293,0.000003861322,0.00008865953,0.00023173913,0.0013483581,0.9658631,0.03195456],"study_design_scores_gemma":[0.00014594848,0.00012108836,0.0005088475,0.00011436056,0.000008573697,0.000051640473,0.000015774465,0.0003287432,0.0005393507,0.0014464115,0.9967091,0.00001005161],"about_ca_topic_score_codex":0.0024721173,"about_ca_topic_score_gemma":0.0036993814,"teacher_disagreement_score":0.4491675,"about_ca_system_score_codex":0.0016935421,"about_ca_system_score_gemma":0.0063419463,"threshold_uncertainty_score":0.78569573},"labels":[],"label_agreement":null},{"id":"W7072023979","doi":"","title":"Understanding Goals of Care for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy: A Qualitative Descriptive Study","year":2024,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Qualitative research; Content analysis; Health care; Descriptive statistics; Health professionals; Nurse practitioners; Descriptive research; Chimeric antigen receptor","score_opus":0.0781463891152325,"score_gpt":0.32092183032084565,"score_spread":0.24277544120561315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7072023979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98380846,0.001237455,0.003055462,0.00565809,0.00016816094,0.00050791807,0.00041255326,0.000026699548,0.0051251156],"genre_scores_gemma":[0.99158114,0.0015520412,0.0017555236,0.0020266492,0.000033239026,0.00065483863,0.00017093796,0.000034749126,0.0021907922],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9874406,0.00908651,0.0004398074,0.0006015383,0.00078120374,0.0016503768],"domain_scores_gemma":[0.974459,0.018725777,0.0016807227,0.00045854566,0.0020463122,0.0026296852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017072773,0.00068842823,0.0011155063,0.0015691731,0.009261706,0.005383738,0.0021446722,0.0021177267,0.0038584103],"category_scores_gemma":[0.027045699,0.00087481394,0.0007867793,0.0016234546,0.008628994,0.005334214,0.0060530105,0.005217145,0.00046172555],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032063435,0.000049366732,0.0024069478,0.00016763931,0.000005147287,0.00046468127,0.9923725,0.000035680358,0.0002807631,0.0008774191,0.00057576114,0.0027320068],"study_design_scores_gemma":[0.0000031379054,0.00003135478,0.00055448554,0.00011314659,0.0000024907908,0.00014132053,0.99556965,0.000044977598,0.00007079494,0.00017775621,0.0032811868,0.000009718993],"about_ca_topic_score_codex":0.0101431245,"about_ca_topic_score_gemma":0.013759697,"teacher_disagreement_score":0.017072773,"about_ca_system_score_codex":0.0073813456,"about_ca_system_score_gemma":0.008538261,"threshold_uncertainty_score":0.09029049},"labels":[],"label_agreement":null},{"id":"W7083882660","doi":"","title":"U.S. health officials alarmed by paralyzing illness in kids","year":2019,"lang":"en","type":"other","venue":"Internet Archive (Internet Archive)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Health care; MEDLINE; Sociology of health and illness","score_opus":0.019011597961485247,"score_gpt":0.30973603303536773,"score_spread":0.29072443507388246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7083882660","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06425527,0.018271191,0.0003790464,0.43346164,0.007656452,0.000083674364,0.0112055475,0.0006979983,0.46398914],"genre_scores_gemma":[0.3005211,0.031202875,0.0013202307,0.17325531,0.0056038382,0.00011647211,0.0072889864,0.00027152145,0.48041964],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996934,0.000085415704,0.000022011673,0.000031728658,0.00007845036,0.00008904625],"domain_scores_gemma":[0.9986217,0.00026191433,0.00025391974,0.000057793408,0.00033581496,0.0004688397],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040707784,0.00022075027,0.00010835766,0.0007973159,0.0016504508,0.0010507366,0.00021643692,0.0014914271,0.04168914],"category_scores_gemma":[0.0014639441,0.00013413308,0.00023773227,0.0004921608,0.00054946955,0.0006462674,0.0007537226,0.0013613462,0.008304386],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055731078,0.000056483128,0.023247045,0.00009773911,0.000004242096,0.00059872173,0.0003613293,0.000022514256,0.00037438583,0.0011675449,0.92060286,0.053411365],"study_design_scores_gemma":[0.000037935726,0.00012469145,0.07962926,0.00058341667,0.000020670821,0.0026898072,0.0034688397,0.00008238726,0.0008576169,0.0009783324,0.9114997,0.000027312431],"about_ca_topic_score_codex":0.028683947,"about_ca_topic_score_gemma":0.06977774,"teacher_disagreement_score":0.95831084,"about_ca_system_score_codex":0.0010508172,"about_ca_system_score_gemma":0.0013086699,"threshold_uncertainty_score":0.13946402},"labels":[],"label_agreement":null},{"id":"W7084101606","doi":"10.6084/m9.figshare.29982898.v1","title":"Raw data for Quebec dairy herd housing and management survey (2020–2021)","year":2025,"lang":"en","type":"dataset","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Raw data; Survey data collection; Herd; Aerial survey; Raw milk; Dairy farming","score_opus":0.12636119696762343,"score_gpt":0.3878958058395975,"score_spread":0.26153460887197405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084101606","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018281973,0.000040554587,0.000029300936,0.000050907514,0.000010304555,0.00000798462,0.9991278,0.00007811773,0.00047224326],"genre_scores_gemma":[0.0012223034,0.000046956688,0.00019122029,0.000053302043,0.0000073378187,0.000058840847,0.996851,0.000027955093,0.00154114],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9992067,0.00009021941,0.0000519391,0.00017251278,0.00028060374,0.00019799276],"domain_scores_gemma":[0.99608094,0.0003888494,0.0002483688,0.00041984866,0.0025154154,0.00034650814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010667183,0.0012660222,0.0009250979,0.0027871735,0.0011408378,0.0016286907,0.0020714556,0.0011566437,0.05506972],"category_scores_gemma":[0.005995173,0.00045056932,0.0007288484,0.0060481783,0.00030994523,0.00054175284,0.0009360799,0.0011849514,0.029609412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003766176,0.00001037277,0.0024430703,0.00012182131,0.000021398411,0.000012630301,0.000014160017,0.00031232863,0.00003535701,0.0002590167,0.994622,0.0021102962],"study_design_scores_gemma":[0.0001611947,0.000017077726,0.045835707,0.00042950743,0.00003437261,0.000037819784,0.00011646137,0.0012425514,0.0002693352,0.0005104727,0.95130104,0.000044417066],"about_ca_topic_score_codex":0.8966559,"about_ca_topic_score_gemma":0.9277982,"teacher_disagreement_score":0.10334408,"about_ca_system_score_codex":0.009807696,"about_ca_system_score_gemma":0.01256415,"threshold_uncertainty_score":0.20790535},"labels":[],"label_agreement":null},{"id":"W7092477290","doi":"10.51731/cjht.2025.1256","title":"Glofitamab (Columvi)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oxaliplatin; Gemcitabine; Refractory (planetary science); Lymphoma; Drug; Chemotherapy; Diffuse large B-cell lymphoma","score_opus":0.0406180561604166,"score_gpt":0.3553585270236323,"score_spread":0.3147404708632157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7092477290","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032702245,0.09925423,0.007311918,0.027254576,0.005984019,0.0027111748,0.03129841,0.014374086,0.7791095],"genre_scores_gemma":[0.1424095,0.03687913,0.00878934,0.025490876,0.0010312541,0.0012421113,0.046174042,0.0016284996,0.73635536],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9990244,0.00009711941,0.000037060436,0.00020276876,0.00039332762,0.0002453336],"domain_scores_gemma":[0.9991892,0.000054720138,0.00006438821,0.00006980641,0.00021893275,0.00040287751],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011493892,0.0010581984,0.0010079459,0.001627642,0.0010982685,0.0025117097,0.0014845541,0.0023812423,0.19751303],"category_scores_gemma":[0.0015417484,0.00041930104,0.0009246203,0.000776013,0.0007514091,0.0010166875,0.0015692515,0.0032118568,0.10282054],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026815566,0.0005455194,0.002006236,0.00092632143,0.00008098867,0.0009232637,0.00013196592,0.00037138362,0.014822658,0.006312853,0.5134539,0.45774338],"study_design_scores_gemma":[0.0007851744,0.00048944727,0.0015257546,0.0001706127,0.000036153706,0.0009799355,0.00003800717,0.00020069412,0.003068094,0.00068217586,0.9920066,0.000017385606],"about_ca_topic_score_codex":0.014404652,"about_ca_topic_score_gemma":0.02463735,"teacher_disagreement_score":0.19751303,"about_ca_system_score_codex":0.0030457913,"about_ca_system_score_gemma":0.0053307135,"threshold_uncertainty_score":0.66074693},"labels":[],"label_agreement":null},{"id":"W7104251354","doi":"10.71781/6671","title":"Besoins de formation continue d’infirmières en oncologie quant à la thérapie CAR-T : un sondage","year":2025,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Occupational training; Context (archaeology); Research methodology; Retraining","score_opus":0.06682323657882001,"score_gpt":0.4012862733458188,"score_spread":0.3344630367669988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104251354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92556536,0.0408708,0.0038533271,0.009087372,0.0005308243,0.0005437271,0.0027588801,0.000082332226,0.016707432],"genre_scores_gemma":[0.97467303,0.011909789,0.0045760223,0.0015526939,0.00020399463,0.00043041445,0.0012746431,0.000031624557,0.0053477543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954423,0.00151104,0.00052148185,0.00038618373,0.0014283541,0.00071062613],"domain_scores_gemma":[0.9835248,0.0041434714,0.006434976,0.0006158136,0.0037485287,0.0015323398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005469103,0.0005062497,0.00081589137,0.0013601837,0.0014496413,0.0020865442,0.00083916885,0.0009480462,0.0072206804],"category_scores_gemma":[0.022540424,0.00029465219,0.0010222562,0.0015730889,0.0010306289,0.0015245033,0.0018784424,0.0014402145,0.00081597606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017871246,0.0001912718,0.8026596,0.0014122435,0.00029438792,0.00043990582,0.0050237384,0.0002615505,0.000822944,0.00096329657,0.0060693515,0.18007457],"study_design_scores_gemma":[0.0001030079,0.0018567904,0.9367858,0.0029459535,0.00062580046,0.0022162744,0.009069651,0.0006671314,0.0017257474,0.0009680099,0.042936474,0.00009922436],"about_ca_topic_score_codex":0.039990325,"about_ca_topic_score_gemma":0.065924756,"teacher_disagreement_score":0.039990325,"about_ca_system_score_codex":0.003632121,"about_ca_system_score_gemma":0.006955507,"threshold_uncertainty_score":0.07951516},"labels":[],"label_agreement":null},{"id":"W7108450376","doi":"10.1182/blood-2025-6296","title":"Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cohort; Proportional hazards model; Lymphoma; Retrospective cohort study; Survival analysis; Cohort study; Chimeric antigen receptor; Surrogate endpoint; CAR T-cell therapy","score_opus":0.025455255169864653,"score_gpt":0.3288733749213329,"score_spread":0.30341811975146826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108450376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9990152,0.00025780336,0.000036994945,0.000045290813,0.000006156147,0.000004061788,0.00016986202,0.0000031252687,0.00046153498],"genre_scores_gemma":[0.9995938,0.00006291372,0.000012382093,0.00002167919,0.000012177682,0.000002890167,0.00019193174,7.442374e-7,0.00010151596],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99977654,0.00004551744,0.000029356588,0.000045498346,0.00004271603,0.000060511367],"domain_scores_gemma":[0.99847597,0.00017580121,0.00085962465,0.00008080168,0.00012225335,0.00028558198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004611287,0.00018935921,0.00026196093,0.00043759547,0.00031292177,0.0006274024,0.00025064612,0.00024832998,0.001611767],"category_scores_gemma":[0.0016281456,0.000087154156,0.00033367172,0.000499806,0.00023829279,0.00035627166,0.00038729943,0.00055351784,0.00018998298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043589046,0.000073358045,0.99621874,0.000010472056,0.00004546997,0.00012226384,0.000031871255,0.000060175164,0.00018221722,0.000014745856,0.00014915416,0.0026556114],"study_design_scores_gemma":[0.0000063106986,0.00020271755,0.9990683,0.000005908248,0.000028332935,0.0002766126,0.000049870934,0.0001452117,0.000052483065,0.000024194516,0.00013751251,0.0000024196397],"about_ca_topic_score_codex":0.002219398,"about_ca_topic_score_gemma":0.0025786257,"teacher_disagreement_score":0.002219398,"about_ca_system_score_codex":0.00027684227,"about_ca_system_score_gemma":0.00032142797,"threshold_uncertainty_score":0.005391896},"labels":[],"label_agreement":null},{"id":"W7108452450","doi":"10.1182/blood-2025-2395","title":"Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Cytokine release syndrome; Tolerability; Fludarabine; Adverse effect; Clinical trial; Chimeric antigen receptor; Lymphoma; Immunotherapy","score_opus":0.014438933948381607,"score_gpt":0.30784283175018984,"score_spread":0.29340389780180826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108452450","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29596496,0.65324837,0.010295441,0.0109553635,0.00083830714,0.00061327126,0.0011628601,0.00027125262,0.026650239],"genre_scores_gemma":[0.5884908,0.37663856,0.010578064,0.013137506,0.0017488888,0.0004369979,0.002284697,0.00022472563,0.0064598024],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99957544,0.00013398826,0.00006345318,0.00006157993,0.00011421202,0.00005133854],"domain_scores_gemma":[0.9981956,0.0008594309,0.0001771737,0.00008095174,0.0005634372,0.00012342136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037912775,0.0004449424,0.00093919685,0.0004115139,0.00013251498,0.0016506731,0.00075194525,0.0006895416,0.0012086211],"category_scores_gemma":[0.002123549,0.0001952157,0.00073218095,0.0005254423,0.00035660417,0.0009051714,0.00025145875,0.0018849649,0.00064676],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006133103,0.0009414033,0.0075999643,0.002866315,0.00065366464,0.00033906032,0.0002111558,0.001598822,0.041713946,0.002100833,0.014513094,0.92132866],"study_design_scores_gemma":[0.0071067773,0.05395667,0.06060816,0.0031736116,0.004719261,0.004417665,0.0004143852,0.006521318,0.07983943,0.0027633258,0.77633363,0.00014579385],"about_ca_topic_score_codex":0.00058604014,"about_ca_topic_score_gemma":0.001014169,"teacher_disagreement_score":0.0037912775,"about_ca_system_score_codex":0.00102931,"about_ca_system_score_gemma":0.000805469,"threshold_uncertainty_score":0.020050406},"labels":[],"label_agreement":null},{"id":"W7108452504","doi":"10.1182/blood-2025-2287","title":"Real-world sequencing of anti-BCMA CAR T-cells and bispecific T-cell engagers in Relapsed/Refractory multiple myeloma: A multi-country analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Clinical Practice; CAR T-cell therapy; Clinical trial; Multiple myeloma; Real world data; Daratumumab; Bispecific antibody; Hematologic Neoplasms","score_opus":0.02518383271107581,"score_gpt":0.2919276031433316,"score_spread":0.2667437704322558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108452504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9650133,0.0023759285,0.0013136236,0.00033344573,0.000024405916,0.00007232814,0.030224353,0.000026540545,0.000616182],"genre_scores_gemma":[0.9807544,0.00062514463,0.0013414068,0.00035321483,0.000027474194,0.000100325786,0.016605183,0.000031463234,0.0001614805],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953101,0.0019774642,0.0005047674,0.0013728592,0.00038688444,0.00044793732],"domain_scores_gemma":[0.9887235,0.0034875257,0.0046602897,0.0010207632,0.0012920841,0.0008159193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040454236,0.00036338475,0.00085656473,0.0020218801,0.00049080356,0.0014386176,0.0008438234,0.00072462857,0.001911158],"category_scores_gemma":[0.008418397,0.00046915695,0.001191898,0.0037869902,0.00047912094,0.00060841773,0.0013167578,0.0010556389,0.0004004055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007184283,0.00008541141,0.987171,0.00034889806,0.0011229886,0.0002957943,0.00025331872,0.00096200895,0.00052890694,0.00023214152,0.0029555804,0.0053255754],"study_design_scores_gemma":[0.000118316464,0.00036951213,0.98446554,0.0003054565,0.0012016369,0.0013680063,0.0011118398,0.002637662,0.0007237346,0.00026864128,0.007374585,0.000055058747],"about_ca_topic_score_codex":0.006832838,"about_ca_topic_score_gemma":0.0069366246,"teacher_disagreement_score":0.006832838,"about_ca_system_score_codex":0.0009488554,"about_ca_system_score_gemma":0.0009846579,"threshold_uncertainty_score":0.021394491},"labels":[],"label_agreement":null},{"id":"W7108461223","doi":"10.1182/blood-2025-7647","title":"BCMA-targeted CAR-NK cell therapy using lipid nanoparticle mRNA delivery for multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Genetic enhancement; Immunogenicity; Cancer; Cell therapy; Cytokine release syndrome; Immunotherapy","score_opus":0.03345951169619087,"score_gpt":0.3009155936766589,"score_spread":0.267456081980468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108461223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90002024,0.03220426,0.049123324,0.0012479809,0.0006065384,0.00022952852,0.0003342584,0.00074996165,0.01548384],"genre_scores_gemma":[0.9795171,0.005824821,0.0061039845,0.00023380906,0.000035874695,0.00008578483,0.00012911289,0.000036186906,0.00803334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999578,0.0000039682263,0.0000018140648,0.000011596619,0.000014478752,0.000010364209],"domain_scores_gemma":[0.9999888,0.0000015431392,0.0000033106278,8.83317e-7,0.0000030062793,0.000002506676],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000061685474,0.00020201903,0.0001797203,0.00011866526,0.00011411673,0.00020336316,0.00012279981,0.00030032874,0.0016037793],"category_scores_gemma":[0.000051209816,0.00007188062,0.0001895968,0.000095241296,0.00012141481,0.00017054805,0.00020783415,0.00032603485,0.0005251347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001687104,0.0000701507,0.000074294156,0.00018954459,0.000008757309,0.00012214809,0.000021575659,0.0008150397,0.97405124,0.00043522642,0.0006780067,0.023365285],"study_design_scores_gemma":[0.00006622458,0.0007739053,0.00059594586,0.00001744603,0.000042271182,0.00028492115,0.000017374949,0.0064929468,0.9740504,0.00020241368,0.017444877,0.000011283883],"about_ca_topic_score_codex":0.0010737564,"about_ca_topic_score_gemma":0.00086070347,"teacher_disagreement_score":0.0016037793,"about_ca_system_score_codex":0.00049826177,"about_ca_system_score_gemma":0.00024638572,"threshold_uncertainty_score":0.005365193},"labels":[],"label_agreement":null},{"id":"W7108472195","doi":"10.1182/blood-2025-4496","title":"Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Vancouver General Hospital; University of Calgary; Hôpital Maisonneuve-Rosemont; Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Thrombosis; Retrospective cohort study; Incidence (geometry); Population; Venous thrombosis; Deep vein; Cytokine release syndrome","score_opus":0.018863630296467995,"score_gpt":0.29893779854187236,"score_spread":0.2800741682454044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108472195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99639434,0.0006592899,0.00007063518,0.000063394364,0.0000049297505,0.00004095051,0.001675094,0.000007728318,0.0010836136],"genre_scores_gemma":[0.9983569,0.0006056931,0.00008166164,0.000054263302,0.000008594484,0.000012411384,0.00077566685,0.0000028096406,0.000102001344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988586,0.00009038799,0.00012176125,0.0002248808,0.0004268179,0.00027763032],"domain_scores_gemma":[0.9967591,0.00022277518,0.0014138402,0.00012427813,0.0009056839,0.00057430513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057415816,0.0003938291,0.0004673777,0.002584331,0.0015739886,0.0011372718,0.0010346003,0.00046235273,0.0014735318],"category_scores_gemma":[0.0018576735,0.00042679964,0.0005596565,0.005524348,0.0007892738,0.00034995883,0.0006827189,0.00046682474,0.00019919852],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004811487,0.0000128255,0.9984421,0.000015665979,0.000028759732,0.00015433128,0.00010993498,0.000031458385,0.00008503092,0.000016565977,0.00013340257,0.00092183327],"study_design_scores_gemma":[0.000008406512,0.00007697857,0.9977552,0.000017782997,0.00003897098,0.0007607431,0.00065222854,0.00015411865,0.0000812634,0.000007895493,0.00043522584,0.000011063522],"about_ca_topic_score_codex":0.79847795,"about_ca_topic_score_gemma":0.77004904,"teacher_disagreement_score":0.20152205,"about_ca_system_score_codex":0.008842163,"about_ca_system_score_gemma":0.008686084,"threshold_uncertainty_score":0.40541768},"labels":[],"label_agreement":null},{"id":"W7108516095","doi":"10.1182/blood-2025-7650","title":"Pre-clinical characterization and process development of a BCMA-directed CAR NK-cell therapy product for relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Immune system; Cytokine release syndrome; Human leukocyte antigen; Multiple myeloma; Transplantation; Antigen; CAR T-cell therapy; Blood product","score_opus":0.033852035526264625,"score_gpt":0.3372780528990568,"score_spread":0.3034260173727922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108516095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88413787,0.005223003,0.0838384,0.00051617227,0.00015035573,0.0032500294,0.0016441353,0.0009860533,0.020254005],"genre_scores_gemma":[0.9489978,0.001409757,0.032961976,0.00016513697,0.000030943538,0.00050928723,0.0015346823,0.00016368866,0.014226712],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99966514,0.00003791175,0.00001826793,0.00004009292,0.00020693558,0.00003180774],"domain_scores_gemma":[0.99974483,0.000021584405,0.000044630317,0.00002896085,0.00010953231,0.000050531846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004922323,0.00036670998,0.00023505601,0.00039878197,0.0002424082,0.0004402024,0.00033337824,0.00038582977,0.0029594954],"category_scores_gemma":[0.00056693435,0.00013330176,0.0002937798,0.00017255609,0.00021046866,0.00023668785,0.00021803552,0.00055064127,0.0016527914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002565449,0.00032190038,0.00069258414,0.00014495714,0.000013099052,0.00018928185,0.00009017641,0.001233082,0.9662973,0.0003701515,0.00081899815,0.029571887],"study_design_scores_gemma":[0.000067598085,0.002791638,0.0028437055,0.000015683298,0.000038003553,0.00065647066,0.0000247804,0.0029153985,0.96573246,0.0000887234,0.024813425,0.000012229318],"about_ca_topic_score_codex":0.00095758814,"about_ca_topic_score_gemma":0.0010061561,"teacher_disagreement_score":0.0029594954,"about_ca_system_score_codex":0.00041978632,"about_ca_system_score_gemma":0.00071848393,"threshold_uncertainty_score":0.009900451},"labels":[],"label_agreement":null},{"id":"W7108696894","doi":"10.1182/blood-2025-2410","title":"Development of multi-targeting CAR-double-negative T cells for allogeneic immunotherapy in B-cell leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Antigen; Leukemia; Immunotherapy; CD19; Myeloid leukemia; Cancer immunotherapy; Immune system; T cell","score_opus":0.03209382223099345,"score_gpt":0.3197897275302218,"score_spread":0.28769590529922834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108696894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8746502,0.05439739,0.050880063,0.0013320562,0.00049151486,0.00070547604,0.00056552514,0.0007144195,0.016263347],"genre_scores_gemma":[0.96437633,0.012445677,0.017004738,0.00052381365,0.000075378935,0.00034232027,0.00056375,0.00004128944,0.0046267174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999099,0.000013581332,0.0000069929174,0.000019525232,0.000024805218,0.000025162177],"domain_scores_gemma":[0.9999683,0.0000027013352,0.000005449582,0.0000036339661,0.0000074503437,0.000012558441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025274613,0.00032622766,0.00021484164,0.00033649214,0.00010099954,0.00036466465,0.00034831424,0.0003655043,0.0014706693],"category_scores_gemma":[0.000086702225,0.00012977405,0.0002736113,0.00014801195,0.00015194724,0.00026059407,0.00026850819,0.0006278181,0.00059250946],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045533595,0.0005504337,0.0007848712,0.00027293712,0.000025481218,0.00014303453,0.00005648378,0.0011931111,0.8761991,0.0021116093,0.001373981,0.116833635],"study_design_scores_gemma":[0.000963837,0.009287469,0.004239901,0.00011154149,0.00015882995,0.0019344152,0.000052369913,0.011426484,0.8902318,0.0014689671,0.080087446,0.00003689452],"about_ca_topic_score_codex":0.00025842444,"about_ca_topic_score_gemma":0.00027203892,"teacher_disagreement_score":0.0014706693,"about_ca_system_score_codex":0.00026232985,"about_ca_system_score_gemma":0.0002577453,"threshold_uncertainty_score":0.004919827},"labels":[],"label_agreement":null},{"id":"W7108742579","doi":"10.1182/blood-2025-2402","title":"Expansion, differentiation, and culture of hematopoietic stem &amp; progenitor cells using an ancillary GMP-compliant medium","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Stemcell Technologies","funders":"","keywords":"Progenitor cell; Haematopoiesis; Cord blood; Stem cell; Cell therapy; CD34; Induced pluripotent stem cell; Cell culture","score_opus":0.03631323697064287,"score_gpt":0.30975795947561624,"score_spread":0.27344472250497337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108742579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8276958,0.0031611673,0.14613107,0.00023864438,0.0002197206,0.0017988803,0.0045339037,0.0009869345,0.015233859],"genre_scores_gemma":[0.81497985,0.0023832852,0.16677438,0.00015899292,0.00006214091,0.0018743604,0.005613932,0.00013802246,0.008015008],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997123,0.000034344303,0.00005321983,0.000048633177,0.00012956189,0.000021880818],"domain_scores_gemma":[0.9998173,0.000040406205,0.00004156042,0.000030771327,0.000043810353,0.000026027321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040166132,0.00043801364,0.0002570199,0.00036738513,0.000269294,0.0004040329,0.00044326705,0.00025837886,0.0007326171],"category_scores_gemma":[0.00024179326,0.00011719035,0.00021603715,0.00036455688,0.00021339665,0.00017909045,0.00042866424,0.00051194476,0.00059917854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004860147,0.00005556632,0.00028875537,0.00009145651,0.000003422426,0.000109371875,0.00003453276,0.0002653377,0.99514467,0.0002798558,0.00017319054,0.0035051478],"study_design_scores_gemma":[0.000010707792,0.00011175219,0.0010416936,0.000021396241,0.0000156638,0.00017520497,0.000014055033,0.0013812121,0.9894939,0.000060277333,0.0076671205,0.0000068562417],"about_ca_topic_score_codex":0.00049660885,"about_ca_topic_score_gemma":0.0009007251,"teacher_disagreement_score":0.0007326171,"about_ca_system_score_codex":0.00019191836,"about_ca_system_score_gemma":0.00044007,"threshold_uncertainty_score":0.0024508834},"labels":[],"label_agreement":null},{"id":"W7108839697","doi":"10.1182/blood-2025-6140","title":"Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Overfitting; Multiple myeloma; Concordance; Pomalidomide; Logistic regression; Random forest; Framingham Risk Score; Clinical trial; Nomogram","score_opus":0.012459371308312156,"score_gpt":0.2928575631419537,"score_spread":0.28039819183364156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108839697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876621,0.0005261538,0.009935948,0.00018801159,0.000023322305,0.000054252625,0.00045719702,0.00018984487,0.0009632745],"genre_scores_gemma":[0.997157,0.00005187449,0.0022200213,0.000028965002,0.000015024237,0.000019116018,0.00031335469,0.0000053476747,0.00018935798],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951005,0.00021212094,0.0000450121,0.000116361894,0.000071769755,0.000044662833],"domain_scores_gemma":[0.9989191,0.0005699727,0.00023358884,0.000059690512,0.00012389693,0.000093764065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001626724,0.00060582685,0.00046654508,0.0007094391,0.00014520895,0.0009705853,0.00034495906,0.00045468658,0.0012643135],"category_scores_gemma":[0.004016732,0.00010613749,0.0004287593,0.00039524556,0.00018098822,0.0005347059,0.0005063931,0.00047562056,0.00031507414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054720175,0.00068395457,0.7146791,0.000105797415,0.0004319728,0.00011689639,0.00012991617,0.053025194,0.0087295445,0.00033825656,0.0012726875,0.21501468],"study_design_scores_gemma":[0.000087688284,0.0022173324,0.29859048,0.000034569628,0.000270612,0.00016481633,0.00015579234,0.68858,0.0077429414,0.00096888444,0.0011386233,0.00004819667],"about_ca_topic_score_codex":0.0016362795,"about_ca_topic_score_gemma":0.0016194993,"teacher_disagreement_score":0.0016362795,"about_ca_system_score_codex":0.00052606524,"about_ca_system_score_gemma":0.0003410228,"threshold_uncertainty_score":0.008603096},"labels":[],"label_agreement":null},{"id":"W7111239512","doi":"10.5281/zenodo.17860575","title":"Conscience Issue Tracker - December 2025","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Pipeline (software); Drug industry; Government (linguistics); Threatened species; Drug development; Headline; MEDLINE","score_opus":0.03902573762325673,"score_gpt":0.31188429161514586,"score_spread":0.27285855399188913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111239512","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006884373,0.002739914,0.0008327265,0.06062666,0.26996192,0.0005860538,0.0035271177,0.0020414558,0.65899575],"genre_scores_gemma":[0.0017135184,0.00048858026,0.00022637239,0.02490087,0.013748589,0.00016556279,0.0013542016,0.00035358666,0.9570488],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639755,0.00026138083,0.00016313595,0.0002763561,0.002291432,0.0006102317],"domain_scores_gemma":[0.99062437,0.0013697065,0.00048508102,0.0005730863,0.0047298702,0.0022178097],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0035931093,0.0011894935,0.0013093881,0.0021006204,0.0034376413,0.009404995,0.002140842,0.013167358,0.40433687],"category_scores_gemma":[0.016001103,0.0007243124,0.0014833043,0.0013235739,0.0009845336,0.0031250403,0.0031205928,0.009489154,0.32392296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018843946,0.0000152212815,0.00004383769,0.000032607368,0.0000012396496,0.000026423231,0.0000052834666,0.000010014275,0.000034939952,0.0005354791,0.9918154,0.0074607097],"study_design_scores_gemma":[0.000024375333,0.000019206953,0.00041395333,0.00007098624,0.0000018990328,0.00002331845,0.000022514128,0.00004675828,0.00004906894,0.000553744,0.9987657,0.000008494753],"about_ca_topic_score_codex":0.0067412243,"about_ca_topic_score_gemma":0.019959545,"teacher_disagreement_score":0.59566313,"about_ca_system_score_codex":0.0021033569,"about_ca_system_score_gemma":0.004653014,"threshold_uncertainty_score":0.84964114},"labels":[],"label_agreement":null},{"id":"W7111273469","doi":"10.5281/zenodo.17860574","title":"Conscience Issue Tracker - December 2025","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Pipeline (software); Drug industry; Government (linguistics); Threatened species; Drug development; Headline; MEDLINE","score_opus":0.03902573762325673,"score_gpt":0.31188429161514586,"score_spread":0.27285855399188913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111273469","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006884373,0.002739914,0.0008327265,0.06062666,0.26996192,0.0005860538,0.0035271177,0.0020414558,0.65899575],"genre_scores_gemma":[0.0017135184,0.00048858026,0.00022637239,0.02490087,0.013748589,0.00016556279,0.0013542016,0.00035358666,0.9570488],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639755,0.00026138083,0.00016313595,0.0002763561,0.002291432,0.0006102317],"domain_scores_gemma":[0.99062437,0.0013697065,0.00048508102,0.0005730863,0.0047298702,0.0022178097],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0035931093,0.0011894935,0.0013093881,0.0021006204,0.0034376413,0.009404995,0.002140842,0.013167358,0.40433687],"category_scores_gemma":[0.016001103,0.0007243124,0.0014833043,0.0013235739,0.0009845336,0.0031250403,0.0031205928,0.009489154,0.32392296],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018843946,0.0000152212815,0.00004383769,0.000032607368,0.0000012396496,0.000026423231,0.0000052834666,0.000010014275,0.000034939952,0.0005354791,0.9918154,0.0074607097],"study_design_scores_gemma":[0.000024375333,0.000019206953,0.00041395333,0.00007098624,0.0000018990328,0.00002331845,0.000022514128,0.00004675828,0.00004906894,0.000553744,0.9987657,0.000008494753],"about_ca_topic_score_codex":0.0067412243,"about_ca_topic_score_gemma":0.019959545,"teacher_disagreement_score":0.59566313,"about_ca_system_score_codex":0.0021033569,"about_ca_system_score_gemma":0.004653014,"threshold_uncertainty_score":0.84964114},"labels":[],"label_agreement":null},{"id":"W7112568180","doi":"","title":"Étude des toxicités neurologiques (ICANS) chez les patients atteints de lymphome B diffus à grandes cellules traités par CAR-T cells : expérience d'une cohorte bordelaise","year":2025,"lang":"fr","type":"dissertation","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Neurotoxicity; Immunotherapy; Immune system; Ferritin; Cognition; Refractory (planetary science)","score_opus":0.014562375231285646,"score_gpt":0.25743596388841095,"score_spread":0.2428735886571253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112568180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99946076,0.00022278563,0.000058084417,0.000014150621,0.000002266352,0.000009046581,0.00005640456,0.00000205245,0.00017437502],"genre_scores_gemma":[0.99921584,0.00024046341,0.000049184873,0.000019361943,0.000013905603,0.000013471837,0.00019646558,0.0000021295264,0.00024920274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996501,0.00007288474,0.000033803513,0.000086923515,0.00006893622,0.00008736747],"domain_scores_gemma":[0.9994392,0.00012168073,0.00016770558,0.000037949405,0.000079696365,0.0001537404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058916275,0.00045202274,0.00059938617,0.00091404305,0.000871078,0.00113549,0.00028334634,0.0005603622,0.0010536722],"category_scores_gemma":[0.0009063282,0.0003566133,0.0004977038,0.0005752731,0.00042542606,0.0005607781,0.00042874538,0.00044463776,0.00034920181],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037940432,0.00011458875,0.99384564,0.000012741642,0.000064324326,0.0015746439,0.00044068895,0.00006050347,0.0009527141,0.000017760474,0.000060919643,0.0024759953],"study_design_scores_gemma":[0.00006237119,0.00093164854,0.9921795,0.000013759808,0.000068436966,0.0047664274,0.00070996163,0.00023707494,0.00030027956,0.000018795305,0.00069886964,0.000012746135],"about_ca_topic_score_codex":0.010396023,"about_ca_topic_score_gemma":0.0071049607,"teacher_disagreement_score":0.010396023,"about_ca_system_score_codex":0.0007632759,"about_ca_system_score_gemma":0.00045127707,"threshold_uncertainty_score":0.02067107},"labels":[],"label_agreement":null},{"id":"W7112784928","doi":"","title":"Mid-term neurocognitive outcomes after CAR T cell therapy in central nervous system lymphomas: statistical analysis plan","year":2025,"lang":"","type":"preprint","venue":"OSF Preprints (OSF Preprints)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Central nervous system; Primary central nervous system lymphoma; CAR T-cell therapy; T cell; Cognition","score_opus":0.019891959025142233,"score_gpt":0.2980047512375751,"score_spread":0.27811279221243285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112784928","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71465236,0.0051417802,0.23055169,0.0027248722,0.00077281473,0.008137434,0.032900162,0.0015440101,0.0035748887],"genre_scores_gemma":[0.9288775,0.0004023531,0.039117914,0.00040704466,0.00017851467,0.0128690265,0.016177075,0.00017725152,0.0017934475],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.96848184,0.019870486,0.0024347755,0.0041839303,0.003790228,0.0012388687],"domain_scores_gemma":[0.92190254,0.058875285,0.0062248297,0.008640697,0.003111434,0.0012451428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.057994675,0.0010343293,0.0021226208,0.0038942287,0.0005588865,0.0016298898,0.0023393678,0.0013240441,0.006605439],"category_scores_gemma":[0.070997834,0.00031206373,0.007313595,0.0027776395,0.0013451831,0.0014804185,0.0021708815,0.002193335,0.00066362176],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018084353,0.0011459524,0.77564806,0.001672912,0.02039136,0.0005090621,0.00059246,0.022727836,0.0012962266,0.0046487395,0.017376564,0.13590653],"study_design_scores_gemma":[0.0009878163,0.012232584,0.6988657,0.00064250734,0.007525166,0.00075756165,0.0010636178,0.24198245,0.0033521357,0.013461345,0.018898169,0.00023098961],"about_ca_topic_score_codex":0.0020218329,"about_ca_topic_score_gemma":0.0010396235,"teacher_disagreement_score":0.057994675,"about_ca_system_score_codex":0.0014894096,"about_ca_system_score_gemma":0.002230545,"threshold_uncertainty_score":0.3067088},"labels":[],"label_agreement":null},{"id":"W7115194976","doi":"10.18609/cgti.2025.013","title":"Enhancing CAR-T therapy development: harnessing cell selection flexibility","year":2025,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Lonza (Canada)","funders":"","keywords":"Flexibility (engineering); Automation; Cellular manufacturing; Selection (genetic algorithm); Product (mathematics); Upstream (networking); Isolation (microbiology)","score_opus":0.032145931485373466,"score_gpt":0.3007684147657189,"score_spread":0.26862248328034544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115194976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6391934,0.015689649,0.3168523,0.0010727943,0.00033709197,0.00036359075,0.00034893927,0.0020257023,0.024116637],"genre_scores_gemma":[0.91131616,0.006827974,0.075854786,0.00054343184,0.000106969,0.00020863394,0.00030301564,0.0002856421,0.004553359],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994216,0.0001390687,0.00003446886,0.00010262324,0.00021263583,0.000089686546],"domain_scores_gemma":[0.9995522,0.00020927435,0.00007740176,0.000058722868,0.000057124755,0.000045277142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089056866,0.00043161382,0.00035143425,0.00041609723,0.00025650705,0.0013596573,0.00032766987,0.0004453046,0.0020674889],"category_scores_gemma":[0.00074375817,0.00024255824,0.000326019,0.00028595407,0.00048598874,0.0007209157,0.00086744817,0.0006442361,0.0009897453],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011723988,0.000050305174,0.0005901635,0.00016014403,0.000013174024,0.00018009926,0.00014866261,0.0025447845,0.94078594,0.0022384247,0.0005761857,0.05259509],"study_design_scores_gemma":[0.000049582242,0.00067388866,0.0018841852,0.00004259542,0.000049084007,0.0010482696,0.00010410665,0.01240498,0.92429584,0.0016947943,0.057704408,0.000048337733],"about_ca_topic_score_codex":0.0003114464,"about_ca_topic_score_gemma":0.00056651543,"teacher_disagreement_score":0.0020674889,"about_ca_system_score_codex":0.00029987266,"about_ca_system_score_gemma":0.00030526042,"threshold_uncertainty_score":0.006916404},"labels":[],"label_agreement":null},{"id":"W7115567204","doi":"10.18609/cgti.2024.167","title":"From the lab to the bench: scaling up regulatory T cell therapy","year":2024,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Effector; Automation; T cell; Cell therapy; Immune system; Portfolio; Key (lock); Regulatory T cell","score_opus":0.03740910209825789,"score_gpt":0.2891359515679986,"score_spread":0.2517268494697407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115567204","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10603016,0.13853505,0.5373024,0.08933272,0.015717706,0.0021325783,0.0005473758,0.0049736574,0.105428375],"genre_scores_gemma":[0.4113961,0.08076701,0.43558055,0.03432631,0.005327131,0.0012002985,0.00062109943,0.0011065862,0.029674986],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995858,0.0011799062,0.0002355255,0.00050789496,0.0018471796,0.0003714103],"domain_scores_gemma":[0.9966376,0.0011846746,0.00029601261,0.0005276671,0.00080745993,0.0005465116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0065771886,0.0007146714,0.00070215605,0.00081937446,0.00083231216,0.0047448194,0.0012099509,0.0019534335,0.009056321],"category_scores_gemma":[0.005211889,0.00030665327,0.00087542355,0.0004384508,0.0017095299,0.004169799,0.002750358,0.0040792655,0.0044038286],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002963715,0.00086530944,0.0015056821,0.0012080055,0.000060513477,0.00045423605,0.0007777083,0.0043325736,0.08666429,0.038986363,0.029103104,0.8357459],"study_design_scores_gemma":[0.00026878188,0.0060773734,0.0025475088,0.0014492209,0.00012922852,0.0016735116,0.0016888275,0.008518044,0.073481426,0.066757984,0.83727556,0.00013261507],"about_ca_topic_score_codex":0.0006741111,"about_ca_topic_score_gemma":0.0008188074,"teacher_disagreement_score":0.009056321,"about_ca_system_score_codex":0.0011698779,"about_ca_system_score_gemma":0.0033065637,"threshold_uncertainty_score":0.03478396},"labels":[],"label_agreement":null},{"id":"W7115817632","doi":"","title":"Bastin_Donald_J_2017Sept_MSc","year":2017,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncolytic virus; Adoptive cell transfer; Antigen; Chimeric antigen receptor; Context (archaeology); Cancer; Immunotherapy","score_opus":0.02734260555132089,"score_gpt":0.2781799247809676,"score_spread":0.2508373192296467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115817632","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005534019,0.0056411196,0.0016037093,0.0041258014,0.002677731,0.00012344304,0.0020912073,0.0009837303,0.9772192],"genre_scores_gemma":[0.01301132,0.003159336,0.0010589381,0.00077021384,0.00024647842,0.00005098448,0.0008457967,0.00031257523,0.98054427],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99958736,0.00003687604,0.000020510108,0.00017899567,0.000108387285,0.00006786055],"domain_scores_gemma":[0.99949646,0.00013158369,0.000028352055,0.000048715225,0.00010047468,0.00019441651],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003092274,0.0013324083,0.0005584778,0.0007045544,0.00090838404,0.0028612346,0.0006262604,0.0019904275,0.69919324],"category_scores_gemma":[0.0005799717,0.0004229804,0.00046280184,0.0006253199,0.00061924936,0.0007515326,0.001263776,0.0020154621,0.39724287],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009619663,0.00035914016,0.0013459995,0.00044224734,0.000050557916,0.0013877213,0.000116862924,0.0009762666,0.011207387,0.011572012,0.18388112,0.78769875],"study_design_scores_gemma":[0.000073019306,0.00012761503,0.001937612,0.00014930825,0.000013268643,0.0010083573,0.00008018378,0.0003814753,0.0024372975,0.0017424867,0.9920357,0.000013734361],"about_ca_topic_score_codex":0.0018076658,"about_ca_topic_score_gemma":0.0041290103,"teacher_disagreement_score":0.69919324,"about_ca_system_score_codex":0.0009957175,"about_ca_system_score_gemma":0.00077746226,"threshold_uncertainty_score":0.42906433},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["insufficient_payload"],"domain":null,"study_design":"design_other","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W7116844175","doi":"10.1016/s2352-3026(25)00318-7","title":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Université de Montréal; Université de Sherbrooke; McGill University Health Centre","funders":"Fonds de recherche du Québec","keywords":"Bispecific antibody; Chimeric antigen receptor; Sequence (biology); Antibody; Antigen; Antibody therapy; Immunotherapy","score_opus":0.10609664797253764,"score_gpt":0.39051698920371775,"score_spread":0.2844203412311801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116844175","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014699521,0.98266673,0.00065145426,0.0002485633,0.000251077,0.00019544242,0.0009114771,0.00003584731,0.00033999144],"genre_scores_gemma":[0.5720494,0.41972497,0.0024045308,0.0026210262,0.00041242654,0.00070021104,0.0011809195,0.00007555156,0.0008309234],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99422365,0.0026220656,0.001420262,0.00094360876,0.0004849124,0.00030562383],"domain_scores_gemma":[0.98996884,0.0066645388,0.0023099496,0.00040497305,0.00045124057,0.00020033898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007088534,0.0020337494,0.014494021,0.002637992,0.00042860498,0.0025077334,0.0020161893,0.0023357691,0.005092558],"category_scores_gemma":[0.014510438,0.0011899899,0.02894769,0.0044316924,0.00082447665,0.0017176078,0.0015481706,0.0019722981,0.0004666472],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044314833,0.000026347308,0.005979177,0.17273223,0.8080128,0.000112367095,0.000073219504,0.00041304508,0.00035945114,0.000119183744,0.00071714824,0.007023584],"study_design_scores_gemma":[0.0012939924,0.00019334332,0.003380505,0.005272731,0.9884558,0.000057215766,0.000037577232,0.00010697073,0.00005569631,0.00012278883,0.0010053279,0.000018086015],"about_ca_topic_score_codex":0.0053531765,"about_ca_topic_score_gemma":0.016139086,"teacher_disagreement_score":0.014494021,"about_ca_system_score_codex":0.0018329595,"about_ca_system_score_gemma":0.0020461008,"threshold_uncertainty_score":0.037488163},"labels":[],"label_agreement":null},{"id":"W7116897573","doi":"10.1016/j.soncn.2025.152095","title":"Theoretical Perspectives on Patient and Caregiver Experiences After CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Seminars in Oncology Nursing","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Encana (Canada)","funders":"","keywords":"MEDLINE; Qualitative research; Nursing practice; Clinical Practice","score_opus":0.010609680346704016,"score_gpt":0.3485681004946785,"score_spread":0.3379584201479745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116897573","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74876505,0.0064710905,0.0061663245,0.089494154,0.0026410283,0.00021258395,0.00022824902,0.000050811013,0.14597075],"genre_scores_gemma":[0.9885436,0.0014936678,0.00047286556,0.0039576674,0.00018364395,0.00008801397,0.000051122006,0.000021030952,0.005188571],"study_design_codex":"qualitative","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9895126,0.0077849445,0.00018018839,0.00032687388,0.0005030625,0.0016922557],"domain_scores_gemma":[0.9881364,0.0071077244,0.0010397973,0.00018124963,0.00083319115,0.0027017232],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009894088,0.0009120921,0.00049815606,0.0010887576,0.01323465,0.009502493,0.0018672744,0.003287658,0.008410813],"category_scores_gemma":[0.013846709,0.00040759682,0.0006525975,0.000841991,0.013930411,0.0056539006,0.00855632,0.007953803,0.0007386819],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010640201,0.00022020597,0.0031404288,0.00015323191,0.000014720259,0.00285107,0.951475,0.0001167124,0.00031685474,0.03131632,0.0045776404,0.0057114656],"study_design_scores_gemma":[0.000014643874,0.000059626018,0.0009369033,0.00014437226,0.0000062341487,0.0010729731,0.9777134,0.00007667326,0.000108480075,0.0040128008,0.015833745,0.00002016544],"about_ca_topic_score_codex":0.003683332,"about_ca_topic_score_gemma":0.00440851,"teacher_disagreement_score":0.01323465,"about_ca_system_score_codex":0.0061299293,"about_ca_system_score_gemma":0.006367986,"threshold_uncertainty_score":0.052325547},"labels":[],"label_agreement":null},{"id":"W7117120037","doi":"10.1111/bph.70296","title":"Immunotherapy in cancer: novel approaches and future perspectives","year":2025,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"","keywords":"Immunotherapy; Chimeric antigen receptor; Tumor microenvironment; Cancer immunotherapy; Immune system; Cancer; Cancer therapy","score_opus":0.03375880342256229,"score_gpt":0.36619829137457494,"score_spread":0.33243948795201267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117120037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039755617,0.9620637,0.0014937063,0.02882311,0.0032878232,0.000013157118,0.000029690826,0.0000429848,0.0038482086],"genre_scores_gemma":[0.00515072,0.9660739,0.002699276,0.011295284,0.011962576,0.00006008438,0.00007244139,0.000017543363,0.002668261],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986873,0.0004903546,0.00010189033,0.0001569544,0.00032445096,0.00023901027],"domain_scores_gemma":[0.9973008,0.001291764,0.00015288945,0.00014776105,0.0005957361,0.0005110464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0063669276,0.0011607701,0.0018464783,0.0018096889,0.00088685047,0.004862348,0.0017607253,0.005077389,0.008571827],"category_scores_gemma":[0.0022950405,0.00035672417,0.0011957694,0.0015736874,0.0036000847,0.008908352,0.0025048875,0.007790301,0.0033263161],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003832618,0.00045244867,0.00051317504,0.0071522444,0.00011130337,0.0008103839,0.00033223533,0.0009784679,0.0029418943,0.071793176,0.12176284,0.79276854],"study_design_scores_gemma":[0.000101499,0.0005535324,0.000637576,0.0039124843,0.00006490684,0.0017886454,0.0004912109,0.00060460815,0.00058775814,0.076333515,0.91487086,0.0000533902],"about_ca_topic_score_codex":0.0006823471,"about_ca_topic_score_gemma":0.0019642913,"teacher_disagreement_score":0.008571827,"about_ca_system_score_codex":0.0018618664,"about_ca_system_score_gemma":0.0028557968,"threshold_uncertainty_score":0.033671916},"labels":[],"label_agreement":null},{"id":"W7117247313","doi":"10.14740/jmc5211","title":"Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cyclophosphamide; Neurotoxicity; Cytokine release syndrome; Refractory (planetary science); Immune system; Chimeric antigen receptor; Effector","score_opus":0.02515273333043373,"score_gpt":0.33416742708227276,"score_spread":0.30901469375183904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117247313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389036,0.029679814,0.0076242466,0.0042824834,0.0005656826,0.00032503586,0.00017874474,0.00039391595,0.018046418],"genre_scores_gemma":[0.99055487,0.0053746756,0.0010515719,0.0009398641,0.0001830048,0.000039023624,0.00014280457,0.000015294232,0.0016988837],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9999423,0.000010057238,0.0000068273903,0.000007463292,0.000010217722,0.000023136181],"domain_scores_gemma":[0.99991715,0.00001875911,0.00002048782,0.00000848453,0.0000056332806,0.000029553654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000104299725,0.0003354694,0.00033548332,0.00034979905,0.0004325593,0.00022192913,0.00026206885,0.00054624234,0.0009868677],"category_scores_gemma":[0.0003104598,0.00008686202,0.00030740732,0.00022059794,0.00022189424,0.00022123555,0.00023442955,0.0008095919,0.00026620083],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016754058,0.00055082556,0.019200874,0.0007632213,0.00013775512,0.7681867,0.000265131,0.0012413069,0.032458413,0.0021158056,0.0065562883,0.16684818],"study_design_scores_gemma":[0.00052099826,0.002003956,0.027892096,0.00024166709,0.00019250775,0.9142921,0.00012434534,0.003356918,0.019389566,0.00160125,0.030354701,0.00002989145],"about_ca_topic_score_codex":0.000583687,"about_ca_topic_score_gemma":0.0019459928,"teacher_disagreement_score":0.0009868677,"about_ca_system_score_codex":0.00041565223,"about_ca_system_score_gemma":0.0003839773,"threshold_uncertainty_score":0.0033014417},"labels":[],"label_agreement":null},{"id":"W7117300967","doi":"10.3390/curroncol33010009","title":"Abstracts of the Cell Therapy Transplant Canada 2024 Annual Conference","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of Manitoba; Capital District Health Authority; McMaster University; Hamilton Health Sciences; University of Alberta; Université de Montréal; Université Laval","funders":"","keywords":"Presentation (obstetrics); Session (web analytics); Transplantation; Alternative medicine; MEDLINE; Case presentation","score_opus":0.0765301098284932,"score_gpt":0.39302016838052695,"score_spread":0.3164900585520337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117300967","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0048323637,0.063262396,0.002417068,0.1091538,0.34201008,0.0012534204,0.01034049,0.00068785326,0.46604252],"genre_scores_gemma":[0.011171198,0.026125055,0.0011749241,0.010991959,0.027424298,0.0004364948,0.0049410285,0.00037841318,0.9173566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996302,0.00025415776,0.00010861618,0.0002075123,0.0027004532,0.00042720756],"domain_scores_gemma":[0.99137855,0.00028391727,0.00020714225,0.00011579007,0.00499989,0.0030146507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031271933,0.0013402228,0.0008503044,0.0020144677,0.0037157496,0.0078418525,0.0015791768,0.0026791287,0.23977034],"category_scores_gemma":[0.004674451,0.0003668322,0.00095362985,0.0017586832,0.00089809246,0.0010669582,0.0018651756,0.0027582205,0.07522844],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027496597,0.000012845836,0.00007029971,0.00007162379,0.0000022144986,0.00003475992,0.00001824341,0.000028140474,0.00017166472,0.0002126229,0.9892497,0.010100372],"study_design_scores_gemma":[0.000010098243,0.000013517672,0.00053101865,0.00009668216,0.0000033074898,0.00004420897,0.00010192805,0.00003390596,0.0001165319,0.00011367254,0.99892765,0.0000075636453],"about_ca_topic_score_codex":0.16390282,"about_ca_topic_score_gemma":0.29001406,"teacher_disagreement_score":0.8360972,"about_ca_system_score_codex":0.015531823,"about_ca_system_score_gemma":0.036017396,"threshold_uncertainty_score":0.8021117},"labels":[],"label_agreement":null},{"id":"W7117308422","doi":"10.1038/s41409-025-02786-w","title":"Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Alberta Health Services","funders":"","keywords":"Mantle cell lymphoma; Lymphoma; Aggressive lymphoma; Hematopoietic cell; Bone marrow; Stem cell","score_opus":0.021781706536507857,"score_gpt":0.31696089384082893,"score_spread":0.2951791873043211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117308422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994843,0.0006457359,0.00017472846,0.0022970634,0.000012435659,0.000016600901,0.0005974208,0.0000062298996,0.0014067864],"genre_scores_gemma":[0.99937147,0.00014776258,0.00007563936,0.00017397891,0.000012898158,0.000012484619,0.0001456204,0.0000050019526,0.000055330653],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99366003,0.003451796,0.0007574502,0.00045195612,0.00057882664,0.0010999751],"domain_scores_gemma":[0.97790194,0.0069141057,0.01106105,0.0005337946,0.0012244371,0.0023646387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0050868713,0.00009215975,0.00027786216,0.0010595325,0.00072536827,0.0023431045,0.00071607233,0.00079058966,0.002857352],"category_scores_gemma":[0.029487528,0.0001987322,0.0002813677,0.0022704352,0.00085402,0.001567826,0.0012316133,0.0009991251,0.0003679261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054906326,0.000178111,0.9817529,0.00007540069,0.00007665698,0.00018402282,0.001397326,0.0003208298,0.00023924086,0.00071135594,0.0015469342,0.01296823],"study_design_scores_gemma":[0.00002658527,0.00020882598,0.9831203,0.00014559312,0.00006925067,0.00067913125,0.008648801,0.0013331529,0.0002994999,0.0010116918,0.004419489,0.000037716094],"about_ca_topic_score_codex":0.009600916,"about_ca_topic_score_gemma":0.01278498,"teacher_disagreement_score":0.009600916,"about_ca_system_score_codex":0.0016298472,"about_ca_system_score_gemma":0.0017092339,"threshold_uncertainty_score":0.026902258},"labels":[],"label_agreement":null},{"id":"W7117311906","doi":"10.1016/j.iotech.2025.101202","title":"117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"In vitro; Radiation therapy; Cell; Cancer therapy; Cancer; Cell therapy","score_opus":0.016533222373132594,"score_gpt":0.38570954537494284,"score_spread":0.36917632300181025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117311906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623925,0.0029919553,0.00411347,0.000115551586,0.0000656757,0.000129028,0.00035763916,0.000047459554,0.0059398664],"genre_scores_gemma":[0.98890615,0.0012055972,0.0030624203,0.000050873456,0.000019144305,0.00010577427,0.0006570856,0.000013907843,0.005978932],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9995925,0.00014967112,0.00002712597,0.00003262902,0.00012314052,0.00007500406],"domain_scores_gemma":[0.9998853,0.00005062703,0.00000829003,0.000009568812,0.000030160489,0.000016020833],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050124165,0.00029606267,0.00033637605,0.00024927175,0.00017529454,0.0004236965,0.00026050664,0.00044662607,0.0026472115],"category_scores_gemma":[0.0002410622,0.00015395679,0.0002515662,0.00023201735,0.00012982466,0.0002242367,0.00015726476,0.00057918427,0.0006580066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037010328,0.00033931524,0.00021752862,0.00011737599,0.0000206985,0.00010076687,0.00005192112,0.0010863681,0.99208814,0.00019312279,0.00016742482,0.0052472767],"study_design_scores_gemma":[0.00003533664,0.0018404622,0.0009173825,0.0000057041916,0.000035408488,0.000103410355,0.000029906445,0.002763138,0.9925465,0.000023811797,0.0016950235,0.0000038575554],"about_ca_topic_score_codex":0.0019496026,"about_ca_topic_score_gemma":0.0020141245,"teacher_disagreement_score":0.0026472115,"about_ca_system_score_codex":0.00028500202,"about_ca_system_score_gemma":0.00038635908,"threshold_uncertainty_score":0.00885582},"labels":[],"label_agreement":null},{"id":"W7117312005","doi":"10.1016/j.iotech.2025.101572","title":"395P Synthetic IL-12 immunotherapy reverses immune suppression and halts metastasis in pancreatic cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Pancreatic cancer; Immune system; Pancreatic ductal adenocarcinoma; Metastasis; Cytokine; Infiltration (HVAC); Tumor microenvironment","score_opus":0.016928231344369164,"score_gpt":0.3463640821661589,"score_spread":0.3294358508217897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117312005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849609,0.0042633126,0.0052476036,0.000565634,0.00021164033,0.00006099149,0.00036185404,0.00035850517,0.003969651],"genre_scores_gemma":[0.99068403,0.0016370816,0.0025287168,0.000107386135,0.00002544403,0.000051253763,0.00036457684,0.00003382111,0.0045676706],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99991906,0.000012552687,0.000005006116,0.00001150798,0.000029340787,0.000022551092],"domain_scores_gemma":[0.9999604,0.000007693955,0.0000073305837,0.000005023694,0.0000039698984,0.000015706539],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001132995,0.0002394379,0.00021648585,0.00022137439,0.000107909014,0.00021693856,0.0001886747,0.0002644962,0.002049252],"category_scores_gemma":[0.000089118905,0.00009300623,0.00014447985,0.0001406761,0.0002679599,0.00016570475,0.00015423258,0.00090621685,0.0004513502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007196939,0.00029234964,0.000106111074,0.000113761336,0.000009697899,0.00011987539,0.000028410352,0.0008871291,0.9834012,0.0004772374,0.0005543931,0.01329009],"study_design_scores_gemma":[0.00029468842,0.003280137,0.0011724497,0.000014276705,0.000025777033,0.00044873852,0.000031294643,0.0034427475,0.9785265,0.00022469764,0.012529826,0.0000089299265],"about_ca_topic_score_codex":0.00040586,"about_ca_topic_score_gemma":0.00063749135,"teacher_disagreement_score":0.002049252,"about_ca_system_score_codex":0.00022221052,"about_ca_system_score_gemma":0.00030126018,"threshold_uncertainty_score":0.0068553686},"labels":[],"label_agreement":null},{"id":"W7118063928","doi":"10.1093/geroni/igaf122.3203","title":"Geriatric assessment in patients aged 70 and over considered for CAR-T therapy: Adescriptive study","year":2025,"lang":"en","type":"article","venue":"Innovation in Aging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Geriatric oncology; Geriatrics; Medical record; Geriatric care; Risk assessment; Clinical Practice; Cancer; MEDLINE","score_opus":0.046763167701504474,"score_gpt":0.379507360857487,"score_spread":0.3327441931559825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7118063928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966523,0.00054706197,0.00012002685,0.00008154639,0.0000146223465,0.0001302966,0.00078506436,0.0000027713809,0.0016662639],"genre_scores_gemma":[0.99838996,0.00024103418,0.00010435631,0.0001087414,0.000022589109,0.000083692226,0.0005368327,8.958619e-7,0.0005118814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995191,0.000119617165,0.00004713875,0.00007031877,0.00010724286,0.00013657595],"domain_scores_gemma":[0.99893373,0.000107047344,0.000383071,0.000050045728,0.00028694823,0.0002391518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089459814,0.00036169676,0.00039603267,0.0009292999,0.00083556544,0.0007535833,0.0003574181,0.00037231154,0.0018911724],"category_scores_gemma":[0.0020858431,0.0001373054,0.0005980725,0.0012764807,0.0003002025,0.00059023657,0.00056610524,0.0004377707,0.00028315868],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003263583,0.0002046699,0.9956226,0.000029408404,0.00005079422,0.000085831285,0.00017779907,0.000030304795,0.00006564966,0.000035367742,0.00034748463,0.0030236612],"study_design_scores_gemma":[0.000040994433,0.00058829127,0.9973537,0.000026370564,0.00005304831,0.00012619831,0.0007216132,0.0001919917,0.000031843178,0.000025441257,0.00083327875,0.0000072705193],"about_ca_topic_score_codex":0.13071889,"about_ca_topic_score_gemma":0.18160245,"teacher_disagreement_score":0.13071889,"about_ca_system_score_codex":0.0024253896,"about_ca_system_score_gemma":0.0021824122,"threshold_uncertainty_score":0.259916},"labels":[],"label_agreement":null},{"id":"W7130728508","doi":"10.6084/m9.figshare.28537978","title":"Additional file 1 of Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Thermo Fisher Scientific (Canada)","funders":"","keywords":"Potency; Set (abstract data type); Stability (learning theory); Statistical analysis; Table (database)","score_opus":0.11822858874791327,"score_gpt":0.3380872051762991,"score_spread":0.21985861642838583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7130728508","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002907064,0.000019923684,0.00044025783,0.00012691124,0.000021702492,0.00012438867,0.9963726,0.00027728186,0.0023262268],"genre_scores_gemma":[0.015911082,0.00023226716,0.0062470445,0.0009970989,0.0001303353,0.0028518445,0.9497039,0.001084184,0.022842303],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99816614,0.00033758662,0.0002938645,0.00037171342,0.00064565876,0.00018499457],"domain_scores_gemma":[0.9332153,0.051650252,0.0032676123,0.0031304348,0.008148738,0.00058771914],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037370247,0.0008022158,0.00082718884,0.0026608303,0.00080525904,0.0016110283,0.0012127548,0.0011887335,0.8495966],"category_scores_gemma":[0.04643636,0.00052629795,0.00078868924,0.003194171,0.00031768772,0.0013901137,0.00086593354,0.0010196543,0.20900573],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042527902,0.0001551553,0.0025144366,0.0014409632,0.00003843756,0.000044980767,0.000051202962,0.00041111515,0.00019979263,0.00095267384,0.98165375,0.012112155],"study_design_scores_gemma":[0.0022881562,0.0003655757,0.024242528,0.002161601,0.00016030217,0.0003054594,0.0003857642,0.0014513929,0.0015502408,0.0072009093,0.9597886,0.000099371784],"about_ca_topic_score_codex":0.0054403767,"about_ca_topic_score_gemma":0.007965856,"teacher_disagreement_score":0.8495966,"about_ca_system_score_codex":0.001289634,"about_ca_system_score_gemma":0.0024056116,"threshold_uncertainty_score":0.21453208},"labels":[],"label_agreement":null},{"id":"W7131812083","doi":"10.5376/cge.2025.13.0021","title":"Bottlenecks and Breakthrough Pathways of CAR-T Cell Therapy in Solid Tumors","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cell therapy; Cell; Cancer therapy; Radiation therapy; Antibody therapy; Cancer","score_opus":0.0310972616995913,"score_gpt":0.32711754724674585,"score_spread":0.29602028554715454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131812083","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40518534,0.3761353,0.070838064,0.09076139,0.0020288962,0.00027118076,0.0022734331,0.0011033242,0.051403094],"genre_scores_gemma":[0.89931124,0.07973738,0.0076437257,0.0044582323,0.00087555166,0.00017767058,0.0004982519,0.00013346679,0.0071644816],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9990914,0.0002154048,0.000053382006,0.00019067543,0.00020723142,0.00024197648],"domain_scores_gemma":[0.9987675,0.00051323953,0.0001598414,0.00010868432,0.00024663494,0.00020411803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030675803,0.00048078457,0.001092903,0.0010212847,0.00083901285,0.003440897,0.000892048,0.0013376672,0.0074829855],"category_scores_gemma":[0.0028357669,0.00031786104,0.00058047636,0.00086922786,0.0022041227,0.006408,0.0016776625,0.00311826,0.0012542611],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001908098,0.00050871185,0.010803536,0.0023196419,0.00028774855,0.0012171065,0.0012788582,0.012905486,0.10578704,0.5619129,0.020470588,0.28060034],"study_design_scores_gemma":[0.00030945402,0.0019872289,0.011869722,0.0006833484,0.0003636921,0.0020342574,0.0026334012,0.019600358,0.08892169,0.5749459,0.2964793,0.00017165595],"about_ca_topic_score_codex":0.0015696901,"about_ca_topic_score_gemma":0.0015910048,"teacher_disagreement_score":0.0074829855,"about_ca_system_score_codex":0.002867265,"about_ca_system_score_gemma":0.0030846687,"threshold_uncertainty_score":0.025033057},"labels":[],"label_agreement":null},{"id":"W7131875803","doi":"10.5376/cge.2025.13.0014","title":"Trends in CAR-T Cell Therapy for Hematologic Malignancies","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Radiation therapy; Antibody therapy; Cancer; Immunotherapy; Cell therapy; Disease","score_opus":0.04609918735745401,"score_gpt":0.3568766324347804,"score_spread":0.3107774450773264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131875803","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007857215,0.8978945,0.0041935947,0.07152211,0.0031817686,0.000042924494,0.00036081386,0.00028218344,0.014664861],"genre_scores_gemma":[0.07866011,0.8590817,0.0076378356,0.032776304,0.0081612,0.00011840883,0.000563166,0.00012721344,0.012874082],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99945194,0.00014178979,0.00005902825,0.00011366811,0.00014087111,0.00009285721],"domain_scores_gemma":[0.99818784,0.00092783384,0.00017624327,0.00005439664,0.00042877177,0.00022489979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026950638,0.000410435,0.0007687488,0.0010178457,0.00040707435,0.002317601,0.0007680214,0.001807635,0.010437553],"category_scores_gemma":[0.0024822531,0.0002492437,0.0005997942,0.0011568405,0.0013261606,0.0035408055,0.00065254624,0.004376569,0.0032053827],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005641977,0.00047745535,0.0029286484,0.0033727768,0.00010782041,0.00033537898,0.00021957552,0.001401733,0.014417966,0.035488527,0.086945474,0.8537404],"study_design_scores_gemma":[0.00012972575,0.000995208,0.0031130356,0.0010768318,0.00013389885,0.0009173323,0.00032703142,0.0014498485,0.0054500923,0.014219172,0.9721556,0.000032258733],"about_ca_topic_score_codex":0.0010565318,"about_ca_topic_score_gemma":0.003756179,"teacher_disagreement_score":0.010437553,"about_ca_system_score_codex":0.0017172676,"about_ca_system_score_gemma":0.0020337687,"threshold_uncertainty_score":0.034917057},"labels":[],"label_agreement":null},{"id":"W7132882460","doi":"","title":"Allogeneic Double Negative T cell Therapy as a Novel Treatment for AML Patients","year":2019,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T cell; Leukemia; Peripheral blood mononuclear cell; Priming (agriculture); Transplantation; Bone marrow; Minimal residual disease; Graft-versus-host disease; Disease","score_opus":0.06602140056888346,"score_gpt":0.40649389517122275,"score_spread":0.3404724946023393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132882460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69434977,0.17294358,0.041741576,0.007820322,0.0024312283,0.0007151868,0.00078843755,0.0009375866,0.07827242],"genre_scores_gemma":[0.85867965,0.07952253,0.022336712,0.0032924416,0.00096660556,0.00041996606,0.000759852,0.00007148835,0.033950705],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99995863,0.0000070014266,0.0000026539744,0.000008525722,0.000016096255,0.0000071426703],"domain_scores_gemma":[0.9999814,0.0000024904332,0.0000047696103,0.000002360516,0.0000023658752,0.0000066119906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009014559,0.00015822425,0.000169568,0.00015279894,0.000113510374,0.00037082256,0.00017169495,0.00017266539,0.0019396315],"category_scores_gemma":[0.00006379141,0.000049986123,0.00015219214,0.000091283975,0.0001345811,0.00019372822,0.0002089803,0.00054696004,0.00061206706],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077713805,0.000806794,0.0027253511,0.00074154005,0.00004195393,0.0009148719,0.00021928654,0.00094115705,0.39587831,0.009067505,0.014224486,0.5736617],"study_design_scores_gemma":[0.00057455513,0.0062393337,0.008697696,0.000355254,0.00018537155,0.012321812,0.00016492982,0.003190086,0.28048983,0.005448241,0.68229795,0.00003493994],"about_ca_topic_score_codex":0.00006361925,"about_ca_topic_score_gemma":0.00018853624,"teacher_disagreement_score":0.0019396315,"about_ca_system_score_codex":0.00013119396,"about_ca_system_score_gemma":0.00018017895,"threshold_uncertainty_score":0.006488681},"labels":[],"label_agreement":null},{"id":"W7132905998","doi":"","title":"Development of Class II-agnostic CAR T Cell Therapy Targeting WT1 Peptide Presented by Diverse HLA class II Molecules","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T-cell receptor; Epitope; Chimeric antigen receptor; Human leukocyte antigen; T cell; Antigen; MHC class II; MHC class I; Peptide","score_opus":0.025819202718483175,"score_gpt":0.34084757167315133,"score_spread":0.3150283689546681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132905998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9511201,0.0049807206,0.03654579,0.00028240937,0.00011567111,0.00037798908,0.00034081773,0.00037850023,0.0058580986],"genre_scores_gemma":[0.9805886,0.0027605852,0.011545868,0.00014941381,0.000023010405,0.00025442606,0.00043373043,0.000027628868,0.0042167646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999008,0.000010637864,0.000005986624,0.000027534137,0.000023885597,0.000031217587],"domain_scores_gemma":[0.99997497,0.0000021493179,0.0000061017236,0.0000028025572,0.0000053441167,0.000008614827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010462306,0.00042607827,0.00027961907,0.0002646372,0.000094123,0.00025067697,0.0002836288,0.00032994474,0.0007966327],"category_scores_gemma":[0.000070527,0.00015920993,0.00023748896,0.00016674258,0.00011877075,0.00023559676,0.00020555458,0.00055462157,0.00034963485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007234199,0.000104791434,0.00012803293,0.00006384036,0.000008263184,0.00008739109,0.00002557742,0.0005832044,0.9876736,0.00044381537,0.0001871492,0.01062206],"study_design_scores_gemma":[0.00009001501,0.0017904696,0.00096855307,0.000009976375,0.00004518506,0.0008125388,0.000017191302,0.0055813906,0.9758095,0.000117491305,0.014743672,0.000014008176],"about_ca_topic_score_codex":0.00036165782,"about_ca_topic_score_gemma":0.00031966038,"teacher_disagreement_score":0.0007966327,"about_ca_system_score_codex":0.00022214655,"about_ca_system_score_gemma":0.00020636994,"threshold_uncertainty_score":0.0026650429},"labels":[],"label_agreement":null},{"id":"W7132935331","doi":"","title":"Elucidating Cytotoxic Mechanisms of Allogeneic Double-Negative T cells Against Acute Myeloid Leukemia","year":2025,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytotoxic T cell; Myeloid leukemia; Leukemia; Haematopoiesis; Myeloid; Cytokine; Immunotherapy; Stem cell; Effector","score_opus":0.02953809217371737,"score_gpt":0.3558772237053055,"score_spread":0.3263391315315881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132935331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928329,0.001522549,0.004131825,0.000079964186,0.0000112341695,0.00007263747,0.00013698034,0.000034717552,0.0011771737],"genre_scores_gemma":[0.9909471,0.0026500204,0.0039482443,0.000098616336,0.000016266054,0.00008028469,0.0004166442,0.000007294471,0.0018355218],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.999899,0.000013207574,0.0000062294816,0.000017445007,0.000036313675,0.000027717031],"domain_scores_gemma":[0.99995136,0.0000105831605,0.000016544045,0.0000048291777,0.000008961482,0.000007679767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013655424,0.00030272713,0.00018368367,0.00030474403,0.00009504187,0.00031286062,0.00018321995,0.00016349104,0.00052853755],"category_scores_gemma":[0.000107895015,0.00009718674,0.00019777984,0.00012112353,0.00013345563,0.00023763368,0.00016013929,0.00035429277,0.00018684275],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000921857,0.00004650549,0.00086267845,0.000060977065,0.000003995388,0.000031596195,0.00002505388,0.0002684788,0.9904242,0.00020348634,0.000048289025,0.007932499],"study_design_scores_gemma":[0.000027777216,0.0013048123,0.0069584716,0.000015395051,0.000028856532,0.00035692938,0.000053024185,0.0030727624,0.98470163,0.00037825553,0.0030967046,0.0000053216313],"about_ca_topic_score_codex":0.000107815096,"about_ca_topic_score_gemma":0.00015344545,"teacher_disagreement_score":0.00052853755,"about_ca_system_score_codex":0.00015443066,"about_ca_system_score_gemma":0.0001620812,"threshold_uncertainty_score":0.0017681718},"labels":[],"label_agreement":null},{"id":"W7133054292","doi":"","title":"Donor-derived Double Negative T cells as a Vehicle for the Off-the-shelf Delivery of Chimeric Antigen Receptor Therapies for B-ALL","year":2021,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Toronto General Hospital Research Institute, University Health Network","keywords":"Chimeric antigen receptor; Antigen; In vitro; Leukemia; Receptor; Monoclonal antibody; Refractory (planetary science)","score_opus":0.045298494829115125,"score_gpt":0.36837171112693623,"score_spread":0.3230732162978211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133054292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84962153,0.023100827,0.088910095,0.00074064697,0.00041767376,0.00072017056,0.0010694284,0.0005326242,0.034887053],"genre_scores_gemma":[0.9230774,0.0133569045,0.027410742,0.00026428566,0.000059943086,0.0002658963,0.001233884,0.000108514345,0.03422246],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999274,0.000012789806,0.000004357538,0.000013087964,0.000029829158,0.000012502935],"domain_scores_gemma":[0.99998343,0.0000030942413,0.0000042948304,0.0000019914085,0.0000036455904,0.0000035554363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001482258,0.00020506045,0.00011841002,0.00016833177,0.00010985855,0.00027653255,0.00013880875,0.00024787983,0.0023224906],"category_scores_gemma":[0.000061944134,0.00009045437,0.00016613223,0.000100711404,0.00013448195,0.00014167305,0.00015027508,0.00043640533,0.00097472843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000459791,0.00005272973,0.00004963691,0.000078605444,0.0000025589384,0.00003515701,0.000027428108,0.00017781646,0.98647887,0.0007555174,0.00033296656,0.011962615],"study_design_scores_gemma":[0.000034875447,0.0005175709,0.0004743154,0.000015540578,0.000018109578,0.00029695657,0.000016573445,0.0005573339,0.96801,0.0001305288,0.029924033,0.000004197667],"about_ca_topic_score_codex":0.00028817452,"about_ca_topic_score_gemma":0.000453103,"teacher_disagreement_score":0.0023224906,"about_ca_system_score_codex":0.00019445403,"about_ca_system_score_gemma":0.00027791937,"threshold_uncertainty_score":0.007769525},"labels":[],"label_agreement":null},{"id":"W7133088234","doi":"","title":"Expansion and Characterization of Tumour Derived T Lymphocytes from Undifferentiated Pleomorphic Sarcoma","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sarcoma; CD8; Limiting; Soft tissue sarcoma; Phenotype; Soft tissue; Adoptive cell transfer; T cell","score_opus":0.027783520130231214,"score_gpt":0.3268898674382498,"score_spread":0.2991063473080186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133088234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866107,0.0014178071,0.006657069,0.00007018911,0.00003464379,0.00025852045,0.00046669095,0.00003417285,0.0044502458],"genre_scores_gemma":[0.98027,0.0012741864,0.0068225437,0.00016678419,0.00004474519,0.00026012157,0.002062162,0.000026441488,0.009073025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999206,0.000014412887,0.000008661371,0.000013767465,0.000021905904,0.000020549707],"domain_scores_gemma":[0.9999416,0.000012257749,0.0000050198446,0.000007862051,0.000015593754,0.000017682125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013470872,0.00016024025,0.000081012666,0.00019950986,0.000096596894,0.0002669646,0.00012483739,0.00016555456,0.001438462],"category_scores_gemma":[0.00015572422,0.00007009006,0.0001416617,0.00013574633,0.0000707806,0.00013494953,0.00014283879,0.00042992897,0.0010072029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012429933,0.00007907543,0.00083451305,0.00004918181,0.0000026228781,0.00014845503,0.0000850254,0.00015570273,0.99021965,0.00014242266,0.00009944553,0.0080597],"study_design_scores_gemma":[0.0001282255,0.0038684302,0.027659478,0.0000740333,0.000059915474,0.0019694534,0.00041610844,0.0023882908,0.9273327,0.00043715967,0.0356498,0.000016342872],"about_ca_topic_score_codex":0.00015902985,"about_ca_topic_score_gemma":0.0003060026,"teacher_disagreement_score":0.001438462,"about_ca_system_score_codex":0.00007262093,"about_ca_system_score_gemma":0.00012623204,"threshold_uncertainty_score":0.004812181},"labels":[],"label_agreement":null},{"id":"W7133092310","doi":"","title":"In Vitro Generation of Human CD4 T Lineage Cells from Stem Cells","year":2024,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytotoxic T cell; Stem cell; T cell; CD8; Progenitor cell; Interleukin 21; Natural killer T cell; Antigen-presenting cell","score_opus":0.05747263454086639,"score_gpt":0.39209500581805756,"score_spread":0.3346223712771912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133092310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7720379,0.00875512,0.13503605,0.00064581673,0.00070946943,0.001518569,0.012477754,0.0011479423,0.06767137],"genre_scores_gemma":[0.82518345,0.0096456595,0.082422,0.0003209653,0.000108883796,0.00095320336,0.014670681,0.00022675809,0.06646837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99989974,0.000015708913,0.000014275926,0.00001632892,0.00003721664,0.000016680257],"domain_scores_gemma":[0.999969,0.0000076835795,0.0000045886004,0.000006815901,0.0000062583636,0.0000056112935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016429195,0.0002840106,0.00015588036,0.00021708672,0.00016071904,0.00044722442,0.00019946917,0.00020500591,0.003502242],"category_scores_gemma":[0.000097262295,0.00014256718,0.00022619894,0.00017627254,0.00011150509,0.000120958706,0.00022372951,0.0005240551,0.0021438233],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069376474,0.0000472001,0.00017666115,0.00011177799,0.0000052228283,0.000089451394,0.000063331405,0.00026014182,0.9922808,0.0006454156,0.0004773228,0.005773434],"study_design_scores_gemma":[0.000019885594,0.0001527194,0.00042932612,0.000012861924,0.00001421467,0.00014562083,0.000017430717,0.00044077705,0.96415985,0.00010610086,0.034498304,0.0000029360722],"about_ca_topic_score_codex":0.00047434462,"about_ca_topic_score_gemma":0.00076888915,"teacher_disagreement_score":0.003502242,"about_ca_system_score_codex":0.00016896952,"about_ca_system_score_gemma":0.00026976605,"threshold_uncertainty_score":0.011716187},"labels":[],"label_agreement":null},{"id":"W7147334668","doi":"10.1093/immadv/ltaf038","title":"Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells <i>in vitro</i>","year":2025,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"CD28; T-cell receptor; Cytotoxic T cell; Chimeric antigen receptor; Antigen; Effector; Streptamer; Signal transduction; Jurkat cells","score_opus":0.015110604342451496,"score_gpt":0.30191830494043137,"score_spread":0.2868077005979799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7147334668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99442697,0.00052740244,0.0032579578,0.00003915181,0.000026510017,0.000044937802,0.00022270673,0.00007409592,0.0013802431],"genre_scores_gemma":[0.99527115,0.00021819428,0.0024810997,0.000036673242,0.000012380236,0.000028416038,0.00042669591,0.000020164309,0.0015052534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99981517,0.000034758785,0.000017410603,0.000033994354,0.000043431453,0.000055313478],"domain_scores_gemma":[0.99990976,0.00003071237,0.000015140077,0.000010807946,0.000011001496,0.000022550454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017707965,0.00047937673,0.00018704044,0.00013441374,0.000064597814,0.00029573173,0.00011660392,0.0002446775,0.0011351812],"category_scores_gemma":[0.00010052383,0.000108610075,0.00021708423,0.00009243127,0.00011761699,0.000111030706,0.00016107652,0.0005401447,0.0005036122],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008971818,0.000032259388,0.000059328264,0.000010247277,0.0000017859426,0.000022664133,0.000007528427,0.000100221674,0.9991917,0.00001931163,0.000021380532,0.00044381985],"study_design_scores_gemma":[0.000021285332,0.00030141696,0.00073719275,0.0000028430989,0.000008858367,0.00008821615,0.0000071308145,0.0012928614,0.99677294,0.000012115103,0.00075336423,0.0000017620001],"about_ca_topic_score_codex":0.00031051962,"about_ca_topic_score_gemma":0.00031786587,"teacher_disagreement_score":0.0011351812,"about_ca_system_score_codex":0.00017410617,"about_ca_system_score_gemma":0.00009407357,"threshold_uncertainty_score":0.0037975311},"labels":[],"label_agreement":null},{"id":"W7165358678","doi":"10.32598/jvc.5.3.175.1","title":"Optimizing Allogeneic Stem Cell Transplantation Following CAR-T Therapy in Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Vessels and Circulation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Lymphoblastic Leukemia; Stem cell; Transplantation; Hematopoietic stem cell transplantation; Acute lymphocytic leukemia; Myeloid leukemia; Immunotherapy","score_opus":0.023898680649489353,"score_gpt":0.2946250213738157,"score_spread":0.27072634072432633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7165358678","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044626375,0.991028,0.0001865948,0.0009814451,0.00032313305,0.000069011185,0.00020429661,0.0000075239886,0.0027374525],"genre_scores_gemma":[0.040911537,0.95624614,0.0007155326,0.0010054699,0.000437622,0.00008507169,0.00023121311,0.000004402424,0.00036306787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99904734,0.00042145373,0.00025480243,0.00005930934,0.00018874928,0.000028414843],"domain_scores_gemma":[0.9981686,0.0011852853,0.00038820002,0.000026508778,0.00020089389,0.000030647487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012730592,0.00028085502,0.0009940639,0.0020608273,0.00013883112,0.0012537666,0.000455837,0.0009373472,0.0032822562],"category_scores_gemma":[0.004782879,0.00007949011,0.00079818175,0.0030646257,0.00029379912,0.0008850178,0.00033871504,0.00040381402,0.0003606669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008128007,0.00013613232,0.002251398,0.32564875,0.0009781847,0.0008476211,0.00020342451,0.00031586172,0.0018088068,0.0016416905,0.0077305185,0.6576248],"study_design_scores_gemma":[0.0010243461,0.0022735978,0.023453573,0.2669898,0.014713262,0.007911598,0.0020292976,0.000629759,0.0072955154,0.00564906,0.6679609,0.00006933489],"about_ca_topic_score_codex":0.00086945103,"about_ca_topic_score_gemma":0.0015765798,"teacher_disagreement_score":0.0032822562,"about_ca_system_score_codex":0.0005489178,"about_ca_system_score_gemma":0.0018430348,"threshold_uncertainty_score":0.010980189},"labels":[],"label_agreement":null}]}